Fine	O
needle	O
aspiration	O
cytology	O
of	O
primary	O
thyroid	O
lymphoma	O
:	O
a	O
report	O
of	O
ten	O
cases	O
Primary	O
lymphoma	O
is	O
an	O
uncommon	O
malignancy	O
of	O
the	O
thyroid	O
","	O
comprising	O
of	O
0	O
.	O
6	O
to	O
5	O
per	O
cent	O
of	O
thyroid	O
cancers	O
in	O
most	O
series	O
.	O
Primary	O
thyroid	O
lymphomas	O
(	O
PTL	O
)	O
occur	O
most	O
commonly	O
in	O
elderly	O
women	O
and	O
are	O
commonly	O
of	O
B	O
-	O
cell	O
origin	O
.	O
These	O
frequently	O
present	O
in	O
clinical	O
stage	O
IE	O
and	O
IIE	O
.	O
We	O
report	O
here	O
ten	O
cases	O
of	O
PTL	O
diagnosed	O
over	O
a	O
period	O
of	O
about	O
7	O
years	O
in	O
our	O
institute	O
.	O
Out	O
of	O
these	O
ten	O
cases	O
","	O
nine	O
were	O
diagnosed	O
on	O
fine	O
needle	O
aspiration	O
cytology	O
(	O
FNAC	O
)	O
and	O
one	O
case	O
was	O
misdiagnosed	O
as	O
lymphocytic	O
thyroiditis	O
.	O
This	O
case	O
was	O
diagnosed	O
as	O
Non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
on	O
surgical	O
specimen	O
.	O
Five	O
patients	O
are	O
disease	O
free	O
and	O
doing	O
well	O
","	O
while	O
two	O
died	O
of	O
disease	O
and	O
the	O
other	O
two	O
were	O
lost	O
to	O
follow	O
-	O
up	O
.	O
One	O
patient	O
is	O
currently	O
on	O
chemotherapy	O
.	O
The	O
salient	O
clinical	O
","	O
biochemical	O
","	O
radiological	O
features	O
","	O
FNA	O
findings	O
along	O
with	O
diagnostic	O
difficulties	O
are	O
discussed	O
.	O
Introduction	O
Primary	O
thyroid	O
lymphoma	O
is	O
a	O
rare	O
disease	O
that	O
continues	O
to	O
produce	O
diagnostic	O
and	O
therapeutic	O
dilemmas	O
.	O
Most	O
thyroid	O
lymphomas	O
are	O
of	O
B	O
-	O
cell	O
origin	O
[	O
1	O
].	O
There	O
appear	O
to	O
be	O
two	O
distinct	O
clinical	O
and	O
prognostic	O
groups	O
of	O
these	O
rare	O
tumors	O
.	O
The	O
more	O
common	O
subtype	O
","	O
comprising	O
of	O
up	O
to	O
70	O
%	O
of	O
cases	O
","	O
is	O
a	O
diffuse	O
large	O
B	O
-	O
cell	O
lymphoma	O
[	O
1	O
].	O
This	O
subtype	O
appears	O
to	O
have	O
the	O
most	O
aggressive	O
clinical	O
course	O
with	O
almost	O
60	O
%	O
of	O
these	O
tumors	O
diagnosed	O
with	O
disseminated	O
disease	O
.	O
The	O
other	O
subtype	O
is	O
mucosa	O
-	O
associated	O
lymphoid	O
tissue	O
(	O
MALT	O
)	O
lymphomas	O
comprising	O
of	O
approximately	O
6	O
%	O
to	O
27	O
%	O
of	O
thyroid	O
lymphomas	O
[	O
1	O
].	O
These	O
have	O
a	O
relatively	O
indolent	O
course	O
.	O
These	O
occur	O
more	O
commonly	O
in	O
females	O
with	O
female	O
to	O
male	O
ratio	O
of	O
2	O
â€“	O
4	O
:	O
1	O
.	O
The	O
majority	O
of	O
these	O
patients	O
have	O
underlying	O
Hashimoto	O
'	O
s	O
thyroiditis	O
","	O
which	O
increases	O
the	O
risk	O
for	O
thyroid	O
lymphoma	O
by	O
50	O
times	O
[	O
2	O
].	O
The	O
importance	O
of	O
recognizing	O
primary	O
thyroid	O
lymphoma	O
lies	O
in	O
the	O
fact	O
that	O
this	O
disease	O
is	O
quite	O
curable	O
without	O
the	O
need	O
for	O
extensive	O
surgery	O
if	O
recognized	O
early	O
and	O
treated	O
appropriately	O
.	O
In	O
this	O
report	O
","	O
we	O
discuss	O
FNA	O
findings	O
of	O
ten	O
such	O
patients	O
.	O
Materials	O
and	O
methods	O
Ten	O
cases	O
of	O
primary	O
thyroid	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
(	O
PTL	O
)	O
were	O
retrieved	O
from	O
files	O
of	O
department	O
of	O
Cytopathology	O
","	O
Postgraduate	O
Institute	O
of	O
Medical	O
Education	O
and	O
Research	O
","	O
Chandigarh	O
","	O
India	O
over	O
a	O
seven	O
year	O
period	O
(	O
Jan	O
1998	O
-	O
Oct	O
2004	O
"),"	O
during	O
this	O
period	O
about	O
4500	O
patients	O
were	O
aspirated	O
for	O
thyroid	O
enlargement	O
.	O
Clinical	O
information	O
including	O
age	O
","	O
sex	O
","	O
presenting	O
symptoms	O
","	O
treatment	O
and	O
subsequent	O
course	O
were	O
recorded	O
.	O
FNAC	O
was	O
performed	O
with	O
23	O
G	O
needle	O
and	O
on	O
an	O
average	O
2	O
â€“	O
3	O
passes	O
were	O
taken	O
to	O
obtain	O
adequate	O
material	O
for	O
diagnosis	O
.	O
Histopathology	O
of	O
the	O
surgically	O
resected	O
specimens	O
was	O
available	O
in	O
three	O
cases	O
.	O
Immunocytochemistry	O
(	O
ICC	O
)	O
was	O
performed	O
for	O
leukocyte	O
common	O
antigen	O
(	O
LCA	O
"),"	O
cytokeratin	O
","	O
CD	O
20	O
and	O
CD3	O
in	O
six	O
cases	O
.	O
Results	O
Of	O
the	O
10	O
cases	O
","	O
5	O
were	O
female	O
and	O
5	O
were	O
males	O
with	O
female	O
to	O
male	O
ratio	O
of	O
1	O
:	O
1	O
.	O
The	O
age	O
ranged	O
from	O
10	O
â€“	O
61	O
years	O
with	O
a	O
mean	O
age	O
of	O
39	O
.	O
6	O
years	O
.	O
Two	O
patients	O
were	O
less	O
than	O
15	O
years	O
of	O
age	O
.	O
Duration	O
of	O
follow	O
-	O
up	O
ranged	O
from	O
1	O
month	O
to	O
4	O
.	O
3	O
years	O
.	O
A	O
summary	O
of	O
clinical	O
information	O
and	O
cytological	O
findings	O
is	O
shown	O
in	O
Table	O
1	O
.	O
All	O
patients	O
presented	O
with	O
thyroid	O
enlargement	O
of	O
variable	O
duration	O
(	O
20	O
days	O
to	O
2	O
years	O
).	O
Seven	O
patients	O
presented	O
with	O
a	O
diffuse	O
goiter	O
","	O
two	O
patients	O
had	O
a	O
multinodular	O
goiter	O
and	O
only	O
one	O
patient	O
presented	O
as	O
a	O
solitary	O
thyroid	O
nodule	O
.	O
Other	O
signs	O
and	O
symptoms	O
included	O
stridor	O
","	O
hoarseness	O
","	O
dyspnoea	O
","	O
dysphagia	O
and	O
sense	O
of	O
heaviness	O
in	O
the	O
neck	O
.	O
Four	O
patients	O
had	O
associated	O
cervical	O
lymphadenopathy	O
and	O
three	O
of	O
them	O
had	O
lymphomatous	O
involvement	O
while	O
one	O
had	O
reactive	O
hyperplasia	O
.	O
showing	O
clinical	O
presentation	O
","	O
biochemical	O
investigations	O
and	O
follow	O
-	O
up	O
of	O
ten	O
cases	O
of	O
primary	O
thyroid	O
lymphoma	O
.	O
Imaging	O
modalities	O
and	O
bone	O
marrow	O
examination	O
did	O
not	O
reveal	O
other	O
areas	O
of	O
involvement	O
.	O
CT	O
scan	O
done	O
in	O
these	O
cases	O
revealed	O
a	O
lesion	O
primarily	O
involving	O
the	O
thyroid	O
gland	O
(	O
Figure	O
1	O
).	O
Hematological	O
parameters	O
","	O
serum	O
biochemistry	O
and	O
thyroid	O
function	O
tests	O
were	O
normal	O
at	O
presentation	O
except	O
in	O
three	O
patients	O
","	O
who	O
were	O
hypothyroid	O
.	O
Thyroid	O
microsomal	O
antibody	O
(	O
TMA	O
)	O
titer	O
was	O
significantly	O
increased	O
(	O
1	O
:	O
80	O
)	O
in	O
six	O
patients	O
.	O
CECT	O
scan	O
showing	O
a	O
homogenous	O
isodense	O
soft	O
tissue	O
mass	O
(	O
3	O
.	O
2	O
Ã—	O
4	O
.	O
5	O
cm	O
)	O
in	O
the	O
region	O
of	O
left	O
lobe	O
of	O
thyroid	O
.	O
Cytologically	O
in	O
nine	O
cases	O
","	O
a	O
diagnosis	O
of	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
(	O
NHL	O
)	O
was	O
offered	O
on	O
FNAC	O
.	O
These	O
included	O
six	O
cases	O
of	O
high	O
grade	O
NHL	O
and	O
three	O
cases	O
of	O
intermediate	O
grade	O
NHL	O
.	O
The	O
smears	O
in	O
high	O
grade	O
NHL	O
cases	O
were	O
cellular	O
and	O
comprised	O
of	O
monomorphic	O
population	O
of	O
large	O
atypical	O
lymphoid	O
cells	O
.	O
These	O
cells	O
were	O
2	O
â€“	O
3	O
times	O
the	O
size	O
of	O
a	O
mature	O
lymphocyte	O
with	O
opened	O
up	O
chromatin	O
and	O
conspicuous	O
1	O
â€“	O
2	O
nucleoli	O
(	O
Figure	O
2	O
).	O
In	O
the	O
background	O
many	O
lymphoglandular	O
bodies	O
were	O
seen	O
.	O
One	O
of	O
these	O
six	O
cases	O
had	O
subsequent	O
histological	O
confirmation	O
.	O
Aspiration	O
smear	O
showing	O
monomorphic	O
population	O
of	O
atypical	O
lymphoid	O
cells	O
in	O
a	O
case	O
of	O
high	O
grade	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
(	O
MGG	O
Ã—	O
512	O
).	O
In	O
three	O
cases	O
","	O
FNAC	O
smears	O
showed	O
a	O
dual	O
population	O
of	O
lymphoid	O
cells	O
comprising	O
of	O
an	O
admixture	O
of	O
mature	O
lymphocytes	O
and	O
larger	O
lymphoid	O
cells	O
.	O
These	O
large	O
lymphoid	O
cells	O
were	O
2	O
â€“	O
3	O
times	O
the	O
size	O
of	O
a	O
mature	O
lymphocyte	O
and	O
had	O
opened	O
up	O
chromatin	O
and	O
conspicuous	O
nucleoli	O
(	O
Figure	O
3	O
).	O
Many	O
monocytoid	O
cells	O
were	O
also	O
seen	O
.	O
A	O
diagnosis	O
of	O
florid	O
lymphocytic	O
thyroiditis	O
was	O
considered	O
less	O
likely	O
","	O
because	O
","	O
in	O
thyroiditis	O
","	O
a	O
reactive	O
population	O
of	O
lymphoid	O
cells	O
of	O
variable	O
sizes	O
admixed	O
with	O
plasma	O
cells	O
and	O
tingible	O
body	O
macrophages	O
is	O
usually	O
present	O
.	O
Hence	O
","	O
in	O
these	O
three	O
cases	O
","	O
combining	O
the	O
clinical	O
presentation	O
and	O
cytological	O
findings	O
","	O
a	O
diagnosis	O
of	O
NHL	O
â€“	O
intermediate	O
grade	O
was	O
suggested	O
.	O
Aspiration	O
smear	O
showing	O
a	O
typical	O
dual	O
population	O
of	O
lymphoid	O
cells	O
in	O
a	O
case	O
of	O
intermediate	O
grade	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
(	O
H	O
&	O
E	O
Ã—	O
512	O
).	O
In	O
one	O
case	O
","	O
the	O
diagnosis	O
of	O
lymphoma	O
was	O
missed	O
on	O
FNA	O
.	O
The	O
patient	O
presented	O
with	O
a	O
diffuse	O
rather	O
than	O
a	O
nodular	O
swelling	O
and	O
cytology	O
revealed	O
a	O
polymorphic	O
infiltrate	O
consistent	O
with	O
a	O
reactive	O
hyperplasia	O
which	O
was	O
seen	O
to	O
infiltrate	O
the	O
follicular	O
epithelial	O
cell	O
clusters	O
.	O
Hence	O
a	O
diagnosis	O
of	O
lymphocytic	O
thyroiditis	O
was	O
offered	O
.	O
A	O
subtotal	O
thyroidectomy	O
was	O
performed	O
because	O
of	O
associated	O
pressure	O
symptoms	O
.	O
Histopathology	O
revealed	O
a	O
Non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
morphologically	O
and	O
immunohistochemically	O
consistent	O
with	O
a	O
marginal	O
zone	O
B	O
cell	O
lymphoma	O
.	O
In	O
six	O
cases	O
","	O
immunocytochemistry	O
(	O
ICC	O
)	O
was	O
performed	O
on	O
the	O
fine	O
needle	O
aspirate	O
and	O
all	O
cases	O
were	O
CD	O
20	O
positive	O
and	O
CD3	O
negative	O
.	O
In	O
all	O
the	O
cases	O
","	O
protocol	O
staging	O
as	O
per	O
the	O
ANN	O
Arbor	O
staging	O
of	O
NHL	O
was	O
performed	O
.	O
Bone	O
marrow	O
examination	O
","	O
whole	O
body	O
67Gallium	B-Chemical
scan	O
","	O
CECT	O
abdomen	O
and	O
chest	O
and	O
CSF	O
for	O
malignant	O
cytology	O
was	O
done	O
in	O
all	O
patients	O
before	O
labeling	O
a	O
case	O
as	O
primary	O
thyroid	O
lymphoma	O
.	O
In	O
the	O
present	O
series	O
","	O
7	O
cases	O
were	O
of	O
stage	O
I	O
(	O
E	O
)	O
and	O
three	O
cases	O
were	O
of	O
stage	O
II	O
(	O
E	O
).	O
Lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
levels	O
were	O
done	O
in	O
six	O
out	O
of	O
ten	O
patients	O
and	O
the	O
mean	O
LDH	O
level	O
was	O
628	O
U	O
/	O
L	O
.	O
Follow	O
-	O
up	O
information	O
All	O
the	O
patients	O
received	O
combination	O
chemotherapy	O
(	O
CHOP	B-Chemical
regime	I-Chemical
)	O
with	O
local	O
radiotherapy	O
.	O
Five	O
patients	O
are	O
alive	O
and	O
are	O
free	O
of	O
disease	O
till	O
date	O
","	O
whereas	O
","	O
two	O
patients	O
died	O
of	O
the	O
disease	O
.	O
These	O
two	O
patients	O
had	O
high	O
grade	O
lymphoma	O
and	O
succumbed	O
to	O
disseminated	O
disease	O
.	O
Two	O
were	O
lost	O
to	O
follow	O
-	O
up	O
and	O
one	O
patient	O
is	O
currently	O
on	O
chemotherapy	O
.	O
Discussion	O
Primary	O
thyroid	O
lymphoma	O
(	O
PTL	O
)	O
is	O
defined	O
as	O
a	O
lymphomatous	O
process	O
involving	O
the	O
thyroid	O
gland	O
without	O
contiguous	O
spread	O
or	O
distant	O
metastases	O
from	O
other	O
areas	O
of	O
involvement	O
at	O
diagnosis	O
[	O
3	O
].	O
PTL	O
constitutes	O
5	O
%	O
of	O
all	O
thyroid	O
malignancies	O
and	O
occurs	O
in	O
less	O
than	O
1	O
%	O
of	O
all	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphomas	O
[	O
3	O
].	O
The	O
majority	O
of	O
patients	O
are	O
middle	O
to	O
old	O
aged	O
women	O
[	O
4	O
].	O
Studies	O
have	O
shown	O
that	O
PTL	O
typically	O
arises	O
in	O
the	O
setting	O
of	O
autoimmune	O
thyroiditis	O
and	O
it	O
takes	O
","	O
on	O
an	O
average	O
","	O
20	O
to	O
30	O
years	O
to	O
develop	O
after	O
the	O
onset	O
of	O
lymphocytic	O
thyroiditis	O
[	O
5	O
].	O
A	O
short	O
history	O
of	O
a	O
rapidly	O
enlarging	O
neck	O
mass	O
often	O
associated	O
with	O
dyspnoea	O
","	O
difficulty	O
in	O
swallowing	O
","	O
or	O
voice	O
change	O
is	O
the	O
hallmark	O
presentation	O
of	O
thyroid	O
lymphoma	O
[	O
6	O
].	O
Therefore	O
","	O
clinically	O
this	O
may	O
be	O
confused	O
with	O
anaplastic	O
thyroid	O
carcinoma	O
.	O
Hoarseness	O
","	O
respiratory	O
distress	O
","	O
cough	O
and	O
dysphagia	O
were	O
the	O
usual	O
presenting	O
manifestations	O
in	O
our	O
patients	O
.	O
Hypothyroidism	O
at	O
the	O
time	O
of	O
diagnosis	O
is	O
documented	O
in	O
30	O
â€“	O
40	O
%	O
of	O
patients	O
due	O
to	O
replacement	O
of	O
thyroid	O
parenchyma	O
by	O
the	O
lymphomatous	O
process	O
or	O
due	O
to	O
underlying	O
Hashimoto	O
'	O
s	O
thyroiditis	O
.	O
Thyrotoxicosis	O
is	O
exceedingly	O
rare	O
[	O
7	O
].	O
Seven	O
of	O
our	O
patients	O
at	O
presentation	O
were	O
euthyroid	O
and	O
three	O
were	O
hypothyroid	O
.	O
Circulating	O
antibodies	O
to	O
thyroid	O
peroxidase	O
are	O
positive	O
in	O
60	O
â€“	O
80	O
%	O
of	O
patients	O
suggesting	O
underlying	O
lymphocytic	O
thyroiditis	O
as	O
a	O
predisposing	O
factor	O
.	O
In	O
the	O
present	O
series	O
","	O
six	O
patients	O
had	O
significantly	O
elevated	O
thyroid	O
microsomal	O
antibody	O
titer	O
.	O
Fine	O
needle	O
aspiration	O
has	O
become	O
the	O
procedure	O
of	O
choice	O
for	O
the	O
initial	O
pathological	O
diagnosis	O
of	O
thyroid	O
nodule	O
.	O
However	O
","	O
studies	O
have	O
also	O
shown	O
inconsistent	O
results	O
in	O
the	O
diagnosis	O
of	O
lymphoma	O
of	O
the	O
thyroid	O
.	O
In	O
one	O
series	O
","	O
a	O
correct	O
diagnosis	O
with	O
FNAC	O
was	O
made	O
in	O
70	O
â€“	O
80	O
%	O
of	O
patients	O
with	O
thyroid	O
lymphoma	O
[	O
8	O
"],"	O
but	O
in	O
others	O
","	O
FNA	O
was	O
suggestive	O
but	O
not	O
diagnostic	O
in	O
only	O
50	O
â€“	O
60	O
%	O
of	O
patients	O
[	O
9	O
-	O
12	O
].	O
In	O
the	O
present	O
study	O
","	O
nine	O
out	O
of	O
ten	O
cases	O
(	O
90	O
%)	O
of	O
the	O
cases	O
of	O
PTL	O
were	O
correctly	O
diagnosed	O
by	O
FNA	O
.	O
A	O
primary	O
thyroid	O
non	O
-	O
Hodgkin	O
lymphoma	O
is	O
usually	O
of	O
large	O
cell	O
type	O
[	O
13	O
]	O
and	O
a	O
diagnosis	O
of	O
large	O
cell	O
lymphoma	O
is	O
easy	O
on	O
FNA	O
and	O
features	O
like	O
lack	O
of	O
cellular	O
cohesion	O
and	O
presence	O
of	O
lymphoglandular	O
bodies	O
in	O
the	O
background	O
are	O
features	O
strongly	O
against	O
a	O
diagnosis	O
of	O
anaplastic	O
carcinoma	O
[	O
14	O
].	O
ICC	O
confirms	O
the	O
lymphoid	O
origin	O
of	O
the	O
cells	O
and	O
their	O
B	O
or	O
T	O
-	O
lineage	O
.	O
By	O
contrast	O
","	O
cytological	O
diagnosis	O
of	O
MALT	O
-	O
lymphomas	O
is	O
difficult	O
","	O
because	O
of	O
heterogeneous	O
appearance	O
of	O
the	O
neoplastic	O
infiltrate	O
[	O
14	O
].	O
The	O
principal	O
problem	O
with	O
a	O
cytological	O
diagnosis	O
of	O
low	O
-	O
grade	O
lymphoma	O
of	O
the	O
thyroid	O
is	O
its	O
differentiation	O
from	O
HT	O
.	O
The	O
distinguishing	O
features	O
may	O
be	O
the	O
abundance	O
of	O
lymphoid	O
tissue	O
and	O
a	O
high	O
proportion	O
of	O
intermediate	O
centrocyte	O
-	O
like	O
cells	O
in	O
low	O
-	O
grade	O
NHL	O
as	O
compared	O
to	O
HT	O
.	O
FALSE	O
negative	O
results	O
may	O
be	O
due	O
to	O
sampling	O
error	O
also	O
as	O
low	O
-	O
grade	O
B	O
-	O
cell	O
MALT	O
lymphoma	O
originates	O
from	O
HT	O
and	O
the	O
two	O
usually	O
coexist	O
[	O
14	O
].	O
Due	O
attention	O
to	O
dual	O
population	O
of	O
lymphoid	O
cells	O
","	O
presence	O
of	O
monocytoid	O
cells	O
in	O
FNA	O
smears	O
and	O
extensive	O
follicular	O
epithelial	O
destruction	O
and	O
the	O
clinical	O
setting	O
enabled	O
us	O
to	O
diagnose	O
three	O
cases	O
of	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
of	O
intermediate	O
grade	O
.	O
However	O
","	O
we	O
missed	O
the	O
diagnosis	O
of	O
NHL	O
on	O
FNAC	O
in	O
one	O
case	O
reported	O
as	O
lymphocytic	O
thyroiditis	O
","	O
which	O
on	O
subsequent	O
subtotal	O
thyroidectomy	O
","	O
was	O
reported	O
as	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O
FNAC	O
cytomorphology	O
in	O
conjunction	O
with	O
flow	O
cytometric	O
(	O
FC	O
)	O
immunophenotyping	O
has	O
become	O
a	O
reliable	O
and	O
accurate	O
method	O
for	O
the	O
diagnosis	O
and	O
classification	O
of	O
many	O
lymphoproliferative	O
disorders	O
.	O
CD4	O
/	O
CD8	O
T	O
-	O
cell	O
ratio	O
comparisons	O
are	O
made	O
with	O
cytomorphological	O
diagnoses	O
of	O
reactive	O
","	O
atypical	O
","	O
non	O
-	O
Hodgkin	O
lymphoma	O
","	O
and	O
Hodgkin	O
lymphoma	O
cases	O
[	O
15	O
","	O
16	O
].	O
PTL	O
frequently	O
present	O
in	O
clinical	O
stage	O
IE	O
and	O
IIE	O
.	O
Treatment	O
is	O
similar	O
to	O
other	O
nodal	O
lymphoma	O
.	O
For	O
patients	O
with	O
intermediate	O
or	O
high	O
-	O
grade	O
lymphoma	O
","	O
the	O
best	O
results	O
are	O
obtained	O
from	O
cyclophosphamide	B-Chemical
","	O
daunorubicin	B-Chemical
","	O
vincrstine	B-Chemical
and	O
prednisolone	B-Chemical
(	O
CHOP	B-Chemical
)	O
based	O
chemotherapy	O
.	O
Radiation	O
therapy	O
is	O
used	O
most	O
commonly	O
after	O
3	O
â€“	O
6	O
courses	O
of	O
chemotherapy	O
in	O
form	O
of	O
modified	O
mantle	O
irradiation	O
including	O
thyroid	O
","	O
bilateral	O
neck	O
","	O
supraclavicular	O
area	O
and	O
mediastinum	O
[	O
17	O
].	O
Our	O
patients	O
received	O
CHOP	B-Chemical
based	O
chemotherapy	O
","	O
two	O
of	O
our	O
patients	O
had	O
relapsed	O
with	O
bone	O
marrow	O
involvement	O
and	O
local	O
nodal	O
recurrence	O
.	O
One	O
died	O
of	O
lymphomatous	O
process	O
and	O
other	O
was	O
controlled	O
with	O
radiotherapy	O
.	O
The	O
poor	O
prognostic	O
factors	O
include	O
age	O
more	O
than	O
60	O
years	O
","	O
performance	O
status	O
grater	O
than	O
1	O
","	O
elevated	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
and	O
Î²2	O
microglobulin	O
","	O
extranodal	O
sites	O
more	O
than	O
1	O
and	O
Ann	O
-	O
Arbor	O
staged	O
III	O
-	O
IV	O
[	O
18	O
","	O
19	O
].	O
In	O
summary	O
","	O
we	O
report	O
a	O
retrospective	O
study	O
of	O
ten	O
cases	O
of	O
primary	O
thyroid	O
lymphomas	O
.	O
The	O
diagnosis	O
was	O
established	O
by	O
fine	O
needle	O
aspiration	O
in	O
nine	O
cases	O
and	O
one	O
case	O
was	O
misdiagnosed	O
as	O
lymphocytic	O
thyroiditis	O
","	O
which	O
was	O
diagnosed	O
on	O
surgical	O
specimen	O
.	O
The	O
cytological	O
diagnosis	O
of	O
high	O
grade	O
lymphoma	O
is	O
easy	O
and	O
ICC	O
can	O
confirm	O
suspicious	O
cases	O
.	O
The	O
diagnosis	O
of	O
low	O
grade	O
lymphoma	O
is	O
more	O
difficult	O
but	O
clinical	O
and	O
radiological	O
suspicion	O
and	O
cytomorphological	O
features	O
can	O
help	O
reaching	O
the	O
correct	O
diagnosis	O
in	O
such	O
cases	O
.	O
Abbreviations	O
NHL	O
â€“	O
Non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
HG	O
-	O
High	O
grade	O
IG	O
-	O
Intermediate	O
grade	O
TMA	O
-	O
Thyroid	O
microsomal	O
antibody	O
HT	O
-	O
Hashimoto	O
'	O
s	O
thyroiditis	O
LT	O
-	O
Lymphocytic	O
thyroiditis	O
RT	O
-	O
Radiotherapy	O
SVC	O
-	O
Superior	O
vena	O
cava	O
.	O
Selection	O
of	O
reference	O
genes	O
for	O
gene	O
expression	O
studies	O
in	O
pig	O
tissues	O
using	O
SYBR	B-Chemical
green	I-Chemical
qPCR	O
Background	O
Real	O
-	O
time	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
is	O
a	O
method	O
for	O
rapid	O
and	O
reliable	O
quantification	O
of	O
mRNA	O
transcription	O
.	O
Internal	O
standards	O
such	O
as	O
reference	O
genes	O
are	O
used	O
to	O
normalise	O
mRNA	O
levels	O
between	O
different	O
samples	O
for	O
an	O
exact	O
comparison	O
of	O
mRNA	O
transcription	O
level	O
.	O
Selection	O
of	O
high	O
quality	O
reference	O
genes	O
is	O
of	O
crucial	O
importance	O
for	O
the	O
interpretation	O
of	O
data	O
generated	O
by	O
real	O
-	O
time	O
qPCR	O
.	O
Results	O
In	O
this	O
study	O
nine	O
commonly	O
used	O
reference	O
genes	O
were	O
investigated	O
in	O
17	O
different	O
pig	O
tissues	O
using	O
real	O
-	O
time	O
qPCR	O
with	O
SYBR	B-Chemical
green	I-Chemical
.	O
The	O
genes	O
included	O
beta	O
-	O
actin	O
(	O
ACTB	O
"),"	O
beta	O
-	O
2	O
-	O
microglobulin	O
(	O
B2M	O
"),"	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
"),"	O
hydroxymethylbilane	O
synthase	O
(	O
HMBS	O
"),"	O
hypoxanthine	O
phosphoribosyltransferase	O
1	O
(	O
HPRT1	O
"),"	O
ribosomal	O
protein	O
L4	O
(	O
RPL4	O
"),"	O
succinate	O
dehydrogenase	O
complex	O
subunit	O
A	O
(	O
SDHA	O
"),"	O
TATA	O
box	O
binding	O
protein	O
(	O
TPB	O
)	O
and	O
tyrosine	O
3	O
-	O
monooxygenase	O
/	O
tryptophan	O
5	O
-	O
monooxygenase	O
activation	O
protein	O
zeta	O
polypeptide	O
(	O
YWHAZ	O
).	O
The	O
stability	O
of	O
these	O
reference	O
genes	O
in	O
different	O
pig	O
tissues	O
was	O
investigated	O
using	O
the	O
geNorm	O
application	O
.	O
The	O
range	O
of	O
expression	O
stability	O
in	O
the	O
genes	O
analysed	O
was	O
(	O
from	O
the	O
most	O
stable	O
to	O
the	O
least	O
stable	O
):	O
ACTB	O
/	O
RPL4	O
","	O
TBP	O
","	O
HPRT	O
","	O
HMBS	O
","	O
YWHAZ	O
","	O
SDHA	O
","	O
B2M	O
and	O
GAPDH	O
.	O
Conclusion	O
Expression	O
stability	O
varies	O
greatly	O
between	O
genes	O
.	O
ACTB	O
","	O
RPL4	O
","	O
TPB	O
and	O
HPRT1	O
were	O
found	O
to	O
have	O
the	O
highest	O
stability	O
across	O
tissues	O
.	O
Based	O
on	O
both	O
expression	O
stability	O
and	O
expression	O
level	O
","	O
our	O
data	O
suggest	O
that	O
ACTB	O
and	O
RPL4	O
are	O
good	O
reference	O
genes	O
for	O
high	O
abundant	O
transcripts	O
while	O
TPB	O
and	O
HPRT1	O
are	O
good	O
reference	O
genes	O
for	O
low	O
abundant	O
transcripts	O
in	O
expression	O
studies	O
across	O
different	O
pig	O
tissues	O
.	O
Background	O
Real	O
-	O
time	O
quantitative	O
PCR	O
(	O
qPCR	O
)	O
is	O
an	O
efficient	O
method	O
for	O
quantification	O
of	O
mRNA	O
transcription	O
levels	O
due	O
to	O
its	O
high	O
sensitivity	O
","	O
reproducibility	O
and	O
large	O
dynamic	O
range	O
;	O
in	O
addition	O
","	O
real	O
-	O
time	O
qPCR	O
is	O
fast	O
","	O
easy	O
to	O
use	O
and	O
provides	O
simultaneous	O
measurement	O
of	O
gene	O
expression	O
in	O
many	O
different	O
samples	O
for	O
a	O
limited	O
number	O
of	O
genes	O
.	O
One	O
of	O
the	O
critical	O
steps	O
in	O
comparing	O
transcription	O
profiles	O
is	O
accurate	O
normalisation	O
","	O
therefore	O
","	O
a	O
number	O
of	O
variables	O
should	O
be	O
controlled	O
such	O
as	O
amount	O
of	O
starting	O
material	O
","	O
enzymatic	O
efficiencies	O
","	O
differences	O
in	O
transcriptional	O
activity	O
and	O
presence	O
of	O
inhibitors	O
in	O
different	O
sample	O
materials	O
.	O
One	O
way	O
to	O
standardize	O
samples	O
is	O
to	O
quantify	O
the	O
starting	O
material	O
i	O
.	O
e	O
.	O
number	O
of	O
cells	O
or	O
quantity	O
of	O
RNA	O
.	O
However	O
","	O
this	O
does	O
not	O
take	O
the	O
RNA	O
quality	O
and	O
enzymatic	O
efficiencies	O
into	O
account	O
.	O
To	O
control	O
these	O
variables	O
","	O
which	O
are	O
not	O
a	O
result	O
of	O
the	O
experimental	O
design	O
","	O
normalisation	O
using	O
reference	O
genes	O
are	O
routinely	O
used	O
e	O
.	O
g	O
.	O
[	O
1	O
-	O
3	O
].	O
The	O
accurate	O
quantification	O
of	O
reference	O
genes	O
allows	O
normalisation	O
of	O
differences	O
in	O
amount	O
of	O
the	O
amplified	O
cDNA	O
in	O
individual	O
samples	O
.	O
The	O
normalisation	O
adjusts	O
for	O
differences	O
in	O
amount	O
and	O
quality	O
of	O
starting	O
material	O
and	O
differences	O
in	O
RNA	O
preparation	O
and	O
cDNA	O
synthesis	O
","	O
since	O
the	O
reference	O
gene	O
is	O
exposed	O
to	O
the	O
same	O
preparation	O
steps	O
as	O
the	O
gene	O
of	O
interest	O
.	O
Recently	O
a	O
set	O
of	O
reference	O
genes	O
(	O
ACTB	O
","	O
TBP	O
and	O
topoisomerase	O
(	O
DNA	O
)	O
II	O
beta	O
(	O
TOP2B	O
))	O
have	O
proven	O
suitable	O
for	O
normalisation	O
of	O
qPCR	O
data	O
of	O
backfat	O
and	O
longissimus	O
dorsi	O
muscle	O
in	O
the	O
pig	O
[	O
4	O
].	O
In	O
the	O
present	O
study	O
the	O
expression	O
stability	O
and	O
expression	O
level	O
of	O
nine	O
potential	O
reference	O
genes	O
have	O
been	O
compared	O
in	O
17	O
different	O
pig	O
tissues	O
.	O
This	O
has	O
enabled	O
us	O
to	O
assess	O
the	O
suitability	O
of	O
the	O
genes	O
for	O
normalisation	O
of	O
mRNA	O
across	O
several	O
tissues	O
leading	O
to	O
the	O
identification	O
of	O
the	O
best	O
reference	O
genes	O
for	O
studies	O
of	O
high	O
and	O
low	O
abundance	O
transcripts	O
","	O
respectively	O
.	O
The	O
suitable	O
reference	O
genes	O
from	O
this	O
study	O
can	O
be	O
used	O
for	O
normalisation	O
of	O
qPCR	O
data	O
in	O
several	O
tissues	O
.	O
Thus	O
","	O
the	O
study	O
gives	O
useful	O
information	O
of	O
importance	O
for	O
a	O
broad	O
range	O
of	O
different	O
functional	O
studies	O
.	O
Results	O
Candidate	O
reference	O
genes	O
Nine	O
housekeeping	O
genes	O
were	O
selected	O
from	O
commonly	O
used	O
reference	O
genes	O
[	O
5	O
-	O
7	O
].	O
Gene	O
symbols	O
","	O
their	O
full	O
names	O
","	O
functions	O
and	O
pig	O
EST	O
accession	O
numbers	O
are	O
listed	O
in	O
Table	O
1	O
.	O
Genes	O
with	O
different	O
functions	O
were	O
chosen	O
in	O
order	O
to	O
avoid	O
genes	O
belonging	O
to	O
the	O
same	O
biological	O
pathways	O
that	O
may	O
be	O
co	O
-	O
regulated	O
.	O
The	O
porcine	O
sequences	O
of	O
the	O
genes	O
were	O
obtained	O
by	O
fasta	O
search	O
with	O
the	O
human	O
cDNA	O
sequence	O
for	O
each	O
gene	O
against	O
a	O
porcine	O
EST	O
database	O
[	O
8	O
].	O
Selected	O
candidate	O
reference	O
genes	O
QPCR	O
efficiency	O
and	O
variability	O
Standard	O
curves	O
were	O
generated	O
using	O
relative	O
concentration	O
vs	O
.	O
the	O
threshold	O
cycle	O
(	O
Ct	O
).	O
The	O
linear	O
correlation	O
coefficient	O
(	O
R2	O
)	O
of	O
all	O
the	O
nine	O
genes	O
ranged	O
from	O
0	O
.	O
998	O
to	O
1	O
.	O
0	O
.	O
Based	O
on	O
the	O
slopes	O
of	O
the	O
standard	O
curves	O
","	O
the	O
amplification	O
efficiencies	O
of	O
the	O
standards	O
ranged	O
from	O
93	O
%~	O
103	O
"%,"	O
(	O
derived	O
from	O
the	O
formula	O
E	O
=	O
10	O
1	O
/-	O
slope	O
-	O
1	O
).	O
This	O
calculation	O
method	O
results	O
in	O
efficiencies	O
higher	O
than	O
100	O
%	O
which	O
is	O
an	O
overestimate	O
of	O
the	O
real	O
efficiency	O
[	O
9	O
].	O
The	O
not	O
normalised	O
Ct	O
values	O
of	O
all	O
the	O
nine	O
genes	O
in	O
all	O
the	O
samples	O
were	O
within	O
13	O
.	O
5	O
to	O
30	O
.	O
5	O
cycles	O
","	O
covered	O
by	O
the	O
range	O
of	O
the	O
standard	O
curves	O
.	O
Expression	O
level	O
and	O
stability	O
of	O
putative	O
reference	O
genes	O
in	O
various	O
tissues	O
The	O
range	O
of	O
expression	O
stability	O
calculated	O
by	O
geNorm	O
[	O
6	O
]	O
in	O
the	O
genes	O
analysed	O
was	O
(	O
from	O
the	O
most	O
stable	O
to	O
the	O
least	O
stable	O
):	O
ACTB	O
/	O
RPL4	O
","	O
TBP	O
","	O
HPRT1	O
","	O
HMBS	O
","	O
YWHAZ	O
","	O
SDHA	O
","	O
B2M	O
and	O
GAPDH	O
(	O
Figure	O
1	O
).	O
The	O
M	O
values	O
for	O
ACTB	O
","	O
RPL4	O
","	O
TBP	O
","	O
HPRT1	O
","	O
HMBS	O
","	O
YWHAZ	O
and	O
SDHA	O
were	O
lower	O
than	O
1	O
.	O
5	O
","	O
and	O
therefore	O
it	O
was	O
concluded	O
that	O
these	O
genes	O
have	O
comparable	O
stability	O
in	O
different	O
pig	O
tissues	O
.	O
For	O
calculation	O
of	O
normalization	O
factor	O
(	O
NF	O
)	O
geNorm	O
suggested	O
the	O
five	O
most	O
stable	O
reference	O
genes	O
.	O
The	O
NF	O
was	O
calculated	O
based	O
on	O
the	O
geometric	O
mean	O
of	O
the	O
Ct	O
values	O
.	O
Normalised	O
Ct	O
values	O
are	O
shown	O
in	O
Table	O
2	O
.	O
After	O
normalization	O
against	O
the	O
NF	O
","	O
the	O
ranking	O
of	O
the	O
relative	O
expression	O
levels	O
was	O
(	O
from	O
high	O
to	O
low	O
):	O
B2M	O
","	O
RPL4	O
","	O
ACTB	O
","	O
GAPDH	O
","	O
YWHAZ	O
","	O
SDHA	O
","	O
HPRT1	O
","	O
TBP	O
and	O
HMBS	O
(	O
Figure	O
2	O
).	O
Furthermore	O
","	O
HMBS	O
","	O
and	O
GAPDH	O
showed	O
tissue	O
-	O
specific	O
regulation	O
","	O
i	O
.	O
e	O
.	O
HMBS	O
is	O
clearly	O
up	O
-	O
regulated	O
in	O
bone	O
marrow	O
and	O
GAPDH	O
is	O
clearly	O
up	O
-	O
regulated	O
in	O
muscle	O
tissue	O
.	O
Gene	O
expression	O
stability	O
of	O
candidate	O
reference	O
genes	O
.	O
Gene	O
expression	O
stability	O
of	O
candidate	O
reference	O
genes	O
in	O
different	O
pig	O
tissues	O
analyzed	O
by	O
the	O
geNorm	O
program	O
.	O
Threshold	O
for	O
eliminating	O
a	O
gene	O
as	O
unstable	O
was	O
M	O
â‰¥	O
1	O
.	O
5	O
.	O
The	O
respective	O
genes	O
and	O
gene	O
names	O
are	O
:	O
beta	O
-	O
actin	O
(	O
ACTB	O
"),"	O
beta	O
-	O
2	O
-	O
microglobulin	O
(	O
B2M	O
"),"	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
"),"	O
hydroxymethylbilane	O
synthase	O
(	O
HMBS	O
"),"	O
ribosomal	O
protein	O
L4	O
(	O
RPL4	O
"),"	O
succinate	O
dehydrogenase	O
complex	O
subunit	O
A	O
(	O
SDHA	O
"),"	O
TATA	O
box	O
binding	O
protein	O
(	O
TPB	O
)	O
and	O
tyrosine	O
3	O
-	O
monooxygenase	O
/	O
tryptophan	O
5	O
-	O
monooxygenase	O
activation	O
protein	O
zeta	O
polypeptide	O
(	O
YWHAZ	O
).	O
The	O
relative	O
expression	O
level	O
of	O
the	O
reference	O
candidate	O
genes	O
in	O
pig	O
tissues	O
.	O
The	O
relative	O
expression	O
level	O
of	O
the	O
reference	O
candidate	O
genes	O
in	O
pig	O
tissues	O
.	O
HMBS	O
was	O
the	O
lowest	O
expressed	O
gene	O
and	O
B2M	O
was	O
the	O
highest	O
expressed	O
gene	O
.	O
The	O
respective	O
genes	O
and	O
gene	O
names	O
are	O
:	O
beta	O
-	O
actin	O
(	O
ACTB	O
"),"	O
beta	O
-	O
2	O
-	O
microglobulin	O
(	O
B2M	O
"),"	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	O
"),"	O
hydroxymethylbilane	O
synthase	O
(	O
HMBS	O
"),"	O
ribosomal	O
protein	O
L4	O
(	O
RPL4	O
"),"	O
succinate	O
dehydrogenase	O
complex	O
subunit	O
A	O
(	O
SDHA	O
"),"	O
TATA	O
box	O
binding	O
protein	O
(	O
TPB	O
)	O
and	O
tyrosine	O
3	O
-	O
monooxygenase	O
/	O
tryptophan	O
5	O
-	O
monooxygenase	O
activation	O
protein	O
zeta	O
polypeptide	O
(	O
YWHAZ	O
).	O
RNA	O
transcription	O
levels	O
(	O
normalised	O
Ct	O
values	O
)	O
of	O
the	O
candidate	O
reference	O
genes	O
.	O
Values	O
in	O
parentheses	O
shows	O
the	O
ranking	O
of	O
genes	O
in	O
the	O
specific	O
tissue	O
calculated	O
by	O
GeNorm	O
.	O
Values	O
in	O
bold	O
have	O
an	O
M	O
-	O
value	O
above	O
1	O
.	O
5	O
.	O
Discussion	O
For	O
an	O
exact	O
comparison	O
of	O
mRNA	O
transcription	O
in	O
different	O
samples	O
or	O
tissues	O
it	O
is	O
crucial	O
to	O
choose	O
the	O
appropriate	O
reference	O
gene	O
.	O
The	O
optimal	O
reference	O
gene	O
should	O
be	O
constantly	O
transcribed	O
in	O
all	O
types	O
of	O
cells	O
at	O
any	O
time	O
in	O
cell	O
cycle	O
and	O
differentiation	O
.	O
Moreover	O
the	O
transcription	O
of	O
such	O
a	O
gene	O
should	O
not	O
be	O
regulated	O
by	O
internal	O
or	O
external	O
influences	O
","	O
at	O
least	O
not	O
more	O
than	O
the	O
general	O
variation	O
in	O
RNA	O
synthesis	O
.	O
The	O
reference	O
gene	O
used	O
for	O
normalisation	O
of	O
gene	O
expression	O
in	O
real	O
-	O
time	O
qPCR	O
studies	O
should	O
also	O
pass	O
through	O
the	O
same	O
steps	O
of	O
analysis	O
as	O
the	O
gene	O
to	O
be	O
quantified	O
.	O
However	O
","	O
such	O
a	O
perfect	O
reference	O
gene	O
does	O
probably	O
not	O
exist	O
.	O
The	O
stability	O
in	O
expression	O
of	O
often	O
used	O
reference	O
genes	O
such	O
as	O
GAPDH	O
and	O
ACTB	O
has	O
been	O
shown	O
to	O
vary	O
considerably	O
and	O
are	O
consequently	O
unsuitable	O
as	O
reference	O
genes	O
for	O
normalisation	O
of	O
gene	O
expression	O
analysis	O
in	O
some	O
cases	O
[	O
5	O
","	O
10	O
-	O
12	O
].	O
Also	O
the	O
low	O
expressed	O
reference	O
gene	O
TBP	O
is	O
highly	O
regulated	O
when	O
comparing	O
normal	O
and	O
tumour	O
tissues	O
[	O
13	O
].	O
Numerous	O
studies	O
have	O
been	O
carried	O
out	O
in	O
order	O
to	O
evaluate	O
reference	O
genes	O
in	O
specific	O
tissues	O
in	O
several	O
species	O
.	O
The	O
majority	O
of	O
these	O
studies	O
are	O
directed	O
towards	O
specific	O
tissues	O
[	O
1	O
","	O
3	O
","	O
7	O
","	O
14	O
].	O
They	O
clearly	O
demonstrate	O
that	O
it	O
is	O
very	O
difficult	O
to	O
find	O
a	O
'	O
universal	O
'	O
reference	O
gene	O
having	O
stable	O
expression	O
in	O
all	O
cell	O
types	O
and	O
tissues	O
","	O
and	O
in	O
particular	O
to	O
find	O
reference	O
genes	O
that	O
remain	O
stable	O
between	O
samples	O
taken	O
at	O
different	O
time	O
points	O
under	O
different	O
experimental	O
conditions	O
.	O
The	O
first	O
priority	O
","	O
however	O
","	O
is	O
to	O
identify	O
genes	O
with	O
stable	O
expression	O
preferably	O
across	O
cell	O
types	O
since	O
many	O
real	O
-	O
time	O
qPCR	O
studies	O
are	O
performed	O
on	O
cDNA	O
isolated	O
from	O
tissues	O
with	O
a	O
mixed	O
cell	O
population	O
.	O
There	O
have	O
been	O
limited	O
experiments	O
of	O
reference	O
gene	O
selection	O
for	O
use	O
in	O
other	O
livestock	O
and	O
production	O
animal	O
species	O
.	O
Bogaert	O
et	O
al	O
.	O
[	O
15	O
]	O
proposed	O
ubiquitin	O
(	O
UBB	O
"),"	O
ACTB	O
and	O
B2M	O
as	O
reference	O
genes	O
for	O
normalisation	O
of	O
qPCR	O
data	O
for	O
normal	O
equine	O
skin	O
.	O
In	O
cattle	O
studies	O
","	O
De	O
Ketelaere	O
et	O
al	O
.	O
[	O
16	O
]	O
selected	O
SDHA	O
","	O
YWHAZ	O
","	O
and	O
18S	O
rRNA	O
as	O
being	O
the	O
most	O
stable	O
genes	O
for	O
accurate	O
normalisation	O
of	O
qPCR	O
of	O
bovine	O
polymorphonuclear	O
leukocytes	O
and	O
Goossens	O
et	O
al	O
.	O
[	O
2	O
]	O
found	O
YWHAZ	O
","	O
GAPDH	O
and	O
SDHA	O
to	O
be	O
the	O
most	O
stable	O
reference	O
genes	O
across	O
different	O
preimplantation	O
embryonic	O
stages	O
.	O
Common	O
for	O
the	O
bovine	O
studies	O
are	O
the	O
target	O
of	O
the	O
studies	O
","	O
which	O
are	O
single	O
cell	O
populations	O
.	O
Garcia	O
-	O
Crespo	O
et	O
al	O
.	O
[	O
17	O
]	O
compared	O
expression	O
of	O
six	O
potential	O
reference	O
genes	O
in	O
sheep	O
tissues	O
and	O
found	O
GAPDH	O
with	O
the	O
lowest	O
variation	O
among	O
the	O
panel	O
of	O
six	O
tissues	O
","	O
whereas	O
ACTB	O
and	O
YWHAZ	O
showed	O
the	O
worst	O
score	O
in	O
variability	O
.	O
This	O
is	O
not	O
in	O
agreement	O
with	O
our	O
findings	O
but	O
can	O
be	O
a	O
result	O
of	O
the	O
tissue	O
composition	O
.	O
At	O
present	O
three	O
studies	O
have	O
examined	O
reference	O
genes	O
in	O
pig	O
i	O
.	O
e	O
.	O
Foss	O
et	O
al	O
.	O
[	O
18	O
]	O
describes	O
the	O
use	O
of	O
GAPDH	O
","	O
ACTB	O
and	O
HPRT	O
in	O
immune	O
cells	O
and	O
tissues	O
using	O
northern	O
blot	O
and	O
PCR	O
.	O
In	O
this	O
study	O
GAPDH	O
was	O
shown	O
to	O
be	O
more	O
stable	O
than	O
ACTB	O
.	O
Erkens	O
et	O
al	O
[	O
4	O
]	O
validated	O
mRNA	O
expression	O
stability	O
of	O
10	O
reference	O
genes	O
in	O
porcine	O
backfat	O
and	O
longissimus	O
dorsi	O
muscle	O
.	O
The	O
most	O
stable	O
reference	O
genes	O
suitable	O
for	O
normalisation	O
of	O
qPCR	O
data	O
of	O
backfat	O
and	O
longissimus	O
dorsi	O
muscle	O
in	O
the	O
pig	O
was	O
ACTB	O
","	O
TBP	O
and	O
TOP2B	O
.	O
Kuijk	O
et	O
al	O
.	O
[	O
19	O
]	O
investigated	O
transcription	O
levels	O
of	O
seven	O
frequently	O
used	O
reference	O
genes	O
(	O
inclusive	O
B2M	O
","	O
ACTB	O
","	O
GAPDH	O
)	O
at	O
different	O
stages	O
of	O
early	O
porcine	O
embryonic	O
development	O
.	O
Our	O
study	O
is	O
the	O
first	O
detailed	O
study	O
of	O
the	O
stability	O
and	O
level	O
of	O
pig	O
reference	O
genes	O
across	O
a	O
large	O
number	O
of	O
tissues	O
.	O
Our	O
findings	O
confirm	O
studies	O
demonstrating	O
tissue	O
specific	O
regulation	O
of	O
some	O
of	O
the	O
commonly	O
used	O
housekeeping	O
genes	O
.	O
Furthermore	O
","	O
it	O
provides	O
recommendations	O
for	O
choice	O
of	O
reference	O
genes	O
in	O
studies	O
where	O
high	O
and	O
low	O
abundant	O
transcripts	O
are	O
under	O
investigation	O
.	O
In	O
agreement	O
with	O
the	O
findings	O
of	O
Erkens	O
et	O
al	O
.	O
[	O
4	O
]	O
both	O
TBP	O
and	O
ACTB	O
are	O
suitable	O
reference	O
genes	O
.	O
However	O
","	O
our	O
data	O
show	O
that	O
ACTB	O
is	O
most	O
relevant	O
for	O
high	O
abundant	O
transcripts	O
","	O
while	O
TPB	O
is	O
most	O
relevant	O
for	O
low	O
abundant	O
transcripts	O
.	O
It	O
is	O
clear	O
from	O
both	O
Erkens	O
et	O
al	O
.	O
[	O
4	O
]	O
and	O
our	O
study	O
that	O
GAPDH	O
is	O
quite	O
unstable	O
and	O
not	O
suitable	O
as	O
a	O
reference	O
gene	O
.	O
Conclusion	O
Our	O
study	O
demonstrates	O
that	O
expression	O
stability	O
varies	O
greatly	O
between	O
genes	O
.	O
Seven	O
of	O
the	O
nine	O
genes	O
investigated	O
(	O
i	O
.	O
e	O
.	O
ACTB	O
","	O
RPL4	O
","	O
TBP	O
","	O
HPRT1	O
","	O
HMBS	O
","	O
YWHAZ	O
","	O
SDHA	O
)	O
were	O
found	O
to	O
have	O
a	O
high	O
stability	O
across	O
tissues	O
.	O
Two	O
of	O
the	O
genes	O
investigated	O
were	O
shown	O
to	O
have	O
tissue	O
-	O
specific	O
regulation	O
","	O
i	O
.	O
e	O
.	O
HMBS	O
is	O
clearly	O
up	O
-	O
regulated	O
in	O
bone	O
marrow	O
and	O
GAPDH	O
is	O
clearly	O
up	O
-	O
regulated	O
in	O
muscle	O
.	O
Based	O
on	O
both	O
expression	O
stability	O
and	O
expression	O
level	O
","	O
our	O
data	O
suggest	O
that	O
ACTB	O
and	O
RPL4	O
are	O
good	O
reference	O
genes	O
for	O
high	O
abundant	O
transcripts	O
while	O
TPB	O
and	O
HPRT1	O
are	O
good	O
reference	O
genes	O
for	O
low	O
abundant	O
transcripts	O
in	O
expression	O
studies	O
across	O
different	O
pig	O
tissues	O
.	O
Methods	O
Candidate	O
reference	O
genes	O
and	O
primer	O
design	O
Nine	O
housekeeping	O
genes	O
were	O
selected	O
from	O
commonly	O
used	O
reference	O
genes	O
[	O
5	O
-	O
7	O
].	O
The	O
porcine	O
sequences	O
of	O
the	O
genes	O
were	O
obtained	O
by	O
fasta	O
search	O
with	O
the	O
human	O
cDNA	O
sequence	O
for	O
each	O
gene	O
against	O
a	O
porcine	O
EST	O
database	O
[	O
8	O
].	O
The	O
consensus	O
sequences	O
were	O
used	O
for	O
comparison	O
with	O
genomic	O
porcine	O
sequences	O
","	O
if	O
available	O
","	O
to	O
reveal	O
the	O
exon	O
-	O
intron	O
structure	O
.	O
When	O
no	O
genomic	O
porcine	O
sequence	O
was	O
available	O
the	O
gene	O
structure	O
was	O
obtained	O
by	O
comparison	O
of	O
the	O
pig	O
sequence	O
with	O
human	O
and	O
mouse	O
genomic	O
sequence	O
assuming	O
that	O
the	O
exon	O
-	O
exon	O
boundaries	O
are	O
conserved	O
between	O
human	O
","	O
mouse	O
and	O
pig	O
.	O
All	O
the	O
primers	O
were	O
designed	O
by	O
Primer	O
3	O
software	O
[	O
20	O
].	O
For	O
information	O
on	O
primer	O
sequences	O
see	O
Table	O
3	O
.	O
Primers	O
spanning	O
at	O
least	O
one	O
intron	O
were	O
chosen	O
to	O
minimize	O
inaccuracies	O
due	O
to	O
genomic	O
DNA	O
contamination	O
.	O
If	O
the	O
genes	O
had	O
known	O
pseudogenes	O
","	O
primers	O
were	O
chosen	O
according	O
to	O
the	O
alignment	O
results	O
between	O
the	O
genes	O
and	O
the	O
pseudogenes	O
","	O
so	O
the	O
primers	O
were	O
unique	O
to	O
the	O
genes	O
and	O
different	O
from	O
the	O
pseudogenes	O
.	O
The	O
secondary	O
structure	O
of	O
the	O
amplicons	O
was	O
analyzed	O
by	O
Mfold	O
using	O
the	O
criteria	O
-	O
3	O
<	O
dG	O
<	O
0	O
[	O
21	O
]	O
to	O
optimize	O
the	O
PCR	O
efficiency	O
.	O
Primers	O
and	O
amplicons	O
were	O
in	O
silico	O
verified	O
with	O
BLASTN	O
for	O
specificity	O
and	O
the	O
size	O
of	O
the	O
PCR	O
products	O
was	O
confirmed	O
with	O
gel	O
electrophoresis	O
.	O
Primers	O
","	O
PCR	O
conditions	O
and	O
qPCR	O
efficiency	O
RNA	O
extraction	O
Seventeen	O
different	O
porcine	O
tissues	O
were	O
collected	O
from	O
three	O
young	O
female	O
siblings	O
.	O
Total	O
RNA	O
was	O
extracted	O
using	O
different	O
protocols	O
depending	O
of	O
the	O
tissue	O
:	O
TRIreagent	O
Â®	O
(	O
Molecular	O
Research	O
Centre	O
","	O
inc	O
.)	O
for	O
liver	O
","	O
kidney	O
","	O
thymus	O
","	O
RNeasy	O
lipid	O
kit	O
(	O
Qiagen	O
)	O
for	O
adipose	O
(	O
subcutaneous	O
"),"	O
cortex	O
cerebri	O
","	O
cerebellum	O
","	O
hippocampus	O
","	O
lymph	O
nodules	O
(	O
jejunal	O
"),"	O
RNeasy	O
Fibrous	O
Kit	O
(	O
Qiagen	O
)	O
for	O
muscle	O
(	O
longissimus	O
dorsi	O
"),"	O
heart	O
(	O
muscle	O
"),"	O
skin	O
(	O
dermis	O
and	O
epidermis	O
)	O
and	O
RNeasy	O
kit	O
(	O
Qiagen	O
)	O
for	O
pancreas	O
","	O
bone	O
marrow	O
","	O
bladder	O
","	O
lung	O
","	O
stomach	O
(	O
mucosal	O
membranes	O
"),"	O
small	O
intestine	O
(	O
mucosal	O
membranes	O
)	O
according	O
to	O
each	O
manufacturer	O
protocol	O
.	O
Contaminating	O
DNA	O
was	O
degraded	O
by	O
treating	O
each	O
sample	O
with	O
RQ1	O
RNase	O
-	O
free	O
DNase	O
(	O
Promega	O
)	O
according	O
to	O
the	O
instructions	O
manual	O
","	O
followed	O
by	O
a	O
spin	O
-	O
column	O
purification	O
(	O
Qiagen	O
RNeasy	O
).	O
The	O
total	O
RNA	O
was	O
quantified	O
by	O
optical	O
density	O
and	O
the	O
quality	O
was	O
evaluated	O
by	O
gel	O
electrophoresis	O
.	O
Intact	O
rRNA	O
subunit	O
of	O
28S	O
and	O
18S	O
were	O
observed	O
on	O
the	O
gel	O
indicating	O
minimal	O
degradation	O
of	O
the	O
RNA	O
.	O
cDNA	O
synthesis	O
One	O
Î¼g	O
of	O
total	O
RNA	O
was	O
reverse	O
transcribed	O
at	O
42	O
Â°	O
C	O
using	O
Improm	O
-	O
II	O
â„¢	O
reverse	O
trancriptase	O
(	O
Promega	O
)	O
and	O
Oligo	O
(	O
dT	O
)	O
according	O
to	O
the	O
manufacturers	O
recommendations	O
.	O
Prior	O
to	O
use	O
in	O
qPCR	O
cDNA	O
was	O
diluted	O
1	O
:	O
8	O
with	O
H2O	B-Chemical
.	O
Quantitative	O
PCR	O
with	O
SYBR	B-Chemical
green	I-Chemical
For	O
each	O
transcript	O
a	O
standard	O
curve	O
was	O
constructed	O
using	O
the	O
purified	O
PCR	O
product	O
generated	O
for	O
each	O
specific	O
primer	O
pair	O
.	O
Single	O
reactions	O
were	O
prepared	O
for	O
each	O
cDNA	O
along	O
with	O
each	O
serial	O
of	O
dilution	O
using	O
the	O
Brilliant	O
Â®	O
SYBR	B-Chemical
Â®	I-Chemical
Green	I-Chemical
Master	O
Mix	O
(	O
Stratagene	O
).	O
Each	O
PCR	O
reaction	O
also	O
included	O
a	O
reverse	O
transcription	O
negative	O
control	O
(	O
without	O
reverse	O
transcriptase	O
)	O
to	O
confirm	O
the	O
absence	O
of	O
genomic	O
DNA	O
","	O
a	O
non	O
template	O
negative	O
control	O
to	O
check	O
for	O
primer	O
-	O
dimer	O
and	O
a	O
porcine	O
genomic	O
DNA	O
control	O
to	O
verify	O
no	O
specific	O
amplification	O
with	O
the	O
primers	O
.	O
Each	O
reaction	O
consisted	O
of	O
20	O
Î¼l	O
containing	O
2	O
Î¼l	O
of	O
cDNA	O
and	O
5	O
pmol	O
of	O
each	O
primer	O
.	O
The	O
real	O
time	O
qPCR	O
was	O
run	O
on	O
MX3000p	O
(	O
Stratagene	O
).	O
The	O
cycling	O
conditions	O
were	O
1	O
cycle	O
of	O
denaturation	O
at	O
95	O
Â°	O
C	O
/	O
10	O
min	O
","	O
followed	O
by	O
40	O
three	O
-	O
segment	O
cycles	O
of	O
amplification	O
(	O
95	O
Â°	O
C	O
/	O
30	O
sec	O
","	O
58	O
Â°	O
C	O
â€“	O
63	O
Â°	O
C	O
(	O
gene	O
depending	O
","	O
see	O
table	O
2	O
)/	O
1	O
min	O
","	O
72	O
Â°	O
C	O
/	O
30	O
sec	O
)	O
where	O
the	O
fluorescence	O
was	O
automatically	O
measured	O
during	O
PCR	O
and	O
one	O
three	O
-	O
segment	O
cycle	O
of	O
product	O
melting	O
(	O
95	O
Â°	O
C	O
/	O
1	O
min	O
","	O
55	O
Â°	O
C	O
/	O
30	O
sec	O
","	O
95	O
Â°	O
C	O
/	O
30	O
sec	O
).	O
The	O
baseline	O
adjustment	O
method	O
of	O
the	O
Mx3000	O
(	O
Stratagene	O
)	O
software	O
was	O
used	O
to	O
determine	O
the	O
Ct	O
in	O
each	O
reaction	O
.	O
A	O
melting	O
curve	O
was	O
constructed	O
for	O
each	O
primer	O
pair	O
to	O
verify	O
the	O
presence	O
of	O
one	O
gene	O
-	O
specific	O
peak	O
and	O
the	O
absence	O
of	O
primer	O
dimmer	O
.	O
All	O
samples	O
were	O
amplified	O
in	O
duplicates	O
and	O
the	O
mean	O
was	O
used	O
for	O
further	O
analysis	O
.	O
Analysis	O
of	O
expression	O
stability	O
The	O
gene	O
expression	O
levels	O
were	O
measured	O
by	O
real	O
-	O
time	O
qPCR	O
","	O
and	O
the	O
expression	O
stabilities	O
were	O
evaluated	O
by	O
the	O
M	O
value	O
of	O
geNorm	O
[	O
6	O
].	O
The	O
M	O
value	O
for	O
each	O
reference	O
gene	O
is	O
the	O
average	O
pairwise	O
variation	O
for	O
that	O
gene	O
with	O
all	O
the	O
other	O
tested	O
control	O
genes	O
.	O
Stepwise	O
exclusion	O
of	O
the	O
gene	O
with	O
the	O
highest	O
M	O
value	O
allows	O
ranking	O
of	O
the	O
tested	O
genes	O
according	O
to	O
their	O
expression	O
stability	O
.	O
Authors	O
'	O
contributions	O
ABN	O
has	O
been	O
responsible	O
for	O
the	O
experimental	O
work	O
and	O
made	O
substantial	O
contributions	O
to	O
conception	O
and	O
design	O
of	O
the	O
study	O
.	O
Furthermore	O
","	O
she	O
has	O
been	O
involved	O
in	O
drafting	O
the	O
manuscript	O
.	O
CBJ	O
has	O
made	O
substantial	O
contributions	O
to	O
conception	O
and	O
design	O
of	O
the	O
study	O
and	O
been	O
involved	O
in	O
drafting	O
the	O
manuscript	O
and	O
revising	O
it	O
critically	O
for	O
important	O
intellectual	O
content	O
.	O
SC	O
has	O
made	O
substantial	O
contributions	O
to	O
the	O
experimental	O
work	O
and	O
been	O
involved	O
in	O
drafting	O
the	O
manuscript	O
and	O
revising	O
it	O
critically	O
for	O
important	O
intellectual	O
content	O
.	O
MF	O
has	O
made	O
substantial	O
contributions	O
to	O
conception	O
and	O
design	O
of	O
the	O
study	O
.	O
She	O
has	O
been	O
involved	O
in	O
drafting	O
the	O
manuscript	O
and	O
revising	O
it	O
critically	O
for	O
important	O
intellectual	O
content	O
","	O
and	O
given	O
final	O
approval	O
for	O
the	O
version	O
to	O
be	O
published	O
.	O
High	O
Genetic	O
Stability	O
of	O
Dengue	O
Virus	O
Propagated	O
in	O
MRC	O
-	O
5	O
Cells	O
as	O
Compared	O
to	O
the	O
Virus	O
Propagated	O
in	O
Vero	O
Cells	O
This	O
work	O
investigated	O
the	O
replication	O
kinetics	O
of	O
the	O
four	O
dengue	O
virus	O
serotypes	O
(	O
DEN	O
-	O
1	O
to	O
DEN	O
-	O
4	O
"),"	O
including	O
dengue	O
virus	O
type	O
4	O
(	O
DEN	O
-	O
4	O
)	O
recovered	O
from	O
an	O
infectious	O
cDNA	O
clone	O
","	O
in	O
Vero	O
cells	O
and	O
in	O
MRC	O
-	O
5	O
cells	O
grown	O
on	O
Cytodex	B-Chemical
1	I-Chemical
microcarriers	O
.	O
DEN	O
-	O
1	O
strain	O
Hawaii	O
","	O
DEN	O
-	O
2	O
strain	O
NGC	O
","	O
DEN	O
-	O
3	O
strain	O
H	O
-	O
87	O
","	O
and	O
DEN	O
-	O
4	O
strain	O
H	O
-	O
241	O
","	O
and	O
DEN	O
-	O
4	O
strain	O
814669	O
derived	O
from	O
cloned	O
DNA	O
","	O
were	O
used	O
to	O
infect	O
Vero	O
cells	O
and	O
MRC	O
-	O
5	O
cells	O
grown	O
in	O
serum	O
-	O
free	O
or	O
serum	O
-	O
containing	O
microcarrier	O
cultures	O
.	O
Serum	O
-	O
free	O
and	O
serum	O
-	O
containing	O
cultures	O
were	O
found	O
to	O
yield	O
comparable	O
titers	O
of	O
these	O
viruses	O
.	O
The	O
cloned	O
DNA	O
-	O
derived	O
DEN	O
-	O
4	O
started	O
genetically	O
more	O
homogeneous	O
was	O
used	O
to	O
investigate	O
the	O
genetic	O
stability	O
of	O
the	O
virus	O
propagated	O
in	O
Vero	O
cells	O
and	O
MRC	O
-	O
5	O
cells	O
.	O
Sequence	O
analysis	O
revealed	O
that	O
the	O
DEN	O
-	O
4	O
propagated	O
in	O
MRC	O
-	O
5	O
cells	O
maintained	O
a	O
high	O
genetic	O
stability	O
","	O
compared	O
to	O
the	O
virus	O
propagated	O
in	O
Vero	O
cells	O
.	O
Amino	B-Chemical
acid	I-Chemical
substitutions	O
of	O
Gly104Cys	B-Chemical
and	O
Phe108Ile	B-Chemical
were	O
detected	O
at	O
70	O
"%,"	O
60	O
"%,"	O
respectively	O
","	O
in	O
the	O
envelope	O
(	O
E	O
)	O
protein	O
of	O
DEN	O
-	O
4	O
propagated	O
in	O
Vero	O
cells	O
","	O
whereas	O
a	O
single	O
mutation	O
of	O
Glu345Lys	B-Chemical
was	O
detected	O
at	O
50	O
%	O
in	O
E	O
of	O
the	O
virus	O
propagated	O
in	O
MRC	O
-	O
5	O
cells	O
.	O
Sequencing	O
of	O
multiple	O
clones	O
of	O
three	O
separate	O
DNA	O
fragments	O
spanning	O
40	O
%	O
of	O
the	O
genome	O
also	O
indicated	O
that	O
DEN	O
-	O
4	O
propagated	O
in	O
Vero	O
cells	O
contained	O
a	O
higher	O
number	O
of	O
mutations	O
than	O
the	O
virus	O
growing	O
in	O
MRC	O
-	O
5	O
cells	O
.	O
Although	O
Vero	O
cells	O
yielded	O
a	O
peak	O
virus	O
titer	O
approximately	O
1	O
to	O
17	O
folds	O
higher	O
than	O
MRC	O
-	O
5	O
cells	O
","	O
cloned	O
DEN	O
-	O
4	O
from	O
MRC	O
-	O
5	O
cells	O
maintained	O
a	O
greater	O
stability	O
than	O
the	O
virus	O
from	O
Vero	O
cells	O
.	O
Serum	O
-	O
free	O
microcarrier	O
cultures	O
of	O
MRC	O
-	O
5	O
cells	O
offer	O
a	O
potentially	O
valuable	O
system	O
for	O
the	O
large	O
-	O
scale	O
production	O
of	O
live	O
-	O
attenuated	O
DEN	O
vaccines	O
.	O
Introduction	O
The	O
four	O
dengue	O
serotype	O
viruses	O
(	O
DEN	O
-	O
1	O
to	O
DEN	O
-	O
4	O
)	O
(	O
genus	O
flavivirus	O
","	O
family	O
Flaviviridae	O
)	O
are	O
single	O
stranded	O
","	O
positive	O
-	O
sense	O
RNA	O
viruses	O
that	O
are	O
transmitted	O
to	O
humans	O
primarily	O
by	O
Aedes	O
aegypti	O
mosquitoes	O
.	O
The	O
RNA	O
genome	O
contain	O
sequences	O
coding	O
for	O
three	O
structural	O
protein	O
genes	O
(	O
core	O
C	O
","	O
precursor	O
membrane	O
prM	O
","	O
and	O
envelope	O
E	O
"),"	O
seven	O
non	O
-	O
structural	O
protein	O
genes	O
(	O
NS1	O
","	O
NS2A	O
","	O
NS2B	O
","	O
NS3	O
","	O
NS4A	O
","	O
NS4B	O
","	O
NS5	O
"),"	O
and	O
the	O
flanking	O
non	O
-	O
translating	O
regions	O
.	O
DEN	O
infection	O
in	O
humans	O
causes	O
a	O
spectrum	O
of	O
illnesses	O
","	O
ranging	O
from	O
dengue	O
fever	O
(	O
DF	O
)	O
to	O
dengue	O
hemorrhagic	O
fever	O
(	O
DHF	O
)	O
and	O
dengue	O
shock	O
syndrome	O
(	O
DSS	O
)	O
.	O
Approximately	O
50	O
â€“	O
100	O
million	O
infections	O
","	O
including	O
250	O
","	O
0	O
cases	O
of	O
DHF	O
with	O
fatality	O
rates	O
varying	O
from	O
<	O
1	O
%	O
to	O
5	O
"%,"	O
occur	O
every	O
year	O
mostly	O
in	O
tropical	O
and	O
subtropical	O
areas	O
.	O
Dengue	O
is	O
endemic	O
in	O
South	O
-	O
east	O
Asia	O
","	O
where	O
the	O
severe	O
form	O
of	O
DHF	O
/	O
DSS	O
frequently	O
associated	O
with	O
secondary	O
DEN	O
infections	O
is	O
the	O
major	O
cause	O
of	O
hospitalization	O
of	O
young	O
children	O
.	O
A	O
safe	O
and	O
effective	O
dengue	O
vaccine	O
is	O
still	O
not	O
available	O
for	O
prevention	O
of	O
DEN	O
infection	O
.	O
The	O
current	O
DEN	O
immunization	O
strategy	O
favors	O
the	O
use	O
of	O
live	O
-	O
attenuated	O
vaccines	O
which	O
offer	O
the	O
advantage	O
of	O
a	O
single	O
dose	O
","	O
delivering	O
a	O
complete	O
set	O
of	O
protective	O
antigens	O
and	O
achieving	O
a	O
long	O
-	O
lasting	O
immunity	O
.	O
Further	O
","	O
the	O
use	O
of	O
a	O
tetravalent	O
DEN	O
vaccine	O
against	O
each	O
of	O
the	O
four	O
serotypes	O
would	O
have	O
the	O
possibility	O
to	O
minimize	O
the	O
risk	O
of	O
severe	O
dengue	O
.	O
Wild	O
type	O
DEN	O
-	O
1	O
","	O
DEN	O
-	O
2	O
","	O
DEN	O
-	O
3	O
","	O
DEN	O
-	O
4	O
strains	O
have	O
been	O
attenuated	O
by	O
serial	O
passage	O
in	O
primary	O
dog	O
kidney	O
cells	O
(	O
or	O
monkey	O
kidney	O
cells	O
)	O
â€“	O
and	O
final	O
vaccines	O
were	O
produced	O
in	O
fetal	O
rhesus	O
lung	O
cells	O
or	O
Vero	O
cells	O
â€“.	O
Extensive	O
clinical	O
trials	O
have	O
demonstrated	O
that	O
each	O
monovalent	O
DEN	O
vaccine	O
appeared	O
to	O
be	O
immunogenic	O
and	O
safe	O
â€“.	O
However	O
","	O
data	O
obtained	O
from	O
clinical	O
trials	O
with	O
a	O
tetravalent	O
vaccine	O
formulation	O
have	O
not	O
shown	O
the	O
predicted	O
response	O
","	O
as	O
immune	O
imbalance	O
or	O
reactogenicity	O
occurred	O
for	O
certain	O
DEN	O
serotypes	O
","	O
.	O
Several	O
other	O
vaccine	O
researchers	O
also	O
have	O
applied	O
the	O
cDNA	O
cloning	O
added	O
by	O
chimeric	O
virus	O
technology	O
and	O
strategic	O
modifications	O
to	O
generate	O
viruses	O
with	O
the	O
growth	O
restriction	O
phenotype	O
in	O
the	O
genetic	O
background	O
of	O
attenuated	O
virus	O
(	O
for	O
example	O
","	O
using	O
DEN	O
-	O
4	O
with	O
a	O
deletion	O
in	O
3	O
â€²	O
NTR	O
","	O
attenuated	O
17D	O
yellow	O
fever	O
vaccine	O
or	O
DEN	O
-	O
2	O
strain	O
PDK	O
-	O
53	O
)	O
â€“.	O
All	O
of	O
these	O
cDNA	O
-	O
derived	O
candidate	O
DEN	O
vaccines	O
have	O
been	O
produced	O
in	O
Vero	O
cells	O
","	O
recently	O
certified	O
for	O
vaccine	O
production	O
.	O
Although	O
clinical	O
trails	O
with	O
a	O
few	O
of	O
these	O
monotypic	O
chimeric	O
vaccines	O
appeared	O
to	O
show	O
desirable	O
immunogenicity	O
and	O
reactogenicity	O
","	O
data	O
from	O
studies	O
with	O
such	O
vaccines	O
of	O
other	O
serotypes	O
or	O
a	O
tetravalent	O
vaccine	O
formulation	O
are	O
still	O
not	O
available	O
.	O
Potential	O
replication	O
interference	O
among	O
the	O
four	O
serotype	O
vaccine	O
components	O
that	O
results	O
in	O
immune	O
imbalance	O
remains	O
a	O
concern	O
.	O
Replication	O
interference	O
could	O
result	O
from	O
loss	O
or	O
increase	O
of	O
infectivity	O
due	O
to	O
genetic	O
instability	O
and	O
accumulation	O
of	O
mutations	O
in	O
certain	O
vaccine	O
components	O
.	O
Passages	O
of	O
DEN	O
viruses	O
or	O
their	O
derived	O
chimeras	O
in	O
Vero	O
cells	O
","	O
have	O
been	O
shown	O
to	O
generate	O
mutations	O
specific	O
for	O
host	O
cell	O
adaptation	O
","	O
virus	O
attenuation	O
","	O
or	O
other	O
properties	O
yet	O
to	O
be	O
characterized	O
.	O
Recently	O
","	O
spot	O
-	O
check	O
sequencing	O
in	O
the	O
manufacturing	O
of	O
chimeric	O
DEN	O
-	O
2	O
PDK	O
-	O
53	O
vaccine	O
components	O
has	O
detected	O
loss	O
of	O
attenuating	O
mutation	O
markers	O
in	O
a	O
number	O
of	O
seed	O
stocks	O
during	O
first	O
several	O
passages	O
in	O
Vero	O
cells	O
and	O
these	O
vaccine	O
seeds	O
were	O
not	O
appropriate	O
for	O
use	O
.	O
It	O
is	O
also	O
possible	O
that	O
passage	O
of	O
virus	O
in	O
certain	O
cells	O
produces	O
host	O
-	O
cell	O
specific	O
mutations	O
which	O
could	O
contribute	O
to	O
host	O
cells	O
'	O
innate	O
immunity	O
response	O
in	O
the	O
vaccinees	O
.	O
The	O
use	O
of	O
appropriate	O
cell	O
substrates	O
and	O
methods	O
for	O
culturing	O
these	O
cells	O
for	O
production	O
of	O
vaccines	O
represents	O
a	O
critical	O
factor	O
affecting	O
the	O
maximum	O
viral	O
yield	O
","	O
genetic	O
stability	O
","	O
immunogenicity	O
","	O
and	O
ultimately	O
vaccine	O
safety	O
and	O
economic	O
feasibility	O
.	O
Recently	O
","	O
a	O
serum	O
-	O
free	O
medium	O
has	O
been	O
developed	O
to	O
support	O
the	O
growth	O
of	O
Vero	O
cells	O
on	O
solid	O
microcarriers	O
and	O
produce	O
a	O
high	O
final	O
yield	O
for	O
reovirus	O
","	O
Japanese	O
encephalitis	O
virus	O
","	O
and	O
enterovirus	O
type	O
71	O
","	O
.	O
Although	O
an	O
attempt	O
has	O
not	O
been	O
made	O
for	O
producing	O
DEN	O
vaccines	O
","	O
human	O
diploid	O
MRC	O
-	O
5	O
cells	O
have	O
been	O
already	O
used	O
for	O
the	O
production	O
of	O
several	O
live	O
-	O
virus	O
vaccines	O
such	O
as	O
oral	O
polio	O
","	O
rubella	O
","	O
small	O
pox	O
","	O
and	O
varicella	O
zoster	O
.	O
This	O
study	O
investigated	O
Vero	O
cells	O
and	O
MRC	O
-	O
5	O
cells	O
for	O
the	O
production	O
of	O
the	O
four	O
wild	O
type	O
DEN	O
serotypes	O
","	O
including	O
DEN	O
-	O
4	O
derived	O
from	O
an	O
infectious	O
DNA	O
clone	O
.	O
We	O
focused	O
on	O
the	O
processes	O
of	O
cell	O
culture	O
using	O
microcarrier	O
systems	O
which	O
can	O
be	O
adapted	O
for	O
large	O
-	O
scale	O
production	O
and	O
serum	O
-	O
free	O
medium	O
to	O
avoid	O
potential	O
contamination	O
from	O
bovine	O
serum	O
.	O
Currently	O
","	O
several	O
panels	O
of	O
tetravalent	O
DEN	O
vaccine	O
candidates	O
have	O
been	O
derived	O
from	O
viruses	O
of	O
diverse	O
genetic	O
background	O
responsible	O
for	O
growth	O
restriction	O
","	O
.	O
In	O
order	O
to	O
simplify	O
interpretation	O
of	O
results	O
","	O
cloned	O
DNA	O
derived	O
wild	O
type	O
DEN	O
-	O
4	O
was	O
used	O
for	O
comparison	O
of	O
progeny	O
genetic	O
stabilities	O
from	O
passages	O
of	O
the	O
virus	O
in	O
Vero	O
cells	O
and	O
in	O
MRC	O
-	O
5	O
cells	O
.	O
This	O
strategy	O
using	O
cloned	O
DNA	O
-	O
derived	O
wild	O
type	O
rather	O
than	O
attenuated	O
DEN	O
-	O
4	O
has	O
been	O
previously	O
used	O
to	O
investigate	O
the	O
genetic	O
mutations	O
of	O
chimeric	O
DEN	O
-	O
4	O
after	O
Vero	O
cell	O
adaptation	O
.	O
Our	O
present	O
studies	O
show	O
that	O
Vero	O
cells	O
yielded	O
a	O
peak	O
virus	O
titer	O
approximately	O
1	O
to	O
17	O
folds	O
higher	O
than	O
MRC	O
-	O
5	O
cells	O
","	O
and	O
DEN	O
-	O
4	O
propagated	O
in	O
MRC	O
-	O
5	O
cells	O
maintained	O
a	O
greater	O
stability	O
than	O
the	O
virus	O
propagated	O
in	O
Vero	O
cells	O
.	O
Serum	O
-	O
free	O
microcarrier	O
cultures	O
of	O
MRC	O
-	O
5	O
cells	O
offer	O
a	O
potentially	O
valuable	O
system	O
for	O
the	O
large	O
-	O
scale	O
production	O
of	O
live	O
-	O
attenuated	O
DEN	O
vaccine	O
.	O
Results	O
Microcarrier	O
cultures	O
of	O
Vero	O
cells	O
and	O
MRC	O
-	O
5	O
cells	O
grown	O
in	O
serum	O
-	O
free	O
and	O
serum	O
-	O
containing	O
media	O
Solid	O
microcarriers	O
(	O
Cytodex	B-Chemical
1	I-Chemical
)	O
have	O
been	O
shown	O
to	O
support	O
the	O
growth	O
of	O
Vero	O
cells	O
in	O
either	O
serum	O
-	O
containing	O
or	O
serum	O
-	O
free	O
medium	O
â€“.	O
To	O
investigate	O
whether	O
microcarriers	O
also	O
support	O
the	O
growth	O
of	O
MRC	O
-	O
5	O
cells	O
","	O
MRC	O
-	O
5	O
cells	O
were	O
seeded	O
at	O
an	O
initial	O
density	O
of	O
3	O
Ã—	O
105	O
cell	O
/	O
ml	O
in	O
serum	O
-	O
containing	O
medium	O
or	O
6	O
Ã—	O
105	O
cells	O
/	O
ml	O
in	O
serum	O
-	O
free	O
medium	O
on	O
microcarriers	O
.	O
Vero	O
cells	O
were	O
also	O
seeded	O
at	O
same	O
density	O
in	O
the	O
respective	O
medium	O
as	O
a	O
control	O
.	O
Three	O
days	O
after	O
incubation	O
","	O
both	O
the	O
Vero	O
cells	O
and	O
MRC	O
-	O
5	O
cells	O
adhered	O
to	O
the	O
entire	O
surface	O
of	O
the	O
microcarrier	O
beads	O
","	O
reaching	O
confluency	O
as	O
seen	O
microscopically	O
(	O
Fig	O
.	O
1	O
).	O
The	O
cell	O
density	O
was	O
determined	O
at	O
1	O
.	O
6	O
Ã—	O
106	O
cells	O
/	O
ml	O
in	O
serum	O
-	O
free	O
medium	O
or	O
1	O
.	O
4	O
Ã—	O
106	O
cells	O
/	O
ml	O
in	O
serum	O
-	O
containing	O
medium	O
for	O
MRC	O
-	O
5	O
cells	O
","	O
compared	O
to	O
1	O
.	O
7	O
Ã—	O
106	O
cells	O
/	O
ml	O
in	O
serum	O
-	O
containing	O
medium	O
or	O
1	O
.	O
8	O
Ã—	O
106	O
cells	O
/	O
ml	O
in	O
serum	O
-	O
free	O
medium	O
for	O
Vero	O
cells	O
.	O
Doubling	O
the	O
cell	O
density	O
in	O
serum	O
-	O
free	O
culture	O
was	O
needed	O
to	O
support	O
the	O
cell	O
growth	O
on	O
microcarriers	O
.	O
Increased	O
cell	O
seed	O
lot	O
consumption	O
in	O
serum	O
-	O
free	O
cultures	O
is	O
a	O
continuing	O
problem	O
in	O
vaccine	O
manufacturing	O
processes	O
","	O
particularly	O
in	O
large	O
-	O
scale	O
microcarrier	O
cultures	O
.	O
We	O
are	O
currently	O
optimizing	O
additional	O
components	O
in	O
the	O
M	O
-	O
VSFM	O
medium	O
to	O
reduce	O
the	O
cell	O
density	O
for	O
initial	O
inoculation	O
in	O
serum	O
-	O
free	O
microcarrier	O
cultures	O
(	O
data	O
not	O
shown	O
).	O
Vero	O
and	O
MRC	O
-	O
5	O
cell	O
growth	O
on	O
Cytodex	B-Chemical
1	I-Chemical
microcarriers	O
in	O
serum	O
-	O
free	O
cultures	O
.	O
Microscopic	O
observation	O
shows	O
(	O
A	O
)	O
Vero	O
and	O
(	O
B	O
)	O
MRC	O
-	O
5	O
cells	O
on	O
microcarriers	O
in	O
M	O
-	O
VSFM	O
after	O
3	O
days	O
culture	O
.	O
Production	O
of	O
DEN	O
-	O
1	O
","	O
DEN	O
-	O
2	O
","	O
DEN	O
-	O
3	O
and	O
DEN	O
-	O
4	O
in	O
infected	O
Vero	O
cells	O
and	O
MRC	O
-	O
5	O
cells	O
Production	O
of	O
DEN	O
-	O
1	O
strain	O
Hawaii	O
","	O
DEN	O
-	O
2	O
strain	O
NGC	O
","	O
DEN	O
-	O
3	O
strain	O
H	O
-	O
87	O
and	O
DEN	O
-	O
4	O
strain	O
H	O
-	O
241	O
in	O
Vero	O
cells	O
and	O
in	O
MRC	O
-	O
5	O
cells	O
grown	O
in	O
serum	O
-	O
containing	O
and	O
serum	O
-	O
free	O
media	O
was	O
studied	O
.	O
Figs	O
.	O
S2	O
","	O
S3	O
","	O
S4	O
and	O
S5	O
show	O
the	O
cell	O
growth	O
and	O
virus	O
replication	O
curves	O
at	O
a	O
multiplicity	O
of	O
infection	O
(	O
MOI	O
)	O
of	O
0	O
.	O
1	O
in	O
serum	O
-	O
free	O
and	O
serum	O
-	O
containing	O
media	O
.	O
In	O
each	O
case	O
the	O
cell	O
density	O
decreased	O
gradually	O
during	O
the	O
10	O
-	O
day	O
period	O
following	O
virus	O
infection	O
","	O
and	O
no	O
appreciable	O
differences	O
were	O
observed	O
between	O
cells	O
growing	O
in	O
serum	O
-	O
free	O
medium	O
and	O
in	O
serum	O
-	O
containing	O
cultures	O
.	O
The	O
virus	O
yields	O
from	O
Vero	O
cells	O
was	O
1	O
to	O
17	O
folds	O
higher	O
than	O
that	O
from	O
MRC	O
-	O
5	O
cells	O
for	O
each	O
serotype	O
virus	O
(	O
Table	O
1	O
"),"	O
whether	O
in	O
serum	O
-	O
containing	O
or	O
serum	O
-	O
free	O
medium	O
.	O
Compared	O
to	O
DEN	O
-	O
2	O
NGC	O
","	O
DEN	O
-	O
3	O
H87	O
and	O
DEN	O
-	O
4	O
H241	O
produced	O
a	O
103	O
-	O
to	O
104	O
-	O
fold	O
lower	O
viral	O
yield	O
from	O
Vero	O
cells	O
or	O
a	O
102	O
-	O
to	O
103	O
-	O
fold	O
lower	O
yield	O
from	O
MRC	O
-	O
5	O
cells	O
in	O
serum	O
-	O
containing	O
medium	O
.	O
The	O
serotype	O
difference	O
was	O
probably	O
not	O
responsible	O
for	O
the	O
low	O
viral	O
yields	O
","	O
as	O
the	O
DEN	O
-	O
4	O
strain	O
derived	O
from	O
cDNA	O
replicated	O
as	O
efficiently	O
as	O
DEN	O
-	O
2	O
.	O
A	O
plausible	O
reason	O
for	O
the	O
unexpected	O
low	O
yields	O
is	O
that	O
these	O
viruses	O
have	O
acquired	O
mutations	O
during	O
passages	O
in	O
cultured	O
cells	O
or	O
in	O
animals	O
.	O
This	O
probability	O
was	O
supported	O
from	O
the	O
analysis	O
of	O
viral	O
yields	O
in	O
similar	O
infections	O
with	O
the	O
wild	O
type	O
DEN	O
-	O
4	O
derived	O
from	O
a	O
cDNA	O
clone	O
(	O
see	O
next	O
section	O
).	O
Importantly	O
","	O
higher	O
viral	O
yields	O
from	O
Vero	O
cells	O
or	O
MRC	O
-	O
5	O
cells	O
were	O
consistently	O
observed	O
at	O
0	O
.	O
3	O
-	O
to	O
2	O
.	O
6	O
-	O
fold	O
higher	O
for	O
the	O
four	O
DEN	O
serotypes	O
in	O
serum	O
-	O
free	O
medium	O
than	O
in	O
serum	O
-	O
containing	O
media	O
.	O
The	O
maximum	O
virus	O
titers	O
for	O
four	O
-	O
serotype	O
DEN	O
virus	O
strains	O
and	O
the	O
cloned	O
DNA	O
-	O
derived	O
DEN	O
-	O
4	O
viruses	O
in	O
Vero	O
cells	O
and	O
MRC	O
-	O
5	O
cells	O
on	O
microcarriers	O
","	O
in	O
serum	O
-	O
containing	O
and	O
serum	O
-	O
free	O
media	O
.	O
Propagation	O
of	O
cloned	O
DNA	O
-	O
derived	O
DEN	O
-	O
4	O
in	O
Vero	O
cells	O
and	O
MRC	O
-	O
5	O
cells	O
and	O
sequence	O
analysis	O
of	O
progeny	O
DEN	O
-	O
4	O
DEN	O
-	O
4	O
strain	O
814669	O
recovered	O
from	O
cloned	O
DNA	O
was	O
propagated	O
in	O
microcarrier	O
cultures	O
of	O
both	O
cell	O
lines	O
.	O
Infection	O
with	O
the	O
virus	O
was	O
carried	O
out	O
at	O
the	O
same	O
multiplicity	O
as	O
described	O
earlier	O
.	O
The	O
density	O
of	O
Vero	O
cells	O
or	O
MRC	O
-	O
5	O
cells	O
decreased	O
steadily	O
during	O
the	O
subsequent	O
10	O
-	O
day	O
period	O
","	O
indicating	O
that	O
both	O
cells	O
were	O
readily	O
infected	O
(	O
Fig	O
.	O
S5	O
).	O
The	O
viral	O
yields	O
of	O
cloned	O
DNA	O
derived	O
DEN	O
-	O
4	O
in	O
microcarrier	O
cultures	O
of	O
both	O
cells	O
were	O
comparable	O
to	O
that	O
observed	O
for	O
DEN	O
-	O
2	O
NGC	O
.	O
There	O
were	O
appreciable	O
differences	O
in	O
the	O
viral	O
yields	O
between	O
cell	O
cultures	O
in	O
serum	O
-	O
containing	O
or	O
serum	O
-	O
free	O
medium	O
(	O
Table	O
1	O
).	O
Vero	O
cells	O
produced	O
a	O
virus	O
titer	O
of	O
cloned	O
DEN	O
-	O
4	O
increased	O
by	O
11	O
folds	O
(	O
serum	O
-	O
free	O
medium	O
)	O
and	O
14	O
folds	O
(	O
serum	O
-	O
containing	O
medium	O
)	O
as	O
compared	O
to	O
MRC	O
-	O
5	O
cells	O
.	O
DEN	O
-	O
4	O
derived	O
from	O
cloned	O
DNA	O
was	O
propagated	O
in	O
the	O
microcarrier	O
cultures	O
of	O
Vero	O
cells	O
or	O
MRC	O
-	O
5	O
cells	O
in	O
serum	O
-	O
free	O
or	O
serum	O
-	O
containing	O
medium	O
for	O
4	O
days	O
.	O
The	O
nucleotide	B-Chemical
sequence	O
of	O
progeny	O
DEN	O
-	O
4	O
was	O
determined	O
from	O
a	O
single	O
cDNA	O
clone	O
representing	O
each	O
of	O
the	O
four	O
overlapping	O
regions	O
","	O
designated	O
as	O
W01	O
/	O
W02R	O
","	O
W03	O
/	O
W04R	O
","	O
W05	O
/	O
W06R	O
","	O
W07	O
/	O
W08R	O
","	O
spanning	O
the	O
entire	O
DEN	O
genome	O
.	O
Each	O
progeny	O
DEN	O
-	O
4	O
sequence	O
was	O
compared	O
with	O
the	O
parent	O
DEN	O
-	O
4	O
DNA	O
sequence	O
(	O
GenBank	O
accession	O
number	O
:	O
AF375822	O
).	O
The	O
results	O
in	O
Table	O
2	O
revealed	O
that	O
there	O
were	O
18	O
nucleotide	B-Chemical
mutations	O
resulting	O
in	O
13	O
amino	B-Chemical
acid	I-Chemical
changes	O
in	O
DEN	O
-	O
4	O
propagated	O
in	O
Vero	O
cells	O
using	O
serum	O
-	O
containing	O
medium	O
","	O
and	O
11	O
nucleotide	B-Chemical
mutations	O
resulting	O
in	O
6	O
amino	B-Chemical
acid	I-Chemical
changes	O
in	O
DEN	O
-	O
4	O
propagated	O
in	O
Vero	O
cells	O
grown	O
in	O
serum	O
-	O
free	O
medium	O
.	O
In	O
contrast	O
","	O
there	O
was	O
only	O
one	O
nucleotide	B-Chemical
mutation	O
resulting	O
in	O
one	O
amino	B-Chemical
acid	I-Chemical
change	O
in	O
each	O
DEN	O
-	O
4	O
propagated	O
in	O
MRC	O
-	O
5	O
cells	O
grown	O
in	O
serum	O
-	O
containing	O
medium	O
or	O
in	O
serum	O
-	O
free	O
medium	O
.	O
None	O
of	O
the	O
amino	B-Chemical
acid	I-Chemical
changes	O
was	O
identical	O
between	O
the	O
DEN	O
-	O
4	O
propagated	O
in	O
Vero	O
cells	O
grown	O
in	O
serum	O
â€“	O
containing	O
medium	O
or	O
in	O
serum	O
-	O
free	O
medium	O
.	O
Further	O
","	O
these	O
amino	B-Chemical
acid	I-Chemical
changes	O
in	O
DEN	O
-	O
4	O
occurred	O
in	O
nearly	O
all	O
gene	O
segments	O
and	O
the	O
number	O
of	O
mutations	O
","	O
ie	O
".,"	O
a	O
total	O
of	O
6	O
each	O
in	O
NS3	O
and	O
in	O
NS4B	O
-	O
NS5	O
","	O
appeared	O
to	O
reflect	O
the	O
large	O
size	O
of	O
the	O
gene	O
segments	O
.	O
This	O
suggests	O
that	O
a	O
host	O
range	O
selection	O
of	O
mutations	O
was	O
probably	O
not	O
involved	O
.	O
By	O
comparison	O
","	O
there	O
was	O
only	O
one	O
amino	B-Chemical
acid	I-Chemical
change	O
in	O
the	O
entire	O
genome	O
of	O
DEN	O
-	O
4	O
from	O
MRC	O
-	O
5	O
cells	O
whether	O
or	O
not	O
serum	O
was	O
present	O
in	O
the	O
medium	O
.	O
This	O
finding	O
indicates	O
that	O
a	O
greater	O
genomic	O
stability	O
of	O
cloned	O
DNA	O
-	O
derived	O
DEN	O
-	O
4	O
was	O
observed	O
when	O
the	O
virus	O
was	O
propagated	O
in	O
MRC	O
-	O
5	O
cells	O
","	O
compared	O
to	O
virus	O
propagated	O
in	O
Vero	O
cells	O
.	O
Genomic	O
sequences	O
of	O
the	O
cloned	O
DNA	O
-	O
derived	O
DEN	O
-	O
4	O
viruses	O
in	O
Vero	O
and	O
MRC	O
-	O
5	O
cells	O
on	O
microcarriers	O
","	O
in	O
serum	O
-	O
containing	O
and	O
serum	O
-	O
free	O
media	O
.	O
Sequences	O
of	O
multiple	O
clones	O
of	O
three	O
genomic	O
fragments	O
Since	O
the	O
previous	O
DEN	O
-	O
4	O
sequence	O
determination	O
was	O
made	O
from	O
one	O
DNA	O
clone	O
representing	O
each	O
of	O
the	O
four	O
genome	O
segments	O
","	O
to	O
further	O
investigate	O
the	O
genome	O
stability	O
of	O
DEN	O
-	O
4	O
during	O
passages	O
in	O
Vero	O
cells	O
and	O
in	O
MRC	O
-	O
5	O
cells	O
","	O
sequences	O
of	O
multiple	O
clones	O
were	O
determined	O
.	O
The	O
DNA	O
-	O
derived	O
DEN	O
-	O
4	O
viruses	O
were	O
obtained	O
in	O
Vero	O
cells	O
or	O
in	O
MRC	O
-	O
5	O
cells	O
at	O
three	O
consecutively	O
passages	O
after	O
in	O
vitro	O
RNA	O
transfection	O
(	O
as	O
P1	O
","	O
P2	O
","	O
P3	O
samples	O
).	O
P1	O
and	O
P2	O
viruses	O
were	O
harvested	O
from	O
cells	O
grown	O
in	O
T	O
flask	O
cultures	O
and	O
the	O
P3	O
passage	O
virus	O
was	O
from	O
a	O
microcarrier	O
culture	O
.	O
Multiple	O
clone	O
sequencings	O
were	O
conducted	O
on	O
the	O
three	O
genomic	O
fragments	O
(	O
WE1	O
/	O
W02R	O
","	O
W28	O
/	O
W29R	O
","	O
W21	O
/	O
W23R	O
)	O
because	O
most	O
mutations	O
identified	O
earlier	O
were	O
localized	O
in	O
these	O
fragments	O
.	O
These	O
fragments	O
are	O
:	O
(	O
i	O
)	O
WE1	O
/	O
W02R	O
","	O
consisting	O
of	O
the	O
full	O
-	O
length	O
E	O
gene	O
and	O
the	O
NS1	O
gene	O
portion	O
encoding	O
the	O
first	O
152	O
amino	B-Chemical
acids	I-Chemical
;	O
(	O
ii	O
)	O
W28	O
/	O
W29R	O
","	O
consisting	O
of	O
part	O
of	O
NS3	O
gene	O
encoding	O
the	O
amino	B-Chemical
acids	I-Chemical
42	O
â€“	O
455	O
;	O
and	O
(	O
iii	O
)	O
W21	O
/	O
W23R	O
","	O
consisting	O
of	O
the	O
entire	O
NS4B	O
gene	O
and	O
the	O
NS5	O
gene	O
portion	O
encoding	O
the	O
first	O
180	O
amino	B-Chemical
acids	I-Chemical
.	O
A	O
total	O
of	O
180	O
independent	O
clones	O
were	O
obtained	O
for	O
sequence	O
determination	O
in	O
this	O
study	O
.	O
No	O
nucleotide	B-Chemical
mutation	O
was	O
found	O
in	O
the	O
WE1	O
/	O
W02R	O
(	O
E	O
-	O
NS1	O
)	O
fragments	O
of	O
P1	O
and	O
P2	O
passages	O
from	O
Vero	O
or	O
MRC	O
-	O
5	O
cells	O
(	O
Table	O
3	O
).	O
However	O
","	O
there	O
were	O
7	O
nucleotide	B-Chemical
differences	O
that	O
resulted	O
in	O
5	O
amino	B-Chemical
acid	I-Chemical
mutations	O
in	O
E	O
protein	O
at	O
G104C	O
","	O
F108I	O
","	O
G427R	O
","	O
V439F	O
","	O
and	O
V463L	O
from	O
Vero	O
cells	O
after	O
three	O
passages	O
.	O
Likewise	O
","	O
there	O
were	O
3	O
nucleotide	B-Chemical
differences	O
including	O
3	O
amino	B-Chemical
acid	I-Chemical
mutations	O
in	O
E	O
protein	O
at	O
E345K	O
","	O
N362K	O
","	O
and	O
G427R	O
from	O
MRC	O
-	O
5	O
cells	O
(	O
Table	O
3	O
).	O
The	O
mutation	O
frequencies	O
of	O
G104C	O
and	O
F108I	O
in	O
Vero	O
cells	O
and	O
E345K	O
in	O
MRC	O
-	O
5	O
cells	O
were	O
70	O
"%,"	O
60	O
"%,"	O
and	O
50	O
%	O
respectively	O
.	O
In	O
the	O
W28	O
/	O
W29R	O
(	O
NS3	O
)	O
fragments	O
","	O
the	O
P3	O
viruses	O
from	O
microcarrier	O
cultures	O
revealed	O
16	O
mutations	O
resulting	O
in	O
11	O
amino	B-Chemical
acid	I-Chemical
changes	O
in	O
Vero	O
cells	O
and	O
3	O
mutations	O
resulting	O
in	O
2	O
amino	B-Chemical
acid	I-Chemical
changes	O
in	O
MRC	O
-	O
5	O
cells	O
.	O
Each	O
of	O
these	O
mutations	O
in	O
the	O
NS3	O
protein	O
occurred	O
at	O
a	O
frequency	O
of	O
10	O
%	O
except	O
E341G	O
at	O
a	O
frequency	O
of	O
20	O
%	O
(	O
Table	O
4	O
).	O
In	O
the	O
W21	O
/	O
W23R	O
(	O
NS4B	O
-	O
NS5	O
)	O
fragment	O
","	O
there	O
were	O
11	O
mutations	O
resulting	O
in	O
10	O
amino	B-Chemical
acid	I-Chemical
changes	O
in	O
the	O
P3	O
virus	O
from	O
Vero	O
cells	O
on	O
microcarriers	O
.	O
The	O
mutations	O
were	O
found	O
at	O
L112F	O
and	O
A240V	O
in	O
the	O
NS4B	O
protein	O
at	O
a	O
frequency	O
of	O
30	O
"%,"	O
while	O
other	O
mutations	O
occurred	O
at	O
a	O
frequency	O
of	O
10	O
%.	O
Interestingly	O
","	O
there	O
was	O
only	O
1	O
nucleotide	B-Chemical
mutation	O
resulting	O
in	O
1	O
amino	B-Chemical
acid	I-Chemical
change	O
in	O
DEN	O
-	O
4	O
from	O
MRC	O
-	O
5	O
cells	O
grown	O
on	O
microcarriers	O
at	O
P3	O
(	O
Table	O
5	O
).	O
10	O
clones	O
were	O
sequenced	O
in	O
each	O
case	O
.	O
Nucleotide	B-Chemical
and	O
amino	B-Chemical
acid	I-Chemical
mutations	O
in	O
the	O
WE1	O
-	O
W02R	O
(	O
E	O
-	O
NS1	O
)	O
genetic	O
fragment	O
of	O
the	O
cloned	O
DNA	O
-	O
derived	O
DEN	O
-	O
4	O
viruses	O
propagated	O
in	O
Vero	O
and	O
MRC	O
-	O
5	O
cells	O
at	O
three	O
consecutive	O
passages	O
using	O
serum	O
-	O
free	O
medium	O
.	O
10	O
clones	O
were	O
sequenced	O
in	O
each	O
case	O
.	O
Nucleotide	B-Chemical
and	O
amino	B-Chemical
acid	I-Chemical
mutations	O
in	O
the	O
W28	O
-	O
W29R	O
(	O
NS3	O
)	O
genetic	O
fragment	O
of	O
the	O
cloned	O
DNA	O
-	O
derived	O
DEN	O
-	O
4	O
viruses	O
propagated	O
in	O
Vero	O
and	O
MRC	O
-	O
5	O
cells	O
at	O
three	O
consecutive	O
passages	O
using	O
serum	O
-	O
free	O
medium	O
.	O
10	O
clones	O
were	O
sequenced	O
in	O
each	O
case	O
.	O
Nucleotide	B-Chemical
and	O
amino	B-Chemical
acid	I-Chemical
mutations	O
in	O
the	O
W21	O
-	O
W23R	O
(	O
NS4B	O
-	O
NS5	O
)	O
genetic	O
fragment	O
of	O
the	O
cloned	O
DNA	O
-	O
derived	O
DEN	O
-	O
4	O
viruses	O
propagated	O
in	O
Vero	O
and	O
MRC	O
-	O
5	O
cells	O
at	O
three	O
consecutive	O
passages	O
using	O
serum	O
-	O
free	O
medium	O
.	O
These	O
results	O
were	O
then	O
analyzed	O
on	O
the	O
basis	O
of	O
amino	B-Chemical
acid	I-Chemical
mutations	O
detected	O
in	O
each	O
of	O
the	O
three	O
fragments	O
sequenced	O
.	O
The	O
mean	O
diversity	O
and	O
mean	O
p	O
-	O
distance	O
of	O
amino	B-Chemical
acid	I-Chemical
mutations	O
in	O
each	O
genomic	O
fragment	O
of	O
10	O
independent	O
clones	O
were	O
calculated	O
(	O
Table	O
6	O
).	O
The	O
numbers	O
of	O
amino	B-Chemical
acid	I-Chemical
mutations	O
within	O
the	O
WE1	O
/	O
W02R	O
","	O
W28	O
/	O
W29R	O
","	O
W21	O
/	O
W23R	O
fragments	O
respectively	O
were	O
17	O
","	O
12	O
","	O
13	O
from	O
Vero	O
cells	O
","	O
and	O
7	O
","	O
2	O
","	O
0	O
from	O
MRC	O
-	O
5	O
cells	O
.	O
The	O
values	O
of	O
mean	O
diversity	O
calculated	O
for	O
these	O
three	O
genomic	O
fragments	O
were	O
0	O
.	O
31	O
(	O
WE1	O
/	O
W02R	O
"),"	O
0	O
.	O
29	O
(	O
W28	O
/	O
W29R	O
"),"	O
and	O
0	O
.	O
31	O
(	O
W21	O
/	O
W23R	O
)	O
in	O
Vero	O
cells	O
","	O
as	O
compared	O
to	O
0	O
.	O
13	O
(	O
WE1	O
/	O
W02R	O
"),"	O
0	O
.	O
5	O
(	O
W28	O
/	O
W29R	O
"),"	O
and	O
0	O
(	O
W21	O
/	O
W23R	O
)	O
in	O
MRC	O
-	O
5	O
cells	O
.	O
The	O
values	O
of	O
mean	O
diversity	O
calculated	O
from	O
MRC	O
-	O
5	O
cells	O
were	O
at	O
least	O
2	O
folds	O
lowered	O
than	O
from	O
Vero	O
cells	O
.	O
Calculation	O
of	O
the	O
p	O
-	O
distance	O
based	O
on	O
pair	O
wise	O
comparisons	O
of	O
amino	B-Chemical
acid	I-Chemical
sequences	O
between	O
clones	O
also	O
showed	O
the	O
values	O
of	O
mean	O
p	O
-	O
distance	O
were	O
0	O
.	O
36	O
(	O
range	O
0	O
â€“	O
0	O
.	O
70	O
)	O
in	O
Vero	O
cells	O
compared	O
to	O
0	O
.	O
19	O
(	O
range	O
0	O
â€“	O
0	O
.	O
50	O
)	O
in	O
MRC	O
-	O
5	O
cells	O
in	O
the	O
WE1	O
-	O
W02R	O
fragment	O
;	O
0	O
.	O
56	O
(	O
range	O
0	O
â€“	O
0	O
.	O
12	O
)	O
in	O
Vero	O
cells	O
compared	O
to	O
0	O
.	O
13	O
(	O
range	O
0	O
â€“	O
0	O
.	O
50	O
)	O
in	O
MRC	O
-	O
5	O
cells	O
in	O
the	O
W28	O
-	O
W29R	O
fragment	O
;	O
0	O
.	O
50	O
(	O
range	O
0	O
â€“	O
1	O
.	O
40	O
)	O
in	O
Vero	O
cells	O
compared	O
to	O
0	O
(	O
range	O
0	O
)	O
in	O
MRC	O
-	O
5	O
cells	O
in	O
the	O
W21	O
-	O
W23R	O
fragment	O
.	O
All	O
of	O
these	O
data	O
demonstrated	O
that	O
the	O
cloned	O
DEN4	O
propagated	O
in	O
MRC	O
-	O
5	O
cells	O
were	O
more	O
stable	O
than	O
those	O
propagated	O
in	O
Vero	O
cells	O
.	O
The	O
mean	O
diversity	O
is	O
the	O
number	O
of	O
substitutions	O
divided	O
by	O
the	O
total	O
number	O
of	O
amino	B-Chemical
acids	I-Chemical
sequenced	O
.	O
p	O
-	O
distances	O
were	O
calculated	O
by	O
pair	O
wise	O
comparison	O
of	O
amino	B-Chemical
acid	I-Chemical
sequences	O
between	O
clones	O
by	O
the	O
program	O
MEGA	O
.	O
The	O
number	O
of	O
amino	B-Chemical
acid	I-Chemical
mutations	O
and	O
the	O
mean	O
diversity	O
for	O
the	O
three	O
genetic	O
fragments	O
of	O
the	O
cloned	O
DNA	O
-	O
derived	O
DEN	O
-	O
4	O
viruses	O
propagated	O
in	O
Vero	O
and	O
MRC	O
-	O
5	O
cells	O
in	O
serum	O
-	O
free	O
cultures	O
.	O
Discussion	O
This	O
work	O
has	O
investigated	O
the	O
replication	O
kinetics	O
of	O
four	O
-	O
serotype	O
and	O
cloned	O
DNA	O
-	O
derived	O
DEN	O
viruses	O
in	O
Vero	O
and	O
MRC	O
-	O
5	O
cells	O
.	O
Vero	O
(	O
African	O
green	O
monkey	O
kidney	O
)	O
cells	O
are	O
polyploidy	O
(	O
recently	O
certified	O
as	O
cell	O
hosts	O
for	O
producing	O
DEN	O
vaccines	O
)	O
and	O
MRC	O
-	O
5	O
(	O
human	O
fetal	O
lung	O
fibroblast	O
cells	O
)	O
are	O
diploid	O
.	O
Both	O
cell	O
lines	O
have	O
been	O
already	O
used	O
to	O
develop	O
several	O
human	O
vaccines	O
","	O
and	O
Vero	O
cells	O
are	O
currently	O
used	O
for	O
candidate	O
DEN	O
vaccine	O
production	O
.	O
However	O
","	O
viral	O
yield	O
and	O
genetic	O
stability	O
of	O
DEN	O
viruses	O
have	O
not	O
been	O
systematically	O
compared	O
between	O
Vero	O
and	O
MRC	O
-	O
5	O
cell	O
lines	O
.	O
High	O
titers	O
of	O
DEN	O
-	O
1	O
(	O
HAWAII	O
)	O
and	O
DEN	O
-	O
2	O
(	O
NGC	O
)	O
but	O
relatively	O
low	O
titers	O
of	O
DEN	O
-	O
3	O
(	O
H	O
-	O
87	O
)	O
and	O
DEN	O
-	O
4	O
(	O
H	O
-	O
241	O
)	O
were	O
obtained	O
in	O
this	O
study	O
in	O
either	O
Vero	O
cells	O
or	O
MRC	O
-	O
5	O
cells	O
","	O
although	O
both	O
cells	O
were	O
grown	O
to	O
a	O
similar	O
density	O
on	O
microcarrieres	O
prior	O
to	O
virus	O
infection	O
.	O
A	O
possible	O
explanation	O
is	O
that	O
the	O
DEN	O
-	O
4	O
(	O
H	O
-	O
241	O
)	O
virus	O
strain	O
used	O
was	O
the	O
non	O
mouse	O
-	O
adapted	O
strain	O
rather	O
than	O
the	O
prototype	O
mouse	O
-	O
adapted	O
strain	O
since	O
the	O
non	O
mouse	O
-	O
adapted	O
strain	O
was	O
associated	O
with	O
two	O
E	O
protein	O
mutations	O
(	O
Ile	B-Chemical
for	O
Thr	B-Chemical
-	O
155	O
","	O
Leu	B-Chemical
for	O
Phe	B-Chemical
-	O
401	O
)	O
.	O
This	O
study	O
obtained	O
high	O
titers	O
(	O
1	O
âˆ¼	O
2	O
Ã—	O
106	O
pfu	O
/	O
ml	O
)	O
of	O
cloned	O
DEN	O
-	O
4	O
(	O
81466	O
strain	O
)	O
in	O
both	O
Vero	O
cells	O
and	O
MRC	O
-	O
5	O
cells	O
.	O
The	O
viral	O
yield	O
of	O
cloned	O
DEN	O
-	O
4	O
(	O
81466	O
strain	O
)	O
produced	O
in	O
MRC	O
-	O
5	O
cells	O
on	O
microcarriers	O
(	O
at	O
P3	O
)	O
was	O
approximately	O
10	O
folds	O
lower	O
and	O
had	O
only	O
one	O
amino	B-Chemical
acid	I-Chemical
change	O
compared	O
to	O
those	O
in	O
Vero	O
cells	O
with	O
thirteen	O
and	O
six	O
amino	B-Chemical
acid	I-Chemical
mutations	O
in	O
serum	O
-	O
free	O
and	O
serum	O
-	O
containing	O
cultures	O
","	O
respectively	O
(	O
Table	O
2	O
).	O
Almost	O
no	O
P1	O
and	O
P2	O
virus	O
mutations	O
in	O
the	O
Vero	O
and	O
MRC	O
-	O
5	O
cells	O
grown	O
in	O
T	O
flasks	O
were	O
found	O
by	O
sequencing	O
of	O
multiple	O
clones	O
(	O
Tables	O
3	O
âˆ¼	O
5	O
).	O
The	O
increased	O
genetic	O
mutations	O
of	O
cloned	O
DEN4	O
observed	O
in	O
Vero	O
cells	O
were	O
probably	O
caused	O
by	O
passage	O
number	O
or	O
high	O
-	O
density	O
microcarrier	O
culture	O
rather	O
than	O
the	O
increased	O
virus	O
yield	O
.	O
Comparative	O
mutation	O
rate	O
in	O
this	O
study	O
was	O
based	O
only	O
on	O
the	O
genomic	O
sequences	O
of	O
the	O
cloned	O
DNA	O
-	O
derived	O
DEN4	O
from	O
passages	O
1	O
through	O
3	O
","	O
the	O
latter	O
representing	O
microcarrier	O
culture	O
viruses	O
.	O
This	O
study	O
did	O
not	O
investigate	O
the	O
genomic	O
characteristics	O
of	O
the	O
non	O
-	O
cloned	O
wild	O
type	O
viruses	O
such	O
as	O
the	O
DEN	O
-	O
1	O
(	O
HAWAII	O
"),"	O
DEN	O
-	O
2	O
(	O
NGC	O
"),"	O
DEN	O
-	O
3	O
(	O
H	O
-	O
87	O
"),"	O
and	O
DEN	O
-	O
4	O
(	O
H	O
-	O
241	O
)	O
strains	O
used	O
for	O
the	O
virus	O
yield	O
studies	O
in	O
Figs	O
S1	O
","	O
S2	O
","	O
S3	O
and	O
S4	O
.	O
Thus	O
","	O
only	O
the	O
cloned	O
DNA	O
-	O
derived	O
DEN	O
-	O
4	O
virus	O
started	O
genetically	O
more	O
homogeneous	O
was	O
analyzed	O
.	O
The	O
genomic	O
changes	O
in	O
the	O
cloned	O
DEN	O
-	O
4	O
viruses	O
in	O
Table	O
2	O
indicate	O
that	O
the	O
mutations	O
occurred	O
in	O
C	O
","	O
E	O
","	O
NS1	O
","	O
NS2A	O
","	O
NS3	O
","	O
NS4A	O
","	O
NS4B	O
","	O
and	O
NS5	O
but	O
not	O
in	O
the	O
5	O
â€²-	O
NTR	O
or	O
3	O
â€²-	O
NTR	O
regions	O
.	O
This	O
result	O
is	O
partly	O
agreed	O
with	O
other	O
related	O
reports	O
of	O
mutations	O
in	O
C	O
","	O
M	O
","	O
E	O
","	O
NS2A	O
","	O
NS4B	O
and	O
NS5	O
regions	O
for	O
the	O
DEN	O
-	O
2	O
/	O
DEN	O
-	O
4	O
chimeric	O
virus	O
","	O
and	O
in	O
5	O
â€²	O
NTR	O
","	O
C	O
","	O
E	O
","	O
NS1	O
","	O
NS3	O
","	O
NS4A	O
","	O
NS4B	O
and	O
NS5	O
regions	O
for	O
the	O
chimeric	O
DEN	O
-	O
4	O
/	O
Japanese	O
encephalitis	O
virus	O
.	O
Multiple	O
cloning	O
experiments	O
showed	O
that	O
most	O
mutations	O
were	O
at	O
10	O
%	O
frequency	O
and	O
occurred	O
in	O
the	O
third	O
passage	O
(	O
P3	O
)	O
using	O
microcarrier	O
cultures	O
(	O
Tables	O
3	O
","	O
4	O
","	O
5	O
).	O
The	O
E	O
-	O
G104C	O
","	O
E	O
-	O
F108I	O
in	O
Vero	O
cells	O
and	O
the	O
E	O
-	O
E345K	O
in	O
MRC	O
-	O
5	O
cells	O
had	O
mutation	O
rates	O
exceeding	O
50	O
%	O
and	O
the	O
NS4B	O
-	O
L112F	O
and	O
NS4B	O
-	O
A240V	O
in	O
Vero	O
cells	O
had	O
mutation	O
rates	O
of	O
30	O
%.	O
These	O
results	O
conflict	O
with	O
the	O
high	O
rate	O
of	O
NS3	O
gene	O
mutation	O
reported	O
in	O
a	O
recent	O
study	O
of	O
the	O
full	O
-	O
genomic	O
sequences	O
of	O
several	O
DEN	O
-	O
3	O
clinical	O
isolates	O
.	O
Reportedly	O
","	O
NS4B	O
is	O
a	O
key	O
determinant	O
of	O
Vero	O
cell	O
adaptation	O
for	O
the	O
intertypic	O
-	O
DEN	O
chimeric	O
viruses	O
","	O
.	O
Our	O
experiments	O
showed	O
that	O
the	O
NS4B	O
-	O
L112F	O
and	O
NS4B	O
-	O
A240V	O
mutations	O
occur	O
in	O
Vero	O
cells	O
at	O
a	O
frequency	O
of	O
only	O
30	O
%	O
(	O
Table	O
5	O
"),"	O
which	O
partially	O
correlates	O
with	O
other	O
studies	O
of	O
infectious	O
clone	O
DEN	O
viruses	O
and	O
5	O
â€²-	O
FU	O
mutagenized	O
DEN	O
viruses	O
.	O
However	O
","	O
the	O
present	O
report	O
found	O
that	O
the	O
E	O
-	O
G104C	O
","	O
E	O
-	O
F108I	O
mutations	O
in	O
Vero	O
cells	O
and	O
the	O
E	O
-	O
E345K	O
mutation	O
in	O
MRC	O
-	O
5	O
cells	O
occurred	O
at	O
a	O
higher	O
frequency	O
than	O
the	O
NS4B	O
-	O
L112F	O
and	O
NS4B	O
-	O
A240V	O
mutations	O
in	O
Vero	O
cells	O
.	O
The	O
DEN2	O
-	O
PDK	O
-	O
53	O
-	O
based	O
chimeric	O
viruses	O
have	O
recently	O
been	O
characterized	O
by	O
multiple	O
plaque	O
selection	O
and	O
spot	O
/	O
genomic	O
sequencing	O
.	O
The	O
current	O
data	O
based	O
on	O
the	O
first	O
three	O
passages	O
have	O
already	O
demonstrated	O
a	O
better	O
genetic	O
stability	O
in	O
MRC	O
-	O
5	O
cells	O
than	O
in	O
Vero	O
cells	O
.	O
Prompted	O
by	O
reports	O
of	O
success	O
in	O
manufacturing	O
the	O
DEN2	O
-	O
PDK	O
-	O
53	O
-	O
based	O
tetravalent	O
vaccine	O
in	O
certified	O
Vero	O
cells	O
","	O
the	O
authors	O
are	O
currently	O
investigating	O
the	O
genetic	O
stability	O
of	O
attenuated	O
chimeric	O
cloned	O
viruses	O
of	O
four	O
serotypes	O
to	O
high	O
passage	O
levels	O
.	O
Passage	O
numbers	O
are	O
limited	O
to	O
less	O
than	O
10	O
since	O
live	O
-	O
attenuated	O
vaccines	O
require	O
limited	O
passage	O
levels	O
from	O
the	O
seed	O
virus	O
to	O
prevent	O
unsafe	O
virus	O
reversion	O
.	O
After	O
all	O
","	O
the	O
data	O
obtained	O
in	O
this	O
study	O
at	O
the	O
third	O
passage	O
of	O
serum	O
-	O
free	O
microcarrier	O
cultures	O
have	O
already	O
shown	O
that	O
the	O
DEN	O
virus	O
propagated	O
in	O
MRC	O
-	O
5	O
cells	O
is	O
genetically	O
more	O
stable	O
than	O
in	O
Vero	O
cells	O
.	O
Therefore	O
","	O
despite	O
the	O
acceptance	O
of	O
Vero	O
cells	O
for	O
many	O
candidate	O
DEN	O
vaccine	O
productions	O
","	O
the	O
current	O
findings	O
indicate	O
that	O
MRC	O
-	O
5	O
cells	O
grown	O
on	O
microcarriers	O
may	O
offer	O
a	O
more	O
stable	O
system	O
for	O
DEN	O
virus	O
production	O
.	O
This	O
study	O
is	O
apparently	O
the	O
first	O
to	O
demonstrate	O
that	O
MRC	O
-	O
5	O
cells	O
are	O
a	O
potentially	O
better	O
cell	O
host	O
for	O
live	O
-	O
attenuated	O
DEN	O
vaccine	O
production	O
.	O
These	O
findings	O
may	O
be	O
helpful	O
in	O
developing	O
a	O
biomanufacturing	O
process	O
for	O
DEN	O
vaccine	O
production	O
using	O
high	O
-	O
density	O
microcarrier	O
cultures	O
.	O
Materials	O
and	O
Methods	O
Cells	O
and	O
Media	O
Vero	O
cells	O
","	O
MRC	O
-	O
5	O
cells	O
and	O
BHK	O
-	O
21	O
cells	O
were	O
obtained	O
from	O
the	O
Bioresource	O
Collection	O
and	O
Research	O
Center	O
(	O
BCRC	O
"),"	O
Food	O
Industrial	O
Research	O
and	O
Development	O
Institute	O
","	O
Hsinchu	O
","	O
Taiwan	O
.	O
Vero	O
cells	O
and	O
MRC	O
-	O
5	O
cells	O
were	O
grown	O
in	O
Dulbecco	B-Chemical
'	I-Chemical
s	I-Chemical
Modified	I-Chemical
Essential	I-Chemical
Medium	I-Chemical
(	O
DMEM	B-Chemical
)	O
(	O
Invitrogen	O
)	O
and	O
BHK	O
-	O
21	O
cells	O
were	O
grown	O
in	O
Eagle	B-Chemical
'	I-Chemical
s	I-Chemical
Minimum	I-Chemical
Essential	I-Chemical
Medium	I-Chemical
(	O
EMEM	B-Chemical
)	O
(	O
Sigma	O
)	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
and	O
100	O
U	O
/	O
ml	O
of	O
penicillin	B-Chemical
G	I-Chemical
sodium	I-Chemical
-	O
Streptomycin	B-Chemical
(	O
Invitrogen	O
).	O
Vero	O
cells	O
and	O
MRC	O
-	O
5	O
cells	O
were	O
also	O
cultured	O
in	O
serum	O
-	O
free	O
medium	O
using	O
M	O
-	O
VSFM	O
serum	O
free	O
medium	O
(	O
Biogro	O
)	O
â€“	O
plus	O
100	O
U	O
/	O
ml	O
of	O
penicillin	B-Chemical
G	I-Chemical
sodium	I-Chemical
-	O
Streptomycin	B-Chemical
.	O
No	O
prior	O
adaptation	O
in	O
reduced	O
serum	O
concentrations	O
was	O
required	O
for	O
serum	O
free	O
cultures	O
.	O
Trypsin	O
inhibitor	O
(	O
GIBCO	O
)	O
was	O
used	O
at	O
0	O
.	O
25	O
%	O
for	O
cell	O
detachment	O
to	O
protect	O
cell	O
damage	O
by	O
trypsin	O
treatment	O
under	O
serum	O
-	O
free	O
conditions	O
.	O
Viruses	O
DEN	O
-	O
1	O
virus	O
(	O
Hawaii	O
"),"	O
DEN	O
-	O
2	O
virus	O
(	O
NGC	O
"),"	O
DEN	O
-	O
3	O
virus	O
(	O
H	O
-	O
87	O
)	O
and	O
DEN	O
-	O
4	O
virus	O
(	O
H	O
-	O
241	O
)	O
were	O
provided	O
by	O
the	O
Center	O
of	O
Disease	O
Control	O
","	O
Department	O
of	O
Health	O
","	O
Taiwan	O
.	O
Stock	O
viruses	O
were	O
prepared	O
from	O
supernatants	O
of	O
infected	O
C6	O
/	O
36	O
cells	O
grown	O
in	O
Hank	B-Chemical
'	I-Chemical
s	I-Chemical
MEM	I-Chemical
medium	O
(	O
GIBCO	O
)	O
plus	O
supplements	O
6	O
days	O
post	O
-	O
infection	O
at	O
28	O
Â°	O
C	O
.	O
The	O
plasmid	O
of	O
DEN	O
-	O
4	O
strain	O
814669	O
contained	O
the	O
full	O
-	O
length	O
genomic	O
sequence	O
.	O
The	O
plasmid	O
was	O
first	O
linearized	O
by	O
cleavage	O
with	O
restriction	O
enzyme	O
Kpn	O
I	O
and	O
then	O
added	O
to	O
a	O
transcription	O
reaction	O
mixture	O
(	O
Promega	O
kit	O
)	O
containing	O
m7G	O
(	O
5	O
â€²)	O
ppp	O
(	O
5	O
â€²)	O
G	O
(	O
Merck	O
)	O
for	O
cap	O
addition	O
at	O
the	O
RNA	O
5	O
â€²-	O
end	O
.	O
After	O
incubation	O
at	O
37	O
Â°	O
C	O
for	O
1	O
.	O
5	O
hour	O
","	O
the	O
RNA	O
product	O
was	O
purified	O
with	O
TRIzol	B-Chemical
reagent	O
(	O
Invitrogen	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
.	O
Prior	O
to	O
RNA	O
transfection	O
","	O
subconfluent	O
Vero	O
cells	O
and	O
MRC	O
-	O
5	O
cells	O
in	O
a	O
24	O
-	O
well	O
plate	O
were	O
rinsed	O
once	O
with	O
serum	O
-	O
free	O
medium	O
and	O
then	O
covered	O
with	O
0	O
.	O
3	O
ml	O
of	O
DMEM	B-Chemical
medium	O
per	O
well	O
.	O
The	O
transfection	O
mixture	O
was	O
prepared	O
by	O
adding	O
4	O
Âµl	O
of	O
DMRIE	B-Chemical
-	I-Chemical
C	I-Chemical
reagent	O
(	O
Invitrogen	O
)	O
to	O
1	O
ml	O
of	O
DMEM	B-Chemical
","	O
then	O
mixing	O
with	O
10	O
Âµg	O
of	O
the	O
RNA	O
product	O
.	O
The	O
transfection	O
mixture	O
was	O
added	O
directly	O
to	O
cell	O
monolayers	O
.	O
After	O
18	O
hours	O
incubation	O
at	O
37	O
Â°	O
C	O
","	O
either	O
DMEM	B-Chemical
+	O
10	O
%	O
FBS	O
or	O
M	O
-	O
VSFM	O
medium	O
were	O
added	O
to	O
the	O
well	O
.	O
Eight	O
days	O
after	O
transfection	O
","	O
culture	O
supernatants	O
were	O
collected	O
.	O
All	O
virus	O
stocks	O
were	O
stored	O
at	O
âˆ’	O
80	O
Â°	O
C	O
freezer	O
for	O
further	O
analysis	O
.	O
Microcarrier	O
cultures	O
Cytodex	B-Chemical
1	I-Chemical
microcarriers	O
(	O
Amersham	O
Biosciences	O
)	O
were	O
prepared	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
.	O
Briefly	O
","	O
the	O
Cytodex	B-Chemical
1	I-Chemical
microcarriers	O
were	O
immersed	O
in	O
phosphate	B-Chemical
buffer	I-Chemical
saline	I-Chemical
(	O
PBS	B-Chemical
)	O
for	O
at	O
least	O
three	O
hours	O
and	O
autoclaved	O
for	O
15	O
min	O
before	O
each	O
experiment	O
.	O
The	O
autoclaved	O
microcarriers	O
were	O
washed	O
twice	O
with	O
the	O
culture	O
medium	O
.	O
Bellco	O
spinner	O
flasks	O
(	O
100	O
-	O
ml	O
)	O
were	O
used	O
in	O
the	O
experiments	O
for	O
a	O
working	O
volume	O
of	O
50	O
ml	O
.	O
The	O
spinner	O
flasks	O
were	O
stirred	O
at	O
60	O
rpm	O
and	O
placed	O
inside	O
an	O
incubator	O
with	O
5	O
%	O
CO2	B-Chemical
at	O
37	O
Â°	O
C	O
.	O
Cells	O
were	O
detached	O
from	O
tissue	O
culture	O
flasks	O
using	O
trypsin	O
-	O
EDTA	B-Chemical
","	O
and	O
then	O
transferred	O
to	O
a	O
spinner	O
flask	O
containing	O
2g	O
/	O
l	O
Cytodex	B-Chemical
1	I-Chemical
microcarriers	O
.	O
Starting	O
cell	O
densities	O
were	O
3	O
Ã—	O
105	O
cells	O
/	O
ml	O
in	O
serum	O
-	O
containing	O
cultures	O
and	O
6	O
Ã—	O
105	O
cells	O
/	O
ml	O
in	O
serum	O
-	O
free	O
cultures	O
.	O
The	O
cell	O
cultures	O
were	O
infected	O
after	O
3	O
day	O
inoculation	O
and	O
by	O
replacing	O
70	O
%	O
of	O
the	O
medium	O
with	O
fresh	O
medium	O
containing	O
the	O
virus	O
inoculum	O
at	O
a	O
multiplicity	O
of	O
infection	O
(	O
MOI	O
)	O
of	O
0	O
.	O
1	O
.	O
Inoculation	O
continued	O
without	O
further	O
replacement	O
with	O
fresh	O
medium	O
or	O
addition	O
of	O
supplements	O
.	O
Determination	O
of	O
cell	O
density	O
and	O
virus	O
titer	O
The	O
number	O
of	O
cells	O
attached	O
to	O
the	O
microcarriers	O
was	O
determined	O
by	O
nuclei	O
staining	O
.	O
Briefly	O
","	O
a	O
1	O
-	O
ml	O
sample	O
of	O
the	O
microcarrier	O
culture	O
was	O
taken	O
and	O
centrifuged	O
at	O
200	O
g	O
for	O
5	O
min	O
to	O
remove	O
the	O
supernatant	O
.	O
The	O
pellets	O
were	O
treated	O
with	O
1	O
ml	O
0	O
.	O
1	O
M	O
citric	B-Chemical
acid	I-Chemical
[	O
containing	O
0	O
.	O
1	O
%	O
(	O
w	O
/	O
v	O
)	O
crystal	B-Chemical
violet	I-Chemical
]	O
and	O
incubated	O
at	O
37	O
Â°	O
C	O
for	O
1	O
hour	O
.	O
The	O
released	O
nuclei	O
were	O
counted	O
in	O
a	O
hemocytometer	O
.	O
The	O
virus	O
titer	O
was	O
measured	O
by	O
10	O
-	O
fold	O
serial	O
dilutions	O
of	O
the	O
culture	O
supernatant	O
in	O
duplicate	O
infections	O
of	O
BHK	O
-	O
21	O
cell	O
monolayers	O
in	O
a	O
6	O
-	O
well	O
plate	O
.	O
After	O
1	O
hour	O
incubation	O
at	O
37	O
Â°	O
C	O
","	O
4	O
ml	O
of	O
medium	O
containing	O
10	O
%	O
FBS	O
and	O
1	O
.	O
1	O
%	O
methylcellulose	B-Chemical
(	O
4	O
ml	O
/	O
well	O
)	O
was	O
added	O
to	O
each	O
well	O
.	O
Virus	O
plaques	O
were	O
stained	O
with	O
naphthol	B-Chemical
blue	I-Chemical
black	I-Chemical
dye	O
six	O
days	O
after	O
incubation	O
.	O
The	O
infectivity	O
titer	O
in	O
plaque	O
forming	O
units	O
(	O
pfu	O
)	O
per	O
ml	O
was	O
determined	O
.	O
Sequencing	O
the	O
entire	O
genome	O
of	O
cloned	O
DNA	O
-	O
derived	O
DEN	O
-	O
4	O
Viral	O
RNA	O
was	O
extracted	O
from	O
culture	O
supernatants	O
using	O
TRIzol	B-Chemical
reagent	O
(	O
Invitrogen	O
"),"	O
and	O
the	O
cDNA	O
synthesized	O
by	O
reverse	O
transcription	O
using	O
Superscript	O
II	O
RTase	O
(	O
Invitrogen	O
).	O
The	O
double	O
-	O
stranded	O
DNA	O
was	O
then	O
generated	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
using	O
Platinum	O
Â®	O
Pfx	O
DNA	O
polymerase	O
(	O
Invitrogen	O
).	O
Four	O
overlapping	O
fragments	O
that	O
span	O
the	O
entire	O
DEN	O
genome	O
were	O
produced	O
using	O
4	O
sets	O
of	O
forward	O
and	O
reverse	O
primers	O
:	O
(	O
i	O
)	O
W01	O
/	O
W02R	O
","	O
(	O
ii	O
)	O
W03	O
/	O
W04R	O
","	O
(	O
iii	O
)	O
W05	O
/	O
W06R	O
","	O
and	O
(	O
iii	O
)	O
W07	O
/	O
W08R	O
as	O
listed	O
in	O
Table	O
S1	O
.	O
The	O
DNA	O
products	O
were	O
purified	O
by	O
Gel	O
/	O
PCR	O
DNA	O
fragments	O
extraction	O
kit	O
(	O
Geneaid	O
","	O
Taiwan	O
"),"	O
cloned	O
into	O
the	O
pGEM	O
T	O
-	O
easy	O
vector	O
(	O
Promega	O
).	O
The	O
nucleotide	B-Chemical
sequences	O
of	O
each	O
of	O
the	O
four	O
fragments	O
cloned	O
into	O
the	O
pGEM	O
T	O
-	O
easy	O
vector	O
(	O
from	O
two	O
upstream	O
promoters	O
SP6	O
and	O
T7	O
at	O
both	O
ends	O
of	O
the	O
vector	O
)	O
were	O
determined	O
by	O
Mission	O
Biotech	O
Inc	O
".,"	O
Taipei	O
","	O
Taiwan	O
.	O
The	O
cloned	O
DNA	O
segments	O
that	O
span	O
the	O
entire	O
DEN	O
genome	O
were	O
mapped	O
using	O
the	O
software	O
Lasergene	O
version	O
6	O
.	O
0	O
(	O
DNASTAR	O
","	O
Inc	O
.	O
USA	O
)	O
to	O
determine	O
the	O
extent	O
of	O
overlapping	O
sequences	O
.	O
Sequencing	O
multiple	O
clones	O
of	O
three	O
DEN	O
-	O
4	O
fragments	O
Three	O
DNA	O
fragments	O
were	O
synthesized	O
from	O
DEN	O
-	O
4	O
RNA	O
by	O
RT	O
-	O
PCR	O
using	O
Platinum	O
Â®	O
Pfx	O
DNA	O
polymerase	O
with	O
their	O
respective	O
forward	O
and	O
reverse	O
primer	O
sets	O
:	O
(	O
i	O
)	O
WE1	O
/	O
W02R	O
","	O
(	O
ii	O
)	O
W28	O
/	O
W29R	O
","	O
and	O
(	O
iii	O
)	O
W21	O
/	O
W23R	O
(	O
see	O
Table	O
S1	O
for	O
sequences	O
and	O
their	O
genomic	O
locations	O
).	O
Each	O
of	O
these	O
DNA	O
fragments	O
was	O
inserted	O
into	O
pGEM	O
T	O
-	O
easy	O
cloning	O
vector	O
to	O
obtain	O
10	O
or	O
more	O
independent	O
clones	O
for	O
sequence	O
analysis	O
.	O
The	O
sequences	O
were	O
aligned	O
in	O
the	O
WE1	O
/	O
W02R	O
region	O
(	O
1	O
","	O
653	O
-	O
bp	O
"),"	O
the	O
W28	O
/	O
W29R	O
region	O
(	O
1	O
","	O
260	O
-	O
bp	O
"),"	O
and	O
the	O
W21	O
/	O
W23R	O
region	O
(	O
1	O
","	O
278	O
-	O
bp	O
)	O
using	O
the	O
program	O
Lasergene	O
version	O
6	O
.	O
0	O
to	O
generate	O
the	O
consensus	O
sequence	O
for	O
each	O
of	O
the	O
three	O
fragemnts	O
.	O
The	O
mean	O
diversity	O
of	O
amino	B-Chemical
acids	I-Chemical
was	O
determined	O
as	O
the	O
number	O
of	O
amino	B-Chemical
acid	I-Chemical
substitutions	O
divided	O
by	O
the	O
total	O
number	O
amino	B-Chemical
acids	I-Chemical
sequenced	O
","	O
","	O
.	O
Pair	O
wise	O
comparisons	O
of	O
amino	B-Chemical
acid	I-Chemical
sequences	O
between	O
clones	O
were	O
performed	O
to	O
determine	O
the	O
mean	O
and	O
range	O
of	O
pair	O
wise	O
distance	O
matrix	O
(	O
p	O
-	O
distance	O
)	O
using	O
the	O
program	O
MEGA	O
version	O
3	O
.	O
1	O
(	O
Molecular	O
Evolutionary	O
Genetics	O
Analysis	O
","	O
Pennsylvania	O
State	O
University	O
","	O
PA	O
).	O
The	O
p	O
-	O
distance	O
is	O
the	O
proportion	O
of	O
amino	B-Chemical
acid	I-Chemical
mutations	O
at	O
which	O
the	O
two	O
sequences	O
to	O
be	O
compared	O
are	O
different	O
.	O
Supporting	O
Information	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O
Funding	O
:	O
This	O
work	O
was	O
supported	O
by	O
the	O
National	O
Health	O
Research	O
Institutes	O
(	O
NHRI	O
-	O
EX95	O
-	O
9534SI	O
)	O
and	O
the	O
National	O
Science	O
Council	O
(	O
NSC94	O
-	O
2214	O
-	O
E	O
-	O
7	O
-	O
14	O
;	O
NSC95	O
-	O
2311	O
-	O
B	O
-	O
7	O
-	O
24	O
-	O
MY3	O
"),"	O
Taiwan	O
.	O
References	O
Genome	O
-	O
Wide	O
Association	O
Study	O
of	O
Plasma	O
Polyunsaturated	B-Chemical
Fatty	I-Chemical
Acids	I-Chemical
in	O
the	O
InCHIANTI	O
Study	O
Polyunsaturated	B-Chemical
fatty	I-Chemical
acids	I-Chemical
(	O
PUFA	B-Chemical
)	O
have	O
a	O
role	O
in	O
many	O
physiological	O
processes	O
","	O
including	O
energy	O
production	O
","	O
modulation	O
of	O
inflammation	O
","	O
and	O
maintenance	O
of	O
cell	O
membrane	O
integrity	O
.	O
High	O
plasma	O
PUFA	B-Chemical
concentrations	O
have	O
been	O
shown	O
to	O
have	O
beneficial	O
effects	O
on	O
cardiovascular	O
disease	O
and	O
mortality	O
.	O
To	O
identify	O
genetic	O
contributors	O
of	O
plasma	O
PUFA	B-Chemical
concentrations	O
","	O
we	O
conducted	O
a	O
genome	O
-	O
wide	O
association	O
study	O
of	O
plasma	O
levels	O
of	O
six	O
omega	B-Chemical
-	I-Chemical
3	I-Chemical
and	I-Chemical
omega	I-Chemical
-	I-Chemical
6	I-Chemical
fatty	I-Chemical
acids	I-Chemical
in	O
1	O
","	O
75	O
participants	O
in	O
the	O
InCHIANTI	O
study	O
on	O
aging	O
.	O
The	O
strongest	O
evidence	O
for	O
association	O
was	O
observed	O
in	O
a	O
region	O
of	O
chromosome	O
11	O
that	O
encodes	O
three	O
fatty	O
acid	O
desaturases	O
(	O
FADS1	O
","	O
FADS2	O
","	O
FADS3	O
).	O
The	O
SNP	O
with	O
the	O
most	O
significant	O
association	O
was	O
rs174537	O
near	O
FADS1	O
in	O
the	O
analysis	O
of	O
arachidonic	B-Chemical
acid	I-Chemical
(	O
AA	B-Chemical
;	O
p	O
=	O
5	O
.	O
95	O
Ã—	O
10	O
âˆ’	O
46	O
).	O
Minor	O
allele	O
homozygotes	O
had	O
lower	O
AA	B-Chemical
compared	O
to	O
the	O
major	O
allele	O
homozygotes	O
and	O
rs174537	O
accounted	O
for	O
18	O
.	O
6	O
%	O
of	O
the	O
additive	O
variance	O
in	O
AA	B-Chemical
concentrations	O
.	O
This	O
SNP	O
was	O
also	O
associated	O
with	O
levels	O
of	O
eicosadienoic	B-Chemical
acid	I-Chemical
(	O
EDA	B-Chemical
;	O
p	O
=	O
6	O
.	O
78	O
Ã—	O
10	O
âˆ’	O
9	O
)	O
and	O
eicosapentanoic	B-Chemical
acid	I-Chemical
(	O
EPA	B-Chemical
;	O
p	O
=	O
1	O
.	O
7	O
Ã—	O
10	O
âˆ’	O
14	O
).	O
Participants	O
carrying	O
the	O
allele	O
associated	O
with	O
higher	O
AA	B-Chemical
","	O
EDA	B-Chemical
","	O
and	O
EPA	B-Chemical
also	O
had	O
higher	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	B-Chemical
-	I-Chemical
C	I-Chemical
)	O
and	O
total	O
cholesterol	B-Chemical
levels	O
.	O
Outside	O
the	O
FADS	O
gene	O
cluster	O
","	O
the	O
strongest	O
region	O
of	O
association	O
mapped	O
to	O
chromosome	O
6	O
in	O
the	O
region	O
encoding	O
an	O
elongase	O
of	O
very	O
long	O
fatty	O
acids	O
2	O
(	O
ELOVL2	O
).	O
In	O
this	O
region	O
","	O
association	O
was	O
observed	O
with	O
EPA	B-Chemical
(	O
rs953413	O
;	O
p	O
=	O
1	O
.	O
1	O
Ã—	O
10	O
âˆ’	O
6	O
).	O
The	O
effects	O
of	O
rs174537	O
were	O
confirmed	O
in	O
an	O
independent	O
sample	O
of	O
1	O
","	O
76	O
subjects	O
participating	O
in	O
the	O
GOLDN	O
study	O
.	O
The	O
ELOVL2	O
SNP	O
was	O
associated	O
with	O
docosapentanoic	B-Chemical
and	O
DHA	B-Chemical
but	O
not	O
with	O
EPA	B-Chemical
in	O
GOLDN	O
.	O
These	O
findings	O
show	O
that	O
polymorphisms	O
of	O
genes	O
encoding	O
enzymes	O
in	O
the	O
metabolism	O
of	O
PUFA	B-Chemical
contribute	O
to	O
plasma	O
concentrations	O
of	O
fatty	B-Chemical
acids	I-Chemical
.	O
Author	O
Summary	O
Polyunsaturated	B-Chemical
fatty	I-Chemical
acids	I-Chemical
(	O
PUFA	B-Chemical
)	O
have	O
a	O
number	O
of	O
beneficial	O
effects	O
on	O
human	O
health	O
.	O
Plasma	O
PUFA	B-Chemical
concentrations	O
are	O
determined	O
by	O
a	O
combination	O
of	O
dietary	O
intake	O
and	O
metabolic	O
efficiency	O
.	O
To	O
determine	O
the	O
genes	O
involved	O
in	O
PUFA	B-Chemical
homeostasis	O
","	O
we	O
scanned	O
the	O
genome	O
for	O
genetic	O
variations	O
associated	O
with	O
plasma	O
PUFA	B-Chemical
concentrations	O
.	O
The	O
fatty	O
acid	O
desaturase	O
gene	O
","	O
studied	O
in	O
previous	O
candidate	O
gene	O
association	O
studies	O
","	O
was	O
the	O
strongest	O
determinant	O
of	O
plasma	O
PUFA	B-Chemical
.	O
A	O
second	O
gene	O
encoding	O
a	O
fatty	O
acid	O
elongase	O
was	O
associated	O
with	O
long	O
chain	O
PUFA	B-Chemical
.	O
The	O
results	O
of	O
this	O
study	O
contribute	O
to	O
our	O
understanding	O
of	O
the	O
genetics	O
of	O
PUFA	B-Chemical
homeostasis	O
.	O
These	O
genetic	O
markers	O
may	O
be	O
useful	O
tools	O
to	O
examine	O
the	O
inter	O
-	O
relationship	O
between	O
diet	O
","	O
genetics	O
","	O
and	O
disease	O
.	O
Introduction	O
Polyunsaturated	B-Chemical
fatty	I-Chemical
acids	I-Chemical
(	O
PUFA	B-Chemical
)	O
refer	O
to	O
the	O
class	O
of	O
fatty	B-Chemical
acids	I-Chemical
with	O
multiple	O
desaturations	O
in	O
the	O
aliphatic	O
tail	O
.	O
Short	O
chain	O
PUFA	B-Chemical
(	O
up	O
to	O
16	O
carbons	B-Chemical
)	O
are	O
synthesized	O
endogenously	O
by	O
fatty	O
acid	O
synthase	O
.	O
Long	O
chain	O
PUFA	B-Chemical
are	O
fatty	B-Chemical
acids	I-Chemical
of	O
18	O
carbons	B-Chemical
or	O
more	O
in	O
length	O
with	O
two	O
or	O
more	O
double	O
bonds	O
.	O
Depending	O
on	O
the	O
position	O
of	O
the	O
first	O
double	O
bond	O
proximate	O
to	O
the	O
methyl	O
end	O
","	O
PUFA	B-Chemical
are	O
classified	O
as	O
n	O
-	O
6	O
or	O
n	O
-	O
3	O
.	O
Long	O
chain	O
PUFA	B-Chemical
are	O
either	O
directly	O
absorbed	O
from	O
food	O
or	O
synthesized	O
from	O
the	O
two	O
essential	O
fatty	B-Chemical
acids	I-Chemical
linoleic	I-Chemical
acid	I-Chemical
(	O
LA	B-Chemical
;	O
18	B-Chemical
:	I-Chemical
2n	I-Chemical
-	I-Chemical
6	I-Chemical
)	O
and	O
alpha	B-Chemical
-	I-Chemical
linolenic	I-Chemical
acid	I-Chemical
(	O
ALA	B-Chemical
;	O
18	B-Chemical
:	I-Chemical
3n	I-Chemical
-	I-Chemical
3	I-Chemical
)	O
through	O
a	O
series	O
of	O
desaturation	O
and	O
elongation	O
processes	O
[	O
1	O
].	O
The	O
initial	O
step	O
in	O
PUFA	B-Chemical
biosynthesis	O
is	O
the	O
desaturation	O
of	O
ALA	B-Chemical
and	O
LA	B-Chemical
by	O
the	O
enzyme	O
d6	O
-	O
desaturase	O
(	O
FADS2	O
;	O
GeneID	O
9415	O
)	O
(	O
Figure	O
1	O
).	O
PUFA	B-Chemical
modulate	O
inflammatory	O
response	O
through	O
a	O
number	O
of	O
different	O
mechanisms	O
including	O
modulation	O
of	O
cyclooxygenase	O
and	O
lipoxigenase	O
activity	O
[	O
2	O
].	O
Cyclooxygenase	O
and	O
lipoxigenase	O
are	O
essential	O
for	O
production	O
of	O
eicosanoids	B-Chemical
and	O
resolvins	B-Chemical
[	O
2	O
]â€“[	O
4	O
].	O
Since	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
and	I-Chemical
n	I-Chemical
-	I-Chemical
6	I-Chemical
fatty	I-Chemical
acids	I-Chemical
compete	O
for	O
the	O
same	O
metabolic	O
pathway	O
and	O
produce	O
eicosanoids	B-Chemical
with	O
differing	O
effects	O
","	O
it	O
has	O
been	O
theorized	O
that	O
the	O
balance	O
of	O
the	O
two	O
classes	O
of	O
PUFA	B-Chemical
may	O
be	O
important	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
diseases	O
.	O
The	O
metabolic	O
pathway	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
and	I-Chemical
n	I-Chemical
-	I-Chemical
6	I-Chemical
fatty	I-Chemical
acids	I-Chemical
.	O
The	O
fatty	B-Chemical
acids	I-Chemical
examined	O
in	O
the	O
study	O
are	O
indicated	O
in	O
bold	O
.	O
The	O
dashed	O
arrows	O
indicate	O
pathways	O
absent	O
in	O
mammals	O
.	O
Epidemiological	O
studies	O
have	O
shown	O
that	O
fatty	B-Chemical
acid	I-Chemical
consumption	O
and	O
plasma	O
levels	O
","	O
in	O
particular	O
of	O
the	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
family	I-Chemical
","	O
are	O
associated	O
with	O
reduced	O
risk	O
of	O
cardiovascular	O
disease	O
[	O
5	O
]â€“[	O
7	O
"],"	O
diabetes	O
[	O
8	O
]â€“[	O
10	O
"],"	O
depression	O
[	O
11	O
"],["	O
12	O
"],"	O
and	O
dementia	O
[	O
13	O
].	O
However	O
","	O
not	O
all	O
studies	O
show	O
significant	O
associations	O
and	O
there	O
has	O
been	O
inconsistencies	O
in	O
the	O
direction	O
of	O
the	O
associations	O
especially	O
for	O
the	O
n	B-Chemical
-	I-Chemical
6	I-Chemical
acids	I-Chemical
[	O
14	O
"],["	O
15	O
].	O
The	O
different	O
methods	O
(	O
dietary	O
questionnaire	O
or	O
biomarkers	O
)	O
for	O
accessing	O
PUFA	B-Chemical
status	O
may	O
contribute	O
to	O
discrepant	O
results	O
[	O
16	O
]â€“[	O
18	O
].	O
The	O
disadvantage	O
of	O
using	O
dietary	O
PUFA	B-Chemical
intake	O
is	O
the	O
evidence	O
of	O
inaccuracies	O
intrinsic	O
in	O
any	O
reporting	O
methods	O
of	O
dietary	O
intake	O
that	O
plasma	O
levels	O
would	O
circumvent	O
.	O
In	O
addition	O
","	O
direct	O
measures	O
of	O
PUFA	B-Chemical
reflect	O
the	O
cumulative	O
effects	O
of	O
intake	O
and	O
endogenous	O
metabolism	O
.	O
Dietary	O
fatty	B-Chemical
acids	I-Chemical
can	O
be	O
converted	O
into	O
longer	O
chain	O
PUFA	B-Chemical
or	O
stored	O
for	O
energy	O
thus	O
another	O
reason	O
for	O
inconsistent	O
results	O
may	O
be	O
due	O
the	O
general	O
lack	O
of	O
control	O
for	O
individual	O
differences	O
in	O
metabolism	O
once	O
fatty	B-Chemical
acids	I-Chemical
are	O
consumed	O
.	O
Previous	O
studies	O
have	O
examined	O
the	O
association	O
of	O
genetic	O
variants	O
","	O
especially	O
polymorphisms	O
in	O
the	O
FADS	O
genes	O
","	O
on	O
fatty	B-Chemical
acid	I-Chemical
concentrations	O
in	O
plasma	O
and	O
erythrocyte	O
membranes	O
[	O
19	O
]â€“[	O
21	O
].	O
There	O
are	O
3	O
FADS	O
(	O
FADS1	O
[	O
GeneID	O
3992	O
]	O
","	O
FADS2	O
","	O
and	O
FADS3	O
[	O
GeneID	O
3992	O
])	O
clustered	O
on	O
chromosome	O
11	O
.	O
Variants	O
in	O
FADS1	O
and	O
FADS2	O
have	O
been	O
consistently	O
shown	O
to	O
be	O
associated	O
with	O
PUFA	B-Chemical
concentrations	O
.	O
It	O
is	O
unknown	O
whether	O
other	O
loci	O
also	O
determine	O
fatty	B-Chemical
acid	I-Chemical
concentrations	O
.	O
To	O
address	O
this	O
question	O
","	O
we	O
conducted	O
a	O
genome	O
-	O
wide	O
association	O
study	O
of	O
plasma	O
fatty	B-Chemical
acid	I-Chemical
concentration	O
in	O
participants	O
in	O
the	O
InCHIANTI	O
study	O
.	O
Results	O
Linoleic	B-Chemical
acid	I-Chemical
(	O
LA	B-Chemical
)	O
constituted	O
the	O
highest	O
proportion	O
of	O
total	O
fatty	B-Chemical
acids	I-Chemical
followed	O
by	O
arachidonic	B-Chemical
acid	I-Chemical
(	O
AA	B-Chemical
)	O
(	O
Table	O
1	O
)	O
The	O
narrow	O
heritability	O
was	O
highest	O
for	O
AA	B-Chemical
(	O
37	O
.	O
7	O
%)	O
followed	O
by	O
LA	B-Chemical
(	O
35	O
.	O
9	O
"%),"	O
eicosadienoic	B-Chemical
acid	I-Chemical
(	O
EDA	B-Chemical
","	O
33	O
.	O
3	O
"%),"	O
alpha	B-Chemical
-	I-Chemical
linolenic	I-Chemical
acid	I-Chemical
(	O
ALA	B-Chemical
","	O
28	O
.	O
1	O
"%),"	O
eicosapentanoic	B-Chemical
acid	I-Chemical
(	O
EPA	B-Chemical
","	O
24	O
.	O
4	O
"%),"	O
and	O
docosahexanoic	B-Chemical
acid	I-Chemical
(	O
DHA	B-Chemical
","	O
12	O
.	O
0	O
%).	O
For	O
EDA	B-Chemical
","	O
AA	B-Chemical
","	O
and	O
EPA	B-Chemical
","	O
genome	O
-	O
wide	O
significant	O
signals	O
fell	O
in	O
the	O
FADS1	O
/	O
FADS2	O
/	O
FADS3	O
region	O
on	O
chromosome	O
11	O
(	O
Figure	O
2	O
","	O
Figure	O
3	O
","	O
Table	O
S1	O
).	O
Of	O
these	O
","	O
the	O
most	O
significant	O
SNP	O
was	O
rs174537	O
for	O
AA	B-Chemical
(	O
P	O
=	O
5	O
.	O
95	O
Ã—	O
10	O
âˆ’	O
46	O
"),"	O
where	O
the	O
variant	O
explained	O
18	O
.	O
6	O
%	O
of	O
the	O
additive	O
variance	O
of	O
AA	B-Chemical
concentrations	O
.	O
This	O
SNP	O
was	O
significantly	O
associated	O
with	O
EDA	B-Chemical
(	O
P	O
=	O
6	O
.	O
78	O
Ã—	O
10	O
âˆ’	O
9	O
"),"	O
and	O
EPA	B-Chemical
(	O
P	O
=	O
1	O
.	O
4	O
Ã—	O
10	O
âˆ’	O
14	O
).	O
The	O
association	O
with	O
LA	B-Chemical
(	O
P	O
=	O
5	O
.	O
58	O
Ã—	O
10	O
âˆ’	O
7	O
)	O
and	O
ALA	B-Chemical
(	O
P	O
=	O
2	O
.	O
76	O
Ã—	O
10	O
âˆ’	O
5	O
)	O
did	O
not	O
reach	O
genome	O
-	O
wide	O
significance	O
","	O
and	O
there	O
was	O
no	O
association	O
with	O
DHA	B-Chemical
(	O
P	O
=	O
0	O
.	O
3188	O
).	O
Presence	O
of	O
the	O
minor	O
allele	O
(	O
T	O
)	O
was	O
associated	O
with	O
lower	O
concentrations	O
of	O
longer	O
chain	O
fatty	B-Chemical
acids	I-Chemical
(	O
EDA	B-Chemical
","	O
AA	B-Chemical
","	O
EPA	B-Chemical
"),"	O
but	O
with	O
higher	O
concentrations	O
of	O
LA	B-Chemical
and	O
ALA	B-Chemical
(	O
Table	O
2	O
).	O
With	O
the	O
exception	O
of	O
DHA	B-Chemical
","	O
the	O
SNPs	O
exhibiting	O
the	O
strongest	O
evidence	O
of	O
association	O
with	O
the	O
fatty	B-Chemical
acids	I-Chemical
examined	O
in	O
this	O
study	O
mapped	O
to	O
the	O
FADS1	O
","	O
FADS2	O
","	O
and	O
FADS3	O
cluster	O
.	O
The	O
most	O
significant	O
SNP	O
for	O
DHA	B-Chemical
was	O
on	O
chromosome	O
12	O
within	O
the	O
SLC26A10	O
gene	O
(	O
GeneID	O
65012	O
","	O
rs2277324	O
;	O
PDHA	O
=	O
2	O
.	O
65	O
Ã—	O
10	O
âˆ’	O
9	O
).	O
In	O
all	O
cases	O
","	O
inclusion	O
of	O
the	O
most	O
significant	O
SNP	O
as	O
a	O
covariate	O
in	O
the	O
model	O
resulted	O
in	O
attenuation	O
of	O
the	O
effect	O
of	O
the	O
other	O
SNPs	O
in	O
the	O
region	O
(	O
Figure	O
S1	O
).	O
Accordingly	O
","	O
associated	O
SNPs	O
in	O
this	O
region	O
were	O
in	O
significant	O
linkage	O
disequilibrium	O
with	O
each	O
other	O
in	O
the	O
InCHIANTI	O
sample	O
(	O
Figure	O
S2	O
).	O
Genome	O
-	O
wide	O
scans	O
of	O
omega	B-Chemical
-	I-Chemical
6	I-Chemical
fatty	I-Chemical
acid	I-Chemical
profiles	O
in	O
InCHIANTI	O
study	O
.	O
Genome	O
-	O
wide	O
associations	O
of	O
plasma	O
linoleic	B-Chemical
acid	I-Chemical
(	O
A	O
"),"	O
eicasadienoic	B-Chemical
acids	I-Chemical
(	O
B	O
)	O
and	O
arachidonic	B-Chemical
acid	I-Chemical
(	O
C	O
)	O
with	O
495	O
","	O
343	O
autosomal	O
and	O
X	O
chromosome	O
SNPs	O
that	O
passed	O
quality	O
control	O
graphed	O
by	O
chromosome	O
position	O
and	O
âˆ’	O
log10	O
p	O
-	O
value	O
.	O
The	O
most	O
significant	O
variant	O
was	O
within	O
the	O
FAD1	O
/	O
FAD2	O
/	O
FAD3	O
cluster	O
on	O
chromosome	O
11	O
.	O
The	O
genes	O
nearby	O
or	O
within	O
the	O
SNPs	O
that	O
were	O
selected	O
for	O
replication	O
in	O
GOLDN	O
are	O
indicated	O
.	O
Genome	O
-	O
wide	O
scans	O
of	O
omega	B-Chemical
-	I-Chemical
3	I-Chemical
fatty	I-Chemical
acid	I-Chemical
profiles	O
in	O
InCHIANTI	O
study	O
.	O
Genome	O
-	O
wide	O
associations	O
of	O
plasma	O
alpha	B-Chemical
linolenic	I-Chemical
acid	I-Chemical
(	O
A	O
"),"	O
eicosapentanoic	B-Chemical
acid	I-Chemical
(	O
B	O
)	O
and	O
docasahexanoic	B-Chemical
acid	I-Chemical
(	O
C	O
)	O
with	O
495	O
","	O
343	O
autosomal	O
and	O
X	O
chromosome	O
SNPs	O
that	O
passed	O
quality	O
control	O
graphed	O
by	O
chromosome	O
position	O
and	O
âˆ’	O
log10	O
p	O
-	O
value	O
.	O
The	O
most	O
significant	O
variant	O
was	O
within	O
the	O
FAD1	O
/	O
FAD2	O
/	O
FAD3	O
cluster	O
on	O
chromosome	O
11	O
.	O
The	O
genes	O
nearby	O
or	O
within	O
the	O
SNPs	O
that	O
were	O
selected	O
for	O
replication	O
in	O
GOLDN	O
are	O
indicated	O
.	O
Descriptive	O
Characteristics	O
of	O
InCHIANTI	O
and	O
GOLDN	O
study	O
.	O
Values	O
represent	O
mean	O
(	O
SD	O
).	O
Fatty	B-Chemical
acids	I-Chemical
are	O
plasma	O
concentrations	O
(%	O
total	O
fatty	B-Chemical
acids	I-Chemical
)	O
for	O
InCHIANTI	O
and	O
erythrocytes	O
concentration	O
for	O
GOLDN	O
.	O
Associations	O
of	O
fatty	B-Chemical
acids	I-Chemical
and	O
plasma	O
lipids	B-Chemical
by	O
rs174537	O
(	O
FADS1	O
)	O
and	O
rs953413	O
(	O
ELOVL2	O
)	O
in	O
InCHIANTI	O
and	O
GOLDN	O
study	O
.	O
Values	O
represent	O
mean	O
(	O
SD	O
).	O
Fatty	B-Chemical
acids	I-Chemical
are	O
plasma	O
concentrations	O
(%	O
total	O
fatty	B-Chemical
acids	I-Chemical
)	O
for	O
InCHIANTI	O
and	O
erythrocytes	O
concentration	O
for	O
GOLDN	O
.	O
To	O
investigate	O
whether	O
this	O
SNP	O
has	O
an	O
effect	O
on	O
other	O
cardiovascular	O
disease	O
risk	O
factors	O
","	O
we	O
examined	O
the	O
association	O
of	O
rs174537	O
with	O
plasma	O
lipid	B-Chemical
parameters	O
.	O
Significant	O
association	O
was	O
observed	O
with	O
total	O
cholesterol	B-Chemical
(	O
P	O
=	O
0	O
.	O
27	O
)	O
and	O
LDL	B-Chemical
-	I-Chemical
cholesterol	I-Chemical
(	O
P	O
=	O
0	O
.	O
11	O
"),"	O
but	O
not	O
with	O
either	O
HDL	B-Chemical
-	I-Chemical
C	I-Chemical
(	O
P	O
=	O
0	O
.	O
775	O
)	O
or	O
triglycerides	B-Chemical
(	O
P	O
=	O
0	O
.	O
862	O
;	O
Table	O
2	O
).	O
The	O
minor	O
allele	O
homozygotes	O
(	O
TT	O
)	O
had	O
8	O
mg	O
/	O
dL	O
lower	O
total	O
cholesterol	B-Chemical
and	O
9	O
mg	O
/	O
dL	O
lower	O
LDL	B-Chemical
-	I-Chemical
C	I-Chemical
compared	O
with	O
GG	O
subjects	O
.	O
To	O
identify	O
other	O
putative	O
chromosome	O
regions	O
associated	O
with	O
fatty	B-Chemical
acid	I-Chemical
concentrations	O
beyond	O
the	O
FADS	O
cluster	O
","	O
we	O
examined	O
the	O
top	O
3	O
non	O
-	O
redundant	O
(	O
r2	O
<	O
0	O
.	O
2	O
)	O
SNPs	O
from	O
the	O
analysis	O
of	O
each	O
fatty	B-Chemical
acid	I-Chemical
and	O
selected	O
the	O
SNPs	O
that	O
mapped	O
to	O
candidate	O
gene	O
regions	O
(	O
defined	O
as	O
20kb	O
upstream	O
of	O
intron	O
1	O
","	O
or	O
downstream	O
of	O
last	O
exon	O
)	O
for	O
replication	O
in	O
an	O
independent	O
study	O
(	O
Table	O
S1	O
).	O
These	O
included	O
rs16940765	O
(	O
HRH4	O
[	O
GeneID	O
59340	O
"],"	O
chr18	O
","	O
PEDA	O
=	O
2	O
.	O
18	O
Ã—	O
10	O
âˆ’	O
6	O
"),"	O
rs17718324	O
(	O
SPARC	O
[	O
GeneID	O
6678	O
"],"	O
chr5	O
","	O
PAA	O
=	O
7	O
.	O
64	O
Ã—	O
10	O
âˆ’	O
7	O
)	O
and	O
rs953413	O
(	O
ELOVL2	O
[	O
GeneID	O
54898	O
"],"	O
chr6	O
","	O
PAA	O
=	O
1	O
.	O
1	O
Ã—	O
10	O
âˆ’	O
6	O
).	O
In	O
the	O
InCHIANTI	O
study	O
","	O
these	O
four	O
SNPs	O
most	O
strongly	O
associated	O
with	O
a	O
specific	O
fatty	B-Chemical
acid	I-Chemical
","	O
unlike	O
FADS	O
cluster	O
that	O
was	O
associated	O
with	O
multiple	O
fatty	B-Chemical
acids	I-Chemical
.	O
We	O
noted	O
","	O
however	O
that	O
rs16940765	O
(	O
HRH4	O
"),"	O
rs953413	O
(	O
ELOVL2	O
)	O
and	O
rs2277324	O
(	O
SLC26A10	O
)	O
showed	O
significant	O
association	O
at	O
the	O
0	O
.	O
5	O
level	O
for	O
AA	B-Chemical
(	O
P	O
=	O
0	O
.	O
3	O
"),"	O
DHA	B-Chemical
(	O
0	O
.	O
4	O
"),"	O
and	O
EPA	B-Chemical
(	O
P	O
=	O
0	O
.	O
4	O
)	O
respectively	O
.	O
In	O
addition	O
","	O
there	O
were	O
four	O
SNPs	O
(	O
rs953413	O
","	O
rs1570069	O
","	O
rs3798719	O
","	O
rs7744440	O
)	O
in	O
the	O
ELOVL2	O
gene	O
were	O
associated	O
with	O
EPA	B-Chemical
with	O
p	O
values	O
ranging	O
from	O
9	O
.	O
51	O
Ã—	O
10	O
âˆ’	O
5	O
to	O
1	O
.	O
10	O
Ã—	O
10	O
âˆ’	O
6	O
(	O
Figure	O
S3	O
).	O
In	O
total	O
","	O
5	O
SNPs	O
(	O
rs174537	O
","	O
rs2277324	O
","	O
rs16940765	O
","	O
rs17718324	O
","	O
rs953413	O
)	O
were	O
selected	O
for	O
replication	O
.	O
In	O
the	O
GOLDN	O
study	O
","	O
there	O
were	O
significant	O
associations	O
of	O
FADS	O
SNP	O
","	O
rs174537	O
","	O
with	O
ALA	B-Chemical
","	O
LA	B-Chemical
","	O
AA	B-Chemical
","	O
EPA	B-Chemical
and	O
DHA	B-Chemical
(	O
P	O
<	O
0	O
.	O
1	O
)	O
and	O
marginal	O
association	O
with	O
docosapentaenoic	B-Chemical
acid	I-Chemical
(	O
DPA	B-Chemical
)	O
(	O
P	O
=	O
0	O
.	O
68	O
)	O
(	O
Table	O
2	O
).	O
As	O
with	O
the	O
InCHIANTI	O
study	O
","	O
presence	O
of	O
the	O
T	O
allele	O
was	O
associated	O
with	O
higher	O
ALA	B-Chemical
and	O
LA	B-Chemical
concentration	O
and	O
lower	O
AA	B-Chemical
","	O
EPA	B-Chemical
","	O
DPA	B-Chemical
and	O
DHA	B-Chemical
concentrations	O
.	O
Consistent	O
with	O
the	O
InCHIANTI	O
study	O
","	O
this	O
SNP	O
was	O
associated	O
with	O
total	O
cholesterol	B-Chemical
and	O
LDL	B-Chemical
-	I-Chemical
C	I-Chemical
but	O
not	O
triglycerides	B-Chemical
or	O
HDL	B-Chemical
-	I-Chemical
C	I-Chemical
.	O
We	O
also	O
observed	O
strong	O
associations	O
of	O
rs953413	O
with	O
docosapentanoic	B-Chemical
acid	I-Chemical
(	O
DPA	B-Chemical
;	O
P	O
=	O
0	O
.	O
2	O
)	O
and	O
DHA	B-Chemical
(	O
P	O
<	O
0	O
.	O
1	O
).	O
The	O
presence	O
of	O
the	O
minor	O
allele	O
(	O
A	O
)	O
was	O
associated	O
with	O
lower	O
DHA	B-Chemical
and	O
higher	O
DPA	B-Chemical
and	O
higher	O
AA	B-Chemical
compared	O
to	O
the	O
minor	O
allele	O
carriers	O
(	O
Table	O
2	O
).	O
The	O
remaining	O
3	O
SNP	O
(	O
rs2277324	O
","	O
rs16940765	O
","	O
rs17718324	O
)	O
were	O
not	O
associated	O
with	O
fatty	B-Chemical
acid	I-Chemical
concentrations	O
in	O
the	O
GOLDN	O
study	O
(	O
data	O
not	O
shown	O
).	O
Discussion	O
The	O
genome	O
-	O
wide	O
association	O
approach	O
enables	O
comprehensive	O
examination	O
of	O
the	O
genome	O
to	O
identify	O
novel	O
loci	O
contributing	O
to	O
PUFA	B-Chemical
homeostasis	O
.	O
In	O
addition	O
","	O
the	O
significance	O
of	O
the	O
genes	O
previously	O
reported	O
in	O
association	O
with	O
PUFA	B-Chemical
can	O
be	O
assessed	O
relative	O
to	O
other	O
regions	O
in	O
the	O
genome	O
.	O
Here	O
","	O
we	O
demonstrated	O
that	O
polymorphisms	O
in	O
the	O
FADS	O
cluster	O
are	O
the	O
strongest	O
determinants	O
of	O
plasma	O
and	O
erythrocyte	O
fatty	B-Chemical
acid	I-Chemical
concentrations	O
","	O
explaining	O
up	O
to	O
18	O
.	O
6	O
%	O
of	O
the	O
additive	O
variance	O
in	O
plasma	O
AA	B-Chemical
levels	O
.	O
Consistent	O
with	O
prior	O
reports	O
","	O
the	O
greatest	O
evidence	O
of	O
association	O
was	O
observed	O
in	O
the	O
region	O
containing	O
FADS1	O
","	O
FEN1	O
(	O
flap	O
structure	O
specific	O
endonuclease	O
","	O
GeneID	O
2237	O
"),"	O
two	O
hypothetical	O
proteins	O
(	O
C11orf9	O
[	O
GeneID	O
745	O
"],"	O
C11orf10	O
[	O
GeneID	O
746	O
"]),"	O
and	O
the	O
promoter	O
region	O
of	O
FADS2	O
[	O
20	O
"],["	O
21	O
].	O
With	O
the	O
exception	O
of	O
EDA	B-Chemical
","	O
the	O
direction	O
of	O
the	O
association	O
of	O
rs174537	O
with	O
plasma	O
and	O
erythrocyte	O
fatty	B-Chemical
acids	I-Chemical
is	O
consistent	O
with	O
previous	O
reports	O
.	O
We	O
find	O
that	O
there	O
are	O
higher	O
levels	O
of	O
ALA	B-Chemical
and	O
LA	B-Chemical
which	O
is	O
suggestive	O
of	O
an	O
accumulation	O
of	O
the	O
initial	O
products	O
of	O
the	O
PUFA	B-Chemical
metabolic	O
pathway	O
.	O
The	O
cluster	O
of	O
SNP	O
ranging	O
from	O
rs174537	O
to	O
rs509360	O
showed	O
the	O
strongest	O
evidence	O
for	O
association	O
","	O
and	O
contains	O
the	O
haplotype	O
block	O
previously	O
examined	O
in	O
relation	O
to	O
plasma	O
and	O
erythrocyte	O
fatty	B-Chemical
acids	I-Chemical
[	O
20	O
"],["	O
21	O
].	O
Based	O
on	O
the	O
HapMap	O
CEU	O
data	O
","	O
the	O
r2	O
between	O
rs174537	O
and	O
previously	O
reported	O
SNPs	O
were	O
â‰¥	O
0	O
.	O
8	O
.	O
If	O
functional	O
polymorphisms	O
exist	O
within	O
this	O
region	O
","	O
it	O
could	O
affect	O
the	O
expression	O
of	O
both	O
desaturases	O
.	O
To	O
this	O
end	O
","	O
in	O
a	O
recent	O
report	O
of	O
genome	O
-	O
wide	O
association	O
of	O
global	O
gene	O
expression	O
","	O
the	O
rs174546	O
that	O
is	O
in	O
LD	O
with	O
the	O
rs174537	O
(	O
r2	O
=	O
0	O
.	O
99	O
)	O
was	O
associated	O
with	O
FADS1	O
expression	O
(	O
LOD	O
=	O
5	O
","	O
P	O
=	O
1	O
.	O
6	O
Ã—	O
10	O
âˆ’	O
6	O
)	O
but	O
not	O
FADS2	O
(	O
LOD	O
=	O
0	O
.	O
7	O
","	O
P	O
=	O
0	O
.	O
7	O
)	O
in	O
lymphoblastoid	O
cells	O
[	O
22	O
"],["	O
23	O
].	O
The	O
allele	O
associated	O
with	O
higher	O
AA	B-Chemical
showed	O
greater	O
expression	O
of	O
FADS1	O
","	O
consistent	O
with	O
our	O
results	O
.	O
Since	O
FADS1	O
and	O
FADS2expression	O
varies	O
by	O
tissue	O
type	O
","	O
it	O
would	O
be	O
of	O
interest	O
to	O
examine	O
the	O
effect	O
of	O
the	O
variant	O
on	O
gene	O
expression	O
in	O
other	O
cell	O
types	O
[	O
24	O
].	O
The	O
T	O
allele	O
associated	O
with	O
lower	O
AA	B-Chemical
was	O
also	O
associated	O
with	O
decreased	O
LDL	B-Chemical
-	I-Chemical
C	I-Chemical
and	O
total	O
cholesterol	B-Chemical
.	O
The	O
association	O
with	O
LDL	B-Chemical
-	I-Chemical
C	I-Chemical
was	O
also	O
observed	O
in	O
a	O
large	O
meta	O
-	O
analysis	O
of	O
plasma	O
lipid	B-Chemical
concentrations	O
in	O
âˆ¼	O
8500	O
subjects	O
[	O
25	O
"],["	O
26	O
].	O
In	O
this	O
meta	O
-	O
analysis	O
","	O
there	O
was	O
stronger	O
evidence	O
of	O
association	O
with	O
high	B-Chemical
density	I-Chemical
lipoprotein	I-Chemical
(	O
HDL	B-Chemical
-	I-Chemical
C	I-Chemical
)	O
and	O
triglycerides	B-Chemical
(	O
TG	B-Chemical
"),"	O
where	O
the	O
T	O
allele	O
displayed	O
lower	O
HDL	B-Chemical
-	I-Chemical
C	I-Chemical
and	O
higher	O
triglyceride	B-Chemical
concentrations	O
.	O
Finally	O
","	O
in	O
the	O
Welcome	O
Trust	O
Case	O
-	O
Control	O
Consortium	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
study	O
","	O
the	O
T	O
allele	O
was	O
associated	O
with	O
increased	O
prevalence	O
of	O
CAD	O
(	O
P	O
=	O
0	O
.	O
375	O
)	O
[	O
27	O
].	O
The	O
increased	O
prevalence	O
of	O
CAD	O
","	O
low	O
HDL	B-Chemical
-	I-Chemical
C	I-Chemical
and	O
high	O
TG	B-Chemical
is	O
consistent	O
with	O
lower	O
AA	B-Chemical
concentrations	O
in	O
the	O
T	O
allele	O
carriers	O
.	O
Endogenous	O
PUFA	B-Chemical
are	O
natural	O
ligands	O
of	O
peroxisome	O
proliferator	O
activating	O
receptor	O
alpha	O
(	O
PPARA	O
)	O
[	O
28	O
].	O
PPARA	O
activation	O
has	O
been	O
shown	O
to	O
elevate	O
HDL	B-Chemical
-	I-Chemical
C	I-Chemical
and	O
lower	O
TG	B-Chemical
by	O
inducing	O
the	O
expression	O
of	O
ApoA1	O
","	O
Apo	O
-	O
AII	O
","	O
lipoprotein	O
lipase	O
and	O
suppressing	O
ApoCIII	O
[	O
29	O
]â€“[	O
32	O
].	O
Thus	O
the	O
low	O
AA	B-Chemical
","	O
EPA	B-Chemical
and	O
EDA	B-Chemical
in	O
the	O
T	O
allele	O
carriers	O
will	O
results	O
in	O
lower	O
PPARA	O
activation	O
.	O
Under	O
this	O
hypothesis	O
","	O
we	O
would	O
expect	O
the	O
T	O
allele	O
carriers	O
to	O
display	O
higher	O
LDL	B-Chemical
-	I-Chemical
C	I-Chemical
since	O
PPARA	O
is	O
known	O
to	O
enhance	O
LDL	B-Chemical
-	I-Chemical
C	I-Chemical
clearance	O
[	O
33	O
]	O
.	O
However	O
","	O
in	O
both	O
the	O
InCHIANTI	O
and	O
GOLDN	O
study	O
","	O
lower	O
concentrations	O
of	O
LDL	B-Chemical
-	I-Chemical
C	I-Chemical
are	O
observed	O
.	O
It	O
is	O
likely	O
that	O
there	O
are	O
other	O
mechanisms	O
by	O
which	O
fatty	B-Chemical
acids	I-Chemical
regulate	O
lipoprotein	B-Chemical
homeostasis	O
","	O
for	O
example	O
through	O
membrane	O
fluidity	O
.	O
It	O
may	O
be	O
possible	O
","	O
that	O
the	O
higher	O
concentrations	O
of	O
linoleic	B-Chemical
and	I-Chemical
linolenic	I-Chemical
acid	I-Chemical
in	O
the	O
T	O
allele	O
carriers	O
results	O
in	O
increased	O
membrane	O
fluidity	O
","	O
thus	O
increasing	O
LDL	O
-	O
receptor	O
recycling	O
leading	O
to	O
lower	O
LDL	B-Chemical
-	I-Chemical
C	I-Chemical
.	O
The	O
elongation	O
of	O
very	O
long	O
chain	O
fatty	O
acid	O
(	O
ELOVL	O
)	O
family	O
genes	O
are	O
elongases	O
that	O
catalyze	O
the	O
rate	O
-	O
limiting	O
condensation	O
reaction	O
resulting	O
in	O
the	O
synthesis	O
of	O
very	O
long	O
chain	O
fatty	B-Chemical
acids	I-Chemical
(	O
VLCFA	O
)	O
[	O
34	O
].	O
To	O
date	O
","	O
six	O
ELOVL	O
genes	O
have	O
been	O
described	O
.	O
The	O
ELOVL1	O
","	O
3	O
and	O
6	O
are	O
involved	O
in	O
synthesis	O
of	O
monounsaturated	O
and	O
saturated	O
long	O
chain	O
fatty	B-Chemical
acids	I-Chemical
while	O
ELOVL2	O
","	O
4	O
and	O
5	O
elongate	O
polyunsaturated	B-Chemical
fatty	I-Chemical
acids	I-Chemical
[	O
35	O
].	O
In	O
this	O
study	O
","	O
rs953413	O
in	O
the	O
ELOVL2	O
was	O
the	O
third	O
most	O
significant	O
SNP	O
in	O
the	O
analysis	O
of	O
EPA	B-Chemical
","	O
with	O
strong	O
","	O
although	O
not	O
genome	O
-	O
wide	O
level	O
significant	O
association	O
with	O
long	O
chain	O
fatty	B-Chemical
acids	I-Chemical
EPA	I-Chemical
and	O
DHA	B-Chemical
.	O
In	O
GOLDN	O
","	O
there	O
were	O
no	O
significant	O
associations	O
of	O
this	O
SNP	O
with	O
EPA	B-Chemical
","	O
but	O
a	O
significant	O
association	O
was	O
observed	O
with	O
DPA	B-Chemical
.	O
In	O
mammals	O
","	O
two	O
elongation	O
steps	O
are	O
required	O
for	O
the	O
synthesis	O
of	O
DHA	B-Chemical
from	O
EPA	B-Chemical
.	O
First	O
","	O
EPA	B-Chemical
is	O
elongated	O
to	O
DPA	B-Chemical
","	O
then	O
to	O
24	O
:	O
5n	O
-	O
3	O
followed	O
by	O
a	O
desaturation	O
and	O
retroconversion	O
step	O
to	O
form	O
DHA	B-Chemical
[	O
1	O
]	O
(	O
Figure	O
1	O
).	O
The	O
two	O
initial	O
elongation	O
steps	O
of	O
20	B-Chemical
and	I-Chemical
22	I-Chemical
-	I-Chemical
C	I-Chemical
fatty	I-Chemical
acids	I-Chemical
are	O
mediated	O
by	O
ELOVL2	O
[	O
36	O
].	O
The	O
rs953413	O
is	O
associated	O
with	O
substrate	O
EPA	B-Chemical
(	O
InCHIANTI	O
"),"	O
and	O
product	O
DPA	B-Chemical
(	O
GOLDN	O
)	O
and	O
DHA	B-Chemical
(	O
both	O
studies	O
)	O
of	O
the	O
EVOLV2	O
pathway	O
.	O
Plasma	O
DPA	B-Chemical
levels	O
were	O
not	O
measured	O
in	O
InCHIANTI	O
","	O
thus	O
whether	O
this	O
association	O
is	O
also	O
observed	O
in	O
this	O
population	O
cannot	O
be	O
investigated	O
.	O
Why	O
the	O
ELOVL2	O
SNP	O
was	O
not	O
associated	O
with	O
EPA	B-Chemical
in	O
GOLDN	O
is	O
not	O
clear	O
","	O
however	O
it	O
may	O
reflect	O
the	O
differences	O
in	O
fatty	B-Chemical
acid	I-Chemical
metabolism	O
in	O
erythrocytes	O
versus	O
plasma	O
as	O
they	O
reflect	O
two	O
slightly	O
different	O
pools	O
of	O
fatty	B-Chemical
acids	I-Chemical
[	O
37	O
].	O
Plasma	O
fatty	B-Chemical
acids	I-Chemical
reflect	O
short	O
term	O
intake	O
of	O
fatty	B-Chemical
acids	I-Chemical
whereas	O
erythrocyte	O
levels	O
reflect	O
long	O
term	O
intake	O
.	O
Thus	O
the	O
different	O
results	O
between	O
the	O
plasma	O
and	O
erythrocyte	O
fatty	B-Chemical
acids	I-Chemical
may	O
reflect	O
dietary	O
differences	O
between	O
subjects	O
in	O
the	O
GOLDN	O
(	O
USA	O
)	O
and	O
the	O
InCHIANTI	O
study	O
(	O
Italy	O
).	O
Regardless	O
of	O
these	O
differences	O
","	O
the	O
results	O
of	O
this	O
study	O
suggestive	O
of	O
the	O
role	O
of	O
ELOVL2	O
in	O
the	O
conversion	O
of	O
EPA	B-Chemical
to	O
DHA	B-Chemical
in	O
humans	O
.	O
The	O
presence	O
of	O
the	O
minor	O
(	O
A	O
)	O
allele	O
was	O
associated	O
with	O
higher	O
EPA	B-Chemical
/	O
DPA	B-Chemical
and	O
lower	O
DHA	B-Chemical
.	O
If	O
rs953413	O
","	O
located	O
in	O
intron	O
1	O
","	O
is	O
the	O
functional	O
SNP	O
(	O
or	O
is	O
in	O
LD	O
with	O
the	O
functional	O
SNP	O
"),"	O
this	O
variant	O
would	O
likely	O
be	O
associated	O
with	O
lower	O
expression	O
of	O
the	O
ELOVL2	O
or	O
result	O
in	O
a	O
less	O
efficient	O
variant	O
of	O
the	O
elongase	O
resulting	O
in	O
decreased	O
elongation	O
of	O
EPA	B-Chemical
to	O
DHA	B-Chemical
.	O
In	O
lymphoblastoid	O
cells	O
","	O
this	O
SNP	O
was	O
not	O
associated	O
with	O
ELOVL2	O
expression	O
(	O
LOD	O
=	O
0	O
.	O
4	O
","	O
P	O
=	O
0	O
.	O
2	O
)	O
[	O
22	O
"],["	O
23	O
].	O
Further	O
investigation	O
in	O
other	O
cell	O
lines	O
and	O
functional	O
analysis	O
of	O
the	O
different	O
variants	O
is	O
warranted	O
.	O
In	O
summary	O
","	O
we	O
have	O
shown	O
that	O
the	O
major	O
loci	O
for	O
fatty	B-Chemical
acid	I-Chemical
concentrations	O
in	O
both	O
plasma	O
and	O
erythrocyte	O
membranes	O
are	O
in	O
genes	O
involved	O
in	O
the	O
metabolism	O
of	O
PUFA	B-Chemical
.	O
The	O
FADS	O
locus	O
on	O
chromosome	O
11	O
was	O
the	O
major	O
contributor	O
of	O
plasma	O
fatty	B-Chemical
acid	I-Chemical
concentrations	O
","	O
and	O
thus	O
may	O
have	O
implications	O
for	O
cardiovascular	O
disease	O
.	O
In	O
addition	O
","	O
we	O
have	O
identified	O
a	O
second	O
promising	O
locus	O
in	O
ELOVL2	O
that	O
is	O
involved	O
in	O
the	O
homeostasis	O
of	O
longer	O
chain	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
fatty	I-Chemical
acids	I-Chemical
.	O
Future	O
studies	O
should	O
investigate	O
the	O
interactions	O
between	O
dietary	O
intake	O
","	O
circulating	O
levels	O
of	O
fatty	B-Chemical
acids	I-Chemical
and	O
genetic	O
variants	O
on	O
risk	O
of	O
diseases	O
such	O
as	O
cardiovascular	O
disease	O
.	O
Material	O
and	O
Methods	O
Sample	O
Description	O
The	O
InCHIANTI	O
study	O
is	O
a	O
population	O
-	O
based	O
epidemiological	O
study	O
aimed	O
at	O
evaluating	O
factors	O
that	O
influence	O
mobility	O
in	O
the	O
older	O
population	O
living	O
in	O
the	O
Chianti	O
region	O
of	O
Tuscany	O
","	O
Italy	O
.	O
Details	O
of	O
the	O
study	O
have	O
been	O
previously	O
reported	O
[	O
38	O
].	O
Briefly	O
","	O
1616	O
residents	O
were	O
selected	O
from	O
the	O
population	O
registry	O
of	O
Greve	O
in	O
Chianti	O
(	O
a	O
rural	O
area	O
:	O
11	O
709	O
residents	O
with	O
19	O
.	O
3	O
%	O
of	O
the	O
population	O
greater	O
than	O
65	O
years	O
of	O
age	O
)	O
and	O
Bagno	O
a	O
Ripoli	O
(	O
Antella	O
village	O
near	O
Florence	O
;	O
4704	O
inhabitants	O
","	O
with	O
20	O
.	O
3	O
%	O
greater	O
than	O
65	O
years	O
of	O
age	O
).	O
The	O
participation	O
rate	O
was	O
90	O
%	O
(	O
n	O
=	O
1453	O
)	O
and	O
participants	O
ranged	O
between	O
21	O
â€“	O
102	O
years	O
of	O
age	O
.	O
Overnight	O
fasted	O
blood	O
samples	O
were	O
collected	O
for	O
genomic	O
DNA	O
extraction	O
and	O
measurement	O
of	O
plasma	O
fatty	B-Chemical
acids	I-Chemical
.	O
Genotyping	O
was	O
completed	O
for	O
1231	O
subjects	O
using	O
the	O
Illumina	O
Infinium	O
HumanHap	O
550	O
genotyping	O
chip	O
(	O
ver1	O
and	O
ver3	O
chips	O
were	O
used	O
).	O
The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
Italian	O
National	O
Institute	O
of	O
Research	O
and	O
Care	O
of	O
Aging	O
Institutional	O
Review	O
.	O
There	O
were	O
85	O
parent	O
-	O
offspring	O
pairs	O
","	O
6	O
sib	O
-	O
pairs	O
and	O
2	O
half	O
-	O
sibling	O
pairs	O
documented	O
.	O
We	O
investigated	O
any	O
further	O
familial	O
relationships	O
using	O
IBD	O
of	O
10	O
","	O
0	O
random	O
SNPs	O
using	O
RELPAIR	O
and	O
uncovered	O
1	O
parent	O
-	O
offspring	O
","	O
79	O
siblings	O
and	O
13	O
half	O
-	O
sibling	O
[	O
39	O
].	O
We	O
utilized	O
the	O
correct	O
family	O
structure	O
inferred	O
from	O
genetic	O
data	O
for	O
all	O
analyses	O
.	O
In	O
addition	O
","	O
we	O
identified	O
2	O
duplicated	O
samples	O
and	O
removed	O
these	O
from	O
the	O
study	O
.	O
Sample	O
quality	O
was	O
assessed	O
using	O
the	O
GAINQC	O
program	O
(	O
http	O
://	O
www	O
.	O
sph	O
.	O
umich	O
.	O
edu	O
/	O
csg	O
/	O
abecasis	O
/	O
GainQC	O
/).	O
The	O
average	O
genotype	O
completeness	O
and	O
heterozygosity	O
rates	O
were	O
98	O
%	O
and	O
32	O
%	O
respectively	O
.	O
We	O
excluded	O
subjects	O
that	O
had	O
less	O
than	O
97	O
%	O
of	O
genotyped	O
completeness	O
(	O
n	O
=	O
12	O
"),"	O
heterozygosity	O
rate	O
of	O
less	O
than	O
30	O
%	O
(	O
n	O
=	O
5	O
)	O
and	O
misspecified	O
sex	O
based	O
on	O
heterozygosity	O
of	O
the	O
X	O
chromosome	O
SNPs	O
(	O
n	O
=	O
1	O
).	O
The	O
final	O
sample	O
size	O
used	O
for	O
SNP	O
quality	O
control	O
was	O
1210	O
.	O
The	O
confirmation	O
study	O
population	O
consisted	O
of	O
1120	O
white	O
men	O
and	O
women	O
in	O
the	O
United	O
States	O
participating	O
in	O
the	O
Genetics	O
of	O
Lipid	O
Lowering	O
Drugs	O
and	O
Diet	O
Network	O
(	O
GOLDN	O
)	O
Study	O
.	O
The	O
majority	O
of	O
participants	O
were	O
re	O
-	O
recruited	O
from	O
the	O
ongoing	O
National	O
Heart	O
and	O
Lung	O
and	O
Blood	O
Institutes	O
(	O
NHLBI	O
)	O
Family	O
Heart	O
Study	O
(	O
FHS	O
)	O
[	O
40	O
]	O
in	O
two	O
genetically	O
homogeneous	O
centers	O
(	O
Minneapolis	O
","	O
MN	O
and	O
Salt	O
Lake	O
City	O
","	O
UT	O
).	O
GOLDN	O
is	O
part	O
of	O
the	O
Program	O
for	O
Genetic	O
Interactions	O
(	O
PROGENI	O
)	O
Network	O
","	O
a	O
group	O
of	O
NIH	O
-	O
funded	O
intervention	O
studies	O
of	O
gene	O
-	O
environmental	O
interactions	O
.	O
The	O
primary	O
aim	O
of	O
the	O
GOLDN	O
study	O
was	O
to	O
characterize	O
the	O
genetic	O
components	O
of	O
triglycerides	B-Chemical
response	O
following	O
a	O
high	O
fat	O
meal	O
and	O
hypolipedemic	O
drug	O
","	O
fenofibrate	B-Chemical
.	O
Detailed	O
study	O
design	O
and	O
methodology	O
has	O
been	O
previously	O
described	O
[	O
41	O
"],["	O
42	O
].	O
In	O
the	O
replication	O
sample	O
","	O
we	O
excluded	O
persons	O
with	O
missing	O
genotypes	O
or	O
extreme	O
fatty	B-Chemical
acid	I-Chemical
values	O
.	O
The	O
final	O
data	O
set	O
consists	O
of	O
information	O
on	O
1076	O
individuals	O
.	O
The	O
protocol	O
for	O
this	O
study	O
was	O
approved	O
by	O
the	O
Human	O
Studies	O
Committee	O
of	O
Institutional	O
Review	O
Board	O
at	O
University	O
of	O
Minnesota	O
","	O
University	O
of	O
Utah	O
and	O
Tufts	O
University	O
/	O
New	O
England	O
Medical	O
Center	O
.	O
Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
participants	O
.	O
Biochemical	O
Measurements	O
InCHIANTI	O
:	O
Plasma	O
fatty	B-Chemical
acid	I-Chemical
measurement	O
methods	O
has	O
been	O
described	O
previously	O
[	O
43	O
].	O
Briefly	O
","	O
blood	O
samples	O
were	O
collected	O
in	O
the	O
morning	O
after	O
a	O
12	O
-	O
hr	O
overnight	O
fast	O
.	O
Aliquots	O
of	O
plasma	O
were	O
immediately	O
obtained	O
and	O
stored	O
at	O
âˆ’	O
80	O
C	O
.	O
Fatty	B-Chemical
acid	I-Chemical
methyl	I-Chemical
esters	I-Chemical
(	O
FAME	B-Chemical
)	O
were	O
prepared	O
through	O
transesterification	O
using	O
Lepage	O
and	O
Roy	O
â€™	O
s	O
method	O
with	O
modification	O
[	O
44	O
"],["	O
45	O
].	O
Separation	O
of	O
FAME	B-Chemical
was	O
carried	O
out	O
on	O
an	O
HP	O
-	O
6890	O
gas	O
chromatograph	O
(	O
Hewlett	O
-	O
Packard	O
","	O
Palo	O
Alto	O
","	O
CA	O
)	O
with	O
a	O
30	O
-	O
m	O
fused	O
silica	B-Chemical
column	O
(	O
HP	O
-	O
225	O
;	O
Hewlett	O
-	O
Packard	O
).	O
FAMEs	O
were	O
identified	O
by	O
comparison	O
with	O
pure	O
standards	O
(	O
NU	O
Chek	O
Prep	O
","	O
Inc	O
".,"	O
Elysian	O
","	O
MA	O
).	O
For	O
quantitative	O
analysis	O
of	O
fatty	B-Chemical
acids	I-Chemical
as	O
methyl	B-Chemical
esters	I-Chemical
","	O
calibration	O
curves	O
for	O
FAME	B-Chemical
(	O
ranging	O
from	O
C14	O
:	O
0	O
to	O
C24	O
:	O
1	O
)	O
were	O
prepared	O
by	O
adding	O
six	O
increasing	O
amounts	O
of	O
individual	O
FAME	B-Chemical
standards	O
to	O
the	O
same	O
amount	O
of	O
internal	O
standard	O
(	O
C17	O
:	O
0	O
;	O
50xg	O
).	O
The	O
correlation	O
coefficients	O
for	O
the	O
calibration	O
curves	O
of	O
fatty	B-Chemical
acids	I-Chemical
were	O
in	O
all	O
cases	O
higher	O
than	O
0	O
.	O
998	O
in	O
the	O
range	O
of	O
concentrations	O
studied	O
.	O
Fatty	B-Chemical
acid	I-Chemical
concentration	O
was	O
expressed	O
as	O
a	O
percentage	O
of	O
total	O
fatty	B-Chemical
acids	I-Chemical
.	O
The	O
coefficient	O
of	O
variation	O
for	O
all	O
fatty	B-Chemical
acids	I-Chemical
was	O
on	O
average	O
1	O
.	O
6	O
%	O
for	O
intraassay	O
and	O
3	O
.	O
3	O
%	O
for	O
interassay	O
.	O
HDL	B-Chemical
-	I-Chemical
C	I-Chemical
","	O
total	O
cholesterol	B-Chemical
and	O
triglycerides	B-Chemical
were	O
determined	O
using	O
commercial	O
enzymatic	O
tests	O
(	O
Roche	O
Diagnostics	O
","	O
Mannheim	O
","	O
Germany	O
).	O
Serum	O
low	B-Chemical
-	I-Chemical
density	I-Chemical
lipoprotein	I-Chemical
cholesterol	I-Chemical
(	O
LDL	B-Chemical
-	I-Chemical
C	I-Chemical
)	O
was	O
computed	O
with	O
the	O
Friedewald	O
formula	O
(	O
LDL	B-Chemical
-	I-Chemical
C	I-Chemical
=	O
total	O
cholesterol	B-Chemical
âˆ’	O
HDL	B-Chemical
-	I-Chemical
C	I-Chemical
âˆ’	O
triglicerides	B-Chemical
/	O
5	O
).	O
GOLDN	O
:	O
Fatty	B-Chemical
acids	I-Chemical
(	O
FA	B-Chemical
)	O
in	O
erythrocyte	O
membrane	O
were	O
measured	O
following	O
procedures	O
described	O
previously	O
[	O
46	O
]	O
Briefly	O
","	O
lipids	B-Chemical
were	O
extracted	O
from	O
the	O
erythrocyte	O
membranes	O
with	O
a	O
mixture	O
of	O
chloroform	B-Chemical
:	O
methanol	B-Chemical
(	O
2	O
:	O
1	O
","	O
v	O
/	O
v	O
"),"	O
collected	O
in	O
heptanes	B-Chemical
and	O
injected	O
onto	O
a	O
capillary	O
Varian	O
CP7420	O
100	O
-	O
m	O
column	O
with	O
a	O
Hewlett	O
Packard	O
5890	O
gas	O
chromatograph	O
(	O
GC	O
)	O
equipped	O
with	O
a	O
HP6890A	O
autosampler	O
.	O
The	O
GC	O
was	O
configured	O
for	O
a	O
single	O
capillary	O
column	O
with	O
a	O
flame	O
ionization	O
detector	O
and	O
interfaced	O
with	O
HP	O
chemstation	O
software	O
.	O
The	O
initial	O
temperature	O
of	O
190	O
Â°	O
C	O
was	O
increased	O
to	O
240	O
Â°	O
C	O
over	O
50	O
minutes	O
.	O
Fatty	B-Chemical
acid	I-Chemical
methylesters	I-Chemical
from	O
12	O
:	O
0	O
through	O
24	O
:	O
1n9	O
were	O
separated	O
","	O
identified	O
and	O
expressed	O
as	O
percent	O
of	O
total	O
fatty	B-Chemical
acid	I-Chemical
.	O
Triglycerides	B-Chemical
were	O
measured	O
using	O
a	O
glycerol	B-Chemical
blanked	O
enzymatic	O
method	O
(	O
Trig	O
/	O
GB	O
","	O
Roche	O
Diagnostics	O
Corporation	O
","	O
Indianapolis	O
","	O
IN	O
)	O
and	O
cholesterol	B-Chemical
was	O
measured	O
using	O
a	O
cholesterol	O
esterase	O
","	O
cholesterol	O
oxidase	O
reaction	O
(	O
Chol	O
R1	O
","	O
Roche	O
Diagnostics	O
Corporation	O
)	O
on	O
the	O
Roche	O
/	O
Hitachi	O
911	O
Automatic	O
Analyzer	O
(	O
Roche	O
Diagnostics	O
Corporation	O
).	O
For	O
HDL	B-Chemical
-	I-Chemical
cholesterol	I-Chemical
","	O
the	O
non	O
-	O
HDL	O
-	O
cholesterol	B-Chemical
was	O
first	O
precipitated	O
with	O
magnesium	B-Chemical
/	O
dextran	B-Chemical
.	O
LDL	B-Chemical
-	I-Chemical
cholesterol	I-Chemical
was	O
measured	O
by	O
a	O
homogeneous	O
direct	O
method	O
(	O
LDL	O
Direct	O
Liquid	O
Select	O
Cholesterol	B-Chemical
Reagent	O
","	O
Equal	O
Diagnostics	O
","	O
Exton	O
","	O
PA	O
).	O
Assessment	O
of	O
Dietary	O
Intake	O
In	O
the	O
InCHIANTI	O
","	O
dietary	O
intake	O
was	O
assessed	O
using	O
a	O
food	O
-	O
frequency	O
questionnaire	O
(	O
FFQ	O
)	O
created	O
for	O
the	O
European	O
Prospective	O
Investigation	O
into	O
Cancer	O
and	O
nutrition	O
(	O
EPIC	O
)	O
study	O
","	O
and	O
has	O
previously	O
been	O
validated	O
to	O
provide	O
good	O
estimates	O
of	O
dietary	O
intake	O
in	O
this	O
study	O
population	O
[	O
47	O
"],["	O
48	O
].	O
In	O
GOLDN	O
","	O
habitual	O
dietary	O
intake	O
was	O
estimated	O
using	O
the	O
validated	O
dietary	O
history	O
questionnaire	O
(	O
DHQ	O
)	O
developed	O
by	O
the	O
National	O
Cancer	O
Institute	O
[	O
49	O
].	O
We	O
excluded	O
subjects	O
that	O
reported	O
<	O
800	O
kcal	O
and	O
>	O
5500	O
kcal	O
in	O
men	O
and	O
<	O
600kcal	O
and	O
>	O
4500kcal	O
in	O
women	O
.	O
Genotyping	O
InCHIANTI	O
:	O
Genome	O
-	O
wide	O
genotyping	O
was	O
performed	O
using	O
the	O
Illumina	O
Infinium	O
HumanHap550	O
genotyping	O
chip	O
(	O
chip	O
version	O
1	O
and	O
3	O
)	O
as	O
previously	O
described	O
[	O
50	O
].	O
The	O
SNP	O
quality	O
control	O
was	O
assessed	O
using	O
GAINQC	O
.	O
The	O
exclusion	O
criteria	O
for	O
SNPs	O
were	O
minor	O
allele	O
frequency	O
<	O
1	O
%	O
(	O
n	O
=	O
25	O
","	O
422	O
"),"	O
genotyping	O
completeness	O
<	O
99	O
%	O
(	O
n	O
=	O
23	O
","	O
610	O
)	O
and	O
Hardy	O
Weinberg	O
-	O
equilibrium	O
(	O
HWE	O
)	O
<	O
0	O
.	O
1	O
(	O
n	O
=	O
517	O
).	O
GOLDN	O
:	O
Five	O
SNPs	O
were	O
selected	O
for	O
replication	O
in	O
the	O
GOLDN	O
study	O
:	O
rs953413	O
","	O
rs2277324	O
","	O
rs16940765	O
","	O
rs17718324	O
and	O
rs174537	O
.	O
One	O
of	O
these	O
","	O
rs2277324	O
","	O
failed	O
genotyping	O
and	O
therefore	O
another	O
SNP	O
in	O
high	O
LD	O
","	O
rs923838	O
(	O
r2	O
=	O
0	O
.	O
89	O
in	O
hapmap	O
"),"	O
was	O
used	O
as	O
a	O
proxy	O
for	O
this	O
SNP	O
.	O
DNA	O
was	O
extracted	O
from	O
blood	O
samples	O
and	O
purified	O
using	O
commercial	O
Puregene	O
reagents	O
(	O
Gentra	O
System	O
","	O
Inc	O
.)	O
following	O
manufacturer	O
â€™	O
s	O
instructions	O
.	O
SNPs	O
were	O
genotyped	O
using	O
the	O
5	O
â€™	O
nuclease	O
allelic	O
discrimination	O
Taqman	O
assay	O
with	O
allelic	O
specific	O
probes	O
on	O
the	O
ABI	O
Prism	O
7900HT	O
Sequence	O
Detection	O
System	O
(	O
Applies	O
Biosystems	O
","	O
Foster	O
City	O
","	O
Calif	O
","	O
USA	O
)	O
according	O
to	O
standard	O
laboratory	O
protocols	O
.	O
The	O
primers	O
and	O
probes	O
were	O
pre	O
-	O
designed	O
(	O
the	O
assay	O
-	O
on	O
-	O
demand	O
)	O
by	O
the	O
manufacturer	O
(	O
Applied	O
Biosystem	O
)	O
(	O
Assay	O
ID	O
:	O
FEN_rs174537	O
:	O
C___2269026_10	O
","	O
HRH4_rs16940765	O
:	O
C__32711739_10	O
","	O
SPARC_rs17718324	O
:	O
C__34334455_10	O
","	O
ELOVL2_rs953413	O
:	O
C___7617198_10	O
","	O
rs923828	O
:	O
C___2022671_10	O
).	O
Statistical	O
Analysis	O
InCHIANTI	O
GWAS	O
:	O
Inverse	O
normal	O
transformation	O
was	O
applied	O
to	O
plasma	O
fatty	B-Chemical
acid	I-Chemical
concentrations	O
to	O
avoid	O
inflated	O
type	O
I	O
error	O
due	O
to	O
non	O
-	O
normality	O
[	O
51	O
].	O
The	O
genotypes	O
were	O
coded	O
0	O
","	O
1	O
and	O
2	O
reflecting	O
the	O
number	O
of	O
copies	O
of	O
an	O
allele	O
being	O
tested	O
(	O
additive	O
genetic	O
model	O
).	O
For	O
X	O
-	O
chromosome	O
analysis	O
","	O
the	O
average	O
phenotype	O
of	O
males	O
hemizygous	O
for	O
a	O
particular	O
allele	O
was	O
treated	O
assumed	O
to	O
match	O
the	O
average	O
phenotype	O
of	O
females	O
homozygous	O
for	O
the	O
same	O
allele	O
.	O
Association	O
analysis	O
was	O
conducted	O
by	O
fitting	O
simple	O
regression	O
test	O
using	O
the	O
fastAssoc	O
option	O
in	O
MERLIN	O
[	O
52	O
].	O
Narrow	O
heritability	O
reflects	O
the	O
ratio	O
of	O
the	O
trait	O
â€™	O
s	O
additive	O
variance	O
to	O
the	O
total	O
variance	O
[	O
51	O
"],["	O
53	O
].	O
In	O
all	O
the	O
analyses	O
","	O
the	O
models	O
were	O
adjusted	O
for	O
sex	O
","	O
age	O
and	O
age	O
squared	O
.	O
The	O
genomic	O
control	O
method	O
was	O
used	O
to	O
control	O
for	O
effects	O
of	O
population	O
structure	O
and	O
cryptic	O
relatedness	O
[	O
54	O
].	O
An	O
approximate	O
genome	O
-	O
wide	O
significance	O
threshold	O
of	O
1	O
Ã—	O
10	O
âˆ’	O
7	O
(âˆ¼	O
0	O
.	O
5	O
/	O
495343	O
SNPs	O
)	O
was	O
used	O
.	O
For	O
each	O
fatty	B-Chemical
acid	I-Chemical
concentration	O
","	O
a	O
second	O
analysis	O
included	O
the	O
most	O
significant	O
SNP	O
from	O
the	O
first	O
pass	O
analysis	O
as	O
a	O
covariate	O
.	O
Linkage	O
disequilibrium	O
coefficints	O
within	O
the	O
region	O
of	O
interest	O
were	O
calculated	O
using	O
GOLD	O
[	O
55	O
].	O
For	O
the	O
other	O
phenotypes	O
(	O
total	O
cholesterol	B-Chemical
","	O
triglycerides	B-Chemical
","	O
LDL	B-Chemical
-	I-Chemical
cholesterol	I-Chemical
","	O
HDL	B-Chemical
-	I-Chemical
cholesterol	I-Chemical
and	O
BMI	O
"),"	O
the	O
traits	O
were	O
normalized	O
either	O
by	O
natural	O
log	O
or	O
square	O
root	O
transformation	O
when	O
necessary	O
.	O
Associations	O
for	O
each	O
SNP	O
were	O
investigated	O
using	O
the	O
general	O
linear	O
model	O
(	O
GLM	O
)	O
procedure	O
in	O
SAS	O
.	O
GOLDN	O
:	O
Inverse	O
normal	O
transformation	O
was	O
applied	O
to	O
erythrocyte	O
membrane	O
fatty	B-Chemical
acid	I-Chemical
concentration	O
to	O
achieve	O
approximate	O
normality	O
.	O
For	O
the	O
additive	O
model	O
","	O
genotype	O
coding	O
was	O
based	O
on	O
the	O
number	O
of	O
variant	O
alleles	O
at	O
the	O
polymorphic	O
site	O
.	O
With	O
no	O
significant	O
sex	O
modification	O
observed	O
","	O
men	O
and	O
women	O
were	O
analyzed	O
together	O
.	O
We	O
used	O
the	O
generalized	O
estimating	O
equation	O
(	O
GEE	O
)	O
linear	O
regression	O
with	O
exchangeable	O
correlation	O
structure	O
as	O
implemented	O
in	O
the	O
GENMOD	O
procedure	O
in	O
SAS	O
(	O
Windows	O
version	O
9	O
.	O
0	O
","	O
SAS	O
Institute	O
","	O
Cary	O
","	O
NC	O
)	O
to	O
adjust	O
for	O
correlated	O
observations	O
due	O
to	O
familial	O
relationships	O
.	O
Potential	O
confounding	O
factors	O
included	O
study	O
center	O
","	O
age	O
","	O
sex	O
","	O
BMI	O
","	O
smoking	O
(	O
never	O
","	O
former	O
and	O
current	O
smoker	O
"),"	O
alcohol	B-Chemical
consumption	O
(	O
non	O
-	O
drinker	O
and	O
current	O
drinker	O
"),"	O
physical	O
activity	O
","	O
drugs	O
for	O
lowering	O
cholesterol	B-Chemical
","	O
diabetes	O
and	O
hypertension	O
and	O
hormones	O
.	O
A	O
two	O
-	O
tailed	O
P	O
value	O
of	O
<	O
0	O
.	O
5	O
was	O
considered	O
to	O
be	O
statistically	O
significant	O
.	O
Supporting	O
Information	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O
This	O
study	O
was	O
supported	O
in	O
part	O
by	O
the	O
R	O
&	O
D	O
contract	O
with	O
MedStar	O
Research	O
Institute	O
","	O
the	O
Intramural	O
Research	O
Program	O
of	O
the	O
NIH	O
","	O
National	O
Institute	O
on	O
Aging	O
and	O
by	O
National	O
Heart	O
","	O
Lung	O
","	O
and	O
Blood	O
Institute	O
Grant	O
U01	O
HL72524	O
","	O
Genetic	O
and	O
Environmental	O
Determinants	O
of	O
Triglycerides	B-Chemical
;	O
Grants	O
HL	O
-	O
54776	O
and	O
DK075030	O
","	O
and	O
by	O
contracts	O
53	O
-	O
K06	O
-	O
5	O
-	O
10	O
and	O
58	O
-	O
1950	O
-	O
9	O
-	O
1	O
from	O
the	O
US	O
Department	O
of	O
Agriculture	O
Research	O
Service	O
.	O
References	O
The	O
synthetic	O
inhibitor	O
of	O
Fibroblast	O
Growth	O
Factor	O
Receptor	O
PD166866	B-Chemical
controls	O
negatively	O
the	O
growth	O
of	O
tumor	O
cells	O
in	O
culture	O
Background	O
Many	O
experimental	O
data	O
evidence	O
that	O
over	O
-	O
expression	O
of	O
various	O
growth	O
factors	O
cause	O
disorders	O
in	O
cell	O
proliferation	O
.	O
The	O
role	O
of	O
the	O
Fibroblast	O
Growth	O
Factors	O
(	O
FGF	O
)	O
in	O
growth	O
control	O
is	O
indisputable	O
:	O
in	O
particular	O
","	O
FGF1	O
and	O
its	O
tyrosine	O
kinase	O
receptor	O
(	O
FGFR1	O
)	O
act	O
through	O
a	O
very	O
complex	O
network	O
of	O
mechanisms	O
and	O
pathways	O
.	O
In	O
this	O
work	O
we	O
have	O
evaluated	O
the	O
antiproliferative	O
activity	O
effect	O
of	O
PD166866	B-Chemical
","	O
a	O
synthetic	O
molecule	O
inhibiting	O
the	O
tyrosin	O
kinase	O
action	O
of	O
FGFR1	O
.	O
Methods	O
Cells	O
were	O
routinely	O
grown	O
in	O
Dulbecco	B-Chemical
Modified	I-Chemical
Eagle	I-Chemical
'	I-Chemical
s	I-Chemical
medium	I-Chemical
supplemented	O
with	O
newborn	O
serum	O
and	O
a	O
penicillin	B-Chemical
-	O
streptomycin	B-Chemical
mixture	O
.	O
Cell	O
viability	O
was	O
evaluated	O
by	O
Mosmann	O
assay	O
and	O
by	O
trypan	B-Chemical
blue	I-Chemical
staining	O
.	O
DNA	O
damage	O
was	O
assessed	O
by	O
in	O
situ	O
fluorescent	O
staining	O
with	O
Terminal	O
Deoxynucleotidyl	O
Transferase	O
dUTP	B-Chemical
nick	O
end	O
labeling	O
(	O
TUNEL	O
assay	O
).	O
Assessment	O
of	O
oxidative	O
stress	O
at	O
membrane	O
level	O
was	O
measured	O
by	O
quantitative	O
analysis	O
of	O
the	O
intra	O
-	O
cellular	O
formation	O
of	O
malonyl	B-Chemical
-	I-Chemical
dialdheyde	I-Chemical
(	O
MDA	B-Chemical
)	O
deriving	O
from	O
the	O
decomposition	O
of	O
poly	B-Chemical
-	I-Chemical
unsaturated	I-Chemical
fatty	I-Chemical
acids	I-Chemical
.	O
The	O
expression	O
of	O
Poly	O
-	O
ADP	O
-	O
Ribose	O
-	O
Polymerase	O
(	O
PARP	O
"),"	O
consequent	O
to	O
DNA	O
fragmentation	O
","	O
was	O
evidenced	O
by	O
immuno	O
-	O
histochemistry	O
utilizing	O
an	O
antibody	O
directed	O
against	O
an	O
N	O
-	O
terminal	O
fragment	O
of	O
the	O
enzyme	O
.	O
Results	O
The	O
bioactivity	O
of	O
the	O
drug	O
was	O
investigated	O
on	O
Hela	O
cells	O
.	O
Cytoxicity	O
was	O
assessed	O
by	O
the	O
Mosmann	O
assay	O
and	O
by	O
vital	O
staining	O
with	O
trypan	B-Chemical
blue	I-Chemical
.	O
The	O
target	O
of	O
the	O
molecule	O
is	O
most	O
likely	O
the	O
cell	O
membrane	O
as	O
shown	O
by	O
the	O
significant	O
increase	O
of	O
the	O
intracellular	O
concentration	O
of	O
malonyl	B-Chemical
-	I-Chemical
dihaldheyde	I-Chemical
.	O
The	O
increase	O
of	O
this	O
compound	O
","	O
as	O
a	O
consequence	O
of	O
the	O
treatment	O
with	O
PD166866	B-Chemical
","	O
is	O
suggestive	O
of	O
membrane	O
lipoperoxidation	O
.	O
The	O
TUNEL	O
assay	O
gave	O
a	O
qualitative	O
","	O
though	O
clear	O
","	O
indication	O
of	O
DNA	O
damage	O
.	O
Furthermore	O
we	O
demonstrate	O
intracellular	O
accumulation	O
of	O
poly	O
-	O
ADP	O
-	O
ribose	O
polymerase	O
I	O
.	O
This	O
enzyme	O
is	O
a	O
sensor	O
of	O
nicks	O
on	O
the	O
DNA	O
strands	O
and	O
this	O
supports	O
the	O
idea	O
that	O
treatment	O
with	O
the	O
drug	O
induces	O
cell	O
death	O
.	O
Conclusions	O
Data	O
presented	O
in	O
this	O
work	O
show	O
that	O
PD166866	B-Chemical
has	O
clear	O
antiproliferative	O
effects	O
.	O
The	O
negative	O
control	O
of	O
cell	O
proliferation	O
may	O
be	O
exerted	O
through	O
the	O
activation	O
of	O
the	O
apoptotic	O
pathway	O
.	O
The	O
results	O
of	O
experiments	O
addressing	O
this	O
specific	O
point	O
","	O
such	O
as	O
:	O
evaluation	O
of	O
DNA	O
damage	O
","	O
lipoperoxidation	O
of	O
the	O
cell	O
membrane	O
and	O
increase	O
of	O
expression	O
of	O
PARP	O
","	O
an	O
enzyme	O
directly	O
involved	O
in	O
DNA	O
repair	O
.	O
Results	O
suggest	O
that	O
cells	O
exposed	O
to	O
PD16866	B-Chemical
undergo	O
apoptosis	O
.	O
However	O
","	O
concomitant	O
modes	O
of	O
cell	O
death	O
cannot	O
be	O
ruled	O
out	O
.	O
The	O
possible	O
use	O
of	O
this	O
drug	O
for	O
therapeutic	O
purposes	O
is	O
discussed	O
.	O
Background	O
The	O
dys	O
-	O
regulation	O
of	O
growth	O
factor	O
expression	O
leads	O
to	O
alterations	O
of	O
cell	O
functions	O
such	O
as	O
growth	O
control	O
and	O
proliferation	O
[	O
1	O
","	O
2	O
];	O
as	O
a	O
matter	O
of	O
fact	O
the	O
role	O
of	O
these	O
factors	O
as	O
well	O
as	O
that	O
of	O
their	O
tyrosine	O
kinase	O
receptors	O
in	O
growth	O
regulation	O
is	O
now	O
a	O
well	O
established	O
notion	O
.	O
This	O
action	O
is	O
exerted	O
through	O
a	O
myriad	O
of	O
mechanisms	O
and	O
pathways	O
and	O
their	O
involvement	O
in	O
biological	O
processes	O
ranging	O
from	O
differentiation	O
to	O
apoptosis	O
has	O
been	O
amply	O
demonstrated	O
[	O
3	O
-	O
6	O
].	O
The	O
aim	O
of	O
this	O
work	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
synthetic	O
molecule	O
","	O
PD166866	B-Chemical
","	O
which	O
is	O
an	O
inhibitor	O
of	O
the	O
tyrosine	O
kinase	O
function	O
exerted	O
by	O
FGFR1	O
.	O
In	O
addition	O
to	O
PD166866	B-Chemical
other	O
tyrosine	O
kinase	O
inhibitor	O
molecules	O
","	O
such	O
as	O
SU	B-Chemical
4984	I-Chemical
and	O
SU	B-Chemical
5402	I-Chemical
have	O
been	O
described	O
.	O
These	O
compounds	O
show	O
a	O
very	O
high	O
selectivity	O
towards	O
FGFR1	O
and	O
inhibit	O
the	O
auto	O
-	O
phosphorylation	O
activity	O
of	O
FGRF1	O
","	O
however	O
PD166866	B-Chemical
shows	O
an	O
about	O
100	O
-	O
fold	O
higher	O
activity	O
[	O
7	O
].	O
Other	O
biological	O
activities	O
have	O
been	O
ascribed	O
to	O
these	O
compounds	O
and	O
it	O
is	O
generally	O
accepted	O
that	O
they	O
may	O
find	O
a	O
possible	O
application	O
for	O
the	O
control	O
of	O
proliferation	O
both	O
of	O
normal	O
and	O
tumor	O
cells	O
[	O
8	O
-	O
10	O
].	O
The	O
results	O
presented	O
here	O
extend	O
a	O
previous	O
study	O
where	O
the	O
activity	O
of	O
PD166866	B-Chemical
was	O
assayed	O
on	O
a	O
normal	O
murine	O
fibroblast	O
cell	O
line	O
in	O
culture	O
[	O
10	O
].	O
The	O
impact	O
of	O
this	O
drug	O
on	O
the	O
overall	O
cell	O
metabolism	O
was	O
also	O
investigated	O
in	O
a	O
previous	O
work	O
from	O
our	O
laboratory	O
[	O
11	O
].	O
Here	O
we	O
evaluate	O
the	O
bioactivity	O
of	O
the	O
drug	O
versus	O
a	O
human	O
tumor	O
cell	O
line	O
(	O
HeLa	O
).	O
The	O
growth	O
inhibition	O
monitored	O
in	O
this	O
study	O
strongly	O
suggests	O
that	O
it	O
may	O
derive	O
from	O
DNA	O
damage	O
and	O
activation	O
of	O
cell	O
death	O
processes	O
most	O
likely	O
of	O
apoptotic	O
nature	O
.	O
Therefore	O
a	O
future	O
clinical	O
use	O
for	O
the	O
control	O
of	O
proliferative	O
pathologies	O
may	O
be	O
envisaged	O
.	O
Methods	O
Growth	O
and	O
maintenance	O
of	O
HeLa	O
cells	O
Cells	O
were	O
maintained	O
in	O
DMEM	B-Chemical
(	O
Dulbecco	B-Chemical
'	I-Chemical
s	I-Chemical
Modified	I-Chemical
Eagle	I-Chemical
'	I-Chemical
s	I-Chemical
Medium	I-Chemical
-	O
high	O
glucose	B-Chemical
"),"	O
supplemented	O
with	O
newborn	O
bovine	O
serum	O
[	O
final	O
concentration	O
(	O
f	O
.	O
c	O
.)	O
10	O
"%],"	O
penicillin	B-Chemical
-	O
streptomycin	B-Chemical
(	O
10000	O
U	O
/	O
ml	O
)	O
and	O
glutamine	B-Chemical
(	O
2	O
mM	O
);	O
the	O
pH	O
of	O
the	O
medium	O
was	O
7	O
.	O
2	O
and	O
incubation	O
was	O
at	O
37	O
Â°	O
C	O
in	O
a	O
5	O
%	O
CO2	B-Chemical
atmosphere	O
.	O
Cells	O
were	O
routinely	O
passaged	O
when	O
confluent	O
.	O
Assessment	O
of	O
cell	O
viability	O
and	O
lipoperoxidation	O
assay	O
Cell	O
viability	O
was	O
evaluated	O
by	O
the	O
colorimetric	O
Mosmann	O
assay	O
[	O
12	O
]	O
which	O
is	O
a	O
quantitative	O
method	O
measuring	O
the	O
level	O
of	O
mitochondrial	O
damage	O
.	O
The	O
MTT	B-Chemical
[	O
3	B-Chemical
-(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
dimetiltiazol	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
yl	I-Chemical
)-	I-Chemical
2	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
difenil	I-Chemical
tetrazolium	I-Chemical
-	I-Chemical
bromide	I-Chemical
]	O
is	O
a	O
yellow	O
water	B-Chemical
soluble	O
salt	O
which	O
is	O
converted	O
into	O
insoluble	O
purple	O
salts	O
formed	O
by	O
the	O
active	O
dehydrogenases	O
present	O
in	O
the	O
mitochondria	O
of	O
vital	O
cells	O
.	O
Absorbance	O
values	O
measured	O
at	O
570	O
nm	O
provide	O
the	O
number	O
of	O
vital	O
cells	O
.	O
The	O
cell	O
survival	O
data	O
were	O
validated	O
by	O
vital	O
staining	O
with	O
trypan	B-Chemical
blue	I-Chemical
performed	O
by	O
a	O
standard	O
laboratory	O
protocol	O
.	O
A	O
commercial	O
kit	O
(	O
LPO	O
-	O
586	O
;	O
Oxis	O
Health	O
Research	O
Products	O
Portland	O
","	O
Or	O
.	O
USA	O
)	O
was	O
used	O
to	O
assess	O
the	O
oxidative	O
stress	O
at	O
membrane	O
level	O
.	O
Briefly	O
","	O
the	O
assay	O
is	O
based	O
on	O
a	O
quantitative	O
analysis	O
of	O
the	O
intra	O
-	O
cellular	O
formation	O
of	O
malonyl	B-Chemical
-	I-Chemical
dialdheyde	I-Chemical
(	O
MDA	B-Chemical
)	O
which	O
derives	O
from	O
the	O
decomposition	O
of	O
poly	B-Chemical
-	I-Chemical
unsaturated	I-Chemical
fatty	I-Chemical
acids	I-Chemical
.	O
The	O
MDA	B-Chemical
molecule	O
reacts	O
with	O
a	O
chromogenic	O
compound	O
(	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
phenylindole	I-Chemical
)	O
thus	O
forming	O
a	O
stable	O
chromophore	O
.	O
Absorbance	O
at	O
586	O
nm	O
is	O
directly	O
transformed	O
in	O
intracellular	O
concentration	O
of	O
MDA	B-Chemical
[	O
13	O
].	O
TUNEL	O
assay	O
and	O
analysis	O
of	O
the	O
DNA	O
fragmentation	O
The	O
activation	O
of	O
the	O
endogenous	O
DNases	O
is	O
one	O
of	O
the	O
consequences	O
of	O
cell	O
death	O
causing	O
the	O
formation	O
of	O
single	O
strand	O
nicks	O
and	O
eventually	O
fragmentation	O
of	O
DNA	O
.	O
The	O
DNA	O
ruptures	O
may	O
be	O
evidenced	O
by	O
in	O
situ	O
labelling	O
.	O
Cell	O
nuclei	O
are	O
permeabilized	O
","	O
fluorescent	O
dUTP	B-Chemical
is	O
added	O
and	O
terminal	O
-	O
deoxynucleotide	O
-	O
transferase	O
conjugates	O
the	O
nucleotide	B-Chemical
where	O
the	O
sugar	B-Chemical
-	I-Chemical
phosphate	I-Chemical
backbone	O
is	O
interrupted	O
.	O
Fluorescence	O
intensity	O
provides	O
a	O
qualitative	O
idea	O
of	O
DNA	O
damage	O
[	O
14	O
].	O
Immunolocalization	O
of	O
Poly	O
-	O
ADP	O
-	O
Ribose	O
-	O
Polymerase	O
(	O
PARP	O
)	O
The	O
enzyme	O
PARP	O
is	O
activated	O
in	O
response	O
to	O
DNA	O
fragmentation	O
.	O
The	O
immunolocalization	O
of	O
PARP	O
was	O
performed	O
as	O
previously	O
published	O
[	O
15	O
].	O
Briefly	O
","	O
HeLa	O
cells	O
were	O
treated	O
with	O
PD166866	B-Chemical
for	O
24	O
hours	O
","	O
the	O
growth	O
medium	O
was	O
removed	O
","	O
the	O
cells	O
were	O
washed	O
with	O
PBS	B-Chemical
and	O
fixed	O
for	O
1	O
hour	O
at	O
25	O
Â°	O
C	O
adding	O
a	O
freshly	O
made	O
paraformaldheyde	B-Chemical
solution	O
(	O
4	O
%	O
in	O
PBS	B-Chemical
).	O
Samples	O
were	O
washed	O
again	O
with	O
PBS	B-Chemical
and	O
the	O
endogenous	O
oxidases	O
were	O
blocked	O
for	O
2	O
minutes	O
in	O
the	O
dark	O
.	O
Further	O
washes	O
with	O
PBS	B-Chemical
followed	O
and	O
blocking	O
the	O
unspecific	O
sites	O
was	O
done	O
for	O
1	O
hour	O
at	O
25	O
Â°	O
C	O
.	O
PARP	O
was	O
evidenced	O
by	O
immunolocalization	O
utilizing	O
a	O
polyclonal	O
antibody	O
(	O
PARP	O
H	O
-	O
250	O
Santa	O
Cruz	O
Biotechnology	O
","	O
Inc	O
.	O
"),"	O
directed	O
against	O
the	O
N	O
-	O
terminal	O
proteolytic	O
fragment	O
.	O
Immuno	O
-	O
reaction	O
was	O
revealed	O
by	O
a	O
secondary	O
anti	O
-	O
rabbit	O
antibody	O
after	O
incubation	O
for	O
16	O
hours	O
at	O
4	O
Â°	O
C	O
.	O
After	O
exhaustive	O
washing	O
with	O
PBS	B-Chemical
the	O
samples	O
were	O
incubated	O
for	O
30	O
minutes	O
in	O
solution	O
ABC	O
(	O
Vectastain	O
ABC	O
-	O
POD	O
Elite	O
","	O
PK	O
-	O
6101	O
kit	O
","	O
used	O
according	O
the	O
supplier	O
'	O
s	O
recommendations	O
).	O
Eventually	O
","	O
DAB	B-Chemical
(	O
3	B-Chemical
","	I-Chemical
3	I-Chemical
'-	I-Chemical
Diaminobenzidine	I-Chemical
)	O
was	O
added	O
and	O
the	O
samples	O
were	O
incubated	O
for	O
10	O
minutes	O
in	O
the	O
dark	O
.	O
The	O
samples	O
were	O
washed	O
again	O
the	O
plates	O
were	O
sealed	O
and	O
ready	O
for	O
microscopic	O
observation	O
(	O
Zeiss	O
Axiophot	O
).	O
Statistical	O
analysis	O
Data	O
were	O
obtained	O
by	O
at	O
least	O
three	O
independent	O
experiments	O
.	O
Statistical	O
analysis	O
was	O
done	O
by	O
one	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
a	O
comparative	O
LSD	O
test	O
(	O
Least	O
Significant	O
Difference	O
).	O
Results	O
were	O
considered	O
significant	O
when	O
p	O
<	O
0	O
.	O
5	O
.	O
Results	O
Cytotoxicity	O
of	O
PD166866	B-Chemical
on	O
HeLa	O
cells	O
in	O
culture	O
We	O
explored	O
the	O
dose	O
/	O
response	O
effect	O
of	O
HeLa	O
cells	O
exposed	O
to	O
a	O
relatively	O
broad	O
range	O
of	O
PD166866	B-Chemical
concentrations	O
(	O
0	O
.	O
1	O
-	O
50	O
Î¼M	O
).	O
Cells	O
were	O
treated	O
for	O
24	O
hours	O
with	O
the	O
drug	O
and	O
their	O
vitality	O
assessed	O
by	O
the	O
MTT	B-Chemical
assay	O
[	O
12	O
].	O
A	O
significant	O
reduction	O
of	O
vital	O
cells	O
can	O
be	O
monitored	O
already	O
at	O
2	O
.	O
5	O
Î¼M	O
concentration	O
(	O
Figure	O
1	O
","	O
left	O
panel	O
).	O
The	O
loss	O
of	O
viability	O
seems	O
to	O
stabilize	O
at	O
25	O
Î¼M	O
(	O
about	O
25	O
%	O
survival	O
)	O
with	O
no	O
further	O
decrease	O
at	O
a	O
50	O
Î¼M	O
concentration	O
of	O
drug	O
.	O
This	O
result	O
may	O
indicate	O
the	O
presence	O
of	O
a	O
cell	O
subpopulation	O
","	O
intrinsically	O
resistant	O
to	O
the	O
drug	O
.	O
This	O
result	O
was	O
confirmed	O
by	O
vital	O
cell	O
count	O
with	O
trypan	B-Chemical
blue	I-Chemical
(	O
only	O
the	O
data	O
obtained	O
at	O
2	O
.	O
5	O
Î¼M	O
of	O
drug	O
is	O
shown	O
;	O
Figure	O
1	O
","	O
right	O
panel	O
).	O
The	O
negative	O
effect	O
of	O
PD166866	B-Chemical
on	O
the	O
cell	O
growth	O
was	O
already	O
observed	O
in	O
a	O
previous	O
works	O
performed	O
on	O
3T6	O
cells	O
:	O
a	O
stabilized	O
murine	O
fibroblast	O
line	O
[	O
10	O
","	O
11	O
].	O
The	O
results	O
presented	O
here	O
validate	O
those	O
already	O
published	O
and	O
","	O
as	O
far	O
as	O
cell	O
survival	O
is	O
concerning	O
","	O
no	O
difference	O
can	O
be	O
monitored	O
on	O
HeLa	O
in	O
comparison	O
to	O
3T6	O
cells	O
in	O
matching	O
experiments	O
also	O
run	O
in	O
this	O
work	O
(	O
not	O
shown	O
).	O
Interestingly	O
","	O
as	O
observed	O
in	O
a	O
former	O
study	O
","	O
HeLa	O
cells	O
showed	O
a	O
significantly	O
higher	O
sensitivity	O
than	O
murine	O
cells	O
towards	O
resveratrol	B-Chemical
","	O
a	O
natural	O
product	O
showing	O
both	O
cytotoxic	O
and	O
antiviral	O
properties	O
[	O
16	O
].	O
One	O
way	O
to	O
rationalize	O
this	O
data	O
is	O
that	O
the	O
cellular	O
/	O
molecular	O
target	O
of	O
the	O
two	O
drugs	O
could	O
be	O
different	O
.	O
Assessment	O
of	O
cell	O
survival	O
after	O
treatment	O
with	O
PD166866	B-Chemical
.	O
Cells	O
were	O
treated	O
with	O
PD166866	B-Chemical
for	O
24	O
hours	O
at	O
the	O
indicated	O
concentrations	O
.	O
At	O
the	O
end	O
of	O
the	O
treatment	O
","	O
the	O
samples	O
were	O
subjected	O
to	O
the	O
Mossman	O
assay	O
(	O
right	O
panel	O
).	O
Alternatively	O
after	O
treatment	O
cells	O
were	O
stained	O
with	O
trypan	B-Chemical
blue	I-Chemical
according	O
to	O
standard	O
laboratory	O
procedures	O
(	O
left	O
panel	O
).	O
In	O
this	O
latter	O
case	O
only	O
the	O
survival	O
at	O
2	O
.	O
5	O
Î¼M	O
is	O
reported	O
.	O
The	O
Mosmann	O
assay	O
[	O
12	O
]	O
indicates	O
membrane	O
damage	O
","	O
essentially	O
at	O
mitochondrion	O
level	O
.	O
Therefore	O
","	O
we	O
investigated	O
the	O
possibility	O
that	O
PD166866	B-Chemical
may	O
be	O
detrimental	O
to	O
the	O
membrane	O
integrity	O
by	O
lipoperoxidation	O
assays	O
[	O
13	O
].	O
Lipoperoxidation	O
shows	O
that	O
PD166866	B-Chemical
causes	O
membrane	O
damage	O
The	O
lipoperoxidation	O
assay	O
is	O
a	O
very	O
powerful	O
tool	O
to	O
evaluate	O
in	O
a	O
quantitative	O
manner	O
the	O
membrane	O
damage	O
deriving	O
from	O
phenomena	O
of	O
oxidative	O
stress	O
.	O
The	O
formation	O
of	O
poly	B-Chemical
-	I-Chemical
unsaturated	I-Chemical
acids	I-Chemical
","	O
consequent	O
to	O
this	O
stress	O
","	O
causes	O
the	O
formation	O
malonyl	B-Chemical
-	I-Chemical
dihaldeyde	I-Chemical
(	O
MDA	B-Chemical
)	O
and	O
of	O
4	B-Chemical
-	I-Chemical
hydroxyhalkenals	I-Chemical
.	O
The	O
concentration	O
of	O
intracellular	O
MDA	B-Chemical
","	O
a	O
compound	O
normally	O
not	O
found	O
in	O
the	O
cytoplasm	O
","	O
is	O
correlated	O
directly	O
to	O
the	O
extent	O
of	O
the	O
membrane	O
damage	O
[	O
13	O
].	O
In	O
this	O
experiment	O
we	O
treated	O
the	O
cells	O
with	O
PD166866	B-Chemical
(	O
50	O
Î¼M	O
)	O
or	O
with	O
H2O2	B-Chemical
which	O
","	O
like	O
other	O
oxygen	B-Chemical
reactive	I-Chemical
species	I-Chemical
is	O
a	O
very	O
well	O
known	O
inducer	O
of	O
oxidative	O
stress	O
in	O
animal	O
and	O
plant	O
cell	O
as	O
well	O
as	O
in	O
diverse	O
pathologies	O
[	O
17	O
-	O
19	O
].	O
The	O
results	O
of	O
Figure	O
2	O
(	O
central	O
bar	O
)	O
show	O
that	O
that	O
treatment	O
with	O
the	O
drug	O
causes	O
an	O
over	O
4	O
-	O
fold	O
increase	O
of	O
the	O
intracellular	O
concentration	O
of	O
MDA	B-Chemical
:	O
thus	O
PD166866	B-Chemical
induces	O
an	O
oxidative	O
stress	O
with	O
consequent	O
membrane	O
damage	O
.	O
However	O
","	O
one	O
should	O
not	O
be	O
misled	O
by	O
the	O
much	O
higher	O
level	O
of	O
MDA	B-Chemical
generated	O
by	O
H2O2	B-Chemical
(	O
Figure	O
2	O
left	O
bar	O
)	O
since	O
the	O
concentration	O
and	O
the	O
power	O
of	O
this	O
compound	O
is	O
by	O
no	O
means	O
comparable	O
with	O
that	O
of	O
PD166866	B-Chemical
in	O
this	O
experimental	O
context	O
.	O
Finally	O
","	O
it	O
is	O
known	O
that	O
an	O
uncontrolled	O
oxidative	O
stress	O
may	O
lead	O
to	O
apoptotic	O
cell	O
death	O
[	O
20	O
","	O
21	O
].	O
Therefore	O
","	O
we	O
analyzed	O
an	O
additional	O
marker	O
diagnostic	O
of	O
apoptosis	O
:	O
DNA	O
damage	O
.	O
Intracellular	O
concentration	O
of	O
malonyl	B-Chemical
-	I-Chemical
dihaldehyde	I-Chemical
(	O
MDA	B-Chemical
)	O
after	O
treatment	O
with	O
PD166866	B-Chemical
.	O
Cells	O
were	O
treated	O
with	O
the	O
drug	O
(	O
50	O
Î¼M	O
)	O
for	O
24	O
hours	O
and	O
processed	O
for	O
the	O
membrane	O
lipoperoxidation	O
test	O
.	O
The	O
intracellular	O
concentration	O
of	O
MDA	B-Chemical
is	O
over	O
4	O
-	O
fold	O
higher	O
in	O
cells	O
treated	O
with	O
the	O
drug	O
(	O
central	O
bar	O
)	O
as	O
compared	O
to	O
untreated	O
control	O
cells	O
(	O
left	O
bar	O
).	O
This	O
indicates	O
membrane	O
damage	O
due	O
to	O
oxidative	O
stress	O
.	O
DNA	O
damage	O
and	O
cell	O
death	O
assessed	O
by	O
fluorescent	O
TUNEL	O
staining	O
The	O
TUNEL	O
assay	O
is	O
an	O
experimental	O
protocol	O
allowing	O
the	O
detection	O
of	O
DNA	O
fragmentation	O
.	O
The	O
specificity	O
of	O
this	O
assay	O
has	O
been	O
disputed	O
but	O
modifications	O
done	O
to	O
the	O
original	O
method	O
[	O
21	O
]	O
improved	O
its	O
accuracy	O
[	O
22	O
].	O
Therefore	O
","	O
it	O
is	O
generally	O
accepted	O
that	O
the	O
correct	O
execution	O
of	O
the	O
TUNEL	O
protocol	O
mainly	O
labels	O
DNA	O
fragmentation	O
in	O
very	O
advanced	O
phases	O
of	O
apoptosis	O
[	O
23	O
","	O
24	O
]	O
thus	O
evidencing	O
cells	O
that	O
have	O
sustained	O
severe	O
DNA	O
damage	O
.	O
The	O
cells	O
were	O
treated	O
with	O
PD166866	B-Chemical
in	O
the	O
usual	O
experimental	O
conditions	O
(	O
50	O
Î¼M	O
for	O
24	O
hours	O
).	O
Results	O
show	O
a	O
very	O
evident	O
fluorescent	O
staining	O
of	O
the	O
cells	O
treated	O
with	O
the	O
drug	O
(	O
Figure	O
3	O
","	O
large	O
panel	O
)	O
which	O
is	O
a	O
sign	O
of	O
extensive	O
DNA	O
rupturing	O
.	O
In	O
the	O
positive	O
control	O
","	O
cells	O
treated	O
with	O
H2O2	B-Chemical
also	O
a	O
very	O
diffuse	O
fluorescence	O
is	O
visible	O
(	O
Figure	O
3	O
","	O
left	O
small	O
panel	O
).	O
On	O
the	O
contrary	O
","	O
little	O
if	O
any	O
fluorescence	O
is	O
monitored	O
in	O
control	O
plates	O
(	O
Figure	O
3	O
","	O
right	O
small	O
panel	O
).	O
Therefore	O
we	O
can	O
conclude	O
that	O
in	O
cells	O
treated	O
for	O
24	O
hours	O
with	O
PD166866	B-Chemical
the	O
apoptotic	O
pathway	O
is	O
in	O
progress	O
.	O
An	O
extensive	O
DNA	O
damage	O
is	O
caused	O
by	O
treatment	O
with	O
PD166866	B-Chemical
.	O
After	O
treatment	O
with	O
the	O
drug	O
(	O
50	O
Î¼M	O
for	O
24	O
hours	O
"),"	O
the	O
cell	O
nuclei	O
were	O
permeabilized	O
.	O
Fluorescent	O
dUTP	B-Chemical
and	O
terminal	O
-	O
deoxynucleotide	O
-	O
transferase	O
were	O
added	O
.	O
The	O
enzyme	O
conjugates	O
the	O
nucleotide	B-Chemical
where	O
the	O
sugar	B-Chemical
-	I-Chemical
phosphate	I-Chemical
backbone	O
is	O
interrupted	O
.	O
The	O
high	O
intensity	O
of	O
fluorescence	O
(	O
large	O
panel	O
)	O
indicated	O
of	O
extensive	O
DNA	O
damage	O
due	O
to	O
the	O
exposure	O
to	O
the	O
drug	O
.	O
This	O
is	O
also	O
monitored	O
in	O
cells	O
treated	O
with	O
H2O2	B-Chemical
(	O
small	O
left	O
panel	O
"),"	O
while	O
it	O
is	O
virtually	O
absent	O
in	O
untreated	O
control	O
cells	O
(	O
small	O
right	O
panel	O
).	O
Poly	O
-	O
ADP	O
-	O
Ribose	O
-	O
Polymerase	O
(	O
PARP	O
)	O
is	O
accumulated	O
after	O
treatment	O
with	O
PD166866	B-Chemical
The	O
nuclear	O
enzyme	O
PARP	O
-	O
1	O
catalyzes	O
the	O
transfer	O
and	O
binds	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymers	O
to	O
itself	O
and	O
other	O
nuclear	O
proteins	O
in	O
response	O
to	O
interruptions	O
of	O
the	O
DNA	O
phosphate	B-Chemical
backbone	O
.	O
The	O
caspases	O
are	O
primarily	O
involved	O
in	O
the	O
cleavage	O
of	O
PARP	O
-	O
1	O
into	O
two	O
fragments	O
and	O
this	O
has	O
become	O
a	O
general	O
hallmark	O
of	O
apoptosis	O
[	O
25	O
-	O
29	O
].	O
Results	O
of	O
Figure	O
4	O
(	O
large	O
panel	O
)	O
show	O
a	O
relevant	O
immuno	O
-	O
positivity	O
to	O
PARP	O
-	O
1	O
in	O
cells	O
treated	O
with	O
PD166866	B-Chemical
(	O
24	O
hours	O
50	O
Î¼M	O
)	O
which	O
is	O
also	O
monitored	O
in	O
positive	O
control	O
cells	O
where	O
apoptosis	O
was	O
caused	O
by	O
the	O
administration	O
of	O
H2O2	B-Chemical
(	O
upper	O
left	O
panel	O
).	O
The	O
overall	O
conclusion	O
is	O
that	O
the	O
cells	O
treated	O
with	O
the	O
drug	O
are	O
found	O
actually	O
in	O
a	O
condition	O
of	O
advanced	O
apoptosis	O
.	O
Accumulation	O
Poly	O
-	O
ADP	O
-	O
Ribose	O
-	O
Polymerase	O
(	O
PARP	O
)	O
in	O
cells	O
treated	O
with	O
PD166866	B-Chemical
evidenced	O
by	O
imuno	O
-	O
histochemistry	O
.	O
Cells	O
were	O
treated	O
with	O
the	O
drug	O
(	O
50	O
Î¼M	O
for	O
24	O
hours	O
)	O
and	O
processed	O
by	O
immuno	O
-	O
histochemical	O
techniques	O
to	O
visualize	O
the	O
intracellular	O
accumulation	O
of	O
PARP	O
.	O
The	O
dark	O
nuclei	O
indicate	O
accumulation	O
of	O
this	O
enzyme	O
in	O
treated	O
cells	O
(	O
large	O
panel	O
).	O
The	O
immuno	O
-	O
reaction	O
also	O
occurs	O
in	O
positive	O
control	O
cells	O
treated	O
with	O
H202	B-Chemical
(	O
left	O
small	O
panel	O
)	O
while	O
it	O
is	O
almost	O
absent	O
in	O
untreated	O
control	O
cells	O
.	O
These	O
results	O
indicate	O
cell	O
death	O
.	O
Discussion	O
The	O
family	O
of	O
Growth	O
Factor	O
Receptors	O
(	O
FGFR	O
)	O
is	O
constituted	O
by	O
tyrosine	O
kinases	O
involved	O
in	O
a	O
number	O
of	O
different	O
cell	O
functions	O
ranging	O
from	O
cell	O
growth	O
control	O
to	O
mytogenesis	O
and	O
differentiation	O
.	O
Consequently	O
","	O
the	O
interruption	O
of	O
the	O
tyrosine	O
-	O
kinase	O
signal	O
transduction	O
is	O
considered	O
a	O
powerful	O
strategy	O
to	O
inhibit	O
angiogenesis	O
and	O
tumor	O
cell	O
proliferation	O
:	O
therefore	O
fibroblast	O
growth	O
factors	O
and	O
their	O
high	O
-	O
affinity	O
receptors	O
play	O
a	O
crucial	O
role	O
for	O
cell	O
growth	O
survival	O
and	O
maintenance	O
.	O
The	O
interplay	O
between	O
growth	O
factors	O
and	O
their	O
receptors	O
is	O
indeed	O
a	O
very	O
complex	O
one	O
;	O
however	O
","	O
the	O
overall	O
emerging	O
picture	O
is	O
that	O
PD166866	B-Chemical
","	O
as	O
a	O
tyrosine	O
kinase	O
inhibitor	O
","	O
is	O
able	O
to	O
invalidate	O
the	O
protective	O
action	O
exerted	O
by	O
different	O
agents	O
inducing	O
apoptosis	O
[	O
30	O
","	O
31	O
].	O
In	O
any	O
case	O
","	O
inhibition	O
of	O
the	O
FGF	O
receptors	O
mediated	O
by	O
small	O
molecules	O
such	O
as	O
SU5402	B-Chemical
and	O
PD166866	B-Chemical
have	O
been	O
recently	O
shown	O
to	O
reduce	O
growth	O
","	O
survival	O
and	O
motility	O
","	O
as	O
well	O
as	O
clonogenic	O
potential	O
in	O
non	O
small	O
cancer	O
lung	O
cell	O
lines	O
(	O
SSCLC	O
)	O
[	O
32	O
].	O
The	O
data	O
reported	O
here	O
indicate	O
that	O
one	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
drug	O
may	O
be	O
the	O
membrane	O
of	O
the	O
HeLa	O
cells	O
which	O
is	O
agreement	O
with	O
the	O
membrane	O
localization	O
of	O
the	O
FGFR	O
.	O
The	O
treatment	O
with	O
PD166866	B-Chemical
apparently	O
causes	O
a	O
mitochondrial	O
deficit	O
and	O
an	O
oxidative	O
stress	O
","	O
as	O
demonstrated	O
respectively	O
","	O
by	O
the	O
MTT	B-Chemical
assay	O
and	O
by	O
the	O
increase	O
of	O
the	O
intracellular	O
concentration	O
of	O
malonyl	B-Chemical
-	I-Chemical
dihaldeyde	I-Chemical
.	O
However	O
","	O
rationalizing	O
how	O
the	O
drug	O
could	O
activate	O
these	O
processes	O
is	O
not	O
an	O
easy	O
task	O
.	O
In	O
any	O
case	O
","	O
the	O
impact	O
of	O
PD166866	B-Chemical
on	O
the	O
overall	O
cell	O
metabolism	O
[	O
11	O
]	O
cannot	O
be	O
disregarded	O
as	O
an	O
element	O
of	O
serious	O
perturbation	O
of	O
the	O
cell	O
homeostasis	O
.	O
It	O
may	O
be	O
argued	O
that	O
apoptosis	O
could	O
not	O
be	O
the	O
only	O
death	O
process	O
activated	O
by	O
PD166866	B-Chemical
.	O
Concerning	O
this	O
particular	O
aspect	O
","	O
the	O
role	O
of	O
PARP	O
in	O
executing	O
the	O
cell	O
death	O
program	O
should	O
be	O
discussed	O
in	O
more	O
detail	O
.	O
In	O
our	O
immunoblotting	O
experiments	O
","	O
PARP	O
-	O
1	O
was	O
revealed	O
by	O
an	O
antibody	O
directed	O
towards	O
N	O
-	O
terminal	O
fragment	O
of	O
the	O
enzyme	O
thus	O
indicating	O
that	O
proteolytic	O
cleavage	O
","	O
mediated	O
by	O
caspases	O
","	O
actually	O
occurs	O
in	O
our	O
experimental	O
model	O
:	O
therefore	O
DNA	O
repair	O
operated	O
by	O
PARP	O
cannot	O
longer	O
occur	O
and	O
the	O
cells	O
exposed	O
to	O
PD166866	B-Chemical
proceed	O
into	O
the	O
apoptotic	O
death	O
.	O
However	O
","	O
it	O
has	O
been	O
shown	O
that	O
in	O
necrotic	O
death	O
","	O
cleavage	O
of	O
PARP	O
-	O
1	O
is	O
caspase	O
resistant	O
and	O
its	O
proteolysis	O
is	O
partly	O
or	O
totally	O
caused	O
by	O
lysosomal	O
proteases	O
[	O
33	O
].	O
Also	O
PARP	O
is	O
not	O
proteolytically	O
cleaved	O
by	O
caspases	O
during	O
apoptosis	O
in	O
hepatocytes	O
[	O
34	O
].	O
A	O
recent	O
literature	O
report	O
demonstrated	O
that	O
cell	O
death	O
may	O
occur	O
in	O
a	O
caspase	O
-	O
independent	O
manner	O
(	O
CICD	O
","	O
Caspase	O
Independent	O
Cell	O
Death	O
)	O
also	O
defined	O
as	O
necroptosis	O
[	O
35	O
].	O
Finally	O
","	O
a	O
further	O
form	O
of	O
cell	O
death	O
has	O
been	O
described	O
recently	O
which	O
is	O
distinct	O
from	O
apoptosis	O
","	O
necrosis	O
","	O
or	O
autophagy	O
and	O
is	O
termed	O
parthanatos	O
.	O
This	O
is	O
a	O
PARP	O
-	O
1	O
-	O
dependent	O
ubiquitarious	O
form	O
of	O
cell	O
death	O
involved	O
in	O
all	O
tissues	O
of	O
the	O
organism	O
and	O
in	O
pathologies	O
as	O
diverse	O
as	O
Parkinson	O
'	O
s	O
disease	O
","	O
stroke	O
","	O
heart	O
attack	O
","	O
diabetes	O
","	O
and	O
ischemia	O
[	O
36	O
].	O
The	O
overall	O
conclusion	O
drawn	O
from	O
the	O
evidence	O
presented	O
here	O
is	O
that	O
cells	O
treated	O
with	O
PD166866	B-Chemical
mainly	O
die	O
by	O
apoptosis	O
;	O
however	O
the	O
possibility	O
that	O
different	O
forms	O
of	O
cell	O
death	O
may	O
occur	O
contemporarily	O
should	O
be	O
also	O
taken	O
into	O
account	O
.	O
In	O
any	O
case	O
","	O
apart	O
from	O
the	O
mode	O
of	O
death	O
","	O
the	O
results	O
discussed	O
in	O
this	O
work	O
corroborate	O
the	O
idea	O
that	O
PD166866	B-Chemical
is	O
able	O
to	O
control	O
in	O
a	O
negative	O
fashion	O
the	O
cell	O
proliferation	O
.	O
With	O
respect	O
to	O
this	O
","	O
the	O
most	O
interesting	O
aspect	O
of	O
the	O
work	O
is	O
that	O
PD166866	B-Chemical
is	O
able	O
to	O
inhibit	O
the	O
proliferation	O
of	O
cultured	O
human	O
tumor	O
cells	O
.	O
Conclusions	O
The	O
results	O
presented	O
here	O
show	O
that	O
the	O
synthetic	O
molecule	O
PD166866	B-Chemical
has	O
significant	O
anti	O
-	O
proliferative	O
effects	O
.	O
These	O
data	O
were	O
obtained	O
by	O
the	O
colorimetric	O
assay	O
of	O
Mosmann	O
and	O
further	O
validated	O
by	O
vital	O
cell	O
count	O
after	O
trypan	B-Chemical
blue	I-Chemical
dying	O
.	O
The	O
TUNEL	O
assay	O
allowed	O
a	O
qualitative	O
assessment	O
of	O
DNA	O
damage	O
which	O
could	O
be	O
one	O
of	O
the	O
reasons	O
leading	O
to	O
cell	O
death	O
:	O
however	O
the	O
possibility	O
of	O
this	O
fluorescent	O
staining	O
to	O
discriminate	O
between	O
apoptosis	O
and	O
necrosis	O
has	O
been	O
long	O
discussed	O
.	O
Therefore	O
we	O
ascertained	O
the	O
type	O
of	O
cell	O
death	O
by	O
immunoprecipitation	O
assays	O
of	O
PARP	O
","	O
enzyme	O
an	O
involved	O
in	O
DNA	O
repair	O
whose	O
expression	O
is	O
enhanced	O
during	O
apoptosis	O
.	O
The	O
extensive	O
immunopositivity	O
monitored	O
in	O
the	O
samples	O
treated	O
with	O
PD166866	B-Chemical
allows	O
us	O
to	O
conclude	O
that	O
this	O
drug	O
causes	O
cell	O
death	O
possibly	O
via	O
the	O
activation	O
of	O
the	O
apoptotic	O
pathway	O
","	O
even	O
though	O
other	O
forms	O
of	O
cell	O
death	O
cannot	O
be	O
ruled	O
out	O
.	O
In	O
addition	O
","	O
the	O
results	O
of	O
the	O
lipoperoxidation	O
assays	O
","	O
which	O
indicate	O
an	O
oxidative	O
stress	O
at	O
membrane	O
level	O
","	O
suggest	O
that	O
this	O
cell	O
district	O
could	O
be	O
a	O
target	O
for	O
this	O
molecule	O
.	O
However	O
","	O
further	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
antitumor	O
potential	O
of	O
PD166866	B-Chemical
:	O
in	O
particular	O
future	O
studies	O
in	O
vivo	O
","	O
in	O
animal	O
model	O
systems	O
","	O
are	O
required	O
to	O
elucidate	O
this	O
aspect	O
.	O
Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O
Authors	O
'	O
contributions	O
GR	O
is	O
the	O
group	O
leader	O
and	O
this	O
work	O
represents	O
one	O
of	O
the	O
research	O
lines	O
pursued	O
in	O
his	O
laboratory	O
;	O
he	O
directly	O
supervised	O
the	O
experimental	O
work	O
.	O
MC	O
carried	O
out	O
most	O
of	O
the	O
experimental	O
work	O
.	O
GG	O
and	O
MC	O
contributed	O
with	O
stimulating	O
suggestions	O
and	O
encouraging	O
discussions	O
.	O
Acknowledgements	O
This	O
work	O
was	O
partially	O
funded	O
by	O
the	O
Italian	O
Ministry	O
of	O
Education	O
and	O
by	O
SIGMA	O
-	O
TAU	O
Industrie	O
Farmaceutiche	O
Riunite	O
","	O
contract	O
nr	O
.	O
DS	O
/	O
2007	O
/	O
C	O
.	O
R	O
.	O
n15	O
(	O
Grants	O
to	O
G	O
.	O
R	O
.).	O
The	O
iconographic	O
work	O
by	O
Riccardo	O
Risuleo	O
is	O
also	O
acknowledged	O
.	O
The	O
small	O
molecule	O
curcumin	B-Chemical
analog	O
FLLL32	B-Chemical
induces	O
apoptosis	O
in	O
melanoma	O
cells	O
via	O
STAT3	O
inhibition	O
and	O
retains	O
the	O
cellular	O
response	O
to	O
cytokines	O
with	O
anti	O
-	O
tumor	O
activity	O
Background	O
We	O
characterized	O
the	O
biologic	O
effects	O
of	O
a	O
novel	O
small	O
molecule	O
STAT3	O
pathway	O
inhibitor	O
that	O
is	O
derived	O
from	O
the	O
natural	O
product	O
curcumin	B-Chemical
.	O
We	O
hypothesized	O
this	O
lead	O
compound	O
would	O
specifically	O
inhibit	O
the	O
STAT3	O
signaling	O
pathway	O
to	O
induce	O
apoptosis	O
in	O
melanoma	O
cells	O
.	O
Results	O
FLLL32	B-Chemical
specifically	O
reduced	O
STAT3	O
phosphorylation	O
at	O
Tyr705	B-Chemical
(	O
pSTAT3	O
)	O
and	O
induced	O
apoptosis	O
at	O
micromolar	O
amounts	O
in	O
human	O
melanoma	O
cell	O
lines	O
and	O
primary	O
melanoma	O
cultures	O
as	O
determined	O
by	O
annexin	O
V	O
/	O
propidium	B-Chemical
iodide	I-Chemical
staining	O
and	O
immunoblot	O
analysis	O
.	O
FLLL32	B-Chemical
treatment	O
reduced	O
expression	O
of	O
STAT3	O
-	O
target	O
genes	O
","	O
induced	O
caspase	O
-	O
dependent	O
apoptosis	O
","	O
and	O
reduced	O
mitochondrial	O
membrane	O
potential	O
.	O
FLLL32	B-Chemical
displayed	O
specificity	O
for	O
STAT3	O
over	O
other	O
homologous	O
STAT	O
proteins	O
.	O
In	O
contrast	O
to	O
other	O
STAT3	O
pathway	O
inhibitors	O
(	O
WP1066	B-Chemical
","	O
JSI	B-Chemical
-	I-Chemical
124	I-Chemical
","	O
Stattic	B-Chemical
"),"	O
FLLL32	B-Chemical
did	O
not	O
abrogate	O
IFN	O
-	O
Î³	O
-	O
induced	O
pSTAT1	O
or	O
downstream	O
STAT1	O
-	O
mediated	O
gene	O
expression	O
as	O
determined	O
by	O
Real	O
Time	O
PCR	O
.	O
In	O
addition	O
","	O
FLLL32	B-Chemical
did	O
not	O
adversely	O
affect	O
the	O
function	O
or	O
viability	O
of	O
immune	O
cells	O
from	O
normal	O
donors	O
.	O
In	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
"),"	O
FLLL32	B-Chemical
inhibited	O
IL	O
-	O
6	O
-	O
induced	O
pSTAT3	O
but	O
did	O
not	O
reduce	O
signaling	O
in	O
response	O
to	O
immunostimulatory	O
cytokines	O
(	O
IFN	O
-	O
Î³	O
","	O
IL	O
2	O
).	O
Treatment	O
of	O
PBMCs	O
or	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
with	O
FLLL32	B-Chemical
also	O
did	O
not	O
decrease	O
viability	O
or	O
granzyme	O
b	O
and	O
IFN	O
-	O
Î³	O
production	O
when	O
cultured	O
with	O
K562	O
targets	O
as	O
compared	O
to	O
vehicle	O
(	O
DMSO	B-Chemical
).	O
Conclusions	O
These	O
data	O
suggest	O
that	O
FLLL32	B-Chemical
represents	O
a	O
lead	O
compound	O
that	O
could	O
serve	O
as	O
a	O
platform	O
for	O
further	O
optimization	O
to	O
develop	O
improved	O
STAT3	O
specific	O
inhibitors	O
for	O
melanoma	O
therapy	O
.	O
Background	O
Malignant	O
melanoma	O
is	O
the	O
most	O
deadly	O
form	O
of	O
skin	O
cancer	O
","	O
and	O
its	O
incidence	O
is	O
rising	O
faster	O
than	O
that	O
of	O
any	O
other	O
cancer	O
.	O
The	O
prognosis	O
for	O
patients	O
with	O
metastatic	O
disease	O
is	O
poor	O
","	O
and	O
even	O
the	O
most	O
effective	O
therapies	O
produce	O
an	O
overall	O
response	O
rate	O
of	O
only	O
10	O
-	O
15	O
%.	O
Therefore	O
","	O
novel	O
approaches	O
for	O
treating	O
this	O
disease	O
are	O
urgently	O
needed	O
.	O
Activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
-	O
3	O
(	O
STAT3	O
)	O
in	O
melanoma	O
tumors	O
is	O
associated	O
with	O
poor	O
prognosis	O
[	O
1	O
-	O
3	O
].	O
This	O
transcription	O
factor	O
can	O
promote	O
cell	O
proliferation	O
and	O
angiogenesis	O
","	O
inhibit	O
apoptosis	O
","	O
and	O
drive	O
invasion	O
and	O
metastasis	O
[	O
1	O
-	O
3	O
].	O
Constitutive	O
STAT3	O
phosphorylation	O
is	O
mediated	O
by	O
several	O
upstream	O
kinases	O
(	O
e	O
.	O
g	O
.	O
Jak2	O
","	O
Src	O
)	O
and	O
is	O
thought	O
to	O
be	O
a	O
key	O
component	O
of	O
the	O
oncogenic	O
process	O
[	O
4	O
","	O
5	O
].	O
Despite	O
its	O
necessity	O
in	O
early	O
embryogenesis	O
","	O
STAT3	O
appears	O
to	O
be	O
largely	O
dispensable	O
in	O
most	O
normal	O
adult	O
cell	O
and	O
tissue	O
types	O
[	O
6	O
","	O
7	O
].	O
These	O
data	O
suggest	O
that	O
STAT3	O
inhibition	O
represents	O
a	O
rational	O
approach	O
to	O
therapy	O
for	O
this	O
disease	O
.	O
Emerging	O
data	O
suggest	O
that	O
natural	O
products	O
may	O
represent	O
effective	O
candidate	O
molecules	O
for	O
drug	O
discovery	O
.	O
Curcumin	B-Chemical
","	O
1	B-Chemical
","	I-Chemical
7	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
3methoxyphenyl	I-Chemical
)-	I-Chemical
1	I-Chemical
","	I-Chemical
6	I-Chemical
-	I-Chemical
heptadien	I-Chemical
-	I-Chemical
3	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
dione	I-Chemical
","	O
is	O
one	O
such	O
candidate	O
[	O
8	O
]	O
based	O
on	O
its	O
chemopreventative	O
and	O
therapeutic	O
properties	O
in	O
experimental	O
models	O
including	O
melanoma	O
and	O
its	O
ability	O
to	O
inhibit	O
a	O
variety	O
of	O
targets	O
including	O
STAT3	O
[	O
9	O
-	O
11	O
].	O
Administration	O
of	O
curcumin	B-Chemical
has	O
been	O
shown	O
to	O
be	O
safe	O
in	O
humans	O
[	O
12	O
","	O
13	O
"],"	O
however	O
its	O
clinical	O
utility	O
is	O
somewhat	O
limited	O
due	O
to	O
the	O
poor	O
bioavailability	O
and	O
target	O
selectivity	O
.	O
The	O
lack	O
of	O
selectivity	O
is	O
due	O
to	O
the	O
numerous	O
molecular	O
targets	O
with	O
which	O
curcumin	B-Chemical
is	O
known	O
to	O
interact	O
.	O
Therefore	O
","	O
efforts	O
are	O
underway	O
by	O
our	O
group	O
and	O
others	O
to	O
design	O
and	O
synthesize	O
novel	O
curcumin	B-Chemical
analogs	O
to	O
focus	O
its	O
inhibitory	O
activity	O
toward	O
the	O
STAT3	O
pathway	O
[	O
14	O
].	O
Indeed	O
prior	O
studies	O
by	O
our	O
group	O
have	O
shown	O
that	O
despite	O
its	O
direct	O
pro	O
-	O
apoptotic	O
effects	O
on	O
human	O
melanoma	O
cells	O
","	O
curcumin	B-Chemical
inhibits	O
the	O
cellular	O
response	O
to	O
clinically	O
relevant	O
cytokines	O
[	O
15	O
].	O
These	O
data	O
suggest	O
that	O
structural	O
analogs	O
of	O
curcumin	B-Chemical
which	O
retain	O
the	O
ability	O
to	O
inhibit	O
the	O
STAT3	O
oncogenic	O
signaling	O
pathways	O
while	O
leaving	O
the	O
STAT1	O
tumor	O
suppressor	O
pathway	O
","	O
and	O
immune	O
effector	O
function	O
intact	O
could	O
be	O
most	O
useful	O
for	O
cancer	O
therapy	O
.	O
The	O
molecular	O
structure	O
of	O
curcumin	B-Chemical
indicates	O
that	O
the	O
molecule	O
exists	O
in	O
two	O
distinct	O
tautomeric	O
forms	O
:	O
1	O
)	O
a	O
diketone	B-Chemical
form	O
and	O
2	O
)	O
a	O
keto	B-Chemical
-	I-Chemical
enol	I-Chemical
form	O
","	O
which	O
each	O
have	O
unique	O
properties	O
relevant	O
for	O
drug	O
design	O
(	O
Figure	O
1A	O
).	O
We	O
developed	O
a	O
series	O
of	O
analogs	O
based	O
on	O
curcumin	B-Chemical
in	O
its	O
diketone	B-Chemical
form	O
which	O
were	O
predicted	O
by	O
computational	O
modeling	O
to	O
interact	O
with	O
the	O
SH2	O
domain	O
of	O
STAT3	O
[	O
16	O
]	O
and	O
inhibit	O
STAT3	O
homodimerization	O
(	O
unpublished	O
observations	O
","	O
Dr	O
.	O
Pui	O
-	O
Kai	O
Li	O
","	O
The	O
Ohio	O
State	O
University	O
).	O
One	O
analog	O
","	O
termed	O
FLLL32	B-Chemical
","	O
was	O
selected	O
as	O
a	O
candidate	O
for	O
inhibition	O
of	O
the	O
Jak2	O
-	O
STAT3	O
pathway	O
(	O
Figure	O
1A	O
).	O
This	O
analog	O
has	O
previously	O
been	O
shown	O
to	O
inhibit	O
the	O
Jak2	O
-	O
STAT3	O
pathway	O
and	O
elicit	O
anti	O
-	O
tumor	O
activity	O
against	O
pancreatic	O
and	O
breast	O
cancer	O
cells	O
[	O
16	O
].	O
The	O
FLLL32	B-Chemical
curcumin	I-Chemical
analog	O
induced	O
apoptosis	O
in	O
human	O
melanoma	O
cells	O
.	O
(	O
A	O
)	O
The	O
molecular	O
structure	O
of	O
curcumin	B-Chemical
indicates	O
that	O
the	O
molecule	O
exists	O
in	O
two	O
distinct	O
tautomeric	O
forms	O
:	O
1	O
)	O
a	O
diketone	B-Chemical
form	O
and	O
2	O
)	O
a	O
keto	B-Chemical
-	I-Chemical
enol	I-Chemical
form	O
.	O
FLLL32	B-Chemical
was	O
designed	O
as	O
a	O
novel	O
structural	O
analog	O
of	O
curcumin	B-Chemical
that	O
approximates	O
a	O
modified	O
version	O
of	O
the	O
molecule	O
when	O
locked	O
into	O
the	O
keto	O
-	O
form	O
.	O
(	O
B	O
)	O
Annexin	O
V	O
/	O
PI	B-Chemical
staining	O
of	O
human	O
metastatic	O
melanoma	O
cells	O
following	O
a	O
48	O
hour	O
treatment	O
with	O
FLLL32	B-Chemical
.	O
Error	O
bars	O
show	O
95	O
%	O
prediction	O
limits	O
based	O
on	O
the	O
model	O
fit	O
at	O
the	O
estimated	O
IC50	O
from	O
two	O
or	O
more	O
independent	O
experiments	O
.	O
The	O
non	O
-	O
responsive	O
1106	O
MEL	O
and	O
1259	O
MEL	O
cell	O
lines	O
were	O
pSTAT3	O
-	O
negative	O
.	O
(	O
C	O
)	O
Annexin	O
V	O
/	O
PI	B-Chemical
staining	O
of	O
representative	O
pSTAT3	O
+	O
melanoma	O
cells	O
treated	O
with	O
either	O
20	O
Î¼M	O
curcumin	B-Chemical
or	O
2	O
Î¼M	O
FLLL32	B-Chemical
.	O
Data	O
are	O
presented	O
as	O
the	O
mean	O
percentage	O
of	O
apoptotic	O
cells	O
.	O
Error	O
bars	O
represent	O
the	O
standard	O
deviation	O
from	O
at	O
least	O
two	O
individual	O
experiments	O
.	O
(	O
D	O
)	O
Immunoblot	O
analysis	O
(	O
left	O
panel	O
)	O
or	O
immunoprecipitation	O
for	O
total	O
Jak2	O
protein	O
(	O
right	O
panel	O
;	O
blot	O
with	O
Jak2	O
or	O
pJak2	O
antibodies	O
)	O
of	O
pSTAT3	O
-	O
positive	O
A375	O
and	O
Hs294T	O
cells	O
following	O
24	O
hour	O
treatment	O
.	O
(	O
E	O
)	O
FLLL32	B-Chemical
treatment	O
reduced	O
pSTAT3	O
","	O
the	O
STAT3	O
-	O
regulated	O
gene	O
","	O
cyclin	O
D1	O
and	O
induced	O
apoptosis	O
in	O
primary	O
human	O
cells	O
derived	O
from	O
recurrent	O
cutaneous	O
melanoma	O
tumors	O
.	O
These	O
primary	O
melanoma	O
cell	O
cultures	O
have	O
been	O
previously	O
described	O
by	O
our	O
group	O
[	O
17	O
].	O
Cells	O
were	O
treated	O
for	O
48	O
hours	O
with	O
the	O
indicated	O
concentrations	O
of	O
FLLL32	B-Chemical
or	O
curcumin	B-Chemical
(	O
20	O
mM	O
)	O
as	O
a	O
biologic	O
control	O
and	O
analyzed	O
by	O
immunoblot	O
.	O
Membranes	O
were	O
probed	O
with	O
Î²	O
actin	O
as	O
a	O
loading	O
control	O
and	O
all	O
blots	O
represent	O
data	O
from	O
at	O
least	O
two	O
independent	O
experiments	O
.	O
In	O
the	O
present	O
report	O
we	O
have	O
characterized	O
the	O
biologic	O
activity	O
of	O
the	O
FLLL32	B-Chemical
curcumin	I-Chemical
analog	O
on	O
human	O
melanoma	O
and	O
immune	O
effector	O
cells	O
.	O
Our	O
data	O
indicate	O
that	O
FLLL32	B-Chemical
can	O
inhibit	O
STAT3	O
phosphorylation	O
and	O
promote	O
caspase	O
-	O
dependent	O
apoptosis	O
of	O
human	O
melanoma	O
cells	O
at	O
concentrations	O
10	O
-	O
fold	O
lower	O
than	O
curcumin	B-Chemical
[	O
15	O
].	O
FLLL32	B-Chemical
displayed	O
a	O
greater	O
specificity	O
for	O
STAT3	O
than	O
curcumin	B-Chemical
or	O
other	O
comparable	O
inhibitors	O
.	O
This	O
compound	O
did	O
appear	O
to	O
alter	O
the	O
activation	O
of	O
other	O
structurally	O
similar	O
STAT	O
proteins	O
","	O
as	O
interferon	O
-	O
induced	O
STAT1	O
signaling	O
and	O
gene	O
expression	O
were	O
intact	O
in	O
the	O
presence	O
of	O
FLLL32	B-Chemical
.	O
Treatment	O
of	O
PBMCs	O
with	O
FLLL32	B-Chemical
also	O
eliminated	O
basal	O
and	O
IL	O
-	O
6	O
induced	O
pSTAT3	O
.	O
In	O
contrast	O
","	O
FLLL32	B-Chemical
did	O
not	O
adversely	O
affect	O
the	O
response	O
of	O
PBMCs	O
to	O
stimulation	O
with	O
IFN	O
-	O
Î³	O
and	O
IL	O
2	O
or	O
the	O
viability	O
and	O
cytotoxicity	O
of	O
NK	O
cells	O
.	O
These	O
data	O
suggest	O
that	O
FLLL32	B-Chemical
represents	O
a	O
promising	O
lead	O
compound	O
that	O
can	O
be	O
optimized	O
further	O
for	O
development	O
as	O
a	O
therapeutic	O
agent	O
in	O
melanoma	O
.	O
Materials	O
and	O
methods	O
Cell	O
Culture	O
and	O
Reagents	O
A375	O
","	O
HT144	O
and	O
Hs294T	O
human	O
melanoma	O
","	O
and	O
the	O
K562	O
leukemia	O
cell	O
lines	O
were	O
purchased	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
","	O
Manassas	O
","	O
VA	O
)	O
and	O
1106	O
MEL	O
","	O
1259	O
MEL	O
","	O
MEL	O
-	O
39	O
and	O
F01	O
human	O
melanoma	O
cell	O
lines	O
were	O
provided	O
by	O
Dr	O
.	O
Soldano	O
Ferrone	O
(	O
University	O
of	O
Pittsburgh	O
","	O
Pittsburgh	O
","	O
PA	O
)	O
and	O
cultured	O
as	O
described	O
[	O
17	O
].	O
Melanoma	O
cell	O
lines	O
were	O
authenticated	O
via	O
karyotype	O
analysis	O
in	O
the	O
Molecular	O
Cytogenetics	O
Core	O
Laboratory	O
of	O
The	O
Ohio	O
State	O
University	O
.	O
The	O
radial	O
growth	O
phase	O
WM	O
1552c	O
and	O
vertical	O
growth	O
phase	O
WM	O
793b	O
human	O
melanoma	O
cell	O
lines	O
were	O
provided	O
by	O
Dr	O
.	O
M	O
.	O
Herlyn	O
(	O
Wistar	O
Institute	O
","	O
Philadelphia	O
","	O
PA	O
)	O
and	O
cultured	O
as	O
described	O
[	O
18	O
].	O
Primary	O
cultures	O
from	O
patients	O
with	O
recurrent	O
cutaneous	O
melanomas	O
were	O
cultured	O
as	O
previously	O
described	O
[	O
17	O
].	O
Tetramethylrhodamine	B-Chemical
ethyl	I-Chemical
ester	I-Chemical
perchlorate	I-Chemical
(	O
TMRE	B-Chemical
)	O
was	O
purchased	O
from	O
Invitrogen	O
(	O
Carlsbad	O
","	O
CA	O
).	O
The	O
pan	O
-	O
caspase	O
inhibitor	O
(	O
Z	B-Chemical
VAD	I-Chemical
-	I-Chemical
FMK	I-Chemical
"),"	O
control	O
(	O
Z	B-Chemical
-	I-Chemical
FA	I-Chemical
-	I-Chemical
FMK	I-Chemical
)	O
and	O
recombinant	O
human	O
IFN	O
-	O
Î³	O
were	O
purchased	O
from	O
R	O
&	O
D	O
Systems	O
","	O
Inc	O
.	O
(	O
Minneapolis	O
","	O
MN	O
).	O
Recombinant	O
human	O
interleukin	O
-	O
6	O
(	O
IL	O
6	O
)	O
was	O
purchased	O
from	O
Peprotech	O
","	O
Inc	O
.	O
(	O
Rocky	O
Hill	O
","	O
NJ	O
).	O
Recombinant	O
human	O
IL	O
-	O
2	O
(	O
specific	O
activity	O
=	O
107	O
U	O
/	O
mg	O
)	O
was	O
purchased	O
from	O
Hoffmann	O
-	O
La	O
Roche	O
Pharmaceuticals	O
(	O
Nutley	O
","	O
NJ	O
).	O
The	O
JSI	B-Chemical
-	I-Chemical
124	I-Chemical
and	O
Stattic	B-Chemical
inhibitors	O
were	O
purchased	O
from	O
Calbiochem	O
(	O
Gibbstown	O
","	O
NJ	O
).	O
WP1066	B-Chemical
was	O
synthesized	O
in	O
the	O
laboratory	O
of	O
Dr	O
.	O
P	O
-	O
K	O
Li	O
[	O
19	O
].	O
FLLL32	B-Chemical
and	O
curcumin	B-Chemical
were	O
synthesized	O
","	O
purified	O
and	O
evaluated	O
for	O
purity	O
as	O
previously	O
described	O
[	O
16	O
","	O
20	O
","	O
21	O
].	O
Peripheral	O
Blood	O
Mononuclear	O
Cell	O
Isolation	O
Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
were	O
isolated	O
from	O
source	O
leukocytes	O
of	O
healthy	O
donors	O
(	O
American	O
Red	O
Cross	O
","	O
Columbus	O
","	O
OH	O
)	O
via	O
density	O
gradient	O
centrifugation	O
using	O
Ficoll	O
-	O
Paque	O
(	O
Amersham	O
","	O
Pharmacia	O
Biotech	O
","	O
Bjorkgatan	O
","	O
Sweeden	O
)	O
as	O
described	O
[	O
22	O
].	O
NK	O
cells	O
were	O
enriched	O
from	O
source	O
leukocytes	O
by	O
negative	O
selection	O
with	O
Rosette	O
Sep	O
reagents	O
(	O
Stem	O
Cell	O
Technologies	O
","	O
Inc	O
".,"	O
Vancouver	O
","	O
British	O
Columbia	O
","	O
Canada	O
).	O
Immunoblot	O
Analysis	O
Lysates	O
were	O
prepared	O
from	O
melanoma	O
cell	O
lines	O
or	O
PBMCs	O
and	O
assayed	O
for	O
protein	O
expression	O
by	O
immunoblot	O
analysis	O
as	O
previously	O
described	O
with	O
antibodies	O
(	O
Ab	O
)	O
to	O
STAT1	O
(	O
BD	O
Biosciences	O
"),"	O
Survivin	O
(	O
Novus	O
Biologicals	O
","	O
Littleton	O
","	O
CO	O
"),"	O
pSTAT1	O
","	O
STAT3	O
","	O
pSTAT3	O
","	O
pSTAT5	O
","	O
STAT5	O
","	O
pJAK2	O
","	O
JAK2	O
","	O
PARP	O
","	O
Cyclin	O
D1	O
","	O
Caspase	O
-	O
3	O
","	O
Caspase	O
-	O
8	O
","	O
Caspase	O
-	O
9	O
","	O
phosphorylated	O
and	O
total	O
Akt	O
(	O
pAkt	O
"),"	O
Src	O
(	O
pSrc	O
"),"	O
p38	O
MAPK	O
(	O
p	O
-	O
p38	O
MAPK	O
"),"	O
ERK	O
(	O
pERK	O
)	O
(	O
Cell	O
Signaling	O
Technology	O
","	O
Danvers	O
","	O
MA	O
"),"	O
or	O
Î²	O
-	O
actin	O
(	O
Sigma	O
)	O
[	O
23	O
].	O
Following	O
incubation	O
with	O
the	O
appropriate	O
horseradish	O
-	O
peroxidase	O
-	O
conjugated	O
secondary	O
Ab	O
","	O
immune	O
complexes	O
were	O
detected	O
using	O
the	O
SuperSignal	O
West	O
Pico	O
Chemiluminescent	O
Substrate	O
(	O
Thermo	O
Fisher	O
Scientific	O
).	O
Annexin	O
V	O
/	O
Propidium	B-Chemical
Iodide	I-Chemical
Staining	O
Phosphatidyl	B-Chemical
serine	I-Chemical
exposure	O
was	O
assessed	O
in	O
tumor	O
cells	O
by	O
flow	O
cytometry	O
using	O
APC	O
-	O
Annexin	O
V	O
and	O
propidium	B-Chemical
iodide	I-Chemical
(	O
PI	B-Chemical
;	O
BD	O
Pharmingen	O
","	O
San	O
Diego	O
","	O
CA	O
)	O
as	O
described	O
[	O
23	O
].	O
Analyses	O
were	O
performed	O
utilizing	O
at	O
least	O
10	O
","	O
0	O
events	O
.	O
STAT3	O
DNA	O
binding	O
assays	O
STAT3	O
DNA	O
binding	O
was	O
measured	O
with	O
the	O
Pierce	O
LightShift	O
Chemiluminescent	O
EMSA	O
kit	O
used	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Thermo	O
Fisher	O
Scientific	O
Inc	O
","	O
Rockford	O
","	O
IL	O
).	O
Nuclear	O
protein	O
was	O
collected	O
using	O
the	O
NucBuster	O
â„¢	O
Protein	O
Extraction	O
kit	O
(	O
EMD	O
Chemicals	O
Inc	O
","	O
Gibbstown	O
","	O
NJ	O
).	O
Binding	O
reactions	O
using	O
equal	O
amounts	O
of	O
nuclear	O
protein	O
were	O
incubated	O
for	O
20	O
minutes	O
at	O
room	O
temperature	O
with	O
DNA	O
probes	O
.	O
A	O
biotinylated	O
STAT3	O
binding	O
sequence	O
in	O
the	O
human	O
survivin	O
promoter	O
(	O
sense	O
5	O
'-	O
GAGACTCAGTTTCAAATAAATAAATAAAC	O
-	O
3	O
')	O
was	O
purchased	O
from	O
Operon	O
Biotechnologies	O
(	O
Huntsville	O
","	O
AL	O
).	O
Reactions	O
with	O
biotinylated	O
target	O
DNA	O
only	O
and	O
nuclear	O
protein	O
with	O
biotinylated	O
target	O
DNA	O
and	O
excess	O
unlabelled	O
target	O
DNA	O
to	O
compete	O
for	O
binding	O
were	O
included	O
.	O
STAT3	O
specificity	O
was	O
confirmed	O
by	O
incubation	O
with	O
6Î¼g	O
of	O
anti	O
-	O
STAT3	O
Ab	O
(	O
Santa	O
Cruz	O
Biotechnology	O
Inc	O
","	O
Santa	O
Cruz	O
","	O
CA	O
)	O
to	O
interfere	O
with	O
the	O
protein	O
-	O
DNA	O
complex	O
.	O
Following	O
electrophoresis	O
","	O
DNA	O
was	O
transferred	O
to	O
a	O
nylon	O
membrane	O
","	O
cross	O
-	O
linked	O
and	O
detected	O
by	O
chemiluminescence	O
.	O
Flow	O
Cytometric	O
Assay	O
of	O
Mitochondrial	O
Membrane	O
Potential	O
The	O
mitochondrial	O
membrane	O
potential	O
(	O
Î”Î¨m	O
)	O
was	O
assayed	O
using	O
150	O
nM	O
TMRE	B-Chemical
in	O
regular	O
medium	O
at	O
37ÂºC	O
for	O
15	O
minutes	O
and	O
by	O
subsequent	O
flow	O
cytometric	O
analysis	O
as	O
described	O
[	O
24	O
].	O
Real	O
Time	O
PCR	O
Real	O
-	O
time	O
PCR	O
was	O
used	O
to	O
evaluate	O
the	O
expression	O
of	O
the	O
IFN	O
-	O
Î³	O
stimulated	O
gene	O
(	O
IRF1	O
)	O
as	O
described	O
[	O
25	O
","	O
26	O
]	O
with	O
pre	O
-	O
designed	O
primer	O
/	O
probe	O
sets	O
(	O
Assays	O
On	O
Demand	O
;	O
Applied	O
Biosystems	O
","	O
Foster	O
City	O
","	O
CA	O
)	O
and	O
2X	O
TaqMan	O
Universal	O
PCR	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
)	O
per	O
manufacturer	O
'	O
s	O
recommendations	O
.	O
Primer	O
/	O
probe	O
sets	O
for	O
18s	O
rRNA	O
(	O
Applied	O
Biosystems	O
)	O
were	O
used	O
to	O
normalize	O
expression	O
values	O
(	O
housekeeping	O
gene	O
).	O
Data	O
were	O
acquired	O
and	O
analyzed	O
using	O
the	O
ABI	O
Prism	O
7900HT	O
Sequence	O
Detection	O
System	O
(	O
Applied	O
Biosystems	O
).	O
ELISPOT	O
Assay	O
for	O
Granzyme	O
B	O
and	O
IFN	O
-	O
Î³	O
To	O
measure	O
granzyme	O
B	O
(	O
GrB	O
)	O
and	O
IFN	O
-	O
Î³	O
secretion	O
","	O
ELISPOT	O
experiments	O
were	O
conducted	O
using	O
MultiScreen	O
96	O
-	O
well	O
plates	O
(	O
Millipore	O
","	O
Bedford	O
","	O
MA	O
)	O
and	O
biotinylated	O
monoclonal	O
anti	O
-	O
human	O
GrB	O
or	O
IFN	O
-	O
Î³	O
detecting	O
Ab	O
(	O
Mabtech	O
)	O
as	O
described	O
[	O
27	O
].	O
Freshly	O
isolated	O
NK	O
cells	O
(	O
effectors	O
)	O
were	O
incubated	O
overnight	O
in	O
IL	O
-	O
2	O
-	O
containing	O
media	O
(	O
1	O
nM	O
)	O
with	O
either	O
5Î¼M	O
FLLL32	B-Chemical
or	O
DMSO	B-Chemical
.	O
Effector	O
cells	O
were	O
then	O
co	O
-	O
incubated	O
in	O
triplicate	O
with	O
K562	O
cells	O
as	O
targets	O
at	O
an	O
effector	O
:	O
target	O
ratio	O
of	O
10	O
:	O
1	O
for	O
four	O
hours	O
.	O
Targets	O
and	O
effectors	O
cultured	O
alone	O
were	O
used	O
as	O
controls	O
.	O
Spots	O
were	O
visualized	O
and	O
counted	O
using	O
the	O
ImmunoSpot	O
Imaging	O
Analyzer	O
(	O
Cellular	O
Technology	O
Ltd	O
","	O
Cleveland	O
","	O
OH	O
).	O
Statistical	O
Analysis	O
The	O
4	O
-	O
parameter	O
logistic	O
or	O
Hill	O
model	O
[	O
28	O
]	O
was	O
the	O
assumed	O
dose	O
-	O
response	O
relationship	O
for	O
FLLL32	B-Chemical
concentration	O
and	O
proportion	O
of	O
apoptotic	O
cells	O
.	O
Nonlinear	O
least	O
squares	O
regression	O
was	O
used	O
to	O
estimate	O
the	O
parameters	O
.	O
ELISPOT	O
data	O
were	O
compared	O
between	O
groups	O
using	O
a	O
two	O
-	O
sample	O
t	O
-	O
test	O
.	O
All	O
analyses	O
were	O
performed	O
in	O
Statistical	O
Analysis	O
System	O
(	O
version	O
9	O
.	O
2	O
;	O
SAS	O
Institute	O
).	O
P	O
-	O
values	O
were	O
considered	O
significant	O
at	O
the	O
0	O
.	O
5	O
level	O
and	O
all	O
tests	O
were	O
two	O
-	O
sided	O
.	O
Results	O
FLLL32	B-Chemical
induces	O
apoptosis	O
in	O
human	O
melanoma	O
cell	O
lines	O
The	O
pro	O
-	O
apoptotic	O
effects	O
of	O
FLLL32	B-Chemical
(	O
Figure	O
1A	O
)	O
were	O
examined	O
by	O
flow	O
cytometry	O
following	O
Annexin	O
V	O
/	O
PI	B-Chemical
staining	O
of	O
a	O
panel	O
of	O
metastatic	O
human	O
melanoma	O
cell	O
lines	O
with	O
basal	O
STAT3	O
phosphorylation	O
(	O
A375	O
","	O
Hs294T	O
","	O
FO1	O
","	O
HT144	O
","	O
MEL	O
-	O
39	O
)	O
and	O
the	O
pSTAT3	O
negative	O
1106	O
MEL	O
and	O
1259	O
MEL	O
cell	O
lines	O
[	O
17	O
].	O
Dose	O
-	O
response	O
studies	O
revealed	O
consistent	O
induction	O
of	O
apoptosis	O
in	O
pSTAT3	O
-	O
positive	O
metastatic	O
human	O
melanoma	O
cell	O
lines	O
following	O
a	O
48	O
hour	O
treatment	O
with	O
FLLL32	B-Chemical
as	O
compared	O
to	O
DMSO	B-Chemical
(	O
vehicle	O
)	O
treated	O
cells	O
(	O
Figure	O
1B	O
).	O
The	O
pSTAT3	O
-	O
positive	O
A375	O
cell	O
line	O
was	O
particularly	O
sensitive	O
to	O
the	O
pro	O
-	O
apoptotic	O
effects	O
of	O
FLLL32	B-Chemical
(	O
IC50	O
=	O
1	O
.	O
3Î¼M	O
at	O
48	O
hours	O
).	O
Similar	O
data	O
were	O
obtained	O
in	O
multiple	O
pSTAT3	O
positive	O
human	O
melanoma	O
cell	O
lines	O
(	O
IC50	O
range	O
=	O
1	O
.	O
9	O
--	O
2	O
.	O
8	O
at	O
48	O
hours	O
).	O
The	O
pSTAT3	O
negative	O
1106	O
MEL	O
and	O
1259	O
MEL	O
cell	O
lines	O
were	O
poorly	O
sensitive	O
to	O
FLLL32	B-Chemical
(	O
Figure	O
1B	O
).	O
FLLL32	B-Chemical
was	O
more	O
potent	O
than	O
curcumin	B-Chemical
at	O
inducing	O
apoptosis	O
(	O
Figure	O
1C	O
).	O
Consistent	O
with	O
prior	O
studies	O
from	O
our	O
group	O
","	O
a	O
10	O
-	O
fold	O
greater	O
concentration	O
of	O
curcumin	B-Chemical
was	O
required	O
to	O
achieve	O
the	O
same	O
degree	O
of	O
apoptosis	O
at	O
the	O
48	O
hour	O
time	O
point	O
[	O
15	O
].	O
FLLL32	B-Chemical
-	O
induced	O
apoptosis	O
was	O
also	O
confirmed	O
in	O
pSTAT3	O
+	O
human	O
melanoma	O
cell	O
lines	O
derived	O
from	O
other	O
disease	O
phenotypes	O
","	O
including	O
the	O
WM	O
1552c	O
radial	O
growth	O
phase	O
and	O
WM	O
793b	O
vertical	O
growth	O
phase	O
lines	O
following	O
treatment	O
with	O
FLLL32	B-Chemical
(	O
data	O
not	O
shown	O
).	O
FLLL32	B-Chemical
inhibits	O
STAT3	O
phosphorylation	O
and	O
gene	O
expression	O
in	O
human	O
melanoma	O
cell	O
lines	O
FLLL32	B-Chemical
inhibited	O
STAT3	O
phosphorylation	O
at	O
Tyr705	B-Chemical
but	O
not	O
at	O
Tyr727	B-Chemical
in	O
multiple	O
human	O
melanoma	O
cell	O
lines	O
after	O
a	O
24	O
hour	O
treatment	O
(	O
Figure	O
1D	O
).	O
Prior	O
studies	O
indicated	O
FLLL32	B-Chemical
could	O
inhibit	O
Jak2	O
kinase	O
activity	O
in	O
an	O
in	O
vitro	O
cell	O
-	O
free	O
assay	O
[	O
16	O
].	O
However	O
","	O
we	O
did	O
not	O
observe	O
an	O
appreciable	O
alteration	O
in	O
Jak2	O
phosphorylation	O
even	O
at	O
a	O
concentration	O
of	O
8	O
Î¼M	O
","	O
suggesting	O
that	O
this	O
compound	O
likely	O
acted	O
directly	O
against	O
the	O
STAT3	O
protein	O
(	O
Figure	O
1D	O
).	O
Time	O
course	O
studies	O
also	O
revealed	O
that	O
fulminant	O
cell	O
death	O
occurred	O
after	O
24	O
hours	O
of	O
continuous	O
culture	O
","	O
yet	O
exposure	O
to	O
FLLL32	B-Chemical
at	O
2	O
-	O
4	O
Î¼M	O
for	O
only	O
4	O
hours	O
was	O
sufficient	O
to	O
reduce	O
pSTAT3	O
and	O
induce	O
cell	O
death	O
(	O
Additional	O
File	O
1	O
:	O
Figure	O
S1A	O
-	O
B	O
).	O
FLLL32	B-Chemical
did	O
not	O
appear	O
to	O
inhibit	O
the	O
phosphorylation	O
of	O
other	O
key	O
signaling	O
pathways	O
that	O
are	O
constitutively	O
active	O
in	O
malignant	O
cells	O
(	O
e	O
.	O
g	O
.	O
Src	O
","	O
Akt	O
)	O
at	O
doses	O
capable	O
of	O
inhibiting	O
STAT3	O
phosphorylation	O
after	O
24	O
hours	O
.	O
Consistent	O
with	O
reciprocal	O
activation	O
of	O
the	O
p38	O
MAPK	O
and	O
STAT3	O
pathways	O
[	O
29	O
"],"	O
FLLL32	B-Chemical
treatment	O
led	O
to	O
increased	O
levels	O
of	O
total	O
p38	O
MAPK	O
protein	O
once	O
pSTAT3	O
decreased	O
(	O
Figure	O
1D	O
).	O
Importantly	O
","	O
FLLL32	B-Chemical
was	O
capable	O
of	O
reducing	O
pSTAT3	O
levels	O
","	O
cyclin	O
D1	O
expression	O
and	O
inducing	O
apoptosis	O
in	O
primary	O
human	O
melanoma	O
cell	O
cultures	O
derived	O
from	O
recurrent	O
cutaneous	O
melanoma	O
tumors	O
[	O
17	O
]	O
(	O
Figure	O
1E	O
).	O
Finally	O
","	O
treatment	O
of	O
basal	O
pSTAT3	O
-	O
positive	O
human	O
melanoma	O
cell	O
lines	O
with	O
FLLL32	B-Chemical
for	O
24	O
hours	O
led	O
to	O
reduced	O
STAT3	O
DNA	O
binding	O
as	O
determined	O
by	O
gel	O
shift	O
assays	O
and	O
expression	O
of	O
the	O
STAT3	O
-	O
regulated	O
genes	O
","	O
cyclin	O
D1	O
and	O
survivin	O
as	O
measured	O
by	O
immunoblot	O
(	O
Figure	O
2A	O
-	O
B	O
).	O
FLLL32	B-Chemical
reduced	O
STAT3	O
DNA	O
binding	O
and	O
gene	O
expression	O
.	O
(	O
A	O
)	O
STAT3	O
DNA	O
binding	O
was	O
measured	O
in	O
A375	O
cells	O
following	O
a	O
16	O
hour	O
treatment	O
with	O
FLLL32	B-Chemical
(	O
2	O
Î¼M	O
or	O
4	O
Î¼M	O
)	O
as	O
described	O
in	O
the	O
Methods	O
section	O
.	O
Unlabeled	O
target	O
DNA	O
were	O
included	O
to	O
compete	O
for	O
binding	O
as	O
indicated	O
","	O
and	O
a	O
STAT3	O
specific	O
Ab	O
was	O
used	O
to	O
were	O
included	O
confirm	O
specificity	O
(	O
last	O
lane	O
).	O
Cell	O
lysates	O
were	O
evaluated	O
concurrently	O
by	O
immunoblot	O
to	O
control	O
for	O
total	O
level	O
of	O
STAT3	O
protein	O
at	O
the	O
16	O
hour	O
time	O
point	O
.	O
(	O
B	O
)	O
FLLL32	B-Chemical
reduced	O
STAT3	O
-	O
regulated	O
gene	O
expression	O
.	O
Expression	O
of	O
STAT3	O
-	O
regulated	O
genes	O
cyclin	O
D1	O
and	O
survivin	O
were	O
evaluated	O
following	O
a	O
24	O
hour	O
treatment	O
with	O
FLLL32	B-Chemical
in	O
melanoma	O
cell	O
lines	O
.	O
Membranes	O
were	O
probed	O
with	O
Î²	O
actin	O
as	O
a	O
loading	O
control	O
and	O
all	O
blots	O
represent	O
data	O
from	O
at	O
least	O
two	O
independent	O
experiments	O
.	O
FLLL32	B-Chemical
induced	O
cell	O
death	O
is	O
caspase	O
-	O
dependent	O
The	O
mechanism	O
by	O
which	O
FLLL32	B-Chemical
induces	O
apoptosis	O
was	O
subsequently	O
investigated	O
in	O
the	O
A375	O
melanoma	O
cell	O
line	O
.	O
Immunoblot	O
analysis	O
demonstrated	O
a	O
concentration	O
-	O
dependent	O
increase	O
in	O
the	O
processing	O
of	O
both	O
initiator	O
(	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
9	O
)	O
and	O
effector	O
caspases	O
(	O
caspase	O
-	O
3	O
)	O
following	O
a	O
24	O
hour	O
treatment	O
with	O
FLLL32	B-Chemical
(	O
Figure	O
3A	O
).	O
Treatment	O
of	O
with	O
FLLL32	B-Chemical
also	O
resulted	O
in	O
a	O
concentration	O
-	O
dependent	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
as	O
measured	O
by	O
flow	O
cytometry	O
(	O
Figure	O
3B	O
).	O
These	O
data	O
support	O
the	O
involvement	O
of	O
the	O
mitochondrial	O
amplification	O
loop	O
in	O
promoting	O
cell	O
death	O
in	O
response	O
to	O
this	O
treatment	O
.	O
Apoptosis	O
was	O
caspase	O
-	O
dependent	O
","	O
as	O
culture	O
with	O
a	O
pan	O
-	O
caspase	O
inhibitor	O
(	O
Z	B-Chemical
-	I-Chemical
VAD	I-Chemical
-	I-Chemical
FMK	I-Chemical
)	O
inhibited	O
melanoma	O
cell	O
death	O
as	O
compared	O
to	O
culture	O
with	O
the	O
Z	B-Chemical
-	I-Chemical
FA	I-Chemical
-	I-Chemical
FMK	I-Chemical
control	O
compound	O
(	O
Figure	O
3C	O
and	O
Additional	O
File	O
1	O
:	O
Figure	O
S2	O
).	O
These	O
data	O
were	O
confirmed	O
at	O
the	O
48	O
hour	O
time	O
point	O
by	O
flow	O
cytometry	O
following	O
annexin	O
V	O
/	O
PI	B-Chemical
staining	O
","	O
and	O
by	O
reduced	O
PARP	O
cleavage	O
by	O
immunoblot	O
analysis	O
(	O
Figure	O
3C	O
-	O
D	O
).	O
Interestingly	O
","	O
reduced	O
levels	O
of	O
pSTAT3	O
and	O
cyclin	O
D1	O
occurred	O
following	O
treatment	O
of	O
A375	O
cells	O
with	O
FLLL32	B-Chemical
in	O
the	O
presence	O
of	O
the	O
pan	O
-	O
caspase	O
inhibitor	O
(	O
Figure	O
3D	O
).	O
These	O
data	O
are	O
consistent	O
with	O
a	O
mechanism	O
that	O
places	O
reduced	O
pSTAT3	O
and	O
its	O
cellular	O
targets	O
upstream	O
of	O
the	O
caspase	O
cascade	O
and	O
subsequent	O
apoptosis	O
.	O
FLLL32	B-Chemical
induced	O
caspase	O
-	O
dependent	O
apoptosis	O
and	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
.	O
(	O
A	O
)	O
Processing	O
of	O
caspase	O
proteins	O
was	O
measured	O
by	O
immunoblot	O
following	O
a	O
24	O
hour	O
treatment	O
of	O
A375	O
cells	O
with	O
FLLL32	B-Chemical
.	O
The	O
molecular	O
weight	O
of	O
each	O
pro	O
-	O
caspase	O
and	O
their	O
active	O
forms	O
are	O
listed	O
on	O
each	O
blot	O
in	O
kilodaltons	O
(	O
kDa	O
).	O
Data	O
shown	O
are	O
representative	O
of	O
at	O
least	O
two	O
independent	O
experiments	O
.	O
(	O
B	O
)	O
A375	O
cells	O
were	O
treated	O
for	O
24	O
hours	O
with	O
FLLL32	B-Chemical
and	O
stained	O
with	O
150	O
nM	O
TMRE	B-Chemical
to	O
assay	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
(	O
Î”Î¨m	O
)	O
by	O
flow	O
cytometry	O
.	O
Voltage	O
was	O
set	O
using	O
unstained	O
cells	O
(	O
M1	O
).	O
The	O
percentage	O
of	O
cells	O
with	O
reduced	O
Î”Î¨m	O
is	O
denoted	O
above	O
each	O
histogram	O
.	O
Data	O
are	O
representative	O
of	O
three	O
or	O
more	O
independent	O
experiments	O
.	O
Flow	O
cytometric	O
analysis	O
of	O
annexin	O
V	O
/	O
PI	B-Chemical
staining	O
following	O
a	O
48	O
hour	O
treatment	O
of	O
(	O
C	O
)	O
A375	O
cells	O
with	O
FLLL32	B-Chemical
in	O
the	O
presence	O
of	O
the	O
Z	B-Chemical
VAD	I-Chemical
-	I-Chemical
FMK	I-Chemical
pan	O
-	O
caspase	O
inhibitor	O
or	O
the	O
Z	B-Chemical
-	I-Chemical
FA	I-Chemical
-	I-Chemical
FMK	I-Chemical
control	O
compound	O
.	O
Inhibitors	O
were	O
used	O
at	O
50Î¼M	O
and	O
the	O
percentage	O
of	O
cells	O
in	O
each	O
quadrant	O
are	O
shown	O
.	O
(	O
D	O
)	O
Immunoblot	O
analysis	O
of	O
A375	O
cells	O
following	O
a	O
48	O
hour	O
treatment	O
with	O
FLLL32	B-Chemical
cultured	O
in	O
the	O
presence	O
of	O
the	O
Z	B-Chemical
-	I-Chemical
VAD	I-Chemical
-	I-Chemical
FMK	I-Chemical
pan	O
caspase	O
inhibitor	O
(+)	O
or	O
the	O
Z	O
FA	O
FMK	O
control	O
compound	O
(-).	O
Data	O
shown	O
are	O
representative	O
of	O
two	O
separate	O
experiments	O
with	O
the	O
A375	O
cell	O
line	O
and	O
were	O
also	O
reproducible	O
in	O
the	O
Hs294T	O
cell	O
line	O
(	O
Additional	O
File	O
1	O
:	O
Figure	O
S2	O
).	O
IFN	O
-	O
Î³	O
induced	O
STAT1	O
signaling	O
and	O
gene	O
expression	O
are	O
not	O
inhibited	O
by	O
FLLL32	B-Chemical
Since	O
many	O
cytokines	O
act	O
via	O
homologous	O
STAT	O
proteins	O
(	O
e	O
.	O
g	O
.	O
STAT1	O
"),"	O
it	O
was	O
imperative	O
to	O
test	O
whether	O
FLLL32	B-Chemical
had	O
deleterious	O
effects	O
on	O
the	O
action	O
of	O
cytokines	O
that	O
might	O
promote	O
an	O
anti	O
-	O
tumor	O
response	O
.	O
Of	O
concern	O
were	O
the	O
effects	O
of	O
FLLL32	B-Chemical
on	O
signal	O
transduction	O
in	O
response	O
to	O
IFN	O
Î³	O
","	O
a	O
cytokine	O
that	O
mediates	O
its	O
cellular	O
effects	O
via	O
phosphorylation	O
of	O
STAT1	O
","	O
and	O
a	O
resulting	O
STAT1	O
-	O
STAT1	O
homodimer	O
[	O
25	O
].	O
To	O
test	O
these	O
interactions	O
in	O
a	O
biologic	O
system	O
","	O
we	O
investigated	O
the	O
effects	O
of	O
FLLL32	B-Chemical
or	O
curcumin	B-Chemical
pre	O
-	O
treatment	O
on	O
IFN	O
-	O
Î³	O
-	O
induced	O
signaling	O
and	O
gene	O
expression	O
.	O
Pre	O
treatment	O
of	O
pSTAT3	O
positive	O
A375	O
and	O
Hs294T	O
cells	O
with	O
FLLL32	B-Chemical
or	O
curcumin	B-Chemical
led	O
to	O
reduced	O
pSTAT3	O
versus	O
DMSO	B-Chemical
-	O
treated	O
cells	O
.	O
However	O
","	O
in	O
contrast	O
to	O
curcumin	B-Chemical
","	O
FLLL32	B-Chemical
did	O
not	O
adversely	O
affect	O
IFN	O
-	O
Î³	O
-	O
induced	O
pSTAT1	O
(	O
Figure	O
4A	O
and	O
Additional	O
File	O
1	O
:	O
Figure	O
S3	O
).	O
A	O
unique	O
advantage	O
of	O
FLLL32	B-Chemical
versus	O
other	O
STAT3	O
pathway	O
inhibitors	O
was	O
its	O
apparent	O
specificity	O
.	O
Despite	O
a	O
similar	O
degree	O
of	O
cytotoxicity	O
and	O
the	O
ability	O
to	O
reduce	O
basal	O
pSTAT3	O
in	O
human	O
melanoma	O
cells	O
(	O
Additional	O
File	O
1	O
:	O
Figure	O
S4	O
"),"	O
the	O
WP1066	B-Chemical
","	O
JSI	B-Chemical
-	I-Chemical
124	I-Chemical
","	O
and	O
Stattic	B-Chemical
compounds	O
also	O
inhibited	O
IFN	O
-	O
Î³	O
-	O
induced	O
STAT1	O
phosphorylation	O
(	O
Figure	O
4B	O
).	O
Pre	O
-	O
treatment	O
with	O
FLLL32	B-Chemical
also	O
enhanced	O
transcription	O
of	O
the	O
pro	O
-	O
apoptotic	O
interferon	O
-	O
regulatory	O
factor	O
-	O
1	O
(	O
IRF1	O
)	O
gene	O
in	O
response	O
to	O
IFN	O
-	O
Î³	O
stimulation	O
as	O
determined	O
by	O
Real	O
Time	O
PCR	O
(	O
Figure	O
4C	O
).	O
This	O
IFN	O
-	O
Î³	O
responsive	O
gene	O
has	O
been	O
shown	O
to	O
be	O
transcribed	O
via	O
STAT1	O
-	O
STAT1	O
homodimers	O
binding	O
to	O
a	O
gamma	O
-	O
activated	O
sequence	O
(	O
GAS	O
)	O
element	O
[	O
25	O
].	O
Consistent	O
with	O
our	O
prior	O
studies	O
[	O
15	O
"],"	O
IFN	O
-	O
Î³	O
stimulated	O
IRF1	O
transcription	O
was	O
reduced	O
in	O
all	O
cells	O
pre	O
-	O
treated	O
with	O
curcumin	B-Chemical
(	O
Figure	O
4C	O
).	O
The	O
induction	O
of	O
IRF1	O
was	O
not	O
enhanced	O
in	O
the	O
pSTAT3	O
negative	O
1106	O
MEL	O
cell	O
line	O
(	O
Figure	O
4C	O
"),"	O
suggesting	O
that	O
cross	O
-	O
reactivity	O
of	O
FLLL32	B-Chemical
with	O
STAT1	O
was	O
negligible	O
","	O
and	O
that	O
IFN	O
-	O
Î³	O
driven	O
gene	O
transcription	O
can	O
be	O
augmented	O
via	O
STAT3	O
inhibition	O
.	O
These	O
data	O
indicated	O
that	O
IFN	O
-	O
Î³	O
-	O
induced	O
signal	O
transduction	O
and	O
gene	O
expression	O
were	O
not	O
reduced	O
by	O
FLLL32	B-Chemical
and	O
that	O
its	O
inhibitory	O
actions	O
were	O
specific	O
for	O
STAT3	O
and	O
not	O
other	O
homologous	O
STAT	O
proteins	O
that	O
function	O
as	O
tumor	O
suppressors	O
(	O
e	O
.	O
g	O
.	O
STAT1	O
)	O
[	O
30	O
-	O
33	O
].	O
IFN	O
-	O
Î³	O
-	O
induced	O
signal	O
transduction	O
was	O
not	O
adversely	O
affected	O
by	O
FLLL32	B-Chemical
.	O
(	O
A	O
)	O
A375	O
cells	O
were	O
pre	O
-	O
treated	O
for	O
16	O
hours	O
with	O
FLLL32	B-Chemical
(	O
2	O
--	O
14	O
Î¼M	O
)	O
or	O
curcumin	B-Chemical
(	O
20	O
Î¼M	O
)	O
and	O
subsequently	O
treated	O
with	O
IFN	O
-	O
Î³	O
(	O
10	O
ng	O
/	O
mL	O
)	O
for	O
15	O
minutes	O
.	O
IFN	O
-	O
Î³	O
-	O
induced	O
pSTAT1	O
and	O
pSTAT3	O
were	O
evaluated	O
by	O
immunoblot	O
.	O
Total	O
STAT1	O
","	O
STAT3	O
and	O
Î²	O
-	O
actin	O
were	O
also	O
measured	O
to	O
control	O
for	O
loading	O
.	O
The	O
data	O
were	O
also	O
summarized	O
by	O
densitometry	O
comparing	O
relative	O
expression	O
of	O
pSTAT1	O
to	O
STAT1	O
and	O
pSTAT3	O
to	O
STAT3	O
.	O
(	O
B	O
)	O
The	O
same	O
experiment	O
was	O
performed	O
whereby	O
A375	O
cells	O
were	O
pre	O
-	O
treated	O
for	O
16	O
hours	O
with	O
other	O
Jak2	O
/	O
STAT3	O
pathway	O
inhibitors	O
(	O
WP1066	B-Chemical
","	O
JSI	B-Chemical
-	I-Chemical
124	I-Chemical
","	O
Stattic	B-Chemical
)	O
prior	O
to	O
IFN	O
-	O
Î³	O
stimulation	O
.	O
Data	O
shown	O
are	O
representative	O
of	O
two	O
separate	O
experiments	O
and	O
similar	O
results	O
were	O
obtained	O
in	O
the	O
Hs294T	O
human	O
melanoma	O
cell	O
line	O
(	O
Additional	O
File	O
1	O
:	O
Figure	O
S3	O
).	O
(	O
C	O
)	O
IFN	O
-	O
Î³	O
-	O
induced	O
gene	O
expression	O
was	O
enhanced	O
in	O
the	O
presence	O
of	O
FLLL32	B-Chemical
.	O
A375	O
","	O
Hs294T	O
or	O
1106	O
MEL	O
cells	O
were	O
pre	O
-	O
treated	O
for	O
1	O
hour	O
with	O
2Î¼M	O
FLLL32	B-Chemical
","	O
20Î¼M	O
curcumin	B-Chemical
or	O
DMSO	B-Chemical
(	O
negative	O
control	O
"),"	O
and	O
subsequently	O
stimulated	O
with	O
IFN	O
-	O
Î³	O
(	O
10	O
ng	O
/	O
mL	O
)	O
or	O
PBS	B-Chemical
(	O
vehicle	O
)	O
for	O
an	O
additional	O
4	O
hours	O
.	O
Expression	O
of	O
IRF1	O
was	O
evaluated	O
by	O
Real	O
Time	O
PCR	O
.	O
Data	O
were	O
normalized	O
to	O
18s	O
rRNA	O
levels	O
(	O
housekeeping	O
gene	O
)	O
and	O
expressed	O
as	O
the	O
mean	O
fold	O
change	O
versus	O
DMSO	B-Chemical
-	O
pre	O
-	O
treated	O
cells	O
stimulated	O
with	O
PBS	B-Chemical
.	O
Error	O
bars	O
represent	O
the	O
standard	O
deviation	O
from	O
n	O
=	O
2	O
independent	O
experiments	O
.	O
Effects	O
of	O
FLLL32	B-Chemical
on	O
immune	O
effector	O
cells	O
STAT3	O
function	O
in	O
immune	O
cells	O
can	O
promote	O
tolerance	O
to	O
developing	O
or	O
established	O
tumors	O
.	O
We	O
therefore	O
evaluated	O
whether	O
FLLL32	B-Chemical
would	O
affect	O
the	O
responsiveness	O
of	O
PBMCs	O
to	O
stimulation	O
with	O
clinically	O
relevant	O
cytokines	O
that	O
mediate	O
tumor	O
progression	O
(	O
IL	O
6	O
"),"	O
immunosurveillance	O
(	O
IFN	O
-	O
Î³	O
)	O
or	O
T	O
and	O
NK	O
cell	O
survival	O
(	O
IL	O
2	O
)	O
[	O
34	O
-	O
36	O
].	O
Pre	O
treatment	O
with	O
increasing	O
doses	O
of	O
FLLL32	B-Chemical
reduced	O
basal	O
pSTAT3	O
in	O
PBMCs	O
from	O
healthy	O
donors	O
and	O
led	O
to	O
reduced	O
IL	O
-	O
6	O
-	O
induced	O
pSTAT3	O
in	O
PBMCs	O
(	O
Figure	O
5A	O
).	O
FLLL32	B-Chemical
pre	O
-	O
treatment	O
also	O
did	O
not	O
adversely	O
affect	O
the	O
level	O
of	O
IFN	O
-	O
Î³	O
-	O
induced	O
pSTAT1	O
or	O
IRF1	O
gene	O
expression	O
in	O
PBMC	O
(	O
Figure	O
5B	O
-	O
C	O
).	O
The	O
level	O
of	O
IL	O
2	O
-	O
induced	O
pSTAT5	O
also	O
was	O
not	O
altered	O
by	O
FLLL32	B-Chemical
pre	O
-	O
treatment	O
(	O
Figure	O
5D	O
).	O
The	O
FLLL32	B-Chemical
compound	O
did	O
not	O
decrease	O
viability	O
of	O
PBMCs	O
after	O
a	O
24	O
hour	O
treatment	O
as	O
compared	O
to	O
treatment	O
with	O
DMSO	B-Chemical
alone	O
as	O
determined	O
by	O
Annexin	O
V	O
/	O
PI	B-Chemical
staining	O
or	O
PARP	O
cleavage	O
(	O
Figure	O
6A	O
-	O
B	O
).	O
Similarly	O
","	O
NK	O
cell	O
viability	O
from	O
healthy	O
donors	O
cultured	O
with	O
IL	O
-	O
2	O
(	O
1	O
nM	O
)	O
was	O
not	O
reduced	O
following	O
a	O
24	O
hour	O
treatment	O
with	O
FLLL32	B-Chemical
as	O
compared	O
to	O
treatment	O
with	O
DMSO	B-Chemical
(	O
Figure	O
6C	O
).	O
In	O
addition	O
","	O
the	O
production	O
of	O
granzyme	O
b	O
and	O
IFN	O
-	O
Î³	O
by	O
NK	O
cells	O
from	O
normal	O
donors	O
when	O
cultured	O
with	O
the	O
K562	O
target	O
cell	O
line	O
was	O
not	O
adversely	O
affected	O
in	O
the	O
presence	O
of	O
FLLL32	B-Chemical
(	O
Figure	O
6D	O
).	O
The	O
mean	O
difference	O
(	O
FLLL32	B-Chemical
-	O
DMSO	B-Chemical
)	O
for	O
granzyme	O
b	O
was	O
41	O
.	O
0	O
spots	O
/	O
well	O
(	O
95	O
%	O
CI	O
:	O
-	O
79	O
.	O
0	O
to	O
161	O
.	O
0	O
)	O
and	O
65	O
spots	O
/	O
well	O
for	O
IFN	O
-	O
Î³	O
(	O
95	O
%	O
CI	O
:	O
-	O
146	O
.	O
0	O
to	O
277	O
.	O
9	O
).	O
FLLL32	B-Chemical
inhibited	O
IL	O
6	O
signaling	O
but	O
did	O
not	O
modulate	O
IFN	O
-	O
Î³	O
or	O
IL	O
2	O
induced	O
signaling	O
in	O
PBMCs	O
.	O
PBMCs	O
from	O
healthy	O
donors	O
were	O
pre	O
-	O
treated	O
for	O
16	O
hours	O
with	O
FLLL32	B-Chemical
and	O
subsequently	O
treated	O
with	O
(	O
A	O
)	O
IL	O
6	O
(	O
0	O
.	O
1	O
ng	O
/	O
mL	O
)	O
or	O
(	O
B	O
)	O
IFN	O
-	O
Î³	O
(	O
10	O
ng	O
/	O
mL	O
)	O
for	O
15	O
minutes	O
.	O
pSTAT3	O
and	O
pSTAT1	O
were	O
evaluated	O
by	O
immunoblot	O
analysis	O
.	O
(	O
C	O
)	O
The	O
expression	O
of	O
the	O
IFN	O
-	O
Î³	O
-	O
stimulated	O
gene	O
","	O
IRF1	O
was	O
evaluated	O
by	O
Real	O
Time	O
PCR	O
following	O
a	O
1	O
hour	O
pre	O
-	O
treatment	O
with	O
FLLL32	B-Chemical
and	O
subsequently	O
stimulated	O
with	O
IFN	O
-	O
Î³	O
(	O
10	O
ng	O
/	O
mL	O
)	O
or	O
PBS	B-Chemical
for	O
an	O
additional	O
4	O
hours	O
.	O
Real	O
Time	O
PCR	O
data	O
were	O
expressed	O
as	O
fold	O
change	O
versus	O
DMSO	B-Chemical
-	O
pre	O
-	O
treated	O
cells	O
stimulated	O
with	O
PBS	B-Chemical
.	O
Data	O
were	O
normalized	O
to	O
18s	O
rRNA	O
levels	O
.	O
(	O
D	O
)	O
PBMCs	O
were	O
pre	O
-	O
treated	O
for	O
16	O
hours	O
and	O
subsequently	O
treated	O
with	O
8	O
nM	O
IL	O
2	O
for	O
15	O
minutes	O
.	O
IL	O
2	O
-	O
induced	O
pSTAT5	O
was	O
evaluated	O
by	O
immunoblot	O
analysis	O
.	O
All	O
data	O
are	O
representative	O
of	O
PBMCs	O
from	O
two	O
separate	O
healthy	O
donors	O
.	O
FLLL32	B-Chemical
did	O
not	O
adversely	O
affect	O
viability	O
of	O
immune	O
cells	O
or	O
NK	O
cell	O
function	O
.	O
Viability	O
of	O
normal	O
donor	O
PBMCs	O
treated	O
with	O
FLLL32	B-Chemical
","	O
curcumin	B-Chemical
(	O
Cur	B-Chemical
;	O
20Î¼M	O
)	O
or	O
DMSO	B-Chemical
was	O
assessed	O
by	O
(	O
A	O
)	O
flow	O
cytometric	O
analysis	O
following	O
annexin	O
V	O
/	O
PI	B-Chemical
staining	O
and	O
(	O
B	O
)	O
by	O
immunoblot	O
analysis	O
.	O
(	O
C	O
)	O
Viability	O
of	O
normal	O
donor	O
NK	O
cells	O
as	O
measured	O
by	O
trypan	B-Chemical
blue	I-Chemical
staining	O
after	O
24	O
hours	O
in	O
the	O
presence	O
of	O
IL	O
-	O
2	O
(	O
1	O
nM	O
)	O
and	O
either	O
FLLL32	B-Chemical
(	O
5Î¼M	O
)	O
or	O
DMSO	B-Chemical
.	O
Data	O
are	O
presented	O
as	O
the	O
mean	O
percentage	O
of	O
viable	O
NK	O
cells	O
and	O
error	O
bars	O
represent	O
the	O
standard	O
deviation	O
from	O
n	O
=	O
3	O
individual	O
donors	O
.	O
(	O
D	O
)	O
NK	O
cell	O
mediated	O
Gzmb	O
and	O
IFN	O
Î¼	O
secretion	O
was	O
not	O
altered	O
in	O
the	O
presence	O
of	O
FLLL32	B-Chemical
(	O
5Î¼M	O
)	O
as	O
measured	O
by	O
ELISPOT	O
against	O
K562	O
targets	O
(	O
10	O
:	O
1	O
E	O
:	O
T	O
ratio	O
).	O
Data	O
are	O
presented	O
as	O
the	O
mean	O
number	O
of	O
Gzmb	O
or	O
IFN	O
-	O
Î³	O
spots	O
and	O
error	O
bars	O
represent	O
the	O
standard	O
deviation	O
from	O
n	O
=	O
3	O
individual	O
donors	O
.	O
Discussion	O
We	O
have	O
characterized	O
the	O
biologic	O
activity	O
of	O
the	O
curcumin	B-Chemical
analog	O
","	O
FLLL32	B-Chemical
on	O
melanoma	O
and	O
immune	O
effector	O
cells	O
.	O
The	O
present	O
study	O
has	O
demonstrated	O
that	O
the	O
FLLL32	B-Chemical
small	O
molecule	O
can	O
inhibit	O
STAT3	O
signal	O
transduction	O
and	O
induce	O
caspase	O
-	O
dependent	O
","	O
pro	O
-	O
apoptotic	O
effects	O
against	O
human	O
melanoma	O
cell	O
lines	O
and	O
primary	O
melanoma	O
cultures	O
at	O
micromolar	O
concentrations	O
.	O
In	O
contrast	O
to	O
curcumin	B-Chemical
and	O
other	O
STAT3	O
pathway	O
inhibitors	O
","	O
IFN	O
-	O
Î³	O
-	O
induced	O
STAT1	O
phosphorylation	O
was	O
not	O
altered	O
in	O
the	O
presence	O
of	O
FLLL32	B-Chemical
.	O
This	O
compound	O
did	O
not	O
inhibit	O
the	O
viability	O
of	O
PBMCs	O
","	O
NK	O
cells	O
or	O
their	O
cellular	O
responsiveness	O
to	O
clinically	O
relevant	O
cytokines	O
.	O
These	O
data	O
show	O
that	O
FLLL32	B-Chemical
represents	O
a	O
novel	O
small	O
molecule	O
curcumin	B-Chemical
analog	O
with	O
STAT3	O
pathway	O
specificity	O
that	O
will	O
be	O
considered	O
as	O
a	O
lead	O
compound	O
for	O
further	O
drug	O
development	O
in	O
melanoma	O
.	O
FLLL32	B-Chemical
represents	O
a	O
structural	O
analog	O
of	O
curcumin	B-Chemical
when	O
locked	O
into	O
its	O
diketone	B-Chemical
tautomeric	O
form	O
.	O
A	O
number	O
of	O
favorable	O
biologic	O
properties	O
resulting	O
from	O
these	O
modifications	O
have	O
been	O
characterized	O
in	O
this	O
study	O
.	O
First	O
","	O
FLLL32	B-Chemical
was	O
ten	O
-	O
fold	O
more	O
potent	O
than	O
curcumin	B-Chemical
at	O
inducing	O
apoptosis	O
of	O
melanoma	O
cells	O
[	O
15	O
].	O
Second	O
","	O
FLLL32	B-Chemical
did	O
not	O
appear	O
to	O
have	O
toxic	O
effects	O
on	O
either	O
normal	O
PBMCs	O
or	O
NK	O
cells	O
.	O
Third	O
","	O
FLLL32	B-Chemical
was	O
designed	O
to	O
specifically	O
target	O
the	O
oncogenic	O
STAT3	O
pathway	O
","	O
while	O
leaving	O
the	O
STAT1	O
pathway	O
intact	O
.	O
Data	O
from	O
the	O
present	O
report	O
indicate	O
that	O
in	O
terms	O
of	O
in	O
vitro	O
specificity	O
","	O
FLLL32	B-Chemical
was	O
superior	O
to	O
other	O
STAT3	O
pathway	O
inhibitors	O
or	O
to	O
curcumin	B-Chemical
.	O
In	O
fact	O
","	O
prior	O
studies	O
from	O
our	O
group	O
have	O
demonstrated	O
that	O
curcumin	B-Chemical
inhibited	O
the	O
phosphorylation	O
of	O
numerous	O
STAT	O
proteins	O
in	O
response	O
to	O
clinically	O
relevant	O
cytokines	O
including	O
IFN	O
-	O
Î³	O
(	O
STAT1	O
"),"	O
IFN	O
-	O
Î³	O
(	O
STAT1	O
)	O
and	O
IL	O
2	O
(	O
STAT5	O
)	O
[	O
15	O
].	O
These	O
inhibitory	O
effects	O
of	O
curcumin	B-Chemical
were	O
observed	O
in	O
both	O
melanoma	O
cell	O
lines	O
and	O
in	O
PBMCs	O
from	O
healthy	O
donors	O
.	O
As	O
a	O
result	O
","	O
design	O
of	O
the	O
FLLL32	B-Chemical
analog	O
was	O
focused	O
on	O
maximizing	O
the	O
target	O
specificity	O
for	O
STAT3	O
over	O
other	O
STAT	O
proteins	O
.	O
The	O
present	O
data	O
support	O
the	O
STAT3	O
specificity	O
of	O
the	O
FLLL32	B-Chemical
lead	O
compound	O
","	O
although	O
they	O
do	O
not	O
conclusively	O
exclude	O
that	O
FLLL32	B-Chemical
could	O
modulate	O
the	O
phosphorylation	O
of	O
other	O
unidentified	O
kinases	O
.	O
Numerous	O
early	O
generation	O
small	O
molecule	O
STAT3	O
inhibitors	O
(	O
e	O
.	O
g	O
.	O
Stattic	B-Chemical
","	O
STA	B-Chemical
-	I-Chemical
21	I-Chemical
","	O
LLL12	B-Chemical
","	O
S32	B-Chemical
M2001	I-Chemical
","	O
S3I	B-Chemical
-	I-Chemical
201	I-Chemical
)	O
have	O
been	O
reported	O
to	O
induce	O
apoptosis	O
via	O
inhibition	O
of	O
STAT3	O
activation	O
and	O
/	O
or	O
dimerization	O
[	O
33	O
","	O
37	O
"],"	O
while	O
siRNA	O
specific	O
for	O
the	O
SH2	O
coding	O
region	O
of	O
STAT3	O
could	O
induce	O
apoptosis	O
in	O
prostate	O
cancer	O
cells	O
in	O
vitro	O
and	O
in	O
nude	O
mice	O
bearing	O
human	O
xenograft	O
tumors	O
[	O
32	O
].	O
Finally	O
","	O
studies	O
have	O
also	O
shown	O
that	O
platinum	B-Chemical
complexes	O
can	O
promote	O
anti	O
-	O
tumor	O
activity	O
by	O
virtue	O
of	O
their	O
ability	O
to	O
inhibit	O
STAT3	O
[	O
38	O
].	O
Collectively	O
","	O
these	O
studies	O
provide	O
precedent	O
for	O
targeting	O
STAT3	O
as	O
a	O
means	O
of	O
inducing	O
tumor	O
cell	O
apoptosis	O
.	O
However	O
","	O
the	O
specificity	O
of	O
many	O
existing	O
inhibitory	O
strategies	O
for	O
STAT3	O
and	O
not	O
other	O
STAT	O
proteins	O
(	O
e	O
.	O
g	O
.	O
STAT1	O
)	O
or	O
oncogenic	O
pathways	O
has	O
not	O
been	O
validated	O
in	O
biological	O
systems	O
.	O
An	O
attractive	O
aspect	O
of	O
FLLL32	B-Chemical
was	O
its	O
specificity	O
and	O
activity	O
at	O
micromolar	O
concentrations	O
.	O
Data	O
from	O
the	O
present	O
study	O
suggest	O
that	O
FLLL32	B-Chemical
represents	O
a	O
unique	O
molecule	O
that	O
can	O
be	O
optimized	O
further	O
for	O
inhibition	O
of	O
the	O
STAT3	O
pathway	O
.	O
STAT3	O
can	O
promote	O
immune	O
tolerance	O
in	O
the	O
setting	O
of	O
cancer	O
and	O
thus	O
represents	O
an	O
attractive	O
target	O
to	O
enhance	O
immunotherapy	O
(	O
Reviewed	O
in	O
[	O
39	O
]).	O
Recent	O
studies	O
from	O
our	O
group	O
and	O
others	O
have	O
demonstrated	O
that	O
the	O
presence	O
of	O
constitutively	O
active	O
STAT3	O
in	O
melanoma	O
cells	O
is	O
correlated	O
with	O
reduced	O
responsiveness	O
to	O
cytokines	O
which	O
act	O
via	O
STAT1	O
signal	O
transduction	O
[	O
17	O
].	O
These	O
data	O
suggest	O
that	O
the	O
balance	O
between	O
pSTAT1	O
and	O
pSTAT3	O
may	O
influence	O
cellular	O
responsiveness	O
to	O
immunostimulatory	O
cytokines	O
and	O
ultimately	O
immune	O
-	O
mediated	O
tumor	O
regression	O
[	O
17	O
","	O
40	O
].	O
Data	O
from	O
this	O
report	O
also	O
shows	O
that	O
FLLL32	B-Chemical
inhibited	O
IL	O
-	O
6	O
induced	O
STAT3	O
phosphorylation	O
within	O
PBMCs	O
.	O
Of	O
note	O
","	O
elevated	O
levels	O
of	O
IL	O
6	O
are	O
associated	O
with	O
poor	O
prognosis	O
in	O
melanoma	O
","	O
and	O
contribute	O
to	O
the	O
generation	O
of	O
immunosuppressive	O
lymphoid	O
cell	O
populations	O
[	O
41	O
].	O
Finally	O
","	O
our	O
studies	O
indicate	O
that	O
FLLL32	B-Chemical
-	O
mediated	O
inhibition	O
of	O
STAT3	O
does	O
not	O
alter	O
production	O
of	O
granzyme	O
b	O
or	O
IFN	O
Î³	O
by	O
NK	O
cells	O
from	O
normal	O
donors	O
when	O
cultured	O
with	O
K562	O
targets	O
","	O
or	O
their	O
viability	O
when	O
cultured	O
with	O
IL	O
-	O
2	O
.	O
These	O
properties	O
are	O
of	O
importance	O
based	O
on	O
recent	O
murine	O
studies	O
showing	O
the	O
Jak2	O
inhibitor	O
WP1193	B-Chemical
can	O
augment	O
immunotherapy	O
with	O
IFN	O
-	O
Î±	O
[	O
42	O
"],"	O
and	O
STAT3	O
siRNA	O
-	O
CpG	O
oligodeoxynucleotides	O
can	O
elicit	O
anti	O
-	O
tumor	O
immune	O
responses	O
[	O
43	O
].	O
Together	O
these	O
data	O
suggest	O
that	O
STAT3	O
pathway	O
inhibition	O
could	O
be	O
investigated	O
further	O
as	O
a	O
potential	O
means	O
by	O
which	O
to	O
overcome	O
immune	O
tolerance	O
and	O
augment	O
responsiveness	O
to	O
standard	O
or	O
experimental	O
immune	O
-	O
based	O
therapies	O
.	O
Despite	O
its	O
improved	O
STAT3	O
specificity	O
","	O
the	O
FLLL32	B-Chemical
analog	O
retains	O
some	O
structural	O
properties	O
of	O
its	O
parent	O
compound	O
","	O
curcumin	B-Chemical
which	O
as	O
expected	O
","	O
limit	O
its	O
solubility	O
and	O
bioavailability	O
(	O
data	O
not	O
shown	O
).	O
Therefore	O
","	O
our	O
group	O
is	O
pursuing	O
additional	O
structural	O
modifications	O
or	O
formulation	O
approaches	O
to	O
further	O
improve	O
upon	O
the	O
bioavailability	O
of	O
this	O
small	O
molecule	O
","	O
in	O
light	O
of	O
its	O
potent	O
and	O
specific	O
in	O
vitro	O
activity	O
.	O
The	O
present	O
results	O
provide	O
evidence	O
that	O
the	O
FLLL32	B-Chemical
curcumin	I-Chemical
analog	O
represents	O
a	O
promising	O
lead	O
compound	O
on	O
which	O
to	O
base	O
the	O
further	O
development	O
of	O
STAT3	O
-	O
specific	O
inhibitors	O
against	O
melanoma	O
.	O
The	O
ability	O
of	O
FLLL32	B-Chemical
to	O
specifically	O
inhibit	O
the	O
STAT3	O
pathway	O
while	O
retaining	O
the	O
cellular	O
response	O
to	O
cytokines	O
with	O
anti	O
-	O
tumor	O
activity	O
is	O
a	O
particular	O
advantage	O
that	O
will	O
be	O
optimized	O
in	O
future	O
pre	O
-	O
clinical	O
studies	O
.	O
Competing	O
interests	O
JRF	O
","	O
CL	O
","	O
JL	O
","	O
and	O
PK	O
are	O
listed	O
as	O
inventors	O
on	O
a	O
full	O
patent	O
that	O
has	O
been	O
filed	O
.	O
Authors	O
'	O
contributions	O
Study	O
concept	O
and	O
design	O
:	O
JRF	O
","	O
CL	O
","	O
JL	O
","	O
PL	O
","	O
GBL	O
;	O
Acquisition	O
of	O
data	O
:	O
MAB	O
","	O
JY	O
","	O
CB	O
","	O
DB	O
","	O
SLF	O
","	O
GBL	O
;	O
Analysis	O
and	O
Interpretation	O
of	O
Data	O
:	O
MAB	O
","	O
JY	O
","	O
CB	O
","	O
DB	O
","	O
SLF	O
","	O
PL	O
","	O
GBL	O
;	O
drafting	O
of	O
the	O
manuscript	O
:	O
GY	O
","	O
GBL	O
;	O
statistical	O
analysis	O
:	O
GY	O
;	O
obtained	O
funding	O
:	O
JRF	O
","	O
DB	O
","	O
WEC	O
","	O
GBL	O
;	O
technical	O
and	O
material	O
support	O
JRF	O
","	O
CL	O
","	O
EBS	O
","	O
DA	O
","	O
JL	O
","	O
DGH	O
.	O
All	O
authors	O
have	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
Supplementary	O
Material	O
Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
NIH	O
Grants	O
K22CA134551	O
(	O
Lesinski	O
"),"	O
1R21CA141434	O
-	O
01A1	O
(	O
Lesinski	O
"),"	O
P01CA95426	O
(	O
Caligiuri	O
"),"	O
P30CA16058	O
(	O
Caligiuri	O
"),"	O
CA84402	O
","	O
K24CA93670	O
(	O
Carson	O
);	O
The	O
Valvano	O
Foundation	O
for	O
Cancer	O
Research	O
(	O
Lesinski	O
"),"	O
and	O
Grant	O
#	O
IRG	O
-	O
67	O
-	O
3	O
-	O
44	O
from	O
the	O
American	O
Cancer	O
Society	O
(	O
Benson	O
and	O
Fuchs	O
).	O
The	O
project	O
described	O
was	O
supported	O
by	O
Award	O
Number	O
UL1RR025755	O
from	O
the	O
National	O
Center	O
for	O
Research	O
Resources	O
","	O
funded	O
by	O
the	O
Office	O
of	O
the	O
Director	O
","	O
National	O
Institutes	O
of	O
Health	O
(	O
OD	O
)	O
and	O
supported	O
by	O
the	O
NIH	O
Roadmap	O
for	O
Medical	O
Research	O
.	O
The	O
content	O
is	O
solely	O
the	O
responsibility	O
of	O
the	O
authors	O
and	O
does	O
not	O
necessarily	O
represent	O
the	O
official	O
views	O
of	O
the	O
National	O
Center	O
for	O
Research	O
Resources	O
or	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O
We	O
also	O
thank	O
the	O
OSU	O
CCC	O
Analytical	O
Cytometry	O
","	O
Nucleic	O
Acid	O
","	O
Molecular	O
Cytogenetics	O
","	O
Pharmacoanalytical	O
and	O
Biostatistics	O
Shared	O
Resources	O
.	O
We	O
also	O
thank	O
Dr	O
.	O
Mitch	O
Phelps	O
","	O
Dr	O
.	O
Cheryl	O
London	O
and	O
Dr	O
.	O
Samuel	O
Kulp	O
for	O
their	O
guidance	O
associated	O
with	O
this	O
project	O
.	O
Synthesis	O
","	O
X	O
-	O
Ray	O
Structure	O
","	O
and	O
Characterization	O
of	O
Catena	B-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
benzoate	I-Chemical
)	I-Chemical
bis	I-Chemical
{	I-Chemical
N	I-Chemical
","	I-Chemical
N	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
hydroxyethyl	I-Chemical
)	I-Chemical
glycinate	I-Chemical
}	I-Chemical
cadmium	I-Chemical
(	I-Chemical
II	I-Chemical
)	I-Chemical
The	O
reaction	O
of	O
N	B-Chemical
","	I-Chemical
N	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
hydroxyethyl	I-Chemical
)	I-Chemical
glycine	I-Chemical
(	O
bicine	B-Chemical
;	O
bicH3	B-Chemical
)	O
with	O
Cd	B-Chemical
(	I-Chemical
O2CPh	I-Chemical
)	I-Chemical
2	I-Chemical
Â·	I-Chemical
2H2O	I-Chemical
in	O
MeOH	B-Chemical
yielded	O
the	O
polymeric	O
compound	O
[	B-Chemical
Cd2	I-Chemical
(	I-Chemical
O2CPh	I-Chemical
)	I-Chemical
2	I-Chemical
(	I-Chemical
bicH2	I-Chemical
)	I-Chemical
2	I-Chemical
]	I-Chemical
n	I-Chemical
(	I-Chemical
1	I-Chemical
).	I-Chemical
The	O
complex	O
crystallizes	O
in	O
the	O
tetragonal	O
space	O
group	O
P41212	O
.	O
The	O
lattice	O
constants	O
are	O
a	O
=	O
b	O
=	O
12	O
.	O
737	O
(	O
5	O
)	O
and	O
c	O
=	O
18	O
.	O
288	O
(	O
7	O
)	O
Ã…	O
.	O
The	O
compound	O
contains	O
chains	O
of	O
repeating	O
{	B-Chemical
Cd2	I-Chemical
(	I-Chemical
O2CPh	I-Chemical
)	I-Chemical
2	I-Chemical
(	I-Chemical
bicH2	I-Chemical
)	I-Chemical
2	I-Chemical
}	I-Chemical
units	O
.	O
One	O
CdII	B-Chemical
atom	O
is	O
coordinated	O
by	O
two	O
carboxylate	B-Chemical
oxygen	I-Chemical
","	O
four	O
hydroxyl	B-Chemical
oxygen	I-Chemical
","	O
and	O
two	O
nitrogen	B-Chemical
atoms	O
from	O
two	O
symmetry	O
-	O
related	O
2	O
.	O
21111	O
(	O
Harris	O
notation	O
)	O
bicH2	O
âˆ’	O
ligands	O
.	O
The	O
other	O
CdII	B-Chemical
atom	O
is	O
coordinated	O
by	O
six	O
carboxylate	B-Chemical
oxygen	I-Chemical
atoms	O
","	O
four	O
from	O
two	O
bicH2	O
âˆ’	O
ligands	O
and	O
two	O
from	O
the	O
monodentate	O
benzoate	B-Chemical
groups	O
.	O
Each	O
bicinate	O
(-	O
1	O
)	O
ligand	O
chelates	O
the	O
8	O
-	O
coordinate	O
","	O
square	O
antiprismatic	O
CdII	B-Chemical
atom	O
through	O
one	O
carboxylate	B-Chemical
oxygen	I-Chemical
","	O
the	O
nitrogen	B-Chemical
","	O
and	O
both	O
hydroxyl	B-Chemical
oxygen	I-Chemical
atoms	O
and	O
bridges	O
the	O
second	O
","	O
six	O
-	O
coordinate	O
trigonal	O
prismatic	O
CdII	B-Chemical
center	O
through	O
its	O
carboxylate	B-Chemical
oxygen	I-Chemical
atoms	O
.	O
Compound	O
1	O
is	O
the	O
first	O
structurally	O
characterized	O
cadmium	B-Chemical
(	I-Chemical
II	I-Chemical
)	I-Chemical
complex	O
containing	O
any	O
anionic	O
form	O
of	O
bicine	B-Chemical
as	O
ligand	O
.	O
IR	O
data	O
of	O
1	O
are	O
discussed	O
in	O
terms	O
of	O
the	O
coordination	O
modes	O
of	O
the	O
ligands	O
and	O
the	O
known	O
structure	O
.	O
1	O
.	O
Introduction	O
There	O
are	O
many	O
areas	O
illustrating	O
the	O
importance	O
of	O
cadmium	B-Chemical
coordination	O
and	O
bioinorganic	O
chemistry	O
and	O
the	O
need	O
for	O
further	O
research	O
in	O
this	O
field	O
.	O
The	O
mobilization	O
and	O
immobilization	O
of	O
CdII	B-Chemical
in	O
the	O
environment	O
","	O
in	O
the	O
organisms	O
","	O
and	O
in	O
some	O
technical	O
processes	O
can	O
depend	O
significantly	O
on	O
the	O
complexation	O
by	O
chelating	O
organic	O
ligands	O
[].	O
For	O
example	O
","	O
anthropogenic	O
chelators	O
released	O
into	O
the	O
environment	O
","	O
humic	O
acids	O
","	O
and	O
several	O
types	O
of	O
ligands	O
produced	O
by	O
microorganisms	O
contribute	O
to	O
the	O
transfer	O
of	O
this	O
metal	O
ion	O
between	O
solid	O
and	O
aqueous	O
phases	O
[].	O
Examples	O
of	O
applied	O
cadmium	B-Chemical
coordination	O
chemistry	O
are	O
found	O
in	O
wastewater	O
treatment	O
and	O
organic	O
separation	O
problems	O
"[,"	O
].	O
Cadmium	B-Chemical
is	O
also	O
important	O
in	O
the	O
interdisciplinary	O
field	O
of	O
Bioinorganic	O
Chemistry	O
.	O
Though	O
CdII	B-Chemical
probably	O
does	O
not	O
have	O
any	O
biological	O
function	O
","	O
the	O
body	O
of	O
a	O
normal	O
human	O
adult	O
usually	O
contains	O
some	O
milligrams	O
of	O
it	O
"[],"	O
mainly	O
in	O
metallothioneins	O
","	O
where	O
it	O
is	O
tightly	O
bonded	O
to	O
cysteinyl	O
sulfur	B-Chemical
atoms	O
[].	O
In	O
special	O
cases	O
of	O
cadmium	B-Chemical
poisoning	O
","	O
the	O
so	O
-	O
called	O
â€œ	O
chelation	O
therapy	O
â€	O
can	O
be	O
applied	O
in	O
which	O
synthetic	O
chelators	O
","	O
like	O
EDTA4	B-Chemical
âˆ’	I-Chemical
and	O
2	B-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
dimercapto	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
propanol	I-Chemical
(	O
BAL	B-Chemical
"),"	O
are	O
given	O
as	O
antidotes	O
[].	O
A	O
number	O
of	O
research	O
groups	O
have	O
been	O
also	O
using	O
113Cd	B-Chemical
NMR	O
spectroscopy	O
as	O
a	O
â€œ	O
spin	O
spy	O
â€	O
in	O
the	O
study	O
of	O
ZnII	B-Chemical
-	O
containing	O
proteins	O
[].	O
Systematic	O
comparative	O
studies	O
on	O
the	O
coordination	O
chemistry	O
of	O
CdII	B-Chemical
and	O
ZnII	B-Chemical
with	O
ligands	O
containing	O
donor	O
groups	O
of	O
biological	O
relevance	O
are	O
useful	O
in	O
this	O
topic	O
.	O
The	O
stereochemical	O
adaptability	O
of	O
this	O
d10	O
metal	O
ion	O
favours	O
structural	O
variations	O
","	O
and	O
this	O
fact	O
makes	O
CdII	B-Chemical
a	O
central	O
â€œ	O
player	O
â€	O
in	O
the	O
fields	O
of	O
Crystal	O
Engineering	O
and	O
Metallosupramolecular	O
Chemistry	O
"[,"	O
].	O
Amongst	O
the	O
ligands	O
that	O
have	O
never	O
been	O
used	O
for	O
the	O
preparation	O
and	O
study	O
of	O
CdII	B-Chemical
complexes	O
","	O
neither	O
in	O
the	O
solid	O
state	O
nor	O
in	O
solution	O
","	O
is	O
N	B-Chemical
","	I-Chemical
N	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
hydroxyethyl	I-Chemical
)	I-Chemical
glycine	I-Chemical
","	O
generally	O
known	O
as	O
bicine	B-Chemical
(	O
bicH3	B-Chemical
","	O
Scheme	O
1	O
).	O
This	O
is	O
a	O
currently	O
â€œ	O
hot	O
â€	O
ligand	O
in	O
Bioinorganic	O
Chemistry	O
.	O
Bicine	B-Chemical
was	O
first	O
prepared	O
in	O
1926	O
by	O
Kiprianov	O
and	O
subsequently	O
became	O
a	O
widely	O
used	O
buffer	O
substance	O
in	O
many	O
biochemical	O
studies	O
[].	O
As	O
with	O
its	O
parent	O
compound	O
","	O
the	O
amino	B-Chemical
acid	I-Chemical
glycine	I-Chemical
(	O
glyH	B-Chemical
)	O
also	O
shown	O
in	O
Scheme	O
1	O
","	O
the	O
monoanion	O
of	O
bicine	B-Chemical
","	O
that	O
is	O
","	O
the	O
bicinate	O
(âˆ’	O
1	O
)	O
ion	O
(	O
bicH2	O
"âˆ’),"	O
forms	O
metal	O
complexes	O
.	O
The	O
stability	O
constants	O
of	O
many	O
divalent	O
transition	O
metal	O
complexes	O
of	O
bicinate	O
(âˆ’	O
1	O
)	O
have	O
been	O
determined	O
","	O
and	O
it	O
has	O
been	O
found	O
that	O
the	O
[	B-Chemical
M	I-Chemical
(	I-Chemical
bicH2	I-Chemical
)(	I-Chemical
H2O	I-Chemical
)	I-Chemical
x	I-Chemical
]+	I-Chemical
species	O
is	O
always	O
the	O
predominant	O
species	O
in	O
solution	O
[].	O
It	O
has	O
repeatedly	O
emphasized	O
[â€“]	O
that	O
as	O
a	O
consequence	O
of	O
its	O
strong	O
complexation	O
properties	O
","	O
the	O
use	O
of	O
bicine	B-Chemical
as	O
a	O
pH	O
buffer	O
in	O
biochemical	O
or	O
medical	O
studies	O
under	O
the	O
assumption	O
that	O
only	O
little	O
(	O
or	O
no	O
)	O
interaction	O
with	O
divalent	O
metal	O
ions	O
occurs	O
is	O
not	O
justified	O
.	O
It	O
has	O
been	O
shown	O
that	O
not	O
only	O
do	O
bicH3	B-Chemical
and	O
related	O
compounds	O
buffer	O
H	B-Chemical
+	I-Chemical
concentrations	O
but	O
also	O
the	O
resultant	O
metal	O
complexes	O
buffer	O
H	B-Chemical
+	I-Chemical
and	O
metal	O
ion	O
concentrations	O
;	O
therefore	O
the	O
employment	O
of	O
bicH3	B-Chemical
as	O
a	O
buffer	O
requires	O
great	O
care	O
to	O
avoid	O
conflicting	O
data	O
and	O
erroneous	O
conclusions	O
[â€“].	O
Even	O
though	O
bicinate	B-Chemical
metal	I-Chemical
complexes	O
have	O
been	O
studied	O
in	O
solution	O
for	O
years	O
"[â€“],"	O
mainly	O
through	O
the	O
excellent	O
research	O
of	O
Sigel	O
"[],"	O
only	O
few	O
metal	O
complexes	O
have	O
been	O
structurally	O
characterized	O
in	O
the	O
solid	O
state	O
through	O
single	O
-	O
crystal	O
","	O
X	O
-	O
ray	O
crystallography	O
.	O
In	O
those	O
structural	O
studies	O
it	O
was	O
found	O
(	O
see	O
â€œ	O
Results	O
and	O
Discussion	O
â€)	O
that	O
the	O
anionic	O
bicH2	O
"âˆ’,"	O
bicH2	O
"âˆ’,"	O
and	O
bic3	O
âˆ’	O
ligands	O
are	O
versatile	O
and	O
behave	O
in	O
a	O
variety	O
of	O
terminal	O
and	O
bridging	O
modes	O
.	O
Due	O
to	O
this	O
versatility	O
","	O
the	O
anionic	O
forms	O
of	O
bicine	B-Chemical
are	O
promising	O
ligands	O
for	O
the	O
isolation	O
of	O
polynuclear	O
transition	O
metal	O
complexes	O
(	O
clusters	O
)	O
"[,"	O
].	O
Transition	O
metal	O
cluster	O
chemistry	O
is	O
a	O
currently	O
â€œ	O
hot	O
â€	O
research	O
field	O
in	O
contemporary	O
inorganic	O
chemistry	O
[].	O
In	O
this	O
paper	O
we	O
report	O
the	O
amalgamation	O
of	O
the	O
above	O
-	O
mentioned	O
two	O
research	O
areas	O
by	O
reporting	O
the	O
preparation	O
","	O
structural	O
characterization	O
","	O
and	O
spectroscopic	O
study	O
of	O
the	O
first	O
cadmium	B-Chemical
(	I-Chemical
II	I-Chemical
)	I-Chemical
bicinate	I-Chemical
complex	O
.	O
This	O
paper	O
can	O
be	O
considered	O
as	O
a	O
continuation	O
of	O
our	O
interest	O
in	O
the	O
coordination	O
chemistry	O
of	O
bicine	B-Chemical
[]	O
and	O
in	O
the	O
CdII	B-Chemical
carboxylate	I-Chemical
chemistry	O
[].	O
2	O
.	O
Experiments	O
All	O
manipulations	O
were	O
performed	O
under	O
aerobic	O
conditions	O
using	O
materials	O
and	O
solvents	O
as	O
received	O
.	O
Cd	B-Chemical
(	I-Chemical
O2CPh	I-Chemical
)	I-Chemical
2	I-Chemical
Â·	I-Chemical
2H2O	I-Chemical
was	O
prepared	O
by	O
the	O
reaction	O
of	O
Cd	B-Chemical
(	I-Chemical
O2CMe	I-Chemical
)	I-Chemical
2	I-Chemical
Â·	I-Chemical
2H2O	I-Chemical
with	O
an	O
excess	O
of	O
PhCO2H	B-Chemical
in	O
CHCl3	B-Chemical
under	O
reflux	O
.	O
C	B-Chemical
","	O
H	B-Chemical
","	O
and	O
N	B-Chemical
analyses	O
were	O
performed	O
with	O
a	O
Carlo	O
Erba	O
EA	O
108	O
analyzer	O
.	O
IR	O
spectra	O
(	O
400	O
â€“	O
450	O
cm	O
âˆ’	O
1	O
)	O
were	O
performed	O
with	O
a	O
Perkin	O
-	O
Elmer	O
PC16	O
FT	O
-	O
IR	O
spectrometer	O
with	O
samples	O
prepared	O
as	O
KBr	B-Chemical
pellets	O
.	O
[	B-Chemical
Cd2	I-Chemical
(	I-Chemical
O2CPh	I-Chemical
)	I-Chemical
2	I-Chemical
(	I-Chemical
bicH2	I-Chemical
)	I-Chemical
2	I-Chemical
]	I-Chemical
n	I-Chemical
(	I-Chemical
1	I-Chemical
)	I-Chemical
Solid	O
bicH3	B-Chemical
(	O
0	O
.	O
120	O
g	O
","	O
0	O
.	O
74	O
mmol	O
)	O
was	O
added	O
to	O
a	O
colourless	O
solution	O
of	O
Cd	B-Chemical
(	I-Chemical
O2CPh	I-Chemical
)	I-Chemical
2	I-Chemical
Â·	I-Chemical
2H2O	I-Chemical
(	O
0	O
.	O
289	O
g	O
","	O
0	O
.	O
74	O
mmol	O
)	O
in	O
MeOH	B-Chemical
(	O
40	O
cm3	O
);	O
the	O
solid	O
soon	O
dissolved	O
.	O
The	O
solution	O
was	O
refluxed	O
for	O
20	O
min	O
and	O
allowed	O
to	O
slowly	O
evaporate	O
at	O
room	O
temperature	O
.	O
Well	O
-	O
formed	O
","	O
X	O
-	O
ray	O
quality	O
colourless	O
crystals	O
of	O
the	O
product	O
appeared	O
within	O
a	O
period	O
of	O
three	O
days	O
.	O
The	O
crystals	O
were	O
collected	O
by	O
vacuum	O
filtration	O
","	O
washed	O
with	O
cold	O
MeOH	B-Chemical
(	O
2	O
Ã—	O
2	O
cm3	O
)	O
and	O
Et2O	B-Chemical
(	O
3	O
Ã—	O
5	O
cm3	O
"),"	O
and	O
dried	O
in	O
air	O
.	O
The	O
yield	O
was	O
ca	O
.	O
75	O
%.	O
Found	O
%:	O
C	B-Chemical
","	O
39	O
.	O
12	O
;	O
H	B-Chemical
","	O
3	O
.	O
97	O
;	O
N	B-Chemical
","	O
3	O
.	O
50	O
.	O
Calc	O
%	O
for	O
C26H34N2O12Cd2	B-Chemical
:	O
C	B-Chemical
","	O
39	O
.	O
46	O
;	O
H	B-Chemical
","	O
4	O
.	O
34	O
;	O
N	B-Chemical
","	O
3	O
.	O
54	O
.	O
IR	O
data	O
(	O
KBr	B-Chemical
","	O
cm	O
âˆ’	O
1	O
):	O
3235	O
(	O
sb	O
"),"	O
3070	O
(	O
mb	O
"),"	O
2972	O
(	O
m	O
"),"	O
2940	O
(	O
w	O
"),"	O
2894	O
(	O
w	O
"),"	O
1606	O
(	O
s	O
"),"	O
1582	O
(	O
s	O
"),"	O
1490	O
(	O
w	O
"),"	O
1445	O
(	O
w	O
"),"	O
1418	O
(	O
m	O
"),"	O
1384	O
(	O
s	O
"),"	O
1334	O
(	O
m	O
"),"	O
1264	O
(	O
m	O
"),"	O
1237	O
(	O
m	O
"),"	O
1174	O
(	O
w	O
"),"	O
1157	O
(	O
w	O
"),"	O
1138	O
(	O
m	O
"),"	O
1069	O
(	O
s	O
"),"	O
1017	O
(	O
s	O
"),"	O
992	O
(	O
w	O
"),"	O
943	O
(	O
m	O
"),"	O
885	O
(	O
s	O
"),"	O
846	O
(	O
m	O
"),"	O
797	O
(	O
w	O
"),"	O
727	O
(	O
s	O
"),"	O
608	O
(	O
m	O
"),"	O
584	O
(	O
m	O
"),"	O
552	O
(	O
w	O
).	O
2	O
.	O
1	O
.	O
X	O
-	O
ray	O
Crystallography	O
X	O
-	O
ray	O
data	O
were	O
collected	O
at	O
298	O
K	O
using	O
a	O
Crystal	O
LOGIC	O
dual	O
Goniometer	O
diffractometer	O
with	O
graphite	B-Chemical
-	O
monochromated	O
Mo	B-Chemical
-	O
Ka	O
radiation	O
(	O
Î»	O
=	O
0	O
.	O
71073	O
Ã…	O
).	O
The	O
appropriate	O
crystal	O
was	O
mounted	O
in	O
air	O
and	O
covered	O
with	O
epoxy	B-Chemical
glue	O
.	O
Unit	O
cell	O
dimensions	O
were	O
determined	O
and	O
refined	O
by	O
using	O
the	O
angular	O
settings	O
of	O
25	O
automatically	O
centered	O
reflections	O
in	O
the	O
range	O
11	O
<	O
2Î¸	O
<	O
23	O
Â°.	O
Intensity	O
data	O
were	O
recorded	O
using	O
a	O
Î¸	O
â€“	O
2Î¸scan	O
.	O
Three	O
standard	O
reflections	O
showed	O
less	O
than	O
3	O
%	O
variation	O
and	O
no	O
decay	O
.	O
Lorentz	O
polarization	O
and	O
Î¨	O
-	O
scan	O
absorption	O
corrections	O
were	O
applied	O
using	O
Crystal	O
Logic	O
software	O
.	O
The	O
structure	O
was	O
solved	O
by	O
direct	O
methods	O
using	O
SHELXS	O
-	O
97	O
[]	O
and	O
refined	O
by	O
full	O
-	O
matrix	O
least	O
-	O
squares	O
techniques	O
on	O
F	O
2	O
with	O
SHELX	O
-	O
97	O
[].	O
Hydrogen	B-Chemical
atoms	O
were	O
located	O
by	O
difference	O
maps	O
and	O
refined	O
isotropically	O
","	O
except	O
those	O
on	O
O	B-Chemical
(	O
3	O
"),"	O
C	B-Chemical
(	O
6	O
"),"	O
and	O
C	B-Chemical
(	O
15	O
)	O
which	O
were	O
introduced	O
at	O
calculated	O
positions	O
as	O
riding	O
on	O
bonded	O
atoms	O
with	O
U	O
equal	O
1	O
.	O
3	O
times	O
the	O
U	O
(	O
eq	O
)	O
of	O
the	O
respective	O
atom	O
.	O
All	O
nonhydrogen	O
atoms	O
were	O
refined	O
anisotropically	O
.	O
CCDC	O
771321	O
contains	O
the	O
supplementary	O
crystallographic	O
data	O
for	O
this	O
paper	O
.	O
This	O
data	O
can	O
be	O
obtained	O
free	O
of	O
charge	O
at	O
http	O
://	O
www	O
.	O
ccdc	O
.	O
cam	O
.	O
ac	O
.	O
uk	O
/	O
conts	O
/	O
retrieving	O
.	O
html	O
[	O
or	O
from	O
the	O
Cambridge	O
Crystallographic	O
Data	O
Centre	O
","	O
12	O
Union	O
Road	O
","	O
Cambridge	O
CB2	O
1EZ	O
","	O
UK	O
;	O
Fax	O
:	O
++	O
44	O
-	O
1223	O
-	O
336	O
33	O
;	O
E	O
-	O
mail	O
:	O
deposit	O
@	O
ccdc	O
.	O
cam	O
.	O
ac	O
.	O
uk	O
].	O
Important	O
crystal	O
data	O
and	O
parameters	O
for	O
data	O
collection	O
and	O
refinement	O
are	O
listed	O
in	O
Table	O
1	O
.	O
3	O
.	O
Results	O
and	O
Discussion	O
3	O
.	O
1	O
.	O
Synthetic	O
Comments	O
Treatment	O
of	O
bicH3	B-Chemical
with	O
1	O
.	O
5	O
equivalent	O
of	O
Cd	B-Chemical
(	I-Chemical
O2CPh	I-Chemical
)	I-Chemical
2	I-Chemical
Â·	I-Chemical
2H2O	I-Chemical
in	O
refluxing	O
MeOH	B-Chemical
gave	O
a	O
colourless	O
solution	O
from	O
which	O
complex	O
[	B-Chemical
Cd2	I-Chemical
(	I-Chemical
O2CPh	I-Chemical
)	I-Chemical
2	I-Chemical
(	I-Chemical
bicH2	I-Chemical
)	I-Chemical
2	I-Chemical
]	I-Chemical
n	I-Chemical
(	I-Chemical
1	I-Chemical
)	I-Chemical
was	O
obtained	O
in	O
60	O
%	O
yield	O
(	O
based	O
on	O
the	O
ligand	O
).	O
Its	O
formation	O
can	O
be	O
represented	O
by	O
the	O
stoichiometric	O
equation	O
The	O
â€œ	O
wrong	O
â€	O
CdII	B-Chemical
to	O
bicH3	B-Chemical
reaction	O
ratio	O
(	O
1	O
.	O
5	O
:	O
1	O
)	O
employed	O
for	O
the	O
preparation	O
of	O
1	O
did	O
not	O
prove	O
detrimental	O
to	O
the	O
formation	O
of	O
the	O
product	O
.	O
With	O
the	O
identity	O
of	O
1	O
established	O
by	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
crystallography	O
","	O
the	O
â€œ	O
correct	O
â€	O
stoichiometry	O
(	O
1	O
:	O
1	O
)	O
was	O
employed	O
and	O
led	O
to	O
the	O
pure	O
compound	O
in	O
75	O
%	O
yield	O
(	O
see	O
Section	O
2	O
).	O
The	O
PhCO2	B-Chemical
âˆ’	O
group	O
present	O
in	O
the	O
reaction	O
mixture	O
plays	O
a	O
double	O
role	O
.	O
It	O
helps	O
the	O
deprotonation	O
of	O
bicH3	B-Chemical
and	O
participates	O
in	O
the	O
complex	O
as	O
ligand	O
.	O
As	O
a	O
next	O
step	O
we	O
decided	O
to	O
use	O
a	O
large	O
excess	O
of	O
Cd	B-Chemical
(	I-Chemical
O2CPh	I-Chemical
)	I-Chemical
2	I-Chemical
Â·	I-Chemical
2H2O	I-Chemical
(	O
CdII	B-Chemical
:	O
bicH3	B-Chemical
=	O
3	O
:	O
1	O
)	O
or	O
to	O
add	O
base	O
(	O
LiOH	B-Chemical
","	O
Et3N	B-Chemical
","	O
Bun	B-Chemical
4NOH	I-Chemical
)	O
in	O
the	O
reaction	O
mixture	O
targeting	O
the	O
double	O
or	O
/	O
and	O
triple	O
deprotonation	O
of	O
bicine	B-Chemical
.	O
We	O
repeatedly	O
isolated	O
a	O
powder	O
","	O
analyzed	O
as	O
Cd2	B-Chemical
(	I-Chemical
O2CPh	I-Chemical
)(	I-Chemical
bic	I-Chemical
)(	I-Chemical
H2O	I-Chemical
)	I-Chemical
2	I-Chemical
","	O
but	O
we	O
could	O
not	O
crystallize	O
it	O
;	O
thus	O
this	O
second	O
product	O
has	O
yet	O
to	O
be	O
structurally	O
characterized	O
.	O
3	O
.	O
2	O
.	O
Description	O
of	O
Structure	O
Selected	O
interatomic	O
distances	O
and	O
angles	O
for	O
complex	O
1	O
are	O
listed	O
in	O
Table	O
2	O
.	O
The	O
molecular	O
structure	O
of	O
the	O
compound	O
is	O
shown	O
in	O
Figure	O
1	O
.	O
The	O
compound	O
contains	O
chains	O
of	O
repeating	O
{	B-Chemical
Cd2	I-Chemical
(	I-Chemical
O2CPh	I-Chemical
)	I-Chemical
2	I-Chemical
(	I-Chemical
bicH2	I-Chemical
)	I-Chemical
2	I-Chemical
}	I-Chemical
units	O
.	O
Each	O
unit	O
contains	O
two	O
crystallographically	O
independent	O
CdII	B-Chemical
atoms	O
[	O
Cd	B-Chemical
(	O
1	O
"),"	O
Cd	B-Chemical
(	O
2	O
)]	O
which	O
lie	O
on	O
crystallographic	O
twofold	O
axes	O
.	O
Cd	B-Chemical
(	O
1	O
)	O
is	O
coordinated	O
by	O
two	O
carboxylate	B-Chemical
oxygen	I-Chemical
atoms	O
[	O
O	B-Chemical
(	O
1	O
"),"	O
O	B-Chemical
(	O
1	O
"â€²)],"	O
four	O
hydroxyl	B-Chemical
oxygen	I-Chemical
atoms	O
[	O
O	B-Chemical
(	O
3	O
"),"	O
O	B-Chemical
(	O
4	O
"),"	O
O	B-Chemical
(	O
3	O
"â€²),"	O
O	B-Chemical
(	O
4	O
â€²)]	O
and	O
two	O
nitrogen	B-Chemical
atoms	O
[	O
N	B-Chemical
(	O
1	O
"),"	O
N	B-Chemical
(	O
1	O
â€²)]	O
from	O
two	O
symmetry	O
-	O
related	O
bicinate	O
(âˆ’	O
1	O
"),"	O
that	O
is	O
","	O
bicH2	O
"âˆ’,"	O
ligands	O
.	O
Cd	B-Chemical
(	O
2	O
)	O
is	O
coordinated	O
by	O
six	O
carboxylate	B-Chemical
oxygen	I-Chemical
atoms	O
;	O
four	O
of	O
them	O
[	O
O	B-Chemical
(	O
1	O
"),"	O
O	B-Chemical
(	O
1	O
O	B-Chemical
(	O
2	O
"),"	O
O	B-Chemical
(	O
2	O
â€²â€²)]	O
belong	O
to	O
two	O
symmetry	O
-	O
related	O
bicH2	O
âˆ’	O
ligands	O
","	O
and	O
two	O
[	O
O	B-Chemical
(	O
11	O
"),"	O
O	B-Chemical
(	O
11	O
â€²â€²)]	O
come	O
from	O
two	O
symmetry	O
-	O
related	O
monodentate	O
PhCO2	B-Chemical
âˆ’	I-Chemical
groups	O
.	O
Each	O
bicH2	O
âˆ’	O
simultaneously	O
chelates	O
Cd	B-Chemical
(	O
1	O
)	O
through	O
one	O
carboxylate	B-Chemical
oxygen	I-Chemical
","	O
the	O
nitrogen	B-Chemical
","	O
and	O
both	O
hydroxyl	B-Chemical
oxygen	I-Chemical
atoms	O
forming	O
three	O
stable	O
","	O
5	O
-	O
membered	O
chelating	O
rings	O
and	O
bridges	O
Cd	B-Chemical
(	O
2	O
)	O
through	O
its	O
carboxylate	B-Chemical
oxygen	I-Chemical
atoms	O
;	O
thus	O
","	O
one	O
carboxylate	B-Chemical
oxygen	I-Chemical
atom	O
[	O
O	B-Chemical
(	O
1	O
)]	O
of	O
bicH2	O
âˆ’	O
is	O
Î¼	O
2	O
.	O
Adopting	O
Harris	O
notation	O
in	O
"[],"	O
the	O
crystallographically	O
unique	O
bicH2	O
âˆ’	O
group	O
behaves	O
as	O
a	O
2	O
.	O
21111	O
ligand	O
(	O
Scheme	O
2	O
).	O
The	O
Cd	B-Chemical
-	O
Ocarboxylate	B-Chemical
bond	O
distances	O
are	O
in	O
the	O
wide	O
range	O
2	O
.	O
190	O
(	O
3	O
)â€“	O
2	O
.	O
550	O
(	O
2	O
)	O
Ã…	O
.	O
The	O
bridging	O
Cd	B-Chemical
-	O
O	B-Chemical
(	O
1	O
)	O
distances	O
[	O
2	O
.	O
373	O
(	O
2	O
"),"	O
2	O
.	O
550	O
(	O
2	O
)	O
Ã…	O
]	O
are	O
asymmetric	O
.	O
The	O
Cd	B-Chemical
(	O
2	O
)-	O
O	B-Chemical
(	O
1	O
)	O
bond	O
distance	O
for	O
the	O
bridging	O
bicinate	O
carboxylate	B-Chemical
oxygen	I-Chemical
atom	O
is	O
longer	O
than	O
the	O
distance	O
exhibited	O
by	O
the	O
terminal	O
oxygen	B-Chemical
atom	O
[	O
O	B-Chemical
(	O
2	O
)]	O
to	O
the	O
same	O
CdII	B-Chemical
atom	O
[	O
2	O
.	O
550	O
(	O
2	O
)	O
versus	O
2	O
.	O
311	O
(	O
4	O
)	O
Ã…	O
].	O
The	O
increase	O
in	O
bond	O
length	O
upon	O
bridging	O
relative	O
to	O
terminal	O
ligation	O
has	O
been	O
observed	O
previously	O
[]	O
in	O
complexes	O
containing	O
carboxylate	B-Chemical
ligands	O
with	O
one	O
bridging	O
oxygen	B-Chemical
atom	O
.	O
Based	O
on	O
theoretical	O
and	O
experimental	O
studies	O
which	O
have	O
indicated	O
that	O
the	O
syn	O
-	O
lone	O
pairs	O
of	O
the	O
carboxylate	B-Chemical
group	O
are	O
more	O
basic	O
than	O
the	O
anti	O
-	O
lone	O
pairs	O
"[],"	O
one	O
might	O
expect	O
the	O
Cd	B-Chemical
(	O
2	O
)-	O
O	B-Chemical
(	O
1	O
)	O
distance	O
to	O
be	O
shorter	O
than	O
the	O
Cd	B-Chemical
(	O
1	O
)-	O
O	B-Chemical
(	O
1	O
)	O
distance	O
;	O
however	O
","	O
the	O
reverse	O
relation	O
holds	O
for	O
1	O
(	O
see	O
Table	O
2	O
).	O
This	O
result	O
","	O
which	O
is	O
in	O
accordance	O
with	O
other	O
CdII	B-Chemical
carboxylate	I-Chemical
complexes	O
"[],"	O
suggests	O
that	O
the	O
Cd	B-Chemical
-	O
O	B-Chemical
bond	O
lengths	O
involving	O
Î·	O
1	O
:	O
Î·	O
2	O
:	O
Î¼	O
2	O
carboxylate	B-Chemical
groups	O
are	O
mainly	O
influenced	O
by	O
geometrical	O
factors	O
rather	O
than	O
the	O
electronic	O
properties	O
of	O
the	O
carboxylate	B-Chemical
group	O
.	O
The	O
Cd	B-Chemical
(	O
2	O
)-	O
O	B-Chemical
bond	O
lengths	O
agree	O
well	O
with	O
values	O
found	O
for	O
other	O
6	O
-	O
coordinate	O
cadmium	B-Chemical
(	I-Chemical
II	I-Chemical
)	I-Chemical
carboxylate	I-Chemical
complexes	O
"[,"	O
].	O
The	O
average	O
value	O
for	O
the	O
Cd	B-Chemical
(	O
2	O
)-	O
O	B-Chemical
bond	O
distances	O
[	O
2	O
.	O
350	O
(	O
4	O
)	O
Ã…	O
]	O
is	O
smaller	O
than	O
that	O
for	O
the	O
Cd	B-Chemical
(	O
1	O
)-	O
O	B-Chemical
ones	O
[	O
2	O
.	O
435	O
(	O
3	O
)	O
Ã…	O
"],"	O
due	O
to	O
the	O
lower	O
coordination	O
of	O
Cd	B-Chemical
(	O
2	O
)	O
compared	O
to	O
the	O
coordination	O
number	O
of	O
Cd	B-Chemical
(	O
1	O
)	O
[	O
6	O
versus	O
8	O
].	O
The	O
intrachain	O
Cd	B-Chemical
(	O
1	O
)â‹¯	O
Cd	B-Chemical
(	O
2	O
)	O
distance	O
is	O
4	O
.	O
739	O
(	O
2	O
)	O
Ã…	O
.	O
The	O
coordination	O
geometry	O
of	O
Cd	B-Chemical
(	O
2	O
)	O
can	O
be	O
described	O
as	O
a	O
very	O
distorted	O
trigonal	O
prismatic	O
(	O
Figure	O
2	O
).	O
The	O
two	O
carboxylate	B-Chemical
oxygen	I-Chemical
atoms	O
of	O
bicH2	O
âˆ’	O
and	O
the	O
benzoate	B-Chemical
oxygen	I-Chemical
atom	O
constitute	O
each	O
trigonal	O
face	O
.	O
The	O
angles	O
of	O
triangular	O
faces	O
are	O
in	O
the	O
wide	O
range	O
32	O
.	O
9	O
â€“	O
91	O
.	O
9	O
Â°.	O
The	O
two	O
trigonal	O
faces	O
are	O
not	O
parallel	O
","	O
with	O
the	O
planes	O
defined	O
by	O
O	B-Chemical
(	O
1	O
)-	O
O	B-Chemical
(	O
2	O
)-	O
O	B-Chemical
(	O
11	O
â€²â€²)	O
and	O
O	B-Chemical
(	O
11	O
â€²â€²)-	O
O	B-Chemical
(	O
2	O
â€²â€²)-	O
O	B-Chemical
(	O
11	O
)	O
making	O
an	O
angle	O
of	O
27	O
.	O
6	O
Â°.	O
The	O
coordination	O
polyhedron	O
of	O
the	O
donor	O
atoms	O
about	O
Cd	B-Chemical
(	O
1	O
)	O
is	O
best	O
described	O
as	O
a	O
distorted	O
square	O
antiprism	O
(	O
Figure	O
3	O
).	O
Since	O
even	O
the	O
more	O
stable	O
of	O
the	O
possible	O
8	O
-	O
coordinate	O
geometries	O
(	O
square	O
antiprismatic	O
","	O
triangular	O
dodecahedral	O
","	O
and	O
cubic	O
)	O
differ	O
slightly	O
in	O
energy	O
from	O
one	O
another	O
","	O
the	O
geometry	O
observed	O
may	O
be	O
largely	O
a	O
reflection	O
of	O
constraints	O
placed	O
on	O
the	O
complex	O
by	O
ligand	O
requirements	O
and	O
packing	O
considerations	O
.	O
Compound	O
1	O
is	O
hydrogen	B-Chemical
bonded	O
.	O
Metric	O
parameters	O
for	O
the	O
bonds	O
are	O
listed	O
in	O
Table	O
3	O
.	O
The	O
O	B-Chemical
-	O
H	B-Chemical
â‹¯	O
O	B-Chemical
hydrogen	I-Chemical
bonds	O
are	O
intrachain	O
.	O
Both	O
hydroxyl	B-Chemical
oxygen	I-Chemical
atoms	O
[	O
O	B-Chemical
(	O
3	O
"),"	O
O	B-Chemical
(	O
4	O
)]	O
are	O
involved	O
as	O
donors	O
","	O
while	O
both	O
the	O
coordinated	O
[	O
O	B-Chemical
(	O
11	O
)]	O
and	O
uncoordinated	O
[	O
O	B-Chemical
(	O
12	O
)]	O
benzoate	B-Chemical
oxygen	I-Chemical
atoms	O
act	O
as	O
acceptors	O
.	O
A	O
weak	O
interchain	O
hydrogen	B-Chemical
bond	O
","	O
involving	O
one	O
benzoate	B-Chemical
carbon	I-Chemical
atom	O
[	O
C	B-Chemical
(	O
16	O
)]	O
as	O
donor	O
and	O
the	O
terminally	O
ligated	O
carboxylate	B-Chemical
oxygen	I-Chemical
atom	O
[	O
O	B-Chemical
(	O
2	O
)]	O
of	O
a	O
bicH2	O
âˆ’	O
ligand	O
from	O
a	O
neighbouring	O
chain	O
as	O
acceptor	O
","	O
is	O
responsible	O
for	O
the	O
formation	O
of	O
a	O
2D	O
network	O
.	O
Compound	O
1	O
joins	O
a	O
family	O
of	O
mononuclear	O
","	O
polynuclear	O
","	O
and	O
polymeric	O
complexes	O
with	O
the	O
mono	O
-	O
(	O
bicH2	O
"âˆ’),"	O
di	O
-	O
(	O
bicH2	O
"âˆ’),"	O
and	O
trianionic	O
(	O
bic3	O
-)	O
derivatives	O
of	O
bicine	B-Chemical
as	O
ligands	O
"[,"	O
","	O
].	O
The	O
members	O
of	O
this	O
family	O
are	O
listed	O
in	O
Table	O
4	O
","	O
together	O
with	O
the	O
coordination	O
modes	O
of	O
the	O
bicinate	O
ligands	O
for	O
convenient	O
comparison	O
.	O
The	O
to	O
-	O
date	O
crystallographically	O
established	O
coordination	O
modes	O
of	O
bicH2	O
"âˆ’,"	O
bicH2	O
"âˆ’,"	O
and	O
bic3	O
-	O
are	O
shown	O
in	O
Scheme	O
2	O
.	O
Compound	O
1	O
is	O
the	O
first	O
cadmium	B-Chemical
(	I-Chemical
II	I-Chemical
)	I-Chemical
bicinate	O
complex	O
which	O
has	O
been	O
structurally	O
characterized	O
.	O
The	O
bicH2	O
âˆ’	O
ligand	O
in	O
1	O
adopts	O
the	O
extremely	O
rare	O
coordination	O
mode	O
2	O
.	O
21111	O
;	O
see	O
Scheme	O
2	O
.	O
This	O
ligation	O
mode	O
has	O
been	O
observed	O
in	O
the	O
past	O
only	O
in	O
the	O
1D	O
coordination	O
polymer	O
{	B-Chemical
Mn2	I-Chemical
(	I-Chemical
bicH2	I-Chemical
)	I-Chemical
2	I-Chemical
(	I-Chemical
H2O	I-Chemical
)	I-Chemical
2	I-Chemical
]	I-Chemical
Br2	I-Chemical
Â·	I-Chemical
2H2O	I-Chemical
}	I-Chemical
n	I-Chemical
"[],"	O
in	O
which	O
the	O
MnII	B-Chemical
ions	O
are	O
7	O
coordinate	O
with	O
a	O
slightly	O
distorted	O
pentagonal	O
bipyramidal	O
coordination	O
geometry	O
.	O
3	O
.	O
3	O
.	O
IR	O
Spectroscopy	O
IR	O
assignments	O
of	O
selected	O
diagnostic	O
bands	O
for	O
bicH3	B-Chemical
(	O
the	O
free	O
ligand	O
exists	O
in	O
its	O
zwitterionic	O
form	O
in	O
the	O
solid	O
state	O
with	O
the	O
carboxylic	B-Chemical
group	O
being	O
deprotonated	O
and	O
the	O
tertiary	O
nitrogen	B-Chemical
atom	O
protonated	O
[])	O
and	O
complex	O
1	O
are	O
given	O
in	O
Table	O
5	O
.	O
The	O
IR	O
spectrum	O
of	O
complex	O
1	O
exhibits	O
a	O
medium	O
intensity	O
","	O
broad	O
band	O
at	O
3070	O
cm	O
âˆ’	O
1	O
","	O
attributable	O
to	O
the	O
O	O
-	O
H	O
stretching	O
vibration	O
of	O
the	O
bicinate	O
(âˆ’	O
1	O
)	O
ligand	O
"[,"	O
","	O
].	O
The	O
broadness	O
and	O
low	O
frequency	O
of	O
this	O
band	O
are	O
both	O
indicative	O
of	O
strong	O
hydrogen	B-Chemical
bonding	O
[].	O
The	O
Î½	O
(	O
OH	O
)	O
bicH2	O
âˆ’	O
mode	O
is	O
situated	O
at	O
lower	O
frequencies	O
in	O
the	O
spectrum	O
of	O
1	O
than	O
for	O
free	O
bicH3	B-Chemical
(	O
at	O
3190	O
and	O
3090	O
cm	O
âˆ’	O
1	O
[]);	O
this	O
shift	O
is	O
consistent	O
with	O
the	O
coordination	O
of	O
the	O
â€“	O
OH	O
groups	O
.	O
The	O
Î½	O
as	O
(	O
CO2	B-Chemical
)	O
bicH2	O
âˆ’	O
and	O
Î½	O
s	O
(	O
CO2	B-Chemical
)	O
bicH2	O
âˆ’	O
bands	O
of	O
1	O
appear	O
at	O
1582	O
and	O
1418	O
cm	O
âˆ’	O
1	O
[].	O
The	O
corresponding	O
bands	O
of	O
free	O
","	O
zwitterionic	O
bicH3	B-Chemical
are	O
at	O
1639	O
and	O
1401	O
cm	O
âˆ’	O
1	O
"[,"	O
].	O
The	O
fact	O
that	O
Î”complex	O
(	O
164	O
cm	O
âˆ’	O
1	O
)	O
<	O
Î”bicH3	B-Chemical
(	O
238	O
cm	O
âˆ’	O
1	O
"),"	O
where	O
Î”	O
=	O
Î½	O
as	O
(	O
CO2	B-Chemical
)	O
âˆ’	O
Î½	O
s	O
(	O
CO2	B-Chemical
"),"	O
is	O
in	O
accordance	O
with	O
the	O
crystallographically	O
established	O
chelating	O
-	O
bridging	O
mode	O
(	O
Î·	O
1	O
:	O
Î·	O
2	O
:	O
Î¼	O
2	O
)	O
of	O
the	O
bicinate	O
(âˆ’	O
1	O
)	O
carboxylate	B-Chemical
group	O
[].	O
The	O
strong	O
bands	O
at	O
1606	O
and	O
1384	O
cm	O
âˆ’	O
1	O
in	O
the	O
spectrum	O
of	O
1	O
are	O
assigned	O
to	O
the	O
Î½	O
as	O
(	O
CO2	B-Chemical
)	O
and	O
Î½	O
s	O
(	O
CO2	B-Chemical
)	O
modes	O
of	O
the	O
benzoate	B-Chemical
ligands	O
","	O
respectively	O
[].	O
The	O
parameter	O
Î”	O
is	O
222	O
cm	O
âˆ’	O
1	O
significantly	O
larger	O
than	O
that	O
for	O
NaO2CPh	B-Chemical
(	O
184	O
cm	O
âˆ’	O
1	O
"),"	O
as	O
expected	O
for	O
the	O
monodentate	O
mode	O
of	O
benzoate	B-Chemical
ligation	O
[].	O
4	O
.	O
Conclusions	O
and	O
Perspectives	O
Complex	O
1	O
covers	O
a	O
gap	O
in	O
literature	O
","	O
because	O
it	O
is	O
the	O
first	O
structurally	O
characterized	O
cadmium	B-Chemical
(	I-Chemical
II	I-Chemical
)	I-Chemical
bicinate	I-Chemical
compound	O
.	O
The	O
bicinate	O
(âˆ’	O
1	O
)	O
ligand	O
adopts	O
the	O
extremely	O
rare	O
pentadentate	O
2	O
.	O
21111	O
coordination	O
mode	O
","	O
while	O
the	O
two	O
crystallographically	O
independent	O
CdII	B-Chemical
centers	O
are	O
found	O
in	O
two	O
different	O
stereochemistries	O
.	O
The	O
results	O
presented	O
here	O
support	O
our	O
belief	O
that	O
the	O
bicH3	B-Chemical
/	O
RCO2	B-Chemical
âˆ’	O
(	O
R	O
=	O
various	O
)	O
ligand	O
â€œ	O
blends	O
â€	O
may	O
be	O
effective	O
generators	O
of	O
interesting	O
structural	O
types	O
in	O
the	O
chemistry	O
of	O
other	O
transition	O
metals	O
.	O
Reactions	O
of	O
CdCl2	B-Chemical
","	O
CdBr2	B-Chemical
","	O
CdI2	B-Chemical
","	O
and	O
Cd	B-Chemical
(	I-Chemical
NO3	I-Chemical
)	I-Chemical
2	I-Chemical
with	O
bicH3	B-Chemical
have	O
not	O
been	O
studied	O
to	O
date	O
","	O
and	O
we	O
do	O
believe	O
that	O
the	O
structural	O
types	O
of	O
the	O
products	O
will	O
be	O
dependent	O
on	O
the	O
particular	O
nature	O
of	O
the	O
CdII	B-Chemical
source	O
.	O
Analogues	O
of	O
1	O
with	O
zinc	B-Chemical
(	I-Chemical
II	I-Chemical
)	I-Chemical
have	O
not	O
yet	O
been	O
reported	O
","	O
but	O
preliminary	O
results	O
in	O
our	O
laboratories	O
indicate	O
completely	O
different	O
chemistry	O
compared	O
with	O
that	O
of	O
cadmium	B-Chemical
(	I-Chemical
II	I-Chemical
).	I-Chemical
Synthetic	O
efforts	O
are	O
also	O
in	O
progress	O
to	O
â€œ	O
activate	O
â€	O
the	O
potential	O
of	O
bicH2	O
âˆ’	O
and	O
bic3	O
âˆ’	O
to	O
bridge	O
more	O
than	O
four	O
metal	O
ions	O
.	O
Formulae	O
of	O
N	B-Chemical
","	I-Chemical
N	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
hydroxyethyl	I-Chemical
)	I-Chemical
glycine	I-Chemical
(	O
bicine	B-Chemical
;	O
bicH3	B-Chemical
)	O
and	O
glycine	B-Chemical
(	O
glyH	B-Chemical
)	O
discussed	O
in	O
the	O
paper	O
.	O
The	O
to	O
-	O
date	O
crystallographically	O
established	O
coordination	O
modes	O
of	O
the	O
bicH2	O
"âˆ’,"	O
bicH2	O
"âˆ’,"	O
and	O
bic3	O
âˆ’	O
ligands	O
and	O
the	O
Harris	O
notation	O
in	O
[]	O
that	O
describes	O
these	O
modes	O
.	O
Partially	O
labeled	O
plot	O
of	O
a	O
portion	O
of	O
the	O
chain	O
that	O
is	O
present	O
in	O
complex	O
1	O
.	O
Single	O
and	O
double	O
primes	O
are	O
used	O
for	O
symmetry	O
-	O
related	O
atoms	O
(	O
see	O
footnote	O
of	O
Table	O
2	O
).	O
The	O
distorted	O
trigonal	O
prismatic	O
geometry	O
of	O
Cd	B-Chemical
(	O
2	O
)	O
in	O
complex	O
1	O
.	O
Double	O
primes	O
are	O
used	O
for	O
symmetry	O
-	O
related	O
atoms	O
(	O
see	O
footnote	O
of	O
Table	O
2	O
).	O
The	O
distorted	O
square	O
antiprismatic	O
stereochemistry	O
about	O
Cd	B-Chemical
(	O
1	O
)	O
in	O
complex	O
1	O
.	O
The	O
coordination	O
bonds	O
have	O
not	O
been	O
drawn	O
for	O
clarity	O
.	O
Primes	O
are	O
used	O
for	O
symmetry	O
-	O
related	O
atoms	O
(	O
see	O
footnote	O
of	O
Table	O
2	O
).	O
a	O
I	O
>	O
2Ïƒ	O
(	O
I	O
).	O
Crystal	O
data	O
and	O
structure	O
refinement	O
for	O
complex	O
1	O
.	O
aSymmetry	O
transformations	O
used	O
to	O
generate	O
equivalent	O
atoms	O
:(â€²)	O
y	O
","	O
x	O
","	O
âˆ’	O
z	O
;	O
(â€²â€²)	O
â€“	O
y	O
+	O
1	O
","	O
âˆ’	O
z	O
+	O
1	O
","	O
âˆ’	O
z	O
+	O
1	O
/	O
2	O
.	O
bThis	O
carbon	B-Chemical
atom	O
(	O
not	O
labeled	O
in	O
Figure	O
1	O
)	O
belongs	O
to	O
the	O
carboxylate	B-Chemical
group	O
of	O
the	O
bicinate	O
(âˆ’	O
1	O
)	O
ligand	O
.	O
cThis	O
carbon	B-Chemical
atom	O
(	O
not	O
labeled	O
in	O
Figure	O
1	O
)	O
belongs	O
to	O
the	O
carboxylate	B-Chemical
group	O
of	O
the	O
benzoate	B-Chemical
ligand	O
.	O
Selected	O
bond	O
lengths	O
(	O
Ã…	O
)	O
and	O
angles	O
(Â°)	O
for	O
complex	O
1	O
a	O
.	O
aD	O
=	O
donor	O
atom	O
bA	O
=	O
acceptor	O
atom	O
.	O
Dimensions	O
of	O
the	O
hydrogen	B-Chemical
bonds	O
(	O
distances	O
in	O
Ã…	O
and	O
angles	O
in	O
Â°)	O
for	O
complex	O
1	O
.	O
aSolvate	O
and	O
other	O
lattice	O
molecules	O
have	O
been	O
omitted	O
.	O
bUsing	O
the	O
Harris	O
notation	O
in	O
[].	O
cThe	O
CuII	B-Chemical
ions	O
are	O
bridged	O
by	O
the	O
SCN	O
âˆ’	O
ligands	O
.	O
dbzimH	O
:	O
benzimidazole	B-Chemical
.	O
eIq	O
:	O
isoquinoline	B-Chemical
.	O
fFor	O
the	O
bic3	O
âˆ’	O
ligands	O
.	O
gFor	O
the	O
bicH2	O
âˆ’	O
ligands	O
.	O
Formulae	O
and	O
coordination	O
modes	O
of	O
the	O
bicinate	O
(âˆ’	O
1	O
","	O
âˆ’	O
2	O
","	O
âˆ’	O
3	O
)	O
groups	O
of	O
the	O
structurally	O
characterized	O
metal	O
complexes	O
containing	O
various	O
forms	O
of	O
bicine	B-Chemical
as	O
ligands	O
.	O
Most	O
characteristic	O
and	O
diagnostic	O
IR	O
fundamentals	O
(	O
cm	O
âˆ’	O
1	O
)	O
for	O
bicH3	B-Chemical
and	O
complex	O
1	O
.	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
-	O
a	O
novel	O
and	O
general	O
biomarker	O
of	O
human	O
cancers	O
of	O
head	O
&	O
neck	O
","	O
breast	O
","	O
and	O
cervix	O
Background	O
Poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	O
ribosylation	O
","	O
a	O
reversible	O
post	O
-	O
translational	O
modification	O
of	O
primarily	O
chromosomal	O
proteins	O
","	O
is	O
involved	O
in	O
various	O
cellular	O
and	O
molecular	O
processes	O
including	O
carcinogenesis	O
.	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
or	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adducts	O
are	O
enzymatically	O
added	O
onto	O
or	O
stripped	O
off	O
the	O
target	O
chromosomal	O
proteins	O
during	O
this	O
metabolic	O
process	O
.	O
Due	O
to	O
this	O
","	O
the	O
chromatin	O
superstructure	O
is	O
reversibly	O
altered	O
","	O
which	O
significantly	O
influences	O
the	O
pattern	O
of	O
gene	O
expression	O
.	O
We	O
hypothesize	O
that	O
a	O
decrease	O
in	O
the	O
concentration	O
of	O
total	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adducts	O
of	O
peripheral	O
blood	O
lymphocyte	O
(	O
PBL	O
)	O
proteins	O
strongly	O
correlates	O
with	O
the	O
incidence	O
of	O
human	O
cancer	O
.	O
Results	O
Using	O
a	O
novel	O
immunoprobe	O
assay	O
","	O
we	O
show	O
a	O
statistically	O
significant	O
(	O
P	O
â‰¤	O
0	O
.	O
1	O
)	O
reduction	O
(~	O
42	O
to	O
49	O
%)	O
in	O
the	O
level	O
of	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adducts	O
of	O
PBL	O
proteins	O
of	O
patients	O
with	O
advanced	O
cancers	O
of	O
head	O
&	O
neck	O
(	O
H	O
&	O
N	O
)	O
region	O
(	O
comprising	O
fourteen	O
distinct	O
cancers	O
at	O
different	O
sites	O
"),"	O
breast	O
and	O
cervix	O
in	O
comparison	O
to	O
healthy	O
controls	O
.	O
Conclusions	O
These	O
findings	O
imply	O
potential	O
utility	O
of	O
the	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adducts	O
of	O
PBL	O
proteins	O
as	O
a	O
novel	O
and	O
general	O
biomarker	O
of	O
human	O
cancers	O
with	O
potentials	O
of	O
significant	O
clinical	O
and	O
epidemiological	O
applications	O
.	O
Background	O
Poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	O
ribosylation	O
is	O
an	O
enzyme	O
catalyzed	O
reversible	O
post	O
-	O
translational	O
modification	O
of	O
cellular	O
proteins	O
[	O
reviewed	O
in	O
[	O
1	O
-	O
5	O
]].	O
During	O
this	O
process	O
","	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
units	O
are	O
transferred	O
onto	O
or	O
stripped	O
off	O
the	O
acceptor	O
or	O
target	O
proteins	O
.	O
Accordingly	O
","	O
the	O
target	O
protein	O
becomes	O
poly	O
-	O
ADP	O
-	O
ribosylated	O
or	O
deribosylated	O
","	O
respectively	O
.	O
The	O
biosynthesis	O
of	O
the	O
homopolymer	O
of	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
or	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
(	O
s	O
)	O
is	O
primarily	O
catalysed	O
by	O
the	O
enzyme	O
","	O
poly	O
-	O
ADP	O
-	O
ribose	O
polymerase	O
(	O
PARP	O
"),"	O
which	O
is	O
ubiquitously	O
present	O
in	O
the	O
nuclei	O
of	O
metabolically	O
active	O
cells	O
[	O
1	O
","	O
5	O
","	O
6	O
].	O
The	O
enzyme	O
progressively	O
and	O
sequentially	O
catalyses	O
transfer	O
of	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
units	O
derived	O
from	O
the	O
endogenous	O
nicotinamide	B-Chemical
adenine	I-Chemical
dinucleotide	I-Chemical
(	O
NAD	B-Chemical
+)	I-Chemical
donors	O
onto	O
acceptor	O
or	O
target	O
proteins	O
creating	O
homopolymeric	O
adducts	O
in	O
a	O
variety	O
of	O
linear	O
and	O
branched	O
architectures	O
.	O
Nuclear	O
proteins	O
","	O
particularly	O
histones	O
","	O
are	O
the	O
primary	O
targets	O
of	O
ribosylation	O
[	O
3	O
-	O
5	O
].	O
Poly	O
-	O
ADP	O
-	O
ribose	O
glycohydrolase	O
(	O
PARG	O
)	O
is	O
the	O
main	O
enzyme	O
involved	O
in	O
the	O
breakdown	O
of	O
adducts	O
from	O
the	O
protein	O
[	O
1	O
","	O
3	O
","	O
4	O
].	O
The	O
build	O
up	O
of	O
the	O
adduct	O
on	O
or	O
its	O
breakdown	O
from	O
the	O
chromosomal	O
proteins	O
reversibly	O
alters	O
chromatin	O
superstructure	O
and	O
","	O
thereby	O
","	O
significantly	O
influences	O
the	O
pattern	O
of	O
gene	O
expression	O
[	O
1	O
-	O
5	O
].	O
Consequently	O
","	O
status	O
of	O
ribosylation	O
of	O
chromosomal	O
proteins	O
is	O
intricately	O
involved	O
in	O
carcinogenesis	O
[	O
4	O
","	O
5	O
].	O
Previous	O
detailed	O
investigations	O
done	O
in	O
murine	O
model	O
have	O
shown	O
that	O
the	O
metabolic	O
level	O
of	O
the	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
on	O
total	O
cellular	O
proteins	O
is	O
significantly	O
reduced	O
during	O
different	O
stages	O
of	O
carcinogenesis	O
[	O
7	O
-	O
13	O
].	O
These	O
systematic	O
studies	O
have	O
revealed	O
the	O
existence	O
of	O
an	O
inverse	O
relationship	O
between	O
carcinogenesis	O
and	O
the	O
total	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymers	I-Chemical
or	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
level	O
measured	O
either	O
in	O
cancerous	O
tissue	O
or	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
).	O
Therefore	O
","	O
we	O
hypothesize	O
that	O
a	O
decreased	O
quantum	O
of	O
the	O
total	O
adduct	O
of	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
on	O
human	O
PBL	O
proteins	O
would	O
also	O
correlate	O
with	O
human	O
cancer	O
.	O
In	O
order	O
to	O
test	O
the	O
hypothesis	O
","	O
we	O
have	O
detected	O
and	O
quantified	O
the	O
total	O
concentration	O
of	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
adducts	O
of	O
PBL	O
proteins	O
in	O
healthy	O
individuals	O
(	O
controls	O
)	O
and	O
cancer	O
patients	O
(	O
cases	O
).	O
PBL	O
was	O
chosen	O
since	O
PBL	O
proteins	O
have	O
been	O
shown	O
to	O
mirror	O
the	O
status	O
of	O
ribosylation	O
of	O
cellular	O
proteins	O
of	O
liver	O
","	O
spleen	O
","	O
ascites	O
cells	O
and	O
other	O
tissues	O
[	O
10	O
].	O
In	O
addition	O
","	O
a	O
blood	O
based	O
assay	O
of	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
adducts	O
is	O
the	O
most	O
convenient	O
procedure	O
to	O
perform	O
on	O
humans	O
since	O
it	O
is	O
the	O
most	O
non	O
-	O
invasive	O
medical	O
intervention	O
.	O
An	O
assay	O
using	O
other	O
tissues	O
or	O
biopsies	O
pose	O
practical	O
problems	O
as	O
obtaining	O
the	O
tissue	O
usually	O
requires	O
surgical	O
intervention	O
.	O
Furthermore	O
","	O
the	O
immune	O
system	O
of	O
the	O
body	O
resides	O
in	O
the	O
blood	O
.	O
The	O
PBL	O
are	O
the	O
first	O
responders	O
to	O
foreign	O
invasions	O
across	O
the	O
body	O
.	O
They	O
also	O
communicate	O
with	O
cells	O
as	O
well	O
as	O
cellular	O
matrices	O
of	O
all	O
tissues	O
/	O
organs	O
of	O
the	O
body	O
[	O
14	O
].	O
This	O
circulating	O
tissue	O
","	O
therefore	O
","	O
qualifies	O
to	O
be	O
the	O
sentinel	O
of	O
the	O
whole	O
body	O
[	O
15	O
].	O
We	O
have	O
chosen	O
the	O
PBL	O
for	O
this	O
reason	O
as	O
our	O
aim	O
was	O
to	O
identify	O
and	O
establish	O
a	O
general	O
biomarker	O
of	O
cancer	O
","	O
which	O
can	O
be	O
conveniently	O
monitored	O
.	O
This	O
hypothesis	O
has	O
been	O
tested	O
in	O
total	O
cellular	O
proteins	O
of	O
the	O
PBL	O
of	O
normal	O
human	O
donors	O
(	O
controls	O
)	O
and	O
in	O
patients	O
(	O
cases	O
)	O
with	O
advanced	O
head	O
&	O
neck	O
(	O
H	O
&	O
N	O
"),"	O
breast	O
or	O
cervical	O
cancers	O
using	O
a	O
novel	O
immunoprobe	O
assay	O
that	O
quantitatively	O
measures	O
the	O
total	O
cellular	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
[	O
5	O
","	O
7	O
","	O
8	O
].	O
Results	O
&	O
Discussion	O
Blood	O
samples	O
were	O
collected	O
from	O
new	O
cancer	O
patients	O
(	O
cases	O
"),"	O
who	O
had	O
not	O
received	O
any	O
treatment	O
so	O
far	O
","	O
as	O
well	O
as	O
from	O
healthy	O
volunteers	O
(	O
controls	O
)	O
in	O
accordance	O
with	O
the	O
approvals	O
of	O
Institutional	O
Ethics	O
Committees	O
of	O
NEHU	O
and	O
BBCI	O
.	O
The	O
cases	O
comprised	O
male	O
as	O
well	O
as	O
female	O
patients	O
with	O
advanced	O
stages	O
of	O
cancers	O
at	O
14	O
different	O
sites	O
of	O
head	O
&	O
neck	O
region	O
(	O
grouped	O
as	O
Ca	O
H	O
&	O
N	O
"),"	O
breast	O
and	O
cervix	O
(	O
age	O
range	O
25	O
-	O
80	O
years	O
).	O
The	O
controls	O
consisted	O
of	O
healthy	O
","	O
male	O
and	O
female	O
volunteers	O
with	O
no	O
known	O
history	O
of	O
cancer	O
(	O
age	O
range	O
25	O
-	O
80	O
years	O
).	O
Analysis	O
of	O
age	O
distribution	O
of	O
controls	O
and	O
cases	O
was	O
done	O
using	O
unpaired	O
t	O
-	O
test	O
with	O
Welch	O
correction	O
and	O
Ï‡2	O
test	O
","	O
which	O
showed	O
that	O
statistically	O
older	O
males	O
(	O
P	O
â‰¤	O
0	O
.	O
1	O
"),"	O
but	O
not	O
females	O
(	O
P	O
=	O
0	O
.	O
4250	O
"),"	O
made	O
the	O
case	O
group	O
(	O
Figure	O
1	O
-	O
inset	O
Table	O
).	O
Quantitative	O
assay	O
of	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
adducts	O
and	O
analysis	O
of	O
controls	O
.	O
(	O
a	O
)	O
A	O
typical	O
set	O
of	O
results	O
of	O
slot	O
blot	O
immunoprobe	O
assay	O
used	O
in	O
the	O
study	O
.	O
PBL	O
protein	O
(	O
500	O
ng	O
per	O
slot	O
)	O
samples	O
from	O
a	O
control	O
(	O
A	O
)	O
and	O
a	O
cancer	O
patient	O
(	O
B	O
)	O
were	O
slot	O
blotted	O
on	O
NCM	O
in	O
replicates	O
of	O
five	O
or	O
more	O
.	O
One	O
NCM	O
blot	O
was	O
stained	O
with	O
India	O
ink	O
for	O
total	O
protein	O
(	O
left	O
panel	O
"),"	O
which	O
also	O
served	O
as	O
the	O
loading	O
control	O
","	O
and	O
its	O
replica	O
slot	O
was	O
immunoprobed	O
for	O
total	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
(	O
right	O
panel	O
).	O
After	O
concentration	O
correction	O
","	O
quantification	O
of	O
total	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
of	O
PBL	O
proteins	O
was	O
done	O
as	O
mean	O
net	O
pixel	O
intensity	O
of	O
the	O
immunoprobed	O
slot	O
in	O
arbitrary	O
units	O
(	O
AU	O
).	O
Each	O
sample	O
was	O
independently	O
slotted	O
thrice	O
(	O
3	O
sets	O
)	O
making	O
at	O
least	O
15	O
replicates	O
for	O
each	O
sample	O
(	O
individual	O
).	O
The	O
mean	O
of	O
all	O
replicates	O
for	O
each	O
sample	O
/	O
individual	O
has	O
been	O
plotted	O
as	O
a	O
dot	O
(	O
dark	O
green	O
-	O
female	O
(	O
n	O
=	O
27	O
);	O
light	O
green	O
-	O
male	O
(	O
n	O
=	O
41	O
))	O
in	O
the	O
graphs	O
to	O
highlight	O
the	O
observed	O
individual	O
variance	O
(	O
b	O
-	O
d	O
).	O
Linear	O
regression	O
of	O
the	O
controls	O
(	O
r2	O
=	O
0	O
.	O
3676	O
","	O
P	O
=	O
0	O
.	O
6233	O
","	O
n	O
=	O
68	O
)	O
show	O
that	O
individual	O
value	O
fell	O
within	O
the	O
range	O
of	O
variation	O
(	O
b	O
"),"	O
which	O
was	O
nearly	O
the	O
same	O
when	O
viewed	O
in	O
terms	O
of	O
the	O
age	O
of	O
the	O
individual	O
(	O
c	O
).	O
The	O
control	O
values	O
between	O
gender	O
groups	O
(	O
male	O
and	O
female	O
)	O
were	O
statistically	O
(	O
P	O
=	O
0	O
.	O
463	O
)	O
identical	O
(	O
d	O
).	O
The	O
mean	O
age	O
of	O
male	O
cancer	O
patients	O
(	O
cases	O
)	O
was	O
statistically	O
higher	O
than	O
the	O
control	O
while	O
it	O
was	O
statistically	O
identical	O
in	O
case	O
of	O
females	O
(	O
inset	O
Table	O
).	O
Overall	O
","	O
the	O
cancer	O
patients	O
(	O
cases	O
)	O
were	O
statistically	O
older	O
(	O
47	O
.	O
70	O
years	O
)	O
than	O
the	O
control	O
counterparts	O
(	O
39	O
.	O
90	O
years	O
)	O
(	O
Figure	O
1	O
-	O
inset	O
Table	O
).	O
The	O
PBL	O
protein	O
samples	O
(	O
500	O
ng	O
per	O
slot	O
)	O
were	O
prepared	O
from	O
blood	O
samples	O
of	O
controls	O
(	O
n	O
=	O
68	O
)	O
and	O
cases	O
(	O
total	O
n	O
=	O
112	O
).	O
The	O
cases	O
comprised	O
patients	O
with	O
cancers	O
of	O
14	O
different	O
sites	O
grouped	O
as	O
Ca	O
H	O
&	O
N	O
(	O
total	O
n	O
=	O
66	O
"),"	O
Ca	O
breast	O
(	O
n	O
=	O
22	O
)	O
or	O
Ca	O
cervix	O
(	O
n	O
=	O
24	O
).	O
Samples	O
were	O
subjected	O
to	O
quantitative	O
detection	O
of	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adducts	O
using	O
the	O
novel	O
slot	O
blot	O
immunoprobe	O
assay	O
followed	O
by	O
densitometric	O
analysis	O
as	O
described	O
[	O
7	O
","	O
8	O
].	O
Figure	O
1	O
-	O
a	O
shows	O
a	O
typical	O
slot	O
blot	O
stained	O
for	O
total	O
proteins	O
using	O
India	O
ink	O
(	O
left	O
panel	O
)	O
and	O
its	O
immunoprobed	O
replicum	O
(	O
right	O
panel	O
)	O
for	O
five	O
replicate	O
samples	O
from	O
a	O
control	O
subject	O
(	O
A	O
)	O
and	O
a	O
cancer	O
patient	O
(	O
B	O
).	O
The	O
concentration	O
corrected	O
mean	O
net	O
intensity	O
of	O
each	O
control	O
sample	O
has	O
been	O
plotted	O
as	O
a	O
dot	O
to	O
show	O
the	O
distribution	O
of	O
measured	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
levels	O
in	O
relation	O
to	O
sample	O
number	O
(	O
Figure	O
1	O
-	O
b	O
"),"	O
age	O
of	O
patient	O
(	O
Figure	O
1	O
-	O
c	O
)	O
and	O
gender	O
of	O
patient	O
(	O
Figure	O
1	O
-	O
d	O
)	O
highlight	O
the	O
range	O
of	O
variation	O
in	O
measured	O
control	O
values	O
in	O
arbitrary	O
units	O
(	O
AU	O
)	O
(	O
mean	O
:	O
14573	O
Â±	O
1452	O
AU	O
;	O
range	O
:	O
11950	O
-	O
17540	O
AU	O
).	O
Compared	O
to	O
the	O
control	O
group	O
","	O
the	O
total	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
of	O
PBL	O
proteins	O
of	O
H	O
&	O
N	O
cancer	O
patients	O
showed	O
a	O
statistically	O
significant	O
(	O
P	O
<	O
0	O
.	O
1	O
)	O
reduction	O
in	O
cancers	O
of	O
all	O
14	O
sites	O
(	O
Figure	O
2	O
-	O
a	O
","	O
inset	O
Table	O
).	O
Quantification	O
of	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
adducts	O
in	O
cancer	O
patients	O
.	O
(	O
a	O
)	O
The	O
graph	O
shows	O
the	O
levels	O
of	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
of	O
PBL	O
proteins	O
of	O
each	O
subject	O
as	O
a	O
dot	O
for	O
cancers	O
of	O
different	O
sites	O
in	O
the	O
head	O
and	O
neck	O
region	O
(	O
grouped	O
as	O
cancer	O
of	O
H	O
&	O
N	O
)	O
as	O
compared	O
to	O
all	O
controls	O
(	O
dark	O
green	O
-	O
female	O
(	O
n	O
=	O
27	O
);	O
light	O
green	O
-	O
male	O
(	O
n	O
=	O
41	O
)).	O
In	O
all	O
","	O
14	O
different	O
types	O
of	O
cancers	O
of	O
H	O
&	O
N	O
were	O
examined	O
in	O
this	O
study	O
;	O
for	O
three	O
such	O
cancers	O
we	O
had	O
only	O
one	O
patient	O
each	O
.	O
Individually	O
all	O
cancers	O
of	O
different	O
sites	O
under	O
H	O
&	O
N	O
category	O
declined	O
significantly	O
below	O
the	O
control	O
value	O
(	O
see	O
details	O
in	O
Table	O
1	O
).	O
The	O
results	O
from	O
patients	O
with	O
cancers	O
of	O
breast	O
and	O
cervix	O
have	O
been	O
shown	O
in	O
(	O
b	O
)	O
and	O
(	O
c	O
"),"	O
respectively	O
.	O
Since	O
these	O
two	O
cancers	O
exclusively	O
afflict	O
females	O
","	O
the	O
plot	O
shows	O
individual	O
values	O
of	O
total	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
of	O
PBL	O
proteins	O
for	O
all	O
controls	O
(	O
males	O
+	O
females	O
)	O
as	O
well	O
as	O
only	O
female	O
controls	O
.	O
In	O
all	O
three	O
categories	O
of	O
cancers	O
","	O
the	O
reduction	O
in	O
the	O
level	O
of	O
total	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
of	O
PBL	O
proteins	O
was	O
highly	O
significant	O
(	O
P	O
<	O
0	O
.	O
1	O
)	O
when	O
compared	O
with	O
all	O
controls	O
or	O
only	O
female	O
controls	O
(	O
inset	O
Table	O
).	O
The	O
overall	O
reduction	O
was	O
approximately	O
45	O
%	O
with	O
a	O
mean	O
of	O
net	O
intensity	O
of	O
8060	O
Â±	O
707	O
.	O
10	O
AU	O
(	O
range	O
of	O
6324	O
-	O
10318	O
AU	O
).	O
Cancers	O
of	O
all	O
sites	O
in	O
this	O
group	O
individually	O
(	O
Table	O
1	O
)	O
as	O
well	O
as	O
collectively	O
(	O
Table	O
2	O
)	O
showed	O
significant	O
reduction	O
as	O
revealed	O
by	O
Student	O
'	O
s	O
t	O
-	O
test	O
and	O
ANOVA	O
","	O
respectively	O
.	O
Similarly	O
","	O
there	O
were	O
significant	O
reductions	O
in	O
the	O
total	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
of	O
PBL	O
proteins	O
in	O
cancers	O
of	O
breast	O
(	O
Figure	O
2	O
-	O
b	O
","	O
inset	O
Table	O
)	O
and	O
cervix	O
(	O
Figure	O
2	O
-	O
c	O
","	O
inset	O
Table	O
)	O
in	O
comparison	O
to	O
all	O
controls	O
(	O
males	O
+	O
female	O
controls	O
combined	O
)	O
as	O
well	O
as	O
only	O
female	O
controls	O
.	O
The	O
extent	O
of	O
reduction	O
in	O
the	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
among	O
the	O
cases	O
was	O
47	O
%	O
and	O
43	O
%	O
for	O
breast	O
and	O
cervical	O
cancers	O
","	O
respectively	O
","	O
which	O
are	O
statistically	O
highly	O
significant	O
(	O
P	O
<	O
0	O
.	O
1	O
","	O
unpaired	O
t	O
-	O
test	O
with	O
Welch	O
'	O
s	O
correction	O
)	O
as	O
shown	O
in	O
the	O
inset	O
table	O
(	O
Figure	O
2	O
).	O
These	O
results	O
are	O
in	O
line	O
with	O
previous	O
studies	O
done	O
in	O
murine	O
model	O
","	O
which	O
showed	O
negative	O
and	O
statistically	O
significant	O
correlation	O
between	O
total	O
cellular	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
and	O
carcinogenesis	O
[	O
8	O
-	O
13	O
].	O
Poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
levels	O
in	O
controls	O
and	O
individual	O
cancers	O
of	O
H	O
&	O
N	O
ANOVA	O
of	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
in	O
controls	O
and	O
cancer	O
of	O
H	O
&	O
N	O
region	O
As	O
this	O
report	O
deals	O
with	O
elucidation	O
of	O
a	O
general	O
biomarker	O
of	O
cancer	O
","	O
the	O
mechanistic	O
aspects	O
of	O
lowering	O
of	O
the	O
level	O
of	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
of	O
cellular	O
proteins	O
and	O
its	O
likely	O
implications	O
on	O
the	O
biological	O
functions	O
of	O
chromatin	O
","	O
including	O
gene	O
expression	O
","	O
is	O
not	O
being	O
discussed	O
here	O
.	O
These	O
aspects	O
have	O
been	O
reviewed	O
in	O
details	O
recently	O
[	O
5	O
]	O
as	O
well	O
as	O
earlier	O
[	O
4	O
].	O
It	O
might	O
be	O
prudent	O
to	O
add	O
that	O
in	O
the	O
our	O
considered	O
opinion	O
","	O
the	O
PBL	O
","	O
being	O
the	O
first	O
responders	O
of	O
the	O
body	O
to	O
sense	O
metabolic	O
changes	O
and	O
mount	O
appropriate	O
biological	O
response	O
(	O
s	O
"),"	O
are	O
the	O
most	O
appropriate	O
cells	O
to	O
look	O
for	O
the	O
alterations	O
in	O
the	O
cellular	O
concentration	O
of	O
the	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
during	O
carcinogenesis	O
.	O
The	O
subjects	O
under	O
investigations	O
are	O
likely	O
to	O
be	O
exposed	O
to	O
different	O
and	O
variable	O
etiological	O
factors	O
.	O
Etiological	O
factors	O
could	O
influence	O
both	O
measured	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
level	O
as	O
well	O
as	O
the	O
course	O
of	O
carcinogenesis	O
.	O
Therefore	O
","	O
we	O
also	O
analysed	O
the	O
influence	O
of	O
three	O
most	O
important	O
etiological	O
factors	O
relevant	O
to	O
the	O
study	O
on	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
and	O
human	O
cancer	O
.	O
The	O
factors	O
are	O
habits	O
of	O
(	O
a	O
)	O
wet	O
variety	O
of	O
betel	O
nut	O
(	O
BN	O
)	O
chewing	O
-	O
a	O
social	O
etiquette	O
that	O
is	O
strongly	O
associated	O
with	O
cancers	O
","	O
especially	O
to	O
cancer	O
of	O
H	O
&	O
N	O
[	O
reviewed	O
in	O
[	O
16	O
","	O
17	O
(	O
b	O
)	O
alcohol	B-Chemical
consumption	O
[	O
reviewed	O
in	O
[	O
18	O
]]	O
and	O
(	O
c	O
)	O
tobacco	O
usage	O
[	O
reviewed	O
in	O
[	O
19	O
","	O
20	O
]].	O
These	O
three	O
factors	O
did	O
not	O
show	O
any	O
statistically	O
significant	O
influence	O
on	O
the	O
level	O
of	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
in	O
control	O
subjects	O
as	O
revealed	O
by	O
Spearman	O
rank	O
correlation	O
and	O
Mann	O
-	O
Whitney	O
rank	O
sum	O
test	O
(	O
Table	O
3	O
).	O
However	O
","	O
while	O
BN	O
chewing	O
did	O
not	O
significantly	O
influence	O
the	O
total	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
of	O
PBL	O
proteins	O
in	O
cancer	O
patients	O
(	O
Figure	O
3	O
-	O
c	O
"),"	O
alcohol	B-Chemical
consumption	O
(	O
Figure	O
3	O
-	O
a	O
)	O
and	O
tobacco	O
usage	O
(	O
Figure	O
3	O
-	O
b	O
)	O
were	O
found	O
to	O
lower	O
the	O
level	O
of	O
total	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
of	O
PBL	O
proteins	O
in	O
cancer	O
patients	O
significantly	O
as	O
compared	O
to	O
the	O
patients	O
without	O
these	O
habits	O
(	O
Table	O
4	O
).	O
Influence	O
of	O
selected	O
etiological	O
factors	O
on	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
in	O
control	O
subjects	O
Effects	O
of	O
selected	O
etiological	O
factors	O
on	O
the	O
cellular	O
level	O
of	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
adducts	O
in	O
cancer	O
patients	O
.	O
(	O
a	O
-	O
c	O
)	O
The	O
graphs	O
show	O
the	O
effect	O
of	O
three	O
main	O
cancer	O
related	O
etiological	O
factors	O
on	O
the	O
total	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
of	O
PBL	O
proteins	O
in	O
cancer	O
patients	O
following	O
Spearman	O
rank	O
correlation	O
test	O
and	O
Mann	O
-	O
Whitney	O
rank	O
sum	O
test	O
.	O
The	O
value	O
for	O
each	O
patient	O
is	O
shown	O
as	O
a	O
dot	O
.	O
Cancer	O
patients	O
exposed	O
to	O
alcohol	B-Chemical
recorded	O
a	O
statistically	O
highly	O
significant	O
(	O
P	O
<	O
0	O
.	O
1	O
)	O
reduction	O
in	O
the	O
mean	O
value	O
of	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
of	O
PBL	O
proteins	O
as	O
compared	O
to	O
patients	O
not	O
exposed	O
to	O
alcohol	B-Chemical
(	O
a	O
).	O
Similarly	O
","	O
patients	O
exposed	O
to	O
tobacco	O
also	O
recorded	O
significantly	O
(	O
P	O
=	O
0	O
.	O
33	O
)	O
lower	O
mean	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
value	O
than	O
those	O
not	O
exposed	O
to	O
tobacco	O
(	O
b	O
).	O
In	O
contrast	O
","	O
the	O
wet	O
variety	O
of	O
betel	O
nut	O
chewing	O
habit	O
of	O
cancer	O
patient	O
did	O
not	O
seem	O
to	O
significantly	O
(	O
P	O
=	O
0	O
.	O
935	O
)	O
lower	O
the	O
level	O
of	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
when	O
compared	O
to	O
the	O
non	O
-	O
chewers	O
(	O
c	O
).	O
The	O
values	O
of	O
total	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
of	O
PBL	O
proteins	O
for	O
the	O
age	O
-	O
and	O
gender	O
-	O
matched	O
(	O
male	O
-	O
d	O
;	O
female	O
-	O
e	O
)	O
controls	O
and	O
cancer	O
patients	O
were	O
also	O
plotted	O
.	O
As	O
is	O
evident	O
","	O
the	O
reductions	O
in	O
the	O
level	O
of	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
of	O
PBL	O
proteins	O
is	O
highly	O
significant	O
(	O
inset	O
Table	O
)	O
suggesting	O
that	O
measure	O
of	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
of	O
PBL	O
protein	O
is	O
a	O
general	O
biomarker	O
of	O
cancer	O
in	O
humans	O
.	O
Influence	O
of	O
selected	O
etiological	O
factors	O
on	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
in	O
cancer	O
patients	O
In	O
order	O
to	O
further	O
compare	O
the	O
total	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
of	O
PBL	O
proteins	O
in	O
controls	O
and	O
cases	O
","	O
we	O
matched	O
subjects	O
for	O
age	O
and	O
gender	O
.	O
We	O
obtained	O
28	O
controls	O
(	O
11	O
females	O
and	O
17	O
males	O
)	O
and	O
56	O
cases	O
(	O
33	O
females	O
and	O
23	O
males	O
)	O
in	O
the	O
age	O
range	O
of	O
24	O
-	O
65	O
years	O
(	O
Figure	O
3	O
-	O
d	O
","	O
e	O
and	O
inset	O
Table	O
).	O
Again	O
a	O
statistically	O
highly	O
significant	O
(	O
P	O
<	O
0	O
.	O
1	O
)	O
reduction	O
(~	O
47	O
%	O
in	O
males	O
and	O
~	O
44	O
%	O
in	O
females	O
)	O
in	O
total	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
of	O
PBL	O
proteins	O
was	O
observed	O
in	O
cancer	O
patients	O
when	O
compared	O
with	O
their	O
age	O
and	O
gender	O
adjusted	O
controls	O
.	O
Conclusions	O
In	O
conclusion	O
","	O
our	O
findings	O
reveal	O
statistically	O
highly	O
significant	O
negative	O
correlation	O
between	O
total	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
of	O
PBL	O
proteins	O
in	O
advance	O
human	O
cancers	O
of	O
H	O
&	O
N	O
(	O
14	O
different	O
types	O
"),"	O
breast	O
and	O
cervix	O
in	O
comparison	O
to	O
healthy	O
controls	O
using	O
a	O
novel	O
immunoprobe	O
assay	O
of	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
.	O
Based	O
on	O
the	O
preliminary	O
data	O
","	O
we	O
conclude	O
that	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
of	O
PBL	O
proteins	O
is	O
a	O
useful	O
and	O
general	O
biomarker	O
of	O
cancers	O
in	O
humans	O
.	O
Potentially	O
it	O
can	O
be	O
used	O
as	O
a	O
convenient	O
tool	O
for	O
detection	O
of	O
cancer	O
using	O
the	O
novel	O
immunoprobe	O
assay	O
.	O
The	O
ease	O
with	O
which	O
the	O
assay	O
could	O
be	O
performed	O
along	O
with	O
the	O
results	O
presented	O
in	O
this	O
report	O
support	O
our	O
earlier	O
contention	O
[	O
8	O
","	O
10	O
-	O
13	O
]	O
that	O
the	O
total	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
of	O
PBL	O
proteins	O
can	O
potentially	O
be	O
used	O
as	O
a	O
tool	O
for	O
mass	O
screening	O
of	O
cancer	O
.	O
We	O
are	O
aware	O
of	O
the	O
fact	O
that	O
further	O
studies	O
on	O
patients	O
in	O
early	O
stages	O
of	O
different	O
cancers	O
and	O
patients	O
undergoing	O
chemo	O
-	O
or	O
radiotherapy	O
","	O
etc	O
.	O
would	O
strengthen	O
the	O
reported	O
findings	O
.	O
Methods	O
Chemicals	O
All	O
chemicals	O
were	O
of	O
analytical	O
grade	O
and	O
were	O
used	O
without	O
further	O
purification	O
.	O
All	O
solutions	O
were	O
prepared	O
in	O
sterile	O
ultrapure	O
(	O
Milli	O
-	O
Q	O
)	O
water	B-Chemical
.	O
Histopaque	O
-	O
1077	O
","	O
phenylmethanesulfonyl	B-Chemical
fluoride	I-Chemical
(	O
PMSF	B-Chemical
)	O
and	O
0	O
.	O
45Î¼	O
nitrocellulose	B-Chemical
membrane	O
(	O
NCM	O
)	O
were	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
","	O
USA	O
.	O
RPMI	B-Chemical
-	I-Chemical
1640	I-Chemical
was	O
purchased	O
from	O
HyClone	O
","	O
Utah	O
","	O
USA	O
and	O
India	O
ink	O
from	O
Rotring	O
Zeichentusche	O
Drawing	O
Ink	O
","	O
Hamburg	O
","	O
Germany	O
.	O
Alkaline	O
phosphatase	O
-	O
conjugated	O
goat	O
anti	O
-	O
rabbit	O
IgG	O
(	O
ALP	O
~	O
IgG	O
)	O
and	O
5	B-Chemical
-	I-Chemical
bromo	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
indolyl	I-Chemical
phosphate	I-Chemical
(	O
BCIP	B-Chemical
)/	O
nitroblue	B-Chemical
tetrazolium	I-Chemical
(	O
NBT	B-Chemical
)	O
solution	O
were	O
purchased	O
from	O
Bangalore	O
Genei	O
","	O
India	O
.	O
Polyclonal	O
antibody	O
(	O
PAb	O
)	O
against	O
natural	O
","	O
heterogeneous	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymers	I-Chemical
of	O
spleen	O
cells	O
was	O
raised	O
in	O
the	O
laboratory	O
as	O
described	O
earlier	O
[	O
7	O
","	O
8	O
].	O
Cancer	O
(	O
case	O
)	O
and	O
control	O
groups	O
of	O
individuals	O
/	O
subjects	O
The	O
blood	O
samples	O
were	O
collected	O
from	O
new	O
patients	O
visiting	O
Dr	O
.	O
B	O
.	O
Barooah	O
Cancer	O
Institute	O
(	O
BBCI	O
"),"	O
Guwahati	O
","	O
India	O
in	O
accordance	O
with	O
the	O
Ethics	O
Committee	O
approvals	O
.	O
The	O
informed	O
and	O
consenting	O
(	O
signed	O
)	O
patients	O
","	O
who	O
have	O
not	O
yet	O
been	O
treated	O
for	O
cancer	O
","	O
were	O
recruited	O
for	O
the	O
study	O
following	O
confirmation	O
of	O
cancers	O
(	O
stage	O
III	O
/	O
IV	O
)	O
of	O
different	O
sites	O
in	O
the	O
head	O
&	O
neck	O
(	O
H	O
&	O
N	O
)	O
region	O
","	O
breast	O
and	O
cervix	O
(	O
age	O
range	O
25	O
-	O
80	O
years	O
).	O
Detailed	O
information	O
on	O
each	O
individual	O
patient	O
as	O
well	O
as	O
control	O
was	O
recorded	O
","	O
which	O
included	O
age	O
","	O
gender	O
","	O
and	O
other	O
personal	O
data	O
besides	O
family	O
history	O
","	O
history	O
and	O
pattern	O
of	O
betel	O
nut	O
chewing	O
","	O
alcohol	B-Chemical
consumption	O
and	O
tobacco	O
use	O
","	O
nutritional	O
history	O
","	O
medical	O
history	O
","	O
and	O
radiation	O
exposure	O
history	O
","	O
etc	O
.	O
Different	O
cancers	O
of	O
the	O
H	O
&	O
N	O
included	O
cancer	O
of	O
the	O
oesophagus	O
","	O
tongue	O
","	O
tonsil	O
","	O
nasopharynx	O
","	O
pharynx	O
","	O
buccal	O
mucosa	O
","	O
alveolus	O
","	O
pyriform	O
sinus	O
","	O
larynx	O
","	O
lip	O
","	O
nasal	O
cavity	O
","	O
epiglottis	O
","	O
oral	O
cavity	O
and	O
vocal	O
cord	O
.	O
The	O
control	O
group	O
consisted	O
of	O
normal	O
healthy	O
volunteers	O
with	O
no	O
known	O
history	O
of	O
cancer	O
(	O
age	O
range	O
25	O
-	O
80	O
years	O
).	O
Isolation	O
of	O
peripheral	O
blood	O
lymphocyte	O
(	O
PBL	O
)	O
and	O
preparation	O
of	O
samples	O
for	O
immunoprobe	O
assay	O
Blood	O
was	O
collected	O
in	O
a	O
heparinized	O
tube	O
from	O
the	O
subject	O
.	O
PBL	O
was	O
isolated	O
from	O
the	O
collected	O
blood	O
using	O
Histopaque	O
separation	O
medium	O
as	O
described	O
[	O
10	O
].	O
Briefly	O
","	O
equal	O
volumes	O
of	O
heparinized	O
blood	O
and	O
balanced	B-Chemical
salt	I-Chemical
solution	I-Chemical
(	O
BSS	B-Chemical
;	O
pH	O
7	O
.	O
6	O
containing	O
5	O
.	O
5	O
mM	O
anhydrous	O
D	B-Chemical
-	I-Chemical
glucose	I-Chemical
","	O
5	O
mM	O
CaCl2	B-Chemical
","	O
0	O
.	O
98	O
mM	O
MgCl2	B-Chemical
","	O
5	O
.	O
4	O
mM	O
KCl	B-Chemical
","	O
0	O
.	O
145	O
M	O
Tris	B-Chemical
and	O
0	O
.	O
14	O
M	O
NaCl	B-Chemical
)	O
were	O
mixed	O
and	O
layered	O
over	O
Histopaque	O
.	O
It	O
was	O
centrifuged	O
at	O
400	O
Ã—	O
g	O
for	O
40	O
min	O
at	O
room	O
temperature	O
(	O
RT	O
).	O
The	O
clear	O
lymphocyte	O
layer	O
at	O
the	O
interface	O
was	O
drawn	O
using	O
a	O
Pasteur	O
pipette	O
and	O
washed	O
twice	O
with	O
3	O
volumes	O
of	O
BSS	O
at	O
100	O
Ã—	O
g	O
for	O
10	O
min	O
at	O
RT	O
.	O
The	O
final	O
pellet	O
was	O
suspended	O
in	O
1	O
ml	O
of	O
RPMI	B-Chemical
-	I-Chemical
1640	I-Chemical
and	O
stored	O
at	O
-	O
80	O
Â°	O
C	O
until	O
further	O
use	O
.	O
To	O
prepare	O
the	O
whole	O
homogenate	O
(	O
WH	O
)	O
of	O
the	O
isolated	O
PBL	O
","	O
the	O
lymphocytes	O
in	O
RPMI	B-Chemical
-	I-Chemical
1640	I-Chemical
were	O
pelleted	O
down	O
by	O
centrifugation	O
at	O
250	O
Ã—	O
g	O
for	O
5	O
min	O
at	O
RT	O
and	O
washed	O
with	O
ice	O
cold	O
phosphate	B-Chemical
buffered	I-Chemical
saline	I-Chemical
(	O
PBS	B-Chemical
;	O
3	O
.	O
2	O
mM	O
Na2HPO4	B-Chemical
","	O
0	O
.	O
5	O
mM	O
KH2PO4	B-Chemical
","	O
1	O
.	O
3	O
mM	O
KCl	B-Chemical
and	O
135	O
mM	O
NaCl	B-Chemical
","	O
pH	O
7	O
.	O
4	O
)	O
at	O
200	O
Ã—	O
g	O
for	O
10	O
min	O
at	O
4	O
Â°	O
C	O
.	O
One	O
ml	O
of	O
ice	O
cold	O
lysis	O
buffer	O
(	O
20	O
mM	O
Tris	B-Chemical
-	I-Chemical
Cl	I-Chemical
","	O
pH	O
8	O
","	O
10	O
mM	O
NaCl	B-Chemical
","	O
0	O
.	O
5	O
%	O
Triton	B-Chemical
X	I-Chemical
-	I-Chemical
100	I-Chemical
","	O
5	O
mM	O
EDTA	B-Chemical
and	O
3	O
mM	O
MgCl2	B-Chemical
)	O
was	O
added	O
to	O
the	O
pellet	O
","	O
mixed	O
gently	O
","	O
incubated	O
on	O
ice	O
for	O
30	O
min	O
","	O
and	O
the	O
lysate	O
was	O
centrifuged	O
at	O
5000	O
Ã—	O
g	O
for	O
10	O
min	O
at	O
4	O
Â°	O
C	O
.	O
The	O
protein	O
content	O
of	O
the	O
resulting	O
supernatant	O
","	O
which	O
was	O
used	O
for	O
the	O
assay	O
of	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adducts	O
","	O
was	O
estimated	O
by	O
Bradford	O
method	O
using	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
as	O
a	O
standard	O
.	O
The	O
supernatant	O
was	O
stored	O
at	O
-	O
20	O
Â°	O
C	O
","	O
whenever	O
required	O
","	O
until	O
further	O
use	O
.	O
Immunoprobe	O
assay	O
of	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
The	O
assay	O
for	O
total	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
of	O
the	O
WH	O
proteins	O
of	O
PBL	O
was	O
done	O
by	O
a	O
novel	O
","	O
slot	O
blot	O
immunoprobe	O
assay	O
developed	O
by	O
us	O
","	O
which	O
employs	O
PAb	O
raised	O
against	O
natural	O
","	O
heterogeneous	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymers	I-Chemical
of	O
mouse	O
spleen	O
cells	O
.	O
The	O
novelty	O
of	O
the	O
assay	O
lies	O
in	O
the	O
fact	O
that	O
it	O
quantitatively	O
measures	O
the	O
total	O
cellular	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adducts	O
irrespective	O
of	O
the	O
target	O
protein	O
to	O
which	O
it	O
may	O
be	O
attached	O
.	O
Therefore	O
","	O
the	O
assay	O
reveals	O
the	O
TRUE	O
metabolic	O
level	O
of	O
total	O
cellular	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
.	O
The	O
assay	O
has	O
been	O
described	O
in	O
details	O
earlier	O
[	O
7	O
","	O
8	O
].	O
Briefly	O
","	O
slot	O
-	O
blotting	O
was	O
carried	O
out	O
using	O
a	O
Bio	O
-	O
dot	O
microfiltration	O
apparatus	O
(	O
Bio	O
-	O
Rad	O
).	O
Samples	O
were	O
heat	O
inactivated	O
by	O
dipping	O
the	O
sample	O
tubes	O
in	O
a	O
boiling	O
water	B-Chemical
bath	O
for	O
5	O
min	O
.	O
One	O
hundred	O
Î¼l	O
of	O
sample	O
containing	O
500	O
ng	O
protein	O
was	O
loaded	O
in	O
each	O
well	O
and	O
slot	O
blotted	O
on	O
NCM	O
under	O
slow	O
and	O
regulated	O
vacuum	O
.	O
The	O
NCM	O
was	O
then	O
immunoprobed	O
for	O
total	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
of	O
PBL	O
proteins	O
as	O
well	O
as	O
stained	O
with	O
India	O
ink	O
for	O
total	O
cellular	O
proteins	O
as	O
previously	O
described	O
[	O
8	O
].	O
Immunoprobe	O
assay	O
involved	O
blocking	O
of	O
the	O
NCM	O
by	O
a	O
5	O
%	O
non	O
-	O
fat	O
dry	O
milk	O
in	O
tris	B-Chemical
buffered	I-Chemical
saline	I-Chemical
(	O
TBS	B-Chemical
;	O
20	O
mM	O
Tris	B-Chemical
-	I-Chemical
Cl	I-Chemical
","	O
pH	O
7	O
.	O
5	O
","	O
500	O
mM	O
NaCl	B-Chemical
)	O
at	O
RT	O
","	O
incubation	O
in	O
the	O
primary	O
PAb	O
(	O
1	O
:	O
1000	O
)	O
for	O
1	O
h	O
at	O
37	O
Â°	O
C	O
and	O
incubation	O
in	O
the	O
secondary	O
antibody	O
","	O
ALP	O
~	O
IgG	O
(	O
1	O
:	O
10000	O
"),"	O
for	O
1	O
h	O
at	O
37	O
Â°	O
C	O
.	O
Each	O
of	O
these	O
steps	O
was	O
followed	O
by	O
washing	O
twice	O
in	O
TBS	B-Chemical
and	O
TTBS	B-Chemical
(	O
TBS	B-Chemical
containing	O
0	O
.	O
5	O
%	O
Tween	B-Chemical
20	I-Chemical
)	O
for	O
5	O
min	O
each	O
at	O
RT	O
.	O
The	O
color	O
on	O
the	O
NCM	O
was	O
developed	O
by	O
incubating	O
the	O
NCM	O
in	O
5	B-Chemical
-	I-Chemical
bromo	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
indolyl	I-Chemical
phosphate	I-Chemical
(	O
BCIP	B-Chemical
)/	O
nitroblue	B-Chemical
tetrazolium	I-Chemical
(	O
NBT	B-Chemical
)	O
color	O
developer	O
(	O
5	O
-	O
10	O
min	O
)	O
at	O
RT	O
.	O
Quantitative	O
image	O
analysis	O
Immunoprobed	O
and	O
India	O
ink	O
stained	O
slot	O
blots	O
were	O
scanned	O
(	O
HP	O
Scanjet	O
7000C	O
)	O
and	O
digitized	O
.	O
The	O
densitometric	O
analysis	O
was	O
done	O
using	O
KDS	O
-	O
ID	O
software	O
(	O
Kodak	O
).	O
Each	O
sample	O
was	O
slot	O
blotted	O
in	O
replicates	O
of	O
five	O
and	O
analysed	O
.	O
The	O
results	O
have	O
been	O
expressed	O
as	O
the	O
mean	O
net	O
pixel	O
intensity	O
of	O
bands	O
(Â±	O
SD	O
)	O
in	O
arbitrary	O
units	O
(	O
AU	O
)	O
after	O
concentration	O
correction	O
.	O
Statistical	O
analysis	O
An	O
unpaired	O
t	O
-	O
test	O
with	O
Welch	O
'	O
s	O
correction	O
was	O
used	O
to	O
analyze	O
the	O
distribution	O
of	O
mean	O
age	O
.	O
A	O
linear	O
regression	O
analysis	O
with	O
95	O
%	O
confidence	O
bands	O
was	O
performed	O
to	O
examine	O
the	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
level	O
within	O
the	O
control	O
group	O
.	O
A	O
One	O
way	O
ANOVA	O
was	O
used	O
to	O
compare	O
the	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
levels	O
between	O
controls	O
and	O
patients	O
with	O
cancers	O
of	O
the	O
H	O
&	O
N	O
region	O
.	O
An	O
unpaired	O
t	O
-	O
test	O
with	O
Welch	O
'	O
s	O
correction	O
was	O
used	O
to	O
compare	O
the	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
levels	O
between	O
controls	O
and	O
patients	O
with	O
cancers	O
of	O
the	O
breast	O
and	O
cervix	O
.	O
Spearman	O
rank	O
correlation	O
test	O
was	O
performed	O
to	O
evaluate	O
the	O
correlation	O
between	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
and	O
age	O
.	O
Ï‡2	O
test	O
was	O
used	O
to	O
examine	O
the	O
influence	O
of	O
various	O
factors	O
(	O
age	O
","	O
gender	O
","	O
betel	O
nut	O
","	O
alcohol	B-Chemical
","	O
tobacco	O
consumptions	O
","	O
etc	O
.)	O
in	O
each	O
of	O
the	O
groups	O
.	O
A	O
Fisher	O
'	O
s	O
exact	O
test	O
was	O
applied	O
when	O
necessary	O
.	O
The	O
analysis	O
of	O
influence	O
of	O
different	O
etiological	O
factors	O
in	O
the	O
controls	O
and	O
cases	O
was	O
performed	O
using	O
Mann	O
-	O
Whitney	O
rank	O
sum	O
test	O
.	O
Mann	O
-	O
Whitney	O
rank	O
sum	O
test	O
was	O
also	O
performed	O
to	O
compare	O
the	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	I-Chemical
ribose	I-Chemical
adduct	O
levels	O
in	O
control	O
and	O
cases	O
matched	O
for	O
age	O
and	O
gender	O
.	O
P	O
value	O
of	O
<	O
0	O
.	O
5	O
was	O
taken	O
as	O
statistically	O
significant	O
.	O
In	O
the	O
entire	O
test	O
a	O
two	O
-	O
tailed	O
P	O
value	O
was	O
used	O
.	O
Competing	O
interests	O
Authors	O
declare	O
no	O
competing	O
interest	O
in	O
the	O
reported	O
work	O
.	O
However	O
","	O
RNS	O
holds	O
an	O
Indian	O
patent	O
(	O
IPR	O
/	O
4	O
.	O
18	O
.	O
2	O
/	O
8044	O
)	O
on	O
ADP	B-Chemical
-	I-Chemical
ribose	I-Chemical
polymer	I-Chemical
/	O
poly	B-Chemical
-	I-Chemical
ADP	I-Chemical
-	O
ribosylation	O
as	O
a	O
cancer	O
biomarker	O
and	O
a	O
potential	O
tool	O
for	O
cancer	O
detection	O
and	O
screening	O
program	O
.	O
Authors	O
'	O
contributions	O
RNS	O
conceived	O
the	O
project	O
","	O
designed	O
the	O
study	O
","	O
analyzed	O
the	O
data	O
and	O
wrote	O
the	O
manuscript	O
in	O
association	O
with	O
ROL	O
.	O
ROL	O
collected	O
samples	O
from	O
control	O
and	O
experimental	O
(	O
cancer	O
patients	O
)	O
subjects	O
","	O
completed	O
questionnaire	O
","	O
carried	O
out	O
the	O
assay	O
and	O
quantification	O
","	O
collated	O
the	O
data	O
","	O
prepared	O
the	O
graphs	O
","	O
etc	O
.	O
ACK	O
coordinated	O
collection	O
of	O
samples	O
from	O
cancer	O
patients	O
at	O
Guwahati	O
.	O
All	O
authors	O
have	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
Acknowledgements	O
ROL	O
gratefully	O
acknowledges	O
grant	O
of	O
a	O
research	O
fellowship	O
of	O
CSIR	O
to	O
him	O
(	O
NET	O
-	O
JRF	O
/	O
SRF	O
).	O
RNS	O
is	O
thankful	O
to	O
Professors	O
P	O
.	O
N	O
.	O
Srivastava	O
(	O
Emeritus	O
Professor	O
of	O
Jawaharlal	O
Nehru	O
University	O
","	O
New	O
Delhi	O
"),"	O
T	O
.	O
Nomura	O
(	O
Emeritus	O
Professor	O
of	O
Osaka	O
University	O
and	O
National	O
Institute	O
of	O
Biomedical	O
Innovation	O
","	O
Osaka	O
"),"	O
John	O
P	O
.	O
Cooke	O
(	O
Stanford	O
University	O
School	O
of	O
Medicine	O
","	O
Stanford	O
)	O
and	O
A	O
.	O
T	O
.	O
Natarajan	O
(	O
Emeritus	O
Professor	O
","	O
University	O
of	O
Leiden	O
"),"	O
and	O
Dr	O
.	O
Kamlesh	O
Asotra	O
(	O
TRDPR	O
","	O
University	O
of	O
California	O
System	O
","	O
Oakland	O
)	O
and	O
others	O
for	O
critical	O
comments	O
on	O
the	O
work	O
and	O
the	O
manuscript	O
.	O
Part	O
of	O
the	O
work	O
was	O
done	O
by	O
support	O
from	O
the	O
UPE	O
-	O
NEHU	O
grant	O
to	O
RNS	O
.	O
Effects	O
of	O
asymmetric	B-Chemical
dimethylarginine	I-Chemical
on	O
bovine	O
retinal	O
capillary	O
endothelial	O
cell	O
proliferation	O
","	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
production	O
","	O
permeability	O
","	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
","	O
and	O
occludin	O
expression	O
Purpose	O
Asymmetric	B-Chemical
dimethylarginine	I-Chemical
(	O
ADMA	B-Chemical
"),"	O
an	O
endogenous	O
competitive	O
inhibitor	O
of	O
nitric	O
oxide	O
synthase	O
","	O
is	O
associated	O
with	O
impaired	O
endothelial	O
dysfunction	O
","	O
such	O
as	O
chronic	O
heart	O
failure	O
","	O
hypertension	O
","	O
diabetes	O
","	O
and	O
pulmonary	O
hypertension	O
.	O
The	O
effects	O
of	O
ADMA	B-Chemical
on	O
cell	O
proliferation	O
","	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
production	O
","	O
cell	O
permeability	O
","	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
"),"	O
and	O
tight	O
-	O
junction	O
protein	O
occludin	O
levels	O
in	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
(	O
BRCECs	O
)	O
were	O
investigated	O
.	O
Methods	O
A	O
cell	O
proliferation	O
assay	O
was	O
performed	O
using	O
the	O
novel	O
tetrazolium	B-Chemical
compound	O
3	B-Chemical
-(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
dimethylthiazol	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
yl	I-Chemical
)-	I-Chemical
5	I-Chemical
-(	I-Chemical
3	I-Chemical
-	I-Chemical
carboxymethoxyphenyl	I-Chemical
)-	I-Chemical
2	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
sulfophenyl	I-Chemical
)-	I-Chemical
2H	I-Chemical
-	I-Chemical
tetrazolium	I-Chemical
and	O
an	O
electron	O
coupling	O
reagent	O
.	O
Intracellular	O
ROS	B-Chemical
levels	O
were	O
determined	O
using	O
the	O
fluorescent	O
probe	O
CM	B-Chemical
-	I-Chemical
H2DCFDA	I-Chemical
.	O
Horseradish	O
peroxidase	O
was	O
used	O
for	O
a	O
permeability	O
assay	O
.	O
ICAM	O
-	O
1	O
and	O
tight	O
-	O
junction	O
protein	O
occludin	O
were	O
assessed	O
by	O
western	O
blotting	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O
Results	O
Cell	O
proliferation	O
was	O
significantly	O
inhibited	O
by	O
ADMA	B-Chemical
.	O
ADMA	B-Chemical
increased	O
intracellular	O
ROS	B-Chemical
generation	O
in	O
BRCECs	O
.	O
The	O
increased	O
ROS	B-Chemical
production	O
induced	O
by	O
ADMA	B-Chemical
was	O
markedly	O
inhibited	O
by	O
the	O
angiotensin	O
II	O
receptor	O
-	O
blocker	O
telmisartan	B-Chemical
","	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
benazepril	B-Chemical
","	O
the	O
reduced	O
form	O
of	O
nicotinamide	O
-	O
adenine	O
dinucleotide	O
phosphate	O
(	O
NADPH	O
)	O
oxidase	O
inhibitor	O
diphenyliodonium	B-Chemical
(	O
DPI	B-Chemical
"),"	O
or	O
the	O
antioxidant	O
and	O
free	O
-	O
radical	O
scavenger	O
N	B-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
cysteine	I-Chemical
(	O
NAC	B-Chemical
).	O
ADMA	B-Chemical
significantly	O
increased	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
permeability	O
in	O
BRCECs	O
.	O
Benazepril	B-Chemical
","	O
telmisartan	B-Chemical
","	O
DPI	B-Chemical
","	O
and	O
NAC	B-Chemical
downregulated	O
cell	O
permeability	O
.	O
ADMA	B-Chemical
markedly	O
upregulated	O
ICAM	O
-	O
1	O
expression	O
in	O
BRCECs	O
","	O
which	O
were	O
downregulated	O
by	O
telmisartan	B-Chemical
","	O
DPI	B-Chemical
","	O
and	O
NAC	B-Chemical
.	O
ADMA	B-Chemical
significantly	O
downregulated	O
occludin	O
expression	O
in	O
BRCECs	O
.	O
Benazepril	B-Chemical
and	O
telmisartan	B-Chemical
upregulated	O
occludin	O
expression	O
in	O
BRCECs	O
exposed	O
to	O
ADMA	B-Chemical
.	O
Conclusions	O
Our	O
results	O
provide	O
the	O
first	O
reported	O
evidence	O
that	O
ADMA	B-Chemical
has	O
potent	O
adverse	O
effects	O
on	O
cell	O
proliferation	O
","	O
intracellular	O
ROS	B-Chemical
generation	O
","	O
cell	O
permeability	O
","	O
levels	O
of	O
ICAM	O
-	O
1	O
","	O
and	O
the	O
tight	O
-	O
junction	O
protein	O
occludin	O
.	O
Angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
","	O
angiotensin	O
II	O
receptor	O
blockers	O
","	O
and	O
antioxidants	O
are	O
effective	O
inhibitors	O
of	O
the	O
adverse	O
effects	O
of	O
ADMA	B-Chemical
.	O
Introduction	O
Asymmetric	B-Chemical
dimethylarginine	I-Chemical
(	O
ADMA	B-Chemical
"),"	O
an	O
endogenous	O
competitive	O
inhibitor	O
of	O
nitric	O
oxide	O
synthase	O
","	O
is	O
generated	O
in	O
the	O
presence	O
of	O
type	O
1	O
protein	O
arginine	O
N	O
-	O
methyltransferase	O
(	O
PRMT	O
-	O
1	O
)	O
and	O
is	O
metabolized	O
by	O
dimethylarginine	O
dimethylaminohydrolases	O
(	O
DDAHs	O
)	O
[	O
1	O
].	O
Elevated	O
ADMA	B-Chemical
concentration	O
in	O
plasma	O
is	O
associated	O
with	O
impaired	O
endothelial	O
dysfunction	O
","	O
such	O
as	O
in	O
chronic	O
heart	O
failure	O
","	O
hypertension	O
","	O
renal	O
failure	O
","	O
diabetes	O
","	O
and	O
pulmonary	O
hypertension	O
[	O
2	O
-	O
4	O
].	O
ADMA	B-Chemical
is	O
also	O
related	O
to	O
endothelial	O
dysfunction	O
in	O
diabetic	O
complications	O
.	O
Our	O
previous	O
studies	O
suggested	O
that	O
PRMT	O
-	O
1	O
-	O
and	O
DDAH	O
-	O
induced	O
ADMA	B-Chemical
upregulation	O
was	O
involved	O
in	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)-	O
and	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
)-	O
mediated	O
diabetic	O
retinopathy	O
(	O
DR	O
"),"	O
which	O
may	O
be	O
a	O
novel	O
mechanism	O
for	O
the	O
development	O
or	O
progression	O
of	O
DR	O
[	O
5	O
].	O
Angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
(	O
ACEI	O
"),"	O
angiotensin	O
II	O
receptor	O
blocker	O
(	O
ARB	O
"),"	O
or	O
antioxidants	O
can	O
be	O
used	O
to	O
reduce	O
ROS	B-Chemical
production	O
and	O
lower	O
ADMA	B-Chemical
concentrations	O
","	O
thus	O
ameliorating	O
endothelial	O
dysfunction	O
and	O
improving	O
prognosis	O
in	O
DR	O
[	O
5	O
].	O
DR	O
is	O
a	O
leading	O
cause	O
of	O
acquired	O
visual	O
impairment	O
in	O
working	O
-	O
age	O
adults	O
in	O
developed	O
countries	O
[	O
6	O
].	O
The	O
precise	O
mechanism	O
underlying	O
the	O
progression	O
of	O
DR	O
remains	O
unclear	O
.	O
Several	O
biochemical	O
abnormalities	O
","	O
such	O
as	O
excessive	O
nonenzymatic	O
glycation	O
[	O
7	O
"],"	O
activation	O
of	O
the	O
aldose	O
reductase	O
pathway	O
[	O
8	O
"],"	O
activation	O
of	O
protein	O
kinase	O
C	O
[	O
9	O
"],"	O
and	O
oxidative	O
stress	O
[	O
10	O
"],"	O
have	O
been	O
identified	O
as	O
being	O
involved	O
in	O
the	O
pathogenesis	O
of	O
DR	O
.	O
Oxidative	O
stress	O
induced	O
by	O
hyperglycemia	O
is	O
thought	O
to	O
play	O
a	O
significant	O
role	O
in	O
DR	O
and	O
to	O
contribute	O
to	O
endothelial	O
dysfunction	O
[	O
11	O
].	O
Increases	O
in	O
ROS	B-Chemical
level	O
are	O
correlated	O
with	O
increased	O
leukocyte	O
adhesion	O
to	O
the	O
retinal	O
vasculature	O
(	O
leukostasis	O
)	O
and	O
breakdown	O
of	O
the	O
blood	O
-	O
retinal	O
barrier	O
(	O
BRB	O
)	O
[	O
12	O
","	O
13	O
].	O
Breakdown	O
of	O
the	O
BRB	O
and	O
leukostasis	O
are	O
hallmarks	O
of	O
DR	O
.	O
Increased	O
leukostasis	O
in	O
the	O
early	O
stages	O
of	O
DR	O
occurs	O
through	O
the	O
upregulation	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
[	O
14	O
].	O
Diabetes	O
-	O
induced	O
BRB	O
breakdown	O
is	O
associated	O
with	O
reduced	O
expression	O
of	O
the	O
tight	O
-	O
junction	O
protein	O
occludin	O
","	O
and	O
with	O
its	O
redistribution	O
within	O
the	O
retinal	O
vascular	O
endothelium	O
[	O
15	O
].	O
Recent	O
studies	O
indicated	O
that	O
ADMA	B-Chemical
regulates	O
endothelial	O
permeability	O
and	O
endothelial	O
barrier	O
function	O
[	O
16	O
].	O
The	O
present	O
study	O
was	O
performed	O
to	O
investigate	O
whether	O
ADMA	B-Chemical
affects	O
cell	O
proliferation	O
","	O
ROS	B-Chemical
production	O
","	O
cell	O
permeability	O
","	O
ICAM	O
-	O
1	O
","	O
and	O
tight	O
-	O
junction	O
protein	O
occludin	O
expression	O
in	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
(	O
BRCECs	O
).	O
Moreover	O
","	O
we	O
observed	O
the	O
interfering	O
effects	O
of	O
ACEI	O
","	O
ARB	O
","	O
and	O
antioxidants	O
on	O
the	O
above	O
changes	O
","	O
to	O
assess	O
the	O
role	O
of	O
ADMA	B-Chemical
in	O
retinal	O
capillary	O
endothelial	O
permeability	O
and	O
endothelial	O
barrier	O
function	O
.	O
Methods	O
Cell	O
culture	O
BRCECs	O
were	O
cultured	O
as	O
described	O
previously	O
[	O
17	O
].	O
Briefly	O
","	O
BRCECs	O
were	O
cultured	O
in	O
endothelial	B-Chemical
cell	I-Chemical
medium	I-Chemical
(	O
ECM	B-Chemical
;	O
ScienCell	O
Research	O
Labs	O
","	O
Carlsbad	O
","	O
CA	O
)	O
consisting	O
of	O
5	O
%	O
fetal	O
bovine	O
serum	O
","	O
1	O
%	O
endothelial	O
cell	O
growth	O
supplement	O
","	O
and	O
1	O
%	O
penicillin	B-Chemical
/	O
streptomycin	B-Chemical
solution	O
.	O
Endothelial	O
cells	O
at	O
passage	O
3	O
â€“	O
5	O
were	O
used	O
in	O
the	O
following	O
experiments	O
","	O
including	O
the	O
cell	O
proliferation	O
assay	O
","	O
examination	O
of	O
ROS	B-Chemical
levels	O
","	O
permeability	O
assay	O
","	O
western	O
blotting	O
analysis	O
","	O
and	O
quantitative	O
real	O
-	O
time	O
(	O
RT	O
)-	O
PCR	O
.	O
The	O
cells	O
were	O
washed	O
when	O
at	O
80	O
%	O
confluence	O
and	O
were	O
cultured	O
overnight	O
with	O
endothelial	O
cell	O
basal	O
medium	O
","	O
consisting	O
of	O
0	O
.	O
4	O
%	O
fetal	O
bovine	O
serum	O
and	O
1	O
%	O
penicillin	B-Chemical
/	O
streptomycin	B-Chemical
solution	O
.	O
The	O
cells	O
were	O
then	O
incubated	O
with	O
100	O
Î¼M	O
ADMA	B-Chemical
(	O
Sigma	O
","	O
St	O
.	O
Louis	O
","	O
MO	O
)	O
and	O
100	O
Î¼M	O
ADMA	B-Chemical
plus	O
10	O
Î¼M	O
benazepril	B-Chemical
(	O
Sigma	O
"),"	O
10	O
Î¼M	O
telmisartan	B-Chemical
(	O
Sigma	O
"),"	O
10	O
Î¼M	O
diphenyliodonium	B-Chemical
(	O
DPI	B-Chemical
","	O
an	O
reduced	O
form	O
of	O
nicotinamide	O
-	O
adenine	O
dinucleotide	O
phosphate	O
[	O
NADPH	O
]	O
oxidase	O
inhibitor	O
;	O
Sigma	O
"),"	O
or	O
10	O
mM	O
N	B-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
cysteine	I-Chemical
(	O
NAC	B-Chemical
","	O
an	O
antioxidant	O
and	O
free	O
radical	O
scavenger	O
;	O
Sigma	O
).	O
The	O
control	O
group	O
was	O
cultured	O
in	O
endothelial	O
cell	O
basal	O
medium	O
","	O
consisting	O
of	O
0	O
.	O
4	O
%	O
fetal	O
bovine	O
serum	O
and	O
1	O
%	O
penicillin	B-Chemical
/	O
streptomycin	B-Chemical
solution	O
.	O
Cells	O
were	O
harvested	O
after	O
24	O
h	O
for	O
western	O
blotting	O
analysis	O
","	O
quantitative	O
RT	O
â€“	O
PCR	O
analysis	O
","	O
and	O
examination	O
of	O
ROS	B-Chemical
levels	O
.	O
Cell	O
proliferation	O
assay	O
Cell	O
proliferation	O
assay	O
was	O
performed	O
using	O
the	O
novel	O
tetrazolium	B-Chemical
compound	O
","	O
3	B-Chemical
-(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
dimethylthiazol	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
yl	I-Chemical
)-	I-Chemical
5	I-Chemical
-(	I-Chemical
3	I-Chemical
-	I-Chemical
carboxymethoxyphenyl	I-Chemical
)-	I-Chemical
2	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
sulfophenyl	I-Chemical
)-	I-Chemical
2H	I-Chemical
-	I-Chemical
tetrazolium	I-Chemical
(	O
MTS	B-Chemical
"),"	O
and	O
the	O
electron	O
-	O
coupling	O
reagent	O
","	O
phenazine	B-Chemical
ethosulfate	I-Chemical
(	O
PES	B-Chemical
).	O
PES	B-Chemical
has	O
enhanced	O
chemical	O
stability	O
","	O
which	O
allows	O
it	O
to	O
be	O
combined	O
with	O
MTS	B-Chemical
to	O
form	O
a	O
stable	O
solution	O
.	O
This	O
convenient	O
â€œ	O
one	O
solution	O
â€	O
format	O
is	O
an	O
improvement	O
over	O
the	O
traditional	O
method	O
","	O
where	O
phenazine	B-Chemical
methosulfate	I-Chemical
(	O
PMS	B-Chemical
)	O
is	O
used	O
as	O
the	O
electron	O
-	O
coupling	O
reagent	O
","	O
and	O
PMS	B-Chemical
solution	O
and	O
MTS	B-Chemical
solution	O
are	O
supplied	O
separately	O
.	O
The	O
MTS	B-Chemical
tetrazolium	I-Chemical
compound	O
(	O
Owen	B-Chemical
â€™	I-Chemical
s	I-Chemical
reagent	I-Chemical
)	O
is	O
bioreduced	O
by	O
cells	O
into	O
a	O
colored	O
formazan	B-Chemical
product	O
that	O
is	O
soluble	O
in	O
tissue	O
culture	O
medium	O
.	O
This	O
conversion	O
is	O
presumably	O
accomplished	O
by	O
NADPH	B-Chemical
or	O
reduced	O
form	O
of	O
nicotinamide	B-Chemical
-	I-Chemical
adenine	I-Chemical
dinucleotid	I-Chemical
(	O
NADH	B-Chemical
"),"	O
produced	O
by	O
dehydrogenase	O
enzymes	O
in	O
metabolically	O
active	O
cells	O
[	O
18	O
].	O
The	O
quantity	O
of	O
formazan	B-Chemical
product	O
","	O
as	O
determined	O
by	O
measuring	O
the	O
absorbance	O
at	O
490	O
nm	O
","	O
is	O
directly	O
proportional	O
to	O
the	O
number	O
of	O
living	O
cells	O
in	O
the	O
culture	O
.	O
Endothelial	O
cells	O
were	O
plated	O
in	O
96	O
-	O
well	O
culture	O
plates	O
at	O
an	O
optimal	O
density	O
of	O
1	O
Ã—	O
105	O
cells	O
/	O
ml	O
with	O
100	O
Î¼l	O
of	O
culture	O
medium	O
per	O
well	O
.	O
After	O
3	O
days	O
","	O
cells	O
were	O
cultured	O
with	O
endothelial	O
cell	O
basal	O
medium	O
","	O
consisting	O
of	O
0	O
.	O
4	O
%	O
fetal	O
bovine	O
serum	O
and	O
1	O
%	O
penicillin	B-Chemical
/	O
streptomycin	B-Chemical
solution	O
","	O
overnight	O
.	O
The	O
cells	O
were	O
then	O
incubated	O
with	O
10	O
Î¼M	O
","	O
50	O
Î¼M	O
","	O
100	O
Î¼M	O
","	O
and	O
200	O
Î¼M	O
ADMA	B-Chemical
for	O
24	O
â€“	O
72	O
h	O
.	O
Then	O
","	O
20	O
Î¼l	O
of	O
CellTiter	B-Chemical
96	I-Chemical
Â®	I-Chemical
AQueous	I-Chemical
One	I-Chemical
Solution	I-Chemical
Reagent	I-Chemical
(	O
Promega	O
","	O
Madison	O
","	O
WI	O
)	O
were	O
pipetted	O
into	O
each	O
well	O
of	O
the	O
96	O
-	O
well	O
assay	O
plates	O
containing	O
the	O
samples	O
in	O
100	O
Î¼l	O
of	O
culture	O
medium	O
.	O
The	O
plates	O
were	O
incubated	O
at	O
37	O
Â°	O
C	O
for	O
1	O
â€“	O
4	O
h	O
in	O
a	O
humidified	O
","	O
5	O
%	O
CO2	B-Chemical
atmosphere	O
.	O
The	O
optical	O
density	O
of	O
each	O
sample	O
was	O
determined	O
immediately	O
on	O
an	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
microplate	O
reader	O
(	O
Wallac	O
1420	O
;	O
PerkinElmer	O
","	O
Waltham	O
","	O
MA	O
)	O
at	O
490	O
nm	O
.	O
Samples	O
were	O
tested	O
in	O
duplicate	O
.	O
The	O
corrected	O
absorbance	O
at	O
490	O
nm	O
(	O
y	O
-	O
axis	O
)	O
was	O
plotted	O
against	O
the	O
incubation	O
time	O
of	O
cells	O
with	O
ADMA	B-Chemical
(	O
x	O
-	O
axis	O
).	O
Examination	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
levels	O
in	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
Intracellular	O
ROS	B-Chemical
levels	O
in	O
BRCECs	O
were	O
determined	O
using	O
CM	B-Chemical
-	I-Chemical
H2DCFDA	I-Chemical
(	O
Invitrogen	O
","	O
Carlsbad	O
","	O
CA	O
).	O
Confluent	O
BRCECs	O
in	O
6	O
-	O
well	O
plates	O
were	O
collected	O
","	O
centrifuged	O
","	O
washed	O
with	O
phosphate	B-Chemical
-	I-Chemical
buffered	I-Chemical
saline	I-Chemical
(	O
PBS	B-Chemical
"),"	O
which	O
contained	O
1	O
.	O
6	O
mM	O
monobasic	O
potassium	B-Chemical
phosphate	I-Chemical
","	O
155	O
.	O
17	O
mM	O
sodium	B-Chemical
chloride	I-Chemical
","	O
and	O
2	O
.	O
97	O
mM	O
dibasic	O
sodium	B-Chemical
phosphate	I-Chemical
and	O
incubated	O
with	O
10	O
Î¼M	O
CM	B-Chemical
-	I-Chemical
H2DCFDA	I-Chemical
at	O
37	O
Â°	O
C	O
for	O
30	O
min	O
.	O
BRCECs	O
incubated	O
with	O
PBS	B-Chemical
and	O
dimethyl	B-Chemical
sulfoxide	I-Chemical
served	O
as	O
negative	O
controls	O
.	O
The	O
levels	O
of	O
fluorescence	O
were	O
immediately	O
determined	O
by	O
flow	O
cytometry	O
(	O
XL	O
-	O
4	O
;	O
Beckman	O
-	O
Coulter	O
","	O
Fullerton	O
","	O
CA	O
).	O
Permeability	O
assay	O
BRCECs	O
(	O
1	O
Ã—	O
105	O
cells	O
/	O
ml	O
)	O
were	O
plated	O
in	O
double	O
-	O
chamber	O
tissue	O
culture	O
plates	O
(	O
Transwell	O
","	O
24	O
-	O
well	O
filter	O
chambers	O
with	O
0	O
.	O
4	O
Î¼m	O
pore	O
size	O
membrane	O
;	O
Costar	O
","	O
Coring	O
Inc	O
".,"	O
New	O
York	O
","	O
NY	O
).	O
At	O
80	O
%	O
confluence	O
","	O
cells	O
were	O
cultured	O
with	O
endothelial	O
cell	O
basal	O
medium	O
","	O
consisting	O
of	O
0	O
.	O
4	O
%	O
fetal	O
bovine	O
serum	O
and	O
1	O
%	O
penicillin	B-Chemical
/	O
streptomycin	B-Chemical
solution	O
","	O
overnight	O
.	O
The	O
cells	O
were	O
then	O
incubated	O
with	O
100	O
Î¼M	O
ADMA	B-Chemical
","	O
and	O
100	O
Î¼M	O
ADMA	B-Chemical
plus	O
benazepril	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
telmisartan	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
DPI	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
or	O
NAC	B-Chemical
(	O
10	O
mM	O
)	O
for	O
24	O
h	O
.	O
Controls	O
were	O
cultured	O
with	O
endothelial	O
cell	O
basal	O
medium	O
","	O
consisting	O
of	O
0	O
.	O
4	O
%	O
fetal	O
bovine	O
serum	O
and	O
1	O
%	O
penicillin	B-Chemical
/	O
streptomycin	B-Chemical
solution	O
.	O
For	O
the	O
permeability	O
assay	O
","	O
horseradish	O
peroxidase	O
(	O
HRP	O
","	O
40	O
kDa	O
;	O
Sigma	O
)	O
was	O
added	O
to	O
the	O
upper	O
chambers	O
at	O
a	O
final	O
concentration	O
of	O
50	O
Î¼g	O
/	O
ml	O
.	O
Aliquots	O
of	O
5	O
Î¼l	O
were	O
collected	O
from	O
the	O
lower	O
chamber	O
after	O
15	O
min	O
","	O
30	O
min	O
","	O
45	O
min	O
","	O
and	O
1	O
h	O
.	O
The	O
concentrations	O
of	O
HRP	O
were	O
determined	O
in	O
5	O
Î¼l	O
aliquots	O
added	O
to	O
195	O
Î¼l	O
of	O
freshly	O
made	O
substrate	O
(	O
o	B-Chemical
-	I-Chemical
phenylenediamine	I-Chemical
","	O
400	O
Î¼g	O
/	O
ml	O
in	O
0	O
.	O
5	O
mM	O
citric	B-Chemical
acid	I-Chemical
and	O
0	O
.	O
1	O
mM	O
phosphate	B-Chemical
","	O
with	O
0	O
.	O
12	O
%	O
hydrogen	O
peroxidase	O
","	O
pH	O
5	O
.	O
0	O
).	O
The	O
reaction	O
was	O
terminated	O
by	O
the	O
addition	O
of	O
50	O
Î¼l	O
of	O
0	O
.	O
3	O
mM	O
sulfuric	B-Chemical
acid	I-Chemical
after	O
15	O
min	O
","	O
and	O
optical	O
density	O
was	O
determined	O
using	O
a	O
microplate	O
reader	O
(	O
PerkinElmer	O
","	O
Boston	O
","	O
MA	O
)	O
at	O
490	O
nm	O
.	O
A	O
standard	O
curve	O
was	O
prepared	O
from	O
HRP	O
serial	O
dilutions	O
in	O
each	O
experiment	O
","	O
and	O
the	O
samples	O
were	O
diluted	O
such	O
that	O
all	O
readings	O
fell	O
within	O
the	O
linear	O
range	O
of	O
the	O
standard	O
curve	O
.	O
The	O
readings	O
for	O
each	O
tracer	O
were	O
then	O
converted	O
to	O
nanograms	O
per	O
milliliter	O
by	O
comparison	O
with	O
standard	O
curves	O
generated	O
using	O
tracer	O
samples	O
taken	O
at	O
time	O
zero	O
.	O
Permeability	O
was	O
calculated	O
as	O
flux	O
:	O
(	O
ml	O
/	O
cm2	O
)=(	O
X	O
)	O
B	O
/[(	O
Y	O
)	O
i	O
*	O
A	O
"],"	O
where	O
(	O
X	O
)	O
B	O
(	O
Î¼g	O
)	O
is	O
the	O
level	O
of	O
HRP	O
in	O
the	O
lower	O
chamber	O
","	O
(	O
Y	O
)	O
i	O
(	O
Î¼g	O
/	O
ml	O
)	O
is	O
the	O
concentration	O
of	O
HRP	O
in	O
the	O
upper	O
chamber	O
","	O
and	O
A	O
(	O
cm2	O
)	O
is	O
the	O
effective	O
surface	O
area	O
of	O
the	O
insert	O
.	O
Each	O
experiment	O
was	O
repeated	O
at	O
least	O
three	O
times	O
.	O
Western	O
blotting	O
analysis	O
of	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
and	O
occludin	O
expression	O
Cells	O
were	O
sonicated	O
in	O
Tris	B-Chemical
-	I-Chemical
buffered	I-Chemical
saline	I-Chemical
(	O
TBS	B-Chemical
)	O
containing	O
protease	O
inhibitors	O
.	O
After	O
sonication	O
","	O
the	O
lysate	O
was	O
centrifuged	O
(	O
12	O
","	O
0	O
Ã—	O
g	O
","	O
15	O
min	O
","	O
4	O
Â°	O
C	O
)	O
and	O
the	O
supernatant	O
was	O
transferred	O
to	O
a	O
fresh	O
tube	O
.	O
The	O
protein	O
content	O
was	O
quantified	O
with	O
a	O
Pierce	O
protein	O
assay	O
kit	O
(	O
Pierce	O
","	O
Rockford	O
","	O
IL	O
).	O
Samples	O
of	O
equal	O
concentration	O
(	O
80	O
Î¼g	O
/	O
lane	O
)	O
were	O
separated	O
on	O
10	O
%	O
sodium	B-Chemical
dodecyl	I-Chemical
sulfate	I-Chemical
polyacrylamide	O
gel	O
electropheresis	O
(	O
SDS	B-Chemical
â€“	O
PAGE	O
)	O
and	O
transferred	O
onto	O
polyvinylidene	B-Chemical
difluoride	I-Chemical
(	O
PVDF	B-Chemical
)	O
transfer	O
membranes	O
(	O
Immobilon	O
P	O
;	O
Millipore	O
","	O
Billerica	O
","	O
MA	O
).	O
The	O
membranes	O
were	O
blocked	O
in	O
TBS	B-Chemical
containing	O
0	O
.	O
1	O
%	O
Tween	B-Chemical
-	I-Chemical
20	I-Chemical
and	O
5	O
%	O
nonfat	O
dry	O
milk	O
for	O
2	O
h	O
","	O
followed	O
by	O
overnight	O
incubation	O
at	O
4	O
Â°	O
C	O
with	O
polyclonal	O
antibodies	O
for	O
ICAM	O
-	O
1	O
(	O
Abcam	O
","	O
Cambridge	O
","	O
UK	O
)	O
or	O
occludin	O
(	O
Invitrogen	O
","	O
Carlsbad	O
","	O
CA	O
)	O
at	O
1	O
:	O
1	O
","	O
0	O
dilution	O
.	O
After	O
rinsing	O
in	O
TBS	B-Chemical
with	I-Chemical
Tween	I-Chemical
-	I-Chemical
20	I-Chemical
(	O
TBST	B-Chemical
"),"	O
the	O
membranes	O
were	O
incubated	O
for	O
2	O
h	O
with	O
an	O
HRP	O
-	O
conjugated	O
secondary	O
antibody	O
against	O
mouse	O
IgG	O
(	O
Dako	O
","	O
Glostrup	O
","	O
Denmark	O
)	O
in	O
a	O
1	O
:	O
1	O
","	O
0	O
dilution	O
and	O
rinsed	O
with	O
TBST	B-Chemical
","	O
and	O
bands	O
on	O
the	O
blots	O
were	O
then	O
detected	O
using	O
SuperSignal	O
West	O
Pico	O
Chemiluminescent	O
Substrate	O
(	O
Pierce	O
).	O
The	O
densities	O
of	O
the	O
bands	O
were	O
analyzed	O
using	O
Gel	O
-	O
Pro	O
Analyzer	O
(	O
Media	O
Cybernetics	O
","	O
Bethesda	O
","	O
MD	O
).	O
The	O
expression	O
of	O
Î²	O
-	O
actin	O
(	O
1	O
:	O
5000	O
;	O
monoclonal	O
anti	O
-	O
Î²	O
-	O
actin	O
;	O
Sigma	O
)	O
was	O
used	O
as	O
an	O
internal	O
control	O
.	O
Quantitative	O
real	O
-	O
time	O
PCR	O
After	O
removal	O
of	O
the	O
culture	O
medium	O
","	O
cells	O
were	O
washed	O
with	O
PBS	B-Chemical
","	O
then	O
combined	O
with	O
the	O
TRIzol	B-Chemical
reagent	O
(	O
Invitrogen	O
).	O
Extracted	O
RNA	O
was	O
then	O
quantified	O
spectrophotometrically	O
at	O
260	O
nm	O
and	O
integrity	O
was	O
assessed	O
by	O
agarose	B-Chemical
-	O
formaldehyde	B-Chemical
gel	O
electrophoresis	O
.	O
Total	O
RNA	O
samples	O
were	O
treated	O
with	O
DNase	O
I	O
(	O
RQ1	O
;	O
Promega	O
)	O
and	O
then	O
reverse	O
transcribed	O
using	O
a	O
ReverTra	O
Ace	O
RT	O
â€“	O
PCR	O
kit	O
(	O
Toyobo	O
","	O
Osaka	O
","	O
Japan	O
)	O
according	O
to	O
the	O
manufacturer	O
â€™	O
s	O
instructions	O
.	O
Primers	O
were	O
designed	O
using	O
DNA	O
Star	O
software	O
according	O
to	O
the	O
guidelines	O
supplied	O
with	O
the	O
software	O
.	O
The	O
primer	O
sequences	O
were	O
described	O
in	O
Table	O
1	O
.	O
Primer	O
sequences	O
for	O
quantitative	O
RT	O
â€“	O
PCR	O
.	O
To	O
exclude	O
DNA	O
interference	O
","	O
primers	O
were	O
designed	O
to	O
span	O
at	O
least	O
one	O
intron	O
.	O
To	O
quantify	O
the	O
amounts	O
of	O
specific	O
mRNA	O
(	O
mRNA	O
)	O
in	O
the	O
samples	O
","	O
we	O
generated	O
a	O
standard	O
curve	O
for	O
each	O
run	O
using	O
a	O
plasmid	O
(	O
pGEM	O
-	O
T	O
Easy	O
Vector	O
;	O
Promega	O
)	O
containing	O
the	O
gene	O
of	O
interest	O
as	O
a	O
standard	O
.	O
This	O
enabled	O
standardization	O
of	O
the	O
initial	O
mRNA	O
content	O
of	O
cells	O
relative	O
to	O
the	O
amount	O
of	O
18S	O
rRNA	O
.	O
PCR	O
assays	O
were	O
performed	O
using	O
SLAN	O
Â®	O
RT	O
â€“	O
PCR	O
system	O
(	O
Hongshi	O
","	O
Shanghai	O
","	O
China	O
).	O
The	O
quantitative	O
RT	O
â€“	O
PCR	O
solution	O
consisted	O
of	O
2	O
.	O
0	O
Î¼l	O
of	O
diluted	O
RT	O
â€“	O
PCR	O
product	O
","	O
0	O
.	O
5	O
Î¼l	O
of	O
each	O
primer	O
pair	O
","	O
25	O
Î¼l	O
of	O
RT	O
â€“	O
PCR	O
Master	O
Mix	O
(	O
Toyobo	O
","	O
Osaka	O
","	O
Japan	O
"),"	O
1	O
.	O
0	O
Î¼l	O
of	O
fluorogenic	O
probe	O
","	O
and	O
10	O
Î¼l	O
of	O
PCR	O
-	O
grade	O
water	B-Chemical
.	O
The	O
amplification	O
conditions	O
for	O
ICAM	O
-	O
1	O
and	O
occluding	O
were	O
as	O
follows	O
:	O
94	O
Â°	O
C	O
for	O
3	O
min	O
","	O
followed	O
by	O
40	O
cycles	O
of	O
94	O
Â°	O
C	O
for	O
20	O
s	O
","	O
55	O
Â°	O
C	O
for	O
20	O
s	O
","	O
and	O
72	O
Â°	O
C	O
for	O
20	O
s	O
.	O
The	O
results	O
of	O
quantitative	O
RT	O
â€“	O
PCR	O
were	O
analyzed	O
using	O
the	O
relative	O
standard	O
curve	O
method	O
with	O
the	O
SLAN	O
software	O
(	O
v	O
.	O
5	O
.	O
0	O
).	O
Values	O
were	O
normalized	O
relative	O
to	O
the	O
relative	O
amounts	O
of	O
18S	O
rRNA	O
","	O
which	O
were	O
obtained	O
from	O
a	O
similar	O
standard	O
curve	O
.	O
Statistical	O
analysis	O
All	O
results	O
are	O
expressed	O
as	O
means	O
Â±	O
standard	O
deviation	O
unless	O
otherwise	O
indicated	O
.	O
Statistical	O
evaluation	O
was	O
performed	O
with	O
the	O
SPSS	O
software	O
(	O
ver	O
.	O
14	O
.	O
0	O
for	O
Windows	O
;	O
SPSS	O
","	O
Chicago	O
","	O
IL	O
)	O
using	O
ANOVA	O
with	O
multiple	O
comparisons	O
between	O
groups	O
and	O
Pearson	O
â€™	O
s	O
correlation	O
test	O
.	O
In	O
all	O
analyses	O
","	O
p	O
<	O
0	O
.	O
5	O
was	O
taken	O
to	O
indicate	O
statistical	O
significance	O
.	O
Results	O
Cell	O
proliferation	O
assay	O
Cell	O
proliferation	O
was	O
significantly	O
inhibited	O
after	O
incubation	O
of	O
BRCECs	O
with	O
10	O
Î¼M	O
","	O
50	O
Î¼M	O
","	O
100	O
Î¼M	O
","	O
or	O
200	O
Î¼M	O
ADMA	B-Chemical
for	O
24	O
â€“	O
72	O
h	O
.	O
Moreover	O
","	O
cell	O
proliferation	O
showed	O
more	O
significant	O
inhibition	O
with	O
increasing	O
ADMA	B-Chemical
concentration	O
(	O
Figure	O
1	O
).	O
Cell	O
proliferation	O
analysis	O
of	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
.	O
Cell	O
proliferation	O
was	O
significantly	O
inhibited	O
by	O
asymmetric	B-Chemical
dimethylarginine	I-Chemical
(	O
ADMA	B-Chemical
)	O
for	O
24	O
â€“	O
72	O
h	O
.	O
In	O
group	O
A	O
","	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
(	O
BRCECs	O
)	O
were	O
cultured	O
in	O
endothelial	B-Chemical
cell	I-Chemical
medium	I-Chemical
(	O
ECM	B-Chemical
)	O
with	O
0	O
.	O
4	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
).	O
In	O
groups	O
B	O
throught	O
E	O
","	O
BRCECs	O
were	O
cultured	O
in	O
ECM	B-Chemical
with	O
0	O
.	O
4	O
%	O
FBS	O
plus	O
10	O
Î¼M	O
","	O
50	O
Î¼M	O
","	O
100	O
Î¼M	O
","	O
or	O
200	O
Î¼M	O
ADMA	B-Chemical
.	O
Results	O
are	O
expressed	O
as	O
absorbance	O
at	O
490	O
nm	O
and	O
represent	O
means	O
Â±	O
SEM	O
","	O
n	O
=	O
8	O
:	O
*	O
p	O
<	O
0	O
.	O
5	O
versus	O
group	O
A	O
","	O
**	O
p	O
<	O
0	O
.	O
1	O
versus	O
group	O
A	O
","	O
#	O
p	O
<	O
0	O
.	O
5	O
versus	O
group	O
B	O
","	O
##	O
p	O
<	O
0	O
.	O
1	O
versus	O
group	O
B	O
","	O
+	O
p	O
<	O
0	O
.	O
5	O
versus	O
group	O
C	O
","	O
++	O
p	O
<	O
0	O
.	O
1	O
versus	O
group	O
C	O
","	O
&	O
p	O
<	O
0	O
.	O
5	O
versus	O
group	O
D	O
","	O
&&	O
p	O
<	O
0	O
.	O
1	O
versus	O
group	O
D	O
.	O
Reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
determination	O
After	O
incubation	O
with	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
)	O
for	O
24	O
h	O
","	O
intracellular	O
ROS	B-Chemical
generation	O
in	O
BRCECs	O
was	O
significantly	O
increased	O
","	O
compared	O
with	O
those	O
incubated	O
in	O
normal	O
medium	O
(	O
p	O
<	O
0	O
.	O
1	O
).	O
The	O
increased	O
ROS	B-Chemical
production	O
induced	O
by	O
ADMA	B-Chemical
was	O
markedly	O
inhibited	O
by	O
benazepril	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
telmisartan	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
DPI	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
or	O
NAC	B-Chemical
(	O
10	O
mM	O
;	O
all	O
p	O
<	O
0	O
.	O
1	O
;	O
Figure	O
2	O
).	O
Intracellular	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
generation	O
in	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
for	O
24	O
h	O
","	O
as	O
determined	O
using	O
the	O
fluorescent	O
probe	O
CM	B-Chemical
-	I-Chemical
H2DCFDA	I-Chemical
.	O
symmetric	B-Chemical
dimethylarginine	I-Chemical
(	O
ADMA	B-Chemical
)	O
increased	O
intracellular	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
generation	O
in	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
(	O
BRCECs	O
).	O
The	O
increased	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
production	O
induced	O
by	O
asymmetric	B-Chemical
dimethylarginine	I-Chemical
(	O
ADMA	B-Chemical
)	O
was	O
markedly	O
inhibited	O
by	O
benazepril	B-Chemical
","	O
telmisartan	B-Chemical
","	O
diphenyliodonium	B-Chemical
","	O
or	O
N	B-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
cysteine	I-Chemical
.	O
In	O
group	O
C	O
","	O
BRCECs	O
were	O
cultured	O
in	O
endothelial	B-Chemical
cell	I-Chemical
medium	I-Chemical
with	O
0	O
.	O
4	O
%	O
fetal	O
bovine	O
serum	O
.	O
In	O
group	O
A	O
","	O
BRCECs	O
were	O
cultured	O
in	O
endothelial	B-Chemical
cell	I-Chemical
medium	I-Chemical
with	O
0	O
.	O
4	O
%	O
fetal	O
bovine	O
serum	O
plus	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
).	O
In	O
group	O
â€œ	O
A	O
+	O
B	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
A	O
and	O
10	O
Î¼M	O
benazepril	B-Chemical
.	O
In	O
group	O
â€œ	O
A	O
+	O
T	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
A	O
and	O
10	O
Î¼M	O
telmisartan	B-Chemical
.	O
In	O
group	O
â€œ	O
A	O
+	O
D	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
A	O
and	O
10	O
Î¼M	O
diphenyliodonium	B-Chemical
.	O
In	O
group	O
â€œ	O
A	O
+	O
N	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
group	O
A	O
and	O
10	O
mM	O
N	B-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
cysteine	I-Chemical
(	O
mean	O
Â±	O
SD	O
","	O
n	O
=	O
3	O
).	O
**	O
p	O
<	O
0	O
.	O
1	O
versus	O
group	O
C	O
","	O
##	O
p	O
<	O
0	O
.	O
1	O
versus	O
group	O
A	O
.	O
Permeability	O
assay	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
)	O
significantly	O
increased	O
HRP	O
permeability	O
in	O
BRCECs	O
.	O
Treatment	O
with	O
benazepril	B-Chemical
(	O
10	O
Î¼M	O
)	O
and	O
NAC	B-Chemical
(	O
10	O
mM	O
)	O
for	O
15	O
min	O
decreased	O
HRP	O
permeability	O
in	O
BRCECs	O
exposed	O
to	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
).	O
The	O
increase	O
in	O
permeability	O
by	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
)	O
was	O
significantly	O
downregulated	O
by	O
benazepril	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
telmisartan	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
DPI	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
or	O
NAC	B-Chemical
(	O
10	O
mM	O
)	O
for	O
30	O
min	O
","	O
45	O
min	O
","	O
and	O
1	O
h	O
(	O
Figure	O
3	O
).	O
Horseradish	O
peroxidase	O
(	O
HRP	O
)	O
permeability	O
assay	O
of	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
(	O
BRCECs	O
).	O
Asymmetric	B-Chemical
dimethylarginine	I-Chemical
(	O
ADMA	B-Chemical
)	O
significantly	O
increased	O
HRP	O
permeability	O
in	O
BRCECs	O
.	O
Treatment	O
with	O
benazepril	B-Chemical
and	O
NAC	B-Chemical
for	O
15	O
min	O
decreased	O
HRP	O
permeability	O
in	O
BRCECs	O
.	O
The	O
permeability	O
increase	O
by	O
ADMA	B-Chemical
was	O
significantly	O
downregulated	O
by	O
benazepril	B-Chemical
","	O
telmisartan	B-Chemical
","	O
diphenyliodonium	B-Chemical
(	O
DPI	B-Chemical
"),"	O
or	O
N	B-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
cysteine	I-Chemical
(	O
NAC	B-Chemical
)	O
for	O
30	O
min	O
","	O
45	O
min	O
","	O
and	O
1	O
h	O
.	O
The	O
group	O
C	O
bars	O
are	O
that	O
BRCECs	O
were	O
cultured	O
in	O
endothelial	B-Chemical
cell	I-Chemical
medium	I-Chemical
(	O
ECM	B-Chemical
)	O
with	O
0	O
.	O
4	O
%	O
FBS	O
.	O
In	O
group	O
A	O
","	O
BRCECs	O
were	O
cultured	O
in	O
ECM	B-Chemical
with	O
0	O
.	O
4	O
%	O
FBS	O
plus	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
).	O
In	O
group	O
â€œ	O
A	O
+	O
B	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
A	O
and	O
10	O
Î¼M	O
benazepril	B-Chemical
.	O
Group	O
â€œ	O
A	O
+	O
T	O
â€	O
was	O
the	O
same	O
as	O
for	O
group	O
A	O
and	O
10	O
Î¼M	O
telmisartan	B-Chemical
.	O
In	O
group	O
â€œ	O
A	O
+	O
D	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
group	O
A	O
and	O
10	O
Î¼M	O
DPI	B-Chemical
.	O
In	O
group	O
â€œ	O
A	O
+	O
N	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
group	O
A	O
and	O
10	O
mM	O
NAC	B-Chemical
(	O
mean	O
Â±	O
SD	O
","	O
n	O
=	O
3	O
).	O
*	O
p	O
<	O
0	O
.	O
5	O
versus	O
group	O
C	O
","	O
**	O
p	O
<	O
0	O
.	O
1	O
versus	O
group	O
C	O
","	O
#	O
p	O
<	O
0	O
.	O
5	O
versus	O
group	O
A	O
","	O
##	O
p	O
<	O
0	O
.	O
1	O
versus	O
group	O
A	O
.	O
Western	O
blotting	O
analysis	O
Western	O
blotting	O
analysis	O
indicated	O
that	O
exposure	O
to	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
)	O
for	O
24	O
h	O
markedly	O
upregulated	O
ICAM	O
-	O
1	O
protein	O
expression	O
in	O
BRCECs	O
(	O
p	O
<	O
0	O
.	O
1	O
).	O
Treatment	O
with	O
telmisartan	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
DPI	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
or	O
NAC	B-Chemical
(	O
10	O
mM	O
)	O
downregulated	O
ICAM	O
-	O
1	O
protein	O
expression	O
in	O
BRCECs	O
exposed	O
to	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
;	O
p	O
<	O
0	O
.	O
1	O
).	O
Benazepril	B-Chemical
(	O
10	O
Î¼M	O
)	O
had	O
no	O
effect	O
on	O
ICAM	O
-	O
1	O
expression	O
(	O
p	O
>	O
0	O
.	O
5	O
;	O
Figure	O
4	O
).	O
Intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
protein	O
expression	O
in	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
.	O
A	O
:	O
western	O
blotting	O
analysis	O
showing	O
the	O
presence	O
of	O
ICAM	O
-	O
1	O
protein	O
in	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
(	O
BRCECs	O
).	O
B	O
:	O
Results	O
of	O
statistical	O
analysis	O
of	O
protein	O
levels	O
relative	O
to	O
Î²	O
-	O
actin	O
.	O
Asymmetric	B-Chemical
dimethylarginine	I-Chemical
(	O
ADMA	B-Chemical
)	O
markedly	O
upregulated	O
ICAM	O
-	O
1	O
protein	O
expression	O
in	O
BRCECs	O
.	O
Telmisartan	B-Chemical
","	O
diphenyliodonium	B-Chemical
(	O
DPI	B-Chemical
"),"	O
or	O
N	B-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
cysteine	I-Chemical
(	O
NAC	B-Chemical
)	O
downregulated	O
ICAM	O
-	O
1	O
protein	O
expression	O
in	O
BRCECs	O
exposed	O
to	O
ADMA	B-Chemical
.	O
Benazepril	B-Chemical
had	O
no	O
effect	O
on	O
ICAM	O
-	O
1	O
expression	O
.	O
In	O
group	O
C	O
","	O
BRCECs	O
wrre	O
cultured	O
in	O
endothelial	B-Chemical
cell	I-Chemical
medium	I-Chemical
(	O
ECM	B-Chemical
)	O
with	O
0	O
.	O
4	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
).	O
In	O
group	O
A	O
","	O
BRCECs	O
were	O
cultured	O
in	O
ECM	B-Chemical
with	O
0	O
.	O
4	O
%	O
FBS	O
plus	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
).	O
In	O
group	O
â€œ	O
A	O
+	O
B	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
A	O
and	O
10	O
Î¼M	O
benazepril	B-Chemical
.	O
In	O
group	O
â€œ	O
A	O
+	O
T	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
group	O
A	O
and	O
10	O
Î¼M	O
telmisartan	B-Chemical
.	O
In	O
group	O
â€œ	O
A	O
+	O
D	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
group	O
A	O
and	O
10	O
Î¼M	O
DPI	B-Chemical
.	O
In	O
group	O
â€œ	O
A	O
+	O
N	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
A	O
and	O
10	O
mM	O
NAC	B-Chemical
(	O
mean	O
Â±	O
SD	O
","	O
n	O
=	O
3	O
).	O
**	O
p	O
<	O
0	O
.	O
1	O
versus	O
C	O
","	O
##	O
p	O
<	O
0	O
.	O
1	O
versus	O
group	O
A	O
.	O
Experiments	O
performed	O
in	O
vitro	O
also	O
showed	O
that	O
exposure	O
to	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
)	O
for	O
24	O
h	O
significantly	O
downregulated	O
occludin	O
protein	O
expression	O
in	O
BRCECs	O
(	O
p	O
<	O
0	O
.	O
1	O
).	O
Treatment	O
with	O
benazepril	B-Chemical
(	O
10	O
Î¼M	O
)	O
or	O
telmisartan	B-Chemical
(	O
10	O
Î¼M	O
)	O
upregulated	O
occludin	O
protein	O
expression	O
in	O
BRCECs	O
exposed	O
to	O
ADMA	B-Chemical
(	O
p	O
<	O
0	O
.	O
1	O
"),"	O
while	O
DPI	B-Chemical
(	O
10	O
Î¼M	O
)	O
and	O
NAC	B-Chemical
(	O
10	O
mM	O
)	O
had	O
no	O
effect	O
on	O
occludin	O
expression	O
(	O
p	O
>	O
0	O
.	O
5	O
;	O
Figure	O
5	O
).	O
Occludin	O
protein	O
expression	O
in	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
.	O
A	O
:	O
western	O
blotting	O
analysis	O
showing	O
the	O
presence	O
of	O
occludin	O
protein	O
in	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
(	O
BRCECs	O
).	O
B	O
:	O
The	O
results	O
of	O
statistical	O
analysis	O
of	O
protein	O
level	O
relative	O
to	O
Î²	O
-	O
actin	O
.	O
Asymmetric	B-Chemical
dimethylarginine	I-Chemical
(	O
ADMA	B-Chemical
)	O
significantly	O
downregulated	O
occludin	O
protein	O
expression	O
in	O
BRCECs	O
.	O
Benazepril	B-Chemical
and	O
telmisartan	B-Chemical
upregulated	O
protein	O
expression	O
of	O
occludin	O
in	O
BRCECs	O
exposed	O
to	O
ADMA	B-Chemical
.	O
However	O
","	O
diphenyliodonium	B-Chemical
(	O
DPI	B-Chemical
)	O
and	O
N	B-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
cysteine	I-Chemical
(	O
NAC	B-Chemical
)	O
had	O
no	O
effect	O
on	O
occludin	O
expression	O
.	O
In	O
group	O
C	O
","	O
BRCECs	O
were	O
cultured	O
in	O
ECM	B-Chemical
with	O
0	O
.	O
4	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
).	O
In	O
group	O
A	O
","	O
BRCECs	O
were	O
cultured	O
in	O
ECM	B-Chemical
with	O
0	O
.	O
4	O
%	O
FBS	O
plus	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
).	O
Group	O
â€œ	O
A	O
+	O
B	O
â€	O
represents	O
same	O
as	O
for	O
group	O
A	O
and	O
10	O
Î¼M	O
benazepril	B-Chemical
.	O
Group	O
â€œ	O
A	O
+	O
T	O
â€	O
represents	O
same	O
as	O
for	O
group	O
A	O
and	O
10	O
Î¼M	O
telmisartan	B-Chemical
.	O
Group	O
â€œ	O
A	O
+	O
D	O
â€	O
represents	O
same	O
as	O
for	O
group	O
A	O
and	O
10	O
Î¼M	O
DPI	B-Chemical
.	O
Group	O
â€œ	O
A	O
+	O
N	O
â€	O
represents	O
same	O
as	O
for	O
group	O
A	O
and	O
10	O
mM	O
NAC	B-Chemical
(	O
mean	O
Â±	O
SD	O
","	O
n	O
=	O
3	O
).	O
**	O
p	O
<	O
0	O
.	O
1	O
versus	O
group	O
C	O
","	O
##	O
p	O
<	O
0	O
.	O
1	O
versus	O
group	O
A	O
.	O
Quantitative	O
real	O
-	O
time	O
PCR	O
analysis	O
ICAM	O
-	O
1	O
mRNA	O
expression	O
in	O
BRCECs	O
was	O
markedly	O
upregulated	O
following	O
exposure	O
to	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
)	O
for	O
24	O
h	O
(	O
p	O
<	O
0	O
.	O
1	O
).	O
Benazepril	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
telmisartan	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
DPI	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
or	O
NAC	B-Chemical
(	O
10	O
mM	O
)	O
downregulated	O
ICAM	O
-	O
1	O
mRNA	O
expression	O
in	O
BRCECs	O
exposed	O
to	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
;	O
p	O
<	O
0	O
.	O
1	O
;	O
Figure	O
6	O
).	O
The	O
statistical	O
analysis	O
results	O
of	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
(	O
BRCECs	O
)	O
intercellular	O
adhesion	O
molecule	O
-	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
gene	O
expression	O
relative	O
to	O
18S	O
rRNA	O
for	O
24	O
h	O
.	O
Asymmetric	B-Chemical
dimethylarginine	I-Chemical
(	O
ADMA	B-Chemical
)	O
markedly	O
upregulated	O
ICAM	O
-	O
1	O
mRNA	O
expression	O
in	O
BRCECs	O
for	O
24	O
h	O
.	O
Benazepril	B-Chemical
","	O
telmisartan	B-Chemical
","	O
diphenyliodonium	B-Chemical
(	O
DPI	B-Chemical
"),"	O
or	O
N	B-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
cysteine	I-Chemical
(	O
NAC	B-Chemical
)	O
downregulated	O
ICAM	O
-	O
1	O
mRNA	O
expression	O
in	O
BRCECs	O
exposed	O
to	O
ADMA	B-Chemical
.	O
In	O
group	O
C	O
","	O
BRCECs	O
were	O
cultured	O
in	O
endothelial	B-Chemical
cell	I-Chemical
medium	I-Chemical
(	O
ECM	B-Chemical
)	O
with	O
0	O
.	O
4	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
).	O
In	O
group	O
A	O
","	O
BRCECs	O
were	O
cultured	O
in	O
ECM	B-Chemical
with	O
0	O
.	O
4	O
%	O
FBS	O
plus	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
).	O
â€œ	O
A	O
+	O
B	O
â€	O
represents	O
same	O
as	O
for	O
group	O
A	O
and	O
10	O
Î¼M	O
benazepril	B-Chemical
.	O
In	O
group	O
â€œ	O
A	O
+	O
T	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
group	O
A	O
and	O
10	O
Î¼M	O
telmisartan	B-Chemical
.	O
In	O
group	O
â€œ	O
A	O
+	O
D	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
group	O
A	O
and	O
10	O
Î¼M	O
DPI	B-Chemical
.	O
In	O
group	O
â€œ	O
A	O
+	O
N	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
group	O
A	O
and	O
10	O
mM	O
NAC	B-Chemical
(	O
mean	O
Â±	O
SD	O
","	O
n	O
=	O
3	O
).	O
**	O
p	O
<	O
0	O
.	O
1	O
versus	O
group	O
C	O
","	O
##	O
p	O
<	O
0	O
.	O
1	O
versus	O
group	O
A	O
.	O
Occludin	O
mRNA	O
expression	O
in	O
BRCECs	O
was	O
downregulated	O
when	O
cells	O
were	O
exposed	O
to	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
)	O
for	O
24	O
h	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
Treatment	O
with	O
benazepril	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
telmisartan	B-Chemical
(	O
10	O
Î¼M	O
"),"	O
or	O
DPI	B-Chemical
(	O
10	O
Î¼M	O
)	O
upregulated	O
the	O
occludin	O
mRNA	O
level	O
in	O
BRCECs	O
exposed	O
to	O
ADMA	B-Chemical
(	O
p	O
<	O
0	O
.	O
5	O
).	O
However	O
","	O
NAC	B-Chemical
(	O
10	O
mM	O
)	O
had	O
no	O
effect	O
on	O
the	O
occludin	O
mRNA	O
level	O
(	O
p	O
>	O
0	O
.	O
5	O
;	O
Figure	O
7	O
).	O
Results	O
of	O
statistical	O
analysis	O
of	O
occludin	O
gene	O
expression	O
relative	O
to	O
18S	O
rRNA	O
in	O
bovine	O
retinal	O
capillary	O
endothelial	O
cells	O
(	O
BRCECs	O
)	O
for	O
24	O
h	O
.	O
ADMA	B-Chemical
downregulated	O
occludin	O
mRNA	O
expression	O
in	O
BRCECs	O
for	O
24	O
h	O
.	O
Benazepril	B-Chemical
","	O
telmisartan	B-Chemical
","	O
or	O
diphenyliodonium	B-Chemical
(	O
DPI	B-Chemical
)	O
upregulated	O
occludin	O
mRNA	O
level	O
.	O
However	O
","	O
N	B-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
cysteine	I-Chemical
(	O
NAC	B-Chemical
)	O
had	O
no	O
effect	O
on	O
occludin	O
mRNA	O
level	O
.	O
In	O
group	O
C	O
","	O
BRCECs	O
were	O
cultured	O
in	O
endothelial	B-Chemical
cell	I-Chemical
medium	I-Chemical
(	O
ECM	B-Chemical
)	O
with	O
0	O
.	O
4	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
).	O
In	O
group	O
A	O
","	O
BRCECs	O
were	O
cultured	O
in	O
ECM	B-Chemical
with	O
0	O
.	O
4	O
%	O
FBS	O
plus	O
ADMA	B-Chemical
(	O
100	O
Î¼M	O
).	O
In	O
group	O
â€œ	O
A	O
+	O
B	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
group	O
A	O
and	O
10	O
Î¼M	O
benazepril	B-Chemical
.	O
In	O
â€œ	O
A	O
+	O
T	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
group	O
A	O
and	O
10	O
Î¼M	O
telmisartan	B-Chemical
.	O
In	O
group	O
â€œ	O
A	O
+	O
D	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
group	O
A	O
and	O
10	O
Î¼M	O
DPI	B-Chemical
.	O
In	O
group	O
â€œ	O
A	O
+	O
N	O
",â€"	O
BRCECs	O
were	O
cultured	O
in	O
the	O
same	O
media	O
as	O
group	O
A	O
and	O
10	O
mM	O
NAC	B-Chemical
(	O
mean	O
Â±	O
SD	O
","	O
n	O
=	O
3	O
).	O
*	O
p	O
<	O
0	O
.	O
5	O
versus	O
group	O
C	O
","	O
#	O
p	O
<	O
0	O
.	O
5	O
versus	O
group	O
A	O
.	O
Discussion	O
Kakimoto	O
and	O
Akazawa	O
[	O
19	O
]	O
first	O
isolated	O
and	O
described	O
ADMA	B-Chemical
from	O
human	O
urine	O
in	O
1970	O
.	O
Since	O
their	O
initial	O
observation	O
","	O
ADMA	B-Chemical
has	O
been	O
shown	O
to	O
represent	O
a	O
novel	O
risk	O
factor	O
for	O
the	O
development	O
of	O
endothelial	O
dysfunction	O
.	O
Oxidative	O
stress	O
has	O
been	O
shown	O
to	O
increase	O
the	O
activity	O
of	O
arginine	B-Chemical
-	O
methylating	O
and	O
ADMA	B-Chemical
-	O
degrading	O
enzymes	O
","	O
leading	O
to	O
increased	O
ADMA	B-Chemical
concentrations	O
;	O
moreover	O
","	O
high	O
ADMA	B-Chemical
levels	O
further	O
contribute	O
to	O
the	O
vascular	O
oxidative	O
stress	O
burden	O
in	O
a	O
positive	O
feedback	O
fashion	O
[	O
20	O
","	O
21	O
].	O
As	O
reported	O
previously	O
","	O
BRCECs	O
incubated	O
in	O
the	O
presence	O
of	O
high	O
glucose	B-Chemical
concentrations	O
showed	O
elevated	O
ROS	B-Chemical
production	O
","	O
PRMT	O
-	O
1	O
expression	O
","	O
reduced	O
DDAH	O
activity	O
","	O
and	O
DDAH	O
II	O
expression	O
","	O
and	O
increased	O
the	O
accumulation	O
of	O
ADMA	B-Chemical
in	O
a	O
conditioned	O
medium	O
[	O
5	O
].	O
In	O
the	O
present	O
study	O
","	O
we	O
found	O
that	O
ADMA	B-Chemical
increased	O
intracellular	O
ROS	B-Chemical
generation	O
in	O
BRCECs	O
.	O
Thus	O
","	O
we	O
propose	O
that	O
ADMA	B-Chemical
is	O
not	O
only	O
a	O
marker	O
","	O
but	O
also	O
a	O
producer	O
of	O
oxidative	O
stress	O
","	O
under	O
high	O
-	O
glucose	B-Chemical
conditions	O
.	O
There	O
have	O
been	O
many	O
recent	O
studies	O
regarding	O
the	O
effects	O
of	O
different	O
therapeutic	O
interventions	O
on	O
ADMA	B-Chemical
plasma	O
concentrations	O
.	O
ACEI	O
and	O
ARB	O
have	O
been	O
shown	O
to	O
reduce	O
the	O
levels	O
of	O
ADMA	B-Chemical
and	O
improve	O
endothelial	O
dysfunction	O
in	O
human	O
essential	O
hypertension	O
and	O
diabetes	O
mellitus	O
[	O
22	O
-	O
24	O
].	O
Although	O
the	O
mechanisms	O
of	O
the	O
beneficial	O
effects	O
of	O
ACEI	O
and	O
ARB	O
remain	O
obscure	O
","	O
ADMA	B-Chemical
is	O
known	O
to	O
upregulate	O
several	O
components	O
of	O
microvascular	O
RAS	O
","	O
leading	O
to	O
increased	O
production	O
of	O
angiotensin	O
II	O
","	O
which	O
then	O
activates	O
NADPH	O
oxidase	O
and	O
increases	O
ROS	B-Chemical
production	O
[	O
25	O
].	O
ADMA	B-Chemical
improves	O
the	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
activity	O
in	O
human	O
coronary	O
artery	O
endothelial	O
cells	O
","	O
which	O
may	O
provide	O
a	O
link	O
between	O
ADMA	B-Chemical
and	O
RAS	O
","	O
because	O
ACE	O
protein	O
expression	O
has	O
been	O
shown	O
to	O
be	O
regulated	O
by	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
[	O
26	O
","	O
27	O
].	O
In	O
the	O
present	O
study	O
","	O
the	O
NADPH	O
oxidase	O
inhibitor	O
DPI	B-Chemical
or	O
the	O
free	O
-	O
radical	O
scavenger	O
NAC	B-Chemical
decreased	O
intracellular	O
ROS	B-Chemical
generation	O
in	O
BRCECs	O
incubated	O
with	O
ADMA	B-Chemical
.	O
Benazepril	B-Chemical
or	O
telmisartan	B-Chemical
had	O
effects	O
similar	O
to	O
those	O
from	O
DPI	B-Chemical
and	O
NAC	B-Chemical
","	O
indicating	O
that	O
they	O
may	O
also	O
exert	O
their	O
effects	O
through	O
the	O
oxidase	O
pathway	O
.	O
It	O
has	O
been	O
reported	O
that	O
ADMA	B-Chemical
regulates	O
endothelial	O
permeability	O
and	O
endothelial	O
barrier	O
function	O
.	O
Several	O
possible	O
mechanisms	O
have	O
been	O
proposed	O
to	O
explain	O
the	O
effects	O
of	O
ADMA	B-Chemical
on	O
endothelial	O
barrier	O
function	O
.	O
A	O
previous	O
study	O
indicated	O
that	O
ADMA	B-Chemical
increased	O
pulmonary	O
endothelial	O
permeability	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
","	O
and	O
that	O
this	O
effect	O
was	O
mediated	O
by	O
nitric	B-Chemical
oxide	I-Chemical
","	O
acting	O
via	O
protein	O
kinase	O
G	O
and	O
independent	O
of	O
ROS	B-Chemical
formation	O
[	O
16	O
].	O
Others	O
have	O
demonstrated	O
that	O
ADMA	B-Chemical
compromises	O
the	O
integrity	O
of	O
the	O
glomerular	O
filtration	O
barrier	O
by	O
altering	O
the	O
bioavailability	O
of	O
nitric	B-Chemical
oxide	I-Chemical
and	O
superoxide	B-Chemical
","	O
and	O
that	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
)-	O
independent	O
activation	O
of	O
soluble	O
guanylyl	O
cyclase	O
preserves	O
the	O
integrity	O
of	O
this	O
barrier	O
under	O
conditions	O
of	O
NO	B-Chemical
depletion	O
[	O
28	O
].	O
ADMA	B-Chemical
markedly	O
downregulated	O
connexin43	O
expression	O
and	O
damaged	O
gap	O
junction	O
function	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
by	O
increasing	O
the	O
production	O
of	O
intracellular	O
ROS	B-Chemical
and	O
inducing	O
phosphorylation	O
of	O
p38	O
MAPK	O
[	O
29	O
].	O
However	O
","	O
to	O
date	O
","	O
the	O
role	O
of	O
ADMA	B-Chemical
in	O
the	O
BRB	O
has	O
not	O
been	O
studied	O
.	O
The	O
BRB	O
","	O
an	O
important	O
ocular	O
barrier	O
","	O
consists	O
of	O
two	O
components	O
:	O
the	O
inner	O
and	O
outer	O
BRB	O
.	O
The	O
inner	O
BRB	O
is	O
formed	O
by	O
retinal	O
microvascular	O
endothelial	O
cells	O
with	O
tight	O
junctions	O
between	O
them	O
.	O
The	O
normal	O
inner	O
BRB	O
is	O
determined	O
by	O
the	O
homeostasis	O
of	O
retinal	O
microvessels	O
","	O
and	O
plays	O
a	O
critical	O
role	O
in	O
normal	O
visual	O
function	O
.	O
Enhanced	O
retinal	O
vascular	O
permeability	O
has	O
been	O
shown	O
to	O
aggravate	O
microvascular	O
endothelial	O
cell	O
damage	O
and	O
capillary	O
nonperfusion	O
[	O
30	O
].	O
Several	O
studies	O
linked	O
inflammation	O
to	O
vascular	O
leakage	O
in	O
diabetic	O
retinopathy	O
.	O
Leukocytes	O
adhere	O
to	O
the	O
retinal	O
vascular	O
endothelium	O
early	O
in	O
diabetic	O
retinopathy	O
","	O
the	O
onset	O
of	O
which	O
occurs	O
before	O
the	O
development	O
of	O
any	O
clinical	O
pathology	O
[	O
14	O
].	O
Further	O
","	O
leukocyte	O
adhesion	O
coincides	O
with	O
the	O
development	O
of	O
BRB	O
breakdown	O
and	O
capillary	O
nonperfusion	O
[	O
14	O
].	O
The	O
expression	O
of	O
ICAM	O
-	O
1	O
is	O
upregulated	O
in	O
DR	O
","	O
and	O
the	O
specific	O
inhibition	O
of	O
ICAM	O
-	O
1	O
prevents	O
diabetic	O
retinal	O
leukocyte	O
adhesion	O
and	O
BRB	O
breakdown	O
[	O
14	O
","	O
31	O
","	O
32	O
].	O
In	O
this	O
study	O
","	O
ADMA	B-Chemical
significantly	O
increased	O
BRCEC	O
permeability	O
within	O
1	O
h	O
and	O
was	O
strongly	O
involved	O
in	O
reducing	O
the	O
levels	O
of	O
the	O
tight	O
-	O
junction	O
protein	O
occludin	O
and	O
upregulation	O
of	O
ICAM	O
-	O
1	O
expression	O
in	O
BRCECs	O
.	O
ACEI	O
","	O
ARB	O
","	O
or	O
antioxidants	O
significantly	O
downregulated	O
cell	O
permeability	O
increased	O
by	O
ADMA	B-Chemical
at	O
30	O
min	O
","	O
45	O
min	O
","	O
and	O
1	O
h	O
.	O
Furthermore	O
","	O
we	O
observed	O
that	O
benazepril	B-Chemical
","	O
telmisartan	B-Chemical
","	O
and	O
the	O
antioxidant	O
DPI	B-Chemical
reversed	O
the	O
effects	O
of	O
ADMA	B-Chemical
on	O
occludin	O
and	O
ICAM	O
-	O
1	O
expression	O
.	O
Based	O
on	O
our	O
findings	O
","	O
we	O
hypothesize	O
that	O
the	O
mechanism	O
of	O
ADMA	B-Chemical
damage	O
to	O
the	O
BRB	O
is	O
partly	O
mediated	O
by	O
ROS	B-Chemical
and	O
/	O
or	O
RAS	O
pathways	O
.	O
In	O
summary	O
","	O
ADMA	B-Chemical
can	O
inhibit	O
BRCEC	O
proliferation	O
","	O
increase	O
intracellular	O
ROS	B-Chemical
generation	O
","	O
increase	O
cell	O
permeability	O
and	O
in	O
BRCECs	O
","	O
can	O
reduce	O
levels	O
of	O
the	O
tight	O
-	O
junction	O
protein	O
occludin	O
and	O
increase	O
ICAM	O
-	O
1	O
expression	O
.	O
Further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
mechanisms	O
underlying	O
the	O
effects	O
of	O
ADMA	B-Chemical
in	O
diabetes	O
-	O
induced	O
BRB	O
breakdown	O
and	O
the	O
roles	O
of	O
ACEI	O
","	O
ARB	O
","	O
and	O
antioxidants	O
in	O
the	O
control	O
of	O
retinal	O
endothelial	O
barrier	O
function	O
under	O
diabetic	O
conditions	O
.	O
References	O
Porcine	O
dentin	O
sialoprotein	O
glycosylation	O
and	O
glycosaminoglycan	B-Chemical
attachments	O
Background	O
Dentin	O
sialophosphoprotein	O
(	O
Dspp	O
)	O
is	O
a	O
multidomain	O
","	O
secreted	O
protein	O
that	O
is	O
critical	O
for	O
the	O
formation	O
of	O
tooth	O
dentin	O
.	O
Mutations	O
in	O
DSPP	O
cause	O
inherited	O
dentin	O
defects	O
categorized	O
as	O
dentin	O
dysplasia	O
type	O
II	O
and	O
dentinogenesis	O
imperfecta	O
type	O
II	O
and	O
type	O
III	O
.	O
Dentin	O
sialoprotein	O
(	O
Dsp	O
"),"	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
dentin	O
sialophosphoprotein	O
(	O
Dspp	O
"),"	O
is	O
a	O
highly	O
glycosylated	O
proteoglycan	O
","	O
but	O
little	O
is	O
known	O
about	O
the	O
number	O
","	O
character	O
","	O
and	O
attachment	O
sites	O
of	O
its	O
carbohydrate	B-Chemical
moieties	O
.	O
Results	O
To	O
identify	O
its	O
carbohydrate	B-Chemical
attachment	O
sites	O
we	O
isolated	O
Dsp	O
from	O
developing	O
porcine	O
molars	O
and	O
digested	O
it	O
with	O
endoproteinase	O
Glu	O
-	O
C	O
or	O
pronase	O
","	O
fractionated	O
the	O
digestion	O
products	O
","	O
identified	O
fractions	O
containing	O
glycosylated	O
peptides	O
using	O
a	O
phenol	B-Chemical
sulfuric	I-Chemical
acid	I-Chemical
assay	O
","	O
and	O
characterized	O
the	O
glycopeptides	O
by	O
N	O
-	O
terminal	O
sequencing	O
","	O
amino	B-Chemical
acid	I-Chemical
analyses	O
","	O
or	O
LC	O
/	O
MSMS	O
.	O
To	O
determine	O
the	O
average	O
number	O
of	O
sialic	B-Chemical
acid	I-Chemical
attachments	O
per	O
N	O
-	O
glycosylation	O
","	O
we	O
digested	O
Dsp	O
with	O
glycopeptidase	O
A	O
","	O
labeled	O
the	O
released	O
N	O
-	O
glycosylations	O
with	O
2	B-Chemical
-	I-Chemical
aminobenzoic	I-Chemical
acid	I-Chemical
","	O
and	O
quantified	O
the	O
moles	O
of	O
released	O
glycosylations	O
by	O
comparison	O
to	O
labeled	O
standards	O
of	O
known	O
concentration	O
.	O
Sialic	B-Chemical
acid	I-Chemical
was	O
released	O
by	O
sialidase	O
digestion	O
and	O
quantified	O
by	O
measuring	O
Î²	B-Chemical
-	I-Chemical
NADH	I-Chemical
reduction	O
of	O
pyruvic	B-Chemical
acid	I-Chemical
","	O
which	O
was	O
generated	O
stoichiometrically	O
from	O
sialic	B-Chemical
acid	I-Chemical
by	O
aldolase	O
.	O
To	O
determine	O
its	O
forms	O
","	O
sialic	B-Chemical
acid	I-Chemical
released	O
by	O
sialidase	O
digestion	O
was	O
labeled	O
with	O
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
diamino	I-Chemical
-	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
methyleneoxybenzene	I-Chemical
(	O
DMB	B-Chemical
)	O
and	O
compared	O
to	O
a	O
DMB	B-Chemical
-	O
labeled	O
sialic	B-Chemical
acid	I-Chemical
reference	O
panel	O
by	O
RP	O
-	O
HPLC	O
.	O
To	O
determine	O
the	O
composition	O
of	O
Dsp	O
glycosaminoglycan	B-Chemical
(	O
GAG	B-Chemical
)	O
attachments	O
","	O
we	O
digested	O
Dsp	O
with	O
chondroitinase	O
ABC	O
and	O
compared	O
the	O
chromotagraphic	O
profiles	O
of	O
the	O
released	O
disaccharides	B-Chemical
to	O
commercial	O
standards	O
.	O
N	O
-	O
glycosylations	O
were	O
identified	O
at	O
Asn37	B-Chemical
","	O
Asn77	B-Chemical
","	O
Asn136	B-Chemical
","	O
Asn155	B-Chemical
","	O
Asn161	B-Chemical
","	O
and	O
Asn176	B-Chemical
.	O
Dsp	O
averages	O
one	O
sialic	B-Chemical
acid	I-Chemical
per	O
N	O
-	O
glycosylation	O
","	O
which	O
is	O
always	O
in	O
the	O
form	O
of	O
N	B-Chemical
-	I-Chemical
acetylneuraminic	I-Chemical
acid	I-Chemical
.	O
O	O
-	O
glycosylations	O
were	O
tentatively	O
assigned	O
at	O
Thr200	B-Chemical
","	O
Thr216	B-Chemical
and	O
Thr316	B-Chemical
.	O
Porcine	O
Dsp	O
GAG	B-Chemical
attachments	O
were	O
found	O
at	O
Ser238	B-Chemical
and	O
Ser250	B-Chemical
and	O
were	O
comprised	O
of	O
chondroitin	B-Chemical
6	I-Chemical
-	I-Chemical
sulfate	I-Chemical
and	O
chondroitin	B-Chemical
4	I-Chemical
-	I-Chemical
sulfate	I-Chemical
in	O
a	O
ratio	O
of	O
7	O
to	O
3	O
","	O
respectively	O
.	O
Conclusions	O
The	O
distribution	O
of	O
porcine	O
Dsp	O
posttranslational	O
modifications	O
indicate	O
that	O
porcine	O
Dsp	O
has	O
an	O
N	O
-	O
terminal	O
domain	O
with	O
at	O
least	O
six	O
N	O
-	O
glycosylations	O
and	O
a	O
C	O
-	O
terminal	O
domain	O
with	O
two	O
GAG	B-Chemical
attachments	O
and	O
at	O
least	O
two	O
O	O
-	O
glycosylations	O
.	O
Background	O
Type	O
I	O
collagen	O
and	O
proteolytic	O
cleavage	O
products	O
of	O
dentin	O
sialophosphoprotein	O
(	O
Dspp	O
)	O
are	O
the	O
predominant	O
proteins	O
in	O
tooth	O
dentin	O
.	O
Collagen	O
constitutes	O
about	O
90	O
%	O
of	O
the	O
dentin	O
organic	O
matrix	O
","	O
while	O
Dspp	O
-	O
derived	O
proteins	O
make	O
up	O
more	O
than	O
half	O
of	O
the	O
dentin	O
noncollagenous	O
proteins	O
.	O
Genetic	O
studies	O
have	O
demonstrated	O
the	O
importance	O
of	O
the	O
genes	O
encoding	O
type	O
I	O
collagen	O
(	O
COL1A1	O
","	O
17q21	O
.	O
31	O
-	O
q22	O
;	O
COL1A2	O
","	O
7q22	O
.	O
1	O
)	O
and	O
DSPP	O
(	O
4q21	O
.	O
3	O
)	O
for	O
proper	O
human	O
dentin	O
formation	O
.	O
Inherited	O
dentin	O
defects	O
are	O
classified	O
as	O
dentinogenesis	O
imperfecta	O
(	O
DGI	O
)	O
types	O
I	O
","	O
II	O
","	O
or	O
III	O
","	O
or	O
dentin	O
dysplasia	O
(	O
DD	O
)	O
types	O
I	O
and	O
II	O
.	O
DGI	O
type	O
I	O
is	O
osteogenesis	O
imperfecta	O
with	O
dentinogenesis	O
imperfecta	O
and	O
is	O
caused	O
by	O
mutations	O
in	O
COL1A1	O
and	O
COL1A2	O
.	O
DD	O
type	O
II	O
and	O
DGI	O
types	O
II	O
and	O
type	O
III	O
are	O
caused	O
by	O
mutations	O
in	O
DSPP	O
.	O
There	O
are	O
other	O
potential	O
candidate	O
genes	O
for	O
these	O
disorders	O
","	O
but	O
only	O
DSPP	O
mutations	O
have	O
been	O
found	O
in	O
DD	O
or	O
DGI	O
kindreds	O
.	O
Dentin	O
sialophosphoprotein	O
(	O
Dspp	O
)	O
is	O
a	O
chimeric	O
protein	O
that	O
is	O
cleaved	O
by	O
proteases	O
into	O
its	O
component	O
parts	O
","	O
which	O
are	O
considered	O
to	O
be	O
two	O
parts	O
in	O
rodents	O
and	O
three	O
in	O
pig	O
.	O
The	O
order	O
of	O
the	O
major	O
domains	O
of	O
Dspp	O
is	O
Dsp	O
-	O
Dgp	O
-	O
Dpp	O
","	O
where	O
Dsp	O
is	O
dentin	O
sialoprotein	O
","	O
Dgp	O
is	O
dentin	O
glycoprotein	O
","	O
and	O
Dpp	O
is	O
dentin	O
phosphoprotein	O
.	O
Dspp	O
is	O
expressed	O
predominantly	O
by	O
odontoblasts	O
","	O
but	O
is	O
detected	O
in	O
bone	O
at	O
trace	O
levels	O
(	O
0	O
.	O
25	O
%	O
of	O
the	O
level	O
in	O
dentin	O
).	O
Currently	O
","	O
the	O
human	O
expressed	O
sequence	O
tag	O
database	O
for	O
DSPP	O
expression	O
(	O
Hs	O
.	O
678914	O
)	O
shows	O
zero	O
DSPP	O
transcripts	O
out	O
of	O
71	O
","	O
655	O
total	O
mRNA	O
transcripts	O
characterized	O
from	O
bone	O
.	O
Dspp	O
is	O
a	O
member	O
of	O
the	O
secretory	O
calcium	O
-	O
binding	O
phosphoprotein	O
(	O
SCPP	O
)	O
genes	O
","	O
which	O
are	O
involved	O
in	O
the	O
mineralization	O
of	O
bone	O
","	O
dentin	O
","	O
and	O
enamel	O
.	O
The	O
SCPP	O
family	O
initially	O
arose	O
from	O
a	O
single	O
ancestral	O
gene	O
:	O
SPARCL1	O
or	O
secreted	O
protein	O
","	O
acidic	O
","	O
cysteine	O
-	O
rich	O
like	O
1	O
gene	O
.	O
The	O
common	O
features	O
of	O
SCPP	O
genes	O
are	O
few	O
:	O
their	O
second	O
exon	O
encodes	O
a	O
short	O
signal	O
peptide	O
(~	O
15	O
amino	B-Chemical
acids	I-Chemical
in	O
length	O
)	O
plus	O
the	O
first	O
two	O
amino	B-Chemical
acids	I-Chemical
of	O
the	O
secreted	O
protein	O
.	O
The	O
second	O
coding	O
exon	O
generally	O
encodes	O
a	O
phosphorylation	O
site	O
SXE	O
/	O
S	O
(	O
p	O
)	O
for	O
Golgi	O
casein	O
kinase	O
.	O
All	O
of	O
the	O
introns	O
are	O
type	O
0	O
","	O
that	O
is	O
","	O
the	O
introns	O
do	O
not	O
interrupt	O
codons	O
but	O
are	O
all	O
placed	O
between	O
codon	O
triplets	O
.	O
The	O
SCPPs	O
divide	O
into	O
two	O
groups	O
based	O
upon	O
their	O
distinctive	O
amino	B-Chemical
acid	I-Chemical
compositions	O
.	O
Acidic	O
SCPPs	O
are	O
rich	O
(	O
over	O
25	O
%)	O
in	O
glutamate	B-Chemical
","	O
aspartate	B-Chemical
","	O
and	O
phosphoserine	B-Chemical
.	O
Proline	B-Chemical
and	O
glutamine	B-Chemical
-	O
rich	O
SCPPs	O
are	O
more	O
than	O
20	O
%	O
proline	B-Chemical
and	O
glutamine	B-Chemical
.	O
Dspp	O
belongs	O
to	O
the	O
acidic	O
group	O
","	O
which	O
is	O
also	O
known	O
as	O
the	O
dentin	O
/	O
bone	O
group	O
or	O
the	O
SIBLINGs	O
","	O
for	O
small	O
integrin	O
-	O
binding	O
ligand	O
","	O
N	O
-	O
linked	O
glycoproteins	O
.	O
The	O
second	O
coding	O
exon	O
for	O
Dspp	O
(	O
exon	O
3	O
)	O
is	O
unusual	O
for	O
the	O
SCPP	O
family	O
.	O
In	O
the	O
pig	O
","	O
this	O
exon	O
encodes	O
the	O
protein	O
segment	O
from	O
Val3	B-Chemical
to	O
Gln31	B-Chemical
.	O
None	O
of	O
the	O
amino	B-Chemical
acids	I-Chemical
encoded	O
by	O
exon	O
3	O
are	O
in	O
the	O
appropriate	O
context	O
for	O
phosphorylation	O
or	O
glycosylation	O
.	O
Skipping	O
exon	O
3	O
would	O
not	O
alter	O
the	O
reading	O
frame	O
","	O
but	O
human	O
mutations	O
that	O
cause	O
the	O
skipping	O
of	O
exon	O
3	O
cause	O
dominant	O
negative	O
effects	O
that	O
result	O
in	O
dentin	O
malformations	O
","	O
possibly	O
due	O
to	O
failure	O
to	O
recognize	O
or	O
cleave	O
the	O
signal	O
peptide	O
.	O
All	O
six	O
of	O
the	O
reported	O
intronic	O
mutations	O
in	O
DSPP	O
that	O
cause	O
inherited	O
dentin	O
defects	O
are	O
at	O
the	O
end	O
of	O
intron	O
2	O
or	O
beginning	O
of	O
intron	O
3	O
.	O
Perhaps	O
exon	O
3	O
was	O
acquired	O
by	O
exon	O
capture	O
after	O
the	O
Dspp	O
ancestral	O
gene	O
duplicated	O
from	O
another	O
SCPP	O
gene	O
and	O
is	O
not	O
descended	O
from	O
the	O
short	O
prototypical	O
second	O
coding	O
exon	O
that	O
encodes	O
a	O
serine	B-Chemical
that	O
gets	O
phosphorylated	O
.	O
Exon	O
4	O
encodes	O
the	O
bulk	O
of	O
dentin	O
sialoprotein	O
(	O
Dsp	O
"),"	O
from	O
Asp32	B-Chemical
to	O
Lys368	B-Chemical
.	O
Previously	O
we	O
isolated	O
and	O
characterized	O
a	O
porcine	O
Dsp	O
only	O
transcript	O
.	O
This	O
mRNA	O
transcript	O
terminated	O
at	O
a	O
polyadenylation	O
/	O
cleavage	O
site	O
in	O
intron	O
4	O
.	O
The	O
porcine	O
Dsp	O
cleavage	O
product	O
(	O
Ile1	B-Chemical
to	O
Arg376	B-Chemical
)	O
of	O
Dspp	O
is	O
a	O
highly	O
glycosylated	O
proteoglycan	O
that	O
forms	O
covalent	O
dimers	O
.	O
The	O
Dgp	O
cleavage	O
product	O
(	O
Ser377	B-Chemical
to	O
Gly457	B-Chemical
)	O
of	O
Dspp	O
is	O
encoded	O
by	O
the	O
5	O
'	O
part	O
of	O
exon	O
5	O
.	O
Dgp	O
","	O
which	O
has	O
so	O
far	O
only	O
been	O
described	O
in	O
pig	O
","	O
has	O
a	O
single	O
glycosylation	O
(	O
Asn382	B-Chemical
)	O
and	O
four	O
phosphoserines	B-Chemical
(	O
Ser438	B-Chemical
","	O
Ser440	B-Chemical
","	O
Ser442	B-Chemical
","	O
Ser447	B-Chemical
)	O
that	O
are	O
in	O
a	O
highly	O
conserved	O
region	O
near	O
its	O
carboxyl	O
-	O
terminus	O
.	O
Dentin	O
phosphoprotein	O
(	O
Dpp	O
)	O
is	O
the	O
highly	O
phosphorylated	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
Dspp	O
","	O
and	O
is	O
encoded	O
by	O
the	O
rest	O
of	O
exon	O
5	O
.	O
The	O
coding	O
region	O
of	O
Dpp	O
varies	O
in	O
length	O
among	O
different	O
individuals	O
without	O
affecting	O
function	O
.	O
Astacin	O
proteases	O
","	O
such	O
as	O
Bmp	O
-	O
1	O
cleave	O
Dpp	O
from	O
Dspp	O
","	O
while	O
Mmp	O
-	O
20	O
separates	O
Dsp	O
and	O
Dgp	O
.	O
Dentin	O
sialoprotein	O
(	O
Dsp	O
)	O
was	O
previously	O
thought	O
to	O
be	O
only	O
a	O
minor	O
component	O
of	O
dentin	O
","	O
perhaps	O
only	O
10	O
%	O
as	O
abundant	O
as	O
dentin	O
phosphoprotein	O
(	O
Dpp	O
"),"	O
and	O
later	O
thought	O
to	O
be	O
a	O
nonfunctional	O
pro	O
-	O
domain	O
that	O
was	O
removed	O
by	O
proteases	O
to	O
activate	O
Dpp	O
.	O
Recently	O
","	O
however	O
it	O
has	O
been	O
determined	O
that	O
Dsp	O
and	O
Dpp	O
are	O
expressed	O
in	O
stoichiometric	O
amounts	O
as	O
the	O
N	O
-	O
terminal	O
and	O
C	O
-	O
terminal	O
domains	O
of	O
Dspp	O
and	O
are	O
found	O
in	O
equal	O
molar	O
amounts	O
in	O
dentin	O
.	O
Dspp	O
null	O
mice	O
show	O
severe	O
dentin	O
malformations	O
that	O
resemble	O
those	O
observed	O
in	O
human	O
DGI	O
-	O
III	O
.	O
Transgenic	O
expression	O
of	O
the	O
Dsp	O
domain	O
in	O
the	O
Dspp	O
null	O
background	O
partially	O
","	O
but	O
substantially	O
","	O
restores	O
the	O
dentin	O
phenotype	O
.	O
The	O
widening	O
of	O
predentin	O
observed	O
in	O
the	O
Dspp	O
knockout	O
as	O
well	O
as	O
the	O
reduced	O
volume	O
of	O
mineralized	O
dentin	O
are	O
recovered	O
","	O
indicating	O
that	O
both	O
Dsp	O
and	O
Dpp	O
are	O
necessary	O
for	O
normal	O
dentin	O
mineralization	O
.	O
The	O
mechanisms	O
through	O
which	O
Dsp	O
contributes	O
to	O
dentin	O
formation	O
are	O
unknown	O
.	O
Characterization	O
of	O
its	O
posttranslational	O
modifications	O
(	O
PTMs	O
)	O
is	O
an	O
important	O
step	O
in	O
understanding	O
its	O
function	O
.	O
Results	O
Characterization	O
of	O
Dsp	O
carbohydrate	B-Chemical
attachment	O
sites	O
We	O
previously	O
showed	O
that	O
porcine	O
Dsp	O
is	O
a	O
proteoglycan	O
and	O
that	O
porcine	O
dentin	O
extracts	O
contain	O
the	O
intact	O
Dsp	O
(	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
Dspp	O
"),"	O
as	O
well	O
as	O
lower	O
molecular	O
weight	O
(	O
LMW	O
)	O
cleavage	O
products	O
of	O
Dsp	O
.	O
It	O
was	O
also	O
known	O
that	O
Dsp	O
has	O
glycosylations	O
rich	O
in	O
sialic	B-Chemical
acid	I-Chemical
and	O
that	O
porcine	O
Dsp	O
has	O
eight	O
potential	O
N	O
-	O
glycosylation	O
sites	O
based	O
upon	O
analysis	O
of	O
its	O
primary	O
amino	B-Chemical
acid	I-Chemical
sequence	O
.	O
To	O
identify	O
attachment	O
sites	O
and	O
to	O
better	O
characterize	O
the	O
glycosaminoglycan	B-Chemical
(	O
GAG	B-Chemical
)	O
and	O
other	O
carbohydrate	B-Chemical
attachments	O
in	O
porcine	O
Dsp	O
","	O
we	O
first	O
targeted	O
the	O
small	O
glycosylated	O
Dsp	O
cleavage	O
products	O
(	O
LMW	O
-	O
Dsp	O
)	O
from	O
the	O
N	O
-	O
terminal	O
region	O
of	O
Dsp	O
.	O
As	O
none	O
of	O
the	O
dentin	O
extracts	O
are	O
perfectly	O
homogeneous	O
with	O
respect	O
to	O
their	O
contents	O
","	O
we	O
refer	O
to	O
each	O
extract	O
that	O
we	O
characterized	O
using	O
a	O
notation	O
that	O
reflects	O
the	O
extraction	O
and	O
fractionation	O
steps	O
that	O
produced	O
it	O
(	O
see	O
methods	O
).	O
Routine	O
characterizations	O
of	O
these	O
fractions	O
(	O
SDS	B-Chemical
-	O
PAGE	O
and	O
Western	O
blots	O
)	O
are	O
provided	O
in	O
additional	O
files	O
online	O
.	O
Demineralized	O
dentin	O
powder	O
was	O
subjected	O
to	O
a	O
series	O
of	O
extraction	O
procedures	O
.	O
A	O
flow	O
chart	O
of	O
the	O
extractions	O
is	O
provided	O
in	O
Figure	O
1	O
.	O
Simple	O
analyses	O
of	O
the	O
extracts	O
(	O
SDS	B-Chemical
-	O
PAGE	O
stained	O
with	O
CBB	B-Chemical
and	O
stains	O
-	O
all	O
and	O
a	O
Dsp	O
immunoblot	O
)	O
are	O
shown	O
in	O
Additional	O
file	O
1	O
.	O
Intact	O
Dsp	O
proteoglycan	O
and	O
its	O
cleavage	O
products	O
containing	O
GAG	B-Chemical
attachments	O
segregated	O
in	O
the	O
acid	O
/	O
NaCl	B-Chemical
or	O
AN	O
extract	O
","	O
which	O
was	O
further	O
fractionated	O
by	O
size	O
exclusion	O
chromatography	O
.	O
Dsp	O
degradation	O
products	O
containing	O
the	O
GAG	B-Chemical
attachments	O
displayed	O
a	O
stains	O
-	O
all	O
positive	O
smear	O
migrating	O
between	O
50	O
-	O
to	O
100	O
-	O
kDa	O
on	O
SDS	B-Chemical
-	O
PAGE	O
","	O
which	O
were	O
collected	O
in	O
the	O
third	O
(	O
ANS1	O
/	O
2	O
-	O
R3	O
)	O
of	O
five	O
RP	O
-	O
HPLC	O
fractions	O
(	O
Additional	O
file	O
2	O
).	O
ANS1	O
/	O
2	O
-	O
R3	O
was	O
resolved	O
into	O
two	O
final	O
fractions	O
by	O
repeating	O
the	O
RP	O
-	O
HPLC	O
run	O
.	O
These	O
two	O
fractions	O
(	O
ANS1	O
/	O
2	O
-	O
R3a	O
and	O
ANS1	O
/	O
2	O
-	O
R3b	O
)	O
were	O
digested	O
with	O
chondroitinase	O
ABC	O
to	O
degrade	O
their	O
GAG	B-Chemical
attachments	O
","	O
which	O
converted	O
the	O
proteoglycan	O
smears	O
on	O
SDS	B-Chemical
-	O
PAGE	O
into	O
small	O
peptides	O
(	O
Figure	O
2A	O
)	O
that	O
contained	O
no	O
disulfide	B-Chemical
bridges	O
","	O
as	O
their	O
mobilities	O
were	O
not	O
affected	O
by	O
the	O
presence	O
or	O
absence	O
of	O
Î²	B-Chemical
-	I-Chemical
mercaptoethanol	I-Chemical
(	O
Figure	O
2B	O
).	O
Chondroitinase	O
ABC	O
digestion	O
converted	O
ANS1	O
/	O
2	O
-	O
R3a	O
into	O
four	O
peptides	O
and	O
ANS1	O
/	O
2	O
-	O
R3b	O
into	O
two	O
peptides	O
having	O
apparent	O
molecular	O
weights	O
ranging	O
from	O
8	O
-	O
to	O
25	O
-	O
kDa	O
(	O
Figure	O
2C	O
).	O
These	O
six	O
peptides	O
were	O
excised	O
and	O
eluted	O
from	O
the	O
gel	O
(	O
Figure	O
2D	O
)	O
and	O
then	O
characterized	O
by	O
N	O
-	O
terminal	O
sequencing	O
and	O
by	O
amino	B-Chemical
acid	I-Chemical
analysis	O
(	O
Figure	O
2E	O
).	O
The	O
N	O
-	O
terminal	O
sequence	O
and	O
amino	B-Chemical
acid	I-Chemical
compositions	O
allowed	O
the	O
complete	O
amino	B-Chemical
acid	I-Chemical
sequences	O
of	O
the	O
six	O
peptides	O
to	O
be	O
deduced	O
(	O
Figure	O
2F	O
).	O
Dentin	O
power	O
extraction	O
diagram	O
.	O
The	O
extracts	O
","	O
in	O
bold	O
","	O
are	O
the	O
first	O
guanidine	B-Chemical
extract	O
(	O
G1	O
"),"	O
first	O
guanidine	B-Chemical
pellet	O
(	O
G1P	O
"),"	O
acid	O
(	O
A	O
"),"	O
acid	O
salt	O
(	O
AN	O
"),"	O
Tris	B-Chemical
salt	I-Chemical
(	O
TN	B-Chemical
"),"	O
residual	O
insoluble	O
material	O
(	O
RIM	O
"),"	O
second	O
guanidine	B-Chemical
extract	O
(	O
G2	O
"),"	O
and	O
the	O
second	O
guanidine	B-Chemical
pellet	O
(	O
G2P	O
).	O
Selected	O
extractions	O
were	O
fractionated	O
to	O
isolate	O
Dspp	O
cleavage	O
products	O
.	O
The	O
AN	O
extract	O
was	O
fractionated	O
by	O
size	O
exclusion	O
(	O
S	O
)	O
and	O
RP	O
-	O
HPLC	O
(	O
R	O
)	O
to	O
yield	O
HMW	O
Dsp	O
in	O
fractions	O
ANS1	O
/	O
2	O
-	O
R3	O
","	O
ANS1	O
/	O
2	O
-	O
R4	O
","	O
and	O
ANS1	O
/	O
2	O
-	O
R5	O
.	O
The	O
A	O
extract	O
was	O
fractionated	O
by	O
size	O
exclusion	O
and	O
RP	O
-	O
HPLC	O
to	O
yield	O
LMW	O
Dsp	O
(	O
AS2R	O
-	O
g	O
).	O
Chondroitinase	O
activity	O
was	O
detected	O
in	O
the	O
second	O
ion	O
exchange	O
(	O
Q	O
)	O
fraction	O
of	O
the	O
G2	O
extact	O
(	O
G2Q2	O
).	O
Characterization	O
of	O
small	O
","	O
highly	O
glycosylated	O
Dsp	O
peptides	O
.	O
A	O
:	O
4	O
-	O
20	O
%	O
Tris	B-Chemical
/	O
glycine	B-Chemical
gel	O
stained	O
with	O
stains	O
-	O
all	O
showing	O
fraction	O
ANS1	O
/	O
2R3	O
-	O
a	O
and	O
-	O
b	O
before	O
(-)	O
and	O
after	O
(+)	O
digestion	O
with	O
chondroitinase	O
ABC	O
.	O
The	O
stains	O
-	O
all	O
positive	O
proteoglycan	O
smears	O
coalesced	O
into	O
a	O
group	O
of	O
protein	O
bands	O
having	O
apparent	O
molecular	O
weights	O
ranging	O
from	O
8	O
to	O
20	O
-	O
kDa	O
.	O
B	O
:	O
4	O
-	O
20	O
%	O
Tris	B-Chemical
/	O
glycine	B-Chemical
gel	O
stained	O
with	O
stains	O
-	O
all	O
showing	O
fraction	O
ANS1	O
/	O
2R3	O
-	O
a	O
and	O
-	O
b	O
without	O
(-)	O
and	O
with	O
(+)	O
the	O
reducing	O
agent	O
Î²	B-Chemical
-	I-Chemical
mercaptoethanol	I-Chemical
.	O
The	O
mobilities	O
of	O
the	O
bands	O
did	O
not	O
change	O
indicating	O
the	O
absence	O
of	O
disulfide	B-Chemical
bridges	O
.	O
C	O
:	O
4	O
-	O
20	O
%	O
Tris	B-Chemical
/	O
glycine	B-Chemical
gel	O
stained	O
with	O
stains	O
-	O
all	O
showing	O
the	O
bands	O
from	O
ANS1	O
/	O
2R3	O
-	O
a	O
(	O
3a	O
)	O
and	O
ANS1	O
/	O
2R3	O
-	O
b	O
(	O
3b	O
)	O
following	O
chondroitinase	O
ABC	O
digestion	O
that	O
were	O
excised	O
from	O
the	O
gel	O
and	O
characterized	O
by	O
amino	B-Chemical
acid	I-Chemical
analysis	O
and	O
N	O
-	O
terminal	O
sequencing	O
.	O
D	O
:	O
18	O
%	O
Tris	B-Chemical
/	O
glycine	B-Chemical
gel	O
stained	O
with	O
stains	O
-	O
all	O
showing	O
the	O
bands	O
following	O
electroelution	O
.	O
E	O
:	O
Results	O
of	O
amino	B-Chemical
acid	I-Chemical
analyses	O
showing	O
the	O
percentage	O
(%)	O
of	O
each	O
amino	B-Chemical
acid	I-Chemical
in	O
the	O
6	O
peptides	O
and	O
the	O
deduced	O
numbers	O
(#)	O
of	O
each	O
amino	B-Chemical
acid	I-Chemical
.	O
The	O
percentages	O
were	O
converted	O
into	O
number	O
of	O
amino	B-Chemical
acids	I-Chemical
by	O
dividing	O
all	O
of	O
the	O
percentages	O
by	O
the	O
lowest	O
meaningful	O
percentage	O
","	O
which	O
corresponded	O
to	O
the	O
percentage	O
of	O
a	O
single	O
amino	B-Chemical
acid	I-Chemical
.	O
F	O
:	O
The	O
complete	O
sequences	O
of	O
each	O
peptide	O
.	O
The	O
Edman	O
sequences	O
are	O
underlined	O
with	O
blank	O
cycles	O
indicated	O
by	O
an	O
x	O
Peptides	O
1	O
","	O
2	O
","	O
3	O
and	O
6	O
contained	O
the	O
putative	O
GAG	B-Chemical
attachment	O
site	O
at	O
Ser238	B-Chemical
and	O
the	O
amino	B-Chemical
acid	I-Chemical
compositions	O
for	O
each	O
of	O
these	O
proteins	O
showed	O
one	O
fewer	O
serine	B-Chemical
than	O
expected	O
.	O
N	O
-	O
terminal	O
sequence	O
for	O
peptide	O
3	O
gave	O
a	O
blank	O
cylce	O
for	O
Ser238	B-Chemical
.	O
The	O
other	O
N	O
-	O
terminal	O
sequences	O
did	O
not	O
reach	O
Ser238	B-Chemical
","	O
but	O
the	O
full	O
-	O
length	O
of	O
each	O
peptide	O
could	O
be	O
inferred	O
from	O
its	O
amino	B-Chemical
acid	I-Chemical
composition	O
.	O
A	O
blank	O
cycle	O
strongly	O
suggests	O
the	O
presence	O
of	O
a	O
posttranslational	O
modification	O
","	O
but	O
additional	O
evidence	O
is	O
generally	O
required	O
to	O
support	O
this	O
conclusion	O
.	O
In	O
addition	O
","	O
the	O
four	O
peptides	O
containing	O
Ser238	B-Chemical
were	O
only	O
11	O
or	O
12	O
amino	B-Chemical
acids	I-Chemical
in	O
length	O
","	O
but	O
migrated	O
at	O
15	O
17	O
19	O
-	O
and	O
20	O
-	O
kDa	O
on	O
SDS	B-Chemical
-	O
PAGE	O
","	O
suggesting	O
they	O
retained	O
variable	O
lengths	O
of	O
GAG	B-Chemical
attachment	O
following	O
the	O
chondroitinase	O
ABC	O
digestion	O
.	O
From	O
these	O
data	O
we	O
can	O
safely	O
conclude	O
that	O
Ser238	B-Chemical
is	O
a	O
GAG	B-Chemical
attachment	O
site	O
;	O
however	O
","	O
no	O
information	O
from	O
this	O
experiment	O
was	O
gained	O
on	O
the	O
other	O
putative	O
GAG	B-Chemical
attachment	O
sites	O
on	O
porcine	O
Dsp	O
(	O
at	O
Ser220	B-Chemical
and	O
Ser250	B-Chemical
).	O
No	O
conclusions	O
could	O
be	O
made	O
from	O
the	O
analyses	O
of	O
peptides	O
4	O
and	O
5	O
.	O
A	O
blank	O
cycle	O
was	O
observed	O
at	O
Thr200	B-Chemical
","	O
but	O
the	O
amino	B-Chemical
acid	I-Chemical
composition	O
suggested	O
that	O
this	O
position	O
was	O
a	O
threonine	B-Chemical
","	O
and	O
therefore	O
not	O
necessarily	O
modified	O
.	O
To	O
gain	O
additional	O
information	O
on	O
posttranslational	O
modifications	O
in	O
the	O
GAG	B-Chemical
attachment	O
region	O
of	O
Dsp	O
","	O
fraction	O
ANS1	O
/	O
2	O
-	O
R3	O
was	O
digested	O
with	O
pronase	O
.	O
Larger	O
digestion	O
products	O
from	O
the	O
pronase	O
digestion	O
were	O
recovered	O
by	O
size	O
exclusion	O
chromatography	O
in	O
the	O
first	O
eluted	O
fraction	O
(	O
ANS1	O
/	O
2R3	O
-	O
Pr1	O
)	O
(	O
Additional	O
file	O
3	O
).	O
ANS1	O
/	O
2R3	O
-	O
Pr1	O
resolved	O
into	O
26	O
fractions	O
by	O
RP	O
-	O
HPLC	O
and	O
each	O
was	O
assayed	O
for	O
the	O
presence	O
of	O
glycosylations	O
using	O
the	O
phenol	B-Chemical
-	O
sulfuric	B-Chemical
acid	I-Chemical
assay	O
.	O
Glycosylated	O
peptides	O
were	O
detected	O
in	O
eight	O
of	O
the	O
RP	O
-	O
HPLC	O
fractions	O
:	O
ANS1	O
/	O
2R3Pr1	O
-	O
d	O
","	O
-	O
e	O
","	O
-	O
h	O
through	O
-	O
l	O
","	O
and	O
-	O
p	O
(	O
Additional	O
file	O
3	O
).	O
To	O
identify	O
peptides	O
with	O
GAG	B-Chemical
attachments	O
","	O
the	O
eight	O
glycosylated	O
fractions	O
were	O
digested	O
with	O
chondroitinase	O
ABC	O
.	O
The	O
peptides	O
were	O
separated	O
from	O
the	O
digested	O
carbohydrate	B-Chemical
by	O
ethanol	B-Chemical
precipitation	O
and	O
each	O
supernatant	O
(	O
containing	O
the	O
liberated	O
GAG	B-Chemical
chains	O
)	O
was	O
analyzed	O
by	O
phenol	B-Chemical
sulfuric	I-Chemical
acid	I-Chemical
assay	O
.	O
Fractions	O
positive	O
for	O
glycan	B-Chemical
attachments	O
(-	O
d	O
","	O
-	O
h	O
","	O
-	O
i	O
","	O
-	O
j	O
","	O
and	O
-	O
p	O
)	O
were	O
rechromatographed	O
using	O
the	O
same	O
C	O
-	O
18	O
column	O
that	O
was	O
used	O
prior	O
to	O
the	O
chondroitinase	O
ABC	O
digestion	O
.	O
Rechromatographed	O
fractions	O
showing	O
a	O
shift	O
in	O
their	O
retention	O
times	O
relative	O
to	O
same	O
sample	O
prior	O
to	O
chondroitinase	O
ABC	O
digestion	O
were	O
characterized	O
by	O
N	O
-	O
terminal	O
sequencing	O
(	O
Figure	O
3	O
).	O
One	O
peptide	O
(	O
ANS1	O
/	O
2R3Pr1p	O
-	O
P2	O
)	O
gave	O
a	O
blank	O
cycle	O
for	O
Ser238	B-Chemical
","	O
while	O
three	O
peptides	O
(	O
ANS1	O
/	O
2R3Pr1d	O
-	O
D	O
","	O
ANS1	O
/	O
2R3Pr1h	O
-	O
H	O
","	O
and	O
ANS1	O
/	O
2R3Pr1j	O
-	O
J1	O
)	O
gave	O
blank	O
cycles	O
for	O
Ser250	B-Chemical
.	O
These	O
data	O
demonstrate	O
that	O
Ser238	B-Chemical
and	O
Ser250	B-Chemical
are	O
the	O
GAG	B-Chemical
attachment	O
sites	O
for	O
porcine	O
Dsp	O
.	O
The	O
N	O
-	O
terminal	O
sequences	O
of	O
the	O
peptides	O
in	O
fractions	O
ANS1	O
/	O
2R3Pr1	O
-	O
k	O
and	O
ANS1	O
/	O
2R3Pr1	O
-	O
l	O
","	O
which	O
were	O
negative	O
for	O
GAG	B-Chemical
chains	O
based	O
upon	O
the	O
phenol	B-Chemical
sulfuric	I-Chemical
acid	I-Chemical
assay	O
","	O
were	O
211EETGVxSGGSGA	O
and	O
311TDGDNxSK	O
","	O
respectively	O
.	O
The	O
blank	O
cycles	O
for	O
Thr216	B-Chemical
and	O
Thr316	B-Chemical
suggest	O
these	O
residues	O
are	O
modified	O
","	O
but	O
these	O
sequences	O
also	O
show	O
that	O
Ser220	B-Chemical
and	O
Asn315	B-Chemical
(	O
which	O
did	O
not	O
give	O
blank	O
cycles	O
)	O
are	O
not	O
modified	O
","	O
despite	O
their	O
being	O
in	O
appropriate	O
contexts	O
for	O
GAG	B-Chemical
or	O
N	O
-	O
glycosylation	O
attachments	O
","	O
respectively	O
.	O
Characterization	O
of	O
ANS1	O
/	O
2	O
-	O
R3	O
pronase	O
digestion	O
products	O
with	O
altered	O
retention	O
times	O
following	O
chondroitinase	O
ABC	O
digestion	O
.	O
RP	O
-	O
HPLC	O
chromatograms	O
(	O
Abs230	O
v	O
.	O
min	O
)	O
ANS1	O
/	O
2R3Pr1	O
-	O
d	O
","	O
-	O
h	O
","	O
-	O
i	O
","	O
-	O
j	O
","	O
and	O
-	O
p	O
following	O
chondroitinase	O
ABC	O
digestion	O
.	O
Arrows	O
indicate	O
retention	O
times	O
of	O
the	O
main	O
peak	O
prior	O
to	O
chondroitinase	O
ABC	O
digestion	O
.	O
N	O
-	O
terminal	O
sequences	O
determined	O
for	O
the	O
contents	O
of	O
each	O
labeled	O
peak	O
(	O
D	O
","	O
H	O
","	O
I	O
","	O
J1	O
","	O
J2	O
","	O
P1	O
and	O
P2	O
)	O
are	O
shown	O
on	O
the	O
lower	O
right	O
.	O
Blank	O
cycles	O
","	O
indicated	O
by	O
an	O
x	O
identified	O
Ser238	B-Chemical
and	O
Ser250	B-Chemical
as	O
modified	O
residues	O
.	O
Having	O
established	O
that	O
Ser238	B-Chemical
and	O
Ser250	B-Chemical
","	O
but	O
not	O
Ser220	B-Chemical
","	O
have	O
GAG	B-Chemical
attachments	O
","	O
we	O
then	O
characterized	O
the	O
nature	O
of	O
the	O
disaccharide	B-Chemical
attachments	O
at	O
these	O
two	O
GAG	B-Chemical
attachment	O
sites	O
.	O
Peptides	O
ANS1	O
/	O
2R3Pr1d	O
-	O
D	O
(	O
with	O
the	O
GAG	B-Chemical
attached	O
at	O
Ser250	B-Chemical
)	O
and	O
ANS1	O
/	O
2R3Pr1p	O
-	O
P2	O
(	O
with	O
the	O
GAG	B-Chemical
attached	O
at	O
Ser238	B-Chemical
)	O
were	O
digested	O
by	O
chondroitinase	O
ABC	O
.	O
The	O
released	O
carbohydrates	B-Chemical
were	O
obtained	O
from	O
the	O
supernatant	O
following	O
ethanol	B-Chemical
precipitation	O
of	O
the	O
peptide	O
","	O
and	O
were	O
characterized	O
by	O
their	O
retention	O
times	O
relative	O
to	O
those	O
of	O
disaccharide	B-Chemical
standards	O
on	O
NP	O
-	O
HPLC	O
(	O
Figure	O
4	O
).	O
This	O
determined	O
that	O
both	O
GAG	B-Chemical
attachment	O
sites	O
contained	O
chondroitin	B-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
sulfate	I-Chemical
(	O
C6S	B-Chemical
)	O
and	O
chondroitin	B-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
sulfate	I-Chemical
(	O
C4S	B-Chemical
"),"	O
and	O
integration	O
of	O
the	O
areas	O
under	O
their	O
chromatogram	O
peaks	O
determined	O
that	O
C6	B-Chemical
S	I-Chemical
and	O
C4	B-Chemical
S	I-Chemical
are	O
present	O
in	O
a	O
ratio	O
7	O
to	O
3	O
","	O
respectively	O
.	O
Characterization	O
of	O
disaccharides	B-Chemical
attached	O
at	O
Ser238	B-Chemical
and	O
Ser250	B-Chemical
.	O
Supelcosil	O
LC	O
-	O
NH2	O
chromatograms	O
(	O
Abs232	O
v	O
.	O
min	O
)	O
of	O
GAG	B-Chemical
products	O
released	O
from	O
ANS1	O
/	O
2R3	O
-	O
Prp	O
(	O
Ser238	B-Chemical
)	O
and	O
ANS1	O
/	O
2R3	O
-	O
Prd	O
(	O
Ser250	B-Chemical
)	O
by	O
chondroitinase	O
ABC	O
digestion	O
compared	O
to	O
GAG	B-Chemical
standards	O
(	O
Î”Di	B-Chemical
-	I-Chemical
0S	I-Chemical
;	O
Î”Di	B-Chemical
-	I-Chemical
6S	I-Chemical
;	O
Î”Di	B-Chemical
-	I-Chemical
4S	I-Chemical
;	O
Î”Di	B-Chemical
-	I-Chemical
diSD	I-Chemical
;	O
Î”Di	B-Chemical
-	I-Chemical
diSE	I-Chemical
;	O
Î”Di	B-Chemical
-	I-Chemical
triS	I-Chemical
).	O
Based	O
upon	O
their	O
retention	O
times	O
","	O
the	O
GAG	B-Chemical
attachments	O
are	O
observed	O
to	O
contain	O
chondroitin	B-Chemical
6	I-Chemical
-	I-Chemical
sulfate	I-Chemical
(	O
Î”Di	B-Chemical
-	I-Chemical
6S	I-Chemical
)	O
and	O
chondroitin	B-Chemical
4	I-Chemical
-	I-Chemical
sulfate	I-Chemical
(	O
Î”Di	B-Chemical
-	I-Chemical
4S	I-Chemical
).	O
Integration	O
of	O
the	O
areas	O
under	O
the	O
peaks	O
show	O
the	O
ratio	O
of	O
C6	B-Chemical
S	I-Chemical
to	O
C4	B-Chemical
S	I-Chemical
is	O
7	O
to	O
3	O
.	O
Characterization	O
of	O
R4	O
Pronase	O
Digestion	O
Products	O
Previously	O
we	O
showed	O
that	O
intact	O
Dsp	O
(	O
Dspp	O
-	O
derived	O
protein	O
that	O
lacks	O
the	O
Dgp	O
and	O
Dpp	O
regions	O
)	O
is	O
in	O
fraction	O
ANS1	O
/	O
2	O
-	O
R4	O
.	O
This	O
R4	O
fraction	O
(	O
5	O
mg	O
)	O
was	O
digested	O
with	O
pronase	O
","	O
and	O
glycosylated	O
peptides	O
were	O
collected	O
in	O
the	O
first	O
peak	O
by	O
size	O
exclusion	O
chromatography	O
(	O
Figure	O
5A	O
).	O
These	O
peptides	O
resolved	O
into	O
eight	O
peaks	O
by	O
RP	O
-	O
HPLC	O
(	O
Figure	O
5B	O
).	O
N	O
-	O
terminal	O
sequencing	O
of	O
these	O
peptides	O
gave	O
blank	O
cycles	O
for	O
Asn77	B-Chemical
","	O
Asn155	B-Chemical
","	O
Thr200	B-Chemical
","	O
Thr216	B-Chemical
","	O
and	O
Ser250	B-Chemical
.	O
Characterization	O
of	O
glycosylated	O
pronase	O
digestion	O
products	O
of	O
ANS1	O
/	O
2	O
-	O
R4	O
.	O
A	O
:	O
Size	O
exclusion	O
chromatogram	O
(	O
Abs220	O
v	O
.	O
min	O
)	O
of	O
ANS1	O
/	O
2	O
-	O
R4	O
digested	O
with	O
pronase	O
(	O
top	O
);	O
tubes	O
showing	O
results	O
of	O
phenol	B-Chemical
sulfuric	I-Chemical
acid	I-Chemical
assay	O
performed	O
on	O
each	O
size	O
exclusion	O
fraction	O
(	O
bottom	O
;	O
B	O
is	O
blank	O
for	O
negative	O
control	O
).	O
B	O
:	O
RP	O
-	O
HPLC	O
chromatogram	O
(	O
Abs220	O
v	O
.	O
min	O
)	O
of	O
digestion	O
products	O
in	O
ANS1	O
/	O
2R4	O
-	O
Pr1	O
showing	O
the	O
8	O
fractions	O
(	O
a	O
-	O
h	O
)	O
collected	O
.	O
C	O
:	O
N	O
-	O
terminal	O
sequences	O
determined	O
for	O
the	O
contents	O
of	O
each	O
fraction	O
peak	O
(	O
Pk	O
).	O
Blank	O
cycles	O
(	O
x	O
)	O
indicate	O
modified	O
residues	O
.	O
Characterization	O
of	O
Dsp	O
N	O
-	O
linked	O
glycosylation	O
sites	O
Previously	O
we	O
showed	O
by	O
Western	O
blot	O
analyses	O
that	O
low	O
molecular	O
weight	O
(	O
LMW	O
)	O
peptides	O
from	O
the	O
N	O
-	O
terminal	O
region	O
of	O
Dsp	O
can	O
be	O
found	O
in	O
the	O
acid	O
or	O
A	O
extract	O
.	O
To	O
identify	O
glycosylated	O
amino	B-Chemical
acids	I-Chemical
in	O
these	O
peptides	O
","	O
the	O
A	O
extract	O
was	O
fractionated	O
by	O
size	O
exclusion	O
chromatography	O
followed	O
by	O
RP	O
-	O
HPLC	O
(	O
Additional	O
file	O
4	O
).	O
The	O
LMW	O
Dsp	O
components	O
in	O
fraction	O
AS2R	O
-	O
g	O
(	O
Figure	O
6A	O
)	O
were	O
digested	O
with	O
endoproteinase	O
Glu	O
-	O
C	O
(	O
V8	O
endoproteinase	O
)	O
and	O
the	O
digest	O
was	O
fractionated	O
by	O
RP	O
-	O
HPLC	O
(	O
Figure	O
6B	O
).	O
Fifteen	O
peaks	O
were	O
observed	O
and	O
each	O
of	O
these	O
fractions	O
was	O
digested	O
with	O
glycopeptidase	O
A	O
.	O
Following	O
the	O
N	O
-	O
deglycosylation	O
","	O
each	O
sample	O
was	O
rechromatographed	O
on	O
the	O
same	O
C	O
-	O
18	O
column	O
to	O
demonstrate	O
that	O
deglycosylation	O
of	O
the	O
glycopeptide	O
had	O
altered	O
its	O
retention	O
time	O
.	O
A	O
shift	O
in	O
retention	O
time	O
on	O
the	O
column	O
following	O
deglycosylation	O
was	O
accepted	O
as	O
evidence	O
that	O
the	O
original	O
peptide	O
was	O
glycosylated	O
.	O
Fractions	O
corresponding	O
to	O
the	O
main	O
chromatographic	O
peaks	O
that	O
were	O
not	O
present	O
before	O
the	O
glycopeptidase	O
A	O
digestion	O
(	O
AS2R	O
-	O
g	O
peaks	O
2	O
","	O
3	O
","	O
6	O
","	O
8	O
","	O
10	O
","	O
11	O
and	O
12	O
)	O
were	O
characterized	O
by	O
LC	O
/	O
MSMS	O
analysis	O
(	O
Figure	O
6C	O
).	O
Five	O
N	O
-	O
glycosylation	O
sites	O
were	O
identified	O
:	O
Asn37	B-Chemical
(	O
NDT	O
;	O
peaks	O
6	O
","	O
8	O
","	O
10	O
","	O
11	O
","	O
12	O
"),"	O
Asn77	B-Chemical
(	O
NSS	O
;	O
peaks	O
6	O
","	O
8	O
"),"	O
Asn136	B-Chemical
(	O
NGS	O
;	O
peaks	O
2	O
and	O
3	O
"),"	O
Asn155	B-Chemical
(	O
NAS	O
;	O
peak	O
6	O
"),"	O
Asn161	B-Chemical
(	O
NAT	O
;	O
peaks	O
6	O
","	O
8	O
"),"	O
and	O
Asn176	B-Chemical
(	O
NNS	O
;	O
peak	O
2	O
).	O
Characterization	O
of	O
glycosylated	O
endoproteinase	O
Glu	O
-	O
C	O
digestion	O
products	O
of	O
LMW	O
Dsp	O
.	O
A	O
:	O
Contents	O
of	O
fraction	O
AS2R	O
-	O
g	O
characterized	O
by	O
SDS	B-Chemical
-	O
PAGE	O
stained	O
with	O
CBB	B-Chemical
(	O
1	O
"),"	O
stained	O
with	O
stains	O
-	O
all	O
(	O
2	O
);	O
by	O
Western	O
blotting	O
using	O
the	O
Dsp	O
antibody	O
(	O
3	O
)	O
or	O
Dgp	O
antibody	O
(	O
4	O
).	O
B	O
:	O
RP	O
-	O
HPLC	O
chromatogram	O
(	O
Abs220	O
v	O
.	O
min	O
)	O
of	O
endoproteinase	O
Glu	O
-	O
C	O
digestion	O
products	O
of	O
AS2R	O
-	O
g	O
.	O
C	O
:	O
Table	O
showing	O
the	O
results	O
of	O
mass	O
spectrometric	O
(	O
LC	O
/	O
MSMS	O
)	O
analyses	O
of	O
RP	O
-	O
HPLC	O
fractions	O
following	O
glycopeptidase	O
digestion	O
.	O
Asparagines	B-Chemical
(	O
N	B-Chemical
)	O
in	O
the	O
appropriate	O
context	O
for	O
N	O
-	O
glycosylation	O
that	O
were	O
also	O
found	O
to	O
be	O
1	O
Da	O
smaller	O
than	O
expected	O
(	O
due	O
to	O
deamidation	O
)	O
are	O
indicated	O
in	O
bold	O
and	O
listed	O
as	O
the	O
posttranslational	O
modification	O
(	O
PTM	O
)	O
site	O
on	O
the	O
right	O
.	O
Analysis	O
of	O
Sialic	B-Chemical
Acid	I-Chemical
in	O
Dsp	O
It	O
was	O
known	O
early	O
on	O
that	O
Dsp	O
glycosylations	O
are	O
rich	O
in	O
sialic	B-Chemical
acid	I-Chemical
","	O
which	O
was	O
the	O
basis	O
for	O
its	O
designation	O
as	O
dentin	O
sialoprotein	O
.	O
Sialic	B-Chemical
acid	I-Chemical
refers	O
to	O
N	B-Chemical
-	I-Chemical
acetylneuraminic	I-Chemical
acid	I-Chemical
(	O
Neu5Ac	B-Chemical
)	O
and	O
its	O
derivatives	O
.	O
To	O
determine	O
the	O
amount	O
of	O
N	O
-	O
glycosylations	O
in	O
each	O
Dspp	O
fraction	O
","	O
we	O
released	O
the	O
N	O
-	O
glycosylation	O
with	O
glycopeptidase	O
A	O
and	O
chemically	O
attached	O
a	O
fluorescent	O
label	O
.	O
One	O
fluorescent	O
label	O
was	O
added	O
per	O
N	O
-	O
glycosylation	O
.	O
The	O
amount	O
of	O
N	O
-	O
glycosylation	O
in	O
each	O
Dsp	O
fraction	O
was	O
determined	O
by	O
running	O
an	O
aliquot	O
of	O
labeled	O
glycosylation	O
over	O
an	O
SE	O
-	O
HPLC	O
column	O
and	O
then	O
comparing	O
the	O
areas	O
under	O
the	O
chromatographic	O
peaks	O
to	O
that	O
of	O
a	O
commercial	O
A2	O
glycan	B-Chemical
standard	O
of	O
known	O
amount	O
and	O
fluorescence	O
(	O
Additional	O
file	O
5	O
).	O
To	O
quantify	O
the	O
average	O
number	O
of	O
sialic	B-Chemical
acid	I-Chemical
attachments	O
per	O
N	O
-	O
glycosylation	O
","	O
we	O
digested	O
LMW	O
-	O
Dsp	O
(	O
containing	O
N	O
-	O
terminal	O
fragments	O
of	O
Dsp	O
)	O
and	O
R5	O
-	O
Dsp	O
(	O
containing	O
Dspp	O
minus	O
the	O
Dpp	O
domain	O
)	O
fractions	O
with	O
sialidase	O
.	O
The	O
released	O
sialic	B-Chemical
acid	I-Chemical
was	O
digested	O
with	O
aldolase	O
and	O
the	O
product	O
(	O
pyruvate	B-Chemical
)	O
and	O
lactic	O
dehydrogenase	O
were	O
used	O
to	O
oxidize	O
Î²	B-Chemical
-	I-Chemical
NADH	I-Chemical
to	O
Î²	B-Chemical
-	I-Chemical
NAD	I-Chemical
","	O
which	O
was	O
measured	O
spectrophotometrically	O
.	O
The	O
same	O
series	O
of	O
reactions	O
were	O
conducted	O
on	O
a	O
commercial	O
standard	O
(	O
bovine	O
fetuin	O
).	O
The	O
results	O
showed	O
that	O
there	O
were	O
","	O
on	O
average	O
","	O
1	O
.	O
3	O
sialic	B-Chemical
acids	I-Chemical
per	O
N	O
-	O
glycosylation	O
in	O
the	O
N	O
-	O
terminal	O
region	O
of	O
Dsp	O
","	O
and	O
about	O
0	O
.	O
8	O
molecules	O
of	O
sialic	B-Chemical
acid	I-Chemical
","	O
on	O
average	O
","	O
per	O
N	O
-	O
glycosylation	O
in	O
Dspp	O
(	O
Additional	O
file	O
5	O
).	O
To	O
identify	O
which	O
forms	O
of	O
sialic	B-Chemical
acid	I-Chemical
were	O
present	O
on	O
the	O
N	O
-	O
linked	O
glycosylations	O
","	O
N	O
-	O
glycosylations	O
were	O
released	O
from	O
the	O
various	O
Dsp	O
fractions	O
(	O
LMW	O
-	O
Dsp	O
","	O
R3	O
-	O
Dsp	O
","	O
R4	O
-	O
Dsp	O
","	O
R5	O
-	O
Dsp	O
"),"	O
given	O
a	O
fluorescent	O
label	O
","	O
and	O
purified	O
by	O
size	O
exclusion	O
chromatography	O
.	O
Sialic	B-Chemical
acid	I-Chemical
was	O
released	O
from	O
these	O
glycosylations	O
by	O
sialidase	O
digestion	O
","	O
labeled	O
","	O
and	O
then	O
passed	O
through	O
a	O
RP	O
-	O
HPLC	O
column	O
.	O
By	O
comparing	O
the	O
retention	O
times	O
of	O
the	O
labeled	O
sialic	B-Chemical
acid	I-Chemical
from	O
the	O
Dsp	O
fractions	O
to	O
a	O
similarly	O
-	O
labeled	O
sialic	B-Chemical
acid	I-Chemical
reference	O
panel	O
it	O
was	O
demonstrated	O
that	O
all	O
of	O
the	O
sialic	B-Chemical
acid	I-Chemical
attached	O
to	O
Dsp	O
N	O
-	O
glycosylations	O
are	O
N	B-Chemical
-	I-Chemical
acetylneuraminic	I-Chemical
acid	I-Chemical
(	O
Neu5Ac	B-Chemical
or	O
NANA	B-Chemical
"),"	O
which	O
is	O
the	O
predominant	O
form	O
of	O
sialic	B-Chemical
acid	I-Chemical
in	O
mammalian	O
cells	O
(	O
Additional	O
file	O
5	O
).	O
Discussion	O
In	O
this	O
study	O
we	O
identified	O
six	O
N	O
-	O
linked	O
and	O
three	O
tentative	O
O	O
-	O
linked	O
glycosylation	O
and	O
the	O
two	O
GAG	B-Chemical
attachment	O
sites	O
on	O
porcine	O
Dsp	O
(	O
Figure	O
7	O
).	O
The	O
two	O
GAG	B-Chemical
attachment	O
sites	O
are	O
particularly	O
interesting	O
.	O
Xylosyltransferase	O
I	O
(	O
XYLT1	O
;	O
16p13	O
.	O
1	O
)	O
and	O
xylosyltransferase	O
II	O
(	O
XYLT2	O
;	O
17q21	O
.	O
3	O
)	O
catalyze	O
the	O
initial	O
step	O
in	O
glycosaminoglycan	B-Chemical
biosynthesis	O
and	O
determine	O
if	O
a	O
site	O
will	O
have	O
a	O
GAG	B-Chemical
attachment	O
.	O
Experimentally	O
determined	O
GAG	B-Chemical
attachment	O
sites	O
identify	O
the	O
range	O
of	O
amino	B-Chemical
acid	I-Chemical
contexts	O
that	O
are	O
recognized	O
by	O
these	O
enzymes	O
and	O
provide	O
the	O
data	O
needed	O
to	O
improve	O
the	O
prediction	O
algorythms	O
for	O
GAG	B-Chemical
attachment	O
sites	O
.	O
Porcine	O
Dsp	O
posttranslational	O
modification	O
sites	O
.	O
A	O
:	O
Diagram	O
showing	O
the	O
three	O
regions	O
(	O
Dsp	O
","	O
Dgp	O
","	O
and	O
Dpp	O
)	O
of	O
porcine	O
Dspp	O
.	O
B	O
:	O
Diagram	O
showing	O
N	O
and	O
O	O
-	O
linked	O
glycosylation	O
sites	O
identified	O
in	O
this	O
study	O
.	O
Among	O
the	O
eight	O
asparagines	B-Chemical
in	O
the	O
appropriate	O
context	O
for	O
glycosylation	O
","	O
six	O
were	O
determined	O
to	O
be	O
glycosylated	O
(	O
Asn37	B-Chemical
","	O
Asn77	B-Chemical
","	O
Asn136	B-Chemical
","	O
Asn155	B-Chemical
","	O
Asn161	B-Chemical
","	O
Asn176	B-Chemical
).	O
The	O
glycosylation	O
status	O
Asn67	B-Chemical
was	O
not	O
determined	O
.	O
Asn315	B-Chemical
was	O
shown	O
to	O
not	O
be	O
glycosylated	O
","	O
possibly	O
due	O
to	O
an	O
O	O
-	O
glycosylation	O
of	O
Thr316	B-Chemical
.	O
In	O
porcine	O
Dsp	O
","	O
it	O
was	O
shown	O
that	O
the	O
N	O
-	O
glycosylations	O
contain	O
","	O
on	O
average	O
","	O
one	O
sialic	B-Chemical
acid	I-Chemical
","	O
in	O
the	O
form	O
of	O
N	B-Chemical
-	I-Chemical
acetylneuraminic	I-Chemical
acid	I-Chemical
","	O
per	O
N	O
-	O
glycosylation	O
.	O
Ser238	B-Chemical
and	O
Ser250	B-Chemical
were	O
determined	O
to	O
be	O
GAG	B-Chemical
attachment	O
sites	O
","	O
with	O
the	O
GAG	B-Chemical
attachments	O
being	O
comprised	O
of	O
chondroitin	B-Chemical
6	I-Chemical
-	I-Chemical
sulfate	I-Chemical
and	O
chondroitin	B-Chemical
4	I-Chemical
-	I-Chemical
sulfate	I-Chemical
in	O
a	O
ratio	O
of	O
7	O
to	O
3	O
.	O
O	O
-	O
glycosylations	O
were	O
suggested	O
by	O
blank	O
cycles	O
at	O
Thr200	B-Chemical
","	O
Thr216	B-Chemical
","	O
and	O
Thr316	B-Chemical
in	O
samples	O
that	O
were	O
positive	O
for	O
glycosylation	O
by	O
the	O
phenol	B-Chemical
sulfuric	I-Chemical
acid	I-Chemical
assay	O
and	O
eluted	O
early	O
from	O
a	O
size	O
-	O
exclusion	O
column	O
","	O
but	O
no	O
direct	O
evidence	O
for	O
O	O
-	O
glycosylation	O
was	O
obtained	O
and	O
the	O
conclusion	O
that	O
these	O
residues	O
are	O
glycosylated	O
should	O
be	O
considered	O
tentative	O
.	O
The	O
two	O
GAG	B-Chemical
attachment	O
sites	O
are	O
in	O
the	O
most	O
highly	O
conserved	O
area	O
of	O
Dsp	O
(	O
Additional	O
file	O
6	O
).	O
The	O
context	O
for	O
the	O
second	O
site	O
(	O
Ser250	B-Chemical
;	O
DEEEDKGSGDDEGEE	O
)	O
contains	O
a	O
GSG	O
-	O
motif	O
combined	O
with	O
a	O
high	O
number	O
of	O
surrounding	O
acidic	O
amino	B-Chemical
acids	I-Chemical
","	O
so	O
this	O
sequence	O
would	O
be	O
predicted	O
to	O
be	O
a	O
good	O
acceptor	O
for	O
a	O
xylosylation	O
reaction	O
and	O
result	O
in	O
a	O
high	O
degree	O
of	O
xylosylation	O
catalyzed	O
by	O
both	O
XT	O
-	O
isoforms	O
.	O
The	O
first	O
site	O
(	O
Ser238	B-Chemical
","	O
DNSDGSPSGNGADEEED	O
)	O
has	O
two	O
acidic	O
amino	B-Chemical
acids	I-Chemical
on	O
the	O
N	O
-	O
terminal	O
side	O
and	O
a	O
series	O
of	O
acidic	O
amino	B-Chemical
acids	I-Chemical
starting	O
at	O
positions	O
+	O
5	O
or	O
+	O
6	O
","	O
which	O
are	O
positive	O
features	O
.	O
However	O
","	O
the	O
proline	B-Chemical
in	O
the	O
-	O
1	O
position	O
is	O
thought	O
to	O
have	O
an	O
inhibitory	O
effect	O
on	O
the	O
glycosylation	O
reaction	O
.	O
Despite	O
this	O
","	O
our	O
results	O
indicate	O
that	O
Ser238	B-Chemical
is	O
a	O
GAG	B-Chemical
attachment	O
site	O
.	O
Perhaps	O
the	O
high	O
conservation	O
of	O
the	O
surrounding	O
amino	B-Chemical
acids	I-Chemical
helps	O
ensure	O
its	O
recognition	O
as	O
a	O
target	O
for	O
glycosylation	O
.	O
Recently	O
","	O
it	O
was	O
shown	O
that	O
altering	O
the	O
potential	O
GAG	B-Chemical
attachment	O
sites	O
sequences	O
in	O
rat	O
Dsp	O
diminished	O
the	O
apparent	O
size	O
of	O
the	O
recombinant	O
protein	O
on	O
Western	O
blots	O
","	O
indicating	O
that	O
both	O
of	O
the	O
GAG	B-Chemical
attachments	O
sites	O
identified	O
in	O
this	O
study	O
have	O
GAG	B-Chemical
attachments	O
in	O
rat	O
Dsp	O
.	O
It	O
is	O
clear	O
from	O
our	O
analyses	O
that	O
the	O
repeating	O
disaccharide	B-Chemical
units	O
attached	O
to	O
Ser238	B-Chemical
and	O
Ser250	B-Chemical
are	O
chondroitin	B-Chemical
6	I-Chemical
-	I-Chemical
sulfate	I-Chemical
and	O
chondroitin	B-Chemical
4	I-Chemical
-	I-Chemical
sulfate	I-Chemical
","	O
with	O
C6	B-Chemical
S	I-Chemical
predominating	O
.	O
Based	O
upon	O
antibody	O
analyses	O
","	O
we	O
previously	O
detected	O
only	O
C6	B-Chemical
S	I-Chemical
attached	O
to	O
porcine	O
Dsp	O
.	O
Dentin	O
matrix	O
protein	O
1	O
(	O
Dmp1	O
)	O
is	O
a	O
bone	O
and	O
dentin	O
proteoglycan	O
that	O
plays	O
a	O
role	O
in	O
phosphate	B-Chemical
homeostasis	O
.	O
In	O
rat	O
","	O
the	O
predominant	O
disaccharide	B-Chemical
unit	O
on	O
Dsp	O
and	O
Dmp1	O
is	O
C4	O
S	O
.	O
The	O
role	O
of	O
Dsp	O
GAG	B-Chemical
chains	O
in	O
dentin	O
formation	O
is	O
largely	O
unexplored	O
.	O
Proteoglycans	O
such	O
as	O
decorin	O
are	O
known	O
to	O
regulate	O
collagen	O
fibrillogenesis	O
.	O
GAGs	B-Chemical
are	O
thought	O
to	O
interact	O
directly	O
with	O
dentin	O
collagen	O
fibrils	O
","	O
as	O
an	O
electrondense	O
substance	O
that	O
can	O
be	O
removed	O
from	O
dentin	O
collagen	O
fibrils	O
by	O
chondroitinase	O
treatment	O
.	O
Dsp	O
is	O
the	O
most	O
abundant	O
proteoglycan	O
in	O
dentin	O
and	O
is	O
therefore	O
likely	O
to	O
interact	O
with	O
collagen	O
.	O
Chondroitinase	O
activity	O
in	O
the	O
dentin	O
matrix	O
might	O
regulate	O
interactions	O
between	O
the	O
Dsp	O
GAG	B-Chemical
chains	O
and	O
collagen	O
.	O
Besides	O
having	O
two	O
GAG	B-Chemical
attachments	O
","	O
porcine	O
Dsp	O
has	O
at	O
least	O
six	O
N	O
-	O
glycosylations	O
.	O
All	O
of	O
these	O
sites	O
are	O
on	O
the	O
N	O
-	O
terminal	O
side	O
of	O
the	O
lone	O
cysteine	B-Chemical
(	O
Cys190	B-Chemical
)	O
that	O
covalently	O
links	O
two	O
Dsp	O
proteins	O
into	O
a	O
dimer	O
.	O
Although	O
a	O
high	O
degree	O
of	O
N	O
-	O
glycosylation	O
is	O
a	O
characteristic	O
feature	O
of	O
Dsp	O
","	O
the	O
individual	O
glycosylation	O
sites	O
are	O
not	O
well	O
conserved	O
.	O
The	O
N	O
-	O
linked	O
glycosylations	O
on	O
porcine	O
Dsp	O
average	O
about	O
one	O
sialic	B-Chemical
acid	I-Chemical
per	O
N	O
-	O
glycosylation	O
.	O
Previously	O
it	O
was	O
shown	O
that	O
rat	O
Dsp	O
contained	O
29	O
.	O
6	O
%	O
carbohydrate	B-Chemical
including	O
about	O
9	O
%	O
sialic	B-Chemical
acid	I-Chemical
.	O
Sialic	B-Chemical
acid	I-Chemical
attachments	O
can	O
serve	O
a	O
wide	O
range	O
of	O
functions	O
.	O
Sialic	B-Chemical
acid	I-Chemical
moities	O
can	O
be	O
ligands	O
for	O
other	O
molecules	O
","	O
such	O
as	O
lectins	O
.	O
Perhaps	O
Dsp	O
could	O
form	O
a	O
bridge	O
between	O
molecules	O
that	O
interact	O
with	O
sialic	B-Chemical
acid	I-Chemical
and	O
others	O
that	O
interact	O
with	O
O	O
-	O
glycosylations	O
or	O
GAG	B-Chemical
attachments	O
.	O
The	O
two	O
O	O
-	O
glycosylations	O
and	O
two	O
GAG	B-Chemical
attachments	O
are	O
all	O
on	O
the	O
C	O
-	O
terminal	O
side	O
of	O
Cys190	B-Chemical
.	O
Ser238	B-Chemical
","	O
Ser250	B-Chemical
","	O
and	O
Thr216	B-Chemical
are	O
perfectly	O
conserved	O
","	O
whereas	O
Thr316	B-Chemical
is	O
conserved	O
in	O
all	O
known	O
Dsp	O
sequences	O
except	O
the	O
mouse	O
.	O
Thus	O
the	O
O	O
-	O
glycosylations	O
and	O
glycosaminoglycan	B-Chemical
attachments	O
are	O
structural	O
elements	O
that	O
are	O
likely	O
to	O
be	O
essential	O
for	O
Dsp	O
function	O
.	O
Three	O
predicted	O
Golgi	O
casein	O
kinase	O
phosphorylation	O
sites	O
(	O
Ser294	B-Chemical
","	O
Ser296	B-Chemical
and	O
Ser319	B-Chemical
)	O
are	O
all	O
found	O
in	O
the	O
C	O
-	O
terminal	O
side	O
of	O
Dsp	O
and	O
are	O
perfectly	O
conserved	O
.	O
The	O
map	O
of	O
porcine	O
Dsp	O
posttranslational	O
modifications	O
suggests	O
that	O
Dsp	O
is	O
divided	O
into	O
two	O
domains	O
that	O
are	O
separated	O
by	O
the	O
lone	O
cysteine	B-Chemical
(	O
Cys190	B-Chemical
)	O
that	O
covalently	O
links	O
two	O
Dsp	O
proteins	O
.	O
The	O
N	O
-	O
terminal	O
side	O
is	O
rich	O
in	O
sialidated	O
N	O
-	O
glycosylations	O
;	O
the	O
C	O
-	O
terminal	O
side	O
contains	O
the	O
GAGs	B-Chemical
","	O
O	O
-	O
glycosylations	O
","	O
and	O
phosphorylated	O
serines	B-Chemical
.	O
The	O
Dsp	O
domain	O
of	O
Dspp	O
is	O
not	O
highly	O
phosphorylated	O
(	O
only	O
3	O
predicted	O
sites	O
).	O
In	O
contrast	O
","	O
the	O
small	O
Dgp	O
domain	O
has	O
four	O
perfectly	O
conserved	O
sites	O
","	O
while	O
Dpp	O
has	O
well	O
over	O
a	O
hundred	O
.	O
The	O
Dsp	O
domain	O
is	O
not	O
highly	O
conserved	O
.	O
Only	O
73	O
of	O
377	O
(	O
19	O
%)	O
if	O
its	O
amino	B-Chemical
acids	I-Chemical
are	O
perfectly	O
conserved	O
among	O
the	O
seven	O
mammalian	O
Dsp	O
sequences	O
in	O
GenBank	O
","	O
whereas	O
28	O
/	O
81	O
(	O
35	O
%)	O
of	O
Dgp	O
is	O
perfectly	O
conserved	O
.	O
The	O
most	O
highly	O
conserved	O
regions	O
of	O
Dsp	O
and	O
Dgp	O
are	O
in	O
areas	O
of	O
posttranslational	O
modifications	O
","	O
highlighting	O
their	O
importance	O
for	O
function	O
.	O
Dsp	O
is	O
important	O
for	O
the	O
onset	O
of	O
dentin	O
mineralization	O
","	O
and	O
future	O
studies	O
will	O
investigate	O
the	O
importance	O
PTMs	O
in	O
carrying	O
out	O
these	O
functions	O
.	O
Conclusions	O
Dentin	O
sialoprotein	O
(	O
Dsp	O
"),"	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
dentin	O
sialophosphoprotein	O
(	O
Dspp	O
)	O
was	O
isolated	O
from	O
developing	O
porcine	O
molars	O
and	O
its	O
posttranslational	O
modification	O
were	O
characterized	O
.	O
Porcine	O
Dsp	O
has	O
at	O
least	O
6	O
N	O
-	O
linked	O
glycosylations	O
(	O
Asn37	B-Chemical
","	O
Asn77	B-Chemical
","	O
Asn136	B-Chemical
","	O
Asn155	B-Chemical
","	O
Asn161	B-Chemical
","	O
and	O
Asn176	B-Chemical
)	O
that	O
average	O
one	O
sialic	B-Chemical
acid	I-Chemical
each	O
","	O
all	O
in	O
the	O
form	O
of	O
N	B-Chemical
-	I-Chemical
acetylneuraminic	I-Chemical
acid	I-Chemical
.	O
Porcine	O
Dsp	O
has	O
exactly	O
two	O
glycosaminoglycan	B-Chemical
attachments	O
(	O
Ser238	B-Chemical
and	O
Ser250	B-Chemical
)	O
that	O
are	O
comprised	O
of	O
chondroitin	B-Chemical
6	I-Chemical
-	I-Chemical
sulfate	I-Chemical
and	O
chondroitin	B-Chemical
4	I-Chemical
-	I-Chemical
sulfate	I-Chemical
in	O
a	O
ratio	O
of	O
7	O
to	O
3	O
.	O
Three	O
O	O
-	O
linked	O
glycosylations	O
in	O
Dsp	O
were	O
tentatively	O
assigned	O
(	O
Thr200	B-Chemical
","	O
Thr216	B-Chemical
","	O
and	O
Thr316	B-Chemical
).	O
Glycosylations	O
divide	O
porcine	O
Dsp	O
into	O
a	O
heavily	O
N	O
-	O
glycosylated	O
","	O
sialidated	O
N	O
-	O
terminal	O
domain	O
and	O
a	O
C	O
-	O
terminal	O
domain	O
with	O
two	O
GAG	B-Chemical
attachments	O
","	O
three	O
O	O
-	O
glycosylations	O
","	O
and	O
three	O
potential	O
phosphoserines	B-Chemical
.	O
The	O
two	O
Dsp	O
domains	O
are	O
separated	O
by	O
the	O
lone	O
cysteine	B-Chemical
(	O
Cys190	B-Chemical
)	O
that	O
connects	O
two	O
Dsp	O
chains	O
into	O
a	O
covalent	O
dimer	O
.	O
Knowledge	O
of	O
Dsp	O
structure	O
is	O
an	O
important	O
starting	O
point	O
to	O
understanding	O
the	O
how	O
Dsp	O
serves	O
to	O
initiate	O
mineralization	O
of	O
dentin	O
.	O
Methods	O
All	O
experimental	O
procedures	O
involving	O
the	O
use	O
of	O
animals	O
were	O
reviewed	O
and	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Program	O
at	O
the	O
University	O
of	O
Michigan	O
.	O
Extraction	O
of	O
proteins	O
from	O
dentin	O
powder	O
Maxillary	O
and	O
mandibular	O
second	O
molar	O
tooth	O
germs	O
were	O
extracted	O
from	O
6	O
month	O
old	O
pigs	O
and	O
the	O
soft	O
tissue	O
discarded	O
.	O
Enamel	O
was	O
removed	O
by	O
scraping	O
with	O
a	O
curette	O
and	O
the	O
remaining	O
hard	O
tissue	O
was	O
ground	O
to	O
a	O
powder	O
.	O
All	O
extraction	O
steps	O
were	O
carried	O
out	O
at	O
4	O
Â°	O
C	O
or	O
on	O
ice	O
.	O
The	O
Protease	O
Inhibitor	O
Cocktail	O
Set	O
III	O
(	O
1	O
mM	O
AEBSF	B-Chemical
","	O
0	O
.	O
8	O
Î¼M	O
aprotinin	O
","	O
50	O
Î¼M	O
bestatin	B-Chemical
","	O
15	O
Î¼M	O
E	B-Chemical
-	I-Chemical
64	I-Chemical
","	O
20	O
Î¼M	O
leupeptin	O
","	O
and	O
10	O
Î¼M	O
pepstatin	B-Chemical
)	O
(	O
Calbiochem	O
","	O
San	O
Diego	O
","	O
CA	O
)	O
and	O
1	O
mM	O
1	B-Chemical
","	I-Chemical
10	I-Chemical
-	I-Chemical
phenanthroline	I-Chemical
(	O
Sigma	O
-	O
Aldrich	O
","	O
St	O
.	O
Louis	O
","	O
MO	O
)	O
were	O
added	O
into	O
the	O
buffer	O
during	O
the	O
extraction	O
.	O
The	O
extraction	O
scheme	O
is	O
outlined	O
in	O
Figure	O
1	O
.	O
Forty	O
grams	O
of	O
dentin	O
powder	O
(	O
the	O
amount	O
obtained	O
from	O
32	O
molars	O
)	O
was	O
homogenized	O
at	O
4	O
Â°	O
C	O
in	O
50	O
mM	O
Tris	B-Chemical
-	I-Chemical
HCl	I-Chemical
/	O
4	O
M	O
guanidine	B-Chemical
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
containing	O
protease	O
inhibitors	O
.	O
Insoluble	O
material	O
was	O
pelleted	O
by	O
centrifugation	O
and	O
the	O
supernatant	O
was	O
designated	O
the	O
first	O
guanidine	B-Chemical
(	O
G1	O
)	O
extract	O
.	O
The	O
guanidine	B-Chemical
pellet	O
was	O
dialyzed	O
against	O
4	O
L	O
of	O
0	O
.	O
5	O
M	O
acetic	B-Chemical
acid	I-Chemical
containing	O
protease	O
inhibitors	O
until	O
the	O
tooth	O
mineral	O
has	O
fully	O
dissolved	O
.	O
The	O
dialysis	O
bag	O
contents	O
were	O
centrifuged	O
","	O
and	O
the	O
supernatant	O
was	O
designated	O
the	O
acid	O
(	O
A	O
)	O
extract	O
.	O
The	O
pellet	O
was	O
extracted	O
with	O
0	O
.	O
5	O
M	O
acetic	B-Chemical
acid	I-Chemical
/	O
2	O
M	O
NaCl	B-Chemical
and	O
the	O
supernatant	O
was	O
designated	O
the	O
acid	O
salt	O
(	O
AN	O
)	O
extract	O
.	O
The	O
AN	O
pellet	O
was	O
extracted	O
with	O
50	O
mM	O
Tris	B-Chemical
-	I-Chemical
HCl	I-Chemical
/	O
2	O
M	O
NaCl	B-Chemical
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
and	O
the	O
supernatant	O
designated	O
the	O
Tris	B-Chemical
salt	I-Chemical
(	O
TN	B-Chemical
)	O
extract	O
.	O
The	O
TN	O
pellet	O
was	O
extracted	O
with	O
50	O
mM	O
Tris	B-Chemical
-	I-Chemical
HCl	I-Chemical
/	O
4	O
M	O
guanidine	B-Chemical
buffer	O
(	O
pH	O
7	O
.	O
4	O
).	O
Residual	O
insoluble	O
material	O
(	O
RIM	O
)	O
was	O
pelleted	O
by	O
centrifugation	O
.	O
The	O
guanidine	B-Chemical
supernatant	O
was	O
dialyzed	O
against	O
water	B-Chemical
.	O
Following	O
centrifugation	O
","	O
the	O
pelleted	O
material	O
that	O
had	O
precipitated	O
during	O
dialysis	O
was	O
designated	O
the	O
second	O
guanidine	B-Chemical
pellet	O
(	O
G2P	O
"),"	O
while	O
the	O
supernatant	O
was	O
designated	O
the	O
second	O
guanidine	B-Chemical
extract	O
(	O
G2	O
).	O
Purification	O
of	O
Dspp	O
-	O
derived	O
proteins	O
Western	O
blot	O
analyses	O
using	O
a	O
polyclonal	O
antibody	O
raised	O
against	O
recombinant	O
porcine	O
Dsp	O
showed	O
that	O
low	O
molecular	O
weight	O
(	O
LMW	O
)	O
Dsp	O
components	O
were	O
in	O
the	O
A	O
extract	O
","	O
while	O
high	O
molecular	O
weight	O
(	O
HMW	O
)	O
Dsp	O
components	O
were	O
in	O
the	O
AN	O
extract	O
(	O
Additional	O
file	O
1	O
).	O
The	O
AN	O
and	O
A	O
extracts	O
were	O
fractionated	O
by	O
size	O
exclusion	O
chromatography	O
and	O
the	O
fraction	O
containing	O
Dsp	O
positive	O
material	O
(	O
based	O
upon	O
Western	O
blot	O
analyses	O
)	O
was	O
further	O
fractionated	O
by	O
reversed	O
phase	O
-	O
high	O
performance	O
liquid	O
chromatography	O
(	O
RP	O
-	O
HPLC	O
).	O
For	O
the	O
AN	O
extract	O
","	O
the	O
HMW	O
Dsp	O
components	O
were	O
found	O
in	O
the	O
first	O
two	O
chromatographic	O
peaks	O
(	O
AN	O
-	O
S1	O
and	O
AN	O
-	O
S2	O
"),"	O
which	O
were	O
combined	O
and	O
resolved	O
into	O
five	O
fractions	O
by	O
RP	O
-	O
HPLC	O
.	O
The	O
last	O
three	O
fractions	O
to	O
elute	O
","	O
designated	O
ANS1	O
/	O
2	O
-	O
R3	O
","	O
ANS1	O
/	O
2	O
-	O
R4	O
","	O
and	O
ANS1	O
/	O
2	O
-	O
R5	O
","	O
were	O
comprised	O
of	O
successively	O
larger	O
stains	O
-	O
all	O
positive	O
smears	O
of	O
Dsp	O
proteoglycan	O
","	O
respectively	O
(	O
Additional	O
file	O
2	O
).	O
The	O
LMW	O
Dsp	O
components	O
in	O
the	O
A	O
extract	O
were	O
found	O
in	O
the	O
second	O
(	O
S2	O
)	O
of	O
three	O
fractions	O
produced	O
by	O
size	O
exclusion	O
chromatography	O
.	O
S2	O
resolved	O
into	O
14	O
fractions	O
(	O
designated	O
a	O
through	O
n	O
)	O
on	O
a	O
POROS	O
R2	O
column	O
(	O
4	O
.	O
6	O
mmID	O
Ã—	O
10	O
cm	O
"),"	O
equilibrated	O
with	O
0	O
.	O
5	O
%	O
TFA	B-Chemical
and	O
eluted	O
with	O
a	O
linear	O
acetonitrile	B-Chemical
gradient	O
containing	O
0	O
.	O
5	O
%	O
TFA	B-Chemical
at	O
a	O
flow	O
rate	O
of	O
1	O
.	O
0	O
mL	O
/	O
min	O
at	O
room	O
temperature	O
.	O
The	O
LMW	O
Dsp	O
components	O
were	O
identified	O
in	O
fraction	O
g	O
(	O
AS2R	O
-	O
g	O
;	O
Additional	O
file	O
4	O
).	O
To	O
identify	O
glycosylated	O
peptides	O
in	O
porcine	O
Dsp	O
","	O
the	O
LMW	O
and	O
HMW	O
Dsp	O
components	O
were	O
digested	O
with	O
endoproteinase	O
Glu	O
-	O
C	O
or	O
pronase	O
and	O
the	O
glycopeptide	O
products	O
characterized	O
.	O
Endoproteinase	O
Glu	O
-	O
C	O
(	O
Staphylococcus	O
aureus	O
Protease	O
V8	O
)	O
is	O
a	O
serine	O
proteinase	O
that	O
selectively	O
cleaves	O
peptide	O
bonds	O
C	O
-	O
terminal	O
to	O
acidic	O
residues	O
with	O
a	O
strong	O
preference	O
for	O
glutamic	B-Chemical
over	O
aspartic	B-Chemical
acid	I-Chemical
residues	O
.	O
Pronase	O
is	O
a	O
cocktail	O
of	O
proteolytic	O
enzymes	O
that	O
degrades	O
all	O
but	O
short	O
glycopeptides	O
that	O
are	O
protected	O
from	O
cleavage	O
by	O
bulky	O
carbohydrate	B-Chemical
chains	O
.	O
Chondroitinase	O
ABC	O
digestion	O
and	O
characterization	O
ANS1	O
/	O
2	O
-	O
R3	O
Fraction	O
ANS1	O
/	O
2	O
-	O
R3	O
","	O
which	O
produced	O
a	O
stains	O
-	O
all	O
positive	O
smear	O
on	O
sodium	B-Chemical
dodecyl	I-Chemical
sulfate	I-Chemical
-	O
polyacrylamide	B-Chemical
gel	O
electrophoresis	O
(	O
SDS	B-Chemical
-	O
PAGE	O
"),"	O
was	O
resolved	O
into	O
two	O
parts	O
(	O
ANS1	O
/	O
S2	O
-	O
R3a	O
and	O
ANS1	O
/	O
S2	O
-	O
R3b	O
)	O
by	O
RP	O
-	O
HPLC	O
rechromatography	O
(	O
Additional	O
file	O
2	O
"),"	O
lyophilized	O
","	O
and	O
200	O
Î¼g	O
of	O
each	O
part	O
was	O
resuspended	O
in	O
40	O
mM	O
Tris	B-Chemical
-	I-Chemical
HCl	I-Chemical
/	O
40	O
mM	O
sodium	B-Chemical
acetate	I-Chemical
buffer	O
(	O
pH	O
8	O
.	O
0	O
)	O
and	O
incubated	O
with	O
0	O
.	O
2	O
units	O
of	O
chondroitinase	O
ABC	O
protease	O
free	O
(	O
Associate	O
of	O
Cape	O
Cod	O
Inc	O
".,"	O
East	O
Falmouth	O
","	O
MA	O
)	O
at	O
37	O
Â°	O
C	O
for	O
35	O
h	O
.	O
The	O
digests	O
resolved	O
into	O
six	O
stains	O
-	O
all	O
positive	O
bands	O
on	O
SDS	B-Chemical
-	O
PAGE	O
","	O
which	O
were	O
excised	O
from	O
the	O
gel	O
.	O
Each	O
gel	O
slice	O
was	O
transferred	O
to	O
a	O
DTube	O
Dialyzer	O
(	O
midi	O
size	O
)	O
(	O
Novagen	O
/	O
EMD	O
Chemicals	O
","	O
Inc	O
".,"	O
Gibbstown	O
","	O
NJ	O
)	O
and	O
the	O
protein	O
electroeluted	O
with	O
25	O
mM	O
Tris	B-Chemical
/	O
250	O
mM	O
Tricine	B-Chemical
/	O
0	O
.	O
25	O
%	O
SDS	B-Chemical
buffer	O
(	O
pH	O
8	O
.	O
5	O
)	O
at	O
150	O
volts	O
for	O
3	O
h	O
.	O
Each	O
eluate	O
was	O
precipitated	O
with	O
20	O
%	O
trichloroacetic	B-Chemical
acid	I-Chemical
","	O
incubated	O
in	O
acetone	B-Chemical
overnight	O
at	O
-	O
80	O
Â°	O
C	O
and	O
centrifuged	O
at	O
4	O
Â°	O
C	O
for	O
30	O
min	O
at	O
14	O
","	O
0	O
Ã—	O
g	O
.	O
The	O
supernatant	O
was	O
decanted	O
","	O
the	O
pellet	O
was	O
dried	O
under	O
a	O
hood	O
","	O
and	O
was	O
later	O
characterized	O
by	O
Edman	O
sequencing	O
.	O
Characterization	O
of	O
ANS1	O
/	O
2	O
-	O
R3	O
following	O
pronase	O
digestion	O
Purified	O
ANS1	O
/	O
2	O
-	O
R3	O
(	O
33	O
mg	O
)	O
in	O
50	O
mM	O
Tris	B-Chemical
-	I-Chemical
HCl	I-Chemical
buffer	O
(	O
pH	O
8	O
.	O
0	O
)	O
was	O
incubated	O
with	O
0	O
.	O
2	O
mg	O
of	O
pronase	O
at	O
37	O
Â°	O
C	O
for	O
20	O
h	O
.	O
The	O
digestion	O
products	O
were	O
fractionated	O
by	O
size	O
exclusion	O
chromatography	O
using	O
a	O
Sephadex	B-Chemical
G	I-Chemical
-	I-Chemical
15	I-Chemical
column	O
(	O
1	O
.	O
6	O
cm	O
Ã—	O
60	O
cm	O
).	O
The	O
first	O
eluted	O
fraction	O
of	O
the	O
pronase	O
digest	O
was	O
positive	O
for	O
oligosaccharide	B-Chemical
or	O
glycosaminoglycan	B-Chemical
chains	O
using	O
the	O
phenol	B-Chemical
-	O
sulphuric	B-Chemical
acid	I-Chemical
(	O
PS	B-Chemical
)	O
assay	O
(	O
Additional	O
file	O
3	O
)	O
and	O
was	O
fractionated	O
by	O
RP	O
-	O
HPLC	O
using	O
a	O
Discovery	O
C18	O
column	O
(	O
10	O
mmID	O
Ã—	O
25	O
cm	O
)	O
equilibrated	O
with	O
0	O
.	O
5	O
%	O
TFA	B-Chemical
and	O
eluted	O
with	O
a	O
linear	O
acetonitrile	B-Chemical
gradient	O
containing	O
0	O
.	O
5	O
%	O
TFA	B-Chemical
at	O
a	O
flow	O
rate	O
of	O
1	O
.	O
0	O
mL	O
/	O
min	O
at	O
room	O
temperature	O
.	O
For	O
the	O
PS	B-Chemical
assay	O
","	O
aliquots	O
from	O
each	O
Sephadex	B-Chemical
G	I-Chemical
-	I-Chemical
15	I-Chemical
or	O
Discovery	O
C18	O
fraction	O
were	O
evaporated	O
and	O
0	O
.	O
3	O
mL	O
of	O
water	B-Chemical
","	O
0	O
.	O
3	O
mL	O
of	O
5	O
%	O
phenol	B-Chemical
","	O
and	O
1	O
.	O
5	O
mL	O
of	O
concentrated	O
sulfuric	B-Chemical
acid	I-Chemical
were	O
added	O
.	O
Measuring	O
the	O
absorbance	O
at	O
490	O
nm	O
on	O
a	O
spectrophotometer	O
identified	O
the	O
peak	O
containing	O
oligosaccharides	B-Chemical
.	O
Eight	O
RP	O
-	O
HPLC	O
fractions	O
(	O
Pr1	O
-	O
d	O
","	O
-	O
e	O
","	O
-	O
h	O
","	O
-	O
i	O
","	O
-	O
j	O
","	O
-	O
k	O
","	O
-	O
l	O
and	O
-	O
p	O
)	O
that	O
were	O
positive	O
for	O
the	O
PS	B-Chemical
assay	O
(	O
Additional	O
file	O
3	O
)	O
were	O
digested	O
with	O
chondroitinase	O
ABC	O
as	O
described	O
above	O
.	O
At	O
the	O
end	O
of	O
the	O
incubation	O
period	O
","	O
three	O
volumes	O
of	O
ice	O
-	O
cold	O
ethanol	B-Chemical
were	O
added	O
to	O
the	O
reaction	O
mixture	O
","	O
which	O
was	O
then	O
centrifuged	O
for	O
10	O
min	O
at	O
10	O
","	O
0	O
Ã—	O
g	O
.	O
Both	O
supernatant	O
and	O
pellet	O
were	O
lyophilized	O
and	O
stored	O
at	O
-	O
80	O
Â°	O
C	O
.	O
The	O
lyophilized	O
supernatant	O
was	O
dissolved	O
in	O
0	O
.	O
6	O
mL	O
of	O
water	B-Chemical
and	O
half	O
of	O
the	O
sample	O
was	O
used	O
for	O
the	O
PS	B-Chemical
assay	O
.	O
The	O
rest	O
of	O
the	O
sample	O
was	O
used	O
for	O
characterization	O
of	O
chondroitin	B-Chemical
sulfate	I-Chemical
chains	O
.	O
Two	O
PS	B-Chemical
negative	O
samples	O
(	O
Pr	O
-	O
1k	O
and	O
l	O
)	O
and	O
five	O
PS	B-Chemical
positive	O
samples	O
(	O
Pr1	O
-	O
d	O
","	O
-	O
h	O
","	O
-	O
i	O
","	O
-	O
j	O
and	O
-	O
p	O
)	O
were	O
rechromatographed	O
by	O
RP	O
-	O
HPLC	O
and	O
characterized	O
by	O
Edman	O
sequencing	O
.	O
Characterization	O
of	O
LMW	O
Dsp	O
in	O
the	O
A	O
extract	O
The	O
AS2R	O
-	O
g	O
(	O
0	O
.	O
5	O
mg	O
)	O
fraction	O
containing	O
LMW	O
Dsp	O
(	O
Additional	O
file	O
4	O
)	O
was	O
dissolved	O
with	O
1	O
mL	O
of	O
0	O
.	O
1	O
M	O
ammonium	B-Chemical
bicarbonate	I-Chemical
/	O
1	O
mM	O
EDTA	B-Chemical
-	I-Chemical
2Na	I-Chemical
buffer	O
(	O
pH	O
7	O
.	O
8	O
).	O
Samples	O
were	O
digested	O
by	O
endoproteinase	O
Glu	O
-	O
C	O
(	O
Roche	O
Diagnostics	O
","	O
Indianapolis	O
","	O
IN	O
)	O
using	O
an	O
enzyme	O
/	O
substrate	O
ratio	O
of	O
1	O
/	O
25	O
(	O
w	O
/	O
w	O
)	O
at	O
35	O
Â°	O
C	O
for	O
24	O
h	O
.	O
The	O
digests	O
were	O
applied	O
onto	O
a	O
Discovery	O
C	O
-	O
18	O
(	O
10	O
mm	O
Ã—	O
25	O
cm	O
)	O
column	O
and	O
run	O
at	O
a	O
flow	O
rate	O
of	O
1	O
.	O
0	O
mL	O
/	O
min	O
and	O
monitored	O
at	O
220	O
nm	O
(	O
Buffer	O
A	O
:	O
0	O
.	O
5	O
%	O
TFA	B-Chemical
;	O
Buffer	O
B	O
:	O
80	O
%	O
acetonitrile	B-Chemical
/	O
buffer	O
A	O
).	O
Fifteen	O
fractions	O
were	O
collected	O
","	O
lyophilized	O
","	O
and	O
rechromatographed	O
over	O
the	O
same	O
column	O
.	O
The	O
15	O
purified	O
Glu	O
-	O
C	O
digestion	O
products	O
(	O
approximately	O
50	O
-	O
100	O
Î¼g	O
each	O
)	O
in	O
0	O
.	O
1	O
M	O
citrate	B-Chemical
-	O
phosphate	B-Chemical
buffer	O
(	O
pH	O
5	O
.	O
0	O
)	O
were	O
incubated	O
with	O
0	O
.	O
2	O
mU	O
of	O
glycopeptidase	O
A	O
(	O
Associate	O
of	O
Cape	O
Cod	O
","	O
East	O
Falmouth	O
","	O
MA	O
","	O
USA	O
)	O
containing	O
the	O
Protease	O
Inhibitor	O
Cocktail	B-Chemical
Set	I-Chemical
II	I-Chemical
(	O
0	O
.	O
8	O
mM	O
of	O
AEBSF	B-Chemical
","	O
6	O
.	O
8	O
Î¼M	O
of	O
Bestatin	B-Chemical
","	O
0	O
.	O
8	O
Î¼M	O
of	O
E	B-Chemical
-	I-Chemical
64	I-Chemical
","	O
0	O
.	O
35	O
mM	O
of	O
EDTA	B-Chemical
and	O
8	O
Î¼M	O
of	O
Pepstatin	B-Chemical
A	I-Chemical
;	O
Calbiochem	O
","	O
San	O
Diego	O
","	O
CA	O
","	O
USA	O
)	O
at	O
37	O
Â°	O
C	O
for	O
48	O
h	O
.	O
Three	O
volumes	O
of	O
ice	O
-	O
cold	O
ethanol	B-Chemical
were	O
added	O
","	O
then	O
the	O
reaction	O
mixture	O
was	O
centrifuged	O
for	O
10	O
min	O
at	O
10	O
","	O
0	O
Ã—	O
g	O
.	O
Glycopeptides	O
among	O
the	O
Glu	O
-	O
C	O
digestion	O
products	O
were	O
identified	O
by	O
rechromatography	O
using	O
the	O
same	O
Discovery	O
C	O
-	O
18	O
(	O
10	O
mm	O
Ã—	O
25	O
cm	O
)	O
column	O
.	O
Seven	O
glycopeptides	O
that	O
showed	O
a	O
shift	O
in	O
their	O
retention	O
times	O
following	O
the	O
glycopeptidase	O
A	O
digestion	O
were	O
characterized	O
by	O
LC	O
/	O
MSMS	O
analysis	O
(	O
Nextgen	O
Sciences	O
","	O
Ann	O
Arbor	O
","	O
MI	O
).	O
Qualitative	O
and	O
quantitative	O
analyses	O
of	O
sialic	B-Chemical
acid	I-Chemical
in	O
Dspp	O
-	O
derived	O
proteins	O
N	O
-	O
glycosylations	O
were	O
enzymatically	O
released	O
from	O
purified	O
Dpp	O
(	O
ANS1	O
/	O
2	O
-	O
R2	O
)	O
(	O
190	O
Î¼g	O
"),"	O
Dsp	O
(	O
ANS1	O
/	O
2R3	O
-	O
R5	O
)	O
(	O
170	O
-	O
250	O
Î¼g	O
"),"	O
Dgp	O
(	O
AS2Rd	O
-	O
Rf	O
)	O
(	O
160	O
Î¼g	O
"),"	O
and	O
LMW	O
Dsp	O
(	O
AS2R	O
-	O
g	O
)	O
(	O
180	O
Î¼g	O
)	O
with	O
1	O
mU	O
of	O
glycopeptidase	O
A	O
.	O
The	O
porcine	O
32	O
-	O
kDa	O
enamelin	O
(	O
90	O
Î¼g	O
)	O
was	O
also	O
digested	O
as	O
a	O
positive	O
control	O
.	O
Three	O
volumes	O
of	O
ice	O
-	O
cold	O
ethanol	B-Chemical
were	O
added	O
to	O
precipitate	O
the	O
deglycosylated	O
proteins	O
","	O
which	O
were	O
separated	O
from	O
the	O
released	O
N	O
-	O
glycosylations	O
by	O
centrifugation	O
for	O
10	O
min	O
at	O
10	O
","	O
0	O
Ã—	O
g	O
.	O
N	O
-	O
glycosylations	O
in	O
the	O
supernatants	O
were	O
evaporated	O
and	O
labeled	O
with	O
2	B-Chemical
-	I-Chemical
aminobenzoic	I-Chemical
acid	I-Chemical
(	O
2	B-Chemical
-	I-Chemical
AA	I-Chemical
)	O
using	O
2	B-Chemical
-	I-Chemical
AA	I-Chemical
labeling	O
kit	O
and	O
S	O
Cartridge	O
(	O
QA	O
-	O
bio	O
","	O
Palm	O
Desert	O
","	O
CA	O
).	O
A	O
labeled	O
N	B-Chemical
-	I-Chemical
glycan	I-Chemical
standard	O
(	O
10	O
pmol	O
;	O
A2	O
glycan	B-Chemical
;	O
QA	O
-	O
bio	O
)	O
and	O
the	O
2	B-Chemical
-	I-Chemical
AA	I-Chemical
-	O
glycosylations	O
were	O
separated	O
by	O
size	O
exclusion	O
-	O
HPLC	O
(	O
SE	O
-	O
HPLC	O
)	O
using	O
a	O
Nanofilm	O
-	O
SEC	O
150	O
(	O
7	O
.	O
8	O
mm	O
Ã—	O
30	O
cm	O
)	O
(	O
Sepax	O
Technologies	O
Inc	O
".,"	O
Newark	O
","	O
DE	O
)	O
column	O
equilibrated	O
with	O
PBS	B-Chemical
and	O
was	O
eluted	O
with	O
the	O
same	O
solution	O
at	O
a	O
flow	O
rate	O
of	O
1	O
.	O
0	O
mL	O
/	O
min	O
at	O
the	O
room	O
temperature	O
.	O
The	O
effluent	O
was	O
continuously	O
monitored	O
by	O
a	O
fluorescence	O
monitor	O
(	O
FP	O
-	O
2020	O
","	O
JASCO	O
","	O
Tokyo	O
","	O
Japan	O
)	O
using	O
an	O
excitation	O
wavelength	O
of	O
320	O
nm	O
and	O
an	O
emission	O
wavelength	O
of	O
420	O
nm	O
(	O
Additional	O
file	O
5	O
).	O
The	O
amount	O
of	O
released	O
labeled	O
glycosylations	O
was	O
determined	O
by	O
comparing	O
the	O
area	O
under	O
its	O
chromatographic	O
peak	O
with	O
the	O
labeled	O
A2	O
glycan	B-Chemical
standard	O
.	O
For	O
the	O
qualitative	O
analysis	O
of	O
sialic	B-Chemical
acid	I-Chemical
","	O
each	O
of	O
the	O
purified	O
2	B-Chemical
-	I-Chemical
AA	I-Chemical
glycosylation	O
samples	O
in	O
50	O
mM	O
sodium	B-Chemical
phosphate	I-Chemical
buffer	O
(	O
pH	O
6	O
.	O
0	O
)	O
was	O
incubated	O
with	O
10	O
mU	O
of	O
sialidase	O
Au	O
(	O
QA	O
-	O
bio	O
)	O
for	O
1	O
h	O
at	O
37	O
Â°	O
C	O
.	O
An	O
aliquot	O
of	O
the	O
released	O
sialic	B-Chemical
acid	I-Chemical
was	O
labeled	O
with	O
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
diamino	I-Chemical
-	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
methylenedioxy	I-Chemical
-	I-Chemical
benzene	I-Chemical
(	O
DMB	B-Chemical
)	O
using	O
a	O
sialic	B-Chemical
acid	I-Chemical
labeling	O
kit	O
(	O
QA	O
-	O
bio	O
).	O
The	O
DMB	B-Chemical
-	O
sialic	B-Chemical
acid	I-Chemical
samples	O
were	O
separated	O
by	O
RP	O
-	O
HPLC	O
using	O
a	O
GlycoSep	O
R	O
(	O
2	O
.	O
1	O
mm	O
Ã—	O
15	O
cm	O
)	O
(	O
ProZyme	O
Inc	O
".,"	O
Hayward	O
","	O
CA	O
)	O
column	O
equilibrated	O
with	O
a	O
mixture	O
of	O
acetonitrile	B-Chemical
-	O
methanol	B-Chemical
-	O
water	B-Chemical
(	O
9	O
:	O
7	O
:	O
84	O
","	O
v	O
/	O
v	O
)	O
and	O
eluted	O
with	O
the	O
same	O
solution	O
at	O
a	O
flow	O
rate	O
of	O
1	O
.	O
0	O
mL	O
/	O
min	O
at	O
the	O
room	O
temperature	O
.	O
A	O
fluorescence	O
monitor	O
using	O
an	O
excitation	O
wavelength	O
of	O
373	O
nm	O
and	O
an	O
emission	O
wavelength	O
of	O
448	O
nm	O
continuously	O
monitored	O
the	O
effluent	O
.	O
The	O
form	O
of	O
sialic	B-Chemical
acid	I-Chemical
in	O
each	O
sample	O
was	O
identified	O
by	O
comparing	O
with	O
retention	O
times	O
of	O
a	O
DMB	B-Chemical
-	O
labeled	O
sialic	B-Chemical
acid	I-Chemical
reference	O
panel	O
(	O
QA	O
-	O
bio	O
)	O
(	O
Additional	O
file	O
5	O
).	O
For	O
the	O
quantitative	O
analysis	O
of	O
sialic	B-Chemical
acid	I-Chemical
we	O
used	O
the	O
SialiQuant	O
sialic	B-Chemical
acid	I-Chemical
quantitation	O
kit	O
(	O
QA	O
-	O
bio	O
).	O
LMW	O
Dsp	O
(	O
AS2R	O
-	O
g	O
"),"	O
HMW	O
Dsp	O
(	O
ANS1	O
/	O
2	O
-	O
R5	O
"),"	O
and	O
bovine	O
fetuin	O
(	O
33	O
.	O
6	O
nmol	O
)	O
were	O
digested	O
with	O
sialidase	O
AU	O
.	O
These	O
reactions	O
","	O
as	O
well	O
as	O
10	O
nmol	O
of	O
N	B-Chemical
-	I-Chemical
acetylneuraminic	I-Chemical
acid	I-Chemical
","	O
were	O
digested	O
with	O
N	O
-	O
acetylneuraminic	O
acid	O
aldolase	O
in	O
Tris	B-Chemical
reaction	O
buffer	O
at	O
37	O
Â°	O
C	O
for	O
30	O
min	O
.	O
A	O
solution	O
of	O
Î²	B-Chemical
-	I-Chemical
NADH	I-Chemical
was	O
added	O
and	O
the	O
initial	O
Î²	B-Chemical
-	I-Chemical
NADH	I-Chemical
absorbance	O
was	O
read	O
at	O
340	O
nm	O
(	O
A340	O
initial	O
).	O
The	O
reaction	O
mixture	O
was	O
incubated	O
with	O
lactic	O
dehydrogenase	O
for	O
1	O
h	O
at	O
37	O
Â°	O
C	O
","	O
then	O
the	O
final	O
Î²	B-Chemical
-	I-Chemical
NADH	I-Chemical
absorbance	O
was	O
read	O
(	O
A340	O
final	O
)	O
and	O
the	O
nmoles	O
of	O
sialic	B-Chemical
acid	I-Chemical
calculated	O
:	O
nmoles	O
of	O
sialic	B-Chemical
acid	I-Chemical
=	O
(	O
A340	O
initial	O
-	O
A340	O
final	O
)	O
Ã—	O
1000	O
/	O
6	O
.	O
22	O
(	O
mM	O
extinction	O
coefficient	O
of	O
Î²	B-Chemical
-	I-Chemical
NADH	I-Chemical
is	O
6	O
.	O
22	O
at	O
340	O
nm	O
)	O
(	O
Additional	O
file	O
5	O
).	O
The	O
result	O
for	O
the	O
10	O
nmol	O
of	O
N	B-Chemical
-	I-Chemical
acetylneuraminic	I-Chemical
acid	I-Chemical
was	O
8	O
.	O
68	O
nmol	O
","	O
so	O
the	O
results	O
of	O
other	O
samples	O
were	O
corrected	O
by	O
multiplying	O
by	O
1	O
.	O
15	O
.	O
For	O
the	O
bovine	O
fetuin	O
control	O
this	O
correction	O
gave	O
a	O
result	O
of	O
32	O
.	O
42	O
nmol	O
.	O
SDS	B-Chemical
-	O
PAGE	O
and	O
Western	O
blotting	O
SDS	B-Chemical
-	O
PAGE	O
was	O
performed	O
using	O
Novex	O
4	O
-	O
20	O
%	O
Tris	B-Chemical
-	O
Glycine	B-Chemical
Gel	O
(	O
Invitrogen	O
","	O
Carlsbad	O
","	O
CA	O
","	O
USA	O
).	O
Samples	O
were	O
dissolved	O
in	O
Laemmli	O
sample	O
buffer	O
(	O
Bio	O
-	O
Rad	O
)	O
and	O
electrophoresis	O
was	O
carried	O
out	O
using	O
a	O
current	O
of	O
30	O
mA	O
for	O
about	O
1	O
h	O
.	O
The	O
gels	O
were	O
stained	O
with	O
Simply	B-Chemical
Blue	I-Chemical
Safe	I-Chemical
Stain	I-Chemical
(	O
Invitrogen	O
)	O
or	O
Stains	B-Chemical
-	I-Chemical
all	I-Chemical
(	O
Sigma	O
","	O
St	O
.	O
Louis	O
","	O
MO	O
","	O
USA	O
).	O
The	O
apparent	O
molecular	O
weights	O
of	O
protein	O
bands	O
were	O
estimated	O
by	O
comparison	O
with	O
SeeBlue	O
Â®	O
Plus2	O
Pre	O
-	O
Stained	O
Standard	O
(	O
Invitrogen	O
).	O
Proteins	O
were	O
electrotransferred	O
from	O
SDS	B-Chemical
-	O
PAGE	O
onto	O
a	O
Hybond	O
-	O
ECL	O
nitrocellulose	B-Chemical
membrane	O
(	O
GE	O
Healthcare	O
Bio	O
-	O
Sciences	O
Corp	O
.).	O
Porcine	O
Dsp	O
and	O
mouse	O
chondroitin	B-Chemical
6	I-Chemical
-	I-Chemical
sulfate	I-Chemical
(	O
Î”Ch	O
-	O
6S	O
)	O
antibodies	O
were	O
used	O
at	O
dilution	O
of	O
1	O
:	O
50	O
","	O
0	O
.	O
The	O
membrane	O
was	O
immunostained	O
by	O
chemiluminescent	O
detection	O
with	O
ECL	O
Advance	O
Western	O
Blotting	O
Detection	O
Kit	O
(	O
GE	O
Healthcare	O
Bio	O
-	O
Sciences	O
Corp	O
.	O
).	O
Amino	B-Chemical
Acid	I-Chemical
Analysis	O
The	O
purified	O
Dsp	O
samples	O
(	O
ANS1	O
/	O
2	O
-	O
R3	O
to	O
R5	O
)	O
(	O
20	O
-	O
30	O
Î¼g	O
)	O
were	O
hydrolyzed	O
with	O
6	O
N	O
HCl	B-Chemical
at	O
115	O
Â°	O
C	O
for	O
16	O
h	O
.	O
The	O
amino	B-Chemical
acid	I-Chemical
analyses	O
were	O
performed	O
using	O
a	O
Hitachi	O
L	O
-	O
8900PH	O
instrument	O
at	O
the	O
W	O
.	O
M	O
.	O
Keck	O
Biotechnology	O
Resource	O
Lab	O
at	O
Yale	O
University	O
.	O
Automated	O
Edman	O
Degradation	O
Automated	O
Edman	O
degradation	O
used	O
the	O
494HT	O
ABI	O
Edman	O
Protein	O
Sequencer	O
at	O
the	O
W	O
.	O
M	O
.	O
Keck	O
Biotechnology	O
Resource	O
Lab	O
at	O
Yale	O
University	O
.	O
List	O
of	O
Abbreviations	O
Used	O
A	O
:	O
Acid	O
extract	O
;	O
AN	O
:	O
acid	O
-	O
salt	O
extract	O
;	O
Bmp	O
:	O
bone	O
morphogenetic	O
protein	O
;	O
A2	B-Chemical
glycan	I-Chemical
:	O
disialo	B-Chemical
-	I-Chemical
galactosylated	I-Chemical
biantennary	I-Chemical
oligosaccharide	I-Chemical
;	O
Î”Di	B-Chemical
-	I-Chemical
0S	I-Chemical
:	O
2	B-Chemical
-	I-Chemical
acetamido	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-(	I-Chemical
beta	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
gluco	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
enepyranosyluronic	I-Chemical
acid	I-Chemical
)-	I-Chemical
D	I-Chemical
-	I-Chemical
galactose	I-Chemical
;	O
Î”Di	B-Chemical
-	I-Chemical
4S	I-Chemical
:	O
2	B-Chemical
-	I-Chemical
acetamido	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-(	I-Chemical
beta	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
gluco	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
enepyranosyluronic	I-Chemical
acid	I-Chemical
)-	I-Chemical
4	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
sulfo	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
galactose	I-Chemical
;	O
Î”Di	B-Chemical
-	I-Chemical
6S	I-Chemical
:	O
2	B-Chemical
-	I-Chemical
acetamido	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-(	I-Chemical
beta	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
gluco	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
enepyranosyluronic	I-Chemical
acid	I-Chemical
)-	I-Chemical
6	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
sulfo	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
galactose	I-Chemical
;	O
Î”Di	B-Chemical
-	I-Chemical
diSD	I-Chemical
:	O
2	B-Chemical
-	I-Chemical
acetamide	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-(	I-Chemical
2	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
sulfo	I-Chemical
-	I-Chemical
b	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
gluco	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
enepyranosyluronic	I-Chemical
acid	I-Chemical
)-	I-Chemical
6	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
sulfo	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
galactose	I-Chemical
;	O
Î”Di	B-Chemical
-	I-Chemical
diSE	I-Chemical
:	O
2	B-Chemical
-	I-Chemical
acetamide	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-(	I-Chemical
b	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
gluco	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
enepyranosyluronic	I-Chemical
acid	I-Chemical
)-	I-Chemical
4	I-Chemical
","	I-Chemical
6	I-Chemical
-	I-Chemical
bis	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
sulfo	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
galactose	I-Chemical
;	O
Î”Di	B-Chemical
-	I-Chemical
triS	I-Chemical
:	O
2	B-Chemical
-	I-Chemical
acetamido	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-(	I-Chemical
2	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
sulfo	I-Chemical
-	I-Chemical
b	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
gluco	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
enepyranosyluronic	I-Chemical
acid	I-Chemical
)-	I-Chemical
4	I-Chemical
","	I-Chemical
6	I-Chemical
-	I-Chemical
di	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
sulfo	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
galactose	I-Chemical
;	O
DD	O
:	O
dentin	O
dysplasia	O
;	O
DGI	O
:	O
dentinogenesis	O
imperfecta	O
;	O
Dgp	O
:	O
dentin	O
glycoprotein	O
;	O
DMB	B-Chemical
:	O
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
diamino	I-Chemical
-	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
methyleneoxybenzene	I-Chemical
;	O
Dmp1	O
:	O
dentin	O
matrix	O
protein	O
1	O
;	O
Dsp	O
:	O
dentin	O
sialoprotein	O
;	O
Dspp	O
:	O
dentin	O
sialophosphoprotein	O
;	O
G1	O
:	O
first	O
guanidine	B-Chemical
extract	O
;	O
G2P	O
:	O
second	O
guanidine	B-Chemical
pellet	O
;	O
G2	O
:	O
second	O
guanidine	B-Chemical
extract	O
.	O
GAG	B-Chemical
:	O
glycosaminoglycan	B-Chemical
;	O
LMW	O
:	O
low	O
molecular	O
weight	O
;	O
HMW	O
:	O
high	O
molecular	O
weight	O
;	O
HPLC	O
:	O
high	O
performance	O
liquid	O
chromatography	O
;	O
Mmp	O
:	O
matrix	O
metalloproteinase	O
;	O
Î²	B-Chemical
-	I-Chemical
NADH	I-Chemical
:	O
beta	B-Chemical
-	I-Chemical
nicotinamide	I-Chemical
adenine	I-Chemical
dinucleotide	I-Chemical
.	O
NP	O
-	O
HPLC	O
:	O
normal	O
phase	O
-	O
high	O
performance	O
liquid	O
chromatography	O
;	O
Pr	O
:	O
pronase	O
size	O
exclusion	O
fraction	O
;	O
PS	B-Chemical
:	O
phenol	B-Chemical
-	O
sulphuric	B-Chemical
acid	I-Chemical
;	O
RIM	O
:	O
Residual	O
insoluble	O
material	O
;	O
R	O
:	O
RP	O
-	O
HPLC	O
fraction	O
;	O
RP	O
-	O
HPLC	O
:	O
reversed	O
phase	O
-	O
high	O
performance	O
liquid	O
chromatography	O
;	O
S	O
:	O
size	O
exclusion	O
fraction	O
;	O
SDS	B-Chemical
-	O
PAGE	O
:	O
sodium	B-Chemical
dodecyl	I-Chemical
sulfate	I-Chemical
-	O
polyacrylamide	B-Chemical
gel	O
electrophoresis	O
;	O
SCPP	O
:	O
secretory	O
calcium	O
-	O
binding	O
phosphoprotein	O
;	O
SE	O
-	O
HPLC	O
:	O
size	O
exclusion	O
-	O
high	O
performance	O
liquid	O
chromatography	O
;	O
SIBLINGs	O
:	O
small	O
integrin	O
-	O
binding	O
ligand	O
","	O
N	O
-	O
linked	O
glycoproteins	O
;	O
TN	B-Chemical
:	O
tris	B-Chemical
-	I-Chemical
salt	I-Chemical
extract	O
;	O
2	B-Chemical
-	I-Chemical
AA	I-Chemical
:	O
2	B-Chemical
-	I-Chemical
aminobenzoic	I-Chemical
acid	I-Chemical
.	O
Authors	O
'	O
contributions	O
All	O
authors	O
(	O
YY	O
","	O
TN	O
","	O
JH	O
","	O
FY	O
and	O
JPS	O
)	O
made	O
substantive	O
intellectual	O
contributions	O
to	O
the	O
study	O
","	O
were	O
involved	O
in	O
drafting	O
and	O
revising	O
the	O
manuscript	O
","	O
and	O
have	O
given	O
final	O
approval	O
of	O
the	O
version	O
to	O
be	O
published	O
.	O
Supplementary	O
Material	O
Acknowledgements	O
We	O
thank	O
Dr	O
.	O
Doris	O
Hendig	O
of	O
the	O
Institute	O
of	O
Laboratory	O
and	O
Transfusion	O
Medicine	O
of	O
the	O
Heart	O
and	O
Diabetes	O
Center	O
in	O
Bad	O
Oeynhausen	O
","	O
Germany	O
for	O
her	O
expert	O
opinion	O
regarding	O
putative	O
GAG	B-Chemical
attachment	O
sites	O
;	O
Tom	O
Forton	O
","	O
manager	O
of	O
the	O
Michigan	O
State	O
University	O
Meat	O
Laboratory	O
and	O
members	O
of	O
the	O
Michigan	O
State	O
University	O
Department	O
of	O
Animal	O
Science	O
for	O
their	O
kind	O
assistance	O
in	O
obtaining	O
fresh	O
developing	O
molars	O
from	O
pigs	O
;	O
Nancy	O
Williams	O
","	O
Fernando	O
Pineda	O
and	O
Myron	O
Crawford	O
","	O
for	O
protein	O
sequencing	O
and	O
amino	B-Chemical
acid	I-Chemical
analysis	O
at	O
the	O
W	O
.	O
M	O
.	O
Keck	O
Foundation	O
Biotechnology	O
Resource	O
Laboratory	O
at	O
Yale	O
University	O
;	O
and	O
Dave	O
Allen	O
","	O
Lead	O
Project	O
Manager	O
at	O
NextGen	O
Sciences	O
","	O
Inc	O
for	O
the	O
mass	O
spectrometry	O
analyses	O
.	O
This	O
work	O
was	O
supported	O
by	O
the	O
National	O
Institute	O
of	O
Dental	O
and	O
Craniofacial	O
Research	O
(	O
NIDCR	O
"),"	O
of	O
the	O
U	O
.	O
S	O
.	O
National	O
Institutes	O
of	O
Health	O
","	O
grant	O
DE018020	O
.	O
A	O
meta	O
-	O
analysis	O
of	O
gemcitabine	B-Chemical
containing	O
chemotherapy	O
for	O
locally	O
advanced	O
and	O
metastatic	O
pancreatic	O
adenocarcinoma	O
Background	O
The	O
objectives	O
of	O
the	O
present	O
study	O
are	O
to	O
investigate	O
the	O
efficacy	O
and	O
safety	O
profile	O
of	O
gemcitabine	B-Chemical
-	O
based	O
combinations	O
in	O
the	O
treatment	O
of	O
locally	O
advanced	O
and	O
metastatic	O
pancreatic	O
adenocarcinoma	O
(	O
LA	O
/	O
MPC	O
).	O
Methods	O
We	O
performed	O
a	O
computerized	O
search	O
using	O
combinations	O
of	O
the	O
following	O
keywords	O
:	O
chemotherapy	O
gemcitabine	B-Chemical
trial	O
and	O
pancreatic	O
cancer	O
Results	O
Thirty	O
-	O
five	O
trials	O
were	O
included	O
in	O
the	O
present	O
analysis	O
","	O
with	O
a	O
total	O
of	O
9	O
","	O
979	O
patients	O
accrued	O
.	O
The	O
analysis	O
showed	O
that	O
the	O
gemcitabine	B-Chemical
-	O
based	O
combination	O
therapy	O
was	O
associated	O
with	O
significantly	O
better	O
overall	O
survival	O
(	O
OS	O
)	O
(	O
ORs	O
","	O
1	O
.	O
15	O
;	O
p	O
=	O
0	O
.	O
11	O
"),"	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
(	O
ORs	O
","	O
1	O
.	O
27	O
;	O
p	O
<	O
0	O
.	O
1	O
"),"	O
and	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
(	O
ORs	O
","	O
1	O
.	O
58	O
;	O
p	O
<	O
0	O
.	O
1	O
)	O
than	O
gemcitabine	B-Chemical
monotherapy	O
.	O
Similar	O
results	O
were	O
obtained	O
when	O
the	O
gemcitabine	B-Chemical
-	O
fluoropyrimidine	B-Chemical
combination	O
was	O
compared	O
with	O
gemcitabine	B-Chemical
","	O
with	O
the	O
OS	O
(	O
ORs	O
","	O
1	O
.	O
33	O
;	O
p	O
=	O
0	O
.	O
7	O
"),"	O
PFS	O
(	O
ORs	O
","	O
1	O
.	O
53	O
;	O
p	O
<	O
0	O
.	O
1	O
"),"	O
and	O
ORR	O
(	O
ORs	O
1	O
.	O
47	O
","	O
p	O
=	O
0	O
.	O
3	O
)	O
being	O
better	O
in	O
the	O
case	O
of	O
the	O
former	O
.	O
The	O
OS	O
(	O
ORs	O
","	O
1	O
.	O
33	O
;	O
p	O
=	O
0	O
.	O
19	O
"),"	O
PFS	O
(	O
ORs	O
","	O
1	O
.	O
38	O
;	O
p	O
=	O
0	O
.	O
11	O
"),"	O
and	O
one	O
-	O
year	O
survival	O
(	O
ORs	O
","	O
1	O
.	O
40	O
;	O
p	O
=	O
0	O
.	O
4	O
)	O
achieved	O
with	O
the	O
gemcitabine	B-Chemical
-	I-Chemical
oxaliplatin	I-Chemical
combination	O
were	O
significantly	O
greater	O
than	O
those	O
achieved	O
with	O
gemcitabine	B-Chemical
alone	O
.	O
However	O
","	O
no	O
survival	O
benefit	O
(	O
OS	O
:	O
ORs	O
","	O
1	O
.	O
1	O
","	O
p	O
=	O
0	O
.	O
93	O
;	O
PFS	O
:	O
ORs	O
","	O
1	O
.	O
19	O
","	O
p	O
=	O
0	O
.	O
17	O
)	O
was	O
noted	O
when	O
the	O
gemcitabine	B-Chemical
-	O
cisplatin	B-Chemical
combination	O
was	O
compared	O
to	O
gemcitabine	B-Chemical
monotherapy	O
.	O
The	O
combinations	O
of	O
gemcitabine	B-Chemical
and	O
other	O
cytotoxic	O
agents	O
also	O
afforded	O
disappointing	O
results	O
.	O
Our	O
analysis	O
indicated	O
that	O
the	O
ORR	O
improved	O
when	O
patients	O
were	O
treated	O
with	O
the	O
gemcitabine	B-Chemical
-	O
camptothecin	B-Chemical
combination	O
rather	O
than	O
gemcitabine	B-Chemical
alone	O
(	O
ORs	O
","	O
2	O
.	O
3	O
;	O
p	O
=	O
0	O
.	O
3	O
);	O
however	O
","	O
there	O
were	O
no	O
differences	O
in	O
the	O
OS	O
(	O
ORs	O
","	O
1	O
.	O
3	O
;	O
p	O
=	O
0	O
.	O
82	O
)	O
and	O
PFS	O
(	O
ORs	O
","	O
0	O
.	O
97	O
;	O
p	O
=	O
0	O
.	O
78	O
)	O
in	O
this	O
case	O
.	O
Conclusions	O
Gemcitabine	B-Chemical
in	O
combination	O
with	O
capecitabine	B-Chemical
or	O
oxaliplatin	B-Chemical
was	O
associated	O
with	O
enhanced	O
OS	O
and	O
ORR	O
as	O
compared	O
with	O
gemcitabine	B-Chemical
in	O
monotherapy	O
","	O
which	O
are	O
likely	O
to	O
become	O
the	O
preferred	O
standard	O
first	O
-	O
line	O
treatment	O
of	O
LA	O
/	O
MPC	O
.	O
Background	O
Pancreatic	O
adenocarcinoma	O
is	O
the	O
fifth	O
leading	O
cause	O
of	O
death	O
due	O
to	O
solid	O
tumors	O
in	O
Western	O
industrialized	O
countries	O
.	O
Because	O
pancreatic	O
adenocarcinoma	O
is	O
often	O
difficult	O
to	O
detect	O
in	O
early	O
stages	O
","	O
most	O
patients	O
are	O
diagnosed	O
with	O
advanced	O
or	O
metastatic	O
disease	O
at	O
first	O
presentation	O
.	O
The	O
median	O
survival	O
of	O
patients	O
with	O
locally	O
advanced	O
disease	O
is	O
6	O
to	O
10	O
months	O
","	O
compared	O
to	O
3	O
to	O
6	O
months	O
for	O
patients	O
with	O
metastatic	O
disease	O
.	O
Gemcitabine	B-Chemical
(	O
Gemzar	B-Chemical
â„¢;	O
2	B-Chemical
","	I-Chemical
2	I-Chemical
'-	I-Chemical
difluorodeoxycytidine	I-Chemical
)	O
is	O
a	O
pyrimidine	B-Chemical
antimetabolite	O
and	O
a	O
specific	O
analogue	O
of	O
deoxycytidine	B-Chemical
.	O
At	O
present	O
","	O
gemcitabine	B-Chemical
monotherapy	O
remains	O
the	O
standard	O
care	O
for	O
patients	O
with	O
locally	O
advanced	O
and	O
metastatic	O
pancreatic	O
adenocarcinoma	O
(	O
LA	O
/	O
MPC	O
).	O
However	O
","	O
patients	O
who	O
receive	O
this	O
therapy	O
have	O
a	O
median	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
only	O
5	O
.	O
65	O
months	O
.	O
In	O
an	O
effort	O
to	O
increase	O
the	O
objective	O
response	O
rate	O
(	O
RR	O
)	O
and	O
survival	O
of	O
LA	O
/	O
MPC	O
patients	O
","	O
many	O
trials	O
have	O
been	O
carried	O
out	O
in	O
the	O
last	O
ten	O
years	O
to	O
evaluate	O
gemcitabine	B-Chemical
monotherapy	O
or	O
combination	O
therapy	O
regimens	O
.	O
Currently	O
","	O
the	O
National	O
Comprehensive	O
Cancer	O
Network	O
(	O
NCCN	O
)	O
guidelines	O
indicate	O
that	O
gemcitabine	B-Chemical
combined	O
with	O
one	O
other	O
agent	O
is	O
the	O
optimal	O
treatment	O
for	O
LA	O
/	O
MPC	O
patients	O
with	O
evidence	O
of	O
category	O
2B	O
disease	O
(	O
recommendation	O
based	O
on	O
lower	O
-	O
level	O
evidence	O
).	O
It	O
is	O
unclear	O
whether	O
this	O
regimen	O
is	O
the	O
ideal	O
treatment	O
for	O
LA	O
/	O
MPC	O
or	O
whether	O
it	O
should	O
be	O
reevaluated	O
.	O
Therefore	O
","	O
we	O
undertook	O
a	O
systematic	O
review	O
and	O
quantitative	O
meta	O
-	O
analysis	O
to	O
evaluate	O
the	O
available	O
evidence	O
from	O
relevant	O
randomized	O
trials	O
.	O
This	O
review	O
will	O
summarize	O
the	O
various	O
trials	O
of	O
gemcitabine	B-Chemical
-	O
based	O
chemotherapy	O
regimens	O
in	O
LA	O
/	O
MPC	O
and	O
discuss	O
how	O
these	O
results	O
should	O
affect	O
clinical	O
practice	O
.	O
Methods	O
Search	O
strategy	O
We	O
carried	O
out	O
a	O
comprehensive	O
search	O
of	O
the	O
literature	O
for	O
randomized	O
controlled	O
trials	O
in	O
Pubmed	O
using	O
the	O
terms	O
chemotherapy	O
","	O
gemcitabine	B-Chemical
","	O
trials	O
","	O
and	O
pancreatic	O
cancer	O
(	O
no	O
limitation	O
for	O
language	O
).	O
In	O
addition	O
to	O
full	O
publications	O
","	O
abstracts	O
presented	O
at	O
the	O
annual	O
meetings	O
of	O
the	O
American	O
Society	O
of	O
Clinical	O
Oncology	O
(	O
ASCO	O
)	O
and	O
the	O
European	O
Cancer	O
Conference	O
(	O
ECCO	O
)	O
were	O
included	O
.	O
Selection	O
criteria	O
To	O
be	O
eligible	O
for	O
inclusion	O
","	O
trials	O
were	O
required	O
to	O
be	O
prospective	O
","	O
properly	O
randomized	O
and	O
well	O
designed	O
","	O
which	O
we	O
defined	O
as	O
matched	O
for	O
age	O
","	O
stage	O
and	O
performance	O
status	O
(	O
PS	O
)	O
or	O
Karnofsky	O
performance	O
status	O
(	O
KPS	O
).	O
Patients	O
with	O
locally	O
advanced	O
or	O
metastatic	O
disease	O
were	O
included	O
in	O
the	O
study	O
","	O
and	O
histologic	O
or	O
cytologic	O
confirmation	O
of	O
pancreatic	O
adenocarcinoma	O
was	O
required	O
.	O
If	O
a	O
trial	O
included	O
concomitant	O
interventions	O
such	O
as	O
radiotherapy	O
or	O
radioisotope	O
treatment	O
that	O
differed	O
systematically	O
between	O
the	O
investigated	O
arms	O
","	O
the	O
trial	O
was	O
excluded	O
.	O
Whenever	O
we	O
encountered	O
reports	O
pertaining	O
to	O
overlapping	O
patient	O
populations	O
","	O
we	O
included	O
only	O
the	O
report	O
with	O
longest	O
follow	O
-	O
up	O
(	O
having	O
the	O
largest	O
number	O
of	O
events	O
)	O
in	O
the	O
analysis	O
.	O
Only	O
randomized	O
trials	O
were	O
included	O
","	O
and	O
randomization	O
must	O
have	O
started	O
on	O
or	O
after	O
Jan	O
1	O
","	O
1965	O
.	O
The	O
deadline	O
for	O
eligible	O
trial	O
publication	O
was	O
July	O
30	O
","	O
2010	O
.	O
Data	O
collection	O
Two	O
reviewers	O
(	O
Jing	O
Hu	O
and	O
Gang	O
Zhao	O
)	O
assessed	O
the	O
identified	O
abstracts	O
.	O
Both	O
reviewers	O
independently	O
selected	O
trials	O
for	O
inclusion	O
according	O
to	O
prior	O
agreement	O
regarding	O
the	O
study	O
population	O
and	O
intervention	O
.	O
Lei	O
Tang	O
and	O
Ying	O
-	O
Chun	O
Xu	O
also	O
cross	O
-	O
checked	O
all	O
data	O
collected	O
against	O
the	O
original	O
articles	O
.	O
If	O
one	O
of	O
the	O
reviewers	O
determined	O
that	O
an	O
abstract	O
was	O
eligible	O
","	O
the	O
full	O
text	O
of	O
article	O
was	O
retrieved	O
and	O
reviewed	O
in	O
detail	O
by	O
all	O
reviewers	O
.	O
For	O
the	O
35	O
trials	O
included	O
in	O
the	O
meta	O
-	O
analysis	O
","	O
we	O
gathered	O
the	O
authors	O
'	O
names	O
","	O
journal	O
","	O
year	O
of	O
publication	O
","	O
sample	O
size	O
(	O
randomized	O
and	O
analyzed	O
)	O
per	O
arm	O
","	O
performance	O
status	O
","	O
regimens	O
used	O
","	O
line	O
of	O
treatment	O
","	O
median	O
age	O
of	O
patients	O
and	O
information	O
pertaining	O
to	O
study	O
design	O
(	O
whether	O
the	O
trial	O
reported	O
the	O
mode	O
of	O
randomization	O
","	O
allocation	O
concealment	O
","	O
description	O
of	O
withdrawals	O
per	O
arm	O
and	O
blinding	O
).	O
Statistical	O
analysis	O
The	O
meta	O
-	O
analysis	O
was	O
performed	O
using	O
Review	O
Manager	O
Version	O
4	O
.	O
2	O
(	O
Nordic	O
Cochran	O
Centre	O
","	O
Copenhagen	O
)	O
and	O
Comprehensive	O
Meta	O
Analysis	O
Version	O
2	O
(	O
Biostat	O
"â„¢,"	O
Englewood	O
","	O
NJ	O
).	O
Heterogeneity	O
between	O
the	O
trials	O
was	O
assessed	O
to	O
determine	O
which	O
model	O
should	O
be	O
used	O
.	O
To	O
assess	O
statistical	O
heterogeneity	O
between	O
studies	O
","	O
the	O
Cochran	O
Q	O
test	O
was	O
performed	O
with	O
a	O
predefined	O
significance	O
threshold	O
of	O
0	O
.	O
5	O
.	O
Odds	O
ratios	O
(	O
ORs	O
)	O
were	O
the	O
principal	O
measurements	O
of	O
effect	O
and	O
were	O
presented	O
with	O
a	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
).	O
P	O
values	O
of	O
<	O
0	O
.	O
5	O
were	O
considered	O
statistically	O
significant	O
.	O
All	O
reported	O
p	O
-	O
values	O
result	O
from	O
two	O
-	O
sided	O
versions	O
of	O
the	O
respective	O
tests	O
.	O
The	O
revision	O
of	O
funnel	O
plots	O
did	O
not	O
reveal	O
any	O
considerable	O
publication	O
bias	O
.	O
The	O
primary	O
outcome	O
measurements	O
were	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
","	O
time	O
from	O
randomization	O
to	O
progression	O
or	O
death	O
"),"	O
and	O
secondary	O
endpoints	O
were	O
overall	O
response	O
rate	O
(	O
ORR	O
","	O
number	O
of	O
partial	O
and	O
complete	O
responses	O
)	O
and	O
toxicity	O
.	O
Toxicities	O
recorded	O
by	O
the	O
original	O
research	O
group	O
were	O
recorded	O
in	O
our	O
analysis	O
","	O
and	O
the	O
most	O
frequent	O
events	O
were	O
analyzed	O
.	O
In	O
order	O
to	O
optimize	O
our	O
assessment	O
of	O
response	O
","	O
we	O
used	O
trials	O
that	O
included	O
patients	O
with	O
measurable	O
or	O
assessable	O
diseases	O
and	O
that	O
were	O
analyzed	O
predominantly	O
according	O
to	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
criteria	O
.	O
Toxicity	O
profiles	O
were	O
reported	O
according	O
to	O
the	O
WHO	O
criteria	O
.	O
Results	O
Selection	O
of	O
the	O
trials	O
The	O
literature	O
search	O
uncovered	O
762	O
articles	O
.	O
Primary	O
screening	O
led	O
to	O
the	O
exclusion	O
of	O
390	O
articles	O
for	O
the	O
following	O
reasons	O
:	O
reviews	O
(	O
218	O
"),"	O
other	O
agents	O
/	O
regimens	O
(	O
43	O
"),"	O
radiotherapy	O
/	O
chemoradiation	O
(	O
99	O
"),"	O
letters	O
/	O
comments	O
/	O
editorials	O
or	O
case	O
reports	O
.	O
The	O
remaining	O
372	O
papers	O
were	O
retrieved	O
for	O
more	O
detailed	O
evaluation	O
.	O
Of	O
these	O
","	O
144	O
articles	O
were	O
excluded	O
because	O
of	O
adjuvant	O
chemotherapy	O
","	O
44	O
for	O
biliary	O
tract	O
cancer	O
","	O
110	O
for	O
phase	O
I	O
clinical	O
trials	O
","	O
38	O
for	O
not	O
-	O
controlled	O
design	O
and	O
2	O
for	O
repeated	O
reports	O
.	O
In	O
the	O
end	O
","	O
a	O
total	O
of	O
35	O
randomized	O
clinical	O
trials	O
were	O
eligible	O
for	O
inclusion	O
in	O
our	O
analysis	O
(	O
Figure	O
1	O
).	O
Flow	O
chart	O
for	O
trials	O
selection	O
in	O
the	O
meta	O
-	O
analysis	O
.	O
Characteristics	O
of	O
the	O
trials	O
included	O
in	O
the	O
present	O
analysis	O
Thirty	O
-	O
five	O
trials	O
were	O
included	O
in	O
the	O
present	O
analysis	O
","	O
with	O
a	O
total	O
of	O
9	O
","	O
979	O
patients	O
accrued	O
.	O
Characteristics	O
of	O
the	O
eligible	O
trials	O
are	O
listed	O
in	O
Table	O
1	O
.	O
Most	O
of	O
the	O
trials	O
(	O
34	O
/	O
35	O
","	O
97	O
%)	O
evaluated	O
gemcitabine	B-Chemical
-	O
based	O
chemotherapy	O
for	O
first	O
line	O
or	O
palliative	O
chemotherapy	O
in	O
LA	O
/	O
MPC	O
patients	O
","	O
whereas	O
one	O
trial	O
(	O
Palmer	O
2007	O
)	O
evaluated	O
neoadjuvant	O
chemotherapy	O
.	O
Twenty	O
-	O
three	O
trials	O
compared	O
single	O
-	O
agent	O
gemcitabine	B-Chemical
with	O
gemcitabine	B-Chemical
combined	O
with	O
other	O
cytotoxic	O
agents	O
","	O
nine	O
trials	O
studied	O
gemcitabine	B-Chemical
monotherapy	O
with	O
gemcitabine	B-Chemical
plus	O
targeted	O
therapy	O
","	O
and	O
three	O
trials	O
evaluated	O
triplet	O
therapy	O
for	O
LA	O
/	O
MPC	O
patients	O
.	O
Characteristics	O
of	O
the	O
eligible	O
trials	O
included	O
in	O
the	O
meta	O
-	O
analysis	O
Among	O
the	O
thirty	O
-	O
five	O
trials	O
","	O
the	O
distribution	O
of	O
baseline	O
patient	O
characteristics	O
was	O
homogeneous	O
.	O
The	O
percentage	O
of	O
patients	O
with	O
metastatic	O
disease	O
ranged	O
from	O
50	O
%	O
to	O
91	O
.	O
1	O
"%,"	O
while	O
the	O
median	O
age	O
of	O
patients	O
varied	O
from	O
57	O
.	O
8	O
to	O
66	O
(	O
range	O
:	O
23	O
-	O
96	O
).	O
The	O
details	O
of	O
chemotherapeutic	O
regimens	O
per	O
arm	O
in	O
each	O
trial	O
are	O
shown	O
in	O
Table	O
2	O
.	O
Regimens	O
of	O
the	O
trials	O
included	O
in	O
this	O
analysis	O
.	O
Trials	O
comparing	O
single	O
-	O
agent	O
gemcitabine	B-Chemical
with	O
gemcitabine	B-Chemical
combined	O
with	O
other	O
cytotoxic	O
agents	O
This	O
analysis	O
evaluated	O
23	O
trials	O
(	O
5	O
","	O
577	O
patients	O
)	O
comparing	O
single	O
-	O
agent	O
gemcitabine	B-Chemical
with	O
gemcitabine	B-Chemical
-	O
based	O
combinations	O
with	O
other	O
cytotoxic	O
agents	O
.	O
For	O
the	O
primary	O
endpoint	O
of	O
OS	O
","	O
the	O
gemcitabine	B-Chemical
-	O
based	O
combination	O
therapy	O
was	O
associated	O
with	O
significantly	O
better	O
outcome	O
(	O
ORs	O
","	O
1	O
.	O
15	O
;	O
95	O
%	O
CI	O
","	O
1	O
.	O
3	O
-	O
1	O
.	O
28	O
;	O
p	O
=	O
0	O
.	O
11	O
)	O
than	O
gemcitabine	B-Chemical
in	O
monotherapy	O
(	O
Figure	O
2A	O
).	O
The	O
analysis	O
of	O
PFS	O
also	O
afforded	O
favorable	O
results	O
for	O
the	O
combination	O
arm	O
","	O
with	O
the	O
ORs	O
being	O
1	O
.	O
27	O
(	O
95	O
%	O
CI	O
","	O
1	O
.	O
14	O
-	O
1	O
.	O
42	O
;	O
p	O
<	O
0	O
.	O
1	O
)	O
(	O
Figure	O
2B	O
).	O
A	O
similar	O
advantage	O
for	O
gemcitabine	B-Chemical
-	O
based	O
combinations	O
was	O
observed	O
in	O
terms	O
of	O
the	O
ORR	O
(	O
ORs	O
","	O
1	O
.	O
58	O
;	O
95	O
%	O
CI	O
","	O
1	O
.	O
31	O
-	O
1	O
.	O
91	O
;	O
p	O
<	O
0	O
.	O
1	O
"),"	O
with	O
no	O
significant	O
heterogeneity	O
(	O
p	O
=	O
0	O
.	O
79	O
).	O
Comparison	O
of	O
gemcitabine	B-Chemical
-	O
X	O
combination	O
with	O
gemcitabine	B-Chemical
alone	O
.	O
A	O
","	O
OS	O
;	O
B	O
","	O
PFS	O
.	O
Trials	O
comparing	O
gemcitabine	B-Chemical
alone	O
with	O
gemcitabine	B-Chemical
plus	O
fluoropyrimidine	B-Chemical
Six	O
studies	O
involving	O
1829	O
patients	O
(	O
Cunningham	O
2009	O
","	O
Bernhard	O
2008	O
","	O
Scheithauer	O
2003	O
","	O
Berlin	O
2004	O
","	O
Di	O
Costanzo	O
2005	O
","	O
Riess	O
2005	O
)	O
compared	O
single	O
agent	O
gemcitabine	B-Chemical
with	O
gemcitabine	B-Chemical
plus	O
fluoropyrimidine	B-Chemical
.	O
Both	O
oral	O
capecitabine	B-Chemical
and	O
infused	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
were	O
evaluated	O
in	O
combination	O
with	O
gemcitabine	B-Chemical
in	O
a	O
variety	O
of	O
dosing	O
schedules	O
in	O
these	O
studies	O
.	O
Our	O
analysis	O
showed	O
a	O
significant	O
improvement	O
in	O
OS	O
(	O
ORs	O
","	O
1	O
.	O
33	O
;	O
95	O
%	O
CI	O
","	O
1	O
.	O
8	O
to	O
1	O
.	O
64	O
;	O
p	O
=	O
0	O
.	O
7	O
)	O
(	O
Figure	O
3A	O
"),"	O
PFS	O
(	O
ORs	O
","	O
1	O
.	O
53	O
;	O
95	O
%	O
CI	O
","	O
1	O
.	O
24	O
to	O
1	O
.	O
88	O
;	O
p	O
=	O
0	O
.	O
0	O
)	O
and	O
ORR	O
(	O
ORs	O
","	O
1	O
.	O
47	O
;	O
95	O
%	O
CI	O
","	O
1	O
.	O
4	O
to	O
2	O
.	O
7	O
;	O
p	O
=	O
0	O
.	O
3	O
)	O
when	O
gemcitabine	B-Chemical
was	O
combined	O
with	O
fluoropyrimidine	B-Chemical
.	O
The	O
ORs	O
for	O
1	O
-	O
year	O
survival	O
in	O
the	O
gemcitabine	B-Chemical
plus	O
fluoropyrimidine	B-Chemical
group	O
as	O
compared	O
with	O
the	O
group	O
that	O
received	O
gemcitabine	B-Chemical
alone	O
was	O
1	O
.	O
8	O
(	O
95	O
%	O
CI	O
","	O
0	O
.	O
82	O
to	O
1	O
.	O
43	O
;	O
p	O
=	O
0	O
.	O
58	O
).	O
Comparison	O
of	O
gemcitabine	B-Chemical
plus	O
fluoropyrimidine	B-Chemical
or	O
platinum	B-Chemical
with	O
gemcitabine	B-Chemical
alone	O
on	O
OS	O
and	O
PFS	O
.	O
A	O
","	O
gemcitabine	B-Chemical
/	I-Chemical
fluoropyrimidine	I-Chemical
versus	O
gemcitabine	B-Chemical
alone	O
on	O
OS	O
;	O
B	O
","	O
gemcitabine	B-Chemical
/	I-Chemical
platinum	I-Chemical
versus	O
gemcitabine	B-Chemical
alone	O
on	O
OS	O
;	O
C	O
","	O
gemcitabine	B-Chemical
/	I-Chemical
oxaliplatin	I-Chemical
versus	O
gemcitabine	B-Chemical
alone	O
on	O
OS	O
;	O
D	O
","	O
gemcitabine	B-Chemical
/	I-Chemical
cisplatin	I-Chemical
versus	O
gemcitabine	B-Chemical
alone	O
on	O
OS	O
;	O
E	O
","	O
gemcitabine	B-Chemical
/	I-Chemical
platinum	I-Chemical
versus	O
gemcitabine	B-Chemical
alone	O
on	O
PFS	O
;	O
F	O
","	O
gemcitabine	B-Chemical
/	I-Chemical
oxaliplatin	I-Chemical
versus	O
gemcitabine	B-Chemical
alone	O
on	O
PFS	O
;	O
G	O
","	O
gemcitabine	B-Chemical
/	I-Chemical
cisplatin	I-Chemical
versus	O
gemcitabine	B-Chemical
alone	O
on	O
PFS	O
.	O
Trials	O
comparing	O
gemcitabine	B-Chemical
alone	O
with	O
gemcitabine	B-Chemical
plus	O
platinum	B-Chemical
The	O
combination	O
of	O
gemcitabine	B-Chemical
with	O
platinum	B-Chemical
was	O
evaluated	O
in	O
eleven	O
trials	O
involving	O
2	O
","	O
379	O
patients	O
.	O
Three	O
trials	O
used	O
oxaliplatin	B-Chemical
(	O
Louvet	O
2005	O
","	O
Poplin	O
2009	O
","	O
Yan	O
2007	O
"),"	O
and	O
eight	O
trials	O
(	O
Colucci	O
2010	O
","	O
Colucci	O
2002	O
","	O
Wang	O
2002	O
","	O
Heinemann	O
2006	O
","	O
Palmer	O
2007	O
","	O
Li	O
2004	O
","	O
Kulke	O
2009	O
","	O
Viret	O
2004	O
)	O
used	O
cisplatin	B-Chemical
combined	O
with	O
gemcitabine	B-Chemical
.	O
In	O
these	O
trials	O
","	O
the	O
gemcitabine	B-Chemical
/	I-Chemical
platinum	I-Chemical
combinations	O
prolonged	O
OS	O
in	O
nine	O
trials	O
","	O
whereas	O
no	O
survival	O
benefit	O
was	O
seen	O
in	O
two	O
trials	O
(	O
Colucci	O
2010	O
","	O
Wang	O
X	O
2002	O
).	O
Meta	O
-	O
analysis	O
showed	O
that	O
the	O
combination	O
of	O
gemcitabine	B-Chemical
with	O
platinum	B-Chemical
resulted	O
in	O
a	O
significant	O
improvement	O
in	O
PFS	O
(	O
ORs	O
","	O
1	O
.	O
29	O
;	O
95	O
%	O
CI	O
","	O
1	O
.	O
8	O
to	O
1	O
.	O
54	O
;	O
p	O
=	O
0	O
.	O
5	O
)	O
(	O
Figure	O
3E	O
)	O
as	O
compared	O
with	O
gemcitabine	B-Chemical
in	O
monotherapy	O
","	O
though	O
no	O
statistical	O
significant	O
difference	O
in	O
OS	O
was	O
observed	O
(	O
ORs	O
","	O
1	O
.	O
16	O
;	O
95	O
%	O
CI	O
","	O
0	O
.	O
98	O
to	O
1	O
.	O
38	O
;	O
p	O
=	O
0	O
.	O
8	O
)	O
(	O
Figure	O
3B	O
).	O
When	O
ORR	O
was	O
compared	O
","	O
the	O
platinum	B-Chemical
combination	O
arm	O
showed	O
significantly	O
higher	O
disease	O
control	O
","	O
which	O
was	O
reflected	O
by	O
a	O
pooled	O
ORs	O
of	O
1	O
.	O
48	O
(	O
95	O
%	O
CI	O
","	O
1	O
.	O
15	O
to	O
1	O
.	O
92	O
;	O
p	O
=	O
0	O
.	O
2	O
)	O
in	O
favor	O
of	O
the	O
platinum	B-Chemical
combination	O
(	O
Figure	O
4C	O
.	O
).	O
Comparison	O
of	O
gemcitabine	B-Chemical
plus	O
platinum	B-Chemical
combination	O
with	O
gemcitabine	B-Chemical
alone	O
.	O
A	O
","	O
gemcitabine	B-Chemical
/	I-Chemical
platinum	I-Chemical
versus	O
gemcitabine	B-Chemical
alone	O
on	O
1	O
-	O
year	O
survival	O
;	O
B	O
","	O
gemcitabine	B-Chemical
/	I-Chemical
oxaliplatin	I-Chemical
versus	O
gemcitabine	B-Chemical
alone	O
on	O
1	O
-	O
year	O
survival	O
;	O
C	O
","	O
gemcitabine	B-Chemical
/	I-Chemical
platinum	I-Chemical
versus	O
gemcitabine	B-Chemical
alone	O
on	O
ORR	O
.	O
Subgroup	O
analysis	O
comparing	O
the	O
gemcitabine	B-Chemical
/	I-Chemical
oxaliplatin	I-Chemical
group	O
with	O
the	O
gemcitabine	B-Chemical
alone	O
group	O
gave	O
an	O
ORs	O
of	O
1	O
.	O
33	O
(	O
95	O
%	O
CI	O
","	O
1	O
.	O
5	O
to	O
1	O
.	O
69	O
)	O
for	O
OS	O
and	O
ORs	O
of	O
1	O
.	O
38	O
(	O
95	O
%	O
CI	O
","	O
1	O
.	O
8	O
to	O
1	O
.	O
76	O
)	O
for	O
PFS	O
","	O
which	O
was	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
19	O
","	O
p	O
=	O
0	O
.	O
11	O
","	O
seperately	O
)	O
in	O
favor	O
of	O
gemcitabine	B-Chemical
/	I-Chemical
oxaliplatin	I-Chemical
combination	O
(	O
Figure	O
3C	O
","	O
F	O
).	O
However	O
","	O
the	O
comparison	O
of	O
gemcitabine	B-Chemical
/	I-Chemical
cispiatin	I-Chemical
with	O
gemcitabine	B-Chemical
alone	O
showed	O
that	O
there	O
was	O
no	O
survival	O
benefit	O
(	O
OS	O
:	O
ORs	O
","	O
1	O
.	O
1	O
","	O
p	O
=	O
0	O
.	O
93	O
;	O
PFS	O
:	O
ORs	O
","	O
1	O
.	O
19	O
","	O
p	O
=	O
0	O
.	O
17	O
)	O
(	O
Figure	O
3D	O
","	O
G	O
).	O
There	O
was	O
also	O
a	O
trend	O
toward	O
to	O
increased	O
ORR	O
in	O
the	O
gemcitabine	B-Chemical
/	I-Chemical
cisplatin	I-Chemical
combination	O
versus	O
gemcitabine	B-Chemical
alone	O
","	O
with	O
a	O
pooled	O
ORs	O
of	O
1	O
.	O
38	O
(	O
95	O
%	O
CI	O
","	O
1	O
.	O
0	O
to	O
1	O
.	O
91	O
"),"	O
but	O
the	O
difference	O
was	O
not	O
significant	O
(	O
p	O
=	O
0	O
.	O
5	O
).	O
With	O
regards	O
to	O
one	O
-	O
year	O
survival	O
","	O
we	O
did	O
not	O
find	O
a	O
difference	O
between	O
the	O
gemcitabine	B-Chemical
/	I-Chemical
platinum	I-Chemical
group	O
versus	O
gemcitabine	B-Chemical
alone	O
(	O
OR	O
","	O
1	O
.	O
15	O
;	O
95	O
%	O
CI	O
","	O
0	O
.	O
92	O
to	O
1	O
.	O
44	O
;	O
p	O
=	O
0	O
.	O
22	O
)	O
(	O
Figure	O
4A	O
"),"	O
but	O
there	O
was	O
a	O
significant	O
improvement	O
in	O
the	O
gemcitabine	B-Chemical
/	I-Chemical
oxaliplatin	I-Chemical
group	O
(	O
OR	O
","	O
1	O
.	O
40	O
;	O
95	O
%	O
CI	O
","	O
1	O
.	O
2	O
to	O
1	O
.	O
93	O
;	O
p	O
=	O
0	O
.	O
4	O
)	O
in	O
the	O
subgroup	O
analysis	O
(	O
Figure	O
4B	O
).	O
One	O
trial	O
(	O
Palmer	O
2007	O
)	O
compared	O
gemcitabine	B-Chemical
plus	O
cisplatin	B-Chemical
with	O
gemcitabine	B-Chemical
in	O
the	O
neoadjuvant	O
setting	O
.	O
The	O
study	O
showed	O
that	O
the	O
percentage	O
of	O
patients	O
who	O
underwent	O
resection	O
was	O
38	O
%	O
in	O
gemcitabine	B-Chemical
arm	O
versus	O
70	O
%	O
in	O
the	O
combination	O
arm	O
","	O
with	O
no	O
increase	O
in	O
surgical	O
complications	O
.	O
The	O
12	O
-	O
month	O
survival	O
percentages	O
for	O
the	O
gemcitabine	B-Chemical
and	O
combination	O
groups	O
were	O
42	O
%	O
and	O
62	O
"%,"	O
respectively	O
.	O
Combination	O
therapy	O
with	O
gemcitabine	B-Chemical
and	O
cisplatin	B-Chemical
was	O
associated	O
with	O
a	O
higher	O
resection	O
rate	O
and	O
an	O
encouraging	O
survival	O
rate	O
","	O
suggesting	O
that	O
further	O
study	O
is	O
warranted	O
.	O
Trials	O
comparing	O
gemcitabine	B-Chemical
alone	O
with	O
gemcitabine	B-Chemical
plus	O
camptothecin	B-Chemical
Four	O
randomized	O
trials	O
(	O
n	O
=	O
839	O
)	O
compared	O
the	O
combination	O
of	O
gemcitabine	B-Chemical
and	O
topoisomerase	O
I	O
inhibitors	O
(	O
irinotecan	B-Chemical
or	O
exatecan	B-Chemical
)	O
with	O
gemcitabine	B-Chemical
monotherapy	O
.	O
They	O
included	O
three	O
studies	O
(	O
Kulke	O
2009	O
","	O
Stathopoulos	O
2006	O
","	O
Rocha	O
Lima	O
2004	O
)	O
in	O
which	O
gemcitabine	B-Chemical
was	O
combined	O
with	O
CPT	B-Chemical
-	I-Chemical
11	I-Chemical
(	O
irinotecan	B-Chemical
)	O
and	O
one	O
study	O
(	O
Abou	O
-	O
Alfa	O
2006	O
)	O
in	O
which	O
gemcitabine	B-Chemical
was	O
combined	O
with	O
exatecan	B-Chemical
.	O
The	O
analysis	O
revealed	O
a	O
significant	O
improvement	O
in	O
ORR	O
for	O
gemcitabine	B-Chemical
plus	O
camptothecin	B-Chemical
therapy	O
(	O
ORs	O
2	O
.	O
3	O
;	O
95	O
%	O
CI	O
","	O
1	O
.	O
28	O
to	O
3	O
.	O
23	O
;	O
p	O
=	O
0	O
.	O
3	O
;	O
heterogeneity	O
","	O
p	O
=	O
0	O
.	O
14	O
).	O
However	O
","	O
the	O
combination	O
did	O
not	O
significantly	O
improve	O
OS	O
or	O
PFS	O
.	O
The	O
pooled	O
ORs	O
for	O
OS	O
and	O
PFS	O
were	O
1	O
.	O
3	O
(	O
95	O
%	O
CI	O
","	O
0	O
.	O
81	O
to	O
1	O
.	O
32	O
;	O
p	O
=	O
0	O
.	O
82	O
)	O
and	O
0	O
.	O
97	O
(	O
95	O
%	O
CI	O
","	O
0	O
.	O
76	O
to	O
1	O
.	O
23	O
;	O
p	O
=	O
0	O
.	O
78	O
"),"	O
respectively	O
(	O
Figure	O
5	O
).	O
OS	O
and	O
PFS	O
of	O
gemcitabine	B-Chemical
/	I-Chemical
camptothecin	I-Chemical
combination	O
as	O
compared	O
with	O
gemcitabine	B-Chemical
in	O
monotherapy	O
.	O
A	O
","	O
OS	O
;	O
B	O
","	O
PFS	O
.	O
Trials	O
comparing	O
gemcitabine	B-Chemical
monotherapy	O
with	O
gemcitabine	B-Chemical
plus	O
other	O
agents	O
Various	O
other	O
cytotoxic	O
agents	O
have	O
been	O
tested	O
in	O
combination	O
with	O
gemcitabine	B-Chemical
in	O
LA	O
/	O
MPC	O
patients	O
","	O
including	O
pemetrexed	B-Chemical
(	O
Alimta	B-Chemical
)	O
and	O
docetaxel	B-Chemical
.	O
The	O
analysis	O
included	O
two	O
trials	O
(	O
n	O
=	O
665	O
"),"	O
which	O
indicated	O
that	O
the	O
OS	O
in	O
the	O
combination	O
group	O
was	O
even	O
lower	O
than	O
gemcitabine	B-Chemical
monotherapy	O
(	O
ORs	O
","	O
-	O
0	O
.	O
10	O
;	O
95	O
%	O
CI	O
","	O
-	O
0	O
.	O
16	O
to	O
-	O
0	O
.	O
4	O
;	O
p	O
=	O
0	O
.	O
2	O
"),"	O
although	O
the	O
ORR	O
analysis	O
showed	O
therapeutic	O
benefit	O
of	O
the	O
combination	O
(	O
ORs	O
","	O
1	O
.	O
91	O
;	O
95	O
%	O
CI	O
","	O
1	O
.	O
16	O
to	O
3	O
.	O
16	O
;	O
p	O
=	O
0	O
.	O
1	O
)	O
(	O
Figure	O
5B	O
).	O
Oettle	O
'	O
s	O
trial	O
","	O
a	O
randomized	O
phase	O
III	O
study	O
with	O
565	O
patients	O
comparing	O
the	O
combination	O
of	O
gemcitabine	B-Chemical
and	O
pemetrexed	B-Chemical
to	O
gemcitabine	B-Chemical
alone	O
","	O
showed	O
that	O
OS	O
was	O
not	O
improved	O
in	O
the	O
combination	O
arm	O
(	O
6	O
.	O
2	O
months	O
)	O
compared	O
with	O
the	O
gemcitabine	B-Chemical
alone	O
group	O
(	O
6	O
.	O
3	O
months	O
)	O
(	O
p	O
=	O
0	O
.	O
8477	O
"),"	O
although	O
tumor	O
response	O
rate	O
(	O
14	O
.	O
8	O
%	O
versus	O
7	O
.	O
1	O
%;	O
p	O
=	O
0	O
.	O
4	O
)	O
was	O
significantly	O
better	O
in	O
the	O
combination	O
arm	O
.	O
Trials	O
comparing	O
gemcitabine	B-Chemical
monotherapy	O
with	O
gemcitabine	B-Chemical
plus	O
targeted	O
therapy	O
The	O
role	O
of	O
new	O
","	O
targeted	O
drugs	O
in	O
the	O
treatment	O
of	O
advanced	O
pancreatic	O
adenocarcinoma	O
has	O
been	O
actively	O
explored	O
in	O
the	O
past	O
few	O
years	O
.	O
There	O
are	O
preliminary	O
results	O
and	O
ongoing	O
studies	O
with	O
EGFR	O
inhibitors	O
(	O
erlotinib	B-Chemical
","	O
cetuximab	B-Chemical
"),"	O
farnesyltransferase	O
inhibitors	O
(	O
tipifarnib	B-Chemical
"),"	O
leukotriene	O
B4	O
receptor	O
antagonists	O
(	O
LY293111	B-Chemical
"),"	O
antiangiogenic	O
agents	O
(	O
axitinib	B-Chemical
","	O
cilengitide	B-Chemical
"),"	O
matrix	O
metalloproteinase	O
inhibitors	O
(	O
marimastat	B-Chemical
"),"	O
vascular	O
endothelial	O
growth	O
factor	O
A	O
inhibitors	O
(	O
bevacizumab	B-Chemical
"),"	O
and	O
histone	O
deacetylase	O
inhibitors	O
(	O
CI	B-Chemical
-	I-Chemical
994	I-Chemical
).	O
However	O
","	O
most	O
of	O
these	O
trials	O
showed	O
negative	O
results	O
.	O
In	O
the	O
present	O
analysis	O
","	O
nine	O
trials	O
including	O
3	O
","	O
342	O
patients	O
evaluated	O
gemcitabine	B-Chemical
combined	O
with	O
targeted	O
therapy	O
(	O
Table	O
3	O
).	O
Although	O
the	O
results	O
of	O
the	O
most	O
recent	O
trials	O
(	O
Philip	O
2010	O
","	O
Kindler	O
2010	O
)	O
are	O
now	O
available	O
","	O
which	O
evaluated	O
gemcitabine	B-Chemical
combined	O
with	O
C	B-Chemical
-	I-Chemical
225	I-Chemical
or	O
bevacizumab	B-Chemical
","	O
so	O
far	O
Moore	O
'	O
s	O
trial	O
is	O
still	O
the	O
only	O
study	O
to	O
demonstrate	O
a	O
significant	O
improvement	O
in	O
survival	O
in	O
LA	O
/	O
MPC	O
as	O
a	O
result	O
of	O
adding	O
a	O
targeted	O
agent	O
to	O
gemcitabine	B-Chemical
.	O
Therefore	O
","	O
the	O
addition	O
of	O
other	O
targeted	O
agents	O
is	O
not	O
recommended	O
for	O
the	O
treatment	O
of	O
LA	O
/	O
MPC	O
in	O
the	O
current	O
clinical	O
setting	O
outside	O
of	O
a	O
clinical	O
trials	O
.	O
Median	O
OS	O
and	O
DFS	O
in	O
trials	O
comparing	O
gemcitabine	B-Chemical
combined	O
with	O
targeted	O
therapy	O
with	O
gemcitabine	B-Chemical
alone	O
.	O
Trials	O
discussing	O
gemcitabine	B-Chemical
doublets	O
plus	O
a	O
third	O
targeted	O
reagent	O
Two	O
trials	O
(	O
Cascino	O
2008	O
","	O
Vervenne	O
2008	O
)	O
including	O
691	O
patients	O
evaluated	O
a	O
gemcitabine	B-Chemical
doublet	O
with	O
or	O
without	O
a	O
third	O
targeted	O
reagent	O
.	O
In	O
Cascino	O
'	O
s	O
multicenter	O
randomized	O
phase	O
II	O
trial	O
","	O
the	O
addition	O
of	O
cetuximab	B-Chemical
to	O
the	O
gemcitabine	B-Chemical
/	I-Chemical
cisplatin	I-Chemical
combination	O
did	O
not	O
increase	O
PFS	O
(	O
hazard	O
ratio	O
0	O
.	O
96	O
","	O
95	O
%	O
CI	O
","	O
0	O
.	O
60	O
-	O
1	O
.	O
52	O
","	O
p	O
=	O
0	O
.	O
847	O
)	O
or	O
OS	O
(	O
hazard	O
ratio	O
0	O
.	O
91	O
","	O
95	O
%	O
CI	O
","	O
0	O
.	O
54	O
-	O
1	O
.	O
55	O
","	O
p	O
=	O
0	O
.	O
739	O
).	O
In	O
2008	O
","	O
Vervenne	O
compared	O
the	O
efficacy	O
and	O
safety	O
of	O
adding	O
bevacizumab	B-Chemical
to	O
erlotinib	B-Chemical
and	O
gemcitabine	B-Chemical
in	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
.	O
The	O
results	O
showed	O
that	O
addition	O
of	O
bevacizumab	B-Chemical
to	O
erlotinib	B-Chemical
and	O
gemcitabine	B-Chemical
did	O
not	O
significantly	O
prolong	O
OS	O
","	O
but	O
there	O
was	O
a	O
significant	O
improvement	O
in	O
PFS	O
(	O
p	O
=	O
0	O
.	O
2	O
).	O
This	O
combination	O
requires	O
further	O
investigation	O
in	O
larger	O
-	O
scale	O
clinical	O
trials	O
to	O
assess	O
efficacy	O
and	O
cost	O
effectiveness	O
.	O
Pooled	O
analysis	O
revealed	O
slightly	O
better	O
disease	O
control	O
by	O
adding	O
a	O
third	O
reagent	O
to	O
the	O
gemcitabine	B-Chemical
doublet	O
","	O
with	O
an	O
ORs	O
of	O
1	O
.	O
62	O
(	O
95	O
%	O
CI	O
","	O
1	O
.	O
0	O
to	O
2	O
.	O
62	O
"),"	O
but	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
5	O
).	O
Furthermore	O
","	O
the	O
OS	O
observed	O
in	O
the	O
triplet	O
group	O
was	O
disappointing	O
(	O
ORs	O
","	O
-	O
0	O
.	O
79	O
;	O
95	O
%	O
CI	O
","	O
-	O
0	O
.	O
90	O
to	O
-	O
0	O
.	O
60	O
;	O
p	O
<	O
0	O
.	O
1	O
).	O
Discussion	O
Pancreatic	O
adenocarcinoma	O
is	O
among	O
the	O
most	O
challenging	O
of	O
solid	O
malignancies	O
to	O
treat	O
on	O
account	O
of	O
its	O
propensity	O
for	O
late	O
presentation	O
with	O
inoperable	O
disease	O
","	O
aggressive	O
tumor	O
biology	O
and	O
resistance	O
to	O
chemotherapy	O
.	O
Gemcitabine	B-Chemical
monotherapy	O
has	O
become	O
a	O
cornerstone	O
of	O
therapy	O
for	O
patients	O
with	O
LA	O
/	O
MPC	O
since	O
Burris	O
et	O
al	O
reported	O
their	O
phase	O
III	O
trial	O
results	O
.	O
Although	O
it	O
has	O
shown	O
clinical	O
benefit	O
","	O
gemcitabine	B-Chemical
monotherapy	O
has	O
been	O
associated	O
with	O
limited	O
antitumor	O
activity	O
","	O
with	O
an	O
ORR	O
of	O
5	O
%	O
and	O
median	O
OS	O
of	O
5	O
.	O
7	O
months	O
.	O
In	O
the	O
past	O
decade	O
","	O
many	O
randomized	O
controlled	O
trials	O
evaluated	O
gemcitabine	B-Chemical
combined	O
with	O
various	O
cytotoxic	O
or	O
targeted	O
agents	O
to	O
try	O
to	O
improve	O
outcomes	O
for	O
patients	O
with	O
LA	O
/	O
MPC	O
.	O
Some	O
of	O
these	O
studies	O
have	O
reported	O
improved	O
median	O
OS	O
and	O
one	O
-	O
year	O
survival	O
rates	O
.	O
However	O
","	O
the	O
question	O
of	O
whether	O
gemcitabine	B-Chemical
-	O
based	O
combinations	O
are	O
better	O
than	O
gemcitabine	B-Chemical
monotherapy	O
is	O
still	O
unclear	O
.	O
To	O
compare	O
the	O
efficacy	O
and	O
tolerability	O
of	O
gemcitabine	B-Chemical
-	O
based	O
combinations	O
in	O
the	O
treatment	O
of	O
LA	O
/	O
MPC	O
with	O
sufficient	O
statistical	O
power	O
","	O
we	O
performed	O
this	O
meta	O
-	O
analysis	O
to	O
overcome	O
the	O
statistical	O
limitations	O
(	O
for	O
instance	O
","	O
low	O
case	O
load	O
)	O
of	O
the	O
individual	O
trials	O
and	O
investigate	O
treatment	O
efficacy	O
","	O
safety	O
profile	O
and	O
survival	O
benefit	O
of	O
various	O
therapeutic	O
combinations	O
.	O
The	O
systematic	O
review	O
yielded	O
five	O
major	O
findings	O
.	O
First	O
","	O
the	O
analysis	O
showed	O
that	O
gemcitabine	B-Chemical
-	O
based	O
combination	O
was	O
associated	O
with	O
significantly	O
greater	O
OS	O
(	O
ORs	O
","	O
1	O
.	O
15	O
;	O
p	O
=	O
0	O
.	O
11	O
"),"	O
PFS	O
(	O
ORs	O
","	O
1	O
.	O
27	O
;	O
p	O
<	O
0	O
.	O
1	O
"),"	O
and	O
ORR	O
(	O
ORs	O
","	O
1	O
.	O
58	O
;	O
p	O
<	O
0	O
.	O
1	O
)	O
than	O
gemcitabine	B-Chemical
monotherapy	O
.	O
The	O
study	O
reported	O
by	O
Heinemann	O
revealed	O
similar	O
results	O
;	O
their	O
study	O
considered	O
15	O
trials	O
including	O
4465	O
patients	O
for	O
the	O
analysis	O
of	O
OS	O
.	O
The	O
analysis	O
revealed	O
a	O
significant	O
survival	O
benefit	O
for	O
gemcitabine	B-Chemical
+	O
X	O
(	O
X	O
=	O
cytotoxic	O
agent	O
)	O
with	O
a	O
pooled	O
ORs	O
of	O
0	O
.	O
91	O
(	O
p	O
=	O
0	O
.	O
4	O
)	O
and	O
indicated	O
that	O
patients	O
with	O
a	O
good	O
PS	O
had	O
a	O
marked	O
survival	O
benefit	O
when	O
receiving	O
combination	O
chemotherapy	O
(	O
ORs	O
","	O
0	O
.	O
76	O
;	O
p	O
<	O
0	O
.	O
1	O
).	O
A	O
similar	O
advantage	O
for	O
gemcitabine	B-Chemical
combined	O
with	O
fluoropyrimidine	B-Chemical
was	O
observed	O
in	O
terms	O
of	O
the	O
OS	O
(	O
ORs	O
","	O
1	O
.	O
33	O
;	O
p	O
=	O
0	O
.	O
7	O
"),"	O
PFS	O
(	O
ORs	O
","	O
1	O
.	O
53	O
;	O
p	O
<	O
0	O
.	O
1	O
"),"	O
and	O
ORR	O
(	O
ORs	O
1	O
.	O
47	O
","	O
p	O
=	O
0	O
.	O
3	O
)	O
as	O
compared	O
to	O
gemcitabine	B-Chemical
alone	O
.	O
Although	O
the	O
occurrence	O
of	O
hematological	O
toxicities	O
","	O
including	O
neutropenia	O
(	O
ORs	O
","	O
1	O
.	O
60	O
;	O
p	O
=	O
0	O
.	O
2	O
)	O
and	O
thrombocytopenia	O
(	O
ORs	O
","	O
1	O
.	O
52	O
;	O
p	O
=	O
0	O
.	O
4	O
"),"	O
was	O
higher	O
in	O
the	O
combination	O
group	O
","	O
the	O
incidence	O
of	O
anemia	O
(	O
ORs	O
","	O
0	O
.	O
97	O
;	O
p	O
=	O
0	O
.	O
90	O
)	O
and	O
non	O
-	O
hematological	O
toxicities	O
such	O
as	O
nausea	O
/	O
vomiting	O
(	O
ORs	O
","	O
1	O
.	O
10	O
;	O
p	O
=	O
0	O
.	O
60	O
)	O
were	O
similar	O
in	O
both	O
groups	O
.	O
It	O
remained	O
to	O
be	O
determined	O
whether	O
the	O
combination	O
of	O
gemcitabine	B-Chemical
with	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
or	O
that	O
with	O
capecitabine	B-Chemical
was	O
better	O
.	O
Bolus	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
and	O
high	O
-	O
dose	O
leucovorin	B-Chemical
have	O
not	O
shown	O
meaningful	O
therapeutic	O
benefits	O
in	O
phase	O
II	O
studies	O
.	O
However	O
","	O
researchers	O
have	O
speculated	O
that	O
continuous	O
-	O
infusion	O
of	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
could	O
improve	O
its	O
therapeutic	O
efficacy	O
.	O
Capecitabine	B-Chemical
(	O
N4	B-Chemical
-	I-Chemical
pentyloxycarbonyl	I-Chemical
-	I-Chemical
5	I-Chemical
'-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
fluorocytidine	I-Chemical
)	O
(	O
Xeloda	B-Chemical
;	O
F	O
.	O
Hoffmann	O
-	O
La	O
Roche	O
","	O
Basel	O
","	O
Switzerland	O
"),"	O
an	O
oral	O
tumor	O
-	O
selective	O
fluoropyrimidine	B-Chemical
","	O
has	O
been	O
reported	O
to	O
be	O
as	O
efficacious	O
as	O
continuous	O
-	O
infusion	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
.	O
Capecitabine	B-Chemical
appears	O
to	O
be	O
a	O
reasonable	O
substitute	O
for	O
infused	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
/	I-Chemical
LV	I-Chemical
in	O
combination	O
regimens	O
or	O
as	O
monotherapy	O
","	O
with	O
the	O
added	O
advantage	O
of	O
reducing	O
the	O
inconvenience	O
of	O
long	O
infusion	O
times	O
.	O
Cartwright	O
reported	O
that	O
capecitabine	B-Chemical
alone	O
has	O
an	O
ORR	O
of	O
7	O
.	O
3	O
%	O
and	O
a	O
disease	O
control	O
rate	O
of	O
24	O
%	O
in	O
previously	O
untreated	O
patients	O
with	O
LA	O
/	O
MPC	O
.	O
In	O
Cunningham	O
'	O
s	O
report	O
","	O
gemcitabine	B-Chemical
/	I-Chemical
capecitabine	I-Chemical
significantly	O
improved	O
ORR	O
(	O
19	O
.	O
1	O
%	O
v	O
12	O
.	O
4	O
%;	O
p	O
=	O
0	O
.	O
34	O
)	O
and	O
PFS	O
(	O
hazard	O
ratio	O
","	O
0	O
.	O
78	O
;	O
95	O
%	O
CI	O
","	O
0	O
.	O
66	O
to	O
0	O
.	O
93	O
;	O
p	O
=	O
0	O
.	O
4	O
)	O
and	O
was	O
associated	O
with	O
a	O
trend	O
toward	O
improved	O
OS	O
(	O
hazard	O
ratio	O
","	O
0	O
.	O
86	O
;	O
95	O
%	O
CI	O
","	O
0	O
.	O
72	O
to	O
1	O
.	O
2	O
;	O
p	O
=	O
0	O
.	O
8	O
)	O
compared	O
with	O
gemcitabine	B-Chemical
alone	O
.	O
On	O
the	O
basis	O
of	O
these	O
results	O
","	O
he	O
recommended	O
that	O
gemcitabine	B-Chemical
/	I-Chemical
capecitabine	I-Chemical
should	O
be	O
considered	O
one	O
of	O
the	O
standard	O
first	O
-	O
line	O
options	O
in	O
LA	O
/	O
MPC	O
.	O
In	O
1993	O
","	O
Wils	O
was	O
the	O
first	O
to	O
report	O
that	O
single	O
-	O
agent	O
cisplatin	B-Chemical
has	O
therapeutic	O
activity	O
in	O
LA	O
/	O
MPC	O
with	O
an	O
ORR	O
of	O
21	O
%.	O
Soon	O
afterwards	O
","	O
several	O
phase	O
II	O
studies	O
discussed	O
the	O
gemcitabine	B-Chemical
plus	O
cisplatin	B-Chemical
combination	O
in	O
a	O
variety	O
of	O
schedules	O
.	O
Adding	O
cisplatin	B-Chemical
to	O
gemcitabine	B-Chemical
appeared	O
to	O
be	O
very	O
active	O
","	O
with	O
ORR	O
ranging	O
from	O
9	O
%	O
to	O
31	O
%	O
and	O
median	O
OS	O
from	O
5	O
.	O
6	O
to	O
9	O
.	O
6	O
months	O
in	O
these	O
phase	O
II	O
trials	O
.	O
Furthermore	O
","	O
in	O
the	O
neoadjuvant	O
setting	O
","	O
Palmer	O
(	O
2007	O
)	O
showed	O
that	O
combination	O
therapy	O
with	O
gemcitabine	B-Chemical
and	O
cisplatin	B-Chemical
was	O
associated	O
with	O
a	O
high	O
resection	O
rate	O
and	O
an	O
encouraging	O
survival	O
rate	O
.	O
However	O
","	O
the	O
pooled	O
analysis	O
showed	O
that	O
the	O
PFS	O
and	O
ORR	O
achieved	O
with	O
the	O
gemcitabine	B-Chemical
and	O
platinum	B-Chemical
combination	O
were	O
significantly	O
greater	O
than	O
those	O
achieved	O
with	O
gemcitabine	B-Chemical
monotherapy	O
;	O
however	O
","	O
no	O
statistically	O
significant	O
difference	O
between	O
the	O
2	O
treatment	O
approaches	O
were	O
observed	O
in	O
the	O
case	O
of	O
OS	O
.	O
This	O
result	O
was	O
consistent	O
with	O
that	O
obtained	O
in	O
a	O
study	O
conducted	O
by	O
Bria	O
.	O
In	O
Bria	O
'	O
s	O
meta	O
-	O
analysis	O
","	O
platinum	B-Chemical
combinations	O
led	O
to	O
the	O
greater	O
absolute	O
benefits	O
in	O
terms	O
of	O
PFS	O
and	O
ORR	O
as	O
compared	O
with	O
single	O
-	O
agent	O
gemcitabine	B-Chemical
(	O
10	O
%	O
and	O
6	O
.	O
5	O
"%,"	O
respectively	O
"),"	O
but	O
did	O
not	O
result	O
in	O
an	O
OS	O
benefit	O
.	O
However	O
","	O
Heinemann	O
reported	O
contrary	O
results	O
","	O
with	O
a	O
ORs	O
of	O
0	O
.	O
85	O
(	O
p	O
=	O
0	O
.	O
10	O
)	O
for	O
platinum	B-Chemical
-	O
gemcitabine	B-Chemical
combinations	O
compared	O
to	O
gemcitabine	B-Chemical
alone	O
.	O
Heinemann	O
'	O
s	O
study	O
included	O
15	O
trials	O
with	O
4465	O
patients	O
","	O
whereas	O
Bria	O
'	O
s	O
study	O
included	O
20	O
trials	O
with	O
6296	O
patients	O
;	O
our	O
study	O
included	O
35	O
trials	O
with	O
9979	O
patients	O
.	O
The	O
greater	O
number	O
of	O
included	O
trials	O
and	O
case	O
load	O
in	O
our	O
study	O
may	O
have	O
contributed	O
to	O
the	O
more	O
favorable	O
results	O
obtained	O
in	O
our	O
study	O
.	O
Further	O
","	O
our	O
subgroup	O
analysis	O
showed	O
that	O
the	O
OS	O
(	O
p	O
=	O
0	O
.	O
19	O
"),"	O
PFS	O
(	O
p	O
=	O
0	O
.	O
11	O
"),"	O
and	O
one	O
-	O
year	O
survival	O
(	O
p	O
=	O
0	O
.	O
4	O
)	O
in	O
the	O
gemcitabine	B-Chemical
-	I-Chemical
oxaliplatin	I-Chemical
group	O
were	O
significantly	O
better	O
than	O
those	O
in	O
the	O
gemcitabine	B-Chemical
monotherapy	O
group	O
.	O
On	O
the	O
contrary	O
","	O
the	O
comparison	O
of	O
gemcitabine	B-Chemical
-	O
cisplatin	B-Chemical
with	O
gemcitabine	B-Chemical
alone	O
showed	O
that	O
there	O
was	O
no	O
survival	O
benefit	O
(	O
OS	O
:	O
p	O
=	O
0	O
.	O
93	O
;	O
PFS	O
:	O
p	O
=	O
0	O
.	O
17	O
)	O
with	O
the	O
former	O
.	O
Hence	O
","	O
we	O
concluded	O
that	O
the	O
combination	O
of	O
gemcitabine	B-Chemical
and	O
oxaliplatin	B-Chemical
is	O
superior	O
to	O
gemcitabine	B-Chemical
plus	O
cisplatin	B-Chemical
and	O
may	O
be	O
recommended	O
as	O
one	O
of	O
the	O
standard	O
first	O
-	O
line	O
therapies	O
for	O
LA	O
/	O
MPC	O
.	O
The	O
third	O
key	O
finding	O
was	O
that	O
the	O
combination	O
of	O
gemcitabine	B-Chemical
plus	O
other	O
cytotoxic	O
agents	O
showed	O
disappointing	O
results	O
.	O
According	O
to	O
the	O
literature	O
","	O
the	O
combination	O
of	O
gemcitabine	B-Chemical
and	O
irinotecan	B-Chemical
resulted	O
in	O
an	O
objective	O
response	O
of	O
25	O
%	O
with	O
a	O
median	O
OS	O
ranging	O
from	O
5	O
.	O
7	O
to	O
7	O
months	O
(	O
Rocha	O
-	O
Lima	O
2002	O
","	O
Stathopoulos	O
2004	O
).	O
Although	O
our	O
analysis	O
found	O
an	O
enhanced	O
ORR	O
for	O
gemcitabine	B-Chemical
plus	O
camptothecin	B-Chemical
therapy	O
(	O
ORs	O
","	O
2	O
.	O
3	O
;	O
p	O
=	O
0	O
.	O
3	O
"),"	O
we	O
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
OS	O
(	O
ORs	O
","	O
1	O
.	O
3	O
;	O
p	O
=	O
0	O
.	O
82	O
)	O
or	O
PFS	O
(	O
ORs	O
","	O
0	O
.	O
97	O
;	O
p	O
=	O
0	O
.	O
78	O
)	O
in	O
the	O
comparison	O
.	O
Other	O
single	O
agents	O
including	O
docetaxel	B-Chemical
and	O
pemetrexed	B-Chemical
have	O
also	O
been	O
tested	O
in	O
advanced	O
pancreatic	O
cancer	O
.	O
However	O
","	O
the	O
analysis	O
of	O
two	O
trials	O
(	O
n	O
=	O
665	O
)	O
showed	O
negative	O
results	O
.	O
The	O
OS	O
in	O
the	O
combination	O
group	O
was	O
even	O
lower	O
than	O
that	O
of	O
patients	O
receiving	O
monotherapy	O
(	O
ORs	O
","	O
-	O
0	O
.	O
10	O
;	O
p	O
=	O
0	O
.	O
2	O
"),"	O
although	O
the	O
ORR	O
analysis	O
showed	O
therapeutic	O
benefit	O
for	O
this	O
combination	O
group	O
(	O
ORs	O
","	O
1	O
.	O
91	O
;	O
p	O
=	O
0	O
.	O
1	O
).	O
Fourth	O
","	O
the	O
identification	O
of	O
novel	O
targets	O
is	O
still	O
elusive	O
for	O
the	O
treatment	O
of	O
LA	O
/	O
MPC	O
.	O
Since	O
2002	O
","	O
there	O
has	O
been	O
a	O
series	O
of	O
disappointing	O
results	O
.	O
The	O
only	O
exception	O
is	O
erlotinib	B-Chemical
","	O
which	O
is	O
the	O
first	O
and	O
only	O
targeted	O
agent	O
to	O
demonstrate	O
significantly	O
improved	O
survival	O
in	O
advanced	O
pancreatic	O
cancer	O
when	O
added	O
to	O
gemcitabine	B-Chemical
.	O
Further	O
research	O
should	O
be	O
focused	O
on	O
new	O
combinations	O
or	O
multi	O
-	O
target	O
combined	O
therapy	O
","	O
incorporating	O
new	O
","	O
targeted	O
therapies	O
and	O
identifying	O
potential	O
predictive	O
factors	O
of	O
response	O
.	O
The	O
fifth	O
finding	O
concerned	O
combining	O
a	O
gemcitabine	B-Chemical
doublet	O
with	O
or	O
without	O
a	O
third	O
targeted	O
reagent	O
.	O
Our	O
analysis	O
revealed	O
slightly	O
better	O
disease	O
control	O
by	O
adding	O
a	O
third	O
reagent	O
to	O
a	O
gemcitabine	B-Chemical
doublet	O
","	O
with	O
an	O
ORs	O
of	O
1	O
.	O
62	O
(	O
95	O
%	O
CI	O
","	O
1	O
.	O
0	O
to	O
2	O
.	O
62	O
"),"	O
but	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
5	O
).	O
The	O
OS	O
in	O
the	O
triplet	O
group	O
was	O
also	O
disappointing	O
(	O
ORs	O
","	O
-	O
0	O
.	O
79	O
;	O
p	O
<	O
0	O
.	O
1	O
).	O
Vervenne	O
'	O
s	O
study	O
showed	O
that	O
addition	O
of	O
bevacizumab	B-Chemical
to	O
erlotinib	B-Chemical
and	O
gemcitabine	B-Chemical
did	O
not	O
significantly	O
prolong	O
OS	O
","	O
but	O
there	O
was	O
a	O
significant	O
improvement	O
in	O
PFS	O
(	O
p	O
=	O
0	O
.	O
2	O
).	O
This	O
suggested	O
that	O
multi	O
-	O
target	O
therapy	O
may	O
be	O
a	O
future	O
direction	O
for	O
the	O
treatment	O
of	O
advanced	O
pancreatic	O
cancer	O
.	O
This	O
combination	O
should	O
be	O
further	O
evaluated	O
in	O
larger	O
clinical	O
trials	O
to	O
assess	O
its	O
efficacy	O
and	O
cost	O
effectiveness	O
.	O
The	O
present	O
meta	O
-	O
analysis	O
was	O
not	O
based	O
on	O
individual	O
patient	O
data	O
and	O
was	O
not	O
subjected	O
to	O
an	O
open	O
external	O
-	O
evaluation	O
procedure	O
.	O
Therefore	O
","	O
the	O
analysis	O
is	O
limited	O
in	O
that	O
the	O
use	O
of	O
published	O
data	O
may	O
have	O
led	O
to	O
an	O
overestimation	O
of	O
the	O
treatment	O
effects	O
.	O
Although	O
the	O
risk	O
of	O
publication	O
bias	O
exists	O
in	O
any	O
meta	O
-	O
analysis	O
","	O
we	O
believe	O
that	O
this	O
did	O
not	O
greatly	O
affect	O
our	O
results	O
because	O
many	O
positive	O
and	O
negative	O
trials	O
were	O
included	O
in	O
the	O
study	O
.	O
Moreover	O
","	O
some	O
trials	O
investigated	O
gemcitabine	B-Chemical
-	O
free	O
combinations	O
such	O
as	O
irinotecan	B-Chemical
/	I-Chemical
docetaxel	I-Chemical
or	O
FOLFIRINOX	B-Chemical
for	O
the	O
treatment	O
of	O
LA	O
/	O
MPC	O
.	O
Among	O
them	O
","	O
FOLFIRINOX	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
/	I-Chemical
leucovorin	I-Chemical
","	I-Chemical
irinotecan	I-Chemical
","	I-Chemical
and	I-Chemical
oxaliplatin	I-Chemical
)	O
is	O
an	O
interesting	O
and	O
promising	O
combination	O
.	O
At	O
the	O
2007	O
ASCO	O
annual	O
meeting	O
","	O
Ychou	O
reported	O
that	O
the	O
use	O
of	O
FOLFIRINOX	B-Chemical
as	O
the	O
first	O
-	O
line	O
treatment	O
for	O
advanced	O
pancreatic	O
cancer	O
afforded	O
a	O
response	O
rate	O
of	O
greater	O
than	O
30	O
%	O
with	O
manageable	O
toxicity	O
in	O
ECOG	O
0	O
-	O
1	O
patients	O
.	O
In	O
another	O
study	O
","	O
Breysacher	O
discussed	O
the	O
role	O
of	O
FOLFIRINOX	B-Chemical
as	O
second	O
-	O
line	O
therapy	O
for	O
metastatic	O
pancreatic	O
cancer	O
.	O
No	O
response	O
was	O
seen	O
in	O
13	O
patients	O
","	O
and	O
the	O
one	O
-	O
year	O
survival	O
rate	O
was	O
62	O
%.	O
However	O
","	O
a	O
large	O
-	O
scale	O
randomized	O
clinical	O
trial	O
is	O
required	O
to	O
evaluate	O
the	O
efficacy	O
of	O
FOLFIRINOX	B-Chemical
.	O
In	O
the	O
end	O
","	O
the	O
goals	O
of	O
treatment	O
for	O
advanced	O
pancreatic	O
cancer	O
should	O
be	O
to	O
control	O
tumor	O
progression	O
","	O
alleviate	O
disease	O
-	O
related	O
symptoms	O
and	O
improve	O
and	O
maintain	O
patients	O
'	O
quality	O
of	O
life	O
(	O
QOL	O
).	O
Reni	O
reported	O
on	O
the	O
effects	O
of	O
a	O
gemcitabine	B-Chemical
combination	O
versus	O
monotherapy	O
on	O
patient	O
QOL	O
.	O
The	O
study	O
showed	O
that	O
the	O
largest	O
differences	O
between	O
arms	O
favored	O
the	O
gemcitabine	B-Chemical
combination	O
group	O
.	O
Clinically	O
relevant	O
improvement	O
in	O
QOL	O
from	O
baseline	O
was	O
observed	O
more	O
often	O
after	O
combination	O
therapy	O
than	O
after	O
gemcitabine	B-Chemical
","	O
suggesting	O
that	O
the	O
combination	O
regimen	O
did	O
not	O
impair	O
QOL	O
.	O
Conclusion	O
In	O
general	O
","	O
the	O
benefits	O
of	O
adding	O
capecitabine	B-Chemical
or	O
oxaliplatin	B-Chemical
to	O
gemcitabine	B-Chemical
chemotherapy	O
in	O
LA	O
/	O
MPC	O
are	O
clear	O
","	O
with	O
prolonged	O
survival	O
","	O
improvement	O
in	O
disease	O
control	O
and	O
improvement	O
or	O
stabilization	O
of	O
QOL	O
as	O
compared	O
with	O
gemcitabine	B-Chemical
monotherapy	O
.	O
Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O
Authors	O
'	O
contributions	O
HJ	O
","	O
TL	O
and	O
XYC	O
performed	O
computerized	O
search	O
of	O
trials	O
","	O
contacted	O
experts	O
and	O
participated	O
in	O
the	O
trials	O
selection	O
.	O
MY	O
and	O
ZG	O
participated	O
in	O
the	O
trials	O
selection	O
and	O
performed	O
the	O
statistical	O
analysis	O
.	O
WHX	O
conceived	O
of	O
the	O
study	O
and	O
drafted	O
the	O
manuscript	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
Acknowledgements	O
Grant	O
Support	O
:	O
Leading	O
academic	O
discipline	O
project	O
of	O
Shanghai	O
Municipal	O
Education	O
Committee	O
","	O
Project	O
Number	O
:	O
J50208	O
;	O
Shanghai	O
Municipal	O
Natural	O
Science	O
Foundation	O
","	O
Project	O
Number	O
:	O
09ZR1417900	O
.	O
Preparation	O
","	O
Characterization	O
and	O
Thermal	O
Degradation	O
of	O
Polyimide	B-Chemical
(	O
4	B-Chemical
-	I-Chemical
APS	I-Chemical
/	O
BTDA	B-Chemical
)/	O
SiO2	B-Chemical
Composite	O
Films	O
Polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
were	O
prepared	O
from	O
tetraethoxysilane	B-Chemical
(	O
TEOS	B-Chemical
)	O
and	O
poly	B-Chemical
(	I-Chemical
amic	I-Chemical
acid	I-Chemical
)	I-Chemical
(	O
PAA	B-Chemical
)	O
based	O
on	O
aromatic	O
diamine	B-Chemical
(	O
4	B-Chemical
-	I-Chemical
aminophenyl	I-Chemical
sulfone	I-Chemical
)	O
(	O
4	B-Chemical
-	I-Chemical
APS	I-Chemical
)	O
and	O
aromatic	O
dianhydride	B-Chemical
(	O
3	B-Chemical
","	I-Chemical
3	I-Chemical
","	I-Chemical
4	I-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
benzophenonetetracarboxylic	I-Chemical
dianhydride	I-Chemical
)	O
(	O
BTDA	B-Chemical
)	O
via	O
a	O
sol	O
-	O
gel	O
process	O
in	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
pyrrolidinone	I-Chemical
(	O
NMP	B-Chemical
).	O
The	O
prepared	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
were	O
characterized	O
using	O
X	O
-	O
ray	O
diffraction	O
(	O
XRD	O
"),"	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
(	O
FTIR	O
"),"	O
scanning	O
electron	O
microscope	O
(	O
SEM	O
)	O
and	O
thermogravimetric	O
analysis	O
(	O
TGA	O
).	O
The	O
FTIR	O
results	O
confirmed	O
the	O
synthesis	O
of	O
polyimide	B-Chemical
(	O
4	B-Chemical
-	I-Chemical
APS	I-Chemical
/	O
BTDA	B-Chemical
)	O
and	O
the	O
formation	O
of	O
SiO2	B-Chemical
particles	O
in	O
the	O
polyimide	B-Chemical
matrix	O
.	O
Meanwhile	O
","	O
the	O
SEM	O
images	O
showed	O
that	O
the	O
SiO2	B-Chemical
particles	O
were	O
well	O
dispersed	O
in	O
the	O
polyimide	B-Chemical
matrix	O
.	O
Thermal	O
stability	O
and	O
kinetic	O
parameters	O
of	O
the	O
degradation	O
processes	O
for	O
the	O
prepared	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
were	O
investigated	O
using	O
TGA	O
in	O
N2	B-Chemical
atmosphere	O
.	O
The	O
activation	O
energy	O
of	O
the	O
solid	O
-	O
state	O
process	O
was	O
calculated	O
using	O
Flynn	O
â€“	O
Wall	O
â€“	O
Ozawa	O
â€™	O
s	O
method	O
without	O
the	O
knowledge	O
of	O
the	O
reaction	O
mechanism	O
.	O
The	O
results	O
indicated	O
that	O
thermal	O
stability	O
and	O
the	O
values	O
of	O
the	O
calculated	O
activation	O
energies	O
increased	O
with	O
the	O
increase	O
of	O
the	O
TEOS	B-Chemical
loading	O
and	O
the	O
activation	O
energy	O
also	O
varied	O
with	O
the	O
percentage	O
of	O
weight	O
loss	O
for	O
all	O
compositions	O
.	O
1	O
.	O
Introduction	O
Polyimides	B-Chemical
are	O
a	O
type	O
of	O
organic	O
polymers	B-Chemical
that	O
have	O
been	O
widely	O
used	O
in	O
many	O
applications	O
at	O
high	O
temperatures	O
","	O
such	O
as	O
in	O
aerospace	O
","	O
microelectronic	O
industries	O
","	O
semiconductor	O
and	O
composites	O
.	O
They	O
demonstrate	O
many	O
advantages	O
","	O
which	O
include	O
excellent	O
heat	O
and	O
chemical	O
resistance	O
","	O
as	O
well	O
as	O
outstanding	O
combinations	O
of	O
thermal	O
","	O
mechanical	O
and	O
electrical	O
insulating	O
properties	O
.	O
Thermal	O
property	O
is	O
one	O
of	O
the	O
most	O
important	O
properties	O
for	O
polymeric	O
materials	O
.	O
Many	O
researchers	O
have	O
studied	O
the	O
polyimides	B-Chemical
properties	O
","	O
and	O
most	O
of	O
them	O
have	O
reported	O
excellent	O
thermal	O
stability	O
for	O
polyimides	B-Chemical
.	O
Meng	O
et	O
al	O
.	O
(	O
2007	O
)	O
have	O
reported	O
the	O
thermal	O
properties	O
of	O
a	O
polyimide	B-Chemical
based	O
on	O
2	B-Chemical
","	I-Chemical
6	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
p	I-Chemical
-	I-Chemical
aminophenyl	I-Chemical
)-	I-Chemical
benzo	I-Chemical
[	I-Chemical
1	I-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
d	I-Chemical
;	I-Chemical
5	I-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
d	I-Chemical
]	I-Chemical
bisoxazole	I-Chemical
.	O
The	O
results	O
showed	O
excellent	O
thermal	O
stability	O
","	O
a	O
5	O
%	O
weight	O
loss	O
temperature	O
(	O
T5	O
%)	O
and	O
glass	O
transition	O
temperatures	O
(	O
Tg	O
)	O
at	O
572	O
Â°	O
C	O
and	O
283	O
Â°	O
C	O
in	O
N2	B-Chemical
respectively	O
.	O
Meanwhile	O
","	O
thermal	O
stability	O
and	O
thermal	O
degradation	O
kinetics	O
are	O
significant	O
to	O
production	O
and	O
application	O
.	O
In	O
particular	O
","	O
thermogravimetric	O
analysis	O
(	O
TGA	O
)	O
has	O
been	O
widely	O
employed	O
to	O
investigate	O
thermal	O
degradation	O
kinetic	O
and	O
thermal	O
stability	O
of	O
polymers	B-Chemical
.	O
However	O
","	O
polyimides	B-Chemical
have	O
many	O
intrinsic	O
weaknesses	O
such	O
as	O
low	O
thermal	O
coefficient	O
","	O
poor	O
corona	O
-	O
resistance	O
property	O
and	O
comparatively	O
high	O
thermal	O
expansivity	O
","	O
which	O
can	O
cause	O
restrictions	O
in	O
some	O
of	O
their	O
applications	O
.	O
For	O
enhancement	O
and	O
to	O
obtain	O
the	O
desired	O
improvements	O
of	O
polyimides	B-Chemical
many	O
research	O
activities	O
have	O
been	O
carried	O
out	O
through	O
using	O
a	O
mixture	O
of	O
inorganic	O
in	O
polymer	O
matrices	O
.	O
The	O
sol	O
-	O
gel	O
process	O
is	O
an	O
important	O
method	O
for	O
the	O
preparation	O
of	O
these	O
hybrid	O
materials	O
","	O
whereby	O
both	O
organic	O
and	O
inorganic	O
elements	O
are	O
mixed	O
at	O
a	O
molecular	O
level	O
and	O
the	O
prepared	O
intimate	O
mixing	O
provides	O
various	O
properties	O
which	O
are	O
different	O
from	O
those	O
of	O
the	O
traditional	O
composites	O
.	O
In	O
the	O
present	O
study	O
","	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
were	O
prepared	O
from	O
poly	B-Chemical
(	I-Chemical
amic	I-Chemical
acid	I-Chemical
)	I-Chemical
(	O
PAA	B-Chemical
)	O
based	O
on	O
aromatic	O
diamine	B-Chemical
(	O
4	B-Chemical
-	I-Chemical
Aminophenyl	I-Chemical
sulfone	I-Chemical
)	O
(	O
4	B-Chemical
-	I-Chemical
APS	I-Chemical
)	O
and	O
aromatic	O
dianhydride	B-Chemical
(	O
3	B-Chemical
","	I-Chemical
3	I-Chemical
"â€²,"	I-Chemical
4	I-Chemical
","	I-Chemical
4	I-Chemical
â€²-	I-Chemical
benzophenonetetracarboxylic	I-Chemical
dianhydride	I-Chemical
)	O
(	O
BTDA	B-Chemical
)	O
with	O
tetraethoxysilane	B-Chemical
(	O
TEOS	B-Chemical
)	O
as	O
the	O
SiO2	B-Chemical
source	O
via	O
sol	O
-	O
gel	O
process	O
.	O
The	O
prepared	O
composite	O
films	O
were	O
characterized	O
using	O
by	O
Fourier	O
transform	O
infrared	O
(	O
FTIR	O
)	O
spectroscopy	O
","	O
X	O
-	O
ray	O
diffraction	O
(	O
XRD	O
"),"	O
scanning	O
electron	O
microscope	O
(	O
SEM	O
)	O
and	O
thermogravimetric	O
analysis	O
(	O
TGA	O
).	O
Thermal	O
degradation	O
and	O
kinetic	O
parameters	O
","	O
such	O
as	O
activation	O
energy	O
of	O
thermal	O
degradation	O
processes	O
were	O
also	O
investigated	O
through	O
dynamic	O
thermogravimetric	O
analysis	O
at	O
different	O
heating	O
rates	O
.	O
2	O
.	O
Results	O
and	O
Discussion	O
2	O
.	O
1	O
.	O
Characterization	O
of	O
Polyimide	B-Chemical
/	O
SiO2	B-Chemical
Composite	O
Films	O
2	O
.	O
1	O
.	O
1	O
.	O
Chemical	O
Analysis	O
by	O
FTIR	O
Spectroscopy	O
The	O
FTIR	O
spectra	O
of	O
the	O
prepared	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
","	O
with	O
different	O
contents	O
of	O
silica	B-Chemical
","	O
are	O
depicted	O
in	O
Figure	O
1	O
.	O
The	O
characteristic	O
absorption	O
bands	O
of	O
the	O
imide	O
groups	O
near	O
1780	O
","	O
1720	O
and	O
1378	O
cm	O
âˆ’	O
1	O
were	O
observed	O
in	O
the	O
FTIR	O
spectra	O
of	O
the	O
prepared	O
samples	O
after	O
thermal	O
imidization	O
of	O
the	O
poly	B-Chemical
(	I-Chemical
amic	I-Chemical
acid	I-Chemical
)/	I-Chemical
SiO2	I-Chemical
precursor	O
.	O
Meanwhile	O
","	O
the	O
characteristic	O
absorption	O
of	O
the	O
amide	B-Chemical
carbonyl	O
at	O
1650	O
cm	O
âˆ’	O
1	O
did	O
not	O
appear	O
in	O
the	O
spectra	O
","	O
indicating	O
that	O
the	O
imidization	O
reaction	O
is	O
complete	O
.	O
The	O
characteristic	O
vibration	O
bands	O
of	O
Si	O
â€“	O
O	O
â€“	O
Si	O
hydrolyzed	O
from	O
silica	B-Chemical
were	O
also	O
observed	O
at	O
477	O
cm	O
âˆ’	O
1	O
and	O
near	O
1100	O
cm	O
âˆ’	O
1	O
.	O
As	O
the	O
content	O
of	O
SiO2	B-Chemical
particles	O
increased	O
","	O
the	O
intensity	O
of	O
Si	O
â€“	O
O	O
â€“	O
Si	O
band	O
gradually	O
became	O
stronger	O
in	O
the	O
FTIR	O
spectra	O
of	O
the	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
.	O
2	O
.	O
1	O
.	O
2	O
.	O
X	O
-	O
ray	O
Diffraction	O
Study	O
of	O
Polyimide	B-Chemical
/	O
SiO2	B-Chemical
Composite	O
Films	O
Structure	O
The	O
prepared	O
composite	O
films	O
were	O
also	O
characterized	O
by	O
XRD	O
.	O
Figure	O
2a	O
shows	O
the	O
XRD	O
patterns	O
of	O
the	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
with	O
various	O
contents	O
of	O
SiO2	B-Chemical
","	O
prepared	O
according	O
to	O
processing	O
conditions	O
in	O
Section	O
3	O
.	O
3	O
.	O
Figure	O
2b	O
shows	O
the	O
XRD	O
pattern	O
of	O
prepared	O
SiO2	B-Chemical
particles	O
in	O
the	O
same	O
conditions	O
but	O
in	O
the	O
absence	O
PAA	B-Chemical
where	O
the	O
average	O
size	O
of	O
obtained	O
particles	O
was	O
610	O
nm	O
.	O
As	O
is	O
clearly	O
seen	O
in	O
Figure	O
2a	O
","	O
there	O
is	O
a	O
peak	O
in	O
the	O
diffractogram	O
of	O
the	O
polyimide	B-Chemical
(	O
curve	O
I	O
)	O
as	O
the	O
non	O
-	O
Gaussian	O
distribution	O
pattern	O
that	O
reveals	O
a	O
semi	O
-	O
crystalline	O
structure	O
polymer	O
.	O
This	O
peak	O
was	O
also	O
depicted	O
in	O
the	O
all	O
diffractograms	O
of	O
polyimide	B-Chemical
composite	O
films	O
.	O
As	O
the	O
loading	O
of	O
TEOS	B-Chemical
increased	O
in	O
the	O
PAA	B-Chemical
precursor	O
(	O
curves	O
II	O
â€“	O
IV	O
"),"	O
the	O
peaks	O
shoulder	O
after	O
2Î¸	O
=	O
16	O
also	O
heightened	O
","	O
suggesting	O
that	O
this	O
could	O
be	O
due	O
to	O
the	O
formation	O
of	O
SiO2	B-Chemical
particles	O
and	O
increase	O
of	O
SiO2	B-Chemical
particles	O
content	O
in	O
polyimide	B-Chemical
matrix	O
.	O
2	O
.	O
1	O
.	O
3	O
.	O
Morphology	O
of	O
the	O
Polyimide	B-Chemical
/	O
SiO2	B-Chemical
Composite	O
Film	O
The	O
SEM	O
photographs	O
of	O
the	O
cross	O
-	O
section	O
surfaces	O
of	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
in	O
various	O
percentages	O
of	O
TEOS	B-Chemical
as	O
SiO2	B-Chemical
sources	O
are	O
shown	O
in	O
Figure	O
3	O
.	O
The	O
created	O
SiO2	B-Chemical
particles	O
which	O
are	O
in	O
white	O
globular	O
shapes	O
have	O
dispersed	O
into	O
the	O
polymer	O
matrix	O
uniformly	O
.	O
The	O
average	O
size	O
of	O
the	O
SiO2	B-Chemical
particles	O
in	O
the	O
composite	O
films	O
were	O
estimated	O
to	O
be	O
around	O
265	O
","	O
374	O
","	O
580	O
nm	O
for	O
the	O
prepared	O
composite	O
films	O
with	O
10	O
","	O
30	O
","	O
50	O
wt	O
%	O
of	O
TEOS	B-Chemical
loading	O
respectively	O
.	O
The	O
sizes	O
of	O
the	O
SiO2	B-Chemical
particles	O
for	O
the	O
polyimide	B-Chemical
composite	O
films	O
with	O
various	O
percentages	O
of	O
TEOS	B-Chemical
loading	O
are	O
also	O
compared	O
in	O
Table	O
1	O
.	O
On	O
the	O
basis	O
of	O
the	O
morphological	O
observations	O
","	O
with	O
the	O
increase	O
of	O
the	O
TEOS	B-Chemical
loading	O
","	O
the	O
SiO2	B-Chemical
particles	O
size	O
were	O
increased	O
which	O
can	O
be	O
seen	O
from	O
the	O
increase	O
in	O
the	O
aggregation	O
leaning	O
of	O
the	O
SiO2	B-Chemical
particles	O
.	O
The	O
SEM	O
images	O
also	O
revealed	O
that	O
with	O
the	O
increase	O
of	O
the	O
TEOS	B-Chemical
loading	O
","	O
the	O
dispersion	O
of	O
the	O
SiO2	B-Chemical
particles	O
in	O
the	O
hybrid	O
also	O
became	O
more	O
uniform	O
.	O
The	O
adhesion	O
of	O
the	O
silica	B-Chemical
particles	O
with	O
the	O
polyimide	B-Chemical
matrix	O
is	O
low	O
as	O
the	O
particles	O
seemed	O
to	O
have	O
been	O
completely	O
debonded	O
from	O
the	O
surrounding	O
polyimide	B-Chemical
matrix	O
","	O
indicating	O
a	O
very	O
poor	O
interfacial	O
adhesion	O
between	O
the	O
particles	O
and	O
the	O
matrix	O
.	O
The	O
comparison	O
of	O
the	O
SEM	O
images	O
also	O
indicated	O
that	O
in	O
higher	O
contents	O
of	O
TEOS	B-Chemical
loading	O
","	O
the	O
interfacial	O
adhesion	O
decreased	O
.	O
As	O
is	O
clearly	O
seen	O
","	O
the	O
distribution	O
and	O
dispersion	O
of	O
the	O
SiO2	B-Chemical
particles	O
within	O
the	O
polyimide	B-Chemical
matrix	O
are	O
relatively	O
uniform	O
and	O
this	O
factor	O
can	O
be	O
effective	O
on	O
the	O
thermal	O
stability	O
of	O
composite	O
films	O
.	O
2	O
.	O
1	O
.	O
4	O
.	O
Thermal	O
Properties	O
Study	O
of	O
Polyimide	B-Chemical
/	O
SiO2	B-Chemical
Composite	O
Films	O
The	O
thermal	O
stability	O
of	O
the	O
prepared	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
can	O
be	O
evaluated	O
by	O
TGA	O
.	O
The	O
TG	O
curves	O
of	O
the	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
with	O
various	O
SiO2	B-Chemical
contents	O
at	O
heating	O
rate	O
of	O
5	O
Â°	O
C	O
/	O
min	O
are	O
shown	O
in	O
Figure	O
4a	O
.	O
The	O
TG	O
curves	O
indicate	O
that	O
water	B-Chemical
or	O
solvent	O
has	O
been	O
successfully	O
eliminated	O
from	O
the	O
polyimide	B-Chemical
film	O
and	O
also	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
because	O
there	O
is	O
no	O
weight	O
loss	O
below	O
100	O
Â°	O
C	O
.	O
It	O
can	O
be	O
clearly	O
seen	O
in	O
Figure	O
4a	O
that	O
the	O
residual	O
weight	O
of	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
after	O
thermal	O
decomposition	O
is	O
higher	O
than	O
polyimide	B-Chemical
film	O
above	O
700	O
Â°	O
C	O
.	O
The	O
increase	O
in	O
the	O
weight	O
residues	O
above	O
700	O
Â°	O
C	O
illustrates	O
successful	O
incorporation	O
of	O
higher	O
amounts	O
of	O
silica	B-Chemical
into	O
the	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
and	O
ultimately	O
increases	O
in	O
thermal	O
stability	O
.	O
The	O
temperatures	O
of	O
the	O
thermal	O
decomposition	O
(	O
Td	O
)	O
of	O
the	O
polyimide	B-Chemical
film	O
and	O
polyimide	B-Chemical
composite	O
films	O
are	O
compared	O
in	O
Table	O
1	O
.	O
Results	O
show	O
that	O
thermal	O
decomposition	O
of	O
composite	O
films	O
increases	O
with	O
the	O
increase	O
of	O
SiO2	B-Chemical
contents	O
leading	O
to	O
the	O
assumption	O
that	O
the	O
inorganic	O
components	O
","	O
such	O
as	O
SiO2	B-Chemical
","	O
can	O
improve	O
the	O
thermal	O
stability	O
of	O
organic	O
materials	O
.	O
The	O
improvement	O
of	O
the	O
thermal	O
stability	O
of	O
the	O
prepared	O
polyimide	B-Chemical
with	O
SiO2	B-Chemical
can	O
be	O
based	O
on	O
the	O
fact	O
that	O
these	O
materials	O
have	O
inherently	O
good	O
thermal	O
stability	O
and	O
also	O
due	O
to	O
the	O
strong	O
interaction	O
/	O
chemical	O
bonding	O
that	O
exists	O
between	O
the	O
polyimide	B-Chemical
and	O
silica	B-Chemical
.	O
2	O
.	O
2	O
.	O
Degradation	O
Kinetic	O
Analysis	O
2	O
.	O
2	O
.	O
1	O
.	O
Theoretical	O
Background	O
One	O
application	O
of	O
the	O
thermogravimetric	O
analysis	O
is	O
the	O
determination	O
of	O
the	O
kinetic	O
parameters	O
","	O
such	O
as	O
reaction	O
order	O
","	O
activation	O
energy	O
","	O
etc	O
.	O
In	O
the	O
thermogravimetric	O
analysis	O
","	O
the	O
rate	O
of	O
reaction	O
may	O
be	O
defined	O
as	O
the	O
ratio	O
of	O
the	O
actual	O
weight	O
loss	O
to	O
the	O
total	O
weight	O
loss	O
corresponding	O
to	O
the	O
degradation	O
process	O
;	O
where	O
W0	O
is	O
the	O
initial	O
weight	O
of	O
the	O
sample	O
","	O
Wt	O
is	O
the	O
actual	O
weight	O
of	O
the	O
sample	O
","	O
Wf	O
is	O
the	O
final	O
weight	O
of	O
the	O
sample	O
and	O
X	O
is	O
the	O
degree	O
of	O
decomposition	O
.	O
A	O
typical	O
model	O
for	O
a	O
kinetic	O
process	O
can	O
be	O
represented	O
by	O
the	O
decomposition	O
rate	O
(	O
dX	O
/	O
dt	O
)	O
which	O
is	O
a	O
function	O
of	O
temperature	O
and	O
weight	O
of	O
the	O
sample	O
.	O
The	O
decomposition	O
rate	O
can	O
be	O
expressed	O
as	O
:	O
where	O
dX	O
/	O
dt	O
is	O
the	O
decomposition	O
rate	O
","	O
k	O
is	O
the	O
rate	O
constant	O
and	O
f	O
(	O
X	O
)	O
is	O
the	O
differential	O
expression	O
of	O
a	O
kinetic	O
model	O
function	O
.	O
However	O
","	O
the	O
rate	O
constant	O
k	O
can	O
be	O
defined	O
by	O
the	O
Arrhenius	O
expression	O
:	O
A	O
is	O
the	O
pre	O
-	O
exponential	O
factor	O
(	O
s	O
âˆ’	O
1	O
"),"	O
E	O
is	O
the	O
activation	O
energy	O
of	O
the	O
degradation	O
reaction	O
(	O
kJ	O
/	O
mol	O
"),"	O
R	O
is	O
the	O
universal	O
gas	O
constant	O
(	O
8	O
.	O
314	O
J	O
/	O
mol	O
Â·	O
K	O
)	O
and	O
T	O
is	O
the	O
absolute	O
temperature	O
(	O
K	O
).	O
The	O
combination	O
of	O
Equations	O
(	O
2	O
)	O
and	O
(	O
3	O
)	O
leads	O
to	O
the	O
following	O
equation	O
:	O
In	O
the	O
thermogravimetric	O
analysis	O
","	O
the	O
sample	O
temperature	O
can	O
be	O
changed	O
with	O
a	O
constant	O
heating	O
rate	O
Î²	O
(	O
Î²	O
=	O
dT	O
/	O
dt	O
"),"	O
whereby	O
","	O
whit	O
the	O
introduction	O
of	O
Î²	O
","	O
Equation	O
(	O
4	O
)	O
can	O
be	O
modified	O
as	O
follows	O
:	O
Therefore	O
","	O
Equation	O
(	O
5	O
)	O
is	O
a	O
fundamental	O
relation	O
that	O
determines	O
the	O
kinetic	O
parameters	O
on	O
the	O
basis	O
of	O
thermogravimetric	O
data	O
.	O
Based	O
on	O
the	O
degree	O
of	O
conversion	O
measurement	O
","	O
X	O
","	O
and	O
also	O
the	O
heating	O
rate	O
","	O
Î²	O
there	O
are	O
several	O
methods	O
available	O
for	O
the	O
calculation	O
of	O
the	O
apparent	O
activation	O
energy	O
.	O
Hence	O
","	O
the	O
calculation	O
of	O
the	O
kinetic	O
parameters	O
for	O
the	O
degradation	O
from	O
the	O
thermogravimetric	O
analysis	O
data	O
is	O
strongly	O
dependent	O
on	O
the	O
method	O
of	O
calculation	O
.	O
There	O
are	O
a	O
number	O
of	O
methods	O
used	O
to	O
determine	O
the	O
apparent	O
activation	O
energy	O
based	O
on	O
one	O
or	O
different	O
heating	O
rates	O
of	O
the	O
TGA	O
curves	O
and	O
these	O
include	O
Ozawa	O
","	O
Kissinger	O
","	O
van	O
Krevelen	O
","	O
Coatse	O
-	O
Redfern	O
","	O
etc	O
..	O
In	O
the	O
present	O
study	O
","	O
the	O
Ozawa	O
â€™	O
s	O
method	O
was	O
employed	O
to	O
calculate	O
the	O
apparent	O
activation	O
energy	O
of	O
the	O
thermal	O
degradation	O
of	O
the	O
polyimide	B-Chemical
(	O
4	B-Chemical
-	I-Chemical
APS	I-Chemical
/	O
BTDA	B-Chemical
)	O
and	O
polyimide	B-Chemical
(	O
4	B-Chemical
-	I-Chemical
APS	I-Chemical
/	O
BTDA	B-Chemical
)/	O
SiO2	B-Chemical
composite	O
films	O
.	O
2	O
.	O
2	O
.	O
2	O
.	O
Flynn	O
â€“	O
Wall	O
â€“	O
Ozawa	O
Method	O
The	O
activation	O
energy	O
of	O
the	O
decomposition	O
process	O
can	O
be	O
calculated	O
using	O
the	O
Flynn	O
â€“	O
Wall	O
â€“	O
Ozawa	O
â€™	O
s	O
method	O
without	O
knowing	O
reaction	O
order	O
and	O
differential	O
data	O
of	O
TGA	O
.	O
The	O
integration	O
of	O
Equation	O
(	O
5	O
)	O
from	O
an	O
initial	O
temperature	O
T0	O
","	O
corresponding	O
to	O
a	O
degree	O
of	O
conversion	O
X0	O
","	O
to	O
the	O
peak	O
temperature	O
Tp	O
","	O
where	O
X	O
=	O
Xp	O
","	O
gives	O
:	O
where	O
g	O
(	O
X	O
)	O
is	O
the	O
integral	O
function	O
of	O
conversion	O
.	O
Assuming	O
x	O
=	O
E	O
/	O
RT	O
","	O
Equation	O
(	O
6	O
)	O
can	O
be	O
written	O
as	O
:	O
Ozawa	O
â€™	O
s	O
method	O
is	O
based	O
on	O
Doyle	O
â€™	O
s	O
approximation	O
.	O
Log	O
p	O
(	O
x	O
)	O
â‰ˆ	O
2	O
.	O
315	O
âˆ’	O
0	O
.	O
457x	O
Or	O
lnp	O
(	O
x	O
)	O
â‰ˆ	O
5	O
.	O
330	O
âˆ’	O
1	O
.	O
052x	O
For	O
20	O
<	O
x	O
<	O
60	O
","	O
Equation	O
(	O
7	O
)	O
can	O
be	O
written	O
as	O
:	O
Here	O
","	O
A	O
and	O
R	O
are	O
constant	O
and	O
for	O
a	O
particular	O
conversion	O
","	O
g	O
(	O
X	O
)	O
is	O
a	O
constant	O
.	O
Hence	O
","	O
the	O
value	O
of	O
E	O
can	O
be	O
computed	O
by	O
Ozawa	O
â€™	O
s	O
method	O
for	O
any	O
particular	O
degree	O
of	O
decomposition	O
","	O
being	O
determined	O
from	O
the	O
linear	O
dependence	O
of	O
log	O
Î²	O
versus	O
1	O
/	O
T	O
plot	O
at	O
different	O
heating	O
rates	O
without	O
knowing	O
of	O
the	O
reaction	O
order	O
.	O
To	O
determine	O
apparent	O
activation	O
energy	O
using	O
Ozawa	O
â€™	O
s	O
method	O
","	O
several	O
TGA	O
curves	O
at	O
different	O
heating	O
rates	O
(	O
Î²	O
)	O
are	O
essential	O
.	O
Hence	O
","	O
the	O
dynamic	O
thermogravimetric	O
analysis	O
of	O
polyimide	B-Chemical
and	O
prepared	O
composite	O
films	O
were	O
performed	O
at	O
various	O
heating	O
rates	O
","	O
namely	O
5	O
","	O
10	O
","	O
15	O
and	O
20	O
Â°	O
C	O
/	O
min	O
in	O
N2	B-Chemical
.	O
Figure	O
5	O
shows	O
the	O
thermal	O
degradation	O
curves	O
of	O
the	O
polyimide	B-Chemical
and	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
film	O
with	O
50	O
%	O
of	O
TEOS	B-Chemical
loading	O
at	O
different	O
heating	O
rates	O
of	O
5	O
","	O
10	O
","	O
15	O
and	O
20	O
Â°	O
C	O
/	O
min	O
.	O
As	O
depicted	O
in	O
the	O
figure	O
","	O
the	O
onset	O
decomposition	O
temperature	O
increased	O
with	O
increase	O
of	O
the	O
heating	O
rates	O
for	O
both	O
the	O
compositions	O
.	O
The	O
activation	O
energy	O
of	O
the	O
thermal	O
degradation	O
for	O
pure	O
polyimide	B-Chemical
and	O
composite	O
films	O
were	O
obtained	O
using	O
the	O
Ozawa	O
â€™	O
s	O
method	O
","	O
Equation	O
(	O
8	O
"),"	O
from	O
a	O
linear	O
form	O
a	O
of	O
log	O
Î²	O
versus	O
1000	O
/	O
T	O
at	O
a	O
fixed	O
conversion	O
with	O
the	O
slope	O
of	O
such	O
a	O
line	O
being	O
âˆ’	O
0	O
.	O
4567E	O
/	O
RT	O
.	O
Figure	O
6	O
depicts	O
the	O
relationship	O
between	O
log	O
Î²	O
and	O
1000	O
/	O
T	O
(	O
K	O
)	O
for	O
the	O
different	O
weight	O
loss	O
values	O
.	O
In	O
this	O
study	O
","	O
the	O
chosen	O
conversion	O
values	O
were	O
5	O
","	O
10	O
","	O
15	O
","	O
20	O
","	O
25	O
","	O
30	O
","	O
35	O
","	O
and	O
40	O
%	O
for	O
polyimide	B-Chemical
and	O
5	O
","	O
10	O
","	O
15	O
","	O
20	O
","	O
25	O
and	O
30	O
wt	O
%	O
for	O
the	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
during	O
the	O
thermal	O
degradation	O
in	O
nitrogen	B-Chemical
atmosphere	O
.	O
Similar	O
observations	O
were	O
made	O
for	O
the	O
nanocomposite	O
films	O
polyamide	B-Chemical
with	O
10	O
and	O
30	O
wt	O
%	O
TEOS	B-Chemical
loading	O
according	O
to	O
Figure	O
6	O
which	O
are	O
not	O
shown	O
in	O
the	O
figures	O
.	O
The	O
isoconversional	O
plots	O
are	O
parallel	O
straight	O
lines	O
that	O
indicate	O
a	O
complex	O
weight	O
loss	O
process	O
with	O
several	O
mechanisms	O
.	O
The	O
activation	O
energies	O
for	O
every	O
composition	O
can	O
be	O
calculated	O
from	O
the	O
slopes	O
that	O
correspond	O
to	O
the	O
different	O
conversions	O
.	O
Figure	O
7	O
illustrates	O
the	O
values	O
of	O
the	O
activation	O
energies	O
for	O
the	O
thermal	O
degradation	O
of	O
the	O
polyimide	B-Chemical
and	O
the	O
prepared	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
with	O
different	O
loading	O
of	O
TEOS	B-Chemical
versus	O
percentage	O
of	O
weight	O
loss	O
in	O
the	O
nitrogen	B-Chemical
atmosphere	O
.	O
As	O
depicted	O
","	O
the	O
values	O
of	O
the	O
activation	O
energies	O
vary	O
with	O
the	O
percentages	O
of	O
weight	O
loss	O
for	O
all	O
compositions	O
.	O
From	O
these	O
curves	O
","	O
the	O
mean	O
activation	O
energies	O
of	O
258	O
.	O
7	O
","	O
261	O
.	O
4	O
","	O
266	O
.	O
5	O
and	O
272	O
.	O
4	O
kJ	O
/	O
mol	O
were	O
calculated	O
for	O
the	O
polyimide	B-Chemical
pure	O
and	O
its	O
composites	O
with	O
10	O
","	O
30	O
and	O
50	O
wt	O
%	O
of	O
TEOS	B-Chemical
loading	O
","	O
respectively	O
.	O
The	O
activation	O
energies	O
gradually	O
increased	O
with	O
a	O
smooth	O
slope	O
for	O
the	O
pure	O
polyimide	B-Chemical
before	O
30	O
%	O
and	O
this	O
was	O
before	O
25	O
%	O
of	O
weight	O
loss	O
for	O
the	O
polyimide	B-Chemical
composite	O
films	O
","	O
however	O
","	O
after	O
these	O
values	O
","	O
a	O
jump	O
in	O
the	O
activation	O
energy	O
was	O
observed	O
.	O
This	O
might	O
be	O
due	O
to	O
the	O
residue	O
formed	O
during	O
the	O
thermal	O
degradation	O
.	O
This	O
jump	O
in	O
the	O
polyimide	B-Chemical
composite	O
films	O
happened	O
sooner	O
;	O
this	O
could	O
be	O
due	O
to	O
the	O
presence	O
of	O
SiO2	B-Chemical
particles	O
which	O
had	O
been	O
homogeneously	O
dispersed	O
in	O
the	O
polyimide	B-Chemical
matrix	O
.	O
The	O
dispersed	O
SiO2	B-Chemical
particles	O
in	O
structure	O
of	O
the	O
prepared	O
polyimide	B-Chemical
composite	O
films	O
can	O
prevent	O
the	O
permeability	O
of	O
volatile	O
decomposition	O
product	O
from	O
the	O
polyimide	B-Chemical
.	O
3	O
.	O
Experimental	O
3	O
.	O
1	O
.	O
Materials	O
4	B-Chemical
-	I-Chemical
Aminophenyl	I-Chemical
sulfone	I-Chemical
(	O
4	B-Chemical
-	I-Chemical
APS	I-Chemical
)	O
(	O
Aldrich	O
","	O
97	O
%	O
purity	O
)	O
as	O
diamine	B-Chemical
and	O
3	B-Chemical
","	I-Chemical
3	I-Chemical
"â€²,"	I-Chemical
4	I-Chemical
","	I-Chemical
4	I-Chemical
â€²-	I-Chemical
benzophenontetra	I-Chemical
carboxylic	I-Chemical
dianhydride	I-Chemical
(	O
BTDA	B-Chemical
)	O
(	O
Aldrich	O
","	O
96	O
%	O
purity	O
)	O
as	O
dianhydride	B-Chemical
were	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
","	O
St	O
.	O
Louis	O
","	O
MO	O
","	O
USA	O
","	O
and	O
they	O
were	O
used	O
as	O
the	O
monomers	O
without	O
further	O
purification	O
.	O
N	B-Chemical
-	I-Chemical
Methyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
pyrrolidinone	I-Chemical
(	O
NMP	B-Chemical
)	O
(	O
99	O
.	O
5	O
"%,"	O
extra	O
pure	O
","	O
b	O
.	O
p	O
.	O
202	O
Â°	O
C	O
"),"	O
which	O
was	O
obtained	O
from	O
Acros	O
Organics	O
","	O
was	O
used	O
as	O
the	O
solvent	O
.	O
Purchased	O
Tetraethyl	B-Chemical
orthosilicate	I-Chemical
(	O
TEOS	B-Chemical
)	O
98	O
%	O
as	O
SiO2	B-Chemical
source	O
from	O
Acros	O
Organics	O
was	O
used	O
without	O
further	O
purification	O
.	O
3	O
.	O
2	O
.	O
Preparation	O
of	O
the	O
Polyimide	B-Chemical
As	O
a	O
representative	O
procedure	O
","	O
the	O
polyimide	B-Chemical
can	O
be	O
prepared	O
through	O
thermal	O
imidization	O
.	O
For	O
this	O
purpose	O
a	O
solution	O
of	O
dianhydride	B-Chemical
monomer	O
BTDA	B-Chemical
(	O
0	O
.	O
483	O
g	O
","	O
1	O
.	O
5	O
mmol	O
)	O
in	O
NMP	B-Chemical
(	O
3	O
.	O
0	O
g	O
)	O
was	O
gradually	O
added	O
to	O
a	O
stirred	O
solution	O
of	O
diamine	B-Chemical
monomer	O
4	B-Chemical
-	I-Chemical
APS	I-Chemical
(	O
0	O
.	O
372	O
g	O
","	O
1	O
.	O
5	O
mmol	O
)	O
in	O
NMP	B-Chemical
(	O
3	O
.	O
0	O
g	O
)	O
into	O
a	O
50	O
mL	O
round	O
-	O
bottomed	O
flask	O
that	O
was	O
equipped	O
with	O
a	O
mechanical	O
stirrer	O
.	O
The	O
mixture	O
was	O
stirred	O
at	O
the	O
room	O
temperature	O
for	O
24	O
h	O
to	O
allow	O
viscosity	O
to	O
increase	O
.	O
The	O
prepared	O
PAA	B-Chemical
solution	O
was	O
subsequently	O
cast	O
onto	O
a	O
clean	O
glass	O
plate	O
.	O
The	O
cast	O
film	O
was	O
dried	O
in	O
an	O
oven	O
at	O
80	O
Â°	O
C	O
for	O
5	O
h	O
and	O
then	O
heated	O
at	O
different	O
temperatures	O
and	O
durations	O
(	O
125	O
Â°	O
C	O
for	O
2	O
h	O
","	O
150	O
Â°	O
C	O
for	O
2	O
h	O
","	O
180	O
Â°	O
C	O
for	O
1	O
h	O
","	O
200	O
Â°	O
C	O
for	O
1	O
h	O
","	O
250	O
Â°	O
C	O
for	O
1	O
h	O
and	O
300	O
Â°	O
C	O
for	O
0	O
.	O
5	O
h	O
)	O
to	O
convert	O
the	O
PAA	B-Chemical
into	O
a	O
uniform	O
polyimide	B-Chemical
film	O
and	O
transparent	O
in	O
yellow	O
color	O
with	O
thickness	O
90	O
Î¼m	O
.	O
The	O
temperature	O
and	O
time	O
are	O
both	O
important	O
factors	O
in	O
thermal	O
imidization	O
processing	O
of	O
poly	B-Chemical
(	I-Chemical
amic	I-Chemical
acid	I-Chemical
)	I-Chemical
components	O
.	O
In	O
thermal	O
imidization	O
processing	O
the	O
imide	O
ring	O
is	O
formed	O
with	O
elimination	O
of	O
H2O	B-Chemical
molecule	O
from	O
the	O
amic	B-Chemical
acid	I-Chemical
and	O
carboxylic	B-Chemical
acid	I-Chemical
groups	O
in	O
poly	B-Chemical
(	I-Chemical
amic	I-Chemical
acid	I-Chemical
)	I-Chemical
chains	O
.	O
The	O
results	O
showed	O
that	O
the	O
elimination	O
reaction	O
is	O
not	O
relatively	O
fast	O
.	O
Hence	O
","	O
it	O
â€™	O
s	O
necessary	O
selection	O
of	O
the	O
appropriate	O
combination	O
of	O
temperature	O
and	O
time	O
in	O
the	O
thermal	O
treatment	O
experiments	O
to	O
gradual	O
removal	O
of	O
solvent	O
and	O
formation	O
of	O
imide	O
group	O
rings	O
.	O
3	O
.	O
3	O
.	O
Preparation	O
of	O
the	O
Polyimide	B-Chemical
/	O
SiO2	B-Chemical
Composite	O
by	O
Sol	O
-	O
Gel	O
Process	O
Sol	O
-	O
gel	O
process	O
was	O
employed	O
in	O
the	O
synthesis	O
of	O
the	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
","	O
as	O
depicted	O
in	O
Figure	O
8	O
.	O
0	O
.	O
372	O
g	O
4	B-Chemical
-	I-Chemical
APS	I-Chemical
was	O
added	O
to	O
a	O
round	O
bottom	O
flask	O
and	O
dissolved	O
in	O
NMP	B-Chemical
by	O
stirring	O
.	O
An	O
equimolar	O
amount	O
of	O
BTDA	B-Chemical
(	O
0	O
.	O
483	O
g	O
)	O
solution	O
in	O
NMP	B-Chemical
was	O
then	O
added	O
to	O
the	O
prepared	O
4	B-Chemical
-	I-Chemical
APS	I-Chemical
solution	O
.	O
The	O
mixture	O
was	O
stirred	O
continually	O
for	O
24	O
h	O
","	O
and	O
finally	O
","	O
a	O
mixture	O
of	O
TEOS	B-Chemical
and	O
distilled	O
water	B-Chemical
(	O
4	O
/	O
1	O
based	O
on	O
TEOS	B-Chemical
molars	O
)	O
was	O
added	O
into	O
prepared	O
PAA	B-Chemical
solution	O
12	O
wt	O
%.	O
Hydrochloric	B-Chemical
acid	I-Chemical
(	O
HCl	B-Chemical
)	O
was	O
also	O
added	O
to	O
maintain	O
a	O
pH	O
of	O
4	O
and	O
then	O
","	O
the	O
mixture	O
was	O
stirred	O
at	O
room	O
temperature	O
for	O
24	O
h	O
to	O
yield	O
a	O
transparent	O
solution	O
.	O
The	O
sol	O
-	O
gel	O
process	O
in	O
preparation	O
of	O
PAA	B-Chemical
was	O
performed	O
in	O
two	O
steps	O
;	O
namely	O
the	O
hydrolysis	O
of	O
alkoxides	B-Chemical
to	O
produce	O
the	O
hydroxyl	O
group	O
","	O
and	O
residual	O
alkoxides	B-Chemical
group	O
to	O
form	O
a	O
three	O
-	O
dimensional	O
network	O
.	O
The	O
obtained	O
solution	O
was	O
cast	O
on	O
a	O
clean	O
glass	O
plate	O
and	O
thermally	O
treated	O
in	O
an	O
oven	O
","	O
as	O
explained	O
Section	O
3	O
.	O
2	O
.	O
The	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
obtained	O
in	O
brownish	O
color	O
with	O
thickness	O
90	O
Î¼m	O
.	O
The	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
with	O
various	O
contents	O
of	O
SiO2	B-Chemical
were	O
prepared	O
according	O
to	O
Table	O
2	O
.	O
3	O
.	O
4	O
.	O
Characterization	O
The	O
products	O
of	O
the	O
prepared	O
polyimide	B-Chemical
and	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
were	O
characterized	O
by	O
FTIR	O
spectra	O
(	O
Perkin	O
-	O
Elmer	O
Model	O
:	O
100	O
Series	O
).	O
The	O
created	O
SiO2	B-Chemical
particles	O
into	O
polyimide	B-Chemical
matrix	O
were	O
investigated	O
using	O
X	O
-	O
ray	O
diffractometer	O
(	O
Shimadzu	O
","	O
Model	O
XRD	O
6000	O
).	O
The	O
XRD	O
patterns	O
were	O
recorded	O
at	O
a	O
scan	O
speed	O
of	O
4	O
Â°	O
C	O
/	O
min	O
.	O
The	O
fracture	O
surface	O
morphology	O
of	O
the	O
polyimide	B-Chemical
nanocomposite	O
films	O
were	O
observed	O
by	O
scanning	O
electron	O
microscopy	O
(	O
SEM	O
)	O
using	O
a	O
LEO	O
1455	O
VPSEM	O
.	O
The	O
fracture	O
surfaces	O
were	O
sputter	O
-	O
coated	O
with	O
gold	B-Chemical
before	O
viewing	O
to	O
eliminate	O
electron	O
charging	O
effect	O
.	O
The	O
particles	O
size	O
distribution	O
was	O
determined	O
using	O
the	O
UTHSCSA	O
image	O
Tool	O
Software	O
(	O
Version	O
3	O
.	O
0	O
).	O
The	O
thermal	O
properties	O
were	O
determined	O
using	O
the	O
thermogravimetric	O
analysis	O
(	O
Perkin	O
-	O
Elmer	O
","	O
Model	O
TGA	O
-	O
7	O
).	O
Experiments	O
were	O
performed	O
at	O
different	O
heating	O
rate	O
of	O
5	O
","	O
10	O
","	O
15	O
and	O
20	O
Â°	O
C	O
/	O
min	O
in	O
N2	B-Chemical
.	O
The	O
temperature	O
range	O
for	O
TGA	O
measurements	O
were	O
from	O
35	O
to	O
800	O
Â°	O
C	O
.	O
4	O
.	O
Conclusions	O
Polyimide	B-Chemical
(	O
4	B-Chemical
-	I-Chemical
APS	I-Chemical
/	O
BTDA	B-Chemical
)/	O
SiO2	B-Chemical
composite	O
films	O
with	O
various	O
TEOS	B-Chemical
loadings	O
were	O
prepared	O
by	O
sol	O
-	O
gel	O
process	O
.	O
Synthesis	O
of	O
polyimide	B-Chemical
(	O
4	B-Chemical
-	I-Chemical
APS	I-Chemical
/	O
BTDA	B-Chemical
)	O
and	O
formation	O
of	O
SiO2	B-Chemical
particles	O
were	O
confirmed	O
by	O
FTIR	O
spectroscopy	O
and	O
X	O
-	O
ray	O
diffraction	O
techniques	O
.	O
The	O
SEM	O
microphotographs	O
of	O
the	O
cross	O
-	O
section	O
surfaces	O
of	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
showed	O
that	O
the	O
created	O
white	O
globular	O
SiO2	B-Chemical
particles	O
were	O
dispersed	O
evenly	O
in	O
the	O
polyimide	B-Chemical
matrix	O
.	O
On	O
the	O
basis	O
of	O
morphological	O
observations	O
","	O
the	O
average	O
size	O
of	O
SiO2	B-Chemical
particles	O
increased	O
with	O
the	O
increase	O
of	O
the	O
TEOS	B-Chemical
loading	O
.	O
The	O
TG	O
curves	O
of	O
the	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
with	O
various	O
SiO2	B-Chemical
contents	O
showed	O
that	O
the	O
thermal	O
stability	O
of	O
the	O
prepared	O
polyimide	B-Chemical
composite	O
films	O
increased	O
with	O
increased	O
SiO2	B-Chemical
content	O
.	O
The	O
thermogravimetric	O
analysis	O
results	O
from	O
the	O
prepared	O
polyimide	B-Chemical
composite	O
films	O
also	O
illustrated	O
the	O
apparent	O
activation	O
energies	O
of	O
the	O
thermal	O
decomposition	O
are	O
gradually	O
increased	O
with	O
increased	O
SiO2	B-Chemical
content	O
.	O
The	O
dispersed	O
SiO2	B-Chemical
particles	O
","	O
in	O
the	O
structure	O
of	O
the	O
prepared	O
polyimide	B-Chemical
composite	O
films	O
","	O
may	O
be	O
able	O
to	O
prevent	O
the	O
permeability	O
of	O
volatile	O
decomposition	O
products	O
from	O
the	O
polyimide	B-Chemical
.	O
References	O
Representative	O
Fourier	O
transform	O
infrared	O
(	O
FTIR	O
)	O
spectra	O
of	O
polyimide	B-Chemical
(	O
4	B-Chemical
-	I-Chemical
APS	I-Chemical
-	I-Chemical
BTDA	I-Chemical
)	O
and	O
its	O
composite	O
films	O
with	O
various	O
percentages	O
of	O
SiO2	B-Chemical
.	O
XRD	O
patterns	O
of	O
(	O
a	O
)	O
the	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
with	O
(	O
I	O
â€“	O
IV	O
)	O
0	O
","	O
10	O
","	O
30	O
and	O
50	O
wt	O
%	O
TEOS	B-Chemical
respectively	O
","	O
and	O
(	O
b	O
)	O
SiO2	B-Chemical
particles	O
.	O
SEM	O
photographs	O
of	O
the	O
cross	O
-	O
section	O
surfaces	O
of	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
with	O
various	O
percentages	O
of	O
TEOS	B-Chemical
.	O
(	O
a	O
)	O
and	O
(	O
c	O
)	O
images	O
:	O
10	O
wt	O
%	O
TEOS	B-Chemical
loading	O
","	O
(	O
b	O
)	O
and	O
(	O
d	O
)	O
images	O
:	O
50	O
wt	O
%	O
TEOS	B-Chemical
loading	O
.	O
(	O
a	O
)	O
TGA	O
and	O
(	O
b	O
)	O
DTA	O
thermograms	O
of	O
the	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
with	O
different	O
percentages	O
of	O
TEOS	B-Chemical
.	O
TGA	O
Thermograms	O
of	O
(	O
a	O
)	O
the	O
polyimide	B-Chemical
and	O
(	O
b	O
)	O
the	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
film	O
prepared	O
with	O
50	O
%	O
TEOS	B-Chemical
loading	O
at	O
different	O
heating	O
rates	O
.	O
Flynn	O
â€“	O
Wall	O
â€“	O
Ozawa	O
plots	O
at	O
varying	O
conversion	O
for	O
the	O
degradation	O
of	O
(	O
a	O
)	O
polyimide	B-Chemical
and	O
(	O
b	O
)	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
film	O
with	O
50	O
wt	O
%	O
TEOS	B-Chemical
loading	O
.	O
The	O
percentage	O
weight	O
loss	O
dependence	O
of	O
activation	O
energy	O
for	O
the	O
thermal	O
degradation	O
of	O
(	O
a	O
)	O
polyimide	B-Chemical
and	O
(	O
b	O
â€“	O
d	O
)	O
polyamide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
with	O
10	O
","	O
30	O
","	O
50	O
wt	O
%	O
of	O
TEOS	B-Chemical
loading	O
respectively	O
.	O
Flow	O
sheet	O
explaining	O
the	O
fabrication	O
of	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
film	O
.	O
Comparison	O
of	O
Td	O
and	O
average	O
size	O
of	O
SiO2	B-Chemical
particles	O
in	O
prepared	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
with	O
different	O
percentage	O
of	O
TEOS	B-Chemical
.	O
Weight	O
percentage	O
of	O
HCl	B-Chemical
based	O
on	O
amount	O
of	O
water	B-Chemical
added	O
.	O
The	O
formulations	O
of	O
polyimide	B-Chemical
/	O
SiO2	B-Chemical
composite	O
films	O
.	O
Antioxidant	O
activity	O
and	O
mechanism	O
of	O
Rhizoma	O
Cimicifugae	O
Background	O
As	O
a	O
typical	O
Chinese	O
herbal	O
medicine	O
","	O
rhizoma	O
Cimicifugae	O
(	O
RC	O
","	O
å‡éº»	O
in	O
Chinese	O
)	O
possesses	O
various	O
pharmacological	O
effects	O
involved	O
in	O
antioxidant	O
activity	O
.	O
However	O
","	O
its	O
antioxidant	O
activity	O
has	O
not	O
been	O
reported	O
so	O
far	O
.	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
systematically	O
evaluate	O
the	O
antioxidant	O
ability	O
of	O
RC	O
in	O
vitro	O
","	O
then	O
discuss	O
the	O
mechanism	O
.	O
Methods	O
Firstly	O
","	O
five	O
RC	O
extracts	O
(	O
i	O
.	O
e	O
.	O
petroleum	B-Chemical
ether	I-Chemical
extract	O
PERC	O
","	O
ethyl	B-Chemical
acetate	I-Chemical
extract	O
EARC	O
","	O
absolute	O
ethanol	B-Chemical
extract	O
AERC	O
","	O
95	O
%	O
ethanol	B-Chemical
extract	O
95ERC	O
","	O
and	O
water	B-Chemical
extract	O
WRC	O
)	O
were	O
prepared	O
and	O
determined	O
by	O
various	O
antioxidant	O
methods	O
","	O
including	O
anti	O
-	O
lipidperoxidation	O
","	O
protection	O
against	O
DNA	O
damage	O
","	O
Â·	B-Chemical
OH	I-Chemical
scavenging	O
","	O
Â·	B-Chemical
O2	I-Chemical
-	O
scavenging	O
","	O
DPPH	B-Chemical
Â·	I-Chemical
(	O
1	B-Chemical
","	I-Chemical
1	I-Chemical
-	I-Chemical
diphenyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
picryl	I-Chemical
-	I-Chemical
hydrazl	I-Chemical
radical	O
)	O
scavenging	O
","	O
ABTS	B-Chemical
#NAME?	I-Chemical
(	O
2	B-Chemical
","	I-Chemical
2	I-Chemical
â€™-	I-Chemical
azino	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
ethylbenzo	I-Chemical
-	I-Chemical
thiazoline	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
sulfonic	I-Chemical
acid	I-Chemical
radical	I-Chemical
ion	I-Chemical
)	O
scavenging	O
","	O
Cu2	B-Chemical
+-	I-Chemical
chelating	O
","	O
and	O
Fe3	B-Chemical
+	I-Chemical
reducing	O
assays	O
.	O
Subsequently	O
","	O
we	O
measured	O
the	O
chemical	O
contents	O
of	O
five	O
RC	O
extracts	O
","	O
including	O
total	O
phenolics	B-Chemical
","	O
total	O
saponins	B-Chemical
","	O
total	O
sugars	B-Chemical
","	O
caffeic	B-Chemical
acid	I-Chemical
","	O
ferulic	B-Chemical
acid	I-Chemical
and	O
isoferulic	B-Chemical
acid	I-Chemical
.	O
Finally	O
","	O
we	O
quantitatively	O
analyzed	O
the	O
correlations	O
between	O
antioxidant	O
levels	O
(	O
1	O
/	O
IC50	O
values	O
)	O
and	O
chemical	O
contents	O
.	O
Results	O
In	O
the	O
study	O
","	O
the	O
antioxidant	O
levels	O
and	O
chemical	O
contents	O
(	O
including	O
total	O
phenolics	B-Chemical
","	O
total	O
saponins	B-Chemical
","	O
total	O
sugars	B-Chemical
","	O
caffeic	B-Chemical
acid	I-Chemical
","	O
ferulic	B-Chemical
acid	I-Chemical
and	O
isoferulic	B-Chemical
acid	I-Chemical
)	O
of	O
five	O
RC	O
extracts	O
were	O
determined	O
by	O
various	O
methods	O
.	O
In	O
all	O
antioxidant	O
assays	O
","	O
five	O
RC	O
extracts	O
increased	O
the	O
antioxidant	O
levels	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
However	O
","	O
their	O
antioxidant	O
levels	O
(	O
IC50	O
values	O
)	O
and	O
chemical	O
contents	O
significantly	O
differed	O
from	O
each	O
other	O
.	O
Quantitative	O
analysis	O
of	O
the	O
correlation	O
showed	O
that	O
total	O
phenolic	O
was	O
of	O
significant	O
positive	O
correlations	O
(	O
average	O
R	O
value	O
was	O
0	O
.	O
56	O
)	O
with	O
antioxidant	O
levels	O
;	O
In	O
contrast	O
","	O
total	O
sugars	B-Chemical
and	O
total	O
saponins	B-Chemical
had	O
no	O
positive	O
correlation	O
with	O
antioxidant	O
(	O
the	O
average	O
R	O
values	O
were	O
âˆ’	O
0	O
.	O
20	O
and	O
âˆ’	O
0	O
.	O
26	O
","	O
for	O
total	O
sugars	B-Chemical
and	O
total	O
saponins	B-Chemical
","	O
respectively	O
);	O
Among	O
total	O
phenolics	B-Chemical
","	O
three	O
phenolic	B-Chemical
acids	I-Chemical
(	O
caffeic	B-Chemical
acid	I-Chemical
","	O
ferulic	B-Chemical
acid	I-Chemical
and	O
isoferulic	B-Chemical
acid	I-Chemical
)	O
also	O
displayed	O
positive	O
correlations	O
(	O
the	O
average	O
R	O
values	O
were	O
0	O
.	O
51	O
","	O
0	O
.	O
50	O
","	O
and	O
0	O
.	O
51	O
","	O
for	O
caffeic	B-Chemical
acid	I-Chemical
","	O
ferulic	B-Chemical
acid	I-Chemical
and	O
isoferulic	B-Chemical
acid	I-Chemical
","	O
respectively	O
).	O
Conclusions	O
As	O
an	O
effective	O
antioxidant	O
","	O
Rhizoma	O
Cimicifugae	O
can	O
protect	O
DNA	O
and	O
lipids	O
against	O
oxidative	O
damage	O
.	O
Its	O
antioxidant	O
ability	O
can	O
be	O
responsible	O
for	O
its	O
various	O
pharmacological	O
effects	O
and	O
may	O
be	O
mainly	O
attributed	O
to	O
the	O
existence	O
of	O
total	O
phenolics	B-Chemical
","	O
among	O
which	O
caffeic	B-Chemical
acid	I-Chemical
","	O
ferulic	B-Chemical
acid	I-Chemical
and	O
isoferulic	B-Chemical
acid	I-Chemical
are	O
regarded	O
as	O
main	O
bioactive	O
components	O
.	O
Rhizoma	O
Cimicifugae	O
exerts	O
its	O
antioxidant	O
effect	O
through	O
metal	O
-	O
chelating	O
","	O
and	O
radical	O
-	O
scavenging	O
which	O
is	O
via	O
donating	O
hydrogen	B-Chemical
atom	O
(	O
H	B-Chemical
Â·)	I-Chemical
and	O
donating	O
electron	O
(	O
e	O
).	O
Background	O
As	O
we	O
know	O
","	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
are	O
various	O
forms	O
of	O
activated	O
oxygen	B-Chemical
including	O
free	O
radicals	O
and	O
non	O
-	O
free	O
-	O
radical	O
species	O
.	O
ROS	B-Chemical
can	O
oxidatively	O
damage	O
vital	O
cellular	O
structures	O
such	O
as	O
lipids	O
and	O
DNA	O
[	O
1	O
","	O
2	O
"],"	O
then	O
lead	O
to	O
severe	O
biological	O
consequences	O
including	O
mutation	O
","	O
cell	O
death	O
","	O
carcinogenesis	O
","	O
and	O
aging	O
[	O
3	O
].	O
Therefore	O
","	O
it	O
is	O
important	O
to	O
search	O
for	O
potential	O
therapeutic	O
agents	O
for	O
oxidative	O
damage	O
.	O
In	O
recent	O
years	O
","	O
medicinal	O
plants	O
especially	O
Chinese	O
medicinal	O
herbals	O
have	O
attracted	O
much	O
attention	O
.	O
As	O
a	O
typical	O
Chinese	O
herbal	O
medicine	O
","	O
rhizoma	O
Cimicifugae	O
(	O
RC	O
","	O
å‡éº»	O
in	O
Chinese	O
","	O
the	O
photo	O
is	O
shown	O
in	O
Additional	O
file	O
1	O
)	O
has	O
been	O
used	O
for	O
over	O
2000	O
years	O
[	O
4	O
].	O
From	O
the	O
viewpoint	O
of	O
tradition	O
Chinese	O
medicine	O
(	O
TCM	O
"),"	O
RC	O
can	O
elevate	O
yang	O
","	O
lift	O
qi	O
","	O
clear	O
heat	O
","	O
remove	O
toxic	O
","	O
induce	O
sweats	O
to	O
dispel	O
exopathogens	O
","	O
and	O
promote	O
eruption	O
[	O
5	O
].	O
Modern	O
medicine	O
indicated	O
that	O
RC	O
possessed	O
various	O
pharmacological	O
effects	O
.	O
Ye	O
reported	O
that	O
RC	O
possessed	O
antidepressant	O
-	O
like	O
properties	O
in	O
rodents	O
[	O
6	O
];	O
Kim	O
pointed	O
out	O
that	O
RC	O
can	O
treat	O
pain	O
and	O
inflammation	O
[	O
7	O
];	O
An	O
isopropanolic	B-Chemical
extract	O
of	O
RC	O
","	O
however	O
","	O
was	O
proved	O
to	O
be	O
able	O
to	O
diminish	O
the	O
urinary	O
content	O
of	O
PYR	O
and	O
DPY	O
and	O
the	O
morphometric	O
correlates	O
of	O
bone	O
loss	O
associated	O
with	O
ovariectomy	O
in	O
rats	O
[	O
8	O
];	O
The	O
supply	O
of	O
RC	O
can	O
therefore	O
prevent	O
OVX	O
-	O
induced	O
bone	O
loss	O
in	O
mice	O
[	O
9	O
].	O
In	O
addition	O
","	O
the	O
extract	O
of	O
RC	O
was	O
found	O
to	O
have	O
protective	O
effect	O
against	O
gastric	O
injury	O
[	O
10	O
].	O
According	O
to	O
free	O
radical	O
biology	O
&	O
medicine	O
[	O
11	O
"],"	O
these	O
pharmacological	O
effects	O
are	O
related	O
to	O
antioxidant	O
ability	O
.	O
However	O
","	O
its	O
antioxidant	O
ability	O
has	O
not	O
been	O
explored	O
so	O
far	O
.	O
Therefore	O
","	O
the	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
antioxidant	O
ability	O
of	O
RC	O
in	O
vitro	O
","	O
then	O
further	O
discuss	O
the	O
antioxidant	O
mechanism	O
.	O
Results	O
and	O
discussion	O
As	O
an	O
important	O
biomolecule	O
","	O
lipid	O
can	O
be	O
easily	O
attacked	O
by	O
ROS	B-Chemical
to	O
generate	O
lipid	O
peroxidation	O
which	O
is	O
harmful	O
to	O
cell	O
.	O
For	O
example	O
","	O
the	O
highly	O
reactive	O
Â·	B-Chemical
OH	I-Chemical
radical	O
can	O
attack	O
to	O
lipid	O
to	O
produce	O
lipidperoxidation	O
(	O
Equations	O
1	O
â€“	O
3	O
):	O
In	O
our	O
study	O
","	O
five	O
RC	O
extracts	O
increased	O
the	O
anti	O
-	O
lipidperoxidation	O
percentages	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Additional	O
file	O
2	O
).	O
It	O
means	O
that	O
five	O
RC	O
extracts	O
can	O
effectively	O
protect	O
lipid	O
against	O
oxidative	O
damage	O
.	O
Among	O
them	O
","	O
EARC	O
possessed	O
the	O
highest	O
anti	O
-	O
lipidperoxidation	O
activity	O
(	O
Table	O
1	O
).	O
The	O
IC50values	O
of	O
five	O
RC	O
extracts	O
and	O
the	O
positive	O
controls	O
(	O
Î¼g	O
/	O
mL	O
)	O
Besides	O
lipid	O
","	O
another	O
biomolecule	O
DNA	O
can	O
also	O
be	O
oxidatively	O
damaged	O
by	O
ROS	B-Chemical
(	O
especially	O
Â·	B-Chemical
OH	I-Chemical
).	O
It	O
is	O
well	O
known	O
that	O
DNA	O
consists	O
of	O
deoxyribose	B-Chemical
","	O
organic	O
phosphate	B-Chemical
and	O
various	O
base	O
pairs	O
.	O
When	O
DNA	O
is	O
attacked	O
by	O
Â·	B-Chemical
OH	I-Chemical
radical	O
","	O
MDA	B-Chemical
(	O
malondialdehyde	B-Chemical
)	O
and	O
a	O
number	O
of	O
oxidative	O
lesions	O
are	O
generated	O
[	O
12	O
].	O
MDA	B-Chemical
combines	O
with	O
2	B-Chemical
-	I-Chemical
thiobarbituric	I-Chemical
acid	I-Chemical
(	O
TBA	B-Chemical
)	O
to	O
produce	O
thiobarbituric	B-Chemical
acid	I-Chemical
-	O
reactive	O
substances	O
(	O
TBARS	O
)	O
with	O
Î»max	O
at	O
530	O
nm	O
(	O
Scheme	O
1	O
).	O
The	O
reaction	O
of	O
MDA	B-Chemical
(	O
malondialdehyde	B-Chemical
)	O
and	O
2	B-Chemical
-	I-Chemical
thiobarbituric	I-Chemical
acid	I-Chemical
(	O
TBA	B-Chemical
).	O
Therefore	O
","	O
the	O
A532nm	O
value	O
is	O
proportional	O
to	O
the	O
produced	O
amount	O
of	O
Â·	B-Chemical
OH	I-Chemical
radicals	O
.	O
Higher	O
A532nm	O
values	O
indicate	O
higher	O
levels	O
of	O
Â·	B-Chemical
OH	I-Chemical
radicals	O
.	O
If	O
an	O
antioxidant	O
sample	O
is	O
added	O
","	O
the	O
A532nm	O
value	O
will	O
decrease	O
","	O
suggesting	O
that	O
some	O
Â·	B-Chemical
OH	I-Chemical
radicals	O
are	O
scavenged	O
and	O
the	O
hydroxyl	B-Chemical
-	O
induced	O
DNA	O
damage	O
are	O
protected	O
by	O
the	O
antioxidant	O
.	O
Among	O
five	O
RC	O
extracts	O
","	O
95ERC	O
and	O
EARC	O
were	O
proved	O
to	O
be	O
of	O
protective	O
effect	O
against	O
hydroxyl	B-Chemical
-	O
induced	O
DNA	O
damage	O
(	O
Table	O
1	O
and	O
Additional	O
file	O
2	O
).	O
Previous	O
studies	O
have	O
shown	O
that	O
there	O
are	O
two	O
approaches	O
for	O
natural	O
phenolic	O
antioxidant	O
to	O
protect	O
DNA	O
oxidative	O
damage	O
:	O
one	O
is	O
to	O
scavenge	O
the	O
Â·	B-Chemical
OH	I-Chemical
radicals	O
then	O
to	O
reduce	O
its	O
attack	O
;	O
one	O
is	O
to	O
fast	O
repair	O
the	O
deoxynucleotide	O
radical	O
cations	O
resulting	O
from	O
Â·	B-Chemical
OH	I-Chemical
radicals	O
attack	O
[	O
11	O
].	O
In	O
order	O
to	O
further	O
confirm	O
whether	O
the	O
protective	O
effect	O
against	O
DNA	O
oxidative	O
damage	O
was	O
relevant	O
to	O
radical	O
-	O
scavenging	O
ability	O
","	O
the	O
Â·	B-Chemical
OH	I-Chemical
and	O
Â·	B-Chemical
O2	I-Chemical
-	I-Chemical
radical	O
-	O
scavenging	O
abilities	O
of	O
five	O
RC	O
extracts	O
was	O
determined	O
in	O
vitro	O
.	O
As	O
we	O
know	O
","	O
Â·	B-Chemical
OH	I-Chemical
radical	O
in	O
body	O
is	O
produced	O
by	O
Fenton	O
reaction	O
(	O
Equation	O
4	O
).	O
However	O
","	O
our	O
data	O
suggested	O
that	O
five	O
RC	O
extracts	O
can	O
effectively	O
scavenge	O
Â·	B-Chemical
OH	I-Chemical
radicals	O
(	O
Table	O
1	O
and	O
Additional	O
file	O
2	O
).	O
Besides	O
Â·	B-Chemical
OH	I-Chemical
radical	O
","	O
superoxide	B-Chemical
anion	O
radical	O
(Â·	B-Chemical
O2	I-Chemical
-)	I-Chemical
is	O
also	O
regarded	O
as	O
one	O
important	O
form	O
of	O
ROS	B-Chemical
in	O
living	O
cell	O
.	O
It	O
can	O
directly	O
attack	O
DNA	O
or	O
lipid	O
[	O
13	O
"],"	O
and	O
can	O
transferred	O
into	O
Â·	B-Chemical
OH	I-Chemical
via	O
Haber	O
-	O
Weiss	O
reaction	O
(	O
Equation	O
5	O
)	O
to	O
indirectly	O
damage	O
DNA	O
or	O
lipid	O
as	O
well	O
[	O
2	O
].	O
The	O
results	O
in	O
Table	O
1	O
and	O
Additional	O
file	O
2	O
showed	O
that	O
five	O
RC	O
extracts	O
could	O
also	O
scavenge	O
Â·	B-Chemical
O2	I-Chemical
-	I-Chemical
radicals	O
.	O
Taken	O
together	O
","	O
the	O
protective	O
effect	O
of	O
RC	O
against	O
hydroxyl	B-Chemical
-	O
induced	O
DNA	O
oxidative	O
damage	O
can	O
be	O
assumed	O
to	O
be	O
relevant	O
to	O
the	O
Â·	B-Chemical
OH	I-Chemical
or	O
Â·	B-Chemical
O2	I-Chemical
-	I-Chemical
radical	O
-	O
scavenging	O
ability	O
.	O
However	O
","	O
as	O
illustrated	O
in	O
Equations	O
4	O
and	O
5	O
","	O
the	O
generations	O
of	O
Â·	B-Chemical
OH	I-Chemical
and	O
Â·	B-Chemical
O2	I-Chemical
-	I-Chemical
radicals	O
rely	O
usually	O
on	O
the	O
catalysis	O
of	O
transition	O
metals	O
(	O
especially	O
Fe	B-Chemical
and	O
Cu	B-Chemical
).	O
So	O
we	O
further	O
explored	O
the	O
metal	O
chelating	O
abilities	O
of	O
five	O
RC	O
extracts	O
.	O
The	O
dose	O
â€“	O
response	O
curves	O
showed	O
that	O
five	O
RC	O
extracts	O
possessed	O
effective	O
metal	O
chelating	O
abilities	O
(	O
Additional	O
file	O
2	O
).	O
Our	O
previous	O
reports	O
have	O
shown	O
that	O
the	O
chelating	O
ability	O
might	O
be	O
mainly	O
attributed	O
to	O
ortho	O
dihydroxyl	O
groups	O
in	O
phenolic	B-Chemical
compounds	O
[	O
14	O
].	O
For	O
example	O
","	O
phenolic	B-Chemical
acids	I-Chemical
can	O
bind	O
Fe2	B-Chemical
+	I-Chemical
as	O
the	O
following	O
mechanism	O
(	O
Scheme	O
2	O
)	O
[	O
15	O
].	O
The	O
proposal	O
reaction	O
of	O
phenolic	B-Chemical
acids	I-Chemical
binding	O
Fe2	B-Chemical
+.	I-Chemical
The	O
fact	O
that	O
five	O
RC	O
extracts	O
can	O
effectively	O
bind	O
Fe2	B-Chemical
+	I-Chemical
ion	O
","	O
suggests	O
that	O
metal	O
-	O
chelating	O
may	O
be	O
one	O
of	O
mechanisms	O
for	O
scavenging	O
Â·	B-Chemical
OH	I-Chemical
or	O
Â·	B-Chemical
O2	I-Chemical
-.	I-Chemical
In	O
order	O
to	O
verify	O
whether	O
five	O
RC	O
extracts	O
can	O
directly	O
scavenge	O
radicals	O
.	O
We	O
determined	O
their	O
DPPH	B-Chemical
Â·	I-Chemical
and	O
ABTS	B-Chemical
Â·+	I-Chemical
radical	O
-	O
scavenging	O
abilities	O
.	O
As	O
seen	O
in	O
Table	O
1	O
and	O
Additional	O
file	O
2	O
","	O
five	O
RC	O
extracts	O
scavenged	O
both	O
DPPH	B-Chemical
Â·	I-Chemical
and	O
ABTS	B-Chemical
Â·+	I-Chemical
radicals	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
The	O
previous	O
studies	O
have	O
demonstrated	O
that	O
DPPH	B-Chemical
Â·	I-Chemical
may	O
be	O
scavenged	O
by	O
an	O
antioxidant	O
through	O
donation	O
of	O
hydrogen	B-Chemical
atom	O
(	O
H	B-Chemical
Â·)	I-Chemical
to	O
form	O
a	O
stable	O
DPPH	B-Chemical
-	I-Chemical
H	I-Chemical
molecule	O
[	O
16	O
-	O
18	O
].	O
Caffeic	B-Chemical
acid	I-Chemical
","	O
a	O
phenolic	B-Chemical
acid	I-Chemical
occurring	O
in	O
RC	O
","	O
for	O
example	O
","	O
could	O
scavenge	O
DPPH	B-Chemical
Â·	I-Chemical
via	O
the	O
proposed	O
reaction	O
(	O
Scheme	O
3	O
)	O
[	O
19	O
].	O
The	O
proposal	O
reaction	O
of	O
caffeic	B-Chemical
acid	I-Chemical
to	O
scavenge	O
DPPH	B-Chemical
Â·	I-Chemical
(	O
step	O
1	O
).	O
Radical	O
(	O
A	O
)	O
can	O
be	O
further	O
withdrawn	O
hydrogen	B-Chemical
atom	O
(	O
H	B-Chemical
Â·)	I-Chemical
to	O
form	O
stable	O
quinone	B-Chemical
(	O
B	O
)	O
(	O
Scheme	O
4	O
).	O
The	O
proposal	O
reaction	O
of	O
caffeic	B-Chemical
acid	I-Chemical
to	O
scavenge	O
DPPH	B-Chemical
Â·	I-Chemical
(	O
step	O
2	O
).	O
Unlike	O
DPPH	B-Chemical
Â·	I-Chemical
scavenging	O
","	O
ABTS	B-Chemical
Â·+	I-Chemical
scavenging	O
however	O
is	O
considered	O
as	O
an	O
electron	O
(	O
e	O
)	O
transfer	O
reaction	O
[	O
20	O
].	O
For	O
example	O
","	O
the	O
proposed	O
reaction	O
for	O
caffeic	B-Chemical
acid	I-Chemical
to	O
scavenge	O
ABTS	B-Chemical
Â·+	I-Chemical
can	O
be	O
briefly	O
illustrated	O
using	O
Scheme	O
5	O
.	O
Similarly	O
","	O
if	O
ABTS	B-Chemical
Â·+	I-Chemical
is	O
excessive	O
","	O
radical	O
(	O
A	O
)	O
can	O
also	O
further	O
change	O
to	O
quinone	B-Chemical
(	O
B	O
).	O
The	O
proposal	O
reaction	O
of	O
caffeic	B-Chemical
acid	I-Chemical
and	O
ABTS	B-Chemical
Â·+.	I-Chemical
As	O
illustrated	O
in	O
Scheme	O
3	O
","	O
4	O
and	O
5	O
","	O
the	O
generations	O
of	O
both	O
DPPH	B-Chemical
Â·	I-Chemical
and	O
ABTS	B-Chemical
Â·+	I-Chemical
radicals	O
did	O
not	O
rely	O
on	O
the	O
transition	O
metal	O
catalysis	O
.	O
Based	O
on	O
the	O
discussion	O
above	O
","	O
it	O
can	O
be	O
deduced	O
that	O
direct	O
radical	O
-	O
scavenging	O
was	O
regarded	O
as	O
another	O
mechanism	O
for	O
five	O
RC	O
extract	O
to	O
scavenge	O
Â·	B-Chemical
OH	I-Chemical
or	O
Â·	O
O2	B-Chemical
and	O
they	O
exerted	O
radical	O
-	O
scavenging	O
action	O
by	O
donating	O
hydrogen	B-Chemical
atom	O
(	O
H	B-Chemical
Â·)	I-Chemical
and	O
electron	O
(	O
e	O
).	O
Until	O
now	O
","	O
about	O
200	O
compounds	O
have	O
been	O
found	O
in	O
RC	O
[	O
21	O
].	O
Generally	O
","	O
they	O
belong	O
to	O
three	O
different	O
classes	O
","	O
i	O
.	O
e	O
.	O
phenolics	B-Chemical
","	O
saponins	B-Chemical
","	O
and	O
polysaccharides	B-Chemical
.	O
In	O
the	O
study	O
","	O
we	O
used	O
chemical	O
method	O
to	O
measure	O
the	O
contents	O
of	O
total	O
phenolics	B-Chemical
","	O
total	O
saponins	B-Chemical
","	O
and	O
total	O
sugars	B-Chemical
in	O
fiver	O
RC	O
extracts	O
(	O
Table	O
2	O
).	O
On	O
the	O
other	O
hand	O
","	O
since	O
1	O
/	O
IC50	O
value	O
showed	O
parallelism	O
with	O
antioxidant	O
level	O
","	O
it	O
was	O
therefore	O
used	O
to	O
evaluate	O
antioxidant	O
level	O
in	O
the	O
study	O
(	O
Additional	O
file	O
2	O
).	O
On	O
this	O
basis	O
","	O
forty	O
-	O
eight	O
correlation	O
graphs	O
were	O
plotted	O
to	O
quantitative	O
analyze	O
the	O
correlation	O
between	O
antioxidant	O
levels	O
and	O
chemical	O
contents	O
in	O
five	O
RC	O
extracts	O
(	O
Additional	O
file	O
3	O
).	O
The	O
correlation	O
coefficients	O
(	O
R	O
values	O
)	O
in	O
Table	O
3	O
indicated	O
that	O
","	O
total	O
phenolics	B-Chemical
were	O
of	O
significant	O
positive	O
correlations	O
(	O
R	O
=	O
0	O
.	O
17	O
~	O
0	O
.	O
99	O
;	O
average	O
","	O
0	O
.	O
56	O
)	O
with	O
antioxidant	O
levels	O
","	O
while	O
total	O
sugars	B-Chemical
and	O
total	O
saponins	B-Chemical
had	O
no	O
positive	O
correlations	O
(	O
for	O
total	O
sugars	B-Chemical
","	O
R	O
=	O
âˆ’	O
0	O
.	O
88	O
~	O
0	O
.	O
46	O
","	O
the	O
average	O
was	O
âˆ’	O
0	O
.	O
20	O
;	O
for	O
total	O
saponins	B-Chemical
","	O
R	O
=	O
âˆ’	O
0	O
.	O
92	O
~	O
0	O
.	O
94	O
","	O
the	O
average	O
was	O
âˆ’	O
0	O
.	O
26	O
)	O
with	O
antioxidant	O
levels	O
.	O
The	O
data	O
clearly	O
demonstrated	O
the	O
significant	O
contribution	O
of	O
phenolic	B-Chemical
compounds	O
to	O
the	O
antioxidant	O
of	O
RC	O
.	O
Chemical	O
contents	O
of	O
five	O
RC	O
extracts	O
The	O
R	O
values	O
between	O
chemical	O
contents	O
and	O
1	O
/	O
IC50	O
Among	O
total	O
phenolics	B-Chemical
","	O
several	O
compounds	O
had	O
been	O
isolated	O
from	O
RC	O
","	O
including	O
salicylic	B-Chemical
acid	I-Chemical
","	O
caffeic	B-Chemical
acid	I-Chemical
","	O
ferulic	B-Chemical
acid	I-Chemical
","	O
isoferulic	B-Chemical
acid	I-Chemical
","	O
flavonoids	B-Chemical
and	O
tannins	B-Chemical
.	O
In	O
our	O
study	O
","	O
however	O
","	O
three	O
phenolic	B-Chemical
acids	I-Chemical
caffeic	I-Chemical
acid	I-Chemical
","	O
ferulic	B-Chemical
acid	I-Chemical
and	O
isoferulic	B-Chemical
acid	I-Chemical
were	O
also	O
identified	O
by	O
HPLC	O
assay	O
(	O
Figure	O
1	O
and	O
Additional	O
file	O
4	O
"),"	O
in	O
which	O
peak	O
areas	O
were	O
used	O
to	O
characterize	O
the	O
relative	O
contents	O
of	O
three	O
phenolic	B-Chemical
acids	I-Chemical
.	O
A	O
typical	O
HPLC	O
profile	O
of	O
EARC	O
(	O
ethyl	B-Chemical
acetate	I-Chemical
extract	O
of	O
rhizoma	O
Cimicifugae	O
).	O
Syltech	O
P510	O
HPLC	O
system	O
(	O
Los	O
Angeles	O
","	O
California	O
","	O
USA	O
"),"	O
Dikma	O
Diamonsil	O
C18	O
(	O
250	O
mm	O
Ã—	O
4	O
.	O
6	O
mm	O
","	O
5	O
Î¼m	O
size	O
)	O
(	O
Beijing	O
","	O
China	O
"),"	O
acetonitrile	B-Chemical
-	O
0	O
.	O
5	O
%	O
acetic	B-Chemical
acid	I-Chemical
in	O
water	B-Chemical
(	O
17	O
:	O
83	O
","	O
v	O
:	O
v	O
"),"	O
1	O
.	O
0	O
mL	O
/	O
min	O
flow	O
rate	O
","	O
30	O
Î¼L	O
injection	O
","	O
316	O
nm	O
wavelength	O
.	O
Then	O
","	O
we	O
used	O
the	O
peak	O
areas	O
to	O
plot	O
the	O
correlation	O
graphs	O
vs	O
1	O
/	O
IC50	O
values	O
of	O
five	O
RC	O
extracts	O
","	O
to	O
obtain	O
the	O
correlation	O
coefficients	O
(	O
R	O
values	O
).	O
As	O
shown	O
in	O
Additional	O
file	O
5	O
and	O
Table	O
3	O
","	O
three	O
phenolic	B-Chemical
acids	I-Chemical
all	O
presented	O
significant	O
positive	O
correlations	O
(	O
average	O
R	O
value	O
=	O
0	O
.	O
47	O
","	O
0	O
.	O
44	O
","	O
and	O
0	O
.	O
51	O
","	O
respectively	O
for	O
caffeic	B-Chemical
acid	I-Chemical
","	O
ferulic	B-Chemical
acid	I-Chemical
and	O
isoferulic	B-Chemical
acid	I-Chemical
).	O
On	O
the	O
other	O
hand	O
","	O
previous	O
works	O
have	O
shown	O
that	O
three	O
phenolic	B-Chemical
acids	I-Chemical
possess	O
strong	O
antioxidant	O
ability	O
[	O
22	O
-	O
24	O
].	O
Hence	O
","	O
they	O
are	O
considered	O
as	O
three	O
of	O
main	O
bioactive	O
compounds	O
relevant	O
to	O
antioxidant	O
in	O
RC	O
.	O
Experimental	O
Chemicals	O
and	O
plant	O
material	O
Trolox	B-Chemical
(Â±	I-Chemical
âˆ’	I-Chemical
6	I-Chemical
-	I-Chemical
hydroxyl	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
5	I-Chemical
","	I-Chemical
7	I-Chemical
","	I-Chemical
8	I-Chemical
-	I-Chemical
tetramethlyhromane	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
carboxylic	I-Chemical
acid	I-Chemical
"),"	O
Ferrozin	B-Chemical
[	I-Chemical
3	I-Chemical
-(	I-Chemical
2	I-Chemical
-	I-Chemical
pyridyl	I-Chemical
)-	I-Chemical
5	I-Chemical
","	I-Chemical
6	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
4	I-Chemical
-	I-Chemical
phenylsulfonicacid	I-Chemical
)-	I-Chemical
1	I-Chemical
","	I-Chemical
2	I-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
triazine	I-Chemical
"],"	I-Chemical
DPPH	I-Chemical
Â·	I-Chemical
(	O
1	B-Chemical
","	I-Chemical
1	I-Chemical
-	I-Chemical
Diphenyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
picrylhydrazyl	I-Chemical
radical	O
"),"	O
pyrogallol	B-Chemical
","	O
linoleic	B-Chemical
acid	I-Chemical
","	O
BHT	B-Chemical
(	O
2	B-Chemical
.	I-Chemical
6	I-Chemical
-	I-Chemical
ditertiary	I-Chemical
butyl	I-Chemical
-	I-Chemical
p	I-Chemical
-	I-Chemical
cresol	I-Chemical
)	O
and	O
murexide	B-Chemical
(	O
5	B-Chemical
","	I-Chemical
5	I-Chemical
â€²-	I-Chemical
Nitrilodibarbituric	I-Chemical
acid	I-Chemical
monoammonium	I-Chemical
salt	I-Chemical
)	O
were	O
purchased	O
from	O
Sigma	O
Co	O
.	O
(	O
Sigmaaldrich	O
Trading	O
Co	O
".,"	O
Shanghai	O
","	O
China	O
);	O
ABTS	B-Chemical
diammonium	I-Chemical
salt	I-Chemical
[	O
2	B-Chemical
","	I-Chemical
2	I-Chemical
â€²-	I-Chemical
Azino	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
ethylbenzothiazoline	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
sulfonic	I-Chemical
acid	I-Chemical
diammonium	I-Chemical
salt	I-Chemical
")],"	I-Chemical
D	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
deoxyribose	I-Chemical
","	O
and	O
GSH	B-Chemical
(	O
glutathione	B-Chemical
)	O
were	O
Amresco	O
Inc	O
.	O
(	O
Solon	O
","	O
OH	O
","	O
USA	O
);	O
DNA	O
sodium	O
salt	O
(	O
fish	O
sperm	O
)	O
was	O
purchased	O
from	O
Aladdin	O
Chemistry	O
Co	O
.	O
(	O
Shanghai	O
","	O
China	O
);	O
Ferulic	B-Chemical
acid	I-Chemical
","	O
caffeic	B-Chemical
acid	I-Chemical
were	O
purchased	O
from	O
National	O
Institute	O
for	O
the	O
Control	O
of	O
Pharmaceutical	O
and	O
Biological	O
Products	O
(	O
Beijing	O
","	O
China	O
);	O
Acetonitrile	B-Chemical
","	O
methanol	B-Chemical
and	O
water	B-Chemical
were	O
of	O
HPLC	O
grade	O
;	O
All	O
other	O
chemicals	O
used	O
were	O
in	O
analytical	O
grade	O
.	O
Rhizoma	O
Cimicifugae	O
was	O
purchased	O
from	O
Guangzhou	O
University	O
of	O
Chinese	O
Medicine	O
Yanghe	O
Interlink	O
Limited	O
Company	O
and	O
identified	O
by	O
Prof	O
.	O
Shuhui	O
Tan	O
.	O
A	O
voucher	O
specimen	O
was	O
deposited	O
in	O
our	O
laboratory	O
.	O
Preparation	O
of	O
different	O
extracts	O
of	O
rhizoma	O
Cimicifugae	O
The	O
dried	O
rhizoma	O
Cimicifugae	O
was	O
coarsely	O
powder	O
then	O
extracted	O
in	O
sequence	O
with	O
petroleum	B-Chemical
ether	I-Chemical
(	O
60	O
â€“	O
90	O
"),"	O
ethyl	B-Chemical
acetate	I-Chemical
","	O
ethanol	B-Chemical
","	O
95	O
%	O
ethanol	B-Chemical
and	O
water	B-Chemical
by	O
Soxhlet	O
extractor	O
for	O
12	O
hours	O
.	O
The	O
extracts	O
were	O
concentrated	O
under	O
reduced	O
pressure	O
to	O
a	O
constant	O
weight	O
.	O
Then	O
the	O
dried	O
extracts	O
were	O
stored	O
at	O
4	O
Â°	O
C	O
until	O
used	O
(	O
Figure	O
2	O
).	O
Preparation	O
of	O
five	O
extracts	O
of	O
rhizoma	O
Cimicifugae	O
.	O
Protective	O
effect	O
against	O
lipid	O
-	O
peroxidation	O
The	O
protective	O
effect	O
against	O
lipid	O
-	O
peroxidation	O
was	O
investigated	O
using	O
a	O
linoleic	B-Chemical
acid	I-Chemical
emulsion	O
[	O
25	O
].	O
The	O
linoleic	B-Chemical
acid	I-Chemical
emulsion	O
was	O
prepared	O
by	O
mixing	O
and	O
homogenizing	O
312	O
.	O
6	O
mg	O
of	O
linoleic	B-Chemical
acid	I-Chemical
","	O
78	O
.	O
2	O
mg	O
of	O
Tween	B-Chemical
-	I-Chemical
20	I-Chemical
as	O
emulsifier	O
","	O
and	O
30	O
mL	O
of	O
75	O
%	O
ethanol	B-Chemical
(	O
v	O
/	O
v	O
"),"	O
0	O
.	O
1	O
mL	O
of	O
various	O
concentrations	O
of	O
samples	O
(	O
0	O
.	O
4	O
-	O
2	O
.	O
8	O
mg	O
/	O
mL	O
)	O
were	O
added	O
to	O
1	O
.	O
5	O
mL	O
of	O
linoleic	B-Chemical
acid	I-Chemical
emulsion	O
and	O
0	O
.	O
4	O
mL	O
distilled	O
water	B-Chemical
.	O
The	O
reaction	O
mixture	O
(	O
2	O
mL	O
)	O
was	O
incubated	O
at	O
room	O
temperature	O
in	O
glass	O
bottles	O
for	O
72	O
hours	O
.	O
To	O
0	O
.	O
15	O
mL	O
of	O
sample	O
solution	O
","	O
3	O
.	O
65	O
mL	O
of	O
75	O
%	O
ethanol	B-Chemical
","	O
0	O
.	O
1	O
mL	O
of	O
ammonium	B-Chemical
thiocyanate	I-Chemical
(	O
30	O
"%,"	O
m	O
/	O
v	O
"),"	O
and	O
0	O
.	O
1	O
mL	O
of	O
ferrous	B-Chemical
chloride	I-Chemical
(	O
0	O
.	O
2	O
M	O
in	O
3	O
.	O
6	O
%	O
HCl	B-Chemical
)	O
were	O
added	O
.	O
The	O
mixture	O
was	O
diluted	O
to	O
two	O
-	O
fold	O
volume	O
with	O
methanol	B-Chemical
in	O
case	O
the	O
color	O
was	O
too	O
dark	O
","	O
the	O
peroxide	B-Chemical
value	O
was	O
measured	O
by	O
monitoring	O
absorbance	O
at	O
500	O
nm	O
in	O
a	O
spectrophotometer	O
(	O
Unico	O
2100	O
","	O
Shanghai	O
","	O
China	O
).	O
The	O
percentage	O
of	O
inhibition	O
of	O
lipid	O
-	O
peroxidation	O
in	O
linoleic	B-Chemical
acid	I-Chemical
emulsion	O
was	O
calculated	O
by	O
following	O
equation	O
:	O
Where	O
A	O
is	O
the	O
absorbance	O
with	O
samples	O
","	O
while	O
A0	O
is	O
the	O
absorbance	O
without	O
samples	O
.	O
Protective	O
effect	O
against	O
hydroxyl	B-Chemical
-	O
induced	O
DNA	O
damage	O
The	O
experiment	O
was	O
conducted	O
as	O
described	O
in	O
previous	O
report	O
[	O
26	O
].	O
However	O
","	O
deoxyribose	B-Chemical
was	O
replaced	O
by	O
DNA	O
sodium	O
salt	O
.	O
Briefly	O
","	O
sample	O
was	O
dissolved	O
in	O
methanol	B-Chemical
to	O
prepare	O
the	O
sample	O
solution	O
.	O
Various	O
amounts	O
(	O
10	O
â€“	O
100	O
Î¼L	O
)	O
of	O
sample	O
solutions	O
(	O
10	O
mg	O
/	O
mL	O
)	O
were	O
then	O
separately	O
taken	O
into	O
mini	O
tubes	O
.	O
After	O
evaporating	O
the	O
sample	O
solution	O
in	O
tube	O
to	O
dryness	O
","	O
400	O
Î¼L	O
phosphate	B-Chemical
buffer	O
(	O
0	O
.	O
2	O
M	O
","	O
pH	O
7	O
.	O
4	O
)	O
was	O
brought	O
to	O
the	O
sample	O
residue	O
.	O
Then	O
","	O
50	O
Î¼L	O
DNA	O
(	O
10	O
.	O
0	O
mg	O
/	O
mL	O
"),"	O
75	O
Î¼L	O
H2O2	B-Chemical
(	O
33	O
.	O
6	O
mM	O
"),"	O
50	O
Î¼L	O
FeCl3	B-Chemical
(	O
0	O
.	O
3	O
mM	O
)	O
and	O
100	O
Î¼L	O
Na2EDTA	B-Chemical
solutions	O
(	O
0	O
.	O
5	O
mM	O
)	O
were	O
added	O
.	O
The	O
reaction	O
was	O
initiated	O
by	O
mixing	O
75	O
Î¼L	O
ascorbic	B-Chemical
acid	I-Chemical
(	O
1	O
.	O
2	O
mM	O
)	O
.	O
After	O
incubation	O
in	O
a	O
water	B-Chemical
bath	O
at	O
55	O
Â°	O
C	O
for	O
20	O
min	O
","	O
the	O
reaction	O
was	O
terminated	O
by	O
250	O
Î¼L	O
trichloroacetic	B-Chemical
acid	I-Chemical
(	O
0	O
.	O
6	O
M	O
).	O
The	O
color	O
was	O
then	O
developed	O
by	O
addition	O
of	O
150	O
Î¼L	O
2	B-Chemical
-	I-Chemical
thiobarbituric	I-Chemical
acid	I-Chemical
(	O
TBA	B-Chemical
)	O
(	O
0	O
.	O
4	O
M	O
","	O
in	O
1	O
.	O
25	O
%	O
NaOH	B-Chemical
aqueous	O
solution	O
)	O
and	O
heated	O
in	O
an	O
oven	O
at	O
105	O
Â°	O
C	O
for	O
15	O
min	O
.	O
The	O
mixture	O
was	O
cooled	O
and	O
absorbance	O
was	O
measured	O
at	O
530	O
nm	O
against	O
the	O
buffer	O
(	O
as	O
blank	O
).	O
The	O
percent	O
of	O
protection	O
of	O
DNA	O
is	O
expressed	O
as	O
follows	O
:	O
Where	O
A	O
is	O
the	O
absorbance	O
with	O
samples	O
","	O
while	O
A0	O
is	O
the	O
absorbance	O
without	O
samples	O
.	O
Hydroxyl	B-Chemical
(Â·	I-Chemical
OH	I-Chemical
)	O
radical	O
-	O
scavenging	O
assay	O
The	O
hydroxyl	B-Chemical
radical	I-Chemical
-	O
scavenging	O
activity	O
was	O
investigated	O
by	O
the	O
deoxyribose	B-Chemical
degradation	O
method	O
[	O
26	O
"],"	O
with	O
some	O
modifications	O
.	O
In	O
brief	O
","	O
the	O
sample	O
was	O
dissolved	O
in	O
methanol	B-Chemical
","	O
and	O
then	O
the	O
sample	O
solution	O
was	O
aliquoted	O
into	O
mini	O
tubes	O
.	O
After	O
evaporating	O
the	O
sample	O
solutions	O
in	O
the	O
tubes	O
to	O
dryness	O
(	O
48	O
â€“	O
240	O
Î¼g	O
"),"	O
300	O
Î¼L	O
of	O
phosphate	B-Chemical
buffer	O
(	O
0	O
.	O
2	O
M	O
","	O
pH	O
7	O
.	O
4	O
)	O
was	O
added	O
to	O
the	O
sample	O
residue	O
.	O
Subsequently	O
","	O
50	O
Î¼L	O
deoxyribose	B-Chemical
(	O
2	O
.	O
8	O
mM	O
"),"	O
50	O
Î¼L	O
H2O2	B-Chemical
(	O
2	O
.	O
8	O
mM	O
"),"	O
50	O
Î¼L	O
FeCl3	B-Chemical
(	O
25	O
Î¼M	O
"),"	O
and	O
100	O
Î¼L	O
Na2EDTA	B-Chemical
(	O
0	O
.	O
8	O
mM	O
)	O
were	O
added	O
.	O
The	O
reaction	O
was	O
initiated	O
by	O
mixing	O
50	O
Î¼L	O
ascorbic	B-Chemical
acid	I-Chemical
(	O
1	O
.	O
2	O
mM	O
)	O
and	O
the	O
total	O
volume	O
of	O
the	O
reaction	O
mixture	O
was	O
adjusted	O
to	O
600	O
Î¼L	O
with	O
buffer	O
.	O
After	O
incubation	O
in	O
a	O
water	B-Chemical
bath	O
at	O
50	O
Â°	O
C	O
for	O
20	O
min	O
","	O
the	O
reaction	O
was	O
terminated	O
by	O
addition	O
of	O
500	O
Î¼L	O
trichloroacetic	B-Chemical
acid	I-Chemical
(	O
5	O
"%,"	O
w	O
/	O
w	O
).	O
The	O
color	O
was	O
then	O
developed	O
by	O
addition	O
of	O
500	O
Î¼L	O
TBA	B-Chemical
(	O
1	O
g	O
/	O
100	O
mL	O
","	O
in	O
1	O
.	O
25	O
%	O
NaOH	B-Chemical
aqueous	O
solution	O
)	O
and	O
heated	O
in	O
an	O
oven	O
at	O
105	O
Â°	O
C	O
for	O
15	O
min	O
.	O
The	O
mixture	O
was	O
cooled	O
and	O
the	O
absorbance	O
was	O
measured	O
at	O
532	O
nm	O
against	O
the	O
buffer	O
(	O
as	O
a	O
blank	O
control	O
).	O
The	O
inhibition	O
percentage	O
for	O
Â·	B-Chemical
OH	I-Chemical
was	O
expressed	O
as	O
follows	O
:	O
Where	O
A	O
is	O
the	O
absorbance	O
containing	O
samples	O
","	O
while	O
A0	O
is	O
the	O
absorbance	O
without	O
samples	O
.	O
Superoxide	B-Chemical
anion	O
(Â·	B-Chemical
O2	I-Chemical
-)	I-Chemical
radical	O
-	O
scavenging	O
assay	O
Measurement	O
of	O
superoxide	B-Chemical
anion	O
(Â·	B-Chemical
O2	I-Chemical
âˆ’)	I-Chemical
scavenging	O
activity	O
was	O
based	O
on	O
our	O
method	O
[	O
27	O
].	O
Briefly	O
","	O
samples	O
were	O
dissolved	O
in	O
methanol	B-Chemical
at	O
3	O
mg	O
/	O
mL	O
.	O
The	O
sample	O
solution	O
x	O
Î¼L	O
(	O
x	O
=	O
67	O
","	O
117	O
","	O
167	O
","	O
217	O
","	O
267	O
","	O
and	O
317	O
)	O
was	O
mixed	O
with	O
Tris	B-Chemical
â€“	O
HCl	B-Chemical
buffer	O
(	O
2950	O
-	O
x	O
Î¼L	O
","	O
0	O
.	O
5	O
M	O
","	O
pH	O
8	O
.	O
2	O
)	O
containing	O
EDTA	B-Chemical
(	O
1	O
mM	O
)	O
and	O
pyrogallol	B-Chemical
(	O
50	O
Î¼L	O
","	O
6	O
mM	O
in	O
10	O
.	O
0	O
mM	O
HCl	B-Chemical
"),"	O
then	O
shaken	O
rapidly	O
at	O
37	O
Â°	O
C	O
.	O
The	O
absorbance	O
at	O
325	O
nm	O
of	O
the	O
mixture	O
was	O
measured	O
(	O
Unico	O
2100	O
","	O
Shanghai	O
","	O
China	O
)	O
against	O
the	O
Tris	B-Chemical
â€“	O
HCl	B-Chemical
buffer	O
as	O
blank	O
every	O
30	O
s	O
for	O
5	O
min	O
.	O
The	O
slope	O
of	O
the	O
correlation	O
of	O
absorbance	O
with	O
time	O
was	O
calculated	O
.	O
The	O
reaction	O
mixture	O
without	O
sample	O
was	O
used	O
as	O
the	O
control	O
.	O
The	O
Â·	B-Chemical
O2	I-Chemical
-	I-Chemical
scavenging	O
ability	O
was	O
calculated	O
as	O
:	O
Here	O
","	O
Î”A325nm	O
","	O
control	O
is	O
the	O
increase	O
in	O
A325nm	O
of	O
the	O
mixture	O
without	O
the	O
sample	O
and	O
Î”A325nm	O
","	O
sample	O
is	O
that	O
for	O
the	O
mixture	O
with	O
the	O
sample	O
;	O
T	O
=	O
5	O
min	O
.	O
The	O
experiment	O
temperature	O
was	O
37	O
Â°	O
C	O
.	O
Chelating	O
activity	O
on	O
Cu2	B-Chemical
+	I-Chemical
The	O
Cu2	B-Chemical
+-	I-Chemical
chelating	O
activities	O
of	O
five	O
RC	O
extracts	O
were	O
measured	O
by	O
the	O
method	O
[	O
28	O
].	O
Briefly	O
","	O
60	O
Î¼L	O
CuSO4	B-Chemical
aqueous	O
solution	O
(	O
20	O
mM	O
)	O
was	O
added	O
to	O
hexamine	B-Chemical
HCl	I-Chemical
buffer	O
(	O
pH	O
5	O
.	O
3	O
","	O
30	O
mM	O
)	O
containing	O
30	O
mM	O
KCl	B-Chemical
and	O
0	O
.	O
20	O
mM	O
murexide	B-Chemical
.	O
After	O
incubation	O
for	O
1	O
min	O
at	O
room	O
temperature	O
","	O
80	O
â€“	O
230	O
Î¼L	O
sample	O
solutions	O
(	O
4	O
mg	O
/	O
mL	O
in	O
methanol	B-Chemical
)	O
were	O
added	O
.	O
The	O
final	O
volume	O
was	O
adjusted	O
to	O
1500	O
Î¼L	O
with	O
methanol	B-Chemical
.	O
Then	O
","	O
the	O
mixture	O
was	O
shaken	O
vigorously	O
and	O
left	O
at	O
room	O
temperature	O
for	O
10	O
min	O
.	O
Absorbance	O
of	O
the	O
solution	O
was	O
then	O
measured	O
by	O
a	O
spectrophotometer	O
(	O
Unico	O
2100	O
","	O
Shanghai	O
","	O
China	O
)	O
at	O
485	O
nm	O
and	O
520	O
nm	O
.	O
The	O
absorbance	O
ratio	O
(	O
A485	O
/	O
A520	O
)	O
reflected	O
the	O
free	O
Cu2	B-Chemical
+	I-Chemical
content	O
.	O
Therefore	O
","	O
the	O
percentage	O
of	O
cupric	O
chelating	O
effect	O
was	O
calculated	O
by	O
the	O
following	O
formula	O
:	O
Where	O
is	O
the	O
absorbance	O
ratio	O
of	O
the	O
sample	O
","	O
while	O
is	O
the	O
maximum	O
absorbance	O
ratio	O
and	O
is	O
the	O
minimum	O
absorbance	O
ratio	O
in	O
the	O
test	O
.	O
DPPH	B-Chemical
Â·	I-Chemical
scavenging	O
assay	O
DPPH	B-Chemical
Â·	I-Chemical
radical	O
-	O
scavenging	O
activity	O
was	O
determined	O
as	O
previously	O
described	O
by	O
Li	O
[	O
23	O
].	O
Briefly	O
","	O
0	O
.	O
8	O
mL	O
DPPH	B-Chemical
Â·	I-Chemical
solution	O
(	O
0	O
.	O
1	O
M	O
)	O
was	O
mixed	O
with	O
4	O
.	O
2	O
mL	O
various	O
concentrations	O
(	O
15	O
â€“	O
300	O
Î¼g	O
/	O
mL	O
)	O
of	O
samples	O
dissolved	O
in	O
95	O
%	O
ethanol	B-Chemical
.	O
The	O
mixture	O
was	O
kept	O
at	O
room	O
temperature	O
for	O
30	O
min	O
","	O
and	O
then	O
measured	O
with	O
a	O
spectrophotometer	O
(	O
Unico	O
2100	O
","	O
Shanghai	O
","	O
China	O
)	O
at	O
519	O
nm	O
.	O
The	O
DPPH	B-Chemical
Â·	I-Chemical
inhibition	O
percentage	O
of	O
the	O
samples	O
was	O
calculated	O
:	O
Where	O
A0	O
is	O
the	O
absorbance	O
without	O
samples	O
","	O
while	O
A	O
is	O
the	O
absorbance	O
with	O
samples	O
.	O
ABTS	B-Chemical
Â·+	I-Chemical
scavenging	O
assay	O
The	O
ABTS	B-Chemical
Â·+-	I-Chemical
scavenging	O
activity	O
was	O
measured	O
as	O
described	O
[	O
23	O
]	O
with	O
some	O
modifications	O
.	O
The	O
ABTS	B-Chemical
Â·+	I-Chemical
was	O
produced	O
by	O
mixing	O
0	O
.	O
35	O
mL	O
ABTS	B-Chemical
diammonium	I-Chemical
salt	I-Chemical
(	O
7	O
.	O
4	O
mM	O
)	O
with	O
0	O
.	O
35	O
mL	O
potassium	B-Chemical
persulfate	I-Chemical
(	O
2	O
.	O
6	O
mM	O
).	O
The	O
mixture	O
was	O
kept	O
in	O
the	O
dark	O
at	O
room	O
temperature	O
for	O
12	O
hours	O
to	O
allow	O
completion	O
of	O
radical	O
generation	O
","	O
then	O
diluted	O
with	O
95	O
%	O
ethanol	B-Chemical
(	O
about	O
1	O
:	O
50	O
)	O
so	O
that	O
its	O
absorbance	O
at	O
734	O
nm	O
was	O
0	O
.	O
70	O
Â±	O
0	O
.	O
2	O
.	O
To	O
determine	O
the	O
scavenging	O
activity	O
","	O
1	O
.	O
2	O
mL	O
aliquot	O
of	O
ABTS	B-Chemical
Â·+	I-Chemical
reagent	O
was	O
mixed	O
with	O
0	O
.	O
3	O
mL	O
of	O
sample	O
ethanolic	B-Chemical
solutions	O
(	O
40	O
â€“	O
540	O
Î¼g	O
/	O
mL	O
).	O
After	O
incubation	O
for	O
6	O
min	O
","	O
the	O
absorbance	O
at	O
734	O
nm	O
was	O
read	O
on	O
a	O
spectrophotometer	O
(	O
Unico	O
2100	O
","	O
Shanghai	O
","	O
China	O
).	O
The	O
percentage	O
inhibition	O
of	O
the	O
samples	O
was	O
calculated	O
as	O
:	O
Where	O
A0	O
is	O
the	O
absorbance	O
at	O
734	O
nm	O
without	O
samples	O
","	O
while	O
A	O
is	O
the	O
absorbance	O
at	O
734	O
nm	O
with	O
samples	O
.	O
Reducing	O
power	O
(	O
Fe3	B-Chemical
+)	I-Chemical
assay	O
Ferric	B-Chemical
cyanide	I-Chemical
(	O
Fe3	B-Chemical
+)	I-Chemical
reducing	O
power	O
was	O
determined	O
according	O
to	O
the	O
method	O
of	O
Oyaizu	O
[	O
23	O
","	O
29	O
].	O
In	O
brief	O
","	O
sample	O
solutions	O
x	O
Î¼L	O
(	O
4	O
mg	O
/	O
mL	O
","	O
x	O
=	O
20	O
","	O
40	O
","	O
60	O
","	O
80	O
","	O
and	O
100	O
)	O
were	O
mixed	O
with	O
(	O
350	O
-	O
x	O
)	O
Î¼L	O
Na2HPO4	B-Chemical
/	O
KH2PO4	B-Chemical
buffer	O
(	O
0	O
.	O
2	O
M	O
","	O
pH	O
6	O
.	O
6	O
)	O
and	O
250	O
Î¼L	O
K3Fe	B-Chemical
(	I-Chemical
CN	I-Chemical
)	I-Chemical
6	I-Chemical
aqueous	O
solution	O
(	O
1	O
g	O
/	O
100	O
mL	O
).	O
The	O
mixture	O
was	O
incubated	O
at	O
50	O
Â°	O
C	O
for	O
20	O
min	O
","	O
250	O
Î¼L	O
of	O
trichloroacetic	B-Chemical
acid	I-Chemical
(	O
10	O
g	O
/	O
100	O
mL	O
)	O
was	O
added	O
","	O
and	O
the	O
mixture	O
was	O
centrifuged	O
at	O
3500	O
r	O
/	O
min	O
for	O
10	O
min	O
.	O
As	O
soon	O
as	O
400	O
Î¼L	O
supernatant	O
was	O
mixed	O
with	O
400	O
Î¼L	O
FeCl3	B-Chemical
(	O
0	O
.	O
1	O
g	O
/	O
100	O
mL	O
in	O
distilled	O
water	B-Chemical
"),"	O
the	O
timer	O
was	O
started	O
.	O
At	O
90	O
s	O
","	O
absorbance	O
of	O
the	O
mixture	O
was	O
read	O
at	O
700	O
nm	O
(	O
Unico	O
2100	O
","	O
Shanghai	O
","	O
China	O
).	O
Samples	O
were	O
analyzed	O
in	O
groups	O
of	O
three	O
","	O
and	O
when	O
the	O
analysis	O
of	O
one	O
group	O
has	O
finished	O
","	O
the	O
next	O
group	O
of	O
three	O
samples	O
were	O
mixed	O
with	O
FeCl3	B-Chemical
to	O
prevent	O
the	O
mixture	O
from	O
being	O
oxidized	O
by	O
air	O
.	O
The	O
relative	O
reducing	O
ability	O
of	O
the	O
sample	O
was	O
calculated	O
by	O
using	O
the	O
formula	O
:	O
Here	O
","	O
Amax	O
is	O
the	O
maximum	O
absorbance	O
and	O
Amin	O
is	O
the	O
minimum	O
absorbance	O
in	O
the	O
test	O
.	O
A	O
is	O
the	O
absorbance	O
of	O
sample	O
.	O
HPLC	O
analysis	O
for	O
caffeic	B-Chemical
acid	I-Chemical
","	O
ferulic	B-Chemical
acid	I-Chemical
","	O
and	O
isoferulic	B-Chemical
acid	I-Chemical
Caffeic	B-Chemical
acid	I-Chemical
","	O
ferulic	B-Chemical
acid	I-Chemical
","	O
and	O
isoferulic	B-Chemical
acid	I-Chemical
were	O
identified	O
by	O
comparing	O
their	O
retention	O
times	O
using	O
HPLC	O
method	O
.	O
HPLC	O
analysis	O
was	O
performed	O
on	O
a	O
Syltech	O
P510	O
system	O
(	O
Los	O
Angeles	O
","	O
California	O
","	O
USA	O
)	O
equipped	O
with	O
Dikma	O
Diamonsil	O
C18	O
(	O
250	O
mm	O
Ã—	O
4	O
.	O
6	O
mm	O
","	O
5	O
Î¼m	O
)	O
(	O
Beijing	O
","	O
China	O
).	O
The	O
mobile	O
phase	O
consisted	O
of	O
acetonitrile	B-Chemical
-	O
0	O
.	O
5	O
%	O
acetic	B-Chemical
acid	I-Chemical
in	O
water	B-Chemical
(	O
17	O
:	O
83	O
","	O
v	O
:	O
v	O
"),"	O
the	O
flow	O
rate	O
was	O
1	O
.	O
0	O
mL	O
/	O
min	O
","	O
injection	O
volume	O
was	O
30	O
Î¼L	O
and	O
absorption	O
was	O
measured	O
at	O
316	O
nm	O
.	O
Determination	O
of	O
total	O
phenolics	B-Chemical
","	O
total	O
sugars	B-Chemical
and	O
total	O
saponins	B-Chemical
The	O
total	O
phenolics	B-Chemical
of	O
five	O
RC	O
extracts	O
were	O
determined	O
by	O
the	O
Folin	O
-	O
Ciocalteu	O
method	O
with	O
a	O
little	O
modifications	O
[	O
30	O
].	O
Firstly	O
","	O
0	O
.	O
5	O
mL	O
extract	O
methanolic	O
solution	O
(	O
0	O
.	O
4	O
mg	O
/	O
mL	O
)	O
was	O
mixed	O
with	O
0	O
.	O
5	O
mL	O
0	O
.	O
25	O
M	O
Folin	B-Chemical
-	I-Chemical
Ciocalteu	I-Chemical
reagent	I-Chemical
.	O
After	O
incubation	O
for	O
3	O
min	O
","	O
1	O
mL	O
of	O
Na2CO3	B-Chemical
solution	O
(	O
15	O
"%,"	O
w	O
/	O
v	O
)	O
was	O
added	O
.	O
After	O
standing	O
at	O
the	O
room	O
temperature	O
for	O
30	O
min	O
","	O
the	O
mixture	O
was	O
centrifuged	O
at	O
3500	O
r	O
/	O
min	O
for	O
3	O
min	O
.	O
The	O
absorbance	O
of	O
the	O
supernatant	O
was	O
measured	O
at	O
760	O
nm	O
(	O
Unico	O
2100	O
","	O
Shanghai	O
","	O
China	O
).	O
The	O
determinations	O
were	O
performed	O
in	O
triplicate	O
","	O
and	O
the	O
calculations	O
were	O
based	O
on	O
a	O
calibration	O
curve	O
obtained	O
with	O
pyrogallol	B-Chemical
.	O
The	O
result	O
was	O
expressed	O
as	O
pyrogallol	B-Chemical
equivalents	O
(	O
Pyr	O
.)	O
in	O
milligrams	O
per	O
gram	O
of	O
extract	O
.	O
The	O
total	O
sugars	B-Chemical
were	O
evaluated	O
according	O
to	O
the	O
phenol	B-Chemical
-	O
sulfuric	B-Chemical
acid	I-Chemical
method	O
[	O
30	O
].	O
A	O
40	O
-	O
Î¼L	O
aliquot	O
of	O
sample	O
solution	O
(	O
1	O
mg	O
/	O
mL	O
)	O
was	O
placed	O
in	O
a	O
flask	O
","	O
then	O
210	O
Î¼L	O
distilled	O
water	B-Chemical
","	O
250	O
Î¼L	O
phenol	B-Chemical
solution	O
(	O
5	O
"%,"	O
w	O
/	O
v	O
)	O
and	O
250	O
Î¼L	O
concentrated	O
sulfuric	B-Chemical
acid	I-Chemical
were	O
added	O
.	O
After	O
incubation	O
for	O
20	O
min	O
at	O
room	O
temperature	O
","	O
the	O
absorbance	O
of	O
reaction	O
mixture	O
was	O
measured	O
at	O
490	O
nm	O
(	O
Unico	O
2100	O
","	O
Shanghai	O
","	O
China	O
).	O
The	O
measurements	O
were	O
performed	O
in	O
triplicate	O
","	O
and	O
the	O
calculations	O
were	O
based	O
on	O
a	O
calibration	O
curve	O
obtained	O
with	O
glucose	B-Chemical
.	O
The	O
result	O
was	O
expressed	O
as	O
glucose	B-Chemical
equivalents	O
in	O
milligrams	O
per	O
gram	O
of	O
extract	O
.	O
The	O
total	O
saponins	B-Chemical
were	O
measured	O
according	O
to	O
the	O
method	O
[	O
30	O
].	O
RC	O
extract	O
was	O
dissolved	O
in	O
methanol	B-Chemical
to	O
prepare	O
the	O
sample	O
solution	O
(	O
4	O
mg	O
/	O
mL	O
"),"	O
then	O
a	O
20	O
-	O
Î¼L	O
aliquot	O
of	O
sample	O
solution	O
was	O
taken	O
into	O
a	O
mini	O
tube	O
.	O
After	O
the	O
sample	O
solution	O
in	O
tube	O
was	O
evaporated	O
to	O
dryness	O
(	O
water	B-Chemical
bath	O
","	O
80	O
Â°	O
C	O
"),"	O
0	O
.	O
1	O
mL	O
vanillin	B-Chemical
-	O
acetic	B-Chemical
acid	I-Chemical
solution	O
(	O
5	O
mg	O
/	O
mL	O
)	O
and	O
0	O
.	O
4	O
mL	O
perchloric	B-Chemical
acid	I-Chemical
were	O
added	O
to	O
the	O
sample	O
residue	O
.	O
The	O
reaction	O
mixture	O
was	O
incubated	O
at	O
70	O
Â°	O
C	O
for	O
15	O
min	O
","	O
then	O
diluted	O
by	O
1	O
.	O
25	O
mL	O
acetic	B-Chemical
acid	I-Chemical
.	O
The	O
mixture	O
was	O
measured	O
using	O
a	O
spectrophotometer	O
(	O
Unico	O
2100	O
","	O
Shanghai	O
","	O
China	O
)	O
at	O
540	O
nm	O
against	O
a	O
blank	O
control	O
","	O
which	O
contained	O
all	O
reagents	O
except	O
sample	O
.	O
All	O
analyses	O
were	O
run	O
in	O
triplicate	O
.	O
Quantification	O
was	O
based	O
on	O
the	O
standard	O
curve	O
for	O
oleanic	B-Chemical
acid	I-Chemical
(	O
10	O
â€“	O
79	O
Î¼g	O
/	O
mL	O
)	O
and	O
the	O
results	O
were	O
expressed	O
in	O
milligrams	O
of	O
oleanic	B-Chemical
acid	I-Chemical
(	O
Ole	O
.)	O
equivalents	O
per	O
gram	O
of	O
extract	O
.	O
The	O
correlation	O
graphs	O
and	O
R	O
values	O
In	O
order	O
to	O
investigate	O
the	O
correlation	O
between	O
antioxidant	O
activities	O
and	O
chemical	O
components	O
of	O
five	O
RC	O
extracts	O
","	O
48	O
correlation	O
graphs	O
were	O
plotted	O
between	O
1	O
/	O
IC50	O
values	O
(	O
including	O
of	O
LPO	O
","	O
DNA	O
","	O
Â·	B-Chemical
OH	I-Chemical
","	O
Â·	B-Chemical
O2	I-Chemical
-	I-Chemical
","	O
Cu	B-Chemical
-	O
chelating	O
","	O
DPPH	B-Chemical
"Â·,"	I-Chemical
ABTS	I-Chemical
"Â·+,"	I-Chemical
and	O
reducing	O
power	O
assays	O
)	O
and	O
chemical	O
contents	O
(	O
including	O
total	O
phenolics	B-Chemical
","	O
caffeic	B-Chemical
acid	I-Chemical
","	O
ferulic	B-Chemical
acid	I-Chemical
","	O
isoferulic	B-Chemical
acid	I-Chemical
","	O
total	O
sugars	B-Chemical
","	O
and	O
total	O
saponins	B-Chemical
).	O
In	O
the	O
correlation	O
graphs	O
","	O
the	O
correlation	O
coefficients	O
(	O
R	O
values	O
)	O
were	O
calculated	O
by	O
Origin	O
6	O
.	O
0	O
professional	O
software	O
.	O
Statistical	O
analysis	O
Data	O
are	O
given	O
as	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
measurements	O
.	O
The	O
IC50	O
values	O
were	O
calculated	O
by	O
linear	O
regression	O
analysis	O
.	O
All	O
linear	O
regression	O
in	O
this	O
paper	O
was	O
analyzed	O
by	O
Origin	O
6	O
.	O
0	O
professional	O
software	O
.	O
Significant	O
differences	O
were	O
performed	O
using	O
the	O
T	O
-	O
test	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
The	O
analysis	O
was	O
performed	O
using	O
SPSS	O
software	O
(	O
v	O
.	O
12	O
","	O
SPSS	O
","	O
USA	O
).	O
Conclusion	O
As	O
an	O
effective	O
antioxidant	O
","	O
rhizoma	O
Cimicifugae	O
can	O
protect	O
DNA	O
and	O
lipids	O
against	O
oxidative	O
damage	O
.	O
Its	O
antioxidant	O
ability	O
can	O
be	O
responsible	O
for	O
its	O
various	O
pharmacological	O
effects	O
and	O
may	O
be	O
mainly	O
attributed	O
to	O
the	O
existence	O
of	O
total	O
phenolics	B-Chemical
","	O
among	O
which	O
caffeic	B-Chemical
acid	I-Chemical
","	O
ferulic	B-Chemical
acid	I-Chemical
and	O
isoferulic	B-Chemical
acid	I-Chemical
are	O
regarded	O
as	O
main	O
bioactive	O
components	O
.	O
Rhizoma	O
Cimicifugae	O
exerts	O
its	O
antioxidant	O
effect	O
through	O
metal	O
-	O
chelating	O
","	O
and	O
radical	O
-	O
scavenging	O
which	O
is	O
via	O
donating	O
hydrogen	B-Chemical
atom	O
(	O
H	B-Chemical
Â·)	I-Chemical
and	O
donating	O
electron	O
(	O
e	O
).	O
Abbreviations	O
RC	O
:	O
Rhizoma	O
Cimicifugae	O
;	O
PERC	O
:	O
Petroleum	B-Chemical
ether	I-Chemical
extract	O
from	O
rhizoma	O
Cimicifugae	O
;	O
EARC	O
:	O
Ethyl	B-Chemical
acetate	I-Chemical
extract	O
from	O
rhizoma	O
Cimicifugae	O
;	O
AERC	O
:	O
Absolute	O
ethanol	B-Chemical
extract	O
from	O
rhizoma	O
Cimicifugae	O
;	O
95ERC	O
:	O
95	O
%	O
ethanol	B-Chemical
extract	O
from	O
rhizoma	O
Cimicifugae	O
;	O
WRC	O
:	O
Water	B-Chemical
extract	O
from	O
rhizoma	O
Cimicifugae	O
;	O
DPPH	B-Chemical
Â·:	I-Chemical
1	I-Chemical
","	I-Chemical
1	I-Chemical
-	I-Chemical
diphenyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
picryl	I-Chemical
-	I-Chemical
hydrazl	I-Chemical
radical	O
;	O
ABTS	B-Chemical
:	O
2	B-Chemical
","	I-Chemical
2	I-Chemical
â€²-	I-Chemical
azino	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
3	I-Chemical
-	I-Chemical
ethylbenzo	I-Chemical
-	I-Chemical
thiazoline	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
sulfonic	I-Chemical
acid	I-Chemical
salt	I-Chemical
);	I-Chemical
ROS	I-Chemical
:	O
Reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
;	O
TCM	O
:	O
Traditional	O
Chinese	O
medicine	O
;	O
BHT	B-Chemical
:	O
2	B-Chemical
","	I-Chemical
6	I-Chemical
-	I-Chemical
di	I-Chemical
-	I-Chemical
tert	I-Chemical
-	I-Chemical
butyl	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methyphenol	I-Chemical
;	O
GSH	B-Chemical
:	O
Glutathione	B-Chemical
;	O
BHA	B-Chemical
:	O
Butylated	B-Chemical
hydroxyanisole	I-Chemical
;	O
TBARS	O
:	O
Thiobarbituric	B-Chemical
acid	I-Chemical
reactive	O
substances	O
;	O
TBA	B-Chemical
:	O
Thiobarbituric	B-Chemical
acid	I-Chemical
;	O
MDA	B-Chemical
:	O
Malondialdehyde	B-Chemical
.	O
Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O
Authors	O
â€™	O
contribution	O
XL	O
&	O
JL	O
made	O
a	O
significant	O
contribution	O
to	O
experiment	O
design	O
","	O
acquisition	O
of	O
data	O
","	O
analysis	O
","	O
drafting	O
of	O
the	O
manuscript	O
.	O
YG	O
and	O
WH	O
have	O
made	O
a	O
substantial	O
contribution	O
to	O
interpretation	O
of	O
data	O
","	O
drafting	O
.	O
DC	O
has	O
carefully	O
revised	O
the	O
manuscript	O
for	O
intellectual	O
content	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
Supplementary	O
Material	O
Acknowledgement	O
This	O
work	O
was	O
supported	O
by	O
the	O
National	O
Nature	O
Science	O
Foundation	O
of	O
China	O
(	O
81273896	O
)	O
and	O
National	O
Key	O
Technologies	O
R	O
&	O
D	O
Program	O
of	O
China	O
(	O
No	O
.	O
2008BAI51B01	O
).	O
Ultrasonic	O
irradiation	O
assisted	O
efficient	O
regioselective	O
synthesis	O
of	O
CF3	B-Chemical
-	O
containing	O
pyrazoles	B-Chemical
catalyzed	O
by	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
/	O
Et3N	B-Chemical
Background	O
Most	O
of	O
the	O
known	O
approaches	O
to	O
the	O
synthesis	O
of	O
CF3	B-Chemical
-	O
containing	O
organic	O
compounds	O
suffer	O
from	O
serious	O
drawbacks	O
.	O
For	O
example	O
the	O
starting	O
materials	O
required	O
for	O
these	O
methods	O
are	O
rather	O
difficult	O
to	O
obtain	O
","	O
or	O
they	O
are	O
fairly	O
toxic	O
and	O
inconvenient	O
to	O
work	O
with	O
and	O
methods	O
for	O
direct	O
fluorination	O
and	O
trifluoromethylation	O
do	O
not	O
always	O
allow	O
the	O
introduction	O
of	O
the	O
CF3	B-Chemical
-	O
group	O
at	O
the	O
required	O
position	O
of	O
a	O
molecule	O
.	O
Results	O
An	O
efficient	O
and	O
attractive	O
regioselective	O
synthesis	O
of	O
a	O
series	O
of	O
novel	O
pyrazoles	B-Chemical
containing	O
the	O
trifluromethyl	B-Chemical
moiety	O
was	O
achieved	O
using	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
/	O
Et3N	B-Chemical
as	O
an	O
efficient	O
catalytic	O
system	O
under	O
ultrasonic	O
irradiation	O
.	O
Conclusions	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
/	O
Et3N	B-Chemical
catalyst	O
showed	O
a	O
great	O
advantage	O
over	O
all	O
the	O
investigated	O
catalysts	O
","	O
and	O
the	O
ultrasonic	O
irradiation	O
method	O
offered	O
high	O
yields	O
of	O
pyrazoles	B-Chemical
in	O
short	O
reaction	O
time	O
compared	O
with	O
classical	O
conditions	O
.	O
gHMBC	O
spectra	O
of	O
the	O
product	O
were	O
used	O
to	O
rationalize	O
the	O
observed	O
regioselectivity	O
.	O
Background	O
Over	O
the	O
last	O
two	O
decades	O
there	O
has	O
been	O
rapid	O
progress	O
in	O
synthetic	O
organic	O
chemistry	O
associated	O
with	O
the	O
search	O
for	O
new	O
organic	O
compound	O
derivatives	O
with	O
desirable	O
properties	O
.	O
Such	O
compounds	O
are	O
widely	O
used	O
in	O
the	O
pharmaceutical	O
industry	O
.	O
Among	O
the	O
several	O
FDA	O
approved	O
pharmaceutical	O
drugs	O
","	O
the	O
pyrazole	B-Chemical
core	O
is	O
found	O
in	O
rimonabant	B-Chemical
(	O
1	O
"),"	O
and	O
celecoxib	B-Chemical
(	O
2	O
)	O
(	O
Figure	O
1	O
)	O
[	O
1	O
].	O
Examples	O
of	O
pharmaceutically	O
relevant	O
pyrazoles	B-Chemical
.	O
Pyrazoles	B-Chemical
exhibit	O
significant	O
biological	O
properties	O
such	O
as	O
antihyperglycemic	O
[	O
2	O
"],"	O
analgesic	O
[	O
3	O
"],"	O
anti	O
-	O
inflammatory	O
[	O
4	O
"],"	O
antipyretic	O
[	O
5	O
"],"	O
antibacterial	O
[	O
6	O
"],"	O
hypoglycemic	O
[	O
7	O
]	O
and	O
sedative	O
-	O
hypnotic	O
activities	O
[	O
8	O
].	O
The	O
trifluoromethyl	B-Chemical
group	O
is	O
a	O
very	O
important	O
substituent	O
in	O
medicinal	O
chemistry	O
","	O
due	O
to	O
its	O
unique	O
stereoelectronic	O
properties	O
.	O
A	O
trifluoromethyl	B-Chemical
group	O
usually	O
increases	O
the	O
lipophilicity	O
of	O
a	O
molecule	O
","	O
improving	O
its	O
transport	O
characteristics	O
in	O
vivo	O
.	O
Furthermore	O
","	O
the	O
strength	O
and	O
durability	O
of	O
the	O
C	O
-	O
F	O
bond	O
compared	O
with	O
the	O
Ð¡	O
-	O
Ð	O
bond	O
(	O
116	O
and	O
100	O
kcal	O
/	O
mol	O
respectively	O
)	O
allows	O
undesirable	O
metabolic	O
transformations	O
to	O
be	O
avoided	O
.	O
So	O
the	O
introduction	O
of	O
trifluoromethyl	B-Chemical
groups	O
into	O
bioactive	O
molecules	O
has	O
become	O
very	O
important	O
in	O
pharmaceutical	O
studies	O
","	O
stimulating	O
work	O
directed	O
towards	O
the	O
elaboration	O
of	O
synthetic	O
methodology	O
for	O
compounds	O
containing	O
trifluoromethyl	B-Chemical
groups	O
.	O
Because	O
of	O
all	O
these	O
factors	O
","	O
organofluorine	B-Chemical
chemistry	O
has	O
been	O
vigorously	O
developing	O
during	O
the	O
past	O
two	O
decades	O
[	O
9	O
].	O
Most	O
of	O
the	O
known	O
approaches	O
to	O
the	O
synthesis	O
of	O
CF3	O
-	O
containing	O
organic	O
compounds	O
suffer	O
from	O
serious	O
drawbacks	O
.	O
First	O
of	O
all	O
","	O
the	O
starting	O
materials	O
required	O
for	O
these	O
methods	O
are	O
rather	O
difficult	O
to	O
obtain	O
","	O
or	O
they	O
are	O
fairly	O
toxic	O
and	O
inconvenient	O
to	O
work	O
with	O
.	O
Additionally	O
","	O
methods	O
for	O
direct	O
fluorination	O
and	O
trifluoromethylation	O
do	O
not	O
always	O
allow	O
the	O
introduction	O
of	O
the	O
CF3	O
-	O
group	O
at	O
the	O
required	O
position	O
of	O
a	O
molecule	O
.	O
It	O
is	O
worth	O
mentioning	O
that	O
most	O
of	O
the	O
reported	O
methods	O
for	O
synthesis	O
of	O
CF3	O
-	O
containing	O
pyrazoles	B-Chemical
suffer	O
from	O
formation	O
of	O
mixures	O
of	O
regioisomers	O
.	O
Pavlik	O
et	O
al	O
.	O
studied	O
the	O
reactivity	O
of	O
CF3	B-Chemical
-	I-Chemical
enones	I-Chemical
towards	O
N	O
-	O
substituted	O
hydrazines	B-Chemical
where	O
a	O
mixture	O
of	O
regioisomers	O
was	O
obtained	O
.	O
Also	O
","	O
in	O
the	O
reaction	O
of	O
Î²	O
-	O
alkoxy	O
substituted	O
enones	B-Chemical
with	O
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
hydrazine	I-Chemical
two	O
isomeric	O
dihydropyrazoles	B-Chemical
were	O
obtained	O
[	O
10	O
","	O
11	O
].	O
Singh	O
et	O
al	O
.	O
investigated	O
the	O
reactivity	O
of	O
3	B-Chemical
-(	I-Chemical
ethoxymethylene	I-Chemical
)	I-Chemical
1	I-Chemical
","	I-Chemical
1	I-Chemical
","	I-Chemical
1	I-Chemical
-	I-Chemical
trifluropentan	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
dione	I-Chemical
with	O
various	O
aryl	O
and	O
heteroaryle	O
substituted	O
hydrazines	B-Chemical
","	O
and	O
a	O
mixure	O
of	O
pyrazoles	B-Chemical
formed	O
[	O
12	O
].	O
Nenajdenko	O
et	O
al	O
.	O
obtained	O
CF3	B-Chemical
-	O
conatining	O
pyrazoles	B-Chemical
with	O
100	O
%	O
regioselectivty	O
from	O
the	O
reaction	O
of	O
Î±	B-Chemical
-	I-Chemical
bromo	I-Chemical
-	I-Chemical
ethoxy	I-Chemical
-	I-Chemical
trifluromethyl	I-Chemical
enone	I-Chemical
with	O
aryl	B-Chemical
hydrazine	I-Chemical
","	O
but	O
with	O
lower	O
yield	O
[	O
13	O
].	O
As	O
a	O
result	O
the	O
more	O
flexible	O
â€œ	O
synthon	O
â€	O
approach	O
","	O
based	O
on	O
the	O
application	O
of	O
simple	O
and	O
readily	O
available	O
fluorine	B-Chemical
-	O
containing	O
compounds	O
has	O
gained	O
substantial	O
interest	O
[	O
14	O
].	O
Nitrilimines	B-Chemical
containing	O
a	O
fluro	O
or	O
trifluoromethyl	B-Chemical
moiety	O
(	O
liberated	O
in	O
situ	O
from	O
the	O
corresponding	O
hydrazonyl	B-Chemical
halide	I-Chemical
)	O
are	O
easily	O
available	O
compounds	O
which	O
can	O
be	O
prepared	O
by	O
various	O
methods	O
[	O
15	O
]	O
and	O
fairly	O
convenient	O
building	O
blocks	O
to	O
prepare	O
heterocyclic	O
compounds	O
containing	O
a	O
trifluoromethyl	B-Chemical
group	O
.	O
It	O
is	O
evident	O
from	O
the	O
recent	O
literature	O
that	O
copper	B-Chemical
triflate	I-Chemical
[	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
]	O
has	O
invoked	O
enormous	O
interest	O
as	O
a	O
green	O
and	O
potential	O
Lewis	O
acid	O
catalyst	O
to	O
construct	O
carbon	B-Chemical
â€“	O
carbon	B-Chemical
and	O
carbon	B-Chemical
â€“	O
heteroatom	O
bonds	O
in	O
various	O
organic	O
transformations	O
[	O
16	O
-	O
23	O
].	O
Despite	O
its	O
great	O
importance	O
","	O
only	O
a	O
few	O
papers	O
have	O
reported	O
on	O
its	O
catalytic	O
application	O
in	O
organic	O
synthesis	O
[	O
24	O
].	O
Ultrasound	O
irradiation	O
has	O
been	O
utilized	O
to	O
accelerate	O
a	O
number	O
of	O
synthetically	O
useful	O
reactions	O
during	O
the	O
last	O
few	O
years	O
.	O
Cavitation	O
is	O
the	O
formation	O
","	O
growth	O
and	O
collapse	O
of	O
bubbles	O
in	O
an	O
irradiated	O
liquid	O
.	O
This	O
effect	O
induces	O
very	O
high	O
local	O
pressure	O
and	O
temperatures	O
inside	O
the	O
bubbles	O
and	O
enhances	O
mass	O
transfer	O
and	O
turbulent	O
flow	O
in	O
the	O
liquid	O
[	O
25	O
].	O
Ultrasound	O
has	O
been	O
utilized	O
to	O
accelerate	O
a	O
number	O
of	O
synthetically	O
useful	O
reactions	O
","	O
especially	O
in	O
heterocyclic	O
chemistry	O
[	O
26	O
-	O
36	O
].	O
As	O
part	O
of	O
our	O
ongoing	O
interest	O
in	O
sonochemistry	O
[	O
37	O
-	O
42	O
"],"	O
and	O
in	O
a	O
continuation	O
of	O
our	O
interest	O
in	O
the	O
synthesis	O
of	O
a	O
wide	O
range	O
of	O
heterocyclic	O
systems	O
for	O
biological	O
screening	O
programme	O
in	O
our	O
laboratory	O
[	O
43	O
-	O
51	O
"],"	O
we	O
will	O
introduce	O
here	O
a	O
novel	O
and	O
efficient	O
regioselective	O
synthesis	O
of	O
trifluromethyl	O
containing	O
pyrazoles	B-Chemical
under	O
ultrasonic	O
irradaition	O
promoted	O
by	O
catalytic	O
amount	O
of	O
copper	B-Chemical
triflate	I-Chemical
and	O
triethylamine	B-Chemical
.	O
Results	O
and	O
discussion	O
A	O
wide	O
variety	O
of	O
catalysts	O
were	O
scanned	O
for	O
the	O
reaction	O
of	O
N	B-Chemical
-	I-Chemical
phenyltrifluromethylcarbohydrazonoyl	I-Chemical
benzenesulfonate	I-Chemical
(	O
3	O
)	O
and	O
1	B-Chemical
","	I-Chemical
1	I-Chemical
","	I-Chemical
1	I-Chemical
-	I-Chemical
trifluoropentane	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
dione	I-Chemical
(	O
4a	O
)	O
(	O
Scheme	O
1	O
)	O
in	O
ethanol	B-Chemical
under	O
ultrasound	O
irradiation	O
as	O
a	O
model	O
reaction	O
(	O
Table	O
1	O
).	O
These	O
catalysts	O
are	O
sodium	B-Chemical
ethoxide	I-Chemical
","	O
triethylamine	B-Chemical
","	O
copper	B-Chemical
triflate	I-Chemical
","	O
copper	B-Chemical
triflate	I-Chemical
/	O
triethyl	B-Chemical
amine	I-Chemical
","	O
which	O
were	O
selected	O
to	O
promote	O
the	O
mentioned	O
reaction	O
.	O
Regioselective	O
synthesis	O
of	O
pyrazole	B-Chemical
derivative	O
5a	O
using	O
various	O
catalysts	O
under	O
ultrasonic	O
irradiation	O
.	O
Regioselective	O
synthesis	O
of	O
pyrazole	B-Chemical
derivative	O
5a	O
using	O
various	O
catalysts	O
under	O
ultrasonic	O
irradiation	O
.	O
The	O
yield	O
of	O
pyrazole	B-Chemical
derivative	O
5a	O
obtained	O
using	O
various	O
catalysts	O
under	O
ultrasonic	O
irradiation	O
Absolute	O
ethanol	B-Chemical
was	O
selected	O
as	O
solvent	O
due	O
to	O
the	O
solubility	O
of	O
the	O
two	O
starting	O
materials	O
.	O
Thin	O
layer	O
chromatography	O
(	O
TLC	O
)	O
used	O
to	O
follow	O
the	O
reaction	O
progress	O
.	O
It	O
is	O
clear	O
from	O
the	O
results	O
cited	O
in	O
Table	O
1	O
","	O
that	O
only	O
one	O
isolable	O
unique	O
product	O
was	O
obtained	O
(	O
as	O
examined	O
by	O
TLC	O
).	O
The	O
best	O
yield	O
of	O
90	O
%	O
of	O
the	O
isolated	O
product	O
was	O
reached	O
using	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
and	O
Et3N	B-Chemical
","	O
each	O
of	O
0	O
.	O
5	O
equiv	O
.	O
(	O
entry	O
7	O
).	O
The	O
reaction	O
gave	O
relatively	O
low	O
yield	O
when	O
0	O
.	O
5	O
or	O
0	O
.	O
1	O
equiv	O
.	O
of	O
Et3N	B-Chemical
alone	O
was	O
used	O
(	O
entry	O
3	O
","	O
4	O
).	O
Furthermore	O
","	O
sodium	B-Chemical
ethoxide	I-Chemical
base	O
gave	O
a	O
trace	O
amount	O
of	O
product	O
(	O
entry	O
2	O
)	O
and	O
no	O
reaction	O
was	O
observed	O
in	O
the	O
absence	O
of	O
catalyst	O
or	O
using	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
as	O
catalyst	O
in	O
5	O
or	O
10	O
mol	O
%	O
(	O
entry	O
1	O
","	O
5	O
","	O
6	O
respectively	O
).	O
Also	O
from	O
Table	O
1	O
","	O
the	O
effect	O
of	O
loading	O
(	O
Mol	O
%)	O
on	O
the	O
%	O
yield	O
of	O
isolated	O
product	O
was	O
studied	O
","	O
and	O
it	O
is	O
clear	O
that	O
0	O
.	O
5	O
:	O
0	O
.	O
5	O
equiv	O
.	O
of	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
and	O
Et3N	B-Chemical
furnishes	O
the	O
respective	O
product	O
in	O
a	O
quantitative	O
yield	O
(	O
Table	O
1	O
","	O
entry	O
7	O
","	O
8	O
).	O
It	O
is	O
worth	O
mentioning	O
that	O
we	O
followed	O
the	O
above	O
reaction	O
to	O
completion	O
using	O
GC	O
-	O
MS	O
and	O
the	O
resulting	O
products	O
were	O
identified	O
from	O
their	O
retention	O
times	O
.	O
It	O
was	O
found	O
that	O
100	O
%	O
regioselectivity	O
was	O
attained	O
in	O
presence	O
of	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
with	O
Et3N	B-Chemical
(	O
Table	O
1	O
","	O
entry	O
7	O
and	O
8	O
)	O
but	O
in	O
the	O
presence	O
Et3N	B-Chemical
only	O
(	O
Table	O
1	O
","	O
entry	O
3	O
and	O
4	O
)	O
there	O
was	O
a	O
very	O
small	O
amount	O
(	O
traces	O
)	O
of	O
other	O
product	O
detected	O
by	O
GC	O
-	O
MS	O
","	O
which	O
completely	O
disappeared	O
in	O
recrystalization	O
of	O
the	O
crude	O
product	O
to	O
give	O
only	O
pure	O
5a	O
.	O
The	O
isolated	O
product	O
was	O
identified	O
as	O
the	O
pyrazole	B-Chemical
structure	O
5a	O
","	O
although	O
two	O
regioisomeric	O
cycloadducts	O
5a	O
and	O
6a	O
seemed	O
possible	O
(	O
Scheme	O
1	O
).	O
Unambiguous	O
structure	O
determination	O
of	O
the	O
obtained	O
products	O
is	O
therefore	O
crucial	O
to	O
rationalize	O
the	O
observed	O
regioselectivity	O
.	O
Structure	O
elucidation	O
was	O
conveniently	O
achieved	O
on	O
the	O
basis	O
of	O
the	O
1H	B-Chemical
-	O
13C	B-Chemical
connectivities	O
(	O
gHMBC	O
)	O
showed	O
by	O
methyl	O
protons	O
towards	O
the	O
carbonyl	O
group	O
and	O
C	O
-	O
4	O
of	O
pyrazole	B-Chemical
.	O
On	O
this	O
basis	O
","	O
the	O
analysis	O
of	O
gHMBC	O
spectra	O
of	O
the	O
product	O
led	O
us	O
to	O
attribute	O
the	O
signal	O
at	O
Î´	O
191	O
.	O
65	O
ppm	O
to	O
the	O
quaternary	O
carbon	B-Chemical
(	O
carbonyl	O
group	O
)	O
owing	O
to	O
its	O
correlation	O
peaks	O
with	O
the	O
methyl	O
protons	O
at	O
Î´	O
2	O
.	O
65	O
ppm	O
;	O
also	O
","	O
the	O
signal	O
at	O
Î´	O
112	O
.	O
11	O
ppm	O
to	O
the	O
C	O
-	O
4	O
of	O
the	O
pyrazole	B-Chemical
owing	O
to	O
its	O
correlation	O
peaks	O
with	O
the	O
methyl	O
protons	O
at	O
Î´	O
2	O
.	O
65	O
ppm	O
.	O
This	O
observation	O
indicated	O
that	O
the	O
methyl	O
protons	O
correlate	O
to	O
carbonyl	O
functional	O
group	O
and	O
the	O
C	O
-	O
4	O
of	O
the	O
pyrazole	B-Chemical
","	O
which	O
is	O
in	O
accordance	O
to	O
the	O
structure	O
5a	O
(	O
Figure	O
2	O
).	O
Therefore	O
","	O
1H	B-Chemical
-	O
13C	B-Chemical
HMBC	O
of	O
the	O
product	O
formed	O
provides	O
sharp	O
evidence	O
for	O
the	O
existence	O
of	O
regioisomer	O
5a	O
and	O
rules	O
out	O
the	O
other	O
alternative	O
structure	O
6a	O
.	O
Consequently	O
the	O
reaction	O
product	O
was	O
identified	O
as	O
the	O
pyrazole	B-Chemical
structure	O
5a	O
(	O
Scheme	O
1	O
).	O
Diagnostic	O
correlations	O
in	O
the	O
gHMBC	O
(	O
red	O
arrows	O
)	O
in	O
compound	O
5a	O
.	O
The	O
formation	O
of	O
pyrazole	B-Chemical
product	O
5a	O
is	O
in	O
line	O
with	O
the	O
well	O
established	O
earlier	O
studies	O
for	O
Î²	B-Chemical
-	I-Chemical
diketones	I-Chemical
containing	O
highly	O
fluorinated	O
groups	O
","	O
in	O
which	O
the	O
enolic	O
content	O
predominates	O
","	O
as	O
in	O
Figure	O
3	O
[	O
52	O
-	O
54	O
].	O
The	O
carbonyl	O
group	O
adjacent	O
to	O
the	O
perfluoroalkyl	O
chain	O
enolizes	O
preferentially	O
.	O
It	O
is	O
reasonable	O
to	O
propose	O
a	O
mechanism	O
for	O
formation	O
of	O
the	O
pyrazole	B-Chemical
5a	O
under	O
the	O
adopted	O
reaction	O
conditions	O
(	O
Scheme	O
2	O
).	O
Pyrazole	B-Chemical
5a	O
was	O
assumed	O
to	O
form	O
via	O
nitrile	B-Chemical
imine	I-Chemical
7	O
(	O
liberated	O
in	O
situ	O
from	O
3	O
by	O
the	O
action	O
of	O
triethylamine	B-Chemical
and	O
release	O
triethyl	B-Chemical
ammonium	I-Chemical
salt	I-Chemical
)	O
which	O
involved	O
a	O
more	O
or	O
less	O
concerted	O
cycloaddition	O
reaction	O
.	O
In	O
the	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
-	O
catalyzed	O
addition	O
reactions	O
it	O
reacts	O
with	O
the	O
enolized	O
form	O
of	O
Î²	B-Chemical
-	I-Chemical
diketone	I-Chemical
4aII	O
to	O
generate	O
copper	B-Chemical
(	I-Chemical
II	I-Chemical
)	I-Chemical
intermediate	O
8	O
and	O
release	O
of	O
triflic	B-Chemical
acid	I-Chemical
(	O
TfOH	B-Chemical
).	O
The	O
nitilie	O
imine	B-Chemical
7	O
reacts	O
with	O
intermediate	O
8	O
to	O
give	O
non	O
isolable	O
intermediate	O
5	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
pyrazoline	I-Chemical
derivative	O
9	O
","	O
and	O
cyclizes	O
via	O
elimination	O
of	O
molecule	O
of	O
water	B-Chemical
to	O
yield	O
the	O
desired	O
regioselective	O
pyrazole	B-Chemical
derivatives	O
5a	O
.	O
A	O
Proposed	O
Mechanism	O
for	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
/	O
TEA	B-Chemical
-	O
Catalyzed	O
regioselective	O
synthesis	O
of	O
pyrazole	B-Chemical
.	O
A	O
Proposed	O
Mechanism	O
for	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
/	O
TEA	B-Chemical
-	O
Catalyzed	O
regioselective	O
synthesis	O
of	O
pyrazole	B-Chemical
.	O
Therefore	O
","	O
copper	B-Chemical
(	I-Chemical
II	I-Chemical
)	I-Chemical
triflate	I-Chemical
has	O
an	O
important	O
role	O
in	O
which	O
it	O
activates	O
the	O
enolic	O
O	O
-	O
H	O
bond	O
of	O
Î²	B-Chemical
-	I-Chemical
diketone	I-Chemical
to	O
initiate	O
the	O
reaction	O
.	O
The	O
scope	O
and	O
generality	O
of	O
this	O
protocol	O
was	O
tested	O
using	O
another	O
derivative	O
of	O
Î²	B-Chemical
-	I-Chemical
diketone	I-Chemical
4b	O
with	O
N	B-Chemical
-	I-Chemical
phenyltrifluromethylcarbo	I-Chemical
-	I-Chemical
hydrazonoyl	I-Chemical
benzenesulfonate	I-Chemical
(	O
3	O
)	O
as	O
shown	O
in	O
the	O
Scheme	O
3	O
under	O
the	O
optimized	O
reaction	O
conditions	O
","	O
and	O
the	O
corresponding	O
pyrazole	B-Chemical
derivatives	O
5b	O
were	O
obtained	O
in	O
excellent	O
yield	O
.	O
Regioselective	O
synthesis	O
of	O
pyrazole	B-Chemical
derivatives	O
5a	O
","	O
b	O
using	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
/	O
Et3N	B-Chemical
catalyst	O
under	O
both	O
ultrasonic	O
irradiation	O
and	O
conventional	O
method	O
.	O
Regioselective	O
synthesis	O
of	O
pyrazole	B-Chemical
derivatives	O
5a	O
","	O
b	O
using	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
/	O
Et3N	B-Chemical
catalyst	O
under	O
both	O
ultrasonic	O
irradiation	O
and	O
conventional	O
method	O
.	O
Also	O
","	O
to	O
find	O
the	O
specific	O
effect	O
of	O
ultrasound	O
on	O
these	O
reactions	O
","	O
all	O
previously	O
mentioned	O
reactions	O
were	O
carried	O
out	O
under	O
the	O
same	O
conditions	O
in	O
the	O
absence	O
of	O
ultrasound	O
irradiation	O
(	O
Table	O
2	O
).	O
It	O
was	O
observed	O
that	O
the	O
reaction	O
time	O
increased	O
considerably	O
and	O
the	O
yield	O
of	O
the	O
products	O
decreased	O
.	O
Thus	O
","	O
ultrasound	O
was	O
found	O
to	O
have	O
a	O
beneficial	O
effect	O
on	O
the	O
synthesis	O
of	O
pyrazole	B-Chemical
derivatives	O
","	O
in	O
which	O
the	O
time	O
of	O
the	O
above	O
reactions	O
decreased	O
from	O
8	O
to	O
10	O
h	O
in	O
the	O
conventional	O
procedure	O
to	O
less	O
than	O
1	O
h	O
.	O
Also	O
","	O
there	O
was	O
an	O
improvement	O
in	O
the	O
yields	O
of	O
the	O
reactions	O
under	O
ultrasonic	O
irradiations	O
.	O
The	O
yields	O
of	O
pyrazole	B-Chemical
derivatives	O
5a	O
","	O
b	O
using	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
/	O
Et3N	B-Chemical
catalyst	O
under	O
conventional	O
and	O
ultrasonic	O
irradiations	O
conditions	O
We	O
extended	O
our	O
study	O
to	O
find	O
out	O
the	O
reactivity	O
of	O
Î²	B-Chemical
-	I-Chemical
diketone	I-Chemical
4a	O
","	O
b	O
towards	O
the	O
Î±	B-Chemical
-	I-Chemical
ketohydrazonoyl	I-Chemical
halides	I-Chemical
10a	O
-	O
f	O
under	O
ultrasonic	O
irradiation	O
and	O
/	O
or	O
conventional	O
method	O
to	O
give	O
the	O
corresponding	O
pyrazole	B-Chemical
derivatives	O
11a	O
-	O
l	O
in	O
85	O
â€“	O
91	O
%	O
yields	O
(	O
Scheme	O
4	O
","	O
Table	O
3	O
).	O
Regioselective	O
synthesis	O
of	O
pyrazole	B-Chemical
derivatives	O
11a	O
-	O
l	O
using	O
u	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
/	O
Et3N	B-Chemical
catalyst	O
under	O
both	O
ultrasonic	O
irradiation	O
and	O
conventional	O
method	O
.	O
Regioselective	O
synthesis	O
of	O
pyrazole	B-Chemical
derivatives	O
11a	O
-	O
l	O
using	O
u	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
/	O
Et3N	B-Chemical
catalyst	O
under	O
both	O
ultrasonic	O
irradiation	O
and	O
conventional	O
method	O
.	O
Synthesis	O
of	O
pyrazole	B-Chemical
11a	O
â€“	O
l	O
under	O
both	O
ultrasonic	O
irradiation	O
and	O
conventional	O
method	O
The	O
structure	O
of	O
pyrazole	B-Chemical
derivatives	O
11a	O
â€“	O
l	O
was	O
assigned	O
on	O
the	O
basis	O
of	O
their	O
elemental	O
analyses	O
and	O
spectral	O
data	O
.	O
For	O
example	O
","	O
the	O
1H	B-Chemical
NMR	O
spectrum	O
of	O
compound	O
11a	O
revealed	O
two	O
singlet	O
signals	O
at	O
Î´	O
2	O
.	O
29	O
and	O
2	O
.	O
74	O
due	O
to	O
the	O
two	O
methyl	O
groups	O
in	O
addition	O
to	O
aromatic	O
multiplet	O
at	O
Î´	O
7	O
.	O
31	O
â€“	O
7	O
.	O
71	O
.	O
The	O
mass	O
spectrum	O
of	O
the	O
same	O
compound	O
revealed	O
a	O
peak	O
corresponding	O
to	O
its	O
molecular	O
ion	O
at	O
m	O
/	O
z	O
296	O
.	O
The	O
mechanism	O
of	O
the	O
formation	O
of	O
compounds	O
11a	O
-	O
l	O
is	O
in	O
line	O
with	O
those	O
depicted	O
in	O
Scheme	O
2	O
.	O
From	O
the	O
data	O
cited	O
in	O
Table	O
3	O
","	O
it	O
was	O
observed	O
that	O
the	O
reaction	O
time	O
increased	O
considerably	O
and	O
the	O
yield	O
of	O
the	O
products	O
decreased	O
under	O
conventional	O
method	O
.	O
Thus	O
","	O
ultrasound	O
was	O
found	O
to	O
have	O
beneficial	O
effect	O
on	O
the	O
synthesis	O
of	O
pyrazole	B-Chemical
derivatives	O
in	O
which	O
decrease	O
time	O
of	O
above	O
reactions	O
from	O
7	O
to	O
11	O
h	O
in	O
conventional	O
procedure	O
to	O
45	O
min	O
.	O
to	O
1	O
h	O
.	O
Also	O
","	O
there	O
was	O
a	O
noticeable	O
improvement	O
in	O
the	O
yields	O
of	O
the	O
reactions	O
under	O
ultrasonic	O
irradiations	O
.	O
The	O
improvement	O
induced	O
by	O
ultrasound	O
in	O
the	O
above	O
mentioned	O
reactions	O
can	O
be	O
attributed	O
to	O
the	O
well	O
established	O
theory	O
for	O
the	O
cavitation	O
","	O
The	O
collapse	O
of	O
bubbles	O
caused	O
by	O
cavitation	O
produces	O
intense	O
local	O
heating	O
and	O
high	O
pressures	O
[	O
55	O
","	O
56	O
"],"	O
so	O
reaction	O
time	O
decreases	O
clearly	O
and	O
high	O
%	O
yield	O
was	O
obtained	O
.	O
Conclusion	O
An	O
ultrasonic	O
assisted	O
efficient	O
protocol	O
for	O
the	O
regioselective	O
synthesis	O
a	O
series	O
of	O
novel	O
pyrazoles	B-Chemical
containing	O
the	O
trifluromthyl	O
moiety	O
utilizing	O
an	O
efficient	O
catalytic	O
system	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
/	O
Et3N	B-Chemical
was	O
reported	O
.	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
/	O
Et3N	B-Chemical
catalyst	O
showed	O
a	O
great	O
advantage	O
over	O
all	O
the	O
investigated	O
catalysts	O
and	O
ultrasonic	O
irradiation	O
method	O
offered	O
high	O
yields	O
of	O
pyrazoles	B-Chemical
in	O
short	O
reaction	O
times	O
compared	O
with	O
classical	O
conditions	O
.	O
gHMBC	O
spectra	O
of	O
the	O
product	O
were	O
used	O
to	O
rationalize	O
the	O
observed	O
regioselectivity	O
.	O
Experimental	O
General	O
All	O
organic	O
solvents	O
were	O
purchased	O
from	O
commercial	O
sources	O
and	O
used	O
as	O
received	O
unless	O
otherwise	O
stated	O
.	O
All	O
chemicals	O
were	O
purchased	O
from	O
Merck	O
","	O
Aldrich	O
or	O
Acros	O
and	O
used	O
without	O
further	O
purification	O
","	O
thin	O
-	O
layer	O
chromatography	O
(	O
TLC	O
)	O
was	O
performed	O
on	O
precoated	O
Merck	O
60	O
GF254	O
silica	B-Chemical
gel	I-Chemical
plates	O
with	O
a	O
fluorescent	O
indicator	O
","	O
and	O
detection	O
by	O
means	O
of	O
UV	O
light	O
at	O
254	O
and	O
360	O
nm	O
.	O
All	O
melting	O
points	O
were	O
measured	O
on	O
a	O
Stuart	O
melting	O
point	O
apparatus	O
and	O
are	O
uncorrected	O
.	O
IR	O
spectra	O
were	O
recorded	O
in	O
IR	O
spectra	O
were	O
recorded	O
in	O
the	O
Smart	O
iTR	O
which	O
is	O
an	O
ultra	O
-	O
high	O
-	O
performance	O
","	O
versatile	O
Attenuated	O
Total	O
Reflectance	O
(	O
ATR	O
)	O
sampling	O
accessory	O
on	O
The	O
Nicolet	O
iS10	O
FT	O
-	O
IR	O
spectrometer	O
.	O
The	O
NMR	O
spectra	O
were	O
recorded	O
on	O
a	O
Varian	O
Mercury	O
VX	O
-	O
300	O
NMR	O
spectrometer	O
.	O
1H	B-Chemical
spectra	O
were	O
run	O
at	O
300	O
MHz	O
and	O
13C	B-Chemical
spectra	O
were	O
run	O
at	O
75	O
.	O
46	O
MHz	O
in	O
dimethyl	B-Chemical
sulphoxide	I-Chemical
(	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
).	O
Chemical	O
shifts	O
were	O
related	O
to	O
that	O
of	O
the	O
solvent	O
.	O
Assignments	O
are	O
made	O
using	O
1H	B-Chemical
","	O
13C	B-Chemical
","	O
gHMBC	O
","	O
2D	O
experiments	O
was	O
done	O
using	O
standard	O
Varian	O
methods	O
.	O
Mass	O
spectra	O
were	O
recorded	O
on	O
the	O
Thermo	O
ISQ	O
Single	O
Quadrupole	O
GC	O
-	O
MS	O
.	O
The	O
resulting	O
products	O
were	O
identified	O
from	O
their	O
retention	O
times	O
by	O
GC	O
â€“	O
MS	O
analysis	O
.	O
Elemental	O
analyses	O
were	O
carried	O
out	O
on	O
EuroVector	O
instrument	O
C	O
","	O
H	O
","	O
N	O
","	O
S	O
analyzer	O
EA3000	O
Series	O
.	O
Sonication	O
was	O
performed	O
by	O
Techno	O
-	O
gaz	O
sonicator	O
(	O
with	O
a	O
frequency	O
of	O
37	O
kHz	O
and	O
ultrasonic	O
peak	O
max	O
.	O
320	O
W	O
).	O
N	B-Chemical
-	I-Chemical
phenyltrifluromethylcarbohydrazonoyl	I-Chemical
benzenesulfonate	I-Chemical
(	O
3	O
)[	O
15	O
"],"	O
Î±	B-Chemical
-	I-Chemical
ketohydrazonoyl	I-Chemical
halides	I-Chemical
10a	O
-	O
f	O
[	O
57	O
]	O
were	O
prepared	O
according	O
to	O
the	O
reported	O
literature	O
.	O
General	O
procedure	O
and	O
characterization	O
data	O
Typical	O
procedure	O
for	O
synthesis	O
of	O
pyrazole	B-Chemical
derivatives	O
5a	O
","	O
b	O
and	O
11a	O
-	O
j	O
.	O
Sonicated	O
reactions	O
In	O
an	O
Erlenmeyer	O
flask	O
","	O
a	O
mixture	O
of	O
Î²	B-Chemical
-	I-Chemical
diketone	I-Chemical
(	O
4a	O
","	O
b	O
)	O
(	O
1	O
mmol	O
)	O
and	O
appropriate	O
hydrazonoyl	B-Chemical
benzenesulfonate	I-Chemical
(	O
3	O
)	O
and	O
/	O
or	O
hydrazonyl	B-Chemical
halides	I-Chemical
(	O
10a	O
-	O
e	O
)	O
(	O
1	O
mmol	O
)	O
(	O
3	O
)	O
was	O
taken	O
in	O
absolute	O
ethanol	B-Chemical
(	O
30	O
ml	O
)	O
in	O
the	O
presence	O
of	O
Cu	B-Chemical
(	I-Chemical
OTf	I-Chemical
)	I-Chemical
2	I-Chemical
/	O
Et3N	B-Chemical
(	O
5	O
:	O
5	O
mol	O
%)	O
as	O
catalyst	O
then	O
subjected	O
to	O
ultrasonic	O
irradiations	O
for	O
appropriate	O
time	O
(	O
cf	O
.	O
Tables	O
1	O
","	O
2	O
","	O
3	O
).	O
All	O
The	O
reactions	O
were	O
kept	O
at	O
70	O
â€“	O
80	O
Â°	O
C	O
(	O
the	O
temperature	O
inside	O
reaction	O
vessel	O
was	O
70	O
â€“	O
76	O
Â°	O
C	O
and	O
the	O
reaction	O
flask	O
was	O
put	O
in	O
the	O
mid	O
of	O
sonicator	O
bath	O
to	O
to	O
achieve	O
effective	O
cavitations	O
).	O
The	O
sonochemical	O
reactions	O
were	O
continued	O
until	O
the	O
starting	O
materials	O
were	O
no	O
longer	O
detectable	O
by	O
TLC	O
.	O
After	O
the	O
completion	O
of	O
the	O
reaction	O
","	O
EtOAc	B-Chemical
(	O
30	O
mL	O
)	O
was	O
added	O
to	O
dilute	O
the	O
reaction	O
solution	O
.	O
Then	O
","	O
the	O
mixture	O
was	O
washed	O
with	O
water	B-Chemical
.	O
The	O
combined	O
organic	O
phases	O
were	O
dried	O
and	O
concentrated	O
in	O
vacuo	O
","	O
and	O
the	O
remaining	O
residue	O
was	O
purified	O
by	O
recrystalization	O
from	O
ethanol	B-Chemical
to	O
afford	O
pyrazole	B-Chemical
derivatives	O
5a	O
","	O
b	O
and	O
11a	O
-	O
j	O
.	O
The	O
above	O
reaction	O
was	O
studied	O
also	O
by	O
using	O
various	O
condition	O
and	O
catalysts	O
.	O
(	O
i	O
)	O
in	O
absence	O
of	O
catalyst	O
:	O
this	O
process	O
was	O
performed	O
as	O
described	O
above	O
and	O
no	O
product	O
formed	O
(	O
ii	O
)	O
in	O
presence	O
of	O
equivalent	O
amount	O
from	O
sodium	B-Chemical
methoxide	I-Chemical
","	O
this	O
process	O
was	O
performed	O
as	O
described	O
above	O
and	O
only	O
a	O
trace	O
of	O
product	O
obtained	O
identified	O
as	O
5a	O
(	O
cf	O
.	O
Table	O
1	O
)	O
(	O
iii	O
)	O
in	O
presence	O
of	O
different	O
ratio	O
of	O
triethylamine	B-Chemical
(	O
0	O
.	O
5	O
mmol	O
)	O
or	O
(	O
0	O
.	O
1	O
mmol	O
)	O
also	O
","	O
these	O
processes	O
were	O
performed	O
as	O
described	O
above	O
and	O
the	O
progress	O
of	O
the	O
reaction	O
was	O
monitored	O
by	O
TLC	O
","	O
the	O
product	O
formed	O
was	O
identified	O
as	O
5a	O
in	O
each	O
case	O
(	O
cf	O
.	O
Table	O
1	O
)	O
in	O
different	O
percent	O
yield	O
","	O
(	O
iv	O
)	O
in	O
presence	O
of	O
different	O
ratio	O
of	O
copper	B-Chemical
(	I-Chemical
II	I-Chemical
)	I-Chemical
triflate	I-Chemical
(	O
0	O
.	O
5	O
mmol	O
)	O
or	O
(	O
0	O
.	O
1	O
mmol	O
)	O
also	O
","	O
these	O
processes	O
were	O
performed	O
as	O
described	O
above	O
and	O
no	O
product	O
formed	O
.	O
Silent	O
reactions	O
These	O
processes	O
were	O
performed	O
on	O
the	O
same	O
scale	O
described	O
above	O
for	O
sonicated	O
reaction	O
.	O
Here	O
the	O
reactant	O
and	O
catalyst	O
were	O
put	O
in	O
ethanol	B-Chemical
under	O
reflux	O
for	O
suitable	O
time	O
(	O
cf	O
.	O
Tables	O
2	O
and	O
3	O
)	O
until	O
the	O
starting	O
materials	O
were	O
no	O
longer	O
detectable	O
by	O
TLC	O
.	O
The	O
products	O
were	O
obtained	O
and	O
purified	O
as	O
described	O
above	O
in	O
sonicated	O
reaction	O
.	O
Physical	O
and	O
spectral	O
data	O
of	O
the	O
compounds	O
5a	O
","	O
b	O
and	O
11a	O
-	O
j	O
are	O
listed	O
below	O
4	O
.	O
2	O
.	O
2	O
.	O
1	O
.	O
4	B-Chemical
-	I-Chemical
Acetyl	I-Chemical
-	I-Chemical
3	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
di	I-Chemical
(	I-Chemical
trifluoromethyl	I-Chemical
)-	I-Chemical
1	I-Chemical
-	I-Chemical
phenylpyrazole	I-Chemical
(	O
5a	O
)	O
[	O
58	O
]	O
M	O
.	O
p	O
.	O
=	O
211	O
â€“	O
213	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1712	O
(	O
C	O
=	O
O	O
"),"	O
1611	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
:	O
2	O
.	O
65	O
(	O
s	O
","	O
3H	O
","	O
CH3	O
"),"	O
6	O
.	O
52	O
-	O
7	O
.	O
23	O
(	O
m	O
","	O
5H	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
:	O
31	O
.	O
42	O
","	O
112	O
.	O
11	O
","	O
118	O
.	O
0	O
","	O
119	O
.	O
58	O
","	O
123	O
.	O
89	O
","	O
126	O
.	O
24	O
","	O
129	O
.	O
30	O
","	O
136	O
.	O
87	O
","	O
139	O
.	O
0	O
","	O
154	O
.	O
62	O
","	O
191	O
.	O
65	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
322	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
48	O
.	O
46	O
;	O
H	B-Chemical
","	O
2	O
.	O
50	O
;	O
N	B-Chemical
","	O
8	O
.	O
69	O
.	O
C13H8F6N2O	B-Chemical
Found	O
:	O
C	B-Chemical
","	O
48	O
.	O
72	O
;	O
H	B-Chemical
","	O
2	O
.	O
38	O
;	O
N	B-Chemical
","	O
8	O
.	O
55	O
).	O
4	B-Chemical
-	I-Chemical
Benzoyl	I-Chemical
-	I-Chemical
3	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
di	I-Chemical
(	I-Chemical
trifluoromethyl	I-Chemical
)-	I-Chemical
1	I-Chemical
-	I-Chemical
phenylpyrazole	I-Chemical
(	O
5b	O
)	O
M	O
.	O
p	O
.	O
=	O
227	O
â€“	O
228	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1708	O
(	O
C	O
=	O
O	O
"),"	O
1601	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
:	O
7	O
.	O
22	O
-	O
7	O
.	O
69	O
(	O
m	O
","	O
10H	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
:	O
116	O
.	O
5	O
","	O
119	O
.	O
18	O
","	O
121	O
.	O
94	O
","	O
125	O
.	O
54	O
","	O
126	O
.	O
33	O
","	O
128	O
.	O
52	O
","	O
128	O
.	O
53	O
","	O
129	O
.	O
14	O
","	O
130	O
.	O
25	O
","	O
136	O
.	O
89	O
","	O
139	O
.	O
34	O
","	O
139	O
.	O
74	O
","	O
152	O
.	O
87	O
","	O
193	O
.	O
16	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
384	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
56	O
.	O
26	O
;	O
H	B-Chemical
","	O
2	O
.	O
62	O
;	O
N	B-Chemical
","	O
7	O
.	O
29	O
.	O
C18H10F6N2O	B-Chemical
Found	O
:	O
C	B-Chemical
","	O
56	O
.	O
50	O
;	O
H	B-Chemical
","	O
2	O
.	O
52	O
;	O
N	B-Chemical
","	O
7	O
.	O
15	O
).	O
3	B-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
Diacetyl	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
phenyl	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
trifluoromethylpyrazole	I-Chemical
(	O
11a	O
)	O
M	O
.	O
p	O
.	O
=	O
192	O
â€“	O
194	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1712	O
","	O
1699	O
(	O
2	O
C	O
=	O
O	O
"),"	O
1594	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
2	O
.	O
29	O
(	O
s	O
","	O
3H	O
","	O
CH3	O
"),"	O
2	O
.	O
74	O
(	O
s	O
","	O
3H	O
","	O
CH3	O
"),"	O
7	O
.	O
31	O
-	O
7	O
.	O
71	O
(	O
m	O
","	O
5H	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
29	O
.	O
15	O
","	O
31	O
.	O
54	O
","	O
115	O
.	O
15	O
","	O
122	O
.	O
1	O
","	O
125	O
.	O
53	O
","	O
125	O
.	O
54	O
","	O
127	O
.	O
41	O
","	O
129	O
.	O
14	O
","	O
131	O
.	O
6	O
","	O
139	O
.	O
98	O
","	O
150	O
.	O
98	O
","	O
196	O
.	O
24	O
","	O
199	O
.	O
9	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
296	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
56	O
.	O
76	O
;	O
H	B-Chemical
","	O
3	O
.	O
74	O
;	O
N	B-Chemical
","	O
9	O
.	O
46	O
.	O
C14H11F3N2O2	B-Chemical
Found	O
:	O
C	B-Chemical
","	O
56	O
.	O
50	O
;	O
H	B-Chemical
","	O
2	O
.	O
52	O
;	O
N	B-Chemical
","	O
7	O
.	O
15	O
).	O
3	B-Chemical
-	I-Chemical
Acetyl	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
benzoyl	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
phenyl	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
trifluoromethylpyrazole	I-Chemical
(	O
11b	O
)	O
M	O
.	O
p	O
.	O
=	O
213	O
â€“	O
214	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1710	O
","	O
1701	O
(	O
2	O
C	O
=	O
O	O
"),"	O
1599	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
2	O
.	O
24	O
(	O
s	O
","	O
3H	O
","	O
CH3	O
"),"	O
7	O
.	O
16	O
-	O
7	O
.	O
67	O
(	O
m	O
","	O
10H	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
28	O
.	O
98	O
","	O
115	O
.	O
24	O
","	O
120	O
.	O
7	O
","	O
124	O
.	O
13	O
","	O
126	O
.	O
22	O
","	O
128	O
.	O
11	O
","	O
128	O
.	O
12	O
","	O
129	O
.	O
85	O
","	O
133	O
.	O
54	O
","	O
139	O
.	O
47	O
","	O
152	O
.	O
0	O
","	O
194	O
.	O
1	O
","	O
198	O
.	O
19	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
358	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
63	O
.	O
69	O
;	O
H	B-Chemical
","	O
3	O
.	O
66	O
;	O
N	B-Chemical
","	O
7	O
.	O
82	O
.	O
C19H13F3N2O2	B-Chemical
Found	O
:	O
C	B-Chemical
","	O
63	O
.	O
96	O
;	O
H	B-Chemical
","	O
3	O
.	O
14	O
;	O
N	B-Chemical
","	O
7	O
.	O
67	O
).	O
3	B-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
Diacetyl	I-Chemical
-	I-Chemical
1	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
flurophenyl	I-Chemical
)-	I-Chemical
5	I-Chemical
-	I-Chemical
trifluoromethylpyrazole	I-Chemical
(	O
11c	O
)	O
M	O
.	O
p	O
.	O
=	O
175	O
â€“	O
177	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1711	O
","	O
1697	O
(	O
2	O
C	O
=	O
O	O
"),"	O
1601	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
2	O
.	O
31	O
(	O
s	O
","	O
3H	O
","	O
CH3	O
"),"	O
2	O
.	O
59	O
(	O
s	O
","	O
3H	O
","	O
CH3	O
"),"	O
7	O
.	O
24	O
(	O
d	O
","	O
2H	O
","	O
J	O
=	O
8	O
.	O
4	O
Hz	O
","	O
ArH	O
â€™	O
s	O
"),"	O
7	O
.	O
55	O
(	O
d	O
","	O
2H	O
","	O
J	O
=	O
8	O
.	O
4	O
Hz	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
26	O
.	O
94	O
","	O
31	O
.	O
20	O
","	O
113	O
.	O
54	O
","	O
115	O
.	O
23	O
","	O
119	O
.	O
8	O
","	O
123	O
.	O
94	O
","	O
132	O
.	O
15	O
","	O
137	O
.	O
65	O
","	O
152	O
.	O
89	O
","	O
162	O
.	O
41	O
","	O
195	O
.	O
0	O
","	O
198	O
.	O
23	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
314	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
53	O
.	O
51	O
;	O
H	B-Chemical
","	O
3	O
.	O
21	O
;	O
N	B-Chemical
","	O
8	O
.	O
91	O
.	O
C14H10F4N2O2	B-Chemical
Found	O
:	O
C	B-Chemical
","	O
53	O
.	O
78	O
;	O
H	B-Chemical
","	O
3	O
.	O
10	O
;	O
N	B-Chemical
","	O
8	O
.	O
75	O
).	O
3	B-Chemical
-	I-Chemical
Acetyl	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
benzoyl	I-Chemical
-	I-Chemical
1	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
flurophenyl	I-Chemical
)-	I-Chemical
5	I-Chemical
-	I-Chemical
trifluoromethylpyrazole	I-Chemical
(	O
11d	O
)	O
M	O
.	O
p	O
.	O
=	O
201	O
â€“	O
203	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1719	O
","	O
1701	O
(	O
2	O
C	O
=	O
O	O
"),"	O
1603	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
2	O
.	O
28	O
(	O
s	O
","	O
3H	O
","	O
CH3	O
"),"	O
7	O
.	O
21	O
-	O
7	O
.	O
84	O
(	O
m	O
","	O
9H	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
27	O
.	O
98	O
","	O
112	O
.	O
3	O
","	O
115	O
.	O
87	O
","	O
119	O
.	O
26	O
","	O
125	O
.	O
44	O
","	O
128	O
.	O
31	O
","	O
132	O
.	O
5	O
","	O
135	O
.	O
16	O
","	O
136	O
.	O
49	O
","	O
149	O
.	O
97	O
","	O
162	O
.	O
0	O
","	O
191	O
.	O
24	O
","	O
196	O
.	O
20	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
376	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
60	O
.	O
64	O
;	O
H	B-Chemical
","	O
3	O
.	O
21	O
;	O
N	B-Chemical
","	O
7	O
.	O
44	O
.	O
C19H12F4N2O2	B-Chemical
Found	O
:	O
C	B-Chemical
","	O
60	O
.	O
95	O
;	O
H	B-Chemical
","	O
3	O
.	O
7	O
;	O
N	B-Chemical
","	O
7	O
.	O
27	O
).	O
3	B-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
Diacetyl	I-Chemical
-	I-Chemical
1	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
trifluoromethylphenyl	I-Chemical
)-	I-Chemical
5	I-Chemical
-	I-Chemical
trifluoromethylpyrazole	I-Chemical
(	O
11e	O
)	O
M	O
.	O
p	O
.	O
=	O
194	O
â€“	O
196	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1707	O
","	O
1697	O
(	O
2	O
C	O
=	O
O	O
"),"	O
1600	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
2	O
.	O
26	O
(	O
s	O
","	O
3H	O
","	O
CH3	O
"),"	O
2	O
.	O
61	O
(	O
s	O
","	O
3H	O
","	O
CH3	O
"),"	O
7	O
.	O
44	O
(	O
d	O
","	O
2H	O
","	O
J	O
=	O
8	O
.	O
1	O
Hz	O
","	O
ArH	O
â€™	O
s	O
"),"	O
7	O
.	O
67	O
(	O
d	O
","	O
2H	O
","	O
J	O
=	O
8	O
.	O
1	O
Hz	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
29	O
.	O
91	O
","	O
32	O
.	O
42	O
","	O
117	O
.	O
21	O
","	O
123	O
.	O
94	O
","	O
124	O
.	O
36	O
","	O
124	O
.	O
85	O
","	O
126	O
.	O
3	O
","	O
129	O
.	O
54	O
","	O
138	O
.	O
3	O
","	O
143	O
.	O
11	O
","	O
151	O
.	O
98	O
","	O
192	O
.	O
10	O
","	O
196	O
.	O
85	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
364	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
49	O
.	O
46	O
;	O
H	B-Chemical
","	O
2	O
.	O
77	O
;	O
N	B-Chemical
","	O
7	O
.	O
69	O
.	O
C15H10F6N2O2	B-Chemical
Found	O
:	O
C	B-Chemical
","	O
49	O
.	O
75	O
;	O
H	B-Chemical
","	O
2	O
.	O
63	O
;	O
N	B-Chemical
","	O
7	O
.	O
54	O
).	O
3	B-Chemical
-	I-Chemical
Acetyl	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
benzoyl	I-Chemical
-	I-Chemical
1	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
trifluoromethylphenyl	I-Chemical
)-	I-Chemical
5	I-Chemical
-	I-Chemical
trifluoromethyl	I-Chemical
-	I-Chemical
pyrazole	I-Chemical
(	O
11f	O
)	O
M	O
.	O
p	O
.	O
=	O
210	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1706	O
","	O
1699	O
(	O
2	O
C	O
=	O
O	O
"),"	O
1598	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
2	O
.	O
26	O
(	O
s	O
","	O
3H	O
","	O
CH3	O
"),"	O
7	O
.	O
42	O
-	O
7	O
.	O
85	O
(	O
m	O
","	O
9H	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
27	O
.	O
58	O
","	O
113	O
.	O
13	O
","	O
119	O
.	O
26	O
","	O
121	O
.	O
35	O
","	O
124	O
.	O
8	O
","	O
125	O
.	O
65	O
","	O
127	O
.	O
11	O
","	O
128	O
.	O
45	O
","	O
129	O
.	O
69	O
","	O
132	O
.	O
45	O
","	O
134	O
.	O
0	O
","	O
135	O
.	O
4	O
","	O
143	O
.	O
1	O
","	O
149	O
.	O
19	O
","	O
190	O
.	O
98	O
","	O
196	O
.	O
1	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
426	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
56	O
.	O
35	O
;	O
H	B-Chemical
","	O
2	O
.	O
84	O
;	O
N	B-Chemical
","	O
6	O
.	O
57	O
.	O
C20H12F6N2O2	B-Chemical
Found	O
:	O
C	B-Chemical
","	O
56	O
.	O
68	O
;	O
H	B-Chemical
","	O
2	O
.	O
71	O
;	O
N	B-Chemical
","	O
6	O
.	O
37	O
).	O
Ethyl	B-Chemical
4	I-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
1	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
fluorophenyl	I-Chemical
)-	I-Chemical
5	I-Chemical
-(	I-Chemical
trifluoromethyl	I-Chemical
)-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrazole	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	O
11	O
g	O
)	O
M	O
.	O
p	O
.	O
=	O
180	O
â€“	O
182	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1723	O
","	O
1699	O
(	O
2	O
C	O
=	O
O	O
"),"	O
1598	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
1	O
.	O
29	O
(	O
t	O
","	O
3H	O
","	O
J	O
=	O
7	O
.	O
2	O
Hz	O
","	O
CH3	O
"),"	O
2	O
.	O
23	O
(	O
s	O
","	O
3H	O
","	O
CH3	O
"),"	O
4	O
.	O
1	O
(	O
q	O
","	O
2H	O
","	O
J	O
=	O
7	O
.	O
2	O
Hz	O
","	O
CH2	O
"),"	O
7	O
.	O
28	O
(	O
d	O
","	O
2H	O
","	O
J	O
=	O
8	O
.	O
4	O
Hz	O
","	O
ArH	O
â€™	O
s	O
"),"	O
7	O
.	O
65	O
(	O
d	O
","	O
2H	O
","	O
J	O
=	O
8	O
.	O
4	O
Hz	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
13	O
.	O
11	O
","	O
29	O
.	O
18	O
","	O
58	O
.	O
11	O
","	O
113	O
.	O
26	O
","	O
119	O
.	O
1	O
","	O
125	O
.	O
36	O
","	O
132	O
.	O
58	O
","	O
136	O
.	O
0	O
","	O
148	O
.	O
39	O
","	O
160	O
.	O
7	O
","	O
162	O
.	O
37	O
","	O
192	O
.	O
10	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
344	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
52	O
.	O
33	O
;	O
H	B-Chemical
","	O
3	O
.	O
51	O
;	O
N	B-Chemical
","	O
8	O
.	O
14	O
.	O
C15H12F4N2O3	B-Chemical
Found	O
:	O
C	B-Chemical
","	O
52	O
.	O
61	O
;	O
H	B-Chemical
","	O
3	O
.	O
38	O
;	O
N	B-Chemical
","	O
7	O
.	O
99	O
).	O
Ethyl	B-Chemical
4	I-Chemical
-	I-Chemical
benzoyl	I-Chemical
-	I-Chemical
1	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
fluorophenyl	I-Chemical
)-	I-Chemical
5	I-Chemical
-(	I-Chemical
trifluoromethyl	I-Chemical
)-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrazole	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	O
11h	O
)	O
M	O
.	O
p	O
.	O
=	O
212	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1725	O
","	O
1701	O
(	O
2	O
C	O
=	O
O	O
"),"	O
1598	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
0	O
.	O
91	O
(	O
t	O
","	O
3H	O
","	O
J	O
=	O
7	O
.	O
6	O
Hz	O
CH3	O
"),"	O
4	O
.	O
23	O
(	O
q	O
","	O
2H	O
","	O
J	O
=	O
7	O
.	O
6	O
Hz	O
","	O
CH2	O
"),"	O
7	O
.	O
21	O
-	O
7	O
.	O
78	O
(	O
m	O
","	O
9H	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
13	O
.	O
26	O
","	O
58	O
.	O
25	O
","	O
112	O
.	O
31	O
","	O
115	O
.	O
25	O
","	O
118	O
.	O
1	O
","	O
119	O
.	O
27	O
","	O
125	O
.	O
87	O
","	O
128	O
.	O
97	O
","	O
131	O
.	O
98	O
","	O
132	O
.	O
68	O
","	O
134	O
.	O
85	O
","	O
137	O
.	O
50	O
","	O
148	O
.	O
5	O
","	O
159	O
.	O
98	O
","	O
163	O
.	O
0	O
","	O
194	O
.	O
28	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
406	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
59	O
.	O
12	O
;	O
H	B-Chemical
","	O
3	O
.	O
47	O
;	O
N	B-Chemical
","	O
6	O
.	O
89	O
.	O
C20H14F4N2O3Found	B-Chemical
:	O
C	B-Chemical
","	O
59	O
.	O
39	O
;	O
H	B-Chemical
","	O
3	O
.	O
34	O
;	O
N	B-Chemical
","	O
6	O
.	O
75	O
).	O
Ethyl	B-Chemical
4	I-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
1	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
trifluoromethylphenyl	I-Chemical
)-	I-Chemical
5	I-Chemical
-(	I-Chemical
trifluoromethyl	I-Chemical
)-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrazole	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	O
11i	O
)	O
M	O
.	O
p	O
.	O
=	O
192	O
â€“	O
194	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1721	O
","	O
1699	O
(	O
2	O
C	O
=	O
O	O
"),"	O
1599	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
0	O
.	O
89	O
(	O
t	O
","	O
3H	O
","	O
J	O
=	O
7	O
.	O
2	O
Hz	O
","	O
CH3	O
"),"	O
2	O
.	O
29	O
(	O
s	O
","	O
3H	O
","	O
CH3	O
"),"	O
4	O
.	O
0	O
(	O
q	O
","	O
2H	O
","	O
J	O
=	O
7	O
.	O
2	O
Hz	O
","	O
CH2	O
"),"	O
7	O
.	O
67	O
(	O
d	O
","	O
2H	O
","	O
J	O
=	O
7	O
.	O
8	O
Hz	O
","	O
ArH	O
â€™	O
s	O
"),"	O
7	O
.	O
89	O
(	O
d	O
","	O
2H	O
","	O
J	O
=	O
7	O
.	O
8	O
Hz	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
13	O
.	O
56	O
","	O
28	O
.	O
88	O
","	O
59	O
.	O
58	O
","	O
116	O
.	O
48	O
","	O
121	O
.	O
33	O
","	O
123	O
.	O
58	O
","	O
125	O
.	O
47	O
","	O
126	O
.	O
5	O
","	O
127	O
.	O
89	O
","	O
132	O
.	O
11	O
","	O
141	O
.	O
5	O
","	O
146	O
.	O
36	O
","	O
159	O
.	O
87	O
","	O
192	O
.	O
1	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
394	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
48	O
.	O
74	O
;	O
H	B-Chemical
","	O
3	O
.	O
7	O
;	O
N	B-Chemical
","	O
7	O
.	O
11	O
.	O
C16H12F6N2O3	B-Chemical
Found	O
:	O
C	B-Chemical
","	O
49	O
.	O
5	O
;	O
H	B-Chemical
","	O
2	O
.	O
94	O
;	O
N	B-Chemical
","	O
6	O
.	O
93	O
).	O
Ethyl	B-Chemical
4	I-Chemical
-	I-Chemical
benzoyl	I-Chemical
-	I-Chemical
1	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
trifluoromethylphenyl	I-Chemical
)-	I-Chemical
5	I-Chemical
-(	I-Chemical
trifluoromethyl	I-Chemical
)-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrazole	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	O
11j	O
)	O
M	O
.	O
p	O
.	O
=	O
207	O
â€“	O
208	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1722	O
","	O
1701	O
(	O
2	O
C	O
=	O
O	O
"),"	O
1602	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
1	O
.	O
16	O
(	O
t	O
","	O
3H	O
","	O
J	O
=	O
7	O
.	O
2	O
Hz	O
CH3	O
"),"	O
3	O
.	O
91	O
(	O
q	O
","	O
2H	O
","	O
J	O
=	O
7	O
.	O
2	O
Hz	O
","	O
CH2	O
"),"	O
7	O
.	O
51	O
-	O
7	O
.	O
88	O
(	O
m	O
","	O
9H	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
13	O
.	O
98	O
","	O
59	O
.	O
4	O
","	O
114	O
.	O
52	O
","	O
118	O
.	O
12	O
","	O
121	O
.	O
54	O
","	O
121	O
.	O
55	O
","	O
125	O
.	O
87	O
","	O
126	O
.	O
2	O
","	O
128	O
.	O
11	O
","	O
128	O
.	O
95	O
","	O
132	O
.	O
5	O
","	O
132	O
.	O
97	O
","	O
134	O
.	O
23	O
","	O
142	O
.	O
31	O
","	O
148	O
.	O
0	O
","	O
162	O
.	O
45	O
","	O
196	O
.	O
10	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
456	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
55	O
.	O
27	O
;	O
H	B-Chemical
","	O
3	O
.	O
9	O
;	O
N	B-Chemical
","	O
6	O
.	O
14	O
.	O
C21H14F6N2O3	B-Chemical
Found	O
:	O
C	B-Chemical
","	O
55	O
.	O
58	O
;	O
H	B-Chemical
","	O
2	O
.	O
95	O
;	O
N	B-Chemical
","	O
5	O
.	O
97	O
).	O
Ethyl	B-Chemical
4	I-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
1	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
chlorophenyl	I-Chemical
)-	I-Chemical
5	I-Chemical
-(	I-Chemical
trifluoromethyl	I-Chemical
)-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrazole	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	O
11k	O
)	O
M	O
.	O
p	O
.	O
=	O
227	O
â€“	O
229	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1725	O
","	O
1705	O
(	O
2	O
C	O
=	O
O	O
"),"	O
1602	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
1	O
.	O
19	O
(	O
t	O
","	O
3H	O
","	O
J	O
=	O
7	O
.	O
0	O
Hz	O
","	O
CH3	O
"),"	O
2	O
.	O
21	O
(	O
s	O
","	O
3H	O
","	O
CH3	O
"),"	O
3	O
.	O
95	O
(	O
q	O
","	O
2H	O
","	O
J	O
=	O
7	O
.	O
0	O
Hz	O
","	O
CH2	O
"),"	O
7	O
.	O
60	O
(	O
d	O
","	O
2H	O
","	O
J	O
=	O
7	O
.	O
8	O
Hz	O
","	O
ArH	O
â€™	O
s	O
"),"	O
7	O
.	O
52	O
(	O
d	O
","	O
2H	O
","	O
J	O
=	O
7	O
.	O
8	O
Hz	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
13	O
.	O
52	O
","	O
28	O
.	O
6	O
","	O
58	O
.	O
56	O
","	O
115	O
.	O
18	O
","	O
121	O
.	O
33	O
","	O
125	O
.	O
18	O
","	O
127	O
.	O
51	O
","	O
132	O
.	O
55	O
","	O
133	O
.	O
0	O
","	O
146	O
.	O
15	O
","	O
159	O
.	O
11	O
","	O
190	O
.	O
0	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
360	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
49	O
.	O
95	O
;	O
H	B-Chemical
","	O
3	O
.	O
35	O
;	O
N	B-Chemical
","	O
7	O
.	O
77	O
.	O
C15H12ClF3N2O3	B-Chemical
Found	O
:	O
C	B-Chemical
","	O
50	O
.	O
21	O
;	O
H	B-Chemical
","	O
3	O
.	O
27	O
;	O
N	B-Chemical
","	O
7	O
.	O
59	O
).	O
Ethyl	B-Chemical
4	I-Chemical
-	I-Chemical
benzoyl	I-Chemical
-	I-Chemical
1	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
chlorophenyl	I-Chemical
)-	I-Chemical
5	I-Chemical
-(	I-Chemical
trifluoromethyl	I-Chemical
)-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrazole	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	O
11	O
l	O
)	O
M	O
.	O
p	O
.	O
=	O
250	O
â€“	O
251	O
Â°	O
C	O
;	O
IR	O
(	O
KBr	B-Chemical
):	O
1723	O
","	O
1703	O
(	O
2	O
C	O
=	O
O	O
"),"	O
1602	O
(	O
C	O
=	O
N	O
)	O
cm	O
-	O
1	O
;	O
1H	B-Chemical
NMR	O
(	O
300	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
0	O
.	O
95	O
(	O
t	O
","	O
3H	O
","	O
J	O
=	O
7	O
.	O
2	O
Hz	O
CH3	O
"),"	O
3	O
.	O
99	O
(	O
q	O
","	O
2H	O
","	O
J	O
=	O
7	O
.	O
2	O
Hz	O
","	O
CH2	O
"),"	O
7	O
.	O
62	O
-	O
7	O
.	O
95	O
(	O
m	O
","	O
9H	O
","	O
ArH	O
â€™	O
s	O
);	O
13C	B-Chemical
NMR	O
(	O
75	O
.	O
46	O
MHz	O
","	O
DMSO	B-Chemical
-	I-Chemical
d6	I-Chemical
)	O
Î´	O
:	O
13	O
.	O
90	O
","	O
59	O
.	O
22	O
","	O
114	O
.	O
0	O
","	O
117	O
.	O
45	O
","	O
121	O
.	O
17	O
","	O
126	O
.	O
89	O
","	O
128	O
.	O
12	O
","	O
128	O
.	O
57	O
","	O
132	O
.	O
0	O
","	O
133	O
.	O
9	O
","	O
133	O
.	O
89	O
","	O
139	O
.	O
11	O
","	O
147	O
.	O
52	O
","	O
159	O
.	O
47	O
","	O
192	O
.	O
13	O
.	O
MS	O
(	O
m	O
/	O
z	O
):	O
422	O
(	O
M	O
+).	O
(	O
Calc	O
.	O
:	O
C	B-Chemical
","	O
56	O
.	O
82	O
;	O
H	B-Chemical
","	O
3	O
.	O
34	O
;	O
N	B-Chemical
","	O
6	O
.	O
63	O
.	O
C20H14ClF3N2O3	B-Chemical
Found	O
:	O
C	B-Chemical
","	O
57	O
.	O
3	O
;	O
H	B-Chemical
","	O
3	O
.	O
28	O
;	O
N	B-Chemical
","	O
6	O
.	O
48	O
).	O
Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O
Authors	O
â€™	O
contributions	O
The	O
current	O
study	O
is	O
the	O
outcome	O
of	O
constructive	O
discussions	O
between	O
ASA	O
and	O
TSS	O
","	O
ASA	O
and	O
TSS	O
carry	O
out	O
the	O
synthesis	O
and	O
characterization	O
experiments	O
.	O
HMA	O
carried	O
out	O
the	O
GC	O
-	O
MS	O
analysis	O
and	O
ASA	O
and	O
TSS	O
carried	O
out	O
the	O
1H	B-Chemical
NMR	O
","	O
13C	B-Chemical
NMR	O
and	O
2D	O
NMR	O
.	O
ASA	O
and	O
TSS	O
carried	O
out	O
the	O
elemental	O
analyses	O
.	O
ASA	O
and	O
TSS	O
","	O
were	O
involved	O
in	O
revising	O
the	O
manuscript	O
.	O
All	O
authors	O
have	O
read	O
and	O
approve	O
of	O
the	O
final	O
manuscript	O
.	O
Acknowledgement	O
This	O
project	O
was	O
funded	O
by	O
the	O
Deanship	O
of	O
Scientific	O
Research	O
(	O
DSR	O
"),"	O
King	O
Abdulaziz	O
University	O
","	O
Jeddah	O
","	O
under	O
grant	O
No	O
.	O
(	O
291	O
-	O
372	O
-	O
1432	O
).	O
The	O
authors	O
","	O
therefore	O
","	O
acknowledge	O
with	O
thanks	O
DSR	O
technical	O
and	O
financial	O
support	O
.	O
4	B-Chemical
-	I-Chemical
Hydroxy	I-Chemical
Hexenal	I-Chemical
Derived	O
from	O
Docosahexaenoic	B-Chemical
Acid	I-Chemical
Protects	O
Endothelial	O
Cells	O
via	O
Nrf2	O
Activation	O
Recent	O
studies	O
have	O
proposed	O
that	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
polyunsaturated	I-Chemical
fatty	I-Chemical
acids	I-Chemical
(	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
)	O
have	O
direct	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
effects	O
in	O
vascular	O
tissue	O
","	O
explaining	O
their	O
cardioprotective	O
effects	O
.	O
However	O
","	O
the	O
molecular	O
mechanisms	O
are	O
not	O
yet	O
fully	O
understood	O
.	O
We	O
tested	O
whether	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
showed	O
antioxidant	O
activity	O
through	O
the	O
activation	O
of	O
nuclear	O
factor	O
erythroid	O
2	O
-	O
related	O
factor	O
2	O
(	O
Nrf2	O
"),"	O
a	O
master	O
transcriptional	O
factor	O
for	O
antioxidant	O
genes	O
.	O
C57BL	O
/	O
6	O
or	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
were	O
fed	O
a	O
fish	O
-	O
oil	O
diet	O
for	O
3	O
weeks	O
.	O
Fish	O
-	O
oil	O
diet	O
significantly	O
increased	O
the	O
expression	O
of	O
heme	O
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
"),"	O
and	O
endothelium	O
-	O
dependent	O
vasodilation	O
in	O
the	O
aorta	O
of	O
C57BL	O
/	O
6	O
mice	O
","	O
but	O
not	O
in	O
the	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
.	O
Furthermore	O
","	O
we	O
observed	O
that	O
4	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
hexenal	I-Chemical
(	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
"),"	O
an	O
end	O
-	O
product	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFA	I-Chemical
peroxidation	O
","	O
was	O
significantly	O
increased	O
in	O
the	O
aorta	O
of	O
C57BL	O
/	O
6	O
mice	O
","	O
accompanied	O
by	O
intra	O
-	O
aortic	O
predominant	O
increase	O
in	O
docosahexaenoic	B-Chemical
acid	I-Chemical
(	O
DHA	B-Chemical
)	O
rather	O
than	O
that	O
in	O
eicosapentaenoic	B-Chemical
acid	I-Chemical
(	O
EPA	B-Chemical
).	O
Human	O
umbilical	O
vein	O
endothelial	O
cells	O
were	O
incubated	O
with	O
DHA	B-Chemical
or	O
EPA	B-Chemical
.	O
We	O
found	O
that	O
DHA	B-Chemical
","	O
but	O
not	O
EPA	B-Chemical
","	O
markedly	O
increased	O
intracellular	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
","	O
and	O
nuclear	O
expression	O
and	O
DNA	O
binding	O
of	O
Nrf2	O
.	O
Both	O
DHA	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
also	O
increased	O
the	O
expressions	O
of	O
Nrf2	O
target	O
genes	O
including	O
HO	O
-	O
1	O
","	O
and	O
the	O
siRNA	O
of	O
Nrf2	O
abolished	O
these	O
effects	O
.	O
Furthermore	O
","	O
DHA	B-Chemical
prevented	O
oxidant	O
-	O
induced	O
cellular	O
damage	O
or	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
production	O
","	O
and	O
these	O
effects	O
were	O
disappeared	O
by	O
an	O
HO	O
-	O
1	O
inhibitor	O
or	O
the	O
siRNA	O
of	O
Nrf2	O
.	O
Thus	O
","	O
we	O
found	O
protective	O
effects	O
of	O
DHA	B-Chemical
through	O
Nrf2	O
activation	O
in	O
vascular	O
tissue	O
","	O
accompanied	O
by	O
intra	O
-	O
vascular	O
increases	O
in	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
","	O
which	O
may	O
explain	O
the	O
mechanism	O
of	O
the	O
cardioprotective	O
effects	O
of	O
DHA	B-Chemical
.	O
Introduction	O
N	B-Chemical
-	I-Chemical
3	I-Chemical
polyunsaturated	I-Chemical
fatty	I-Chemical
acids	I-Chemical
(	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
)	O
such	O
as	O
eicosapentaenoic	B-Chemical
(	O
EPA	B-Chemical
)	O
and	O
docosahexaenoic	B-Chemical
acids	I-Chemical
(	O
DHA	B-Chemical
)	O
in	O
fish	O
oil	O
were	O
shown	O
to	O
reduce	O
cardiovascular	O
disease	O
in	O
epidemiological	O
studies	O
of	O
Eskimo	O
during	O
the	O
1970s	O
","	O
.	O
More	O
recent	O
large	O
-	O
scale	O
interventions	O
and	O
cross	O
-	O
sectional	O
studies	O
have	O
shown	O
that	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
reduce	O
cardiovascular	O
events	O
independently	O
of	O
the	O
classical	O
risk	O
factors	O
for	O
atherosclerosis	O
"â€“,"	O
which	O
suggests	O
direct	O
anti	O
-	O
atherogenic	O
effects	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
on	O
vascular	O
tissues	O
.	O
Many	O
studies	O
have	O
already	O
demonstrated	O
that	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
display	O
a	O
variety	O
of	O
bioactive	O
actions	O
such	O
as	O
anti	O
-	O
inflammatory	O
","	O
and	O
antioxidant	O
effects	O
","	O
","	O
improvement	O
of	O
endothelial	O
function	O
","	O
and	O
a	O
suppressive	O
effect	O
on	O
monocyte	O
adhesion	O
in	O
vascular	O
tissue	O
","	O
","	O
explaining	O
the	O
anti	O
-	O
atherogenic	O
effects	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFA	I-Chemical
.	O
In	O
a	O
recent	O
study	O
","	O
enzymatic	O
metabolites	O
from	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
","	O
including	O
resolvins	B-Chemical
and	O
protectins	B-Chemical
","	O
were	O
reported	O
to	O
exert	O
potent	O
anti	O
-	O
inflammatory	O
effects	O
in	O
aortic	O
endothelial	O
cells	O
","	O
leading	O
to	O
atheroprotective	O
effects	O
.	O
It	O
has	O
also	O
been	O
suggested	O
that	O
activation	O
of	O
peroxisome	O
proliferator	O
-	O
activated	O
receptors	O
(	O
PPARs	O
)	O
by	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
in	O
vascular	O
endothelial	O
cells	O
plays	O
an	O
important	O
role	O
in	O
the	O
atheroprotective	O
effects	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
","	O
.	O
A	O
more	O
recent	O
study	O
has	O
shown	O
that	O
DHA	B-Chemical
suppresses	O
NFÎºB	O
activation	O
through	O
G	O
protein	O
-	O
coupled	O
receptor	O
120	O
(	O
GPR120	O
)	O
in	O
macrophages	O
.	O
However	O
","	O
the	O
critical	O
mechanism	O
explaining	O
the	O
cardioprotective	O
effects	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
remains	O
a	O
matter	O
of	O
debate	O
.	O
Nuclear	O
factor	O
erythroid	O
2	O
-	O
related	O
factor	O
2	O
(	O
Nrf2	O
)	O
is	O
a	O
redox	O
-	O
sensitive	O
master	O
regulatory	O
transcriptional	O
factor	O
","	O
and	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
atheroprotective	O
capacity	O
of	O
vascular	O
endothelial	O
cells	O
by	O
regulating	O
endothelial	O
redox	O
balance	O
â€“.	O
In	O
unstimulated	O
cells	O
","	O
Nrf2	O
resides	O
in	O
the	O
cytoplasm	O
bound	O
to	O
Kelch	O
-	O
like	O
ECH	O
-	O
associated	O
protein	O
1	O
(	O
Keap1	O
).	O
Electrophiles	O
","	O
shear	O
stress	O
or	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
instigate	O
modification	O
of	O
the	O
cysteine	B-Chemical
residues	O
of	O
Keap1	O
","	O
which	O
allows	O
translocation	O
to	O
the	O
nucleus	O
and	O
binding	O
to	O
the	O
antioxidant	O
response	O
element	O
(	O
ARE	O
)	O
consensus	O
sequence	O
","	O
resulting	O
in	O
the	O
transcription	O
of	O
antioxidant	O
enzymes	O
such	O
as	O
heme	O
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
"),"	O
Î³	O
-	O
glutamyl	O
-	O
cysteine	O
ligase	O
(	O
GCL	O
"),"	O
and	O
NAD	O
(	O
P	O
)	O
H	O
quinone	O
oxidoreductase	O
1	O
(	O
NQO1	O
)	O
â€“.	O
HO	O
-	O
1	O
in	O
particular	O
","	O
a	O
rate	O
-	O
limiting	O
enzyme	O
in	O
heme	B-Chemical
metabolism	O
","	O
has	O
been	O
recognized	O
as	O
an	O
important	O
factor	O
protecting	O
vascular	O
tissue	O
against	O
atherosclerosis	O
by	O
exerting	O
antioxidant	O
","	O
anti	O
-	O
inflammatory	O
","	O
anti	O
-	O
proliferative	O
","	O
anti	O
-	O
apoptotic	O
and	O
vasodilatory	O
effects	O
on	O
the	O
vasculature	O
.	O
A	O
recent	O
study	O
reported	O
that	O
a	O
fish	O
-	O
oil	O
diet	O
induced	O
HO	O
-	O
1	O
expression	O
in	O
the	O
kidney	O
of	O
obstructive	O
renal	O
injury	O
rats	O
.	O
DHA	B-Chemical
has	O
also	O
been	O
shown	O
to	O
increase	O
HO	O
-	O
1	O
expression	O
in	O
a	O
Nrf2	O
-	O
dependent	O
manner	O
in	O
EA	O
.	O
hy926	O
cells	O
.	O
Furthermore	O
","	O
it	O
has	O
been	O
reported	O
that	O
the	O
suppressive	O
effects	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
such	O
as	O
EPA	B-Chemical
and	O
DHA	B-Chemical
on	O
the	O
LPS	B-Chemical
-	O
induced	O
inflammatory	O
response	O
were	O
absent	O
in	O
peritoneal	O
macrophages	O
isolated	O
from	O
Nrf2	O
null	O
mice	O
","	O
and	O
further	O
studies	O
have	O
proposed	O
that	O
J3	O
and	O
D4	O
isoprostanes	B-Chemical
(	O
as	O
oxidation	O
products	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
)	O
activate	O
Nrf2	O
in	O
HepG2	O
and	O
porcine	O
pulmonary	O
endothelial	O
cells	O
","	O
respectively	O
","	O
.	O
However	O
","	O
it	O
is	O
uncertain	O
whether	O
intake	O
of	O
a	O
fish	O
-	O
oil	O
diet	O
activates	O
Nrf2	O
in	O
vascular	O
tissue	O
","	O
resulting	O
in	O
the	O
vasculoprotective	O
effect	O
.	O
In	O
the	O
present	O
study	O
","	O
we	O
tested	O
the	O
hypothesis	O
that	O
fish	O
-	O
oil	O
diet	O
increases	O
antioxidant	O
enzymes	O
such	O
as	O
HO	O
-	O
1	O
","	O
an	O
important	O
atheroprotective	O
factor	O
","	O
and	O
the	O
endothelium	O
-	O
dependent	O
vasodilatory	O
response	O
","	O
through	O
the	O
activation	O
of	O
Nrf2	O
in	O
vascular	O
tissue	O
.	O
We	O
also	O
investigated	O
whether	O
fish	O
-	O
oil	O
diet	O
increases	O
the	O
intra	O
-	O
vascular	O
concentrations	O
of	O
the	O
peroxidation	O
end	O
-	O
product	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
to	O
discuss	O
the	O
biological	O
mechanisms	O
on	O
the	O
vasculoprotective	O
effects	O
.	O
Furthermore	O
","	O
we	O
investigated	O
the	O
mechanisms	O
of	O
EPA	B-Chemical
and	O
DHA	B-Chemical
on	O
Nrf2	O
-	O
mediated	O
induction	O
of	O
antioxidant	O
enzymes	O
including	O
HO	O
-	O
1	O
and	O
the	O
consequent	O
antioxidant	O
effect	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
).	O
Materials	O
and	O
Methods	O
Reagents	O
Acetylcholine	B-Chemical
(	O
ACh	B-Chemical
)	O
was	O
from	O
Daiichi	O
-	O
Sankyo	O
(	O
Tokyo	O
","	O
Japan	O
).	O
Sodium	B-Chemical
nitroprusside	I-Chemical
(	O
SNP	B-Chemical
)	O
and	O
fatty	B-Chemical
acid	I-Chemical
-	O
free	O
BSA	O
were	O
purchased	O
from	O
Nacalai	O
Tesque	O
(	O
Kyoto	O
","	O
Japan	O
).	O
Papaverine	B-Chemical
hydrochloride	I-Chemical
was	O
from	O
Nichi	O
-	O
iko	O
(	O
Toyama	O
","	O
Japan	O
).	O
2	B-Chemical
"â€²,"	I-Chemical
7	I-Chemical
â€²-	I-Chemical
Dichlorofluorescin	I-Chemical
diacetate	I-Chemical
(	O
H2DCFDA	B-Chemical
)	O
and	O
peroxidase	O
-	O
linked	O
anti	O
-	O
mouse	O
antibody	O
were	O
purchased	O
from	O
Invitrogen	O
(	O
Grand	O
Island	O
","	O
NY	O
).	O
EPA	B-Chemical
","	O
DHA	B-Chemical
","	O
4	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
hexenal	I-Chemical
(	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
"),"	O
NS	B-Chemical
-	I-Chemical
398	I-Chemical
and	O
SC	B-Chemical
-	I-Chemical
58125	I-Chemical
were	O
purchased	O
from	O
Cayman	O
(	O
Ann	O
Arbor	O
","	O
MI	O
).	O
L	B-Chemical
-	I-Chemical
phenylephrine	I-Chemical
","	O
butylated	B-Chemical
hydroxytoluene	I-Chemical
(	O
BHT	B-Chemical
"),"	O
tert	B-Chemical
-	I-Chemical
butyl	I-Chemical
hydroperoxide	I-Chemical
(	O
tBHP	B-Chemical
"),"	O
3	B-Chemical
-(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
dimethyl	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
thiazolyl	I-Chemical
)-	I-Chemical
2	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
diphenyl	I-Chemical
-	I-Chemical
2H	I-Chemical
-	I-Chemical
tetrazolium	I-Chemical
bromide	I-Chemical
(	O
MTT	B-Chemical
"),"	O
zinc	B-Chemical
protoporphyrin	I-Chemical
(	O
ZnPP	B-Chemical
"),"	O
indomethacin	B-Chemical
","	O
Î±	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
and	O
N	B-Chemical
-	I-Chemical
acetylcysteine	I-Chemical
(	O
NAC	B-Chemical
)	O
were	O
obtained	O
from	O
SIGMA	O
-	O
ALDRICH	O
(	O
St	O
.	O
Louis	O
","	O
MO	O
).	O
Anti	O
-	O
HO	O
-	O
1	O
antibody	O
was	O
from	O
Assay	O
design	O
(	O
Ann	O
Arbor	O
","	O
MI	O
).	O
Anti	O
-	O
Î²	O
-	O
actin	O
antibody	O
was	O
purchased	O
from	O
Cell	O
Signaling	O
(	O
Danvers	O
","	O
MA	O
).	O
Anti	O
-	O
Nrf2	O
antibody	O
(	O
H	O
-	O
300	O
"),"	O
anti	O
-	O
lamin	O
A	O
/	O
C	O
antibody	O
and	O
peroxidase	O
-	O
linked	O
anti	O
-	O
rabbit	O
antibody	O
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
","	O
CA	O
).	O
Anti	O
-	O
GCLM	O
antibody	O
was	O
purchased	O
from	O
Abcam	O
(	O
Cambridge	O
","	O
UK	O
).	O
Anti	O
-	O
p62	O
antibody	O
was	O
obtained	O
from	O
BD	O
Biosciences	O
(	O
Franklin	O
Lakes	O
","	O
NJ	O
).	O
Anti	O
-	O
GAPDH	O
antibody	O
(	O
MAB374	O
)	O
was	O
from	O
Millipore	O
(	O
Billerica	O
","	O
MA	O
).	O
Animals	O
All	O
animal	O
experiments	O
were	O
approved	O
by	O
the	O
Shiga	O
University	O
of	O
Medical	O
Science	O
Committee	O
on	O
Animal	O
Research	O
(	O
Permit	O
Number	O
:	O
2009	O
-	O
11	O
-	O
3	O
).	O
Male	O
C57BL	O
/	O
6	O
mice	O
were	O
purchased	O
from	O
CLEA	O
Japan	O
","	O
Inc	O
.	O
C57BL	O
/	O
6	O
background	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
have	O
been	O
previously	O
described	O
.	O
A	O
Fish	O
oil	O
(#	O
112246	O
)	O
or	O
soy	O
oil	O
-	O
based	O
control	O
diet	O
(#	O
110700	O
","	O
AIN	O
-	O
93	O
G	O
","	O
Dyets	O
Inc	O
".,"	O
Bethlehem	O
","	O
PA	O
)	O
was	O
fed	O
to	O
each	O
mouse	O
.	O
Table	O
1	O
shows	O
the	O
detailed	O
composition	O
of	O
each	O
experimental	O
diet	O
.	O
Table	O
2	O
also	O
shows	O
fatty	B-Chemical
acid	I-Chemical
composition	O
of	O
dietary	O
fats	O
used	O
for	O
the	O
experimental	O
diets	O
.	O
Mice	O
were	O
euthanized	O
by	O
isoflurane	B-Chemical
overdose	O
after	O
3	O
weeks	O
of	O
diet	O
","	O
following	O
an	O
overnight	O
fast	O
","	O
to	O
analyze	O
the	O
effect	O
of	O
each	O
diet	O
on	O
mRNA	O
or	O
protein	O
expression	O
of	O
HO	O
-	O
1	O
in	O
thoracic	O
aorta	O
.	O
Composition	O
of	O
the	O
experimental	O
diets	O
.	O
Fatty	B-Chemical
acid	I-Chemical
composition	O
(	O
wt	O
%)	O
of	O
dietary	O
fats	O
.	O
Endothelium	O
-	O
dependent	O
Vasorelaxation	O
C57BL	O
/	O
6	O
and	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
were	O
euthanized	O
by	O
160	O
mg	O
/	O
kg	O
pentobarbital	B-Chemical
sodium	I-Chemical
salt	I-Chemical
after	O
3	O
weeks	O
of	O
diet	O
","	O
following	O
an	O
overnight	O
fast	O
","	O
to	O
analyze	O
the	O
effect	O
of	O
each	O
diet	O
on	O
the	O
endothelium	O
-	O
dependent	O
vasodilatory	O
response	O
in	O
the	O
thoracic	O
aorta	O
.	O
The	O
thoracic	O
aorta	O
was	O
isolated	O
and	O
cut	O
into	O
rings	O
with	O
special	O
care	O
to	O
reserve	O
the	O
endothelium	O
.	O
The	O
rings	O
","	O
under	O
a	O
resting	O
tension	O
of	O
1	O
.	O
0	O
g	O
","	O
were	O
exposed	O
to	O
30	O
mM	O
KCl	B-Chemical
;	O
this	O
contraction	O
was	O
defined	O
as	O
100	O
%	O
for	O
subsequent	O
analysis	O
of	O
contraction	O
in	O
response	O
to	O
agonists	O
.	O
Responses	O
to	O
cumulative	O
concentrations	O
of	O
L	B-Chemical
-	I-Chemical
phenylephrine	I-Chemical
(	O
10	O
âˆ’	O
7	O
to	O
10	O
âˆ’	O
6	O
M	O
)	O
were	O
then	O
obtained	O
.	O
Relaxant	O
responses	O
to	O
ACh	B-Chemical
(	O
10	O
âˆ’	O
9	O
to	O
10	O
âˆ’	O
7	O
M	O
)	O
or	O
SNP	B-Chemical
(	O
10	O
âˆ’	O
9	O
to	O
10	O
âˆ’	O
6	O
M	O
)	O
were	O
obtained	O
in	O
the	O
rings	O
pre	O
-	O
contracted	O
with	O
L	B-Chemical
-	I-Chemical
phenylephrine	I-Chemical
to	O
construct	O
concentration	O
-	O
response	O
curves	O
.	O
At	O
the	O
end	O
of	O
each	O
experiment	O
","	O
10	O
âˆ’	O
4	O
M	O
papaverine	B-Chemical
was	O
added	O
to	O
induce	O
the	O
maximal	O
relaxation	O
","	O
which	O
was	O
taken	O
as	O
100	O
%	O
for	O
comparison	O
with	O
relaxation	O
induced	O
by	O
agonists	O
.	O
Assay	O
for	O
Measuring	O
Intra	O
-	O
aortic	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
and	O
4	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
Nonenal	I-Chemical
(	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
)	O
Intra	O
-	O
aortic	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
and	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
were	O
quantitatively	O
analyzed	O
using	O
a	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
).	O
Thoracic	O
aortas	O
were	O
fractured	O
in	O
liquid	O
nitrogen	B-Chemical
using	O
a	O
Cryo	O
Press	O
(	O
Microtec	O
Co	O
".,"	O
Ltd	O
".,"	O
Chiba	O
","	O
Japan	O
)	O
and	O
subjected	O
to	O
lipid	O
extraction	O
.	O
The	O
samples	O
solubilized	O
in	O
490	O
ÂµL	O
chloroform	B-Chemical
/	O
methanol	B-Chemical
(	O
1	O
âˆ¶	O
1	O
","	O
v	O
/	O
v	O
)	O
and	O
10	O
ÂµL	O
BHT	B-Chemical
solution	O
(	O
10	O
mg	O
/	O
mL	O
in	O
ethanol	B-Chemical
)	O
were	O
incubated	O
at	O
36	O
Â°	O
C	O
for	O
1	O
h	O
.	O
Total	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
and	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
levels	O
were	O
quantitatively	O
measured	O
as	O
previously	O
reported	O
.	O
Briefly	O
","	O
[	B-Chemical
2H3	I-Chemical
]-	I-Chemical
4	I-Chemical
-	I-Chemical
HNE	I-Chemical
(	O
Cayman	O
)	O
as	O
internal	O
solution	O
was	O
spiked	O
to	O
200	O
ÂµL	O
samples	O
obtained	O
from	O
lipid	O
extraction	O
.	O
Then	O
","	O
samples	O
were	O
passed	O
through	O
using	O
a	O
mix	O
-	O
mode	O
anion	O
exchange	O
solid	O
-	O
phase	O
extraction	O
(	O
SPE	O
)	O
cartridge	O
","	O
Oasis	O
MAX	O
(	O
Waters	O
","	O
Milford	O
","	O
MA	O
).	O
After	O
extraction	O
","	O
the	O
eluate	O
was	O
spiked	O
with	O
BHT	B-Chemical
solution	O
and	O
acidified	O
cyclohexanedione	B-Chemical
(	O
CHD	B-Chemical
)	O
reagent	O
was	O
added	O
to	O
derivatize	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
or	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
.	O
CHD	B-Chemical
-	O
derivatization	O
was	O
carried	O
out	O
at	O
60	O
Â°	O
C	O
for	O
1	O
h	O
","	O
and	O
derivatized	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
or	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
was	O
then	O
extracted	O
using	O
a	O
SPE	O
cartridge	O
","	O
Oasis	O
HLB	O
(	O
Waters	O
).	O
The	O
eluate	O
from	O
SPE	O
was	O
injected	O
into	O
a	O
LC	O
-	O
MS	O
/	O
MS	O
system	O
.	O
LC	O
was	O
performed	O
using	O
an	O
ACQUITY	O
UPLC	O
(	O
Waters	O
"),"	O
and	O
an	O
API4000	O
triple	O
quadrupole	O
tandem	O
mass	O
spectrometer	O
(	O
AB	O
Sciex	O
","	O
Foster	O
City	O
","	O
CA	O
)	O
was	O
used	O
as	O
a	O
detector	O
.	O
Chromatographic	O
separation	O
was	O
achieved	O
using	O
a	O
reversed	O
-	O
phase	O
column	O
","	O
ACQUITY	O
CSH	O
C18	O
(	O
Waters	O
"),"	O
with	O
two	O
mobile	O
phases	O
and	O
electrospray	O
ionization	O
in	O
positive	O
ionization	O
with	O
selected	O
reaction	O
monitoring	O
(	O
SRM	O
)	O
mode	O
was	O
used	O
to	O
analyze	O
derivatized	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
and	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
.	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
or	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
levels	O
were	O
normalized	O
to	O
the	O
weight	O
of	O
tissue	O
.	O
Assay	O
for	O
Measuring	O
Intra	O
-	O
aortic	O
DHA	B-Chemical
and	O
EPA	B-Chemical
Intra	O
-	O
aortic	O
DHA	B-Chemical
and	O
EPA	B-Chemical
were	O
also	O
quantitatively	O
analyzed	O
using	O
a	O
LC	O
-	O
MS	O
/	O
MS	O
.	O
Total	O
DHA	B-Chemical
and	O
EPA	B-Chemical
levels	O
were	O
quantitatively	O
measured	O
as	O
previously	O
reported	O
.	O
Briefly	O
","	O
internal	O
solution	O
containing	O
[	B-Chemical
2H5	I-Chemical
]-	I-Chemical
DHA	I-Chemical
(	O
Cayman	O
)	O
and	O
[	B-Chemical
2H5	I-Chemical
]-	I-Chemical
EPA	I-Chemical
(	O
Cayman	O
)	O
was	O
spiked	O
to	O
all	O
samples	O
(	O
20	O
Âµl	O
)	O
obtained	O
from	O
lipid	O
extraction	O
as	O
described	O
above	O
and	O
calibration	O
standard	O
samples	O
","	O
and	O
the	O
samples	O
were	O
evaporated	O
by	O
nitrogen	B-Chemical
gas	O
.	O
Following	O
the	O
addition	O
of	O
acetonitrile	B-Chemical
/	O
6N	O
HCl	B-Chemical
(	O
90	O
/	O
10	O
","	O
v	O
/	O
v	O
"),"	O
samples	O
were	O
incubated	O
at	O
100	O
Â°	O
C	O
for	O
45	O
min	O
.	O
Finally	O
","	O
liquid	O
-	O
liquid	O
extraction	O
with	O
ethyl	B-Chemical
acetate	I-Chemical
was	O
performed	O
and	O
the	O
reconstituted	O
samples	O
were	O
injected	O
into	O
an	O
optimized	O
LC	O
-	O
MS	O
/	O
MS	O
system	O
.	O
LC	O
was	O
performed	O
using	O
an	O
ACQUITY	O
UPLC	O
[	O
a	O
YMC	O
-	O
Triart	O
C18	O
(	O
YMC	O
Co	O
".,"	O
Ltd	O
".,"	O
Kyoto	O
","	O
Japan	O
"),"	O
and	O
a	O
liner	O
gradient	O
combination	O
of	O
two	O
mobile	O
phases	O
]	O
and	O
an	O
API4000	O
triple	O
quadrupole	O
tandem	O
mass	O
spectrometer	O
was	O
used	O
as	O
a	O
detector	O
using	O
atmospheric	O
pressure	O
chemical	O
ionization	O
in	O
negative	O
ionization	O
with	O
SRM	O
mode	O
.	O
DHA	B-Chemical
and	O
EPA	B-Chemical
levels	O
were	O
normalized	O
to	O
the	O
weight	O
of	O
tissue	O
.	O
Cell	O
Culture	O
HUVECs	O
were	O
cultured	O
according	O
to	O
a	O
previously	O
reported	O
method	O
","	O
.	O
When	O
cells	O
reached	O
confluence	O
","	O
they	O
were	O
starved	O
overnight	O
in	O
medium	O
containing	O
2	O
%	O
FBS	O
before	O
their	O
use	O
for	O
the	O
experiments	O
on	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
analysis	O
","	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
","	O
western	O
blotting	O
and	O
Nrf2	O
activity	O
.	O
Fatty	B-Chemical
acids	I-Chemical
or	O
other	O
reagents	O
were	O
dissolved	O
in	O
medium	O
supplemented	O
with	O
2	O
%	O
FBS	O
for	O
the	O
treatment	O
.	O
Fatty	B-Chemical
Acid	I-Chemical
Treatment	O
DHA	B-Chemical
or	O
EPA	B-Chemical
was	O
administered	O
as	O
a	O
complex	O
with	O
fatty	B-Chemical
acid	I-Chemical
-	O
free	O
BSA	O
.	O
DHA	B-Chemical
or	O
EPA	B-Chemical
(	O
0	O
.	O
30	O
mM	O
each	O
)	O
was	O
dissolved	O
in	O
ethanol	B-Chemical
(	O
2	O
.	O
5	O
mL	O
"),"	O
and	O
gradually	O
solubilized	O
in	O
8	O
.	O
4	O
%	O
BSA	O
solution	O
(	O
14	O
.	O
3	O
mL	O
)	O
at	O
37	O
Â°	O
C	O
.	O
BSA	O
-	O
conjugated	O
fatty	B-Chemical
acids	I-Chemical
were	O
dissolved	O
in	O
serum	O
-	O
containing	O
medium	O
at	O
the	O
final	O
desired	O
concentration	O
.	O
The	O
control	O
medium	O
containing	O
BSA	O
was	O
prepared	O
in	O
a	O
similar	O
manner	O
.	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
was	O
dissolved	O
in	O
ethanol	B-Chemical
","	O
and	O
further	O
dissolved	O
in	O
serum	O
-	O
containing	O
medium	O
.	O
Ethanol	B-Chemical
was	O
used	O
as	O
a	O
control	O
for	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
.	O
Assay	O
for	O
Measuring	O
Intracellular	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
and	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
Intracellular	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
and	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
were	O
extracted	O
in	O
13	O
.	O
2	O
mM	O
BHT	B-Chemical
-	O
containing	O
RIPA	B-Chemical
buffer	I-Chemical
(	O
Thermo	O
Scientific	O
","	O
Rockford	O
","	O
IL	O
"),"	O
and	O
subjected	O
to	O
LC	O
-	O
MS	O
/	O
MS	O
analysis	O
as	O
described	O
above	O
.	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
or	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
levels	O
were	O
normalized	O
to	O
the	O
protein	O
concentration	O
in	O
the	O
lysate	O
.	O
RNA	O
Extraction	O
and	O
Real	O
-	O
time	O
PCR	O
Analysis	O
Total	O
RNA	O
was	O
extracted	O
from	O
cells	O
using	O
a	O
Total	O
RNA	O
Mini	O
Kit	O
(	O
Bio	O
-	O
Rad	O
","	O
Hercules	O
","	O
CA	O
).	O
Thoracic	O
aortas	O
were	O
fractured	O
in	O
liquid	O
nitrogen	B-Chemical
using	O
a	O
Cryo	O
Press	O
and	O
subjected	O
to	O
RNA	O
extraction	O
.	O
Single	O
-	O
stranded	O
cDNA	O
was	O
synthesized	O
from	O
0	O
.	O
5	O
Âµg	O
of	O
total	O
RNA	O
using	O
a	O
PrimeScript	O
RT	O
Reagent	O
Kit	O
(	O
Takara	O
Bio	O
","	O
Shiga	O
","	O
Japan	O
"),"	O
and	O
endogenous	O
genomic	O
DNA	O
was	O
degraded	O
by	O
DNase	O
I	O
(	O
Invitrogen	O
).	O
Quantitative	O
analyses	O
of	O
HO	O
-	O
1	O
","	O
GCL	O
","	O
modifier	O
subunit	O
(	O
GCLM	O
"),"	O
sequestosome	O
1	O
(	O
SQSTM1	O
","	O
p62	O
)	O
and	O
Nrf2	O
mRNAs	O
were	O
performed	O
by	O
real	O
-	O
time	O
PCR	O
using	O
the	O
ABI	O
7500	O
Fast	O
Real	O
-	O
Time	O
PCR	O
System	O
(	O
Applied	O
Biosystems	O
","	O
Japan	O
).	O
Premix	O
Ex	O
Taq	O
(	O
Takara	O
Bio	O
)	O
and	O
Assay	O
-	O
on	O
-	O
Demand	O
","	O
Gene	O
Expression	O
Products	O
[	O
mice	O
;	O
Mm00516007_m1	O
for	O
HO	O
-	O
1	O
and	O
Mm00607939_s1	O
for	O
Î²	O
-	O
actin	O
;	O
HUVECs	O
;	O
Hs01110250_m1	O
for	O
HO	O
-	O
1	O
","	O
Hs00157694_m1	O
for	O
GCLM	O
","	O
Hs00177654_m1	O
for	O
p62	O
","	O
Hs00232352_m1	O
for	O
Nrf2	O
and	O
Hs02387368_g1	O
for	O
ribosomal	O
protein	O
S18	O
(	O
RPS18	O
)	O
(	O
Applied	O
Biosystems	O
","	O
Foster	O
City	O
","	O
CA	O
)]	O
were	O
used	O
for	O
quantitative	O
real	O
-	O
time	O
PCR	O
analysis	O
.	O
Quantitative	O
data	O
in	O
vivo	O
or	O
in	O
vitro	O
were	O
respectively	O
normalized	O
to	O
the	O
expression	O
level	O
of	O
Î²	O
-	O
actin	O
and	O
RPS18	O
.	O
Western	O
Blotting	O
Analysis	O
Thoracic	O
aortas	O
were	O
fractured	O
in	O
liquid	O
nitrogen	B-Chemical
using	O
a	O
Cryo	O
Press	O
and	O
then	O
solubilized	O
in	O
RIPA	B-Chemical
buffer	I-Chemical
(	O
Thermo	O
Scientific	O
)	O
containing	O
protease	O
inhibitors	O
(	O
Thermo	O
Scientific	O
).	O
Whole	O
cell	O
lysate	O
from	O
HUVECs	O
was	O
prepared	O
in	O
RIPA	B-Chemical
buffer	I-Chemical
containing	O
protease	O
inhibitors	O
.	O
Nuclear	O
lysates	O
were	O
prepared	O
using	O
a	O
Nuclear	O
/	O
Cytosol	O
Fractionation	O
Kit	O
(	O
BioVision	O
","	O
Mountain	O
View	O
","	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
â€™	O
s	O
protocol	O
.	O
The	O
lysates	O
were	O
denatured	O
by	O
boiling	O
in	O
SDS	B-Chemical
sample	O
buffer	O
(	O
Thermo	O
Scientific	O
"),"	O
resolved	O
by	O
SDS	B-Chemical
-	O
PAGE	O
and	O
then	O
transferred	O
to	O
a	O
nitrocellulose	B-Chemical
membrane	O
by	O
electroblotting	O
.	O
Blots	O
were	O
then	O
incubated	O
with	O
a	O
rabbit	O
anti	O
-	O
HO	O
-	O
1	O
primary	O
antibody	O
","	O
a	O
rabbit	O
anti	O
-	O
Î²	O
-	O
actin	O
primary	O
antibody	O
","	O
a	O
rabbit	O
anti	O
-	O
Nrf2	O
primary	O
antibody	O
","	O
a	O
rabbit	O
anti	O
-	O
lamin	O
A	O
/	O
C	O
primary	O
antibody	O
","	O
a	O
mouse	O
anti	O
-	O
GCLM	O
primary	O
antibody	O
","	O
a	O
mouse	O
anti	O
-	O
p62	O
primary	O
antibody	O
","	O
or	O
a	O
mouse	O
anti	O
-	O
GAPDH	O
primary	O
antibody	O
plus	O
a	O
horseradish	O
peroxidase	O
-	O
linked	O
secondary	O
antibody	O
","	O
and	O
detected	O
by	O
chemiluminescence	O
using	O
an	O
ImageQuant	O
LAS	O
4000mini	O
system	O
(	O
GE	O
Healthcare	O
","	O
Japan	O
).	O
Cell	O
Transfection	O
and	O
Luciferase	O
Assay	O
The	O
ARE	O
-	O
luciferase	O
reporter	O
plasmid	O
(	O
pGL4	O
.	O
27	O
(	O
Nrf2	O
-	O
luc2P	O
/	O
minP	O
/	O
Hygro	O
))	O
was	O
obtained	O
from	O
Promega	O
(	O
Madison	O
","	O
WI	O
).	O
HUVECs	O
(	O
3	O
.	O
4	O
Ã—	O
104	O
)	O
were	O
plated	O
in	O
12	O
-	O
well	O
type	O
I	O
collagen	O
-	O
coated	O
plates	O
for	O
48	O
h	O
.	O
Cells	O
were	O
cotransfected	O
with	O
0	O
.	O
2	O
Âµg	O
luciferase	O
expression	O
plasmid	O
and	O
0	O
.	O
5	O
Âµg	O
of	O
pRL	O
-	O
TK	O
plasmid	O
(	O
Promega	O
)	O
as	O
a	O
normalization	O
reference	O
for	O
transfection	O
efficiency	O
using	O
SuperFect	O
Transfection	O
Reagent	O
(	O
Qiagen	O
","	O
Valencia	O
","	O
CA	O
)	O
for	O
8	O
h	O
","	O
then	O
cells	O
were	O
stimulated	O
with	O
DHA	B-Chemical
","	O
EPA	B-Chemical
or	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
for	O
16	O
h	O
.	O
Cells	O
were	O
harvested	O
","	O
and	O
Firefly	O
and	O
Renilla	O
luciferase	O
activities	O
were	O
determined	O
using	O
a	O
Dual	O
-	O
Luciferase	O
Reporter	O
Assay	O
System	O
(	O
Promega	O
)	O
with	O
a	O
luminometer	O
(	O
GloMax	O
20	O
/	O
20n	O
","	O
Promega	O
).	O
Nrf2	O
DNA	O
Binding	O
Assay	O
Nrf2	O
activation	O
was	O
assayed	O
using	O
Active	O
Motif	O
â€™	O
s	O
(	O
Carlsbad	O
","	O
CA	O
)	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)-	O
based	O
transactivation	O
TransAM	O
kit	O
","	O
following	O
the	O
manufacturer	O
â€™	O
s	O
protocol	O
.	O
Nrf2	O
from	O
nuclear	O
lysate	O
","	O
which	O
specifically	O
binds	O
to	O
its	O
consensus	O
oligonucleotide	B-Chemical
","	O
was	O
analyzed	O
colorimetrically	O
using	O
a	O
spectrophotometer	O
at	O
450	O
nm	O
.	O
Transfection	O
with	O
Small	O
Interfering	O
(	O
si	O
)	O
RNA	O
HUVECs	O
were	O
plated	O
in	O
type	O
I	O
collagen	O
-	O
coated	O
plates	O
until	O
80	O
â€“	O
90	O
%	O
confluency	O
.	O
siRNA	O
against	O
Nrf2	O
or	O
PPARÎ±	O
was	O
used	O
to	O
silence	O
Nrf2	O
or	O
PPARÎ±	O
","	O
respectively	O
(	O
On	O
-	O
TARGET	O
plus	O
SMARTpool	O
Reagent	O
;	O
Thermo	O
Scientific	O
).	O
A	O
control	O
siRNA	O
was	O
also	O
used	O
(	O
On	O
-	O
TARGET	O
plus	O
Non	O
-	O
targeting	O
siRNA	O
#	O
1	O
","	O
Thermo	O
Scientific	O
).	O
HUVECs	O
were	O
transfected	O
with	O
20	O
nM	O
of	O
Nrf2	O
siRNA	O
","	O
PPARÎ±	O
siRNA	O
or	O
control	O
siRNA	O
using	O
DharmaFECT	O
1	O
siRNA	O
Transfection	O
Reagent	O
(	O
Thermo	O
Scientific	O
)	O
and	O
incubated	O
for	O
24	O
h	O
in	O
medium	O
containing	O
2	O
%	O
FBS	O
","	O
after	O
which	O
the	O
medium	O
was	O
refreshed	O
.	O
After	O
incubation	O
for	O
a	O
further	O
24	O
h	O
","	O
HUVECs	O
were	O
stimulated	O
with	O
DHA	B-Chemical
for	O
6	O
h	O
to	O
analyze	O
the	O
effects	O
on	O
mRNA	O
expression	O
.	O
To	O
analyze	O
protein	O
expression	O
","	O
32	O
h	O
after	O
transfection	O
","	O
cells	O
were	O
stimulated	O
with	O
DHA	B-Chemical
or	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
for	O
16	O
h	O
","	O
and	O
then	O
subjected	O
to	O
western	O
blotting	O
analyses	O
.	O
The	O
silencing	O
effects	O
of	O
Nrf2	O
and	O
PPARÎ±	O
were	O
confirmed	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
or	O
western	O
blotting	O
analyses	O
.	O
MTT	B-Chemical
Measurement	O
of	O
Cell	O
Viability	O
HUVECs	O
were	O
seeded	O
on	O
24	O
-	O
well	O
type	O
I	O
collagen	O
-	O
coated	O
plates	O
.	O
To	O
determine	O
the	O
preventive	O
effect	O
of	O
DHA	B-Chemical
on	O
tBHP	B-Chemical
-	O
induced	O
cell	O
toxicity	O
","	O
confluent	O
cells	O
were	O
pretreated	O
with	O
DHA	B-Chemical
(	O
37	O
.	O
5	O
â€“	O
75	O
ÂµM	O
)	O
for	O
16	O
h	O
","	O
washed	O
with	O
phosphate	B-Chemical
-	I-Chemical
buffered	I-Chemical
saline	I-Chemical
(	O
PBS	B-Chemical
"),"	O
and	O
exposed	O
to	O
tBHP	B-Chemical
(	O
250	O
or	O
500	O
ÂµM	O
)	O
for	O
6	O
h	O
.	O
Cell	O
viability	O
was	O
determined	O
by	O
conventional	O
MTT	B-Chemical
reduction	O
assay	O
.	O
MTT	B-Chemical
is	O
a	O
tetrazolium	B-Chemical
salt	I-Chemical
cleaved	O
to	O
formazan	B-Chemical
by	O
the	O
mitochondrial	O
respiratory	O
chain	O
enzyme	O
","	O
succinate	O
dehydrogenase	O
.	O
After	O
treatment	O
with	O
tBHP	B-Chemical
","	O
cells	O
were	O
incubated	O
with	O
MTT	B-Chemical
solution	O
(	O
0	O
.	O
5	O
mg	O
/	O
mL	O
)	O
in	O
culture	O
medium	O
for	O
3	O
h	O
.	O
The	O
culture	O
medium	O
was	O
then	O
removed	O
","	O
the	O
formazan	B-Chemical
product	O
was	O
solubilized	O
in	O
dimethylsulfoxide	B-Chemical
","	O
and	O
the	O
absorbance	O
at	O
577	O
nm	O
was	O
measured	O
using	O
a	O
microplate	O
reader	O
.	O
Values	O
were	O
expressed	O
as	O
percentage	O
of	O
cell	O
survival	O
.	O
Absorbance	O
from	O
tBHP	B-Chemical
-	O
untreated	O
cells	O
was	O
set	O
at	O
100	O
%.	O
To	O
determine	O
the	O
involvement	O
of	O
Nrf2	O
in	O
oxidative	O
stress	O
-	O
induced	O
cell	O
viability	O
","	O
cells	O
were	O
pretreated	O
for	O
16	O
h	O
with	O
DHA	B-Chemical
(	O
75	O
ÂµM	O
)	O
or	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
(	O
5	O
â€“	O
10	O
ÂµM	O
)	O
32	O
h	O
after	O
transfection	O
with	O
Nrf2	O
siRNA	O
","	O
and	O
then	O
exposed	O
to	O
tBHP	B-Chemical
for	O
6	O
h	O
.	O
Intracellular	O
GSH	B-Chemical
and	O
GSSG	B-Chemical
Assay	O
Intracellular	O
GSH	B-Chemical
and	O
GSSG	B-Chemical
levels	O
were	O
measured	O
colorimetrically	O
using	O
a	O
glutathione	B-Chemical
assay	O
kit	O
(	O
GSH	B-Chemical
/	O
GSSG	B-Chemical
-	O
412	O
","	O
OxisResearch	O
","	O
Foster	O
City	O
","	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
â€™	O
s	O
protocol	O
","	O
and	O
normalized	O
to	O
protein	O
concentration	O
in	O
the	O
lysate	O
.	O
Assay	O
for	O
Measuring	O
ROS	B-Chemical
Intracellular	O
ROS	B-Chemical
production	O
was	O
determined	O
using	O
a	O
fluorescence	O
probe	O
","	O
H2DCFDA	B-Chemical
.	O
Confluent	O
HUVECs	O
in	O
24	O
-	O
well	O
culture	O
plates	O
were	O
incubated	O
with	O
75	O
ÂµM	O
DHA	B-Chemical
for	O
16	O
h	O
before	O
treatment	O
with	O
20	O
ÂµM	O
H2DCFDA	B-Chemical
for	O
20	O
min	O
.	O
Following	O
a	O
PBS	B-Chemical
wash	O
","	O
cells	O
were	O
either	O
untreated	O
","	O
or	O
treated	O
with	O
250	O
or	O
500	O
ÂµM	O
tBHP	B-Chemical
in	O
medium	O
containing	O
2	O
%	O
FBS	O
.	O
The	O
fluorescence	O
released	O
from	O
cells	O
was	O
recorded	O
immediately	O
at	O
492	O
nm	O
(	O
excitation	O
)	O
and	O
525	O
nm	O
(	O
emission	O
)	O
using	O
a	O
fluorescent	O
microplate	O
reader	O
at	O
different	O
time	O
intervals	O
over	O
a	O
2	O
-	O
h	O
period	O
.	O
Lactate	O
Dehydrogenase	O
(	O
LDH	O
)	O
Cytotoxicity	O
Assay	O
LDH	O
activity	O
was	O
measured	O
using	O
an	O
LDH	O
Cytotoxicity	O
Assay	O
Kit	O
(	O
Cayman	O
"),"	O
according	O
to	O
the	O
manufacturer	O
â€™	O
s	O
protocol	O
.	O
Statistical	O
Analysis	O
Data	O
are	O
presented	O
as	O
mean	O
Â±	O
SE	O
.	O
Differences	O
between	O
more	O
than	O
three	O
groups	O
were	O
analyzed	O
by	O
two	O
-	O
tailed	O
multiple	O
t	O
-	O
test	O
with	O
Bonferroni	O
correction	O
.	O
Comparisons	O
between	O
two	O
groups	O
were	O
analyzed	O
using	O
a	O
two	O
-	O
tailed	O
Student	O
â€™	O
s	O
t	O
-	O
test	O
.	O
Statistical	O
significance	O
was	O
established	O
at	O
P	O
<	O
0	O
.	O
5	O
.	O
Results	O
Nrf2	O
-	O
mediated	O
Effects	O
of	O
Fish	O
-	O
oil	O
Diet	O
in	O
Aorta	O
To	O
investigate	O
the	O
Nrf2	O
-	O
mediated	O
effects	O
of	O
a	O
fish	O
-	O
oil	O
diet	O
in	O
vascular	O
tissue	O
","	O
we	O
examined	O
expression	O
of	O
the	O
HO	O
-	O
1	O
gene	O
.	O
The	O
fish	O
-	O
oil	O
diet	O
-	O
fed	O
groups	O
showed	O
a	O
smaller	O
increase	O
in	O
body	O
weight	O
compared	O
with	O
the	O
control	O
diet	O
-	O
fed	O
group	O
","	O
but	O
there	O
was	O
no	O
difference	O
between	O
C57BL	O
/	O
6	O
and	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
(	O
Table	O
3	O
).	O
Plasma	O
triglyceride	B-Chemical
was	O
significantly	O
increased	O
in	O
both	O
the	O
Nrf2	O
âˆ’/âˆ’	O
groups	O
","	O
but	O
there	O
were	O
no	O
significant	O
differences	O
in	O
plasma	O
glucose	B-Chemical
","	O
total	O
cholesterol	B-Chemical
or	O
non	B-Chemical
-	I-Chemical
esterified	I-Chemical
fatty	I-Chemical
acid	I-Chemical
(	O
NEFA	B-Chemical
)	O
among	O
the	O
four	O
groups	O
(	O
Table	O
4	O
).	O
Fig	O
.	O
1A	O
shows	O
the	O
effects	O
of	O
a	O
fish	O
-	O
oil	O
diet	O
on	O
HO	O
-	O
1	O
mRNA	O
expression	O
in	O
thoracic	O
aorta	O
tissue	O
of	O
C57BL	O
/	O
6	O
or	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
.	O
The	O
fish	O
-	O
oil	O
diet	O
significantly	O
increased	O
mRNA	O
expression	O
of	O
HO	O
-	O
1	O
in	O
C57BL	O
/	O
6	O
mice	O
","	O
while	O
the	O
increase	O
was	O
not	O
observed	O
in	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
.	O
The	O
increase	O
in	O
HO	O
-	O
1	O
protein	O
expression	O
by	O
fish	O
-	O
oil	O
diet	O
was	O
similarly	O
absent	O
in	O
the	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
as	O
shown	O
in	O
Fig	O
.	O
1B	O
.	O
Next	O
","	O
we	O
examined	O
whether	O
the	O
fish	O
-	O
oil	O
diet	O
altered	O
ACh	B-Chemical
-	O
dependent	O
vasorelaxation	O
in	O
the	O
aorta	O
.	O
The	O
fish	O
-	O
oil	O
diet	O
significantly	O
increased	O
the	O
ACh	B-Chemical
-	O
dependent	O
vasodilatory	O
response	O
compared	O
with	O
control	O
diet	O
in	O
wild	O
type	O
mice	O
.	O
In	O
contrast	O
","	O
there	O
was	O
no	O
effect	O
of	O
the	O
fish	O
-	O
oil	O
diet	O
in	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
(	O
Fig	O
.	O
1C	O
and	O
1D	O
).	O
The	O
effects	O
of	O
fish	O
-	O
oil	O
diet	O
on	O
SNP	B-Chemical
-	O
dependent	O
vasorelaxation	O
were	O
also	O
investigated	O
.	O
Fish	O
-	O
oil	O
diet	O
had	O
no	O
effect	O
on	O
SNP	B-Chemical
-	O
dependent	O
response	O
(	O
Fig	O
.	O
1E	O
and	O
1F	O
).	O
Thus	O
","	O
the	O
data	O
indicate	O
that	O
a	O
fish	O
-	O
oil	O
diet	O
increases	O
the	O
Nrf2	O
-	O
mediated	O
vasodilatory	O
response	O
in	O
an	O
endothelium	O
-	O
dependent	O
manner	O
.	O
Effects	O
of	O
fish	O
-	O
oil	O
diet	O
on	O
HO	O
-	O
1	O
expression	O
and	O
endothelium	O
-	O
dependent	O
vasorelaxation	O
in	O
thoracic	O
aortas	O
.	O
Control	O
or	O
fish	O
-	O
oil	O
diet	O
was	O
fed	O
to	O
C57BL	O
/	O
6	O
or	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
for	O
3	O
weeks	O
.	O
(	O
A	O
)	O
The	O
relative	O
mRNA	O
expressions	O
of	O
HO	O
-	O
1	O
in	O
thoracic	O
aortas	O
were	O
analyzed	O
quantitatively	O
using	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
6	O
â€“	O
10	O
animals	O
.	O
(	O
B	O
)	O
Total	O
cell	O
lysates	O
from	O
thoracic	O
aortas	O
were	O
subjected	O
to	O
western	O
blotting	O
analyses	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
four	O
animals	O
.	O
(	O
C	O
â€“	O
F	O
)	O
Concentration	O
-	O
vasodilatory	O
response	O
curves	O
induced	O
by	O
ACh	B-Chemical
(	O
C	O
","	O
D	O
)	O
or	O
SNP	B-Chemical
(	O
E	O
","	O
F	O
)	O
in	O
aortic	O
rings	O
obtained	O
from	O
C57BL	O
/	O
6	O
(	O
C	O
","	O
E	O
)	O
or	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
(	O
D	O
","	O
F	O
)	O
fed	O
with	O
fish	O
-	O
oil	O
diet	O
for	O
3	O
weeks	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
12	O
â€“	O
18	O
rings	O
.	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
compared	O
with	O
control	O
diet	O
-	O
fed	O
C57BL	O
/	O
6	O
mice	O
.	O
â€ â€ 	O
P	O
<	O
0	O
.	O
1	O
","	O
compared	O
with	O
fish	O
-	O
oil	O
diet	O
-	O
fed	O
C57BL	O
/	O
6	O
mice	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
.	O
Body	O
weight	O
changes	O
of	O
C57BL	O
/	O
6	O
(	O
n	O
=	O
10	O
)	O
and	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
(	O
n	O
=	O
6	O
)	O
fed	O
with	O
fish	O
-	O
oil	O
diet	O
for	O
3	O
weeks	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
.	O
P	O
<	O
0	O
.	O
1	O
","	O
compared	O
with	O
the	O
corresponding	O
group	O
of	O
C57BL	O
/	O
6	O
mice	O
.	O
Plasma	O
characteristics	O
of	O
C57BL	O
/	O
6	O
(	O
n	O
=	O
10	O
)	O
and	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
(	O
n	O
=	O
6	O
)	O
fed	O
with	O
fish	O
-	O
oil	O
diet	O
for	O
3	O
weeks	O
.	O
Effects	O
of	O
Fish	O
-	O
oil	O
Diet	O
on	O
Concentrations	O
of	O
DHA	B-Chemical
","	O
EPA	B-Chemical
and	O
the	O
Peroxidation	O
Products	O
in	O
Aortic	O
Tissue	O
Intra	O
-	O
aortic	O
concentrations	O
of	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
","	O
an	O
end	O
-	O
product	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
peroxidation	O
","	O
as	O
well	O
as	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
","	O
an	O
end	O
-	O
product	O
of	O
n	B-Chemical
-	I-Chemical
6	I-Chemical
PUFAs	I-Chemical
peroxidation	O
","	O
were	O
measured	O
after	O
dietary	O
fish	O
-	O
oil	O
supplementation	O
for	O
3	O
weeks	O
","	O
using	O
LC	O
-	O
MS	O
/	O
MS	O
analyses	O
.	O
Fish	O
-	O
oil	O
diet	O
significantly	O
increased	O
intra	O
-	O
aortic	O
concentration	O
of	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
in	O
C57BL	O
/	O
6	O
mice	O
","	O
whereas	O
that	O
of	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
tended	O
to	O
be	O
decreased	O
(	O
Fig	O
.	O
2A	O
).	O
We	O
also	O
measured	O
intra	O
-	O
aortic	O
concentrations	O
of	O
DHA	B-Chemical
or	O
EPA	B-Chemical
by	O
LC	O
-	O
MS	O
/	O
MS	O
analyses	O
.	O
Fish	O
-	O
oil	O
diet	O
increased	O
intra	O
-	O
aortic	O
concentration	O
of	O
DHA	B-Chemical
rather	O
than	O
EPA	B-Chemical
(	O
Fig	O
.	O
2B	O
"),"	O
despite	O
lower	O
concentration	O
of	O
DHA	B-Chemical
than	O
EPA	B-Chemical
in	O
menhaden	O
oil	O
used	O
for	O
the	O
experimental	O
diet	O
(	O
Table	O
2	O
).	O
Effects	O
of	O
fish	O
-	O
oil	O
diet	O
on	O
concentrations	O
of	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
","	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
","	O
DHA	B-Chemical
and	O
EPA	B-Chemical
in	O
thoracic	O
aortas	O
.	O
Control	O
or	O
fish	O
-	O
oil	O
diet	O
was	O
fed	O
to	O
C57BL	O
/	O
6	O
mice	O
for	O
3	O
weeks	O
.	O
The	O
concentrations	O
of	O
intra	O
-	O
aortic	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
or	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
(	O
A	O
"),"	O
and	O
DHA	B-Chemical
or	O
EPA	B-Chemical
(	O
B	O
)	O
were	O
measured	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
analyses	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
4	O
animals	O
.	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
","	O
compared	O
with	O
each	O
corresponding	O
control	O
.	O
Effects	O
of	O
DHA	B-Chemical
and	O
EPA	B-Chemical
on	O
Intracellular	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
or	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
Production	O
in	O
Vascular	O
Endothelial	O
Cells	O
Intracellular	O
concentrations	O
of	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
and	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
were	O
measured	O
6	O
h	O
after	O
the	O
treatment	O
of	O
HUVECs	O
with	O
DHA	B-Chemical
or	O
EPA	B-Chemical
","	O
using	O
LC	O
-	O
MS	O
/	O
MS	O
analyses	O
.	O
Fig	O
.	O
3A	O
and	O
3B	O
show	O
their	O
respective	O
intracellular	O
concentrations	O
.	O
Cells	O
incubated	O
with	O
DHA	B-Chemical
showed	O
a	O
significant	O
increase	O
in	O
intracellular	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
","	O
and	O
a	O
significant	O
decrease	O
in	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
.	O
In	O
contrast	O
","	O
EPA	B-Chemical
did	O
not	O
affect	O
the	O
intracellular	O
levels	O
of	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
or	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
.	O
The	O
stock	O
solution	O
of	O
BSA	O
-	O
conjugated	O
DHA	B-Chemical
used	O
for	O
the	O
experiment	O
was	O
confirmed	O
to	O
be	O
free	O
of	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
","	O
suggesting	O
that	O
the	O
production	O
of	O
these	O
peroxidation	O
products	O
occurred	O
in	O
the	O
cells	O
(	O
data	O
not	O
shown	O
).	O
Effect	O
of	O
DHA	B-Chemical
on	O
intracellular	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
and	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
levels	O
","	O
or	O
Nrf2	O
activation	O
in	O
HUVECs	O
.	O
(	O
A	O
","	O
B	O
)	O
HUVECs	O
were	O
incubated	O
with	O
75	O
ÂµM	O
DHA	B-Chemical
or	O
EPA	B-Chemical
for	O
6	O
h	O
.	O
The	O
concentrations	O
of	O
intracellular	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
or	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
were	O
measured	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
analyses	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
6	O
â€“	O
8	O
experiments	O
.	O
(	O
C	O
)	O
HUVECs	O
were	O
cotransfected	O
with	O
a	O
reporter	O
plasmid	O
(	O
pGL4	O
.	O
27	O
(	O
Nrf2	O
-	O
luc2P	O
/	O
minP	O
/	O
Hygro	O
))	O
and	O
a	O
control	O
plasmid	O
(	O
pRL	O
-	O
TK	O
).	O
After	O
transfection	O
","	O
HUVECs	O
were	O
incubated	O
with	O
DHA	B-Chemical
","	O
EPA	B-Chemical
or	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
for	O
16	O
h	O
.	O
The	O
ratio	O
(	O
reporter	O
/	O
control	O
luciferase	O
activity	O
)	O
obtained	O
from	O
control	O
cell	O
lysate	O
was	O
set	O
at	O
1	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
four	O
experiments	O
.	O
(	O
D	O
","	O
E	O
)	O
HUVECs	O
were	O
incubated	O
with	O
75	O
ÂµM	O
of	O
DHA	B-Chemical
or	O
EPA	B-Chemical
for	O
6	O
h	O
.	O
(	O
D	O
)	O
Nuclear	O
lysates	O
were	O
subjected	O
to	O
western	O
blotting	O
analyses	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
three	O
experiments	O
.	O
(	O
E	O
)	O
Analysis	O
of	O
the	O
binding	O
of	O
Nrf2	O
in	O
nuclear	O
lysates	O
to	O
its	O
consensus	O
oligonucleotide	B-Chemical
was	O
performed	O
using	O
the	O
ELISA	O
-	O
based	O
TransAM	O
Nrf2	O
kit	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
four	O
experiments	O
.	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
","	O
compared	O
with	O
each	O
corresponding	O
control	O
.	O
Activation	O
of	O
Nrf2	O
by	O
DHA	B-Chemical
or	O
EPA	B-Chemical
Luciferase	O
activities	O
of	O
DHA	B-Chemical
","	O
EPA	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
were	O
evaluated	O
in	O
HUVECs	O
using	O
an	O
ARE	O
-	O
loaded	O
luciferase	O
expression	O
plasmid	O
.	O
DHA	B-Chemical
showed	O
significant	O
and	O
dose	O
-	O
dependent	O
ARE	O
-	O
luciferase	O
activity	O
","	O
as	O
did	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
.	O
However	O
","	O
EPA	B-Chemical
had	O
no	O
effect	O
on	O
the	O
luciferase	O
activity	O
(	O
Fig	O
.	O
3C	O
).	O
Translocation	O
of	O
Nrf2	O
to	O
the	O
nucleus	O
was	O
evaluated	O
by	O
western	O
blotting	O
analysis	O
of	O
Nrf2	O
in	O
the	O
nuclear	O
fraction	O
.	O
As	O
shown	O
in	O
Fig	O
.	O
3D	O
","	O
treatment	O
with	O
DHA	B-Chemical
increased	O
Nrf2	O
in	O
the	O
nuclear	O
lysate	O
","	O
while	O
the	O
effect	O
of	O
EPA	B-Chemical
was	O
much	O
lower	O
than	O
that	O
of	O
DHA	B-Chemical
.	O
The	O
binding	O
activity	O
of	O
Nrf2	O
to	O
its	O
consensus	O
oligonucleotide	B-Chemical
was	O
significantly	O
increased	O
by	O
stimulation	O
with	O
DHA	B-Chemical
","	O
but	O
not	O
increased	O
by	O
stimulation	O
with	O
EPA	B-Chemical
(	O
Fig	O
.	O
3E	O
).	O
However	O
","	O
DHA	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
had	O
no	O
effect	O
on	O
Nrf2	O
mRNA	O
expression	O
(	O
Fig	O
.	O
4D	O
).	O
Effects	O
of	O
DHA	B-Chemical
","	O
EPA	B-Chemical
or	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
on	O
HO	O
-	O
1	O
","	O
GCLM	O
or	O
p62	O
expression	O
in	O
HUVECs	O
.	O
(	O
A	O
â€“	O
D	O
)	O
HUVECs	O
were	O
incubated	O
with	O
DHA	B-Chemical
","	O
EPA	B-Chemical
or	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
for	O
6	O
h	O
.	O
The	O
relative	O
mRNA	O
expressions	O
of	O
HO	O
-	O
1	O
","	O
GCLM	O
","	O
p62	O
or	O
Nrf2	O
were	O
quantitated	O
using	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
3	O
experiments	O
.	O
(	O
E	O
)	O
HUVECs	O
were	O
incubated	O
with	O
DHA	B-Chemical
","	O
EPA	B-Chemical
or	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
for	O
6	O
h	O
.	O
Total	O
cell	O
lysates	O
were	O
subjected	O
to	O
western	O
blotting	O
analyses	O
.	O
(	O
F	O
","	O
G	O
)	O
HUVECs	O
were	O
treated	O
with	O
Nrf2	O
siRNA	O
or	O
control	O
siRNA	O
","	O
and	O
incubated	O
for	O
48	O
h	O
.	O
(	O
F	O
)	O
The	O
relative	O
mRNA	O
expression	O
of	O
Nrf2	O
was	O
analyzed	O
quantitatively	O
using	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
four	O
experiments	O
.	O
(	O
G	O
)	O
Whole	O
cell	O
lysates	O
were	O
subjected	O
to	O
western	O
blotting	O
analyses	O
.	O
(	O
H	O
â€“	O
K	O
)	O
HUVECs	O
were	O
transfected	O
with	O
Nrf2	O
siRNA	O
or	O
control	O
siRNA	O
.	O
(	O
H	O
â€“	O
J	O
)	O
After	O
48	O
h	O
","	O
the	O
cells	O
were	O
incubated	O
with	O
DHA	B-Chemical
for	O
a	O
further	O
6	O
h	O
.	O
The	O
relative	O
mRNA	O
expressions	O
of	O
HO	O
-	O
1	O
","	O
GCLM	O
or	O
p62	O
were	O
quantitated	O
using	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
3	O
experiments	O
.	O
(	O
K	O
)	O
32	O
-	O
h	O
after	O
transfection	O
","	O
the	O
cells	O
were	O
incubated	O
with	O
DHA	B-Chemical
(	O
50	O
ÂµM	O
)	O
or	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
(	O
5	O
ÂµM	O
)	O
for	O
a	O
further	O
16	O
h	O
.	O
Whole	O
cell	O
lysates	O
were	O
subjected	O
to	O
western	O
blotting	O
analyses	O
.	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
","	O
compared	O
with	O
each	O
corresponding	O
control	O
","	O
â€ â€ â€ 	O
P	O
<	O
0	O
.	O
1	O
","	O
compared	O
with	O
the	O
corresponding	O
cells	O
treated	O
with	O
control	O
siRNA	O
.	O
Effects	O
of	O
DHA	B-Chemical
and	O
EPA	B-Chemical
on	O
Expressions	O
of	O
Nrf2	O
Target	O
Gene	O
Because	O
DHA	B-Chemical
but	O
not	O
EPA	B-Chemical
clearly	O
activated	O
Nrf2	O
","	O
the	O
effects	O
of	O
DHA	B-Chemical
","	O
EPA	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
on	O
the	O
expression	O
of	O
Nrf2	O
target	O
genes	O
were	O
investigated	O
in	O
HUVECs	O
.	O
As	O
shown	O
in	O
Fig	O
.	O
4A	O
","	O
4B	O
and	O
4C	O
","	O
both	O
DHA	B-Chemical
(	O
25	O
â€“	O
75	O
ÂµM	O
)	O
and	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
(	O
2	O
.	O
5	O
â€“	O
5	O
ÂµM	O
)	O
dose	O
-	O
dependently	O
increased	O
the	O
mRNA	O
expressions	O
of	O
HO	O
-	O
1	O
","	O
GCLM	O
and	O
p62	O
","	O
those	O
of	O
which	O
contain	O
an	O
ARE	O
in	O
their	O
genes	O
.	O
DHA	B-Chemical
and	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
also	O
markedly	O
increased	O
the	O
protein	O
expressions	O
of	O
HO	O
-	O
1	O
","	O
GCLM	O
and	O
p62	O
(	O
Fig	O
.	O
4E	O
).	O
The	O
impact	O
of	O
EPA	B-Chemical
on	O
these	O
effects	O
was	O
much	O
lower	O
than	O
that	O
of	O
DHA	B-Chemical
at	O
the	O
same	O
concentration	O
.	O
Nrf2	O
-	O
dependence	O
on	O
DHA	B-Chemical
-	O
induced	O
HO	O
-	O
1	O
","	O
GCLM	O
or	O
p62	O
Expression	O
in	O
HUVECs	O
To	O
determine	O
the	O
role	O
of	O
Nrf2	O
in	O
the	O
induction	O
of	O
HO	O
-	O
1	O
","	O
GCLM	O
and	O
p62	O
by	O
DHA	B-Chemical
","	O
HUVECs	O
were	O
treated	O
with	O
either	O
Nrf2	O
siRNA	O
or	O
control	O
siRNA	O
.	O
The	O
expression	O
of	O
Nrf2	O
mRNA	O
in	O
cells	O
treated	O
with	O
Nrf2	O
siRNA	O
was	O
reduced	O
by	O
approximately	O
87	O
%	O
(	O
Fig	O
.	O
4F	O
"),"	O
while	O
Nrf2	O
protein	O
expression	O
in	O
whole	O
cell	O
lysate	O
was	O
also	O
markedly	O
suppressed	O
(	O
Fig	O
.	O
4G	O
).	O
As	O
shown	O
in	O
Fig	O
.	O
4H	O
","	O
4I	O
and	O
4J	O
","	O
the	O
increases	O
in	O
HO	O
-	O
1	O
","	O
GCLM	O
or	O
p62	O
mRNA	O
expression	O
caused	O
by	O
DHA	B-Chemical
were	O
significantly	O
suppressed	O
by	O
Nrf2	O
knockdown	O
.	O
Similarly	O
","	O
knockdown	O
of	O
Nrf2	O
also	O
reduced	O
DHA	B-Chemical
-	O
as	O
well	O
as	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
-	O
induced	O
protein	O
expressions	O
of	O
HO	O
-	O
1	O
","	O
GCLM	O
and	O
p62	O
(	O
Fig	O
.	O
4K	O
).	O
Preventive	O
Effects	O
of	O
DHA	B-Chemical
on	O
Oxidative	O
Stress	O
-	O
induced	O
Cellular	O
Damage	O
Cytoprotective	O
effects	O
of	O
DHA	B-Chemical
against	O
tBHP	B-Chemical
-	O
induced	O
oxidative	O
stress	O
were	O
investigated	O
in	O
HUVECs	O
.	O
Fig	O
.	O
5A	O
shows	O
cell	O
viability	O
assessed	O
using	O
the	O
MTT	B-Chemical
assay	O
6	O
h	O
after	O
the	O
induction	O
of	O
oxidative	O
stress	O
by	O
tBHP	B-Chemical
.	O
Treatment	O
with	O
tBHP	B-Chemical
(	O
250	O
and	O
500	O
ÂµM	O
)	O
showed	O
dose	O
-	O
dependent	O
cell	O
toxicity	O
","	O
while	O
pretreatment	O
with	O
DHA	B-Chemical
for	O
16	O
h	O
significantly	O
protected	O
against	O
tBHP	B-Chemical
-	O
induced	O
cytotoxicity	O
dose	O
-	O
dependently	O
.	O
Antioxidant	O
effects	O
of	O
DHA	B-Chemical
in	O
HUVECs	O
.	O
(	O
A	O
)	O
HUVECs	O
were	O
pretreated	O
with	O
DHA	B-Chemical
for	O
16	O
h	O
","	O
and	O
then	O
stimulated	O
with	O
tBHP	B-Chemical
(	O
250	O
or	O
500	O
ÂµM	O
)	O
for	O
6	O
h	O
.	O
Cell	O
viability	O
was	O
determined	O
by	O
MTT	B-Chemical
assay	O
.	O
Values	O
are	O
expressed	O
as	O
percentage	O
of	O
cell	O
survival	O
","	O
and	O
each	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
4	O
experiments	O
.	O
(	O
B	O
","	O
C	O
)	O
HUVECs	O
were	O
incubated	O
with	O
DHA	B-Chemical
(	O
75	O
ÂµM	O
)	O
for	O
16	O
h	O
.	O
GSH	B-Chemical
concentration	O
(	O
B	O
)	O
and	O
ratio	O
of	O
GSH	B-Chemical
/	O
GSSG	B-Chemical
(	O
C	O
)	O
were	O
determined	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
7	O
experiments	O
.	O
(	O
D	O
)	O
HUVECs	O
were	O
pretreated	O
with	O
DHA	B-Chemical
(	O
75	O
ÂµM	O
)	O
for	O
16	O
h	O
","	O
and	O
exposed	O
to	O
tBHP	B-Chemical
(	O
250	O
or	O
500	O
ÂµM	O
).	O
ROS	B-Chemical
released	O
from	O
cells	O
was	O
determined	O
at	O
different	O
time	O
intervals	O
over	O
2	O
-	O
h	O
period	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
8	O
experiments	O
.	O
***	O
P	O
<	O
0	O
.	O
1	O
","	O
compared	O
with	O
tBHP	B-Chemical
-	O
treated	O
BSA	O
control	O
","	O
â€ â€ â€ 	O
P	O
<	O
0	O
.	O
1	O
","	O
compared	O
with	O
tBHP	B-Chemical
-	O
untreated	O
BSA	O
control	O
.	O
Effects	O
of	O
DHA	B-Chemical
on	O
Redox	O
Homeostasis	O
or	O
Oxidative	O
Stress	O
-	O
induced	O
ROS	B-Chemical
Production	O
in	O
HUVECs	O
Fig	O
.	O
5B	O
and	O
5C	O
show	O
the	O
intracellular	O
GSH	B-Chemical
concentration	O
and	O
the	O
GSH	B-Chemical
/	O
GSSG	B-Chemical
ratio	O
","	O
respectively	O
.	O
Treatment	O
with	O
DHA	B-Chemical
for	O
16	O
h	O
significantly	O
increased	O
intracellular	O
GSH	B-Chemical
concentration	O
1	O
.	O
5	O
fold	O
compared	O
with	O
BSA	O
control	O
without	O
changing	O
the	O
GSH	B-Chemical
/	O
GSSG	B-Chemical
ratio	O
.	O
Furthermore	O
","	O
to	O
investigate	O
the	O
ability	O
of	O
DHA	B-Chemical
to	O
reduce	O
oxidative	O
stress	O
","	O
we	O
assessed	O
ROS	B-Chemical
production	O
from	O
tBHP	B-Chemical
-	O
treated	O
HUVECs	O
.	O
Treatment	O
with	O
tBHP	B-Chemical
(	O
250	O
and	O
500	O
ÂµM	O
)	O
increased	O
ROS	B-Chemical
production	O
dose	O
-	O
dependently	O
as	O
shown	O
in	O
Fig	O
.	O
5D	O
","	O
while	O
pretreatment	O
with	O
DHA	B-Chemical
for	O
16	O
h	O
significantly	O
suppressed	O
the	O
intracellular	O
ROS	B-Chemical
production	O
caused	O
by	O
both	O
concentrations	O
of	O
tBHP	B-Chemical
tested	O
.	O
HO	O
-	O
1	O
-	O
or	O
Nrf2	O
-	O
dependence	O
on	O
Antioxidant	O
Effects	O
of	O
DHA	B-Chemical
in	O
HUVECs	O
To	O
determine	O
the	O
role	O
of	O
HO	O
-	O
1	O
activity	O
in	O
the	O
antioxidant	O
effects	O
of	O
DHA	B-Chemical
","	O
HUVECs	O
were	O
treated	O
with	O
ZnPP	B-Chemical
","	O
an	O
inhibitor	O
of	O
HO	O
-	O
1	O
activity	O
.	O
Treatment	O
with	O
250	O
ÂµM	O
tBHP	B-Chemical
for	O
24	O
h	O
increased	O
LDH	O
leakage	O
into	O
the	O
culture	O
medium	O
","	O
and	O
DHA	B-Chemical
showed	O
preventive	O
effects	O
on	O
tBHP	B-Chemical
-	O
induced	O
LDH	O
leakage	O
.	O
Under	O
these	O
conditions	O
","	O
the	O
effect	O
of	O
DHA	B-Chemical
was	O
abolished	O
by	O
treatment	O
with	O
5	O
ÂµM	O
ZnPP	B-Chemical
(	O
Fig	O
.	O
6A	O
).	O
In	O
addition	O
","	O
HUVECs	O
treated	O
with	O
the	O
siRNA	O
targeted	O
against	O
Nrf2	O
were	O
exposed	O
to	O
tBHP	B-Chemical
(	O
250	O
or	O
500	O
ÂµM	O
)	O
after	O
treatment	O
with	O
DHA	B-Chemical
for	O
16	O
h	O
.	O
As	O
shown	O
in	O
Fig	O
.	O
6B	O
and	O
6D	O
","	O
pretreatment	O
of	O
DHA	B-Chemical
significantly	O
suppressed	O
tBHP	B-Chemical
-	O
induced	O
cell	O
toxicity	O
or	O
ROS	B-Chemical
production	O
in	O
the	O
cells	O
treated	O
with	O
control	O
siRNA	O
","	O
but	O
these	O
effects	O
of	O
DHA	B-Chemical
were	O
disappeared	O
in	O
the	O
cells	O
treated	O
with	O
the	O
siRNA	O
for	O
Nrf2	O
.	O
Furthermore	O
","	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
showed	O
similar	O
Nrf2	O
-	O
mediated	O
effects	O
of	O
DHA	B-Chemical
(	O
Fig	O
.	O
6C	O
"),"	O
suggesting	O
that	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
derived	O
from	O
DHA	B-Chemical
protected	O
cells	O
from	O
oxidative	O
stress	O
through	O
Nrf2	O
-	O
HO	O
-	O
1	O
signaling	O
.	O
Effects	O
of	O
HO	O
-	O
1	O
inhibition	O
and	O
Nrf2	O
knockdown	O
on	O
antioxidant	O
effects	O
of	O
DHA	B-Chemical
or	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
.	O
(	O
A	O
)	O
HUVECs	O
were	O
pretreated	O
in	O
the	O
presence	O
of	O
DHA	B-Chemical
(	O
75	O
ÂµM	O
)	O
with	O
or	O
without	O
ZnPP	B-Chemical
(	O
5	O
ÂµM	O
)	O
for	O
16	O
h	O
","	O
and	O
stimulated	O
with	O
tBHP	B-Chemical
(	O
250	O
ÂµM	O
)	O
for	O
24	O
h	O
.	O
LDH	O
in	O
the	O
supernatant	O
of	O
culture	O
media	O
was	O
quantitatively	O
analyzed	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
6	O
experiments	O
.	O
(	O
B	O
â€“	O
D	O
)	O
HUVECs	O
were	O
transfected	O
with	O
Nrf2	O
siRNA	O
and	O
control	O
siRNA	O
","	O
respectively	O
.	O
32	O
-	O
h	O
later	O
","	O
they	O
were	O
incubated	O
with	O
DHA	B-Chemical
(	O
75	O
ÂµM	O
)	O
or	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
(	O
5	O
or	O
10	O
ÂµM	O
)	O
for	O
additional	O
16	O
h	O
","	O
and	O
then	O
exposed	O
to	O
tBHP	B-Chemical
(	O
250	O
or	O
500	O
ÂµM	O
).	O
(	O
B	O
","	O
C	O
)	O
Cell	O
viability	O
6	O
-	O
h	O
after	O
tBHP	B-Chemical
treatment	O
was	O
measured	O
by	O
MTT	B-Chemical
assay	O
.	O
Values	O
are	O
expressed	O
as	O
percentage	O
of	O
cell	O
survival	O
","	O
and	O
each	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
3	O
â€“	O
4	O
experiments	O
.	O
(	O
D	O
)	O
tBHP	B-Chemical
(	O
500	O
ÂµM	O
)-	O
induced	O
ROS	B-Chemical
release	O
was	O
measured	O
at	O
different	O
time	O
intervals	O
over	O
2	O
-	O
h	O
period	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
4	O
experiments	O
.	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
","	O
compared	O
with	O
tBHP	B-Chemical
-	O
treated	O
corresponding	O
control	O
","	O
â€ â€ â€ 	O
P	O
<	O
0	O
.	O
1	O
","	O
compared	O
with	O
tBHP	B-Chemical
-	O
untreated	O
BSA	O
control	O
.	O
Investigation	O
of	O
the	O
Molecular	O
Mechanisms	O
of	O
DHA	B-Chemical
-	O
induced	O
HO	O
-	O
1	O
Expression	O
in	O
HUVECs	O
To	O
explore	O
the	O
molecular	O
mechanisms	O
of	O
DHA	B-Chemical
on	O
Nrf2	O
activation	O
","	O
we	O
investigated	O
the	O
pathway	O
upstream	O
of	O
Nrf2	O
activation	O
.	O
First	O
","	O
HUVECs	O
were	O
transfected	O
with	O
either	O
PPARÎ±	O
siRNA	O
or	O
control	O
siRNA	O
.	O
Fig	O
.	O
7A	O
shows	O
the	O
knockdown	O
efficiency	O
of	O
mRNA	O
by	O
PPARÎ±	O
siRNA	O
.	O
The	O
expression	O
of	O
PPARÎ±	O
mRNA	O
in	O
the	O
cells	O
treated	O
with	O
PPARÎ±	O
siRNA	O
was	O
reduced	O
by	O
approximately	O
87	O
%.	O
However	O
","	O
DHA	B-Chemical
-	O
induced	O
expression	O
of	O
HO	O
-	O
1	O
mRNA	O
was	O
not	O
reduced	O
in	O
the	O
PPARÎ±	O
knockdown	O
HUVECs	O
(	O
Fig	O
.	O
7B	O
).	O
Second	O
","	O
HUVECs	O
were	O
treated	O
with	O
several	O
cyclooxygenase	O
(	O
COX	O
)	O
inhibitors	O
or	O
antioxidants	O
","	O
and	O
DHA	B-Chemical
-	O
induced	O
expression	O
of	O
HO	O
-	O
1	O
mRNA	O
was	O
examined	O
.	O
As	O
shown	O
in	O
Fig	O
.	O
7C	O
â€“	O
E	O
","	O
inhibitors	O
of	O
COX1	O
or	O
COX2	O
","	O
as	O
well	O
as	O
radical	O
scavengers	O
such	O
as	O
BHT	B-Chemical
and	O
Î±	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
","	O
did	O
not	O
reduce	O
DHA	B-Chemical
-	O
induced	O
expression	O
of	O
HO	O
-	O
1	O
mRNA	O
.	O
In	O
contrast	O
","	O
NAC	B-Chemical
","	O
which	O
is	O
the	O
most	O
bioavailable	O
precursor	O
of	O
glutathione	B-Chemical
","	O
significantly	O
reduced	O
the	O
expression	O
of	O
HO	O
-	O
1	O
mRNA	O
induced	O
by	O
DHA	B-Chemical
or	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
(	O
as	O
shown	O
in	O
Fig	O
.	O
7F	O
).	O
Effects	O
of	O
PPARÎ±	O
siRNA	O
","	O
COX	O
inhibitors	O
or	O
antioxidants	O
on	O
DHA	B-Chemical
-	O
or	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
-	O
induced	O
HO	O
-	O
1	O
mRNA	O
expression	O
.	O
(	O
A	O
)	O
HUVECs	O
were	O
treated	O
with	O
PPARÎ±	O
siRNA	O
or	O
control	O
siRNA	O
","	O
and	O
incubated	O
for	O
48	O
h	O
.	O
The	O
relative	O
mRNA	O
expression	O
of	O
PPARÎ±	O
was	O
quantitated	O
using	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
three	O
experiments	O
.	O
(	O
B	O
)	O
HUVECs	O
were	O
transfected	O
with	O
siRNA	O
targeted	O
against	O
PPARÎ±	O
or	O
control	O
siRNA	O
.	O
After	O
48	O
h	O
","	O
the	O
cells	O
were	O
incubated	O
with	O
DHA	B-Chemical
(	O
25	O
ÂµM	O
)	O
for	O
a	O
further	O
6	O
h	O
.	O
The	O
relative	O
mRNA	O
expression	O
was	O
analyzed	O
quantitatively	O
using	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
three	O
experiments	O
.	O
(	O
C	O
â€“	O
F	O
)	O
HUVECs	O
were	O
pretreated	O
in	O
the	O
presence	O
of	O
indomethacin	B-Chemical
(	O
10	O
ÂµM	O
"),"	O
NS	B-Chemical
-	I-Chemical
398	I-Chemical
(	O
1	O
ÂµM	O
"),"	O
SC	B-Chemical
-	I-Chemical
58125	I-Chemical
(	O
1	O
ÂµM	O
"),"	O
BHT	B-Chemical
(	O
100	O
ÂµM	O
"),"	O
Î±	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
(	O
100	O
ÂµM	O
)	O
or	O
NAC	B-Chemical
(	O
5	O
mM	O
)	O
for	O
1	O
h	O
","	O
and	O
stimulated	O
with	O
DHA	B-Chemical
(	O
25	O
ÂµM	O
)	O
or	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
(	O
5	O
ÂµM	O
)	O
for	O
6	O
h	O
.	O
The	O
relative	O
mRNA	O
expression	O
was	O
quantitated	O
using	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O
Each	O
value	O
represents	O
the	O
mean	O
Â±	O
SE	O
of	O
3	O
â€“	O
5	O
experiments	O
.	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
compared	O
with	O
the	O
control	O
cells	O
treated	O
with	O
control	O
siRNA	O
","	O
â€ â€ 	O
P	O
<	O
0	O
.	O
1	O
","	O
â€ â€ â€ 	O
P	O
<	O
0	O
.	O
1	O
","	O
compared	O
with	O
NAC	B-Chemical
-	O
untreated	O
corresponding	O
cells	O
.	O
Discussion	O
Recent	O
studies	O
have	O
shown	O
that	O
dietary	O
fish	O
oil	O
can	O
increase	O
Nrf2	O
target	O
genes	O
including	O
HO	O
-	O
1	O
in	O
the	O
heart	O
or	O
kidney	O
","	O
.	O
It	O
has	O
also	O
been	O
reported	O
that	O
the	O
suppressive	O
effects	O
of	O
EPA	B-Chemical
and	O
DHA	B-Chemical
on	O
LPS	B-Chemical
-	O
induced	O
expression	O
of	O
inflammatory	O
molecules	O
in	O
isolated	O
peritoneal	O
macrophages	O
were	O
not	O
observed	O
in	O
macrophages	O
isolated	O
from	O
Nrf2	O
âˆ’/âˆ’	O
mice	O
.	O
Furthermore	O
","	O
more	O
recent	O
study	O
has	O
demonstrated	O
that	O
DHA	B-Chemical
activates	O
Nrf2	O
-	O
HO	O
-	O
1	O
pathway	O
","	O
resulting	O
in	O
inhibition	O
of	O
NFÎºB	O
-	O
mediated	O
endothelial	O
inflammation	O
.	O
Although	O
these	O
studies	O
suggest	O
that	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
might	O
have	O
Nrf2	O
-	O
mediated	O
atheroprotective	O
activities	O
","	O
Nrf2	O
-	O
dependent	O
increases	O
in	O
antioxidant	O
activity	O
and	O
vascular	O
endothelial	O
function	O
by	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
have	O
not	O
been	O
reported	O
.	O
In	O
this	O
study	O
","	O
we	O
demonstrated	O
that	O
a	O
fish	O
-	O
oil	O
diet	O
induced	O
the	O
antioxidant	O
adaptive	O
gene	O
HO	O
-	O
1	O
in	O
aortic	O
tissue	O
","	O
and	O
enhanced	O
vasodilatory	O
responses	O
in	O
an	O
endothelium	O
-	O
dependent	O
manner	O
through	O
the	O
Nrf2	O
signaling	O
pathway	O
.	O
This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
Nrf2	O
-	O
mediated	O
increase	O
in	O
endothelial	O
function	O
by	O
fish	O
oil	O
in	O
vivo	O
.	O
We	O
also	O
showed	O
that	O
dietary	O
fish	O
-	O
oil	O
supplementation	O
increases	O
intra	O
-	O
aortic	O
concentration	O
of	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
as	O
an	O
end	O
-	O
product	O
aldehyde	B-Chemical
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
peroxidation	O
","	O
accompanied	O
by	O
intra	O
-	O
aortic	O
predominant	O
increase	O
in	O
DHA	B-Chemical
rather	O
than	O
that	O
in	O
EPA	B-Chemical
.	O
In	O
addition	O
","	O
we	O
observed	O
that	O
DHA	B-Chemical
","	O
but	O
not	O
EPA	B-Chemical
","	O
causes	O
an	O
increase	O
in	O
intracellular	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
in	O
cultured	O
vascular	O
endothelial	O
cells	O
.	O
Next	O
","	O
we	O
demonstrated	O
that	O
DHA	B-Chemical
","	O
but	O
not	O
EPA	B-Chemical
","	O
induces	O
antioxidant	O
enzymes	O
including	O
HO	O
-	O
1	O
through	O
the	O
activation	O
of	O
Nrf2	O
","	O
resulting	O
in	O
increased	O
antioxidant	O
activity	O
.	O
The	O
present	O
study	O
has	O
also	O
shown	O
that	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
induces	O
HO	O
-	O
1	O
expression	O
through	O
Nrf2	O
activation	O
(	O
as	O
reported	O
in	O
our	O
previous	O
study	O
"),"	O
and	O
increases	O
Nrf2	O
-	O
mediated	O
antioxidant	O
activity	O
as	O
shown	O
in	O
Fig	O
.	O
6C	O
.	O
It	O
has	O
already	O
been	O
reported	O
that	O
plasma	O
levels	O
of	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
were	O
elevated	O
following	O
supplementation	O
with	O
800	O
or	O
1600	O
mg	O
/	O
day	O
DHA	B-Chemical
.	O
Furthermore	O
","	O
protein	O
adducts	O
of	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
have	O
been	O
shown	O
to	O
increase	O
in	O
heart	O
or	O
liver	O
of	O
animals	O
fed	O
an	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFA	I-Chemical
-	O
rich	O
diet	O
","	O
.	O
Thus	O
","	O
we	O
speculated	O
that	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
derived	O
from	O
DHA	B-Chemical
might	O
contribute	O
to	O
the	O
vasculoprotective	O
effect	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
(	O
Fig	O
.	O
8	O
).	O
A	O
schematic	O
figure	O
showing	O
the	O
Nrf2	O
-	O
mediated	O
effects	O
of	O
DHA	B-Chemical
on	O
antioxidant	O
activity	O
and	O
endothelial	O
function	O
in	O
aortic	O
tissue	O
.	O
We	O
observed	O
that	O
DHA	B-Chemical
-	O
induced	O
HO	O
-	O
1	O
mRNA	O
expression	O
was	O
dramatically	O
reduced	O
by	O
treatment	O
with	O
NAC	B-Chemical
","	O
probably	O
because	O
cysteine	B-Chemical
residues	O
in	O
NAC	B-Chemical
binds	O
to	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
","	O
leading	O
to	O
protection	O
of	O
the	O
cysteine	B-Chemical
residues	O
in	O
Keap1	O
","	O
a	O
major	O
regulator	O
of	O
Nrf2	O
protein	O
degradation	O
.	O
We	O
have	O
also	O
shown	O
that	O
BHT	B-Chemical
or	O
Î±	B-Chemical
-	I-Chemical
tocopherol	I-Chemical
","	O
as	O
antioxidants	O
","	O
did	O
not	O
affect	O
the	O
DHA	B-Chemical
-	O
induced	O
mRNA	O
expression	O
of	O
HO	O
-	O
1	O
","	O
suggesting	O
a	O
role	O
of	O
increased	O
intra	O
-	O
vascular	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
by	O
DHA	B-Chemical
in	O
Nrf2	O
-	O
mediated	O
antioxidant	O
abilities	O
.	O
This	O
is	O
also	O
supported	O
by	O
a	O
recent	O
study	O
showing	O
that	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
","	O
a	O
lipid	O
peroxidation	O
product	O
of	O
n	B-Chemical
-	I-Chemical
6	I-Chemical
PUFAs	I-Chemical
","	O
can	O
directly	O
modify	O
cysteine	B-Chemical
residues	O
on	O
Keap1	O
","	O
leading	O
to	O
activation	O
of	O
Nrf2	O
.	O
In	O
contrast	O
","	O
recent	O
studies	O
have	O
proposed	O
the	O
participation	O
of	O
the	O
COX	O
-	O
or	O
lipoxygenase	O
-	O
mediated	O
metabolites	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
","	O
or	O
PPARs	O
and	O
GPR120	O
in	O
the	O
cardioprotective	O
effects	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
","	O
","	O
.	O
Thus	O
","	O
we	O
investigated	O
whether	O
previously	O
reported	O
mechanisms	O
of	O
DHA	B-Chemical
are	O
responsible	O
for	O
Nrf2	O
-	O
mediated	O
expression	O
of	O
HO	O
-	O
1	O
.	O
However	O
","	O
our	O
results	O
showed	O
that	O
COX	O
or	O
PPARÎ±	O
was	O
of	O
little	O
relevance	O
to	O
DHA	B-Chemical
-	O
induced	O
HO	O
-	O
1	O
mRNA	O
expression	O
.	O
We	O
also	O
observed	O
no	O
expression	O
of	O
GPR120	O
in	O
HUVECs	O
(	O
data	O
not	O
shown	O
).	O
Thus	O
","	O
we	O
speculated	O
that	O
intra	O
-	O
vascular	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
produced	O
from	O
DHA	B-Chemical
may	O
directly	O
stimulate	O
Keap1	O
-	O
Nrf2	O
pathway	O
and	O
contribute	O
to	O
the	O
cardioprotective	O
effects	O
of	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
.	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
has	O
been	O
considered	O
to	O
be	O
a	O
toxic	O
lipid	O
peroxidation	O
product	O
similar	O
to	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
","	O
a	O
peroxidation	O
product	O
of	O
n	B-Chemical
-	I-Chemical
6	I-Chemical
PUFAs	I-Chemical
.	O
However	O
","	O
a	O
recent	O
study	O
has	O
shown	O
that	O
intravenous	O
administration	O
of	O
4	B-Chemical
-	I-Chemical
HNE	I-Chemical
protected	O
against	O
cardiac	O
ischemia	O
-	O
reperfusion	O
injury	O
in	O
mice	O
via	O
the	O
Nrf2	O
-	O
dependent	O
pathway	O
.	O
Therefore	O
","	O
it	O
is	O
plausible	O
that	O
lower	O
concentrations	O
of	O
intra	O
-	O
vascular	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
associated	O
with	O
the	O
intake	O
of	O
DHA	B-Chemical
may	O
have	O
a	O
beneficial	O
effect	O
through	O
the	O
preconditioning	O
effect	O
of	O
Keap1	O
-	O
Nrf2	O
signaling	O
.	O
A	O
large	O
scale	O
intervention	O
trial	O
for	O
Japanese	O
with	O
hyper	O
-	O
cholesterolemia	O
has	O
shown	O
that	O
purified	O
EPA	B-Chemical
can	O
significantly	O
reduce	O
total	O
coronary	O
events	O
in	O
a	O
group	O
with	O
a	O
previous	O
history	O
of	O
such	O
events	O
","	O
despite	O
less	O
of	O
an	O
effect	O
on	O
Nrf2	O
activation	O
than	O
seen	O
in	O
our	O
study	O
.	O
This	O
implies	O
that	O
mechanisms	O
other	O
than	O
Nrf2	O
activation	O
contribute	O
to	O
the	O
cardioprotective	O
effects	O
of	O
fish	O
oil	O
-	O
derived	O
n	B-Chemical
-	I-Chemical
3	I-Chemical
PUFAs	I-Chemical
.	O
However	O
","	O
recent	O
studies	O
have	O
proposed	O
different	O
beneficial	O
effects	O
between	O
DHA	B-Chemical
and	O
EPA	B-Chemical
on	O
cardiovascular	O
risk	O
factors	O
.	O
Sekikawa	O
et	O
al	O
.	O
have	O
reported	O
that	O
","	O
in	O
contrast	O
to	O
EPA	B-Chemical
","	O
serum	O
DHA	B-Chemical
levels	O
show	O
a	O
significant	O
inverse	O
correlation	O
to	O
intima	O
-	O
media	O
thickness	O
(	O
IMT	O
)	O
in	O
men	O
aged	O
40	O
to	O
49	O
years	O
in	O
Japan	O
and	O
the	O
United	O
States	O
.	O
Furthermore	O
","	O
it	O
has	O
been	O
demonstrated	O
that	O
in	O
overweight	O
","	O
mildly	O
hyperlipidemic	O
men	O
","	O
DHA	B-Chemical
","	O
but	O
not	O
EPA	B-Chemical
","	O
enhances	O
vasodilatory	O
responses	O
compared	O
with	O
olive	O
oil	O
in	O
the	O
microcirculation	O
of	O
the	O
forearm	O
","	O
although	O
this	O
is	O
predominantly	O
due	O
to	O
endothelial	O
-	O
independent	O
mechanisms	O
.	O
Therefore	O
","	O
it	O
can	O
be	O
considered	O
that	O
Nrf2	O
-	O
mediated	O
antioxidant	O
activity	O
of	O
DHA	B-Chemical
might	O
contribute	O
to	O
clinical	O
cardioprotective	O
effects	O
in	O
a	O
manner	O
different	O
to	O
that	O
of	O
EPA	B-Chemical
.	O
Recent	O
studies	O
have	O
demonstrated	O
that	O
HO	O
-	O
1	O
plays	O
an	O
important	O
role	O
in	O
preventing	O
atherogenesis	O
in	O
vivo	O
â€“.	O
In	O
the	O
present	O
study	O
","	O
we	O
demonstrated	O
that	O
dietary	O
fish	O
oil	O
induced	O
HO	O
-	O
1	O
in	O
a	O
manner	O
that	O
was	O
Nrf2	O
-	O
dependent	O
.	O
The	O
antioxidant	O
effects	O
of	O
DHA	B-Chemical
","	O
as	O
assessed	O
by	O
tBHP	B-Chemical
-	O
induced	O
LDH	O
leakage	O
in	O
HUVECs	O
","	O
were	O
obviously	O
decreased	O
by	O
treatment	O
of	O
ZnPP	B-Chemical
","	O
a	O
HO	O
-	O
1	O
inhibitor	O
","	O
suggesting	O
that	O
Nrf2	O
-	O
HO	O
-	O
1	O
signaling	O
is	O
a	O
critical	O
factor	O
for	O
the	O
antioxidant	O
effects	O
of	O
DHA	B-Chemical
.	O
We	O
have	O
already	O
reported	O
that	O
vascular	O
oxidative	O
stress	O
increased	O
by	O
insulin	O
resistance	O
causes	O
decreased	O
tetrahydrobiopterin	B-Chemical
and	O
increased	O
NADPH	O
oxidase	O
activity	O
","	O
resulting	O
in	O
decreased	O
endothelium	O
-	O
dependent	O
vasorelaxation	O
","	O
.	O
In	O
fact	O
","	O
endothelial	O
-	O
specific	O
increases	O
in	O
HO	O
-	O
1	O
expression	O
have	O
been	O
shown	O
to	O
restore	O
the	O
angiotensin	B-Chemical
II	I-Chemical
-	O
induced	O
reduction	O
in	O
ACh	B-Chemical
-	O
dependent	O
vasorelaxation	O
accompanied	O
by	O
an	O
increase	O
in	O
eNOS	O
phosphorylation	O
.	O
It	O
has	O
also	O
been	O
reported	O
that	O
HO	O
-	O
1	O
induction	O
by	O
cobalt	B-Chemical
protoporphyrin	I-Chemical
","	O
a	O
HO	O
-	O
1	O
inducer	O
","	O
restores	O
high	O
-	O
blood	O
-	O
flow	O
-	O
dependent	O
remodeling	O
and	O
endothelial	O
function	O
in	O
mesenteric	O
arteries	O
of	O
old	O
rats	O
.	O
Therefore	O
","	O
HO	O
-	O
1	O
-	O
mediated	O
reduction	O
in	O
oxidative	O
stress	O
might	O
contribute	O
to	O
the	O
Nrf2	O
-	O
dependent	O
vasodilatory	O
response	O
induced	O
by	O
fish	O
-	O
oil	O
diet	O
in	O
the	O
present	O
study	O
.	O
In	O
conclusion	O
","	O
the	O
present	O
study	O
has	O
demonstrated	O
that	O
a	O
fish	O
-	O
oil	O
diet	O
increased	O
HO	O
-	O
1	O
expression	O
and	O
the	O
endothelium	O
-	O
dependent	O
vasodilatory	O
response	O
through	O
the	O
activation	O
of	O
Nrf2	O
.	O
Furthermore	O
","	O
we	O
have	O
demonstrated	O
that	O
DHA	B-Chemical
","	O
but	O
not	O
EPA	B-Chemical
","	O
is	O
able	O
to	O
increase	O
antioxidant	O
activity	O
through	O
Nrf2	O
-	O
mediated	O
HO	O
-	O
1	O
expression	O
in	O
conjunction	O
with	O
increased	O
intra	O
-	O
vascular	O
4	B-Chemical
-	I-Chemical
HHE	I-Chemical
.	O
Therefore	O
","	O
the	O
present	O
study	O
provides	O
a	O
possible	O
novel	O
explanation	O
for	O
the	O
cardioprotective	O
effects	O
of	O
DHA	B-Chemical
.	O
References	O
Characterization	O
of	O
a	O
Self	O
-	O
sufficient	O
Trans	O
-	O
Anethole	O
Oxygenase	O
from	O
Pseudomonas	O
putida	O
JYR	O
-	O
1	O
A	O
novel	O
flavoprotein	O
monooxygenase	O
","	O
trans	O
-	O
anethole	O
oxygenase	O
(	O
TAO	O
"),"	O
from	O
Pseudomonas	O
putida	O
JYR	O
-	O
1	O
","	O
which	O
is	O
capable	O
of	O
catalyzing	O
the	O
oxidation	O
of	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
to	O
p	B-Chemical
-	I-Chemical
anisaldehyde	I-Chemical
","	O
was	O
heterologously	O
expressed	O
in	O
E	O
.	O
coli	O
and	O
purified	O
.	O
Enzymatic	O
kinetics	O
of	O
diverse	O
substrates	O
and	O
cofactors	O
revealed	O
that	O
TAO	O
is	O
likely	O
to	O
be	O
a	O
novel	O
self	O
-	O
sufficient	O
flavoprotein	O
monooxygenase	O
.	O
Enzyme	O
assays	O
of	O
GST	O
-	O
TAO	O
demonstrated	O
that	O
TAO	O
catalyzed	O
a	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
oxidation	O
reaction	O
without	O
auxiliary	O
component	O
enzyme	O
-	O
like	O
electron	O
-	O
transfer	O
flavin	O
reductases	O
.	O
The	O
single	O
component	O
TAO	O
had	O
the	O
ability	O
to	O
reduce	O
flavin	B-Chemical
cofactors	O
and	O
simultaneously	O
oxidize	O
trans	B-Chemical
-	I-Chemical
anthole	I-Chemical
to	O
p	B-Chemical
-	I-Chemical
anisaldehyde	I-Chemical
.	O
In	O
the	O
processes	O
of	O
reduction	O
of	O
flavin	B-Chemical
and	O
oxidation	O
of	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
","	O
TAO	O
accepted	O
various	O
flavin	B-Chemical
and	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
)	I-Chemical
H	I-Chemical
cofactors	O
.	O
TAO	O
also	O
catalyzed	O
oxidation	O
of	O
isoeugenol	B-Chemical
","	O
O	B-Chemical
-	I-Chemical
methyl	I-Chemical
isoeugenol	I-Chemical
","	O
and	O
isosafrole	B-Chemical
","	O
all	O
of	O
which	O
contain	O
the	O
2	O
-	O
propenyl	O
functional	O
group	O
on	O
the	O
aromatic	O
ring	O
structure	O
with	O
different	O
catalytic	O
efficiency	O
.	O
TAO	O
had	O
the	O
greatest	O
catalytic	O
efficiency	O
(	O
k	O
cat	O
/	O
K	O
m	O
)	O
with	O
the	O
original	O
substrate	O
","	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
.	O
Investigation	O
about	O
partially	O
deleted	O
mutants	O
of	O
TAO	O
indicated	O
that	O
reductase	O
active	O
sites	O
appeared	O
to	O
be	O
located	O
near	O
the	O
N	O
terminal	O
.	O
Site	O
directed	O
mutagenesis	O
studies	O
also	O
proved	O
that	O
the	O
proposed	O
flavin	B-Chemical
binding	O
sites	O
","	O
Trp	B-Chemical
-	O
38	O
","	O
Thr	B-Chemical
-	O
43	O
","	O
Tyr	B-Chemical
-	O
55	O
","	O
were	O
critical	O
for	O
flavin	B-Chemical
reduction	O
.	O
However	O
","	O
disruption	O
of	O
any	O
portion	O
of	O
TAO	O
eliminated	O
the	O
oxygenase	O
activity	O
.	O
Introduction	O
Bacterial	O
oxygenases	O
are	O
important	O
biological	O
catalysts	O
incorporating	O
one	O
or	O
two	O
oxygen	B-Chemical
atoms	O
into	O
organic	O
compounds	O
","	O
which	O
is	O
often	O
very	O
difficult	O
to	O
perform	O
via	O
chemical	O
reactions	O
.	O
The	O
oxygenases	O
activate	O
and	O
functionalize	O
molecular	O
oxygen	B-Chemical
by	O
using	O
a	O
reduced	O
metal	O
or	O
organic	O
cofactor	O
through	O
electron	O
-	O
transfer	O
partners	O
","	O
such	O
as	O
iron	O
-	O
sulfur	O
proteins	O
and	O
flavin	O
reductases	O
.	O
Generally	O
","	O
reducing	O
equivalents	O
are	O
supplied	O
by	O
NADH	B-Chemical
or	O
NADPH	B-Chemical
as	O
electron	O
donors	O
.	O
For	O
example	O
","	O
flavoprotein	O
monooxygenases	O
uses	O
a	O
purely	O
organic	O
cofactor	O
","	O
flavin	B-Chemical
","	O
for	O
oxygenation	O
reactions	O
and	O
utilize	O
a	O
general	O
mechanisms	O
whereby	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
)	I-Chemical
H	I-Chemical
reduces	O
the	O
flavin	B-Chemical
","	O
and	O
the	O
reduced	O
flavin	B-Chemical
reacts	O
with	O
O2	B-Chemical
to	O
form	O
a	O
C4a	O
-(	O
hydro	O
)	O
peroxyflavin	O
intermediate	O
","	O
which	O
is	O
the	O
oxygenation	O
agent	O
.	O
The	O
oxygenation	O
reactions	O
catalyzed	O
by	O
the	O
flavoprotein	O
monooxygenases	O
include	O
hydroxylations	O
","	O
epoxidations	O
","	O
halogenations	O
","	O
Baeyer	O
-	O
Villiger	O
oxidations	O
","	O
sulfoxidations	O
","	O
and	O
oxidations	O
of	O
amines	B-Chemical
","	O
selenide	B-Chemical
","	O
phosphate	B-Chemical
esters	I-Chemical
and	O
organoboron	B-Chemical
.	O
While	O
the	O
flavoprotein	O
monooxygenases	O
are	O
classified	O
into	O
six	O
groups	O
based	O
on	O
sequence	O
and	O
structural	O
data	O
","	O
they	O
can	O
also	O
be	O
divideded	O
into	O
two	O
major	O
classes	O
:	O
single	O
-	O
component	O
(	O
or	O
self	O
-	O
sufficient	O
flavoprotein	O
monooxygenase	O
)	O
and	O
a	O
two	O
-	O
component	O
enzymes	O
composed	O
of	O
a	O
reductase	O
and	O
an	O
oxygenase	O
.	O
Hydroxylation	O
and	O
Baeyer	O
-	O
Villiger	O
type	O
oxidation	O
reactions	O
have	O
been	O
known	O
to	O
be	O
catalyzed	O
by	O
either	O
single	O
-	O
component	O
or	O
two	O
-	O
component	O
flavoprotein	O
monooxygenases	O
â€“.	O
However	O
","	O
an	O
epoxidation	O
reaction	O
","	O
which	O
is	O
a	O
well	O
known	O
process	O
in	O
styrene	B-Chemical
metabolism	O
","	O
is	O
catalyzed	O
by	O
mostly	O
two	O
-	O
component	O
flavoprotein	O
monooxygenases	O
â€“.	O
It	O
should	O
be	O
noted	O
that	O
the	O
self	O
-	O
sufficient	O
enzymes	O
appear	O
to	O
have	O
enhanced	O
catalytic	O
efficiency	O
compared	O
to	O
the	O
separated	O
multi	O
-	O
component	O
enzymes	O
","	O
which	O
physically	O
separate	O
the	O
oxygenase	O
and	O
reductase	O
components	O
.	O
It	O
has	O
been	O
postulated	O
that	O
the	O
closer	O
location	O
between	O
the	O
oxygenase	O
and	O
reductase	O
components	O
in	O
the	O
self	O
-	O
sufficient	O
enzymes	O
results	O
in	O
a	O
reduction	O
in	O
auto	O
-	O
oxidation	O
caused	O
by	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
","	O
such	O
as	O
hydrogen	B-Chemical
peroxide	I-Chemical
","	O
between	O
the	O
two	O
components	O
","	O
.	O
This	O
subsequently	O
results	O
in	O
an	O
increased	O
diffusion	O
of	O
the	O
reduced	O
FAD	B-Chemical
in	O
the	O
interprotein	O
transfer	O
process	O
.	O
Moreover	O
","	O
as	O
expected	O
","	O
the	O
self	O
-	O
sufficient	O
oxygenases	O
are	O
better	O
than	O
the	O
multi	O
-	O
component	O
enzyme	O
systems	O
in	O
terms	O
of	O
practical	O
applications	O
for	O
purifying	O
and	O
immobilizing	O
the	O
enzymes	O
in	O
cell	O
-	O
free	O
systems	O
.	O
For	O
this	O
reason	O
","	O
efforts	O
have	O
been	O
devoted	O
to	O
find	O
novel	O
self	O
-	O
sufficient	O
enzymes	O
or	O
create	O
artificial	O
self	O
-	O
sufficient	O
chimeric	O
proteins	O
that	O
have	O
versatile	O
activities	O
with	O
diverse	O
substrates	O
.	O
We	O
previously	O
reported	O
","	O
the	O
isolation	O
of	O
the	O
tao	O
gene	O
from	O
Pseudomonas	O
putida	O
JYR	O
-	O
1	O
encoding	O
trans	O
-	O
anethole	O
oxygenase	O
(	O
TAO	O
)	O
activity	O
.	O
The	O
enzyme	O
catalyzed	O
the	O
oxidation	O
of	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
","	O
a	O
type	O
of	O
phenylpropanoid	B-Chemical
compound	O
formed	O
via	O
terpene	B-Chemical
biosynthesis	O
in	O
plants	O
","	O
to	O
p	B-Chemical
-	I-Chemical
anisaldehyde	I-Chemical
.	O
Interestingly	O
","	O
whole	O
cell	O
assays	O
done	O
with	O
TAO	O
heterologously	O
expressed	O
in	O
E	O
.	O
coli	O
showed	O
that	O
the	O
enzyme	O
also	O
acted	O
on	O
isoeugenol	B-Chemical
","	O
O	B-Chemical
-	I-Chemical
methyl	I-Chemical
isoeugenol	I-Chemical
","	O
and	O
isosafrole	B-Chemical
as	O
substrates	O
","	O
all	O
of	O
which	O
contain	O
the	O
propenyl	O
functional	O
group	O
on	O
the	O
aromatic	O
ring	O
structure	O
.	O
Compared	O
to	O
the	O
extremely	O
narrow	O
substrate	O
range	O
of	O
isoeugenol	O
monooxygenases	O
","	O
Iem	O
","	O
from	O
Pseudomonas	O
nitroreducens	O
Jin1	O
","	O
and	O
Iso	O
from	O
Pseudomonas	O
putida	O
IE27	O
","	O
that	O
only	O
use	O
isoeugenol	B-Chemical
as	O
a	O
substrate	O
","	O
TAO	O
exhibited	O
a	O
relatively	O
broad	O
substrate	O
range	O
.	O
TAO	O
is	O
likely	O
to	O
be	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
)	I-Chemical
H	I-Chemical
-	O
dependent	O
","	O
even	O
though	O
there	O
was	O
no	O
conserved	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
)	I-Chemical
H	I-Chemical
binding	O
domain	O
found	O
from	O
the	O
deduced	O
amino	B-Chemical
acid	I-Chemical
sequence	O
.	O
Since	O
the	O
TAO	O
from	O
Pseudomonas	O
putida	O
JYR	O
-	O
1	O
displayed	O
very	O
low	O
similarity	O
to	O
the	O
deduced	O
amino	B-Chemical
acid	I-Chemical
sequences	O
of	O
other	O
enzymes	O
in	O
currently	O
available	O
databases	O
","	O
it	O
was	O
thought	O
to	O
be	O
a	O
novel	O
enzyme	O
","	O
worthy	O
of	O
further	O
characterization	O
.	O
In	O
the	O
present	O
study	O
","	O
TAO	O
tagged	O
with	O
glutathione	O
S	O
-	O
transferase	O
was	O
heterologously	O
expressed	O
in	O
E	O
.	O
coli	O
and	O
purified	O
.	O
Enzymatic	O
kinetics	O
of	O
GST	O
-	O
TAO	O
was	O
investigated	O
using	O
diverse	O
substrates	O
and	O
cofactors	O
.	O
Results	O
of	O
these	O
studies	O
indicated	O
that	O
TAO	O
is	O
likely	O
a	O
novel	O
self	O
-	O
sufficient	O
flavoprotein	O
monooxygenase	O
.	O
Materials	O
and	O
Methods	O
Plasmids	O
","	O
bacterial	O
strains	O
","	O
and	O
growth	O
conditions	O
All	O
plasmids	O
and	O
bacterial	O
strains	O
used	O
in	O
this	O
study	O
are	O
listed	O
in	O
Table	O
1	O
.	O
P	O
.	O
putida	O
JYR	O
-	O
1	O
was	O
grown	O
in	O
tryptic	B-Chemical
soy	I-Chemical
broth	I-Chemical
(	O
TSB	B-Chemical
)	O
or	O
Stanier	B-Chemical
'	I-Chemical
s	I-Chemical
minimal	I-Chemical
salt	I-Chemical
broth	I-Chemical
(	O
MSB	B-Chemical
)	O
containing	O
10	O
mM	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
and	O
incubated	O
by	O
rotary	O
shaking	O
at	O
200	O
rpm	O
and	O
25	O
Â°	O
C	O
.	O
E	O
.	O
coli	O
strains	O
EPI100	O
","	O
EC100	O
","	O
DH5Î±	O
","	O
and	O
BL21	O
(	O
DE3	O
)	O
were	O
routinely	O
grown	O
in	O
LB	O
medium	O
and	O
incubated	O
at	O
37	O
Â°	O
C	O
by	O
rotary	O
shaking	O
at	O
200	O
rpm	O
.	O
When	O
required	O
","	O
ampicillin	B-Chemical
(	O
Amp	B-Chemical
)	O
at	O
50	O
Âµg	O
/	O
ml	O
","	O
kanamycin	B-Chemical
(	O
Kan	B-Chemical
)	O
at	O
50	O
Âµg	O
/	O
ml	O
","	O
and	O
chloramphenicol	B-Chemical
(	O
Chl	B-Chemical
)	O
at	O
12	O
.	O
5	O
Âµg	O
/	O
ml	O
were	O
used	O
for	O
selection	O
of	O
recombinant	O
E	O
.	O
coli	O
.	O
Bacterial	O
strains	O
and	O
plasmids	O
used	O
in	O
this	O
study	O
.	O
Chemicals	O
trans	B-Chemical
-	I-Chemical
Anethole	I-Chemical
","	O
para	B-Chemical
-	I-Chemical
anisaldehyde	I-Chemical
","	O
isoeugenol	B-Chemical
","	O
O	B-Chemical
-	I-Chemical
methyl	I-Chemical
isoeugenol	I-Chemical
","	O
isosafrole	B-Chemical
","	O
vanillin	B-Chemical
","	O
veratraldehyde	B-Chemical
","	O
piperonal	B-Chemical
","	O
and	O
3	B-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methoxybenzaldehyde	I-Chemical
were	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
Milwaukee	O
","	O
WI	O
).	O
Stock	O
solutions	O
(	O
100	O
mM	O
)	O
were	O
prepared	O
in	O
methanol	B-Chemical
.	O
All	O
organic	O
solvents	O
were	O
HPLC	O
grade	O
and	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Fair	O
Lawn	O
","	O
NJ	O
).	O
Expression	O
and	O
purification	O
of	O
trans	O
-	O
anethole	O
oxygenase	O
The	O
full	O
length	O
TAO	O
from	O
P	O
.	O
putida	O
JYR	O
-	O
1	O
was	O
subcloned	O
into	O
the	O
BamHI	O
and	O
SalI	O
sites	O
of	O
vector	O
pGEX	O
-	O
5X	O
-	O
1	O
(	O
GE	O
Healthcare	O
","	O
Uppsala	O
","	O
Sweden	O
"),"	O
and	O
contained	O
glutathione	O
S	O
-	O
transferase	O
for	O
the	O
N	O
-	O
terminal	O
tagging	O
","	O
resulting	O
in	O
pGEX	O
-	O
TAO	O
.	O
Expression	O
of	O
GST	O
-	O
TAO	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
)	O
(	O
pGEX	O
-	O
TAO	O
)	O
was	O
induced	O
by	O
adding	O
0	O
.	O
1	O
mM	O
isopropyl	B-Chemical
-	I-Chemical
Î²	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
thiogalactoside	I-Chemical
(	O
IPTG	B-Chemical
)	O
when	O
the	O
culture	O
optical	O
density	O
at	O
600	O
nm	O
reached	O
0	O
.	O
5	O
.	O
Cells	O
were	O
grown	O
for	O
an	O
additional	O
16	O
hr	O
at	O
20	O
Â°	O
C	O
and	O
harvested	O
by	O
centrifugation	O
at	O
10	O
","	O
0	O
Ã—	O
g	O
for	O
10	O
min	O
.	O
The	O
cell	O
pellet	O
was	O
resuspended	O
in	O
the	O
PBS	B-Chemical
buffer	O
(	O
140	O
mM	O
NaCl	B-Chemical
","	O
2	O
.	O
7	O
mM	O
KCl	B-Chemical
","	O
10	O
mM	O
Na2HPO4	B-Chemical
","	O
1	O
.	O
8	O
mM	O
KH2PO4	B-Chemical
","	O
pH	O
7	O
.	O
3	O
)	O
and	O
crude	O
cell	O
extracts	O
were	O
prepared	O
by	O
using	O
an	O
ultrasonic	O
disruptor	O
(	O
Cole	O
-	O
Parmer	O
","	O
Chicago	O
","	O
IL	O
","	O
USA	O
)	O
with	O
70	O
%	O
amplitude	O
for	O
10	O
min	O
(	O
3	O
.	O
0	O
S	O
on	O
and	O
9	O
.	O
0	O
S	O
off	O
).	O
The	O
crude	O
lysate	O
was	O
centrifuged	O
","	O
twice	O
","	O
at	O
18	O
","	O
0	O
Ã—	O
g	O
for	O
30	O
min	O
at	O
4	O
Â°	O
C	O
using	O
PBS	B-Chemical
buffer	O
(	O
pH	O
7	O
.	O
3	O
)	O
and	O
ammonium	B-Chemical
sulfate	I-Chemical
was	O
added	O
to	O
the	O
chilled	O
cell	O
extract	O
","	O
with	O
stirring	O
","	O
to	O
25	O
â€“	O
35	O
%	O
saturation	O
.	O
The	O
precipitate	O
was	O
collected	O
by	O
centrifugation	O
at	O
12	O
","	O
0	O
Ã—	O
g	O
for	O
20	O
min	O
","	O
resuspended	O
in	O
PBS	B-Chemical
buffer	O
(	O
pH	O
7	O
.	O
3	O
"),"	O
and	O
filtered	O
through	O
polyvinylidene	B-Chemical
fluoride	I-Chemical
(	O
PVDF	B-Chemical
)	O
syringe	O
filters	O
(	O
Whatman	O
","	O
Maidstone	O
","	O
England	O
).	O
The	O
filtrate	O
was	O
passed	O
through	O
a	O
Hitrap	O
FF	O
desalting	O
column	O
connected	O
a	O
FPLC	O
system	O
(	O
GE	O
Healthcare	O
","	O
Uppsala	O
","	O
Sweden	O
).	O
The	O
desalted	O
elute	O
was	O
loaded	O
into	O
a	O
GSTrap	O
FF	O
column	O
(	O
GE	O
Healthcare	O
","	O
Uppsala	O
","	O
Sweden	O
"),"	O
which	O
was	O
equilibrated	O
with	O
5	O
column	O
volumes	O
(	O
CV	O
)	O
of	O
PBS	B-Chemical
binding	O
buffer	O
","	O
and	O
washed	O
with	O
10	O
CV	O
of	O
PBS	B-Chemical
binding	O
buffer	O
until	O
no	O
material	O
appeared	O
in	O
the	O
effluent	O
.	O
The	O
GST	O
-	O
tagged	O
trans	O
-	O
anethole	O
oxygenase	O
was	O
eluted	O
with	O
elution	O
buffer	O
(	O
50	O
mM	O
Tris	B-Chemical
-	I-Chemical
HCl	I-Chemical
","	O
20	O
mM	O
reduced	O
glutathione	B-Chemical
","	O
10	O
%	O
glycerol	B-Chemical
","	O
pH	O
8	O
.	O
8	O
)	O
and	O
protein	O
eluting	O
at	O
each	O
step	O
was	O
applied	O
to	O
SDS	B-Chemical
-	O
PAGE	O
and	O
visualized	O
with	O
Coomassie	B-Chemical
Blue	I-Chemical
staining	O
(	O
Figure	O
1	O
).	O
The	O
expression	O
and	O
purification	O
of	O
mutated	O
and	O
partially	O
deleted	O
TAO	O
enzymes	O
(	O
Figure	O
S1	O
in	O
File	O
S1	O
)	O
were	O
processed	O
by	O
using	O
the	O
same	O
methods	O
.	O
Purification	O
of	O
the	O
GST	O
-	O
TAO	O
.	O
Protein	O
samples	O
were	O
analyzed	O
by	O
SDS	B-Chemical
-	O
PAGE	O
at	O
different	O
steps	O
of	O
purification	O
.	O
Legend	O
:	O
M	O
","	O
marker	O
protein	O
;	O
lane	O
1	O
","	O
cell	O
extract	O
;	O
lane	O
2	O
","	O
ammonium	B-Chemical
sulfate	I-Chemical
precipitate	O
;	O
lane	O
3	O
","	O
elute	O
from	O
GSTrap	O
column	O
.	O
The	O
arrow	O
indicates	O
purified	O
GST	O
-	O
TAO	O
.	O
Determination	O
of	O
oxygenase	O
activity	O
of	O
GST	O
-	O
TAO	O
The	O
oxygenase	O
activity	O
of	O
GST	O
-	O
TAO	O
toward	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
","	O
isoeugenol	B-Chemical
","	O
O	B-Chemical
-	I-Chemical
methyl	I-Chemical
isoeugenol	I-Chemical
","	O
and	O
isosafrole	B-Chemical
was	O
measured	O
by	O
quantifying	O
the	O
corresponding	O
aldehyde	B-Chemical
products	O
by	O
using	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
).	O
The	O
standard	O
assay	O
was	O
carried	O
out	O
at	O
30	O
Â°	O
C	O
for	O
1	O
hr	O
","	O
The	O
1	O
ml	O
reaction	O
mixture	O
contained	O
200	O
nM	O
GST	O
-	O
TAO	O
","	O
10	O
mM	O
NADH	B-Chemical
","	O
15	O
ÂµM	O
FAD	B-Chemical
","	O
150	O
mM	O
sodium	B-Chemical
formate	I-Chemical
","	O
0	O
.	O
5	O
U	O
formate	O
dehydrogenase	O
from	O
Candida	O
boidinii	O
(	O
Sigma	O
-	O
Aldrich	O
","	O
Milwaukee	O
","	O
WI	O
"),"	O
20	O
mM	O
Tris	B-Chemical
-	I-Chemical
HCl	I-Chemical
(	O
pH	O
8	O
.	O
0	O
"),"	O
1	O
mM	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
","	O
and	O
1	O
mM	O
3	B-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methoxybenzaldehyde	I-Chemical
as	O
internal	O
standard	O
.	O
The	O
reaction	O
was	O
initiated	O
by	O
substrate	O
addition	O
into	O
reaction	O
mixtures	O
.	O
Five	O
volumes	O
of	O
ethyl	B-Chemical
acetate	I-Chemical
were	O
used	O
to	O
extract	O
the	O
reaction	O
solution	O
.	O
The	O
ethyl	B-Chemical
acetate	I-Chemical
extract	O
was	O
evaporated	O
in	O
a	O
Speed	O
vacuum	O
centrifugal	O
concentrator	O
(	O
Vision	O
Scientific	O
Co	O
".,"	O
Suwon	O
","	O
South	O
Korea	O
"),"	O
the	O
residue	O
was	O
dissolved	O
in	O
1	O
ml	O
methanol	B-Chemical
","	O
and	O
filtered	O
through	O
PVDF	B-Chemical
syringe	O
filters	O
(	O
Whatman	O
","	O
Maidstone	O
","	O
England	O
).	O
The	O
amounts	O
of	O
remaining	O
parent	O
compounds	O
","	O
aldehyde	B-Chemical
product	O
","	O
and	O
internal	O
standard	O
3	B-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
methoxybenzaldehyde	I-Chemical
in	O
the	O
reaction	O
solutions	O
were	O
determined	O
by	O
HPLC	O
.	O
Each	O
metabolite	O
was	O
identified	O
by	O
comparison	O
to	O
its	O
retention	O
time	O
on	O
the	O
HPLC	O
column	O
","	O
and	O
by	O
UV	O
spectrum	O
","	O
compared	O
to	O
corresponding	O
authentic	O
compound	O
.	O
Kinetic	O
parameters	O
of	O
GST	O
-	O
TAO	O
were	O
obtained	O
by	O
using	O
the	O
nonlinear	O
regression	O
method	O
","	O
assuming	O
Michaelis	O
-	O
Menten	O
kinetics	O
.	O
The	O
effect	O
of	O
pH	O
on	O
the	O
activity	O
of	O
GST	O
-	O
TAO	O
was	O
investigated	O
at	O
30	O
Â°	O
C	O
in	O
100	O
mM	O
of	O
sodium	B-Chemical
acetate	I-Chemical
buffer	O
(	O
pH	O
4	O
.	O
0	O
â€“	O
5	O
.	O
8	O
"),"	O
potassium	B-Chemical
phosphate	I-Chemical
(	O
pH	O
6	O
.	O
2	O
â€“	O
8	O
.	O
0	O
"),"	O
Tris	B-Chemical
-	I-Chemical
Cl	I-Chemical
buffer	I-Chemical
(	O
pH	O
8	O
.	O
0	O
â€“	O
9	O
.	O
0	O
"),"	O
and	O
glycine	B-Chemical
-	I-Chemical
NaOH	I-Chemical
buffer	I-Chemical
(	O
pH	O
9	O
.	O
0	O
â€“	O
10	O
.	O
6	O
).	O
The	O
effect	O
of	O
temperature	O
on	O
the	O
activity	O
of	O
GST	O
-	O
TAO	O
was	O
determined	O
by	O
using	O
the	O
standard	O
assay	O
conditions	O
at	O
temperatures	O
between	O
15	O
and	O
50	O
Â°	O
C	O
.	O
Thermal	O
stability	O
of	O
GST	O
-	O
TAO	O
was	O
investigated	O
in	O
20	O
mM	O
Tris	B-Chemical
-	I-Chemical
HCl	I-Chemical
buffer	O
or	O
20	O
mM	O
phosphate	B-Chemical
buffer	O
containing	O
10	O
%	O
glycerol	B-Chemical
and	O
1	O
mM	O
DTT	B-Chemical
.	O
The	O
reaction	O
was	O
incubated	O
at	O
25	O
Â°	O
C	O
for	O
0	O
","	O
12	O
","	O
24	O
","	O
48	O
","	O
72	O
","	O
and	O
96	O
hr	O
and	O
enzyme	O
assays	O
were	O
performed	O
as	O
described	O
above	O
.	O
Determination	O
of	O
reductase	O
activity	O
of	O
GST	O
-	O
TAO	O
Reductase	O
activity	O
of	O
GST	O
-	O
TAO	O
was	O
determined	O
by	O
measuring	O
the	O
consumption	O
of	O
NADH	B-Chemical
.	O
The	O
standard	O
assay	O
contained	O
20	O
mM	O
Tris	B-Chemical
-	I-Chemical
HCl	I-Chemical
(	O
pH	O
8	O
.	O
0	O
"),"	O
200	O
nM	O
GST	O
-	O
TAO	O
","	O
200	O
ÂµM	O
NADH	B-Chemical
","	O
and	O
20	O
ÂµM	O
FAD	B-Chemical
in	O
final	O
volume	O
of	O
1	O
ml	O
.	O
The	O
reaction	O
was	O
initiated	O
by	O
the	O
addition	O
of	O
NADH	B-Chemical
into	O
the	O
solution	O
.	O
Progress	O
of	O
the	O
reaction	O
was	O
monitored	O
","	O
continuously	O
","	O
by	O
following	O
the	O
decrease	O
in	O
absorbance	O
of	O
NADH	B-Chemical
at	O
340	O
nm	O
on	O
a	O
UV	O
-	O
1601PC	O
spectrophotometer	O
(	O
Shimazu	O
Corp	O
".,"	O
Kyoto	O
","	O
Japan	O
).	O
Determination	O
of	O
FAD	B-Chemical
binding	O
to	O
GST	O
-	O
TAO	O
and	O
its	O
mutants	O
The	O
binding	O
of	O
FAD	B-Chemical
to	O
GST	O
-	O
TAO	O
and	O
its	O
mutants	O
was	O
determined	O
by	O
measuring	O
the	O
quantity	O
of	O
unbound	O
FAD	B-Chemical
","	O
which	O
filtered	O
out	O
from	O
the	O
solution	O
containing	O
FAD	B-Chemical
and	O
enzymes	O
.	O
Reaction	O
solutions	O
contained	O
3	O
ÂµM	O
FAD	B-Chemical
and	O
3	O
ÂµM	O
enzyme	O
in	O
0	O
.	O
5	O
mL	O
Tris	B-Chemical
-	I-Chemical
HCl	I-Chemical
buffer	O
(	O
20	O
mM	O
","	O
pH	O
8	O
.	O
0	O
).	O
The	O
solution	O
was	O
incubated	O
at	O
25	O
Â°	O
C	O
for	O
60	O
min	O
","	O
loaded	O
onto	O
a	O
Nanosep	O
device	O
centrifugal	O
filter	O
(	O
Molecular	O
Weight	O
Cutoff	O
(	O
MWCO	O
"),"	O
10K	O
","	O
PALL	O
Corporation	O
","	O
Washington	O
","	O
NY	O
)	O
and	O
centrifuged	O
at	O
14	O
","	O
0	O
Ã—	O
g	O
for	O
20	O
min	O
.	O
The	O
unbound	O
FAD	B-Chemical
was	O
collected	O
and	O
adjusted	O
to	O
0	O
.	O
5	O
mL	O
with	O
Tris	B-Chemical
-	I-Chemical
HCl	I-Chemical
buffer	O
(	O
20	O
mM	O
","	O
pH	O
8	O
.	O
0	O
).	O
The	O
concentration	O
of	O
FAD	B-Chemical
was	O
determined	O
by	O
measuring	O
fluorescence	O
at	O
520	O
nm	O
upon	O
excitation	O
at	O
450	O
nm	O
using	O
a	O
Spectro	O
-	O
fluorometer	O
(	O
Spectramax	O
Gemini	O
XS	O
","	O
Gemini	O
Scientific	O
Corporation	O
","	O
Sunnyvale	O
","	O
CA	O
).	O
Site	O
-	O
directed	O
mutagenesis	O
Mutations	O
of	O
the	O
tao	O
gene	O
in	O
plasmid	O
pGEX	O
-	O
5X	O
-	O
1were	O
introduced	O
by	O
using	O
the	O
QuikChange	O
II	O
Site	O
-	O
Directed	O
Mutagenesis	O
Kit	O
(	O
Agilent	O
Technologies	O
Inc	O
".,"	O
Santa	O
Clara	O
","	O
CA	O
)	O
following	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O
PCR	O
products	O
were	O
digested	O
with	O
DpnI	O
and	O
transformed	O
into	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
)	O
by	O
electroporation	O
.	O
Transformants	O
were	O
selected	O
on	O
LB	B-Chemical
agar	I-Chemical
plates	O
containing	O
Amp	B-Chemical
(	O
50	O
Âµg	O
/	O
ml	O
).	O
Plasmids	O
from	O
transformants	O
were	O
isolated	O
using	O
the	O
Bionner	O
Plasmid	O
Mini	O
Kit	O
(	O
Bionner	O
","	O
Daejeon	O
","	O
South	O
Korea	O
)	O
and	O
the	O
desired	O
mutations	O
were	O
confirmed	O
by	O
DNA	O
sequencing	O
(	O
SolGent	O
","	O
Daejeon	O
","	O
South	O
Korea	O
).	O
Analytical	O
methods	O
Analytical	O
HPLC	O
was	O
performed	O
by	O
using	O
a	O
Varian	O
ProStar	O
HPLC	O
equipped	O
with	O
a	O
photodiode	O
array	O
(	O
PDA	O
)	O
detector	O
(	O
Varian	O
","	O
Walnut	O
Creek	O
","	O
CA	O
)	O
and	O
a	O
reverse	O
phase	O
C18	O
column	O
(	O
5	O
Âµm	O
particle	O
size	O
","	O
4	O
.	O
6	O
mm	O
Ã—	O
25	O
cm	O
","	O
Waters	O
","	O
Milford	O
","	O
MA	O
).	O
The	O
mobile	O
phase	O
","	O
which	O
was	O
composed	O
of	O
acetonitrile	B-Chemical
containing	O
0	O
.	O
1	O
%	O
formic	B-Chemical
acid	I-Chemical
and	O
water	B-Chemical
","	O
was	O
programmed	O
as	O
follows	O
:	O
10	O
%	O
acetonitrile	B-Chemical
at	O
0	O
min	O
","	O
60	O
%	O
acetonitrile	B-Chemical
at	O
10	O
min	O
","	O
90	O
%	O
acetonitrile	B-Chemical
at	O
20	O
min	O
","	O
and	O
90	O
%	O
acetonitrile	B-Chemical
at	O
30	O
min	O
.	O
The	O
injection	O
volume	O
was	O
10	O
ÂµL	O
","	O
the	O
flow	O
rate	O
was	O
1	O
mL	O
/	O
min	O
","	O
and	O
UV	O
detection	O
was	O
performed	O
at	O
270	O
nm	O
.	O
LC	O
/	O
MS	O
was	O
performed	O
by	O
coupling	O
an	O
Alliance	O
2695	O
LC	O
system	O
(	O
Waters	O
Corporation	O
","	O
Milford	O
","	O
MA	O
)	O
to	O
a	O
Quattro	O
LC	O
triple	O
quadrupole	O
tandem	O
mass	O
spectrometer	O
(	O
Waters	O
","	O
Milford	O
","	O
MA	O
)	O
in	O
positive	O
electrospray	O
ionization	O
(	O
ESI	O
+)	O
mode	O
.	O
For	O
LC	O
analysis	O
","	O
a	O
SunFire	O
C18	O
column	O
(	O
3	O
.	O
5	O
Âµm	O
","	O
2	O
.	O
1	O
Ã—	O
150	O
mm	O
","	O
Waters	O
)	O
was	O
used	O
and	O
the	O
mobile	O
phase	O
","	O
elution	O
program	O
","	O
and	O
detection	O
were	O
identical	O
to	O
analytical	O
HPLC	O
described	O
above	O
;	O
except	O
the	O
flow	O
rate	O
was	O
0	O
.	O
2	O
ml	O
/	O
min	O
.	O
For	O
MS	O
analysis	O
","	O
the	O
source	O
temperature	O
","	O
desolvation	O
temperature	O
","	O
and	O
capillary	O
voltage	O
were	O
kept	O
at	O
150	O
Â°	O
C	O
","	O
350	O
Â°	O
C	O
and	O
3	O
.	O
2	O
kV	O
","	O
respectively	O
.	O
The	O
cone	O
voltage	O
was	O
20	O
V	O
.	O
The	O
cone	O
and	O
desolvation	O
gas	O
were	O
ultra	O
-	O
pure	O
nitrogen	B-Chemical
at	O
30	O
and	O
500	O
L	O
/	O
hr	O
","	O
respectively	O
.	O
Protein	O
concentration	O
was	O
determined	O
by	O
using	O
the	O
Bradford	O
assay	O
with	O
the	O
Bio	O
-	O
Rad	O
protein	O
assay	O
kit	O
(	O
Bio	O
-	O
Rad	O
","	O
Richmond	O
","	O
CA	O
)	O
and	O
bovine	O
serum	O
albumin	O
as	O
a	O
standard	O
.	O
All	O
analyses	O
were	O
done	O
in	O
triplicate	O
.	O
Results	O
Expression	O
and	O
purification	O
of	O
recombinant	O
GST	O
-	O
TAO	O
in	O
E	O
.	O
coli	O
Due	O
to	O
the	O
insolubility	O
of	O
recombinant	O
TAO	O
and	O
His6	B-Chemical
-	O
TAO	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
"),"	O
a	O
GST	O
-	O
tagged	O
fusion	O
protein	O
was	O
selected	O
for	O
purifying	O
the	O
TAO	O
enzyme	O
.	O
Recombinant	O
GST	O
-	O
TAO	O
in	O
plasmid	O
pGEX	O
-	O
TAO	O
was	O
found	O
to	O
be	O
mainly	O
in	O
the	O
soluble	O
fraction	O
after	O
induction	O
by	O
using	O
0	O
.	O
1	O
mM	O
IPTG	B-Chemical
at	O
20	O
Â°	O
C	O
for	O
16	O
hours	O
.	O
About	O
23	O
mg	O
of	O
purified	O
GST	O
-	O
TAO	O
was	O
obtained	O
from	O
a	O
2	O
L	O
culture	O
of	O
recombinant	O
E	O
.	O
coli	O
cells	O
(	O
approximately	O
OD600	O
=	O
5	O
.	O
0	O
)	O
using	O
a	O
series	O
of	O
purification	O
steps	O
(	O
Table	O
2	O
).	O
The	O
purification	O
yield	O
was	O
âˆ¼	O
2	O
.	O
8	O
%	O
of	O
total	O
protein	O
.	O
A	O
single	O
","	O
GST	O
-	O
TAO	O
band	O
of	O
68	O
kDa	O
(	O
calculated	O
","	O
26	O
","	O
440	O
Da	O
for	O
GST	O
","	O
and	O
39	O
","	O
328	O
Da	O
for	O
TAO	O
)	O
was	O
successfully	O
observed	O
in	O
SDS	B-Chemical
-	O
PAGE	O
(	O
Figure	O
1	O
).	O
Purification	O
of	O
GST	O
-	O
TAO	O
from	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
)(	O
pGex	O
-	O
TAO	O
).	O
Kinetics	O
and	O
substrate	O
specificity	O
of	O
GST	O
-	O
TAO	O
The	O
catalytic	O
kinetics	O
of	O
GST	O
-	O
TAO	O
were	O
determined	O
by	O
measuring	O
the	O
amount	O
of	O
p	B-Chemical
-	I-Chemical
anisaldehyde	I-Chemical
produced	O
from	O
the	O
substrate	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
.	O
The	O
conversion	O
of	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
to	O
p	B-Chemical
-	I-Chemical
anisaldehyde	I-Chemical
followed	O
Mechaelis	O
-	O
Menton	O
kinetics	O
","	O
with	O
an	O
affinity	O
K	O
m	O
of	O
64	O
.	O
70	O
Â±	O
2	O
.	O
40	O
ÂµM	O
and	O
a	O
turnover	O
number	O
k	O
cat	O
of	O
0	O
.	O
49	O
s	O
âˆ’	O
1	O
(	O
Table	O
3	O
).	O
Under	O
the	O
same	O
conditions	O
","	O
the	O
reaction	O
kinetics	O
of	O
purified	O
GST	O
-	O
TAO	O
using	O
isoeugenol	B-Chemical
","	O
O	B-Chemical
-	I-Chemical
methyl	I-Chemical
isoeugenol	I-Chemical
","	O
or	O
isosafrole	B-Chemical
as	O
substrate	O
were	O
determined	O
by	O
measuring	O
the	O
amount	O
of	O
the	O
corresponding	O
aldehyde	B-Chemical
product	O
as	O
previously	O
reported	O
.	O
Comparisons	O
of	O
the	O
activity	O
of	O
GST	O
-	O
TAO	O
to	O
the	O
four	O
substrates	O
indicated	O
that	O
TAO	O
has	O
the	O
best	O
catalytic	O
efficiency	O
(	O
k	O
cat	O
/	O
K	O
m	O
","	O
7	O
.	O
69	O
mM	O
âˆ’	O
1s	O
âˆ’	O
1	O
)	O
with	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
as	O
substrate	O
.	O
Although	O
GST	O
-	O
TAO	O
has	O
the	O
lowest	O
affinity	O
(	O
K	O
m	O
","	O
2255	O
.	O
0	O
Â±	O
346	O
.	O
48	O
ÂµM	O
)	O
to	O
isoeugenol	B-Chemical
","	O
the	O
highest	O
turnover	O
number	O
(	O
k	O
cat	O
","	O
1	O
.	O
13	O
s	O
âˆ’	O
1	O
)	O
was	O
observed	O
with	O
this	O
substrate	O
.	O
The	O
range	O
of	O
substrate	O
concentrations	O
used	O
in	O
the	O
kinetic	O
assays	O
is	O
from	O
0	O
.	O
1	O
mM	O
to	O
6	O
mM	O
.	O
Kinetics	O
of	O
GST	O
-	O
TAO	O
with	O
different	O
substrates	O
in	O
the	O
presence	O
of	O
NADH	B-Chemical
and	O
FAD	B-Chemical
.	O
Influence	O
of	O
flavin	B-Chemical
and	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
)	I-Chemical
H	I-Chemical
cofactors	O
on	O
GST	O
-	O
TAO	O
activity	O
The	O
activity	O
of	O
GST	O
-	O
TAO	O
with	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
as	O
substrate	O
and	O
different	O
flavin	B-Chemical
and	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
)	I-Chemical
H	I-Chemical
cofactors	O
is	O
shown	O
in	O
Table	O
4	O
.	O
Flavin	B-Chemical
and	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
)	I-Chemical
H	I-Chemical
cofactors	O
were	O
necessary	O
for	O
the	O
activity	O
of	O
GST	O
-	O
TAO	O
.	O
When	O
NADH	B-Chemical
was	O
a	O
hydride	O
donor	O
","	O
the	O
catalytic	O
efficiency	O
of	O
GST	O
-	O
TAO	O
with	O
FAD	B-Chemical
(	O
k	O
cat	O
/	O
K	O
m	O
","	O
7	O
.	O
69	O
mM	O
âˆ’	O
1s	O
âˆ’	O
1	O
)	O
as	O
a	O
flavin	B-Chemical
cofactor	O
was	O
around	O
two	O
-	O
fold	O
greater	O
than	O
that	O
of	O
FMN	B-Chemical
(	O
k	O
cat	O
/	O
K	O
m	O
","	O
3	O
.	O
64	O
mM	O
âˆ’	O
1s	O
âˆ’	O
1	O
)	O
and	O
riboflavin	B-Chemical
(	O
k	O
cat	O
/	O
K	O
m	O
","	O
3	O
.	O
64	O
mM	O
âˆ’	O
1s	O
âˆ’	O
1	O
).	O
The	O
catalytic	O
efficiency	O
of	O
TAO	O
with	O
NADH	B-Chemical
(	O
k	O
cat	O
/	O
K	O
m	O
","	O
7	O
.	O
69	O
mM	O
âˆ’	O
1s	O
âˆ’	O
1	O
)	O
was	O
almost	O
two	O
-	O
fold	O
greater	O
than	O
that	O
of	O
NADPH	B-Chemical
(	O
k	O
cat	O
/	O
K	O
m	O
","	O
4	O
.	O
22	O
mM	O
âˆ’	O
1s	O
âˆ’	O
1	O
).	O
These	O
results	O
indicated	O
that	O
FAD	B-Chemical
and	O
NADH	B-Chemical
were	O
the	O
best	O
combined	O
cofactors	O
in	O
the	O
oxygenation	O
of	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
by	O
GST	O
-	O
TAO	O
(	O
Table	O
4	O
).	O
In	O
addition	O
","	O
the	O
K	O
m	O
values	O
of	O
GST	O
-	O
TAO	O
with	O
FAD	B-Chemical
in	O
the	O
presence	O
of	O
NADH	B-Chemical
and	O
NADPH	B-Chemical
and	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
as	O
substrate	O
were	O
63	O
.	O
7	O
ÂµM	O
and	O
109	O
.	O
5	O
ÂµM	O
","	O
respectively	O
.	O
Since	O
the	O
k	O
cat	O
values	O
of	O
GST	O
-	O
TAO	O
to	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
ranged	O
from	O
0	O
.	O
41	O
to	O
0	O
.	O
52	O
regardless	O
of	O
the	O
cofactor	O
combination	O
used	O
for	O
the	O
reaction	O
","	O
the	O
cofactors	O
appear	O
not	O
to	O
affect	O
turnover	O
numbers	O
of	O
GST	O
-	O
TAO	O
.	O
However	O
","	O
the	O
variable	O
K	O
m	O
values	O
with	O
different	O
flavin	B-Chemical
cofactors	O
indicated	O
that	O
FAD	B-Chemical
is	O
the	O
best	O
flavin	B-Chemical
cofactor	O
for	O
substrate	O
binding	O
.	O
NADH	B-Chemical
was	O
a	O
better	O
hydride	O
donor	O
for	O
FAD	B-Chemical
reduction	O
and	O
the	O
further	O
oxygenation	O
reaction	O
than	O
was	O
NADPH	B-Chemical
.	O
Flavins	B-Chemical
and	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
)	I-Chemical
H	I-Chemical
were	O
15	O
ÂµM	O
and	O
10	O
mM	O
","	O
respectively	O
","	O
for	O
saturation	O
.	O
Effect	O
of	O
flavin	B-Chemical
and	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
)	I-Chemical
H	I-Chemical
cofactors	O
on	O
GST	O
-	O
TAO	O
biotransformation	O
activity	O
using	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
as	O
substrate	O
.	O
Oxygenase	O
and	O
reductase	O
activities	O
of	O
wildtype	O
and	O
partially	O
deleted	O
GST	O
-	O
TAO	O
In	O
order	O
to	O
profile	O
the	O
location	O
of	O
oxygenase	O
and	O
reductase	O
active	O
sites	O
in	O
TAO	O
","	O
a	O
series	O
of	O
partially	O
deleted	O
GST	O
-	O
TAO	O
mutant	O
enzymes	O
were	O
expressed	O
in	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
)	O
and	O
purified	O
using	O
the	O
same	O
method	O
as	O
for	O
wild	O
-	O
type	O
TAO	O
.	O
These	O
mutated	O
enzymes	O
","	O
which	O
partially	O
deleted	O
for	O
either	O
their	O
N	O
-	O
or	O
C	O
-	O
termini	O
","	O
showed	O
significantly	O
reduced	O
bioconversion	O
activity	O
(	O
Table	O
5	O
).	O
The	O
N	O
-	O
terminal	O
GST	O
-	O
TAO	O
mutants	O
","	O
(	O
N1	O
-	O
104	O
"),"	O
(	O
N1	O
â€“	O
174	O
"),"	O
(	O
N1	O
â€“	O
261	O
"),"	O
and	O
(	O
N1	O
â€“	O
304	O
"),"	O
which	O
partially	O
delete	O
the	O
C	O
-	O
terminal	O
of	O
TAO	O
","	O
had	O
relative	O
enzyme	O
activities	O
of	O
7	O
.	O
3	O
"%,"	O
6	O
.	O
1	O
"%,"	O
7	O
.	O
6	O
"%,"	O
and	O
26	O
.	O
2	O
%	O
respectively	O
(	O
Table	O
5	O
).	O
In	O
addition	O
","	O
bioconversion	O
activity	O
of	O
the	O
C	O
-	O
terminal	O
GST	O
-	O
TAO	O
mutant	O
(	O
N175	O
â€“	O
348	O
"),"	O
which	O
partially	O
deletes	O
the	O
N	O
-	O
terminal	O
of	O
TAO	O
","	O
was	O
4	O
.	O
7	O
%	O
(	O
Table	O
5	O
).	O
A	O
mixture	O
of	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
GST	O
-	O
TAO	O
mutants	O
(	O
N1	O
â€“	O
174	O
"),"	O
and	O
(	O
N175	O
â€“	O
348	O
)	O
did	O
not	O
recover	O
the	O
oxygenase	O
activity	O
.	O
Moreover	O
","	O
the	O
addition	O
of	O
commercial	O
FMN	O
-	O
NADH	O
reductase	O
to	O
the	O
N	O
-	O
terminal	O
GST	O
-	O
TAO	O
mutants	O
(	O
N1	O
â€“	O
174	O
"),"	O
(	O
N1	O
â€“	O
261	O
"),"	O
and	O
(	O
N1	O
â€“	O
304	O
"),"	O
or	O
the	O
C	O
-	O
terminal	O
GST	O
-	O
TAO	O
mutant	O
(	O
N175	O
â€“	O
348	O
)	O
also	O
did	O
not	O
recover	O
oxygenase	O
activities	O
(	O
Table	O
5	O
).	O
These	O
results	O
indicated	O
that	O
the	O
entire	O
TAO	O
enzyme	O
contributed	O
to	O
the	O
integrity	O
of	O
oxygenase	O
activity	O
.	O
Figure	O
2	O
shows	O
NADH	B-Chemical
consumptions	O
tied	O
to	O
reduction	O
of	O
FAD	B-Chemical
by	O
a	O
series	O
of	O
the	O
mutants	O
and	O
wild	O
type	O
GST	O
-	O
TAO	O
.	O
The	O
N	O
-	O
terminal	O
GST	O
-	O
TAO	O
mutant	O
(	O
N1	O
â€“	O
261	O
)	O
consumed	O
123	O
.	O
5	O
ÂµM	O
NADH	B-Chemical
after	O
60	O
min	O
of	O
incubation	O
","	O
which	O
is	O
the	O
roughly	O
comparable	O
amount	O
of	O
NADH	B-Chemical
consumed	O
by	O
the	O
wild	O
-	O
type	O
GST	O
-	O
TAO	O
","	O
158	O
.	O
6	O
ÂµM	O
.	O
However	O
","	O
the	O
N	O
-	O
terminal	O
GST	O
-	O
TAO	O
mutant	O
(	O
N1	O
â€“	O
104	O
"),"	O
which	O
lost	O
more	O
part	O
from	O
the	O
C	O
-	O
terminal	O
than	O
the	O
GST	O
-	O
TAO	O
(	O
N1	O
â€“	O
261	O
"),"	O
consumed	O
only	O
50	O
.	O
8	O
ÂµM	O
NADH	B-Chemical
.	O
In	O
contrast	O
","	O
the	O
C	O
-	O
terminal	O
GST	O
-	O
TAO	O
mutant	O
(	O
N175	O
â€“	O
348	O
)	O
lost	O
most	O
of	O
its	O
reductase	O
activity	O
and	O
only	O
consumed	O
12	O
.	O
0	O
ÂµM	O
NADH	B-Chemical
(	O
Figure	O
2	O
).	O
NADH	B-Chemical
consumption	O
for	O
reducing	O
FAD	B-Chemical
by	O
wild	O
-	O
type	O
GST	O
-	O
TAO	O
(	O
A	O
"),"	O
its	O
mutants	O
GST	O
-	O
TAO	O
(	O
N1	O
â€“	O
174	O
)	O
(	O
B	O
"),"	O
GST	O
-	O
TAO	O
(	O
N1	O
â€“	O
104	O
)	O
(	O
C	O
"),"	O
GST	O
-	O
TAO	O
(	O
N175	O
â€“	O
348	O
)	O
(	O
D	O
"),"	O
point	O
mutated	O
GST	O
-	O
TAO	O
(	O
W38A	O
/	O
T43A	O
/	O
Y55A	O
)	O
(	O
E	O
"),"	O
and	O
negative	O
control	O
(	O
F	O
)	O
at	O
0	O
min	O
"(â–ª),"	O
30	O
min	O
"(â€¢),"	O
and	O
60	O
min	O
(â–´).	O
Values	O
are	O
means	O
Â±	O
standard	O
deviation	O
obtained	O
from	O
triplicate	O
experiments	O
after	O
subtraction	O
of	O
the	O
heat	O
-	O
killed	O
GST	O
-	O
TAO	O
activity	O
(	O
0	O
.	O
5	O
Â±	O
0	O
.	O
1	O
mM	O
of	O
p	B-Chemical
-	I-Chemical
anisaldehyde	I-Chemical
product	O
).	O
Amount	O
of	O
p	B-Chemical
-	I-Chemical
anisaldehyde	I-Chemical
produced	O
after	O
60	O
min	O
incubation	O
.	O
Commercial	O
FMN	O
-	O
NADH	O
oxidoreductase	O
from	O
Photobacterium	O
fischeri	O
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
Milwaukee	O
","	O
WI	O
).	O
Relative	O
biotransformation	O
activity	O
of	O
purified	O
GST	O
-	O
TAO	O
and	O
its	O
mutants	O
in	O
the	O
presence	O
of	O
NADH	B-Chemical
and	O
FAD	B-Chemical
.	O
FAD	B-Chemical
binding	O
to	O
GST	O
-	O
TAO	O
and	O
its	O
partially	O
deleted	O
mutants	O
The	O
binding	O
of	O
FAD	B-Chemical
to	O
GST	O
-	O
TAO	O
and	O
its	O
mutants	O
is	O
shown	O
in	O
Table	O
6	O
.	O
The	O
N	O
-	O
terminal	O
GST	O
-	O
TAO	O
mutant	O
(	O
N1	O
â€“	O
104	O
)	O
still	O
kept	O
67	O
%	O
of	O
the	O
FAD	B-Chemical
binding	O
activity	O
compared	O
to	O
wild	O
-	O
type	O
.	O
However	O
","	O
the	O
C	O
-	O
terminal	O
GST	O
-	O
TAO	O
mutant	O
(	O
N175	O
â€“	O
348	O
"),"	O
partial	O
deletion	O
of	O
the	O
N	O
-	O
terminus	O
","	O
almost	O
lost	O
FAD	B-Chemical
binding	O
activity	O
(	O
0	O
.	O
2	O
Âµmol	O
FAD	B-Chemical
/	O
Âµmol	O
enzyme	O
).	O
This	O
is	O
about	O
6	O
%	O
of	O
the	O
binding	O
activity	O
compared	O
to	O
wild	O
-	O
type	O
GST	O
-	O
TAO	O
.	O
Binding	O
of	O
FAD	B-Chemical
to	O
purified	O
GST	O
-	O
TAO	O
and	O
its	O
mutants	O
.	O
Oxygenase	O
activitiy	O
","	O
reductase	O
activitiy	O
and	O
FAD	B-Chemical
binding	O
of	O
purified	O
targeted	O
mutant	O
(	O
W38A	O
/	O
T43A	O
/	O
Y55A	O
)	O
of	O
GST	O
-	O
TAO	O
Presumably	O
due	O
to	O
the	O
absence	O
of	O
the	O
conserved	O
FAD	B-Chemical
and	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
)	I-Chemical
H	I-Chemical
binding	O
domains	O
from	O
the	O
deduced	O
amino	B-Chemical
acid	I-Chemical
sequence	O
of	O
TAO	O
","	O
neither	O
the	O
fully	O
integrated	O
protein	O
structure	O
prediction	O
program	O
(	O
Prime	O
","	O
SchrÃ¶dinger	O
Â®)	O
nor	O
the	O
protein	O
structure	O
homology	O
modeling	O
server	O
(	O
SWISS	O
-	O
MODEL	O
)	O
was	O
able	O
to	O
locate	O
the	O
homologous	O
protein	O
of	O
TAO	O
in	O
the	O
protein	O
data	O
bank	O
.	O
Thus	O
","	O
our	O
previous	O
assumption	O
","	O
which	O
the	O
amino	B-Chemical
acid	I-Chemical
residues	O
","	O
Trp	B-Chemical
-	O
38	O
","	O
Thr	B-Chemical
-	O
43	O
","	O
and	O
Tyr	B-Chemical
-	O
55	O
","	O
in	O
TAO	O
are	O
likely	O
to	O
be	O
involved	O
in	O
FAD	B-Chemical
binding	O
","	O
was	O
tested	O
to	O
verify	O
the	O
function	O
with	O
purified	O
protein	O
of	O
the	O
targeted	O
mutant	O
.	O
Purified	O
point	O
-	O
mutated	O
GST	O
-	O
TAO	O
(	O
W38A	O
/	O
T43A	O
/	O
Y55A	O
)	O
lost	O
almost	O
all	O
oxygenase	O
activity	O
(	O
Table	O
5	O
)	O
with	O
no	O
consumption	O
of	O
NADH	B-Chemical
(	O
Figure	O
2	O
).	O
The	O
mutated	O
enzyme	O
also	O
showed	O
substantially	O
decreased	O
FAD	B-Chemical
binding	O
activity	O
at	O
0	O
.	O
6	O
Âµmol	O
FAD	B-Chemical
/	O
Âµmol	O
enzyme	O
as	O
compared	O
to	O
wild	O
-	O
type	O
GST	O
-	O
TAO	O
at	O
0	O
.	O
30	O
Âµmol	O
FAD	B-Chemical
/	O
Âµmol	O
enzyme	O
(	O
Table	O
6	O
).	O
Optimal	O
reaction	O
temperature	O
","	O
pH	O
","	O
and	O
thermostability	O
of	O
TAO	O
The	O
reaction	O
temperature	O
optimum	O
of	O
TAO	O
for	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
was	O
determined	O
by	O
using	O
the	O
standard	O
assay	O
at	O
temperatures	O
from	O
15	O
to	O
50	O
Â°	O
C	O
.	O
The	O
maximum	O
activity	O
of	O
TAO	O
was	O
detected	O
at	O
25	O
Â°	O
C	O
","	O
and	O
an	O
increase	O
in	O
temperature	O
from	O
25	O
to	O
37	O
Â°	O
C	O
resulted	O
in	O
loss	O
of	O
90	O
%	O
of	O
the	O
activity	O
(	O
Figure	O
S2A	O
in	O
File	O
S1	O
).	O
The	O
highest	O
activity	O
of	O
TAO	O
was	O
observed	O
in	O
potassium	B-Chemical
phosphate	I-Chemical
buffer	O
at	O
pH	O
8	O
.	O
0	O
at	O
25	O
Â°	O
C	O
.	O
TAO	O
lost	O
about	O
50	O
%	O
of	O
its	O
relative	O
bioconversion	O
activity	O
at	O
pH	O
7	O
.	O
0	O
and	O
9	O
.	O
0	O
(	O
Figure	O
S2B	O
in	O
File	O
S1	O
).	O
The	O
stability	O
of	O
TAO	O
was	O
investigated	O
by	O
measuring	O
TAO	O
activity	O
after	O
incubation	O
of	O
the	O
enzyme	O
at	O
25	O
Â°	O
C	O
for	O
4	O
days	O
.	O
TAO	O
had	O
76	O
%	O
and	O
30	O
%	O
of	O
relative	O
initial	O
activity	O
after	O
24	O
and	O
96	O
hr	O
","	O
respectively	O
","	O
suggesting	O
that	O
TAO	O
is	O
a	O
relatively	O
stable	O
enzyme	O
(	O
Figure	O
S3	O
in	O
File	O
S1	O
).	O
Discussion	O
The	O
trans	O
-	O
anethole	O
oxygenase	O
(	O
TAO	O
)	O
is	O
a	O
novel	O
flavoprotein	O
monooxygenase	O
capable	O
of	O
catalyzing	O
the	O
oxidation	O
of	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
to	O
p	B-Chemical
-	I-Chemical
anisaldehyde	I-Chemical
.	O
The	O
oxidation	O
reaction	O
was	O
catalyzed	O
without	O
the	O
aid	O
of	O
auxiliary	O
oxidoreductase	O
enzyme	O
components	O
.	O
Although	O
we	O
observed	O
that	O
TAO	O
had	O
both	O
monooxygenase	O
and	O
reductase	O
activities	O
","	O
no	O
monooxygenase	O
or	O
flavin	O
reductase	O
catalytic	O
subunits	O
were	O
found	O
in	O
TAO	O
.	O
Thus	O
","	O
TAO	O
is	O
characterized	O
as	O
a	O
novel	O
self	O
-	O
sufficient	O
flavoprotein	O
monooxygenase	O
.	O
The	O
oxidation	O
reaction	O
of	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
to	O
p	B-Chemical
-	I-Chemical
anisaldehyde	I-Chemical
most	O
likely	O
proceeded	O
via	O
epoxidation	O
","	O
hydrolysis	O
of	O
epoxide	B-Chemical
group	O
","	O
and	O
C	O
-	O
C	O
bond	O
cleavage	O
by	O
TAO	O
itself	O
","	O
.	O
TAO	O
","	O
which	O
is	O
likely	O
a	O
single	O
component	O
enzyme	O
","	O
not	O
only	O
has	O
the	O
ability	O
to	O
reduce	O
flavin	B-Chemical
cofactors	O
","	O
but	O
also	O
oxidizes	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
to	O
p	B-Chemical
-	I-Chemical
anisaldehyde	I-Chemical
(	O
Figure	O
3	O
).	O
Natural	O
flavoprotein	O
monooxygenases	O
","	O
which	O
catalyze	O
epoxidation	O
reactions	O
","	O
have	O
been	O
previously	O
reported	O
as	O
two	O
-	O
components	O
monooxygenases	O
.	O
An	O
oxidoreductase	O
is	O
indispensable	O
for	O
the	O
supply	O
of	O
reduced	O
flavin	B-Chemical
for	O
two	O
-	O
components	O
monooxygenases	O
.	O
The	O
reduced	O
flavin	B-Chemical
diffuses	O
to	O
oxygenase	O
","	O
which	O
reacts	O
with	O
molecular	O
oxygen	B-Chemical
","	O
and	O
yields	O
a	O
reactive	B-Chemical
C4a	I-Chemical
-	I-Chemical
hydroperoxyflavin	I-Chemical
species	I-Chemical
","	O
and	O
the	O
substrate	O
is	O
bound	O
and	O
subjected	O
to	O
an	O
epoxidation	O
reaction	O
.	O
However	O
","	O
diffusion	O
limitations	O
likely	O
reduce	O
catalytic	O
efficiency	O
of	O
these	O
enzymes	O
","	O
.	O
For	O
this	O
reason	O
","	O
efforts	O
have	O
been	O
made	O
to	O
find	O
or	O
construct	O
a	O
single	O
-	O
component	O
","	O
self	O
-	O
sufficient	O
monooxygenase	O
","	O
.	O
Examples	O
of	O
self	O
-	O
sufficient	O
monooxygenases	O
are	O
the	O
Bacillus	O
cytochrome	O
P450	O
BM3	O
and	O
P450	O
PFOR	O
which	O
integrate	O
the	O
entire	O
P450	O
system	O
in	O
a	O
single	O
polypeptide	O
","	O
.	O
In	O
contrast	O
","	O
most	O
cytochrome	O
P450	O
monooxygenases	O
(	O
P450s	O
)	O
contain	O
multiple	O
-	O
components	O
","	O
.	O
Previous	O
difficulties	O
in	O
finding	O
self	O
-	O
sufficient	O
monooxygenases	O
from	O
natural	O
resources	O
has	O
led	O
others	O
to	O
construct	O
an	O
artificial	O
fusion	O
between	O
oxygenase	O
and	O
reductase	O
components	O
and	O
the	O
catalytic	O
activity	O
of	O
chimeric	O
protein	O
with	O
the	O
fusion	O
of	O
P450RhF	O
and	O
redox	O
partner	O
in	O
engineered	O
E	O
.	O
coli	O
have	O
been	O
reported	O
","	O
.	O
A	O
purified	O
chimeric	O
enzyme	O
PikC	O
cytochrome	O
P450	O
fused	O
to	O
RhFRED	O
showed	O
a	O
âˆ¼	O
4	O
-	O
fold	O
enhanced	O
catalytic	O
activity	O
(	O
k	O
cat	O
/	O
K	O
m	O
)	O
in	O
hydroxylation	O
reaction	O
in	O
a	O
macrolide	B-Chemical
biosynthetic	O
pathway	O
.	O
Proposed	O
biochemical	O
mechanism	O
for	O
catalyzing	O
transformation	O
of	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
to	O
p	B-Chemical
-	I-Chemical
anisaldehyde	I-Chemical
by	O
TAO	O
in	O
the	O
presence	O
of	O
NADH	B-Chemical
and	O
FAD	B-Chemical
.	O
In	O
the	O
process	O
of	O
reduction	O
of	O
flavin	B-Chemical
and	O
oxidation	O
of	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
","	O
TAO	O
accepted	O
various	O
flavins	B-Chemical
(	O
FAD	B-Chemical
","	O
FMN	B-Chemical
and	O
riboflavin	B-Chemical
)	O
and	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
)	I-Chemical
H	I-Chemical
cofactors	O
serving	O
as	O
electron	O
transfer	O
intermediates	O
.	O
Stoichiometry	O
indicates	O
that	O
flavin	B-Chemical
accepted	O
one	O
hydride	O
from	O
NAD	B-Chemical
(	I-Chemical
P	I-Chemical
)	I-Chemical
H	I-Chemical
and	O
reduced	O
flavin	B-Chemical
transferred	O
one	O
oxygen	B-Chemical
to	O
the	O
organic	O
substrate	O
","	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
.	O
In	O
addition	O
","	O
the	O
current	O
study	O
indicated	O
that	O
FAD	B-Chemical
is	O
the	O
best	O
flavin	B-Chemical
cofactor	O
","	O
and	O
NADH	B-Chemical
is	O
better	O
than	O
NADPH	B-Chemical
for	O
donating	O
electrons	O
to	O
the	O
catalytic	O
reaction	O
.	O
In	O
accordance	O
with	O
our	O
initial	O
studies	O
done	O
with	O
resting	O
cell	O
assays	O
of	O
heterologously	O
expressed	O
TAO	O
in	O
E	O
.	O
coli	O
","	O
the	O
purified	O
GST	O
-	O
TAO	O
catalyzed	O
transformation	O
of	O
isoeugenol	B-Chemical
","	O
O	B-Chemical
-	I-Chemical
methyl	I-Chemical
isoeugenol	I-Chemical
","	O
and	O
isosafrole	B-Chemical
","	O
all	O
of	O
which	O
contain	O
a	O
2	O
-	O
propenyl	O
functional	O
group	O
on	O
the	O
aromatic	O
ring	O
structure	O
.	O
As	O
expected	O
","	O
TAO	O
had	O
the	O
highest	O
catalytic	O
efficiency	O
(	O
k	O
cat	O
/	O
K	O
m	O
)	O
with	O
its	O
physiological	O
substrate	O
","	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
.	O
Isoeugenol	B-Chemical
","	O
however	O
","	O
had	O
the	O
greatest	O
turnover	O
number	O
(	O
k	O
cat	O
"),"	O
although	O
the	O
affinity	O
for	O
this	O
substrate	O
was	O
approximately	O
35	O
-	O
fold	O
lower	O
than	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
","	O
likely	O
due	O
to	O
the	O
presence	O
of	O
the	O
relatively	O
hydrophilic	O
4	O
-	O
hydroxyl	O
group	O
in	O
its	O
chemical	O
structure	O
.	O
For	O
profiling	O
the	O
distribution	O
of	O
the	O
oxygenase	O
and	O
reductase	O
components	O
in	O
TAO	O
","	O
partial	O
TAO	O
deletion	O
mutants	O
were	O
constructed	O
.	O
Distinct	O
difference	O
in	O
reductase	O
activity	O
between	O
the	O
N	O
terminal	O
portion	O
of	O
TAO	O
","	O
from	O
amino	B-Chemical
acids	I-Chemical
1	O
â€“	O
174	O
and	O
the	O
C	O
terminal	O
part	O
from	O
residues	O
175	O
â€“	O
348	O
","	O
indicated	O
that	O
reductase	O
active	O
sites	O
appeared	O
to	O
be	O
located	O
in	O
the	O
N	O
terminal	O
half	O
of	O
TAO	O
.	O
The	O
combined	O
results	O
of	O
reductase	O
activity	O
(	O
Figure	O
2	O
)	O
and	O
FAD	B-Chemical
binding	O
ability	O
(	O
Table	O
6	O
)	O
between	O
GST	O
-	O
TAO	O
(	O
N1	O
â€“	O
174	O
)	O
and	O
GST	O
-	O
TAO	O
(	O
N1	O
â€“	O
104	O
)	O
further	O
indicated	O
that	O
the	O
amino	B-Chemical
acids	I-Chemical
in	O
positions	O
104	O
to	O
174	O
were	O
critical	O
to	O
the	O
FAD	B-Chemical
reduction	O
reaction	O
.	O
These	O
residues	O
also	O
may	O
contribute	O
to	O
the	O
binding	O
of	O
NADH	B-Chemical
to	O
the	O
enzyme	O
.	O
However	O
","	O
it	O
should	O
be	O
noted	O
that	O
deletion	O
of	O
any	O
portion	O
of	O
TAO	O
resulted	O
in	O
loss	O
of	O
oxygenase	O
activity	O
","	O
which	O
is	O
different	O
from	O
the	O
reductase	O
activity	O
.	O
Furthermore	O
","	O
the	O
three	O
residues	O
Trp	B-Chemical
-	O
38	O
","	O
Thr	B-Chemical
-	O
43	O
","	O
and	O
Tyr	B-Chemical
-	O
55	O
","	O
which	O
appear	O
to	O
be	O
involved	O
in	O
FAD	B-Chemical
binding	O
reported	O
in	O
our	O
previous	O
study	O
","	O
were	O
confirmed	O
to	O
be	O
flavin	B-Chemical
binding	O
sites	O
by	O
using	O
a	O
FAD	B-Chemical
binding	O
assay	O
.	O
In	O
summary	O
","	O
in	O
this	O
study	O
we	O
describe	O
the	O
identification	O
and	O
characterization	O
of	O
a	O
novel	O
self	O
-	O
sufficient	O
trans	O
-	O
anethole	O
oxygenase	O
which	O
was	O
able	O
to	O
catalyze	O
the	O
epoxidation	O
and	O
cleavage	O
of	O
the	O
carbon	B-Chemical
-	O
carbon	B-Chemical
double	O
on	O
the	O
1	O
-	O
propenyl	O
side	O
chain	O
of	O
trans	B-Chemical
-	I-Chemical
anethole	I-Chemical
to	O
produce	O
p	B-Chemical
-	I-Chemical
anisaldehyde	I-Chemical
.	O
In	O
addition	O
","	O
the	O
enzyme	O
also	O
coupled	O
flavin	B-Chemical
reduction	O
by	O
another	O
portion	O
","	O
flavin	O
reductase	O
.	O
Based	O
on	O
the	O
use	O
of	O
partial	O
deletion	O
mutants	O
and	O
point	O
-	O
mutations	O
","	O
the	O
role	O
of	O
each	O
segment	O
in	O
TAO	O
for	O
reductase	O
and	O
oxygenase	O
activities	O
could	O
be	O
deduced	O
.	O
Despite	O
these	O
results	O
","	O
however	O
","	O
it	O
is	O
necessary	O
to	O
further	O
study	O
for	O
the	O
catalytic	O
mechanism	O
of	O
TAO	O
by	O
using	O
structural	O
analysis	O
.	O
We	O
expect	O
this	O
single	O
component	O
self	O
-	O
sufficient	O
trans	O
-	O
anethole	O
oxygenase	O
will	O
provide	O
another	O
novel	O
model	O
system	O
for	O
uncovering	O
the	O
enzymatic	O
function	O
of	O
oxygenases	O
.	O
Moreover	O
","	O
this	O
novel	O
enzyme	O
has	O
great	O
potential	O
as	O
an	O
efficient	O
catalyst	O
for	O
use	O
in	O
the	O
flavor	O
and	O
fragrance	O
industries	O
.	O
Supporting	O
Information	O
References	O
Total	O
Marrow	O
Irradiation	O
as	O
Part	O
of	O
Autologous	O
Stem	O
Cell	O
Transplantation	O
for	O
Asian	O
Patients	O
with	O
Multiple	O
Myeloma	O
To	O
compare	O
the	O
outcomes	O
of	O
melphalan	B-Chemical
200	O
mg	O
/	O
m2	O
(	O
HDM200	B-Chemical
)	O
and	O
8	O
Gy	O
total	O
marrow	O
irradiation	O
(	O
TMI	O
)	O
delivered	O
by	O
helical	O
tomotherapy	O
plus	O
melphalan	B-Chemical
140	O
mg	O
/	O
m2	O
(	O
HDM140	B-Chemical
+	O
TMI	O
8	O
Gy	O
)	O
in	O
newly	O
diagnosed	O
symptomatic	O
multiple	O
myeloma	O
(	O
MM	O
)	O
Asian	O
patients	O
.	O
Between	O
2007	O
and	O
2010	O
","	O
nine	O
consecutive	O
myeloma	O
patients	O
who	O
were	O
scheduled	O
to	O
undergo	O
autologous	O
stem	O
cell	O
transplantation	O
(	O
ASCT	O
)	O
were	O
studied	O
.	O
The	O
patients	O
received	O
three	O
cycles	O
of	O
vincristine	B-Chemical
-	I-Chemical
adriamycin	I-Chemical
-	I-Chemical
dexamethasone	I-Chemical
(	O
VAD	B-Chemical
)	O
regimen	O
as	O
induction	O
chemotherapy	O
","	O
and	O
if	O
they	O
had	O
a	O
partial	O
response	O
","	O
peripheral	O
blood	O
stem	O
cells	O
were	O
collected	O
by	O
dexamethasone	B-Chemical
-	I-Chemical
etoposide	I-Chemical
-	I-Chemical
cyclophosphamide	I-Chemical
-	I-Chemical
cisplatin	I-Chemical
(	O
DECP	B-Chemical
).	O
In	O
arm	O
A	O
","	O
six	O
patients	O
received	O
the	O
HDM200	B-Chemical
.	O
In	O
arm	O
B	O
","	O
three	O
patients	O
received	O
HDM140	B-Chemical
+	O
TMI	O
8	O
Gy	O
.	O
In	O
arm	O
B	O
","	O
the	O
neutropenic	O
duration	O
was	O
slightly	O
longer	O
than	O
in	O
arm	O
A	O
(	O
P	O
=	O
0	O
.	O
48	O
).	O
However	O
","	O
hematologic	O
recovery	O
(	O
except	O
for	O
neutrophils	O
"),"	O
transfusion	O
requirement	O
","	O
median	O
duration	O
of	O
hospitalization	O
","	O
and	O
the	O
dose	O
of	O
G	B-Chemical
-	I-Chemical
CSF	I-Chemical
were	O
similar	O
in	O
both	O
arms	O
.	O
The	O
median	O
duration	O
of	O
overall	O
survival	O
and	O
event	O
-	O
free	O
survival	O
was	O
similar	O
in	O
the	O
two	O
arms	O
(	O
P	O
=	O
0	O
.	O
387	O
).	O
As	O
a	O
conditioning	O
regiment	O
","	O
HDM140	B-Chemical
+	O
TMI	O
8	O
Gy	O
provide	O
another	O
chance	O
for	O
MM	O
Asian	O
patients	O
who	O
were	O
not	O
feasible	O
for	O
HDM200	B-Chemical
.	O
1	O
.	O
Introduction	O
The	O
outcome	O
of	O
autologous	O
stem	O
cell	O
transplantation	O
(	O
ASCT	O
)	O
patients	O
for	O
newly	O
diagnosed	O
multiple	O
myeloma	O
(	O
MM	O
)	O
is	O
superior	O
to	O
that	O
of	O
patients	O
receiving	O
conventional	O
chemotherapy	O
.	O
Attal	O
et	O
al	O
.	O
reported	O
that	O
8	O
Gy	O
total	O
body	O
irradiation	O
(	O
TBI	O
)	O
plus	O
140	O
mg	O
/	O
m2	O
intravenous	O
melphalan	B-Chemical
(	O
HDM140	B-Chemical
)	O
improved	O
the	O
response	O
rate	O
and	O
overall	O
survival	O
compared	O
with	O
conventional	O
chemotherapy	O
in	O
patients	O
with	O
MM	O
.	O
The	O
impact	O
of	O
complete	O
response	O
(	O
CR	O
)	O
achievement	O
has	O
been	O
shown	O
with	O
high	O
dose	O
preconditioning	O
.	O
To	O
improve	O
survival	O
","	O
the	O
objective	O
is	O
to	O
increase	O
CR	O
rates	O
before	O
autologous	O
stem	O
cell	O
transplantation	O
(	O
ASCT	O
);	O
a	O
total	O
of	O
200	O
mg	O
/	O
m2	O
melphalan	B-Chemical
(	O
HDM200	B-Chemical
)	O
without	O
TBI	O
is	O
an	O
alternative	O
method	O
.	O
The	O
Intergroupe	O
Francophone	O
du	O
Mye	O
'	O
lome	O
(	O
IFM	O
)	O
9502	O
trial	O
compared	O
the	O
conditioning	O
regimen	O
8	O
Gy	O
TBI	O
+	O
HDM140	B-Chemical
and	O
HDM200	B-Chemical
without	O
TBI	O
followed	O
by	O
ASCT	O
.	O
The	O
results	O
revealed	O
that	O
HDM200	B-Chemical
could	O
be	O
an	O
alternative	O
conditioning	O
regimen	O
for	O
MM	O
.	O
The	O
complications	O
cause	O
by	O
TBI	O
have	O
been	O
reported	O
.	O
The	O
pulmonary	O
complications	O
were	O
concerned	O
by	O
TBI	O
position	O
","	O
with	O
beam	O
energy	O
(	O
P	O
=	O
0	O
.	O
2	O
)	O
and	O
the	O
absence	O
of	O
lung	O
shielding	O
.	O
Helical	O
tomotherapy	O
(	O
HT	O
","	O
Tomotherapy	O
Hi	O
-	O
Art	O
System	O
","	O
v	O
.	O
3	O
.	O
2	O
.	O
2	O
.	O
35	O
".,"	O
TomoTherapy	O
Inc	O
".,"	O
Madison	O
","	O
WI	O
)	O
is	O
new	O
CT	O
-	O
based	O
rotational	O
intensity	O
modulated	O
radiotherapy	O
.	O
Total	O
marrow	O
irradiation	O
(	O
TMI	O
)	O
with	O
HT	O
is	O
designed	O
to	O
avoid	O
the	O
complications	O
of	O
TBI	O
while	O
achieving	O
the	O
effectiveness	O
of	O
TBI	O
.	O
Dosimetric	O
studies	O
showed	O
reduced	O
doses	O
to	O
adjacent	O
critical	O
normal	O
organs	O
reduced	O
toxicity	O
after	O
TMI	O
.	O
The	O
advantages	O
","	O
acute	O
toxicities	O
","	O
initial	O
clinical	O
experiences	O
","	O
and	O
challenges	O
of	O
TMI	O
were	O
reported	O
recently	O
.	O
Recently	O
","	O
we	O
reported	O
the	O
Asian	O
experience	O
with	O
treating	O
newly	O
diagnosed	O
MM	O
patients	O
with	O
8	O
Gy	O
TMI	O
by	O
HT	O
plus	O
HDM140	B-Chemical
;	O
patients	O
subsequently	O
received	O
maintenance	O
therapy	O
with	O
thalidomide	B-Chemical
and	O
dexamethasone	B-Chemical
.	O
We	O
found	O
that	O
HDM140	B-Chemical
+	O
TMI	O
8	O
Gy	O
regimen	O
was	O
an	O
acceptable	O
conditioning	O
regimen	O
for	O
MM	O
patients	O
.	O
The	O
preliminary	O
outcomes	O
were	O
similar	O
for	O
Asians	O
as	O
for	O
other	O
races	O
.	O
In	O
the	O
current	O
follow	O
-	O
up	O
study	O
","	O
we	O
compared	O
the	O
acute	O
and	O
early	O
chronic	O
toxicities	O
","	O
CR	O
rates	O
","	O
very	O
good	O
partial	O
response	O
(	O
VGPR	O
)	O
rates	O
","	O
and	O
early	O
results	O
of	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
patients	O
treated	O
with	O
HDM140	B-Chemical
+	O
TMI	O
8	O
Gy	O
or	O
HDM200	B-Chemical
without	O
TBI	O
followed	O
by	O
ASCT	O
.	O
2	O
.	O
Materials	O
and	O
Methods	O
2	O
.	O
1	O
.	O
Patient	O
Characteristics	O
We	O
enrolled	O
nine	O
consecutive	O
myeloma	O
patients	O
who	O
underwent	O
ASCT	O
at	O
Far	O
Eastern	O
Memorial	O
Hospital	O
(	O
diagnosed	O
between	O
2007	O
and	O
2010	O
).	O
Eligibility	O
criteria	O
included	O
age	O
less	O
than	O
65	O
years	O
and	O
symptomatic	O
MM	O
.	O
Patients	O
were	O
excluded	O
if	O
they	O
had	O
the	O
following	O
:	O
(	O
1	O
)	O
stable	O
stage	O
I	O
MM	O
(	O
Durie	O
-	O
Salmon	O
classification	O
);	O
(	O
2	O
)	O
previous	O
cytotoxic	O
chemotherapy	O
or	O
radiotherapy	O
;	O
(	O
3	O
)	O
severe	O
abnormalities	O
of	O
cardiac	O
","	O
pulmonary	O
","	O
or	O
hepatic	O
function	O
;	O
or	O
(	O
4	O
)	O
serum	O
creatinine	B-Chemical
levels	O
>	O
2	O
mg	O
/	O
dL	O
.	O
All	O
patients	O
gave	O
informed	O
consent	O
","	O
and	O
the	O
study	O
was	O
approved	O
by	O
the	O
institutional	O
ethics	O
committee	O
of	O
the	O
Far	O
Eastern	O
Memorial	O
Hospital	O
.	O
2	O
.	O
2	O
.	O
Autologous	O
Stem	O
Cell	O
Transplantation	O
Regimen	O
The	O
treatment	O
protocol	O
was	O
modified	O
from	O
the	O
Intergroupe	O
Francophone	O
du	O
MyÃ©lome	O
9502	O
randomized	O
trial	O
.	O
Briefly	O
","	O
the	O
patients	O
received	O
three	O
cycles	O
of	O
the	O
vincristine	B-Chemical
-	I-Chemical
adriamycin	I-Chemical
-	I-Chemical
dexamethasone	I-Chemical
(	O
VAD	B-Chemical
)	O
regimen	O
","	O
as	O
in	O
the	O
trial	O
(	O
Figure	O
1	O
).	O
If	O
they	O
achieved	O
a	O
partial	O
response	O
(	O
M	O
-	O
protein	O
reduced	O
by	O
<	O
50	O
"%),"	O
then	O
they	O
received	O
one	O
course	O
of	O
dexamethasone	B-Chemical
-	I-Chemical
etoposide	I-Chemical
-	I-Chemical
cyclophosphamide	I-Chemical
-	I-Chemical
cisplatin	I-Chemical
(	O
DECP	B-Chemical
)	O
with	O
granulocyte	B-Chemical
colony	I-Chemical
-	I-Chemical
stimulating	I-Chemical
factor	I-Chemical
(	O
G	B-Chemical
-	I-Chemical
CSF	I-Chemical
)	O
mobilization	O
.	O
Two	O
weeks	O
later	O
","	O
peripheral	O
blood	O
stem	O
cells	O
(	O
PBSCs	O
)	O
were	O
collected	O
.	O
Stem	O
cells	O
were	O
collected	O
after	O
G	B-Chemical
-	I-Chemical
CSF	I-Chemical
priming	O
(	O
10	O
Î¼g	O
/	O
kg	O
/	O
d	O
)	O
in	O
steady	O
state	O
.	O
Daily	O
apheresis	O
was	O
continued	O
until	O
at	O
least	O
2	O
Ã—	O
106	O
CD34	O
cells	O
per	O
kilogram	O
were	O
collected	O
.	O
No	O
CD34	O
+	O
selection	O
was	O
performed	O
.	O
Two	O
weeks	O
after	O
PBSC	O
collection	O
","	O
the	O
evaluation	O
for	O
ASCT	O
was	O
done	O
.	O
If	O
cardiopulmonary	O
","	O
hepatic	O
","	O
and	O
renal	O
functions	O
remained	O
adequate	O
","	O
the	O
patients	O
received	O
HDM140	B-Chemical
+	O
TMI	O
8	O
Gy	O
or	O
HDM200	B-Chemical
;	O
the	O
time	O
from	O
pre	O
-	O
HSCT	O
evaluation	O
to	O
start	O
of	O
HDM140	B-Chemical
+	O
TMI	O
8	O
Gy	O
or	O
HDM200	B-Chemical
(	O
preconditioning	O
)	O
treatment	O
was	O
about	O
4	O
weeks	O
.	O
All	O
of	O
the	O
patients	O
received	O
thalidomide	B-Chemical
for	O
maintenance	O
therapy	O
after	O
stem	O
cell	O
transplantation	O
.	O
In	O
arm	O
A	O
","	O
HDM200	B-Chemical
was	O
administered	O
for	O
two	O
days	O
by	O
infusion	O
over	O
30	O
minutes	O
.	O
In	O
arm	O
B	O
","	O
patients	O
received	O
8	O
Gy	O
TMI	O
by	O
HT	O
delivered	O
in	O
four	O
fractions	O
over	O
a	O
4	O
-	O
day	O
period	O
(	O
days	O
6	O
","	O
5	O
","	O
4	O
","	O
and	O
3	O
)	O
plus	O
HDM140	B-Chemical
.	O
HDM140	B-Chemical
was	O
administered	O
for	O
two	O
days	O
by	O
infusion	O
over	O
30	O
minutes	O
","	O
too	O
.	O
PBSC	O
transplantation	O
was	O
performed	O
on	O
day	O
0	O
.	O
Hematopoietic	O
growth	O
factor	O
support	O
with	O
G	B-Chemical
-	I-Chemical
CSF	I-Chemical
was	O
provided	O
on	O
day	O
5	O
after	O
transplantation	O
until	O
granulocyte	O
recovery	O
.	O
Thalidomide	B-Chemical
(	O
50	O
â€“	O
200	O
mg	O
/	O
d	O
)	O
was	O
started	O
100	O
days	O
or	O
later	O
after	O
TMI	O
and	O
was	O
continued	O
for	O
6	O
months	O
following	O
the	O
achievement	O
of	O
complete	O
remission	O
","	O
or	O
for	O
at	O
least	O
12	O
months	O
for	O
patients	O
with	O
persistent	O
evidence	O
of	O
residual	O
disease	O
.	O
2	O
.	O
3	O
.	O
Radiotherapy	O
Technique	O
Details	O
of	O
the	O
HT	O
technique	O
have	O
been	O
previously	O
published	O
.	O
Briefly	O
","	O
An	O
AccuFix	O
Cantilever	O
Board	O
(	O
WFR	O
/	O
Aquaplast	O
Corporation	O
and	O
Q	O
-	O
Fix	O
Systems	O
","	O
LLC	O
","	O
Wyckoff	O
","	O
New	O
Jersey	O
","	O
USA	O
)	O
with	O
thermoplastic	O
fixation	O
or	O
type	O
-	O
S	O
thermoplastics	O
head	O
frame	O
(	O
MT	O
-	O
CHFN	O
-	O
C	O
","	O
Civco	O
MedTec	O
","	O
Kalona	O
","	O
Iowa	O
","	O
USA	O
)	O
with	O
mold	O
care	O
cushion	O
was	O
used	O
for	O
head	O
and	O
shoulder	O
immobilization	O
.	O
A	O
BlueBAG	O
BodyFIX	O
total	O
body	O
cushion	O
system	O
(	O
Medical	O
Intelligence	O
","	O
SchwabmÃ¼nchen	O
","	O
Germany	O
"),"	O
which	O
used	O
a	O
vacuum	O
to	O
produce	O
a	O
uniform	O
pressure	O
","	O
was	O
used	O
to	O
fix	O
the	O
main	O
trunk	O
and	O
extremities	O
in	O
place	O
.	O
The	O
radiotherapy	O
was	O
planned	O
with	O
patients	O
in	O
a	O
supine	O
position	O
for	O
head	O
-	O
first	O
upper	O
torso	O
therapy	O
and	O
with	O
feet	O
-	O
first	O
lower	O
extremity	O
therapy	O
.	O
The	O
planning	O
CT	O
images	O
were	O
performed	O
using	O
dual	O
source	O
CT	O
(	O
Siemens	O
SOMATOM	O
Definition	O
","	O
Siemens	O
Healthcare	O
","	O
Erlangen	O
","	O
Germany	O
)	O
where	O
three	O
sets	O
of	O
images	O
were	O
acquired	O
during	O
normal	O
breathing	O
","	O
inspiration	O
","	O
and	O
shallow	O
expiration	O
for	O
the	O
upper	O
torso	O
.	O
All	O
of	O
the	O
CT	O
images	O
were	O
sent	O
to	O
the	O
Pinnacle3	O
Treatment	O
Planning	O
System	O
(	O
Philips	O
Healthcare	O
","	O
Madison	O
","	O
Wisconsin	O
","	O
USA	O
)	O
for	O
contouring	O
.	O
The	O
clinical	O
target	O
volume	O
(	O
CTV	O
)	O
included	O
the	O
entire	O
skeletal	O
system	O
.	O
The	O
margins	O
for	O
the	O
planning	O
target	O
volume	O
(	O
PTV	O
)	O
were	O
0	O
.	O
8	O
cm	O
for	O
CTV	O
extremities	O
and	O
0	O
.	O
5	O
cm	O
for	O
all	O
other	O
bones	O
of	O
the	O
CTV	O
.	O
The	O
organs	O
at	O
risk	O
(	O
OAR	O
)	O
included	O
the	O
brain	O
","	O
optic	O
nerves	O
","	O
lenses	O
","	O
eyes	O
","	O
parotid	O
glands	O
","	O
oral	O
cavity	O
","	O
thyroid	O
gland	O
","	O
bilateral	O
lungs	O
","	O
esophagus	O
","	O
heart	O
","	O
liver	O
","	O
spleen	O
","	O
pancreases	O
","	O
kidneys	O
","	O
bowel	O
","	O
bladder	O
","	O
and	O
reproductive	O
organs	O
.	O
After	O
contouring	O
the	O
targets	O
and	O
critical	O
organs	O
","	O
the	O
images	O
and	O
structure	O
set	O
were	O
sent	O
to	O
the	O
Tomotherapy	O
Hi	O
-	O
Art	O
Planning	O
Station	O
for	O
processing	O
(	O
Tomotherapy	O
","	O
Inc	O
".,"	O
Madison	O
","	O
Wisconsin	O
","	O
USA	O
).	O
The	O
prescription	O
dose	O
was	O
200	O
cGy	O
per	O
day	O
(	O
in	O
4	O
fractions	O
)	O
for	O
a	O
total	O
dose	O
of	O
800	O
cGy	O
to	O
the	O
PTV	O
.	O
For	O
the	O
planning	O
objective	O
","	O
at	O
least	O
95	O
%	O
of	O
the	O
volume	O
of	O
PTV	O
was	O
to	O
receive	O
800	O
cGy	O
","	O
with	O
the	O
mean	O
dose	O
to	O
the	O
OAR	O
reduced	O
to	O
50	O
%	O
of	O
the	O
prescribed	O
dose	O
.	O
The	O
field	O
width	O
","	O
pitch	O
","	O
and	O
modulation	O
factor	O
(	O
MF	O
)	O
used	O
for	O
the	O
treatment	O
planning	O
optimization	O
were	O
2	O
.	O
5	O
cm	O
","	O
0	O
.	O
32	O
","	O
and	O
3	O
.	O
0	O
for	O
the	O
upper	O
torso	O
and	O
5	O
.	O
0	O
cm	O
","	O
0	O
.	O
4	O
","	O
and	O
2	O
.	O
0	O
for	O
the	O
lower	O
extremities	O
","	O
respectively	O
.	O
2	O
.	O
4	O
.	O
Follow	O
-	O
Up	O
and	O
Response	O
Criteria	O
Mandatory	O
evaluations	O
included	O
physical	O
assessment	O
","	O
routine	O
hemogram	O
","	O
and	O
comprehensive	O
chemistry	O
panel	O
","	O
serum	O
protein	O
electrophoresis	O
every	O
3	O
months	O
","	O
and	O
bone	O
radiographs	O
and	O
bone	O
marrow	O
biopsies	O
at	O
30	O
days	O
and	O
6	O
and	O
12	O
months	O
post	O
-	O
TMI	O
or	O
HDM200	B-Chemical
and	O
yearly	O
thereafter	O
.	O
Toxicity	O
of	O
treatment	O
was	O
scored	O
according	O
to	O
the	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
v3	O
.	O
0	O
.	O
Complete	O
response	O
(	O
CR	O
)	O
was	O
defined	O
as	O
the	O
absence	O
of	O
serum	O
and	O
urinary	O
M	O
-	O
protein	O
and	O
no	O
more	O
than	O
5	O
%	O
plasma	O
cells	O
on	O
bone	O
marrow	O
.	O
Very	O
good	O
partial	O
response	O
(	O
VGPR	O
)	O
was	O
defined	O
as	O
90	O
%	O
or	O
greater	O
decrease	O
in	O
bone	O
marrow	O
plasma	O
cells	O
and	O
blood	O
M	O
-	O
protein	O
levels	O
.	O
Partial	O
response	O
(	O
PR	O
)	O
was	O
defined	O
as	O
50	O
%	O
or	O
greater	O
decrease	O
in	O
blood	O
and	O
bone	O
marrow	O
findings	O
.	O
Stable	O
disease	O
was	O
defined	O
as	O
less	O
than	O
25	O
%	O
decrease	O
in	O
blood	O
and	O
bone	O
marrow	O
findings	O
for	O
a	O
minimum	O
of	O
3	O
months	O
.	O
Progression	O
was	O
defined	O
as	O
greater	O
than	O
25	O
%	O
increase	O
in	O
M	O
protein	O
","	O
greater	O
than	O
25	O
%	O
increase	O
in	O
bone	O
marrow	O
plasma	O
cells	O
","	O
or	O
new	O
bone	O
lesions	O
.	O
2	O
.	O
5	O
.	O
Analysis	O
Descriptive	O
statistical	O
analyses	O
were	O
applied	O
for	O
patient	O
and	O
disease	O
characteristics	O
","	O
treatment	O
features	O
","	O
and	O
toxicity	O
.	O
All	O
analyses	O
were	O
performed	O
using	O
the	O
SPSS	O
","	O
version	O
12	O
.	O
0	O
(	O
SPSS	O
","	O
Chicago	O
","	O
IL	O
","	O
USA	O
).	O
3	O
.	O
Results	O
3	O
.	O
1	O
.	O
Patient	O
Population	O
Nine	O
patients	O
were	O
enrolled	O
between	O
2007	O
and	O
2010	O
.	O
In	O
arm	O
A	O
","	O
six	O
patients	O
received	O
the	O
common	O
conditioning	O
regimen	O
of	O
200	O
mg	O
/	O
m2	O
melphalan	B-Chemical
.	O
In	O
arm	O
B	O
","	O
three	O
patients	O
received	O
the	O
new	O
regimen	O
of	O
8	O
Gy	O
TMI	O
plus	O
140	O
mg	O
/	O
m2	O
melphalan	B-Chemical
.	O
All	O
of	O
the	O
patients	O
received	O
thalidomide	B-Chemical
for	O
maintenance	O
therapy	O
after	O
stem	O
cell	O
transplantation	O
.	O
Patient	O
characteristics	O
for	O
the	O
nine	O
patients	O
are	O
given	O
in	O
Table	O
1	O
.	O
The	O
median	O
age	O
was	O
54	O
for	O
arm	O
A	O
(	O
range	O
:	O
47	O
â€“	O
62	O
)	O
and	O
55	O
for	O
arm	O
B	O
(	O
range	O
:	O
55	O
â€“	O
56	O
).	O
The	O
majority	O
of	O
patients	O
were	O
treated	O
for	O
stage	O
III	O
disease	O
.	O
No	O
patient	O
had	O
received	O
prior	O
radiotherapy	O
.	O
3	O
.	O
2	O
.	O
Response	O
to	O
Induction	O
VAD	B-Chemical
Regimen	I-Chemical
and	O
HDT	O
In	O
arm	O
A	O
","	O
one	O
patient	O
achieved	O
CR	O
and	O
the	O
other	O
one	O
achieved	O
VGPR	O
before	O
ASCT	O
.	O
In	O
arm	O
B	O
","	O
one	O
patient	O
achieved	O
VGPR	O
before	O
ASCT	O
.	O
For	O
arm	O
A	O
versus	O
arm	O
B	O
","	O
the	O
CR	O
rate	O
to	O
HDT	O
was	O
1	O
/	O
6	O
versus	O
1	O
/	O
3	O
;	O
the	O
VGPR	O
rate	O
to	O
HDT	O
was	O
4	O
/	O
6	O
versus	O
1	O
/	O
3	O
;	O
the	O
median	O
OS	O
and	O
PFS	O
were	O
1223	O
versus	O
1556	O
days	O
and	O
982	O
versus	O
1101	O
days	O
","	O
respectively	O
(	O
Table	O
2	O
).	O
The	O
PFS	O
was	O
similar	O
in	O
the	O
two	O
arms	O
(	O
P	O
=	O
0	O
.	O
387	O
","	O
Figure	O
2	O
).	O
Each	O
group	O
had	O
one	O
patient	O
death	O
due	O
to	O
disease	O
progression	O
.	O
3	O
.	O
3	O
.	O
Toxicities	O
Table	O
3	O
illustrates	O
engraftment	O
","	O
hospitalization	O
time	O
","	O
and	O
transplantation	O
-	O
related	O
toxicities	O
.	O
In	O
arm	O
B	O
","	O
the	O
duration	O
of	O
neutropenia	O
was	O
one	O
day	O
longer	O
than	O
in	O
arm	O
A	O
(	O
P	O
=	O
0	O
.	O
48	O
","	O
Table	O
3	O
).	O
Similar	O
side	O
effects	O
were	O
noted	O
in	O
the	O
two	O
groups	O
.	O
However	O
","	O
arm	O
B	O
experienced	O
a	O
shorter	O
duration	O
of	O
thrombocytopenia	O
","	O
fewer	O
platelet	O
and	O
red	O
blood	O
cell	O
transfusions	O
","	O
and	O
a	O
shorter	O
duration	O
of	O
intravenous	O
antibiotic	O
therapy	O
than	O
in	O
arm	O
A	O
.	O
4	O
.	O
Discussion	O
In	O
newly	O
diagnosed	O
patients	O
with	O
MM	O
treated	O
with	O
high	O
-	O
dose	O
radiotherapy	O
","	O
the	O
goal	O
of	O
the	O
conditioning	O
regimen	O
is	O
to	O
achieve	O
the	O
best	O
response	O
rate	O
with	O
the	O
least	O
toxicity	O
.	O
The	O
most	O
widely	O
used	O
conditioning	O
regimens	O
are	O
HDM200	B-Chemical
and	O
HDM140	B-Chemical
+	O
TBI	O
.	O
The	O
Intergroupe	O
Francophone	O
du	O
MyÃ©lome	O
90	O
trial	O
prospectively	O
compared	O
conventional	O
chemotherapy	O
with	O
high	O
-	O
dose	O
radiotherapy	O
.	O
In	O
this	O
trial	O
the	O
conditioning	O
regimen	O
consisted	O
of	O
8	O
Gy	O
TBI	O
plus	O
HDM140	B-Chemical
.	O
The	O
CR	O
rate	O
after	O
intensive	O
therapy	O
was	O
22	O
"%,"	O
and	O
the	O
response	O
rate	O
","	O
event	O
-	O
free	O
survival	O
","	O
and	O
overall	O
survival	O
in	O
patients	O
with	O
MM	O
were	O
improved	O
.	O
Furthermore	O
","	O
Moreau	O
et	O
al	O
.	O
compared	O
HDM200	B-Chemical
and	O
HDM140	B-Chemical
+	O
8	O
Gy	O
TBI	O
as	O
conditioning	O
regimens	O
for	O
peripheral	O
blood	O
stem	O
cell	O
transplantation	O
in	O
patients	O
with	O
newly	O
diagnosed	O
MM	O
.	O
They	O
reported	O
that	O
HDM200	B-Chemical
could	O
be	O
an	O
alternative	O
conditioning	O
regimen	O
for	O
MM	O
.	O
The	O
pulmonary	O
complications	O
were	O
statistically	O
increased	O
by	O
prone	O
and	O
supine	O
versus	O
lateral	O
TBI	O
position	O
(	O
P	O
=	O
0	O
.	O
2	O
)	O
and	O
with	O
15	O
MV	O
versus	O
9	O
MV	O
beam	O
energy	O
(	O
P	O
=	O
0	O
.	O
2	O
).	O
A	O
conditioning	O
regimen	O
of	O
12	O
Gy	O
TBI	O
in	O
6	O
daily	O
fractions	O
induces	O
an	O
interstitial	O
pneumonitis	O
incidence	O
of	O
about	O
11	O
%	O
in	O
the	O
absence	O
of	O
lung	O
shielding	O
.	O
Fatal	O
interstitial	O
pneumonitis	O
using	O
hyperfractionated	O
TBI	O
with	O
standing	O
position	O
was	O
still	O
as	O
high	O
as	O
18	O
%.	O
Compared	O
with	O
TBI	O
technique	O
","	O
doses	O
to	O
the	O
sensitive	O
organs	O
in	O
TMI	O
techniques	O
were	O
reduced	O
by	O
15	O
%â€“	O
70	O
%	O
of	O
the	O
target	O
dose	O
or	O
1	O
.	O
7	O
-	O
to	O
7	O
.	O
5	O
-	O
fold	O
reduction	O
in	O
median	O
organ	O
doses	O
.	O
Somlo	O
et	O
al	O
.	O
reported	O
that	O
the	O
estimated	O
median	O
radiation	O
dose	O
to	O
normal	O
organs	O
was	O
11	O
%	O
to	O
81	O
%	O
of	O
the	O
prescribed	O
marrow	O
dose	O
.	O
In	O
our	O
previous	O
report	O
","	O
the	O
dose	O
reduction	O
of	O
TMI	O
tomotherapy	O
to	O
various	O
OARs	O
of	O
head	O
","	O
chest	O
","	O
and	O
abdomen	O
relative	O
to	O
TBI	O
varied	O
from	O
31	O
%	O
to	O
74	O
"%,"	O
21	O
%	O
to	O
51	O
"%,"	O
and	O
46	O
%	O
to	O
63	O
"%,"	O
respectively	O
.	O
The	O
potential	O
advantages	O
","	O
acute	O
toxicities	O
","	O
initial	O
clinical	O
experiences	O
","	O
and	O
challenges	O
of	O
this	O
approach	O
were	O
reported	O
recently	O
.	O
The	O
maximum	O
tolerated	O
dose	O
for	O
TMI	O
was	O
1	O
","	O
600	O
cGy	O
(	O
200	O
cGy	O
twice	O
daily	O
Ã—	O
4	O
days	O
).	O
Under	O
these	O
doses	O
","	O
grade	O
3	O
or	O
4	O
nausea	O
/	O
emesis	O
","	O
fatigue	O
","	O
and	O
metabolic	O
abnormality	O
were	O
2	O
/	O
22	O
","	O
2	O
/	O
22	O
","	O
and	O
4	O
/	O
22	O
","	O
respectively	O
.	O
Wong	O
et	O
al	O
.	O
reported	O
that	O
grade	O
2	O
nausea	O
and	O
grade	O
1	O
emesis	O
occurred	O
only	O
briefly	O
on	O
day	O
2	O
of	O
TMI	O
.	O
Skin	O
erythema	O
","	O
oral	O
mucositis	O
","	O
esophagitis	O
","	O
and	O
enteritis	O
were	O
not	O
observed	O
.	O
In	O
our	O
previous	O
experience	O
of	O
TMI	O
treatment	O
","	O
one	O
with	O
grade	O
1	O
vomiting	O
","	O
two	O
with	O
grade	O
1	O
nausea	O
","	O
one	O
with	O
grade	O
1	O
mucositis	O
","	O
and	O
three	O
with	O
grade	O
1	O
anorexia	O
were	O
noted	O
.	O
These	O
data	O
hit	O
the	O
potential	O
dosimetric	O
and	O
clinical	O
advantages	O
of	O
TMI	O
.	O
Interestingly	O
","	O
the	O
outcomes	O
for	O
the	O
HDM200	B-Chemical
and	O
HDM140	B-Chemical
+	O
TMI	O
8	O
Gy	O
conditioning	O
regimens	O
for	O
MM	O
are	O
still	O
inconclusive	O
.	O
In	O
the	O
current	O
study	O
","	O
the	O
CR	O
and	O
VGPR	O
rates	O
for	O
arm	O
A	O
and	O
arm	O
B	O
were	O
16	O
.	O
7	O
%	O
and	O
33	O
.	O
3	O
"%,"	O
66	O
.	O
7	O
%	O
and	O
33	O
.	O
3	O
"%,"	O
respectively	O
.	O
The	O
median	O
OS	O
and	O
PFS	O
were	O
1223	O
versus	O
1556	O
days	O
and	O
982	O
versus	O
1101	O
days	O
","	O
respectively	O
(	O
Table	O
2	O
).	O
Additionally	O
","	O
the	O
PFS	O
rate	O
was	O
similar	O
(	O
Figure	O
2	O
).	O
With	O
similar	O
results	O
as	O
HDM200	B-Chemical
","	O
HDM140	B-Chemical
+	O
TMI	O
8	O
Gy	O
provide	O
another	O
chance	O
to	O
think	O
about	O
for	O
MM	O
Asian	O
patients	O
who	O
were	O
not	O
feasible	O
for	O
HDM200	B-Chemical
.	O
However	O
","	O
the	O
lower	O
relapse	O
probability	O
is	O
noted	O
in	O
the	O
patients	O
receiving	O
the	O
higher	O
dose	O
of	O
total	O
body	O
irradiation	O
.	O
In	O
the	O
current	O
study	O
","	O
the	O
dose	O
of	O
TMI	O
is	O
only	O
8	O
Gy	O
.	O
There	O
still	O
are	O
spaces	O
to	O
titrate	O
the	O
radiation	O
dose	O
for	O
the	O
Asian	O
in	O
the	O
future	O
.	O
Thalidomide	B-Chemical
has	O
a	O
broad	O
spectrum	O
of	O
activities	O
in	O
multiple	O
myeloma	O
and	O
is	O
considered	O
to	O
improve	O
event	O
-	O
free	O
survival	O
and	O
OS	O
.	O
The	O
multiple	O
effects	O
include	O
direct	O
inhibition	O
of	O
myeloma	O
cell	O
growth	O
and	O
survival	O
","	O
direct	O
stimulation	O
of	O
the	O
cellular	O
immune	O
system	O
","	O
modulation	O
of	O
integrins	O
compromising	O
the	O
adhesive	O
interactions	O
between	O
the	O
myeloma	O
cells	O
and	O
bone	O
marrow	O
stroma	O
","	O
and	O
antiangiogenic	O
effects	O
.	O
Previous	O
studies	O
demonstrated	O
the	O
impact	O
of	O
thalidomide	B-Chemical
maintenance	O
of	O
response	O
after	O
stem	O
cell	O
transplantation	O
that	O
improved	O
event	O
-	O
free	O
survival	O
","	O
complete	O
response	O
rate	O
","	O
and	O
PFS	O
rate	O
.	O
In	O
the	O
current	O
study	O
","	O
since	O
the	O
median	O
PFS	O
was	O
similar	O
between	O
the	O
groups	O
","	O
HDM140	B-Chemical
+	O
TMI	O
8	O
Gy	O
appears	O
to	O
be	O
as	O
effective	O
as	O
HDM200	B-Chemical
for	O
Asians	O
with	O
MM	O
.	O
Compared	O
with	O
HDM200	B-Chemical
","	O
HDM140	B-Chemical
+	O
TBI	O
had	O
a	O
greater	O
toxicity	O
regarding	O
severe	O
mucositis	O
","	O
duration	O
of	O
neutropenia	O
and	O
thrombocytopenia	O
","	O
number	O
of	O
red	O
blood	O
cell	O
and	O
platelet	O
transfusions	O
","	O
number	O
of	O
days	O
on	O
antibiotics	O
","	O
and	O
duration	O
of	O
hospitalization	O
.	O
In	O
the	O
total	O
therapy	O
program	O
","	O
Barlogie	O
et	O
al	O
.	O
used	O
HDM200	B-Chemical
for	O
the	O
second	O
transplantation	O
in	O
responding	O
patients	O
.	O
They	O
found	O
that	O
HDM140	B-Chemical
+	O
8	O
.	O
5	O
-	O
to	O
10	O
-	O
Gy	O
TBI	O
was	O
quite	O
toxic	O
","	O
and	O
only	O
10	O
%	O
of	O
the	O
patients	O
had	O
no	O
serious	O
extramedullary	O
toxicity	O
.	O
Treatment	O
-	O
related	O
mortality	O
was	O
2	O
%	O
with	O
the	O
second	O
autotransplantation	O
using	O
HDM200	B-Chemical
alone	O
and	O
rose	O
to	O
5	O
%	O
with	O
added	O
TBI	O
.	O
In	O
another	O
retrospective	O
evaluation	O
","	O
the	O
duration	O
of	O
hospitalization	O
was	O
significantly	O
reduced	O
in	O
the	O
HDM200	B-Chemical
cohort	O
compared	O
with	O
HDM140	B-Chemical
+	O
TBI	O
or	O
HDM140	B-Chemical
+	O
busulfan	B-Chemical
cohort	O
.	O
No	O
treatment	O
-	O
related	O
mortality	O
was	O
noted	O
in	O
the	O
current	O
study	O
.	O
In	O
addition	O
","	O
there	O
were	O
no	O
statistically	O
significant	O
differences	O
between	O
groups	O
for	O
engraftment	O
","	O
duration	O
of	O
thrombocytopenia	O
","	O
number	O
of	O
red	O
blood	O
cell	O
and	O
platelet	O
transfusions	O
","	O
duration	O
of	O
antibiotic	O
infusion	O
days	O
","	O
and	O
hospitalization	O
time	O
.	O
HDM140	B-Chemical
+	O
TMI	O
8	O
Gy	O
provided	O
the	O
similar	O
effects	O
and	O
toxicities	O
of	O
a	O
conditioning	O
regimen	O
as	O
HDM200	B-Chemical
dosing	O
.	O
Moreau	O
et	O
al	O
.	O
noted	O
slower	O
engraftment	O
after	O
HDM140	B-Chemical
+	O
TBI	O
","	O
despite	O
the	O
higher	O
median	O
number	O
of	O
CD34	O
cells	O
infused	O
than	O
with	O
HDM200	B-Chemical
(	O
7	O
.	O
3	O
versus	O
5	O
","	O
P	O
=	O
0	O
.	O
3	O
).	O
Furthermore	O
","	O
compared	O
with	O
pregraft	O
and	O
normal	O
control	O
samples	O
","	O
patients	O
treated	O
with	O
high	O
-	O
dose	O
radiotherapy	O
and	O
autologous	O
bone	O
marrow	O
transplantation	O
revealed	O
that	O
conditioning	O
regimens	O
with	O
TBI	O
led	O
more	O
frequently	O
to	O
nonconfluent	O
stromal	O
layers	O
.	O
Another	O
study	O
group	O
analyzed	O
fibroblast	O
colony	O
-	O
forming	O
units	O
","	O
the	O
precursor	O
compartment	O
for	O
the	O
microenvironmental	O
lineages	O
essential	O
to	O
hematopoietic	O
stem	O
cell	O
survival	O
","	O
proliferation	O
","	O
and	O
differentiation	O
.	O
The	O
authors	O
imply	O
that	O
the	O
fibroblast	O
damage	O
could	O
be	O
due	O
to	O
the	O
pretransplantation	O
conditioning	O
regimen	O
.	O
Bentley	O
et	O
al	O
.	O
described	O
patients	O
who	O
remained	O
platelet	O
and	O
/	O
or	O
red	O
cell	O
transfusion	O
dependent	O
for	O
100	O
days	O
or	O
more	O
after	O
transplantation	O
even	O
after	O
substantial	O
neutrophil	O
recovery	O
.	O
A	O
significantly	O
higher	O
proportion	O
of	O
these	O
patients	O
had	O
received	O
TBI	O
as	O
part	O
of	O
their	O
conditioning	O
regimen	O
.	O
Together	O
with	O
these	O
data	O
","	O
TBI	O
may	O
in	O
some	O
cases	O
impair	O
the	O
early	O
and	O
late	O
capacities	O
of	O
the	O
marrow	O
microenvironment	O
to	O
support	O
transplanted	O
stem	O
cells	O
.	O
We	O
noted	O
similar	O
median	O
numbers	O
of	O
CD34	O
cells	O
infused	O
and	O
numbers	O
of	O
red	O
blood	O
cell	O
and	O
platelet	O
transfusions	O
in	O
both	O
groups	O
","	O
except	O
for	O
the	O
duration	O
of	O
neutropenia	O
.	O
These	O
data	O
suggest	O
a	O
potential	O
benefit	O
of	O
TMI	O
that	O
could	O
diminish	O
impairment	O
of	O
the	O
marrow	O
microenvironment	O
and	O
provide	O
similar	O
results	O
as	O
HDM200	B-Chemical
.	O
There	O
are	O
some	O
limitations	O
to	O
our	O
current	O
study	O
.	O
First	O
","	O
the	O
small	O
case	O
number	O
and	O
the	O
retrospective	O
study	O
design	O
make	O
statistical	O
conclusions	O
highly	O
tentative	O
.	O
However	O
","	O
in	O
the	O
current	O
study	O
","	O
the	O
percentages	O
of	O
stage	O
III	O
for	O
both	O
groups	O
were	O
more	O
than	O
80	O
%.	O
With	O
the	O
similar	O
progression	O
-	O
free	O
survival	O
days	O
for	O
both	O
groups	O
","	O
HDM	B-Chemical
140	O
+	O
TMI	O
regimen	O
provided	O
another	O
chance	O
for	O
multiple	O
myloma	O
Asian	O
patients	O
who	O
could	O
not	O
tolerate	O
HDM200	B-Chemical
regimen	O
.	O
Second	O
","	O
the	O
follow	O
-	O
up	O
time	O
was	O
short	O
so	O
that	O
late	O
effects	O
are	O
insufficiently	O
addressed	O
.	O
5	O
.	O
Conclusions	O
Based	O
on	O
these	O
preliminary	O
data	O
","	O
we	O
are	O
encouraged	O
by	O
the	O
clinical	O
results	O
of	O
HDM140	B-Chemical
+	O
TMI	O
8	O
Gy	O
treatment	O
of	O
Asian	O
patients	O
with	O
MM	O
.	O
This	O
regimen	O
has	O
manageable	O
toxicity	O
and	O
is	O
at	O
least	O
as	O
effective	O
of	O
a	O
conditioning	O
regimen	O
as	O
HDM200	B-Chemical
.	O
Further	O
evaluation	O
is	O
needed	O
to	O
learn	O
what	O
longer	O
-	O
term	O
effect	O
the	O
regimen	O
will	O
have	O
on	O
disease	O
control	O
.	O
Additionally	O
","	O
long	O
-	O
term	O
followup	O
is	O
needed	O
to	O
characterize	O
the	O
long	O
-	O
term	O
toxicities	O
and	O
assess	O
the	O
full	O
impact	O
in	O
this	O
new	O
approach	O
to	O
ASCT	O
pretreatment	O
in	O
Asian	O
patients	O
with	O
MM	O
.	O
Study	O
design	O
profile	O
.	O
Cumulative	O
(	O
Cum	O
)	O
survival	O
curves	O
for	O
patients	O
treated	O
with	O
HDM200	B-Chemical
or	O
HDM140	B-Chemical
+	O
TMI	O
8	O
Gy	O
.	O
Curve	O
for	O
progression	O
-	O
free	O
survival	O
(	O
according	O
to	O
treatment	O
group	O
)	O
was	O
illustrated	O
.	O
Cum	O
survival	O
:	O
Cumulative	O
survival	O
.	O
Main	O
characteristics	O
at	O
diagnosis	O
of	O
the	O
nine	O
patients	O
according	O
to	O
treatment	O
group	O
.	O
CR	O
:	O
complete	O
response	O
;	O
VGPR	O
:	O
very	O
good	O
partial	O
response	O
;	O
PR	O
:	O
partial	O
response	O
.	O
Response	O
to	O
induction	O
vincristine	B-Chemical
-	I-Chemical
adriamycin	I-Chemical
-	I-Chemical
dexamethasone	I-Chemical
(	O
VAD	B-Chemical
)	O
regimen	O
and	O
high	O
dose	O
therapy	O
(	O
HDT	O
).	O
*:	O
P	O
value	O
<	O
0	O
.	O
5	O
.	O
Engraftment	O
","	O
hospitalization	O
time	O
","	O
and	O
transplantation	O
-	O
related	O
toxicity	O
.	O
Study	O
on	O
the	O
Apoptosis	O
Mechanism	O
Induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
Toxin	I-Chemical
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
is	O
known	O
to	O
induce	O
apoptosis	O
in	O
mammalian	O
cells	O
.	O
The	O
mechanism	O
of	O
apoptosis	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
has	O
been	O
proposed	O
to	O
be	O
linked	O
with	O
oxidative	O
stress	O
and	O
mitochondrial	O
pathway	O
.	O
In	O
the	O
current	O
study	O
","	O
the	O
toxic	O
effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
on	O
Hela	O
","	O
Bel	O
-	O
7402	O
","	O
and	O
Chang	O
liver	O
cells	O
was	O
examined	O
in	O
dose	O
-	O
dependent	O
and	O
time	O
-	O
dependent	O
manner	O
by	O
MTT	B-Chemical
assay	O
.	O
Caspase	O
-	O
3	O
was	O
found	O
to	O
be	O
up	O
-	O
regulated	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
","	O
which	O
suggested	O
that	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
induced	O
cell	O
apoptosis	O
.	O
Endogenous	O
GSH	B-Chemical
and	O
MDA	B-Chemical
levels	O
in	O
all	O
three	O
cell	O
lines	O
were	O
found	O
down	O
-	O
and	O
up	O
-	O
regulated	O
respectively	O
","	O
which	O
indicated	O
the	O
link	O
between	O
toxic	O
effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
and	O
intracellular	O
oxidative	O
stress	O
.	O
It	O
was	O
also	O
found	O
by	O
MTT	B-Chemical
assay	O
that	O
NAC	B-Chemical
","	O
which	O
maintained	O
the	O
level	O
of	O
GSH	B-Chemical
in	O
cells	O
","	O
could	O
protect	O
cells	O
from	O
death	O
.	O
Western	O
-	O
blot	O
result	O
showed	O
that	O
the	O
level	O
of	O
both	O
activated	O
Caspase	O
-	O
8	O
and	O
Caspase	O
-	O
9	O
increased	O
when	O
cells	O
were	O
treated	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
Caspase	O
-	O
9	O
was	O
found	O
to	O
be	O
activated	O
earlier	O
than	O
Caspase	O
-	O
8	O
.	O
It	O
was	O
also	O
found	O
that	O
p53	O
was	O
up	O
-	O
regulated	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
in	O
the	O
study	O
.	O
These	O
results	O
implied	O
that	O
the	O
effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
on	O
cells	O
was	O
apoptosis	O
rather	O
than	O
necrosis	O
","	O
and	O
it	O
was	O
probably	O
induced	O
through	O
mitochondrial	O
pathway	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
","	O
the	O
present	O
study	O
is	O
the	O
first	O
to	O
show	O
that	O
JunD	O
is	O
down	O
-	O
regulated	O
in	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
induced	O
apoptosis	O
.	O
By	O
construction	O
of	O
an	O
over	O
-	O
expression	O
vector	O
for	O
the	O
JunD	O
gene	O
","	O
we	O
observed	O
that	O
the	O
survival	O
ratio	O
of	O
JunD	O
over	O
-	O
expressed	O
cells	O
obviously	O
increased	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
.	O
These	O
results	O
suggested	O
that	O
the	O
mechanism	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
induced	O
cell	O
death	O
was	O
closely	O
connected	O
with	O
oxidative	O
stress	O
","	O
and	O
that	O
JunD	O
plays	O
an	O
important	O
role	O
in	O
the	O
defensive	O
process	O
against	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
.	O
Introduction	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
","	O
a	O
fungal	O
secondary	O
metabolite	O
","	O
is	O
one	O
of	O
the	O
type	O
A	O
Trichothecenes	B-Chemical
","	O
.	O
Ingestion	O
by	O
humans	O
or	O
livestock	O
of	O
cereals	O
contaminated	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
can	O
cause	O
adverse	O
reactions	O
","	O
such	O
as	O
vomit	O
","	O
diarrhea	O
","	O
and	O
even	O
death	O
","	O
.	O
Alimentary	O
toxic	O
aleukia	O
(	O
ATA	O
"),"	O
mainly	O
due	O
to	O
ingestion	O
of	O
cereal	O
containing	O
large	O
amounts	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
has	O
been	O
reported	O
to	O
cause	O
the	O
death	O
of	O
a	O
large	O
number	O
of	O
people	O
.	O
Injection	O
of	O
large	O
dose	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
to	O
rat	O
caused	O
cardiomyopathy	O
","	O
which	O
was	O
similar	O
to	O
the	O
symptom	O
of	O
ATA	O
","	O
.	O
In	O
view	O
of	O
the	O
great	O
harm	O
to	O
the	O
health	O
of	O
human	O
and	O
livestock	O
","	O
the	O
toxicological	O
effects	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
was	O
reported	O
in	O
the	O
Joint	O
Food	O
and	O
Agriculture	O
Organization	O
/	O
World	O
Health	O
Organization	O
(	O
FAO	O
/	O
WHO	O
)	O
Expert	O
Committee	O
on	O
Food	O
Additives	O
","	O
â€“.	O
It	O
was	O
reported	O
that	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
could	O
affect	O
protein	O
synthesis	O
by	O
its	O
affinity	O
with	O
trans	O
-	O
peptidase	O
","	O
one	O
of	O
the	O
important	O
subunits	O
in	O
ribosome	O
","	O
and	O
the	O
biosynthesis	O
of	O
DNA	O
and	O
RNA	O
were	O
also	O
inhibited	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
","	O
.	O
It	O
was	O
also	O
found	O
that	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
could	O
interfere	O
with	O
the	O
cytomembrane	O
phosphorylation	O
and	O
cause	O
lipid	O
peroxidation	O
in	O
liver	O
.	O
Islam	O
et	O
al	O
.	O
(	O
1998	O
)	O
reported	O
that	O
the	O
effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
on	O
mice	O
thymocytes	O
was	O
apoptosis	O
.	O
Shinozuka	O
et	O
al	O
.	O
(	O
1997	O
)	O
also	O
found	O
that	O
the	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
induced	O
lymphocyte	O
death	O
was	O
by	O
apoptosis	O
.	O
It	O
was	O
confirmed	O
by	O
in	O
situ	O
hybridization	O
that	O
the	O
apoptotic	O
process	O
was	O
accompanied	O
by	O
DNA	O
damage	O
.	O
Wang	O
et	O
al	O
.	O
(	O
2012	O
)	O
further	O
reported	O
that	O
JAK	O
/	O
STAT	O
(	O
Janus	O
kinase	O
/	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
trichothecenes	B-Chemical
induced	O
apoptosis	O
.	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
mainly	O
acted	O
on	O
the	O
metabolically	O
active	O
organs	O
","	O
such	O
as	O
spleen	O
","	O
thymus	O
","	O
marrow	O
","	O
stem	O
cells	O
","	O
and	O
so	O
on	O
","	O
","	O
.	O
The	O
apoptotic	O
process	O
is	O
initiated	O
by	O
a	O
series	O
of	O
oxidative	O
stress	O
","	O
and	O
subsequently	O
cells	O
enter	O
the	O
mitochondrial	O
death	O
pathway	O
","	O
.	O
It	O
was	O
reported	O
that	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
not	O
only	O
could	O
down	O
-	O
regulate	O
intracellular	O
reduced	O
GSH	B-Chemical
(	O
Glutathione	B-Chemical
"),"	O
but	O
also	O
could	O
up	O
-	O
regulate	O
intracellular	O
total	O
ROS	B-Chemical
(	O
Reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
)	O
","	O
which	O
showed	O
intrinsic	O
link	O
between	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
-	O
induced	O
apoptosis	O
and	O
oxidative	O
stress	O
.	O
But	O
the	O
mechanism	O
of	O
how	O
oxidative	O
stress	O
induces	O
apoptosis	O
is	O
still	O
unclear	O
.	O
JunD	O
","	O
a	O
member	O
of	O
the	O
AP	O
-	O
1	O
family	O
of	O
transcription	O
factors	O
","	O
regulates	O
genes	O
involved	O
in	O
antioxidant	O
defense	O
.	O
Gerald	O
et	O
al	O
.	O
(	O
2004	O
)	O
found	O
that	O
JunD	O
could	O
reduce	O
angiogenesis	O
in	O
tumor	O
by	O
reducing	O
ROS	B-Chemical
","	O
and	O
demonstrated	O
that	O
JunD	O
involved	O
in	O
regulation	O
of	O
antioxidant	O
defense	O
.	O
Toullec	O
et	O
al	O
.	O
(	O
2010	O
)	O
took	O
advantage	O
of	O
JunD	O
deletion	O
cell	O
strain	O
to	O
examine	O
the	O
role	O
of	O
ROS	B-Chemical
in	O
tumor	O
development	O
","	O
and	O
uncovered	O
the	O
role	O
of	O
JunD	O
in	O
the	O
suppression	O
of	O
the	O
migratory	O
properties	O
of	O
stromal	O
fibroblasts	O
","	O
which	O
in	O
turn	O
potentiate	O
tumor	O
dissemination	O
.	O
However	O
","	O
there	O
are	O
still	O
not	O
any	O
reports	O
on	O
the	O
effect	O
of	O
JunD	O
in	O
the	O
process	O
of	O
apoptosis	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
In	O
view	O
of	O
the	O
harmful	O
effects	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
","	O
this	O
study	O
focused	O
on	O
the	O
mechanism	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
-	O
induced	O
apoptosis	O
","	O
and	O
on	O
the	O
role	O
of	O
oxidative	O
stress	O
","	O
especially	O
the	O
function	O
of	O
JunD	O
","	O
in	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
induced	O
apoptotic	O
process	O
.	O
Materials	O
and	O
Methods	O
Ethics	O
Statement	O
All	O
animal	O
work	O
was	O
performed	O
according	O
to	O
relevant	O
national	O
and	O
international	O
guidelines	O
.	O
All	O
animal	O
experiments	O
were	O
complied	O
with	O
the	O
rules	O
by	O
the	O
Animal	O
Ethics	O
Committee	O
of	O
the	O
Fujian	O
Agriculture	O
and	O
Forestry	O
University	O
.	O
Materials	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
was	O
purchased	O
from	O
Sigma	O
Corporation	O
(	O
USA	O
"),"	O
and	O
caspase	O
-	O
3	O
colorimetric	O
assay	O
kit	O
and	O
MTT	B-Chemical
(	O
3	B-Chemical
-(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
Dimethylthiazol	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
yl	I-Chemical
)-	I-Chemical
2	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
diphenyltetrazolium	I-Chemical
)	O
assay	O
kit	O
were	O
from	O
Nanjing	O
Keygen	O
Biotech	O
Co	O
.	O
Ltd	O
(	O
China	O
).	O
Lipofectamine	B-Chemical
2000	I-Chemical
","	O
anti	O
-	O
caspase	O
-	O
3	O
antibody	O
","	O
anti	O
-	O
caspase	O
-	O
8	O
antibody	O
","	O
anti	O
-	O
caspase	O
-	O
9	O
antibody	O
","	O
anti	O
-	O
JunD	O
antibody	O
","	O
GSH	B-Chemical
assay	O
kit	O
","	O
and	O
MDA	B-Chemical
(	O
Malondialdehyde	B-Chemical
)	O
assay	O
kit	O
were	O
from	O
Beyotime	O
Institute	O
of	O
Biotechnology	O
(	O
China	O
).	O
The	O
other	O
chemical	O
reagents	O
used	O
were	O
of	O
analytical	O
grade	O
.	O
E	O
.	O
coli	O
BL21	O
(	O
DE3	O
)	O
and	O
DH5Î±	O
","	O
and	O
interference	O
vector	O
pSliencer4	O
.	O
1	O
were	O
preserved	O
in	O
our	O
lab	O
.	O
Cell	O
lines	O
(	O
Hela	O
","	O
Bel	O
-	O
7402	O
","	O
and	O
Chang	O
liver	O
cells	O
)	O
were	O
purchased	O
from	O
a	O
typical	O
cell	O
culture	O
collection	O
Committee	O
of	O
the	O
Chinese	O
Academy	O
of	O
Sciences	O
Library	O
","	O
and	O
cultured	O
in	O
RPMI	B-Chemical
medium	I-Chemical
1640	I-Chemical
supplemented	O
with	O
10	O
%	O
FBS	O
(	O
fetal	O
bovine	O
serum	O
","	O
Biotechnology	O
Ltd	O
.	O
Co	O
".,"	O
Shanghai	O
","	O
China	O
)	O
.	O
Inhibition	O
Effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
Toxin	I-Chemical
on	O
Cells	O
Cells	O
(	O
Hela	O
","	O
Bel	O
-	O
7402	O
","	O
and	O
Chang	O
liver	O
)	O
in	O
logarithmic	O
growth	O
phase	O
were	O
transferred	O
into	O
96	O
-	O
well	O
plate	O
(	O
106	O
cells	O
per	O
well	O
","	O
the	O
cell	O
density	O
in	O
the	O
following	O
experiments	O
was	O
the	O
same	O
"),"	O
and	O
were	O
cultivated	O
overnight	O
.	O
Then	O
","	O
100	O
ÂµL	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
of	O
various	O
concentration	O
(	O
2000	O
","	O
1000	O
","	O
500	O
","	O
250	O
","	O
125	O
","	O
62	O
","	O
and	O
30	O
ng	O
/	O
mL	O
)	O
was	O
added	O
respectively	O
.	O
DMSO	B-Chemical
(	O
Dimethyl	B-Chemical
sulfoxide	I-Chemical
"),"	O
the	O
solvent	O
for	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
","	O
was	O
added	O
as	O
control	O
.	O
After	O
the	O
cells	O
were	O
incubated	O
with	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
for	O
24	O
h	O
","	O
MTT	B-Chemical
was	O
added	O
.	O
Finally	O
","	O
the	O
OD570	O
value	O
was	O
detected	O
with	O
microplate	O
reader	O
.	O
The	O
survival	O
rate	O
was	O
calculated	O
with	O
the	O
control	O
as	O
the	O
reference	O
.	O
The	O
lgIC50	O
of	O
different	O
cell	O
lines	O
was	O
detected	O
by	O
the	O
instruction	O
of	O
MTT	B-Chemical
assay	O
kit	O
:	O
lgIC50	O
=	O
Xm	O
â€“	O
I	O
*(	O
P	O
âˆ’	O
0	O
.	O
5	O
"),"	O
Xm	O
:	O
maximum	O
dose	O
","	O
I	O
:	O
maximum	O
dose	O
/	O
adjacent	O
dose	O
","	O
P	O
:	O
the	O
sum	O
of	O
all	O
mortality	O
.	O
Inhibition	O
rate	O
=	O
(	O
1	O
â€“	O
OD	O
value	O
of	O
test	O
group	O
)/	O
OD	O
value	O
of	O
control	O
group	O
.	O
Detection	O
of	O
the	O
GSH	B-Chemical
and	O
MDA	B-Chemical
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
Toxin	I-Chemical
Stress	O
Cells	O
in	O
logarithmic	O
growth	O
phase	O
were	O
transferred	O
into	O
96	O
-	O
well	O
plate	O
","	O
and	O
were	O
cultivated	O
overnight	O
.	O
In	O
every	O
well	O
","	O
1	O
.	O
6	O
mL	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
at	O
a	O
concentration	O
of	O
LC50	O
(	O
50	O
%	O
lethal	O
concentration	O
)	O
was	O
added	O
","	O
and	O
the	O
cells	O
were	O
cultivated	O
for	O
0	O
","	O
4	O
","	O
8	O
","	O
16	O
","	O
24	O
h	O
respectively	O
.	O
After	O
the	O
incubation	O
","	O
cells	O
were	O
washed	O
twice	O
by	O
PBS	B-Chemical
","	O
the	O
cells	O
were	O
mixed	O
with	O
protein	O
removal	O
reagent	O
(	O
S	O
solution	O
)	O
at	O
an	O
amount	O
of	O
three	O
times	O
volume	O
of	O
cell	O
pellet	O
","	O
and	O
fully	O
shocked	O
by	O
vortex	O
.	O
Following	O
twice	O
rapid	O
freezing	O
in	O
liquid	O
nitrogen	B-Chemical
and	O
thawing	O
in	O
37	O
Â°	O
C	O
water	B-Chemical
bath	O
","	O
the	O
samples	O
were	O
keep	O
on	O
ice	O
for	O
5	O
min	O
and	O
centrifuged	O
at	O
10000	O
g	O
for	O
10	O
min	O
under	O
4	O
Â°	O
C	O
.	O
At	O
last	O
","	O
the	O
volume	O
of	O
endogenic	O
GSH	B-Chemical
was	O
detected	O
following	O
the	O
instruction	O
of	O
GSH	B-Chemical
extract	O
and	O
assay	O
kit	O
","	O
and	O
the	O
volume	O
of	O
endogenic	O
MDA	B-Chemical
was	O
detected	O
following	O
the	O
instruction	O
of	O
MDA	B-Chemical
extract	O
and	O
assay	O
kit	O
.	O
Effect	O
of	O
NAC	B-Chemical
on	O
Cells	O
â€™	O
Viability	O
and	O
GSH	B-Chemical
Level	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
Toxin	I-Chemical
Stress	O
Cells	O
in	O
logarithmic	O
growth	O
phase	O
were	O
transferred	O
into	O
96	O
-	O
well	O
plate	O
","	O
and	O
were	O
cultivated	O
overnight	O
.	O
In	O
every	O
well	O
100	O
ÂµL	O
5	O
Âµmol	O
/	O
L	O
NAC	B-Chemical
(	O
N	B-Chemical
-	I-Chemical
acetyl	I-Chemical
cysteine	I-Chemical
)	O
was	O
added	O
and	O
incubated	O
for	O
4	O
h	O
.	O
After	O
the	O
cells	O
were	O
washed	O
twice	O
by	O
PBS	B-Chemical
","	O
every	O
well	O
was	O
treated	O
with	O
100	O
ÂµL	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
at	O
a	O
concentration	O
of	O
LC50	O
","	O
and	O
cultivated	O
for	O
6	O
","	O
12	O
","	O
18	O
","	O
24	O
h	O
respectively	O
.	O
Following	O
steps	O
referred	O
to	O
the	O
methods	O
mentioned	O
in	O
MTT	B-Chemical
assay	O
kit	O
and	O
GSH	B-Chemical
detection	O
and	O
assay	O
kit	O
.	O
Detection	O
of	O
Caspase	O
-	O
3	O
","	O
8	O
","	O
9	O
","	O
p53	O
","	O
and	O
JunD	O
by	O
Western	O
-	O
blot	O
Analysis	O
Cellular	O
cultivation	O
and	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
treatment	O
was	O
the	O
same	O
to	O
that	O
mentioned	O
above	O
.	O
The	O
cells	O
in	O
96	O
-	O
well	O
plate	O
were	O
cultivated	O
for	O
8	O
","	O
16	O
","	O
24	O
h	O
respectively	O
.	O
After	O
the	O
cells	O
were	O
collected	O
and	O
washed	O
twice	O
by	O
PBS	B-Chemical
","	O
cells	O
were	O
lysed	O
for	O
3	O
min	O
in	O
100	O
ÂµL	O
lysis	O
buffer	O
","	O
then	O
were	O
centrifuged	O
at	O
1000	O
g	O
for	O
10	O
min	O
","	O
and	O
the	O
supernatant	O
was	O
kept	O
on	O
ice	O
for	O
further	O
Western	O
-	O
blot	O
analysis	O
.	O
Samples	O
were	O
used	O
for	O
SDS	B-Chemical
/	O
PAGE	O
on	O
12	O
%	O
gels	O
by	O
discontinuous	O
buffer	O
system	O
at	O
15	O
mA	O
.	O
Proteins	O
from	O
the	O
gels	O
were	O
transferred	O
to	O
Nitrocellulose	B-Chemical
(	O
NC	B-Chemical
)	O
membranes	O
for	O
1	O
h	O
at	O
60	O
V	O
in	O
transfer	O
buffer	O
(	O
48	O
mM	O
Tris	B-Chemical
","	O
39	O
mM	O
glycine	B-Chemical
and	O
20	O
%	O
methanol	B-Chemical
)	O
at	O
4	O
Â°	O
C	O
.	O
The	O
membranes	O
were	O
incubated	O
with	O
corresponding	O
antibody	O
at	O
a	O
dilution	O
of	O
1	O
âˆ¶	O
1000	O
in	O
TNT	B-Chemical
buffer	I-Chemical
(	O
1	O
.	O
211	O
g	O
Tris	B-Chemical
","	O
8	O
.	O
77	O
g	O
NaCl	B-Chemical
and	O
500	O
mL	O
tween	B-Chemical
-	I-Chemical
20	I-Chemical
in	O
1	O
L	O
TNT	B-Chemical
","	O
pH	O
7	O
.	O
0	O
)	O
containing	O
5	O
%	O
skim	O
milk	O
for	O
1	O
h	O
at	O
room	O
temperature	O
on	O
a	O
gentle	O
shaker	O
.	O
The	O
membranes	O
were	O
rinsed	O
three	O
times	O
for	O
10	O
min	O
with	O
TNT	B-Chemical
buffer	I-Chemical
and	O
incubated	O
with	O
goat	O
anti	O
-	O
mouse	O
HRP	O
-	O
conjuaged	O
IgG	O
at	O
a	O
dilution	O
of	O
1	O
âˆ¶	O
4000	O
in	O
TNT	B-Chemical
buffer	I-Chemical
containing	O
5	O
%	O
skim	O
milk	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O
The	O
membranes	O
were	O
developed	O
with	O
substrate	O
(	O
ECL	O
","	O
Electrochemiluminescence	O
)	O
until	O
optimum	O
color	O
developed	O
.	O
Effect	O
of	O
Over	O
-	O
expressed	O
JunD	O
on	O
Cells	O
â€™	O
Viability	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
Toxin	I-Chemical
Stress	O
The	O
recombinant	O
plasmid	O
(	O
JunD	O
-	O
PCDNA3	O
.	O
0	O
","	O
constructed	O
previously	O
in	O
our	O
lab	O
)	O
was	O
extracted	O
from	O
E	O
.	O
coli	O
DH5a	O
","	O
and	O
transfected	O
into	O
cells	O
by	O
liposome	O
(	O
Lipofectamine	B-Chemical
2000	I-Chemical
).	O
After	O
screening	O
by	O
G418	O
","	O
the	O
JunD	O
expression	O
level	O
was	O
detected	O
by	O
Western	O
-	O
blot	O
analysis	O
with	O
anti	O
-	O
JunD	O
antibody	O
as	O
the	O
first	O
antibody	O
.	O
The	O
survival	O
rate	O
was	O
calculated	O
according	O
to	O
that	O
mentioned	O
in	O
MTT	B-Chemical
assay	O
.	O
Statistical	O
Analysis	O
The	O
data	O
from	O
this	O
experiment	O
was	O
analyzed	O
by	O
statistic	O
software	O
(	O
SPSS	O
13	O
.	O
0	O
"),"	O
and	O
all	O
data	O
was	O
presented	O
on	O
the	O
form	O
of	O
mean	O
Â±	O
standard	O
deviation	O
(	O
x	O
Â±	O
s	O
).	O
The	O
comparison	O
between	O
each	O
group	O
was	O
based	O
on	O
single	O
-	O
factor	O
analysis	O
of	O
variance	O
.	O
The	O
comparison	O
between	O
parallel	O
groups	O
was	O
analyzed	O
with	O
LSD	O
test	O
.	O
The	O
assessment	O
of	O
statistical	O
significance	O
of	O
differences	O
was	O
carried	O
out	O
with	O
one	O
way	O
ANOVA	O
in	O
Microsoft	O
Excel	O
.	O
P	O
<	O
0	O
.	O
5	O
means	O
that	O
the	O
differences	O
are	O
statistically	O
significant	O
.	O
Results	O
Dose	O
and	O
Time	O
Dependent	O
Cytotoxicity	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
Toxin	I-Chemical
to	O
Cells	O
MTT	B-Chemical
assay	O
was	O
used	O
to	O
detect	O
the	O
inhibition	O
effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
on	O
cells	O
.	O
It	O
could	O
be	O
concluded	O
from	O
Figure	O
1A	O
that	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
was	O
toxic	O
to	O
three	O
lines	O
of	O
cells	O
(	O
Hela	O
","	O
Bel	O
-	O
7402	O
","	O
and	O
Chang	O
liver	O
cell	O
"),"	O
and	O
the	O
virulence	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
was	O
different	O
towards	O
different	O
cells	O
.	O
With	O
the	O
increase	O
of	O
the	O
toxin	O
dose	O
","	O
the	O
cell	O
mortality	O
was	O
increased	O
","	O
too	O
.	O
According	O
to	O
the	O
method	O
provided	O
above	O
","	O
LC50	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
at	O
24	O
h	O
to	O
three	O
cell	O
lines	O
(	O
Hela	O
","	O
Bel	O
-	O
7402	O
","	O
and	O
Chang	O
liver	O
cells	O
)	O
was	O
found	O
to	O
be	O
357	O
","	O
63	O
","	O
and	O
412	O
ng	O
/	O
mL	O
respectively	O
.	O
The	O
concentrations	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
used	O
in	O
subsequent	O
experiments	O
were	O
the	O
LC50	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
presented	O
above	O
.	O
Time	O
effect	O
was	O
also	O
observed	O
when	O
cells	O
were	O
stressed	O
under	O
LC50	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
It	O
could	O
be	O
found	O
from	O
the	O
Figure	O
1B	O
that	O
as	O
the	O
time	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
stress	O
extended	O
","	O
the	O
survival	O
rates	O
of	O
all	O
three	O
cell	O
lines	O
were	O
decreasing	O
obviously	O
.	O
It	O
indicated	O
that	O
the	O
effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
on	O
cells	O
survival	O
rate	O
was	O
not	O
only	O
dose	O
-	O
dependent	O
","	O
but	O
also	O
time	O
-	O
dependent	O
.	O
The	O
inhibition	O
effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
on	O
three	O
cell	O
strains	O
.	O
A	O
.	O
Dose	O
-	O
dependent	O
inhibition	O
ration	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
at	O
24	O
h	O
.	O
B	O
.	O
Time	O
-	O
dependent	O
effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
to	O
cells	O
.	O
Data	O
was	O
presented	O
as	O
mean	O
Â±	O
SD	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
**	O
p	O
<	O
0	O
.	O
1	O
","	O
***	O
p	O
<	O
0	O
.	O
1	O
.	O
The	O
Effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
Toxin	I-Chemical
on	O
Endogenous	O
GSH	B-Chemical
and	O
MDA	B-Chemical
Endogenic	O
GSH	B-Chemical
is	O
an	O
important	O
antioxidant	O
in	O
cells	O
","	O
and	O
its	O
level	O
impacts	O
on	O
cell	O
anti	O
-	O
oxidative	O
capacity	O
directly	O
.	O
The	O
decrease	O
in	O
GSH	B-Chemical
level	O
would	O
initiate	O
intracellular	O
oxidative	O
stress	O
.	O
It	O
could	O
be	O
found	O
from	O
Figure	O
2A	O
that	O
with	O
the	O
elongation	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
treatment	O
time	O
","	O
endogenic	O
GSH	B-Chemical
in	O
these	O
cells	O
was	O
gradually	O
reduced	O
","	O
and	O
the	O
endogenous	O
GSH	B-Chemical
in	O
test	O
groups	O
was	O
less	O
than	O
half	O
of	O
that	O
in	O
the	O
control	O
group	O
at	O
24	O
h	O
.	O
This	O
indicated	O
that	O
the	O
level	O
of	O
endogenous	O
GSH	B-Chemical
would	O
decrease	O
when	O
The	O
cells	O
were	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
","	O
and	O
certain	O
degree	O
of	O
oxidative	O
stress	O
took	O
place	O
in	O
the	O
cells	O
.	O
This	O
was	O
a	O
hint	O
for	O
us	O
to	O
explore	O
the	O
level	O
of	O
MDA	B-Chemical
","	O
a	O
product	O
of	O
lipid	O
peroxidation	O
.	O
The	O
level	O
of	O
MDA	B-Chemical
inside	O
cells	O
usually	O
increases	O
significantly	O
","	O
when	O
the	O
cells	O
are	O
under	O
oxidative	O
stress	O
.	O
As	O
shown	O
in	O
Figure	O
2B	O
","	O
all	O
three	O
cell	O
lines	O
produced	O
different	O
levels	O
of	O
MDA	B-Chemical
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
","	O
and	O
the	O
level	O
of	O
MDA	B-Chemical
was	O
gradually	O
increased	O
with	O
the	O
elongation	O
of	O
the	O
treatment	O
time	O
.	O
These	O
results	O
and	O
previous	O
reports	O
showed	O
that	O
there	O
was	O
a	O
link	O
between	O
the	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
and	O
intracellular	O
oxidative	O
stress	O
.	O
Intracellular	O
redox	O
level	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
A	O
.	O
Level	O
of	O
endogenous	O
GSH	B-Chemical
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
.	O
B	O
.	O
Levels	O
of	O
endogenous	O
MDA	B-Chemical
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
.	O
Data	O
was	O
presented	O
as	O
mean	O
Â±	O
SD	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
**	O
p	O
<	O
0	O
.	O
1	O
","	O
***	O
p	O
<	O
0	O
.	O
1	O
.	O
The	O
Protective	O
Effect	O
of	O
Antioxidant	O
NAC	B-Chemical
to	O
the	O
Cells	O
against	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
Toxin	I-Chemical
Stress	O
In	O
the	O
study	O
","	O
antioxidant	O
NAC	B-Chemical
was	O
employed	O
to	O
test	O
if	O
it	O
had	O
protective	O
effect	O
on	O
cells	O
stressed	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
It	O
could	O
be	O
found	O
from	O
Figure	O
3A	O
that	O
the	O
survival	O
rate	O
of	O
NAC	B-Chemical
pretreated	O
Hela	O
cells	O
increased	O
compared	O
to	O
the	O
control	O
group	O
","	O
which	O
meant	O
that	O
the	O
antioxidant	O
NAC	B-Chemical
could	O
relief	O
the	O
virulence	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
","	O
and	O
alleviate	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
induced	O
cell	O
death	O
.	O
Endogenous	O
GSH	B-Chemical
was	O
detected	O
","	O
and	O
the	O
result	O
from	O
Figure	O
3B	O
showed	O
that	O
there	O
was	O
more	O
GSH	B-Chemical
in	O
NAC	B-Chemical
pretreated	O
Hela	O
cells	O
.	O
But	O
no	O
obvious	O
protective	O
effect	O
of	O
NAC	B-Chemical
to	O
the	O
Chang	O
liver	O
and	O
Bel	O
-	O
7402	O
cell	O
lines	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
was	O
observed	O
(	O
data	O
no	O
shown	O
).	O
These	O
results	O
suggested	O
that	O
the	O
pernicious	O
effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
on	O
cells	O
was	O
at	O
least	O
partially	O
caused	O
by	O
oxidative	O
stress	O
","	O
and	O
the	O
protective	O
effect	O
of	O
NAC	B-Chemical
to	O
Hela	O
cells	O
against	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
was	O
through	O
protecting	O
GSH	B-Chemical
.	O
Antioxidation	O
of	O
NAC	B-Chemical
in	O
cell	O
death	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
A	O
.	O
Antioxidation	O
of	O
NAC	B-Chemical
in	O
the	O
cell	O
death	O
process	O
of	O
Hela	O
cells	O
.	O
B	O
.	O
Endogenous	O
GSH	B-Chemical
level	O
of	O
Hela	O
under	O
protection	O
of	O
NAC	B-Chemical
.	O
Data	O
was	O
presented	O
as	O
mean	O
Â±	O
SD	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
**	O
p	O
<	O
0	O
.	O
1	O
","	O
***	O
p	O
<	O
0	O
.	O
1	O
.	O
The	O
Effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
Toxin	I-Chemical
Stress	O
on	O
Caspase	O
-	O
3	O
Caspase	O
3	O
","	O
an	O
important	O
factor	O
in	O
apoptosis	O
","	O
is	O
activated	O
in	O
both	O
death	O
ligand	O
and	O
mitochondrial	O
pathways	O
.	O
In	O
cell	O
","	O
Caspase	O
3	O
is	O
an	O
enzyme	O
precursor	O
that	O
is	O
activated	O
only	O
when	O
cell	O
initiates	O
an	O
apoptotic	O
process	O
.	O
In	O
the	O
study	O
","	O
the	O
hydrolase	O
activity	O
of	O
Caspase	O
3	O
was	O
detected	O
to	O
reflect	O
the	O
activity	O
level	O
of	O
Caspase	O
-	O
3	O
in	O
cells	O
(	O
Hela	O
","	O
Bel	O
-	O
7402	O
","	O
and	O
Chang	O
liver	O
)	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
.	O
It	O
could	O
be	O
observed	O
from	O
Figure	O
4A	O
that	O
the	O
activity	O
of	O
Caspase	O
-	O
3	O
in	O
three	O
cell	O
lines	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
was	O
increased	O
2	O
â€“	O
7	O
times	O
compared	O
to	O
control	O
group	O
at	O
24	O
h	O
.	O
These	O
results	O
reflected	O
that	O
Caspase	O
-	O
3	O
played	O
an	O
important	O
role	O
in	O
the	O
process	O
","	O
and	O
preliminary	O
suggested	O
that	O
the	O
process	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
in	O
cells	O
was	O
apoptosis	O
.	O
Activation	O
of	O
Caspase	O
-	O
3	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
A	O
.	O
Detection	O
of	O
Caspase	O
-	O
3	O
hydrolase	O
activity	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
.	O
B	O
.	O
Western	O
blot	O
result	O
of	O
Caspase	O
-	O
3	O
activated	O
fragments	O
in	O
Hela	O
cells	O
when	O
treated	O
with	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
at	O
the	O
concentration	O
of	O
LC50	O
for	O
8	O
","	O
16	O
","	O
and	O
24	O
h	O
respectively	O
.	O
C	O
.	O
Western	O
blot	O
result	O
of	O
Caspase	O
-	O
3	O
activated	O
fragments	O
in	O
Changliver	O
cells	O
.	O
D	O
.	O
Caspase	O
-	O
3	O
activity	O
in	O
Bel	O
-	O
7402	O
cell	O
.	O
Data	O
was	O
presented	O
as	O
mean	O
Â±	O
SD	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
**	O
p	O
<	O
0	O
.	O
1	O
","	O
***	O
p	O
<	O
0	O
.	O
1	O
.	O
The	O
hydrolyzed	O
or	O
activated	O
fragment	O
of	O
Caspase	O
-	O
3	O
was	O
further	O
analyzed	O
by	O
Western	O
-	O
blot	O
analysis	O
.	O
The	O
result	O
showed	O
that	O
the	O
level	O
of	O
activated	O
hydrolysis	O
fragment	O
increased	O
in	O
all	O
three	O
cell	O
lines	O
(	O
Figure	O
4	O
C	O
â€“	O
D	O
).	O
These	O
results	O
illuminated	O
the	O
effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
to	O
cells	O
was	O
apoptosis	O
rather	O
than	O
necrosis	O
.	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
Toxin	I-Chemical
Induced	O
Apoptosis	O
by	O
Mitochondrial	O
Pathway	O
Members	O
of	O
the	O
Caspase	O
family	O
are	O
critical	O
in	O
the	O
process	O
of	O
apoptosis	O
.	O
Caspase	O
-	O
8	O
mainly	O
takes	O
part	O
in	O
the	O
death	O
receptor	O
pathway	O
","	O
and	O
Caspase	O
-	O
9	O
is	O
primarily	O
working	O
in	O
mitochondrial	O
pathway	O
.	O
The	O
results	O
of	O
our	O
Western	O
-	O
blot	O
analysis	O
(	O
Figure	O
5	O
)	O
in	O
present	O
study	O
showed	O
that	O
Caspase	O
-	O
8	O
was	O
hydrolyzed	O
and	O
activated	O
at	O
about	O
16	O
h	O
","	O
and	O
Caspase	O
-	O
9	O
was	O
activated	O
at	O
about	O
8	O
h	O
(	O
Figure	O
5A	O
and	O
B	O
).	O
The	O
same	O
situation	O
happened	O
to	O
the	O
line	O
of	O
Bel	O
-	O
7402	O
","	O
and	O
Caspase	O
-	O
8	O
was	O
hydrolyzed	O
and	O
activated	O
relatively	O
later	O
than	O
that	O
of	O
Caspase	O
-	O
9	O
.	O
Caspase	O
-	O
8	O
was	O
activated	O
at	O
about	O
24	O
h	O
","	O
but	O
Caspase	O
-	O
9	O
was	O
about	O
16	O
h	O
(	O
Figure	O
5C	O
).	O
These	O
results	O
indicated	O
that	O
the	O
apoptosis	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
was	O
probably	O
through	O
mitochondrial	O
pathway	O
","	O
which	O
coincided	O
with	O
the	O
previous	O
reports	O
","	O
.	O
Western	O
-	O
blot	O
analysis	O
on	O
activated	O
Caspase	O
-	O
8	O
and	O
Caspase	O
-	O
9	O
level	O
.	O
A	O
.	O
Activated	O
Caspase	O
-	O
8	O
and	O
Caspase	O
-	O
9	O
level	O
in	O
Hela	O
cells	O
when	O
treated	O
with	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
at	O
the	O
concentration	O
of	O
LC50	O
for	O
8	O
","	O
16	O
","	O
and	O
24	O
h	O
respectively	O
.	O
B	O
.	O
Activated	O
Caspase	O
-	O
8	O
and	O
Caspase	O
-	O
9	O
level	O
in	O
Changliver	O
cells	O
were	O
treated	O
with	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
C	O
.	O
Bel	O
-	O
7402	O
cells	O
were	O
treated	O
with	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
The	O
Effect	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
Toxin	I-Chemical
on	O
the	O
Level	O
of	O
p53	O
The	O
role	O
of	O
p53	O
in	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
induced	O
apoptosis	O
has	O
been	O
controversial	O
.	O
Some	O
reports	O
declared	O
that	O
the	O
level	O
of	O
p53	O
did	O
not	O
change	O
in	O
the	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
mediated	O
apoptosis	O
","	O
other	O
reports	O
found	O
that	O
p53	O
level	O
was	O
up	O
-	O
regulated	O
in	O
the	O
process	O
.	O
So	O
it	O
is	O
necessary	O
to	O
further	O
clarify	O
the	O
role	O
of	O
p53	O
played	O
in	O
the	O
apoptotic	O
process	O
.	O
We	O
found	O
that	O
the	O
protein	O
level	O
of	O
p53	O
in	O
these	O
three	O
cell	O
lines	O
(	O
Hela	O
","	O
Chang	O
liver	O
","	O
and	O
Bel	O
-	O
7402	O
)	O
was	O
up	O
-	O
regulated	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
(	O
Figure	O
6	O
A	O
â€“	O
C	O
)	O
suggesting	O
that	O
p53	O
took	O
part	O
in	O
the	O
apoptotic	O
process	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
Levels	O
of	O
p53	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
.	O
A	O
.	O
Levels	O
of	O
p53	O
in	O
Hela	O
cells	O
when	O
treated	O
with	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
at	O
the	O
concentration	O
of	O
LC50	O
for	O
8	O
","	O
16	O
","	O
and	O
24	O
h	O
respectively	O
.	O
B	O
.	O
Levels	O
of	O
p53	O
in	O
Changliver	O
cells	O
.	O
C	O
.	O
Bel	O
-	O
7402	O
cells	O
were	O
treated	O
with	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
Toxin	I-Chemical
.	O
The	O
Effect	O
of	O
Up	O
-	O
regulated	O
JunD	O
on	O
Cells	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
Toxin	I-Chemical
Stress	O
JunD	O
plays	O
a	O
role	O
in	O
intracellular	O
antioxidant	O
system	O
.	O
In	O
the	O
present	O
study	O
","	O
we	O
explored	O
the	O
relationship	O
between	O
JunD	O
and	O
apoptosis	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
By	O
Western	O
-	O
blot	O
analysis	O
","	O
we	O
found	O
that	O
the	O
protein	O
levels	O
of	O
intracellular	O
JunD	O
were	O
obviously	O
suppressed	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
in	O
all	O
three	O
cell	O
lines	O
we	O
used	O
(	O
Figure	O
7A	O
).	O
The	O
down	O
-	O
regulation	O
of	O
JunD	O
results	O
in	O
the	O
suppression	O
of	O
intracellular	O
antioxidant	O
system	O
","	O
which	O
makes	O
the	O
cells	O
susceptible	O
to	O
oxidative	O
stress	O
.	O
The	O
effect	O
of	O
up	O
-	O
regulated	O
JunD	O
on	O
cells	O
.	O
A	O
.	O
The	O
expression	O
levels	O
of	O
JunD	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
B	O
.	O
The	O
expression	O
of	O
JunD	O
after	O
transfection	O
of	O
JunD	O
over	O
-	O
expression	O
vector	O
in	O
three	O
cell	O
strains	O
.	O
wt	O
:	O
wild	O
type	O
.	O
+:	O
cell	O
strains	O
transfected	O
with	O
over	O
-	O
expression	O
vector	O
.	O
C	O
.	O
The	O
effect	O
of	O
over	O
-	O
expressed	O
JunD	O
on	O
cell	O
survival	O
rate	O
.	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
:	O
wild	O
-	O
type	O
cells	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
.	O
JunD	O
(+/+):	O
JunD	O
over	O
-	O
expressied	O
cell	O
lines	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
.	O
Data	O
was	O
presented	O
as	O
mean	O
Â±	O
SD	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
**	O
p	O
<	O
0	O
.	O
1	O
","	O
***	O
p	O
<	O
0	O
.	O
1	O
.	O
These	O
three	O
cell	O
lines	O
(	O
Hela	O
","	O
Chang	O
liver	O
","	O
and	O
Bel	O
-	O
7402	O
)	O
were	O
all	O
transfected	O
with	O
an	O
over	O
-	O
expression	O
vectors	O
of	O
JunD	O
.	O
As	O
shown	O
in	O
Figure	O
7B	O
","	O
the	O
expression	O
levels	O
of	O
JunD	O
were	O
obviously	O
up	O
-	O
regulated	O
in	O
all	O
three	O
cell	O
lines	O
after	O
transfection	O
.	O
It	O
could	O
also	O
be	O
seen	O
from	O
Figure	O
7C	O
that	O
the	O
survival	O
rate	O
of	O
cell	O
lines	O
transfected	O
with	O
JunD	O
over	O
-	O
expression	O
vector	O
was	O
significantly	O
increased	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
compared	O
to	O
wild	O
-	O
type	O
cells	O
.	O
These	O
results	O
showed	O
that	O
JunD	O
played	O
a	O
critical	O
role	O
in	O
the	O
apoptotic	O
process	O
","	O
and	O
its	O
over	O
-	O
expression	O
could	O
effectively	O
prevent	O
the	O
cells	O
from	O
damaging	O
effects	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
Discussion	O
It	O
had	O
been	O
found	O
in	O
many	O
reports	O
that	O
intracellular	O
reduced	O
GSH	B-Chemical
was	O
down	O
-	O
regulated	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
","	O
and	O
at	O
the	O
same	O
time	O
","	O
lipid	O
oxidation	O
occurred	O
and	O
total	O
intracellular	O
ROS	B-Chemical
was	O
up	O
-	O
regulated	O
","	O
.	O
Reduced	O
GSH	B-Chemical
can	O
effectively	O
remove	O
intracellular	O
free	O
radicals	O
","	O
and	O
the	O
decline	O
in	O
GSH	B-Chemical
expression	O
level	O
would	O
lead	O
to	O
unbalance	O
of	O
intracellular	O
antioxidant	O
system	O
.	O
The	O
up	O
-	O
regulated	O
ROS	B-Chemical
and	O
MDA	B-Chemical
reflected	O
that	O
cells	O
had	O
been	O
coerced	O
by	O
oxidative	O
stress	O
.	O
In	O
the	O
current	O
study	O
","	O
it	O
was	O
clear	O
that	O
all	O
three	O
cell	O
lines	O
(	O
Hela	O
","	O
Bel	O
-	O
7402	O
","	O
and	O
Chang	O
liver	O
)	O
could	O
be	O
induced	O
into	O
the	O
process	O
of	O
apoptosis	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
","	O
and	O
the	O
death	O
effect	O
of	O
the	O
toxin	O
against	O
cells	O
was	O
time	O
-	O
dependent	O
and	O
dose	O
-	O
dependent	O
.	O
Oxidative	O
stress	O
might	O
be	O
the	O
main	O
factor	O
which	O
leads	O
to	O
apoptosis	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
.	O
In	O
the	O
experiment	O
in	O
which	O
antioxidant	O
NAC	B-Chemical
was	O
used	O
to	O
pretreat	O
cells	O
.	O
The	O
cell	O
line	O
","	O
Hela	O
","	O
was	O
protected	O
efficiently	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
","	O
but	O
there	O
was	O
no	O
significant	O
effect	O
in	O
Bel	O
-	O
7402	O
and	O
Chang	O
liver	O
.	O
This	O
may	O
be	O
due	O
to	O
the	O
different	O
sensitivity	O
to	O
NAC	B-Chemical
for	O
different	O
cell	O
lines	O
.	O
He	O
et	O
al	O
.	O
(	O
2012	O
)	O
also	O
found	O
that	O
NAC	B-Chemical
could	O
provide	O
a	O
protective	O
effect	O
towards	O
the	O
apoptosis	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
From	O
the	O
reports	O
and	O
results	O
provided	O
above	O
","	O
it	O
could	O
be	O
concluded	O
that	O
oxidative	O
stress	O
plays	O
an	O
important	O
role	O
in	O
apoptosis	O
triggered	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
Caspase	O
family	O
members	O
are	O
very	O
critical	O
in	O
the	O
process	O
of	O
apoptosis	O
","	O
and	O
they	O
are	O
precisely	O
regulated	O
in	O
the	O
whole	O
process	O
of	O
apoptosis	O
.	O
When	O
they	O
are	O
hydrolyzed	O
by	O
upstream	O
proteases	O
and	O
become	O
activated	O
","	O
they	O
will	O
participate	O
in	O
the	O
process	O
of	O
apoptosis	O
.	O
In	O
the	O
current	O
study	O
","	O
it	O
was	O
suggested	O
that	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
induced	O
cells	O
apoptosis	O
rather	O
than	O
necrosis	O
by	O
increasing	O
the	O
expression	O
level	O
of	O
Caspase	O
-	O
3	O
.	O
Caspase	O
-	O
8	O
plays	O
an	O
important	O
role	O
in	O
death	O
receptor	O
pathway	O
","	O
and	O
Caspase	O
-	O
9	O
takes	O
part	O
in	O
the	O
mitochondrial	O
pathway	O
","	O
.	O
Therefore	O
","	O
The	O
pathway	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
induced	O
apoptosis	O
could	O
be	O
illustrated	O
by	O
detecting	O
the	O
protein	O
level	O
of	O
the	O
both	O
proteins	O
.	O
In	O
this	O
study	O
","	O
it	O
was	O
found	O
that	O
the	O
activation	O
of	O
Caspase	O
-	O
9	O
(	O
about	O
8	O
h	O
)	O
was	O
earlier	O
than	O
that	O
of	O
Caspase	O
-	O
8	O
(	O
about	O
24	O
h	O
).	O
So	O
it	O
implied	O
that	O
the	O
apoptosis	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
was	O
mainly	O
by	O
mitochondrial	O
pathway	O
.	O
The	O
tumor	O
suppressor	O
p53	O
plays	O
a	O
very	O
important	O
role	O
in	O
maintaining	O
the	O
integrity	O
of	O
cellular	O
genes	O
and	O
controlling	O
cell	O
growth	O
.	O
So	O
the	O
expression	O
of	O
p53	O
inside	O
cell	O
is	O
subjected	O
to	O
strict	O
regulation	O
.	O
The	O
apoptosis	O
induced	O
by	O
p53	O
is	O
through	O
mitochondrial	O
pathway	O
by	O
activating	O
transcription	O
of	O
some	O
pro	O
-	O
apoptotic	O
factors	O
(	O
such	O
as	O
Puma	O
","	O
Bax	O
","	O
p53AIP1	O
","	O
Bcl2	O
","	O
PIGs	O
and	O
so	O
on	O
)	O
","	O
.	O
In	O
previous	O
studies	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
induced	O
apoptosis	O
","	O
the	O
role	O
of	O
p53	O
has	O
been	O
controversial	O
.	O
Some	O
studies	O
have	O
reported	O
that	O
p53	O
does	O
not	O
change	O
in	O
the	O
process	O
","	O
whereas	O
some	O
results	O
confirm	O
that	O
p53	O
is	O
up	O
-	O
regulated	O
in	O
the	O
process	O
","	O
.	O
Thus	O
","	O
we	O
found	O
it	O
is	O
important	O
to	O
clarify	O
the	O
role	O
of	O
p53	O
in	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
induced	O
apoptosis	O
.	O
It	O
was	O
confirmed	O
in	O
the	O
present	O
study	O
that	O
p53	O
was	O
up	O
-	O
regulated	O
","	O
which	O
also	O
suggested	O
that	O
the	O
pathway	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
induced	O
apoptosis	O
was	O
through	O
the	O
mitochondrial	O
pathway	O
.	O
AP	O
-	O
1	O
(	O
activator	O
protein	O
-	O
1	O
)	O
transcription	O
factor	O
family	O
plays	O
a	O
key	O
role	O
in	O
the	O
regulation	O
of	O
transcription	O
by	O
Ras	O
which	O
is	O
mainly	O
composed	O
of	O
c	O
-	O
Jun	O
","	O
JunB	O
","	O
and	O
JunD	O
","	O
and	O
it	O
is	O
usually	O
considered	O
that	O
JunD	O
plays	O
an	O
important	O
role	O
in	O
intracellular	O
antioxidant	O
system	O
â€“.	O
These	O
evidences	O
revealed	O
that	O
there	O
might	O
be	O
an	O
intrinsic	O
link	O
between	O
JunD	O
and	O
oxidative	O
stress	O
","	O
but	O
there	O
is	O
no	O
report	O
about	O
JunD	O
in	O
the	O
study	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
induced	O
apoptosis	O
.	O
In	O
our	O
study	O
","	O
we	O
found	O
that	O
JunD	O
was	O
of	O
importance	O
in	O
the	O
apoptotic	O
process	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
Initially	O
","	O
we	O
found	O
by	O
Western	O
-	O
blot	O
analysis	O
that	O
the	O
protein	O
levels	O
of	O
JunD	O
were	O
down	O
-	O
regulated	O
in	O
the	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
induced	O
apoptosis	O
.	O
In	O
further	O
studies	O
on	O
the	O
cell	O
survival	O
rate	O
during	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
","	O
we	O
found	O
that	O
the	O
JunD	O
over	O
-	O
expression	O
cell	O
lines	O
could	O
effectively	O
prevent	O
the	O
effects	O
induced	O
by	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
.	O
However	O
","	O
there	O
was	O
no	O
obvious	O
difference	O
in	O
the	O
survival	O
rate	O
between	O
wild	O
-	O
type	O
cell	O
lines	O
and	O
JunD	O
interfered	O
cell	O
lines	O
","	O
which	O
might	O
suggest	O
that	O
there	O
are	O
other	O
factors	O
that	O
could	O
complement	O
the	O
function	O
of	O
JunD	O
.	O
Thus	O
","	O
we	O
conclude	O
that	O
JunD	O
could	O
effectively	O
protect	O
cells	O
from	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
induced	O
apoptosis	O
.	O
It	O
is	O
","	O
however	O
","	O
still	O
unclear	O
how	O
JunD	O
protected	O
the	O
cells	O
from	O
apoptosis	O
under	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
toxin	I-Chemical
stress	O
.	O
Further	O
study	O
on	O
the	O
pathway	O
by	O
which	O
JunD	O
prevent	O
apoptosis	O
would	O
illuminate	O
the	O
molecular	O
mechanism	O
of	O
T	B-Chemical
-	I-Chemical
2	I-Chemical
induced	O
apoptosis	O
.	O
References	O
The	O
hOGG1	O
Ser326Cys	B-Chemical
Gene	O
Polymorphism	O
and	O
the	O
Risk	O
of	O
Coronary	O
Ectasia	O
in	O
the	O
Chinese	O
Population	O
Oxidative	O
stress	O
(	O
OS	O
)	O
is	O
related	O
to	O
vascular	O
inflammation	O
possibly	O
","	O
contributing	O
to	O
the	O
development	O
of	O
coronary	O
ectasia	O
(	O
CE	O
).	O
Base	B-Chemical
excision	O
repair	O
(	O
BER	O
)	O
and	O
nucleotide	B-Chemical
excision	O
repair	O
are	O
the	O
main	O
DNA	O
repair	O
pathways	O
that	O
can	O
help	O
to	O
remove	O
8	B-Chemical
-	I-Chemical
hydroxydeoxyguanine	I-Chemical
(	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
"),"	O
a	O
marker	O
of	O
OS	O
.	O
Human	O
8	O
-	O
oxoguanine	O
DNA	O
glycosylase	O
1	O
(	O
hOGG1	O
)	O
is	O
a	O
key	O
enzyme	O
of	O
the	O
BER	O
pathway	O
and	O
catalyzes	O
the	O
removal	O
of	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
.	O
The	O
aim	O
of	O
our	O
study	O
was	O
to	O
investigate	O
the	O
association	O
between	O
hOGG1	O
Ser326Cys	B-Chemical
gene	O
polymorphism	O
and	O
CE	O
in	O
a	O
Chinese	O
population	O
.	O
Five	O
-	O
hundred	O
forty	O
-	O
seven	O
patients	O
who	O
underwent	O
diagnostic	O
coronary	O
angiography	O
in	O
a	O
tertiary	O
medical	O
center	O
were	O
recruited	O
.	O
The	O
angiographic	O
definition	O
of	O
CE	O
is	O
the	O
diameter	O
of	O
the	O
ectatic	O
segment	O
being	O
more	O
than	O
1	O
.	O
5	O
times	O
larger	O
compared	O
with	O
an	O
adjacent	O
healthy	O
reference	O
segment	O
.	O
The	O
gene	O
polymorphisms	O
were	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
.	O
The	O
urine	O
8OHdG	B-Chemical
concentration	O
was	O
measured	O
using	O
a	O
commercial	O
ELISA	O
kit	O
.	O
The	O
distribution	O
of	O
hOGG1	O
Ser326Cys	B-Chemical
genotypes	O
was	O
significantly	O
different	O
between	O
CE	O
and	O
non	O
-	O
CE	O
groups	O
(	O
p	O
=	O
0	O
.	O
33	O
).	O
The	O
odds	O
ratio	O
of	O
CE	O
development	O
for	O
the	O
Ser	B-Chemical
to	O
the	O
Cys	B-Chemical
variant	O
was	O
1	O
.	O
55	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
"),"	O
1	O
.	O
4	O
â€“	O
2	O
.	O
31	O
","	O
p	O
=	O
0	O
.	O
33	O
).	O
Both	O
univariate	O
and	O
logistic	O
regression	O
analysis	O
showed	O
a	O
significant	O
association	O
of	O
hOGG1	O
Ser326Cys	B-Chemical
polymorphism	O
in	O
the	O
dominant	O
model	O
with	O
CE	O
development	O
(	O
p	O
=	O
0	O
.	O
9	O
and	O
0	O
.	O
11	O
","	O
respectively	O
).	O
Urine	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
levels	O
were	O
significantly	O
higher	O
in	O
subjects	O
carrying	O
the	O
hOGG1	O
Ser	B-Chemical
variant	O
than	O
in	O
those	O
with	O
the	O
Cys	B-Chemical
/	O
Cys	B-Chemical
genotype	O
(	O
p	O
<	O
0	O
.	O
3	O
).	O
In	O
conclusion	O
","	O
our	O
study	O
suggests	O
that	O
the	O
hOGG1	O
Ser326Cys	B-Chemical
gene	O
variant	O
might	O
play	O
a	O
role	O
in	O
susceptibility	O
to	O
the	O
development	O
of	O
CE	O
.	O
Introduction	O
Coronary	O
ectasia	O
(	O
CE	O
)	O
is	O
an	O
uncommon	O
disease	O
","	O
and	O
its	O
incidence	O
is	O
usually	O
between	O
0	O
.	O
3	O
%	O
and	O
5	O
%	O
in	O
different	O
studies	O
[	O
1	O
â€“	O
5	O
].	O
It	O
has	O
been	O
defined	O
as	O
the	O
diameter	O
of	O
the	O
ectatic	O
segment	O
being	O
more	O
than	O
1	O
.	O
5	O
times	O
larger	O
compared	O
with	O
an	O
adjacent	O
healthy	O
reference	O
segment	O
[	O
2	O
].	O
Most	O
cases	O
of	O
CE	O
are	O
considered	O
as	O
a	O
variant	O
of	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
[	O
6	O
].	O
Although	O
the	O
pathogenesis	O
of	O
CE	O
is	O
not	O
completely	O
understood	O
","	O
it	O
is	O
likely	O
to	O
involve	O
the	O
destruction	O
of	O
the	O
arterial	O
media	O
","	O
increased	O
wall	O
stress	O
","	O
thinning	O
of	O
the	O
arterial	O
wall	O
and	O
progressive	O
dilatation	O
of	O
the	O
coronary	O
artery	O
segment	O
[	O
7	O
].	O
In	O
addition	O
","	O
CE	O
is	O
also	O
reported	O
to	O
be	O
associated	O
with	O
increased	O
plasma	O
levels	O
of	O
inflammatory	O
markers	O
","	O
cytokines	O
and	O
oxidative	O
stress	O
[	O
8	O
â€“	O
10	O
].	O
Oxidative	O
stress	O
represents	O
an	O
imbalance	O
between	O
the	O
production	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
and	O
a	O
biological	O
system	O
â€™	O
s	O
ability	O
to	O
detoxify	O
the	O
reactive	O
intermediates	O
and	O
repair	O
the	O
resulting	O
damage	O
.	O
It	O
is	O
thought	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
many	O
human	O
diseases	O
","	O
including	O
atherosclerosis	O
[	O
11	O
","	O
12	O
].	O
Oxidative	O
stress	O
is	O
usually	O
associated	O
with	O
increased	O
free	O
radical	O
formation	O
and	O
causes	O
increased	O
ROS	B-Chemical
concentrations	O
.	O
ROS	B-Chemical
modify	O
proteins	O
and	O
phospholipids	B-Chemical
and	O
lead	O
to	O
lipid	B-Chemical
peroxidation	O
[	O
13	O
].	O
These	O
substances	O
may	O
lead	O
to	O
inflammatory	O
responses	O
","	O
such	O
as	O
leukocyte	O
activation	O
","	O
the	O
expression	O
of	O
adhesion	O
molecules	O
and	O
the	O
release	O
of	O
cytokines	O
[	O
14	O
].	O
Atherosclerosis	O
is	O
the	O
result	O
of	O
the	O
oxidative	O
modification	O
of	O
low	O
density	O
lipoproteins	O
(	O
LDL	O
)	O
in	O
the	O
arterial	O
wall	O
by	O
ROS	B-Chemical
.	O
ROS	B-Chemical
are	O
key	O
mediators	O
of	O
signaling	O
pathways	O
that	O
underlie	O
vascular	O
inflammation	O
in	O
atherosclerosis	O
starting	O
from	O
the	O
development	O
of	O
a	O
fatty	O
streak	O
","	O
through	O
lesion	O
progression	O
to	O
ultimate	O
plaque	O
rupture	O
[	O
15	O
].	O
Genomic	O
DNA	O
is	O
also	O
susceptible	O
to	O
being	O
attacked	O
by	O
ROS	B-Chemical
","	O
and	O
multiple	O
DNA	O
repair	O
enzymes	O
protect	O
DNA	O
against	O
such	O
oxidative	O
damage	O
[	O
16	O
].	O
8	B-Chemical
-	I-Chemical
Hydroxydeoxyguanine	I-Chemical
(	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
)	O
is	O
a	O
major	O
component	O
of	O
the	O
oxidative	O
DNA	O
damage	O
induced	O
by	O
reactive	O
free	B-Chemical
radicals	I-Chemical
and	O
has	O
been	O
considered	O
as	O
a	O
key	O
biomarker	O
of	O
oxidative	O
DNA	O
damage	O
in	O
the	O
literature	O
[	O
17	O
","	O
18	O
].	O
On	O
the	O
contrary	O
","	O
base	B-Chemical
excision	O
repair	O
(	O
BER	O
)	O
and	O
nucleotide	B-Chemical
excision	O
repair	O
are	O
the	O
main	O
DNA	O
repair	O
pathways	O
that	O
can	O
help	O
to	O
remove	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
.	O
Human	O
8	O
-	O
oxoguanine	O
DNA	O
glycosylase	O
1	O
(	O
hOGG1	O
)	O
is	O
a	O
key	O
enzyme	O
of	O
the	O
base	B-Chemical
excision	O
repair	O
pathway	O
and	O
catalyzes	O
the	O
removal	O
of	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
[	O
19	O
","	O
20	O
].	O
A	O
functional	O
polymorphism	O
","	O
Ser326Cys	B-Chemical
","	O
is	O
the	O
common	O
single	O
nucleotide	B-Chemical
polymorphism	O
(	O
SNP	O
)	O
in	O
the	O
hOGG1	O
gene	O
and	O
is	O
reported	O
to	O
be	O
associated	O
with	O
risks	O
of	O
several	O
cancers	O
","	O
diabetes	O
and	O
CAD	O
[	O
21	O
â€“	O
29	O
].	O
Because	O
CE	O
is	O
correlated	O
to	O
atherosclerosis	O
and	O
oxidative	O
stress	O
","	O
we	O
aimed	O
to	O
investigate	O
the	O
association	O
between	O
the	O
functional	O
hOGG1	O
Ser326Cys	B-Chemical
gene	O
polymorphism	O
and	O
CE	O
in	O
a	O
Chinese	O
population	O
in	O
this	O
study	O
[	O
6	O
","	O
30	O
].	O
Results	O
and	O
Discussion	O
Clinical	O
Characteristics	O
We	O
finally	O
enrolled	O
547	O
patients	O
","	O
including	O
53	O
(	O
9	O
.	O
7	O
%)	O
patients	O
with	O
and	O
494	O
(	O
90	O
.	O
3	O
%)	O
without	O
CE	O
.	O
The	O
average	O
age	O
is	O
61	O
.	O
8	O
Â±	O
12	O
.	O
4	O
years	O
old	O
","	O
and	O
the	O
percentage	O
of	O
males	O
is	O
71	O
.	O
3	O
%.	O
Three	O
-	O
hundred	O
seventy	O
-	O
four	O
(	O
68	O
.	O
4	O
%)	O
patients	O
had	O
significant	O
CAD	O
","	O
including	O
120	O
(	O
21	O
.	O
9	O
%)	O
with	O
one	O
-	O
vessel	O
disease	O
(	O
1VD	O
"),"	O
96	O
(	O
17	O
.	O
6	O
%)	O
with	O
two	O
-	O
vessel	O
disease	O
(	O
2VD	O
)	O
and	O
158	O
(	O
28	O
.	O
9	O
%)	O
with	O
three	O
-	O
vessel	O
disease	O
(	O
3VD	O
).	O
Table	O
1	O
summarizes	O
the	O
demographic	O
information	O
between	O
those	O
with	O
and	O
without	O
CE	O
.	O
There	O
was	O
no	O
significant	O
difference	O
between	O
sex	O
","	O
age	O
","	O
incidence	O
of	O
diabetes	O
","	O
hypertension	O
and	O
hypercholesterolemia	O
","	O
history	O
of	O
smoking	O
","	O
family	O
history	O
of	O
premature	O
CAD	O
","	O
diseased	O
vessels	O
numbers	O
","	O
body	O
mass	O
index	O
(	O
BMI	O
"),"	O
history	O
of	O
previous	O
acute	O
coronary	O
syndrome	O
and	O
the	O
use	O
of	O
medications	O
.	O
Table	O
2	O
summarizes	O
the	O
angiographic	O
characteristics	O
of	O
the	O
patients	O
.	O
Four	O
-	O
hundred	O
ninety	O
-	O
four	O
(	O
90	O
.	O
3	O
%)	O
patients	O
had	O
no	O
CE	O
.	O
Among	O
53	O
patients	O
with	O
CE	O
","	O
42	O
(	O
7	O
.	O
7	O
%)	O
patients	O
had	O
CE	O
involving	O
one	O
major	O
vessel	O
(	O
right	O
coronary	O
artery	O
:	O
29	O
patients	O
;	O
left	O
anterior	O
descending	O
artery	O
:	O
one	O
patient	O
;	O
left	O
circumflex	O
artery	O
:	O
12	O
patients	O
);	O
eight	O
(	O
1	O
.	O
4	O
%)	O
patients	O
had	O
CE	O
involving	O
two	O
major	O
vessels	O
(	O
five	O
patients	O
with	O
right	O
coronary	O
artery	O
and	O
left	O
anterior	O
descending	O
artery	O
;	O
three	O
patients	O
with	O
right	O
coronary	O
artery	O
and	O
left	O
circumflex	O
artery	O
);	O
and	O
","	O
three	O
(	O
0	O
.	O
5	O
%)	O
patients	O
had	O
CE	O
involving	O
all	O
three	O
vessels	O
.	O
Furthermore	O
","	O
we	O
did	O
not	O
find	O
significant	O
association	O
between	O
the	O
number	O
of	O
ectatic	O
vessels	O
and	O
hOGG1	O
Ser326Cys	B-Chemical
polymorphism	O
(	O
p	O
=	O
0	O
.	O
165	O
).	O
hOGG1	O
Ser326Cys	B-Chemical
Genotype	O
Among	O
547	O
study	O
subjects	O
","	O
192	O
(	O
35	O
.	O
1	O
%)	O
were	O
Cys	B-Chemical
/	O
Cys	B-Chemical
","	O
279	O
(	O
51	O
.	O
0	O
%)	O
Ser	B-Chemical
/	O
Cys	B-Chemical
","	O
and	O
76	O
(	O
13	O
.	O
9	O
%)	O
were	O
Ser	B-Chemical
/	O
Ser	B-Chemical
genotype	O
.	O
The	O
genotypic	O
distribution	O
was	O
in	O
Hardy	O
â€“	O
Weinberg	O
equilibrium	O
.	O
Defining	O
patients	O
with	O
hOGG1	O
Ser326Cys	B-Chemical
Cys	B-Chemical
/	O
Cys	B-Chemical
genotype	O
as	O
the	O
reference	O
","	O
the	O
relative	O
possibility	O
of	O
the	O
presence	O
of	O
CE	O
was	O
2	O
.	O
45	O
for	O
patients	O
with	O
Ser	B-Chemical
/	O
Cys	B-Chemical
genotype	O
(	O
odds	O
ratio	O
(	O
OR	O
):	O
2	O
.	O
45	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
95	O
â€“	O
6	O
.	O
28	O
;	O
p	O
=	O
0	O
.	O
63	O
)	O
and	O
2	O
.	O
53	O
for	O
patients	O
with	O
Ser	B-Chemical
/	O
Ser	B-Chemical
genotype	O
(	O
OR	O
:	O
2	O
.	O
53	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
22	O
â€“	O
5	O
.	O
25	O
;	O
p	O
=	O
0	O
.	O
13	O
)	O
(	O
Table	O
3	O
).	O
Using	O
the	O
dominant	O
genetic	O
model	O
(	O
Cys	B-Chemical
/	O
Cys	B-Chemical
vs	O
.	O
Ser	B-Chemical
/	O
Cys	B-Chemical
plus	O
Ser	B-Chemical
/	O
Ser	B-Chemical
"),"	O
patients	O
with	O
the	O
Ser	B-Chemical
allele	O
were	O
2	O
.	O
51	O
times	O
more	O
likely	O
to	O
have	O
CE	O
than	O
Cys	B-Chemical
/	O
Cys	B-Chemical
genotype	O
carriers	O
(	O
OR	O
:	O
2	O
.	O
51	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
23	O
â€“	O
5	O
.	O
11	O
;	O
p	O
=	O
0	O
.	O
11	O
).	O
Although	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
CAD	O
number	O
between	O
non	O
-	O
CE	O
and	O
CE	O
patients	O
","	O
we	O
performed	O
a	O
subgroup	O
analysis	O
to	O
avoid	O
the	O
possible	O
influence	O
of	O
CAD	O
on	O
the	O
hOGG1	O
Ser326Cys	B-Chemical
polymorphism	O
.	O
Among	O
547	O
study	O
subjects	O
","	O
we	O
excluded	O
the	O
patients	O
with	O
angiographic	O
CAD	O
in	O
the	O
non	O
-	O
CE	O
patients	O
to	O
set	O
up	O
a	O
control	O
group	O
without	O
CAD	O
(	O
n	O
=	O
156	O
"),"	O
and	O
finally	O
","	O
209	O
subjects	O
were	O
analyzed	O
.	O
Defining	O
patients	O
with	O
hOGG1	O
Ser326Cys	B-Chemical
Cys	B-Chemical
/	O
Cys	B-Chemical
genotype	O
as	O
the	O
reference	O
","	O
the	O
relative	O
possibility	O
of	O
the	O
presence	O
of	O
CE	O
was	O
2	O
.	O
61	O
for	O
patients	O
with	O
Ser	B-Chemical
/	O
Cys	B-Chemical
genotype	O
(	O
OR	O
:	O
2	O
.	O
61	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
94	O
â€“	O
7	O
.	O
31	O
;	O
p	O
=	O
0	O
.	O
67	O
)	O
and	O
2	O
.	O
80	O
for	O
patients	O
with	O
Ser	B-Chemical
/	O
Ser	B-Chemical
genotype	O
(	O
OR	O
:	O
2	O
.	O
80	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
28	O
â€“	O
6	O
.	O
13	O
;	O
p	O
=	O
0	O
.	O
10	O
)	O
(	O
Table	O
4	O
).	O
Using	O
the	O
dominant	O
genetic	O
model	O
(	O
Cys	B-Chemical
/	O
Cys	B-Chemical
vs	O
.	O
Ser	B-Chemical
/	O
Cys	B-Chemical
plus	O
Ser	B-Chemical
/	O
Ser	B-Chemical
"),"	O
patients	O
with	O
the	O
Ser	B-Chemical
allele	O
were	O
2	O
.	O
76	O
times	O
more	O
likely	O
to	O
have	O
CE	O
than	O
Cys	B-Chemical
/	O
Cys	B-Chemical
genotype	O
carriers	O
(	O
OR	O
:	O
2	O
.	O
76	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
29	O
â€“	O
5	O
.	O
90	O
;	O
p	O
=	O
0	O
.	O
9	O
).	O
Furthermore	O
","	O
we	O
did	O
not	O
find	O
a	O
significant	O
association	O
between	O
CAD	O
and	O
hOGG1	O
Ser326Cys	B-Chemical
polymorphism	O
in	O
our	O
current	O
study	O
(	O
p	O
=	O
0	O
.	O
258	O
).	O
Urinary	O
Levels	O
of	O
8OHdG	B-Chemical
All	O
of	O
the	O
urine	O
samples	O
were	O
collected	O
from	O
healthy	O
subjects	O
during	O
a	O
health	O
exam	O
.	O
We	O
compared	O
those	O
carrying	O
the	O
hOGG1	O
Ser326Cys	B-Chemical
Ser	B-Chemical
genotype	O
(	O
n	O
=	O
30	O
)	O
with	O
those	O
carrying	O
the	O
Cys	B-Chemical
/	O
Cys	B-Chemical
genotype	O
(	O
n	O
=	O
15	O
).	O
Urine	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
levels	O
were	O
significantly	O
higher	O
in	O
subjects	O
carrying	O
the	O
hOGG1	O
Ser	B-Chemical
variant	O
than	O
in	O
those	O
with	O
the	O
Cys	B-Chemical
/	O
Cys	B-Chemical
genotype	O
(	O
log	O
of	O
urine	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
/	O
creatinine	B-Chemical
:	O
0	O
.	O
77	O
Â±	O
0	O
.	O
126	O
vs	O
.	O
0	O
.	O
66	O
Â±	O
0	O
.	O
148	O
ng	O
/	O
mL	O
;	O
p	O
=	O
0	O
.	O
22	O
)	O
(	O
Figure	O
1	O
).	O
Multivariate	O
Regression	O
Analysis	O
By	O
stepwise	O
binary	O
logistic	O
regression	O
analysis	O
after	O
adjusting	O
for	O
age	O
","	O
sex	O
","	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
traditional	O
coronary	O
risk	O
factors	O
","	O
including	O
hypertension	O
","	O
diabetes	O
","	O
hypercholesterolemia	O
","	O
smoking	O
and	O
family	O
history	O
of	O
premature	O
CAD	O
","	O
hOGG1	O
Ser326Cys	B-Chemical
polymorphism	O
in	O
the	O
dominant	O
model	O
and	O
BMI	O
were	O
significantly	O
independent	O
predictors	O
for	O
the	O
presence	O
of	O
CE	O
(	O
p	O
=	O
0	O
.	O
11	O
and	O
0	O
.	O
9	O
","	O
respectively	O
)	O
(	O
Table	O
5	O
).	O
Discussion	O
There	O
were	O
two	O
major	O
findings	O
in	O
the	O
present	O
study	O
.	O
First	O
","	O
subjects	O
carrying	O
the	O
hOGG1	O
Ser326Cys	B-Chemical
Ser	B-Chemical
variant	O
had	O
1	O
.	O
55	O
times	O
the	O
risk	O
for	O
having	O
coronary	O
ectasia	O
.	O
Second	O
","	O
hOGG1	O
Ser326Cys	B-Chemical
polymorphism	O
in	O
the	O
dominant	O
model	O
is	O
associated	O
with	O
the	O
presence	O
of	O
coronary	O
ectasia	O
after	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O
The	O
hOGG1	O
repair	O
enzyme	O
is	O
an	O
important	O
component	O
responsible	O
for	O
repairing	O
the	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
","	O
which	O
is	O
a	O
sensitive	O
biomarker	O
for	O
indicating	O
the	O
presence	O
of	O
oxidative	O
DNA	O
damage	O
[	O
19	O
","	O
20	O
].	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
is	O
excreted	O
in	O
to	O
the	O
urine	O
during	O
DNA	O
repair	O
.	O
Urinary	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
has	O
been	O
measured	O
frequently	O
to	O
indicate	O
the	O
extent	O
of	O
oxidative	O
damage	O
","	O
due	O
to	O
its	O
simple	O
and	O
noninvasive	O
technique	O
.	O
Numerous	O
pieces	O
of	O
evidence	O
have	O
indicated	O
that	O
urinary	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
not	O
only	O
is	O
a	O
biomarker	O
of	O
generalized	O
","	O
cellular	O
oxidative	O
stress	O
","	O
but	O
might	O
also	O
be	O
a	O
risk	O
factor	O
for	O
cancer	O
","	O
atherosclerosis	O
and	O
diabetes	O
[	O
18	O
","	O
30	O
â€“	O
33	O
].	O
In	O
addition	O
","	O
there	O
were	O
many	O
studies	O
focusing	O
on	O
the	O
functional	O
hOGG1	O
Ser326Cys	B-Chemical
polymorphism	O
[	O
21	O
â€“	O
29	O
","	O
34	O
","	O
35	O
].	O
Aka	O
et	O
al	O
.	O
reported	O
that	O
the	O
DNA	O
repair	O
capacity	O
in	O
individuals	O
with	O
Ser	B-Chemical
/	O
Cys	B-Chemical
or	O
Cys	B-Chemical
/	O
Cys	B-Chemical
OGG1	O
genotypes	O
was	O
lower	O
than	O
those	O
with	O
the	O
Ser	B-Chemical
/	O
Ser	B-Chemical
hOGG1	O
genotype	O
[	O
34	O
].	O
Thomas	O
D	O
.	O
et	O
al	O
.	O
found	O
that	O
the	O
inactivation	O
of	O
hOGG1	O
increases	O
the	O
frequency	O
of	O
G	O
â€“	O
C	O
to	O
T	O
â€“	O
A	O
transversion	O
mutations	O
in	O
Saccharomyces	O
cerevisiae	O
[	O
35	O
].	O
These	O
studies	O
revealed	O
that	O
the	O
hOGG1	O
Cys326	B-Chemical
variant	O
causes	O
the	O
reduction	O
of	O
repair	O
enzyme	O
activity	O
to	O
remove	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
and	O
leads	O
to	O
the	O
accumulation	O
of	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
and	O
increases	O
DNA	O
damage	O
[	O
12	O
].	O
CAD	O
is	O
characterized	O
by	O
the	O
formation	O
of	O
atherosclerotic	O
plaque	O
within	O
the	O
walls	O
of	O
the	O
coronary	O
arteries	O
and	O
is	O
also	O
a	O
chronic	O
inflammatory	O
disease	O
[	O
36	O
].	O
The	O
pathogenesis	O
of	O
atherosclerosis	O
is	O
related	O
to	O
oxidative	O
stress	O
","	O
which	O
causes	O
the	O
oxidative	O
modification	O
of	O
LDL	O
by	O
ROS	B-Chemical
and	O
further	O
leads	O
to	O
atherosclerotic	O
plaques	O
progression	O
and	O
possible	O
rupture	O
[	O
11	O
","	O
12	O
","	O
15	O
].	O
Our	O
recent	O
study	O
also	O
revealed	O
that	O
hOGG1	O
Ser326Cys	B-Chemical
polymorphism	O
was	O
associated	O
with	O
the	O
risk	O
of	O
CAD	O
and	O
multi	O
-	O
vessel	O
disease	O
and	O
might	O
be	O
a	O
novel	O
genetic	O
marker	O
for	O
the	O
development	O
and	O
severity	O
of	O
CAD	O
in	O
the	O
Chinese	O
population	O
[	O
29	O
].	O
CE	O
is	O
a	O
variant	O
of	O
coronary	O
artery	O
abnormality	O
[	O
6	O
].	O
It	O
may	O
be	O
congenital	O
or	O
acquired	O
.	O
Acquired	O
causes	O
include	O
CAD	O
","	O
various	O
inflammatory	O
and	O
infectious	O
diseases	O
and	O
Kawasaki	O
disease	O
[	O
2	O
â€“	O
6	O
","	O
8	O
â€“	O
10	O
].	O
However	O
","	O
most	O
cases	O
of	O
CE	O
are	O
correlated	O
with	O
atherosclerosis	O
and	O
had	O
the	O
coexistence	O
of	O
obstructive	O
CAD	O
[	O
2	O
","	O
6	O
].	O
In	O
addition	O
","	O
CE	O
was	O
also	O
reported	O
to	O
be	O
associated	O
with	O
oxidative	O
stress	O
in	O
a	O
recent	O
study	O
[	O
10	O
].	O
Sezen	O
Y	O
.	O
et	O
al	O
.	O
found	O
that	O
total	O
oxidant	O
status	O
and	O
the	O
oxidative	O
stress	O
index	O
were	O
significantly	O
increased	O
","	O
and	O
the	O
total	O
antioxidant	O
status	O
was	O
decreased	O
in	O
the	O
CE	O
group	O
compared	O
to	O
the	O
control	O
group	O
[	O
10	O
].	O
In	O
the	O
current	O
study	O
","	O
we	O
discovered	O
that	O
CE	O
is	O
significantly	O
associated	O
with	O
hOGG1	O
Ser326Cys	B-Chemical
gene	O
polymorphism	O
in	O
a	O
dominant	O
model	O
after	O
adjusting	O
the	O
possible	O
confounding	O
factors	O
.	O
This	O
finding	O
was	O
still	O
noted	O
in	O
the	O
subgroup	O
analysis	O
using	O
patients	O
without	O
CAD	O
as	O
the	O
control	O
group	O
.	O
Although	O
CE	O
is	O
considered	O
as	O
a	O
variant	O
of	O
CAD	O
","	O
its	O
pathogenesis	O
has	O
not	O
yet	O
been	O
completely	O
illustrated	O
.	O
Even	O
in	O
patients	O
with	O
isolated	O
CE	O
without	O
coronary	O
stenosis	O
","	O
there	O
is	O
still	O
a	O
higher	O
incidence	O
of	O
adverse	O
events	O
in	O
this	O
population	O
compared	O
to	O
people	O
with	O
normal	O
coronary	O
arteries	O
.	O
CE	O
could	O
produce	O
sluggish	O
blood	O
flow	O
and	O
predisposes	O
patients	O
to	O
acute	O
myocardial	O
infarction	O
","	O
even	O
without	O
obstructed	O
coronary	O
arteries	O
[	O
37	O
].	O
In	O
the	O
current	O
study	O
","	O
we	O
did	O
not	O
find	O
a	O
significant	O
association	O
between	O
CAD	O
and	O
hOGG1	O
Ser326Cys	B-Chemical
polymorphism	O
","	O
which	O
might	O
be	O
related	O
to	O
a	O
limited	O
sample	O
size	O
in	O
comparison	O
with	O
our	O
previous	O
study	O
.	O
However	O
","	O
we	O
discovered	O
a	O
significant	O
association	O
between	O
CE	O
and	O
hOGG1	O
Ser326Cys	B-Chemical
polymorphism	O
.	O
These	O
results	O
might	O
suggest	O
that	O
patients	O
with	O
CE	O
have	O
greater	O
oxidative	O
stress	O
than	O
those	O
with	O
CAD	O
.	O
In	O
addition	O
","	O
we	O
also	O
found	O
that	O
urinary	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
levels	O
were	O
significantly	O
higher	O
in	O
subjects	O
carrying	O
the	O
hOGG1	O
Ser	B-Chemical
variant	O
than	O
in	O
those	O
with	O
the	O
Cys	B-Chemical
/	O
Cys	B-Chemical
genotype	O
.	O
These	O
findings	O
could	O
further	O
confirm	O
the	O
association	O
of	O
oxidative	O
stress	O
with	O
CE	O
and	O
indicates	O
that	O
the	O
hOGG1	O
Ser326Cys	B-Chemical
gene	O
variant	O
might	O
play	O
a	O
role	O
in	O
the	O
individual	O
â€™	O
s	O
susceptibility	O
to	O
the	O
development	O
of	O
CE	O
in	O
the	O
Chinese	O
population	O
.	O
A	O
previous	O
study	O
had	O
reported	O
that	O
obesity	O
was	O
the	O
only	O
coronary	O
risk	O
factor	O
that	O
showed	O
a	O
statistically	O
significant	O
correlation	O
with	O
CE	O
[	O
38	O
].	O
In	O
this	O
study	O
","	O
obesity	O
was	O
present	O
in	O
60	O
%	O
of	O
the	O
patients	O
who	O
had	O
CE	O
","	O
compared	O
with	O
42	O
%	O
of	O
patients	O
who	O
did	O
not	O
have	O
CE	O
.	O
This	O
finding	O
is	O
compatible	O
with	O
the	O
findings	O
in	O
our	O
study	O
.	O
In	O
our	O
study	O
","	O
higher	O
BMI	O
was	O
still	O
significantly	O
associated	O
with	O
CE	O
after	O
multivariate	O
regression	O
analysis	O
.	O
Hence	O
","	O
obesity	O
might	O
also	O
be	O
a	O
risk	O
factor	O
in	O
the	O
development	O
of	O
CE	O
.	O
The	O
possible	O
mechanism	O
might	O
be	O
related	O
to	O
the	O
interaction	O
of	O
connective	O
tissue	O
elements	O
with	O
lipoprotein	O
particles	O
","	O
which	O
weakens	O
the	O
structure	O
of	O
the	O
arterial	O
wall	O
and	O
the	O
association	O
between	O
obesity	O
and	O
abnormal	O
lipoprotein	O
metabolism	O
[	O
38	O
].	O
However	O
","	O
further	O
studies	O
are	O
needed	O
to	O
clarify	O
the	O
detailed	O
mechanism	O
.	O
There	O
are	O
several	O
limitations	O
of	O
this	O
study	O
.	O
First	O
","	O
the	O
findings	O
should	O
be	O
taken	O
with	O
caution	O
","	O
because	O
they	O
are	O
based	O
on	O
a	O
limited	O
sample	O
size	O
.	O
Therefore	O
","	O
the	O
results	O
need	O
to	O
be	O
replicated	O
for	O
confirmation	O
by	O
further	O
studies	O
using	O
larger	O
samples	O
.	O
Second	O
","	O
the	O
association	O
between	O
hOGG1	O
Ser326Cys	B-Chemical
genotypes	O
and	O
urinary	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
levels	O
were	O
based	O
on	O
limited	O
samples	O
from	O
healthy	O
subjects	O
instead	O
of	O
all	O
enrolled	O
patients	O
.	O
However	O
","	O
our	O
data	O
might	O
reduce	O
the	O
confounding	O
factors	O
and	O
truly	O
demonstrate	O
the	O
influence	O
of	O
the	O
genetic	O
variant	O
on	O
urine	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
concentrations	O
.	O
Third	O
","	O
since	O
this	O
is	O
only	O
a	O
clinical	O
association	O
study	O
","	O
a	O
detailed	O
discussion	O
on	O
the	O
potential	O
mechanisms	O
should	O
be	O
limited	O
.	O
Experimental	O
Section	O
Study	O
Subjects	O
We	O
consecutively	O
evaluated	O
patients	O
scheduled	O
for	O
diagnostic	O
coronary	O
angiography	O
from	O
Kaohsiung	O
Medical	O
University	O
Hospital	O
(	O
KMUH	O
)	O
in	O
Taiwan	O
.	O
Patients	O
with	O
a	O
history	O
of	O
coronary	O
artery	O
bypass	O
surgery	O
","	O
a	O
history	O
of	O
percutaneous	O
coronary	O
intervention	O
","	O
uninterpretable	O
restriction	O
digest	O
results	O
or	O
inadequate	O
angiograms	O
for	O
evaluation	O
were	O
excluded	O
.	O
We	O
collected	O
patients	O
â€™	O
demographic	O
and	O
baseline	O
information	O
","	O
including	O
sex	O
","	O
age	O
","	O
duration	O
of	O
chest	O
pain	O
","	O
history	O
of	O
diabetes	O
","	O
hypertension	O
","	O
hypercholesterolemia	O
","	O
cigarette	O
smoking	O
and	O
medication	O
.	O
The	O
research	O
protocol	O
was	O
approved	O
and	O
registered	O
by	O
the	O
local	O
institution	O
ethics	O
committee	O
(	O
KMUH	O
-	O
IRB	O
"),"	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patients	O
.	O
Coronary	O
Angiography	O
The	O
coronary	O
artery	O
angiography	O
films	O
were	O
reviewed	O
by	O
two	O
experienced	O
cardiologists	O
blind	O
to	O
the	O
patients	O
â€™	O
clinical	O
characteristics	O
.	O
A	O
third	O
reviewer	O
blinded	O
to	O
the	O
readings	O
of	O
the	O
first	O
two	O
reviewers	O
served	O
as	O
the	O
arbitrator	O
of	O
the	O
differences	O
","	O
if	O
needed	O
.	O
Coronary	O
angiography	O
was	O
performed	O
by	O
the	O
femoral	O
or	O
radial	O
approach	O
with	O
6	O
French	O
diagnostic	O
catheters	O
.	O
Images	O
were	O
recorded	O
in	O
multiple	O
projections	O
for	O
left	O
and	O
right	O
coronary	O
arteries	O
.	O
Coronary	O
artery	O
stenosis	O
was	O
determined	O
by	O
quantitative	O
coronary	O
angiography	O
.	O
The	O
presence	O
of	O
CAD	O
is	O
defined	O
as	O
coronary	O
diameter	O
stenosis	O
more	O
than	O
50	O
%.	O
CE	O
is	O
defined	O
as	O
the	O
diameter	O
of	O
the	O
ectatic	O
segment	O
being	O
more	O
than	O
1	O
.	O
5	O
times	O
larger	O
compared	O
with	O
an	O
adjacent	O
healthy	O
reference	O
segment	O
[	O
2	O
].	O
The	O
recorded	O
data	O
also	O
included	O
the	O
location	O
of	O
CAD	O
and	O
CE	O
and	O
the	O
number	O
and	O
percentage	O
of	O
stenosis	O
of	O
the	O
diseased	O
vessels	O
.	O
DNA	O
Isolation	O
and	O
Genotyping	O
Blood	O
samples	O
for	O
genotyping	O
(	O
hOGG1	O
polymorphisms	O
in	O
codon	O
326	O
","	O
rs1052133	O
)	O
were	O
collected	O
during	O
coronary	O
catheterization	O
.	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
EDTA	B-Chemical
whole	O
blood	O
samples	O
following	O
standard	O
procedures	O
and	O
stored	O
at	O
âˆ’	O
20	O
ÂºC	O
.	O
The	O
genotype	O
was	O
determined	O
with	O
the	O
TaqMan	O
allelic	O
discrimination	O
assay	O
(	O
Applied	O
Biosystems	O
","	O
ABI	O
","	O
Foster	O
City	O
","	O
CA	O
","	O
USA	O
"),"	O
following	O
the	O
manufacturer	O
â€™	O
s	O
instructions	O
.	O
SNP	O
allele	O
-	O
specific	O
primers	O
and	O
probes	O
were	O
designed	O
and	O
synthesized	O
by	O
ABI	O
(	O
Foster	O
City	O
","	O
CA	O
","	O
USA	O
).	O
Nucleotide	B-Chemical
primers	O
were	O
5	O
â€²	O
CTCCTACAGGTGCTGTTCAGT3	O
â€²	O
(	O
forward	O
primer	O
)	O
and	O
5	O
â€²	O
ACCCTTTCTGCGCTTTGCT3	O
â€²	O
(	O
reverse	O
primer	O
).	O
The	O
probe	O
for	O
Ser326	B-Chemical
was	O
5	O
â€²	O
CCAATCCCGCCATGC3	O
"â€²,"	O
and	O
for	O
Cys326	B-Chemical
","	O
it	O
was	O
5	O
â€²	O
CAATGCCGCCATGC3	O
â€².	O
Probe	O
5	O
â€²	O
ends	O
were	O
labeled	O
","	O
the	O
Cys326	B-Chemical
probe	O
with	O
6	B-Chemical
-	I-Chemical
carboxy	I-Chemical
-	I-Chemical
fluorescein	I-Chemical
(	O
FAM	B-Chemical
)	O
and	O
the	O
Ser326	B-Chemical
with	O
2	B-Chemical
â€²-	I-Chemical
chloro	I-Chemical
-	I-Chemical
7	I-Chemical
â€²-	I-Chemical
phenyl	I-Chemical
-	I-Chemical
1	I-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
dichloro	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
carboxyfluorescein	I-Chemical
(	O
VIC	B-Chemical
).	O
After	O
thermal	O
cycling	O
(	O
50	O
ÂºC	O
for	O
2	O
min	O
","	O
95	O
ÂºC	O
for	O
10	O
min	O
","	O
then	O
40	O
cycles	O
at	O
95	O
ÂºC	O
for	O
15	O
s	O
and	O
at	O
60	O
ÂºC	O
for	O
90	O
s	O
"),"	O
allelic	O
discrimination	O
was	O
performed	O
(	O
Applied	O
Biosystems	O
7900	O
real	O
-	O
time	O
PCR	O
system	O
","	O
ABI	O
","	O
Foster	O
City	O
","	O
CA	O
","	O
USA	O
).	O
Urine	O
8OHdG	B-Chemical
Measurement	O
by	O
Enzyme	O
-	O
Linked	O
Immunosorbent	O
Assay	O
(	O
ELISA	O
)	O
The	O
urine	O
values	O
of	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
could	O
be	O
determined	O
in	O
45	O
subjects	O
from	O
a	O
healthy	O
general	O
population	O
(	O
15	O
subjects	O
for	O
each	O
genotype	O
).	O
Urine	O
samples	O
were	O
stored	O
in	O
polypropylene	B-Chemical
tubes	O
or	O
polystyrene	B-Chemical
tubes	O
at	O
âˆ’	O
80	O
ÂºC	O
until	O
the	O
time	O
of	O
analysis	O
.	O
To	O
determine	O
urine	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
levels	O
","	O
an	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
Check	O
ELISA	O
kit	O
(	O
from	O
Japan	O
Institute	O
for	O
the	O
Control	O
of	O
Aging	O
","	O
Fukuroi	O
","	O
Japan	O
)	O
was	O
used	O
.	O
The	O
kits	O
utilize	O
the	O
highly	O
specific	O
monoclonal	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
antibody	O
(	O
clone	O
N45	O
.	O
1	O
).	O
All	O
assays	O
were	O
done	O
according	O
to	O
the	O
manufacturer	O
â€™	O
s	O
instructions	O
.	O
Statistical	O
Analysis	O
All	O
data	O
were	O
expressed	O
as	O
the	O
mean	O
Â±	O
standard	O
deviation	O
.	O
If	O
the	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
for	O
hOGG1	O
Ser326Cys	B-Chemical
polymorphism	O
among	O
the	O
non	O
-	O
CE	O
group	O
was	O
estimated	O
to	O
be	O
0	O
.	O
384	O
","	O
the	O
study	O
should	O
enroll	O
at	O
least	O
51	O
patients	O
with	O
the	O
non	O
-	O
CE	O
group	O
to	O
have	O
more	O
than	O
80	O
%	O
statistical	O
power	O
to	O
detect	O
an	O
association	O
with	O
Odds	O
ratios	O
(	O
ORs	O
)	O
â‰¥	O
2	O
.	O
5	O
.	O
The	O
independent	O
t	O
-	O
test	O
was	O
used	O
for	O
continuous	O
variables	O
analysis	O
between	O
two	O
groups	O
.	O
The	O
genotypic	O
distribution	O
was	O
tested	O
by	O
the	O
Hardy	O
â€“	O
Weinberg	O
equilibrium	O
.	O
A	O
chi	O
-	O
square	O
test	O
was	O
used	O
to	O
compare	O
categorical	O
data	O
.	O
ORs	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
CI	O
)	O
were	O
calculated	O
as	O
a	O
measure	O
of	O
the	O
association	O
of	O
hOGG1	O
genotypes	O
in	O
a	O
different	O
genetic	O
analysis	O
model	O
with	O
CE	O
.	O
The	O
relevant	O
correlated	O
variables	O
and	O
the	O
appropriate	O
genetic	O
model	O
were	O
further	O
analyzed	O
by	O
logistic	O
regression	O
analysis	O
.	O
All	O
p	O
-	O
values	O
were	O
two	O
-	O
sided	O
with	O
a	O
significant	O
level	O
of	O
p	O
<	O
0	O
.	O
5	O
.	O
The	O
Statistical	O
Package	O
for	O
the	O
Social	O
Sciences	O
(	O
SPSS	O
)	O
11	O
.	O
0	O
for	O
Windows	O
(	O
SPSS	O
Inc	O
".,"	O
Chicago	O
","	O
IL	O
","	O
USA	O
)	O
was	O
used	O
for	O
statistical	O
analysis	O
.	O
Conclusions	O
To	O
our	O
best	O
knowledge	O
","	O
this	O
is	O
the	O
first	O
report	O
discussing	O
the	O
association	O
between	O
Ser326Cys	B-Chemical
gene	O
polymorphism	O
and	O
CE	O
.	O
In	O
this	O
study	O
","	O
we	O
discovered	O
a	O
significant	O
association	O
of	O
the	O
hOGG1	O
Ser326Cys	B-Chemical
gene	O
variant	O
in	O
the	O
dominant	O
model	O
with	O
CE	O
development	O
.	O
These	O
findings	O
indicate	O
that	O
the	O
hOGG1	O
Ser326Cys	B-Chemical
gene	O
variant	O
might	O
be	O
a	O
novel	O
genetic	O
marker	O
in	O
the	O
susceptibility	O
to	O
the	O
development	O
of	O
CE	O
in	O
the	O
Chinese	O
population	O
.	O
Conflicts	O
of	O
Interest	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O
References	O
Urine	O
8	B-Chemical
-	I-Chemical
OHdG	I-Chemical
concentrations	O
in	O
different	O
genetic	O
variants	O
.	O
CC	O
","	O
Ser	B-Chemical
/	O
Ser	B-Chemical
;	O
CG	O
","	O
Ser	B-Chemical
/	O
Cys	B-Chemical
;	O
GG	O
","	O
Cys	B-Chemical
/	O
Cys	B-Chemical
.	O
Patients	O
â€™	O
baseline	O
characteristics	O
.	O
Abbreviations	O
:	O
SD	O
","	O
standard	O
deviation	O
;	O
CAD	O
","	O
coronary	O
artery	O
disease	O
;	O
CE	O
","	O
coronary	O
ectasia	O
;	O
DM	O
","	O
diabetes	O
mellitus	O
;	O
ACS	O
","	O
acute	O
coronary	O
syndrome	O
;	O
BMI	O
","	O
body	O
mass	O
index	O
;	O
ACEI	O
","	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
;	O
ARB	O
","	O
angiotensin	O
receptor	O
blocker	O
;	O
CCB	O
","	O
calcium	O
channel	O
blocker	O
.	O
Angiographic	O
characteristics	O
among	O
the	O
53	O
coronary	O
ectasia	O
patients	O
.	O
hOGG1	O
Ser326Cys	B-Chemical
genotype	O
and	O
ectasia	O
status	O
.	O
aOR	O
","	O
adjusted	O
odds	O
ratio	O
;	O
CE	O
","	O
coronary	O
ectasia	O
;	O
CI	O
","	O
confidence	O
interval	O
;	O
hOGG1	O
","	O
Human	O
8	O
-	O
oxoguanine	O
DNA	O
glycosylase	O
;	O
OR	O
:	O
odds	O
ratio	O
.	O
aOR	O
is	O
based	O
on	O
logistic	O
regression	O
adjusted	O
for	O
age	O
","	O
sex	O
","	O
body	O
mass	O
index	O
and	O
traditional	O
coronary	O
risk	O
factors	O
","	O
including	O
hypertension	O
","	O
diabetes	O
","	O
hypercholesterolemia	O
","	O
smoking	O
and	O
family	O
history	O
of	O
premature	O
coronary	O
artery	O
disease	O
.	O
hOGG1	O
Ser326Cys	B-Chemical
genotype	O
and	O
ectasia	O
status	O
in	O
subgroup	O
patients	O
.	O
aOR	O
","	O
adjusted	O
odds	O
ratio	O
;	O
CE	O
","	O
coronary	O
ectasia	O
;	O
CI	O
","	O
confidence	O
interval	O
;	O
hOGG1	O
","	O
Human	O
8	O
-	O
oxoguanine	O
DNA	O
glycosylase	O
;	O
OR	O
:	O
odds	O
ratio	O
.	O
aOR	O
is	O
based	O
on	O
logistic	O
regression	O
adjusted	O
for	O
age	O
","	O
sex	O
","	O
body	O
mass	O
index	O
and	O
traditional	O
coronary	O
risk	O
factors	O
","	O
including	O
hypertension	O
","	O
diabetes	O
","	O
hypercholesterolemia	O
","	O
smoking	O
and	O
family	O
history	O
of	O
premature	O
coronary	O
artery	O
disease	O
.	O
Results	O
obtained	O
from	O
the	O
binary	O
logistic	O
analysis	O
.	O
CAD	O
","	O
coronary	O
artery	O
disease	O
;	O
CI	O
","	O
confidence	O
interval	O
;	O
hOGG1	O
","	O
Human	O
8	O
-	O
oxoguanine	O
DNA	O
glycosylase	O
;	O
OR	O
","	O
odds	O
ratio	O
.	O
Thapsigargin	B-Chemical
Induces	O
Apoptosis	O
by	O
Impairing	O
Cytoskeleton	O
Dynamics	O
in	O
Human	O
Lung	O
Adenocarcinoma	O
Cells	O
The	O
objective	O
of	O
this	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
effects	O
of	O
thapsigargin	B-Chemical
on	O
apoptosis	O
","	O
actin	O
cytoskeletal	O
dynamics	O
","	O
and	O
actin	O
cytoskeletal	O
proteins	O
in	O
human	O
lung	O
adenocarcinoma	O
cell	O
.	O
Thapsigargin	B-Chemical
is	O
a	O
specific	O
irreversible	O
inhibitor	O
of	O
ER	O
calcium	O
-	O
ATPase	O
","	O
which	O
may	O
promote	O
ER	O
stress	O
by	O
depletion	O
of	O
lumenal	O
calcium	B-Chemical
stores	O
and	O
show	O
potential	O
to	O
induce	O
cell	O
death	O
.	O
The	O
effects	O
of	O
thapsigargin	B-Chemical
on	O
the	O
apoptosis	O
in	O
A549	O
cells	O
were	O
assayed	O
by	O
Hoechst	B-Chemical
staining	O
.	O
Moreover	O
","	O
the	O
F	O
-	O
actin	O
staining	O
by	O
Rhodamine	B-Chemical
-	I-Chemical
phalloidin	I-Chemical
and	O
RhoA	O
antibody	O
for	O
cytoskeleton	O
organizations	O
were	O
applied	O
to	O
A549	O
cells	O
.	O
To	O
confirm	O
the	O
impairment	O
of	O
cytoskeletal	O
dynamics	O
treated	O
with	O
thapsigargin	B-Chemical
","	O
western	O
blots	O
were	O
applied	O
to	O
analyze	O
the	O
protein	O
levels	O
of	O
p	O
-	O
Cofilin	O
-	O
1	O
(	O
Ser3	B-Chemical
"),"	O
Cofilin	O
-	O
1	O
","	O
and	O
pPaxillin	O
(	O
Tyr118	B-Chemical
"),"	O
as	O
well	O
as	O
RhoA	O
and	O
pS6	O
(	O
S240	O
/	O
244	O
).	O
Results	O
suggest	O
that	O
thapsigargin	B-Chemical
may	O
induce	O
cell	O
death	O
in	O
A549	O
cells	O
with	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O
The	O
F	O
-	O
actin	O
fibers	O
and	O
RhoA	O
signals	O
are	O
also	O
reduced	O
with	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
by	O
thapsigargin	B-Chemical
treatment	O
.	O
The	O
phosphorylation	O
forms	O
of	O
Cofilin	O
-	O
1	O
and	O
paxillin	O
are	O
attenuated	O
by	O
1	O
Î¼M	O
thapsigargin	B-Chemical
treatment	O
for	O
24	O
h	O
.	O
These	O
alternations	O
may	O
be	O
caused	O
by	O
the	O
inhibition	O
of	O
of	O
mTORC1	O
activities	O
(	O
indicated	O
by	O
pS6	O
(	O
Ser240	B-Chemical
/	O
244	O
))	O
and	O
RhoA	O
pathways	O
after	O
thapsigargin	B-Chemical
treatment	O
.	O
The	O
present	O
findings	O
highlight	O
important	O
roles	O
of	O
calcium	B-Chemical
entry	O
in	O
cytoskeleton	O
organization	O
and	O
apoptosis	O
in	O
human	O
lung	O
adenocarcinoma	O
cells	O
and	O
will	O
help	O
to	O
set	O
a	O
stage	O
to	O
the	O
clinical	O
treatment	O
of	O
cancer	O
cell	O
metastasis	O
.	O
1	O
.	O
Introduction	O
Cytoskeleton	O
is	O
required	O
for	O
many	O
biological	O
processes	O
","	O
such	O
as	O
embryonic	O
morphogenesis	O
","	O
immune	O
surveillance	O
","	O
tissue	O
repair	O
","	O
and	O
regeneration	O
.	O
Aberrant	O
regulation	O
of	O
cytoskeleton	O
dynamics	O
drives	O
progression	O
of	O
cancer	O
invasion	O
and	O
metastasis	O
.	O
Cancer	O
cell	O
metastasis	O
is	O
a	O
multistage	O
process	O
involving	O
invasion	O
into	O
surrounding	O
tissue	O
","	O
intravasation	O
","	O
transit	O
in	O
the	O
blood	O
or	O
lymph	O
","	O
extravasation	O
","	O
and	O
growth	O
at	O
a	O
new	O
site	O
.	O
Many	O
of	O
these	O
steps	O
require	O
cell	O
motility	O
","	O
which	O
is	O
driven	O
by	O
cycles	O
of	O
actin	O
polymerization	O
and	O
depolymerization	O
.	O
Actin	O
networks	O
consist	O
of	O
branched	O
or	O
linear	O
filaments	O
and	O
regulate	O
many	O
essential	O
cellular	O
processes	O
.	O
The	O
actin	O
cytoskeleton	O
functions	O
in	O
the	O
generation	O
and	O
maintenance	O
of	O
cell	O
morphology	O
and	O
polarity	O
and	O
in	O
endocytosis	O
","	O
intracellular	O
trafficking	O
","	O
contractility	O
","	O
motility	O
","	O
and	O
cell	O
division	O
.	O
The	O
assembly	O
and	O
disassembly	O
of	O
actin	O
filaments	O
","	O
as	O
well	O
as	O
their	O
organizations	O
into	O
functional	O
higher	O
-	O
order	O
networks	O
","	O
are	O
regulated	O
by	O
several	O
actin	O
-	O
binding	O
proteins	O
","	O
many	O
of	O
which	O
are	O
conserved	O
from	O
yeast	O
to	O
human	O
.	O
Malignant	O
cancer	O
cells	O
utilize	O
their	O
intrinsic	O
migratory	O
ability	O
to	O
invade	O
adjacent	O
tissues	O
and	O
the	O
vasculature	O
and	O
ultimately	O
to	O
metastasize	O
.	O
The	O
motility	O
of	O
tumor	O
cells	O
is	O
driven	O
by	O
the	O
polymerization	O
of	O
actin	O
monomers	O
into	O
polarized	O
filaments	O
.	O
These	O
filaments	O
","	O
termed	O
F	O
-	O
actin	O
","	O
are	O
in	O
a	O
constant	O
state	O
of	O
flux	O
with	O
new	O
monomers	O
being	O
added	O
.	O
One	O
of	O
the	O
proteins	O
identified	O
in	O
F	O
-	O
actin	O
formation	O
is	O
Cofilin	O
-	O
1	O
.	O
Cofilin	O
-	O
1	O
is	O
an	O
actin	O
-	O
depolymerizing	O
factor	O
and	O
regulates	O
actin	O
cytoskeletal	O
reorganization	O
.	O
Phosphorylation	O
of	O
Cofilin	O
-	O
1	O
on	O
Serine	B-Chemical
-	O
3	O
is	O
known	O
to	O
block	O
these	O
activities	O
","	O
which	O
is	O
regulated	O
by	O
RhoA	O
GTPases	O
through	O
mTORC1	O
-	O
RhoA	O
-	O
Limk	O
-	O
Cofilin	O
-	O
1	O
pathways	O
.	O
Earlier	O
results	O
have	O
been	O
coupled	O
with	O
intracellular	O
calcium	B-Chemical
influx	O
and	O
cytoskeletal	O
dynamic	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
For	O
example	O
","	O
calcium	B-Chemical
influx	O
into	O
rat	O
brain	O
synaptosomes	O
causes	O
the	O
breakdown	O
of	O
F	O
-	O
actin	O
under	O
the	O
plasma	O
membrane	O
.	O
And	O
inhibition	O
of	O
actin	O
polymerization	O
has	O
a	O
biphasic	O
time	O
-	O
dependent	O
effect	O
on	O
calcium	B-Chemical
entry	O
","	O
showing	O
an	O
initial	O
potentiation	O
followed	O
by	O
inhibition	O
of	O
calcium	B-Chemical
entry	O
.	O
Moreover	O
","	O
thapsigargin	B-Chemical
","	O
a	O
specific	O
irreversible	O
inhibitor	O
of	O
ER	O
calcium	O
-	O
ATPase	O
","	O
has	O
been	O
used	O
to	O
investigate	O
the	O
effect	O
of	O
a	O
disturbed	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
calcium	B-Chemical
homeostasis	O
on	O
different	O
processes	O
of	O
cells	O
","	O
including	O
cytoskeleton	O
dynamics	O
.	O
It	O
is	O
interesting	O
that	O
thapsigargin	B-Chemical
-	O
induced	O
depletion	O
of	O
ER	O
calcium	B-Chemical
stores	O
severely	O
inhibits	O
F	O
-	O
actin	O
contents	O
in	O
human	O
monocytic	O
cells	O
.	O
Thus	O
","	O
thapsigargin	B-Chemical
may	O
prove	O
to	O
be	O
a	O
useful	O
tool	O
for	O
investigating	O
calcium	B-Chemical
influx	O
and	O
cytoskeleton	O
dynamics	O
underlying	O
cell	O
apoptosis	O
.	O
Although	O
progress	O
has	O
been	O
made	O
","	O
it	O
is	O
still	O
largely	O
unknown	O
whether	O
the	O
calcium	B-Chemical
influx	O
couples	O
with	O
cytoskeletal	O
dynamics	O
and	O
affects	O
cell	O
apoptosis	O
","	O
especially	O
in	O
cancer	O
cells	O
.	O
To	O
examine	O
the	O
critical	O
role	O
between	O
calcium	B-Chemical
signaling	O
","	O
cytoskeleton	O
","	O
and	O
cell	O
apoptosis	O
","	O
we	O
focus	O
on	O
the	O
effect	O
of	O
ectopic	O
entry	O
of	O
calcium	B-Chemical
influx	O
by	O
thapsigargin	B-Chemical
on	O
actin	O
cytoskeleton	O
apoptosis	O
in	O
A549	O
human	O
lung	O
adenocarcinoma	O
cell	O
lines	O
.	O
Our	O
findings	O
demonstrate	O
that	O
thapsigargin	B-Chemical
treatment	O
may	O
induce	O
cell	O
death	O
in	O
A549	O
cells	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O
For	O
ectopic	O
entry	O
of	O
calcium	B-Chemical
influx	O
being	O
induced	O
thapsigargin	B-Chemical
","	O
we	O
find	O
that	O
the	O
cytoskeletal	O
dynamics	O
is	O
impaired	O
by	O
thapsigargin	B-Chemical
treatment	O
","	O
indicated	O
by	O
F	O
-	O
actin	O
staining	O
and	O
biochemical	O
evidence	O
.	O
The	O
effects	O
of	O
thapsigargin	B-Chemical
on	O
cell	O
death	O
in	O
A549	O
tumor	O
cells	O
may	O
be	O
mediated	O
by	O
mTORC1	O
-	O
RhoA	O
-	O
Cofilin	O
-	O
1	O
pathway	O
","	O
because	O
thapsigargin	B-Chemical
treatment	O
may	O
dramatically	O
inhibit	O
mTORC1	O
activity	O
and	O
RhoA	O
protein	O
level	O
.	O
Our	O
work	O
will	O
help	O
to	O
understand	O
a	O
novel	O
clue	O
regarding	O
the	O
relationship	O
between	O
calcium	B-Chemical
signaling	O
","	O
cytoskeleton	O
","	O
and	O
cell	O
apoptosis	O
in	O
A549	O
tumor	O
cells	O
.	O
2	O
.	O
Materials	O
and	O
Methods	O
2	O
.	O
1	O
.	O
Chemicals	O
and	O
Materials	O
The	O
inhibitor	O
of	O
ER	O
calcium	O
-	O
ATPase	O
thapsigargin	B-Chemical
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
.	O
Louis	O
","	O
MO	O
","	O
USA	O
).	O
Dulbecco	B-Chemical
'	I-Chemical
s	I-Chemical
Modified	I-Chemical
Essential	I-Chemical
Medium	I-Chemical
(	O
DMEM	B-Chemical
"),"	O
Fetal	O
Bovine	O
Serum	O
(	O
FBS	O
"),"	O
and	O
F	O
-	O
actin	O
probes	O
of	O
Rhodamine	B-Chemical
Phalloidin	I-Chemical
R415	O
were	O
purchased	O
from	O
Gibco	O
Invitrogen	O
Corporation	O
(	O
Carlsbad	O
","	O
CA	O
","	O
USA	O
).	O
The	O
Hoechst	B-Chemical
kit	O
was	O
from	O
Beyotime	O
Biotechnology	O
Co	O
.	O
(	O
Haimen	O
","	O
Jiangsu	O
","	O
China	O
).	O
The	O
following	O
antibodies	O
","	O
anti	O
-	O
p	O
-	O
Cofilin	O
-	O
1	O
","	O
anti	O
-	O
Cofilin	O
-	O
1	O
","	O
and	O
anti	O
-	O
RhoA	O
were	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
","	O
CA	O
","	O
USA	O
).	O
The	O
p	O
-	O
Paxillin	O
(	O
Tyr118	B-Chemical
)	O
and	O
pS6	O
(	O
Ser240	B-Chemical
/	O
244	O
)	O
antibodies	O
were	O
from	O
Cell	O
Signaling	O
Technology	O
(	O
Danvers	O
","	O
MA	O
","	O
USA	O
)	O
and	O
anti	O
-	O
GAPDH	O
was	O
from	O
Millipore	O
(	O
Billerica	O
","	O
MA	O
","	O
USA	O
).	O
Other	O
chemicals	O
were	O
of	O
the	O
highest	O
purity	O
available	O
.	O
2	O
.	O
2	O
.	O
Assays	O
of	O
Cell	O
Culture	O
A	O
widely	O
used	O
human	O
lung	O
adenocarcinoma	O
cell	O
line	O
A549	O
was	O
chosen	O
as	O
in	O
vitro	O
experiment	O
system	O
","	O
which	O
was	O
obtained	O
from	O
Shanghai	O
Institute	O
of	O
Cell	O
Biology	O
(	O
Introduced	O
from	O
American	O
Type	O
Culture	O
Collection	O
).	O
A549	O
cells	O
were	O
derived	O
from	O
a	O
lung	O
adenocarcinoma	O
and	O
widely	O
used	O
to	O
study	O
the	O
amplification	O
process	O
in	O
tumors	O
.	O
In	O
the	O
present	O
study	O
","	O
A549	O
cells	O
were	O
plated	O
in	O
6	O
-	O
well	O
plates	O
at	O
1	O
.	O
0	O
Ã—	O
106	O
cells	O
/	O
mL	O
.	O
The	O
cells	O
were	O
incubated	O
in	O
Dulbecco	B-Chemical
'	I-Chemical
s	I-Chemical
Modified	I-Chemical
Essential	I-Chemical
Medium	I-Chemical
(	O
DMEM	B-Chemical
)	O
containing	O
10	O
%	O
Fetal	O
Bovine	O
Serum	O
(	O
FBS	O
)	O
plus	O
antibiotics	O
for	O
24	O
h	O
in	O
5	O
%	O
CO2	B-Chemical
at	O
37	O
Â°	O
C	O
.	O
2	O
.	O
3	O
.	O
Pharmacological	O
Manipulations	O
For	O
ectopic	O
calcium	B-Chemical
influx	O
in	O
A549	O
cells	O
","	O
the	O
final	O
concentrations	O
(	O
1	O
","	O
100	O
","	O
and	O
1000	O
nM	O
)	O
of	O
thapsigargin	B-Chemical
were	O
applied	O
to	O
these	O
cells	O
and	O
then	O
incubated	O
from	O
6	O
h	O
to	O
24	O
h	O
.	O
No	O
additives	O
were	O
used	O
as	O
internal	O
controls	O
.	O
After	O
culturing	O
","	O
the	O
cells	O
were	O
harvested	O
for	O
subsequent	O
Hoechst	B-Chemical
stainings	O
and	O
immunostainings	O
.	O
To	O
further	O
study	O
the	O
role	O
of	O
thapsigargin	B-Chemical
on	O
cytoskeleton	O
molecules	O
in	O
A549	O
cells	O
","	O
thapsigargin	B-Chemical
of	O
1	O
Î¼M	O
for	O
6	O
h	O
was	O
applied	O
to	O
A549	O
cells	O
for	O
biochemical	O
examinations	O
.	O
2	O
.	O
4	O
.	O
Assay	O
of	O
Hoechst	B-Chemical
Staining	O
For	O
the	O
preparation	O
of	O
Hoechst	B-Chemical
staining	O
","	O
A549	O
cells	O
were	O
plated	O
with	O
1	O
.	O
0	O
Ã—	O
105	O
cells	O
/	O
mL	O
in	O
6	O
-	O
well	O
plates	O
.	O
After	O
pharmacological	O
manipulations	O
","	O
cells	O
were	O
directly	O
stained	O
with	O
Hoechst	B-Chemical
kit	O
from	O
Beyotime	O
.	O
The	O
cell	O
counting	O
was	O
carried	O
out	O
through	O
the	O
use	O
of	O
National	O
Institutes	O
of	O
Health	O
software	O
ImageJ	O
","	O
which	O
is	O
available	O
at	O
http	O
://	O
rsbweb	O
.	O
nih	O
.	O
gov	O
.	O
2	O
.	O
5	O
.	O
Assay	O
of	O
F	O
-	O
Actin	O
Staining	O
and	O
Immunostaining	O
To	O
detect	O
the	O
F	O
-	O
actin	O
fibers	O
in	O
thapsigargin	B-Chemical
-	O
treated	O
A549	O
cells	O
","	O
the	O
Rhodamine	B-Chemical
Phalloidin	I-Chemical
R415	O
probes	O
were	O
applied	O
to	O
stain	O
the	O
F	O
-	O
actin	O
fibers	O
.	O
For	O
the	O
preparation	O
of	O
Rhodamine	B-Chemical
Phalloidin	I-Chemical
staining	O
","	O
A549	O
cells	O
were	O
plated	O
with	O
1	O
.	O
0	O
Ã—	O
105	O
cells	O
/	O
mL	O
in	O
6	O
-	O
well	O
plates	O
.	O
After	O
thapsigargin	B-Chemical
-	O
treated	O
at	O
different	O
concentrations	O
from	O
6	O
h	O
to	O
24	O
h	O
","	O
cells	O
were	O
fixed	O
with	O
4	O
%	O
Paraformaldehyde	B-Chemical
(	O
PFA	B-Chemical
)	O
and	O
4	O
%	O
sucrose	B-Chemical
in	O
phosphate	B-Chemical
-	I-Chemical
buffered	I-Chemical
saline	I-Chemical
for	O
30	O
min	O
and	O
then	O
permeabilized	O
with	O
0	O
.	O
25	O
%	O
Triton	B-Chemical
-	I-Chemical
X	I-Chemical
100	I-Chemical
in	O
PBS	B-Chemical
for	O
another	O
5	O
min	O
at	O
room	O
temperature	O
.	O
Anti	O
-	O
RhoA	O
antibody	O
was	O
used	O
to	O
detect	O
RhoA	O
signals	O
in	O
these	O
cells	O
.	O
After	O
washing	O
extensively	O
","	O
Rhodamine	B-Chemical
Phalloidin	I-Chemical
R415	O
probes	O
were	O
added	O
into	O
these	O
cells	O
","	O
as	O
well	O
as	O
antibodies	O
-	O
Alexa	B-Chemical
Fluor	I-Chemical
594	I-Chemical
goat	O
anti	O
-	O
mouse	O
IgG	O
(	O
Invitrogen	O
","	O
Carlsbad	O
","	O
CA	O
).	O
Then	O
after	O
a	O
second	O
washing	O
for	O
three	O
times	O
","	O
the	O
cover	O
slips	O
were	O
mounted	O
onto	O
glass	O
slides	O
with	O
antifade	O
reagent	O
with	O
4	B-Chemical
"â€²,"	I-Chemical
6	I-Chemical
-	I-Chemical
diamidino	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
phenylindole	I-Chemical
(	O
DAPI	B-Chemical
)	O
for	O
nuclear	O
labellings	O
.	O
2	O
.	O
6	O
.	O
Assay	O
of	O
Western	O
Blots	O
To	O
extract	O
proteins	O
","	O
cultured	O
A549	O
cells	O
were	O
sonicated	O
with	O
lysis	O
buffer	O
(	O
PBS	B-Chemical
with	O
1	O
%	O
Triton	B-Chemical
X	I-Chemical
-	I-Chemical
100	I-Chemical
and	O
protease	O
inhibitors	O
).	O
The	O
cell	O
lysate	O
supernatants	O
were	O
harvested	O
by	O
centrifugation	O
at	O
l0000	O
rpm	O
for	O
10	O
min	O
at	O
4	O
Â°	O
C	O
.	O
Protein	O
concentrations	O
of	O
the	O
cell	O
supernatants	O
were	O
evaluated	O
and	O
measured	O
by	O
BCA	O
Protein	O
Assay	O
kit	O
(	O
Thermo	O
Fisher	O
Scientific	O
Inc	O
".,"	O
Rockford	O
","	O
IL	O
","	O
USA	O
).	O
Equal	O
amounts	O
of	O
the	O
proteins	O
from	O
each	O
extract	O
were	O
separated	O
in	O
a	O
SDS	B-Chemical
-	O
polyacrylamide	B-Chemical
gel	O
(	O
12	O
.	O
6	O
%)	O
with	O
5	O
%	O
stacking	O
gel	O
in	O
SDS	B-Chemical
-	O
Tris	B-Chemical
-	O
glycine	B-Chemical
running	O
buffer	O
.	O
The	O
proteins	O
were	O
then	O
transferred	O
electrophoretically	O
using	O
a	O
PVDF	B-Chemical
membrane	O
by	O
standard	O
procedures	O
.	O
The	O
membranes	O
were	O
then	O
blocked	O
by	O
5	O
%	O
nonfat	O
dry	O
milk	O
in	O
PBST	B-Chemical
(	O
PBS	B-Chemical
with	O
0	O
.	O
1	O
%	O
Tween	B-Chemical
20	I-Chemical
","	O
pH	O
7	O
.	O
6	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
and	O
probed	O
overnight	O
by	O
proper	O
primary	O
antibodies	O
diluted	O
in	O
PBST	B-Chemical
at	O
4	O
Â°	O
C	O
.	O
The	O
membranes	O
were	O
rinsed	O
3	O
times	O
with	O
PBST	B-Chemical
and	O
incubated	O
with	O
proper	O
secondary	O
antibodies	O
diluted	O
in	O
PBST	B-Chemical
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O
Then	O
","	O
the	O
membranes	O
were	O
rinsed	O
another	O
3	O
times	O
with	O
PBST	B-Chemical
at	O
room	O
temperature	O
for	O
10	O
min	O
","	O
and	O
proteins	O
were	O
detected	O
by	O
Super	O
Signal	O
enhanced	O
chemiluminescence	O
development	O
(	O
ECL	O
)	O
(	O
Thermo	O
Scientific	O
Pierce	O
)	O
reagent	O
and	O
exposed	O
to	O
films	O
(	O
Kodak	O
).	O
The	O
protein	O
level	O
quantification	O
was	O
carried	O
out	O
by	O
ImageJ	O
.	O
2	O
.	O
7	O
.	O
Statistical	O
Analysis	O
All	O
statistical	O
analysis	O
was	O
performed	O
by	O
Image	O
software	O
.	O
Quantitative	O
data	O
were	O
shown	O
in	O
x	O
âˆ’	O
Â±	O
s	O
using	O
t	O
-	O
tests	O
for	O
comparisons	O
.	O
The	O
values	O
0	O
.	O
5	O
"(*),"	O
0	O
.	O
1	O
"(**),"	O
and	O
0	O
.	O
1	O
(***)	O
were	O
assumed	O
as	O
the	O
level	O
of	O
significance	O
for	O
the	O
statistic	O
tests	O
carried	O
out	O
.	O
3	O
.	O
Results	O
3	O
.	O
1	O
.	O
Thapsigargin	B-Chemical
Induces	O
Cell	O
Apoptosis	O
in	O
A549	O
Cells	O
To	O
examine	O
whether	O
the	O
thapsigargin	B-Chemical
treatment	O
may	O
induce	O
the	O
cell	O
death	O
in	O
A549	O
cells	O
","	O
we	O
applied	O
Hoechst	B-Chemical
staining	O
to	O
A549	O
cells	O
treated	O
by	O
thapsigargin	B-Chemical
(	O
Figure	O
1	O
).	O
The	O
results	O
show	O
that	O
thapsigargin	B-Chemical
has	O
slight	O
effects	O
on	O
cell	O
death	O
at	O
the	O
final	O
concentration	O
of	O
1	O
nM	O
(	O
cell	O
death	O
by	O
5	O
.	O
2	O
%)	O
or	O
100	O
nM	O
(	O
by	O
7	O
.	O
4	O
%)	O
for	O
6	O
h	O
treatment	O
(	O
Figure	O
1	O
(	O
b	O
)).	O
The	O
percentage	O
of	O
cell	O
death	O
increases	O
significantly	O
to	O
24	O
.	O
1	O
%	O
at	O
the	O
concentration	O
of	O
1	O
Î¼M	O
(	O
Figure	O
1	O
(	O
b	O
)).	O
To	O
examine	O
whether	O
the	O
effects	O
of	O
thapsigargin	B-Chemical
on	O
cell	O
death	O
of	O
A549	O
cells	O
is	O
time	O
-	O
dependent	O
or	O
not	O
","	O
we	O
prolonged	O
the	O
treated	O
time	O
of	O
thapsigargin	B-Chemical
on	O
A549	O
cells	O
to	O
24	O
h	O
.	O
Our	O
results	O
suggest	O
that	O
the	O
percentages	O
of	O
cell	O
death	O
increase	O
to	O
9	O
.	O
4	O
%	O
(	O
1	O
nM	O
"),"	O
25	O
.	O
8	O
%	O
(	O
100	O
nM	O
"),"	O
and	O
41	O
.	O
2	O
%	O
(	O
1	O
Î¼M	O
)	O
after	O
thapsigargin	B-Chemical
treatment	O
(	O
Figure	O
1	O
(	O
b	O
)).	O
These	O
findings	O
support	O
the	O
notion	O
that	O
thapsigargin	B-Chemical
may	O
induce	O
cell	O
death	O
in	O
A549	O
cells	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O
3	O
.	O
2	O
.	O
Thapsigargin	B-Chemical
Impairs	O
Actin	O
Cytoskeleton	O
Organizations	O
in	O
A549	O
Cells	O
To	O
study	O
the	O
cellular	O
mechanisms	O
of	O
how	O
thapsigargin	B-Chemical
induces	O
cell	O
death	O
in	O
A549	O
cells	O
","	O
we	O
focused	O
on	O
the	O
cytoskeletal	O
dynamics	O
","	O
because	O
we	O
noted	O
that	O
A549	O
cells	O
tended	O
to	O
shrink	O
after	O
thapsigargin	B-Chemical
treatment	O
(	O
Data	O
not	O
shown	O
).	O
Thus	O
","	O
we	O
carried	O
out	O
F	O
-	O
actin	O
staining	O
by	O
Rhodamine	B-Chemical
labeled	I-Chemical
Phalloidin	I-Chemical
probes	O
in	O
A549	O
cells	O
.	O
Being	O
consistent	O
with	O
Hoechst	B-Chemical
stainings	O
","	O
our	O
results	O
show	O
that	O
the	O
F	O
-	O
actin	O
fibers	O
are	O
reduced	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
after	O
thapsigargin	B-Chemical
treatment	O
(	O
Figure	O
2	O
).	O
Moreover	O
","	O
RhoA	O
signals	O
","	O
indicated	O
by	O
the	O
greed	O
-	O
fluorescence	O
","	O
are	O
also	O
reduced	O
after	O
thapsigargin	B-Chemical
treatment	O
","	O
in	O
parallel	O
with	O
Rhodamine	B-Chemical
-	I-Chemical
phalloidin	I-Chemical
signals	O
","	O
while	O
DAPI	B-Chemical
signals	O
labelled	O
blue	O
indicate	O
the	O
nuclear	O
locations	O
(	O
Figure	O
2	O
).	O
The	O
parallel	O
reduction	O
of	O
F	O
-	O
actin	O
and	O
RhoA	O
signals	O
by	O
thapsigargin	B-Chemical
treatment	O
confirms	O
that	O
thapsigargin	B-Chemical
may	O
impair	O
the	O
cytoskeleton	O
dynamics	O
and	O
organizations	O
.	O
3	O
.	O
3	O
.	O
Thapsigargin	B-Chemical
Disrupts	O
Actin	O
Cytoskeletal	O
Proteins	O
in	O
A549	O
Cells	O
To	O
confirm	O
the	O
impairment	O
of	O
cytoskeletal	O
dynamics	O
in	O
thapsigargin	B-Chemical
treated	O
A549	O
cells	O
","	O
we	O
examined	O
the	O
cellular	O
pathways	O
regulating	O
F	O
-	O
actin	O
organizations	O
.	O
By	O
western	O
blots	O
","	O
we	O
show	O
that	O
Cofilin	O
-	O
1	O
phosphorylations	O
are	O
reduced	O
after	O
thapsigargin	B-Chemical
treatment	O
","	O
while	O
the	O
total	O
protein	O
levels	O
of	O
Cofilin	O
-	O
1	O
are	O
not	O
altered	O
(	O
Figure	O
3	O
(	O
a	O
)).	O
The	O
ratio	O
of	O
p	O
-	O
Cofilin	O
-	O
1	O
to	O
Cofilin	O
-	O
1	O
reduces	O
to	O
67	O
.	O
4	O
%	O
after	O
thapsigargin	B-Chemical
treatment	O
of	O
1	O
Î¼M	O
for	O
6	O
h	O
","	O
and	O
to	O
40	O
.	O
9	O
%	O
after	O
1	O
Î¼M	O
for	O
24	O
h	O
(	O
Figure	O
3	O
(	O
b	O
)).	O
Consistently	O
","	O
the	O
phosphorylation	O
of	O
paxillin	O
is	O
also	O
reduced	O
to	O
33	O
.	O
9	O
%	O
after	O
1	O
Î¼M	O
thapsigargin	B-Chemical
treatment	O
for	O
24	O
h	O
(	O
Figures	O
3	O
(	O
a	O
)	O
and	O
3	O
(	O
b	O
)).	O
It	O
is	O
of	O
note	O
that	O
the	O
protein	O
level	O
of	O
p	O
-	O
Paxillin	O
is	O
not	O
altered	O
with	O
statistical	O
difference	O
after	O
1	O
Î¼M	O
thapsigargin	B-Chemical
treatment	O
for	O
6	O
h	O
(	O
Figures	O
3	O
(	O
a	O
)	O
and	O
3	O
(	O
b	O
)).	O
This	O
may	O
be	O
due	O
to	O
the	O
delay	O
effect	O
of	O
thapsigargin	B-Chemical
on	O
regulator	O
molecules	O
of	O
cytoskeletons	O
.	O
Taken	O
together	O
","	O
our	O
findings	O
suggest	O
that	O
thapsigargin	B-Chemical
treatment	O
may	O
impair	O
the	O
balance	O
of	O
cytoskeletal	O
dynamics	O
","	O
depolymerizing	O
actin	O
fibers	O
","	O
and	O
inhibiting	O
actin	O
reorganizations	O
.	O
3	O
.	O
4	O
.	O
Thapsigargin	B-Chemical
Impairs	O
Cytoskeletal	O
Dynamics	O
via	O
mTOR	O
-	O
RhoA	O
Pathways	O
in	O
A549	O
Cells	O
To	O
study	O
the	O
molecular	O
mechanism	O
of	O
thapsigargin	B-Chemical
'	O
s	O
effect	O
on	O
cytoskeleton	O
dynamics	O
","	O
the	O
protein	O
levels	O
of	O
mTORC1	O
indicators	O
and	O
downstream	O
factor	O
RhoA	O
were	O
examined	O
.	O
Our	O
results	O
reveal	O
that	O
the	O
protein	O
levels	O
of	O
pS6	O
(	O
Ser240	B-Chemical
/	O
244	O
"),"	O
a	O
well	O
-	O
known	O
indicator	O
of	O
mTORC1	O
activity	O
","	O
are	O
reduced	O
to	O
61	O
.	O
1	O
%	O
(	O
1	O
Î¼M	O
for	O
6	O
h	O
)	O
and	O
non	O
-	O
detectable	O
(	O
1	O
Î¼M	O
for	O
24	O
h	O
)	O
after	O
thapsigargin	B-Chemical
treatment	O
(	O
Figures	O
4	O
(	O
a	O
)	O
and	O
4	O
(	O
b	O
)).	O
Subsequently	O
","	O
the	O
protein	O
levels	O
of	O
RhoA	O
","	O
a	O
key	O
regulator	O
of	O
actin	O
cytoskeletal	O
dynamics	O
","	O
are	O
also	O
reduced	O
to	O
52	O
.	O
9	O
%	O
(	O
1	O
Î¼M	O
for	O
6	O
h	O
)	O
and	O
17	O
.	O
7	O
%	O
(	O
1	O
Î¼M	O
for	O
24	O
h	O
)	O
after	O
thapsigargin	B-Chemical
treatment	O
(	O
Figures	O
4	O
(	O
a	O
)	O
and	O
4	O
(	O
b	O
)).	O
The	O
reduction	O
of	O
RhoA	O
protein	O
levels	O
is	O
consistent	O
with	O
previous	O
reduction	O
of	O
signals	O
of	O
RhoA	O
immunostaining	O
after	O
thapsigargin	B-Chemical
treatment	O
(	O
Figure	O
2	O
).	O
These	O
results	O
indicated	O
that	O
thapsigargin	B-Chemical
may	O
impair	O
cytoskeletal	O
dynamics	O
through	O
mTOR	O
-	O
RhoA	O
pathways	O
in	O
A549	O
cells	O
.	O
4	O
.	O
Discussion	O
Cancer	O
progression	O
is	O
a	O
multistep	O
process	O
that	O
enables	O
tumor	O
cells	O
to	O
disperse	O
to	O
points	O
far	O
from	O
a	O
given	O
primary	O
tumor	O
mass	O
","	O
and	O
this	O
often	O
leads	O
to	O
metastasis	O
.	O
Cell	O
movement	O
through	O
tissue	O
thus	O
plays	O
a	O
crucial	O
and	O
primary	O
role	O
in	O
cancer	O
progression	O
.	O
This	O
process	O
requires	O
a	O
series	O
of	O
distinct	O
but	O
concerted	O
biological	O
events	O
in	O
which	O
the	O
actin	O
cytoskeleton	O
plays	O
essential	O
roles	O
.	O
In	O
decades	O
","	O
our	O
understanding	O
of	O
the	O
molecules	O
involved	O
in	O
regulating	O
actin	O
cytoskeletal	O
dynamics	O
has	O
increased	O
.	O
Thapsigargin	B-Chemical
has	O
been	O
reported	O
to	O
induce	O
cell	O
death	O
in	O
several	O
tumor	O
cell	O
lines	O
","	O
by	O
either	O
increasing	O
the	O
store	O
-	O
mediated	O
calcium	B-Chemical
entry	O
or	O
ER	O
stress	O
.	O
It	O
has	O
been	O
reported	O
that	O
thapsigargin	B-Chemical
treatment	O
rapidly	O
induce	O
a	O
sustained	O
increase	O
in	O
calcium	B-Chemical
concentration	O
and	O
DNA	O
fragmentation	O
and	O
induce	O
cell	O
death	O
by	O
altering	O
cell	O
morphology	O
or	O
activating	O
apoptotic	O
pathways	O
.	O
In	O
the	O
present	O
study	O
","	O
we	O
demonstrate	O
that	O
thapsigargin	B-Chemical
","	O
a	O
specific	O
irreversible	O
inhibitor	O
of	O
ER	O
calcium	O
-	O
ATPase	O
","	O
induces	O
cell	O
death	O
by	O
impairing	O
the	O
cytoskeletal	O
dynamics	O
and	O
actin	O
organizations	O
in	O
A549	O
human	O
lung	O
adenocarcinoma	O
cell	O
line	O
.	O
This	O
process	O
may	O
be	O
mediated	O
by	O
the	O
mTOR	O
-	O
RhoA	O
-	O
Cofilin	O
-	O
1	O
pathways	O
","	O
because	O
thapsigargin	B-Chemical
treatment	O
may	O
dramatically	O
inhibit	O
mTORC1	O
activity	O
","	O
and	O
reduce	O
RhoA	O
proteins	O
and	O
attenuating	O
Cofilin	O
-	O
1	O
phosphorylations	O
(	O
Figure	O
4	O
(	O
c	O
)).	O
mTOR	O
is	O
a	O
central	O
controller	O
of	O
cell	O
proliferation	O
","	O
growth	O
","	O
and	O
survival	O
and	O
functions	O
in	O
cells	O
at	O
least	O
as	O
two	O
complexes	O
","	O
mTORC1	O
and	O
mTORC2	O
.	O
It	O
has	O
been	O
reported	O
that	O
mTOR	O
pathways	O
regulate	O
tumor	O
cell	O
migration	O
and	O
cancer	O
metastasis	O
.	O
For	O
example	O
","	O
rapamycin	B-Chemical
suppresses	O
IGF	O
-	O
1	O
stimulated	O
F	O
-	O
actin	O
reorganization	O
and	O
migration	O
in	O
various	O
tumor	O
cell	O
lines	O
by	O
inhibiting	O
mTORC1	O
activity	O
.	O
Rapamycin	B-Chemical
may	O
also	O
inhibit	O
F	O
-	O
actin	O
reorganization	O
and	O
cell	O
motility	O
by	O
downregulation	O
of	O
RhoA	O
protein	O
expression	O
and	O
activity	O
.	O
Our	O
findings	O
highlight	O
an	O
important	O
role	O
of	O
calcium	B-Chemical
entry	O
in	O
cytoskeleton	O
organization	O
and	O
apoptosis	O
and	O
set	O
a	O
stage	O
to	O
the	O
clinical	O
treatment	O
of	O
tumor	O
cell	O
metastasis	O
.	O
The	O
actin	O
cytoskeleton	O
functions	O
in	O
the	O
generation	O
and	O
maintenance	O
of	O
cell	O
morphology	O
and	O
polarity	O
","	O
in	O
endocytosis	O
and	O
intracellular	O
trafficking	O
","	O
contractility	O
","	O
motility	O
","	O
and	O
cell	O
division	O
.	O
The	O
assembly	O
and	O
disassembly	O
of	O
actin	O
filaments	O
","	O
as	O
well	O
as	O
their	O
organization	O
into	O
functional	O
higher	O
-	O
order	O
networks	O
","	O
are	O
regulated	O
by	O
several	O
extracellular	O
and	O
intracellular	O
signalings	O
.	O
Thapsigargin	B-Chemical
activates	O
of	O
calcium	B-Chemical
entry	O
following	O
the	O
depletion	O
of	O
intracellular	O
calcium	B-Chemical
stores	O
and	O
couples	O
with	O
cytoskeleton	O
organizations	O
.	O
For	O
example	O
","	O
thapsigargin	B-Chemical
has	O
been	O
reported	O
to	O
induce	O
actin	O
depolymerization	O
and	O
produce	O
a	O
net	O
decrease	O
in	O
F	O
-	O
actin	O
content	O
in	O
human	O
monocytic	O
cells	O
.	O
In	O
turn	O
","	O
prolonged	O
treatment	O
of	O
inhibitors	O
of	O
actin	O
polymerisation	O
abolishes	O
calcium	B-Chemical
entry	O
by	O
50	O
%	O
in	O
human	O
platelets	O
.	O
Thus	O
","	O
the	O
coupling	O
of	O
calcium	B-Chemical
signaling	O
and	O
actin	O
cytoskeletal	O
dynamics	O
need	O
to	O
be	O
further	O
consolidated	O
.	O
Our	O
findings	O
reveal	O
that	O
ectopic	O
opening	O
of	O
calcium	B-Chemical
influx	O
by	O
thapsigargin	B-Chemical
may	O
disrupt	O
the	O
organizations	O
of	O
actin	O
cytoskeletons	O
","	O
which	O
may	O
help	O
to	O
understand	O
the	O
relationship	O
of	O
calcium	B-Chemical
signaling	O
and	O
cytoskeletal	O
dynamics	O
.	O
It	O
is	O
well	O
established	O
that	O
increased	O
F	O
-	O
actin	O
may	O
promote	O
cell	O
longevity	O
","	O
whereas	O
decreased	O
actin	O
turnover	O
seems	O
to	O
trigger	O
cell	O
death	O
.	O
The	O
actin	O
regulatory	O
protein	O
Cofilin	O
-	O
1	O
has	O
been	O
shown	O
to	O
have	O
a	O
key	O
role	O
in	O
the	O
apoptotic	O
process	O
.	O
Cofilin	O
-	O
1	O
is	O
a	O
member	O
of	O
the	O
Cofilin	O
-	O
1	O
/	O
ADF	O
(	O
actin	O
depolymerizing	O
factor	O
)	O
family	O
and	O
regulates	O
actin	O
dynamics	O
by	O
promoting	O
the	O
depolymerization	O
and	O
severing	O
of	O
actin	O
filaments	O
","	O
and	O
regulating	O
the	O
recycling	O
of	O
the	O
resulting	O
monomers	O
.	O
It	O
has	O
been	O
shown	O
that	O
the	O
active	O
(	O
dephosphorylated	O
)	O
form	O
of	O
Cofilin	O
-	O
1	O
is	O
targeted	O
to	O
mitochondria	O
after	O
initiation	O
of	O
apoptosis	O
.	O
Mitochondrial	O
targeting	O
of	O
Cofilin	O
-	O
1	O
is	O
sufficient	O
to	O
induce	O
cytochrome	O
c	O
leakage	O
from	O
the	O
mitochondria	O
and	O
strongly	O
induced	O
apoptosis	O
.	O
Moreover	O
","	O
paxillin	O
","	O
a	O
multidomain	O
protein	O
","	O
is	O
one	O
of	O
the	O
key	O
components	O
of	O
for	O
integrin	O
-	O
mediated	O
cytoskeletal	O
reorganization	O
.	O
In	O
tumor	O
cells	O
","	O
paxillin	O
is	O
highly	O
phosphorylated	O
at	O
Tyr118	B-Chemical
and	O
recruits	O
other	O
signalling	O
molecules	O
to	O
focal	O
adhesions	O
for	O
tumor	O
metastasis	O
.	O
In	O
the	O
present	O
study	O
","	O
our	O
findings	O
suggested	O
that	O
thapsigargin	B-Chemical
treatment	O
may	O
dramatically	O
reduce	O
Cofilin	O
-	O
1	O
phosphorylations	O
and	O
increase	O
its	O
activity	O
(	O
Figures	O
3	O
(	O
a	O
)	O
and	O
3	O
(	O
b	O
")),"	O
which	O
contribute	O
to	O
the	O
actin	O
depolymerization	O
and	O
initiation	O
of	O
apoptosis	O
.	O
To	O
clarify	O
how	O
thapsigargin	B-Chemical
inhibits	O
Cofilin	O
-	O
1	O
phosphorylations	O
","	O
we	O
focus	O
on	O
the	O
mTOR	O
-	O
RhoA	O
pathways	O
.	O
mTOR	O
has	O
been	O
shown	O
to	O
integrate	O
signals	O
from	O
a	O
variety	O
of	O
extracellular	O
inputs	O
","	O
including	O
growth	O
factors	O
","	O
amino	B-Chemical
acids	I-Chemical
","	O
glucose	B-Chemical
","	O
ATP	B-Chemical
","	O
and	O
oxygen	B-Chemical
.	O
mTOR	O
-	O
dependent	O
signaling	O
modulates	O
numerous	O
cellular	O
properties	O
","	O
including	O
cell	O
proliferation	O
","	O
cell	O
motility	O
","	O
and	O
protein	O
translation	O
.	O
Inhibition	O
of	O
mTOR	O
kinase	O
activity	O
by	O
rapamycin	B-Chemical
impairs	O
mTOR	O
-	O
mediated	O
protein	O
synthesis	O
and	O
activities	O
of	O
the	O
small	O
GTPases	O
(	O
e	O
.	O
g	O
".,"	O
RhoA	O
"),"	O
leading	O
to	O
inhibition	O
of	O
F	O
-	O
actin	O
organization	O
and	O
cell	O
motility	O
.	O
Moreover	O
","	O
the	O
inhibitory	O
effect	O
of	O
rapamycin	B-Chemical
on	O
expression	O
of	O
RhoA	O
is	O
also	O
observed	O
in	O
other	O
tumor	O
cell	O
lines	O
","	O
including	O
those	O
derived	O
from	O
cervical	O
cancer	O
(	O
HeLa	O
"),"	O
prostate	O
cancer	O
(	O
PC	O
-	O
3	O
"),"	O
Ewing	O
sarcoma	O
(	O
Rh1	O
"),"	O
and	O
glioblastoma	O
(	O
U	O
-	O
373	O
"),"	O
suggesting	O
that	O
this	O
is	O
not	O
cell	O
-	O
type	O
dependent	O
.	O
Here	O
","	O
our	O
results	O
suggested	O
that	O
thapsigargin	B-Chemical
may	O
also	O
down	O
-	O
regualte	O
mTOR	O
kinase	O
activity	O
and	O
inhibit	O
RhoA	O
protein	O
level	O
in	O
A549	O
human	O
lung	O
adenocarcinoma	O
cells	O
.	O
These	O
findings	O
may	O
contribute	O
to	O
the	O
impairment	O
of	O
actin	O
cytoskeletons	O
by	O
thapsigargin	B-Chemical
.	O
Thus	O
","	O
our	O
work	O
has	O
set	O
up	O
links	O
of	O
calcium	B-Chemical
influx	O
","	O
mTOR	O
-	O
RhoA	O
pathways	O
","	O
and	O
cytoskeletal	O
dynamics	O
.	O
5	O
.	O
Conclusion	O
In	O
summary	O
","	O
the	O
present	O
studies	O
reveal	O
that	O
ectopic	O
calcium	B-Chemical
influx	O
by	O
thapsigargin	B-Chemical
inhibits	O
mTOR	O
kinase	O
activity	O
and	O
RhoA	O
expressions	O
","	O
thus	O
leading	O
to	O
the	O
increasing	O
of	O
Cofilin	O
-	O
1	O
activity	O
and	O
actin	O
depolymerizations	O
.	O
The	O
impairment	O
of	O
actin	O
cytoskeletal	O
dynamics	O
finally	O
triggers	O
cell	O
death	O
in	O
A549	O
human	O
lung	O
adenocarcinoma	O
cells	O
.	O
Our	O
work	O
suggests	O
that	O
therapies	O
that	O
specifically	O
target	O
calcium	B-Chemical
-	O
cytoskeleton	O
signaling	O
molecules	O
may	O
prove	O
useful	O
for	O
the	O
treatment	O
of	O
tumor	O
cell	O
metastasis	O
.	O
Conflict	O
of	O
Interests	O
There	O
is	O
no	O
conflict	O
of	O
interests	O
to	O
declare	O
","	O
and	O
each	O
author	O
certifies	O
that	O
they	O
have	O
no	O
commercial	O
associations	O
that	O
might	O
pose	O
a	O
conflict	O
of	O
interests	O
in	O
connection	O
with	O
this	O
paper	O
.	O
Thapsigargin	B-Chemical
induces	O
cell	O
apoptosis	O
in	O
A549	O
cells	O
.	O
(	O
a	O
)	O
Hoechst	B-Chemical
staining	O
(	O
blue	O
)	O
showing	O
the	O
increasing	O
of	O
apoptotic	O
A549	O
cells	O
by	O
thapsigargin	B-Chemical
(	O
1	O
nM	O
","	O
100	O
nM	O
","	O
and	O
1	O
Î¼M	O
)	O
treatment	O
for	O
6	O
and	O
24	O
h	O
(	O
white	O
arrows	O
).	O
(	O
b	O
)	O
Histograms	O
showing	O
the	O
quantification	O
of	O
the	O
cell	O
death	O
(%)	O
in	O
A549	O
cells	O
after	O
thapsigargin	B-Chemical
treatment	O
.	O
Results	O
are	O
averages	O
of	O
three	O
independent	O
experiments	O
.	O
Data	O
represent	O
mean	O
Â±	O
SEM	O
.	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
and	O
***	O
P	O
<	O
0	O
.	O
1	O
.	O
Thapsigargin	B-Chemical
impairs	O
actin	O
cytoskeleton	O
organizations	O
in	O
A549	O
cells	O
.	O
The	O
reductions	O
of	O
F	O
-	O
actin	O
fibers	O
by	O
thapsigargin	B-Chemical
(	O
1	O
nM	O
","	O
100	O
nM	O
","	O
and	O
1	O
Î¼M	O
for	O
6	O
and	O
24	O
h	O
)	O
treatments	O
were	O
shown	O
by	O
immunostaining	O
.	O
Red	O
fluorescence	O
is	O
indicated	O
by	O
Rhodamine	B-Chemical
-	I-Chemical
phalloidin	I-Chemical
probes	O
","	O
green	O
by	O
RhoA	O
antibody	O
","	O
and	O
blue	O
by	O
DAPI	B-Chemical
.	O
Thapsigargin	B-Chemical
disrupts	O
actin	O
cytoskeletal	O
proteins	O
in	O
A549	O
cells	O
.	O
The	O
reductions	O
of	O
protein	O
levels	O
of	O
p	O
-	O
Cofilin	O
-	O
1	O
(	O
Ser3	B-Chemical
)	O
and	O
p	O
-	O
Paxillin	O
(	O
Tyr118	B-Chemical
)	O
by	O
thapsigargin	B-Chemical
treatment	O
(	O
1	O
Î¼M	O
for	O
6	O
and	O
24	O
h	O
)	O
in	O
A549	O
cells	O
were	O
shown	O
by	O
Western	O
blots	O
(	O
a	O
)	O
and	O
histograms	O
(	O
b	O
).	O
Notes	O
showed	O
that	O
the	O
protein	O
level	O
of	O
total	O
Cofilin	O
-	O
1	O
is	O
not	O
affected	O
by	O
thapsigargin	B-Chemical
treatment	O
.	O
Results	O
are	O
averages	O
of	O
four	O
independent	O
experiments	O
.	O
Data	O
represent	O
mean	O
Â±	O
SEM	O
.	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
","	O
N	O
.	O
S	O
","	O
and	O
no	O
statistical	O
difference	O
.	O
Thapsigargin	B-Chemical
impairs	O
cytoskeletal	O
dynamics	O
via	O
mTOR	O
-	O
RhoA	O
pathways	O
in	O
A549	O
cells	O
.	O
The	O
changes	O
in	O
the	O
protein	O
levels	O
of	O
RhoA	O
and	O
pS6	O
(	O
S240	O
/	O
244	O
)	O
by	O
thapsigargin	B-Chemical
treatment	O
(	O
1	O
Î¼M	O
for	O
6	O
and	O
24	O
h	O
)	O
in	O
A549	O
cells	O
were	O
shown	O
by	O
Western	O
blots	O
(	O
a	O
)	O
and	O
histograms	O
(	O
b	O
).	O
Results	O
are	O
averages	O
of	O
four	O
independent	O
experiments	O
.	O
Data	O
represent	O
mean	O
Â±	O
SEM	O
.	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
.	O
(	O
c	O
)	O
Schematic	O
representation	O
highlighting	O
the	O
models	O
of	O
thapsigargin	B-Chemical
inducing	O
cell	O
apoptosis	O
by	O
impairing	O
actin	O
cytoskeletons	O
in	O
A549	O
cells	O
.	O
Thapsigargin	B-Chemical
may	O
induce	O
cell	O
death	O
in	O
A549	O
cells	O
","	O
by	O
disrupting	O
the	O
actin	O
cytoskeleton	O
organizations	O
","	O
which	O
is	O
mediated	O
by	O
inhibiting	O
mTOR	O
-	O
RhoA	O
-	O
Cofilin	O
-	O
1	O
pathways	O
.	O
Bioconversion	O
of	O
Airborne	O
Methylamine	B-Chemical
by	O
Immobilized	O
Recombinant	O
Amine	O
Oxidase	O
from	O
the	O
Thermotolerant	O
Yeast	O
Hansenula	O
polymorpha	O
Aliphatic	B-Chemical
amines	I-Chemical
","	O
including	O
methylamine	B-Chemical
","	O
are	O
air	O
-	O
pollutants	O
","	O
due	O
to	O
their	O
intensive	O
use	O
in	O
industry	O
and	O
the	O
natural	O
degradation	O
of	O
proteins	O
","	O
amino	B-Chemical
acids	I-Chemical
","	O
and	O
other	O
nitrogen	B-Chemical
-	O
containing	O
compounds	O
in	O
biological	O
samples	O
.	O
It	O
is	O
necessary	O
to	O
develop	O
systems	O
for	O
removal	O
of	O
methylamine	B-Chemical
from	O
the	O
air	O
","	O
since	O
airborne	O
methylamine	B-Chemical
has	O
a	O
negative	O
effect	O
on	O
human	O
health	O
.	O
The	O
primary	O
amine	O
oxidase	O
(	O
primary	O
amine	O
:	O
oxygen	O
oxidoreductase	O
(	O
deaminating	O
)	O
or	O
amine	O
oxidase	O
","	O
AMO	O
;	O
EC	O
1	O
.	O
4	O
.	O
3	O
.	O
21	O
"),"	O
a	O
copper	B-Chemical
-	O
containing	O
enzyme	O
from	O
the	O
thermotolerant	O
yeast	O
Hansenula	O
polymorpha	O
which	O
was	O
overexpressed	O
in	O
baker	O
'	O
s	O
yeast	O
Saccharomyces	O
cerevisiae	O
","	O
was	O
tested	O
for	O
its	O
ability	O
to	O
oxidize	O
airborne	O
methylamine	B-Chemical
.	O
A	O
continuous	O
fluidized	O
bed	O
bioreactor	O
(	O
CFBR	O
)	O
was	O
designed	O
to	O
enable	O
bioconversion	O
of	O
airborne	O
methylamine	B-Chemical
by	O
AMO	O
immobilized	O
in	O
calcium	B-Chemical
alginate	I-Chemical
(	O
CA	B-Chemical
)	O
beads	O
.	O
The	O
results	O
demonstrated	O
that	O
the	O
bioreactor	O
with	O
immobilized	O
AMO	O
eliminates	O
nearly	O
97	O
%	O
of	O
the	O
airborne	O
methylamine	B-Chemical
.	O
However	O
","	O
the	O
enzymatic	O
activity	O
of	O
AMO	O
causes	O
formation	O
of	O
formaldehyde	B-Chemical
.	O
A	O
two	O
-	O
step	O
bioconversion	O
process	O
was	O
therefore	O
proposed	O
.	O
In	O
the	O
first	O
step	O
","	O
airborne	O
methylamine	B-Chemical
was	O
fed	O
into	O
a	O
CFBR	O
which	O
contained	O
immobilized	O
AMO	O
.	O
In	O
the	O
second	O
step	O
","	O
the	O
gas	O
flow	O
was	O
passed	O
through	O
another	O
CFBR	O
","	O
with	O
alcohol	O
oxidase	O
from	O
the	O
yeast	O
H	O
.	O
polymorpha	O
immobilized	O
in	O
CA	B-Chemical
","	O
in	O
order	O
to	O
decompose	O
the	O
formaldehyde	B-Chemical
formed	O
in	O
the	O
first	O
step	O
.	O
The	O
proposed	O
system	O
provided	O
almost	O
total	O
elimination	O
of	O
the	O
airborne	O
methylamine	B-Chemical
and	O
the	O
formaldehyde	B-Chemical
.	O
1	O
.	O
Introduction	O
Outdoor	O
and	O
indoor	O
organic	O
air	O
-	O
pollutants	O
pose	O
a	O
serious	O
threat	O
to	O
public	O
health	O
.	O
According	O
to	O
estimates	O
of	O
the	O
World	O
Health	O
Organization	O
(	O
WHO	O
"),"	O
nearly	O
800	O
","	O
0	O
people	O
worldwide	O
die	O
annually	O
from	O
diseases	O
caused	O
by	O
the	O
effects	O
of	O
air	O
-	O
pollution	O
[].	O
Methylamine	B-Chemical
(	O
MA	B-Chemical
)	O
is	O
the	O
simplest	O
primary	B-Chemical
amine	I-Chemical
which	O
is	O
used	O
to	O
produce	O
a	O
variety	O
of	O
important	O
chemical	O
products	O
:	O
pharmaceuticals	O
","	O
pesticides	O
","	O
fuel	O
additives	O
","	O
explosives	O
","	O
solvents	O
","	O
cleaning	O
agents	O
","	O
photographic	O
processing	O
reagents	O
","	O
and	O
chemicals	O
for	O
the	O
tanning	O
of	O
leather	O
and	O
dye	O
processes	O
.	O
MA	B-Chemical
pollutes	O
the	O
air	O
because	O
of	O
its	O
intensive	O
use	O
in	O
industry	O
and	O
as	O
a	O
result	O
of	O
natural	O
degradation	O
of	O
proteins	O
","	O
amino	B-Chemical
acids	I-Chemical
","	O
and	O
other	O
nitrogen	B-Chemical
-	O
containing	O
compounds	O
in	O
biological	O
samples	O
.	O
Exposure	O
to	O
MA	B-Chemical
at	O
normal	O
background	O
levels	O
is	O
unlikely	O
to	O
have	O
any	O
negative	O
effects	O
on	O
human	O
health	O
.	O
However	O
","	O
inhalation	O
of	O
air	O
that	O
contains	O
high	O
levels	O
of	O
MA	B-Chemical
can	O
result	O
in	O
a	O
number	O
of	O
adverse	O
health	O
effects	O
","	O
such	O
as	O
breathing	O
difficulties	O
","	O
a	O
burning	O
sensation	O
","	O
sore	O
throat	O
","	O
headache	O
","	O
and	O
accumulation	O
of	O
fluid	O
in	O
the	O
lungs	O
(	O
pulmonary	O
oedema	O
)	O
[].	O
MA	B-Chemical
can	O
be	O
found	O
in	O
very	O
high	O
concentrations	O
in	O
some	O
kinds	O
of	O
fish	O
","	O
especially	O
of	O
the	O
Gadoid	O
species	O
","	O
due	O
to	O
the	O
enzymatic	O
degradation	O
of	O
a	O
natural	O
osmolyte	O
","	O
trimethylamine	B-Chemical
N	I-Chemical
-	I-Chemical
oxide	I-Chemical
"[,"	O
].	O
Recombinant	O
Saccharomyces	O
cerevisiae	O
yeast	O
was	O
constructed	O
to	O
overproduce	O
primary	O
amine	O
oxidase	O
(	O
primary	O
amine	O
:	O
oxygen	O
oxidoreductase	O
(	O
deaminating	O
)	O
or	O
amine	O
oxidase	O
","	O
AMO	O
;	O
EC	O
1	O
.	O
4	O
.	O
3	O
.	O
21	O
"),"	O
from	O
the	O
thermotolerant	O
yeast	O
Hansenula	O
polymorpha	O
.	O
This	O
copper	B-Chemical
-	O
containing	O
enzyme	O
is	O
known	O
for	O
its	O
ability	O
to	O
decompose	O
primary	B-Chemical
amines	I-Chemical
into	O
aldehydes	B-Chemical
.	O
The	O
following	O
reaction	O
represents	O
a	O
process	O
of	O
MA	B-Chemical
bioconversion	O
"[,"	O
]:	O
This	O
enzyme	O
has	O
been	O
used	O
for	O
bioanalytical	O
purposes	O
","	O
for	O
example	O
","	O
for	O
spectrophotometric	O
monitoring	O
of	O
the	O
enzymatic	O
decomposition	O
of	O
MA	B-Chemical
by	O
amine	O
oxidases	O
[].	O
To	O
date	O
","	O
this	O
enzyme	O
has	O
not	O
been	O
exploited	O
for	O
bioremediation	O
purposes	O
","	O
that	O
is	O
","	O
for	O
bioconversion	O
of	O
MA	B-Chemical
into	O
nontoxic	O
products	O
.	O
The	O
aim	O
of	O
the	O
present	O
work	O
was	O
to	O
construct	O
a	O
recombinant	O
overproducer	O
of	O
AMO	O
from	O
thermostable	O
H	O
.	O
polymorpha	O
","	O
isolate	O
and	O
purify	O
the	O
enzyme	O
from	O
the	O
recombinant	O
yeast	O
cells	O
","	O
and	O
design	O
a	O
continuous	O
bioreactor	O
based	O
on	O
immobilized	O
AMO	O
for	O
bioconversion	O
of	O
airborne	O
MA	B-Chemical
.	O
A	O
two	O
-	O
step	O
continuous	O
fluidized	O
bed	O
bioreactor	O
(	O
CFBR	O
)	O
based	O
on	O
immobilized	O
AMO	O
(	O
step	O
1	O
)	O
and	O
alcohol	O
oxidase	O
(	O
AOX	O
)	O
(	O
step	O
2	O
)	O
was	O
designed	O
for	O
bioconversion	O
of	O
airborne	O
MA	B-Chemical
and	O
the	O
formaldehyde	B-Chemical
(	O
FA	B-Chemical
)	O
which	O
is	O
produced	O
in	O
this	O
process	O
.	O
In	O
our	O
previous	O
work	O
we	O
presented	O
a	O
one	O
-	O
step	O
CFBR	O
that	O
performed	O
bioconversion	O
of	O
airborne	O
FA	B-Chemical
into	O
formic	B-Chemical
acid	I-Chemical
by	O
AOX	O
from	O
the	O
yeast	O
H	O
.	O
polymorpha	O
that	O
was	O
immobilized	O
in	O
calcium	B-Chemical
alginate	I-Chemical
(	O
CA	B-Chemical
)	O
beads	O
[].	O
2	O
.	O
Materials	O
and	O
Methods	O
2	O
.	O
1	O
.	O
Chemicals	O
Paraformaldehyde	B-Chemical
","	O
MA	B-Chemical
(	O
40	O
%	O
aqueous	O
solution	O
"),"	O
PMSF	B-Chemical
","	O
chromotropic	B-Chemical
acid	I-Chemical
","	O
and	O
sodium	B-Chemical
alginate	I-Chemical
were	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
Israel	O
).	O
FA	B-Chemical
solution	O
(	O
1	O
M	O
)	O
was	O
prepared	O
by	O
hydrolysis	O
of	O
the	O
corresponding	O
amount	O
of	O
paraformaldehyde	B-Chemical
in	O
water	B-Chemical
(	O
300	O
mg	O
in	O
10	O
mL	O
water	B-Chemical
)	O
by	O
heating	O
the	O
suspension	O
in	O
a	O
sealed	O
ampoule	O
at	O
105	O
Â°	O
C	O
for	O
6	O
h	O
.	O
2	O
.	O
2	O
.	O
Cloning	O
of	O
the	O
AMO	O
Gene	O
into	O
the	O
Expression	O
Vector	O
pYEX	O
-	O
4T	O
-	O
1	O
The	O
pYEX	O
-	O
4T	O
-	O
1	O
plasmid	O
(	O
CLONTECH	O
)	O
was	O
modified	O
prior	O
to	O
cloning	O
of	O
the	O
AMO	O
gene	O
.	O
The	O
fragment	O
of	O
the	O
vector	O
containing	O
the	O
CUP1	O
promoter	O
and	O
GST	O
was	O
cut	O
out	O
.	O
The	O
sequence	O
encoding	O
the	O
CUP1	O
promoter	O
was	O
amplified	O
by	O
PCR	O
and	O
inserted	O
into	O
the	O
plasmid	O
to	O
produce	O
pYEX4T	O
-	O
1	O
-	O
delGST	O
.	O
In	O
order	O
to	O
clone	O
the	O
H	O
.	O
polymorpha	O
AMO	O
gene	O
into	O
pYEX4T	O
-	O
1	O
-	O
delGST	O
BamHI	O
and	O
NotI	O
restriction	O
sites	O
as	O
well	O
as	O
the	O
sequence	O
encoding	O
for	O
(	O
His	B-Chemical
)	O
6	O
-	O
tag	O
were	O
introduced	O
by	O
amplifying	O
the	O
gene	O
with	O
the	O
primers	O
AMO	O
-	O
for	O
and	O
AMO	O
-	O
rev	O
.	O
The	O
pADES	O
-	O
AMO	O
plasmid	O
was	O
used	O
as	O
a	O
template	O
[].	O
The	O
PCR	O
product	O
containing	O
the	O
AMO	O
gene	O
was	O
cleaved	O
with	O
BamHI	O
and	O
NotI	O
restrictases	O
(	O
Fermentas	O
","	O
Lithuania	O
)	O
and	O
cloned	O
into	O
pYEX	O
-	O
4T	O
-	O
1	O
-	O
del	O
-	O
GST	O
.	O
The	O
resulting	O
plasmid	O
was	O
marked	O
as	O
pYEX	O
-	O
4	O
-	O
AMO	O
(	O
Figure	O
1	O
"),"	O
and	O
the	O
correct	O
nucleotide	B-Chemical
sequence	O
of	O
the	O
AMO	O
reading	O
frame	O
was	O
confirmed	O
by	O
sequencing	O
.	O
2	O
.	O
3	O
.	O
Copper	B-Chemical
-	O
Inducible	O
Expression	O
of	O
AMO	O
in	O
Saccharomyces	O
cerevisiae	O
Transformants	O
of	O
the	O
yeast	O
strain	O
S	O
.	O
cerevisiae	O
C13ABYS86	O
(	O
Mat	O
a	O
","	O
leu2	O
-	O
3	O
","	O
ura3	O
","	O
his	O
","	O
pra1	O
-	O
1	O
","	O
prb1	O
-	O
1	O
","	O
prc1	O
-	O
1	O
","	O
and	O
cps1	O
-	O
3	O
)	O
were	O
grown	O
for	O
18	O
h	O
at	O
30	O
Â°	O
C	O
in	O
minimal	O
synthetic	O
medium	O
containing	O
histidine	B-Chemical
.	O
The	O
cells	O
were	O
harvested	O
by	O
centrifugation	O
(	O
3	O
","	O
0	O
Ã—	O
g	O
","	O
5	O
min	O
"),"	O
resuspended	O
in	O
the	O
same	O
medium	O
","	O
and	O
grown	O
for	O
2	O
h	O
to	O
restore	O
log	O
phase	O
growth	O
.	O
Expression	O
was	O
induced	O
by	O
the	O
addition	O
of	O
cupric	B-Chemical
sulfate	I-Chemical
to	O
0	O
.	O
5	O
mM	O
","	O
and	O
the	O
cultures	O
were	O
maintained	O
for	O
6	O
â€“	O
8	O
h	O
before	O
harvest	O
.	O
2	O
.	O
4	O
.	O
Assay	O
of	O
Enzyme	O
Activities	O
AMO	O
activity	O
was	O
measured	O
at	O
30	O
Â°	O
C	O
and	O
pH	O
7	O
.	O
0	O
according	O
to	O
the	O
method	O
described	O
by	O
Haywood	O
and	O
Large	O
[].	O
Kinetic	O
studies	O
were	O
carried	O
out	O
under	O
the	O
same	O
conditions	O
within	O
an	O
MA	B-Chemical
concentration	O
range	O
from	O
0	O
.	O
2	O
to	O
5	O
mM	O
.	O
The	O
AMO	O
concentration	O
in	O
the	O
incubation	O
mixture	O
was	O
40	O
ng	O
mL	O
âˆ’	O
1	O
.	O
AOX	O
activity	O
was	O
measured	O
as	O
described	O
previously	O
[].	O
One	O
unit	O
(	O
1	O
U	O
)	O
of	O
activity	O
of	O
AMO	O
and	O
AOX	O
was	O
defined	O
as	O
the	O
amount	O
of	O
enzyme	O
which	O
forms	O
1	O
Î¼mole	O
of	O
the	O
product	O
per	O
1	O
min	O
under	O
standard	O
conditions	O
of	O
the	O
assay	O
.	O
Protein	O
concentration	O
was	O
estimated	O
by	O
the	O
Lowry	O
method	O
.	O
SDS	B-Chemical
-	O
PAGE	O
was	O
performed	O
in	O
12	O
%	O
gel	O
according	O
to	O
the	O
Laemmli	O
procedure	O
[].	O
2	O
.	O
5	O
.	O
Isolation	O
and	O
Purification	O
of	O
AMO	O
The	O
cells	O
were	O
resuspended	O
in	O
0	O
.	O
1	O
M	O
Tris	B-Chemical
-	O
sulfate	B-Chemical
buffer	O
","	O
pH	O
9	O
.	O
4	O
","	O
and	O
treated	O
with	O
10	O
mM	O
DTT	B-Chemical
at	O
30	O
Â°	O
C	O
for	O
10	O
min	O
.	O
After	O
washing	O
","	O
the	O
cells	O
were	O
suspended	O
in	O
20	O
mM	O
potassium	B-Chemical
phosphate	I-Chemical
buffer	O
","	O
pH	O
7	O
.	O
4	O
","	O
containing	O
1	O
.	O
2	O
M	O
sorbitol	B-Chemical
and	O
2	O
mg	O
of	O
Zymolyase	O
20T	O
(	O
Seikagaku	O
Corp	O
".,"	O
Japan	O
)	O
per	O
1	O
g	O
of	O
wet	O
cell	O
weight	O
and	O
incubated	O
at	O
30	O
Â°	O
C	O
for	O
45	O
min	O
.	O
The	O
spheroplasts	O
were	O
washed	O
once	O
with	O
sorbitol	B-Chemical
solution	O
and	O
resuspended	O
in	O
50	O
mM	O
sodium	B-Chemical
phosphate	I-Chemical
buffer	O
","	O
pH	O
8	O
.	O
0	O
","	O
containing	O
300	O
mM	O
NaCl	B-Chemical
and	O
2	O
mM	O
Î²	B-Chemical
-	I-Chemical
mercaptoethanol	I-Chemical
.	O
The	O
spheroplasts	O
were	O
disrupted	O
with	O
glass	O
beads	O
in	O
a	O
BeadBeater	O
(	O
BioSpec	O
Products	O
","	O
USA	O
).	O
After	O
removal	O
of	O
unbroken	O
cells	O
and	O
cell	O
debris	O
by	O
low	O
speed	O
centrifugation	O
","	O
the	O
supernatant	O
was	O
centrifuged	O
at	O
40	O
","	O
0	O
Ã—	O
g	O
for	O
45	O
min	O
.	O
The	O
crude	O
extract	O
from	O
1	O
L	O
of	O
culture	O
containing	O
120	O
mg	O
of	O
protein	O
was	O
applied	O
to	O
a	O
1	O
mL	O
Hi	O
-	O
Trap	O
Ni	B-Chemical
-	O
agarose	B-Chemical
column	O
(	O
Pharmacia	O
).	O
After	O
removal	O
of	O
nonspecifically	O
bound	O
proteins	O
by	O
washing	O
with	O
50	O
mM	O
sodium	B-Chemical
phosphate	I-Chemical
buffer	O
","	O
pH	O
8	O
.	O
0	O
","	O
containing	O
300	O
mM	O
NaCl	B-Chemical
and	O
2	O
mM	O
Î²	B-Chemical
-	I-Chemical
mercaptoethanol	I-Chemical
","	O
the	O
(	O
His	B-Chemical
)	O
6	O
-	O
AMO	O
was	O
eluted	O
by	O
a	O
FPLC	O
-	O
mediated	O
10	O
â€“	O
500	O
mM	O
imidazole	B-Chemical
gradient	O
.	O
The	O
fractions	O
containing	O
high	O
AMO	O
activity	O
were	O
pooled	O
","	O
dialyzed	O
against	O
50	O
mM	O
sodium	B-Chemical
phosphate	I-Chemical
buffer	O
","	O
pH	O
8	O
.	O
0	O
","	O
supplemented	O
with	O
300	O
mM	O
NaCl	B-Chemical
and	O
2	O
mM	O
Î²	B-Chemical
-	I-Chemical
mercaptoethanol	I-Chemical
","	O
and	O
were	O
used	O
as	O
the	O
final	O
AMO	O
preparation	O
.	O
The	O
specific	O
activity	O
of	O
the	O
pooled	O
preparation	O
was	O
3	O
.	O
2	O
U	O
mg	O
âˆ’	O
1	O
protein	O
","	O
but	O
in	O
some	O
fractions	O
it	O
reached	O
13	O
.	O
7	O
U	O
mg	O
âˆ’	O
1	O
.	O
2	O
.	O
6	O
.	O
Isolation	O
and	O
Purification	O
of	O
AOX	O
Cells	O
of	O
the	O
mutant	O
strain	O
H	O
.	O
polymorpha	O
C	O
-	O
105	O
(	O
gcr1	O
catX	O
)	O
overproducing	O
AOX	O
with	O
an	O
additional	O
catalase	O
inactivation	O
mutation	O
"[,"	O
]	O
were	O
grown	O
in	O
glucose	B-Chemical
medium	O
"[,"	O
]	O
and	O
served	O
as	O
a	O
source	O
for	O
AOX	O
isolation	O
.	O
Purification	O
of	O
the	O
enzyme	O
was	O
carried	O
out	O
using	O
a	O
two	O
-	O
step	O
precipitation	O
with	O
ammonium	B-Chemical
sulfate	I-Chemical
(	O
at	O
40	O
and	O
60	O
%	O
saturation	O
)	O
in	O
the	O
presence	O
of	O
1	O
mM	O
EDTA	B-Chemical
and	O
0	O
.	O
4	O
mM	O
PMSF	B-Chemical
to	O
inhibit	O
proteases	O
.	O
At	O
40	O
%	O
saturation	O
","	O
the	O
protein	O
precipitate	O
was	O
discarded	O
","	O
and	O
the	O
AOX	O
precipitate	O
obtained	O
at	O
60	O
%	O
saturation	O
was	O
collected	O
by	O
centrifugation	O
.	O
The	O
final	O
activity	O
of	O
the	O
enzyme	O
portions	O
used	O
for	O
immobilization	O
was	O
6	O
â€“	O
8	O
U	O
mg	O
âˆ’	O
1	O
protein	O
.	O
2	O
.	O
7	O
.	O
Immobilization	O
of	O
AMO	O
and	O
AOX	O
in	O
CA	B-Chemical
Gel	O
Aliquots	O
of	O
1	O
mL	O
AMO	O
or	O
AOX	O
solutions	O
in	O
0	O
.	O
5	O
M	O
PBS	B-Chemical
","	O
pH	O
7	O
.	O
5	O
(	O
buffer	O
A	O
"),"	O
with	O
2	O
â€“	O
40	O
U	O
mL	O
âˆ’	O
1	O
activity	O
","	O
were	O
mixed	O
with	O
2	O
mL	O
of	O
3	O
%	O
(	O
w	O
/	O
v	O
)	O
sodium	B-Chemical
alginate	I-Chemical
.	O
The	O
mixtures	O
were	O
dropped	O
into	O
a	O
2	O
.	O
5	O
mM	O
CaCl2	B-Chemical
aqueous	O
solution	O
using	O
a	O
syringe	O
with	O
a	O
21	O
G	O
needle	O
under	O
stirring	O
at	O
room	O
temperature	O
and	O
kept	O
for	O
45	O
min	O
for	O
beads	O
formation	O
.	O
The	O
obtained	O
gel	O
beads	O
were	O
washed	O
with	O
buffer	O
A	O
.	O
2	O
.	O
8	O
.	O
One	O
-	O
Step	O
Bioconversion	O
of	O
MA	B-Chemical
in	O
a	O
CFBR	O
The	O
gel	O
beads	O
with	O
immobilized	O
AMO	O
(	O
8	O
.	O
8	O
â€“	O
26	O
.	O
6	O
U	O
g	O
âˆ’	O
1	O
of	O
CA	O
)	O
were	O
applied	O
onto	O
a	O
bioreactor	O
of	O
the	O
CFBR	O
type	O
built	O
as	O
a	O
1	O
Ã—	O
30	O
cm	O
column	O
(	O
1	O
.	O
5	O
g	O
of	O
beads	O
in	O
20	O
mL	O
of	O
buffer	O
A	O
)	O
connected	O
to	O
an	O
air	O
source	O
with	O
a	O
known	O
MA	B-Chemical
concentration	O
using	O
a	O
scheme	O
analogous	O
to	O
the	O
one	O
described	O
previously	O
by	O
us	O
[].	O
The	O
10	O
â€“	O
100	O
ppm	O
MA	B-Chemical
concentrations	O
in	O
air	O
were	O
obtained	O
by	O
bubbling	O
an	O
air	O
flow	O
of	O
7	O
â€“	O
132	O
mL	O
min	O
â¡âˆ’	O
1	O
using	O
a	O
multichannel	O
Ecoline	O
peristaltic	O
pump	O
(	O
Ismatec	O
","	O
Switzerland	O
)	O
through	O
a	O
0	O
.	O
9	O
â€“	O
9	O
mM	O
aqueous	O
MA	B-Chemical
solution	O
at	O
25	O
Â°	O
C	O
.	O
The	O
MA	B-Chemical
concentration	O
in	O
the	O
gaseous	O
phase	O
at	O
the	O
inlet	O
was	O
calculated	O
","	O
according	O
to	O
Henry	O
'	O
s	O
law	O
","	O
taking	O
the	O
Henry	O
constant	O
at	O
25	O
Â°	O
C	O
as	O
1	O
.	O
125	O
Pa	O
m3	O
mol	O
âˆ’	O
1	O
[].	O
It	O
was	O
also	O
measured	O
at	O
the	O
inlet	O
and	O
at	O
the	O
outlet	O
by	O
means	O
of	O
adsorption	O
of	O
MA	B-Chemical
in	O
analytical	O
tubes	O
containing	O
XAD	B-Chemical
-	I-Chemical
7	I-Chemical
beads	O
covered	O
with	O
10	O
%	O
4	B-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
7	I-Chemical
-	I-Chemical
nitrobenz	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
oxa	I-Chemical
-	I-Chemical
1	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diazole	I-Chemical
chloride	I-Chemical
(	O
SKC	O
Inc	O
".,"	O
USA	O
)	O
and	O
extraction	O
of	O
MA	B-Chemical
by	O
tetrahydrofuran	B-Chemical
(	O
Sigma	O
","	O
Israel	O
)	O
and	O
analyzing	O
the	O
extract	O
by	O
HPLC	O
(	O
Jasco	O
PU	O
1580	O
","	O
Japan	O
)	O
supplied	O
with	O
a	O
UV	O
/	O
Vis	O
-	O
1578	O
detector	O
(	O
465	O
nm	O
)	O
on	O
the	O
Goldsil	O
-	O
100	O
C18	O
column	O
(	O
0	O
.	O
46	O
Ã—	O
25	O
cm	O
","	O
5	O
Î¼m	O
)	O
according	O
to	O
OSHA	O
Protocol	O
no	O
.	O
40	O
[].	O
The	O
MA	B-Chemical
concentration	O
in	O
the	O
aqueous	O
phase	O
was	O
determined	O
by	O
a	O
reaction	O
with	O
lactose	B-Chemical
and	O
measured	O
by	O
a	O
colorimetric	O
method	O
[]	O
at	O
545	O
nm	O
with	O
UV	O
-	O
Vis	O
Cary	O
-	O
50	O
(	O
Varian	O
","	O
Australia	O
).	O
The	O
control	O
CFBR	O
column	O
contained	O
CA	B-Chemical
gel	O
beads	O
without	O
AMO	O
.	O
2	O
.	O
9	O
.	O
Two	O
-	O
Step	O
CFBR	O
System	O
for	O
Continuous	O
Bioconversion	O
of	O
Airborne	O
MA	B-Chemical
and	O
Produced	O
FA	B-Chemical
A	O
two	O
-	O
step	O
system	O
consisting	O
of	O
two	O
1	O
Ã—	O
30	O
cm	O
CFBR	O
columns	O
connected	O
in	O
series	O
was	O
built	O
according	O
to	O
Figure	O
2	O
.	O
The	O
first	O
reactor	O
","	O
R1	O
","	O
contained	O
gel	O
beads	O
with	O
immobilized	O
AMO	O
(	O
13	O
.	O
3	O
U	O
g	O
âˆ’	O
1	O
of	O
CA	B-Chemical
)	O
and	O
the	O
second	O
reactor	O
","	O
R2	O
","	O
contained	O
immobilized	O
AOX	O
(	O
6	O
.	O
6	O
U	O
g	O
âˆ’	O
1	O
of	O
CA	B-Chemical
).	O
Two	O
additional	O
columns	O
(	O
R3	O
and	O
R4	O
)	O
with	O
blank	O
gel	O
beads	O
served	O
as	O
the	O
control	O
.	O
A	O
flow	O
of	O
airborne	O
MA	B-Chemical
was	O
split	O
into	O
two	O
streams	O
.	O
The	O
1st	O
stream	O
was	O
bubbled	O
through	O
R1	O
and	O
R2	O
","	O
where	O
the	O
outlet	O
from	O
R1	O
was	O
connected	O
to	O
the	O
inlet	O
of	O
R2	O
.	O
The	O
2nd	O
stream	O
was	O
bubbled	O
through	O
R3	O
which	O
was	O
connected	O
to	O
R4	O
.	O
The	O
MA	B-Chemical
and	O
FA	B-Chemical
concentrations	O
were	O
tested	O
in	O
the	O
gaseous	O
phase	O
at	O
the	O
outlets	O
of	O
all	O
four	O
reactors	O
","	O
R1	O
â€“	O
R4	O
","	O
and	O
in	O
the	O
aqueous	O
phase	O
within	O
the	O
reactors	O
.	O
The	O
FA	B-Chemical
concentration	O
in	O
the	O
gaseous	O
phase	O
was	O
measured	O
with	O
the	O
formaldehyde	B-Chemical
gas	O
detector	O
(	O
Model	O
FP	O
-	O
40	O
Riken	O
Keiki	O
","	O
Japan	O
)	O
and	O
in	O
the	O
liquid	O
phase	O
by	O
a	O
standard	O
photometric	O
method	O
using	O
a	O
reaction	O
with	O
1	O
%	O
chromotropic	B-Chemical
acid	I-Chemical
[].	O
3	O
.	O
Results	O
and	O
Discussion	O
3	O
.	O
1	O
.	O
Cloning	O
of	O
the	O
AMO	O
Gene	O
in	O
an	O
Expression	O
Vector	O
The	O
AMO	O
gene	O
","	O
encoding	O
for	O
the	O
microbody	O
matrix	O
enzyme	O
AMO	O
(	O
EC	O
1	O
.	O
4	O
.	O
3	O
.	O
21	O
)	O
from	O
the	O
yeast	O
H	O
.	O
polymorpha	O
","	O
has	O
been	O
cloned	O
","	O
sequenced	O
","	O
and	O
found	O
to	O
contain	O
an	O
open	O
reading	O
frame	O
of	O
692	O
amino	B-Chemical
acids	I-Chemical
.	O
The	O
enzyme	O
has	O
a	O
dimeric	O
structure	O
with	O
a	O
subunit	O
molecular	O
weight	O
of	O
78	O
kDa	O
"[,"	O
].	O
The	O
copper	B-Chemical
-	O
inducible	O
system	O
used	O
for	O
expression	O
of	O
the	O
AMO	O
gene	O
was	O
based	O
on	O
the	O
pYEX	O
-	O
4T	O
-	O
1	O
plasmid	O
","	O
a	O
shuttle	O
expression	O
vector	O
developed	O
for	O
high	O
-	O
level	O
expression	O
of	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
fusion	O
proteins	O
in	O
the	O
yeast	O
.	O
The	O
copper	B-Chemical
-	O
inducible	O
CUP1	O
promoter	O
from	O
the	O
S	O
.	O
cerevisiae	O
metallothionein	O
gene	O
drove	O
the	O
expression	O
of	O
the	O
fusion	O
cassette	O
.	O
pYEX	O
-	O
4T	O
-	O
1	O
included	O
the	O
Escherichia	O
coli	O
AmpR	O
gene	O
","	O
the	O
yeast	O
selectable	O
markers	O
leu2	O
-	O
d	O
(	O
a	O
LEU2	O
gene	O
with	O
a	O
truncated	O
but	O
functional	O
promoter	O
"),"	O
and	O
URA3	O
.	O
The	O
AMO	O
gene	O
was	O
expressed	O
as	O
a	O
(	O
His	B-Chemical
)	O
6	O
-	O
tagged	O
protein	O
to	O
facilitate	O
its	O
purification	O
.	O
The	O
expression	O
system	O
was	O
based	O
on	O
a	O
modified	O
pYEX	O
-	O
4T	O
-	O
1	O
vector	O
(	O
see	O
Section	O
2	O
).	O
The	O
constructed	O
plasmid	O
","	O
designated	O
as	O
pYEX	O
-	O
4	O
-	O
AMO	O
","	O
expressed	O
the	O
(	O
His	B-Chemical
)	O
6	O
-	O
tagged	O
-	O
AMO	O
protein	O
under	O
control	O
of	O
the	O
CUP1	O
promoter	O
(	O
Figure	O
1	O
).	O
3	O
.	O
2	O
.	O
Expression	O
and	O
Purification	O
of	O
Recombinant	O
AMO	O
Yeast	O
cells	O
carrying	O
the	O
recombinant	O
plasmid	O
were	O
incubated	O
in	O
Cu2	B-Chemical
+-	I-Chemical
containing	O
selective	O
medium	O
in	O
order	O
to	O
express	O
the	O
AMO	O
gene	O
.	O
The	O
active	O
enzyme	O
was	O
accumulated	O
in	O
S	O
.	O
cerevisiae	O
cells	O
to	O
a	O
level	O
of	O
0	O
.	O
7	O
U	O
mg	O
âˆ’	O
1	O
of	O
protein	O
.	O
The	O
highest	O
expression	O
was	O
obtained	O
6	O
â€“	O
8	O
h	O
after	O
induction	O
.	O
The	O
crude	O
extracts	O
were	O
prepared	O
as	O
described	O
in	O
Section	O
2	O
","	O
and	O
(	O
His	B-Chemical
)	O
6	O
-	O
tagged	O
AMO	O
was	O
purified	O
by	O
Ni	B-Chemical
-	O
affinity	O
chromatography	O
.	O
The	O
SDS	B-Chemical
-	O
PAGE	O
results	O
","	O
that	O
illustrate	O
the	O
purification	O
","	O
are	O
presented	O
in	O
Figure	O
3	O
.	O
Fractions	O
8	O
â€“	O
13	O
contained	O
high	O
AMO	O
activity	O
and	O
were	O
pooled	O
and	O
used	O
as	O
the	O
final	O
AMO	O
preparation	O
.	O
The	O
enzyme	O
fraction	O
with	O
the	O
highest	O
AMO	O
specific	O
activity	O
of	O
13	O
.	O
7	O
U	O
mg	O
âˆ’	O
1	O
was	O
used	O
for	O
kinetic	O
studies	O
.	O
The	O
specific	O
activity	O
of	O
AMO	O
increased	O
from	O
4	O
.	O
6	O
to	O
20	O
-	O
fold	O
during	O
the	O
course	O
of	O
the	O
purification	O
procedure	O
","	O
and	O
the	O
final	O
yield	O
of	O
AMO	O
protein	O
was	O
1	O
.	O
6	O
mg	O
L	O
âˆ’	O
1	O
culture	O
.	O
Previous	O
works	O
of	O
others	O
reported	O
a	O
specific	O
activity	O
of	O
1	O
.	O
1	O
U	O
mg	O
âˆ’	O
1	O
protein	O
","	O
which	O
was	O
determined	O
in	O
the	O
process	O
of	O
MA	B-Chemical
oxidation	O
by	O
AMO	O
","	O
isolated	O
from	O
the	O
wild	O
type	O
H	O
.	O
polymorpha	O
[]	O
and	O
5	O
.	O
6	O
U	O
mg	O
âˆ’	O
1	O
protein	O
for	O
the	O
recombinant	O
AMO	O
expressed	O
in	O
S	O
.	O
cerevisiae	O
[].	O
These	O
data	O
show	O
that	O
the	O
(	O
His	B-Chemical
)	O
6	O
-	O
tagged	O
enzyme	O
which	O
we	O
constructed	O
was	O
at	O
least	O
as	O
active	O
as	O
the	O
recombinant	O
AMO	O
described	O
by	O
Cai	O
and	O
Klinman	O
","	O
without	O
any	O
change	O
in	O
protein	O
structure	O
[].	O
The	O
kinetic	O
parameters	O
of	O
the	O
purified	O
(	O
His	B-Chemical
)	O
6	O
-	O
tagged	O
AMO	O
with	O
a	O
specific	O
activity	O
of	O
13	O
.	O
7	O
U	O
mg	O
âˆ’	O
1	O
protein	O
were	O
studied	O
.	O
The	O
K	O
m	O
and	O
V	O
max	O
â¡	O
(	O
at	O
an	O
enzyme	O
concentration	O
of	O
40	O
ng	O
mL	O
âˆ’	O
1	O
)	O
for	O
MA	B-Chemical
oxidation	O
at	O
30	O
Â°	O
C	O
","	O
pH	O
7	O
.	O
0	O
","	O
were	O
0	O
.	O
22	O
Â±	O
0	O
.	O
11	O
mM	O
and	O
0	O
.	O
624	O
Â±	O
0	O
.	O
50	O
nmol	O
mL	O
âˆ’	O
1	O
min	O
â¡âˆ’	O
1	O
","	O
respectively	O
","	O
and	O
the	O
k	O
cat	O
was	O
40	O
.	O
0	O
Â±	O
3	O
.	O
1	O
s	O
âˆ’	O
1	O
.	O
For	O
comparison	O
","	O
AMO	O
isolated	O
from	O
the	O
wild	O
type	O
H	O
.	O
polymorpha	O
had	O
K	O
m	O
and	O
k	O
cat	O
values	O
of	O
0	O
.	O
344	O
mM	O
and	O
6	O
.	O
2	O
s	O
âˆ’	O
1	O
","	O
respectively	O
","	O
at	O
25	O
Â°	O
C	O
and	O
pH	O
8	O
.	O
0	O
[].	O
The	O
k	O
cat	O
/	O
K	O
m	O
ratio	O
for	O
the	O
(	O
His	B-Chemical
)	O
6	O
-	O
tagged	O
enzyme	O
was	O
found	O
to	O
be	O
approximately	O
the	O
same	O
as	O
for	O
the	O
wild	O
type	O
enzyme	O
(	O
182	O
and	O
180	O
mM	O
âˆ’	O
1	O
s	O
âˆ’	O
1	O
","	O
resp	O
.	O
).	O
It	O
must	O
be	O
emphasized	O
that	O
the	O
recombinant	O
form	O
of	O
the	O
AMO	O
which	O
we	O
constructed	O
differs	O
considerably	O
from	O
the	O
native	O
AMO	O
(	O
without	O
His	B-Chemical
-	O
tag	O
)	O
previously	O
described	O
in	O
the	O
literature	O
[].	O
This	O
AMO	O
contains	O
the	O
(	O
His	B-Chemical
)	O
6	O
-	O
tag	O
attached	O
to	O
the	O
N	O
-	O
terminus	O
which	O
was	O
introduced	O
in	O
order	O
to	O
facilitate	O
its	O
purification	O
by	O
affinity	O
chromatography	O
on	O
Ni	B-Chemical
-	I-Chemical
NTA	I-Chemical
-	O
Sepharose	B-Chemical
.	O
The	O
correct	O
nucleotide	B-Chemical
sequence	O
of	O
the	O
AMO	O
-	O
reading	O
frame	O
was	O
confirmed	O
by	O
DNA	O
sequencing	O
","	O
so	O
we	O
assume	O
that	O
changes	O
in	O
kinetic	O
parameters	O
can	O
be	O
explained	O
by	O
the	O
presence	O
of	O
an	O
additional	O
â€œ	O
tail	O
â€	O
in	O
the	O
protein	O
structure	O
.	O
3	O
.	O
3	O
.	O
Continuous	O
Bioconversion	O
of	O
Airborne	O
MA	B-Chemical
The	O
fundamental	O
possibility	O
for	O
bioconversion	O
of	O
airborne	O
MA	B-Chemical
was	O
studied	O
using	O
a	O
continuous	O
reactor	O
of	O
the	O
CFBR	O
type	O
that	O
contained	O
CA	O
-	O
gel	O
beads	O
with	O
immobilized	O
AMO	O
","	O
compared	O
to	O
a	O
control	O
system	O
with	O
blank	O
CA	B-Chemical
-	O
gel	O
beads	O
.	O
An	O
air	O
stream	O
obtained	O
by	O
bubbling	O
various	O
flow	O
rates	O
through	O
aqueous	O
MA	B-Chemical
solutions	O
with	O
concentrations	O
calculated	O
according	O
to	O
Henry	O
'	O
s	O
law	O
was	O
used	O
in	O
order	O
to	O
obtain	O
airborne	O
MA	B-Chemical
at	O
the	O
desired	O
concentrations	O
[].	O
The	O
MA	B-Chemical
concentration	O
was	O
monitored	O
in	O
the	O
aqueous	O
phase	O
within	O
the	O
reactor	O
and	O
in	O
the	O
gaseous	O
phase	O
at	O
the	O
outlet	O
from	O
the	O
reactor	O
.	O
In	O
the	O
first	O
stage	O
","	O
effective	O
loading	O
of	O
AMO	O
to	O
the	O
CA	B-Chemical
-	O
gel	O
was	O
chosen	O
.	O
Bioconversion	O
of	O
MA	B-Chemical
was	O
tested	O
with	O
three	O
AMO	O
loadings	O
","	O
while	O
the	O
remaining	O
conditions	O
â€”	O
the	O
10	O
ppm	O
inlet	O
MA	B-Chemical
concentration	O
in	O
the	O
air	O
and	O
airflow	O
of	O
7	O
mL	O
min	O
â¡âˆ’	O
1	O
â€”	O
were	O
kept	O
constant	O
(	O
Figure	O
4	O
).	O
This	O
MA	B-Chemical
concentration	O
was	O
chosen	O
because	O
it	O
lies	O
between	O
the	O
TLV	O
-	O
TWA	O
(	O
5	O
ppm	O
)	O
and	O
the	O
TLV	O
-	O
STEL	O
(	O
15	O
ppm	O
)	O
values	O
","	O
where	O
the	O
former	O
corresponds	O
to	O
the	O
level	O
permitted	O
for	O
average	O
chronic	O
exposure	O
based	O
on	O
an	O
8	O
h	O
/	O
day	O
and	O
40	O
h	O
/	O
week	O
work	O
schedule	O
and	O
the	O
latter	O
to	O
acute	O
exposure	O
to	O
MA	B-Chemical
for	O
a	O
duration	O
of	O
15	O
min	O
that	O
cannot	O
be	O
repeated	O
more	O
than	O
4	O
times	O
per	O
day	O
with	O
at	O
least	O
60	O
min	O
between	O
exposure	O
periods	O
[].	O
The	O
MA	B-Chemical
concentration	O
in	O
the	O
aqueous	O
phase	O
of	O
the	O
bioreactor	O
increased	O
up	O
to	O
ca	O
.	O
0	O
.	O
8	O
mM	O
within	O
the	O
two	O
first	O
hours	O
in	O
all	O
series	O
.	O
In	O
the	O
control	O
experiment	O
(	O
CA	B-Chemical
without	O
AMO	O
"),"	O
this	O
MA	B-Chemical
concentration	O
remained	O
almost	O
unchanged	O
during	O
the	O
10	O
-	O
day	O
period	O
","	O
with	O
only	O
10	O
%	O
reduction	O
(	O
Figure	O
4	O
).	O
The	O
MA	B-Chemical
concentration	O
in	O
the	O
bioreactors	O
decreased	O
after	O
2	O
â€“	O
5	O
days	O
","	O
depending	O
on	O
the	O
AMO	O
loading	O
","	O
and	O
reached	O
low	O
equilibrium	O
values	O
:	O
0	O
.	O
35	O
mM	O
at	O
an	O
AMO	O
loading	O
of	O
26	O
.	O
6	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
","	O
0	O
.	O
6	O
mM	O
at	O
a	O
loading	O
of	O
13	O
.	O
3	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
","	O
and	O
0	O
.	O
8	O
mM	O
at	O
a	O
loading	O
of	O
8	O
.	O
8	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
(	O
Figure	O
4	O
).	O
The	O
MA	B-Chemical
concentration	O
in	O
the	O
gaseous	O
phase	O
at	O
the	O
outlet	O
of	O
the	O
bioreactors	O
did	O
not	O
exceed	O
0	O
.	O
3	O
â€“	O
0	O
.	O
5	O
ppm	O
in	O
all	O
cases	O
","	O
whereas	O
in	O
the	O
control	O
experiment	O
it	O
was	O
1	O
.	O
3	O
ppm	O
.	O
The	O
results	O
of	O
this	O
experiment	O
showed	O
that	O
although	O
the	O
best	O
results	O
were	O
obtained	O
with	O
the	O
highest	O
AMO	O
loading	O
","	O
as	O
expected	O
","	O
13	O
.	O
3	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
loading	O
of	O
AMO	O
on	O
the	O
gel	O
may	O
be	O
enough	O
for	O
practical	O
purposes	O
","	O
since	O
96	O
%	O
elimination	O
of	O
airborne	O
MA	B-Chemical
was	O
achieved	O
.	O
The	O
further	O
experiments	O
were	O
therefore	O
carried	O
out	O
with	O
this	O
loading	O
.	O
In	O
the	O
next	O
experiment	O
","	O
the	O
system	O
'	O
s	O
ability	O
to	O
bioconvert	O
MA	B-Chemical
was	O
studied	O
using	O
the	O
100	O
ppm	O
MA	B-Chemical
inlet	O
concentration	O
.	O
When	O
bubbling	O
the	O
airborne	O
MA	B-Chemical
at	O
this	O
concentration	O
","	O
the	O
concentration	O
of	O
MA	B-Chemical
in	O
the	O
aqueous	O
phase	O
quickly	O
increased	O
to	O
ca	O
.	O
8	O
mM	O
in	O
both	O
the	O
CFBR	O
and	O
the	O
control	O
column	O
","	O
and	O
in	O
the	O
latter	O
case	O
it	O
remained	O
high	O
during	O
the	O
entire	O
experiment	O
.	O
In	O
contradistinction	O
","	O
the	O
MA	B-Chemical
concentration	O
in	O
the	O
CFBR	O
with	O
immobilized	O
AMO	O
dropped	O
to	O
0	O
.	O
46	O
mM	O
after	O
3	O
days	O
and	O
decreased	O
further	O
until	O
the	O
end	O
of	O
the	O
experimental	O
period	O
(	O
Figure	O
5	O
(	O
a	O
)).	O
The	O
MA	B-Chemical
concentration	O
in	O
the	O
gaseous	O
phase	O
at	O
the	O
outlet	O
of	O
the	O
control	O
column	O
remained	O
at	O
10	O
â€“	O
12	O
ppm	O
","	O
and	O
at	O
the	O
outlet	O
of	O
the	O
bioreactor	O
it	O
did	O
not	O
exceed	O
the	O
safety	O
level	O
of	O
0	O
.	O
5	O
ppm	O
during	O
the	O
entire	O
experimental	O
period	O
(	O
Figure	O
5	O
(	O
b	O
)).	O
The	O
CFBR	O
was	O
further	O
examined	O
at	O
a	O
high	O
airflow	O
rate	O
of	O
132	O
mL	O
min	O
â¡âˆ’	O
1	O
when	O
the	O
AMO	O
loading	O
was	O
13	O
.	O
3	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
and	O
the	O
inlet	O
concentration	O
of	O
the	O
airborne	O
MA	B-Chemical
was	O
10	O
ppm	O
(	O
Figure	O
6	O
).	O
It	O
can	O
be	O
seen	O
that	O
the	O
system	O
functioned	O
at	O
high	O
efficiency	O
in	O
this	O
case	O
as	O
well	O
","	O
and	O
the	O
whole	O
picture	O
was	O
very	O
similar	O
to	O
that	O
obtained	O
with	O
the	O
flow	O
of	O
7	O
mL	O
min	O
â¡âˆ’	O
1	O
shown	O
in	O
Figure	O
4	O
(	O
the	O
AMO	O
-	O
13	O
.	O
3	O
curve	O
).	O
MA	B-Chemical
was	O
oxidized	O
to	O
a	O
concentration	O
of	O
less	O
than	O
0	O
.	O
1	O
mM	O
in	O
the	O
aqueous	O
phase	O
and	O
to	O
no	O
more	O
than	O
0	O
.	O
4	O
ppm	O
at	O
the	O
outlet	O
of	O
the	O
gaseous	O
phase	O
(	O
Figures	O
6	O
(	O
a	O
)	O
and	O
6	O
(	O
b	O
"),"	O
resp	O
.	O
).	O
3	O
.	O
4	O
.	O
Two	O
-	O
Step	O
Continuous	O
Bioconversion	O
of	O
Airborne	O
MA	B-Chemical
and	O
Produced	O
FA	B-Chemical
Bioconversion	O
of	O
MA	B-Chemical
is	O
known	O
to	O
produce	O
FA	B-Chemical
","	O
and	O
","	O
therefore	O
","	O
a	O
system	O
of	O
two	O
continuous	O
CFBR	O
","	O
connected	O
in	O
series	O
","	O
was	O
built	O
for	O
bioconversion	O
of	O
both	O
the	O
airborne	O
MA	B-Chemical
and	O
the	O
produced	O
FA	B-Chemical
(	O
Figure	O
2	O
).	O
The	O
first	O
CFBR	O
(	O
R1	O
)	O
contained	O
CA	B-Chemical
beads	O
with	O
immobilized	O
AMO	O
(	O
13	O
.	O
3	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
)	O
and	O
the	O
second	O
(	O
R2	O
)	O
contained	O
beads	O
with	O
immobilized	O
AOX	O
(	O
6	O
.	O
6	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
).	O
Airborne	O
MA	B-Chemical
was	O
fed	O
in	O
a	O
continuous	O
regime	O
at	O
the	O
inlet	O
of	O
R1	O
and	O
the	O
airflow	O
containing	O
the	O
produced	O
FA	B-Chemical
flowed	O
from	O
the	O
R1	O
outlet	O
into	O
the	O
R2	O
inlet	O
.	O
A	O
parallel	O
experiment	O
was	O
performed	O
using	O
the	O
control	O
R3	O
and	O
R4	O
reactors	O
which	O
contained	O
blank	O
CA	B-Chemical
-	O
gel	O
beads	O
.	O
MA	B-Chemical
and	O
FA	B-Chemical
were	O
sampled	O
from	O
the	O
aqueous	O
phases	O
of	O
R1	O
â€“	O
R4	O
and	O
from	O
the	O
gaseous	O
phase	O
at	O
the	O
outlets	O
from	O
all	O
four	O
columns	O
.	O
The	O
results	O
of	O
the	O
experiment	O
are	O
presented	O
in	O
Figure	O
7	O
.	O
The	O
two	O
-	O
step	O
CFBR	O
system	O
demonstrated	O
very	O
high	O
efficiency	O
in	O
eliminating	O
the	O
fed	O
MA	B-Chemical
and	O
the	O
produced	O
FA	B-Chemical
(	O
Figure	O
7	O
).	O
As	O
in	O
the	O
previous	O
experiments	O
","	O
the	O
MA	B-Chemical
concentration	O
in	O
the	O
aqueous	O
phase	O
first	O
increased	O
to	O
0	O
.	O
8	O
mM	O
and	O
then	O
decreased	O
to	O
ca	O
.	O
0	O
.	O
3	O
mM	O
in	O
the	O
equilibrium	O
state	O
","	O
while	O
the	O
FA	B-Chemical
concentration	O
concomitantly	O
increased	O
to	O
0	O
.	O
8	O
mM	O
(	O
Figure	O
7	O
(	O
a	O
"),"	O
R1	O
(	O
MA	B-Chemical
)	O
and	O
R1	O
(	O
FA	B-Chemical
"),"	O
resp	O
.).	O
This	O
fact	O
indicates	O
that	O
MA	B-Chemical
was	O
really	O
converted	O
into	O
FA	B-Chemical
by	O
the	O
enzymatic	O
reaction	O
.	O
In	O
the	O
control	O
experiment	O
","	O
the	O
MA	B-Chemical
concentration	O
remained	O
at	O
the	O
0	O
.	O
7	O
â€“	O
0	O
.	O
8	O
mM	O
level	O
throughout	O
the	O
experiment	O
and	O
FA	B-Chemical
was	O
not	O
produced	O
at	O
all	O
(	O
Figure	O
7	O
(	O
a	O
"),"	O
R3	O
(	O
MA	B-Chemical
)	O
and	O
R3	O
(	O
FA	B-Chemical
"),"	O
resp	O
.).	O
The	O
MA	B-Chemical
and	O
FA	B-Chemical
concentrations	O
in	O
the	O
gaseous	O
phase	O
at	O
the	O
outlet	O
from	O
R1	O
were	O
0	O
.	O
4	O
ppm	O
and	O
0	O
.	O
14	O
ppm	O
","	O
respectively	O
(	O
Figure	O
7	O
(	O
b	O
"),"	O
R1	O
(	O
MA	B-Chemical
)	O
and	O
R1	O
(	O
FA	B-Chemical
")),"	O
whereas	O
","	O
in	O
the	O
control	O
experiment	O
","	O
the	O
MA	B-Chemical
concentration	O
was	O
6	O
â€“	O
6	O
.	O
5	O
ppm	O
and	O
FA	B-Chemical
was	O
absent	O
(	O
Figure	O
7	O
(	O
b	O
"),"	O
R3	O
(	O
MA	B-Chemical
)	O
and	O
R3	O
(	O
FA	B-Chemical
)).	O
The	O
MA	B-Chemical
concentration	O
in	O
the	O
aqueous	O
phase	O
of	O
the	O
R2	O
reactor	O
was	O
zero	O
","	O
and	O
the	O
FA	B-Chemical
concentration	O
decreased	O
from	O
0	O
.	O
6	O
mM	O
at	O
the	O
beginning	O
of	O
the	O
experiment	O
to	O
0	O
.	O
9	O
mM	O
in	O
the	O
equilibrium	O
state	O
(	O
Figure	O
7	O
(	O
c	O
"),"	O
R2	O
(	O
MA	B-Chemical
)	O
and	O
R2	O
(	O
FA	B-Chemical
)).	O
MA	B-Chemical
in	O
the	O
control	O
R4	O
reactor	O
accumulated	O
in	O
the	O
aqueous	O
phase	O
and	O
reached	O
more	O
than	O
0	O
.	O
4	O
mM	O
in	O
the	O
equilibrium	O
state	O
(	O
Figure	O
7	O
(	O
c	O
"),"	O
R4	O
(	O
MA	B-Chemical
)).	O
The	O
FA	B-Chemical
concentration	O
was	O
zero	O
","	O
as	O
expected	O
(	O
Figure	O
7	O
(	O
c	O
"),"	O
R4	O
(	O
FA	B-Chemical
)).	O
The	O
outlet	O
MA	B-Chemical
concentrations	O
in	O
the	O
gaseous	O
phase	O
were	O
zero	O
and	O
1	O
.	O
6	O
ppm	O
for	O
the	O
R2	O
and	O
R4	O
reactors	O
","	O
respectively	O
(	O
Figure	O
7	O
(	O
d	O
"),"	O
R2	O
(	O
MA	B-Chemical
)	O
and	O
R4	O
(	O
MA	B-Chemical
)).	O
The	O
outlet	O
FA	B-Chemical
concentration	O
was	O
zero	O
in	O
both	O
cases	O
(	O
data	O
not	O
shown	O
).	O
The	O
data	O
presented	O
in	O
Figure	O
7	O
clearly	O
show	O
that	O
airborne	O
MA	B-Chemical
was	O
bioconverted	O
into	O
FA	B-Chemical
in	O
the	O
R1	O
reactor	O
and	O
that	O
the	O
produced	O
FA	B-Chemical
was	O
degraded	O
in	O
the	O
R2	O
reactor	O
","	O
whereas	O
in	O
the	O
control	O
system	O
MA	B-Chemical
was	O
not	O
oxidized	O
and	O
","	O
accordingly	O
","	O
FA	B-Chemical
was	O
not	O
produced	O
at	O
all	O
.	O
Simple	O
trapping	O
of	O
airborne	O
MA	B-Chemical
by	O
two	O
columns	O
did	O
not	O
lead	O
to	O
its	O
elimination	O
and	O
caused	O
accumulation	O
of	O
MA	B-Chemical
in	O
the	O
aqueous	O
phase	O
of	O
the	O
R3	O
and	O
R4	O
as	O
well	O
as	O
MA	B-Chemical
exhaust	O
in	O
the	O
gaseous	O
phase	O
.	O
Several	O
methods	O
have	O
been	O
previously	O
proposed	O
for	O
removal	O
of	O
MA	B-Chemical
from	O
indoor	O
air	O
.	O
Chou	O
and	O
Shiu	O
[]	O
reported	O
bioconversion	O
of	O
MA	B-Chemical
on	O
biofilters	O
arranged	O
in	O
three	O
stages	O
","	O
which	O
contained	O
microorganisms	O
from	O
activated	O
sludge	O
that	O
was	O
obtained	O
from	O
a	O
food	O
-	O
processing	O
wastewater	O
plant	O
.	O
The	O
authors	O
showed	O
that	O
the	O
influent	O
airborne	O
MA	B-Chemical
","	O
with	O
an	O
input	O
concentration	O
of	O
100	O
ppm	O
","	O
was	O
hydrolyzed	O
to	O
ammonia	B-Chemical
","	O
about	O
a	O
third	O
of	O
the	O
ammonia	B-Chemical
nitrogen	I-Chemical
was	O
nitrified	O
to	O
nitrate	B-Chemical
","	O
and	O
a	O
third	O
was	O
converted	O
into	O
organic	O
or	O
cell	O
nitrogen	B-Chemical
.	O
Ho	O
'	O
s	O
group	O
[]	O
developed	O
a	O
biofilter	O
based	O
on	O
granular	O
activated	O
carbon	B-Chemical
coated	O
with	O
immobilized	O
Paracoccus	O
sp	O
.	O
CP2	O
for	O
elimination	O
of	O
10	O
â€“	O
250	O
ppm	O
trimethylamine	B-Chemical
(	O
TMA	B-Chemical
"),"	O
dimethylamine	B-Chemical
(	O
DMA	B-Chemical
"),"	O
and	O
MA	B-Chemical
.	O
The	O
system	O
effectively	O
treated	O
MA	B-Chemical
(>	O
93	O
"%),"	O
DMA	B-Chemical
(>	O
90	O
"%),"	O
and	O
TMA	B-Chemical
(>	O
85	O
%).	O
The	O
coimmobilized	O
Paracoccus	O
sp	O
.	O
CP2	O
and	O
Arthrobacter	O
sp	O
.	O
CP1	O
system	O
was	O
used	O
to	O
achieve	O
complete	O
degradation	O
of	O
TMA	B-Chemical
and	O
to	O
reduce	O
NH3	B-Chemical
emission	O
.	O
Methods	O
for	O
the	O
bioconversion	O
of	O
MA	B-Chemical
traditionally	O
compete	O
with	O
chemical	O
methods	O
of	O
degradation	O
.	O
Kachina	O
et	O
al	O
.	O
[]	O
investigated	O
continuous	O
photocatalytic	O
MA	B-Chemical
oxidation	O
.	O
The	O
authors	O
used	O
titanium	B-Chemical
dioxide	I-Chemical
illuminated	O
with	O
UV	O
light	O
at	O
365	O
nm	O
as	O
a	O
catalyst	O
.	O
The	O
oxidation	O
process	O
was	O
efficient	O
and	O
the	O
TiO2	B-Chemical
catalyst	O
showed	O
no	O
deactivation	O
.	O
However	O
","	O
the	O
authors	O
found	O
nitrogen	B-Chemical
and	O
nitrous	B-Chemical
oxides	I-Chemical
among	O
the	O
products	O
of	O
the	O
MA	B-Chemical
oxidation	O
","	O
in	O
addition	O
to	O
ammonia	B-Chemical
","	O
which	O
overshadowed	O
the	O
advantages	O
of	O
the	O
method	O
.	O
Besides	O
destructive	O
methods	O
for	O
the	O
elimination	O
of	O
airborne	O
MA	B-Chemical
","	O
methods	O
of	O
physical	O
adsorption	O
of	O
airborne	O
MA	B-Chemical
on	O
several	O
carbon	B-Chemical
materials	O
were	O
also	O
studied	O
[].	O
Despite	O
a	O
high	O
adsorption	O
efficiency	O
","	O
physical	O
adsorption	O
does	O
not	O
lead	O
to	O
degradation	O
of	O
MA	B-Chemical
and	O
is	O
therefore	O
less	O
preferable	O
than	O
chemical	O
or	O
biological	O
conversion	O
methods	O
.	O
The	O
two	O
-	O
step	O
AMO	O
/	O
AOX	O
enzyme	O
system	O
presented	O
in	O
this	O
study	O
enabled	O
the	O
achievement	O
of	O
complete	O
bioconversion	O
of	O
MA	B-Chemical
and	O
of	O
FA	B-Chemical
.	O
It	O
also	O
enabled	O
the	O
neutralization	O
of	O
the	O
ammonia	B-Chemical
by	O
-	O
product	O
of	O
the	O
first	O
process	O
by	O
the	O
formic	B-Chemical
acid	I-Chemical
by	O
-	O
product	O
of	O
the	O
second	O
process	O
","	O
since	O
","	O
according	O
to	O
the	O
stoichiometry	O
of	O
the	O
bioconversion	O
processes	O
","	O
these	O
by	O
-	O
products	O
are	O
produced	O
in	O
equal	O
concentrations	O
.	O
4	O
.	O
Conclusions	O
A	O
recombinant	O
S	O
.	O
cerevisiae	O
yeast	O
overproducing	O
AMO	O
from	O
the	O
thermotolerant	O
yeast	O
H	O
.	O
polymorpha	O
was	O
constructed	O
.	O
The	O
novel	O
(	O
His	B-Chemical
)	O
6	O
-	O
tagged	O
enzyme	O
was	O
purified	O
from	O
the	O
cell	O
-	O
free	O
extract	O
of	O
the	O
recombinant	O
strain	O
by	O
metal	O
-	O
affinity	O
chromatography	O
and	O
characterized	O
electrophoretically	O
and	O
kinetically	O
.	O
The	O
enzyme	O
that	O
was	O
immobilized	O
in	O
CA	B-Chemical
beads	O
demonstrated	O
a	O
high	O
capability	O
for	O
eliminating	O
airborne	O
MA	B-Chemical
in	O
a	O
continuous	O
regime	O
","	O
when	O
employed	O
in	O
a	O
two	O
-	O
step	O
CFBR	O
designed	O
for	O
bioconversion	O
of	O
airborne	O
MA	B-Chemical
and	O
the	O
produced	O
FA	B-Chemical
.	O
Conflict	O
of	O
Interests	O
The	O
authors	O
declare	O
that	O
there	O
is	O
no	O
conflict	O
of	O
interests	O
regarding	O
the	O
publication	O
of	O
this	O
paper	O
.	O
Cloning	O
of	O
the	O
AMO	O
gene	O
into	O
the	O
expression	O
vector	O
pYEX	O
-	O
4T	O
-	O
1	O
.	O
Scheme	O
of	O
a	O
two	O
-	O
step	O
CFBR	O
system	O
for	O
bioconversion	O
of	O
airborne	O
MA	B-Chemical
by	O
AMO	O
immobilized	O
in	O
CA	B-Chemical
(	O
R1	O
)	O
and	O
for	O
oxidation	O
of	O
the	O
produced	O
FA	B-Chemical
by	O
immobilized	O
AOX	O
(	O
R2	O
).	O
The	O
control	O
columns	O
(	O
R3	O
and	O
R4	O
)	O
contained	O
blank	O
CA	O
-	O
gel	O
beads	O
.	O
(	O
1	O
)	O
an	O
airflow	O
bubbled	O
through	O
aqueous	O
MA	B-Chemical
solution	O
;	O
(	O
2	O
)	O
a	O
flow	O
of	O
airborne	O
MA	B-Chemical
;	O
(	O
3	O
)	O
a	O
system	O
of	O
two	O
CFBR	O
in	O
series	O
;	O
(	O
4	O
)	O
a	O
control	O
system	O
and	O
P	O
-	O
a	O
peristaltic	O
pump	O
.	O
SDS	B-Chemical
-	O
PAGE	O
in	O
12	O
%	O
gel	O
of	O
the	O
purified	O
AMO	O
using	O
chromatography	O
on	O
Ni	B-Chemical
-	I-Chemical
NTA	I-Chemical
-	O
agarose	B-Chemical
.	O
(	O
1	O
)	O
crude	O
extract	O
","	O
100	O
Î¼g	O
;	O
(	O
2	O
)	O
flow	O
through	O
the	O
column	O
","	O
100	O
Î¼g	O
;	O
(	O
3	O
)	O
washing	O
with	O
8	O
mM	O
imidazole	B-Chemical
","	O
20	O
Î¼L	O
;	O
(	O
4	O
)	O
protein	O
molecular	O
weight	O
markers	O
(	O
MW	O
","	O
kDa	O
","	O
20	O
","	O
26	O
","	O
34	O
","	O
47	O
","	O
86	O
","	O
and	O
120	O
;	O
1	O
.	O
2	O
Î¼g	O
of	O
each	O
protein	O
);	O
(	O
5	O
)â€“(	O
14	O
)	O
elution	O
fractions	O
obtained	O
in	O
10	O
â€“	O
500	O
mM	O
imidazole	B-Chemical
gradient	O
","	O
20	O
Î¼L	O
.	O
MA	B-Chemical
concentration	O
in	O
the	O
aqueous	O
phase	O
of	O
the	O
CFBR	O
upon	O
oxidation	O
of	O
MA	B-Chemical
in	O
the	O
7	O
mL	O
min	O
â¡âˆ’	O
1	O
air	O
flow	O
with	O
10	O
ppm	O
MA	B-Chemical
inlet	O
concentration	O
by	O
immobilized	O
AMO	O
at	O
various	O
loadings	O
on	O
CA	B-Chemical
gel	O
:	O
26	O
.	O
6	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
","	O
AMO	O
-	O
26	O
.	O
6	O
;	O
13	O
.	O
3	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
","	O
AMO	O
-	O
13	O
.	O
3	O
;	O
and	O
8	O
.	O
8	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
","	O
AMO	O
-	O
8	O
.	O
8	O
.	O
C	O
(	O
control	O
)â€”	O
blank	O
beads	O
of	O
CA	B-Chemical
-	O
gel	O
tested	O
at	O
the	O
same	O
inlet	O
conditions	O
.	O
MA	B-Chemical
concentration	O
in	O
the	O
aqueous	O
(	O
a	O
)	O
and	O
in	O
the	O
gaseous	O
(	O
b	O
)	O
phase	O
of	O
the	O
CFBR	O
upon	O
oxidation	O
of	O
MA	B-Chemical
in	O
the	O
7	O
mL	O
min	O
â¡âˆ’	O
1	O
air	O
flow	O
at	O
100	O
ppm	O
MA	B-Chemical
inlet	O
concentration	O
by	O
immobilized	O
AMO	O
at	O
the	O
13	O
.	O
3	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
loading	O
.	O
C	O
(	O
control	O
)	O
blank	O
beads	O
of	O
CA	B-Chemical
-	O
gel	O
","	O
tested	O
at	O
the	O
same	O
inlet	O
conditions	O
.	O
MA	B-Chemical
concentration	O
in	O
the	O
aqueous	O
(	O
a	O
)	O
and	O
in	O
the	O
gaseous	O
(	O
b	O
)	O
phase	O
of	O
the	O
CFBR	O
upon	O
oxidation	O
of	O
MA	B-Chemical
in	O
the	O
132	O
mL	O
min	O
â¡âˆ’	O
1	O
air	O
flow	O
with	O
10	O
ppm	O
MA	B-Chemical
inlet	O
concentration	O
by	O
immobilized	O
AMO	O
at	O
the	O
13	O
.	O
3	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
loading	O
.	O
C	O
(	O
control	O
)	O
blank	O
beads	O
of	O
the	O
CA	B-Chemical
-	O
gel	O
tested	O
at	O
the	O
same	O
inlet	O
conditions	O
.	O
MA	B-Chemical
and	O
FA	B-Chemical
concentration	O
in	O
the	O
aqueous	O
((	O
a	O
)	O
and	O
(	O
c	O
))	O
and	O
in	O
the	O
gaseous	O
((	O
b	O
)	O
and	O
(	O
d	O
))	O
phase	O
of	O
the	O
two	O
-	O
step	O
CFBR	O
system	O
for	O
bioconversion	O
of	O
MA	B-Chemical
in	O
the	O
7	O
mL	O
min	O
â¡âˆ’	O
1	O
air	O
flow	O
with	O
10	O
ppm	O
MA	B-Chemical
inlet	O
concentration	O
by	O
immobilized	O
AMO	O
at	O
the	O
13	O
.	O
3	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
loading	O
(	O
R1	O
)	O
and	O
for	O
oxidation	O
of	O
the	O
produced	O
FA	B-Chemical
by	O
immobilized	O
AOX	O
at	O
6	O
.	O
6	O
U	O
g	O
âˆ’	O
1	O
CA	B-Chemical
loading	O
(	O
R2	O
).	O
R3	O
and	O
R4	O
-	O
control	O
reactors	O
connected	O
in	O
series	O
and	O
containing	O
blank	O
beads	O
of	O
CA	B-Chemical
-	O
gel	O
tested	O
at	O
the	O
same	O
inlet	O
conditions	O
.	O
Prophylactic	O
cannabinoid	B-Chemical
administration	O
blocks	O
the	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
nociception	O
during	O
analgesic	O
treatment	O
and	O
following	O
cessation	O
of	O
drug	O
delivery	O
Background	O
Chemotherapeutic	O
treatment	O
results	O
in	O
chronic	O
pain	O
in	O
an	O
estimated	O
30	O
-	O
40	O
percent	O
of	O
patients	O
.	O
Limited	O
and	O
often	O
ineffective	O
treatments	O
make	O
the	O
need	O
for	O
new	O
therapeutics	O
an	O
urgent	O
one	O
.	O
We	O
compared	O
the	O
effects	O
of	O
prophylactic	O
cannabinoids	B-Chemical
as	O
a	O
preventative	O
strategy	O
for	O
suppressing	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
nociception	O
.	O
The	O
mixed	O
CB1	O
/	O
CB2	O
agonist	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
was	O
compared	O
with	O
the	O
cannabilactone	O
CB2	O
-	O
selective	O
agonist	O
AM1710	B-Chemical
","	O
administered	O
subcutaneously	O
(	O
s	O
.	O
c	O
.	O
"),"	O
via	O
osmotic	O
mini	O
pumps	O
before	O
","	O
during	O
","	O
and	O
after	O
paclitaxel	B-Chemical
treatment	O
.	O
Pharmacological	O
specificity	O
was	O
assessed	O
using	O
CB1	O
(	O
AM251	B-Chemical
)	O
and	O
CB2	O
(	O
AM630	B-Chemical
)	O
antagonists	O
.	O
The	O
impact	O
of	O
chronic	O
drug	O
infusion	O
on	O
transcriptional	O
regulation	O
of	O
mRNA	O
markers	O
of	O
astrocytes	O
(	O
GFAP	O
"),"	O
microglia	O
(	O
CD11b	O
)	O
and	O
cannabinoid	O
receptors	O
(	O
CB1	O
","	O
CB2	O
)	O
was	O
assessed	O
in	O
lumbar	O
spinal	O
cords	O
of	O
paclitaxel	B-Chemical
and	O
vehicle	O
-	O
treated	O
rats	O
.	O
Results	O
Both	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
and	O
AM1710	B-Chemical
blocked	O
the	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
and	O
cold	O
allodynia	O
;	O
anti	O
-	O
allodynic	O
efficacy	O
persisted	O
for	O
approximately	O
two	O
to	O
three	O
weeks	O
following	O
cessation	O
of	O
drug	O
delivery	O
.	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
1	O
and	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
the	O
development	O
of	O
both	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
and	O
cold	O
allodynia	O
.	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
-	O
mediated	O
suppression	O
of	O
mechanical	O
hypersensitivity	O
was	O
dominated	O
by	O
CB1	O
activation	O
whereas	O
suppression	O
of	O
cold	O
allodynia	O
was	O
relatively	O
insensitive	O
to	O
blockade	O
by	O
either	O
CB1	O
(	O
AM251	B-Chemical
;	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
or	O
CB2	O
(	O
AM630	B-Chemical
;	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
antagonists	O
.	O
AM1710	B-Chemical
(	O
0	O
.	O
32	O
and	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
)	O
suppressed	O
development	O
of	O
mechanical	O
allodynia	O
whereas	O
only	O
the	O
highest	O
dose	O
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
cold	O
allodynia	O
.	O
Anti	O
-	O
allodynic	O
effects	O
of	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
were	O
mediated	O
by	O
CB2	O
.	O
Anti	O
-	O
allodynic	O
efficacy	O
of	O
AM1710	B-Chemical
outlasted	O
that	O
produced	O
by	O
chronic	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
infusion	O
.	O
mRNA	O
expression	O
levels	O
of	O
the	O
astrocytic	O
marker	O
GFAP	O
was	O
marginally	O
increased	O
by	O
paclitaxel	B-Chemical
treatment	O
whereas	O
expression	O
of	O
the	O
microglial	O
marker	O
CD11b	O
was	O
unchanged	O
.	O
Both	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
increased	O
CB1	O
and	O
CB2	O
mRNA	O
expression	O
in	O
lumbar	O
spinal	O
cord	O
of	O
paclitaxel	B-Chemical
-	O
treated	O
rats	O
in	O
a	O
manner	O
blocked	O
by	O
AM630	B-Chemical
.	O
Conclusions	O
and	O
implications	O
Cannabinoids	B-Chemical
block	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathy	O
and	O
protect	O
against	O
neuropathic	O
allodynia	O
following	O
cessation	O
of	O
drug	O
delivery	O
.	O
Chronic	O
treatment	O
with	O
both	O
mixed	O
CB1	O
/	O
CB2	O
and	O
CB2	O
selective	O
cannabinoids	B-Chemical
increased	O
mRNA	O
expression	O
of	O
cannabinoid	O
receptors	O
(	O
CB1	O
","	O
CB2	O
)	O
in	O
a	O
CB2	O
-	O
dependent	O
fashion	O
.	O
Our	O
results	O
support	O
the	O
therapeutic	O
potential	O
of	O
cannabinoids	B-Chemical
for	O
suppressing	O
chemotherapy	O
-	O
induced	O
neuropathy	O
in	O
humans	O
.	O
Background	O
Cannabinoids	B-Chemical
attenuate	O
or	O
","	O
in	O
some	O
cases	O
","	O
prevent	O
pain	O
associated	O
with	O
surgery	O
[	O
1	O
"],"	O
inflammation	O
[	O
2	O
"],"	O
internal	O
organs	O
[	O
3	O
"],"	O
and	O
neuropathies	O
(	O
for	O
review	O
see	O
[	O
4	O
]).	O
Neuropathic	O
pain	O
is	O
associated	O
with	O
abnormal	O
changes	O
in	O
the	O
peripheral	O
and	O
/	O
or	O
central	O
nervous	O
system	O
resulting	O
in	O
non	O
-	O
adaptive	O
","	O
chronic	O
pain	O
.	O
Clinical	O
manifestations	O
of	O
neuropathic	O
pain	O
are	O
notoriously	O
unresponsive	O
to	O
traditional	O
analgesics	O
.	O
Chemotherapeutic	O
treatment	O
with	O
antineoplastic	O
agents	O
","	O
while	O
effective	O
at	O
eliminating	O
harmful	O
malignancies	O
","	O
is	O
also	O
associated	O
with	O
severe	O
side	O
effects	O
.	O
Of	O
these	O
side	O
effects	O
","	O
emesis	O
","	O
alopecia	O
","	O
and	O
myelosuppression	O
have	O
received	O
the	O
spotlight	O
;	O
however	O
","	O
a	O
new	O
front	O
runner	O
has	O
recently	O
emerged	O
.	O
Neuropathic	O
pain	O
associated	O
with	O
chemotherapeutic	O
treatment	O
is	O
dose	O
-	O
limiting	O
and	O
a	O
major	O
factor	O
influencing	O
discontinuation	O
of	O
treatment	O
[	O
5	O
","	O
6	O
].	O
Chemotherapy	O
-	O
induced	O
neuropathy	O
is	O
positively	O
correlated	O
with	O
cumulative	O
chemotherapeutic	O
dose	O
[	O
7	O
"],"	O
and	O
affected	O
patients	O
are	O
more	O
likely	O
to	O
experience	O
other	O
neuropathies	O
[	O
8	O
].	O
An	O
aging	O
US	O
population	O
","	O
coupled	O
with	O
diagnostic	O
and	O
medical	O
advances	O
in	O
cancer	O
treatment	O
","	O
means	O
that	O
more	O
cancer	O
survivors	O
will	O
be	O
impacted	O
by	O
","	O
and	O
living	O
longer	O
with	O
","	O
chemotherapy	O
-	O
induced	O
neuropathy	O
.	O
Thus	O
","	O
identification	O
of	O
prophylactic	O
treatments	O
that	O
block	O
development	O
of	O
chemotherapy	O
-	O
induced	O
neuropathy	O
represents	O
an	O
urgent	O
medical	O
need	O
.	O
Chemotherapeutic	O
agents	O
are	O
divided	O
into	O
three	O
mechanistically	O
distinct	O
classes	O
.	O
These	O
classes	O
include	O
the	O
vinca	B-Chemical
alkaloids	I-Chemical
","	O
platinum	B-Chemical
-	O
derived	O
agents	O
","	O
and	O
taxanes	B-Chemical
.	O
Taxanes	B-Chemical
(	O
e	O
.	O
g	O
".,"	O
paclitaxel	B-Chemical
","	O
docetaxel	B-Chemical
)	O
produce	O
antineoplastic	O
effects	O
by	O
stabilizing	O
microtubules	O
through	O
binding	O
to	O
Î²	O
-	O
tubulin	O
","	O
thereby	O
disrupting	O
normal	O
cell	O
mitosis	O
and	O
triggering	O
the	O
mitochondrial	O
apoptosis	O
pathway	O
[	O
9	O
].	O
Paclitaxel	B-Chemical
is	O
a	O
preferred	O
agent	O
for	O
treatment	O
of	O
ovarian	O
","	O
breast	O
","	O
and	O
lung	O
cancers	O
;	O
however	O
","	O
a	O
high	O
percentage	O
of	O
patients	O
experience	O
neuropathic	O
pain	O
â€“	O
a	O
type	O
of	O
pain	O
poorly	O
treated	O
with	O
available	O
drugs	O
[	O
10	O
].	O
Mechanisms	O
underlying	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathy	O
remain	O
incompletely	O
understood	O
but	O
may	O
involve	O
changes	O
in	O
glial	O
activation	O
[	O
11	O
","	O
12	O
].	O
Cannabinoid	B-Chemical
agonists	O
suppress	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
nociception	O
in	O
animal	O
models	O
through	O
activation	O
of	O
both	O
CB1	O
[	O
13	O
]	O
and	O
CB2	O
[	O
14	O
-	O
16	O
]	O
cannabinoid	O
receptor	O
subtypes	O
.	O
Our	O
laboratory	O
first	O
demonstrated	O
CB2	O
receptor	O
-	O
mediated	O
suppression	O
of	O
neuropathic	O
allodynia	O
induced	O
by	O
chemotherapeutic	O
treatment	O
with	O
vincristine	B-Chemical
[	O
17	O
"],"	O
paclitaxel	B-Chemical
[	O
14	O
","	O
18	O
"],"	O
and	O
cisplatin	B-Chemical
[	O
15	O
].	O
Previous	O
prophylactic	O
treatment	O
strategies	O
with	O
cannabinoids	B-Chemical
in	O
a	O
traumatic	O
nerve	O
injury	O
model	O
demonstrated	O
that	O
pre	O
-	O
emptive	O
cannabinoids	B-Chemical
produced	O
greater	O
antinociception	O
relative	O
to	O
post	O
-	O
injury	O
treatment	O
[	O
19	O
].	O
Here	O
we	O
investigate	O
the	O
therapeutic	O
efficacy	O
of	O
prophylactically	O
administered	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
","	O
a	O
mixed	O
cannabinoid	B-Chemical
(	O
CB1	O
/	O
CB2	O
)	O
agonist	O
","	O
and	O
AM1710	B-Chemical
","	O
a	O
CB2	O
-	O
preferring	O
agonist	O
","	O
on	O
the	O
development	O
of	O
chemotherapy	O
-	O
induced	O
neuropathy	O
in	O
the	O
paclitaxel	B-Chemical
model	O
.	O
Osmotic	O
mini	O
pumps	O
were	O
used	O
to	O
continuously	O
infuse	O
cannabinoids	B-Chemical
before	O
","	O
during	O
","	O
and	O
after	O
paclitaxel	B-Chemical
treatment	O
","	O
to	O
emulate	O
a	O
prophylactic	O
analgesic	O
strategy	O
achievable	O
in	O
clinical	O
oncology	O
settings	O
.	O
We	O
compared	O
development	O
of	O
mechanical	O
and	O
cold	O
allodynia	O
","	O
both	O
common	O
clinical	O
manifestations	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathy	O
[	O
10	O
","	O
20	O
].	O
We	O
hypothesized	O
that	O
chronic	O
prophylactic	O
cannabinoid	B-Chemical
infusion	O
would	O
produce	O
sustained	O
suppression	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
behavioral	O
sensitization	O
to	O
mechanical	O
and	O
cold	O
stimulation	O
.	O
Furthermore	O
","	O
we	O
evaluated	O
whether	O
long	O
-	O
term	O
transcriptional	O
changes	O
in	O
mRNA	O
markers	O
of	O
astrocytes	O
(	O
GFAP	O
"),"	O
microglia	O
(	O
CD11b	O
"),"	O
and	O
cannabinoid	O
receptors	O
(	O
CB1	O
","	O
CB2	O
)	O
would	O
accompany	O
long	O
lasting	O
anti	O
-	O
allodynic	O
efficacy	O
of	O
cannabinoids	B-Chemical
.	O
Results	O
General	O
results	O
Paclitaxel	B-Chemical
-	O
treated	O
animals	O
showed	O
reduced	O
sensitivity	O
to	O
heat	O
on	O
day	O
6	O
(	O
F1	O
","	O
10	O
=	O
20	O
.	O
745	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
Figure	O
1a	O
"),"	O
but	O
not	O
at	O
subsequent	O
time	O
points	O
(	O
P	O
>	O
0	O
.	O
16	O
"),"	O
while	O
the	O
same	O
animals	O
developed	O
hypersensitivity	O
to	O
mechanical	O
stimulation	O
(	O
i	O
.	O
e	O
".,"	O
mechanical	O
allodynia	O
)	O
(	O
F1	O
","	O
10	O
=	O
6	O
.	O
191	O
","	O
P	O
<	O
0	O
.	O
5	O
;	O
Figure	O
1b	O
).	O
Based	O
upon	O
these	O
results	O
","	O
animals	O
implanted	O
with	O
osmotic	O
pumps	O
were	O
evaluated	O
for	O
responsiveness	O
to	O
mechanical	O
and	O
cold	O
stimulation	O
only	O
.	O
Paclitaxel	B-Chemical
induces	O
mechanical	O
allodynia	O
without	O
producing	O
hypersensitivity	O
to	O
heat	O
.	O
a	O
.	O
Paclitaxel	B-Chemical
treatment	O
produced	O
transient	O
heat	O
hypoalgesia	O
but	O
no	O
long	O
-	O
term	O
changes	O
in	O
paw	O
withdrawal	O
latencies	O
to	O
heat	O
whereas	O
b	O
.	O
the	O
same	O
animals	O
developed	O
mechanical	O
allodynia	O
.	O
Inj	O
indicates	O
days	O
when	O
injections	O
of	O
paclitaxel	B-Chemical
or	O
cremophor	B-Chemical
vehicle	O
occurred	O
.	O
Taxol	B-Chemical
;	O
paclitaxel	B-Chemical
.	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Cremophor	B-Chemical
Vehicle	O
","	O
(	O
ANOVA	O
).	O
N	O
=	O
6	O
per	O
group	O
.	O
Osmotic	O
mini	O
pump	O
dispersion	O
volume	O
was	O
calculated	O
by	O
subtracting	O
the	O
fill	O
volume	O
from	O
the	O
residual	O
volume	O
in	O
the	O
pump	O
reservoir	O
following	O
pump	O
removal	O
(	O
day	O
22	O
).	O
The	O
pump	O
dispersion	O
volume	O
differed	O
between	O
groups	O
in	O
which	O
drugs	O
were	O
dissolved	O
in	O
the	O
DMSO	B-Chemical
:	O
PEG400	B-Chemical
vehicle	O
(	O
F19	O
","	O
180	O
=	O
2	O
.	O
213	O
","	O
P	O
<	O
0	O
.	O
1	O
).	O
Post	O
-	O
hoc	O
analysis	O
revealed	O
that	O
pump	O
dispersion	O
volume	O
for	O
the	O
Taxol	B-Chemical
-	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
1	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
group	O
was	O
less	O
than	O
half	O
(<	O
43	O
%)	O
of	O
other	O
groups	O
dissolved	O
in	O
the	O
same	O
vehicle	O
.	O
No	O
other	O
differences	O
were	O
found	O
.	O
Mechanical	O
withdrawal	O
thresholds	O
did	O
not	O
differ	O
between	O
either	O
the	O
right	O
or	O
left	O
paw	O
on	O
any	O
given	O
day	O
for	O
animals	O
tested	O
up	O
to	O
20	O
(	O
P	O
>	O
0	O
.	O
98	O
)	O
or	O
50	O
(	O
P	O
>	O
0	O
.	O
71	O
)	O
days	O
post	O
-	O
chemotherapy	O
treatment	O
;	O
therefore	O
","	O
withdrawal	O
thresholds	O
are	O
presented	O
as	O
the	O
mean	O
of	O
duplicate	O
measurements	O
","	O
averaged	O
across	O
paws	O
.	O
Two	O
dependent	O
measures	O
for	O
cold	O
allodynia	O
were	O
evaluated	O
:	O
percentage	O
of	O
paw	O
withdrawals	O
and	O
duration	O
of	O
paw	O
withdrawal	O
.	O
Duration	O
of	O
paw	O
withdrawal	O
in	O
response	O
to	O
topical	O
acetone	B-Chemical
application	O
is	O
a	O
reported	O
measure	O
of	O
cold	O
allodynia	O
[	O
21	O
-	O
23	O
].	O
However	O
","	O
we	O
found	O
this	O
measure	O
highly	O
variable	O
in	O
rat	O
subjects	O
(	O
data	O
not	O
shown	O
)	O
and	O
consequently	O
only	O
the	O
percentage	O
of	O
paw	O
withdrawals	O
is	O
reported	O
here	O
.	O
Percentage	O
of	O
paw	O
withdrawals	O
to	O
cold	O
stimulation	O
did	O
not	O
differ	O
between	O
either	O
paw	O
on	O
any	O
given	O
day	O
for	O
animals	O
tested	O
up	O
to	O
21	O
(	O
P	O
>	O
0	O
.	O
33	O
)	O
or	O
51	O
(	O
P	O
>	O
0	O
.	O
82	O
)	O
days	O
post	O
-	O
paclitaxel	B-Chemical
;	O
therefore	O
","	O
the	O
percentage	O
of	O
paw	O
withdrawals	O
is	O
presented	O
as	O
the	O
mean	O
of	O
duplicate	O
measurements	O
averaged	O
across	O
paws	O
.	O
To	O
control	O
for	O
any	O
possible	O
effects	O
associated	O
with	O
the	O
vehicle	O
used	O
to	O
dissolve	O
cannabinoids	B-Chemical
(	O
DMSO	B-Chemical
:	O
PEG	B-Chemical
400	I-Chemical
in	O
a	O
1	O
:	O
1	O
ratio	O
"),"	O
a	O
subset	O
of	O
animals	O
treated	O
with	O
either	O
paclitaxel	B-Chemical
or	O
cremophor	B-Chemical
received	O
saline	B-Chemical
in	O
their	O
osmotic	O
mini	O
pumps	O
.	O
No	O
differences	O
were	O
detected	O
between	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
that	O
received	O
vehicle	O
(	O
DMSO	B-Chemical
:	O
PEG	B-Chemical
400	I-Chemical
;	O
n	O
=	O
14	O
)	O
or	O
saline	O
(	O
n	O
=	O
4	O
)	O
in	O
any	O
behavioral	O
parameter	O
assessed	O
(	O
i	O
.	O
e	O
".,"	O
mechanical	O
threshold	O
","	O
cold	O
withdrawal	O
frequency	O
","	O
and	O
locomotor	O
activity	O
).	O
Similarly	O
","	O
no	O
differences	O
were	O
noted	O
between	O
cremophor	B-Chemical
-	O
treated	O
animals	O
receiving	O
chronic	O
infusions	O
of	O
vehicle	O
(	O
DMSO	B-Chemical
:	O
PEG	B-Chemical
400	I-Chemical
;	O
n	O
=	O
8	O
)	O
or	O
saline	B-Chemical
(	O
n	O
=	O
4	O
).	O
Therefore	O
","	O
vehicle	O
and	O
saline	B-Chemical
groups	O
were	O
combined	O
for	O
each	O
condition	O
and	O
are	O
referred	O
to	O
as	O
the	O
Taxol	B-Chemical
-	O
vehicle	O
group	O
and	O
cremophor	B-Chemical
-	O
vehicle	O
group	O
","	O
respectively	O
.	O
Body	O
weight	O
Body	O
weight	O
did	O
not	O
differ	O
between	O
paclitaxel	B-Chemical
-	O
or	O
cremophor	B-Chemical
-	O
treated	O
animals	O
receiving	O
infusions	O
of	O
vehicle	O
(	O
P	O
=	O
0	O
.	O
69	O
;	O
Figure	O
2a	O
).	O
Moreover	O
","	O
no	O
differences	O
in	O
body	O
weight	O
were	O
observed	O
between	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
receiving	O
either	O
vehicle	O
or	O
saline	B-Chemical
(	O
data	O
not	O
shown	O
).	O
However	O
","	O
cremophor	B-Chemical
-	O
treated	O
animals	O
receiving	O
saline	B-Chemical
infusions	O
exhibited	O
greater	O
weight	O
gain	O
on	O
days	O
14	O
â€“	O
21	O
(	O
F12	O
","	O
204	O
=	O
8	O
.	O
455	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
day	O
)	O
relative	O
to	O
those	O
receiving	O
vehicle	O
.	O
The	O
mixed	O
CB1	O
/	O
CB2	O
agonist	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
and	O
the	O
CB2	O
-	O
preferring	O
agonist	O
AM1710	B-Chemical
suppressed	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
and	O
cold	O
allodynia	O
without	O
significantly	O
altering	O
body	O
weight	O
.	O
a	O
.	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
increased	O
whereas	O
b	O
.	O
AM1710	B-Chemical
did	O
not	O
alter	O
body	O
weight	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
.	O
Mechanical	O
and	O
cold	O
allodynia	O
were	O
suppressed	O
by	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
1	O
and	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
;	O
c	O
.	O
and	O
e	O
".,"	O
respectively	O
)	O
and	O
AM1710	B-Chemical
(	O
0	O
.	O
32	O
and	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
;	O
d	O
.	O
and	O
f	O
".,"	O
respectively	O
).	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
#	O
P	O
<	O
0	O
.	O
5	O
","	O
##	O
P	O
<	O
0	O
.	O
1	O
","	O
###	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
xP	O
<	O
0	O
.	O
5	O
vs	O
.	O
Taxol	B-Chemical
-	O
Agonist	O
(	O
high	O
dose	O
"),"	O
+	O
P	O
<	O
0	O
.	O
5	O
","	O
++	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Taxol	B-Chemical
-	O
Agonist	O
(	O
middle	O
dose	O
"),"	O
$	O
P	O
<	O
0	O
.	O
5	O
","	O
vs	O
.	O
Taxol	B-Chemical
-	O
Agonist	O
(	O
low	O
dose	O
"),"	O
Î²P	O
<	O
0	O
.	O
5	O
","	O
Î²Î²P	O
<	O
0	O
.	O
1	O
","	O
Î²Î²Î²P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
(	O
middle	O
and	O
low	O
doses	O
)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
",âŸ‚âŸ‚"	O
P	O
<	O
0	O
.	O
1	O
","	O
âŸ‚âŸ‚âŸ‚	O
P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
(	O
high	O
and	O
low	O
doses	O
)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
Î±P	O
<	O
0	O
.	O
5	O
Taxol	B-Chemical
-	O
Agonist	O
(	O
all	O
doses	O
)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
Ï•Ï•Ï•P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Taxol	B-Chemical
-	O
Agonist	O
(	O
middle	O
and	O
low	O
doses	O
).	O
The	O
first	O
drug	O
listed	O
indicates	O
assignment	O
to	O
cremophor	B-Chemical
or	O
paclitaxel	B-Chemical
(	O
Taxol	B-Chemical
)	O
treatment	O
.	O
The	O
second	O
drug	O
indicates	O
drug	O
administered	O
via	O
osmotic	O
mini	O
pump	O
chronic	O
infusion	O
.	O
Day	O
numbers	O
reference	O
days	O
post	O
-	O
chemotherapeutic	O
treatment	O
(	O
i	O
.	O
e	O
".,"	O
negative	O
days	O
indicate	O
days	O
prior	O
to	O
chemotherapeutic	O
treatment	O
).	O
Surgery	O
indicates	O
the	O
day	O
(	O
day	O
-	O
6	O
)	O
on	O
which	O
osmotic	O
mini	O
pumps	O
were	O
implanted	O
subcutaneously	O
.	O
(	O
ANOVA	O
;	O
Dunnett	O
and	O
Tukey	O
post	O
-	O
hoc	O
tests	O
).	O
N	O
=	O
8	O
â€“	O
18	O
per	O
group	O
.	O
Paclitaxel	B-Chemical
-	O
treated	O
animals	O
receiving	O
infusions	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
showed	O
greater	O
weight	O
gain	O
over	O
the	O
study	O
(	O
F68	O
","	O
935	O
=	O
3	O
.	O
932	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
)	O
relative	O
to	O
other	O
groups	O
(	O
F4	O
","	O
55	O
=	O
2	O
.	O
627	O
","	O
P	O
<	O
0	O
.	O
5	O
;	O
Figure	O
2a	O
).	O
Body	O
weight	O
did	O
not	O
differ	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
receiving	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
","	O
0	O
.	O
32	O
","	O
and	O
0	O
.	O
32	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
(	O
P	O
>	O
0	O
.	O
86	O
;	O
Figure	O
2b	O
)	O
or	O
either	O
antagonist	O
(	O
P	O
>	O
0	O
.	O
93	O
;	O
Figure	O
3a	O
).	O
Neither	O
of	O
the	O
agonists	O
altered	O
weight	O
gain	O
relative	O
to	O
vehicle	O
in	O
cremophor	B-Chemical
-	O
treated	O
groups	O
(	O
P	O
=	O
0	O
.	O
137	O
;	O
data	O
not	O
shown	O
).	O
Neither	O
the	O
CB1	O
antagonist	O
AM251	B-Chemical
nor	O
the	O
CB2	O
antagonist	O
AM630	B-Chemical
altered	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
or	O
cold	O
allodynia	O
.	O
a	O
.	O
No	O
changes	O
in	O
body	O
weight	O
","	O
responsiveness	O
to	O
b	O
.	O
mechanical	O
","	O
or	O
c	O
.	O
cold	O
stimulation	O
were	O
observed	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
receiving	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
or	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
relative	O
to	O
Taxol	B-Chemical
-	O
vehicle	O
animals	O
.	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
^	O
P	O
<	O
0	O
.	O
5	O
","	O
^^	O
P	O
<	O
0	O
.	O
1	O
","	O
^^^	O
P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
Taxol	B-Chemical
-	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
#	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
Ï•P	O
<	O
0	O
.	O
5	O
Taxol	B-Chemical
-	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
Taxol	B-Chemical
-	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
and	O
Cremophor	B-Chemical
-	O
Vehicle	O
.	O
Doses	O
are	O
in	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
(	O
ANOVA	O
;	O
Dunnett	O
and	O
Tukey	O
post	O
-	O
hoc	O
tests	O
).	O
N	O
=	O
10	O
â€“	O
18	O
per	O
group	O
.	O
Effects	O
of	O
prophylactic	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
and	O
AM1710	B-Chemical
treatment	O
on	O
paclitaxel	B-Chemical
-	O
evoked	O
mechanical	O
allodynia	O
Anti	O
-	O
allodynic	O
effects	O
of	O
the	O
mixed	O
CB1	O
/	O
CB2	O
agonist	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
Paclitaxel	B-Chemical
-	O
treated	O
animals	O
receiving	O
vehicle	O
infusions	O
developed	O
mechanical	O
allodynia	O
relative	O
to	O
cremophor	B-Chemical
-	O
treated	O
counterparts	O
;	O
mechanical	O
allodynia	O
was	O
apparent	O
on	O
day	O
2	O
and	O
persisted	O
until	O
the	O
final	O
test	O
day	O
prior	O
to	O
pump	O
removal	O
(	O
day	O
20	O
)	O
(	O
F48	O
","	O
660	O
=	O
3	O
.	O
880	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
1	O
for	O
each	O
comparison	O
;	O
Figure	O
2c	O
).	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
produced	O
a	O
transient	O
antinociceptive	O
effect	O
prior	O
to	O
paclitaxel	B-Chemical
treatment	O
on	O
day	O
-	O
2	O
(	O
P	O
<	O
0	O
.	O
5	O
);	O
this	O
antinociceptive	O
effect	O
was	O
observed	O
relative	O
to	O
paclitaxel	B-Chemical
-	O
treated	O
groups	O
receiving	O
either	O
vehicle	O
or	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
1	O
.	O
0	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.).	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
blocked	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
(	O
F4	O
","	O
55	O
=	O
32	O
.	O
964	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
Figure	O
2c	O
)	O
and	O
normalized	O
mechanical	O
thresholds	O
relative	O
to	O
the	O
Taxol	B-Chemical
-	O
vehicle	O
group	O
at	O
all	O
time	O
points	O
(	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
also	O
suppressed	O
the	O
development	O
of	O
paclitaxel	B-Chemical
-	O
evoked	O
mechanical	O
allodynia	O
over	O
the	O
time	O
course	O
corresponding	O
to	O
drug	O
delivery	O
(	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
)	O
but	O
failed	O
to	O
normalize	O
thresholds	O
relative	O
to	O
cremophor	B-Chemical
-	O
vehicle	O
levels	O
.	O
Anti	O
-	O
allodynic	O
effects	O
of	O
the	O
CB2	O
agonist	O
AM1710	B-Chemical
AM1710	B-Chemical
(	O
3	O
.	O
2	O
and	O
0	O
.	O
32	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
blocked	O
development	O
of	O
paclitaxel	B-Chemical
-	O
evoked	O
mechanical	O
allodynia	O
(	O
F4	O
","	O
59	O
=	O
41	O
.	O
988	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
Figure	O
2d	O
)	O
over	O
the	O
time	O
course	O
corresponding	O
to	O
drug	O
delivery	O
(	O
F48	O
","	O
708	O
=	O
5	O
.	O
186	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
1	O
for	O
each	O
comparison	O
).	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
and	O
0	O
.	O
32	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
increased	O
mechanical	O
withdrawal	O
thresholds	O
relative	O
to	O
the	O
Taxol	B-Chemical
-	O
vehicle	O
group	O
beginning	O
on	O
day	O
4	O
and	O
this	O
effect	O
was	O
maintained	O
for	O
the	O
duration	O
of	O
the	O
study	O
(	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
The	O
high	O
dose	O
of	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
preferentially	O
increased	O
mechanical	O
paw	O
withdrawal	O
thresholds	O
relative	O
to	O
the	O
middle	O
dose	O
(	O
0	O
.	O
32	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
from	O
days	O
12	O
â€“	O
20	O
(	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
Moreover	O
","	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
)	O
normalized	O
paw	O
withdrawal	O
thresholds	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
to	O
those	O
observed	O
in	O
the	O
cremophor	B-Chemical
-	O
vehicle	O
group	O
at	O
all	O
time	O
points	O
.	O
Effects	O
of	O
prophylactic	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
and	O
AM1710	B-Chemical
treatment	O
on	O
paclitaxel	B-Chemical
-	O
evoked	O
cold	O
allodynia	O
Anti	O
-	O
allodynic	O
effects	O
of	O
the	O
mixed	O
CB1	O
/	O
CB2	O
agonist	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
Paclitaxel	B-Chemical
-	O
induced	O
cold	O
allodynia	O
developed	O
by	O
day	O
5	O
and	O
was	O
stable	O
until	O
the	O
final	O
test	O
day	O
associated	O
with	O
drug	O
delivery	O
(	O
day	O
21	O
)	O
(	O
F20	O
","	O
275	O
=	O
7	O
.	O
197	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
2e	O
).	O
The	O
middle	O
and	O
low	O
doses	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
and	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
blocked	O
development	O
of	O
cold	O
allodynia	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
(	O
F4	O
","	O
55	O
=	O
11	O
.	O
428	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
2e	O
)	O
for	O
the	O
duration	O
of	O
drug	O
delivery	O
.	O
The	O
high	O
dose	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
1	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
failed	O
to	O
fully	O
suppress	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
cold	O
allodynia	O
.	O
However	O
","	O
animals	O
in	O
this	O
group	O
nonetheless	O
showed	O
protection	O
against	O
cold	O
allodynia	O
relative	O
to	O
paclitaxel	B-Chemical
-	O
vehicle	O
treated	O
animals	O
at	O
some	O
observation	O
intervals	O
(	O
i	O
.	O
e	O
".,"	O
days	O
11	O
and	O
21	O
;	O
P	O
<	O
0	O
.	O
1	O
).	O
Anti	O
-	O
allodynic	O
effects	O
of	O
the	O
CB2	O
-	O
preferring	O
agonist	O
AM1710	B-Chemical
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
cold	O
allodynia	O
(	O
F4	O
","	O
59	O
=	O
14	O
.	O
299	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
)	O
over	O
the	O
time	O
course	O
of	O
drug	O
delivery	O
(	O
F20	O
","	O
295	O
=	O
6	O
.	O
871	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
2f	O
).	O
Lower	O
doses	O
of	O
AM1710	B-Chemical
(	O
0	O
.	O
32	O
and	O
0	O
.	O
32	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
had	O
a	O
shorter	O
duration	O
of	O
action	O
;	O
suppression	O
of	O
cold	O
allodynia	O
was	O
only	O
observed	O
until	O
day	O
11	O
(	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
Comparison	O
of	O
anti	O
-	O
allodynic	O
efficacy	O
of	O
AM1710	B-Chemical
and	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
We	O
compared	O
the	O
anti	O
-	O
allodynic	O
efficacy	O
of	O
the	O
maximally	O
efficacious	O
doses	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
under	O
analogous	O
conditions	O
(	O
Figure	O
4	O
).	O
Both	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
elevated	O
mechanical	O
withdrawal	O
thresholds	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
relative	O
to	O
cremophor	B-Chemical
-	O
vehicle	O
treated	O
rats	O
(	O
F5	O
","	O
66	O
=	O
66	O
.	O
292	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
1	O
for	O
each	O
comparison	O
;	O
Figure	O
4a	O
)	O
from	O
day	O
4	O
through	O
the	O
final	O
test	O
day	O
corresponding	O
to	O
drug	O
delivery	O
(	O
F60	O
","	O
792	O
=	O
4	O
.	O
888	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
normalized	O
mechanical	O
withdrawal	O
thresholds	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
groups	O
with	O
two	O
exceptions	O
;	O
a	O
transient	O
drop	O
in	O
threshold	O
on	O
days	O
8	O
and	O
16	O
was	O
observed	O
relative	O
to	O
the	O
cremophor	B-Chemical
-	O
vehicle	O
group	O
(	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
By	O
contrast	O
","	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
effectively	O
normalized	O
mechanical	O
thresholds	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
to	O
those	O
observed	O
in	O
the	O
cremophor	B-Chemical
-	O
vehicle	O
group	O
.	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
and	O
AM1710	B-Chemical
suppressed	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
cold	O
allodynia	O
with	O
similar	O
efficacy	O
(	O
F5	O
","	O
66	O
=	O
12	O
.	O
365	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
4b	O
)	O
over	O
the	O
time	O
course	O
(	O
F25	O
","	O
330	O
=	O
6	O
.	O
892	O
","	O
P	O
<	O
0	O
.	O
1	O
).	O
Neither	O
agonist	O
produced	O
antinociception	O
to	O
either	O
mechanical	O
or	O
cold	O
stimulation	O
in	O
animals	O
that	O
received	O
cremophor	B-Chemical
vehicle	O
in	O
lieu	O
of	O
paclitaxel	B-Chemical
.	O
The	O
mixed	O
cannabinoid	B-Chemical
CB1	O
/	O
CB2	O
agonist	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
the	O
CB2	O
-	O
preferring	O
agonist	O
","	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
the	O
development	O
of	O
both	O
a	O
.	O
mechanical	O
and	O
b	O
.	O
cold	O
allodynia	O
associated	O
with	O
paclitaxel	B-Chemical
treatment	O
.	O
No	O
antinociception	O
was	O
observed	O
in	O
cremophor	B-Chemical
animals	O
treated	O
with	O
either	O
cannabinoid	B-Chemical
agonist	O
in	O
response	O
to	O
mechanical	O
or	O
cold	O
stimulation	O
.	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
1	O
",***"	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
#	O
P	O
<	O
0	O
.	O
5	O
","	O
##	O
P	O
<	O
0	O
.	O
1	O
","	O
###	O
P	O
<	O
0	O
.	O
1	O
All	O
conditions	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
(	O
ANOVA	O
;	O
Dunnett	O
and	O
Tukey	O
post	O
-	O
hoc	O
tests	O
).	O
N	O
=	O
10	O
â€“	O
18	O
per	O
group	O
.	O
Pharmacological	O
specificity	O
Mechanical	O
allodynia	O
Pharmacological	O
specificity	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
-	O
mediated	O
anti	O
-	O
allodynia	O
Simultaneous	O
infusion	O
of	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
anti	O
-	O
allodynic	O
effects	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
(	O
F4	O
","	O
57	O
=	O
38	O
.	O
335	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
Figure	O
5a	O
)	O
beginning	O
on	O
day	O
6	O
and	O
lasting	O
through	O
the	O
final	O
test	O
day	O
(	O
day	O
20	O
)	O
corresponding	O
to	O
active	O
drug	O
delivery	O
(	O
F48	O
","	O
684	O
=	O
4	O
.	O
112	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
The	O
CB2	O
-	O
specific	O
antagonist	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
)	O
showed	O
inconsistent	O
efficacy	O
in	O
blocking	O
anti	O
-	O
allodynic	O
effects	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
(	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
Pharmacological	O
specificity	O
of	O
cannabinoid	B-Chemical
agonist	O
-	O
induced	O
suppression	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
and	O
cold	O
allodynia	O
.	O
a	O
.	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
)-	O
mediated	O
suppression	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
was	O
dominated	O
by	O
CB1	O
receptor	O
activation	O
with	O
some	O
involvement	O
of	O
CB2	O
receptors	O
.	O
b	O
.	O
The	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
)-	O
induced	O
suppression	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
was	O
blocked	O
by	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
but	O
not	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)).	O
c	O
.	O
Neither	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
nor	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
reliably	O
altered	O
the	O
anti	O
-	O
allodynic	O
effects	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
following	O
acetone	B-Chemical
application	O
.	O
d	O
.	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
"),"	O
but	O
not	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
"),"	O
blocked	O
the	O
anti	O
-	O
allodynic	O
effects	O
of	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
to	O
cold	O
stimulation	O
.	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
#	O
P	O
<	O
0	O
.	O
5	O
","	O
##	O
P	O
<	O
0	O
.	O
1	O
","	O
###	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
++	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Taxol	B-Chemical
-	O
Agonist	O
","	O
xxP	O
<	O
0	O
.	O
1	O
","	O
xxxP	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
and	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM251	B-Chemical
(	O
3	O
)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
tP	O
<	O
0	O
.	O
5	O
vs	O
.	O
Taxol	B-Chemical
-	O
Agonist	O
","	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM630	B-Chemical
(	O
3	O
"),"	O
and	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
Ï•P	O
<	O
0	O
.	O
5	O
","	O
Ï•Ï•P	O
<	O
0	O
.	O
1	O
","	O
Ï•Ï•Ï•P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM630	B-Chemical
(	O
3	O
)	O
and	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM251	B-Chemical
(	O
3	O
)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Agonist	O
","	O
âŸ‚	O
P	O
<	O
0	O
.	O
5	O
","	O
âŸ‚âŸ‚	O
P	O
<	O
0	O
.	O
1	O
","	O
âŸ‚âŸ‚âŸ‚	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Taxol	B-Chemical
-	O
Agonist	O
","	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM251	B-Chemical
(	O
3	O
"),"	O
and	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
Î´P	O
<	O
0	O
.	O
5	O
","	O
Î´Î´Î´P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
","	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM251	B-Chemical
(	O
3	O
"),"	O
and	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM630	B-Chemical
(	O
3	O
)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
.	O
Doses	O
are	O
in	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
(	O
ANOVA	O
;	O
Dunnett	O
and	O
Tukey	O
post	O
-	O
hoc	O
tests	O
).	O
N	O
=	O
10	O
â€“	O
18	O
per	O
group	O
.	O
Pharmacological	O
specificity	O
of	O
AM1710	B-Chemical
-	O
mediated	O
anti	O
-	O
allodynia	O
Simultaneous	O
infusion	O
of	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
anti	O
-	O
allodynic	O
effects	O
of	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
(	O
F4	O
","	O
61	O
=	O
44	O
.	O
885	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
Figure	O
5b	O
)	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
rats	O
from	O
days	O
8	O
through	O
20	O
(	O
F48	O
","	O
732	O
=	O
6	O
.	O
161	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
By	O
contrast	O
","	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
failed	O
to	O
block	O
the	O
anti	O
-	O
allodynic	O
effects	O
of	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
);	O
thresholds	O
differed	O
reliably	O
from	O
paclitaxel	B-Chemical
-	O
vehicle	O
treatment	O
throughout	O
the	O
observation	O
interval	O
(	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
Effects	O
of	O
antagonists	O
administered	O
alone	O
Neither	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
nor	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
)	O
altered	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
relative	O
to	O
vehicle	O
treatment	O
.	O
Paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
developed	O
equivalently	O
in	O
groups	O
receiving	O
infusions	O
of	O
either	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
or	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
)	O
relative	O
to	O
cremophor	B-Chemical
-	O
vehicle	O
(	O
F3	O
","	O
44	O
=	O
58	O
.	O
77	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
3b	O
)	O
throughout	O
the	O
time	O
course	O
(	O
F36	O
","	O
528	O
=	O
6	O
.	O
134	O
","	O
P	O
<	O
0	O
.	O
1	O
).	O
Cold	O
allodynia	O
Pharmacological	O
specificity	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
effects	O
on	O
cold	O
allodynia	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
)-	O
induced	O
suppression	O
of	O
cold	O
allodynia	O
was	O
not	O
reliably	O
blocked	O
by	O
either	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
or	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
(	O
F4	O
","	O
57	O
=	O
10	O
.	O
343	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
Figure	O
5c	O
)	O
(	O
F20	O
","	O
285	O
=	O
8	O
.	O
415	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
Pharmacological	O
specificity	O
of	O
AM1710	B-Chemical
-	O
mediated	O
anti	O
-	O
allodynia	O
The	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
)-	O
induced	O
suppression	O
of	O
cold	O
allodynia	O
was	O
blocked	O
by	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
(	O
F4	O
","	O
61	O
=	O
14	O
.	O
178	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
Figure	O
5d	O
)	O
but	O
not	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.).	O
This	O
blockade	O
was	O
fully	O
apparent	O
by	O
days	O
17	O
and	O
21	O
post	O
-	O
paclitaxel	B-Chemical
(	O
F20	O
","	O
305	O
=	O
8	O
.	O
201	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
Cold	O
allodynia	O
developed	O
similarly	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
rats	O
that	O
received	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
together	O
with	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
alone	O
.	O
Effects	O
of	O
antagonists	O
administered	O
alone	O
Paclitaxel	B-Chemical
-	O
treated	O
animals	O
receiving	O
either	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
or	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
developed	O
cold	O
allodynia	O
(	O
F3	O
","	O
44	O
=	O
12	O
.	O
138	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
Figure	O
3c	O
)	O
relative	O
to	O
cremophor	B-Chemical
-	O
vehicle	O
control	O
animals	O
(	O
F15	O
","	O
220	O
=	O
7	O
.	O
742	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
Taxol	B-Chemical
-	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
animals	O
showed	O
attenuated	O
cold	O
allodynia	O
relative	O
to	O
Taxol	B-Chemical
-	O
vehicle	O
animals	O
on	O
days	O
11	O
","	O
17	O
and	O
21	O
(	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
)	O
Responsiveness	O
to	O
acetone	B-Chemical
was	O
","	O
nonetheless	O
","	O
elevated	O
relative	O
to	O
cremophor	B-Chemical
-	O
vehicle	O
treatment	O
at	O
each	O
time	O
point	O
(	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
Protective	O
effects	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
and	O
AM1710	B-Chemical
following	O
drug	O
removal	O
Mechanical	O
allodynia	O
Paclitaxel	B-Chemical
produced	O
long	O
-	O
lasting	O
mechanical	O
allodynia	O
in	O
rats	O
receiving	O
infusions	O
of	O
vehicle	O
relative	O
to	O
cremophor	B-Chemical
-	O
vehicle	O
treatment	O
(	O
F75	O
","	O
500	O
=	O
2	O
.	O
218	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
6a	O
);	O
these	O
effects	O
persisted	O
until	O
the	O
final	O
test	O
day	O
(	O
day	O
50	O
).	O
We	O
next	O
examined	O
the	O
protective	O
effects	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
and	O
AM1710	B-Chemical
following	O
cessation	O
of	O
drug	O
delivery	O
(	O
Figure	O
6	O
).	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
and	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
".,"	O
delivered	O
from	O
days	O
-	O
6	O
through	O
22	O
)	O
blocked	O
the	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
(	O
F3	O
","	O
20	O
=	O
48	O
.	O
189	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
Figure	O
6a	O
)	O
for	O
approximately	O
11	O
days	O
following	O
cessation	O
of	O
drug	O
delivery	O
(	O
F75	O
","	O
500	O
=	O
2	O
.	O
218	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
Similarly	O
","	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
protected	O
against	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
for	O
17	O
days	O
following	O
drug	O
removal	O
(	O
i	O
.	O
e	O
".,"	O
day	O
38	O
);	O
(	O
F3	O
","	O
22	O
=	O
41	O
.	O
754	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
6b	O
).	O
The	O
low	O
dose	O
of	O
AM1710	B-Chemical
(	O
0	O
.	O
32	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
also	O
increased	O
paw	O
withdrawal	O
thresholds	O
up	O
to	O
17	O
days	O
following	O
drug	O
removal	O
(	O
P	O
<	O
0	O
.	O
1	O
for	O
each	O
comparison	O
);	O
however	O
","	O
thresholds	O
in	O
this	O
group	O
failed	O
to	O
differ	O
from	O
the	O
paclitaxel	B-Chemical
-	O
vehicle	O
condition	O
on	O
several	O
days	O
(	O
days	O
28	O
and	O
34	O
"),"	O
suggesting	O
that	O
mechanical	O
allodynia	O
was	O
beginning	O
to	O
develop	O
.	O
The	O
high	O
dose	O
of	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
produced	O
longer	O
protection	O
(	O
F75	O
","	O
550	O
=	O
2	O
.	O
584	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
6c	O
)	O
against	O
mechanical	O
allodynia	O
development	O
compared	O
to	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
F3	O
","	O
22	O
=	O
69	O
.	O
8	O
","	O
P	O
<	O
0	O
.	O
1	O
).	O
Protective	O
effects	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
and	O
AM1710	B-Chemical
on	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
following	O
drug	O
removal	O
.	O
a	O
.	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
11	O
days	O
(	O
day	O
32	O
)	O
following	O
drug	O
removal	O
.	O
b	O
.	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
and	O
0	O
.	O
32	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
hypersensitivity	O
to	O
mechanical	O
stimulation	O
up	O
to	O
17	O
days	O
following	O
drug	O
removal	O
(	O
until	O
day	O
38	O
).	O
c	O
.	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
produced	O
a	O
longer	O
duration	O
of	O
protection	O
against	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
relative	O
to	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.).	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
#	O
P	O
<	O
0	O
.	O
5	O
","	O
##	O
P	O
<	O
0	O
.	O
1	O
","	O
###	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
âŸ‚	O
P	O
<	O
0	O
.	O
5	O
","	O
âŸ‚âŸ‚	O
P	O
<	O
0	O
.	O
1	O
","	O
âŸ‚âŸ‚âŸ‚	O
P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
(	O
both	O
doses	O
)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
^	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
all	O
groups	O
","	O
$	O
P	O
<	O
0	O
.	O
5	O
","	O
$$$	O
P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
(	O
both	O
doses	O
)	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
Î±P	O
<	O
0	O
.	O
5	O
Taxol	B-Chemical
-	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
+	O
P	O
<	O
0	O
.	O
5	O
","	O
++	O
P	O
<	O
0	O
.	O
1	O
","	O
Taxol	B-Chemical
-	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
Taxol	B-Chemical
-	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
Ï•P	O
<	O
0	O
.	O
5	O
","	O
Ï•Ï•P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
Î´P	O
<	O
0	O
.	O
5	O
","	O
Î´Î´P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
tP	O
<	O
0	O
.	O
5	O
","	O
ttP	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
Taxol	B-Chemical
-	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
(	O
ANOVA	O
;	O
Dunnett	O
and	O
Tukey	O
post	O
hoc	O
tests	O
).	O
N	O
=	O
4	O
â€“	O
8	O
per	O
group	O
.	O
Cold	O
allodynia	O
Paclitaxel	B-Chemical
increased	O
responsiveness	O
to	O
acetone	B-Chemical
in	O
animals	O
receiving	O
infusions	O
of	O
vehicle	O
throughout	O
the	O
time	O
course	O
(	O
F30	O
","	O
200	O
=	O
3	O
.	O
784	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
7a	O
).	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
and	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
cold	O
allodynia	O
(	O
F3	O
","	O
20	O
=	O
12	O
.	O
367	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
Figure	O
7a	O
)	O
up	O
to	O
12	O
(	O
day	O
33	O
)	O
and	O
18	O
days	O
(	O
day	O
39	O
)	O
following	O
cessation	O
of	O
analgesic	O
drug	O
delivery	O
","	O
respectively	O
.	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
development	O
and	O
postponed	O
emergence	O
of	O
cold	O
allodynia	O
(	O
F3	O
","	O
22	O
=	O
16	O
.	O
132	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
7b	O
)	O
for	O
18	O
days	O
following	O
cessation	O
of	O
drug	O
delivery	O
(	O
F30	O
","	O
220	O
=	O
4	O
.	O
709	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
The	O
low	O
dose	O
of	O
AM1710	B-Chemical
(	O
0	O
.	O
32	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
cold	O
allodynia	O
through	O
day	O
33	O
(	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparisons	O
"),"	O
indicating	O
a	O
shorter	O
duration	O
of	O
protection	O
relative	O
to	O
the	O
high	O
dose	O
.	O
Both	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
protected	O
against	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
cold	O
allodynia	O
(	O
F3	O
","	O
22	O
=	O
13	O
.	O
216	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
7c	O
)	O
over	O
the	O
time	O
course	O
(	O
F30	O
","	O
220	O
=	O
4	O
.	O
439	O
","	O
P	O
<	O
0	O
.	O
1	O
)	O
The	O
high	O
dose	O
of	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
delayed	O
the	O
emergence	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
cold	O
allodynia	O
longer	O
than	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
).	O
Protective	O
effects	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
and	O
AM1710	B-Chemical
on	O
paclitaxel	B-Chemical
-	O
induced	O
cold	O
allodynia	O
following	O
drug	O
removal	O
.	O
a	O
.	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
and	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
paclitaxel	B-Chemical
-	O
induced	O
cold	O
allodynia	O
for	O
12	O
and	O
18	O
days	O
(	O
until	O
day	O
33	O
and	O
39	O
","	O
respectively	O
)	O
following	O
cessation	O
of	O
drug	O
delivery	O
.	O
b	O
.	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
cold	O
allodynia	O
for	O
18	O
days	O
following	O
drug	O
removal	O
(	O
until	O
day	O
39	O
).	O
c	O
.	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
produced	O
a	O
longer	O
duration	O
of	O
protection	O
against	O
cold	O
allodynia	O
compared	O
to	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.).	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
#	O
P	O
<	O
0	O
.	O
5	O
","	O
##	O
P	O
<	O
0	O
.	O
1	O
","	O
###	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
âŸ‚	O
P	O
<	O
0	O
.	O
5	O
","	O
âŸ‚âŸ‚	O
P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
(	O
both	O
doses	O
)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
Ï•P	O
<	O
0	O
.	O
5	O
","	O
Ï•Ï•P	O
<	O
0	O
.	O
1	O
","	O
Ï•Ï•Ï•P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
Taxol	B-Chemical
-	O
WIN	B-Chemical
-	I-Chemical
55	I-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
(	O
ANOVA	O
;	O
Dunnett	O
and	O
Tukey	O
post	O
-	O
hoc	O
tests	O
).	O
N	O
=	O
4	O
â€“	O
8	O
per	O
group	O
.	O
Pharmacological	O
specificity	O
of	O
protective	O
effects	O
Mechanical	O
allodynia	O
Animals	O
in	O
the	O
Taxol	B-Chemical
-	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
)	O
+	O
AM630	B-Chemical
(	O
3	O
)	O
group	O
did	O
not	O
fully	O
develop	O
mechanical	O
allodynia	O
until	O
day	O
34	O
(	O
F4	O
","	O
27	O
=	O
41	O
.	O
884	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
8a	O
"),"	O
consistent	O
with	O
the	O
anti	O
-	O
allodynic	O
efficacy	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
alone	O
.	O
The	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
+	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
group	O
only	O
developed	O
mechanical	O
allodynia	O
after	O
day	O
38	O
(	O
F4	O
","	O
27	O
=	O
25	O
.	O
46	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
8b	O
"),"	O
when	O
protective	O
effects	O
of	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
alone	O
were	O
no	O
longer	O
apparent	O
.	O
Pharmacological	O
specificity	O
of	O
cannabinoid	B-Chemical
-	O
mediated	O
protection	O
against	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
following	O
drug	O
removal	O
.	O
a	O
.	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
)-	O
mediated	O
anti	O
-	O
allodynia	O
following	O
drug	O
removal	O
was	O
dominated	O
by	O
CB1	O
receptor	O
activation	O
.	O
b	O
.	O
The	O
protective	O
effects	O
of	O
AM1710	B-Chemical
were	O
blocked	O
by	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
but	O
not	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)).	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
#	O
P	O
<	O
0	O
.	O
5	O
","	O
##	O
P	O
<	O
0	O
.	O
1	O
","	O
###	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
xP	O
<	O
0	O
.	O
5	O
","	O
xxP	O
<	O
0	O
.	O
1	O
","	O
xxxP	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
and	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM251	B-Chemical
(	O
3	O
)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
âŸ‚	O
P	O
<	O
0	O
.	O
5	O
","	O
âŸ‚âŸ‚	O
P	O
<	O
0	O
.	O
1	O
","	O
âŸ‚âŸ‚âŸ‚	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Taxol	B-Chemical
-	O
Agonist	O
","	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM251	B-Chemical
(	O
3	O
)	O
and	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
Î±P	O
<	O
0	O
.	O
5	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM630	B-Chemical
(	O
3	O
)	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
Î²P	O
<	O
0	O
.	O
5	O
","	O
Î²Î²P	O
<	O
0	O
.	O
1	O
","	O
Î²Î²Î²P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
","	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM251	B-Chemical
(	O
3	O
"),"	O
and	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM630	B-Chemical
(	O
3	O
)	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
Ï•Ï•P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM251	B-Chemical
(	O
3	O
"),"	O
and	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM630	B-Chemical
(	O
3	O
)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Agonist	O
and	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
+	O
P	O
<	O
0	O
.	O
5	O
","	O
++	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Taxol	B-Chemical
-	O
Agonist	O
","	O
ttP	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM251	B-Chemical
(	O
3	O
)	O
and	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM630	B-Chemical
(	O
3	O
)	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
.	O
Doses	O
are	O
in	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
(	O
ANOVA	O
;	O
Dunnett	O
and	O
Tukey	O
post	O
-	O
hoc	O
tests	O
).	O
N	O
=	O
6	O
â€“	O
8	O
per	O
group	O
.	O
Cold	O
allodynia	O
Neither	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
nor	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
blocked	O
anti	O
-	O
allodynic	O
effects	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
(	O
F4	O
","	O
27	O
=	O
8	O
.	O
965	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
9a	O
).	O
Both	O
groups	O
showed	O
anti	O
-	O
allodynic	O
effects	O
relative	O
to	O
the	O
cremophor	B-Chemical
-	O
vehicle	O
group	O
for	O
18	O
days	O
following	O
drug	O
removal	O
(	O
i	O
.	O
e	O
".,"	O
up	O
to	O
day	O
39	O
)	O
(	O
F40	O
","	O
270	O
=	O
3	O
.	O
677	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
The	O
anti	O
-	O
allodynic	O
effects	O
observed	O
in	O
the	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
blockade	O
conditions	O
outlasted	O
protective	O
effects	O
observed	O
with	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
administered	O
alone	O
.	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
blocked	O
anti	O
-	O
allodynic	O
effects	O
of	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
(	O
F4	O
","	O
27	O
=	O
12	O
.	O
388	O
","	O
P	O
<	O
0	O
.	O
1	O
","	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
;	O
Figure	O
9b	O
)	O
until	O
day	O
39	O
(	O
F40	O
","	O
270	O
=	O
3	O
.	O
687	O
","	O
P	O
<	O
0	O
.	O
1	O
).	O
By	O
contrast	O
","	O
the	O
Taxol	B-Chemical
-	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
+	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
group	O
did	O
not	O
develop	O
cold	O
allodynia	O
until	O
day	O
45	O
(	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
Pharmacological	O
specificity	O
of	O
cannabinoid	B-Chemical
-	O
mediated	O
protection	O
against	O
paclitaxel	B-Chemical
-	O
induced	O
cold	O
allodynia	O
following	O
drug	O
removal	O
.	O
a	O
.	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
)-	O
induced	O
protection	O
against	O
paclitaxel	B-Chemical
-	O
induced	O
cold	O
allodynia	O
was	O
not	O
blocked	O
by	O
either	O
a	O
CB1	O
(	O
AM251	B-Chemical
","	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
or	O
CB2	O
(	O
AM630	B-Chemical
","	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
antagonist	O
.	O
b	O
.	O
Protective	O
anti	O
-	O
allodynic	O
effects	O
associated	O
with	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
were	O
mediated	O
via	O
CB2	O
receptor	O
activation	O
.	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
#	O
P	O
<	O
0	O
.	O
5	O
","	O
##	O
P	O
<	O
0	O
.	O
1	O
","	O
###	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
+	O
P	O
<	O
0	O
.	O
5	O
","	O
++	O
P	O
<	O
0	O
.	O
1	O
vs	O
.	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM630	B-Chemical
(	O
3	O
"),"	O
xP	O
<	O
0	O
.	O
5	O
","	O
xxP	O
<	O
0	O
.	O
1	O
","	O
Taxol	B-Chemical
-	O
Agonist	O
and	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM251	B-Chemical
(	O
3	O
)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
âŸ‚	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
Taxol	B-Chemical
-	O
Agonist	O
","	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM251	B-Chemical
(	O
3	O
)	O
and	O
Cremophor	B-Chemical
-	O
Vehicle	O
Ï•P	O
<	O
0	O
.	O
5	O
","	O
Ï•Ï•Ï•P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
","	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM251	B-Chemical
(	O
3	O
)	O
and	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM630	B-Chemical
(	O
3	O
)	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
^^	O
P	O
<	O
0	O
.	O
1	O
Taxol	B-Chemical
-	O
Agonist	O
and	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM630	B-Chemical
(	O
3	O
)	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
Î±P	O
<	O
0	O
.	O
5	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM630	B-Chemical
(	O
3	O
)	O
and	O
Taxol	B-Chemical
-	O
Agonist	O
+	O
AM251	B-Chemical
(	O
3	O
)	O
vs	O
.	O
Cremophor	B-Chemical
-	O
Vehicle	O
.	O
All	O
doses	O
are	O
in	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
(	O
ANOVA	O
;	O
Dunnett	O
and	O
Tukey	O
post	O
-	O
hoc	O
tests	O
).	O
N	O
=	O
6	O
â€“	O
8	O
per	O
group	O
.	O
Locomotor	O
activity	O
Total	O
distance	O
traveled	O
did	O
not	O
differ	O
in	O
paclitaxel	B-Chemical
-	O
or	O
cremophor	B-Chemical
-	O
vehicle	O
groups	O
either	O
during	O
(	O
day	O
19	O
:	O
P	O
>	O
0	O
.	O
11	O
)	O
or	O
after	O
(	O
day	O
31	O
:	O
P	O
>	O
0	O
.	O
19	O
)	O
chronic	O
drug	O
infusion	O
(	O
Table	O
1	O
).	O
Moreover	O
","	O
antagonists	O
did	O
not	O
alter	O
locomotor	O
activity	O
relative	O
to	O
vehicle	O
during	O
infusion	O
(	O
day	O
19	O
:	O
P	O
>	O
0	O
.	O
31	O
).	O
The	O
combination	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
with	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
increased	O
total	O
distance	O
traveled	O
(	O
day	O
19	O
:	O
F5	O
","	O
54	O
=	O
2	O
.	O
951	O
","	O
P	O
<	O
0	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
relevant	O
comparison	O
;	O
Table	O
1	O
)	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
relative	O
to	O
cremophor	B-Chemical
-	O
vehicle	O
animals	O
.	O
After	O
completion	O
of	O
chronic	O
infusions	O
","	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
that	O
previously	O
received	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
in	O
combination	O
with	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
also	O
showed	O
increased	O
distance	O
traveled	O
relative	O
to	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
alone	O
(	O
day	O
31	O
:	O
F5	O
","	O
30	O
=	O
2	O
.	O
769	O
","	O
P	O
<	O
0	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
5	O
for	O
relevant	O
comparison	O
;	O
Table	O
1	O
).	O
There	O
were	O
no	O
differences	O
in	O
distance	O
traveled	O
in	O
any	O
AM1710	B-Chemical
-	O
treated	O
group	O
at	O
any	O
time	O
point	O
(	O
day	O
19	O
:	O
P	O
>	O
0	O
.	O
13	O
;	O
day	O
31	O
:	O
P	O
>	O
0	O
.	O
19	O
;	O
Table	O
1	O
).	O
Locomotor	O
activity	O
during	O
(	O
Day	O
19	O
)	O
and	O
after	O
(	O
Day	O
31	O
)	O
chronic	O
drug	O
infusions	O
Lumbar	O
spinal	O
cord	O
mRNA	O
levels	O
of	O
GFAP	O
","	O
CD11b	O
","	O
CB1	O
and	O
CB2	O
receptors	O
To	O
understand	O
the	O
potential	O
molecular	O
targets	O
mediating	O
the	O
suppression	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathy	O
by	O
WIN55212	B-Chemical
-	I-Chemical
2	I-Chemical
and	O
AM1710	B-Chemical
after	O
cessation	O
of	O
drug	O
delivery	O
","	O
we	O
examined	O
the	O
mRNA	O
levels	O
of	O
markers	O
of	O
astrocytes	O
and	O
microglia	O
as	O
well	O
as	O
CB1	O
and	O
CB2	O
receptor	O
mRNA	O
levels	O
.	O
We	O
used	O
RT	O
-	O
PCR	O
to	O
measure	O
the	O
mRNA	O
levels	O
of	O
the	O
astrocytic	O
marker	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
and	O
microglial	O
marker	O
cluster	O
of	O
differentiation	O
molecule	O
11B	O
(	O
CD11b	O
)	O
(	O
Figure	O
10a	O
).	O
RT	O
-	O
PCR	O
analysis	O
revealed	O
a	O
trend	O
towards	O
increased	O
expression	O
of	O
GFAP	O
(	O
P	O
=	O
0	O
.	O
59	O
","	O
one	O
-	O
tailed	O
planned	O
comparison	O
t	O
-	O
test	O
;	O
Figure	O
10a	O
)	O
in	O
lumbar	O
spinal	O
cords	O
of	O
paclitaxel	B-Chemical
-	O
relative	O
to	O
cremophor	B-Chemical
-	O
vehicle	O
controls	O
on	O
day	O
22	O
.	O
No	O
alterations	O
in	O
CD11b	O
mRNA	O
levels	O
were	O
observed	O
at	O
the	O
same	O
time	O
point	O
(	O
P	O
=	O
0	O
.	O
413	O
).	O
Neither	O
infusion	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
nor	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
altered	O
GFAP	O
or	O
CD11b	O
mRNA	O
expression	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
(	O
day	O
22	O
;	O
P	O
>	O
0	O
.	O
122	O
for	O
each	O
comparison	O
;	O
Figure	O
10a	O
).	O
Cannabinoid	O
receptor	O
activation	O
by	O
chronic	O
agonists	O
may	O
produce	O
compensatory	O
changes	O
in	O
receptor	O
levels	O
[	O
16	O
"],"	O
and	O
pathological	O
pain	O
may	O
alter	O
expression	O
levels	O
of	O
cannabinoid	O
receptors	O
[	O
24	O
-	O
27	O
].	O
We	O
","	O
therefore	O
","	O
measured	O
levels	O
of	O
CB1	O
and	O
CB2	O
mRNA	O
after	O
various	O
treatments	O
(	O
Figure	O
10b	O
).	O
Both	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
increased	O
mRNA	O
expression	O
of	O
cannabinoid	B-Chemical
CB1	O
(	O
F5	O
","	O
23	O
=	O
9	O
.	O
527	O
","	O
P	O
<	O
0	O
.	O
1	O
)	O
and	O
CB2	O
(	O
F5	O
","	O
23	O
=	O
15	O
.	O
117	O
","	O
P	O
<	O
0	O
.	O
1	O
;	O
Figure	O
10b	O
)	O
receptors	O
in	O
lumbar	O
spinal	O
cord	O
.	O
These	O
agonist	O
-	O
induced	O
increases	O
in	O
CB1	O
and	O
CB2	O
receptor	O
mRNA	O
expression	O
were	O
blocked	O
in	O
animals	O
that	O
received	O
concurrent	O
administration	O
of	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
(	O
P	O
<	O
0	O
.	O
5	O
for	O
each	O
comparison	O
).	O
Impact	O
of	O
paclitaxel	B-Chemical
and	O
long	O
term	O
drug	O
infusions	O
on	O
mRNA	O
levels	O
of	O
astrocytes	O
","	O
microglia	O
","	O
and	O
cannabinoid	O
receptors	O
in	O
lumbar	O
spinal	O
cord	O
.	O
a	O
.	O
Paclitaxel	B-Chemical
marginally	O
altered	O
long	O
term	O
expression	O
of	O
mRNA	O
markers	O
of	O
astrocytes	O
(	O
GFAP	O
)	O
but	O
not	O
microglia	O
(	O
CD11b	O
)	O
in	O
lumbar	O
spinal	O
cord	O
(	O
L4	O
-	O
L6	O
)	O
tissue	O
samples	O
relative	O
to	O
cremophor	B-Chemical
conditions	O
.	O
Chronic	O
infusions	O
of	O
the	O
mixed	O
CB1	O
/	O
CB2	O
agonist	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
the	O
CB2	O
-	O
preferring	O
agonist	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
did	O
not	O
alter	O
either	O
GFAP	O
or	O
CD11b	O
b	O
.	O
but	O
increased	O
both	O
CB1	O
and	O
CB2	O
mRNA	O
expression	O
in	O
the	O
same	O
tissues	O
.	O
Transcriptional	O
regulation	O
of	O
CB1	O
and	O
CB2	O
mRNAs	O
were	O
blocked	O
by	O
the	O
CB2	O
antagonist	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.).	O
+	O
P	O
=	O
0	O
.	O
59	O
vs	O
.	O
cremophor	B-Chemical
-	O
vehicle	O
(	O
planned	O
comparison	O
one	O
-	O
tailed	O
t	O
-	O
test	O
"),"	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
","	O
vs	O
.	O
all	O
groups	O
except	O
Taxol	B-Chemical
-	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
"),"	O
#	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
Taxol	B-Chemical
-	O
Vehicle	O
","	O
Cremophor	B-Chemical
-	O
Vehicle	O
","	O
and	O
Taxol	B-Chemical
-	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
)	O
+	O
AM630	B-Chemical
(	O
3	O
)	O
(	O
ANOVA	O
;	O
Dunnett	O
and	O
Tukey	O
post	O
hoc	O
tests	O
).	O
N	O
=	O
4	O
per	O
group	O
.	O
Discussion	O
Prophylactic	O
administration	O
of	O
cannabinoid	B-Chemical
analgesics	O
protected	O
against	O
the	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
hypersensitivities	O
to	O
mechanical	O
and	O
cold	O
stimulation	O
in	O
a	O
preventative	O
fashion	O
.	O
Both	O
the	O
mixed	O
cannabinoid	B-Chemical
CB1	O
/	O
CB2	O
agonist	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
and	O
the	O
CB2	O
agonist	O
AM1710	B-Chemical
blocked	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
and	O
cold	O
allodynia	O
.	O
Strikingly	O
","	O
the	O
protective	O
prophylactic	O
effects	O
of	O
both	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
and	O
AM1710	B-Chemical
were	O
preserved	O
following	O
drug	O
removal	O
","	O
with	O
the	O
CB2	O
-	O
specific	O
agonist	O
providing	O
a	O
longer	O
duration	O
of	O
protection	O
against	O
allodynia	O
development	O
for	O
both	O
mechanical	O
and	O
cold	O
modalities	O
.	O
In	O
our	O
study	O
","	O
paclitaxel	B-Chemical
produced	O
marked	O
mechanical	O
and	O
cold	O
allodynia	O
but	O
not	O
heat	O
hyperalgesia	O
","	O
as	O
observed	O
in	O
a	O
different	O
dosing	O
paradigm	O
(	O
cumulative	O
dose	O
:	O
4	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.)	O
[	O
28	O
].	O
In	O
vehicle	O
(	O
cremophor	B-Chemical
)	O
treated	O
controls	O
","	O
the	O
most	O
efficacious	O
doses	O
of	O
these	O
cannabinoids	B-Chemical
also	O
failed	O
to	O
produce	O
antinociception	O
","	O
suggesting	O
that	O
cannabinoids	B-Chemical
were	O
anti	O
-	O
allodynic	O
rather	O
than	O
analgesic	O
under	O
these	O
conditions	O
.	O
Prophylactic	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
suppresses	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
and	O
cold	O
allodynia	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
and	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
suppressed	O
the	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
and	O
cold	O
allodynia	O
both	O
during	O
drug	O
delivery	O
and	O
following	O
drug	O
removal	O
.	O
Our	O
study	O
is	O
the	O
first	O
to	O
evaluate	O
duration	O
of	O
efficacy	O
","	O
dose	O
response	O
","	O
and	O
pharmacological	O
specificity	O
of	O
prophylactic	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
.	O
Anti	O
-	O
allodynic	O
effects	O
of	O
both	O
doses	O
were	O
present	O
11	O
(	O
mechanical	O
)	O
and	O
12	O
(	O
cold	O
)	O
days	O
following	O
cessation	O
of	O
drug	O
delivery	O
.	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.	O
)-	O
induced	O
suppression	O
of	O
mechanical	O
hypersensitivity	O
was	O
dominated	O
by	O
CB1	O
receptor	O
activation	O
because	O
anti	O
-	O
allodynic	O
efficacy	O
was	O
blocked	O
by	O
AM251	B-Chemical
.	O
The	O
CB2	O
antagonist	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
prevented	O
anti	O
-	O
allodynic	O
efficacy	O
of	O
AM1710	B-Chemical
but	O
failed	O
to	O
eliminate	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
-	O
mediated	O
anti	O
-	O
allodynia	O
.	O
Interestingly	O
","	O
blockade	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
-	O
mediated	O
anti	O
-	O
allodynic	O
effects	O
to	O
cold	O
was	O
not	O
achieved	O
with	O
either	O
antagonist	O
.	O
However	O
","	O
the	O
same	O
antagonist	O
infusion	O
conditions	O
blocked	O
either	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
mediated	O
suppression	O
of	O
mechanical	O
allodynia	O
(	O
AM251	B-Chemical
)	O
or	O
AM1710	B-Chemical
-	O
mediated	O
suppression	O
of	O
both	O
mechanical	O
and	O
cold	O
allodynia	O
(	O
AM630	B-Chemical
"),"	O
documenting	O
efficacy	O
of	O
antagonist	O
infusion	O
conditions	O
employed	O
here	O
.	O
We	O
could	O
find	O
only	O
one	O
report	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
-	O
induced	O
suppression	O
of	O
cold	O
allodynia	O
in	O
a	O
neuropathic	O
pain	O
model	O
(	O
spinal	O
nerve	O
ligation	O
)	O
where	O
pharmacological	O
specificity	O
was	O
assessed	O
;	O
anti	O
-	O
allodynic	O
effects	O
were	O
blocked	O
by	O
a	O
CB1	O
(	O
SR141716a	B-Chemical
)	O
but	O
not	O
a	O
CB2	O
(	O
SR144528	B-Chemical
)	O
antagonist	O
[	O
29	O
].	O
Blockade	O
of	O
both	O
CB1	O
and	O
CB2	O
receptors	O
may	O
be	O
required	O
to	O
fully	O
prevent	O
anti	O
-	O
allodynic	O
effects	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
.	O
However	O
","	O
limitations	O
in	O
compound	O
solubility	O
prohibited	O
co	O
-	O
administration	O
of	O
both	O
antagonists	O
in	O
one	O
pump	O
.	O
Few	O
studies	O
have	O
examined	O
cannabinoid	B-Chemical
-	O
mediated	O
modulation	O
of	O
cold	O
allodynia	O
and	O
/	O
or	O
its	O
development	O
in	O
neuropathic	O
pain	O
models	O
and	O
more	O
work	O
is	O
necessary	O
to	O
determine	O
functional	O
contributions	O
of	O
each	O
receptor	O
.	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
treatment	O
increased	O
both	O
CB1	O
and	O
CB2	O
receptor	O
mRNA	O
expression	O
within	O
lumbar	O
spinal	O
cord	O
of	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
on	O
day	O
22	O
","	O
an	O
effect	O
blocked	O
by	O
concurrent	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
treatment	O
.	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
also	O
ameliorates	O
established	O
paclitaxel	B-Chemical
-	O
induced	O
nociception	O
[	O
13	O
]	O
and	O
repeated	O
administration	O
(	O
1	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
Ã—	O
14	O
days	O
)	O
prevents	O
nociception	O
development	O
during	O
drug	O
delivery	O
[	O
11	O
].	O
Prophylactic	O
AM1710	B-Chemical
suppresses	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
and	O
cold	O
allodynia	O
Strikingly	O
","	O
doses	O
of	O
AM1710	B-Chemical
as	O
low	O
as	O
0	O
.	O
32	O
mg	O
/	O
kg	O
/	O
day	O
blocked	O
the	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
allodynia	O
in	O
our	O
study	O
and	O
these	O
effects	O
were	O
preserved	O
for	O
approximately	O
three	O
weeks	O
following	O
cessation	O
of	O
drug	O
delivery	O
.	O
Prophylactic	O
AM1710	B-Chemical
treatment	O
suppressed	O
development	O
of	O
both	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
and	O
cold	O
allodynia	O
","	O
with	O
high	O
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
and	O
low	O
(	O
0	O
.	O
32	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
doses	O
exhibiting	O
the	O
greatest	O
efficacy	O
.	O
A	O
similar	O
U	O
-	O
shaped	O
dose	O
response	O
curve	O
was	O
obtained	O
for	O
thermal	O
antinociception	O
(	O
plantar	O
test	O
)	O
in	O
naive	O
animals	O
without	O
observable	O
CB1	O
-	O
mediated	O
side	O
effects	O
[	O
30	O
].	O
Protective	O
effects	O
of	O
prophylactic	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
lasted	O
17	O
â€“	O
18	O
days	O
following	O
drug	O
removal	O
and	O
outlasted	O
the	O
anti	O
-	O
allodynic	O
effects	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
.	O
Unlike	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
","	O
anti	O
-	O
allodynic	O
effects	O
of	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
were	O
mediated	O
by	O
CB2	O
activation	O
only	O
.	O
Our	O
lab	O
previously	O
demonstrated	O
AM1710	B-Chemical
-	O
mediated	O
amelioration	O
of	O
allodynia	O
during	O
the	O
maintenance	O
phase	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
nociception	O
(	O
day	O
20	O
)	O
following	O
acute	O
administration	O
[	O
15	O
].	O
Four	O
CB2	O
agonists	O
have	O
been	O
shown	O
to	O
ameliorate	O
established	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
nociception	O
[	O
14	O
","	O
15	O
","	O
31	O
","	O
32	O
].	O
Notably	O
","	O
repeated	O
administration	O
of	O
the	O
CB2	O
agonist	O
MDA7	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
Ã—	O
14	O
days	O
)	O
15	O
min	O
prior	O
to	O
behavioral	O
evaluations	O
also	O
blocked	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
through	O
a	O
CB2	O
mechanism	O
during	O
the	O
phase	O
of	O
drug	O
delivery	O
(	O
i	O
.	O
e	O
".,"	O
behavioral	O
effects	O
blocked	O
by	O
AM630	B-Chemical
and	O
absent	O
in	O
CB2	O
-/-	O
mice	O
)	O
[	O
16	O
].	O
Long	O
-	O
term	O
alterations	O
in	O
lumbar	O
spinal	O
cord	O
CB1	O
or	O
CB2	O
mRNA	O
expression	O
(	O
day	O
22	O
)	O
were	O
not	O
induced	O
by	O
paclitaxel	B-Chemical
-	O
relative	O
to	O
cremophor	B-Chemical
-	O
treatment	O
in	O
our	O
study	O
by	O
RT	O
-	O
PCR	O
.	O
However	O
","	O
prophylactic	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
increased	O
both	O
CB1	O
and	O
CB2	O
mRNA	O
expression	O
","	O
an	O
effect	O
blocked	O
by	O
concurrent	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
administration	O
.	O
By	O
contrast	O
","	O
MDA7	B-Chemical
(	O
15	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
Ã—	O
14	O
days	O
)	O
has	O
been	O
reported	O
to	O
normalize	O
paclitaxel	B-Chemical
-	O
induced	O
increases	O
in	O
lumbar	O
spinal	O
cord	O
CB2	O
receptor	O
protein	O
[	O
16	O
].	O
Differences	O
in	O
paclitaxel	B-Chemical
dosing	O
(	O
cumulative	O
dose	O
:	O
8	O
vs	O
.	O
4	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
"),"	O
CB2	O
agonist	O
(	O
AM1710	B-Chemical
vs	O
.	O
MDA7	B-Chemical
"),"	O
route	O
of	O
administration	O
(	O
mini	O
pump	O
vs	O
.	O
once	O
-	O
daily	O
injections	O
"),"	O
or	O
protein	O
vs	O
.	O
mRNA	O
analysis	O
could	O
help	O
account	O
for	O
these	O
differential	O
findings	O
.	O
Lack	O
of	O
side	O
effects	O
after	O
either	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
or	O
AM1710	B-Chemical
treatment	O
In	O
our	O
study	O
","	O
animals	O
remained	O
in	O
good	O
health	O
and	O
showed	O
either	O
normal	O
or	O
enhanced	O
weight	O
gain	O
.	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
increased	O
weight	O
gain	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
rats	O
.	O
CB1	O
activation	O
can	O
produce	O
both	O
orexigenic	O
and	O
metabolic	O
effects	O
to	O
promote	O
weight	O
gain	O
[	O
33	O
].	O
Interestingly	O
","	O
higher	O
doses	O
of	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
1	O
â€“	O
2	O
mg	O
/	O
kg	O
/	O
day	O
i	O
.	O
p	O
.)	O
failed	O
to	O
attenuate	O
anorexia	O
or	O
weight	O
loss	O
in	O
animals	O
treated	O
with	O
cisplatin	B-Chemical
[	O
34	O
].	O
Activity	O
meter	O
assessments	O
conducted	O
during	O
prophylactic	O
treatment	O
(	O
day	O
19	O
)	O
and	O
following	O
drug	O
removal	O
(	O
day	O
31	O
"),"	O
failed	O
to	O
reveal	O
major	O
differences	O
between	O
groups	O
.	O
Thus	O
","	O
chronic	O
infusion	O
of	O
either	O
the	O
mixed	O
CB1	O
/	O
CB2	O
agonist	O
or	O
the	O
CB2	O
agonist	O
was	O
unlikely	O
to	O
nonselectively	O
activate	O
CB1	O
receptors	O
;	O
no	O
evidence	O
for	O
hypoactivity	O
[	O
35	O
"],"	O
a	O
cardinal	O
sign	O
of	O
CB1	O
activation	O
","	O
was	O
observed	O
.	O
These	O
findings	O
are	O
consistent	O
with	O
the	O
results	O
documenting	O
absence	O
of	O
cardinal	O
signs	O
of	O
CB1	O
receptor	O
activation	O
following	O
acute	O
administration	O
of	O
AM1710	B-Chemical
[	O
30	O
].	O
Potential	O
mechanisms	O
of	O
action	O
for	O
cannabinoid	B-Chemical
-	O
mediated	O
suppression	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
nociception	O
Glial	O
activation	O
mediates	O
alterations	O
in	O
synaptic	O
transmission	O
for	O
a	O
number	O
of	O
excitatory	O
and	O
inhibitory	O
mediators	O
known	O
to	O
be	O
important	O
for	O
the	O
maintenance	O
of	O
neuropathic	O
pain	O
states	O
[	O
36	O
].	O
Because	O
of	O
the	O
prolonged	O
suppression	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathy	O
after	O
removal	O
of	O
cannabinoid	B-Chemical
agonists	O
","	O
we	O
chose	O
to	O
analyze	O
transcriptional	O
changes	O
in	O
markers	O
of	O
glial	O
activation	O
.	O
GFAP	O
mRNA	O
expression	O
in	O
lumbar	O
spinal	O
cord	O
on	O
day	O
22	O
(	O
i	O
.	O
e	O
".,"	O
approximately	O
24	O
h	O
after	O
the	O
pump	O
ceased	O
to	O
release	O
drug	O
)	O
showed	O
a	O
trend	O
toward	O
increased	O
expression	O
in	O
paclitaxel	B-Chemical
-	O
relative	O
to	O
cremophor	B-Chemical
-	O
treated	O
controls	O
","	O
while	O
no	O
change	O
in	O
CD11b	O
expression	O
was	O
observed	O
.	O
Increases	O
in	O
astrocytic	O
activation	O
(	O
GFAP	O
)	O
with	O
no	O
corresponding	O
changes	O
in	O
microglial	O
activation	O
(	O
OX42	O
","	O
Iba1	O
","	O
and	O
phosphorylated	O
p38	O
)	O
were	O
also	O
recently	O
observed	O
with	O
the	O
same	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathy	O
dosing	O
protocol	O
used	O
here	O
[	O
12	O
].	O
In	O
another	O
study	O
","	O
paclitaxel	B-Chemical
failed	O
to	O
produce	O
microglial	O
activation	O
(%	O
of	O
cremophor	B-Chemical
-	O
control	O
staining	O
)	O
on	O
day	O
27	O
post	O
-	O
treatment	O
[	O
37	O
].	O
By	O
contrast	O
","	O
MDA7	B-Chemical
and	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
suppressed	O
paclitaxel	B-Chemical
-	O
induced	O
glial	O
activation	O
(	O
on	O
days	O
28	O
and	O
29	O
post	O
-	O
treatment	O
","	O
respectively	O
)	O
when	O
immunohistochemical	O
staining	O
for	O
astrocytes	O
(	O
GFAP	O
)	O
and	O
microglia	O
(	O
CD11b	O
)	O
was	O
compared	O
with	O
naive	O
animals	O
[	O
11	O
"],"	O
and	O
it	O
remains	O
unclear	O
whether	O
vehicle	O
or	O
cremophor	B-Chemical
administration	O
alters	O
glial	O
activation	O
[	O
16	O
].	O
Cremophor	B-Chemical
can	O
produce	O
side	O
effects	O
in	O
both	O
clinical	O
use	O
and	O
animal	O
models	O
[	O
38	O
"],"	O
and	O
assumptions	O
that	O
it	O
is	O
inert	O
are	O
not	O
appropriate	O
.	O
Prophylactic	O
treatment	O
with	O
either	O
a	O
mixed	O
CB1	O
/	O
CB2	O
agonist	O
or	O
a	O
CB2	O
agonist	O
","	O
while	O
failing	O
to	O
produce	O
robust	O
alterations	O
in	O
lumbar	O
spinal	O
cord	O
glial	O
expression	O
","	O
increased	O
CB1	O
and	O
CB2	O
mRNA	O
expression	O
.	O
This	O
effect	O
was	O
blocked	O
by	O
CB2	O
receptor	O
blockade	O
.	O
Upregulation	O
of	O
endocannabinoids	O
and	O
cannabinoid	O
receptors	O
is	O
associated	O
with	O
several	O
neuropathic	O
pain	O
models	O
(	O
for	O
review	O
see	O
[	O
39	O
]).	O
However	O
","	O
to	O
our	O
knowledge	O
","	O
very	O
few	O
","	O
if	O
any	O
","	O
studies	O
have	O
evaluated	O
alterations	O
following	O
prophylactic	O
cannabinoid	B-Chemical
treatment	O
.	O
Increased	O
receptor	O
densities	O
could	O
increase	O
the	O
potency	O
or	O
efficacy	O
of	O
prophylactic	O
cannabinoids	B-Chemical
in	O
this	O
model	O
.	O
More	O
work	O
is	O
necessary	O
to	O
determine	O
whether	O
changes	O
in	O
CB1	O
and	O
CB2	O
mRNA	O
levels	O
observed	O
here	O
are	O
also	O
associated	O
with	O
changes	O
in	O
receptor	O
protein	O
.	O
Alternatively	O
","	O
increased	O
CB1	O
and	O
CB2	O
mRNA	O
expression	O
could	O
reflect	O
compensatory	O
changes	O
in	O
transcription	O
following	O
chronic	O
agonist	O
-	O
induced	O
downregulation	O
of	O
receptors	O
.	O
More	O
work	O
is	O
necessary	O
to	O
fully	O
characterize	O
the	O
duration	O
of	O
these	O
effects	O
and	O
their	O
therapeutic	O
implications	O
.	O
Translation	O
to	O
the	O
clinic	O
Our	O
preclinical	O
studies	O
[	O
14	O
","	O
15	O
","	O
17	O
","	O
18	O
]	O
motivated	O
completion	O
of	O
a	O
pilot	O
clinical	O
trial	O
utilizing	O
Sativex	O
","	O
an	O
oromucosal	O
extract	O
containing	O
Î”9	B-Chemical
-	I-Chemical
tetrahydrocannabinol	I-Chemical
and	O
cannabidiol	B-Chemical
","	O
for	O
treatment	O
of	O
chemotherapy	O
-	O
induced	O
neuropathy	O
.	O
Sativex	O
suppressed	O
established	O
chemotherapy	O
-	O
induced	O
neuropathic	O
pain	O
in	O
a	O
subset	O
of	O
responders	O
(	O
5	O
of	O
18	O
)	O
in	O
this	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
crossover	O
pilot	O
[	O
40	O
"],"	O
supporting	O
a	O
further	O
evaluation	O
of	O
the	O
clinical	O
viability	O
of	O
cannabinoid	B-Chemical
-	O
based	O
pharmacotherapy	O
.	O
Conclusion	O
Prophylactic	O
treatment	O
has	O
been	O
tested	O
as	O
a	O
preventive	O
strategy	O
for	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
nociception	O
with	O
multiple	O
drugs	O
(	O
for	O
review	O
see	O
[	O
41	O
]).	O
Here	O
","	O
we	O
demonstrate	O
that	O
cannabinoid	B-Chemical
agonists	O
with	O
different	O
mechanisms	O
of	O
action	O
prevent	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
nociception	O
during	O
treatment	O
and	O
approximately	O
two	O
to	O
three	O
weeks	O
following	O
cessation	O
of	O
drug	O
delivery	O
.	O
Paclitaxel	B-Chemical
treatment	O
marginally	O
altered	O
long	O
-	O
term	O
GFAP	O
mRNA	O
expression	O
in	O
lumbar	O
spinal	O
cord	O
and	O
this	O
expression	O
was	O
unaffected	O
by	O
prophylactic	O
cannabinoids	B-Chemical
","	O
whereas	O
CD11b	O
mRNA	O
expression	O
was	O
unchanged	O
.	O
Prophylactic	O
treatment	O
with	O
either	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
or	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
in	O
paclitaxel	B-Chemical
animals	O
did	O
","	O
however	O
","	O
increase	O
both	O
CB1	O
and	O
CB2	O
receptor	O
mRNA	O
expression	O
","	O
an	O
effect	O
blocked	O
by	O
concurrent	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
administration	O
.	O
Some	O
inroads	O
have	O
been	O
made	O
toward	O
discovering	O
mechanisms	O
for	O
cannabinoid	B-Chemical
-	O
mediated	O
suppression	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathy	O
","	O
but	O
more	O
work	O
is	O
necessary	O
to	O
determine	O
the	O
scope	O
and	O
time	O
course	O
of	O
this	O
complex	O
interaction	O
.	O
Our	O
study	O
suggests	O
that	O
further	O
clinical	O
cannabinoid	B-Chemical
trials	O
[	O
40	O
]	O
for	O
chemotherapy	O
-	O
induced	O
peripheral	O
neuropathy	O
are	O
warranted	O
.	O
Methods	O
Subjects	O
Rats	O
One	O
hundred	O
seventy	O
-	O
six	O
adult	O
male	O
Sprague	O
â€“	O
Dawley	O
rats	O
(	O
beginning	O
weight	O
:	O
300	O
-	O
400	O
g	O
;	O
Harlan	O
","	O
Indianapolis	O
","	O
IN	O
)	O
were	O
used	O
in	O
these	O
experiments	O
.	O
All	O
procedures	O
were	O
approved	O
by	O
the	O
University	O
of	O
Georgia	O
Animal	O
Care	O
and	O
Use	O
Committee	O
and	O
followed	O
the	O
guidelines	O
for	O
the	O
treatment	O
of	O
animals	O
of	O
the	O
International	O
Association	O
for	O
the	O
Study	O
of	O
Pain	O
.	O
Animal	O
experiments	O
were	O
conducted	O
in	O
full	O
compliance	O
with	O
local	O
","	O
national	O
","	O
ethical	O
and	O
regulatory	O
principles	O
","	O
and	O
local	O
licensing	O
regulations	O
of	O
the	O
Association	O
for	O
Assessment	O
and	O
Accreditation	O
of	O
Laboratory	O
Animal	O
Care	O
(	O
AAALAC	O
)	O
International	O
â€™	O
s	O
expectations	O
for	O
animal	O
care	O
and	O
use	O
/	O
ethics	O
committees	O
.	O
Animals	O
were	O
allowed	O
a	O
minimum	O
of	O
one	O
week	O
habituation	O
prior	O
to	O
beginning	O
the	O
study	O
.	O
Animals	O
were	O
single	O
housed	O
and	O
maintained	O
in	O
a	O
temperature	O
(	O
70	O
-	O
72	O
Â°	O
F	O
Â±	O
4	O
Â°	O
F	O
)	O
and	O
humidity	O
(	O
30	O
-	O
70	O
%)	O
controlled	O
facility	O
on	O
a	O
12	O
hour	O
light	O
cycle	O
(	O
lights	O
on	O
:	O
7	O
:	O
0	O
and	O
lights	O
off	O
:	O
19	O
:	O
0	O
).	O
Food	O
and	O
water	B-Chemical
was	O
available	O
ad	O
libitum	O
.	O
Following	O
the	O
initial	O
pilot	O
study	O
(	O
n	O
=	O
17	O
"),"	O
all	O
animals	O
with	O
osmotic	O
mini	O
pumps	O
were	O
allowed	O
nyla	O
bones	O
(	O
BioServe	O
;	O
Frenchtown	O
","	O
NJ	O
)	O
due	O
to	O
the	O
study	O
duration	O
.	O
Corn	O
cob	O
bedding	O
containing	O
metabolized	O
paclitaxel	B-Chemical
was	O
treated	O
as	O
chemical	O
hazard	O
waste	O
and	O
disposed	O
of	O
according	O
to	O
appropriate	O
institutional	O
guidelines	O
.	O
Drugs	O
and	O
chemicals	O
Paclitaxel	B-Chemical
(	O
Taxol	B-Chemical
)	O
was	O
obtained	O
from	O
Tecoland	O
(	O
Edison	O
","	O
NJ	O
).	O
Polyethylene	B-Chemical
Glycol	I-Chemical
400	I-Chemical
(	O
PEG	B-Chemical
400	I-Chemical
)	O
was	O
purchased	O
from	O
VWR	O
International	O
(	O
West	O
Chester	O
","	O
PA	O
).	O
Acetone	B-Chemical
was	O
purchased	O
from	O
J	O
.	O
T	O
.	O
Baker	O
(	O
Phillipsburg	O
","	O
NJ	O
).	O
Cremophor	B-Chemical
EL	I-Chemical
","	O
Dimethyl	B-Chemical
Sulfoxide	I-Chemical
(	O
DMSO	B-Chemical
"),"	O
and	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
((	I-Chemical
R	I-Chemical
)-(+)-[	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
Dihydro	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
3	I-Chemical
[(	I-Chemical
4	I-Chemical
-	I-Chemical
morpholinyl	I-Chemical
)	I-Chemical
methyl	I-Chemical
]	I-Chemical
pyrrolo	I-Chemical
[	I-Chemical
1	I-Chemical
","	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
de	I-Chemical
]-	I-Chemical
1	I-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
benzoxazinyl	I-Chemical
]-(	I-Chemical
1	I-Chemical
-	I-Chemical
naphthalenyl	I-Chemical
)	I-Chemical
methanone	I-Chemical
mesylate	I-Chemical
salt	I-Chemical
)	O
were	O
obtained	O
from	O
Sigma	O
Aldrich	O
(	O
St	O
.	O
Louis	O
","	O
MO	O
).	O
AM1710	B-Chemical
(	O
3	B-Chemical
-(	I-Chemical
1	I-Chemical
"â€™,"	I-Chemical
1	I-Chemical
â€™-	I-Chemical
dimethylheptyl	I-Chemical
)-	I-Chemical
1	I-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
9	I-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
6H	I-Chemical
-	I-Chemical
benzo	I-Chemical
[	I-Chemical
c	I-Chemical
]	I-Chemical
chromene	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
one	I-Chemical
"),"	O
AM251	B-Chemical
(	O
N	B-Chemical
-(	I-Chemical
Piperidin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)-	I-Chemical
5	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
iodophenyl	I-Chemical
)-	I-Chemical
1	I-Chemical
-(	I-Chemical
2	I-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
dichlorophenyl	I-Chemical
)-	I-Chemical
4	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrazole	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxamide	I-Chemical
"),"	O
and	O
AM630	B-Chemical
(	O
6	B-Chemical
-	I-Chemical
Iodo	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
1	I-Chemical
-[	I-Chemical
2	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
morpholinyl	I-Chemical
)	I-Chemical
ethyl	I-Chemical
]-	I-Chemical
1H	I-Chemical
-	I-Chemical
indol	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
yl	I-Chemical
](	I-Chemical
4	I-Chemical
-	I-Chemical
methoxyphenyl	I-Chemical
)	I-Chemical
methanone	I-Chemical
(	O
Iodopravadoline	B-Chemical
)	O
were	O
synthesized	O
in	O
the	O
Center	O
for	O
Drug	O
Discovery	O
by	O
one	O
of	O
the	O
authors	O
(	O
by	O
GT	O
","	O
VKV	O
","	O
and	O
AZ	O
respectively	O
).	O
Rat	O
subjects	O
received	O
paclitaxel	B-Chemical
dissolved	O
as	O
previously	O
described	O
[	O
42	O
"],"	O
administered	O
in	O
a	O
volume	O
of	O
1	O
ml	O
/	O
kg	O
.	O
Briefly	O
","	O
paclitaxel	B-Chemical
was	O
dissolved	O
in	O
a	O
1	O
:	O
2	O
ratio	O
of	O
working	O
stock	O
(	O
1	O
:	O
1	O
ratio	O
of	O
cremophor	B-Chemical
EL	I-Chemical
and	O
95	O
%	O
ethanol	B-Chemical
)	O
to	O
saline	O
.	O
AM1710	B-Chemical
","	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
","	O
AM251	B-Chemical
","	O
and	O
AM630	B-Chemical
were	O
dissolved	O
in	O
a	O
vehicle	O
of	O
DMSO	B-Chemical
:	O
PEG	B-Chemical
400	I-Chemical
in	O
a	O
1	O
:	O
1	O
ratio	O
.	O
The	O
selected	O
vehicle	O
was	O
the	O
most	O
compatible	O
for	O
dissolving	O
cannabinoids	B-Chemical
to	O
be	O
used	O
in	O
Alzet	O
osmotic	O
mini	O
pumps	O
with	O
no	O
reported	O
adverse	O
side	O
effects	O
[	O
43	O
-	O
45	O
].	O
General	O
experimental	O
methods	O
In	O
an	O
initial	O
study	O
","	O
animals	O
were	O
evaluated	O
for	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
behavioral	O
sensitization	O
to	O
mechanical	O
and	O
heat	O
stimulation	O
.	O
Responsiveness	O
to	O
different	O
modalities	O
of	O
cutaneous	O
stimulation	O
was	O
assessed	O
on	O
alternate	O
days	O
to	O
avoid	O
sensitization	O
.	O
All	O
subsequent	O
studies	O
used	O
animals	O
surgically	O
implanted	O
with	O
osmotic	O
mini	O
pumps	O
.	O
Baseline	O
assessments	O
of	O
withdrawal	O
thresholds	O
to	O
mechanical	O
and	O
cold	O
(	O
acetone	B-Chemical
drops	O
)	O
stimulation	O
of	O
the	O
hind	O
paw	O
occurred	O
48	O
h	O
(	O
day	O
-	O
8	O
)	O
and	O
24	O
h	O
(	O
day	O
-	O
7	O
)	O
prior	O
to	O
surgery	O
","	O
respectively	O
.	O
Osmotic	O
mini	O
pumps	O
(	O
Alzet	O
model	O
2ML4	O
","	O
Cupertino	O
","	O
CA	O
)	O
were	O
implanted	O
subcutaneously	O
through	O
an	O
incision	O
between	O
the	O
scapulae	O
.	O
Responsiveness	O
to	O
mechanical	O
and	O
cold	O
stimulation	O
was	O
reassessed	O
post	O
-	O
surgery	O
(	O
i	O
.	O
e	O
".,"	O
after	O
pump	O
implantation	O
but	O
within	O
48	O
h	O
prior	O
to	O
initiation	O
(	O
on	O
day	O
0	O
)	O
of	O
paclitaxel	B-Chemical
dosing	O
).	O
Animals	O
were	O
weighed	O
on	O
all	O
testing	O
and	O
surgical	O
/	O
sacrifice	O
dates	O
.	O
A	O
subset	O
of	O
animals	O
was	O
sacrificed	O
via	O
live	O
decapitation	O
(	O
day	O
22	O
)	O
to	O
extract	O
lumbar	O
spinal	O
cords	O
.	O
Certain	O
groups	O
(	O
e	O
.	O
g	O
".,"	O
antagonist	O
alone	O
conditions	O
","	O
submaximal	O
doses	O
of	O
agonists	O
","	O
cremophor	B-Chemical
-	O
agonist	O
groups	O
)	O
were	O
only	O
tested	O
through	O
day	O
22	O
.	O
Osmotic	O
mini	O
pumps	O
were	O
removed	O
in	O
all	O
remaining	O
animals	O
(	O
day	O
22	O
"),"	O
and	O
following	O
a	O
short	O
recovery	O
period	O
","	O
responses	O
to	O
mechanical	O
and	O
cold	O
stimulation	O
were	O
reassessed	O
until	O
day	O
51	O
post	O
-	O
paclitaxel	B-Chemical
.	O
Drug	O
doses	O
were	O
estimated	O
based	O
on	O
the	O
peak	O
osmotic	O
mini	O
pump	O
performance	O
reported	O
by	O
the	O
manufacturer	O
(	O
2	O
.	O
5	O
Î¼l	O
/	O
hr	O
)	O
and	O
an	O
average	O
rat	O
weight	O
of	O
375	O
grams	O
.	O
A	O
small	O
percentage	O
of	O
animals	O
(	O
4	O
.	O
2	O
%)	O
presented	O
with	O
edema	O
around	O
the	O
pump	O
site	O
(	O
seromas	O
).	O
Alzet	O
reports	O
this	O
side	O
effect	O
in	O
<	O
5	O
%	O
of	O
animals	O
.	O
Treatment	O
for	O
these	O
animals	O
was	O
supervised	O
by	O
the	O
attending	O
veterinarian	O
and	O
consisted	O
of	O
draining	O
fluid	O
every	O
3	O
days	O
","	O
or	O
as	O
needed	O
.	O
Six	O
animals	O
(	O
3	O
.	O
6	O
%)	O
were	O
re	O
-	O
sutured	O
following	O
surgery	O
.	O
One	O
of	O
the	O
six	O
animals	O
developed	O
an	O
infection	O
and	O
was	O
treated	O
(	O
from	O
days	O
16	O
â€“	O
22	O
)	O
with	O
daily	O
injections	O
of	O
an	O
antibiotic	O
(	O
Enrofloxacin	B-Chemical
4	O
.	O
5	O
mg	O
/	O
ml	O
","	O
0	O
.	O
4	O
cc	O
s	O
.	O
c	O
".,"	O
2	O
Ã—	O
daily	O
)	O
and	O
sterile	O
water	B-Chemical
(	O
1	O
cc	O
s	O
.	O
c	O
".,"	O
1	O
Ã—	O
daily	O
)	O
as	O
prescribed	O
by	O
the	O
staff	O
veterinarian	O
.	O
One	O
animal	O
died	O
during	O
the	O
first	O
paclitaxel	B-Chemical
injection	O
and	O
this	O
animal	O
was	O
excluded	O
from	O
all	O
analyses	O
.	O
Behavioral	O
measurements	O
","	O
surgeries	O
","	O
chemotherapeutic	O
treatment	O
","	O
and	O
tissue	O
removal	O
were	O
performed	O
by	O
a	O
single	O
experimenter	O
(	O
EJR	O
).	O
Coded	O
testing	O
sheets	O
were	O
used	O
to	O
preserve	O
blinding	O
.	O
Behavioral	O
testing	O
was	O
performed	O
in	O
the	O
presence	O
of	O
a	O
white	O
noise	O
generator	O
to	O
mask	O
extraneous	O
noise	O
.	O
Surgical	O
implantation	O
and	O
removal	O
of	O
osmotic	O
mini	O
pumps	O
Osmotic	O
mini	O
pumps	O
were	O
implanted	O
under	O
isoflurane	B-Chemical
anesthesia	O
(	O
Isoflo	O
"Â®,"	O
Abbott	O
Laboratories	O
","	O
Chicago	O
","	O
IL	O
).	O
The	O
osmotic	O
mini	O
pump	O
was	O
inserted	O
through	O
a	O
surgical	O
incision	O
made	O
between	O
the	O
scapulae	O
;	O
incisions	O
were	O
sutured	O
closed	O
.	O
In	O
the	O
instances	O
where	O
two	O
pumps	O
were	O
implanted	O
(	O
i	O
.	O
e	O
".,"	O
agonist	O
and	O
antagonist	O
co	O
-	O
administration	O
conditions	O
"),"	O
pumps	O
were	O
placed	O
in	O
the	O
same	O
pocket	O
.	O
The	O
Alzet	O
model	O
2ML4	O
pump	O
has	O
an	O
approximate	O
2	O
ml	O
reservoir	O
that	O
releases	O
a	O
preloaded	O
drug	O
or	O
vehicle	O
at	O
a	O
rate	O
of	O
2	O
.	O
5	O
ul	O
/	O
hr	O
for	O
approximately	O
28	O
days	O
.	O
The	O
pump	O
begins	O
to	O
release	O
the	O
preloaded	O
drug	O
approximately	O
4	O
â€“	O
6	O
hours	O
after	O
implantation	O
;	O
the	O
flow	O
rate	O
is	O
not	O
subject	O
to	O
variations	O
in	O
body	O
temperature	O
.	O
Osmotic	O
mini	O
pumps	O
were	O
weighed	O
before	O
and	O
after	O
being	O
filled	O
with	O
drug	O
or	O
vehicle	O
.	O
The	O
difference	O
of	O
these	O
two	O
values	O
provided	O
an	O
approximate	O
pump	O
fill	O
volume	O
.	O
The	O
animals	O
were	O
given	O
three	O
days	O
(	O
days	O
-	O
5	O
through	O
-	O
3	O
)	O
to	O
recover	O
from	O
surgery	O
before	O
testing	O
resumed	O
.	O
Animals	O
were	O
either	O
sacrificed	O
or	O
underwent	O
surgery	O
on	O
day	O
22	O
to	O
remove	O
pumps	O
;	O
this	O
time	O
point	O
corresponds	O
to	O
the	O
29th	O
day	O
following	O
pump	O
implantation	O
","	O
at	O
which	O
point	O
the	O
pump	O
should	O
have	O
released	O
its	O
contents	O
.	O
Following	O
pump	O
removal	O
","	O
the	O
residual	O
pump	O
volume	O
was	O
estimated	O
by	O
withdrawing	O
the	O
remaining	O
fluid	O
within	O
the	O
pump	O
reservoir	O
.	O
Animals	O
that	O
underwent	O
surgical	O
removal	O
of	O
osmotic	O
mini	O
pumps	O
were	O
allowed	O
three	O
days	O
of	O
recovery	O
(	O
days	O
23	O
â€“	O
25	O
)	O
prior	O
to	O
resumption	O
of	O
behavioral	O
testing	O
.	O
Induction	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
nociception	O
Rats	O
received	O
four	O
once	O
daily	O
intraperitoneal	O
(	O
i	O
.	O
p	O
.)	O
injections	O
of	O
either	O
paclitaxel	B-Chemical
(	O
2	O
mg	O
/	O
kg	O
/	O
day	O
i	O
.	O
p	O
.	O
;	O
cumulative	O
dose	O
of	O
8	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.)	O
or	O
cremophor	B-Chemical
:	O
ethanol	B-Chemical
:	O
saline	B-Chemical
vehicle	O
(	O
1	O
ml	O
/	O
kg	O
/	O
day	O
i	O
.	O
p	O
.	O
"),"	O
administered	O
on	O
alternate	O
days	O
(	O
days	O
0	O
","	O
2	O
","	O
4	O
","	O
and	O
6	O
)	O
as	O
described	O
previously	O
[	O
28	O
].	O
Behavioral	O
testing	O
was	O
always	O
performed	O
prior	O
to	O
paclitaxel	B-Chemical
/	O
vehicle	O
administration	O
.	O
Assessment	O
of	O
paw	O
withdrawal	O
latencies	O
to	O
heat	O
stimulation	O
Paw	O
withdrawal	O
latencies	O
to	O
radiant	O
heat	O
were	O
measured	O
in	O
duplicate	O
for	O
each	O
paw	O
using	O
the	O
Hargreaves	O
test	O
[	O
46	O
]	O
and	O
a	O
commercially	O
available	O
plantar	O
stimulation	O
unit	O
(	O
IITC	O
model	O
336	O
;	O
Woodland	O
Hills	O
","	O
CA	O
).	O
Rats	O
were	O
placed	O
underneath	O
inverted	O
plastic	O
cages	O
positioned	O
on	O
an	O
elevated	O
glass	O
platform	O
and	O
allowed	O
a	O
minimum	O
of	O
20	O
min	O
to	O
habituate	O
prior	O
to	O
testing	O
.	O
Radiant	O
heat	O
was	O
presented	O
to	O
the	O
hind	O
paw	O
midplantar	O
region	O
through	O
the	O
floor	O
of	O
the	O
glass	O
platform	O
.	O
The	O
intensity	O
of	O
the	O
heat	O
source	O
was	O
adjusted	O
such	O
that	O
an	O
average	O
baseline	O
latency	O
of	O
approximately	O
20	O
sec	O
was	O
achieved	O
[	O
47	O
].	O
Stimulation	O
was	O
terminated	O
upon	O
paw	O
withdrawal	O
or	O
after	O
40	O
s	O
to	O
prevent	O
tissue	O
damage	O
.	O
Approximately	O
4	O
minute	O
interstimulation	O
intervals	O
were	O
allowed	O
between	O
tests	O
.	O
Thermal	O
withdrawal	O
latencies	O
were	O
evaluated	O
before	O
(	O
day	O
0	O
)	O
and	O
on	O
days	O
2	O
","	O
6	O
","	O
10	O
","	O
14	O
and	O
18	O
following	O
initiation	O
of	O
paclitaxel	B-Chemical
dosing	O
.	O
The	O
same	O
animals	O
were	O
tested	O
for	O
the	O
development	O
of	O
mechanical	O
allodynia	O
.	O
Baseline	O
responses	O
to	O
mechanical	O
stimulation	O
(	O
methodology	O
below	O
)	O
were	O
measured	O
(	O
on	O
day	O
0	O
)	O
before	O
baseline	O
responses	O
to	O
thermal	O
stimulation	O
.	O
A	O
minimum	O
of	O
1	O
hour	O
was	O
allowed	O
to	O
elapse	O
between	O
baseline	O
measurements	O
.	O
Assessment	O
of	O
mechanical	O
withdrawal	O
thresholds	O
Mechanical	O
withdrawal	O
thresholds	O
were	O
assessed	O
using	O
a	O
digital	O
Electrovonfrey	O
Anesthesiometer	O
(	O
IITC	O
model	O
Alemo	O
2390	O
â€“	O
5	O
;	O
Woodland	O
Hills	O
","	O
CA	O
)	O
equipped	O
with	O
a	O
rigid	O
tip	O
.	O
Rats	O
were	O
placed	O
underneath	O
inverted	O
plastic	O
cages	O
positioned	O
on	O
an	O
elevated	O
mesh	O
platform	O
and	O
allowed	O
a	O
20	O
min	O
habituation	O
period	O
prior	O
to	O
testing	O
.	O
Stimulation	O
was	O
applied	O
to	O
the	O
hind	O
paw	O
midplantar	O
region	O
through	O
the	O
floor	O
of	O
a	O
mesh	O
platform	O
.	O
Mechanical	O
stimulation	O
was	O
terminated	O
upon	O
paw	O
withdrawal	O
;	O
consequently	O
","	O
no	O
upper	O
threshold	O
limit	O
was	O
set	O
for	O
termination	O
of	O
a	O
trial	O
.	O
Two	O
thresholds	O
were	O
taken	O
for	O
each	O
paw	O
.	O
Approximately	O
2	O
minute	O
interstimulation	O
intervals	O
were	O
allowed	O
between	O
tests	O
.	O
Mechanical	O
withdrawal	O
thresholds	O
were	O
measured	O
on	O
days	O
0	O
","	O
4	O
","	O
8	O
","	O
12	O
","	O
16	O
and	O
20	O
for	O
animals	O
that	O
did	O
not	O
receive	O
osmotic	O
mini	O
pumps	O
(	O
Figure	O
1	O
).	O
Mechanical	O
withdrawal	O
thresholds	O
were	O
measured	O
every	O
2	O
â€“	O
6	O
days	O
(	O
i	O
.	O
e	O
".,"	O
days	O
-	O
8	O
","	O
-	O
2	O
","	O
0	O
","	O
2	O
","	O
4	O
","	O
6	O
","	O
8	O
","	O
10	O
","	O
12	O
","	O
14	O
","	O
16	O
","	O
18	O
","	O
and	O
20	O
)	O
for	O
all	O
animals	O
that	O
received	O
osmotic	O
mini	O
pumps	O
.	O
A	O
subset	O
of	O
osmotic	O
mini	O
pump	O
animals	O
were	O
tested	O
until	O
day	O
50	O
(	O
testing	O
continued	O
with	O
the	O
following	O
schedule	O
:	O
days	O
26	O
","	O
28	O
","	O
30	O
","	O
32	O
","	O
34	O
","	O
36	O
","	O
38	O
","	O
40	O
","	O
42	O
","	O
44	O
","	O
46	O
","	O
48	O
","	O
and	O
50	O
).	O
Assessment	O
of	O
cold	O
allodynia	O
Cold	O
allodynia	O
was	O
assessed	O
using	O
acetone	B-Chemical
drops	O
applied	O
to	O
the	O
hind	O
paw	O
midplantar	O
surface	O
as	O
previously	O
described	O
[	O
15	O
","	O
48	O
].	O
Rats	O
were	O
placed	O
underneath	O
inverted	O
plastic	O
cages	O
positioned	O
on	O
an	O
elevated	O
mesh	O
platform	O
and	O
allowed	O
a	O
20	O
min	O
habituation	O
period	O
prior	O
to	O
testing	O
.	O
Acetone	B-Chemical
was	O
loaded	O
into	O
a	O
one	O
cc	O
syringe	O
barrel	O
with	O
no	O
needle	O
tip	O
.	O
One	O
drop	O
of	O
acetone	B-Chemical
(	O
approximately	O
20	O
Î¼l	O
)	O
was	O
applied	O
through	O
the	O
mesh	O
platform	O
onto	O
the	O
hind	O
paw	O
midplantar	O
surface	O
.	O
Care	O
was	O
taken	O
to	O
gently	O
apply	O
the	O
bubble	O
of	O
acetone	B-Chemical
to	O
the	O
skin	O
without	O
inducing	O
mechanical	O
stimulation	O
by	O
syringe	O
barrel	O
contact	O
with	O
the	O
paw	O
.	O
Paw	O
withdrawal	O
was	O
recorded	O
as	O
a	O
binary	O
response	O
(	O
presence	O
or	O
absence	O
)	O
and	O
was	O
frequently	O
accompanied	O
by	O
nocifensive	O
behaviors	O
(	O
e	O
.	O
g	O
".,"	O
rapid	O
flicking	O
of	O
the	O
paw	O
","	O
chattering	O
","	O
biting	O
","	O
and	O
/	O
or	O
licking	O
of	O
the	O
paw	O
).	O
These	O
nocifensive	O
behaviors	O
were	O
recorded	O
as	O
duration	O
of	O
acetone	B-Chemical
response	O
.	O
Five	O
measurements	O
were	O
taken	O
for	O
each	O
paw	O
.	O
Testing	O
order	O
alternated	O
between	O
paws	O
(	O
i	O
.	O
e	O
".,"	O
right	O
","	O
left	O
).	O
No	O
cut	O
-	O
off	O
latency	O
was	O
enforced	O
.	O
Approximately	O
2	O
min	O
interstimulation	O
intervals	O
were	O
allowed	O
between	O
testing	O
of	O
right	O
and	O
left	O
paws	O
.	O
A	O
minimum	O
interstimulation	O
interval	O
of	O
5	O
min	O
was	O
allowed	O
between	O
testing	O
each	O
pair	O
of	O
paws	O
(	O
right	O
and	O
left	O
).	O
Cold	O
allodynia	O
testing	O
took	O
place	O
on	O
days	O
-	O
7	O
","	O
-	O
1	O
","	O
5	O
","	O
11	O
","	O
17	O
and	O
21	O
for	O
all	O
animals	O
with	O
osmotic	O
mini	O
pumps	O
.	O
Five	O
days	O
were	O
allowed	O
between	O
assessments	O
of	O
cold	O
allodynia	O
to	O
avoid	O
hypersensitivity	O
with	O
one	O
exception	O
.	O
Animals	O
were	O
tested	O
on	O
day	O
21	O
because	O
osmotic	O
mini	O
pumps	O
would	O
purportedly	O
still	O
be	O
releasing	O
drug	O
(	O
i	O
.	O
e	O
".,"	O
28	O
days	O
following	O
pump	O
implantation	O
).	O
A	O
subset	O
of	O
animals	O
was	O
tested	O
to	O
day	O
51	O
(	O
i	O
.	O
e	O
".,"	O
testing	O
for	O
these	O
animals	O
continued	O
with	O
the	O
following	O
schedule	O
:	O
days	O
27	O
","	O
33	O
","	O
39	O
","	O
45	O
","	O
and	O
51	O
).	O
Locomotor	O
activity	O
Total	O
distance	O
traveled	O
(	O
cm	O
)	O
was	O
assessed	O
using	O
an	O
activity	O
monitor	O
chamber	O
(	O
Coulbourn	O
Instruments	O
","	O
Whitehall	O
","	O
PA	O
)	O
measuring	O
40	O
.	O
64	O
cm3	O
.	O
The	O
apparatus	O
was	O
housed	O
in	O
a	O
darkened	O
room	O
and	O
red	O
light	O
was	O
used	O
to	O
provide	O
illumination	O
.	O
Tracking	O
beams	O
were	O
positioned	O
2	O
.	O
54	O
cm	O
apart	O
giving	O
1	O
.	O
27	O
cm	O
in	O
spatial	O
resolution	O
.	O
Activity	O
was	O
automatically	O
measured	O
by	O
computerized	O
analysis	O
of	O
photobeam	O
interrupts	O
(	O
TruScan	O
2	O
.	O
0	O
;	O
Coulbourn	O
Instruments	O
","	O
Whitehall	O
","	O
PA	O
).	O
Animals	O
were	O
allowed	O
a	O
minimum	O
of	O
15	O
minutes	O
to	O
habituate	O
to	O
the	O
room	O
prior	O
to	O
being	O
placed	O
undisturbed	O
in	O
the	O
activity	O
meter	O
for	O
15	O
min	O
.	O
Chlorhexidine	B-Chemical
was	O
used	O
to	O
clean	O
the	O
activity	O
meter	O
after	O
each	O
animal	O
.	O
Activity	O
meter	O
assessment	O
took	O
place	O
both	O
during	O
(	O
day	O
19	O
)	O
and	O
following	O
termination	O
(	O
day	O
31	O
)	O
of	O
drug	O
delivery	O
in	O
a	O
subset	O
of	O
animals	O
that	O
received	O
chronic	O
infusions	O
.	O
Prophylactic	O
drug	O
groups	O
Animals	O
were	O
randomly	O
assigned	O
to	O
drug	O
treatments	O
.	O
Animals	O
assigned	O
to	O
the	O
paclitaxel	B-Chemical
condition	O
received	O
pumps	O
filled	O
with	O
the	O
mixed	O
CB1	O
/	O
CB2	O
agonist	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
1	O
","	O
0	O
.	O
5	O
","	O
or	O
0	O
.	O
1	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
".,"	O
n	O
=	O
8	O
â€“	O
10	O
per	O
group	O
"),"	O
the	O
CB2	O
-	O
preferring	O
agonist	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
","	O
0	O
.	O
32	O
","	O
or	O
0	O
.	O
32	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
".,"	O
n	O
=	O
8	O
â€“	O
14	O
per	O
group	O
"),"	O
vehicle	O
(	O
DMSO	B-Chemical
:	O
PEG	B-Chemical
400	I-Chemical
","	O
n	O
=	O
14	O
"),"	O
or	O
saline	O
(	O
n	O
=	O
4	O
).	O
Animals	O
assigned	O
to	O
the	O
cremophor	B-Chemical
-	O
vehicle	O
control	O
condition	O
received	O
pumps	O
filled	O
with	O
either	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
".,"	O
n	O
=	O
8	O
"),"	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
".,"	O
n	O
=	O
8	O
"),"	O
vehicle	O
(	O
DMSO	B-Chemical
:	O
PEG	B-Chemical
400	I-Chemical
","	O
n	O
=	O
10	O
"),"	O
or	O
saline	B-Chemical
(	O
n	O
=	O
4	O
).	O
Pharmacological	O
specificity	O
was	O
assessed	O
in	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
implanted	O
concurrently	O
with	O
two	O
osmotic	O
mini	O
pumps	O
.	O
One	O
pump	O
contained	O
an	O
antagonist	O
(	O
either	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.)	O
or	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
.))	O
and	O
the	O
other	O
pump	O
contained	O
an	O
agonist	O
(	O
either	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
".,"	O
n	O
=	O
10	O
per	O
group	O
)	O
or	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
".,"	O
n	O
=	O
10	O
per	O
group	O
)).	O
Separate	O
groups	O
of	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
received	O
pumps	O
filled	O
with	O
either	O
AM251	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
".,"	O
n	O
=	O
8	O
)	O
or	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
s	O
.	O
c	O
".,"	O
n	O
=	O
8	O
).	O
Quantification	O
of	O
lumbar	O
spinal	O
cord	O
mRNA	O
Real	O
time	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
quantify	O
mRNA	O
levels	O
in	O
lumbar	O
spinal	O
cords	O
removed	O
from	O
animals	O
sacrificed	O
on	O
day	O
22	O
.	O
Methods	O
are	O
described	O
previously	O
[	O
49	O
].	O
RNA	O
from	O
paclitaxel	B-Chemical
-	O
treated	O
animals	O
that	O
received	O
vehicle	O
","	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
"),"	O
WIN55	B-Chemical
","	I-Chemical
212	I-Chemical
-	I-Chemical
2	I-Chemical
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
+	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
"),"	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
"),"	O
AM1710	B-Chemical
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
/	O
day	O
)	O
+	O
AM630	B-Chemical
(	O
3	O
mg	O
/	O
kg	O
/	O
day	O
"),"	O
or	O
from	O
cremophor	B-Chemical
-	O
vehicle	O
-	O
treated	O
animals	O
(	O
n	O
=	O
4	O
per	O
group	O
)	O
were	O
extracted	O
using	O
a	O
TRIzol	B-Chemical
(	O
Invitrogen	O
)/	O
RNeasy	O
(	O
Qiagen	O
)	O
hybrid	O
protocol	O
according	O
to	O
manufacturer	O
â€™	O
s	O
instructions	O
.	O
Purified	O
RNA	O
from	O
each	O
sample	O
was	O
then	O
treated	O
with	O
DNase	O
1	O
.	O
Expression	O
levels	O
of	O
GFAP	O
","	O
CD11b	O
","	O
CB1	O
","	O
and	O
CB2	O
mRNAs	O
were	O
quantified	O
using	O
one	O
step	O
RT	O
-	O
PCR	O
in	O
a	O
Mastercycler	O
ep	O
realplex	O
RT	O
-	O
PCR	O
machine	O
(	O
Eppendorf	O
North	O
America	O
Inc	O
".,"	O
Hauppauge	O
","	O
NY	O
)	O
using	O
PowerSYBR	O
green	O
PCR	O
kit	O
(	O
Applied	O
Biosystems	O
","	O
Carlsbad	O
","	O
CA	O
).	O
GAPDH	O
(	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
)	O
was	O
used	O
as	O
internal	O
standard	O
to	O
normalize	O
mRNA	O
levels	O
.	O
Primers	O
used	O
were	O
as	O
follows	O
:	O
rat	O
GAPDH	O
(	O
sense	O
:	O
5	O
â€²-	O
ATGACTCTACCCACGGCAAG	O
-	O
3	O
"â€²,"	O
anti	O
-	O
sense	O
:	O
5	O
â€²	O
CATACTCTGCACCAGCATCTC	O
-	O
3	O
â€²);	O
rat	O
GFAP	O
(	O
sense	O
:	O
5	O
â€²-	O
GAGTCCACAACCATCCTTCTGAG	O
-	O
3	O
"â€²,"	O
anti	O
-	O
sense	O
:	O
5	O
â€²-	O
ACACCAGGCTGCTTGAACAC	O
-	O
3	O
â€²);	O
rat	O
CD11b	O
(	O
sense	O
:	O
5	O
â€²-	O
CTGGGAGATGTGAATGGAG	O
-	O
3	O
"â€²,"	O
anti	O
-	O
sense	O
:	O
5	O
â€²-	O
ACTGATGCTGGCTACTGATG	O
-	O
3	O
â€²);	O
rat	O
CB1	O
(	O
sense	O
:	O
5	O
â€²-	O
CTACTGGTGCTGTGTGTCATC	O
-	O
3	O
â€²	O
and	O
anti	O
-	O
sense	O
:	O
5	O
â€²-	O
GCTGTCTTTACGGTGGAATAC	O
-	O
3	O
â€²);	O
rat	O
CB2	O
(	O
sense	O
:	O
5	O
â€²-	O
GCAGCCTGCTGCTGACCGCTG	O
-	O
3	O
"â€²,"	O
anti	O
-	O
sense	O
:	O
5	O
â€²-	O
TGCTTTCCAGAGGACATACCC	O
-	O
3	O
â€²).	O
Statistical	O
analyses	O
Percentage	O
of	O
paw	O
withdrawals	O
from	O
acetone	B-Chemical
application	O
to	O
the	O
hind	O
paws	O
was	O
calculated	O
using	O
the	O
following	O
formula	O
:	O
((	O
Total	O
number	O
of	O
paw	O
withdrawals	O
)	O
*	O
100	O
)/	O
10	O
.	O
Data	O
were	O
analyzed	O
using	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
for	O
repeated	O
measures	O
","	O
one	O
-	O
way	O
ANOVA	O
","	O
or	O
planned	O
comparison	O
t	O
-	O
test	O
as	O
appropriate	O
.	O
SPSS	O
19	O
.	O
0	O
(	O
SPSS	O
Incorporated	O
","	O
Chicago	O
","	O
IL	O
","	O
USA	O
)	O
statistical	O
software	O
was	O
employed	O
.	O
The	O
Greenhouse	O
-	O
Geisser	O
correction	O
was	O
applied	O
to	O
all	O
repeated	O
factors	O
where	O
the	O
epsilon	O
value	O
from	O
Mauchly	O
â€™	O
s	O
Test	O
of	O
Sphericity	O
was	O
<	O
0	O
.	O
75	O
and	O
significance	O
level	O
was	O
P	O
<	O
0	O
.	O
5	O
.	O
Degrees	O
of	O
freedom	O
reported	O
for	O
interaction	O
terms	O
of	O
repeated	O
factors	O
are	O
uncorrected	O
values	O
in	O
cases	O
where	O
the	O
Greenhouse	O
-	O
Geisser	O
correction	O
factor	O
was	O
applied	O
.	O
Post	O
-	O
hoc	O
comparisons	O
between	O
the	O
primary	O
control	O
group	O
(	O
paclitaxel	B-Chemical
-	O
vehicle	O
)	O
and	O
other	O
experimental	O
groups	O
were	O
performed	O
using	O
the	O
Dunnett	O
test	O
(	O
2	O
-	O
sided	O
).	O
Post	O
-	O
hoc	O
comparisons	O
between	O
different	O
experimental	O
groups	O
were	O
also	O
performed	O
to	O
assess	O
dose	O
â€“	O
response	O
relationships	O
and	O
pharmacological	O
specificity	O
using	O
the	O
Tukey	O
test	O
.	O
Levene	O
â€™	O
s	O
test	O
for	O
homoscedasticity	O
was	O
applied	O
to	O
all	O
planned	O
comparison	O
t	O
-	O
tests	O
.	O
P	O
<	O
0	O
.	O
5	O
was	O
considered	O
statistically	O
significant	O
.	O
Abbreviations	O
CD11b	O
:	O
Cluster	O
of	O
differentiation	O
molecule	O
11B	O
;	O
GFAP	O
:	O
Glial	O
fibrillary	O
acidic	O
protein	O
;	O
i	O
.	O
p	O
.	O
:	O
Intraperitoneal	O
;	O
PEG	B-Chemical
400	I-Chemical
:	O
polyethylene	B-Chemical
glycol	I-Chemical
400	I-Chemical
;	O
s	O
.	O
c	O
.	O
:	O
Subcutaneous	O
.	O
Competing	O
interests	O
Dr	O
.	O
Alexandros	O
Makriyannis	O
serves	O
as	O
a	O
consultant	O
for	O
MAK	O
Scientific	O
.	O
No	O
other	O
authors	O
declare	O
competing	O
interests	O
.	O
Authors	O
â€™	O
contributions	O
EJR	O
contributed	O
to	O
experimental	O
design	O
","	O
completed	O
all	O
surgeries	O
","	O
behavioral	O
studies	O
","	O
and	O
tissue	O
extractions	O
","	O
analyzed	O
data	O
and	O
drafted	O
the	O
manuscript	O
.	O
LD	O
isolated	O
RNA	O
","	O
carried	O
out	O
the	O
RT	O
-	O
PCR	O
studies	O
and	O
analyzed	O
data	O
.	O
GAT	O
synthesized	O
AM1710	B-Chemical
.	O
VKV	O
synthesized	O
AM251	B-Chemical
and	O
AM630	B-Chemical
.	O
AMZ	O
synthesized	O
AM630	B-Chemical
.	O
YYL	O
assisted	O
with	O
RT	O
-	O
PCR	O
and	O
contributed	O
to	O
manuscript	O
preparation	O
and	O
data	O
interpretation	O
.	O
AM	O
provided	O
cannabinoid	B-Chemical
compounds	O
and	O
contributed	O
to	O
data	O
interpretation	O
.	O
AGH	O
designed	O
the	O
study	O
","	O
participated	O
in	O
its	O
coordination	O
and	O
implementation	O
","	O
and	O
wrote	O
the	O
manuscript	O
with	O
EJR	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
Acknowledgments	O
This	O
work	O
was	O
supported	O
by	O
DA021644	O
","	O
DA028200	O
","	O
DA022478	O
","	O
and	O
DA037673	O
(	O
to	O
AGH	O
)	O
and	O
DA9158	O
","	O
DA3801	O
(	O
to	O
AM	O
).	O
EJR	O
was	O
supported	O
by	O
an	O
ARCS	O
Foundation	O
Fellowship	O
","	O
an	O
APF	O
Graduate	O
Fellowship	O
","	O
a	O
Psi	O
Chi	O
Graduate	O
Research	O
Grant	O
and	O
a	O
Sigma	O
Xi	O
Grant	O
-	O
in	O
-	O
Aid	O
of	O
Research	O
Award	O
.	O
The	O
green	O
tea	O
extract	O
epigallocatechin	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
gallate	I-Chemical
inhibits	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
in	O
adult	O
rats	O
The	O
present	O
study	O
evaluated	O
the	O
effect	O
of	O
epigallocatechin	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
gallate	I-Chemical
(	O
EGCG	B-Chemical
"),"	O
the	O
most	O
abundant	O
catechin	B-Chemical
in	O
green	O
tea	O
","	O
on	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
and	O
elucidated	O
its	O
mechanism	O
of	O
action	O
.	O
A	O
rat	O
model	O
of	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
was	O
generated	O
using	O
a	O
60Co	B-Chemical
irradiator	O
and	O
a	O
dose	O
of	O
22	O
Gy	O
.	O
Rats	O
were	O
intraperitoneally	O
injected	O
with	O
EGCG	B-Chemical
(	O
25	O
mg	O
/	O
kg	O
)	O
or	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
;	O
5	O
mg	O
/	O
kg	O
)	O
daily	O
for	O
30	O
days	O
.	O
Mortality	O
rates	O
and	O
lung	O
index	O
values	O
were	O
calculated	O
.	O
The	O
severity	O
of	O
fibrosis	O
was	O
evaluated	O
by	O
assaying	O
the	O
hydroxyproline	B-Chemical
(	O
Hyp	B-Chemical
)	O
contents	O
of	O
pulmonary	O
and	O
lung	O
tissue	O
sections	O
post	O
-	O
irradiation	O
.	O
Alveolitis	O
and	O
fibrosis	O
scores	O
were	O
obtained	O
from	O
semi	O
-	O
quantitative	O
analyses	O
of	O
hematoxylin	B-Chemical
and	I-Chemical
eosin	I-Chemical
(	O
H	B-Chemical
&	I-Chemical
E	I-Chemical
)	O
and	O
Masson	B-Chemical
â€™	I-Chemical
s	I-Chemical
trichrome	I-Chemical
lung	O
section	O
staining	O
","	O
respectively	O
.	O
The	O
serum	O
levels	O
of	O
transforming	O
growth	O
factor	O
Î²1	O
(	O
TGF	O
-	O
Î²1	O
"),"	O
interleukin	O
(	O
IL	O
)-	O
6	O
","	O
IL	O
-	O
10	O
","	O
and	O
tumor	O
necrosis	O
factor	O
-	O
Î±	O
(	O
TNF	O
-	O
Î±	O
)	O
were	O
also	O
measured	O
.	O
Surfactant	O
protein	O
-	O
B	O
(	O
SPB	O
)	O
and	O
Î±	O
-	O
SMA	O
expression	O
patterns	O
were	O
evaluated	O
using	O
immunohistochemistry	O
","	O
and	O
the	O
protein	O
levels	O
of	O
nuclear	O
transcription	O
factor	O
NF	O
-	O
E2	O
-	O
related	O
factor	O
2	O
(	O
Nrf	O
-	O
2	O
)	O
and	O
its	O
associated	O
antioxidant	O
enzymes	O
heme	O
oxygenase	O
-	O
1	O
enzyme	O
(	O
HO	O
-	O
1	O
)	O
and	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
oxidoreductase	O
-	O
1	O
(	O
NQO	O
-	O
1	O
)	O
were	O
examined	O
via	O
western	O
blot	O
analysis	O
.	O
Treatment	O
with	O
EGCG	B-Chemical
","	O
but	O
not	O
DEX	B-Chemical
","	O
reduced	O
mortality	O
rates	O
and	O
lung	O
index	O
scores	O
","	O
improved	O
histological	O
changes	O
in	O
the	O
lung	O
","	O
reduced	O
collagen	O
depositions	O
","	O
reduced	O
MDA	B-Chemical
content	O
","	O
enhanced	O
SOD	O
activity	O
","	O
inhibited	O
(	O
myo	O
)	O
fibroblast	O
proliferation	O
","	O
protected	O
alveolar	O
epithelial	O
type	O
II	O
(	O
AE2	O
)	O
cells	O
","	O
and	O
regulated	O
serum	O
levels	O
of	O
TGF	O
-	O
Î²1	O
","	O
IL	O
-	O
6	O
","	O
IL	O
-	O
10	O
","	O
and	O
TNF	O
-	O
Î±	O
.	O
Treatment	O
with	O
EGCG	B-Chemical
","	O
but	O
not	O
DEX	B-Chemical
","	O
activated	O
Nrf	O
-	O
2	O
and	O
its	O
downstream	O
antioxidant	O
enzymes	O
HO	O
-	O
1	O
and	O
NQO	O
-	O
1	O
.	O
Taken	O
together	O
","	O
these	O
results	O
showed	O
that	O
EGCG	B-Chemical
treatment	O
significantly	O
inhibits	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O
Furthermore	O
","	O
the	O
results	O
suggested	O
promising	O
clinical	O
EGCG	B-Chemical
therapies	O
to	O
treat	O
this	O
disorder	O
.	O
Introduction	O
Irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
is	O
a	O
major	O
complication	O
associated	O
with	O
total	O
body	O
irradiation	O
for	O
hematopoietic	O
stem	O
cell	O
transplantation	O
","	O
nuclear	O
accidents	O
","	O
and	O
thoracic	O
radiotherapy	O
for	O
lung	O
cancer	O
","	O
breast	O
cancer	O
","	O
thymoma	O
","	O
and	O
lymphoma	O
(	O
1	O
","	O
2	O
).	O
This	O
complication	O
develops	O
~	O
6	O
months	O
to	O
several	O
years	O
after	O
radiation	O
exposure	O
in	O
humans	O
and	O
100	O
â€“	O
120	O
days	O
post	O
-	O
irradiation	O
in	O
the	O
C57BL	O
/	O
6J	O
mouse	O
model	O
(	O
2	O
).	O
Recent	O
clinical	O
data	O
have	O
demonstrated	O
that	O
the	O
incidence	O
of	O
irradiation	O
-	O
related	O
pulmonary	O
injury	O
among	O
patients	O
with	O
cancer	O
who	O
received	O
radiotherapy	O
ranged	O
from	O
20	O
.	O
3	O
%	O
to	O
36	O
.	O
9	O
%	O
(	O
3	O
â€“	O
6	O
).	O
The	O
current	O
clinical	O
treatment	O
for	O
pulmonary	O
fibrosis	O
primarily	O
involves	O
drugs	O
such	O
as	O
steroids	B-Chemical
or	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
agents	O
and	O
immunosuppressive	O
agents	O
.	O
These	O
drugs	O
can	O
decrease	O
acute	O
pneumonitis	O
for	O
2	O
â€“	O
3	O
months	O
after	O
irradiation	O
","	O
but	O
they	O
cannot	O
effectively	O
mitigate	O
fibrosis	O
(	O
2	O
).	O
In	O
addition	O
","	O
immunosuppressive	O
agents	O
can	O
cause	O
serious	O
side	O
-	O
effects	O
","	O
including	O
death	O
.	O
Oxidative	O
stress	O
begins	O
at	O
radiation	O
exposure	O
and	O
is	O
sustained	O
throughout	O
the	O
disease	O
â€™	O
s	O
progression	O
","	O
presumably	O
through	O
the	O
radiation	O
-	O
induced	O
activation	O
of	O
oxidant	O
-	O
generating	O
enzymes	O
","	O
mitochondrial	O
leakage	O
","	O
and	O
the	O
activation	O
of	O
the	O
respiratory	O
burst	O
in	O
the	O
phagocytic	O
cells	O
that	O
infiltrate	O
damaged	O
tissue	O
(	O
7	O
).	O
Therefore	O
","	O
antioxidant	O
treatment	O
strategies	O
are	O
being	O
developed	O
to	O
treat	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O
Epigallocatechin	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
gallate	I-Chemical
(	O
EGCG	B-Chemical
)	O
is	O
a	O
natural	O
antioxidant	O
derived	O
from	O
green	O
tea	O
that	O
has	O
attracted	O
particular	O
attention	O
and	O
recognition	O
for	O
its	O
potential	O
applications	O
in	O
the	O
treatment	O
of	O
oxidative	O
stress	O
-	O
related	O
diseases	O
including	O
cancer	O
","	O
cardiovascular	O
diseases	O
","	O
and	O
neurodegenerative	O
diseases	O
(	O
8	O
).	O
EGCG	B-Chemical
is	O
the	O
primary	O
component	O
of	O
tea	O
polyphenols	B-Chemical
","	O
and	O
it	O
has	O
shown	O
a	O
wide	O
range	O
of	O
biological	O
activities	O
and	O
pharmacological	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
","	O
including	O
antioxidant	O
","	O
anti	O
-	O
free	B-Chemical
radical	I-Chemical
","	O
anti	O
-	O
mutagenic	O
","	O
and	O
antitumor	O
effects	O
(	O
9	O
).	O
EGCG	B-Chemical
inhibits	O
chemical	O
-	O
induced	O
lung	O
fibrosis	O
(	O
10	O
â€“	O
13	O
)	O
and	O
liver	O
fibrosis	O
(	O
14	O
).	O
However	O
","	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
and	O
acute	O
chemical	O
-	O
induced	O
lung	O
injury	O
are	O
not	O
identical	O
","	O
particularly	O
with	O
respect	O
to	O
their	O
pathogeneses	O
.	O
As	O
yet	O
","	O
no	O
study	O
has	O
examined	O
the	O
efficacy	O
or	O
mechanism	O
of	O
action	O
of	O
EGCG	B-Chemical
with	O
regard	O
to	O
preventing	O
or	O
treating	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O
To	O
counteract	O
the	O
oxidative	O
stress	O
induced	O
by	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
"),"	O
lung	O
cells	O
activate	O
a	O
wide	O
variety	O
of	O
endogenous	O
antioxidant	O
enzymes	O
including	O
catalase	O
","	O
superoxide	O
dismutases	O
","	O
and	O
peroxiredoxins	O
.	O
The	O
transcription	O
of	O
these	O
cytoprotective	O
enzymes	O
is	O
regulated	O
by	O
the	O
nuclear	O
transcription	O
factor	O
NF	O
-	O
E2	O
-	O
related	O
factor	O
2	O
(	O
Nrf2	O
"),"	O
which	O
plays	O
a	O
central	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
redox	O
status	O
.	O
Under	O
normal	O
homeostatic	O
conditions	O
","	O
Nrf2	O
transcription	O
is	O
repressed	O
by	O
its	O
negative	O
regulator	O
Kelch	O
-	O
like	O
ECH	O
-	O
associated	O
protein	O
1	O
(	O
Keap1	O
).	O
However	O
","	O
following	O
exposure	O
to	O
ROS	B-Chemical
","	O
Nrf2	O
dissociates	O
from	O
cytosolic	O
Keap1	O
and	O
translocates	O
to	O
the	O
nucleus	O
","	O
where	O
it	O
binds	O
to	O
the	O
antioxidant	O
response	O
element	O
(	O
ARE	O
)	O
in	O
the	O
promoter	O
regions	O
of	O
the	O
genes	O
that	O
encode	O
antioxidant	O
enzymes	O
and	O
induce	O
their	O
transcription	O
(	O
15	O
).	O
The	O
antioxidant	O
enzyme	O
system	O
regulated	O
by	O
the	O
Nrf2	O
-	O
ARE	O
signaling	O
pathway	O
is	O
primarily	O
composed	O
of	O
heme	O
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
"),"	O
Î³	O
-	O
glutamine	O
cysteine	O
synthetase	O
(	O
Î³	O
-	O
GCS	O
"),"	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
oxidoreductase	O
-	O
1	O
(	O
NQO	O
-	O
1	O
)	O
and	O
superoxide	O
dismutase	O
(	O
SOD	O
).	O
In	O
the	O
present	O
study	O
","	O
we	O
hypothesized	O
that	O
the	O
administration	O
of	O
EGCG	B-Chemical
would	O
significantly	O
inhibit	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O
We	O
first	O
evaluated	O
the	O
efficacy	O
of	O
EGCG	B-Chemical
to	O
ameliorate	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
and	O
then	O
examined	O
whether	O
EGCG	B-Chemical
treatment	O
influenced	O
Nrf	O
-	O
2	O
","	O
HO	O
-	O
1	O
and	O
NQO	O
-	O
1	O
levels	O
in	O
irradiated	O
rats	O
.	O
To	O
the	O
best	O
of	O
our	O
knowledge	O
","	O
this	O
study	O
is	O
the	O
first	O
to	O
assess	O
and	O
highlight	O
the	O
efficacy	O
of	O
EGCG	B-Chemical
in	O
the	O
treatment	O
of	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O
Materials	O
and	O
methods	O
Animals	O
Male	O
6	O
-	O
to	O
8	O
-	O
week	O
-	O
old	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
(	O
Laboratory	O
Animal	O
Center	O
","	O
Academy	O
of	O
Military	O
Medical	O
Sciences	O
","	O
Beijing	O
","	O
China	O
)	O
weighing	O
180	O
â€“	O
200	O
g	O
were	O
housed	O
in	O
an	O
SPF	O
-	O
graded	O
animal	O
care	O
facility	O
according	O
to	O
the	O
guidelines	O
of	O
the	O
National	O
Institutes	O
of	O
Health	O
and	O
Academy	O
of	O
Military	O
Medical	O
Sciences	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	O
.	O
The	O
Committee	O
on	O
the	O
Ethics	O
of	O
Animal	O
Experiments	O
of	O
the	O
Affiliated	O
Hospital	O
of	O
Academy	O
of	O
Military	O
Medical	O
Sciences	O
approved	O
the	O
protocol	O
.	O
All	O
interventions	O
were	O
performed	O
under	O
sodium	B-Chemical
pentobarbital	I-Chemical
anesthesia	O
","	O
and	O
all	O
efforts	O
were	O
made	O
to	O
minimize	O
suffering	O
.	O
Rats	O
were	O
provided	O
with	O
pathogen	O
-	O
free	O
water	O
and	O
food	O
for	O
maintenance	O
and	O
caged	O
in	O
a	O
controlled	O
SPF	O
environment	O
with	O
a	O
12	O
/	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
.	O
Rats	O
were	O
observed	O
daily	O
up	O
to	O
4	O
months	O
post	O
-	O
irradiation	O
","	O
with	O
particular	O
attention	O
afforded	O
to	O
difficulties	O
in	O
breathing	O
","	O
ruffling	O
of	O
the	O
fur	O
","	O
hunched	O
posture	O
","	O
and	O
decreased	O
breathing	O
rate	O
.	O
The	O
natural	O
death	O
of	O
the	O
animals	O
was	O
recorded	O
.	O
Irradiation	O
and	O
treatment	O
A	O
60Co	B-Chemical
irradiator	O
[	O
Reviss	O
Services	O
(	O
UK	O
"),"	O
Ltd	O
".,"	O
Buckinghamshire	O
","	O
UK	O
]	O
was	O
used	O
to	O
generate	O
gamma	O
-	O
ray	O
radiation	O
.	O
The	O
rats	O
were	O
irradiated	O
to	O
22	O
Gy	O
at	O
a	O
dose	O
rate	O
of	O
290	O
cGy	O
/	O
min	O
.	O
The	O
beam	O
was	O
restricted	O
to	O
the	O
entire	O
thorax	O
.	O
After	O
anesthetization	O
with	O
3	O
%	O
sodium	B-Chemical
pentobarbital	I-Chemical
(	O
45	O
mg	O
/	O
kg	O
)	O
and	O
irradiation	O
as	O
described	O
above	O
","	O
the	O
rats	O
were	O
intraperitoneally	O
injected	O
with	O
EGCG	B-Chemical
(	O
25	O
mg	O
/	O
kg	O
;	O
Sigma	O
","	O
St	O
.	O
Louis	O
","	O
MO	O
","	O
USA	O
)	O
(	O
n	O
=	O
40	O
)	O
or	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
;	O
n	O
=	O
40	O
;	O
5	O
mg	O
/	O
kg	O
;	O
Tianjing	O
Pharmaceuticals	O
Group	O
Corp	O
".,"	O
Tianjing	O
","	O
China	O
)	O
daily	O
for	O
30	O
days	O
.	O
Irradiated	O
rats	O
(	O
radiation	O
only	O
;	O
n	O
=	O
40	O
)	O
received	O
radiation	O
without	O
treatment	O
.	O
The	O
control	O
group	O
(	O
n	O
=	O
40	O
)	O
was	O
composed	O
of	O
normally	O
fed	O
","	O
age	O
-	O
matched	O
animals	O
that	O
were	O
not	O
irradiated	O
.	O
Similar	O
doses	O
of	O
EGCG	B-Chemical
(	O
25	O
mg	O
/	O
kg	O
)	O
were	O
used	O
in	O
previous	O
studies	O
(	O
11	O
â€“	O
13	O
).	O
Specimen	O
processing	O
and	O
histopathology	O
After	O
measuring	O
body	O
weight	O
","	O
six	O
rats	O
from	O
each	O
group	O
were	O
sacrificed	O
at	O
15	O
","	O
30	O
","	O
60	O
or	O
120	O
days	O
after	O
initiation	O
of	O
the	O
experiment	O
.	O
The	O
wet	O
weight	O
of	O
the	O
lungs	O
was	O
recorded	O
for	O
each	O
animal	O
.	O
The	O
left	O
lungs	O
were	O
frozen	O
with	O
dry	O
ice	O
powder	O
and	O
kept	O
at	O
âˆ’	O
70	O
Â°	O
C	O
for	O
later	O
use	O
.	O
The	O
right	O
lungs	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	B-Chemical
for	O
histological	O
and	O
immunohistochemical	O
analyses	O
.	O
Blood	O
samples	O
were	O
collected	O
from	O
the	O
heart	O
and	O
allowed	O
to	O
clot	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O
Serum	O
samples	O
were	O
obtained	O
by	O
centrifugation	O
at	O
3	O
","	O
500	O
rpm	O
for	O
5	O
min	O
at	O
4	O
Â°	O
C	O
and	O
then	O
stored	O
at	O
âˆ’	O
70	O
Â°	O
C	O
.	O
The	O
right	O
lungs	O
were	O
dehydrated	O
in	O
ethanol	B-Chemical
and	O
embedded	O
in	O
paraffin	B-Chemical
.	O
Lung	O
sections	O
(	O
5	O
Î¼m	O
)	O
were	O
stained	O
with	O
hematoxylin	B-Chemical
and	I-Chemical
eosin	I-Chemical
(	O
H	B-Chemical
&	I-Chemical
E	I-Chemical
"),"	O
Masson	B-Chemical
â€™	I-Chemical
s	I-Chemical
trichrome	I-Chemical
(	O
Masson	B-Chemical
)	O
and	O
Sirius	B-Chemical
red	I-Chemical
.	O
Lung	O
index	O
measurement	O
The	O
ratio	O
of	O
the	O
lung	O
wet	O
weight	O
(	O
mg	O
)	O
to	O
body	O
weight	O
(	O
g	O
)	O
was	O
used	O
as	O
the	O
lung	O
index	O
.	O
Measurement	O
of	O
collagen	O
content	O
in	O
the	O
lungs	O
Lung	O
collagen	O
content	O
was	O
determined	O
using	O
the	O
hydroxyproline	B-Chemical
(	O
Hyp	B-Chemical
)	O
assay	O
according	O
to	O
the	O
manufacturer	O
â€™	O
s	O
protocol	O
(	O
Nanjing	O
Jiancheng	O
Bioengineering	O
Institute	O
","	O
Nanjing	O
","	O
China	O
).	O
Approximately	O
100	O
mg	O
of	O
left	O
lung	O
tissue	O
was	O
hydrolyzed	O
in	O
1	O
ml	O
of	O
lysis	O
buffer	O
solution	O
at	O
100	O
Â°	O
C	O
for	O
20	O
min	O
.	O
The	O
absorbance	O
of	O
colored	O
products	O
was	O
measured	O
at	O
550	O
nm	O
.	O
Malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
content	O
and	O
SOD	O
activity	O
measurements	O
in	O
serum	O
Serum	O
samples	O
were	O
assayed	O
for	O
MDA	B-Chemical
content	O
and	O
SOD	O
activity	O
using	O
commercially	O
available	O
kits	O
according	O
to	O
the	O
manufacturer	O
â€™	O
s	O
instructions	O
(	O
Nanjing	O
Jiancheng	O
Bioengineering	O
Institute	O
).	O
MDA	B-Chemical
","	O
an	O
end	O
product	O
of	O
ROS	B-Chemical
-	O
induced	O
peroxidation	O
of	O
cell	O
membrane	O
lipids	B-Chemical
","	O
is	O
a	O
reliable	O
marker	O
of	O
oxidative	O
damage	O
(	O
16	O
).	O
MDA	B-Chemical
content	O
was	O
determined	O
by	O
measuring	O
chromogen	O
generation	O
from	O
the	O
reaction	O
of	O
MDA	B-Chemical
with	O
2	B-Chemical
-	I-Chemical
thiobarbituric	I-Chemical
acid	I-Chemical
.	O
SOD	O
activity	O
was	O
measured	O
by	O
monitoring	O
the	O
sample	O
â€™	O
s	O
capacity	O
to	O
inhibit	O
the	O
reduction	O
of	O
ferricytochrome	O
c	O
via	O
xanthine	B-Chemical
/	O
xanthine	O
oxidase	O
.	O
Briefly	O
","	O
this	O
method	O
is	O
dependent	O
on	O
the	O
inhibition	O
of	O
nitroblue	B-Chemical
tetrazolium	I-Chemical
(	O
NBT	B-Chemical
)	O
reduction	O
via	O
the	O
xanthine	B-Chemical
/	O
xanthine	O
oxidase	O
system	O
as	O
a	O
superoxide	B-Chemical
generator	O
(	O
17	O
).	O
Immunohistochemical	O
analyses	O
Lung	O
sections	O
(	O
5	O
Î¼m	O
)	O
were	O
deparaffinized	O
","	O
rehydrated	O
through	O
a	O
graded	O
alcohol	B-Chemical
series	O
","	O
and	O
exposed	O
to	O
a	O
microwave	O
-	O
based	O
antigen	O
retrieval	O
with	O
a	O
citrate	B-Chemical
buffer	O
(	O
10	O
mM	O
of	O
sodium	B-Chemical
citrate	I-Chemical
","	O
pH	O
6	O
.	O
0	O
for	O
15	O
min	O
).	O
Endogenous	O
peroxidases	O
were	O
quenched	O
using	O
3	O
%	O
H2O2	B-Chemical
for	O
5	O
min	O
.	O
The	O
sections	O
were	O
incubated	O
with	O
surfactant	O
protein	O
-	O
B	O
(	O
SPB	O
;	O
1	O
:	O
200	O
)	O
or	O
Î±	O
smooth	O
muscle	O
actin	O
(	O
Î±	O
-	O
SMA	O
;	O
1	O
:	O
200	O
)	O
(	O
both	O
from	O
Boster	O
Biological	O
Technology	O
","	O
Wuhan	O
","	O
China	O
)	O
antibodies	O
at	O
37	O
Â°	O
C	O
for	O
2	O
h	O
.	O
The	O
primary	O
antibody	O
was	O
omitted	O
in	O
the	O
negative	O
control	O
samples	O
.	O
After	O
washing	O
with	O
PBS	B-Chemical
","	O
the	O
sections	O
were	O
incubated	O
with	O
poly	O
-	O
peroxidase	O
-	O
conjugated	O
anti	O
-	O
mouse	O
/	O
rabbit	O
IgG	O
for	O
30	O
min	O
at	O
37	O
Â°	O
C	O
using	O
the	O
Polymer	O
-	O
HRP	O
Detection	O
System	O
(	O
Zymed	O
Laboratories	O
","	O
South	O
San	O
Francisco	O
","	O
CA	O
","	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
â€™	O
s	O
instructions	O
.	O
The	O
slides	O
were	O
visualized	O
with	O
diaminobenzidine	B-Chemical
(	O
DAB	B-Chemical
;	O
Dako	O
","	O
Glostrup	O
","	O
Denmark	O
"),"	O
counterstained	O
with	O
Mayer	O
â€™	O
s	O
hematoxylin	B-Chemical
","	O
dehydrated	O
through	O
increasing	O
concentrations	O
of	O
alcohol	B-Chemical
","	O
cleared	O
in	O
xylene	B-Chemical
","	O
and	O
mounted	O
in	O
neutral	B-Chemical
balsam	I-Chemical
(	O
Sigma	O
).	O
Serum	O
cytokine	O
levels	O
Serum	O
levels	O
of	O
TGF	O
-	O
Î²1	O
were	O
determined	O
using	O
the	O
commercially	O
available	O
TGF	O
-	O
Î²1	O
ELISA	O
kit	O
according	O
to	O
the	O
manufacturer	O
â€™	O
s	O
instructions	O
(	O
Boster	O
Biological	O
Technology	O
).	O
The	O
OD	O
value	O
was	O
determined	O
at	O
450	O
nm	O
using	O
an	O
ELISA	O
reader	O
and	O
calculated	O
at	O
the	O
linear	O
portion	O
of	O
the	O
curve	O
.	O
Serum	O
levels	O
of	O
IL	O
-	O
6	O
","	O
IL	O
-	O
10	O
","	O
and	O
TNF	O
-	O
Î±	O
were	O
measured	O
using	O
flow	O
cytometric	O
bead	O
assays	O
according	O
to	O
the	O
manufacturer	O
â€™	O
s	O
instructions	O
(	O
BD	O
â„¢	O
CBA	O
Flex	O
Set	O
;	O
BD	O
","	O
Sparks	O
","	O
MD	O
","	O
USA	O
).	O
Western	O
blot	O
analysis	O
Frozen	O
left	O
lungs	O
were	O
pulverized	O
and	O
lysed	O
in	O
RIPA	O
buffer	O
.	O
Lysates	O
were	O
centrifuged	O
at	O
12	O
","	O
0	O
rpm	O
and	O
4	O
Â°	O
C	O
for	O
10	O
min	O
","	O
and	O
the	O
supernatants	O
were	O
collected	O
for	O
total	O
protein	O
analysis	O
.	O
A	O
BCA	O
protein	O
assay	O
kit	O
(	O
Beyotime	O
Institute	O
of	O
Biotechnology	O
","	O
Jiangsu	O
","	O
China	O
)	O
was	O
used	O
to	O
determine	O
protein	O
concentrations	O
.	O
Equal	O
amounts	O
of	O
protein	O
were	O
separated	O
by	O
SDS	B-Chemical
-	O
PAGE	O
","	O
transferred	O
to	O
a	O
PVDF	B-Chemical
membrane	O
(	O
Millipore	O
Corp	O
".,"	O
Billerica	O
","	O
MA	O
","	O
USA	O
"),"	O
and	O
incubated	O
with	O
5	O
%	O
BSA	O
at	O
room	O
temperature	O
for	O
2	O
.	O
5	O
h	O
to	O
block	O
non	O
-	O
specific	O
binding	O
.	O
The	O
membranes	O
were	O
then	O
incubated	O
with	O
the	O
following	O
primary	O
antibodies	O
at	O
room	O
temperature	O
for	O
3	O
h	O
:	O
Nrf	O
-	O
2	O
(	O
1	O
:	O
200	O
;	O
Sigma	O
"),"	O
HO	O
-	O
1	O
(	O
1	O
:	O
200	O
"),"	O
NQO	O
-	O
1	O
(	O
1	O
:	O
200	O
)	O
(	O
both	O
from	O
Millipore	O
)	O
or	O
Î²	O
-	O
actin	O
(	O
1	O
:	O
2	O
","	O
0	O
;	O
Cell	O
Signaling	O
Technology	O
","	O
Inc	O
".,"	O
Danvers	O
","	O
MA	O
","	O
USA	O
).	O
After	O
washing	O
with	O
TBS	B-Chemical
-	I-Chemical
T	I-Chemical
","	O
the	O
membranes	O
were	O
incubated	O
with	O
HRP	O
-	O
conjugated	O
secondary	O
antibodies	O
.	O
The	O
protein	O
bands	O
were	O
visualized	O
using	O
enhanced	O
chemiluminescence	O
with	O
a	O
Super	O
Signal	O
detection	O
kit	O
(	O
Boster	O
Biological	O
Technology	O
).	O
Morphometric	O
analyses	O
Following	O
the	O
methodology	O
described	O
by	O
Szapiel	O
et	O
al	O
(	O
18	O
"),"	O
lung	O
sections	O
stained	O
with	O
H	B-Chemical
&	I-Chemical
E	I-Chemical
or	O
Masson	B-Chemical
â€™	I-Chemical
s	I-Chemical
trichrome	I-Chemical
were	O
scored	O
for	O
alveolitis	O
and	O
fibrosis	O
","	O
respectively	O
.	O
Briefly	O
","	O
the	O
severity	O
of	O
alveolitis	O
and	O
fibrosis	O
was	O
graded	O
and	O
scored	O
on	O
a	O
scale	O
of	O
0	O
â€“	O
3	O
(	O
18	O
):	O
grade	O
0	O
","	O
normal	O
lung	O
;	O
grade	O
1	O
","	O
minimal	O
lesion	O
(	O
lesion	O
area	O
<	O
20	O
%);	O
grade	O
2	O
","	O
moderate	O
lesion	O
(	O
lesion	O
area	O
","	O
20	O
â€“	O
50	O
%);	O
or	O
grade	O
3	O
","	O
severe	O
lesion	O
(	O
lesion	O
area	O
>	O
50	O
%).	O
Ten	O
fields	O
per	O
section	O
at	O
Ã—	O
100	O
magnification	O
were	O
randomly	O
selected	O
per	O
rat	O
","	O
and	O
two	O
blinded	O
pathologists	O
carefully	O
and	O
independently	O
examined	O
60	O
fields	O
per	O
group	O
using	O
an	O
Olympus	O
microscope	O
(	O
Olympus	O
","	O
Tokyo	O
","	O
Japan	O
).	O
The	O
total	O
score	O
of	O
each	O
section	O
was	O
calculated	O
","	O
and	O
the	O
mean	O
score	O
of	O
each	O
group	O
was	O
determined	O
as	O
the	O
total	O
score	O
of	O
all	O
sections	O
divided	O
by	O
six	O
.	O
Lung	O
sections	O
stained	O
with	O
Sirius	B-Chemical
red	I-Chemical
were	O
observed	O
and	O
images	O
were	O
captured	O
using	O
a	O
polarizing	O
microscope	O
.	O
For	O
the	O
immunohistochemical	O
analyses	O
of	O
SPB	O
and	O
Î±	O
-	O
SMA	O
","	O
staining	O
density	O
was	O
determined	O
using	O
Image	O
Proplus	O
software	O
in	O
one	O
field	O
with	O
a	O
prominent	O
DAB	B-Chemical
reaction	O
for	O
each	O
section	O
under	O
Ã—	O
200	O
magnification	O
for	O
a	O
total	O
of	O
six	O
fields	O
per	O
group	O
.	O
Large	O
airways	O
and	O
lung	O
vessels	O
were	O
excluded	O
from	O
all	O
analyses	O
.	O
Statistical	O
analysis	O
Data	O
were	O
expressed	O
as	O
the	O
means	O
Â±	O
standard	O
deviations	O
(	O
SDs	O
).	O
Between	O
-	O
group	O
differences	O
were	O
tested	O
using	O
a	O
two	O
-	O
way	O
ANOVA	O
followed	O
by	O
Tukey	O
â€™	O
s	O
post	O
-	O
hoc	O
test	O
.	O
Two	O
-	O
group	O
comparisons	O
were	O
performed	O
using	O
independent	O
-	O
samples	O
Student	O
â€™	O
s	O
t	O
-	O
tests	O
.	O
P	O
<	O
0	O
.	O
5	O
was	O
considered	O
significant	O
.	O
Results	O
EGCG	B-Chemical
reduces	O
mortality	O
and	O
inhibits	O
the	O
formation	O
of	O
fibrous	O
nodules	O
in	O
pulmonary	O
tissue	O
Irradiated	O
rats	O
treated	O
with	O
EGCG	B-Chemical
(	O
17	O
.	O
5	O
"%,"	O
7	O
/	O
40	O
)	O
had	O
a	O
lower	O
mortality	O
rate	O
compared	O
with	O
irradiated	O
rats	O
treated	O
with	O
DEX	B-Chemical
(	O
27	O
.	O
5	O
"%,"	O
11	O
/	O
40	O
)	O
and	O
those	O
that	O
received	O
radiation	O
only	O
(	O
25	O
.	O
0	O
"%,"	O
10	O
/	O
40	O
).	O
All	O
control	O
animals	O
survived	O
to	O
4	O
months	O
without	O
death	O
.	O
Congested	O
edema	O
and	O
bleeding	O
sites	O
were	O
significantly	O
attenuated	O
in	O
DEX	B-Chemical
-	O
treated	O
pulmonary	O
tissues	O
compared	O
with	O
radiation	O
-	O
only	O
animals	O
at	O
15	O
and	O
30	O
days	O
post	O
-	O
irradiation	O
.	O
Pulmonary	O
collapse	O
and	O
gray	O
fibrous	O
nodules	O
were	O
similar	O
in	O
DEX	B-Chemical
-	O
treated	O
and	O
radiation	O
-	O
only	O
animals	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
Bleeding	O
sites	O
were	O
seldom	O
observed	O
in	O
EGCG	B-Chemical
-	O
treated	O
pulmonary	O
tissues	O
at	O
15	O
days	O
post	O
-	O
irradiation	O
.	O
Signs	O
of	O
congested	O
edema	O
were	O
also	O
significantly	O
attenuated	O
in	O
EGCG	B-Chemical
-	O
treated	O
pulmonary	O
tissues	O
compared	O
with	O
DEX	B-Chemical
-	O
treated	O
and	O
radiation	O
-	O
only	O
tissues	O
at	O
15	O
","	O
30	O
and	O
60	O
days	O
post	O
-	O
irradiation	O
.	O
At	O
120	O
days	O
post	O
-	O
irradiation	O
","	O
the	O
lungs	O
of	O
EGCG	B-Chemical
-	O
treated	O
rats	O
showed	O
signs	O
of	O
edema	O
and	O
uneven	O
surfaces	O
as	O
well	O
as	O
scattered	O
punctuate	O
bleeding	O
points	O
.	O
However	O
","	O
neither	O
pulmonary	O
collapse	O
nor	O
gray	O
fibrous	O
nodules	O
were	O
found	O
in	O
EGCG	B-Chemical
-	O
treated	O
animals	O
at	O
120	O
days	O
post	O
-	O
irradiation	O
(	O
Fig	O
.	O
1	O
).	O
These	O
results	O
suggested	O
that	O
EGCG	B-Chemical
significantly	O
ameliorates	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O
EGCG	B-Chemical
reduces	O
the	O
lung	O
index	O
score	O
We	O
examined	O
whether	O
EGCG	B-Chemical
treatment	O
influenced	O
the	O
lung	O
index	O
","	O
which	O
refers	O
to	O
the	O
ratio	O
of	O
lung	O
wet	O
weight	O
to	O
body	O
weight	O
.	O
The	O
lung	O
index	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
EGCG	B-Chemical
-	O
treated	O
animals	O
relative	O
to	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
30	O
and	O
60	O
days	O
post	O
-	O
irradiation	O
but	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
at	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
This	O
result	O
matches	O
the	O
morphometric	O
observations	O
of	O
lung	O
appearance	O
in	O
EGCG	B-Chemical
-	O
treated	O
animals	O
at	O
120	O
days	O
post	O
-	O
irradiation	O
(	O
Fig	O
.	O
1	O
).	O
At	O
this	O
time	O
point	O
","	O
edema	O
was	O
still	O
detectable	O
in	O
EGCG	B-Chemical
-	O
treated	O
animals	O
but	O
was	O
not	O
detected	O
in	O
DEX	B-Chemical
-	O
treated	O
and	O
untreated	O
irradiated	O
animals	O
.	O
The	O
lung	O
index	O
score	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
among	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
relative	O
to	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
15	O
","	O
30	O
and	O
60	O
days	O
post	O
-	O
irradiation	O
but	O
similar	O
at	O
120	O
days	O
post	O
-	O
irradiation	O
(	O
p	O
>	O
0	O
.	O
5	O
;	O
Fig	O
.	O
2A	O
).	O
These	O
results	O
indicated	O
that	O
EGCG	B-Chemical
significantly	O
attenuated	O
congested	O
edema	O
in	O
pulmonary	O
tissues	O
post	O
-	O
irradiation	O
.	O
EGCG	B-Chemical
improves	O
histological	O
changes	O
and	O
reduces	O
collagen	O
deposition	O
in	O
pulmonary	O
tissues	O
We	O
examined	O
whether	O
EGCG	B-Chemical
treatment	O
improves	O
the	O
histological	O
changes	O
that	O
occur	O
in	O
pulmonary	O
tissues	O
post	O
-	O
irradiation	O
.	O
We	O
performed	O
H	B-Chemical
&	I-Chemical
E	I-Chemical
","	O
Masson	B-Chemical
â€™	I-Chemical
s	I-Chemical
trichrome	I-Chemical
and	O
Sirius	B-Chemical
red	I-Chemical
staining	O
of	O
the	O
lung	O
sections	O
to	O
observe	O
histological	O
changes	O
.	O
A	O
semi	O
-	O
quantitative	O
analysis	O
involving	O
alveolitis	O
and	O
fibrosis	O
scores	O
was	O
performed	O
on	O
the	O
H	B-Chemical
&	I-Chemical
E	I-Chemical
-	O
and	O
Masson	B-Chemical
-	O
stained	O
sections	O
following	O
Szapiel	O
â€™	O
s	O
method	O
(	O
18	O
).	O
Markedly	O
thickened	O
alveolar	O
walls	O
","	O
collapsed	O
alveoli	O
","	O
foam	O
-	O
like	O
cells	O
in	O
the	O
alveolar	O
space	O
","	O
diffuse	O
accumulations	O
of	O
inflammatory	O
cells	O
","	O
extensive	O
depositions	O
of	O
collagen	O
","	O
and	O
regional	O
fibrotic	O
foci	O
were	O
observed	O
in	O
the	O
H	B-Chemical
&	I-Chemical
E	I-Chemical
-	O
stained	O
irradiated	O
pulmonary	O
tissues	O
at	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
Treatment	O
with	O
EGCG	B-Chemical
","	O
but	O
not	O
DEX	B-Chemical
","	O
significantly	O
improved	O
irradiation	O
-	O
induced	O
pathological	O
changes	O
(	O
Fig	O
.	O
3	O
","	O
left	O
column	O
).	O
Similarly	O
","	O
Masson	B-Chemical
â€™	I-Chemical
s	I-Chemical
trichrome	I-Chemical
(	O
Fig	O
.	O
3	O
","	O
middle	O
column	O
)	O
and	O
Sirius	B-Chemical
red	I-Chemical
staining	O
(	O
Fig	O
.	O
3	O
","	O
right	O
column	O
)	O
of	O
the	O
lung	O
sections	O
revealed	O
that	O
the	O
regional	O
fibrotic	O
foci	O
and	O
collagen	O
depositions	O
were	O
greatly	O
reduced	O
after	O
EGCG	B-Chemical
treatment	O
.	O
The	O
alveolitis	O
and	O
fibrosis	O
scores	O
of	O
EGCG	B-Chemical
-	O
treated	O
animals	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
than	O
those	O
of	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
alveolitis	O
score	O
of	O
the	O
latter	O
group	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
than	O
that	O
of	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
15	O
and	O
30	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
fibrosis	O
score	O
of	O
DEX	B-Chemical
-	O
treated	O
animals	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
than	O
that	O
of	O
radiation	O
-	O
only	O
animals	O
at	O
30	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
alveolitis	O
and	O
fibrosis	O
scores	O
of	O
DEX	B-Chemical
-	O
treated	O
animals	O
were	O
similar	O
to	O
those	O
of	O
radiation	O
-	O
only	O
animals	O
but	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
than	O
those	O
of	O
EGCG	B-Chemical
-	O
treated	O
animals	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
(	O
Fig	O
.	O
2B	O
and	O
C	O
).	O
We	O
also	O
examined	O
the	O
degree	O
to	O
which	O
EGCG	B-Chemical
treatment	O
eliminated	O
Hyp	B-Chemical
","	O
the	O
major	O
constituent	O
of	O
collagen	O
","	O
from	O
pulmonary	O
tissues	O
.	O
The	O
amount	O
of	O
Hyp	B-Chemical
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
EGCG	B-Chemical
-	O
treated	O
animals	O
than	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
Hyp	B-Chemical
content	O
of	O
the	O
latter	O
group	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
than	O
that	O
of	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
15	O
and	O
30	O
days	O
post	O
-	O
irradiation	O
but	O
similar	O
to	O
that	O
of	O
these	O
animals	O
","	O
and	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
than	O
that	O
of	O
the	O
EGCG	B-Chemical
-	O
treated	O
animals	O
","	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
Together	O
","	O
these	O
results	O
showed	O
marked	O
anti	O
-	O
fibrotic	O
effects	O
of	O
EGCG	B-Chemical
in	O
vivo	O
(	O
Fig	O
.	O
2D	O
).	O
EGCG	B-Chemical
modulates	O
the	O
serum	O
redox	O
state	O
We	O
investigated	O
whether	O
EGCG	B-Chemical
treatment	O
regulates	O
the	O
redox	O
balance	O
post	O
-	O
irradiation	O
.	O
Serum	O
MDA	B-Chemical
content	O
and	O
SOD	O
activity	O
were	O
measured	O
to	O
assess	O
the	O
oxidative	O
and	O
antioxidant	O
statuses	O
","	O
respectively	O
.	O
The	O
serum	O
MDA	B-Chemical
concentration	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
EGCG	B-Chemical
-	O
treated	O
animals	O
than	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
MDA	B-Chemical
concentration	O
in	O
DEX	B-Chemical
-	O
treated	O
animals	O
was	O
similar	O
to	O
that	O
of	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
(	O
Fig	O
.	O
4A	O
).	O
Serum	O
SOD	O
activity	O
was	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
EGCG	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
Levels	O
of	O
SOD	O
activity	O
in	O
the	O
latter	O
group	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
than	O
those	O
of	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
30	O
days	O
post	O
-	O
irradiation	O
but	O
similar	O
at	O
15	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
(	O
Fig	O
.	O
4B	O
).	O
These	O
results	O
demonstrated	O
that	O
EGCG	B-Chemical
treatment	O
modulates	O
redox	O
balance	O
in	O
vivo	O
.	O
EGCG	B-Chemical
inhibits	O
(	O
myo	O
)	O
fibroblast	O
proliferation	O
and	O
protects	O
alveolar	O
epithelial	O
type	O
II	O
(	O
AE2	O
)	O
cells	O
from	O
injury	O
The	O
activation	O
and	O
proliferation	O
of	O
(	O
myo	O
)	O
fibroblasts	O
are	O
important	O
contributors	O
to	O
pulmonary	O
fibrosis	O
.	O
Injury	O
to	O
the	O
AE2	O
cells	O
directly	O
and	O
indirectly	O
contributes	O
to	O
the	O
effects	O
of	O
irradiation	O
-	O
induced	O
pulmonary	O
injury	O
.	O
Therefore	O
","	O
we	O
investigated	O
the	O
effects	O
of	O
EGCG	B-Chemical
on	O
(	O
myo	O
)	O
fibroblasts	O
and	O
AE2	O
cells	O
.	O
The	O
expression	O
of	O
Î±	O
-	O
SMA	O
","	O
a	O
(	O
myo	O
)	O
fibroblast	O
marker	O
","	O
and	O
SPB	O
","	O
an	O
AE2	O
marker	O
","	O
was	O
investigated	O
using	O
immunohistochemistry	O
on	O
the	O
lung	O
sections	O
.	O
Strong	O
Î±	O
-	O
SMA	O
expression	O
was	O
observed	O
in	O
the	O
irradiated	O
pulmonary	O
tissues	O
at	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
Treatment	O
with	O
EGCG	B-Chemical
","	O
but	O
not	O
DEX	B-Chemical
","	O
significantly	O
reduced	O
Î±	O
-	O
SMA	O
expression	O
(	O
Fig	O
.	O
5	O
","	O
left	O
column	O
).	O
Conversely	O
","	O
weak	O
SPB	O
expression	O
was	O
observed	O
in	O
the	O
irradiated	O
pulmonary	O
tissues	O
at	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
Treatment	O
with	O
EGCG	B-Chemical
","	O
but	O
not	O
DEX	B-Chemical
","	O
significantly	O
enhanced	O
SPB	O
expression	O
(	O
Fig	O
.	O
5	O
","	O
right	O
column	O
).	O
A	O
morphometric	O
analysis	O
of	O
Î±	O
-	O
SMA	O
and	O
SPB	O
immunohistochemistry	O
as	O
described	O
in	O
Materials	O
and	O
methods	O
was	O
performed	O
.	O
The	O
OD	O
value	O
for	O
Î±	O
-	O
SMA	O
immunohistochemistry	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
the	O
EGCG	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
OD	O
value	O
for	O
Î±	O
-	O
SMA	O
immunohistochemistry	O
in	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
was	O
similar	O
to	O
that	O
of	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
(	O
p	O
>	O
0	O
.	O
5	O
;	O
Fig	O
.	O
4C	O
).	O
Conversely	O
","	O
the	O
OD	O
value	O
for	O
SPB	O
immunohistochemistry	O
was	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
the	O
EGCG	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
OD	O
value	O
for	O
SPB	O
immunohistochemistry	O
in	O
the	O
latter	O
group	O
was	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
than	O
that	O
of	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
(	O
Fig	O
.	O
4D	O
).	O
These	O
results	O
confirmed	O
that	O
EGCG	B-Chemical
inhibits	O
(	O
myo	O
)	O
fibroblast	O
proliferation	O
and	O
protects	O
AE2	O
cells	O
from	O
injury	O
post	O
-	O
irradiation	O
.	O
EGCG	B-Chemical
regulates	O
serum	O
cytokine	O
levels	O
We	O
examined	O
whether	O
treatment	O
with	O
EGCG	B-Chemical
reverses	O
the	O
abnormal	O
expression	O
of	O
cytokines	O
in	O
serum	O
following	O
irradiation	O
.	O
Therefore	O
","	O
we	O
measured	O
the	O
serum	O
levels	O
of	O
TGF	O
-	O
Î²1	O
using	O
ELISA	O
as	O
well	O
as	O
IL	O
-	O
6	O
","	O
IL	O
-	O
10	O
","	O
and	O
TNF	O
-	O
Î±	O
using	O
the	O
BD	O
â„¢	O
CBA	O
Flex	O
Set	O
.	O
The	O
serum	O
level	O
of	O
TGF	O
-	O
Î²1	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
the	O
EGCG	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
","	O
whereas	O
the	O
level	O
observed	O
in	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
was	O
similar	O
to	O
that	O
of	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
the	O
same	O
time	O
points	O
(	O
Fig	O
.	O
6A	O
).	O
The	O
serum	O
levels	O
of	O
IL	O
-	O
6	O
","	O
IL	O
-	O
10	O
and	O
TNF	O
-	O
Î±	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
the	O
EGCG	B-Chemical
-	O
treated	O
animals	O
than	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
IL	O
-	O
6	O
and	O
TNF	O
-	O
Î±	O
levels	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
the	O
DEX	B-Chemical
group	O
compared	O
with	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
15	O
and	O
30	O
days	O
post	O
-	O
irradiation	O
.	O
IL	O
-	O
10	O
was	O
significantly	O
reduced	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
30	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
levels	O
of	O
IL	O
-	O
6	O
","	O
IL	O
-	O
10	O
and	O
TNF	O
-	O
Î±	O
in	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
were	O
similar	O
to	O
those	O
of	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
(	O
Fig	O
.	O
6B	O
â€“	O
D	O
).	O
EGCG	B-Chemical
activates	O
Nrf	O
-	O
2	O
and	O
its	O
downstream	O
antioxidant	O
enzymes	O
in	O
pulmonary	O
tissues	O
We	O
also	O
examined	O
whether	O
EGCG	B-Chemical
treatment	O
activates	O
Nrf	O
-	O
2	O
signaling	O
and	O
its	O
associated	O
antioxidant	O
enzymes	O
.	O
The	O
protein	O
levels	O
of	O
Nrf	O
-	O
2	O
","	O
HO	O
-	O
1	O
and	O
NQO	O
-	O
1	O
were	O
assessed	O
by	O
western	O
blot	O
analysis	O
.	O
This	O
analysis	O
revealed	O
that	O
EGCG	B-Chemical
administration	O
strongly	O
activated	O
Nrf	O
-	O
2	O
","	O
HO	O
-	O
1	O
","	O
and	O
NQO	O
-	O
1	O
protein	O
levels	O
","	O
whereas	O
DEX	B-Chemical
administration	O
weakly	O
activated	O
Nrf	O
-	O
2	O
levels	O
at	O
15	O
days	O
post	O
irradiation	O
(	O
Fig	O
.	O
7	O
).	O
The	O
protein	O
levels	O
of	O
Nrf	O
-	O
2	O
","	O
HO	O
-	O
1	O
","	O
and	O
NQO	O
-	O
1	O
were	O
significantly	O
greater	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
the	O
pulmonary	O
homogenates	O
from	O
the	O
EGCG	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
those	O
of	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
Nrf	O
-	O
2	O
","	O
HO	O
-	O
1	O
and	O
NQO	O
-	O
1	O
levels	O
of	O
the	O
latter	O
group	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
than	O
those	O
of	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
15	O
and	O
30	O
days	O
post	O
-	O
irradiation	O
but	O
similar	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
(	O
Fig	O
.	O
8	O
).	O
Discussion	O
Results	O
of	O
the	O
present	O
study	O
have	O
shown	O
that	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
in	O
rats	O
is	O
principally	O
ameliorated	O
by	O
EGCG	B-Chemical
administration	O
.	O
EGCG	B-Chemical
treatment	O
reduced	O
the	O
mortality	O
rate	O
and	O
lung	O
index	O
score	O
","	O
alleviated	O
lung	O
histological	O
damage	O
","	O
reduced	O
collagen	O
deposition	O
","	O
modulated	O
the	O
redox	O
state	O
of	O
serum	O
","	O
inhibited	O
(	O
myo	O
)	O
fibroblast	O
proliferation	O
","	O
protected	O
AE2	O
cells	O
","	O
and	O
regulated	O
the	O
serum	O
levels	O
of	O
TGF	O
-	O
Î²1	O
","	O
IL	O
-	O
6	O
","	O
IL	O
-	O
10	O
","	O
and	O
TNF	O
-	O
Î±	O
.	O
We	O
also	O
showed	O
that	O
EGCG	B-Chemical
treatment	O
activated	O
Nrf	O
-	O
2	O
and	O
its	O
downstream	O
antioxidant	O
enzymes	O
HO	O
-	O
1	O
and	O
NQO	O
-	O
1	O
.	O
The	O
DEX	B-Chemical
treatment	O
of	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
did	O
not	O
produce	O
similarly	O
ameliorative	O
effects	O
.	O
Given	O
these	O
results	O
","	O
we	O
demonstrated	O
that	O
EGCG	B-Chemical
treatment	O
significantly	O
ameliorates	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O
Our	O
data	O
reveal	O
that	O
EGCG	B-Chemical
has	O
potential	O
for	O
treatments	O
of	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O
Increasing	O
evidence	O
indicates	O
that	O
oxidative	O
stress	O
and	O
ROS	B-Chemical
contribute	O
directly	O
and	O
indirectly	O
to	O
the	O
formation	O
of	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
(	O
19	O
).	O
The	O
ROS	B-Chemical
-	O
induced	O
activation	O
of	O
inflammatory	O
cells	O
(	O
including	O
macrophages	O
","	O
monocytes	O
","	O
and	O
neutrophils	O
)	O
can	O
cause	O
a	O
positive	O
feedback	O
loop	O
in	O
which	O
an	O
increased	O
expression	O
of	O
a	O
variety	O
of	O
intracellular	O
oxidative	O
enzymes	O
and	O
large	O
amounts	O
of	O
ROS	B-Chemical
and	O
reactive	B-Chemical
nitrogen	I-Chemical
species	I-Chemical
(	O
RNS	B-Chemical
)	O
are	O
synthesized	O
and	O
released	O
to	O
remove	O
necrotic	O
tissue	O
(	O
20	O
","	O
21	O
).	O
The	O
dynamics	O
of	O
the	O
oxidant	O
/	O
antioxidant	O
balance	O
in	O
the	O
lung	O
are	O
destroyed	O
","	O
and	O
tissue	O
damage	O
persistently	O
increases	O
.	O
Therefore	O
","	O
any	O
therapeutic	O
intervention	O
that	O
defends	O
against	O
or	O
alleviates	O
oxidant	O
insults	O
may	O
be	O
used	O
to	O
treat	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O
Due	O
to	O
its	O
potent	O
antioxidant	O
activity	O
","	O
a	O
variety	O
of	O
animal	O
models	O
have	O
shown	O
that	O
the	O
tea	O
polyphenol	B-Chemical
EGCG	I-Chemical
is	O
an	O
effective	O
scavenger	O
of	O
ROS	B-Chemical
and	O
free	B-Chemical
radicals	I-Chemical
with	O
regard	O
to	O
tumors	O
","	O
cardiovascular	O
diseases	O
","	O
and	O
neurological	O
diseases	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
(	O
15	O
).	O
The	O
antioxidant	O
activity	O
of	O
EGCG	B-Chemical
(	O
which	O
likely	O
involves	O
the	O
quenching	O
of	O
ROS	B-Chemical
","	O
the	O
interception	O
of	O
free	B-Chemical
radicals	I-Chemical
","	O
or	O
both	O
)	O
is	O
most	O
likely	O
mediated	O
by	O
an	O
H	B-Chemical
-	O
atom	O
transfer	O
(	O
HAT	O
)	O
reaction	O
in	O
which	O
intramolecular	O
hydrogen	B-Chemical
bonding	O
stabilizes	O
the	O
resultant	O
phenoxy	B-Chemical
radical	I-Chemical
(	O
22	O
).	O
Previous	O
studies	O
have	O
suggested	O
that	O
EGCG	B-Chemical
administration	O
inhibits	O
lipopolysaccharide	B-Chemical
(	O
8	O
)	O
and	O
bleomycin	B-Chemical
-	O
induced	O
pulmonary	O
fibrosis	O
(	O
11	O
â€“	O
13	O
).	O
Thus	O
","	O
we	O
hypothesized	O
that	O
scavenging	O
free	B-Chemical
radicals	I-Chemical
with	O
EGCG	B-Chemical
","	O
a	O
natural	O
antioxidant	O
extracted	O
from	O
green	O
tea	O
","	O
inhibits	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
.	O
MDA	B-Chemical
levels	O
and	O
total	O
SOD	O
activity	O
in	O
serum	O
are	O
important	O
indicators	O
of	O
oxidative	O
stress	O
and	O
the	O
body	O
â€™	O
s	O
capacity	O
to	O
respond	O
to	O
induced	O
oxidative	O
stress	O
.	O
MDA	B-Chemical
levels	O
most	O
likely	O
reflect	O
the	O
degree	O
of	O
organic	O
lipid	B-Chemical
peroxidation	O
","	O
which	O
denotes	O
the	O
severity	O
of	O
damage	O
to	O
cell	O
membranes	O
(	O
23	O
).	O
Conversely	O
","	O
SOD	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
organic	O
oxidative	O
/	O
antioxidant	O
balance	O
.	O
This	O
enzyme	O
can	O
neutralize	O
free	B-Chemical
radical	I-Chemical
forms	O
of	O
oxygen	B-Chemical
","	O
thereby	O
protecting	O
cells	O
from	O
oxidative	O
damage	O
.	O
Moreover	O
","	O
injections	O
of	O
SOD	O
(	O
24	O
)	O
and	O
the	O
SOD	O
mimetic	O
AEOL	B-Chemical
10113	I-Chemical
(	O
25	O
)	O
have	O
shown	O
protective	O
effects	O
in	O
animal	O
models	O
of	O
radiation	O
-	O
induced	O
fibrosis	O
.	O
Our	O
investigation	O
showed	O
that	O
the	O
serum	O
levels	O
of	O
MDA	B-Chemical
and	O
inflammatory	O
cytokines	O
decreased	O
","	O
and	O
serum	O
SOD	O
activity	O
increased	O
in	O
DEX	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
radiation	O
-	O
only	O
animals	O
at	O
15	O
and	O
30	O
days	O
post	O
-	O
irradiation	O
.	O
However	O
","	O
these	O
therapeutic	O
benefits	O
ceased	O
with	O
treatment	O
.	O
EGCG	B-Chemical
-	O
treated	O
rats	O
had	O
greater	O
SOD	O
activity	O
than	O
any	O
other	O
group	O
of	O
rats	O
","	O
including	O
the	O
non	O
-	O
irradiated	O
normal	O
controls	O
","	O
at	O
all	O
time	O
points	O
(	O
15	O
â€“	O
120	O
days	O
post	O
-	O
irradiation	O
).	O
This	O
result	O
suggests	O
that	O
EGCG	B-Chemical
reduced	O
oxidative	O
stress	O
","	O
at	O
least	O
in	O
part	O
","	O
by	O
increasing	O
the	O
systemic	O
production	O
of	O
antioxidant	O
proteins	O
.	O
Overall	O
","	O
our	O
results	O
have	O
demonstrated	O
that	O
EGCG	B-Chemical
is	O
superior	O
to	O
DEX	B-Chemical
with	O
regard	O
to	O
increasing	O
the	O
body	O
â€™	O
s	O
capacity	O
to	O
handle	O
oxidative	O
stress	O
due	O
to	O
ROS	B-Chemical
/	O
RNS	B-Chemical
","	O
and	O
these	O
effects	O
were	O
sustained	O
long	O
after	O
treatment	O
was	O
discontinued	O
.	O
The	O
development	O
of	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
is	O
also	O
related	O
to	O
the	O
expression	O
of	O
inflammatory	O
cytokines	O
","	O
which	O
play	O
an	O
important	O
role	O
in	O
creating	O
a	O
positive	O
feedback	O
loop	O
to	O
reinforce	O
the	O
chemotaxis	O
of	O
macrophages	O
and	O
neutrophils	O
and	O
sustaining	O
oxidative	O
stress	O
by	O
supporting	O
the	O
enhanced	O
production	O
of	O
ROS	B-Chemical
/	O
RNS	B-Chemical
(	O
26	O
).	O
TGF	O
-	O
Î²1	O
is	O
a	O
powerful	O
cytokine	O
that	O
can	O
promote	O
fibroblast	O
proliferation	O
and	O
maturation	O
","	O
thereby	O
accelerating	O
the	O
development	O
of	O
pulmonary	O
fibrosis	O
(	O
27	O
).	O
Wang	O
et	O
al	O
demonstrated	O
that	O
TGF	O
-	O
Î²1	O
levels	O
were	O
positively	O
correlated	O
with	O
the	O
incidence	O
of	O
radiation	O
-	O
treatment	O
-	O
induced	O
lung	O
injury	O
among	O
patients	O
with	O
lung	O
cancer	O
(	O
28	O
).	O
TNF	O
-	O
Î±	O
is	O
a	O
driving	O
factor	O
within	O
pro	O
-	O
inflammatory	O
and	O
immunoregulatory	O
networks	O
and	O
is	O
likely	O
involved	O
in	O
the	O
development	O
and	O
progression	O
of	O
radiation	O
-	O
induced	O
pneumonitis	O
(	O
29	O
).	O
In	O
addition	O
","	O
TNF	O
-	O
Î±	O
stimulates	O
the	O
proliferation	O
of	O
fibroblasts	O
and	O
the	O
secretion	O
of	O
proinflammatory	O
cytokines	O
","	O
including	O
IL	O
-	O
1	O
and	O
IL	O
-	O
6	O
","	O
from	O
neutrophils	O
and	O
macrophages	O
(	O
30	O
).	O
IL	O
-	O
6	O
plays	O
an	O
important	O
role	O
in	O
the	O
formation	O
and	O
proliferation	O
of	O
fibrous	O
connective	O
tissue	O
","	O
potentially	O
by	O
increasing	O
collagen	O
aggregation	O
","	O
inhibiting	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
degradation	O
","	O
and	O
stimulating	O
fibroblast	O
proliferation	O
.	O
Previous	O
studies	O
have	O
suggested	O
that	O
IL	O
-	O
6	O
leads	O
to	O
inflammation	O
and	O
fibrosis	O
associated	O
with	O
hypersensitivity	O
pneumonitis	O
in	O
mice	O
.	O
These	O
results	O
suggest	O
a	O
close	O
relationship	O
in	O
IL	O
-	O
6	O
and	O
pneumonitis	O
and	O
fibrotic	O
development	O
(	O
31	O
).	O
IL	O
-	O
10	O
may	O
inhibit	O
monocytes	O
","	O
macrophages	O
","	O
and	O
Th1	O
cells	O
as	O
well	O
as	O
enhance	O
B	O
-	O
cell	O
immune	O
regulation	O
function	O
(	O
32	O
).	O
In	O
addition	O
","	O
IL	O
-	O
10	O
is	O
a	O
T	O
-	O
cell	O
-	O
derived	O
cytokine	O
of	O
the	O
Th	O
-	O
2	O
family	O
that	O
suppresses	O
inflammation	O
by	O
inhibiting	O
numerous	O
pro	O
-	O
inflammatory	O
cytokines	O
(	O
33	O
).	O
Findings	O
of	O
Barbarin	O
et	O
al	O
have	O
shown	O
that	O
silica	B-Chemical
-	O
induced	O
pneumonia	O
and	O
pulmonary	O
fibrosis	O
in	O
mice	O
caused	O
the	O
overexpression	O
of	O
IL	O
-	O
10	O
","	O
thereby	O
contributing	O
to	O
the	O
increased	O
lung	O
damage	O
caused	O
by	O
fibrosis	O
(	O
34	O
).	O
To	O
investigate	O
the	O
effects	O
of	O
EGCG	B-Chemical
treatment	O
on	O
systemic	O
inflammation	O
","	O
we	O
measured	O
the	O
serum	O
levels	O
of	O
key	O
inflammatory	O
cytokines	O
including	O
TGF	O
-	O
Î²1	O
","	O
IL	O
-	O
6	O
","	O
IL	O
-	O
10	O
","	O
and	O
TNF	O
-	O
Î±	O
.	O
These	O
cytokines	O
were	O
significantly	O
reduced	O
in	O
the	O
EGCG	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
the	O
untreated	O
and	O
steroid	B-Chemical
-	O
treated	O
rats	O
","	O
and	O
this	O
effect	O
lasted	O
for	O
months	O
after	O
treatment	O
ceased	O
.	O
The	O
lower	O
alveolitis	O
score	O
of	O
the	O
EGCG	B-Chemical
-	O
treated	O
rats	O
also	O
suggested	O
that	O
EGCG	B-Chemical
reduces	O
the	O
infiltration	O
of	O
inflammatory	O
immune	O
cells	O
.	O
Results	O
of	O
this	O
study	O
are	O
in	O
agreement	O
with	O
those	O
of	O
previous	O
studies	O
that	O
have	O
shown	O
significant	O
anti	O
-	O
inflammatory	O
effects	O
from	O
the	O
administration	O
of	O
EGCG	B-Chemical
(	O
10	O
","	O
35	O
","	O
36	O
).	O
This	O
study	O
also	O
investigated	O
the	O
protective	O
effect	O
of	O
EGCG	B-Chemical
on	O
AE2	O
cells	O
.	O
AE2	O
and	O
vascular	O
endothelial	O
cells	O
are	O
the	O
two	O
major	O
targets	O
of	O
radiation	O
-	O
induced	O
lung	O
injury	O
from	O
inflammation	O
and	O
oxidative	O
stress	O
.	O
Results	O
of	O
the	O
SPB	O
staining	O
analysis	O
in	O
the	O
lung	O
revealed	O
that	O
EGCG	B-Chemical
-	O
treated	O
rats	O
showed	O
a	O
more	O
normalized	O
distribution	O
of	O
AE2	O
cells	O
in	O
the	O
parenchyma	O
compared	O
with	O
radiation	O
-	O
only	O
and	O
DEX	B-Chemical
-	O
treated	O
rats	O
.	O
AE2	O
cells	O
were	O
abundant	O
in	O
alveolar	O
walls	O
of	O
the	O
lung	O
tissues	O
of	O
the	O
EGCG	B-Chemical
-	O
treated	O
rats	O
","	O
although	O
no	O
evidence	O
of	O
dysplasia	O
was	O
found	O
.	O
These	O
results	O
suggest	O
that	O
EGCG	B-Chemical
protected	O
parenchymal	O
and	O
AE2	O
cells	O
from	O
free	B-Chemical
radical	I-Chemical
damage	O
.	O
In	O
addition	O
","	O
the	O
myofibroblast	O
proliferation	O
in	O
the	O
lung	O
(	O
as	O
demonstrated	O
by	O
Î±	O
-	O
SMA	O
staining	O
)	O
observed	O
in	O
the	O
radiation	O
-	O
only	O
and	O
DEX	B-Chemical
-	O
treated	O
groups	O
was	O
significantly	O
reduced	O
in	O
rats	O
treated	O
with	O
EGCG	B-Chemical
at	O
60	O
and	O
120	O
days	O
after	O
irradiation	O
","	O
suggesting	O
that	O
EGCG	B-Chemical
-	O
inhibited	O
pulmonary	O
fibrosis	O
partially	O
inhibits	O
myofibroblast	O
transformation	O
and	O
proliferation	O
.	O
We	O
also	O
examined	O
whether	O
EGCG	B-Chemical
improves	O
the	O
ability	O
of	O
the	O
endogenous	O
oxidative	O
stress	O
response	O
system	O
by	O
activating	O
Nrf2	O
and	O
its	O
downstream	O
antioxidant	O
enzymes	O
.	O
Sriram	O
et	O
al	O
investigated	O
the	O
protective	O
effects	O
of	O
EGCG	B-Chemical
in	O
a	O
bleomycin	B-Chemical
-	O
induced	O
acute	O
lung	O
injury	O
animal	O
model	O
and	O
presented	O
the	O
first	O
evidence	O
that	O
EGCG	B-Chemical
protection	O
against	O
lung	O
injury	O
is	O
associated	O
with	O
the	O
Nrf2	O
-	O
based	O
activation	O
of	O
the	O
oxidative	O
stress	O
response	O
(	O
12	O
).	O
Nrf2	O
plays	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
the	O
major	O
antioxidant	O
enzymes	O
HO	O
-	O
1	O
and	O
NQO	O
-	O
1	O
.	O
Sahin	O
et	O
al	O
(	O
37	O
)	O
reported	O
that	O
EGCG	B-Chemical
significantly	O
reduced	O
the	O
production	O
of	O
peroxides	B-Chemical
and	O
the	O
subsequent	O
peroxidation	O
of	O
lipids	B-Chemical
by	O
enhancing	O
the	O
expression	O
of	O
antioxidant	O
enzymes	O
(	O
e	O
.	O
g	O
".,"	O
SOD	O
","	O
CAT	O
","	O
and	O
GPx	O
)	O
to	O
improve	O
the	O
oxidative	O
stress	O
response	O
.	O
Those	O
authors	O
also	O
showed	O
that	O
EGCG	B-Chemical
may	O
increase	O
the	O
downstream	O
expression	O
of	O
other	O
antioxidant	O
enzymes	O
by	O
activating	O
Nrf2	O
and	O
HO	O
-	O
1	O
","	O
thereby	O
regulating	O
oxidative	O
stress	O
.	O
Our	O
western	O
blot	O
analysis	O
results	O
revealed	O
that	O
EGCG	B-Chemical
significantly	O
enhanced	O
the	O
expression	O
levels	O
of	O
Nrf	O
-	O
2	O
","	O
HO	O
-	O
1	O
","	O
and	O
NQO	O
-	O
1	O
in	O
rat	O
lung	O
tissues	O
compared	O
with	O
radiation	O
-	O
only	O
and	O
DEX	B-Chemical
-	O
treated	O
rats	O
","	O
thereby	O
confirming	O
the	O
results	O
of	O
Sriram	O
et	O
al	O
and	O
Sahin	O
et	O
al	O
(	O
12	O
","	O
37	O
)	O
as	O
well	O
as	O
supporting	O
our	O
hypothesis	O
that	O
EGCG	B-Chemical
relieves	O
oxidative	O
stress	O
by	O
activating	O
Nrf2	O
and	O
its	O
associated	O
antioxidant	O
enzymes	O
.	O
Since	O
glucocorticosteroids	O
are	O
commonly	O
used	O
to	O
treat	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
and	O
other	O
forms	O
of	O
lung	O
fibrosis	O
in	O
humans	O
","	O
DEX	B-Chemical
was	O
selected	O
as	O
a	O
baseline	O
to	O
compare	O
the	O
efficacy	O
of	O
EGCG	B-Chemical
using	O
various	O
measures	O
of	O
lung	O
inflammation	O
","	O
the	O
oxidative	O
stress	O
response	O
","	O
and	O
fibrosis	O
.	O
A	O
marginal	O
effectiveness	O
was	O
achieved	O
with	O
DEX	B-Chemical
therapy	O
at	O
15	O
and	O
30	O
days	O
post	O
-	O
irradiation	O
;	O
however	O
","	O
these	O
improvements	O
ceased	O
following	O
discontinuing	O
steroid	B-Chemical
therapy	O
(	O
i	O
.	O
e	O
".,"	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
).	O
The	O
measures	O
of	O
lung	O
inflammation	O
","	O
oxidative	O
stress	O
","	O
and	O
fibrosis	O
among	O
the	O
DEX	B-Chemical
-	O
treated	O
rats	O
were	O
similar	O
to	O
those	O
of	O
the	O
radiation	O
-	O
only	O
group	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
","	O
suggesting	O
a	O
lack	O
of	O
persistent	O
therapeutic	O
effects	O
.	O
Conversely	O
","	O
our	O
results	O
demonstrate	O
that	O
EGCG	B-Chemical
was	O
superior	O
to	O
glucocorticoids	O
with	O
regard	O
to	O
reducing	O
inflammation	O
","	O
fibrosis	O
","	O
and	O
oxidative	O
stress	O
during	O
the	O
treatment	O
period	O
(	O
which	O
ended	O
at	O
30	O
days	O
post	O
-	O
irradiation	O
).	O
In	O
addition	O
","	O
the	O
therapeutic	O
effects	O
of	O
EGCG	B-Chemical
were	O
sustained	O
even	O
after	O
treatment	O
ceased	O
","	O
unlike	O
the	O
steroid	B-Chemical
treatment	O
.	O
Collectively	O
","	O
results	O
of	O
the	O
present	O
study	O
have	O
shown	O
that	O
EGCG	B-Chemical
treatment	O
provides	O
strong	O
","	O
persistent	O
antioxidant	O
","	O
anti	O
-	O
inflammatory	O
","	O
and	O
anti	O
-	O
proliferative	O
effects	O
that	O
protect	O
against	O
irradiation	O
-	O
induced	O
pulmonary	O
fibrosis	O
in	O
rats	O
.	O
The	O
findings	O
suggest	O
that	O
these	O
effects	O
are	O
mediated	O
by	O
inhibiting	O
pro	O
-	O
inflammatory	O
immune	O
cells	O
from	O
infiltrating	O
alveoli	O
and	O
lung	O
parenchyma	O
","	O
suppressing	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
factors	O
","	O
and	O
inhibiting	O
the	O
synthesis	O
and	O
secretion	O
of	O
ROS	B-Chemical
/	O
RNS	B-Chemical
-	O
free	B-Chemical
radicals	I-Chemical
that	O
cause	O
extensive	O
oxidative	O
damage	O
to	O
parenchymal	O
cells	O
.	O
EGCG	B-Chemical
also	O
inhibited	O
myofibroblast	O
proliferation	O
and	O
AE2	O
cell	O
dysplasia	O
","	O
presumably	O
by	O
suppressing	O
the	O
secretion	O
of	O
TGF	O
-	O
Î²1	O
.	O
Of	O
note	O
","	O
the	O
findings	O
demonstrate	O
that	O
these	O
effects	O
reduced	O
the	O
rates	O
of	O
morbidity	O
and	O
mortality	O
compared	O
with	O
those	O
among	O
the	O
rats	O
in	O
the	O
DEX	B-Chemical
group	O
.	O
Abbreviations	O
EGCG	B-Chemical
epigallocatechin	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
gallate	I-Chemical
DEX	B-Chemical
dexamethasone	B-Chemical
MDA	B-Chemical
malondialdehyde	B-Chemical
SOD	O
superoxide	O
dismutase	O
TGF	O
-	O
Î²1	O
transforming	O
growth	O
factor	O
Î²1	O
IL	O
-	O
6	O
interleukin	O
-	O
6	O
IL	O
-	O
10	O
interleukin	O
-	O
10	O
TNF	O
-	O
Î±	O
tumor	O
necrosis	O
factor	O
Î±	O
SPB	O
surfactant	O
protein	O
-	O
B	O
Î±	O
-	O
SMA	O
Î±	O
smooth	O
muscle	O
actin	O
Nrf	O
-	O
2	O
nuclear	O
transcription	O
factor	O
NF	O
-	O
E2	O
-	O
related	O
factor	O
2	O
HO	O
-	O
1	O
heme	O
oxygenase	O
-	O
1	O
enzyme	O
NQO	O
-	O
1	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
oxidoreductase	O
-	O
1	O
enzyme	O
AE2	O
alveolar	O
epithelial	O
type	O
II	O
References	O
Effect	O
of	O
epigallocatechin	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
gallate	I-Chemical
(	O
EGCG	B-Chemical
)	O
on	O
the	O
lung	O
appearance	O
at	O
120	O
days	O
post	O
gamma	O
-	O
ray	O
irradiation	O
.	O
(	O
A	O
)	O
Hematoxylin	B-Chemical
and	I-Chemical
eosin	I-Chemical
(	O
H	B-Chemical
&	I-Chemical
E	I-Chemical
)	O
staining	O
of	O
lung	O
tissue	O
from	O
non	O
-	O
irradiated	O
normal	O
control	O
","	O
(	O
B	O
)	O
untreated	O
irradiated	O
","	O
but	O
(	O
C	O
)	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
)-	O
treated	O
irradiated	O
and	O
(	O
D	O
)	O
EGCG	B-Chemical
-	O
treated	O
irradiated	O
rats	O
.	O
Untreated	O
irradiated	O
and	O
DEX	B-Chemical
-	O
treated	O
irradiated	O
animals	O
show	O
marked	O
lung	O
collapse	O
","	O
rough	O
surfaces	O
and	O
gray	O
fibrous	O
nodule	O
development	O
.	O
EGCG	B-Chemical
treatment	O
animals	O
show	O
lung	O
tissue	O
edema	O
","	O
rough	O
surfaces	O
","	O
scattered	O
punctate	O
bleeding	O
","	O
but	O
no	O
lung	O
collapse	O
and	O
gray	O
fibrous	O
nodules	O
.	O
Bar	O
","	O
0	O
.	O
5	O
cm	O
.	O
(	O
A	O
)	O
The	O
effect	O
of	O
epigallocatechin	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
gallate	I-Chemical
(	O
EGCG	B-Chemical
)	O
on	O
the	O
lung	O
index	O
score	O
","	O
(	O
B	O
)	O
combined	O
alveolitis	O
score	O
","	O
(	O
C	O
)	O
combined	O
fibrosis	O
score	O
","	O
and	O
(	O
D	O
)	O
hydroxyproline	B-Chemical
(	O
Hyp	B-Chemical
)	O
content	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
(	O
A	O
)	O
Lung	O
index	O
values	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
among	O
the	O
EGCG	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
those	O
of	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
30	O
and	O
0	O
days	O
post	O
-	O
irradiation	O
but	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
at	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
Lung	O
index	O
values	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
among	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
)-	O
treated	O
animals	O
compared	O
with	O
those	O
of	O
untreated	O
animals	O
at	O
15	O
","	O
30	O
and	O
60	O
days	O
post	O
-	O
irradiation	O
but	O
similar	O
at	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
(	O
B	O
)	O
The	O
combined	O
alveolitis	O
score	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
among	O
EGCG	B-Chemical
-	O
treated	O
animals	O
than	O
that	O
among	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
This	O
score	O
was	O
also	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
among	O
DEX	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
that	O
of	O
untreated	O
animals	O
at	O
15	O
and	O
30	O
days	O
post	O
-	O
irradiation	O
but	O
similar	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
(	O
C	O
)	O
The	O
combined	O
fibrosis	O
score	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
among	O
EGCG	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
that	O
of	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
fibrosis	O
score	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
among	O
DEX	B-Chemical
-	O
treated	O
rats	O
compared	O
with	O
that	O
of	O
untreated	O
rats	O
at	O
30	O
days	O
post	O
-	O
irradiation	O
but	O
similar	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
(	O
D	O
)	O
The	O
Hyp	B-Chemical
content	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
among	O
EGCG	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
that	O
of	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
This	O
parameter	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
among	O
the	O
DEX	B-Chemical
-	O
treated	O
rats	O
relative	O
to	O
that	O
of	O
the	O
untreated	O
animals	O
at	O
15	O
and	O
30	O
days	O
post	O
-	O
irradiation	O
but	O
similar	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
bars	O
in	O
the	O
graph	O
are	O
the	O
standard	O
deviations	O
(	O
SDs	O
).	O
Asterisks	O
show	O
significance	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
compared	O
with	O
the	O
untreated	O
radiation	O
-	O
only	O
rats	O
","	O
and	O
stars	O
show	O
significance	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
compared	O
with	O
DEX	B-Chemical
-	O
treated	O
animals	O
.	O
Effect	O
of	O
epigallocatechin	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
gallate	I-Chemical
(	O
EGCG	B-Chemical
)	O
on	O
the	O
histological	O
changes	O
in	O
lung	O
tissue	O
at	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
Photomicrographs	O
show	O
staining	O
of	O
rat	O
lung	O
tissue	O
sections	O
with	O
hematoxylin	B-Chemical
and	I-Chemical
eosin	I-Chemical
(	O
H	B-Chemical
&	I-Chemical
E	I-Chemical
)	O
(	O
left	O
column	O
"),"	O
Masson	B-Chemical
â€™	I-Chemical
s	I-Chemical
trichrome	I-Chemical
(	O
middle	O
column	O
)	O
and	O
Sirius	B-Chemical
red	I-Chemical
(	O
right	O
column	O
)	O
from	O
animals	O
in	O
the	O
non	O
-	O
irradiated	O
control	O
(	O
normal	O
"),"	O
irradiated	O
but	O
untreated	O
(	O
radiation	O
)	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
)-	O
treated	O
","	O
and	O
EGCG	B-Chemical
-	O
treated	O
(	O
EGCG	B-Chemical
)	O
groups	O
.	O
Note	O
that	O
inflammatory	O
cell	O
infiltration	O
","	O
fibrotic	O
lesions	O
and	O
collagen	O
fiber	O
deposition	O
were	O
significantly	O
improved	O
in	O
EGCG	B-Chemical
-	O
treated	O
animals	O
.	O
Bar	O
","	O
100	O
Î¼m	O
.	O
(	O
A	O
)	O
The	O
effect	O
of	O
epigallocatechin	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
gallate	I-Chemical
(	O
EGCG	B-Chemical
)	O
on	O
serum	O
malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
concentrations	O
","	O
(	O
B	O
)	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
activity	O
","	O
(	O
C	O
)	O
Î±	O
smooth	O
muscle	O
actin	O
(	O
Î±	O
-	O
SMA	O
)	O
levels	O
and	O
(	O
D	O
)	O
surfactant	O
protein	O
-	O
B	O
(	O
SPB	O
)	O
levels	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
(	O
A	O
)	O
The	O
MDA	B-Chemical
concentration	O
in	O
serum	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
among	O
the	O
EGCG	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
that	O
of	O
the	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
)-	O
treated	O
animals	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
Conversely	O
","	O
the	O
MDA	B-Chemical
concentrations	O
of	O
the	O
DEX	B-Chemical
-	O
treated	O
and	O
untreated	O
animals	O
were	O
comparable	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
(	O
B	O
)	O
Serum	O
SOD	O
activity	O
was	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
among	O
the	O
EGCG	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
SOD	O
activity	O
of	O
the	O
latter	O
group	O
was	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
than	O
that	O
of	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
30	O
days	O
post	O
-	O
irradiation	O
but	O
similar	O
at	O
15	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
(	O
C	O
)	O
The	O
OD	O
value	O
of	O
Î±	O
-	O
SMA	O
immunohistochemical	O
(	O
IHC	O
)	O
was	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
among	O
EGCG	B-Chemical
-	O
treated	O
animals	O
than	O
that	O
of	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
Conversely	O
","	O
the	O
OD	O
value	O
of	O
Î±	O
-	O
SMA	O
IHC	O
among	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
was	O
comparable	O
to	O
that	O
of	O
the	O
untreated	O
animals	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
(	O
p	O
>	O
0	O
.	O
5	O
).	O
(	O
D	O
)	O
The	O
OD	O
value	O
of	O
SPB	O
IHC	O
was	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
among	O
the	O
EGCG	B-Chemical
-	O
treated	O
animals	O
relative	O
to	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
OD	O
value	O
of	O
SPB	O
IHC	O
among	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
was	O
similar	O
to	O
that	O
of	O
the	O
untreated	O
animals	O
at	O
15	O
days	O
post	O
-	O
irradiation	O
but	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
at	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
bars	O
in	O
the	O
graph	O
are	O
the	O
standard	O
deviations	O
(	O
SDs	O
).	O
Asterisks	O
show	O
significance	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
compared	O
with	O
the	O
untreated	O
radiation	O
-	O
only	O
animals	O
","	O
and	O
stars	O
show	O
significance	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
compared	O
with	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
.	O
Effect	O
of	O
epigallocatechin	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
gallate	I-Chemical
(	O
EGCG	B-Chemical
)	O
on	O
the	O
Î±	O
smooth	O
muscle	O
actin	O
(	O
Î±	O
-	O
SMA	O
)	O
and	O
surfactant	O
protein	O
-	O
B	O
(	O
SPB	O
)	O
immunohistochemistry	O
at	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
Photomicrographs	O
show	O
the	O
immunohistochemical	O
(	O
IHC	O
)	O
staining	O
with	O
antibodies	O
detecting	O
Î±	O
-	O
SMA	O
(	O
left	O
column	O
)	O
or	O
SPB	O
(	O
right	O
column	O
)	O
in	O
lung	O
tissue	O
from	O
rats	O
in	O
the	O
non	O
-	O
irradiated	O
(	O
normal	O
"),"	O
irradiated	O
but	O
untreated	O
(	O
Radiation	O
"),"	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
)-	O
treated	O
","	O
and	O
EGCG	B-Chemical
-	O
treated	O
(	O
EGCG	B-Chemical
)	O
groups	O
.	O
Myofibroblast	O
accumulation	O
hyperplasia	O
as	O
stained	O
by	O
Î±	O
-	O
SMA	O
IHC	O
was	O
significantly	O
reduced	O
","	O
and	O
alveolar	O
type	O
II	O
cells	O
(	O
stained	O
by	O
SPB	O
IHC	O
)	O
were	O
significantly	O
increased	O
in	O
EGCG	B-Chemical
-	O
treated	O
animals	O
.	O
Bar	O
","	O
100	O
Î¼m	O
.	O
(	O
A	O
)	O
The	O
effect	O
of	O
epigallocatechin	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
gallate	I-Chemical
(	O
EGCG	B-Chemical
)	O
on	O
the	O
serum	O
levels	O
of	O
transforming	O
growth	O
factor	O
Î²1	O
(	O
TGF	O
-	O
Î²1	O
"),"	O
(	O
B	O
)	O
interleukin	O
(	O
IL	O
)-	O
6	O
","	O
(	O
C	O
)	O
IL	O
-	O
10	O
","	O
and	O
(	O
D	O
)	O
tumor	O
necrosis	O
factor	O
Î±	O
(	O
TNF	O
-	O
Î±	O
)	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
(	O
A	O
)	O
Serum	O
TGF	O
-	O
Î²1	O
levels	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
the	O
EGCG	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
those	O
in	O
the	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
)-	O
treated	O
animals	O
at	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
serum	O
TGF	O
-	O
Î²1	O
levels	O
in	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
were	O
similar	O
to	O
those	O
of	O
the	O
untreated	O
animals	O
at	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
(	O
B	O
â€“	O
D	O
)	O
The	O
serum	O
levels	O
of	O
IL	O
-	O
6	O
","	O
IL	O
-	O
10	O
","	O
and	O
TNF	O
-	O
Î±	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
the	O
EGCG	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
serum	O
levels	O
of	O
IL	O
-	O
6	O
and	O
TNF	O
-	O
Î±	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
compared	O
with	O
those	O
in	O
the	O
untreated	O
animals	O
at	O
15	O
and	O
30	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
serum	O
levels	O
of	O
IL	O
-	O
10	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
than	O
those	O
in	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
30	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
serum	O
levels	O
of	O
IL	O
-	O
6	O
","	O
IL	O
-	O
10	O
","	O
and	O
TNF	O
-	O
Î±	O
in	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
were	O
similar	O
to	O
those	O
in	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
bars	O
in	O
each	O
graph	O
are	O
the	O
standard	O
deviations	O
(	O
SDs	O
).	O
Asterisks	O
show	O
significance	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
compared	O
with	O
the	O
untreated	O
animals	O
and	O
stars	O
show	O
significance	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
compared	O
with	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
.	O
(	O
A	O
)	O
Epigallocatechin	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
gallate	I-Chemical
(	O
EGCG	B-Chemical
)	O
activates	O
nuclear	O
transcription	O
factor	O
NF	O
-	O
E2	O
-	O
related	O
factor	O
2	O
(	O
Nrf	O
-	O
2	O
"),"	O
(	O
B	O
)	O
heme	O
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
and	O
(	O
C	O
)	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
oxidoreductase	O
-	O
1	O
(	O
NQO	O
-	O
1	O
)	O
protein	O
expression	O
as	O
detected	O
by	O
western	O
blot	O
analysis	O
of	O
lung	O
tissue	O
extracts	O
at	O
15	O
days	O
post	O
-	O
irradiation	O
.	O
Immunoblot	O
analysis	O
revealed	O
that	O
the	O
protein	O
expression	O
of	O
Nrf	O
-	O
2	O
","	O
HO	O
-	O
1	O
","	O
and	O
NQO	O
-	O
1	O
was	O
strongly	O
activated	O
by	O
EGCG	B-Chemical
administration	O
","	O
while	O
Nrf	O
-	O
2	O
was	O
weakly	O
activated	O
by	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
).	O
(	O
A	O
)	O
The	O
protein	O
levels	O
of	O
nuclear	O
transcription	O
factor	O
NF	O
-	O
E2	O
-	O
related	O
factor	O
2	O
(	O
Nrf	O
-	O
2	O
"),"	O
(	O
B	O
)	O
heme	O
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
and	O
(	O
C	O
)	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
oxidoreductase	O
-	O
1	O
enzyme	O
(	O
NQO	O
-	O
1	O
)	O
were	O
compared	O
using	O
western	O
blot	O
analysis	O
of	O
lung	O
tissue	O
extracts	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
20	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
relative	O
protein	O
expression	O
levels	O
of	O
Nrf	O
-	O
2	O
","	O
HO	O
-	O
1	O
","	O
and	O
NQO	O
-	O
1	O
in	O
lung	O
homogenates	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
in	O
the	O
epigallocatechin	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
gallate	I-Chemical
(	O
EGCG	B-Chemical
)-	O
treated	O
animals	O
than	O
the	O
dexamethasone	B-Chemical
(	O
DEX	B-Chemical
)-	O
treated	O
animals	O
at	O
15	O
","	O
30	O
","	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
The	O
expression	O
levels	O
of	O
these	O
proteins	O
in	O
the	O
latter	O
group	O
were	O
significantly	O
higher	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
than	O
those	O
of	O
the	O
radiation	O
-	O
only	O
animals	O
at	O
15	O
and	O
30	O
days	O
post	O
-	O
irradiation	O
but	O
similar	O
at	O
60	O
and	O
120	O
days	O
post	O
-	O
irradiation	O
.	O
Experiments	O
were	O
performed	O
with	O
n	O
=	O
6	O
rats	O
per	O
group	O
","	O
and	O
the	O
western	O
blot	O
analysis	O
OD	O
data	O
were	O
normalized	O
to	O
OD	O
values	O
for	O
Î²	O
-	O
actin	O
.	O
Data	O
are	O
presented	O
as	O
the	O
means	O
Â±	O
standard	O
deviations	O
(	O
SDs	O
).	O
Asterisks	O
show	O
significance	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
compared	O
with	O
the	O
untreated	O
animals	O
","	O
and	O
stars	O
show	O
significance	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
compared	O
with	O
the	O
DEX	B-Chemical
-	O
treated	O
animals	O
.	O
Supplementation	O
with	O
conjugated	B-Chemical
linoeic	I-Chemical
acid	I-Chemical
decreases	O
pig	O
back	O
fat	O
deposition	O
by	O
inducing	O
adipocyte	O
apoptosis	O
Background	O
Conjugated	B-Chemical
linoleic	I-Chemical
acid	I-Chemical
(	O
CLA	B-Chemical
"),"	O
a	O
C18	B-Chemical
fatty	I-Chemical
acid	I-Chemical
with	O
conjugated	O
double	O
bonds	O
","	O
has	O
been	O
shown	O
to	O
serve	O
as	O
a	O
powerful	O
anti	O
-	O
obesity	O
agent	O
by	O
several	O
research	O
groups	O
","	O
although	O
the	O
precise	O
mechanism	O
remains	O
elusive	O
.	O
Previous	O
studies	O
showed	O
that	O
CLA	B-Chemical
induced	O
apoptosis	O
in	O
3T3	O
-	O
L1	O
cells	O
and	O
in	O
mice	O
.	O
The	O
aim	O
of	O
this	O
research	O
was	O
to	O
clarify	O
the	O
role	O
of	O
CLA	B-Chemical
in	O
adipocyte	O
apoptosis	O
in	O
pigs	O
","	O
a	O
relevant	O
model	O
for	O
obesity	O
research	O
.	O
Results	O
Our	O
results	O
clearly	O
show	O
that	O
back	O
fat	O
deposition	O
of	O
CLA	B-Chemical
-	O
fed	O
pigs	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
pigs	O
in	O
the	O
control	O
group	O
.	O
Moreover	O
","	O
some	O
typical	O
apoptotic	O
cells	O
were	O
observed	O
among	O
the	O
adipocytes	O
of	O
CLA	B-Chemical
-	O
fed	O
pigs	O
.	O
Furthermore	O
","	O
the	O
CLA	B-Chemical
-	O
fed	O
pigs	O
had	O
reduced	O
expression	O
of	O
the	O
anti	O
-	O
apoptosis	O
factor	O
Bcl	O
-	O
2	O
and	O
increased	O
expression	O
of	O
the	O
pro	O
-	O
apoptosis	O
factors	O
Bax	O
and	O
P53	O
.	O
Subsequently	O
","	O
increased	O
cytochrome	O
C	O
was	O
released	O
from	O
the	O
mitochondria	O
to	O
the	O
endochylema	O
","	O
and	O
the	O
caspase	O
cascade	O
was	O
activated	O
","	O
resulting	O
in	O
cellular	O
apoptosis	O
.	O
These	O
results	O
are	O
consistent	O
with	O
the	O
effects	O
of	O
Bcl	O
-	O
2	O
and	O
Bax	O
in	O
regulating	O
CLA	B-Chemical
-	O
induced	O
adipocyte	O
apoptosis	O
via	O
the	O
mitochondrial	O
signaling	O
pathway	O
.	O
However	O
","	O
the	O
increased	O
expression	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
Î±	O
and	O
its	O
receptor	O
TNFR	O
indicate	O
that	O
the	O
effect	O
of	O
CLA	B-Chemical
might	O
partly	O
be	O
through	O
the	O
death	O
receptor	O
signaling	O
pathway	O
in	O
adipose	O
cells	O
.	O
Conclusions	O
Our	O
study	O
has	O
demonstrated	O
that	O
CLA	B-Chemical
reduces	O
pig	O
body	O
fat	O
deposition	O
","	O
an	O
outcome	O
that	O
is	O
partly	O
meditated	O
by	O
apoptosis	O
of	O
adipose	O
cells	O
","	O
and	O
that	O
both	O
the	O
mitochondrial	O
pathway	O
and	O
the	O
death	O
receptor	O
pathway	O
are	O
involved	O
in	O
this	O
effect	O
.	O
Background	O
Conjugated	B-Chemical
linoleic	I-Chemical
acid	I-Chemical
(	O
CLA	B-Chemical
)	O
belongs	O
to	O
the	O
family	O
of	O
18	B-Chemical
carbon	I-Chemical
fatty	I-Chemical
acids	I-Chemical
containing	O
conjugated	O
double	O
bonds	O
.	O
It	O
is	O
found	O
in	O
dairy	O
products	O
and	O
ruminant	O
meats	O
as	O
a	O
mixture	O
of	O
positional	O
and	O
geometric	O
(	O
Cis	O
or	O
Trans	O
)	O
isomers	O
of	O
linoleic	B-Chemical
acid	I-Chemical
(	O
18	O
:	O
2	O
n	O
-	O
6	O
).	O
There	O
is	O
increasing	O
evidence	O
that	O
CLA	B-Chemical
has	O
powerful	O
anti	O
-	O
adiposity	O
functions	O
in	O
both	O
humans	O
and	O
animals	O
[	O
1	O
-	O
3	O
].	O
CLA	B-Chemical
treatment	O
notably	O
decreases	O
body	O
fat	O
deposition	O
and	O
changes	O
the	O
route	O
of	O
fat	O
metabolism	O
","	O
effects	O
that	O
have	O
been	O
observed	O
in	O
several	O
different	O
studies	O
[	O
2	O
-	O
6	O
].	O
Although	O
the	O
precise	O
mechanism	O
is	O
still	O
unclear	O
","	O
results	O
of	O
these	O
studies	O
demonstrate	O
that	O
CLA	B-Chemical
may	O
inhibit	O
the	O
proliferation	O
and	O
/	O
or	O
differentiation	O
of	O
adipose	O
cells	O
","	O
and	O
the	O
synthesis	O
and	O
accumulation	O
of	O
triglycerides	B-Chemical
in	O
adipocytes	O
.	O
Recently	O
","	O
some	O
research	O
groups	O
have	O
shown	O
that	O
CLA	B-Chemical
can	O
induce	O
apoptosis	O
of	O
fat	O
cells	O
in	O
mice	O
and	O
in	O
3T3	O
-	O
L1	O
adipocytes	O
.	O
In	O
2000	O
","	O
Tsuboyama	O
-	O
Kasaoka	O
et	O
al	O
.	O
first	O
reported	O
that	O
supplying	O
feed	O
supplemented	O
with	O
1	O
%	O
CLA	B-Chemical
to	O
C57BL	O
/	O
6	O
J	O
mice	O
for	O
5	O
months	O
resulted	O
in	O
a	O
clear	O
decrease	O
in	O
the	O
abdominal	O
fat	O
pad	O
of	O
the	O
mice	O
","	O
with	O
the	O
adipocytes	O
exhibiting	O
typical	O
apoptotic	O
characteristics	O
","	O
such	O
as	O
DNA	O
fragmentation	O
[	O
7	O
].	O
Subsequent	O
studies	O
showed	O
that	O
CLA	B-Chemical
also	O
induced	O
adipose	O
cell	O
apoptosis	O
either	O
in	O
vitro	O
or	O
in	O
vivo	O
[	O
8	O
-	O
11	O
].	O
It	O
has	O
long	O
been	O
known	O
that	O
CLA	B-Chemical
has	O
anti	O
-	O
cancer	O
effects	O
and	O
can	O
directly	O
induce	O
apoptosis	O
of	O
a	O
number	O
of	O
different	O
tumor	O
cell	O
types	O
[	O
12	O
-	O
15	O
].	O
However	O
","	O
the	O
effects	O
of	O
CLA	B-Chemical
on	O
apoptosis	O
in	O
adipose	O
cells	O
have	O
not	O
been	O
widely	O
reported	O
","	O
and	O
the	O
molecular	O
mechanisms	O
by	O
which	O
these	O
effects	O
occur	O
are	O
still	O
unclear	O
.	O
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
clarify	O
the	O
role	O
of	O
CLA	B-Chemical
in	O
adipocyte	O
apoptosis	O
in	O
pigs	O
","	O
whose	O
physiological	O
characteristics	O
are	O
similar	O
to	O
humans	O
","	O
thus	O
making	O
them	O
a	O
highly	O
relevant	O
model	O
for	O
obesity	O
research	O
.	O
Additionally	O
","	O
the	O
molecules	O
that	O
regulate	O
apoptosis	O
in	O
adipocytes	O
were	O
investigated	O
.	O
Results	O
CLA	B-Chemical
supplementation	O
reduces	O
back	O
fat	O
accumulation	O
in	O
pigs	O
In	O
our	O
experiment	O
","	O
piglets	O
were	O
fed	O
with	O
0	O
","	O
1	O
"%,"	O
or	O
2	O
%	O
CLA	B-Chemical
for	O
30	O
days	O
.	O
Both	O
the	O
1	O
%	O
and	O
2	O
%	O
CLA	B-Chemical
-	O
fed	O
pigs	O
demonstrated	O
a	O
loss	O
of	O
body	O
weight	O
compared	O
with	O
the	O
control	O
pigs	O
by	O
the	O
end	O
of	O
the	O
experiment	O
.	O
Back	O
fat	O
tissue	O
and	O
abdominal	O
fat	O
pads	O
of	O
the	O
piglets	O
were	O
collected	O
","	O
weighed	O
","	O
and	O
analyzed	O
.	O
The	O
results	O
showed	O
that	O
CLA	B-Chemical
-	O
fed	O
pigs	O
had	O
less	O
body	O
fat	O
deposition	O
","	O
particularly	O
of	O
back	O
fat	O
(	O
P	O
<	O
0	O
.	O
5	O
","	O
Table	O
1	O
).	O
Additionally	O
","	O
CLA	B-Chemical
-	O
fed	O
pigs	O
demonstrated	O
an	O
increased	O
accumulation	O
of	O
intramuscular	O
fat	O
","	O
indicating	O
that	O
CLA	B-Chemical
has	O
tissue	O
-	O
based	O
differential	O
effects	O
on	O
fat	O
metabolism	O
.	O
Body	O
weight	O
and	O
body	O
fat	O
CLA	B-Chemical
supplementation	O
induces	O
apoptosis	O
of	O
adipose	O
cells	O
In	O
the	O
present	O
study	O
","	O
some	O
typical	O
apoptotic	O
phenomena	O
such	O
as	O
cell	O
shrinkage	O
","	O
chromatin	O
condensation	O
","	O
fluorescence	O
enhancement	O
","	O
and	O
degradation	O
of	O
DNA	O
in	O
cellular	O
chromatin	O
were	O
observed	O
in	O
the	O
adipose	O
cells	O
of	O
CLA	B-Chemical
-	O
fed	O
pigs	O
(	O
particularly	O
2	O
%	O
CLA	B-Chemical
-	O
fed	O
pigs	O
)	O
using	O
the	O
TUNEL	O
assay	O
(	O
Figure	O
1	O
"),"	O
Hoechst	B-Chemical
33258	I-Chemical
staining	O
(	O
Figure	O
2	O
"),"	O
and	O
agarose	B-Chemical
gel	O
electrophoresis	O
of	O
DNA	O
(	O
Figure	O
3	O
).	O
These	O
results	O
indicate	O
that	O
CLA	B-Chemical
supplementation	O
induces	O
and	O
/	O
or	O
promotes	O
apoptosis	O
of	O
pig	O
adipocytes	O
.	O
TUNEL	O
assay	O
of	O
apoptotic	O
cells	O
(	O
200	O
Ã—	O
magnification	O
).	O
Pig	O
back	O
fat	O
cryosections	O
were	O
analyzed	O
using	O
a	O
TdT	O
-	O
mediated	O
dUTP	B-Chemical
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
apoptosis	O
detection	O
kit	O
(	O
Beyotime	O
","	O
China	O
)	O
according	O
to	O
the	O
manufacturer	O
â€™	O
s	O
instructions	O
.	O
Typical	O
apoptotic	O
cells	O
(	O
brown	O
spots	O
)	O
are	O
emphasized	O
with	O
red	O
rings	O
in	O
this	O
figure	O
.	O
This	O
clearly	O
shows	O
that	O
the	O
2	O
%	O
CLA	B-Chemical
-	O
fed	O
pigs	O
had	O
more	O
apoptotic	O
fat	O
cells	O
.	O
Hoechst	B-Chemical
33258	I-Chemical
staining	O
of	O
back	O
fat	O
sections	O
(	O
100	O
Ã—	O
magnification	O
).	O
Pig	O
back	O
fat	O
cryosections	O
were	O
fixed	O
in	O
4	O
%	O
neutral	O
formalin	B-Chemical
and	O
stained	O
with	O
Hoechst	B-Chemical
33258	I-Chemical
(	O
10	O
Î¼g	O
/	O
mL	O
).	O
The	O
number	O
of	O
apoptotic	O
cells	O
(	O
i	O
.	O
e	O
".,"	O
those	O
showing	O
chromatin	O
condensation	O
and	O
fluorescence	O
enhancement	O
)	O
was	O
assessed	O
by	O
observation	O
with	O
an	O
inverted	O
fluorescence	O
microscope	O
.	O
There	O
were	O
more	O
apoptotic	O
cells	O
present	O
in	O
the	O
2	O
%	O
CLA	B-Chemical
-	O
fed	O
pigs	O
than	O
in	O
pigs	O
in	O
the	O
other	O
two	O
groups	O
.	O
Agarose	B-Chemical
gel	O
electrophoresis	O
of	O
DNA	O
fragments	O
in	O
back	O
fat	O
samples	O
from	O
piglets	O
.	O
Genomic	O
DNA	O
from	O
the	O
fat	O
tissue	O
was	O
extracted	O
","	O
and	O
assessed	O
using	O
agarose	B-Chemical
gel	O
electrophoresis	O
with	O
ethidium	B-Chemical
bromide	I-Chemical
.	O
M	O
stands	O
for	O
the	O
DNA	O
marker	O
.	O
Compared	O
with	O
control	O
piglets	O
","	O
the	O
2	O
%	O
CLA	B-Chemical
treatment	O
showed	O
increased	O
numbers	O
of	O
DNA	O
fragments	O
(	O
length	O
less	O
than	O
200	O
bp	O
)	O
in	O
the	O
back	O
fat	O
of	O
piglets	O
.	O
Mitochondrial	O
signaling	O
pathway	O
plays	O
an	O
important	O
role	O
in	O
CLA	B-Chemical
-	O
induced	O
apoptosis	O
A	O
number	O
of	O
molecules	O
and	O
signal	O
transduction	O
pathways	O
participate	O
in	O
the	O
apoptotic	O
process	O
.	O
Back	O
fat	O
tissue	O
of	O
CLA	B-Chemical
-	O
fed	O
pigs	O
had	O
lower	O
expression	O
of	O
Bcl	O
-	O
2	O
","	O
a	O
key	O
inhibitor	O
of	O
cellular	O
apoptosis	O
","	O
at	O
both	O
mRNA	O
(	O
Figure	O
4A	O
)	O
and	O
protein	O
(	O
Figure	O
4B	O
)	O
levels	O
.	O
Furthermore	O
","	O
mRNA	O
and	O
protein	O
expression	O
of	O
the	O
pro	O
-	O
apoptotic	O
molecule	O
Bax	O
were	O
slightly	O
increased	O
in	O
the	O
back	O
fat	O
of	O
CLA	B-Chemical
-	O
fed	O
pigs	O
(	O
Figure	O
4A	O
and	O
B	O
).	O
These	O
two	O
factors	O
function	O
in	O
the	O
early	O
part	O
of	O
the	O
mitochondrial	O
signaling	O
pathway	O
","	O
and	O
changes	O
in	O
their	O
expression	O
initiate	O
activation	O
","	O
and	O
significantly	O
increase	O
the	O
expression	O
","	O
of	O
P53	O
","	O
as	O
well	O
as	O
the	O
release	O
of	O
cytochrome	O
c	O
to	O
the	O
cytoplasm	O
(	O
Figure	O
4A	O
and	O
B	O
).	O
Activity	O
of	O
caspase	O
-	O
9	O
showed	O
a	O
corresponding	O
increase	O
to	O
1	O
.	O
4	O
fold	O
(	O
Figure	O
4C	O
"),"	O
and	O
expression	O
level	O
and	O
activity	O
of	O
caspase	O
-	O
3	O
(	O
Figure	O
4A	O
and	O
D	O
"),"	O
a	O
key	O
apoptotic	O
protein	O
","	O
both	O
increased	O
significantly	O
.	O
These	O
results	O
suggest	O
that	O
the	O
mitochondrial	O
signaling	O
pathway	O
plays	O
a	O
key	O
role	O
in	O
CLA	B-Chemical
-	O
induced	O
apoptosis	O
of	O
pig	O
adipocytes	O
.	O
Expression	O
and	O
activity	O
changes	O
of	O
apoptotic	O
regulators	O
.	O
A	O
.	O
mRNA	O
levels	O
of	O
apoptotic	O
regulators	O
in	O
back	O
fat	O
of	O
pigs	O
.	O
mRNA	O
levels	O
were	O
measured	O
using	O
RT	O
-	O
qPCR	O
.	O
B	O
.	O
Protein	O
concentrations	O
of	O
apoptotic	O
regulators	O
in	O
back	O
fat	O
of	O
pigs	O
.	O
C	O
.	O
Caspase	O
-	O
9	O
activity	O
in	O
back	O
fat	O
of	O
pigs	O
.	O
D	O
.	O
Caspase	O
-	O
3	O
activity	O
in	O
back	O
fat	O
of	O
pigs	O
.	O
data	O
are	O
shown	O
as	O
fold	O
-	O
change	O
compared	O
with	O
control	O
.	O
n	O
=	O
5	O
","	O
*	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
Control	O
.	O
Death	O
receptor	O
signaling	O
pathway	O
trigged	O
by	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)-	O
Î±	O
also	O
participates	O
in	O
CLA	B-Chemical
-	O
induced	O
apoptosis	O
We	O
also	O
examined	O
the	O
mRNA	O
level	O
and	O
the	O
circulating	O
concentration	O
of	O
TNF	O
-	O
Î±	O
","	O
an	O
inflammatory	O
factor	O
and	O
apoptosis	O
inducer	O
secreted	O
by	O
adipocytes	O
.	O
A	O
previous	O
study	O
reported	O
that	O
TNF	O
-	O
Î±	O
could	O
induce	O
cellular	O
apoptosis	O
as	O
a	O
ligand	O
that	O
activates	O
the	O
death	O
receptor	O
signaling	O
pathway	O
[	O
16	O
].	O
Compared	O
with	O
control	O
pigs	O
","	O
2	O
%	O
CLA	B-Chemical
â€“	O
fed	O
pigs	O
showed	O
significantly	O
increased	O
TNF	O
-	O
Î±	O
mRNA	O
expression	O
(	O
Figure	O
5A	O
)	O
in	O
their	O
back	O
fat	O
tissue	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
However	O
","	O
the	O
circulating	O
concentration	O
of	O
TNF	O
-	O
Î±	O
protein	O
(	O
Figure	O
5B	O
)	O
was	O
significantly	O
decreased	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
Therefore	O
","	O
we	O
speculate	O
that	O
a	O
high	O
level	O
of	O
TNF	O
-	O
Î±	O
in	O
back	O
fat	O
might	O
play	O
a	O
role	O
in	O
the	O
induction	O
of	O
adipocyte	O
apoptosis	O
by	O
CLA	B-Chemical
.	O
Furthermore	O
","	O
higher	O
expression	O
levels	O
of	O
TNFR	O
(	O
Figure	O
5C	O
and	O
D	O
)	O
and	O
higher	O
activity	O
of	O
caspase	O
-	O
8	O
(	O
Figure	O
5E	O
)	O
in	O
the	O
fat	O
tissue	O
of	O
CLA	B-Chemical
-	O
fed	O
pigs	O
indirectly	O
support	O
this	O
suggestion	O
.	O
TNF	O
-	O
Î±	O
and	O
TNFR	O
expression	O
and	O
caspase	O
-	O
8	O
activity	O
.	O
A	O
.	O
TNF	O
-	O
Î±	O
mRNA	O
in	O
back	O
fat	O
of	O
pigs	O
.	O
B	O
.	O
Serum	O
TNF	O
-	O
Î±	O
in	O
pigs	O
","	O
C	O
.	O
TNFR	O
mRNA	O
in	O
back	O
fat	O
of	O
pigs	O
","	O
D	O
.	O
TNFR	O
protein	O
levels	O
in	O
back	O
fat	O
of	O
pigs	O
.	O
E	O
.	O
Caspase	O
-	O
8	O
activity	O
in	O
back	O
fat	O
of	O
pigs	O
.	O
n	O
=	O
5	O
","	O
*	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
Control	O
.	O
Discussion	O
Fat	O
metabolism	O
and	O
its	O
related	O
syndromes	O
have	O
been	O
a	O
primary	O
focus	O
of	O
scientific	O
research	O
for	O
many	O
years	O
.	O
An	O
increasing	O
number	O
of	O
agents	O
have	O
been	O
discovered	O
for	O
treating	O
obesity	O
","	O
hypertension	O
","	O
hyperlipidemia	O
","	O
and	O
type	O
2	O
diabetes	O
[	O
17	O
","	O
18	O
].	O
In	O
recent	O
years	O
","	O
CLA	B-Chemical
","	O
because	O
of	O
its	O
robust	O
anti	O
-	O
obesity	O
effects	O
","	O
has	O
gained	O
increasing	O
attention	O
in	O
studies	O
on	O
fat	O
metabolism	O
.	O
Our	O
results	O
are	O
in	O
agreement	O
with	O
previous	O
studies	O
showing	O
that	O
young	O
pigs	O
administered	O
CLA	B-Chemical
-	O
supplemented	O
feeds	O
have	O
less	O
body	O
fat	O
(	O
particularly	O
back	O
fat	O
).	O
The	O
apoptotic	O
process	O
is	O
characterized	O
by	O
programmed	O
cell	O
death	O
regulated	O
by	O
numerous	O
genes	O
[	O
19	O
].	O
Owing	O
to	O
the	O
characteristics	O
of	O
adipocytes	O
(	O
a	O
large	O
amount	O
of	O
intracellular	O
lipid	O
droplets	O
and	O
a	O
consequent	O
difficulty	O
to	O
form	O
apoptotic	O
bodies	O
"),"	O
apoptosis	O
research	O
in	O
adipocytes	O
has	O
been	O
less	O
than	O
that	O
in	O
other	O
cell	O
types	O
.	O
However	O
","	O
some	O
recent	O
studies	O
have	O
led	O
to	O
the	O
belief	O
that	O
there	O
is	O
no	O
obvious	O
difference	O
between	O
apoptosis	O
in	O
adipocytes	O
and	O
apoptosis	O
in	O
other	O
cells	O
[	O
20	O
","	O
21	O
].	O
CLA	B-Chemical
has	O
long	O
been	O
considered	O
an	O
effective	O
anti	O
-	O
cancer	O
drug	O
because	O
it	O
can	O
induce	O
apoptosis	O
in	O
various	O
tumor	O
cells	O
and	O
/	O
or	O
enhance	O
the	O
cells	O
â€™	O
susceptibility	O
to	O
apoptosis	O
.	O
Very	O
few	O
papers	O
have	O
reported	O
that	O
CLA	B-Chemical
can	O
also	O
induce	O
adipocyte	O
apoptosis	O
in	O
rodents	O
","	O
or	O
in	O
adipocyte	O
cell	O
lines	O
[	O
7	O
-	O
10	O
].	O
To	O
investigate	O
whether	O
CLA	B-Chemical
also	O
induces	O
apoptosis	O
in	O
pig	O
adipocytes	O
","	O
the	O
key	O
aim	O
of	O
the	O
current	O
study	O
","	O
we	O
examined	O
(	O
and	O
detected	O
typical	O
apoptotic	O
phenomena	O
in	O
adipose	O
cells	O
from	O
the	O
CLA	B-Chemical
-	O
fed	O
pigs	O
(	O
particularly	O
in	O
the	O
2	O
%	O
CLA	B-Chemical
-	O
fed	O
pigs	O
"),"	O
as	O
we	O
had	O
expected	O
.	O
We	O
therefore	O
have	O
reason	O
to	O
believe	O
that	O
CLA	B-Chemical
can	O
exert	O
its	O
anti	O
-	O
obesity	O
function	O
","	O
at	O
least	O
partly	O
","	O
via	O
inducing	O
apoptosis	O
in	O
adipose	O
cells	O
.	O
The	O
mechanisms	O
of	O
apoptosis	O
are	O
highly	O
complex	O
and	O
sophisticated	O
","	O
involving	O
an	O
energy	O
-	O
dependent	O
cascade	O
of	O
molecular	O
events	O
[	O
19	O
].	O
To	O
date	O
","	O
research	O
indicates	O
that	O
there	O
are	O
two	O
main	O
apoptotic	O
pathways	O
","	O
the	O
extrinsic	O
or	O
death	O
receptor	O
pathway	O
and	O
the	O
intrinsic	O
or	O
mitochondrial	O
pathway	O
[	O
19	O
","	O
22	O
].	O
The	O
extrinsic	O
and	O
intrinsic	O
pathways	O
converge	O
on	O
the	O
same	O
execution	O
pathway	O
.	O
This	O
pathway	O
is	O
initiated	O
by	O
the	O
cleavage	O
of	O
caspase	O
-	O
3	O
and	O
results	O
in	O
DNA	O
fragmentation	O
","	O
degradation	O
of	O
cytoskeletal	O
and	O
nuclear	O
proteins	O
","	O
cross	O
-	O
linking	O
of	O
proteins	O
","	O
formation	O
of	O
apoptotic	O
bodies	O
","	O
and	O
finally	O
uptake	O
by	O
phagocytic	O
cells	O
[	O
23	O
].	O
Changes	O
in	O
both	O
expression	O
and	O
activity	O
of	O
key	O
apoptosis	O
factors	O
in	O
the	O
current	O
experiment	O
suggest	O
that	O
both	O
the	O
intrinsic	O
and	O
extrinsic	O
apoptotic	O
pathways	O
were	O
activated	O
in	O
the	O
fat	O
tissue	O
of	O
CLA	B-Chemical
-	O
fed	O
pigs	O
(	O
Figure	O
6	O
).	O
In	O
fact	O
","	O
there	O
is	O
recent	O
evidence	O
showing	O
that	O
the	O
two	O
pathways	O
are	O
linked	O
","	O
and	O
that	O
molecules	O
in	O
one	O
pathway	O
can	O
influence	O
the	O
other	O
[	O
24	O
].	O
Apoptotic	O
signal	O
transduction	O
in	O
adipocytes	O
induced	O
by	O
conjugated	B-Chemical
linoleic	I-Chemical
acid	I-Chemical
(	O
CLA	B-Chemical
).	O
In	O
the	O
intrinsic	O
pathway	O
","	O
stimuli	O
such	O
as	O
drugs	O
","	O
radiation	O
","	O
or	O
hypoxia	O
induce	O
DNA	O
injury	O
","	O
change	O
mitochondrial	O
permeability	O
","	O
and	O
then	O
discharge	O
more	O
active	O
apoptotic	O
molecules	O
such	O
as	O
cytochrome	O
C	O
","	O
which	O
then	O
combine	O
with	O
apoptotic	O
protease	O
activating	O
factor	O
-	O
1	O
(	O
Apaf	O
-	O
1	O
)	O
and	O
procaspase	O
-	O
9	O
to	O
form	O
an	O
apoptosome	O
.	O
In	O
this	O
complex	O
","	O
self	O
-	O
cleavage	O
and	O
activation	O
of	O
procaspase	O
-	O
9	O
generates	O
caspase	O
-	O
9	O
","	O
which	O
in	O
turn	O
activates	O
caspase	O
-	O
3	O
in	O
the	O
presence	O
of	O
ATP	B-Chemical
.	O
In	O
this	O
process	O
","	O
the	O
Bcl	O
-	O
2	O
protein	O
family	O
plays	O
a	O
critical	O
role	O
.	O
The	O
family	O
includes	O
many	O
proteins	O
that	O
are	O
categorized	O
based	O
on	O
their	O
function	O
as	O
either	O
pro	O
-	O
apoptotic	O
proteins	O
(	O
Bcl	O
-	O
2	O
","	O
Bcl	O
-	O
xl	O
","	O
and	O
Bcl	O
-	O
w	O
)	O
or	O
anti	O
-	O
apoptotic	O
proteins	O
(	O
Bax	O
","	O
Bak	O
","	O
Bad	O
","	O
and	O
Bid	O
)	O
[	O
25	O
","	O
26	O
].	O
Bcl	O
-	O
2	O
inhibits	O
the	O
release	O
of	O
cytochrome	O
C	O
and	O
inhibits	O
the	O
function	O
of	O
activated	O
caspases	O
while	O
Bax	O
has	O
the	O
opposite	O
effect	O
.	O
P53	O
is	O
a	O
transcription	O
factor	O
that	O
is	O
often	O
seen	O
as	O
an	O
important	O
pro	O
-	O
apoptotic	O
factor	O
because	O
DNA	O
-	O
injury	O
-	O
increased	O
P53	O
induces	O
the	O
expression	O
of	O
Bax	O
and	O
promotes	O
the	O
release	O
of	O
cytochrome	O
C	O
[	O
27	O
","	O
28	O
].	O
Based	O
on	O
the	O
changes	O
in	O
the	O
expression	O
and	O
activity	O
of	O
Bcl	O
-	O
2	O
","	O
Bax	O
","	O
cytochrome	O
C	O
","	O
P53	O
","	O
and	O
caspase	O
-	O
9	O
","	O
our	O
results	O
suggest	O
that	O
the	O
intrinsic	O
pathway	O
plays	O
an	O
important	O
role	O
in	O
the	O
CLA	B-Chemical
-	O
induced	O
apoptosis	O
of	O
adipocytes	O
.	O
Similar	O
studies	O
have	O
also	O
shown	O
the	O
importance	O
of	O
the	O
intrinsic	O
pathway	O
in	O
this	O
process	O
.	O
In	O
the	O
extrinsic	O
pathway	O
","	O
death	O
factors	O
(	O
such	O
as	O
TNF	O
-	O
Î±	O
)	O
function	O
as	O
ligands	O
that	O
bind	O
to	O
their	O
respective	O
receptor	O
proteins	O
(	O
for	O
example	O
","	O
TNFR	O
is	O
a	O
receptor	O
for	O
TNF	O
-	O
Î±	O
"),"	O
which	O
then	O
induces	O
Fas	O
-	O
associated	O
with	O
death	O
domain	O
protein	O
to	O
combine	O
with	O
procaspase	O
-	O
8	O
to	O
form	O
a	O
death	O
-	O
inducing	O
signaling	O
complex	O
(	O
DISC	O
).	O
Self	O
-	O
cleavage	O
and	O
activation	O
of	O
procaspase	O
-	O
8	O
in	O
the	O
DISC	O
generates	O
caspase	O
-	O
8	O
and	O
subsequently	O
activates	O
caspase	O
-	O
3	O
[	O
29	O
].	O
TNF	O
-	O
Î±	O
is	O
a	O
powerful	O
pro	O
-	O
apoptotic	O
factor	O
secreted	O
by	O
fat	O
in	O
mammals	O
[	O
30	O
].	O
Tsuboyama	O
-	O
Kasaoka	O
et	O
al	O
.	O
observed	O
a	O
six	O
-	O
fold	O
increase	O
of	O
Tnfa	O
mRNA	O
level	O
in	O
1	O
%	O
CLA	B-Chemical
-	O
fed	O
mice	O
","	O
and	O
suggested	O
that	O
the	O
increase	O
was	O
related	O
to	O
adipocyte	O
apoptosis	O
and	O
decreased	O
fat	O
deposition	O
[	O
7	O
].	O
In	O
our	O
studies	O
","	O
the	O
increased	O
expression	O
of	O
TNF	O
-	O
Î±	O
","	O
TNFR	O
and	O
the	O
increased	O
activity	O
of	O
caspase	O
-	O
8	O
demonstrate	O
that	O
the	O
extrinsic	O
pathway	O
also	O
participates	O
in	O
adipocyte	O
apoptosis	O
induced	O
by	O
CLA	B-Chemical
.	O
Conclusion	O
As	O
a	O
potent	O
anti	O
-	O
obesity	O
agent	O
","	O
CLA	B-Chemical
has	O
gained	O
a	O
lot	O
of	O
attention	O
and	O
its	O
mechanism	O
of	O
action	O
is	O
gradually	O
becoming	O
clear	O
.	O
Though	O
some	O
studies	O
have	O
demonstrated	O
that	O
the	O
inhibition	O
of	O
differentiation	O
of	O
adipocytes	O
is	O
the	O
main	O
mechanism	O
by	O
which	O
CLA	B-Chemical
induces	O
anti	O
-	O
obesity	O
effects	O
","	O
we	O
believe	O
that	O
CLA	B-Chemical
decreases	O
body	O
fat	O
deposition	O
in	O
pigs	O
at	O
least	O
partly	O
by	O
inducing	O
adipocyte	O
apoptosis	O
.	O
Furthermore	O
","	O
both	O
the	O
extrinsic	O
pathway	O
and	O
the	O
intrinsic	O
pathway	O
participate	O
in	O
this	O
event	O
.	O
Methods	O
Ethics	O
statement	O
The	O
present	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
Chongqing	O
Academy	O
of	O
Animal	O
Science	O
(	O
Approval	O
No	O
.	O
2013	O
-	O
622	O
"),"	O
and	O
the	O
animal	O
euthanasia	O
and	O
sample	O
collection	O
were	O
in	O
strict	O
accordance	O
with	O
the	O
requirements	O
of	O
the	O
Ethics	O
Procedures	O
and	O
Guidelines	O
of	O
the	O
People	O
â€™	O
s	O
Republic	O
of	O
China	O
.	O
Animal	O
and	O
sample	O
collection	O
The	O
experimental	O
animals	O
were	O
fed	O
in	O
a	O
standardized	O
commercial	O
pig	O
farm	O
with	O
a	O
spacious	O
and	O
clean	O
housing	O
.	O
Forty	O
-	O
eight	O
healthy	O
pigs	O
(	O
Duroc	O
Ã—	O
landrace	O
Ã—	O
yorkshire	O
","	O
male	O
)	O
of	O
approximately	O
14	O
kg	O
body	O
weight	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
(	O
n	O
=	O
16	O
in	O
each	O
group	O
):	O
a	O
control	O
group	O
(	O
0	O
CLA	B-Chemical
"),"	O
a	O
1	O
%	O
CLA	B-Chemical
group	O
","	O
and	O
a	O
2	O
%	O
CLA	B-Chemical
group	O
","	O
and	O
their	O
feed	O
was	O
supplemented	O
with	O
the	O
corresponding	O
level	O
of	O
a	O
CLA	B-Chemical
mixture	O
(	O
c9	B-Chemical
","	I-Chemical
t11	I-Chemical
-	I-Chemical
CLA	I-Chemical
:	O
t10	B-Chemical
","	I-Chemical
c12	I-Chemical
-	I-Chemical
CLA	I-Chemical
=	O
1	O
:	O
1	O
","	O
purchased	O
from	O
Aohai	O
Biotechnology	O
Co	O
","	O
Ltd	O
.	O
Qingdao	O
","	O
China	O
).	O
The	O
experiment	O
was	O
conducted	O
for	O
30	O
days	O
","	O
and	O
food	O
and	O
water	O
were	O
offered	O
to	O
the	O
animals	O
ad	O
libitum	O
during	O
this	O
period	O
.	O
The	O
diet	O
formulation	O
met	O
the	O
Chinese	O
meat	O
-	O
fat	O
type	O
pig	O
feeding	O
standard	O
(	O
NY	O
/	O
T	O
95	O
-	O
2004	O
).	O
All	O
the	O
piglets	O
were	O
weighed	O
on	O
days	O
1	O
","	O
15	O
","	O
and	O
30	O
of	O
the	O
study	O
.	O
After	O
weighing	O
on	O
days	O
15	O
and	O
30	O
","	O
five	O
randomly	O
selected	O
piglets	O
from	O
each	O
group	O
were	O
bled	O
and	O
then	O
euthanized	O
.	O
The	O
blood	O
was	O
collected	O
to	O
obtain	O
plasma	O
by	O
centrifugation	O
at	O
1	O
","	O
500	O
Ã—	O
g	O
for	O
15	O
min	O
.	O
The	O
back	O
fat	O
tissue	O
and	O
the	O
abdominal	O
fat	O
pad	O
were	O
collected	O
for	O
frozen	O
sections	O
","	O
RNA	O
","	O
DNA	O
","	O
and	O
protein	O
extraction	O
.	O
These	O
tissue	O
samples	O
were	O
snap	O
frozen	O
in	O
liquid	O
nitrogen	B-Chemical
as	O
soon	O
as	O
they	O
were	O
obtained	O
and	O
stored	O
at	O
âˆ’	O
80	O
Â°	O
C	O
until	O
analysis	O
.	O
DNA	O
laddering	O
detection	O
DNA	O
was	O
extracted	O
from	O
the	O
fat	O
tissue	O
samples	O
using	O
a	O
standard	O
phenol	B-Chemical
/	O
chloroform	B-Chemical
/	O
isoamyl	B-Chemical
alcohol	I-Chemical
technique	O
.	O
The	O
extracted	O
DNA	O
was	O
separated	O
on	O
a	O
2	O
%	O
agarose	B-Chemical
gel	O
containing	O
0	O
.	O
5	O
g	O
/	O
mL	O
ethidium	B-Chemical
bromide	I-Chemical
and	O
visualized	O
on	O
an	O
ultraviolet	O
transilluminator	O
and	O
photographed	O
.	O
Fragmented	O
DNA	O
appeared	O
as	O
a	O
DNA	O
ladder	O
on	O
the	O
gel	O
","	O
indicative	O
of	O
apoptotic	O
cell	O
death	O
.	O
TUNEL	O
assay	O
Apoptotic	O
cells	O
can	O
be	O
detected	O
by	O
terminal	O
deoxynucleotidyl	O
transferase	O
(	O
TdT	O
)-	O
mediated	O
dUTP	B-Chemical
nick	O
end	O
labeling	O
(	O
TUNEL	O
).	O
The	O
fat	O
tissue	O
of	O
pigs	O
was	O
assayed	O
using	O
a	O
colorimetric	O
TUNEL	O
Apoptosis	O
Assay	O
Kit	O
(	O
Beyotime	O
","	O
Beijing	O
","	O
China	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O
Frozen	O
sections	O
of	O
5	O
Î¼m	O
thickness	O
were	O
incubated	O
with	O
H2O2	B-Chemical
(	O
0	O
.	O
3	O
%	O
H2O2	B-Chemical
in	O
methanol	B-Chemical
)	O
at	O
room	O
temperature	O
(	O
RT	O
)	O
for	O
30	O
min	O
.	O
After	O
rinsing	O
with	O
0	O
.	O
1	O
mol	O
/	O
L	O
PBS	B-Chemical
","	O
the	O
sections	O
were	O
treated	O
with	O
biotin	B-Chemical
-	I-Chemical
dUTP	I-Chemical
in	O
TdT	O
reaction	O
buffer	O
at	O
37	O
Â°	O
C	O
for	O
60	O
min	O
followed	O
by	O
incubation	O
with	O
streptavidin	O
-	O
HRP	O
at	O
RT	O
","	O
and	O
then	O
rinsed	O
twice	O
with	O
PBS	B-Chemical
.	O
Finally	O
","	O
the	O
sections	O
were	O
stained	O
with	O
DAB	B-Chemical
and	O
observed	O
under	O
light	O
microscopy	O
.	O
Hoechst	B-Chemical
33258	I-Chemical
staining	O
Frozen	O
fat	O
sections	O
(	O
5	O
Î¼m	O
thickness	O
)	O
were	O
fixed	O
for	O
10	O
min	O
in	O
4	O
%	O
formaldehyde	B-Chemical
solution	O
at	O
4	O
Â°	O
C	O
.	O
Following	O
a	O
rinse	O
in	O
PBS	B-Chemical
","	O
the	O
sections	O
were	O
incubated	O
with	O
an	O
aqueous	O
solution	O
of	O
Hoechst	B-Chemical
33258	I-Chemical
(	O
10	O
Î¼g	O
/	O
mL	O
","	O
Sigmaaldrich	O
","	O
China	O
)	O
at	O
RT	O
in	O
the	O
dark	O
for	O
20	O
min	O
.	O
The	O
sections	O
were	O
then	O
rinsed	O
again	O
with	O
water	O
and	O
evaluated	O
by	O
fluorescence	O
microscopy	O
(	O
ultraviolet	O
light	O
","	O
340	O
nm	O
).	O
Analysis	O
of	O
the	O
activity	O
of	O
caspase	O
-	O
3	O
","	O
8	O
","	O
and	O
9	O
Activity	O
levels	O
of	O
caspase	O
-	O
3	O
","	O
-	O
8	O
","	O
and	O
-	O
9	O
in	O
the	O
fat	O
tissue	O
were	O
measured	O
using	O
commercial	O
assay	O
kits	O
(	O
Beyotime	O
","	O
Beijing	O
","	O
China	O
)	O
according	O
to	O
the	O
manufacturer	O
â€™	O
s	O
instructions	O
.	O
Total	O
protein	O
was	O
extracted	O
from	O
the	O
fat	O
tissue	O
after	O
grinding	O
and	O
subsequent	O
lysing	O
of	O
the	O
tissue	O
in	O
lysis	O
buffer	O
on	O
ice	O
.	O
The	O
protein	O
concentration	O
was	O
measured	O
using	O
a	O
bicinchoninic	B-Chemical
acid	I-Chemical
(	O
BCA	B-Chemical
)	O
Protein	O
Assay	O
Reagent	O
(	O
TianGen	O
","	O
Beijing	O
","	O
China	O
).	O
For	O
the	O
caspase	O
-	O
3	O
activity	O
assay	O
","	O
equal	O
amounts	O
of	O
total	O
lysates	O
were	O
mixed	O
with	O
caspase	O
-	O
3	O
assay	O
buffer	O
containing	O
the	O
fluorogenic	O
substrate	O
Ac	B-Chemical
-	I-Chemical
DEVD	I-Chemical
-	I-Chemical
pNA	I-Chemical
(	O
2	O
mM	O
)	O
in	O
a	O
96	O
-	O
well	O
plate	O
in	O
triplicate	O
.	O
Caspase	O
-	O
3	O
mediated	O
cleavage	O
of	O
Ac	B-Chemical
-	I-Chemical
DEVD	I-Chemical
-	I-Chemical
pNA	I-Chemical
into	O
free	O
pNA	B-Chemical
(	O
yellow	O
)	O
was	O
measured	O
using	O
an	O
excitation	O
wavelength	O
of	O
380	O
nm	O
and	O
emission	O
wavelength	O
of	O
460	O
nm	O
","	O
in	O
a	O
microplate	O
reader	O
(	O
Gene	O
Company	O
Limited	O
","	O
Hong	O
Kong	O
","	O
China	O
).	O
The	O
fluorogenic	O
substrates	O
in	O
the	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
9	O
activity	O
assays	O
were	O
Ac	B-Chemical
-	I-Chemical
IETD	I-Chemical
-	I-Chemical
pNA	I-Chemical
(	O
for	O
caspase	O
-	O
8	O
)	O
and	O
Ac	B-Chemical
-	I-Chemical
LEHD	I-Chemical
-	I-Chemical
pNA	I-Chemical
(	O
for	O
caspase	O
-	O
9	O
"),"	O
and	O
the	O
absorption	O
wavelength	O
used	O
for	O
both	O
was	O
405	O
nm	O
.	O
Protein	O
extraction	O
and	O
western	O
blotting	O
The	O
fat	O
tissue	O
extracts	O
were	O
prepared	O
using	O
500	O
Î¼L	O
lysis	O
buffer	O
(	O
Beyotime	O
","	O
Beijing	O
","	O
China	O
)	O
per	O
20	O
mg	O
fat	O
tissue	O
","	O
for	O
30	O
min	O
at	O
4	O
Â°	O
C	O
.	O
Following	O
centrifugation	O
at	O
12	O
","	O
0	O
Ã—	O
g	O
for	O
10	O
min	O
at	O
4	O
Â°	O
C	O
","	O
the	O
supernatants	O
were	O
removed	O
and	O
their	O
protein	O
concentrations	O
determined	O
using	O
the	O
BCA	B-Chemical
method	O
.	O
Total	O
protein	O
extracts	O
were	O
separated	O
by	O
12	O
%	O
SDS	B-Chemical
-	O
PAGE	O
and	O
transferred	O
to	O
polyvinylidene	B-Chemical
membranes	O
(	O
60	O
V	O
for	O
4	O
h	O
).	O
The	O
membranes	O
were	O
blocked	O
with	O
5	O
%	O
nonfat	O
milk	O
in	O
Tris	B-Chemical
-	O
buffered	O
saline	B-Chemical
containing	O
0	O
.	O
1	O
%	O
Tween	B-Chemical
20	I-Chemical
(	O
TBST	B-Chemical
)	O
at	O
RT	O
for	O
2	O
h	O
","	O
and	O
probed	O
overnight	O
with	O
primary	O
antibodies	O
at	O
4	O
Â°	O
C	O
(	O
anti	O
-	O
BCL2	O
","	O
anti	O
-	O
BAX	O
","	O
anti	O
-	O
cleaved	O
caspase	O
-	O
3	O
","	O
anti	O
-	O
P53	O
","	O
anti	O
-	O
TNFR	O
:	O
Beyotime	O
","	O
Shanghai	O
","	O
China	O
;	O
anti	O
-	O
caspase3	O
:	O
ABcam	O
","	O
UK	O
;	O
anti	O
-	O
tubulin	O
:	O
Santa	O
Cruz	O
","	O
USA	O
).	O
After	O
washing	O
with	O
TBST	B-Chemical
","	O
the	O
membranes	O
were	O
probed	O
with	O
a	O
horseradish	O
peroxidase	O
-	O
labeled	O
secondary	O
antibody	O
(	O
1	O
:	O
10	O
","	O
0	O
","	O
Santa	O
Cruz	O
","	O
USA	O
)	O
at	O
RT	O
for	O
1	O
.	O
5	O
h	O
.	O
Blots	O
were	O
visualized	O
with	O
a	O
chemiluminescence	O
reagent	O
(	O
Millipore	O
","	O
MA	O
","	O
USA	O
)	O
using	O
an	O
imaging	O
system	O
(	O
BioRad	O
","	O
CA	O
","	O
USA	O
).	O
RNA	O
extraction	O
and	O
RT	O
-	O
qPCR	O
analysis	O
The	O
mRNA	O
levels	O
of	O
apoptosis	O
regulators	O
were	O
measured	O
using	O
Real	O
-	O
time	O
qPCR	O
.	O
PCR	O
was	O
performed	O
using	O
a	O
StepOne	O
system	O
(	O
ABI	O
","	O
NY	O
","	O
USA	O
)	O
using	O
a	O
20	O
-	O
Î¼L	O
reaction	O
mixture	O
containing	O
12	O
.	O
5	O
Î¼L	O
SYBR	O
Premix	O
Ex	O
Taq	O
â„¢	O
II	O
(	O
Takara	O
","	O
Dalian	O
","	O
China	O
"),"	O
1	O
Î¼L	O
forward	O
primer	O
","	O
1	O
Î¼L	O
reverse	O
primer	O
","	O
2	O
Î¼L	O
template	O
cDNA	O
","	O
and	O
8	O
.	O
5	O
Î¼L	O
ddH2O	B-Chemical
.	O
The	O
primer	O
sequences	O
are	O
shown	O
in	O
Table	O
2	O
.	O
The	O
cycling	O
conditions	O
consisted	O
of	O
an	O
initial	O
single	O
cycle	O
of	O
30	O
s	O
at	O
95	O
Â°	O
C	O
followed	O
by	O
40	O
cycles	O
of	O
5	O
s	O
at	O
95	O
Â°	O
C	O
and	O
35	O
s	O
at	O
60	O
Â°	O
C	O
.	O
To	O
correct	O
differences	O
in	O
the	O
amounts	O
of	O
template	O
DNA	O
","	O
mRNA	O
levels	O
are	O
shown	O
as	O
a	O
ratio	O
relative	O
to	O
the	O
Î²	O
-	O
actin	O
mRNA	O
level	O
.	O
Primer	O
sequences	O
of	O
qPCR	O
Measurement	O
of	O
TNF	O
-	O
Î±	O
concentration	O
in	O
serum	O
A	O
commercial	O
ELISA	O
kit	O
(	O
R	O
&	O
D	O
systems	O
","	O
USA	O
)	O
for	O
porcine	O
TNF	O
-	O
Î±	O
was	O
used	O
to	O
measure	O
TNF	O
-	O
Î±	O
concentration	O
in	O
the	O
serum	O
of	O
piglets	O
","	O
according	O
to	O
the	O
manufacturer	O
â€™	O
s	O
instructions	O
.	O
Statistical	O
analysis	O
Results	O
are	O
expressed	O
as	O
mean	O
Â±	O
SEM	O
","	O
and	O
comparisons	O
between	O
groups	O
or	O
within	O
groups	O
were	O
made	O
using	O
one	O
-	O
way	O
ANOVA	O
","	O
followed	O
by	O
Tukey	O
â€™	O
s	O
Multiple	O
Comparison	O
Test	O
.	O
The	O
Student	O
â€™	O
s	O
t	O
-	O
test	O
was	O
used	O
to	O
determine	O
significance	O
when	O
only	O
two	O
groups	O
were	O
compared	O
","	O
and	O
P	O
<	O
0	O
.	O
5	O
was	O
considered	O
statistically	O
significant	O
.	O
Abbreviations	O
BCL	O
-	O
2	O
:	O
B	O
-	O
cell	O
lymphoma	O
-	O
2	O
;	O
Caspase	O
:	O
Cysteinyl	O
aspartate	O
specific	O
proteinase	O
;	O
CLA	B-Chemical
:	O
Conjugated	B-Chemical
linoleic	I-Chemical
acid	I-Chemical
;	O
TNF	O
-	O
Î±	O
:	O
Tumor	O
necrosis	O
factor	O
Î±	O
;	O
TNFR	O
:	O
Tumor	O
necrosis	O
factor	O
receptors	O
.	O
Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O
Authors	O
â€™	O
contributions	O
RQ	O
and	O
ZL	O
conceived	O
the	O
study	O
and	O
participated	O
in	O
its	O
design	O
.	O
FY	O
","	O
JH	O
","	O
and	O
HP	O
carried	O
out	O
the	O
animal	O
experiment	O
and	O
molecular	O
studies	O
.	O
YL	O
performed	O
the	O
statistical	O
analysis	O
.	O
All	O
authors	O
have	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
Acknowledgments	O
This	O
work	O
was	O
supported	O
by	O
the	O
National	O
Basic	O
Research	O
Program	O
of	O
China	O
(	O
Project	O
Number	O
2012CB124702	O
"),"	O
the	O
National	O
Nature	O
Science	O
Foundation	O
of	O
China	O
(	O
Project	O
Number	O
31302055	O
"),"	O
and	O
the	O
Fund	O
of	O
the	O
Chongqing	O
Agricultural	O
Development	O
(	O
Project	O
Number	O
13412	O
"),"	O
and	O
the	O
Chongqing	O
Fundamental	O
Research	O
Project	O
(	O
13426	O
).	O
Lysophosphatidic	B-Chemical
acid	I-Chemical
and	O
its	O
receptors	O
LPA1	O
and	O
LPA3	O
mediate	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
in	O
mice	O
Background	O
Paclitaxel	B-Chemical
","	O
which	O
is	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
solid	O
tumors	O
","	O
causes	O
neuropathic	O
pain	O
via	O
poorly	O
understood	O
mechanisms	O
.	O
Previously	O
","	O
we	O
have	O
demonstrated	O
that	O
lysophosphatidic	B-Chemical
acid	I-Chemical
(	O
LPA	B-Chemical
)	O
and	O
its	O
receptors	O
(	O
LPA1	O
and	O
LPA3	O
)	O
are	O
required	O
for	O
the	O
initiation	O
of	O
peripheral	O
nerve	O
injury	O
-	O
induced	O
neuropathic	O
pain	O
.	O
The	O
present	O
study	O
aimed	O
to	O
clarify	O
whether	O
LPA	B-Chemical
and	O
its	O
receptors	O
could	O
mediate	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
.	O
Results	O
Intraperitoneal	O
administration	O
of	O
paclitaxel	B-Chemical
triggered	O
a	O
marked	O
increase	O
in	O
production	O
of	O
LPA	B-Chemical
species	O
(	O
18	O
:	O
1	O
16	O
:	O
0	O
and	O
18	O
:	O
0	O
-	O
LPA	B-Chemical
)	O
in	O
the	O
spinal	O
dorsal	O
horn	O
.	O
Also	O
","	O
we	O
found	O
significant	O
activations	O
of	O
spinal	O
cytosolic	O
phospholipase	O
A2	O
and	O
calcium	O
-	O
independent	O
phospholipase	O
A2	O
after	O
the	O
paclitaxel	B-Chemical
treatment	O
.	O
The	O
paclitaxel	B-Chemical
-	O
induced	O
LPA	B-Chemical
production	O
was	O
completely	O
abolished	O
not	O
only	O
by	O
intrathecal	O
pretreatment	O
with	O
neurokinin	O
1	O
(	O
NK1	O
)	O
or	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
antagonist	O
","	O
but	O
also	O
in	O
LPA1	O
receptor	O
-	O
deficient	O
(	O
Lpar1	O
âˆ’/âˆ’)	O
and	O
LPA3	O
receptor	O
-	O
deficient	O
(	O
Lpar3	O
âˆ’/âˆ’)	O
mice	O
.	O
In	O
addition	O
","	O
the	O
pharmacological	O
blockade	O
of	O
NK1	O
or	O
NMDA	O
receptor	O
prevented	O
a	O
reduction	O
in	O
the	O
paw	O
withdrawal	O
threshold	O
against	O
mechanical	O
stimulation	O
after	O
paclitaxel	B-Chemical
treatments	O
.	O
Importantly	O
","	O
the	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
was	O
absent	O
in	O
Lpar1	O
âˆ’/âˆ’	O
and	O
Lpar3	O
âˆ’/âˆ’	O
mice	O
.	O
Conclusions	O
These	O
results	O
suggest	O
that	O
LPA1	O
and	O
LPA3	O
receptors	O
-	O
mediated	O
amplification	O
of	O
spinal	O
LPA	B-Chemical
production	O
is	O
required	O
for	O
the	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
.	O
Background	O
Peripheral	O
neuropathic	O
pain	O
is	O
produced	O
by	O
multiple	O
etiologies	O
","	O
including	O
physical	O
trauma	O
","	O
metabolic	O
diseases	O
","	O
viral	O
infections	O
","	O
and	O
chemotherapeutic	O
agents	O
[	O
1	O
","	O
2	O
].	O
Paclitaxel	B-Chemical
(	O
Taxol	B-Chemical
Â®)	O
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
chemotherapeutic	O
agents	O
for	O
various	O
types	O
of	O
solid	O
tumors	O
such	O
as	O
breast	O
","	O
ovarian	O
","	O
and	O
lung	O
cancers	O
.	O
The	O
treatment	O
with	O
paclitaxel	B-Chemical
is	O
often	O
accompanied	O
by	O
neuropathic	O
pain	O
","	O
which	O
is	O
a	O
major	O
dose	O
-	O
limiting	O
adverse	O
effect	O
and	O
impairs	O
the	O
quality	O
of	O
life	O
in	O
patients	O
[	O
3	O
","	O
4	O
].	O
The	O
abnormal	O
pain	O
can	O
be	O
developed	O
as	O
early	O
as	O
day	O
1	O
in	O
patients	O
[	O
5	O
]	O
and	O
several	O
hours	O
in	O
animals	O
[	O
6	O
]	O
after	O
initial	O
treatment	O
","	O
and	O
last	O
for	O
months	O
to	O
years	O
after	O
repeated	O
administrations	O
[	O
4	O
].	O
Until	O
now	O
","	O
there	O
is	O
a	O
lack	O
of	O
effective	O
treatment	O
for	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
owing	O
to	O
the	O
poor	O
understanding	O
of	O
its	O
molecular	O
mechanisms	O
.	O
Previously	O
","	O
we	O
have	O
clarified	O
that	O
lysophosphatidic	O
acid	O
receptor	O
(	O
LPA1	O
)	O
signaling	O
initiates	O
peripheral	O
nerve	O
injury	O
-	O
induced	O
neuropathic	O
pain	O
and	O
its	O
underlying	O
mechanisms	O
","	O
including	O
demyelination	O
[	O
7	O
].	O
Also	O
","	O
a	O
single	O
intrathecal	O
injection	O
of	O
LPA	B-Chemical
evokes	O
abnormal	O
pain	O
that	O
mimics	O
nerve	O
injury	O
-	O
induced	O
neuropathic	O
pain	O
","	O
in	O
terms	O
of	O
its	O
pain	O
phenotype	O
","	O
pharmacological	O
characterization	O
","	O
and	O
biochemical	O
alterations	O
[	O
7	O
â€“	O
10	O
].	O
Regarding	O
the	O
biosynthesis	O
of	O
LPA	B-Chemical
in	O
the	O
spinal	O
cord	O
","	O
simultaneous	O
intense	O
stimulation	O
with	O
neurokinin	O
1	O
(	O
NK1	O
)	O
and	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptors	O
activates	O
phospholipase	O
A2	O
to	O
produce	O
lysophosphatidylcholine	B-Chemical
(	O
LPC	B-Chemical
"),"	O
which	O
is	O
then	O
converted	O
to	O
LPA	B-Chemical
by	O
extracellular	O
autotaxin	O
enzyme	O
[	O
11	O
].	O
Interestingly	O
","	O
intrathecally	O
administrated	O
LPA	B-Chemical
is	O
capable	O
of	O
causing	O
amplification	O
of	O
spinal	O
LPA	B-Chemical
production	O
[	O
12	O
","	O
13	O
].	O
Furthermore	O
","	O
nerve	O
injury	O
causes	O
amplification	O
of	O
spinal	O
LPA	B-Chemical
production	O
via	O
LPA1	O
and	O
LPA3	O
receptors	O
[	O
13	O
"],"	O
and	O
","	O
accordingly	O
","	O
nerve	O
injury	O
-	O
induced	O
neuropathic	O
pain	O
is	O
absent	O
in	O
mice	O
that	O
are	O
deficient	O
in	O
LPA1	O
or	O
LPA3	O
receptors	O
[	O
7	O
","	O
13	O
].	O
These	O
facts	O
have	O
suggested	O
that	O
LPA1	O
and	O
LPA3	O
receptors	O
-	O
mediated	O
amplification	O
of	O
spinal	O
LPA	B-Chemical
production	O
is	O
required	O
for	O
the	O
induction	O
of	O
neuropathic	O
pain	O
after	O
nerve	O
injury	O
.	O
However	O
","	O
whether	O
LPA	B-Chemical
and	O
its	O
receptors	O
could	O
contribute	O
to	O
different	O
types	O
of	O
peripheral	O
neuropathic	O
pain	O
","	O
including	O
chemotherapy	O
-	O
induced	O
neuropathic	O
pain	O
","	O
remains	O
to	O
be	O
determined	O
.	O
The	O
present	O
study	O
showed	O
that	O
paclitaxel	B-Chemical
triggered	O
LPA1	O
and	O
LPA3	O
receptors	O
-	O
mediated	O
amplification	O
of	O
spinal	O
LPA	B-Chemical
production	O
","	O
by	O
using	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
-	O
MS	O
)	O
with	O
phosphate	B-Chemical
-	O
capture	O
molecule	O
","	O
Phos	B-Chemical
-	I-Chemical
tag	I-Chemical
.	O
Furthermore	O
","	O
we	O
found	O
that	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
was	O
robustly	O
abolished	O
in	O
mice	O
deficient	O
in	O
LPA1	O
or	O
LPA3	O
receptors	O
.	O
Methods	O
Animals	O
Male	O
C57BL	O
/	O
6J	O
mice	O
(	O
TEXAM	O
corporation	O
","	O
Nagasaki	O
","	O
Japan	O
)	O
and	O
homozygous	O
mutant	O
mice	O
for	O
the	O
LPA1	O
[	O
14	O
]	O
and	O
LPA3	O
[	O
15	O
]	O
receptor	O
genes	O
(	O
Lpar1	O
âˆ’/âˆ’	O
and	O
Lpar3	O
âˆ’/âˆ’)	O
were	O
used	O
.	O
These	O
mutant	O
mice	O
were	O
kindly	O
provided	O
by	O
Prof	O
.	O
Jerold	O
Chun	O
(	O
The	O
Scripps	O
Research	O
Institute	O
","	O
La	O
Jolla	O
","	O
USA	O
).	O
Mice	O
used	O
in	O
this	O
study	O
weighed	O
20	O
â€“	O
24	O
g	O
.	O
They	O
were	O
kept	O
in	O
a	O
room	O
maintained	O
at	O
21	O
Â±	O
2	O
Â°	O
C	O
and	O
55	O
Â±	O
5	O
%	O
relative	O
humidity	O
with	O
a	O
12	O
h	O
light	O
/	O
dark	O
cycle	O
","	O
and	O
had	O
free	O
access	O
to	O
a	O
standard	O
laboratory	O
diet	O
and	O
tap	O
water	O
.	O
All	O
procedures	O
used	O
in	O
this	O
work	O
were	O
approved	O
by	O
the	O
Nagasaki	O
University	O
Animal	O
Care	O
Committee	O
","	O
and	O
complied	O
with	O
the	O
fundamental	O
guidelines	O
for	O
the	O
proper	O
conduct	O
of	O
animal	O
experiments	O
and	O
related	O
activities	O
in	O
academic	O
research	O
institutions	O
under	O
the	O
jurisdiction	O
of	O
the	O
Ministry	O
of	O
Education	O
","	O
Culture	O
","	O
Sports	O
","	O
Science	O
and	O
Technology	O
","	O
Japan	O
.	O
Drug	O
treatments	O
Paclitaxel	B-Chemical
(	O
Taxol	B-Chemical
Â®)	O
was	O
kindly	O
provided	O
by	O
Bristol	O
-	O
Myers	O
Squibb	O
Co	O
.	O
(	O
NY	O
","	O
USA	O
).	O
This	O
drug	O
was	O
dissolved	O
in	O
Cremophor	B-Chemical
EL	I-Chemical
and	O
ethanol	B-Chemical
(	O
1	O
:	O
1	O
","	O
v	O
/	O
v	O
"),"	O
and	O
then	O
diluted	O
by	O
physiological	O
saline	B-Chemical
just	O
before	O
administration	O
.	O
A	O
single	O
or	O
repeated	O
intraperitoneal	O
injection	O
of	O
paclitaxel	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
)	O
on	O
4	O
alternate	O
days	O
(	O
day	O
0	O
","	O
2	O
","	O
4	O
","	O
and	O
6	O
;	O
cumulative	O
dose	O
of	O
16	O
mg	O
/	O
kg	O
)	O
was	O
carried	O
out	O
.	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
(	O
St	O
.	O
Louis	O
","	O
MO	O
","	O
USA	O
"),"	O
while	O
CP	B-Chemical
-	I-Chemical
99994	I-Chemical
was	O
generously	O
provided	O
by	O
Pfizer	O
Inc	O
.	O
(	O
NY	O
","	O
USA	O
).	O
These	O
two	O
inhibitors	O
were	O
dissolved	O
in	O
artificial	B-Chemical
cerebrospinal	I-Chemical
fluid	I-Chemical
(	O
aCSF	O
;	O
125	O
mM	O
NaCl	B-Chemical
","	O
3	O
.	O
8	O
mM	O
KCl	B-Chemical
","	O
1	O
.	O
2	O
mM	O
KH2PO4	B-Chemical
","	O
26	O
mM	O
NaHCO3	B-Chemical
","	O
10	O
mM	O
glucose	B-Chemical
","	O
pH7	O
.	O
4	O
).	O
CP	B-Chemical
-	I-Chemical
99994	I-Chemical
(	O
10	O
nmol	O
/	O
5	O
Î¼l	O
)	O
and	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
10	O
nmol	O
/	O
5	O
Î¼l	O
)	O
were	O
intrathecally	O
administrated	O
30	O
min	O
prior	O
to	O
paclitaxel	B-Chemical
injection	O
.	O
The	O
intrathecal	O
injection	O
was	O
given	O
into	O
the	O
space	O
between	O
spinal	O
L5	O
and	O
L6	O
segments	O
","	O
according	O
to	O
the	O
method	O
of	O
Hylden	O
and	O
Wilcox	O
[	O
16	O
].	O
Phospholipase	O
A2	O
activity	O
assays	O
According	O
to	O
the	O
manufacturer	O
â€™	O
s	O
protocol	O
and	O
our	O
previous	O
studies	O
[	O
13	O
","	O
17	O
"],"	O
the	O
activities	O
of	O
cytosolic	O
phospholipase	O
A2	O
(	O
cPLA2	O
)	O
and	O
calcium	O
-	O
independent	O
phospholipase	O
A2	O
(	O
iPLA2	O
)	O
in	O
the	O
dorsal	O
half	O
of	O
spinal	O
cord	O
were	O
assessed	O
by	O
using	O
cPLA2	O
assay	O
kit	O
(	O
Cayman	O
Chemicals	O
","	O
Ann	O
Arbor	O
","	O
MI	O
","	O
USA	O
).	O
To	O
assess	O
cPLA2	O
activity	O
","	O
bromoenol	B-Chemical
lactone	I-Chemical
","	O
a	O
specific	O
iPLA2	O
inhibitor	O
[	O
18	O
"],"	O
was	O
added	O
to	O
the	O
assay	O
buffer	O
.	O
To	O
measure	O
the	O
activity	O
of	O
iPLA2	O
","	O
sample	O
was	O
incubated	O
with	O
the	O
substrate	O
arachidonoyl	B-Chemical
thio	I-Chemical
-	I-Chemical
phosphorylcholine	I-Chemical
in	O
modified	O
Ca2	B-Chemical
+-	I-Chemical
free	O
buffer	O
(	O
4	O
mM	O
EGTA	B-Chemical
","	O
160	O
mM	O
HEPES	B-Chemical
pH	O
7	O
.	O
4	O
","	O
300	O
mM	O
NaCl	B-Chemical
","	O
8	O
mM	O
Triton	B-Chemical
X	I-Chemical
-	I-Chemical
100	I-Chemical
","	O
60	O
%	O
glycerol	B-Chemical
","	O
2	O
mg	O
/	O
ml	O
of	O
bovine	O
serum	O
albumin	O
).	O
The	O
activity	O
of	O
PLA2	O
was	O
defined	O
as	O
the	O
percentage	O
of	O
the	O
control	O
activity	O
as	O
follows	O
:	O
paclitaxel	B-Chemical
-	O
treated	O
tissues	O
(	O
absorbance	O
/	O
mg	O
of	O
protein	O
)/	O
normal	O
tissues	O
(	O
absorbance	O
/	O
mg	O
of	O
protein	O
)	O
Ã—	O
100	O
.	O
Extraction	O
of	O
LPA	B-Chemical
and	O
MALDI	O
-	O
TOF	O
-	O
MS	O
analysis	O
LPA	B-Chemical
was	O
extracted	O
from	O
the	O
unilateral	O
dorsal	O
half	O
of	O
the	O
lumber	O
(	O
L4	O
-	O
L6	O
)	O
spinal	O
cord	O
(	O
6	O
.	O
15	O
mg	O
tissue	O
weight	O
"),"	O
as	O
reported	O
previously	O
[	O
13	O
","	O
19	O
","	O
20	O
].	O
The	O
final	O
sample	O
was	O
dissolved	O
in	O
50	O
Î¼l	O
of	O
methanol	B-Chemical
containing	O
0	O
.	O
1	O
%	O
aqueous	O
ammonia	B-Chemical
for	O
MALDI	O
-	O
TOF	O
-	O
MS	O
analysis	O
.	O
One	O
Î¼l	O
sample	O
was	O
spotted	O
on	O
a	O
MALDI	O
plate	O
(	O
Bruker	O
Daltonics	O
","	O
Inc	O
".,"	O
CA	O
","	O
USA	O
).	O
Immediately	O
","	O
1	O
Î¼l	O
of	O
2	B-Chemical
"â€™,"	I-Chemical
4	I-Chemical
"â€™,"	I-Chemical
6	I-Chemical
â€™-	I-Chemical
trihydroxyacetophenone	I-Chemical
monohydrate	I-Chemical
solution	O
(	O
10	O
mg	O
/	O
ml	O
in	O
acetonitrile	B-Chemical
)	O
was	O
layered	O
on	O
the	O
mixture	O
as	O
matrix	O
solution	O
.	O
After	O
drying	O
","	O
the	O
sample	O
was	O
applied	O
to	O
Ultraflex	O
-	O
I	O
â„¢	O
TOF	O
/	O
TOF	O
systems	O
(	O
Bruker	O
Daltonics	O
","	O
Inc	O
".,"	O
CA	O
","	O
USA	O
).	O
Mass	O
spectrometry	O
was	O
performed	O
in	O
the	O
positive	O
mode	O
","	O
using	O
an	O
accelerating	O
voltage	O
of	O
25	O
kV	O
.	O
The	O
laser	O
was	O
used	O
at	O
energy	O
of	O
30	O
-	O
50	O
%	O
(	O
3	O
.	O
0	O
-	O
5	O
.	O
0	O
Î¼J	O
)	O
and	O
a	O
repetition	O
rate	O
of	O
10	O
-	O
Hz	O
.	O
The	O
mass	O
spectra	O
were	O
calibrated	O
externally	O
using	O
Peptide	O
calibration	O
standard	O
(	O
Bruker	O
Daltonics	O
","	O
Inc	O
".,"	O
CA	O
","	O
USA	O
).	O
Each	O
spectrum	O
was	O
produced	O
by	O
accumulating	O
data	O
from	O
150	O
or	O
300	O
consecutive	O
laser	O
shots	O
.	O
Standard	O
of	O
18	O
:	O
1	O
-	O
LPA	B-Chemical
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
(	O
St	O
.	O
Louis	O
","	O
MO	O
","	O
USA	O
"),"	O
while	O
standards	O
of	O
16	O
:	O
0	O
17	O
:	O
0	O
-	O
and	O
18	O
:	O
0	O
-	O
LPA	B-Chemical
were	O
obtained	O
from	O
Doosan	O
Serdary	O
Research	O
Laboratories	O
(	O
London	O
","	O
ON	O
","	O
Canada	O
).	O
Nociception	O
test	O
The	O
mechanical	O
paw	O
pressure	O
test	O
was	O
carried	O
out	O
","	O
as	O
described	O
previously	O
[	O
7	O
].	O
Briefly	O
","	O
mice	O
were	O
placed	O
in	O
a	O
plexiglass	O
chamber	O
on	O
a	O
6	O
Ã—	O
6	O
mm	O
wire	O
mesh	O
grid	O
floor	O
and	O
allowed	O
to	O
acclimatize	O
for	O
a	O
period	O
of	O
1	O
h	O
.	O
A	O
mechanical	O
stimulus	O
was	O
then	O
delivered	O
onto	O
the	O
middle	O
of	O
the	O
plantar	O
surface	O
of	O
the	O
animal	O
using	O
a	O
Transducer	O
Indicator	O
(	O
Model	O
1601	O
;	O
IITC	O
Inc	O
".,"	O
Woodland	O
Hills	O
","	O
CA	O
","	O
USA	O
).	O
The	O
pressure	O
needed	O
to	O
evoke	O
a	O
flexor	O
response	O
was	O
defined	O
as	O
the	O
pain	O
threshold	O
.	O
A	O
cut	O
-	O
off	O
pressure	O
of	O
20	O
g	O
was	O
set	O
to	O
avoid	O
tissue	O
damage	O
.	O
Statistical	O
analysis	O
Statistical	O
analysis	O
was	O
evaluated	O
using	O
the	O
Dunnett	O
â€™	O
s	O
test	O
or	O
a	O
one	O
-	O
way	O
ANOVA	O
with	O
Tukey	O
-	O
Kramer	O
multiple	O
comparison	O
post	O
hoc	O
analysis	O
.	O
The	O
criterion	O
of	O
significance	O
was	O
set	O
at	O
p	O
<	O
0	O
.	O
5	O
.	O
All	O
results	O
are	O
expressed	O
as	O
mean	O
Â±	O
SEM	O
.	O
Results	O
Paclitaxel	B-Chemical
-	O
induced	O
LPA	B-Chemical
production	O
and	O
activations	O
of	O
iPLA2	O
an	O
cPLA2	O
enzymes	O
in	O
the	O
spinal	O
dorsal	O
horn	O
Increase	O
in	O
spinal	O
LPA	B-Chemical
level	O
after	O
paclitaxel	B-Chemical
injection	O
.	O
Time	O
courses	O
of	O
18	O
:	O
1	O
-	O
LPA	B-Chemical
","	O
16	O
:	O
0	O
-	O
LPA	B-Chemical
","	O
and	O
18	O
:	O
0	O
-	O
LPA	B-Chemical
levels	O
in	O
the	O
spinal	O
dorsal	O
horn	O
after	O
the	O
intraperitoneal	O
injection	O
of	O
paclitaxel	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
)	O
were	O
assessed	O
by	O
using	O
MALDI	O
-	O
TOF	O
-	O
MS	O
with	O
Phos	B-Chemical
-	I-Chemical
tag	I-Chemical
.	O
Data	O
represent	O
means	O
Â±	O
SEM	O
from	O
experiments	O
using	O
3	O
â€“	O
4	O
mice	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
versus	O
corresponding	O
0	O
h	O
.	O
Firstly	O
","	O
we	O
assessed	O
whether	O
paclitaxel	B-Chemical
could	O
induce	O
LPA	B-Chemical
production	O
in	O
the	O
spinal	O
dorsal	O
horn	O
.	O
In	O
order	O
to	O
measure	O
the	O
levels	O
of	O
LPA	B-Chemical
species	O
(	O
18	O
:	O
1	O
16	O
:	O
0	O
and	O
18	O
:	O
0	O
-	O
LPA	B-Chemical
"),"	O
we	O
performed	O
quantitative	O
MALDI	O
-	O
TOF	O
-	O
MS	O
method	O
with	O
phosphate	B-Chemical
-	O
capture	O
molecule	O
","	O
Phos	B-Chemical
-	I-Chemical
tag	I-Chemical
","	O
as	O
reported	O
previously	O
[	O
13	O
","	O
19	O
â€“	O
21	O
].	O
According	O
to	O
the	O
ratios	O
of	O
ion	O
-	O
peak	O
intensities	O
with	O
each	O
standard	O
of	O
LPA	B-Chemical
species	O
to	O
that	O
with	O
internal	O
standard	O
17	O
:	O
0	O
LPA	B-Chemical
(	O
0	O
.	O
2	O
nmol	O
"),"	O
we	O
have	O
already	O
validated	O
the	O
linearity	O
of	O
each	O
calibration	O
curve	O
over	O
the	O
concentration	O
range	O
of	O
0	O
.	O
1	O
-	O
2	O
.	O
0	O
nmol	O
[	O
13	O
].	O
Based	O
on	O
the	O
calibration	O
curves	O
","	O
the	O
concentrations	O
of	O
LPA	B-Chemical
species	O
were	O
determined	O
by	O
measuring	O
the	O
ion	O
-	O
signals	O
at	O
m	O
/	O
z	O
997	O
","	O
1023	O
","	O
and	O
1025	O
","	O
corresponding	O
to	O
16	O
:	O
0	O
18	O
:	O
1	O
and	O
18	O
:	O
0	O
-	O
LPA	B-Chemical
","	O
respectively	O
.	O
As	O
shown	O
in	O
Figure	O
1	O
","	O
the	O
level	O
of	O
18	O
:	O
1	O
-	O
LPA	B-Chemical
","	O
which	O
preferentially	O
activates	O
LPA1	O
and	O
LPA3	O
receptors	O
to	O
initiate	O
nerve	O
injury	O
-	O
induced	O
neuropathic	O
pain	O
[	O
13	O
"],"	O
was	O
gradually	O
increased	O
in	O
the	O
spinal	O
dorsal	O
horn	O
after	O
intraperitoneal	O
injection	O
of	O
paclitaxel	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
)	O
and	O
peaked	O
at	O
24	O
h	O
post	O
-	O
injection	O
","	O
followed	O
by	O
decline	O
at	O
72	O
h	O
post	O
-	O
injection	O
.	O
Similar	O
alterations	O
were	O
also	O
seen	O
in	O
the	O
16	O
:	O
0	O
-	O
and	O
18	O
:	O
0	O
-	O
LPA	B-Chemical
levels	O
(	O
Figure	O
1	O
).	O
Activations	O
of	O
iPLA	O
2	O
and	O
cPLA	O
2	O
enzymes	O
after	O
paclitaxel	B-Chemical
injection	O
.	O
(	O
A	O
and	O
B	O
)	O
Activations	O
of	O
spinal	O
iPLA2	O
(	O
A	O
)	O
and	O
cPLA2	O
(	O
B	O
)	O
were	O
measured	O
by	O
using	O
iPLA2	O
and	O
cPLA2	O
assays	O
at	O
indicated	O
time	O
points	O
after	O
the	O
paclitaxel	B-Chemical
injection	O
.	O
Data	O
represent	O
means	O
Â±	O
SEM	O
from	O
experiments	O
using	O
3	O
â€“	O
5	O
mice	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
versus	O
corresponding	O
0	O
h	O
.	O
Our	O
previous	O
studies	O
have	O
demonstrated	O
that	O
iPLA2	O
and	O
cPLA2	O
mediate	O
the	O
production	O
of	O
LPC	B-Chemical
","	O
a	O
precursor	O
of	O
LPA	B-Chemical
[	O
11	O
","	O
22	O
","	O
23	O
"],"	O
in	O
the	O
spinal	O
cord	O
[	O
11	O
","	O
13	O
","	O
17	O
].	O
Here	O
","	O
we	O
therefore	O
carried	O
out	O
iPLA2	O
and	O
cPLA2	O
assays	O
to	O
test	O
whether	O
paclitaxel	B-Chemical
could	O
activate	O
spinal	O
iPLA2	O
and	O
cPLA2	O
enzymes	O
.	O
The	O
enzymatic	O
activities	O
of	O
iPLA2	O
and	O
cPLA2	O
in	O
the	O
spinal	O
dorsal	O
horn	O
were	O
significantly	O
elevated	O
at	O
12	O
h	O
after	O
the	O
paclitaxel	B-Chemical
injection	O
","	O
followed	O
by	O
decline	O
to	O
the	O
control	O
levels	O
at	O
48	O
h	O
post	O
-	O
injection	O
(	O
Figure	O
2A	O
and	O
B	O
).	O
Involvement	O
of	O
substance	O
P	O
and	O
glutamate	O
receptors	O
in	O
paclitaxel	B-Chemical
-	O
induced	O
LPA	B-Chemical
production	O
Blockade	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
LPA	B-Chemical
production	O
.	O
Level	O
of	O
18	O
:	O
1	O
-	O
LPA	B-Chemical
in	O
the	O
spinal	O
dorsal	O
horn	O
at	O
24	O
h	O
after	O
the	O
injection	O
of	O
paclitaxel	B-Chemical
or	O
vehicle	O
was	O
measured	O
by	O
using	O
MALDI	O
-	O
TOF	O
-	O
MS	O
with	O
Phos	B-Chemical
-	I-Chemical
tag	I-Chemical
.	O
(	O
A	O
)	O
CP	B-Chemical
-	I-Chemical
99994	I-Chemical
(	O
10	O
nmol	O
"),"	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
10	O
nmol	O
"),"	O
or	O
aCSF	O
was	O
intrathecally	O
injected	O
at	O
30	O
min	O
prior	O
to	O
the	O
paclitaxel	B-Chemical
injection	O
.	O
Data	O
represent	O
means	O
Â±	O
SEM	O
from	O
experiments	O
using	O
3	O
mice	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
versus	O
aCSF	O
-	O
vehicle	O
-	O
treated	O
mice	O
;	O
#	O
p	O
<	O
0	O
.	O
5	O
","	O
versus	O
aCSF	O
-	O
paclitaxel	B-Chemical
-	O
treated	O
mice	O
.	O
(	O
B	O
)	O
Wild	O
-	O
type	O
(	O
WT	O
"),"	O
Lpar1	O
and	O
Lpar3	O
âˆ’/âˆ’	O
mice	O
were	O
used	O
to	O
evaluate	O
LPA	B-Chemical
level	O
at	O
24	O
h	O
after	O
paclitaxel	B-Chemical
administration	O
.	O
Data	O
represent	O
means	O
Â±	O
SEM	O
from	O
experiments	O
using	O
3	O
â€“	O
5	O
mice	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
versus	O
vehicle	O
-	O
treated	O
WT	O
mice	O
;	O
#	O
p	O
<	O
0	O
.	O
5	O
","	O
versus	O
paclitaxel	B-Chemical
-	O
treated	O
WT	O
mice	O
.	O
It	O
has	O
been	O
shown	O
that	O
excitatory	O
neurotransmitters	O
","	O
substance	O
P	O
(	O
SP	O
)	O
and	O
glutamate	B-Chemical
","	O
cooperatively	O
evoke	O
LPA	B-Chemical
production	O
in	O
the	O
spinal	O
cord	O
[	O
11	O
].	O
In	O
order	O
to	O
clarify	O
the	O
involvement	O
of	O
these	O
factors	O
in	O
the	O
paclitaxel	B-Chemical
-	O
induced	O
LPA	B-Chemical
production	O
","	O
mice	O
were	O
intrathecally	O
pretreated	O
with	O
CP	B-Chemical
-	I-Chemical
99994	I-Chemical
(	O
10	O
nmol	O
/	O
5	O
Î¼l	O
"),"	O
an	O
NK1	O
antagonist	O
","	O
or	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
10	O
nmol	O
/	O
5	O
Î¼l	O
"),"	O
an	O
NMDA	O
receptor	O
antagonist	O
","	O
at	O
30	O
min	O
prior	O
to	O
the	O
paclitaxel	B-Chemical
treatment	O
.	O
MALDI	O
-	O
TOF	O
-	O
MS	O
analysis	O
revealed	O
that	O
paclitaxel	B-Chemical
-	O
induced	O
production	O
of	O
18	O
:	O
1	O
-	O
LPA	B-Chemical
was	O
completely	O
blocked	O
by	O
the	O
pretreatment	O
with	O
CP	B-Chemical
-	I-Chemical
99994	I-Chemical
or	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
Figure	O
3A	O
).	O
Similarly	O
","	O
these	O
inhibitors	O
also	O
abolished	O
the	O
paclitaxel	B-Chemical
-	O
induced	O
increases	O
in	O
16	O
:	O
0	O
-	O
and	O
18	O
:	O
0	O
-	O
LPA	B-Chemical
levels	O
(	O
data	O
not	O
shown	O
).	O
Paclitaxel	B-Chemical
-	O
induced	O
amplification	O
of	O
LPA	B-Chemical
production	O
via	O
LPA1	O
and	O
LPA3	O
receptors	O
Our	O
previous	O
studies	O
have	O
shown	O
that	O
LPA	B-Chemical
itself	O
induces	O
spinal	O
LPA	B-Chemical
production	O
[	O
12	O
","	O
13	O
"],"	O
and	O
the	O
amplification	O
of	O
LPA	B-Chemical
biosynthesis	O
after	O
peripheral	O
nerve	O
injury	O
is	O
abolished	O
in	O
Lpar1	O
âˆ’/âˆ’	O
and	O
Lpar3	O
âˆ’/âˆ’	O
mice	O
[	O
13	O
"],"	O
indicating	O
the	O
critical	O
involvement	O
of	O
LPA1	O
and	O
LPA3	O
receptors	O
.	O
We	O
therefore	O
tested	O
whether	O
paclitaxel	B-Chemical
could	O
trigger	O
LPA1	O
and	O
LPA3	O
receptors	O
-	O
mediated	O
amplification	O
of	O
LPA	B-Chemical
production	O
in	O
the	O
spinal	O
cord	O
.	O
As	O
shown	O
in	O
Figure	O
3B	O
","	O
paclitaxel	B-Chemical
-	O
induced	O
production	O
of	O
18	O
:	O
1	O
-	O
LPA	B-Chemical
was	O
absent	O
in	O
Lpar1	O
âˆ’/âˆ’	O
and	O
Lpar3	O
âˆ’/âˆ’	O
mice	O
.	O
Also	O
","	O
Lpar1	O
âˆ’/âˆ’	O
and	O
Lpar3	O
âˆ’/âˆ’	O
mice	O
showed	O
a	O
lack	O
of	O
16	O
:	O
0	O
-	O
and	O
18	O
:	O
0	O
-	O
LPA	B-Chemical
production	O
after	O
paclitaxel	B-Chemical
injection	O
(	O
data	O
not	O
shown	O
).	O
Blockade	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
by	O
NK1	O
and	O
NMDA	O
receptor	O
antagonists	O
Prevention	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
by	O
pharmacological	O
blockade	O
of	O
NK1	O
or	O
NMDA	O
receptor	O
.	O
Paclitaxel	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
)	O
was	O
injected	O
on	O
4	O
alternate	O
days	O
(	O
day	O
0	O
","	O
2	O
","	O
4	O
","	O
and	O
6	O
).	O
CP	B-Chemical
-	I-Chemical
99994	I-Chemical
(	O
10	O
nmol	O
"),"	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
10	O
nmol	O
)	O
or	O
aCSF	B-Chemical
was	O
intrathecally	O
injected	O
at	O
30	O
min	O
prior	O
to	O
the	O
initial	O
injection	O
of	O
paclitaxel	B-Chemical
.	O
Mechanical	O
paw	O
withdrawal	O
latencies	O
(	O
PWT	O
","	O
in	O
g	O
)	O
were	O
measured	O
at	O
14	O
day	O
after	O
the	O
initial	O
paclitaxel	B-Chemical
injection	O
","	O
by	O
using	O
mechanical	O
paw	O
withdrawal	O
test	O
.	O
Data	O
represent	O
means	O
Â±	O
SEM	O
from	O
experiments	O
using	O
6	O
â€“	O
10	O
mice	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
versus	O
aCSF	B-Chemical
-	O
vehicle	O
-	O
treated	O
mice	O
;	O
#	O
p	O
<	O
0	O
.	O
5	O
","	O
versus	O
aCSF	B-Chemical
-	O
paclitaxel	B-Chemical
-	O
treated	O
mice	O
.	O
Based	O
on	O
the	O
findings	O
that	O
pharmacological	O
blockade	O
of	O
NK1	O
and	O
NMDA	O
receptors	O
inhibited	O
paclitaxel	B-Chemical
-	O
induced	O
spinal	O
LPA	B-Chemical
production	O
(	O
Figure	O
3A	O
"),"	O
we	O
investigated	O
whether	O
SP	O
and	O
glutamate	B-Chemical
could	O
mediate	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
allodynia	O
.	O
The	O
intraperitoneal	O
treatments	O
with	O
paclitaxel	B-Chemical
(	O
4	O
mg	O
/	O
kg	O
)	O
on	O
4	O
alternate	O
days	O
(	O
day	O
0	O
","	O
2	O
","	O
4	O
","	O
and	O
6	O
;	O
cumulative	O
dose	O
of	O
16	O
mg	O
/	O
kg	O
)	O
significantly	O
reduced	O
the	O
pain	O
thresholds	O
against	O
mechanical	O
stimuli	O
at	O
day	O
14	O
after	O
the	O
initial	O
treatment	O
(	O
Figure	O
4	O
).	O
The	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
was	O
completely	O
blocked	O
by	O
the	O
intrathecal	O
pretreatment	O
with	O
CP	B-Chemical
-	I-Chemical
99994	I-Chemical
(	O
10	O
nmol	O
/	O
5	O
Î¼l	O
)	O
or	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
10	O
nmol	O
/	O
5	O
Î¼l	O
)	O
(	O
Figure	O
4	O
).	O
In	O
contrast	O
","	O
CP	B-Chemical
-	I-Chemical
99994	I-Chemical
and	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
had	O
no	O
effects	O
on	O
the	O
mechanical	O
pain	O
thresholds	O
in	O
vehicle	O
-	O
treated	O
mice	O
(	O
Figure	O
4	O
).	O
Involvement	O
of	O
LPA1	O
and	O
LPA3	O
receptors	O
in	O
the	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
Absence	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
in	O
LPA	O
1	O
and	O
LPA	O
3	O
knockout	O
mice	O
.	O
Time	O
course	O
of	O
mechanical	O
paw	O
withdrawal	O
latencies	O
(	O
PWT	O
","	O
in	O
g	O
)	O
after	O
intraperitoneal	O
injections	O
of	O
paclitaxel	B-Chemical
on	O
4	O
alternate	O
days	O
(	O
day	O
0	O
","	O
2	O
","	O
4	O
","	O
and	O
6	O
)	O
in	O
wild	O
-	O
type	O
(	O
WT	O
"),"	O
Lpar1	O
and	O
Lpar3	O
âˆ’/âˆ’	O
mice	O
.	O
Mechanical	O
pain	O
thresholds	O
were	O
evaluated	O
by	O
using	O
mechanical	O
paw	O
withdrawal	O
test	O
.	O
Data	O
represent	O
means	O
Â±	O
SEM	O
from	O
experiments	O
using	O
4	O
â€“	O
6	O
mice	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
versus	O
vehicle	O
-	O
treated	O
WT	O
mice	O
;	O
#	O
p	O
<	O
0	O
.	O
5	O
","	O
versus	O
paclitaxel	B-Chemical
-	O
treated	O
WT	O
mice	O
.	O
To	O
test	O
whether	O
LPA	O
receptors	O
could	O
participate	O
in	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
","	O
we	O
used	O
mice	O
deficient	O
in	O
LPA1	O
or	O
LPA3	O
receptors	O
","	O
both	O
of	O
which	O
are	O
required	O
for	O
the	O
development	O
of	O
peripheral	O
nerve	O
injury	O
-	O
induced	O
neuropathic	O
pain	O
[	O
7	O
","	O
13	O
].	O
The	O
paclitaxel	B-Chemical
treatments	O
produced	O
mechanical	O
allodynia	O
as	O
early	O
as	O
day	O
1	O
after	O
the	O
first	O
injection	O
in	O
wild	O
-	O
type	O
animals	O
(	O
Figure	O
5	O
).	O
Intriguingly	O
","	O
the	O
paclitaxel	B-Chemical
-	O
induced	O
mechanical	O
allodynia	O
was	O
absent	O
in	O
Lpar1	O
âˆ’/âˆ’	O
and	O
Lpar3	O
âˆ’/âˆ’	O
mice	O
(	O
Figure	O
5	O
"),"	O
suggesting	O
the	O
critical	O
contribution	O
of	O
LPA1	O
and	O
LPA3	O
receptors	O
to	O
the	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
.	O
Discussion	O
There	O
is	O
emerging	O
evidence	O
that	O
LPA	B-Chemical
mediates	O
not	O
only	O
peripheral	O
nerve	O
injury	O
-	O
induced	O
neuropathic	O
pain	O
[	O
7	O
"],"	O
but	O
also	O
other	O
chronic	O
pain	O
","	O
such	O
as	O
ischemia	O
-	O
induced	O
central	O
neuropathic	O
pain	O
[	O
24	O
]	O
and	O
bone	O
cancer	O
pain	O
[	O
25	O
].	O
Here	O
","	O
we	O
focused	O
on	O
the	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
that	O
can	O
be	O
observed	O
in	O
both	O
clinic	O
and	O
animal	O
studies	O
[	O
3	O
].	O
The	O
most	O
important	O
finding	O
of	O
the	O
present	O
study	O
is	O
that	O
paclitaxel	B-Chemical
-	O
induced	O
spinal	O
LPA	B-Chemical
production	O
and	O
the	O
development	O
of	O
neuropathic	O
pain	O
were	O
absent	O
in	O
Lpar1	O
âˆ’/âˆ’	O
and	O
Lpar3	O
âˆ’/âˆ’	O
mice	O
.	O
This	O
suggests	O
","	O
for	O
the	O
first	O
time	O
","	O
the	O
critical	O
involvement	O
of	O
LPA	B-Chemical
and	O
its	O
receptors	O
LPA1	O
and	O
LPA3	O
in	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
","	O
a	O
predictable	O
adverse	O
effect	O
.	O
Our	O
previous	O
report	O
has	O
shown	O
that	O
peripheral	O
nerve	O
injury	O
activates	O
spinal	O
iPLA2	O
and	O
cPLA2	O
at	O
1	O
h	O
post	O
-	O
injury	O
","	O
followed	O
by	O
spinal	O
LPA	B-Chemical
production	O
at	O
3	O
h	O
post	O
-	O
injury	O
[	O
17	O
].	O
Regarding	O
mechanisms	O
for	O
the	O
LPA	B-Chemical
biosynthesis	O
","	O
simultaneous	O
stimuli	O
of	O
excitatory	O
neurotransmitters	O
","	O
SP	O
and	O
glutamate	B-Chemical
","	O
are	O
capable	O
of	O
evoking	O
LPA	B-Chemical
production	O
in	O
the	O
spinal	O
cord	O
slices	O
[	O
11	O
].	O
Indeed	O
","	O
pharmacological	O
blockade	O
of	O
NK1	O
or	O
NMDA	O
receptor	O
completely	O
inhibits	O
injury	O
-	O
induced	O
iPLA2	O
and	O
cPLA2	O
activation	O
and	O
LPA	B-Chemical
production	O
[	O
13	O
].	O
In	O
the	O
present	O
study	O
","	O
we	O
found	O
that	O
paclitaxel	B-Chemical
caused	O
a	O
significant	O
increase	O
in	O
spinal	O
iPLA2	O
and	O
cPLA2	O
activities	O
at	O
12	O
h	O
post	O
-	O
injection	O
","	O
followed	O
by	O
spinal	O
LPA	B-Chemical
production	O
at	O
24	O
h	O
post	O
-	O
injection	O
.	O
In	O
addition	O
","	O
the	O
pretreatment	O
with	O
intrathecal	O
NK1	O
or	O
NMDA	O
receptor	O
antagonist	O
completely	O
blocked	O
the	O
paclitaxel	B-Chemical
-	O
induced	O
LPA	B-Chemical
production	O
.	O
These	O
findings	O
prompted	O
us	O
to	O
hypothesize	O
that	O
paclitaxel	B-Chemical
could	O
activate	O
spinal	O
iPLA2	O
and	O
cPLA2	O
","	O
possibly	O
via	O
the	O
increase	O
in	O
SP	O
and	O
glutamate	B-Chemical
levels	O
","	O
thereby	O
leading	O
to	O
LPA	B-Chemical
production	O
.	O
In	O
this	O
context	O
","	O
paclitaxel	B-Chemical
","	O
which	O
poorly	O
penetrates	O
blood	O
â€“	O
brain	O
-	O
barrier	O
","	O
is	O
known	O
to	O
accumulate	O
in	O
the	O
dorsal	O
root	O
ganglion	O
[	O
26	O
â€“	O
28	O
"],"	O
indicating	O
that	O
paclitaxel	B-Chemical
could	O
alter	O
the	O
functions	O
of	O
primary	O
afferents	O
to	O
cause	O
peripheral	O
and	O
central	O
sensitization	O
.	O
For	O
instance	O
","	O
there	O
are	O
reports	O
showing	O
that	O
paclitaxel	B-Chemical
induces	O
SP	O
release	O
from	O
cultured	O
primary	O
afferent	O
neurons	O
[	O
29	O
","	O
30	O
].	O
Moreover	O
","	O
paclitaxel	B-Chemical
has	O
been	O
found	O
to	O
cause	O
a	O
down	O
-	O
regulation	O
of	O
glial	O
transporters	O
","	O
such	O
as	O
glutamate	O
-	O
aspartate	O
transporter	O
and	O
glutamate	O
transporter	O
-	O
1	O
in	O
the	O
spinal	O
astrocyte	O
as	O
early	O
as	O
4	O
h	O
after	O
paclitaxel	B-Chemical
injection	O
[	O
31	O
"],"	O
indicating	O
that	O
synaptic	O
glutamate	B-Chemical
level	O
would	O
be	O
increased	O
in	O
the	O
spinal	O
dorsal	O
horn	O
after	O
paclitaxel	B-Chemical
administration	O
.	O
These	O
mechanisms	O
might	O
explain	O
the	O
reasons	O
why	O
the	O
paclitaxel	B-Chemical
-	O
induced	O
spinal	O
iPLA2	O
and	O
cPLA2	O
activation	O
and	O
subsequent	O
LPA	B-Chemical
production	O
are	O
delayed	O
as	O
compared	O
with	O
the	O
case	O
of	O
peripheral	O
nerve	O
injury	O
.	O
Previously	O
","	O
we	O
have	O
demonstrated	O
that	O
a	O
single	O
intrathecal	O
injection	O
of	O
LPA	B-Chemical
increases	O
spinal	O
LPA	B-Chemical
level	O
[	O
12	O
","	O
13	O
].	O
Also	O
","	O
nerve	O
injury	O
-	O
induced	O
production	O
of	O
LPA	B-Chemical
species	O
is	O
absent	O
in	O
Lpar1	O
âˆ’/âˆ’	O
and	O
Lpar3	O
âˆ’/âˆ’	O
mice	O
[	O
13	O
"],"	O
indicating	O
the	O
involvement	O
of	O
LPA1	O
and	O
LPA3	O
receptors	O
in	O
self	O
-	O
amplification	O
of	O
LPA	B-Chemical
production	O
.	O
Interestingly	O
","	O
18	O
:	O
1	O
-	O
LPA	B-Chemical
","	O
which	O
preferentially	O
activates	O
LPA1	O
and	O
LPA3	O
receptors	O
","	O
induces	O
not	O
only	O
amplification	O
of	O
LPA	B-Chemical
production	O
but	O
also	O
neuropathic	O
thermal	O
hyperalgesia	O
[	O
13	O
].	O
In	O
contrast	O
","	O
neither	O
16	O
:	O
0	O
-	O
nor	O
18	O
:	O
0	O
-	O
LPA	B-Chemical
triggers	O
LPA	B-Chemical
production	O
and	O
neuropathic	O
pain	O
-	O
like	O
behavior	O
[	O
13	O
].	O
Here	O
","	O
we	O
showed	O
that	O
paclitaxel	B-Chemical
evoked	O
a	O
significant	O
production	O
of	O
LPA	B-Chemical
species	O
(	O
18	O
:	O
1	O
16	O
:	O
0	O
and	O
18	O
:	O
0	O
-	O
LPA	B-Chemical
"),"	O
and	O
such	O
LPA	B-Chemical
production	O
was	O
absent	O
in	O
Lpar1	O
âˆ’/âˆ’	O
and	O
Lpar3	O
âˆ’/âˆ’	O
mice	O
.	O
Therefore	O
","	O
it	O
is	O
logical	O
to	O
postulate	O
that	O
activations	O
of	O
LPA1	O
and	O
LPA3	O
receptors	O
","	O
possibly	O
by	O
18	O
:	O
1	O
-	O
LPA	B-Chemical
","	O
are	O
required	O
for	O
paclitaxel	B-Chemical
-	O
induced	O
amplification	O
of	O
LPA	B-Chemical
production	O
.	O
LPA	B-Chemical
can	O
activate	O
primary	O
afferents	O
","	O
thereby	O
evoking	O
the	O
release	O
of	O
SP	O
from	O
nerve	O
endings	O
via	O
LPA1	O
receptor	O
[	O
32	O
","	O
33	O
].	O
Therefore	O
","	O
there	O
is	O
a	O
possibility	O
that	O
LPA1	O
receptor	O
might	O
be	O
involved	O
in	O
amplification	O
of	O
LPA	B-Chemical
production	O
via	O
the	O
release	O
of	O
SP	O
from	O
presynaptic	O
terminals	O
in	O
the	O
spinal	O
dorsal	O
horn	O
.	O
Alternatively	O
","	O
LPA1	O
and	O
LPA3	O
receptors	O
are	O
expressed	O
in	O
microglia	O
[	O
34	O
","	O
35	O
"],"	O
indicating	O
microglial	O
LPA1	O
and	O
LPA3	O
receptors	O
might	O
induce	O
the	O
release	O
of	O
biological	O
factors	O
that	O
activate	O
iPLA2	O
and	O
cPLA2	O
to	O
cause	O
LPA	B-Chemical
production	O
.	O
One	O
such	O
candidate	O
is	O
interleukin	O
-	O
1Î²	O
","	O
which	O
mediates	O
LPA	B-Chemical
-	O
induced	O
LPA	B-Chemical
production	O
via	O
activations	O
of	O
iPLA2	O
and	O
cPLA2	O
[	O
36	O
].	O
Tatsushima	O
et	O
al	O
.	O
reported	O
that	O
a	O
single	O
intrathecal	O
injection	O
of	O
NK1	O
receptor	O
antagonist	O
alleviates	O
the	O
established	O
mechanical	O
allodynia	O
after	O
repeated	O
treatments	O
with	O
paclitaxel	B-Chemical
[	O
30	O
"],"	O
suggesting	O
an	O
involvement	O
of	O
SP	O
in	O
the	O
maintenance	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
.	O
Although	O
NMDA	O
receptor	O
antagonist	O
reverses	O
the	O
established	O
mechanical	O
allodynia	O
after	O
paclitaxel	B-Chemical
injections	O
[	O
37	O
"],"	O
inconsistent	O
observation	O
has	O
been	O
reported	O
[	O
38	O
].	O
Therefore	O
","	O
the	O
authors	O
have	O
mentioned	O
that	O
NMDA	O
receptor	O
activation	O
is	O
unlikely	O
to	O
have	O
a	O
major	O
role	O
in	O
the	O
maintenance	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
[	O
37	O
","	O
38	O
].	O
On	O
the	O
other	O
hand	O
","	O
the	O
present	O
study	O
clearly	O
showed	O
that	O
the	O
intrathecal	O
pretreatment	O
with	O
NK1	O
and	O
NMDA	O
receptor	O
antagonists	O
blocked	O
paclitaxel	B-Chemical
-	O
induced	O
spinal	O
LPA	B-Chemical
production	O
and	O
mechanical	O
allodynia	O
","	O
suggesting	O
that	O
SP	O
and	O
glutamate	B-Chemical
are	O
key	O
mediators	O
of	O
the	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
via	O
causing	O
LPA	B-Chemical
production	O
.	O
Furthermore	O
","	O
the	O
paclitaxel	B-Chemical
-	O
induced	O
spinal	O
LPA	B-Chemical
production	O
and	O
mechanical	O
allodynia	O
were	O
absent	O
in	O
Lpar1	O
âˆ’/âˆ’	O
and	O
Lpar3	O
âˆ’/âˆ’	O
mice	O
.	O
Collectively	O
","	O
these	O
findings	O
strongly	O
suggest	O
that	O
spinally	O
synthesized	O
LPA	B-Chemical
","	O
whose	O
production	O
is	O
amplified	O
via	O
LPA1	O
and	O
LPA3	O
receptors	O
","	O
participates	O
in	O
the	O
pathogenesis	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
.	O
Regarding	O
the	O
molecular	O
basis	O
for	O
induction	O
of	O
neuropathic	O
pain	O
","	O
we	O
have	O
demonstrated	O
that	O
LPA	B-Chemical
evokes	O
demyelination	O
of	O
sensory	O
fibers	O
in	O
the	O
dorsal	O
root	O
[	O
7	O
].	O
In	O
addition	O
","	O
LPA	B-Chemical
also	O
causes	O
altered	O
expression	O
of	O
pain	O
-	O
related	O
molecules	O
in	O
the	O
dorsal	O
root	O
ganglion	O
and	O
spinal	O
dorsal	O
horn	O
[	O
7	O
].	O
Furthermore	O
","	O
gene	O
profiling	O
analysis	O
has	O
clarified	O
that	O
LPA	B-Chemical
initially	O
up	O
-	O
regulates	O
gene	O
expression	O
of	O
ephrinB1	O
","	O
which	O
contributes	O
to	O
LPA	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
via	O
activation	O
of	O
spinal	O
NMDA	O
receptor	O
[	O
39	O
].	O
On	O
the	O
other	O
hand	O
","	O
it	O
has	O
been	O
proposed	O
that	O
multiple	O
mechanisms	O
","	O
including	O
mitochondrial	O
dysfunction	O
","	O
altered	O
gene	O
expression	O
","	O
and	O
glial	O
activation	O
","	O
are	O
implicated	O
in	O
the	O
mechanisms	O
for	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
[	O
27	O
","	O
40	O
].	O
Intriguingly	O
","	O
it	O
seems	O
that	O
some	O
of	O
the	O
mechanisms	O
","	O
such	O
as	O
demyelination	O
and	O
up	O
-	O
regulations	O
of	O
calcium	O
channel	O
Î±2Î´	O
-	O
1	O
subunit	O
","	O
would	O
be	O
commonly	O
observed	O
in	O
the	O
neuropathic	O
pain	O
caused	O
by	O
paclitaxel	B-Chemical
and	O
LPA	B-Chemical
[	O
7	O
","	O
41	O
","	O
42	O
].	O
Alternatively	O
","	O
a	O
recent	O
paper	O
by	O
Wright	O
et	O
al	O
.	O
has	O
shown	O
that	O
phosphatidylinositol	O
4	O
-	O
phosphate	O
5	O
kinase	O
type	O
1C	O
has	O
an	O
important	O
role	O
in	O
LPA	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
[	O
43	O
"],"	O
raising	O
possibility	O
that	O
such	O
lipid	O
kinase	O
might	O
be	O
involved	O
in	O
the	O
LPA	B-Chemical
actions	O
underlying	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
.	O
Further	O
studies	O
are	O
required	O
for	O
the	O
elucidation	O
of	O
mechanisms	O
via	O
LPA1	O
and	O
LPA3	O
receptors	O
underlying	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
.	O
Conclusions	O
The	O
present	O
study	O
demonstrated	O
that	O
LPA1	O
and	O
LPA3	O
receptors	O
-	O
mediated	O
amplification	O
of	O
spinal	O
LPA	B-Chemical
production	O
is	O
required	O
for	O
the	O
development	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
.	O
The	O
molecular	O
machineries	O
underlying	O
LPA	B-Chemical
production	O
might	O
serve	O
as	O
novel	O
potential	O
therapeutic	O
targets	O
in	O
the	O
prevention	O
of	O
paclitaxel	B-Chemical
-	O
induced	O
neuropathic	O
pain	O
.	O
Abbreviations	O
aCSF	B-Chemical
Artificial	B-Chemical
cerebrospinal	I-Chemical
fluid	I-Chemical
cPLA2	O
Cytosolic	O
phospholipase	O
A2	O
iPLA2	O
Calcium	O
-	O
independent	O
phospholipase	O
A2	O
LPA	B-Chemical
Lysophosphatidic	B-Chemical
acid	I-Chemical
Lpar1	O
âˆ’/âˆ’	O
LPA1	O
receptor	O
-	O
deficient	O
mice	O
Lpar3	O
âˆ’/âˆ’	O
LPA3	O
receptor	O
-	O
deficient	O
mice	O
LPC	B-Chemical
Lysophosphatidylcholine	B-Chemical
MALDI	O
-	O
TOF	O
-	O
MS	O
Matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
NK1	O
Neurokinin	O
1	O
NMDA	B-Chemical
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
aspartate	I-Chemical
SP	O
Substance	O
P	O
.	O
Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O
Authors	O
â€™	O
contributions	O
JN	O
performed	O
biochemical	O
and	O
animal	O
experiments	O
.	O
H	O
.	O
Uchida	O
participated	O
in	O
experimental	O
design	O
","	O
statistical	O
analyses	O
","	O
and	O
writing	O
the	O
manuscripts	O
.	O
H	O
.	O
Ueda	O
is	O
responsible	O
for	O
the	O
experimental	O
design	O
and	O
writing	O
the	O
manuscript	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
References	O
A	O
nationwide	O
survey	O
of	O
hereditary	O
angioedema	O
due	O
to	O
C1	O
inhibitor	O
deficiency	O
in	O
Italy	O
Introduction	O
Hereditary	O
angioedema	O
due	O
to	O
C1	O
-	O
inhibitor	O
deficiency	O
(	O
C1	O
-	O
INH	O
-	O
HAE	O
type	O
I	O
)	O
or	O
dysfunction	O
(	O
C1	O
-	O
INH	O
-	O
HAE	O
type	O
II	O
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
recurrent	O
episodes	O
of	O
edema	O
with	O
an	O
estimated	O
frequency	O
of	O
1	O
:	O
50	O
","	O
0	O
in	O
the	O
global	O
population	O
without	O
racial	O
or	O
gender	O
differences	O
.	O
In	O
this	O
study	O
we	O
present	O
the	O
results	O
of	O
a	O
nationwide	O
survey	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
patients	O
referring	O
to	O
17	O
Italian	O
centers	O
","	O
the	O
Italian	O
network	O
for	O
C1	O
-	O
INH	O
-	O
HAE	O
","	O
ITACA	O
.	O
Methods	O
Italian	O
patients	O
diagnosed	O
with	O
C1	O
-	O
INH	O
-	O
HAE	O
from	O
1973	O
to	O
2013	O
were	O
included	O
in	O
the	O
study	O
.	O
Diagnosis	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
was	O
based	O
on	O
family	O
and	O
/	O
or	O
personal	O
history	O
of	O
recurrent	O
angioedema	O
without	O
urticaria	O
and	O
on	O
antigenic	O
and	O
/	O
or	O
functional	O
C1	O
-	O
INH	O
deficiency	O
.	O
Results	O
983	O
patients	O
(	O
53	O
%	O
female	O
)	O
from	O
376	O
unrelated	O
families	O
were	O
included	O
in	O
this	O
survey	O
.	O
Since	O
1973	O
","	O
63	O
(	O
6	O
%)	O
patients	O
diagnosed	O
with	O
C1	O
-	O
INH	O
-	O
HAE	O
died	O
and	O
data	O
from	O
3	O
patients	O
were	O
missing	O
when	O
analysis	O
was	O
performed	O
.	O
Accordingly	O
","	O
the	O
minimum	O
prevalence	O
of	O
HAE	O
in	O
Italy	O
in	O
2013	O
is	O
920	O
:	O
59	O
","	O
394	O
","	O
0	O
inhabitants	O
","	O
equivalent	O
to	O
1	O
:	O
64	O
","	O
935	O
.	O
Compared	O
to	O
the	O
general	O
population	O
","	O
patients	O
are	O
less	O
represented	O
in	O
the	O
early	O
and	O
late	O
decades	O
of	O
life	O
:	O
men	O
start	O
reducing	O
after	O
the	O
5th	O
decade	O
and	O
women	O
after	O
the	O
6th	O
.	O
Median	O
age	O
of	O
patients	O
is	O
45	O
(	O
IQ	O
28	O
-	O
57	O
"),"	O
median	O
age	O
at	O
diagnosis	O
is	O
26	O
years	O
(	O
IQ	O
13	O
-	O
41	O
).	O
C1	O
-	O
INH	O
-	O
HAE	O
type	O
1	O
are	O
87	O
"%,"	O
with	O
median	O
age	O
at	O
diagnosis	O
of	O
25	O
(	O
13	O
-	O
40	O
);	O
type	O
2	O
are	O
13	O
%	O
with	O
median	O
age	O
at	O
diagnosis	O
of	O
31	O
(	O
IQ	O
16	O
-	O
49	O
).	O
Functional	O
C1INH	O
is	O
â‰¤	O
50	O
%	O
in	O
99	O
%	O
of	O
patients	O
.	O
Antigen	O
C1INH	O
is	O
â‰¤	O
50	O
%	O
in	O
99	O
%	O
of	O
type	O
1	O
.	O
C4	O
is	O
â‰¤	O
50	O
%	O
in	O
96	O
%	O
of	O
patients	O
.	O
The	O
chance	O
of	O
having	O
C1	O
-	O
INH	O
-	O
HAE	O
with	O
C4	O
plasma	O
levels	O
>	O
50	O
%	O
is	O
<	O
0	O
.	O
5	O
.	O
Conclusion	O
This	O
nationwide	O
survey	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
provides	O
for	O
Italy	O
a	O
prevalence	O
of	O
1	O
:	O
64	O
","	O
935	O
.	O
C1	O
-	O
INH	O
-	O
HAE	O
patients	O
listed	O
in	O
our	O
database	O
have	O
a	O
shorter	O
life	O
expectancy	O
than	O
the	O
general	O
population	O
.	O
An	O
increased	O
awareness	O
of	O
the	O
disease	O
is	O
needed	O
to	O
reduce	O
this	O
discrepancy	O
.	O
Measurement	O
of	O
C4	O
antigen	O
can	O
exclude	O
diagnosis	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
with	O
an	O
accuracy	O
>	O
95	O
%.	O
This	O
parameter	O
should	O
be	O
therefore	O
considered	O
for	O
initial	O
screening	O
in	O
differential	O
diagnosis	O
of	O
angioedema	O
.	O
Background	O
Hereditary	O
angioedema	O
(	O
HAE	O
)	O
due	O
to	O
C1	O
Inhibitor	O
(	O
C1	O
-	O
INH	O
)	O
deficiency	O
(	O
C1	O
-	O
INH	O
-	O
HAE	O
)	O
is	O
a	O
rare	O
autosomal	O
dominant	O
disease	O
due	O
to	O
reduced	O
C1	O
-	O
INH	O
plasma	O
levels	O
(	O
C1	O
-	O
INH	O
-	O
HAE	O
type	O
I	O
)	O
or	O
to	O
the	O
presence	O
of	O
a	O
dysfunctional	O
C1	O
-	O
INH	O
(	O
C1	O
-	O
INH	O
-	O
HAE	O
type	O
II	O
)	O
[	O
1	O
].	O
C1	O
-	O
INH	O
-	O
HAE	O
type	O
I	O
is	O
estimated	O
to	O
occur	O
in	O
approximately	O
85	O
%	O
of	O
patients	O
","	O
type	O
II	O
occurs	O
in	O
the	O
remaining	O
15	O
%.	O
C4	O
is	O
reduced	O
in	O
both	O
C1	O
-	O
INH	O
-	O
HAE	O
type	O
I	O
and	O
II	O
while	O
C3	O
is	O
normal	O
[	O
2	O
].	O
The	O
disease	O
is	O
caused	O
by	O
mutation	O
in	O
C1	O
-	O
INH	O
gene	O
(	O
SERPING1	O
).	O
De	O
novo	O
mutants	O
","	O
i	O
.	O
e	O
.	O
the	O
subjects	O
whose	O
parents	O
have	O
a	O
normal	O
C1	O
-	O
INH	O
","	O
can	O
be	O
identified	O
in	O
approximately	O
25	O
%	O
of	O
the	O
families	O
[	O
3	O
].	O
The	O
deficiency	O
of	O
C1	O
-	O
INH	O
results	O
in	O
uncontrolled	O
activation	O
of	O
the	O
contact	O
system	O
and	O
release	O
of	O
bradykinin	O
","	O
the	O
mediator	O
of	O
increased	O
vascular	O
permeability	O
and	O
angioedema	O
manifestations	O
[	O
4	O
","	O
5	O
].	O
C1	O
-	O
INH	O
-	O
HAE	O
manifests	O
with	O
recurrent	O
episodes	O
of	O
edema	O
of	O
the	O
skin	O
","	O
gastrointestinal	O
tract	O
and	O
upper	O
airway	O
.	O
The	O
disease	O
is	O
disabling	O
and	O
laryngeal	O
edema	O
can	O
lead	O
to	O
asphyxiation	O
and	O
death	O
if	O
left	O
untreated	O
[	O
2	O
].	O
Data	O
on	O
the	O
prevalence	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
are	O
sparse	O
.	O
The	O
estimated	O
frequency	O
worldwide	O
reported	O
in	O
literature	O
varies	O
from	O
1	O
every	O
10	O
","	O
0	O
to	O
1	O
every	O
150	O
","	O
0	O
persons	O
without	O
racial	O
or	O
gender	O
differences	O
[	O
6	O
-	O
8	O
].	O
A	O
nationwide	O
survey	O
in	O
Denmark	O
","	O
based	O
on	O
76	O
HAE	O
patients	O
","	O
reported	O
a	O
minimum	O
prevalence	O
of	O
1	O
:	O
70	O
","	O
922	O
inhabitants	O
[	O
9	O
].	O
Previous	O
Norwegian	O
and	O
Spanish	O
studies	O
based	O
on	O
67	O
and	O
444	O
patients	O
respectively	O
found	O
a	O
minimal	O
prevalence	O
of	O
1	O
:	O
66	O
","	O
225	O
and	O
1	O
:	O
91	O
","	O
743	O
inhabitants	O
[	O
10	O
","	O
11	O
].	O
Two	O
more	O
recent	O
surveys	O
in	O
Sweden	O
and	O
in	O
Slovenia	O
based	O
respectively	O
on	O
145	O
and	O
17	O
patients	O
reported	O
a	O
prevalence	O
of	O
1	O
:	O
66	O
.	O
0	O
and	O
1	O
:	O
105	O
","	O
263	O
[	O
12	O
","	O
13	O
].	O
Since	O
C1	O
-	O
INH	O
-	O
HAE	O
is	O
a	O
genetic	O
disease	O
","	O
the	O
deficiency	O
of	O
C1	O
-	O
INH	O
is	O
present	O
from	O
birth	O
.	O
Nevertheless	O
a	O
minority	O
of	O
patients	O
have	O
perinatal	O
angioedema	O
symptoms	O
.	O
Patients	O
typically	O
begin	O
to	O
present	O
clinical	O
manifestations	O
in	O
childhood	O
and	O
attacks	O
frequency	O
often	O
increase	O
around	O
puberty	O
.	O
Before	O
the	O
second	O
decade	O
of	O
life	O
the	O
majority	O
of	O
patients	O
manifest	O
symptoms	O
of	O
angioedema	O
[	O
14	O
].	O
Due	O
to	O
the	O
rarity	O
of	O
the	O
disease	O
and	O
to	O
the	O
fact	O
that	O
the	O
clinical	O
symptoms	O
overlap	O
with	O
those	O
of	O
other	O
forms	O
of	O
angioedema	O
","	O
C1	O
-	O
INH	O
-	O
HAE	O
is	O
frequently	O
misdiagnosed	O
.	O
Consequently	O
C1	O
-	O
INH	O
-	O
HAE	O
patients	O
may	O
experience	O
considerable	O
delay	O
between	O
first	O
symptoms	O
and	O
diagnosis	O
.	O
In	O
a	O
recent	O
international	O
observational	O
study	O
analyzing	O
data	O
of	O
patients	O
eligible	O
for	O
Icatibant	B-Chemical
treatment	O
(	O
Icatibant	B-Chemical
Outcome	O
Survey	O
","	O
IOS	O
)	O
conducted	O
in	O
8	O
European	O
countries	O
the	O
mean	O
delay	O
in	O
diagnosis	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
patients	O
was	O
12	O
.	O
8	O
years	O
[	O
15	O
].	O
Previous	O
nationwide	O
surveys	O
in	O
France	O
","	O
Spain	O
","	O
and	O
Denmark	O
have	O
reported	O
mean	O
delays	O
in	O
diagnosis	O
of	O
12	O
","	O
13	O
.	O
1	O
and	O
16	O
.	O
3	O
years	O
","	O
respectively	O
[	O
9	O
","	O
10	O
","	O
16	O
].	O
In	O
1973	O
Agostoni	O
et	O
al	O
.	O
reported	O
the	O
first	O
Italian	O
family	O
with	O
C1	O
-	O
INH	O
-	O
HAE	O
[	O
17	O
].	O
After	O
that	O
few	O
centers	O
in	O
Italy	O
have	O
been	O
active	O
in	O
diagnosing	O
and	O
treating	O
this	O
disease	O
[	O
14	O
","	O
18	O
].	O
In	O
2007	O
a	O
multidisciplinary	O
panel	O
of	O
Italian	O
experts	O
in	O
C1	O
-	O
INH	O
-	O
HAE	O
met	O
for	O
a	O
Consensus	O
Conference	O
held	O
in	O
Torino	O
to	O
define	O
Italian	O
guidelines	O
for	O
the	O
diagnosis	O
and	O
therapy	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
[	O
19	O
].	O
More	O
recently	O
","	O
in	O
2012	O
an	O
Italian	O
network	O
for	O
C1	O
-	O
INH	O
-	O
HAE	O
(	O
ITACA	O
)	O
was	O
established	O
.	O
ITACA	O
","	O
working	O
together	O
with	O
the	O
Italian	O
Hereditary	O
Angioedema	O
Patients	O
â€™	O
Association	O
","	O
collected	O
data	O
from	O
C1	O
-	O
INH	O
-	O
HAE	O
patients	O
referring	O
to	O
17	O
centers	O
active	O
in	O
Italy	O
.	O
Here	O
we	O
provide	O
the	O
results	O
of	O
the	O
analysis	O
of	O
these	O
aggregate	O
data	O
.	O
Methods	O
Patients	O
Patients	O
diagnosed	O
with	O
C1	O
-	O
INH	O
-	O
HAE	O
at	O
one	O
of	O
the	O
17	O
Italian	O
centres	O
from	O
1973	O
to	O
December	O
2013	O
were	O
included	O
in	O
the	O
study	O
.	O
Diagnosis	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
was	O
based	O
on	O
personal	O
and	O
/	O
or	O
family	O
history	O
of	O
angioedema	O
and	O
on	O
C1	O
-	O
INH	O
functional	O
or	O
antigenic	O
plasma	O
levels	O
â‰¤	O
50	O
%	O
of	O
normal	O
.	O
All	O
patients	O
gave	O
informed	O
consent	O
to	O
use	O
their	O
anonymized	O
data	O
.	O
Italian	O
population	O
Data	O
on	O
demografic	O
characteristics	O
of	O
the	O
Italian	O
general	O
population	O
were	O
collected	O
from	O
the	O
Italian	O
Institute	O
for	O
Statistic	O
(	O
December	O
2013	O
"),"	O
www	O
.	O
istat	O
.	O
it	O
.	O
Data	O
collection	O
For	O
each	O
patient	O
the	O
following	O
information	O
were	O
collected	O
from	O
medical	O
records	O
:	O
date	O
of	O
birth	O
","	O
date	O
of	O
diagnosis	O
","	O
condition	O
(	O
dead	O
or	O
alive	O
"),"	O
plasma	O
levels	O
of	O
C1	O
-	O
INH	O
and	O
C4	O
at	O
diagnosis	O
.	O
Patients	O
were	O
not	O
on	O
prophylactic	O
treatment	O
when	O
complement	O
parameters	O
were	O
measured	O
.	O
Independent	O
families	O
were	O
identified	O
and	O
the	O
first	O
diagnosed	O
member	O
of	O
a	O
family	O
was	O
considered	O
as	O
proband	O
.	O
Laboratory	O
methods	O
C1	O
-	O
INH	O
antigenic	O
and	O
C4	O
were	O
quantified	O
using	O
radial	O
immunodiffusion	O
or	O
nephelometry	O
;	O
C1	O
-	O
INH	O
function	O
was	O
measured	O
using	O
a	O
chromogenic	O
or	O
an	O
immunoenzimatic	O
assay	O
.	O
Results	O
were	O
normalized	O
as	O
percentage	O
of	O
normal	O
value	O
(	O
functional	O
C1	O
-	O
INH	O
normal	O
range	O
70	O
-	O
130	O
%;	O
antigenic	O
C1	O
-	O
INH	O
normal	O
range	O
70	O
-	O
115	O
%;	O
antigenic	O
C4	O
normal	O
range	O
60	O
-	O
140	O
%).	O
Diagnosis	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
Type	O
I	O
and	O
II	O
Patients	O
were	O
diagnosed	O
as	O
C1	O
-	O
INH	O
-	O
HAE	O
type	O
I	O
when	O
functional	O
and	O
antigenic	O
C1	O
-	O
INH	O
were	O
â‰¤	O
50	O
%	O
of	O
normal	O
","	O
and	O
as	O
type	O
II	O
when	O
functional	O
C1	O
-	O
INH	O
was	O
â‰¤	O
50	O
%	O
and	O
antigenic	O
was	O
>	O
50	O
%	O
of	O
normal	O
.	O
Statistical	O
analysis	O
Descriptive	O
analysis	O
of	O
data	O
from	O
the	O
Italian	O
C1	O
-	O
INH	O
-	O
HAE	O
population	O
was	O
performed	O
;	O
results	O
were	O
reported	O
as	O
mean	O
","	O
median	O
","	O
25th	O
and	O
75th	O
percentiles	O
range	O
for	O
each	O
parameter	O
.	O
Differences	O
in	O
decade	O
from	O
C1	O
-	O
INH	O
-	O
HAE	O
population	O
and	O
Italian	O
population	O
were	O
analyzed	O
using	O
Chi	O
square	O
test	O
at	O
the	O
95	O
%	O
significant	O
level	O
and	O
p	O
-	O
value	O
<	O
0	O
.	O
5	O
.	O
Results	O
Demographic	O
characteristics	O
and	O
laboratory	O
assessments	O
of	O
Italian	O
C1	O
-	O
INH	O
-	O
HAE	O
patients	O
Distribution	O
per	O
decades	O
of	O
life	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
patients	O
compared	O
to	O
Italian	O
population	O
(*	O
p	O
<	O
0	O
.	O
5	O
versus	O
general	O
population	O
).	O
Overall	O
983	O
patients	O
(	O
53	O
%	O
female	O
)	O
with	O
C1	O
-	O
INH	O
-	O
HAE	O
from	O
376	O
unrelated	O
families	O
were	O
included	O
in	O
this	O
analysis	O
.	O
Since	O
1973	O
","	O
63	O
(	O
6	O
%)	O
patients	O
died	O
;	O
furthermore	O
data	O
from	O
3	O
patients	O
were	O
missing	O
when	O
analysis	O
were	O
performed	O
.	O
Accordingly	O
","	O
the	O
minimal	O
prevalence	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
in	O
Italy	O
in	O
2013	O
is	O
1	O
.	O
54	O
:	O
100	O
","	O
0	O
inhabitants	O
","	O
equivalent	O
to	O
a	O
prevalence	O
of	O
1	O
:	O
64	O
","	O
935	O
.	O
Median	O
age	O
of	O
patients	O
is	O
45	O
(	O
IQ	O
28	O
-	O
57	O
"),"	O
median	O
age	O
at	O
diagnosis	O
is	O
26	O
years	O
(	O
IQ	O
13	O
-	O
41	O
).	O
The	O
majority	O
of	O
patients	O
","	O
859	O
(	O
87	O
"%),"	O
have	O
C1	O
-	O
INH	O
-	O
HAE	O
type	O
I	O
with	O
median	O
age	O
at	O
diagnosis	O
of	O
25	O
(	O
13	O
-	O
40	O
);	O
patients	O
with	O
type	O
II	O
are	O
124	O
(	O
13	O
%)	O
with	O
median	O
age	O
at	O
diagnosis	O
of	O
31	O
(	O
IQ	O
16	O
-	O
49	O
).	O
Demographic	O
characteristics	O
and	O
laboratory	O
assessments	O
are	O
summarized	O
in	O
Table	O
1	O
.	O
Comparing	O
the	O
distribution	O
per	O
decades	O
of	O
life	O
of	O
patients	O
and	O
of	O
the	O
Italian	O
population	O
we	O
found	O
that	O
patients	O
are	O
less	O
represented	O
in	O
the	O
first	O
decade	O
and	O
after	O
the	O
7th	O
decade	O
compared	O
to	O
Italian	O
population	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
(	O
Figure	O
1	O
).	O
Median	O
age	O
at	O
diagnosis	O
of	O
probands	O
from	O
1973	O
to	O
2013	O
.	O
Numbers	O
reported	O
on	O
top	O
of	O
histogram	O
indicate	O
new	O
families	O
diagnosed	O
in	O
each	O
5	O
-	O
year	O
-	O
period	O
.	O
Of	O
the	O
367	O
unrelated	O
families	O
","	O
338	O
(	O
92	O
%)	O
have	O
type	O
I	O
and	O
53	O
type	O
II	O
.	O
â€œ	O
Families	O
â€	O
with	O
only	O
one	O
subject	O
diagnosed	O
as	O
C1	O
-	O
INH	O
-	O
HAE	O
are	O
157	O
(	O
43	O
%).	O
The	O
median	O
age	O
of	O
probands	O
at	O
diagnosis	O
is	O
34	O
years	O
.	O
Analyzing	O
5	O
year	O
periods	O
","	O
starting	O
from	O
the	O
first	O
diagnosis	O
in	O
the	O
seventies	O
","	O
the	O
number	O
of	O
new	O
probands	O
increased	O
until	O
1995	O
and	O
remained	O
stable	O
afterwards	O
(	O
Figure	O
2	O
).	O
Functional	O
C1	O
-	O
INH	O
is	O
â‰¤	O
50	O
%	O
in	O
99	O
%	O
of	O
patients	O
.	O
Antigen	O
C1INH	O
is	O
â‰¤	O
50	O
%	O
in	O
99	O
%	O
of	O
type	O
1	O
patients	O
.	O
C4	O
antigen	O
is	O
â‰¤	O
50	O
%	O
of	O
normal	O
in	O
96	O
%	O
of	O
patients	O
.	O
Discussion	O
This	O
first	O
nationwide	O
survey	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
in	O
Italy	O
provides	O
a	O
minimum	O
prevalence	O
of	O
1	O
:	O
64	O
","	O
935	O
","	O
the	O
highest	O
value	O
ever	O
registered	O
for	O
this	O
disease	O
compared	O
to	O
previous	O
studies	O
.	O
Assuming	O
that	O
our	O
centres	O
collected	O
data	O
on	O
the	O
majority	O
of	O
Italian	O
C1	O
-	O
INH	O
-	O
HAE	O
population	O
","	O
patients	O
not	O
referring	O
to	O
these	O
centres	O
or	O
not	O
diagnosed	O
certainly	O
exist	O
.	O
It	O
is	O
therefore	O
very	O
likely	O
that	O
the	O
real	O
prevalence	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
is	O
higher	O
approaching	O
the	O
prevalence	O
of	O
1	O
:	O
50	O
","	O
0	O
usually	O
reported	O
in	O
literature	O
[	O
20	O
].	O
Male	O
and	O
female	O
patients	O
are	O
equally	O
represented	O
as	O
expected	O
from	O
an	O
autosomal	O
dominant	O
pattern	O
of	O
inheritance	O
of	O
C1	O
-	O
INH	O
deficiency	O
.	O
Comparing	O
C1	O
-	O
INH	O
-	O
HAE	O
subjects	O
and	O
general	O
Italian	O
population	O
for	O
distribution	O
in	O
different	O
decades	O
of	O
life	O
","	O
patients	O
are	O
less	O
represented	O
in	O
the	O
early	O
and	O
late	O
decades	O
.	O
In	O
the	O
literature	O
there	O
is	O
no	O
evidence	O
regarding	O
life	O
expectancy	O
in	O
C1	O
-	O
INH	O
-	O
HAE	O
patients	O
.	O
The	O
reduced	O
number	O
in	O
the	O
first	O
and	O
second	O
decade	O
for	O
men	O
can	O
be	O
explained	O
with	O
the	O
delay	O
in	O
diagnosis	O
","	O
which	O
is	O
often	O
made	O
after	O
the	O
second	O
decade	O
of	O
life	O
[	O
1	O
].	O
The	O
reduced	O
number	O
of	O
patients	O
in	O
first	O
decade	O
can	O
also	O
be	O
explained	O
by	O
the	O
absence	O
of	O
symptoms	O
and	O
by	O
not	O
having	O
systematically	O
studied	O
all	O
the	O
members	O
of	O
the	O
family	O
of	O
every	O
newly	O
diagnosed	O
C1	O
-	O
INH	O
-	O
HAE	O
patient	O
in	O
the	O
past	O
.	O
Interestingly	O
","	O
from	O
7th	O
decades	O
there	O
are	O
fewer	O
individuals	O
in	O
patients	O
â€™	O
group	O
compared	O
to	O
general	O
population	O
.	O
In	O
1992	O
Cicardi	O
and	O
Agostoni	O
","	O
analyzing	O
the	O
family	O
histories	O
of	O
an	O
Italian	O
cohort	O
of	O
patients	O
with	O
C1	O
-	O
INH	O
-	O
HAE	O
","	O
reported	O
that	O
up	O
to	O
50	O
%	O
of	O
patients	O
could	O
have	O
died	O
for	O
asphyxia	O
[	O
12	O
].	O
This	O
could	O
explain	O
the	O
reason	O
why	O
in	O
Italy	O
C1	O
-	O
INH	O
-	O
HAE	O
patients	O
have	O
had	O
fewer	O
chances	O
","	O
compared	O
to	O
the	O
general	O
population	O
","	O
to	O
reach	O
the	O
late	O
decades	O
.	O
We	O
expect	O
that	O
diagnostic	O
tools	O
and	O
therapeutic	O
options	O
available	O
today	O
will	O
eliminate	O
asphyxia	O
as	O
a	O
common	O
cause	O
of	O
death	O
for	O
C1	O
-	O
INH	O
-	O
HAE	O
patients	O
.	O
This	O
should	O
lead	O
to	O
have	O
patients	O
and	O
general	O
population	O
equally	O
represented	O
in	O
late	O
decades	O
","	O
unless	O
other	O
factors	O
may	O
affect	O
life	O
expectancy	O
.	O
The	O
fact	O
that	O
C1	O
-	O
INH	O
-	O
HAE	O
patients	O
are	O
less	O
represented	O
than	O
general	O
population	O
in	O
the	O
late	O
decades	O
could	O
been	O
related	O
to	O
underdiagnosis	O
in	O
the	O
past	O
.	O
The	O
awareness	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
has	O
increased	O
in	O
recent	O
years	O
and	O
it	O
is	O
possible	O
that	O
younger	O
patients	O
had	O
more	O
opportunities	O
to	O
be	O
diagnosed	O
than	O
elder	O
patients	O
.	O
Median	O
age	O
at	O
diagnosis	O
in	O
our	O
patients	O
is	O
26	O
year	O
old	O
","	O
which	O
is	O
slightly	O
later	O
than	O
in	O
patients	O
enrolled	O
in	O
IOS	O
study	O
(	O
24	O
.	O
3	O
year	O
old	O
)	O
[	O
14	O
].	O
Our	O
study	O
does	O
not	O
report	O
data	O
on	O
delay	O
in	O
diagnosis	O
(	O
defined	O
as	O
time	O
between	O
onset	O
of	O
symptom	O
and	O
diagnosis	O
"),"	O
but	O
assuming	O
that	O
the	O
large	O
majority	O
of	O
patients	O
becomes	O
symptomatic	O
around	O
puberty	O
we	O
could	O
estimate	O
a	O
minimum	O
delay	O
in	O
diagnosis	O
of	O
10	O
years	O
.	O
This	O
result	O
is	O
similar	O
to	O
the	O
delay	O
in	O
diagnosis	O
reported	O
in	O
previous	O
studies	O
.	O
In	O
the	O
cohort	O
of	O
patients	O
analyzed	O
in	O
IOS	O
study	O
the	O
mean	O
delay	O
in	O
diagnosis	O
was	O
12	O
.	O
8	O
years	O
[	O
15	O
].	O
In	O
previous	O
nationwide	O
surveys	O
in	O
France	O
","	O
Spain	O
and	O
Denmark	O
mean	O
delay	O
in	O
diagnosis	O
was	O
12	O
","	O
13	O
.	O
1	O
and	O
16	O
.	O
3	O
years	O
","	O
respectively	O
[	O
9	O
","	O
10	O
","	O
16	O
].	O
Furthermore	O
","	O
we	O
found	O
a	O
considerable	O
difference	O
in	O
the	O
median	O
age	O
at	O
diagnosis	O
between	O
patients	O
with	O
C1	O
-	O
INH	O
-	O
HAE	O
type	O
I	O
and	O
II	O
","	O
26	O
and	O
31	O
years	O
respectively	O
.	O
This	O
difference	O
was	O
even	O
higher	O
in	O
IOS	O
study	O
","	O
27	O
.	O
3	O
and	O
39	O
.	O
4	O
respectively	O
.	O
Since	O
diagnosis	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
type	O
II	O
is	O
made	O
measuring	O
C1	O
-	O
INH	O
function	O
","	O
the	O
limited	O
availability	O
of	O
this	O
test	O
may	O
explain	O
why	O
diagnosing	O
C1	O
-	O
INH	O
-	O
HAE	O
type	O
II	O
is	O
more	O
difficult	O
.	O
The	O
number	O
of	O
new	O
diagnosis	O
","	O
calculated	O
as	O
number	O
of	O
probands	O
to	O
avoid	O
the	O
effect	O
caused	O
by	O
large	O
family	O
groups	O
","	O
increased	O
up	O
to	O
1996	O
","	O
likely	O
due	O
to	O
an	O
improving	O
awareness	O
for	O
this	O
disease	O
.	O
Since	O
that	O
time	O
the	O
annual	O
rate	O
of	O
new	O
diagnosis	O
has	O
remained	O
stable	O
without	O
a	O
trend	O
in	O
reduction	O
suggesting	O
that	O
we	O
are	O
approaching	O
the	O
point	O
at	O
which	O
most	O
Italian	O
C	O
-	O
INH	O
-	O
HAE	O
patients	O
have	O
been	O
diagnosed	O
.	O
â€œ	O
Families	O
â€	O
with	O
only	O
one	O
subject	O
diagnosed	O
as	O
C1	O
-	O
INH	O
-	O
HAE	O
are	O
157	O
(	O
43	O
%).	O
The	O
number	O
of	O
de	O
novo	O
mutants	O
reported	O
in	O
literature	O
is	O
approximately	O
25	O
%	O
of	O
the	O
families	O
[	O
3	O
].	O
The	O
high	O
percentage	O
of	O
families	O
with	O
only	O
one	O
subject	O
affected	O
likely	O
includes	O
de	O
novo	O
mutants	O
and	O
patients	O
with	O
non	O
-	O
diagnosed	O
family	O
members	O
.	O
It	O
is	O
mandatory	O
after	O
diagnosis	O
a	O
new	O
patients	O
to	O
evaluate	O
other	O
family	O
members	O
.	O
According	O
to	O
diagnostic	O
criteria	O
all	O
patients	O
had	O
either	O
C1	O
-	O
INH	O
antigen	O
or	O
function	O
â‰¤	O
50	O
%.	O
In	O
absence	O
of	O
published	O
criteria	O
to	O
distinguish	O
type	O
I	O
and	O
II	O
","	O
we	O
considered	O
as	O
type	O
II	O
patients	O
with	O
C1	O
-	O
INH	O
antigen	O
>	O
50	O
%	O
of	O
normal	O
.	O
According	O
to	O
these	O
criteria	O
","	O
2	O
patients	O
with	O
C1	O
-	O
INH	O
antigen	O
levels	O
slightly	O
above	O
50	O
%	O
should	O
have	O
been	O
diagnosed	O
as	O
type	O
II	O
","	O
but	O
they	O
were	O
classified	O
as	O
type	O
I	O
because	O
of	O
","	O
belonging	O
to	O
families	O
whose	O
other	O
members	O
were	O
type	O
I	O
.	O
Similarly	O
","	O
we	O
should	O
have	O
considered	O
as	O
type	O
I	O
12	O
patients	O
with	O
C1	O
-	O
INH	O
antigen	O
levels	O
equal	O
or	O
slightly	O
below	O
50	O
%	O
of	O
normal	O
despite	O
other	O
family	O
members	O
were	O
type	O
II	O
.	O
Finally	O
","	O
6	O
patients	O
","	O
with	O
personal	O
and	O
family	O
history	O
of	O
angioedema	O
and	O
C1	O
-	O
INH	O
antigen	O
clearly	O
below	O
50	O
%	O
of	O
normal	O
","	O
had	O
C1	O
-	O
INH	O
functional	O
levels	O
slightly	O
above	O
50	O
%.	O
These	O
rare	O
and	O
small	O
discrepancies	O
between	O
suggested	O
diagnostic	O
criteria	O
and	O
actual	O
data	O
highlight	O
the	O
need	O
for	O
comprehensive	O
and	O
thoughtful	O
evaluation	O
of	O
clinical	O
and	O
laboratory	O
findings	O
before	O
placing	O
definitive	O
diagnosis	O
.	O
The	O
actual	O
value	O
of	O
antigenic	O
C4	O
in	O
diagnosing	O
C1	O
-	O
INH	O
-	O
HAE	O
has	O
remained	O
vague	O
.	O
Rosen	O
et	O
al	O
in	O
1971	O
first	O
proved	O
the	O
importance	O
of	O
C4	O
consumption	O
for	O
detecting	O
C1	O
-	O
INH	O
deficiency	O
[	O
21	O
].	O
Our	O
study	O
demonstrates	O
that	O
C4	O
plasma	O
levels	O
>	O
50	O
%	O
were	O
rare	O
in	O
C1	O
-	O
INH	O
-	O
HAE	O
patients	O
and	O
can	O
exclude	O
diagnosis	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
with	O
an	O
error	O
probability	O
lower	O
than	O
0	O
.	O
5	O
.	O
Conclusion	O
This	O
nationwide	O
survey	O
on	O
a	O
large	O
number	O
of	O
patients	O
provided	O
evidence	O
that	O
the	O
estimated	O
prevalence	O
of	O
1	O
:	O
50	O
","	O
0	O
for	O
C1	O
-	O
INH	O
-	O
HAE	O
is	O
probably	O
close	O
to	O
the	O
real	O
prevalence	O
in	O
general	O
population	O
.	O
Patients	O
with	O
HAE	O
-	O
C1	O
-	O
INH	O
might	O
have	O
a	O
shorter	O
life	O
expectancy	O
compared	O
to	O
general	O
population	O
.	O
An	O
increased	O
awareness	O
of	O
the	O
disease	O
","	O
pedigree	O
â€™	O
s	O
study	O
","	O
appropriate	O
diagnosis	O
and	O
treatment	O
is	O
needed	O
to	O
reduce	O
the	O
discrepancy	O
in	O
the	O
distribution	O
of	O
decade	O
of	O
life	O
between	O
general	O
population	O
and	O
HAE	O
-	O
C1	O
-	O
INH	O
patients	O
.	O
Measurement	O
of	O
C4	O
antigen	O
","	O
a	O
cheap	O
assay	O
commonly	O
available	O
in	O
laboratories	O
","	O
can	O
exclude	O
diagnosis	O
of	O
C1	O
-	O
INH	O
-	O
HAE	O
with	O
an	O
accuracy	O
>	O
95	O
%.	O
This	O
parameter	O
along	O
with	O
clinical	O
data	O
should	O
be	O
therefore	O
considered	O
for	O
initial	O
screening	O
in	O
differential	O
diagnosis	O
of	O
angioedema	O
.	O
Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O
Authors	O
â€™	O
contributions	O
All	O
the	O
authors	O
partecipated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
","	O
AZ	O
performed	O
the	O
statistical	O
analysis	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
References	O
The	O
Disastrous	O
Effects	O
of	O
Salt	B-Chemical
Dust	O
Deposition	O
on	O
Cotton	O
Leaf	O
Photosynthesis	O
and	O
the	O
Cell	O
Physiological	O
Properties	O
in	O
the	O
Ebinur	O
Basin	O
in	O
Northwest	O
China	O
Salt	B-Chemical
dust	O
in	O
rump	O
lake	O
areas	O
in	O
arid	O
regions	O
has	O
long	O
been	O
considered	O
an	O
extreme	O
stressor	O
for	O
both	O
native	O
plants	O
and	O
crops	O
.	O
In	O
recent	O
years	O
","	O
research	O
on	O
the	O
harmful	O
effects	O
of	O
salt	B-Chemical
dust	O
on	O
native	O
plants	O
has	O
been	O
published	O
by	O
many	O
scholars	O
","	O
but	O
the	O
effect	O
on	O
crops	O
has	O
been	O
little	O
studied	O
.	O
In	O
this	O
work	O
","	O
in	O
order	O
to	O
determine	O
the	O
impact	O
of	O
salt	B-Chemical
dust	O
storms	O
on	O
cotton	O
","	O
we	O
simulated	O
salt	B-Chemical
dust	O
exposure	O
of	O
cotton	O
leaves	O
in	O
Ebinur	O
Basin	O
in	O
Northwest	O
China	O
","	O
and	O
measured	O
the	O
particle	O
sizes	O
and	O
salt	B-Chemical
ions	I-Chemical
in	O
the	O
dust	O
","	O
and	O
the	O
photosynthesis	O
","	O
the	O
structure	O
and	O
the	O
cell	O
physiological	O
properties	O
of	O
the	O
cotton	O
leaves	O
.	O
(	O
1	O
)	O
Analysis	O
found	O
that	O
the	O
salt	B-Chemical
ions	I-Chemical
and	O
particle	O
sizes	O
in	O
the	O
salt	B-Chemical
dust	O
used	O
in	O
the	O
experiments	O
were	O
consistent	O
with	O
the	O
natural	O
salt	B-Chemical
dust	O
and	O
modeled	O
the	O
salt	B-Chemical
dust	O
deposition	O
on	O
cotton	O
leaves	O
in	O
this	O
region	O
.	O
(	O
2	O
)	O
The	O
main	O
salt	B-Chemical
cations	I-Chemical
on	O
the	O
surface	O
and	O
inside	O
the	O
cotton	O
leaves	O
were	O
Na	B-Chemical
"+,"	I-Chemical
Ca2	I-Chemical
"+,"	I-Chemical
Cl	I-Chemical
-	I-Chemical
and	O
SO4	B-Chemical
2	I-Chemical
while	O
the	O
amounts	O
of	O
CO3	B-Chemical
-	I-Chemical
and	O
HCO3	B-Chemical
-	I-Chemical
were	O
low	O
.	O
From	O
the	O
analysis	O
","	O
we	O
can	O
order	O
the	O
quantity	O
of	O
the	O
salt	B-Chemical
cations	I-Chemical
and	I-Chemical
anions	I-Chemical
ions	O
present	O
on	O
the	O
surface	O
and	O
inside	O
the	O
cotton	O
leaves	O
as	O
Na	B-Chemical
+>	I-Chemical
Ca2	I-Chemical
+>	I-Chemical
Mg2	I-Chemical
+>	I-Chemical
K	I-Chemical
+	I-Chemical
and	O
Cl	B-Chemical
->	I-Chemical
SO4	I-Chemical
2	I-Chemical
->	I-Chemical
HCO3	I-Chemical
->	I-Chemical
CO3	I-Chemical
respectively	O
.	O
Furthermore	O
","	O
the	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
in	O
terms	O
of	O
the	O
total	O
salt	B-Chemical
ions	I-Chemical
on	O
both	O
the	O
surface	O
and	O
inside	O
the	O
cotton	O
leaves	O
were	O
A	O
(	O
500g	O
.	O
m	O
-	O
2	O
)>	O
B	O
(	O
400g	O
.	O
m	O
-	O
2	O
)>	O
C	O
(	O
300g	O
.	O
m	O
-	O
2	O
)>	O
D	O
(	O
200g	O
.	O
m	O
-	O
2	O
)>	O
E	O
(	O
100g	O
.	O
m	O
-	O
2	O
)>	O
F	O
(	O
0g	O
.	O
m	O
-	O
2	O
).	O
(	O
3	O
)	O
The	O
salt	B-Chemical
dust	O
that	O
landed	O
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
can	O
significantly	O
influence	O
the	O
photosynthetic	O
traits	O
of	O
Pn	O
","	O
PE	O
","	O
Ci	O
","	O
Ti	O
","	O
Gs	O
","	O
Tr	O
","	O
WUE	O
","	O
Ls	O
","	O
Ï†	O
","	O
Amax	O
","	O
k	O
and	O
Rady	O
of	O
the	O
cotton	O
leaves	O
.	O
(	O
4	O
)	O
Salt	B-Chemical
dust	O
can	O
significantly	O
damage	O
the	O
physiological	O
functions	O
of	O
the	O
cotton	O
leaves	O
","	O
resulting	O
in	O
a	O
decrease	O
in	O
leaf	O
chlorophyll	B-Chemical
and	O
carotenoid	B-Chemical
content	O
","	O
and	O
increasing	O
cytoplasmic	O
membrane	O
permeability	O
and	O
malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
content	O
by	O
increasing	O
the	O
soluble	O
sugar	B-Chemical
and	O
proline	B-Chemical
to	O
adjust	O
for	O
the	O
loss	O
of	O
the	O
cell	O
cytosol	O
.	O
This	O
increases	O
the	O
activity	O
of	O
antioxidant	O
enzymes	O
to	O
eliminate	O
harmful	O
materials	O
","	O
such	O
as	O
the	O
intracellular	O
reactive	B-Chemical
oxygen	I-Chemical
and	O
MDA	B-Chemical
","	O
thus	O
reducing	O
the	O
damage	O
caused	O
by	O
the	O
salt	B-Chemical
dust	O
and	O
maintaining	O
normal	O
physiological	O
functioning	O
.	O
Overall	O
","	O
this	O
work	O
found	O
that	O
the	O
salt	B-Chemical
dust	O
deposition	O
was	O
a	O
problem	O
for	O
the	O
crop	O
and	O
the	O
salt	B-Chemical
dust	O
could	O
significantly	O
influence	O
the	O
physiological	O
and	O
biochemical	O
processes	O
of	O
the	O
cotton	O
leaves	O
.	O
This	O
will	O
eventually	O
damage	O
the	O
leaves	O
and	O
reduce	O
the	O
cotton	O
production	O
","	O
leading	O
to	O
agricultural	O
economic	O
loss	O
.	O
Therefore	O
","	O
attention	O
should	O
be	O
paid	O
to	O
salt	B-Chemical
dust	O
storms	O
in	O
the	O
Ebinur	O
Basin	O
and	O
efficient	O
measures	O
should	O
be	O
undertaken	O
to	O
protect	O
the	O
environment	O
.	O
Introduction	O
Salt	B-Chemical
dust	O
storms	O
are	O
extreme	O
weather	O
phenomena	O
that	O
primarily	O
originate	O
from	O
wind	O
erosion	O
of	O
dried	O
up	O
salt	B-Chemical
ion	I-Chemical
rich	O
lake	O
sediments	O
(	O
Fig	O
1	O
)	O
[â€“].	O
These	O
salt	B-Chemical
dust	O
storms	O
differ	O
from	O
the	O
typical	O
sand	O
storms	O
in	O
that	O
they	O
contain	O
a	O
high	O
density	O
of	O
very	O
small	O
particles	O
of	O
sulfate	B-Chemical
","	O
chloride	B-Chemical
","	O
pesticide	O
dust	O
and	O
harmful	O
heavy	B-Chemical
metals	I-Chemical
","	O
including	O
Pb	B-Chemical
","	O
Cu	B-Chemical
","	O
Cr	B-Chemical
","	O
Hg	B-Chemical
and	O
Zn	B-Chemical
[â€“].	O
The	O
frequent	O
occurrence	O
of	O
salt	B-Chemical
dust	O
storms	O
within	O
the	O
Ebinur	O
Basin	O
has	O
led	O
to	O
a	O
large	O
amount	O
of	O
scattering	O
of	O
saline	O
dust	O
to	O
the	O
surrounding	O
areas	O
","	O
which	O
can	O
cause	O
desertification	O
of	O
lakesides	O
and	O
plains	O
","	O
damage	O
vegetation	O
and	O
catalyze	O
the	O
formation	O
of	O
new	O
desert	O
[].	O
Salt	B-Chemical
dust	O
is	O
also	O
a	O
serious	O
air	O
pollutant	O
that	O
is	O
very	O
harmful	O
to	O
human	O
health	O
.	O
Furthermore	O
","	O
the	O
frequent	O
occurrence	O
of	O
salt	B-Chemical
dust	O
storms	O
in	O
the	O
Ebinur	O
Basin	O
has	O
negatively	O
impacted	O
railway	O
traffic	O
","	O
even	O
necessitating	O
suspension	O
of	O
railway	O
service	O
"[,â€“]."	O
In	O
agriculture	O
","	O
the	O
salt	B-Chemical
dust	O
pollution	O
can	O
affect	O
soil	O
quality	O
","	O
available	O
soil	O
nutrients	O
and	O
minerals	O
","	O
organic	O
matter	O
","	O
pH	O
and	O
amount	O
of	O
clay	O
[â€“].	O
Salt	B-Chemical
dust	O
storms	O
can	O
also	O
significantly	O
influence	O
plant	O
height	O
","	O
root	O
length	O
and	O
seed	O
germination	O
rate	O
","	O
and	O
cause	O
changes	O
in	O
root	O
","	O
stem	O
and	O
leaf	O
morphology	O
","	O
such	O
as	O
a	O
decrease	O
in	O
fresh	O
weight	O
"[,,,]."	O
Distribution	O
of	O
saline	O
lakes	O
","	O
playas	O
and	O
similar	O
landforms	O
in	O
arid	O
and	O
semiarid	O
areas	O
susceptible	O
to	O
salt	B-Chemical
dust	O
storms	O
.	O
When	O
salt	B-Chemical
dust	O
lands	O
on	O
plant	O
leaves	O
","	O
the	O
leaf	O
surface	O
becomes	O
covered	O
","	O
which	O
captures	O
the	O
plant	O
â€™	O
s	O
moisture	O
and	O
blocks	O
the	O
stomata	O
","	O
respiration	O
and	O
photosynthesis	O
that	O
normally	O
occurs	O
.	O
This	O
salt	B-Chemical
dust	O
covering	O
shades	O
the	O
leaves	O
from	O
radiation	O
from	O
the	O
sun	O
","	O
affects	O
photosynthesis	O
and	O
leaf	O
reflectance	O
","	O
increases	O
the	O
leaf	O
temperature	O
","	O
affects	O
the	O
surface	O
humidity	O
","	O
gas	O
exchange	O
and	O
assimilation	O
of	O
the	O
blades	O
","	O
and	O
influences	O
pollination	O
This	O
can	O
result	O
in	O
degeneration	O
in	O
the	O
plant	O
â€™	O
s	O
ability	O
to	O
function	O
","	O
decreasing	O
the	O
biomass	O
and	O
yield	O
and	O
","	O
thus	O
","	O
causing	O
serious	O
agricultural	O
economic	O
loss	O
"[,]."	O
Previous	O
studies	O
have	O
tended	O
to	O
focus	O
on	O
plants	O
in	O
high	O
and	O
low	O
temperatures	O
","	O
drought	O
","	O
stress	O
caused	O
by	O
cement	O
and	O
fly	O
ash	O
dust	O
","	O
and	O
crops	O
including	O
wheat	O
","	O
cotton	O
","	O
corn	O
and	O
vegetables	O
.	O
The	O
studied	O
parameters	O
included	O
amount	O
of	O
leaf	O
chlorophyll	B-Chemical
","	O
changes	O
in	O
leaf	O
cell	O
structure	O
","	O
blade	O
internal	O
physiological	O
indexes	O
of	O
cytoplasm	O
membrane	O
permeability	O
","	O
MDA	B-Chemical
content	O
","	O
active	O
oxygen	B-Chemical
changes	O
","	O
and	O
substances	O
involved	O
in	O
osmotic	O
regulation	O
","	O
such	O
as	O
proline	B-Chemical
","	O
betaine	B-Chemical
and	O
soluble	O
sugar	B-Chemical
","	O
and	O
antioxidant	O
enzymes	O
","	O
such	O
as	O
superoxide	O
dismutase	O
(	O
SOD	O
"),"	O
peroxidase	O
(	O
POD	O
)	O
and	O
catalase	O
(	O
CAT	O
).	O
However	O
","	O
there	O
have	O
been	O
no	O
reports	O
concerning	O
the	O
impact	O
of	O
salt	B-Chemical
dust	O
on	O
cotton	O
crops	O
","	O
including	O
on	O
the	O
salt	B-Chemical
ion	I-Chemical
distribution	O
on	O
the	O
cotton	O
leaves	O
","	O
and	O
the	O
internal	O
and	O
structural	O
changes	O
to	O
the	O
cotton	O
leaf	O
under	O
salt	B-Chemical
dust	O
deposition	O
.	O
Xinjiang	O
is	O
China	O
'	O
s	O
major	O
cotton	O
producing	O
region	O
","	O
and	O
is	O
worldwide	O
famous	O
for	O
its	O
high	O
quality	O
cotton	O
production	O
[].	O
The	O
Ebinur	O
Basin	O
is	O
located	O
in	O
the	O
south	O
of	O
the	O
famous	O
Alataw	O
Pass	O
in	O
Northwest	O
China	O
.	O
In	O
this	O
region	O
","	O
the	O
wind	O
speed	O
can	O
be	O
greater	O
than	O
8	O
m	O
.	O
s	O
-	O
1	O
up	O
to	O
164	O
days	O
of	O
the	O
year	O
with	O
a	O
maximum	O
instantaneous	O
wind	O
speed	O
of	O
55	O
ms	O
-	O
1	O
throughout	O
the	O
year	O
"[,]."	O
Since	O
the	O
1950s	O
","	O
the	O
development	O
of	O
industrial	O
and	O
agricultural	O
production	O
in	O
the	O
Ebinur	O
Basin	O
has	O
resulted	O
in	O
large	O
quantities	O
of	O
water	O
resources	O
being	O
used	O
for	O
irrigation	O
without	O
a	O
corresponding	O
increase	O
in	O
the	O
amount	O
of	O
precipitation	O
.	O
This	O
has	O
led	O
to	O
a	O
dramatic	O
decrease	O
in	O
the	O
amount	O
of	O
water	O
in	O
Ebinur	O
from	O
1200	O
km2	O
to	O
500	O
km2	O
","	O
lowering	O
the	O
water	O
level	O
of	O
the	O
lake	O
and	O
drying	O
up	O
areas	O
.	O
This	O
dried	O
bare	O
lake	O
bottom	O
has	O
caused	O
serious	O
ecological	O
problems	O
in	O
this	O
basin	O
"[,,,]."	O
The	O
loose	O
sediment	O
at	O
the	O
bottom	O
of	O
the	O
dry	O
lake	O
is	O
rich	O
in	O
salt	B-Chemical
ions	I-Chemical
that	O
are	O
susceptible	O
to	O
wind	O
erosion	O
at	O
wind	O
speeds	O
as	O
low	O
as	O
4	O
.	O
3	O
â€“	O
6	O
.	O
4	O
m	O
.	O
s	O
-	O
1	O
.	O
The	O
strong	O
winds	O
from	O
Alataw	O
Pass	O
can	O
easily	O
blow	O
about	O
this	O
loose	O
sediment	O
and	O
spread	O
the	O
salt	B-Chemical
dust	O
(	O
particle	O
size	O
often	O
2	O
â€“	O
63	O
Î¼m	O
as	O
measured	O
by	O
Liu	O
et	O
al	O
.	O
[].	O
This	O
salt	B-Chemical
dust	O
can	O
cause	O
a	O
disastrous	O
salt	B-Chemical
storm	O
and	O
can	O
be	O
transported	O
up	O
to	O
thousands	O
of	O
kilometers	O
away	O
.	O
The	O
Ebinur	O
Basin	O
is	O
a	O
famous	O
salt	B-Chemical
dust	O
source	O
in	O
Northwest	O
China	O
and	O
central	O
Asia	O
"[,]."	O
Since	O
the	O
1970s	O
","	O
the	O
frequent	O
occurrence	O
of	O
salt	B-Chemical
dust	O
storms	O
in	O
the	O
Ebinur	O
Basin	O
has	O
seriously	O
harmed	O
the	O
surrounding	O
environment	O
.	O
Amounts	O
this	O
high	O
of	O
salt	B-Chemical
dust	O
have	O
damaged	O
the	O
vegetation	O
","	O
reduced	O
agricultural	O
production	O
","	O
desertified	O
grassland	O
and	O
the	O
surrounding	O
lake	O
plain	O
","	O
and	O
accelerated	O
the	O
formation	O
of	O
new	O
desert	O
.	O
However	O
","	O
current	O
studies	O
still	O
fail	O
to	O
assess	O
the	O
impact	O
of	O
salt	B-Chemical
dust	O
storms	O
on	O
agriculture	O
","	O
including	O
on	O
the	O
main	O
crop	O
of	O
the	O
Ebinur	O
Basin	O
and	O
arid	O
regions	O
","	O
cotton	O
.	O
Simulation	O
experiments	O
were	O
used	O
in	O
this	O
work	O
to	O
study	O
the	O
influence	O
of	O
salt	B-Chemical
dust	O
on	O
the	O
salt	B-Chemical
content	O
of	O
the	O
cotton	O
leaves	O
","	O
particle	O
size	O
distribution	O
","	O
photosynthesis	O
","	O
leaf	O
blade	O
cell	O
structure	O
","	O
amounts	O
of	O
chlorophyll	B-Chemical
","	O
proline	B-Chemical
","	O
soluble	O
sugar	B-Chemical
and	O
MDA	B-Chemical
","	O
and	O
antioxidant	O
enzyme	O
activity	O
.	O
From	O
this	O
","	O
we	O
can	O
provide	O
a	O
scientific	O
basis	O
for	O
studying	O
the	O
salt	B-Chemical
dust	O
storms	O
in	O
this	O
region	O
and	O
other	O
similar	O
regions	O
around	O
the	O
world	O
","	O
and	O
then	O
take	O
proper	O
measures	O
to	O
protect	O
the	O
environment	O
.	O
Experimental	O
Setup	O
and	O
Data	O
Acquisition	O
The	O
sample	O
collection	O
and	O
test	O
were	O
all	O
permitted	O
in	O
our	O
country	O
and	O
no	O
specific	O
permissions	O
were	O
required	O
for	O
these	O
locations	O
/	O
activities	O
","	O
we	O
confirm	O
that	O
the	O
field	O
studies	O
did	O
not	O
involve	O
endangered	O
or	O
protected	O
species	O
.	O
The	O
salt	B-Chemical
dust	O
for	O
the	O
experiments	O
was	O
obtained	O
from	O
the	O
Alataw	O
Pass	O
in	O
Xinjiang	O
in	O
Northwest	O
China	O
as	O
follows	O
.	O
First	O
","	O
loose	O
saline	O
soil	O
was	O
broken	O
up	O
and	O
ground	O
up	O
","	O
then	O
pushed	O
through	O
a	O
fine	O
screen	O
(	O
0	O
.	O
2	O
mm	O
).	O
Then	O
","	O
under	O
windless	O
and	O
sunny	O
conditions	O
on	O
June	O
6th	O
","	O
2013	O
","	O
we	O
ran	O
an	O
artificial	O
simulation	O
of	O
salt	B-Chemical
dust	O
deposition	O
consisting	O
of	O
five	O
salt	B-Chemical
dust	O
spray	O
gradients	O
of	O
0	O
g	O
.	O
m	O
-	O
2	O
","	O
100	O
g	O
.	O
m	O
-	O
2	O
","	O
200	O
g	O
.	O
m	O
-	O
2	O
","	O
300	O
g	O
.	O
m	O
-	O
2	O
","	O
400	O
g	O
.	O
m	O
-	O
2	O
and	O
500	O
g	O
.	O
m	O
-	O
2	O
in	O
the	O
cotton	O
fields	O
in	O
the	O
southwest	O
of	O
Jinghe	O
county	O
in	O
the	O
Ebinur	O
Basin	O
","	O
China	O
(	O
Fig	O
2	O
"),"	O
and	O
four	O
-	O
replication	O
groups	O
of	O
each	O
salt	B-Chemical
dust	O
simulated	O
level	O
were	O
settled	O
.	O
Setup	O
of	O
simulation	O
experiments	O
.	O
After	O
allowing	O
the	O
experiment	O
to	O
run	O
for	O
15	O
days	O
(	O
June	O
21th	O
","	O
2013	O
"),"	O
the	O
salt	B-Chemical
dust	O
that	O
had	O
landed	O
on	O
the	O
cotton	O
leaves	O
was	O
collected	O
.	O
From	O
this	O
","	O
the	O
particle	O
sizes	O
","	O
composition	O
of	O
the	O
salt	B-Chemical
ions	I-Chemical
on	O
the	O
surface	O
and	O
inside	O
the	O
leaves	O
","	O
and	O
photosynthesis	O
of	O
the	O
leaves	O
(	O
using	O
parameters	O
of	O
the	O
net	O
photosynthetic	O
rate	O
(	O
P	O
n	O
"),"	O
light	O
use	O
efficiency	O
(	O
PE	O
"),"	O
intercellular	O
CO2	B-Chemical
concentration	O
(	O
C	O
i	O
"),"	O
leaf	O
temperature	O
(	O
T	O
i	O
"),"	O
stomatal	O
conductance	O
(	O
G	O
s	O
"),"	O
transpiration	O
rate	O
(	O
T	O
r	O
"),"	O
water	B-Chemical
use	O
efficiency	O
(	O
WUE	O
"),"	O
limiting	O
value	O
of	O
stomata	O
(	O
L	O
s	O
)	O
and	O
the	O
light	O
response	O
)	O
were	O
all	O
measured	O
and	O
each	O
value	O
was	O
chosen	O
as	O
the	O
average	O
of	O
four	O
-	O
replication	O
groups	O
of	O
each	O
salt	B-Chemical
dust	O
simulated	O
level	O
.	O
The	O
WUE	O
was	O
calculated	O
as	O
the	O
ratio	O
of	O
the	O
net	O
photosynthetic	O
rate	O
(	O
P	O
n	O
)	O
and	O
the	O
T	O
r	O
.	O
The	O
limiting	O
value	O
of	O
the	O
stomata	O
(	O
L	O
s	O
)	O
was	O
calculated	O
as	O
C	O
a	O
-	O
C	O
i	O
/	O
C	O
a	O
Ã—	O
100	O
"%,"	O
in	O
which	O
C	O
a	O
is	O
the	O
concentration	O
of	O
atmospheric	O
CO2	B-Chemical
and	O
C	O
i	O
is	O
the	O
intercellular	O
CO2	B-Chemical
concentration	O
.	O
From	O
there	O
","	O
we	O
calculated	O
the	O
light	O
response	O
parameters	O
of	O
the	O
cotton	O
leaves	O
each	O
day	O
.	O
Determination	O
of	O
salt	B-Chemical
dust	O
particle	O
size	O
distribution	O
on	O
the	O
cotton	O
leaves	O
To	O
determine	O
the	O
particle	O
size	O
of	O
the	O
salt	B-Chemical
dust	O
on	O
the	O
cotton	O
leaves	O
","	O
the	O
following	O
steps	O
were	O
taken	O
.	O
First	O
","	O
30	O
%	O
hydrogen	B-Chemical
peroxide	I-Chemical
was	O
added	O
at	O
72	O
Â°	O
C	O
to	O
remove	O
any	O
organic	O
matter	O
from	O
the	O
salt	B-Chemical
dust	O
","	O
which	O
had	O
been	O
collected	O
from	O
the	O
surface	O
cotton	O
leaves	O
in	O
the	O
monitoring	O
area	O
using	O
a	O
fine	O
wool	O
brush	O
.	O
We	O
added	O
hydrochloric	B-Chemical
acid	I-Chemical
to	O
remove	O
the	O
carbonate	B-Chemical
","	O
then	O
ultrapure	O
water	B-Chemical
to	O
dilute	O
the	O
solution	O
and	O
let	O
it	O
stand	O
for	O
30	O
min	O
to	O
remove	O
the	O
supernatant	O
acid	B-Chemical
.	O
Next	O
","	O
quieted	O
it	O
over	O
and	O
over	O
again	O
until	O
the	O
pH	O
reached	O
6	O
.	O
5	O
â€“	O
7	O
.	O
0	O
.	O
Finally	O
","	O
we	O
added	O
sodium	B-Chemical
hexametaphosphate	I-Chemical
after	O
30	O
min	O
of	O
ultrasound	O
dispose	O
","	O
we	O
used	O
a	O
Mastersizer	O
2000	O
(	O
Melvin	O
laser	O
particle	O
size	O
analyzer	O
","	O
USA	O
)	O
with	O
a	O
range	O
of	O
0	O
.	O
2	O
â€“	O
2	O
.	O
0	O
Î¼m	O
to	O
measure	O
the	O
particle	O
sizes	O
of	O
the	O
salt	B-Chemical
dust	O
.	O
Measurement	O
of	O
the	O
salt	B-Chemical
ions	I-Chemical
on	O
the	O
surface	O
and	O
inside	O
cotton	O
leaves	O
In	O
this	O
work	O
","	O
the	O
salt	B-Chemical
ions	I-Chemical
on	O
the	O
surface	O
of	O
the	O
cotton	O
blade	O
were	O
collected	O
in	O
water	B-Chemical
used	O
to	O
rinse	O
the	O
cotton	O
leaves	O
.	O
First	O
","	O
we	O
collected	O
the	O
cotton	O
leaves	O
and	O
put	O
them	O
into	O
deionized	O
water	B-Chemical
for	O
2	O
â€“	O
4	O
min	O
to	O
rinse	O
off	O
the	O
surface	O
particles	O
into	O
fluid	O
.	O
Then	O
","	O
the	O
Na	B-Chemical
+	I-Chemical
and	O
K	B-Chemical
+	I-Chemical
contents	O
in	O
the	O
rinsing	O
water	B-Chemical
were	O
tested	O
by	O
FD640	O
type	O
flame	O
photometer	O
","	O
Ca2	B-Chemical
+	I-Chemical
and	O
Mg2	B-Chemical
+	I-Chemical
were	O
tested	O
with	O
a	O
general	O
TAS990	O
type	O
flame	O
atomic	O
absorption	O
spectrophotometer	O
","	O
Cl	B-Chemical
-	I-Chemical
was	O
tested	O
using	O
nitric	B-Chemical
acid	I-Chemical
silver	I-Chemical
titration	O
","	O
CO3	B-Chemical
2	I-Chemical
-	I-Chemical
and	O
HCO	B-Chemical
-	I-Chemical
were	O
tested	O
using	O
the	O
double	O
indicator	O
method	O
and	O
the	O
SO4	B-Chemical
2	I-Chemical
-	I-Chemical
was	O
tested	O
using	O
EDTA	B-Chemical
titration	O
[].	O
The	O
salt	B-Chemical
ions	I-Chemical
inside	O
the	O
cotton	O
blade	O
were	O
collected	O
by	O
boiling	O
the	O
blade	O
in	O
liquid	O
.	O
After	O
the	O
cotton	O
leaves	O
were	O
rinsed	O
as	O
described	O
above	O
","	O
removing	O
any	O
salt	B-Chemical
ions	I-Chemical
on	O
the	O
surface	O
of	O
the	O
leaves	O
","	O
we	O
boiled	O
them	O
for	O
30	O
min	O
to	O
extract	O
the	O
salt	B-Chemical
ions	I-Chemical
inside	O
the	O
cotton	O
leaves	O
.	O
Then	O
","	O
the	O
Na	B-Chemical
+	I-Chemical
and	O
K	B-Chemical
+	I-Chemical
contents	O
in	O
the	O
rinsing	O
water	B-Chemical
were	O
tested	O
by	O
FD640	O
type	O
flame	O
photometer	O
","	O
Ca2	B-Chemical
+	I-Chemical
and	O
Mg2	B-Chemical
+	I-Chemical
were	O
tested	O
with	O
a	O
general	O
TAS990	O
type	O
flame	O
atomic	O
absorption	O
spectrophotometer	O
","	O
Cl	B-Chemical
-	I-Chemical
was	O
tested	O
using	O
nitric	B-Chemical
acid	I-Chemical
silver	I-Chemical
titration	O
","	O
CO3	B-Chemical
2	I-Chemical
-	I-Chemical
and	O
HCO	B-Chemical
-	I-Chemical
were	O
tested	O
using	O
the	O
double	O
indicator	O
method	O
and	O
the	O
SO4	B-Chemical
2	I-Chemical
-	I-Chemical
was	O
tested	O
using	O
EDTA	B-Chemical
titration	O
[].	O
Measurement	O
of	O
photosynthesis	O
by	O
the	O
cotton	O
leaves	O
The	O
photosynthesis	O
of	O
the	O
cotton	O
leaves	O
was	O
measured	O
on	O
a	O
sunny	O
day	O
from	O
10	O
:	O
0	O
â€“	O
20	O
:	O
0	O
.	O
The	O
test	O
equipment	O
was	O
a	O
Li	O
-	O
6400	O
portable	O
photosynthesis	O
measuring	O
system	O
(	O
Li	O
-	O
Cor	O
","	O
Lincon	O
","	O
NE	O
","	O
USA	O
).	O
The	O
tested	O
indicators	O
of	O
photosynthesis	O
were	O
the	O
P	O
n	O
","	O
PE	O
","	O
C	O
i	O
","	O
T	O
l	O
","	O
G	O
s	O
","	O
L	O
s	O
","	O
T	O
r	O
and	O
WUE	O
.	O
During	O
the	O
test	O
","	O
each	O
of	O
the	O
above	O
parameters	O
was	O
tested	O
three	O
times	O
for	O
each	O
sediment	O
group	O
per	O
hour	O
from	O
10	O
:	O
0	O
to	O
20	O
:	O
0	O
","	O
and	O
each	O
value	O
of	O
them	O
was	O
chosen	O
as	O
the	O
average	O
of	O
the	O
four	O
-	O
replication	O
groups	O
of	O
each	O
salt	B-Chemical
dust	O
simulated	O
level	O
(	O
from	O
0	O
g	O
.	O
m	O
-	O
2	O
to	O
500	O
g	O
.	O
m	O
-	O
2	O
).	O
We	O
then	O
calculated	O
the	O
average	O
value	O
of	O
these	O
three	O
values	O
to	O
obtain	O
the	O
final	O
test	O
value	O
.	O
Next	O
","	O
the	O
L	O
s	O
and	O
WUE	O
of	O
the	O
cotton	O
leaves	O
were	O
calculated	O
as	O
(	O
C	O
a	O
-	O
C	O
i	O
)/	O
C	O
a	O
Ã—	O
100	O
%	O
and	O
P	O
n	O
/	O
T	O
r	O
","	O
respectively	O
.	O
Generation	O
of	O
light	O
response	O
curves	O
of	O
the	O
cotton	O
leaves	O
Light	O
response	O
curves	O
were	O
calculated	O
using	O
the	O
nonrectangular	O
hyperbola	O
model	O
with	O
relevant	O
parameters	O
and	O
a	O
derivation	O
of	O
equation	O
fitting	O
of	O
P	O
n	O
and	O
PAR	O
.	O
First	O
","	O
we	O
used	O
the	O
model	O
to	O
calculate	O
the	O
parameters	O
of	O
the	O
curved	O
angle	O
(	O
K	O
"),"	O
the	O
apparent	O
quantum	O
efficiency	O
(	O
Î¸	O
"),"	O
the	O
maximum	O
net	O
photosynthetic	O
rate	O
(	O
A	O
max	O
)	O
and	O
the	O
respiratory	O
rate	O
(	O
R	O
ady	O
).	O
Then	O
","	O
we	O
calculated	O
the	O
light	O
linear	O
equation	O
of	O
effective	O
photosynthetic	O
radiation	O
under	O
200	O
Î¼mol	O
.	O
m	O
-	O
2	O
.	O
s	O
-	O
1	O
and	O
the	O
intersection	O
of	O
these	O
two	O
straight	O
lines	O
.	O
Leaf	O
blade	O
surface	O
morphology	O
Cotton	O
leaves	O
where	O
salt	B-Chemical
dust	O
had	O
landed	O
and	O
where	O
no	O
salt	B-Chemical
dust	O
had	O
landed	O
were	O
collected	O
.	O
These	O
leaves	O
were	O
then	O
dried	O
and	O
processed	O
according	O
to	O
standard	O
scanning	O
electron	O
microscopy	O
(	O
SEM	O
)	O
biological	O
sample	O
preparation	O
protocols	O
.	O
An	O
IB	O
-	O
5	O
Ion	O
sputtering	O
apparatus	O
plating	O
was	O
used	O
to	O
pin	O
gold	B-Chemical
film	O
","	O
and	O
a	O
scanning	O
electron	O
microscope	O
with	O
type	O
LECM430VP	O
was	O
used	O
to	O
observe	O
and	O
photograph	O
the	O
cotton	O
samples	O
.	O
Measurement	O
of	O
chlorophyll	B-Chemical
content	O
The	O
acetone	B-Chemical
grinding	O
extraction	O
method	O
was	O
used	O
to	O
measure	O
the	O
chlorophyll	B-Chemical
content	O
of	O
the	O
cotton	O
leaves	O
[].	O
Briefly	O
","	O
80	O
%	O
acetone	B-Chemical
was	O
used	O
to	O
extract	O
fluid	O
for	O
testing	O
","	O
a	O
type	O
756MC	O
ultraviolet	O
-	O
visible	O
spectrophotometer	O
was	O
used	O
to	O
measure	O
the	O
absorbance	O
(	O
D	O
)	O
at	O
wavelengths	O
of	O
663	O
","	O
646	O
and	O
470	O
nm	O
","	O
and	O
then	O
the	O
total	O
chlorophyll	B-Chemical
content	O
was	O
calculated	O
.	O
Each	O
value	O
of	O
them	O
was	O
chosen	O
as	O
the	O
average	O
of	O
the	O
four	O
-	O
replication	O
groups	O
of	O
each	O
salt	B-Chemical
dust	O
simulated	O
level	O
.	O
Measurement	O
of	O
the	O
carotenoid	B-Chemical
content	O
in	O
the	O
cotton	O
leaves	O
First	O
","	O
2	O
g	O
of	O
cotton	O
leaves	O
were	O
ground	O
after	O
freezing	O
with	O
liquid	O
nitrogen	B-Chemical
.	O
Next	O
","	O
8	O
mL	O
of	O
acetone	B-Chemical
were	O
added	O
to	O
the	O
extraction	O
and	O
incubated	O
at	O
4	O
Â°	O
C	O
in	O
the	O
dark	O
.	O
After	O
24	O
h	O
","	O
the	O
mixture	O
was	O
centrifuged	O
at	O
10	O
","	O
0	O
g	O
for	O
5	O
min	O
and	O
the	O
supernatant	O
was	O
transferred	O
to	O
a	O
new	O
10	O
mL	O
centrifuge	O
tube	O
","	O
then	O
7	O
mL	O
of	O
acetone	B-Chemical
were	O
added	O
to	O
the	O
residue	O
.	O
The	O
extraction	O
was	O
repeated	O
3	O
times	O
and	O
all	O
the	O
supernatants	O
were	O
added	O
together	O
.	O
Acetone	B-Chemical
was	O
added	O
to	O
the	O
supernatants	O
to	O
make	O
a	O
total	O
volume	O
of	O
25	O
mL	O
.	O
Prior	O
to	O
testing	O
","	O
the	O
solution	O
was	O
passed	O
through	O
a	O
0	O
.	O
22	O
mm	O
organic	O
filter	O
head	O
.	O
Take	O
extracting	O
solution	O
of	O
10	O
mL	O
","	O
the	O
total	O
carotenoid	B-Chemical
content	O
in	O
the	O
solution	O
was	O
then	O
measured	O
using	O
a	O
UV755B	O
ultraviolet	O
-	O
visible	O
spectrophotometer	O
at	O
a	O
wavelength	O
of	O
450	O
nm	O
and	O
calculated	O
based	O
on	O
these	O
measurements	O
[].	O
Measurement	O
of	O
the	O
soluble	O
sugar	B-Chemical
in	O
the	O
cotton	O
leaves	O
The	O
anthrone	B-Chemical
colorimetry	O
method	O
was	O
used	O
to	O
test	O
the	O
soluble	O
sugar	B-Chemical
content	O
of	O
the	O
cotton	O
leaves	O
[].	O
First	O
","	O
1	O
mL	O
extraction	O
liquid	O
was	O
prepared	O
","	O
mixed	O
with	O
5	O
mL	O
anthrone	B-Chemical
reagent	O
","	O
put	O
in	O
a	O
boiling	O
water	B-Chemical
bath	O
for	O
ten	O
min	O
","	O
and	O
then	O
cooled	O
.	O
A	O
756MC	O
ultraviolet	O
-	O
visible	O
spectrophotometer	O
was	O
used	O
to	O
measure	O
the	O
absorbance	O
(	O
D	O
)	O
at	O
a	O
wavelength	O
of	O
625	O
nm	O
.	O
The	O
absorbances	O
were	O
compared	O
to	O
the	O
absorbances	O
of	O
different	O
concentrations	O
of	O
standard	O
solutions	O
and	O
then	O
the	O
soluble	O
sugar	B-Chemical
concentration	O
curves	O
were	O
drawn	O
.	O
Measurement	O
of	O
the	O
proline	B-Chemical
content	O
of	O
the	O
cotton	O
leaves	O
The	O
acidic	O
indene	O
three	O
ketone	B-Chemical
chromogenic	O
method	O
was	O
used	O
to	O
measure	O
the	O
proline	B-Chemical
content	O
of	O
the	O
cotton	O
leaves	O
under	O
different	O
salt	B-Chemical
dust	O
deposition	O
conditions	O
.	O
First	O
","	O
l	O
mL	O
fluid	O
was	O
prepared	O
for	O
the	O
test	O
","	O
and	O
then	O
5	O
mL	O
glacial	B-Chemical
acetic	I-Chemical
acid	I-Chemical
was	O
added	O
","	O
followed	O
by	O
5	O
mL	O
indene	O
three	O
ketone	B-Chemical
color	O
liquid	O
.	O
This	O
solution	O
was	O
incubated	O
at	O
a	O
constant	O
80	O
Â°	O
C	O
in	O
a	O
water	B-Chemical
bath	O
for	O
40	O
min	O
","	O
then	O
cooled	O
to	O
room	O
temperature	O
and	O
shaken	O
well	O
with	O
distilled	O
water	B-Chemical
constant	O
volume	O
.	O
Finally	O
","	O
an	O
ultraviolet	O
-	O
visible	O
spectrophotometer	O
was	O
used	O
to	O
measure	O
the	O
absorbance	O
(	O
D	O
)	O
at	O
a	O
wavelength	O
of	O
520	O
nm	O
.	O
These	O
obtained	O
absorbances	O
were	O
compared	O
to	O
the	O
absorbances	O
at	O
different	O
concentrations	O
of	O
a	O
standard	O
solution	O
","	O
and	O
a	O
proline	B-Chemical
concentration	O
curve	O
was	O
drawn	O
and	O
used	O
to	O
calculate	O
the	O
proline	B-Chemical
content	O
in	O
the	O
fluid	O
[].	O
Measurement	O
of	O
the	O
MDA	B-Chemical
content	O
The	O
MDA	B-Chemical
content	O
of	O
the	O
cotton	O
leaves	O
was	O
measured	O
using	O
the	O
glucosinolates	B-Chemical
barbituric	I-Chemical
acid	I-Chemical
method	O
under	O
different	O
salt	B-Chemical
dust	O
deposition	O
conditions	O
.	O
First	O
","	O
extraction	O
was	O
performed	O
by	O
grinding	O
cotton	O
leaves	O
in	O
an	O
ice	O
bath	O
.	O
2	O
mL	O
of	O
0	O
.	O
67	O
%	O
glucosinolates	B-Chemical
barbituric	I-Chemical
acid	I-Chemical
were	O
added	O
","	O
the	O
solution	O
was	O
mixed	O
and	O
boiled	O
in	O
a	O
water	B-Chemical
bath	O
for	O
30	O
min	O
","	O
and	O
then	O
centrifuged	O
at	O
3	O
","	O
0	O
rpm	O
for	O
10	O
min	O
after	O
cooling	O
.	O
Finally	O
","	O
an	O
ultraviolet	O
-	O
visible	O
spectrophotometer	O
was	O
used	O
to	O
measure	O
the	O
absorbance	O
(	O
D	O
)	O
at	O
wavelengths	O
of	O
450	O
","	O
532	O
and	O
600	O
nm	O
","	O
and	O
these	O
values	O
were	O
used	O
to	O
calculate	O
the	O
MDA	B-Chemical
content	O
[].	O
Measurement	O
of	O
antioxidant	O
enzymes	O
in	O
the	O
cotton	O
leaves	O
Superoxide	O
dismutase	O
(	O
SOD	O
)	O
The	O
nitroblue	B-Chemical
tetrazolium	I-Chemical
(	O
NBT	B-Chemical
)	O
method	O
was	O
used	O
to	O
measure	O
the	O
SOD	O
content	O
of	O
the	O
cotton	O
leaves	O
under	O
different	O
salt	B-Chemical
dust	O
deposition	O
conditions	O
.	O
First	O
","	O
the	O
leaf	O
samples	O
were	O
ground	O
in	O
an	O
ice	O
bath	O
","	O
then	O
prepared	O
for	O
testing	O
by	O
mixing	O
with	O
the	O
reaction	O
liquid	O
and	O
letting	O
the	O
color	O
develop	O
under	O
a	O
4	O
","	O
0	O
Lx	O
fluorescent	O
lamp	O
.	O
After	O
20	O
min	O
","	O
color	O
comparisons	O
were	O
made	O
and	O
an	O
ultraviolet	O
-	O
visible	O
spectrophotometer	O
was	O
used	O
to	O
measure	O
the	O
absorbance	O
(	O
D	O
)	O
at	O
a	O
wavelength	O
of	O
560	O
nm	O
.	O
These	O
values	O
were	O
converted	O
into	O
the	O
SOD	O
content	O
[].	O
Peroxidase	O
(	O
POD	O
)	O
The	O
guaiacol	B-Chemical
method	O
was	O
used	O
to	O
measure	O
the	O
POD	O
content	O
of	O
the	O
cotton	O
leaves	O
.	O
First	O
","	O
the	O
leaf	O
samples	O
were	O
ground	O
in	O
an	O
ice	O
bath	O
.	O
Then	O
","	O
the	O
ground	O
leaves	O
were	O
mixed	O
with	O
a	O
reaction	O
liquid	O
","	O
incubated	O
for	O
3	O
min	O
in	O
a	O
34	O
Â°	O
C	O
water	O
bath	O
","	O
and	O
an	O
ultraviolet	O
-	O
visible	O
spectrophotometer	O
was	O
used	O
to	O
measure	O
the	O
absorbance	O
(	O
D	O
)	O
at	O
a	O
wavelength	O
of	O
470	O
nm	O
at	O
consecutive	O
time	O
points	O
over	O
4	O
min	O
.	O
By	O
comparing	O
these	O
values	O
to	O
the	O
standard	O
curve	O
","	O
the	O
POD	O
content	O
was	O
determined	O
[].	O
Catalase	O
(	O
CAT	O
)	O
The	O
guaiacol	B-Chemical
method	O
was	O
used	O
to	O
measure	O
CAT	O
content	O
of	O
the	O
cotton	O
leaves	O
.	O
First	O
","	O
the	O
cotton	O
leaves	O
were	O
ground	O
in	O
an	O
ice	B-Chemical
bath	O
","	O
and	O
then	O
mixed	O
with	O
a	O
reaction	O
liquid	O
and	O
300	O
Î¼L	O
deionized	O
water	B-Chemical
.	O
Finally	O
","	O
an	O
ultraviolet	O
-	O
visible	O
spectrophotometer	O
was	O
used	O
to	O
measure	O
the	O
absorbance	O
(	O
D	O
)	O
at	O
a	O
wavelength	O
of	O
240	O
nm	O
","	O
making	O
consecutive	O
measurements	O
over	O
4	O
min	O
.	O
By	O
comparing	O
the	O
values	O
to	O
the	O
standard	O
curve	O
","	O
the	O
CAT	O
content	O
was	O
obtained	O
[].	O
Statistics	O
To	O
determine	O
whether	O
there	O
is	O
significant	O
influence	O
of	O
five	O
salt	B-Chemical
dust	O
deposition	O
groups	O
and	O
the	O
control	O
group	O
for	O
the	O
distribution	O
of	O
salt	B-Chemical
ions	I-Chemical
and	O
measure	O
the	O
photosynthesis	O
in	O
the	O
cotton	O
leaves	O
","	O
the	O
One	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
(	O
P	O
<	O
0	O
.	O
5	O
)	O
was	O
used	O
.	O
Then	O
if	O
the	O
ANOVA	O
indicated	O
significant	O
treatment	O
effects	O
","	O
the	O
LSD	O
test	O
was	O
used	O
to	O
test	O
for	O
the	O
differences	O
among	O
these	O
treatments	O
.	O
In	O
this	O
research	O
","	O
data	O
processing	O
was	O
performed	O
using	O
the	O
software	O
SPSS	O
19	O
.	O
0	O
and	O
Matlab	O
7	O
.	O
0	O
","	O
while	O
all	O
work	O
with	O
images	O
was	O
done	O
with	O
CorelDraw	O
12	O
.	O
0	O
.	O
Results	O
and	O
Analysis	O
Particle	O
size	O
distribution	O
and	O
salt	B-Chemical
ion	I-Chemical
content	O
of	O
the	O
salt	B-Chemical
dust	O
on	O
the	O
cotton	O
leaves	O
Particle	O
size	O
distribution	O
of	O
the	O
salt	B-Chemical
dust	O
on	O
and	O
the	O
surface	O
morphology	O
of	O
the	O
cotton	O
leaves	O
(	O
1	O
)	O
Overall	O
","	O
the	O
salt	B-Chemical
dust	O
for	O
this	O
experiment	O
totaled	O
465	O
g	O
.	O
k	O
-	O
1g	O
with	O
Na	B-Chemical
+	I-Chemical
and	O
Ca2	B-Chemical
+	I-Chemical
accounting	O
for	O
39	O
.	O
9	O
%	O
of	O
the	O
salt	B-Chemical
ions	I-Chemical
and	O
Mg2	B-Chemical
+	I-Chemical
and	O
K	B-Chemical
+	I-Chemical
only	O
accounting	O
for	O
3	O
.	O
18	O
%	O
(	O
Fig	O
3a	O
).	O
The	O
water	B-Chemical
-	O
soluble	O
anions	B-Chemical
consisted	O
mainly	O
of	O
Cl	B-Chemical
-	I-Chemical
and	O
SO4	B-Chemical
2	I-Chemical
which	O
were	O
53	O
.	O
94	O
"%,"	O
while	O
CO3	B-Chemical
2	I-Chemical
-	I-Chemical
and	O
HCO3	B-Chemical
-	I-Chemical
were	O
only	O
2	O
.	O
97	O
%.	O
Measuring	O
the	O
particle	O
size	O
of	O
the	O
salt	B-Chemical
dust	O
that	O
landed	O
on	O
the	O
surface	O
cotton	O
leaves	O
(	O
Fig	O
3b	O
)	O
showed	O
that	O
for	O
the	O
salt	B-Chemical
dust	O
that	O
had	O
a	O
total	O
mass	O
of	O
389	O
g	O
.	O
kg	O
-	O
1	O
","	O
the	O
main	O
salt	B-Chemical
cations	I-Chemical
were	O
Na	B-Chemical
+	I-Chemical
and	O
Ca2	B-Chemical
+	I-Chemical
(	O
34	O
.	O
9	O
"%),"	O
the	O
water	B-Chemical
-	O
soluble	O
anions	B-Chemical
were	O
mainly	O
Cl	B-Chemical
-	I-Chemical
and	O
SO4	B-Chemical
2	I-Chemical
"-,("	I-Chemical
45	O
.	O
94	O
"%),"	O
and	O
the	O
salt	B-Chemical
ions	I-Chemical
of	O
Mg2	B-Chemical
+	I-Chemical
and	O
K	B-Chemical
+	I-Chemical
were	O
14	O
.	O
13	O
%.	O
The	O
particles	O
sized	O
1	O
.	O
2	O
â€“	O
58	O
microns	O
","	O
the	O
silty	O
sand	O
fraction	O
","	O
made	O
up	O
69	O
.	O
48	O
"%,"	O
less	O
than	O
4	O
microns	O
made	O
up	O
12	O
.	O
5	O
"%,"	O
and	O
more	O
than	O
58	O
microns	O
made	O
up	O
27	O
.	O
2	O
%.	O
Overall	O
","	O
these	O
data	O
indicate	O
that	O
the	O
salt	B-Chemical
dusts	O
used	O
for	O
experiments	O
reflected	O
the	O
natural	O
salt	B-Chemical
dust	O
found	O
on	O
the	O
cotton	O
plants	O
in	O
the	O
region	O
of	O
interest	O
.	O
Salt	B-Chemical
ion	I-Chemical
fractions	O
in	O
(	O
a	O
)	O
and	O
particle	O
size	O
distributions	O
(	O
b	O
)	O
of	O
the	O
salt	B-Chemical
dust	O
(	O
Î¼m	O
).	O
(	O
2	O
)	O
By	O
using	O
the	O
Field	O
Emission	O
Scanning	O
Electron	O
Microscope	O
(	O
FESEM	O
)	O
(	O
ZEISS	O
SUPRA55	O
VP	O
","	O
Germany	O
"),"	O
we	O
observed	O
that	O
the	O
stomata	O
of	O
the	O
cotton	O
leaves	O
were	O
labiate	O
with	O
a	O
long	O
axis	O
and	O
a	O
short	O
axis	O
(	O
Fig	O
4d	O
","	O
4e	O
and	O
4f	O
).	O
The	O
particle	O
size	O
range	O
of	O
the	O
salt	B-Chemical
dust	O
that	O
landed	O
on	O
the	O
cotton	O
leaves	O
was	O
predominantly	O
0	O
â€“	O
30	O
Î¼m	O
(	O
Fig	O
4a	O
","	O
4b	O
and	O
4c	O
)	O
with	O
a	O
width	O
of	O
1	O
â€“	O
6	O
Î¼m	O
.	O
SEM	O
also	O
showed	O
that	O
the	O
length	O
of	O
the	O
stomata	O
of	O
the	O
cotton	O
leaves	O
was	O
mainly	O
6	O
â€“	O
12	O
Î¼m	O
and	O
the	O
width	O
was	O
1	O
.	O
5	O
â€“	O
3	O
.	O
5	O
Î¼m	O
","	O
demonstrating	O
that	O
the	O
salt	B-Chemical
dust	O
within	O
this	O
size	O
range	O
can	O
easily	O
fall	O
into	O
the	O
stomata	O
.	O
These	O
data	O
also	O
show	O
that	O
the	O
shape	O
of	O
the	O
dust	O
widely	O
varies	O
","	O
and	O
when	O
salt	B-Chemical
dust	O
within	O
this	O
range	O
lands	O
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
and	O
covers	O
the	O
blade	O
","	O
it	O
can	O
form	O
a	O
covered	O
area	O
that	O
influences	O
the	O
physiological	O
functions	O
of	O
the	O
cotton	O
leaves	O
","	O
including	O
photosynthesis	O
and	O
cellular	O
respiration	O
","	O
and	O
elements	O
such	O
as	O
salt	B-Chemical
ions	I-Chemical
may	O
increase	O
the	O
salt	B-Chemical
content	O
in	O
the	O
cotton	O
leaves	O
.	O
Thus	O
the	O
internal	O
physiological	O
functions	O
of	O
the	O
cotton	O
leaves	O
can	O
be	O
influenced	O
as	O
well	O
","	O
leading	O
to	O
damage	O
to	O
the	O
cotton	O
leaves	O
.	O
The	O
surface	O
morphology	O
of	O
the	O
cotton	O
leaves	O
.	O
Distribution	O
of	O
the	O
salt	B-Chemical
cations	I-Chemical
on	O
the	O
cotton	O
leaves	O
From	O
the	O
analysis	O
(	O
Fig	O
5	O
"),"	O
we	O
determined	O
the	O
order	O
of	O
the	O
salt	B-Chemical
cations	I-Chemical
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
of	O
the	O
control	O
and	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
as	O
:	O
Na	B-Chemical
+>	I-Chemical
Ca2	I-Chemical
+>	I-Chemical
Mg2	I-Chemical
+>	I-Chemical
K	I-Chemical
+	I-Chemical
and	O
the	O
order	O
of	O
salt	B-Chemical
ions	I-Chemical
inside	O
the	O
cotton	O
leaves	O
as	O
:	O
Na	B-Chemical
+>	I-Chemical
Ca2	I-Chemical
+>	I-Chemical
Mg2	I-Chemical
+>	I-Chemical
K	I-Chemical
+.	I-Chemical
Furthermore	O
","	O
the	O
analysis	O
showed	O
the	O
total	O
salt	B-Chemical
content	O
on	O
the	O
surface	O
of	O
and	O
inside	O
the	O
cotton	O
leaves	O
corresponded	O
to	O
the	O
treatment	O
groups	O
","	O
which	O
was	O
ordered	O
as	O
:	O
500	O
g	O
.	O
m	O
-	O
2	O
>	O
400	O
g	O
.	O
m	O
-	O
2	O
>	O
300	O
g	O
.	O
m	O
-	O
2	O
>	O
200	O
g	O
.	O
m	O
-	O
2	O
>	O
100	O
g	O
.	O
m	O
-	O
2	O
.	O
Distribution	O
of	O
the	O
salt	B-Chemical
cations	I-Chemical
on	O
the	O
cotton	O
leaves	O
.	O
ANOVA	O
showed	O
that	O
the	O
salt	B-Chemical
dust	O
deposition	O
had	O
significant	O
influence	O
on	O
the	O
salt	B-Chemical
cation	I-Chemical
contents	O
of	O
the	O
surface	O
cotton	O
leaves	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
and	O
the	O
differences	O
among	O
these	O
groups	O
are	O
significant	O
.	O
Then	O
the	O
further	O
LSD	O
test	O
showed	O
that	O
by	O
comparing	O
the	O
treatment	O
groups	O
to	O
the	O
control	O
","	O
it	O
was	O
found	O
the	O
Na	B-Chemical
+	I-Chemical
content	O
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
trended	O
an	O
increase	O
in	O
all	O
the	O
five	O
treatment	O
groups	O
","	O
comparing	O
with	O
the	O
control	O
group	O
.	O
There	O
were	O
significant	O
differences	O
between	O
groups	O
A	O
","	O
B	O
","	O
C	O
","	O
D	O
","	O
or	O
E	O
and	O
F	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
A	O
","	O
B	O
","	O
C	O
","	O
D	O
","	O
and	O
E	O
.	O
Compared	O
with	O
the	O
control	O
","	O
the	O
K	B-Chemical
+	I-Chemical
content	O
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
also	O
increased	O
in	O
the	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
with	O
significant	O
differences	O
found	O
between	O
groups	O
A	O
and	O
(	O
B	O
","	O
C	O
","	O
D	O
","	O
and	O
E	O
"),"	O
and	O
F	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
no	O
significant	O
differences	O
were	O
found	O
between	O
groups	O
B	O
","	O
C	O
","	O
D	O
","	O
and	O
E	O
)	O
(	O
P	O
>	O
0	O
.	O
5	O
).	O
For	O
the	O
Na	B-Chemical
+	I-Chemical
content	O
inside	O
the	O
cotton	O
leaves	O
","	O
compared	O
with	O
the	O
control	O
","	O
there	O
were	O
significant	O
differences	O
between	O
groups	O
of	O
A	O
and	O
B	O
","	O
C	O
","	O
D	O
","	O
E	O
","	O
or	O
F	O
)	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
of	O
B	O
","	O
C	O
","	O
D	O
","	O
E	O
","	O
and	O
F	O
).	O
For	O
the	O
K	B-Chemical
+	I-Chemical
content	O
inside	O
the	O
cotton	O
leaves	O
","	O
compared	O
with	O
the	O
control	O
","	O
there	O
were	O
significant	O
differences	O
between	O
groups	O
A	O
and	O
(	O
B	O
","	O
C	O
","	O
and	O
D	O
"),"	O
and	O
E	O
","	O
and	O
F	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
B	O
","	O
C	O
","	O
and	O
D	O
.	O
As	O
compared	O
to	O
the	O
control	O
","	O
the	O
Ca2	B-Chemical
+	I-Chemical
content	O
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
increased	O
in	O
the	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
.	O
Compared	O
with	O
the	O
control	O
","	O
there	O
were	O
significant	O
differences	O
between	O
groups	O
(	O
A	O
","	O
B	O
)	O
and	O
(	O
C	O
","	O
D	O
"),"	O
and	O
E	O
","	O
and	O
F	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
(	O
A	O
","	O
B	O
)	O
and	O
(	O
C	O
","	O
D	O
"),"	O
respectively	O
","	O
(	O
P	O
>	O
0	O
.	O
5	O
).	O
Inside	O
the	O
cotton	O
leaves	O
","	O
there	O
were	O
significant	O
differences	O
between	O
groups	O
A	O
","	O
and	O
B	O
","	O
and	O
(	O
C	O
","	O
D	O
"),"	O
and	O
(	O
E	O
","	O
F	O
"),"	O
as	O
compared	O
to	O
the	O
control	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
there	O
have	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
of	O
(	O
C	O
","	O
D	O
)	O
and	O
(	O
E	O
","	O
F	O
"),"	O
respectively	O
.	O
As	O
compared	O
to	O
the	O
control	O
","	O
the	O
Mg2	B-Chemical
+	I-Chemical
content	O
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
increased	O
in	O
the	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
.	O
There	O
were	O
significant	O
differences	O
between	O
groups	O
A	O
and	O
B	O
","	O
and	O
C	O
","	O
and	O
(	O
D	O
","	O
E	O
)	O
and	O
F	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
salt	B-Chemical
dust	O
groups	O
D	O
and	O
E	O
.	O
A	O
similar	O
trend	O
was	O
observed	O
inside	O
the	O
cotton	O
leaves	O
.	O
There	O
were	O
significant	O
differences	O
between	O
groups	O
A	O
and	O
B	O
","	O
and	O
C	O
","	O
and	O
(	O
D	O
","	O
E	O
)	O
and	O
F	O
as	O
compared	O
to	O
the	O
control	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
salt	B-Chemical
dust	O
groups	O
D	O
and	O
E	O
.	O
I	O
is	O
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
;	O
IIis	O
inside	O
of	O
the	O
cotton	O
leaves	O
The	O
control	O
(	O
A	O
"),"	O
and	O
groups	O
treated	O
with	O
100g	O
.	O
m	O
-	O
2	O
(	O
B	O
"),"	O
200g	O
.	O
m	O
-	O
2	O
(	O
C	O
"),"	O
300g	O
.	O
m	O
-	O
2	O
(	O
D	O
"),"	O
400	O
g	O
.	O
m	O
-	O
2	O
(	O
E	O
"),"	O
and	O
500	O
g	O
.	O
m	O
-	O
2	O
(	O
F	O
).	O
Samples	O
within	O
one	O
index	O
with	O
different	O
lowercase	O
letters	O
a	O
","	O
b	O
","	O
c	O
","	O
d	O
and	O
e	O
had	O
significant	O
(	O
P	O
<	O
0	O
.	O
5	O
)	O
differences	O
between	O
different	O
salt	B-Chemical
dust	O
treatment	O
groups	O
","	O
while	O
samples	O
with	O
matching	O
lowercase	O
letters	O
had	O
no	O
significant	O
differences	O
(	O
P	O
>	O
0	O
.	O
5	O
).	O
The	O
same	O
below	O
.	O
Distribution	O
of	O
the	O
salt	B-Chemical
anions	I-Chemical
on	O
the	O
cotton	O
leaves	O
From	O
the	O
analysis	O
(	O
Fig	O
6	O
"),"	O
the	O
salt	B-Chemical
anions	I-Chemical
on	O
the	O
surface	O
of	O
and	O
inside	O
the	O
cotton	O
leaves	O
of	O
control	O
and	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
were	O
ordered	O
as	O
Cl	B-Chemical
->	I-Chemical
SO4	I-Chemical
2	I-Chemical
->	I-Chemical
HCO3	I-Chemical
->	I-Chemical
CO3	I-Chemical
-.	I-Chemical
In	O
the	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
","	O
the	O
order	O
of	O
the	O
total	O
salt	B-Chemical
content	O
on	O
and	O
in	O
the	O
cotton	O
leaves	O
was	O
500	O
g	O
.	O
m	O
-	O
2	O
>	O
400	O
g	O
.	O
m	O
-	O
2	O
>	O
300	O
g	O
.	O
m	O
-	O
2	O
>	O
200	O
g	O
.	O
m	O
-	O
2	O
>	O
100	O
g	O
.	O
m	O
-	O
2	O
.	O
Distribution	O
of	O
the	O
salt	B-Chemical
anions	I-Chemical
on	O
the	O
cotton	O
leaves	O
.	O
ANOVA	O
showed	O
that	O
the	O
salt	B-Chemical
dust	O
deposition	O
had	O
significant	O
influence	O
on	O
the	O
salt	B-Chemical
anionic	O
contents	O
of	O
the	O
surface	O
cotton	O
leaves	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
and	O
the	O
differences	O
among	O
these	O
groups	O
were	O
significant	O
.	O
Then	O
the	O
further	O
LSD	O
test	O
showed	O
that	O
compared	O
to	O
the	O
control	O
","	O
the	O
Cl	B-Chemical
-	I-Chemical
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
of	O
the	O
treatment	O
groups	O
showed	O
an	O
increasing	O
trend	O
.	O
Specifically	O
","	O
there	O
were	O
significant	O
differences	O
between	O
groups	O
(	O
A	O
","	O
B	O
","	O
C	O
","	O
D	O
","	O
and	O
E	O
)	O
and	O
F	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
A	O
","	O
B	O
","	O
C	O
","	O
D	O
","	O
and	O
E	O
.	O
Inside	O
the	O
cotton	O
leaves	O
","	O
there	O
was	O
an	O
increase	O
in	O
Cl	B-Chemical
-	I-Chemical
in	O
the	O
treatment	O
groups	O
compared	O
to	O
the	O
control	O
","	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
A	O
","	O
B	O
","	O
C	O
","	O
D	O
","	O
E	O
","	O
and	O
F	O
(	O
Fig	O
6	O
).	O
The	O
salt	B-Chemical
anion	I-Chemical
SO4	I-Chemical
2	I-Chemical
-	I-Chemical
content	O
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
increased	O
in	O
the	O
five	O
treatment	O
groups	O
compared	O
to	O
the	O
control	O
with	O
significant	O
differences	O
between	O
groups	O
(	O
A	O
","	O
B	O
and	O
C	O
"),"	O
and	O
(	O
D	O
","	O
E	O
"),"	O
and	O
F	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
there	O
have	O
no	O
significant	O
differences	O
between	O
groups	O
(	O
A	O
","	O
B	O
and	O
C	O
)	O
and	O
(	O
D	O
","	O
E	O
"),"	O
respectively	O
.	O
Inside	O
the	O
cotton	O
leaves	O
","	O
the	O
SO4	B-Chemical
2	I-Chemical
-	I-Chemical
content	O
increased	O
in	O
the	O
five	O
treatment	O
groups	O
compared	O
to	O
the	O
control	O
","	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
A	O
","	O
B	O
","	O
and	O
C	O
.	O
The	O
LSD	O
test	O
showed	O
an	O
increase	O
in	O
CO3	B-Chemical
-	I-Chemical
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
of	O
the	O
five	O
treatment	O
groups	O
compared	O
to	O
the	O
control	O
with	O
significant	O
differences	O
between	O
groups	O
(	O
A	O
","	O
B	O
","	O
C	O
)	O
and	O
(	O
D	O
","	O
E	O
","	O
F	O
)	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
(	O
A	O
","	O
B	O
","	O
C	O
)	O
and	O
(	O
D	O
","	O
E	O
","	O
F	O
"),"	O
respectively	O
.	O
Inside	O
the	O
cotton	O
leaves	O
","	O
the	O
CO3	B-Chemical
-	I-Chemical
increased	O
in	O
the	O
five	O
treatment	O
groups	O
compared	O
to	O
the	O
control	O
","	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
of	O
A	O
and	O
B	O
and	O
C	O
","	O
and	O
D	O
and	O
(	O
E	O
","	O
F	O
)	O
(	O
P	O
>	O
0	O
.	O
5	O
).	O
An	O
increase	O
was	O
observed	O
in	O
content	O
of	O
HCO3	B-Chemical
-	I-Chemical
on	O
the	O
cotton	O
leaf	O
surface	O
in	O
the	O
salt	B-Chemical
dust	O
treatment	O
groups	O
compared	O
to	O
the	O
control	O
.	O
There	O
were	O
significant	O
differences	O
between	O
groups	O
(	O
A	O
","	O
B	O
)	O
and	O
C	O
","	O
and	O
D	O
","	O
and	O
E	O
and	O
F	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
Inside	O
the	O
cotton	O
leaves	O
","	O
the	O
CO3	B-Chemical
-	I-Chemical
showed	O
an	O
increasing	O
trend	O
in	O
the	O
five	O
treatment	O
groups	O
compared	O
to	O
the	O
control	O
","	O
but	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
groups	O
(	O
A	O
","	O
B	O
)	O
and	O
(	O
E	O
","	O
F	O
).	O
Changes	O
in	O
the	O
photosynthesis	O
of	O
the	O
cotton	O
leaves	O
P	O
n	O
and	O
PE	O
changes	O
in	O
the	O
cotton	O
leaves	O
A	O
bimodal	O
curve	O
of	O
the	O
net	O
photosynthetic	O
rate	O
(	O
P	O
n	O
)	O
was	O
observed	O
when	O
testing	O
the	O
photosynthesis	O
of	O
the	O
cotton	O
leaves	O
","	O
where	O
a	O
lunch	O
break	O
phenomenon	O
occurred	O
at	O
16	O
:	O
0	O
.	O
The	O
curves	O
of	O
the	O
net	O
photosynthetic	O
rate	O
(	O
P	O
n	O
)	O
and	O
the	O
light	O
use	O
efficiency	O
(	O
PE	O
)	O
decreased	O
as	O
the	O
salt	B-Chemical
dust	O
sediment	O
increased	O
from	O
100g	O
.	O
m	O
-	O
2	O
to	O
500g	O
.	O
m	O
-	O
2	O
.	O
Compared	O
to	O
the	O
control	O
area	O
","	O
the	O
P	O
n	O
and	O
PE	O
curves	O
were	O
lower	O
and	O
became	O
smaller	O
in	O
the	O
five	O
salt	B-Chemical
dust	O
sedimentation	O
areas	O
with	O
significant	O
differences	O
in	O
the	O
average	O
value	O
per	O
day	O
(	O
Fig	O
7	O
;	O
Table	O
1	O
).	O
This	O
suggests	O
that	O
higher	O
amounts	O
of	O
salt	B-Chemical
dust	O
had	O
more	O
influence	O
on	O
P	O
n	O
and	O
PE	O
of	O
the	O
cotton	O
leaves	O
"[,]."	O
The	O
P	O
n	O
and	O
PE	O
values	O
of	O
the	O
cotton	O
leaves	O
in	O
the	O
salt	B-Chemical
dust	O
treatment	O
groups	O
all	O
showed	O
a	O
decreasing	O
trend	O
compared	O
to	O
the	O
control	O
with	O
significant	O
differences	O
between	O
groups	O
A	O
and	O
(	O
B	O
","	O
C	O
"),"	O
and	O
D	O
","	O
and	O
E	O
","	O
and	O
F	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
groups	O
B	O
and	O
C	O
.	O
Effect	O
of	O
different	O
salt	B-Chemical
dust	O
treatments	O
on	O
the	O
net	O
rate	O
of	O
photosynthesis	O
(	O
P	O
n	O
)	O
and	O
efficiency	O
of	O
light	O
use	O
(	O
PE	O
)	O
by	O
the	O
cotton	O
leaves	O
.	O
Samples	O
within	O
one	O
index	O
with	O
different	O
lowercase	O
letters	O
a	O
","	O
b	O
","	O
c	O
","	O
d	O
and	O
e	O
had	O
significant	O
differences	O
between	O
different	O
salt	B-Chemical
dust	O
treatment	O
groups	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
while	O
samples	O
with	O
matching	O
lowercase	O
letters	O
had	O
no	O
significant	O
differences	O
.	O
Average	O
gas	O
exchange	O
indexes	O
of	O
the	O
cotton	O
blades	O
of	O
the	O
control	O
and	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
(	O
Mean	O
Â±	O
SE	O
)	O
(	O
n	O
=	O
6	O
).	O
Transpiration	O
rate	O
(	O
T	O
r	O
)	O
and	O
water	B-Chemical
use	O
efficiency	O
(	O
WUE	O
)	O
changes	O
in	O
the	O
cotton	O
leaves	O
As	O
shown	O
in	O
Fig	O
8	O
","	O
ANOVA	O
showed	O
that	O
the	O
salt	B-Chemical
dust	O
deposition	O
had	O
significant	O
influence	O
on	O
T	O
r	O
and	O
WUE	O
values	O
of	O
the	O
surface	O
cotton	O
leaves	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
and	O
the	O
differences	O
among	O
these	O
groups	O
are	O
significant	O
","	O
then	O
the	O
LSD	O
test	O
showed	O
that	O
(	O
Table	O
1	O
"),"	O
T	O
r	O
and	O
WUE	O
of	O
the	O
cotton	O
leaves	O
decreased	O
in	O
the	O
five	O
salt	B-Chemical
dust	O
treated	O
groups	O
compared	O
to	O
the	O
control	O
with	O
significant	O
differences	O
between	O
the	O
groups	O
of	O
A	O
","	O
and	O
(	O
B	O
and	O
C	O
"),"	O
and	O
(	O
D	O
"),"	O
(	O
E	O
and	O
F	O
)	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
However	O
","	O
there	O
were	O
no	O
significant	O
difference	O
in	O
T	O
r	O
and	O
WUE	O
of	O
the	O
cotton	O
leaves	O
between	O
salt	B-Chemical
dust	O
treated	O
groups	O
(	O
B	O
and	O
C	O
"),"	O
and	O
(	O
E	O
and	O
F	O
"),"	O
respectively	O
.	O
Effect	O
of	O
different	O
salt	B-Chemical
dust	O
treatments	O
on	O
the	O
rate	O
of	O
transpiration	O
(	O
T	O
r	O
)	O
of	O
and	O
efficiency	O
of	O
water	B-Chemical
use	O
(	O
WUE	O
)	O
by	O
the	O
cotton	O
leaves	O
.	O
Changes	O
in	O
the	O
G	O
s	O
and	O
L	O
s	O
of	O
the	O
cotton	O
canopy	O
As	O
shown	O
in	O
Fig	O
9	O
","	O
the	O
G	O
s	O
and	O
L	O
s	O
of	O
the	O
cotton	O
leaves	O
in	O
all	O
the	O
groups	O
displayed	O
an	O
â€œ	O
M	O
â€	O
phenomenon	O
.	O
This	O
analysis	O
showed	O
that	O
compared	O
to	O
the	O
control	O
","	O
the	O
G	O
s	O
and	O
L	O
s	O
of	O
the	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
decreased	O
from	O
100	O
g	O
.	O
m	O
-	O
2	O
to	O
500	O
g	O
.	O
m	O
-	O
2	O
.	O
The	O
LSD	O
test	O
showed	O
that	O
there	O
were	O
significant	O
differences	O
in	O
the	O
daily	O
mean	O
G	O
s	O
and	O
L	O
s	O
values	O
between	O
groups	O
A	O
and	O
(	O
B	O
and	O
C	O
"),"	O
and	O
(	O
D	O
and	O
E	O
)	O
and	O
(	O
F	O
)	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
salt	B-Chemical
dust	O
groups	O
(	O
B	O
and	O
C	O
"),"	O
and	O
(	O
D	O
and	O
E	O
"),"	O
respectively	O
.	O
Effect	O
of	O
different	O
salt	B-Chemical
dust	O
treatments	O
on	O
the	O
stomatal	O
conductance	O
(	O
G	O
s	O
)	O
and	O
the	O
limiting	O
value	O
of	O
the	O
stomata	O
(	O
L	O
s	O
)	O
of	O
the	O
cotton	O
leaves	O
.	O
Changes	O
in	O
the	O
C	O
i	O
and	O
T	O
l	O
of	O
the	O
cotton	O
canopy	O
As	O
shown	O
in	O
Fig	O
10	O
","	O
there	O
was	O
a	O
decrease	O
in	O
the	O
C	O
i	O
and	O
T	O
i	O
each	O
day	O
in	O
the	O
salt	B-Chemical
dust	O
treatment	O
groups	O
compared	O
to	O
the	O
control	O
.	O
All	O
the	O
groups	O
displayed	O
a	O
â€œ	O
single	O
peak	O
â€	O
phenomonon	O
for	O
the	O
C	O
i	O
and	O
T	O
i	O
.	O
The	O
further	O
LSD	O
test	O
showed	O
that	O
there	O
were	O
significant	O
differences	O
between	O
the	O
control	O
and	O
five	O
salt	B-Chemical
dust	O
sediment	O
groups	O
(	O
P	O
<	O
0	O
.	O
5	O
)	O
(	O
Table	O
1	O
"),"	O
with	O
significant	O
differences	O
between	O
groups	O
A	O
and	O
(	O
B	O
and	O
C	O
"),"	O
and	O
(	O
D	O
","	O
E	O
and	O
F	O
)(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
no	O
significant	O
differences	O
between	O
(	O
B	O
and	O
C	O
"),"	O
and	O
(	O
D	O
","	O
E	O
and	O
F	O
)	O
groups	O
","	O
respectively	O
.	O
Effect	O
of	O
different	O
salt	B-Chemical
dust	O
treatments	O
on	O
the	O
intercellular	O
CO2	B-Chemical
concentration	O
(	O
C	O
i	O
)	O
and	O
temperature	O
(	O
T	O
l	O
)	O
of	O
the	O
cotton	O
leaves	O
.	O
Changes	O
in	O
the	O
light	O
response	O
model	O
parameters	O
of	O
the	O
cotton	O
canopy	O
In	O
order	O
to	O
determine	O
the	O
impact	O
of	O
the	O
salt	B-Chemical
dust	O
on	O
the	O
cotton	O
canopy	O
","	O
we	O
used	O
the	O
light	O
response	O
curve	O
model	O
"[,]."	O
First	O
","	O
we	O
calculated	O
the	O
maximum	O
net	O
photosynthetic	O
rate	O
(	O
A	O
max	O
)	O
and	O
the	O
related	O
parameters	O
and	O
we	O
generated	O
a	O
straight	O
line	O
parallel	O
to	O
the	O
X	O
-	O
axis	O
.	O
Then	O
","	O
we	O
calculated	O
the	O
intersection	O
point	O
of	O
these	O
two	O
straight	O
lines	O
","	O
which	O
corresponds	O
to	O
the	O
light	O
saturation	O
point	O
.	O
The	O
results	O
showed	O
significant	O
differences	O
in	O
the	O
curved	O
angle	O
(	O
K	O
"),"	O
apparent	O
quantum	O
efficiency	O
(	O
Ï†	O
"),"	O
net	O
photosynthetic	O
rate	O
(	O
Amax	O
)	O
and	O
respiratory	O
rate	O
(	O
R	O
ady	O
)	O
between	O
the	O
control	O
and	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
.	O
The	O
K	O
","	O
Ï†	O
","	O
A	O
max	O
and	O
R	O
ady	O
all	O
decreased	O
in	O
the	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
going	O
from	O
100g	O
.	O
m	O
-	O
2	O
to	O
500	O
g	O
.	O
m	O
-	O
2	O
.	O
ANOVA	O
showed	O
that	O
the	O
salt	B-Chemical
dust	O
deposition	O
had	O
significant	O
influence	O
on	O
K	O
","	O
Ï†	O
","	O
A	O
max	O
and	O
R	O
ady	O
values	O
of	O
different	O
groups	O
(	O
Table	O
2	O
"),"	O
the	O
LSD	O
test	O
showed	O
that	O
among	O
five	O
salt	B-Chemical
dust	O
groups	O
and	O
the	O
control	O
group	O
","	O
there	O
were	O
significant	O
differences	O
between	O
A	O
and	O
(	O
B	O
","	O
C	O
)	O
and	O
D	O
","	O
and	O
E	O
and	O
F	O
groups	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
there	O
was	O
little	O
difference	O
between	O
B	O
and	O
C	O
groups	O
(	O
100	O
g	O
.	O
m	O
-	O
2	O
and	O
200	O
g	O
.	O
m	O
-	O
2	O
).	O
Samples	O
within	O
one	O
index	O
with	O
different	O
lowercase	O
letters	O
a	O
","	O
b	O
","	O
c	O
","	O
d	O
and	O
e	O
had	O
significant	O
differences	O
between	O
different	O
salt	B-Chemical
dust	O
treatment	O
groups	O
","	O
while	O
samples	O
with	O
matching	O
lowercase	O
letters	O
had	O
no	O
significant	O
differences	O
.	O
The	O
light	O
response	O
model	O
parameters	O
of	O
the	O
cotton	O
leaves	O
.	O
Changes	O
in	O
the	O
chlorophyll	B-Chemical
","	O
carotenoid	B-Chemical
","	O
soluble	O
sugar	B-Chemical
and	O
proline	B-Chemical
content	O
in	O
the	O
cotton	O
leaves	O
The	O
amount	O
of	O
chlorophyll	B-Chemical
in	O
plant	O
leaves	O
can	O
directly	O
influence	O
the	O
photosynthetic	O
intensity	O
to	O
a	O
certain	O
extent	O
.	O
The	O
discretion	O
of	O
the	O
chlorophyll	B-Chemical
content	O
of	O
the	O
plant	O
leaves	O
is	O
also	O
an	O
important	O
symbol	O
about	O
the	O
leaf	O
function	O
continuous	O
length	O
.	O
By	O
testing	O
the	O
total	O
chlorophyll	B-Chemical
content	O
in	O
the	O
cotton	O
leaves	O
from	O
different	O
salt	B-Chemical
dust	O
treatment	O
groups	O
","	O
we	O
found	O
that	O
","	O
compared	O
to	O
the	O
control	O
group	O
","	O
the	O
levels	O
of	O
chorophyll	B-Chemical
decreased	O
for	O
the	O
five	O
salt	B-Chemical
dust	O
deposition	O
groups	O
from	O
100	O
g	O
.	O
m	O
-	O
2	O
to	O
500	O
g	O
.	O
m	O
-	O
2	O
.	O
The	O
most	O
significant	O
difference	O
appeared	O
between	O
100	O
g	O
.	O
m	O
-	O
2	O
and	O
200	O
g	O
.	O
m	O
-	O
2	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
Among	O
the	O
five	O
salt	B-Chemical
dust	O
groups	O
and	O
the	O
control	O
group	O
","	O
there	O
were	O
significant	O
differences	O
in	O
the	O
mean	O
value	O
of	O
the	O
chlorophyll	B-Chemical
beween	O
groups	O
(	O
A	O
","	O
B	O
)	O
and	O
(	O
C	O
","	O
D	O
","	O
E	O
and	O
F	O
)(	O
Fig	O
11	O
"),"	O
but	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
salt	B-Chemical
dust	O
groups	O
(	O
A	O
","	O
B	O
)	O
and	O
(	O
C	O
","	O
D	O
","	O
E	O
","	O
and	O
F	O
"),"	O
respectively	O
.	O
Changes	O
in	O
quantities	O
of	O
chlorophyll	B-Chemical
","	O
carotenoids	B-Chemical
","	O
soluble	O
sugars	B-Chemical
and	O
proline	B-Chemical
in	O
the	O
cotton	O
leaves	O
.	O
Normally	O
","	O
carotenoids	B-Chemical
are	O
widely	O
distributed	O
and	O
heavily	O
synthesized	O
during	O
higher	O
plant	O
photosynthesis	O
and	O
in	O
photosynthetic	O
tissues	O
","	O
including	O
leaves	O
","	O
flowers	O
","	O
fruit	O
and	O
roots	O
","	O
as	O
well	O
as	O
in	O
microbes	O
","	O
including	O
algae	O
and	O
photosynthetic	O
bacteria	O
.	O
These	O
carotenoids	B-Chemical
are	O
important	O
photosynthetic	O
auxiliary	O
materials	O
that	O
can	O
supplement	O
the	O
chlorophyll	B-Chemical
content	O
of	O
the	O
plant	O
leaves	O
","	O
and	O
assist	O
during	O
plant	O
photosynthesis	O
"[,]."	O
How	O
high	O
or	O
low	O
the	O
carotenoid	B-Chemical
content	O
in	O
a	O
plant	O
can	O
be	O
an	O
indicator	O
of	O
the	O
strength	O
of	O
the	O
plant	O
leaf	O
photosynthesis	O
.	O
By	O
measuring	O
the	O
carotenoid	B-Chemical
levels	O
of	O
the	O
cotton	O
leaves	O
from	O
different	O
salt	B-Chemical
dust	O
treatment	O
groups	O
","	O
we	O
found	O
that	O
with	O
increasing	O
salt	B-Chemical
dust	O
deposition	O
","	O
the	O
carotenoid	B-Chemical
content	O
increased	O
as	O
compared	O
to	O
the	O
control	O
.	O
Among	O
five	O
salt	B-Chemical
dust	O
groups	O
and	O
the	O
control	O
group	O
","	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
B	O
","	O
C	O
","	O
D	O
","	O
E	O
and	O
F	O
(	O
Fig	O
11	O
).	O
Soluble	O
sugars	B-Chemical
are	O
the	O
primary	O
products	O
of	O
photosynthesis	O
in	O
higher	O
plants	O
","	O
they	O
can	O
form	O
the	O
starch	B-Chemical
","	O
fat	B-Chemical
","	O
protein	O
","	O
fiber	O
and	O
other	O
compounds	O
of	O
the	O
plant	O
","	O
and	O
they	O
can	O
maintain	O
the	O
carbon	B-Chemical
and	O
nitrogen	B-Chemical
metabolism	O
during	O
the	O
growth	O
period	O
of	O
the	O
plants	O
.	O
They	O
are	O
also	O
part	O
of	O
a	O
class	O
of	O
osmotic	O
regulation	O
substances	O
","	O
which	O
are	O
known	O
to	O
play	O
a	O
significant	O
role	O
in	O
plant	O
growth	O
and	O
development	O
[].	O
By	O
testing	O
the	O
soluble	O
sugar	B-Chemical
in	O
the	O
cotton	O
leaves	O
of	O
salt	B-Chemical
dust	O
treatment	O
groups	O
and	O
the	O
control	O
","	O
we	O
found	O
that	O
as	O
salt	B-Chemical
dust	O
deposition	O
increased	O
","	O
the	O
soluble	O
sugar	B-Chemical
content	O
of	O
the	O
cotton	O
leaves	O
also	O
increased	O
with	O
the	O
most	O
significant	O
differences	O
appearing	O
between	O
the	O
0	O
g	O
.	O
m	O
-	O
2	O
and	O
100	O
g	O
.	O
m	O
-	O
2	O
groups	O
(	O
P	O
<	O
0	O
.	O
5	O
)	O
(	O
Fig	O
11	O
).	O
Among	O
five	O
salt	B-Chemical
dust	O
groups	O
and	O
the	O
control	O
group	O
","	O
there	O
were	O
significant	O
differences	O
in	O
the	O
mean	O
value	O
of	O
the	O
the	O
soluble	O
sugar	B-Chemical
content	O
beween	O
groups	O
A	O
","	O
and	O
B	O
","	O
and	O
(	O
C	O
","	O
D	O
","	O
E	O
and	O
F	O
"),"	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
groups	O
C	O
","	O
D	O
","	O
E	O
and	O
F	O
"),"	O
respectively	O
.	O
Proline	B-Chemical
is	O
one	O
of	O
the	O
most	O
widely	O
distributed	O
osmotic	O
substances	O
","	O
and	O
","	O
under	O
stress	O
","	O
the	O
plants	O
increase	O
the	O
synthesis	O
and	O
decrease	O
the	O
degradation	O
.	O
This	O
result	O
in	O
an	O
accumulation	O
of	O
a	O
large	O
amount	O
of	O
proline	B-Chemical
in	O
the	O
plant	O
body	O
that	O
can	O
help	O
adjust	O
the	O
osmotic	O
balance	O
and	O
reduce	O
the	O
harm	O
to	O
the	O
plants	O
caused	O
by	O
osmotic	O
stress	O
by	O
scavenging	O
free	B-Chemical
radicals	I-Chemical
and	O
protecting	O
the	O
plant	O
cell	O
structure	O
[].	O
From	O
this	O
analysis	O
","	O
it	O
was	O
determined	O
that	O
with	O
increased	O
salt	B-Chemical
dust	O
deposition	O
","	O
the	O
proline	B-Chemical
content	O
in	O
the	O
cotton	O
leaves	O
showed	O
increasing	O
trends	O
with	O
the	O
most	O
significant	O
difference	O
appearing	O
between	O
200	O
g	O
.	O
m	O
-	O
2	O
and	O
300	O
g	O
.	O
m	O
-	O
2	O
(	O
P	O
<	O
0	O
.	O
5	O
)	O
(	O
Fig	O
11	O
).	O
Among	O
five	O
salt	B-Chemical
dust	O
groups	O
and	O
the	O
control	O
group	O
","	O
there	O
were	O
significant	O
differences	O
in	O
the	O
mean	O
value	O
of	O
the	O
proline	B-Chemical
content	O
beween	O
groups	O
(	O
A	O
","	O
B	O
and	O
C	O
"),"	O
and	O
(	O
D	O
","	O
E	O
and	O
F	O
"),"	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
salt	B-Chemical
dust	O
groups	O
(	O
A	O
","	O
B	O
and	O
C	O
)	O
and	O
(	O
D	O
","	O
E	O
and	O
F	O
"),"	O
respectively	O
.	O
Changes	O
in	O
the	O
MDA	B-Chemical
content	O
and	O
the	O
activity	O
of	O
antioxidant	O
enzymes	O
in	O
the	O
cotton	O
leaves	O
MDA	B-Chemical
is	O
common	O
membrane	O
of	O
lipid	B-Chemical
peroxide	I-Chemical
and	O
can	O
be	O
an	O
indicator	O
of	O
the	O
plant	O
membrane	B-Chemical
lipid	I-Chemical
peroxidation	O
","	O
which	O
can	O
change	O
under	O
conditions	O
of	O
stress	O
such	O
as	O
drought	O
","	O
high	O
temperature	O
and	O
salt	B-Chemical
stress	O
","	O
under	O
which	O
the	O
active	B-Chemical
oxygen	I-Chemical
balance	O
is	O
disrupted	O
and	O
plant	O
cells	O
are	O
damaged	O
.	O
Therefore	O
","	O
the	O
MDA	B-Chemical
content	O
in	O
plant	O
can	O
reflect	O
the	O
degree	O
of	O
the	O
membrane	B-Chemical
lipid	I-Chemical
peroxidation	O
of	O
plant	O
cells	O
.	O
The	O
analysis	O
performed	O
in	O
this	O
work	O
determined	O
that	O
when	O
the	O
salt	B-Chemical
dust	O
deposition	O
increased	O
","	O
the	O
MDA	B-Chemical
content	O
of	O
the	O
cotton	O
leaves	O
increased	O
with	O
the	O
most	O
significant	O
difference	O
occurring	O
between	O
200	O
g	O
.	O
m	O
-	O
2	O
and	O
300	O
g	O
.	O
m	O
-	O
2	O
(	O
P	O
<	O
0	O
.	O
5	O
)	O
(	O
Fig	O
12	O
).	O
Among	O
five	O
salt	B-Chemical
dust	O
groups	O
and	O
the	O
control	O
group	O
","	O
there	O
were	O
significant	O
differences	O
in	O
the	O
mean	O
value	O
of	O
the	O
MDA	B-Chemical
content	O
beween	O
groups	O
(	O
A	O
","	O
B	O
"),"	O
and	O
C	O
","	O
and	O
(	O
D	O
","	O
E	O
","	O
and	O
F	O
"),"	O
while	O
there	O
were	O
no	O
significant	O
differences	O
beween	O
groups	O
(	O
A	O
","	O
B	O
"),"	O
and	O
(	O
D	O
","	O
E	O
","	O
and	O
F	O
"),"	O
respectively	O
.	O
Changes	O
in	O
malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
and	O
antioxidant	O
enzyme	O
activity	O
in	O
the	O
cotton	O
leaves	O
.	O
SOD	O
is	O
a	O
protein	O
with	O
physiological	O
activity	O
that	O
can	O
eliminate	O
harmful	O
metabolites	O
.	O
It	O
is	O
also	O
an	O
antioxidant	O
","	O
which	O
can	O
prevent	O
and	O
repair	O
the	O
damaged	O
cells	O
","	O
and	O
remove	O
free	B-Chemical
radicals	I-Chemical
from	O
the	O
plant	O
","	O
especially	O
the	O
oxygen	B-Chemical
free	I-Chemical
radicals	I-Chemical
","	O
and	O
oxidize	O
them	O
as	O
peroxide	B-Chemical
oxygen	I-Chemical
.	O
Therefore	O
","	O
the	O
SOD	O
activity	O
in	O
the	O
plant	O
tissue	O
can	O
reflect	O
the	O
strength	O
of	O
the	O
plant	O
resistance	O
when	O
in	O
a	O
stressful	O
environment	O
[].	O
In	O
this	O
work	O
","	O
it	O
was	O
found	O
that	O
with	O
increased	O
salt	B-Chemical
dust	O
deposition	O
","	O
the	O
SOD	O
content	O
of	O
the	O
cotton	O
leaves	O
increased	O
with	O
the	O
most	O
significant	O
difference	O
appearing	O
between	O
200	O
g	O
.	O
m	O
-	O
2	O
and	O
300	O
g	O
.	O
m	O
-	O
2	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
Among	O
five	O
salt	B-Chemical
dust	O
groups	O
and	O
the	O
control	O
group	O
","	O
there	O
were	O
significant	O
differences	O
in	O
the	O
mean	O
value	O
of	O
the	O
SOD	O
content	O
beween	O
groups	O
(	O
A	O
","	O
B	O
and	O
C	O
)	O
and	O
(	O
D	O
","	O
E	O
and	O
F	O
)	O
(	O
P	O
<	O
0	O
.	O
5	O
"),"	O
but	O
no	O
significant	O
differences	O
were	O
found	O
between	O
groups	O
(	O
A	O
","	O
B	O
and	O
C	O
)	O
and	O
(	O
D	O
","	O
E	O
and	O
F	O
"),"	O
respectively	O
.	O
POD	O
is	O
a	O
redox	O
enzyme	O
that	O
uses	O
peroxide	B-Chemical
as	O
an	O
electron	O
acceptor	O
","	O
and	O
is	O
oxidized	O
by	O
the	O
catalysis	O
of	O
substrates	O
.	O
It	O
can	O
also	O
catalyze	O
peroxide	B-Chemical
and	O
oxidize	O
amines	B-Chemical
to	O
remove	O
the	O
toxicity	O
of	O
the	O
amine	B-Chemical
and	O
peroxide	B-Chemical
oxygen	I-Chemical
.	O
It	O
also	O
has	O
a	O
close	O
relationship	O
with	O
respiration	O
and	O
photosynthesis	O
in	O
plants	O
[].	O
This	O
analysis	O
found	O
as	O
salt	B-Chemical
dust	O
deposition	O
increased	O
from	O
100	O
g	O
.	O
m	O
-	O
2	O
to	O
500	O
g	O
.	O
m	O
-	O
2	O
","	O
the	O
POD	O
content	O
in	O
the	O
cotton	O
leaves	O
increased	O
with	O
the	O
most	O
significant	O
difference	O
appearing	O
between	O
0	O
g	O
.	O
m	O
-	O
2	O
and	O
100	O
g	O
.	O
m	O
-	O
2	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
Among	O
five	O
salt	B-Chemical
dust	O
groups	O
and	O
the	O
control	O
group	O
","	O
there	O
were	O
significant	O
differences	O
in	O
the	O
mean	O
POD	O
values	O
beween	O
groups	O
A	O
","	O
and	O
(	O
B	O
","	O
C	O
","	O
and	O
D	O
"),"	O
and	O
(	O
E	O
and	O
F	O
"),"	O
but	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
groups	O
of	O
(	O
B	O
","	O
C	O
and	O
D	O
)	O
and	O
(	O
E	O
and	O
F	O
"),"	O
respectively	O
.	O
CAT	O
resides	O
in	O
the	O
chloroplasts	O
","	O
mitochondria	O
and	O
endoplasmic	O
reticulum	O
of	O
cells	O
","	O
and	O
is	O
especially	O
concentrated	O
in	O
the	O
body	O
of	O
POD	O
.	O
It	O
is	O
an	O
enzyme	O
scavenger	O
that	O
can	O
catalyze	O
peroxide	B-Chemical
oxygen	I-Chemical
into	O
oxygen	B-Chemical
and	O
water	B-Chemical
","	O
thereby	O
removing	O
peroxide	B-Chemical
oxygen	I-Chemical
from	O
the	O
plant	O
body	O
and	O
preventing	O
H2O2	B-Chemical
poisoning	O
of	O
the	O
cells	O
.	O
Therefore	O
","	O
it	O
has	O
antioxidant	O
properties	O
.	O
This	O
analysis	O
found	O
that	O
as	O
salt	B-Chemical
dust	O
deposition	O
increased	O
from	O
100	O
g	O
.	O
m	O
-	O
2	O
to	O
500	O
g	O
.	O
m	O
-	O
2	O
","	O
the	O
CAT	O
content	O
in	O
the	O
cotton	O
leaves	O
increased	O
with	O
the	O
most	O
significant	O
difference	O
appearing	O
between	O
300	O
g	O
.	O
m	O
-	O
2	O
and	O
400	O
g	O
.	O
m	O
-	O
2	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
Among	O
five	O
salt	B-Chemical
dust	O
groups	O
and	O
the	O
control	O
group	O
","	O
there	O
were	O
significant	O
differences	O
in	O
the	O
mean	O
value	O
of	O
the	O
CAT	O
content	O
beween	O
groups	O
(	O
A	O
","	O
B	O
and	O
C	O
"),"	O
and	O
(	O
D	O
"),"	O
and	O
(	O
E	O
","	O
F	O
"),"	O
there	O
were	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
groups	O
(	O
A	O
","	O
B	O
and	O
C	O
"),"	O
(	O
E	O
and	O
F	O
"),"	O
respectively	O
.	O
Discussion	O
By	O
testing	O
the	O
salt	B-Chemical
ion	I-Chemical
content	O
","	O
it	O
was	O
determined	O
that	O
the	O
composition	O
and	O
sizes	O
of	O
the	O
particles	O
in	O
the	O
salt	B-Chemical
dust	O
were	O
similar	O
to	O
the	O
physical	O
and	O
the	O
chemical	O
properties	O
of	O
the	O
natural	O
salt	B-Chemical
dust	O
as	O
described	O
by	O
Liu	O
et	O
al	O
.	O
[]	O
and	O
Jilili	O
and	O
Mu	O
[].	O
This	O
indicates	O
the	O
salt	B-Chemical
dust	O
used	O
in	O
these	O
experiments	O
reflects	O
the	O
natural	O
salt	B-Chemical
dust	O
found	O
on	O
cotton	O
leaves	O
in	O
the	O
region	O
of	O
interest	O
.	O
Using	O
SEM	O
imaging	O
","	O
it	O
was	O
seen	O
the	O
salt	B-Chemical
dust	O
sedimentation	O
covered	O
an	O
area	O
on	O
the	O
cotton	O
leaves	O
and	O
directly	O
affected	O
photosynthesis	O
","	O
respiration	O
","	O
transpiration	O
and	O
stomatal	O
conductance	O
.	O
Furthermore	O
","	O
the	O
smaller	O
particles	O
in	O
the	O
salt	B-Chemical
dust	O
could	O
fall	O
into	O
the	O
stomata	O
of	O
the	O
cotton	O
leaves	O
","	O
directly	O
conveying	O
the	O
salt	B-Chemical
ions	I-Chemical
and	O
other	O
elements	O
","	O
such	O
as	O
heavy	B-Chemical
metals	I-Chemical
","	O
into	O
the	O
plant	O
leaves	O
","	O
and	O
increasing	O
the	O
salt	B-Chemical
ions	I-Chemical
inside	O
the	O
cotton	O
leaves	O
.	O
Work	O
by	O
Micklin	O
[]	O
found	O
that	O
the	O
dust	O
can	O
cover	O
areas	O
on	O
plant	O
leaves	O
","	O
which	O
can	O
cause	O
a	O
significant	O
decrease	O
in	O
photosynthesis	O
by	O
the	O
cotton	O
leaves	O
.	O
McTainsh	O
and	O
Strong	O
[]	O
determined	O
that	O
tiny	O
dust	O
particles	O
can	O
cover	O
plant	O
leaf	O
stomata	O
specifically	O
and	O
","	O
thereby	O
","	O
affect	O
foliar	O
respiration	O
","	O
photosynthesis	O
and	O
transpiration	O
in	O
the	O
plant	O
leaves	O
.	O
A	O
study	O
by	O
Gao	O
et	O
al	O
.	O
[]	O
showed	O
that	O
after	O
dust	O
fell	O
into	O
the	O
plant	O
stomata	O
","	O
salt	B-Chemical
ions	I-Chemical
within	O
the	O
salt	B-Chemical
dust	O
entered	O
the	O
plant	O
and	O
joined	O
into	O
the	O
plant	O
nutrient	O
cycle	O
","	O
thus	O
increasing	O
the	O
Na	B-Chemical
+	I-Chemical
and	O
Cl	B-Chemical
-	I-Chemical
content	O
inside	O
the	O
plant	O
leaves	O
.	O
Previous	O
work	O
revealed	O
that	O
","	O
if	O
the	O
salt	B-Chemical
ions	I-Chemical
forming	O
the	O
dust	O
on	O
the	O
surface	O
of	O
the	O
plant	O
leaves	O
reach	O
a	O
threshold	O
value	O
inside	O
the	O
plant	O
leaves	O
","	O
ions	O
are	O
produced	O
that	O
poison	O
the	O
plants	O
and	O
harm	O
plant	O
normal	O
physiological	O
functions	O
","	O
thus	O
influencing	O
plant	O
growth	O
and	O
development	O
.	O
From	O
the	O
analysis	O
performed	O
in	O
this	O
work	O
","	O
we	O
determined	O
the	O
order	O
of	O
the	O
salt	B-Chemical
ions	I-Chemical
inside	O
the	O
cotton	O
leaves	O
of	O
the	O
control	O
and	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
:	O
Na	B-Chemical
+>	I-Chemical
Ca2	I-Chemical
+>	I-Chemical
Mg2	I-Chemical
+>	I-Chemical
K	I-Chemical
"+,"	I-Chemical
while	O
the	O
order	O
of	O
the	O
salt	B-Chemical
anions	O
on	O
the	O
surface	O
and	O
inside	O
the	O
cotton	O
leaves	O
was	O
Cl	B-Chemical
->	I-Chemical
SO4	I-Chemical
2	I-Chemical
->	I-Chemical
HCO3	I-Chemical
->	I-Chemical
CO3	I-Chemical
-.	I-Chemical
It	O
was	O
found	O
that	O
in	O
this	O
work	O
","	O
due	O
to	O
their	O
high	O
permeability	O
","	O
Na	B-Chemical
+	I-Chemical
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
was	O
the	O
large	O
contributor	O
to	O
the	O
salt	B-Chemical
ion	I-Chemical
content	O
inside	O
the	O
cotton	O
leaves	O
[].	O
This	O
is	O
in	O
contrast	O
to	O
the	O
high	O
amount	O
of	O
K	B-Chemical
+	I-Chemical
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
","	O
yet	O
little	O
K	B-Chemical
+	I-Chemical
inside	O
the	O
cotton	O
leaves	O
"[,]."	O
According	O
to	O
work	O
done	O
by	O
Tuerxun	O
et	O
al	O
.	O
"[],"	O
when	O
the	O
soil	O
supply	O
is	O
deficient	O
in	O
potassium	B-Chemical
","	O
there	O
will	O
be	O
a	O
low	O
concentration	O
of	O
K	B-Chemical
+	I-Chemical
in	O
the	O
plant	O
cells	O
.	O
In	O
order	O
to	O
maintain	O
normal	O
cell	O
turgor	O
pressure	O
and	O
functioning	O
of	O
the	O
plant	O
","	O
Na	B-Chemical
+	I-Chemical
contained	O
within	O
the	O
plants	O
can	O
partially	O
make	O
up	O
for	O
the	O
lack	O
of	O
K	B-Chemical
+	I-Chemical
and	O
relieve	O
the	O
symptoms	O
of	O
potassium	B-Chemical
deficiency	O
","	O
suggesting	O
an	O
accumulation	O
of	O
Na	B-Chemical
+	I-Chemical
inside	O
the	O
leaves	O
.	O
Previous	O
research	O
has	O
shown	O
that	O
K	B-Chemical
+	I-Chemical
ions	O
have	O
low	O
permeability	O
","	O
therefore	O
","	O
when	O
salt	B-Chemical
dust	O
lands	O
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
","	O
it	O
enters	O
inside	O
the	O
cotton	O
leaf	O
at	O
a	O
lower	O
rate	O
than	O
the	O
Na	B-Chemical
+	I-Chemical
ions	O
.	O
This	O
also	O
indicates	O
the	O
K	B-Chemical
+	I-Chemical
inside	O
the	O
leaves	O
may	O
come	O
from	O
the	O
soil	O
after	O
being	O
absorbed	O
by	O
the	O
cotton	O
plant	O
roots	O
"[,]."	O
By	O
comparison	O
","	O
Cl	B-Chemical
-	I-Chemical
and	O
SO4	B-Chemical
2	I-Chemical
-	I-Chemical
can	O
be	O
easily	O
absorbed	O
by	O
the	O
cotton	O
leaves	O
"[,,â€“]."	O
In	O
this	O
study	O
","	O
we	O
also	O
found	O
a	O
higher	O
content	O
of	O
Cl	B-Chemical
-	I-Chemical
inside	O
the	O
cotton	O
leaves	O
that	O
came	O
from	O
salt	B-Chemical
dust	O
settling	O
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
.	O
Additionally	O
","	O
Cl	B-Chemical
-	I-Chemical
may	O
come	O
from	O
the	O
soil	O
when	O
absorbed	O
by	O
the	O
cotton	O
plant	O
roots	O
and	O
transferred	O
to	O
the	O
leaves	O
.	O
This	O
may	O
explain	O
why	O
in	O
this	O
study	O
some	O
of	O
the	O
cotton	O
leaves	O
turned	O
yellow	O
in	O
the	O
500	O
g	O
.	O
m	O
-	O
2	O
salt	B-Chemical
dust	O
deposition	O
group	O
.	O
The	O
high	O
content	O
of	O
Na	B-Chemical
+	I-Chemical
and	O
Cl	B-Chemical
-	I-Chemical
absorbed	O
by	O
the	O
roots	O
from	O
the	O
soil	O
and	O
salt	B-Chemical
dust	O
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
accumulated	O
and	O
turned	O
the	O
plant	O
leaves	O
yellow	O
","	O
which	O
is	O
consistent	O
with	O
previous	O
research	O
"[,,,]."	O
In	O
this	O
work	O
","	O
we	O
found	O
little	O
difference	O
between	O
the	O
HCO3	B-Chemical
-	I-Chemical
and	O
CO3	B-Chemical
-	I-Chemical
on	O
the	O
surface	O
and	O
inside	O
the	O
cotton	O
leaves	O
","	O
and	O
the	O
overall	O
amount	O
present	O
was	O
very	O
low	O
on	O
both	O
the	O
surface	O
and	O
inside	O
the	O
leaves	O
","	O
indicating	O
HCO3	B-Chemical
-	I-Chemical
and	O
CO3	B-Chemical
-	I-Chemical
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
contributed	O
little	O
to	O
the	O
inside	O
of	O
the	O
cotton	O
leaves	O
.	O
Previous	O
studies	O
have	O
found	O
that	O
HCO3	B-Chemical
-	I-Chemical
and	O
CO3	B-Chemical
-	I-Chemical
have	O
low	O
permeability	O
and	O
","	O
therefore	O
","	O
do	O
not	O
get	O
inside	O
the	O
plants	O
as	O
easily	O
as	O
Na	B-Chemical
+	I-Chemical
and	O
Cl	B-Chemical
-	I-Chemical
"[,]."	O
Plant	O
leaf	O
photosynthesis	O
is	O
very	O
sensitive	O
to	O
environmental	O
changes	O
[â€“]	O
and	O
can	O
be	O
influenced	O
by	O
many	O
environmental	O
factors	O
","	O
such	O
as	O
light	O
intensity	O
","	O
temperature	O
","	O
moisture	O
and	O
salt	B-Chemical
stress	O
"[,â€“]."	O
Salt	B-Chemical
dust	O
deposition	O
poses	O
a	O
challenge	O
to	O
the	O
plant	O
.	O
Previous	O
work	O
has	O
shown	O
that	O
when	O
a	O
certain	O
amount	O
of	O
substance	O
landed	O
on	O
the	O
plant	O
surface	O
","	O
plant	O
photosynthesis	O
was	O
affected	O
In	O
this	O
work	O
","	O
we	O
determined	O
that	O
salt	B-Chemical
dust	O
can	O
have	O
a	O
significant	O
impact	O
on	O
the	O
physiological	O
characteristics	O
of	O
cotton	O
","	O
and	O
","	O
compared	O
to	O
the	O
control	O
","	O
there	O
were	O
significant	O
changes	O
in	O
the	O
photosynthetic	O
characteristics	O
indexes	O
of	O
P	O
n	O
","	O
PE	O
","	O
C	O
i	O
T	O
i	O
","	O
G	O
s	O
","	O
L	O
s	O
","	O
T	O
r	O
and	O
WUE	O
of	O
the	O
cotton	O
leaves	O
","	O
as	O
well	O
as	O
in	O
K	O
","	O
Ï†	O
","	O
A	O
max	O
and	O
R	O
ady	O
in	O
the	O
cotton	O
leaves	O
from	O
the	O
salt	B-Chemical
dust	O
treated	O
groups	O
.	O
Many	O
studies	O
have	O
found	O
that	O
an	O
increase	O
in	O
salt	B-Chemical
ion	I-Chemical
content	O
in	O
the	O
sand	O
and	O
dust	O
that	O
landed	O
on	O
the	O
surface	O
of	O
the	O
plant	O
leaves	O
causes	O
a	O
decreae	O
in	O
most	O
of	O
the	O
physiological	O
indexes	O
","	O
such	O
as	O
P	O
n	O
","	O
G	O
s	O
","	O
L	O
s	O
","	O
C	O
i	O
","	O
PE	O
","	O
K	O
","	O
Ï†	O
and	O
A	O
max	O
"[,,,,]."	O
In	O
this	O
work	O
","	O
compared	O
with	O
the	O
control	O
","	O
there	O
was	O
an	O
increased	O
effect	O
on	O
the	O
photosynthetic	O
traits	O
of	O
the	O
cotton	O
leaves	O
as	O
the	O
salt	B-Chemical
dust	O
treatment	O
increased	O
","	O
which	O
was	O
even	O
obvious	O
between	O
the	O
five	O
salt	B-Chemical
dust	O
groups	O
.	O
Observations	O
made	O
during	O
the	O
experiments	O
found	O
that	O
there	O
were	O
yellow	O
cottons	O
leaves	O
in	O
the	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
","	O
indicating	O
the	O
salt	B-Chemical
dust	O
not	O
only	O
influenced	O
the	O
cotton	O
â€™	O
s	O
photosynthetic	O
abilities	O
","	O
but	O
also	O
the	O
internal	O
physical	O
properties	O
of	O
the	O
cotton	O
leaves	O
"[,]."	O
The	O
blades	O
are	O
the	O
source	O
organs	O
of	O
the	O
plants	O
","	O
and	O
undertake	O
the	O
substance	O
production	O
that	O
supplies	O
the	O
whole	O
plant	O
.	O
They	O
also	O
have	O
a	O
significant	O
influence	O
on	O
the	O
growth	O
and	O
development	O
of	O
the	O
crops	O
.	O
Previous	O
research	O
has	O
shown	O
that	O
when	O
dust	O
landed	O
on	O
the	O
plant	O
leaves	O
it	O
can	O
form	O
an	O
adhesive	O
layer	O
that	O
can	O
seal	O
the	O
stoma	O
and	O
hinder	O
the	O
respiration	O
","	O
photosynthesis	O
and	O
transpiration	O
of	O
the	O
plant	O
.	O
In	O
this	O
work	O
","	O
we	O
found	O
that	O
in	O
the	O
salt	B-Chemical
dust	O
treated	O
groups	O
","	O
the	O
respiration	O
","	O
photosynthesis	O
and	O
transpiration	O
of	O
the	O
cotton	O
leaves	O
decreased	O
.	O
In	O
comparison	O
to	O
the	O
control	O
group	O
","	O
the	O
stomatal	O
conductance	O
and	O
limitation	O
of	O
the	O
cotton	O
leaves	O
of	O
the	O
salt	B-Chemical
dust	O
treated	O
groups	O
all	O
decreased	O
","	O
indicating	O
a	O
decrease	O
in	O
the	O
respiration	O
","	O
photosynthesis	O
and	O
transpiration	O
of	O
the	O
cotton	O
leaves	O
from	O
this	O
.	O
Chen	O
et	O
al	O
.	O
[]	O
measured	O
the	O
physiological	O
and	O
ecological	O
responses	O
of	O
22	O
plants	O
to	O
the	O
dust	O
and	O
found	O
that	O
in	O
some	O
plants	O
","	O
the	O
rate	O
of	O
plant	O
transpiration	O
dropped	O
significantly	O
","	O
while	O
it	O
significantly	O
rose	O
in	O
others	O
due	O
to	O
the	O
adaptation	O
of	O
the	O
plant	O
leaves	O
to	O
the	O
dust	O
in	O
a	O
short	O
period	O
of	O
time	O
.	O
In	O
this	O
study	O
","	O
we	O
found	O
that	O
when	O
the	O
cotton	O
leaves	O
suffered	O
from	O
salt	B-Chemical
dust	O
deposition	O
","	O
the	O
respiration	O
","	O
photosynthesis	O
and	O
transpiration	O
of	O
the	O
cotton	O
leaves	O
all	O
decreased	O
","	O
which	O
likely	O
reflects	O
the	O
adaptation	O
of	O
the	O
cotton	O
leaves	O
to	O
the	O
salt	B-Chemical
dust	O
stress	O
in	O
a	O
short	O
period	O
of	O
time	O
.	O
Because	O
landing	O
of	O
salt	B-Chemical
dust	O
on	O
the	O
surface	O
of	O
the	O
cotton	O
blade	O
can	O
block	O
the	O
absorption	O
of	O
CO2	B-Chemical
by	O
cotton	O
stomata	O
","	O
there	O
is	O
a	O
reduction	O
in	O
the	O
stomatal	O
conductivity	O
that	O
will	O
eventually	O
influence	O
respiration	O
","	O
photosynthesis	O
and	O
transpiration	O
of	O
the	O
cotton	O
leaves	O
.	O
The	O
total	O
chlorophyll	B-Chemical
and	O
carotenoid	B-Chemical
content	O
of	O
the	O
cotton	O
leaves	O
plays	O
an	O
important	O
role	O
in	O
the	O
photosynthesis	O
of	O
the	O
plants	O
and	O
will	O
influence	O
the	O
normal	O
growth	O
and	O
productivity	O
.	O
Studies	O
performed	O
both	O
at	O
home	O
and	O
abroad	O
have	O
shown	O
that	O
the	O
total	O
chlorophyll	B-Chemical
and	O
carotenoid	B-Chemical
content	O
decreased	O
when	O
the	O
plant	O
suffered	O
from	O
stresses	O
such	O
as	O
drought	O
","	O
salinity	O
","	O
and	O
low	O
and	O
high	O
temperatures	O
"[,,,]."	O
Work	O
by	O
Pandey	O
and	O
Sinha	O
[]	O
found	O
that	O
the	O
total	O
chlorophyll	B-Chemical
content	O
significantly	O
decreased	O
when	O
the	O
maize	O
leaves	O
encountered	O
coal	O
smoke	O
pollution	O
.	O
This	O
also	O
occurs	O
in	O
wheat	O
leaves	O
when	O
they	O
undergo	O
cement	O
dust	O
deposition	O
.	O
Work	O
by	O
Migahid	O
et	O
al	O
.	O
[]	O
found	O
that	O
cement	O
dust	O
deposition	O
can	O
result	O
in	O
a	O
significant	O
reduction	O
in	O
the	O
total	O
chlorophyll	B-Chemical
and	O
carotenoid	B-Chemical
content	O
of	O
soybean	O
leaves	O
.	O
In	O
this	O
work	O
we	O
found	O
that	O
salt	B-Chemical
dust	O
deposition	O
on	O
cotton	O
leaves	O
led	O
to	O
a	O
decrease	O
in	O
the	O
total	O
chlorophyll	B-Chemical
and	O
carotenoid	B-Chemical
content	O
of	O
the	O
cotton	O
leaves	O
.	O
This	O
is	O
consistent	O
with	O
the	O
above	O
described	O
research	O
","	O
indicating	O
that	O
salt	B-Chemical
dust	O
deposition	O
significantly	O
influences	O
the	O
photosynthesis	O
of	O
cotton	O
leaves	O
","	O
which	O
will	O
eventually	O
influence	O
cotton	O
production	O
.	O
Carbohydrates	B-Chemical
are	O
important	O
components	O
of	O
plants	O
.	O
Soluble	O
sugar	B-Chemical
is	O
the	O
primary	O
product	O
of	O
photosynthesis	O
in	O
higher	O
plants	O
and	O
it	O
can	O
form	O
the	O
starch	B-Chemical
","	O
fat	B-Chemical
","	O
protein	O
","	O
fiber	O
and	O
other	O
compounds	O
found	O
in	O
the	O
plant	O
.	O
It	O
can	O
also	O
maintain	O
the	O
carbon	B-Chemical
and	O
nitrogen	B-Chemical
metabolism	O
during	O
the	O
growth	O
period	O
of	O
plant	O
.	O
Furthermore	O
","	O
it	O
is	O
in	O
the	O
class	O
of	O
cell	O
osmotic	O
regulation	O
substances	O
","	O
and	O
","	O
therefore	O
","	O
plays	O
a	O
significant	O
role	O
in	O
plant	O
growth	O
and	O
development	O
.	O
Previous	O
research	O
has	O
shown	O
that	O
when	O
plants	O
suffer	O
from	O
salt	B-Chemical
stress	O
","	O
arid	O
conditions	O
or	O
freezing	O
","	O
the	O
soluble	O
sugar	B-Chemical
content	O
of	O
the	O
plants	O
will	O
increase	O
"[,]."	O
In	O
this	O
work	O
","	O
we	O
found	O
that	O
compared	O
to	O
the	O
control	O
group	O
","	O
the	O
soluble	O
sugar	B-Chemical
content	O
of	O
the	O
cotton	O
leaves	O
in	O
the	O
salt	B-Chemical
dust	O
treated	O
groups	O
increased	O
as	O
the	O
salt	B-Chemical
dust	O
deposition	O
led	O
to	O
the	O
increase	O
in	O
sugar	B-Chemical
content	O
was	O
more	O
significantly	O
.	O
In	O
this	O
work	O
","	O
Na	B-Chemical
"+,"	I-Chemical
Cl	I-Chemical
and	O
SO4	B-Chemical
2	I-Chemical
-	I-Chemical
within	O
the	O
salt	B-Chemical
dust	O
landing	O
on	O
the	O
surface	O
of	O
the	O
cotton	O
leaves	O
strongly	O
contributed	O
to	O
the	O
salt	B-Chemical
ion	I-Chemical
content	O
inside	O
the	O
cotton	O
leaves	O
.	O
This	O
resulted	O
in	O
stress	O
from	O
the	O
salt	B-Chemical
ions	I-Chemical
on	O
the	O
cotton	O
leaves	O
and	O
led	O
to	O
water	O
loss	O
in	O
the	O
cotton	O
cells	O
through	O
an	O
increase	O
in	O
the	O
soluble	O
sugar	B-Chemical
content	O
to	O
adjust	O
the	O
osmotic	O
potential	O
in	O
an	O
effort	O
to	O
maintain	O
normal	O
physiological	O
functioning	O
of	O
the	O
cells	O
.	O
Currently	O
","	O
research	O
on	O
the	O
influence	O
of	O
stresses	O
on	O
the	O
cytoplasm	O
membrane	O
structure	O
and	O
function	O
of	O
the	O
plant	O
often	O
focus	O
on	O
increasing	O
MDA	B-Chemical
content	O
","	O
which	O
is	O
directly	O
related	O
to	O
the	O
degree	O
of	O
injury	O
to	O
the	O
plant	O
cells	O
.	O
In	O
this	O
work	O
","	O
in	O
comparison	O
to	O
the	O
groups	O
that	O
weren	O
â€™	O
t	O
exposed	O
to	O
salt	B-Chemical
dust	O
","	O
the	O
leaves	O
exposed	O
to	O
salt	B-Chemical
dust	O
had	O
an	O
increased	O
MDA	B-Chemical
content	O
","	O
suggesting	O
the	O
salt	B-Chemical
dust	O
deposition	O
significantly	O
damaged	O
the	O
cells	O
of	O
the	O
cotton	O
leaves	O
.	O
This	O
led	O
to	O
the	O
production	O
of	O
harmful	O
substances	O
","	O
such	O
as	O
the	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
O2	B-Chemical
OH	I-Chemical
H2O	I-Chemical
","	O
OH	B-Chemical
etc	O
.)	O
in	O
the	O
blade	O
cells	O
","	O
which	O
can	O
cause	O
membrane	B-Chemical
lipid	I-Chemical
peroxidation	O
","	O
thus	O
destroying	O
the	O
membrane	O
structure	O
of	O
the	O
plant	O
cells	O
.	O
A	O
number	O
of	O
studies	O
have	O
shown	O
that	O
in	O
cases	O
of	O
stress	O
","	O
such	O
as	O
that	O
from	O
salt	B-Chemical
","	O
drought	O
or	O
high	O
temperature	O
","	O
the	O
MDA	B-Chemical
content	O
of	O
the	O
plant	O
cells	O
will	O
increase	O
through	O
enhancement	O
of	O
antioxidant	O
enzyme	O
activity	O
to	O
remove	O
the	O
harmful	O
material	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
to	O
reduce	O
the	O
negative	O
influence	O
on	O
plant	O
cell	O
functioning	O
"[,]."	O
In	O
this	O
work	O
","	O
we	O
found	O
that	O
compared	O
to	O
the	O
control	O
group	O
","	O
the	O
antioxidant	O
enzymes	O
of	O
SOD	O
","	O
POD	O
and	O
CAT	O
were	O
increased	O
in	O
the	O
salt	B-Chemical
dust	O
treatment	O
groups	O
.	O
This	O
shows	O
that	O
the	O
salt	B-Chemical
dust	O
deposition	O
was	O
a	O
stress	O
just	O
like	O
drought	O
","	O
high	O
and	O
low	O
temperatures	O
","	O
and	O
can	O
damage	O
the	O
plant	O
cells	O
and	O
raise	O
the	O
MDA	B-Chemical
content	O
by	O
enhancing	O
the	O
activity	O
of	O
antioxidant	O
enzymes	O
to	O
remove	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
.	O
This	O
is	O
consistent	O
with	O
published	O
work	O
.	O
This	O
work	O
found	O
that	O
when	O
salt	B-Chemical
dust	O
landed	O
on	O
the	O
surface	O
of	O
cotton	O
leaves	O
","	O
it	O
impacted	O
the	O
photosynthesis	O
","	O
respiration	O
and	O
transpiration	O
of	O
the	O
cotton	O
leaves	O
","	O
which	O
then	O
affected	O
physiological	O
and	O
biochemical	O
processes	O
","	O
such	O
as	O
nutrient	O
absorption	O
","	O
and	O
chlorophyll	B-Chemical
and	O
carotenoid	B-Chemical
content	O
.	O
This	O
can	O
also	O
destroy	O
the	O
structure	O
of	O
the	O
cotton	O
leaves	O
cells	O
","	O
and	O
increase	O
the	O
MDA	B-Chemical
content	O
of	O
the	O
cotton	O
leaves	O
by	O
increasing	O
osmotic	O
adjustment	O
substances	O
","	O
such	O
as	O
proline	B-Chemical
and	O
soluble	O
sugar	B-Chemical
","	O
to	O
reduce	O
cytosolic	O
extravasation	O
.	O
There	O
is	O
also	O
an	O
increase	O
in	O
the	O
activity	O
of	O
antioxidant	O
enzymes	O
","	O
such	O
as	O
the	O
SOD	O
","	O
POD	O
and	O
CAT	O
","	O
to	O
remove	O
reactive	O
oxygen	B-Chemical
and	O
MDA	B-Chemical
in	O
the	O
cotton	O
leaves	O
to	O
maintain	O
normal	O
functioning	O
of	O
the	O
cotton	O
leaves	O
.	O
Over	O
the	O
past	O
50	O
years	O
with	O
the	O
rapid	O
land	O
-	O
use	O
changes	O
in	O
the	O
Ebinur	O
Basin	O
","	O
man	O
has	O
significantly	O
affected	O
and	O
modified	O
the	O
natural	O
landscape	O
of	O
this	O
area	O
.	O
These	O
changes	O
increased	O
as	O
the	O
population	O
density	O
increased	O
and	O
agriculture	O
intensified	O
"[,]."	O
The	O
conversion	O
of	O
land	O
into	O
that	O
used	O
for	O
agriculture	O
","	O
and	O
other	O
driving	O
forces	O
of	O
land	O
-	O
use	O
changes	O
are	O
the	O
leading	O
factors	O
behind	O
the	O
excessive	O
use	O
of	O
water	O
resources	O
in	O
this	O
area	O
","	O
which	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
the	O
surface	O
water	O
resources	O
that	O
flow	O
into	O
the	O
Ebinur	O
"[,]."	O
Overall	O
","	O
in	O
the	O
water	O
area	O
of	O
the	O
Ebinur	O
to	O
the	O
remaining	O
500	O
square	O
kilometers	O
that	O
resulted	O
in	O
a	O
large	O
bared	O
area	O
of	O
dry	O
lake	O
bottom	O
.	O
This	O
dry	O
lake	O
bottom	O
has	O
become	O
a	O
huge	O
salt	B-Chemical
dust	O
storm	O
source	O
in	O
Northwest	O
China	O
and	O
Central	O
Asia	O
"[,,,]."	O
These	O
areas	O
face	O
the	O
serious	O
threat	O
of	O
the	O
salt	B-Chemical
dust	O
storms	O
.	O
In	O
order	O
to	O
protect	O
the	O
environment	O
and	O
reduce	O
the	O
effect	O
of	O
the	O
salt	B-Chemical
dust	O
storms	O
on	O
agriculture	O
and	O
economy	O
","	O
we	O
should	O
pay	O
increased	O
attention	O
to	O
these	O
phenomena	O
and	O
take	O
efficient	O
protective	O
measures	O
in	O
this	O
area	O
.	O
Conclusion	O
The	O
salt	B-Chemical
ion	I-Chemical
content	O
","	O
composition	O
and	O
particle	O
size	O
of	O
the	O
salt	B-Chemical
dust	O
used	O
in	O
these	O
experiments	O
were	O
similar	O
to	O
those	O
of	O
natural	O
salt	B-Chemical
dust	O
","	O
suggesting	O
the	O
salt	B-Chemical
dust	O
on	O
the	O
cotton	O
leaves	O
was	O
from	O
salt	B-Chemical
dust	O
storms	O
in	O
this	O
region	O
.	O
The	O
primary	O
salt	B-Chemical
cations	I-Chemical
on	O
the	O
surface	O
and	O
inside	O
the	O
cotton	O
leaves	O
were	O
Na	B-Chemical
"+,"	I-Chemical
Ca2	I-Chemical
"+,"	I-Chemical
Cl	I-Chemical
-	I-Chemical
and	O
SO4	B-Chemical
2	I-Chemical
while	O
the	O
CO3	B-Chemical
-	I-Chemical
and	O
HCO3	B-Chemical
-	I-Chemical
contents	O
were	O
present	O
only	O
at	O
low	O
levels	O
.	O
Overall	O
","	O
the	O
salt	B-Chemical
cation	I-Chemical
and	I-Chemical
anion	I-Chemical
content	O
on	O
the	O
surface	O
and	O
inside	O
the	O
cotton	O
leaves	O
can	O
be	O
ordered	O
as	O
Na	B-Chemical
+>	I-Chemical
Ca2	I-Chemical
+>	I-Chemical
Mg2	I-Chemical
+>	I-Chemical
K	I-Chemical
+	I-Chemical
and	O
Cl	B-Chemical
->	I-Chemical
SO4	I-Chemical
2	I-Chemical
->	I-Chemical
HCO3	I-Chemical
->	I-Chemical
CO3	I-Chemical
respectively	O
.	O
There	O
were	O
significant	O
differences	O
in	O
the	O
Na	B-Chemical
"+,"	I-Chemical
Ca2	I-Chemical
"+,"	I-Chemical
Mg2	I-Chemical
"+,"	I-Chemical
K	I-Chemical
"+,"	I-Chemical
Cl	I-Chemical
SO4	I-Chemical
2	I-Chemical
HCO3	I-Chemical
-	I-Chemical
and	O
CO3	B-Chemical
-	I-Chemical
found	O
on	O
the	O
surface	O
and	O
inside	O
the	O
cotton	O
leaves	O
of	O
the	O
salt	B-Chemical
dust	O
treated	O
groups	O
compared	O
to	O
the	O
control	O
","	O
but	O
the	O
differences	O
varied	O
between	O
salt	B-Chemical
dust	O
groups	O
.	O
Both	O
Na	B-Chemical
+	I-Chemical
and	O
Cl	B-Chemical
-	I-Chemical
found	O
on	O
the	O
surface	O
of	O
the	O
leaves	O
contributed	O
strongly	O
to	O
the	O
amount	O
inside	O
the	O
cotton	O
leaves	O
.	O
Overall	O
","	O
the	O
five	O
salt	B-Chemical
dust	O
treatment	O
groups	O
are	O
ordered	O
according	O
to	O
total	O
amount	O
of	O
salt	B-Chemical
ions	I-Chemical
on	O
the	O
surface	O
and	O
inside	O
the	O
cotton	O
leaves	O
as	O
:	O
500	O
g	O
.	O
m	O
-	O
2	O
>	O
400	O
g	O
.	O
m	O
-	O
2	O
>	O
300	O
g	O
.	O
m	O
-	O
2	O
>	O
200	O
g	O
.	O
m	O
-	O
2	O
>	O
100	O
g	O
.	O
m	O
-	O
2	O
.	O
The	O
salt	B-Chemical
dust	O
that	O
lands	O
on	O
the	O
surface	O
of	O
cotton	O
leaves	O
can	O
significantly	O
influence	O
the	O
photosynthetic	O
traits	O
of	O
P	O
n	O
","	O
PE	O
","	O
C	O
i	O
T	O
i	O
","	O
G	O
s	O
","	O
T	O
r	O
","	O
WUE	O
","	O
L	O
s	O
","	O
Ï†	O
","	O
A	O
max	O
","	O
k	O
","	O
and	O
R	O
ady	O
of	O
the	O
cotton	O
leaves	O
","	O
as	O
the	O
differences	O
between	O
the	O
control	O
and	O
the	O
groups	O
treated	O
with	O
salt	B-Chemical
dust	O
groups	O
were	O
significant	O
.	O
However	O
","	O
differences	O
between	O
the	O
five	O
salt	B-Chemical
dust	O
groups	O
varied	O
.	O
Salt	B-Chemical
dust	O
can	O
significantly	O
hinder	O
the	O
physiological	O
functions	O
of	O
cotton	O
leaves	O
","	O
such	O
as	O
causing	O
a	O
decrease	O
in	O
leaf	O
chlorophyll	B-Chemical
and	O
carotenoid	B-Chemical
content	O
","	O
and	O
increasing	O
cytoplasmic	O
membrane	O
permeability	O
and	O
the	O
MDA	B-Chemical
content	O
.	O
The	O
MDA	B-Chemical
content	O
is	O
increased	O
by	O
increasing	O
the	O
soluble	O
sugar	B-Chemical
and	O
proline	B-Chemical
content	O
to	O
adjust	O
for	O
the	O
loss	O
of	O
the	O
cytosol	O
in	O
the	O
cells	O
","	O
the	O
activity	O
of	O
antioxidant	O
enzymes	O
to	O
eliminate	O
harmful	O
molecules	O
","	O
such	O
as	O
intracellular	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
","	O
in	O
an	O
effort	O
to	O
reduce	O
the	O
damage	O
caused	O
by	O
salt	B-Chemical
dust	O
stress	O
and	O
maintain	O
normal	O
physiological	O
functions	O
.	O
As	O
a	O
whole	O
","	O
salt	B-Chemical
dust	O
deposition	O
is	O
a	O
hardship	O
for	O
the	O
cotton	O
crops	O
","	O
which	O
is	O
consistent	O
with	O
previously	O
published	O
work	O
concerning	O
the	O
effect	O
of	O
salt	B-Chemical
dust	O
on	O
other	O
plants	O
.	O
By	O
studying	O
the	O
influence	O
of	O
salt	B-Chemical
dust	O
in	O
Ebinur	O
Basin	O
on	O
the	O
salt	B-Chemical
ion	I-Chemical
content	O
of	O
cotton	O
leaves	O
on	O
photosynthesis	O
","	O
leaf	O
blade	O
surface	O
morphology	O
","	O
and	O
biochemical	O
processes	O
","	O
we	O
reached	O
the	O
following	O
conclusions	O
:	O
This	O
study	O
revealed	O
that	O
salt	B-Chemical
dust	O
can	O
significantly	O
influence	O
the	O
physiological	O
and	O
biochemical	O
processes	O
of	O
cotton	O
leaves	O
","	O
which	O
will	O
eventually	O
cause	O
plant	O
damage	O
and	O
reduce	O
cotton	O
production	O
and	O
","	O
therefore	O
","	O
lead	O
to	O
agricultural	O
economic	O
loss	O
.	O
Therefore	O
","	O
much	O
attention	O
should	O
be	O
paid	O
to	O
the	O
salt	B-Chemical
dust	O
storms	O
in	O
the	O
Ebinur	O
Basin	O
and	O
efficient	O
measures	O
should	O
be	O
undertaken	O
to	O
protect	O
the	O
environment	O
.	O
Measures	O
Isolation	O
technology	O
should	O
be	O
used	O
to	O
limit	O
the	O
perennial	O
water	O
deposition	O
and	O
dry	O
lake	O
area	O
with	O
the	O
goals	O
of	O
returning	O
farmland	O
to	O
forests	O
","	O
grassland	O
and	O
lake	O
to	O
stabilize	O
and	O
increase	O
the	O
water	O
area	O
of	O
the	O
Ebinur	O
","	O
as	O
well	O
as	O
curb	O
the	O
source	O
of	O
the	O
sand	O
in	O
this	O
area	O
.	O
Biological	O
control	O
techniques	O
should	O
be	O
used	O
to	O
cultivate	O
salt	B-Chemical
tolerant	O
shrubs	O
and	O
trees	O
","	O
such	O
as	O
Saxoul	O
","	O
Tamarix	O
","	O
and	O
Populus	O
euphratica	O
","	O
in	O
order	O
to	O
decrease	O
the	O
uptake	O
of	O
the	O
salt	B-Chemical
dust	O
from	O
the	O
dry	O
salt	B-Chemical
bottom	O
of	O
the	O
lake	O
and	O
the	O
threat	O
of	O
wind	O
erosion	O
in	O
this	O
basin	O
.	O
Strict	O
water	O
management	O
systems	O
should	O
be	O
implemented	O
to	O
reduce	O
the	O
irresponsible	O
use	O
and	O
waste	O
of	O
water	O
resources	O
in	O
the	O
river	O
basin	O
.	O
Specifically	O
","	O
the	O
use	O
of	O
water	O
resources	O
from	O
the	O
Bortala	O
and	O
Jing	O
rivers	O
","	O
which	O
are	O
the	O
main	O
rivers	O
feeding	O
into	O
Ebinur	O
","	O
should	O
be	O
reduced	O
.	O
The	O
exploitation	O
of	O
groundwater	O
in	O
this	O
area	O
should	O
be	O
reduced	O
and	O
precipitation	O
should	O
be	O
artificially	O
enhanced	O
to	O
maintain	O
the	O
water	O
resources	O
in	O
this	O
area	O
and	O
water	O
levels	O
of	O
the	O
lake	O
.	O
New	O
agricultural	O
techniques	O
","	O
such	O
as	O
plastic	O
membrane	O
mulching	O
and	O
drip	O
irrigation	O
","	O
should	O
be	O
used	O
","	O
especially	O
in	O
cotton	O
fields	O
","	O
to	O
improve	O
the	O
use	O
of	O
the	O
limited	O
water	O
resources	O
","	O
and	O
to	O
raise	O
the	O
price	O
lever	O
of	O
the	O
water	O
resources	O
used	O
by	O
industry	O
.	O
Furthermore	O
","	O
industrial	O
projects	O
","	O
such	O
as	O
coal	O
and	O
silicon	B-Chemical
chemical	O
enterprises	O
","	O
should	O
be	O
restricted	O
as	O
they	O
can	O
be	O
harmful	O
to	O
the	O
natural	O
environment	O
.	O
The	O
Ebinur	O
Basin	O
should	O
be	O
established	O
as	O
a	O
nature	O
reserve	O
in	O
order	O
to	O
strength	O
the	O
soil	O
and	O
water	O
conservation	O
and	O
afforestation	O
","	O
strengthen	O
management	O
of	O
the	O
Ebinur	O
Basin	O
","	O
prohibit	O
deforestation	O
","	O
rotten	O
dig	O
herbs	O
and	O
exploitation	O
of	O
the	O
grassland	O
","	O
and	O
ensure	O
the	O
normal	O
growth	O
and	O
natural	O
regeneration	O
of	O
the	O
natural	O
vegetation	O
","	O
predominantly	O
Sacsaoul	O
forest	O
.	O
These	O
measures	O
should	O
reduce	O
the	O
negative	O
influence	O
of	O
the	O
sand	O
from	O
the	O
dried	O
bottom	O
of	O
the	O
Ebinur	O
Basin	O
and	O
","	O
thus	O
","	O
protect	O
the	O
natural	O
environment	O
.	O
Measures	O
should	O
be	O
taken	O
to	O
recover	O
the	O
crop	O
output	O
of	O
crops	O
after	O
damage	O
from	O
the	O
salt	B-Chemical
dust	O
in	O
the	O
area	O
","	O
such	O
as	O
enhancing	O
the	O
fertilizer	O
with	O
N	B-Chemical
","	O
P	B-Chemical
","	O
and	O
K	B-Chemical
to	O
improve	O
the	O
absorption	O
of	O
the	O
nutrients	O
from	O
the	O
soil	O
and	O
increasing	O
the	O
amount	O
of	O
irrigation	O
","	O
to	O
promote	O
crop	O
productivity	O
and	O
reduce	O
damage	O
to	O
the	O
economy	O
.	O
In	O
order	O
to	O
reduce	O
the	O
negative	O
effects	O
of	O
salt	B-Chemical
dust	O
storms	O
in	O
the	O
Ebinur	O
Basin	O
area	O
","	O
we	O
suggest	O
the	O
following	O
measures	O
:	O
References	O
Blockade	O
of	O
the	O
N	O
-	O
Methyl	O
-	O
D	O
-	O
Aspartate	O
Glutamate	O
Receptor	O
Ameliorates	O
Lipopolysaccharide	B-Chemical
-	O
Induced	O
Renal	O
Insufficiency	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
activation	O
in	O
rat	O
kidney	O
reduces	O
renal	O
perfusion	O
and	O
ultrafiltration	O
.	O
Hypoperfusion	O
-	O
induced	O
ischemia	O
is	O
the	O
most	O
frequent	O
cause	O
of	O
functional	O
insufficiency	O
in	O
the	O
endotoxemic	O
kidney	O
.	O
Here	O
","	O
we	O
used	O
non	O
-	O
hypotensive	O
rat	O
model	O
of	O
lipopolysaccharide	B-Chemical
-	O
induced	O
endotoxemia	O
to	O
examine	O
whether	O
NMDA	O
receptor	O
hyperfunction	O
contributes	O
to	O
acute	O
kidney	O
injury	O
.	O
Lipopolysaccharide	B-Chemical
-	O
induced	O
renal	O
damage	O
via	O
increased	O
enzymuria	O
and	O
hemodynamic	O
impairments	O
were	O
ameliorated	O
by	O
co	O
-	O
treatment	O
with	O
the	O
NMDA	O
receptor	O
blocker	O
","	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
.	O
The	O
NMDA	O
receptor	O
NR1	O
subunit	O
in	O
the	O
rat	O
kidney	O
mainly	O
co	O
-	O
localized	O
with	O
serine	O
racemase	O
","	O
an	O
enzyme	O
responsible	O
for	O
synthesizing	O
the	O
NMDA	O
receptor	O
co	O
-	O
agonist	O
","	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
.	O
The	O
NMDA	O
receptor	O
hyperfunction	O
in	O
lipopolysaccharide	B-Chemical
-	O
treated	O
kidneys	O
was	O
demonstrated	O
by	O
NR1	O
and	O
serine	O
racemase	O
upregulation	O
","	O
particularly	O
in	O
renal	O
tubules	O
","	O
and	O
by	O
increased	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
.	O
Lipopolysaccharide	B-Chemical
also	O
induced	O
cell	O
damage	O
in	O
cultured	O
tubular	O
cell	O
lines	O
and	O
primary	O
rat	O
proximal	O
tubular	O
cells	O
.	O
This	O
damage	O
was	O
mitigated	O
by	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
and	O
by	O
small	O
interfering	O
RNA	O
targeting	O
NR1	O
.	O
Lipopolysaccharide	B-Chemical
increased	O
cytokine	O
release	O
in	O
tubular	O
cell	O
lines	O
via	O
toll	O
-	O
like	O
receptor	O
4	O
.	O
The	O
release	O
of	O
interleukin	O
-	O
1Î²	O
from	O
these	O
cells	O
are	O
the	O
most	O
abundant	O
.	O
An	O
interleukin	O
-	O
1	O
receptor	O
antagonist	O
not	O
only	O
attenuated	O
cell	O
death	O
but	O
also	O
abolished	O
lipopolysaccharide	B-Chemical
-	O
induced	O
NR1	O
and	O
serine	O
racemase	O
upregulation	O
and	O
increases	O
in	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
secretion	O
","	O
suggesting	O
that	O
interleukin	O
-	O
1Î²	O
-	O
mediated	O
NMDA	O
receptor	O
hyperfunction	O
participates	O
in	O
lipopolysaccharide	B-Chemical
-	O
induced	O
tubular	O
damage	O
.	O
The	O
results	O
of	O
this	O
study	O
indicate	O
NMDA	O
receptor	O
hyperfunction	O
via	O
cytokine	O
effect	O
participates	O
in	O
lipopolysaccharide	B-Chemical
-	O
induced	O
renal	O
insufficiency	O
.	O
Blockade	O
of	O
NMDA	O
receptors	O
may	O
represent	O
a	O
promising	O
therapeutic	O
strategy	O
for	O
the	O
treatment	O
of	O
sepsis	O
-	O
associated	O
renal	O
failure	O
.	O
Introduction	O
The	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
is	O
an	O
ionotropic	O
receptor	O
/	O
calcium	O
channel	O
within	O
the	O
CNS	O
that	O
is	O
activated	O
by	O
the	O
excitatory	O
neurotransmitter	O
","	O
glutamate	B-Chemical
","	O
to	O
perform	O
critical	O
functions	O
that	O
control	O
synaptic	O
plasticity	O
during	O
learning	O
and	O
memory	O
formation	O
[].	O
The	O
NMDA	O
receptor	O
is	O
also	O
expressed	O
in	O
extraneural	O
tissues	O
including	O
the	O
kidney	O
"[â€“],"	O
where	O
its	O
functions	O
are	O
less	O
well	O
-	O
known	O
.	O
Enhanced	O
NMDA	O
receptor	O
function	O
induced	O
by	O
channel	O
overexpression	O
mediates	O
cytotoxicity	O
due	O
to	O
massive	O
calcium	B-Chemical
influx	O
[].	O
The	O
entry	O
of	O
calcium	B-Chemical
through	O
NMDA	O
receptors	O
is	O
mainly	O
gated	O
by	O
the	O
NR1	O
subunit	O
","	O
which	O
forms	O
a	O
tetramer	O
with	O
other	O
modulatory	O
subunits	O
[].	O
Different	O
NMDA	O
receptor	O
subunits	O
are	O
present	O
in	O
the	O
glomeruli	O
","	O
arterioles	O
","	O
and	O
tubules	O
of	O
the	O
rat	O
kidney	O
[â€“].	O
In	O
addition	O
","	O
the	O
glutamate	B-Chemical
recognition	O
site	O
on	O
the	O
NR1	O
subunit	O
","	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
","	O
is	O
thought	O
to	O
bind	O
stereo	O
-	O
selectively	O
to	O
the	O
glycine	B-Chemical
-	O
regulatory	O
site	O
.	O
The	O
effects	O
on	O
NMDA	O
receptor	O
activation	O
in	O
motor	O
neurons	O
are	O
either	O
equal	O
to	O
or	O
100	O
-	O
fold	O
more	O
potent	O
than	O
those	O
of	O
glycine	B-Chemical
[];	O
thus	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
may	O
be	O
a	O
physiological	O
co	O
-	O
agonist	O
for	O
receptor	O
activation	O
[].	O
Furthermore	O
","	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
is	O
endogenously	O
synthesized	O
from	O
L	B-Chemical
-	I-Chemical
serine	I-Chemical
by	O
the	O
enzyme	O
","	O
serine	O
racemase	O
(	O
S	O
-	O
Race	O
)	O
[].	O
We	O
previously	O
showed	O
that	O
S	O
-	O
Race	O
is	O
also	O
present	O
in	O
the	O
rat	O
kidney	O
"[],"	O
clearly	O
indicating	O
the	O
presence	O
of	O
a	O
complete	O
NMDA	O
receptor	O
system	O
.	O
The	O
effect	O
of	O
NMDA	O
receptors	O
on	O
renal	O
hemodynamic	O
regulation	O
","	O
however	O
","	O
is	O
unclear	O
.	O
Inhibition	O
of	O
NMDA	O
receptors	O
by	O
systemic	O
application	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
a	O
channel	O
blocker	O
)	O
and	O
5	B-Chemical
","	I-Chemical
7	I-Chemical
-	I-Chemical
dichlorokynurenic	I-Chemical
acid	I-Chemical
(	O
a	O
glycine	B-Chemical
antagonist	O
)	O
induces	O
renal	O
vasoconstriction	O
and	O
attenuates	O
renal	O
vasodilatory	O
responses	O
to	O
glycine	B-Chemical
infusion	O
","	O
indicating	O
that	O
renal	O
NMDA	O
receptors	O
act	O
as	O
vasodilators	O
[].	O
We	O
previously	O
showed	O
that	O
direct	O
activation	O
of	O
renal	O
NMDA	O
receptors	O
by	O
intrarenal	O
arterial	O
infusion	O
of	O
NMDA	B-Chemical
decreases	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
and	O
urine	O
and	O
salt	O
excretion	O
"[],"	O
indicating	O
that	O
renal	O
NMDA	O
receptors	O
act	O
as	O
vasoconstrictors	O
.	O
Different	O
intensities	O
and	O
durations	O
of	O
NMDA	O
receptor	O
activation	O
may	O
explain	O
the	O
discrepancy	O
between	O
these	O
observations	O
","	O
suggesting	O
that	O
renal	O
NMDA	O
receptors	O
may	O
play	O
a	O
role	O
in	O
hemodynamic	O
regulation	O
.	O
Interestingly	O
","	O
renal	O
NMDA	O
receptor	O
hyperactivity	O
contributes	O
to	O
kidney	O
injury	O
caused	O
by	O
channel	O
overexpression	O
","	O
as	O
demonstrated	O
in	O
disease	O
models	O
utilizing	O
short	O
-	O
term	O
treatment	O
with	O
the	O
nephrotoxic	O
drug	O
gentamicin	B-Chemical
or	O
ischemia	O
-	O
reperfusion	O
"[,"	O
].	O
Despite	O
recent	O
advances	O
in	O
medical	O
treatment	O
","	O
the	O
overall	O
mortality	O
of	O
sepsis	O
caused	O
by	O
multiple	O
organ	O
failure	O
remains	O
high	O
[â€“].	O
Patients	O
with	O
sepsis	O
often	O
suffer	O
acute	O
renal	O
failure	O
"[],"	O
so	O
identifying	O
molecular	O
targets	O
that	O
will	O
enable	O
effective	O
treatment	O
of	O
sepsis	O
-	O
related	O
kidney	O
dysfunction	O
is	O
therefore	O
of	O
utmost	O
importance	O
.	O
NMDA	O
receptor	O
inhibition	O
attenuates	O
hippocampal	O
neuronal	O
degeneration	O
and	O
reduces	O
inflammation	O
or	O
oxidative	O
stress	O
in	O
intestine	O
","	O
liver	O
","	O
and	O
lung	O
tissues	O
of	O
rat	O
models	O
of	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)-	O
induced	O
endotoxemia	O
or	O
sepsis	O
[â€“].	O
This	O
suggests	O
that	O
NMDA	O
receptor	O
hyperfunction	O
is	O
involved	O
in	O
LPS	B-Chemical
-	O
induced	O
multiple	O
organ	O
failure	O
.	O
However	O
","	O
it	O
is	O
not	O
known	O
whether	O
NMDA	O
receptors	O
influence	O
LPS	B-Chemical
-	O
induced	O
renal	O
insufficiency	O
","	O
although	O
we	O
previously	O
showed	O
that	O
LPS	B-Chemical
impairs	O
renal	O
function	O
via	O
increased	O
inflammatory	O
cytokine	O
release	O
[].	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
whether	O
NMDA	O
receptor	O
hyperfunction	O
exacerbates	O
renal	O
excretory	O
function	O
in	O
a	O
rat	O
model	O
of	O
LPS	B-Chemical
-	O
induced	O
endotoxemia	O
.	O
Since	O
NR1	O
is	O
expressed	O
in	O
porcine	O
kidney	O
epithelial	O
cells	O
(	O
LLC	O
-	O
PK1	O
)	O
and	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
(	O
MDCK	O
)	O
cells	O
"[],"	O
which	O
represent	O
cells	O
of	O
proximal	O
and	O
distal	O
tubule	O
origin	O
","	O
respectively	O
.	O
The	O
direct	O
effect	O
of	O
LPS	B-Chemical
on	O
these	O
cells	O
and	O
on	O
proximal	O
tubular	O
cells	O
isolated	O
from	O
rat	O
kidneys	O
was	O
also	O
tested	O
as	O
a	O
model	O
of	O
tubular	O
cell	O
damage	O
.	O
Materials	O
and	O
Methods	O
Experimental	O
animals	O
Experiments	O
were	O
performed	O
using	O
male	O
Wistar	O
rats	O
(	O
BioLasco	O
","	O
Taipei	O
","	O
Taiwan	O
)	O
weighing	O
approximately	O
200	O
â€“	O
250	O
g	O
.	O
All	O
animal	O
studies	O
were	O
reviewed	O
and	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
Fu	O
Jen	O
Catholic	O
University	O
(	O
permit	O
numbers	O
:	O
A10128	O
and	O
A10247	O
"),"	O
and	O
animal	O
care	O
and	O
experimental	O
protocols	O
were	O
performed	O
in	O
accordance	O
with	O
the	O
guidelines	O
for	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	O
(	O
National	O
Academy	O
Press	O
","	O
Washington	O
DC	O
","	O
2011	O
).	O
All	O
surgery	O
was	O
performed	O
under	O
sodium	B-Chemical
pentobarbital	I-Chemical
anesthesia	O
","	O
and	O
all	O
efforts	O
were	O
made	O
to	O
minimize	O
suffering	O
.	O
Induction	O
of	O
endotoxemia	O
and	O
NMDA	O
receptor	O
inhibition	O
Rats	O
received	O
an	O
intraperitoneal	O
injection	O
of	O
LPS	B-Chemical
(	O
4	O
mg	O
kg	O
-	O
1	O
;	O
Escherichia	O
coli	O
serotype	O
55	O
:	O
B5	O
;	O
Sigma	O
-	O
Aldrich	O
","	O
St	O
.	O
Louis	O
","	O
MO	O
)	O
to	O
induce	O
endotoxemia	O
","	O
as	O
previously	O
described	O
[].	O
These	O
rats	O
were	O
termed	O
the	O
â€œ	O
LPS	B-Chemical
group	O
â€.	O
Control	O
groups	O
received	O
identical	O
volumes	O
of	O
phosphate	B-Chemical
-	I-Chemical
buffered	I-Chemical
saline	I-Chemical
(	O
PBS	B-Chemical
","	O
pH	O
7	O
.	O
4	O
).	O
Basic	O
body	O
data	O
and	O
hemodynamic	O
parameters	O
were	O
evaluated	O
at	O
8	O
","	O
24	O
","	O
and	O
48	O
h	O
post	O
-	O
LPS	B-Chemical
injection	O
.	O
To	O
examine	O
the	O
role	O
of	O
NMDA	O
receptors	O
","	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
Sigma	O
-	O
Aldrich	O
)	O
was	O
co	O
-	O
administered	O
to	O
LPS	B-Chemical
-	O
treated	O
(	O
the	O
LPS	B-Chemical
+	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
group	O
)	O
and	O
PBS	B-Chemical
-	O
treated	O
(	O
the	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
group	O
)	O
rats	O
(	O
0	O
.	O
3	O
mg	O
kg	O
-	O
1	O
via	O
subcutaneous	O
injection	O
"),"	O
as	O
previously	O
described	O
[].	O
This	O
dose	O
did	O
not	O
produce	O
obvious	O
side	O
effects	O
","	O
such	O
as	O
behavioral	O
changes	O
"[],"	O
and	O
the	O
final	O
concentration	O
in	O
treated	O
animals	O
was	O
comparable	O
with	O
that	O
reported	O
in	O
a	O
previous	O
study	O
[].	O
Surgical	O
preparation	O
for	O
hemodynamic	O
measurements	O
After	O
induction	O
","	O
rats	O
were	O
anesthetized	O
with	O
sodium	B-Chemical
pentobarbital	I-Chemical
(	O
50	O
mg	O
kg	O
-	O
1	O
","	O
i	O
.	O
p	O
.)	O
and	O
underwent	O
surgical	O
preparation	O
for	O
measurement	O
of	O
systemic	O
and	O
renal	O
hemodynamics	O
and	O
urine	O
collection	O
as	O
previously	O
described	O
"[,"	O
].	O
The	O
PE	O
-	O
50	O
catheter	O
was	O
placed	O
into	O
the	O
left	O
carotid	O
artery	O
for	O
blood	O
sampling	O
and	O
for	O
continuous	O
measurement	O
of	O
the	O
systemic	O
mean	O
arterial	O
blood	O
pressure	O
(	O
MABP	O
).	O
The	O
heart	O
rate	O
(	O
HR	O
)	O
was	O
measured	O
by	O
arterial	O
pulse	O
wave	O
analysis	O
using	O
MP36	O
AcqKnowledge	O
software	O
(	O
Biopac	O
","	O
Los	O
Angeles	O
","	O
CA	O
).	O
Another	O
catheter	O
was	O
inserted	O
into	O
the	O
left	O
femoral	O
vein	O
to	O
facilitate	O
saline	B-Chemical
supplementation	O
.	O
The	O
left	O
kidney	O
was	O
exposed	O
via	O
a	O
flank	O
incision	O
and	O
the	O
ureter	O
was	O
cannulated	O
by	O
PE	O
-	O
10	O
catheter	O
for	O
urine	O
collection	O
.	O
The	O
renal	O
blood	O
flow	O
(	O
RBF	O
)	O
was	O
measured	O
using	O
an	O
ultrasound	O
flow	O
probe	O
(	O
Transonic	O
Systems	O
","	O
Ithaca	O
","	O
NY	O
).	O
Regional	O
blood	O
perfusion	O
in	O
the	O
renal	O
cortex	O
of	O
the	O
left	O
kidney	O
","	O
termed	O
cortical	O
microvascular	O
blood	O
flow	O
(	O
CMBF	O
"),"	O
was	O
monitored	O
using	O
a	O
flowmeter	O
(	O
Transonic	O
Systems	O
).	O
All	O
hemodynamic	O
parameters	O
were	O
continuously	O
recorded	O
and	O
displayed	O
on	O
a	O
monitor	O
.	O
Arterial	O
blood	O
(	O
200	O
Î¼l	O
)	O
was	O
then	O
sampled	O
for	O
creatinine	B-Chemical
assays	O
.	O
Measurement	O
of	O
renal	O
function	O
Following	O
a	O
1	O
h	O
recovery	O
period	O
","	O
the	O
rats	O
were	O
prepared	O
for	O
renal	O
clearance	O
studies	O
[].	O
Saline	O
","	O
containing	O
2	O
%	O
inulin	O
(	O
BioPAL	O
","	O
Inc	O
".,"	O
Worcester	O
","	O
MA	O
"),"	O
was	O
administered	O
intravenously	O
(	O
1	O
.	O
2	O
ml	O
h	O
-	O
1	O
)	O
throughout	O
the	O
experiment	O
.	O
An	O
arterial	O
blood	O
sample	O
(	O
200	O
Î¼l	O
)	O
was	O
obtained	O
from	O
the	O
carotid	O
arterial	O
catheter	O
half	O
way	O
through	O
a	O
1	O
h	O
clearance	O
period	O
.	O
Biochemical	O
assays	O
and	O
urinalysis	O
All	O
assays	O
were	O
performed	O
as	O
described	O
previously	O
"[,"	O
","	O
","	O
].	O
Plasma	O
creatinine	B-Chemical
levels	O
were	O
measured	O
using	O
a	O
commercial	O
kit	O
(	O
Bio	O
-	O
Quant	O
","	O
San	O
Diego	O
","	O
CA	O
).	O
Urine	O
volume	O
was	O
estimated	O
gravimetrically	O
to	O
determine	O
the	O
urinary	O
flow	O
rate	O
","	O
and	O
hematocrit	O
was	O
measured	O
by	O
a	O
capillary	O
tube	O
after	O
centrifugation	O
.	O
The	O
inulin	B-Chemical
concentration	O
in	O
urine	O
and	O
plasma	O
was	O
measured	O
by	O
spectrophotometry	O
","	O
and	O
the	O
GFR	O
was	O
estimated	O
according	O
to	O
inulin	B-Chemical
clearance	O
.	O
Sodium	B-Chemical
levels	O
in	O
urine	O
or	O
plasma	O
were	O
measured	O
using	O
flame	O
photometry	O
to	O
determine	O
the	O
excretory	O
rate	O
of	O
sodium	B-Chemical
and	O
fractional	O
excretion	O
of	O
sodium	B-Chemical
.	O
Fractional	O
excretion	O
of	O
sodium	B-Chemical
(%)	O
was	O
calculated	O
as	O
[	O
urinary	O
excretion	O
rate	O
of	O
sodium	B-Chemical
/(	O
plasma	O
sodium	B-Chemical
concentration	O
Ã—	O
GFR	O
)]	O
Ã—	O
100	O
.	O
Renal	O
filtration	O
fraction	O
(%)	O
was	O
calculated	O
as	O
{	O
GFR	O
/[	O
RBF	O
Ã—(	O
1	O
-	O
hematocrit	O
)]	O
Ã—	O
100	O
}.	O
Urinary	O
levels	O
of	O
protein	O
","	O
Î±	O
-	O
GST	O
","	O
and	O
Î¼	O
-	O
GST	O
were	O
measured	O
using	O
commercial	O
kits	O
","	O
as	O
previously	O
described	O
[].	O
Tubular	O
cell	O
cultures	O
and	O
drug	O
treatment	O
For	O
the	O
in	O
vitro	O
assays	O
","	O
LLC	O
-	O
PK1	O
and	O
MDCK	O
cells	O
were	O
used	O
as	O
a	O
model	O
of	O
proximal	O
and	O
distal	O
tubule	O
cells	O
","	O
respectively	O
","	O
and	O
rat	O
proximal	O
tubular	O
cells	O
were	O
isolated	O
for	O
use	O
as	O
the	O
primary	O
culture	O
model	O
.	O
LLC	O
-	O
PK1	O
and	O
MDCK	O
cells	O
were	O
purchased	O
from	O
the	O
Bioresource	O
Collection	O
and	O
Research	O
Center	O
(	O
Hsinchu	O
","	O
Taiwan	O
).	O
Tubular	O
cell	O
lines	O
were	O
originally	O
derived	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
lines	O
CL	O
-	O
101	O
(	O
for	O
LLC	O
-	O
PK1	O
)	O
and	O
CCL	O
-	O
34	O
(	O
for	O
MDCK	O
).	O
All	O
culture	O
medium	O
and	O
supplements	O
were	O
purchased	O
from	O
Thermo	O
Scientific	O
HyClone	O
(	O
South	O
Logan	O
","	O
UT	O
).	O
LLC	O
-	O
PK1	O
cells	O
were	O
cultured	O
at	O
37	O
Â°	O
C	O
/	O
5	O
%	O
CO2	B-Chemical
in	O
Medium	B-Chemical
199	I-Chemical
containing	O
3	O
%	O
fetal	O
bovine	O
serum	O
","	O
sodium	B-Chemical
bicarbonate	I-Chemical
(	O
1	O
.	O
5	O
g	O
l	O
-	O
1	O
"),"	O
penicillin	B-Chemical
(	O
10	O
","	O
0	O
U	O
ml	O
-	O
1	O
)	O
and	O
streptomycin	B-Chemical
(	O
10	O
","	O
0	O
Î¼g	O
ml	O
-	O
1	O
).	O
Cells	O
were	O
subcultured	O
when	O
they	O
reached	O
confluence	O
(	O
approximately	O
every	O
2	O
â€“	O
3	O
days	O
).	O
MDCK	O
cells	O
were	O
cultured	O
in	O
Eagle	O
â€™	O
s	O
Minimum	O
Essential	O
Medium	O
containing	O
10	O
%	O
fetal	O
bovine	O
serum	O
","	O
2	O
mM	O
L	B-Chemical
-	I-Chemical
glutamine	I-Chemical
","	O
1	O
.	O
5	O
g	O
l	O
-	O
1	O
sodium	B-Chemical
bicarbonate	I-Chemical
","	O
0	O
.	O
1	O
mM	O
nonessential	O
amino	B-Chemical
acids	I-Chemical
","	O
1	O
mM	O
sodium	B-Chemical
pyruvate	I-Chemical
","	O
and	O
the	O
same	O
concentrations	O
of	O
penicillin	B-Chemical
and	O
streptomycin	B-Chemical
.	O
Cells	O
were	O
treated	O
with	O
PBS	B-Chemical
","	O
LPS	B-Chemical
(	O
50	O
Î¼g	O
ml	O
-	O
1	O
"),"	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
(	O
1	O
Î¼M	O
"),"	O
a	O
TLR	O
-	O
4	O
antagonist	O
(	O
LPS	B-Chemical
from	O
Rhodobacter	O
sphaeroides	O
","	O
LPS	B-Chemical
-	O
RS	O
;	O
20	O
ng	O
ml	O
-	O
1	O
;	O
Sigma	O
-	O
Aldrich	O
"),"	O
an	O
IL	O
-	O
1	O
receptor	O
antagonist	O
(	O
IL	O
-	O
1Ra	O
","	O
10	O
ng	O
ml	O
-	O
1	O
;	O
Sigma	O
-	O
Aldrich	O
"),"	O
or	O
a	O
combination	O
of	O
these	O
for	O
4	O
","	O
8	O
","	O
or	O
24	O
h	O
.	O
Dosing	O
was	O
determined	O
by	O
reference	O
to	O
the	O
IC50	O
of	O
each	O
antagonist	O
.	O
Proximal	O
tubular	O
cells	O
were	O
isolated	O
from	O
rat	O
kidneys	O
by	O
enzymatic	O
digestion	O
using	O
a	O
commercial	O
kit	O
(	O
Chi	O
Scientific	O
","	O
Maynard	O
","	O
MA	O
).	O
Kidneys	O
were	O
removed	O
from	O
anesthetized	O
rats	O
and	O
washed	O
with	O
ice	O
-	O
cold	O
tissue	O
washing	O
medium	O
(	O
modified	O
DMEM	O
medium	O
containing	O
amphotericin	B-Chemical
","	O
gentamycin	B-Chemical
","	O
and	O
fetal	O
bovine	O
serum	O
)	O
to	O
remove	O
blood	O
.	O
Renal	O
cortical	O
tissue	O
was	O
collected	O
with	O
the	O
help	O
of	O
a	O
stereomicroscope	O
(	O
Olympus	O
","	O
Center	O
Valley	O
","	O
PA	O
).	O
Cortical	O
samples	O
were	O
sliced	O
into	O
pieces	O
(~	O
1	O
mm	O
wide	O
)	O
and	O
digested	O
with	O
tissue	O
dissociation	O
medium	O
containing	O
collagenase	O
and	O
trypsin	O
at	O
37	O
Â°	O
C	O
for	O
30	O
min	O
with	O
stirring	O
.	O
The	O
suspension	O
was	O
then	O
filtered	O
through	O
a	O
sieve	O
with	O
a	O
mesh	O
size	O
of	O
80	O
Î¼m	O
.	O
The	O
cells	O
were	O
collected	O
from	O
the	O
sieve	O
after	O
centrifugation	O
and	O
then	O
suspended	O
in	O
basal	O
culture	O
medium	O
containing	O
fibroblast	O
growth	O
inhibitor	O
","	O
rat	O
epidermal	O
growth	O
factor	O
","	O
hydrocortisone	B-Chemical
","	O
and	O
penicillin	B-Chemical
/	O
streptomycin	B-Chemical
.	O
Cells	O
were	O
plated	O
at	O
an	O
appropriate	O
cell	O
density	O
in	O
a	O
collagen	O
-	O
coated	O
dish	O
and	O
then	O
cultured	O
at	O
37	O
Â°	O
C	O
/	O
5	O
%	O
CO2	B-Chemical
.	O
The	O
culture	O
medium	O
was	O
changed	O
after	O
24	O
h	O
to	O
remove	O
nonadherent	O
cells	O
and	O
residual	O
cellular	O
fragments	O
.	O
After	O
5	O
days	O
","	O
the	O
cell	O
cultures	O
with	O
80	O
%	O
of	O
confluent	O
were	O
treated	O
with	O
LPS	B-Chemical
or	O
siRNA	O
.	O
RNA	O
interference	O
for	O
NR1	O
A	O
commercially	O
available	O
siRNA	O
targeting	O
NR1	O
(	O
Ambion	O
","	O
Life	O
Technologies	O
","	O
Carlsbad	O
","	O
CA	O
)	O
was	O
used	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O
Tubular	O
cells	O
were	O
plated	O
in	O
96	O
-	O
well	O
plates	O
.	O
When	O
the	O
cells	O
reached	O
80	O
%	O
confluence	O
","	O
the	O
culture	O
medium	O
was	O
replaced	O
with	O
fresh	O
serum	O
-	O
and	O
antibiotic	O
-	O
free	O
medium	O
.	O
The	O
NR1	O
siRNA	O
(	O
Ambion	O
)	O
sense	O
strand	O
sequence	O
was	O
5	O
â€²-	O
GGAGAAUAUCACUGACCCAtt	O
-	O
3	O
â€².	O
Briefly	O
","	O
transfection	O
reagent	O
(	O
siPROT	O
","	O
Ambion	O
)	O
and	O
siRNA	O
(	O
final	O
concentration	O
","	O
30	O
nM	O
)	O
were	O
mixed	O
in	O
serum	O
-	O
free	O
medium	O
and	O
incubated	O
at	O
room	O
temperature	O
for	O
20	O
min	O
.	O
The	O
mixture	O
was	O
then	O
added	O
to	O
the	O
cells	O
in	O
each	O
well	O
for	O
12	O
h	O
of	O
incubation	O
before	O
LPS	B-Chemical
treatment	O
.	O
After	O
transfection	O
","	O
the	O
culture	O
medium	O
was	O
replaced	O
with	O
fresh	O
medium	O
prior	O
to	O
LPS	B-Chemical
treatment	O
.	O
Cell	O
viability	O
and	O
assays	O
Commercial	O
kits	O
were	O
used	O
to	O
measure	O
the	O
levels	O
of	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
(	O
Roche	O
Applied	O
Science	O
","	O
IN	O
"),"	O
IFN	O
-	O
Î³	O
","	O
IL	O
-	O
1Î²	O
","	O
and	O
TNF	O
-	O
Î±	O
(	O
R	O
&	O
D	O
Systems	O
","	O
Inc	O
".,"	O
Minneapolis	O
","	O
MN	O
)	O
in	O
the	O
cell	O
culture	O
medium	O
.	O
Measurement	O
of	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
An	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
was	O
used	O
to	O
measure	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
","	O
as	O
previously	O
described	O
"[,"	O
].	O
Renal	O
tissues	O
","	O
brain	O
cortex	O
","	O
and	O
cell	O
pellets	O
were	O
homogenized	O
in	O
ice	O
-	O
cold	O
distilled	O
water	O
","	O
and	O
the	O
supernatant	O
of	O
homogenized	O
samples	O
and	O
culture	O
medium	O
were	O
collected	O
for	O
use	O
in	O
the	O
assay	O
.	O
The	O
protein	O
concentration	O
in	O
sample	O
was	O
determined	O
using	O
a	O
colorimetric	O
assay	O
kit	O
from	O
Bio	O
-	O
Rad	O
(	O
Hercules	O
","	O
CA	O
).	O
Glutaraldehyde	B-Chemical
(	O
25	O
Î¼l	O
)	O
was	O
added	O
to	O
100	O
Î¼l	O
of	O
each	O
extract	O
(	O
containing	O
1	O
mg	O
ml	O
-	O
1	O
sample	O
protein	O
)	O
or	O
to	O
100	O
Î¼l	O
of	O
a	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
standard	O
(	O
0	O
.	O
1	O
â€“	O
10	O
nM	O
)	O
in	O
PBS	B-Chemical
containing	O
0	O
.	O
2	O
mg	O
ml	O
-	O
1	O
BSA	O
.	O
The	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
standard	O
solutions	O
and	O
samples	O
containing	O
glutaraldehyde	B-Chemical
were	O
mixed	O
thoroughly	O
","	O
and	O
50	O
Î¼l	O
of	O
this	O
solution	O
was	O
added	O
to	O
a	O
96	O
-	O
well	O
plate	O
in	O
duplicate	O
.	O
After	O
2	O
h	O
of	O
incubation	O
at	O
room	O
temperature	O
","	O
the	O
wells	O
were	O
washed	O
with	O
PBS	B-Chemical
containing	O
Tween	B-Chemical
20	I-Chemical
(	O
PBST	B-Chemical
)	O
and	O
air	O
dried	O
.	O
Blocking	O
buffer	O
(	O
2	O
%	O
nonfat	O
milk	O
in	O
PBST	B-Chemical
;	O
50	O
Î¼l	O
)	O
was	O
added	O
to	O
each	O
well	O
and	O
incubated	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O
The	O
plates	O
were	O
then	O
washed	O
three	O
times	O
in	O
PBST	B-Chemical
(	O
300	O
Î¼l	O
per	O
well	O
).	O
A	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
-	O
specific	O
antibody	O
(	O
Santa	O
Cruz	O
Biotechnology	O
","	O
Dallas	O
","	O
TX	O
)	O
was	O
diluted	O
1	O
:	O
1	O
","	O
0	O
in	O
PBST	B-Chemical
containing	O
1	O
%	O
BSA	O
.	O
Fifty	O
microliters	O
of	O
this	O
solution	O
was	O
then	O
added	O
to	O
each	O
well	O
and	O
incubated	O
for	O
1	O
h	O
","	O
followed	O
by	O
three	O
washes	O
with	O
PBST	B-Chemical
.	O
A	O
horseradish	O
peroxidase	O
-	O
linked	O
anti	O
-	O
rabbit	O
antibody	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
was	O
then	O
added	O
for	O
30	O
min	O
","	O
followed	O
by	O
three	O
washes	O
in	O
PBST	B-Chemical
.	O
A	O
solution	O
of	O
2	B-Chemical
","	I-Chemical
2	I-Chemical
'-	I-Chemical
azinobis	I-Chemical
[	I-Chemical
3	I-Chemical
-	I-Chemical
ethylbenzothiazoline	I-Chemical
-	I-Chemical
6	I-Chemical
-	I-Chemical
sulfonic	I-Chemical
acid	I-Chemical
]-	I-Chemical
diammonium	I-Chemical
salt	I-Chemical
(	O
50	O
Î¼l	O
","	O
Sigma	O
-	O
Aldrich	O
)	O
was	O
added	O
to	O
each	O
well	O
and	O
the	O
resulting	O
colorimetric	O
reaction	O
was	O
measured	O
at	O
405	O
nm	O
.	O
The	O
amount	O
of	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
in	O
sample	O
was	O
expressed	O
as	O
nmole	O
per	O
mg	O
of	O
protein	O
.	O
Detection	O
of	O
protein	O
and	O
mRNA	O
expression	O
Western	O
blotting	O
was	O
performed	O
using	O
antibodies	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
against	O
NR1	O
(	O
1	O
:	O
1000	O
"),"	O
S	O
-	O
Race	O
(	O
1	O
:	O
5000	O
"),"	O
TLR4	O
(	O
1	O
:	O
2000	O
"),"	O
or	O
actin	O
(	O
1	O
:	O
5000	O
"),"	O
as	O
described	O
previously	O
[].	O
Semi	O
-	O
quantitative	O
or	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
detect	O
NR1	O
or	O
S	O
-	O
Race	O
mRNA	O
expression	O
","	O
as	O
previously	O
described	O
[].	O
Complementary	O
DNA	O
(	O
cDNA	O
)	O
was	O
synthesized	O
using	O
10	O
Î¼g	O
of	O
total	O
RNA	O
and	O
amplified	O
","	O
as	O
previously	O
described	O
(	O
8	O
).	O
The	O
NR1	O
primer	O
sequences	O
for	O
conventional	O
PCR	O
were	O
as	O
follows	O
:	O
5	O
â€™-	O
ACG	O
GAA	O
TGA	O
TGG	O
GCG	O
AGC	O
-	O
3	O
â€™	O
(	O
sense	O
)	O
and	O
5	O
â€™-	O
GGC	O
ATC	O
CTT	O
GTG	O
TCG	O
CTT	O
GTA	O
G	O
-	O
3	O
â€™	O
(	O
antisense	O
)	O
(	O
transcript	O
product	O
","	O
1	O
","	O
33	O
bp	O
;	O
NM_017010	O
).	O
The	O
S	O
-	O
Race	O
primers	O
were	O
as	O
follows	O
:	O
5	O
â€™-	O
CCC	O
AAA	O
GCC	O
GTT	O
GTT	O
ACT	O
CAC	O
A	O
-	O
3	O
â€™	O
(	O
sense	O
)	O
and	O
5	O
â€™-	O
CAT	O
TGG	O
AAG	O
GTT	O
CAG	O
CAG	O
CGT	O
ACA	O
-	O
3	O
â€™	O
(	O
antisense	O
)	O
(	O
395	O
bp	O
;	O
NM_198757	O
).	O
Actin	O
primers	O
were	O
as	O
follows	O
:	O
5	O
â€™-	O
TCA	O
GGT	O
CAT	O
CAC	O
TAT	O
CGG	O
G	O
-	O
3	O
â€™	O
(	O
sense	O
)	O
and	O
5	O
â€™-	O
CAG	O
TAA	O
TCT	O
CCT	O
TCT	O
GCA	O
TC	O
-	O
3	O
â€™	O
(	O
antisense	O
)	O
(	O
221	O
bp	O
;	O
NM_031144	O
.	O
3	O
).	O
PCR	O
began	O
with	O
a	O
denaturation	O
step	O
of	O
1	O
min	O
at	O
94	O
Â°	O
C	O
followed	O
by	O
40	O
cycles	O
for	O
NR1	O
","	O
S	O
-	O
Race	O
","	O
and	O
actin	O
at	O
94	O
Â°	O
C	O
for	O
30	O
s	O
","	O
58	O
Â°	O
C	O
for	O
1	O
min	O
","	O
and	O
72	O
Â°	O
C	O
for	O
1	O
min	O
.	O
The	O
PCR	O
products	O
were	O
electrophoresed	O
on	O
a	O
2	O
%	O
agarose	B-Chemical
gel	O
and	O
visualized	O
by	O
ethidium	B-Chemical
bromide	I-Chemical
staining	O
.	O
The	O
densities	O
of	O
the	O
bands	O
were	O
measured	O
using	O
an	O
image	O
analytic	O
system	O
(	O
Diagnostic	O
Instruments	O
"),"	O
and	O
mRNA	O
levels	O
are	O
expressed	O
as	O
the	O
ratio	O
of	O
NR1	O
or	O
S	O
-	O
Race	O
to	O
actin	O
.	O
The	O
primer	O
sequences	O
for	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
were	O
listed	O
in	O
S1	O
Table	O
.	O
The	O
comparative	O
CT	O
(	O
Î”Î”CT	O
)	O
method	O
was	O
used	O
to	O
quantify	O
NR1	O
mRNA	O
levels	O
.	O
The	O
calculation	O
used	O
was	O
:	O
Î”Î”CT	O
=	O
[	O
CT	O
NR1	O
(	O
unknown	O
sample	O
)â€”	O
CT	O
GAPDH	O
(	O
unknown	O
sample	O
)]â€”[	O
CT	O
NR1	O
(	O
calibrator	O
sample	O
)â€”	O
CT	O
GAPDH	O
(	O
calibrator	O
sample	O
)].	O
The	O
cDNA	O
of	O
calibrator	O
sample	O
was	O
obtained	O
from	O
rat	O
brain	O
cortex	O
.	O
Indirect	O
immunofluorescent	O
staining	O
was	O
used	O
to	O
examine	O
the	O
cellular	O
distribution	O
of	O
FLK	O
-	O
1	O
(	O
Santa	O
Cruz	O
Biotechnology	O
"),"	O
NR1	O
","	O
or	O
S	O
-	O
Race	O
and	O
their	O
co	O
-	O
localization	O
in	O
renal	O
tissues	O
or	O
tubular	O
cells	O
","	O
as	O
described	O
previously	O
[].	O
Briefly	O
","	O
postfixed	O
kidneys	O
were	O
stored	O
in	O
10	O
%	O
sucrose	B-Chemical
prepared	O
in	O
4	O
%	O
paraformaldehyde	B-Chemical
solution	O
at	O
4	O
Â°	O
C	O
","	O
embedded	O
in	O
O	O
.	O
C	O
.	O
T	O
.	O
compound	O
(	O
Tissue	O
-	O
Tek	O
","	O
Sakura	O
Finetek	O
","	O
Torrence	O
","	O
CA	O
"),"	O
and	O
frozen	O
at	O
â€“	O
20	O
Â°	O
C	O
","	O
and	O
then	O
cut	O
into	O
5	O
Î¼m	O
sections	O
on	O
a	O
cryostat	O
(	O
Microm	O
","	O
Heidelberg	O
","	O
Germany	O
"),"	O
which	O
were	O
thaw	O
-	O
mounted	O
on	O
coated	O
slides	O
.	O
Cells	O
were	O
cultured	O
on	O
poly	B-Chemical
-	I-Chemical
D	I-Chemical
-	I-Chemical
lysine	I-Chemical
-	O
precoated	O
glass	O
dishes	O
and	O
postfixed	O
in	O
4	O
%	O
paraformaldehyde	B-Chemical
solution	O
at	O
4	O
Â°	O
C	O
for	O
2	O
h	O
.	O
After	O
being	O
rehydrated	O
and	O
washed	O
with	O
PBS	B-Chemical
","	O
tissue	O
sections	O
and	O
culture	O
dishes	O
were	O
processed	O
for	O
indirect	O
immunofluorescence	O
using	O
a	O
tyramide	B-Chemical
signal	O
amplification	O
kit	O
(	O
PerkinElmer	O
","	O
Waltham	O
","	O
MA	O
).	O
After	O
being	O
blocked	O
with	O
5	O
%	O
skimmed	O
milk	O
prepared	O
in	O
PBS	B-Chemical
for	O
1	O
h	O
","	O
sections	O
were	O
incubated	O
overnight	O
at	O
4	O
Â°	O
C	O
with	O
an	O
anti	O
-	O
NR1	O
antibody	O
and	O
then	O
for	O
1	O
h	O
at	O
room	O
temperature	O
(	O
RT	O
)	O
with	O
the	O
corresponding	O
cyanine	B-Chemical
3	I-Chemical
-	O
conjugated	O
secondary	O
antibody	O
.	O
After	O
detection	O
of	O
NR1	O
","	O
tissue	O
sections	O
or	O
culture	O
dishes	O
were	O
incubated	O
overnight	O
at	O
4	O
Â°	O
C	O
with	O
an	O
anti	O
-	O
S	O
-	O
Race	O
or	O
anti	O
-	O
FLK	O
-	O
1	O
antibody	O
","	O
and	O
then	O
for	O
1	O
h	O
at	O
RT	O
with	O
the	O
corresponding	O
fluorescein	B-Chemical
-	O
conjugated	O
secondary	O
antibody	O
","	O
and	O
examined	O
on	O
an	O
inverted	O
microscope	O
(	O
Leica	O
Microsystems	O
GmbH	O
","	O
Wetzlar	O
","	O
Germany	O
)	O
equipped	O
with	O
a	O
fluorescence	O
image	O
analytic	O
system	O
(	O
Diagnostic	O
Instruments	O
","	O
Sterling	O
Heights	O
","	O
MI	O
).	O
Nuclei	O
were	O
counterstained	O
using	O
DAPI	B-Chemical
.	O
The	O
specificity	O
of	O
each	O
antibody	O
was	O
tested	O
by	O
preincubation	O
with	O
the	O
specific	O
blocking	O
peptide	O
provided	O
by	O
Santa	O
Cruz	O
Biotechnology	O
(	O
150	O
Î¼g	O
ml	O
-	O
1	O
)	O
before	O
performing	O
the	O
test	O
.	O
Statistical	O
analysis	O
Data	O
are	O
expressed	O
as	O
the	O
mean	O
Â±	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
).	O
Plasma	O
creatinine	B-Chemical
","	O
proteinuria	O
","	O
and	O
enzymuria	O
data	O
that	O
are	O
not	O
normally	O
distributed	O
are	O
expressed	O
as	O
median	O
and	O
interquartile	O
range	O
(	O
IQR	O
).	O
Statistical	O
analysis	O
was	O
performed	O
using	O
analysis	O
of	O
variance	O
coupled	O
with	O
Bonferroni	O
post	O
hoc	O
analysis	O
or	O
non	O
-	O
parametric	O
Mann	O
-	O
Whitney	O
test	O
for	O
multiple	O
comparisons	O
between	O
groups	O
.	O
A	O
P	O
value	O
of	O
<	O
0	O
.	O
5	O
was	O
considered	O
significant	O
.	O
Results	O
NMDA	O
receptor	O
inhibition	O
attenuates	O
LPS	B-Chemical
-	O
induced	O
impairment	O
of	O
renal	O
function	O
Compared	O
with	O
the	O
control	O
group	O
","	O
LPS	B-Chemical
increased	O
plasma	O
creatinine	B-Chemical
levels	O
at	O
24	O
and	O
48	O
h	O
(	O
Fig	O
1	O
)	O
and	O
this	O
was	O
associated	O
with	O
increased	O
urinary	O
protein	O
excretion	O
at	O
all	O
time	O
-	O
points	O
(	O
P	O
<	O
0	O
.	O
5	O
).	O
Moreover	O
","	O
LPS	B-Chemical
significantly	O
increased	O
urinary	O
excretion	O
of	O
the	O
specific	O
tubular	O
markers	O
","	O
Î±	O
-	O
glutathione	O
S	O
-	O
transferase	O
(	O
Î±	O
-	O
GST	O
","	O
a	O
proximal	O
tubular	O
cell	O
marker	O
of	O
cytoplasmic	O
leakage	O
)	O
and	O
Î¼	O
-	O
GST	O
(	O
a	O
distal	O
tubular	O
cell	O
marker	O
"),"	O
at	O
4	O
â€“	O
48	O
h	O
and	O
at	O
24	O
â€“	O
48	O
h	O
","	O
respectively	O
.	O
Body	O
weight	O
","	O
left	O
kidney	O
weight	O
","	O
hematocrit	O
","	O
and	O
plasma	O
sodium	B-Chemical
concentration	O
were	O
similar	O
for	O
all	O
groups	O
(	O
S2	O
Table	O
).	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
reduced	O
LPS	B-Chemical
-	O
induced	O
increases	O
in	O
plasma	O
creatinine	B-Chemical
","	O
with	O
a	O
significant	O
effect	O
observed	O
at	O
48	O
h	O
.	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
also	O
abrogated	O
LPS	B-Chemical
-	O
induced	O
enzymuria	O
.	O
Effects	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
on	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)-	O
mediated	O
changes	O
in	O
plasma	O
creatinine	B-Chemical
","	O
proteinuria	O
","	O
and	O
enzymuria	O
.	O
The	O
bar	O
represents	O
50	O
%	O
of	O
the	O
values	O
(	O
median	O
)	O
with	O
the	O
upper	O
bar	O
representing	O
the	O
75th	O
percentile	O
(	O
Q3	O
)	O
and	O
the	O
lower	O
bar	O
representing	O
the	O
25th	O
percentile	O
(	O
Q1	O
).	O
N	O
=	O
8	O
in	O
each	O
group	O
.	O
*	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
control	O
groups	O
.	O
#	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
LPS	B-Chemical
group	O
at	O
the	O
same	O
time	O
-	O
point	O
.	O
â€ 	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
group	O
.	O
There	O
were	O
no	O
differences	O
in	O
MABP	O
among	O
groups	O
(	O
Fig	O
2	O
).	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
abolished	O
tachycardia	O
in	O
the	O
LPS48	O
group	O
.	O
LPS	B-Chemical
impaired	O
renal	O
function	O
in	O
the	O
left	O
kidney	O
by	O
reducing	O
RBF	O
","	O
CMBF	O
","	O
GFR	O
","	O
and	O
filtration	O
fraction	O
at	O
24	O
or	O
48	O
h	O
","	O
but	O
not	O
at	O
8	O
h	O
.	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
significantly	O
improved	O
the	O
LPS	B-Chemical
-	O
induced	O
functional	O
decline	O
","	O
although	O
low	O
GFRs	O
were	O
still	O
seen	O
at	O
24	O
and	O
48	O
h	O
.	O
Baseline	O
urinary	O
output	O
and	O
Na	B-Chemical
+	O
excretion	O
were	O
similar	O
among	O
groups	O
.	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
reversed	O
the	O
LPS	B-Chemical
-	O
induced	O
increases	O
in	O
fractional	O
excretion	O
of	O
sodium	B-Chemical
at	O
24	O
and	O
48	O
h	O
","	O
indicating	O
NMDA	O
receptor	O
inhibition	O
ameliorates	O
sodium	B-Chemical
-	O
wasting	O
.	O
Effects	O
of	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
on	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)-	O
mediated	O
renal	O
functional	O
impairment	O
.	O
N	O
=	O
8	O
in	O
each	O
group	O
.	O
*	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
control	O
groups	O
.	O
#	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
LPS	B-Chemical
group	O
at	O
the	O
same	O
time	O
-	O
point	O
.	O
â€ 	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
group	O
.	O
Detection	O
of	O
NR1	O
and	O
S	O
-	O
Race	O
expression	O
in	O
renal	O
tissues	O
LPS	B-Chemical
caused	O
a	O
gradual	O
and	O
time	O
-	O
dependent	O
increase	O
in	O
NR1	O
expression	O
in	O
the	O
renal	O
cortex	O
and	O
medulla	O
(	O
Fig	O
3A	O
).	O
By	O
contrast	O
","	O
LPS	B-Chemical
caused	O
an	O
abrupt	O
increase	O
in	O
S	O
-	O
Race	O
expression	O
after	O
8	O
h	O
of	O
treatment	O
","	O
which	O
remained	O
high	O
thereafter	O
.	O
Immunostaining	O
identified	O
NR1	O
in	O
the	O
endothelial	O
lining	O
of	O
renal	O
vessels	O
(	O
marked	O
by	O
FLK	O
-	O
1	O
","	O
a	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
","	O
Fig	O
3B	O
)	O
and	O
at	O
the	O
apical	O
membrane	O
of	O
the	O
proximal	O
tubules	O
and	O
collecting	O
ducts	O
","	O
with	O
a	O
more	O
limited	O
distribution	O
in	O
the	O
glomeruli	O
of	O
control	O
kidneys	O
(	O
Fig	O
3C	O
).	O
S	O
-	O
Race	O
was	O
mostly	O
localized	O
in	O
the	O
renal	O
tubules	O
","	O
although	O
there	O
was	O
some	O
expression	O
in	O
the	O
renal	O
vessels	O
.	O
No	O
signal	O
was	O
observed	O
in	O
the	O
glomeruli	O
.	O
NR1	O
mainly	O
co	O
-	O
localized	O
with	O
S	O
-	O
Race	O
.	O
Compared	O
with	O
that	O
in	O
the	O
control	O
group	O
","	O
there	O
was	O
a	O
marked	O
increase	O
in	O
the	O
NR1	O
signal	O
in	O
the	O
tubules	O
and	O
vessels	O
in	O
LPS48	O
-	O
treated	O
kidneys	O
;	O
however	O
","	O
increased	O
S	O
-	O
Race	O
expression	O
was	O
only	O
observed	O
in	O
tubules	O
in	O
which	O
NR1	O
was	O
also	O
present	O
.	O
LPS	B-Chemical
treatment	O
also	O
increased	O
the	O
expression	O
of	O
NR1	O
and	O
S	O
-	O
Race	O
mRNA	O
(	O
Fig	O
3D	O
).	O
Changes	O
in	O
NR1	O
and	O
S	O
-	O
Race	O
expression	O
in	O
the	O
rat	O
kidney	O
.	O
(	O
A	O
)	O
The	O
upper	O
panels	O
show	O
representative	O
blots	O
from	O
control	O
and	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)-	O
treated	O
kidneys	O
at	O
8	O
","	O
24	O
","	O
and	O
48	O
h	O
(	O
n	O
=	O
3	O
"),"	O
together	O
with	O
a	O
positive	O
sample	O
obtained	O
from	O
brain	O
cortex	O
(	O
Bc	O
).	O
Bar	O
graphs	O
show	O
the	O
ratio	O
of	O
NR1	O
or	O
S	O
-	O
Race	O
to	O
actin	O
[	O
expressed	O
as	O
densitometric	O
units	O
(	O
DU	O
)]	O
(	O
n	O
=	O
8	O
).	O
(	O
B	O
)	O
Representative	O
micrographs	O
of	O
FLK	O
-	O
1	O
-	O
(	O
green	O
)	O
and	O
NR1	O
-	O
(	O
red	O
)	O
positive	O
immunoreactivity	O
","	O
and	O
co	O
-	O
localized	O
immunofluorescence	O
(	O
yellow	O
color	O
in	O
merged	O
picture	O
)	O
in	O
the	O
control	O
kidney	O
.	O
Nuclei	O
were	O
counterstained	O
with	O
DAPI	B-Chemical
(	O
blue	O
).	O
G	O
","	O
glomerulus	O
.	O
The	O
horizontal	O
bars	O
in	O
merged	O
pictures	O
indicate	O
150	O
Î¼m	O
.	O
(	O
C	O
)	O
Representative	O
pictures	O
of	O
NR1	O
-	O
(	O
red	O
)	O
and	O
S	O
-	O
Race	O
-	O
(	O
green	O
)	O
expression	O
","	O
and	O
co	O
-	O
localization	O
(	O
orange	O
color	O
in	O
merged	O
picture	O
)	O
in	O
the	O
control	O
kidney	O
(	O
upper	O
)	O
and	O
LPS48	O
kidney	O
(	O
lower	O
).	O
Magnification	O
:	O
Ã—	O
200	O
in	O
B	O
and	O
C	O
.	O
(	O
D	O
)	O
Right	O
panels	O
:	O
representative	O
gels	O
showing	O
NR1	O
and	O
S	O
-	O
Race	O
mRNA	O
expression	O
.	O
M	O
","	O
100	O
bp	O
DNA	O
ladder	O
;	O
C	O
","	O
control	O
;	O
Bc	O
","	O
brain	O
cortex	O
;	O
NTC	O
","	O
no	O
template	O
control	O
.	O
The	O
bar	O
graphs	O
on	O
the	O
left	O
show	O
the	O
DU	O
ratio	O
(	O
n	O
=	O
8	O
).	O
*	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
control	O
group	O
.	O
Effects	O
of	O
LPS	B-Chemical
on	O
renal	O
tubular	O
cells	O
LPS	B-Chemical
-	O
induced	O
cytotoxicity	O
in	O
tubular	O
cells	O
was	O
examined	O
in	O
a	O
LDH	O
release	O
assay	O
(	O
Fig	O
4A	O
).	O
LPS	B-Chemical
induced	O
a	O
gradual	O
increase	O
in	O
LDH	O
release	O
from	O
both	O
LLC	O
-	O
PK1	O
and	O
MDCK	O
cells	O
","	O
and	O
from	O
a	O
primary	O
culture	O
of	O
rat	O
proximal	O
tubular	O
cells	O
.	O
LPS	B-Chemical
-	O
induced	O
LDH	O
release	O
was	O
markedly	O
attenuated	O
by	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
.	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
alone	O
had	O
no	O
effect	O
on	O
LDH	O
release	O
.	O
In	O
the	O
absence	O
of	O
LPS	B-Chemical
","	O
rat	O
proximal	O
tubular	O
cells	O
showed	O
the	O
typical	O
cobblestone	O
appearance	O
of	O
a	O
normal	O
epithelial	O
cell	O
monolayer	O
(	O
Fig	O
4B	O
).	O
When	O
the	O
cells	O
were	O
exposed	O
to	O
LPS	B-Chemical
for	O
24	O
h	O
","	O
a	O
number	O
of	O
cells	O
became	O
swollen	O
and	O
enlarged	O
","	O
a	O
typical	O
feature	O
of	O
necrosis	O
.	O
LPS	B-Chemical
increased	O
the	O
expression	O
of	O
both	O
NR1	O
and	O
S	O
-	O
Race	O
in	O
all	O
tested	O
cells	O
(	O
Fig	O
4C	O
).	O
The	O
increase	O
in	O
NR1	O
expression	O
in	O
LLC	O
-	O
PK1	O
and	O
MDCK	O
cells	O
was	O
gradual	O
(	O
over	O
24	O
h	O
"),"	O
whereas	O
S	O
-	O
Race	O
expression	O
peaked	O
after	O
4	O
h	O
of	O
treatment	O
and	O
remained	O
high	O
thereafter	O
.	O
Immunocytostaining	O
revealed	O
the	O
presence	O
of	O
NR1	O
and	O
S	O
-	O
Race	O
in	O
untreated	O
LLC	O
-	O
PK1	O
cells	O
","	O
with	O
co	O
-	O
localization	O
of	O
most	O
signals	O
(	O
Fig	O
4D	O
).	O
We	O
next	O
determined	O
whether	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
targeting	O
NR1	O
could	O
silence	O
the	O
LPS	B-Chemical
-	O
mediated	O
upregulation	O
of	O
NR1	O
.	O
LPS	B-Chemical
significantly	O
increased	O
NR1	O
expression	O
at	O
mRNA	O
and	O
protein	O
levels	O
and	O
LDH	O
release	O
in	O
all	O
tested	O
cells	O
after	O
24	O
h	O
of	O
treatment	O
(	O
Fig	O
4E	O
).	O
NR1	O
silencing	O
alone	O
showed	O
no	O
effect	O
on	O
NR1	O
mRNA	O
expression	O
but	O
reduced	O
NR1	O
protein	O
expression	O
in	O
LLC	O
-	O
PK1	O
and	O
MDCK	O
cells	O
.	O
Both	O
mRNA	O
and	O
protein	O
expression	O
of	O
NR1	O
in	O
cells	O
treated	O
with	O
NR1	O
siRNA	O
followed	O
by	O
LPS	B-Chemical
was	O
reduced	O
to	O
levels	O
lowered	O
or	O
similar	O
to	O
that	O
in	O
control	O
cells	O
","	O
and	O
these	O
were	O
associated	O
with	O
a	O
reduction	O
in	O
LPS	B-Chemical
-	O
induced	O
LDH	O
release	O
.	O
Effects	O
of	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
on	O
renal	O
tubular	O
cells	O
.	O
(	O
A	O
)	O
Panels	O
show	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
release	O
in	O
LLC	O
-	O
PK1	O
(	O
left	O
"),"	O
MDCK	O
(	O
middle	O
"),"	O
and	O
primary	O
rat	O
proximal	O
tubular	O
cells	O
(	O
right	O
)	O
treated	O
with	O
LPS	B-Chemical
","	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
","	O
or	O
PBS	B-Chemical
(	O
control	O
)	O
(	O
n	O
=	O
6	O
).	O
(	O
B	O
)	O
Representative	O
images	O
showing	O
morphological	O
changes	O
in	O
primary	O
rat	O
proximal	O
tubular	O
cells	O
treated	O
with	O
either	O
PBS	B-Chemical
(	O
control	O
)	O
or	O
LPS	B-Chemical
for	O
24	O
h	O
.	O
(	O
C	O
)	O
Representative	O
blots	O
of	O
NR1	O
","	O
S	O
-	O
Race	O
","	O
and	O
actin	O
obtained	O
from	O
three	O
separate	O
culture	O
wells	O
.	O
The	O
bar	O
graphs	O
below	O
show	O
the	O
densitometry	O
data	O
from	O
six	O
assays	O
.	O
(	O
D	O
)	O
Representative	O
images	O
of	O
immunofluorescence	O
staining	O
for	O
NR1	O
(	O
red	O
)	O
and	O
S	O
-	O
Race	O
(	O
green	O
)	O
in	O
untreated	O
LLC	O
-	O
PK1	O
cells	O
.	O
Co	O
-	O
localized	O
staining	O
is	O
orange	O
(	O
merged	O
picture	O
).	O
Nuclei	O
were	O
counterstained	O
with	O
DAPI	B-Chemical
(	O
blue	O
).	O
Magnification	O
:	O
Ã—	O
400	O
in	O
B	O
and	O
D	O
.	O
The	O
horizontal	O
bar	O
in	O
merged	O
picture	O
indicates	O
10	O
Î¼m	O
.	O
(	O
E	O
)	O
The	O
upper	O
bar	O
graphs	O
show	O
silencing	O
of	O
NR1	O
mRNA	O
as	O
analyzed	O
by	O
real	O
time	O
RT	O
-	O
PCR	O
.	O
Results	O
were	O
expressed	O
as	O
fold	O
changes	O
with	O
respect	O
to	O
LLC	O
-	O
PK1	O
(	O
left	O
column	O
"),"	O
MDCK	O
(	O
middle	O
column	O
"),"	O
and	O
primary	O
rat	O
proximal	O
tubular	O
cells	O
(	O
right	O
column	O
)	O
receiving	O
a	O
negative	O
control	O
siRNA	O
(	O
C	O
)	O
(	O
n	O
=	O
6	O
).	O
The	O
middle	O
representative	O
blots	O
and	O
bar	O
graphs	O
(	O
n	O
=	O
6	O
)	O
show	O
changes	O
in	O
protein	O
expression	O
of	O
NR1	O
in	O
tubular	O
cells	O
after	O
LPS	B-Chemical
treatment	O
with	O
or	O
without	O
NR1	O
siRNA	O
by	O
Western	O
blot	O
analysis	O
.	O
The	O
lower	O
bar	O
graphs	O
show	O
the	O
effects	O
of	O
NR1	O
siRNA	O
on	O
LDH	O
release	O
in	O
tubular	O
cells	O
treated	O
with	O
various	O
combinations	O
of	O
LPS	B-Chemical
or	O
siRNA	O
(	O
n	O
=	O
6	O
).	O
*	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
control	O
(	O
C	O
)	O
groups	O
.	O
#	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
LPS	B-Chemical
group	O
at	O
the	O
same	O
time	O
-	O
point	O
or	O
the	O
LPS24	O
plus	O
NR1	O
siRNA	O
(	O
NR1si	O
)-	O
treated	O
group	O
.	O
â€ 	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
group	O
or	O
the	O
NR1	O
siRNA	O
-	O
treated	O
group	O
.	O
Changes	O
in	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
To	O
measure	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
","	O
a	O
standard	O
curve	O
was	O
generated	O
using	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
/	O
BSA	O
conjugates	O
.	O
This	O
demonstrated	O
a	O
linear	O
relationship	O
between	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
concentration	O
(	O
within	O
a	O
range	O
of	O
0	O
.	O
1	O
â€“	O
10	O
nM	O
)	O
and	O
optical	O
density	O
(	O
S1	O
Fig	O
).	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
was	O
detected	O
in	O
control	O
kidneys	O
at	O
10	O
.	O
5	O
Â±	O
6	O
.	O
3	O
%	O
(	O
renal	O
cortex	O
)	O
and	O
6	O
.	O
8	O
Â±	O
3	O
.	O
4	O
%	O
(	O
renal	O
medulla	O
)	O
of	O
the	O
levels	O
detected	O
in	O
the	O
cerebral	O
cortex	O
(	O
Fig	O
5A	O
).	O
LPS	B-Chemical
treatment	O
increased	O
renal	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
","	O
with	O
a	O
maximal	O
response	O
observed	O
after	O
8	O
h	O
.	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
was	O
detected	O
in	O
cell	O
lysates	O
and	O
culture	O
medium	O
from	O
the	O
tubular	O
cell	O
lines	O
(	O
Fig	O
5B	O
).	O
LPS	B-Chemical
treatment	O
led	O
to	O
increases	O
in	O
intracellular	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
and	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
in	O
the	O
culture	O
medium	O
(	O
all	O
P	O
<	O
0	O
.	O
5	O
"),"	O
indicating	O
its	O
de	O
novo	O
synthesis	O
and	O
subsequent	O
release	O
.	O
Changes	O
in	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
in	O
renal	O
tissues	O
and	O
tubular	O
cells	O
.	O
(	O
A	O
)	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
in	O
rat	O
kidneys	O
following	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
or	O
control	O
treatment	O
(	O
n	O
=	O
8	O
).	O
Bc	O
","	O
brain	O
cortex	O
.	O
(	O
B	O
)	O
Intracellular	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
(	O
upper	O
panels	O
)	O
and	O
levels	O
of	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
released	O
into	O
the	O
culture	O
medium	O
(	O
lower	O
panels	O
)	O
following	O
LPS	B-Chemical
or	O
control	O
treatment	O
(	O
n	O
=	O
5	O
).	O
*	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
control	O
(	O
PBS	B-Chemical
-	O
treated	O
)	O
group	O
at	O
the	O
same	O
time	O
-	O
point	O
.	O
Cytokine	O
effects	O
in	O
tubular	O
cells	O
The	O
LPS	O
receptor	O
","	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
"),"	O
was	O
detected	O
in	O
both	O
cell	O
lines	O
with	O
higher	O
expression	O
in	O
MDCK	O
cells	O
than	O
LLC	O
-	O
PK1	O
cells	O
(	O
Fig	O
6A	O
).	O
LPS	B-Chemical
increased	O
the	O
release	O
of	O
IFN	O
-	O
Î³	O
","	O
IL	O
-	O
1Î²	O
","	O
and	O
TNF	O
-	O
Î±	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
with	O
peak	O
expression	O
around	O
4	O
â€“	O
8	O
h	O
(	O
Fig	O
6B	O
).	O
The	O
increase	O
in	O
LPS	B-Chemical
-	O
induced	O
IL	O
-	O
1Î²	O
release	O
was	O
the	O
most	O
prominent	O
among	O
the	O
cytokines	O
examined	O
","	O
especially	O
in	O
the	O
LLC	O
-	O
PK1	O
cell	O
line	O
.	O
Treatment	O
with	O
the	O
TLR4	O
antagonist	O
","	O
LPS	B-Chemical
-	O
RS	O
","	O
for	O
8	O
h	O
markedly	O
attenuated	O
LPS	B-Chemical
-	O
induced	O
IL	O
-	O
1Î²	O
release	O
in	O
LLC	O
-	O
PK1	O
and	O
MDCK	O
cells	O
(	O
Fig	O
6C	O
).	O
Co	O
-	O
treatment	O
of	O
both	O
cell	O
lines	O
with	O
LPS	B-Chemical
and	O
IL	O
-	O
1	O
receptor	O
antagonist	O
(	O
IL	O
-	O
1Ra	O
)	O
led	O
to	O
a	O
significant	O
reduction	O
in	O
LPS	B-Chemical
-	O
induced	O
cytotoxicity	O
(	O
by	O
79	O
Â±	O
8	O
%	O
and	O
59	O
Â±	O
6	O
"%,"	O
respectively	O
)	O
through	O
suppressed	O
LDH	O
release	O
(	O
Fig	O
6D	O
).	O
In	O
addition	O
to	O
reducing	O
cytotoxicity	O
","	O
IL	O
-	O
1Ra	O
also	O
attenuated	O
LPS	B-Chemical
-	O
mediated	O
increases	O
in	O
NR1	O
and	O
S	O
-	O
Race	O
expression	O
in	O
both	O
cell	O
lines	O
(	O
Fig	O
6E	O
).	O
Treatment	O
of	O
MDCK	O
cells	O
with	O
IL	O
-	O
1Ra	O
alone	O
also	O
reduced	O
the	O
expression	O
of	O
NR1	O
.	O
Interestingly	O
","	O
IL	O
-	O
1Ra	O
abrogated	O
the	O
LPS	B-Chemical
-	O
induced	O
de	O
novo	O
synthesis	O
and	O
release	O
of	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
in	O
both	O
cell	O
lines	O
(	O
Fig	O
6F	O
).	O
Cytokine	O
effects	O
of	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)-	O
induced	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
hyperfunction	O
in	O
tubular	O
cells	O
.	O
(	O
A	O
)	O
Representative	O
blots	O
of	O
TLR4	O
expression	O
(	O
left	O
)	O
with	O
densitometry	O
data	O
(	O
right	O
)	O
pooled	O
from	O
four	O
separate	O
cultures	O
.	O
"+,"	O
positive	O
sample	O
extracted	O
from	O
rat	O
liver	O
.	O
(	O
B	O
)	O
Graphs	O
show	O
IFN	O
-	O
Î³	O
","	O
IL	O
-	O
1Î²	O
","	O
and	O
TNF	O
-	O
Î±	O
release	O
into	O
culture	O
medium	O
before	O
(	O
zero	O
time	O
-	O
point	O
)	O
and	O
after	O
LPS	B-Chemical
treatment	O
(	O
n	O
=	O
6	O
)	O
in	O
both	O
LLC	O
-	O
PK1	O
(	O
left	O
)	O
and	O
MDCK	O
cells	O
(	O
right	O
).	O
(	O
C	O
)	O
TLR4	O
antagonist	O
LPS	B-Chemical
-	O
RS	O
were	O
co	O
-	O
treated	O
with	O
LPS	B-Chemical
in	O
tubular	O
cells	O
for	O
8	O
h	O
.	O
The	O
release	O
of	O
IL	O
-	O
1Î²	O
in	O
medium	O
was	O
determined	O
(	O
n	O
=	O
6	O
).	O
(	O
D	O
)	O
IL	O
-	O
1	O
receptor	O
antagonist	O
(	O
IL	O
-	O
1Ra	O
)	O
attenuates	O
LPS	B-Chemical
-	O
mediated	O
LDH	O
release	O
after	O
24	O
h	O
of	O
treatment	O
(	O
n	O
=	O
5	O
).	O
(	O
E	O
)	O
Representative	O
blots	O
showing	O
NR1	O
","	O
S	O
-	O
Race	O
","	O
and	O
actin	O
expression	O
in	O
cells	O
treated	O
with	O
LPS	B-Chemical
","	O
IL	O
-	O
1Ra	O
","	O
or	O
a	O
combination	O
of	O
the	O
two	O
.	O
The	O
lower	O
panels	O
show	O
densitometry	O
data	O
pooled	O
from	O
five	O
separate	O
cultures	O
.	O
(	O
F	O
)	O
Intracellular	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
(	O
upper	O
panels	O
)	O
and	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
in	O
the	O
culture	O
medium	O
(	O
lower	O
panels	O
)	O
at	O
24	O
h	O
post	O
-	O
treatment	O
with	O
LPS	B-Chemical
","	O
IL	O
-	O
1Ra	O
","	O
or	O
a	O
combination	O
of	O
the	O
two	O
(	O
n	O
=	O
5	O
).	O
*	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
LLC	O
-	O
PK1	O
","	O
the	O
zero	O
time	O
-	O
point	O
","	O
or	O
the	O
control	O
groups	O
.	O
#	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
LPS24	O
group	O
.	O
â€ 	O
P	O
<	O
0	O
.	O
5	O
vs	O
.	O
the	O
IL	O
-	O
1Ra	O
group	O
.	O
Discussion	O
As	O
summarized	O
in	O
the	O
schematic	O
shown	O
in	O
Fig	O
7	O
","	O
this	O
study	O
provides	O
novel	O
evidence	O
demonstrating	O
that	O
NMDA	O
receptor	O
hyperfunction	O
contributes	O
to	O
acute	O
renal	O
failure	O
during	O
LPS	B-Chemical
-	O
induced	O
endotoxemia	O
.	O
LPS	B-Chemical
induced	O
IL	O
-	O
1Î²	O
release	O
and	O
caused	O
upregulation	O
of	O
NR1	O
and	O
S	O
-	O
Race	O
","	O
leading	O
to	O
NMDA	O
receptor	O
over	O
-	O
activation	O
in	O
tubular	O
cells	O
via	O
S	O
-	O
Race	O
-	O
derived	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
production	O
and	O
secretion	O
.	O
The	O
poor	O
renal	O
perfusion	O
and	O
ultrafiltration	O
in	O
LPS	B-Chemical
-	O
treated	O
kidneys	O
was	O
due	O
to	O
the	O
vasoconstrictor	O
effects	O
of	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
on	O
NMDA	O
receptors	O
.	O
Inhibition	O
of	O
NMDA	O
receptors	O
attenuated	O
LPS	B-Chemical
-	O
induced	O
functional	O
deterioration	O
and	O
tubular	O
cell	O
damage	O
in	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O
Schematic	O
diagram	O
showing	O
how	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
induces	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
hyperfunction	O
and	O
renal	O
damage	O
in	O
endotoxemia	O
.	O
LPS	B-Chemical
binds	O
to	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
and	O
induces	O
interleukin	O
(	O
IL	O
)-	O
1Î²	O
release	O
from	O
tubular	O
cells	O
.	O
TLR4	O
and	O
IL	O
-	O
1	O
receptor	O
(	O
IL	O
-	O
1R	O
)	O
signaling	O
in	O
tubular	O
cells	O
increases	O
expression	O
of	O
the	O
NMDA	O
receptor	O
NR1	O
subunit	O
and	O
serine	O
racemase	O
.	O
Upregulation	O
of	O
NR1	O
and	O
serine	O
racemase	O
","	O
together	O
with	O
increased	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
","	O
results	O
in	O
NMDA	O
receptor	O
hyperfunction	O
.	O
NMDA	O
receptor	O
hyperfunction	O
in	O
LPS	B-Chemical
causes	O
tubular	O
cell	O
damage	O
and	O
poor	O
renal	O
perfusion	O
through	O
vasoconstriction	O
leading	O
to	O
acute	O
renal	O
failure	O
.	O
Disturbances	O
in	O
systemic	O
hemodynamic	O
function	O
during	O
endotoxemia	O
invariably	O
lead	O
to	O
multiple	O
organ	O
failure	O
due	O
to	O
inadequate	O
tissue	O
perfusion	O
"[,"	O
].	O
The	O
dose	O
of	O
LPS	B-Chemical
given	O
in	O
this	O
study	O
caused	O
a	O
significant	O
reduction	O
in	O
renal	O
perfusion	O
but	O
not	O
in	O
systemic	O
arterial	O
pressure	O
(	O
Fig	O
2	O
).	O
This	O
is	O
in	O
agreement	O
with	O
previous	O
results	O
from	O
a	O
conscious	O
rat	O
model	O
","	O
which	O
show	O
that	O
LPS	B-Chemical
decreases	O
glomerular	O
ultrafiltration	O
without	O
eliciting	O
a	O
reduction	O
in	O
blood	O
pressure	O
[].	O
However	O
","	O
the	O
apparent	O
lack	O
of	O
any	O
effect	O
on	O
blood	O
pressure	O
may	O
be	O
a	O
compensatory	O
result	O
of	O
tachycardia	O
(	O
Fig	O
2	O
"),"	O
which	O
is	O
caused	O
by	O
baroreceptor	O
reflex	O
-	O
mediated	O
sympathetic	O
activation	O
in	O
response	O
to	O
LPS	B-Chemical
-	O
mediated	O
vasodilation	O
[].	O
Interestingly	O
","	O
NMDA	O
receptors	O
have	O
been	O
identified	O
in	O
(	O
and	O
are	O
functionally	O
present	O
in	O
)	O
neural	O
pathways	O
involved	O
in	O
the	O
reflex	O
control	O
of	O
blood	O
pressure	O
and	O
heart	O
rate	O
"[,"	O
].	O
We	O
speculate	O
that	O
LPS	B-Chemical
may	O
stimulate	O
NMDA	O
receptors	O
within	O
the	O
CNS	O
pathways	O
that	O
mediates	O
tachycardia	O
.	O
A	O
previous	O
in	O
vitro	O
study	O
demonstrated	O
that	O
LPS	B-Chemical
selectively	O
induces	O
vasoconstriction	O
in	O
the	O
renal	O
artery	O
","	O
but	O
not	O
in	O
the	O
superior	O
mesenteric	O
artery	O
","	O
by	O
impairing	O
acetylcholine	B-Chemical
-	O
induced	O
endothelium	O
-	O
dependent	O
relaxation	O
in	O
rats	O
[].	O
In	O
this	O
study	O
","	O
NMDA	O
receptor	O
inhibition	O
prevented	O
reductions	O
in	O
renal	O
perfusion	O
and	O
ameliorated	O
decline	O
in	O
ultrafiltration	O
(	O
Fig	O
2	O
)	O
but	O
not	O
NR1	O
expression	O
(	O
S2	O
Fig	O
"),"	O
indicating	O
that	O
NMDA	O
receptor	O
hyperfunction	O
contributes	O
to	O
renal	O
vasoconstriction	O
in	O
endotoxemic	O
kidneys	O
.	O
This	O
is	O
consistent	O
with	O
our	O
previous	O
findings	O
that	O
direct	O
activation	O
of	O
NMDA	O
receptors	O
(	O
via	O
intrarenal	O
arterial	O
administration	O
of	O
NMDA	B-Chemical
)	O
reduced	O
the	O
GFR	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
[];	O
however	O
","	O
acute	O
administration	O
of	O
NMDA	B-Chemical
had	O
no	O
effect	O
on	O
renal	O
blood	O
flow	O
","	O
which	O
was	O
decreased	O
by	O
LPS	B-Chemical
.	O
The	O
LPS	B-Chemical
-	O
induced	O
NMDA	O
receptor	O
upregulation	O
in	O
disease	O
states	O
may	O
explain	O
this	O
difference	O
.	O
Nevertheless	O
","	O
the	O
pathophysiological	O
role	O
of	O
NMDA	O
receptor	O
hyperfunction	O
in	O
renal	O
injury	O
is	O
well	O
established	O
.	O
Expression	O
of	O
both	O
renal	O
NR1	O
protein	O
and	O
mRNA	O
is	O
upregulated	O
during	O
ischemia	O
-	O
reperfusion	O
insult	O
and	O
by	O
short	O
-	O
term	O
treatment	O
with	O
gentamicin	B-Chemical
"[,"	O
"],"	O
as	O
well	O
as	O
in	O
the	O
endotoxemic	O
model	O
reported	O
herein	O
.	O
In	O
addition	O
to	O
regulating	O
renal	O
vascular	O
tone	O
","	O
the	O
presence	O
of	O
NMDA	O
receptors	O
in	O
renal	O
tubules	O
possibly	O
might	O
affect	O
tubular	O
reabsorption	O
"[,"	O
","	O
].	O
The	O
immunostaining	O
results	O
presented	O
herein	O
support	O
this	O
view	O
because	O
NR1	O
was	O
identified	O
in	O
both	O
the	O
proximal	O
and	O
distal	O
tubules	O
(	O
Fig	O
3	O
).	O
We	O
did	O
not	O
examine	O
how	O
LPS	B-Chemical
and	O
NMDA	O
receptors	O
affect	O
tubular	O
transport	O
.	O
However	O
","	O
NMDA	O
receptor	O
blockade	O
prevented	O
sodium	B-Chemical
-	O
wasting	O
caused	O
by	O
LPS	B-Chemical
(	O
Fig	O
2	O
).	O
Moreover	O
","	O
LPS	B-Chemical
enhances	O
enzymuria	O
of	O
tubular	O
markers	O
in	O
vivo	O
and	O
increases	O
tubular	O
cytotoxicity	O
in	O
vitro	O
(	O
Figs	O
1	O
and	O
4A	O
"),"	O
suggesting	O
tubular	O
cell	O
damage	O
or	O
loss	O
could	O
be	O
one	O
of	O
the	O
mechanisms	O
underlying	O
salt	O
-	O
wasting	O
after	O
LPS	B-Chemical
treatment	O
.	O
The	O
mechanism	O
underlying	O
LPS	B-Chemical
-	O
mediated	O
tubular	O
damage	O
is	O
dependent	O
on	O
NMDA	O
receptor	O
hyperfunction	O
because	O
cell	O
damage	O
was	O
ameliorated	O
by	O
MK	B-Chemical
-	I-Chemical
801	I-Chemical
and	O
NR1	O
silencing	O
(	O
Fig	O
4	O
).	O
Our	O
hypothesis	O
that	O
LPS	B-Chemical
causes	O
NMDA	O
receptor	O
hyperfunction	O
is	O
further	O
supported	O
by	O
the	O
observation	O
that	O
LPS	B-Chemical
upregulates	O
NR1	O
and	O
S	O
-	O
Race	O
expression	O
","	O
and	O
also	O
by	O
increases	O
in	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
levels	O
in	O
the	O
rat	O
kidney	O
and	O
in	O
cultured	O
tubular	O
cells	O
.	O
Interestingly	O
","	O
the	O
temporal	O
changes	O
in	O
NR1	O
and	O
S	O
-	O
Race	O
expression	O
observed	O
in	O
LPS	B-Chemical
-	O
treated	O
tubular	O
cell	O
cultures	O
were	O
similar	O
to	O
those	O
observed	O
in	O
rat	O
kidneys	O
","	O
indicating	O
that	O
most	O
of	O
the	O
LPS	B-Chemical
-	O
induced	O
increases	O
in	O
protein	O
expression	O
were	O
of	O
tubular	O
origin	O
.	O
High	O
plasma	O
levels	O
of	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
are	O
nephrotoxic	O
because	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
can	O
be	O
reabsorbed	O
by	O
straight	O
segments	O
of	O
the	O
proximal	O
tubules	O
","	O
which	O
causes	O
tubular	O
cell	O
necrosis	O
[â€“].	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
taken	O
up	O
by	O
tubular	O
cells	O
is	O
metabolized	O
by	O
an	O
intracellular	O
enzyme	O
","	O
D	O
-	O
amino	O
acid	O
oxidase	O
","	O
which	O
generates	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
via	O
the	O
depletion	O
of	O
reduced	O
glutathione	B-Chemical
","	O
thereby	O
contributing	O
to	O
tubular	O
damage	O
[].	O
It	O
is	O
not	O
known	O
whether	O
there	O
is	O
an	O
increase	O
in	O
plasma	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
in	O
LPS	B-Chemical
-	O
treated	O
animals	O
;	O
however	O
","	O
increased	O
levels	O
of	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
in	O
renal	O
tissues	O
(	O
Fig	O
5	O
)	O
suggest	O
a	O
direct	O
toxic	O
effect	O
on	O
the	O
kidney	O
.	O
This	O
suggestion	O
is	O
supported	O
by	O
the	O
de	O
novo	O
synthesis	O
and	O
release	O
of	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
by	O
cultured	O
tubular	O
cells	O
during	O
LPS	B-Chemical
-	O
mediated	O
tubular	O
cell	O
damage	O
(	O
Fig	O
5	O
).	O
Since	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
acts	O
as	O
an	O
endogenous	O
ligand	O
for	O
the	O
NMDA	O
receptor	O
","	O
and	O
NR1	O
is	O
present	O
in	O
renal	O
tubules	O
"[,"	O
"],"	O
we	O
speculate	O
that	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
-	O
induced	O
nephrotoxicity	O
may	O
be	O
the	O
result	O
of	O
NMDA	O
receptor	O
over	O
-	O
stimulation	O
","	O
as	O
demonstrated	O
by	O
previous	O
studies	O
[â€“].	O
Whether	O
the	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
-	O
mediated	O
effects	O
on	O
NMDA	O
receptor	O
function	O
influence	O
nephrotoxicity	O
warrants	O
further	O
study	O
.	O
The	O
LPS	O
receptor	O
","	O
TLR4	O
","	O
is	O
expressed	O
in	O
murine	O
kidneys	O
and	O
shows	O
a	O
largely	O
tubular	O
distribution	O
"[,"	O
].	O
TLR4	O
was	O
also	O
expressed	O
in	O
the	O
tubular	O
cell	O
lines	O
used	O
herein	O
","	O
and	O
its	O
expression	O
was	O
higher	O
in	O
MDCK	O
cells	O
than	O
in	O
LLC	O
-	O
PK1	O
cells	O
at	O
the	O
same	O
amount	O
of	O
protein	O
loading	O
(	O
Fig	O
6	O
).	O
It	O
is	O
therefore	O
possible	O
that	O
MDCK	O
cells	O
may	O
be	O
more	O
responsive	O
to	O
LPS	B-Chemical
than	O
LLC	O
-	O
PK1	O
cells	O
.	O
However	O
","	O
LLC	O
-	O
PK1	O
cells	O
released	O
more	O
LDH	O
than	O
MDCK	O
cells	O
in	O
response	O
to	O
LPS	B-Chemical
(	O
Fig	O
6	O
"),"	O
indicating	O
that	O
a	O
mechanism	O
downstream	O
of	O
TLR4	O
might	O
be	O
involved	O
in	O
LPS	B-Chemical
-	O
induced	O
tubular	O
cell	O
injury	O
.	O
Other	O
studies	O
have	O
shown	O
that	O
TLR4	O
is	O
the	O
primary	O
effector	O
of	O
LPS	B-Chemical
-	O
mediated	O
cellular	O
responses	O
","	O
including	O
the	O
rapid	O
release	O
of	O
cytokines	O
[].	O
This	O
study	O
shows	O
that	O
LPS	B-Chemical
enhances	O
cytokine	O
release	O
in	O
both	O
of	O
the	O
tubular	O
cell	O
types	O
studied	O
(	O
Fig	O
6	O
).	O
Among	O
the	O
cytokines	O
released	O
","	O
IL	O
-	O
1Î²	O
release	O
was	O
the	O
most	O
prominent	O
(	O
Fig	O
6	O
).	O
Moreover	O
","	O
TLR4	O
inhibition	O
markedly	O
attenuated	O
IL	O
-	O
1Î²	O
release	O
with	O
a	O
76	O
%	O
and	O
48	O
%	O
reduction	O
in	O
LLC	O
-	O
PK1	O
and	O
MDCK	O
cells	O
","	O
respectively	O
.	O
Though	O
TLR4	O
was	O
less	O
abundant	O
in	O
LLC	O
-	O
PK1	O
than	O
in	O
MDCK	O
cells	O
","	O
TLR4	O
-	O
mediated	O
signaling	O
(	O
triggering	O
IL	O
-	O
1Î²	O
release	O
)	O
seemed	O
to	O
be	O
more	O
efficient	O
in	O
LLC	O
-	O
PK1	O
cells	O
than	O
in	O
MDCK	O
cells	O
.	O
Hence	O
","	O
LLC	O
-	O
PK1	O
cells	O
appeared	O
to	O
be	O
more	O
sensitive	O
to	O
LPS	B-Chemical
treatment	O
than	O
MDCK	O
cells	O
.	O
Interestingly	O
","	O
the	O
results	O
agree	O
with	O
previous	O
findings	O
that	O
stimulation	O
with	O
toxic	O
agents	O
","	O
such	O
as	O
oxalate	B-Chemical
","	O
the	O
environmental	O
pollutant	O
cadmium	B-Chemical
","	O
and	O
the	O
nephrotoxic	O
drug	O
cyclosporine	B-Chemical
","	O
results	O
in	O
stronger	O
responses	O
in	O
LLC	O
-	O
PK1	O
cells	O
than	O
in	O
MDCK	O
cells	O
[â€“].	O
IL	O
-	O
1	O
receptor	O
inhibition	O
completely	O
abrogated	O
LPS	B-Chemical
-	O
induced	O
cell	O
injury	O
","	O
indicating	O
that	O
IL	O
-	O
1Î²	O
is	O
the	O
main	O
cytokine	O
that	O
triggers	O
tubular	O
cell	O
death	O
.	O
We	O
previously	O
showed	O
that	O
a	O
renoprotective	O
strategy	O
involving	O
hypoxic	O
preconditioning	O
protects	O
rat	O
kidneys	O
against	O
the	O
effects	O
of	O
LPS	B-Chemical
by	O
attenuating	O
IL	O
-	O
1Î²	O
synthesis	O
[].	O
Interestingly	O
","	O
IL	O
-	O
1	O
receptor	O
inhibition	O
also	O
attenuated	O
LPS	B-Chemical
-	O
induced	O
upregulation	O
of	O
NR1	O
and	O
S	O
-	O
Race	O
","	O
as	O
well	O
as	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
synthesis	O
and	O
secretion	O
(	O
Fig	O
6	O
"),"	O
suggesting	O
that	O
IL	O
-	O
1Î²	O
-	O
mediated	O
NMDA	O
receptor	O
hyperfunction	O
could	O
be	O
the	O
mechanism	O
by	O
which	O
LPS	B-Chemical
induces	O
tubular	O
cell	O
damage	O
.	O
This	O
finding	O
is	O
corroborated	O
by	O
observations	O
that	O
signal	O
pathways	O
downstream	O
of	O
the	O
IL	O
-	O
1	O
receptor	O
and	O
TLR4	O
","	O
including	O
the	O
activation	O
of	O
nuclear	O
factor	O
ÎºB	O
(	O
NF	O
-	O
ÎºB	O
)	O
and	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
"),"	O
induce	O
LPS	B-Chemical
-	O
mediated	O
pleiotropic	O
inflammatory	O
responses	O
[].	O
NF	O
-	O
ÎºB	O
translocates	O
to	O
the	O
nucleus	O
during	O
P19	O
cell	O
differentiation	O
into	O
neurons	O
and	O
markedly	O
increases	O
NR1	O
promoter	O
activity	O
[].	O
Another	O
mechanism	O
of	O
relevance	O
to	O
NF	O
-	O
ÎºB	O
signaling	O
is	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
-	O
mediated	O
oxidative	O
stress	O
","	O
which	O
we	O
previously	O
demonstrated	O
in	O
LPS	B-Chemical
-	O
treated	O
kidneys	O
[].	O
Oxidative	O
stress	O
","	O
induced	O
by	O
exposure	O
to	O
superoxide	B-Chemical
","	O
peroxynitrite	B-Chemical
","	O
and	O
hydrogen	B-Chemical
peroxide	I-Chemical
","	O
upregulates	O
NR1	O
expression	O
in	O
bEnd3	O
cells	O
","	O
an	O
endothelial	O
cell	O
derived	O
from	O
primary	O
murine	O
brain	O
microvasculature	O
[].	O
This	O
","	O
however	O
","	O
can	O
be	O
completely	O
blocked	O
by	O
an	O
inhibitor	O
of	O
NF	O
-	O
ÎºB	O
activation	O
[].	O
It	O
is	O
therefore	O
likely	O
that	O
LPS	B-Chemical
-	O
mediated	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
formation	O
and	O
NF	O
-	O
ÎºB	O
activation	O
will	O
have	O
profound	O
effects	O
on	O
NR1	O
upregulation	O
.	O
Although	O
the	O
S	O
-	O
Race	O
gene	O
is	O
not	O
a	O
target	O
for	O
NF	O
-	O
ÎºB	O
","	O
S	O
-	O
Race	O
expression	O
in	O
MG5	O
microglial	O
cells	O
is	O
upregulated	O
by	O
LPS	B-Chemical
through	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
MAPK	O
signaling	O
[].	O
Further	O
work	O
is	O
required	O
to	O
determine	O
whether	O
MAPKs	O
via	O
LPS	B-Chemical
affect	O
S	O
-	O
Race	O
expression	O
in	O
tubular	O
cells	O
.	O
In	O
conclusion	O
","	O
the	O
results	O
presented	O
herein	O
show	O
that	O
LPS	B-Chemical
-	O
induced	O
renal	O
injury	O
is	O
dependent	O
on	O
the	O
NMDA	O
receptor	O
.	O
Upregulation	O
of	O
NR1	O
and	O
S	O
-	O
Race	O
","	O
together	O
with	O
increases	O
in	O
D	B-Chemical
-	I-Chemical
serine	I-Chemical
content	O
","	O
cause	O
NMDA	O
receptor	O
hyperfunction	O
in	O
tubular	O
epithelium	O
after	O
LPS	B-Chemical
treatment	O
.	O
This	O
","	O
in	O
turn	O
","	O
induces	O
renal	O
vasoconstriction	O
and	O
hypoperfusion	O
in	O
vivo	O
and	O
further	O
contributes	O
to	O
tubular	O
cell	O
death	O
in	O
vitro	O
.	O
Finally	O
","	O
LPS	B-Chemical
-	O
dependent	O
IL	O
-	O
1Î²	O
release	O
plays	O
a	O
critical	O
role	O
in	O
NR1	O
and	O
S	O
-	O
Race	O
upregulation	O
in	O
tubular	O
cells	O
.	O
Supporting	O
Information	O
References	O
Adaptor	O
protein	O
-	O
2	O
sigma	O
subunit	O
mutations	O
causing	O
familial	O
hypocalciuric	O
hypercalcaemia	O
type	O
3	O
(	O
FHH3	O
)	O
demonstrate	O
genotype	O
â€“	O
phenotype	O
correlations	O
","	O
codon	O
bias	O
and	O
dominant	O
-	O
negative	O
effects	O
The	O
adaptor	O
protein	O
-	O
2	O
sigma	O
subunit	O
(	O
AP2Ïƒ2	O
)	O
is	O
pivotal	O
for	O
clathrin	O
-	O
mediated	O
endocytosis	O
of	O
plasma	O
membrane	O
constituents	O
such	O
as	O
the	O
calcium	O
-	O
sensing	O
receptor	O
(	O
CaSR	O
).	O
Mutations	O
of	O
the	O
AP2Ïƒ2	O
Arg15	B-Chemical
residue	O
result	O
in	O
familial	O
hypocalciuric	O
hypercalcaemia	O
type	O
3	O
(	O
FHH3	O
"),"	O
a	O
disorder	O
of	O
extracellular	O
calcium	B-Chemical
(	O
Ca2	B-Chemical
+	I-Chemical
o	O
)	O
homeostasis	O
.	O
To	O
elucidate	O
the	O
role	O
of	O
AP2Ïƒ2	O
in	O
Ca2	B-Chemical
+	I-Chemical
o	O
regulation	O
","	O
we	O
investigated	O
65	O
FHH	O
probands	O
","	O
without	O
other	O
FHH	O
-	O
associated	O
mutations	O
","	O
for	O
AP2Ïƒ2	O
mutations	O
","	O
characterized	O
their	O
functional	O
consequences	O
and	O
investigated	O
the	O
genetic	O
mechanisms	O
leading	O
to	O
FHH3	O
.	O
AP2Ïƒ2	O
mutations	O
were	O
identified	O
in	O
17	O
probands	O
","	O
comprising	O
5	O
Arg15Cys	B-Chemical
","	O
4	O
Arg15His	B-Chemical
and	O
8	O
Arg15Leu	B-Chemical
mutations	O
.	O
A	O
genotype	O
â€“	O
phenotype	O
correlation	O
was	O
observed	O
with	O
the	O
Arg15Leu	B-Chemical
mutation	O
leading	O
to	O
marked	O
hypercalcaemia	O
.	O
FHH3	O
probands	O
harboured	O
additional	O
phenotypes	O
such	O
as	O
cognitive	O
dysfunction	O
.	O
All	O
three	O
FHH3	O
-	O
causing	O
AP2Ïƒ2	O
mutations	O
impaired	O
CaSR	O
signal	O
transduction	O
in	O
a	O
dominant	O
-	O
negative	O
manner	O
.	O
Mutational	O
bias	O
was	O
observed	O
at	O
the	O
AP2Ïƒ2	O
Arg15	B-Chemical
residue	O
as	O
other	O
predicted	O
missense	O
substitutions	O
(	O
Arg15Gly	B-Chemical
","	O
Arg15Pro	B-Chemical
and	O
Arg15Ser	B-Chemical
"),"	O
which	O
also	O
caused	O
CaSR	O
loss	O
-	O
of	O
-	O
function	O
","	O
were	O
not	O
detected	O
in	O
FHH	O
probands	O
","	O
and	O
these	O
mutations	O
were	O
found	O
to	O
reduce	O
the	O
numbers	O
of	O
CaSR	O
-	O
expressing	O
cells	O
.	O
FHH3	O
probands	O
had	O
significantly	O
greater	O
serum	O
calcium	B-Chemical
(	O
sCa	B-Chemical
)	O
and	O
magnesium	B-Chemical
(	O
sMg	B-Chemical
)	O
concentrations	O
with	O
reduced	O
urinary	O
calcium	B-Chemical
to	O
creatinine	B-Chemical
clearance	O
ratios	O
(	O
CCCR	O
)	O
in	O
comparison	O
with	O
FHH1	O
probands	O
with	O
CaSR	O
mutations	O
","	O
and	O
a	O
calculated	O
index	O
of	O
sCa	B-Chemical
Ã—	O
sMg	B-Chemical
/	O
100	O
Ã—	O
CCCR	O
","	O
which	O
was	O
â‰¥	O
5	O
.	O
0	O
","	O
had	O
a	O
diagnostic	O
sensitivity	O
and	O
specificity	O
of	O
83	O
and	O
86	O
"%,"	O
respectively	O
","	O
for	O
FHH3	O
.	O
Thus	O
","	O
our	O
studies	O
demonstrate	O
AP2Ïƒ2	O
mutations	O
to	O
result	O
in	O
a	O
more	O
severe	O
FHH	O
phenotype	O
with	O
genotype	O
â€“	O
phenotype	O
correlations	O
","	O
and	O
a	O
dominant	O
-	O
negative	O
mechanism	O
of	O
action	O
with	O
mutational	O
bias	O
at	O
the	O
Arg15	B-Chemical
residue	O
.	O
Introduction	O
Familial	O
hypocalciuric	O
hypercalcaemia	O
(	O
FHH	O
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
of	O
extracellular	O
calcium	B-Chemical
(	O
Ca2	B-Chemical
+	I-Chemical
o	O
)	O
homeostasis	O
characterized	O
by	O
lifelong	O
mild	O
-	O
to	O
-	O
moderate	O
elevations	O
of	O
serum	O
calcium	B-Chemical
concentrations	O
","	O
mild	O
hypermagnesaemia	O
","	O
normal	O
or	O
elevated	O
circulating	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
concentrations	O
and	O
inappropriately	O
low	O
urinary	O
calcium	B-Chemical
excretion	O
[	O
mean	O
urinary	O
calcium	B-Chemical
to	O
creatinine	B-Chemical
clearance	O
ratio	O
(	O
CCCR	O
)	O
<	O
0	O
.	O
1	O
].	O
FHH	O
is	O
a	O
genetically	O
heterogeneous	O
disorder	O
comprising	O
three	O
reported	O
variants	O
.	O
FHH	O
types	O
1	O
and	O
2	O
(	O
FHH1	O
","	O
OMIM	O
#	O
145980	O
;	O
FHH2	O
","	O
OMIM	O
#	O
145981	O
)	O
are	O
due	O
to	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
of	O
the	O
calcium	O
-	O
sensing	O
receptor	O
(	O
CaSR	O
)	O
and	O
G	O
-	O
protein	O
","	O
GÎ±11	O
","	O
encoded	O
by	O
the	O
CASR	O
and	O
GNA11	O
genes	O
","	O
respectively	O
.	O
CaSR	O
and	O
GÎ±11	O
are	O
widely	O
expressed	O
","	O
including	O
in	O
the	O
parathyroid	O
glands	O
and	O
kidneys	O
","	O
and	O
play	O
a	O
pivotal	O
role	O
in	O
Ca2	B-Chemical
+	I-Chemical
o	O
homeostasis	O
by	O
detecting	O
alterations	O
in	O
Ca2	B-Chemical
+	I-Chemical
o	O
concentrations	O
and	O
initiating	O
multiple	O
intracellular	O
signalling	O
cascades	O
that	O
include	O
phospholipase	O
C	O
-	O
mediated	O
accumulation	O
of	O
inositol	B-Chemical
1	I-Chemical
","	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
trisphosphate	I-Chemical
and	O
increases	O
in	O
intracellular	O
calcium	B-Chemical
(	O
Ca2	B-Chemical
+	I-Chemical
i	O
)	O
concentrations	O
","	O
which	O
in	O
turn	O
lead	O
to	O
alterations	O
in	O
PTH	O
secretion	O
and	O
urinary	O
calcium	B-Chemical
excretion	O
.	O
FHH	O
type	O
3	O
(	O
FHH3	O
","	O
OMIM	O
#	O
600740	O
)	O
is	O
associated	O
with	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
of	O
AP2S1	O
","	O
located	O
on	O
chromosome	O
19q13	O
.	O
3	O
.	O
AP2S1	O
encodes	O
the	O
Ïƒ2	O
-	O
subunit	O
of	O
the	O
ubiquitously	O
expressed	O
heterotetrameric	O
adaptor	O
protein	O
-	O
2	O
(	O
AP2	O
)	O
complex	O
","	O
which	O
also	O
comprises	O
Î±	O
Î²2	O
-	O
and	O
Î¼2	O
-	O
subunits	O
.	O
The	O
AP2	O
complex	O
is	O
a	O
central	O
component	O
of	O
clathrin	O
-	O
coated	O
vesicles	O
and	O
facilitates	O
the	O
endocytosis	O
of	O
plasma	O
membrane	O
constituents	O
such	O
as	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
(	O
GPCRs	O
).	O
AP2S1	O
mutations	O
have	O
been	O
reported	O
in	O
19	O
FHH	O
patients	O
and	O
families	O
to	O
date	O
","	O
and	O
these	O
all	O
comprise	O
heterozygous	O
missense	O
substitutions	O
of	O
the	O
AP2	O
Ïƒ2	O
-	O
subunit	O
(	O
AP2Ïƒ2	O
)	O
Arg15	B-Chemical
residue	O
(	O
Arg15Cys	B-Chemical
","	O
Arg15His	B-Chemical
and	O
Arg15Leu	B-Chemical
).	O
This	O
Arg	B-Chemical
residue	O
is	O
located	O
in	O
a	O
positively	O
charged	O
region	O
of	O
AP2Ïƒ2	O
that	O
binds	O
to	O
specific	O
peptide	O
motifs	O
on	O
membrane	O
cargo	O
proteins	O
.	O
It	O
is	O
predicted	O
that	O
FHH3	O
-	O
causing	O
Arg15	B-Chemical
mutations	O
disrupt	O
binding	O
of	O
the	O
AP2	O
complex	O
to	O
the	O
intracellular	O
carboxyl	O
terminus	O
of	O
the	O
CaSR	O
","	O
thereby	O
impairing	O
endocytosis	O
of	O
this	O
GPCR	O
.	O
This	O
hypothesis	O
is	O
supported	O
by	O
in	O
vitro	O
expression	O
studies	O
that	O
have	O
demonstrated	O
AP2S1	O
mutations	O
to	O
affect	O
CaSR	O
cell	O
-	O
surface	O
expression	O
and	O
signal	O
transduction	O
.	O
These	O
studies	O
of	O
AP2S1	O
mutations	O
have	O
highlighted	O
a	O
role	O
for	O
the	O
AP2	O
endocytic	O
complex	O
in	O
Ca2	B-Chemical
+	I-Chemical
o	O
homeostasis	O
.	O
To	O
date	O
","	O
19	O
FHH3	O
patients	O
have	O
been	O
reported	O
with	O
AP2Ïƒ2	O
mutations	O
","	O
comprising	O
8	O
Arg15Cys	B-Chemical
","	O
4	O
Arg15His	B-Chemical
and	O
7	O
Arg15Leu	B-Chemical
.	O
To	O
further	O
elucidate	O
the	O
role	O
and	O
spectrum	O
of	O
AP2Ïƒ2	O
mutations	O
in	O
the	O
aetiology	O
of	O
the	O
phenotypic	O
features	O
of	O
FHH3	O
","	O
we	O
conducted	O
studies	O
to	O
characterise	O
the	O
structural	O
/	O
functional	O
consequences	O
of	O
AP2Ïƒ2	O
mutations	O
together	O
with	O
their	O
underlying	O
genetic	O
mechanisms	O
in	O
additional	O
FHH	O
patients	O
","	O
who	O
did	O
not	O
have	O
CASR	O
or	O
GNA11	O
mutations	O
.	O
Our	O
study	O
identified	O
AP2Ïƒ2	O
mutations	O
in	O
17	O
hypercalcaemic	O
probands	O
and	O
their	O
families	O
","	O
and	O
further	O
analysis	O
of	O
these	O
AP2Ïƒ2	O
mutants	O
has	O
revealed	O
the	O
presence	O
of	O
a	O
genotype	O
â€“	O
phenotype	O
correlation	O
","	O
a	O
mutational	O
bias	O
of	O
the	O
AP2Ïƒ2	O
Arg15	B-Chemical
residue	O
with	O
a	O
likely	O
dominant	O
-	O
negative	O
action	O
and	O
a	O
clinical	O
approach	O
to	O
differentiate	O
patients	O
with	O
FHH3	O
from	O
those	O
with	O
FHH1	O
.	O
Results	O
AP2S1	O
mutations	O
and	O
clinical	O
phenotypes	O
Normal	O
serum	O
ranges	O
:	O
albumin	O
adjusted	O
-	O
calcium	B-Chemical
","	O
a2	O
.	O
10	O
â€“	O
2	O
.	O
60	O
mmol	O
/	O
l	O
;	O
ionized	O
calcium	B-Chemical
","	O
b1	O
.	O
19	O
â€“	O
1	O
.	O
35	O
mmol	O
/	O
l	O
;	O
phosphate	B-Chemical
(	O
Pi	O
"),"	O
c0	O
.	O
70	O
â€“	O
1	O
.	O
40	O
mmol	O
/	O
l	O
;	O
magnesium	B-Chemical
(	O
Mg	B-Chemical
"),"	O
d0	O
.	O
70	O
â€“	O
1	O
.	O
0	O
mmol	O
/	O
l	O
;	O
total	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
activity	O
","	O
e30	O
â€“	O
130	O
U	O
/	O
l	O
","	O
f70	O
â€“	O
330	O
U	O
/	O
l	O
;	O
PTH	O
","	O
g10	O
â€“	O
65	O
ng	O
/	O
l	O
;	O
h1	O
.	O
3	O
â€“	O
7	O
.	O
6	O
pmol	O
/	O
l	O
.	O
Normal	O
urine	O
ranges	O
;	O
calcium	B-Chemical
-	O
to	O
-	O
creatinine	B-Chemical
clearance	O
ratio	O
(	O
CCCR	O
"),"	O
i	O
>	O
0	O
.	O
2	O
;	O
calcium	B-Chemical
-	O
to	O
-	O
creatinine	B-Chemical
ratio	O
","	O
j0	O
.	O
3	O
â€“	O
0	O
.	O
7	O
.	O
kBMD	O
Z	O
-	O
scores	O
are	O
provided	O
for	O
subjects	O
of	O
<	O
50	O
years	O
old	O
and	O
lBMD	O
T	O
-	O
scores	O
are	O
provided	O
for	O
subjects	O
of	O
>	O
50	O
years	O
old	O
;	O
mforearm	O
BMD	O
T	O
-	O
score	O
=	O
âˆ’	O
2	O
.	O
5	O
for	O
proband	O
3	O
/	O
13b	O
;	O
nwhole	O
-	O
body	O
BMD	O
Z	O
-	O
score	O
=	O
âˆ’	O
2	O
.	O
0	O
for	O
proband	O
6	O
/	O
13b	O
;	O
odiagnosed	O
in	O
early	O
infancy	O
.	O
A	O
","	O
atrial	O
septal	O
defect	O
;	O
B	O
","	O
irritable	O
bowel	O
syndrome	O
co	O
-	O
segregating	O
with	O
hypercalcaemia	O
in	O
family	O
7	O
/	O
14	O
;	O
FN	O
","	O
femoral	O
neck	O
;	O
H	O
","	O
hypercalcaemic	O
symptoms	O
;	O
L	O
","	O
mild	O
-	O
to	O
-	O
moderate	O
learning	O
disability	O
;	O
LS	O
","	O
lumbar	O
spine	O
;	O
N	O
","	O
normal	O
;	O
S	O
","	O
short	O
stature	O
(	O
height	O
<	O
third	O
centile	O
);	O
P	O
","	O
pancreatitis	O
;	O
"â€”,"	O
not	O
known	O
.	O
Clinical	O
and	O
biochemical	O
findings	O
in	O
17	O
FHH	O
probands	O
with	O
AP2S1	O
mutations	O
Detection	O
of	O
de	O
novo	O
AP2S1	O
mutations	O
in	O
families	O
2	O
/	O
3	O
and	O
6	O
/	O
13b	O
.	O
(	O
A	O
)	O
DNA	O
sequence	O
analyses	O
of	O
the	O
probands	O
(	O
arrowed	O
)	O
revealed	O
a	O
G	O
-	O
to	O
-	O
T	O
transversion	O
at	O
codon	O
15	O
","	O
predicted	O
to	O
result	O
in	O
a	O
missense	O
amino	B-Chemical
acid	I-Chemical
substitution	O
of	O
Arg	B-Chemical
to	O
Leu	B-Chemical
","	O
and	O
loss	O
of	O
a	O
HhaI	O
restriction	O
endonuclease	O
site	O
.	O
(	O
B	O
)	O
Restriction	O
map	O
showing	O
that	O
HhaI	O
digestion	O
would	O
result	O
in	O
two	O
products	O
of	O
143	O
and	O
252	O
bp	O
from	O
the	O
wild	O
-	O
type	O
(	O
WT	O
)	O
sequence	O
","	O
but	O
would	O
not	O
affect	O
the	O
mutant	O
(	O
m	O
)	O
sequence	O
.	O
PCR	O
and	O
HhaI	O
digestion	O
revealed	O
the	O
probands	O
[	O
individual	O
II	O
.	O
4	O
of	O
family	O
2	O
/	O
3	O
(	O
C	O
)	O
and	O
individual	O
II	O
.	O
1	O
of	O
family	O
6	O
/	O
13b	O
(	O
D	O
)]	O
to	O
be	O
heterozygous	O
for	O
the	O
Arg15Leu	B-Chemical
mutation	O
.	O
The	O
absence	O
of	O
the	O
Arg15Leu	B-Chemical
mutation	O
in	O
the	O
unaffected	O
parents	O
of	O
both	O
probands	O
is	O
consistent	O
with	O
the	O
mutation	O
arising	O
de	O
novo	O
.	O
DNA	O
sequence	O
analysis	O
of	O
the	O
entire	O
AP2S1	O
429	O
-	O
bp	O
coding	O
region	O
and	O
8	O
exon	O
â€“	O
intron	O
boundaries	O
was	O
undertaken	O
in	O
65	O
unrelated	O
FHH	O
probands	O
without	O
CASR	O
or	O
GNA11	O
mutations	O
(	O
22	O
males	O
and	O
43	O
females	O
).	O
This	O
revealed	O
the	O
presence	O
of	O
AP2S1	O
mutations	O
in	O
17	O
probands	O
(	O
7	O
males	O
and	O
10	O
females	O
"),"	O
thereby	O
representing	O
a	O
>	O
25	O
%	O
AP2S1	O
mutation	O
detection	O
rate	O
in	O
this	O
cohort	O
of	O
FHH	O
patients	O
without	O
CASR	O
and	O
GNA11	O
mutations	O
.	O
The	O
FHH3	O
-	O
associated	O
mutations	O
only	O
affected	O
the	O
AP2Ïƒ2	O
Arg15	B-Chemical
(	O
R15	O
)	O
residue	O
and	O
consisted	O
of	O
five	O
Arg15Cys	B-Chemical
(	O
R15C	O
"),"	O
four	O
Arg15His	B-Chemical
(	O
R15H	O
)	O
and	O
eight	O
Arg15Leu	B-Chemical
(	O
R15L	O
)	O
mutations	O
(	O
Table	O
1	O
"),"	O
all	O
of	O
which	O
had	O
previously	O
been	O
reported	O
to	O
represent	O
pathogenic	O
mutations	O
.	O
Two	O
unrelated	O
FHH3	O
female	O
probands	O
","	O
aged	O
7	O
and	O
15	O
years	O
","	O
harboured	O
Arg15Leu	B-Chemical
mutations	O
that	O
were	O
demonstrated	O
to	O
be	O
absent	O
in	O
both	O
of	O
their	O
parents	O
","	O
and	O
hence	O
likely	O
to	O
be	O
arising	O
de	O
novo	O
(	O
Fig	O
.	O
1	O
).	O
Four	O
FHH3	O
subjects	O
had	O
symptoms	O
attributable	O
to	O
hypercalcaemia	O
","	O
including	O
lethargy	O
","	O
constipation	O
","	O
widespread	O
musculoskeletal	O
pain	O
and	O
polydipsia	O
(	O
Table	O
1	O
).	O
Eleven	O
FHH3	O
probands	O
had	O
clinical	O
features	O
in	O
addition	O
to	O
hypercalcaemia	O
and	O
hypocalciuria	O
(	O
Table	O
1	O
).	O
In	O
particular	O
","	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
was	O
noted	O
to	O
be	O
low	O
(	O
T	O
-	O
score	O
<	O
âˆ’	O
1	O
.	O
0	O
or	O
Z	O
-	O
score	O
<	O
âˆ’	O
2	O
.	O
0	O
)	O
at	O
the	O
lumbar	O
spine	O
or	O
femoral	O
neck	O
in	O
5	O
of	O
10	O
patients	O
aged	O
14	O
to	O
64	O
years	O
(	O
Table	O
1	O
).	O
The	O
low	O
BMD	O
in	O
all	O
five	O
patients	O
was	O
not	O
associated	O
with	O
renal	O
dysfunction	O
","	O
hyperparathyroidism	O
","	O
vitamin	B-Chemical
D	I-Chemical
deficiency	O
or	O
thyrotoxicosis	O
.	O
Furthermore	O
","	O
seven	O
FHH3	O
patients	O
(	O
aged	O
3	O
â€“	O
37	O
years	O
)	O
were	O
noted	O
to	O
have	O
learning	O
disabilities	O
characterized	O
by	O
cognitive	O
deficits	O
and	O
/	O
or	O
behavioural	O
disturbances	O
(	O
Table	O
1	O
).	O
In	O
addition	O
","	O
the	O
father	O
of	O
a	O
proband	O
with	O
learning	O
disabilities	O
(	O
6	O
/	O
13a	O
","	O
Table	O
1	O
)	O
also	O
had	O
a	O
cognitive	O
deficit	O
in	O
association	O
with	O
hypercalcaemia	O
.	O
Two	O
of	O
the	O
Arg15Leu	B-Chemical
probands	O
with	O
cognitive	O
deficits	O
(	O
2	O
/	O
3	O
and	O
2	O
/	O
11	O
","	O
Table	O
1	O
)	O
had	O
short	O
stature	O
with	O
height	O
at	O
or	O
below	O
the	O
third	O
centile	O
","	O
and	O
one	O
of	O
these	O
probands	O
(	O
2	O
/	O
3	O
","	O
Table	O
1	O
)	O
was	O
found	O
to	O
harbour	O
an	O
atrial	O
septal	O
defect	O
","	O
whereas	O
the	O
other	O
individual	O
(	O
2	O
/	O
11	O
","	O
Table	O
1	O
)	O
suffered	O
from	O
recurrent	O
episodes	O
of	O
pancreatitis	O
.	O
The	O
pancreatitis	O
in	O
this	O
patient	O
was	O
not	O
due	O
to	O
gallstones	O
or	O
alcohol	B-Chemical
abuse	O
","	O
and	O
analysis	O
of	O
genes	O
known	O
to	O
be	O
associated	O
with	O
pancreatitis	O
","	O
such	O
as	O
SPINK1	O
","	O
CFTR	O
","	O
PRSS1	O
and	O
CTRC	O
","	O
did	O
not	O
reveal	O
any	O
mutations	O
.	O
Genotype	O
â€“	O
phenotype	O
correlations	O
at	O
the	O
AP2Ïƒ2	O
Arg15	B-Chemical
residue	O
Assessment	O
of	O
genotype	O
â€“	O
phenotype	O
correlations	O
between	O
probands	O
harbouring	O
Arg15His	B-Chemical
(	O
R15H	O
"),"	O
Arg15Cys	B-Chemical
(	O
R15C	O
)	O
or	O
Arg15Leu	B-Chemical
(	O
R15L	O
)	O
AP2S1	O
mutations	O
.	O
Serum	O
and	O
urine	O
biochemical	O
values	O
are	O
shown	O
as	O
scatter	O
plots	O
.	O
(	O
A	O
)	O
Probands	O
with	O
R15L	O
mutations	O
had	O
significantly	O
greater	O
elevations	O
of	O
serum	O
adjusted	O
-	O
calcium	B-Chemical
concentrations	O
than	O
probands	O
with	O
R15C	O
or	O
R15H	O
mutations	O
.	O
Probands	O
with	O
R15C	O
mutations	O
were	O
significantly	O
more	O
hypercalcaemic	O
than	O
probands	O
with	O
R15H	O
mutations	O
.	O
(	O
B	O
â€“	O
F	O
)	O
No	O
significant	O
differences	O
in	O
serum	O
concentrations	O
of	O
phosphate	B-Chemical
","	O
magnesium	B-Chemical
","	O
ALP	O
activity	O
","	O
PTH	O
or	O
urinary	O
CCCR	O
were	O
observed	O
between	O
probands	O
harbouring	O
each	O
of	O
the	O
three	O
AP2S1	O
R15	O
mutations	O
.	O
Mean	O
values	O
for	O
the	O
respective	O
groups	O
are	O
indicated	O
by	O
horizontal	O
solid	O
lines	O
.	O
The	O
normal	O
ranges	O
[	O
mean	O
Â±	O
2	O
standard	O
deviations	O
(	O
SDs	O
)]	O
for	O
serum	O
calcium	B-Chemical
","	O
phosphate	B-Chemical
and	O
magnesium	B-Chemical
are	O
indicated	O
by	O
the	O
grey	O
areas	O
.	O
The	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
for	O
the	O
assay	O
that	O
was	O
used	O
for	O
serum	O
ALP	O
activity	O
and	O
PTH	O
concentrations	O
are	O
represented	O
by	O
the	O
broken	O
line	O
.	O
For	O
CCCR	O
","	O
the	O
lower	O
limit	O
(<	O
0	O
.	O
1	O
)	O
for	O
the	O
consideration	O
of	O
hypocalciuria	O
is	O
represented	O
by	O
the	O
broken	O
line	O
.	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
1	O
.	O
We	O
examined	O
for	O
phenotypic	O
differences	O
between	O
patients	O
with	O
Arg15Cys	B-Chemical
","	O
Arg15His	B-Chemical
or	O
Arg15Leu	B-Chemical
AP2S1	O
mutations	O
.	O
Analysis	O
of	O
biochemical	O
and	O
clinical	O
data	O
available	O
for	O
a	O
total	O
of	O
27	O
FHH3	O
probands	O
[	O
17	O
from	O
this	O
study	O
and	O
10	O
from	O
our	O
previously	O
reported	O
study	O
]	O
revealed	O
that	O
patients	O
with	O
the	O
Arg15Leu	B-Chemical
mutation	O
had	O
significantly	O
greater	O
elevations	O
of	O
serum	O
albumin	O
adjusted	O
-	O
calcium	B-Chemical
concentrations	O
when	O
compared	O
with	O
those	O
with	O
the	O
Arg15Cys	B-Chemical
and	O
Arg15His	B-Chemical
AP2Ïƒ2	O
mutations	O
(	O
3	O
.	O
6	O
Â±	O
0	O
.	O
4	O
mmol	O
/	O
l	O
for	O
Arg15Leu	B-Chemical
versus	O
2	O
.	O
83	O
Â±	O
0	O
.	O
3	O
mmol	O
/	O
l	O
for	O
Arg15Cys	B-Chemical
and	O
2	O
.	O
74	O
Â±	O
0	O
.	O
3	O
mmol	O
/	O
l	O
for	O
Arg15His	B-Chemical
","	O
P	O
<	O
0	O
.	O
1	O
).	O
Moreover	O
","	O
patients	O
with	O
the	O
Arg15Cys	B-Chemical
mutation	O
had	O
a	O
significantly	O
greater	O
hypercalcaemia	O
(	O
P	O
<	O
0	O
.	O
5	O
)	O
than	O
patients	O
harbouring	O
the	O
Arg15His	B-Chemical
mutation	O
.	O
Such	O
differences	O
were	O
not	O
observed	O
for	O
other	O
biochemical	O
indices	O
of	O
mineral	O
metabolism	O
(	O
Fig	O
.	O
2	O
).	O
Phenotypic	O
differences	O
between	O
FHH3	O
and	O
FHH1	O
Comparison	O
of	O
biochemical	O
phenotypes	O
between	O
FHH1	O
and	O
FHH3	O
.	O
Scatter	O
plots	O
of	O
serum	O
concentrations	O
of	O
(	O
A	O
)	O
adjusted	O
-	O
calcium	B-Chemical
","	O
(	O
B	O
)	O
phosphate	B-Chemical
","	O
(	O
C	O
)	O
magnesium	B-Chemical
","	O
(	O
D	O
)	O
ALP	O
activity	O
","	O
(	O
E	O
)	O
PTH	O
","	O
(	O
F	O
)	O
urinary	O
CCCR	O
and	O
(	O
G	O
)	O
CMCR	O
index	O
","	O
which	O
is	O
calculated	O
as	O
sCa	B-Chemical
Ã—	O
sMg	B-Chemical
/	O
100	O
Ã—	O
CCCR	O
","	O
for	O
FHH3	O
probands	O
are	O
shown	O
.	O
Such	O
biochemical	O
values	O
are	O
also	O
provided	O
for	O
an	O
age	O
-	O
and	O
gender	O
-	O
matched	O
cohort	O
of	O
previously	O
reported	O
FHH1	O
probands	O
with	O
CASR	O
mutations	O
.	O
All	O
biochemical	O
parameters	O
comprising	O
the	O
CMCR	O
index	O
were	O
measured	O
in	O
millimole	O
per	O
litre	O
.	O
FHH3	O
probands	O
","	O
when	O
compared	O
with	O
FHH1	O
probands	O
","	O
had	O
significantly	O
greater	O
elevations	O
of	O
serum	O
adjusted	O
-	O
calcium	B-Chemical
and	O
magnesium	B-Chemical
concentrations	O
","	O
reduced	O
CCCR	O
values	O
and	O
elevated	O
CMCR	O
.	O
Mean	O
values	O
for	O
the	O
respective	O
groups	O
are	O
indicated	O
by	O
horizontal	O
solid	O
lines	O
.	O
The	O
normal	O
ranges	O
(	O
mean	O
Â±	O
2	O
SDs	O
)	O
for	O
serum	O
calcium	B-Chemical
","	O
phosphate	B-Chemical
and	O
magnesium	B-Chemical
are	O
indicated	O
by	O
the	O
grey	O
areas	O
.	O
The	O
ULN	O
for	O
the	O
assay	O
that	O
was	O
used	O
for	O
serum	O
ALP	O
activity	O
and	O
PTH	O
concentrations	O
are	O
represented	O
by	O
the	O
broken	O
line	O
.	O
For	O
CCCR	O
","	O
the	O
lower	O
limit	O
(<	O
0	O
.	O
1	O
)	O
for	O
the	O
consideration	O
of	O
hypocalciuria	O
is	O
represented	O
by	O
the	O
broken	O
line	O
.	O
For	O
CMCR	O
index	O
","	O
the	O
cut	O
-	O
off	O
value	O
of	O
5	O
.	O
0	O
","	O
above	O
which	O
a	O
diagnosis	O
of	O
FHH3	O
should	O
be	O
considered	O
","	O
is	O
represented	O
by	O
the	O
broken	O
line	O
.	O
(	O
H	O
)	O
ROC	O
of	O
discriminatory	O
power	O
of	O
CMCR	O
index	O
to	O
distinguish	O
between	O
FHH3	O
and	O
FHH1	O
.	O
The	O
CMCR	O
had	O
an	O
AUC	O
of	O
0	O
.	O
85	O
","	O
which	O
was	O
significantly	O
greater	O
than	O
that	O
of	O
the	O
reference	O
line	O
(	O
P	O
<	O
0	O
.	O
1	O
).	O
**	O
P	O
<	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
.	O
To	O
determine	O
whether	O
FHH3	O
is	O
associated	O
with	O
any	O
differences	O
in	O
the	O
biochemical	O
phenotype	O
when	O
compared	O
with	O
FHH1	O
","	O
we	O
analysed	O
the	O
serum	O
and	O
urine	O
biochemistry	O
from	O
51	O
FHH3	O
subjects	O
that	O
included	O
affected	O
members	O
of	O
the	O
previously	O
reported	O
multi	O
-	O
generational	O
FHH3	O
kindreds	O
from	O
Oklahoma	O
(	O
FHHOK	O
)	O
and	O
Northern	O
Ireland	O
(	O
FHHNI	O
"),"	O
and	O
43	O
previously	O
reported	O
FHH1	O
probands	O
","	O
who	O
all	O
harboured	O
CASR	O
mutations	O
.	O
This	O
revealed	O
FHH3	O
patients	O
to	O
have	O
a	O
greater	O
degree	O
of	O
hypercalcaemia	O
than	O
the	O
FHH1	O
patients	O
(	O
serum	O
adjusted	O
-	O
calcium	B-Chemical
=	O
2	O
.	O
87	O
Â±	O
0	O
.	O
2	O
mmol	O
/	O
l	O
for	O
FHH3	O
versus	O
2	O
.	O
76	O
Â±	O
0	O
.	O
2	O
mmol	O
/	O
l	O
for	O
FHH1	O
","	O
P	O
<	O
0	O
.	O
1	O
)	O
(	O
Fig	O
.	O
3	O
).	O
FHH3	O
patients	O
when	O
compared	O
with	O
FHH1	O
patients	O
also	O
had	O
significantly	O
marked	O
hypermagnesaemia	O
(	O
serum	O
magnesium	B-Chemical
=	O
1	O
.	O
4	O
Â±	O
0	O
.	O
2	O
mmol	O
/	O
l	O
for	O
FHH3	O
versus	O
0	O
.	O
95	O
Â±	O
0	O
.	O
2	O
mmol	O
/	O
l	O
for	O
FHH1	O
","	O
P	O
<	O
0	O
.	O
1	O
)	O
and	O
hypocalciuria	O
(	O
CCCR	O
=	O
0	O
.	O
4	O
Â±	O
0	O
.	O
1	O
for	O
FHH3	O
versus	O
0	O
.	O
7	O
Â±	O
0	O
.	O
1	O
for	O
FHH1	O
","	O
P	O
<	O
0	O
.	O
1	O
)	O
(	O
Fig	O
.	O
3	O
).	O
There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
serum	O
concentrations	O
of	O
phosphate	B-Chemical
","	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
activity	O
or	O
PTH	O
between	O
the	O
FHH3	O
and	O
FHH1	O
patients	O
(	O
Fig	O
.	O
3	O
).	O
As	O
serum	O
adjusted	O
-	O
calcium	B-Chemical
","	O
serum	O
magnesium	B-Chemical
and	O
CCCR	O
values	O
were	O
significantly	O
different	O
between	O
FHH3	O
and	O
FHH1	O
patients	O
","	O
we	O
investigated	O
whether	O
the	O
combined	O
use	O
of	O
these	O
biochemical	O
parameters	O
could	O
be	O
utilized	O
to	O
discriminate	O
between	O
these	O
two	O
hypercalcaemic	O
disorders	O
.	O
Based	O
on	O
the	O
observation	O
that	O
serum	O
adjusted	O
-	O
calcium	B-Chemical
(	O
sCa	B-Chemical
)	O
and	O
serum	O
magnesium	B-Chemical
(	O
sMg	B-Chemical
)	O
values	O
are	O
elevated	O
","	O
whereas	O
CCCR	O
is	O
reduced	O
in	O
FHH3	O
","	O
a	O
calculated	O
index	O
(	O
sCa	B-Chemical
Ã—	O
sMg	B-Chemical
/	O
100	O
Ã—	O
CCCR	O
"),"	O
designated	O
CMCR	O
","	O
was	O
determined	O
for	O
each	O
of	O
the	O
subjects	O
in	O
the	O
FHH1	O
and	O
FHH3	O
groups	O
(	O
Fig	O
.	O
3	O
)	O
with	O
all	O
biochemical	O
parameters	O
being	O
measured	O
in	O
millimole	O
per	O
litre	O
.	O
Receiver	O
â€“	O
operator	O
curve	O
(	O
ROC	O
)	O
analysis	O
of	O
the	O
CMCR	O
index	O
(	O
Fig	O
.	O
3	O
)	O
revealed	O
an	O
area	O
-	O
under	O
-	O
the	O
curve	O
(	O
AUC	O
)	O
of	O
0	O
.	O
85	O
(	O
P	O
<	O
0	O
.	O
1	O
)	O
and	O
an	O
optimal	O
cut	O
-	O
off	O
value	O
of	O
5	O
.	O
0	O
for	O
discriminating	O
between	O
FHH3	O
and	O
FHH1	O
","	O
which	O
provides	O
a	O
diagnostic	O
sensitivity	O
of	O
83	O
%	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
61	O
â€“	O
95	O
]	O
and	O
specificity	O
of	O
86	O
%	O
(	O
95	O
%	O
CI	O
=	O
57	O
â€“	O
98	O
"),"	O
and	O
positive	O
and	O
negative	O
predictive	O
values	O
of	O
90	O
%	O
(	O
95	O
%	O
CI	O
=	O
70	O
â€“	O
98	O
)	O
and	O
80	O
%	O
(	O
95	O
%	O
CI	O
=	O
52	O
â€“	O
95	O
"),"	O
respectively	O
.	O
Analysis	O
of	O
AP2Ïƒ2	O
codon	O
15	O
mutation	O
bias	O
Observed	O
and	O
predicted	O
mutations	O
at	O
the	O
AP2S1	O
Arg15	B-Chemical
(	O
R15	O
)	O
residue	O
.	O
(	O
A	O
)	O
Schematic	O
representation	O
of	O
possible	O
nucleotide	B-Chemical
and	O
amino	B-Chemical
acid	I-Chemical
substitutions	O
affecting	O
codon	O
15	O
.	O
Substitutions	O
affecting	O
the	O
first	O
or	O
second	O
nucleotide	B-Chemical
of	O
codon	O
15	O
(	O
CGC	O
)	O
are	O
predicted	O
to	O
lead	O
to	O
one	O
of	O
six	O
possible	O
non	O
-	O
synonymous	O
mutations	O
or	O
variants	O
","	O
which	O
are	O
Cys15	B-Chemical
(	O
TGC	O
"),"	O
Gly15	B-Chemical
(	O
GGC	O
"),"	O
His15	B-Chemical
(	O
CAC	O
"),"	O
Leu15	B-Chemical
(	O
CTC	O
"),"	O
Pro15	B-Chemical
(	O
CCC	O
)	O
or	O
Ser15	B-Chemical
(	O
AGC	O
).	O
Substitutions	O
affecting	O
the	O
third	O
nucleotide	B-Chemical
of	O
the	O
CGC	O
triplet	O
are	O
predicted	O
to	O
lead	O
to	O
synonymous	O
variants	O
only	O
.	O
(	O
B	O
)	O
Crystal	O
structure	O
of	O
the	O
Î±	O
-	O
subunit	O
(	O
green	O
)	O
and	O
Ïƒ2	O
-	O
subunit	O
(	O
blue	O
)	O
of	O
the	O
AP2	O
heterotetrameric	O
complex	O
bound	O
to	O
an	O
acidic	O
(	O
Gln	B-Chemical
-	O
containing	O
)	O
dileucine	O
cargo	O
protein	O
motif	O
[	O
PDB	O
file	O
2JKR	O
].	O
The	O
key	O
polar	O
contacts	O
(	O
black	O
dashed	O
lines	O
)	O
between	O
the	O
Ïƒ2	O
-	O
subunit	O
Arg15	B-Chemical
residue	O
(	O
ÏƒArg15	B-Chemical
","	O
red	O
)	O
and	O
Î±	O
-	O
subunit	O
Arg21	B-Chemical
residue	O
(	O
Î±Arg21	B-Chemical
","	O
grey	O
"),"	O
and	O
a	O
Gln	B-Chemical
residue	O
located	O
four	O
residues	O
from	O
the	O
first	O
Leu	B-Chemical
residue	O
of	O
the	O
acidic	O
dileucine	O
motif	O
[	O
Gln	B-Chemical
(	O
Leu	B-Chemical
-	O
4	O
"),"	O
orange	O
"],"	O
are	O
shown	O
.	O
(	O
C	O
â€“	O
G	O
)	O
Structural	O
analysis	O
of	O
six	O
potential	O
Arg15	B-Chemical
mutations	O
demonstrating	O
that	O
the	O
observed	O
mutants	O
(	O
Cys15	B-Chemical
","	O
His15	B-Chemical
and	O
Leu15	B-Chemical
)	O
and	O
non	O
-	O
observed	O
mutants	O
(	O
Gly15	B-Chemical
","	O
Pro15	B-Chemical
and	O
Ser15	B-Chemical
)	O
are	O
all	O
predicted	O
to	O
result	O
in	O
the	O
loss	O
of	O
the	O
key	O
polar	O
contact	O
with	O
the	O
cargo	O
protein	O
Gln	B-Chemical
(	O
Leu	B-Chemical
-	O
4	O
)	O
residue	O
.	O
The	O
present	O
study	O
has	O
identified	O
17	O
hypercalcaemic	O
patients	O
with	O
AP2S1	O
mutations	O
that	O
all	O
affected	O
the	O
AP2Ïƒ2	O
Arg15	B-Chemical
residue	O
","	O
and	O
previous	O
studies	O
have	O
reported	O
19	O
AP2S1	O
mutations	O
that	O
all	O
affect	O
the	O
Arg15	B-Chemical
residue	O
yielding	O
a	O
total	O
of	O
36	O
FHH3	O
-	O
causing	O
mutations	O
identified	O
to	O
date	O
.	O
These	O
36	O
AP2S1	O
mutations	O
involving	O
substitutions	O
of	O
Arg15	B-Chemical
comprise	O
13	O
Arg15Cys	B-Chemical
","	O
8	O
Arg15His	B-Chemical
and	O
15	O
Arg15Leu	B-Chemical
.	O
Analysis	O
of	O
the	O
DNA	O
sequence	O
of	O
the	O
Arg15	B-Chemical
codon	O
reveals	O
it	O
to	O
be	O
CGC	O
indicating	O
that	O
missense	O
substitutions	O
affecting	O
the	O
first	O
or	O
second	O
nucleotides	B-Chemical
would	O
be	O
predicted	O
to	O
be	O
non	O
-	O
synonymous	O
and	O
lead	O
to	O
one	O
of	O
six	O
possible	O
amino	B-Chemical
acid	I-Chemical
substitutions	O
","	O
which	O
comprise	O
Cys	B-Chemical
","	O
Gly	B-Chemical
","	O
His	B-Chemical
","	O
Leu	B-Chemical
","	O
Pro	B-Chemical
and	O
Ser	B-Chemical
(	O
Fig	O
.	O
4	O
).	O
This	O
expected	O
observation	O
of	O
six	O
different	O
amino	B-Chemical
acid	I-Chemical
substitutions	O
contrasts	O
significantly	O
(	O
P	O
<	O
0	O
.	O
1	O
","	O
Chi	O
-	O
squared	O
test	O
)	O
with	O
the	O
three	O
Arg15	B-Chemical
-	O
mutant	O
substitutions	O
observed	O
in	O
FHH3	O
patients	O
.	O
Functional	O
expression	O
of	O
AP2S1	O
Arg15	B-Chemical
(	O
R15	O
)	O
mutants	O
.	O
(	O
A	O
)	O
Fluorescence	O
microscopy	O
of	O
HEK293	O
cells	O
stably	O
transfected	O
with	O
CaSR	O
and	O
transiently	O
transfected	O
with	O
wild	O
-	O
type	O
R15	O
(	O
WT	O
-	O
R15	O
"),"	O
and	O
FHH3	O
-	O
associated	O
mutants	O
(	O
Cys15	B-Chemical
","	O
C15	O
;	O
His15	B-Chemical
","	O
H15	O
;	O
Leu15	B-Chemical
","	O
L15	O
)	O
or	O
other	O
possible	O
R15	O
mutants	O
(	O
Fig	O
.	O
4	O
)	O
(	O
Gly15	B-Chemical
","	O
G15	O
;	O
Pro15	B-Chemical
","	O
P15	O
;	O
Ser15	B-Chemical
","	O
S15	O
"),"	O
or	O
pBI	O
-	O
CMV4	O
-	O
RFP	O
expression	O
vector	O
only	O
(	O
V	O
).	O
RFP	O
expression	O
in	O
these	O
cells	O
indicates	O
successful	O
transfection	O
and	O
expression	O
by	O
these	O
constructs	O
.	O
Bar	O
indicates	O
20	O
Î¼m	O
.	O
(	O
B	O
)	O
Western	O
blot	O
analysis	O
of	O
whole	O
-	O
cell	O
lysates	O
using	O
anti	O
-	O
CaSR	O
","	O
anti	O
-	O
GAPDH	O
and	O
anti	O
-	O
RFP	O
antibodies	O
.	O
The	O
FHH3	O
-	O
mutant	O
AP2Ïƒ2	O
and	O
predicted	O
possible	O
R15	O
mutant	O
proteins	O
were	O
expressed	O
at	O
similar	O
levels	O
.	O
UT	O
","	O
untransfected	O
cells	O
.	O
(	O
C	O
)	O
Measurement	O
of	O
Ca2	B-Chemical
+	I-Chemical
i	O
responses	O
following	O
stimulation	O
with	O
varying	O
Ca2	B-Chemical
+	I-Chemical
o	O
concentrations	O
revealed	O
cells	O
expressing	O
observed	O
FHH3	O
-	O
associated	O
mutants	O
or	O
the	O
non	O
-	O
observed	O
possible	O
R15	O
mutants	O
(	O
Fig	O
.	O
4	O
)	O
to	O
have	O
significantly	O
raised	O
EC50	O
values	O
when	O
compared	O
with	O
cells	O
expressing	O
the	O
wild	O
-	O
type	O
AP2Ïƒ2	O
(	O
WT	O
-	O
R15	O
)	O
protein	O
.	O
Results	O
are	O
from	O
eight	O
to	O
ten	O
assays	O
and	O
three	O
independent	O
transfections	O
.	O
(	O
D	O
)	O
Growth	O
of	O
cells	O
expressing	O
WT	O
or	O
mutant	O
AP2Ïƒ2	O
proteins	O
.	O
Cells	O
expressing	O
the	O
non	O
-	O
observed	O
possible	O
R15	O
mutants	O
showed	O
a	O
significantly	O
reduced	O
percentage	O
increase	O
in	O
cell	O
numbers	O
over	O
a	O
24	O
-	O
h	O
period	O
when	O
compared	O
with	O
cells	O
expressing	O
WT	O
or	O
FHH3	O
-	O
associated	O
mutant	O
AP2Ïƒ2	O
proteins	O
","	O
consistent	O
with	O
an	O
impairment	O
of	O
proliferation	O
.	O
Results	O
are	O
from	O
11	O
to	O
18	O
assays	O
and	O
4	O
independent	O
transfections	O
.	O
*	O
P	O
<	O
0	O
.	O
5	O
and	O
â€ 	O
P	O
<	O
0	O
.	O
1	O
.	O
To	O
investigate	O
the	O
potential	O
occurrence	O
of	O
the	O
Arg15Cys	B-Chemical
","	O
Arg15His	B-Chemical
and	O
Arg15Leu	B-Chemical
","	O
and	O
the	O
absence	O
of	O
Arg15Gly	B-Chemical
","	O
Arg15Pro	B-Chemical
and	O
Arg15Ser	B-Chemical
variants	O
","	O
we	O
assessed	O
the	O
effects	O
of	O
all	O
six	O
potential	O
Arg15	B-Chemical
mutants	O
on	O
the	O
structure	O
and	O
function	O
of	O
AP2	O
.	O
Analysis	O
of	O
the	O
AP2	O
complex	O
crystal	O
structure	O
predicted	O
that	O
all	O
the	O
six	O
Arg15	B-Chemical
missense	O
substitutions	O
","	O
including	O
the	O
Arg15Gly	B-Chemical
","	O
Arg15Pro	B-Chemical
and	O
Arg15Ser	B-Chemical
variants	O
that	O
have	O
not	O
been	O
observed	O
in	O
FHH3	O
","	O
would	O
impair	O
AP2	O
complex	O
function	O
by	O
disrupting	O
a	O
key	O
polar	O
contact	O
between	O
the	O
AP2	O
complex	O
and	O
the	O
cargo	O
protein	O
dileucine	O
recognition	O
motif	O
(	O
Fig	O
.	O
4	O
).	O
Thus	O
","	O
all	O
the	O
six	O
Arg15	B-Chemical
missense	O
substitutions	O
would	O
significantly	O
alter	O
the	O
structure	O
","	O
and	O
we	O
therefore	O
determined	O
their	O
functional	O
consequences	O
on	O
CaSR	O
activity	O
","	O
by	O
expressing	O
them	O
in	O
HEK293	O
cells	O
that	O
stably	O
expressed	O
the	O
CaSR	O
(	O
HEK	O
-	O
CaSR	O
).	O
Transient	O
transfection	O
of	O
the	O
wild	O
-	O
type	O
or	O
mutant	O
AP2S1	O
-	O
pBI	O
-	O
CMV4	O
-	O
RFP	O
expression	O
constructs	O
","	O
or	O
vector	O
containing	O
the	O
red	O
fluorescence	O
protein	O
(	O
RFP	O
)	O
reporter	O
gene	O
alone	O
","	O
was	O
undertaken	O
in	O
the	O
HEK	O
-	O
CaSR	O
cells	O
.	O
Expression	O
of	O
the	O
CaSR	O
and	O
RFP	O
","	O
which	O
represents	O
a	O
surrogate	O
of	O
AP2Ïƒ2	O
expression	O
","	O
was	O
detected	O
by	O
immunofluorescence	O
and	O
western	O
blotting	O
of	O
whole	O
-	O
cell	O
lysates	O
(	O
Fig	O
.	O
5	O
"),"	O
and	O
the	O
responses	O
of	O
Ca2	B-Chemical
+	I-Chemical
i	O
concentrations	O
to	O
alterations	O
in	O
Ca2	B-Chemical
+	I-Chemical
o	O
concentrations	O
were	O
then	O
assayed	O
by	O
flow	O
cytometry	O
.	O
The	O
number	O
(	O
N	O
)	O
of	O
replicate	O
experiments	O
from	O
three	O
independent	O
transfections	O
is	O
indicated	O
.	O
NS	O
","	O
not	O
significant	O
;	O
CI	O
","	O
confidence	O
interval	O
.	O
EC50	O
values	O
of	O
observed	O
and	O
non	O
-	O
observed	O
AP2Ïƒ2	O
Arg15	B-Chemical
mutants	O
HEK	O
-	O
CaSR	O
cells	O
expressing	O
each	O
of	O
the	O
six	O
Arg15	B-Chemical
missense	O
AP2Ïƒ2	O
variants	O
(	O
i	O
.	O
e	O
.	O
the	O
three	O
observed	O
Arg15Cys	B-Chemical
","	O
Arg15His	B-Chemical
and	O
Arg15Leu	B-Chemical
and	O
the	O
three	O
non	O
-	O
observed	O
Arg15Gly	B-Chemical
","	O
Arg15Pro	B-Chemical
and	O
Arg15Ser	B-Chemical
AP2Ïƒ2	O
variants	O
)	O
were	O
found	O
to	O
have	O
half	O
-	O
maximal	O
effective	O
concentration	O
(	O
EC50	O
)	O
values	O
that	O
were	O
significantly	O
higher	O
(	O
P	O
<	O
0	O
.	O
1	O
)	O
than	O
cells	O
expressing	O
the	O
wild	O
-	O
type	O
AP2Ïƒ2	O
protein	O
.	O
Thus	O
","	O
the	O
three	O
non	O
-	O
observed	O
Arg15	B-Chemical
AP2Ïƒ2	O
variants	O
decreased	O
the	O
sensitivity	O
of	O
HEK	O
-	O
CaSR	O
cells	O
to	O
Ca2	B-Chemical
+	I-Chemical
o	O
concentrations	O
in	O
a	O
similar	O
manner	O
to	O
the	O
three	O
FHH3	O
-	O
causing	O
AP2Ïƒ2	O
mutations	O
(	O
Fig	O
.	O
5	O
and	O
Table	O
2	O
).	O
However	O
","	O
cells	O
expressing	O
the	O
non	O
-	O
observed	O
Arg15Gly	B-Chemical
","	O
Arg15Pro	B-Chemical
or	O
Arg15Ser	B-Chemical
AP2Ïƒ2	O
mutants	O
were	O
found	O
to	O
have	O
significantly	O
reduced	O
increases	O
in	O
cell	O
numbers	O
over	O
a	O
24	O
-	O
h	O
period	O
","	O
when	O
compared	O
with	O
cells	O
expressing	O
wild	O
-	O
type	O
or	O
FHH3	O
-	O
mutant	O
AP2Ïƒ2	O
proteins	O
(	O
Fig	O
.	O
5	O
).	O
These	O
results	O
indicate	O
that	O
the	O
Arg15Gly	B-Chemical
","	O
Arg15Pro	B-Chemical
and	O
Arg15Ser	B-Chemical
AP2Ïƒ2	O
mutants	O
are	O
likely	O
not	O
observed	O
as	O
they	O
are	O
associated	O
with	O
an	O
impairment	O
of	O
cell	O
growth	O
","	O
when	O
compared	O
with	O
wild	O
-	O
type	O
or	O
the	O
FHH3	O
-	O
associated	O
mutant	O
AP2Ïƒ2	O
proteins	O
(	O
Fig	O
.	O
5	O
and	O
Supplementary	O
Material	O
","	O
Fig	O
.	O
S1	O
).	O
Dominant	O
-	O
negative	O
effects	O
of	O
AP2S1	O
mutations	O
Comparison	O
of	O
EC50	O
values	O
for	O
HEK	O
-	O
CaSR	O
cells	O
transfected	O
with	O
increasing	O
amounts	O
of	O
wild	O
-	O
type	O
(	O
WT	O
)	O
or	O
mutant	O
AP2S1	O
-	O
pBI	O
-	O
CMV4	O
-	O
RFP	O
expression	O
constructs	O
.	O
(	O
A	O
)	O
During	O
flow	O
cytometry	O
","	O
fluorescence	O
over	O
a	O
1	O
â€“	O
10	O
0	O
range	O
can	O
be	O
detected	O
.	O
The	O
first	O
large	O
peak	O
represents	O
cells	O
not	O
expressing	O
RFP	O
but	O
displaying	O
low	O
levels	O
of	O
auto	O
-	O
fluorescence	O
.	O
Cells	O
displaying	O
increased	O
fluorescence	O
with	O
respect	O
to	O
this	O
population	O
reflect	O
those	O
expressing	O
RFP	O
.	O
Cells	O
from	O
five	O
different	O
RFP	O
fluorescences	O
were	O
selected	O
on	O
the	O
basis	O
of	O
mean	O
fluorescence	O
(	O
gate	O
1	O
log	O
mean	O
fluorescence	O
=	O
50	O
â€“	O
100	O
","	O
gate	O
2	O
log	O
mean	O
fluorescence	O
=	O
125	O
â€“	O
250	O
","	O
gate	O
3	O
log	O
mean	O
fluorescence	O
=	O
500	O
â€“	O
1000	O
","	O
gate	O
4	O
log	O
mean	O
fluorescence	O
=	O
1250	O
â€“	O
2500	O
and	O
gate	O
5	O
log	O
mean	O
fluorescence	O
=	O
5000	O
â€“	O
10000	O
"),"	O
consistent	O
with	O
a	O
fluorescence	O
ranging	O
from	O
between	O
1	O
-	O
and	O
100	O
-	O
fold	O
over	O
baseline	O
","	O
i	O
.	O
e	O
.	O
between	O
gate	O
1	O
and	O
gate	O
5	O
","	O
which	O
represent	O
the	O
lowest	O
and	O
the	O
highest	O
levels	O
of	O
RFP	O
fluorescence	O
","	O
and	O
therefore	O
AP2Ïƒ2	O
","	O
respectively	O
.	O
(	O
B	O
)	O
Predicted	O
linear	O
regressions	O
of	O
mean	O
EC50	O
with	O
effects	O
owing	O
to	O
dominant	O
-	O
negative	O
and	O
haploinsufficiency	O
mutants	O
.	O
Loss	O
-	O
of	O
-	O
function	O
mutants	O
with	O
dominant	O
-	O
negative	O
effects	O
on	O
the	O
WT	O
protein	O
will	O
exert	O
greater	O
effects	O
on	O
EC50	O
values	O
with	O
increasing	O
concentrations	O
(	O
red	O
line	O
"),"	O
whereas	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
associated	O
with	O
haploinsufficiency	O
of	O
the	O
WT	O
protein	O
will	O
not	O
affect	O
the	O
EC50	O
values	O
with	O
increasing	O
concentrations	O
as	O
the	O
EC50	O
will	O
depend	O
on	O
the	O
concentration	O
of	O
WT	O
protein	O
","	O
which	O
will	O
remain	O
constant	O
(	O
blue	O
line	O
).	O
(	O
C	O
â€“	O
E	O
)	O
Linear	O
regression	O
of	O
the	O
mean	O
EC50	O
of	O
cells	O
with	O
increasing	O
levels	O
of	O
AP2Ïƒ2	O
expression	O
demonstrate	O
no	O
significant	O
deviation	O
from	O
zero	O
in	O
cells	O
transfected	O
with	O
the	O
WT	O
-	O
R15	O
AP2S1	O
-	O
pBI	O
-	O
CMV4	O
-	O
RFP	O
expression	O
construct	O
(	O
r2	O
=	O
0	O
.	O
7	O
","	O
P	O
=	O
0	O
.	O
67	O
"),"	O
whereas	O
a	O
significantly	O
positive	O
incline	O
to	O
the	O
slope	O
is	O
observed	O
in	O
cells	O
transfected	O
with	O
the	O
mutant	O
AP2S1	O
-	O
pBI	O
-	O
CMV4	O
-	O
RFP	O
expression	O
constructs	O
(	O
C15	O
r2	O
=	O
0	O
.	O
82	O
","	O
P	O
<	O
0	O
.	O
5	O
;	O
H15	O
r2	O
=	O
0	O
.	O
84	O
","	O
P	O
<	O
0	O
.	O
5	O
;	O
L15	O
r2	O
=	O
0	O
.	O
99	O
","	O
P	O
<	O
0	O
.	O
1	O
"),"	O
thereby	O
indicating	O
that	O
FHH3	O
-	O
associated	O
AP2Ïƒ2	O
mutations	O
may	O
act	O
in	O
a	O
dominant	O
-	O
negative	O
manner	O
.	O
All	O
experiments	O
were	O
conducted	O
on	O
N	O
=	O
8	O
separate	O
occasions	O
.	O
FHH3	O
is	O
associated	O
with	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
AP2Ïƒ2	O
mutations	O
","	O
and	O
these	O
could	O
be	O
causing	O
the	O
disease	O
by	O
either	O
haploinsufficiency	O
(	O
i	O
.	O
e	O
.	O
a	O
reduced	O
dosage	O
of	O
the	O
wild	O
-	O
type	O
AP2Ïƒ2	O
protein	O
)	O
or	O
dominant	O
-	O
negative	O
effects	O
on	O
the	O
heterotetrameric	O
AP2	O
complex	O
.	O
To	O
investigate	O
these	O
genetic	O
mechanisms	O
","	O
we	O
studied	O
the	O
effects	O
of	O
altering	O
the	O
dosage	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
AP2Ïƒ2	O
proteins	O
on	O
the	O
EC50	O
responses	O
of	O
HEK	O
-	O
CaSR	O
cells	O
that	O
were	O
transiently	O
transfected	O
with	O
wild	O
-	O
type	O
or	O
mutant	O
AP2S1	O
-	O
pBI	O
-	O
CMV4	O
-	O
RFP	O
expression	O
constructs	O
.	O
We	O
used	O
the	O
bidirectional	O
AP2S1	O
-	O
pBI	O
-	O
CMV4	O
-	O
RFP	O
vector	O
as	O
it	O
expresses	O
RFP	O
and	O
AP2Ïƒ2	O
at	O
equivalent	O
levels	O
","	O
thereby	O
enabling	O
RFP	O
expression	O
to	O
be	O
used	O
as	O
a	O
surrogate	O
for	O
AP2Ïƒ2	O
expression	O
.	O
We	O
selected	O
populations	O
of	O
cells	O
with	O
increasing	O
levels	O
of	O
RFP	O
expression	O
by	O
flow	O
cytometry	O
(	O
Fig	O
.	O
6	O
)	O
and	O
assessed	O
the	O
effects	O
of	O
altering	O
wild	O
-	O
type	O
and	O
mutant	O
AP2Ïƒ2	O
dosage	O
by	O
measuring	O
the	O
Ca2	B-Chemical
+	I-Chemical
i	O
responses	O
of	O
the	O
HEK	O
-	O
CaSR	O
cells	O
to	O
changes	O
in	O
Ca2	B-Chemical
+	I-Chemical
o	O
concentrations	O
","	O
and	O
determining	O
the	O
linear	O
regression	O
of	O
mean	O
EC50	O
values	O
against	O
expression	O
levels	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
AP2Ïƒ2	O
proteins	O
.	O
In	O
this	O
experiment	O
","	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
with	O
dominant	O
-	O
negative	O
actions	O
","	O
which	O
would	O
exert	O
greater	O
effects	O
with	O
increasing	O
protein	O
concentrations	O
","	O
will	O
show	O
a	O
positive	O
correlation	O
between	O
mutant	O
protein	O
concentration	O
and	O
EC50	O
.	O
However	O
","	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
associated	O
with	O
haploinsufficiency	O
would	O
not	O
exert	O
effects	O
on	O
the	O
wild	O
-	O
type	O
protein	O
","	O
whose	O
concentration	O
would	O
remain	O
constant	O
","	O
and	O
hence	O
there	O
would	O
be	O
absent	O
correlation	O
between	O
mutant	O
protein	O
concentrations	O
and	O
EC50	O
values	O
(	O
Fig	O
.	O
6	O
).	O
The	O
results	O
of	O
such	O
linear	O
regression	O
analyses	O
revealed	O
that	O
increased	O
expression	O
levels	O
of	O
FHH3	O
-	O
causing	O
Arg15	B-Chemical
-	O
mutant	O
AP2Ïƒ2	O
proteins	O
progressively	O
impaired	O
the	O
sensitivity	O
of	O
HEK	O
-	O
CaSR	O
cells	O
","	O
as	O
highlighted	O
by	O
a	O
significantly	O
positive	O
relationship	O
between	O
the	O
expression	O
levels	O
of	O
all	O
three	O
AP2Ïƒ2	O
mutants	O
and	O
the	O
mean	O
cellular	O
EC50	O
responses	O
(	O
Cys15	B-Chemical
r2	O
=	O
0	O
.	O
82	O
","	O
P	O
<	O
0	O
.	O
5	O
;	O
His15	B-Chemical
r2	O
=	O
0	O
.	O
84	O
","	O
P	O
<	O
0	O
.	O
5	O
;	O
Leu15	B-Chemical
r2	O
=	O
0	O
.	O
99	O
","	O
P	O
<	O
0	O
.	O
1	O
"),"	O
but	O
that	O
increased	O
expression	O
levels	O
of	O
wild	O
-	O
type	O
AP2Ïƒ2	O
had	O
no	O
effect	O
on	O
EC50	O
values	O
(	O
r2	O
=	O
0	O
.	O
7	O
","	O
P	O
=	O
0	O
.	O
67	O
)	O
(	O
Fig	O
.	O
6	O
).	O
These	O
findings	O
indicate	O
a	O
potential	O
dominant	O
-	O
negative	O
effect	O
of	O
the	O
FHH3	O
-	O
causing	O
Arg15	B-Chemical
AP2Ïƒ2	O
mutants	O
.	O
Discussion	O
Our	O
results	O
","	O
which	O
have	O
identified	O
AP2S1	O
mutations	O
that	O
only	O
result	O
in	O
missense	O
substitutions	O
of	O
the	O
Arg15	B-Chemical
residue	O
in	O
17	O
additional	O
FHH	O
probands	O
","	O
have	O
helped	O
to	O
establish	O
a	O
genotype	O
â€“	O
phenotype	O
correlation	O
between	O
AP2Ïƒ2	O
mutants	O
and	O
the	O
severity	O
of	O
hypercalcaemia	O
;	O
devise	O
an	O
index	O
based	O
on	O
measurements	O
of	O
plasma	O
calcium	B-Chemical
and	O
magnesium	B-Chemical
concentrations	O
and	O
urinary	O
clearances	O
of	O
calcium	B-Chemical
and	O
creatinine	B-Chemical
to	O
differentiate	O
between	O
FHH1	O
and	O
FHH3	O
;	O
elucidate	O
the	O
occurrence	O
of	O
a	O
mutational	O
bias	O
at	O
the	O
AP2Ïƒ2	O
Arg15	B-Chemical
residue	O
in	O
FHH3	O
patients	O
and	O
define	O
the	O
likely	O
genetic	O
mechanism	O
for	O
AP2Ïƒ2	O
mutations	O
as	O
being	O
a	O
dominant	O
-	O
negative	O
action	O
in	O
causing	O
FHH3	O
.	O
In	O
addition	O
","	O
our	O
study	O
shows	O
that	O
FHH3	O
can	O
be	O
associated	O
with	O
de	O
novo	O
AP2S1	O
mutations	O
","	O
consistent	O
with	O
a	O
previous	O
report	O
","	O
thereby	O
indicating	O
that	O
patients	O
may	O
not	O
have	O
a	O
family	O
history	O
of	O
the	O
disorder	O
and	O
that	O
AP2S1	O
mutations	O
may	O
be	O
associated	O
with	O
non	O
-	O
familial	O
forms	O
of	O
hypercalcaemia	O
and	O
hypocalciuria	O
.	O
The	O
identification	O
by	O
this	O
study	O
of	O
AP2S1	O
mutations	O
in	O
17	O
additional	O
probands	O
with	O
FHH3	O
","	O
together	O
with	O
ours	O
and	O
other	O
previous	O
reports	O
","	O
yields	O
a	O
total	O
of	O
36	O
probands	O
with	O
such	O
AP2Ïƒ2	O
mutations	O
","	O
which	O
all	O
involve	O
the	O
Arg15	B-Chemical
residue	O
and	O
result	O
in	O
1	O
of	O
3	O
missense	O
substitutions	O
comprising	O
Arg15Cys	B-Chemical
","	O
Arg15His	B-Chemical
and	O
Arg15Leu	B-Chemical
.	O
Our	O
analyses	O
of	O
these	O
subjects	O
reveal	O
genotype	O
â€“	O
phenotype	O
correlations	O
for	O
these	O
AP2Ïƒ2	O
mutations	O
","	O
in	O
which	O
the	O
Arg15Leu	B-Chemical
mutation	O
is	O
associated	O
with	O
the	O
most	O
pronounced	O
hypercalcaemia	O
","	O
whereas	O
Arg15His	B-Chemical
is	O
associated	O
with	O
the	O
mildest	O
increase	O
in	O
serum	O
calcium	B-Chemical
concentrations	O
.	O
This	O
is	O
surprising	O
and	O
the	O
mechanisms	O
underlying	O
these	O
genotype	O
â€“	O
phenotype	O
correlations	O
are	O
unclear	O
","	O
as	O
three	O
-	O
dimensional	O
modelling	O
and	O
in	O
vitro	O
functional	O
expression	O
studies	O
indicate	O
that	O
all	O
three	O
Arg15	B-Chemical
AP2Ïƒ2	O
mutations	O
disrupt	O
CaSR	O
activity	O
to	O
a	O
similar	O
extent	O
","	O
and	O
the	O
basis	O
for	O
the	O
differences	O
between	O
our	O
in	O
vivo	O
clinical	O
observations	O
and	O
in	O
vitro	O
results	O
remains	O
to	O
be	O
elucidated	O
.	O
Clinical	O
approach	O
to	O
distinguishing	O
between	O
FHH1	O
and	O
FHH3	O
in	O
a	O
hypercalcaemic	O
patient	O
.	O
sCa	B-Chemical
","	O
serum	O
calcium	B-Chemical
;	O
sMg	B-Chemical
","	O
serum	O
magnesium	B-Chemical
;	O
sPTH	O
","	O
serum	O
PTH	O
;	O
CCCR	O
","	O
calcium	B-Chemical
to	O
creatinine	B-Chemical
clearance	O
ratio	O
;	O
CMCR	O
=	O
sCa	B-Chemical
Ã—	O
sMg	B-Chemical
/	O
100	O
Ã—	O
CCCR	O
;	O
PHPT	O
;	O
primary	O
hyperparathyroidism	O
.	O
*	O
In	O
a	O
hypercalcaemic	O
patient	O
with	O
normal	O
/	O
raised	O
sPTH	O
","	O
a	O
CCCR	O
of	O
<	O
0	O
.	O
1	O
is	O
consistent	O
with	O
a	O
diagnosis	O
of	O
FHH	O
","	O
provided	O
that	O
thiazide	B-Chemical
diuretic	I-Chemical
use	O
","	O
vitamin	B-Chemical
D	I-Chemical
deficiency	O
and	O
renal	O
impairment	O
have	O
been	O
excluded	O
.	O
Our	O
study	O
has	O
also	O
revealed	O
phenotypic	O
differences	O
between	O
FHH1	O
and	O
FHH3	O
.	O
In	O
particular	O
","	O
FHH3	O
was	O
associated	O
with	O
significantly	O
greater	O
elevations	O
of	O
serum	O
calcium	B-Chemical
","	O
and	O
>	O
20	O
%	O
of	O
FHH3	O
patients	O
in	O
this	O
cohort	O
had	O
symptomatic	O
hypercalcaemia	O
.	O
These	O
findings	O
are	O
not	O
typical	O
of	O
FHH	O
","	O
which	O
is	O
considered	O
to	O
be	O
a	O
benign	O
and	O
asymptomatic	O
disorder	O
","	O
and	O
in	O
general	O
associated	O
with	O
serum	O
calcium	B-Chemical
concentrations	O
that	O
remain	O
within	O
10	O
%	O
of	O
the	O
upper	O
limit	O
of	O
the	O
normal	O
range	O
.	O
In	O
addition	O
to	O
the	O
more	O
severe	O
hypercalcaemia	O
","	O
FHH3	O
was	O
associated	O
with	O
more	O
pronounced	O
suppression	O
of	O
urinary	O
calcium	B-Chemical
excretion	O
than	O
FHH1	O
.	O
The	O
more	O
marked	O
serum	O
and	O
urinary	O
calcium	B-Chemical
phenotype	O
of	O
FHH3	O
contrasts	O
with	O
the	O
results	O
of	O
in	O
vitro	O
studies	O
that	O
indicate	O
FHH3	O
-	O
causing	O
AP2S1	O
mutations	O
to	O
lead	O
to	O
a	O
milder	O
shift	O
in	O
the	O
set	O
point	O
of	O
CaSR	O
-	O
expressing	O
cells	O
when	O
compared	O
with	O
FHH1	O
-	O
causing	O
CASR	O
mutations	O
.	O
These	O
findings	O
suggest	O
that	O
AP2Ïƒ2	O
mutations	O
may	O
influence	O
Ca2	B-Chemical
+	I-Chemical
o	O
homeostasis	O
through	O
effects	O
on	O
cell	O
membrane	O
proteins	O
other	O
than	O
the	O
CaSR	O
.	O
Indeed	O
","	O
the	O
renal	O
thick	O
ascending	O
limb	O
Na	O
+/	O
K	O
+/	O
2Cl	O
âˆ’	O
(	O
NKCC2	O
)	O
transporter	O
","	O
which	O
is	O
pivotal	O
for	O
urinary	O
calcium	B-Chemical
reabsorption	O
","	O
has	O
been	O
demonstrated	O
to	O
be	O
regulated	O
by	O
clathrin	O
-	O
mediated	O
endocytosis	O
.	O
Other	O
phenotypic	O
differences	O
between	O
FHH3	O
and	O
FHH1	O
included	O
the	O
occurrence	O
of	O
low	O
BMD	O
and	O
cognitive	O
dysfunction	O
in	O
FHH3	O
.	O
Low	O
BMD	O
occurred	O
in	O
five	O
FHH3	O
probands	O
with	O
AP2S1	O
mutations	O
whereas	O
patients	O
with	O
FHH1	O
","	O
owing	O
to	O
CASR	O
mutations	O
","	O
have	O
been	O
reported	O
to	O
have	O
normal	O
bone	O
resorption	O
rates	O
and	O
BMD	O
measurements	O
at	O
the	O
spine	O
","	O
hip	O
and	O
forearm	O
.	O
Cognitive	O
dysfunction	O
was	O
observed	O
in	O
seven	O
FHH3	O
probands	O
","	O
four	O
of	O
which	O
presented	O
with	O
serum	O
calcium	B-Chemical
concentrations	O
of	O
>	O
3	O
.	O
0	O
mmol	O
/	O
l	O
","	O
and	O
exposure	O
to	O
marked	O
hypercalcaemia	O
in	O
infancy	O
or	O
childhood	O
may	O
have	O
led	O
to	O
developmental	O
delay	O
and	O
adversely	O
affected	O
neurological	O
development	O
in	O
these	O
individuals	O
.	O
It	O
is	O
also	O
possible	O
that	O
expression	O
of	O
mutant	O
AP2Ïƒ2	O
subunits	O
within	O
the	O
brain	O
may	O
directly	O
influence	O
neurological	O
development	O
","	O
consistent	O
with	O
the	O
role	O
of	O
the	O
AP2	O
complex	O
in	O
mediating	O
receptor	O
trafficking	O
within	O
neuronal	O
synapses	O
of	O
the	O
hippocampus	O
","	O
a	O
region	O
of	O
the	O
brain	O
required	O
for	O
memory	O
acquisition	O
and	O
spatial	O
orientation	O
.	O
The	O
Arg15Leu	B-Chemical
AP2S1	O
mutation	O
was	O
also	O
associated	O
with	O
recurrent	O
pancreatitis	O
in	O
one	O
FHH3	O
proband	O
","	O
a	O
finding	O
consistent	O
with	O
FHH1	O
","	O
in	O
which	O
recurrent	O
pancreatitis	O
has	O
occasionally	O
been	O
reported	O
.	O
However	O
","	O
FHH1	O
probands	O
with	O
pancreatitis	O
typically	O
harbour	O
heterozygous	O
mutations	O
of	O
both	O
the	O
CASR	O
and	O
serine	O
protease	O
inhibitor	O
","	O
Kazal	O
type	O
1	O
(	O
SPINK1	O
)	O
genes	O
.	O
In	O
contrast	O
","	O
the	O
affected	O
FHH3	O
proband	O
did	O
not	O
harbour	O
a	O
mutation	O
of	O
SPINK1	O
or	O
other	O
genes	O
associated	O
with	O
pancreatitis	O
","	O
and	O
this	O
proband	O
'	O
s	O
marked	O
hypercalcaemia	O
may	O
have	O
been	O
sufficient	O
to	O
disrupt	O
pancreatic	O
function	O
.	O
Given	O
these	O
possible	O
phenotypic	O
differences	O
between	O
FHH3	O
and	O
FHH1	O
","	O
we	O
sought	O
to	O
design	O
an	O
index	O
based	O
on	O
clinical	O
biochemistry	O
tests	O
of	O
serum	O
and	O
urine	O
that	O
would	O
help	O
to	O
differentiate	O
the	O
two	O
disorders	O
.	O
The	O
findings	O
that	O
FHH3	O
is	O
associated	O
with	O
greater	O
elevations	O
in	O
serum	O
calcium	B-Chemical
and	O
magnesium	B-Chemical
concentrations	O
","	O
and	O
reductions	O
in	O
urinary	O
calcium	B-Chemical
excretion	O
","	O
when	O
compared	O
with	O
FHH1	O
","	O
led	O
us	O
to	O
design	O
the	O
calcium	B-Chemical
â€“	O
magnesium	B-Chemical
â€“	O
calcium	B-Chemical
clearance	O
ratio	O
(	O
CMCR	O
"),"	O
calculated	O
as	O
sCa	B-Chemical
Ã—	O
sMg	B-Chemical
/	O
100	O
Ã—	O
CCCR	O
.	O
Assessment	O
of	O
the	O
performance	O
characteristics	O
of	O
this	O
index	O
indicated	O
that	O
FHH	O
patients	O
with	O
CMCR	O
â‰¥	O
5	O
.	O
0	O
were	O
significantly	O
more	O
likely	O
to	O
have	O
FHH3	O
.	O
Thus	O
","	O
the	O
CMCR	O
index	O
may	O
have	O
utility	O
in	O
the	O
clinical	O
setting	O
for	O
directing	O
FHH	O
patients	O
for	O
either	O
CASR	O
or	O
AP2S1	O
gene	O
analysis	O
","	O
with	O
patients	O
having	O
a	O
CMCR	O
value	O
of	O
â‰¥	O
5	O
.	O
0	O
being	O
prioritized	O
for	O
AP2S1	O
analysis	O
(	O
Fig	O
.	O
7	O
).	O
However	O
","	O
âˆ¼	O
30	O
%	O
of	O
FHH3	O
patients	O
have	O
CMCR	O
values	O
that	O
overlap	O
with	O
that	O
of	O
FHH1	O
patients	O
(	O
Fig	O
.	O
3	O
"),"	O
and	O
combined	O
analysis	O
of	O
the	O
CASR	O
","	O
AP2S1	O
and	O
GNA11	O
genes	O
is	O
suggested	O
in	O
individuals	O
with	O
CMCR	O
values	O
of	O
<	O
5	O
.	O
0	O
(	O
Fig	O
.	O
7	O
).	O
No	O
correlation	O
was	O
observed	O
between	O
the	O
CMCR	O
index	O
and	O
codon	O
15	O
genotype	O
of	O
the	O
FHH3	O
patients	O
.	O
The	O
CMCR	O
index	O
requires	O
further	O
validation	O
in	O
studies	O
of	O
other	O
populations	O
and	O
using	O
alternate	O
biochemical	O
assays	O
.	O
The	O
finding	O
that	O
all	O
the	O
36	O
reported	O
FHH3	O
patients	O
","	O
of	O
which	O
17	O
are	O
from	O
this	O
study	O
","	O
harbour	O
either	O
an	O
Arg15Cys	B-Chemical
","	O
Arg15His	B-Chemical
or	O
Arg15Leu	B-Chemical
mutation	O
","	O
highlights	O
the	O
importance	O
of	O
this	O
evolutionary	O
conserved	O
residue	O
for	O
AP2	O
-	O
mediated	O
Ca2	B-Chemical
+	I-Chemical
o	O
homeostasis	O
.	O
Furthermore	O
","	O
the	O
absence	O
of	O
the	O
other	O
possible	O
missense	O
substitutions	O
at	O
this	O
codon	O
(	O
Arg15Gly	B-Chemical
","	O
Arg15Pro	B-Chemical
or	O
Arg15Ser	B-Chemical
)	O
indicates	O
mutation	O
bias	O
at	O
the	O
AP2Ïƒ2	O
Arg15	B-Chemical
residue	O
.	O
Our	O
in	O
vitro	O
characterization	O
of	O
the	O
non	O
-	O
observed	O
Gly15	B-Chemical
","	O
Pro15	B-Chemical
or	O
Ser15	B-Chemical
mutations	O
demonstrated	O
these	O
mutant	O
AP2Ïƒ2	O
proteins	O
to	O
be	O
expressed	O
and	O
to	O
result	O
in	O
an	O
impairment	O
of	O
CaSR	O
activity	O
.	O
However	O
","	O
the	O
Gly15	B-Chemical
","	O
Pro15	B-Chemical
or	O
Ser15	B-Chemical
mutants	O
had	O
additional	O
deleterious	O
effects	O
that	O
led	O
to	O
a	O
reduction	O
in	O
the	O
numbers	O
of	O
cells	O
expressing	O
these	O
mutants	O
.	O
These	O
findings	O
indicate	O
a	O
potential	O
role	O
for	O
the	O
AP2	O
complex	O
in	O
cell	O
growth	O
or	O
viability	O
and	O
are	O
consistent	O
with	O
a	O
previously	O
reported	O
study	O
of	O
mice	O
harbouring	O
a	O
germline	O
ablation	O
of	O
the	O
AP2Î¼2	O
subunit	O
","	O
which	O
led	O
to	O
early	O
embryonic	O
lethality	O
","	O
thus	O
highlighting	O
the	O
involvement	O
of	O
the	O
ubiquitously	O
expressed	O
AP2	O
complex	O
in	O
mammalian	O
development	O
.	O
Thus	O
","	O
a	O
possible	O
explanation	O
for	O
the	O
absence	O
of	O
the	O
Arg15Gly	B-Chemical
","	O
Arg15Pro	B-Chemical
and	O
Arg15Ser	B-Chemical
AP2Ïƒ2	O
mutations	O
in	O
patients	O
is	O
that	O
these	O
deleterious	O
mutations	O
likely	O
result	O
in	O
embryonic	O
lethality	O
","	O
whereas	O
the	O
FHH3	O
-	O
causing	O
AP2Ïƒ2	O
mutations	O
Arg15Cys	B-Chemical
","	O
Arg15His	B-Chemical
and	O
Arg15Leu	B-Chemical
are	O
observed	O
in	O
patients	O
","	O
as	O
these	O
mutations	O
are	O
not	O
associated	O
with	O
deleterious	O
effects	O
on	O
cell	O
growth	O
","	O
but	O
are	O
tolerated	O
and	O
compatible	O
with	O
embryonic	O
and	O
post	O
-	O
natal	O
survival	O
.	O
Our	O
findings	O
of	O
a	O
likely	O
dominant	O
-	O
negative	O
effect	O
of	O
FHH3	O
-	O
causing	O
Arg15	B-Chemical
AP2Ïƒ2	O
mutations	O
are	O
consistent	O
with	O
previous	O
mutagenesis	O
studies	O
of	O
the	O
AP2	O
complex	O
.	O
Indeed	O
","	O
overexpression	O
of	O
a	O
mutated	O
Î¼2	O
-	O
subunit	O
(	O
AP2Î¼2	O
"),"	O
which	O
displayed	O
diminished	O
capacity	O
to	O
bind	O
to	O
some	O
cargo	O
proteins	O
","	O
has	O
been	O
reported	O
to	O
inhibit	O
receptor	O
trafficking	O
in	O
a	O
dominant	O
-	O
negative	O
manner	O
.	O
The	O
precise	O
mechanisms	O
of	O
such	O
dominant	O
-	O
negative	O
actions	O
remain	O
to	O
be	O
established	O
but	O
three	O
possibilities	O
are	O
(	O
1	O
)	O
the	O
incorporation	O
of	O
a	O
mutant	O
Ïƒ2	O
subunit	O
may	O
impair	O
the	O
assembly	O
of	O
the	O
tetrameric	O
complex	O
","	O
(	O
2	O
)	O
incorporation	O
of	O
the	O
mutant	O
Ïƒ2	O
subunit	O
may	O
alter	O
the	O
structure	O
of	O
the	O
AP2	O
complex	O
and	O
hinder	O
the	O
efficiency	O
of	O
wild	O
-	O
type	O
AP2Î±	O
","	O
AP2Î²	O
and	O
AP2Î¼	O
subunits	O
and	O
(	O
3	O
)	O
the	O
mutant	O
AP2	O
complex	O
may	O
potentially	O
sequester	O
the	O
CaSR	O
at	O
the	O
plasma	O
membrane	O
and	O
prevent	O
wild	O
-	O
type	O
AP2	O
molecules	O
from	O
effectively	O
trafficking	O
this	O
GPCR	O
.	O
In	O
summary	O
","	O
our	O
studies	O
of	O
AP2S1	O
mutations	O
","	O
which	O
highlight	O
FHH3	O
as	O
a	O
distinct	O
disorder	O
of	O
Ca2	B-Chemical
+	I-Chemical
o	O
homeostasis	O
and	O
demonstrate	O
the	O
importance	O
of	O
the	O
AP2Ïƒ2	O
Arg15	B-Chemical
residue	O
for	O
AP2	O
function	O
","	O
have	O
revealed	O
genotype	O
â€“	O
phenotype	O
correlations	O
with	O
mutation	O
bias	O
at	O
the	O
Arg15	B-Chemical
residue	O
","	O
as	O
well	O
as	O
a	O
likely	O
dominant	O
-	O
negative	O
mechanism	O
of	O
action	O
.	O
Materials	O
and	O
Methods	O
Subjects	O
Informed	O
consent	O
was	O
obtained	O
from	O
individuals	O
","	O
using	O
protocols	O
approved	O
by	O
the	O
local	O
and	O
national	O
ethics	O
committees	O
(	O
MREC	O
/	O
2	O
/	O
2	O
/	O
93	O
).	O
Sixty	O
-	O
five	O
unrelated	O
probands	O
(	O
22	O
males	O
and	O
43	O
females	O
)	O
were	O
ascertained	O
.	O
The	O
age	O
at	O
diagnosis	O
or	O
presentation	O
ranged	O
from	O
early	O
infancy	O
to	O
76	O
years	O
","	O
and	O
all	O
probands	O
had	O
hypercalcaemia	O
with	O
normal	O
or	O
elevated	O
PTH	O
concentrations	O
","	O
in	O
association	O
with	O
inappropriately	O
low	O
urinary	O
calcium	B-Chemical
excretion	O
.	O
Previous	O
mutational	O
analysis	O
of	O
CASR	O
and	O
GNA11	O
had	O
not	O
identified	O
any	O
abnormalities	O
of	O
the	O
coding	O
regions	O
and	O
exon	O
â€“	O
intron	O
boundaries	O
of	O
these	O
genes	O
.	O
DNA	O
sequence	O
analysis	O
Leukocyte	O
DNA	O
was	O
extracted	O
from	O
venous	O
blood	O
samples	O
and	O
quantified	O
using	O
the	O
High	O
sensitivity	O
Qubit	O
system	O
(	O
Invitrogen	O
).	O
AP2S1	O
-	O
specific	O
primers	O
were	O
used	O
to	O
perform	O
PCR	O
amplification	O
of	O
the	O
five	O
exons	O
and	O
eight	O
intron	O
-	O
exon	O
boundaries	O
of	O
the	O
AP2S1	O
gene	O
","	O
as	O
previously	O
reported	O
.	O
DNA	O
sequence	O
analysis	O
of	O
the	O
PCR	O
products	O
was	O
performed	O
using	O
the	O
BigDye	O
Terminator	O
v3	O
.	O
1	O
Cycle	O
Sequencing	O
Kit	O
(	O
Life	O
Technologies	O
)	O
and	O
an	O
ABI	O
automated	O
capillary	O
sequencer	O
(	O
Applied	O
Biosystems	O
"),"	O
as	O
reported	O
.	O
DNA	O
sequence	O
abnormalities	O
and	O
co	O
-	O
segregation	O
in	O
families	O
were	O
confirmed	O
by	O
restriction	O
endonuclease	O
analysis	O
(	O
New	O
England	O
Biolabs	O
"),"	O
as	O
described	O
.	O
Computer	O
modelling	O
of	O
the	O
AP2	O
structure	O
The	O
crystal	O
structure	O
of	O
the	O
AP2	O
heterotetramer	O
bound	O
to	O
an	O
acidic	O
dileucine	B-Chemical
peptide	I-Chemical
has	O
been	O
reported	O
previously	O
.	O
The	O
PyMOL	O
Molecular	O
Graphics	O
System	O
(	O
version	O
1	O
.	O
2r3pre	O
","	O
SchrÃ¶dinger	O
)	O
was	O
used	O
to	O
model	O
the	O
effect	O
of	O
the	O
FHH3	O
-	O
associated	O
AP2Ïƒ2	O
mutations	O
on	O
the	O
interaction	O
with	O
the	O
acidic	O
dileucine	O
motif	O
peptide	O
using	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
AP2	O
archived	O
in	O
the	O
Protein	O
Data	O
Bank	O
at	O
the	O
European	O
Bioinformatics	O
Institute	O
with	O
the	O
accession	O
number	O
2JKR	O
.	O
The	O
effect	O
of	O
the	O
Arg15Cys	B-Chemical
","	O
Arg15Leu	B-Chemical
","	O
Arg15His	B-Chemical
","	O
Arg15Pro	B-Chemical
","	O
Arg15Ser	B-Chemical
and	O
Arg15Gly	B-Chemical
mutations	O
on	O
the	O
interaction	O
of	O
AP2Ïƒ2	O
subunit	O
with	O
the	O
acidic	O
dileucine	B-Chemical
peptide	I-Chemical
was	O
modelled	O
using	O
PyMod	O
plug	O
-	O
in	O
and	O
Modeller	O
.	O
21	O
.	O
Generation	O
of	O
AP2S1	O
expression	O
constructs	O
An	O
AP2Ïƒ2	O
expression	O
construct	O
was	O
generated	O
by	O
cloning	O
the	O
full	O
-	O
length	O
AP2S1	O
coding	O
region	O
into	O
the	O
bidirectional	O
cloning	O
vector	O
pBI	O
-	O
CMV4	O
-	O
RFP	O
(	O
Clontech	O
"),"	O
which	O
allows	O
for	O
co	O
-	O
expression	O
of	O
AP2Ïƒ2	O
and	O
RFP	O
at	O
equivalent	O
levels	O
.	O
The	O
use	O
of	O
RFP	O
minimized	O
overlap	O
between	O
the	O
emission	O
spectra	O
of	O
this	O
reporter	O
gene	O
and	O
the	O
indo	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
AM	I-Chemical
Ca2	I-Chemical
+-	I-Chemical
binding	I-Chemical
fluorophore	I-Chemical
.	O
AP2S1	O
mutations	O
were	O
introduced	O
into	O
the	O
construct	O
by	O
site	O
-	O
directed	O
mutagenesis	O
(	O
QuikChange	O
Lightning	O
","	O
Stratagene	O
)	O
and	O
confirmed	O
by	O
DNA	O
sequence	O
analysis	O
","	O
as	O
described	O
.	O
Cell	O
culture	O
and	O
transfection	O
Functional	O
studies	O
of	O
AP2S1	O
mutations	O
were	O
performed	O
in	O
HEK293	O
cells	O
that	O
stably	O
expressed	O
the	O
CaSR	O
.	O
HEK293	O
cells	O
were	O
used	O
because	O
suitable	O
parathyroid	O
and	O
renal	O
tubular	O
cells	O
are	O
not	O
available	O
","	O
and	O
HEK293	O
cells	O
have	O
been	O
established	O
as	O
a	O
model	O
for	O
such	O
studies	O
.	O
The	O
reported	O
stably	O
CaSR	O
-	O
transfected	O
HEK293	O
cell	O
line	O
(	O
HEK	O
-	O
CaSR	O
)	O
was	O
cultured	O
in	O
high	B-Chemical
-	I-Chemical
glucose	I-Chemical
DMEM	I-Chemical
(	O
Invitrogen	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
and	O
1	O
%	O
geneticin	B-Chemical
.	O
A	O
high	O
level	O
of	O
CaSR	O
expression	O
in	O
these	O
cells	O
was	O
confirmed	O
by	O
western	O
blot	O
analysis	O
of	O
whole	O
-	O
cell	O
protein	O
extract	O
using	O
a	O
mouse	O
monoclonal	O
antibody	O
to	O
human	O
CaSR	O
(	O
ADD	O
;	O
Abcam	O
","	O
ab19347	O
","	O
1	O
:	O
1000	O
).	O
The	O
wild	O
-	O
type	O
and	O
mutant	O
AP2Ïƒ2	O
constructs	O
were	O
transiently	O
transfected	O
into	O
HEK	O
-	O
CaSR	O
cells	O
using	O
Lipofectamine	B-Chemical
2000	I-Chemical
(	O
Invitrogen	O
).	O
Expression	O
of	O
RFP	O
was	O
used	O
as	O
a	O
surrogate	O
for	O
AP2Ïƒ2	O
expression	O
as	O
it	O
is	O
expressed	O
at	O
equivalent	O
levels	O
to	O
AP2Ïƒ2	O
by	O
the	O
pBI	O
-	O
CMV4	O
-	O
RFP	O
bidirectional	O
vector	O
.	O
Western	O
blot	O
analysis	O
of	O
cellular	O
protein	O
extract	O
was	O
undertaken	O
using	O
a	O
rabbit	O
polyclonal	O
antibody	O
to	O
RFP	O
(	O
Thermo	O
Scientific	O
","	O
PA1	O
-	O
986	O
","	O
1	O
:	O
500	O
).	O
The	O
membrane	O
was	O
re	O
-	O
probed	O
with	O
mouse	O
anti	O
-	O
GAPDH	O
antibody	O
(	O
Abcam	O
","	O
ab8245	O
","	O
1	O
:	O
3000	O
)	O
as	O
a	O
loading	O
control	O
.	O
Successful	O
transfection	O
was	O
also	O
confirmed	O
by	O
visualising	O
RFP	O
fluorescence	O
using	O
an	O
Eclipse	O
E400	O
fluorescence	O
microscope	O
with	O
an	O
epifluorescence	O
filter	O
","	O
and	O
images	O
were	O
captured	O
using	O
a	O
DXM1200C	O
digital	O
camera	O
and	O
NIS	O
Elements	O
software	O
(	O
Nikon	O
).	O
The	O
effect	O
of	O
mutant	O
AP2Ïƒ2	O
proteins	O
on	O
cell	O
growth	O
was	O
assessed	O
by	O
determining	O
the	O
percentage	O
increase	O
in	O
cell	O
numbers	O
over	O
a	O
24	O
-	O
h	O
period	O
","	O
as	O
follows	O
.	O
Twenty	O
-	O
four	O
hours	O
after	O
transfection	O
","	O
equal	O
numbers	O
of	O
cells	O
were	O
seeded	O
into	O
a	O
96	O
-	O
well	O
plate	O
","	O
and	O
the	O
cells	O
were	O
imaged	O
","	O
at	O
48	O
and	O
72	O
h	O
","	O
using	O
fluorescence	O
microscopy	O
","	O
as	O
mentioned	O
above	O
.	O
Following	O
blinding	O
to	O
both	O
transfection	O
and	O
time	O
point	O
","	O
the	O
numbers	O
of	O
transfected	O
cells	O
were	O
counted	O
manually	O
at	O
48	O
and	O
72	O
h	O
post	O
-	O
transfection	O
","	O
and	O
the	O
percentage	O
increase	O
in	O
cells	O
determined	O
using	O
Microsoft	O
Excel	O
and	O
statistical	O
analysis	O
undertaken	O
in	O
GraphPad	O
Prism	O
(	O
GraphPad	O
).	O
Measurement	O
of	O
Ca2	B-Chemical
+	I-Chemical
i	O
responses	O
The	O
effect	O
of	O
mutant	O
AP2Ïƒ2	O
proteins	O
on	O
CaSR	O
-	O
mediated	O
Ca2	B-Chemical
+	I-Chemical
i	O
responses	O
were	O
assessed	O
by	O
determining	O
EC50	O
values	O
(	O
i	O
.	O
e	O
.	O
[	O
Ca2	B-Chemical
+]	I-Chemical
o	O
required	O
for	O
50	O
%	O
of	O
the	O
maximal	O
response	O
)	O
and	O
comparing	O
these	O
to	O
the	O
wild	O
-	O
type	O
EC50	O
","	O
as	O
reported	O
.	O
Briefly	O
","	O
48	O
h	O
after	O
transfection	O
","	O
the	O
cells	O
were	O
harvested	O
","	O
washed	O
in	O
calcium	B-Chemical
-	O
and	O
magnesium	B-Chemical
-	O
free	O
Hank	B-Chemical
'	I-Chemical
s	I-Chemical
balanced	I-Chemical
salt	I-Chemical
solution	I-Chemical
(	O
HBSS	B-Chemical
)	O
(	O
Invitrogen	O
)	O
and	O
loaded	O
with	O
1	O
Î¼g	O
/	O
ml	O
indo	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
acetoxymethylester	I-Chemical
(	O
Indo	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
am	I-Chemical
)	O
(	O
Molecular	O
Probes	O
)	O
for	O
1	O
h	O
at	O
37	O
Â°	O
C	O
.	O
After	O
the	O
removal	O
of	O
free	O
dye	O
","	O
the	O
cells	O
were	O
resuspended	O
in	O
calcium	B-Chemical
-	O
and	O
magnesium	B-Chemical
-	O
free	O
HBSS	B-Chemical
and	O
maintained	O
at	O
37	O
Â°	O
C	O
.	O
Flow	O
cytometry	O
was	O
performed	O
with	O
a	O
Beckman	O
Coulter	O
MoFlo	O
XDP	O
equipped	O
with	O
JDSUY	O
Xcyte	O
UV	O
Laser	O
and	O
a	O
Coherent	O
Sapphire	O
488	O
Laser	O
using	O
a	O
550LP	O
dichroic	O
mirror	O
and	O
580	O
/	O
30	O
bandpass	O
filter	O
.	O
Single	O
cells	O
were	O
isolated	O
from	O
debris	O
on	O
the	O
basis	O
of	O
morphology	O
using	O
forward	O
scatter	O
and	O
side	O
scatter	O
readings	O
.	O
Cells	O
were	O
stimulated	O
by	O
sequentially	O
adding	O
calcium	B-Chemical
to	O
the	O
calcium	B-Chemical
-	O
and	O
magnesium	B-Chemical
-	O
free	O
HBSS	B-Chemical
to	O
progressively	O
increase	O
the	O
[	O
Ca2	B-Chemical
+]	I-Chemical
o	O
from	O
0	O
to	O
15	O
mm	O
.	O
The	O
baseline	O
fluorescence	O
ratio	O
was	O
measured	O
for	O
2	O
min	O
","	O
the	O
fluorescence	O
ratio	O
compared	O
with	O
the	O
time	O
was	O
recorded	O
and	O
data	O
were	O
collected	O
for	O
2	O
min	O
at	O
each	O
[	O
Ca2	B-Chemical
+]	I-Chemical
o	O
.	O
Cytomation	O
Summit	O
software	O
was	O
used	O
to	O
determine	O
the	O
peak	O
mean	O
fluorescence	O
ratio	O
of	O
the	O
transient	O
response	O
after	O
each	O
individual	O
stimulus	O
expressed	O
as	O
a	O
normalized	O
response	O
.	O
Analysis	O
of	O
five	O
separate	O
populations	O
of	O
cells	O
gated	O
for	O
increasing	O
RFP	O
as	O
a	O
concordant	O
surrogate	O
for	O
increasing	O
AP2Ïƒ2	O
expression	O
was	O
undertaken	O
and	O
concentration	O
â€“	O
response	O
curves	O
generated	O
using	O
the	O
normalized	O
response	O
at	O
each	O
of	O
nine	O
different	O
[	O
Ca2	B-Chemical
+]	I-Chemical
o	O
(	O
0	O
â€“	O
15	O
mm	O
)	O
for	O
each	O
separate	O
experiment	O
.	O
Nonlinear	O
regression	O
of	O
the	O
concentration	O
â€“	O
response	O
curves	O
was	O
performed	O
with	O
GraphPad	O
Prism	O
(	O
GraphPad	O
)	O
to	O
calculate	O
the	O
EC50	O
for	O
each	O
separate	O
experiment	O
.	O
Subsequent	O
linear	O
regression	O
of	O
the	O
mean	O
EC50	O
(	O
N	O
=	O
8	O
experiments	O
)	O
for	O
each	O
AP2S1	O
-	O
pBI	O
-	O
CMV4	O
-	O
RFP	O
expression	O
vector	O
was	O
undertaken	O
with	O
GraphPad	O
Prism	O
(	O
GraphPad	O
).	O
Statistical	O
analyses	O
The	O
phenotypic	O
data	O
from	O
this	O
study	O
were	O
pooled	O
with	O
those	O
of	O
our	O
previous	O
studies	O
of	O
FHH3	O
patients	O
and	O
families	O
.	O
To	O
undertake	O
a	O
comparison	O
of	O
phenotypes	O
between	O
FHH3	O
and	O
FHH1	O
","	O
we	O
used	O
data	O
from	O
43	O
previously	O
reported	O
unrelated	O
FHH1	O
probands	O
(	O
13	O
males	O
and	O
30	O
females	O
","	O
aged	O
1	O
â€“	O
84	O
years	O
)	O
who	O
had	O
germline	O
heterozygous	O
CASR	O
mutations	O
.	O
Comparisons	O
of	O
continuous	O
variables	O
between	O
two	O
groups	O
were	O
undertaken	O
using	O
the	O
Mann	O
â€“	O
Whitney	O
U	O
test	O
","	O
and	O
the	O
Kruskal	O
â€“	O
Wallis	O
test	O
was	O
used	O
to	O
compare	O
multiple	O
groups	O
.	O
Categorical	O
variables	O
were	O
analysed	O
using	O
the	O
Chi	O
-	O
squared	O
test	O
.	O
ROC	O
analysis	O
using	O
values	O
of	O
the	O
CMCR	O
sensitivity	O
and	O
specificity	O
was	O
performed	O
to	O
study	O
the	O
discriminatory	O
power	O
of	O
the	O
CMCR	O
index	O
to	O
distinguish	O
between	O
FHH1	O
and	O
FHH3	O
.	O
Comparisons	O
of	O
EC50	O
values	O
were	O
performed	O
using	O
the	O
F	O
test	O
","	O
as	O
described	O
.	O
The	O
Mann	O
â€“	O
Whitney	O
U	O
test	O
was	O
used	O
to	O
compare	O
the	O
proliferation	O
rates	O
of	O
cells	O
expressing	O
wild	O
-	O
type	O
or	O
mutant	O
AP2Ïƒ2	O
proteins	O
.	O
All	O
analyses	O
were	O
undertaken	O
using	O
GraphPad	O
Prism	O
(	O
GraphPad	O
)	O
and	O
are	O
presented	O
as	O
mean	O
Â±	O
SEM	O
unless	O
otherwise	O
stated	O
.	O
A	O
value	O
of	O
P	O
<	O
0	O
.	O
5	O
was	O
considered	O
significant	O
for	O
all	O
analyses	O
.	O
Supplementary	O
Material	O
Supplementary	O
Material	O
is	O
available	O
at	O
HMG	O
online	O
.	O
Funding	O
This	O
work	O
was	O
supported	O
by	O
the	O
programme	O
grants	O
â€”	O
and	O
(	O
to	O
M	O
.	O
A	O
.	O
N	O
".,"	O
F	O
.	O
M	O
.	O
H	O
.	O
and	O
R	O
.	O
V	O
.	O
T	O
.)	O
and	O
()	O
Oxford	O
Biomedical	O
Research	O
Centre	O
Programme	O
(	O
to	O
M	O
.	O
A	O
.	O
N	O
.	O
and	O
R	O
.	O
V	O
.	O
T	O
.).	O
S	O
.	O
A	O
.	O
H	O
.	O
and	O
A	O
.	O
R	O
.	O
are	O
.	O
Funding	O
to	O
pay	O
the	O
Open	O
Access	O
publication	O
charges	O
for	O
this	O
article	O
was	O
provided	O
by	O
Medical	O
Research	O
Council	O
(	O
MRC	O
"),"	O
UK	O
and	O
Wellcome	O
Trust	O
Open	O
Access	O
Block	O
Grants	O
.	O
Supplementary	O
Material	O
References	O
The	O
Effectiveness	O
of	O
Pemetrexed	B-Chemical
Monotherapy	O
Depending	O
on	O
Polymorphisms	O
in	O
TS	O
and	O
MTHFR	O
Genes	O
as	O
Well	O
as	O
Clinical	O
Factors	O
in	O
Advanced	O
NSCLC	O
Patients	O
In	O
NSCLC	O
","	O
second	O
-	O
line	O
chemotherapy	O
using	O
pemetrexed	B-Chemical
or	O
docetaxel	B-Chemical
has	O
limited	O
efficacy	O
and	O
should	O
be	O
dedicated	O
to	O
selected	O
groups	O
of	O
patients	O
.	O
Pemetrexed	B-Chemical
is	O
an	O
antifolate	O
compound	O
with	O
the	O
ability	O
to	O
inhibit	O
enzymes	O
(	O
TS	O
","	O
DHFR	O
and	O
GARFT	O
)	O
involved	O
in	O
pyrimidine	B-Chemical
and	O
purine	B-Chemical
synthesis	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
association	O
between	O
polymorphisms	O
of	O
TS	O
and	O
MHFR	O
genes	O
and	O
clinical	O
outcomes	O
in	O
NSCLC	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
.	O
DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
of	O
72	O
non	O
-	O
squamous	O
NSCLC	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
.	O
Using	O
PCR	O
and	O
RFLP	O
methods	O
","	O
the	O
variable	O
number	O
of	O
tandem	O
repeats	O
(	O
VNTR	O
"),"	O
the	O
G	O
>	O
C	O
SNP	O
in	O
these	O
repeats	O
and	O
insertion	O
/	O
deletion	O
polymorphism	O
of	O
TS	O
gene	O
as	O
well	O
as	O
677C	O
>	O
T	O
SNP	O
in	O
MTHFR	O
gene	O
were	O
analyzed	O
and	O
correlated	O
with	O
disease	O
control	O
rate	O
","	O
progression	O
-	O
free	O
survival	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
of	O
NSCLC	O
patients	O
.	O
Carriers	O
of	O
2R	O
/	O
3R	O
(	O
G	O
"),"	O
3R	O
(	O
C	O
)/	O
3R	O
(	O
G	O
"),"	O
3R	O
(	O
G	O
)/	O
3R	O
(	O
G	O
)	O
genotypes	O
showed	O
significantly	O
more	O
frequent	O
early	O
progression	O
than	O
carriers	O
of	O
2R	O
/	O
2R	O
","	O
2R	O
/	O
3R	O
(	O
C	O
"),"	O
3R	O
(	O
C	O
)/	O
3R	O
(	O
C	O
)	O
genotypes	O
of	O
TS	O
gene	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
Among	O
carriers	O
of	O
triple	O
28	O
bp	O
tandem	O
repeats	O
(	O
3R	O
)	O
in	O
TS	O
gene	O
and	O
C	O
/	O
C	O
genotype	O
of	O
MTHFR	O
gene	O
a	O
significantly	O
shorter	O
OS	O
was	O
observed	O
(	O
HR	O
=	O
3	O
.	O
7	O
;	O
p	O
=	O
0	O
.	O
3	O
).	O
In	O
multivariate	O
analysis	O
","	O
significantly	O
higher	O
risk	O
of	O
death	O
was	O
observed	O
in	O
carriers	O
of	O
both	O
3R	O
/	O
3R	O
genotype	O
in	O
TS	O
and	O
C	O
/	O
C	O
genotype	O
in	O
677C	O
>	O
T	O
SNP	O
in	O
MTHFR	O
(	O
HR	O
=	O
3	O
.	O
85	O
;	O
p	O
<	O
0	O
.	O
5	O
)	O
as	O
well	O
as	O
in	O
patients	O
with	O
short	O
duration	O
of	O
response	O
to	O
first	O
-	O
line	O
chemotherapy	O
(	O
HR	O
=	O
2	O
.	O
9	O
;	O
p	O
<	O
0	O
.	O
5	O
).	O
Results	O
of	O
our	O
study	O
suggested	O
that	O
genetic	O
factors	O
may	O
have	O
a	O
high	O
predictive	O
and	O
prognostic	O
value	O
(	O
even	O
greater	O
than	O
clinical	O
factors	O
)	O
for	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
.	O
Introduction	O
Lung	O
cancer	O
is	O
the	O
most	O
prevalent	O
cause	O
of	O
death	O
due	O
to	O
malignancies	O
worldwide	O
.	O
There	O
is	O
very	O
low	O
percentage	O
of	O
early	O
diagnosed	O
NSCLC	O
patients	O
which	O
results	O
in	O
only	O
15	O
%	O
chance	O
of	O
surgical	O
resection	O
[	O
1	O
].	O
Systemic	O
therapy	O
(	O
chemo	O
-	O
and	O
radiotherapy	O
)	O
is	O
considered	O
to	O
be	O
the	O
main	O
form	O
of	O
lung	O
cancer	O
treatment	O
.	O
Unfortunately	O
","	O
first	O
-	O
line	O
treatment	O
is	O
of	O
low	O
effectiveness	O
and	O
progression	O
is	O
observed	O
in	O
the	O
vast	O
majority	O
of	O
patients	O
.	O
Pemetrexed	B-Chemical
is	O
one	O
of	O
the	O
novel	O
3rd	O
generation	O
drugs	O
with	O
the	O
least	O
side	O
effects	O
reported	O
.	O
In	O
the	O
first	O
-	O
line	O
study	O
","	O
cisplatin	B-Chemical
with	O
pemetrexed	B-Chemical
proved	O
to	O
be	O
more	O
effective	O
in	O
non	O
-	O
squamous	O
histology	O
of	O
NSCLC	O
and	O
as	O
a	O
result	O
it	O
was	O
registered	O
in	O
only	O
such	O
histology	O
of	O
lung	O
cancer	O
[	O
2	O
].	O
Second	O
-	O
line	O
treatment	O
with	O
pemetrexed	B-Chemical
monotherapy	O
is	O
possible	O
in	O
non	O
-	O
squamous	O
patients	O
with	O
good	O
performance	O
status	O
who	O
progressed	O
after	O
non	O
-	O
pemetrexed	B-Chemical
first	O
-	O
line	O
chemotherapy	O
","	O
which	O
was	O
proven	O
by	O
a	O
comparative	O
study	O
with	O
docetaxel	B-Chemical
[	O
3	O
].	O
Pemetrexed	B-Chemical
","	O
a	O
multitarget	O
antifolate	O
","	O
is	O
effective	O
in	O
non	O
-	O
squamous	O
NSCLC	O
and	O
malignant	O
pleural	O
mesothelioma	O
","	O
with	O
the	O
main	O
focus	O
on	O
inhibition	O
of	O
enzymes	O
involved	O
in	O
pyrimidine	B-Chemical
and	O
purine	B-Chemical
synthesis	O
such	O
as	O
thymidylate	O
synthase	O
(	O
TS	O
"),"	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
and	O
glycinamide	O
ribonucleotide	O
formyltransferase	O
(	O
GARFT	O
).	O
TS	O
catalyzes	O
transformation	O
of	O
dUMP	B-Chemical
into	O
dTMP	B-Chemical
.	O
Decreased	O
levels	O
of	O
dTMP	B-Chemical
results	O
in	O
inhibition	O
of	O
DNA	O
repair	O
and	O
synthesis	O
","	O
thus	O
cell	O
death	O
[	O
2	O
â€“	O
4	O
].	O
Studies	O
have	O
shown	O
that	O
expression	O
levels	O
of	O
pemetrexed	B-Chemical
target	O
enzymes	O
may	O
alter	O
the	O
effectiveness	O
of	O
the	O
drug	O
[	O
5	O
","	O
6	O
","	O
7	O
].	O
Squamous	O
cell	O
carcinoma	O
was	O
shown	O
to	O
have	O
higher	O
expression	O
of	O
TS	O
than	O
adenocarcinoma	O
","	O
thus	O
being	O
more	O
resistant	O
to	O
pemetrexed	B-Chemical
treatment	O
[	O
8	O
","	O
9	O
].	O
Free	O
circulating	O
folates	O
may	O
regulate	O
pemetrexed	B-Chemical
targets	O
â€™	O
activity	O
.	O
Increased	O
level	O
of	O
methyltetrahydrofolate	B-Chemical
(	O
5	B-Chemical
-	I-Chemical
methylTHF	I-Chemical
)	O
is	O
a	O
result	O
of	O
changes	O
in	O
the	O
activity	O
of	O
5	O
","	O
10	O
-	O
methylenetetrahydrofolate	O
reductase	O
(	O
MTHFR	O
"),"	O
which	O
results	O
in	O
higher	O
TS	O
activity	O
and	O
thus	O
reduces	O
pemetrexed	B-Chemical
efficacy	O
[	O
10	O
].	O
There	O
are	O
three	O
well	O
known	O
polymorphic	O
changes	O
that	O
affect	O
TS	O
mRNA	O
level	O
and	O
TS	O
protein	O
expression	O
:	O
various	O
number	O
of	O
28	O
-	O
base	O
pair	O
tandem	O
repeats	O
(	O
VNTR	O
)	O
located	O
in	O
the	O
5	O
â€²	O
end	O
untranslated	O
region	O
of	O
TS	O
gene	O
;	O
a	O
single	O
nucleotide	B-Chemical
polymorphism	O
(	O
SNP	O
)	O
G	O
>	O
C	O
in	O
the	O
second	O
repeat	O
of	O
the	O
28	O
-	O
bp	O
tandem	O
repeats	O
;	O
and	O
a	O
6	O
-	O
bp	O
deletion	O
at	O
the	O
3	O
â€™	O
end	O
of	O
the	O
TS	O
gene	O
(	O
1494del6	O
)	O
[	O
11	O
â€“	O
13	O
].	O
Polymorphisms	O
in	O
TS	O
gene	O
are	O
known	O
to	O
alter	O
effectiveness	O
of	O
5	B-Chemical
-	I-Chemical
fluorouracil	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
FU	I-Chemical
)	O
in	O
colorectal	O
cancer	O
[	O
14	O
].	O
Moreover	O
","	O
MTHFR	O
gene	O
polymorphism	O
677C	O
>	O
T	O
is	O
causing	O
lower	O
expression	O
of	O
MTHFR	O
and	O
decreased	O
levels	O
of	O
5	B-Chemical
-	I-Chemical
methylTHF	I-Chemical
in	O
colon	O
and	O
breast	O
cancer	O
cell	O
lines	O
[	O
15	O
].	O
This	O
retrospective	O
","	O
non	O
-	O
randomized	O
","	O
multicenter	O
study	O
was	O
carried	O
out	O
in	O
order	O
to	O
assess	O
the	O
usefulness	O
of	O
TS	O
and	O
MTHFR	O
gene	O
polymorphisms	O
as	O
predictive	O
markers	O
in	O
NSCLC	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
.	O
Materials	O
and	O
Methods	O
The	O
whole	O
studied	O
group	O
consisted	O
of	O
72	O
NSCLC	O
patients	O
(	O
46	O
male	O
","	O
26	O
female	O
;	O
median	O
age	O
61	O
)	O
with	O
non	O
-	O
squamous	O
histology	O
","	O
who	O
were	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
.	O
Clinical	O
data	O
was	O
collected	O
from	O
all	O
patients	O
.	O
500	O
mg	O
/	O
m2	O
of	O
pemetrexed	B-Chemical
was	O
administered	O
as	O
an	O
intravenous	O
infusion	O
on	O
day	O
1	O
of	O
each	O
21	O
day	O
cycle	O
.	O
In	O
order	O
to	O
reduce	O
toxicity	O
","	O
patients	O
received	O
folic	B-Chemical
acid	I-Chemical
and	O
B12	B-Chemical
vitamin	I-Chemical
prior	O
to	O
treatment	O
.	O
The	O
response	O
to	O
chemotherapy	O
was	O
assessed	O
according	O
to	O
RECIST	O
criteria	O
.	O
The	O
observation	O
period	O
was	O
from	O
2008	O
until	O
February	O
2014	O
","	O
when	O
progression	O
was	O
observed	O
in	O
60	O
patients	O
of	O
whom	O
45	O
died	O
.	O
The	O
material	O
for	O
the	O
study	O
were	O
blood	O
samples	O
collected	O
in	O
four	O
oncology	O
centres	O
in	O
Poland	O
.	O
All	O
genetic	O
testing	O
was	O
performed	O
in	O
clinical	O
laboratory	O
in	O
Pneumonology	O
","	O
Oncology	O
and	O
Allergology	O
Department	O
in	O
Lublin	O
.	O
Venous	O
blood	O
samples	O
of	O
5	O
ml	O
have	O
been	O
collected	O
to	O
EDTA	B-Chemical
-	O
covered	O
tubes	O
.	O
DNA	O
was	O
extracted	O
using	O
QIAamp	O
DNA	O
Mini	O
Kit	O
(	O
Qiagen	O
","	O
Germany	O
).	O
The	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Medical	O
University	O
in	O
Lublin	O
(	O
No	O
.	O
KE	O
-	O
254	O
/	O
219	O
/	O
2010	O
).	O
Genotyping	O
of	O
TS	O
and	O
MTHFR	O
All	O
studied	O
polymorphism	O
were	O
analysed	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
).	O
Primers	O
used	O
in	O
TS	O
gene	O
VNTR	O
polymorphism	O
analysis	O
were	O
previously	O
described	O
by	O
Iacopetta	O
et	O
al	O
.	O
[	O
16	O
].	O
The	O
analysis	O
of	O
G	O
>	O
C	O
SNP	O
in	O
tandem	O
repeats	O
of	O
TS	O
gene	O
was	O
carried	O
out	O
using	O
allele	O
-	O
specific	O
PCR	O
(	O
ASP	O
-	O
PCR	O
)	O
with	O
forward	O
primers	O
designed	O
specifically	O
for	O
G	B-Chemical
or	I-Chemical
C	I-Chemical
nucleotide	I-Chemical
(	O
5	O
â€™	O
CGTCCCGCCGCGCCACTTG	O
3	O
â€™	O
and	O
5	O
â€™	O
CGTCCCGCCGCGCCACTTC	O
3	O
"â€™,"	O
respectively	O
).	O
The	O
reverse	O
primer	O
was	O
the	O
same	O
one	O
used	O
in	O
the	O
VNTR	O
analysis	O
","	O
described	O
by	O
Iacopetta	O
et	O
al	O
.	O
The	O
ASP	O
-	O
PCR	O
was	O
carried	O
out	O
in	O
two	O
separate	O
PCR	O
tubes	O
","	O
one	O
for	O
G	O
-	O
ending	O
primer	O
and	O
one	O
for	O
C	O
-	O
ending	O
primer	O
.	O
The	O
1494del6	O
deletion	O
on	O
the	O
3	O
â€™	O
end	O
of	O
TS	O
gene	O
and	O
MTHFR	O
677C	O
>	O
T	O
SNP	O
were	O
detected	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
technique	O
.	O
Primers	O
used	O
for	O
the	O
detection	O
of	O
1494del6	O
were	O
previously	O
described	O
by	O
Dotor	O
et	O
al	O
.	O
[	O
17	O
"],"	O
while	O
the	O
MTHFR	O
677C	O
>	O
T	O
SNP	O
primers	O
were	O
previously	O
described	O
by	O
Frosst	O
et	O
al	O
.	O
[	O
18	O
].	O
For	O
the	O
RFLP	O
reaction	O
Fermentas	O
FastDigest	O
DraI	O
(	O
Thermo	O
Scientific	O
","	O
USA	O
)	O
for	O
TS	O
1494del6	O
polymorphism	O
and	O
Fermentas	O
FastDigest	O
HinfI	O
(	O
Thermo	O
Scientific	O
","	O
USA	O
)	O
for	O
MTHFR	O
677C	O
>	O
T	O
SNP	O
restriction	O
enzymes	O
were	O
used	O
.	O
The	O
digestion	O
process	O
was	O
carried	O
out	O
under	O
the	O
following	O
conditions	O
:	O
10	O
min	O
.	O
incubtion	O
in	O
37	O
Â°	O
followed	O
by	O
5	O
min	O
.	O
digestion	O
in	O
65	O
Â°.	O
Every	O
polymorphism	O
analysis	O
was	O
carried	O
out	O
in	O
the	O
same	O
reaction	O
mixture	O
of	O
20	O
Î¼l	O
","	O
with	O
only	O
PCR	O
primers	O
being	O
changed	O
specifically	O
for	O
the	O
polymorphism	O
.	O
The	O
mixture	O
contained	O
:	O
100	O
ng	O
of	O
sample	O
DNA	O
","	O
1	O
Î¼M	O
of	O
each	O
primer	O
","	O
0	O
.	O
2	O
mM	O
of	O
each	O
dNTP	B-Chemical
","	O
2	O
.	O
4	O
mM	O
of	O
MgCl2	B-Chemical
and	O
1	O
U	O
Taq	O
polymerase	O
with	O
1	O
Ã—	O
Reaction	O
Buffer	O
(	O
Thermo	O
Scientific	O
","	O
USA	O
).	O
All	O
reactions	O
were	O
carried	O
out	O
in	O
a	O
Biometra	O
TPersonal	O
thermocycler	O
(	O
Biometra	O
","	O
Germany	O
).	O
Products	O
of	O
PCR	O
were	O
visualised	O
on	O
2	O
%	O
agarose	B-Chemical
gel	O
with	O
ethidium	B-Chemical
bromide	I-Chemical
.	O
TS	O
VNTR	O
polymorphism	O
PCR	O
products	O
differed	O
according	O
to	O
the	O
number	O
of	O
28	O
bp	O
repeats	O
.	O
In	O
Caucasian	O
population	O
the	O
most	O
often	O
described	O
genotypes	O
consist	O
of	O
two	O
or	O
three	O
repeats	O
:	O
2R	O
/	O
2R	O
and	O
3R	O
/	O
3R	O
homozygotes	O
","	O
and	O
2R	O
/	O
3R	O
heterozygotes	O
.	O
2R	O
/	O
2R	O
homozygotes	O
produce	O
a	O
116	O
bp	O
band	O
on	O
the	O
gel	O
","	O
3R	O
/	O
3R	O
homozygotes	O
produce	O
a	O
144	O
bp	O
band	O
","	O
and	O
heterozygotes	O
show	O
both	O
bands	O
-	O
116	O
and	O
144	O
bp	O
.	O
The	O
ASP	O
-	O
PCR	O
for	O
the	O
G	O
>	O
C	O
SNP	O
in	O
TS	O
gene	O
shows	O
two	O
band	O
patterns	O
:	O
the	O
common	O
G	B-Chemical
nucleotide	I-Chemical
presented	O
three	O
bands	O
:	O
124	O
and	O
96	O
bp	O
specific	O
for	O
G	O
-	O
ending	O
primer	O
and	O
68	O
bp	O
band	O
specific	O
for	O
C	O
-	O
ending	O
primer	O
","	O
the	O
rare	O
C	B-Chemical
nucleotide	I-Chemical
presented	O
three	O
bands	O
of	O
124	O
bp	O
for	O
G	O
-	O
ending	O
primer	O
and	O
two	O
bands	O
of	O
96	O
and	O
68	O
bp	O
for	O
C	O
-	O
ending	O
primer	O
.	O
The	O
reaction	O
products	O
of	O
G	O
>	O
C	O
SNP	O
are	O
shown	O
in	O
two	O
separate	O
lanes	O
","	O
one	O
for	O
G	O
-	O
ending	O
primer	O
and	O
one	O
for	O
C	O
-	O
ending	O
primer	O
.	O
The	O
6	O
bp	O
deletion	O
at	O
the	O
3	O
â€™	O
end	O
of	O
TS	O
gene	O
shows	O
two	O
band	O
types	O
:	O
142	O
bp	O
for	O
âˆ’	O
6	O
/âˆ’	O
6	O
genotype	O
and	O
148	O
bp	O
for	O
+	O
6	O
/+	O
6	O
bp	O
.	O
The	O
PCR	O
products	O
digestion	O
with	O
DraI	O
restriction	O
enzyme	O
is	O
possible	O
only	O
when	O
the	O
insertion	O
genotype	O
is	O
present	O
","	O
so	O
it	O
creates	O
two	O
smaller	O
bands	O
of	O
88	O
and	O
60	O
bp	O
.	O
The	O
heterozygous	O
genotype	O
+	O
6	O
/âˆ’	O
6	O
presents	O
four	O
bands	O
of	O
148	O
","	O
142	O
","	O
88	O
and	O
60	O
bp	O
.	O
The	O
products	O
of	O
PCR	O
for	O
677C	O
>	O
T	O
SNP	O
in	O
MTHFR	O
gene	O
present	O
following	O
patterns	O
:	O
198	O
bp	O
band	O
for	O
C	O
/	O
C	O
genotype	O
and	O
175	O
and	O
23	O
bp	O
band	O
for	O
T	O
/	O
T	O
genotype	O
when	O
digested	O
with	O
HinfI	O
restriction	O
enzyme	O
.	O
The	O
C	O
/	O
T	O
heterozygote	O
is	O
present	O
on	O
the	O
gel	O
as	O
three	O
band	O
of	O
198	O
","	O
175	O
and	O
23	O
bp	O
.	O
The	O
smallest	O
band	O
of	O
23	O
bp	O
is	O
not	O
visible	O
on	O
the	O
gel	O
as	O
it	O
is	O
migrating	O
on	O
the	O
gel	O
with	O
reaction	O
primers	O
.	O
Statistical	O
Analysis	O
Yates	O
â€™	O
chi	O
-	O
square	O
test	O
was	O
used	O
to	O
assess	O
differences	O
between	O
categorical	O
variables	O
and	O
deviation	O
from	O
the	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
.	O
Groups	O
of	O
patients	O
with	O
different	O
clinical	O
and	O
molecular	O
factors	O
were	O
compared	O
using	O
Kaplan	O
-	O
Meier	O
method	O
","	O
in	O
order	O
to	O
determine	O
the	O
probability	O
of	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
).	O
To	O
determine	O
the	O
influence	O
of	O
the	O
studied	O
factors	O
on	O
PFS	O
and	O
OS	O
of	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
","	O
the	O
Cox	O
regression	O
model	O
with	O
step	O
-	O
by	O
-	O
step	O
selection	O
was	O
used	O
.	O
Results	O
The	O
studied	O
group	O
consisted	O
of	O
NSCLC	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
in	O
second	O
-	O
or	O
third	O
-	O
line	O
and	O
first	O
-	O
line	O
patients	O
who	O
were	O
not	O
eligible	O
for	O
cisplatin	B-Chemical
.	O
In	O
this	O
group	O
there	O
were	O
24	O
carriers	O
of	O
double	O
28	O
bp	O
tandem	O
repeats	O
(	O
33	O
.	O
3	O
"%),"	O
17	O
triple	O
repeats	O
(	O
23	O
.	O
6	O
"%),"	O
the	O
rest	O
(	O
43	O
.	O
1	O
%)	O
were	O
heterozygous	O
.	O
Among	O
the	O
carriers	O
of	O
triple	O
repeats	O
in	O
one	O
or	O
both	O
alleles	O
","	O
the	O
G	B-Chemical
nucleotide	I-Chemical
in	O
the	O
second	O
repeat	O
of	O
28	O
bp	O
appeared	O
in	O
25	O
patients	O
(	O
34	O
.	O
7	O
%).	O
The	O
presence	O
of	O
1494del6	O
deletion	O
was	O
observed	O
in	O
8	O
patients	O
(	O
11	O
.	O
1	O
"%),"	O
there	O
were	O
28	O
carriers	O
of	O
one	O
allele	O
with	O
deletion	O
(	O
38	O
.	O
95	O
%)	O
and	O
the	O
insertion	O
was	O
present	O
in	O
50	O
%	O
of	O
patients	O
.	O
Allele	O
T	O
in	O
677C	O
>	O
T	O
SNP	O
in	O
MTHFR	O
gene	O
was	O
present	O
in	O
40	O
patients	O
(	O
55	O
.	O
6	O
%)	O
among	O
which	O
there	O
were	O
11	O
T	O
/	O
T	O
homozygous	O
patients	O
(	O
15	O
.	O
3	O
%	O
of	O
the	O
whole	O
studied	O
group	O
).	O
66	O
.	O
7	O
%	O
of	O
the	O
studied	O
group	O
showed	O
disease	O
control	O
during	O
pemetrexed	B-Chemical
monotherapy	O
","	O
of	O
whom	O
only	O
7	O
reached	O
partial	O
response	O
(	O
PR	O
)	O
(	O
9	O
.	O
7	O
%).	O
In	O
24	O
patients	O
(	O
33	O
.	O
3	O
%)	O
disease	O
progression	O
was	O
observed	O
during	O
first	O
two	O
months	O
after	O
pemetrexed	B-Chemical
monotherapy	O
.	O
Median	O
progression	O
-	O
free	O
survival	O
reached	O
4	O
.	O
5	O
months	O
","	O
while	O
median	O
overall	O
survival	O
reached	O
9	O
months	O
.	O
Correlation	O
between	O
clinical	O
factors	O
and	O
risk	O
of	O
early	O
progression	O
","	O
duration	O
of	O
PFS	O
and	O
OS	O
in	O
non	O
-	O
squamous	O
NSCLC	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
Surprisingly	O
","	O
among	O
all	O
the	O
analyzed	O
clinical	O
factors	O
","	O
none	O
has	O
significantly	O
influenced	O
the	O
risk	O
of	O
early	O
disease	O
progression	O
or	O
progression	O
-	O
free	O
survival	O
.	O
Slightly	O
prolonged	O
overall	O
survival	O
(	O
HR	O
=	O
0	O
.	O
58	O
","	O
p	O
=	O
0	O
.	O
76	O
)	O
was	O
observed	O
among	O
patients	O
with	O
PFS	O
longer	O
than	O
6	O
months	O
after	O
first	O
-	O
line	O
non	O
-	O
pemetrexed	B-Chemical
chemotherapy	O
(	O
Table	O
1	O
).	O
Correlation	O
between	O
molecular	O
factors	O
and	O
risk	O
of	O
early	O
progression	O
","	O
duration	O
of	O
PFS	O
and	O
OS	O
in	O
non	O
-	O
squamous	O
NSCLC	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
Impact	O
of	O
TS	O
VNTR	O
polymorphism	O
and	O
a	O
677C	O
>	O
T	O
SNP	O
in	O
MTHFR	O
gene	O
on	O
progression	O
free	O
survival	O
in	O
non	O
-	O
squamous	O
NSCLC	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
It	O
was	O
observed	O
that	O
among	O
carriers	O
of	O
triple	O
28	O
bp	O
tandem	O
repeats	O
with	O
G	O
allele	O
in	O
the	O
second	O
tandem	O
repeat	O
","	O
disease	O
progression	O
was	O
significantly	O
more	O
frequent	O
(	O
p	O
=	O
0	O
.	O
287	O
)	O
than	O
among	O
carriers	O
of	O
other	O
genotype	O
combinations	O
.	O
PFS	O
and	O
OS	O
were	O
shorter	O
in	O
carriers	O
of	O
such	O
genotype	O
","	O
however	O
these	O
were	O
not	O
statistically	O
significant	O
differences	O
(	O
Table	O
2	O
).	O
Only	O
among	O
carriers	O
of	O
both	O
triple	O
tandem	O
repeats	O
in	O
TS	O
gene	O
and	O
C	O
/	O
C	O
genotype	O
in	O
MTHFR	O
677C	O
>	O
T	O
polymorphism	O
","	O
a	O
double	O
shortening	O
of	O
PFS	O
may	O
be	O
observed	O
in	O
comparison	O
to	O
carriers	O
of	O
other	O
genotype	O
combinations	O
.	O
However	O
","	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
either	O
(	O
Fig	O
.	O
1	O
","	O
Table	O
2	O
).	O
Impact	O
of	O
TS	O
VNTR	O
polymorphism	O
and	O
a	O
677C	O
>	O
T	O
SNP	O
in	O
MTHFR	O
gene	O
on	O
overall	O
survival	O
in	O
non	O
-	O
squamous	O
NSCLC	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
Carriers	O
of	O
both	O
triple	O
28	O
bp	O
tandem	O
repeats	O
in	O
both	O
alleles	O
of	O
TS	O
gene	O
and	O
C	O
/	O
C	O
genotype	O
in	O
677C	O
>	O
T	O
SNP	O
in	O
MTHFR	O
gene	O
had	O
significantly	O
shorter	O
overall	O
survival	O
in	O
comparison	O
to	O
carriers	O
of	O
other	O
genotype	O
combinations	O
(	O
6	O
.	O
75	O
vs	O
.	O
12	O
months	O
","	O
p	O
=	O
0	O
.	O
31	O
)	O
(	O
Fig	O
.	O
2	O
","	O
Table	O
2	O
).	O
Multivariate	O
Cox	O
logistic	O
regression	O
model	O
of	O
factors	O
affecting	O
the	O
overall	O
survival	O
of	O
non	O
-	O
squamous	O
NSCLC	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
Using	O
Cox	O
logistic	O
regression	O
we	O
were	O
unable	O
to	O
create	O
a	O
model	O
evaluating	O
the	O
power	O
of	O
the	O
impact	O
of	O
the	O
studied	O
clinical	O
and	O
molecular	O
factors	O
on	O
the	O
risk	O
of	O
early	O
progression	O
due	O
to	O
the	O
lack	O
of	O
significance	O
of	O
each	O
determinant	O
.	O
The	O
model	O
created	O
for	O
the	O
risk	O
of	O
early	O
death	O
has	O
reached	O
the	O
significance	O
threshold	O
","	O
however	O
the	O
only	O
variable	O
","	O
which	O
significantly	O
influenced	O
this	O
risk	O
","	O
was	O
the	O
presence	O
of	O
both	O
triple	O
28	O
bp	O
tandem	O
repeats	O
in	O
TS	O
gene	O
and	O
C	O
/	O
C	O
genotype	O
in	O
677C	O
>	O
T	O
SNP	O
in	O
MTHFR	O
gene	O
as	O
well	O
as	O
short	O
duration	O
of	O
PFS	O
after	O
first	O
-	O
line	O
non	O
-	O
pemetrexed	B-Chemical
chemotherapy	O
(	O
Table	O
3	O
).	O
Discussion	O
In	O
second	O
-	O
line	O
therapy	O
","	O
pemetrexed	B-Chemical
is	O
administered	O
as	O
monotherapy	O
","	O
and	O
this	O
form	O
was	O
registered	O
based	O
on	O
a	O
large	O
-	O
scale	O
","	O
multicenter	O
","	O
randomized	O
","	O
phase	O
III	O
clinical	O
trial	O
performed	O
on	O
571	O
NSCLC	O
patients	O
.	O
The	O
study	O
compared	O
the	O
effectiveness	O
of	O
second	O
-	O
line	O
pemetrexed	B-Chemical
or	O
docetaxel	B-Chemical
monotherapy	O
and	O
it	O
did	O
not	O
show	O
differences	O
in	O
efficacy	O
of	O
the	O
drugs	O
","	O
however	O
significantly	O
less	O
toxicity	O
was	O
observed	O
after	O
pemetrexed	B-Chemical
treatment	O
.	O
In	O
pemetrexed	B-Chemical
arm	O
objective	O
response	O
and	O
stable	O
disease	O
was	O
observed	O
in	O
71	O
.	O
2	O
%	O
of	O
the	O
studied	O
group	O
","	O
PFS	O
reached	O
2	O
.	O
9	O
months	O
and	O
OS	O
â€“	O
8	O
.	O
3	O
months	O
.	O
The	O
study	O
also	O
revealed	O
that	O
the	O
basic	O
clinical	O
factors	O
such	O
as	O
good	O
performance	O
status	O
(	O
PS	O
=	O
0	O
"),"	O
locally	O
advanced	O
disease	O
and	O
time	O
since	O
last	O
chemotherapy	O
over	O
3	O
months	O
are	O
positively	O
influencing	O
overall	O
survival	O
in	O
NSCLC	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
[	O
3	O
].	O
Pemetrexed	B-Chemical
monotherapy	O
was	O
compared	O
with	O
a	O
pemetrexed	B-Chemical
/	O
carboplatin	B-Chemical
regime	O
","	O
in	O
second	O
-	O
line	O
of	O
NSCLC	O
treatment	O
","	O
in	O
GOIRC	O
2	O
â€“	O
2006	O
clinical	O
trial	O
.	O
PFS	O
in	O
the	O
pemetrexed	B-Chemical
arm	O
reached	O
3	O
.	O
6	O
months	O
and	O
OS	O
â€“	O
8	O
.	O
8	O
months	O
","	O
which	O
were	O
similar	O
to	O
the	O
result	O
of	O
the	O
Hanna	O
et	O
al	O
.	O
trial	O
.	O
Two	O
-	O
drug	O
regime	O
showed	O
slightly	O
higher	O
effectiveness	O
but	O
for	O
a	O
price	O
of	O
higher	O
toxicity	O
[	O
19	O
].	O
Maintenance	O
therapy	O
using	O
pemetrexed	B-Chemical
is	O
possible	O
in	O
selected	O
non	O
-	O
squamous	O
NSCLC	O
patients	O
.	O
The	O
PARAMOUNT	O
clinical	O
trial	O
showed	O
that	O
pemetrexed	B-Chemical
monotherapy	O
after	O
successful	O
first	O
-	O
line	O
pemetrexed	B-Chemical
/	O
platinum	B-Chemical
therapy	O
","	O
extends	O
progression	O
-	O
free	O
survival	O
to	O
4	O
.	O
1	O
months	O
and	O
overall	O
survival	O
to	O
13	O
.	O
9	O
months	O
[	O
20	O
].	O
In	O
our	O
study	O
","	O
we	O
reached	O
results	O
similar	O
to	O
the	O
ones	O
obtained	O
by	O
Hanna	O
et	O
al	O
.	O
Median	O
PFS	O
in	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
was	O
4	O
.	O
5	O
months	O
and	O
OS	O
â€“	O
9	O
months	O
.	O
Such	O
results	O
were	O
reached	O
even	O
though	O
only	O
18	O
%	O
of	O
our	O
studied	O
group	O
received	O
further	O
treatment	O
lines	O
.	O
Only	O
slight	O
but	O
not	O
significant	O
differences	O
in	O
OS	O
are	O
visible	O
between	O
patients	O
with	O
different	O
PS	O
(	O
12	O
.	O
5	O
vs	O
.	O
10	O
.	O
5	O
months	O
for	O
PS	O
=	O
0	O
and	O
PS	O
=	O
1	O
","	O
respectively	O
"),"	O
in	O
patients	O
with	O
or	O
without	O
anemia	O
(	O
9	O
.	O
5	O
vs	O
.	O
12	O
.	O
5	O
months	O
)	O
and	O
in	O
patients	O
with	O
long	O
and	O
short	O
response	O
to	O
first	O
-	O
line	O
non	O
-	O
pemetrexed	B-Chemical
chemotherapy	O
(	O
12	O
vs	O
.	O
7	O
months	O
).	O
Clinical	O
factors	O
are	O
important	O
in	O
proper	O
qualification	O
to	O
chemotherapy	O
but	O
it	O
is	O
not	O
always	O
possible	O
to	O
choose	O
the	O
best	O
option	O
based	O
only	O
on	O
them	O
","	O
thus	O
molecular	O
factors	O
are	O
being	O
studied	O
more	O
and	O
more	O
intensively	O
in	O
order	O
to	O
find	O
relevant	O
ones	O
","	O
also	O
in	O
pemetrexed	B-Chemical
treatment	O
.	O
The	O
most	O
often	O
studied	O
molecular	O
factor	O
is	O
the	O
expression	O
of	O
thymidylate	O
synthase	O
.	O
A	O
study	O
on	O
110	O
NSCLC	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
in	O
third	O
-	O
or	O
fourth	O
-	O
line	O
did	O
not	O
show	O
any	O
significant	O
influence	O
of	O
TS	O
expression	O
on	O
PFS	O
or	O
OS	O
.	O
However	O
it	O
is	O
worth	O
mentioning	O
that	O
the	O
researchers	O
had	O
only	O
limited	O
access	O
to	O
cancer	O
tissue	O
(	O
only	O
13	O
out	O
of	O
55	O
samples	O
were	O
eligible	O
for	O
immunohistochemical	O
analysis	O
)	O
[	O
21	O
].	O
Analysis	O
of	O
pemetrexed	B-Chemical
target	O
genes	O
(	O
TS	O
","	O
DHFR	O
","	O
GARFT	O
and	O
MTHFR	O
)	O
was	O
carried	O
out	O
on	O
90	O
adenocarcinoma	O
Asian	O
patients	O
treated	O
with	O
pemetrexed	B-Chemical
monotherapy	O
in	O
third	O
-	O
or	O
further	O
lines	O
.	O
No	O
relationship	O
was	O
found	O
between	O
the	O
polymorphisms	O
and	O
response	O
rates	O
","	O
but	O
it	O
is	O
interesting	O
that	O
carriers	O
of	O
â€œ	O
high	O
expression	O
â€	O
genotypes	O
in	O
TS	O
gene	O
(	O
2R	O
/	O
3R	O
(	O
G	O
"),"	O
3R	O
(	O
C	O
)/	O
3R	O
(	O
G	O
"),"	O
3R	O
(	O
G	O
)/	O
3R	O
(	O
G	O
))	O
reached	O
longer	O
PFS	O
(	O
5	O
.	O
2	O
vs	O
.	O
3	O
.	O
7	O
months	O
)	O
and	O
OS	O
(	O
31	O
.	O
8	O
vs	O
.	O
18	O
.	O
5	O
months	O
)	O
than	O
carriers	O
of	O
â€œ	O
low	O
expression	O
â€	O
genotypes	O
(	O
2R	O
/	O
2R	O
","	O
2R	O
/	O
3R	O
(	O
C	O
"),"	O
3R	O
(	O
C	O
)/	O
3R	O
(	O
C	O
")),"	O
which	O
is	O
in	O
contradiction	O
to	O
the	O
results	O
from	O
the	O
studies	O
of	O
the	O
same	O
polymorphism	O
but	O
in	O
first	O
-	O
line	O
pemetrexed	B-Chemical
treatment	O
[	O
22	O
].	O
Smit	O
et	O
al	O
.	O
carried	O
out	O
a	O
comparison	O
of	O
pemetrexed	B-Chemical
monotherapy	O
with	O
pemetrexed	B-Chemical
/	O
carboplatin	B-Chemical
regime	O
in	O
second	O
-	O
line	O
treatment	O
of	O
NSCLC	O
patients	O
.	O
As	O
a	O
part	O
of	O
the	O
study	O
a	O
pharmacogenetic	O
analysis	O
was	O
carried	O
out	O
.	O
There	O
was	O
no	O
connection	O
between	O
â€œ	O
low	O
/	O
high	O
expression	O
â€	O
genotypes	O
of	O
TS	O
gene	O
and	O
treatment	O
results	O
","	O
but	O
a	O
significant	O
correlation	O
was	O
observed	O
in	O
carriers	O
of	O
T	O
/	O
T	O
genotype	O
of	O
MTHFR	O
677C	O
>	O
T	O
polymorphism	O
","	O
where	O
PFS	O
was	O
longer	O
for	O
such	O
patients	O
when	O
compared	O
to	O
carriers	O
of	O
other	O
genotypes	O
(	O
7	O
.	O
9	O
vs	O
.	O
2	O
.	O
9	O
months	O
;	O
p	O
=	O
0	O
.	O
3	O
)	O
[	O
23	O
].	O
The	O
analysis	O
of	O
two	O
clinical	O
trials	O
:	O
GOIRC	O
2	O
â€“	O
2006	O
(	O
19	O
)	O
and	O
NVALT	O
-	O
7	O
(	O
23	O
"),"	O
for	O
polymorphisms	O
connected	O
with	O
pemetrexed	B-Chemical
effectiveness	O
","	O
showed	O
that	O
T	O
/	O
T	O
genotype	O
of	O
MTHFR	O
677C	O
>	O
T	O
polymorphism	O
is	O
correlated	O
with	O
longer	O
PFS	O
(	O
5	O
.	O
4	O
vs	O
.	O
3	O
.	O
4	O
months	O
;	O
p	O
=	O
0	O
.	O
12	O
)	O
and	O
OS	O
(	O
16	O
.	O
4	O
vs	O
.	O
8	O
.	O
5	O
months	O
;	O
p	O
=	O
0	O
.	O
26	O
)	O
when	O
compared	O
to	O
other	O
genotypes	O
(	O
C	O
/	O
C	O
and	O
C	O
/	O
T	O
)	O
[	O
24	O
].	O
In	O
our	O
study	O
carriers	O
of	O
â€œ	O
high	O
expression	O
â€	O
genotypes	O
in	O
TS	O
gene	O
showed	O
significantly	O
more	O
frequent	O
early	O
progression	O
than	O
carriers	O
of	O
â€œ	O
low	O
expression	O
â€	O
genotypes	O
.	O
Small	O
(	O
but	O
not	O
statistically	O
significant	O
)	O
differences	O
in	O
OS	O
were	O
observed	O
among	O
carriers	O
of	O
different	O
genotypes	O
of	O
MTHFR	O
gene	O
677C	O
>	O
T	O
polymorphism	O
(	O
17	O
.	O
5	O
vs	O
.	O
11	O
months	O
for	O
carriers	O
of	O
T	O
/	O
T	O
and	O
C	O
/	O
C	O
+	O
C	O
/	O
T	O
","	O
respectively	O
).	O
Among	O
carriers	O
of	O
3R	O
/	O
3R	O
genotype	O
in	O
TS	O
gene	O
and	O
C	O
/	O
C	O
genotype	O
of	O
MTHFR	O
677C	O
>	O
T	O
polymorphism	O
a	O
significantly	O
shorter	O
OS	O
was	O
observed	O
(	O
6	O
.	O
75	O
vs	O
.	O
12	O
months	O
for	O
carriers	O
of	O
3R	O
/	O
3R	O
+	O
C	O
/	O
C	O
and	O
carriers	O
of	O
other	O
genotype	O
combinations	O
respectively	O
;	O
p	O
=	O
0	O
.	O
31	O
).	O
Moreover	O
","	O
in	O
multivariate	O
analysis	O
","	O
significantly	O
higher	O
risk	O
of	O
death	O
was	O
observed	O
in	O
carriers	O
of	O
both	O
3R	O
/	O
3R	O
genotype	O
in	O
TS	O
gene	O
and	O
C	O
/	O
C	O
genotype	O
in	O
677C	O
>	O
T	O
SNP	O
in	O
MTHFR	O
gene	O
as	O
well	O
as	O
in	O
patients	O
with	O
short	O
PFS	O
after	O
first	O
-	O
line	O
non	O
-	O
pemetrexed	B-Chemical
chemotherapy	O
.	O
These	O
results	O
are	O
in	O
line	O
with	O
other	O
studies	O
","	O
where	O
the	O
presence	O
of	O
3R	O
/	O
3R	O
genotype	O
in	O
TS	O
gene	O
and	O
C	O
/	O
C	O
genotype	O
in	O
MTHFR	O
gene	O
where	O
considered	O
negative	O
predictive	O
factor	O
in	O
pemetrexed	B-Chemical
therapy	O
.	O
Molecular	O
factors	O
become	O
more	O
meaningful	O
when	O
considering	O
a	O
relevant	O
treatment	O
option	O
for	O
cancer	O
patients	O
.	O
Studies	O
carried	O
out	O
on	O
first	O
-	O
line	O
pemetrexed	B-Chemical
/	O
platinum	B-Chemical
treated	O
patients	O
seem	O
to	O
confirm	O
usefulness	O
of	O
some	O
factors	O
such	O
as	O
thymidylate	O
synthase	O
expression	O
","	O
but	O
in	O
pemetrexed	B-Chemical
monotherapy	O
group	O
there	O
is	O
still	O
very	O
little	O
relevant	O
information	O
.	O
It	O
is	O
also	O
worth	O
mentioning	O
that	O
patients	O
who	O
receive	O
second	O
or	O
further	O
lines	O
of	O
chemotherapy	O
usually	O
have	O
worse	O
prognosis	O
than	O
those	O
who	O
are	O
treated	O
with	O
first	O
-	O
line	O
.	O
Therefore	O
","	O
based	O
on	O
our	O
study	O
","	O
it	O
appears	O
that	O
the	O
studied	O
genetic	O
factors	O
may	O
have	O
high	O
predictive	O
and	O
prognostic	O
value	O
(	O
as	O
high	O
as	O
clinical	O
factors	O
).	O
Our	O
results	O
show	O
that	O
analysis	O
of	O
VNTR	O
polymorphism	O
in	O
TS	O
gene	O
","	O
an	O
inside	O
G	O
>	O
C	O
SNP	O
in	O
VNTRs	O
and	O
MTHFR	O
gene	O
677C	O
>	O
T	O
SNP	O
might	O
help	O
in	O
selecting	O
a	O
group	O
of	O
non	O
-	O
squamous	O
NSCLC	O
patients	O
who	O
will	O
benefit	O
significantly	O
from	O
pemetrexed	B-Chemical
monotherapy	O
","	O
but	O
in	O
order	O
to	O
evaluate	O
properly	O
the	O
usefulness	O
of	O
the	O
chosen	O
molecular	O
factors	O
more	O
large	O
-	O
scale	O
and	O
prospective	O
studies	O
on	O
more	O
representative	O
groups	O
are	O
needed	O
.	O
References	O
Free	B-Chemical
fatty	I-Chemical
acids	I-Chemical
","	O
not	O
triglycerides	B-Chemical
","	O
are	O
associated	O
with	O
non	O
-	O
alcoholic	O
liver	O
injury	O
progression	O
in	O
high	O
fat	B-Chemical
diet	O
induced	O
obese	O
rats	O
Background	O
The	O
incidence	O
of	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
"),"	O
commonly	O
associated	O
with	O
obesity	O
and	O
metabolic	O
syndrome	O
","	O
is	O
increasing	O
worldwide	O
.	O
However	O
","	O
the	O
specific	O
mechanisms	O
that	O
mediate	O
the	O
progression	O
from	O
simple	O
steatosis	O
to	O
non	O
-	O
alcoholic	O
steatohepatitis	O
remain	O
largely	O
unclear	O
.	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
timedependent	O
changes	O
of	O
triglyceride	B-Chemical
(	O
TG	B-Chemical
)	O
and	O
free	B-Chemical
fatty	I-Chemical
acid	I-Chemical
(	O
FFA	B-Chemical
)	O
levels	O
in	O
the	O
blood	O
and	O
liver	O
over	O
24	O
weeks	O
in	O
high	O
-	O
fat	B-Chemical
diet	O
-	O
induced	O
obese	O
rats	O
with	O
NAFLD	O
and	O
to	O
clarify	O
the	O
role	O
of	O
high	O
FFA	B-Chemical
levels	O
in	O
the	O
progression	O
of	O
liver	O
injury	O
.	O
Methods	O
Male	O
Wistar	O
rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
(	O
n	O
=	O
30	O
per	O
group	O
):	O
the	O
Control	O
group	O
","	O
fed	O
standard	O
chow	O
;	O
the	O
High	O
-	O
fat	B-Chemical
diet	O
(	O
HFD	O
)	O
group	O
","	O
fed	O
high	O
-	O
fat	B-Chemical
chow	O
;	O
and	O
the	O
Acipimox	B-Chemical
group	O
","	O
fed	O
an	O
HFD	O
plus	O
acipimox	B-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
d	O
","	O
ig	O
)	O
for	O
8	O
","	O
16	O
and	O
24	O
weeks	O
.	O
After	O
treatment	O
","	O
blood	O
and	O
liver	O
samples	O
were	O
collected	O
for	O
biochemical	O
analyses	O
","	O
western	O
blotting	O
analysis	O
and	O
a	O
histopathological	O
study	O
.	O
Results	O
The	O
visceral	O
fat	O
/	O
weight	O
and	O
liver	O
/	O
body	O
weight	O
ratios	O
were	O
higher	O
in	O
both	O
the	O
HFD	O
and	O
Acipimox	B-Chemical
groups	O
than	O
in	O
the	O
Control	O
group	O
.	O
The	O
TG	B-Chemical
and	O
FFA	B-Chemical
concentrations	O
in	O
blood	O
and	O
liver	O
were	O
increased	O
in	O
the	O
HFD	O
group	O
and	O
associated	O
with	O
elevated	O
serum	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
liver	O
malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
levels	O
and	O
macro	O
/	O
microvesicular	O
steatosis	O
on	O
hepatic	O
fragments	O
.	O
Although	O
the	O
TG	B-Chemical
levels	O
in	O
the	O
liver	O
were	O
similar	O
between	O
the	O
HFD	O
and	O
Acipimox	B-Chemical
groups	O
(	O
p	O
>	O
0	O
.	O
5	O
"),"	O
the	O
FFA	B-Chemical
concentrations	O
in	O
the	O
blood	O
and	O
liver	O
were	O
much	O
lower	O
in	O
the	O
latter	O
group	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
The	O
Acipimox	B-Chemical
group	O
showed	O
normal	O
ALT	O
and	O
MDA	B-Chemical
levels	O
as	O
well	O
as	O
less	O
severe	O
hepatic	O
histological	O
changes	O
than	O
did	O
the	O
HFD	O
group	O
(	O
NAFLD	O
activity	O
score	O
:	O
2	O
.	O
14	O
Â±	O
0	O
.	O
14	O
","	O
2	O
.	O
43	O
Â±	O
0	O
.	O
20	O
and	O
2	O
.	O
63	O
Â±	O
0	O
.	O
26	O
at	O
8	O
","	O
16	O
and	O
24	O
weeks	O
","	O
respectively	O
;	O
p	O
<	O
0	O
.	O
5	O
versus	O
the	O
HFD	O
group	O
at	O
24	O
weeks	O
).	O
The	O
diacylglycerol	O
acyltransferase	O
2	O
(	O
DGAT2	O
)	O
protein	O
levels	O
were	O
similar	O
between	O
the	O
HFD	O
and	O
Acipimox	B-Chemical
groups	O
(	O
p	O
>	O
0	O
.	O
5	O
"),"	O
but	O
the	O
protein	O
expression	O
level	O
of	O
carnitine	O
palmitoyltransferase	O
1a	O
(	O
CPT	O
-	O
1a	O
)	O
was	O
higher	O
in	O
the	O
Acipimox	B-Chemical
group	O
.	O
Conclusions	O
Liver	O
TG	B-Chemical
accumulation	O
does	O
not	O
cause	O
cellular	O
injury	O
in	O
the	O
liver	O
;	O
rather	O
","	O
FFAs	B-Chemical
or	O
their	O
metabolites	O
are	O
responsible	O
for	O
liver	O
injury	O
via	O
increased	O
oxidative	O
stress	O
.	O
It	O
is	O
suggested	O
that	O
the	O
therapeutic	O
efforts	O
to	O
prevent	O
non	O
-	O
alcoholic	O
liver	O
injury	O
progression	O
should	O
be	O
focused	O
on	O
reducing	O
the	O
burden	O
of	O
fatty	B-Chemical
acids	I-Chemical
transported	O
to	O
the	O
liver	O
or	O
those	O
being	O
synthesized	O
in	O
the	O
liver	O
.	O
Background	O
Non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
has	O
rapidly	O
become	O
the	O
most	O
common	O
cause	O
of	O
chronic	O
liver	O
disease	O
worldwide	O
.	O
Clinical	O
epidemiological	O
data	O
indicate	O
that	O
the	O
prevalence	O
of	O
NAFLD	O
ranges	O
from	O
20	O
%	O
to	O
30	O
%	O
in	O
Western	O
countries	O
and	O
is	O
15	O
%	O
in	O
Asian	O
countries	O
[	O
1	O
].	O
NAFLD	O
encompasses	O
a	O
spectrum	O
of	O
histological	O
findings	O
ranging	O
from	O
steatosis	O
to	O
steatohepatitis	O
","	O
and	O
steatohepatitis	O
can	O
eventually	O
progress	O
to	O
cirrhosis	O
and	O
even	O
hepatocellular	O
carcinoma	O
[	O
2	O
","	O
3	O
].	O
By	O
some	O
estimates	O
","	O
10	O
~	O
20	O
%	O
of	O
patients	O
with	O
simple	O
steatosis	O
will	O
convert	O
into	O
non	O
-	O
alcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
[	O
4	O
]	O
and	O
1	O
.	O
5	O
%	O
to	O
3	O
%	O
will	O
develop	O
advanced	O
liver	O
fibrosis	O
[	O
5	O
"],"	O
which	O
seriously	O
threatens	O
the	O
health	O
of	O
patients	O
.	O
Thus	O
","	O
to	O
reduce	O
the	O
development	O
of	O
NASH	O
and	O
liver	O
fibrosis	O
/	O
cirrhosis	O
","	O
it	O
is	O
necessary	O
to	O
explore	O
the	O
pathophysiology	O
and	O
risk	O
factors	O
that	O
influence	O
the	O
progression	O
from	O
simple	O
fatty	O
liver	O
to	O
NASH	O
and	O
to	O
formulate	O
early	O
intervention	O
strategies	O
.	O
Although	O
the	O
model	O
of	O
the	O
â€œ	O
two	O
-	O
hit	O
theory	O
â€	O
is	O
widely	O
accepted	O
to	O
explain	O
the	O
pathogenesis	O
of	O
NAFLD	O
","	O
the	O
specific	O
mechanisms	O
that	O
mediate	O
the	O
progression	O
from	O
simple	O
steatosis	O
to	O
non	O
-	O
alcoholic	O
steatohepatitis	O
and	O
those	O
that	O
lead	O
the	O
maintenance	O
of	O
simple	O
steatosis	O
in	O
some	O
patients	O
are	O
poorly	O
understood	O
.	O
The	O
presence	O
of	O
steatosis	O
is	O
a	O
prerequisite	O
for	O
NASH	O
","	O
but	O
it	O
is	O
not	O
causal	O
for	O
the	O
development	O
of	O
NAFLD	O
.	O
Some	O
recent	O
studies	O
have	O
found	O
that	O
lipid	B-Chemical
accumulation	O
in	O
the	O
liver	O
may	O
be	O
a	O
protective	O
mechanism	O
for	O
patients	O
with	O
obesity	O
/	O
insulin	O
resistance	O
/	O
elevated	O
free	B-Chemical
fatty	I-Chemical
acids	I-Chemical
(	O
FFAs	B-Chemical
)	O
[	O
6	O
","	O
7	O
].	O
Hepatocytes	O
","	O
exposure	O
to	O
high	O
levels	O
of	O
circulating	O
FFAs	B-Chemical
","	O
and	O
stored	O
FFAs	B-Chemical
in	O
the	O
form	O
of	O
triglycerides	B-Chemical
(	O
TGs	B-Chemical
)	O
may	O
ease	O
FFA	B-Chemical
-	O
induced	O
oxidative	O
stress	O
and	O
chronic	O
inflammation	O
","	O
thereby	O
preventing	O
further	O
hepatocellular	O
damage	O
.	O
However	O
","	O
whether	O
elevated	O
FFA	B-Chemical
levels	O
in	O
the	O
bloodstream	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
NAFLD	O
and	O
whether	O
lowering	O
plasma	O
and	O
liver	O
FFA	B-Chemical
levels	O
can	O
exert	O
a	O
protective	O
effect	O
on	O
hepatocytes	O
remains	O
unclear	O
.	O
Thus	O
","	O
to	O
clarify	O
the	O
role	O
of	O
high	O
FFA	B-Chemical
concentration	O
in	O
the	O
progression	O
of	O
NAFLD	O
","	O
we	O
induced	O
NAFLD	O
in	O
rats	O
using	O
a	O
high	O
-	O
fat	B-Chemical
diet	O
and	O
observed	O
the	O
time	O
-	O
dependent	O
changes	O
of	O
TG	B-Chemical
","	O
FFAs	B-Chemical
","	O
liver	O
enzymes	O
","	O
oxidative	O
stress	O
levels	O
","	O
and	O
the	O
protein	O
expression	O
levels	O
related	O
to	O
TG	B-Chemical
synthesis	O
and	O
fatty	B-Chemical
acid	I-Chemical
oxidation	O
.	O
In	O
addition	O
","	O
we	O
utilized	O
acipimox	B-Chemical
","	O
a	O
lipolysis	O
inhibitor	O
","	O
to	O
reduce	O
blood	O
FFA	B-Chemical
levels	O
[	O
8	O
","	O
9	O
]	O
and	O
determined	O
whether	O
reduced	O
FFA	B-Chemical
levels	O
had	O
a	O
protective	O
effect	O
on	O
the	O
liver	O
.	O
Methods	O
Study	O
animals	O
and	O
treatments	O
Compositions	O
of	O
the	O
chow	O
and	O
high	O
-	O
fat	B-Chemical
diets	O
Eight	O
-	O
week	O
-	O
old	O
male	O
Wistar	O
rats	O
weighing	O
270	O
Â±	O
10	O
g	O
were	O
obtained	O
from	O
the	O
animal	O
resources	O
centre	O
(	O
Sichuan	O
University	O
","	O
China	O
).	O
All	O
of	O
the	O
protocols	O
were	O
approved	O
by	O
the	O
Ethic	O
Committee	O
of	O
West	O
China	O
Hospital	O
","	O
and	O
the	O
animals	O
were	O
handled	O
according	O
to	O
the	O
â€œ	O
Principles	O
of	O
Laboratory	O
Animal	O
Care	O
.â€	O
The	O
animals	O
were	O
maintained	O
on	O
a	O
12	O
-	O
h	O
light	O
/	O
dark	O
cycle	O
with	O
controlled	O
room	O
temperature	O
(	O
20	O
Â±	O
2	O
Â°	O
C	O
)	O
and	O
had	O
access	O
to	O
food	O
and	O
water	B-Chemical
ad	O
libitum	O
.	O
After	O
an	O
adaptation	O
period	O
of	O
1	O
week	O
","	O
the	O
rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
:	O
(	O
1	O
)	O
the	O
Control	O
group	O
(	O
n	O
=	O
30	O
"),"	O
fed	O
standard	O
rat	O
chow	O
;	O
(	O
2	O
)	O
the	O
High	O
-	O
fat	B-Chemical
diet	O
(	O
HFD	O
)	O
group	O
(	O
n	O
=	O
30	O
"),"	O
fed	O
high	O
-	O
fat	B-Chemical
chow	O
;	O
and	O
(	O
3	O
)	O
the	O
Acipimox	B-Chemical
group	O
(	O
n	O
=	O
30	O
"),"	O
fed	O
high	O
-	O
fat	B-Chemical
chow	O
plus	O
acipimox	B-Chemical
(	O
100	O
mg	O
/	O
kg	O
/	O
day	O
","	O
ig	O
).	O
The	O
percentages	O
of	O
grams	O
and	O
energy	O
of	O
the	O
macronutrients	O
in	O
the	O
diets	O
are	O
listed	O
in	O
Table	O
1	O
.	O
Body	O
weight	O
was	O
measured	O
weekly	O
during	O
the	O
feeding	O
period	O
and	O
compared	O
with	O
liver	O
weight	O
and	O
visceral	O
fat	O
mass	O
after	O
the	O
animals	O
were	O
sacrificed	O
.	O
At	O
the	O
end	O
of	O
8	O
","	O
16	O
","	O
and	O
24	O
weeks	O
","	O
10	O
rats	O
in	O
each	O
of	O
the	O
three	O
groups	O
were	O
sacrificed	O
under	O
pentobarbital	B-Chemical
sodium	I-Chemical
anaesthesia	O
.	O
On	O
the	O
day	O
prior	O
to	O
sacrifice	O
","	O
the	O
rats	O
were	O
subjected	O
to	O
overnight	O
fasting	O
.	O
Blood	O
samples	O
were	O
obtained	O
from	O
the	O
heart	O
by	O
cardiac	O
puncture	O
","	O
and	O
serum	O
samples	O
were	O
preserved	O
at	O
âˆ’	O
80	O
Â°	O
C	O
for	O
biochemical	O
analyses	O
as	O
described	O
below	O
.	O
Liver	O
samples	O
were	O
weighed	O
and	O
processed	O
for	O
biochemical	O
and	O
histopathological	O
studies	O
and	O
western	O
blotting	O
analysis	O
.	O
Abdominal	O
visceral	O
fat	O
(	O
including	O
perirenal	O
","	O
epididymal	O
","	O
and	O
mesenteric	O
fat	O
)	O
was	O
collected	O
and	O
weighed	O
.	O
Blood	O
biochemical	O
analysis	O
The	O
total	O
cholesterol	B-Chemical
(	O
TC	B-Chemical
)	O
and	O
TG	B-Chemical
levels	O
were	O
determined	O
using	O
enzymatic	O
assays	O
in	O
commercial	O
kits	O
(	O
Huili	O
Biotechnologies	O
Inc	O
".,"	O
Changchun	O
","	O
China	O
).	O
The	O
FFA	B-Chemical
levels	O
were	O
assayed	O
using	O
the	O
colorimetric	O
method	O
with	O
a	O
serum	O
FFA	B-Chemical
kit	O
(	O
E1001	O
","	O
Applygen	O
Technologies	O
Inc	O
".,"	O
Beijing	O
","	O
China	O
).	O
The	O
serum	O
ALT	O
activity	O
","	O
a	O
biomarker	O
for	O
liver	O
damage	O
","	O
was	O
measured	O
using	O
an	O
ELISA	O
and	O
a	O
rat	O
ALT	O
kit	O
.	O
Assessments	O
of	O
hepatic	O
TGs	B-Chemical
and	O
FFAs	B-Chemical
The	O
liver	O
TG	B-Chemical
(	O
LTG	B-Chemical
)	O
concentrations	O
were	O
quantified	O
using	O
a	O
commercially	O
available	O
tissue	O
TG	B-Chemical
kit	O
(	O
E1013	O
","	O
Applygen	O
Technologies	O
Inc	O
".,"	O
Beijing	O
","	O
China	O
).	O
Fatty	B-Chemical
acids	I-Chemical
were	O
extracted	O
from	O
the	O
liver	O
using	O
previously	O
described	O
methods	O
[	O
10	O
","	O
11	O
].	O
Briefly	O
","	O
0	O
.	O
2	O
g	O
of	O
liver	O
was	O
weighed	O
and	O
placed	O
into	O
a	O
manual	O
glass	O
homogenizer	O
with	O
lysis	O
buffer	O
(	O
200	O
Î¼L	O
of	O
20	O
mM	O
EDTA	B-Chemical
","	O
2	O
mM	O
NaCl	B-Chemical
","	O
and	O
50	O
mM	O
sodium	B-Chemical
phosphate	I-Chemical
buffer	O
","	O
pH	O
7	O
.	O
4	O
).	O
Next	O
","	O
10	O
Î¼L	O
of	O
homogenate	O
was	O
mixed	O
with	O
10	O
Î¼L	O
of	O
tert	B-Chemical
-	I-Chemical
butyl	I-Chemical
alcohol	I-Chemical
and	O
5	O
Î¼l	O
of	O
Triton	B-Chemical
X	I-Chemical
-	I-Chemical
100	I-Chemical
/	O
methyl	B-Chemical
alcohol	I-Chemical
mixture	O
(	O
1	O
:	O
1	O
vol	O
/	O
vol	O
)	O
for	O
lipid	B-Chemical
extraction	O
[	O
11	O
].	O
The	O
FFAs	B-Chemical
were	O
measured	O
using	O
an	O
enzymatic	O
method	O
.	O
The	O
protein	O
concentrations	O
in	O
the	O
liver	O
extracts	O
were	O
determined	O
using	O
the	O
BCA	O
protein	O
assay	O
kit	O
.	O
Determination	O
of	O
malondialdehyde	B-Chemical
(	O
MDA	B-Chemical
)	O
and	O
glutathione	O
peroxidase	O
(	O
GSH	O
-	O
Px	O
)	O
in	O
liver	O
tissues	O
The	O
levels	O
of	O
MDA	B-Chemical
in	O
the	O
liver	O
tissue	O
were	O
determined	O
using	O
the	O
thiobarbutaric	B-Chemical
acid	I-Chemical
(	O
TBA	B-Chemical
)	O
method	O
with	O
a	O
commercially	O
available	O
kit	O
(	O
Jiancheng	O
Bioengineering	O
Institute	O
","	O
Nanjing	O
","	O
China	O
"),"	O
and	O
the	O
activity	O
of	O
GSH	O
-	O
Px	O
was	O
measured	O
using	O
the	O
velocity	O
method	O
with	O
a	O
GSH	O
-	O
Px	O
kit	O
(	O
Jiancheng	O
Bioengineering	O
Institute	O
","	O
Nanjing	O
","	O
China	O
).	O
Liver	O
histopathology	O
Hepatic	O
tissue	O
was	O
removed	O
from	O
each	O
rat	O
","	O
and	O
the	O
same	O
part	O
of	O
each	O
liver	O
was	O
dissected	O
","	O
fixed	O
in	O
10	O
%	O
formalin	B-Chemical
","	O
and	O
then	O
embedded	O
in	O
paraffin	B-Chemical
wax	O
for	O
staining	O
with	O
haematoxylin	B-Chemical
and	O
eosin	B-Chemical
(	O
H	B-Chemical
&	I-Chemical
E	I-Chemical
)	O
and	O
Masson	B-Chemical
â€™	I-Chemical
s	I-Chemical
trichrome	I-Chemical
.	O
Coded	O
sections	O
were	O
examined	O
for	O
histopathological	O
changes	O
by	O
an	O
experienced	O
pathologist	O
.	O
Liver	O
steatosis	O
and	O
NAFLD	O
activity	O
scores	O
were	O
semi	O
-	O
quantitatively	O
evaluated	O
as	O
previously	O
reported	O
[	O
12	O
].	O
In	O
brief	O
","	O
steatosis	O
scores	O
were	O
defined	O
as	O
follows	O
:	O
score	O
0	O
","	O
presence	O
of	O
intrahepatic	O
fat	O
droplets	O
in	O
<	O
5	O
%	O
of	O
hepatocytes	O
;	O
score	O
1	O
","	O
presence	O
of	O
intrahepatic	O
fat	O
droplets	O
in	O
5	O
â€“	O
33	O
%	O
of	O
hepatocytes	O
;	O
score	O
2	O
","	O
presence	O
of	O
intrahepatic	O
fat	O
droplets	O
in	O
33	O
â€“	O
66	O
%	O
of	O
hepatocytes	O
;	O
and	O
score	O
3	O
","	O
presence	O
of	O
intrahepatic	O
fat	O
droplets	O
in	O
>	O
67	O
%	O
of	O
hepatocytes	O
.	O
The	O
NAFLD	O
activity	O
score	O
is	O
the	O
sum	O
of	O
three	O
equal	O
weighted	O
features	O
:	O
steatosis	O
(	O
0	O
â€“	O
3	O
"),"	O
lobular	O
inflammation	O
(	O
0	O
â€“	O
3	O
)	O
and	O
hepatocellular	O
ballooning	O
(	O
0	O
â€“	O
2	O
).	O
Western	O
blotting	O
analysis	O
For	O
the	O
western	O
blot	O
analysis	O
","	O
50	O
mg	O
of	O
hepatic	O
tissue	O
was	O
homogenized	O
on	O
ice	O
in	O
radioimmunoprecipitation	O
lysis	O
buffer	O
containing	O
a	O
complete	O
protease	O
inhibitor	O
cocktail	O
(	O
Roche	O
Diagnostics	O
).	O
The	O
homogenates	O
were	O
centrifuged	O
to	O
collect	O
the	O
supernatants	O
.	O
The	O
protein	O
concentration	O
was	O
determined	O
using	O
a	O
BCA	O
protein	O
assay	O
kit	O
(	O
Thermo	O
Scientific	O
).	O
Protein	O
samples	O
were	O
subjected	O
to	O
SDS	B-Chemical
-	O
PAGE	O
and	O
transferred	O
onto	O
polyvinylidene	B-Chemical
difluoride	I-Chemical
(	O
PVDF	B-Chemical
)	O
membranes	O
.	O
After	O
being	O
blocked	O
with	O
5	O
%	O
bovine	O
serum	O
albumin	O
in	O
PBST	B-Chemical
at	O
room	O
temperature	O
for	O
2	O
h	O
","	O
the	O
membranes	O
were	O
incubated	O
with	O
anti	O
-	O
DGAT2	O
antibodies	O
(	O
rabbit	O
anti	O
-	O
DGAT2	O
;	O
1	O
:	O
400	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
and	O
anti	O
-	O
CPT	O
-	O
1a	O
antibodies	O
(	O
rabbit	O
anti	O
-	O
CPT	O
-	O
1a	O
;	O
1	O
:	O
400	O
;	O
Santa	O
Cruz	O
Biotechnology	O
)	O
at	O
4	O
Â°	O
C	O
overnight	O
.	O
Subsequently	O
","	O
the	O
membranes	O
were	O
washed	O
three	O
times	O
with	O
PBST	B-Chemical
and	O
incubated	O
with	O
the	O
relevant	O
secondary	O
HRP	O
-	O
conjugated	O
antibodies	O
(	O
1	O
:	O
5000	O
;	O
ZSGB	O
-	O
BIO	O
","	O
Beijing	O
","	O
China	O
)	O
for	O
90	O
min	O
.	O
Î²	O
-	O
actin	O
(	O
mouse	O
anti	O
-	O
Î²	O
-	O
actin	O
;	O
1	O
:	O
500	O
;	O
ZSGB	O
-	O
BIO	O
","	O
Beijing	O
","	O
China	O
)	O
was	O
used	O
as	O
the	O
loading	O
control	O
.	O
The	O
intensity	O
was	O
measured	O
using	O
Quantity	O
One	O
densitometric	O
software	O
(	O
Bio	O
-	O
Rad	O
).	O
Statistical	O
analysis	O
All	O
results	O
are	O
expressed	O
as	O
means	O
Â±	O
standard	O
error	O
.	O
Significant	O
differences	O
between	O
the	O
groups	O
were	O
determined	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
Scheffe	O
â€™	O
s	O
post	O
hoc	O
test	O
using	O
the	O
SPSS	O
16	O
.	O
0	O
statistical	O
package	O
.	O
A	O
p	O
-	O
value	O
<	O
0	O
.	O
5	O
was	O
considered	O
statistically	O
significant	O
.	O
Results	O
Biometric	O
parameters	O
Weight	O
","	O
visceral	O
fat	O
","	O
visceral	O
fat	O
/	O
weight	O
ratio	O
","	O
and	O
liver	O
/	O
body	O
weight	O
ratio	O
in	O
the	O
groups	O
As	O
shown	O
in	O
Table	O
2	O
","	O
the	O
body	O
weight	O
and	O
visceral	O
fat	O
mass	O
of	O
the	O
rats	O
in	O
each	O
group	O
increased	O
with	O
age	O
.	O
At	O
8	O
weeks	O
","	O
rats	O
in	O
both	O
the	O
HFD	O
and	O
Acipimox	B-Chemical
groups	O
exhibited	O
higher	O
visceral	O
fat	O
mass	O
and	O
a	O
higher	O
visceral	O
fat	O
/	O
weight	O
ratio	O
than	O
did	O
the	O
age	O
-	O
matched	O
control	O
group	O
","	O
although	O
no	O
statistically	O
significant	O
differences	O
were	O
observed	O
in	O
body	O
weight	O
among	O
the	O
three	O
groups	O
.	O
This	O
phenomenon	O
was	O
more	O
significant	O
at	O
the	O
end	O
of	O
16	O
and	O
24	O
weeks	O
","	O
when	O
body	O
weight	O
","	O
visceral	O
fat	O
mass	O
","	O
and	O
the	O
visceral	O
fat	O
/	O
weight	O
ratio	O
in	O
both	O
the	O
HFD	O
and	O
Acipimox	B-Chemical
groups	O
were	O
all	O
markedly	O
increased	O
compared	O
with	O
the	O
corresponding	O
values	O
in	O
the	O
Control	O
group	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
The	O
liver	O
/	O
body	O
weight	O
ratio	O
in	O
the	O
Control	O
group	O
did	O
not	O
change	O
with	O
time	O
","	O
whereas	O
it	O
was	O
much	O
higher	O
in	O
the	O
HFD	O
and	O
Acipimox	B-Chemical
groups	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
At	O
24	O
weeks	O
","	O
rats	O
in	O
the	O
Acipimox	B-Chemical
group	O
exhibited	O
lower	O
visceral	O
fat	O
mass	O
and	O
a	O
lower	O
visceral	O
fat	O
/	O
weight	O
ratio	O
than	O
did	O
the	O
rats	O
in	O
the	O
age	O
-	O
matched	O
HFD	O
group	O
","	O
and	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
HFD	O
and	O
Acipimox	B-Chemical
groups	O
with	O
respect	O
to	O
body	O
weight	O
or	O
the	O
liver	O
/	O
body	O
weight	O
ratio	O
during	O
the	O
study	O
period	O
(	O
p	O
>	O
0	O
.	O
5	O
).	O
Serum	O
biochemical	O
analysis	O
Values	O
of	O
serum	O
TC	B-Chemical
","	O
TG	B-Chemical
","	O
and	O
FFAs	B-Chemical
in	O
the	O
studied	O
groups	O
As	O
shown	O
in	O
Table	O
3	O
","	O
rats	O
fed	O
an	O
HFD	O
displayed	O
higher	O
circulating	O
levels	O
of	O
TGs	B-Chemical
","	O
TC	B-Chemical
","	O
and	O
FFAs	B-Chemical
than	O
did	O
the	O
Control	O
group	O
rats	O
.	O
After	O
8	O
weeks	O
","	O
the	O
serum	O
TG	B-Chemical
levels	O
in	O
the	O
HFD	O
group	O
increased	O
approximately	O
3	O
.	O
4	O
-	O
fold	O
compared	O
to	O
the	O
Control	O
group	O
","	O
whereas	O
the	O
FFA	B-Chemical
concentration	O
only	O
increased	O
by	O
48	O
%	O
in	O
the	O
HFD	O
group	O
;	O
no	O
significant	O
difference	O
was	O
observed	O
between	O
the	O
HFD	O
and	O
Control	O
groups	O
with	O
respect	O
to	O
circulating	O
TC	B-Chemical
levels	O
.	O
By	O
24	O
weeks	O
","	O
the	O
HFD	O
group	O
showed	O
a	O
2	O
.	O
2	O
-	O
fold	O
increase	O
in	O
serum	O
TG	B-Chemical
levels	O
and	O
a	O
56	O
%	O
increase	O
in	O
serum	O
TC	B-Chemical
levels	O
","	O
and	O
the	O
serum	O
FFA	B-Chemical
concentration	O
of	O
the	O
HFD	O
group	O
had	O
increased	O
to	O
2	O
.	O
7	O
-	O
fold	O
that	O
of	O
the	O
Control	O
group	O
.	O
Acipimox	B-Chemical
treatment	O
decreased	O
the	O
concentrations	O
of	O
TC	B-Chemical
","	O
TG	B-Chemical
and	O
FFAs	B-Chemical
compared	O
to	O
the	O
HFD	O
rats	O
by	O
16	O
and	O
24	O
weeks	O
(	O
p	O
<	O
0	O
.	O
5	O
"),"	O
and	O
no	O
significant	O
differences	O
were	O
observed	O
between	O
the	O
Acipimox	B-Chemical
and	O
Control	O
groups	O
at	O
any	O
time	O
point	O
(	O
p	O
>	O
0	O
.	O
5	O
)	O
regarding	O
the	O
circulating	O
lipid	B-Chemical
profile	O
.	O
The	O
serum	O
ALT	O
levels	O
in	O
the	O
Control	O
group	O
remained	O
stable	O
during	O
the	O
study	O
period	O
(	O
142	O
Â±	O
2	O
.	O
3	O
","	O
146	O
Â±	O
4	O
.	O
4	O
","	O
and	O
144	O
Â±	O
3	O
.	O
4	O
IU	O
/	O
L	O
at	O
8	O
","	O
16	O
and	O
24	O
weeks	O
","	O
respectively	O
).	O
The	O
ALT	O
level	O
was	O
141	O
Â±	O
3	O
.	O
7	O
IU	O
/	O
L	O
in	O
the	O
HFD	O
group	O
at	O
8	O
weeks	O
and	O
increased	O
progressively	O
over	O
time	O
.	O
By	O
16	O
and	O
24	O
weeks	O
","	O
the	O
circulating	O
ALT	O
levels	O
in	O
the	O
HFD	O
group	O
reached	O
155	O
Â±	O
5	O
and	O
170	O
Â±	O
4	O
.	O
0	O
IU	O
/	O
L	O
","	O
respectively	O
.	O
Compared	O
to	O
the	O
Control	O
group	O
","	O
HFD	O
treatment	O
caused	O
an	O
18	O
%	O
increase	O
in	O
the	O
serum	O
ALT	O
level	O
at	O
the	O
end	O
of	O
24	O
weeks	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
The	O
serum	O
ALT	O
levels	O
in	O
the	O
Acipimox	B-Chemical
group	O
were	O
142	O
Â±	O
2	O
.	O
6	O
","	O
154	O
Â±	O
4	O
.	O
4	O
","	O
and	O
150	O
Â±	O
2	O
.	O
7	O
IU	O
/	O
L	O
by	O
8	O
","	O
16	O
and	O
24	O
weeks	O
","	O
respectively	O
","	O
and	O
these	O
findings	O
were	O
consistent	O
with	O
the	O
levels	O
observed	O
in	O
the	O
Control	O
group	O
(	O
p	O
>	O
0	O
.	O
5	O
).	O
Hepatic	O
TG	B-Chemical
and	O
FFA	B-Chemical
contents	O
Time	O
-	O
dependent	O
changes	O
of	O
liver	O
TGs	B-Chemical
(	O
a	O
)	O
and	O
FFAs	B-Chemical
(	O
b	O
).	O
Data	O
are	O
shown	O
as	O
means	O
Â±	O
SEM	O
;	O
*	O
p	O
<	O
0	O
.	O
5	O
versus	O
the	O
corresponding	O
Control	O
group	O
;	O
**	O
p	O
<	O
0	O
.	O
1	O
versus	O
the	O
corresponding	O
Control	O
group	O
;	O
##	O
p	O
<	O
0	O
.	O
1	O
versus	O
the	O
corresponding	O
Acipimox	B-Chemical
group	O
;	O
HFD	O
:	O
high	O
-	O
fat	B-Chemical
diet	O
group	O
;	O
TGs	B-Chemical
:	O
triglycerides	B-Chemical
;	O
FFAs	B-Chemical
:	O
free	B-Chemical
fatty	I-Chemical
acids	I-Chemical
Both	O
the	O
HFD	O
and	O
Acipimox	B-Chemical
groups	O
exhibited	O
significantly	O
higher	O
liver	O
TG	B-Chemical
levels	O
than	O
did	O
the	O
Control	O
group	O
.	O
By	O
8	O
","	O
16	O
and	O
24	O
weeks	O
","	O
the	O
hepatic	O
TG	B-Chemical
levels	O
were	O
4	O
.	O
3	O
4	O
.	O
5	O
-	O
and	O
2	O
.	O
4	O
-	O
fold	O
higher	O
in	O
the	O
HFD	O
group	O
than	O
in	O
the	O
Control	O
group	O
.	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
liver	O
TG	B-Chemical
level	O
between	O
the	O
Acipimox	B-Chemical
and	O
HFD	O
groups	O
during	O
the	O
study	O
period	O
.	O
The	O
HFD	O
treatment	O
progressively	O
increased	O
the	O
concentrations	O
of	O
hepatic	O
FFAs	B-Chemical
over	O
time	O
.	O
The	O
liver	O
FFA	B-Chemical
level	O
in	O
the	O
HFD	O
group	O
increased	O
by	O
38	O
%	O
at	O
16	O
weeks	O
and	O
by	O
57	O
%	O
at	O
24	O
weeks	O
relative	O
to	O
the	O
level	O
in	O
the	O
Control	O
group	O
.	O
Acipimox	B-Chemical
can	O
effectively	O
reduce	O
the	O
hepatic	O
FFA	B-Chemical
content	O
","	O
and	O
no	O
difference	O
in	O
liver	O
FFA	B-Chemical
level	O
was	O
detected	O
between	O
the	O
Acipimox	B-Chemical
and	O
Control	O
groups	O
at	O
8	O
and	O
16	O
weeks	O
.	O
By	O
24	O
weeks	O
","	O
the	O
Acipimox	B-Chemical
group	O
showed	O
a	O
slightly	O
higher	O
hepatic	O
FFA	B-Chemical
content	O
than	O
did	O
the	O
Control	O
group	O
","	O
but	O
this	O
difference	O
did	O
not	O
reach	O
statistical	O
significance	O
","	O
and	O
the	O
hepatic	O
FFA	B-Chemical
level	O
in	O
the	O
Acipimox	B-Chemical
group	O
was	O
still	O
significantly	O
lower	O
than	O
that	O
of	O
the	O
HFD	O
group	O
(	O
Fig	O
.	O
1	O
).	O
Changes	O
in	O
MDA	B-Chemical
and	O
GSH	O
-	O
Px	O
concentrations	O
in	O
the	O
liver	O
Values	O
of	O
hepatic	O
MDA	B-Chemical
and	O
GSH	O
-	O
Px	O
in	O
the	O
studied	O
groups	O
As	O
shown	O
in	O
Table	O
4	O
","	O
the	O
concentration	O
of	O
hepatic	O
MDA	B-Chemical
progressively	O
increased	O
in	O
the	O
HFD	O
group	O
over	O
the	O
24	O
weeks	O
.	O
By	O
16	O
and	O
24	O
weeks	O
","	O
the	O
liver	O
MDA	B-Chemical
levels	O
were	O
2	O
.	O
5	O
-	O
and	O
3	O
-	O
fold	O
higher	O
in	O
the	O
HFD	O
group	O
than	O
in	O
the	O
Control	O
group	O
.	O
Acipimox	B-Chemical
treatment	O
markedly	O
decreased	O
the	O
liver	O
MDA	B-Chemical
levels	O
compared	O
with	O
the	O
HFD	O
group	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
After	O
16	O
weeks	O
","	O
the	O
Acipimox	B-Chemical
group	O
exhibited	O
higher	O
liver	O
MDA	B-Chemical
levels	O
than	O
did	O
the	O
Control	O
group	O
","	O
and	O
no	O
difference	O
was	O
observed	O
between	O
the	O
Acipimox	B-Chemical
and	O
Control	O
groups	O
regarding	O
the	O
hepatic	O
MDA	B-Chemical
levels	O
at	O
8	O
and	O
24	O
weeks	O
.	O
Rats	O
in	O
the	O
HFD	O
and	O
Acipimox	B-Chemical
groups	O
all	O
displayed	O
lower	O
liver	O
GSH	O
-	O
Px	O
activity	O
than	O
did	O
the	O
Control	O
group	O
at	O
8	O
and	O
16	O
weeks	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
After	O
24	O
weeks	O
","	O
no	O
significant	O
difference	O
in	O
hepatic	O
GSH	O
-	O
Px	O
activity	O
was	O
detected	O
among	O
the	O
three	O
groups	O
.	O
Changes	O
in	O
the	O
TG	B-Chemical
synthesis	O
and	O
FFA	B-Chemical
oxidation	O
rate	O
-	O
limiting	O
enzymes	O
in	O
the	O
liver	O
Hepatic	O
protein	O
expression	O
levels	O
of	O
DGAT2	O
(	O
a	O
)	O
and	O
CPT	O
-	O
1a	O
(	O
b	O
)	O
in	O
the	O
studied	O
groups	O
.	O
Left	O
","	O
protein	O
level	O
of	O
DGAT2	O
","	O
CPT	O
-	O
1a	O
and	O
Î²	O
-	O
actin	O
in	O
rats	O
liver	O
treated	O
as	O
indicated	O
.	O
Right	O
","	O
densitometry	O
quantification	O
of	O
DGAT2	O
and	O
CPT	O
-	O
1a	O
protein	O
expression	O
levels	O
normalized	O
to	O
Î²	O
-	O
actin	O
.	O
Experiments	O
were	O
repeated	O
three	O
times	O
.	O
Data	O
are	O
shown	O
as	O
means	O
Â±	O
SEM	O
(	O
n	O
=	O
5	O
-	O
7	O
).	O
*	O
p	O
<	O
0	O
.	O
5	O
versus	O
the	O
corresponding	O
Control	O
group	O
;	O
**	O
p	O
<	O
0	O
.	O
1	O
versus	O
the	O
corresponding	O
Control	O
group	O
;	O
#	O
p	O
<	O
0	O
.	O
5	O
versus	O
the	O
corresponding	O
Acipimox	B-Chemical
group	O
;	O
HFD	O
:	O
high	O
-	O
fat	B-Chemical
diet	O
group	O
;	O
DGAT2	O
:	O
diacylglycerol	O
acyltransferase	O
2	O
;	O
CPT	O
-	O
1a	O
:	O
carnitine	O
palmitoyltransferase	O
1a	O
To	O
understand	O
the	O
potential	O
in	O
vivo	O
mechanisms	O
that	O
induced	O
the	O
changes	O
in	O
liver	O
TG	B-Chemical
and	O
FFA	B-Chemical
levels	O
","	O
we	O
measured	O
the	O
hepatic	O
protein	O
expression	O
levels	O
of	O
DGAT2	O
","	O
a	O
TG	B-Chemical
synthesis	O
rate	O
-	O
limiting	O
enzyme	O
","	O
and	O
the	O
FFA	B-Chemical
oxidation	O
-	O
related	O
enzyme	O
CPT	O
-	O
1a	O
.	O
The	O
HFD	O
and	O
Acipimox	B-Chemical
groups	O
exhibited	O
pronounced	O
increases	O
in	O
DGAT2	O
protein	O
level	O
compared	O
with	O
the	O
Control	O
group	O
.	O
At	O
the	O
end	O
of	O
16	O
and	O
24	O
weeks	O
","	O
the	O
DGAT2	O
protein	O
expression	O
level	O
had	O
increased	O
by	O
61	O
%	O
and	O
39	O
%	O
(	O
HFD	O
group	O
)	O
and	O
by	O
48	O
%	O
and	O
58	O
%	O
(	O
Acipimox	B-Chemical
group	O
"),"	O
respectively	O
.	O
No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
DGAT2	O
protein	O
level	O
between	O
the	O
HFD	O
and	O
Acipimox	B-Chemical
groups	O
at	O
any	O
time	O
point	O
.	O
The	O
protein	O
expression	O
level	O
of	O
CPT	O
-	O
1a	O
was	O
markedly	O
reduced	O
in	O
the	O
HFD	O
group	O
compared	O
with	O
the	O
Control	O
group	O
at	O
24	O
weeks	O
","	O
although	O
it	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
at	O
8	O
and	O
16	O
weeks	O
.	O
The	O
hepatic	O
CPT	O
-	O
1a	O
concentration	O
can	O
be	O
effectively	O
maintained	O
by	O
acipimox	B-Chemical
feeding	O
and	O
was	O
similar	O
between	O
the	O
Acipimox	B-Chemical
and	O
Control	O
groups	O
(	O
Fig	O
.	O
2	O
).	O
Hepatic	O
histological	O
changes	O
Liver	O
sections	O
stained	O
with	O
haematoxylin	B-Chemical
and	O
eosin	B-Chemical
from	O
rats	O
fed	O
with	O
regular	O
chow	O
for	O
8	O
weeks	O
(	O
a	O
"),"	O
16	O
weeks	O
(	O
d	O
"),"	O
or	O
24	O
weeks	O
(	O
g	O
);	O
from	O
rats	O
fed	O
an	O
HFD	O
for	O
8	O
weeks	O
(	O
b	O
"),"	O
16	O
weeks	O
(	O
e	O
"),"	O
or	O
24	O
weeks	O
(	O
h	O
);	O
or	O
from	O
rats	O
fed	O
an	O
HFD	O
+	O
acipimox	B-Chemical
for	O
8	O
weeks	O
(	O
c	O
"),"	O
16	O
weeks	O
(	O
f	O
"),"	O
or	O
24	O
weeks	O
(	O
i	O
).	O
Original	O
magnification	O
","	O
200	O
"Ã—,"	O
and	O
the	O
length	O
of	O
the	O
calibration	O
bar	O
is	O
50	O
um	O
.	O
HFD	O
:	O
high	O
-	O
fat	B-Chemical
diet	O
Representative	O
histological	O
images	O
of	O
H	B-Chemical
&	I-Chemical
E	I-Chemical
-	O
stained	O
liver	O
sections	O
are	O
shown	O
in	O
Fig	O
.	O
3	O
.	O
The	O
HFD	O
successfully	O
induced	O
hepatic	O
steatosis	O
","	O
and	O
HFD	O
-	O
fed	O
rats	O
displayed	O
prominent	O
hepatic	O
steatosis	O
(	O
steatosis	O
score	O
:	O
2	O
.	O
25	O
Â±	O
0	O
.	O
2	O
)	O
at	O
the	O
end	O
of	O
8	O
weeks	O
.	O
At	O
24	O
weeks	O
","	O
the	O
liver	O
steatosis	O
score	O
was	O
2	O
.	O
6	O
Â±	O
0	O
.	O
2	O
and	O
was	O
accompanied	O
by	O
ballooned	O
hepatocytes	O
and	O
mild	O
to	O
moderate	O
inflammatory	O
cell	O
infiltration	O
.	O
In	O
the	O
HFD	O
group	O
","	O
the	O
NAFLD	O
activity	O
score	O
(	O
NAS	O
"),"	O
a	O
score	O
that	O
reflects	O
the	O
pathological	O
severity	O
of	O
the	O
liver	O
","	O
gradually	O
increased	O
from	O
2	O
.	O
3	O
Â±	O
0	O
.	O
2	O
at	O
8	O
weeks	O
to	O
3	O
.	O
5	O
Â±	O
0	O
.	O
2	O
at	O
24	O
weeks	O
(	O
p	O
<	O
0	O
.	O
5	O
).	O
The	O
Acipimox	B-Chemical
-	O
treated	O
rats	O
demonstrated	O
HFD	O
-	O
induced	O
hepatic	O
steatosis	O
(	O
steatosis	O
score	O
:	O
2	O
.	O
1	O
Â±	O
0	O
.	O
1	O
at	O
8	O
weeks	O
and	O
2	O
.	O
4	O
Â±	O
0	O
.	O
2	O
at	O
24	O
weeks	O
"),"	O
but	O
ballooned	O
hepatocytes	O
were	O
not	O
observed	O
in	O
liver	O
sections	O
","	O
and	O
inflammation	O
was	O
less	O
severe	O
and	O
less	O
prevalent	O
than	O
that	O
observed	O
in	O
the	O
HFD	O
group	O
at	O
24	O
weeks	O
(	O
NAS	O
:	O
2	O
.	O
6	O
Â±	O
0	O
.	O
3	O
;	O
p	O
<	O
0	O
.	O
5	O
versus	O
HFD	O
group	O
).	O
No	O
rats	O
in	O
any	O
treatment	O
showed	O
centrilobular	O
or	O
perisinusoidal	O
fibrosis	O
with	O
Masson	B-Chemical
â€™	I-Chemical
s	I-Chemical
trichrome	I-Chemical
stain	O
","	O
and	O
the	O
liver	O
sections	O
of	O
the	O
Control	O
group	O
did	O
not	O
display	O
any	O
histological	O
abnormalities	O
.	O
Discussion	O
At	O
present	O
","	O
numerous	O
dietary	O
and	O
/	O
or	O
genetic	O
methods	O
can	O
be	O
used	O
to	O
induce	O
animal	O
models	O
","	O
which	O
can	O
simulate	O
the	O
human	O
condition	O
of	O
NAFLD	O
in	O
many	O
aspects	O
[	O
13	O
].	O
An	O
HFD	O
is	O
one	O
of	O
these	O
methods	O
.	O
In	O
addition	O
to	O
hepatic	O
steatosis	O
","	O
an	O
HFD	O
can	O
often	O
induce	O
insulin	O
resistance	O
","	O
lipid	B-Chemical
metabolism	O
disorders	O
","	O
and	O
other	O
metabolic	O
syndrome	O
components	O
with	O
pathophysiology	O
that	O
is	O
more	O
similar	O
to	O
that	O
observed	O
in	O
human	O
NAFLD	O
than	O
that	O
generated	O
by	O
other	O
animal	O
models	O
of	O
NAFLD	O
[	O
13	O
","	O
14	O
].	O
In	O
this	O
study	O
","	O
we	O
fed	O
eight	O
-	O
week	O
-	O
old	O
male	O
Wistar	O
rats	O
high	O
-	O
fat	B-Chemical
chow	O
","	O
and	O
after	O
8	O
to	O
24	O
weeks	O
of	O
dietary	O
treatment	O
","	O
the	O
rats	O
in	O
the	O
HFD	O
group	O
exhibited	O
increased	O
body	O
weight	O
","	O
visceral	O
fat	O
mass	O
","	O
visceral	O
fat	O
/	O
body	O
weight	O
ratio	O
and	O
liver	O
/	O
body	O
weight	O
ratio	O
when	O
compared	O
with	O
the	O
levels	O
in	O
the	O
age	O
-	O
matched	O
control	O
rats	O
.	O
HFD	O
treatment	O
also	O
caused	O
significant	O
increments	O
in	O
the	O
serum	O
TC	B-Chemical
","	O
TG	B-Chemical
level	O
","	O
elevated	O
hepatic	O
TG	B-Chemical
content	O
and	O
marked	O
lipid	B-Chemical
droplet	O
deposition	O
in	O
the	O
liver	O
sections	O
","	O
suggesting	O
that	O
the	O
model	O
of	O
obesity	O
accompanied	O
by	O
NAFLD	O
was	O
successfully	O
induced	O
in	O
this	O
study	O
.	O
It	O
is	O
interesting	O
to	O
note	O
that	O
after	O
8	O
weeks	O
of	O
dietary	O
treatment	O
","	O
the	O
HFD	O
group	O
exhibited	O
a	O
3	O
.	O
4	O
-	O
fold	O
increase	O
in	O
serum	O
TG	B-Chemical
level	O
and	O
a	O
4	O
.	O
3	O
-	O
fold	O
increase	O
in	O
hepatic	O
TG	B-Chemical
content	O
compared	O
with	O
the	O
levels	O
in	O
control	O
rats	O
.	O
However	O
","	O
the	O
increase	O
in	O
serum	O
FFAs	B-Chemical
was	O
only	O
48	O
"%,"	O
and	O
no	O
significant	O
change	O
in	O
hepatic	O
FFA	B-Chemical
content	O
was	O
observed	O
in	O
HFD	O
-	O
fed	O
rats	O
compared	O
with	O
normal	O
chow	O
-	O
fed	O
rats	O
.	O
These	O
findings	O
suggest	O
that	O
for	O
the	O
first	O
8	O
weeks	O
of	O
the	O
HFD	O
","	O
circulating	O
FFAs	B-Chemical
were	O
normally	O
converted	O
to	O
TGs	B-Chemical
in	O
the	O
liver	O
and	O
were	O
stored	O
in	O
adipose	O
tissue	O
","	O
the	O
liver	O
","	O
and	O
other	O
tissues	O
","	O
resulting	O
in	O
increases	O
in	O
body	O
weight	O
and	O
fat	O
mass	O
.	O
At	O
this	O
time	O
","	O
the	O
liver	O
enzyme	O
levels	O
were	O
normal	O
","	O
although	O
the	O
liver	O
/	O
body	O
weight	O
ratio	O
was	O
increased	O
and	O
the	O
liver	O
tissue	O
sections	O
indicated	O
microvesicular	O
steatosis	O
","	O
which	O
are	O
consistent	O
with	O
signs	O
of	O
fatty	O
liver	O
.	O
As	O
the	O
HFD	O
treatment	O
progressed	O
","	O
this	O
trend	O
was	O
reversed	O
.	O
By	O
24	O
weeks	O
","	O
the	O
increase	O
in	O
serum	O
TG	B-Chemical
level	O
in	O
the	O
HFD	O
group	O
was	O
only	O
2	O
.	O
2	O
-	O
fold	O
that	O
of	O
normal	O
rats	O
","	O
whereas	O
the	O
hepatic	O
TG	B-Chemical
content	O
was	O
only	O
increased	O
2	O
.	O
4	O
-	O
fold	O
compared	O
with	O
normal	O
rats	O
.	O
However	O
","	O
the	O
serum	O
FFA	B-Chemical
levels	O
were	O
2	O
.	O
7	O
times	O
higher	O
and	O
the	O
liver	O
FFA	B-Chemical
content	O
increased	O
by	O
57	O
%	O
in	O
HFD	O
-	O
fed	O
rats	O
compared	O
with	O
the	O
Control	O
group	O
.	O
We	O
propose	O
that	O
the	O
main	O
mechanism	O
for	O
these	O
changes	O
at	O
24	O
weeks	O
might	O
be	O
due	O
to	O
an	O
impaired	O
ability	O
of	O
the	O
liver	O
to	O
synthesize	O
TGs	B-Chemical
","	O
resulting	O
in	O
significantly	O
elevated	O
serum	O
and	O
hepatic	O
FFAs	B-Chemical
levels	O
.	O
In	O
addition	O
","	O
at	O
this	O
time	O
point	O
","	O
the	O
serum	O
ALT	O
levels	O
in	O
the	O
HFD	O
group	O
were	O
elevated	O
","	O
and	O
the	O
NAS	O
was	O
3	O
.	O
5	O
Â±	O
0	O
.	O
2	O
","	O
which	O
suggest	O
the	O
possibility	O
of	O
steatohepatitis	O
.	O
Several	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
have	O
indicated	O
that	O
hepatic	O
TG	B-Chemical
deposition	O
may	O
not	O
be	O
harmful	O
;	O
rather	O
","	O
it	O
may	O
represent	O
a	O
protective	O
mechanism	O
against	O
FFA	B-Chemical
-	O
induced	O
lipotoxic	O
liver	O
injury	O
by	O
storing	O
FFAs	B-Chemical
in	O
the	O
form	O
of	O
TGs	B-Chemical
[	O
6	O
","	O
7	O
","	O
15	O
].	O
To	O
further	O
study	O
the	O
role	O
of	O
an	O
elevated	O
serum	O
FFA	B-Chemical
level	O
on	O
NASH	O
","	O
we	O
treated	O
the	O
HFD	O
-	O
fed	O
rats	O
with	O
acipimox	B-Chemical
to	O
reduce	O
plasma	O
FFA	B-Chemical
levels	O
by	O
inhibiting	O
lipolysis	O
.	O
These	O
results	O
showed	O
that	O
the	O
serum	O
FFA	B-Chemical
and	O
TG	B-Chemical
concentrations	O
in	O
the	O
Acipimox	B-Chemical
group	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
the	O
HFD	O
group	O
.	O
Although	O
the	O
Acipimox	B-Chemical
group	O
did	O
not	O
significantly	O
differ	O
from	O
the	O
HFD	O
group	O
in	O
liver	O
TG	B-Chemical
content	O
","	O
the	O
content	O
of	O
hepatic	O
FFAs	B-Chemical
in	O
the	O
Acipimox	B-Chemical
group	O
was	O
consistent	O
with	O
that	O
of	O
the	O
Control	O
group	O
.	O
Despite	O
the	O
increase	O
in	O
the	O
liver	O
/	O
body	O
weight	O
ratio	O
","	O
the	O
Acipimox	B-Chemical
group	O
did	O
not	O
show	O
any	O
obvious	O
changes	O
in	O
serum	O
ALT	O
levels	O
","	O
and	O
the	O
NAS	O
in	O
the	O
Acipimox	B-Chemical
group	O
was	O
also	O
lower	O
than	O
that	O
of	O
the	O
HFD	O
group	O
","	O
indicating	O
that	O
acipimox	B-Chemical
treatment	O
reduced	O
liver	O
damage	O
in	O
HFD	O
-	O
fed	O
rats	O
.	O
These	O
findings	O
suggest	O
that	O
increased	O
serum	O
and	O
liver	O
FFAs	B-Chemical
concentrations	O
rather	O
than	O
TGs	B-Chemical
may	O
be	O
a	O
key	O
link	O
between	O
obesity	O
and	O
the	O
development	O
of	O
NAFLD	O
.	O
An	O
elevated	O
circulating	O
FFA	B-Chemical
level	O
is	O
one	O
of	O
the	O
clinical	O
characteristics	O
of	O
subjects	O
with	O
obesity	O
/	O
metabolic	O
syndrome	O
.	O
Under	O
conditions	O
of	O
insulin	O
resistance	O
","	O
defects	O
in	O
the	O
Î²	O
-	O
oxidation	O
of	O
FFAs	B-Chemical
are	O
observed	O
.	O
Elevated	O
FFA	B-Chemical
levels	O
in	O
the	O
liver	O
can	O
cause	O
hepatocyte	O
injury	O
via	O
the	O
formation	O
of	O
various	O
toxic	O
metabolites	O
","	O
such	O
as	O
ceramides	B-Chemical
","	O
diacylglycerols	B-Chemical
","	O
and	O
lysophosphatidylcholine	B-Chemical
[	O
16	O
].	O
These	O
metabolites	O
can	O
result	O
in	O
mitochondria	O
dysfunction	O
via	O
multiple	O
methods	O
","	O
such	O
as	O
inhibiting	O
the	O
mitochondrial	O
oxidative	O
respiratory	O
chain	O
[	O
17	O
"],"	O
activating	O
NADPH	O
oxidase	O
","	O
or	O
depolarising	O
the	O
mitochondrial	O
membrane	O
[	O
18	O
","	O
19	O
"],"	O
which	O
can	O
result	O
in	O
increased	O
ROS	B-Chemical
production	O
","	O
thereby	O
enhancing	O
oxidative	O
stress	O
-	O
induced	O
liver	O
injury	O
.	O
It	O
has	O
been	O
shown	O
that	O
MDA	B-Chemical
","	O
an	O
index	O
of	O
oxidative	O
stress	O
","	O
can	O
damage	O
cells	O
and	O
tissues	O
","	O
whereas	O
GSH	O
-	O
Px	O
","	O
one	O
of	O
the	O
body	O
â€™	O
s	O
endogenous	O
antioxidants	O
","	O
can	O
protect	O
hepatocytes	O
against	O
oxidative	O
damage	O
via	O
chemical	O
or	O
enzymatic	O
reactions	O
.	O
In	O
our	O
study	O
","	O
hepatic	O
MDA	B-Chemical
levels	O
were	O
obviously	O
elevated	O
and	O
progressively	O
increased	O
in	O
the	O
HFD	O
group	O
over	O
24	O
weeks	O
compared	O
with	O
the	O
Control	O
group	O
.	O
Furthermore	O
","	O
the	O
decrease	O
in	O
hepatic	O
GSH	O
-	O
Px	O
activity	O
occurred	O
at	O
8	O
weeks	O
in	O
the	O
HFD	O
group	O
.	O
The	O
hepatic	O
MDA	B-Chemical
level	O
in	O
the	O
Acipimox	B-Chemical
group	O
was	O
similar	O
to	O
that	O
of	O
the	O
control	O
group	O
and	O
was	O
markedly	O
lower	O
than	O
that	O
of	O
the	O
corresponding	O
HFD	O
group	O
.	O
Taken	O
together	O
","	O
these	O
findings	O
suggest	O
that	O
a	O
high	O
serum	O
FFA	B-Chemical
level	O
may	O
induce	O
steatohepatitis	O
by	O
enhancing	O
oxidative	O
stress	O
.	O
When	O
the	O
level	O
of	O
FFAs	B-Chemical
is	O
lowered	O
with	O
acipimox	B-Chemical
","	O
hepatic	O
oxidative	O
stress	O
levels	O
decrease	O
","	O
thereby	O
reducing	O
liver	O
damage	O
and	O
delaying	O
the	O
occurrence	O
of	O
NASH	O
.	O
In	O
the	O
NAFLD	O
state	O
","	O
the	O
synthesis	O
of	O
hepatic	O
TGs	B-Chemical
was	O
increased	O
.	O
Although	O
the	O
classic	O
â€œ	O
two	O
hit	O
â€	O
theory	O
considers	O
hepatic	O
TG	B-Chemical
deposition	O
to	O
be	O
a	O
prerequisite	O
for	O
the	O
development	O
of	O
NASH	O
","	O
emerging	O
studies	O
have	O
suggested	O
that	O
TG	B-Chemical
accumulation	O
may	O
only	O
be	O
an	O
â€œ	O
innocent	O
bystander	O
â€	O
or	O
even	O
a	O
protective	O
mechanism	O
in	O
the	O
progression	O
of	O
NAFLD	O
to	O
NASH	O
[	O
7	O
","	O
20	O
].	O
In	O
our	O
study	O
","	O
the	O
serum	O
and	O
liver	O
FFA	B-Chemical
levels	O
progressively	O
increased	O
in	O
the	O
HFD	O
group	O
over	O
24	O
weeks	O
","	O
but	O
TG	B-Chemical
accumulation	O
in	O
the	O
HFD	O
group	O
markedly	O
decreased	O
from	O
4	O
.	O
3	O
-	O
fold	O
at	O
8	O
weeks	O
to	O
2	O
.	O
4	O
-	O
fold	O
at	O
24	O
weeks	O
compared	O
with	O
the	O
Control	O
group	O
","	O
indicating	O
that	O
the	O
ability	O
of	O
the	O
liver	O
to	O
synthesize	O
TGs	B-Chemical
is	O
impaired	O
with	O
progression	O
of	O
the	O
disease	O
.	O
To	O
further	O
explore	O
the	O
potential	O
mechanism	O
that	O
induces	O
the	O
change	O
in	O
liver	O
TG	B-Chemical
content	O
","	O
we	O
measured	O
the	O
hepatic	O
protein	O
expression	O
levels	O
of	O
the	O
TG	B-Chemical
synthesis	O
-	O
related	O
enzyme	O
DGAT2	O
.	O
DGAT2	O
is	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
TG	B-Chemical
synthesis	O
and	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
fatty	O
liver	O
diseases	O
[	O
21	O
].	O
Previous	O
studies	O
have	O
shown	O
that	O
the	O
levels	O
of	O
DGAT2	O
mRNA	O
/	O
protein	O
are	O
elevated	O
in	O
the	O
NAFLD	O
state	O
[	O
22	O
","	O
23	O
].	O
The	O
results	O
of	O
the	O
present	O
study	O
are	O
consistent	O
with	O
those	O
of	O
previous	O
studies	O
.	O
Compared	O
with	O
the	O
Control	O
group	O
","	O
the	O
HFD	O
group	O
exhibited	O
a	O
pronounced	O
increase	O
in	O
DGAT2	O
protein	O
level	O
.	O
Regarding	O
the	O
HFD	O
group	O
","	O
no	O
significant	O
change	O
in	O
the	O
expression	O
of	O
DGAT2	O
protein	O
was	O
observed	O
during	O
the	O
course	O
of	O
the	O
disease	O
","	O
and	O
thus	O
we	O
speculate	O
that	O
an	O
impairment	O
of	O
TG	B-Chemical
synthesis	O
due	O
to	O
a	O
decrease	O
in	O
DGAT2	O
protein	O
expression	O
was	O
unlikely	O
.	O
It	O
is	O
well	O
known	O
that	O
CPT	O
-	O
1a	O
is	O
a	O
gated	O
enzyme	O
that	O
regulates	O
mitochondrial	O
Î²	O
-	O
oxidation	O
in	O
the	O
liver	O
.	O
Previous	O
studies	O
have	O
revealed	O
conflicting	O
results	O
regarding	O
the	O
change	O
in	O
CPT	O
-	O
1a	O
in	O
NAFLD	O
[	O
24	O
","	O
25	O
].	O
The	O
present	O
study	O
indicated	O
that	O
CPT	O
-	O
1a	O
expression	O
was	O
similar	O
between	O
the	O
HFD	O
and	O
Control	O
groups	O
at	O
8	O
weeks	O
.	O
By	O
24	O
weeks	O
","	O
CPT	O
-	O
1a	O
expression	O
was	O
markedly	O
decreased	O
in	O
HFD	O
-	O
fed	O
rats	O
.	O
After	O
treatment	O
with	O
acipimox	B-Chemical
","	O
the	O
level	O
of	O
CPT	O
-	O
1a	O
protein	O
expression	O
was	O
similar	O
to	O
that	O
of	O
the	O
Control	O
group	O
","	O
suggesting	O
that	O
during	O
the	O
progression	O
of	O
the	O
disease	O
","	O
the	O
oxidative	O
capacity	O
of	O
mitochondrial	O
fatty	B-Chemical
acids	I-Chemical
declines	O
and	O
that	O
lowering	O
hepatic	O
FFAs	B-Chemical
levels	O
may	O
maintain	O
the	O
function	O
of	O
mitochondrial	O
lipid	B-Chemical
oxidation	O
","	O
thus	O
maintaining	O
the	O
balance	O
of	O
energy	O
metabolism	O
.	O
We	O
speculate	O
that	O
the	O
decline	O
in	O
the	O
oxidative	O
capacity	O
of	O
mitochondrial	O
lipids	O
and	O
oxidative	O
stress	O
-	O
induced	O
mitochondrial	O
damage	O
could	O
jointly	O
cause	O
a	O
decrease	O
in	O
ATP	B-Chemical
synthesis	O
","	O
resulting	O
in	O
an	O
energy	O
deficit	O
in	O
TG	B-Chemical
synthesis	O
and	O
subsequently	O
impaired	O
TG	B-Chemical
synthesis	O
.	O
Finally	O
","	O
our	O
study	O
demonstrated	O
that	O
declining	O
elevated	O
serum	O
FFAs	B-Chemical
levels	O
were	O
beneficial	O
in	O
preventing	O
the	O
conversion	O
of	O
simple	O
steatosis	O
to	O
steatohepatitis	O
.	O
Nonpharmacologic	O
interventions	O
such	O
as	O
weight	O
loss	O
in	O
obese	O
patients	O
","	O
reduced	O
carbohydrate	B-Chemical
intake	O
","	O
especially	O
intake	O
of	O
high	O
glycemic	O
and	O
high	O
fructose	B-Chemical
foods	O
","	O
and	O
aerobic	O
exercise	O
should	O
be	O
first	O
-	O
line	O
choices	O
.	O
A	O
number	O
of	O
agents	O
","	O
such	O
as	O
fibrates	B-Chemical
and	O
nicotinic	B-Chemical
acid	I-Chemical
","	O
can	O
be	O
used	O
to	O
reduce	O
serum	O
FFAs	B-Chemical
levels	O
if	O
nonpharmacologic	O
interventions	O
fail	O
.	O
In	O
addition	O
","	O
nutraceuticals	O
and	O
functional	O
food	O
ingredients	O
(	O
such	O
as	O
fish	O
oil	O
and	O
soyabean	O
)	O
that	O
are	O
beneficial	O
to	O
the	O
lipid	B-Chemical
profile	O
may	O
reduce	O
the	O
risk	O
of	O
fatty	O
liver	O
by	O
acting	O
in	O
parallel	O
to	O
pharmacologic	O
therapy	O
","	O
as	O
adjuvants	O
in	O
case	O
of	O
failure	O
or	O
in	O
situations	O
where	O
pharmacologic	O
therapy	O
cannot	O
be	O
used	O
[	O
24	O
","	O
26	O
].	O
The	O
main	O
limitation	O
of	O
the	O
current	O
study	O
is	O
that	O
we	O
failed	O
to	O
induce	O
NASH	O
","	O
mainly	O
due	O
to	O
the	O
limitations	O
of	O
the	O
HFD	O
-	O
induced	O
NAFLD	O
model	O
[	O
13	O
].	O
Although	O
this	O
drawback	O
limits	O
the	O
extension	O
of	O
our	O
results	O
","	O
we	O
observed	O
that	O
the	O
degree	O
of	O
liver	O
damage	O
was	O
gradually	O
increased	O
as	O
the	O
HFD	O
feeding	O
period	O
progressed	O
via	O
changes	O
in	O
NAS	O
and	O
serum	O
ALT	O
levels	O
","	O
and	O
the	O
hepatic	O
FFA	B-Chemical
content	O
and	O
oxidative	O
stress	O
level	O
showed	O
pronounced	O
changes	O
.	O
Therefore	O
","	O
we	O
speculate	O
that	O
these	O
changes	O
should	O
be	O
more	O
pronounced	O
when	O
the	O
disease	O
progresses	O
to	O
NASH	O
.	O
Conclusions	O
This	O
study	O
indicated	O
that	O
during	O
the	O
development	O
of	O
NAFLD	O
","	O
FFA	B-Chemical
levels	O
increased	O
significantly	O
and	O
were	O
accompanied	O
by	O
an	O
increase	O
in	O
oxidative	O
stress	O
.	O
Then	O
a	O
reduction	O
in	O
FFA	B-Chemical
levels	O
was	O
observed	O
","	O
which	O
can	O
effectively	O
reduce	O
oxidative	O
stress	O
and	O
liver	O
injury	O
.	O
These	O
findings	O
suggest	O
that	O
although	O
liver	O
TG	B-Chemical
deposition	O
is	O
the	O
primary	O
characteristic	O
of	O
NAFLD	O
","	O
it	O
may	O
be	O
an	O
â€œ	O
innocent	O
bystander	O
â€	O
or	O
a	O
protective	O
mechanism	O
in	O
the	O
development	O
of	O
NAFLD	O
.	O
However	O
","	O
FFAs	B-Chemical
and	O
their	O
metabolites	O
are	O
likely	O
","	O
at	O
least	O
in	O
part	O
","	O
the	O
pivotal	O
factor	O
that	O
promotes	O
the	O
development	O
of	O
NAFLD	O
.	O
Future	O
studies	O
are	O
needed	O
to	O
obtain	O
definitive	O
results	O
regarding	O
this	O
issue	O
.	O
If	O
this	O
is	O
the	O
case	O
","	O
then	O
treatments	O
should	O
focus	O
on	O
how	O
to	O
effectively	O
reduce	O
the	O
lipotoxicity	O
of	O
FFAs	B-Chemical
rather	O
than	O
inhibiting	O
the	O
deposition	O
of	O
hepatic	O
TGs	B-Chemical
.	O
Consent	O
for	O
publication	O
Not	O
applicable	O
.	O
Open	O
access	O
This	O
article	O
is	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Attribution	O
4	O
.	O
0	O
International	O
License	O
(	O
http	O
://	O
creativecommons	O
.	O
org	O
/	O
licenses	O
/	O
by	O
/	O
4	O
.	O
0	O
"/),"	O
which	O
permits	O
unrestricted	O
use	O
","	O
distribution	O
","	O
and	O
reproduction	O
in	O
any	O
medium	O
","	O
provided	O
you	O
give	O
appropriate	O
credit	O
to	O
the	O
original	O
author	O
(	O
s	O
)	O
and	O
the	O
source	O
","	O
provide	O
a	O
link	O
to	O
the	O
Creative	O
Commons	O
license	O
","	O
and	O
indicate	O
if	O
changes	O
were	O
made	O
.	O
The	O
Creative	O
Commons	O
Public	O
Domain	O
Dedication	O
waiver	O
(	O
http	O
://	O
creativecommons	O
.	O
org	O
/	O
publicdomain	O
/	O
zero	O
/	O
1	O
.	O
0	O
/)	O
applies	O
to	O
the	O
data	O
made	O
available	O
in	O
this	O
article	O
","	O
unless	O
otherwise	O
stated	O
.	O
Abbreviations	O
NAFLD	O
Non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
NASH	O
Non	O
-	O
alcoholic	O
steatohepatitis	O
HFD	O
High	O
fat	B-Chemical
diet	O
TG	B-Chemical
Triglycerides	B-Chemical
FFAs	B-Chemical
Free	B-Chemical
fatty	I-Chemical
acids	I-Chemical
TC	B-Chemical
Total	O
cholesterol	B-Chemical
MDA	B-Chemical
Malondialdehyde	B-Chemical
ALT	O
Alanine	O
aminotransferase	O
GSH	O
-	O
Px	O
Glutathione	O
peroxidase	O
DGAT2	O
Diacylglycerol	O
acyltrasferase	O
2	O
CPT	O
-	O
1a	O
Carnitine	O
palmitoyltransferase	O
1a	O
Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O
Authors	O
â€™	O
contributions	O
J	O
.	O
L	O
.	O
Liu	O
","	O
L	O
.	O
N	O
.	O
Han	O
and	O
Y	O
.	O
R	O
.	O
Yu	O
designed	O
the	O
study	O
.	O
J	O
.	O
L	O
.	O
Liu	O
","	O
L	O
.	O
N	O
.	O
Han	O
and	O
L	O
.	O
L	O
.	O
Zhu	O
performed	O
the	O
animal	O
study	O
and	O
tissue	O
preparation	O
/	O
analysis	O
.	O
J	O
.	O
L	O
.	O
Liu	O
wrote	O
the	O
manuscript	O
","	O
and	O
analyzed	O
the	O
data	O
.	O
Y	O
.	O
Yu	O
revised	O
the	O
article	O
and	O
contributed	O
to	O
it	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
References	O
Organocatalytic	O
asymmetric	O
Henry	O
reaction	O
of	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diones	I-Chemical
with	O
bifunctional	O
amine	B-Chemical
-	O
thiourea	B-Chemical
catalysts	O
bearing	O
multiple	O
hydrogen	B-Chemical
-	O
bond	O
donors	O
Summary	O
For	O
the	O
first	O
time	O
","	O
a	O
catalytic	O
asymmetric	O
Henry	O
reaction	O
of	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diones	I-Chemical
was	O
achieved	O
with	O
a	O
chiral	O
bifunctional	O
amine	B-Chemical
-	O
thiourea	B-Chemical
as	O
a	O
catalyst	O
possessing	O
multiple	O
hydrogen	B-Chemical
-	O
bond	O
donors	O
.	O
With	O
this	O
developed	O
method	O
","	O
a	O
range	O
of	O
3	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
nitromethyl	I-Chemical
-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrrol	I-Chemical
-	I-Chemical
2	I-Chemical
(	I-Chemical
3H	I-Chemical
)-	I-Chemical
ones	I-Chemical
bearing	O
quaternary	O
stereocenters	O
were	O
obtained	O
in	O
acceptable	O
yield	O
(	O
up	O
to	O
75	O
%)	O
and	O
enantioselectivity	O
(	O
up	O
to	O
73	O
%	O
ee	O
).	O
Introduction	O
Asymmetric	O
organocatalysis	O
has	O
been	O
demonstrated	O
to	O
be	O
an	O
effective	O
and	O
versatile	O
strategy	O
in	O
facilitating	O
a	O
variety	O
of	O
organic	O
transformations	O
over	O
the	O
past	O
decade	O
","	O
and	O
numerous	O
catalytic	O
asymmetric	O
reactions	O
have	O
been	O
developed	O
with	O
various	O
activation	O
modes	O
[	O
1	O
â€“	O
6	O
].	O
In	O
this	O
realm	O
","	O
chiral	O
bifunctional	O
catalysts	O
","	O
possessing	O
two	O
active	O
sites	O
","	O
have	O
captured	O
tremendous	O
attention	O
in	O
particular	O
due	O
to	O
their	O
unique	O
ability	O
of	O
the	O
simultaneous	O
activation	O
of	O
the	O
nucleophile	O
and	O
the	O
electrophile	O
in	O
the	O
same	O
transition	O
state	O
[	O
7	O
â€“	O
11	O
].	O
Among	O
them	O
","	O
chiral	O
bifunctional	O
thioureas	B-Chemical
bearing	O
multiple	O
hydrogen	B-Chemical
-	O
bond	O
donors	O
have	O
been	O
successfully	O
used	O
as	O
chiral	O
organocatalysts	O
for	O
the	O
asymmetric	O
Michael	O
addition	O
and	O
Mannich	O
reactions	O
[	O
12	O
â€“	O
14	O
].	O
Meanwhile	O
","	O
the	O
Henry	O
reaction	O
is	O
one	O
of	O
the	O
most	O
important	O
carbon	B-Chemical
â€“	O
carbon	B-Chemical
bond	O
-	O
forming	O
reactions	O
that	O
provides	O
straightforward	O
access	O
to	O
Î²	B-Chemical
-	I-Chemical
nitroalcohols	I-Chemical
","	O
which	O
can	O
be	O
further	O
transformed	O
into	O
amino	B-Chemical
-	I-Chemical
alcohols	I-Chemical
","	O
amino	B-Chemical
acids	I-Chemical
and	O
carbonyl	O
compounds	O
[	O
15	O
].	O
Much	O
attention	O
has	O
been	O
devoted	O
to	O
the	O
development	O
of	O
an	O
efficient	O
catalytic	O
asymmetric	O
version	O
of	O
this	O
reaction	O
from	O
readily	O
accessible	O
nitroalkanes	B-Chemical
and	O
carbonyl	O
compounds	O
[	O
16	O
"],"	O
such	O
as	O
aldehydes	B-Chemical
[	O
17	O
â€“	O
19	O
"],"	O
Î±	B-Chemical
-	I-Chemical
ketoesters	I-Chemical
[	O
20	O
"],"	O
Î±	B-Chemical
-	I-Chemical
ketophosphonates	I-Chemical
[	O
21	O
â€“	O
22	O
"],"	O
fluoromethyl	B-Chemical
ketones	I-Chemical
[	O
23	O
â€“	O
24	O
]	O
and	O
isatins	B-Chemical
[	O
25	O
â€“	O
26	O
].	O
Despite	O
these	O
significant	O
advances	O
described	O
above	O
","	O
the	O
use	O
of	O
more	O
challenging	O
ketones	B-Chemical
with	O
heterocyclic	O
structures	O
as	O
Henry	O
acceptors	O
has	O
remained	O
relatively	O
less	O
explored	O
.	O
In	O
this	O
context	O
","	O
developing	O
a	O
new	O
Henry	O
reaction	O
for	O
the	O
construction	O
of	O
the	O
useful	O
and	O
versatile	O
Î²	B-Chemical
-	I-Chemical
nitroalcohol	I-Chemical
scaffolds	O
is	O
still	O
desirable	O
.	O
Pyrrole	B-Chemical
skeletons	O
represent	O
an	O
important	O
class	O
of	O
heterocycles	O
and	O
are	O
frequently	O
found	O
in	O
many	O
biologically	O
active	O
molecules	O
and	O
natural	O
products	O
[	O
27	O
â€“	O
28	O
].	O
Particularly	O
","	O
3	B-Chemical
-	I-Chemical
substituted	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrrol	I-Chemical
-	I-Chemical
2	I-Chemical
(	I-Chemical
3H	I-Chemical
)-	I-Chemical
one	I-Chemical
derivatives	O
exhibit	O
a	O
wide	O
spectrum	O
of	O
biological	O
activities	O
[	O
29	O
].	O
The	O
reaction	O
of	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diones	I-Chemical
with	O
various	O
nucleophiles	O
should	O
be	O
a	O
straightforward	O
way	O
to	O
access	O
diverse	O
and	O
interesting	O
3	B-Chemical
-	I-Chemical
substituted	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrrol	I-Chemical
-	I-Chemical
2	I-Chemical
(	I-Chemical
3H	I-Chemical
)-	I-Chemical
ones	I-Chemical
.	O
A	O
survey	O
of	O
the	O
literature	O
reveals	O
that	O
the	O
study	O
of	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diones	I-Chemical
is	O
mainly	O
focused	O
on	O
three	O
-	O
component	O
spiro	O
-	O
heterocyclization	O
reactions	O
[	O
30	O
â€“	O
32	O
].	O
However	O
","	O
for	O
the	O
catalytic	O
asymmetric	O
transformation	O
","	O
only	O
one	O
example	O
of	O
an	O
aldol	B-Chemical
reaction	O
of	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diones	I-Chemical
with	O
ketones	B-Chemical
has	O
been	O
reported	O
so	O
far	O
(	O
Scheme	O
1	O
)	O
[	O
33	O
].	O
Recently	O
","	O
our	O
group	O
developed	O
a	O
chiral	O
bifunctional	O
multiple	O
hydrogen	B-Chemical
-	O
bond	O
amine	B-Chemical
-	O
thiourea	B-Chemical
-	O
catalyzed	O
Michael	O
reaction	O
of	O
acetyl	B-Chemical
phosphonates	I-Chemical
with	O
nitroolefins	B-Chemical
","	O
giving	O
a	O
series	O
of	O
Î²	O
-	O
substituted	O
nitro	B-Chemical
compounds	I-Chemical
with	O
excellent	O
stereoselectivity	O
[	O
34	O
].	O
Therefore	O
","	O
as	O
part	O
of	O
our	O
research	O
program	O
aimed	O
at	O
establishing	O
new	O
methods	O
for	O
the	O
construction	O
of	O
quaternary	O
stereocenters	O
[	O
35	O
â€“	O
37	O
"],"	O
we	O
envisioned	O
that	O
the	O
Henry	O
reaction	O
of	O
nitroalkanes	B-Chemical
with	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diones	I-Chemical
should	O
take	O
place	O
with	O
a	O
chiral	O
bifunctional	O
amine	B-Chemical
-	O
thiourea	B-Chemical
catalyst	O
","	O
leading	O
to	O
3	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
nitromethyl	I-Chemical
-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrrol	I-Chemical
-	I-Chemical
2	I-Chemical
(	I-Chemical
3H	I-Chemical
)-	I-Chemical
ones	I-Chemical
bearing	O
quaternary	O
stereocenters	O
(	O
Scheme	O
1	O
)	O
[	O
14	O
].	O
Notably	O
","	O
this	O
work	O
represents	O
the	O
first	O
example	O
of	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diones	I-Chemical
used	O
as	O
Henry	O
acceptors	O
for	O
the	O
asymmetric	O
reaction	O
.	O
Herein	O
","	O
we	O
report	O
our	O
preliminary	O
results	O
on	O
this	O
subject	O
.	O
The	O
strategy	O
to	O
construct	O
chiral	O
3	B-Chemical
-	I-Chemical
substituted	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrrol	I-Chemical
-	I-Chemical
2	I-Chemical
(	I-Chemical
3H	I-Chemical
)-	I-Chemical
ones	I-Chemical
.	O
Results	O
and	O
Discussion	O
We	O
started	O
our	O
studies	O
with	O
the	O
reaction	O
of	O
ethyl	B-Chemical
1	I-Chemical
-	I-Chemical
benzyl	I-Chemical
-	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
dioxo	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
phenyl	I-Chemical
-	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
dihydro	I-Chemical
-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
carboxylate	I-Chemical
(	O
1a	O
)	O
and	O
nitromethane	B-Chemical
(	O
2a	O
)	O
in	O
the	O
presence	O
of	O
various	O
chiral	O
bifunctional	O
organocatalysts	O
3a	O
â€“	O
e	O
in	O
dichloromethane	B-Chemical
(	O
Table	O
1	O
).	O
As	O
expected	O
","	O
the	O
reaction	O
proceeded	O
and	O
gave	O
the	O
desired	O
product	O
4a	O
in	O
18	O
%	O
yield	O
and	O
28	O
%	O
ee	O
with	O
cinchonidine	B-Chemical
and	O
L	B-Chemical
-	I-Chemical
valine	I-Chemical
-	O
based	O
catalyst	O
3a	O
(	O
Table	O
1	O
","	O
entry	O
1	O
).	O
The	O
bifunctional	O
","	O
thiourea	B-Chemical
-	O
tertiary	O
amine	B-Chemical
catalyst	O
3b	O
","	O
derived	O
from	O
quinine	B-Chemical
and	O
L	B-Chemical
-	I-Chemical
valine	I-Chemical
","	O
furnished	O
a	O
similar	O
result	O
to	O
catalyst	O
3a	O
(	O
Table	O
1	O
","	O
entry	O
2	O
).	O
Next	O
","	O
the	O
reaction	O
was	O
attempted	O
with	O
catalyst	O
3c	O
derived	O
from	O
L	B-Chemical
-	I-Chemical
phenylalanine	I-Chemical
and	O
catalyst	O
3d	O
derived	O
from	O
L	B-Chemical
-	I-Chemical
phenylglycine	I-Chemical
","	O
and	O
improvements	O
in	O
enantioselectivity	O
were	O
observed	O
(	O
Table	O
1	O
","	O
entries	O
3	O
and	O
4	O
).	O
Changing	O
L	B-Chemical
-	I-Chemical
phenylalanine	I-Chemical
to	O
D	B-Chemical
-	I-Chemical
phenylalanine	I-Chemical
furnished	O
catalyst	O
3e	O
","	O
and	O
the	O
enantioselectivity	O
was	O
improved	O
to	O
61	O
%	O
ee	O
(	O
Table	O
1	O
","	O
entry	O
5	O
).	O
Having	O
identified	O
3e	O
as	O
the	O
best	O
catalyst	O
","	O
we	O
undertook	O
a	O
solvent	O
screening	O
for	O
this	O
transformation	O
with	O
20	O
mol	O
%	O
3e	O
at	O
30	O
Â°	O
C	O
(	O
Table	O
1	O
","	O
entries	O
6	O
â€“	O
12	O
).	O
Arenes	B-Chemical
such	O
as	O
toluene	B-Chemical
and	O
mesitylene	B-Chemical
gave	O
relatively	O
lower	O
ee	O
values	O
(	O
Table	O
1	O
","	O
entries	O
6	O
and	O
7	O
).	O
In	O
contrast	O
","	O
the	O
reactions	O
in	O
ethers	B-Chemical
gave	O
improved	O
yield	O
with	O
slightly	O
increased	O
enantioselectivity	O
(	O
Table	O
1	O
","	O
entries	O
8	O
â€“	O
10	O
).	O
However	O
","	O
strong	O
polar	O
solvents	O
such	O
as	O
acetonitrile	B-Chemical
and	O
ethyl	B-Chemical
acetate	I-Chemical
proved	O
inferior	O
to	O
this	O
Henry	O
reaction	O
(	O
Table	O
1	O
","	O
entries	O
11	O
and	O
12	O
).	O
The	O
solvent	O
survey	O
revealed	O
that	O
THF	B-Chemical
was	O
the	O
suitable	O
solvent	O
in	O
terms	O
of	O
the	O
yield	O
and	O
enantioselectivity	O
(	O
Table	O
1	O
","	O
entry	O
8	O
).	O
Screening	O
of	O
the	O
catalysts	O
and	O
solvents	O
.	O
a	O
Entry	O
Catalyst	O
Solvent	O
Yield	O
(%)	O
b	O
ee	O
(%)	O
c	O
1	O
3a	O
DCM	O
18	O
28	O
2	O
3b	O
DCM	O
25	O
27	O
3	O
3c	O
DCM	O
25	O
38	O
4	O
3d	O
DCM	O
29	O
41	O
5	O
3e	O
DCM	O
23	O
61	O
6	O
3e	O
toluene	B-Chemical
24	O
46	O
7	O
3e	O
mesitylene	B-Chemical
36	O
58	O
8	O
3e	O
THF	B-Chemical
61	O
61	O
9	O
3e	O
dioxane	B-Chemical
59	O
53	O
10	O
3e	O
Et2O	B-Chemical
48	O
62	O
11	O
3e	O
CH3CN	O
14	O
40	O
12	O
3e	O
EtOAc	B-Chemical
18	O
59	O
aUnless	O
otherwise	O
noted	O
","	O
the	O
reactions	O
were	O
carried	O
out	O
with	O
1a	O
(	O
0	O
.	O
2	O
mmol	O
"),"	O
2a	O
(	O
2	O
.	O
0	O
mmol	O
"),"	O
catalyst	O
3	O
(	O
20	O
mol	O
%)	O
in	O
solvent	O
(	O
2	O
mL	O
)	O
at	O
30	O
Â°	O
C	O
for	O
14	O
h	O
.	O
bIsolated	O
yield	O
.	O
cDetermined	O
by	O
chiral	O
HPLC	O
analysis	O
.	O
To	O
further	O
optimize	O
the	O
reaction	O
conditions	O
","	O
the	O
substituent	O
at	O
the	O
nitrogen	B-Chemical
atom	O
in	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diones	I-Chemical
1	O
and	O
the	O
substrate	O
concentration	O
were	O
investigated	O
.	O
The	O
results	O
are	O
summarized	O
in	O
Table	O
2	O
.	O
It	O
was	O
found	O
that	O
an	O
isopropyl	O
group	O
furnished	O
a	O
better	O
yield	O
and	O
ee	O
value	O
than	O
a	O
benzyl	O
group	O
(	O
Table	O
2	O
","	O
entry	O
2	O
vs	O
entry	O
1	O
).	O
Changing	O
the	O
isopropyl	O
group	O
to	O
a	O
methyl	O
group	O
decreased	O
the	O
enantioselectivity	O
(	O
Table	O
2	O
","	O
entry	O
3	O
).	O
To	O
enhance	O
the	O
reactivity	O
of	O
the	O
substrate	O
","	O
we	O
also	O
tried	O
to	O
introduce	O
some	O
electron	O
-	O
withdrawing	O
substituents	O
on	O
the	O
nitrogen	B-Chemical
atom	O
.	O
However	O
","	O
we	O
could	O
not	O
obtain	O
the	O
desired	O
substrates	O
.	O
Afterwards	O
","	O
upon	O
the	O
investigation	O
of	O
substrate	O
concentration	O
(	O
Table	O
2	O
","	O
entries	O
4	O
and	O
5	O
"),"	O
it	O
was	O
found	O
that	O
increasing	O
the	O
substrate	O
concentration	O
could	O
slightly	O
increase	O
the	O
yield	O
with	O
unchanged	O
enantioselectivity	O
(	O
Table	O
2	O
","	O
entry	O
4	O
).	O
Ultimately	O
","	O
the	O
effects	O
of	O
the	O
reaction	O
temperature	O
and	O
the	O
additive	O
were	O
also	O
examined	O
and	O
no	O
improved	O
results	O
were	O
obtained	O
(	O
Table	O
2	O
","	O
entries	O
6	O
â€“	O
8	O
).	O
Based	O
on	O
these	O
observations	O
","	O
the	O
most	O
appropriate	O
conditions	O
for	O
the	O
Henry	O
reaction	O
could	O
be	O
established	O
:	O
1	O
equiv	O
of	O
1a	O
and	O
10	O
equiv	O
of	O
2a	O
with	O
20	O
mol	O
%	O
catalyst	O
3e	O
in	O
1	O
.	O
0	O
mL	O
THF	B-Chemical
at	O
30	O
Â°	O
C	O
(	O
Table	O
2	O
","	O
entry	O
4	O
).	O
Further	O
optimization	O
of	O
conditions	O
.	O
a	O
Entry	O
1	O
x	O
Time	O
(	O
h	O
)	O
4	O
Yield	O
(%)	O
b	O
ee	O
(%)	O
c	O
1	O
1a	O
2	O
14	O
4a	O
61	O
61	O
2	O
1b	O
2	O
14	O
4b	O
64	O
71	O
3	O
1c	O
2	O
14	O
4c	O
19	O
57	O
4	O
1b	O
1	O
14	O
4b	O
69	O
71	O
5	O
1b	O
3	O
14	O
4b	O
60	O
70	O
6d	O
1b	O
1	O
14	O
4b	O
64	O
46	O
7e	O
1b	O
1	O
62	O
4b	O
trace	O
ND	O
8f	O
1b	O
1	O
14	O
4b	O
75	O
66	O
aUnless	O
otherwise	O
noted	O
","	O
the	O
reactions	O
were	O
carried	O
out	O
with	O
1a	O
(	O
0	O
.	O
2	O
mmol	O
"),"	O
2a	O
(	O
2	O
.	O
0	O
mmol	O
)	O
and	O
catalyst	O
3e	O
(	O
20	O
mol	O
%)	O
in	O
THF	B-Chemical
for	O
the	O
specified	O
reaction	O
time	O
.	O
bIsolated	O
yield	O
.	O
cDetermined	O
by	O
chiral	O
HPLC	O
analysis	O
.	O
dRun	O
at	O
50	O
Â°	O
C	O
;	O
eRun	O
at	O
0	O
Â°	O
C	O
.	O
f4	O
Ã…	O
MS	O
was	O
added	O
.	O
ND	O
","	O
not	O
determined	O
.	O
Under	O
the	O
optimal	O
reaction	O
conditions	O
","	O
the	O
substrate	O
scope	O
and	O
the	O
limitation	O
of	O
this	O
organocatalytic	O
Henry	O
reaction	O
were	O
explored	O
.	O
The	O
results	O
are	O
summarized	O
in	O
Table	O
3	O
.	O
First	O
","	O
we	O
investigated	O
the	O
effects	O
of	O
the	O
alkyl	B-Chemical
ester	I-Chemical
of	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diones	I-Chemical
1	O
.	O
The	O
replacement	O
of	O
the	O
ethyl	O
group	O
by	O
either	O
a	O
methyl	O
or	O
a	O
butyl	O
group	O
had	O
only	O
a	O
slight	O
effect	O
on	O
the	O
ee	O
value	O
but	O
an	O
obvious	O
effect	O
on	O
the	O
yield	O
(	O
Table	O
3	O
","	O
entries	O
1	O
and	O
2	O
vs	O
Table	O
2	O
","	O
entry	O
4	O
).	O
After	O
introducing	O
different	O
substituent	O
groups	O
on	O
the	O
phenyl	O
ring	O
of	O
substrate	O
1	O
","	O
it	O
was	O
observed	O
that	O
the	O
reactions	O
take	O
place	O
","	O
and	O
the	O
corresponding	O
products	O
in	O
44	O
â€“	O
73	O
%	O
yield	O
with	O
up	O
to	O
73	O
%	O
ee	O
were	O
furnished	O
.	O
This	O
was	O
TRUE	O
regardless	O
of	O
the	O
electronic	O
nature	O
and	O
position	O
of	O
the	O
substituents	O
on	O
the	O
phenyl	O
ring	O
(	O
Table	O
3	O
","	O
entries	O
3	O
â€“	O
10	O
).	O
When	O
the	O
substituent	O
was	O
in	O
the	O
ortho	O
-	O
position	O
of	O
the	O
phenyl	O
ring	O
of	O
the	O
R2	O
group	O
","	O
a	O
diastereoselectivity	O
was	O
observed	O
that	O
may	O
be	O
due	O
to	O
the	O
steric	O
hindrance	O
of	O
ortho	O
substituents	O
led	O
to	O
the	O
atropisomers	O
(	O
Table	O
3	O
","	O
entry	O
3	O
).	O
A	O
similar	O
result	O
was	O
observed	O
for	O
the	O
bulky	O
1	O
-	O
naphthyl	O
group	O
(	O
Table	O
3	O
","	O
entry	O
11	O
).	O
The	O
reaction	O
was	O
also	O
performed	O
with	O
a	O
2	O
-	O
thienyl	O
residue	O
and	O
the	O
desired	O
product	O
was	O
obtained	O
in	O
51	O
%	O
yield	O
and	O
71	O
%	O
ee	O
(	O
Table	O
3	O
","	O
entry	O
10	O
).	O
In	O
addition	O
","	O
substrate	O
1o	O
with	O
no	O
substituent	O
on	O
the	O
nitrogen	B-Chemical
atom	O
gave	O
the	O
desired	O
product	O
in	O
41	O
%	O
and	O
48	O
%	O
ee	O
(	O
Table	O
3	O
","	O
entry	O
12	O
).	O
The	O
introduction	O
of	O
a	O
phenyl	O
group	O
on	O
the	O
nitrogen	B-Chemical
atom	O
had	O
a	O
negative	O
effect	O
on	O
the	O
reaction	O
(	O
Table	O
3	O
","	O
entry	O
13	O
).	O
Nitroethane	B-Chemical
was	O
also	O
used	O
to	O
react	O
with	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
dione	I-Chemical
1b	O
","	O
and	O
a	O
good	O
diastereoselectivity	O
was	O
achieved	O
with	O
an	O
unfavorable	O
yield	O
and	O
ee	O
value	O
(	O
Table	O
3	O
","	O
entry	O
14	O
).	O
For	O
the	O
substrates	O
with	O
methoxy	O
groups	O
on	O
the	O
phenyl	O
rings	O
","	O
the	O
reaction	O
gave	O
relatively	O
better	O
results	O
(	O
Table	O
3	O
","	O
entries	O
4	O
and	O
7	O
).	O
We	O
also	O
tested	O
the	O
substrates	O
1q	O
and	O
1r	O
containing	O
a	O
methyl	B-Chemical
ester	I-Chemical
","	O
and	O
acceptable	O
results	O
were	O
obtained	O
(	O
Table	O
3	O
","	O
entries	O
15	O
and	O
16	O
).	O
The	O
absolute	O
configuration	O
of	O
the	O
major	O
isomer	O
4i	O
was	O
unambiguously	O
determined	O
to	O
be	O
S	O
by	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
analysis	O
(	O
Fig	O
.	O
1	O
)	O
[	O
38	O
].	O
The	O
configurations	O
of	O
the	O
other	O
products	O
were	O
assigned	O
by	O
analogy	O
.	O
Scope	O
of	O
the	O
reaction	O
.	O
a	O
Entry	O
R	O
/	O
R1	O
/	O
R2	O
2	O
Time	O
(	O
h	O
)	O
4	O
Yield	O
(%)	O
b	O
ee	O
(%)	O
c	O
1	O
iPr	O
/	O
Me	O
/	O
Ph	O
(	O
1d	O
)	O
2a	O
14	O
4d	O
55	O
65	O
2	O
iPr	O
/	O
n	O
-	O
Bu	O
/	O
Ph	O
(	O
1e	O
)	O
2a	O
70	O
4e	O
52	O
70	O
3	O
iPr	O
/	O
Et	O
/	O
2	O
-	O
ClC6H4	O
(	O
1f	O
)	O
2a	O
62	O
4f	O
53	O
73d	O
4	O
iPr	O
/	O
Et	O
/	O
3	O
-	O
MeOC6H4	O
(	O
1g	O
)	O
2a	O
62	O
4g	O
73	O
71	O
5	O
iPr	O
/	O
Et	O
/	O
3	B-Chemical
-	I-Chemical
ClC6H4	I-Chemical
(	O
1h	O
)	O
2a	O
120	O
4h	O
47	O
71	O
6	O
iPr	O
/	O
Et	O
/	O
3	O
-	O
BrC6H4	O
(	O
1i	O
)	O
2a	O
120	O
4i	O
44	O
70	O
7	O
iPr	O
/	O
Et	O
/	O
4	O
-	O
MeOC6H4	O
(	O
1j	O
)	O
2a	O
62	O
4j	O
61	O
72	O
8	O
iPr	O
/	O
Et	O
/	O
4	O
-	O
MeC6H4	O
(	O
1k	O
)	O
2a	O
48	O
4k	O
64	O
69	O
9	O
iPr	O
/	O
Et	O
/	O
4	O
-	O
FC6H4	O
(	O
1l	O
)	O
2a	O
62	O
4l	O
73	O
70	O
10	O
iPr	O
/	O
Et	O
/	O
2	O
-	O
thienyl	O
(	O
1m	O
)	O
2a	O
120	O
4m	O
51	O
71	O
11	O
iPr	O
/	O
Et	O
/	O
1	O
-	O
naphthyl	O
(	O
1n	O
)	O
2a	O
120	O
4n	O
75	O
51e	O
12	O
H	O
/	O
Me	O
/	O
Ph	O
(	O
1o	O
)	O
2a	O
120	O
4o	O
41	O
48	O
13	O
Ph	O
/	O
Et	O
/	O
Ph	O
(	O
1p	O
)	O
2a	O
120	O
4p	O
42	O
29	O
14	O
iPr	O
/	O
Et	O
/	O
Ph	O
(	O
1b	O
)	O
2b	O
24	O
4q	O
23	O
22f	O
15	O
iPr	O
/	O
Me	O
/	O
4	O
-	O
MeOC6H4	O
(	O
1q	O
)	O
2a	O
84	O
4r	O
51	O
69	O
16	O
iPr	O
/	O
Me	O
/	O
3	O
-	O
MeOC6H4	O
(	O
1r	O
)	O
2a	O
120	O
4s	O
71	O
58	O
aUnless	O
otherwise	O
noted	O
","	O
the	O
reactions	O
were	O
carried	O
out	O
with	O
1	O
(	O
0	O
.	O
2	O
mmol	O
"),"	O
2	O
(	O
2	O
.	O
0	O
mmol	O
).	O
bIsolated	O
yield	O
.	O
cDetermined	O
by	O
chiral	O
HPLC	O
analysis	O
.	O
dee	O
for	O
the	O
major	O
isomer	O
and	O
ee	O
of	O
another	O
isomer	O
is	O
60	O
"%,"	O
and	O
54	O
:	O
46	O
dr	O
was	O
observed	O
.	O
eee	O
for	O
the	O
major	O
isomer	O
and	O
ee	O
of	O
another	O
isomer	O
is	O
49	O
"%,"	O
and	O
53	O
:	O
47	O
dr	O
was	O
observed	O
.	O
fee	O
for	O
the	O
major	O
isomer	O
","	O
and	O
94	O
:	O
6	O
dr	O
was	O
observed	O
.	O
The	O
X	O
-	O
ray	O
structure	O
of	O
compound	O
4i	O
.	O
On	O
the	O
basis	O
of	O
our	O
experimental	O
results	O
and	O
the	O
related	O
reports	O
about	O
the	O
bifunctional	O
activation	O
mode	O
of	O
nitromethane	B-Chemical
with	O
different	O
electrophiles	O
[	O
14	O
","	O
17	O
","	O
39	O
"],"	O
we	O
propose	O
a	O
possible	O
model	O
to	O
explain	O
the	O
stereochemistry	O
of	O
this	O
transformation	O
.	O
As	O
shown	O
in	O
Fig	O
.	O
2	O
","	O
nitromethane	B-Chemical
is	O
activated	O
by	O
the	O
tertiary	O
amine	B-Chemical
to	O
form	O
the	O
nitro	B-Chemical
enolate	I-Chemical
.	O
Simultaneously	O
","	O
the	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diones	I-Chemical
1	O
are	O
orientated	O
by	O
the	O
multiple	O
hydrogen	B-Chemical
bonds	O
of	O
the	O
catalyst	O
.	O
Thus	O
","	O
the	O
nitro	B-Chemical
enolate	I-Chemical
attacks	O
the	O
keto	O
carbonyl	O
group	O
of	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diones	I-Chemical
(	O
to	O
the	O
si	O
-	O
face	O
)	O
to	O
furnish	O
the	O
corresponding	O
product	O
with	O
S	O
-	O
configuration	O
(	O
Fig	O
.	O
2	O
).	O
A	O
proposed	O
transition	O
state	O
for	O
the	O
asymmetric	O
Henry	O
reaction	O
.	O
Conclusion	O
In	O
conclusion	O
","	O
we	O
have	O
developed	O
an	O
asymmetric	O
Henry	O
reaction	O
of	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diones	I-Chemical
with	O
a	O
chiral	O
bifunctional	O
amine	B-Chemical
-	O
thiourea	B-Chemical
possessing	O
multiple	O
hydrogen	B-Chemical
-	O
bond	O
donors	O
as	O
the	O
catalyst	O
.	O
With	O
the	O
developed	O
protocol	O
","	O
a	O
range	O
of	O
3	B-Chemical
-	I-Chemical
hydroxy	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
nitromethyl	I-Chemical
-	I-Chemical
1H	I-Chemical
-	I-Chemical
pyrrol	I-Chemical
-	I-Chemical
2	I-Chemical
(	I-Chemical
3H	I-Chemical
)-	I-Chemical
ones	I-Chemical
bearing	O
quaternary	O
stereocenters	O
were	O
obtained	O
in	O
good	O
yield	O
(	O
up	O
to	O
75	O
%)	O
and	O
with	O
moderate	O
to	O
good	O
enantioselectivity	O
(	O
up	O
to	O
73	O
%	O
ee	O
).	O
A	O
possible	O
transition	O
-	O
state	O
model	O
","	O
characterized	O
by	O
the	O
bifunctional	O
catalyst	O
acting	O
as	O
a	O
multiple	O
hydrogen	B-Chemical
-	O
bond	O
donor	O
","	O
is	O
also	O
proposed	O
.	O
The	O
application	O
of	O
1H	B-Chemical
-	I-Chemical
pyrrole	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diones	I-Chemical
in	O
the	O
catalytic	O
asymmetric	O
reactions	O
for	O
the	O
preparation	O
of	O
biologically	O
relevant	O
compounds	O
is	O
currently	O
underway	O
.	O
Supporting	O
Information	O
Effects	O
of	O
Atorvastatin	B-Chemical
Dose	O
and	O
Concomitant	O
Use	O
of	O
Angiotensin	O
-	O
Converting	O
Enzyme	O
Inhibitors	O
on	O
Renal	O
Function	O
Changes	O
over	O
Time	O
in	O
Patients	O
with	O
Stable	O
Coronary	O
Artery	O
Disease	O
:	O
A	O
Prospective	O
Observational	O
Study	O
Angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
(	O
ACEI	O
)	O
and	O
statins	O
are	O
widely	O
used	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
(	O
CAD	O
).	O
Our	O
aim	O
was	O
to	O
compare	O
changes	O
in	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
over	O
time	O
in	O
subjects	O
with	O
stable	O
CAD	O
according	O
to	O
atorvastatin	B-Chemical
dose	O
and	O
concomitant	O
use	O
of	O
ACEI	O
.	O
We	O
studied	O
78	O
men	O
with	O
stable	O
CAD	O
referred	O
for	O
an	O
elective	O
coronary	O
angiography	O
who	O
attained	O
the	O
then	O
-	O
current	O
guideline	O
-	O
recommended	O
target	O
level	O
of	O
low	O
-	O
density	O
lipoproteins	O
(	O
LDL	O
)	O
cholesterol	O
below	O
2	O
.	O
5	O
mmol	O
/	O
L	O
in	O
a	O
routine	O
fasting	O
lipid	B-Chemical
panel	O
on	O
admission	O
and	O
were	O
receiving	O
atorvastatin	B-Chemical
at	O
a	O
daily	O
dose	O
of	O
10	O
â€“	O
40	O
mg	O
for	O
â‰¥	O
3	O
months	O
preceding	O
the	O
index	O
hospitalization	O
.	O
Due	O
to	O
an	O
observational	O
study	O
design	O
","	O
atorvastatin	B-Chemical
dosage	O
was	O
not	O
intentionally	O
modified	O
for	O
other	O
reasons	O
.	O
GFR	O
was	O
estimated	O
during	O
index	O
hospitalization	O
and	O
at	O
about	O
one	O
year	O
after	O
discharge	O
from	O
our	O
center	O
.	O
Irrespective	O
of	O
ACEI	O
use	O
","	O
a	O
prevention	O
of	O
kidney	O
function	O
loss	O
was	O
observed	O
only	O
in	O
those	O
treated	O
with	O
the	O
highest	O
atorvastatin	B-Chemical
dose	O
.	O
In	O
38	O
subjects	O
on	O
ACEI	O
","	O
both	O
of	O
the	O
higher	O
atorvastatin	B-Chemical
doses	O
were	O
associated	O
with	O
increasing	O
beneficial	O
effects	O
on	O
GFR	O
changes	O
(	O
mean	O
Â±	O
SEM	O
:	O
âˆ’	O
4	O
.	O
2	O
Â±	O
2	O
.	O
4	O
","	O
1	O
.	O
1	O
Â±	O
1	O
.	O
6	O
","	O
5	O
.	O
2	O
Â±	O
2	O
.	O
4	O
mL	O
/	O
min	O
per	O
1	O
.	O
73	O
m2	O
for	O
the	O
10	O
-	O
mg	O
","	O
20	O
-	O
mg	O
and	O
40	O
-	O
mg	O
atorvastatin	B-Chemical
group	O
","	O
respectively	O
","	O
p	O
=	O
0	O
.	O
2	O
by	O
ANOVA	O
;	O
Spearman	O
â€™	O
s	O
rho	O
=	O
0	O
.	O
50	O
","	O
p	O
=	O
0	O
.	O
1	O
for	O
trend	O
).	O
In	O
sharp	O
contrast	O
","	O
in	O
40	O
patients	O
without	O
ACEI	O
","	O
no	O
significant	O
trend	O
effect	O
was	O
observed	O
across	O
increasing	O
atorvastatin	B-Chemical
dosage	O
(	O
respective	O
GFR	O
changes	O
:	O
âˆ’	O
1	O
.	O
3	O
Â±	O
1	O
.	O
0	O
","	O
âˆ’	O
4	O
.	O
7	O
Â±	O
2	O
.	O
1	O
","	O
4	O
.	O
8	O
Â±	O
3	O
.	O
6	O
mL	O
/	O
min	O
per	O
1	O
.	O
73	O
m2	O
","	O
p	O
=	O
0	O
.	O
2	O
by	O
ANOVA	O
;	O
rho	O
=	O
0	O
.	O
8	O
","	O
p	O
=	O
0	O
.	O
6	O
for	O
trend	O
).	O
The	O
results	O
were	O
substantially	O
unchanged	O
after	O
adjustment	O
for	O
baseline	O
GFR	O
or	O
time	O
-	O
dependent	O
variations	O
of	O
LDL	O
cholesterol	O
.	O
Thus	O
","	O
concomitant	O
ACEI	O
use	O
appears	O
to	O
facilitate	O
the	O
ability	O
of	O
increasing	O
atorvastatin	B-Chemical
doses	O
to	O
beneficially	O
modulate	O
time	O
-	O
dependent	O
changes	O
in	O
GFR	O
in	O
men	O
with	O
stable	O
CAD	O
.	O
1	O
.	O
Introduction	O
As	O
early	O
as	O
2001	O
","	O
a	O
meta	O
-	O
analysis	O
of	O
randomized	O
controlled	O
studies	O
by	O
Fried	O
et	O
al	O
.	O
[	O
1	O
]	O
suggested	O
the	O
ability	O
of	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
-	O
coenzyme	O
A	O
(	O
HMG	O
-	O
CoA	O
)	O
reductase	O
inhibitors	O
(	O
statins	O
"),"	O
to	O
slow	O
down	O
renal	O
function	O
decline	O
in	O
patients	O
with	O
renal	O
diseases	O
.	O
Five	O
years	O
later	O
","	O
a	O
meta	O
-	O
analysis	O
by	O
Sandhu	O
et	O
al	O
.	O
[	O
2	O
]	O
also	O
identified	O
renal	O
benefits	O
of	O
statins	O
","	O
including	O
a	O
small	O
yet	O
significant	O
reduction	O
in	O
the	O
rate	O
of	O
kidney	O
function	O
loss	O
","	O
especially	O
in	O
populations	O
with	O
atherosclerotic	O
cardiovascular	O
(	O
CV	O
)	O
disease	O
.	O
However	O
","	O
according	O
to	O
some	O
recent	O
meta	O
-	O
analyses	O
","	O
despite	O
a	O
lower	O
risk	O
of	O
CV	O
events	O
in	O
predialysis	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
subjects	O
on	O
statins	O
","	O
renoprotective	O
statin	O
effects	O
were	O
unclear	O
with	O
a	O
significant	O
heterogeneity	O
across	O
the	O
included	O
CKD	O
studies	O
[	O
3	O
","	O
4	O
].	O
Nikolic	O
et	O
al	O
.	O
[	O
5	O
]	O
have	O
recently	O
reported	O
a	O
beneficial	O
effect	O
of	O
statins	O
on	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
changes	O
only	O
for	O
between	O
one	O
and	O
three	O
years	O
of	O
statin	O
therapy	O
in	O
CKD	O
.	O
In	O
contrast	O
to	O
these	O
inconsistent	O
results	O
","	O
a	O
meta	O
-	O
analysis	O
of	O
controlled	O
studies	O
in	O
CKD	O
patients	O
treated	O
with	O
atorvastatin	B-Chemical
revealed	O
an	O
evidence	O
of	O
the	O
atorvastatin	B-Chemical
-	O
induced	O
renoprotection	O
that	O
was	O
independent	O
of	O
follow	O
-	O
up	O
duration	O
and	O
persisted	O
after	O
exclusion	O
of	O
any	O
single	O
trial	O
from	O
the	O
analysis	O
including	O
the	O
largest	O
Treating	O
to	O
New	O
Targets	O
(	O
TNT	O
)	O
study	O
[	O
6	O
].	O
These	O
discrepancies	O
could	O
be	O
partially	O
linked	O
to	O
a	O
dosage	O
-	O
dependence	O
of	O
renal	O
benefits	O
of	O
statins	O
","	O
recently	O
demonstrated	O
irrespective	O
of	O
the	O
presence	O
of	O
CKD	O
[	O
7	O
","	O
8	O
].	O
Angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
(	O
ACEI	O
)	O
are	O
recommended	O
in	O
CKD	O
due	O
to	O
their	O
well	O
-	O
recognized	O
ability	O
to	O
reduce	O
proteinuria	O
and	O
delay	O
renal	O
function	O
decline	O
.	O
In	O
addition	O
","	O
ACEI	O
should	O
be	O
considered	O
for	O
CV	O
event	O
prevention	O
even	O
in	O
patients	O
with	O
stable	O
angina	O
and	O
without	O
coexistent	O
strong	O
indications	O
for	O
this	O
class	O
of	O
drugs	O
","	O
i	O
.	O
e	O
".,"	O
left	O
ventricular	O
systolic	O
dysfunction	O
","	O
diabetes	O
or	O
hypertension	O
[	O
9	O
","	O
10	O
].	O
However	O
","	O
ACEI	O
were	O
used	O
by	O
only	O
about	O
28	O
%	O
of	O
the	O
subjects	O
participating	O
in	O
the	O
TNT	O
trial	O
that	O
demonstrated	O
greater	O
improvements	O
in	O
GFR	O
over	O
five	O
years	O
in	O
patients	O
with	O
stable	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
randomized	O
to	O
80	O
-	O
mg	O
atorvastatin	B-Chemical
vs	O
.	O
10	O
-	O
mg	O
atorvastatin	B-Chemical
[	O
11	O
].	O
Of	O
note	O
","	O
in	O
the	O
Protection	O
Against	O
Nephropathy	O
in	O
Diabetes	O
with	O
Atorvastatin	B-Chemical
(	O
PANDA	O
)	O
trial	O
two	O
-	O
year	O
GFR	O
changes	O
were	O
similar	O
in	O
type	O
2	O
diabetics	O
with	O
early	O
nephropathy	O
allocated	O
80	O
-	O
mg	O
and	O
10	O
-	O
mg	O
atorvastatin	B-Chemical
","	O
all	O
of	O
whom	O
were	O
receiving	O
either	O
ACEI	O
or	O
angiotensin	O
II	O
type	O
1	O
receptor	O
blockers	O
(	O
ARB	O
)	O
[	O
12	O
].	O
Therefore	O
","	O
we	O
hypothesized	O
that	O
dose	O
-	O
dependent	O
effects	O
of	O
atorvastatin	B-Chemical
on	O
renal	O
function	O
might	O
be	O
modified	O
by	O
ACEI	O
use	O
.	O
Thus	O
","	O
the	O
aim	O
of	O
our	O
observational	O
study	O
was	O
to	O
compare	O
GFR	O
changes	O
over	O
time	O
in	O
men	O
with	O
stable	O
CAD	O
according	O
to	O
the	O
dose	O
of	O
atorvastatin	B-Chemical
and	O
concomitant	O
usage	O
of	O
ACEI	O
.	O
2	O
.	O
Results	O
Clinical	O
and	O
biochemical	O
characteristics	O
of	O
our	O
patients	O
according	O
to	O
atorvastatin	B-Chemical
dose	O
have	O
been	O
shown	O
in	O
Table	O
1	O
.	O
Patients	O
â€™	O
characteristics	O
according	O
to	O
atorvastatin	B-Chemical
dose	O
.	O
Data	O
are	O
shown	O
as	O
mean	O
Â±	O
SD	O
;	O
p	O
-	O
values	O
by	O
one	O
-	O
way	O
ANOVA	O
or	O
chi	O
-	O
squared	O
test	O
.	O
HDL	O
:	O
high	O
-	O
density	O
lipoproteins	O
;	O
LDL	O
:	O
low	O
-	O
density	O
lipoproteins	O
;	O
NS	O
:	O
non	O
-	O
significant	O
.	O
Baseline	O
GFR	O
did	O
not	O
differ	O
significantly	O
across	O
subgroups	O
of	O
patients	O
treated	O
with	O
different	O
atorvastatin	B-Chemical
doses	O
(	O
mean	O
Â±	O
SEM	O
:	O
52	O
.	O
4	O
Â±	O
2	O
.	O
6	O
","	O
59	O
.	O
3	O
Â±	O
3	O
.	O
5	O
","	O
62	O
.	O
5	O
Â±	O
3	O
.	O
1	O
mL	O
/	O
min	O
per	O
1	O
.	O
73	O
m2	O
for	O
the	O
10	O
-	O
mg	O
","	O
20	O
-	O
mg	O
and	O
40	O
-	O
mg	O
atorvastatin	B-Chemical
group	O
","	O
respectively	O
;	O
p	O
=	O
0	O
.	O
4	O
by	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
[	O
ANOVA	O
]).	O
Out	O
of	O
78	O
study	O
subjects	O
","	O
40	O
patients	O
were	O
receiving	O
no	O
ACEI	O
","	O
largely	O
due	O
to	O
a	O
history	O
of	O
adverse	O
renal	O
side	O
-	O
effects	O
","	O
which	O
resulted	O
in	O
a	O
significantly	O
higher	O
GFR	O
in	O
those	O
with	O
ACEI	O
(	O
69	O
.	O
5	O
Â±	O
2	O
.	O
7	O
vs	O
.	O
43	O
.	O
5	O
Â±	O
2	O
.	O
0	O
mL	O
/	O
min	O
per	O
1	O
.	O
73	O
m2	O
","	O
p	O
<	O
0	O
.	O
1	O
).	O
Among	O
ACEI	O
users	O
","	O
study	O
subjects	O
were	O
treated	O
mainly	O
with	O
ramipril	B-Chemical
(	O
2	O
.	O
5	O
â€“	O
10	O
mg	O
daily	O
"),"	O
perindopril	B-Chemical
(	O
2	O
â€“	O
8	O
mg	O
daily	O
)	O
or	O
enalapril	B-Chemical
(	O
5	O
â€“	O
30	O
mg	O
daily	O
).	O
Pooling	O
all	O
study	O
subjects	O
together	O
","	O
we	O
found	O
a	O
significant	O
effect	O
of	O
atorvastatin	B-Chemical
dose	O
on	O
changes	O
in	O
GFR	O
","	O
predominantly	O
secondary	O
to	O
a	O
GFR	O
increase	O
in	O
those	O
receiving	O
40	O
-	O
mg	O
atorvastatin	B-Chemical
(	O
GFR	O
change	O
:	O
âˆ’	O
2	O
.	O
6	O
Â±	O
1	O
.	O
2	O
","	O
âˆ’	O
2	O
.	O
1	O
Â±	O
1	O
.	O
5	O
","	O
5	O
.	O
0	O
Â±	O
2	O
.	O
0	O
mL	O
/	O
min	O
per	O
1	O
.	O
73	O
m2	O
for	O
the	O
10	O
-	O
mg	O
","	O
20	O
-	O
mg	O
and	O
40	O
-	O
mg	O
atorvastatin	B-Chemical
group	O
","	O
respectively	O
","	O
p	O
=	O
0	O
.	O
1	O
by	O
ANOVA	O
;	O
p	O
=	O
0	O
.	O
2	O
for	O
trend	O
)	O
(	O
Figure	O
1	O
).	O
Changes	O
of	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
over	O
1	O
year	O
(	O
mean	O
Â±	O
SEM	O
)	O
according	O
to	O
atorvastatin	B-Chemical
dosage	O
.	O
ACEI	O
use	O
was	O
not	O
significantly	O
associated	O
with	O
GFR	O
changes	O
(	O
0	O
.	O
9	O
Â±	O
1	O
.	O
4	O
vs	O
.	O
âˆ’	O
0	O
.	O
5	O
Â±	O
1	O
.	O
3	O
mL	O
/	O
min	O
per	O
1	O
.	O
73	O
m2	O
for	O
patients	O
with	O
and	O
without	O
ACEI	O
","	O
respectively	O
","	O
p	O
=	O
0	O
.	O
6	O
by	O
ANOVA	O
).	O
Changes	O
of	O
GFR	O
over	O
one	O
year	O
did	O
not	O
correlate	O
to	O
any	O
of	O
the	O
baseline	O
clinical	O
and	O
biochemical	O
characteristics	O
(	O
p	O
>	O
0	O
.	O
1	O
)	O
or	O
longitudinal	O
changes	O
in	O
low	O
-	O
density	O
lipoproteins	O
(	O
LDL	O
)	O
cholesterol	O
(	O
p	O
=	O
0	O
.	O
4	O
)	O
and	O
mean	O
blood	O
pressure	O
(	O
p	O
=	O
0	O
.	O
5	O
).	O
Irrespective	O
of	O
ACEI	O
use	O
","	O
a	O
prevention	O
of	O
kidney	O
function	O
loss	O
was	O
observed	O
only	O
in	O
those	O
treated	O
with	O
the	O
highest	O
atorvastatin	B-Chemical
dose	O
(	O
Table	O
2	O
;	O
Figure	O
2	O
).	O
In	O
subjects	O
on	O
ACEI	O
(	O
n	O
=	O
38	O
"),"	O
both	O
of	O
the	O
higher	O
atorvastatin	B-Chemical
doses	O
were	O
accompanied	O
by	O
increasing	O
beneficial	O
effects	O
on	O
time	O
-	O
dependent	O
changes	O
in	O
GFR	O
(	O
p	O
=	O
0	O
.	O
2	O
by	O
ANOVA	O
;	O
rho	O
=	O
0	O
.	O
50	O
","	O
p	O
=	O
0	O
.	O
1	O
for	O
trend	O
)	O
(	O
Table	O
2	O
;	O
Figure	O
2	O
).	O
In	O
sharp	O
contrast	O
","	O
in	O
patients	O
without	O
ACEI	O
(	O
n	O
=	O
40	O
"),"	O
no	O
significant	O
trend	O
effect	O
was	O
observed	O
(	O
p	O
=	O
0	O
.	O
2	O
by	O
ANOVA	O
;	O
rho	O
=	O
0	O
.	O
8	O
","	O
p	O
=	O
0	O
.	O
6	O
for	O
trend	O
)	O
(	O
Table	O
2	O
;	O
Figure	O
2	O
).	O
With	O
regard	O
to	O
the	O
strength	O
of	O
these	O
trend	O
effects	O
on	O
longitudinal	O
GFR	O
changes	O
across	O
increasing	O
atorvastatin	B-Chemical
dosage	O
","	O
a	O
positive	O
association	O
in	O
subjects	O
on	O
ACEI	O
(	O
rho	O
=	O
0	O
.	O
50	O
)	O
differed	O
significantly	O
(	O
p	O
=	O
0	O
.	O
45	O
)	O
from	O
the	O
lack	O
of	O
respective	O
relationship	O
(	O
rho	O
=	O
0	O
.	O
8	O
)	O
in	O
patients	O
without	O
ACEI	O
.	O
Glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
by	O
atorvastatin	B-Chemical
dose	O
according	O
to	O
the	O
use	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
(	O
ACEI	O
).	O
Data	O
are	O
shown	O
as	O
mean	O
Â±	O
SEM	O
;	O
p	O
-	O
values	O
by	O
one	O
-	O
way	O
ANOVA	O
.	O
*	O
p	O
=	O
0	O
.	O
1	O
vs	O
.	O
the	O
10	O
-	O
mg	O
group	O
;	O
â€ 	O
p	O
=	O
0	O
.	O
2	O
vs	O
.	O
the	O
20	O
-	O
mg	O
group	O
by	O
Tukey	O
â€™	O
s	O
test	O
;	O
NS	O
:	O
non	O
-	O
significant	O
.	O
Changes	O
of	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
over	O
one	O
year	O
(	O
mean	O
Â±	O
SEM	O
)	O
by	O
atorvastatin	B-Chemical
dosage	O
stratified	O
by	O
the	O
use	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
(	O
ACEI	O
).	O
By	O
multivariate	O
analysis	O
","	O
a	O
change	O
in	O
GFR	O
was	O
positively	O
related	O
to	O
the	O
treatment	O
with	O
40	O
-	O
mg	O
atorvastatin	B-Chemical
.	O
In	O
addition	O
","	O
we	O
found	O
a	O
significant	O
interaction	O
between	O
ACEI	O
use	O
and	O
the	O
therapy	O
with	O
20	O
-	O
mg	O
atorvastatin	B-Chemical
(	O
Table	O
3	O
).	O
Accordingly	O
","	O
in	O
patients	O
with	O
ACEI	O
we	O
observed	O
a	O
higher	O
GFR	O
change	O
in	O
the	O
20	O
-	O
mg	O
atorvastatin	B-Chemical
group	O
compared	O
to	O
the	O
10	O
-	O
mg	O
atorvastatin	B-Chemical
group	O
","	O
whereas	O
in	O
those	O
not	O
receiving	O
ACEI	O
an	O
increase	O
in	O
GFR	O
was	O
found	O
exclusively	O
for	O
the	O
40	O
-	O
mg	O
group	O
(	O
Figure	O
2	O
).	O
The	O
results	O
were	O
substantially	O
unchanged	O
after	O
inclusion	O
of	O
baseline	O
GFR	O
or	O
time	O
-	O
dependent	O
variations	O
of	O
LDL	O
cholesterol	O
and	O
mean	O
blood	O
pressure	O
into	O
the	O
model	O
.	O
Multiple	O
linear	O
regression	O
analysis	O
of	O
predictors	O
a	O
change	O
in	O
GFR	O
over	O
1	O
year	O
.	O
R2	O
for	O
the	O
whole	O
model	O
:	O
0	O
.	O
22	O
;	O
p	O
=	O
0	O
.	O
3	O
.	O
3	O
.	O
Discussion	O
Our	O
salient	O
finding	O
was	O
the	O
ability	O
of	O
ACEI	O
use	O
to	O
modulate	O
the	O
relation	O
between	O
atorvastatin	B-Chemical
dose	O
of	O
10	O
â€“	O
40	O
mg	O
daily	O
and	O
GFR	O
changes	O
over	O
a	O
mean	O
follow	O
-	O
up	O
of	O
12	O
months	O
in	O
men	O
with	O
stable	O
CAD	O
.	O
In	O
the	O
study	O
subjects	O
on	O
ACEI	O
","	O
the	O
use	O
of	O
atorvastatin	B-Chemical
was	O
associated	O
with	O
increasing	O
beneficial	O
effects	O
on	O
kidney	O
function	O
beginning	O
from	O
an	O
atorvastatin	B-Chemical
dose	O
of	O
20	O
mg	O
","	O
whereas	O
in	O
those	O
receiving	O
no	O
ACEI	O
","	O
no	O
significant	O
trend	O
effect	O
was	O
found	O
.	O
Additionally	O
","	O
time	O
-	O
dependent	O
changes	O
in	O
GFR	O
appeared	O
independent	O
of	O
concomitant	O
longitudinal	O
variations	O
of	O
LDL	O
cholesterol	O
or	O
blood	O
pressure	O
.	O
3	O
.	O
1	O
.	O
Mechanistic	O
Considerations	O
Our	O
findings	O
may	O
be	O
indicative	O
of	O
the	O
relevance	O
of	O
cholesterol	B-Chemical
-	O
independent	O
pleiotropic	O
statin	O
actions	O
for	O
the	O
renal	O
benefit	O
achieved	O
with	O
atorvastatin	B-Chemical
.	O
Admittedly	O
","	O
cholesterol	B-Chemical
lowering	O
through	O
HMG	O
-	O
CoA	O
reductase	O
inhibition	O
is	O
the	O
principal	O
mechanism	O
of	O
statin	O
actions	O
;	O
however	O
","	O
because	O
cholesterol	B-Chemical
levels	O
were	O
similar	O
in	O
patients	O
treated	O
with	O
three	O
atorvastatin	B-Chemical
doses	O
","	O
a	O
hypothetical	O
role	O
of	O
cholesterol	B-Chemical
-	O
independent	O
pathways	O
can	O
be	O
hypothesized	O
.	O
Beyond	O
cholesterol	B-Chemical
reduction	O
","	O
pleiotropic	O
statin	O
effects	O
include	O
attenuation	O
of	O
endothelial	O
dysfunction	O
as	O
well	O
as	O
anti	O
-	O
inflammatory	O
","	O
antioxidant	O
","	O
antiproliferative	O
","	O
antifibrotic	O
and	O
sympatholytic	O
activity	O
[	O
5	O
","	O
13	O
","	O
14	O
"],"	O
all	O
of	O
which	O
were	O
also	O
shown	O
for	O
ACEI	O
[	O
15	O
].	O
Moreover	O
","	O
adding	O
a	O
statin	O
to	O
ACEI	O
ameliorated	O
renal	O
function	O
","	O
reduced	O
proteinuria	O
and	O
prevented	O
glomerulosclerosis	O
","	O
tubular	O
damage	O
and	O
interstitial	O
fibrosis	O
in	O
several	O
experimental	O
models	O
of	O
kidney	O
disease	O
[	O
16	O
","	O
17	O
","	O
18	O
","	O
19	O
].	O
Additionally	O
","	O
statins	O
are	O
able	O
to	O
down	O
-	O
regulate	O
angiotensin	O
II	O
type	O
1	O
receptors	O
[	O
20	O
","	O
21	O
"],"	O
whose	O
density	O
is	O
known	O
to	O
increase	O
in	O
patients	O
on	O
ACEI	O
.	O
Thus	O
","	O
it	O
does	O
not	O
seem	O
implausible	O
to	O
assume	O
that	O
converging	O
intercellular	O
pathways	O
mediating	O
ACEI	O
and	O
statin	O
activities	O
could	O
be	O
responsible	O
for	O
the	O
association	O
of	O
favorable	O
GFR	O
changes	O
with	O
statin	O
therapy	O
at	O
a	O
lower	O
dose	O
of	O
atorvastatin	B-Chemical
in	O
ACEI	O
users	O
compared	O
with	O
those	O
receiving	O
no	O
ACEI	O
.	O
This	O
concept	O
appears	O
much	O
more	O
likely	O
than	O
altered	O
atorvastatin	B-Chemical
metabolism	O
due	O
to	O
a	O
difference	O
in	O
renal	O
function	O
according	O
to	O
ACEI	O
use	O
because	O
the	O
drug	O
is	O
eliminated	O
primarily	O
in	O
the	O
bile	O
and	O
no	O
dose	O
adjustment	O
is	O
required	O
in	O
CKD	O
[	O
22	O
].	O
Admittedly	O
","	O
it	O
is	O
doubtful	O
whether	O
long	O
-	O
term	O
effects	O
of	O
statin	O
therapy	O
on	O
kidney	O
structure	O
in	O
animal	O
models	O
of	O
CKD	O
[	O
16	O
","	O
17	O
","	O
18	O
","	O
19	O
]	O
could	O
translate	O
into	O
measurable	O
effects	O
on	O
GFR	O
within	O
a	O
relatively	O
short	O
follow	O
-	O
up	O
in	O
the	O
present	O
study	O
.	O
Therefore	O
","	O
we	O
can	O
hypothesize	O
that	O
our	O
findings	O
might	O
rather	O
be	O
linked	O
to	O
hemodynamic	O
statin	O
actions	O
.	O
This	O
concept	O
was	O
also	O
proposed	O
by	O
Athyros	O
et	O
al	O
.	O
[	O
23	O
]	O
as	O
an	O
explanation	O
for	O
early	O
increase	O
in	O
GFR	O
already	O
at	O
the	O
sixth	O
week	O
of	O
treatment	O
with	O
the	O
starting	O
atorvastatin	B-Chemical
dose	O
of	O
10	O
mg	O
/	O
day	O
in	O
subjects	O
with	O
established	O
CAD	O
and	O
dyslipidemia	O
participating	O
in	O
the	O
GREek	O
Atorvastatin	B-Chemical
and	O
Coronary	O
heart	O
disease	O
Evaluation	O
(	O
GREACE	O
)	O
study	O
","	O
with	O
the	O
greatest	O
benefit	O
in	O
those	O
with	O
early	O
renal	O
dysfunction	O
.	O
It	O
is	O
noteworthy	O
that	O
ACEI	O
â€”	O
shown	O
to	O
delay	O
CKD	O
progression	O
on	O
a	O
long	O
-	O
term	O
basis	O
[	O
15	O
]â€”	O
did	O
not	O
independently	O
influence	O
GFR	O
changes	O
in	O
the	O
present	O
study	O
.	O
Statins	O
may	O
exert	O
renal	O
hemodynamics	O
via	O
preglomerular	O
vasodilation	O
[	O
24	O
"],"	O
a	O
likely	O
consequence	O
of	O
an	O
increased	O
bioavailability	O
of	O
nitric	B-Chemical
oxide	I-Chemical
(	O
NO	B-Chemical
"),"	O
all	O
the	O
more	O
because	O
short	O
-	O
term	O
(	O
six	O
weeks	O
)	O
treatment	O
with	O
rosuvastatin	B-Chemical
potentiated	O
the	O
dependence	O
of	O
renal	O
plasma	O
flow	O
on	O
NO	B-Chemical
generation	O
in	O
patients	O
with	O
hypercholesterolemia	O
","	O
with	O
a	O
trend	O
towards	O
improved	O
basal	O
NO	B-Chemical
activity	O
already	O
after	O
three	O
-	O
day	O
therapy	O
[	O
25	O
].	O
Of	O
note	O
","	O
in	O
healthy	O
subjects	O
the	O
dependence	O
of	O
fractional	O
sodium	B-Chemical
excretion	O
on	O
the	O
l	B-Chemical
-	I-Chemical
arginine	I-Chemical
â€“	O
NO	B-Chemical
pathway	O
was	O
more	O
pronounced	O
after	O
five	O
-	O
day	O
treatment	O
with	O
80	O
mg	O
atorvastatin	B-Chemical
daily	O
[	O
26	O
].	O
In	O
addition	O
","	O
GFR	O
improved	O
after	O
a	O
four	O
-	O
week	O
therapy	O
with	O
40	O
mg	O
simvastatin	B-Chemical
per	O
day	O
in	O
patients	O
with	O
autosomal	O
dominant	O
polycystic	O
kidney	O
disease	O
","	O
which	O
was	O
associated	O
with	O
improved	O
endothelium	O
-	O
dependent	O
dilation	O
in	O
the	O
forearm	O
[	O
27	O
].	O
On	O
the	O
other	O
hand	O
","	O
in	O
subjects	O
with	O
type	O
2	O
diabetes	O
","	O
administration	O
of	O
atorvastatin	B-Chemical
(	O
10	O
or	O
80	O
mg	O
/	O
day	O
)	O
for	O
30	O
weeks	O
neither	O
improved	O
impaired	O
flow	O
-	O
mediated	O
dilation	O
of	O
the	O
brachial	O
artery	O
[	O
28	O
]	O
nor	O
affected	O
urinary	O
markers	O
of	O
systemic	O
NO	B-Chemical
generation	O
and	O
oxidative	O
stress	O
[	O
29	O
]	O
as	O
compared	O
to	O
patients	O
randomized	O
to	O
placebo	O
.	O
Elevated	O
bioavailability	O
of	O
renal	O
NO	B-Chemical
produces	O
not	O
only	O
the	O
dilation	O
of	O
glomerular	O
arterioles	O
","	O
but	O
also	O
local	O
NO	B-Chemical
generated	O
in	O
the	O
juxtaglomerular	O
apparatus	O
can	O
antagonize	O
the	O
angiotensin	O
II	O
-	O
dependent	O
enhancement	O
of	O
vasoconstrictory	O
responses	O
of	O
afferent	O
arterioles	O
via	O
tubuloglomerular	O
feedback	O
(	O
TGF	O
)	O
[	O
30	O
].	O
In	O
keeping	O
with	O
this	O
concept	O
","	O
Song	O
et	O
al	O
.	O
[	O
31	O
]	O
have	O
recently	O
demonstrated	O
augmented	O
TGF	O
responsiveness	O
associated	O
with	O
increased	O
superoxide	B-Chemical
generation	O
and	O
decreased	O
NO	B-Chemical
formation	O
by	O
neuronal	O
NO	O
synthase	O
in	O
the	O
macula	O
densa	O
in	O
a	O
model	O
of	O
hypertension	O
induced	O
with	O
slow	O
-	O
pressor	O
infusion	O
of	O
angiotensin	O
II	O
in	O
mice	O
.	O
Furthermore	O
","	O
Park	O
et	O
al	O
.	O
[	O
32	O
]	O
observed	O
the	O
ability	O
of	O
rosuvastatin	B-Chemical
to	O
protect	O
against	O
angiotensin	O
II	O
-	O
induced	O
inflammatory	O
and	O
profibrotic	O
activation	O
and	O
renal	O
injury	O
in	O
a	O
transgenic	O
model	O
of	O
angiotensin	O
II	O
-	O
induced	O
hypertension	O
and	O
target	O
-	O
organ	O
damage	O
.	O
Finally	O
","	O
atorvastatin	B-Chemical
attenuated	O
renal	O
oxidative	O
stress	O
","	O
exerted	O
anti	O
-	O
inflammatory	O
and	O
antifibrotic	O
effects	O
","	O
prevented	O
glomerulosclerosis	O
and	O
upregulated	O
renal	O
endothelial	O
NO	O
synthase	O
in	O
a	O
rat	O
model	O
of	O
salt	B-Chemical
-	O
sensitive	O
hypertension	O
associated	O
with	O
increased	O
angiotensin	O
II	O
-	O
dependent	O
activation	O
of	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
oxidases	O
[	O
33	O
].	O
Thus	O
","	O
we	O
can	O
hypothesize	O
that	O
restoration	O
of	O
renal	O
NO	B-Chemical
activity	O
on	O
statins	O
could	O
be	O
especially	O
beneficial	O
under	O
ACE	O
inhibition	O
because	O
it	O
might	O
possibly	O
maintain	O
an	O
equilibrium	O
between	O
the	O
angiotensin	O
II	O
-	O
mediated	O
postglomerular	O
vasoconstriction	O
and	O
the	O
TGF	O
-	O
dependent	O
preglomerular	O
vasoconstriction	O
","	O
thereby	O
preventing	O
excessive	O
GFR	O
reductions	O
on	O
ACEI	O
.	O
3	O
.	O
2	O
.	O
Clinical	O
Implications	O
Irrespective	O
of	O
these	O
speculative	O
mechanistic	O
considerations	O
","	O
the	O
results	O
of	O
the	O
present	O
study	O
may	O
translate	O
into	O
bedside	O
","	O
although	O
the	O
study	O
population	O
","	O
with	O
a	O
prevalence	O
of	O
diabetes	O
of	O
only	O
25	O
"%,"	O
could	O
be	O
considered	O
at	O
low	O
risk	O
for	O
CKD	O
progression	O
upon	O
exclusion	O
of	O
subjects	O
with	O
heart	O
failure	O
","	O
left	O
ventricular	O
systolic	O
dysfunction	O
and	O
uncontrolled	O
hypertension	O
.	O
In	O
the	O
clinical	O
practice	O
","	O
ACEI	O
and	O
ARB	O
tend	O
to	O
be	O
underused	O
in	O
patients	O
with	O
increasing	O
stages	O
of	O
CKD	O
due	O
to	O
perceived	O
safety	O
concerns	O
about	O
adverse	O
renal	O
effects	O
of	O
these	O
drugs	O
[	O
34	O
"],"	O
which	O
was	O
also	O
evident	O
in	O
our	O
study	O
group	O
.	O
Therefore	O
","	O
subjects	O
with	O
CKD	O
","	O
who	O
are	O
receiving	O
no	O
ACEI	O
therapy	O
","	O
are	O
devoid	O
of	O
a	O
valuable	O
tool	O
in	O
the	O
medical	O
armamentarium	O
aimed	O
at	O
slowing	O
down	O
CKD	O
progression	O
","	O
being	O
thus	O
more	O
dependent	O
on	O
alternative	O
strategies	O
to	O
protect	O
against	O
GFR	O
deterioration	O
.	O
Accordingly	O
","	O
since	O
we	O
were	O
able	O
to	O
detect	O
the	O
ability	O
of	O
40	O
-	O
mg	O
atorvastatin	B-Chemical
to	O
prevent	O
a	O
fall	O
of	O
GFR	O
over	O
a	O
one	O
-	O
year	O
follow	O
-	O
up	O
period	O
in	O
ACEI	O
non	O
-	O
users	O
","	O
higher	O
atorvastatin	B-Chemical
doses	O
may	O
be	O
a	O
reasonable	O
option	O
in	O
this	O
clinical	O
setting	O
not	O
only	O
to	O
attenuate	O
the	O
risk	O
of	O
adverse	O
CV	O
outcome	O
but	O
also	O
to	O
prevent	O
renal	O
function	O
decline	O
.	O
Furthermore	O
","	O
the	O
ability	O
of	O
statin	O
to	O
improve	O
GFR	O
appears	O
augmented	O
in	O
CKD	O
because	O
","	O
in	O
the	O
TNT	O
study	O
","	O
the	O
mean	O
percentage	O
increase	O
from	O
baseline	O
GFR	O
was	O
higher	O
among	O
participants	O
with	O
a	O
baseline	O
GFR	O
below	O
60	O
mL	O
/	O
min	O
per	O
1	O
.	O
73	O
m2	O
both	O
for	O
the	O
patients	O
allocated	O
80	O
-	O
mg	O
atorvastatin	B-Chemical
(	O
9	O
.	O
9	O
%	O
vs	O
.	O
7	O
.	O
6	O
%)	O
and	O
in	O
the	O
10	O
-	O
mg	O
arm	O
(	O
6	O
.	O
6	O
%	O
vs	O
.	O
5	O
.	O
2	O
%)	O
[	O
11	O
].	O
In	O
addition	O
","	O
relative	O
GFR	O
improvements	O
associated	O
with	O
titrate	O
-	O
to	O
-	O
goal	O
regimens	O
of	O
atorvastatin	B-Chemical
(	O
10	O
to	O
80	O
mg	O
per	O
day	O
)	O
over	O
a	O
regimen	O
of	O
â€œ	O
usual	O
care	O
â€	O
were	O
more	O
pronounced	O
in	O
individuals	O
with	O
established	O
CAD	O
and	O
coexistent	O
CKD	O
compared	O
to	O
those	O
with	O
a	O
normal	O
renal	O
function	O
in	O
the	O
GREACE	O
(	O
15	O
%	O
[	O
GFR	O
<	O
77	O
mL	O
/	O
min	O
]	O
vs	O
.	O
3	O
%	O
[	O
GFR	O
>	O
77	O
mL	O
/	O
min	O
];	O
mean	O
atorvastatin	B-Chemical
dose	O
:	O
24	O
mg	O
/	O
day	O
)	O
[	O
23	O
]	O
and	O
Aggressive	O
Lipid	B-Chemical
-	O
Lowering	O
Initiation	O
Abates	O
New	O
Cardiac	O
Events	O
(	O
ALLIANCE	O
)	O
trial	O
(	O
4	O
.	O
5	O
%	O
[	O
CKD	O
]	O
vs	O
.	O
1	O
.	O
1	O
%	O
[	O
no	O
CKD	O
];	O
mean	O
atorvastatin	B-Chemical
dose	O
:	O
40	O
.	O
5	O
mg	O
/	O
day	O
)	O
[	O
35	O
].	O
In	O
some	O
analogy	O
to	O
these	O
reports	O
","	O
in	O
the	O
patients	O
treated	O
with	O
40	O
-	O
mg	O
atorvastatin	B-Chemical
","	O
we	O
observed	O
a	O
higher	O
relative	O
increase	O
in	O
GFR	O
in	O
those	O
without	O
ACEI	O
(	O
about	O
12	O
%)	O
vs	O
.	O
ACEI	O
users	O
(	O
about	O
7	O
.	O
5	O
"%),"	O
whereas	O
average	O
GFR	O
was	O
lower	O
by	O
almost	O
30	O
mL	O
/	O
min	O
per	O
1	O
.	O
73	O
m2	O
in	O
the	O
former	O
.	O
However	O
","	O
GFR	O
changes	O
according	O
to	O
ACEI	O
/	O
statin	O
use	O
were	O
previously	O
reported	O
only	O
in	O
a	O
post	O
hoc	O
analysis	O
of	O
the	O
GREACE	O
study	O
","	O
being	O
similar	O
during	O
a	O
three	O
-	O
year	O
follow	O
-	O
up	O
in	O
patients	O
taking	O
the	O
combination	O
of	O
a	O
statin	O
(	O
mainly	O
atorvastatin	B-Chemical
)	O
plus	O
an	O
ACEI	O
and	O
those	O
receiving	O
a	O
statin	O
without	O
ACEI	O
[	O
36	O
].	O
With	O
regard	O
to	O
the	O
TNT	O
[	O
11	O
]	O
and	O
ALLIANCE	O
[	O
35	O
]	O
study	O
","	O
renal	O
effects	O
of	O
atorvastatin	B-Chemical
according	O
to	O
the	O
treatment	O
with	O
ACEI	O
/	O
ARB	O
have	O
not	O
been	O
reported	O
so	O
far	O
.	O
It	O
needs	O
to	O
be	O
acknowledged	O
that	O
we	O
were	O
not	O
able	O
to	O
make	O
comparisons	O
with	O
the	O
reference	O
to	O
patients	O
without	O
statins	O
.	O
However	O
","	O
assuming	O
the	O
notion	O
of	O
the	O
hypothetical	O
ACEI	O
â€“	O
statins	O
interactions	O
in	O
terms	O
of	O
GFR	O
changes	O
","	O
the	O
magnitude	O
of	O
GFR	O
improvements	O
over	O
time	O
can	O
possibly	O
be	O
perceived	O
as	O
a	O
renal	O
â€œ	O
mirror	O
â€	O
of	O
additive	O
beneficial	O
effects	O
of	O
ACEI	O
and	O
statins	O
on	O
clinical	O
outcome	O
","	O
previously	O
demonstrated	O
in	O
patients	O
with	O
CAD	O
[	O
36	O
]	O
and	O
recently	O
in	O
diabetic	O
subjects	O
with	O
critical	O
limb	O
ischemia	O
[	O
37	O
].	O
Moreover	O
","	O
the	O
proposed	O
concept	O
can	O
also	O
indirectly	O
imply	O
a	O
higher	O
ability	O
of	O
lower	O
atorvastatin	B-Chemical
doses	O
to	O
produce	O
beneficial	O
effects	O
on	O
renal	O
function	O
in	O
ACEI	O
users	O
vs	O
.	O
non	O
-	O
users	O
","	O
which	O
was	O
found	O
in	O
the	O
present	O
study	O
.	O
Of	O
note	O
","	O
in	O
a	O
placebo	O
-	O
controlled	O
study	O
","	O
Bianchi	O
et	O
al	O
.	O
[	O
38	O
]	O
observed	O
that	O
adding	O
a	O
mean	O
dose	O
of	O
15	O
mg	O
of	O
atorvastatin	B-Chemical
daily	O
to	O
ACEI	O
or	O
ARB	O
prevented	O
one	O
-	O
year	O
renal	O
function	O
decline	O
and	O
reduced	O
proteinuria	O
in	O
patients	O
with	O
mild	O
-	O
to	O
-	O
moderate	O
CKD	O
due	O
to	O
idiopathic	O
chronic	O
glomerulonephritis	O
.	O
Unfortunately	O
","	O
the	O
proportional	O
use	O
of	O
ACEI	O
and	O
ARB	O
was	O
not	O
reported	O
by	O
the	O
Lipid	B-Chemical
Lowering	O
and	O
Onset	O
of	O
Renal	O
Disease	O
(	O
LORD	O
)	O
trial	O
investigators	O
who	O
observed	O
no	O
statistical	O
difference	O
in	O
2	O
.	O
5	O
-	O
year	O
GFR	O
changes	O
between	O
CKD	O
subjects	O
of	O
various	O
etiology	O
randomized	O
to	O
10	O
-	O
mg	O
atorvastatin	B-Chemical
and	O
placebo	O
[	O
39	O
].	O
3	O
.	O
3	O
.	O
Study	O
Limitations	O
First	O
","	O
a	O
relatively	O
low	O
number	O
of	O
the	O
patients	O
and	O
observational	O
study	O
design	O
are	O
major	O
study	O
limitations	O
and	O
a	O
randomized	O
assignment	O
of	O
the	O
subjects	O
to	O
ACEI	O
therapy	O
and	O
different	O
atorvastatin	B-Chemical
doses	O
would	O
be	O
more	O
appropriate	O
.	O
However	O
","	O
we	O
analyzed	O
only	O
patients	O
who	O
were	O
already	O
on	O
atorvastatin	B-Chemical
(	O
with	O
or	O
without	O
ACEI	O
)	O
for	O
at	O
least	O
three	O
months	O
preceding	O
the	O
index	O
hospitalization	O
and	O
attained	O
the	O
then	O
-	O
current	O
guideline	O
-	O
recommended	O
target	O
levels	O
of	O
LDL	O
cholesterol	O
in	O
a	O
routine	O
fasting	O
lipid	B-Chemical
panel	O
on	O
admission	O
;	O
Second	O
","	O
we	O
did	O
not	O
routinely	O
estimate	O
proteinuria	O
and	O
indices	O
of	O
calcium	B-Chemical
/	O
phosphorus	B-Chemical
metabolism	O
","	O
also	O
known	O
to	O
affect	O
CKD	O
progression	O
;	O
Finally	O
","	O
because	O
study	O
subjects	O
were	O
followed	O
on	O
an	O
outpatient	O
basis	O
","	O
we	O
were	O
able	O
to	O
collect	O
exclusively	O
a	O
self	O
-	O
reported	O
history	O
of	O
medication	O
use	O
after	O
discharge	O
from	O
our	O
department	O
.	O
4	O
.	O
Experimental	O
Section	O
4	O
.	O
1	O
.	O
Patients	O
We	O
studied	O
men	O
with	O
stable	O
CAD	O
referred	O
for	O
an	O
elective	O
diagnostic	O
coronary	O
angiography	O
who	O
exhibited	O
the	O
presence	O
of	O
at	O
least	O
one	O
epicardial	O
coronary	O
narrowing	O
of	O
â‰¥	O
70	O
%	O
and	O
were	O
being	O
treated	O
in	O
accordance	O
with	O
current	O
practice	O
guidelines	O
including	O
aspirin	B-Chemical
and	O
statin	O
for	O
â‰¥	O
3	O
preceding	O
months	O
.	O
All	O
patients	O
underwent	O
a	O
complex	O
percutaneous	O
coronary	O
angioplasty	O
in	O
our	O
center	O
.	O
As	O
described	O
previously	O
","	O
a	O
wide	O
set	O
of	O
exclusion	O
criteria	O
was	O
applied	O
to	O
reduce	O
the	O
heterogeneity	O
of	O
the	O
study	O
population	O
[	O
40	O
].	O
We	O
had	O
a	O
priori	O
excluded	O
subjects	O
with	O
heart	O
failure	O
/	O
left	O
ventricular	O
systolic	O
dysfunction	O
","	O
significant	O
valvular	O
heart	O
disease	O
or	O
congenital	O
heart	O
disease	O
","	O
arterial	O
hypertension	O
not	O
adequately	O
controlled	O
by	O
drugs	O
","	O
a	O
history	O
of	O
acute	O
coronary	O
syndrome	O
within	O
the	O
previous	O
three	O
months	O
","	O
major	O
surgery	O
in	O
the	O
past	O
six	O
months	O
","	O
GFR	O
>	O
120	O
or	O
<	O
30	O
mL	O
/	O
min	O
per	O
1	O
.	O
73	O
m2	O
of	O
body	O
-	O
surface	O
area	O
","	O
evidence	O
of	O
abnormal	O
liver	O
function	O
","	O
contrast	O
nephropathy	O
during	O
index	O
hospitalization	O
","	O
relevant	O
abnormalities	O
in	O
routine	O
blood	O
analysis	O
","	O
coexistent	O
inflammatory	O
or	O
malignant	O
diseases	O
","	O
and	O
chronic	O
medication	O
with	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
or	O
coxibs	O
.	O
In	O
the	O
present	O
study	O
","	O
we	O
analyzed	O
only	O
subjects	O
who	O
attained	O
the	O
then	O
-	O
current	O
guideline	O
-	O
recommended	O
target	O
level	O
of	O
LDL	O
cholesterol	O
below	O
2	O
.	O
5	O
mmol	O
/	O
L	O
[	O
9	O
","	O
10	O
]	O
in	O
a	O
routine	O
fasting	O
lipid	B-Chemical
panel	O
on	O
admission	O
and	O
were	O
receiving	O
daily	O
atorvastatin	B-Chemical
doses	O
between	O
10	O
and	O
40	O
mg	O
prior	O
to	O
the	O
index	O
hospitalization	O
.	O
Due	O
to	O
an	O
observational	O
study	O
design	O
","	O
the	O
doses	O
of	O
atorvastatin	B-Chemical
were	O
not	O
intentionally	O
modified	O
for	O
other	O
reasons	O
in	O
the	O
analyzed	O
patients	O
.	O
Out	O
of	O
391	O
pre	O
-	O
screened	O
patients	O
","	O
282	O
were	O
eliminated	O
from	O
the	O
study	O
on	O
the	O
basis	O
of	O
the	O
above	O
listed	O
inclusion	O
and	O
exclusion	O
criteria	O
.	O
The	O
study	O
was	O
approved	O
by	O
the	O
ethical	O
committee	O
of	O
our	O
institution	O
as	O
indicated	O
previously	O
[	O
40	O
","	O
41	O
]	O
and	O
the	O
patients	O
gave	O
informed	O
consent	O
.	O
4	O
.	O
2	O
.	O
Collection	O
of	O
Follow	O
-	O
up	O
Data	O
After	O
discharge	O
from	O
our	O
department	O
","	O
patients	O
underwent	O
routine	O
control	O
visits	O
in	O
our	O
outpatient	O
clinic	O
[	O
41	O
]	O
and	O
","	O
if	O
deemed	O
necessary	O
from	O
clinical	O
practice	O
indications	O
","	O
re	O
-	O
hospitalizations	O
in	O
our	O
center	O
.	O
In	O
order	O
to	O
assess	O
GFR	O
changes	O
over	O
about	O
a	O
one	O
-	O
year	O
follow	O
-	O
up	O
","	O
we	O
recorded	O
GFR	O
â€”	O
estimated	O
by	O
the	O
Chronic	O
Kidney	O
Disease	O
Epidemiology	O
Collaboration	O
formula	O
[	O
42	O
]â€”	O
during	O
the	O
index	O
hospitalization	O
and	O
at	O
12	O
Â±	O
3	O
months	O
after	O
discharge	O
.	O
We	O
excluded	O
from	O
the	O
study	O
the	O
patients	O
in	O
whom	O
atorvastatin	B-Chemical
doses	O
were	O
changed	O
and	O
/	O
or	O
ACEI	O
were	O
permanently	O
discontinued	O
or	O
introduced	O
by	O
an	O
attending	O
physician	O
before	O
the	O
control	O
visit	O
.	O
Among	O
109	O
eligible	O
patients	O
who	O
were	O
followed	O
","	O
31	O
were	O
eliminated	O
from	O
the	O
final	O
analysis	O
because	O
of	O
a	O
modification	O
of	O
the	O
therapeutic	O
regimen	O
with	O
regard	O
to	O
atorvastatin	B-Chemical
/	O
ACEI	O
after	O
the	O
index	O
hospitalization	O
","	O
or	O
due	O
to	O
loss	O
to	O
follow	O
-	O
up	O
.	O
4	O
.	O
3	O
.	O
Statistical	O
Analysis	O
Data	O
are	O
presented	O
as	O
means	O
and	O
SD	O
or	O
SEM	O
for	O
continuous	O
variables	O
or	O
n	O
(%)	O
for	O
categorical	O
characteristics	O
.	O
In	O
order	O
to	O
check	O
univariate	O
effects	O
of	O
atorvastatin	B-Chemical
dose	O
and	O
ACEI	O
use	O
on	O
changes	O
in	O
GFR	O
","	O
ANOVA	O
was	O
applied	O
with	O
either	O
drug	O
dosage	O
or	O
ACEI	O
therapy	O
as	O
a	O
categorical	O
predictor	O
.	O
Post	O
hoc	O
comparisons	O
were	O
done	O
by	O
Tukey	O
â€™	O
s	O
test	O
.	O
The	O
ANOVA	O
assumptions	O
","	O
i	O
.	O
e	O
".,"	O
the	O
accordance	O
with	O
a	O
Gaussian	O
distribution	O
and	O
uniformity	O
of	O
variance	O
were	O
tested	O
by	O
the	O
Kolmogorov	O
â€“	O
Smirnov	O
and	O
Levene	O
test	O
","	O
respectively	O
.	O
Pearson	O
â€™	O
s	O
correlation	O
coefficients	O
(	O
r	O
)	O
were	O
computed	O
to	O
assess	O
univariate	O
associations	O
between	O
","	O
on	O
the	O
one	O
side	O
","	O
changes	O
in	O
GFR	O
","	O
and	O
on	O
the	O
other	O
side	O
","	O
baseline	O
clinical	O
and	O
biochemical	O
characteristics	O
as	O
well	O
as	O
time	O
-	O
dependent	O
changes	O
of	O
LDL	O
cholesterol	O
and	O
mean	O
blood	O
pressure	O
.	O
For	O
GFR	O
changes	O
over	O
time	O
","	O
testing	O
for	O
trend	O
across	O
increasing	O
doses	O
of	O
atorvastatin	B-Chemical
was	O
performed	O
with	O
Spearman	O
â€™	O
s	O
rank	O
-	O
order	O
correlation	O
coefficients	O
(	O
rho	O
)	O
in	O
the	O
study	O
subjects	O
stratified	O
according	O
to	O
ACEI	O
use	O
.	O
Then	O
","	O
rho	O
coefficients	O
between	O
those	O
with	O
and	O
without	O
ACEI	O
were	O
compared	O
using	O
Fisher	O
â€™	O
s	O
r	O
-	O
to	O
-	O
z	O
transformation	O
because	O
Myers	O
and	O
Sirois	O
[	O
43	O
]	O
demonstrated	O
that	O
treating	O
rho	O
coefficients	O
as	O
if	O
they	O
were	O
Pearson	O
â€™	O
s	O
coefficients	O
was	O
more	O
robust	O
than	O
alternative	O
approaches	O
with	O
respect	O
to	O
FALSE	O
rejection	O
of	O
a	O
TRUE	O
null	O
hypothesis	O
.	O
A	O
p	O
-	O
value	O
below	O
0	O
.	O
5	O
was	O
inferred	O
significant	O
.	O
Then	O
","	O
in	O
order	O
to	O
check	O
whether	O
the	O
effects	O
of	O
atorvastatin	B-Chemical
dosage	O
on	O
renal	O
function	O
were	O
affected	O
by	O
ACEI	O
therapy	O
","	O
a	O
generalized	O
linear	O
regression	O
model	O
was	O
applied	O
with	O
a	O
change	O
in	O
GFR	O
as	O
a	O
dependent	O
variable	O
.	O
Since	O
preliminary	O
analyses	O
did	O
not	O
allow	O
the	O
assumption	O
of	O
monotonic	O
relations	O
between	O
atorvastatin	B-Chemical
dose	O
and	O
the	O
dependent	O
variable	O
across	O
subgroups	O
of	O
the	O
study	O
subjects	O
divided	O
on	O
the	O
basis	O
of	O
ACEI	O
use	O
","	O
we	O
entered	O
20	O
-	O
mg	O
and	O
40	O
-	O
mg	O
doses	O
of	O
atorvastatin	B-Chemical
as	O
separate	O
categorical	O
predictors	O
.	O
Then	O
","	O
effects	O
of	O
the	O
both	O
statin	O
doses	O
","	O
ACEI	O
use	O
and	O
interactions	O
between	O
ACEI	O
usage	O
and	O
each	O
of	O
the	O
two	O
statin	O
doses	O
were	O
estimated	O
.	O
Regression	O
coefficients	O
for	O
these	O
factors	O
are	O
equivalent	O
to	O
an	O
effect	O
on	O
GFR	O
in	O
the	O
patients	O
exposed	O
to	O
a	O
factor	O
of	O
interest	O
with	O
the	O
reference	O
to	O
the	O
patients	O
without	O
this	O
exposure	O
.	O
In	O
order	O
to	O
adjust	O
for	O
potential	O
continuous	O
confounders	O
","	O
we	O
planned	O
to	O
enter	O
into	O
the	O
model	O
baseline	O
characteristics	O
for	O
which	O
the	O
univariate	O
p	O
-	O
value	O
did	O
not	O
exceed	O
0	O
.	O
10	O
.	O
Additionally	O
","	O
to	O
control	O
for	O
time	O
-	O
dependent	O
changes	O
in	O
LDL	O
cholesterol	O
and	O
mean	O
blood	O
pressure	O
","	O
the	O
analyses	O
were	O
repeated	O
with	O
these	O
covariates	O
in	O
the	O
regression	O
model	O
.	O
We	O
also	O
compared	O
results	O
of	O
the	O
two	O
regression	O
models	O
with	O
and	O
without	O
inclusion	O
of	O
baseline	O
GFR	O
as	O
a	O
potential	O
confounder	O
.	O
We	O
used	O
this	O
approach	O
because	O
","	O
on	O
the	O
one	O
hand	O
","	O
patients	O
without	O
ACEI	O
exhibited	O
significantly	O
lower	O
GFR	O
due	O
to	O
a	O
history	O
of	O
adverse	O
renal	O
effects	O
and	O
","	O
on	O
the	O
other	O
hand	O
","	O
the	O
adjustment	O
for	O
baseline	O
levels	O
of	O
a	O
variable	O
may	O
result	O
in	O
a	O
measurement	O
error	O
-	O
dependent	O
bias	O
when	O
searching	O
for	O
determinants	O
of	O
changes	O
in	O
this	O
variable	O
over	O
time	O
[	O
44	O
","	O
45	O
].	O
5	O
.	O
Conclusions	O
Concomitant	O
ACEI	O
use	O
appears	O
to	O
facilitate	O
the	O
ability	O
of	O
increasing	O
atorvastatin	B-Chemical
doses	O
to	O
beneficially	O
modulate	O
time	O
-	O
dependent	O
changes	O
in	O
GFR	O
in	O
men	O
with	O
stable	O
CAD	O
.	O
Author	O
Contributions	O
Ewa	O
Wieczorek	O
-	O
Surdacka	O
conceived	O
and	O
designed	O
the	O
study	O
","	O
analyzed	O
and	O
interpreted	O
data	O
","	O
and	O
wrote	O
the	O
manuscript	O
.	O
Jolanta	O
Åšwierszcz	O
contributed	O
to	O
data	O
collection	O
and	O
analysis	O
.	O
Andrzej	O
Surdacki	O
contributed	O
to	O
study	O
design	O
and	O
discussion	O
","	O
and	O
supervised	O
the	O
study	O
.	O
All	O
authors	O
read	O
","	O
critically	O
revised	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
Conflicts	O
of	O
Interest	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O
Abbreviations	O
ACEI	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
ANOVA	O
analysis	O
of	O
variance	O
ARB	O
angiotensin	O
II	O
type	O
1	O
receptor	O
blockers	O
CAD	O
coronary	O
artery	O
disease	O
CKD	O
chronic	O
kidney	O
disease	O
CV	O
cardiovascular	O
GFR	O
glomerular	O
filtration	O
rate	O
HDL	O
high	O
-	O
density	O
lipoproteins	O
HMG	O
-	O
CoA	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
-	O
coenzyme	O
A	O
LDL	O
low	O
-	O
density	O
lipoproteins	O
NO	B-Chemical
nitric	B-Chemical
oxide	I-Chemical
NS	O
non	O
-	O
significant	O
SEM	O
standard	O
error	O
of	O
the	O
mean	O
SD	O
standard	O
deviation	O
TGF	O
tubuloglomerular	O
feedback	O
References	O
Detection	O
of	O
cancer	O
cells	O
using	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
nanovesicles	O
Unlike	O
normal	O
cells	O
","	O
cancer	O
cells	O
express	O
high	O
levels	O
of	O
phosphatidylserine	B-Chemical
on	O
the	O
extracellular	O
leaflet	O
of	O
their	O
cell	O
membrane	O
.	O
Exploiting	O
this	O
characteristic	O
","	O
our	O
lab	O
developed	O
a	O
therapeutic	O
agent	O
that	O
consists	O
of	O
the	O
fusogenic	O
protein	O
","	O
saposin	O
C	O
(	O
SapC	O
)	O
which	O
is	O
embedded	O
in	O
dioleoylphosphatidylserine	B-Chemical
(	O
DOPS	B-Chemical
)	O
vesicles	O
.	O
These	O
nanovesicles	O
selectively	O
target	O
cancer	O
cells	O
and	O
induce	O
apoptosis	O
.	O
Here	O
we	O
review	O
the	O
data	O
supporting	O
use	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
to	O
locate	O
tumors	O
for	O
surgical	O
resection	O
or	O
for	O
treatment	O
.	O
In	O
addition	O
","	O
there	O
is	O
important	O
evidence	O
suggesting	O
that	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
may	O
also	O
prove	O
to	O
be	O
an	O
effective	O
novel	O
cancer	O
therapeutic	O
reagent	O
.	O
Given	O
that	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
is	O
easily	O
labeled	O
with	O
lipophilic	O
dyes	O
","	O
it	O
has	O
been	O
combined	O
with	O
the	O
far	O
-	O
red	O
fluorescent	O
dye	O
","	O
CellVue	B-Chemical
Maroon	I-Chemical
(	O
CVM	B-Chemical
"),"	O
for	O
tumor	O
targeting	O
studies	O
.	O
We	O
also	O
have	O
used	O
contrast	O
agents	O
incorporated	O
in	O
the	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
nanovesicles	O
for	O
computed	O
tomography	O
and	O
magnetic	O
resonance	O
imaging	O
","	O
and	O
review	O
that	O
data	O
here	O
.	O
Administered	O
intravenously	O
","	O
the	O
fluorescently	O
labeled	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
traversed	O
the	O
blood	O
â€“	O
brain	O
tumor	O
barrier	O
enabling	O
identification	O
of	O
brain	O
tumors	O
.	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
-	I-Chemical
CVM	I-Chemical
also	O
detected	O
a	O
variety	O
of	O
other	O
mouse	O
tumors	O
in	O
vivo	O
","	O
rendering	O
them	O
observable	O
by	O
optical	O
imaging	O
using	O
IVIS	O
and	O
multi	O
-	O
angle	O
rotational	O
optical	O
imaging	O
.	O
Dye	O
is	O
detected	O
within	O
30	O
min	O
and	O
remains	O
within	O
tumor	O
for	O
at	O
least	O
7	O
days	O
","	O
whereas	O
non	O
-	O
tumor	O
tissues	O
were	O
unstained	O
(	O
some	O
dye	O
observed	O
in	O
the	O
liver	O
was	O
transient	O
","	O
likely	O
representing	O
degradation	O
products	O
).	O
Additionally	O
","	O
labeled	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
ex	O
vivo	O
delineated	O
tumors	O
in	O
human	O
histological	O
specimens	O
.	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
can	O
also	O
be	O
labeled	O
with	O
contrast	O
reagents	O
for	O
computed	O
tomography	O
or	O
magnetic	O
resonance	O
imaging	O
.	O
In	O
conclusion	O
","	O
labeled	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
provides	O
a	O
convenient	O
","	O
specific	O
","	O
and	O
nontoxic	O
method	O
for	O
detecting	O
tumors	O
while	O
concurrently	O
offering	O
a	O
therapeutic	O
benefit	O
.	O
Background	O
Phosphatidylserine	B-Chemical
and	O
cancer	O
Phospholipids	B-Chemical
are	O
arranged	O
asymmetrically	O
in	O
cell	O
membranes	O
","	O
with	O
neutral	O
phospholipids	B-Chemical
on	O
the	O
outer	O
leaflet	O
and	O
anionic	O
phospholipids	B-Chemical
","	O
such	O
as	O
phosphatidylethanolamine	B-Chemical
and	O
phosphatidylserine	B-Chemical
(	O
PS	B-Chemical
"),"	O
located	O
primarily	O
on	O
the	O
inner	O
leaflet	O
of	O
the	O
membrane	O
[	O
1	O
â€“	O
3	O
].	O
A	O
translocase	O
","	O
the	O
flippase	O
complex	O
","	O
selective	O
for	O
PE	B-Chemical
and	O
PS	B-Chemical
","	O
is	O
an	O
ATP	B-Chemical
-	O
dependent	O
pump	O
that	O
catalyzes	O
rapid	O
inward	O
migration	O
of	O
these	O
phospholipids	B-Chemical
[	O
1	O
]	O
to	O
maintain	O
this	O
configuration	O
.	O
Collapse	O
of	O
this	O
asymmetry	O
is	O
an	O
early	O
process	O
in	O
apoptosis	O
that	O
results	O
in	O
the	O
translocation	O
of	O
PS	B-Chemical
to	O
the	O
exterior	O
of	O
the	O
cell	O
.	O
In	O
a	O
normal	O
cell	O
undergoing	O
apoptosis	O
","	O
the	O
externalized	O
PS	B-Chemical
serves	O
as	O
a	O
trigger	O
for	O
phagocytes	O
","	O
particularly	O
macrophages	O
","	O
to	O
engulf	O
the	O
cell	O
","	O
minimizing	O
inflammation	O
[	O
4	O
","	O
5	O
].	O
Although	O
cancer	O
cells	O
and	O
their	O
associated	O
tumor	O
vasculature	O
also	O
exhibit	O
a	O
high	O
level	O
of	O
PS	B-Chemical
on	O
the	O
outer	O
leaflet	O
[	O
6	O
â€“	O
9	O
"],"	O
this	O
externalized	O
phospholipid	B-Chemical
is	O
not	O
associated	O
with	O
apoptosis	O
.	O
Critically	O
","	O
the	O
mechanisms	O
by	O
which	O
cancer	O
cells	O
actually	O
resist	O
phagocytosis	O
remain	O
incompletely	O
understood	O
[	O
9	O
].	O
Compared	O
with	O
non	O
-	O
malignant	O
cells	O
","	O
expression	O
of	O
PS	B-Chemical
on	O
the	O
cell	O
surface	O
is	O
a	O
consistent	O
marker	O
of	O
malignancy	O
in	O
both	O
primary	O
and	O
metastatic	O
cell	O
lines	O
[	O
6	O
â€“	O
12	O
].	O
In	O
their	O
study	O
focused	O
on	O
difficult	O
-	O
to	O
-	O
treat	O
primary	O
cancers	O
","	O
including	O
metastatic	O
melanoma	O
","	O
glioblastoma	O
","	O
and	O
metastatic	O
lesions	O
","	O
Riedl	O
et	O
al	O
.	O
[	O
11	O
]	O
demonstrated	O
the	O
specificity	O
of	O
abundant	O
externalized	O
PS	B-Chemical
for	O
malignant	O
tumors	O
.	O
While	O
virtually	O
all	O
cancer	O
cells	O
exhibit	O
high	O
external	O
PS	B-Chemical
compared	O
with	O
normal	O
cells	O
","	O
the	O
quantity	O
of	O
surface	O
PS	B-Chemical
varies	O
widely	O
among	O
different	O
cancer	O
cells	O
","	O
even	O
of	O
the	O
same	O
type	O
[	O
10	O
","	O
12	O
].	O
The	O
increase	O
in	O
surface	O
PS	B-Chemical
has	O
led	O
to	O
the	O
use	O
of	O
a	O
number	O
of	O
proteins	O
or	O
peptides	B-Chemical
that	O
bind	O
to	O
PS	B-Chemical
to	O
study	O
apoptotic	O
and	O
tumor	O
cells	O
[	O
2	O
","	O
4	O
","	O
13	O
];	O
among	O
these	O
are	O
annexin	O
A5	O
(	O
ANXA5	O
"),"	O
an	O
endogenous	O
anticoagulant	O
protein	O
","	O
and	O
lactadherin	O
(	O
MFGE8	O
)	O
[	O
2	O
","	O
14	O
"],"	O
a	O
major	O
glycoprotein	O
in	O
milk	O
that	O
promotes	O
cellular	O
adhesion	O
.	O
Additionally	O
","	O
monoclonal	O
antibodies	O
to	O
PS	B-Chemical
have	O
been	O
generated	O
that	O
demonstrate	O
anti	O
-	O
tumor	O
activity	O
[	O
6	O
","	O
15	O
].	O
All	O
of	O
these	O
have	O
been	O
conjugated	O
to	O
a	O
number	O
of	O
markers	O
to	O
detect	O
the	O
location	O
of	O
PS	B-Chemical
.	O
In	O
this	O
review	O
","	O
we	O
discuss	O
Saposin	B-Chemical
C	I-Chemical
-	I-Chemical
Dioleoylphosphatidylserine	I-Chemical
(	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
"),"	O
a	O
stable	O
nanovesicle	O
that	O
specifically	O
binds	O
PS	B-Chemical
but	O
","	O
importantly	O
","	O
also	O
has	O
demonstrated	O
therapeutic	O
properties	O
against	O
a	O
variety	O
of	O
cancer	O
types	O
.	O
Given	O
the	O
specificity	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
for	O
cells	O
that	O
have	O
undergone	O
neoplastic	O
transformation	O
and	O
the	O
resultant	O
enhancement	O
seen	O
on	O
imaging	O
studies	O
owing	O
to	O
the	O
externalization	O
of	O
PS	B-Chemical
on	O
cancer	O
cells	O
","	O
we	O
review	O
this	O
new	O
paradigm	O
for	O
improved	O
diagnosis	O
and	O
early	O
detection	O
of	O
malignancy	O
that	O
may	O
overcome	O
some	O
of	O
the	O
limitations	O
of	O
current	O
imaging	O
related	O
to	O
the	O
cancer	O
â€™	O
s	O
type	O
and	O
site	O
or	O
to	O
other	O
underlying	O
medical	O
conditions	O
(	O
e	O
.	O
g	O
".,"	O
diabetes	O
and	O
kidney	O
disease	O
).	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
Generation	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
.	O
Saposin	O
C	O
(	O
SapC	O
)	O
is	O
a	O
low	O
molecular	O
weight	O
","	O
heat	O
-	O
stable	O
protein	O
which	O
can	O
fuse	O
lipid	B-Chemical
vesicles	O
into	O
cells	O
by	O
binding	O
to	O
phosphatidylserine	B-Chemical
(	O
PS	B-Chemical
)	O
in	O
an	O
acidic	O
environment	O
.	O
Mixing	O
SapC	O
with	O
dioleoylphosphatidylserine	B-Chemical
(	O
DOPS	B-Chemical
)	O
at	O
a	O
low	O
pH	O
results	O
in	O
the	O
formation	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
vesicles	O
with	O
a	O
mean	O
diameter	O
of	O
~	O
200	O
nm	O
.	O
Used	O
with	O
permission	O
Â©	O
2015	O
Glia	O
Media	O
Mechanism	O
of	O
cancer	O
cell	O
killing	O
by	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
.	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
binds	O
to	O
PS	B-Chemical
-	O
rich	O
patches	O
of	O
cell	O
membranes	O
.	O
Once	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
binds	O
","	O
SapC	O
activates	O
acid	O
sphingomyelinase	O
to	O
initiate	O
the	O
ceramide	B-Chemical
cascade	O
","	O
which	O
results	O
in	O
cell	O
death	O
.	O
Used	O
with	O
permission	O
Â©	O
2015	O
Glia	O
Media	O
Saposin	O
C	O
(	O
SapC	O
)	O
is	O
a	O
small	O
","	O
fusogenic	O
glycoprotein	O
that	O
is	O
remarkably	O
heat	O
-	O
stable	O
and	O
protease	O
-	O
resistant	O
[	O
16	O
â€“	O
19	O
].	O
While	O
SapC	O
itself	O
is	O
non	O
-	O
enzymatic	O
","	O
it	O
is	O
an	O
activator	O
of	O
lysosomal	O
enzymes	O
","	O
particularly	O
acid	O
sphingomyelinase	O
and	O
acid	O
beta	O
-	O
glucosidase	O
","	O
which	O
catalyze	O
the	O
breakdown	O
of	O
sphingomyelin	B-Chemical
and	O
glucosylceramide	B-Chemical
into	O
phosphocholine	B-Chemical
and	O
ceramide	B-Chemical
","	O
and	O
glucose	B-Chemical
and	O
ceramide	B-Chemical
","	O
respectively	O
[	O
20	O
â€“	O
22	O
].	O
Although	O
the	O
precise	O
mechanism	O
is	O
unclear	O
","	O
this	O
increase	O
in	O
ceramide	B-Chemical
levels	O
may	O
result	O
in	O
cell	O
death	O
","	O
as	O
ceramide	B-Chemical
has	O
been	O
previously	O
implicated	O
in	O
apoptosis	O
[	O
23	O
"],"	O
possibly	O
through	O
the	O
actions	O
of	O
caspases	O
[	O
24	O
].	O
In	O
order	O
for	O
SapC	O
to	O
activate	O
these	O
enzymes	O
","	O
it	O
must	O
bind	O
the	O
PS	B-Chemical
of	O
the	O
intracellular	O
vesicles	O
â€™	O
membranes	O
.	O
In	O
vitro	O
","	O
at	O
low	O
pH	O
","	O
SapC	O
and	O
dioleoylphosphatidylserine	B-Chemical
(	O
DOPS	B-Chemical
)	O
will	O
spontaneously	O
form	O
nanovesicles	O
with	O
a	O
mean	O
diameter	O
of	O
approximately	O
200	O
nm	O
(	O
Fig	O
.	O
1	O
).	O
The	O
amino	O
-	O
and	O
carboxyl	O
termini	O
of	O
SapC	O
are	O
amphipathic	O
helices	O
that	O
insert	O
into	O
the	O
lipid	B-Chemical
bilayer	O
","	O
while	O
the	O
middle	O
region	O
is	O
exposed	O
to	O
solvent	O
.	O
Conformational	O
changes	O
of	O
SapC	O
induced	O
by	O
PS	B-Chemical
interaction	O
suggest	O
a	O
reorientation	O
of	O
the	O
functional	O
helical	O
domains	O
[	O
25	O
].	O
Importantly	O
","	O
the	O
cytotoxicity	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
positively	O
correlates	O
with	O
the	O
level	O
of	O
surface	O
PS	B-Chemical
:	O
the	O
higher	O
the	O
external	O
PS	B-Chemical
","	O
the	O
more	O
effectively	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
[	O
10	O
","	O
12	O
]	O
will	O
bind	O
the	O
cell	O
and	O
trigger	O
the	O
ceramide	B-Chemical
cascade	O
","	O
ultimately	O
resulting	O
in	O
apoptosis	O
(	O
Fig	O
.	O
2	O
).	O
Main	O
Text	O
Use	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
as	O
a	O
tumor	O
detection	O
agent	O
Histological	O
sections	O
In	O
our	O
lab	O
","	O
the	O
role	O
of	O
PS	B-Chemical
as	O
a	O
tumor	O
marker	O
has	O
been	O
validated	O
repeatedly	O
for	O
a	O
variety	O
of	O
cancer	O
types	O
[	O
10	O
","	O
24	O
","	O
26	O
â€“	O
30	O
].	O
In	O
particular	O
","	O
the	O
targeting	O
of	O
PS	B-Chemical
by	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
was	O
demonstrated	O
to	O
be	O
a	O
novel	O
method	O
to	O
achieve	O
accurate	O
and	O
effective	O
identification	O
of	O
cancer	O
cells	O
.	O
The	O
validation	O
of	O
PS	B-Chemical
as	O
a	O
reliable	O
tumor	O
marker	O
","	O
coupled	O
with	O
the	O
high	O
affinity	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
for	O
PS	B-Chemical
on	O
a	O
variety	O
of	O
cancer	O
cell	O
surfaces	O
","	O
provides	O
a	O
promising	O
advancement	O
for	O
accurate	O
detection	O
of	O
several	O
cancer	O
types	O
.	O
Tumor	O
detection	O
by	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
.	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
nanovesicles	O
can	O
be	O
labeled	O
with	O
imaging	O
agents	O
during	O
formulation	O
.	O
For	O
histological	O
specimens	O
and	O
in	O
vivo	O
studies	O
with	O
small	O
animals	O
","	O
optical	O
imaging	O
with	O
the	O
far	O
red	O
fluorophore	O
","	O
CellVue	B-Chemical
Maroon	I-Chemical
(	O
CVM	B-Chemical
)	O
can	O
be	O
used	O
.	O
For	O
in	O
vivo	O
MRI	O
imaging	O
","	O
the	O
gadolinium	B-Chemical
chelate	O
(	O
Gd	B-Chemical
-	I-Chemical
DTAP	I-Chemical
-	I-Chemical
BSA	I-Chemical
)	O
or	O
the	O
ultra	B-Chemical
-	I-Chemical
small	I-Chemical
cuperparamagnetic	I-Chemical
firon	I-Chemical
oxide	I-Chemical
(	O
USPIO	B-Chemical
)	O
can	O
be	O
incorporated	O
and	O
used	O
as	O
MRI	O
contrast	O
agents	O
.	O
Used	O
with	O
permission	O
Â©	O
2015	O
Glia	O
Media	O
The	O
lipophilic	O
properties	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
make	O
it	O
an	O
ideal	O
carrier	O
of	O
detection	O
moieties	O
","	O
such	O
as	O
fluorescent	O
markers	O
or	O
clinically	O
applicable	O
contrast	O
agents	O
(	O
Fig	O
.	O
3	O
).	O
Experiments	O
coupling	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
to	O
the	O
far	O
-	O
red	O
fluorescent	O
probe	O
CellVue	B-Chemical
Maroon	I-Chemical
(	O
CVM	B-Chemical
)	O
have	O
been	O
performed	O
to	O
distinguish	O
neoplastic	O
tumor	O
regions	O
on	O
histologic	O
slides	O
and	O
individual	O
patient	O
-	O
derived	O
neoplastic	O
cell	O
lines	O
","	O
as	O
well	O
as	O
in	O
vivo	O
[	O
10	O
","	O
24	O
","	O
26	O
â€“	O
28	O
","	O
31	O
].	O
In	O
several	O
studies	O
showing	O
the	O
specificity	O
of	O
this	O
reagent	O
","	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
-	I-Chemical
CVM	I-Chemical
was	O
internalized	O
by	O
live	O
tumor	O
cells	O
but	O
not	O
normal	O
cells	O
","	O
clearly	O
delineating	O
the	O
tumor	O
in	O
tissue	O
slices	O
.	O
A	O
caveat	O
of	O
using	O
histological	O
slides	O
is	O
that	O
their	O
generation	O
requires	O
slicing	O
the	O
cells	O
","	O
so	O
that	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
or	O
other	O
PS	B-Chemical
detection	O
agents	O
will	O
bind	O
to	O
PS	B-Chemical
on	O
both	O
the	O
exterior	O
and	O
interior	O
of	O
the	O
membrane	O
.	O
However	O
","	O
fluorescently	O
labeled	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
can	O
be	O
used	O
with	O
flow	O
cytometry	O
to	O
distinguish	O
only	O
the	O
externalized	O
PS	B-Chemical
.	O
Of	O
particular	O
interest	O
is	O
the	O
role	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
in	O
detecting	O
cancers	O
that	O
pose	O
diagnostic	O
challenges	O
because	O
of	O
the	O
tumor	O
site	O
or	O
the	O
intrinsic	O
properties	O
of	O
the	O
malignancy	O
itself	O
","	O
by	O
targeting	O
surface	O
PS	B-Chemical
of	O
cancer	O
cells	O
and	O
tumor	O
vessels	O
.	O
Such	O
cancers	O
include	O
glioblastoma	O
and	O
pancreatic	O
adenocarcinoma	O
","	O
each	O
of	O
which	O
carries	O
a	O
devastating	O
prognosis	O
despite	O
years	O
of	O
diagnostic	O
and	O
therapeutic	O
research	O
.	O
Fluorescent	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
detection	O
in	O
mice	O
Previous	O
studies	O
have	O
taken	O
in	O
vitro	O
data	O
of	O
fluorescently	O
labeled	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
a	O
step	O
further	O
by	O
evaluating	O
diagnostic	O
efficacy	O
in	O
vivo	O
using	O
mouse	O
models	O
.	O
In	O
one	O
such	O
study	O
","	O
mice	O
bearing	O
human	O
neuroblastoma	O
xenografts	O
were	O
injected	O
intravenously	O
with	O
four	O
different	O
reagents	O
:	O
(	O
1	O
)	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
conjugated	O
to	O
CVM	B-Chemical
","	O
(	O
2	O
)	O
unconjugated	O
SapC	O
and	O
CVM	B-Chemical
","	O
(	O
3	O
)	O
DOPS	B-Chemical
and	O
CVM	B-Chemical
","	O
or	O
(	O
4	O
)	O
PBS	B-Chemical
alone	O
[	O
24	O
].	O
The	O
mice	O
then	O
underwent	O
optical	O
imaging	O
at	O
time	O
intervals	O
ranging	O
from	O
0	O
to	O
48	O
h	O
post	O
-	O
injection	O
.	O
The	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
-	I-Chemical
CVM	I-Chemical
fluorescent	O
signal	O
was	O
diffuse	O
between	O
0	O
and	O
5	O
h	O
","	O
and	O
had	O
accumulated	O
specifically	O
within	O
the	O
tumor	O
region	O
by	O
24	O
h	O
","	O
persisting	O
for	O
up	O
to	O
100	O
h	O
.	O
However	O
","	O
there	O
was	O
no	O
fluorescence	O
signal	O
when	O
uncoupled	O
SapC	O
was	O
administered	O
with	O
DOPS	B-Chemical
-	I-Chemical
CVM	I-Chemical
[	O
24	O
].	O
Similar	O
results	O
were	O
demonstrated	O
by	O
Kaimal	O
et	O
al	O
.	O
[	O
29	O
]	O
in	O
their	O
mouse	O
xenograft	O
models	O
of	O
pancreatic	O
adenocarcinoma	O
and	O
neuroblastoma	O
and	O
a	O
murine	O
rhabdomyosarcoma	O
model	O
.	O
These	O
studies	O
demonstrated	O
the	O
specificity	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
for	O
cells	O
that	O
have	O
undergone	O
neoplastic	O
transformation	O
","	O
with	O
the	O
consequent	O
externalization	O
of	O
PS	B-Chemical
.	O
As	O
such	O
","	O
this	O
is	O
a	O
new	O
paradigm	O
for	O
improved	O
diagnosis	O
and	O
early	O
detection	O
of	O
malignancy	O
.	O
In	O
multi	O
-	O
angle	O
rotational	O
optical	O
imaging	O
(	O
MAROI	O
)	O
to	O
detect	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
-	I-Chemical
CVM	I-Chemical
in	O
mice	O
[	O
32	O
"],"	O
we	O
used	O
a	O
rotational	O
bed	O
to	O
obtain	O
the	O
in	O
vivo	O
image	O
.	O
Analysis	O
of	O
the	O
MAROI	O
signal	O
curve	O
provided	O
multispectral	O
and	O
multimodal	O
data	O
derived	O
from	O
complete	O
rotational	O
coverage	O
.	O
We	O
confirmed	O
that	O
optimal	O
imaging	O
depended	O
on	O
correct	O
orientation	O
during	O
positioning	O
;	O
the	O
fluorescence	O
intensity	O
decreased	O
by	O
as	O
much	O
as	O
9	O
â€“	O
12	O
%	O
with	O
each	O
10	O
Â°	O
of	O
movement	O
.	O
Use	O
of	O
anatomical	O
landmarks	O
and	O
concurrent	O
X	O
-	O
ray	O
imaging	O
achieved	O
both	O
in	O
vivo	O
localization	O
of	O
the	O
tumor	O
and	O
quantitation	O
of	O
fluorescent	O
marker	O
intensity	O
.	O
These	O
findings	O
can	O
then	O
be	O
used	O
in	O
longitudinal	O
studies	O
to	O
correlate	O
fluorescent	O
signal	O
distribution	O
directly	O
with	O
mapping	O
of	O
tumor	O
location	O
.	O
Impediments	O
to	O
clinical	O
detection	O
of	O
malignancy	O
using	O
mulimodality	O
imaging	O
Comparison	O
of	O
non	O
-	O
invasive	O
imaging	O
procedures	O
for	O
cancer	O
detection	O
Among	O
the	O
factors	O
considered	O
when	O
determining	O
an	O
optimal	O
treatment	O
plan	O
for	O
patients	O
diagnosed	O
with	O
cancer	O
","	O
especially	O
important	O
are	O
the	O
size	O
and	O
location	O
of	O
the	O
primary	O
tumor	O
and	O
the	O
extent	O
of	O
metastatic	O
disease	O
","	O
if	O
present	O
.	O
To	O
define	O
these	O
characteristics	O
and	O
facilitate	O
treatment	O
","	O
effective	O
imaging	O
modalities	O
currently	O
available	O
include	O
computed	O
tomography	O
(	O
CT	O
"),"	O
positron	O
emission	O
tomography	O
(	O
PET	O
"),"	O
and	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
).	O
Each	O
modality	O
can	O
help	O
define	O
cancer	O
staging	O
and	O
diagnosis	O
","	O
but	O
can	O
also	O
be	O
limited	O
in	O
its	O
effectiveness	O
","	O
depending	O
on	O
the	O
type	O
and	O
site	O
of	O
the	O
cancer	O
or	O
the	O
patient	O
â€™	O
s	O
underlying	O
medical	O
conditions	O
.	O
When	O
such	O
limitations	O
exist	O
","	O
invasive	O
procedures	O
or	O
a	O
combination	O
of	O
diverse	O
imaging	O
techniques	O
may	O
be	O
needed	O
to	O
make	O
a	O
definitive	O
diagnosis	O
;	O
this	O
can	O
be	O
both	O
time	O
-	O
consuming	O
and	O
cost	O
prohibitive	O
(	O
see	O
Table	O
1	O
).	O
CT	O
has	O
played	O
a	O
pivotal	O
role	O
in	O
both	O
diagnosis	O
and	O
staging	O
of	O
malignancy	O
for	O
several	O
years	O
.	O
Although	O
CT	O
has	O
been	O
successful	O
in	O
upstaging	O
many	O
cancers	O
at	O
the	O
time	O
of	O
diagnosis	O
to	O
improve	O
treatment	O
outcomes	O
","	O
several	O
limitations	O
prevent	O
its	O
universal	O
applicability	O
in	O
cancer	O
diagnosis	O
","	O
particularly	O
in	O
cases	O
of	O
local	O
","	O
microscopic	O
disease	O
spread	O
.	O
In	O
a	O
study	O
of	O
957	O
lymph	O
nodes	O
evaluated	O
from	O
patients	O
with	O
head	O
and	O
neck	O
cancers	O
","	O
Don	O
et	O
al	O
.	O
[	O
33	O
]	O
found	O
that	O
20	O
%	O
of	O
malignant	O
lymph	O
nodes	O
had	O
extracapsular	O
spread	O
;	O
almost	O
one	O
third	O
of	O
these	O
nodes	O
were	O
smaller	O
than	O
10	O
mm	O
","	O
which	O
is	O
the	O
size	O
cut	O
-	O
off	O
used	O
to	O
define	O
pathological	O
adenopathy	O
on	O
radiographic	O
review	O
.	O
In	O
addition	O
","	O
central	O
necrosis	O
","	O
a	O
common	O
characteristic	O
used	O
to	O
identify	O
malignant	O
lymph	O
nodes	O
by	O
CT	O
","	O
were	O
found	O
primarily	O
in	O
lymph	O
nodes	O
that	O
were	O
20	O
mm	O
or	O
larger	O
","	O
suggesting	O
that	O
central	O
necrosis	O
is	O
a	O
late	O
event	O
in	O
metastatic	O
adenopathy	O
.	O
Such	O
findings	O
suggest	O
a	O
deficiency	O
in	O
our	O
ability	O
to	O
detect	O
metastatic	O
disease	O
early	O
in	O
its	O
course	O
[	O
33	O
].	O
In	O
contrast	O
with	O
CT	O
and	O
MRI	O
","	O
detection	O
by	O
PET	O
imaging	O
has	O
proven	O
superior	O
for	O
regional	O
nodal	O
and	O
distant	O
metastases	O
","	O
but	O
inferior	O
for	O
several	O
primary	O
malignancies	O
[	O
34	O
].	O
Moreover	O
","	O
PET	O
has	O
very	O
poor	O
spatial	O
resolution	O
","	O
limiting	O
accurate	O
biopsy	O
because	O
of	O
poor	O
localization	O
of	O
the	O
potential	O
malignancy	O
.	O
While	O
this	O
problem	O
can	O
be	O
offset	O
in	O
part	O
by	O
combined	O
PET	O
-	O
CT	O
scanning	O
","	O
defects	O
in	O
registration	O
between	O
the	O
signals	O
can	O
still	O
pose	O
problems	O
with	O
tumor	O
localization	O
[	O
34	O
].	O
As	O
such	O
","	O
currently	O
available	O
imaging	O
modalities	O
present	O
shortcomings	O
in	O
our	O
ability	O
to	O
detect	O
occult	O
spread	O
of	O
malignancy	O
","	O
which	O
inevitably	O
leads	O
to	O
delays	O
in	O
diagnosis	O
of	O
metastatic	O
disease	O
until	O
it	O
has	O
spread	O
more	O
widely	O
.	O
At	O
that	O
point	O
","	O
few	O
treatment	O
options	O
may	O
remain	O
.	O
Such	O
studies	O
highlight	O
the	O
need	O
for	O
sensitive	O
imaging	O
techniques	O
that	O
focus	O
on	O
specifically	O
revealing	O
malignant	O
cells	O
","	O
rather	O
than	O
probing	O
tentative	O
neoplastic	O
properties	O
of	O
lymph	O
nodes	O
that	O
may	O
imply	O
","	O
but	O
are	O
not	O
always	O
specific	O
for	O
","	O
malignancy	O
.	O
Detection	O
of	O
intracranial	O
neoplasms	O
","	O
such	O
as	O
glioblastoma	O
multiforme	O
","	O
also	O
poses	O
a	O
diagnostic	O
challenge	O
by	O
currently	O
available	O
imaging	O
techniques	O
.	O
PET	O
imaging	O
","	O
for	O
example	O
","	O
relies	O
on	O
underlying	O
tissue	O
metabolism	O
to	O
detect	O
malignancy	O
","	O
given	O
that	O
neoplastic	O
cells	O
have	O
increased	O
metabolic	O
activity	O
compared	O
with	O
normal	O
tissue	O
.	O
Non	O
-	O
malignant	O
brain	O
tissue	O
","	O
however	O
","	O
has	O
metabolic	O
activity	O
comparable	O
to	O
tumors	O
found	O
in	O
areas	O
outside	O
of	O
the	O
brain	O
.	O
Because	O
intracranial	O
neoplasms	O
cannot	O
be	O
accurately	O
identified	O
on	O
PET	O
imaging	O
","	O
a	O
second	O
mode	O
of	O
imaging	O
is	O
needed	O
to	O
detect	O
either	O
primary	O
or	O
metastatic	O
disease	O
in	O
the	O
brain	O
.	O
Similarly	O
","	O
a	O
CT	O
of	O
the	O
brain	O
can	O
delineate	O
brain	O
lesions	O
but	O
often	O
cannot	O
definitively	O
distinguish	O
neoplastic	O
tumors	O
from	O
other	O
causes	O
of	O
brain	O
lesions	O
","	O
including	O
infections	O
or	O
demyelinating	O
diseases	O
.	O
Therefore	O
","	O
detection	O
of	O
intracranial	O
malignancy	O
currently	O
relies	O
on	O
MRI	O
for	O
evaluation	O
and	O
characterization	O
.	O
Such	O
studies	O
","	O
however	O
","	O
require	O
prolonged	O
acquisition	O
time	O
","	O
which	O
can	O
cause	O
increased	O
motion	O
artifact	O
and	O
result	O
in	O
poor	O
image	O
quality	O
unless	O
the	O
patient	O
is	O
sedated	O
","	O
as	O
for	O
pediatric	O
patients	O
","	O
which	O
increases	O
patient	O
risk	O
.	O
Beyond	O
accurate	O
detection	O
of	O
malignancy	O
","	O
limitations	O
in	O
current	O
imaging	O
modalities	O
also	O
relate	O
to	O
any	O
underlying	O
medical	O
conditions	O
of	O
the	O
patient	O
.	O
For	O
example	O
","	O
CT	O
imaging	O
often	O
requires	O
an	O
intravenous	O
contrast	O
agent	O
.	O
Contrast	O
can	O
be	O
particularly	O
nephrotoxic	O
for	O
patients	O
with	O
acute	O
or	O
chronic	O
kidney	O
disease	O
.	O
This	O
comorbidity	O
is	O
common	O
in	O
patients	O
at	O
the	O
time	O
of	O
cancer	O
diagnosis	O
because	O
of	O
poor	O
oral	O
intake	O
and	O
prolonged	O
cachexia	O
","	O
and	O
can	O
also	O
be	O
a	O
frequent	O
consequence	O
of	O
several	O
chemotherapeutic	O
regimens	O
.	O
Thus	O
","	O
contrast	O
-	O
enhanced	O
CT	O
imaging	O
is	O
commonly	O
avoided	O
in	O
patients	O
with	O
underlying	O
kidney	O
disease	O
.	O
Similar	O
caution	O
must	O
be	O
taken	O
when	O
using	O
gadolinium	B-Chemical
contrast	O
for	O
MRI	O
in	O
patients	O
with	O
kidney	O
disease	O
because	O
of	O
the	O
possibility	O
of	O
adverse	O
outcomes	O
","	O
such	O
as	O
nephrogenic	O
systemic	O
sclerosis	O
","	O
which	O
carries	O
a	O
high	O
rate	O
of	O
morbidity	O
and	O
mortality	O
.	O
Limitations	O
in	O
PET	O
imaging	O
occur	O
in	O
diabetic	O
patients	O
","	O
because	O
blood	O
glucose	B-Chemical
levels	O
can	O
significantly	O
impact	O
tumor	O
uptake	O
of	O
fluorodeoxyglucose	B-Chemical
(	O
FDG	B-Chemical
"),"	O
the	O
agent	O
used	O
to	O
detect	O
malignancy	O
.	O
In	O
these	O
cases	O
","	O
FDG	B-Chemical
and	O
glucose	B-Chemical
compete	O
for	O
glucose	B-Chemical
transport	O
and	O
phosphorylation	O
[	O
35	O
].	O
Guidelines	O
currently	O
require	O
both	O
tight	O
glycemic	O
control	O
(	O
i	O
.	O
e	O
".,"	O
glucose	B-Chemical
levels	O
below	O
200	O
mg	O
/	O
dL	O
)	O
before	O
PET	O
imaging	O
and	O
that	O
patients	O
abstain	O
from	O
all	O
glucose	B-Chemical
-	O
containing	O
food	O
and	O
drink	O
for	O
at	O
least	O
6	O
h	O
prior	O
to	O
the	O
study	O
.	O
However	O
","	O
these	O
restrictions	O
have	O
often	O
proven	O
difficult	O
to	O
achieve	O
","	O
thus	O
compromising	O
imaging	O
quality	O
and	O
accuracy	O
.	O
Advances	O
in	O
combined	O
PET	O
/	O
CT	O
[	O
36	O
]	O
and	O
PET	O
/	O
MRI	O
[	O
37	O
]	O
have	O
solved	O
some	O
of	O
these	O
problems	O
.	O
However	O
","	O
the	O
toxicity	O
of	O
contrast	O
agents	O
and	O
their	O
inability	O
to	O
cross	O
the	O
blood	O
â€“	O
brain	O
barrier	O
limit	O
their	O
effectiveness	O
and	O
demonstrate	O
the	O
necessity	O
for	O
a	O
diagnostic	O
agent	O
with	O
limited	O
side	O
effects	O
","	O
few	O
clinical	O
restrictions	O
","	O
and	O
enhanced	O
specificity	O
for	O
neoplastic	O
cells	O
.	O
Detection	O
of	O
malignancy	O
using	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
in	O
preclinical	O
studies	O
a	O
High	O
-	O
resolution	O
MRI	O
of	O
a	O
glioma	O
in	O
a	O
mouse	O
in	O
vivo	O
.	O
MRI	O
was	O
performed	O
at	O
7T	O
.	O
T2	O
*	O
weighted	O
3D	O
FLASH	O
sequence	O
(	O
TE	O
/	O
TR	O
=	O
10	O
ms	O
/	O
20	O
ms	O
/	O
FA	O
=	O
10	O
Â°)	O
were	O
used	O
with	O
a	O
320	O
Ã—	O
320	O
Ã—	O
64	O
matrix	O
and	O
3	O
.	O
2	O
Ã—	O
3	O
.	O
2	O
Ã—	O
0	O
.	O
64	O
cm	O
FOV	O
resulting	O
in	O
an	O
isotropic	O
100	O
mm	O
resolution	O
.	O
Negative	O
contrast	O
enhancement	O
is	O
observed	O
4	O
h	O
following	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
-	I-Chemical
USPIO	I-Chemical
(	O
adapted	O
from	O
[	O
28	O
]).	O
b	O
MicroPET	O
imaging	O
of	O
a	O
glioblastoma	O
in	O
a	O
mouse	O
brain	O
24	O
h	O
after	O
administration	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
-	I-Chemical
124I	I-Chemical
Â·	I-Chemical
(	I-Chemical
2a	I-Chemical
)	I-Chemical
nanovesicles	O
.	O
2a	B-Chemical
is	O
a	O
phenol	B-Chemical
-	O
substituted	O
analog	O
of	O
indodicarbocyanine	B-Chemical
(	O
DiD	B-Chemical
).	O
A	O
CT	O
scan	O
was	O
acquired	O
for	O
anatomical	O
co	O
-	O
registration	O
and	O
attenuation	O
correction	O
of	O
the	O
PET	O
data	O
.	O
Concurrent	O
bioluminescence	O
imaging	O
(	O
BLI	O
)	O
confirmed	O
the	O
presence	O
of	O
glioblastoma	O
(	O
adapted	O
from	O
[	O
40	O
]).	O
To	O
improve	O
MRI	O
sensitivity	O
","	O
shorten	O
scanning	O
time	O
","	O
and	O
improve	O
safety	O
","	O
we	O
have	O
used	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
as	O
a	O
carrier	O
for	O
contrast	O
agents	O
.	O
The	O
method	O
of	O
Bogdanov	O
et	O
al	O
.	O
[	O
38	O
]	O
was	O
implemented	O
to	O
encapsulate	O
ferumoxtran	B-Chemical
-	I-Chemical
10	I-Chemical
","	O
an	O
ultra	B-Chemical
-	I-Chemical
small	I-Chemical
super	I-Chemical
-	I-Chemical
paramagnetic	I-Chemical
iron	I-Chemical
oxide	I-Chemical
(	O
USPIO	B-Chemical
)	O
contrast	O
agent	O
","	O
into	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
vesicles	O
.	O
The	O
resulting	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
-	I-Chemical
USPIO	I-Chemical
was	O
used	O
with	O
MRI	O
to	O
detect	O
tumors	O
in	O
mice	O
[	O
29	O
].	O
The	O
T2	O
relaxation	O
time	O
(	O
i	O
.	O
e	O
".,"	O
time	O
for	O
the	O
transverse	O
magnetization	O
to	O
fall	O
to	O
approximately	O
37	O
%	O
of	O
its	O
initial	O
value	O
after	O
magnetization	O
)	O
of	O
subcutaneous	O
xenografts	O
of	O
neuroblastomas	O
or	O
pancreatic	O
tumors	O
was	O
decreased	O
by	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
-	I-Chemical
USPIO	I-Chemical
","	O
thus	O
indicating	O
the	O
uptake	O
of	O
the	O
agent	O
by	O
tumors	O
.	O
This	O
allowed	O
specific	O
detection	O
of	O
the	O
malignancy	O
(	O
Fig	O
.	O
4a	O
).	O
Additionally	O
","	O
we	O
incorporated	O
the	O
paramagnetic	O
contrast	O
agent	O
","	O
gadolinium	B-Chemical
","	O
into	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
vesicles	O
by	O
using	O
the	O
lipophilic	O
gadolinium	B-Chemical
chelate	O
","	O
gadolinium	B-Chemical
-	I-Chemical
DTPA	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
stearylamide	I-Chemical
)	I-Chemical
[	O
39	O
].	O
These	O
vesicles	O
produced	O
a	O
9	O
%	O
increase	O
in	O
the	O
longitudinal	O
relaxation	O
rate	O
(	O
R1	O
)	O
of	O
orthotopic	O
glioblastoma	O
multiforme	O
tumors	O
in	O
mice	O
within	O
10	O
h	O
post	O
-	O
injection	O
","	O
but	O
only	O
minimal	O
changes	O
in	O
normal	O
brain	O
tissue	O
;	O
again	O
this	O
demonstrated	O
improved	O
specificity	O
of	O
tumor	O
detection	O
.	O
We	O
have	O
recently	O
used	O
a	O
phenol	B-Chemical
-	O
substituted	O
lipophilic	O
dye	O
to	O
label	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
with	O
124I	B-Chemical
","	O
a	O
positron	O
emitter	O
.	O
We	O
then	O
used	O
this	O
labeled	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
for	O
PET	O
imaging	O
.	O
As	O
shown	O
in	O
Fig	O
.	O
4b	O
we	O
were	O
able	O
to	O
selectively	O
enhance	O
the	O
intracranial	O
glioblastomas	O
with	O
PET	O
scanning	O
[	O
40	O
].	O
Concurrent	O
studies	O
with	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
labeled	O
with	O
125I	B-Chemical
instead	O
of	O
124I	B-Chemical
indicated	O
that	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
specifically	O
targeted	O
the	O
tumor	O
","	O
although	O
some	O
label	O
was	O
detected	O
in	O
the	O
liver	O
and	O
spleen	O
","	O
likely	O
disposal	O
routes	O
.	O
These	O
studies	O
indicate	O
the	O
ability	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
to	O
transverse	O
the	O
blood	O
brain	O
barrier	O
without	O
requiring	O
either	O
alteration	O
of	O
the	O
barrier	O
or	O
direct	O
intracranial	O
administration	O
of	O
the	O
agent	O
[	O
12	O
].	O
This	O
suggests	O
a	O
potential	O
role	O
for	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
in	O
improving	O
the	O
safety	O
and	O
convenience	O
of	O
detecting	O
(	O
and	O
treating	O
)	O
intracranial	O
neoplasms	O
.	O
The	O
pharmacologic	O
safety	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
has	O
been	O
evaluated	O
in	O
mice	O
at	O
12	O
Ã—	O
the	O
typical	O
therapeutic	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
of	O
Sap	O
C	O
and	O
2	O
mg	O
/	O
kg	O
of	O
DOPS	B-Chemical
[	O
24	O
].	O
Even	O
at	O
these	O
levels	O
","	O
no	O
acute	O
toxicity	O
or	O
weight	O
loss	O
was	O
demonstrated	O
with	O
administration	O
.	O
Furthermore	O
","	O
histological	O
examination	O
of	O
vital	O
organs	O
(	O
i	O
.	O
e	O
".,"	O
lung	O
","	O
liver	O
","	O
spleen	O
","	O
kidney	O
","	O
heart	O
","	O
brain	O
)	O
revealed	O
neither	O
damage	O
nor	O
toxic	O
changes	O
.	O
Chronic	O
toxicity	O
studies	O
were	O
also	O
performed	O
with	O
injection	O
of	O
2	O
Ã—	O
therapeutic	O
concentrations	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
weekly	O
for	O
5	O
weeks	O
.	O
Again	O
","	O
these	O
studies	O
demonstrated	O
no	O
significant	O
toxicity	O
on	O
histological	O
review	O
of	O
the	O
vital	O
organs	O
listed	O
above	O
[	O
24	O
].	O
In	O
comparison	O
","	O
the	O
contrast	O
agents	O
currently	O
used	O
for	O
image	O
enhancement	O
during	O
CT	O
and	O
MRI	O
scanning	O
can	O
place	O
patients	O
at	O
risk	O
for	O
kidney	O
damage	O
or	O
systemic	O
disease	O
.	O
Beyond	O
the	O
pharmacologic	O
safety	O
evidence	O
","	O
we	O
compared	O
survival	O
data	O
for	O
mice	O
with	O
pancreatic	O
tumors	O
treated	O
with	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
versus	O
control	O
groups	O
.	O
Mice	O
treated	O
with	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
lived	O
significantly	O
longer	O
compared	O
with	O
untreated	O
control	O
groups	O
:	O
specifically	O
","	O
all	O
control	O
mice	O
had	O
died	O
by	O
23	O
weeks	O
after	O
treatment	O
","	O
while	O
4	O
of	O
the	O
6	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
-	O
treated	O
mice	O
were	O
still	O
alive	O
[	O
10	O
].	O
Similar	O
results	O
were	O
obtained	O
with	O
a	O
brain	O
tumor	O
model	O
[	O
28	O
].	O
Mice	O
bearing	O
orthotopic	O
glioblastoma	O
multiforme	O
that	O
were	O
treated	O
with	O
DOPS	B-Chemical
alone	O
all	O
died	O
within	O
20	O
days	O
.	O
However	O
","	O
25	O
%	O
of	O
those	O
treated	O
with	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
survived	O
at	O
least	O
350	O
days	O
.	O
In	O
addition	O
","	O
the	O
tumors	O
were	O
smaller	O
in	O
the	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
treated	O
mice	O
.	O
Again	O
","	O
these	O
studies	O
provide	O
pre	O
-	O
clinical	O
data	O
to	O
support	O
the	O
safety	O
of	O
systemic	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
administration	O
for	O
diagnostic	O
and	O
therapeutic	O
purposes	O
.	O
Although	O
there	O
is	O
some	O
therapeutic	O
value	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
with	O
the	O
dose	O
that	O
would	O
be	O
injected	O
for	O
diagnostic	O
purposes	O
","	O
multiple	O
doses	O
are	O
generally	O
given	O
to	O
shrink	O
tumors	O
.	O
Additionally	O
","	O
as	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
is	O
a	O
nanovesicle	O
it	O
can	O
be	O
loaded	O
with	O
radioisotopes	O
or	O
chemotherapeutic	O
drugs	O
to	O
provide	O
further	O
benefit	O
.	O
Conclusions	O
Our	O
data	O
indicate	O
that	O
the	O
novel	O
and	O
PS	B-Chemical
-	O
targeted	O
nanovesicle	O
","	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
","	O
can	O
be	O
used	O
for	O
exposure	O
of	O
hard	O
to	O
detect	O
malignancies	O
","	O
whether	O
due	O
to	O
size	O
or	O
location	O
.	O
Although	O
further	O
studies	O
are	O
required	O
","	O
our	O
preclinical	O
studies	O
suggest	O
that	O
the	O
tumor	O
â€“	O
selective	O
nanovesicles	O
may	O
greatly	O
contribute	O
to	O
improving	O
the	O
precision	O
of	O
early	O
cancer	O
diagnosis	O
.	O
In	O
addition	O
","	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
may	O
have	O
a	O
therapeutic	O
benefit	O
and	O
be	O
used	O
as	O
a	O
â€œ	O
theranostic	O
â€	O
compound	O
.	O
Ongoing	O
studies	O
are	O
to	O
provide	O
support	O
for	O
the	O
inclusion	O
of	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
in	O
the	O
battery	O
of	O
tests	O
conducted	O
by	O
oncologists	O
to	O
enhance	O
the	O
accuracy	O
and	O
sensitivity	O
of	O
tumor	O
diagnosis	O
.	O
Ethics	O
approval	O
The	O
ethical	O
approval	O
for	O
the	O
animal	O
studies	O
described	O
in	O
this	O
review	O
are	O
provided	O
in	O
the	O
original	O
publications	O
.	O
Abbreviations	O
CT	O
computed	O
tomography	O
CVM	B-Chemical
CellVue	B-Chemical
Maroon	I-Chemical
FDG	B-Chemical
fluorodeoxyglucose	B-Chemical
MAROI	O
multi	O
-	O
angle	O
rotational	O
optical	O
imaging	O
MRI	O
magnetic	O
resonance	O
imaging	O
PET	O
positron	O
emission	O
tomography	O
PS	B-Chemical
phosphatidylserine	B-Chemical
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
saposin	B-Chemical
C	I-Chemical
-	I-Chemical
Dioleophosphatidylserine	I-Chemical
USPIO	B-Chemical
ultra	B-Chemical
-	I-Chemical
small	I-Chemical
super	I-Chemical
-	I-Chemical
paramagnetic	I-Chemical
iron	I-Chemical
oxide	I-Chemical
Competing	O
interests	O
Xiaoyang	O
Qi	O
","	O
Ph	O
.	O
D	O
.	O
is	O
listed	O
as	O
an	O
inventor	O
on	O
the	O
patent	O
for	O
the	O
technology	O
(	O
SapC	B-Chemical
-	I-Chemical
DOPS	I-Chemical
)	O
that	O
is	O
the	O
subject	O
of	O
this	O
research	O
.	O
Consistent	O
with	O
current	O
Cincinnati	O
Children	O
â€™	O
s	O
Hospital	O
Medical	O
Center	O
policies	O
","	O
the	O
development	O
and	O
commercialization	O
of	O
this	O
technology	O
has	O
been	O
licensed	O
to	O
Bexion	O
Pharmaceuticals	O
","	O
LLC	O
","	O
in	O
which	O
Dr	O
.	O
Qi	O
holds	O
a	O
minor	O
(<	O
5	O
%)	O
equity	O
interest	O
.	O
This	O
work	O
was	O
supported	O
in	O
part	O
by	O
R01CA158372	O
-	O
01A0	O
(	O
to	O
X	O
.	O
Qi	O
"),"	O
R21NS095047	O
-	O
01A0	O
(	O
to	O
X	O
.	O
Qi	O
"),"	O
Brain	O
Tumor	O
Center	O
Research	O
Funds	O
and	O
Hematology	O
-	O
Oncology	O
Programmatic	O
Support	O
from	O
University	O
of	O
Cincinnati	O
College	O
of	O
Medicine	O
(	O
to	O
X	O
.	O
Qi	O
"),"	O
and	O
New	O
Drug	O
State	O
Key	O
Project	O
Grant	O
Number	O
009ZX09102	O
-	O
205	O
(	O
to	O
X	O
.	O
Qi	O
).	O
Authors	O
â€™	O
contributions	O
XQ	O
conceived	O
of	O
this	O
review	O
article	O
.	O
HWD	O
and	O
NH	O
participated	O
in	O
its	O
design	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
References	O
The	O
Glutathione	B-Chemical
Derivative	O
","	O
GSH	B-Chemical
Monoethyl	I-Chemical
Ester	I-Chemical
","	O
May	O
Effectively	O
Whiten	O
Skin	O
but	O
GSH	B-Chemical
Does	O
Not	O
Glutathione	B-Chemical
in	O
its	O
reduced	O
form	O
(	O
GSH	B-Chemical
)	O
is	O
an	O
antioxidant	O
and	O
also	O
is	O
involved	O
in	O
pheomelanin	B-Chemical
formation	O
.	O
Thus	O
","	O
it	O
has	O
been	O
long	O
believed	O
that	O
GSH	B-Chemical
has	O
a	O
skin	O
whitening	O
effect	O
.	O
However	O
","	O
its	O
actual	O
or	O
direct	O
effect	O
is	O
unproven	O
.	O
We	O
evaluated	O
the	O
anti	O
-	O
melanogenic	O
effects	O
of	O
GSH	B-Chemical
and	O
its	O
derivatives	O
in	O
vitro	O
.	O
We	O
examined	O
change	O
of	O
melanogenesis	O
and	O
its	O
related	O
proteins	O
by	O
GSH	B-Chemical
itself	O
and	O
its	O
derivatives	O
","	O
including	O
GSH	B-Chemical
monoethyl	I-Chemical
ester	I-Chemical
(	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
"),"	O
GSH	B-Chemical
diethyl	I-Chemical
ester	I-Chemical
(	O
GSH	B-Chemical
-	I-Chemical
DEE	I-Chemical
)	O
and	O
GSH	B-Chemical
monoisopropyl	I-Chemical
ester	I-Chemical
(	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
)	O
in	O
Melan	O
-	O
A	O
cells	O
","	O
Mel	O
-	O
Ab	O
cells	O
","	O
and	O
B16F10	O
cells	O
.	O
GSH	B-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
did	O
not	O
display	O
cytotoxic	O
activity	O
","	O
but	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
DEE	I-Chemical
did	O
.	O
Intriguingly	O
","	O
GSH	B-Chemical
itself	O
had	O
no	O
inhibitory	O
effect	O
on	O
melanin	B-Chemical
production	O
or	O
intracellular	O
tyrosinase	O
activity	O
.	O
Rather	O
","	O
it	O
was	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
that	O
profoundly	O
reduced	O
the	O
amount	O
of	O
melanin	B-Chemical
and	O
intracellular	O
tyrosinase	O
activity	O
.	O
Thus	O
","	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
was	O
selected	O
as	O
a	O
suitable	O
candidate	O
skin	O
-	O
whitening	O
agent	O
and	O
it	O
did	O
not	O
alter	O
melanogenesis	O
-	O
associated	O
proteins	O
such	O
as	O
microphthalmia	O
-	O
associated	O
transcription	O
factor	O
(	O
MITF	O
"),"	O
tyrosinase	O
","	O
tyrosinase	O
-	O
related	O
protein	O
(	O
TRP	O
)-	O
1	O
","	O
and	O
TRP	O
-	O
2	O
","	O
but	O
it	O
did	O
increase	O
the	O
amount	O
of	O
suggested	O
pheomelanin	B-Chemical
and	O
suggested	O
pheomelanin	B-Chemical
/	O
eumelanin	B-Chemical
ratio	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
was	O
effective	O
for	O
anti	O
-	O
melanogenesis	O
","	O
whereas	O
GSH	B-Chemical
itself	O
was	O
not	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
could	O
be	O
developed	O
as	O
a	O
safe	O
and	O
efficient	O
agent	O
for	O
the	O
treatment	O
of	O
hyperpigmentation	O
skin	O
disorders	O
.	O
1	O
.	O
Introduction	O
Melasma	O
and	O
other	O
skin	O
hyperpigmentation	O
disorders	O
are	O
often	O
difficult	O
to	O
treat	O
and	O
often	O
require	O
multimodal	O
approaches	O
","	O
including	O
anti	O
-	O
melanogenesis	O
(	O
mostly	O
anti	O
-	O
tyrosinase	O
)	O
and	O
antioxidant	O
strategies	O
.	O
Glutathione	B-Chemical
has	O
long	O
been	O
considered	O
and	O
even	O
used	O
as	O
an	O
intravenous	O
product	O
for	O
skin	O
whitening	O
and	O
for	O
the	O
treatment	O
of	O
melasma	O
","	O
but	O
its	O
real	O
or	O
direct	O
effect	O
remains	O
unproven	O
.	O
Because	O
melasma	O
is	O
often	O
refractory	O
to	O
various	O
treatments	O
","	O
an	O
anti	O
-	O
melasma	O
oral	O
formulation	O
composed	O
of	O
cysteine	B-Chemical
(	O
a	O
component	O
of	O
GSH	B-Chemical
"),"	O
Vitamin	B-Chemical
C	I-Chemical
","	O
and	O
tranexamic	B-Chemical
acid	I-Chemical
is	O
also	O
popular	O
.	O
A	O
report	O
[	O
1	O
]	O
involving	O
a	O
small	O
number	O
of	O
subjects	O
in	O
Thailand	O
","	O
and	O
short	O
-	O
term	O
follow	O
up	O
","	O
showed	O
that	O
oral	O
administration	O
of	O
glutathione	B-Chemical
resulted	O
in	O
lightening	O
of	O
skin	O
color	O
.	O
The	O
skin	O
is	O
purposefully	O
placed	O
at	O
the	O
interface	O
with	O
the	O
external	O
environment	O
where	O
it	O
has	O
been	O
developed	O
to	O
detect	O
","	O
incorporate	O
and	O
respond	O
to	O
various	O
stressors	O
including	O
ultraviolet	O
(	O
UV	O
)	O
radiation	O
[	O
2	O
].	O
Within	O
the	O
role	O
of	O
the	O
skin	O
as	O
a	O
stress	O
organ	O
","	O
melanogenesis	O
acts	O
as	O
a	O
molecular	O
sensor	O
and	O
transducer	O
of	O
noxious	O
stimuli	O
and	O
as	O
controller	O
of	O
local	O
homeostasis	O
[	O
3	O
].	O
l	B-Chemical
-	I-Chemical
tyrosine	I-Chemical
and	O
l	B-Chemical
-	I-Chemical
dihydroxyphenylalanine	I-Chemical
(	O
l	B-Chemical
-	I-Chemical
DOPA	I-Chemical
)	O
not	O
only	O
serve	O
as	O
substrates	O
and	O
intermediates	O
of	O
melanogenesis	O
","	O
but	O
are	O
also	O
known	O
to	O
be	O
modulatory	O
agents	O
acting	O
as	O
inducers	O
and	O
positive	O
regulators	O
of	O
melanogenesis	O
as	O
well	O
as	O
regulators	O
of	O
other	O
cellular	O
functions	O
[	O
4	O
].	O
Although	O
the	O
primary	O
function	O
of	O
melanin	B-Chemical
pigment	O
and	O
melanogenic	O
apparatus	O
is	O
to	O
protect	O
the	O
normal	O
melanocytes	O
from	O
UV	O
radiation	O
and	O
oxidative	O
stress	O
","	O
at	O
times	O
","	O
melanin	B-Chemical
can	O
affect	O
melanoma	O
â€™	O
s	O
progression	O
[	O
5	O
].	O
Melanogenesis	O
is	O
mostly	O
affected	O
by	O
the	O
activity	O
of	O
tyrosinase	O
.	O
The	O
melanin	B-Chemical
pigment	O
is	O
produced	O
from	O
l	B-Chemical
-	I-Chemical
tyrosine	I-Chemical
that	O
is	O
converted	O
to	O
dopaquinone	B-Chemical
by	O
the	O
enzymatic	O
activity	O
of	O
tyrosinase	O
.	O
This	O
reaction	O
proceeds	O
spontaneously	O
via	O
dopachrome	O
to	O
the	O
monomeric	O
indolic	O
precursors	O
of	O
eumelanin	B-Chemical
.	O
Upon	O
reaction	O
with	O
cysteine	B-Chemical
","	O
dopaquinone	B-Chemical
forms	O
2	B-Chemical
-	I-Chemical
or	I-Chemical
5	I-Chemical
-	I-Chemical
S	I-Chemical
-	I-Chemical
cysteinyldopa	I-Chemical
that	O
produces	O
benzothiazine	B-Chemical
precursors	O
of	O
pheomelanin	B-Chemical
polymer	O
[	O
3	O
","	O
6	O
].	O
Glutathione	B-Chemical
","	O
a	O
tripeptide	O
component	O
of	O
cysteine	B-Chemical
","	O
glutamate	B-Chemical
and	O
glycine	B-Chemical
","	O
is	O
a	O
key	O
antioxidant	O
in	O
the	O
body	O
and	O
serves	O
crucial	O
roles	O
in	O
maintaining	O
intracellular	O
thiol	B-Chemical
status	O
","	O
and	O
in	O
detoxification	O
of	O
electrophilic	O
metabolites	O
as	O
well	O
as	O
in	O
xenobiotics	O
.	O
Although	O
glutathione	B-Chemical
is	O
present	O
in	O
its	O
both	O
reduced	O
(	O
GSH	B-Chemical
)	O
and	O
oxidized	O
(	O
GSSG	B-Chemical
)	O
states	O
","	O
the	O
majority	O
of	O
it	O
found	O
in	O
the	O
body	O
is	O
in	O
the	O
reduced	O
form	O
.	O
GSH	B-Chemical
conducts	O
antioxidant	O
activity	O
by	O
scavenging	O
free	O
-	O
radicals	O
during	O
reductive	O
detoxification	O
of	O
hydrogen	B-Chemical
peroxide	I-Chemical
and	O
lipid	B-Chemical
peroxide	I-Chemical
[	O
7	O
].	O
In	O
addition	O
to	O
its	O
antioxidant	O
effect	O
by	O
removing	O
free	O
radicals	O
and	O
peroxides	B-Chemical
that	O
assist	O
tyrosinase	O
activation	O
and	O
melanin	B-Chemical
production	O
","	O
GSH	B-Chemical
is	O
known	O
to	O
be	O
essential	O
for	O
pheomelanin	B-Chemical
formation	O
because	O
it	O
mediates	O
the	O
mechanism	O
for	O
switching	O
from	O
eumelanin	B-Chemical
to	O
pheomelanin	B-Chemical
production	O
","	O
which	O
may	O
provide	O
another	O
powerful	O
strategy	O
for	O
skin	O
whitening	O
.	O
Another	O
proposed	O
mechanism	O
of	O
GSH	B-Chemical
action	O
involves	O
the	O
direct	O
suppression	O
of	O
the	O
tyrosinase	O
activity	O
when	O
GSH	B-Chemical
binds	O
to	O
the	O
copper	B-Chemical
-	O
containing	O
active	O
site	O
of	O
tyrosinase	O
[	O
8	O
].	O
Although	O
intra	O
-	O
melanocytic	O
GSH	B-Chemical
has	O
been	O
known	O
to	O
affect	O
the	O
regulation	O
of	O
melanogenesis	O
","	O
the	O
effect	O
of	O
exogenous	O
GSH	B-Chemical
is	O
unclear	O
.	O
It	O
is	O
generally	O
believed	O
that	O
GSH	B-Chemical
itself	O
is	O
not	O
transported	O
across	O
the	O
cell	O
membrane	O
.	O
Moreover	O
","	O
the	O
presence	O
of	O
GSH	B-Chemical
carriers	O
for	O
melanosomal	O
transport	O
has	O
not	O
been	O
reported	O
","	O
nor	O
does	O
it	O
seem	O
likely	O
that	O
simple	O
diffusion	O
or	O
a	O
membrane	O
channel	O
could	O
enable	O
GSH	B-Chemical
entry	O
into	O
melanosomes	O
.	O
Therefore	O
","	O
we	O
hypothesized	O
that	O
the	O
ester	B-Chemical
forms	O
of	O
GSH	B-Chemical
derivatives	O
could	O
have	O
de	O
-	O
pigmenting	O
efficacy	O
superior	O
to	O
GSH	B-Chemical
","	O
because	O
the	O
ester	B-Chemical
form	O
of	O
GSH	B-Chemical
derivatives	O
could	O
be	O
delivered	O
to	O
intracellular	O
spaces	O
.	O
In	O
this	O
study	O
","	O
we	O
examined	O
the	O
anti	O
-	O
melanogenic	O
efficacy	O
of	O
GSH	B-Chemical
and	O
its	O
derivatives	O
","	O
and	O
sought	O
to	O
elucidate	O
the	O
underlying	O
cellular	O
mechanisms	O
.	O
2	O
.	O
Results	O
2	O
.	O
1	O
.	O
GSH	B-Chemical
and	O
GSH	B-Chemical
Monoethyl	I-Chemical
Ester	I-Chemical
(	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
)	O
Did	O
Not	O
Affect	O
Cellular	O
Viability	O
GSH	B-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
(	O
Figure	O
1a	O
)	O
did	O
not	O
affect	O
cellular	O
viability	O
in	O
Melan	O
-	O
A	O
cells	O
(	O
Figure	O
1b	O
).	O
GSH	B-Chemical
monoisopropyl	I-Chemical
ester	I-Chemical
(	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
)	O
had	O
slight	O
cellular	O
toxicity	O
(	O
80	O
%	O
cell	O
viability	O
of	O
control	O
at	O
8	O
mM	O
","	O
Figure	O
1b	O
)	O
and	O
GSH	B-Chemical
diethyl	I-Chemical
ester	I-Chemical
(	O
GSH	B-Chemical
-	I-Chemical
DEE	I-Chemical
)	O
had	O
a	O
profound	O
cellular	O
toxicity	O
in	O
Melan	O
-	O
A	O
cells	O
","	O
even	O
at	O
concentrations	O
as	O
low	O
as	O
2	O
mM	O
(	O
Figure	O
1b	O
).	O
For	O
this	O
reason	O
","	O
GSH	B-Chemical
-	I-Chemical
DEE	I-Chemical
was	O
not	O
used	O
in	O
subsequent	O
experiments	O
.	O
2	O
.	O
2	O
.	O
Whereas	O
GSH	B-Chemical
Itself	O
Did	O
Not	O
Suppress	O
Melanogenesis	O
","	O
Its	O
Derivative	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
Did	O
Reduce	O
Melanogenesis	O
We	O
then	O
determined	O
the	O
effect	O
of	O
GSH	B-Chemical
","	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
and	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
on	O
melanogenesis	O
.	O
Surprisingly	O
","	O
GSH	B-Chemical
had	O
no	O
inhibitory	O
effect	O
on	O
melanogenesis	O
:	O
the	O
melanin	B-Chemical
content	O
did	O
not	O
change	O
at	O
any	O
concentration	O
tested	O
(	O
Figure	O
2a	O
","	O
b	O
).	O
However	O
","	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
decreased	O
melanin	B-Chemical
production	O
in	O
Melan	O
-	O
A	O
cells	O
(	O
Figure	O
2a	O
).	O
The	O
decrease	O
of	O
melanin	B-Chemical
content	O
by	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
was	O
reproduced	O
in	O
another	O
melanocyte	O
-	O
derived	O
cell	O
line	O
","	O
Mel	O
-	O
Ab	O
(	O
Figure	O
2c	O
).	O
We	O
next	O
examined	O
the	O
effects	O
of	O
GSH	B-Chemical
","	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
and	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
on	O
tyrosinase	O
activity	O
.	O
In	O
Melan	O
-	O
A	O
cells	O
","	O
as	O
expected	O
","	O
GSH	B-Chemical
did	O
not	O
affect	O
intracellular	O
activity	O
of	O
tyrosinase	O
","	O
but	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
inhibited	O
the	O
activity	O
of	O
intracellular	O
tyrosinase	O
(	O
Figure	O
2d	O
).	O
Although	O
both	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
showed	O
evident	O
antimelanogenic	O
effects	O
","	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
was	O
considered	O
a	O
more	O
promising	O
candidate	O
de	O
-	O
pigmenting	O
agent	O
because	O
it	O
did	O
not	O
compromise	O
cellular	O
viability	O
.	O
Therefore	O
","	O
further	O
experiments	O
were	O
focused	O
on	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
.	O
To	O
evalute	O
how	O
the	O
concentration	O
of	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
affects	O
melanongenesis	O
","	O
cells	O
were	O
treated	O
with	O
2	O
â€“	O
8	O
mM	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
.	O
Two	O
days	O
after	O
","	O
the	O
melanin	B-Chemical
content	O
was	O
measured	O
.	O
The	O
results	O
revealed	O
the	O
negative	O
regulatory	O
effect	O
of	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
on	O
melanin	B-Chemical
synthesis	O
in	O
both	O
Melan	O
-	O
A	O
cells	O
and	O
B16F10	O
cells	O
(	O
Figure	O
3a	O
","	O
b	O
).	O
The	O
intracellular	O
tyrosinase	O
activity	O
was	O
also	O
suppressed	O
in	O
both	O
cells	O
(	O
Figure	O
3c	O
","	O
d	O
"),"	O
and	O
the	O
responses	O
of	O
melanogenesis	O
and	O
tyrosinase	O
activity	O
to	O
various	O
doses	O
of	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
were	O
in	O
accordance	O
with	O
each	O
other	O
.	O
However	O
","	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
did	O
not	O
reduce	O
the	O
protein	O
levels	O
of	O
tyrosinase	O
","	O
microphthalmia	O
-	O
associated	O
transcription	O
factor	O
(	O
MITF	O
"),"	O
tyrosinase	O
-	O
related	O
protein	O
(	O
TRP	O
)-	O
1	O
","	O
and	O
TRP	O
-	O
2	O
significantly	O
at	O
the	O
test	O
-	O
doses	O
above	O
(	O
Figure	O
3d	O
).	O
These	O
data	O
suggest	O
that	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
regulates	O
intracellular	O
activity	O
of	O
tyrosinase	O
and	O
subsequently	O
downregulates	O
melanin	B-Chemical
synthesis	O
.	O
2	O
.	O
3	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
Suppresses	O
Levels	O
of	O
the	O
Melanin	B-Chemical
with	O
Absorbance	O
at	O
350	O
nm	O
(	O
A350	O
)	O
Production	O
","	O
but	O
Induces	O
the	O
Melanin	B-Chemical
with	O
Absorbance	O
at	O
400	O
nm	O
(	O
A400	O
)	O
Production	O
in	O
Melan	O
-	O
A	O
Cells	O
Finally	O
","	O
we	O
sought	O
to	O
determine	O
whether	O
the	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
-	O
mediated	O
decrease	O
in	O
melanin	B-Chemical
synthesis	O
results	O
from	O
its	O
regulation	O
of	O
suggested	O
pheomelanin	B-Chemical
and	O
eumelanin	B-Chemical
production	O
.	O
Melan	O
-	O
A	O
cells	O
were	O
incubated	O
with	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
for	O
48	O
h	O
","	O
and	O
then	O
the	O
suggested	O
eumelanin	B-Chemical
and	O
pheomelanin	B-Chemical
content	O
was	O
measured	O
using	O
spectrophotometric	O
analysis	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
increased	O
the	O
melanin	B-Chemical
with	O
A400	O
production	O
and	O
decreased	O
the	O
melanin	B-Chemical
with	O
A350	O
.	O
(	O
Figure	O
3e	O
).	O
The	O
A350	O
values	O
are	O
referred	O
to	O
as	O
spectrophotometric	O
eumelanin	B-Chemical
and	O
the	O
A400	O
values	O
are	O
referred	O
to	O
as	O
spectrophotometric	O
pheomelanin	B-Chemical
.	O
Taken	O
together	O
","	O
these	O
results	O
indicate	O
that	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
may	O
have	O
a	O
de	O
-	O
pigmenting	O
effect	O
by	O
inhibiting	O
tyrosinase	O
activity	O
","	O
resulting	O
in	O
reduction	O
of	O
suggested	O
eumelanin	B-Chemical
synthesis	O
and	O
increase	O
of	O
suggested	O
pheomelanin	B-Chemical
synthesis	O
.	O
3	O
.	O
Discussion	O
The	O
majority	O
of	O
glutathione	B-Chemical
is	O
present	O
in	O
its	O
reduced	O
form	O
","	O
GSH	B-Chemical
","	O
which	O
is	O
a	O
well	O
-	O
known	O
antioxidant	O
.	O
Accordingly	O
","	O
GSH	B-Chemical
is	O
expected	O
to	O
repress	O
melanin	B-Chemical
production	O
by	O
redox	O
mechanisms	O
.	O
Exhaustion	O
of	O
GSH	B-Chemical
in	O
the	O
skin	O
by	O
UV	O
radiation	O
might	O
induce	O
the	O
accumulation	O
of	O
hydrogen	B-Chemical
peroxide	I-Chemical
as	O
a	O
result	O
of	O
insufficient	O
detoxification	O
.	O
Subsequently	O
","	O
increased	O
melanin	B-Chemical
synthesis	O
could	O
be	O
further	O
promoted	O
by	O
hydrogen	B-Chemical
peroxide	I-Chemical
or	O
other	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
[	O
9	O
","	O
10	O
","	O
11	O
].	O
On	O
the	O
other	O
hand	O
","	O
for	O
more	O
than	O
30	O
years	O
","	O
GSH	B-Chemical
has	O
been	O
known	O
to	O
be	O
a	O
regulatory	O
molecule	O
in	O
mammalian	O
melanogenesis	O
","	O
that	O
is	O
","	O
an	O
endogenous	O
reductant	O
diverting	O
dopaquinone	B-Chemical
to	O
pheomelanin	B-Chemical
pathway	O
ultimately	O
leading	O
to	O
skin	O
whitening	O
.	O
In	O
addition	O
","	O
it	O
was	O
proposed	O
that	O
GSH	B-Chemical
affects	O
melanogenesis	O
by	O
inhibiting	O
tyrosinase	O
activity	O
[	O
12	O
","	O
13	O
","	O
14	O
","	O
15	O
].	O
Tyrosinase	O
plays	O
the	O
main	O
enzymatic	O
role	O
in	O
melanogenesis	O
","	O
catalyzing	O
the	O
conversion	O
of	O
l	B-Chemical
-	I-Chemical
tyrosine	I-Chemical
into	O
l	B-Chemical
-	I-Chemical
dopaquinone	I-Chemical
.	O
It	O
was	O
reported	O
thiol	B-Chemical
groups	O
directly	O
inhibit	O
tyrosinase	O
by	O
acting	O
on	O
copper	B-Chemical
at	O
the	O
active	O
site	O
of	O
the	O
enzyme	O
[	O
16	O
].	O
For	O
this	O
reason	O
","	O
the	O
skin	O
whitening	O
effect	O
of	O
exogenous	O
GSH	B-Chemical
has	O
been	O
assumed	O
for	O
long	O
","	O
even	O
though	O
the	O
effect	O
of	O
an	O
intravenous	O
product	O
for	O
the	O
treatment	O
of	O
melasma	O
and	O
other	O
hyperpigmentary	O
disorders	O
was	O
unclear	O
and	O
unproven	O
.	O
Thus	O
","	O
the	O
data	O
regarding	O
the	O
effect	O
of	O
GSH	B-Chemical
on	O
pigmentation	O
is	O
inconclusive	O
[	O
1	O
].	O
Also	O
","	O
if	O
GSH	B-Chemical
had	O
a	O
direct	O
regulatory	O
effect	O
on	O
melanogenesis	O
","	O
at	O
the	O
least	O
","	O
it	O
would	O
be	O
required	O
that	O
GSH	B-Chemical
be	O
transported	O
into	O
melanosomes	O
.	O
Carrier	O
-	O
mediated	O
lysosomal	O
membrane	O
transport	O
systems	O
remain	O
for	O
cysteine	B-Chemical
[	O
17	O
].	O
However	O
","	O
GSH	B-Chemical
is	O
not	O
transported	O
into	O
melanosomes	O
","	O
nor	O
is	O
GSH	B-Chemical
likely	O
to	O
be	O
capable	O
of	O
enter	O
melanosomes	O
by	O
simple	O
diffusion	O
or	O
through	O
a	O
membrane	O
channel	O
.	O
(	O
Figure	O
4	O
)	O
[	O
18	O
].	O
Therefore	O
","	O
we	O
hypothesized	O
that	O
the	O
ester	B-Chemical
form	O
of	O
a	O
GSH	B-Chemical
derivative	O
would	O
be	O
more	O
effective	O
at	O
entering	O
melanosomes	O
because	O
the	O
GSH	B-Chemical
ester	I-Chemical
form	O
is	O
more	O
lipophilic	O
(	O
Figure	O
4	O
).	O
In	O
our	O
study	O
","	O
we	O
determined	O
the	O
effects	O
of	O
GSH	B-Chemical
and	O
GSH	B-Chemical
derivatives	O
on	O
melanin	B-Chemical
synthesis	O
","	O
and	O
evaluated	O
the	O
cellular	O
mechanism	O
of	O
the	O
regulation	O
of	O
melanogenesis	O
in	O
vitro	O
.	O
Intriguingly	O
","	O
we	O
found	O
that	O
GSH	B-Chemical
did	O
neither	O
suppress	O
the	O
enzymatic	O
activity	O
of	O
tyrosinase	O
","	O
nor	O
reduce	O
melanin	B-Chemical
synthesis	O
.	O
However	O
","	O
its	O
derivatives	O
","	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
did	O
reduce	O
melanin	B-Chemical
synthesis	O
.	O
These	O
findings	O
are	O
consistent	O
with	O
our	O
null	O
hypothesis	O
that	O
the	O
esterified	O
derivatives	O
of	O
GSH	B-Chemical
would	O
show	O
superior	O
efficacy	O
because	O
of	O
the	O
feasibility	O
of	O
intracellular	O
and	O
intra	O
-	O
melanosomal	O
delivery	O
[	O
19	O
","	O
20	O
].	O
In	O
our	O
study	O
","	O
among	O
the	O
esterified	O
derivatives	O
of	O
GSH	B-Chemical
","	O
the	O
most	O
suitable	O
candidate	O
whitening	O
agent	O
was	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
.	O
Furthermore	O
","	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
has	O
a	O
lipophilic	O
nature	O
that	O
makes	O
it	O
better	O
able	O
to	O
penetrate	O
skin	O
as	O
a	O
topical	O
agent	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
demonstrated	O
itself	O
to	O
be	O
an	O
effective	O
compound	O
for	O
inhibiting	O
cellular	O
melanin	B-Chemical
synthesis	O
","	O
and	O
was	O
also	O
not	O
cytotoxic	O
","	O
unlike	O
the	O
other	O
esterified	O
derivatives	O
of	O
GSH	B-Chemical
","	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
DEE	I-Chemical
.	O
We	O
further	O
evaluated	O
the	O
regulation	O
mechanism	O
of	O
the	O
anti	O
-	O
melanogenic	O
effect	O
caused	O
by	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
.	O
It	O
did	O
not	O
significantly	O
decrease	O
the	O
levels	O
of	O
melanogenesis	O
-	O
associated	O
proteins	O
such	O
as	O
MITF	O
","	O
tyrosinase	O
","	O
TRP	O
-	O
1	O
","	O
and	O
TRP	O
-	O
2	O
","	O
but	O
it	O
increased	O
the	O
amount	O
of	O
suggested	O
pheomelanin	B-Chemical
and	O
the	O
ratio	O
of	O
suggested	O
pheomelanin	B-Chemical
/	O
eumelanin	B-Chemical
.	O
The	O
biosynthesis	O
of	O
melanin	B-Chemical
takes	O
place	O
through	O
a	O
complex	O
but	O
orderly	O
sequence	O
of	O
enzymatic	O
and	O
chemical	O
reactions	O
.	O
The	O
melanins	O
produced	O
are	O
conventionally	O
classified	O
into	O
two	O
major	O
types	O
:	O
eumelanins	B-Chemical
(	O
brown	O
or	O
black	O
)	O
and	O
sulfur	B-Chemical
-	O
containing	O
pheomelanins	B-Chemical
(	O
red	O
or	O
yellow	O
)	O
[	O
21	O
].	O
Within	O
the	O
melanocytes	O
","	O
sulfhydryl	B-Chemical
compounds	I-Chemical
such	O
as	O
GSH	B-Chemical
and	O
its	O
precursor	O
cysteine	B-Chemical
","	O
are	O
actively	O
involved	O
in	O
the	O
melanogenic	O
process	O
of	O
making	O
pheomelanin	B-Chemical
[	O
6	O
].	O
Besides	O
their	O
essential	O
roles	O
in	O
pigmentation	O
","	O
the	O
intracellular	O
concentrations	O
of	O
GSH	B-Chemical
and	O
cysteine	B-Chemical
are	O
also	O
a	O
crucial	O
regulator	O
of	O
the	O
switch	O
of	O
eumelanin	B-Chemical
to	O
pheomelanin	B-Chemical
[	O
22	O
].	O
Decreased	O
tyrosinase	O
activity	O
is	O
also	O
associated	O
with	O
a	O
more	O
marked	O
shift	O
to	O
pheomelanin	B-Chemical
synthesis	O
","	O
as	O
it	O
is	O
considered	O
to	O
be	O
the	O
default	O
pathway	O
[	O
23	O
].	O
A	O
recent	O
study	O
showed	O
anti	O
-	O
melanogenic	O
effects	O
of	O
exogenous	O
GSH	B-Chemical
in	O
melanoma	O
cells	O
[	O
24	O
].	O
We	O
speculated	O
that	O
the	O
discrepancy	O
might	O
be	O
related	O
with	O
the	O
extracellular	O
metabolism	O
of	O
GSH	B-Chemical
.	O
Î³	O
-	O
glutamyltranspeptidase	O
(	O
GGT	O
"),"	O
an	O
ectoenzyme	O
involved	O
in	O
the	O
degradation	O
of	O
GSH	B-Chemical
derivatives	O
exported	O
from	O
cytosol	O
cleaves	O
the	O
Î³	O
-	O
glutamyl	O
peptide	O
bond	O
of	O
GSH	B-Chemical
to	O
generate	O
cysteinylglycine	B-Chemical
and	O
transfers	O
the	O
Î³	O
-	O
glutamyl	O
group	O
to	O
another	O
amino	B-Chemical
acid	I-Chemical
including	O
cysteine	B-Chemical
[	O
20	O
].	O
The	O
first	O
limitation	O
of	O
this	O
study	O
to	O
be	O
addressed	O
was	O
using	O
the	O
spectrophotometric	O
analysis	O
to	O
measure	O
concentrations	O
of	O
eumelanin	B-Chemical
and	O
pheomelanin	B-Chemical
.	O
The	O
measurement	O
of	O
degraded	O
products	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
or	O
the	O
noninvasive	O
method	O
of	O
electron	O
paramagnetic	O
resonance	O
(	O
EPR	O
)	O
are	O
more	O
analytical	O
methods	O
to	O
measure	O
concentrations	O
of	O
eumelanin	B-Chemical
and	O
pheomelanin	B-Chemical
than	O
the	O
spectrophotometric	O
analysis	O
used	O
in	O
this	O
study	O
[	O
25	O
","	O
26	O
].	O
The	O
second	O
limitation	O
of	O
this	O
study	O
was	O
the	O
strict	O
focus	O
on	O
mouse	O
melanocytes	O
lines	O
and	O
inconsistent	O
use	O
of	O
cell	O
lines	O
.	O
Therefore	O
","	O
further	O
studies	O
to	O
determine	O
the	O
anti	O
-	O
melanogenic	O
effect	O
of	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
on	O
other	O
mouse	O
melanocytes	O
and	O
human	O
melanocytes	O
will	O
be	O
needed	O
.	O
4	O
.	O
Materials	O
and	O
Methods	O
4	O
.	O
1	O
.	O
Reagents	O
GSH	B-Chemical
and	O
its	O
derivatives	O
(	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
GSH	B-Chemical
-	I-Chemical
DEE	I-Chemical
","	O
and	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
)	O
were	O
acquired	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
.	O
Louis	O
","	O
MO	O
","	O
USA	O
)	O
and	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
","	O
CA	O
","	O
USA	O
"),"	O
respectively	O
.	O
Primary	O
antibodies	O
against	O
mouse	O
proteins	O
were	O
acquired	O
from	O
the	O
following	O
sources	O
:	O
anti	O
-	O
Î²	O
-	O
actin	O
(	O
Sigma	O
-	O
Aldrich	O
"),"	O
anti	O
-	O
MITF	O
(	O
NeoMarkers	O
","	O
Fremont	O
","	O
CA	O
","	O
USA	O
"),"	O
anti	O
-	O
tyrosinase	O
(	O
Santa	O
Cruz	O
","	O
CA	O
","	O
USA	O
"),"	O
anti	O
-	O
TRP	O
-	O
1	O
","	O
and	O
anti	O
-	O
TRP	O
-	O
2	O
(	O
Abcam	O
","	O
Cambridge	O
","	O
UK	O
).	O
4	O
.	O
2	O
.	O
Cells	O
and	O
Cell	O
Culture	O
Melan	O
-	O
A	O
mouse	O
melanocytes	O
were	O
cultured	O
in	O
RPMI	B-Chemical
1640	I-Chemical
(	O
Gibco	O
","	O
Carlsbad	O
","	O
CA	O
","	O
USA	O
"),"	O
containing	O
Phorbol	B-Chemical
12	I-Chemical
-	I-Chemical
myristate	I-Chemical
13	I-Chemical
-	I-Chemical
acetate	I-Chemical
(	O
PMA	B-Chemical
;	O
200	O
nM	O
"),"	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
","	O
Gibco	O
"),"	O
and	O
1	O
%	O
antibiotic	O
-	O
antimycotic	O
100	O
Ã—	O
(	O
Gibco	O
).	O
The	O
Mel	O
-	O
Ab	O
cell	O
line	O
is	O
a	O
mouse	O
-	O
derived	O
spontaneously	O
immortalized	O
cell	O
line	O
of	O
melanocytes	O
[	O
27	O
].	O
Mel	O
-	O
Ab	O
cells	O
were	O
contained	O
in	O
Dulbecco	B-Chemical
â€™	I-Chemical
s	I-Chemical
modified	I-Chemical
Eagle	I-Chemical
â€™	I-Chemical
s	I-Chemical
medium	I-Chemical
(	O
DMEM	B-Chemical
","	O
Welgene	O
","	O
Deagu	O
","	O
Korea	O
)	O
mixed	O
with	O
10	O
%	O
FBS	O
","	O
100	O
nM	O
12	B-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
tetradecanoylphorbol	I-Chemical
-	I-Chemical
13	I-Chemical
-	I-Chemical
acetate	I-Chemical
(	O
TPA	B-Chemical
"),"	O
1	O
nM	O
cholera	O
toxin	O
(	O
CT	O
"),"	O
50	O
Âµg	O
/	O
mL	O
streptomycin	B-Chemical
","	O
and	O
50	O
U	O
/	O
mL	O
penicillin	B-Chemical
.	O
The	O
B16F10	O
mouse	O
melanoma	O
cells	O
were	O
obtained	O
from	O
the	O
Korean	O
Cell	O
Line	O
Bank	O
(	O
Seoul	O
","	O
Korea	O
).	O
The	O
B16F10	O
mouse	O
melanoma	O
cells	O
were	O
incubated	O
in	O
DMEM	B-Chemical
(	O
Welgene	O
"),"	O
supplemented	O
with	O
10	O
%	O
FBS	O
(	O
Gibco	O
)	O
and	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
penicillin	B-Chemical
-	O
streptomycin	B-Chemical
(	O
Gibco	O
).	O
All	O
cells	O
were	O
grown	O
at	O
37	O
Â°	O
C	O
in	O
a	O
humidified	O
atmosphere	O
containing	O
5	O
%	O
CO2	B-Chemical
.	O
4	O
.	O
3	O
.	O
Cellular	O
Viability	O
Analysis	O
Following	O
treatment	O
with	O
each	O
of	O
the	O
GSH	B-Chemical
and	O
its	O
derivatives	O
for	O
two	O
days	O
","	O
cellular	O
viability	O
was	O
determined	O
using	O
EZ	O
-	O
Cytox	O
cell	O
growth	O
assay	O
kit	O
(	O
ITSBIO	O
","	O
Seoul	O
","	O
Korea	O
).	O
Briefly	O
","	O
cells	O
were	O
seeded	O
in	O
triplicate	O
in	O
96	O
-	O
well	O
plates	O
at	O
a	O
density	O
1	O
Ã—	O
103	O
cells	O
/	O
well	O
.	O
EZ	O
-	O
Cytox	O
was	O
added	O
at	O
10	O
ÂµL	O
/	O
well	O
and	O
the	O
plates	O
were	O
incubated	O
at	O
37	O
Â°	O
C	O
for	O
30	O
min	O
to	O
2	O
h	O
.	O
Absorbance	O
was	O
measured	O
at	O
450	O
nm	O
using	O
an	O
enzyme	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
reader	O
(	O
Molecular	O
Devices	O
Co	O
".,"	O
Sunnyvale	O
","	O
CA	O
","	O
USA	O
)	O
with	O
the	O
reference	O
wavelength	O
600	O
â€“	O
650	O
nm	O
.	O
4	O
.	O
4	O
.	O
Total	O
Melanin	B-Chemical
Content	O
Assay	O
and	O
Spectrophotometric	O
Determination	O
of	O
Eumelanin	B-Chemical
and	O
Pheomelanin	B-Chemical
Total	O
melanin	B-Chemical
content	O
was	O
measured	O
as	O
described	O
previously	O
[	O
28	O
].	O
Briefly	O
","	O
Melan	O
-	O
A	O
cells	O
were	O
treated	O
with	O
each	O
of	O
the	O
GSH	B-Chemical
and	O
its	O
derivatives	O
in	O
culture	O
medium	O
containing	O
PMA	B-Chemical
(	O
200	O
nM	O
)	O
for	O
48	O
h	O
.	O
B16F10	O
cells	O
were	O
incubated	O
at	O
a	O
density	O
of	O
1	O
Ã—	O
105	O
cells	O
in	O
6	O
-	O
well	O
plates	O
overnight	O
.	O
Î±	B-Chemical
-	I-Chemical
melanocyte	I-Chemical
-	I-Chemical
stimulating	I-Chemical
hormone	I-Chemical
(	O
Î±	B-Chemical
-	I-Chemical
MSH	I-Chemical
","	O
200	O
nM	O
)	O
was	O
then	O
added	O
and	O
cells	O
were	O
treated	O
with	O
increasing	O
concentrations	O
of	O
the	O
GSH	B-Chemical
and	O
its	O
derivatives	O
in	O
phenol	B-Chemical
red	I-Chemical
-	O
free	O
DMEM	B-Chemical
for	O
3	O
days	O
.	O
Cells	O
were	O
re	O
-	O
suspended	O
in	O
600	O
ÂµL	O
of	O
1	O
g	O
/	O
L	O
NaOH	B-Chemical
at	O
100	O
Â°	O
C	O
for	O
30	O
min	O
and	O
centrifuged	O
at	O
13	O
","	O
0	O
rpm	O
for	O
5	O
min	O
.	O
The	O
optical	O
densities	O
(	O
OD	O
)	O
of	O
the	O
supernatants	O
were	O
measured	O
using	O
an	O
ELISA	O
reader	O
at	O
405	O
nm	O
.	O
The	O
melanin	B-Chemical
content	O
was	O
calculated	O
by	O
normalizing	O
the	O
melanin	B-Chemical
content	O
to	O
total	O
cellular	O
protein	O
content	O
","	O
as	O
measured	O
by	O
a	O
Micro	O
BCA	O
assay	O
kit	O
(	O
Pierce	O
Biotechnology	O
","	O
Rockford	O
","	O
IL	O
","	O
USA	O
).	O
In	O
separate	O
experiments	O
","	O
contents	O
of	O
eumelanin	B-Chemical
and	O
pheomelanin	B-Chemical
candidates	O
were	O
measured	O
using	O
spectrophotometric	O
assay	O
methods	O
specific	O
for	O
the	O
respective	O
melanin	B-Chemical
type	O
[	O
29	O
","	O
30	O
","	O
31	O
].	O
For	O
the	O
spectrophotometric	O
measurement	O
of	O
eumelanin	B-Chemical
","	O
2	O
.	O
4	O
Ã—	O
107	O
cells	O
were	O
heated	O
for	O
20	O
h	O
at	O
130	O
Â°	O
C	O
in	O
500	O
ÂµL	O
hydriodic	B-Chemical
acid	I-Chemical
with	O
30	O
ÂµL	O
H2O2	B-Chemical
","	O
and	O
insoluble	O
eumelanin	B-Chemical
was	O
solubilized	O
by	O
heating	O
for	O
30	O
min	O
at	O
100	O
Â°	O
C	O
in	O
1	O
mol	O
Â·	O
L	O
âˆ’	O
1	O
NaOH	B-Chemical
in	O
the	O
existence	O
of	O
H2O2	B-Chemical
","	O
and	O
analysed	O
for	O
A350	O
[	O
30	O
].	O
The	O
A350	O
values	O
are	O
suggested	O
as	O
eumelanin	B-Chemical
.	O
For	O
the	O
spectrophotometric	O
assay	O
of	O
pheomelanin	B-Chemical
","	O
1	O
.	O
6	O
Ã—	O
107	O
cells	O
were	O
isolated	O
with	O
0	O
.	O
1	O
mol	O
Â·	O
L	O
âˆ’	O
1	O
sodium	B-Chemical
phosphate	I-Chemical
buffer	O
","	O
pH	O
10	O
.	O
5	O
.	O
Supernatants	O
were	O
analyzed	O
for	O
A400	O
.	O
These	O
values	O
are	O
suggested	O
as	O
pheomelanin	B-Chemical
.	O
4	O
.	O
5	O
.	O
Intracellular	O
Tyrosinase	O
Activity	O
Assay	O
Tyrosinase	O
activity	O
assay	O
was	O
performed	O
as	O
described	O
previously	O
[	O
31	O
","	O
32	O
].	O
Briefly	O
","	O
Melan	O
-	O
A	O
cells	O
and	O
B16F10	O
cells	O
were	O
seeded	O
in	O
6	O
-	O
well	O
plates	O
and	O
incubated	O
with	O
GSH	B-Chemical
derivatives	O
for	O
2	O
or	O
3	O
days	O
.	O
The	O
cells	O
were	O
washed	O
with	O
ice	O
-	O
cold	O
PBS	B-Chemical
and	O
lysed	O
with	O
phosphate	B-Chemical
buffer	O
(	O
pH	O
6	O
.	O
8	O
)	O
containing	O
1	O
%	O
Triton	B-Chemical
X	I-Chemical
-	I-Chemical
100	I-Chemical
.	O
They	O
were	O
then	O
discomposed	O
by	O
freezing	O
and	O
thawing	O
","	O
and	O
lysates	O
were	O
clarified	O
by	O
centrifugation	O
at	O
15	O
","	O
0	O
rpm	O
for	O
10	O
min	O
.	O
After	O
measuring	O
the	O
protein	O
levels	O
of	O
the	O
lysate	O
and	O
adjusting	O
the	O
protein	O
concentrations	O
with	O
lysis	O
buffer	O
","	O
90	O
mL	O
of	O
each	O
lysate	O
containing	O
equal	O
amounts	O
of	O
protein	O
was	O
added	O
in	O
each	O
well	O
of	O
a	O
96	O
-	O
well	O
plate	O
","	O
and	O
10	O
mL	O
of	O
10	O
mM	O
l	B-Chemical
-	I-Chemical
dihydroxyphenylalanine	I-Chemical
(	O
l	B-Chemical
-	I-Chemical
DOPA	I-Chemical
)	O
was	O
then	O
placed	O
in	O
each	O
well	O
.	O
The	O
control	O
wells	O
were	O
composed	O
of	O
90	O
mL	O
of	O
lysis	O
buffer	O
and	O
10	O
mL	O
of	O
10	O
mM	O
l	B-Chemical
-	I-Chemical
DOPA	I-Chemical
.	O
Following	O
incubation	O
at	O
37	O
Â°	O
C	O
","	O
absorbance	O
at	O
475	O
nm	O
was	O
analysed	O
every	O
10	O
min	O
for	O
at	O
least	O
1	O
h	O
using	O
a	O
microplate	O
reader	O
.	O
4	O
.	O
6	O
.	O
Western	O
Blot	O
Analysis	O
Total	O
proteins	O
were	O
isolated	O
using	O
PRO	B-Chemical
-	I-Chemical
PREP	I-Chemical
extraction	I-Chemical
solution	I-Chemical
(	O
Intron	O
","	O
Daejeon	O
","	O
Korea	O
).	O
Protein	O
concentrations	O
were	O
evaluated	O
using	O
the	O
BCA	O
Protein	O
Assay	O
Reagent	O
(	O
Pierce	O
).	O
Equally	O
loaded	O
proteins	O
from	O
each	O
sample	O
were	O
resolved	O
in	O
SDS	B-Chemical
-	O
PAGE	O
gels	O
(	O
Invitrogen	O
","	O
Merelbeke	O
","	O
Belgium	O
)	O
and	O
transferred	O
to	O
nitrocellulose	O
membranes	O
(	O
Whatman	O
"â„¢,"	O
GE	O
Healthcare	O
Life	O
Sciences	O
","	O
Buckinghamshire	O
","	O
UK	O
"),"	O
which	O
were	O
blocked	O
for	O
1	O
h	O
at	O
room	O
temperature	O
in	O
tris	B-Chemical
buffered	I-Chemical
saline	I-Chemical
with	O
Tween	B-Chemical
20	I-Chemical
(	O
TBS	B-Chemical
-	I-Chemical
T	I-Chemical
)	O
and	O
5	O
%	O
nonfat	O
dry	O
milk	O
.	O
The	O
membrane	O
was	O
then	O
incubated	O
over	O
-	O
night	O
at	O
a	O
temperature	O
of	O
4	O
Â°	O
C	O
with	O
the	O
primary	O
antibody	O
diluted	O
in	O
5	O
%	O
nonfat	O
dry	O
milk	O
","	O
or	O
5	O
%	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
mixed	O
in	O
TBS	B-Chemical
-	I-Chemical
T	I-Chemical
.	O
The	O
membranes	O
were	O
then	O
washed	O
","	O
and	O
incubated	O
for	O
another	O
1	O
h	O
at	O
room	O
temperature	O
with	O
horseradish	O
peroxidase	O
-	O
conjugated	O
secondary	O
antibody	O
(	O
Cell	O
Signaling	O
Technology	O
).	O
After	O
additional	O
washing	O
with	O
TBS	B-Chemical
-	I-Chemical
T	I-Chemical
","	O
protein	O
bands	O
were	O
visualized	O
by	O
the	O
use	O
of	O
a	O
SuperSignal	O
West	O
Pico	O
Trial	O
kit	O
(	O
Thermo	O
Scientific	O
","	O
Rockford	O
","	O
IL	O
","	O
USA	O
).	O
Primary	O
antibodies	O
against	O
the	O
following	O
proteins	O
were	O
used	O
:	O
Î²	O
-	O
actin	O
","	O
MITF	O
","	O
tyrosinase	O
","	O
TRP	O
-	O
1	O
","	O
and	O
TRP	O
-	O
2	O
.	O
4	O
.	O
7	O
.	O
Statistical	O
Analysis	O
The	O
statistical	O
significance	O
of	O
any	O
differences	O
between	O
groups	O
was	O
determined	O
by	O
the	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
"),"	O
followed	O
by	O
the	O
Dunnett	O
â€™	O
s	O
test	O
or	O
Tukey	O
â€™	O
s	O
test	O
.	O
p	O
Values	O
<	O
0	O
.	O
5	O
were	O
considered	O
to	O
be	O
significant	O
statistically	O
.	O
5	O
.	O
Conclusions	O
In	O
our	O
study	O
","	O
esterified	O
GSH	B-Chemical
derivative	O
","	O
particularly	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
(	O
but	O
not	O
GSH	B-Chemical
itself	O
"),"	O
was	O
effective	O
without	O
affecting	O
cellular	O
viability	O
for	O
reducing	O
melanin	B-Chemical
and	O
tyrosinase	O
activity	O
and	O
raising	O
the	O
suggested	O
pheomelanin	B-Chemical
/	O
eumelanin	B-Chemical
ratio	O
.	O
Taken	O
together	O
","	O
this	O
novel	O
esterified	O
GSH	B-Chemical
derivative	O
could	O
be	O
developed	O
as	O
a	O
safe	O
and	O
efficient	O
agent	O
for	O
the	O
treatment	O
of	O
hyperpigmentary	O
skin	O
disorders	O
.	O
Author	O
Contributions	O
Sung	O
Eun	O
Chang	O
and	O
Young	O
-	O
Hoon	O
Kim	O
conceived	O
and	O
designed	O
the	O
experiments	O
;	O
So	O
Ra	O
Choi	O
performed	O
the	O
experiments	O
;	O
Bo	O
Young	O
Chung	O
and	O
Ik	O
Jun	O
Moon	O
analyzed	O
the	O
data	O
;	O
Chun	O
Wook	O
Park	O
revised	O
the	O
paper	O
;	O
Bo	O
Young	O
Chung	O
wrote	O
the	O
paper	O
.	O
All	O
authors	O
read	O
and	O
agreed	O
with	O
the	O
final	O
manuscript	O
.	O
Sung	O
Eun	O
Chang	O
and	O
Young	O
-	O
Hoon	O
Kim	O
are	O
corresponding	O
authors	O
and	O
are	O
responsible	O
for	O
all	O
contact	O
and	O
correspondence	O
.	O
Conflicts	O
of	O
Interest	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O
Abbreviations	O
GSH	B-Chemical
Reduced	I-Chemical
glutathione	I-Chemical
UV	O
Ultraviolet	O
l	B-Chemical
-	I-Chemical
DOPA	I-Chemical
l	I-Chemical
-	I-Chemical
dihydroxyphenylalanine	I-Chemical
GSSG	I-Chemical
Oxidized	I-Chemical
glutathione	I-Chemical
GSH	I-Chemical
-	I-Chemical
MEE	I-Chemical
GSH	I-Chemical
monoethyl	I-Chemical
ester	I-Chemical
GSH	I-Chemical
-	I-Chemical
DEE	I-Chemical
GSH	I-Chemical
diethyl	I-Chemical
ester	I-Chemical
GSH	I-Chemical
-	I-Chemical
MIPE	I-Chemical
GSH	I-Chemical
monoisopropyl	I-Chemical
ester	I-Chemical
MITF	O
Microphthalmia	O
-	O
associated	O
transcription	O
factor	O
TRP	O
-	O
1	O
Tyrosinase	O
-	O
related	O
protein	O
-	O
1	O
TRP	O
-	O
2	O
Tyrosinase	O
-	O
related	O
protein	O
-	O
2	O
PMA	B-Chemical
Phorbol	I-Chemical
12	I-Chemical
-	I-Chemical
myristate	I-Chemical
13	I-Chemical
-	I-Chemical
acetate	I-Chemical
FBS	O
Fetal	O
bovine	O
serum	O
DMEM	B-Chemical
Dulbecco	I-Chemical
â€™	I-Chemical
s	I-Chemical
modified	I-Chemical
Eagle	I-Chemical
â€™	I-Chemical
s	I-Chemical
medium	I-Chemical
TPA	I-Chemical
12	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
tetradecanoylphorbol	I-Chemical
-	I-Chemical
13	I-Chemical
-	I-Chemical
acetate	I-Chemical
CT	O
Cholera	O
toxin	O
ELISA	O
Enzyme	O
immunosorbent	O
assay	O
Î±	B-Chemical
-	I-Chemical
MSH	I-Chemical
Î±	I-Chemical
-	I-Chemical
melanocyte	I-Chemical
-	I-Chemical
stimulating	I-Chemical
hormone	I-Chemical
OD	O
Optical	O
densities	O
A350	O
Absorbance	O
at	O
350	O
nm	O
A400	O
Absorbance	O
at	O
400	O
nm	O
TBS	B-Chemical
-	I-Chemical
T	I-Chemical
Tris	I-Chemical
buffered	I-Chemical
saline	I-Chemical
with	O
Tween	B-Chemical
20	I-Chemical
BSA	O
Bovine	O
serum	O
albumin	O
ANOVA	O
Analysis	O
of	O
variance	O
GGT	O
Î³	O
-	O
glutamyltranspeptidase	O
HPLC	O
High	O
-	O
performance	O
liquid	O
chromatography	O
EPR	O
Electron	O
paramagnetic	O
resonance	O
References	O
(	O
a	O
)	O
Chemical	O
structures	O
of	O
reduced	O
glutathione	B-Chemical
(	O
GSH	B-Chemical
)	O
and	O
GSH	B-Chemical
monoethyl	I-Chemical
ester	I-Chemical
(	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
);	O
(	O
b	O
)	O
Effect	O
of	O
GSH	B-Chemical
derivatives	O
on	O
cellular	O
viability	O
.	O
GSH	B-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
had	O
no	O
effect	O
on	O
cellular	O
viability	O
","	O
but	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
DEE	I-Chemical
showed	O
toxicity	O
in	O
Melan	O
-	O
A	O
cells	O
.	O
Data	O
are	O
shown	O
as	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
replicates	O
","	O
and	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
**	O
p	O
<	O
0	O
.	O
1	O
","	O
and	O
***	O
p	O
<	O
0	O
.	O
1	O
compared	O
to	O
untreated	O
controls	O
.	O
GSH	B-Chemical
","	O
reduced	O
glutathione	B-Chemical
;	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
GSH	B-Chemical
monoethyl	I-Chemical
ester	I-Chemical
;	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
","	O
GSH	B-Chemical
monoisopropyl	I-Chemical
ester	I-Chemical
;	O
GSH	B-Chemical
-	I-Chemical
DEE	I-Chemical
","	O
GSH	B-Chemical
diethyl	I-Chemical
ester	I-Chemical
;	O
SD	O
","	O
standard	O
deviation	O
.	O
(	O
a	O
)	O
Effect	O
of	O
GSH	B-Chemical
derivatives	O
on	O
melanin	B-Chemical
content	O
in	O
Melan	O
-	O
A	O
cells	O
.	O
GSH	B-Chemical
exhibited	O
no	O
inhibitory	O
effect	O
on	O
melanin	B-Chemical
production	O
","	O
but	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
decreased	O
the	O
melanin	B-Chemical
synthesis	O
in	O
Melan	O
-	O
A	O
cells	O
.	O
Arbutin	B-Chemical
(	O
100	O
Âµg	O
/	O
mL	O
)	O
was	O
treated	O
to	O
serve	O
as	O
a	O
positive	O
control	O
.	O
The	O
melanin	B-Chemical
content	O
was	O
calculated	O
by	O
normalizing	O
the	O
melanin	B-Chemical
content	O
to	O
total	O
cellular	O
protein	O
and	O
reported	O
as	O
a	O
percentage	O
of	O
control	O
.	O
Data	O
are	O
shown	O
as	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
replicates	O
","	O
and	O
**	O
p	O
<	O
0	O
.	O
1	O
","	O
and	O
***	O
p	O
<	O
0	O
.	O
1	O
.	O
GSH	B-Chemical
","	O
reduced	O
glutathione	B-Chemical
;	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
GSH	B-Chemical
monoethyl	I-Chemical
ester	I-Chemical
;	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
","	O
GSH	B-Chemical
monoisopropyl	I-Chemical
ester	I-Chemical
;	O
SD	O
","	O
standard	O
deviation	O
;	O
(	O
b	O
)	O
The	O
effect	O
of	O
GSH	B-Chemical
on	O
melanin	B-Chemical
production	O
in	O
Melan	O
-	O
A	O
cells	O
.	O
GSH	B-Chemical
had	O
no	O
inhibitory	O
effect	O
on	O
melanin	B-Chemical
production	O
in	O
Melan	O
-	O
A	O
cells	O
.	O
Each	O
sample	O
was	O
quantified	O
with	O
the	O
same	O
amount	O
of	O
protein	O
and	O
reported	O
as	O
a	O
percentage	O
of	O
control	O
.	O
Data	O
are	O
shown	O
as	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
replicates	O
;	O
(	O
c	O
)	O
Effect	O
of	O
GSH	B-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
on	O
melanin	B-Chemical
content	O
in	O
Mel	O
-	O
Ab	O
cells	O
GSH	B-Chemical
had	O
no	O
inhibitory	O
effect	O
on	O
melanin	B-Chemical
production	O
","	O
but	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
decreased	O
the	O
synthesis	O
of	O
melanin	B-Chemical
significantly	O
in	O
Mel	O
-	O
Ab	O
cells	O
.	O
Arbutin	B-Chemical
(	O
100	O
Âµg	O
/	O
mL	O
)	O
was	O
treated	O
as	O
a	O
positive	O
control	O
.	O
The	O
melanin	B-Chemical
content	O
was	O
calculated	O
by	O
normalizing	O
the	O
melanin	B-Chemical
content	O
to	O
total	O
cellular	O
protein	O
and	O
reported	O
it	O
as	O
a	O
percentage	O
of	O
control	O
.	O
Data	O
are	O
shown	O
as	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
replicates	O
","	O
and	O
**	O
p	O
<	O
0	O
.	O
1	O
;	O
(	O
d	O
)	O
the	O
effect	O
of	O
GSH	B-Chemical
derivatives	O
on	O
intracellular	O
tyrosinase	O
activity	O
in	O
Melan	O
-	O
A	O
cells	O
.	O
GSH	B-Chemical
had	O
no	O
significant	O
effect	O
on	O
intracellular	O
tyrosinase	O
activity	O
","	O
but	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
and	O
GSH	B-Chemical
-	I-Chemical
MIPE	I-Chemical
decreased	O
the	O
activity	O
of	O
intracellular	O
tyrosinase	O
in	O
Melan	O
-	O
A	O
cells	O
.	O
Arbutin	B-Chemical
(	O
100	O
Âµg	O
/	O
mL	O
)	O
was	O
treated	O
as	O
a	O
positive	O
control	O
.	O
Each	O
sample	O
was	O
quantified	O
with	O
the	O
same	O
amount	O
of	O
protein	O
and	O
reported	O
as	O
a	O
percentage	O
of	O
control	O
.	O
Data	O
are	O
shown	O
as	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
replicates	O
","	O
and	O
***	O
p	O
<	O
0	O
.	O
1	O
.	O
(	O
a	O
)	O
Effect	O
of	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
on	O
melanin	B-Chemical
production	O
in	O
Melan	O
-	O
A	O
cells	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
decreased	O
the	O
production	O
of	O
melanin	B-Chemical
in	O
a	O
dose	O
-	O
dependent	O
manner	O
in	O
Melan	O
-	O
A	O
cells	O
.	O
Arbutin	B-Chemical
(	O
100	O
Âµg	O
/	O
mL	O
)	O
was	O
treated	O
as	O
a	O
positive	O
control	O
.	O
The	O
melanin	B-Chemical
content	O
was	O
calculated	O
by	O
normalizing	O
the	O
melanin	B-Chemical
content	O
to	O
total	O
cellular	O
protein	O
and	O
reported	O
as	O
a	O
percentage	O
of	O
control	O
.	O
Data	O
are	O
shown	O
as	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
replicates	O
","	O
and	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
**	O
p	O
<	O
0	O
.	O
1	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
reduced	O
glutathione	B-Chemical
monoethyl	I-Chemical
ester	I-Chemical
;	O
SD	O
","	O
standard	O
deviation	O
;	O
(	O
b	O
)	O
Effect	O
of	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
on	O
melanin	B-Chemical
content	O
in	O
B16F10	O
cells	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
decreased	O
the	O
amount	O
of	O
melanin	B-Chemical
produced	O
by	O
B16F10	O
cells	O
.	O
Arbutin	B-Chemical
(	O
100	O
Âµg	O
/	O
mL	O
)	O
was	O
treated	O
as	O
a	O
positive	O
control	O
.	O
The	O
melanin	B-Chemical
content	O
was	O
calculated	O
by	O
normalizing	O
the	O
melanin	B-Chemical
contents	O
to	O
total	O
cellular	O
protein	O
and	O
reported	O
as	O
a	O
percentage	O
of	O
control	O
.	O
Data	O
are	O
shown	O
as	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
replicates	O
","	O
and	O
***	O
p	O
<	O
0	O
.	O
1	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
reduced	O
glutathione	B-Chemical
monoethyl	I-Chemical
ester	I-Chemical
;	O
Î±	B-Chemical
-	I-Chemical
MSH	I-Chemical
","	O
Î±	B-Chemical
-	I-Chemical
melanocyte	I-Chemical
-	I-Chemical
stimulating	I-Chemical
hormone	I-Chemical
;	O
SD	O
","	O
standard	O
deviation	O
;	O
(	O
c	O
)	O
Effect	O
of	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
on	O
intracellular	O
tyrosinase	O
activity	O
in	O
Melan	O
-	O
A	O
cells	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
decreased	O
the	O
activity	O
of	O
intracellular	O
tyrosinase	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
in	O
Melan	O
-	O
A	O
cells	O
.	O
Arbutin	B-Chemical
(	O
100	O
Âµg	O
/	O
mL	O
)	O
was	O
treated	O
as	O
a	O
positive	O
control	O
.	O
Each	O
sample	O
was	O
quantified	O
with	O
the	O
same	O
amount	O
of	O
protein	O
and	O
reported	O
as	O
a	O
percentage	O
of	O
control	O
.	O
Data	O
are	O
shown	O
as	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
replicates	O
","	O
and	O
**	O
p	O
<	O
0	O
.	O
1	O
","	O
and	O
***	O
p	O
<	O
0	O
.	O
1	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
reduced	O
glutathione	B-Chemical
monoethyl	I-Chemical
ester	I-Chemical
;	O
SD	O
","	O
standard	O
deviation	O
;	O
(	O
d	O
)	O
Effect	O
of	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
on	O
intracellular	O
tyrosinase	O
activity	O
in	O
B16F10	O
cells	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
decreased	O
the	O
activity	O
of	O
intracellular	O
tyrosinase	O
in	O
B16F10	O
cells	O
.	O
Arbutin	B-Chemical
(	O
100	O
Âµg	O
/	O
mL	O
)	O
was	O
treated	O
as	O
a	O
positive	O
control	O
.	O
Each	O
sample	O
was	O
quantified	O
with	O
the	O
same	O
amount	O
of	O
protein	O
and	O
reported	O
as	O
a	O
percentage	O
of	O
control	O
.	O
Data	O
are	O
shown	O
as	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
replicates	O
","	O
and	O
***	O
p	O
<	O
0	O
.	O
1	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
reduced	O
glutathione	B-Chemical
monoethyl	I-Chemical
ester	I-Chemical
;	O
Î±	O
-	O
MSH	O
","	O
Î±	B-Chemical
-	I-Chemical
melanocyte	I-Chemical
-	I-Chemical
stimulating	I-Chemical
hormone	I-Chemical
;	O
SD	O
","	O
standard	O
deviation	O
;	O
(	O
e	O
)	O
Effect	O
of	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
on	O
the	O
expression	O
of	O
melanogenesis	O
-	O
related	O
proteins	O
.	O
When	O
Melan	O
-	O
A	O
cells	O
were	O
treated	O
with	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
the	O
expression	O
levels	O
of	O
MITF	O
","	O
tyrosinase	O
","	O
TRP	O
-	O
1	O
","	O
and	O
TRP	O
-	O
2	O
did	O
not	O
change	O
significantly	O
.	O
Arbutin	B-Chemical
(	O
100	O
Âµg	O
/	O
mL	O
)	O
was	O
treated	O
as	O
a	O
positive	O
control	O
","	O
and	O
Î²	O
â€‘	O
actin	O
expression	O
was	O
used	O
as	O
the	O
loading	O
control	O
.	O
These	O
results	O
represents	O
three	O
independent	O
experiments	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
reduced	O
glutathione	B-Chemical
monoethyl	I-Chemical
ester	I-Chemical
;	O
MITF	O
","	O
microphthalmia	O
-	O
associated	O
transcription	O
factor	O
;	O
TRP	O
-	O
1	O
","	O
tyrosinase	O
-	O
related	O
protein	O
-	O
1	O
;	O
TRP	O
-	O
2	O
","	O
tyrosinase	O
-	O
related	O
protein	O
-	O
2	O
;	O
(	O
f	O
)	O
Effect	O
of	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
on	O
suggested	O
eumelanin	B-Chemical
and	O
pheomelanin	B-Chemical
production	O
.	O
When	O
Melan	O
-	O
A	O
cells	O
were	O
treated	O
with	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
the	O
synthesis	O
of	O
melanin	B-Chemical
with	O
absorbance	O
at	O
400	O
nm	O
(	O
A400	O
","	O
suggestive	O
of	O
eumelanin	B-Chemical
)	O
increased	O
","	O
whereas	O
the	O
production	O
of	O
melanin	B-Chemical
with	O
absorbance	O
at	O
350	O
(	O
A350	O
","	O
suggestive	O
of	O
pheomelanin	B-Chemical
)	O
decreased	O
.	O
Arbutin	B-Chemical
(	O
100	O
Âµg	O
/	O
mL	O
)	O
was	O
treated	O
as	O
a	O
positive	O
control	O
.	O
The	O
melanin	B-Chemical
content	O
was	O
calculated	O
by	O
normalizing	O
the	O
melanin	B-Chemical
contents	O
to	O
total	O
cellular	O
proteins	O
and	O
reported	O
as	O
a	O
percentage	O
of	O
control	O
.	O
Data	O
are	O
shown	O
as	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
replicates	O
","	O
and	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
**	O
p	O
<	O
0	O
.	O
1	O
","	O
and	O
***	O
p	O
<	O
0	O
.	O
1	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
reduced	O
glutathione	B-Chemical
monoethyl	I-Chemical
ester	I-Chemical
;	O
A400	O
","	O
absorbance	O
at	O
400	O
nm	O
;	O
A350	O
","	O
absorbance	O
at	O
350	O
nm	O
;	O
SD	O
","	O
standard	O
deviation	O
.	O
Possible	O
effects	O
of	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
GSH	B-Chemical
","	O
and	O
cysteine	B-Chemical
on	O
melanogenesis	O
.	O
GSH	B-Chemical
synthesize	O
intracellularly	O
and	O
exported	O
to	O
extracellular	O
space	O
.	O
Cellular	O
uptake	O
of	O
GSH	B-Chemical
itself	O
is	O
not	O
probable	O
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
cross	O
the	O
biological	O
membranes	O
by	O
simple	O
diffusion	O
and	O
metabolize	O
intracellularly	O
to	O
generate	O
GSH	B-Chemical
.	O
Cysteine	B-Chemical
is	O
readily	O
transported	O
across	O
cell	O
membranes	O
but	O
potentially	O
toxic	O
at	O
high	O
concentrations	O
due	O
to	O
generation	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
and	O
depletion	O
of	O
pyridoxal	B-Chemical
phosphate	I-Chemical
.	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
(	O
but	O
not	O
GSH	B-Chemical
itself	O
)	O
could	O
suppress	O
the	O
melanin	B-Chemical
production	O
and	O
tyrosinase	O
activity	O
and	O
raise	O
the	O
suggested	O
pheomelanin	B-Chemical
/	O
eumelanin	B-Chemical
ratio	O
.	O
black	O
arrows	O
","	O
melanin	B-Chemical
synthesis	O
process	O
flow	O
;	O
dotted	O
black	O
arrows	O
","	O
transport	O
process	O
flows	O
of	O
GSH	B-Chemical
","	O
cysteine	B-Chemical
","	O
and	O
cysteine	B-Chemical
","	O
bold	O
black	O
arrows	O
","	O
transport	O
process	O
flow	O
of	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
;	O
question	O
marks	O
","	O
not	O
yet	O
confirmed	O
;	O
"+,"	O
positive	O
effects	O
(	O
activation	O
);	O
"âˆ’,"	O
negative	O
effects	O
(	O
suppression	O
);	O
purple	O
shape	O
","	O
membrane	O
channel	O
.	O
GSH	B-Chemical
","	O
reduced	O
glutathione	B-Chemical
;	O
GSH	B-Chemical
-	I-Chemical
MEE	I-Chemical
","	O
GSH	B-Chemical
monoethyl	I-Chemical
ester	I-Chemical
;	O
DOPA	B-Chemical
","	O
dihydroxyphenylalanine	B-Chemical
;	O
DQ	B-Chemical
","	O
dopaquinone	B-Chemical
.	O
Small	O
RNA	O
and	O
degradome	O
deep	O
sequencing	O
reveals	O
drought	O
â€	O
and	O
tissue	O
â€	O
specific	O
micrornas	O
and	O
their	O
important	O
roles	O
in	O
drought	O
â€	O
sensitive	O
and	O
drought	O
â€	O
tolerant	O
tomato	O
genotypes	O
Summary	O
Drought	O
stress	O
has	O
adverse	O
impacts	O
on	O
plant	O
production	O
and	O
productivity	O
.	O
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
one	O
class	O
of	O
noncoding	O
RNAs	O
regulating	O
gene	O
expression	O
post	O
â€	O
transcriptionally	O
.	O
In	O
this	O
study	O
","	O
we	O
employed	O
small	O
RNA	O
and	O
degradome	O
sequencing	O
to	O
systematically	O
investigate	O
the	O
tissue	O
â€	O
specific	O
miRNAs	O
responsible	O
to	O
drought	O
stress	O
","	O
which	O
are	O
understudied	O
in	O
tomato	O
.	O
For	O
this	O
purpose	O
","	O
root	O
and	O
upground	O
tissues	O
of	O
two	O
different	O
drought	O
â€	O
responsive	O
tomato	O
genotypes	O
(	O
Lycopersicon	O
esculentum	O
as	O
sensitive	O
and	O
L	O
.	O
esculentum	O
var	O
.	O
cerasiforme	O
as	O
tolerant	O
)	O
were	O
subjected	O
to	O
stress	O
with	O
5	O
%	O
polyethylene	B-Chemical
glycol	I-Chemical
for	O
7	O
days	O
.	O
A	O
total	O
of	O
699	O
conserved	O
miRNAs	O
belonging	O
to	O
578	O
families	O
were	O
determined	O
and	O
688	O
miRNAs	O
were	O
significantly	O
differentially	O
expressed	O
between	O
different	O
treatments	O
","	O
tissues	O
and	O
genotypes	O
.	O
Using	O
degradome	O
sequencing	O
","	O
44	O
target	O
genes	O
were	O
identified	O
associated	O
with	O
36	O
miRNA	O
families	O
.	O
Drought	O
â€	O
related	O
miRNAs	O
and	O
their	O
targets	O
were	O
enriched	O
functionally	O
by	O
Gene	O
Ontology	O
(	O
GO	O
)	O
and	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
pathway	O
analyses	O
.	O
Totally	O
","	O
53	O
miRNAs	O
targeted	O
23	O
key	O
drought	O
stress	O
â€	O
and	O
tissue	O
development	O
â€	O
related	O
genes	O
","	O
including	O
DRP	O
(	O
dehydration	O
â€	O
responsive	O
protein	O
"),"	O
GTs	O
(	O
glycosyltransferases	O
"),"	O
ERF	O
(	O
ethylene	O
responsive	O
factor	O
"),"	O
PSII	O
(	O
photosystem	O
II	O
)	O
protein	O
","	O
HD	O
â€	O
ZIP	O
(	O
homeodomain	O
â€	O
leucine	O
zipper	O
"),"	O
MYB	O
and	O
NAC	O
â€	O
domain	O
transcription	O
factors	O
.	O
miR160	O
","	O
miR165	O
","	O
miR166	O
","	O
miR171	O
","	O
miR398	O
","	O
miR408	O
","	O
miR827	O
","	O
miR9472	O
","	O
miR9476	O
and	O
miR9552	O
were	O
the	O
key	O
miRNAs	O
functioning	O
in	O
regulation	O
of	O
these	O
genes	O
and	O
involving	O
in	O
tomato	O
response	O
to	O
drought	O
stress	O
.	O
Additionally	O
","	O
plant	O
hormone	O
signal	O
transduction	O
pathway	O
genes	O
were	O
differentially	O
regulated	O
by	O
miR169	O
","	O
miR172	O
","	O
miR393	O
","	O
miR5641	O
","	O
miR5658	O
and	O
miR7997	O
in	O
both	O
tissues	O
of	O
both	O
sensitive	O
and	O
tolerant	O
genotypes	O
.	O
These	O
results	O
provide	O
new	O
insight	O
into	O
the	O
regulatory	O
role	O
of	O
miRNAs	O
in	O
drought	O
response	O
with	O
plant	O
hormone	O
signal	O
transduction	O
and	O
drought	O
â€	O
tolerant	O
tomato	O
breeding	O
.	O
Introduction	O
Drought	O
is	O
one	O
of	O
the	O
destructive	O
environmental	O
stress	O
condition	O
that	O
restricts	O
crop	O
production	O
and	O
reproduction	O
in	O
plants	O
(	O
Ding	O
et	O
al	O
".,"	O
2013	O
).	O
Plants	O
cope	O
with	O
drought	O
stress	O
by	O
recruiting	O
drought	O
avoidance	O
and	O
/	O
or	O
drought	O
tolerance	O
mechanisms	O
at	O
the	O
morphological	O
","	O
physiological	O
","	O
biochemical	O
","	O
cellular	O
and	O
molecular	O
levels	O
such	O
as	O
decreased	O
stomatal	O
conductance	O
","	O
photosynthesis	O
and	O
respiration	O
alterations	O
","	O
production	O
of	O
antioxidant	O
and	O
scavenger	O
compounds	O
","	O
osmotic	O
re	O
â€	O
adjustment	O
and	O
hormonal	O
metabolism	O
changes	O
(	O
Bartels	O
and	O
Sunkar	O
","	O
2005	O
;	O
Bhargava	O
and	O
Sawant	O
","	O
2013	O
;	O
Ding	O
et	O
al	O
".,"	O
2013	O
;	O
Fang	O
and	O
Xiong	O
","	O
2015	O
).	O
All	O
of	O
these	O
strategies	O
cause	O
gene	O
expression	O
induction	O
and	O
accumulation	O
of	O
some	O
enzymes	O
and	O
drought	O
â€	O
related	O
proteins	O
(	O
Ding	O
et	O
al	O
".,"	O
2013	O
;	O
Ramachandra	O
Reddy	O
et	O
al	O
".,"	O
2004	O
;	O
Shinozaki	O
and	O
Yamaguchi	O
â€	O
Shinozaki	O
","	O
2007	O
).	O
Control	O
of	O
gene	O
expression	O
is	O
one	O
of	O
the	O
regulatory	O
mechanisms	O
on	O
plant	O
response	O
to	O
drought	O
(	O
Golldack	O
et	O
al	O
".,"	O
2011	O
).	O
Epigenetic	O
regulations	O
such	O
as	O
methylation	O
","	O
histone	O
modifications	O
and	O
post	O
â€	O
transcriptional	O
alterations	O
are	O
stress	O
â€	O
inducible	O
mechanisms	O
and	O
have	O
important	O
roles	O
in	O
stress	O
tolerance	O
(	O
Bhargava	O
and	O
Sawant	O
","	O
2013	O
).	O
In	O
plants	O
","	O
small	O
RNA	O
â€	O
mediated	O
regulatory	O
mechanisms	O
play	O
crucial	O
roles	O
on	O
biological	O
processes	O
including	O
growth	O
","	O
development	O
","	O
maturation	O
","	O
transposon	O
silencing	O
","	O
response	O
to	O
abiotic	O
stress	O
and	O
pathogen	O
defence	O
(	O
Xie	O
et	O
al	O
".,"	O
2012	O
;	O
Li	O
and	O
Zhang	O
","	O
2016	O
).	O
Small	O
RNAs	O
","	O
especially	O
microRNAs	O
(	O
miRNAs	O
"),"	O
regulate	O
abiotic	O
stress	O
â€	O
related	O
gene	O
expression	O
post	O
â€	O
transcriptionally	O
","	O
down	O
â€	O
regulating	O
their	O
target	O
genes	O
","	O
while	O
their	O
expression	O
changes	O
conversely	O
(	O
Carrington	O
and	O
Ambros	O
","	O
2003	O
;	O
Ding	O
et	O
al	O
".,"	O
2013	O
;	O
Sunkar	O
","	O
2010	O
;	O
Zhang	O
","	O
2015	O
;	O
Zhang	O
and	O
Wang	O
","	O
2015	O
).	O
Many	O
miRNAs	O
response	O
to	O
drought	O
stress	O
via	O
signal	O
transduction	O
pathways	O
such	O
as	O
auxin	B-Chemical
signalling	O
","	O
ABA	B-Chemical
â€	O
mediated	O
regulation	O
","	O
osmoprotectant	O
biosynthesis	O
and	O
scavenging	O
of	O
antioxidants	O
(	O
Ding	O
et	O
al	O
".,"	O
2013	O
).	O
Drought	O
â€	O
related	O
miRNAs	O
and	O
their	O
targets	O
have	O
been	O
identified	O
in	O
different	O
plants	O
such	O
as	O
Arabidopsis	O
(	O
Liu	O
et	O
al	O
".,"	O
2008	O
;	O
Sunkar	O
and	O
Zhu	O
","	O
2004	O
"),"	O
cotton	O
(	O
Xie	O
et	O
al	O
".,"	O
2015	O
"),"	O
switchgrass	O
(	O
Xie	O
et	O
al	O
".,"	O
2014	O
)	O
rice	O
(	O
Zhao	O
et	O
al	O
".,"	O
2007	O
;	O
Zhou	O
et	O
al	O
".,"	O
2010	O
)	O
and	O
soya	O
bean	O
(	O
Kulcheski	O
et	O
al	O
".,"	O
2011	O
).	O
However	O
","	O
no	O
systematical	O
study	O
has	O
been	O
performed	O
on	O
tomato	O
.	O
Tomato	O
(	O
Lycopersicon	O
esculentum	O
)	O
is	O
an	O
economically	O
important	O
crop	O
due	O
to	O
demand	O
for	O
fresh	O
vegetable	O
market	O
and	O
processed	O
food	O
industry	O
worldwide	O
(	O
Klee	O
and	O
Giovannoni	O
","	O
2011	O
).	O
Tomato	O
contains	O
strong	O
antioxidant	O
enzymes	O
","	O
high	O
level	O
of	O
lycopene	B-Chemical
","	O
rich	O
iron	B-Chemical
content	O
","	O
and	O
vitamins	B-Chemical
A	I-Chemical
and	I-Chemical
C	I-Chemical
(	O
Rai	O
et	O
al	O
".,"	O
2013	O
).	O
Tomato	O
is	O
also	O
one	O
of	O
the	O
most	O
favoured	O
models	O
for	O
fleshly	O
fruit	O
ripening	O
and	O
epigenetic	O
researches	O
(	O
Gonzalez	O
et	O
al	O
".,"	O
2013	O
;	O
Klee	O
and	O
Giovannoni	O
","	O
2011	O
).	O
Tomato	O
growth	O
","	O
productivity	O
and	O
nutritional	O
quality	O
are	O
generally	O
affected	O
by	O
environmental	O
stress	O
factors	O
such	O
as	O
drought	O
","	O
salt	O
","	O
flooding	O
and	O
pathogen	O
infection	O
(	O
Rai	O
et	O
al	O
".,"	O
2013	O
).	O
Cultivated	O
tomatoes	O
(	O
L	O
.	O
esculentum	O
)	O
are	O
known	O
as	O
sensitive	O
to	O
drought	O
at	O
all	O
stages	O
of	O
plant	O
development	O
","	O
while	O
seed	O
germination	O
and	O
early	O
seedling	O
stages	O
are	O
mostly	O
affected	O
(	O
Foolad	O
et	O
al	O
".,"	O
2003	O
).	O
However	O
","	O
their	O
wild	O
types	O
such	O
as	O
L	O
.	O
pimpinellifolium	O
","	O
L	O
.	O
pennellii	O
","	O
L	O
.	O
chilense	O
and	O
L	O
.	O
esculentum	O
var	O
.	O
cerasiforme	O
are	O
drought	O
â€	O
tolerant	O
species	O
(	O
Sadashiva	O
et	O
al	O
".,"	O
2013	O
).	O
Researches	O
are	O
in	O
progress	O
to	O
clarify	O
molecular	O
pathways	O
on	O
drought	O
response	O
of	O
plants	O
(	O
Sadashiva	O
et	O
al	O
".,"	O
2013	O
"),"	O
and	O
miRNAs	O
can	O
be	O
alternatives	O
to	O
identify	O
drought	O
metabolism	O
","	O
as	O
they	O
play	O
crucial	O
role	O
on	O
abiotic	O
stress	O
response	O
regulating	O
the	O
stress	O
â€	O
related	O
mRNAs	O
(	O
Kumar	O
","	O
2014	O
).	O
Determination	O
and	O
functional	O
characterization	O
of	O
stress	O
â€	O
related	O
miRNAs	O
and	O
target	O
identification	O
are	O
important	O
in	O
breeding	O
programmes	O
and	O
can	O
contribute	O
to	O
developing	O
new	O
strategies	O
for	O
improving	O
stress	O
tolerance	O
(	O
Barrera	O
â€	O
Figueroa	O
et	O
al	O
".,"	O
2013	O
).	O
Although	O
several	O
studies	O
have	O
been	O
performed	O
on	O
tomato	O
miRNAs	O
(	O
Cao	O
et	O
al	O
".,"	O
2014	O
;	O
Feng	O
et	O
al	O
".,"	O
2014	O
;	O
Karlova	O
et	O
al	O
".,"	O
2013	O
;	O
Korir	O
et	O
al	O
".,"	O
2013	O
;	O
Moxon	O
et	O
al	O
".,"	O
2008	O
;	O
Pilcher	O
et	O
al	O
".,"	O
2007	O
"),"	O
there	O
is	O
no	O
study	O
on	O
genomewide	O
drought	O
â€	O
responsive	O
miRNA	O
identification	O
of	O
tomato	O
in	O
tissue	O
â€	O
specific	O
manner	O
.	O
In	O
this	O
study	O
","	O
we	O
aimed	O
to	O
identify	O
miRNAs	O
and	O
determine	O
their	O
expressions	O
in	O
different	O
tissues	O
under	O
drought	O
stress	O
.	O
For	O
this	O
purpose	O
","	O
we	O
sequenced	O
both	O
root	O
and	O
upground	O
tissues	O
of	O
drought	O
â€	O
sensitive	O
(	O
L	O
.	O
esculentum	O
)	O
and	O
drought	O
â€	O
tolerant	O
(	O
L	O
.	O
esculentum	O
var	O
.	O
cerasiforme	O
)	O
tomato	O
genotypes	O
.	O
Also	O
we	O
carried	O
out	O
degradome	O
sequencing	O
for	O
identifying	O
the	O
targets	O
of	O
drought	O
â€	O
related	O
miRNAs	O
.	O
From	O
here	O
","	O
we	O
identified	O
a	O
total	O
of	O
699	O
conserved	O
miRNAs	O
belonging	O
to	O
578	O
families	O
","	O
in	O
which	O
688	O
miRNAs	O
were	O
differentially	O
expressed	O
between	O
different	O
treatments	O
","	O
tissues	O
and	O
genotypes	O
.	O
We	O
also	O
identified	O
44	O
target	O
genes	O
associated	O
with	O
36	O
miRNA	O
families	O
.	O
These	O
miRNAs	O
and	O
their	O
targets	O
play	O
an	O
important	O
role	O
in	O
tomato	O
response	O
to	O
drought	O
stress	O
.	O
Results	O
Data	O
mining	O
of	O
small	O
RNA	O
sequencing	O
To	O
reveal	O
tissue	O
â€	O
specific	O
and	O
tolerance	O
â€	O
related	O
miRNAs	O
under	O
drought	O
conditions	O
","	O
eight	O
small	O
RNA	O
libraries	O
were	O
constructed	O
and	O
sequenced	O
.	O
These	O
samples	O
included	O
four	O
drought	O
â€	O
treated	O
(	O
D	O
)	O
and	O
four	O
untreated	O
(	O
C	O
)	O
samples	O
","	O
in	O
which	O
each	O
contained	O
two	O
roots	O
(	O
R	O
)	O
and	O
two	O
upgrounds	O
(	O
U	O
)	O
tissues	O
belonging	O
to	O
drought	O
â€	O
sensitive	O
L	O
.	O
esculentum	O
(	O
S	O
)	O
and	O
drought	O
â€	O
tolerant	O
L	O
.	O
esculentum	O
var	O
.	O
cerasiforme	O
(	O
T	O
)	O
genotypes	O
.	O
After	O
sequencing	O
","	O
a	O
total	O
of	O
194	O
625	O
986	O
raw	O
and	O
192	O
387	O
328	O
clean	O
reads	O
were	O
obtained	O
with	O
the	O
average	O
of	O
24	O
328	O
248	O
and	O
24	O
48	O
416	O
(	O
98	O
.	O
85	O
%)	O
reads	O
in	O
each	O
library	O
","	O
respectively	O
(	O
Table	O
S1	O
).	O
The	O
clean	O
tags	O
were	O
used	O
for	O
analysing	O
the	O
distribution	O
of	O
16	O
â€	O
to	O
28	O
â€	O
nt	O
â€	O
length	O
small	O
RNAs	O
and	O
94	O
.	O
78	O
%	O
of	O
them	O
were	O
determined	O
among	O
20	O
â€“	O
24	O
nt	O
","	O
while	O
the	O
most	O
abundant	O
sRNAs	O
were	O
21	O
and	O
24	O
nt	O
lengths	O
with	O
the	O
percentage	O
of	O
21	O
.	O
75	O
%	O
and	O
35	O
.	O
60	O
"%,"	O
respectively	O
(	O
Figure	O
1	O
).	O
However	O
","	O
the	O
small	O
RNA	O
distributions	O
of	O
two	O
libraries	O
(	O
Sensitive	O
C	O
â€	O
R	O
and	O
Sensitive	O
D	O
â€	O
R	O
)	O
were	O
a	O
little	O
different	O
from	O
common	O
results	O
","	O
in	O
which	O
20	O
â€	O
nt	O
small	O
RNAs	O
are	O
also	O
dominant	O
except	O
21	O
â€	O
nt	O
and	O
24	O
â€	O
nt	O
small	O
RNAs	O
.	O
This	O
has	O
not	O
been	O
reported	O
in	O
other	O
plant	O
species	O
.	O
However	O
","	O
the	O
reason	O
for	O
this	O
is	O
unclear	O
;	O
20	O
â€	O
nt	O
small	O
RNAs	O
may	O
have	O
some	O
role	O
in	O
this	O
situation	O
.	O
About	O
70	O
.	O
29	O
%	O
and	O
69	O
.	O
10	O
%	O
unique	O
and	O
83	O
.	O
72	O
%	O
and	O
83	O
.	O
1	O
%	O
redundant	O
reads	O
were	O
mapped	O
to	O
tomato	O
genome	O
database	O
(	O
ITAG	O
Release	O
2	O
.	O
4	O
)	O
in	O
root	O
and	O
upground	O
libraries	O
","	O
respectively	O
(	O
Tables	O
1	O
and	O
2	O
).	O
Using	O
the	O
blastn	O
and	O
blastall	O
alignments	O
against	O
Genbank	O
and	O
Rfam	O
databases	O
","	O
small	O
RNAs	O
were	O
annotated	O
to	O
root	O
and	O
upground	O
tissues	O
of	O
tomato	O
genotypes	O
which	O
have	O
different	O
response	O
to	O
drought	O
stress	O
.	O
In	O
root	O
libraries	O
","	O
most	O
abundant	O
RNA	O
class	O
was	O
rRNA	O
for	O
unique	O
reads	O
with	O
the	O
mean	O
value	O
of	O
2	O
.	O
32	O
"%,"	O
followed	O
by	O
tRNA	O
(	O
0	O
.	O
23	O
"%),"	O
snRNA	O
(	O
0	O
.	O
13	O
%)	O
and	O
snoRNA	O
(	O
0	O
.	O
12	O
%).	O
As	O
for	O
redundant	O
reads	O
","	O
tRNAs	O
were	O
most	O
abundant	O
(	O
21	O
.	O
41	O
%)	O
and	O
other	O
RNAs	O
had	O
quantity	O
with	O
the	O
average	O
of	O
10	O
.	O
47	O
%	O
(	O
rRNA	O
"),"	O
0	O
.	O
23	O
%	O
(	O
snRNA	O
)	O
and	O
0	O
.	O
17	O
%	O
(	O
snoRNA	O
)	O
(	O
Table	O
1	O
).	O
For	O
upground	O
libraries	O
","	O
the	O
annotation	O
results	O
were	O
similar	O
and	O
rRNA	O
proportion	O
was	O
highest	O
(	O
1	O
.	O
26	O
%)	O
in	O
unique	O
reads	O
followed	O
by	O
tRNA	O
(	O
0	O
.	O
13	O
"%),"	O
snRNA	O
(	O
0	O
.	O
6	O
%)	O
and	O
snoRNA	O
(	O
0	O
.	O
4	O
%).	O
In	O
redundant	O
reads	O
","	O
tRNA	O
amount	O
was	O
10	O
.	O
78	O
%	O
with	O
the	O
highest	O
value	O
","	O
followed	O
by	O
rRNA	O
(	O
3	O
.	O
65	O
"%),"	O
snRNA	O
(	O
0	O
.	O
5	O
%)	O
and	O
snoRNA	O
(	O
0	O
.	O
3	O
%)	O
(	O
Table	O
2	O
).	O
Length	O
distribution	O
of	O
unique	O
small	O
RNAs	O
in	O
drought	O
â€	O
sensitive	O
and	O
drought	O
â€	O
tolerant	O
tomato	O
roots	O
and	O
upgrounds	O
.	O
C	O
","	O
control	O
;	O
D	O
","	O
drought	O
;	O
R	O
","	O
root	O
;	O
U	O
","	O
upground	O
.	O
Small	O
RNA	O
categorization	O
in	O
tomato	O
roots	O
Small	O
RNA	O
categorization	O
in	O
tomato	O
upgrounds	O
S	O
","	O
sensitive	O
;	O
T	O
","	O
tolerant	O
;	O
C	O
","	O
control	O
;	O
D	O
","	O
drought	O
;	O
Mapped	O
","	O
mapped	O
to	O
tomato	O
genome	O
(	O
ITAG	O
Release	O
2	O
.	O
4	O
);	O
Unann	O
","	O
unannotated	O
tags	O
.	O
Identification	O
of	O
miRNAs	O
from	O
deep	O
sequencing	O
To	O
identify	O
miRNAs	O
","	O
the	O
clean	O
sequence	O
tags	O
were	O
aligned	O
to	O
all	O
plant	O
miRNA	O
mature	O
sequences	O
deposited	O
in	O
miRBase	O
database	O
(	O
Kozomara	O
and	O
Griffiths	O
â€	O
Jones	O
","	O
2014	O
).	O
The	O
average	O
of	O
44	O
46	O
(	O
0	O
.	O
72	O
%)	O
and	O
44	O
780	O
(	O
0	O
.	O
69	O
%)	O
unique	O
","	O
and	O
2	O
157	O
79	O
(	O
8	O
.	O
94	O
%)	O
and	O
4	O
609	O
840	O
(	O
19	O
.	O
19	O
%)	O
redundant	O
reads	O
were	O
matched	O
to	O
the	O
currently	O
known	O
miRNA	O
sequences	O
for	O
root	O
and	O
upground	O
libraries	O
","	O
respectively	O
(	O
Tables	O
1	O
and	O
2	O
).	O
Totally	O
","	O
699	O
miRNAs	O
were	O
obtained	O
from	O
sequencing	O
in	O
eight	O
libraries	O
which	O
belong	O
to	O
578	O
families	O
(	O
Table	O
S2	O
).	O
Among	O
578	O
families	O
","	O
sly	O
â€	O
miR171	O
was	O
represented	O
with	O
seven	O
members	O
","	O
as	O
the	O
largest	O
one	O
","	O
followed	O
by	O
sly	O
â€	O
miR166	O
and	O
sly	O
â€	O
miR319	O
with	O
five	O
members	O
(	O
Table	O
S2	O
).	O
Eleven	O
miRNA	O
families	O
(	O
sly	O
â€	O
miR156	O
","	O
sly	O
â€	O
miR157	O
","	O
sly	O
â€	O
miR164	O
","	O
sly	O
â€	O
miR166	O
","	O
sly	O
â€	O
miR167	O
","	O
sly	O
â€	O
miR168	O
","	O
sly	O
â€	O
miR4414	O
","	O
sly	O
â€	O
miR6022	O
","	O
sly	O
â€	O
miR6027	O
","	O
sly	O
â€	O
miR7822	O
and	O
sly	O
â€	O
miR9471	O
)	O
were	O
represented	O
with	O
the	O
top	O
read	O
abundance	O
above	O
10	O
0	O
at	O
all	O
libraries	O
(	O
Table	O
S2	O
).	O
We	O
evaluated	O
the	O
miRNA	O
distribution	O
among	O
libraries	O
and	O
determined	O
that	O
197	O
miRNAs	O
were	O
common	O
among	O
control	O
and	O
drought	O
â€	O
treated	O
samples	O
of	O
both	O
sensitive	O
and	O
tolerant	O
genotypes	O
in	O
root	O
libraries	O
(	O
Figure	O
2a	O
).	O
When	O
we	O
compared	O
the	O
genotypes	O
separately	O
","	O
35	O
miRNAs	O
were	O
common	O
between	O
control	O
and	O
drought	O
samples	O
of	O
sensitive	O
genotype	O
and	O
32	O
miRNAs	O
such	O
as	O
sly	O
â€	O
miR166k	O
","	O
sly	O
â€	O
miR408	O
â€	O
3p	O
and	O
sly	O
â€	O
miR9552b	O
â€	O
3p	O
were	O
specific	O
to	O
control	O
plants	O
","	O
whereas	O
25	O
miRNAs	O
such	O
as	O
sly	O
â€	O
miR1101	O
â€	O
3p	O
","	O
sly	O
â€	O
miR2628	O
and	O
sly	O
â€	O
miR3932b	O
â€	O
3p	O
were	O
expressed	O
only	O
in	O
drought	O
â€	O
treated	O
roots	O
of	O
sensitive	O
genotype	O
(	O
Table	O
S2	O
).	O
In	O
tolerant	O
genotype	O
","	O
32	O
miRNAs	O
such	O
as	O
sly	O
â€	O
miR165b	O
â€	O
5p	O
","	O
sly	O
â€	O
miR2867	O
â€	O
3p	O
and	O
sly	O
â€	O
miR7520	O
were	O
expressed	O
only	O
in	O
control	O
conditions	O
","	O
while	O
74	O
miRNAs	O
such	O
as	O
sly	O
â€	O
miR171f	O
â€	O
5p	O
","	O
sly	O
â€	O
mir838	O
â€	O
5p	O
and	O
sly	O
â€	O
miR8046	O
â€	O
3p	O
were	O
expressed	O
specifically	O
after	O
drought	O
exposure	O
(	O
Table	O
S2	O
).	O
Additionally	O
","	O
85	O
miRNAs	O
were	O
commonly	O
expressed	O
between	O
control	O
and	O
drought	O
treatments	O
in	O
tolerant	O
genotype	O
(	O
Figure	O
2a	O
).	O
In	O
upground	O
samples	O
","	O
222	O
miRNAs	O
were	O
common	O
among	O
four	O
samples	O
.	O
Additionally	O
","	O
in	O
control	O
and	O
drought	O
â€	O
treated	O
samples	O
","	O
37	O
miRNAs	O
such	O
as	O
sly	O
â€	O
miR171a	O
â€	O
3p	O
","	O
sly	O
â€	O
miR6024	O
â€	O
3p	O
and	O
sly	O
â€	O
miR7997a	O
were	O
expressed	O
specifically	O
in	O
control	O
conditions	O
","	O
while	O
44	O
miRNAs	O
such	O
as	O
sly	O
â€	O
miR845a	O
","	O
sly	O
â€	O
miR5797	O
and	O
sly	O
â€	O
miR8762d	O
were	O
specific	O
to	O
drought	O
â€	O
treated	O
upground	O
tissues	O
in	O
sensitive	O
genotype	O
(	O
Table	O
S2	O
","	O
Figure	O
2b	O
).	O
In	O
terms	O
of	O
tolerant	O
genotype	O
","	O
47	O
miRNAs	O
such	O
as	O
sly	O
â€	O
miR166d	O
â€	O
5p	O
","	O
sly	O
â€	O
miR4392	O
and	O
sly	O
â€	O
miR6288a	O
showed	O
specific	O
expression	O
in	O
control	O
sample	O
","	O
whereas	O
28	O
miRNAs	O
such	O
as	O
sly	O
â€	O
miR904a	O
","	O
sly	O
â€	O
miR5171a	O
and	O
sly	O
â€	O
miR6485	O
were	O
expressed	O
specifically	O
in	O
response	O
to	O
dehydration	O
stress	O
(	O
Table	O
S2	O
","	O
Figure	O
2b	O
).	O
Furthermore	O
","	O
sensitive	O
control	O
and	O
drought	O
libraries	O
shared	O
48	O
miRNAs	O
","	O
while	O
tolerant	O
control	O
and	O
drought	O
libraries	O
had	O
50	O
common	O
miRNAs	O
(	O
Figure	O
2b	O
).	O
When	O
we	O
compared	O
eight	O
libraries	O
consisting	O
of	O
699	O
miRNAs	O
","	O
we	O
determined	O
165	O
miRNAs	O
to	O
be	O
expressed	O
commonly	O
in	O
all	O
samples	O
","	O
while	O
63	O
and	O
90	O
miRNAs	O
were	O
expressed	O
only	O
in	O
sensitive	O
(	O
C	O
â€	O
R	O
","	O
16	O
;	O
D	O
â€	O
R	O
","	O
14	O
;	O
C	O
â€	O
U	O
","	O
24	O
;	O
D	O
â€	O
U	O
","	O
19	O
)	O
and	O
tolerant	O
genotypes	O
(	O
C	O
â€	O
R	O
","	O
11	O
;	O
D	O
â€	O
R	O
","	O
39	O
;	O
C	O
â€	O
U	O
","	O
27	O
;	O
D	O
â€	O
U	O
","	O
13	O
"),"	O
respectively	O
(	O
Figure	O
2c	O
).	O
Distribution	O
of	O
tomato	O
miRNAs	O
(	O
a	O
)	O
in	O
root	O
tissues	O
","	O
(	O
b	O
)	O
in	O
upground	O
tissues	O
","	O
(	O
c	O
)	O
in	O
all	O
samples	O
.	O
Expression	O
analyses	O
of	O
miRNAs	O
A	O
total	O
of	O
688	O
of	O
699	O
(	O
98	O
.	O
4	O
%)	O
miRNAs	O
belonging	O
to	O
eight	O
libraries	O
were	O
expressed	O
significantly	O
based	O
on	O
fold	O
change	O
(â‰¥	O
1	O
or	O
â‰¤âˆ’	O
1	O
)	O
and	O
P	O
/	O
q	O
â€	O
value	O
(<	O
0	O
.	O
5	O
)	O
criteria	O
(	O
Table	O
S2	O
)	O
and	O
at	O
least	O
130	O
miRNAs	O
expressed	O
approximately	O
in	O
all	O
tomato	O
libraries	O
(	O
Figure	O
3	O
).	O
Some	O
miRNAs	O
expressed	O
differentially	O
in	O
root	O
and	O
upground	O
tissues	O
of	O
sensitive	O
and	O
tolerant	O
genotypes	O
under	O
control	O
and	O
drought	O
conditions	O
.	O
Generally	O
","	O
the	O
majority	O
of	O
miRNAs	O
were	O
down	O
â€	O
regulated	O
in	O
sensitive	O
genotype	O
(	O
mostly	O
in	O
upgrounds	O
"),"	O
while	O
up	O
â€	O
regulated	O
in	O
tolerant	O
genotype	O
(	O
mostly	O
in	O
roots	O
)	O
by	O
drought	O
stress	O
treatment	O
(	O
Table	O
S2	O
).	O
A	O
total	O
of	O
11	O
miRNAs	O
showed	O
significant	O
expression	O
in	O
all	O
tissues	O
of	O
two	O
genotypes	O
in	O
response	O
to	O
drought	O
stress	O
(	O
Figure	O
4a	O
","	O
Table	O
S2	O
).	O
For	O
example	O
","	O
the	O
expression	O
of	O
sly	O
â€	O
miR169a	O
â€	O
5p	O
was	O
decreased	O
in	O
all	O
tissues	O
","	O
even	O
the	O
decrease	O
was	O
higher	O
in	O
root	O
tissues	O
.	O
However	O
","	O
the	O
expression	O
of	O
sly	O
â€	O
miR6261	O
was	O
decreased	O
in	O
root	O
and	O
upground	O
tissues	O
in	O
sensitive	O
genotype	O
","	O
whereas	O
increased	O
in	O
tolerant	O
genotype	O
.	O
In	O
root	O
","	O
specific	O
expression	O
changes	O
were	O
observed	O
.	O
Some	O
miRNAs	O
were	O
down	O
â€	O
regulated	O
in	O
sensitive	O
genotype	O
","	O
while	O
up	O
â€	O
regulated	O
in	O
tolerant	O
by	O
drought	O
exposure	O
;	O
these	O
miRNAs	O
include	O
sly	O
â€	O
miR403	O
â€	O
3p	O
and	O
sly	O
â€	O
miR845a	O
â€	O
3p	O
.	O
Contrary	O
to	O
this	O
","	O
sly	O
â€	O
miR5512a	O
and	O
sly	O
â€	O
miR9559	O
â€	O
5p	O
were	O
up	O
â€	O
regulated	O
in	O
sensitive	O
genotype	O
","	O
but	O
down	O
â€	O
regulated	O
in	O
tolerant	O
genotype	O
.	O
Additionally	O
","	O
the	O
expression	O
patterns	O
were	O
similar	O
for	O
certain	O
miRNAs	O
in	O
both	O
sensitive	O
and	O
tolerant	O
genotypes	O
.	O
For	O
instance	O
","	O
sly	O
â€	O
miR399a	O
â€	O
5p	O
and	O
sly	O
â€	O
miR5282	O
were	O
down	O
â€	O
regulated	O
with	O
drought	O
","	O
while	O
sly	O
â€	O
miR4346	O
and	O
sly	O
â€	O
miR6269	O
were	O
up	O
â€	O
regulated	O
in	O
root	O
tissues	O
of	O
two	O
genotypes	O
(	O
Figure	O
4b	O
","	O
Table	O
S2	O
).	O
Similarly	O
","	O
same	O
expression	O
alteration	O
patterns	O
were	O
observed	O
in	O
upground	O
tissues	O
.	O
For	O
example	O
","	O
the	O
expressions	O
of	O
sly	O
â€	O
miR7494b	O
and	O
sly	O
â€	O
miR7997c	O
were	O
increased	O
","	O
whereas	O
sly	O
â€	O
miR5029	O
were	O
decreased	O
in	O
two	O
genotypes	O
.	O
In	O
addition	O
","	O
some	O
adverse	O
alterations	O
were	O
observed	O
in	O
two	O
genotypes	O
.	O
Sly	O
â€	O
miR479	O
and	O
sly	O
â€	O
miR837	O
â€	O
3p	O
were	O
down	O
â€	O
regulated	O
","	O
but	O
up	O
â€	O
regulated	O
in	O
sensitive	O
and	O
tolerant	O
genotypes	O
","	O
respectively	O
;	O
sly	O
â€	O
miR3954	O
and	O
sly	O
â€	O
miR9471a	O
â€	O
5p	O
were	O
up	O
â€	O
regulated	O
","	O
but	O
down	O
â€	O
regulated	O
in	O
sensitive	O
and	O
tolerant	O
genotypes	O
","	O
respectively	O
(	O
Figure	O
4c	O
","	O
Table	O
S2	O
).	O
Some	O
miRNAs	O
showed	O
tissue	O
â€	O
and	O
genotype	O
â€	O
specific	O
expression	O
patterns	O
.	O
For	O
example	O
","	O
several	O
miRNAs	O
were	O
expressed	O
only	O
in	O
root	O
tissues	O
in	O
sensitive	O
genotype	O
and	O
repressed	O
/	O
downregulated	O
by	O
drought	O
exposure	O
such	O
as	O
sly	O
â€	O
miR166k	O
","	O
sly	O
â€	O
miR408	O
â€	O
3p	O
and	O
sly	O
â€	O
miR9552b	O
â€	O
3p	O
(	O
Table	O
S2	O
).	O
Similarly	O
","	O
some	O
miRNAs	O
showed	O
expression	O
only	O
in	O
upground	O
tissues	O
of	O
sensitive	O
genotype	O
and	O
the	O
expression	O
level	O
was	O
decreased	O
or	O
repressed	O
after	O
drought	O
stress	O
such	O
as	O
sly	O
â€	O
miR171a	O
â€	O
3p	O
","	O
sly	O
â€	O
miR1426	O
","	O
sly	O
â€	O
miR5239	O
","	O
sly	O
â€	O
miR6024	O
â€	O
3p	O
and	O
sly	O
â€	O
miR7997a	O
(	O
Table	O
S2	O
).	O
In	O
tolerant	O
genotype	O
","	O
the	O
expression	O
of	O
some	O
miRNAs	O
(	O
sly	O
â€	O
miR2867	O
â€	O
3p	O
","	O
sly	O
â€	O
miR3514	O
â€	O
5p	O
","	O
sly	O
â€	O
miR5251	O
","	O
sly	O
â€	O
miR5763	O
","	O
sly	O
â€	O
miR7520	O
","	O
sly	O
â€	O
miR7730	O
â€	O
5p	O
","	O
sly	O
â€	O
mi8751b	O
and	O
sly	O
â€	O
miR9493	O
)	O
was	O
also	O
specific	O
to	O
root	O
tissues	O
and	O
suppressed	O
/	O
decreased	O
by	O
dehydration	O
(	O
Table	O
S2	O
).	O
Likewise	O
","	O
some	O
miRNAs	O
were	O
expressed	O
specifically	O
in	O
drought	O
â€	O
tolerant	O
upground	O
tissues	O
and	O
down	O
â€	O
regulated	O
or	O
repressed	O
with	O
drought	O
treatment	O
such	O
as	O
sly	O
â€	O
miR166d	O
â€	O
5p	O
","	O
sly	O
â€	O
miR408a	O
â€	O
3p	O
","	O
sly	O
â€	O
miR1507c	O
â€	O
5p	O
","	O
sly	O
â€	O
miR1857	O
â€	O
5p	O
","	O
sly	O
â€	O
miR4392	O
","	O
sly	O
â€	O
miR6288a	O
and	O
sly	O
â€	O
miR9722	O
(	O
Table	O
S2	O
).	O
Certain	O
miRNAs	O
were	O
induced	O
/	O
upregulated	O
by	O
drought	O
treatment	O
in	O
all	O
tissues	O
and	O
genotypes	O
.	O
Among	O
them	O
","	O
sly	O
â€	O
miR319a	O
","	O
sly	O
â€	O
miR1101a	O
â€	O
3p	O
","	O
sly	O
â€	O
miR2628	O
and	O
sly	O
â€	O
miR3932b	O
â€	O
5p	O
were	O
specific	O
to	O
sensitive	O
root	O
tissues	O
;	O
sly	O
â€	O
miR845a	O
","	O
sly	O
â€	O
miR1511	O
â€	O
3p	O
","	O
sly	O
â€	O
miR5259	O
","	O
sly	O
â€	O
miR5797	O
and	O
sly	O
â€	O
miR6440b	O
to	O
sensitive	O
upground	O
tissues	O
;	O
sly	O
â€	O
miR171f	O
â€	O
5p	O
","	O
sly	O
â€	O
miR838	O
â€	O
5p	O
","	O
sly	O
â€	O
miR946a	O
â€	O
5p	O
","	O
sly	O
â€	O
miR1846a	O
â€	O
5p	O
","	O
sly	O
â€	O
miR3637	O
â€	O
3p	O
","	O
sly	O
â€	O
miR5035	O
â€	O
3p	O
","	O
sly	O
â€	O
miR5760	O
and	O
sly	O
â€	O
miR6172	O
to	O
tolerant	O
root	O
;	O
and	O
sly	O
â€	O
miR904a	O
","	O
sly	O
â€	O
miR5171a	O
","	O
sly	O
â€	O
miR6173	O
","	O
sly	O
â€	O
miR6225	O
â€	O
3p	O
and	O
sly	O
â€	O
miR6485	O
to	O
tolerant	O
upground	O
tissues	O
(	O
Table	O
S2	O
).	O
When	O
we	O
evaluated	O
the	O
drought	O
â€	O
sensitive	O
and	O
tolerant	O
genotypes	O
","	O
we	O
determined	O
that	O
a	O
total	O
of	O
20	O
miRNAs	O
were	O
expressed	O
in	O
all	O
four	O
libraries	O
belonging	O
to	O
sensitive	O
genotype	O
such	O
as	O
sly	O
â€	O
miR529	O
g	O
and	O
sly	O
â€	O
miR5817	O
(	O
Figure	O
5a	O
","	O
Table	O
S2	O
).	O
Similarly	O
","	O
28	O
miRNAs	O
showed	O
expression	O
only	O
in	O
all	O
tolerant	O
â€	O
related	O
libraries	O
such	O
as	O
sly	O
â€	O
miR415	O
","	O
sly	O
â€	O
miR1520	O
g	O
and	O
sly	O
â€	O
miR2111	O
(	O
Figure	O
5b	O
","	O
Table	O
S2	O
).	O
Differential	O
expression	O
of	O
130	O
most	O
abundant	O
conserved	O
miRNAs	O
in	O
drought	O
â€	O
sensitive	O
and	O
drought	O
â€	O
tolerant	O
tomato	O
roots	O
and	O
upgrounds	O
.	O
The	O
miRNA	O
expressions	O
were	O
shown	O
as	O
Z	O
â€	O
score	O
.	O
S	O
","	O
sensitive	O
;	O
T	O
","	O
tolerant	O
;	O
C	O
","	O
control	O
;	O
D	O
","	O
drought	O
;	O
Up	O
","	O
upground	O
.	O
Comparisons	O
of	O
conserved	O
miRNA	O
expression	O
changes	O
after	O
drought	O
exposure	O
according	O
to	O
the	O
deep	O
sequencing	O
results	O
.	O
(	O
a	O
)	O
Common	O
miRNAs	O
among	O
root	O
and	O
upground	O
tissues	O
of	O
sensitive	O
and	O
tolerant	O
genotypes	O
;	O
(	O
b	O
)	O
Common	O
miRNAs	O
only	O
in	O
root	O
tissues	O
of	O
sensitive	O
and	O
tolerant	O
genotypes	O
;	O
(	O
c	O
)	O
Common	O
miRNAs	O
only	O
in	O
upground	O
tissues	O
of	O
sensitive	O
and	O
tolerant	O
genotypes	O
.	O
Normalized	O
read	O
abundance	O
comparisons	O
of	O
conserved	O
miRNAs	O
belong	O
to	O
control	O
and	O
drought	O
â€	O
treated	O
root	O
and	O
upground	O
tissues	O
specific	O
to	O
(	O
a	O
)	O
sensitive	O
genotype	O
","	O
(	O
b	O
)	O
tolerant	O
genotype	O
.	O
Target	O
prediction	O
and	O
degradome	O
analyses	O
psRNATarget	O
server	O
(	O
http	O
://	O
plantgrn	O
.	O
noble	O
.	O
org	O
/	O
psRNATarget	O
/)	O
was	O
used	O
to	O
predict	O
miRNA	O
target	O
transcripts	O
;	O
a	O
total	O
of	O
41	O
300	O
miRNA	O
target	O
pairs	O
were	O
obtained	O
which	O
contain	O
688	O
significantly	O
expressed	O
miRNAs	O
(	O
Table	O
S3	O
).	O
These	O
targets	O
were	O
mainly	O
transcription	O
factors	O
","	O
stress	O
â€	O
and	O
dehydration	O
â€/	O
drought	O
â€	O
related	O
proteins	O
","	O
resistance	O
â€	O
associated	O
proteins	O
and	O
significant	O
cellular	O
enzymes	O
like	O
kinases	O
","	O
transferases	O
and	O
phosphatases	O
(	O
Table	O
S3	O
).	O
Among	O
these	O
","	O
360	O
miRNAs	O
(	O
such	O
as	O
sly	O
â€	O
miR319	O
â€	O
3p	O
","	O
sly	O
â€	O
miR2089	O
â€	O
3p	O
and	O
sly	O
â€	O
miR5671a	O
)	O
targeted	O
plant	O
development	O
and	O
stress	O
response	O
â€	O
related	O
transcription	O
factors	O
","	O
such	O
as	O
MYB	O
","	O
WRKY	O
","	O
GRAS	O
","	O
TCP	O
","	O
NAC	O
â€	O
domain	O
","	O
ARF	O
(	O
auxin	O
response	O
factor	O
"),"	O
SBP	O
(	O
squamosa	O
promoter	O
â€	O
binding	O
â€	O
protein	O
â€	O
like	O
"),"	O
LEA	O
(	O
late	O
embryogenesis	O
abundant	O
)	O
protein	O
and	O
ERF	O
(	O
ethylene	O
responsive	O
factor	O
)	O
families	O
(	O
Table	O
S3	O
).	O
Additionally	O
","	O
stress	O
â€	O
related	O
proteins	O
known	O
as	O
stress	O
â€	O
responsive	O
protein	O
","	O
stress	O
â€	O
enhanced	O
protein	O
","	O
universal	O
stress	O
protein	O
and	O
stress	O
â€	O
induced	O
protein	O
were	O
potentially	O
targeted	O
by	O
49	O
miRNAs	O
","	O
such	O
as	O
sly	O
â€	O
miR164a	O
","	O
sly	O
â€	O
miR1074	O
","	O
sly	O
â€	O
miR1873	O
","	O
sly	O
â€	O
miR2628	O
and	O
sly	O
â€	O
miR5029	O
.	O
Also	O
","	O
especially	O
some	O
miRNA	O
target	O
genes	O
were	O
associated	O
with	O
dehydration	O
/	O
drought	O
stress	O
directly	O
.	O
These	O
transcripts	O
included	O
dehydration	O
â€	O
responsive	O
family	O
protein	O
","	O
DRP	O
(	O
dehydration	O
â€	O
responsive	O
protein	O
"),"	O
ERD	O
(	O
early	O
responsive	O
to	O
dehydration	O
â€	O
like	O
)	O
protein	O
","	O
DREB	O
(	O
dehydration	O
â€	O
responsive	O
element	O
binding	O
)	O
and	O
Di19	O
protein	O
(	O
dehydration	O
â€/	O
drought	O
â€	O
induced	O
19	O
protein	O
)	O
and	O
potentially	O
regulated	O
by	O
38	O
tomato	O
miRNAs	O
;	O
these	O
miRNAs	O
included	O
sly	O
â€	O
miR160a	O
â€	O
3p	O
","	O
sly	O
â€	O
miR170	O
â€	O
3p	O
","	O
sly	O
â€	O
miR1074	O
","	O
sly	O
â€	O
miR3948	O
","	O
sly	O
â€	O
miR5081	O
","	O
sly	O
â€	O
miR5758	O
","	O
sly	O
â€	O
miR8001b	O
â€	O
5p	O
and	O
sly	O
â€	O
miR9748	O
.	O
We	O
employed	O
degradome	O
sequencing	O
to	O
identify	O
miRNA	O
targets	O
.	O
After	O
sequencing	O
","	O
a	O
total	O
of	O
10	O
819	O
148	O
raw	O
and	O
10	O
799	O
28	O
clean	O
tags	O
(	O
99	O
.	O
81	O
%)	O
were	O
obtained	O
.	O
Then	O
","	O
the	O
clean	O
tags	O
were	O
mapped	O
to	O
the	O
reference	O
genome	O
database	O
of	O
tomato	O
ITAG	O
2	O
.	O
4	O
Release	O
(	O
ftp	O
://	O
ftp	O
.	O
solgenomics	O
.	O
net	O
/	O
genomes	O
/	O
Solanum_lycopersicum	O
/	O
annotation	O
/	O
ITAG2	O
.	O
4_release	O
/	O
ITAG2	O
.	O
4	O
genomic	O
.	O
fasta	O
)	O
by	O
SOAP2	O
.	O
20	O
(	O
Li	O
et	O
al	O
".,"	O
2009	O
)	O
and	O
7	O
422	O
369	O
matched	O
tags	O
(	O
68	O
.	O
73	O
%)	O
were	O
determined	O
.	O
With	O
the	O
classification	O
of	O
these	O
tags	O
","	O
cDNA_sense	O
tags	O
were	O
selected	O
and	O
the	O
identified	O
1	O
249	O
158	O
(	O
46	O
.	O
86	O
%)	O
unique	O
5	O
â€²	O
cDNA	O
tags	O
were	O
used	O
for	O
the	O
prediction	O
of	O
cleavage	O
sites	O
of	O
tomato	O
miRNAs	O
.	O
After	O
prediction	O
using	O
CleaveLand	O
v3	O
.	O
0	O
.	O
1	O
pipeline	O
(	O
Addo	O
â€	O
Quaye	O
et	O
al	O
".,"	O
2009	O
"),"	O
a	O
total	O
of	O
59	O
cleavage	O
sites	O
were	O
determined	O
associated	O
with	O
62	O
miRNAs	O
and	O
44	O
target	O
genes	O
and	O
115	O
specific	O
miRNA	O
â€“	O
mRNA	O
pairs	O
were	O
predicted	O
at	O
cleavage	O
sites	O
with	O
P	O
â€	O
value	O
<	O
0	O
.	O
5	O
(	O
Table	O
S4	O
).	O
For	O
the	O
identification	O
of	O
cleavage	O
sites	O
","	O
degradome	O
peaks	O
are	O
classified	O
into	O
five	O
categories	O
according	O
to	O
the	O
peak	O
height	O
at	O
mRNA	O
position	O
and	O
the	O
targets	O
with	O
category	O
0	O
or	O
1	O
were	O
evaluated	O
as	O
the	O
most	O
significant	O
(	O
Karlova	O
et	O
al	O
".,"	O
2013	O
).	O
In	O
tomato	O
degradome	O
results	O
","	O
15	O
target	O
genes	O
were	O
related	O
to	O
stimulus	O
response	O
such	O
as	O
ARF	O
and	O
disease	O
resistance	O
proteins	O
were	O
identified	O
in	O
category	O
0	O
cleaved	O
by	O
sly	O
â€	O
miR160	O
","	O
sly	O
â€	O
miR168	O
","	O
sly	O
â€	O
miR172	O
","	O
sly	O
â€	O
miR396	O
","	O
sly	O
â€	O
miR482	O
","	O
sly	O
â€	O
miR6023	O
and	O
sly	O
â€	O
miR6024	O
families	O
(	O
Figure	O
6	O
","	O
Table	O
S4	O
).	O
In	O
category	O
1	O
","	O
only	O
two	O
genes	O
cleaved	O
by	O
miR156	O
and	O
miR162	O
families	O
were	O
obtained	O
(	O
Table	O
S4	O
).	O
In	O
another	O
significant	O
class	O
of	O
peaks	O
","	O
category	O
2	O
","	O
mostly	O
stimulus	O
â€	O
and	O
cellular	O
component	O
organization	O
â€	O
associated	O
47	O
mRNAs	O
like	O
PSII	O
(	O
photosystem	O
II	O
)	O
protein	O
","	O
NAD	O
(	O
H	O
)	O
kinase	O
","	O
phosphorus	O
transporter	O
","	O
ATP	O
â€	O
sulfurylase	O
and	O
SCL	O
(	O
scarecrow	O
â€	O
like	O
)	O
protein	O
were	O
determined	O
.	O
These	O
targets	O
were	O
cleaved	O
by	O
sly	O
â€	O
miR156	O
","	O
sly	O
â€	O
miR164	O
","	O
sly	O
â€	O
miR166	O
","	O
sly	O
â€	O
miR169	O
","	O
sly	O
â€	O
miR171	O
","	O
sly	O
â€	O
miR395	O
and	O
sly	O
â€	O
mir9477	O
(	O
Table	O
S4	O
).	O
The	O
rest	O
of	O
51	O
target	O
genes	O
were	O
belonged	O
to	O
less	O
significant	O
categories	O
3	O
and	O
4	O
.	O
One	O
of	O
the	O
stimulus	O
response	O
â€	O
associated	O
target	O
PSII	O
degraded	O
by	O
16	O
miRNA	O
families	O
such	O
as	O
sly	O
â€	O
miR167	O
","	O
sly	O
â€	O
miR319	O
","	O
sly	O
â€	O
miR390	O
","	O
sly	O
â€	O
miR482	O
","	O
sly	O
â€	O
mir1919	O
","	O
sly	O
â€	O
miR5302	O
and	O
sly	O
â€	O
miR9479	O
.	O
Other	O
two	O
stress	O
â€	O
related	O
genes	O
","	O
SBP	O
and	O
ARF	O
","	O
were	O
cleaved	O
by	O
sly	O
â€	O
miR156	O
and	O
sly	O
â€	O
miR160	O
families	O
","	O
respectively	O
.	O
Sly	O
â€	O
miR171	O
","	O
sly	O
â€	O
miR403	O
and	O
sly	O
â€	O
miR6027	O
families	O
targeted	O
histone	O
â€	O
arginine	O
methyltransferase	O
involved	O
in	O
cellular	O
and	O
developmental	O
process	O
","	O
and	O
sly	O
â€	O
miR395	O
and	O
sly	O
â€	O
miR9477	O
degraded	O
acyltransferase	O
gene	O
","	O
the	O
cellular	O
and	O
metabolic	O
process	O
â€	O
associated	O
target	O
(	O
Table	O
S4	O
).	O
Target	O
(	O
T	O
)	O
plots	O
and	O
miRNA	O
â€“	O
mRNA	O
alignments	O
of	O
tomato	O
.	O
(	O
a	O
)	O
sly	O
â€	O
miR160a	O
cleaves	O
ARF17	O
gene	O
;	O
(	O
b	O
)	O
sly	O
â€	O
miR396a	O
â€	O
5p	O
cleaves	O
GRF5	O
gene	O
;	O
(	O
c	O
)	O
sly	O
â€	O
miR482d	O
â€	O
3p	O
cleaves	O
NBS	O
protein	O
.	O
The	O
red	O
arrows	O
represent	O
the	O
cleavage	O
nucleotide	B-Chemical
positions	O
on	O
the	O
target	O
genes	O
.	O
GO	O
enrichment	O
and	O
KEGG	O
pathway	O
analyses	O
Gene	O
ontology	O
(	O
GO	O
)â€	O
based	O
enrichment	O
analysis	O
was	O
performed	O
to	O
further	O
investigate	O
the	O
potential	O
role	O
of	O
miRNAs	O
in	O
tomato	O
response	O
to	O
drought	O
stress	O
.	O
A	O
total	O
of	O
9810	O
potential	O
miRNA	O
targets	O
were	O
classified	O
into	O
665	O
biological	O
processes	O
","	O
45	O
molecular	O
functions	O
and	O
72	O
cellular	O
components	O
(	O
Table	O
S5	O
).	O
Some	O
of	O
the	O
significant	O
biological	O
processes	O
with	O
the	O
highest	O
target	O
numbers	O
were	O
cellular	O
process	O
(	O
GO	O
:	O
9987	O
"),"	O
cellular	O
metabolic	O
process	O
(	O
GO	O
:	O
44237	O
"),"	O
response	O
to	O
stimulus	O
(	O
GO	O
:	O
50896	O
"),"	O
response	O
to	O
abiotic	O
stimulus	O
(	O
GO	O
:	O
9628	O
"),"	O
response	O
to	O
stress	O
(	O
GO	O
:	O
6950	O
)	O
and	O
response	O
to	O
water	O
deprivation	O
(	O
GO	O
:	O
9414	O
)	O
(	O
Table	O
S5	O
).	O
Binding	O
(	O
GO	O
:	O
5488	O
"),"	O
catalytic	O
activity	O
(	O
GO	O
:	O
3824	O
"),"	O
nucleotide	B-Chemical
binding	O
(	O
166	O
)	O
and	O
hydrolase	O
activity	O
(	O
16787	O
)	O
were	O
among	O
the	O
most	O
abundant	O
classes	O
in	O
molecular	O
function	O
category	O
(	O
Table	O
S5	O
).	O
The	O
common	O
cellular	O
component	O
terms	O
were	O
cell	O
part	O
(	O
GO	O
:	O
44464	O
"),"	O
intracellular	O
part	O
(	O
GO	O
:	O
44424	O
"),"	O
organelle	O
part	O
(	O
GO	O
:	O
43226	O
)	O
and	O
cytoplasmic	O
part	O
(	O
GO	O
:	O
44444	O
)	O
(	O
Table	O
S5	O
).	O
We	O
employed	O
agriGO	O
web	O
â€	O
based	O
tool	O
to	O
visualize	O
the	O
enriched	O
biological	O
process	O
","	O
molecular	O
function	O
and	O
cellular	O
component	O
categories	O
and	O
draw	O
hierarchical	O
graphs	O
of	O
significantly	O
enriched	O
GO	O
terms	O
(	O
Du	O
et	O
al	O
".,"	O
2010	O
).	O
In	O
biological	O
process	O
","	O
stress	O
â€	O
associated	O
terms	O
such	O
as	O
response	O
to	O
hormone	O
stimulus	O
(	O
GO	O
:	O
9725	O
)	O
like	O
abscisic	B-Chemical
acid	I-Chemical
(	O
GO	O
:	O
9737	O
"),"	O
jasmonic	B-Chemical
acid	I-Chemical
(	O
GO	O
:	O
9753	O
"),"	O
auxin	B-Chemical
(	O
GO	O
:	O
9733	O
"),"	O
ethylene	B-Chemical
(	O
GO	O
:	O
9723	O
)	O
and	O
salicylic	B-Chemical
acid	I-Chemical
(	O
GO	O
:	O
9751	O
"),"	O
response	O
to	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
GO	O
:	O
302	O
"),"	O
response	O
to	O
water	O
deprivation	O
(	O
GO	O
:	O
9414	O
"),"	O
response	O
to	O
salt	O
stress	O
(	O
GO	O
:	O
9651	O
)	O
and	O
signal	O
transduction	O
(	O
GO	O
:	O
7165	O
)	O
were	O
related	O
to	O
each	O
other	O
(	O
Figures	O
7a	O
and	O
8	O
)	O
and	O
development	O
â€	O
related	O
ontologies	O
like	O
fruit	O
development	O
(	O
GO	O
:	O
10154	O
"),"	O
shoot	O
development	O
(	O
GO	O
:	O
48367	O
"),"	O
seed	O
development	O
(	O
GO	O
:	O
4831	O
"),"	O
root	O
development	O
(	O
GO	O
:	O
48364	O
)	O
and	O
leaf	O
development	O
(	O
GO	O
:	O
48366	O
)	O
were	O
determined	O
(	O
Figure	O
8	O
).	O
Pyrophosphatase	O
activity	O
(	O
GO	O
:	O
16452	O
"),"	O
nucleoside	O
â€	O
triphosphatase	O
activity	O
(	O
GO	O
:	O
17111	O
"),"	O
ATPase	O
activity	O
(	O
GO	O
:	O
16887	O
"),"	O
purine	B-Chemical
ribonucleotide	I-Chemical
binding	O
(	O
GO	O
:	O
3255	O
)	O
and	O
ATP	B-Chemical
binding	O
(	O
GO	O
:	O
5524	O
)	O
were	O
some	O
of	O
the	O
significantly	O
enriched	O
molecular	O
function	O
terms	O
(	O
Figure	O
7b	O
","	O
Table	O
S5	O
).	O
In	O
cellular	O
component	O
category	O
","	O
organelle	O
subcompartment	O
(	O
GO	O
:	O
31984	O
"),"	O
cell	O
junction	O
(	O
GO	O
:	O
30054	O
"),"	O
vacuole	O
(	O
GO	O
:	O
31984	O
)	O
and	O
chloroplast	O
thylakoid	O
(	O
GO	O
:	O
9534	O
)	O
were	O
categorized	O
significantly	O
(	O
Figure	O
7c	O
","	O
Table	O
S5	O
).	O
Diagrams	O
of	O
enriched	O
GO	O
terms	O
of	O
drought	O
â€	O
responsive	O
miRNA	O
â€	O
associated	O
tomato	O
targets	O
constructed	O
by	O
AGRIGO	O
.	O
(	O
a	O
)	O
biological	O
process	O
","	O
(	O
b	O
)	O
molecular	O
function	O
and	O
(	O
c	O
)	O
cellular	O
component	O
.	O
Red	O
to	O
yellow	O
colours	O
represent	O
decreasing	O
significance	O
levels	O
(	O
Red	O
is	O
most	O
","	O
yellow	O
is	O
least	O
significant	O
).	O
Red	O
and	O
green	O
arrows	O
mean	O
positive	O
and	O
negative	O
regulation	O
of	O
terms	O
.	O
Functional	O
annotation	O
of	O
GO	O
biological	O
process	O
related	O
with	O
drought	O
stress	O
in	O
tomato	O
by	O
AGRIGO	O
.	O
KEGG	O
(	O
The	O
Kyoto	O
Encyclopedia	O
of	O
Gene	O
and	O
Genome	O
)	O
annotation	O
was	O
carried	O
out	O
for	O
pathway	O
analysis	O
","	O
and	O
289	O
KEGG	O
pathways	O
were	O
obtained	O
.	O
Thirty	O
â€	O
six	O
pathways	O
including	O
2414	O
genes	O
were	O
detected	O
as	O
closely	O
associated	O
with	O
drought	O
stress	O
including	O
plant	O
â€“	O
pathogen	O
interaction	O
","	O
biosynthesis	O
of	O
plant	O
hormones	O
","	O
plant	O
hormone	O
signal	O
transduction	O
","	O
oxidative	O
phosphorylation	O
","	O
calcium	B-Chemical
signalling	O
pathway	O
","	O
carotenoid	B-Chemical
metabolism	O
","	O
alpha	B-Chemical
â€	I-Chemical
Linolenic	I-Chemical
acid	I-Chemical
metabolism	O
","	O
brassinosteroid	B-Chemical
biosynthesis	O
and	O
photosynthesis	O
(	O
Figure	O
9	O
).	O
Plant	O
hormone	O
signal	O
transduction	O
pathway	O
was	O
represented	O
by	O
134	O
genes	O
and	O
contained	O
auxin	B-Chemical
"â€,"	O
cytokinine	B-Chemical
"â€,"	O
gibberellin	B-Chemical
"â€,"	O
abscisic	B-Chemical
acid	I-Chemical
"â€,"	O
ethylene	B-Chemical
"â€,"	O
brassinosteroid	B-Chemical
"â€,"	O
jasmonic	B-Chemical
acid	I-Chemical
â€	O
and	O
salicylic	B-Chemical
acid	I-Chemical
â€	O
associated	O
signalling	O
genes	O
inducible	O
via	O
abiotic	O
and	O
biotic	O
stresses	O
(	O
Figure	O
10	O
).	O
For	O
example	O
","	O
carotenoid	B-Chemical
biosynthesis	O
was	O
involved	O
in	O
the	O
pathway	O
","	O
contributes	O
to	O
abscisic	B-Chemical
acid	I-Chemical
synthesis	O
","	O
contained	O
enriched	O
phosphatase	O
2C	O
(	O
PP2C	O
"),"	O
plant	O
â€	O
specific	O
serine	O
/	O
threonine	O
kinase	O
(	O
SnRK2	O
)	O
and	O
abscisic	O
acid	O
â€	O
responsive	O
element	O
binding	O
factor	O
(	O
ABF	O
).	O
These	O
genes	O
were	O
regulated	O
by	O
sly	O
â€	O
miR172a	O
","	O
sly	O
â€	O
miR172e	O
â€	O
3p	O
","	O
sly	O
â€	O
miR393a	O
","	O
sly	O
â€	O
miR2628	O
","	O
sly	O
â€	O
miR5265	O
","	O
sly	O
â€	O
miR5641	O
","	O
sly	O
â€	O
miR6020a	O
â€	O
5p	O
and	O
sly	O
â€	O
miR7696a	O
â€	O
3p	O
(	O
Figure	O
10	O
).	O
Similarly	O
","	O
jasmonic	O
acid	O
â€“	O
amido	O
synthetase	O
JAR1	O
","	O
jasmonate	O
ZIM	O
domain	O
(	O
JAZ	O
)	O
and	O
MYC2	O
genes	O
were	O
enriched	O
to	O
alpha	B-Chemical
â€	I-Chemical
Linolenic	I-Chemical
acid	I-Chemical
metabolism	O
associated	O
with	O
jasmonic	B-Chemical
acid	I-Chemical
synthesis	O
","	O
and	O
these	O
genes	O
were	O
targeted	O
by	O
sly	O
â€	O
miR162a	O
â€	O
3p	O
","	O
sly	O
â€	O
miR169a	O
â€	O
5p	O
","	O
sly	O
â€	O
miR172a	O
","	O
sly	O
â€	O
miR827	O
â€	O
5p	O
","	O
sly	O
â€	O
miR5083	O
","	O
sly	O
â€	O
miR5298a	O
","	O
sly	O
â€	O
miR5658	O
","	O
sly	O
â€	O
miR6476a	O
and	O
sly	O
â€	O
miR8576	O
(	O
Figure	O
10	O
).	O
Functional	O
annotation	O
of	O
KEGG	O
pathways	O
in	O
tomato	O
by	O
KEGG	O
database	O
.	O
Plant	O
hormone	O
signal	O
transduction	O
pathway	O
and	O
related	O
miRNAs	O
.	O
Cytoscape	O
platform	O
was	O
further	O
employed	O
to	O
build	O
the	O
network	O
between	O
the	O
drought	O
â€	O
responsive	O
miRNAs	O
and	O
their	O
targets	O
.	O
Totally	O
","	O
53	O
miRNAs	O
(	O
such	O
as	O
sly	O
â€	O
miR164	O
","	O
sly	O
â€	O
miR166	O
and	O
sly	O
â€	O
miR408	O
)	O
targeted	O
23	O
genes	O
associated	O
with	O
drought	O
response	O
and	O
tissue	O
development	O
","	O
which	O
included	O
NAC	O
â€	O
domain	O
","	O
HD	O
â€	O
ZIP	O
and	O
BCP	O
(	O
blue	O
copper	O
protein	O
).	O
Sly	O
â€	O
miR5641	O
targeted	O
10	O
drought	O
â€	O
and	O
development	O
â€	O
related	O
genes	O
such	O
as	O
DRP	O
","	O
LEA	O
","	O
ERF	O
and	O
SBP	O
(	O
Figure	O
11a	O
).	O
Different	O
gene	O
families	O
were	O
targeted	O
by	O
different	O
numbers	O
of	O
miRNAs	O
.	O
For	O
example	O
","	O
DRP	O
was	O
targeted	O
by	O
20	O
miRNAs	O
","	O
followed	O
by	O
GTs	O
(	O
glycosyltransferases	O
)	O
with	O
16	O
miRNAs	O
;	O
MYB	O
with	O
11	O
miRNAs	O
;	O
NAC	O
with	O
8	O
miRNAs	O
;	O
HD	O
â€	O
ZIP	O
with	O
7	O
miRNAs	O
;	O
and	O
PSII	O
and	O
ERF	O
with	O
6	O
miRNAs	O
(	O
Figure	O
11a	O
).	O
In	O
plant	O
hormone	O
signal	O
transduction	O
pathway	O
","	O
23	O
miRNAs	O
targeted	O
19	O
genes	O
that	O
play	O
roles	O
in	O
cell	O
division	O
","	O
plant	O
growth	O
","	O
stomatal	O
closure	O
and	O
stress	O
response	O
.	O
For	O
example	O
","	O
sly	O
â€	O
miR5641	O
potentially	O
targeted	O
seven	O
genes	O
involved	O
in	O
this	O
pathway	O
.	O
Additionally	O
","	O
sly	O
â€	O
miR393	O
/	O
miR6476	O
and	O
sly	O
â€	O
miR172	O
/	O
miR5658	O
potentially	O
targeted	O
5	O
and	O
4	O
related	O
genes	O
","	O
respectively	O
(	O
Figure	O
11b	O
).	O
Relationships	O
between	O
miRNAs	O
and	O
their	O
targets	O
associated	O
with	O
(	O
a	O
)	O
drought	O
response	O
","	O
(	O
b	O
)	O
plant	O
hormone	O
signal	O
transduction	O
pathway	O
.	O
qRT	O
â€	O
PCR	O
validation	O
of	O
miRNA	O
expressions	O
We	O
performed	O
qRT	O
â€	O
PCR	O
to	O
validate	O
the	O
deep	O
sequencing	O
results	O
with	O
randomly	O
selected	O
eight	O
miRNAs	O
(	O
sly	O
â€	O
miR156a	O
â€	O
5p	O
","	O
sly	O
â€	O
miR169e	O
â€	O
3p	O
","	O
sly	O
â€	O
miR172a	O
","	O
sly	O
â€	O
miR393a	O
â€	O
5p	O
","	O
sly	O
â€	O
miR399a	O
â€	O
5p	O
","	O
sly	O
â€	O
miR408b	O
â€	O
5p	O
","	O
sly	O
â€	O
miR482d	O
â€	O
3p	O
and	O
sly	O
â€	O
miR9472	O
â€	O
5p	O
).	O
For	O
this	O
purpose	O
","	O
we	O
used	O
root	O
tissues	O
of	O
tolerant	O
genotype	O
under	O
control	O
and	O
drought	O
conditions	O
and	O
we	O
figured	O
out	O
the	O
expression	O
levels	O
between	O
drought	O
â€	O
treated	O
versus	O
control	O
samples	O
using	O
log2	O
fold	O
change	O
()	O
values	O
with	O
three	O
technical	O
and	O
three	O
biological	O
replicates	O
.	O
The	O
expression	O
results	O
of	O
root	O
tissues	O
in	O
tolerant	O
genotype	O
exposed	O
to	O
drought	O
were	O
similar	O
to	O
the	O
deep	O
sequencing	O
data	O
(	O
Figure	O
12	O
).	O
Three	O
miRNAs	O
(	O
sly	O
â€	O
miR172a	O
","	O
sly	O
â€	O
miR482d	O
â€	O
3p	O
and	O
sly	O
â€	O
miR9472	O
â€	O
5p	O
)	O
were	O
up	O
â€	O
regulated	O
in	O
qRT	O
â€	O
PCR	O
analysis	O
showing	O
a	O
positive	O
correlation	O
with	O
deep	O
sequencing	O
results	O
.	O
Similarly	O
","	O
the	O
other	O
miRNAs	O
were	O
down	O
â€	O
regulated	O
in	O
both	O
qRT	O
â€	O
PCR	O
and	O
high	O
â€	O
throughput	O
sequencing	O
results	O
(	O
Figure	O
12	O
).	O
qRT	O
â€	O
PCR	O
validation	O
of	O
randomly	O
selected	O
drought	O
â€	O
responsive	O
eight	O
miRNAs	O
in	O
tolerant	O
root	O
tissues	O
.	O
Discussion	O
MicroRNAs	O
","	O
the	O
post	O
â€	O
transcriptional	O
gene	O
regulators	O
","	O
are	O
associated	O
with	O
drought	O
stress	O
evidenced	O
by	O
that	O
miRNAs	O
target	O
a	O
wide	O
range	O
of	O
drought	O
â€	O
related	O
genes	O
","	O
such	O
as	O
ARF	O
","	O
MYB	O
","	O
TCP	O
and	O
GRAS	O
family	O
transcription	O
factors	O
","	O
dehydrins	O
","	O
glutathione	O
S	O
â€	O
transferase	O
(	O
GST	O
)	O
and	O
abscisic	B-Chemical
acid	I-Chemical
â€	O
related	O
genes	O
(	O
Ferdous	O
et	O
al	O
".,"	O
2015	O
).	O
Using	O
microarray	O
and	O
deep	O
sequencing	O
approaches	O
","	O
several	O
drought	O
â€	O
responsive	O
miRNAs	O
were	O
identified	O
in	O
wheat	O
(	O
Kantar	O
et	O
al	O
".,"	O
2011	O
"),"	O
sorghum	O
(	O
Pasini	O
et	O
al	O
".,"	O
2014	O
"),"	O
sugarcane	O
(	O
Thiebaut	O
et	O
al	O
".,"	O
2014	O
"),"	O
tobacco	O
(	O
Yin	O
et	O
al	O
".,"	O
2014	O
"),"	O
potato	O
(	O
Zhang	O
et	O
al	O
".,"	O
2014	O
)	O
and	O
barley	O
(	O
Hackenberg	O
et	O
al	O
".,"	O
2015	O
).	O
However	O
","	O
there	O
is	O
no	O
study	O
on	O
systematical	O
identification	O
and	O
expression	O
analysis	O
of	O
miRNAs	O
in	O
tomato	O
response	O
to	O
drought	O
stress	O
using	O
microarray	O
or	O
deep	O
sequencing	O
approaches	O
.	O
In	O
this	O
study	O
","	O
we	O
employed	O
deep	O
sequencing	O
technology	O
to	O
systematically	O
study	O
the	O
effect	O
of	O
drought	O
exposure	O
on	O
miRNA	O
expression	O
in	O
two	O
different	O
tomato	O
genotypes	O
with	O
different	O
drought	O
sensitivity	O
in	O
a	O
tissue	O
â€	O
specific	O
manner	O
.	O
Based	O
on	O
our	O
study	O
","	O
a	O
total	O
of	O
775	O
miRNAs	O
were	O
differentially	O
affected	O
by	O
drought	O
;	O
among	O
them	O
","	O
438	O
miRNAs	O
were	O
down	O
â€	O
regulated	O
in	O
sensitive	O
genotype	O
(	O
Table	O
S2	O
).	O
We	O
also	O
performed	O
degradome	O
sequencing	O
to	O
identify	O
miRNA	O
targets	O
.	O
Our	O
results	O
were	O
different	O
from	O
that	O
in	O
tomato	O
fruit	O
development	O
(	O
Karlova	O
et	O
al	O
".,"	O
2013	O
).	O
In	O
our	O
study	O
","	O
we	O
found	O
44	O
target	O
genes	O
","	O
but	O
only	O
the	O
targets	O
of	O
4	O
miRNAs	O
(	O
sly	O
â€	O
miR156	O
","	O
sly	O
â€	O
miR160	O
","	O
sly	O
â€	O
miR166	O
and	O
sly	O
â€	O
miR482	O
)	O
were	O
matched	O
with	O
their	O
results	O
(	O
Table	O
S4	O
).	O
We	O
identified	O
not	O
only	O
the	O
common	O
targets	O
as	O
reported	O
previously	O
but	O
also	O
new	O
targets	O
in	O
tomato	O
.	O
For	O
example	O
","	O
miR156	O
targets	O
SBP	O
transcription	O
factors	O
","	O
but	O
sly	O
â€	O
miR156d	O
â€	O
3p	O
targeted	O
NAD	O
(	O
H	O
)â€	O
like	O
kinase	O
protein	O
","	O
while	O
sly	O
â€	O
miR156e	O
â€	O
5p	O
targeted	O
four	O
genes	O
including	O
SBP6	O
and	O
PSII	O
protein	O
.	O
Except	O
the	O
previous	O
report	O
that	O
miR160	O
was	O
found	O
to	O
target	O
ARF10	O
","	O
ARF16	O
and	O
ARF17	O
(	O
Karlova	O
et	O
al	O
".,"	O
2013	O
"),"	O
we	O
also	O
found	O
that	O
miR160	O
targeted	O
ARF18	O
â€	O
like	O
and	O
PSII	O
protein	O
(	O
Table	O
S4	O
).	O
Several	O
other	O
drought	O
â€	O
related	O
miRNAs	O
targeted	O
several	O
new	O
genes	O
.	O
Despite	O
the	O
similarity	O
of	O
each	O
member	O
in	O
a	O
same	O
miRNA	O
family	O
(	O
Zhang	O
et	O
al	O
".,"	O
2006	O
"),"	O
they	O
may	O
response	O
differently	O
to	O
drought	O
stress	O
with	O
a	O
tissue	O
â€	O
and	O
genotype	O
â€	O
dependent	O
manner	O
(	O
Table	O
S2	O
).	O
For	O
example	O
","	O
miR165	O
/	O
166	O
families	O
were	O
known	O
to	O
target	O
HD	O
â€	O
ZIP	O
III	O
transcription	O
factor	O
which	O
is	O
crucial	O
for	O
leaf	O
polarity	O
","	O
lateral	O
root	O
development	O
and	O
vascular	O
patterning	O
(	O
Elhiti	O
and	O
Stasolla	O
","	O
2009	O
;	O
Williams	O
et	O
al	O
".,"	O
2005	O
;	O
Zhong	O
and	O
Ye	O
","	O
2007	O
).	O
The	O
expressions	O
of	O
miR165	O
/	O
166	O
family	O
were	O
generally	O
decreased	O
by	O
drought	O
treatment	O
in	O
other	O
plant	O
species	O
such	O
as	O
rice	O
(	O
Zhou	O
et	O
al	O
".,"	O
2010	O
"),"	O
cotton	O
(	O
Xie	O
et	O
al	O
".,"	O
2015	O
"),"	O
wheat	O
(	O
Kantar	O
et	O
al	O
".,"	O
2011	O
)	O
and	O
peach	O
(	O
Eldem	O
et	O
al	O
".,"	O
2012	O
).	O
However	O
","	O
the	O
expression	O
of	O
miR166	O
was	O
increased	O
in	O
Medicago	O
truncatula	O
by	O
drought	O
stress	O
and	O
the	O
expression	O
level	O
was	O
higher	O
in	O
roots	O
in	O
comparison	O
with	O
upper	O
parts	O
(	O
Trindade	O
et	O
al	O
".,"	O
2010	O
).	O
Moreover	O
","	O
overexpressions	O
of	O
miR165	O
/	O
166	O
caused	O
formations	O
of	O
vascular	O
bundles	O
and	O
decreased	O
lateral	O
roots	O
","	O
respectively	O
(	O
Boualem	O
et	O
al	O
".,"	O
2008	O
;	O
Zhong	O
and	O
Ye	O
","	O
2007	O
).	O
These	O
results	O
suggest	O
that	O
miR165	O
/	O
166	O
families	O
regulate	O
root	O
development	O
and	O
drought	O
response	O
.	O
In	O
our	O
study	O
","	O
drought	O
majorly	O
induced	O
the	O
expression	O
of	O
miR165	O
","	O
but	O
inhibited	O
the	O
expression	O
of	O
miR166	O
in	O
roots	O
.	O
Additionally	O
","	O
sly	O
â€	O
miR165a	O
â€	O
5p	O
/	O
miR166k	O
and	O
sly	O
â€	O
miR165b	O
â€	O
5p	O
were	O
root	O
specific	O
in	O
sensitive	O
and	O
tolerant	O
genotypes	O
","	O
respectively	O
","	O
whereas	O
sly	O
â€	O
miR166d	O
â€	O
5p	O
was	O
specific	O
to	O
upground	O
tissues	O
of	O
tolerant	O
genotype	O
.	O
Drought	O
did	O
not	O
affect	O
the	O
sensitive	O
genotype	O
significantly	O
in	O
miR165	O
family	O
.	O
However	O
","	O
in	O
root	O
tissues	O
of	O
tolerant	O
genotype	O
","	O
the	O
expression	O
of	O
miR165b	O
â€	O
5p	O
was	O
decreased	O
by	O
âˆ’	O
8	O
.	O
25	O
â€	O
fold	O
after	O
drought	O
treatment	O
","	O
whereas	O
miR165a	O
â€	O
3p	O
was	O
up	O
â€	O
regulated	O
(	O
3	O
.	O
10	O
â€	O
fold	O
)	O
in	O
upground	O
tissues	O
.	O
Sly	O
â€	O
miR166a	O
and	O
sly	O
â€	O
miR166	O
g	O
â€	O
3p	O
were	O
up	O
â€	O
regulated	O
by	O
19	O
.	O
50	O
â€	O
and	O
2	O
.	O
34	O
â€	O
fold	O
","	O
respectively	O
","	O
in	O
upground	O
tissues	O
of	O
tolerant	O
genotype	O
with	O
dehydration	O
","	O
while	O
miR166d	O
â€	O
5p	O
expression	O
was	O
decreased	O
sharply	O
(âˆ’	O
10	O
.	O
98	O
â€	O
fold	O
).	O
In	O
sensitive	O
root	O
samples	O
","	O
sly	O
â€	O
miR166	O
g	O
â€	O
5p	O
was	O
up	O
â€	O
regulated	O
(	O
11	O
.	O
64	O
â€	O
fold	O
)	O
by	O
drought	O
stress	O
","	O
whereas	O
miR166k	O
expression	O
was	O
decreased	O
at	O
the	O
same	O
time	O
by	O
âˆ’	O
18	O
.	O
71	O
â€	O
fold	O
(	O
Table	O
S2	O
).	O
These	O
results	O
suggest	O
that	O
miR165	O
and	O
miR166	O
regulated	O
concurrently	O
the	O
drought	O
â€	O
responsive	O
gene	O
expression	O
as	O
positively	O
or	O
negatively	O
.	O
One	O
of	O
the	O
main	O
targets	O
of	O
miR398	O
is	O
copper	O
/	O
zinc	O
superoxide	O
dismutase	O
(	O
Cu	O
/	O
Zn	O
â€	O
SOD	O
","	O
CSD	O
"),"	O
a	O
scavenger	O
enzyme	O
of	O
ROS	B-Chemical
(	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
)	O
detoxifying	O
superoxide	B-Chemical
radicals	I-Chemical
(	O
Sunkar	O
et	O
al	O
".,"	O
2006	O
).	O
miR398	O
was	O
down	O
â€	O
regulated	O
by	O
drought	O
in	O
tomato	O
(	O
Luan	O
et	O
al	O
".,"	O
2014	O
"),"	O
M	O
.	O
truncatula	O
(	O
Wang	O
et	O
al	O
".,"	O
2011	O
)	O
and	O
cotton	O
(	O
Xie	O
et	O
al	O
".,"	O
2015	O
"),"	O
whereas	O
up	O
â€	O
regulated	O
in	O
another	O
M	O
.	O
truncatula	O
species	O
(	O
Trindade	O
et	O
al	O
".,"	O
2010	O
)	O
and	O
wheat	O
(	O
Kantar	O
et	O
al	O
".,"	O
2011	O
).	O
Down	O
â€	O
regulation	O
of	O
this	O
miRNA	O
results	O
in	O
increase	O
in	O
CSD	O
expression	O
and	O
tolerance	O
to	O
oxidative	O
stress	O
(	O
Ding	O
et	O
al	O
".,"	O
2013	O
).	O
Consistently	O
","	O
the	O
overexpression	O
of	O
miR398	O
led	O
to	O
down	O
â€	O
regulation	O
of	O
CSD1	O
and	O
2	O
enzymes	O
and	O
caused	O
sensitivity	O
to	O
drought	O
stress	O
in	O
rice	O
(	O
Lu	O
et	O
al	O
".,"	O
2010	O
).	O
Our	O
target	O
identification	O
results	O
were	O
consistent	O
with	O
the	O
literature	O
and	O
sly	O
â€	O
miR398a	O
â€	O
3p	O
targeted	O
CSD	O
enzyme	O
also	O
(	O
Table	O
S3	O
).	O
However	O
","	O
sly	O
â€	O
miR398a	O
â€	O
3p	O
expression	O
did	O
not	O
change	O
significantly	O
by	O
drought	O
(	O
Figure	O
3	O
","	O
Table	O
S2	O
).	O
Sly	O
â€	O
miR398a	O
â€	O
5p	O
was	O
down	O
â€	O
regulated	O
in	O
sensitive	O
upground	O
and	O
tolerant	O
root	O
tissues	O
by	O
2	O
.	O
65	O
â€	O
and	O
1	O
.	O
17	O
â€	O
fold	O
","	O
respectively	O
","	O
with	O
drought	O
treatment	O
(	O
Table	O
S2	O
).	O
This	O
miRNA	O
targeted	O
the	O
development	O
and	O
drought	O
â€	O
related	O
NAC	O
â€	O
domain	O
","	O
HD	O
â€	O
ZIP	O
III	O
and	O
auxin	O
response	O
proteins	O
according	O
to	O
the	O
target	O
prediction	O
results	O
(	O
Table	O
S3	O
).	O
Sly	O
â€	O
miR398a	O
â€	O
5p	O
expressed	O
higher	O
in	O
roots	O
of	O
sensitive	O
genotype	O
in	O
control	O
(	O
1	O
.	O
29	O
â€	O
fold	O
)	O
and	O
drought	O
(	O
4	O
.	O
9	O
â€	O
fold	O
)	O
conditions	O
","	O
but	O
generally	O
miR398	O
family	O
expression	O
was	O
decreased	O
in	O
upground	O
tissues	O
excluding	O
sly	O
â€	O
miR398a	O
â€	O
3p	O
in	O
sensitive	O
genotype	O
.	O
This	O
up	O
â€	O
regulation	O
(	O
2	O
.	O
3	O
â€	O
fold	O
)	O
may	O
be	O
responsible	O
for	O
the	O
sensitivity	O
of	O
L	O
.	O
esculentum	O
decreasing	O
CSD	O
activity	O
.	O
The	O
other	O
copper	O
proteins	O
plantacyanin	O
(	O
basic	O
blue	O
)	O
and	O
laccase	O
were	O
the	O
predicted	O
targets	O
of	O
miR408	O
family	O
(	O
Abdel	O
â€	O
Ghany	O
and	O
Pilon	O
","	O
2008	O
"),"	O
and	O
the	O
expression	O
of	O
this	O
family	O
usually	O
decreased	O
by	O
dehydration	O
in	O
plant	O
species	O
such	O
as	O
rice	O
(	O
Zhou	O
et	O
al	O
".,"	O
2010	O
"),"	O
M	O
.	O
truncatula	O
(	O
Trindade	O
et	O
al	O
".,"	O
2010	O
"),"	O
Populus	O
(	O
Ren	O
et	O
al	O
".,"	O
2012	O
"),"	O
peach	O
(	O
Eldem	O
et	O
al	O
".,"	O
2012	O
)	O
and	O
cotton	O
(	O
Xie	O
et	O
al	O
".,"	O
2015	O
).	O
miR408	O
is	O
necessary	O
for	O
the	O
adjustment	O
of	O
copper	B-Chemical
levels	O
in	O
cells	O
as	O
the	O
copper	B-Chemical
deficiency	O
causes	O
production	O
of	O
ROS	O
and	O
oxidative	O
stress	O
(	O
Abdel	O
â€	O
Ghany	O
and	O
Pilon	O
","	O
2008	O
).	O
The	O
overexpression	O
of	O
miR408	O
in	O
chickpea	O
led	O
to	O
the	O
inhibition	O
of	O
plantacyanin	O
expression	O
and	O
accumulation	O
of	O
copper	B-Chemical
and	O
also	O
induction	O
of	O
DREB	O
expression	O
by	O
drought	O
(	O
Hajyzadeh	O
et	O
al	O
".,"	O
2015	O
)	O
and	O
overexpression	O
of	O
DREB	O
transcription	O
factors	O
increased	O
drought	O
tolerance	O
in	O
rice	O
(	O
Chen	O
et	O
al	O
".,"	O
2008	O
)	O
and	O
Arabidopsis	O
(	O
Xu	O
et	O
al	O
".,"	O
2009	O
).	O
According	O
to	O
our	O
results	O
","	O
miR408a	O
â€	O
3p	O
targeted	O
laccase	O
protein	O
as	O
well	O
as	O
other	O
drought	O
â€	O
related	O
genes	O
GTs	O
and	O
LEA	O
proteins	O
(	O
Table	O
S3	O
).	O
The	O
expression	O
of	O
miR408	O
was	O
decreased	O
after	O
drought	O
treatment	O
.	O
Especially	O
","	O
miR408	O
â€	O
3p	O
was	O
down	O
â€	O
regulated	O
by	O
âˆ’	O
10	O
.	O
9	O
â€	O
fold	O
in	O
root	O
tissues	O
of	O
sensitive	O
genotype	O
and	O
this	O
miRNA	O
was	O
suggested	O
as	O
root	O
specific	O
to	O
sensitive	O
genotype	O
as	O
it	O
was	O
expressed	O
only	O
in	O
root	O
tissues	O
of	O
L	O
.	O
esculentum	O
.	O
Besides	O
","	O
miR408a	O
â€	O
3p	O
expression	O
was	O
decreased	O
by	O
âˆ’	O
1	O
.	O
2	O
â€	O
fold	O
in	O
upground	O
tissues	O
of	O
tolerant	O
genotypes	O
and	O
was	O
suggested	O
as	O
upground	O
specific	O
in	O
L	O
.	O
esculentum	O
var	O
.	O
cerasiforme	O
.	O
High	O
â€	O
level	O
of	O
decrease	O
in	O
miR408	O
â€	O
3p	O
expression	O
in	O
L	O
.	O
esculentum	O
may	O
be	O
the	O
reason	O
of	O
drought	O
sensitivity	O
by	O
comparison	O
with	O
miR408a	O
â€	O
3p	O
expression	O
change	O
in	O
tolerant	O
genotype	O
.	O
The	O
expression	O
of	O
miR9552	O
showed	O
drought	O
"â€,"	O
tissue	O
â€	O
and	O
genotype	O
â€	O
specific	O
pattern	O
.	O
Sly	O
â€	O
miR9552a	O
â€	O
3p	O
was	O
only	O
expressed	O
in	O
the	O
roots	O
of	O
sensitive	O
genotype	O
and	O
induced	O
(	O
12	O
.	O
38	O
â€	O
fold	O
)	O
by	O
drought	O
treatment	O
","	O
whereas	O
repressed	O
(âˆ’	O
14	O
.	O
16	O
â€	O
fold	O
and	O
âˆ’	O
13	O
.	O
64	O
â€	O
fold	O
)	O
in	O
upground	O
tissues	O
of	O
sensitive	O
and	O
tolerant	O
genotypes	O
(	O
Table	O
S2	O
).	O
miR9552	O
targeted	O
SAUR	O
protein	O
whose	O
expression	O
is	O
regulated	O
by	O
auxin	B-Chemical
(	O
Abel	O
and	O
Theologis	O
","	O
1996	O
).	O
Overexpression	O
of	O
SAUR39	O
gene	O
caused	O
the	O
formation	O
of	O
shorter	O
plants	O
with	O
less	O
leaves	O
in	O
rice	O
indicating	O
negative	O
correlation	O
with	O
auxin	B-Chemical
biosynthesis	O
(	O
Kant	O
et	O
al	O
".,"	O
2009	O
).	O
In	O
contrast	O
","	O
overexpression	O
of	O
SAUR19	O
â€	O
24	O
genes	O
led	O
to	O
large	O
leaves	O
and	O
hypocotyls	O
implying	O
cell	O
enlargement	O
and	O
plant	O
growth	O
function	O
of	O
SAUR	O
proteins	O
induced	O
by	O
auxin	B-Chemical
(	O
Spartz	O
et	O
al	O
".,"	O
2012	O
).	O
Biotic	O
and	O
abiotic	O
stress	O
induced	O
the	O
differential	O
expression	O
of	O
SAUR	O
genes	O
.	O
For	O
instance	O
","	O
11	O
randomly	O
selected	O
SAUR	O
genes	O
were	O
expressed	O
in	O
different	O
tomato	O
tissues	O
and	O
mostly	O
down	O
â€	O
regulated	O
by	O
drought	O
treatment	O
(	O
Wu	O
et	O
al	O
".,"	O
2012	O
).	O
However	O
","	O
in	O
our	O
results	O
","	O
SAUR	O
expression	O
was	O
found	O
to	O
be	O
down	O
â€	O
regulated	O
in	O
root	O
tissues	O
","	O
while	O
up	O
â€	O
regulated	O
in	O
upground	O
tissues	O
contrary	O
to	O
miRNA	O
expression	O
profiles	O
indicating	O
tissue	O
â€	O
specific	O
function	O
of	O
drought	O
signalling	O
in	O
tomato	O
.	O
Sly	O
â€	O
miR9552b	O
â€	O
3p	O
was	O
expressed	O
only	O
in	O
root	O
tissues	O
of	O
sensitive	O
genotype	O
under	O
control	O
conditions	O
and	O
suppressed	O
in	O
response	O
to	O
stress	O
treatment	O
","	O
so	O
this	O
miRNA	O
might	O
be	O
suggested	O
as	O
root	O
specific	O
in	O
L	O
.	O
esculentum	O
.	O
One	O
of	O
the	O
predicted	O
targets	O
of	O
this	O
miRNA	O
was	O
UDP	O
â€	O
glucosyltransferase	O
(	O
UGT	O
)	O
(	O
Table	O
S3	O
).	O
Glycosyltransferase	O
enzymes	O
of	O
plants	O
(	O
GTs	O
","	O
EC	O
2	O
.	O
4	O
)	O
function	O
in	O
secondary	O
metabolism	O
and	O
hormone	O
modification	O
catalysing	O
sugar	B-Chemical
addition	O
to	O
acceptor	O
molecules	O
such	O
as	O
auxin	B-Chemical
","	O
ABA	B-Chemical
and	O
flavonoids	B-Chemical
(	O
Bowles	O
et	O
al	O
".,"	O
2005	O
;	O
Tognetti	O
et	O
al	O
".,"	O
2010	O
)	O
and	O
play	O
a	O
role	O
in	O
biotic	O
and	O
abiotic	O
stress	O
tolerance	O
(	O
Vogt	O
and	O
Jones	O
","	O
2000	O
).	O
One	O
of	O
the	O
common	O
glycosyltransferase	O
UGT71C5	O
was	O
investigated	O
for	O
the	O
elucidation	O
of	O
ABA	B-Chemical
impact	O
on	O
drought	O
adaptation	O
in	O
Arabidopsis	O
plants	O
","	O
and	O
when	O
the	O
gene	O
was	O
down	O
â€	O
regulated	O
","	O
drought	O
tolerance	O
increased	O
but	O
decreased	O
after	O
overexpression	O
of	O
UGT71C5	O
(	O
Liu	O
et	O
al	O
".,"	O
2015	O
).	O
These	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
sly	O
â€	O
miR9552b	O
â€	O
3p	O
expression	O
with	O
drought	O
may	O
increase	O
UGT	O
level	O
in	O
roots	O
and	O
decrease	O
drought	O
tolerance	O
in	O
sensitive	O
genotype	O
.	O
Plant	O
hormone	O
signal	O
transduction	O
pathway	O
Plant	O
hormones	O
play	O
a	O
key	O
role	O
in	O
signalling	O
networks	O
involving	O
in	O
plant	O
development	O
and	O
stress	O
response	O
(	O
Golldack	O
et	O
al	O
".,"	O
2014	O
).	O
Different	O
miRNAs	O
regulate	O
the	O
expression	O
of	O
plant	O
hormone	O
â€	O
associated	O
genes	O
in	O
response	O
to	O
different	O
environmental	O
stresses	O
.	O
For	O
example	O
","	O
a	O
stress	O
â€	O
responsive	O
gene	O
ARF	O
which	O
is	O
related	O
with	O
auxin	B-Chemical
signalling	O
was	O
targeted	O
by	O
sly	O
â€	O
miR160	O
","	O
sly	O
â€	O
miR2199	O
and	O
sly	O
â€	O
miR6426	O
in	O
response	O
to	O
drought	O
stress	O
in	O
our	O
study	O
.	O
However	O
","	O
ARF	O
was	O
targeted	O
by	O
miR167	O
after	O
selenium	B-Chemical
treatment	O
in	O
Astragalus	O
(	O
Cakir	O
et	O
al	O
".,"	O
2015	O
).	O
One	O
of	O
the	O
important	O
phytohormones	O
","	O
ABA	B-Chemical
","	O
functions	O
centrally	O
in	O
drought	O
and	O
salinity	O
tolerance	O
regulating	O
main	O
transcriptional	O
processes	O
(	O
Cutler	O
et	O
al	O
".,"	O
2010	O
).	O
The	O
carotenoid	B-Chemical
biosynthesis	O
of	O
plant	O
signal	O
transduction	O
pathway	O
is	O
regulated	O
by	O
ABA	B-Chemical
signals	O
and	O
these	O
signals	O
finally	O
stimulate	O
ABA	O
â€	O
responsive	O
genes	O
regulating	O
the	O
activation	O
/	O
inactivation	O
of	O
type	O
2C	O
protein	O
phosphatases	O
(	O
PP2Cs	O
"),"	O
SNF1	O
â€	O
related	O
protein	O
kinases	O
(	O
SnRK2s	O
)	O
and	O
ABA	O
â€	O
responsive	O
promoter	O
elements	O
binding	O
factors	O
(	O
ABFs	O
)	O
(	O
Golldack	O
et	O
al	O
".,"	O
2014	O
;	O
Ma	O
et	O
al	O
".,"	O
2009	O
;	O
Vlad	O
et	O
al	O
".,"	O
2009	O
).	O
Our	O
results	O
found	O
that	O
PP2C	O
was	O
targeted	O
by	O
5	O
miRNAs	O
such	O
as	O
sly	O
â€	O
miR393a	O
and	O
sly	O
â€	O
miR7696a	O
â€	O
3p	O
(	O
Figures	O
10	O
and	O
11b	O
).	O
miR393	O
was	O
up	O
â€	O
regulated	O
in	O
rice	O
(	O
Zhou	O
et	O
al	O
".,"	O
2010	O
"),"	O
Arabidopsis	O
(	O
Liu	O
et	O
al	O
".,"	O
2008	O
)	O
and	O
wheat	O
(	O
Kantar	O
et	O
al	O
".,"	O
2011	O
"),"	O
while	O
down	O
â€	O
regulated	O
in	O
cotton	O
(	O
Xie	O
et	O
al	O
".,"	O
2015	O
)	O
and	O
peach	O
(	O
Eldem	O
et	O
al	O
".,"	O
2012	O
).	O
Overexpression	O
of	O
miR393	O
led	O
to	O
decrease	O
in	O
drought	O
tolerance	O
affecting	O
growth	O
in	O
rice	O
(	O
Xia	O
et	O
al	O
".,"	O
2012	O
).	O
However	O
","	O
in	O
this	O
study	O
sly	O
â€	O
miR393	O
was	O
down	O
â€	O
regulated	O
in	O
root	O
tissues	O
of	O
sensitive	O
genotype	O
","	O
whereas	O
up	O
â€	O
regulated	O
in	O
upground	O
tissues	O
of	O
drought	O
â€	O
responsive	O
tomato	O
(	O
Table	O
S2	O
).	O
miR7696	O
also	O
targeted	O
ABA	B-Chemical
signalling	O
pathway	O
","	O
whose	O
expression	O
was	O
significantly	O
altered	O
in	O
upground	O
tissues	O
of	O
sensitive	O
and	O
tolerant	O
genotypes	O
and	O
down	O
â€	O
regulated	O
sharply	O
by	O
âˆ’	O
12	O
.	O
33	O
â€	O
fold	O
in	O
sensitive	O
genotype	O
","	O
whereas	O
up	O
â€	O
regulated	O
by	O
12	O
.	O
25	O
â€	O
fold	O
in	O
tolerant	O
genotype	O
after	O
drought	O
exposure	O
.	O
However	O
","	O
this	O
miRNA	O
was	O
expressed	O
higher	O
in	O
root	O
tissues	O
under	O
control	O
conditions	O
(	O
Figure	O
3	O
","	O
Table	O
S2	O
).	O
These	O
results	O
indicate	O
differential	O
regulation	O
of	O
PP2C	O
by	O
several	O
miRNAs	O
in	O
root	O
and	O
upground	O
tissues	O
of	O
drought	O
â€	O
sensitive	O
and	O
tolerant	O
genotypes	O
.	O
Similarly	O
","	O
ABF	O
was	O
targeted	O
by	O
sly	O
â€	O
miR172a	O
/	O
miR172e	O
â€	O
3p	O
and	O
sly	O
â€	O
miR5641	O
(	O
Figures	O
10	O
and	O
11b	O
).	O
When	O
the	O
tomato	O
plants	O
were	O
exposed	O
to	O
drought	O
stress	O
","	O
miR172	O
family	O
expressed	O
significantly	O
only	O
in	O
upground	O
tissues	O
of	O
sensitive	O
genotype	O
and	O
sly	O
â€	O
miR172a	O
and	O
sly	O
â€	O
miR172e	O
â€	O
3p	O
were	O
down	O
â€	O
regulated	O
in	O
response	O
to	O
drought	O
by	O
âˆ’	O
2	O
.	O
1	O
â€	O
and	O
âˆ’	O
1	O
.	O
7	O
â€	O
fold	O
","	O
respectively	O
(	O
Figure	O
3	O
","	O
Table	O
S2	O
).	O
Sly	O
â€	O
miR172	O
expression	O
was	O
decreased	O
after	O
drought	O
treatment	O
in	O
rice	O
(	O
Zhou	O
et	O
al	O
".,"	O
2010	O
"),"	O
barley	O
(	O
Hackenberg	O
et	O
al	O
".,"	O
2015	O
)	O
and	O
cotton	O
(	O
Xie	O
et	O
al	O
".,"	O
2015	O
"),"	O
whereas	O
up	O
â€	O
regulated	O
in	O
Arabidopsis	O
(	O
Jones	O
â€	O
Rhoades	O
and	O
Bartel	O
","	O
2004	O
"),"	O
wheat	O
(	O
Kantar	O
et	O
al	O
".,"	O
2011	O
)	O
and	O
Populus	O
(	O
Ren	O
et	O
al	O
".,"	O
2012	O
).	O
Sly	O
â€	O
miR5641	O
was	O
also	O
down	O
â€	O
regulated	O
by	O
âˆ’	O
4	O
.	O
31	O
â€	O
fold	O
in	O
root	O
tissues	O
of	O
tolerant	O
genotype	O
(	O
Figure	O
3	O
","	O
Table	O
S2	O
).	O
The	O
results	O
show	O
that	O
miR172	O
is	O
different	O
in	O
response	O
to	O
drought	O
among	O
plant	O
species	O
and	O
ABF	O
gene	O
is	O
regulated	O
by	O
different	O
miRNAs	O
in	O
different	O
tissues	O
and	O
genotypes	O
under	O
drought	O
stress	O
.	O
ABA	B-Chemical
usually	O
interacts	O
with	O
gibberellic	B-Chemical
acid	I-Chemical
(	O
GA	B-Chemical
)	O
and	O
jasmonate	B-Chemical
(	O
JA	B-Chemical
)	O
during	O
plant	O
development	O
and	O
response	O
to	O
drought	O
stress	O
(	O
Golldack	O
et	O
al	O
".,"	O
2014	O
).	O
GA	B-Chemical
signalling	O
is	O
controlled	O
by	O
GID1	O
(	O
GIBBERELLIN	O
INSENSITIVE	O
DWARF1	O
)	O
receptors	O
and	O
DELLA	O
proteins	O
","	O
the	O
subgroup	O
of	O
GA	B-Chemical
â€	O
responsive	O
GRAS	O
family	O
transcription	O
factors	O
(	O
Griffiths	O
et	O
al	O
".,"	O
2006	O
;	O
Tyler	O
et	O
al	O
".,"	O
2004	O
).	O
DELLA	O
protein	O
was	O
targeted	O
by	O
12	O
tomato	O
miRNAs	O
containing	O
sly	O
â€	O
miR172	O
","	O
sly	O
â€	O
miR845	O
","	O
sly	O
â€	O
miR5641	O
and	O
sly	O
â€	O
miR7696	O
(	O
Figures	O
10	O
and	O
11b	O
).	O
miR845	O
was	O
expressed	O
differentially	O
in	O
two	O
tissues	O
and	O
genotypes	O
.	O
Sly	O
â€	O
miR845a	O
â€	O
3p	O
was	O
down	O
â€	O
regulated	O
(âˆ’	O
8	O
.	O
86	O
â€	O
fold	O
)	O
in	O
sensitive	O
root	O
tissues	O
","	O
whereas	O
up	O
â€	O
regulated	O
(	O
10	O
.	O
9	O
â€	O
fold	O
)	O
in	O
tolerant	O
roots	O
(	O
Figures	O
3	O
and	O
4b	O
","	O
Table	O
S2	O
).	O
In	O
upground	O
tissues	O
","	O
sly	O
â€	O
miR845a	O
â€	O
3p	O
and	O
miR845b	O
â€	O
5p	O
were	O
down	O
â€	O
regulated	O
(~	O
âˆ’	O
11	O
.	O
0	O
â€	O
fold	O
"),"	O
while	O
miR845a	O
was	O
up	O
â€	O
regulated	O
by	O
8	O
.	O
84	O
â€	O
fold	O
(	O
Figures	O
3	O
and	O
4c	O
","	O
Table	O
S2	O
).	O
The	O
results	O
not	O
only	O
indicate	O
the	O
different	O
regulatory	O
roles	O
of	O
unique	O
miRNA	O
members	O
in	O
different	O
tissues	O
and	O
genotypes	O
","	O
but	O
also	O
show	O
the	O
function	O
of	O
the	O
miRNAs	O
in	O
more	O
than	O
one	O
signalling	O
way	O
.	O
In	O
JA	B-Chemical
signalling	O
","	O
there	O
are	O
three	O
key	O
receptor	O
proteins	O
known	O
as	O
Jasmonate	O
Resistant	O
1	O
(	O
JAR1	O
"),"	O
Jasmonate	O
ZIM	O
Domain	O
(	O
JAZ	O
)	O
and	O
Jasmonate	O
Insensitive	O
1	O
(	O
JIN1	O
","	O
also	O
known	O
as	O
MYC2	O
)	O
(	O
Kazan	O
and	O
Manners	O
","	O
2008	O
).	O
JAR1	O
was	O
targeted	O
by	O
sly	O
â€	O
miR827	O
â€	O
5p	O
(	O
Figures	O
10	O
and	O
11b	O
)	O
whose	O
expression	O
was	O
decreased	O
(âˆ’	O
2	O
.	O
50	O
â€	O
fold	O
)	O
in	O
sensitive	O
upground	O
tissues	O
","	O
while	O
increased	O
(	O
1	O
.	O
2	O
â€	O
fold	O
)	O
in	O
tolerant	O
upground	O
samples	O
in	O
response	O
to	O
dehydration	O
stress	O
(	O
Figures	O
3	O
and	O
4c	O
","	O
Table	O
S2	O
).	O
The	O
root	O
tissues	O
were	O
not	O
affected	O
by	O
drought	O
","	O
but	O
generally	O
miR827	O
â€	O
5p	O
expression	O
was	O
higher	O
in	O
roots	O
(	O
Figure	O
3	O
","	O
Table	O
S2	O
).	O
In	O
same	O
signalling	O
cascade	O
","	O
JAZ	O
receptor	O
was	O
targeted	O
by	O
sly	O
â€	O
miR169a	O
â€	O
5p	O
(	O
Figures	O
10	O
and	O
11b	O
).	O
In	O
our	O
results	O
","	O
sly	O
â€	O
miR169a	O
â€	O
5p	O
expression	O
was	O
decreased	O
in	O
all	O
tissues	O
with	O
drought	O
(	O
Figure	O
4a	O
","	O
b	O
","	O
Table	O
S2	O
).	O
miR169	O
targets	O
Jasmonate	O
ZIM	O
Domain	O
(	O
JAZ	O
)	O
and	O
nuclear	O
transcription	O
factor	O
Y	O
subunit	O
A	O
â€	O
3	O
(	O
NFYA	O
â€	O
3	O
)	O
in	O
tomato	O
fruits	O
(	O
Karlova	O
et	O
al	O
".,"	O
2013	O
)	O
and	O
this	O
is	O
further	O
validated	O
in	O
our	O
study	O
(	O
Table	O
S3	O
).	O
Additionally	O
","	O
sly	O
â€	O
miR169	O
expression	O
was	O
increased	O
in	O
tomato	O
by	O
drought	O
treatment	O
","	O
while	O
three	O
SlNFYA	O
(	O
1	O
/	O
2	O
/	O
3	O
)	O
genes	O
were	O
down	O
â€	O
regulated	O
(	O
Zhang	O
et	O
al	O
".,"	O
2011	O
).	O
Moreover	O
","	O
overexpression	O
of	O
sly	O
â€	O
miR169c	O
caused	O
significantly	O
down	O
â€	O
regulation	O
of	O
tomato	O
target	O
genes	O
and	O
induced	O
the	O
increased	O
drought	O
tolerance	O
of	O
tomato	O
(	O
Zhang	O
et	O
al	O
".,"	O
2011	O
"),"	O
whereas	O
overexpression	O
of	O
miR169a	O
led	O
to	O
drought	O
sensitivity	O
in	O
Arabidopsis	O
plants	O
(	O
Li	O
et	O
al	O
".,"	O
2008b	O
).	O
Our	O
results	O
were	O
similar	O
with	O
Arabidopsis	O
result	O
indicating	O
NFYA	O
up	O
â€	O
regulation	O
by	O
drought	O
in	O
an	O
ABA	B-Chemical
â€	O
dependent	O
manner	O
(	O
Li	O
et	O
al	O
".,"	O
2008b	O
).	O
ABA	B-Chemical
â€	O
dependent	O
signalling	O
of	O
drought	O
results	O
in	O
stomatal	O
closure	O
(	O
Figure	O
10	O
"),"	O
and	O
stomatal	O
closure	O
is	O
the	O
first	O
response	O
of	O
plants	O
to	O
drought	O
stress	O
(	O
Schroeder	O
et	O
al	O
".,"	O
2001	O
).	O
This	O
response	O
is	O
controlled	O
by	O
not	O
only	O
ABA	B-Chemical
","	O
but	O
also	O
interactions	O
of	O
ABA	B-Chemical
with	O
the	O
other	O
phytohormones	O
JA	B-Chemical
","	O
ethylene	B-Chemical
","	O
auxin	B-Chemical
and	O
cytokinine	B-Chemical
(	O
Nemhauser	O
et	O
al	O
".,"	O
2006	O
).	O
ABA	B-Chemical
and	O
JA	B-Chemical
positively	O
regulate	O
the	O
stoma	O
closure	O
","	O
while	O
auxin	B-Chemical
and	O
cytokinine	B-Chemical
regulate	O
negatively	O
and	O
ethylene	B-Chemical
response	O
depends	O
on	O
tissues	O
and	O
stresses	O
(	O
Daszkowska	O
â€	O
Golec	O
and	O
Szarejko	O
","	O
2013	O
;	O
Huang	O
et	O
al	O
".,"	O
2008	O
;	O
Nemhauser	O
et	O
al	O
".,"	O
2006	O
).	O
Excitingly	O
","	O
48	O
miRNAs	O
target	O
plant	O
hormone	O
signal	O
transduction	O
pathway	O
(	O
Figures	O
10	O
and	O
11b	O
).	O
In	O
conclusion	O
","	O
we	O
identified	O
699	O
known	O
miRNAs	O
and	O
the	O
majority	O
of	O
them	O
were	O
expressed	O
significantly	O
in	O
response	O
to	O
drought	O
stress	O
in	O
a	O
tissue	O
â€	O
and	O
genotype	O
â€	O
specific	O
manner	O
.	O
According	O
to	O
the	O
GO	O
and	O
KEGG	O
analyses	O
","	O
the	O
majority	O
of	O
these	O
miRNAs	O
involved	O
in	O
response	O
to	O
hormone	O
stimulus	O
/	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
/	O
water	O
deprivation	O
/	O
salt	O
stress	O
","	O
signal	O
transduction	O
","	O
fruit	O
","	O
shoot	O
","	O
seed	O
and	O
root	O
development	O
(	O
Figures	O
7a	O
and	O
8	O
)	O
and	O
plant	O
â€“	O
pathogen	O
interaction	O
","	O
biosynthesis	O
of	O
plant	O
hormones	O
and	O
plant	O
hormone	O
signal	O
transduction	O
pathways	O
(	O
Figures	O
9	O
and	O
10	O
).	O
Drought	O
â€	O
responsive	O
miRNAs	O
(	O
such	O
as	O
sly	O
â€	O
miR160	O
","	O
sly	O
â€	O
miR165	O
","	O
sly	O
â€	O
miR166	O
","	O
sly	O
â€	O
miR171	O
","	O
sly	O
â€	O
miR398	O
","	O
sly	O
â€	O
miR408	O
","	O
sly	O
â€	O
miR827	O
","	O
sly	O
â€	O
miR9472	O
","	O
sly	O
â€	O
miR9476	O
and	O
sly	O
â€	O
miR9552	O
)	O
regulated	O
drought	O
and	O
development	O
â€	O
associated	O
genes	O
like	O
DRP	O
","	O
HD	O
â€	O
ZIP	O
","	O
MYB	O
","	O
NAC	O
and	O
PSII	O
in	O
root	O
and	O
upground	O
tissues	O
(	O
Figure	O
11a	O
).	O
Likewise	O
","	O
sly	O
â€	O
miR169	O
","	O
sly	O
â€	O
miR172	O
","	O
sly	O
â€	O
miR393	O
","	O
sly	O
â€	O
miR5641	O
","	O
sly	O
â€	O
miR5658	O
and	O
sly	O
â€	O
miR7997	O
function	O
in	O
plant	O
hormone	O
signal	O
transduction	O
pathway	O
and	O
related	O
proteins	O
(	O
Figures	O
10	O
and	O
11b	O
).	O
These	O
results	O
reveal	O
drought	O
â€	O
responsive	O
miRNA	O
profiles	O
of	O
drought	O
â€	O
sensitive	O
and	O
drought	O
â€	O
tolerant	O
tomato	O
genotypes	O
in	O
tissue	O
â€	O
specific	O
pattern	O
and	O
contribute	O
to	O
the	O
development	O
of	O
drought	O
â€	O
tolerant	O
tomato	O
plants	O
.	O
Materials	O
and	O
methods	O
Plant	O
material	O
and	O
drought	O
treatment	O
The	O
seeds	O
of	O
drought	O
â€	O
sensitive	O
(	O
CGN24169	O
:	O
Lycopersicon	O
esculentum	O
","	O
L	O
.	O
M	O
.	O
I	O
â€	O
56	O
)	O
and	O
drought	O
â€	O
tolerant	O
(	O
CGN18399	O
:	O
L	O
.	O
esculentum	O
var	O
.	O
cerasiforme	O
","	O
Tomatillo	O
;	O
PI	O
187002	O
selection	O
1	O
)	O
tomato	O
genotypes	O
were	O
obtained	O
from	O
the	O
Centre	O
for	O
Genetic	O
Resources	O
","	O
The	O
Netherlands	O
(	O
CGN	O
"),"	O
Wageningen	O
University	O
and	O
Research	O
Centre	O
","	O
The	O
Netherlands	O
.	O
The	O
seeds	O
were	O
surface	O
â€	O
sterilized	O
with	O
75	O
%	O
(	O
v	O
/	O
v	O
)	O
ethanol	B-Chemical
for	O
15	O
s	O
","	O
followed	O
by	O
20	O
%	O
bleach	O
(	O
v	O
/	O
v	O
)	O
for	O
15	O
min	O
and	O
washed	O
with	O
sterilized	O
distilled	O
water	B-Chemical
for	O
at	O
least	O
three	O
times	O
.	O
Sterilized	O
seeds	O
were	O
germinated	O
on	O
MS	O
(	O
Murashige	O
and	O
Skoog	O
","	O
1962	O
)	O
medium	O
(	O
pH	O
5	O
.	O
8	O
"),"	O
containing	O
3	O
%	O
sucrose	B-Chemical
and	O
0	O
.	O
8	O
%	O
agar	B-Chemical
in	O
a	O
growth	O
chamber	O
with	O
fluorescent	O
light	O
(~	O
1400	O
/	O
mol2	O
/	O
ms	O
)	O
under	O
16	O
â€	O
h	O
light	O
/	O
8	O
â€	O
h	O
dark	O
cycle	O
at	O
25	O
Â±	O
2	O
Â°	O
C	O
for	O
14	O
days	O
.	O
For	O
drought	O
treatment	O
","	O
14	O
â€	O
day	O
â€	O
old	O
seedlings	O
were	O
exposed	O
to	O
5	O
%	O
polyethylene	B-Chemical
glycol	I-Chemical
for	O
7	O
days	O
.	O
For	O
control	O
and	O
drought	O
treatments	O
","	O
four	O
seeds	O
were	O
germinated	O
in	O
Magenta	O
boxes	O
and	O
the	O
experiments	O
were	O
replicated	O
six	O
times	O
in	O
six	O
individual	O
vessels	O
.	O
After	O
stress	O
treatment	O
for	O
7	O
days	O
","	O
the	O
root	O
and	O
upground	O
tissues	O
were	O
collected	O
from	O
seedlings	O
and	O
immediately	O
frozen	O
in	O
liquid	O
nitrogen	B-Chemical
.	O
The	O
samples	O
were	O
stored	O
at	O
âˆ’	O
80	O
Â°	O
C	O
till	O
RNA	O
extraction	O
.	O
Small	O
RNA	O
library	O
construction	O
and	O
sequencing	O
Total	O
RNAs	O
were	O
extracted	O
from	O
root	O
and	O
upground	O
tissues	O
of	O
drought	O
â€	O
sensitive	O
and	O
tolerant	O
tomato	O
plants	O
using	O
the	O
mirVana	O
â„¢	O
miRNA	O
Isolation	O
Kit	O
(	O
Ambion	O
","	O
Austin	O
","	O
TX	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O
The	O
quality	O
and	O
quantity	O
of	O
RNAs	O
were	O
measured	O
with	O
a	O
NanoDrop	O
ND	O
â€	O
2000	O
spectrophotometer	O
(	O
Thermo	O
Scientific	O
","	O
Wilmington	O
","	O
DE	O
).	O
RNA	O
isolation	O
was	O
carried	O
out	O
individually	O
for	O
each	O
sample	O
with	O
four	O
biological	O
replicates	O
","	O
then	O
the	O
RNAs	O
were	O
sent	O
to	O
BGI	O
(	O
Shenzen	O
","	O
China	O
)	O
for	O
small	O
RNA	O
library	O
construction	O
and	O
high	O
â€	O
throughput	O
sequencing	O
using	O
Illumina	O
HiSeq2000	O
platform	O
.	O
Identification	O
of	O
tomato	O
miRNAs	O
using	O
deep	O
sequencing	O
The	O
raw	O
reads	O
were	O
first	O
cleaned	O
up	O
","	O
including	O
removing	O
adapter	O
sequences	O
and	O
eliminating	O
low	O
â€	O
quality	O
reads	O
.	O
Then	O
","	O
the	O
length	O
distribution	O
of	O
clean	O
reads	O
was	O
categorized	O
to	O
analyse	O
the	O
composition	O
of	O
small	O
RNA	O
data	O
","	O
and	O
16	O
â€	O
to	O
28	O
â€	O
nt	O
â€	O
length	O
small	O
RNAs	O
were	O
used	O
for	O
further	O
analysis	O
.	O
High	O
â€	O
quality	O
clean	O
small	O
RNA	O
tags	O
were	O
mapped	O
to	O
tomato	O
genome	O
(	O
ftp	O
://	O
ftp	O
.	O
solgenomics	O
.	O
net	O
/	O
tomato_genome	O
/	O
annotation	O
/	O
ITAG2	O
.	O
4_release	O
/	O
ITAG2	O
.	O
4_genomic	O
.	O
fasta	O
)	O
by	O
SOAP	O
(	O
short	O
oligonucleotide	B-Chemical
alignment	O
program	O
)	O
to	O
find	O
out	O
their	O
expression	O
and	O
distribution	O
on	O
the	O
genome	O
(	O
Li	O
et	O
al	O
".,"	O
2008a	O
).	O
Then	O
","	O
the	O
matched	O
tags	O
were	O
aligned	O
to	O
NCBI	O
GenBank	O
(	O
http	O
://	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
genbank	O
/)	O
(	O
Benson	O
et	O
al	O
".,"	O
2015	O
)	O
and	O
Rfam	O
11	O
.	O
0	O
(	O
http	O
://	O
rfam	O
.	O
xfam	O
.	O
org	O
/)	O
(	O
Burge	O
et	O
al	O
".,"	O
2013	O
)	O
databases	O
using	O
BLASTall	O
and	O
BLASTn	O
to	O
determine	O
rRNA	O
","	O
tRNA	O
","	O
snRNA	O
and	O
snoRNAs	O
.	O
Following	O
this	O
search	O
","	O
repeat	O
â€	O
containing	O
RNAs	O
","	O
sense	O
and	O
antisense	O
exon	O
and	O
intron	O
sequences	O
were	O
detected	O
","	O
and	O
fully	O
matched	O
all	O
RNA	O
types	O
excluding	O
miRNAs	O
were	O
gotten	O
rid	O
of	O
.	O
Then	O
","	O
for	O
annotation	O
of	O
remaining	O
sequences	O
","	O
conserved	O
miRNAs	O
were	O
mapped	O
to	O
miRBase	O
Release	O
(	O
v21	O
on	O
June	O
26th	O
","	O
2014	O
)	O
database	O
(	O
http	O
://	O
www	O
.	O
mirbase	O
.	O
org	O
/	O
ftp	O
.	O
shtml	O
)	O
(	O
Kozomara	O
and	O
Griffiths	O
â€	O
Jones	O
","	O
2014	O
)	O
and	O
researched	O
for	O
L	O
.	O
esculentum	O
miRNAs	O
.	O
The	O
expression	O
of	O
miRNAs	O
was	O
calculated	O
simultaneously	O
by	O
summing	O
the	O
count	O
of	O
tags	O
overlapping	O
at	O
least	O
16	O
nt	O
and	O
/	O
or	O
two	O
mismatches	O
with	O
aligned	O
known	O
miRNAs	O
in	O
database	O
.	O
DEGseq	O
package	O
was	O
used	O
for	O
differential	O
expression	O
analysis	O
of	O
miRNAs	O
","	O
after	O
normalizing	O
raw	O
read	O
numbers	O
with	O
trimmed	O
mean	O
of	O
M	O
â€	O
values	O
(	O
TMM	O
)	O
normalization	O
method	O
(	O
Robinson	O
and	O
Oshlack	O
","	O
2010	O
;	O
Wang	O
et	O
al	O
".,"	O
2010	O
).	O
For	O
normalization	O
","	O
firstly	O
the	O
normalization	O
factors	O
were	O
calculated	O
and	O
then	O
normalized	O
read	O
numbers	O
were	O
determined	O
using	O
following	O
formula	O
:	O
[	O
raw	O
read	O
counts	O
/(	O
library	O
size	O
Ã—	O
normalization	O
factor	O
)	O
Ã—	O
106	O
]	O
(	O
Bai	O
et	O
al	O
".,"	O
2014	O
).	O
Fold	O
changes	O
were	O
calculated	O
with	O
the	O
formula	O
[	O
log2	O
(	O
normalized	O
read	O
numbers	O
of	O
group2	O
/	O
group1	O
)].	O
Then	O
","	O
for	O
the	O
identification	O
of	O
significantly	O
expressed	O
miRNAs	O
","	O
the	O
criteria	O
were	O
used	O
as	O
if	O
(	O
fold	O
change	O
â‰¥	O
1	O
or	O
â‰¤âˆ’	O
1	O
)	O
and	O
(	O
P	O
or	O
q	O
â€	O
value	O
<	O
0	O
.	O
5	O
)	O
(	O
Storey	O
","	O
2003	O
).	O
To	O
show	O
differential	O
expression	O
profile	O
among	O
drought	O
â€	O
sensitive	O
and	O
drought	O
â€	O
tolerant	O
tomato	O
root	O
and	O
upgrounds	O
","	O
heatmap	O
was	O
constructed	O
for	O
the	O
most	O
abundant	O
130	O
conserved	O
using	O
Qlucore	O
Omics	O
Explorer	O
3	O
.	O
0	O
(	O
Qlucore	O
AB	O
)	O
(	O
http	O
://	O
www	O
.	O
qlucore	O
.	O
com	O
/).	O
Target	O
prediction	O
","	O
GO	O
enrichment	O
and	O
KEGG	O
pathway	O
analysis	O
Significantly	O
expressed	O
miRNAs	O
were	O
used	O
for	O
target	O
prediction	O
using	O
psRNATarget	O
server	O
(	O
http	O
://	O
plantgrn	O
.	O
noble	O
.	O
org	O
/	O
psRNATarget	O
/)	O
with	O
default	O
parameters	O
","	O
including	O
maximum	O
expectation	O
score	O
(	O
3	O
.	O
0	O
"),"	O
length	O
for	O
complementarity	O
(	O
17	O
bp	O
)	O
and	O
range	O
of	O
central	O
mismatch	O
(	O
10	O
â€“	O
11	O
nt	O
)	O
(	O
Dai	O
and	O
Zhao	O
","	O
2011	O
).	O
Solanum	O
lycopersicum	O
(	O
tomato	O
)	O
cDNA	O
library	O
","	O
version	O
2	O
.	O
4	O
(	O
ftp	O
://	O
ftp	O
.	O
solgenomics	O
.	O
net	O
/	O
tomato_genome	O
/	O
annotation	O
/	O
ITAG2	O
.	O
4_release	O
/	O
ITAG2	O
.	O
4_cdna	O
.	O
fasta	O
)	O
was	O
used	O
to	O
predict	O
target	O
genes	O
","	O
and	O
for	O
functional	O
annotation	O
and	O
enrichment	O
analysis	O
of	O
target	O
genes	O
","	O
agriGO	O
(	O
GO	O
Analysis	O
Toolkit	O
and	O
Database	O
for	O
Agricultural	O
Community	O
)	O
web	O
â€	O
based	O
tool	O
was	O
used	O
(	O
Du	O
et	O
al	O
".,"	O
2010	O
).	O
Firstly	O
","	O
the	O
protein	O
sequences	O
of	O
target	O
genes	O
(	O
ftp	O
://	O
ftp	O
.	O
solgenomics	O
.	O
net	O
/	O
tomato_genome	O
/	O
annotation	O
/	O
ITAG2	O
.	O
4_release	O
/	O
ITAG2	O
.	O
4_proteins	O
.	O
fasta	O
)	O
were	O
aligned	O
against	O
Arabidopsis	O
protein	O
sequences	O
(	O
ftp	O
://	O
ftp	O
.	O
arabidopsis	O
.	O
org	O
/	O
home	O
/	O
tair	O
/	O
Sequences	O
/	O
blast_datasets	O
/	O
TAIR10_blastsets	O
/	O
TAIR10_pep_20101214_updated	O
)	O
to	O
find	O
out	O
the	O
homologues	O
.	O
Then	O
","	O
the	O
matched	O
gene	O
list	O
was	O
submitted	O
to	O
agriGO	O
query	O
list	O
as	O
TAIR10	O
locus	O
ID	O
","	O
and	O
GO	O
classification	O
was	O
performed	O
.	O
The	O
enriched	O
GO	O
terms	O
of	O
biological	O
process	O
","	O
molecular	O
function	O
and	O
cellular	O
component	O
categories	O
were	O
visualized	O
with	O
DAGs	O
(	O
directed	O
acyclic	O
hierarchical	O
graph	O
)	O
and	O
bar	O
charts	O
and	O
pathway	O
analyses	O
were	O
performed	O
using	O
KEGG	O
(	O
The	O
Kyoto	O
Encyclopedia	O
of	O
Gene	O
and	O
Genome	O
)	O
database	O
(	O
http	O
://	O
www	O
.	O
genome	O
.	O
jp	O
/	O
kegg	O
/	O
kegg1	O
.	O
html	O
)	O
using	O
target	O
gene	O
IDs	O
as	O
queries	O
(	O
Kanehisa	O
et	O
al	O
".,"	O
2014	O
).	O
The	O
relationship	O
between	O
drought	O
â€	O
responsive	O
miRNAs	O
and	O
their	O
putative	O
targets	O
was	O
visualized	O
using	O
Cytoscape	O
network	O
platform	O
(	O
Saito	O
et	O
al	O
".,"	O
2012	O
).	O
Validation	O
of	O
miRNA	O
expressions	O
with	O
qRT	O
â€	O
PCR	O
analysis	O
Total	O
RNAs	O
of	O
tolerant	O
root	O
tissues	O
belonging	O
to	O
drought	O
â€	O
treated	O
and	O
control	O
samples	O
isolated	O
for	O
deep	O
sequencing	O
were	O
used	O
to	O
validate	O
miRNA	O
expression	O
results	O
.	O
Firstly	O
","	O
stem	O
â€	O
loop	O
reverse	O
transcription	O
(	O
RT	O
)	O
was	O
carried	O
out	O
using	O
TaqMan	O
Â®	O
MicroRNA	O
Reverse	O
Transcription	O
Kit	O
(	O
Applied	O
Biosystems	O
","	O
Foster	O
City	O
","	O
CA	O
).	O
A	O
total	O
of	O
15	O
Î¼L	O
RT	O
reaction	O
contained	O
1	O
mm	O
dNTPs	O
with	O
dTTP	O
","	O
1	O
Ã—	O
RT	O
buffer	O
","	O
50U	O
MultiScribe	O
â„¢	O
Reverse	O
Transcriptase	O
","	O
3	O
.	O
8U	O
RNase	O
inhibitor	O
and	O
500	O
ng	O
total	O
RNAs	O
and	O
nuclease	O
â€	O
free	O
water	B-Chemical
.	O
Also	O
1	O
.	O
3	O
Î¼m	O
miRNA	O
â€	O
specific	O
stem	O
â€	O
loop	O
RT	O
primers	O
were	O
used	O
to	O
generate	O
single	O
â€	O
stranded	O
cDNA	O
for	O
miRNAs	O
(	O
Table	O
S6	O
).	O
The	O
following	O
temperature	O
program	O
was	O
used	O
to	O
perform	O
RT	O
reaction	O
as	O
30	O
min	O
at	O
16	O
Â°	O
C	O
","	O
30	O
min	O
at	O
42	O
Â°	O
C	O
","	O
5	O
min	O
at	O
85	O
Â°	O
C	O
","	O
and	O
then	O
holding	O
at	O
4	O
Â°	O
C	O
.	O
Before	O
quantitative	O
real	O
â€	O
time	O
PCR	O
(	O
qRT	O
â€	O
PCR	O
"),"	O
the	O
cDNAs	O
were	O
diluted	O
in	O
100	O
Î¼L	O
DNase	O
/	O
RNase	O
â€	O
free	O
water	B-Chemical
.	O
Eight	O
miRNAs	O
(	O
sly	O
â€	O
miR156a	O
â€	O
5p	O
","	O
sly	O
â€	O
miR169e	O
â€	O
3p	O
","	O
sly	O
â€	O
miR172a	O
","	O
sly	O
â€	O
miR393a	O
â€	O
5p	O
","	O
sly	O
â€	O
miR399a	O
â€	O
5p	O
","	O
sly	O
â€	O
miR408b	O
â€	O
5p	O
","	O
sly	O
â€	O
miR482d	O
â€	O
3p	O
and	O
sly	O
â€	O
miR9472	O
â€	O
5p	O
)	O
were	O
randomly	O
selected	O
","	O
and	O
specific	O
forward	O
primers	O
and	O
universal	O
reverse	O
primer	O
were	O
designed	O
to	O
amplify	O
the	O
miRNAs	O
(	O
Table	O
S6	O
).	O
qRT	O
â€	O
PCRs	O
were	O
carried	O
out	O
using	O
2	O
Ã—	O
SensiFAST	O
SYBR	O
Â®	O
Hi	O
â€	O
ROX	O
mix	O
(	O
Bioline	O
","	O
Taunton	O
","	O
MA	O
)	O
on	O
a	O
Applied	O
Biosystems	O
7300	O
Real	O
â€	O
Time	O
PCR	O
System	O
.	O
Briefly	O
","	O
each	O
20	O
Î¼L	O
reactions	O
contained	O
10	O
Î¼L	O
SensiFAST	O
mix	O
","	O
6	O
Î¼L	O
nuclease	O
â€	O
free	O
water	B-Chemical
","	O
2	O
Î¼L	O
cDNA	O
product	O
and	O
2	O
Î¼L	O
primer	O
mix	O
.	O
The	O
reactions	O
were	O
performed	O
with	O
the	O
following	O
temperature	O
program	O
:	O
10	O
min	O
at	O
95	O
Â°	O
C	O
for	O
enzyme	O
activation	O
","	O
40	O
cycles	O
of	O
15	O
s	O
at	O
95	O
Â°	O
C	O
for	O
denaturation	O
and	O
60	O
s	O
at	O
60	O
Â°	O
C	O
for	O
annealing	O
/	O
extension	O
","	O
followed	O
by	O
a	O
dissociation	O
step	O
for	O
1	O
cycle	O
of	O
95	O
Â°	O
C	O
for	O
15	O
s	O
","	O
60	O
Â°	O
C	O
for	O
60	O
s	O
","	O
95	O
Â°	O
C	O
for	O
15	O
s	O
and	O
60	O
Â°	O
C	O
for	O
15	O
s	O
.	O
Three	O
technical	O
replicates	O
for	O
each	O
biological	O
reactions	O
and	O
three	O
biological	O
replicates	O
were	O
performed	O
for	O
root	O
tissues	O
of	O
tolerant	O
genotype	O
.	O
Actin	O
â€	O
7	O
gene	O
was	O
used	O
for	O
normalization	O
of	O
qRT	O
â€	O
PCR	O
data	O
.	O
The	O
fold	O
changes	O
were	O
calculated	O
using	O
2	O
â€(	O
Î”Î”Ct	O
)	O
values	O
","	O
and	O
relative	O
expressions	O
were	O
shown	O
as	O
log2	O
fold	O
changes	O
.	O
Degradome	O
library	O
construction	O
","	O
sequencing	O
and	O
data	O
analysis	O
For	O
degradome	O
sequencing	O
","	O
the	O
RNAs	O
were	O
first	O
pooled	O
from	O
all	O
samples	O
at	O
a	O
same	O
amount	O
.	O
Firstly	O
","	O
polyadenylated	O
RNAs	O
were	O
isolated	O
with	O
oligo	B-Chemical
â€	I-Chemical
d	I-Chemical
(	I-Chemical
T	I-Chemical
)	I-Chemical
bead	O
extraction	O
.	O
Then	O
","	O
MmeI	O
recognition	O
site	O
carrying	O
5	O
â€²â€	O
RNA	O
adapter	O
was	O
ligated	O
to	O
5	O
â€²â€	O
end	O
that	O
has	O
mRNA	O
fragments	O
of	O
miRNA	O
â€	O
induced	O
cleavage	O
.	O
Afterwards	O
","	O
the	O
fragments	O
were	O
converted	O
to	O
cDNA	O
by	O
reverse	O
transcription	O
and	O
amplified	O
by	O
PCR	O
(	O
German	O
et	O
al	O
".,"	O
2009	O
).	O
The	O
PCR	O
products	O
of	O
degradome	O
library	O
were	O
sequenced	O
on	O
Illumina	O
HiSeq2000	O
sequencing	O
system	O
","	O
and	O
the	O
adapter	O
sequences	O
","	O
low	O
â€	O
quality	O
reads	O
and	O
N	O
â€	O
containing	O
fragments	O
were	O
filtered	O
from	O
the	O
raw	O
reads	O
.	O
After	O
preprocessing	O
","	O
sRNAs	O
were	O
eliminated	O
by	O
Genbank	O
and	O
Rfam	O
11	O
.	O
0	O
databases	O
","	O
and	O
then	O
KEGG	O
(	O
Kanehisa	O
et	O
al	O
".,"	O
2014	O
)	O
and	O
NR	O
(	O
nonredundant	O
)	O
(	O
ftp	O
://	O
ftp	O
.	O
ncbi	O
.	O
nih	O
.	O
gov	O
/	O
blast	O
/	O
db	O
/	O
FASTA	O
/	O
nr	O
.	O
gz	O
)	O
databases	O
were	O
used	O
for	O
the	O
annotation	O
of	O
cleaved	O
target	O
genes	O
.	O
Then	O
","	O
clean	O
tags	O
were	O
matched	O
to	O
the	O
tomato	O
genome	O
(	O
ITAG2	O
.	O
4	O
Release	O
cDNA	O
library	O
)	O
by	O
SOAP2	O
.	O
20	O
(	O
Li	O
et	O
al	O
".,"	O
2009	O
)	O
with	O
allowing	O
only	O
two	O
mismatches	O
","	O
and	O
with	O
the	O
classification	O
of	O
clean	O
tags	O
","	O
the	O
sense	O
strand	O
of	O
tomato	O
cDNA	O
library	O
were	O
used	O
to	O
predict	O
miRNA	O
cleavage	O
sites	O
using	O
CleaveLand	O
v3	O
.	O
0	O
.	O
1	O
(	O
August	O
26	O
","	O
2011	O
)	O
pipeline	O
(	O
Addo	O
â€	O
Quaye	O
et	O
al	O
".,"	O
2009	O
).	O
The	O
potential	O
targets	O
of	O
miRNAs	O
were	O
analysed	O
by	O
PAREsnip	O
software	O
with	O
P	O
â€	O
value	O
<	O
0	O
.	O
5	O
(	O
Folkes	O
et	O
al	O
".,"	O
2012	O
"),"	O
and	O
T	O
â€	O
plot	O
figures	O
were	O
drawn	O
.	O
Supporting	O
information	O
References	O
The	O
Vesicle	O
Priming	O
Factor	O
CAPS	O
Functions	O
as	O
a	O
Homodimer	O
via	O
C2	O
Domain	O
Interactions	O
to	O
Promote	O
Regulated	O
Vesicle	O
Exocytosis	O
*	O
Neurotransmitters	O
and	O
peptide	O
hormones	O
are	O
secreted	O
by	O
regulated	O
vesicle	O
exocytosis	O
.	O
CAPS	O
(	O
also	O
known	O
as	O
CADPS	O
)	O
is	O
a	O
145	O
-	O
kDa	O
cytosolic	O
and	O
peripheral	O
membrane	O
protein	O
required	O
for	O
vesicle	O
docking	O
and	O
priming	O
steps	O
that	O
precede	O
Ca2	B-Chemical
+-	I-Chemical
triggered	O
vesicle	O
exocytosis	O
.	O
CAPS	O
binds	O
phosphatidylinositol	B-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
bisphosphate	I-Chemical
(	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
)	O
and	O
SNARE	O
proteins	O
and	O
is	O
proposed	O
to	O
promote	O
SNARE	O
protein	O
complex	O
assembly	O
for	O
vesicle	O
docking	O
and	O
priming	O
.	O
We	O
characterized	O
purified	O
soluble	O
CAPS	O
as	O
mainly	O
monomer	O
in	O
equilibrium	O
with	O
small	O
amounts	O
of	O
dimer	O
.	O
However	O
","	O
the	O
active	O
form	O
of	O
CAPS	O
bound	O
to	O
PC12	O
cell	O
membranes	O
or	O
to	O
liposomes	O
containing	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
and	O
Q	O
-	O
SNARE	O
proteins	O
was	O
mainly	O
dimer	O
.	O
CAPS	O
dimer	O
formation	O
required	O
its	O
C2	O
domain	O
based	O
on	O
mutation	O
or	O
deletion	O
studies	O
.	O
Moreover	O
","	O
C2	O
domain	O
mutations	O
or	O
deletions	O
resulted	O
in	O
a	O
loss	O
of	O
CAPS	O
function	O
in	O
regulated	O
vesicle	O
exocytosis	O
","	O
indicating	O
that	O
dimerization	O
is	O
essential	O
for	O
CAPS	O
function	O
.	O
Comparison	O
of	O
the	O
CAPS	O
C2	O
domain	O
to	O
a	O
structurally	O
defined	O
Munc13	O
-	O
1	O
C2A	O
domain	O
dimer	O
revealed	O
conserved	O
residues	O
involved	O
in	O
CAPS	O
dimerization	O
.	O
We	O
conclude	O
that	O
CAPS	O
functions	O
as	O
a	O
C2	O
domain	O
-	O
mediated	O
dimer	O
in	O
regulated	O
vesicle	O
exocytosis	O
.	O
The	O
unique	O
tandem	O
C2	O
-	O
PH	O
domain	O
of	O
CAPS	O
may	O
serve	O
as	O
a	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
-	O
triggered	O
switch	O
for	O
dimerization	O
.	O
CAPS	O
dimerization	O
may	O
be	O
coupled	O
to	O
oligomeric	O
SNARE	O
complex	O
assembly	O
for	O
vesicle	O
docking	O
and	O
priming	O
.	O
Introduction	O
In	O
regulated	O
exocytosis	O
","	O
vesicles	O
fuse	O
with	O
the	O
plasma	O
membrane	O
in	O
response	O
to	O
Ca2	B-Chemical
+	I-Chemical
elevations	O
","	O
releasing	O
cargo	O
such	O
as	O
peptide	O
hormones	O
or	O
neurotransmitters	O
to	O
the	O
extracellular	O
space	O
.	O
CAPS3	O
(	O
also	O
known	O
as	O
CAPS	O
-	O
1	O
","	O
CADPS	O
","	O
and	O
Unc	O
-	O
31p	O
)	O
was	O
discovered	O
by	O
its	O
activity	O
in	O
promoting	O
Ca2	B-Chemical
+-	I-Chemical
triggered	O
dense	O
core	O
vesicle	O
exocytosis	O
in	O
permeable	O
neuroendocrine	O
cells	O
(	O
1	O
","	O
2	O
).	O
Subsequent	O
studies	O
demonstrated	O
the	O
essential	O
role	O
of	O
CAPS	O
in	O
the	O
docking	O
and	O
priming	O
of	O
dense	O
core	O
vesicles	O
and	O
synaptic	O
vesicles	O
in	O
endocrine	O
and	O
neural	O
cells	O
(	O
3	O
â€“	O
14	O
).	O
CAPS	O
proteins	O
contain	O
at	O
least	O
three	O
important	O
functional	O
domains	O
corresponding	O
to	O
the	O
C2	O
domain	O
","	O
pleckstrin	O
homology	O
(	O
PH	O
)	O
domain	O
","	O
and	O
Munc13	O
homology	O
domain	O
1	O
(	O
MHD1	O
)	O
(	O
Fig	O
.	O
6A	O
)	O
(	O
15	O
).	O
Based	O
on	O
sequence	O
homology	O
in	O
C	O
-	O
terminal	O
regions	O
","	O
CAPS	O
is	O
a	O
member	O
of	O
a	O
CATCHR	O
(	O
complexes	O
associated	O
with	O
tethering	O
containing	O
helical	O
rods	O
)	O
family	O
of	O
tethering	O
/	O
priming	O
proteins	O
that	O
operate	O
at	O
various	O
stages	O
in	O
the	O
secretory	O
pathway	O
(	O
16	O
â€“	O
18	O
).	O
Munc13	O
-	O
1	O
/	O
2	O
proteins	O
in	O
this	O
family	O
function	O
similarly	O
to	O
CAPS	O
but	O
non	O
-	O
redundantly	O
at	O
priming	O
steps	O
in	O
vesicle	O
exocytosis	O
(	O
3	O
","	O
7	O
","	O
12	O
","	O
19	O
","	O
21	O
).	O
The	O
three	O
annotated	O
CAPS	O
domains	O
are	O
important	O
for	O
activity	O
in	O
regulated	O
vesicle	O
exocytosis	O
.	O
The	O
C2	O
domain	O
of	O
CAPS	O
is	O
essential	O
for	O
nervous	O
system	O
function	O
in	O
Caenorhabditis	O
elegans	O
indicated	O
by	O
the	O
uncoordinated	O
phenotype	O
of	O
unc	O
-	O
31	O
(	O
e714	O
)	O
and	O
unc	O
-	O
31	O
(	O
ox299	O
)	O
strains	O
that	O
harbor	O
point	O
mutations	O
in	O
the	O
C2	O
domain	O
of	O
the	O
conserved	O
worm	O
CAPS	O
ortholog	O
UNC	O
-	O
31p	O
(	O
22	O
).	O
The	O
exact	O
role	O
of	O
the	O
C2	O
domain	O
in	O
CAPS	O
function	O
was	O
unknown	O
and	O
is	O
revealed	O
in	O
the	O
current	O
study	O
.	O
The	O
adjacent	O
PH	O
domain	O
of	O
CAPS	O
has	O
been	O
characterized	O
as	O
a	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
-	O
binding	O
domain	O
required	O
for	O
CAPS	O
activity	O
in	O
supporting	O
regulated	O
exocytosis	O
in	O
cells	O
and	O
for	O
enabling	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
-	O
and	O
SNARE	O
-	O
dependent	O
liposome	O
fusion	O
(	O
4	O
","	O
19	O
","	O
23	O
â€“	O
25	O
).	O
The	O
PH	O
and	O
C2	O
domains	O
of	O
CAPS	O
are	O
closely	O
adjacent	O
(	O
Fig	O
.	O
6A	O
)	O
and	O
could	O
exhibit	O
mutual	O
regulation	O
as	O
in	O
other	O
tandem	O
domain	O
proteins	O
(	O
26	O
).	O
Last	O
","	O
CAPS	O
interacts	O
with	O
Q	O
-	O
SNAREs	O
(	O
syntaxin	O
-	O
1	O
and	O
SNAP	O
-	O
25	O
)	O
and	O
","	O
at	O
lower	O
affinity	O
","	O
with	O
the	O
R	O
-	O
SNARE	O
(	O
VAMP2	O
)	O
that	O
comprise	O
the	O
neuronal	O
SNARE	O
complex	O
(	O
27	O
).	O
SNARE	O
binding	O
by	O
CAPS	O
is	O
mediated	O
by	O
MHD1	O
or	O
more	O
C	O
-	O
terminal	O
domains	O
within	O
the	O
CATCHR	O
region	O
(	O
15	O
","	O
28	O
).	O
Current	O
models	O
for	O
function	O
in	O
vesicle	O
exocytosis	O
suggest	O
that	O
CAPS	O
on	O
dense	O
core	O
vesicles	O
(	O
3	O
)	O
engages	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
and	O
Q	O
-	O
SNAREs	O
on	O
the	O
plasma	O
membrane	O
via	O
its	O
PH	O
and	O
MHD1	O
domains	O
","	O
respectively	O
","	O
to	O
promote	O
SNARE	O
complex	O
assembly	O
for	O
vesicle	O
docking	O
and	O
priming	O
(	O
17	O
","	O
29	O
).	O
CAPS	O
promotes	O
the	O
formation	O
of	O
dimers	O
of	O
SNARE	O
complexes	O
on	O
liposomes	O
","	O
but	O
it	O
was	O
unclear	O
whether	O
this	O
was	O
mediated	O
by	O
the	O
dimerization	O
of	O
CAPS	O
(	O
23	O
","	O
30	O
).	O
Early	O
hydrodynamic	O
studies	O
of	O
partially	O
purified	O
protein	O
suggested	O
that	O
CAPS	O
was	O
a	O
dimer	O
(	O
2	O
).	O
However	O
","	O
three	O
protein	O
bands	O
were	O
identified	O
in	O
native	O
gel	O
electrophoresis	O
of	O
purified	O
CAPS	O
","	O
but	O
the	O
oligomerization	O
state	O
of	O
these	O
CAPS	O
forms	O
was	O
not	O
established	O
(	O
31	O
).	O
Here	O
we	O
report	O
that	O
purified	O
soluble	O
recombinant	O
CAPS	O
is	O
in	O
monomer	O
-	O
dimer	O
equilibrium	O
favoring	O
the	O
monomer	O
but	O
that	O
the	O
membrane	O
-	O
bound	O
active	O
form	O
of	O
CAPS	O
is	O
a	O
dimer	O
.	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
and	O
Q	O
-	O
SNARE	O
interactions	O
stabilize	O
the	O
CAPS	O
dimer	O
.	O
The	O
role	O
of	O
the	O
CAPS	O
C2	O
domain	O
in	O
mediating	O
homodimerization	O
was	O
revealed	O
by	O
studies	O
of	O
the	O
mammalian	O
counterparts	O
of	O
unc	O
-	O
31	O
C2	O
domain	O
mutants	O
(	O
22	O
)	O
and	O
a	O
C2	O
domain	O
deletion	O
that	O
exhibit	O
altered	O
dimer	O
formation	O
and	O
loss	O
of	O
function	O
in	O
vesicle	O
exocytosis	O
.	O
Last	O
","	O
analysis	O
suggests	O
that	O
CAPS	O
dimerizes	O
similarly	O
to	O
Munc13	O
-	O
1	O
/	O
2	O
using	O
conserved	O
homodimerization	O
residues	O
in	O
its	O
C2	O
domain	O
.	O
Results	O
Biochemical	O
Characterization	O
of	O
CAPS	O
Oligomerization	O
We	O
reported	O
that	O
native	O
CAPS	O
is	O
a	O
dimer	O
","	O
but	O
this	O
analysis	O
was	O
conducted	O
with	O
partially	O
purified	O
protein	O
using	O
indirect	O
hydrodynamic	O
criteria	O
(	O
2	O
).	O
However	O
","	O
a	O
reassessment	O
of	O
oligomerization	O
with	O
a	O
highly	O
purified	O
active	O
recombinant	O
CAPS	O
-	O
Myc	O
-	O
His	O
protein	O
(	O
32	O
)	O
indicated	O
that	O
the	O
protein	O
migrated	O
in	O
blue	O
native	O
gel	O
electrophoresis	O
as	O
a	O
major	O
350	O
-	O
kDa	O
and	O
a	O
minor	O
700	O
kDa	O
band	O
(	O
Fig	O
.	O
1A	O
).	O
Treatment	O
of	O
the	O
protein	O
with	O
SDS	B-Chemical
","	O
which	O
was	O
effective	O
at	O
disassembling	O
oligomeric	O
molecular	O
mass	O
standards	O
","	O
collapsed	O
the	O
700	O
-	O
kDa	O
but	O
not	O
the	O
350	O
-	O
kDa	O
form	O
of	O
the	O
protein	O
(	O
Fig	O
.	O
1B	O
).	O
This	O
suggested	O
that	O
the	O
350	O
kDa	O
band	O
corresponds	O
to	O
a	O
monomer	O
","	O
whereas	O
the	O
700	O
-	O
kDa	O
band	O
is	O
an	O
oligomer	O
.	O
Consistent	O
with	O
this	O
","	O
zero	O
length	O
cross	O
-	O
linking	O
partially	O
converted	O
the	O
CAPS	O
-	O
Myc	O
-	O
His	O
monomer	O
to	O
an	O
oligomer	O
that	O
resisted	O
SDS	B-Chemical
-	O
induced	O
disassembly	O
(	O
Fig	O
.	O
1C	O
).	O
The	O
minor	O
amounts	O
(âˆ¼	O
6	O
%)	O
of	O
oligomer	O
in	O
CAPS	O
-	O
Myc	O
-	O
His	O
(	O
n	O
=	O
27	O
)	O
did	O
not	O
differ	O
significantly	O
from	O
that	O
detected	O
in	O
native	O
cytosolic	O
CAPS	O
(	O
n	O
=	O
11	O
"),"	O
indicating	O
that	O
epitope	O
tags	O
were	O
not	O
responsible	O
for	O
oligomer	O
formation	O
(	O
e	O
.	O
g	O
.	O
see	O
Fig	O
.	O
4C	O
).	O
The	O
molecular	O
mass	O
of	O
CAPS	O
-	O
Myc	O
-	O
His	O
on	O
SDS	B-Chemical
-	O
PAGE	O
is	O
âˆ¼	O
145	O
kDa	O
","	O
which	O
indicates	O
that	O
the	O
350	O
-	O
kDa	O
CAPS	O
-	O
Myc	O
-	O
His	O
form	O
in	O
blue	O
native	O
gels	O
migrates	O
as	O
a	O
non	O
-	O
globular	O
protein	O
with	O
an	O
oblate	O
shape	O
.	O
To	O
assess	O
its	O
native	O
molecular	O
mass	O
independent	O
of	O
shape	O
","	O
purified	O
CAPS	O
-	O
Myc	O
-	O
His	O
was	O
analyzed	O
by	O
analytical	O
equilibrium	O
ultracentrifugation	O
","	O
which	O
showed	O
that	O
the	O
major	O
species	O
of	O
soluble	O
CAPS	O
-	O
Myc	O
-	O
His	O
is	O
a	O
âˆ¼	O
150	O
-	O
kDa	O
monomer	O
(	O
Fig	O
.	O
1D	O
).	O
Minor	O
amounts	O
of	O
a	O
higher	O
molecular	O
weight	O
oligomer	O
(	O
s	O
)	O
were	O
not	O
well	O
resolved	O
by	O
this	O
method	O
.	O
Soluble	O
CAPS	O
is	O
predominantly	O
monomeric	O
.	O
A	O
","	O
BN	O
-	O
PAGE	O
(	O
blue	O
native	O
gel	O
","	O
6	O
â€“	O
14	O
%)	O
of	O
NativeMarkTM	O
protein	O
ladder	O
and	O
purified	O
recombinant	O
CAPS	O
-	O
Myc	O
-	O
His	O
","	O
representative	O
of	O
eight	O
similar	O
analyses	O
.	O
B	O
","	O
Western	O
blot	O
(	O
Î±	O
-	O
CAPS	O
)	O
from	O
BN	O
-	O
PAGE	O
of	O
purified	O
CAPS	O
-	O
Myc	O
-	O
His	O
without	O
or	O
with	O
2	O
%	O
SDS	B-Chemical
(	O
left	O
)	O
and	O
NativeMarkTM	O
protein	O
ladder	O
without	O
or	O
with	O
2	O
%	O
SDS	B-Chemical
(	O
right	O
"),"	O
representative	O
of	O
three	O
similar	O
analyses	O
.	O
C	O
","	O
Western	O
blot	O
(	O
Î±	O
-	O
CAPS	O
)	O
of	O
purified	O
CAPS	O
-	O
Myc	O
-	O
His	O
from	O
CN	O
-	O
PAGE	O
(	O
clear	O
native	O
gel	O
)	O
without	O
or	O
with	O
2	O
%	O
SDS	B-Chemical
and	O
with	O
2	O
%	O
SDS	B-Chemical
following	O
CAPS	O
cross	O
-	O
linking	O
with	O
0	O
.	O
5	O
mm	O
1	B-Chemical
-	I-Chemical
ethyl	I-Chemical
-	I-Chemical
3	I-Chemical
-(	I-Chemical
3	I-Chemical
-	I-Chemical
dimethylaminopropyl	I-Chemical
)	I-Chemical
carbodiimide	I-Chemical
and	O
1	O
.	O
25	O
mm	O
sulfo	B-Chemical
-	I-Chemical
NHS	I-Chemical
for	O
2	O
h	O
at	O
room	O
temperature	O
","	O
representative	O
of	O
two	O
similar	O
studies	O
.	O
Arrows	O
","	O
high	O
mobility	O
CAPS	O
-	O
Myc	O
-	O
His	O
monomer	O
and	O
low	O
mobility	O
CAPS	O
-	O
Myc	O
-	O
His	O
oligomer	O
.	O
D	O
","	O
sedimentation	O
equilibrium	O
data	O
from	O
analytical	O
ultracentrifugation	O
of	O
CAPS	O
.	O
Raw	O
data	O
(	O
squares	O
)	O
are	O
shown	O
for	O
three	O
different	O
speeds	O
(	O
3600	O
(	O
blue	O
"),"	O
6000	O
(	O
green	O
"),"	O
and	O
8800	O
(	O
red	O
)	O
rpm	O
)	O
with	O
three	O
different	O
loading	O
concentrations	O
for	O
each	O
speed	O
.	O
Fits	O
(	O
black	O
lines	O
)	O
were	O
derived	O
from	O
a	O
non	O
-	O
interconverting	O
two	O
-	O
species	O
model	O
where	O
the	O
observed	O
molecular	O
weight	O
/	O
monomer	O
molecular	O
weight	O
for	O
each	O
species	O
is	O
âˆ¼	O
1	O
.	O
0	O
and	O
âˆ¼	O
14	O
","	O
corresponding	O
to	O
monomer	O
and	O
higher	O
molecular	O
weight	O
unresolved	O
components	O
","	O
respectively	O
.	O
Gel	O
filtration	O
studies	O
indicated	O
that	O
the	O
dominant	O
form	O
of	O
CAPS	O
-	O
Myc	O
-	O
His	O
migrates	O
with	O
a	O
Stokes	O
radius	O
(	O
RS	O
)	O
of	O
âˆ¼	O
59	O
â„«	O
similar	O
to	O
a	O
350	O
-	O
kDa	O
globular	O
protein	O
(	O
Fig	O
.	O
2A	O
).	O
This	O
is	O
consistent	O
with	O
a	O
moderately	O
elongated	O
145	O
-	O
kDa	O
monomer	O
with	O
an	O
RS	O
/	O
Rmin	O
value	O
of	O
âˆ¼	O
1	O
.	O
7	O
(	O
33	O
).	O
The	O
0	O
.	O
17	O
Kav	O
monomer	O
fractions	O
from	O
gel	O
filtration	O
analyzed	O
by	O
native	O
gels	O
contained	O
ratios	O
of	O
monomer	O
to	O
oligomer	O
similar	O
to	O
the	O
input	O
","	O
indicating	O
that	O
gel	O
-	O
filtered	O
monomer	O
partially	O
converts	O
to	O
oligomer	O
(	O
Fig	O
.	O
2A	O
).	O
Long	O
exposure	O
of	O
the	O
Western	O
blot	O
revealed	O
oligomer	O
in	O
the	O
0	O
.	O
6	O
â€“	O
0	O
.	O
12	O
Kav	O
fractions	O
(	O
Fig	O
.	O
2B	O
"),"	O
but	O
analysis	O
of	O
these	O
fractions	O
1	O
day	O
later	O
showed	O
substantial	O
conversion	O
to	O
monomer	O
(	O
Fig	O
.	O
2C	O
).	O
We	O
conclude	O
that	O
soluble	O
CAPS	O
-	O
Myc	O
-	O
His	O
is	O
in	O
dynamic	O
monomer	O
-	O
oligomer	O
equilibrium	O
favoring	O
monomer	O
.	O
Oligomeric	O
forms	O
of	O
CAPS	O
are	O
in	O
dynamic	O
equilibrium	O
.	O
A	O
","	O
gel	O
filtration	O
of	O
CAPS	O
-	O
Myc	O
-	O
His	O
detected	O
by	O
Western	O
blot	O
of	O
CN	O
-	O
PAGE	O
.	O
Input	O
to	O
the	O
column	O
is	O
indicated	O
.	O
The	O
column	O
was	O
calibrated	O
by	O
the	O
elution	O
of	O
aldolase	O
","	O
ferritin	O
","	O
and	O
thyroglobulin	O
.	O
0	O
.	O
16	O
â€“	O
0	O
.	O
19	O
Kav	O
fractions	O
correspond	O
to	O
CAPS	O
monomer	O
.	O
B	O
","	O
longer	O
exposure	O
of	O
Western	O
blot	O
of	O
0	O
.	O
6	O
â€“	O
0	O
.	O
12	O
Kav	O
fractions	O
to	O
detect	O
oligomer	O
.	O
Gel	O
analysis	O
was	O
conducted	O
immediately	O
after	O
gel	O
filtration	O
.	O
C	O
","	O
Western	O
blot	O
of	O
0	O
.	O
11	O
and	O
0	O
.	O
12	O
Kav	O
fractions	O
kept	O
on	O
ice	O
for	O
24	O
h	O
after	O
gel	O
filtration	O
.	O
Purified	O
oligomer	O
partially	O
dissociated	O
to	O
monomer	O
.	O
Results	O
shown	O
are	O
representative	O
of	O
two	O
replicate	O
studies	O
.	O
Atomic	O
Force	O
and	O
Single	O
Molecule	O
Microscopy	O
To	O
further	O
assess	O
the	O
oligomerization	O
state	O
of	O
CAPS	O
","	O
we	O
employed	O
atomic	O
force	O
microscopy	O
(	O
AFM	O
)	O
and	O
single	O
-	O
molecule	O
microscopy	O
.	O
AFM	O
measures	O
protein	O
volume	O
and	O
can	O
be	O
used	O
to	O
determine	O
oligomer	O
stoichiometry	O
(	O
34	O
).	O
The	O
volume	O
of	O
CAPS	O
-	O
Myc	O
-	O
His	O
was	O
measured	O
after	O
drying	O
directly	O
onto	O
mica	B-Chemical
or	O
after	O
it	O
was	O
added	O
to	O
a	O
supported	O
lipid	O
bilayer	O
(	O
SLB	O
)	O
on	O
mica	B-Chemical
with	O
or	O
without	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
.	O
The	O
majority	O
of	O
CAPS	O
-	O
Myc	O
-	O
His	O
on	O
mica	B-Chemical
(	O
Fig	O
.	O
3A	O
)	O
or	O
on	O
the	O
SLB	O
lacking	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
(	O
Fig	O
.	O
3B	O
","	O
top	O
)	O
was	O
monomer	O
.	O
However	O
","	O
the	O
inclusion	O
of	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
in	O
SLBs	O
strikingly	O
enhanced	O
the	O
amount	O
of	O
CAPS	O
-	O
Myc	O
-	O
His	O
present	O
as	O
a	O
dimer	O
(	O
Fig	O
.	O
3B	O
","	O
bottom	O
).	O
The	O
stimulatory	O
effect	O
of	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
on	O
CAPS	O
-	O
Myc	O
-	O
His	O
oligomerization	O
was	O
confirmed	O
in	O
native	O
gel	O
electrophoresis	O
studies	O
showing	O
that	O
CAPS	O
-	O
Myc	O
-	O
His	O
oligomerized	O
upon	O
incubation	O
with	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
micelles	O
(	O
Fig	O
.	O
3C	O
).	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
was	O
the	O
most	O
effective	O
phosphoinositide	B-Chemical
for	O
inducing	O
oligomerization	O
(	O
Fig	O
.	O
3D	O
).	O
The	O
results	O
indicate	O
that	O
CAPS	O
-	O
Myc	O
-	O
His	O
exists	O
in	O
two	O
states	O
and	O
that	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
binding	O
promotes	O
the	O
formation	O
of	O
oligomers	O
that	O
correspond	O
to	O
dimers	O
.	O
CAPS	O
oligomer	O
is	O
a	O
dimer	O
.	O
A	O
","	O
atomic	O
force	O
microscopy	O
volume	O
analysis	O
of	O
purified	O
CAPS	O
dried	O
onto	O
mica	B-Chemical
(	O
n	O
=	O
108	O
).	O
Representative	O
images	O
of	O
AFM	O
field	O
(	O
left	O
"),"	O
representative	O
images	O
of	O
single	O
CAPS	O
-	O
Myc	O
-	O
His	O
molecules	O
(	O
middle	O
"),"	O
and	O
histograms	O
of	O
the	O
CAPS	O
-	O
Myc	O
-	O
His	O
volume	O
distribution	O
(	O
right	O
)	O
are	O
shown	O
.	O
Volume	O
data	O
were	O
fit	O
to	O
a	O
double	O
Gaussian	O
with	O
volumes	O
of	O
109	O
nm3	O
for	O
monomer	O
and	O
264	O
nm3	O
for	O
dimer	O
.	O
B	O
","	O
atomic	O
force	O
microscopy	O
analysis	O
of	O
purified	O
CAPS	O
-	O
Myc	O
-	O
His	O
added	O
to	O
SLB	O
(	O
top	O
","	O
n	O
=	O
448	O
)	O
or	O
SLB	O
containing	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
(	O
bottom	O
","	O
n	O
=	O
238	O
)	O
detected	O
monomers	O
at	O
94	O
nm3	O
or	O
monomers	O
at	O
115	O
nm3	O
plus	O
dimer	O
at	O
261	O
nm3	O
","	O
respectively	O
.	O
Inclusion	O
of	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
in	O
SLBs	O
significantly	O
increased	O
the	O
amount	O
of	O
CAPS	O
-	O
Myc	O
-	O
His	O
dimer	O
(	O
p	O
<	O
0	O
.	O
1	O
","	O
Mann	O
-	O
Whitney	O
-	O
Wilcox	O
test	O
).	O
C	O
","	O
CAPS	O
-	O
Myc	O
-	O
His	O
dimers	O
increased	O
upon	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
addition	O
as	O
indicated	O
by	O
BN	O
-	O
PAGE	O
of	O
5	O
Î¼g	O
of	O
CAPS	O
-	O
Myc	O
-	O
His	O
incubated	O
with	O
1	O
.	O
5	O
Î¼g	O
of	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
for	O
0	O
â€“	O
30	O
min	O
.	O
Arrows	O
","	O
high	O
mobility	O
monomer	O
and	O
low	O
mobility	O
dimer	O
.	O
Results	O
shown	O
are	O
representative	O
of	O
six	O
experiments	O
.	O
D	O
","	O
incubations	O
and	O
analysis	O
similar	O
to	O
C	O
were	O
conducted	O
with	O
the	O
indicated	O
phospholipids	B-Chemical
showing	O
that	O
CAPS	O
-	O
Myc	O
-	O
His	O
dimers	O
were	O
preferentially	O
induced	O
(-	O
fold	O
increase	O
is	O
shown	O
)	O
by	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
(	O
mean	O
Â±	O
S	O
.	O
D	O
.	O
(	O
error	O
bars	O
);	O
"*,"	O
p	O
<	O
0	O
.	O
1	O
","	O
n	O
=	O
5	O
).	O
E	O
","	O
pull	O
-	O
down	O
of	O
single	O
CAPS	O
-	O
mKate2	O
-	O
His	O
molecules	O
.	O
TIRF	O
microscopy	O
images	O
showed	O
puncta	O
when	O
CAPS	O
-	O
mKate2	O
-	O
His	O
was	O
retained	O
by	O
His	B-Chemical
antibody	O
(	O
middle	O
)	O
but	O
not	O
with	O
control	O
antibody	O
(	O
right	O
).	O
Scale	O
bar	O
","	O
10	O
Î¼m	O
.	O
F	O
","	O
TIRF	O
images	O
(	O
collected	O
at	O
2	O
Hz	O
)	O
showing	O
a	O
one	O
-	O
step	O
photobleach	O
event	O
for	O
immobilized	O
CAPS	O
-	O
mKate2	O
-	O
His	O
.	O
Image	O
size	O
is	O
2	O
.	O
5	O
Ã—	O
2	O
.	O
5	O
Î¼m	O
.	O
G	O
","	O
representative	O
fluorescence	O
intensity	O
versus	O
time	O
analysis	O
for	O
1	O
-	O
step	O
and	O
2	O
-	O
step	O
photobleach	O
events	O
for	O
CAPS	O
-	O
mKate2	O
-	O
His	O
.	O
H	O
","	O
percentages	O
of	O
puncta	O
exhibiting	O
two	O
photobleaching	O
steps	O
were	O
quantified	O
for	O
CAPS	O
-	O
mKate2	O
-	O
His	O
tethered	O
by	O
His	B-Chemical
antibodies	O
(	O
n	O
=	O
486	O
"),"	O
CAPS	O
-	O
mKate2	O
-	O
His	O
bound	O
to	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
SLBs	O
(	O
n	O
=	O
296	O
"),"	O
CAPS	O
-	O
mKate2	O
(	O
lacking	O
His	B-Chemical
tag	O
)	O
bound	O
to	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
SLBs	O
(	O
n	O
=	O
209	O
"),"	O
and	O
mKate2	O
-	O
His	O
(	O
n	O
=	O
307	O
)	O
or	O
(	O
mKate2	O
)	O
2	O
-	O
His	O
(	O
n	O
=	O
117	O
)	O
tethered	O
by	O
His	B-Chemical
antibodies	O
.	O
Note	O
that	O
the	O
(	O
mKate2	O
)	O
2	O
-	O
His	O
dimer	O
was	O
only	O
50	O
%	O
pure	O
and	O
contaminated	O
with	O
fluorescent	O
monomeric	O
mKate2	O
.	O
Values	O
are	O
mean	O
Â±	O
S	O
.	O
D	O
.	O
Single	O
molecule	O
microscopy	O
can	O
be	O
used	O
to	O
determine	O
oligomeric	O
state	O
by	O
monitoring	O
the	O
number	O
of	O
photobleaching	O
steps	O
for	O
fluorescently	O
tagged	O
proteins	O
(	O
35	O
).	O
CAPS	O
-	O
mKate2	O
-	O
His	O
molecules	O
were	O
held	O
by	O
His	B-Chemical
antibodies	O
(	O
Fig	O
.	O
3E	O
"),"	O
and	O
photobleaching	O
steps	O
were	O
monitored	O
by	O
total	O
internal	O
reflectance	O
fluorescence	O
(	O
TIRF	O
)	O
microscopy	O
(	O
Fig	O
.	O
3	O
","	O
F	O
and	O
G	O
).	O
As	O
controls	O
","	O
monomeric	O
mKate2	O
was	O
shown	O
to	O
exhibit	O
one	O
-	O
step	O
bleaching	O
","	O
whereas	O
dimeric	O
mKate2	O
exhibited	O
an	O
increased	O
number	O
of	O
two	O
-	O
step	O
bleaches	O
(	O
Fig	O
.	O
3H	O
).	O
CAPS	O
-	O
mKate2	O
-	O
His	O
mainly	O
exhibited	O
1	O
-	O
step	O
bleaching	O
","	O
but	O
âˆ¼	O
5	O
%	O
of	O
the	O
molecules	O
exhibited	O
two	O
-	O
step	O
bleaching	O
","	O
indicating	O
that	O
a	O
minor	O
population	O
of	O
dimers	O
is	O
present	O
(	O
Fig	O
.	O
3H	O
).	O
The	O
inclusion	O
of	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
markedly	O
enhanced	O
dimerization	O
of	O
the	O
CAPS	O
-	O
mKate2	O
-	O
His	O
protein	O
(	O
Fig	O
.	O
3H	O
).	O
To	O
exclude	O
the	O
role	O
of	O
the	O
His	B-Chemical
tag	O
","	O
we	O
prepared	O
a	O
CAPS	O
-	O
mKate2	O
protein	O
","	O
which	O
exhibited	O
similar	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
-	O
enhanced	O
dimerization	O
(	O
Fig	O
.	O
3H	O
).	O
Collectively	O
","	O
the	O
AFM	O
and	O
single	O
molecule	O
studies	O
indicate	O
that	O
CAPS	O
oligomers	O
correspond	O
to	O
dimers	O
and	O
that	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
enhances	O
CAPS	O
dimerization	O
.	O
CAPS	O
Dimers	O
Are	O
Functional	O
in	O
Vesicle	O
Exocytosis	O
To	O
determine	O
the	O
functional	O
significance	O
of	O
the	O
oligomeric	O
states	O
of	O
CAPS	O
","	O
we	O
assessed	O
whether	O
there	O
was	O
a	O
preferential	O
association	O
of	O
CAPS	O
monomer	O
or	O
dimer	O
with	O
PC12	O
cell	O
membranes	O
.	O
CAPS	O
is	O
a	O
soluble	O
cytosolic	O
protein	O
that	O
partitions	O
onto	O
membranes	O
(	O
3	O
","	O
25	O
","	O
36	O
).	O
PC12	O
cells	O
were	O
mechanically	O
permeabilized	O
and	O
washed	O
to	O
remove	O
soluble	O
contents	O
(	O
Fig	O
.	O
4A	O
(	O
i	O
)).	O
Extensively	O
washed	O
permeable	O
cells	O
retain	O
small	O
amounts	O
of	O
bound	O
native	O
CAPS	O
(	O
4	O
)	O
that	O
is	O
efficiently	O
extracted	O
by	O
a	O
high	O
salt	O
wash	O
(	O
Fig	O
.	O
4B	O
)	O
or	O
by	O
direct	O
electrophoresis	O
into	O
native	O
gels	O
(	O
not	O
shown	O
).	O
In	O
contrast	O
to	O
native	O
cytosolic	O
CAPS	O
","	O
which	O
was	O
âˆ¼	O
5	O
%	O
dimer	O
","	O
the	O
extracted	O
membrane	O
-	O
bound	O
CAPS	O
was	O
entirely	O
dimer	O
as	O
analyzed	O
on	O
native	O
gels	O
(	O
Fig	O
.	O
4C	O
).	O
Similar	O
studies	O
were	O
conducted	O
by	O
adding	O
purified	O
CAPS	O
-	O
Myc	O
-	O
His	O
to	O
the	O
permeable	O
cells	O
(	O
Fig	O
.	O
4A	O
(	O
ii	O
)).	O
The	O
addition	O
of	O
purified	O
CAPS	O
to	O
permeable	O
PC12	O
cells	O
stimulates	O
Ca2	B-Chemical
+-	I-Chemical
dependent	O
dense	O
core	O
vesicle	O
exocytosis	O
(	O
4	O
","	O
31	O
).	O
We	O
tested	O
the	O
activity	O
of	O
the	O
added	O
purified	O
CAPS	O
-	O
Myc	O
-	O
His	O
and	O
compared	O
this	O
with	O
the	O
activity	O
of	O
bound	O
CAPS	O
-	O
Myc	O
-	O
His	O
after	O
a	O
wash	O
to	O
remove	O
unbound	O
CAPS	O
-	O
Myc	O
-	O
His	O
(	O
Fig	O
.	O
4A	O
(	O
iii	O
)).	O
CAPS	O
-	O
Myc	O
-	O
His	O
bound	O
to	O
the	O
permeable	O
cells	O
was	O
exclusively	O
dimer	O
(	O
Fig	O
.	O
4D	O
)	O
and	O
exhibited	O
âˆ¼	O
50	O
%	O
of	O
the	O
activity	O
(	O
Fig	O
.	O
4E	O
","	O
curve	O
iii	O
)	O
of	O
added	O
CAPS	O
-	O
Myc	O
-	O
His	O
(	O
Fig	O
.	O
4E	O
","	O
curve	O
ii	O
)	O
in	O
promoting	O
Ca2	B-Chemical
+-	I-Chemical
dependent	O
secretion	O
.	O
Control	O
studies	O
showed	O
that	O
the	O
activity	O
of	O
bound	O
CAPS	O
-	O
Myc	O
-	O
His	O
was	O
inhibited	O
by	O
neutralizing	O
CAPS	O
antibodies	O
but	O
not	O
by	O
control	O
IgGs	O
(	O
Fig	O
.	O
4F	O
).	O
Strikingly	O
","	O
the	O
bound	O
CAPS	O
-	O
Myc	O
-	O
His	O
dimer	O
represented	O
only	O
âˆ¼	O
1	O
%	O
of	O
the	O
input	O
CAPS	O
-	O
Myc	O
-	O
His	O
(	O
Fig	O
.	O
4D	O
)	O
but	O
accounted	O
for	O
40	O
â€“	O
60	O
%	O
of	O
the	O
detected	O
activity	O
(	O
Fig	O
.	O
4E	O
).	O
The	O
results	O
indicate	O
that	O
dimer	O
is	O
the	O
active	O
membrane	O
-	O
bound	O
form	O
of	O
CAPS	O
associated	O
with	O
Ca2	B-Chemical
+-	I-Chemical
triggered	O
exocytosis	O
.	O
CAPS	O
dimer	O
is	O
the	O
functional	O
form	O
of	O
CAPS	O
.	O
A	O
","	O
PC12	O
cells	O
were	O
passed	O
through	O
a	O
ball	O
homogenizer	O
(	O
10	O
-	O
Î¼m	O
clearance	O
)	O
to	O
tear	O
the	O
plasma	O
membrane	O
and	O
were	O
washed	O
in	O
KGlu	B-Chemical
/	O
BSA	O
to	O
remove	O
cytosol	O
(	O
i	O
).	O
Purified	O
CAPS	O
-	O
Myc	O
-	O
His	O
was	O
added	O
to	O
20	O
nm	O
(	O
ii	O
"),"	O
and	O
cell	O
ghosts	O
were	O
washed	O
with	O
KGlu	B-Chemical
/	O
BSA	O
to	O
remove	O
unbound	O
CAPS	O
-	O
Myc	O
-	O
His	O
(	O
iii	O
).	O
These	O
three	O
states	O
were	O
assessed	O
for	O
activity	O
in	O
E	O
.	O
B	O
","	O
washed	O
cell	O
ghosts	O
(	O
i	O
)	O
were	O
sequentially	O
extracted	O
with	O
300	O
mm	O
NaCl	B-Chemical
(	O
high	B-Chemical
salt	I-Chemical
(	O
HS	B-Chemical
")),"	O
1	O
%	O
Triton	B-Chemical
X	I-Chemical
-	I-Chemical
100	I-Chemical
(	O
TX100	B-Chemical
"),"	O
and	O
SDS	B-Chemical
sample	O
buffer	O
(	O
SB	O
)	O
with	O
boiling	O
.	O
Samples	O
were	O
analyzed	O
by	O
Western	O
blotting	O
from	O
SDS	B-Chemical
-	O
PAGE	O
with	O
CAPS	O
antibody	O
.	O
Results	O
shown	O
are	O
representative	O
of	O
three	O
studies	O
.	O
C	O
","	O
cytosol	O
from	O
PC12	O
cells	O
(	O
left	O
lane	O
)	O
was	O
compared	O
with	O
HS	B-Chemical
extract	O
of	O
endogenous	O
CAPS	O
from	O
cell	O
ghosts	O
(	O
i	O
","	O
right	O
lane	O
)	O
in	O
electrophoresis	O
by	O
CN	O
-	O
PAGE	O
and	O
Western	O
blotting	O
with	O
CAPS	O
antibody	O
.	O
Results	O
shown	O
are	O
representative	O
of	O
four	O
studies	O
.	O
D	O
","	O
purified	O
CAPS	O
-	O
Myc	O
-	O
His	O
(	O
1	O
%	O
of	O
input	O
shown	O
)	O
was	O
compared	O
with	O
50	O
%	O
of	O
HS	B-Chemical
extract	O
from	O
cell	O
ghosts	O
(	O
iii	O
)	O
in	O
electrophoresis	O
by	O
CN	O
-	O
PAGE	O
and	O
Western	O
blotting	O
with	O
Myc	O
antibody	O
.	O
Results	O
shown	O
are	O
representative	O
of	O
two	O
studies	O
.	O
Endogenous	O
CAPS	O
(	O
C	O
)	O
or	O
exogenous	O
CAPS	O
-	O
Myc	O
-	O
His	O
(	O
D	O
)	O
retained	O
by	O
PC12	O
cell	O
ghosts	O
migrated	O
as	O
dimer	O
.	O
E	O
","	O
Ca2	B-Chemical
+-	I-Chemical
dependent	O
norepinephrine	B-Chemical
secretion	O
was	O
monitored	O
by	O
rotating	O
disk	O
electrode	O
voltammetry	O
from	O
cell	O
ghosts	O
indicated	O
as	O
i	O
","	O
ii	O
","	O
and	O
iii	O
in	O
A	O
.	O
Ca2	B-Chemical
+	I-Chemical
was	O
injected	O
at	O
zero	O
time	O
.	O
The	O
results	O
from	O
three	O
studies	O
were	O
averaged	O
in	O
the	O
histogram	O
(	O
means	O
Â±	O
S	O
.	O
E	O
.	O
(	O
error	O
bars	O
));	O
"*,"	O
p	O
<	O
0	O
.	O
5	O
.	O
F	O
","	O
neutralizing	O
CAPS	O
antibodies	O
inhibited	O
the	O
stimulation	O
of	O
secretion	O
by	O
prebound	O
CAPS	O
(	O
iii	O
).	O
Rabbit	O
IgGs	O
(	O
Î±	O
-	O
rabbit	O
)	O
were	O
used	O
as	O
the	O
control	O
for	O
CAPS	O
antibodies	O
(	O
Î±	O
-	O
CAPS	O
).	O
Results	O
shown	O
are	O
representative	O
of	O
two	O
studies	O
.	O
Binding	O
to	O
SNARE	O
proteins	O
and	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
is	O
required	O
for	O
CAPS	O
activity	O
in	O
exocytosis	O
(	O
15	O
","	O
19	O
"),"	O
so	O
we	O
assessed	O
the	O
oligomeric	O
state	O
of	O
purified	O
CAPS	O
bound	O
to	O
liposomes	O
containing	O
Q	O
-	O
SNAREs	O
and	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
.	O
The	O
CAPS	O
-	O
Myc	O
-	O
His	O
bound	O
to	O
Q	O
-	O
SNARE	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
-	O
containing	O
liposomes	O
purified	O
by	O
flotation	O
(	O
Fig	O
.	O
5A	O
)	O
exhibited	O
increased	O
dimer	O
compared	O
with	O
input	O
(	O
Fig	O
.	O
5	O
","	O
B	O
and	O
C	O
).	O
CAPS	O
-	O
Myc	O
-	O
His	O
dimers	O
were	O
not	O
evident	O
in	O
flotation	O
studies	O
with	O
PC	B-Chemical
/	O
PS	B-Chemical
-	O
containing	O
liposomes	O
(	O
Fig	O
.	O
5	O
","	O
B	O
and	O
C	O
)	O
or	O
with	O
liposomes	O
containing	O
only	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
(	O
Fig	O
.	O
5C	O
).	O
Although	O
these	O
results	O
appeared	O
to	O
differ	O
from	O
the	O
AFM	O
studies	O
with	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
-	O
containing	O
SLBs	O
(	O
Fig	O
.	O
3B	O
"),"	O
we	O
attribute	O
this	O
to	O
the	O
dissociation	O
of	O
CAPS	O
-	O
Myc	O
-	O
His	O
during	O
flotation	O
when	O
bound	O
at	O
low	O
affinity	O
to	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
-	O
containing	O
liposomes	O
.	O
The	O
recovery	O
of	O
CAPS	O
-	O
Myc	O
-	O
His	O
from	O
liposomes	O
containing	O
only	O
Q	O
-	O
SNAREs	O
was	O
also	O
low	O
(	O
Fig	O
.	O
5C	O
)	O
but	O
corresponds	O
to	O
the	O
synergy	O
between	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
and	O
Q	O
-	O
SNAREs	O
for	O
CAPS	O
activity	O
on	O
liposomes	O
(	O
23	O
).	O
Collectively	O
","	O
the	O
results	O
show	O
that	O
CAPS	O
dimers	O
preferentially	O
associate	O
with	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
and	O
Q	O
-	O
SNAREs	O
and	O
that	O
membrane	O
-	O
bound	O
dimers	O
are	O
the	O
functionally	O
active	O
form	O
of	O
CAPS	O
.	O
CAPS	O
dimers	O
are	O
enriched	O
on	O
liposomes	O
containing	O
Q	O
-	O
SNAREs	O
and	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
.	O
A	O
","	O
diagram	O
of	O
flotation	O
assay	O
to	O
separate	O
bound	O
from	O
unbound	O
CAPS	O
-	O
Myc	O
-	O
His	O
in	O
liposome	O
binding	O
studies	O
.	O
B	O
","	O
BN	O
-	O
PAGE	O
Western	O
blot	O
of	O
input	O
(	O
left	O
"),"	O
bound	O
(	O
right	O
"),"	O
and	O
unbound	O
(	O
bottom	O
)	O
CAPS	O
-	O
Myc	O
-	O
His	O
after	O
flotation	O
with	O
either	O
protein	O
-	O
free	O
(	O
PF	O
)	O
or	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
-	O
and	O
Q	O
-	O
SNARE	O
-	O
containing	O
liposomes	O
.	O
Liposomes	O
contained	O
PC	B-Chemical
/	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
(	O
95	O
:	O
5	O
).	O
Results	O
shown	O
are	O
representative	O
of	O
two	O
studies	O
.	O
C	O
","	O
BN	O
-	O
PAGE	O
Western	O
blot	O
of	O
bound	O
CAPS	O
-	O
Myc	O
-	O
His	O
after	O
flotation	O
with	O
either	O
protein	O
-	O
free	O
liposomes	O
composed	O
of	O
PC	B-Chemical
/	O
PS	B-Chemical
(	O
85	O
:	O
15	O
)	O
or	O
PC	B-Chemical
/	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
(	O
95	O
:	O
5	O
)	O
or	O
Q	O
-	O
SNARE	O
-	O
containing	O
liposomes	O
with	O
the	O
same	O
lipid	O
compositions	O
as	O
indicated	O
.	O
Liposomes	O
were	O
also	O
extracted	O
into	O
1	O
%	O
Triton	B-Chemical
X	I-Chemical
-	I-Chemical
100	I-Chemical
to	O
ensure	O
complete	O
removal	O
of	O
bound	O
CAPS	O
-	O
Myc	O
-	O
His	O
.	O
Results	O
shown	O
are	O
representative	O
of	O
two	O
studies	O
.	O
CAPS	O
C2	O
Domain	O
Mediates	O
Dimerization	O
Additional	O
evidence	O
for	O
the	O
importance	O
of	O
dimerization	O
in	O
CAPS	O
activity	O
and	O
for	O
the	O
role	O
of	O
the	O
C2	O
domain	O
in	O
dimer	O
formation	O
was	O
provided	O
by	O
studies	O
of	O
CAPS	O
C2	O
domain	O
mutants	O
.	O
Mutant	O
proteins	O
assessed	O
were	O
rat	O
CAPS	O
(	O
G476E	O
)	O
and	O
CAPS	O
(	O
L468K	O
)	O
plus	O
variants	O
(	O
Fig	O
.	O
6A	O
)	O
corresponding	O
to	O
the	O
unc	O
-	O
31	O
(	O
e714	O
)	O
and	O
unc	O
-	O
31	O
(	O
ox299	O
)	O
alleles	O
in	O
C	O
.	O
elegans	O
","	O
respectively	O
(	O
22	O
).	O
We	O
also	O
generated	O
a	O
C2	O
domain	O
deletion	O
protein	O
CAPS	O
(	O
Î”C2	O
).	O
Mutant	O
proteins	O
were	O
purified	O
as	O
Myc	O
-	O
His	O
fusion	O
proteins	O
and	O
analyzed	O
by	O
native	O
gel	O
electrophoresis	O
to	O
determine	O
oligomerization	O
state	O
(	O
Fig	O
.	O
6	O
","	O
B	O
and	O
C	O
"),"	O
and	O
in	O
the	O
permeable	O
PC12	O
cell	O
assay	O
to	O
determine	O
activity	O
(	O
Fig	O
.	O
6E	O
).	O
The	O
alleles	O
at	O
Leu	B-Chemical
-	O
468	O
(	O
L468E	O
and	O
L468K	O
)	O
had	O
significantly	O
reduced	O
dimer	O
and	O
exhibited	O
loss	O
of	O
function	O
in	O
the	O
permeable	O
cell	O
assay	O
(	O
Fig	O
.	O
6	O
","	O
B	O
","	O
C	O
","	O
and	O
E	O
).	O
The	O
deletion	O
construct	O
CAPS	O
(	O
Î”C2	O
)	O
also	O
exhibited	O
reduced	O
dimerization	O
as	O
well	O
as	O
reduced	O
activity	O
(	O
Fig	O
.	O
6	O
","	O
B	O
","	O
C	O
","	O
and	O
E	O
).	O
We	O
also	O
tested	O
the	O
CAPS	O
(	O
Î”C2	O
)	O
protein	O
with	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
and	O
found	O
that	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
-	O
induced	O
dimerization	O
was	O
similarly	O
attenuated	O
(	O
Fig	O
.	O
6D	O
).	O
Loss	O
of	O
function	O
CAPS	O
mutants	O
exhibit	O
altered	O
dimerization	O
.	O
A	O
","	O
domain	O
architecture	O
for	O
R	O
.	O
norvegicus	O
CAPS	O
(	O
NP_037351	O
.	O
1	O
).	O
C2	O
and	O
PH	O
domains	O
were	O
identified	O
by	O
multiple	O
alignments	O
in	O
the	O
SMART	O
database	O
.	O
The	O
MHD1	O
domain	O
is	O
from	O
Ref	O
.	O
25	O
.	O
The	O
DCV	O
binding	O
domain	O
is	O
from	O
Ref	O
.	O
57	O
.	O
Ser	B-Chemical
phosphorylation	O
(	O
P	O
)	O
is	O
from	O
Ref	O
.	O
31	O
.	O
CATCHR	O
homology	O
(	O
boldface	O
underline	O
)	O
is	O
from	O
Ref	O
.	O
20	O
.	O
B	O
","	O
loss	O
of	O
function	O
C2	O
domain	O
mutants	O
of	O
CAPS	O
exhibit	O
abnormal	O
dimerization	O
.	O
100	O
ng	O
of	O
purified	O
wild	O
-	O
type	O
CAPS	O
-	O
Myc	O
-	O
His	O
and	O
mutants	O
were	O
analyzed	O
by	O
CN	O
-	O
PAGE	O
and	O
visualized	O
by	O
Western	O
blot	O
with	O
Myc	O
antibody	O
.	O
The	O
CAPS	O
-	O
Myc	O
-	O
His	O
band	O
corresponding	O
to	O
dephosphorylated	O
CAPS	O
(	O
Dephos	O
)	O
(	O
31	O
)	O
was	O
not	O
routinely	O
resolved	O
from	O
monomer	O
in	O
other	O
CN	O
-	O
PAGE	O
studies	O
.	O
C	O
","	O
the	O
percentage	O
of	O
dimer	O
for	O
each	O
protein	O
indicated	O
below	O
each	O
lane	O
in	O
B	O
is	O
plotted	O
as	O
histograms	O
showing	O
means	O
Â±	O
S	O
.	O
E	O
.	O
(	O
error	O
bars	O
)	O
for	O
the	O
indicated	O
n	O
values	O
.	O
Comparisons	O
with	O
wild	O
-	O
type	O
protein	O
are	O
indicated	O
"(**,"	O
p	O
<	O
0	O
.	O
1	O
).	O
D	O
","	O
wild	O
-	O
type	O
CAPS	O
-	O
Myc	O
-	O
His	O
and	O
CAPS	O
(	O
Î”C2	O
)-	O
Myc	O
-	O
His	O
were	O
tested	O
for	O
dimerization	O
in	O
the	O
absence	O
(âˆ’)	O
or	O
presence	O
(+)	O
of	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
as	O
in	O
Fig	O
.	O
3C	O
by	O
BN	O
-	O
PAGE	O
"(**,"	O
p	O
<	O
0	O
.	O
1	O
;	O
n	O
=	O
3	O
).	O
E	O
","	O
activities	O
of	O
purified	O
CAPS	O
and	O
mutants	O
in	O
a	O
permeable	O
cell	O
secretion	O
assay	O
tested	O
at	O
20	O
nm	O
in	O
triplicate	O
(	O
mean	O
Â±	O
S	O
.	O
E	O
.	O
;	O
p	O
<	O
0	O
.	O
1	O
).	O
Wild	O
-	O
type	O
CAPS	O
activity	O
was	O
set	O
to	O
100	O
%.	O
Surprisingly	O
","	O
the	O
CAPS	O
(	O
G476E	O
)	O
mutant	O
exhibited	O
strongly	O
increased	O
oligomerization	O
(	O
Fig	O
.	O
6	O
","	O
B	O
and	O
C	O
)	O
but	O
was	O
strongly	O
loss	O
of	O
function	O
in	O
the	O
permeable	O
cell	O
assay	O
(	O
Fig	O
.	O
6E	O
).	O
By	O
contrast	O
","	O
a	O
CAPS	O
(	O
G476A	O
)	O
variant	O
was	O
similar	O
to	O
wild	O
-	O
type	O
protein	O
(	O
data	O
not	O
shown	O
).	O
Collectively	O
","	O
the	O
data	O
indicate	O
that	O
the	O
C2	O
domain	O
of	O
CAPS	O
","	O
previously	O
of	O
unknown	O
function	O
","	O
is	O
involved	O
in	O
CAPS	O
dimer	O
formation	O
and	O
that	O
altered	O
dimerization	O
inhibits	O
CAPS	O
function	O
.	O
C2	O
Domain	O
Is	O
Essential	O
for	O
CAPS	O
Function	O
in	O
Cells	O
We	O
assessed	O
the	O
activity	O
of	O
the	O
C2	O
domain	O
mutants	O
in	O
regulated	O
dense	O
core	O
vesicle	O
exocytosis	O
in	O
live	O
PC12	O
cells	O
(	O
19	O
).	O
Cells	O
expressing	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
)-	O
EGFP	O
as	O
vesicle	O
cargo	O
(	O
Fig	O
.	O
7A	O
)	O
were	O
depolarized	O
to	O
promote	O
Ca2	B-Chemical
+	I-Chemical
influx	O
.	O
Vesicle	O
fusion	O
events	O
were	O
detected	O
by	O
the	O
brightening	O
of	O
BDNF	O
-	O
EGFP	O
in	O
TIRF	O
microscopy	O
(	O
Fig	O
.	O
7B	O
).	O
The	O
knockdown	O
of	O
CAPS	O
in	O
PC12	O
cells	O
with	O
shRNA	O
(>	O
95	O
%	O
reduction	O
in	O
CAPS	O
(	O
19	O
))	O
strongly	O
reduced	O
Ca2	B-Chemical
+-	I-Chemical
stimulated	O
exocytosis	O
(	O
Fig	O
.	O
7C	O
).	O
Full	O
rescue	O
was	O
achieved	O
by	O
expressing	O
a	O
CAPS	O
-	O
TagRFP	O
construct	O
harboring	O
silent	O
mutations	O
that	O
bypass	O
the	O
shRNA	O
(	O
Fig	O
.	O
7D	O
).	O
By	O
contrast	O
","	O
CAPS	O
(	O
G476E	O
"),"	O
CAPS	O
(	O
Î”C2	O
"),"	O
or	O
CAPS	O
(	O
L468K	O
)	O
proteins	O
all	O
failed	O
to	O
rescue	O
Ca2	B-Chemical
+-	I-Chemical
stimulated	O
exocytosis	O
(	O
Fig	O
.	O
7	O
","	O
D	O
â€“	O
F	O
)	O
despite	O
normal	O
expression	O
(	O
Fig	O
.	O
8	O
).	O
Intriguingly	O
","	O
CAPS	O
(	O
G476E	O
)	O
expression	O
also	O
strongly	O
reduced	O
the	O
number	O
of	O
dense	O
core	O
vesicles	O
visible	O
in	O
the	O
TIRF	O
field	O
","	O
whereas	O
expression	O
of	O
other	O
mutants	O
did	O
not	O
(	O
data	O
not	O
shown	O
).	O
To	O
determine	O
whether	O
reduced	O
exocytosis	O
with	O
CAPS	O
(	O
G476E	O
)	O
expression	O
(	O
Fig	O
.	O
7D	O
)	O
was	O
solely	O
attributable	O
to	O
the	O
reduced	O
number	O
of	O
vesicles	O
in	O
the	O
TIRF	O
field	O
","	O
the	O
data	O
were	O
replotted	O
as	O
the	O
number	O
of	O
fusion	O
events	O
normalized	O
to	O
the	O
number	O
of	O
vesicles	O
in	O
the	O
TIRF	O
field	O
.	O
CAPS	O
(	O
G476E	O
)	O
was	O
confirmed	O
as	O
strong	O
loss	O
of	O
function	O
for	O
exocytosis	O
as	O
were	O
the	O
CAPS	O
(	O
L468K	O
)	O
and	O
Î”C2	O
CAPS	O
mutants	O
(	O
Fig	O
.	O
7G	O
).	O
The	O
live	O
cell	O
studies	O
agree	O
with	O
the	O
permeable	O
cell	O
activity	O
assay	O
results	O
(	O
Fig	O
.	O
6E	O
)	O
and	O
further	O
indicate	O
the	O
essential	O
nature	O
of	O
the	O
C2	O
domain	O
for	O
CAPS	O
function	O
in	O
vesicle	O
exocytosis	O
.	O
C2	O
domain	O
mutants	O
exhibit	O
reduced	O
activity	O
in	O
dense	O
core	O
vesicle	O
exocytosis	O
.	O
A	O
","	O
representative	O
TIRF	O
image	O
of	O
PC12	O
cell	O
expressing	O
BDNF	O
-	O
GFP	O
.	O
Scale	O
bar	O
","	O
10	O
Î¼m	O
.	O
B	O
","	O
fluorescence	O
intensity	O
changes	O
for	O
a	O
single	O
vesicle	O
fusion	O
event	O
.	O
Vesicle	O
fluorescence	O
is	O
evident	O
in	O
the	O
TIRF	O
field	O
before	O
fusion	O
(	O
1	O
);	O
fluorescence	O
increases	O
at	O
the	O
time	O
of	O
fusion	O
pore	O
opening	O
(	O
2	O
);	O
and	O
fluorescence	O
subsequently	O
decreases	O
due	O
to	O
reacidification	O
of	O
the	O
cavicaptured	O
vesicle	O
(	O
3	O
).	O
The	O
width	O
of	O
each	O
image	O
in	O
the	O
montage	O
is	O
1	O
.	O
5	O
Î¼m	O
.	O
C	O
","	O
exocytosis	O
was	O
evoked	O
by	O
depolarization	O
with	O
the	O
addition	O
of	O
56	O
mm	O
KCl	B-Chemical
buffer	O
at	O
zero	O
time	O
.	O
Curves	O
indicate	O
cumulative	O
number	O
of	O
fusion	O
events	O
per	O
cell	O
.	O
CAPS	O
knockdown	O
significantly	O
impaired	O
secretion	O
compared	O
with	O
control	O
cells	O
(	O
mean	O
Â±	O
S	O
.	O
E	O
.	O
(	O
error	O
bars	O
"),"	O
n	O
=	O
14	O
).	O
D	O
","	O
rescue	O
studies	O
in	O
CAPS	O
knockdown	O
cells	O
for	O
CAPS	O
-	O
TagRFP	O
(	O
n	O
=	O
14	O
)	O
or	O
CAPS	O
(	O
G476E	O
)-	O
TagRFP	O
(	O
n	O
=	O
11	O
).	O
E	O
","	O
similar	O
to	O
D	O
for	O
rescue	O
studies	O
with	O
CAPS	O
-	O
TagRFP	O
(	O
n	O
=	O
14	O
)	O
or	O
CAPS	O
(	O
Î”C2	O
)-	O
TagRFP	O
(	O
n	O
=	O
15	O
).	O
F	O
","	O
similar	O
to	O
D	O
for	O
rescue	O
studies	O
with	O
CAPS	O
-	O
TagRFP	O
(	O
n	O
=	O
14	O
)	O
or	O
CAPS	O
(	O
L468K	O
)-	O
TagRFP	O
(	O
n	O
=	O
15	O
).	O
The	O
similar	O
expression	O
of	O
CAPS	O
proteins	O
was	O
confirmed	O
by	O
fluorescence	O
of	O
CAPS	O
-	O
TagRFP	O
constructs	O
.	O
Significant	O
differences	O
are	O
indicated	O
:	O
p	O
<	O
0	O
.	O
1	O
;	O
"*,"	O
p	O
<	O
0	O
.	O
5	O
.	O
G	O
","	O
summary	O
of	O
CAPS	O
C2	O
domain	O
mutants	O
compared	O
with	O
wild	O
-	O
type	O
CAPS	O
.	O
Fusion	O
events	O
per	O
cell	O
were	O
normalized	O
to	O
the	O
number	O
of	O
vesicles	O
visible	O
in	O
the	O
TIRF	O
field	O
(	O
mean	O
Â±	O
S	O
.	O
E	O
.	O
;	O
"*,"	O
p	O
<	O
0	O
.	O
5	O
;	O
p	O
<	O
0	O
.	O
1	O
).	O
CAPS	O
(	O
G476E	O
)	O
Cluster	O
Dense	O
Core	O
Vesicles	O
CAPS	O
in	O
PC12	O
cells	O
is	O
cytoplasmic	O
as	O
well	O
as	O
bound	O
to	O
dense	O
core	O
vesicles	O
(	O
3	O
).	O
CAPS	O
(	O
G476E	O
)	O
was	O
loss	O
of	O
function	O
for	O
vesicle	O
exocytosis	O
(	O
Fig	O
.	O
7	O
","	O
D	O
and	O
G	O
)	O
but	O
also	O
interfered	O
with	O
the	O
transit	O
of	O
vesicles	O
to	O
the	O
plasma	O
membrane	O
.	O
To	O
further	O
assess	O
this	O
","	O
we	O
determined	O
the	O
localization	O
of	O
CAPS	O
(	O
G476E	O
)	O
in	O
cells	O
by	O
confocal	O
microscopy	O
.	O
Expression	O
of	O
wild	O
-	O
type	O
CAPS	O
-	O
EGFP	O
or	O
CAPS	O
-	O
TagRFP	O
resulted	O
in	O
a	O
global	O
cytoplasmic	O
distribution	O
that	O
largely	O
obscured	O
the	O
dense	O
core	O
vesicle	O
localization	O
previously	O
shown	O
by	O
TIRF	O
microscopy	O
(	O
3	O
)	O
(	O
Fig	O
.	O
8	O
","	O
A	O
and	O
B	O
).	O
CAPS	O
(	O
L468K	O
)	O
and	O
CAPS	O
(	O
Î”C2	O
)	O
proteins	O
were	O
expressed	O
well	O
and	O
localized	O
similarly	O
to	O
the	O
wild	O
-	O
type	O
protein	O
as	O
cytoplasmic	O
.	O
In	O
striking	O
contrast	O
","	O
CAPS	O
(	O
G476E	O
)	O
localized	O
to	O
large	O
structures	O
within	O
the	O
cells	O
(	O
Fig	O
.	O
8	O
","	O
A	O
and	O
C	O
)	O
that	O
also	O
contained	O
dense	O
core	O
vesicle	O
proteins	O
synaptotagmin	O
-	O
1	O
and	O
chromogranin	O
B	O
but	O
not	O
Golgi	O
proteins	O
TGN	O
-	O
38	O
or	O
syntaxin	O
-	O
6	O
(	O
Fig	O
.	O
8C	O
).	O
This	O
suggested	O
that	O
CAPS	O
(	O
G476E	O
)	O
expression	O
induced	O
the	O
cytoplasmic	O
clustering	O
of	O
mature	O
dense	O
core	O
vesicles	O
.	O
We	O
confirmed	O
this	O
by	O
electron	O
microscopy	O
","	O
which	O
revealed	O
cytoplasmic	O
clusters	O
of	O
intact	O
dense	O
core	O
vesicles	O
in	O
cells	O
expressing	O
CAPS	O
(	O
G476E	O
)	O
(	O
Fig	O
.	O
8D	O
).	O
Localization	O
of	O
CAPS	O
C2	O
domain	O
mutants	O
in	O
PC12	O
cells	O
.	O
A	O
","	O
representative	O
confocal	O
images	O
of	O
PC12	O
cells	O
expressing	O
wild	O
-	O
type	O
or	O
mutant	O
CAPS	O
-	O
GFP	O
fusion	O
proteins	O
.	O
Wild	O
-	O
type	O
CAPS	O
and	O
CAPS	O
(	O
L468K	O
)	O
are	O
broadly	O
distributed	O
in	O
the	O
cytoplasm	O
","	O
whereas	O
CAPS	O
(	O
G476E	O
)-	O
GFP	O
localizes	O
to	O
large	O
structures	O
.	O
Scale	O
bar	O
","	O
10	O
Î¼m	O
.	O
B	O
","	O
confocal	O
images	O
of	O
live	O
PC12	O
cells	O
expressing	O
BDNF	O
-	O
GFP	O
(	O
vesicle	O
cargo	O
)	O
and	O
either	O
wild	O
-	O
type	O
CAPS	O
","	O
CAPS	O
(	O
Î”C2	O
"),"	O
or	O
CAPS	O
(	O
L468K	O
)	O
as	O
TagRFP	O
fusions	O
.	O
Scale	O
bar	O
","	O
10	O
Î¼m	O
.	O
C	O
","	O
confocal	O
images	O
of	O
fixed	O
PC12	O
cells	O
expressing	O
CAPS	O
(	O
G476E	O
)-	O
GFP	O
and	O
immunostained	O
for	O
dense	O
core	O
vesicle	O
proteins	O
synaptotagmin	O
-	O
1	O
(	O
Syt1	O
)	O
or	O
chromogranin	O
B	O
(	O
CgB	O
"),"	O
for	O
trans	O
-	O
Golgi	O
protein	O
TGN	O
-	O
38	O
","	O
or	O
for	O
Golgi	O
and	O
immature	O
vesicle	O
protein	O
syntaxin	O
-	O
6	O
(	O
Syn	O
-	O
6	O
).	O
Scale	O
bar	O
","	O
15	O
Î¼m	O
.	O
D	O
","	O
electron	O
micrograph	O
of	O
fixed	O
PC12	O
cell	O
expressing	O
CAPS	O
-	O
GFP	O
or	O
CAPS	O
(	O
G476E	O
)-	O
GFP	O
.	O
An	O
enlarged	O
region	O
containing	O
clusters	O
of	O
dense	O
core	O
vesicles	O
is	O
shown	O
.	O
Scale	O
bar	O
","	O
200	O
nm	O
.	O
Clustering	O
was	O
determined	O
by	O
the	O
number	O
of	O
additional	O
vesicles	O
in	O
a	O
400	O
-	O
nm	O
radius	O
surrounding	O
a	O
vesicle	O
;	O
binning	O
results	O
for	O
0	O
â€“	O
1	O
or	O
â‰¥	O
2	O
vesicles	O
/	O
circle	O
are	O
shown	O
.	O
CAPS	O
(	O
G476E	O
)-	O
GFP	O
(	O
n	O
=	O
7	O
sections	O
)	O
significantly	O
increased	O
the	O
percentage	O
of	O
vesicles	O
with	O
â‰¥	O
2	O
adjacent	O
vesicles	O
"(**,"	O
p	O
<	O
0	O
.	O
1	O
)	O
compared	O
with	O
CAPS	O
-	O
GFP	O
(	O
n	O
=	O
8	O
sections	O
).	O
Error	O
bars	O
indicate	O
S	O
.	O
D	O
.	O
E	O
","	O
CAPS	O
(	O
G476E	O
)	O
clustering	O
of	O
dense	O
core	O
vesicles	O
is	O
dependent	O
on	O
the	O
vesicle	O
binding	O
domain	O
of	O
CAPS	O
.	O
C	O
-	O
terminal	O
truncation	O
of	O
135	O
residues	O
from	O
CAPS	O
abolished	O
vesicle	O
clustering	O
by	O
CAPS	O
(	O
G476E	O
).	O
Scale	O
bar	O
","	O
15	O
Î¼m	O
.	O
F	O
","	O
model	O
of	O
dense	O
core	O
vesicle	O
clustering	O
by	O
CAPS	O
(	O
G476E	O
)	O
depicting	O
C2	O
domain	O
self	O
-	O
interactions	O
and	O
C	O
-	O
terminal	O
vesicle	O
-	O
binding	O
domain	O
.	O
Vesicle	O
clustering	O
by	O
CAPS	O
(	O
G476E	O
)	O
may	O
be	O
due	O
to	O
its	O
increased	O
oligomerization	O
(	O
Fig	O
.	O
6B	O
)	O
coupled	O
with	O
its	O
binding	O
to	O
dense	O
core	O
vesicles	O
(	O
Fig	O
.	O
8F	O
).	O
CAPS	O
binding	O
to	O
dense	O
core	O
vesicles	O
requires	O
a	O
C	O
-	O
terminal	O
domain	O
(	O
Fig	O
.	O
6A	O
)	O
(	O
3	O
","	O
25	O
).	O
We	O
constructed	O
a	O
C	O
-	O
terminally	O
truncated	O
version	O
of	O
CAPS	O
(	O
G476E	O
)	O
and	O
found	O
that	O
vesicle	O
clustering	O
was	O
eliminated	O
(	O
Fig	O
.	O
8E	O
).	O
The	O
results	O
indicate	O
that	O
the	O
G476E	O
mutation	O
enhances	O
CAPS	O
self	O
-	O
interactions	O
even	O
in	O
trans	O
across	O
vesicle	O
membranes	O
.	O
Such	O
results	O
are	O
consistent	O
with	O
a	O
role	O
for	O
the	O
C2	O
domain	O
in	O
CAPS	O
dimerization	O
(	O
Fig	O
.	O
8F	O
).	O
Bioinformatic	O
Analysis	O
of	O
CAPS	O
C2	O
Domain	O
Dimerization	O
may	O
be	O
mediated	O
by	O
homotypic	O
interactions	O
between	O
C2	O
domains	O
.	O
Structures	O
of	O
C2	O
domain	O
homodimers	O
have	O
been	O
reported	O
for	O
C2B	O
of	O
RIM1Î±	O
","	O
C2B	O
of	O
Rgp3	O
","	O
and	O
C2A	O
of	O
Munc13	O
-	O
1	O
(	O
37	O
","	O
38	O
).	O
Analysis	O
of	O
these	O
structures	O
reveals	O
several	O
conserved	O
patterns	O
for	O
C2	O
homodimer	O
formation	O
.	O
Residues	O
involved	O
in	O
dimerization	O
","	O
while	O
uniquely	O
positioned	O
on	O
each	O
structure	O
","	O
are	O
in	O
the	O
same	O
Î²	O
-	O
strands	O
.	O
These	O
residues	O
interact	O
with	O
residues	O
on	O
other	O
Î²	O
strands	O
or	O
with	O
loops	O
that	O
connect	O
the	O
Î²	O
strands	O
.	O
Each	O
of	O
the	O
three	O
structures	O
contains	O
an	O
electrostatic	O
lysine	B-Chemical
-	O
aspartate	B-Chemical
interaction	O
stabilized	O
by	O
interaction	O
with	O
an	O
aromatic	O
residue	O
and	O
by	O
a	O
hydrogen	B-Chemical
bond	O
from	O
a	O
third	O
residue	O
(	O
see	O
below	O
).	O
We	O
determined	O
whether	O
any	O
of	O
these	O
dimerization	O
residues	O
were	O
conserved	O
in	O
CAPS	O
by	O
conducting	O
C2	O
domain	O
alignments	O
with	O
Cn3D	O
","	O
which	O
supplements	O
traditional	O
sequence	O
alignment	O
methods	O
with	O
structural	O
data	O
(	O
39	O
).	O
Alignments	O
revealed	O
that	O
residues	O
involved	O
in	O
Munc13	O
-	O
1	O
C2A	O
homodimerization	O
are	O
conserved	O
in	O
the	O
CAPS	O
C2	O
domain	O
(	O
Fig	O
.	O
9A	O
).	O
Specifically	O
","	O
two	O
types	O
of	O
interactions	O
are	O
conserved	O
.	O
Both	O
C2	O
domains	O
exhibit	O
a	O
characteristic	O
partial	O
chelation	O
of	O
a	O
charged	O
residue	O
by	O
three	O
residues	O
on	O
the	O
opposing	O
domain	O
and	O
exhibit	O
a	O
lysine	B-Chemical
-	O
glutamate	B-Chemical
electrostatic	O
interaction	O
(	O
Fig	O
.	O
9A	O
).	O
The	O
positions	O
of	O
these	O
latter	O
residues	O
are	O
flipped	O
between	O
CAPS	O
C2	O
and	O
Munc13	O
-	O
1	O
C2A	O
","	O
which	O
could	O
function	O
to	O
prevent	O
CAPS	O
-	O
Munc13	O
-	O
1	O
heterodimer	O
formation	O
.	O
To	O
test	O
the	O
sequence	O
alignment	O
predictions	O
","	O
we	O
generated	O
two	O
charge	O
reversal	O
mutants	O
in	O
the	O
CAPS	O
C2	O
domain	O
that	O
are	O
predicted	O
to	O
reduce	O
dimerization	O
.	O
In	O
accord	O
with	O
prediction	O
","	O
CAPS	O
(	O
K428D	O
)	O
and	O
CAPS	O
(	O
D472K	O
)	O
exhibited	O
impaired	O
dimerization	O
(	O
Fig	O
.	O
9	O
","	O
B	O
and	O
C	O
).	O
Importantly	O
","	O
both	O
CAPS	O
C2	O
domain	O
mutants	O
showed	O
reduced	O
activity	O
in	O
the	O
permeable	O
PC12	O
cell	O
assay	O
(	O
Fig	O
.	O
9D	O
).	O
We	O
suggest	O
that	O
the	O
mechanism	O
of	O
C2	O
domain	O
homodimerization	O
is	O
conserved	O
between	O
the	O
CAPS	O
C2	O
domain	O
and	O
the	O
Munc13	O
-	O
1	O
C2A	O
domain	O
.	O
Identifying	O
conserved	O
homodimerization	O
motifs	O
in	O
Munc13	O
-	O
1	O
C2A	O
and	O
CAPS	O
C2	O
.	O
A	O
","	O
sequence	O
alignment	O
of	O
C2	O
domains	O
generated	O
by	O
Cn3D	O
.	O
A	O
spatially	O
conserved	O
residue	O
alignment	O
for	O
C2	O
domains	O
was	O
created	O
with	O
97	O
published	O
C2	O
structures	O
.	O
This	O
template	O
was	O
used	O
to	O
compare	O
Munc13	O
-	O
1	O
C2A	O
(	O
Protein	O
Data	O
Bank	O
code	O
2CJT	O
"),"	O
CAPS	O
RN	O
(	O
R	O
.	O
norvegicus	O
","	O
NP_037351	O
"),"	O
CAPS	O
MM	O
(	O
Mus	O
musculus	O
","	O
NP_036191	O
"),"	O
CAPS	O
HS	O
(	O
Homo	O
sapiens	O
","	O
Q9ULU8	O
"),"	O
CAPS	O
DM	O
(	O
Drosophila	O
melanogaster	O
","	O
AAN06591	O
"),"	O
and	O
CAPS	O
CE	O
(	O
C	O
.	O
elegans	O
","	O
NP_001255666	O
)	O
sequences	O
.	O
Boldface	O
type	O
indicates	O
residues	O
that	O
are	O
spatially	O
conserved	O
across	O
all	O
97	O
structures	O
.	O
Red	O
and	O
blue	O
","	O
partial	O
chelation	O
of	O
a	O
charged	O
residue	O
(	O
lysine	B-Chemical
","	O
blue	O
)	O
by	O
3	O
opposing	O
residues	O
(	O
red	O
)	O
is	O
conserved	O
for	O
Munc13	O
-	O
1	O
and	O
CAPS	O
.	O
Green	O
","	O
electrostatic	O
interaction	O
between	O
a	O
lysine	B-Chemical
and	O
glutamine	B-Chemical
is	O
conserved	O
spatially	O
","	O
although	O
the	O
residue	O
positions	O
are	O
inverted	O
between	O
CAPS	O
and	O
Munc13	O
-	O
1	O
.	O
Orange	O
","	O
Munc13	O
-	O
1	O
homodimer	O
interactions	O
that	O
involve	O
residues	O
with	O
variable	O
spatial	O
positioning	O
between	O
C2	O
domains	O
.	O
Yellow	O
","	O
Leu	B-Chemical
-	O
468	O
and	O
Gly	B-Chemical
-	O
476	O
residues	O
identified	O
in	O
CAPS	O
(	O
22	O
"),"	O
where	O
mutation	O
causes	O
loss	O
of	O
function	O
.	O
B	O
","	O
charge	O
reversal	O
mutations	O
(	O
K428D	O
and	O
D472K	O
)	O
in	O
residues	O
conserved	O
in	O
Munc13	O
-	O
1	O
C2A	O
and	O
CAPS	O
C2	O
domains	O
impair	O
CAPS	O
dimerization	O
.	O
Similar	O
amounts	O
of	O
the	O
indicated	O
proteins	O
were	O
analyzed	O
by	O
CN	O
-	O
PAGE	O
and	O
Western	O
blotting	O
with	O
CAPS	O
antibody	O
.	O
C	O
","	O
data	O
from	O
B	O
were	O
quantitated	O
","	O
indicating	O
decreased	O
dimerization	O
in	O
K428D	O
and	O
D472K	O
proteins	O
compared	O
with	O
wild	O
type	O
"(*,"	O
p	O
<	O
0	O
.	O
5	O
","	O
mean	O
Â±	O
S	O
.	O
D	O
.	O
(	O
error	O
bars	O
"),"	O
n	O
=	O
3	O
).	O
D	O
","	O
CAPS	O
(	O
K428D	O
)	O
and	O
CAPS	O
(	O
D472K	O
)	O
proteins	O
were	O
tested	O
at	O
20	O
nm	O
in	O
the	O
permeable	O
cell	O
secretion	O
assay	O
and	O
found	O
to	O
be	O
significantly	O
impaired	O
compared	O
with	O
wild	O
-	O
type	O
CAPS	O
"(*,"	O
p	O
<	O
0	O
.	O
5	O
","	O
mean	O
Â±	O
S	O
.	O
D	O
".,"	O
n	O
=	O
3	O
).	O
Discussion	O
Essential	O
Role	O
of	O
CAPS	O
C2	O
Domain	O
We	O
provide	O
evidence	O
that	O
the	O
C2	O
domain	O
is	O
essential	O
for	O
CAPS	O
activity	O
as	O
a	O
regulator	O
of	O
vesicle	O
exocytosis	O
.	O
This	O
conclusion	O
initially	O
emerged	O
from	O
sequencing	O
the	O
unc	O
-	O
31	O
(	O
e714	O
)	O
and	O
unc	O
-	O
31	O
(	O
ox299	O
)	O
loss	O
of	O
function	O
alleles	O
in	O
C	O
.	O
elegans	O
that	O
correspond	O
to	O
rat	O
CAPS	O
(	O
G476E	O
)	O
and	O
CAPS	O
(	O
L468K	O
"),"	O
respectively	O
(	O
22	O
).	O
These	O
single	O
point	O
mutations	O
in	O
the	O
CAPS	O
C2	O
domain	O
are	O
separated	O
by	O
seven	O
residues	O
.	O
Studies	O
of	O
regulated	O
dense	O
core	O
vesicle	O
exocytosis	O
(	O
Figs	O
.	O
6	O
and	O
7	O
)	O
showed	O
that	O
CAPS	O
(	O
G476E	O
)	O
was	O
entirely	O
inactive	O
","	O
whereas	O
CAPS	O
(	O
L468K	O
)	O
was	O
partially	O
active	O
.	O
Importantly	O
","	O
CAPS	O
(	O
Î”C2	O
)	O
exhibited	O
no	O
activity	O
(	O
Figs	O
.	O
6	O
and	O
7	O
).	O
The	O
results	O
strongly	O
indicate	O
that	O
the	O
C2	O
domain	O
is	O
required	O
for	O
CAPS	O
activity	O
in	O
Ca2	B-Chemical
+-	I-Chemical
dependent	O
dense	O
core	O
vesicle	O
exocytosis	O
.	O
The	O
CAPS	O
C2	O
domain	O
lacks	O
the	O
canonical	O
array	O
of	O
five	O
aspartate	B-Chemical
residues	O
characteristic	O
of	O
Ca2	B-Chemical
+-	I-Chemical
dependent	O
","	O
PS	B-Chemical
-	O
binding	O
C2	O
domains	O
(	O
40	O
).	O
We	O
were	O
unable	O
to	O
demonstrate	O
Ca2	B-Chemical
+-	I-Chemical
dependent	O
PS	B-Chemical
binding	O
for	O
CAPS	O
C2	O
domain	O
constructs	O
that	O
we	O
have	O
produced	O
.	O
However	O
","	O
C2	O
domains	O
in	O
proteins	O
also	O
mediate	O
protein	O
-	O
protein	O
interactions	O
(	O
38	O
","	O
41	O
â€“	O
47	O
).	O
C2	O
domains	O
can	O
also	O
homodimerize	O
","	O
such	O
as	O
in	O
piccolo	O
","	O
dysferlin	O
","	O
RIM1a	O
","	O
Munc13	O
-	O
1	O
","	O
and	O
Rgp3	O
(	O
38	O
","	O
48	O
â€“	O
50	O
).	O
That	O
the	O
CAPS	O
C2	O
domain	O
mediates	O
homodimerization	O
is	O
suggested	O
by	O
the	O
findings	O
that	O
monomeric	O
CAPS	O
in	O
solution	O
is	O
in	O
dynamic	O
equilibrium	O
with	O
a	O
pool	O
of	O
dimer	O
and	O
that	O
a	O
large	O
number	O
of	O
C2	O
domain	O
mutant	O
CAPS	O
proteins	O
(	O
L468E	O
","	O
L468A	O
","	O
L468K	O
","	O
K428D	O
","	O
D472K	O
","	O
and	O
Î”C2	O
)	O
exhibit	O
strong	O
reductions	O
in	O
dimerization	O
.	O
It	O
is	O
unlikely	O
that	O
these	O
mutant	O
CAPS	O
proteins	O
are	O
either	O
globally	O
or	O
locally	O
misfolded	O
because	O
they	O
express	O
at	O
wild	O
-	O
type	O
levels	O
in	O
cells	O
","	O
bind	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
similarly	O
to	O
wild	O
-	O
type	O
CAPS	O
","	O
and	O
exhibit	O
similar	O
patterns	O
of	O
limited	O
proteolysis	O
.	O
4	O
It	O
is	O
likely	O
that	O
these	O
mutant	O
proteins	O
exhibit	O
reduced	O
affinity	O
for	O
C2	O
domain	O
self	O
-	O
interactions	O
.	O
The	O
CAPS	O
(	O
G476E	O
)	O
mutant	O
corresponding	O
to	O
the	O
unc	O
-	O
31	O
(	O
e714	O
)	O
allele	O
has	O
unusual	O
properties	O
that	O
nonetheless	O
support	O
the	O
idea	O
of	O
C2	O
domain	O
-	O
mediated	O
oligomerization	O
.	O
CAPS	O
(	O
G476E	O
)	O
is	O
strongly	O
loss	O
of	O
function	O
at	O
the	O
level	O
of	O
vesicle	O
exocytosis	O
(	O
Figs	O
.	O
6	O
and	O
7	O
"),"	O
and	O
it	O
also	O
clusters	O
dense	O
core	O
vesicles	O
in	O
the	O
cytoplasm	O
of	O
cells	O
(	O
Fig	O
.	O
8	O
).	O
We	O
interpret	O
this	O
to	O
indicate	O
that	O
the	O
G476E	O
C2	O
domain	O
gains	O
affinity	O
for	O
self	O
-	O
interaction	O
so	O
that	O
it	O
dimerizes	O
in	O
trans	O
across	O
membranes	O
(	O
Fig	O
.	O
8F	O
).	O
Indeed	O
","	O
CAPS	O
(	O
G476E	O
)	O
exhibits	O
a	O
very	O
strong	O
tendency	O
to	O
oligomerize	O
as	O
dimers	O
as	O
well	O
as	O
possible	O
tetramers	O
(	O
Fig	O
.	O
6B	O
).	O
We	O
cannot	O
eliminate	O
the	O
possibility	O
that	O
the	O
C2	O
domain	O
in	O
this	O
mutant	O
is	O
locally	O
misfolded	O
by	O
substitution	O
of	O
a	O
small	O
uncharged	O
side	O
chain	O
by	O
a	O
charged	O
side	O
chain	O
.	O
The	O
G476A	O
allele	O
","	O
by	O
contrast	O
","	O
exhibited	O
wild	O
-	O
type	O
properties	O
.	O
Gly	B-Chemical
-	O
476	O
is	O
highly	O
conserved	O
in	O
CAPS	O
and	O
in	O
other	O
C2	O
domains	O
(	O
Fig	O
.	O
9A	O
"),"	O
residing	O
near	O
the	O
beginning	O
of	O
a	O
flexible	O
linker	O
that	O
connects	O
two	O
Î²	O
strands	O
.	O
Whether	O
the	O
Gly	B-Chemical
to	O
Glu	B-Chemical
substitution	O
promotes	O
local	O
unfolding	O
of	O
the	O
C2	O
domain	O
or	O
introduces	O
additional	O
electrostatic	O
interactions	O
is	O
unclear	O
","	O
but	O
the	O
G476E	O
substitution	O
appears	O
to	O
strongly	O
enhance	O
C2	O
-	O
C2	O
domain	O
interactions	O
.	O
That	O
both	O
decreased	O
(	O
e	O
.	O
g	O
.	O
CAPS	O
(	O
Î”C2	O
)	O
and	O
CAPS	O
(	O
L468K	O
))	O
as	O
well	O
as	O
increased	O
(	O
e	O
.	O
g	O
.	O
CAPS	O
(	O
G476E	O
))	O
dimerization	O
result	O
in	O
loss	O
of	O
CAPS	O
function	O
suggests	O
that	O
a	O
cycle	O
of	O
dimerization	O
and	O
its	O
reversal	O
plays	O
a	O
role	O
in	O
CAPS	O
function	O
.	O
CAPS	O
dimerization	O
may	O
need	O
to	O
be	O
locally	O
activated	O
with	O
correct	O
timing	O
such	O
that	O
premature	O
dimerization	O
inhibits	O
activity	O
.	O
Consistent	O
with	O
this	O
","	O
complete	O
dephosphorylation	O
inactivates	O
CAPS	O
and	O
shifts	O
it	O
toward	O
an	O
oligomeric	O
state	O
(	O
31	O
).	O
It	O
should	O
be	O
noted	O
that	O
the	O
current	O
work	O
reassigns	O
the	O
speculated	O
dimer	O
-	O
tetramer	O
equilibrium	O
of	O
that	O
previous	O
study	O
(	O
31	O
)	O
to	O
a	O
monomer	O
-	O
dimer	O
equilibrium	O
.	O
Distinct	O
Roles	O
for	O
Dimerization	O
in	O
CAPS	O
and	O
Munc13	O
-	O
1	O
Function	O
CAPS	O
and	O
Munc13	O
-	O
1	O
proteins	O
comprise	O
a	O
subgroup	O
of	O
CATCHR	O
family	O
proteins	O
exhibiting	O
âˆ¼	O
40	O
%	O
sequence	O
similarity	O
in	O
a	O
âˆ¼	O
500	O
-	O
residue	O
region	O
that	O
is	O
C	O
-	O
terminal	O
to	O
the	O
C2	O
domain	O
of	O
CAPS	O
.	O
Dimerization	O
of	O
the	O
Munc13	O
-	O
1	O
protein	O
has	O
not	O
been	O
directly	O
determined	O
but	O
is	O
proposed	O
based	O
on	O
C2A	O
-	O
C2A	O
dimer	O
structures	O
(	O
38	O
).	O
Mutations	O
that	O
disrupt	O
C2A	O
-	O
C2A	O
dimers	O
(	O
K32E	O
)	O
were	O
found	O
to	O
enhance	O
Munc13	O
-	O
1	O
function	O
in	O
neurons	O
","	O
suggesting	O
that	O
Munc13	O
-	O
1	O
monomers	O
are	O
active	O
(	O
50	O
).	O
A	O
proposed	O
mechanism	O
for	O
Munc13	O
-	O
1	O
activation	O
involves	O
RIM1	O
-	O
induced	O
dissociation	O
of	O
C2A	O
-	O
C2A	O
dimers	O
to	O
activate	O
Munc13	O
-	O
1	O
as	O
a	O
monomer	O
(	O
38	O
","	O
50	O
).	O
This	O
contrasts	O
with	O
our	O
results	O
for	O
CAPS	O
","	O
which	O
indicate	O
that	O
C2	O
domain	O
-	O
mediated	O
dimerization	O
is	O
required	O
for	O
function	O
in	O
vesicle	O
exocytosis	O
.	O
The	O
monomer	O
-	O
dimer	O
equilibrium	O
strongly	O
favoring	O
monomer	O
for	O
CAPS	O
indicates	O
that	O
the	O
affinity	O
for	O
self	O
-	O
interaction	O
between	O
soluble	O
CAPS	O
monomers	O
is	O
low	O
","	O
which	O
contrasts	O
with	O
the	O
reported	O
high	O
affinity	O
for	O
Munc13	O
-	O
1	O
C2A	O
-	O
C2A	O
interactions	O
(	O
38	O
).	O
Although	O
CAPS	O
and	O
Munc13	O
-	O
1	O
are	O
each	O
proposed	O
to	O
promote	O
the	O
assembly	O
of	O
SNARE	O
complexes	O
for	O
vesicle	O
priming	O
","	O
the	O
two	O
proteins	O
function	O
distinctively	O
and	O
non	O
-	O
redundantly	O
(	O
3	O
","	O
7	O
","	O
12	O
","	O
19	O
","	O
21	O
).	O
CAPS	O
promotes	O
the	O
formation	O
of	O
dimers	O
of	O
heterotrimeric	O
SNARE	O
complexes	O
on	O
liposomes	O
","	O
which	O
may	O
be	O
mediated	O
by	O
multivalent	O
interactions	O
of	O
an	O
active	O
membrane	O
dimer	O
of	O
CAPS	O
with	O
SNARE	O
proteins	O
(	O
30	O
).	O
This	O
is	O
similar	O
to	O
mechanisms	O
suggested	O
for	O
a	O
number	O
of	O
dimeric	O
tethering	O
factors	O
(	O
51	O
","	O
52	O
).	O
By	O
contrast	O
","	O
Munc13	O
-	O
1	O
is	O
suggested	O
to	O
open	O
a	O
closed	O
form	O
of	O
syntaxin	O
-	O
1	O
(	O
53	O
"),"	O
which	O
may	O
be	O
well	O
suited	O
for	O
an	O
active	O
monomeric	O
Munc13	O
-	O
1	O
protein	O
.	O
Despite	O
divergent	O
roles	O
for	O
dimerization	O
in	O
function	O
","	O
the	O
mechanism	O
of	O
dimerization	O
for	O
CAPS	O
and	O
Munc13	O
-	O
1	O
may	O
be	O
similar	O
.	O
Munc13	O
-	O
1	O
C2A	O
and	O
CAPS	O
C2	O
domains	O
exhibit	O
41	O
%	O
amino	B-Chemical
acid	I-Chemical
sequence	O
similarity	O
","	O
and	O
neither	O
is	O
a	O
Ca2	B-Chemical
+-	I-Chemical
dependent	O
phospholipid	B-Chemical
-	O
binding	O
domain	O
(	O
50	O
).	O
Conserved	O
residues	O
in	O
the	O
CAPS	O
C2	O
domain	O
(	O
Lys	B-Chemical
-	O
428	O
and	O
Asp	B-Chemical
-	O
472	O
)	O
were	O
identified	O
based	O
on	O
the	O
Munc13	O
-	O
1	O
C2A	O
homodimer	O
structure	O
(	O
38	O
).	O
Charge	O
reversal	O
mutations	O
in	O
these	O
residues	O
impaired	O
CAPS	O
dimerization	O
and	O
function	O
","	O
supporting	O
the	O
conclusion	O
that	O
dimerization	O
mechanisms	O
for	O
CAPS	O
and	O
Munc13	O
-	O
1	O
are	O
conserved	O
.	O
Regulation	O
of	O
CAPS	O
Dimer	O
Formation	O
and	O
Function	O
The	O
binding	O
of	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
to	O
CAPS	O
markedly	O
enhanced	O
dimer	O
formation	O
(	O
Fig	O
.	O
3	O
).	O
Binding	O
of	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
to	O
the	O
PH	O
domain	O
of	O
CAPS	O
(	O
25	O
)	O
may	O
induce	O
dimer	O
formation	O
by	O
synergistic	O
interactions	O
within	O
the	O
central	O
C2	O
-	O
PH	O
region	O
of	O
CAPS	O
(	O
Fig	O
.	O
6A	O
).	O
The	O
PH	O
domain	O
is	O
immediately	O
adjacent	O
to	O
the	O
C2	O
domain	O
so	O
that	O
binding	O
of	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
in	O
the	O
membrane	O
could	O
drive	O
C2	O
domain	O
-	O
mediated	O
dimerization	O
.	O
PH	O
domains	O
can	O
also	O
dimerize	O
(	O
54	O
","	O
55	O
"),"	O
which	O
could	O
account	O
for	O
the	O
incomplete	O
loss	O
of	O
dimerization	O
in	O
CAPS	O
(	O
Î”C2	O
).	O
Dimerization	O
of	O
the	O
PH	O
domain	O
in	O
CAPS	O
could	O
increase	O
the	O
avidity	O
for	O
binding	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
","	O
which	O
would	O
further	O
stabilize	O
dimers	O
on	O
the	O
membrane	O
.	O
More	O
C	O
-	O
terminal	O
domains	O
in	O
dimerized	O
CAPS	O
such	O
as	O
MHD1	O
might	O
in	O
turn	O
exhibit	O
multivalent	O
interactions	O
with	O
SNARE	O
proteins	O
to	O
promote	O
the	O
assembly	O
of	O
dimers	O
of	O
SNARE	O
complexes	O
","	O
as	O
observed	O
on	O
liposomes	O
(	O
30	O
).	O
Thus	O
","	O
the	O
unique	O
central	O
C2	O
-	O
PH	O
domain	O
of	O
CAPS	O
could	O
serve	O
as	O
an	O
important	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
-	O
dependent	O
switch	O
for	O
the	O
activation	O
of	O
CAPS	O
as	O
a	O
dimer	O
on	O
membrane	O
.	O
This	O
model	O
would	O
account	O
for	O
the	O
essential	O
roles	O
for	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
binding	O
and	O
dimerization	O
in	O
CAPS	O
function	O
.	O
Experimental	O
Procedures	O
DNA	O
Constructs	O
A	O
site	O
-	O
directed	O
mutagenesis	O
kit	O
(	O
Qiagen	O
","	O
Hilden	O
","	O
Germany	O
)	O
was	O
used	O
with	O
pcDNA3	O
.	O
1	O
CAPS	O
-	O
Myc	O
-	O
His	O
(	O
Rattus	O
norvegicus	O
)	O
as	O
the	O
template	O
to	O
introduce	O
L468A	O
","	O
L468E	O
","	O
L468K	O
","	O
G476A	O
","	O
G476E	O
","	O
K428D	O
","	O
or	O
D472K	O
single	O
point	O
mutations	O
.	O
For	O
the	O
Î”C2	O
-	O
CAPS	O
","	O
overlap	O
extension	O
PCR	O
was	O
used	O
to	O
delete	O
amino	B-Chemical
acids	I-Chemical
400	O
â€“	O
516	O
from	O
the	O
CAPS	O
ORF	O
.	O
This	O
allowed	O
residue	O
399	O
to	O
be	O
directly	O
fused	O
to	O
residue	O
517	O
without	O
introduction	O
of	O
a	O
restriction	O
site	O
.	O
Primers	O
used	O
were	O
f1	O
(	O
CCAGGACCGATTCCAGGCTTTCCTCAATGG	O
","	O
f2	O
(	O
TCCTTCTCCTTGGAGCAAAACATGAAGCACTCTGG	O
"),"	O
r1	O
(	O
AGAGTGCTTCATGTTTTGCTCCAAGGAGAAGGACAG	O
"),"	O
and	O
r2	O
(	O
CCTGAAATGTGTAATTTGATTTTCCAGCAGAACTCGG	O
).	O
CAPS	O
-	O
mKATE2	O
-	O
His	O
constructs	O
were	O
created	O
by	O
cutting	O
CAPS	O
-	O
Myc	O
-	O
His	O
from	O
pcDNA3	O
.	O
1	O
with	O
XhoI	O
and	O
AfeI	O
and	O
ligating	O
into	O
a	O
similarly	O
cut	O
mKate2	O
-	O
C	O
(	O
Evrogen	O
","	O
Moscow	O
","	O
Russia	O
)	O
appended	O
with	O
a	O
C	O
-	O
terminal	O
His	B-Chemical
purification	O
tag	O
.	O
All	O
constructs	O
were	O
confirmed	O
by	O
Sanger	O
sequencing	O
.	O
Protein	O
Purification	O
For	O
purification	O
of	O
CAPS	O
-	O
Myc	O
-	O
His	O
and	O
CAPS	O
-	O
mKate2	O
-	O
His	O
","	O
CAPS	O
was	O
transfected	O
into	O
HEK293	O
-	O
FT	O
(	O
Invitrogen	O
)	O
cells	O
using	O
a	O
standard	O
calcium	B-Chemical
phosphate	I-Chemical
protocol	O
.	O
Two	O
days	O
after	O
transfection	O
","	O
cells	O
were	O
washed	O
and	O
removed	O
with	O
PBS	B-Chemical
.	O
Cells	O
were	O
resuspended	O
in	O
0	O
.	O
5	O
%	O
Triton	B-Chemical
X	I-Chemical
-	I-Chemical
100	I-Chemical
","	O
20	O
mm	O
HEPES	B-Chemical
","	O
300	O
mm	O
NaCl	B-Chemical
","	O
5	O
mm	O
imidazole	B-Chemical
(	O
IDA	B-Chemical
)	O
with	O
protease	O
inhibitors	O
and	O
pelleted	O
to	O
remove	O
cell	O
debris	O
.	O
Supernatants	O
were	O
loaded	O
onto	O
a	O
nickel	B-Chemical
-	I-Chemical
nitrilotriacetic	I-Chemical
acid	I-Chemical
column	O
(	O
Qiagen	O
"),"	O
washed	O
","	O
and	O
eluted	O
with	O
20	O
mm	O
HEPES	B-Chemical
","	O
300	O
mm	O
NaCl	B-Chemical
","	O
200	O
mm	O
IDA	B-Chemical
.	O
Eluates	O
were	O
diluted	O
with	O
20	O
mm	O
HEPES	B-Chemical
to	O
20	O
mm	O
NaCl	B-Chemical
","	O
100	O
mm	O
NaCl	B-Chemical
and	O
concentrated	O
to	O
âˆ¼	O
10	O
Î¼m	O
CAPS	O
.	O
Blue	O
and	O
Clear	O
Native	O
PAGE	O
For	O
clear	O
native	O
PAGE	O
","	O
purified	O
CAPS	O
-	O
Myc	O
-	O
His	O
and	O
mutants	O
in	O
20	O
mm	O
HEPES	B-Chemical
","	O
10	O
mm	O
NaCl	B-Chemical
","	O
10	O
mm	O
imidazole	B-Chemical
","	O
5	O
%	O
glycerol	B-Chemical
","	O
pH	O
7	O
.	O
4	O
","	O
were	O
loaded	O
onto	O
a	O
6	O
%	O
polyacrylamide	B-Chemical
gel	O
without	O
SDS	B-Chemical
or	O
DTT	B-Chemical
.	O
Gels	O
were	O
run	O
at	O
150	O
V	O
for	O
2	O
h	O
at	O
4	O
ÂºC	O
.	O
For	O
immunodetection	O
","	O
native	O
gels	O
were	O
subjected	O
to	O
a	O
standard	O
blotting	O
protocol	O
.	O
Blue	O
native	O
PAGE	O
was	O
performed	O
as	O
described	O
previously	O
(	O
56	O
).	O
Briefly	O
","	O
5	O
â€“	O
14	O
%	O
acrylamide	B-Chemical
resolving	O
gels	O
were	O
poured	O
with	O
a	O
3	O
.	O
3	O
%	O
acrylamide	B-Chemical
stacking	O
gel	O
(	O
Buchler	O
Instruments	O
","	O
Fort	O
Lee	O
","	O
NJ	O
).	O
Protein	O
samples	O
were	O
mixed	O
with	O
2	O
Ã—	O
sample	O
buffer	O
(	O
0	O
.	O
25	O
%	O
Coomassie	B-Chemical
G250	I-Chemical
","	O
75	O
mm	O
BisTris	B-Chemical
","	O
10	O
%	O
glycerol	B-Chemical
","	O
1	O
.	O
5	O
m	O
6	B-Chemical
-	I-Chemical
aminocaproic	I-Chemical
acid	I-Chemical
","	O
pH	O
7	O
.	O
0	O
)	O
and	O
directly	O
loaded	O
into	O
the	O
gel	O
.	O
Gels	O
were	O
run	O
at	O
150	O
V	O
through	O
the	O
stack	O
and	O
then	O
turned	O
up	O
to	O
250	O
V	O
for	O
2	O
h	O
.	O
Gels	O
were	O
fixed	O
in	O
40	O
%	O
methanol	B-Chemical
","	O
30	O
%	O
acetic	B-Chemical
acid	I-Chemical
","	O
2	O
.	O
5	O
%	O
glycerol	B-Chemical
followed	O
by	O
Coomassie	B-Chemical
G250	I-Chemical
staining	O
or	O
subjected	O
to	O
immunoblotting	O
.	O
Western	O
blotting	O
was	O
conducted	O
with	O
polyclonal	O
antibodies	O
generated	O
against	O
purified	O
full	O
-	O
length	O
rat	O
CAPS	O
or	O
with	O
Myc	O
monoclonal	O
9.00E+11	O
(	O
Covance	O
","	O
Dedham	O
","	O
MA	O
).	O
Analytical	O
Ultracentrifugation	O
Three	O
different	O
CAPS	O
concentrations	O
(	O
0	O
.	O
2	O
â€“	O
8	O
.	O
4	O
Î¼m	O
)	O
were	O
analyzed	O
.	O
âˆ¼	O
100	O
Î¼l	O
of	O
each	O
sample	O
was	O
loaded	O
into	O
sectors	O
of	O
1	O
.	O
2	O
-	O
cm	O
charcoal	B-Chemical
-	O
filled	O
epon	B-Chemical
centerpieces	O
with	O
âˆ¼	O
110	O
Î¼l	O
of	O
the	O
final	O
dialysate	O
buffer	O
in	O
the	O
reference	O
sector	O
.	O
Data	O
were	O
collected	O
at	O
4	O
Â°	O
C	O
with	O
the	O
gradients	O
monitored	O
at	O
279	O
nm	O
.	O
From	O
the	O
CAPS	O
sequence	O
","	O
the	O
partial	O
specific	O
volume	O
was	O
0	O
.	O
733	O
ml	O
/	O
g	O
and	O
is	O
uncorrected	O
for	O
temperature	O
.	O
The	O
buffer	O
composition	O
was	O
100	O
mm	O
NaCl	B-Chemical
","	O
1	O
mm	O
EDTA	B-Chemical
in	O
HEPES	B-Chemical
buffer	O
at	O
pH	O
7	O
.	O
4	O
.	O
The	O
density	O
at	O
4	O
Â°	O
C	O
was	O
1	O
.	O
44	O
g	O
/	O
ml	O
","	O
as	O
calculated	O
from	O
density	O
increments	O
(	O
Laue	O
diffraction	O
)	O
and	O
corrected	O
to	O
4	O
(	O
no	O
increment	O
was	O
available	O
for	O
HEPES	B-Chemical
","	O
and	O
its	O
contribution	O
was	O
neglected	O
).	O
CAPS	O
molecular	O
mass	O
was	O
computed	O
as	O
150	O
","	O
613	O
.	O
An	O
extinction	O
coefficient	O
of	O
138	O
","	O
660	O
/	O
m	O
/	O
cm	O
was	O
used	O
based	O
on	O
Pace	O
'	O
s	O
average	O
extinction	O
(	O
58	O
)	O
and	O
does	O
not	O
include	O
the	O
disulfide	B-Chemical
bonds	O
.	O
Equilibrium	O
data	O
were	O
collected	O
at	O
3600	O
","	O
6000	O
","	O
and	O
8800	O
rpm	O
.	O
Equilibrium	O
was	O
assumed	O
when	O
gradients	O
collected	O
â‰¥	O
3	O
h	O
apart	O
were	O
superimposable	O
.	O
After	O
a	O
high	O
speed	O
spin	O
for	O
a	O
few	O
hours	O
depleted	O
all	O
protein	O
material	O
","	O
the	O
remaining	O
absorbance	O
in	O
the	O
low	O
field	O
region	O
was	O
taken	O
as	O
a	O
measure	O
of	O
non	O
-	O
sedimentable	O
absorbance	O
","	O
which	O
was	O
<	O
0	O
.	O
1	O
and	O
treated	O
as	O
fixed	O
during	O
various	O
model	O
fittings	O
.	O
The	O
range	O
of	O
absorbance	O
in	O
the	O
data	O
included	O
in	O
the	O
analysis	O
ranged	O
from	O
0	O
.	O
3	O
to	O
1	O
.	O
4	O
(	O
at	O
1	O
.	O
2	O
-	O
cm	O
path	O
length	O
)	O
or	O
a	O
concentration	O
of	O
0	O
.	O
2	O
â€“	O
8	O
.	O
4	O
Î¼m	O
.	O
For	O
data	O
shown	O
(	O
Fig	O
.	O
1D	O
"),"	O
the	O
three	O
lines	O
for	O
each	O
color	O
represent	O
different	O
rotor	O
speeds	O
for	O
the	O
high	O
(	O
green	O
"),"	O
medium	O
(	O
blue	O
"),"	O
and	O
low	O
(	O
red	O
)	O
loading	O
concentration	O
.	O
Atomic	O
Force	O
Microscopy	O
CAPS	O
was	O
imaged	O
by	O
adding	O
100	O
pm	O
CAPS	O
to	O
freshly	O
cleaved	O
mica	B-Chemical
disks	O
and	O
allowed	O
to	O
dry	O
or	O
imaged	O
submerged	O
with	O
SLBs	O
at	O
10	O
nm	O
.	O
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
Dioleoyl	I-Chemical
-	I-Chemical
sn	I-Chemical
-	I-Chemical
glycero	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
phosphocholine	I-Chemical
(	O
DOPC	B-Chemical
"),"	O
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
dioleoyl	I-Chemical
-	I-Chemical
sn	I-Chemical
-	I-Chemical
glycero	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
phospho	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
serine	I-Chemical
(	O
DOPS	B-Chemical
"),"	O
and	O
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
dioleoyl	I-Chemical
-	I-Chemical
sn	I-Chemical
-	I-Chemical
glycero	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
phospho	I-Chemical
-(	I-Chemical
1	I-Chemical
â€²-	I-Chemical
myo	I-Chemical
-	I-Chemical
inositol	I-Chemical
-	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
bisphosphate	I-Chemical
)	I-Chemical
(	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
"),"	O
obtained	O
from	O
Avanti	O
Polar	O
Lipids	O
(	O
Birmingham	O
","	O
AL	O
)	O
as	O
chloroform	B-Chemical
stocks	O
","	O
were	O
mixed	O
at	O
molar	O
ratios	O
of	O
75	O
%	O
phosphatidylcholine	B-Chemical
","	O
25	O
%	O
phosphatidylserine	B-Chemical
or	O
75	O
%	O
phosphatidylcholine	B-Chemical
","	O
22	O
%	O
phosphatidylserine	B-Chemical
","	O
3	O
%	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
.	O
Chloroform	B-Chemical
was	O
evaporated	O
under	O
a	O
stream	O
of	O
nitrogen	B-Chemical
","	O
and	O
the	O
lipids	O
were	O
rehydrated	O
overnight	O
in	O
water	B-Chemical
(	O
MilliQ	O
)	O
at	O
a	O
lipid	O
concentration	O
of	O
2	O
mg	O
/	O
ml	O
.	O
The	O
lipid	O
suspension	O
was	O
incubated	O
at	O
65	O
Â°	O
C	O
for	O
30	O
min	O
and	O
then	O
cooled	O
to	O
room	O
temperature	O
.	O
CAPS	O
","	O
NaCl	B-Chemical
","	O
HEPES	B-Chemical
-	I-Chemical
NaOH	I-Chemical
","	O
and	O
CaCl2	B-Chemical
were	O
added	O
to	O
produce	O
a	O
liposome	O
suspension	O
containing	O
10	O
nm	O
CAPS	O
in	O
HEPES	B-Chemical
-	I-Chemical
buffered	I-Chemical
saline	I-Chemical
(	O
HBS	B-Chemical
;	O
100	O
mm	O
NaCl	B-Chemical
","	O
20	O
mm	O
HEPES	B-Chemical
","	O
pH	O
7	O
.	O
6	O
)	O
and	O
1	O
mm	O
CaCl2	B-Chemical
.	O
The	O
suspension	O
was	O
incubated	O
at	O
37	O
Â°	O
C	O
for	O
30	O
min	O
and	O
then	O
deposited	O
onto	O
freshly	O
cleaved	O
mica	B-Chemical
disks	O
(	O
Agar	O
Scientific	O
","	O
Stansted	O
","	O
UK	O
).	O
After	O
a	O
3	O
-	O
min	O
adsorption	O
","	O
the	O
sample	O
was	O
rinsed	O
with	O
HBS	B-Chemical
containing	O
CaCl2	B-Chemical
to	O
remove	O
unadsorbed	O
liposomes	O
and	O
transferred	O
to	O
the	O
atomic	O
force	O
microscope	O
.	O
AFM	O
imaging	O
was	O
carried	O
out	O
at	O
room	O
temperature	O
using	O
a	O
Bruker	O
Multimode	O
atomic	O
force	O
microscope	O
equipped	O
with	O
an	O
E	O
-	O
scanner	O
and	O
a	O
Nanoscope	O
IIIa	O
controller	O
","	O
with	O
an	O
in	O
-	O
line	O
electronics	O
extender	O
module	O
(	O
Bruker	O
","	O
Coventry	O
","	O
UK	O
).	O
All	O
images	O
were	O
collected	O
using	O
tapping	O
mode	O
in	O
fluid	O
with	O
Micromasch	O
AFM	O
cantilevers	O
NSC18	O
/	O
AL	O
BS	O
MikroMasch	O
Â®	O
(	O
Innovative	O
Solutions	O
Bulgaria	O
Ltd	O
".,"	O
Sofia	O
","	O
Bulgaria	O
).	O
The	O
cantilevers	O
(	O
typically	O
exhibiting	O
a	O
spring	O
constant	O
of	O
2	O
.	O
8	O
newtons	O
/	O
m	O
)	O
were	O
tuned	O
to	O
10	O
â€“	O
20	O
%	O
below	O
the	O
peak	O
of	O
the	O
resonance	O
frequency	O
","	O
generally	O
between	O
25	O
and	O
35	O
kHz	O
.	O
The	O
drive	O
amplitude	O
was	O
set	O
to	O
generate	O
a	O
root	O
mean	O
square	O
amplitude	O
of	O
2	O
V	O
.	O
The	O
microscope	O
was	O
engaged	O
with	O
a	O
0	O
-	O
nm	O
scan	O
area	O
to	O
allow	O
for	O
tuning	O
.	O
The	O
set	O
point	O
was	O
applied	O
to	O
the	O
sample	O
.	O
Images	O
(	O
2	O
Ã—	O
2	O
Î¼m	O
)	O
were	O
captured	O
at	O
a	O
scan	O
rate	O
of	O
2	O
Hz	O
and	O
with	O
512	O
scan	O
lines	O
/	O
area	O
.	O
Data	O
analysis	O
was	O
performed	O
using	O
commercially	O
available	O
software	O
(	O
NanoScope	O
III	O
","	O
Digital	O
Instruments	O
)	O
or	O
with	O
ImageJ	O
.	O
Multiple	O
images	O
were	O
taken	O
from	O
one	O
supported	O
lipid	O
bilayer	O
for	O
each	O
condition	O
.	O
Single	O
Molecule	O
Microscopy	O
Single	O
molecules	O
of	O
CAPS	O
-	O
mKate2	O
-	O
His	O
","	O
mKate2	O
-	O
His	O
","	O
or	O
the	O
dimeric	O
(	O
mKate2	O
)	O
2	O
-	O
His	O
were	O
immobilized	O
on	O
glass	O
by	O
SiMPull	O
(	O
35	O
).	O
Briefly	O
","	O
an	O
imaging	O
chamber	O
was	O
created	O
by	O
sandwiching	O
24	O
Ã—	O
60	O
-	O
mm	O
number	O
1	O
.	O
5	O
and	O
22	O
Ã—	O
60	O
-	O
mm	O
number	O
1	O
.	O
5	O
glass	O
slides	O
between	O
lines	O
of	O
high	O
vacuum	O
grease	O
to	O
create	O
4	O
â€“	O
5	O
channels	O
with	O
a	O
volume	O
between	O
20	O
and	O
50	O
Î¼l	O
.	O
Chambers	O
were	O
rinsed	O
with	O
10	O
chamber	O
volumes	O
of	O
buffer	O
(	O
25	O
mm	O
HEPES	B-Chemical
","	O
100	O
mm	O
KCl	B-Chemical
","	O
pH	O
7	O
.	O
4	O
)	O
to	O
remove	O
dust	O
and	O
a	O
BSA	O
/	O
antibody	O
solution	O
(	O
FC	O
protein	O
(	O
10	O
mg	O
/	O
ml	O
"),"	O
monoclonal	O
His	B-Chemical
tag	O
antibody	O
(	O
Penta	B-Chemical
-	I-Chemical
His	I-Chemical
(	O
Qiagen	O
))	O
concentration	O
of	O
0	O
.	O
1	O
mg	O
/	O
ml	O
"),"	O
incubated	O
for	O
10	O
min	O
","	O
and	O
flushed	O
with	O
5	O
chamber	O
volumes	O
of	O
buffer	O
","	O
and	O
50	O
pm	O
CAPS	O
-	O
mKate2	O
-	O
His	O
was	O
added	O
to	O
the	O
chamber	O
;	O
protein	O
was	O
diluted	O
in	O
prelubricated	O
1	O
.	O
7	O
-	O
ml	O
Eppendorf	O
tubes	O
to	O
minimize	O
nonspecific	O
absorption	O
to	O
the	O
plastic	O
surface	O
(	O
Costar	O
","	O
catalog	O
no	O
.	O
3207	O
).	O
Alternatively	O
","	O
CAPS	O
-	O
mKate2	O
-	O
His	O
was	O
immobilized	O
on	O
5	O
%	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
-	O
containing	O
SLBs	O
.	O
CAPS	O
-	O
mKate2	O
lacking	O
the	O
His	B-Chemical
tag	O
was	O
prepared	O
by	O
cleavage	O
with	O
tobacco	O
etch	O
virus	O
protease	O
(	O
R	O
&	O
D	O
Systems	O
","	O
Minneapolis	O
","	O
MN	O
)	O
and	O
similarly	O
bound	O
to	O
SLBs	O
.	O
Unbound	O
protein	O
was	O
removed	O
with	O
5	O
chamber	O
volumes	O
of	O
buffer	O
","	O
and	O
the	O
bound	O
protein	O
was	O
imaged	O
by	O
TIRF	O
microscopy	O
on	O
a	O
TE2000	O
inverted	O
scope	O
(	O
Nikon	O
)	O
stationed	O
on	O
a	O
floating	O
table	O
.	O
A	O
514	O
-	O
nm	O
laser	O
line	O
excited	O
the	O
fluorophore	O
and	O
was	O
imaged	O
with	O
an	O
Evolve	O
digital	O
monochrome	O
EMCCD	O
camera	O
(	O
Photometrics	O
","	O
Tucson	O
","	O
AZ	O
).	O
500	O
-	O
frame	O
movies	O
with	O
a	O
capture	O
rate	O
of	O
2	O
Hz	O
were	O
recorded	O
.	O
Movies	O
were	O
drift	O
-	O
corrected	O
using	O
the	O
ImageJ	O
plugin	O
Descriptor	O
-	O
based	O
registration	O
(	O
2d	O
/	O
3d	O
+	O
t	O
);	O
movies	O
with	O
significant	O
drift	O
were	O
discarded	O
.	O
Movies	O
were	O
processed	O
via	O
a	O
Matlab	O
script	O
generously	O
provided	O
by	O
Dr	O
.	O
Aaron	O
Hoskins	O
(	O
University	O
of	O
Wisconsin	O
","	O
Madison	O
","	O
WI	O
).	O
Photobleaching	O
steps	O
were	O
manually	O
recorded	O
if	O
a	O
spot	O
maintained	O
uniform	O
fluorescence	O
before	O
photobleaching	O
","	O
did	O
not	O
display	O
x	O
","	O
y	O
-	O
drift	O
","	O
and	O
underwent	O
photobleaching	O
in	O
one	O
frame	O
.	O
Gel	O
Filtration	O
Gel	O
filtration	O
of	O
purified	O
CAPS	O
-	O
Myc	O
-	O
His	O
was	O
conducted	O
on	O
a	O
Sephacryl	B-Chemical
-	I-Chemical
300	I-Chemical
(	O
Amersham	O
Biosciences	O
","	O
Little	O
Chalfont	O
","	O
UK	O
)	O
prepacked	O
column	O
via	O
FPLC	O
.	O
The	O
column	O
was	O
calibrated	O
by	O
monitoring	O
the	O
elutions	O
of	O
thyroglobulin	O
(	O
670	O
kDa	O
"),"	O
ferritin	O
(	O
440	O
kDa	O
"),"	O
and	O
aldolase	O
(	O
158	O
kDa	O
).	O
Purified	O
CAPS	O
-	O
Myc	O
-	O
His	O
was	O
loaded	O
onto	O
the	O
column	O
","	O
and	O
72	O
1	O
.	O
2	O
-	O
ml	O
fractions	O
were	O
collected	O
and	O
analyzed	O
by	O
clear	O
native	O
gels	O
and	O
immunoblotting	O
.	O
Cell	O
Ghost	O
Binding	O
PC12	O
cells	O
were	O
washed	O
twice	O
with	O
PBS	B-Chemical
","	O
removed	O
with	O
KGlu	B-Chemical
/	O
BSA	O
buffer	O
(	O
120	O
mm	O
potassium	B-Chemical
glutamate	I-Chemical
","	O
20	O
mm	O
potassium	B-Chemical
acetate	I-Chemical
","	O
20	O
mm	O
HEPES	B-Chemical
","	O
2	O
mm	O
EGTA	B-Chemical
","	O
1	O
mg	O
/	O
ml	O
BSA	O
","	O
pH	O
7	O
.	O
2	O
"),"	O
and	O
passed	O
once	O
through	O
a	O
ball	O
homogenizer	O
(	O
10	O
-	O
Î¼m	O
clearance	O
).	O
100	O
mm	O
EGTA	B-Chemical
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
10	O
mm	O
","	O
and	O
permeable	O
cells	O
were	O
incubated	O
on	O
ice	O
for	O
30	O
â€“	O
60	O
min	O
and	O
washed	O
with	O
KGlu	B-Chemical
/	O
BSA	O
to	O
remove	O
cytosolic	O
proteins	O
.	O
Cell	O
ghosts	O
were	O
divided	O
into	O
Eppendorf	O
tubes	O
","	O
resuspended	O
in	O
20	O
nm	O
CAPS	O
-	O
Myc	O
-	O
His	O
in	O
priming	O
solution	O
(	O
Mg	B-Chemical
-	I-Chemical
ATP	I-Chemical
/	O
rat	O
brain	O
cytosol	O
)	O
for	O
12	O
min	O
at	O
30	O
Â°	O
C	O
","	O
and	O
washed	O
two	O
times	O
in	O
1	O
ml	O
of	O
KGlu	B-Chemical
/	O
BSA	O
.	O
Bound	O
CAPS	O
was	O
either	O
extracted	O
with	O
300	O
mm	O
NaCl	B-Chemical
(	O
high	O
salt	O
)	O
or	O
loaded	O
directly	O
onto	O
native	O
gels	O
.	O
50	O
%	O
glycerol	B-Chemical
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
5	O
%	O
before	O
loading	O
onto	O
native	O
gels	O
.	O
Liposome	O
-	O
binding	O
Assays	O
Proteoliposomes	O
were	O
prepared	O
by	O
co	O
-	O
micellization	O
as	O
described	O
previously	O
(	O
23	O
).	O
Briefly	O
","	O
syntaxin	O
-	O
1	O
/	O
SNAP	O
-	O
25	O
in	O
25	O
mm	O
HEPES	B-Chemical
","	O
pH	O
7	O
.	O
4	O
","	O
100	O
mm	O
KCl	B-Chemical
","	O
50	O
mm	O
IDA	B-Chemical
","	O
1	O
%	O
Î²	B-Chemical
-	I-Chemical
octyl	I-Chemical
glucoside	I-Chemical
was	O
used	O
to	O
resuspend	O
a	O
dried	O
film	O
of	O
2	O
.	O
5	O
mm	O
lipid	O
of	O
DOPC	B-Chemical
","	O
5	O
%	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
.	O
After	O
resuspension	O
","	O
mixtures	O
were	O
rapidly	O
diluted	O
into	O
25	O
mm	O
HEPES	B-Chemical
","	O
100	O
mm	O
KCl	B-Chemical
","	O
pH	O
7	O
.	O
4	O
;	O
dialyzed	O
overnight	O
into	O
25	O
mm	O
HEPES	B-Chemical
","	O
100	O
mm	O
KCl	B-Chemical
","	O
1	O
mm	O
DTT	B-Chemical
","	O
pH	O
7	O
.	O
4	O
","	O
with	O
1	O
g	O
/	O
liter	O
Biobeads	O
;	O
and	O
purified	O
on	O
an	O
Accudenz	B-Chemical
medium	I-Chemical
(	O
Accurate	O
Chemical	O
Corp	O
".,"	O
Westbury	O
","	O
NY	O
)	O
gradient	O
.	O
Liposomes	O
were	O
made	O
identically	O
with	O
the	O
omission	O
of	O
the	O
SNARE	O
proteins	O
.	O
The	O
addition	O
of	O
3H	B-Chemical
-	O
labeled	O
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
dipalmitoyl	I-Chemical
phosphatidylcholine	I-Chemical
to	O
liposomes	O
was	O
used	O
to	O
monitor	O
lipid	O
recovery	O
","	O
and	O
SDS	B-Chemical
-	O
PAGE	O
densitometry	O
of	O
the	O
Q	O
-	O
SNAREs	O
was	O
used	O
to	O
assess	O
protein	O
content	O
.	O
1	O
Î¼m	O
CAPS	O
-	O
Myc	O
-	O
His	O
was	O
incubated	O
with	O
Q	O
-	O
SNARE	O
proteoliposomes	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O
Reactions	O
were	O
mixed	O
1	O
:	O
1	O
with	O
80	O
%	O
Accudenz	B-Chemical
and	O
pipetted	O
into	O
a	O
thin	O
walled	O
polycarbonate	B-Chemical
tube	O
","	O
overlaid	O
with	O
30	O
%	O
Accudenz	B-Chemical
and	O
a	O
20	O
mm	O
HEPES	B-Chemical
","	O
100	O
mm	O
KCl	B-Chemical
","	O
pH	O
7	O
.	O
4	O
","	O
layer	O
for	O
centrifugation	O
(	O
45000	O
rpm	O
","	O
SW50	O
swinging	O
bucket	O
rotor	O
).	O
Floated	O
fractions	O
were	O
withdrawn	O
and	O
analyzed	O
by	O
either	O
blue	O
native	O
or	O
SDS	B-Chemical
-	O
PAGE	O
.	O
For	O
blue	O
native	O
analysis	O
where	O
indicated	O
","	O
Triton	B-Chemical
X	I-Chemical
-	I-Chemical
100	I-Chemical
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
0	O
.	O
5	O
%	O
for	O
several	O
minutes	O
followed	O
by	O
2	O
Ã—	O
blue	O
native	O
PAGE	O
buffer	O
(	O
0	O
.	O
25	O
%	O
Coomassie	B-Chemical
G250	I-Chemical
","	O
75	O
mm	O
BisTris	B-Chemical
","	O
10	O
%	O
glycerol	B-Chemical
","	O
1	O
.	O
5	O
m	O
6	B-Chemical
-	I-Chemical
aminocaproic	I-Chemical
acid	I-Chemical
","	O
pH	O
7	O
.	O
0	O
)	O
for	O
5	O
min	O
.	O
When	O
quantification	O
was	O
required	O
","	O
floated	O
fractions	O
were	O
monitored	O
by	O
the	O
total	O
amount	O
of	O
3H	B-Chemical
-	O
labeled	O
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
dipalmitoyl	I-Chemical
phosphatidylcholine	I-Chemical
.	O
Permeable	O
Cell	O
Secretion	O
Assay	O
Rotating	O
disc	O
electrode	O
voltammetry	O
was	O
used	O
to	O
detect	O
norepinephrine	B-Chemical
secretion	O
from	O
PC12	O
cell	O
ghosts	O
as	O
described	O
previously	O
(	O
4	O
)	O
using	O
PC12	O
cells	O
loaded	O
overnight	O
with	O
1	O
.	O
5	O
mm	O
norepinephrine	B-Chemical
","	O
0	O
.	O
5	O
mm	O
ascorbate	B-Chemical
.	O
Cell	O
ghosts	O
were	O
prepared	O
as	O
described	O
above	O
","	O
washed	O
in	O
KGlu	B-Chemical
/	O
BSA	O
","	O
and	O
incubated	O
in	O
priming	O
solution	O
(	O
rat	O
brain	O
cytosol	O
at	O
1	O
:	O
10	O
dilution	O
and	O
2	O
mm	O
Mg	B-Chemical
-	I-Chemical
ATP	I-Chemical
)	O
for	O
12	O
min	O
at	O
30	O
Â°	O
C	O
","	O
which	O
generates	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
on	O
the	O
plasma	O
membrane	O
","	O
washed	O
","	O
and	O
resuspended	O
in	O
KGlu	B-Chemical
/	O
BSA	O
.	O
Cell	O
ghosts	O
were	O
added	O
directly	O
to	O
the	O
rotating	O
disc	O
electrode	O
chamber	O
with	O
10	O
nm	O
CAPS	O
","	O
and	O
Ca2	B-Chemical
+	I-Chemical
was	O
injected	O
.	O
A	O
rotating	O
carbon	B-Chemical
disc	O
electrode	O
with	O
an	O
applied	O
potential	O
of	O
+	O
500	O
MV	O
detected	O
norepinephrine	B-Chemical
release	O
.	O
The	O
output	O
was	O
processed	O
by	O
a	O
Dataq	O
analog	O
to	O
digital	O
data	O
acquisition	O
system	O
and	O
analyzed	O
by	O
WinDaq	O
software	O
.	O
Live	O
PC12	O
Secretion	O
Assay	O
The	O
Ca2	B-Chemical
+-	I-Chemical
dependent	O
exocytosis	O
of	O
BDNF	O
-	O
GFP	O
-	O
containing	O
vesicles	O
from	O
live	O
PC12	O
cells	O
was	O
monitored	O
by	O
TIRF	O
microscopy	O
as	O
described	O
previously	O
(	O
19	O
).	O
Briefly	O
","	O
PC12	O
cells	O
were	O
transfected	O
with	O
BDNF	O
-	O
GFP	O
","	O
a	O
CAPS	O
shRNA	O
plasmid	O
","	O
and	O
a	O
CAPS	O
-	O
mKate2	O
construct	O
and	O
plated	O
on	O
MatTek	O
glass	O
bottom	O
dishes	O
.	O
After	O
48	O
h	O
","	O
cells	O
were	O
imaged	O
by	O
TIRF	O
on	O
a	O
Nikon	O
TE2000	O
-	O
U	O
microscope	O
.	O
Resting	O
cells	O
in	O
15	O
mm	O
HEPES	B-Chemical
","	O
pH	O
7	O
.	O
4	O
","	O
145	O
mm	O
NaCl	B-Chemical
","	O
5	O
.	O
6	O
mm	O
KCl	B-Chemical
","	O
2	O
.	O
2	O
mm	O
CaCl2	B-Chemical
","	O
0	O
.	O
5	O
mm	O
MgCl2	B-Chemical
","	O
5	O
.	O
6	O
mm	O
glucose	B-Chemical
","	O
0	O
.	O
5	O
mm	O
ascorbic	B-Chemical
acid	I-Chemical
","	O
0	O
.	O
1	O
%	O
BSA	O
were	O
stimulated	O
by	O
buffer	O
exchange	O
into	O
15	O
mm	O
HEPES	B-Chemical
","	O
pH	O
7	O
.	O
4	O
","	O
95	O
mm	O
NaCl	B-Chemical
","	O
56	O
mm	O
KCl	B-Chemical
","	O
2	O
.	O
2	O
mm	O
CaCl2	B-Chemical
","	O
0	O
.	O
5	O
mm	O
MgCl2	B-Chemical
","	O
5	O
.	O
6	O
mm	O
glucose	B-Chemical
","	O
0	O
.	O
5	O
mm	O
ascorbic	B-Chemical
acid	I-Chemical
","	O
0	O
.	O
1	O
%	O
BSA	O
.	O
GFP	O
fluorescence	O
was	O
excited	O
with	O
a	O
488	O
-	O
nm	O
laser	O
","	O
and	O
mKate2	O
fluorescence	O
was	O
excited	O
with	O
a	O
514	O
-	O
nm	O
laser	O
and	O
imaged	O
at	O
4	O
Hz	O
with	O
either	O
a	O
CoolSNAP	O
-	O
ES	O
digital	O
monochrome	O
CCD	O
camera	O
(	O
Photometrics	O
","	O
Tucson	O
","	O
AZ	O
)	O
or	O
an	O
Evolve	O
digital	O
monochrome	O
EMCCD	O
camera	O
(	O
Photometrics	O
)	O
and	O
analyzed	O
by	O
ImageJ	O
software	O
.	O
Exocytic	O
events	O
were	O
scored	O
manually	O
.	O
Confocal	O
and	O
Electron	O
Microscopy	O
PC12	O
cells	O
were	O
transfected	O
with	O
an	O
Electroporator	O
II	O
instrument	O
(	O
Invitrogen	O
)	O
and	O
plated	O
on	O
glass	O
coverslips	O
","	O
and	O
48	O
h	O
later	O
","	O
cells	O
were	O
fixed	O
with	O
4	O
%	O
formaldehyde	B-Chemical
plus	O
PBS	B-Chemical
for	O
20	O
min	O
at	O
room	O
temperature	O
.	O
For	O
immunostaining	O
","	O
fixed	O
cells	O
were	O
extracted	O
in	O
0	O
.	O
1	O
%	O
Triton	B-Chemical
X	I-Chemical
-	I-Chemical
100	I-Chemical
.	O
Cells	O
were	O
washed	O
with	O
PBS	B-Chemical
and	O
blocked	O
for	O
30	O
min	O
in	O
10	O
%	O
BSA	O
plus	O
PBS	B-Chemical
.	O
Fixed	O
cells	O
were	O
incubated	O
with	O
primary	O
antibody	O
for	O
1	O
h	O
","	O
washed	O
","	O
and	O
incubated	O
with	O
secondary	O
antibody	O
for	O
1	O
h	O
.	O
After	O
washes	O
in	O
PBS	B-Chemical
","	O
cells	O
were	O
mounted	O
and	O
imaged	O
on	O
a	O
Nikon	O
C1	O
confocal	O
microscope	O
(	O
TE2000	O
-	O
U	O
).	O
Primary	O
antibodies	O
used	O
were	O
chromogranin	O
B	O
monoclonal	O
generously	O
provided	O
by	O
W	O
.	O
B	O
.	O
Huttner	O
(	O
Max	O
Planck	O
Institute	O
of	O
Molecular	O
Cell	O
Biology	O
and	O
Genetics	O
","	O
Dresden	O
","	O
Germany	O
"),"	O
TGN38	O
monoclonal	O
generously	O
provided	O
by	O
K	O
.	O
E	O
.	O
Howell	O
(	O
University	O
of	O
Colorado	O
","	O
Denver	O
","	O
CO	O
"),"	O
syntaxin	O
6	O
monoclonal	O
antibody	O
(	O
catalog	O
no	O
.	O
610636	O
","	O
BD	O
Biosciences	O
"),"	O
and	O
synaptotagmin	O
-	O
1	O
N	O
-	O
terminal	O
polyclonal	O
antibody	O
(	O
Sigma	O
-	O
Aldrich	O
).	O
For	O
electron	O
microscopy	O
","	O
PC12	O
cells	O
were	O
transfected	O
with	O
pCMV	O
CAPS	O
-	O
GFP	O
or	O
CAPS	O
(	O
G476E	O
)-	O
GFP	O
for	O
48	O
h	O
","	O
sorted	O
by	O
FACS	O
on	O
a	O
SORP	O
BD	O
FACSAria	O
(	O
University	O
of	O
Wisconsin	O
Carbone	O
Cancer	O
Center	O
Flow	O
Cytometry	O
Laboratory	O
)	O
to	O
remove	O
untransfected	O
cells	O
","	O
and	O
fixed	O
.	O
Cells	O
on	O
glass	O
coverslips	O
were	O
fixed	O
in	O
a	O
solution	O
of	O
2	O
.	O
5	O
%	O
glutaraldehyde	B-Chemical
","	O
2	O
.	O
0	O
%	O
paraformaldehyde	B-Chemical
in	O
0	O
.	O
1	O
m	O
sodium	B-Chemical
phosphate	I-Chemical
buffer	O
(	O
PB	B-Chemical
"),"	O
pH	O
7	O
.	O
4	O
","	O
for	O
âˆ¼	O
1	O
h	O
at	O
room	O
temperature	O
.	O
Samples	O
were	O
rinsed	O
5	O
times	O
for	O
5	O
min	O
in	O
0	O
.	O
1	O
m	O
PB	B-Chemical
.	O
The	O
rinsed	O
cultures	O
were	O
post	O
-	O
fixed	O
in	O
1	O
%	O
osmium	B-Chemical
tetroxide	I-Chemical
","	O
1	O
%	O
potassium	B-Chemical
ferrocyanide	I-Chemical
in	O
PB	B-Chemical
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O
The	O
samples	O
were	O
rinsed	O
in	O
PB	B-Chemical
followed	O
by	O
distilled	O
water	O
rinses	O
three	O
times	O
for	O
5	O
min	O
each	O
to	O
clear	O
phosphates	B-Chemical
.	O
Samples	O
were	O
en	O
bloc	O
stained	O
in	O
saturated	O
aqueous	O
uranyl	B-Chemical
acetate	I-Chemical
for	O
2	O
h	O
at	O
room	O
temperature	O
and	O
rinsed	O
in	O
distilled	O
water	O
three	O
times	O
for	O
5	O
min	O
each	O
.	O
Dehydration	O
was	O
performed	O
at	O
room	O
temperature	O
in	O
a	O
graded	O
ethanol	B-Chemical
series	O
(	O
35	O
","	O
50	O
","	O
70	O
","	O
80	O
","	O
and	O
90	O
%	O
for	O
5	O
min	O
","	O
95	O
%	O
for	O
10	O
min	O
","	O
100	O
%	O
three	O
times	O
for	O
10	O
min	O
)	O
and	O
transitioned	O
in	O
propylene	B-Chemical
oxide	I-Chemical
two	O
times	O
for	O
7	O
min	O
each	O
.	O
Durcupan	B-Chemical
ACM	I-Chemical
(	O
Fluka	O
AG	O
","	O
Buchs	O
","	O
Switzerland	O
)	O
resin	O
was	O
used	O
during	O
infiltration	O
and	O
embedding	O
.	O
Increasing	O
concentrations	O
of	O
accelerated	O
(	O
10	O
ml	O
of	O
A	O
/	O
M	O
","	O
10	O
ml	O
of	O
B	O
","	O
300	O
Î¼l	O
of	O
C	O
","	O
100	O
Î¼l	O
of	O
D	O
components	O
)	O
Durcupan	B-Chemical
were	O
used	O
for	O
infiltration	O
.	O
All	O
infiltration	O
steps	O
were	O
done	O
with	O
the	O
coverslips	O
","	O
cell	O
side	O
up	O
","	O
in	O
aluminum	B-Chemical
weighing	O
dishes	O
in	O
covered	O
glass	O
Petri	O
dishes	O
to	O
minimize	O
evaporation	O
.	O
The	O
cultures	O
were	O
embedded	O
in	O
open	O
aluminum	B-Chemical
weighing	O
dishes	O
at	O
60	O
Â°	O
C	O
in	O
a	O
drying	O
oven	O
overnight	O
until	O
polymerized	O
.	O
Samples	O
were	O
floated	O
in	O
concentrated	O
hydrofluoric	B-Chemical
acid	I-Chemical
","	O
glass	O
side	O
down	O
","	O
for	O
15	O
min	O
to	O
etch	O
off	O
the	O
glass	O
","	O
revealing	O
the	O
embedded	O
cells	O
.	O
Sections	O
were	O
viewed	O
with	O
a	O
Philips	O
CM120	O
transmission	O
electron	O
microscope	O
","	O
and	O
images	O
were	O
documented	O
with	O
a	O
MegaView	O
III	O
(	O
Olympus	O
-	O
SIS	O
","	O
Lakewood	O
","	O
CO	O
)	O
side	O
-	O
mounted	O
digital	O
camera	O
.	O
Sequence	O
Alignments	O
We	O
used	O
the	O
C2	O
domain	O
conserved	O
protein	O
domain	O
family	O
(	O
CD00030	O
)	O
as	O
a	O
seed	O
for	O
C2	O
domain	O
alignments	O
.	O
It	O
is	O
produced	O
by	O
an	O
automated	O
algorithm	O
","	O
which	O
employs	O
generic	O
search	O
parameters	O
that	O
invariably	O
contain	O
omissions	O
and	O
misalignments	O
that	O
require	O
refinement	O
.	O
Only	O
32	O
of	O
97	O
C2	O
domain	O
structures	O
represented	O
in	O
the	O
C2	O
domain	O
PFAM	O
(	O
PF00168	O
)	O
were	O
included	O
(	O
at	O
the	O
time	O
of	O
submission	O
","	O
this	O
PFAM	O
has	O
105	O
structures	O
).	O
The	O
missing	O
structures	O
were	O
imported	O
into	O
Cn3D	O
and	O
aligned	O
with	O
the	O
provided	O
block	O
alignment	O
algorithm	O
.	O
The	O
sequence	O
alignment	O
of	O
every	O
structure	O
was	O
manually	O
refined	O
by	O
assessing	O
the	O
resulting	O
spatial	O
overlap	O
between	O
the	O
C2	O
domain	O
in	O
question	O
with	O
all	O
other	O
C2	O
structures	O
.	O
After	O
assessing	O
every	O
Î²	O
strand	O
for	O
all	O
structures	O
","	O
we	O
were	O
able	O
to	O
create	O
a	O
sequence	O
alignment	O
for	O
all	O
C2	O
domain	O
structures	O
that	O
is	O
based	O
on	O
a	O
high	O
degree	O
of	O
spatial	O
overlap	O
between	O
all	O
C2	O
domain	O
residues	O
.	O
The	O
aligned	O
residues	O
represent	O
the	O
core	O
C2	O
domain	O
residues	O
that	O
have	O
an	O
invariant	O
spatial	O
positioning	O
between	O
these	O
97	O
crystal	O
structures	O
.	O
Using	O
these	O
core	O
C2	O
residues	O
as	O
a	O
search	O
query	O
","	O
DALI	O
identified	O
all	O
other	O
C2	O
domain	O
structures	O
in	O
the	O
C2	O
PFAM	O
","	O
yielding	O
an	O
average	O
root	O
mean	O
square	O
deviation	O
of	O
1	O
â„«	O
that	O
accounts	O
for	O
100	O
of	O
the	O
residues	O
tested	O
for	O
spatial	O
overlap	O
.	O
It	O
is	O
common	O
to	O
observe	O
backbone	O
atoms	O
of	O
two	O
aligned	O
C2	O
domains	O
in	O
these	O
conserved	O
regions	O
with	O
distances	O
between	O
0	O
.	O
4	O
and	O
0	O
.	O
6	O
â„«	O
","	O
less	O
than	O
that	O
of	O
an	O
H	O
â€“	O
H	O
bond	O
.	O
Author	O
Contributions	O
M	O
.	O
P	O
".,"	O
J	O
.	O
E	O
".,"	O
and	O
T	O
.	O
F	O
.	O
J	O
.	O
M	O
.	O
designed	O
the	O
study	O
and	O
wrote	O
the	O
paper	O
.	O
M	O
.	O
P	O
.	O
conducted	O
most	O
of	O
the	O
experimental	O
work	O
;	O
J	O
.	O
E	O
.	O
conducted	O
single	O
molecule	O
","	O
bioinformatic	O
","	O
and	O
mutagenesis	O
studies	O
;	O
G	O
.	O
K	O
.	O
conducted	O
cellular	O
studies	O
on	O
CAPS	O
mutants	O
;	O
and	O
S	O
.	O
M	O
.	O
conducted	O
permeable	O
cell	O
secretion	O
assays	O
.	O
H	O
.	O
T	O
.	O
and	O
J	O
.	O
M	O
.	O
E	O
.	O
designed	O
and	O
conducted	O
the	O
AFM	O
studies	O
.	O
All	O
authors	O
reviewed	O
the	O
results	O
and	O
approved	O
the	O
final	O
version	O
of	O
the	O
manuscript	O
.	O
This	O
work	O
was	O
supported	O
by	O
National	O
Institutes	O
of	O
Health	O
Grants	O
DK040428	O
and	O
GM119158	O
(	O
to	O
T	O
.	O
F	O
.	O
J	O
.	O
M	O
.)	O
and	O
a	O
Newton	O
International	O
Fellowship	O
(	O
to	O
H	O
.	O
T	O
.).	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
conflicts	O
of	O
interest	O
with	O
the	O
contents	O
of	O
this	O
article	O
.	O
The	O
content	O
is	O
solely	O
the	O
responsibility	O
of	O
the	O
authors	O
and	O
does	O
not	O
necessarily	O
represent	O
the	O
official	O
views	O
of	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O
M	O
.	O
Petrie	O
","	O
unpublished	O
observations	O
.	O
CAPS	O
Ca2	O
+-	O
dependent	O
activator	O
protein	O
in	O
secretion	O
PI	B-Chemical
(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
)	I-Chemical
P2	I-Chemical
phosphatidylinositol	B-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
bisphosphate	I-Chemical
C2	O
domain	O
homologous	O
to	O
second	O
domain	O
of	O
protein	O
kinase	O
C	O
PH	O
pleckstrin	O
homology	O
CATCHR	O
complexes	O
associated	O
with	O
tethering	O
containing	O
helical	O
rods	O
MHD	O
Munc13	O
homology	O
domain	O
TIRF	O
total	O
internal	O
reflection	O
fluorescence	O
SLB	O
supported	O
lipid	O
bilayer	O
AFM	O
atomic	O
force	O
microscopy	O
IDA	B-Chemical
imidazole	B-Chemical
BisTris	B-Chemical
2	B-Chemical
-[	I-Chemical
bis	I-Chemical
(	I-Chemical
2	I-Chemical
-	I-Chemical
hydroxyethyl	I-Chemical
)	I-Chemical
amino	I-Chemical
]-	I-Chemical
2	I-Chemical
-(	I-Chemical
hydroxymethyl	I-Chemical
)	I-Chemical
propane	I-Chemical
-	I-Chemical
1	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
diol	I-Chemical
DOPC	B-Chemical
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
dioleoyl	I-Chemical
-	I-Chemical
sn	I-Chemical
-	I-Chemical
glycero	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
phosphocholine	I-Chemical
DOPS	B-Chemical
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
dioleoyl	I-Chemical
-	I-Chemical
sn	I-Chemical
-	I-Chemical
glycero	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
phospho	I-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
serine	I-Chemical
PC	B-Chemical
phosphatidylcholine	B-Chemical
PS	B-Chemical
phosphatidylserine	B-Chemical
CN	O
clear	O
native	O
gel	O
BN	O
blue	O
native	O
gel	O
.	O
The	O
abbreviations	O
used	O
are	O
:	O
References	O
Urinary	O
metabolomics	O
of	O
young	O
Italian	O
autistic	O
children	O
supports	O
abnormal	O
tryptophan	B-Chemical
and	O
purine	B-Chemical
metabolism	O
Background	O
Autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
is	O
still	O
diagnosed	O
through	O
behavioral	O
observation	O
","	O
due	O
to	O
a	O
lack	O
of	O
laboratory	O
biomarkers	O
","	O
which	O
could	O
greatly	O
aid	O
clinicians	O
in	O
providing	O
earlier	O
and	O
more	O
reliable	O
diagnoses	O
.	O
Metabolomics	O
on	O
human	O
biofluids	O
provides	O
a	O
sensitive	O
tool	O
to	O
identify	O
metabolite	O
profiles	O
potentially	O
usable	O
as	O
biomarkers	O
for	O
ASD	O
.	O
Initial	O
metabolomic	O
studies	O
","	O
analyzing	O
urines	O
and	O
plasma	O
of	O
ASD	O
and	O
control	O
individuals	O
","	O
suggested	O
that	O
autistic	O
patients	O
may	O
share	O
some	O
metabolic	O
abnormalities	O
","	O
despite	O
several	O
inconsistencies	O
stemming	O
from	O
differences	O
in	O
technology	O
","	O
ethnicity	O
","	O
age	O
range	O
","	O
and	O
definition	O
of	O
â€œ	O
control	O
â€	O
status	O
.	O
Methods	O
ASD	O
-	O
specific	O
urinary	O
metabolomic	O
patterns	O
were	O
explored	O
at	O
an	O
early	O
age	O
in	O
30	O
ASD	O
children	O
and	O
30	O
matched	O
controls	O
(	O
age	O
range	O
2	O
â€“	O
7	O
","	O
M	O
:	O
F	O
=	O
22	O
:	O
8	O
)	O
using	O
hydrophilic	O
interaction	O
chromatography	O
(	O
HILIC	O
)-	O
UHPLC	O
and	O
mass	O
spectrometry	O
","	O
a	O
highly	O
sensitive	O
","	O
accurate	O
","	O
and	O
unbiased	O
approach	O
.	O
Metabolites	O
were	O
then	O
subjected	O
to	O
multivariate	O
statistical	O
analysis	O
and	O
grouped	O
by	O
metabolic	O
pathway	O
.	O
Results	O
Urinary	O
metabolites	O
displaying	O
the	O
largest	O
differences	O
between	O
young	O
ASD	O
and	O
control	O
children	O
belonged	O
to	O
the	O
tryptophan	B-Chemical
and	O
purine	B-Chemical
metabolic	O
pathways	O
.	O
Also	O
","	O
vitamin	B-Chemical
B6	I-Chemical
","	O
riboflavin	B-Chemical
","	O
phenylalanine	B-Chemical
-	O
tyrosine	B-Chemical
-	O
tryptophan	B-Chemical
biosynthesis	O
","	O
pantothenate	B-Chemical
and	O
CoA	B-Chemical
","	O
and	O
pyrimidine	B-Chemical
metabolism	O
differed	O
significantly	O
.	O
ASD	O
children	O
preferentially	O
transform	O
tryptophan	B-Chemical
into	O
xanthurenic	B-Chemical
acid	I-Chemical
and	O
quinolinic	B-Chemical
acid	I-Chemical
(	O
two	O
catabolites	O
of	O
the	O
kynurenine	B-Chemical
pathway	O
"),"	O
at	O
the	O
expense	O
of	O
kynurenic	B-Chemical
acid	I-Chemical
and	O
especially	O
of	O
melatonin	B-Chemical
.	O
Also	O
","	O
the	O
gut	O
microbiome	O
contributes	O
to	O
altered	O
tryptophan	B-Chemical
metabolism	O
","	O
yielding	O
increased	O
levels	O
of	O
indolyl	B-Chemical
3	I-Chemical
-	I-Chemical
acetic	I-Chemical
acid	I-Chemical
and	O
indolyl	B-Chemical
lactate	I-Chemical
.	O
Conclusions	O
The	O
metabolic	O
pathways	O
most	O
distinctive	O
of	O
young	O
Italian	O
autistic	O
children	O
largely	O
overlap	O
with	O
those	O
found	O
in	O
rodent	O
models	O
of	O
ASD	O
following	O
maternal	O
immune	O
activation	O
or	O
genetic	O
manipulations	O
.	O
These	O
results	O
are	O
consistent	O
with	O
the	O
proposal	O
of	O
a	O
purine	B-Chemical
-	O
driven	O
cell	O
danger	O
response	O
","	O
accompanied	O
by	O
overproduction	O
of	O
epileptogenic	O
and	O
excitotoxic	O
quinolinic	B-Chemical
acid	I-Chemical
","	O
large	O
reductions	O
in	O
melatonin	B-Chemical
synthesis	O
","	O
and	O
gut	O
dysbiosis	O
.	O
These	O
metabolic	O
abnormalities	O
could	O
underlie	O
several	O
comorbidities	O
frequently	O
associated	O
to	O
ASD	O
","	O
such	O
as	O
seizures	O
","	O
sleep	O
disorders	O
","	O
and	O
gastrointestinal	O
symptoms	O
","	O
and	O
could	O
contribute	O
to	O
autism	O
severity	O
.	O
Their	O
diagnostic	O
sensitivity	O
","	O
disease	O
-	O
specificity	O
","	O
and	O
interethnic	O
variability	O
will	O
merit	O
further	O
investigation	O
.	O
Electronic	O
supplementary	O
material	O
The	O
online	O
version	O
of	O
this	O
article	O
(	O
doi	O
:	O
10	O
.	O
1186	O
/	O
s13229	O
-	O
16	O
-	O
109	O
-	O
5	O
)	O
contains	O
supplementary	O
material	O
","	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O
Background	O
Autism	O
spectrum	O
disorder	O
(	O
ASD	O
)	O
represents	O
a	O
highly	O
heterogeneous	O
collection	O
of	O
neurodevelopmental	O
conditions	O
characterized	O
by	O
social	O
and	O
communication	O
deficits	O
","	O
stereotypic	O
and	O
rigid	O
patterns	O
of	O
behavior	O
","	O
restricted	O
interests	O
","	O
and	O
unusual	O
sensory	O
processing	O
with	O
onset	O
in	O
early	O
childhood	O
[	O
1	O
].	O
The	O
prevalence	O
of	O
autism	O
has	O
increased	O
significantly	O
during	O
the	O
last	O
two	O
decades	O
from	O
2	O
â€“	O
5	O
/	O
10	O
","	O
0	O
to	O
1	O
:	O
68	O
children	O
[	O
2	O
","	O
3	O
].	O
Changes	O
in	O
diagnostic	O
criteria	O
and	O
increased	O
attention	O
by	O
the	O
medical	O
community	O
have	O
certainly	O
contributed	O
to	O
this	O
trend	O
[	O
4	O
].	O
Also	O
","	O
increasing	O
parental	O
age	O
at	O
conception	O
has	O
been	O
shown	O
to	O
confer	O
ASD	O
risk	O
[	O
5	O
"],"	O
as	O
well	O
as	O
some	O
environmental	O
factors	O
","	O
active	O
especially	O
during	O
critical	O
periods	O
in	O
prenatal	O
/	O
early	O
postnatal	O
neurodevelopment	O
[	O
6	O
].	O
Finally	O
","	O
genetic	O
susceptibility	O
plays	O
a	O
prominent	O
role	O
in	O
ASD	O
pathogenesis	O
through	O
complex	O
and	O
heterogeneous	O
underpinnings	O
","	O
ranging	O
from	O
rare	O
variants	O
endowed	O
with	O
full	O
penetrance	O
to	O
common	O
variants	O
each	O
explaining	O
very	O
small	O
proportions	O
of	O
the	O
overall	O
phenotypic	O
variance	O
","	O
either	O
alone	O
or	O
through	O
gene	O
Ã—	O
environment	O
interactions	O
[	O
7	O
","	O
8	O
].	O
Despite	O
major	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
pathophysiology	O
of	O
ASD	O
","	O
this	O
level	O
of	O
complexity	O
and	O
interindividual	O
heterogeneity	O
has	O
largely	O
hampered	O
the	O
translation	O
of	O
scientific	O
knowledge	O
into	O
more	O
effective	O
clinical	O
practices	O
.	O
ASD	O
is	O
still	O
diagnosed	O
exclusively	O
through	O
observation	O
","	O
standardized	O
behavioral	O
scales	O
","	O
and	O
parental	O
interviews	O
;	O
developmental	O
trajectories	O
of	O
ASD	O
children	O
are	O
periodically	O
monitored	O
but	O
cannot	O
be	O
reliably	O
predicted	O
especially	O
at	O
an	O
early	O
age	O
.	O
Sensitive	O
and	O
specific	O
quantitative	O
biomarkers	O
","	O
measurable	O
through	O
laboratory	O
","	O
brain	O
imaging	O
","	O
and	O
/	O
or	O
electrophysiological	O
techniques	O
","	O
could	O
greatly	O
aid	O
clinicians	O
in	O
providing	O
earlier	O
diagnoses	O
","	O
more	O
timely	O
referrals	O
to	O
behavioral	O
intervention	O
programs	O
","	O
and	O
evidence	O
-	O
based	O
prognostic	O
predictions	O
[	O
9	O
].	O
Metabolomic	O
technologies	O
offer	O
a	O
sensitive	O
means	O
to	O
search	O
human	O
biofluids	O
for	O
metabolite	O
profiles	O
potentially	O
usable	O
as	O
biomarkers	O
for	O
neurodevelopmental	O
disorders	O
.	O
A	O
few	O
studies	O
have	O
recently	O
begun	O
exploring	O
the	O
potential	O
of	O
urinary	O
metabolomics	O
in	O
identifying	O
ASD	O
-	O
specific	O
metabolic	O
patterns	O
or	O
in	O
stratifying	O
ASD	O
patients	O
into	O
pathophysiologically	O
meaningful	O
subgroups	O
[	O
10	O
â€“	O
17	O
].	O
Most	O
studies	O
have	O
been	O
performed	O
on	O
urines	O
[	O
10	O
â€“	O
16	O
];	O
one	O
study	O
has	O
explored	O
blood	O
plasma	O
[	O
17	O
].	O
The	O
analytical	O
platforms	O
most	O
commonly	O
used	O
to	O
identify	O
and	O
quantify	O
metabolites	O
are	O
gas	O
or	O
liquid	O
chromatography	O
combined	O
with	O
mass	O
spectroscopy	O
(	O
gas	O
chromatography	O
(	O
GC	O
)-	O
mass	O
spectroscopy	O
(	O
MS	O
)	O
and	O
liquid	O
chromatography	O
(	O
LC	O
)-	O
MS	O
","	O
respectively	O
)	O
[	O
12	O
","	O
16	O
]	O
and	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
(	O
NMR	O
)	O
[	O
10	O
","	O
13	O
","	O
14	O
","	O
16	O
","	O
18	O
","	O
19	O
].	O
In	O
general	O
","	O
NMR	O
displays	O
greater	O
speed	O
and	O
good	O
reproducibility	O
but	O
also	O
lower	O
sensitivity	O
compared	O
to	O
MS	O
.	O
Hence	O
","	O
MS	O
-	O
and	O
NMR	O
-	O
based	O
techniques	O
should	O
be	O
viewed	O
as	O
complementary	O
","	O
not	O
as	O
superimposable	O
approaches	O
.	O
An	O
initial	O
study	O
","	O
using	O
1H	B-Chemical
-	O
NMR	O
methods	O
","	O
showed	O
an	O
abnormal	O
composition	O
of	O
urinary	O
solutes	O
indicative	O
of	O
perturbations	O
in	O
(	O
a	O
)	O
the	O
tryptophan	B-Chemical
/	O
nicotinic	B-Chemical
acid	I-Chemical
metabolic	O
pathway	O
","	O
(	O
b	O
)	O
sulfur	B-Chemical
and	O
amino	B-Chemical
acid	I-Chemical
metabolisms	O
","	O
and	O
(	O
c	O
)	O
gut	O
microbiome	O
","	O
with	O
an	O
excess	O
of	O
several	O
gut	O
-	O
derived	O
co	O
-	O
metabolites	O
[	O
10	O
].	O
Two	O
other	O
studies	O
presumably	O
assessing	O
the	O
same	O
clinical	O
sample	O
with	O
two	O
different	O
NMR	O
-	O
based	O
technologies	O
largely	O
replicated	O
these	O
initial	O
findings	O
[	O
13	O
","	O
14	O
].	O
Other	O
studies	O
using	O
GC	O
-	O
MS	O
","	O
either	O
alone	O
[	O
12	O
","	O
15	O
]	O
or	O
in	O
combination	O
with	O
liquid	O
chromatography	O
[	O
11	O
"],"	O
also	O
identified	O
perturbations	O
in	O
amino	B-Chemical
acid	I-Chemical
metabolism	O
and	O
gut	O
microbial	O
co	O
-	O
metabolites	O
","	O
as	O
well	O
as	O
metabolic	O
signatures	O
of	O
oxidative	O
stress	O
.	O
Only	O
one	O
very	O
recent	O
study	O
used	O
both	O
NMR	O
and	O
LC	O
-	O
MS	O
","	O
providing	O
support	O
for	O
abnormalities	O
in	O
tryptophan	B-Chemical
metabolism	O
","	O
gut	O
bacterial	O
-	O
derived	O
compounds	O
","	O
purine	B-Chemical
and	O
pyrimidine	B-Chemical
metabolism	O
[	O
16	O
].	O
The	O
only	O
study	O
exploring	O
blood	O
plasma	O
reported	O
metabolomic	O
patterns	O
compatible	O
with	O
(	O
a	O
)	O
mitochondrial	O
dysfunction	O
","	O
yielding	O
reduced	O
energy	O
production	O
and	O
unbalanced	O
redox	O
status	O
","	O
(	O
b	O
)	O
excess	O
gut	O
microbial	O
co	O
-	O
metabolites	O
","	O
and	O
(	O
c	O
)	O
unbalances	O
in	O
various	O
metabolic	O
pathways	O
","	O
such	O
as	O
the	O
Krebs	O
cycle	O
[	O
17	O
].	O
Collectively	O
","	O
metabolomic	O
studies	O
performed	O
to	O
this	O
date	O
suggest	O
that	O
autistic	O
patients	O
may	O
share	O
several	O
metabolic	O
abnormalities	O
","	O
especially	O
involving	O
some	O
amino	B-Chemical
acid	I-Chemical
metabolisms	O
","	O
energy	O
production	O
","	O
and	O
oxidative	O
stress	O
","	O
as	O
well	O
as	O
the	O
gut	O
microbiome	O
.	O
Moving	O
from	O
broad	O
metabolic	O
pathways	O
to	O
single	O
compounds	O
unveils	O
inconsistencies	O
between	O
studies	O
","	O
which	O
may	O
stem	O
from	O
several	O
potential	O
confounds	O
.	O
Interethnic	O
differences	O
in	O
the	O
gut	O
microbiota	O
","	O
stemming	O
from	O
differences	O
in	O
the	O
nutrient	O
composition	O
of	O
local	O
diets	O
","	O
as	O
well	O
as	O
age	O
-	O
related	O
changes	O
in	O
both	O
gut	O
microbiota	O
and	O
human	O
metabolism	O
indeed	O
require	O
that	O
case	O
and	O
control	O
samples	O
be	O
tightly	O
matched	O
for	O
these	O
two	O
variables	O
.	O
Age	O
-	O
related	O
changes	O
may	O
be	O
especially	O
relevant	O
to	O
studies	O
of	O
ASD	O
","	O
where	O
we	O
have	O
recently	O
reported	O
levels	O
of	O
urinary	O
p	B-Chemical
-	I-Chemical
cresol	I-Chemical
to	O
be	O
elevated	O
in	O
autistic	O
children	O
compared	O
to	O
age	O
-	O
matched	O
controls	O
both	O
in	O
Italy	O
and	O
in	O
France	O
","	O
but	O
exclusively	O
up	O
until	O
8	O
years	O
of	O
age	O
[	O
20	O
","	O
21	O
].	O
Similar	O
age	O
-	O
related	O
changes	O
in	O
ASD	O
have	O
been	O
previously	O
described	O
for	O
other	O
parameters	O
","	O
such	O
as	O
brain	O
serotonin	B-Chemical
synthesis	O
capacity	O
[	O
22	O
","	O
23	O
]	O
and	O
excessive	O
head	O
growth	O
rates	O
[	O
24	O
].	O
Finally	O
","	O
some	O
studies	O
have	O
contrasted	O
ASD	O
patients	O
with	O
unrelated	O
population	O
controls	O
[	O
11	O
","	O
14	O
","	O
16	O
","	O
17	O
"],"	O
while	O
others	O
have	O
enrolled	O
unaffected	O
siblings	O
as	O
controls	O
[	O
15	O
]	O
and	O
one	O
study	O
has	O
used	O
both	O
[	O
10	O
].	O
These	O
strategies	O
are	O
not	O
equivalent	O
","	O
as	O
first	O
-	O
degree	O
relatives	O
often	O
fall	O
within	O
the	O
broad	O
autism	O
spectrum	O
(	O
i	O
.	O
e	O
".,"	O
they	O
display	O
behavioral	O
phenotypes	O
intermediate	O
between	O
patients	O
and	O
population	O
controls	O
)	O
[	O
25	O
].	O
In	O
addition	O
","	O
siblings	O
may	O
carry	O
protective	O
gene	O
variants	O
with	O
peculiar	O
functional	O
correlates	O
","	O
possibly	O
distinct	O
from	O
the	O
metabolic	O
patterns	O
of	O
unrelated	O
typically	O
developing	O
children	O
.	O
Taking	O
into	O
consideration	O
these	O
methodological	O
issues	O
","	O
in	O
order	O
to	O
maximize	O
the	O
probability	O
of	O
reliably	O
detecting	O
differences	O
in	O
urinary	O
metabolic	O
patterns	O
","	O
we	O
focused	O
on	O
autistic	O
and	O
unrelated	O
typically	O
developing	O
children	O
2	O
â€“	O
8	O
years	O
old	O
","	O
tightly	O
matched	O
by	O
age	O
","	O
sex	O
","	O
Italian	O
ancestry	O
","	O
and	O
city	O
of	O
origin	O
within	O
the	O
country	O
[	O
20	O
].	O
To	O
ensure	O
broad	O
metabolite	O
detection	O
coverage	O
on	O
urine	O
samples	O
","	O
which	O
comprise	O
molecules	O
generated	O
both	O
by	O
human	O
cells	O
and	O
by	O
the	O
gut	O
microbiome	O
","	O
we	O
employed	O
hydrophilic	O
interaction	O
chromatography	O
(	O
HILIC	O
)-	O
LC	O
-	O
electrospray	O
ionization	O
(	O
ESI	O
)-	O
MS	O
","	O
a	O
technology	O
particularly	O
suitable	O
to	O
separate	O
simple	O
and	O
complex	O
mixtures	O
of	O
carbohydrates	B-Chemical
","	O
amino	B-Chemical
acids	I-Chemical
","	O
glycosides	B-Chemical
","	O
and	O
other	O
natural	O
polar	O
products	O
in	O
biological	O
fluids	O
","	O
such	O
as	O
human	O
urine	O
and	O
plasma	O
[	O
26	O
","	O
27	O
].	O
Applying	O
this	O
experimental	O
approach	O
","	O
urinary	O
metabolites	O
most	O
significantly	O
distinguishing	O
autistic	O
from	O
typically	O
developing	O
children	O
were	O
found	O
to	O
primarily	O
fall	O
into	O
the	O
tryptophan	B-Chemical
and	O
purine	B-Chemical
metabolic	O
pathways	O
.	O
Methods	O
Subjects	O
Thirty	O
children	O
with	O
idiopathic	O
ASD	O
and	O
thirty	O
typically	O
developing	O
controls	O
were	O
recruited	O
in	O
Central	O
and	O
Northern	O
Italy	O
.	O
These	O
represent	O
the	O
vast	O
majority	O
of	O
the	O
64	O
cases	O
and	O
controls	O
aged	O
3	O
â€“	O
7	O
years	O
assessed	O
for	O
urinary	O
p	B-Chemical
-	I-Chemical
cresol	I-Chemical
in	O
our	O
previous	O
study	O
[	O
20	O
].	O
Their	O
demographic	O
and	O
clinical	O
characteristics	O
are	O
summarized	O
in	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
.	O
Diagnostic	O
assessments	O
and	O
medical	O
screening	O
have	O
been	O
previously	O
described	O
[	O
20	O
]	O
(	O
also	O
see	O
Additional	O
file	O
2	O
with	O
Supplementary	O
Methods	O
).	O
Tight	O
sex	O
-	O
and	O
age	O
-	O
matching	O
(Â±	O
1	O
year	O
)	O
was	O
applied	O
to	O
recruit	O
typically	O
developing	O
children	O
devoid	O
of	O
any	O
overt	O
ASD	O
symptomatology	O
among	O
the	O
offspring	O
of	O
clinical	O
/	O
academic	O
personnel	O
[	O
20	O
].	O
Mean	O
age	O
(Â±	O
SEM	O
)	O
of	O
cases	O
and	O
controls	O
was	O
4	O
.	O
83	O
Â±	O
0	O
.	O
30	O
and	O
5	O
.	O
3	O
Â±	O
0	O
.	O
32	O
years	O
","	O
respectively	O
(	O
Student	O
â€™	O
s	O
t	O
=	O
âˆ’	O
0	O
.	O
459	O
","	O
58	O
df	O
","	O
P	O
=	O
0	O
.	O
648	O
","	O
n	O
.	O
s	O
.	O
"),"	O
and	O
the	O
M	O
:	O
F	O
ratio	O
was	O
22	O
:	O
8	O
.	O
All	O
cases	O
and	O
controls	O
were	O
of	O
Italian	O
descent	O
and	O
matched	O
by	O
geographical	O
area	O
or	O
city	O
of	O
origin	O
.	O
Urine	O
collection	O
and	O
metabolite	O
extraction	O
First	O
-	O
morning	O
urines	O
were	O
collected	O
at	O
home	O
by	O
parents	O
using	O
sterile	O
containers	O
untreated	O
with	O
preservatives	O
and	O
were	O
brought	O
to	O
each	O
clinical	O
center	O
the	O
same	O
morning	O
in	O
wet	O
ice	B-Chemical
.	O
Urine	O
samples	O
were	O
then	O
frozen	O
","	O
shipped	O
in	O
dry	B-Chemical
ice	I-Chemical
","	O
and	O
stored	O
at	O
âˆ’	O
80	O
Â°	O
C	O
continuously	O
until	O
analysis	O
.	O
Urinary	O
specific	O
gravity	O
was	O
measured	O
by	O
refractometry	O
following	O
centrifugation	O
at	O
13	O
","	O
000g	O
for	O
10	O
min	O
)	O
using	O
a	O
digital	O
refractometer	O
(	O
Euromex	O
Clinical	O
Digital	O
Refractometer	O
RD	O
.	O
5712	O
","	O
NL	O
)	O
previously	O
calibrated	O
with	O
LC	O
-	O
MS	O
grade	O
water	B-Chemical
.	O
Urine	O
aliquots	O
(	O
200	O
Î¼l	O
)	O
were	O
mixed	O
with	O
200	O
Î¼l	O
of	O
methanol	B-Chemical
:	O
acetonitrile	B-Chemical
:	O
water	B-Chemical
(	O
50	O
:	O
30	O
:	O
20	O
"),"	O
vortexed	O
for	O
30	O
min	O
at	O
max	O
speed	O
at	O
4	O
Â°	O
C	O
and	O
then	O
centrifuged	O
at	O
16	O
","	O
000g	O
for	O
15	O
min	O
at	O
4	O
Â°	O
C	O
.	O
Supernatants	O
were	O
collected	O
for	O
metabolomic	O
analysis	O
.	O
Quality	O
controls	O
(	O
QCs	O
)	O
were	O
obtained	O
from	O
a	O
pooled	O
mixture	O
of	O
10	O
Î¼l	O
aliquots	O
of	O
all	O
urine	O
samples	O
and	O
were	O
analyzed	O
every	O
15	O
samples	O
.	O
HILIC	O
-	O
UHPLC	O
Metabolite	O
separation	O
was	O
performed	O
as	O
previously	O
described	O
[	O
28	O
"],"	O
by	O
hydrophilic	O
interaction	O
chromatography	O
(	O
HILIC	O
)	O
using	O
the	O
Ultimate	O
3000	O
Rapid	O
Resolution	O
HPLC	O
system	O
(	O
Dionex	O
","	O
Sunnyvale	O
","	O
CA	O
"),"	O
featuring	O
a	O
binary	O
pump	O
and	O
vacuum	O
degasser	O
","	O
well	O
-	O
plate	O
autosampler	O
with	O
a	O
six	O
-	O
port	O
micro	O
-	O
switching	O
valve	O
","	O
and	O
a	O
thermostated	O
column	O
compartment	O
.	O
A	O
Phenomenex	O
Luna	O
3	O
Î¼m	O
HILIC	O
200	O
A	O
(	O
150	O
Ã—	O
2	O
.	O
0	O
mm	O
)	O
column	O
","	O
protected	O
by	O
a	O
HILIC	O
4	O
Ã—	O
2	O
.	O
0	O
mm	O
ID	O
guard	O
column	O
(	O
Phenomenex	O
","	O
Torrance	O
","	O
CA	O
"),"	O
was	O
used	O
to	O
perform	O
metabolite	O
separation	O
over	O
a	O
phase	O
B	O
-	O
to	O
-	O
phase	O
A	O
gradient	O
lasting	O
35	O
min	O
.	O
For	O
the	O
HILIC	O
separation	O
","	O
mobile	O
phase	O
â€œ	O
A	O
â€	O
consisted	O
in	O
50	O
mM	O
ammonium	B-Chemical
acetate	I-Chemical
mixed	O
with	O
acetonitrile	B-Chemical
(	O
95	O
:	O
5	O
","	O
v	O
/	O
v	O
"),"	O
while	O
eluent	O
â€œ	O
B	O
â€	O
was	O
composed	O
of	O
a	O
mixture	O
of	O
50	O
mM	O
ammonium	B-Chemical
acetate	I-Chemical
:	O
water	B-Chemical
plus	O
acetonitrile	B-Chemical
(	O
95	O
:	O
5	O
","	O
v	O
/	O
v	O
).	O
Acetonitrile	B-Chemical
","	O
formic	B-Chemical
acid	I-Chemical
","	O
and	O
HPLC	O
-	O
grade	O
water	B-Chemical
were	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St	O
.	O
Louis	O
","	O
MO	O
).	O
Mass	O
spectrometry	O
MS	O
analysis	O
was	O
carried	O
out	O
on	O
an	O
electrospray	O
hybrid	O
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
instrument	O
MicroTOF	O
-	O
Q	O
(	O
Bruker	O
-	O
Daltonik	O
","	O
Bremen	O
","	O
Germany	O
)	O
equipped	O
with	O
an	O
ESI	O
ion	O
source	O
","	O
as	O
previously	O
described	O
[	O
29	O
].	O
Mass	O
spectra	O
for	O
metabolite	O
-	O
extracted	O
samples	O
were	O
acquired	O
both	O
in	O
positive	O
and	O
in	O
negative	O
ion	O
modes	O
;	O
only	O
data	O
produced	O
in	O
negative	O
mode	O
are	O
shown	O
","	O
because	O
more	O
powerful	O
in	O
analyzing	O
urinary	O
samples	O
.	O
ESI	O
capillary	O
voltage	O
was	O
set	O
at	O
4500	O
V	O
(âˆ’)	O
ion	O
mode	O
.	O
The	O
liquid	O
nebulizer	O
was	O
set	O
at	O
27	O
psi	O
","	O
and	O
the	O
nitrogen	B-Chemical
drying	O
gas	O
was	O
set	O
to	O
a	O
flow	O
rate	O
of	O
6	O
L	O
/	O
min	O
.	O
Dry	O
gas	O
temperature	O
was	O
maintained	O
at	O
200	O
Â°	O
C	O
.	O
Data	O
were	O
stored	O
in	O
centroid	O
mode	O
and	O
acquired	O
with	O
a	O
stored	O
mass	O
range	O
of	O
50	O
â€“	O
1200	O
m	O
/	O
z	O
.	O
Instrument	O
calibration	O
was	O
performed	O
externally	O
every	O
day	O
with	O
10	O
mM	O
sodium	B-Chemical
hydroxide	I-Chemical
in	O
50	O
%	O
isopropanol	B-Chemical
:	O
water	B-Chemical
","	O
0	O
.	O
1	O
%	O
formic	B-Chemical
acid	I-Chemical
.	O
Automated	O
internal	O
mass	O
scale	O
calibration	O
was	O
performed	O
through	O
direct	O
automated	O
injection	O
of	O
the	O
calibration	O
solution	O
at	O
the	O
beginning	O
and	O
at	O
the	O
end	O
of	O
each	O
run	O
by	O
a	O
six	O
-	O
port	O
divert	O
valve	O
.	O
Data	O
elaboration	O
and	O
statistical	O
analysis	O
Data	O
were	O
normalized	O
by	O
urinary	O
specific	O
gravity	O
","	O
because	O
creatinine	B-Chemical
excretion	O
may	O
be	O
abnormally	O
reduced	O
in	O
ASD	O
children	O
[	O
30	O
].	O
Replicates	O
were	O
exported	O
as	O
mzXML	O
files	O
and	O
processed	O
through	O
MAVEN	O
.	O
52	O
(	O
available	O
at	O
http	O
://	O
genomics	O
-	O
pubs	O
.	O
princeton	O
.	O
edu	O
/	O
mzroll	O
/	O
index	O
.	O
php	O
?	O
show	O
=	O
index	O
)	O
[	O
31	O
].	O
Mass	O
spectrometry	O
chromatograms	O
were	O
elaborated	O
for	O
peak	O
alignment	O
","	O
matching	O
and	O
comparison	O
of	O
parent	O
and	O
fragment	O
ions	O
","	O
and	O
tentative	O
metabolite	O
identification	O
(	O
within	O
a	O
10	O
-	O
ppm	O
mass	O
deviation	O
range	O
between	O
observed	O
and	O
expected	O
results	O
against	O
the	O
imported	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
(	O
KEGG	O
)	O
database	O
).	O
Representative	O
examples	O
of	O
mass	O
determination	O
and	O
MS	O
/	O
MS	O
fragmentation	O
graphs	O
are	O
presented	O
for	O
kynurenine	B-Chemical
","	O
melatonin	B-Chemical
","	O
and	O
tryptophan	B-Chemical
in	O
Additional	O
file	O
3	O
:	O
Figure	O
S1	O
.	O
Multivariate	O
statistical	O
analyses	O
were	O
performed	O
on	O
the	O
entire	O
metabolomics	O
data	O
set	O
using	O
the	O
MetaboAnalyst	O
3	O
.	O
0	O
software	O
(	O
http	O
://	O
www	O
.	O
metaboanalyst	O
.	O
ca	O
)	O
[	O
32	O
"],"	O
which	O
also	O
overviewed	O
data	O
variance	O
structure	O
in	O
an	O
unsupervised	O
manner	O
and	O
produced	O
scatter	O
plots	O
.	O
Orthogonal	O
partial	O
least	O
squares	O
discriminant	O
analysis	O
(	O
OPLS	O
-	O
DA	O
"),"	O
which	O
defines	O
a	O
predictive	O
model	O
that	O
describes	O
the	O
direction	O
of	O
the	O
maximum	O
covariance	O
between	O
a	O
dataset	O
(	O
X	O
)	O
and	O
class	O
membership	O
(	O
Y	O
"),"	O
was	O
then	O
used	O
to	O
maximize	O
the	O
difference	O
in	O
metabolic	O
profiles	O
between	O
cases	O
and	O
controls	O
[	O
33	O
","	O
34	O
].	O
OPLS	O
-	O
DA	O
was	O
performed	O
using	O
the	O
Excel	O
add	O
-	O
in	O
Multibase	O
package	O
(	O
Numerical	O
Dynamics	O
","	O
Japan	O
;	O
http	O
://	O
www	O
.	O
numericaldynamics	O
.	O
com	O
/)	O
by	O
applying	O
orthogonal	O
signal	O
correction	O
on	O
the	O
metabolite	O
concentrations	O
shifted	O
","	O
log10	O
transformed	O
","	O
centered	O
","	O
and	O
scaled	O
to	O
unit	O
variance	O
.	O
Performance	O
of	O
the	O
optimal	O
model	O
was	O
tested	O
by	O
a	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
analysis	O
and	O
the	O
validation	O
data	O
set	O
","	O
as	O
performed	O
using	O
MetaboAnalyst	O
3	O
.	O
0	O
software	O
(	O
http	O
://	O
www	O
.	O
metaboanalyst	O
.	O
ca	O
)	O
[	O
32	O
].	O
For	O
case	O
-	O
control	O
contrasts	O
of	O
single	O
urinary	O
metabolites	O
","	O
significance	O
threshold	O
was	O
held	O
at	O
a	O
nominal	O
P	O
<	O
0	O
.	O
5	O
with	O
no	O
correction	O
for	O
multiple	O
testing	O
","	O
because	O
(	O
a	O
)	O
differences	O
in	O
single	O
metabolite	O
concentrations	O
were	O
tested	O
only	O
following	O
significant	O
differences	O
in	O
pathway	O
enrichment	O
were	O
detected	O
","	O
(	O
b	O
)	O
intra	O
-	O
pathway	O
variability	O
of	O
single	O
metabolites	O
is	O
non	O
-	O
independent	O
","	O
and	O
(	O
c	O
)	O
also	O
different	O
metabolic	O
pathways	O
are	O
not	O
fully	O
independent	O
","	O
as	O
some	O
metabolites	O
fall	O
into	O
more	O
than	O
one	O
pathway	O
.	O
Detailed	O
and	O
summary	O
statistics	O
are	O
provided	O
in	O
Additional	O
files	O
4	O
and	O
5	O
.	O
Results	O
OPLS	O
-	O
DA	O
3D	O
plot	O
based	O
on	O
normalized	O
and	O
mean	O
-	O
centered	O
data	O
.	O
Each	O
data	O
point	O
represents	O
the	O
metabolome	O
of	O
a	O
single	O
individual	O
.	O
Some	O
data	O
points	O
may	O
be	O
superimposed	O
to	O
each	O
other	O
The	O
top	O
25	O
most	O
discriminating	O
metabolite	O
ASD	O
cases	O
from	O
controls	O
","	O
ranked	O
by	O
variable	O
importance	O
in	O
projection	O
(	O
VIP	O
)	O
scores	O
","	O
and	O
their	O
KEGG	O
biochemical	O
pathway	O
.	O
VIP	O
scores	O
>	O
1	O
.	O
0	O
were	O
considered	O
significant	O
Metabolic	O
pathway	O
analysis	O
plot	O
.	O
Color	O
intensity	O
(	O
white	O
to	O
red	O
)	O
reflects	O
increasing	O
statistical	O
significance	O
","	O
while	O
circle	O
diameter	O
covaries	O
with	O
pathway	O
impact	O
.	O
The	O
graph	O
was	O
obtained	O
plotting	O
on	O
the	O
y	O
-	O
axis	O
the	O
âˆ’	O
log	O
of	O
p	O
values	O
from	O
the	O
pathway	O
enrichment	O
analysis	O
and	O
on	O
the	O
x	O
-	O
axis	O
the	O
pathway	O
impact	O
values	O
derived	O
from	O
the	O
pathway	O
topology	O
analysis	O
The	O
urinary	O
metabolomes	O
of	O
young	O
autistic	O
and	O
typically	O
developing	O
children	O
are	O
largely	O
distinguishable	O
on	O
the	O
three	O
-	O
dimensional	O
OPLS	O
-	O
DA	O
plot	O
depicting	O
the	O
first	O
three	O
principal	O
components	O
(	O
PC	O
"),"	O
which	O
together	O
explain	O
31	O
.	O
4	O
%	O
of	O
the	O
total	O
variance	O
(	O
Fig	O
.	O
1	O
;	O
accuracy	O
","	O
Q2	O
and	O
R2	O
data	O
are	O
shown	O
in	O
Additional	O
file	O
6	O
).	O
Approximately	O
10	O
","	O
0	O
peaks	O
per	O
sample	O
were	O
obtained	O
referring	O
to	O
the	O
KEGG	O
database	O
;	O
among	O
them	O
","	O
202	O
metabolites	O
were	O
analyzed	O
more	O
precisely	O
and	O
identified	O
.	O
The	O
top	O
25	O
most	O
discriminating	O
metabolites	O
between	O
cases	O
and	O
controls	O
were	O
further	O
defined	O
based	O
on	O
â€œ	O
variable	O
influence	O
on	O
the	O
projection	O
â€	O
(	O
VIP	O
)	O
scores	O
>	O
1	O
(	O
Fig	O
.	O
2	O
).	O
ROC	O
analysis	O
using	O
this	O
set	O
of	O
25	O
metabolites	O
yielded	O
an	O
AUC	O
=	O
0	O
.	O
893	O
(	O
95	O
%	O
CI	O
0	O
.	O
72	O
â€“	O
0	O
.	O
96	O
"),"	O
as	O
shown	O
in	O
Additional	O
file	O
7	O
.	O
The	O
â€œ	O
metabolome	O
overview	O
â€	O
obtained	O
through	O
metabolic	O
pathway	O
analysis	O
(	O
MetPA	O
)	O
shows	O
tryptophan	B-Chemical
metabolism	O
","	O
purine	B-Chemical
metabolism	O
","	O
vitamin	B-Chemical
B6	I-Chemical
metabolism	O
","	O
and	O
phenylalanine	B-Chemical
-	O
tyrosine	B-Chemical
-	O
tryptophan	B-Chemical
biosynthesis	O
as	O
the	O
four	O
most	O
perturbed	O
metabolic	O
pathways	O
in	O
ASD	O
(	O
Fig	O
.	O
3	O
).	O
The	O
kynurenine	B-Chemical
pathway	O
displays	O
increases	O
in	O
xanthurenic	B-Chemical
acid	I-Chemical
and	O
especially	O
in	O
quinolinic	B-Chemical
acid	I-Chemical
","	O
paralleled	O
by	O
a	O
considerable	O
decrease	O
in	O
kynurenic	B-Chemical
acid	I-Chemical
(	O
Fig	O
.	O
4	O
","	O
path	O
A	O
).	O
The	O
serotonin	B-Chemical
pathway	O
shows	O
a	O
significant	O
decrease	O
in	O
melatonin	B-Chemical
and	O
its	O
catabolite	O
N	B-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
methoxytryptamine	I-Chemical
","	O
which	O
have	O
the	O
same	O
molecular	O
weight	O
and	O
thus	O
fall	O
under	O
the	O
same	O
MS	O
peak	O
(	O
Fig	O
.	O
4	O
","	O
path	O
B	O
).	O
Bacterial	O
degradation	O
of	O
tryptophan	B-Chemical
yields	O
in	O
ASD	O
","	O
compared	O
to	O
controls	O
","	O
prominently	O
larger	O
urinary	O
concentrations	O
of	O
indoxyl	B-Chemical
sulfate	I-Chemical
and	O
other	O
indole	B-Chemical
derivatives	O
","	O
including	O
indolyl	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
acetic	I-Chemical
acid	I-Chemical
and	O
especially	O
indolyl	B-Chemical
lactate	I-Chemical
(	O
Fig	O
.	O
4	O
","	O
paths	O
C	O
and	O
D	O
).	O
Quantification	O
of	O
tryptophan	B-Chemical
metabolites	O
:	O
a	O
kynurenine	B-Chemical
pathway	O
;	O
b	O
serotonin	B-Chemical
/	O
melatonin	B-Chemical
pathway	O
;	O
c	O
â€“	O
d	O
bacterial	O
degradation	O
products	O
.	O
Peak	O
areas	O
for	O
each	O
metabolite	O
were	O
normalized	O
by	O
urinary	O
specific	O
gravity	O
.	O
Nominal	O
P	O
values	O
:	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
Given	O
the	O
relevance	O
of	O
tryptophan	B-Chemical
-	O
derived	O
compounds	O
in	O
many	O
neural	O
functions	O
","	O
tryptophan	B-Chemical
metabolism	O
was	O
assessed	O
in	O
greater	O
detail	O
at	O
the	O
level	O
of	O
specific	O
intermediates	O
(	O
Fig	O
.	O
4	O
):	O
Quantification	O
of	O
purine	B-Chemical
metabolites	O
.	O
Peak	O
areas	O
for	O
each	O
metabolite	O
were	O
normalized	O
by	O
urinary	O
specific	O
gravity	O
.	O
Nominal	O
P	O
values	O
:	O
*	O
P	O
<	O
0	O
.	O
5	O
","	O
**	O
P	O
<	O
0	O
.	O
0	O
.	O
1	O
","	O
***	O
P	O
<	O
0	O
.	O
1	O
Also	O
","	O
purine	B-Chemical
metabolism	O
was	O
found	O
to	O
convey	O
sizable	O
discriminative	O
power	O
","	O
because	O
ASD	O
cases	O
display	O
higher	O
urinary	O
concentrations	O
of	O
many	O
purine	B-Chemical
metabolites	O
compared	O
to	O
controls	O
","	O
including	O
","	O
among	O
others	O
","	O
inosine	B-Chemical
","	O
hypoxanthine	B-Chemical
","	O
and	O
xanthosine	B-Chemical
(	O
Fig	O
.	O
5	O
).	O
Discussion	O
The	O
present	O
study	O
reports	O
significant	O
urinary	O
metabolomic	O
differences	O
between	O
young	O
children	O
with	O
idiopathic	O
ASD	O
and	O
typically	O
developing	O
controls	O
.	O
At	O
least	O
some	O
of	O
the	O
metabolic	O
perturbations	O
described	O
here	O
may	O
reflect	O
pathophysiologically	O
meaningful	O
abnormalities	O
","	O
possibly	O
bearing	O
functional	O
consequences	O
at	O
the	O
clinical	O
level	O
.	O
Three	O
strengths	O
of	O
the	O
experimental	O
design	O
may	O
have	O
contributed	O
to	O
this	O
positive	O
outcome	O
:	O
(	O
a	O
)	O
a	O
focus	O
on	O
early	O
infancy	O
","	O
by	O
recruiting	O
children	O
within	O
a	O
relatively	O
narrow	O
age	O
window	O
precisely	O
defined	O
on	O
the	O
basis	O
of	O
previous	O
urinary	O
metabolic	O
data	O
[	O
20	O
","	O
21	O
];	O
(	O
b	O
)	O
the	O
use	O
of	O
UHPLC	O
-	O
MS	O
paired	O
with	O
HILIC	O
","	O
a	O
very	O
sensitive	O
and	O
reliable	O
method	O
ensuring	O
maximum	O
accuracy	O
in	O
the	O
separation	O
of	O
small	O
urinary	O
solutes	O
[	O
26	O
","	O
27	O
];	O
(	O
b	O
)	O
a	O
pathway	O
-	O
centered	O
approach	O
","	O
moving	O
beyond	O
the	O
identification	O
of	O
single	O
urinary	O
ASD	O
markers	O
[	O
10	O
â€“	O
17	O
"],"	O
as	O
beautifully	O
exemplified	O
by	O
urinary	O
metabolomic	O
studies	O
of	O
rodent	O
models	O
of	O
ASD	O
[	O
35	O
â€“	O
37	O
].	O
In	O
particular	O
","	O
our	O
recruitment	O
strategy	O
substantially	O
differs	O
from	O
previous	O
case	O
-	O
control	O
study	O
designs	O
","	O
minimizing	O
age	O
-	O
dependent	O
heterogeneity	O
by	O
setting	O
data	O
-	O
driven	O
age	O
thresholds	O
(	O
i	O
.	O
e	O
".,"	O
2	O
â€“	O
8	O
years	O
old	O
)	O
[	O
20	O
","	O
21	O
"],"	O
and	O
applying	O
tight	O
age	O
and	O
sex	O
matching	O
between	O
cases	O
and	O
controls	O
.	O
This	O
strategy	O
seemingly	O
circumvents	O
sample	O
size	O
limitations	O
which	O
would	O
apply	O
to	O
an	O
unfocused	O
and	O
unmatched	O
case	O
-	O
control	O
design	O
.	O
Future	O
replications	O
obtained	O
applying	O
similar	O
recruitment	O
criteria	O
will	O
enhance	O
confidence	O
in	O
the	O
pathophysiological	O
relevance	O
and	O
the	O
interethnic	O
generalizability	O
of	O
our	O
findings	O
.	O
The	O
tryptophan	B-Chemical
metabolic	O
pathway	O
collectively	O
displays	O
the	O
largest	O
perturbations	O
in	O
ASD	O
(	O
Fig	O
.	O
3	O
).	O
Over	O
90	O
â€“	O
95	O
%	O
of	O
dietary	O
l	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
is	O
usually	O
metabolized	O
along	O
the	O
kynurenine	B-Chemical
pathway	O
","	O
1	O
â€“	O
2	O
%	O
is	O
converted	O
to	O
serotonin	B-Chemical
","	O
and	O
approximately	O
4	O
â€“	O
6	O
%	O
undergoes	O
bacterial	O
degradation	O
prior	O
to	O
gut	O
absorption	O
through	O
the	O
Na	O
+-	O
amino	O
acid	O
co	O
-	O
transporter	O
B0AT1	O
(	O
Slc6a19	O
)	O
[	O
38	O
","	O
39	O
].	O
The	O
latter	O
pathway	O
yields	O
indole	B-Chemical
derivatives	O
not	O
produced	O
by	O
mammalian	O
metabolism	O
","	O
such	O
as	O
indoxyl	B-Chemical
sulfate	I-Chemical
[	O
40	O
].	O
Hence	O
","	O
changes	O
in	O
urinary	O
amounts	O
of	O
multiple	O
metabolites	O
provide	O
more	O
reliable	O
evidence	O
of	O
perturbed	O
tryptophan	B-Chemical
metabolism	O
","	O
as	O
compared	O
to	O
determinations	O
of	O
single	O
metabolites	O
or	O
tryptophan	B-Chemical
itself	O
","	O
which	O
also	O
suffer	O
from	O
reduced	O
statistical	O
power	O
due	O
to	O
control	O
for	O
multiple	O
testing	O
(	O
Figs	O
.	O
4	O
and	O
5	O
).	O
In	O
the	O
urines	O
of	O
young	O
autistic	O
children	O
","	O
we	O
have	O
indeed	O
observed	O
a	O
substantial	O
increase	O
of	O
xanthurenic	B-Chemical
acid	I-Chemical
and	O
especially	O
of	O
quinolinic	B-Chemical
acid	I-Chemical
","	O
paralleled	O
by	O
a	O
decrease	O
in	O
kynurenine	B-Chemical
and	O
kynurenic	B-Chemical
acid	I-Chemical
(	O
Fig	O
.	O
4	O
","	O
path	O
A	O
).	O
This	O
pattern	O
is	O
extremely	O
interesting	O
but	O
must	O
be	O
interpreted	O
with	O
some	O
caution	O
in	O
the	O
absence	O
of	O
parallel	O
assessments	O
of	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
).	O
On	O
the	O
one	O
hand	O
","	O
the	O
enzymes	O
responsible	O
for	O
the	O
synthesis	O
of	O
quinolinic	B-Chemical
acid	I-Chemical
and	O
xanthurenic	B-Chemical
acid	I-Chemical
are	O
primarily	O
expressed	O
in	O
the	O
microglia	O
and	O
in	O
macrophages	O
","	O
whereas	O
the	O
path	O
leading	O
to	O
kynurenic	B-Chemical
acid	I-Chemical
is	O
functional	O
in	O
astrocytes	O
[	O
41	O
].	O
Hence	O
","	O
it	O
would	O
be	O
tempting	O
to	O
speculate	O
that	O
these	O
opposite	O
trends	O
between	O
cases	O
and	O
controls	O
reflect	O
an	O
abnormal	O
activation	O
of	O
microglia	O
","	O
which	O
has	O
been	O
repeatedly	O
seen	O
in	O
ASD	O
postmortem	O
brains	O
[	O
42	O
â€“	O
44	O
"],"	O
even	O
as	O
early	O
as	O
at	O
4	O
years	O
of	O
age	O
[	O
45	O
].	O
On	O
the	O
other	O
hand	O
","	O
urinary	O
levels	O
of	O
quinolinic	B-Chemical
acid	I-Chemical
and	O
kynurenic	B-Chemical
acid	I-Chemical
reflect	O
peripheral	O
production	O
of	O
these	O
compounds	O
","	O
which	O
do	O
not	O
pass	O
the	O
blood	O
-	O
brain	O
barrier	O
[	O
41	O
].	O
However	O
","	O
3	B-Chemical
-	I-Chemical
hydroxykynurenine	I-Chemical
does	O
pass	O
the	O
blood	O
-	O
brain	O
barrier	O
[	O
41	O
].	O
Interestingly	O
","	O
urinary	O
concentrations	O
of	O
metabolite	O
downstream	O
of	O
this	O
compound	O
(	O
quinolinic	B-Chemical
acid	I-Chemical
and	O
xanthurenic	B-Chemical
acid	I-Chemical
)	O
are	O
elevated	O
in	O
autistic	O
children	O
","	O
whereas	O
metabolite	O
upstream	O
of	O
3	B-Chemical
-	I-Chemical
hydroxykinurenine	I-Chemical
(	O
kynurenine	B-Chemical
and	O
kynurenic	B-Chemical
acid	I-Chemical
)	O
are	O
higher	O
among	O
controls	O
(	O
Fig	O
.	O
4	O
","	O
path	O
A	O
).	O
Conceivably	O
","	O
these	O
trends	O
could	O
reflect	O
an	O
outflow	O
of	O
3	B-Chemical
-	I-Chemical
hydroxykynurenine	I-Chemical
from	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
into	O
the	O
systemic	O
circulation	O
","	O
where	O
macrophage	O
activation	O
presumably	O
at	O
the	O
level	O
of	O
the	O
gut	O
or	O
in	O
other	O
peripheral	O
organs	O
","	O
can	O
transform	O
this	O
compound	O
into	O
quinolinic	B-Chemical
acid	I-Chemical
and	O
xanthurenic	B-Chemical
acid	I-Chemical
","	O
as	O
well	O
as	O
into	O
nicotinic	B-Chemical
acid	I-Chemical
(	O
NAD	B-Chemical
"),"	O
in	O
agreement	O
with	O
previous	O
data	O
[	O
10	O
].	O
It	O
will	O
thus	O
be	O
important	O
to	O
verify	O
this	O
metabolomic	O
scenario	O
in	O
the	O
CSF	O
","	O
because	O
it	O
could	O
have	O
at	O
least	O
two	O
important	O
clinical	O
implications	O
:	O
(	O
a	O
)	O
quinolinic	B-Chemical
acid	I-Chemical
acts	O
as	O
gliotoxin	B-Chemical
","	O
proinflammatory	O
mediator	O
","	O
and	O
pro	O
-	O
oxidant	O
molecule	O
","	O
boosting	O
oxidative	O
stress	O
by	O
stimulating	O
microglia	O
to	O
release	O
large	O
amounts	O
of	O
NO	B-Chemical
and	O
superoxide	B-Chemical
;	O
(	O
b	O
)	O
quinolinic	B-Chemical
acid	I-Chemical
exerts	O
excitotoxic	O
effects	O
by	O
acting	O
as	O
an	O
N	O
-	O
methyl	O
-	O
d	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
agonist	O
","	O
stimulating	O
glutamate	B-Chemical
release	O
","	O
blocking	O
glutamate	B-Chemical
reuptake	O
into	O
astrocytes	O
","	O
and	O
reducing	O
the	O
activity	O
of	O
glutamine	B-Chemical
synthase	O
;	O
instead	O
","	O
kynurenic	B-Chemical
acid	I-Chemical
exerts	O
neuroprotection	O
via	O
NMDA	B-Chemical
antagonism	O
at	O
the	O
glycine	B-Chemical
binding	O
site	O
","	O
as	O
well	O
as	O
antioxidant	O
effects	O
[	O
41	O
","	O
46	O
","	O
47	O
].	O
In	O
summary	O
","	O
the	O
urinary	O
metabolic	O
imbalance	O
documented	O
here	O
","	O
if	O
present	O
also	O
in	O
the	O
CNS	O
","	O
could	O
favor	O
enhanced	O
oxidative	O
stress	O
and	O
the	O
well	O
-	O
known	O
excitation	O
>	O
inhibition	O
imbalance	O
present	O
in	O
ASD	O
","	O
fostering	O
seizures	O
in	O
as	O
many	O
as	O
20	O
%	O
of	O
autistic	O
individuals	O
[	O
48	O
].	O
Another	O
consequence	O
of	O
the	O
preferential	O
metabolization	O
of	O
tryptophan	B-Chemical
along	O
the	O
main	O
branch	O
of	O
the	O
kynurenine	B-Chemical
pathway	O
is	O
the	O
relative	O
decrease	O
in	O
the	O
production	O
of	O
serotonin	B-Chemical
and	O
melatonin	B-Chemical
(	O
Fig	O
.	O
4	O
","	O
path	O
B	O
).	O
The	O
serotonin	B-Chemical
pathway	O
sees	O
tryptophan	B-Chemical
being	O
converted	O
into	O
5	B-Chemical
-	I-Chemical
hydroxytryptophan	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
HTP	I-Chemical
)	O
by	O
tryptophan	O
hydroxylase	O
and	O
onwards	O
to	O
5	B-Chemical
-	I-Chemical
hydroxytryptamine	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
HT	I-Chemical
)	O
or	O
serotonin	B-Chemical
by	O
5	B-Chemical
-	I-Chemical
HTP	I-Chemical
decarboxylase	I-Chemical
.	O
Serotonin	B-Chemical
can	O
then	O
be	O
catabolized	O
to	O
5	B-Chemical
-	I-Chemical
hydroxyindoleacetic	I-Chemical
acid	I-Chemical
(	O
5	B-Chemical
-	I-Chemical
HIAA	I-Chemical
)	O
or	O
transformed	O
into	O
N	B-Chemical
-	I-Chemical
acetylserotonin	I-Chemical
by	O
arylalkylamine	O
N	O
-	O
acetyltransferase	O
(	O
AANAT	O
).	O
N	B-Chemical
-	I-Chemical
acetylserotonin	I-Chemical
is	O
further	O
methylated	O
by	O
N	O
-	O
acetylserotonin	O
O	O
-	O
methyltransferase	O
(	O
ASMT	O
)	O
to	O
generate	O
the	O
neurohormone	O
5	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
tryptamine	I-Chemical
or	O
melatonin	B-Chemical
.	O
Decreases	O
in	O
the	O
serotonin	B-Chemical
metabolite	O
5	B-Chemical
-	I-Chemical
HIAA	I-Chemical
are	O
only	O
modest	O
","	O
while	O
urinary	O
melatonin	B-Chemical
and	O
its	O
catabolite	O
N	B-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
methoxytryptamine	I-Chemical
display	O
a	O
more	O
pronounced	O
mean	O
reduction	O
(	O
both	O
share	O
the	O
same	O
molecular	O
weight	O
and	O
fall	O
under	O
the	O
same	O
MS	O
peak	O
","	O
labeled	O
in	O
Fig	O
.	O
4	O
","	O
path	O
B	O
","	O
as	O
â€œ	O
melatonin	B-Chemical
â€	O
only	O
).	O
This	O
confirms	O
previous	O
assessments	O
performed	O
in	O
plasma	O
or	O
urine	O
[	O
10	O
","	O
49	O
â€“	O
52	O
"],"	O
while	O
lending	O
further	O
support	O
to	O
blunted	O
melatonin	B-Chemical
synthesis	O
possibly	O
due	O
to	O
reduced	O
ASMT	O
enzyme	O
activity	O
in	O
ASD	O
[	O
53	O
","	O
54	O
].	O
Melatonin	B-Chemical
is	O
synthesized	O
and	O
released	O
by	O
the	O
pineal	O
gland	O
into	O
the	O
systemic	O
circulation	O
and	O
readily	O
passes	O
the	O
blood	O
-	O
brain	O
barrier	O
[	O
55	O
].	O
Its	O
well	O
-	O
known	O
role	O
in	O
circadian	O
rhythmicity	O
makes	O
it	O
an	O
ideal	O
candidate	O
to	O
explain	O
the	O
frequent	O
occurrence	O
","	O
especially	O
at	O
the	O
onset	O
of	O
ASD	O
and	O
during	O
early	O
infancy	O
","	O
of	O
sleep	O
disorders	O
highly	O
responsive	O
to	O
melatonin	B-Chemical
as	O
a	O
pharmacological	O
therapy	O
[	O
56	O
].	O
Metabolites	O
produced	O
by	O
gut	O
bacteria	O
are	O
well	O
-	O
represented	O
also	O
in	O
our	O
ASD	O
sample	O
","	O
as	O
in	O
previous	O
studies	O
[	O
10	O
â€“	O
17	O
].	O
In	O
addition	O
to	O
urinary	O
p	B-Chemical
-	I-Chemical
cresol	I-Chemical
","	O
found	O
elevated	O
in	O
these	O
same	O
urine	O
samples	O
both	O
here	O
(	O
Fig	O
.	O
3	O
)	O
and	O
previously	O
using	O
a	O
different	O
technology	O
[	O
20	O
"],"	O
we	O
also	O
detect	O
a	O
significant	O
increase	O
in	O
indole	B-Chemical
derivatives	O
of	O
bacterial	O
tryptophan	B-Chemical
including	O
indolyl	B-Chemical
3	I-Chemical
-	I-Chemical
acetic	I-Chemical
acid	I-Chemical
","	O
indoxyl	B-Chemical
sulfate	I-Chemical
","	O
and	O
most	O
prominently	O
","	O
indolyl	B-Chemical
lactate	I-Chemical
(	O
Fig	O
.	O
4	O
","	O
path	O
C	O
).	O
Bacterial	O
species	O
expressing	O
tryptophanase	O
","	O
the	O
enzyme	O
responsible	O
for	O
transforming	O
tryptophan	B-Chemical
into	O
indole	B-Chemical
derivatives	O
","	O
include	O
Escherichia	O
coli	O
","	O
Proteus	O
vulgaris	O
","	O
Paracolobactrum	O
coliform	O
","	O
Achromobacter	O
liquefaciens	O
","	O
and	O
Bacteroides	O
spp	O
.	O
[	O
40	O
].	O
Once	O
produced	O
in	O
the	O
gut	O
lumen	O
","	O
indole	B-Chemical
is	O
absorbed	O
","	O
oxidized	O
to	O
indoxyl	B-Chemical
","	O
conjugated	O
with	O
sulfate	B-Chemical
","	O
and	O
excreted	O
as	O
urinary	O
indoxyl	B-Chemical
sulfate	I-Chemical
.	O
About	O
3	O
%	O
of	O
tryptophan	B-Chemical
entered	O
with	O
the	O
diet	O
is	O
excreted	O
as	O
indoxyl	B-Chemical
sulfate	I-Chemical
[	O
37	O
].	O
Additional	O
small	O
amounts	O
of	O
tryptophan	B-Chemical
are	O
converted	O
into	O
other	O
indole	B-Chemical
derivatives	O
found	O
elevated	O
here	O
in	O
ASD	O
children	O
","	O
such	O
as	O
indolyl	B-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
acetic	I-Chemical
acid	I-Chemical
and	O
indolyl	B-Chemical
lactate	I-Chemical
(	O
Fig	O
.	O
4	O
","	O
path	O
C	O
).	O
The	O
latter	O
compound	O
and	O
indolyl	B-Chemical
3	I-Chemical
-	I-Chemical
acetic	I-Chemical
acid	I-Chemical
are	O
direct	O
precursors	O
of	O
indolylacrylol	B-Chemical
glycine	I-Chemical
","	O
found	O
elevated	O
in	O
ASD	O
by	O
some	O
[	O
57	O
]	O
but	O
not	O
all	O
studies	O
[	O
58	O
","	O
59	O
].	O
Predictably	O
","	O
the	O
exact	O
urinary	O
bacterial	O
compounds	O
found	O
elevated	O
in	O
ASD	O
do	O
differ	O
in	O
distinct	O
metabolomic	O
studies	O
.	O
This	O
is	O
not	O
surprising	O
since	O
","	O
in	O
addition	O
to	O
differences	O
in	O
sample	O
demographics	O
and	O
sensitivity	O
of	O
available	O
technologies	O
","	O
ethnicity	O
also	O
exerts	O
profound	O
influences	O
on	O
the	O
microbiome	O
","	O
reflecting	O
dietary	O
","	O
genetic	O
","	O
and	O
immunological	O
specificities	O
involved	O
in	O
the	O
host	O
-	O
microbiome	O
interactions	O
[	O
60	O
].	O
Despite	O
these	O
discrepancies	O
at	O
the	O
level	O
of	O
single	O
compounds	O
","	O
urinary	O
metabolomic	O
studies	O
consistently	O
report	O
an	O
excess	O
of	O
microbiome	O
-	O
derived	O
urinary	O
metabolites	O
","	O
collectively	O
supporting	O
gut	O
dysbiosis	O
in	O
ASD	O
.	O
These	O
results	O
point	O
toward	O
possible	O
negative	O
effects	O
on	O
CNS	O
function	O
exerted	O
by	O
microbiome	O
-	O
derived	O
metabolites	O
.	O
At	O
least	O
three	O
examples	O
are	O
available	O
","	O
albeit	O
with	O
different	O
degrees	O
of	O
support	O
:	O
(	O
a	O
)	O
urinary	O
p	B-Chemical
-	I-Chemical
cresol	I-Chemical
amounts	O
were	O
found	O
correlated	O
with	O
ASD	O
severity	O
[	O
20	O
]	O
or	O
with	O
the	O
intensity	O
of	O
stereotypic	O
behaviors	O
in	O
young	O
autistic	O
children	O
[	O
21	O
];	O
(	O
b	O
)	O
i	O
.	O
c	O
.	O
v	O
.	O
injection	O
of	O
propionic	B-Chemical
acid	I-Chemical
","	O
an	O
enteric	O
-	O
derived	O
short	B-Chemical
chain	I-Chemical
fatty	I-Chemical
acid	I-Chemical
","	O
produces	O
ASD	O
-	O
like	O
behaviors	O
in	O
the	O
rat	O
[	O
61	O
];	O
(	O
c	O
)	O
indoxyl	B-Chemical
sulfate	I-Chemical
is	O
a	O
known	O
risk	O
factor	O
for	O
cognitive	O
impairment	O
in	O
chronic	O
renal	O
disease	O
[	O
62	O
]:	O
its	O
influx	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
using	O
the	O
organic	O
anion	O
transporter	O
3	O
significantly	O
reduces	O
the	O
efflux	O
of	O
various	O
neurotransmitter	O
metabolites	O
through	O
the	O
same	O
transporter	O
","	O
leading	O
to	O
their	O
accumulation	O
[	O
63	O
].	O
Importantly	O
","	O
sizable	O
improvements	O
in	O
behavioral	O
and	O
serum	O
metabolome	O
abnormalities	O
were	O
recorded	O
using	O
the	O
maternal	O
immune	O
activation	O
(	O
MIA	O
)	O
rodent	O
model	O
of	O
ASD	O
following	O
the	O
correction	O
of	O
gut	O
dysbiosis	O
using	O
Bacteroides	O
fragilis	O
[	O
64	O
].	O
Purine	B-Chemical
metabolites	O
are	O
also	O
well	O
represented	O
in	O
the	O
urines	O
of	O
ASD	O
children	O
","	O
which	O
display	O
a	O
large	O
excess	O
of	O
inosine	B-Chemical
","	O
hypoxanthine	B-Chemical
","	O
and	O
xanthosine	B-Chemical
(	O
Figs	O
.	O
3	O
and	O
5	O
).	O
This	O
pattern	O
bears	O
an	O
interesting	O
resemblance	O
to	O
the	O
excess	O
of	O
urinary	O
inosine	B-Chemical
and	O
hypoxanthine	B-Chemical
detected	O
in	O
Fmr1	O
knock	O
-	O
out	O
mice	O
","	O
an	O
animal	O
model	O
of	O
fragile	O
-	O
X	O
syndrome	O
[	O
35	O
].	O
Also	O
","	O
mice	O
exposed	O
prenatally	O
to	O
MIA	O
triggered	O
by	O
poly	O
(	O
I	O
:	O
C	O
)	O
injected	O
at	O
E12	O
.	O
5	O
and	O
E17	O
.	O
5	O
show	O
an	O
excess	O
of	O
urinary	O
inosine	B-Chemical
[	O
36	O
].	O
This	O
excess	O
of	O
urinary	O
purinergic	O
metabolites	O
has	O
been	O
interpreted	O
as	O
part	O
of	O
a	O
â€œ	O
cell	O
danger	O
metabolic	O
response	O
â€	O
involving	O
mitochondrial	O
dysfunction	O
","	O
adenosine	B-Chemical
triphosphate	I-Chemical
(	O
ATP	B-Chemical
"),"	O
and	O
adenosine	B-Chemical
diphosphate	I-Chemical
(	O
ADP	B-Chemical
)	O
release	O
","	O
activation	O
of	O
a	O
variety	O
of	O
purinergic	O
receptors	O
yielding	O
microglial	O
activation	O
","	O
innate	O
","	O
and	O
adaptive	O
immunity	O
responses	O
and	O
leukocyte	O
chemotactics	O
[	O
65	O
].	O
Inborn	O
errors	O
of	O
purine	B-Chemical
metabolism	O
are	O
associated	O
with	O
behavioral	O
abnormalities	O
including	O
autistic	O
features	O
[	O
66	O
].	O
Strikingly	O
","	O
inhibition	O
of	O
purine	B-Chemical
metabolism	O
by	O
suramin	B-Chemical
","	O
a	O
competitive	O
antagonist	O
at	O
P2X	O
and	O
P2Y	O
purinergic	O
receptors	O
","	O
reverses	O
behavioral	O
","	O
neurochemical	O
","	O
transcriptional	O
","	O
and	O
metabolomics	O
abnormalities	O
both	O
in	O
the	O
Fmr1	O
knock	O
-	O
out	O
mouse	O
and	O
in	O
MIA	O
mice	O
exposed	O
to	O
poly	B-Chemical
(	I-Chemical
I	I-Chemical
:	I-Chemical
C	I-Chemical
)	I-Chemical
during	O
pregnancy	O
[	O
35	O
â€“	O
37	O
].	O
Conceivably	O
","	O
this	O
metabolic	O
abnormality	O
","	O
shared	O
between	O
human	O
ASD	O
and	O
genetic	O
/	O
immunological	O
rodent	O
models	O
could	O
thus	O
represent	O
a	O
valuable	O
biomarker	O
to	O
help	O
guide	O
therapeutic	O
interventions	O
.	O
In	O
addition	O
","	O
the	O
cell	O
danger	O
response	O
also	O
yields	O
relative	O
vitamin	B-Chemical
B6	I-Chemical
deficiency	O
and	O
the	O
enzyme	O
kynureninase	O
is	O
B6	B-Chemical
dependent	O
[	O
65	O
];	O
hence	O
","	O
a	O
cell	O
danger	O
metabolic	O
response	O
in	O
the	O
presence	O
of	O
adequate	O
tryptophan	B-Chemical
intake	O
could	O
also	O
explain	O
the	O
decreased	O
kynurenine	B-Chemical
and	O
increased	O
xanthurenic	B-Chemical
and	O
quinolinic	B-Chemical
acid	I-Chemical
observed	O
here	O
(	O
Fig	O
.	O
4	O
).	O
Interestingly	O
","	O
these	O
abnormalities	O
have	O
been	O
sometimes	O
overcome	O
with	O
vitamin	B-Chemical
B6	I-Chemical
supplementation	O
[	O
67	O
"],"	O
a	O
therapeutic	O
approach	O
initially	O
proposed	O
for	O
ASD	O
in	O
conjunction	O
with	O
magnesium	B-Chemical
supplementation	O
[	O
68	O
].	O
In	O
light	O
of	O
the	O
present	O
data	O
","	O
B6	B-Chemical
-	O
Mg	B-Chemical
++	I-Chemical
supplementation	O
in	O
ASD	O
may	O
deserve	O
further	O
scrutiny	O
in	O
urinary	O
biomarker	O
-	O
driven	O
therapeutic	O
trials	O
","	O
as	O
no	O
firm	O
conclusion	O
on	O
its	O
potential	O
efficacy	O
has	O
yet	O
been	O
reached	O
[	O
69	O
].	O
Conclusions	O
Targeting	O
young	O
autistic	O
children	O
and	O
tightly	O
matched	O
controls	O
","	O
using	O
the	O
sensitive	O
approach	O
HILIC	O
UHPLC	O
-	O
MS	O
","	O
and	O
applying	O
metabolic	O
pathway	O
analysis	O
","	O
we	O
identified	O
several	O
urinary	O
metabolic	O
pathways	O
significantly	O
altered	O
in	O
ASD	O
:	O
tryptophan	B-Chemical
","	O
purine	B-Chemical
","	O
and	O
vitamin	B-Chemical
B6	I-Chemical
metabolisms	O
;	O
phenylalanine	B-Chemical
","	O
and	O
tyrosine	B-Chemical
biosynthesis	O
;	O
and	O
to	O
a	O
lesser	O
extent	O
","	O
pantothenate	B-Chemical
and	O
CoA	B-Chemical
","	O
riboflavin	B-Chemical
","	O
and	O
pyrimidine	B-Chemical
metabolisms	O
.	O
Several	O
of	O
these	O
same	O
pathways	O
","	O
especially	O
tryptophan	B-Chemical
","	O
purine	B-Chemical
","	O
and	O
gut	O
microbiome	O
metabolisms	O
","	O
are	O
also	O
abnormal	O
in	O
animal	O
models	O
of	O
ASD	O
and	O
provide	O
very	O
interesting	O
leads	O
toward	O
possible	O
pathophysiological	O
explanations	O
for	O
specific	O
symptoms	O
present	O
in	O
many	O
autistic	O
children	O
","	O
such	O
as	O
seizures	O
and	O
sleep	O
disorders	O
.	O
These	O
metabolic	O
abnormalities	O
may	O
apply	O
to	O
young	O
children	O
only	O
","	O
as	O
suggested	O
by	O
studies	O
of	O
urinary	O
p	B-Chemical
-	I-Chemical
cresol	I-Chemical
[	O
20	O
","	O
21	O
].	O
It	O
will	O
indeed	O
be	O
very	O
important	O
to	O
now	O
perform	O
a	O
similar	O
metabolomic	O
assessment	O
on	O
ASD	O
individuals	O
and	O
controls	O
older	O
than	O
8	O
years	O
of	O
age	O
.	O
Investigations	O
of	O
CSF	O
metabolomics	O
will	O
be	O
necessary	O
to	O
verify	O
to	O
what	O
extent	O
peripheral	O
results	O
reflect	O
CNS	O
pathophysiology	O
.	O
Finally	O
","	O
studies	O
involving	O
other	O
diagnostic	O
groups	O
bordering	O
with	O
ASD	O
","	O
such	O
as	O
ADHD	O
","	O
intellectual	O
disability	O
","	O
expressive	O
language	O
disorder	O
","	O
and	O
obsessive	O
-	O
compulsive	O
disorder	O
","	O
will	O
be	O
required	O
to	O
assess	O
the	O
disease	O
specificity	O
of	O
the	O
metabolomic	O
abnormalities	O
reported	O
here	O
and	O
to	O
determine	O
their	O
potential	O
value	O
as	O
ASD	O
-	O
specific	O
biomarkers	O
","	O
possibly	O
able	O
to	O
aid	O
clinicians	O
in	O
providing	O
more	O
reliable	O
diagnoses	O
in	O
early	O
infancy	O
.	O
Additional	O
files	O
Abbreviations	O
5	B-Chemical
-	I-Chemical
HIAA	I-Chemical
5	B-Chemical
-	I-Chemical
hydroxyindoleacetic	I-Chemical
acid	I-Chemical
5	B-Chemical
-	I-Chemical
HT	I-Chemical
5	B-Chemical
-	I-Chemical
hydroxytryptamine	I-Chemical
5	B-Chemical
-	I-Chemical
HTTP	I-Chemical
5	B-Chemical
-	I-Chemical
hydroxytryptophan	I-Chemical
AANAT	O
N	B-Chemical
-	I-Chemical
acetylserotonin	I-Chemical
by	O
arylalkylamine	O
N	O
-	O
acetyltransferase	O
ADHD	O
attention	O
deficit	O
hyperactivity	O
disorder	O
ADP	B-Chemical
adenosine	B-Chemical
diphosphate	I-Chemical
ASD	O
autism	O
spectrum	O
disorder	O
ASMT	O
N	O
-	O
acetylserotonin	O
O	O
-	O
methyltransferase	O
ATP	B-Chemical
adenosine	B-Chemical
triphosphate	I-Chemical
CNS	O
central	O
nervous	O
system	O
CSF	O
cerebrospinal	O
fluid	O
ESI	O
electrospray	O
ionization	O
GC	O
gas	O
chromatography	O
HILIC	O
hydrophilic	O
interaction	O
chromatography	O
KEGG	O
Kyoto	O
Encyclopedia	O
of	O
Genes	O
and	O
Genomes	O
LC	O
liquid	O
chromatography	O
MetPA	O
metabolic	O
pathway	O
analysis	O
MIA	O
maternal	O
immune	O
activation	O
MS	O
mass	O
spectroscopy	O
NAD	B-Chemical
nicotinic	B-Chemical
acid	I-Chemical
NMDA	B-Chemical
N	B-Chemical
-	I-Chemical
methyl	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
aspartate	I-Chemical
NMR	O
nuclear	O
magnetic	O
resonance	O
OPLS	O
-	O
DA	O
orthogonal	O
partial	O
least	O
squares	O
discriminant	O
analysis	O
TOF	O
time	O
of	O
flight	O
VIP	O
variable	O
influence	O
on	O
the	O
projection	O
References	O
MyoD	O
phosphorylation	O
on	O
multiple	O
C	O
terminal	O
sites	O
regulates	O
myogenic	O
conversion	O
activity	O
MyoD	O
is	O
a	O
master	O
regulator	O
of	O
myogenesis	O
with	O
a	O
potent	O
ability	O
to	O
redirect	O
the	O
cell	O
fate	O
of	O
even	O
terminally	O
differentiated	O
cells	O
.	O
Hence	O
","	O
enhancing	O
the	O
activity	O
of	O
MyoD	O
is	O
an	O
important	O
step	O
to	O
maximising	O
its	O
potential	O
utility	O
for	O
in	O
vitro	O
disease	O
modelling	O
and	O
cell	O
replacement	O
therapies	O
.	O
We	O
have	O
previously	O
shown	O
that	O
the	O
reprogramming	O
activity	O
of	O
several	O
neurogenic	O
bHLH	O
proteins	O
can	O
be	O
substantially	O
enhanced	O
by	O
inhibiting	O
their	O
multi	O
-	O
site	O
phosphorylation	O
by	O
proline	O
-	O
directed	O
kinases	O
.	O
Here	O
we	O
have	O
used	O
Xenopus	O
embryos	O
as	O
an	O
in	O
vivo	O
developmental	O
and	O
reprogramming	O
system	O
to	O
investigate	O
the	O
multi	O
-	O
site	O
phospho	O
-	O
regulation	O
of	O
MyoD	O
during	O
muscle	O
differentiation	O
.	O
We	O
show	O
that	O
","	O
in	O
addition	O
to	O
modification	O
of	O
a	O
previously	O
well	O
-	O
characterised	O
site	O
","	O
Serine	B-Chemical
200	O
","	O
MyoD	O
is	O
phosphorylated	O
on	O
multiple	O
additional	O
serine	B-Chemical
/	O
threonine	B-Chemical
sites	O
during	O
primary	O
myogenesis	O
.	O
Through	O
mutational	O
analysis	O
","	O
we	O
derive	O
an	O
optimally	O
active	O
phospho	O
-	O
mutant	O
form	O
of	O
MyoD	O
that	O
has	O
a	O
dramatically	O
enhanced	O
ability	O
to	O
drive	O
myogenic	O
reprogramming	O
in	O
vivo	O
.	O
Mechanistically	O
","	O
this	O
is	O
achieved	O
through	O
increased	O
protein	O
stability	O
and	O
enhanced	O
chromatin	O
association	O
.	O
Therefore	O
","	O
multi	O
-	O
site	O
phospho	O
-	O
regulation	O
of	O
class	O
II	O
bHLH	O
proteins	O
is	O
conserved	O
across	O
cell	O
lineages	O
and	O
germ	O
layers	O
","	O
and	O
manipulation	O
of	O
phosphorylation	O
of	O
these	O
key	O
regulators	O
may	O
have	O
further	O
potential	O
for	O
enhancing	O
mammalian	O
cell	O
reprogramming	O
.	O
Highlights	O
MyoD	O
is	O
phosphorylated	O
on	O
multiple	O
S	O
/	O
T	O
-	O
P	O
sites	O
in	O
muscle	O
differentiation	O
.	O
Myogenic	O
activity	O
of	O
MyoD	O
is	O
regulated	O
by	O
up	O
to	O
five	O
C	O
terminal	O
phospho	O
-	O
sites	O
.	O
Our	O
optimal	O
phospho	O
-	O
mutant	O
form	O
of	O
MyoD	O
dramatically	O
enhances	O
myogenesis	O
in	O
vivo	O
.	O
MyoD	O
multi	O
-	O
site	O
phosphorylation	O
controls	O
protein	O
stability	O
and	O
chromatin	O
association	O
.	O
Multi	O
-	O
site	O
phospho	O
-	O
regulation	O
is	O
a	O
conserved	O
mechanism	O
across	O
cell	O
lineages	O
.	O
Introduction	O
The	O
basic	O
-	O
Helix	O
-	O
Loop	O
-	O
Helix	O
(	O
bHLH	O
)	O
protein	O
MyoD	O
is	O
an	O
extensively	O
studied	O
Muscle	O
Regulatory	O
Factor	O
(	O
MRF	O
)	O
that	O
plays	O
a	O
pivotal	O
role	O
during	O
muscle	O
development	O
","	O
and	O
has	O
also	O
received	O
much	O
attention	O
for	O
its	O
ability	O
to	O
direct	O
a	O
myogenic	O
program	O
even	O
in	O
terminally	O
differentiated	O
somatic	O
cells	O
[	O
1	O
"],"	O
[	O
2	O
].	O
Using	O
MyoD	O
to	O
direct	O
trans	O
-	O
differentiation	O
has	O
potential	O
utility	O
in	O
cellular	O
reprogramming	O
efforts	O
directed	O
at	O
in	O
vitro	O
modelling	O
of	O
muscle	O
diseases	O
for	O
drug	O
screening	O
[	O
3	O
]	O
and	O
in	O
cell	O
replacement	O
therapies	O
[	O
4	O
].	O
However	O
","	O
refining	O
of	O
these	O
reprogramming	O
methods	O
requires	O
optimising	O
the	O
myogenic	O
activity	O
of	O
MyoD	O
.	O
We	O
have	O
previously	O
studied	O
other	O
master	O
regulatory	O
proneural	O
bHLH	O
transcription	O
factors	O
that	O
drive	O
differentiation	O
in	O
the	O
neural	O
lineage	O
","	O
namely	O
Neurogenin2	O
","	O
Ascl1	O
and	O
NeuroD4	O
[	O
5	O
"],"	O
[	O
6	O
"],"	O
[	O
7	O
"],"	O
[	O
8	O
].	O
We	O
see	O
that	O
phosphorylation	O
of	O
these	O
factors	O
on	O
multiple	O
serine	B-Chemical
-	O
proline	B-Chemical
and	O
threonine	B-Chemical
-	O
proline	B-Chemical
(	O
SP	B-Chemical
and	O
TP	B-Chemical
)	O
sites	O
suppressed	O
both	O
their	O
ability	O
to	O
drive	O
neuronal	O
differentiation	O
during	O
development	O
[	O
5	O
"],"	O
[	O
7	O
]	O
and	O
during	O
cellular	O
reprogramming	O
of	O
mammalian	O
cells	O
[	O
6	O
].	O
MyoD	O
phosphorylation	O
on	O
Serine	B-Chemical
200	O
(	O
S200	B-Chemical
)	O
and	O
S5	B-Chemical
","	O
sites	O
both	O
found	O
as	O
part	O
of	O
an	O
SP	B-Chemical
motif	O
","	O
has	O
long	O
been	O
recognised	O
to	O
underlie	O
the	O
characteristic	O
MyoD	O
protein	O
fluctuations	O
and	O
activity	O
that	O
vary	O
with	O
cell	O
cycle	O
phase	O
in	O
proliferating	O
myoblasts	O
[	O
9	O
"],"	O
[	O
10	O
"],"	O
[	O
11	O
"],"	O
[	O
12	O
"],"	O
[	O
13	O
].	O
MyoD	O
also	O
contains	O
multiple	O
additional	O
SP	B-Chemical
and	O
TP	B-Chemical
sites	O
which	O
may	O
","	O
by	O
analogy	O
with	O
proneural	O
factors	O
","	O
play	O
an	O
additional	O
role	O
in	O
regulation	O
of	O
the	O
ability	O
of	O
MyoD	O
to	O
promote	O
myogenic	O
conversion	O
and	O
differentiation	O
.	O
Here	O
","	O
using	O
the	O
Xenopus	O
tadpole	O
as	O
a	O
model	O
to	O
test	O
MyoD	O
'	O
s	O
myogenic	O
conversion	O
potential	O
","	O
we	O
show	O
that	O
myogenic	O
activity	O
of	O
MyoD	O
is	O
regulated	O
by	O
up	O
to	O
five	O
S	B-Chemical
/	I-Chemical
TP	I-Chemical
kinase	O
sites	O
specifically	O
located	O
in	O
the	O
C	O
terminus	O
of	O
the	O
protein	O
.	O
Furthermore	O
","	O
we	O
see	O
that	O
multi	O
-	O
site	O
phosphorylation	O
regulates	O
both	O
MyoD	O
protein	O
stability	O
and	O
chromatin	O
association	O
.	O
Finally	O
","	O
we	O
identify	O
an	O
optimal	O
phospho	O
-	O
mutant	O
form	O
of	O
MyoD	O
that	O
dramatically	O
enhances	O
myogenic	O
conversion	O
of	O
embryonic	O
ectoderm	O
in	O
vivo	O
.	O
Materials	O
and	O
methods	O
Cloning	O
Wild	O
-	O
type	O
(	O
WT	O
)	O
mouse	O
MyoD	O
in	O
pCS2	O
has	O
been	O
described	O
[	O
14	O
].	O
A	O
single	O
C	O
terminal	O
HA	O
tag	O
was	O
added	O
by	O
PCR	O
using	O
the	O
primers	O
:	O
5	O
â€²	O
GATCGGATCCACCATGGAGCTTCTATCGCCG	O
-	O
3	O
â€²;	O
5	O
â€²	O
GATCCTCGAGTCAAGCGTAATCTGGAACATCGTATGGGTAAAGCACCTGATAAATCGCATT	O
-	O
3	O
â€².	O
All	O
single	O
or	O
multiple	O
site	O
mutations	O
were	O
performed	O
using	O
the	O
QuikChange	O
II	O
or	O
QuikChange	O
Multi	O
Site	O
-	O
Directed	O
Mutagenesis	O
Kit	O
(	O
Agilent	O
Technologies	O
)	O
respectively	O
(	O
PCR	O
primers	O
available	O
on	O
request	O
).	O
Nucleotide	O
and	O
protein	O
sequence	O
alignments	O
were	O
conducted	O
using	O
ClustalW	O
software	O
[	O
15	O
].	O
Xenopus	O
laevis	O
embryo	O
manipulation	O
Acquisition	O
of	O
Xenopus	O
laevis	O
embryos	O
","	O
preparation	O
and	O
injection	O
of	O
synthetic	O
mRNA	O
","	O
staging	O
of	O
embryos	O
and	O
in	O
situ	O
hybridisation	O
(	O
ISH	O
)	O
were	O
conducted	O
as	O
described	O
previously	O
[	O
6	O
"],"	O
[	O
16	O
"],"	O
[	O
17	O
].	O
Dig	B-Chemical
-	I-Chemical
oxigenin	I-Chemical
-	O
labelled	O
anti	O
-	O
sense	O
probes	O
were	O
synthesised	O
from	O
linearised	O
plasmid	O
Actc1	O
in	O
pSP64T	O
(	O
Xenbase	O
;	O
EcoR1	O
","	O
SP6	O
).	O
Semi	O
-	O
quantitative	O
scoring	O
was	O
conducted	O
for	O
Muscle	O
Actin	O
staining	O
on	O
the	O
injected	O
side	O
of	O
the	O
embryo	O
relative	O
to	O
the	O
uninjected	O
side	O
;	O
grades	O
were	O
assigned	O
0	O
â€“	O
3	O
","	O
where	O
0	O
indicates	O
no	O
increase	O
in	O
myogenesis	O
","	O
through	O
to	O
3	O
indicating	O
extensive	O
myogenesis	O
.	O
Quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
Whole	O
embryo	O
RNA	O
was	O
extracted	O
using	O
the	O
Qiagen	O
RNeasy	O
Â®	O
Mini	O
Kit	O
and	O
cDNAs	O
were	O
prepared	O
with	O
the	O
QuantiTect	O
Â®	O
Reverse	O
Transcription	O
Kit	O
(	O
Qiagen	O
).	O
qPCR	O
analysis	O
was	O
conducted	O
using	O
the	O
Quantifast	O
Â®	O
SYBR	O
Green	O
PCR	O
Kit	O
(	O
Qiagen	O
)	O
in	O
a	O
LightCycler	O
Â®	O
480	O
(	O
Roche	O
).	O
Thermal	O
cycling	O
parameters	O
are	O
described	O
in	O
Ref	O
.	O
[	O
5	O
"],"	O
and	O
primer	O
sequences	O
(	O
5	O
â€²â€“	O
3	O
â€²):	O
EF1Î±F	O
=	O
CACCATGAAGCCCTTACTGAG	O
;	O
EF1Î±R	O
=	O
TGATAACCTGTGCGGTAAATG	O
;	O
xMyh4F	O
=	O
GAACAAGGACCCACTGAACG	O
;	O
xMyh4R	O
=	O
TCCACCTTTACCAGCAGCAT	O
.	O
Western	O
blotting	O
Protein	O
extracts	O
were	O
prepared	O
from	O
whole	O
embryos	O
and	O
incubated	O
with	O
or	O
without	O
lambda	O
protein	O
phosphatase	O
(	O
NEB	O
)	O
as	O
described	O
[	O
7	O
"],"	O
prior	O
to	O
separation	O
on	O
an	O
18	O
%	O
Tris	B-Chemical
/	O
Glycine	B-Chemical
/	O
SDS	B-Chemical
gel	O
by	O
standard	O
methods	O
.	O
For	O
assay	O
of	O
chromatin	O
association	O
","	O
cross	O
linking	O
","	O
cytoplasmic	O
and	O
chromatin	O
fractionation	O
","	O
western	O
blot	O
and	O
protein	O
quantification	O
were	O
conducted	O
as	O
described	O
[	O
7	O
].	O
Statistical	O
analysis	O
For	O
western	O
blotting	O
","	O
experiments	O
were	O
performed	O
in	O
independent	O
duplicate	O
with	O
representative	O
results	O
shown	O
.	O
For	O
qPCR	O
data	O
","	O
mRNA	O
expression	O
was	O
normalised	O
to	O
expression	O
of	O
the	O
housekeeping	O
gene	O
Elongation	O
Factor	O
1Î±	O
(	O
EF1Î±	O
"),"	O
and	O
for	O
analysis	O
","	O
mRNA	O
levels	O
in	O
injected	O
embryos	O
were	O
calculated	O
relative	O
to	O
stage	O
-	O
matched	O
uninjected	O
controls	O
.	O
Mean	O
values	O
and	O
the	O
standard	O
error	O
of	O
the	O
mean	O
(	O
s	O
.	O
e	O
.	O
m	O
.)	O
were	O
calculated	O
from	O
at	O
least	O
three	O
independent	O
experiments	O
(	O
n	O
=	O
3	O
).	O
Statistical	O
significance	O
was	O
determined	O
using	O
a	O
paired	O
two	O
-	O
tailed	O
Student	O
'	O
s	O
t	O
-	O
test	O
with	O
(	O
p	O
<	O
0	O
.	O
5	O
)	O
=	O
*;	O
(	O
p	O
<	O
0	O
.	O
25	O
)	O
=	O
**;	O
(	O
p	O
<	O
0	O
.	O
125	O
)	O
=	O
***.	O
For	O
in	O
situ	O
hybridisation	O
data	O
","	O
experiments	O
were	O
conducted	O
in	O
independent	O
duplicate	O
or	O
triplicate	O
and	O
the	O
n	O
numbers	O
reported	O
refer	O
to	O
the	O
range	O
of	O
total	O
numbers	O
of	O
embryos	O
in	O
each	O
injection	O
category	O
.	O
Statistical	O
significance	O
was	O
determined	O
between	O
categories	O
using	O
a	O
Fisher	O
'	O
s	O
Exact	O
Test	O
for	O
Count	O
Data	O
","	O
and	O
p	O
values	O
are	O
as	O
described	O
above	O
.	O
Results	O
MyoD	O
is	O
phosphorylated	O
on	O
sites	O
in	O
addition	O
to	O
S200	B-Chemical
during	O
Xenopus	O
primary	O
myogenesis	O
Early	O
studies	O
investigating	O
phospho	O
-	O
regulation	O
of	O
MyoD	O
largely	O
focused	O
on	O
its	O
modification	O
in	O
proliferating	O
cells	O
in	O
culture	O
;	O
either	O
C2C12	O
myoblasts	O
or	O
C3H10T1	O
/	O
2	O
fibroblasts	O
transfected	O
with	O
MyoD	O
[	O
10	O
"],"	O
[	O
12	O
].	O
To	O
investigate	O
phosphorylation	O
of	O
MyoD	O
and	O
its	O
reprogramming	O
activity	O
in	O
vivo	O
","	O
we	O
chose	O
the	O
highly	O
versatile	O
Xenopus	O
embryo	O
system	O
","	O
which	O
can	O
be	O
used	O
to	O
study	O
mammalian	O
MyoD	O
activity	O
both	O
in	O
the	O
endogenous	O
myotome	O
and	O
also	O
for	O
reprogramming	O
activity	O
in	O
the	O
non	O
-	O
myogenic	O
ectoderm	O
tissue	O
[	O
14	O
].	O
Furthermore	O
","	O
the	O
first	O
cleavage	O
of	O
the	O
fertilised	O
egg	O
bisects	O
the	O
embryos	O
into	O
future	O
left	O
and	O
right	O
sides	O
","	O
so	O
unilateral	O
mRNA	O
injection	O
allows	O
MyoD	O
activity	O
to	O
be	O
directly	O
compared	O
between	O
injected	O
and	O
uninjected	O
embryo	O
sides	O
.	O
Firstly	O
","	O
we	O
explored	O
whether	O
MyoD	O
is	O
phosphorylated	O
during	O
primary	O
myogenesis	O
.	O
Extracts	O
were	O
prepared	O
from	O
stage	O
12	O
.	O
5	O
embryos	O
injected	O
with	O
mRNA	O
encoding	O
HA	O
-	O
tagged	O
Wild	O
-	O
Type	O
(	O
WT	O
)	O
MyoD	O
","	O
or	O
S200A	B-Chemical
MyoD	O
","	O
a	O
mutant	O
version	O
with	O
S200	B-Chemical
mutated	O
to	O
alanine	B-Chemical
to	O
prevent	O
phosphorylation	O
at	O
this	O
established	O
site	O
.	O
Western	O
blot	O
analysis	O
reveals	O
a	O
broad	O
protein	O
band	O
for	O
both	O
WT	O
and	O
S200A	B-Chemical
proteins	O
(	O
Fig	O
.	O
1A	O
"),"	O
with	O
more	O
S200A	B-Chemical
protein	O
than	O
WT	O
","	O
consistent	O
with	O
previous	O
reports	O
that	O
demonstrate	O
a	O
longer	O
half	O
-	O
life	O
for	O
this	O
mutant	O
protein	O
[	O
10	O
"],"	O
[	O
11	O
"],"	O
[	O
12	O
].	O
Incubation	O
with	O
a	O
broad	O
spectrum	O
protein	O
phosphatase	O
enhances	O
the	O
migration	O
of	O
both	O
WT	O
and	O
S200A	B-Chemical
","	O
indicating	O
phosphorylation	O
on	O
at	O
least	O
one	O
additional	O
site	O
during	O
differentiation	O
in	O
vivo	O
.	O
A	O
multi	O
-	O
site	O
phospho	O
-	O
mutant	O
MyoD	O
promotes	O
enhanced	O
myogenesis	O
in	O
vivo	O
Mouse	O
MyoD	O
protein	O
contains	O
seven	O
potential	O
proline	O
-	O
directed	O
kinase	O
sites	O
(	O
six	O
serine	B-Chemical
-	O
proline	B-Chemical
(	O
SP	B-Chemical
"),"	O
and	O
one	O
threonine	B-Chemical
-	O
proline	B-Chemical
(	O
TP	B-Chemical
))	O
that	O
are	O
highly	O
conserved	O
with	O
human	O
MyoD	O
(	O
Supplementary	O
Fig	O
.	O
1	O
).	O
To	O
further	O
explore	O
a	O
potential	O
regulatory	O
role	O
of	O
S	B-Chemical
/	I-Chemical
TP	I-Chemical
sites	O
additional	O
to	O
S200	B-Chemical
during	O
myogenesis	O
","	O
a	O
panel	O
of	O
phospho	O
-	O
mutant	O
forms	O
of	O
MyoD	O
were	O
created	O
(	O
Fig	O
.	O
1B	O
):	O
7T	O
/	O
S	O
-	O
A	O
MyoD	O
contains	O
all	O
seven	O
SP	B-Chemical
/	O
TP	B-Chemical
sites	O
mutated	O
to	O
alanine	B-Chemical
-	O
proline	B-Chemical
(	O
AP	B-Chemical
"),"	O
while	O
6T	O
/	O
S	O
-	O
A	O
(	O
S200	B-Chemical
)	O
has	O
the	O
S200	B-Chemical
site	O
restored	O
but	O
the	O
remaining	O
six	O
sites	O
mutated	O
.	O
In	O
order	O
to	O
compare	O
their	O
myogenic	O
activity	O
","	O
mRNA	O
encoding	O
these	O
proteins	O
was	O
injected	O
unilaterally	O
into	O
two	O
-	O
cell	O
stage	O
Xenopus	O
embryos	O
","	O
and	O
myogenesis	O
was	O
assayed	O
in	O
stage	O
18	O
embryos	O
by	O
RT	O
-	O
qPCR	O
and	O
in	O
situ	O
hybridisation	O
(	O
ISH	O
)	O
for	O
muscle	O
structural	O
genes	O
Myosin	O
Heavy	O
Chain	O
or	O
Muscle	O
Actin	O
respectively	O
(	O
Fig	O
.	O
1C	O
â€“	O
E	O
).	O
At	O
this	O
level	O
of	O
over	O
-	O
expression	O
","	O
WT	O
MyoD	O
induces	O
a	O
small	O
increase	O
in	O
myogenesis	O
","	O
largely	O
confined	O
to	O
expansion	O
of	O
the	O
myotome	O
on	O
the	O
injected	O
side	O
.	O
By	O
comparison	O
","	O
both	O
S200A	B-Chemical
and	O
full	O
phospho	O
-	O
mutant	O
7T	O
/	O
S	O
-	O
A	O
induce	O
a	O
marked	O
increase	O
in	O
myogenesis	O
spreading	O
laterally	O
","	O
and	O
demonstrating	O
reprogramming	O
of	O
ectoderm	O
tissue	O
.	O
Interestingly	O
","	O
6T	O
/	O
S	O
-	O
A	O
(	O
S200	B-Chemical
)	O
also	O
induces	O
a	O
significant	O
increase	O
in	O
myogenesis	O
relative	O
to	O
WT	O
MyoD	O
","	O
albeit	O
with	O
less	O
activity	O
than	O
S200A	B-Chemical
or	O
7T	O
/	O
S	O
-	O
A	O
MyoDs	O
.	O
This	O
demonstrates	O
that	O
sites	O
in	O
addition	O
to	O
S200	B-Chemical
can	O
regulate	O
myogenic	O
activity	O
of	O
MyoD	O
.	O
Regulatory	O
activity	O
resides	O
in	O
C	O
terminal	O
phosphorylation	O
sites	O
We	O
have	O
previously	O
described	O
a	O
model	O
for	O
phospho	O
-	O
regulation	O
of	O
proneural	O
protein	O
activity	O
","	O
where	O
the	O
number	O
","	O
rather	O
than	O
location	O
of	O
available	O
phospho	O
-	O
sites	O
is	O
the	O
key	O
determinant	O
of	O
bHLH	O
activity	O
;	O
mutation	O
of	O
increasing	O
numbers	O
of	O
phosphorylation	O
sites	O
additively	O
increases	O
the	O
neurogenic	O
activity	O
of	O
the	O
mutant	O
proteins	O
[	O
5	O
"],"	O
[	O
7	O
].	O
To	O
explore	O
if	O
a	O
similar	O
phenomenon	O
may	O
control	O
regulation	O
of	O
MyoD	O
","	O
a	O
panel	O
of	O
MyoD	O
phospho	O
-	O
mutants	O
were	O
made	O
with	O
SP	B-Chemical
/	O
TP	B-Chemical
sites	O
cumulatively	O
mutated	O
from	O
the	O
N	O
terminus	O
to	O
generate	O
1S	O
-	O
A	O
","	O
2S	O
-	O
A	O
etc	O
(	O
Fig	O
.	O
2A	O
).	O
Due	O
to	O
the	O
immediate	O
proximity	O
of	O
T296	B-Chemical
/	O
S298	B-Chemical
","	O
these	O
sites	O
were	O
mutated	O
simultaneously	O
.	O
Embryos	O
were	O
injected	O
with	O
mRNA	O
as	O
before	O
and	O
scored	O
for	O
myogenesis	O
at	O
stage	O
18	O
by	O
ISH	O
(	O
Fig	O
.	O
2B	O
â€“	O
C	O
).	O
Mutation	O
of	O
the	O
N	O
terminal	O
SP	B-Chemical
sites	O
in	O
MyoD	O
has	O
no	O
significant	O
effect	O
on	O
its	O
activity	O
relative	O
to	O
the	O
wild	O
-	O
type	O
protein	O
.	O
Similarly	O
","	O
mutation	O
of	O
S200	B-Chemical
in	O
addition	O
to	O
the	O
two	O
N	O
terminal	O
sites	O
(	O
i	O
.	O
e	O
.	O
3S	O
-	O
A	O
)	O
produces	O
a	O
level	O
of	O
myogenesis	O
comparable	O
to	O
mutation	O
of	O
the	O
single	O
S200	B-Chemical
site	O
alone	O
","	O
suggesting	O
that	O
the	O
N	O
terminal	O
sites	O
do	O
not	O
contribute	O
to	O
regulation	O
of	O
MyoD	O
myogenic	O
activity	O
.	O
However	O
","	O
mutation	O
of	O
C	O
terminal	O
residues	O
in	O
addition	O
to	O
S200	B-Chemical
results	O
in	O
a	O
more	O
active	O
MyoD	O
than	O
the	O
single	O
phosphorylation	O
site	O
mutant	O
S200A	B-Chemical
MyoD	O
.	O
Thus	O
","	O
for	O
MyoD	O
","	O
both	O
number	O
and	O
location	O
of	O
phospho	O
-	O
sites	O
contribute	O
to	O
its	O
regulation	O
.	O
S200	B-Chemical
is	O
the	O
most	O
important	O
individual	O
C	O
terminal	O
site	O
for	O
regulating	O
myogenic	O
activity	O
The	O
five	O
C	O
terminal	O
phospho	O
-	O
sites	O
in	O
mouse	O
MyoD	O
are	O
also	O
the	O
phospho	O
-	O
sites	O
that	O
are	O
most	O
conserved	O
with	O
both	O
human	O
and	O
Xenopus	O
MyoD	O
(	O
Supplementary	O
Fig	O
.	O
1	O
);	O
S200	B-Chemical
and	O
S262	B-Chemical
are	O
highly	O
conserved	O
between	O
all	O
three	O
species	O
","	O
suggesting	O
that	O
these	O
may	O
have	O
enhanced	O
functional	O
significance	O
.	O
We	O
therefore	O
sought	O
to	O
address	O
whether	O
myogenic	O
activity	O
depends	O
on	O
any	O
particular	O
C	O
terminal	O
phospho	O
-	O
site	O
.	O
Each	O
C	O
terminal	O
site	O
was	O
mutated	O
individually	O
and	O
myogenic	O
activity	O
was	O
assayed	O
as	O
described	O
above	O
(	O
Fig	O
.	O
2D	O
â€“	O
E	O
).	O
Mutation	O
of	O
any	O
individual	O
C	O
terminal	O
phospho	O
-	O
site	O
results	O
in	O
significantly	O
enhanced	O
myogenesis	O
compared	O
to	O
WT	O
MyoD	O
.	O
Furthermore	O
","	O
the	O
three	O
most	O
C	O
terminal	O
sites	O
when	O
mutated	O
individually	O
(	O
S262	B-Chemical
","	O
S277	B-Chemical
and	O
T296	B-Chemical
/	O
S298	B-Chemical
)	O
are	O
very	O
similar	O
to	O
each	O
other	O
in	O
inducing	O
a	O
moderate	O
increase	O
in	O
myogenesis	O
.	O
By	O
comparison	O
","	O
mutation	O
of	O
the	O
S200	B-Chemical
site	O
alone	O
results	O
in	O
myogenic	O
activity	O
that	O
is	O
significantly	O
greater	O
than	O
any	O
other	O
single	O
site	O
mutant	O
","	O
yet	O
this	O
is	O
still	O
not	O
as	O
active	O
as	O
the	O
full	O
7T	O
/	O
S	O
-	O
A	O
phospho	O
-	O
mutant	O
.	O
Therefore	O
","	O
S200	B-Chemical
confers	O
the	O
most	O
significant	O
regulatory	O
activity	O
but	O
its	O
mutation	O
alone	O
is	O
not	O
sufficient	O
to	O
maximally	O
activate	O
MyoD	O
;	O
additional	O
C	O
terminal	O
residues	O
must	O
also	O
be	O
mutated	O
.	O
Identification	O
of	O
an	O
optimal	O
phospho	O
-	O
mutant	O
MyoD	O
with	O
maximal	O
myogenic	O
activity	O
For	O
the	O
purposes	O
of	O
cellular	O
reprogramming	O
","	O
an	O
optimal	O
form	O
of	O
MyoD	O
would	O
have	O
maximal	O
activity	O
in	O
driving	O
myogenic	O
conversion	O
of	O
non	O
-	O
muscle	O
tissue	O
.	O
Therefore	O
","	O
we	O
finally	O
sought	O
to	O
derive	O
an	O
optimal	O
phospho	O
-	O
mutant	O
MyoD	O
in	O
our	O
Xenopus	O
assay	O
.	O
For	O
the	O
proneural	O
proteins	O
","	O
maximal	O
activity	O
is	O
achieved	O
by	O
mutation	O
of	O
all	O
available	O
phospho	O
-	O
sites	O
[	O
5	O
"],"	O
[	O
6	O
"],"	O
[	O
7	O
"],"	O
but	O
for	O
MyoD	O
","	O
we	O
see	O
that	O
N	O
terminal	O
sites	O
do	O
not	O
contribute	O
to	O
regulation	O
(	O
Fig	O
.	O
2	O
).	O
S200	B-Chemical
is	O
the	O
most	O
important	O
single	O
C	O
terminal	O
site	O
(	O
Fig	O
.	O
2	O
"),"	O
so	O
additional	O
constructs	O
were	O
made	O
to	O
mutate	O
S200	B-Chemical
in	O
combination	O
with	O
other	O
C	O
terminal	O
sites	O
(	O
data	O
not	O
shown	O
).	O
In	O
all	O
assays	O
conducted	O
","	O
the	O
most	O
extensive	O
myogenesis	O
is	O
induced	O
by	O
CT	O
5T	O
/	O
S	O
-	O
A	O
MyoD	O
","	O
in	O
which	O
all	O
five	O
C	O
terminal	O
phospho	O
-	O
sites	O
are	O
mutated	O
but	O
the	O
two	O
N	O
-	O
terminal	O
phospho	O
-	O
sites	O
are	O
intact	O
.	O
These	O
results	O
are	O
summarised	O
in	O
Fig	O
.	O
3	O
","	O
where	O
NT	O
2S	O
-	O
A	O
MyoD	O
shows	O
equivalent	O
activity	O
to	O
WT	O
protein	O
","	O
and	O
CT	O
5T	O
/	O
S	O
-	O
A	O
MyoD	O
is	O
more	O
active	O
than	O
the	O
full	O
7T	O
/	O
S	O
-	O
A	O
phospho	O
-	O
mutant	O
.	O
We	O
note	O
that	O
both	O
of	O
these	O
multi	O
-	O
site	O
mutants	O
are	O
significantly	O
more	O
active	O
than	O
the	O
single	O
S200A	B-Chemical
mutant	O
","	O
inducing	O
extensive	O
conversion	O
of	O
the	O
lateral	O
ectoderm	O
to	O
a	O
myogenic	O
cell	O
fate	O
","	O
often	O
seen	O
bilaterally	O
over	O
the	O
embryo	O
.	O
Thus	O
","	O
while	O
S200	B-Chemical
shows	O
the	O
greatest	O
regulatory	O
role	O
of	O
any	O
individual	O
site	O
","	O
phosphorylation	O
must	O
be	O
prevented	O
on	O
all	O
five	O
C	O
-	O
terminal	O
serine	B-Chemical
/	O
threonines	B-Chemical
for	O
maximal	O
differentiation	O
activity	O
.	O
CT	O
5T	O
/	O
S	O
-	O
A	O
MyoD	O
has	O
both	O
increased	O
protein	O
accumulation	O
and	O
enhanced	O
chromatin	O
binding	O
relative	O
to	O
WT	O
and	O
S200A	B-Chemical
MyoD	O
Having	O
established	O
an	O
optimal	O
phospho	O
-	O
mutant	O
form	O
of	O
MyoD	O
that	O
has	O
superior	O
myogenic	O
activity	O
in	O
vivo	O
","	O
we	O
investigated	O
the	O
mechanisms	O
by	O
which	O
this	O
enhanced	O
differentiation	O
is	O
achieved	O
.	O
One	O
mechanism	O
may	O
be	O
by	O
enhancing	O
MyoD	O
protein	O
stability	O
.	O
We	O
have	O
already	O
shown	O
that	O
injection	O
of	O
equal	O
amounts	O
of	O
WT	O
and	O
S200A	B-Chemical
MyoD	O
mRNA	O
produces	O
a	O
greater	O
accumulation	O
of	O
S200A	B-Chemical
protein	O
relative	O
to	O
WT	O
MyoD	O
(	O
Fig	O
.	O
1	O
)	O
so	O
we	O
next	O
determined	O
whether	O
the	O
optimal	O
phospho	O
-	O
mutant	O
CT	O
5T	O
/	O
S	O
-	O
A	O
MyoD	O
showed	O
further	O
enhancement	O
of	O
stability	O
.	O
HA	O
-	O
tagged	O
mRNA	O
was	O
injected	O
into	O
Xenopus	O
embryos	O
","	O
and	O
protein	O
extracts	O
were	O
prepared	O
at	O
stage	O
12	O
.	O
5	O
for	O
western	O
blot	O
analysis	O
;	O
the	O
density	O
of	O
each	O
MyoD	O
protein	O
band	O
was	O
calculated	O
relative	O
to	O
the	O
respective	O
tubulin	O
loading	O
control	O
(	O
Fig	O
.	O
4A	O
","	O
C	O
).	O
While	O
injection	O
of	O
the	O
same	O
amount	O
of	O
mRNA	O
results	O
in	O
an	O
almost	O
three	O
-	O
fold	O
increase	O
in	O
S200A	B-Chemical
protein	O
relative	O
to	O
WT	O
MyoD	O
","	O
CT	O
5T	O
/	O
S	O
-	O
A	O
MyoD	O
protein	O
accumulates	O
to	O
a	O
level	O
that	O
is	O
more	O
than	O
four	O
-	O
fold	O
higher	O
than	O
WT	O
MyoD	O
.	O
Thus	O
","	O
whilst	O
S200	B-Chemical
is	O
an	O
established	O
phospho	O
-	O
site	O
that	O
regulates	O
MyoD	O
stability	O
[	O
10	O
"],"	O
[	O
12	O
"],"	O
further	O
enhancement	O
of	O
MyoD	O
protein	O
stability	O
accompanies	O
mutation	O
of	O
additional	O
C	O
-	O
terminal	O
SP	B-Chemical
sites	O
.	O
Phospho	O
-	O
mutant	O
proneural	O
proteins	O
show	O
both	O
an	O
enhanced	O
stability	O
compared	O
to	O
their	O
wild	O
-	O
type	O
counterparts	O
","	O
but	O
also	O
exhibit	O
enhanced	O
DNA	O
binding	O
affinity	O
","	O
and	O
both	O
of	O
these	O
attributes	O
contribute	O
to	O
superior	O
reprogramming	O
activity	O
[	O
5	O
"],"	O
[	O
7	O
].	O
To	O
test	O
whether	O
MyoD	O
phospho	O
-	O
status	O
influences	O
protein	O
binding	O
to	O
embryonic	O
chromatin	O
","	O
embryos	O
were	O
injected	O
as	O
before	O
","	O
and	O
cross	O
-	O
linking	O
was	O
performed	O
in	O
stage	O
13	O
embryos	O
prior	O
to	O
nuclear	O
extraction	O
","	O
chromatin	O
isolation	O
and	O
western	O
blot	O
analysis	O
(	O
Fig	O
.	O
4B	O
","	O
D	O
).	O
Cytoplasmic	O
samples	O
were	O
also	O
collected	O
and	O
MyoD	O
protein	O
accumulation	O
was	O
calculated	O
relative	O
to	O
tubulin	O
or	O
histone	O
H3	O
loading	O
controls	O
in	O
cytoplasmic	O
and	O
chromatin	O
fractions	O
respectively	O
.	O
The	O
absence	O
of	O
tubulin	O
protein	O
in	O
the	O
chromatin	O
fraction	O
confirms	O
successful	O
chromatin	O
isolation	O
","	O
and	O
no	O
MyoD	O
protein	O
was	O
detected	O
in	O
the	O
uninjected	O
embryos	O
","	O
confirming	O
specificity	O
of	O
the	O
anti	O
-	O
HA	O
antibody	O
.	O
Comparing	O
the	O
relative	O
amounts	O
of	O
chromatin	O
bound	O
MyoD	O
protein	O
(	O
Fig	O
.	O
4D	O
)	O
with	O
the	O
relative	O
amounts	O
of	O
whole	O
embryo	O
MyoD	O
protein	O
(	O
Fig	O
.	O
4C	O
"),"	O
S200A	B-Chemical
MyoD	O
is	O
only	O
1	O
.	O
6	O
-	O
fold	O
higher	O
than	O
WT	O
MyoD	O
in	O
chromatin	O
samples	O
","	O
suggesting	O
that	O
S200A	B-Chemical
displays	O
greater	O
protein	O
stability	O
than	O
WT	O
MyoD	O
","	O
but	O
no	O
greater	O
chromatin	O
binding	O
affinity	O
.	O
Therefore	O
","	O
protein	O
stability	O
alone	O
contributes	O
to	O
the	O
enhanced	O
activity	O
of	O
this	O
mutant	O
S200A	B-Chemical
protein	O
.	O
In	O
contrast	O
","	O
chromatin	O
-	O
bound	O
CT	O
5T	O
/	O
S	O
-	O
A	O
MyoD	O
accumulates	O
to	O
five	O
-	O
fold	O
higher	O
than	O
WT	O
and	O
three	O
-	O
fold	O
higher	O
than	O
S200A	B-Chemical
MyoD	O
","	O
demonstrating	O
an	O
increased	O
chromatin	O
binding	O
affinity	O
in	O
addition	O
to	O
increased	O
protein	O
accumulation	O
.	O
Thus	O
","	O
our	O
optimal	O
phospho	O
-	O
mutant	O
CT	O
5T	O
/	O
S	O
-	O
A	O
dramatically	O
enhances	O
myogenesis	O
in	O
vivo	O
by	O
a	O
combination	O
of	O
increased	O
protein	O
accumulation	O
and	O
enhanced	O
chromatin	O
binding	O
;	O
this	O
latter	O
feature	O
being	O
unique	O
to	O
the	O
CT	O
5T	O
/	O
S	O
-	O
A	O
MyoD	O
phospho	O
-	O
mutant	O
and	O
not	O
shared	O
with	O
S200A	B-Chemical
MyoD	O
.	O
Discussion	O
The	O
bHLH	O
transcription	O
factor	O
MyoD	O
is	O
a	O
master	O
regulator	O
of	O
myogenesis	O
","	O
and	O
manipulating	O
its	O
activity	O
both	O
for	O
in	O
vitro	O
modelling	O
of	O
muscle	O
disease	O
and	O
for	O
cell	O
replacement	O
therapy	O
has	O
huge	O
potential	O
in	O
translation	O
medicine	O
and	O
cellular	O
reprogramming	O
[	O
18	O
].	O
We	O
set	O
out	O
to	O
engineer	O
a	O
maximally	O
active	O
form	O
of	O
MyoD	O
for	O
in	O
vivo	O
reprogramming	O
in	O
the	O
Xenopus	O
frog	O
system	O
.	O
Neurogenin2	O
","	O
Ascl1	O
and	O
NeuroD4	O
","	O
bHLH	O
transcription	O
factors	O
regulating	O
neurogenesis	O
","	O
undergo	O
multi	O
-	O
site	O
phosphorylation	O
that	O
coordinates	O
neuronal	O
differentiation	O
with	O
the	O
cellular	O
kinase	O
environment	O
in	O
vivo	O
[	O
5	O
"],"	O
[	O
6	O
"],"	O
[	O
7	O
"],"	O
[	O
8	O
].	O
As	O
such	O
","	O
multi	O
-	O
site	O
bHLH	O
protein	O
phosphorylation	O
in	O
rapidly	O
dividing	O
cells	O
suppresses	O
their	O
ability	O
to	O
drive	O
neuronal	O
differentiation	O
;	O
a	O
multiply	O
phospho	O
-	O
mutant	O
form	O
of	O
these	O
proneural	O
proteins	O
substantially	O
enhances	O
their	O
ability	O
to	O
reprogram	O
both	O
Xenopus	O
ectoderm	O
and	O
mammalian	O
fibroblasts	O
into	O
neurons	O
[	O
5	O
"],"	O
[	O
6	O
"],"	O
[	O
7	O
"],"	O
[	O
8	O
].	O
Here	O
","	O
we	O
show	O
here	O
that	O
multi	O
-	O
site	O
phosphorylation	O
also	O
controls	O
the	O
ability	O
of	O
MyoD	O
to	O
regulate	O
cellular	O
reprogramming	O
to	O
muscle	O
in	O
vivo	O
","	O
demonstrating	O
conservation	O
of	O
a	O
similar	O
regulation	O
of	O
bHLH	O
proteins	O
across	O
cell	O
lineages	O
and	O
germ	O
layers	O
.	O
Analogous	O
to	O
our	O
findings	O
for	O
proneural	O
bHLH	O
proteins	O
[	O
5	O
"],"	O
[	O
6	O
"],"	O
[	O
7	O
"],"	O
[	O
8	O
"],"	O
we	O
see	O
that	O
MyoD	O
is	O
phospho	O
-	O
regulated	O
on	O
multiple	O
proline	O
-	O
directed	O
kinase	O
sites	O
during	O
developmental	O
myogenesis	O
.	O
Moreover	O
","	O
by	O
combining	O
mutational	O
analysis	O
with	O
this	O
in	O
vivo	O
assay	O
system	O
","	O
we	O
have	O
identified	O
an	O
optimal	O
phospho	O
-	O
mutant	O
form	O
of	O
MyoD	O
","	O
CT	O
5T	O
/	O
S	O
-	O
A	O
MyoD	O
","	O
that	O
displays	O
markedly	O
enhanced	O
ability	O
to	O
drive	O
myogenic	O
differentiation	O
compared	O
to	O
any	O
previously	O
described	O
phospho	O
-	O
mutant	O
[	O
9	O
"],"	O
[	O
10	O
"],"	O
[	O
11	O
"],"	O
[	O
12	O
"],"	O
[	O
13	O
].	O
Our	O
optimal	O
C	O
terminal	O
phospho	O
-	O
mutant	O
protein	O
displays	O
increased	O
protein	O
stability	O
relative	O
to	O
both	O
WT	O
MyoD	O
and	O
S200A	B-Chemical
MyoD	O
","	O
a	O
mutant	O
previously	O
shown	O
to	O
have	O
enhanced	O
stability	O
and	O
activity	O
compared	O
to	O
the	O
WT	O
protein	O
[	O
10	O
"],"	O
[	O
11	O
"],"	O
[	O
12	O
].	O
In	O
addition	O
","	O
we	O
also	O
see	O
that	O
CT	O
5T	O
/	O
S	O
-	O
A	O
MyoD	O
has	O
increased	O
chromatin	O
affinity	O
that	O
is	O
not	O
shared	O
by	O
S200A	B-Chemical
MyoD	O
.	O
The	O
data	O
we	O
present	O
here	O
","	O
in	O
combination	O
with	O
previous	O
work	O
on	O
proneural	O
proteins	O
[	O
5	O
"],"	O
[	O
6	O
"],"	O
[	O
7	O
"],"	O
[	O
8	O
"],"	O
support	O
the	O
conservation	O
of	O
a	O
phospho	O
-	O
regulatory	O
model	O
of	O
bHLH	O
protein	O
action	O
","	O
both	O
functionally	O
and	O
mechanistically	O
","	O
across	O
both	O
nerve	O
and	O
muscle	O
cell	O
lineages	O
.	O
However	O
","	O
in	O
contrast	O
to	O
proneural	O
proteins	O
where	O
only	O
the	O
number	O
of	O
available	O
phospho	O
-	O
sites	O
is	O
key	O
to	O
regulating	O
protein	O
function	O
[	O
5	O
"],"	O
[	O
6	O
"],"	O
[	O
7	O
"],"	O
[	O
8	O
"],"	O
we	O
find	O
that	O
both	O
number	O
and	O
location	O
of	O
phospho	O
-	O
sites	O
are	O
important	O
for	O
MyoD	O
","	O
with	O
regulatory	O
phospho	O
-	O
sites	O
located	O
solely	O
in	O
the	O
C	O
terminus	O
of	O
the	O
protein	O
.	O
In	O
contrast	O
to	O
MyoD	O
N	O
terminal	O
phospho	O
-	O
sites	O
","	O
C	O
terminal	O
sites	O
show	O
strong	O
sequence	O
conservation	O
between	O
species	O
.	O
Indeed	O
","	O
even	O
in	O
proliferating	O
myoblasts	O
","	O
four	O
major	O
isoforms	O
of	O
MyoD	O
were	O
found	O
to	O
be	O
subsequently	O
resolved	O
by	O
phosphatase	O
treatment	O
[	O
10	O
"],"	O
and	O
an	O
early	O
in	O
vitro	O
assay	O
found	O
increased	O
reporter	O
transactivation	O
when	O
other	O
individual	O
C	O
terminal	O
proline	O
-	O
directed	O
kinase	O
sites	O
were	O
mutated	O
[	O
12	O
].	O
These	O
were	O
found	O
not	O
to	O
be	O
phosphorylated	O
by	O
cdks	O
in	O
dividing	O
culture	O
cells	O
","	O
but	O
they	O
may	O
be	O
targeted	O
by	O
other	O
proline	O
-	O
directed	O
kinases	O
such	O
as	O
MAPKs	O
in	O
the	O
environment	O
of	O
the	O
differentiating	O
myotome	O
.	O
The	O
distinct	O
C	O
terminal	O
location	O
of	O
regulatory	O
phospho	O
-	O
sites	O
may	O
also	O
relate	O
to	O
the	O
complexity	O
of	O
MyoD	O
function	O
that	O
is	O
being	O
revealed	O
by	O
genome	O
-	O
wide	O
analysis	O
.	O
MyoD	O
temporally	O
orchestrates	O
expression	O
of	O
multiple	O
subsets	O
of	O
genes	O
during	O
the	O
specification	O
and	O
differentiation	O
stages	O
of	O
myogenesis	O
[	O
19	O
].	O
Additionally	O
","	O
MyoD	O
has	O
been	O
found	O
to	O
bind	O
at	O
sites	O
throughout	O
the	O
genome	O
where	O
it	O
induces	O
histone	O
modifications	O
rather	O
than	O
gene	O
expression	O
[	O
20	O
].	O
Thus	O
","	O
for	O
MyoD	O
","	O
DNA	O
binding	O
affinity	O
does	O
not	O
always	O
correlate	O
with	O
transcriptional	O
activation	O
and	O
instead	O
","	O
the	O
timing	O
and	O
location	O
of	O
cofactor	O
association	O
may	O
be	O
the	O
critical	O
determinant	O
for	O
temporal	O
and	O
spatial	O
activity	O
.	O
For	O
example	O
","	O
genome	O
-	O
wide	O
analysis	O
has	O
shown	O
that	O
MyoD	O
transcriptional	O
activity	O
is	O
temporally	O
regulated	O
through	O
a	O
direct	O
repression	O
of	O
promoter	O
-	O
bound	O
MyoD	O
[	O
19	O
].	O
A	O
comparison	O
of	O
the	O
genome	O
-	O
wide	O
promoter	O
occupancy	O
of	O
both	O
WT	O
and	O
phospho	O
-	O
mutant	O
MyoD	O
may	O
reveal	O
clues	O
as	O
to	O
potential	O
differential	O
phospho	O
-	O
regulation	O
of	O
distinct	O
downstream	O
MyoD	O
targets	O
.	O
Furthermore	O
","	O
consistent	O
with	O
a	O
role	O
in	O
cofactor	O
association	O
","	O
the	O
ability	O
of	O
MyoD	O
to	O
activate	O
transcription	O
in	O
inaccessible	O
chromatin	O
has	O
been	O
mapped	O
to	O
the	O
C	O
terminal	O
domain	O
[	O
21	O
"],"	O
and	O
partly	O
attributed	O
to	O
the	O
helix	O
3	O
domain	O
[	O
22	O
]	O
that	O
enables	O
binding	O
to	O
pioneer	O
factors	O
Pbx	O
/	O
Meis	O
[	O
23	O
];	O
spanning	O
resides	O
218	O
â€“	O
269	O
","	O
this	O
includes	O
the	O
S262	B-Chemical
phospho	O
-	O
site	O
.	O
It	O
will	O
be	O
interesting	O
to	O
determine	O
whether	O
co	O
-	O
factor	O
binding	O
is	O
regulated	O
by	O
MyoD	O
phosphorylation	O
.	O
In	O
conclusion	O
","	O
we	O
have	O
characterised	O
multi	O
-	O
site	O
phospho	O
-	O
regulation	O
of	O
MyoD	O
on	O
C	O
-	O
terminal	O
S	B-Chemical
/	I-Chemical
TP	I-Chemical
sites	O
that	O
controls	O
its	O
ability	O
to	O
drive	O
myogenesis	O
in	O
vivo	O
:	O
Whilst	O
there	O
are	O
differences	O
between	O
the	O
myogenic	O
and	O
neurogenic	O
bHLH	O
factors	O
","	O
the	O
essence	O
of	O
multi	O
-	O
site	O
phospho	O
-	O
regulation	O
is	O
both	O
functionally	O
and	O
mechanistically	O
conserved	O
in	O
muscle	O
and	O
nerve	O
.	O
Using	O
an	O
in	O
vivo	O
developmental	O
and	O
reprogramming	O
assay	O
system	O
in	O
Xenopus	O
embryos	O
","	O
we	O
have	O
derived	O
a	O
novel	O
C	O
terminal	O
phospho	O
-	O
mutant	O
MyoD	O
protein	O
that	O
has	O
significantly	O
enhanced	O
myogenic	O
activity	O
compared	O
to	O
any	O
previously	O
described	O
mutants	O
.	O
This	O
has	O
the	O
potential	O
for	O
enhancing	O
trans	O
-	O
differentiation	O
of	O
mammalian	O
cells	O
into	O
muscle	O
for	O
translational	O
applications	O
","	O
and	O
this	O
should	O
form	O
the	O
basis	O
of	O
further	O
investigations	O
.	O
References	O
Supplementary	O
data	O
The	O
following	O
is	O
the	O
supplementary	O
data	O
related	O
to	O
this	O
article	O
:	O
Transparency	O
document	O
Supplementary	O
data	O
related	O
to	O
this	O
article	O
can	O
be	O
found	O
at	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1016	O
/	O
j	O
.	O
bbrc	O
.	O
2016	O
.	O
11	O
.	O
9	O
.	O
Transparency	O
document	O
related	O
to	O
this	O
article	O
can	O
be	O
found	O
online	O
at	O
http	O
://	O
dx	O
.	O
doi	O
.	O
org	O
/	O
10	O
.	O
1016	O
/	O
j	O
.	O
bbrc	O
.	O
2016	O
.	O
11	O
.	O
9	O
.	O
MyoD	O
is	O
phospho	O
-	O
regulated	O
on	O
sites	O
in	O
addition	O
to	O
S200	B-Chemical
during	O
primary	O
myogenesis	O
.	O
(	O
A	O
)	O
Western	O
blot	O
analysis	O
of	O
protein	O
extracts	O
from	O
stage	O
12	O
.	O
5	O
embryos	O
injected	O
with	O
200	O
pg	O
mRNA	O
encoding	O
HA	O
-	O
tagged	O
WT	O
or	O
S200A	B-Chemical
-	O
MyoD	O
.	O
Samples	O
were	O
incubated	O
with	O
or	O
without	O
lambda	O
protein	O
phosphatase	O
.	O
Tubulin	O
provided	O
a	O
loading	O
control	O
.	O
(	O
B	O
)	O
Schematic	O
representation	O
of	O
WT	O
mouse	O
MyoD	O
protein	O
and	O
phospho	O
-	O
mutant	O
variants	O
","	O
showing	O
approximate	O
locations	O
of	O
SP	B-Chemical
/	O
TP	B-Chemical
sites	O
that	O
are	O
mutated	O
to	O
AP	B-Chemical
in	O
each	O
.	O
(	O
C	O
â€“	O
E	O
)	O
Embryos	O
were	O
unilaterally	O
injected	O
at	O
the	O
2	O
-	O
cell	O
stage	O
with	O
100	O
pg	O
mRNA	O
encoding	O
the	O
respective	O
MyoD	O
constructs	O
.	O
At	O
stage	O
18	O
","	O
embryos	O
were	O
assayed	O
by	O
RT	O
-	O
qPCR	O
for	O
Myosin	O
Heavy	O
Chain	O
expression	O
(	O
C	O
[	O
n	O
=	O
3	O
])	O
or	O
by	O
ISH	O
with	O
semi	O
-	O
quantitative	O
scoring	O
for	O
Muscle	O
Actin	O
expression	O
(	O
D	O
[	O
n	O
=	O
52	O
â€“	O
73	O
])	O
as	O
described	O
in	O
the	O
methods	O
.	O
Representative	O
embryos	O
are	O
shown	O
in	O
(	O
E	O
);	O
injected	O
side	O
to	O
the	O
right	O
.	O
*	O
=	O
(	O
p	O
<	O
0	O
.	O
5	O
);	O
**	O
=	O
(	O
p	O
<	O
0	O
.	O
25	O
);	O
***	O
=	O
(	O
p	O
<	O
0	O
.	O
125	O
).	O
Fig	O
.	O
1	O
Mutational	O
analysis	O
shows	O
regulatory	O
activity	O
of	O
S200	B-Chemical
and	O
additional	O
C	O
terminal	O
phosphorylation	O
sites	O
.	O
Schematic	O
representation	O
of	O
phospho	O
-	O
mutant	O
constructs	O
with	O
mutation	O
of	O
cumulative	O
(	O
A	O
)	O
or	O
individual	O
(	O
D	O
)	O
sites	O
.	O
Two	O
-	O
cell	O
stage	O
embryos	O
were	O
unilaterally	O
injected	O
with	O
100	O
pg	O
mRNA	O
of	O
the	O
respective	O
MyoD	O
construct	O
and	O
assayed	O
at	O
stage	O
18	O
for	O
expression	O
of	O
Muscle	O
Actin	O
by	O
ISH	O
:	O
(	O
B	O
)	O
Cumulative	O
mutant	O
series	O
[	O
n	O
=	O
68	O
â€“	O
74	O
]	O
with	O
representative	O
images	O
shown	O
in	O
(	O
C	O
).	O
(	O
D	O
)	O
Single	O
site	O
mutants	O
[	O
n	O
=	O
52	O
â€“	O
83	O
].	O
NS	O
=	O
Not	O
significant	O
;	O
*	O
=	O
(	O
p	O
<	O
0	O
.	O
5	O
);	O
**	O
=	O
(	O
p	O
<	O
0	O
.	O
25	O
);	O
***	O
=	O
(	O
p	O
<	O
0	O
.	O
125	O
).	O
Fig	O
.	O
2	O
Maximal	O
myogenic	O
activity	O
is	O
achieved	O
by	O
mutation	O
of	O
multiple	O
C	O
terminal	O
sites	O
.	O
(	O
A	O
)	O
Schematic	O
representation	O
of	O
phospho	O
-	O
mutant	O
constructs	O
.	O
(	O
B	O
)	O
Two	O
-	O
cell	O
stage	O
embryos	O
were	O
unilaterally	O
injected	O
with	O
100	O
pg	O
mRNA	O
of	O
the	O
respective	O
MyoD	O
construct	O
and	O
assayed	O
at	O
stage	O
18	O
as	O
before	O
[	O
n	O
=	O
32	O
â€“	O
41	O
]	O
with	O
representative	O
images	O
shown	O
in	O
(	O
C	O
).	O
NS	O
=	O
Not	O
significant	O
;	O
*	O
=	O
(	O
p	O
<	O
0	O
.	O
5	O
);	O
**	O
=	O
(	O
p	O
<	O
0	O
.	O
25	O
);	O
***	O
=	O
(	O
p	O
<	O
0	O
.	O
125	O
).	O
Fig	O
.	O
3	O
CT	O
5T	O
/	O
S	O
-	O
A	O
MyoD	O
shows	O
enhanced	O
protein	O
stability	O
and	O
enhanced	O
chromatin	O
binding	O
relative	O
to	O
both	O
WT	O
and	O
S200A	B-Chemical
MyoD	O
.	O
Embryos	O
were	O
injected	O
with	O
200	O
pg	O
mRNA	O
encoding	O
HA	O
-	O
tagged	O
MyoD	O
constructs	O
as	O
indicated	O
","	O
and	O
western	O
blot	O
analysis	O
was	O
performed	O
on	O
whole	O
embryo	O
extracts	O
at	O
stage	O
12	O
.	O
5	O
(	O
A	O
)	O
or	O
cross	O
linking	O
and	O
cytoplasmic	O
/	O
chromatin	O
extracts	O
at	O
stage	O
13	O
(	O
B	O
).	O
MyoD	O
protein	O
density	O
was	O
quantified	O
relative	O
to	O
tubulin	O
loading	O
control	O
for	O
whole	O
embryo	O
extracts	O
(	O
C	O
)	O
and	O
cytoplasmic	O
fractions	O
(	O
D	O
"),"	O
or	O
relative	O
to	O
histone	O
H3	O
for	O
chromatin	O
fractions	O
(	O
D	O
).	O
Mean	O
values	O
are	O
shown	O
from	O
independent	O
duplicate	O
samples	O
with	O
standard	O
error	O
of	O
the	O
mean	O
.	O
Fig	O
.	O
4	O
Reactivation	O
of	O
occult	O
HBV	O
infection	O
in	O
an	O
HIV	O
/	O
HCV	O
Co	O
-	O
infected	O
patient	O
successfully	O
treated	O
with	O
sofosbuvir	B-Chemical
/	I-Chemical
ledipasvir	I-Chemical
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
Background	O
Reactivation	O
of	O
occult	O
or	O
inactive	O
Hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
infection	O
during	O
immunosuppressant	O
treatments	O
is	O
well	O
known	O
and	O
widely	O
described	O
in	O
literature	O
.	O
The	O
same	O
observation	O
has	O
been	O
made	O
in	O
Hepatitis	O
C	O
(	O
HCV	O
)-	O
infected	O
patients	O
previously	O
exposed	O
to	O
HBV	O
and	O
treated	O
with	O
interferon	O
-	O
free	O
DAA	O
treatments	O
.	O
Because	O
of	O
common	O
transmission	O
routes	O
","	O
persons	O
may	O
have	O
been	O
exposed	O
to	O
HCV	O
","	O
HBV	O
and	O
HIV	O
","	O
but	O
few	O
cases	O
have	O
been	O
reported	O
in	O
this	O
scenario	O
to	O
date	O
.	O
Frequency	O
of	O
HBV	O
reactivation	O
in	O
HIV	O
/	O
HCV	O
co	O
-	O
infected	O
patients	O
previously	O
exposed	O
to	O
HBV	O
and	O
treated	O
with	O
DAA	O
remains	O
unclear	O
.	O
Herein	O
","	O
we	O
report	O
an	O
episode	O
of	O
HBV	O
reactivation	O
in	O
an	O
HIV	O
/	O
HCV	O
co	O
-	O
infected	O
patient	O
prescribed	O
with	O
sofosbuvir	B-Chemical
/	I-Chemical
ledipasvir	I-Chemical
for	O
HCV	O
.	O
Case	O
presentation	O
The	O
patient	O
is	O
a	O
Caucasian	O
54	O
-	O
years	O
old	O
female	O
","	O
with	O
HIV	O
/	O
HCV	O
co	O
-	O
infection	O
(	O
genotype	O
4	O
"),"	O
and	O
a	O
previous	O
exposure	O
to	O
HBV	O
","	O
documented	O
by	O
negativity	O
of	O
HBsAg	O
and	O
positivity	O
of	O
HBsAb	O
and	O
HBcAb	O
.	O
Her	O
medical	O
history	O
included	O
:	O
myocardial	O
infarct	O
","	O
chronic	O
kidney	O
disease	O
stage	O
3	O
","	O
chronic	O
obstructive	O
pulmonary	O
disease	O
","	O
and	O
mild	O
pulmonary	O
hypertension	O
.	O
HCV	O
had	O
not	O
been	O
treated	O
with	O
interferon	O
(	O
IFN	O
)-	O
based	O
regimens	O
and	O
liver	O
stiffness	O
was	O
10	O
.	O
5	O
KPa	O
(	O
Metavir	O
stage	O
F3	O
)	O
at	O
hepatic	O
elastography	O
.	O
Because	O
of	O
CKD	O
","	O
she	O
was	O
prescribed	O
with	O
a	O
nucleoside	O
reverse	O
transcriptase	O
(	O
NRTI	O
)-	O
sparing	O
regimen	O
including	O
darunavir	B-Chemical
/	I-Chemical
ritonavir	I-Chemical
plus	O
etravirine	B-Chemical
","	O
and	O
thereafter	O
with	O
sofosbuvir	B-Chemical
/	I-Chemical
ledipasvir	I-Chemical
for	O
12	O
weeks	O
.	O
Four	O
weeks	O
after	O
DAA	O
termination	O
","	O
the	O
patient	O
was	O
hospitalized	O
with	O
symptoms	O
of	O
acute	O
hepatitis	O
.	O
Blood	O
tests	O
showed	O
HCV	O
RNA	O
<	O
12	O
IU	O
/	O
ml	O
","	O
but	O
positivity	O
of	O
HBAg	O
","	O
HBeAg	O
","	O
and	O
of	O
anti	O
-	O
core	O
antibodies	O
(	O
IgM	O
and	O
IgG	O
"),"	O
while	O
anti	O
-	O
HBs	O
and	O
anti	O
-	O
HBe	O
antibodies	O
were	O
negative	O
.	O
HBV	O
DNA	O
was	O
6	O
.	O
6	O
Log10	O
IU	O
/	O
ml	O
.	O
Entecavir	O
was	O
started	O
obtaining	O
resolution	O
of	O
symptoms	O
","	O
normalization	O
of	O
liver	O
enzymes	O
","	O
as	O
well	O
as	O
reduction	O
of	O
HBV	O
DNA	O
and	O
of	O
quantitative	O
HBV	O
surface	O
antigen	O
.	O
Conclusions	O
This	O
case	O
-	O
report	O
highlights	O
the	O
risk	O
of	O
HBV	O
reactivation	O
with	O
interferon	O
-	O
free	O
DAA	O
treatment	O
in	O
HIV	O
/	O
HCV	O
co	O
-	O
infected	O
patients	O
previously	O
exposed	O
to	O
HBV	O
and	O
who	O
have	O
contraindications	O
for	O
treatment	O
with	O
nucleoside	O
/	O
nucleotide	O
reverse	O
transcriptase	O
Inhibitors	O
because	O
of	O
comorbid	O
conditions	O
.	O
In	O
the	O
setting	O
of	O
HIV	O
infection	O
","	O
clinicians	O
prescribing	O
DAA	O
should	O
be	O
aware	O
of	O
this	O
risk	O
","	O
and	O
HBV	O
assessment	O
at	O
treatment	O
start	O
as	O
well	O
as	O
virological	O
monitoring	O
during	O
DAA	O
treatment	O
is	O
recommended	O
.	O
Large	O
epidemiological	O
and	O
virological	O
studies	O
are	O
needed	O
to	O
investigate	O
reactivation	O
of	O
occult	O
HBV	O
infection	O
more	O
in	O
depth	O
.	O
Background	O
Reactivation	O
of	O
HBV	O
infection	O
during	O
immunosuppressant	O
treatments	O
is	O
well	O
known	O
and	O
widely	O
described	O
in	O
literature	O
[	O
1	O
].	O
The	O
risk	O
concerns	O
subjects	O
with	O
occult	O
HBV	O
infection	O
(	O
HBV	O
DNA	O
detected	O
in	O
serum	O
or	O
in	O
the	O
liver	O
in	O
HBsAg	O
-	O
negative	O
patients	O
with	O
or	O
without	O
serologic	O
markers	O
of	O
previous	O
viral	O
exposure	O
)	O
or	O
inactive	O
HBV	O
chronic	O
carriers	O
(	O
HBsAg	O
-	O
positive	O
with	O
normal	O
ALT	O
and	O
HBV	O
DNA	O
<	O
3	O
.	O
30	O
log10	O
IU	O
/	O
ml	O
"),"	O
either	O
undergoing	O
transplant	O
or	O
treated	O
with	O
chemotherapy	O
or	O
immunosuppressant	O
drugs	O
for	O
hematologic	O
malignancies	O
or	O
rheumatologic	O
disorders	O
[	O
2	O
].	O
In	O
the	O
past	O
","	O
with	O
the	O
use	O
of	O
interferon	O
(	O
IFN	O
)-	O
based	O
HCV	O
therapy	O
","	O
exacerbation	O
of	O
acute	O
HBV	O
hepatitis	O
in	O
HBV	O
-	O
exposed	O
patients	O
has	O
been	O
described	O
and	O
an	O
immune	O
modulating	O
role	O
of	O
IFN	O
postulated	O
[	O
3	O
].	O
More	O
recently	O
","	O
a	O
similar	O
observation	O
has	O
been	O
made	O
with	O
the	O
use	O
of	O
interferon	O
-	O
free	O
directly	O
acting	O
antivirals	O
(	O
DAA	O
)	O
for	O
HCV	O
treatment	O
[	O
4	O
].	O
In	O
HIV	O
/	O
HCV	O
co	O
-	O
infected	O
patients	O
","	O
who	O
show	O
HCV	O
cure	O
rates	O
comparable	O
to	O
the	O
general	O
population	O
[	O
5	O
"],"	O
only	O
very	O
few	O
cases	O
of	O
HBV	O
reactivation	O
have	O
been	O
reported	O
[	O
6	O
â€“	O
10	O
].	O
Thus	O
","	O
the	O
frequency	O
of	O
HBV	O
reactivation	O
in	O
HIV	O
/	O
HCV	O
co	O
-	O
infected	O
patients	O
previously	O
exposed	O
to	O
HBV	O
and	O
treated	O
with	O
DAA	O
remains	O
unclear	O
.	O
Herein	O
","	O
we	O
report	O
an	O
episode	O
of	O
reactivation	O
of	O
occult	O
HBV	O
infection	O
in	O
an	O
HIV	O
/	O
HCV	O
co	O
-	O
infected	O
patient	O
prescribed	O
with	O
sofosbuvir	B-Chemical
/	I-Chemical
ledipasvir	I-Chemical
for	O
HCV	O
treatment	O
.	O
Further	O
","	O
a	O
short	O
review	O
of	O
similar	O
cases	O
published	O
in	O
literature	O
is	O
outlined	O
.	O
Case	O
presentation	O
Plasma	O
HIV	O
","	O
HCV	O
","	O
HBV	O
viral	O
loads	O
","	O
liver	O
function	O
and	O
CD4	O
cell	O
count	O
depicted	O
over	O
time	O
The	O
patient	O
is	O
a	O
Caucasian	O
54	O
-	O
years	O
old	O
female	O
diagnosed	O
with	O
HIV	O
in	O
1986	O
and	O
with	O
chronic	O
HCV	O
hepatitis	O
(	O
genotype	O
4	O
)	O
in	O
1992	O
.	O
For	O
many	O
years	O
","	O
she	O
was	O
lost	O
to	O
follow	O
-	O
up	O
and	O
refused	O
antiretroviral	O
therapy	O
presenting	O
only	O
once	O
in	O
2011	O
","	O
when	O
blood	O
tests	O
showed	O
HIV	O
RNA	O
4	O
.	O
93	O
log10	O
IU	O
/	O
ml	O
","	O
CD4	O
cells	O
245	O
/	O
mmc	O
.	O
Concurrently	O
","	O
previous	O
exposure	O
to	O
HBV	O
infection	O
was	O
documented	O
:	O
12	O
.	O
2	O
mIU	O
/	O
ml	O
HBsAb	O
(	O
positive	O
>	O
10	O
mIU	O
/	O
ml	O
"),"	O
positive	O
HBcAb	O
","	O
and	O
negative	O
HBsAg	O
at	O
0	O
.	O
1	O
IU	O
/	O
ml	O
(	O
positive	O
>	O
0	O
.	O
5	O
IU	O
/	O
ml	O
).	O
Afterwards	O
she	O
showed	O
up	O
again	O
in	O
June	O
2015	O
","	O
when	O
viroimmunological	O
exams	O
showed	O
:	O
HIV	O
RNA	O
5	O
.	O
28	O
log10	O
copies	O
/	O
ml	O
and	O
CD4	O
count	O
218	O
/	O
mmc	O
.	O
At	O
that	O
time	O
","	O
her	O
medical	O
history	O
included	O
:	O
myocardial	O
infarct	O
","	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
stage	O
3	O
","	O
chronic	O
obstructive	O
pulmonary	O
disease	O
","	O
and	O
mild	O
pulmonary	O
hypertension	O
.	O
HCV	O
had	O
not	O
been	O
treated	O
with	O
IFN	O
-	O
based	O
regimens	O
and	O
liver	O
stiffness	O
was	O
10	O
.	O
5	O
KPa	O
(	O
Metavir	O
stage	O
F3	O
)	O
at	O
hepatic	O
elastography	O
.	O
Because	O
of	O
CKD	O
","	O
first	O
-	O
line	O
antiretroviral	O
treatment	O
was	O
a	O
nucleoside	O
reverse	O
transcriptase	O
(	O
NRTI	O
)-	O
sparing	O
regimen	O
including	O
darunavir	B-Chemical
/	I-Chemical
ritonavir	I-Chemical
800	O
/	O
100	O
mg	O
plus	O
etravirine	B-Chemical
400	O
mg	O
QD	O
.	O
In	O
January	O
2016	O
","	O
blood	O
tests	O
showed	O
HIV	O
RNA	O
not	O
detected	O
<	O
40	O
copies	O
/	O
ml	O
with	O
CD4	O
cells	O
283	O
/	O
mmc	O
and	O
treatment	O
with	O
sofosbuvir	B-Chemical
/	I-Chemical
ledipasvir	I-Chemical
400	O
/	O
90	O
mg	O
once	O
daily	O
was	O
prescribed	O
for	O
12	O
weeks	O
.	O
In	O
May	O
2016	O
","	O
four	O
weeks	O
after	O
treatment	O
completion	O
","	O
the	O
patient	O
presented	O
with	O
jaundice	O
reporting	O
vomiting	O
","	O
nausea	O
","	O
and	O
abdominal	O
pain	O
.	O
She	O
was	O
admitted	O
to	O
hospital	O
","	O
and	O
an	O
elevation	O
of	O
liver	O
enzymes	O
(	O
ALT	O
435	O
IU	O
/	O
l	O
and	O
AST	O
410	O
IU	O
/	O
l	O
","	O
respectively	O
)	O
and	O
total	O
bilirubin	B-Chemical
at	O
7	O
.	O
1	O
mg	O
/	O
dl	O
were	O
documented	O
.	O
HCV	O
RNA	O
was	O
<	O
12	O
IU	O
/	O
ml	O
","	O
HIV	O
RNA	O
<	O
40	O
copies	O
/	O
ml	O
and	O
CD4	O
count	O
had	O
increased	O
to	O
561	O
/	O
mmc	O
.	O
With	O
regards	O
to	O
HBV	O
markers	O
","	O
HBsAg	O
(	O
3	O
.	O
71	O
log10	O
IU	O
/	O
ml	O
)	O
and	O
HBeAg	O
changed	O
into	O
positive	O
together	O
with	O
IgM	O
and	O
IgG	O
HBcAb	O
","	O
while	O
HBsAb	O
and	O
HBeAb	O
remained	O
negative	O
.	O
Furthermore	O
","	O
HBV	O
DNA	O
was	O
6	O
.	O
6	O
log10	O
IU	O
/	O
ml	O
.	O
Treatment	O
with	O
entecavir	O
0	O
.	O
5	O
mg	O
once	O
daily	O
was	O
promptly	O
started	O
obtaining	O
resolution	O
of	O
symptoms	O
.	O
One	O
month	O
later	O
","	O
blood	O
tests	O
documented	O
normalization	O
of	O
transaminases	O
and	O
reduction	O
of	O
HBV	O
DNA	O
at	O
3	O
.	O
78	O
log10	O
IU	O
/	O
l	O
","	O
of	O
HBsAg	O
1	O
.	O
91	O
log10	O
IU	O
/	O
ml	O
and	O
negativization	O
of	O
HBeAg	O
(	O
Fig	O
.	O
1	O
).	O
Treatment	O
for	O
HBV	O
infection	O
is	O
still	O
ongoing	O
without	O
adverse	O
events	O
and	O
sustained	O
virological	O
response	O
for	O
HCV	O
was	O
achieved	O
at	O
12	O
and	O
at	O
24	O
weeks	O
of	O
observation	O
.	O
Discussion	O
Characteristics	O
of	O
patients	O
with	O
HBV	O
reactivation	O
during	O
or	O
after	O
DAA	O
treatment	O
for	O
HCV	O
published	O
in	O
literature	O
HBV	O
reactivation	O
of	O
occult	O
or	O
inactive	O
HBV	O
infection	O
in	O
HCV	O
-	O
infected	O
persons	O
during	O
or	O
after	O
DAA	O
therapy	O
is	O
considered	O
a	O
rare	O
event	O
","	O
even	O
though	O
lately	O
an	O
important	O
warning	O
by	O
the	O
FDA	O
about	O
24	O
cases	O
of	O
HBV	O
reactivation	O
during	O
DAA	O
HCV	O
treatment	O
has	O
been	O
released	O
[	O
11	O
].	O
In	O
literature	O
to	O
date	O
","	O
only	O
six	O
cases	O
of	O
these	O
have	O
been	O
reported	O
and	O
characteristics	O
are	O
summarized	O
in	O
Table	O
1	O
:	O
all	O
events	O
occurred	O
in	O
subjects	O
aged	O
50	O
years	O
or	O
more	O
","	O
mostly	O
infected	O
by	O
HCV	O
genotype	O
1	O
","	O
with	O
frequent	O
previous	O
IFN	O
exposure	O
","	O
and	O
treated	O
with	O
sofobuvir	B-Chemical
-	O
or	O
daclatasvir	B-Chemical
-	O
based	O
DAA	O
regimens	O
.	O
Notably	O
","	O
only	O
one	O
case	O
referred	O
to	O
a	O
person	O
with	O
HIV	O
co	O
-	O
infection	O
.	O
Occasionally	O
HBV	O
reactivation	O
occurred	O
during	O
DAA	O
treatment	O
","	O
while	O
otherwise	O
it	O
developed	O
after	O
treatment	O
completion	O
.	O
In	O
some	O
cases	O
","	O
diagnosis	O
was	O
retrospectively	O
established	O
.	O
To	O
date	O
","	O
risk	O
of	O
HBV	O
reactivation	O
during	O
treatment	O
with	O
ledipasvir	B-Chemical
/	I-Chemical
sofosbuvir	I-Chemical
seems	O
low	O
","	O
and	O
our	O
patient	O
is	O
only	O
the	O
second	O
case	O
described	O
in	O
literature	O
[	O
7	O
].	O
Regarding	O
frequency	O
of	O
the	O
event	O
","	O
reassuring	O
data	O
are	O
available	O
from	O
a	O
recent	O
study	O
by	O
Sulkowski	O
et	O
al	O
".,"	O
which	O
retrospectively	O
reanalyzed	O
HBV	O
markers	O
in	O
serum	O
samples	O
of	O
173	O
HCV	O
-	O
infected	O
patients	O
without	O
active	O
HBV	O
or	O
HIV	O
infection	O
and	O
treated	O
with	O
a	O
combination	O
of	O
ledipasvir	B-Chemical
/	I-Chemical
sofosbuvir	I-Chemical
.	O
Notably	O
","	O
HBV	O
reactivation	O
during	O
or	O
after	O
HCV	O
clearance	O
was	O
found	O
in	O
none	O
out	O
of	O
the	O
103	O
previously	O
HBV	O
-	O
exposed	O
patients	O
[	O
12	O
].	O
Differently	O
","	O
in	O
patients	O
with	O
HCV	O
and	O
HBV	O
co	O
-	O
infection	O
","	O
transitory	O
HBV	O
DNA	O
reactivation	O
rate	O
seems	O
very	O
high	O
","	O
reaching	O
88	O
%	O
of	O
a	O
small	O
case	O
series	O
treated	O
with	O
ledipasvir	B-Chemical
/	I-Chemical
sofosbuvir	I-Chemical
[	O
13	O
].	O
Since	O
accurate	O
information	O
regarding	O
risk	O
of	O
HBV	O
reactivation	O
in	O
patients	O
undergoing	O
DAA	O
therapy	O
is	O
lacking	O
","	O
an	O
important	O
prospective	O
study	O
is	O
ongoing	O
in	O
patients	O
with	O
active	O
HBV	O
/	O
HCV	O
infection	O
[	O
13	O
"],"	O
but	O
the	O
issue	O
should	O
also	O
be	O
addressed	O
in	O
HCV	O
-	O
infected	O
patients	O
with	O
occult	O
HBV	O
infection	O
.	O
In	O
our	O
patient	O
","	O
the	O
rapid	O
clearance	O
of	O
HCV	O
RNA	O
with	O
DAA	O
treatment	O
could	O
have	O
triggered	O
HBV	O
reactivation	O
leading	O
to	O
acute	O
symptomatic	O
hepatitis	O
B	O
.	O
It	O
also	O
should	O
to	O
be	O
noted	O
that	O
","	O
the	O
low	O
levels	O
of	O
HBsAb	O
in	O
2011	O
and	O
the	O
absence	O
of	O
this	O
protective	O
marker	O
at	O
hepatitis	O
onset	O
","	O
might	O
have	O
played	O
an	O
important	O
role	O
in	O
allowing	O
HBV	O
reactivation	O
.	O
In	O
fact	O
","	O
our	O
patient	O
was	O
not	O
taking	O
any	O
ARV	O
regimen	O
for	O
15	O
years	O
after	O
HIV	O
diagnosis	O
and	O
this	O
has	O
led	O
to	O
marked	O
immunodeficiency	O
:	O
similarly	O
to	O
what	O
happens	O
in	O
patients	O
undergoing	O
allogenic	O
stem	O
cells	O
transplantation	O
","	O
we	O
can	O
assume	O
that	O
she	O
may	O
have	O
lost	O
her	O
immunity	O
against	O
HBV	O
[	O
14	O
].	O
The	O
molecular	O
mechanisms	O
involved	O
in	O
HCV	O
/	O
HBV	O
interferences	O
are	O
controversial	O
and	O
incompletely	O
understood	O
.	O
It	O
seems	O
that	O
HBV	O
can	O
be	O
chronically	O
suppressed	O
by	O
HCV	O
infection	O
with	O
alternate	O
phases	O
of	O
dominance	O
of	O
one	O
virus	O
on	O
the	O
other	O
[	O
15	O
","	O
16	O
]	O
and	O
a	O
suppressing	O
effect	O
of	O
HCV	O
core	O
proteins	O
on	O
HBV	O
replication	O
has	O
been	O
postulated	O
in	O
some	O
studies	O
[	O
17	O
","	O
18	O
].	O
Other	O
studies	O
have	O
suggested	O
that	O
","	O
host	O
genes	O
and	O
immune	O
regulation	O
","	O
such	O
as	O
kinase	O
pathways	O
or	O
microRNA	O
pathways	O
","	O
mediate	O
the	O
mechanism	O
of	O
underlying	O
HBV	O
inhibition	O
[	O
19	O
","	O
20	O
].	O
Regardless	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
HCV	O
/	O
HBV	O
co	O
-	O
infection	O
","	O
the	O
introduction	O
of	O
DAA	O
drugs	O
that	O
are	O
specifically	O
directed	O
against	O
HCV	O
without	O
inhibitory	O
effect	O
on	O
HBV	O
may	O
unbalance	O
viral	O
and	O
/	O
or	O
host	O
interactions	O
and	O
eventually	O
allow	O
HBV	O
reactivation	O
[	O
21	O
].	O
Our	O
case	O
report	O
poses	O
some	O
further	O
questions	O
","	O
because	O
the	O
patient	O
had	O
HBV	O
reactivation	O
after	O
DAA	O
treatment	O
","	O
but	O
also	O
was	O
HIV	O
-	O
positive	O
making	O
the	O
scenario	O
even	O
more	O
complex	O
.	O
On	O
one	O
side	O
","	O
HIV	O
-	O
infected	O
patients	O
may	O
experience	O
various	O
levels	O
of	O
immune	O
deficiency	O
","	O
because	O
of	O
lower	O
CD4	O
cell	O
count	O
and	O
immune	O
dysregulation	O
[	O
22	O
"],"	O
malignancies	O
or	O
rheumatologic	O
diseases	O
.	O
Also	O
immune	O
reconstitution	O
in	O
antiretroviral	O
-	O
treated	O
patients	O
may	O
play	O
a	O
role	O
in	O
the	O
same	O
direction	O
.	O
In	O
fact	O
","	O
reactivation	O
of	O
several	O
latent	O
infections	O
","	O
including	O
HBV	O
infection	O
","	O
is	O
facilitated	O
by	O
immune	O
reconstitution	O
[	O
23	O
"],"	O
and	O
our	O
patient	O
experienced	O
a	O
relevant	O
increase	O
in	O
CD4	O
cell	O
count	O
when	O
comparing	O
values	O
before	O
and	O
after	O
DAA	O
treatment	O
.	O
On	O
the	O
contrary	O
however	O
","	O
it	O
is	O
likely	O
that	O
a	O
considerable	O
proportion	O
of	O
patients	O
with	O
HIV	O
infection	O
will	O
receive	O
anti	O
-	O
HBV	O
agents	O
","	O
like	O
lamivudine	B-Chemical
","	O
emtricitabine	B-Chemical
or	O
tenofovir	B-Chemical
","	O
as	O
part	O
of	O
their	O
antiretroviral	O
therapy	O
during	O
DAA	O
therapy	O
","	O
and	O
therefore	O
will	O
be	O
protected	O
from	O
HBV	O
reactivation	O
.	O
Nonetheless	O
","	O
this	O
may	O
not	O
apply	O
to	O
a	O
considerable	O
number	O
of	O
HIV	O
-	O
positive	O
patients	O
","	O
that	O
have	O
contraindications	O
for	O
treatment	O
with	O
nucleoside	O
/	O
nucleotide	O
reverse	O
transcriptase	O
Inhibitors	O
because	O
of	O
comorbid	O
conditions	O
and	O
who	O
receive	O
dual	O
regimens	O
[	O
24	O
].	O
Conclusions	O
In	O
conclusion	O
","	O
this	O
case	O
-	O
report	O
highlights	O
the	O
risk	O
of	O
HBV	O
reactivation	O
with	O
interferon	O
-	O
free	O
DAA	O
treatment	O
in	O
HIV	O
/	O
HCV	O
co	O
-	O
infected	O
patients	O
previously	O
exposed	O
to	O
HBV	O
and	O
who	O
have	O
contraindications	O
for	O
treatment	O
with	O
nucleoside	O
/	O
nucleotide	O
reverse	O
transcriptase	O
Inhibitors	O
because	O
of	O
comorbid	O
conditions	O
.	O
In	O
the	O
setting	O
of	O
HIV	O
infection	O
","	O
clinicians	O
prescribing	O
DAA	O
should	O
be	O
aware	O
of	O
this	O
risk	O
","	O
and	O
HBV	O
assessment	O
at	O
treatment	O
start	O
as	O
well	O
as	O
virological	O
monitoring	O
during	O
DAA	O
treatment	O
is	O
recommended	O
.	O
Large	O
epidemiological	O
and	O
virological	O
studies	O
are	O
needed	O
to	O
investigate	O
reactivation	O
of	O
occult	O
HBV	O
infection	O
more	O
in	O
depth	O
.	O
Abbreviations	O
CKD	O
chronic	O
kidney	O
disease	O
DAA	O
direct	O
antiviral	O
agents	O
DAA	O
direct	O
antiviral	O
agents	O
IFN	O
interferon	O
NRTI	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
References	O
Occupancy	O
of	O
the	O
Zinc	B-Chemical
-	O
binding	O
Site	O
by	O
Transition	O
Metals	O
Decreases	O
the	O
Substrate	O
Affinity	O
of	O
the	O
Human	O
Dopamine	O
Transporter	O
by	O
an	O
Allosteric	O
Mechanism	O
*	O
The	O
human	O
dopamine	O
transporter	O
(	O
DAT	O
)	O
has	O
a	O
tetrahedral	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
.	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
sites	O
are	O
also	O
recognized	O
by	O
other	O
first	O
-	O
row	O
transition	O
metals	O
.	O
Excessive	O
accumulation	O
of	O
manganese	B-Chemical
or	O
of	O
copper	B-Chemical
can	O
lead	O
to	O
parkinsonism	O
because	O
of	O
dopamine	B-Chemical
deficiency	O
.	O
Accordingly	O
","	O
we	O
examined	O
the	O
effect	O
of	O
Mn2	B-Chemical
"+,"	I-Chemical
Co2	I-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
and	O
Cu2	B-Chemical
+	I-Chemical
on	O
transport	O
-	O
associated	O
currents	O
through	O
DAT	O
and	O
DAT	O
-	O
H193K	O
","	O
a	O
mutant	O
with	O
a	O
disrupted	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
.	O
All	O
transition	O
metals	O
except	O
Mn2	B-Chemical
+	I-Chemical
modulated	O
the	O
transport	O
cycle	O
of	O
wild	O
-	O
type	O
DAT	O
with	O
affinities	O
in	O
the	O
low	O
micromolar	O
range	O
.	O
In	O
this	O
concentration	O
range	O
","	O
they	O
were	O
devoid	O
of	O
any	O
action	O
on	O
DAT	O
-	O
H193K	O
.	O
The	O
active	O
transition	O
metals	O
reduced	O
the	O
affinity	O
of	O
DAT	O
for	O
dopamine	B-Chemical
.	O
The	O
affinity	O
shift	O
was	O
most	O
pronounced	O
for	O
Cu2	B-Chemical
"+,"	I-Chemical
followed	O
by	O
Ni2	B-Chemical
+	I-Chemical
and	O
Zn2	B-Chemical
+	I-Chemical
(=	O
Co2	B-Chemical
+).	I-Chemical
The	O
extent	O
of	O
the	O
affinity	O
shift	O
and	O
the	O
reciprocal	O
effect	O
of	O
substrate	O
on	O
metal	O
affinity	O
accounted	O
for	O
the	O
different	O
modes	O
of	O
action	O
:	O
Ni2	B-Chemical
+	I-Chemical
and	O
Cu2	B-Chemical
+	I-Chemical
uniformly	O
stimulated	O
and	O
inhibited	O
","	O
respectively	O
","	O
the	O
substrate	O
-	O
induced	O
steady	O
-	O
state	O
currents	O
through	O
DAT	O
.	O
In	O
contrast	O
","	O
Zn2	B-Chemical
+	I-Chemical
elicited	O
biphasic	O
effects	O
on	O
transport	O
","	O
i	O
.	O
e	O
.	O
stimulation	O
at	O
1	O
Î¼m	O
and	O
inhibition	O
at	O
10	O
Î¼m	O
.	O
A	O
kinetic	O
model	O
that	O
posited	O
preferential	O
binding	O
of	O
transition	O
metal	O
ions	O
to	O
the	O
outward	O
-	O
facing	O
apo	O
state	O
of	O
DAT	O
and	O
a	O
reciprocal	O
interaction	O
of	O
dopamine	B-Chemical
and	O
transition	O
metals	O
recapitulated	O
all	O
experimental	O
findings	O
.	O
Allosteric	O
activation	O
of	O
DAT	O
via	O
the	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
may	O
be	O
of	O
interest	O
to	O
restore	O
transport	O
in	O
loss	O
-	O
of	O
-	O
function	O
mutants	O
.	O
Introduction	O
The	O
physiological	O
role	O
of	O
the	O
dopamine	O
transporter	O
(	O
DAT	O
/	O
SLC6A3	O
)	O
3	O
is	O
to	O
clear	O
the	O
extracellular	O
space	O
from	O
previously	O
released	O
dopamine	B-Chemical
and	O
to	O
replenish	O
vesicular	O
stores	O
(	O
1	O
).	O
Accordingly	O
","	O
the	O
transport	O
capacity	O
of	O
DAT	O
shapes	O
the	O
synaptic	O
response	O
.	O
We	O
recently	O
showed	O
that	O
the	O
endogenous	O
ligand	O
Zn2	B-Chemical
+	I-Chemical
increases	O
the	O
turnover	O
rate	O
of	O
DAT	O
(	O
2	O
).	O
This	O
action	O
of	O
Zn2	B-Chemical
+	I-Chemical
is	O
presumably	O
of	O
physiological	O
relevance	O
:	O
Zn2	B-Chemical
+	I-Chemical
is	O
accumulated	O
in	O
synaptic	O
vesicles	O
via	O
a	O
dedicated	O
transporter	O
(	O
ZnT3	O
/	O
SLC30A3	O
)	O
and	O
released	O
as	O
a	O
co	O
-	O
transmitter	O
(	O
3	O
).	O
Numerous	O
proteins	O
require	O
Zn2	B-Chemical
+	I-Chemical
for	O
their	O
activity	O
;	O
it	O
has	O
been	O
estimated	O
that	O
about	O
10	O
%	O
of	O
the	O
proteins	O
encoded	O
by	O
the	O
human	O
genome	O
bind	O
Zn2	B-Chemical
+	I-Chemical
(	O
4	O
).	O
Similarly	O
","	O
about	O
30	O
%	O
of	O
all	O
enzymes	O
are	O
thought	O
to	O
require	O
Zn2	B-Chemical
+	I-Chemical
for	O
catalysis	O
(	O
5	O
).	O
In	O
addition	O
","	O
structural	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
sites	O
are	O
important	O
for	O
protein	O
stability	O
","	O
e	O
.	O
g	O
.	O
in	O
transcription	O
factors	O
harboring	O
the	O
eponymous	O
zinc	O
fingers	O
(	O
6	O
).	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
sites	O
rely	O
on	O
the	O
permutation	O
of	O
specific	O
arrangements	O
of	O
cysteine	B-Chemical
","	O
histidine	B-Chemical
","	O
aspartate	B-Chemical
","	O
and	O
glutamate	B-Chemical
residues	O
and	O
","	O
in	O
catalytic	O
Zn2	B-Chemical
+	I-Chemical
sites	O
","	O
of	O
water	B-Chemical
.	O
The	O
resulting	O
affinities	O
range	O
from	O
picomolar	O
to	O
micromolar	O
(	O
7	O
).	O
However	O
","	O
other	O
first	O
-	O
row	O
transition	O
metal	O
ions	O
can	O
also	O
be	O
trapped	O
by	O
these	O
binding	O
sites	O
(	O
5	O
","	O
8	O
).	O
As	O
an	O
approximation	O
","	O
the	O
stability	O
of	O
their	O
interaction	O
increases	O
across	O
the	O
period	O
to	O
a	O
maximum	O
stability	O
for	O
complexes	O
containing	O
Cu2	B-Chemical
"+,"	I-Chemical
resulting	O
in	O
the	O
Irving	O
-	O
Williams	O
series	O
:	O
Mn2	B-Chemical
+	I-Chemical
<	O
Fe2	B-Chemical
+	I-Chemical
<	O
Co2	B-Chemical
+	I-Chemical
<	O
Ni2	B-Chemical
+	I-Chemical
<	O
Cu2	B-Chemical
+	I-Chemical
>	O
Zn2	B-Chemical
+	I-Chemical
(	O
9	O
).	O
It	O
is	O
thought	O
that	O
mismetallation	O
of	O
proteins	O
is	O
prevented	O
by	O
controlling	O
the	O
concentration	O
of	O
metal	O
ions	O
in	O
the	O
compartment	O
in	O
which	O
the	O
target	O
protein	O
operates	O
(	O
4	O
","	O
7	O
).	O
Mismetallation	O
of	O
DAT	O
may	O
be	O
of	O
toxicological	O
relevance	O
.	O
It	O
has	O
long	O
been	O
known	O
that	O
occupational	O
exposure	O
to	O
manganese	B-Chemical
can	O
result	O
in	O
a	O
syndrome	O
resembling	O
idiopathic	O
Parkinson	O
'	O
s	O
disease	O
(	O
10	O
","	O
11	O
).	O
Studies	O
in	O
primates	O
indicate	O
that	O
manganese	B-Chemical
poisoning	O
impairs	O
dopamine	B-Chemical
release	O
in	O
the	O
basal	O
ganglia	O
(	O
12	O
).	O
Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
manganese	O
transporter	O
SLC39A14	O
result	O
in	O
manganese	B-Chemical
overload	O
and	O
cause	O
a	O
syndrome	O
of	O
childhood	O
dystonia	O
/	O
parkinsonism	O
(	O
13	O
).	O
This	O
is	O
reminiscent	O
of	O
inactivating	O
mutations	O
of	O
DAT	O
/	O
SLC6A3	O
(	O
14	O
).	O
Inactivating	O
mutations	O
in	O
SLC30A10	O
","	O
another	O
manganese	B-Chemical
extruder	O
","	O
also	O
gives	O
rise	O
to	O
parkinsonism	O
(	O
15	O
).	O
Similarly	O
","	O
Wilson	O
'	O
s	O
disease	O
is	O
caused	O
by	O
a	O
deficiency	O
in	O
the	O
copper	O
transporter	O
ATP7B	O
","	O
which	O
results	O
in	O
copper	B-Chemical
accumulation	O
in	O
the	O
basal	O
ganglia	O
and	O
produces	O
","	O
inter	O
alia	O
","	O
Parkinsonian	O
symptoms	O
(	O
16	O
).	O
Before	O
the	O
link	O
between	O
dopamine	B-Chemical
deficiency	O
and	O
Parkinson	O
'	O
s	O
disease	O
had	O
been	O
established	O
","	O
it	O
was	O
noted	O
that	O
dopamine	B-Chemical
excretion	O
was	O
augmented	O
in	O
patients	O
suffering	O
from	O
Wilson	O
'	O
s	O
disease	O
(	O
17	O
).	O
Accordingly	O
","	O
in	O
this	O
study	O
","	O
we	O
explored	O
the	O
effect	O
of	O
transition	O
metals	O
on	O
human	O
DAT	O
.	O
In	O
our	O
analysis	O
","	O
we	O
relied	O
on	O
electrophysiological	O
recordings	O
because	O
they	O
provided	O
the	O
time	O
resolution	O
required	O
to	O
dissect	O
the	O
actions	O
of	O
the	O
transition	O
metals	O
on	O
individual	O
steps	O
of	O
the	O
transport	O
cycle	O
.	O
We	O
observed	O
that	O
individual	O
metals	O
differ	O
in	O
their	O
ability	O
to	O
affect	O
the	O
transport	O
cycle	O
of	O
DAT	O
because	O
they	O
differed	O
in	O
the	O
extent	O
to	O
which	O
they	O
were	O
subject	O
to	O
a	O
reciprocal	O
modulation	O
by	O
substrate	O
.	O
Results	O
Effects	O
of	O
Transition	O
Metals	O
on	O
the	O
Steady	O
-	O
state	O
Current	O
through	O
DAT	O
When	O
challenged	O
with	O
substrate	O
","	O
monoamine	O
transporters	O
of	O
the	O
SLC6	O
family	O
produce	O
two	O
types	O
of	O
currents	O
that	O
can	O
be	O
recorded	O
in	O
the	O
whole	O
-	O
cell	O
patch	O
clamp	O
configuration	O
:	O
an	O
initial	O
capacitive	O
peak	O
current	O
that	O
reflects	O
the	O
binding	O
of	O
substrate	O
and	O
co	O
-	O
substrate	O
ions	O
to	O
the	O
transporter	O
and	O
their	O
movement	O
in	O
the	O
electric	O
field	O
of	O
the	O
membrane	O
(	O
18	O
","	O
19	O
)	O
and	O
a	O
sustained	O
","	O
steady	O
-	O
state	O
current	O
that	O
reflects	O
movement	O
of	O
the	O
transporter	O
through	O
the	O
transport	O
cycle	O
(	O
18	O
).	O
These	O
two	O
components	O
can	O
be	O
seen	O
when	O
dopamine	B-Chemical
is	O
applied	O
to	O
a	O
voltage	O
-	O
clamped	O
HEK293	O
cell	O
expressing	O
DAT	O
in	O
the	O
whole	O
-	O
cell	O
patch	O
clamp	O
configuration	O
(	O
cf	O
.	O
Fig	O
.	O
1	O
","	O
A	O
â€“	O
E	O
).	O
Zn2	B-Chemical
+	I-Chemical
accelerates	O
the	O
return	O
step	O
","	O
i	O
.	O
e	O
.	O
the	O
transition	O
of	O
the	O
empty	O
inward	O
-	O
facing	O
to	O
the	O
outward	O
-	O
facing	O
state	O
of	O
the	O
transporter	O
(	O
2	O
).	O
The	O
resulting	O
acceleration	O
of	O
the	O
transport	O
cycle	O
resulted	O
in	O
an	O
increase	O
in	O
the	O
steady	O
-	O
state	O
current	O
when	O
Zn2	B-Chemical
+	I-Chemical
was	O
applied	O
while	O
the	O
cell	O
was	O
continuously	O
superfused	O
with	O
dopamine	B-Chemical
(	O
Fig	O
.	O
1E	O
).	O
We	O
employed	O
Zn2	B-Chemical
+	I-Chemical
at	O
10	O
Î¼m	O
because	O
this	O
was	O
shown	O
previously	O
to	O
be	O
a	O
saturating	O
concentration	O
(	O
20	O
â€“	O
23	O
).	O
We	O
compared	O
the	O
action	O
of	O
the	O
transition	O
metals	O
Mn2	B-Chemical
"+,"	I-Chemical
Co2	I-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
and	O
Cu2	B-Chemical
+	I-Chemical
(	O
Fig	O
.	O
1	O
","	O
A	O
â€“	O
D	O
)	O
with	O
that	O
of	O
Zn2	B-Chemical
+	I-Chemical
(	O
Fig	O
.	O
1E	O
).	O
We	O
found	O
Mn2	B-Chemical
+	I-Chemical
to	O
be	O
ineffective	O
at	O
concentrations	O
between	O
1	O
and	O
100	O
Î¼m	O
.	O
In	O
Fig	O
.	O
1	O
","	O
A	O
and	O
F	O
","	O
we	O
show	O
the	O
absence	O
of	O
any	O
effect	O
at	O
30	O
and	O
100	O
Î¼m	O
.	O
Effects	O
of	O
first	O
-	O
row	O
transition	O
metals	O
on	O
the	O
steady	O
-	O
state	O
current	O
amplitude	O
(	O
Isteady	O
-	O
state	O
)	O
carried	O
by	O
hDAT	O
.	O
HEK293	O
cells	O
stably	O
expressing	O
hDAT	O
were	O
voltage	O
-	O
clamped	O
to	O
âˆ’	O
60	O
mV	O
.	O
The	O
cells	O
were	O
challenged	O
with	O
30	O
Î¼m	O
dopamine	B-Chemical
(	O
DA	B-Chemical
).	O
After	O
2	O
s	O
","	O
the	O
transition	O
metal	O
was	O
co	O
-	O
applied	O
for	O
3	O
s	O
as	O
indicated	O
.	O
A	O
","	O
co	O
-	O
application	O
of	O
30	O
Î¼m	O
Mn2	B-Chemical
+	I-Chemical
was	O
ineffective	O
.	O
B	O
","	O
C	O
","	O
and	O
E	O
","	O
co	O
-	O
application	O
of	O
10	O
Î¼m	O
Co2	B-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
or	O
Zn2	B-Chemical
+	I-Chemical
stimulated	O
the	O
current	O
.	O
D	O
","	O
10	O
Î¼m	O
Cu2	B-Chemical
+	I-Chemical
led	O
to	O
inhibition	O
.	O
In	O
all	O
instances	O
","	O
the	O
steady	O
-	O
state	O
current	O
recovered	O
to	O
its	O
initial	O
amplitude	O
upon	O
metal	O
removal	O
.	O
F	O
","	O
the	O
steady	O
-	O
state	O
current	O
upon	O
co	O
-	O
application	O
of	O
the	O
indicated	O
transition	O
metals	O
was	O
related	O
to	O
that	O
seen	O
prior	O
to	O
metal	O
application	O
(-	O
fold	O
change	O
=	O
Isteady	O
-	O
state	O
after	O
application	O
/	O
Isteady	O
-	O
state	O
before	O
application	O
)	O
to	O
normalize	O
for	O
differences	O
in	O
current	O
sizes	O
in	O
individual	O
cells	O
.	O
Data	O
represent	O
mean	O
Â±	O
S	O
.	O
D	O
.	O
The	O
respective	O
-	O
fold	O
changes	O
were	O
tested	O
against	O
the	O
hypothetical	O
value	O
1	O
(=	O
no	O
change	O
","	O
indicated	O
as	O
a	O
dotted	O
line	O
in	O
the	O
bar	O
graph	O
)	O
using	O
Wilcoxon	O
matched	O
pairs	O
signed	O
-	O
rank	O
test	O
.	O
In	O
contrast	O
","	O
application	O
of	O
10	O
Î¼m	O
Co2	B-Chemical
+	I-Chemical
(	O
Fig	O
.	O
1B	O
)	O
led	O
to	O
a	O
small	O
but	O
significant	O
increase	O
in	O
the	O
steady	O
-	O
state	O
current	O
amplitude	O
by	O
about	O
10	O
%.	O
The	O
current	O
did	O
not	O
increase	O
further	O
in	O
the	O
presence	O
of	O
30	O
Î¼m	O
Co2	B-Chemical
+	I-Chemical
(	O
Fig	O
.	O
1F	O
).	O
This	O
weak	O
stimulatory	O
effect	O
of	O
Co2	B-Chemical
+	I-Chemical
precluded	O
further	O
analysis	O
.	O
Application	O
of	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
resulted	O
in	O
a	O
robust	O
increase	O
in	O
the	O
steady	O
-	O
state	O
current	O
","	O
which	O
relaxed	O
to	O
its	O
initial	O
amplitude	O
upon	O
removal	O
of	O
Ni2	B-Chemical
+	I-Chemical
(	O
Fig	O
.	O
1C	O
).	O
We	O
also	O
tested	O
3	O
and	O
30	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
(	O
summarized	O
in	O
Fig	O
.	O
1F	O
).	O
The	O
effect	O
elicited	O
by	O
30	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
was	O
essentially	O
comparable	O
with	O
that	O
caused	O
by	O
10	O
Î¼m	O
Ni2	B-Chemical
"+,"	I-Chemical
indicating	O
that	O
","	O
at	O
saturating	O
levels	O
of	O
Ni2	B-Chemical
"+,"	I-Chemical
the	O
steady	O
-	O
state	O
currents	O
were	O
about	O
1	O
.	O
3	O
-	O
fold	O
larger	O
than	O
in	O
the	O
absence	O
of	O
any	O
metal	O
.	O
Contrary	O
to	O
Co2	B-Chemical
+	I-Chemical
and	O
Ni2	B-Chemical
"+,"	I-Chemical
Cu2	I-Chemical
+	I-Chemical
reversibly	O
inhibited	O
the	O
steady	O
-	O
state	O
current	O
through	O
DAT	O
(	O
Fig	O
.	O
1D	O
)	O
with	O
an	O
IC50	O
of	O
4	O
.	O
4	O
Î¼m	O
(	O
2	O
.	O
3	O
â€“	O
8	O
.	O
2	O
Î¼m	O
","	O
95	O
%	O
confidence	O
interval	O
).	O
These	O
observations	O
suggest	O
that	O
all	O
tested	O
transition	O
metals	O
except	O
Mn2	B-Chemical
+	I-Chemical
either	O
stimulate	O
or	O
inhibit	O
the	O
transport	O
cycle	O
of	O
DAT	O
.	O
Two	O
explanations	O
can	O
account	O
for	O
the	O
inability	O
of	O
Mn2	B-Chemical
+	I-Chemical
to	O
modulate	O
the	O
activity	O
of	O
DAT	O
:	O
Mn2	B-Chemical
+	I-Chemical
binds	O
but	O
neither	O
stimulates	O
nor	O
inhibits	O
the	O
transport	O
cycle	O
","	O
or	O
the	O
affinity	O
of	O
Mn2	B-Chemical
+	I-Chemical
for	O
the	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
of	O
DAT	O
is	O
too	O
low	O
.	O
We	O
distinguished	O
between	O
these	O
two	O
possibilities	O
by	O
first	O
concomitantly	O
applying	O
30	O
Î¼m	O
dopamine	B-Chemical
and	O
100	O
Î¼m	O
Mn2	B-Chemical
+	I-Chemical
to	O
elicit	O
the	O
steady	O
-	O
state	O
current	O
through	O
DAT	O
.	O
If	O
Mn2	B-Chemical
+	I-Chemical
had	O
occupied	O
the	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
of	O
DAT	O
","	O
then	O
it	O
should	O
preclude	O
the	O
increase	O
in	O
steady	O
-	O
state	O
current	O
resulting	O
from	O
the	O
subsequent	O
application	O
of	O
Zn2	B-Chemical
+.	I-Chemical
This	O
","	O
however	O
","	O
was	O
not	O
the	O
case	O
.	O
As	O
can	O
be	O
seen	O
in	O
Fig	O
.	O
2A	O
","	O
wash	O
-	O
in	O
of	O
Zn2	B-Chemical
+	I-Chemical
induced	O
a	O
robust	O
stimulation	O
of	O
the	O
current	O
that	O
was	O
similar	O
to	O
that	O
seen	O
in	O
the	O
absence	O
of	O
Mn2	B-Chemical
+	I-Chemical
(	O
cf	O
.	O
Fig	O
.	O
2F	O
","	O
first	O
and	O
fifth	O
columns	O
).	O
Interaction	O
of	O
Co2	B-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
and	O
Cu2	B-Chemical
+	I-Chemical
but	O
not	O
Mn2	B-Chemical
+	I-Chemical
with	O
the	O
endogenous	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
of	O
DAT	O
.	O
A	O
â€“	O
E	O
","	O
HEK293	O
cells	O
stably	O
expressing	O
hDAT	O
(	O
A	O
)	O
or	O
transiently	O
transfected	O
with	O
the	O
mutant	O
hDAT	O
-	O
H193K	O
(	O
B	O
â€“	O
E	O
)	O
were	O
clamped	O
to	O
âˆ’	O
60	O
mV	O
.	O
Currents	O
were	O
evoked	O
by	O
30	O
Î¼m	O
dopamine	B-Chemical
.	O
A	O
","	O
representative	O
trace	O
of	O
a	O
current	O
recorded	O
in	O
the	O
continuous	O
presence	O
of	O
100	O
Î¼m	O
Mn2	B-Chemical
+.	I-Chemical
Co	O
-	O
application	O
of	O
10	O
Î¼m	O
Zn2	B-Chemical
+	I-Chemical
increased	O
the	O
current	O
amplitude	O
.	O
B	O
â€“	O
E	O
","	O
representative	O
traces	O
of	O
currents	O
carried	O
by	O
DAT	O
-	O
H193K	O
.	O
Co	O
-	O
application	O
of	O
10	O
Î¼m	O
Co2	B-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
Cu2	I-Chemical
"+,"	I-Chemical
or	O
Zn2	B-Chemical
+	I-Chemical
did	O
not	O
affect	O
the	O
current	O
.	O
F	O
","	O
summary	O
of	O
A	O
â€“	O
E	O
.	O
The	O
steady	O
-	O
state	O
current	O
upon	O
co	O
-	O
application	O
of	O
the	O
indicated	O
transition	O
metals	O
was	O
related	O
to	O
that	O
seen	O
prior	O
to	O
metal	O
application	O
(-	O
fold	O
change	O
);	O
Zn2	B-Chemical
+	I-Chemical
increased	O
the	O
current	O
carried	O
by	O
hDAT	O
in	O
the	O
continuous	O
presence	O
of	O
100	O
Î¼m	O
Mn2	B-Chemical
+.	I-Chemical
Currents	O
by	O
hDAT	O
-	O
H193K	O
were	O
unchanged	O
upon	O
co	O
-	O
application	O
of	O
10	O
Î¼m	O
Co2	B-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
Cu2	I-Chemical
"+,"	I-Chemical
or	O
Zn2	B-Chemical
"+,"	I-Chemical
respectively	O
.	O
Data	O
represent	O
mean	O
Â±	O
S	O
.	O
D	O
.	O
The	O
respective	O
-	O
fold	O
changes	O
were	O
tested	O
against	O
the	O
hypothetical	O
value	O
1	O
(=	O
no	O
change	O
","	O
indicated	O
as	O
a	O
dotted	O
line	O
in	O
the	O
bar	O
graph	O
)	O
using	O
Wilcoxon	O
matched	O
pairs	O
signed	O
-	O
rank	O
test	O
.	O
We	O
also	O
verified	O
that	O
both	O
the	O
stimulatory	O
action	O
of	O
Co2	B-Chemical
+	I-Chemical
and	O
Ni2	B-Chemical
+	I-Chemical
and	O
the	O
inhibitory	O
action	O
of	O
Cu2	B-Chemical
+	I-Chemical
required	O
the	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
of	O
DAT	O
by	O
examining	O
their	O
action	O
on	O
steady	O
-	O
state	O
currents	O
through	O
DAT	O
-	O
H193K	O
.	O
In	O
this	O
mutant	O
","	O
the	O
Zn2	B-Chemical
+-	I-Chemical
coordinating	O
histidine	B-Chemical
is	O
replaced	O
by	O
lysine	B-Chemical
","	O
the	O
residue	O
found	O
at	O
the	O
equivalent	O
position	O
of	O
the	O
norepinephrine	O
transporter	O
.	O
The	O
norepinephrine	O
transporter	O
is	O
the	O
closest	O
relative	O
of	O
DAT	O
but	O
is	O
insensitive	O
to	O
Zn2	B-Chemical
+.	I-Chemical
Accordingly	O
","	O
the	O
mutation	O
of	O
His193	B-Chemical
to	O
Lys	B-Chemical
eliminates	O
high	O
-	O
affinity	O
Zn2	B-Chemical
+	I-Chemical
binding	O
to	O
DAT	O
(	O
20	O
","	O
21	O
).	O
It	O
is	O
evident	O
from	O
the	O
current	O
traces	O
shown	O
in	O
Fig	O
.	O
2	O
","	O
B	O
â€“	O
E	O
","	O
and	O
the	O
summary	O
shown	O
in	O
Fig	O
.	O
1F	O
that	O
both	O
the	O
stimulation	O
of	O
the	O
steady	O
-	O
state	O
current	O
by	O
Co2	B-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
and	O
Zn2	B-Chemical
+	I-Chemical
and	O
its	O
inhibition	O
by	O
Cu2	B-Chemical
+	I-Chemical
were	O
abrogated	O
in	O
DAT	O
-	O
H193K	O
.	O
This	O
comparison	O
is	O
based	O
on	O
recordings	O
done	O
in	O
a	O
stable	O
cell	O
line	O
and	O
transiently	O
transfected	O
cells	O
for	O
wild	O
-	O
type	O
DAT	O
(	O
Fig	O
.	O
1	O
)	O
and	O
the	O
DAT	O
-	O
H193K	O
mutant	O
(	O
Fig	O
.	O
2	O
"),"	O
respectively	O
.	O
We	O
also	O
recorded	O
currents	O
through	O
wild	O
-	O
type	O
DAT	O
in	O
transiently	O
transfected	O
HEK293	O
cells	O
.	O
These	O
experiments	O
recapitulated	O
the	O
data	O
shown	O
in	O
Fig	O
.	O
1	O
","	O
i	O
.	O
e	O
.	O
stimulation	O
of	O
substrate	O
-	O
induced	O
currents	O
by	O
Co2	B-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
and	O
Zn2	B-Chemical
"+,"	I-Chemical
their	O
inhibition	O
by	O
Cu2	B-Chemical
"+,"	I-Chemical
and	O
the	O
absence	O
of	O
any	O
effect	O
in	O
the	O
presence	O
of	O
Mn2	B-Chemical
+	I-Chemical
(	O
data	O
not	O
shown	O
).	O
Hence	O
","	O
we	O
rule	O
out	O
that	O
differences	O
between	O
transiently	O
and	O
stably	O
transfected	O
cells	O
can	O
account	O
for	O
the	O
distinct	O
effects	O
of	O
transition	O
metals	O
on	O
wild	O
-	O
type	O
and	O
DAT	O
-	O
H913K	O
.	O
Transition	O
Metal	O
-	O
induced	O
Shifts	O
of	O
EC50	O
for	O
Substrate	O
-	O
induced	O
Steady	O
-	O
state	O
Currents	O
through	O
hDAT	O
The	O
substrate	O
-	O
induced	O
steady	O
-	O
state	O
current	O
reflects	O
cycling	O
of	O
DAT	O
through	O
the	O
forward	O
transport	O
mode	O
(	O
18	O
).	O
Dopamine	B-Chemical
increased	O
the	O
steady	O
-	O
state	O
current	O
through	O
DAT	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Fig	O
.	O
3A	O
).	O
This	O
concentration	O
-	O
response	O
curve	O
was	O
shifted	O
by	O
all	O
transition	O
metals	O
;	O
representative	O
original	O
traces	O
are	O
shown	O
in	O
Fig	O
.	O
3	O
","	O
B	O
â€“	O
E	O
","	O
for	O
dopamine	B-Chemical
-	O
induced	O
steady	O
-	O
state	O
currents	O
in	O
the	O
presence	O
of	O
10	O
Î¼m	O
Zn2	B-Chemical
"+,"	I-Chemical
Co2	I-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
and	O
Cu2	B-Chemical
"+,"	I-Chemical
respectively	O
.	O
The	O
pertinent	O
analysis	O
for	O
all	O
transition	O
metals	O
is	O
summarized	O
in	O
Fig	O
.	O
3E	O
;	O
the	O
concentration	O
-	O
response	O
curve	O
was	O
adequately	O
described	O
by	O
a	O
saturation	O
hyperbola	O
.	O
More	O
importantly	O
","	O
all	O
transition	O
metals	O
reduced	O
the	O
apparent	O
affinity	O
of	O
dopamine	B-Chemical
","	O
but	O
the	O
magnitude	O
of	O
the	O
shift	O
differed	O
.	O
In	O
the	O
absence	O
of	O
any	O
metal	O
","	O
the	O
EC50	O
for	O
the	O
currents	O
induced	O
by	O
dopamine	B-Chemical
was	O
0	O
.	O
8	O
Î¼m	O
(	O
0	O
.	O
6	O
â€“	O
1	O
Î¼m	O
","	O
95	O
%	O
confidence	O
interval	O
)	O
and	O
increased	O
to	O
EC50	O
Zn2	B-Chemical
+	I-Chemical
=	O
1	O
.	O
6	O
Î¼m	O
(	O
1	O
.	O
2	O
â€“	O
2	O
.	O
2	O
Î¼m	O
"),"	O
EC50	O
Co2	B-Chemical
+	I-Chemical
=	O
2	O
.	O
4	O
Î¼m	O
(	O
2	O
.	O
1	O
â€“	O
2	O
.	O
8	O
Î¼m	O
"),"	O
EC50	O
Ni2	B-Chemical
+	I-Chemical
=	O
4	O
.	O
3	O
Î¼m	O
(	O
3	O
.	O
5	O
â€“	O
4	O
.	O
7	O
Î¼m	O
"),"	O
and	O
EC50	O
Cu2	B-Chemical
+	I-Chemical
=	O
36	O
.	O
5	O
Î¼m	O
(	O
17	O
.	O
1	O
â€“	O
72	O
.	O
2	O
Î¼m	O
)	O
in	O
the	O
presence	O
of	O
Zn2	B-Chemical
"+,"	I-Chemical
Co2	I-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
and	O
Cu2	B-Chemical
"+,"	I-Chemical
respectively	O
.	O
Rightward	O
shift	O
by	O
Zn2	B-Chemical
"+,"	I-Chemical
Co2	I-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
and	O
Cu2	B-Chemical
+	I-Chemical
in	O
the	O
EC50	O
of	O
dopamine	B-Chemical
in	O
eliciting	O
the	O
steady	O
-	O
state	O
current	O
through	O
DAT	O
.	O
HEK293	O
cells	O
stably	O
expressing	O
hDAT	O
were	O
clamped	O
to	O
âˆ’	O
60	O
mV	O
.	O
Currents	O
through	O
DAT	O
were	O
evoked	O
by	O
5	O
-	O
s	O
applications	O
of	O
increasing	O
dopamine	B-Chemical
concentrations	O
(	O
0	O
.	O
3	O
â€“	O
100	O
Î¼m	O
)	O
in	O
the	O
absence	O
and	O
presence	O
of	O
10	O
Î¼m	O
Zn2	B-Chemical
"+,"	I-Chemical
Co2	I-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
and	O
Cu2	B-Chemical
+.	I-Chemical
A	O
â€“	O
E	O
","	O
representative	O
traces	O
of	O
currents	O
through	O
hDAT	O
evoked	O
by	O
increasing	O
dopamine	B-Chemical
concentrations	O
in	O
the	O
absence	O
(	O
A	O
)	O
or	O
presence	O
of	O
10	O
Î¼m	O
Zn2	B-Chemical
"+,"	I-Chemical
Co2	I-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
and	O
Cu2	B-Chemical
"+,"	I-Chemical
respectively	O
(	O
B	O
â€“	O
E	O
).	O
F	O
","	O
the	O
concentration	O
-	O
response	O
curve	O
of	O
the	O
steady	O
-	O
state	O
current	O
was	O
shifted	O
to	O
higher	O
dopamine	B-Chemical
concentrations	O
in	O
the	O
presence	O
of	O
the	O
metals	O
.	O
The	O
amplitudes	O
of	O
the	O
steady	O
-	O
state	O
current	O
were	O
normalized	O
to	O
the	O
current	O
at	O
saturation	O
.	O
The	O
EC50	O
values	O
were	O
estimated	O
by	O
a	O
fit	O
to	O
a	O
binding	O
hyperbola	O
.	O
EC50	O
control	O
=	O
0	O
.	O
8	O
Î¼m	O
(	O
0	O
.	O
6	O
â€“	O
1	O
","	O
n	O
=	O
9	O
"),"	O
EC50	O
Zn2	B-Chemical
+	I-Chemical
=	O
1	O
.	O
6	O
Î¼m	O
(	O
1	O
.	O
2	O
â€“	O
2	O
.	O
2	O
","	O
n	O
=	O
8	O
"),"	O
EC50	O
Co2	B-Chemical
+	I-Chemical
=	O
2	O
.	O
4	O
Î¼m	O
(	O
2	O
.	O
1	O
â€“	O
2	O
.	O
8	O
","	O
n	O
=	O
8	O
"),"	O
EC50	O
Ni2	B-Chemical
+	I-Chemical
=	O
4	O
.	O
3	O
Î¼m	O
(	O
3	O
.	O
5	O
â€“	O
4	O
.	O
7	O
","	O
n	O
=	O
6	O
"),"	O
and	O
EC50	O
Cu2	B-Chemical
+	I-Chemical
=	O
36	O
.	O
5	O
Î¼m	O
(	O
17	O
.	O
1	O
â€“	O
72	O
.	O
2	O
","	O
n	O
=	O
6	O
).	O
Data	O
represent	O
mean	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
in	O
parentheses	O
).	O
Sole	O
Activation	O
of	O
DAT	O
by	O
Ni2	B-Chemical
+	I-Chemical
Taken	O
together	O
","	O
the	O
data	O
summarized	O
in	O
Figs	O
.	O
1	O
â€“	O
3	O
indicate	O
that	O
transition	O
metals	O
induced	O
distinct	O
effects	O
on	O
the	O
transport	O
cycle	O
of	O
DAT	O
despite	O
their	O
binding	O
to	O
the	O
same	O
site	O
:	O
Cu2	B-Chemical
+	I-Chemical
was	O
uniformly	O
inhibitory	O
.	O
The	O
action	O
of	O
Zn2	B-Chemical
+	I-Chemical
depends	O
on	O
the	O
substrate	O
concentration	O
and	O
the	O
internal	O
Na	B-Chemical
+	I-Chemical
concentration	O
(	O
see	O
below	O
and	O
Refs	O
.	O
2	O
","	O
22	O
â€“	O
24	O
).	O
Accordingly	O
","	O
we	O
selected	O
Ni2	B-Chemical
+	I-Chemical
as	O
an	O
additional	O
representative	O
of	O
the	O
transition	O
metals	O
to	O
understand	O
their	O
action	O
on	O
DAT	O
because	O
","	O
contrary	O
to	O
Co2	B-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
+	I-Chemical
elicited	O
a	O
robust	O
enhancement	O
of	O
the	O
steady	O
-	O
state	O
current	O
.	O
We	O
recently	O
demonstrated	O
that	O
current	O
stimulation	O
by	O
Zn2	B-Chemical
+	I-Chemical
is	O
caused	O
by	O
an	O
enhancement	O
of	O
the	O
turnover	O
rate	O
of	O
DAT	O
(	O
2	O
).	O
We	O
verified	O
that	O
this	O
was	O
also	O
TRUE	O
for	O
Ni2	B-Chemical
+	I-Chemical
by	O
examining	O
the	O
turnover	O
rate	O
;	O
the	O
pertinent	O
protocol	O
and	O
representative	O
current	O
traces	O
are	O
shown	O
in	O
Fig	O
.	O
4	O
.	O
The	O
approach	O
relies	O
on	O
the	O
paired	O
application	O
of	O
substrate	O
(	O
i	O
.	O
e	O
.	O
dopamine	B-Chemical
)	O
pulses	O
.	O
The	O
first	O
application	O
elicits	O
a	O
robust	O
peak	O
current	O
that	O
corresponds	O
to	O
the	O
conformational	O
transition	O
associated	O
with	O
substrate	O
binding	O
and	O
drives	O
DAT	O
into	O
the	O
transport	O
cycle	O
","	O
which	O
gives	O
rise	O
to	O
the	O
sustained	O
steady	O
-	O
state	O
current	O
.	O
This	O
steady	O
-	O
state	O
current	O
decays	O
when	O
substrate	O
is	O
withheld	O
.	O
During	O
this	O
decay	O
","	O
only	O
a	O
fraction	O
of	O
the	O
transporters	O
are	O
available	O
for	O
binding	O
of	O
dopamine	B-Chemical
because	O
they	O
have	O
not	O
yet	O
reached	O
the	O
outward	O
-	O
facing	O
conformation	O
.	O
Full	O
recovery	O
of	O
the	O
peak	O
current	O
is	O
achieved	O
only	O
after	O
all	O
transporters	O
have	O
completed	O
the	O
transport	O
cycle	O
.	O
Hence	O
","	O
the	O
rate	O
of	O
peak	O
current	O
recovery	O
is	O
a	O
measure	O
of	O
the	O
turnover	O
rate	O
.	O
The	O
time	O
-	O
dependent	O
recovery	O
of	O
the	O
peak	O
current	O
is	O
evident	O
from	O
the	O
original	O
traces	O
shown	O
in	O
Fig	O
.	O
4A	O
.	O
The	O
shorter	O
the	O
interval	O
between	O
the	O
first	O
and	O
the	O
second	O
substrate	O
pulse	O
","	O
the	O
smaller	O
a	O
peak	O
current	O
was	O
elicited	O
by	O
the	O
second	O
dopamine	B-Chemical
pulse	O
.	O
Full	O
recovery	O
was	O
accomplished	O
within	O
2	O
s	O
with	O
a	O
time	O
course	O
that	O
was	O
adequately	O
described	O
by	O
a	O
monoexponential	O
rise	O
(	O
Fig	O
.	O
4B	O
","	O
open	O
symbols	O
.	O
In	O
the	O
presence	O
of	O
Ni2	B-Chemical
"+,"	I-Chemical
the	O
peak	O
current	O
recovered	O
at	O
a	O
faster	O
rate	O
(	O
Fig	O
.	O
4B	O
","	O
closed	O
symbols	O
).	O
Thus	O
","	O
similar	O
to	O
Zn2	B-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
+	I-Chemical
significantly	O
accelerated	O
the	O
transport	O
cycle	O
of	O
hDAT	O
(	O
p	O
<	O
0	O
.	O
1	O
","	O
F	O
test	O
).	O
Ni2	B-Chemical
+-	I-Chemical
induced	O
increase	O
in	O
the	O
turnover	O
rate	O
of	O
DAT	O
.	O
HEK293	O
cells	O
stably	O
expressing	O
hDAT	O
were	O
voltage	O
-	O
clamped	O
to	O
âˆ’	O
60	O
mV	O
.	O
A	O
","	O
protocol	O
to	O
measure	O
the	O
turnover	O
rate	O
of	O
DAT	O
.	O
30	O
Î¼m	O
dopamine	B-Chemical
was	O
applied	O
to	O
the	O
cell	O
for	O
0	O
.	O
5	O
s	O
.	O
This	O
was	O
followed	O
by	O
a	O
second	O
pulse	O
(	O
30	O
Î¼m	O
dopamine	B-Chemical
for	O
0	O
.	O
5	O
s	O
)	O
applied	O
after	O
different	O
wash	O
intervals	O
(	O
0	O
.	O
1	O
","	O
0	O
.	O
2	O
","	O
0	O
.	O
5	O
","	O
0	O
.	O
8	O
","	O
1	O
","	O
1	O
.	O
5	O
","	O
and	O
2	O
s	O
).	O
The	O
peak	O
current	O
recovered	O
over	O
time	O
and	O
reached	O
its	O
full	O
amplitude	O
after	O
prolonged	O
dopamine	B-Chemical
-	O
free	O
intervals	O
.	O
B	O
","	O
the	O
peak	O
current	O
recovers	O
faster	O
in	O
the	O
presence	O
of	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
(	O
green	O
circle	O
)	O
in	O
comparison	O
with	O
the	O
control	O
.	O
The	O
peak	O
currents	O
were	O
normalized	O
to	O
the	O
respective	O
largest	O
peak	O
current	O
from	O
the	O
same	O
cell	O
.	O
The	O
time	O
course	O
of	O
the	O
peak	O
current	O
recovery	O
was	O
fit	O
to	O
a	O
monoexponential	O
function	O
(	O
black	O
lines	O
","	O
R2	O
=	O
0	O
.	O
96	O
and	O
0	O
.	O
96	O
).	O
The	O
time	O
constants	O
estimated	O
by	O
the	O
fits	O
were	O
as	O
follows	O
:	O
control	O
","	O
0	O
.	O
55	O
s	O
(	O
0	O
.	O
51	O
â€“	O
0	O
.	O
60	O
","	O
n	O
=	O
6	O
);	O
Ni2	B-Chemical
"+,"	I-Chemical
0	O
.	O
38	O
s	O
(	O
0	O
.	O
35	O
â€“	O
0	O
.	O
42	O
","	O
n	O
=	O
6	O
).	O
Data	O
represent	O
mean	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
in	O
parentheses	O
).	O
This	O
analysis	O
of	O
currents	O
through	O
DAT	O
is	O
consistent	O
with	O
the	O
interpretation	O
that	O
Ni2	B-Chemical
+	I-Chemical
acts	O
as	O
a	O
stimulator	O
of	O
substrate	O
uptake	O
.	O
We	O
verified	O
this	O
conjecture	O
by	O
comparing	O
cellular	O
uptake	O
of	O
dopamine	B-Chemical
by	O
hDAT	O
in	O
the	O
absence	O
and	O
presence	O
of	O
1	O
and	O
10	O
Î¼m	O
Zn2	B-Chemical
+	I-Chemical
(	O
Fig	O
.	O
5A	O
)	O
and	O
Ni2	B-Chemical
+	I-Chemical
(	O
Fig	O
.	O
5C	O
).	O
Uptake	O
of	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
dopamine	I-Chemical
uptake	O
was	O
stimulated	O
at	O
both	O
Ni2	B-Chemical
+	I-Chemical
concentrations	O
.	O
In	O
contrast	O
","	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
dopamine	I-Chemical
uptake	O
was	O
stimulated	O
by	O
1	O
Î¼m	O
Zn2	B-Chemical
+	I-Chemical
but	O
inhibited	O
by	O
10	O
Î¼m	O
Zn2	B-Chemical
+.	I-Chemical
This	O
biphasic	O
action	O
of	O
Zn2	B-Chemical
+	I-Chemical
on	O
substrate	O
uptake	O
in	O
HEK293	O
cells	O
has	O
not	O
been	O
reported	O
previously	O
(	O
20	O
","	O
21	O
).	O
However	O
","	O
in	O
earlier	O
studies	O
","	O
the	O
action	O
of	O
Zn2	B-Chemical
+	I-Chemical
on	O
substrate	O
uptake	O
by	O
hDAT	O
was	O
explored	O
at	O
substrate	O
concentrations	O
below	O
the	O
Km	O
of	O
the	O
transporter	O
.	O
Thus	O
","	O
we	O
surmise	O
that	O
the	O
stimulation	O
at	O
low	O
Zn2	B-Chemical
+	I-Chemical
concentrations	O
escaped	O
detection	O
in	O
studies	O
(	O
20	O
","	O
21	O
)	O
that	O
examined	O
the	O
action	O
of	O
Zn2	B-Chemical
+	I-Chemical
at	O
non	O
-	O
saturating	O
substrate	O
concentrations	O
.	O
We	O
explored	O
the	O
biphasic	O
effect	O
of	O
Zn2	B-Chemical
+	I-Chemical
in	O
the	O
presence	O
of	O
saturating	O
substrate	O
concentrations	O
(	O
30	O
Î¼m	O
dopamine	B-Chemical
)	O
in	O
the	O
absence	O
and	O
presence	O
of	O
0	O
.	O
1	O
","	O
1	O
","	O
3	O
","	O
10	O
","	O
and	O
30	O
Î¼m	O
Zn2	B-Chemical
+	I-Chemical
(	O
Fig	O
.	O
5B	O
).	O
Under	O
these	O
conditions	O
","	O
the	O
stimulation	O
of	O
maximal	O
transport	O
velocity	O
peaks	O
at	O
about	O
1	O
Î¼m	O
Zn2	B-Chemical
+.	I-Chemical
We	O
also	O
explored	O
the	O
effect	O
of	O
Ni2	B-Chemical
+	I-Chemical
at	O
saturating	O
substrate	O
concentrations	O
(	O
30	O
Î¼m	O
dopamine	B-Chemical
)	O
in	O
the	O
absence	O
and	O
presence	O
of	O
1	O
","	O
10	O
","	O
and	O
30	O
Î¼m	O
Ni2	B-Chemical
+.	I-Chemical
We	O
found	O
substrate	O
uptake	O
stimulated	O
for	O
Ni2	B-Chemical
+	I-Chemical
concentrations	O
up	O
to	O
30	O
Î¼m	O
(	O
Fig	O
.	O
5D	O
).	O
At	O
concentrations	O
exceeding	O
30	O
Î¼m	O
","	O
Ni2	B-Chemical
+	I-Chemical
causes	O
a	O
nonspecific	O
inhibition	O
of	O
transport	O
","	O
i	O
.	O
e	O
.	O
this	O
inhibition	O
is	O
also	O
seen	O
in	O
DAT	O
-	O
H193K	O
(	O
data	O
not	O
shown	O
).	O
Accordingly	O
","	O
it	O
was	O
not	O
possible	O
to	O
examine	O
how	O
higher	O
concentrations	O
of	O
Ni2	B-Chemical
+	I-Chemical
affected	O
substrate	O
transport	O
via	O
the	O
transition	O
metal	O
ion	O
-	O
binding	O
site	O
.	O
Ni2	B-Chemical
+-	I-Chemical
mediated	O
stimulation	O
of	O
substrate	O
uptake	O
by	O
hDAT	O
.	O
A	O
and	O
C	O
","	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
dopamine	I-Chemical
(	O
DA	B-Chemical
)	O
uptake	O
in	O
the	O
absence	O
and	O
in	O
the	O
presence	O
of	O
1	O
and	O
10	O
Î¼m	O
Zn2	B-Chemical
+	I-Chemical
(	O
A	O
)	O
or	O
Ni2	B-Chemical
+	I-Chemical
(	O
C	O
"),"	O
respectively	O
.	O
Each	O
data	O
point	O
in	O
A	O
and	O
C	O
is	O
the	O
mean	O
of	O
five	O
independent	O
experiments	O
.	O
The	O
data	O
were	O
fit	O
to	O
the	O
Michaelis	O
-	O
Menten	O
equation	O
","	O
and	O
the	O
estimated	O
parameters	O
were	O
as	O
follows	O
(	O
Km	O
in	O
micromolar	O
","	O
Vmax	O
in	O
picomoles	O
per	O
million	O
per	O
minute	O
).	O
A	O
","	O
control	O
","	O
Km	O
=	O
1	O
.	O
6	O
(	O
0	O
.	O
6	O
â€“	O
2	O
.	O
7	O
","	O
Vmax	O
=	O
27	O
.	O
3	O
(	O
22	O
.	O
6	O
â€“	O
31	O
.	O
9	O
);	O
1	O
Î¼m	O
Zn2	B-Chemical
"+,"	O
Km	O
=	O
1	O
.	O
5	O
(	O
0	O
.	O
5	O
â€“	O
3	O
.	O
0	O
"),"	O
Vmax	O
=	O
50	O
.	O
3	O
(	O
35	O
.	O
8	O
â€“	O
64	O
.	O
0	O
);	O
10	O
Î¼m	O
Zn2	B-Chemical
"+,"	I-Chemical
Km	O
=	O
2	O
.	O
9	O
(	O
0	O
.	O
9	O
â€“	O
4	O
.	O
9	O
"),"	O
Vmax	O
=	O
18	O
.	O
3	O
(	O
14	O
.	O
0	O
â€“	O
21	O
.	O
0	O
).	O
C	O
","	O
control	O
","	O
Km	O
=	O
1	O
.	O
6	O
(	O
0	O
.	O
3	O
â€“	O
3	O
.	O
0	O
"),"	O
Vmax	O
=	O
136	O
(	O
107	O
.	O
5	O
â€“	O
164	O
.	O
7	O
);	O
1	O
Î¼m	O
Ni2	B-Chemical
"+,"	I-Chemical
Km	O
=	O
1	O
.	O
8	O
(	O
0	O
.	O
7	O
â€“	O
2	O
.	O
9	O
"),"	O
Vmax	O
=	O
174	O
.	O
3	O
(	O
144	O
.	O
0	O
â€“	O
204	O
.	O
0	O
);	O
10	O
Î¼m	O
Ni2	B-Chemical
"+,"	I-Chemical
Km	O
=	O
3	O
.	O
4	O
(	O
1	O
.	O
4	O
â€“	O
5	O
.	O
3	O
"),"	O
Vmax	O
=	O
223	O
.	O
2	O
(	O
180	O
.	O
9	O
â€“	O
265	O
.	O
0	O
).	O
Data	O
represent	O
mean	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
in	O
parentheses	O
).	O
The	O
estimated	O
Vmax	O
values	O
were	O
significantly	O
different	O
between	O
0	O
","	O
1	O
","	O
and	O
10	O
Î¼m	O
Zn2	B-Chemical
+	I-Chemical
(	O
p	O
<	O
0	O
.	O
8	O
","	O
F	O
-	O
test	O
)	O
and	O
between	O
0	O
","	O
1	O
","	O
and	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
(	O
p	O
<	O
0	O
.	O
24	O
","	O
F	O
-	O
test	O
).	O
B	O
and	O
D	O
","	O
Vmax	O
(=	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
dopamine	I-Chemical
uptake	O
at	O
a	O
final	O
concentration	O
of	O
30	O
Î¼m	O
dopamine	B-Chemical
)	O
as	O
a	O
function	O
of	O
the	O
applied	O
Zn2	B-Chemical
+	I-Chemical
or	O
Ni2	B-Chemical
+	I-Chemical
concentration	O
.	O
The	O
blue	O
line	O
in	O
B	O
and	O
the	O
green	O
line	O
in	O
D	O
show	O
spline	O
fits	O
through	O
the	O
data	O
points	O
.	O
The	O
error	O
bars	O
indicate	O
standard	O
deviation	O
(	O
n	O
=	O
6	O
).	O
Stimulation	O
of	O
Currents	O
through	O
DAT	O
by	O
Ni2	B-Chemical
+	I-Chemical
at	O
High	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
The	O
action	O
of	O
Zn2	B-Chemical
+	I-Chemical
depends	O
on	O
the	O
intracellular	O
sodium	B-Chemical
concentration	O
.	O
At	O
low	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
","	O
Zn2	B-Chemical
+	I-Chemical
acts	O
as	O
an	O
activator	O
of	O
dopamine	B-Chemical
transport	O
","	O
but	O
it	O
is	O
inhibitory	O
when	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
is	O
high	O
.	O
This	O
is	O
the	O
case	O
in	O
HEK293	O
cells	O
overexpressing	O
DAT	O
(	O
2	O
","	O
22	O
â€“	O
24	O
).	O
Accordingly	O
","	O
the	O
finding	O
that	O
Ni2	B-Chemical
+	I-Chemical
increased	O
substrate	O
uptake	O
into	O
HEK293	O
cells	O
suggested	O
that	O
Ni2	B-Chemical
+	I-Chemical
can	O
also	O
stimulate	O
DAT	O
at	O
high	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
.	O
We	O
tested	O
this	O
conjecture	O
by	O
comparing	O
the	O
action	O
of	O
10	O
Î¼m	O
Zn2	B-Chemical
+	I-Chemical
and	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
on	O
currents	O
by	O
DAT	O
in	O
the	O
presence	O
of	O
25	O
mm	O
Na	B-Chemical
+	I-Chemical
i	O
.	O
Fig	O
.	O
6A	O
shows	O
representative	O
currents	O
through	O
hDAT	O
that	O
were	O
induced	O
by	O
the	O
rapid	O
application	O
of	O
30	O
Î¼m	O
dopamine	B-Chemical
followed	O
by	O
the	O
concomitant	O
superfusion	O
with	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
(	O
Fig	O
.	O
6A	O
","	O
left	O
panel	O
)	O
or	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
(	O
Fig	O
.	O
6A	O
","	O
right	O
panel	O
)	O
for	O
5	O
s	O
.	O
It	O
is	O
evident	O
from	O
these	O
recordings	O
that	O
","	O
in	O
the	O
presence	O
of	O
25	O
mm	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
","	O
Zn2	B-Chemical
+	I-Chemical
inhibits	O
the	O
steady	O
-	O
state	O
current	O
whereas	O
Ni2	B-Chemical
+	I-Chemical
does	O
not	O
.	O
Although	O
we	O
failed	O
to	O
detect	O
current	O
inhibition	O
in	O
the	O
presence	O
of	O
10	O
Î¼m	O
Ni2	B-Chemical
"+,"	I-Chemical
it	O
is	O
worth	O
pointing	O
out	O
that	O
the	O
stimulatory	O
effect	O
of	O
Ni2	B-Chemical
+	I-Chemical
was	O
lower	O
with	O
25	O
mm	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
than	O
the	O
one	O
observed	O
with	O
6	O
mm	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
(	O
Fig	O
.	O
1C	O
).	O
This	O
suggests	O
that	O
","	O
although	O
the	O
inhibitory	O
action	O
of	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
is	O
smaller	O
with	O
Ni2	B-Chemical
+	I-Chemical
than	O
with	O
Zn2	B-Chemical
"+,"	I-Chemical
it	O
is	O
not	O
fully	O
eliminated	O
.	O
Inhibition	O
by	O
Zn2	B-Chemical
+	I-Chemical
but	O
not	O
by	O
Ni2	B-Chemical
+	I-Chemical
of	O
steady	O
-	O
state	O
currents	O
through	O
DAT	O
in	O
the	O
presence	O
of	O
25	O
mm	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
.	O
A	O
","	O
a	O
HEK293	O
cell	O
stably	O
expressing	O
hDAT	O
was	O
clamped	O
to	O
âˆ’	O
60	O
mV	O
with	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
set	O
to	O
25	O
mm	O
.	O
The	O
cell	O
was	O
challenged	O
with	O
30	O
Î¼m	O
dopamine	B-Chemical
to	O
elicit	O
a	O
current	O
.	O
Although	O
co	O
-	O
application	O
of	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
led	O
to	O
a	O
small	O
increase	O
in	O
the	O
current	O
amplitude	O
","	O
co	O
-	O
application	O
of	O
10	O
Î¼m	O
Zn2	B-Chemical
+	I-Chemical
decreased	O
it	O
.	O
B	O
","	O
-	O
fold	O
change	O
of	O
the	O
steady	O
-	O
state	O
current	O
at	O
25	O
mm	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
in	O
the	O
presence	O
of	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
(	O
green	O
column	O
)	O
and	O
10	O
Î¼m	O
Zn2	B-Chemical
+	I-Chemical
(	O
blue	O
column	O
).	O
Data	O
represent	O
mean	O
Â±	O
S	O
.	O
D	O
.	O
The	O
respective	O
-	O
fold	O
changes	O
were	O
tested	O
against	O
the	O
hypothetical	O
value	O
1	O
(=	O
no	O
change	O
","	O
indicated	O
as	O
a	O
dotted	O
line	O
in	O
the	O
bar	O
graph	O
)	O
using	O
Wilcoxon	O
matched	O
pairs	O
signed	O
-	O
rank	O
test	O
.	O
Differential	O
Modulation	O
of	O
the	O
Peak	O
Current	O
Amplitude	O
by	O
Ni2	B-Chemical
+	I-Chemical
and	O
Zn2	B-Chemical
+	I-Chemical
The	O
substrate	O
-	O
induced	O
peak	O
current	O
reflects	O
the	O
initiation	O
of	O
the	O
transport	O
cycle	O
","	O
where	O
substrate	O
and	O
co	O
-	O
substrate	O
ions	O
are	O
bound	O
by	O
the	O
transporter	O
and	O
moved	O
through	O
the	O
electric	O
field	O
of	O
the	O
membrane	O
(	O
18	O
","	O
19	O
).	O
Zn2	B-Chemical
+	I-Chemical
decreases	O
the	O
amplitude	O
of	O
this	O
substrate	O
-	O
induced	O
peak	O
current	O
(	O
2	O
"),"	O
presumably	O
because	O
Zn2	B-Chemical
+	I-Chemical
does	O
not	O
only	O
favor	O
the	O
return	O
of	O
the	O
empty	O
transporter	O
(	O
forward	O
transport	O
mode	O
)	O
but	O
also	O
the	O
return	O
of	O
the	O
substrate	O
-	O
bound	O
transporter	O
to	O
the	O
outward	O
-	O
facing	O
state	O
(	O
substrate	O
exchange	O
mode	O
)	O
(	O
2	O
).	O
Accordingly	O
","	O
the	O
charge	O
that	O
gives	O
rise	O
to	O
the	O
inwardly	O
directed	O
peak	O
current	O
is	O
moved	O
into	O
the	O
opposite	O
direction	O
","	O
and	O
","	O
hence	O
","	O
the	O
peak	O
current	O
amplitude	O
is	O
decreased	O
.	O
Ni2	B-Chemical
+	I-Chemical
and	O
Zn2	B-Chemical
+	I-Chemical
differed	O
in	O
their	O
ability	O
to	O
stimulate	O
steady	O
-	O
state	O
transport	O
.	O
In	O
the	O
micromolar	O
range	O
","	O
Ni2	B-Chemical
+	I-Chemical
uniformly	O
stimulated	O
substrate	O
uptake	O
","	O
but	O
Zn2	B-Chemical
+	I-Chemical
gave	O
rise	O
to	O
a	O
stimulation	O
at	O
1	O
Î¼m	O
and	O
inhibition	O
at	O
10	O
Î¼m	O
(	O
cf	O
.	O
Fig	O
.	O
5A	O
).	O
This	O
suggests	O
that	O
Zn2	B-Chemical
+	I-Chemical
and	O
Ni2	B-Chemical
+	I-Chemical
do	O
not	O
affect	O
the	O
conformational	O
transitions	O
hDAT	O
must	O
undergo	O
during	O
the	O
transport	O
cycle	O
in	O
the	O
same	O
way	O
.	O
Hence	O
","	O
we	O
compared	O
the	O
effect	O
of	O
Ni2	B-Chemical
+	I-Chemical
on	O
the	O
dopamine	B-Chemical
-	O
induced	O
peak	O
current	O
by	O
employing	O
the	O
protocol	O
shown	O
in	O
Fig	O
.	O
7A	O
.	O
We	O
applied	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
or	O
Zn2	B-Chemical
+	I-Chemical
for	O
5	O
s	O
to	O
a	O
HEK293	O
cell	O
expressing	O
hDAT	O
.	O
Subsequently	O
","	O
test	O
pulses	O
of	O
30	O
Î¼m	O
dopamine	B-Chemical
were	O
applied	O
immediately	O
or	O
0	O
.	O
2	O
","	O
0	O
.	O
5	O
","	O
1	O
","	O
and	O
2	O
s	O
after	O
removal	O
of	O
the	O
metal	O
ion	O
.	O
As	O
can	O
be	O
seen	O
in	O
Fig	O
.	O
7B	O
","	O
the	O
effect	O
of	O
Ni2	B-Chemical
+	I-Chemical
on	O
the	O
peak	O
current	O
was	O
much	O
smaller	O
than	O
that	O
of	O
Zn2	B-Chemical
+.	I-Chemical
Although	O
Zn2	B-Chemical
+	I-Chemical
decreased	O
the	O
peak	O
current	O
amplitude	O
by	O
about	O
30	O
"%,"	O
Ni2	B-Chemical
+	I-Chemical
only	O
affected	O
it	O
to	O
a	O
very	O
minor	O
extent	O
.	O
Comparison	O
of	O
Ni2	B-Chemical
+-	I-Chemical
and	O
Zn2	B-Chemical
+-	I-Chemical
induced	O
changes	O
in	O
the	O
peak	O
current	O
.	O
A	O
","	O
protocol	O
for	O
determining	O
the	O
effect	O
of	O
Ni2	B-Chemical
+	I-Chemical
(	O
or	O
Zn2	B-Chemical
+)	I-Chemical
on	O
the	O
peak	O
current	O
by	O
hDAT	O
.	O
A	O
HEK293	O
cell	O
stably	O
expressing	O
hDAT	O
was	O
clamped	O
to	O
âˆ’	O
60	O
mV	O
and	O
exposed	O
to	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
for	O
5	O
s	O
.	O
After	O
wash	O
periods	O
of	O
0	O
.	O
2	O
","	O
0	O
.	O
5	O
","	O
1	O
","	O
2	O
","	O
and	O
5	O
s	O
","	O
a	O
peak	O
current	O
was	O
triggered	O
by	O
rapid	O
application	O
of	O
30	O
Î¼m	O
dopamine	B-Chemical
(	O
0	O
.	O
5	O
s	O
).	O
The	O
original	O
traces	O
are	O
from	O
a	O
representative	O
experiment	O
that	O
was	O
reproduced	O
in	O
seven	O
independent	O
experiments	O
with	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
and	O
Zn2	B-Chemical
"+,"	I-Chemical
respectively	O
.	O
B	O
","	O
recovery	O
of	O
the	O
peak	O
current	O
following	O
application	O
of	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
(	O
green	O
circles	O
)	O
and	O
10	O
Î¼m	O
Zn2	B-Chemical
+	I-Chemical
(	O
blue	O
circles	O
"),"	O
respectively	O
.	O
The	O
peak	O
current	O
amplitudes	O
were	O
normalized	O
to	O
the	O
respective	O
largest	O
current	O
and	O
plotted	O
as	O
a	O
function	O
of	O
the	O
wash	O
time	O
interval	O
.	O
The	O
two	O
sets	O
of	O
data	O
points	O
were	O
each	O
fit	O
to	O
a	O
monoexponential	O
function	O
(	O
green	O
and	O
blue	O
lines	O
).	O
The	O
fits	O
yielded	O
the	O
following	O
parameters	O
:	O
Ni2	B-Chemical
"+,"	I-Chemical
Trecovery	O
=	O
0	O
.	O
15	O
s	O
(	O
0	O
.	O
7	O
â€“	O
5	O
.	O
66	O
"),"	O
blocked	O
fraction	O
13	O
%	O
(	O
10	O
â€“	O
17	O
);	O
Zn2	B-Chemical
"+,"	I-Chemical
Trecovery	O
=	O
1	O
.	O
25	O
s	O
(	O
0	O
.	O
82	O
â€“	O
2	O
.	O
5	O
"),"	O
blocked	O
fraction	O
28	O
%	O
(	O
22	O
â€“	O
33	O
).	O
Data	O
represent	O
mean	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
in	O
parentheses	O
).	O
The	O
estimated	O
blocked	O
fractions	O
were	O
significantly	O
different	O
(	O
p	O
<	O
0	O
.	O
1	O
","	O
F	O
-	O
test	O
).	O
Amphetamine	B-Chemical
-	O
induced	O
Substrate	O
Release	O
in	O
the	O
Presence	O
of	O
Zn2	B-Chemical
+	I-Chemical
and	O
Ni2	B-Chemical
+	I-Chemical
During	O
amphetamine	B-Chemical
-	O
induced	O
substrate	O
release	O
","	O
DAT	O
operates	O
in	O
the	O
substrate	O
exchange	O
mode	O
rather	O
than	O
the	O
forward	O
transport	O
mode	O
","	O
i	O
.	O
e	O
.	O
amphetamine	B-Chemical
is	O
carried	O
inward	O
and	O
exchanged	O
for	O
dopamine	B-Chemical
(	O
25	O
","	O
26	O
","	O
27	O
).	O
As	O
outlined	O
above	O
","	O
Zn2	B-Chemical
+	I-Chemical
inhibits	O
the	O
peak	O
current	O
because	O
it	O
favors	O
substrate	O
exchange	O
.	O
Accordingly	O
","	O
Zn2	B-Chemical
+	I-Chemical
increases	O
amphetamine	B-Chemical
-	O
induced	O
substrate	O
release	O
mediated	O
by	O
DAT	O
(	O
21	O
).	O
In	O
contrast	O
","	O
Ni2	B-Chemical
+	I-Chemical
reduced	O
the	O
peak	O
current	O
amplitude	O
only	O
to	O
a	O
very	O
modest	O
extent	O
(	O
cf	O
.	O
Fig	O
.	O
7	O
)	O
and	O
did	O
not	O
block	O
the	O
steady	O
-	O
state	O
current	O
(	O
i	O
.	O
e	O
.	O
the	O
forward	O
transport	O
mode	O
)	O
in	O
the	O
presence	O
of	O
elevated	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
.	O
Based	O
on	O
our	O
model	O
","	O
these	O
findings	O
predict	O
that	O
","	O
contrary	O
to	O
Zn2	B-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
+	I-Chemical
does	O
not	O
enhance	O
amphetamine	B-Chemical
-	O
induced	O
substrate	O
efflux	O
.	O
This	O
conjecture	O
was	O
verified	O
(	O
Fig	O
.	O
8	O
).	O
In	O
hDAT	O
-	O
expressing	O
HEK293	O
cells	O
that	O
had	O
been	O
preloaded	O
with	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
MPP	I-Chemical
"+,"	I-Chemical
superfusion	O
with	O
3	O
Î¼m	O
d	B-Chemical
-	I-Chemical
amphetamine	I-Chemical
(	O
AMPH	B-Chemical
)	O
caused	O
a	O
robust	O
release	O
of	O
radioactive	O
substrate	O
that	O
was	O
further	O
augmented	O
by	O
the	O
concomitant	O
application	O
of	O
10	O
Î¼m	O
Zn2	B-Chemical
+.	I-Chemical
In	O
contrast	O
","	O
Ni2	B-Chemical
+	I-Chemical
did	O
not	O
enhance	O
amphetamine	B-Chemical
-	O
induced	O
substrate	O
release	O
.	O
Stimulation	O
of	O
amphetamine	B-Chemical
-	O
induced	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
MPP	I-Chemical
+	I-Chemical
release	O
by	O
Zn2	B-Chemical
+	I-Chemical
but	O
not	O
Ni2	B-Chemical
+.	I-Chemical
HEK293	O
cells	O
transfected	O
with	O
hDAT	O
loaded	O
with	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
MPP	I-Chemical
+	I-Chemical
were	O
superfused	O
with	O
KHP	B-Chemical
buffer	O
for	O
45	O
min	O
(	O
see	O
â€œ	O
Experimental	O
Procedures	O
â€).	O
Thereafter	O
(	O
time	O
point	O
0	O
"),"	O
2	O
-	O
min	O
fractions	O
were	O
collected	O
.	O
The	O
prior	O
interval	O
of	O
45	O
min	O
allowed	O
for	O
establishing	O
a	O
stable	O
baseline	O
as	O
verified	O
by	O
the	O
first	O
seven	O
fractions	O
.	O
After	O
12	O
min	O
","	O
3	O
Î¼m	O
AMPH	B-Chemical
was	O
added	O
","	O
which	O
resulted	O
in	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
MPP	I-Chemical
+	I-Chemical
release	O
(	O
black	O
circles	O
).	O
This	O
increase	O
was	O
larger	O
in	O
the	O
presence	O
of	O
10	O
Î¼m	O
Zn2	B-Chemical
+	I-Chemical
(	O
blue	O
circles	O
)	O
but	O
unchanged	O
in	O
the	O
presence	O
of	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
(	O
green	O
circles	O
).	O
The	O
data	O
are	O
averages	O
of	O
12	O
experiments	O
.	O
The	O
data	O
points	O
at	O
20	O
and	O
22	O
min	O
were	O
used	O
to	O
conduct	O
a	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
Kruskal	O
-	O
Wallis	O
test	O
)	O
followed	O
by	O
Dunn	O
'	O
s	O
multiple	O
comparisons	O
test	O
(	O
post	O
hoc	O
test	O
).	O
The	O
difference	O
between	O
AMPH	B-Chemical
and	O
AMPH	B-Chemical
+	O
10	O
Î¼m	O
Zn2	B-Chemical
+	I-Chemical
is	O
significant	O
(	O
p	O
=	O
0	O
.	O
26	O
).	O
Discussion	O
DAT	O
has	O
a	O
tetrahedral	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
.	O
The	O
coordination	O
sphere	O
is	O
comprised	O
of	O
H193	O
in	O
extracellular	O
loop	O
2	O
(	O
EL2	O
"),"	O
His375	B-Chemical
and	O
Glu396	B-Chemical
","	O
which	O
reside	O
on	O
top	O
of	O
transmembrane	O
helix	O
7	O
in	O
the	O
first	O
helical	O
part	O
of	O
extracellular	O
loop	O
4	O
(	O
EL4A	O
)	O
and	O
on	O
top	O
of	O
transmembrane	O
helix	O
8	O
in	O
the	O
second	O
helix	O
of	O
extracellular	O
loop	O
4	O
(	O
EL4B	O
"),"	O
respectively	O
(	O
28	O
"),"	O
and	O
Asp206	B-Chemical
in	O
EL2	O
(	O
29	O
).	O
The	O
extracellular	O
loops	O
are	O
thought	O
to	O
be	O
flexible	O
","	O
in	O
particular	O
the	O
extended	O
EL2	O
(	O
29	O
).	O
Accordingly	O
","	O
it	O
is	O
not	O
surprising	O
that	O
this	O
binding	O
site	O
can	O
accommodate	O
transition	O
metals	O
other	O
than	O
Zn2	B-Chemical
+	I-Chemical
even	O
when	O
their	O
optimum	O
coordination	O
geometries	O
differ	O
(	O
5	O
).	O
In	O
fact	O
","	O
our	O
observations	O
are	O
in	O
line	O
with	O
the	O
general	O
prediction	O
of	O
the	O
Irving	O
-	O
William	O
series	O
.	O
It	O
was	O
","	O
however	O
","	O
surprising	O
that	O
the	O
effects	O
elicited	O
by	O
individual	O
metal	O
ions	O
","	O
in	O
particular	O
Zn2	B-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
and	O
Cu2	B-Chemical
"+,"	I-Chemical
differed	O
substantially	O
.	O
Ni2	B-Chemical
+	I-Chemical
and	O
Cu2	B-Chemical
+	I-Chemical
uniformly	O
stimulated	O
and	O
inhibited	O
","	O
respectively	O
","	O
the	O
forward	O
transport	O
mode	O
of	O
DAT	O
.	O
In	O
contrast	O
","	O
Zn2	B-Chemical
+	I-Chemical
elicited	O
biphasic	O
effects	O
.	O
In	O
addition	O
","	O
and	O
most	O
importantly	O
","	O
Zn2	B-Chemical
+	I-Chemical
was	O
the	O
only	O
transition	O
metal	O
ion	O
that	O
also	O
promoted	O
the	O
substrate	O
exchange	O
mode	O
.	O
The	O
different	O
modes	O
of	O
action	O
of	O
the	O
metals	O
must	O
be	O
accounted	O
for	O
by	O
a	O
plausible	O
model	O
of	O
the	O
transport	O
cycle	O
.	O
It	O
is	O
a	O
priori	O
reasonable	O
to	O
posit	O
that	O
occupancy	O
of	O
the	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
produces	O
the	O
same	O
primary	O
effect	O
.	O
In	O
fact	O
","	O
this	O
was	O
the	O
case	O
.	O
All	O
effective	O
metals	O
shifted	O
the	O
EC50	O
of	O
dopamine	B-Chemical
for	O
eliciting	O
the	O
substrate	O
-	O
induced	O
steady	O
-	O
state	O
current	O
","	O
albeit	O
to	O
a	O
different	O
extent	O
.	O
The	O
shift	O
was	O
most	O
pronounced	O
for	O
Cu2	B-Chemical
"+,"	I-Chemical
followed	O
by	O
Ni2	B-Chemical
+	I-Chemical
and	O
Zn2	B-Chemical
+	I-Chemical
(	O
and	O
Co2	B-Chemical
+).	I-Chemical
These	O
shifts	O
indicate	O
that	O
Zn2	B-Chemical
"+,"	I-Chemical
and	O
","	O
to	O
a	O
larger	O
extent	O
","	O
Ni2	B-Chemical
+	I-Chemical
and	O
Cu2	B-Chemical
"+,"	I-Chemical
destabilized	O
the	O
substrate	O
-	O
bound	O
conformation	O
(	O
s	O
).	O
Destabilization	O
is	O
most	O
parsimoniously	O
explained	O
by	O
preferred	O
binding	O
of	O
these	O
metals	O
to	O
the	O
apo	O
conformation	O
(	O
s	O
)	O
of	O
DAT	O
.	O
Thermodynamics	O
dictate	O
that	O
the	O
effect	O
on	O
affinity	O
must	O
be	O
reciprocal	O
.	O
If	O
the	O
transition	O
metal	O
lowers	O
the	O
affinity	O
of	O
DAT	O
for	O
substrate	O
","	O
then	O
raising	O
the	O
substrate	O
concentration	O
must	O
lower	O
the	O
affinity	O
for	O
metals	O
.	O
In	O
addition	O
","	O
because	O
individual	O
metals	O
differed	O
in	O
their	O
ability	O
to	O
shift	O
the	O
EC50	O
of	O
dopamine	B-Chemical
","	O
they	O
must	O
discriminate	O
between	O
apo	O
and	O
substrate	O
-	O
bound	O
transporters	O
to	O
different	O
extents	O
","	O
with	O
Zn2	B-Chemical
+	I-Chemical
and	O
Cu2	B-Chemical
+	I-Chemical
having	O
the	O
least	O
and	O
most	O
pronounced	O
affinity	O
differences	O
","	O
respectively	O
.	O
We	O
implemented	O
this	O
information	O
into	O
a	O
kinetic	O
model	O
(	O
18	O
)	O
that	O
was	O
extended	O
to	O
account	O
for	O
metal	O
-	O
bound	O
states	O
(	O
Fig	O
.	O
9A	O
).	O
This	O
allowed	O
for	O
recapitulating	O
all	O
experimental	O
findings	O
.	O
1	O
)	O
It	O
is	O
","	O
for	O
instance	O
","	O
possible	O
to	O
account	O
for	O
the	O
observation	O
that	O
low	O
Zn2	B-Chemical
+	I-Chemical
concentrations	O
(	O
1	O
Î¼m	O
)	O
increased	O
substrate	O
uptake	O
in	O
the	O
presence	O
of	O
high	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
and	O
for	O
the	O
biphasic	O
effect	O
of	O
Zn2	B-Chemical
+	I-Chemical
on	O
substrate	O
uptake	O
.	O
The	O
conformation	O
that	O
displays	O
the	O
highest	O
affinity	O
for	O
Zn2	B-Chemical
+	I-Chemical
is	O
the	O
outward	O
-	O
facing	O
apo	O
state	O
of	O
DAT	O
;	O
the	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
is	O
fully	O
occupied	O
at	O
1	O
Î¼m	O
.	O
Upon	O
substrate	O
binding	O
","	O
the	O
affinity	O
at	O
the	O
binding	O
site	O
decreases	O
","	O
and	O
Zn2	B-Chemical
+	I-Chemical
dissociates	O
.	O
Thus	O
","	O
at	O
low	O
concentrations	O
(	O
1	O
Î¼m	O
"),"	O
Zn2	B-Chemical
+	I-Chemical
interacts	O
almost	O
exclusively	O
with	O
the	O
apo	O
conformations	O
.	O
This	O
leads	O
to	O
an	O
acceleration	O
of	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
the	O
transport	O
cycle	O
and	O
stimulation	O
of	O
substrate	O
uptake	O
.	O
At	O
elevated	O
concentrations	O
(	O
e	O
.	O
g	O
.	O
10	O
Î¼m	O
"),"	O
Zn2	B-Chemical
+	I-Chemical
also	O
binds	O
to	O
the	O
substrate	O
-	O
loaded	O
conformations	O
.	O
This	O
gives	O
rise	O
to	O
Zn2	B-Chemical
+-	I-Chemical
induced	O
inhibition	O
when	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
is	O
high	O
(	O
Fig	O
.	O
9	O
","	O
E	O
and	O
G	O
).	O
2	O
)	O
The	O
key	O
actions	O
of	O
Ni2	B-Chemical
+	I-Chemical
were	O
reproduced	O
when	O
the	O
observation	O
that	O
Ni2	B-Chemical
+	I-Chemical
induced	O
a	O
larger	O
shift	O
in	O
the	O
EC50	O
of	O
dopamine	B-Chemical
than	O
Zn2	B-Chemical
+	I-Chemical
was	O
incorporated	O
into	O
the	O
model	O
.	O
These	O
actions	O
are	O
stimulation	O
of	O
the	O
dopamine	B-Chemical
-	O
induced	O
steady	O
-	O
state	O
current	O
by	O
Ni2	B-Chemical
+	I-Chemical
(	O
Fig	O
.	O
9B	O
"),"	O
the	O
modest	O
effect	O
of	O
Ni2	B-Chemical
+	I-Chemical
on	O
the	O
peak	O
current	O
(	O
Fig	O
.	O
9H	O
"),"	O
and	O
the	O
stimulatory	O
action	O
of	O
Ni2	B-Chemical
+	I-Chemical
despite	O
elevated	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
(	O
Fig	O
.	O
9F	O
).	O
3	O
)	O
Finally	O
","	O
the	O
model	O
also	O
accounts	O
for	O
current	O
inhibition	O
by	O
Cu2	B-Chemical
+	I-Chemical
(	O
Fig	O
.	O
9C	O
).	O
In	O
the	O
presence	O
of	O
Cu2	B-Chemical
"+,"	I-Chemical
the	O
shift	O
in	O
EC50	O
was	O
most	O
pronounced	O
","	O
i	O
.	O
e	O
.	O
larger	O
than	O
with	O
any	O
other	O
transition	O
metal	O
(	O
cf	O
.	O
Figs	O
.	O
3C	O
and	O
9D	O
).	O
This	O
observation	O
indicated	O
that	O
Cu2	B-Chemical
+	I-Chemical
had	O
the	O
highest	O
preference	O
for	O
the	O
apo	O
conformations	O
.	O
Hence	O
","	O
its	O
uniform	O
inhibitory	O
action	O
can	O
be	O
rationalized	O
as	O
follows	O
.	O
In	O
the	O
absence	O
of	O
Cu2	B-Chemical
"+,"	I-Chemical
30	O
Î¼m	O
dopamine	B-Chemical
is	O
a	O
saturating	O
concentration	O
that	O
induces	O
maximal	O
currents	O
and	O
allows	O
the	O
transporter	O
to	O
cycle	O
at	O
maximum	O
velocity	O
in	O
the	O
forward	O
transport	O
mode	O
.	O
In	O
contrast	O
","	O
Cu2	B-Chemical
+	I-Chemical
lowers	O
the	O
affinity	O
of	O
dopamine	B-Chemical
to	O
an	O
extent	O
that	O
a	O
dopamine	B-Chemical
concentration	O
of	O
30	O
Î¼m	O
does	O
not	O
suffice	O
for	O
saturation	O
(	O
Fig	O
.	O
9D	O
).	O
This	O
leads	O
to	O
a	O
decrease	O
in	O
current	O
amplitude	O
","	O
which	O
reflects	O
inhibition	O
of	O
dopamine	B-Chemical
transport	O
by	O
Cu2	B-Chemical
+.	I-Chemical
Thus	O
","	O
the	O
parsimonious	O
explanation	O
for	O
the	O
action	O
of	O
transition	O
metals	O
on	O
DAT	O
is	O
the	O
reciprocal	O
effect	O
of	O
substrate	O
and	O
metal	O
:	O
binding	O
of	O
one	O
lowers	O
the	O
affinity	O
for	O
the	O
respective	O
other	O
.	O
Given	O
the	O
location	O
of	O
the	O
coordinating	O
residues	O
","	O
it	O
is	O
attractive	O
to	O
assume	O
that	O
occupancy	O
of	O
the	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
by	O
metals	O
precludes	O
the	O
transition	O
of	O
DAT	O
from	O
the	O
outward	O
open	O
to	O
the	O
occluded	O
state	O
.	O
By	O
definition	O
","	O
this	O
reduces	O
the	O
apparent	O
substrate	O
affinity	O
because	O
the	O
substrate	O
can	O
more	O
readily	O
dissociate	O
from	O
the	O
outward	O
open	O
than	O
from	O
the	O
occluded	O
state	O
.	O
Conversely	O
","	O
in	O
the	O
occluded	O
state	O
","	O
the	O
relative	O
position	O
of	O
the	O
residues	O
that	O
coordinate	O
the	O
transition	O
metal	O
is	O
likely	O
to	O
change	O
.	O
This	O
is	O
predicted	O
to	O
translate	O
into	O
a	O
decline	O
in	O
affinity	O
for	O
the	O
metal	O
.	O
A	O
kinetic	O
model	O
of	O
the	O
action	O
of	O
first	O
-	O
row	O
transition	O
metals	O
on	O
the	O
transport	O
cycle	O
of	O
DAT	O
.	O
A	O
","	O
the	O
model	O
scheme	O
","	O
which	O
is	O
the	O
same	O
as	O
in	O
Li	O
et	O
al	O
.	O
(	O
2	O
).	O
X	O
indicates	O
transition	O
metals	O
.	O
For	O
each	O
metal	O
there	O
is	O
a	O
separate	O
set	O
of	O
parameters	O
(	O
see	O
supplemental	O
Table	O
1	O
).	O
Parameters	O
are	O
shared	O
between	O
these	O
sets	O
when	O
they	O
describe	O
conformational	O
rearrangements	O
and	O
binding	O
reactions	O
within	O
DAT	O
that	O
are	O
unaffected	O
by	O
the	O
metals	O
.	O
Red	O
and	O
orange	O
arrows	O
indicate	O
metal	O
binding	O
to	O
substrate	O
-	O
bound	O
states	O
","	O
and	O
arrows	O
in	O
violet	O
and	O
blue	O
indicate	O
metal	O
binding	O
to	O
apo	O
states	O
.	O
B	O
and	O
C	O
","	O
simulated	O
current	O
evoked	O
by	O
30	O
Î¼m	O
dopamine	B-Chemical
stimulated	O
by	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
(	O
B	O
)	O
or	O
inhibited	O
by	O
10	O
Î¼m	O
Cu2	B-Chemical
+	I-Chemical
(	O
C	O
).	O
D	O
","	O
simulated	O
concentration	O
dependence	O
of	O
dopamine	B-Chemical
-	O
induced	O
currents	O
in	O
the	O
absence	O
and	O
presence	O
of	O
10	O
Î¼m	O
Zn2	B-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
and	O
Cu2	B-Chemical
"+,"	I-Chemical
respectively	O
.	O
E	O
","	O
simulated	O
Vmax	O
of	O
dopamine	B-Chemical
uptake	O
by	O
DAT	O
in	O
the	O
absence	O
and	O
presence	O
of	O
1	O
and	O
10	O
Î¼m	O
Zn2	B-Chemical
"+,"	I-Chemical
assuming	O
25	O
mm	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
.	O
F	O
","	O
simulated	O
currents	O
induced	O
by	O
30	O
Î¼m	O
dopamine	B-Chemical
with	O
[	O
Na	B-Chemical
+]	I-Chemical
i	O
set	O
to	O
25	O
mm	O
.	O
Under	O
this	O
condition	O
","	O
the	O
model	O
predicts	O
current	O
stimulation	O
by	O
Ni2	B-Chemical
+	I-Chemical
and	O
inhibition	O
by	O
Zn2	B-Chemical
+.	I-Chemical
G	O
","	O
simulated	O
peak	O
current	O
recovery	O
after	O
application	O
of	O
10	O
Î¼m	O
Ni2	B-Chemical
+	I-Chemical
(	O
green	O
circles	O
)	O
or	O
Zn2	B-Chemical
+	I-Chemical
(	O
blue	O
circles	O
).	O
The	O
simulations	O
evidently	O
account	O
for	O
the	O
measured	O
data	O
.	O
The	O
affinity	O
of	O
Mn2	B-Chemical
+	I-Chemical
for	O
the	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
of	O
DAT	O
was	O
so	O
low	O
that	O
there	O
was	O
no	O
appreciable	O
occupancy	O
up	O
to	O
100	O
Î¼m	O
Mn2	B-Chemical
+.	I-Chemical
This	O
low	O
affinity	O
is	O
consistent	O
with	O
the	O
Irving	O
-	O
Williams	O
series	O
(	O
5	O
","	O
8	O
","	O
9	O
).	O
Based	O
on	O
this	O
low	O
affinity	O
","	O
it	O
appears	O
unlikely	O
that	O
mismetallation	O
of	O
the	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
by	O
manganese	B-Chemical
is	O
relevant	O
to	O
the	O
mechanistic	O
understanding	O
of	O
manganese	B-Chemical
-	O
induced	O
dopamine	B-Chemical
deficiency	O
(	O
10	O
â€“	O
15	O
).	O
In	O
contrast	O
","	O
in	O
the	O
low	O
micromolar	O
range	O
","	O
Cu2	B-Chemical
+	I-Chemical
caused	O
a	O
profound	O
inhibition	O
of	O
DAT	O
.	O
Hence	O
","	O
this	O
inhibition	O
may	O
be	O
relevant	O
to	O
understand	O
symptoms	O
that	O
occur	O
in	O
the	O
course	O
of	O
Wilson	O
'	O
s	O
disease	O
for	O
the	O
following	O
reasons	O
.	O
1	O
)	O
Although	O
it	O
is	O
difficult	O
to	O
estimate	O
the	O
free	O
concentration	O
of	O
Cu2	B-Chemical
+	I-Chemical
in	O
the	O
brain	O
","	O
the	O
serum	O
concentration	O
of	O
free	O
Cu2	B-Chemical
+	I-Chemical
(	O
i	O
.	O
e	O
.	O
not	O
bound	O
to	O
coeruloplasmin	O
)	O
is	O
in	O
the	O
micromolar	O
range	O
(	O
30	O
).	O
The	O
concentration	O
of	O
Cu2	B-Chemical
+	I-Chemical
at	O
the	O
site	O
of	O
dopaminergic	O
projections	O
is	O
thought	O
to	O
exceed	O
that	O
in	O
serum	O
because	O
Cu2	B-Chemical
+	I-Chemical
accumulates	O
in	O
several	O
brain	O
regions	O
","	O
including	O
the	O
corpus	O
striatum	O
.	O
Thus	O
","	O
Cu2	B-Chemical
+	I-Chemical
levels	O
in	O
the	O
brain	O
are	O
likely	O
to	O
reach	O
concentrations	O
that	O
impair	O
retrieval	O
of	O
dopamine	B-Chemical
by	O
DAT	O
and	O
thus	O
lead	O
to	O
a	O
hypodopaminergic	O
state	O
.	O
2	O
)	O
Imaging	O
studies	O
suggest	O
that	O
a	O
presynaptic	O
dopaminergic	O
deficit	O
contributes	O
to	O
the	O
neurological	O
symptoms	O
from	O
which	O
patients	O
with	O
Wilson	O
'	O
s	O
disease	O
suffer	O
(	O
31	O
â€“	O
33	O
).	O
3	O
)	O
In	O
addition	O
","	O
patients	O
with	O
Wilson	O
'	O
s	O
disease	O
are	O
very	O
susceptible	O
to	O
side	O
effects	O
of	O
neuroleptic	O
drugs	O
that	O
arise	O
from	O
dopamine	B-Chemical
receptor	O
blockage	O
in	O
the	O
caudate	O
nucleus	O
and	O
putamen	O
.	O
When	O
erroneously	O
treated	O
with	O
both	O
typical	O
and	O
atypical	O
neuroleptic	O
/	O
antipsychotic	O
drugs	O
","	O
these	O
patients	O
are	O
prone	O
to	O
develop	O
drug	O
-	O
induced	O
extrapyramidal	O
symptoms	O
(	O
34	O
).	O
This	O
enhanced	O
susceptibility	O
presumably	O
arises	O
from	O
low	O
D2	O
receptor	O
occupancy	O
by	O
endogenous	O
dopamine	B-Chemical
because	O
of	O
impaired	O
synaptic	O
release	O
.	O
4	O
)	O
Finally	O
","	O
administration	O
of	O
zinc	B-Chemical
(	O
e	O
.	O
g	O
.	O
150	O
mg	O
of	O
zinc	B-Chemical
acetate	I-Chemical
/	O
day	O
)	O
is	O
an	O
effective	O
treatment	O
for	O
Wilson	O
'	O
s	O
disease	O
and	O
can	O
be	O
used	O
as	O
an	O
alternative	O
to	O
chelation	O
therapy	O
with	O
d	B-Chemical
-	I-Chemical
penicillamine	I-Chemical
or	O
trientine	B-Chemical
(	O
16	O
","	O
30	O
).	O
The	O
effect	O
relies	O
on	O
the	O
Zn2	B-Chemical
+-	I-Chemical
dependent	O
induction	O
of	O
metallothionein	O
into	O
the	O
gut	O
epithelium	O
and	O
the	O
resulting	O
reduced	O
systemic	O
bioavailability	O
of	O
dietary	O
copper	B-Chemical
(	O
16	O
).	O
Interestingly	O
","	O
Zn2	B-Chemical
+	I-Chemical
has	O
been	O
found	O
to	O
be	O
particularly	O
effective	O
in	O
improving	O
neurological	O
deficits	O
(	O
30	O
","	O
35	O
)	O
even	O
when	O
prior	O
chelation	O
therapy	O
failed	O
(	O
36	O
","	O
37	O
).	O
Based	O
on	O
this	O
circumstantial	O
evidence	O
and	O
on	O
our	O
observations	O
","	O
we	O
propose	O
that	O
displacement	O
of	O
Cu2	B-Chemical
+	I-Chemical
from	O
the	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
of	O
DAT	O
may	O
contribute	O
to	O
the	O
therapeutic	O
efficacy	O
of	O
Zn2	B-Chemical
+	I-Chemical
in	O
Wilson	O
'	O
s	O
disease	O
.	O
Occupancy	O
of	O
the	O
allosteric	O
Zn2	B-Chemical
+-	I-Chemical
binding	O
site	O
allows	O
for	O
a	O
wide	O
range	O
of	O
effects	O
","	O
i	O
.	O
e	O
.	O
stimulation	O
and	O
inhibition	O
of	O
the	O
forward	O
transport	O
mode	O
and	O
enhancing	O
the	O
substrate	O
exchange	O
mode	O
.	O
It	O
is	O
likely	O
that	O
this	O
binding	O
site	O
can	O
be	O
addressed	O
by	O
compounds	O
other	O
than	O
transition	O
metals	O
.	O
Allosteric	O
activators	O
of	O
the	O
forward	O
transport	O
mode	O
are	O
of	O
particular	O
interest	O
.	O
There	O
are	O
several	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
coding	O
sequence	O
of	O
human	O
DAT	O
that	O
lead	O
to	O
a	O
syndrome	O
of	O
infantile	O
or	O
juvenile	O
dystonia	O
and	O
parkinsonism	O
(	O
14	O
).	O
The	O
vast	O
majority	O
of	O
these	O
mutations	O
result	O
in	O
defective	O
folding	O
and	O
","	O
hence	O
","	O
retention	O
of	O
the	O
mutated	O
proteins	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O
However	O
","	O
there	O
are	O
some	O
mutants	O
that	O
do	O
reach	O
the	O
cell	O
surface	O
but	O
fail	O
to	O
transport	O
dopamine	B-Chemical
with	O
adequate	O
turnover	O
rates	O
.	O
A	O
search	O
for	O
allosteric	O
activators	O
is	O
therefore	O
justified	O
because	O
they	O
may	O
act	O
as	O
correctors	O
and	O
restore	O
the	O
forward	O
transport	O
mode	O
to	O
a	O
velocity	O
that	O
is	O
commensurate	O
with	O
normal	O
dopaminergic	O
transmission	O
(	O
40	O
).	O
In	O
fact	O
","	O
it	O
appears	O
worthwhile	O
to	O
test	O
whether	O
Ni2	B-Chemical
+	I-Chemical
(	O
or	O
any	O
other	O
transition	O
metal	O
)	O
accelerates	O
transport	O
in	O
these	O
mutants	O
.	O
Experimental	O
Procedures	O
Whole	O
-	O
cell	O
Patch	O
Clamp	O
HEK293	O
cells	O
stably	O
expressing	O
hDAT	O
or	O
transiently	O
expressing	O
hDAT	O
H193K	O
were	O
seeded	O
at	O
low	O
density	O
24	O
h	O
before	O
recordings	O
.	O
Currents	O
by	O
the	O
transporter	O
were	O
measured	O
in	O
the	O
whole	O
-	O
cell	O
patch	O
clamp	O
configuration	O
.	O
The	O
electrode	O
resistances	O
were	O
between	O
2	O
â€“	O
5	O
megohms	O
.	O
For	O
the	O
majority	O
of	O
the	O
recordings	O
","	O
we	O
used	O
the	O
following	O
internal	O
solution	O
:	O
133	O
mm	O
potassium	B-Chemical
gluconate	I-Chemical
","	O
6	O
mm	O
NaCl	B-Chemical
","	O
1	O
mm	O
CaCl2	B-Chemical
","	O
0	O
.	O
7	O
mm	O
MgCl2	B-Chemical
","	O
10	O
mm	O
EGTA	B-Chemical
","	O
and	O
10	O
mm	O
HEPES	B-Chemical
adjusted	O
to	O
pH	O
7	O
.	O
2	O
with	O
KOH	B-Chemical
.	O
For	O
some	O
experiments	O
we	O
used	O
an	O
internal	O
solution	O
containing	O
25	O
mm	O
Na	B-Chemical
"+,"	I-Chemical
25	O
mm	O
NaCl	B-Chemical
","	O
125	O
mm	O
KCl	B-Chemical
","	O
1	O
mm	O
CaCl2	B-Chemical
","	O
0	O
.	O
7	O
mm	O
MgCl2	B-Chemical
","	O
10	O
mm	O
EGTA	B-Chemical
","	O
and	O
10	O
mm	O
HEPES	B-Chemical
(	O
pH	O
7	O
.	O
2	O
with	O
KOH	B-Chemical
).	O
The	O
external	O
solution	O
in	O
all	O
experiments	O
was	O
140	O
mm	O
NaCl	B-Chemical
","	O
3	O
mm	O
KCl	B-Chemical
","	O
2	O
.	O
5	O
mm	O
CaCl2	B-Chemical
","	O
2	O
mm	O
MgCl2	B-Chemical
","	O
20	O
mm	O
glucose	B-Chemical
","	O
and	O
10	O
mm	O
HEPES	B-Chemical
adjusted	O
to	O
pH	O
7	O
.	O
4	O
with	O
NaOH	B-Chemical
.	O
For	O
rapid	O
solution	O
exchange	O
","	O
we	O
used	O
an	O
OctaFlow	O
superfusion	O
device	O
(	O
ALA	O
Scientific	O
","	O
Farmingdale	O
","	O
NY	O
).	O
Cells	O
were	O
continuously	O
superfused	O
either	O
with	O
blank	O
external	O
solution	O
or	O
an	O
external	O
solution	O
containing	O
dopamine	B-Chemical
","	O
respectively	O
.	O
For	O
the	O
solutions	O
containing	O
Mn2	B-Chemical
"+,"	I-Chemical
Co2	I-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
Zn2	I-Chemical
"+,"	I-Chemical
or	O
Cu2	B-Chemical
"+,"	I-Chemical
we	O
used	O
the	O
respective	O
chloride	B-Chemical
salts	I-Chemical
(	O
Sigma	O
-	O
Aldrich	O
","	O
St	O
.	O
Louis	O
","	O
MO	O
).	O
For	O
current	O
acquisition	O
","	O
we	O
employed	O
an	O
Axopatch	O
200B	O
amplifier	O
and	O
pClamp	O
10	O
.	O
2	O
software	O
(	O
Molecular	O
Devices	O
","	O
Sunnyvale	O
","	O
CA	O
).	O
The	O
cells	O
were	O
clamped	O
to	O
âˆ’	O
60	O
mV	O
","	O
and	O
the	O
washout	O
period	O
following	O
substrate	O
application	O
was	O
30	O
s	O
in	O
all	O
cases	O
.	O
Current	O
traces	O
were	O
filtered	O
at	O
1	O
kHz	O
and	O
digitized	O
at	O
10	O
kHz	O
using	O
a	O
Digidata	O
1550	O
(	O
Molecular	O
Devices	O
).	O
The	O
currents	O
induced	O
by	O
dopamine	B-Chemical
were	O
quantified	O
using	O
Clampfit	O
10	O
.	O
2	O
software	O
.	O
Passive	O
holding	O
currents	O
were	O
subtracted	O
","	O
and	O
the	O
traces	O
were	O
filtered	O
using	O
a	O
100	O
-	O
Hz	O
digital	O
Gaussian	O
low	O
-	O
pass	O
filter	O
.	O
Uptake	O
Assay	O
HEK293	O
cells	O
stably	O
expressing	O
hDAT	O
were	O
seeded	O
on	O
48	O
-	O
well	O
plates	O
precoated	O
with	O
poly	B-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
lysine	I-Chemical
(	O
0	O
.	O
5	O
Ã—	O
105	O
cells	O
/	O
well	O
)	O
24	O
h	O
before	O
the	O
assay	O
.	O
Cells	O
were	O
first	O
washed	O
with	O
500	O
Î¼l	O
/	O
well	O
Krebs	B-Chemical
-	I-Chemical
HEPES	I-Chemical
buffer	O
(	O
KHP	B-Chemical
):	O
130	O
mm	O
NaCl	B-Chemical
","	O
10	O
mm	O
HEPES	B-Chemical
","	O
1	O
.	O
3	O
mm	O
KH2PO4	B-Chemical
","	O
1	O
.	O
5	O
mm	O
CaCl2	B-Chemical
","	O
and	O
0	O
.	O
5	O
mm	O
MgSO4	B-Chemical
(	O
pH	O
7	O
.	O
4	O
)	O
with	O
NaOH	B-Chemical
.	O
The	O
cells	O
were	O
then	O
incubated	O
in	O
200	O
Î¼l	O
of	O
KHP	B-Chemical
buffer	O
containing	O
0	O
.	O
1	O
Î¼m	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
dopamine	I-Chemical
and	O
diluted	O
with	O
the	O
respective	O
cold	O
substrates	O
to	O
reach	O
final	O
concentrations	O
ranging	O
from	O
0	O
.	O
1	O
â€“	O
100	O
Î¼m	O
","	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
1	O
and	O
10	O
Î¼m	O
ZnCl2	B-Chemical
or	O
NiCl2	B-Chemical
","	O
respectively	O
.	O
The	O
cells	O
were	O
incubated	O
at	O
room	O
temperature	O
for	O
1	O
min	O
with	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
dopamine	I-Chemical
.	O
A	O
subsequent	O
wash	O
with	O
500	O
Î¼l	O
/	O
well	O
of	O
ice	O
-	O
cold	O
KHP	B-Chemical
buffer	O
terminated	O
uptake	O
.	O
Cells	O
were	O
finally	O
lysed	O
with	O
500	O
Î¼l	O
of	O
1	O
%	O
SDS	B-Chemical
","	O
transferred	O
into	O
2	O
ml	O
of	O
scintillation	O
mixture	O
(	O
Rotiszint	O
Eco	O
Plus	O
LSC	O
","	O
Art	O
.	O
16	O
.	O
3	O
","	O
Carl	O
Roth	O
GmbH	O
+	O
Co	O
.	O
KG	O
","	O
Karlsruhe	O
","	O
Germany	O
"),"	O
and	O
counted	O
in	O
a	O
Packard	O
2300TR	O
TriCarb	O
liquid	O
scintillation	O
analyzer	O
(	O
PerkinElmer	O
Life	O
Sciences	O
).	O
Superfusion	O
Experiments	O
HEK293	O
cells	O
stably	O
expressing	O
hDAT	O
(	O
2	O
.	O
5	O
Ã—	O
104	O
cells	O
/	O
coverslip	O
)	O
were	O
preloaded	O
with	O
0	O
.	O
2	O
Î¼m	O
[	B-Chemical
3H	I-Chemical
]	I-Chemical
MPP	I-Chemical
+	I-Chemical
for	O
30	O
min	O
.	O
The	O
coverslips	O
were	O
transferred	O
to	O
superfusion	O
chambers	O
and	O
perfused	O
with	O
KHP	B-Chemical
buffer	O
(	O
0	O
.	O
7	O
ml	O
/	O
min	O
at	O
22	O
Â°	O
C	O
).	O
After	O
an	O
initial	O
wash	O
period	O
of	O
45	O
min	O
","	O
fractions	O
were	O
collected	O
every	O
2	O
min	O
.	O
The	O
collection	O
of	O
the	O
first	O
fraction	O
defined	O
time	O
point	O
zero	O
.	O
Cells	O
were	O
exposed	O
10	O
Î¼m	O
ZnCl2	B-Chemical
or	O
10	O
Î¼m	O
NiCl2	B-Chemical
after	O
two	O
baseline	O
fractions	O
(	O
4	O
min	O
).	O
3	O
Î¼m	O
d	B-Chemical
-	I-Chemical
amphetamine	I-Chemical
was	O
added	O
to	O
the	O
superfusion	O
buffer	O
after	O
12	O
min	O
.	O
All	O
fractions	O
were	O
analyzed	O
by	O
liquid	O
scintillation	O
counting	O
(	O
see	O
above	O
).	O
Modeling	O
The	O
recorded	O
currents	O
were	O
emulated	O
with	O
a	O
previously	O
published	O
kinetic	O
model	O
of	O
the	O
transport	O
cycle	O
of	O
DAT	O
(	O
2	O
).	O
This	O
model	O
was	O
extended	O
to	O
account	O
for	O
the	O
binding	O
of	O
Zn2	B-Chemical
"+,"	I-Chemical
Ni2	I-Chemical
"+,"	I-Chemical
and	O
Cu2	B-Chemical
+.	I-Chemical
The	O
time	O
-	O
dependent	O
changes	O
in	O
state	O
occupancies	O
were	O
evaluated	O
by	O
numerical	O
integration	O
of	O
the	O
resulting	O
system	O
of	O
differential	O
equations	O
using	O
Systems	O
Biology	O
Toolbox	O
(	O
38	O
)	O
and	O
Matlab	O
2012a	O
(	O
Mathworks	O
","	O
Natick	O
","	O
MA	O
).	O
The	O
voltage	O
dependence	O
of	O
individual	O
rates	O
was	O
modeled	O
according	O
to	O
Laeuger	O
(	O
39	O
"),"	O
assuming	O
a	O
symmetric	O
barrier	O
as	O
kij	O
=	O
k0ijexp	O
(âˆ’	O
zQijFV	O
/	O
2RT	O
"),"	O
with	O
F	O
=	O
96	O
","	O
485	O
Cmol	O
âˆ’	O
1	O
","	O
r	O
=	O
8	O
.	O
314	O
JK	O
âˆ’	O
1mol	O
âˆ’	O
1	O
","	O
V	O
the	O
membrane	O
voltage	O
in	O
volts	O
","	O
and	O
T	O
=	O
293	O
K	O
.	O
The	O
extra	O
-	O
and	O
intracellular	O
ion	O
concentrations	O
were	O
set	O
to	O
the	O
values	O
used	O
in	O
the	O
experiments	O
.	O
Substrate	O
uptake	O
was	O
modeled	O
as	O
(	O
TiClS	O
Ã—	O
kSioff	O
âˆ’	O
TiCl	O
Ã—	O
Si	O
Ã—	O
kSion	O
+	O
TiClSZn	O
Ã—	O
kSioff	O
âˆ’	O
TiClZn	O
Ã—	O
Si	O
Ã—	O
kSion	O
)	O
Ã—	O
NC	O
/	O
NA	O
","	O
where	O
NC	O
is	O
the	O
number	O
of	O
transporters	O
and	O
NA	O
is	O
the	O
Avogadro	O
constant	O
.	O
Currents	O
and	O
substrate	O
uptake	O
were	O
simulated	O
assuming	O
a	O
transporter	O
density	O
of	O
25	O
Ã—	O
106	O
/	O
cell	O
.	O
Author	O
Contributions	O
Y	O
.	O
L	O
".,"	O
F	O
.	O
P	O
.	O
M	O
".,"	O
P	O
.	O
S	O
.	O
H	O
".,"	O
K	O
.	O
S	O
".,"	O
M	O
.	O
F	O
".,"	O
and	O
W	O
.	O
S	O
.	O
conceptualized	O
the	O
study	O
and	O
designed	O
the	O
experiments	O
.	O
P	O
.	O
S	O
.	O
H	O
".,"	O
K	O
.	O
S	O
".,"	O
and	O
W	O
.	O
S	O
.	O
designed	O
the	O
model	O
.	O
Y	O
.	O
L	O
".,"	O
F	O
.	O
P	O
.	O
M	O
".,"	O
and	O
V	O
.	O
B	O
.	O
performed	O
all	O
experiments	O
and	O
analyzed	O
the	O
data	O
.	O
Y	O
.	O
L	O
".,"	O
F	O
.	O
P	O
.	O
M	O
".,"	O
H	O
.	O
H	O
.	O
S	O
".,"	O
M	O
.	O
F	O
".,"	O
and	O
W	O
.	O
S	O
.	O
wrote	O
the	O
manuscript	O
.	O
This	O
work	O
was	O
supported	O
by	O
the	O
Austrian	O
Science	O
Fund	O
/	O
FWF	O
Project	O
P28090	O
(	O
to	O
W	O
.	O
S	O
.	O
"),"	O
Project	O
Program	O
Grant	O
SFB35	O
(	O
Grants	O
F3506	O
to	O
H	O
.	O
H	O
.	O
S	O
.	O
and	O
F3510	O
to	O
M	O
.	O
F	O
.	O
"),"	O
Project	O
W1232	O
(	O
to	O
H	O
.	O
H	O
.	O
S	O
.	O
"),"	O
and	O
Chinese	O
Scholarship	O
Council	O
Grant	O
2.01E+11	O
(	O
to	O
Y	O
.	O
L	O
.).	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
conflicts	O
of	O
interest	O
with	O
the	O
contents	O
of	O
this	O
article	O
.	O
This	O
article	O
contains	O
supplemental	O
Table	O
1	O
.	O
DAT	O
dopamine	O
transporter	O
hDAT	O
human	O
dopamine	O
transporter	O
AMPH	B-Chemical
d	B-Chemical
-	I-Chemical
amphetamine	I-Chemical
EL	O
extracellular	O
loop	O
DA	B-Chemical
dopamine	B-Chemical
EC50	O
half	O
-	O
maximal	O
effective	O
concentration	O
.	O
The	O
abbreviations	O
used	O
are	O
:	O
References	O
Fisetin	B-Chemical
Protects	O
PC12	O
Cells	O
from	O
Tunicamycin	B-Chemical
-	O
Mediated	O
Cell	O
Death	O
via	O
Reactive	B-Chemical
Oxygen	I-Chemical
Species	I-Chemical
Scavenging	O
and	O
Modulation	O
of	O
Nrf2	O
-	O
Driven	O
Gene	O
Expression	O
","	O
SIRT1	O
and	O
MAPK	O
Signaling	O
in	O
PC12	O
Cells	O
Background	O
:	O
Fisetin	B-Chemical
(	O
3	B-Chemical
","	I-Chemical
7	I-Chemical
","	I-Chemical
3	I-Chemical
"â€²,"	I-Chemical
4	I-Chemical
â€²-	I-Chemical
tetrahydroxyflavone	I-Chemical
)	O
is	O
a	O
dietary	O
flavonol	B-Chemical
and	O
exhibits	O
antioxidant	O
","	O
anti	O
-	O
inflammatory	O
","	O
and	O
neuroprotective	O
activities	O
.	O
However	O
","	O
high	O
concentration	O
of	O
fisetin	B-Chemical
is	O
reported	O
to	O
produce	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
"),"	O
induce	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
and	O
cause	O
cytotoxicity	O
in	O
cancer	O
cells	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
cytoprotective	O
effects	O
of	O
low	O
concentration	O
of	O
fisetin	B-Chemical
against	O
tunicamycin	B-Chemical
(	O
Tm	B-Chemical
)-	O
mediated	O
cytotoxicity	O
in	O
neuronal	O
-	O
like	O
catecholaminergic	O
PC12	O
cells	O
.	O
Methods	O
:	O
Cell	O
viability	O
was	O
assayed	O
by	O
MTT	B-Chemical
(	O
3	B-Chemical
-(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
dimethylthiazol	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
yl	I-Chemical
)-	I-Chemical
2	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
diphenyltetrazolium	I-Chemical
bromide	I-Chemical
)	O
and	O
apoptotic	O
and	O
autophagic	O
markers	O
were	O
analyzed	O
by	O
Western	O
blot	O
.	O
Gene	O
expression	O
of	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
and	O
Phase	O
II	O
enzymes	O
was	O
further	O
investigated	O
using	O
RT	O
-	O
Q	O
-	O
PCR	O
or	O
Western	O
blotting	O
.	O
Intracellular	O
ROS	B-Chemical
level	O
was	O
measured	O
using	O
2	B-Chemical
"â€²,"	I-Chemical
7	I-Chemical
â€²-	I-Chemical
dichlorodihydrofluorescein	I-Chemical
diacetate	I-Chemical
(	O
H2DCFDA	B-Chemical
)	O
by	O
a	O
fluorometer	O
.	O
The	O
effects	O
of	O
fisetin	B-Chemical
on	O
mitogen	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
)	O
and	O
SIRT1	O
(	O
Sirtuin	O
1	O
)	O
signaling	O
pathways	O
were	O
examined	O
using	O
Western	O
blotting	O
and	O
specific	O
inhibitors	O
.	O
Results	O
:	O
Fisetin	B-Chemical
(<	O
20	O
ÂµM	O
)	O
restored	O
cell	O
viability	O
and	O
repressed	O
apoptosis	O
","	O
autophagy	O
and	O
ROS	B-Chemical
production	O
in	O
Tm	B-Chemical
-	O
treated	O
cells	O
.	O
Fisetin	B-Chemical
attenuated	O
Tm	B-Chemical
-	O
mediated	O
expression	O
of	O
ER	O
stress	O
genes	O
","	O
such	O
as	O
glucose	O
-	O
regulated	O
proteins	O
78	O
(	O
GRP78	O
"),"	O
C	O
/	O
EBP	O
homologous	O
protein	O
(	O
CHOP	O
also	O
known	O
as	O
GADD153	O
)	O
and	O
Tribbles	O
homolog	O
3	O
(	O
TRB3	O
"),"	O
but	O
induced	O
the	O
expression	O
of	O
nuclear	O
E2	O
related	O
factor	O
(	O
Nrf	O
)	O
2	O
-	O
targeted	O
heme	O
oxygenase	O
(	O
HO	O
)-	O
1	O
","	O
glutamate	O
cysteine	O
ligase	O
(	O
GCL	O
)	O
and	O
cystine	O
/	O
glutamate	O
transporter	O
(	O
xCT	O
/	O
SLC7A11	O
"),"	O
in	O
both	O
the	O
presence	O
and	O
absence	O
of	O
Tm	B-Chemical
.	O
Moreover	O
","	O
fisetin	B-Chemical
enhanced	O
phosphorylation	O
of	O
ERK	O
(	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
"),"	O
JNK	O
(	O
c	O
-	O
JUN	O
NH2	O
-	O
terminal	O
protein	O
kinase	O
"),"	O
and	O
p38	O
MAPK	O
.	O
Addition	O
of	O
JNK	O
and	O
p38	O
MAPK	O
inhibitor	O
significantly	O
antagonized	O
its	O
cytoprotective	O
activity	O
and	O
modulatory	O
effects	O
on	O
UPR	O
.	O
Fisetin	B-Chemical
also	O
restored	O
Tm	B-Chemical
-	O
inhibited	O
SIRT1	O
expression	O
and	O
addition	O
of	O
sirtinol	B-Chemical
(	O
SIRT1	O
activation	O
inhibitor	O
)	O
significantly	O
blocked	O
fisetin	B-Chemical
-	O
mediated	O
cytoprotection	O
.	O
In	O
conclusion	O
","	O
this	O
result	O
shows	O
that	O
fisetin	B-Chemical
activates	O
Nrf2	O
","	O
MAPK	O
and	O
SIRT1	O
","	O
which	O
may	O
elicit	O
adaptive	O
cellular	O
stress	O
response	O
pathways	O
so	O
as	O
to	O
protect	O
cells	O
from	O
Tm	B-Chemical
-	O
induced	O
cytotoxicity	O
.	O
1	O
.	O
Introduction	O
Endoplasmic	O
reticulum	O
(	O
ER	O
)	O
is	O
a	O
dynamic	O
organelle	O
responsible	O
for	O
the	O
synthesis	O
","	O
correct	O
folding	O
","	O
post	O
-	O
translational	O
modification	O
and	O
transport	O
of	O
secretory	O
proteins	O
.	O
Disturbance	O
of	O
ER	O
function	O
leads	O
to	O
the	O
accumulation	O
of	O
unfolded	O
or	O
misfolded	O
proteins	O
in	O
the	O
ER	O
lumen	O
","	O
and	O
is	O
referred	O
to	O
as	O
ER	O
stress	O
[	O
1	O
].	O
The	O
correlations	O
between	O
ER	O
stress	O
and	O
neuronal	O
degenerative	O
diseases	O
","	O
including	O
Alzheimer	O
â€™	O
s	O
(	O
AD	O
"),"	O
Parkinson	O
â€™	O
s	O
(	O
PD	O
)	O
and	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
"),"	O
are	O
well	O
documented	O
[	O
2	O
].	O
ER	O
stress	O
can	O
also	O
be	O
chemically	O
induced	O
by	O
tunicamycin	B-Chemical
(	O
Tm	B-Chemical
"),"	O
an	O
antibiotic	O
produced	O
by	O
Streptomyces	O
lysosuperificus	O
.	O
Tm	B-Chemical
induces	O
ER	O
stress	O
by	O
inhibiting	O
microsomal	O
enzyme	O
N	O
-	O
acetylglucosamine	O
-	O
1	O
-	O
phosphate	O
transferase	O
","	O
which	O
is	O
responsible	O
for	O
the	O
glycosylation	O
of	O
newly	O
synthesized	O
proteins	O
[	O
3	O
].	O
The	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
is	O
a	O
series	O
of	O
events	O
that	O
cells	O
activate	O
in	O
order	O
to	O
cope	O
with	O
ER	O
stress	O
and	O
to	O
re	O
-	O
establish	O
ER	O
homeostasis	O
[	O
4	O
","	O
5	O
].	O
UPR	O
contains	O
three	O
parallel	O
signalling	O
branches	O
:	O
IRE1	O
(	O
inositol	O
-	O
requiringprotein1	O
)-	O
XBP1	O
(	O
X	O
-	O
box	O
-	O
binding	O
protein	O
1	O
"),"	O
ATF6	O
(	O
activating	O
transcription	O
factor	O
6	O
)	O
and	O
PERK	O
(	O
protein	O
kinase	O
RNA	O
-	O
like	O
ER	O
kinase	O
)-	O
eIF2Î±	O
(	O
eukaryotic	O
translation	O
initiation	O
factor	O
2Î±	O
)-	O
ATF4	O
(	O
activating	O
transcription	O
factor	O
4	O
).	O
The	O
three	O
transcription	O
factors	O
activated	O
","	O
XBP1	O
","	O
ATF6	O
","	O
and	O
ATF4	O
","	O
individually	O
and	O
collectively	O
upregulate	O
the	O
transcription	O
of	O
ER	O
chaperones	O
","	O
such	O
as	O
glucose	O
-	O
regulated	O
proteins	O
78	O
(	O
GRP78	O
"),"	O
ER	O
biosynthetic	O
machinery	O
","	O
and	O
ER	O
associated	O
degradation	O
(	O
ERAD	O
)	O
components	O
in	O
order	O
to	O
resolve	O
ER	O
stress	O
[	O
6	O
].	O
In	O
the	O
case	O
of	O
chronic	O
or	O
unmitigated	O
ER	O
stress	O
","	O
cell	O
death	O
pathways	O
are	O
induced	O
[	O
7	O
].	O
ER	O
stress	O
-	O
induced	O
apoptosis	O
is	O
mediated	O
mainly	O
by	O
C	O
/	O
EBP	O
homologous	O
protein	O
(	O
CHOP	O
/	O
GADD153	O
)	O
[	O
8	O
","	O
9	O
].	O
Emerging	O
data	O
also	O
suggest	O
that	O
","	O
in	O
addition	O
to	O
UPR	O
","	O
autophagy	O
is	O
part	O
of	O
the	O
global	O
ER	O
stress	O
response	O
[	O
10	O
","	O
11	O
].	O
Autophagy	O
is	O
an	O
evolutionarily	O
conserved	O
mechanism	O
that	O
sequesters	O
undesired	O
cellular	O
material	O
into	O
autophagosomes	O
for	O
delivery	O
to	O
lysosomes	O
for	O
degradation	O
[	O
12	O
].	O
Autophagosome	O
formation	O
is	O
controlled	O
by	O
a	O
well	O
-	O
orchestrated	O
action	O
of	O
a	O
distinctive	O
set	O
of	O
autophagy	O
-	O
related	O
(	O
Atg	O
)	O
proteins	O
.	O
A	O
key	O
reaction	O
involves	O
the	O
lipidation	O
of	O
Atg8	O
in	O
autophagic	O
membranes	O
","	O
which	O
is	O
facilitated	O
by	O
the	O
Atg12	O
â€“	O
Atg5	O
conjugate	O
[	O
13	O
].	O
Flavonoids	B-Chemical
are	O
a	O
group	O
of	O
bioactive	O
compounds	O
that	O
are	O
commonly	O
found	O
in	O
fruits	O
","	O
vegetables	O
","	O
nuts	O
and	O
beans	O
.	O
Flavonoids	B-Chemical
and	O
their	O
metabolites	O
can	O
transport	O
across	O
the	O
blood	O
â€“	O
brain	O
barrier	O
(	O
BBB	O
"),"	O
making	O
them	O
ideal	O
targets	O
in	O
the	O
therapeutic	O
utility	O
for	O
neurodegenerative	O
disorders	O
[	O
14	O
].	O
Numerous	O
studies	O
indicate	O
that	O
the	O
anti	O
-	O
neurodegeneration	O
effects	O
of	O
flavonoids	B-Chemical
are	O
consistent	O
with	O
their	O
roles	O
as	O
activators	O
of	O
mitogen	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
"),"	O
SIRT1	O
(	O
Sirtuin	O
1	O
)	O
or	O
Nrf2	O
(	O
nuclear	O
E2	O
related	O
factor	O
2	O
)-	O
ARE	O
(	O
antioxidant	O
response	O
element	O
)	O
[	O
15	O
","	O
16	O
","	O
17	O
","	O
18	O
].	O
The	O
MAPK	O
family	O
","	O
including	O
ERK	O
(	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
"),"	O
JNK	O
(	O
c	O
-	O
JUN	O
NH2	O
-	O
terminal	O
protein	O
kinase	O
"),"	O
and	O
p38	O
","	O
plays	O
an	O
essential	O
role	O
in	O
transduction	O
extracellular	O
signals	O
to	O
cellular	O
response	O
via	O
a	O
cascade	O
of	O
phosphorylation	O
events	O
[	O
19	O
].	O
SIRT1	O
is	O
an	O
NAD	O
+-	O
dependent	O
class	O
III	O
histone	O
deacetylase	O
","	O
which	O
regulates	O
cellular	O
metabolism	O
","	O
stress	O
resistance	O
","	O
cellular	O
survival	O
","	O
cellular	O
senescence	O
/	O
aging	O
","	O
and	O
inflammation	O
-	O
immune	O
function	O
[	O
20	O
].	O
It	O
has	O
been	O
shown	O
that	O
SIRT1	O
overexpression	O
in	O
neurons	O
promotes	O
neurite	O
outgrowth	O
and	O
cell	O
survival	O
[	O
21	O
].	O
Recently	O
","	O
it	O
has	O
been	O
reported	O
that	O
the	O
combination	O
of	O
tyrosol	B-Chemical
","	O
a	O
natural	O
antioxidant	O
phenol	B-Chemical
","	O
and	O
S	B-Chemical
-	I-Chemical
adenosylmethionine	I-Chemical
increased	O
SIRT1	O
protein	O
and	O
its	O
nuclear	O
relocalization	O
in	O
ethanol	B-Chemical
-	O
treated	O
HepG2	O
cells	O
and	O
protected	O
cells	O
from	O
oxidative	O
stress	O
[	O
22	O
].	O
Nrf2	O
-	O
ARE	O
is	O
a	O
primary	O
sensor	O
and	O
oxidative	O
stress	O
regulator	O
[	O
23	O
].	O
Nrf2	O
activation	O
upregulates	O
the	O
expression	O
of	O
a	O
group	O
of	O
functionally	O
diverse	O
cytoprotective	O
proteins	O
","	O
such	O
as	O
NAD	O
(	O
P	O
)	O
H	O
","	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
oxidoreductase	O
1	O
(	O
NQO1	O
"),"	O
superoxide	O
dismutase	O
(	O
SOD	O
"),"	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
"),"	O
glutathione	O
peroxidase	O
(	O
GPx	O
"),"	O
heme	O
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
"),"	O
glutamate	O
-	O
cysteine	O
ligase	O
(	O
GCL	O
"),"	O
catalase	O
","	O
and	O
thioredoxin	O
[	O
16	O
].	O
Fisetin	B-Chemical
(	O
3	B-Chemical
","	I-Chemical
7	I-Chemical
","	I-Chemical
3	I-Chemical
"â€²,"	I-Chemical
4	I-Chemical
â€²-	I-Chemical
tetrahydroxyflavone	I-Chemical
","	O
Figure	O
1a	O
)	O
is	O
a	O
flavonol	B-Chemical
with	O
a	O
wide	O
range	O
of	O
bioactivites	O
","	O
including	O
antioxidant	O
","	O
anti	O
-	O
inflammatory	O
","	O
anti	O
-	O
cancer	O
and	O
neuroprotective	O
effects	O
.	O
It	O
has	O
been	O
reported	O
that	O
fisetin	B-Chemical
protects	O
rat	O
pheochromocytoma	O
PC12	O
cells	O
from	O
MPP	B-Chemical
+-	I-Chemical
induced	O
toxicity	O
by	O
upregulation	O
of	O
the	O
expression	O
of	O
Nrf2	O
-	O
induced	O
antioxidant	O
enzymes	O
[	O
24	O
].	O
Fisetin	B-Chemical
has	O
been	O
shown	O
to	O
promote	O
neuronal	O
differentiation	O
and	O
long	O
-	O
term	O
potentiation	O
","	O
maintain	O
cognitive	O
function	O
and	O
enhance	O
memory	O
in	O
an	O
animal	O
model	O
[	O
25	O
","	O
26	O
","	O
27	O
].	O
Fisetin	B-Chemical
also	O
protects	O
PC12	O
cells	O
from	O
hypoxia	O
-	O
induced	O
PC12	O
cell	O
death	O
via	O
activating	O
the	O
HIF1Î±	O
","	O
MAPK	O
and	O
PI3K	O
/	O
Akt	O
signaling	O
pathways	O
[	O
28	O
].	O
Taken	O
together	O
","	O
these	O
studies	O
show	O
that	O
fisetin	B-Chemical
is	O
a	O
potential	O
compound	O
with	O
neuroprotective	O
activity	O
.	O
However	O
","	O
the	O
cytoprotective	O
effect	O
of	O
fisetin	B-Chemical
on	O
neuronal	O
cells	O
exposed	O
to	O
ER	O
stress	O
inducer	O
is	O
still	O
unknown	O
.	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
dissect	O
the	O
molecular	O
and	O
biochemical	O
pathways	O
involved	O
in	O
fisetin	B-Chemical
-	O
mediated	O
cytoprotection	O
in	O
Tm	B-Chemical
-	O
treated	O
PC12	O
cells	O
.	O
2	O
.	O
Results	O
2	O
.	O
1	O
.	O
Fisetin	B-Chemical
Protects	O
PC12	O
Cells	O
from	O
Tm	B-Chemical
-	O
Mediated	O
Cell	O
Death	O
It	O
was	O
reported	O
that	O
fisetin	B-Chemical
at	O
low	O
concentrations	O
provides	O
neuroprotection	O
in	O
several	O
models	O
[	O
25	O
","	O
26	O
","	O
27	O
","	O
28	O
","	O
29	O
"],"	O
while	O
at	O
high	O
concentrations	O
it	O
induces	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
production	O
","	O
ER	O
stress	O
and	O
cell	O
death	O
in	O
some	O
tumor	O
cells	O
[	O
30	O
","	O
31	O
","	O
32	O
].	O
We	O
found	O
that	O
treatment	O
of	O
PC12	O
cells	O
with	O
fisetin	B-Chemical
(	O
up	O
to	O
40	O
ÂµM	O
)	O
alone	O
for	O
16	O
h	O
did	O
not	O
alter	O
cell	O
viability	O
(	O
Figure	O
1b	O
).	O
It	O
is	O
known	O
that	O
Tm	B-Chemical
blocks	O
N	O
-	O
glycosylation	O
of	O
proteins	O
","	O
thus	O
leading	O
to	O
ER	O
stress	O
[	O
3	O
]	O
and	O
ultimately	O
apoptosis	O
in	O
PC12	O
cells	O
[	O
33	O
","	O
34	O
].	O
Figure	O
1c	O
shows	O
that	O
Tm	B-Chemical
(	O
1	O
â€“	O
5	O
Âµg	O
/	O
mL	O
)	O
caused	O
30	O
â€“	O
40	O
%	O
PC12	O
cell	O
death	O
after	O
16	O
h	O
.	O
Treatment	O
of	O
PC12	O
cells	O
with	O
fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
dose	O
-	O
dependently	O
reversed	O
1	O
Âµg	O
/	O
mL	O
Tm	B-Chemical
-	O
mediated	O
cell	O
death	O
(	O
Figure	O
1d	O
).	O
The	O
cytoprotective	O
effects	O
of	O
fisetin	B-Chemical
were	O
reconfirmed	O
by	O
Calcein	B-Chemical
AM	I-Chemical
viability	O
dye	O
staining	O
(	O
Figure	O
S1	O
)	O
[	O
35	O
].	O
2	O
.	O
2	O
.	O
Fisetin	B-Chemical
Inhibits	O
Tm	B-Chemical
-	O
Mediated	O
Apoptotic	O
and	O
Autophagic	O
Marker	O
Protein	O
Expression	O
Poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
-	O
1	O
(	O
PARP	O
-	O
1	O
)	O
is	O
specifically	O
proteolysed	O
by	O
caspases	O
to	O
a	O
24	O
and	O
a	O
89	O
kDa	O
fragment	O
during	O
the	O
execution	O
of	O
the	O
apoptotic	O
program	O
[	O
36	O
].	O
Figure	O
2a	O
shows	O
that	O
treatment	O
of	O
PC12	O
cells	O
with	O
fisetin	B-Chemical
(	O
10	O
â€“	O
20	O
ÂµM	O
)	O
in	O
the	O
absence	O
of	O
Tm	B-Chemical
for	O
16	O
h	O
decreased	O
PARP	O
-	O
1	O
processing	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
","	O
although	O
it	O
did	O
not	O
significantly	O
change	O
cell	O
viability	O
(	O
Figure	O
1b	O
).	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
treatment	O
increased	O
PARP	O
-	O
1	O
cleavage	O
as	O
compared	O
with	O
no	O
Tm	B-Chemical
control	O
","	O
and	O
co	O
-	O
treatment	O
with	O
fisetin	B-Chemical
counteracted	O
this	O
reaction	O
(	O
Figure	O
2b	O
).	O
Band	O
quantification	O
shows	O
that	O
Tm	B-Chemical
induced	O
a	O
significant	O
increase	O
in	O
the	O
ratio	O
of	O
cleaved	O
/	O
full	O
length	O
PARP	O
-	O
1	O
","	O
and	O
fisetin	B-Chemical
(	O
10	O
â€’	O
20	O
ÂµM	O
)	O
dose	O
-	O
dependently	O
attenuated	O
Tm	B-Chemical
-	O
mediated	O
cleavage	O
.	O
This	O
result	O
indicates	O
that	O
fisetin	B-Chemical
serves	O
as	O
an	O
anti	O
-	O
apoptotic	O
agent	O
in	O
PC12	O
cells	O
.	O
Autophagy	O
and	O
apoptosis	O
are	O
important	O
and	O
interconnected	O
stress	O
response	O
mechanisms	O
.	O
Microtubule	O
-	O
associated	O
protein	O
1	O
light	O
chain	O
3	O
(	O
LC3	O
)	O
is	O
the	O
mammalian	O
ortholog	O
of	O
yeast	O
Atg8	O
","	O
and	O
is	O
required	O
for	O
the	O
formation	O
of	O
autophagosome	O
membrane	O
.	O
The	O
conversion	O
of	O
LC3Î²	O
from	O
LC3Î²	O
-	O
I	O
(	O
free	O
form	O
","	O
18	O
kDa	O
)	O
to	O
LC3Î²	O
-	O
II	O
(	O
phosphatidylethanolamine	B-Chemical
-	O
conjugated	O
form	O
","	O
16	O
kDa	O
)	O
is	O
an	O
initiating	O
step	O
in	O
autophagy	O
in	O
mammals	O
[	O
37	O
].	O
PC12	O
cells	O
cultured	O
in	O
the	O
absence	O
of	O
Tm	B-Chemical
did	O
not	O
cause	O
the	O
conversion	O
of	O
LC3Î²	O
(	O
Figure	O
2a	O
).	O
In	O
comparison	O
","	O
Figure	O
2c	O
shows	O
that	O
an	O
increase	O
in	O
the	O
LC3Î²	O
-	O
II	O
in	O
PC12	O
cells	O
was	O
observed	O
in	O
the	O
presence	O
of	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
"),"	O
confirming	O
that	O
autophagy	O
was	O
induced	O
by	O
Tm	B-Chemical
.	O
Co	O
-	O
treatment	O
of	O
cells	O
with	O
10	O
and	O
20	O
ÂµM	O
fisetin	B-Chemical
dose	O
-	O
dependently	O
reduced	O
Tm	B-Chemical
-	O
mediated	O
increase	O
in	O
the	O
ratio	O
of	O
LC3Î²	O
-	O
II	O
/	O
LC3Î²	O
-	O
I	O
.	O
The	O
formation	O
of	O
Atg12	O
â€“	O
Atg5	O
conjugate	O
is	O
a	O
key	O
factor	O
in	O
regulating	O
the	O
formation	O
of	O
autophagosome	O
[	O
38	O
].	O
In	O
parallel	O
to	O
the	O
results	O
found	O
for	O
LC3Î²	O
conversion	O
","	O
Tm	B-Chemical
treatment	O
for	O
16	O
h	O
also	O
enhanced	O
Atg12	O
â€“	O
Atg5	O
conjugate	O
formation	O
and	O
co	O
-	O
treatment	O
of	O
fisetin	B-Chemical
(	O
10	O
and	O
20	O
ÂµM	O
)	O
blocked	O
its	O
formation	O
.	O
This	O
result	O
suggests	O
that	O
fisetin	B-Chemical
represses	O
Tm	B-Chemical
-	O
mediated	O
autophagy	O
in	O
PC12	O
cells	O
.	O
2	O
.	O
3	O
.	O
Fisetin	B-Chemical
Inhibits	O
Tm	B-Chemical
-	O
Mediated	O
Endoplasmic	O
Reticulum	O
(	O
ER	O
)	O
Stress	O
Gene	O
Expression	O
We	O
further	O
investigated	O
the	O
effect	O
of	O
fisetin	B-Chemical
on	O
Tm	B-Chemical
-	O
mediated	O
ER	O
stress	O
response	O
.	O
The	O
first	O
target	O
was	O
X	O
-	O
box	O
-	O
binding	O
protein	O
1	O
(	O
XBP1	O
)	O
mRNA	O
splicing	O
","	O
a	O
critical	O
signal	O
transducer	O
in	O
the	O
unfolded	O
protein	O
response	O
.	O
The	O
levels	O
of	O
the	O
unspliced	O
XBP1	O
(	O
XBP1u	O
)	O
and	O
active	O
spliced	O
XBP1	O
(	O
XBP1s	O
)	O
mRNA	O
were	O
measured	O
by	O
RT	O
-	O
PCR	O
and	O
subsequent	O
polyacrylamide	B-Chemical
electrophoresis	O
.	O
It	O
was	O
found	O
that	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
treatment	O
significantly	O
increased	O
XBP1	O
splicing	O
","	O
but	O
co	O
-	O
treatment	O
with	O
fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
did	O
not	O
change	O
the	O
relative	O
level	O
of	O
XBP1s	O
to	O
that	O
of	O
XBP1u	O
(	O
Figure	O
3a	O
).	O
A	O
similar	O
phenomenon	O
was	O
also	O
observed	O
for	O
eIF2Î±	O
phosphorylation	O
","	O
another	O
ER	O
stress	O
signal	O
transducer	O
upstream	O
of	O
ATF4	O
.	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
treatment	O
markedly	O
induced	O
eIF2Î±	O
phosphorylation	O
","	O
while	O
fisetin	B-Chemical
(	O
10	O
â€“	O
20	O
ÂµM	O
)	O
did	O
not	O
change	O
its	O
level	O
(	O
Figure	O
3b	O
).	O
These	O
results	O
indicate	O
that	O
fisetin	B-Chemical
did	O
not	O
affect	O
Tm	B-Chemical
-	O
activated	O
IRE1	O
-	O
XBP1	O
or	O
PERK	O
-	O
eIF2	O
pathway	O
.	O
We	O
then	O
investigated	O
whether	O
fisetin	B-Chemical
affected	O
Tm	B-Chemical
-	O
mediated	O
ER	O
-	O
target	O
gene	O
expression	O
.	O
GRP78	O
and	O
CHOP	O
are	O
canonically	O
upregulated	O
during	O
apoptosis	O
induced	O
by	O
ER	O
stress	O
.	O
It	O
was	O
found	O
that	O
Tm	B-Chemical
treatment	O
caused	O
a	O
strong	O
increase	O
in	O
GRP78	O
mRNA	O
expression	O
","	O
up	O
by	O
~	O
20	O
-	O
fold	O
","	O
while	O
co	O
-	O
treatment	O
with	O
fisetin	B-Chemical
(	O
10	O
â€“	O
20	O
ÂµM	O
)	O
dose	O
-	O
dependently	O
reduced	O
its	O
expression	O
and	O
90	O
%	O
inhibition	O
was	O
noted	O
at	O
20	O
ÂµM	O
(	O
Figure	O
3c	O
).	O
Figure	O
3d	O
shows	O
that	O
Tm	B-Chemical
induced	O
CHOP	O
mRNA	O
by	O
~	O
22	O
-	O
fold	O
and	O
co	O
-	O
treatment	O
with	O
15	O
and	O
20	O
ÂµM	O
fisetin	B-Chemical
could	O
dose	O
-	O
dependently	O
attenuate	O
the	O
upregulation	O
by	O
77	O
%	O
and	O
88	O
"%,"	O
respectively	O
.	O
It	O
has	O
been	O
reported	O
that	O
tribbles	O
-	O
related	O
protein	O
3	O
(	O
TRB3	O
"),"	O
a	O
target	O
gene	O
of	O
CHOP	O
","	O
was	O
responsible	O
for	O
Tm	B-Chemical
-	O
mediated	O
PC12	O
apoptosis	O
[	O
39	O
].	O
In	O
parallel	O
to	O
the	O
results	O
found	O
for	O
CHOP	O
mRNA	O
expression	O
","	O
Figure	O
3e	O
shows	O
that	O
treatment	O
of	O
PC12	O
cells	O
with	O
1	O
Âµg	O
/	O
mL	O
Tm	B-Chemical
increased	O
TRB3	O
mRNA	O
expression	O
by	O
24	O
.	O
7	O
-	O
fold	O
","	O
and	O
15	O
and	O
20	O
ÂµM	O
fisetin	B-Chemical
could	O
dose	O
-	O
dependently	O
attenuate	O
its	O
upregulation	O
.	O
In	O
conclusion	O
","	O
fisetin	B-Chemical
(	O
10	O
â€“	O
20	O
ÂµM	O
)	O
inhibited	O
Tm	B-Chemical
-	O
upregulated	O
UPR	O
mRNA	O
expression	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
Western	O
blotting	O
reveals	O
that	O
treatment	O
of	O
PC12	O
cells	O
with	O
Tm	B-Chemical
modestly	O
increased	O
GRP78	O
and	O
CHOP	O
protein	O
expression	O
.	O
Fisetin	B-Chemical
dose	O
-	O
dependently	O
attenuated	O
GRP78	O
expression	O
;	O
while	O
its	O
effect	O
on	O
Tm	B-Chemical
-	O
mediated	O
CHOP	O
protein	O
expression	O
was	O
less	O
prominent	O
(	O
Figure	O
3f	O
).	O
The	O
less	O
obvious	O
inhibition	O
on	O
CHOP	O
protein	O
expression	O
could	O
be	O
due	O
to	O
the	O
poor	O
detection	O
sensitivity	O
and	O
specificity	O
of	O
antibodies	O
against	O
rat	O
CHOP	O
.	O
2	O
.	O
4	O
.	O
Fisetin	B-Chemical
Scavenges	O
Reactive	B-Chemical
Oxygen	I-Chemical
Species	I-Chemical
(	O
ROS	B-Chemical
)	O
Production	O
It	O
has	O
been	O
reported	O
that	O
Tm	B-Chemical
induces	O
apoptosis	O
in	O
leukemia	O
U937	O
cells	O
through	O
ROS	B-Chemical
generation	O
[	O
40	O
].	O
Figure	O
4a	O
shows	O
that	O
treatment	O
of	O
PC12	O
cells	O
with	O
fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
alone	O
for	O
16	O
h	O
could	O
decrease	O
ROS	B-Chemical
level	O
by	O
about	O
15	O
â€“	O
20	O
%.	O
Treatment	O
of	O
PC12	O
cells	O
with	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
for	O
16	O
h	O
modestly	O
increased	O
intracellular	O
ROS	B-Chemical
production	O
by	O
about	O
11	O
%	O
(	O
Figure	O
4b	O
).	O
Fisetin	B-Chemical
(	O
10	O
â€“	O
20	O
ÂµM	O
)	O
and	O
N	B-Chemical
-	I-Chemical
acetyl	I-Chemical
-	I-Chemical
cysteine	I-Chemical
(	O
NAC	B-Chemical
)	O
(	O
1	O
mM	O
"),"	O
a	O
well	O
-	O
known	O
antioxidant	O
","	O
completely	O
abolished	O
Tm	B-Chemical
-	O
mediated	O
ROS	B-Chemical
overproduction	O
to	O
a	O
level	O
lower	O
than	O
that	O
of	O
vehicle	O
control	O
.	O
Current	O
data	O
support	O
the	O
notion	O
that	O
fisetin	B-Chemical
serves	O
as	O
a	O
ROS	B-Chemical
scavenger	O
in	O
PC12	O
cells	O
[	O
28	O
].	O
2	O
.	O
5	O
.	O
Fisetin	B-Chemical
Induces	O
Nrf2	O
-	O
Driven	O
Oxidative	O
Stress	O
Response	O
Gene	O
Expression	O
Nrf2	O
(	O
nuclear	O
E2	O
related	O
factor	O
2	O
)-	O
ARE	O
(	O
antioxidant	O
response	O
element	O
)	O
is	O
a	O
primary	O
sensor	O
and	O
oxidative	O
stress	O
regulator	O
[	O
23	O
].	O
Fisetin	B-Chemical
(	O
10	O
ÂµM	O
)	O
was	O
reported	O
to	O
cause	O
activation	O
of	O
Nrf2	O
-	O
ARE	O
and	O
upregulation	O
of	O
heme	O
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
"),"	O
cystine	O
/	O
glutamate	O
transporter	O
(	O
xCT	O
/	O
SLC7A11	O
)	O
and	O
glutamate	O
cysteine	O
ligase	O
(	O
GCL	O
)	O
in	O
HT22	O
cells	O
[	O
25	O
","	O
41	O
].	O
Figure	O
5a	O
shows	O
that	O
fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
treatment	O
for	O
6	O
h	O
significantly	O
induced	O
HO	O
-	O
1	O
mRNA	O
expression	O
in	O
an	O
inverted	O
U	O
curve	O
","	O
and	O
the	O
greatest	O
increase	O
(	O
22	O
-	O
fold	O
)	O
was	O
found	O
for	O
10	O
ÂµM	O
.	O
Consequently	O
","	O
HO	O
-	O
1	O
protein	O
expression	O
was	O
significantly	O
stimulated	O
after	O
fisetin	B-Chemical
treatment	O
(	O
Figure	O
5b	O
).	O
Band	O
quantification	O
shows	O
that	O
a	O
hormetic	O
dose	O
â€“	O
response	O
curve	O
was	O
noted	O
after	O
8	O
h	O
treatment	O
and	O
~	O
4	O
.	O
5	O
-	O
fold	O
induction	O
was	O
caused	O
by	O
10	O
and	O
15	O
ÂµM	O
fisetin	B-Chemical
(	O
Figure	O
5c	O
).	O
Treatment	O
with	O
fisetin	B-Chemical
for	O
16	O
h	O
induced	O
less	O
HO	O
-	O
1	O
protein	O
expression	O
than	O
treatment	O
for	O
8	O
h	O
","	O
and	O
plateau	O
induction	O
(~	O
3	O
.	O
7	O
-	O
fold	O
)	O
was	O
reached	O
by	O
doses	O
equal	O
to	O
or	O
higher	O
than	O
15	O
ÂµM	O
.	O
Parallel	O
induction	O
effects	O
were	O
also	O
observed	O
for	O
Nrf2	O
-	O
driven	O
mRNA	O
expression	O
of	O
glutathione	B-Chemical
metabolism	O
related	O
genes	O
","	O
such	O
as	O
GCLC	O
(	O
catalytic	O
subunit	O
of	O
GCL	O
"),"	O
GCLM	O
(	O
modifier	O
subunit	O
of	O
GCL	O
)	O
and	O
xCT	O
(	O
Figure	O
5d	O
â€“	O
f	O
).	O
These	O
results	O
suggest	O
that	O
fisetin	B-Chemical
induced	O
a	O
hormetic	O
effect	O
on	O
Nrf2	O
-	O
driven	O
mRNA	O
expression	O
of	O
Phase	O
II	O
antioxidant	O
enzymes	O
.	O
We	O
further	O
investigated	O
how	O
fisetin	B-Chemical
affected	O
Nrf2	O
-	O
driven	O
gene	O
expression	O
in	O
the	O
presence	O
of	O
Tm	B-Chemical
.	O
Figure	O
6a	O
shows	O
that	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
only	O
slightly	O
stimulated	O
HO	O
-	O
1	O
mRNA	O
expression	O
by	O
1	O
.	O
84	O
-	O
fold	O
","	O
and	O
co	O
-	O
treatment	O
with	O
fisetin	B-Chemical
(	O
10	O
â€“	O
20	O
ÂµM	O
)	O
enhanced	O
HO	O
-	O
1	O
upregulation	O
dose	O
-	O
dependently	O
.	O
Figure	O
6b	O
shows	O
that	O
in	O
parallel	O
to	O
the	O
results	O
observed	O
in	O
mRNA	O
expression	O
","	O
treatment	O
of	O
PC12	O
cells	O
with	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
for	O
16	O
h	O
slightly	O
upregulated	O
HO	O
-	O
1	O
protein	O
expression	O
and	O
fisetin	B-Chemical
enhanced	O
HO	O
-	O
1	O
protein	O
expression	O
dose	O
-	O
dependently	O
.	O
To	O
further	O
investigate	O
whether	O
the	O
increased	O
survival	O
rate	O
seen	O
in	O
fisetin	B-Chemical
-	O
treated	O
cells	O
was	O
dependent	O
on	O
HO	O
-	O
1	O
activity	O
","	O
PC12	O
cells	O
were	O
treated	O
with	O
ZnPP	B-Chemical
(	O
zinc	B-Chemical
protoporphyrin	I-Chemical
IX	I-Chemical
"),"	O
a	O
potent	O
competitive	O
inhibitor	O
of	O
HO	O
enzyme	O
activity	O
","	O
for	O
30	O
min	O
","	O
followed	O
by	O
various	O
concentrations	O
of	O
fisetin	B-Chemical
for	O
30	O
min	O
before	O
exposure	O
to	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
for	O
16	O
h	O
.	O
Figure	O
6c	O
shows	O
that	O
the	O
addition	O
of	O
ZnPP	B-Chemical
(	O
0	O
.	O
25	O
and	O
1	O
ÂµM	O
)	O
caused	O
cytotoxicity	O
on	O
PC12	O
cells	O
in	O
all	O
groups	O
","	O
and	O
attenuated	O
the	O
fisetin	B-Chemical
-	O
mediated	O
cytoprotective	O
effect	O
dose	O
-	O
dependently	O
.	O
These	O
results	O
indicate	O
that	O
HO	O
-	O
1	O
activity	O
may	O
provide	O
a	O
survival	O
advantage	O
in	O
PC12	O
cells	O
.	O
We	O
then	O
turned	O
to	O
investigate	O
how	O
Tm	B-Chemical
affects	O
GSH	B-Chemical
-	O
related	O
gene	O
expression	O
.	O
The	O
expressions	O
of	O
GCLC	O
and	O
GCLM	O
were	O
not	O
affected	O
by	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
(	O
Figure	O
6d	O
","	O
e	O
).	O
Fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
induced	O
GCLM	O
expression	O
dose	O
-	O
dependently	O
(	O
Figure	O
6e	O
"),"	O
while	O
GCLC	O
expression	O
was	O
impacted	O
following	O
a	O
hormetic	O
dose	O
â€“	O
response	O
curve	O
(	O
Figure	O
6d	O
).	O
It	O
was	O
reported	O
that	O
xCT	O
expression	O
was	O
upregulated	O
by	O
both	O
Nrf2	O
and	O
ATF4	O
[	O
42	O
].	O
We	O
found	O
that	O
","	O
different	O
from	O
other	O
Nrf2	O
-	O
driven	O
genes	O
","	O
Tm	B-Chemical
strongly	O
stimulated	O
xCT	O
expression	O
by	O
10	O
-	O
fold	O
.	O
In	O
parallel	O
to	O
the	O
results	O
observed	O
in	O
the	O
absence	O
of	O
Tm	B-Chemical
","	O
fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
enhanced	O
xCT	O
overexpression	O
in	O
an	O
inverted	O
U	O
response	O
curve	O
in	O
the	O
presence	O
of	O
Tm	B-Chemical
(	O
Figure	O
6f	O
).	O
2	O
.	O
6	O
.	O
Fisetin	B-Chemical
Activates	O
Mitogen	O
-	O
Activated	O
Protein	O
Kinase	O
(	O
MAPK	O
)	O
Signaling	O
Pathways	O
Induction	O
of	O
Nrf2	O
by	O
flavonoids	B-Chemical
has	O
been	O
associated	O
with	O
the	O
activation	O
of	O
various	O
members	O
of	O
the	O
MAPK	O
family	O
[	O
43	O
].	O
To	O
investigate	O
how	O
fisetin	B-Chemical
affects	O
MAPK	O
activation	O
","	O
PC12	O
cells	O
were	O
treated	O
with	O
10	O
","	O
15	O
and	O
20	O
Î¼M	O
fisetin	B-Chemical
for	O
30	O
min	O
prior	O
to	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
exposure	O
for	O
2	O
and	O
4	O
h	O
","	O
and	O
cell	O
lysates	O
were	O
immunoblotted	O
with	O
specific	O
antibodies	O
.	O
Figure	O
7a	O
","	O
b	O
show	O
that	O
treatment	O
of	O
1	O
Âµg	O
/	O
mL	O
Tm	B-Chemical
for	O
2	O
and	O
4	O
h	O
induced	O
ERK	O
and	O
JNK	O
activation	O
","	O
but	O
not	O
p38	O
MAPK	O
activation	O
.	O
Co	O
-	O
treatment	O
with	O
fisetin	B-Chemical
(	O
10	O
â€“	O
20	O
ÂµM	O
)	O
significantly	O
augmented	O
ERK	O
","	O
JNK	O
and	O
p38	O
MAPK	O
activation	O
with	O
different	O
patterns	O
:	O
enhancement	O
of	O
ERK	O
and	O
JNK	O
activation	O
was	O
noted	O
during	O
the	O
test	O
period	O
","	O
while	O
p38	O
MAPK	O
phosphorylation	O
was	O
only	O
found	O
2	O
h	O
after	O
Tm	B-Chemical
insult	O
.	O
To	O
study	O
the	O
cytoprotective	O
role	O
of	O
the	O
MAPK	O
pathways	O
","	O
PC12	O
cells	O
were	O
pre	O
-	O
incubated	O
for	O
30	O
min	O
with	O
5	O
ÂµM	O
inhibitor	O
for	O
each	O
pathway	O
","	O
U0126	B-Chemical
(	O
ERK	O
"),"	O
SP600125	B-Chemical
(	O
JNK	O
)	O
and	O
SB203580	B-Chemical
(	O
p38	O
MAPK	O
"),"	O
and	O
5	O
â€“	O
20	O
ÂµM	O
fisetin	B-Chemical
was	O
then	O
added	O
30	O
min	O
prior	O
to	O
Tm	B-Chemical
(	O
1	O
ÂµM	O
)	O
exposure	O
for	O
16	O
h	O
.	O
Figure	O
7c	O
","	O
d	O
show	O
that	O
addition	O
of	O
JNK	O
inhibitor	O
SP600125	B-Chemical
and	O
p38	O
MAPK	O
specific	O
inhibitor	O
SB203580	B-Chemical
significantly	O
exacerbated	O
Tm	B-Chemical
-	O
mediated	O
cytotoxicity	O
and	O
attenuated	O
the	O
cytoprotective	O
effects	O
of	O
fisetin	B-Chemical
.	O
On	O
the	O
other	O
hand	O
","	O
MEK	O
inhibitor	O
U0126	B-Chemical
did	O
not	O
exert	O
any	O
effect	O
on	O
cell	O
viability	O
in	O
the	O
presence	O
of	O
Tm	B-Chemical
(	O
Figure	O
S2	O
).	O
These	O
results	O
indicate	O
that	O
JNK	O
and	O
p38	O
MAPK	O
signaling	O
pathways	O
","	O
but	O
not	O
ERK	O
","	O
may	O
be	O
associated	O
with	O
the	O
cytoprotective	O
effect	O
of	O
fisetin	B-Chemical
.	O
2	O
.	O
7	O
.	O
Contribution	O
of	O
JNK	O
and	O
p38	O
MAPK	O
Pathways	O
to	O
ER	O
Stress	O
and	O
Nrf2	O
-	O
Driven	O
Gene	O
Expression	O
We	O
further	O
investigated	O
whether	O
JNK	O
and	O
p38	O
MAPK	O
are	O
involved	O
in	O
fisetin	B-Chemical
-	O
mediated	O
oxidative	O
stress	O
response	O
gene	O
expression	O
.	O
Figure	O
8a	O
","	O
b	O
show	O
that	O
SB203580	B-Chemical
significantly	O
attenuated	O
fisetin	B-Chemical
-	O
enhanced	O
HO	O
-	O
1	O
and	O
xCT	O
expression	O
.	O
This	O
implies	O
that	O
fisetin	B-Chemical
-	O
activated	O
p38	O
MAPK	O
signaling	O
may	O
be	O
involved	O
in	O
upregulation	O
of	O
Nrf2	O
-	O
driven	O
gene	O
expression	O
.	O
Furthermore	O
","	O
we	O
investigated	O
the	O
role	O
of	O
JNK	O
and	O
p38	O
MAPK	O
on	O
ER	O
stress	O
responsive	O
gene	O
expression	O
.	O
Figure	O
8c	O
","	O
d	O
show	O
that	O
Tm	B-Chemical
-	O
mediated	O
CHOP	O
expression	O
was	O
increased	O
by	O
both	O
SP600125	B-Chemical
and	O
SB203580	B-Chemical
","	O
but	O
GRP78	O
was	O
only	O
enhanced	O
by	O
SP600125	B-Chemical
.	O
Furthermore	O
","	O
the	O
20	O
ÂµM	O
fisetin	B-Chemical
-	O
inhibited	O
expressions	O
of	O
CHOP	O
and	O
GRP78	O
were	O
reversed	O
by	O
both	O
SP600125	B-Chemical
and	O
SB203580	B-Chemical
.	O
This	O
indicates	O
that	O
both	O
fisetin	B-Chemical
-	O
mediated	O
JNK	O
and	O
p38	O
MAPK	O
activation	O
may	O
participate	O
in	O
down	O
-	O
regulation	O
of	O
ER	O
stress	O
.	O
This	O
result	O
is	O
in	O
agreement	O
with	O
a	O
previous	O
finding	O
that	O
Tm	B-Chemical
-	O
induced	O
p38	O
MAPK	O
activation	O
may	O
serve	O
as	O
an	O
upstream	O
negative	O
regulator	O
of	O
ER	O
stress	O
","	O
and	O
confer	O
adaptive	O
cytoprotection	O
against	O
Tm	B-Chemical
-	O
mediated	O
cell	O
injury	O
[	O
35	O
].	O
2	O
.	O
8	O
.	O
Effect	O
of	O
Fisetin	B-Chemical
on	O
Sirtuin	O
1	O
(	O
SIRT1	O
)	O
Expression	O
Fisetin	B-Chemical
is	O
a	O
SIRT1	O
activator	O
that	O
extends	O
lifespan	O
in	O
lower	O
organisms	O
[	O
44	O
].	O
Fisetin	B-Chemical
also	O
induces	O
SIRT1	O
expression	O
and	O
inhibits	O
early	O
adipogenesis	O
in	O
3T3	O
-	O
L1	O
cells	O
[	O
45	O
].	O
We	O
found	O
here	O
that	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
treatment	O
for	O
16	O
h	O
significantly	O
decreased	O
SIRT1	O
expression	O
","	O
but	O
co	O
-	O
treatment	O
with	O
fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
reversed	O
the	O
reduction	O
(	O
Figure	O
9a	O
","	O
b	O
).	O
To	O
further	O
examine	O
the	O
cytoprotective	O
role	O
of	O
SIRT1	O
","	O
we	O
examined	O
whether	O
the	O
increased	O
survival	O
rate	O
seen	O
in	O
fisetin	B-Chemical
-	O
treated	O
cells	O
was	O
dependent	O
on	O
SIRT1	O
activity	O
.	O
We	O
pre	O
-	O
treated	O
cells	O
with	O
sirtinol	B-Chemical
(	O
SIRT1	O
activation	O
inhibitor	O
)	O
for	O
30	O
min	O
","	O
followed	O
by	O
fisetin	B-Chemical
for	O
30	O
min	O
before	O
exposure	O
to	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
for	O
16	O
h	O
.	O
Figure	O
9c	O
shows	O
that	O
the	O
addition	O
of	O
sirtinol	B-Chemical
(	O
15	O
ÂµM	O
)	O
did	O
not	O
significantly	O
cause	O
cytotoxicity	O
in	O
PC12	O
cells	O
in	O
the	O
absence	O
of	O
Tm	B-Chemical
.	O
However	O
","	O
sirtinol	B-Chemical
completely	O
blocked	O
the	O
fisetin	B-Chemical
-	O
mediated	O
cytoprotective	O
effect	O
against	O
Tm	B-Chemical
.	O
These	O
results	O
indicate	O
that	O
SIRT1	O
activity	O
is	O
involved	O
in	O
fisetin	B-Chemical
-	O
induced	O
cytoprotection	O
.	O
3	O
.	O
Discussion	O
Phytochemicals	O
are	O
being	O
studied	O
for	O
the	O
therapeutic	O
usage	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
neurodegenerative	O
disorders	O
.	O
Fisetin	B-Chemical
","	O
a	O
flavonoid	B-Chemical
existing	O
in	O
many	O
different	O
plant	O
-	O
based	O
food	O
products	O
","	O
has	O
been	O
reported	O
to	O
possess	O
antioxidant	O
","	O
neurotrophic	O
and	O
neuroprotective	O
activities	O
by	O
directly	O
scavenging	O
ROS	B-Chemical
or	O
affecting	O
signaling	O
pathways	O
in	O
the	O
maintenance	O
of	O
neuronal	O
function	O
and	O
cell	O
survival	O
[	O
25	O
","	O
26	O
","	O
27	O
","	O
28	O
].	O
However	O
","	O
little	O
is	O
known	O
regarding	O
how	O
fisetin	B-Chemical
affects	O
signaling	O
molecules	O
in	O
response	O
to	O
ER	O
stress	O
in	O
neuronal	O
cells	O
.	O
We	O
found	O
here	O
that	O
Tm	B-Chemical
caused	O
PC12	O
cell	O
death	O
.	O
Addition	O
of	O
fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
significantly	O
reversed	O
the	O
cytotoxicity	O
.	O
We	O
also	O
tested	O
whether	O
fisetin	B-Chemical
could	O
protect	O
PC12	O
cells	O
from	O
another	O
ER	O
stress	O
inducer	O
","	O
sesquiterpene	B-Chemical
lactone	I-Chemical
thapsigargin	I-Chemical
(	O
Tg	B-Chemical
).	O
It	O
was	O
found	O
that	O
Tg	B-Chemical
(	O
0	O
.	O
3	O
Âµg	O
/	O
mL	O
)	O
caused	O
45	O
%	O
PC12	O
cell	O
death	O
and	O
co	O
-	O
treatment	O
with	O
fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
exerted	O
a	O
dose	O
-	O
dependent	O
cytoprotective	O
effect	O
.	O
The	O
above	O
results	O
indicate	O
that	O
fisetin	B-Chemical
can	O
prevent	O
ER	O
stress	O
-	O
induced	O
cell	O
death	O
in	O
PC12	O
cells	O
(	O
Figure	O
S3	O
).	O
Furthermore	O
","	O
we	O
also	O
found	O
that	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
caused	O
33	O
%	O
adherent	O
PC12	O
cell	O
death	O
","	O
and	O
only	O
those	O
cells	O
supplemented	O
with	O
15	O
and	O
20	O
ÂµM	O
fisetin	B-Chemical
could	O
slightly	O
attenuate	O
the	O
cytotoxicity	O
","	O
indicating	O
that	O
the	O
cytoprotective	O
effect	O
of	O
fisetin	B-Chemical
is	O
valid	O
to	O
PC12	O
cells	O
grown	O
in	O
both	O
suspension	O
and	O
as	O
monolayers	O
on	O
poly	B-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
lysine	I-Chemical
-	O
coated	O
plates	O
(	O
Figure	O
S4	O
).	O
Autophagy	O
and	O
apoptosis	O
are	O
cell	O
death	O
mechanisms	O
with	O
complex	O
interactions	O
between	O
each	O
other	O
[	O
46	O
].	O
We	O
found	O
that	O
fisetin	B-Chemical
inhibited	O
Tm	B-Chemical
-	O
mediated	O
apoptosis	O
","	O
as	O
indicated	O
by	O
decreased	O
levels	O
of	O
activated	O
PARP	O
-	O
1	O
.	O
Fisetin	B-Chemical
also	O
decreased	O
Tm	B-Chemical
-	O
induced	O
LC3	O
-	O
II	O
accumulation	O
and	O
Atg12	O
â€“	O
Atg5	O
conjugate	O
","	O
indicating	O
that	O
Tm	B-Chemical
-	O
mediated	O
autophagy	O
was	O
also	O
attenuated	O
.	O
Furthermore	O
","	O
our	O
data	O
show	O
that	O
in	O
the	O
absence	O
of	O
Tm	B-Chemical
","	O
fisetin	B-Chemical
alone	O
could	O
protect	O
PC12	O
cells	O
from	O
apoptotic	O
damage	O
.	O
In	O
contrast	O
to	O
the	O
results	O
observed	O
for	O
higher	O
concentrations	O
of	O
fisetin	B-Chemical
","	O
which	O
induced	O
apoptosis	O
[	O
30	O
","	O
31	O
"],"	O
this	O
study	O
is	O
the	O
first	O
to	O
document	O
that	O
low	O
concentration	O
of	O
fisetin	B-Chemical
has	O
anti	O
-	O
apoptotic	O
and	O
anti	O
-	O
autophagic	O
effects	O
in	O
PC12	O
cells	O
under	O
ER	O
stress	O
.	O
To	O
dissect	O
the	O
mechanism	O
underlying	O
the	O
protective	O
effect	O
of	O
fisetin	B-Chemical
","	O
we	O
first	O
investigated	O
whether	O
fisetin	B-Chemical
inhibited	O
Tm	B-Chemical
-	O
induced	O
ER	O
stress	O
gene	O
expression	O
.	O
Our	O
results	O
show	O
that	O
fisetin	B-Chemical
did	O
not	O
inhibit	O
XBP1	O
splicing	O
or	O
eIF2Î±	O
phosphorylation	O
.	O
However	O
","	O
it	O
significantly	O
attenuated	O
Tm	B-Chemical
-	O
mediated	O
mRNA	O
expressions	O
of	O
GRP78	O
","	O
CHOP	O
and	O
TRB3	O
.	O
Significant	O
inhibition	O
against	O
GRP78	O
protein	O
overexpression	O
was	O
also	O
noted	O
.	O
These	O
results	O
suggest	O
that	O
fisetin	B-Chemical
down	O
-	O
regulated	O
ER	O
stress	O
-	O
target	O
gene	O
expression	O
without	O
directly	O
affecting	O
Tm	B-Chemical
-	O
activated	O
IRE	O
or	O
PERK	O
signaling	O
.	O
It	O
has	O
been	O
reported	O
that	O
high	O
concentration	O
of	O
fisetin	B-Chemical
induces	O
ER	O
stress	O
gene	O
expression	O
in	O
cancer	O
cells	O
[	O
30	O
","	O
32	O
].	O
We	O
therefore	O
investigate	O
whether	O
low	O
concentration	O
of	O
fisetin	B-Chemical
alone	O
could	O
upregulate	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
gene	O
expression	O
in	O
order	O
to	O
conquer	O
ER	O
stress	O
.	O
Figure	O
S5a	O
shows	O
that	O
no	O
XBP1s	O
RNA	O
could	O
be	O
induced	O
by	O
fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
after	O
6	O
h	O
treatment	O
.	O
It	O
has	O
been	O
reported	O
that	O
fisetin	B-Chemical
(<	O
10	O
ÂµM	O
)	O
dose	O
-	O
and	O
time	O
-	O
dependently	O
induces	O
ATF4	O
expression	O
in	O
immortalized	O
mouse	O
hippocampal	O
HT22	O
cells	O
[	O
41	O
].	O
In	O
concert	O
with	O
this	O
","	O
we	O
found	O
that	O
treatment	O
of	O
PC12	O
cells	O
with	O
fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
alone	O
for	O
6	O
h	O
caused	O
modest	O
stimulation	O
with	O
regard	O
to	O
mRNA	O
expression	O
of	O
ATF4	O
","	O
GRP78	O
and	O
CHOP	O
following	O
a	O
hormetic	O
dose	O
â€“	O
response	O
curve	O
","	O
and	O
the	O
highest	O
induction	O
was	O
found	O
at	O
10	O
â€“	O
15	O
ÂµM	O
by	O
1	O
.	O
5	O
-	O
to	O
2	O
.	O
5	O
-	O
fold	O
(	O
Figure	O
S5b	O
â€“	O
d	O
).	O
This	O
suggests	O
that	O
the	O
modest	O
induction	O
of	O
UPR	O
by	O
fisetin	B-Chemical
alone	O
may	O
play	O
a	O
part	O
in	O
protecting	O
cells	O
from	O
Tm	B-Chemical
-	O
mediated	O
ER	O
stress	O
.	O
It	O
was	O
reported	O
that	O
Tm	B-Chemical
induced	O
ROS	B-Chemical
production	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
40	O
","	O
47	O
].	O
In	O
the	O
current	O
study	O
","	O
we	O
found	O
that	O
both	O
fisetin	B-Chemical
and	O
NAC	B-Chemical
","	O
a	O
synthetic	O
precursor	O
of	O
GSH	B-Chemical
","	O
can	O
block	O
Tm	B-Chemical
-	O
mediated	O
ROS	B-Chemical
production	O
","	O
as	O
measured	O
by	O
the	O
reduced	O
DCF	B-Chemical
fluorescence	O
.	O
However	O
","	O
ROS	B-Chemical
are	O
difficult	O
to	O
measure	O
and	O
prone	O
to	O
artifacts	O
that	O
can	O
generate	O
FALSE	O
-	O
positive	O
signals	O
[	O
48	O
].	O
Many	O
inherent	O
problems	O
","	O
such	O
as	O
being	O
oxidized	O
by	O
other	O
reactive	O
molecules	O
","	O
exist	O
in	O
using	O
fluorescence	O
probe	O
H2DCFH	B-Chemical
to	O
analyze	O
H2O2	B-Chemical
levels	O
[	O
49	O
].	O
In	O
addition	O
","	O
studies	O
using	O
antioxidants	O
to	O
demonstrate	O
involvement	O
of	O
ROS	B-Chemical
[	O
50	O
","	O
51	O
]	O
are	O
not	O
always	O
conclusive	O
.	O
However	O
","	O
until	O
newer	O
ROS	B-Chemical
-	O
detection	O
techniques	O
are	O
evolved	O
","	O
a	O
clear	O
picture	O
of	O
Tm	B-Chemical
-	O
induced	O
ROS	B-Chemical
in	O
PC12	O
cells	O
will	O
be	O
lacking	O
.	O
Nrf2	O
and	O
ATF4	O
are	O
critical	O
transcription	O
factors	O
involved	O
in	O
GSH	B-Chemical
metabolism	O
[	O
52	O
","	O
53	O
].	O
Therefore	O
","	O
compounds	O
that	O
upregulate	O
both	O
Nrf2	O
and	O
ATF4	O
are	O
potentially	O
useful	O
in	O
neuroprotection	O
through	O
their	O
effects	O
on	O
GSH	B-Chemical
metabolism	O
.	O
It	O
has	O
been	O
reported	O
that	O
fisetin	B-Chemical
concurrently	O
regulates	O
Nrf2	O
-	O
and	O
ATF4	O
-	O
driven	O
gene	O
expression	O
","	O
and	O
increases	O
GSH	B-Chemical
levels	O
at	O
both	O
normal	O
and	O
under	O
oxidative	O
stress	O
conditions	O
in	O
HT22	O
cells	O
[	O
41	O
].	O
In	O
accordance	O
with	O
this	O
","	O
we	O
found	O
that	O
in	O
addition	O
to	O
the	O
abovementioned	O
ATF4	O
induction	O
","	O
fisetin	B-Chemical
alone	O
also	O
stimulates	O
Nrf	O
-	O
2	O
-	O
driven	O
mRNA	O
expression	O
of	O
Phase	O
II	O
antioxidant	O
enzymes	O
","	O
HO	O
-	O
1	O
","	O
GCL	O
and	O
xCT	O
in	O
a	O
hormetic	O
effect	O
.	O
Tm	B-Chemical
alone	O
only	O
weakly	O
or	O
insignificantly	O
induced	O
HO	O
-	O
1	O
","	O
GCLC	O
and	O
GCLM	O
expression	O
.	O
On	O
the	O
other	O
hand	O
","	O
xCT	O
was	O
stimulated	O
by	O
Tm	B-Chemical
alone	O
more	O
than	O
10	O
-	O
fold	O
","	O
supporting	O
the	O
notion	O
that	O
it	O
was	O
upregulated	O
by	O
both	O
ATF4	O
and	O
Nrf2	O
.	O
Fisetin	B-Chemical
treatment	O
further	O
enhanced	O
HO	O
-	O
1	O
expression	O
dose	O
-	O
dependently	O
","	O
and	O
the	O
cytoprotective	O
role	O
of	O
HO	O
-	O
1	O
was	O
confirmed	O
by	O
the	O
addition	O
of	O
competitive	O
inhibitor	O
","	O
Znpp	B-Chemical
.	O
Fisetin	B-Chemical
also	O
upregulated	O
the	O
genes	O
involved	O
in	O
GSH	B-Chemical
metabolism	O
in	O
the	O
presence	O
of	O
Tm	B-Chemical
.	O
In	O
conclusion	O
","	O
fisetin	B-Chemical
may	O
exert	O
a	O
cytoprotective	O
effect	O
by	O
increasing	O
HO	O
-	O
1	O
expression	O
and	O
maintaining	O
the	O
GSH	B-Chemical
level	O
via	O
upregulating	O
GCL	O
and	O
xCT	O
expression	O
[	O
25	O
].	O
We	O
also	O
found	O
that	O
fisetin	B-Chemical
activated	O
ERK	O
","	O
JNK	O
and	O
p38	O
MAPK	O
","	O
and	O
attenuation	O
of	O
JNK	O
and	O
p38	O
MAPK	O
phosphorylation	O
reduced	O
its	O
cytoprotective	O
effects	O
.	O
Many	O
studies	O
reveal	O
that	O
the	O
upregulation	O
of	O
HO	O
-	O
1	O
requires	O
p38	O
MAPK	O
activation	O
[	O
35	O
","	O
54	O
","	O
55	O
","	O
56	O
].	O
In	O
agreement	O
with	O
this	O
","	O
we	O
found	O
that	O
SB203580	B-Chemical
(	O
p38	O
inhibitor	O
"),"	O
but	O
not	O
SP600125	B-Chemical
(	O
JNK	O
inhibitor	O
"),"	O
attenuated	O
fisetin	B-Chemical
-	O
mediated	O
HO	O
-	O
1	O
overexpression	O
.	O
It	O
was	O
also	O
reported	O
that	O
p38	O
MAPK	O
mediates	O
cell	O
survival	O
in	O
response	O
to	O
oxidative	O
stress	O
via	O
induction	O
of	O
other	O
Phase	O
II	O
antioxidant	O
enzymes	O
[	O
57	O
].	O
Inhibition	O
of	O
fisetin	B-Chemical
-	O
activated	O
p38	O
MAPK	O
also	O
strongly	O
enhanced	O
expression	O
of	O
ER	O
stress	O
-	O
induced	O
apoptotic	O
CHOP	O
","	O
and	O
a	O
less	O
prominent	O
effect	O
was	O
found	O
for	O
those	O
cells	O
treated	O
with	O
JNK	O
inhibitor	O
.	O
The	O
above	O
results	O
suggest	O
that	O
fisetin	B-Chemical
-	O
induced	O
p38	O
MAPK	O
phosphorylation	O
","	O
and	O
to	O
a	O
lesser	O
extent	O
","	O
JNK	O
phosphorylation	O
","	O
may	O
both	O
confer	O
adaptive	O
responses	O
to	O
resist	O
Tm	B-Chemical
-	O
mediated	O
ER	O
stress	O
and	O
cytotoxicity	O
.	O
The	O
development	O
of	O
sirtuin	O
-	O
activating	O
compounds	O
(	O
STACs	O
)	O
as	O
nutraceuticals	O
in	O
the	O
management	O
of	O
chronic	O
diseases	O
has	O
attracted	O
considerable	O
research	O
interest	O
in	O
recent	O
years	O
","	O
with	O
fisetin	B-Chemical
found	O
to	O
be	O
a	O
SIRT1	O
activator	O
and	O
inducer	O
[	O
44	O
","	O
45	O
].	O
We	O
found	O
that	O
fisetin	B-Chemical
reversed	O
Tm	B-Chemical
-	O
inhibited	O
SIRT1	O
expression	O
in	O
PC12	O
cells	O
.	O
In	O
the	O
presence	O
of	O
SIRT1	O
inhibitor	O
sirtinol	B-Chemical
","	O
no	O
fisetin	B-Chemical
-	O
mediated	O
cytoprotective	O
effect	O
could	O
be	O
observed	O
.	O
These	O
results	O
indicate	O
that	O
fisetin	B-Chemical
suppresses	O
neuronal	O
toxicity	O
","	O
possibly	O
via	O
modulating	O
SIRT1	O
activation	O
and	O
expression	O
.	O
4	O
.	O
Materials	O
and	O
Methods	O
4	O
.	O
1	O
.	O
Materials	O
Fisetin	B-Chemical
(â‰¥	O
98	O
"%),"	O
tunicamycin	B-Chemical
(	O
Tm	B-Chemical
"),"	O
MTT	B-Chemical
(	O
3	B-Chemical
-(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
dimethylthiazol	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
yl	I-Chemical
)-	I-Chemical
2	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
diphenyltetrazolium	I-Chemical
bromide	I-Chemical
"),"	O
RPMI	B-Chemical
-	I-Chemical
1640	I-Chemical
medium	I-Chemical
","	O
and	O
other	O
chemicals	O
were	O
from	O
Sigma	O
-	O
Aldrich	O
Co	O
.	O
(	O
St	O
.	O
Louis	O
","	O
MO	O
","	O
USA	O
"),"	O
unless	O
otherwise	O
indicated	O
.	O
1	B-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
Diamino	I-Chemical
-	I-Chemical
2	I-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
dicyano	I-Chemical
-	I-Chemical
1	I-Chemical
","	I-Chemical
4	I-Chemical
-	I-Chemical
bis	I-Chemical
(	I-Chemical
o	I-Chemical
-	I-Chemical
aminophenylmercapto	I-Chemical
)	I-Chemical
butadiene	I-Chemical
(	O
U0126	B-Chemical
"),"	O
a	O
selective	O
and	O
potent	O
inhibitor	O
of	O
MEK	O
activity	O
and	O
activation	O
of	O
ERK1	O
/	O
2	O
","	O
and	O
4	B-Chemical
-(	I-Chemical
4	I-Chemical
â€²-	I-Chemical
fluorophenyl	I-Chemical
)-	I-Chemical
2	I-Chemical
-(	I-Chemical
4	I-Chemical
â€²-	I-Chemical
methylsulfinylphenyl	I-Chemical
)-	I-Chemical
5	I-Chemical
-(	I-Chemical
4	I-Chemical
â€²-	I-Chemical
pyridyl	I-Chemical
)-	I-Chemical
imidazole	I-Chemical
(	O
SB	B-Chemical
203580	I-Chemical
"),"	O
a	O
p38	O
MAP	O
kinase	O
inhibitor	O
","	O
were	O
purchased	O
from	O
Promega	O
(	O
Madison	O
","	O
WI	O
","	O
USA	O
).	O
SP600125	B-Chemical
(	O
1	B-Chemical
","	I-Chemical
9	I-Chemical
-	I-Chemical
pyrazoloanthron	I-Chemical
"),"	O
an	O
inhibitor	O
of	O
JNK	O
","	O
was	O
from	O
Calbiochem	O
(	O
San	O
Diego	O
","	O
CA	O
","	O
USA	O
).	O
Sirtinol	B-Chemical
","	O
a	O
specific	O
inhibitor	O
of	O
SIRT1	O
and	O
SIRT2	O
","	O
was	O
from	O
Santa	O
Cruz	O
(	O
Dallas	O
","	O
TX	O
","	O
USA	O
).	O
4	O
.	O
2	O
.	O
PC12	O
Cell	O
Culture	O
The	O
rat	O
adrenal	O
pheochromocytoma	O
cell	O
line	O
PC12	O
was	O
obtained	O
from	O
the	O
Bioresource	O
Collection	O
and	O
Research	O
Center	O
(	O
Hsinchu	O
","	O
Taiwan	O
)	O
and	O
maintained	O
in	O
RPMI	B-Chemical
-	I-Chemical
1640	I-Chemical
medium	I-Chemical
","	O
which	O
contains	O
2	O
mM	O
glutamine	B-Chemical
","	O
1	O
.	O
5	O
g	O
/	O
L	O
sodium	B-Chemical
bicarbonate	I-Chemical
","	O
4	O
.	O
5	O
g	O
/	O
L	O
glucose	B-Chemical
","	O
10	O
mM	O
HEPES	B-Chemical
","	O
1	O
mM	O
sodium	B-Chemical
pyruvate	I-Chemical
","	O
100	O
U	O
/	O
mL	O
penicillin	B-Chemical
and	O
streptomycin	B-Chemical
","	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
horse	O
serum	O
(	O
Hyclone	O
","	O
Logan	O
","	O
UT	O
","	O
USA	O
)	O
and	O
5	O
%	O
fetal	O
bovine	O
serum	O
(	O
Invitrogen	O
","	O
Carlsbad	O
","	O
CA	O
","	O
USA	O
)	O
in	O
5	O
%	O
CO2	B-Chemical
incubator	O
at	O
37	O
Â°	O
C	O
.	O
4	O
.	O
3	O
.	O
Drug	O
Treatments	O
and	O
Cell	O
Viability	O
Assay	O
For	O
experiments	O
testing	O
the	O
ability	O
of	O
tunicamycin	B-Chemical
(	O
Tm	B-Chemical
)	O
to	O
induce	O
cytotoxicity	O
","	O
cells	O
were	O
incubated	O
in	O
serum	O
-	O
free	O
RPMI	O
medium	O
in	O
the	O
presence	O
of	O
Tm	B-Chemical
[	O
34	O
].	O
PC12	O
cells	O
(	O
5	O
Ã—	O
105	O
/	O
mL	O
)	O
were	O
seeded	O
in	O
24	O
-	O
well	O
plates	O
and	O
pretreated	O
with	O
the	O
indicated	O
concentration	O
of	O
fisetin	B-Chemical
or	O
an	O
equivalent	O
volume	O
of	O
DMSO	B-Chemical
vehicle	O
control	O
(	O
final	O
concentration	O
of	O
0	O
.	O
1	O
%)	O
for	O
30	O
min	O
","	O
followed	O
by	O
Tm	B-Chemical
treatment	O
for	O
16	O
h	O
.	O
To	O
measure	O
the	O
cell	O
viability	O
of	O
adherent	O
PC12	O
cells	O
that	O
had	O
undergone	O
Tm	B-Chemical
-	O
induced	O
damage	O
","	O
PC12	O
cells	O
(	O
5	O
Ã—	O
105	O
/	O
mL	O
)	O
were	O
seeded	O
on	O
poly	B-Chemical
-	I-Chemical
l	I-Chemical
-	I-Chemical
lysine	I-Chemical
-	O
coated	O
6	O
-	O
well	O
plates	O
in	O
low	O
serum	O
(	O
0	O
.	O
5	O
%	O
fetal	O
bovine	O
serum	O
and	O
1	O
%	O
horse	O
serum	O
)	O
medium	O
for	O
16	O
h	O
.	O
Fisetin	B-Chemical
or	O
an	O
equivalent	O
volume	O
of	O
DMSO	B-Chemical
vehicle	O
(	O
final	O
concentration	O
of	O
0	O
.	O
1	O
%)	O
was	O
then	O
added	O
and	O
incubated	O
for	O
30	O
min	O
prior	O
to	O
Tm	B-Chemical
treatment	O
for	O
an	O
additional	O
16	O
h	O
.	O
A	O
cell	O
-	O
free	O
blank	O
with	O
medium	O
and	O
tested	O
reagent	O
was	O
employed	O
in	O
parallel	O
.	O
Cell	O
viability	O
was	O
assessed	O
by	O
the	O
mitochondrial	O
-	O
dependent	O
reduction	O
of	O
MTT	B-Chemical
to	O
purple	O
formazan	B-Chemical
[	O
58	O
].	O
The	O
cell	O
viability	O
was	O
calculated	O
by	O
subtracting	O
the	O
OD550	O
of	O
cell	O
-	O
free	O
blank	O
from	O
OD550	O
of	O
each	O
sample	O
and	O
was	O
expressed	O
as	O
percentage	O
of	O
the	O
control	O
(	O
100	O
%).	O
An	O
esterase	O
-	O
dependent	O
cell	O
viability	O
analysis	O
Calcein	B-Chemical
AM	I-Chemical
(	O
Invitrogen	O
)	O
was	O
used	O
for	O
reconfirmation	O
of	O
MTT	B-Chemical
data	O
[	O
59	O
].	O
Briefly	O
","	O
cells	O
were	O
incubated	O
with	O
5	O
ÂµM	O
Calcein	B-Chemical
AM	I-Chemical
for	O
30	O
min	O
at	O
37	O
Â°	O
C	O
","	O
and	O
the	O
fluorescent	O
signal	O
was	O
monitored	O
using	O
485	O
nm	O
excitation	O
and	O
530	O
nm	O
emission	O
wavelengths	O
.	O
4	O
.	O
4	O
.	O
Protein	O
Extraction	O
and	O
Immunoblotting	O
RIPA	B-Chemical
buffer	I-Chemical
(	O
Thermo	O
Fisher	O
Scientific	O
","	O
Inc	O
".,"	O
Rockford	O
","	O
IL	O
","	O
USA	O
)	O
was	O
used	O
for	O
preparation	O
of	O
whole	O
cell	O
extracts	O
and	O
the	O
protein	O
concentration	O
was	O
measured	O
by	O
the	O
Bradford	O
method	O
(	O
Bio	O
-	O
Rad	O
Laboratories	O
","	O
Hercules	O
","	O
CA	O
","	O
USA	O
).	O
Equal	O
amounts	O
of	O
cell	O
lysates	O
were	O
separated	O
on	O
SDS	B-Chemical
-	O
PAGE	O
and	O
then	O
transferred	O
onto	O
Hybond	B-Chemical
-	I-Chemical
P	I-Chemical
PVDF	I-Chemical
(	O
GE	O
Healthcare	O
","	O
Buckinghamshire	O
","	O
UK	O
)	O
using	O
a	O
CAPS	B-Chemical
transfer	I-Chemical
buffer	I-Chemical
at	O
30	O
mA	O
overnight	O
at	O
4	O
Â°	O
C	O
.	O
The	O
membranes	O
were	O
blocked	O
in	O
a	O
freshly	O
made	O
blocking	O
buffer	O
(	O
5	O
%	O
skim	O
milk	O
in	O
PBS	B-Chemical
with	O
0	O
.	O
5	O
%	O
Tween	B-Chemical
20	I-Chemical
","	O
pH	O
7	O
.	O
4	O
","	O
PBS	B-Chemical
-	I-Chemical
T	I-Chemical
)	O
for	O
6	O
h	O
at	O
room	O
temperature	O
.	O
After	O
washing	O
with	O
PBS	B-Chemical
-	I-Chemical
T	I-Chemical
","	O
the	O
membranes	O
were	O
incubated	O
with	O
an	O
appropriate	O
dilution	O
(	O
1	O
:	O
1000	O
â€’	O
1	O
:	O
5000	O
)	O
of	O
primary	O
antibody	O
(	O
Table	O
1	O
)	O
overnight	O
at	O
4	O
Â°	O
C	O
on	O
a	O
rocking	O
platform	O
.	O
The	O
membranes	O
were	O
then	O
washed	O
and	O
incubated	O
with	O
suitable	O
horseradish	O
peroxidase	O
-	O
conjugated	O
secondary	O
antibody	O
(	O
Jackson	O
ImmunoResearch	O
","	O
West	O
Grove	O
","	O
PA	O
","	O
USA	O
","	O
at	O
a	O
dilution	O
of	O
1	O
:	O
10	O
","	O
0	O
â€’	O
1	O
:	O
25	O
","	O
0	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O
The	O
blots	O
of	O
were	O
incubated	O
by	O
ECL	O
Prime	O
(	O
GE	O
Healthcare	O
"),"	O
and	O
the	O
chemiluminescent	O
signals	O
were	O
then	O
visualized	O
with	O
X	O
-	O
ray	O
film	O
.	O
Densitometry	O
of	O
the	O
bands	O
was	O
analyzed	O
by	O
ImageJ	O
software	O
version	O
1	O
.	O
50	O
(	O
National	O
Institutes	O
of	O
Health	O
","	O
Bethesda	O
","	O
MD	O
","	O
USA	O
).	O
4	O
.	O
5	O
.	O
RNA	O
Extraction	O
","	O
Real	O
-	O
Time	O
RT	O
-	O
PCR	O
","	O
and	O
Semi	O
-	O
Quantitative	O
RT	O
-	O
PCR	O
Illustra	O
RNAspin	O
Mini	O
RNA	O
Isolation	O
Kit	O
(	O
GE	O
Healthcare	O
)	O
was	O
used	O
for	O
preparation	O
of	O
total	O
RNA	O
.	O
High	O
-	O
Capacity	O
cDNA	O
Archive	O
Kit	O
(	O
Applied	O
Biosystems	O
","	O
Waltham	O
","	O
MA	O
","	O
USA	O
)	O
was	O
used	O
to	O
prepare	O
cDNA	O
from	O
1	O
Âµg	O
RNA	O
.	O
Real	O
-	O
time	O
PCR	O
(	O
StepOne	O
Real	O
-	O
Time	O
PCR	O
System	O
","	O
Applied	O
Biosystems	O
)	O
was	O
performed	O
with	O
2	O
ÂµL	O
of	O
the	O
cDNA	O
","	O
200	O
nM	O
primers	O
(	O
Table	O
2	O
)	O
and	O
Fast	O
SYBR	O
Green	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
)	O
in	O
25	O
ÂµL	O
reaction	O
mixture	O
.	O
The	O
amplification	O
conditions	O
were	O
as	O
follows	O
:	O
95	O
Â°	O
C	O
for	O
2	O
min	O
","	O
40	O
cycles	O
at	O
94	O
Â°	O
C	O
for	O
15	O
s	O
","	O
and	O
60	O
Â°	O
C	O
for	O
60	O
s	O
.	O
Target	O
gene	O
expression	O
was	O
measured	O
and	O
normalized	O
to	O
the	O
respective	O
Î²	O
-	O
actin	O
expression	O
level	O
.	O
The	O
identity	O
and	O
purity	O
of	O
the	O
amplified	O
product	O
was	O
checked	O
through	O
analysis	O
of	O
the	O
melting	O
curve	O
carried	O
out	O
at	O
the	O
end	O
of	O
amplification	O
.	O
Relative	O
expression	O
was	O
evaluated	O
with	O
the	O
Î”Î”Ct	O
method	O
.	O
XBP1s	O
and	O
XBP1u	O
mRNA	O
levels	O
were	O
measured	O
using	O
regular	O
PCR	O
as	O
described	O
in	O
our	O
previous	O
publication	O
[	O
60	O
].	O
4	O
.	O
6	O
.	O
Intracellular	O
ROS	B-Chemical
Analysis	O
Cellular	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
were	O
analyzed	O
using	O
the	O
fluorescence	O
probe	O
2	B-Chemical
"â€²,"	I-Chemical
7	I-Chemical
â€²-	I-Chemical
dichlorodihydrofluorescein	I-Chemical
diacetate	I-Chemical
(	O
H2DCFDA	B-Chemical
)	O
(	O
Invitrogen	O
"),"	O
which	O
passively	O
diffuses	O
into	O
the	O
cell	O
and	O
is	O
cleaved	O
and	O
oxidized	O
to	O
2	B-Chemical
"â€²,"	I-Chemical
7	I-Chemical
â€²-	I-Chemical
dichlorofluorescein	I-Chemical
(	O
DCF	B-Chemical
).	O
PC12	O
cells	O
were	O
stained	O
with	O
20	O
ÂµM	O
H2DCFDA	B-Chemical
at	O
37	O
Â°	O
C	O
for	O
30	O
min	O
in	O
the	O
dark	O
and	O
then	O
washed	O
once	O
in	O
PBS	B-Chemical
.	O
Fluorescence	O
dye	O
loaded	O
cells	O
were	O
seeded	O
in	O
black	O
96	O
-	O
well	O
plates	O
(	O
2	O
Ã—	O
105	O
/	O
well	O
)	O
and	O
treated	O
with	O
fisetin	B-Chemical
or	O
in	O
combination	O
with	O
Tm	B-Chemical
for	O
16	O
h	O
.	O
The	O
signals	O
were	O
then	O
read	O
at	O
EX485	O
nm	O
/	O
Em535	O
nm	O
using	O
a	O
fluorometer	O
.	O
4	O
.	O
7	O
.	O
Statistical	O
Analysis	O
All	O
experiments	O
were	O
repeated	O
at	O
least	O
three	O
times	O
.	O
The	O
results	O
were	O
analyzed	O
using	O
Kruskal	O
â€“	O
Wallis	O
H	O
Test	O
by	O
SPSS	O
version	O
18	O
.	O
If	O
the	O
Kruskal	O
â€“	O
Wallis	O
H	O
Test	O
shows	O
a	O
significant	O
difference	O
between	O
the	O
groups	O
","	O
then	O
pairwise	O
comparisons	O
were	O
employed	O
by	O
Mann	O
â€“	O
Whitney	O
U	O
Tests	O
","	O
and	O
a	O
p	O
-	O
value	O
of	O
<	O
0	O
.	O
5	O
was	O
taken	O
to	O
be	O
significant	O
.	O
5	O
.	O
Conclusions	O
Fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
protected	O
PC12	O
cells	O
from	O
Tm	B-Chemical
-	O
induced	O
cell	O
death	O
.	O
Fisetin	B-Chemical
mitigated	O
Tm	B-Chemical
-	O
mediated	O
apoptosis	O
","	O
autophagy	O
and	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
production	O
.	O
Its	O
cytoprotective	O
effects	O
were	O
likely	O
associated	O
with	O
modulation	O
of	O
UPR	O
and	O
resulted	O
in	O
down	O
-	O
regulation	O
of	O
ER	O
stress	O
target	O
genes	O
","	O
GRP78	O
","	O
CHOP	O
","	O
and	O
TRB3	O
.	O
Furthermore	O
","	O
treatment	O
of	O
cells	O
with	O
fisetin	B-Chemical
induced	O
expression	O
of	O
Nrf2	O
target	O
genes	O
","	O
HO	O
-	O
1	O
","	O
GCLC	O
","	O
GCLM	O
and	O
xCT	O
.	O
Fisetin	B-Chemical
restored	O
SIRT1	O
expression	O
and	O
enhanced	O
MAPK	O
activation	O
","	O
which	O
may	O
confer	O
an	O
adaptive	O
response	O
to	O
modulate	O
Tm	B-Chemical
-	O
mediated	O
stress	O
responses	O
and	O
cytotoxicity	O
.	O
Supplementary	O
Materials	O
Supplementary	O
materials	O
can	O
be	O
found	O
at	O
.	O
Author	O
Contributions	O
Jui	O
-	O
Hung	O
Yen	O
and	O
Ming	O
-	O
Jiuan	O
Wu	O
conceived	O
and	O
designed	O
the	O
experiments	O
;	O
Pei	O
-	O
Shan	O
Wu	O
performed	O
the	O
experiments	O
;	O
Pei	O
-	O
Shan	O
Wu	O
and	O
Ming	O
-	O
Jiuan	O
Wu	O
analyzed	O
the	O
data	O
;	O
Jui	O
-	O
Hung	O
Yen	O
","	O
Shu	O
-	O
Fen	O
Chen	O
and	O
Ming	O
-	O
Jiuan	O
Wu	O
contributed	O
reagents	O
/	O
materials	O
;	O
Ming	O
-	O
Jiuan	O
Wu	O
wrote	O
the	O
paper	O
.	O
Authorship	O
must	O
be	O
limited	O
to	O
those	O
who	O
have	O
contributed	O
substantially	O
to	O
the	O
work	O
reported	O
.	O
Conflicts	O
of	O
Interest	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O
References	O
Effects	O
of	O
fisetin	B-Chemical
on	O
tunicamycin	B-Chemical
(	O
Tm	B-Chemical
)-	O
induced	O
PC12	O
cell	O
death	O
.	O
(	O
a	O
)	O
Chemical	O
structure	O
of	O
fisetin	B-Chemical
;	O
(	O
b	O
)	O
Fisetin	B-Chemical
alone	O
does	O
not	O
change	O
the	O
cell	O
viability	O
of	O
PC12	O
cells	O
;	O
(	O
c	O
)	O
Tm	B-Chemical
causes	O
cell	O
death	O
in	O
PC12	O
cells	O
;	O
(	O
d	O
)	O
Fisetin	B-Chemical
inhibits	O
Tm	B-Chemical
-	O
mediated	O
cytotoxicity	O
in	O
PC12	O
cells	O
.	O
Cells	O
were	O
treated	O
with	O
the	O
indicated	O
concentration	O
of	O
compound	O
or	O
vehicle	O
control	O
(	O
0	O
.	O
1	O
%	O
dimethyl	B-Chemical
sulfoxide	I-Chemical
","	O
DMSO	B-Chemical
)	O
for	O
30	O
min	O
followed	O
by	O
exposure	O
to	O
Tm	B-Chemical
for	O
an	O
additional	O
16	O
h	O
at	O
37	O
Â°	O
C	O
.	O
Cell	O
viability	O
was	O
measured	O
by	O
MTT	B-Chemical
(	O
3	B-Chemical
-(	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
dimethylthiazol	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
yl	I-Chemical
)-	I-Chemical
2	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
diphenyltetrazolium	I-Chemical
bromide	I-Chemical
"),"	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O
**	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
vehicle	O
control	O
(	O
Con	O
","	O
without	O
Tm	B-Chemical
).	O
##	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
the	O
Tm	B-Chemical
-	O
treated	O
vehicle	O
(	O
veh	O
).	O
Effect	O
of	O
fisetin	B-Chemical
on	O
apoptotic	O
and	O
autophagic	O
marker	O
protein	O
expression	O
.	O
(	O
a	O
)	O
Effect	O
of	O
fisetin	B-Chemical
alone	O
on	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
-	O
1	O
(	O
PARP	O
-	O
1	O
)	O
activation	O
and	O
microtubule	O
-	O
associated	O
protein	O
1	O
light	O
chain	O
3	O
(	O
LC3	O
)	O
conversion	O
;	O
(	O
b	O
)	O
Effect	O
of	O
fisetin	B-Chemical
on	O
Tm	B-Chemical
-	O
activated	O
PARP	O
-	O
1	O
activation	O
;	O
(	O
c	O
)	O
Effect	O
of	O
fisetin	B-Chemical
on	O
Tm	B-Chemical
-	O
mediated	O
conversion	O
of	O
LC3B	O
and	O
formation	O
of	O
Atg12	O
â€“	O
Atg5	O
conjugate	O
.	O
Cells	O
were	O
treated	O
with	O
the	O
indicated	O
reagent	O
for	O
16	O
h	O
and	O
cell	O
lysates	O
were	O
prepared	O
and	O
subjected	O
to	O
immunoblotting	O
.	O
The	O
blots	O
are	O
representative	O
from	O
one	O
of	O
three	O
independent	O
experiments	O
.	O
Data	O
obtained	O
from	O
immunoblots	O
were	O
then	O
analyzed	O
using	O
ImageJ	O
software	O
.	O
Data	O
represent	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O
(	O
a	O
)	O
**	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
no	O
fisetin	B-Chemical
control	O
;	O
(	O
b	O
","	O
c	O
)	O
**	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
vehicle	O
control	O
(	O
without	O
Tm	B-Chemical
).	O
#	O
p	O
<	O
0	O
.	O
5	O
;	O
##	O
p	O
<	O
0	O
.	O
1	O
represent	O
significant	O
differences	O
compared	O
with	O
the	O
Tm	B-Chemical
-	O
treated	O
vehicle	O
group	O
.	O
Effect	O
of	O
fisetin	B-Chemical
on	O
Tm	B-Chemical
-	O
mediated	O
unfolded	O
protein	O
response	O
(	O
UPR	O
).	O
(	O
a	O
","	O
c	O
â€“	O
e	O
)	O
Cells	O
were	O
treated	O
with	O
the	O
indicated	O
reagent	O
for	O
6	O
h	O
at	O
37	O
Â°	O
C	O
and	O
RNA	O
was	O
prepared	O
.	O
Semi	O
-	O
quantitative	O
RT	O
-	O
PCR	O
and	O
polyacrylamide	B-Chemical
electrophoresis	O
was	O
employed	O
for	O
the	O
analysis	O
of	O
mRNA	O
levels	O
of	O
XBP1s	O
and	O
XBP1u	O
.	O
RT	O
-	O
Q	O
-	O
PCR	O
was	O
used	O
for	O
the	O
analysis	O
of	O
mRNA	O
levels	O
of	O
glucose	O
-	O
regulated	O
proteins	O
78	O
(	O
GRP78	O
"),"	O
C	O
/	O
EBP	O
homologous	O
protein	O
(	O
CHOP	O
)	O
and	O
tribbles	O
-	O
related	O
protein	O
3	O
(	O
TRB3	O
);	O
(	O
b	O
)	O
Cells	O
were	O
treated	O
with	O
the	O
indicated	O
reagent	O
for	O
4	O
h	O
and	O
levels	O
of	O
phospho	O
-	O
eIF2Î±	O
and	O
eIF2Î±	O
were	O
analyzed	O
using	O
immunoblotting	O
;	O
(	O
f	O
)	O
Cells	O
were	O
treated	O
with	O
the	O
indicated	O
reagent	O
for	O
8	O
h	O
and	O
GRP78	O
and	O
CHOP	O
in	O
cell	O
lysates	O
were	O
analyzed	O
using	O
immunoblotting	O
.	O
Data	O
represent	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O
**	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
vehicle	O
control	O
(	O
without	O
Tm	B-Chemical
).	O
##	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
the	O
Tm	B-Chemical
-	O
treated	O
vehicle	O
group	O
.	O
Effects	O
of	O
fisetin	B-Chemical
on	O
intracellular	O
ROS	B-Chemical
production	O
.	O
(	O
a	O
)	O
PC12	O
cells	O
were	O
treated	O
with	O
fisetin	B-Chemical
for	O
16	O
h	O
at	O
37	O
Â°	O
C	O
;	O
(	O
b	O
)	O
PC12	O
cells	O
were	O
treated	O
with	O
fisetin	B-Chemical
30	O
min	O
prior	O
to	O
Tm	B-Chemical
insult	O
for	O
16	O
h	O
at	O
37	O
Â°	O
C	O
.	O
Intracellular	O
ROS	B-Chemical
production	O
was	O
measured	O
by	O
2	B-Chemical
"â€²,"	I-Chemical
7	I-Chemical
â€²-	I-Chemical
dichlorodihydrofluorescein	I-Chemical
diacetate	I-Chemical
(	O
H2DCFDA	B-Chemical
).	O
Data	O
represent	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O
(	O
a	O
)	O
**	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
no	O
fisetin	B-Chemical
control	O
;	O
(	O
b	O
)	O
**	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
control	O
.	O
##	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
the	O
Tm	B-Chemical
-	O
treated	O
vehicle	O
group	O
.	O
Fisetin	B-Chemical
induces	O
Nrf2	O
-	O
targeted	O
gene	O
expression	O
in	O
the	O
absence	O
of	O
Tm	B-Chemical
.	O
(	O
a	O
","	O
d	O
â€“	O
f	O
)	O
PC12	O
cells	O
were	O
treated	O
with	O
5	O
â€“	O
20	O
ÂµM	O
Fisetin	B-Chemical
for	O
6	O
h	O
.	O
RNA	O
was	O
prepared	O
and	O
the	O
mRNA	O
levels	O
of	O
HO	O
-	O
1	O
","	O
GCLC	O
","	O
GCLM	O
and	O
xCT	O
were	O
analyzed	O
by	O
RT	O
-	O
Q	O
-	O
PCR	O
and	O
normalized	O
to	O
Î²	O
-	O
actin	O
;	O
(	O
b	O
","	O
c	O
)	O
PC12	O
cells	O
were	O
treated	O
with	O
5	O
â€“	O
20	O
ÂµM	O
fisetin	B-Chemical
for	O
8	O
or	O
16	O
h	O
;	O
subsequently	O
","	O
the	O
cell	O
lysates	O
were	O
subjected	O
to	O
immunoblotting	O
for	O
HO	O
-	O
1	O
and	O
Î±	O
-	O
tubulin	O
.	O
Immunoblots	O
were	O
then	O
analyzed	O
using	O
ImageJ	O
software	O
.	O
Data	O
represent	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O
*	O
p	O
<	O
0	O
.	O
5	O
","	O
and	O
**	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
vehicle	O
control	O
.	O
Effects	O
of	O
fisetin	B-Chemical
on	O
Nrf2	O
-	O
targeted	O
gene	O
expression	O
in	O
the	O
presence	O
of	O
Tm	B-Chemical
.	O
(	O
a	O
","	O
d	O
â€“	O
f	O
)	O
PC12	O
cells	O
were	O
treated	O
with	O
fisetin	B-Chemical
30	O
min	O
prior	O
to	O
Tm	B-Chemical
co	O
-	O
treatment	O
for	O
12	O
h	O
at	O
37	O
Â°	O
C	O
.	O
The	O
mRNA	O
levels	O
of	O
HO	O
-	O
1	O
","	O
GCLC	O
","	O
GCLM	O
and	O
xCT	O
were	O
analyzed	O
by	O
RT	O
-	O
Q	O
-	O
PCR	O
and	O
normalized	O
to	O
Î²	O
-	O
actin	O
;	O
(	O
b	O
)	O
PC12	O
cells	O
were	O
treated	O
with	O
fisetin	B-Chemical
30	O
min	O
prior	O
to	O
Tm	B-Chemical
co	O
-	O
treatment	O
for	O
16	O
h	O
.	O
Immunoblotting	O
of	O
HO	O
-	O
1	O
and	O
Î±	O
-	O
tubulin	O
were	O
employed	O
and	O
the	O
bands	O
were	O
quantitated	O
using	O
ImageJ	O
.	O
The	O
data	O
represent	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O
**	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
vehicle	O
control	O
(	O
without	O
Tm	B-Chemical
);	O
#	O
p	O
<	O
0	O
.	O
1	O
","	O
and	O
##	O
p	O
<	O
0	O
.	O
1	O
represent	O
significant	O
differences	O
compared	O
with	O
the	O
Tm	B-Chemical
-	O
treated	O
vehicle	O
group	O
;	O
(	O
c	O
)	O
Effects	O
of	O
inhibition	O
of	O
HO	O
-	O
1	O
activity	O
on	O
cell	O
viability	O
.	O
PC12	O
cells	O
were	O
pretreated	O
for	O
30	O
min	O
with	O
Znpp	B-Chemical
","	O
and	O
fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
was	O
then	O
added	O
30	O
min	O
prior	O
to	O
Tm	B-Chemical
exposure	O
for	O
16	O
h	O
.	O
MTT	B-Chemical
was	O
used	O
to	O
analyze	O
the	O
cell	O
viability	O
.	O
Data	O
represent	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O
**	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
the	O
Tm	B-Chemical
-	O
treated	O
respective	O
vehicle	O
group	O
.	O
##	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
the	O
respective	O
no	O
inhibitor	O
group	O
.	O
Involvement	O
of	O
MAPK	O
signaling	O
pathways	O
in	O
the	O
cytoprotective	O
effects	O
of	O
fisetin	B-Chemical
.	O
(	O
a	O
","	O
b	O
)	O
Effects	O
of	O
fisetin	B-Chemical
on	O
MAPK	O
activation	O
.	O
PC12	O
cells	O
were	O
treated	O
with	O
fisetin	B-Chemical
30	O
min	O
prior	O
to	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
treatment	O
for	O
2	O
and	O
4	O
h	O
at	O
37	O
Â°	O
C	O
.	O
Cell	O
lysates	O
were	O
prepared	O
and	O
the	O
levels	O
of	O
MAPK	O
activation	O
were	O
analyzed	O
by	O
immunoblotting	O
;	O
(	O
c	O
","	O
d	O
)	O
Effects	O
of	O
inhibition	O
of	O
JNK	O
and	O
p38	O
MAPK	O
activation	O
on	O
cell	O
viability	O
.	O
PC12	O
cells	O
were	O
pretreated	O
for	O
30	O
min	O
with	O
5	O
ÂµM	O
JNK	O
(	O
SP600125	B-Chemical
)	O
or	O
p38	O
MAPK	O
inhibitor	O
(	O
SB203580	B-Chemical
)	O
and	O
5	O
â€“	O
20	O
ÂµM	O
fisetin	B-Chemical
was	O
then	O
added	O
30	O
min	O
prior	O
to	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
exposure	O
for	O
16	O
h	O
.	O
MTT	B-Chemical
was	O
used	O
to	O
analyze	O
the	O
cell	O
viability	O
.	O
Data	O
represent	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O
**	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
the	O
Tm	B-Chemical
-	O
treated	O
respective	O
vehicle	O
group	O
.	O
#	O
p	O
<	O
0	O
.	O
5	O
and	O
##	O
p	O
<	O
0	O
.	O
1	O
represent	O
significant	O
differences	O
compared	O
with	O
the	O
respective	O
no	O
inhibitor	O
group	O
.	O
Effects	O
of	O
JNK	O
and	O
p38	O
MAPK	O
inhibitors	O
on	O
UPR	O
and	O
oxidative	O
stress	O
response	O
gene	O
expression	O
in	O
response	O
to	O
Tm	B-Chemical
.	O
PC12	O
cells	O
were	O
pretreated	O
for	O
30	O
min	O
with	O
5	O
ÂµM	O
JNK	O
(	O
SP600125	B-Chemical
)	O
or	O
p38	O
MAPK	O
inhibitor	O
(	O
SB203580	B-Chemical
)	O
and	O
fisetin	B-Chemical
was	O
then	O
added	O
30	O
min	O
prior	O
to	O
Tm	B-Chemical
exposure	O
.	O
(	O
a	O
","	O
b	O
)	O
The	O
mRNA	O
levels	O
of	O
HO	O
-	O
1	O
and	O
xCT	O
were	O
analyzed	O
from	O
RNA	O
isolated	O
after	O
12	O
h	O
treatment	O
of	O
Tm	B-Chemical
;	O
(	O
c	O
","	O
d	O
)	O
The	O
mRNA	O
levels	O
of	O
CHOP	O
and	O
GRP78	O
were	O
analyzed	O
from	O
RNA	O
isolated	O
after	O
6	O
h	O
treatment	O
of	O
Tm	B-Chemical
.	O
Data	O
represent	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O
**	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
the	O
Tm	B-Chemical
-	O
treated	O
respective	O
vehicle	O
group	O
.	O
##	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
the	O
respective	O
no	O
inhibitor	O
group	O
.	O
SIRT1	O
activity	O
and	O
overexpression	O
is	O
involved	O
in	O
the	O
fisetin	B-Chemical
-	O
mediated	O
cytoprotective	O
effect	O
.	O
(	O
a	O
","	O
b	O
)	O
Fisetin	B-Chemical
reverses	O
Tm	B-Chemical
-	O
mediated	O
SIRT1	O
downregulation	O
.	O
PC12	O
cells	O
were	O
treated	O
with	O
fisetin	B-Chemical
(	O
5	O
â€“	O
20	O
ÂµM	O
)	O
30	O
min	O
prior	O
to	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
treatment	O
for	O
16	O
h	O
at	O
37	O
Â°	O
C	O
.	O
Cell	O
lysates	O
were	O
prepared	O
and	O
the	O
levels	O
of	O
SIRT1	O
and	O
Î±	O
-	O
tubulin	O
were	O
analyzed	O
by	O
immunoblotting	O
.	O
Data	O
represent	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O
**	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
control	O
.	O
##	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
the	O
Tm	B-Chemical
-	O
treated	O
vehicle	O
group	O
;	O
(	O
c	O
)	O
Effects	O
of	O
inhibition	O
of	O
SIRT1	O
activity	O
on	O
cell	O
viability	O
.	O
PC12	O
cells	O
were	O
pretreated	O
for	O
30	O
min	O
with	O
15	O
ÂµM	O
sirtinol	B-Chemical
and	O
10	O
or	O
20	O
ÂµM	O
fisetin	B-Chemical
was	O
then	O
added	O
30	O
min	O
prior	O
to	O
Tm	B-Chemical
(	O
1	O
Âµg	O
/	O
mL	O
)	O
exposure	O
for	O
16	O
h	O
.	O
MTT	B-Chemical
was	O
used	O
to	O
analyze	O
the	O
cell	O
viability	O
.	O
Data	O
represent	O
the	O
mean	O
Â±	O
SD	O
of	O
three	O
independent	O
experiments	O
.	O
**	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
the	O
Tm	B-Chemical
-	O
treated	O
respective	O
vehicle	O
group	O
.	O
##	O
p	O
<	O
0	O
.	O
1	O
represents	O
significant	O
differences	O
compared	O
with	O
the	O
respective	O
no	O
inhibitor	O
group	O
.	O
Primary	O
antibodies	O
used	O
in	O
Western	O
blotting	O
.	O
Primer	O
pairs	O
used	O
in	O
RT	O
-	O
Q	O
-	O
PCR	O
.	O
Occupational	O
exposure	O
to	O
chlorinated	O
solvents	O
and	O
risk	O
of	O
head	O
and	O
neck	O
cancer	O
in	O
men	O
:	O
a	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
in	O
France	O
Background	O
Few	O
epidemiological	O
studies	O
have	O
investigated	O
the	O
link	O
between	O
occupational	O
exposure	O
to	O
solvents	O
and	O
head	O
and	O
neck	O
cancer	O
risk	O
","	O
and	O
available	O
findings	O
are	O
sparse	O
and	O
inconsistent	O
.	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
association	O
between	O
occupational	O
exposure	O
to	O
chlorinated	O
solvents	O
and	O
head	O
and	O
neck	O
cancer	O
risk	O
.	O
Methods	O
We	O
analyzed	O
data	O
from	O
4637	O
men	O
(	O
1857	O
cases	O
and	O
2780	O
controls	O
)	O
included	O
in	O
a	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
","	O
ICARE	O
(	O
France	O
).	O
Occupational	O
exposure	O
to	O
five	O
chlorinated	O
solvents	O
(	O
perchloroethylene	B-Chemical
[	O
PCE	B-Chemical
"],"	O
trichloroethylene	B-Chemical
[	O
TCE	B-Chemical
"],"	O
methylene	B-Chemical
chloride	I-Chemical
[	O
MC	B-Chemical
"],"	O
chloroform	B-Chemical
[	O
CF	B-Chemical
"],"	O
and	O
carbon	B-Chemical
tetrachloride	I-Chemical
[	O
CT	B-Chemical
])	O
was	O
assessed	O
through	O
job	O
-	O
exposure	O
matrices	O
.	O
Odds	O
ratios	O
(	O
ORs	O
)	O
and	O
confidence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
were	O
estimated	O
by	O
unconditional	O
logistic	O
regression	O
","	O
adjusted	O
for	O
age	O
","	O
tobacco	O
smoking	O
","	O
alcohol	B-Chemical
consumption	O
","	O
asbestos	B-Chemical
exposure	O
","	O
and	O
other	O
potential	O
confounders	O
.	O
Results	O
We	O
observed	O
no	O
association	O
between	O
chlorinated	O
solvent	O
exposure	O
and	O
head	O
and	O
neck	O
cancer	O
risk	O
","	O
despite	O
a	O
non	O
-	O
significant	O
increase	O
in	O
risk	O
among	O
subjects	O
who	O
had	O
the	O
highest	O
cumulative	O
level	O
of	O
exposure	O
to	O
PCE	B-Chemical
","	O
(	O
OR	O
=	O
1	O
.	O
81	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
68	O
to	O
4	O
.	O
82	O
).	O
In	O
subsite	O
analysis	O
","	O
the	O
risk	O
of	O
laryngeal	O
cancer	O
increased	O
with	O
cumulative	O
exposure	O
to	O
PCE	B-Chemical
(	O
p	O
for	O
trend	O
=	O
0	O
.	O
4	O
).	O
The	O
OR	O
was	O
3	O
.	O
86	O
(	O
95	O
%	O
CI	O
=	O
1	O
.	O
30	O
to	O
11	O
.	O
48	O
)	O
for	O
those	O
exposed	O
to	O
the	O
highest	O
levels	O
of	O
PCE	B-Chemical
.	O
A	O
non	O
-	O
significant	O
elevated	O
risk	O
of	O
hypopharyngeal	O
cancer	O
was	O
also	O
observed	O
in	O
subjects	O
exposed	O
to	O
the	O
highest	O
levels	O
of	O
MC	B-Chemical
(	O
OR	O
=	O
2	O
.	O
36	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
98	O
to	O
5	O
.	O
85	O
).	O
Conclusion	O
Our	O
findings	O
provide	O
evidence	O
that	O
high	O
exposure	O
to	O
PCE	B-Chemical
increases	O
the	O
risk	O
of	O
laryngeal	O
cancer	O
","	O
and	O
suggest	O
an	O
association	O
between	O
exposure	O
to	O
MC	B-Chemical
and	O
hypopharyngeal	O
cancer	O
.	O
Exposure	O
to	O
other	O
chlorinated	O
solvents	O
was	O
not	O
associated	O
with	O
the	O
risk	O
of	O
head	O
and	O
neck	O
cancer	O
.	O
Electronic	O
supplementary	O
material	O
The	O
online	O
version	O
of	O
this	O
article	O
(	O
doi	O
:	O
10	O
.	O
1186	O
/	O
s12940	O
-	O
17	O
-	O
286	O
-	O
5	O
)	O
contains	O
supplementary	O
material	O
","	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O
Background	O
Until	O
recently	O
","	O
chlorinated	O
solvents	O
have	O
been	O
widely	O
used	O
in	O
practically	O
all	O
branches	O
of	O
modern	O
industry	O
.	O
Their	O
use	O
has	O
since	O
decreased	O
in	O
response	O
to	O
various	O
factors	O
","	O
including	O
increasing	O
knowledge	O
pertaining	O
to	O
their	O
toxicity	O
and	O
environmental	O
impact	O
[â€“].	O
Several	O
chlorinated	O
solvents	O
are	O
known	O
or	O
suspected	O
carcinogens	O
.	O
Commonly	O
used	O
for	O
metal	O
cleaning	O
and	O
degreasing	O
","	O
trichloroethylene	B-Chemical
(	O
TCE	B-Chemical
)	O
was	O
classified	O
in	O
2012	O
as	O
carcinogenic	O
for	O
humans	O
(	O
group	O
1	O
)	O
by	O
the	O
International	O
Agency	O
for	O
Research	O
on	O
Cancer	O
(	O
IARC	O
"),"	O
based	O
on	O
sufficient	O
evidence	O
that	O
it	O
causes	O
kidney	O
cancer	O
and	O
limited	O
evidence	O
for	O
liver	O
cancer	O
and	O
non	O
-	O
Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
[].	O
The	O
same	O
year	O
","	O
perchloroethylene	B-Chemical
(	O
PCE	B-Chemical
"),"	O
widely	O
used	O
in	O
the	O
dry	O
cleaning	O
sector	O
","	O
was	O
classified	O
as	O
a	O
probable	O
carcinogen	O
(	O
group	O
2A	O
"),"	O
based	O
on	O
limited	O
evidence	O
of	O
an	O
increased	O
risk	O
of	O
bladder	O
cancer	O
[].	O
More	O
recently	O
","	O
methylene	B-Chemical
chloride	I-Chemical
(	O
MC	B-Chemical
)	O
was	O
also	O
classified	O
as	O
a	O
probable	O
carcinogen	O
(	O
group	O
2A	O
)	O
based	O
on	O
limited	O
evidence	O
that	O
it	O
causes	O
biliary	O
tract	O
cancer	O
and	O
NHL	O
[].	O
Moreover	O
","	O
chloroform	B-Chemical
(	O
CF	B-Chemical
)	O
and	O
carbon	B-Chemical
tetrachloride	I-Chemical
(	O
CT	B-Chemical
)	O
are	O
considered	O
to	O
be	O
possibly	O
carcinogenic	O
(	O
group	O
2B	O
)	O
[].	O
Few	O
epidemiological	O
studies	O
have	O
examined	O
the	O
link	O
between	O
occupational	O
exposure	O
to	O
chlorinated	O
solvents	O
and	O
head	O
and	O
neck	O
cancer	O
risk	O
","	O
and	O
available	O
findings	O
are	O
sparse	O
and	O
inconsistent	O
.	O
Cohort	O
studies	O
could	O
not	O
control	O
for	O
smoking	O
and	O
alcohol	B-Chemical
use	O
and	O
lacked	O
statistical	O
power	O
to	O
detect	O
moderate	O
increases	O
in	O
risk	O
","	O
because	O
they	O
were	O
often	O
conducted	O
in	O
countries	O
where	O
the	O
incidence	O
of	O
head	O
and	O
neck	O
cancer	O
is	O
low	O
.	O
However	O
","	O
non	O
-	O
significant	O
increases	O
in	O
the	O
risk	O
of	O
oral	O
","	O
pharyngeal	O
","	O
and	O
laryngeal	O
cancer	O
were	O
found	O
in	O
several	O
cohorts	O
of	O
workers	O
exposed	O
to	O
TCE	B-Chemical
or	O
PCE	B-Chemical
"[,"	O
].	O
Case	O
-	O
control	O
studies	O
included	O
proper	O
adjustment	O
for	O
confounders	O
","	O
but	O
exposure	O
to	O
solvents	O
was	O
often	O
not	O
well	O
characterized	O
.	O
Exposure	O
to	O
solvents	O
in	O
general	O
has	O
been	O
found	O
to	O
be	O
associated	O
with	O
oral	O
and	O
pharyngeal	O
[]	O
or	O
laryngeal	O
and	O
hypopharyngeal	O
[]	O
cancer	O
risk	O
","	O
although	O
others	O
did	O
not	O
find	O
an	O
association	O
[].	O
Shangina	O
et	O
al	O
.	O
found	O
a	O
significantly	O
increased	O
risk	O
of	O
laryngeal	O
cancer	O
associated	O
with	O
chlorinated	O
solvent	O
exposure	O
[]	O
and	O
Vaughan	O
et	O
al	O
.	O
found	O
a	O
non	O
-	O
significant	O
increased	O
risk	O
of	O
oral	O
","	O
pharyngeal	O
","	O
and	O
laryngeal	O
cancer	O
among	O
subjects	O
exposed	O
to	O
PCE	B-Chemical
[].	O
No	O
study	O
has	O
yet	O
examined	O
the	O
association	O
between	O
exposure	O
to	O
several	O
specific	O
chlorinated	O
solvents	O
and	O
head	O
and	O
neck	O
cancer	O
risk	O
","	O
by	O
cancer	O
site	O
.	O
In	O
a	O
previous	O
analysis	O
of	O
our	O
study	O
population	O
by	O
occupation	O
","	O
we	O
observed	O
increased	O
risks	O
of	O
head	O
and	O
neck	O
cancer	O
in	O
dry	O
cleaners	O
and	O
metal	O
workers	O
","	O
suggesting	O
a	O
possible	O
role	O
of	O
exposure	O
to	O
chlorinated	O
solvents	O
[].	O
Here	O
","	O
our	O
objective	O
was	O
to	O
investigate	O
the	O
association	O
between	O
exposure	O
to	O
five	O
chlorinated	O
solvents	O
and	O
head	O
and	O
neck	O
cancer	O
risk	O
","	O
using	O
data	O
from	O
a	O
large	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
","	O
the	O
ICARE	O
study	O
.	O
Methods	O
Study	O
design	O
and	O
population	O
The	O
ICARE	O
study	O
is	O
a	O
French	O
multicenter	O
","	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
","	O
conducted	O
between	O
2001	O
and	O
2007	O
in	O
ten	O
geographical	O
areas	O
covered	O
by	O
a	O
cancer	O
registry	O
.	O
The	O
study	O
design	O
has	O
been	O
described	O
in	O
detail	O
elsewhere	O
[].	O
Incident	O
cases	O
of	O
head	O
and	O
neck	O
cancers	O
were	O
identified	O
in	O
almost	O
all	O
healthcare	O
establishments	O
in	O
each	O
area	O
","	O
in	O
collaboration	O
with	O
the	O
cancer	O
registries	O
.	O
All	O
new	O
patients	O
with	O
histologically	O
confirmed	O
primitive	O
tumors	O
of	O
the	O
oral	O
cavity	O
","	O
pharynx	O
","	O
sinonasal	O
cavities	O
","	O
and	O
larynx	O
(	O
International	O
Classification	O
of	O
Diseases	O
for	O
Oncology	O
3rd	O
revision	O
(	O
ICD	O
-	O
O	O
-	O
3	O
)	O
codes	O
C00	O
-	O
C14	O
;	O
C30	O
-	O
C32	O
"),"	O
between	O
18	O
and	O
75	O
years	O
old	O
","	O
who	O
were	O
diagnosed	O
during	O
the	O
study	O
period	O
","	O
were	O
eligible	O
for	O
the	O
study	O
.	O
Selection	O
of	O
the	O
control	O
population	O
was	O
made	O
by	O
incidence	O
density	O
sampling	O
.	O
Controls	O
were	O
frequency	O
-	O
matched	O
to	O
cases	O
by	O
gender	O
and	O
age	O
(<	O
40	O
","	O
40	O
â€“	O
54	O
","	O
55	O
â€“	O
64	O
","	O
â‰¥	O
65	O
years	O
old	O
)	O
and	O
further	O
stratification	O
was	O
performed	O
to	O
match	O
the	O
socioeconomic	O
distribution	O
of	O
controls	O
and	O
that	O
of	O
the	O
general	O
population	O
.	O
Among	O
the	O
4047	O
eligible	O
head	O
and	O
neck	O
cancer	O
cases	O
","	O
596	O
(	O
14	O
.	O
7	O
%)	O
patients	O
could	O
not	O
be	O
located	O
","	O
299	O
(	O
7	O
.	O
4	O
%)	O
died	O
before	O
the	O
interview	O
","	O
and	O
225	O
(	O
5	O
.	O
6	O
%)	O
could	O
not	O
be	O
interviewed	O
due	O
to	O
poor	O
health	O
.	O
Among	O
the	O
2927	O
potential	O
subjects	O
who	O
were	O
contacted	O
","	O
2415	O
(	O
82	O
.	O
5	O
%)	O
agreed	O
to	O
participate	O
and	O
were	O
interviewed	O
","	O
on	O
average	O
","	O
within	O
three	O
months	O
of	O
diagnosis	O
"[,"	O
].	O
The	O
present	O
study	O
was	O
restricted	O
to	O
men	O
","	O
as	O
women	O
were	O
analyzed	O
separately	O
"[],"	O
and	O
to	O
squamous	O
cell	O
carcinomas	O
of	O
the	O
oral	O
cavity	O
(	O
Codes	O
of	O
the	O
International	O
Classification	O
of	O
Diseases	O
for	O
Oncology	O
","	O
third	O
edition	O
(	O
ICD	O
-	O
O	O
-	O
3	O
):	O
oral	O
cavity	O
(	O
C00	O
.	O
3	O
â€“	O
9	O
;	O
C02	O
.	O
0	O
â€“	O
3	O
;	O
C03	O
.	O
0	O
â€“	O
1	O
;	O
C03	O
.	O
9	O
","	O
C04	O
.	O
0	O
â€“	O
1	O
;	O
C04	O
.	O
8	O
â€“	O
9	O
;	O
C05	O
.	O
0	O
;	O
C06	O
.	O
0	O
â€“	O
2	O
;	O
C06	O
.	O
8	O
â€“	O
9	O
"),"	O
oropharynx	O
(	O
C01	O
.	O
9	O
;	O
C02	O
.	O
4	O
;	O
C05	O
.	O
1	O
â€“	O
2	O
;	O
C09	O
.	O
0	O
â€“	O
1	O
;	O
C09	O
.	O
8	O
â€“	O
9	O
;	O
C10	O
.	O
0	O
â€“	O
4	O
;	O
C10	O
.	O
8	O
â€“	O
9	O
"),"	O
hypopharynx	O
(	O
C12	O
.	O
9	O
;	O
C13	O
.	O
0	O
â€“	O
2	O
;	O
C13	O
.	O
8	O
;	O
C13	O
.	O
9	O
"),"	O
oral	O
cavity	O
or	O
pharynx	O
not	O
otherwise	O
specified	O
or	O
overlapping	O
(	O
C02	O
.	O
8	O
","	O
C02	O
.	O
9	O
","	O
C05	O
.	O
8	O
","	O
C05	O
.	O
9	O
","	O
C14	O
.	O
0	O
","	O
C14	O
.	O
2	O
","	O
C14	O
.	O
8	O
)	O
and	O
larynx	O
(	O
C32	O
.	O
0	O
â€“	O
3	O
;	O
C	O
32	O
.	O
8	O
â€“	O
9	O
).	O
Overall	O
","	O
1857	O
male	O
cases	O
(	O
350	O
with	O
oral	O
cavity	O
cancers	O
","	O
543	O
with	O
oropharyngeal	O
cancers	O
","	O
383	O
with	O
hypopharyngeal	O
cancers	O
","	O
454	O
with	O
laryngeal	O
cancers	O
","	O
127	O
with	O
cancer	O
of	O
the	O
oral	O
cavity	O
or	O
pharynx	O
not	O
otherwise	O
specified	O
or	O
overlapping	O
)	O
and	O
2780	O
male	O
controls	O
were	O
included	O
.	O
Data	O
collection	O
Trained	O
interviewers	O
conducted	O
face	O
to	O
face	O
interviews	O
using	O
a	O
standardized	O
questionnaire	O
.	O
Data	O
included	O
sociodemographic	O
characteristics	O
","	O
smoking	O
and	O
alcohol	B-Chemical
consumption	O
history	O
","	O
and	O
a	O
detailed	O
lifetime	O
occupational	O
history	O
","	O
which	O
covered	O
all	O
jobs	O
held	O
for	O
at	O
least	O
one	O
month	O
.	O
For	O
subjects	O
who	O
had	O
difficulty	O
answering	O
because	O
of	O
sickness	O
or	O
tiredness	O
","	O
a	O
shorter	O
version	O
of	O
the	O
questionnaire	O
was	O
used	O
for	O
either	O
in	O
-	O
person	O
interview	O
or	O
to	O
interview	O
a	O
next	O
-	O
of	O
-	O
kin	O
.	O
This	O
shorter	O
version	O
included	O
mainly	O
information	O
on	O
smoking	O
","	O
alcohol	B-Chemical
consumption	O
","	O
and	O
occupational	O
history	O
and	O
was	O
used	O
for	O
11	O
%	O
of	O
the	O
cases	O
and	O
2	O
%	O
of	O
the	O
controls	O
.	O
Occupations	O
and	O
branches	O
of	O
industry	O
were	O
coded	O
by	O
trained	O
coders	O
","	O
blinded	O
to	O
the	O
case	O
-	O
control	O
status	O
of	O
the	O
subjects	O
","	O
according	O
to	O
the	O
International	O
Standard	O
Classification	O
of	O
Occupations	O
(	O
ISCO	O
)	O
[]	O
and	O
the	O
French	O
Nomenclature	O
of	O
Activities	O
(	O
NAF	O
)	O
[].	O
Assessment	O
of	O
occupational	O
exposure	O
Occupational	O
exposure	O
to	O
TCE	B-Chemical
","	O
PCE	B-Chemical
","	O
MC	B-Chemical
","	O
CF	B-Chemical
and	O
CT	B-Chemical
was	O
assessed	O
using	O
job	O
-	O
exposure	O
matrices	O
(	O
JEMs	O
"),"	O
developed	O
in	O
the	O
context	O
of	O
the	O
MatgÃ©nÃ©	O
program	O
[].	O
For	O
each	O
combination	O
of	O
ISCO	O
and	O
NAF	O
codes	O
","	O
the	O
JEMs	O
provided	O
three	O
indices	O
of	O
exposure	O
:	O
(	O
i	O
)	O
the	O
probability	O
of	O
exposure	O
expressed	O
as	O
the	O
percentage	O
of	O
exposed	O
workers	O
(	O
categorized	O
into	O
not	O
exposed	O
","	O
1	O
â€“	O
10	O
","	O
11	O
â€“	O
20	O
","	O
21	O
â€“	O
30	O
","	O
up	O
to	O
91	O
â€“	O
100	O
"%),"	O
(	O
ii	O
)	O
the	O
intensity	O
of	O
exposure	O
(	O
for	O
PCE	B-Chemical
","	O
TCE	B-Chemical
and	O
MC	B-Chemical
:	O
not	O
exposed	O
","	O
5	O
â€“	O
25	O
","	O
26	O
â€“	O
50	O
","	O
51	O
â€“	O
100	O
","	O
>	O
100	O
ppm	O
;	O
for	O
CT	B-Chemical
and	O
CF	B-Chemical
:	O
not	O
exposed	O
","	O
very	O
low	O
","	O
low	O
","	O
medium	O
","	O
and	O
high	O
)	O
and	O
(	O
iii	O
)	O
the	O
frequency	O
of	O
exposure	O
(	O
not	O
exposed	O
","	O
1	O
â€“	O
10	O
","	O
11	O
â€“	O
20	O
","	O
21	O
â€“	O
30	O
","	O
up	O
to	O
91	O
â€“	O
100	O
%	O
of	O
working	O
time	O
).	O
In	O
addition	O
","	O
a	O
specific	O
JEM	O
assessed	O
the	O
probability	O
of	O
exposure	O
to	O
at	O
least	O
one	O
of	O
these	O
five	O
chlorinated	O
solvents	O
","	O
together	O
with	O
the	O
average	O
level	O
of	O
exposure	O
during	O
a	O
usual	O
working	O
day	O
.	O
Exposure	O
indices	O
were	O
provided	O
for	O
different	O
calendar	O
periods	O
(	O
1950	O
â€“	O
1969	O
","	O
1970	O
â€“	O
1984	O
","	O
1985	O
â€“	O
1994	O
","	O
>	O
1995	O
)	O
to	O
account	O
for	O
changes	O
in	O
working	O
practices	O
and	O
regulation	O
over	O
time	O
.	O
As	O
an	O
example	O
","	O
in	O
France	O
","	O
for	O
methylene	B-Chemical
chloride	I-Chemical
","	O
exposure	O
limits	O
decreased	O
from	O
100	O
ppm	O
in	O
1985	O
to	O
50	O
ppm	O
in	O
1995	O
","	O
and	O
a	O
general	O
improvement	O
in	O
working	O
conditions	O
was	O
assumed	O
to	O
occur	O
at	O
the	O
beginning	O
of	O
the	O
1970	O
â€™	O
s	O
.	O
After	O
linking	O
these	O
indices	O
with	O
lifetime	O
occupational	O
history	O
","	O
the	O
following	O
exposure	O
variables	O
were	O
obtained	O
for	O
each	O
subject	O
:	O
â€˜	O
ever	O
/	O
never	O
â€™	O
exposed	O
to	O
a	O
specific	O
chlorinated	O
solvent	O
(â€˜	O
ever	O
â€™	O
defined	O
as	O
having	O
worked	O
in	O
at	O
least	O
one	O
job	O
with	O
a	O
probability	O
of	O
exposure	O
greater	O
than	O
zero	O
"),"	O
total	O
duration	O
of	O
exposure	O
","	O
and	O
cumulative	O
exposure	O
index	O
(	O
CEI	O
).	O
CEIs	O
were	O
calculated	O
by	O
summing	O
the	O
product	O
of	O
the	O
exposure	O
probability	O
","	O
frequency	O
","	O
intensity	O
","	O
and	O
duration	O
of	O
each	O
job	O
period	O
","	O
over	O
the	O
entire	O
work	O
history	O
","	O
using	O
the	O
central	O
value	O
of	O
the	O
classes	O
.	O
For	O
exposure	O
to	O
at	O
least	O
one	O
solvent	O
","	O
as	O
the	O
JEM	O
provides	O
the	O
average	O
level	O
and	O
the	O
probability	O
of	O
exposure	O
","	O
the	O
CEI	O
was	O
calculated	O
by	O
summing	O
the	O
product	O
of	O
exposure	O
probability	O
","	O
average	O
level	O
and	O
duration	O
.	O
We	O
then	O
categorized	O
these	O
variables	O
.	O
The	O
duration	O
of	O
exposure	O
to	O
solvents	O
was	O
categorized	O
into	O
four	O
classes	O
:	O
â€˜	O
never	O
exposed	O
"â€™,"	O
and	O
three	O
categories	O
according	O
to	O
approximate	O
tertiles	O
of	O
the	O
distribution	O
among	O
exposed	O
controls	O
","	O
â€˜	O
short	O
"â€™,"	O
â€˜	O
intermediate	O
"â€™,"	O
and	O
â€˜	O
long	O
â€™	O
exposure	O
.	O
To	O
examine	O
potential	O
effects	O
of	O
the	O
highest	O
exposures	O
to	O
chlorinated	O
solvents	O
","	O
CEIs	O
were	O
categorized	O
as	O
follows	O
:	O
â€˜	O
never	O
exposed	O
"â€™,"	O
and	O
three	O
categories	O
according	O
to	O
the	O
percentiles	O
of	O
the	O
distribution	O
among	O
exposed	O
controls	O
(	O
low	O
:	O
<	O
50th	O
;	O
medium	O
:	O
50th	O
â€“	O
90th	O
;	O
high	O
:	O
>	O
90th	O
).	O
The	O
CEI	O
categories	O
â€œ	O
medium	O
â€	O
and	O
â€œ	O
high	O
â€	O
for	O
exposure	O
to	O
CF	B-Chemical
and	O
CT	B-Chemical
were	O
combined	O
because	O
of	O
the	O
small	O
number	O
of	O
subjects	O
in	O
these	O
groups	O
.	O
We	O
estimated	O
the	O
prevalence	O
of	O
lifelong	O
exposure	O
to	O
chlorinated	O
solvents	O
by	O
weighting	O
the	O
number	O
of	O
subjects	O
exposed	O
in	O
each	O
class	O
of	O
maximum	O
probability	O
by	O
the	O
central	O
value	O
of	O
the	O
class	O
.	O
Non	O
-	O
exposed	O
subjects	O
were	O
then	O
recalculated	O
accordingly	O
.	O
Occupational	O
exposure	O
to	O
asbestos	B-Chemical
was	O
assessed	O
through	O
a	O
specific	O
JEM	O
[].	O
Other	O
variables	O
Covariates	O
included	O
age	O
at	O
interview	O
in	O
categories	O
[	O
years	O
]	O
(<	O
40	O
;	O
[	O
40	O
â€“	O
49	O
];	O
[	O
50	O
â€“	O
59	O
];	O
[	O
60	O
â€“	O
69	O
];	O
â‰¥	O
70	O
"),"	O
area	O
of	O
residence	O
","	O
alcohol	B-Chemical
consumption	O
in	O
categories	O
[	O
glasses	O
/	O
day	O
]	O
(<	O
0	O
.	O
3	O
:	O
occasional	O
consumption	O
;	O
[	O
0	O
.	O
3	O
â€“	O
2	O
.	O
0	O
];	O
[	O
2	O
.	O
1	O
â€“	O
5	O
.	O
0	O
];	O
[	O
5	O
.	O
1	O
â€“	O
8	O
.	O
0	O
];	O
[	O
8	O
.	O
1	O
â€“	O
12	O
.	O
0	O
];	O
>	O
12	O
"),"	O
daily	O
amount	O
of	O
tobacco	O
in	O
categories	O
[	O
g	O
/	O
day	O
]	O
(	O
0	O
;	O
[	O
0	O
â€“	O
10	O
]	O
[	O
11	O
â€“	O
20	O
];	O
[	O
21	O
â€“	O
25	O
];	O
â‰¥	O
25	O
"),"	O
duration	O
of	O
tobacco	O
smoking	O
in	O
categories	O
[	O
years	O
]	O
(	O
0	O
;	O
[	O
0	O
â€“	O
20	O
];	O
[	O
21	O
â€“	O
30	O
];	O
[	O
31	O
â€“	O
40	O
];	O
â‰¥	O
40	O
"),"	O
smoking	O
status	O
(â€˜	O
never	O
"â€™,"	O
â€˜	O
former	O
â€™	O
[	O
time	O
since	O
stopping	O
smoking	O
>	O
2	O
years	O
before	O
the	O
interview	O
"],"	O
and	O
â€˜	O
current	O
â€™	O
[	O
time	O
since	O
stopping	O
smoking	O
â‰¤	O
2	O
years	O
before	O
the	O
interview	O
]).	O
We	O
also	O
fitted	O
models	O
with	O
and	O
without	O
cumulative	O
asbestos	B-Chemical
exposure	O
in	O
four	O
categories	O
(	O
never	O
exposed	O
","	O
and	O
tertiles	O
according	O
to	O
the	O
distribution	O
among	O
exposed	O
controls	O
).	O
As	O
the	O
inclusion	O
of	O
asbestos	B-Chemical
exposure	O
resulted	O
in	O
changes	O
in	O
ORs	O
for	O
most	O
solvents	O
and	O
no	O
change	O
in	O
OR	O
point	O
estimate	O
without	O
loss	O
of	O
precision	O
for	O
the	O
others	O
","	O
we	O
present	O
below	O
the	O
models	O
adjusted	O
for	O
asbestos	B-Chemical
exposure	O
(	O
to	O
assess	O
the	O
magnitude	O
of	O
confounding	O
","	O
OR	O
estimates	O
without	O
adjustment	O
for	O
asbestos	B-Chemical
are	O
presented	O
in	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
).	O
Statistical	O
analysis	O
Multivariable	O
unconditional	O
logistic	O
regression	O
models	O
were	O
used	O
to	O
model	O
associations	O
between	O
chlorinated	O
solvents	O
and	O
head	O
and	O
neck	O
cancer	O
risk	O
.	O
Odds	O
-	O
ratios	O
(	O
ORs	O
)	O
and	O
corresponding	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
were	O
adjusted	O
for	O
previously	O
described	O
covariates	O
.	O
Each	O
solvent	O
was	O
analyzed	O
separately	O
.	O
We	O
also	O
estimated	O
mutually	O
adjusted	O
ORs	O
in	O
a	O
model	O
including	O
all	O
solvents	O
.	O
Tests	O
for	O
linear	O
trends	O
were	O
performed	O
by	O
modelling	O
the	O
median	O
of	O
each	O
category	O
as	O
a	O
continuous	O
variable	O
.	O
Additional	O
analyses	O
were	O
performed	O
in	O
separate	O
models	O
adjusting	O
for	O
educational	O
level	O
or	O
occupational	O
class	O
of	O
the	O
longest	O
job	O
held	O
.	O
We	O
also	O
conducted	O
analyses	O
by	O
cancer	O
site	O
(	O
oral	O
cavity	O
","	O
oropharynx	O
","	O
hypopharynx	O
","	O
oral	O
cavity	O
or	O
pharynx	O
not	O
specified	O
","	O
and	O
larynx	O
)	O
and	O
subsites	O
using	O
polytomous	O
logistic	O
regression	O
.	O
Finally	O
","	O
to	O
determine	O
whether	O
joint	O
-	O
exposure	O
to	O
several	O
chlorinated	O
solvents	O
was	O
associated	O
with	O
head	O
and	O
neck	O
cancer	O
risk	O
","	O
we	O
examined	O
the	O
risk	O
associated	O
with	O
combinations	O
of	O
chlorinated	O
solvents	O
with	O
sufficient	O
numbers	O
(	O
at	O
least	O
10	O
exposed	O
cases	O
"),"	O
using	O
â€œ	O
never	O
exposed	O
to	O
any	O
chlorinated	O
solvents	O
â€	O
as	O
the	O
reference	O
category	O
.	O
For	O
each	O
solvent	O
","	O
we	O
also	O
assessed	O
potential	O
interactions	O
with	O
smoking	O
","	O
alcohol	B-Chemical
drinking	O
and	O
asbestos	B-Chemical
exposure	O
by	O
including	O
cross	O
-	O
product	O
terms	O
in	O
the	O
models	O
.	O
None	O
of	O
the	O
interactions	O
were	O
statistically	O
significant	O
","	O
and	O
the	O
results	O
were	O
not	O
presented	O
.	O
We	O
also	O
conducted	O
sensitivity	O
analyses	O
excluding	O
subjects	O
with	O
the	O
shorter	O
version	O
of	O
the	O
questionnaire	O
","	O
and	O
the	O
results	O
were	O
similar	O
(	O
data	O
not	O
shown	O
).	O
Results	O
Main	O
characteristics	O
of	O
cases	O
and	O
controls	O
The	O
age	O
distribution	O
differed	O
slightly	O
between	O
cases	O
and	O
controls	O
","	O
but	O
the	O
mean	O
age	O
was	O
similar	O
.	O
Cases	O
had	O
a	O
lower	O
level	O
of	O
education	O
than	O
controls	O
and	O
were	O
more	O
often	O
blue	O
collar	O
workers	O
.	O
As	O
expected	O
","	O
cases	O
were	O
more	O
often	O
smokers	O
than	O
controls	O
and	O
had	O
a	O
higher	O
level	O
of	O
alcohol	B-Chemical
consumption	O
(	O
Table	O
1	O
).	O
Concerning	O
lifetime	O
exposure	O
to	O
chlorinated	O
solvents	O
","	O
the	O
most	O
prevalent	O
exposure	O
was	O
to	O
TCE	B-Chemical
with	O
8	O
.	O
76	O
%	O
of	O
cases	O
and	O
7	O
.	O
53	O
%	O
of	O
controls	O
exposed	O
followed	O
by	O
MC	B-Chemical
with	O
1	O
.	O
43	O
%	O
of	O
cases	O
and	O
1	O
.	O
14	O
%	O
of	O
controls	O
exposed	O
.	O
The	O
prevalence	O
of	O
exposure	O
to	O
PCE	B-Chemical
","	O
CF	B-Chemical
","	O
and	O
CT	B-Chemical
was	O
lower	O
with	O
0	O
.	O
44	O
"%,"	O
0	O
.	O
9	O
"%,"	O
and	O
0	O
.	O
6	O
%	O
of	O
cases	O
","	O
and	O
0	O
.	O
28	O
"%,"	O
0	O
.	O
16	O
"%,"	O
and	O
0	O
.	O
9	O
%	O
of	O
controls	O
","	O
respectively	O
.	O
Exposures	O
to	O
solvents	O
were	O
correlated	O
","	O
and	O
were	O
also	O
correlated	O
with	O
exposure	O
to	O
asbestos	B-Chemical
(	O
Additional	O
File	O
1	O
:	O
Fig	O
.	O
S1	O
).	O
Association	O
between	O
head	O
and	O
neck	O
cancer	O
and	O
exposure	O
to	O
chlorinated	O
solvents	O
Individual	O
analysis	O
of	O
the	O
solvents	O
(	O
Table	O
2	O
)	O
showed	O
no	O
significant	O
association	O
between	O
ever	O
exposure	O
","	O
duration	O
of	O
exposure	O
","	O
or	O
cumulative	O
exposure	O
to	O
PCE	B-Chemical
","	O
TCE	B-Chemical
","	O
MC	B-Chemical
","	O
CF	B-Chemical
","	O
or	O
CT	B-Chemical
and	O
head	O
and	O
neck	O
cancer	O
risk	O
.	O
However	O
","	O
we	O
observed	O
a	O
non	O
-	O
significant	O
increased	O
risk	O
among	O
subjects	O
who	O
had	O
the	O
highest	O
cumulative	O
levels	O
of	O
exposure	O
to	O
PCE	B-Chemical
or	O
MC	B-Chemical
relative	O
to	O
never	O
exposed	O
subjects	O
(	O
OR	O
=	O
1	O
.	O
81	O
","	O
95	O
%	O
CI	O
[	O
0	O
.	O
68	O
to	O
4	O
.	O
82	O
]	O
and	O
OR	O
=	O
1	O
.	O
42	O
","	O
95	O
%	O
CI	O
[	O
0	O
.	O
70	O
to	O
2	O
.	O
87	O
"],"	O
respectively	O
).	O
Further	O
adjustment	O
for	O
the	O
level	O
of	O
education	O
or	O
occupational	O
class	O
did	O
not	O
substantially	O
modify	O
the	O
results	O
(	O
see	O
Additional	O
file	O
1	O
:	O
Tables	O
S2	O
and	O
S3	O
).	O
Association	O
between	O
head	O
and	O
neck	O
cancer	O
and	O
exposure	O
to	O
chlorinated	O
solvents	O
.	O
Mutually	O
adjusted	O
ORs	O
The	O
results	O
remained	O
globally	O
unchanged	O
when	O
we	O
included	O
all	O
solvents	O
in	O
the	O
model	O
(	O
Table	O
3	O
).	O
Association	O
between	O
head	O
and	O
neck	O
cancer	O
sites	O
and	O
exposure	O
to	O
chlorinated	O
solvents	O
Analysis	O
of	O
specific	O
head	O
and	O
neck	O
cancer	O
sites	O
(	O
Table	O
4	O
)	O
showed	O
a	O
significant	O
dose	O
-	O
response	O
relationship	O
between	O
cumulative	O
exposure	O
to	O
PCE	B-Chemical
and	O
laryngeal	O
cancer	O
risk	O
(	O
p	O
for	O
trend	O
=	O
0	O
.	O
4	O
"),"	O
and	O
subjects	O
who	O
had	O
the	O
highest	O
cumulative	O
levels	O
of	O
exposure	O
to	O
PCE	B-Chemical
had	O
a	O
significantly	O
higher	O
risk	O
of	O
laryngeal	O
cancer	O
(	O
OR	O
=	O
3	O
.	O
86	O
;	O
95	O
%	O
CI	O
=	O
[	O
1	O
.	O
30	O
to	O
11	O
.	O
48	O
]).	O
The	O
OR	O
was	O
lower	O
than	O
1	O
in	O
the	O
medium	O
exposure	O
category	O
","	O
but	O
the	O
confidence	O
intervals	O
around	O
each	O
OR	O
were	O
wide	O
.	O
We	O
used	O
restricted	O
cubic	O
splines	O
(	O
4	O
knots	O
)	O
to	O
verify	O
the	O
linearity	O
assumption	O
","	O
and	O
no	O
significant	O
departure	O
from	O
linearity	O
was	O
found	O
(	O
p	O
=	O
0	O
.	O
61	O
).	O
In	O
addition	O
","	O
we	O
observed	O
an	O
elevated	O
OR	O
(	O
OR	O
=	O
2	O
.	O
36	O
;	O
95	O
%	O
CI	O
[	O
0	O
.	O
98	O
to	O
5	O
.	O
85	O
])	O
for	O
hypopharyngeal	O
cancer	O
among	O
subjects	O
with	O
the	O
highest	O
levels	O
of	O
exposure	O
to	O
MC	B-Chemical
","	O
although	O
the	O
trend	O
was	O
not	O
significant	O
(	O
p	O
=	O
0	O
.	O
22	O
).	O
The	O
risk	O
of	O
laryngeal	O
cancer	O
associated	O
with	O
the	O
highest	O
level	O
of	O
cumulative	O
exposure	O
to	O
PCE	B-Chemical
remained	O
significantly	O
elevated	O
when	O
adjusted	O
for	O
occupational	O
class	O
(	O
OR	O
=	O
3	O
.	O
9	O
;	O
95	O
%	O
CI	O
[	O
1	O
.	O
5	O
to	O
9	O
.	O
13	O
])	O
or	O
level	O
of	O
education	O
(	O
OR	O
=	O
3	O
.	O
42	O
;	O
95	O
%	O
CI	O
[	O
1	O
.	O
9	O
to	O
5	O
.	O
77	O
]).	O
However	O
","	O
adjustment	O
for	O
occupational	O
class	O
and	O
level	O
of	O
education	O
for	O
high	O
levels	O
of	O
exposure	O
to	O
MC	B-Chemical
decreased	O
the	O
OR	O
of	O
hypopharyngeal	O
cancer	O
(	O
OR	O
=	O
2	O
.	O
8	O
;	O
95	O
%	O
CI	O
[	O
0	O
.	O
86	O
to	O
5	O
.	O
4	O
]	O
and	O
OR	O
=	O
1	O
.	O
57	O
;	O
95	O
%	O
CI	O
[	O
0	O
.	O
60	O
to	O
4	O
.	O
12	O
"],"	O
respectively	O
).	O
Association	O
between	O
head	O
and	O
neck	O
cancer	O
and	O
exclusive	O
exposure	O
to	O
combinations	O
of	O
chlorinated	O
solvents	O
We	O
found	O
no	O
significant	O
association	O
between	O
combinations	O
of	O
chlorinated	O
solvents	O
with	O
at	O
least	O
10	O
exposed	O
cases	O
and	O
head	O
and	O
neck	O
cancer	O
risk	O
","	O
or	O
specific	O
subsites	O
(	O
Table	O
5	O
).	O
However	O
","	O
although	O
we	O
observed	O
no	O
increase	O
in	O
laryngeal	O
cancer	O
risk	O
for	O
subjects	O
who	O
were	O
exposed	O
to	O
only	O
TCE	B-Chemical
(	O
OR	O
=	O
0	O
.	O
84	O
;	O
95	O
%	O
CI	O
[	O
0	O
.	O
63	O
to	O
1	O
.	O
12	O
"]),"	O
or	O
the	O
combination	O
of	O
TCE	B-Chemical
and	O
MC	B-Chemical
(	O
OR	O
=	O
0	O
.	O
95	O
;	O
95	O
%	O
CI	O
[	O
0	O
.	O
59	O
to	O
1	O
.	O
53	O
"]),"	O
the	O
risk	O
of	O
laryngeal	O
cancer	O
was	O
non	O
-	O
significantly	O
elevated	O
for	O
subjects	O
who	O
were	O
exposed	O
to	O
the	O
combination	O
of	O
TCE	B-Chemical
","	O
PCE	B-Chemical
","	O
and	O
MC	B-Chemical
(	O
OR	O
=	O
1	O
.	O
32	O
;	O
95	O
%	O
CI	O
[	O
0	O
.	O
68	O
to	O
2	O
.	O
55	O
]).	O
Finally	O
","	O
we	O
investigated	O
the	O
association	O
between	O
PCE	B-Chemical
exposure	O
and	O
the	O
risk	O
of	O
cancer	O
of	O
subsites	O
of	O
the	O
larynx	O
(	O
glottis	O
/	O
subglottis	O
","	O
supraglottis	O
","	O
and	O
other	O
or	O
non	O
-	O
specified	O
).	O
The	O
OR	O
associated	O
with	O
the	O
highest	O
cumulative	O
level	O
of	O
exposure	O
to	O
PCE	B-Chemical
was	O
higher	O
for	O
cancer	O
of	O
the	O
glottis	O
/	O
subglottis	O
(	O
OR	O
=	O
5	O
.	O
95	O
;	O
95	O
%	O
CI	O
[	O
1	O
.	O
73	O
to	O
20	O
.	O
53	O
];	O
five	O
exposed	O
cases	O
)	O
than	O
for	O
cancer	O
of	O
the	O
supraglottis	O
(	O
OR	O
=	O
3	O
.	O
96	O
;	O
95	O
%	O
CI	O
[	O
0	O
.	O
72	O
to	O
21	O
.	O
78	O
];	O
two	O
exposed	O
cases	O
)	O
or	O
of	O
other	O
/	O
non	O
-	O
specified	O
subsites	O
(	O
OR	O
=	O
1	O
.	O
76	O
;	O
95	O
%	O
CI	O
[	O
0	O
.	O
19	O
to	O
16	O
.	O
12	O
];	O
one	O
exposed	O
case	O
"),"	O
but	O
the	O
ORs	O
were	O
not	O
significantly	O
different	O
.	O
Discussion	O
In	O
the	O
present	O
study	O
","	O
exposure	O
to	O
chlorinated	O
solvents	O
was	O
not	O
associated	O
with	O
an	O
overall	O
risk	O
of	O
head	O
and	O
neck	O
cancer	O
.	O
However	O
","	O
high	O
exposure	O
to	O
PCE	B-Chemical
or	O
MC	B-Chemical
was	O
associated	O
with	O
higher	O
risks	O
of	O
laryngeal	O
and	O
hypopharyngeal	O
cancers	O
","	O
respectively	O
.	O
These	O
results	O
suggest	O
that	O
these	O
commonly	O
used	O
chlorinated	O
solvents	O
may	O
have	O
a	O
deleterious	O
impact	O
on	O
the	O
upper	O
respiratory	O
tract	O
.	O
Few	O
epidemiological	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
solvents	O
on	O
head	O
and	O
neck	O
cancers	O
","	O
and	O
even	O
fewer	O
the	O
effects	O
of	O
chlorinated	O
solvents	O
on	O
these	O
cancers	O
.	O
Previous	O
epidemiological	O
studies	O
have	O
most	O
examine	O
exposure	O
to	O
non	O
-	O
specific	O
solvents	O
.	O
In	O
a	O
case	O
-	O
control	O
study	O
","	O
after	O
adjustment	O
for	O
occupational	O
agents	O
and	O
potential	O
non	O
-	O
occupational	O
confounders	O
","	O
a	O
higher	O
risk	O
of	O
both	O
hypopharyngeal	O
and	O
laryngeal	O
cancer	O
was	O
observed	O
for	O
subjects	O
â€˜	O
ever	O
exposed	O
â€™	O
to	O
solvents	O
relative	O
to	O
those	O
who	O
were	O
not	O
exposed	O
[].	O
Another	O
study	O
which	O
considered	O
â€˜	O
all	O
chlorinated	O
solvents	O
â€™	O
as	O
exposure	O
","	O
also	O
reported	O
an	O
increased	O
risk	O
of	O
laryngeal	O
cancer	O
","	O
although	O
there	O
was	O
no	O
dose	O
-	O
response	O
relationship	O
[].	O
To	O
a	O
lesser	O
extent	O
","	O
various	O
other	O
studies	O
have	O
shown	O
a	O
non	O
-	O
significant	O
increased	O
risk	O
of	O
head	O
and	O
neck	O
cancers	O
when	O
solvents	O
were	O
considered	O
overall	O
"[,"	O
","	O
","	O
].	O
However	O
","	O
direct	O
comparison	O
with	O
our	O
results	O
is	O
difficult	O
as	O
the	O
solvent	O
classes	O
were	O
not	O
clearly	O
specified	O
in	O
the	O
previous	O
studies	O
.	O
Indeed	O
","	O
few	O
studies	O
have	O
focused	O
on	O
the	O
specific	O
effect	O
of	O
a	O
single	O
chlorinated	O
solvent	O
on	O
the	O
head	O
and	O
neck	O
.	O
Among	O
the	O
few	O
studies	O
that	O
have	O
investigated	O
TCE	B-Chemical
exposure	O
","	O
Blair	O
et	O
al	O
.	O
found	O
a	O
standardized	O
mortality	O
ratio	O
close	O
to	O
the	O
null	O
value	O
for	O
oral	O
cavity	O
and	O
pharyngeal	O
cancers	O
"[],"	O
whereas	O
Raaschou	O
-	O
Nielsen	O
et	O
al	O
.	O
found	O
a	O
non	O
-	O
significant	O
increase	O
in	O
the	O
incidence	O
of	O
oral	O
cavity	O
","	O
pharyngeal	O
","	O
and	O
laryngeal	O
cancer	O
among	O
blue	O
-	O
collar	O
workers	O
exposed	O
to	O
TCE	B-Chemical
[].	O
A	O
pooled	O
analysis	O
of	O
three	O
Nordic	O
cohort	O
studies	O
","	O
also	O
showed	O
a	O
non	O
-	O
significant	O
increase	O
in	O
the	O
risk	O
of	O
oral	O
","	O
pharyngeal	O
","	O
and	O
laryngeal	O
cancers	O
[].	O
Similar	O
findings	O
were	O
obtained	O
in	O
another	O
study	O
","	O
which	O
showed	O
a	O
non	O
-	O
significantly	O
higher	O
hazards	O
ratio	O
for	O
death	O
by	O
cancer	O
of	O
the	O
oral	O
cavity	O
and	O
pharynx	O
among	O
male	O
workers	O
exposed	O
to	O
TCE	B-Chemical
[].	O
Moreover	O
","	O
a	O
non	O
-	O
significant	O
excess	O
of	O
mortality	O
from	O
oral	O
","	O
pharyngeal	O
and	O
laryngeal	O
cancer	O
linked	O
to	O
TCE	B-Chemical
exposure	O
has	O
also	O
been	O
reported	O
[].	O
No	O
information	O
on	O
smoking	O
or	O
alcohol	B-Chemical
consumption	O
was	O
provided	O
by	O
these	O
studies	O
.	O
In	O
our	O
study	O
","	O
we	O
did	O
not	O
find	O
any	O
association	O
between	O
exposure	O
to	O
TCE	B-Chemical
and	O
cancer	O
of	O
the	O
oral	O
cavity	O
","	O
pharynx	O
","	O
or	O
larynx	O
after	O
adjustment	O
for	O
smoking	O
","	O
drinking	O
","	O
and	O
exposure	O
to	O
asbestos	B-Chemical
.	O
An	O
association	O
between	O
exposure	O
to	O
TCE	B-Chemical
and	O
head	O
and	O
neck	O
cancer	O
risk	O
was	O
reported	O
among	O
women	O
in	O
the	O
ICARE	O
study	O
[].	O
In	O
women	O
","	O
confounding	O
by	O
asbestos	B-Chemical
was	O
minimal	O
and	O
adjustment	O
for	O
asbestos	B-Chemical
did	O
not	O
modify	O
the	O
estimates	O
related	O
to	O
exposure	O
to	O
TCE	B-Chemical
and	O
head	O
and	O
neck	O
cancer	O
risk	O
.	O
In	O
contrast	O
","	O
more	O
than	O
90	O
%	O
of	O
the	O
men	O
exposed	O
to	O
TCE	B-Chemical
were	O
also	O
exposed	O
to	O
asbestos	B-Chemical
","	O
and	O
inclusion	O
of	O
asbestos	B-Chemical
in	O
the	O
models	O
may	O
have	O
led	O
to	O
overadjustment	O
.	O
We	O
repeated	O
the	O
analyses	O
among	O
subjects	O
never	O
exposed	O
to	O
asbestos	B-Chemical
(	O
479	O
cases	O
and	O
1159	O
controls	O
"),"	O
and	O
found	O
no	O
association	O
with	O
exposure	O
to	O
TCE	B-Chemical
(	O
OR	O
=	O
1	O
.	O
6	O
;	O
95	O
%	O
CI	O
[	O
0	O
.	O
66	O
to	O
1	O
.	O
70	O
];	O
55	O
exposed	O
cases	O
"),"	O
even	O
if	O
the	O
risk	O
of	O
head	O
and	O
neck	O
cancer	O
increased	O
for	O
those	O
with	O
the	O
highest	O
levels	O
of	O
cumulative	O
exposure	O
(	O
OR	O
=	O
1	O
.	O
40	O
;	O
95	O
%	O
CI	O
[	O
0	O
.	O
48	O
to	O
4	O
.	O
6	O
];	O
eight	O
exposed	O
cases	O
).	O
Among	O
men	O
never	O
exposed	O
to	O
asbestos	B-Chemical
","	O
those	O
exposed	O
to	O
only	O
TCE	B-Chemical
had	O
a	O
non	O
-	O
significantly	O
elevated	O
risk	O
of	O
head	O
and	O
neck	O
cancer	O
(	O
OR	O
=	O
1	O
.	O
30	O
;	O
95	O
%	O
CI	O
[	O
0	O
.	O
74	O
to	O
2	O
.	O
27	O
];	O
36	O
exposed	O
cases	O
).	O
The	O
rare	O
studies	O
that	O
examined	O
PCE	B-Chemical
exposure	O
in	O
relation	O
with	O
head	O
and	O
neck	O
cancer	O
yielded	O
inconsistent	O
results	O
.	O
Cohort	O
studies	O
reported	O
no	O
increase	O
[]	O
or	O
a	O
non	O
-	O
significant	O
increase	O
in	O
the	O
frequency	O
of	O
head	O
and	O
neck	O
cancers	O
"[,"	O
"],"	O
but	O
were	O
based	O
on	O
a	O
small	O
number	O
of	O
cases	O
","	O
and	O
were	O
not	O
adjusted	O
for	O
tobacco	O
and	O
alcohol	B-Chemical
consumptions	O
.	O
A	O
small	O
population	O
based	O
case	O
-	O
control	O
study	O
on	O
dry	O
cleaners	O
that	O
examined	O
PCE	B-Chemical
exposure	O
showed	O
a	O
higher	O
risk	O
of	O
oral	O
cavity	O
or	O
laryngeal	O
cancers	O
in	O
subjects	O
exposed	O
to	O
PCE	B-Chemical
than	O
those	O
who	O
were	O
not	O
","	O
with	O
some	O
evidence	O
of	O
dose	O
-	O
response	O
and	O
duration	O
-	O
response	O
relationships	O
for	O
laryngeal	O
cancer	O
[].	O
Although	O
these	O
results	O
were	O
not	O
significant	O
due	O
to	O
the	O
small	O
number	O
of	O
exposed	O
cases	O
(	O
seven	O
for	O
oral	O
cavity	O
","	O
four	O
for	O
laryngeal	O
cancer	O
"),"	O
they	O
support	O
our	O
findings	O
","	O
particularly	O
for	O
the	O
association	O
between	O
occupational	O
exposure	O
to	O
PCE	B-Chemical
and	O
an	O
increased	O
risk	O
of	O
laryngeal	O
cancer	O
.	O
Moreover	O
","	O
the	O
ICARE	O
study	O
has	O
recently	O
shown	O
that	O
exposure	O
to	O
PCE	B-Chemical
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
laryngeal	O
cancer	O
risk	O
in	O
women	O
"[],"	O
and	O
an	O
increased	O
risk	O
of	O
lung	O
cancer	O
"[],"	O
further	O
supporting	O
a	O
carcinogenic	O
effect	O
of	O
PCE	B-Chemical
on	O
the	O
respiratory	O
tract	O
.	O
However	O
","	O
there	O
were	O
no	O
studies	O
to	O
suggest	O
mechanisms	O
underlying	O
these	O
effects	O
.	O
Several	O
potential	O
genotoxic	O
and	O
non	O
-	O
genotoxic	O
mechanisms	O
of	O
liver	O
carcinogenesis	O
for	O
perchlorethylene	B-Chemical
have	O
been	O
identified	O
","	O
but	O
are	O
unlikely	O
to	O
be	O
relevant	O
for	O
respiratory	O
cancer	O
[].	O
However	O
","	O
the	O
upper	O
airways	O
are	O
in	O
direct	O
contact	O
with	O
inhaled	O
toxicants	O
","	O
and	O
chronic	O
irritation	O
and	O
inflammation	O
may	O
contribute	O
to	O
the	O
promotion	O
or	O
progression	O
of	O
otherwise	O
initiated	O
lesions	O
.	O
PCE	B-Chemical
exposure	O
may	O
also	O
facilitate	O
the	O
penetration	O
of	O
other	O
carcinogens	O
in	O
the	O
mucosa	O
","	O
although	O
the	O
lack	O
of	O
statistical	O
interaction	O
in	O
our	O
data	O
between	O
PCE	B-Chemical
exposure	O
and	O
other	O
risk	O
factors	O
does	O
not	O
support	O
this	O
hypothesis	O
.	O
Our	O
findings	O
also	O
provide	O
limited	O
evidence	O
of	O
an	O
association	O
between	O
exposure	O
to	O
MC	B-Chemical
and	O
hypopharyngeal	O
cancer	O
.	O
No	O
other	O
study	O
has	O
specifically	O
examined	O
the	O
risk	O
of	O
head	O
and	O
neck	O
cancer	O
associated	O
with	O
MC	B-Chemical
exposure	O
[].	O
Only	O
two	O
cohort	O
studies	O
of	O
workers	O
exposed	O
to	O
MC	B-Chemical
reported	O
results	O
for	O
head	O
and	O
neck	O
cancer	O
by	O
subsite	O
","	O
and	O
found	O
either	O
no	O
"[],"	O
or	O
a	O
non	O
-	O
significant	O
increased	O
risk	O
for	O
oral	O
cancer	O
[].	O
Our	O
study	O
has	O
limitations	O
that	O
may	O
affect	O
the	O
interpretation	O
of	O
the	O
results	O
.	O
First	O
","	O
occupational	O
exposure	O
was	O
retrospectively	O
assessed	O
","	O
and	O
the	O
use	O
of	O
job	O
-	O
exposure	O
matrices	O
generates	O
systematic	O
misclassification	O
","	O
which	O
is	O
likely	O
to	O
be	O
independent	O
of	O
case	O
-	O
control	O
status	O
.	O
Such	O
non	O
differential	O
misclassification	O
could	O
result	O
in	O
an	O
average	O
bias	O
toward	O
the	O
null	O
[].	O
Second	O
","	O
the	O
number	O
of	O
exposed	O
cases	O
was	O
small	O
for	O
some	O
chlorinated	O
solvents	O
resulting	O
in	O
large	O
confidence	O
intervals	O
.	O
Investigation	O
of	O
combinations	O
of	O
chlorinated	O
solvents	O
was	O
limited	O
for	O
the	O
same	O
reason	O
and	O
it	O
was	O
not	O
possible	O
to	O
investigate	O
the	O
association	O
between	O
exclusive	O
occupational	O
exposure	O
to	O
PCE	B-Chemical
and	O
head	O
and	O
neck	O
cancer	O
risk	O
.	O
Our	O
study	O
also	O
has	O
several	O
strengths	O
.	O
The	O
large	O
number	O
of	O
subjects	O
provided	O
sufficient	O
statistical	O
power	O
to	O
detect	O
moderate	O
associations	O
","	O
and	O
allowed	O
assessment	O
of	O
cancer	O
sites	O
and	O
subsites	O
.	O
Detailed	O
information	O
on	O
lifelong	O
occupational	O
histories	O
was	O
available	O
","	O
allowing	O
us	O
to	O
assess	O
the	O
level	O
of	O
exposure	O
to	O
chlorinated	O
solvents	O
and	O
investigate	O
dose	O
-	O
response	O
relationships	O
.	O
We	O
adjusted	O
for	O
major	O
confounders	O
","	O
such	O
as	O
tobacco	O
and	O
alcohol	B-Chemical
consumption	O
","	O
as	O
well	O
as	O
exposure	O
to	O
asbestos	B-Chemical
.	O
Additional	O
adjustments	O
for	O
educational	O
level	O
","	O
socioeconomic	O
status	O
","	O
and	O
exposure	O
to	O
other	O
chlorinated	O
solvents	O
showed	O
that	O
confounding	O
due	O
to	O
these	O
variables	O
was	O
minimal	O
.	O
Selection	O
bias	O
","	O
although	O
always	O
possible	O
","	O
was	O
probably	O
not	O
an	O
important	O
issue	O
in	O
this	O
study	O
.	O
The	O
distribution	O
of	O
the	O
included	O
cases	O
by	O
age	O
and	O
cancer	O
site	O
was	O
similar	O
to	O
that	O
generally	O
observed	O
in	O
France	O
[].	O
The	O
lifetime	O
prevalence	O
of	O
exposure	O
to	O
chlorinated	O
solvents	O
among	O
our	O
controls	O
was	O
close	O
to	O
that	O
observed	O
in	O
a	O
representative	O
sample	O
of	O
the	O
French	O
male	O
population	O
[].	O
Conclusions	O
In	O
summary	O
","	O
our	O
findings	O
suggest	O
that	O
high	O
occupational	O
exposure	O
to	O
PCE	B-Chemical
may	O
increase	O
the	O
risk	O
of	O
laryngeal	O
cancer	O
.	O
Data	O
from	O
the	O
ICARE	O
study	O
has	O
recently	O
suggested	O
that	O
occupational	O
exposure	O
to	O
PCE	B-Chemical
also	O
increases	O
the	O
risk	O
of	O
lung	O
cancer	O
[].	O
Our	O
results	O
extend	O
these	O
findings	O
by	O
suggesting	O
a	O
likely	O
carcinogenic	O
effect	O
of	O
PCE	B-Chemical
on	O
other	O
parts	O
of	O
the	O
respiratory	O
tract	O
.	O
Additional	O
file	O
Abbreviations	O
CEI	O
Cumulative	O
exposure	O
index	O
CF	B-Chemical
Chloroform	B-Chemical
CI	O
Confidence	O
interval	O
CT	B-Chemical
Carbon	B-Chemical
tetrachloride	I-Chemical
MC	B-Chemical
Methylene	B-Chemical
chloride	I-Chemical
OR	O
Odds	O
-	O
ratio	O
PCE	B-Chemical
Perchloroethylene	B-Chemical
TCE	B-Chemical
Trichloroethylene	B-Chemical
Electronic	O
supplementary	O
material	O
The	O
online	O
version	O
of	O
this	O
article	O
(	O
doi	O
:	O
10	O
.	O
1186	O
/	O
s12940	O
-	O
17	O
-	O
286	O
-	O
5	O
)	O
contains	O
supplementary	O
material	O
","	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O
Authors	O
â€™	O
contributions	O
DL	O
and	O
CB	O
designed	O
the	O
current	O
study	O
","	O
conducted	O
the	O
analyses	O
and	O
drafted	O
the	O
manuscript	O
;	O
AF	O
and	O
MC	O
contributed	O
to	O
the	O
statistical	O
analysis	O
and	O
interpretation	O
of	O
the	O
results	O
.	O
CP	O
was	O
involved	O
in	O
exposure	O
assessment	O
.	O
ASW	O
contributed	O
to	O
data	O
collection	O
and	O
quality	O
control	O
.	O
DL	O
and	O
IS	O
are	O
the	O
principal	O
investigators	O
of	O
the	O
ICARE	O
study	O
","	O
conceived	O
this	O
study	O
and	O
coordinated	O
the	O
original	O
collection	O
of	O
the	O
data	O
.	O
All	O
the	O
authors	O
critically	O
reviewed	O
and	O
revised	O
the	O
manuscript	O
","	O
and	O
gave	O
their	O
approval	O
for	O
its	O
final	O
version	O
.	O
Ethics	O
approval	O
and	O
consent	O
to	O
participate	O
Institutional	O
Review	O
Board	O
of	O
the	O
French	O
National	O
Institute	O
of	O
Health	O
and	O
Medical	O
Research	O
(	O
IRB	O
-	O
Inserm	O
","	O
number	O
1	O
â€“	O
36	O
)	O
and	O
the	O
French	O
Data	O
Protection	O
Authority	O
(	O
CNIL	O
number	O
90	O
120	O
).	O
Each	O
participant	O
gave	O
a	O
written	O
consent	O
.	O
Consent	O
for	O
publication	O
Not	O
applicable	O
.	O
Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O
References	O
Vitamin	B-Chemical
D	I-Chemical
Supplementation	O
Enhances	O
C18	B-Chemical
(	I-Chemical
dihydro	I-Chemical
)	I-Chemical
ceramide	I-Chemical
Levels	O
in	O
Type	O
2	O
Diabetes	O
Patients	O
Sphingolipids	B-Chemical
are	O
characterized	O
by	O
a	O
broad	O
range	O
of	O
bioactive	O
properties	O
.	O
Particularly	O
","	O
the	O
development	O
of	O
insulin	O
resistance	O
","	O
a	O
major	O
pathophysiological	O
hallmark	O
of	O
Type	O
2	O
Diabetes	O
mellitus	O
(	O
T2D	O
"),"	O
has	O
been	O
linked	O
to	O
ceramide	B-Chemical
signaling	O
.	O
Since	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
may	O
slow	O
down	O
T2D	O
progression	O
by	O
improving	O
glucose	B-Chemical
concentrations	O
and	O
insulin	O
sensitivity	O
","	O
we	O
investigated	O
whether	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
impacts	O
on	O
plasma	O
sphingolipid	B-Chemical
levels	O
in	O
T2D	O
patients	O
.	O
Thus	O
","	O
plasma	O
samples	O
of	O
59	O
patients	O
with	O
non	O
-	O
insulin	O
-	O
requiring	O
T2D	O
from	O
a	O
placebo	O
-	O
controlled	O
","	O
randomized	O
","	O
and	O
double	O
-	O
blind	O
study	O
were	O
retrospectively	O
analyzed	O
.	O
Once	O
per	O
week	O
","	O
patients	O
received	O
either	O
20	O
drops	O
of	O
Vigantol	B-Chemical
oil	I-Chemical
","	O
corresponding	O
to	O
a	O
daily	O
dose	O
of	O
1904	O
IU	O
/	O
d	O
vitamin	B-Chemical
D	I-Chemical
(	O
verum	O
:	O
n	O
=	O
31	O
"),"	O
or	O
a	O
placebo	O
oil	O
consisting	O
of	O
medium	O
chain	O
triglycerides	B-Chemical
(	O
placebo	O
:	O
n	O
=	O
28	O
).	O
Blood	O
samples	O
were	O
taken	O
from	O
all	O
of	O
the	O
participants	O
at	O
three	O
different	O
time	O
points	O
:	O
1	O
)	O
at	O
the	O
beginning	O
of	O
the	O
study	O
(	O
baseline	O
"),"	O
2	O
)	O
after	O
6	O
months	O
supplementation	O
","	O
and	O
3	O
)	O
after	O
an	O
additional	O
6	O
months	O
of	O
follow	O
-	O
up	O
.	O
Plasma	O
sphingolipids	B-Chemical
were	O
measured	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
.	O
At	O
baseline	O
and	O
6	O
months	O
follow	O
-	O
up	O
","	O
no	O
significant	O
differences	O
in	O
plasma	O
sphingolipid	B-Chemical
species	O
were	O
detected	O
between	O
the	O
placebo	O
and	O
verum	O
groups	O
.	O
After	O
6	O
months	O
","	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
significantly	O
enhanced	O
plasma	O
C18dihydroceramide	B-Chemical
(	O
dhCer	B-Chemical
;	O
N	B-Chemical
-	I-Chemical
stearoyl	I-Chemical
-	I-Chemical
sphinganine	I-Chemical
(	O
d18	O
:	O
0	O
/	O
18	O
:	O
0	O
))	O
and	O
C18ceramide	B-Chemical
(	O
Cer	B-Chemical
;	O
N	B-Chemical
-	I-Chemical
stearoyl	I-Chemical
-	I-Chemical
sphingosine	I-Chemical
(	O
d18	O
:	O
1	O
/	O
18	O
:	O
0	O
))	O
levels	O
were	O
observed	O
in	O
the	O
verum	O
group	O
compared	O
to	O
the	O
placebo	O
group	O
.	O
This	O
was	O
accompanied	O
by	O
significantly	O
higher	O
25	B-Chemical
-	I-Chemical
hydroxyvitamin	I-Chemical
D3	I-Chemical
(	O
25	B-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
D3	I-Chemical
)	O
blood	O
levels	O
in	O
patients	O
receiving	O
vitamin	B-Chemical
D	I-Chemical
compared	O
to	O
the	O
placebo	O
group	O
.	O
Taken	O
together	O
","	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
induced	O
changes	O
of	O
the	O
C18	O
chain	O
-	O
length	O
-	O
specific	O
dhCer	B-Chemical
and	O
Cer	B-Chemical
plasma	O
levels	O
in	O
patients	O
with	O
T2D	O
.	O
The	O
regulation	O
of	O
sphingolipid	B-Chemical
signaling	O
by	O
vitamin	B-Chemical
D	I-Chemical
may	O
thus	O
unravel	O
a	O
novel	O
mechanism	O
by	O
which	O
vitamin	B-Chemical
D	I-Chemical
can	O
influence	O
glucose	B-Chemical
utilization	O
and	O
insulin	O
action	O
.	O
Whether	O
this	O
acts	O
favorably	O
or	O
unfavorably	O
for	O
the	O
progression	O
of	O
T2D	O
needs	O
to	O
be	O
clarified	O
.	O
1	O
.	O
Introduction	O
Today	O
","	O
globally	O
","	O
more	O
than	O
415	O
million	O
patients	O
suffer	O
from	O
diabetes	O
mellitus	O
","	O
one	O
of	O
the	O
major	O
health	O
problems	O
worldwide	O
with	O
increasing	O
prevalence	O
.	O
By	O
2040	O
","	O
one	O
in	O
ten	O
adults	O
will	O
have	O
diabetes	O
.	O
Almost	O
90	O
%	O
of	O
all	O
patients	O
will	O
have	O
Type	O
2	O
Diabetes	O
mellitus	O
(	O
T2D	O
"),"	O
the	O
most	O
prevalent	O
form	O
in	O
industrial	O
countries	O
(	O
International	O
Diabetes	O
Federation	O
","	O
â€œ	O
Diabetes	O
Atlas	O
â€”	O
the	O
7th	O
edition	O
â€).	O
The	O
development	O
of	O
T2D	O
is	O
believed	O
to	O
be	O
influenced	O
by	O
a	O
combination	O
of	O
genetic	O
background	O
and	O
multiple	O
environmental	O
factors	O
","	O
among	O
which	O
vitamin	B-Chemical
D	I-Chemical
status	O
has	O
been	O
identified	O
[].	O
The	O
active	O
form	O
of	O
vitamin	B-Chemical
D	I-Chemical
","	O
1Î±	B-Chemical
","	I-Chemical
25	I-Chemical
-	I-Chemical
dihydroxyvitamin	I-Chemical
D3	I-Chemical
(	O
1	B-Chemical
","	I-Chemical
25	I-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
2D3	I-Chemical
vitamin	I-Chemical
D	I-Chemical
","	O
calcitriol	B-Chemical
"),"	O
is	O
synthesized	O
from	O
cholesterol	B-Chemical
through	O
a	O
photochemical	O
reaction	O
to	O
sunlight	O
in	O
the	O
skin	O
","	O
followed	O
by	O
enzymatic	O
conversions	O
in	O
the	O
liver	O
and	O
kidney	O
.	O
Although	O
it	O
can	O
be	O
taken	O
up	O
partially	O
by	O
food	O
","	O
synthesis	O
due	O
to	O
natural	O
sunlight	O
exposure	O
in	O
the	O
skin	O
remains	O
the	O
major	O
source	O
of	O
vitamin	B-Chemical
D	I-Chemical
","	O
which	O
explains	O
why	O
vitamin	B-Chemical
D	I-Chemical
deficiency	O
is	O
a	O
common	O
problem	O
in	O
healthy	O
humans	O
[].	O
Since	O
it	O
is	O
more	O
stable	O
and	O
highly	O
abundant	O
in	O
blood	O
","	O
the	O
first	O
metabolite	O
25	B-Chemical
-	I-Chemical
hydroxyvitamin	I-Chemical
D3	I-Chemical
(	O
25	B-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
D3	I-Chemical
)	O
is	O
normally	O
used	O
to	O
determine	O
the	O
vitamin	O
â€™	O
s	O
status	O
in	O
human	O
blood	O
.	O
Vitamin	B-Chemical
D	I-Chemical
deficiency	O
is	O
defined	O
by	O
25	B-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
D3	I-Chemical
blood	O
levels	O
less	O
than	O
20	O
ng	O
/	O
mL	O
","	O
and	O
was	O
found	O
to	O
be	O
associated	O
with	O
an	O
increasing	O
risk	O
for	O
numerous	O
diseases	O
including	O
hypertension	O
","	O
obesity	O
","	O
and	O
diabetes	O
"[,]."	O
In	O
this	O
context	O
","	O
several	O
studies	O
revealed	O
that	O
patients	O
with	O
T2D	O
have	O
lower	O
levels	O
of	O
25	B-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
D3	I-Chemical
","	O
which	O
correlates	O
with	O
a	O
higher	O
risk	O
for	O
the	O
development	O
of	O
T2D	O
On	O
the	O
other	O
hand	O
","	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
may	O
slow	O
down	O
T2D	O
progression	O
by	O
improving	O
glucose	B-Chemical
concentrations	O
and	O
insulin	O
sensitivity	O
Mechanistically	O
","	O
vitamin	B-Chemical
D	I-Chemical
can	O
influence	O
the	O
insulin	O
sensitivity	O
directly	O
by	O
(	O
1	O
)	O
the	O
stimulation	O
of	O
the	O
expression	O
of	O
insulin	O
receptor	O
and	O
(	O
2	O
)	O
the	O
activation	O
of	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
delta	O
or	O
(	O
3	O
)	O
indirectly	O
via	O
the	O
regulation	O
of	O
calcium	B-Chemical
homeostasis	O
[].	O
Interestingly	O
","	O
the	O
development	O
of	O
insulin	O
resistance	O
","	O
a	O
major	O
pathophysiological	O
hallmark	O
of	O
T2D	O
","	O
has	O
been	O
linked	O
to	O
sphingolipid	B-Chemical
signaling	O
"[,]."	O
Sphingolipids	B-Chemical
consist	O
of	O
more	O
than	O
300	O
structural	O
diverse	O
molecules	O
with	O
a	O
broad	O
range	O
of	O
bioactive	O
properties	O
.	O
Various	O
members	O
of	O
this	O
special	O
class	O
of	O
lipids	B-Chemical
were	O
identified	O
as	O
important	O
mediators	O
in	O
the	O
pathogenesis	O
of	O
several	O
diseases	O
"[,]."	O
Particularly	O
","	O
the	O
role	O
of	O
ceramide	B-Chemical
for	O
the	O
progression	O
of	O
diabetes	O
mellitus	O
was	O
extensively	O
investigated	O
in	O
the	O
last	O
years	O
.	O
In	O
general	O
","	O
ceramide	B-Chemical
inhibits	O
signaling	O
pathways	O
downstream	O
of	O
the	O
insulin	O
receptor	O
","	O
e	O
.	O
g	O
".,"	O
insulin	O
receptor	O
substrate	O
1	O
phosphorylation	O
","	O
activation	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
","	O
and	O
Akt	O
/	O
PKB	O
","	O
and	O
thereby	O
blocks	O
the	O
translocation	O
of	O
glucose	O
transporter	O
GLUT4	O
and	O
induces	O
pancreatic	O
Î²	O
-	O
cell	O
apoptosis	O
"[,]."	O
In	O
line	O
with	O
these	O
findings	O
","	O
different	O
studies	O
revealed	O
that	O
the	O
accumulation	O
of	O
ceramide	B-Chemical
occurs	O
in	O
the	O
skeletal	O
muscle	O
of	O
insulin	O
-	O
resistant	O
humans	O
"[],"	O
which	O
negatively	O
correlates	O
with	O
insulin	O
sensitivity	O
[].	O
However	O
","	O
another	O
study	O
failed	O
to	O
demonstrate	O
enhanced	O
muscle	O
ceramide	B-Chemical
levels	O
in	O
insulin	O
resistant	O
and	O
T2D	O
patients	O
","	O
fostering	O
ongoing	O
discussions	O
on	O
its	O
contribution	O
to	O
insulin	O
resistance	O
"[,]."	O
In	O
the	O
current	O
study	O
","	O
we	O
investigated	O
whether	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
influences	O
the	O
plasma	O
content	O
of	O
long	O
chain	O
and	O
very	O
long	O
chain	O
ceramides	B-Chemical
and	O
their	O
precursor	O
â€™	O
s	O
dihydroceramides	B-Chemical
","	O
as	O
well	O
as	O
the	O
degradation	O
products	O
sphinganine	B-Chemical
","	O
sphingosine	B-Chemical
","	O
and	O
their	O
1	B-Chemical
-	I-Chemical
phosphate	I-Chemical
derivatives	O
.	O
To	O
our	O
knowledge	O
","	O
this	O
is	O
the	O
first	O
report	O
investigating	O
a	O
possible	O
link	O
between	O
vitamin	B-Chemical
D	I-Chemical
uptake	O
and	O
changes	O
in	O
plasma	O
sphingolipid	B-Chemical
levels	O
in	O
humans	O
.	O
2	O
.	O
Results	O
2	O
.	O
1	O
.	O
Clinical	O
and	O
Biochemical	O
Parameters	O
The	O
characteristics	O
of	O
all	O
patients	O
(	O
placebo	O
group	O
:	O
28	O
(	O
13	O
male	O
/	O
15	O
female	O
"),"	O
verum	O
group	O
:	O
31	O
(	O
16	O
male	O
/	O
15	O
female	O
))	O
included	O
in	O
this	O
retrospective	O
analysis	O
are	O
shown	O
in	O
Table	O
1	O
.	O
The	O
median	O
age	O
of	O
the	O
patients	O
in	O
the	O
placebo	O
group	O
was	O
60	O
years	O
and	O
in	O
the	O
verum	O
group	O
62	O
years	O
with	O
a	O
median	O
diabetes	O
duration	O
of	O
7	O
and	O
5	O
years	O
","	O
respectively	O
.	O
The	O
median	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
31	O
kg	O
/	O
m2	O
in	O
both	O
groups	O
.	O
As	O
shown	O
in	O
Table	O
2	O
","	O
the	O
blood	O
cholesterol	B-Chemical
","	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)-	O
cholesterol	B-Chemical
","	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)-	O
cholesterol	B-Chemical
","	O
and	O
triglyceride	B-Chemical
levels	O
were	O
not	O
significantly	O
different	O
between	O
the	O
placebo	O
and	O
verum	O
groups	O
at	O
baseline	O
.	O
Further	O
","	O
treatment	O
with	O
1904	O
IU	O
/	O
d	O
vitamin	B-Chemical
D	I-Chemical
for	O
6	O
months	O
did	O
not	O
influence	O
the	O
amounts	O
of	O
total	O
cholesterol	B-Chemical
","	O
HDL	O
-	O
cholesterol	B-Chemical
","	O
LDL	O
-	O
cholesterol	B-Chemical
","	O
and	O
triglycerides	B-Chemical
in	O
blood	O
compared	O
to	O
the	O
placebo	O
-	O
treated	O
group	O
(	O
Table	O
2	O
).	O
According	O
to	O
the	O
previous	O
publication	O
"[],"	O
all	O
patients	O
included	O
in	O
the	O
current	O
analysis	O
showed	O
at	O
baseline	O
a	O
vitamin	B-Chemical
D	I-Chemical
deficiency	O
with	O
25	B-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
D3	I-Chemical
concentrations	O
of	O
12	O
(	O
8	O
.	O
6	O
â€“	O
15	O
)	O
ng	O
/	O
mL	O
in	O
the	O
placebo	O
group	O
and	O
13	O
(	O
8	O
.	O
7	O
â€“	O
18	O
)	O
ng	O
/	O
mL	O
in	O
the	O
verum	O
group	O
.	O
After	O
6	O
months	O
of	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
","	O
the	O
patients	O
in	O
the	O
verum	O
group	O
had	O
significantly	O
higher	O
25	B-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
D3	I-Chemical
levels	O
compared	O
to	O
the	O
placebo	O
group	O
(	O
placebo	O
group	O
:	O
11	O
(	O
7	O
.	O
2	O
â€“	O
16	O
)	O
ng	O
/	O
mL	O
","	O
verum	O
group	O
:	O
29	O
(	O
21	O
â€“	O
32	O
)	O
ng	O
/	O
mL	O
","	O
p	O
<	O
0	O
.	O
1	O
).	O
After	O
an	O
additional	O
6	O
months	O
of	O
follow	O
-	O
up	O
","	O
the	O
25	B-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
D3	I-Chemical
levels	O
were	O
still	O
significantly	O
elevated	O
in	O
the	O
verum	O
group	O
compared	O
to	O
the	O
placebo	O
group	O
(	O
placebo	O
group	O
:	O
12	O
(	O
9	O
.	O
9	O
â€“	O
16	O
)	O
ng	O
/	O
mL	O
","	O
verum	O
group	O
:	O
19	O
(	O
15	O
â€“	O
22	O
)	O
ng	O
/	O
mL	O
","	O
p	O
=	O
0	O
.	O
7	O
).	O
2	O
.	O
2	O
.	O
Plasma	O
Sphingolipid	B-Chemical
Levels	O
Here	O
","	O
we	O
could	O
show	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
analysis	O
that	O
the	O
plasma	O
concentrations	O
of	O
chain	O
-	O
length	O
specific	O
ceramides	B-Chemical
and	O
dihydroceramides	B-Chemical
","	O
bioactive	O
synthetic	O
precursors	O
of	O
ceramides	B-Chemical
","	O
in	O
patients	O
suffering	O
from	O
T2D	O
were	O
influenced	O
by	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
.	O
After	O
6	O
months	O
of	O
vitamin	B-Chemical
D	I-Chemical
treatment	O
","	O
plasma	O
levels	O
of	O
C18dhCer	B-Chemical
were	O
significantly	O
elevated	O
in	O
the	O
verum	O
group	O
compared	O
to	O
the	O
placebo	O
group	O
(	O
placebo	O
group	O
:	O
11	O
.	O
6	O
(	O
5	O
.	O
21	O
â€“	O
18	O
.	O
9	O
)	O
ng	O
/	O
mL	O
","	O
verum	O
group	O
:	O
18	O
.	O
8	O
(	O
10	O
.	O
2	O
â€“	O
24	O
.	O
5	O
)	O
ng	O
/	O
mL	O
","	O
p	O
=	O
0	O
.	O
36	O
;	O
Figure	O
1	O
).	O
In	O
line	O
with	O
this	O
","	O
the	O
subsequent	O
C18Cer	B-Chemical
levels	O
were	O
also	O
significantly	O
higher	O
in	O
the	O
vitamin	B-Chemical
D	I-Chemical
-	O
treated	O
group	O
compared	O
to	O
the	O
placebo	O
group	O
(	O
placebo	O
group	O
:	O
24	O
.	O
3	O
(	O
18	O
.	O
5	O
â€“	O
32	O
.	O
1	O
)	O
ng	O
/	O
mL	O
","	O
verum	O
group	O
:	O
33	O
.	O
0	O
(	O
26	O
.	O
7	O
â€“	O
39	O
.	O
4	O
)	O
ng	O
/	O
mL	O
","	O
p	O
=	O
0	O
.	O
40	O
;	O
Figure	O
2	O
).	O
At	O
baseline	O
","	O
C18dhCer	B-Chemical
and	O
C18Cer	B-Chemical
were	O
similar	O
in	O
the	O
placebo	O
and	O
verum	O
groups	O
(	O
C18dhCer	B-Chemical
:	O
placebo	O
group	O
:	O
14	O
.	O
5	O
(	O
8	O
.	O
86	O
â€“	O
33	O
.	O
3	O
)	O
ng	O
/	O
mL	O
","	O
verum	O
group	O
:	O
17	O
.	O
3	O
(	O
13	O
.	O
6	O
â€“	O
25	O
.	O
2	O
)	O
ng	O
/	O
mL	O
","	O
p	O
=	O
0	O
.	O
250	O
(	O
missing	O
data	O
:	O
n	O
=	O
27	O
(	O
placebo	O
group	O
"),"	O
n	O
=	O
30	O
(	O
verum	O
group	O
);	O
C18Cer	B-Chemical
:	O
placebo	O
group	O
:	O
30	O
.	O
3	O
(	O
24	O
.	O
0	O
â€“	O
46	O
.	O
1	O
)	O
ng	O
/	O
mL	O
","	O
verum	O
group	O
:	O
36	O
.	O
0	O
(	O
24	O
.	O
7	O
â€“	O
39	O
.	O
4	O
)	O
ng	O
/	O
mL	O
","	O
p	O
=	O
0	O
.	O
856	O
).	O
Interestingly	O
","	O
after	O
6	O
months	O
follow	O
-	O
up	O
","	O
no	O
significant	O
differences	O
in	O
C18dhCer	B-Chemical
and	O
C18Cer	B-Chemical
levels	O
were	O
detected	O
between	O
the	O
placebo	O
group	O
and	O
the	O
verum	O
group	O
(	O
C18dhCer	B-Chemical
:	O
placebo	O
group	O
:	O
9	O
.	O
16	O
(	O
3	O
.	O
82	O
â€“	O
23	O
.	O
5	O
)	O
ng	O
/	O
mL	O
","	O
verum	O
group	O
:	O
20	O
.	O
1	O
(	O
5	O
.	O
60	O
â€“	O
26	O
.	O
3	O
)	O
ng	O
/	O
mL	O
","	O
p	O
=	O
0	O
.	O
170	O
;	O
C18Cer	B-Chemical
:	O
placebo	O
group	O
:	O
21	O
.	O
4	O
(	O
10	O
.	O
6	O
â€“	O
32	O
.	O
0	O
)	O
ng	O
/	O
mL	O
","	O
verum	O
group	O
:	O
23	O
.	O
1	O
(	O
18	O
.	O
4	O
â€“	O
35	O
.	O
9	O
)	O
ng	O
/	O
mL	O
","	O
p	O
=	O
0	O
.	O
211	O
).	O
As	O
illustrated	O
in	O
Figure	O
1	O
and	O
Figure	O
2	O
","	O
all	O
other	O
dihydroceramides	B-Chemical
and	O
ceramides	B-Chemical
remain	O
unchanged	O
after	O
6	O
months	O
of	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
.	O
Moreover	O
","	O
no	O
differences	O
between	O
the	O
placebo	O
group	O
and	O
the	O
verum	O
group	O
were	O
observed	O
in	O
the	O
plasma	O
levels	O
of	O
sphingosine	B-Chemical
","	O
sphinganine	B-Chemical
","	O
and	O
their	O
1	B-Chemical
-	I-Chemical
phosphate	I-Chemical
derivatives	O
(	O
Figure	O
3	O
).	O
In	O
line	O
with	O
these	O
findings	O
","	O
no	O
significant	O
differences	O
in	O
the	O
plasma	O
levels	O
of	O
all	O
of	O
the	O
other	O
dihydroceramides	B-Chemical
and	O
ceramides	B-Chemical
","	O
sphingosine	B-Chemical
","	O
sphinganine	B-Chemical
","	O
dhS1P	B-Chemical
","	O
and	O
S1P	B-Chemical
were	O
present	O
between	O
the	O
placebo	O
and	O
verum	O
groups	O
at	O
baseline	O
(	O
Table	O
S1	O
)	O
and	O
6	O
months	O
follow	O
-	O
up	O
after	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
(	O
Table	O
S2	O
).	O
3	O
.	O
Discussion	O
Beside	O
the	O
well	O
-	O
known	O
effects	O
on	O
bone	O
formation	O
and	O
mineralization	O
"[],"	O
there	O
is	O
growing	O
evidence	O
for	O
pleiotropic	O
actions	O
of	O
vitamin	B-Chemical
D	I-Chemical
via	O
the	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
that	O
is	O
expressed	O
abundantly	O
[].	O
With	O
regards	O
to	O
T2D	O
","	O
these	O
extraskeletal	O
effects	O
are	O
particularly	O
evident	O
for	O
the	O
immune	O
system	O
and	O
endothelial	O
function	O
","	O
with	O
controversial	O
discussions	O
about	O
the	O
clinical	O
studies	O
[].	O
Nevertheless	O
","	O
several	O
studies	O
showed	O
beneficial	O
effects	O
of	O
vitamin	B-Chemical
D	I-Chemical
on	O
glucose	B-Chemical
status	O
","	O
as	O
well	O
as	O
on	O
insulin	O
sensitivity	O
and	O
resistance	O
In	O
line	O
with	O
these	O
findings	O
","	O
we	O
could	O
previously	O
show	O
that	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
enhanced	O
25OHD	B-Chemical
in	O
plasma	O
levels	O
","	O
which	O
was	O
associated	O
","	O
e	O
.	O
g	O
".,"	O
with	O
significantly	O
lower	O
HbA1c	O
levels	O
[].	O
Vitamin	B-Chemical
D	I-Chemical
supplementation	O
may	O
therefore	O
stabilize	O
glucose	B-Chemical
homeostasis	O
and	O
help	O
to	O
slow	O
the	O
progression	O
of	O
T2D	O
[].	O
Here	O
","	O
we	O
used	O
a	O
total	O
number	O
of	O
59	O
plasma	O
samples	O
from	O
our	O
previous	O
study	O
to	O
investigate	O
retrospectively	O
whether	O
the	O
uptake	O
of	O
1904	O
IU	O
/	O
d	O
vitamin	B-Chemical
D	I-Chemical
for	O
6	O
months	O
had	O
an	O
impact	O
on	O
plasma	O
sphingolipid	B-Chemical
levels	O
in	O
patients	O
suffering	O
from	O
T2D	O
.	O
Several	O
studies	O
reveal	O
that	O
sphingolipids	B-Chemical
such	O
as	O
ceramide	B-Chemical
influence	O
metabolic	O
pathways	O
and	O
the	O
cells	O
involved	O
in	O
the	O
development	O
of	O
diabetes	O
[].	O
However	O
","	O
to	O
our	O
knowledge	O
","	O
there	O
has	O
not	O
been	O
any	O
study	O
yet	O
about	O
vitamin	B-Chemical
D	I-Chemical
â€™	O
s	O
effects	O
on	O
sphingolipid	B-Chemical
metabolism	O
in	O
diabetes	O
patients	O
.	O
By	O
using	O
LC	O
-	O
MS	O
/	O
MS	O
analyses	O
","	O
we	O
observed	O
that	O
the	O
levels	O
of	O
both	O
C18Cer	B-Chemical
and	O
its	O
precursor	O
C18dhCer	B-Chemical
were	O
significantly	O
enhanced	O
by	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
compared	O
to	O
the	O
placebo	O
group	O
.	O
All	O
of	O
the	O
other	O
dihydroceramides	B-Chemical
and	O
ceramides	B-Chemical
as	O
well	O
as	O
their	O
degradation	O
products	O
remain	O
unchanged	O
by	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
.	O
In	O
general	O
","	O
C18dhCer	B-Chemical
and	O
C18Cer	B-Chemical
concentrations	O
are	O
known	O
to	O
be	O
in	O
a	O
lower	O
micromolar	O
range	O
in	O
plasma	O
and	O
serum	O
compared	O
to	O
very	O
long	O
-	O
chain	O
ceramides	B-Chemical
"[],"	O
which	O
is	O
contrary	O
in	O
tissues	O
such	O
as	O
skleletal	O
muscle	O
[].	O
However	O
","	O
the	O
potential	O
of	O
single	O
ceramides	B-Chemical
to	O
influence	O
the	O
progression	O
of	O
T2D	O
seems	O
not	O
to	O
be	O
concentration	O
but	O
chain	O
-	O
length	O
dependent	O
.	O
Overall	O
","	O
there	O
is	O
strong	O
evidence	O
that	O
ceramide	B-Chemical
species	O
exert	O
different	O
effects	O
depending	O
on	O
the	O
chain	O
-	O
lengths	O
of	O
the	O
fatty	B-Chemical
acid	I-Chemical
bound	O
to	O
the	O
sphingosine	B-Chemical
backbone	O
.	O
For	O
example	O
","	O
C16Cer	B-Chemical
and	O
C18Cer	B-Chemical
induce	O
cell	O
death	O
","	O
whereas	O
very	O
long	O
chain	O
C24Cer	B-Chemical
and	O
C24	B-Chemical
:	I-Chemical
1Cer	I-Chemical
mediate	O
anti	O
-	O
apoptotic	O
effects	O
"[,]."	O
In	O
the	O
context	O
of	O
T2D	O
development	O
","	O
Sugimoto	O
et	O
al	O
.	O
[]	O
suggested	O
that	O
enhanced	O
plasma	O
levels	O
of	O
very	O
long	O
chain	O
ceramides	B-Chemical
contribute	O
to	O
the	O
elevated	O
glucose	B-Chemical
clearance	O
observed	O
in	O
sphingomyelin	O
synthase	O
2	O
knockout	O
mice	O
.	O
The	O
overexpression	O
of	O
CerS2	B-Chemical
","	O
necessary	O
for	O
the	O
formation	O
of	O
very	O
long	O
chain	O
ceramides	B-Chemical
(	O
C20Cer	B-Chemical
/	O
C24Cer	B-Chemical
/	O
C24	B-Chemical
:	I-Chemical
1Cer	I-Chemical
)	O
"[],"	O
led	O
to	O
an	O
improvement	O
in	O
insulin	O
signal	O
transduction	O
","	O
as	O
well	O
as	O
decreased	O
endoplasmic	O
reticulum	O
stress	O
and	O
markers	O
for	O
gluconeogenesis	O
in	O
mouse	O
hepatocytes	O
[].	O
On	O
the	O
other	O
hand	O
","	O
the	O
lack	O
of	O
CerS2	B-Chemical
","	O
and	O
the	O
subsequent	O
elimination	O
of	O
these	O
ceramide	B-Chemical
species	O
causes	O
hepatic	O
insulin	O
resistance	O
in	O
mice	O
[].	O
Overall	O
","	O
these	O
data	O
reveal	O
a	O
protective	O
role	O
of	O
long	O
chain	O
ceramides	B-Chemical
against	O
the	O
development	O
of	O
glucose	B-Chemical
intolerance	O
and	O
hepatic	O
insulin	O
resistance	O
.	O
In	O
many	O
studies	O
","	O
elevated	O
short	O
chain	O
ceramide	B-Chemical
levels	O
have	O
been	O
linked	O
to	O
insulin	O
resistence	O
and	O
the	O
development	O
of	O
T2D	O
.	O
For	O
example	O
","	O
Haus	O
et	O
al	O
.	O
[]	O
showed	O
that	O
enhanced	O
plasma	O
ceramide	B-Chemical
levels	O
in	O
patients	O
with	O
T2D	O
correlate	O
with	O
the	O
severity	O
of	O
insulin	O
resistance	O
.	O
The	O
authors	O
suggested	O
that	O
the	O
activation	O
of	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
by	O
short	O
chain	O
C18Cer	B-Chemical
and	O
C18	B-Chemical
:	I-Chemical
1Cer	I-Chemical
may	O
contribute	O
to	O
insulin	O
resistance	O
in	O
patients	O
[].	O
In	O
addition	O
","	O
it	O
was	O
shown	O
that	O
glucolipotoxicity	O
induces	O
Î²	O
-	O
cell	O
apoptosis	O
through	O
the	O
formation	O
of	O
ceramides	B-Chemical
with	O
specific	O
N	O
-	O
acyl	O
chain	O
lengths	O
","	O
such	O
as	O
C18Cer	B-Chemical
and	O
its	O
corresponding	O
dihydroceramides	B-Chemical
[].	O
Most	O
interestingly	O
","	O
in	O
a	O
recent	O
publication	O
Wigger	O
et	O
al	O
.	O
[]	O
demonstrated	O
elevated	O
dihydroceramide	B-Chemical
levels	O
in	O
individuals	O
who	O
will	O
progress	O
to	O
diabetes	O
up	O
to	O
9	O
years	O
before	O
the	O
disease	O
â€™	O
s	O
onset	O
.	O
Therefore	O
","	O
the	O
authors	O
suggested	O
that	O
these	O
lipids	B-Chemical
may	O
serve	O
as	O
early	O
biomarkers	O
for	O
T2D	O
development	O
.	O
The	O
authors	O
also	O
showed	O
that	O
ceramides	B-Chemical
/	O
dihydrceramides	B-Chemical
positively	O
correlate	O
with	O
glucose	B-Chemical
intolerance	O
and	O
negatively	O
correlate	O
to	O
insulin	O
sensitivity	O
[].	O
From	O
our	O
data	O
","	O
we	O
can	O
neither	O
confirm	O
nor	O
exclude	O
that	O
the	O
observed	O
changes	O
in	O
C18dhCer	B-Chemical
and	O
C18Cer	B-Chemical
upon	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
can	O
influence	O
glucose	B-Chemical
uptake	O
","	O
insulin	O
resistance	O
","	O
and	O
thereby	O
the	O
course	O
of	O
T2D	O
favorably	O
or	O
unfavorably	O
.	O
Thus	O
","	O
further	O
studies	O
need	O
to	O
answer	O
by	O
which	O
mechanism	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
influences	O
T2D	O
progression	O
.	O
One	O
of	O
the	O
mechanisms	O
may	O
include	O
elevated	O
C18dhCer	B-Chemical
and	O
C18Cer	B-Chemical
levels	O
.	O
In	O
order	O
to	O
elucidate	O
the	O
mechanisms	O
","	O
we	O
would	O
dissect	O
whether	O
vitamin	B-Chemical
D	I-Chemical
can	O
activate	O
specific	O
CerS	B-Chemical
.	O
CerS2	B-Chemical
and	O
4	O
are	O
the	O
most	O
prominent	O
isoforms	O
in	O
blood	O
","	O
which	O
catalyze	O
the	O
formation	O
of	O
either	O
C20	B-Chemical
-	I-Chemical
26Cer	I-Chemical
(	O
CerS2	B-Chemical
)	O
or	O
C18	B-Chemical
/	I-Chemical
20Cer	I-Chemical
(	O
CerS4	B-Chemical
"),"	O
as	O
well	O
as	O
their	O
dihydroceramide	B-Chemical
analogs	O
[].	O
To	O
date	O
","	O
there	O
is	O
no	O
evidence	O
from	O
the	O
literature	O
that	O
vitamin	B-Chemical
D	I-Chemical
can	O
influence	O
specific	O
CerS	B-Chemical
isoforms	O
in	O
order	O
to	O
generate	O
chain	O
length	O
-	O
specific	O
ceramides	B-Chemical
and	O
dihydroceramides	B-Chemical
.	O
However	O
","	O
since	O
we	O
found	O
out	O
that	O
vitamin	B-Chemical
D	I-Chemical
selectively	O
enhanced	O
C18	B-Chemical
(	I-Chemical
dh	I-Chemical
)	I-Chemical
Cer	I-Chemical
levels	O
in	O
T2D	O
patients	O
â€™	O
plasma	O
","	O
CerS4	B-Chemical
seems	O
to	O
be	O
an	O
attractive	O
target	O
for	O
future	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
.	O
Interestingly	O
","	O
recent	O
publications	O
shed	O
new	O
light	O
on	O
the	O
shingolipids	B-Chemical
Â´	O
potential	O
in	O
T2D	O
prediction	O
.	O
Wigger	O
et	O
al	O
.	O
[]	O
showed	O
the	O
effect	O
of	O
vitamin	B-Chemical
D	I-Chemical
uptake	O
on	O
C18dhCer	B-Chemical
and	O
C18Cer	B-Chemical
levels	O
at	O
the	O
onset	O
of	O
T2D	O
in	O
humans	O
.	O
A	O
large	O
population	O
-	O
based	O
study	O
of	O
individuals	O
","	O
some	O
of	O
whom	O
later	O
developed	O
T2D	O
"[],"	O
shows	O
a	O
strong	O
predictive	O
power	O
for	O
1	B-Chemical
-	I-Chemical
deoxySL	I-Chemical
levels	O
","	O
indicative	O
of	O
T2D	O
development	O
in	O
the	O
next	O
5	O
years	O
","	O
particularly	O
in	O
non	O
-	O
obese	O
individuals	O
.	O
Together	O
with	O
our	O
observations	O
","	O
this	O
illustrates	O
the	O
so	O
far	O
neglected	O
potential	O
of	O
sphingolipid	B-Chemical
markers	O
in	O
T2D	O
.	O
4	O
.	O
Materials	O
and	O
Methods	O
4	O
.	O
1	O
.	O
Patients	O
and	O
Sampling	O
In	O
the	O
current	O
study	O
","	O
we	O
evaluated	O
retrospectively	O
the	O
effect	O
of	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
on	O
plasma	O
sphingolipid	B-Chemical
levels	O
of	O
patients	O
with	O
noninsulin	O
-	O
requiring	O
T2D	O
from	O
the	O
city	O
of	O
Frankfurt	O
am	O
Main	O
(	O
Germany	O
).	O
Overall	O
","	O
plasma	O
samples	O
of	O
59	O
patients	O
from	O
a	O
placebo	O
-	O
controlled	O
","	O
randomized	O
","	O
and	O
double	O
-	O
blind	O
study	O
were	O
analyzed	O
[].	O
The	O
study	O
was	O
performed	O
in	O
accord	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
Frankfurt	O
University	O
Hospital	O
(	O
21	O
January	O
2008	O
","	O
Reference	O
number	O
:	O
9	O
/	O
7	O
","	O
Protocoll	O
number	O
:	O
EMD	O
28162	O
-	O
600	O
","	O
EudraCT	O
:	O
2006	O
-	O
6180	O
-	O
23	O
).	O
All	O
patients	O
had	O
provided	O
written	O
informed	O
consent	O
before	O
their	O
inclusion	O
in	O
the	O
study	O
.	O
All	O
participants	O
were	O
not	O
treated	O
with	O
bisphosphonates	B-Chemical
","	O
calcimimetics	O
","	O
glucocorticoids	O
","	O
phenytoin	B-Chemical
","	O
glycosides	B-Chemical
","	O
or	O
benzodiazepine	B-Chemical
","	O
before	O
or	O
during	O
the	O
study	O
period	O
.	O
Further	O
","	O
all	O
patients	O
did	O
not	O
receive	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
for	O
at	O
least	O
3	O
months	O
before	O
the	O
beginning	O
of	O
the	O
study	O
(	O
baseline	O
).	O
At	O
baseline	O
","	O
patients	O
â€™	O
characteristics	O
(	O
age	O
","	O
gender	O
","	O
duration	O
of	O
T2D	O
","	O
body	O
mass	O
index	O
(	O
BMI	O
))	O
were	O
determnined	O
and	O
the	O
participants	O
were	O
randomized	O
into	O
two	O
parallel	O
groups	O
.	O
During	O
6	O
months	O
","	O
patients	O
received	O
once	O
weekly	O
either	O
20	O
drops	O
of	O
Vigantol	B-Chemical
oil	I-Chemical
","	O
corresponding	O
to	O
a	O
daily	O
dose	O
of	O
1904	O
IU	O
/	O
d	O
vitamin	B-Chemical
D	I-Chemical
(	O
verum	O
group	O
:	O
n	O
=	O
31	O
"),"	O
or	O
a	O
placebo	O
oil	O
consisting	O
of	O
medium	O
chain	O
triglycerides	B-Chemical
(	O
placebo	O
group	O
:	O
n	O
=	O
28	O
)	O
at	O
baseline	O
.	O
Blood	O
laboratory	O
parameters	O
(	O
triglycerides	B-Chemical
","	O
cholesterol	B-Chemical
","	O
low	O
density	O
lipoproteins	O
(	O
LDL	O
"),"	O
high	O
density	O
lipoproteins	O
(	O
HDL	O
))	O
were	O
determined	O
at	O
baseline	O
and	O
after	O
6	O
months	O
of	O
supplementation	O
.	O
For	O
the	O
sphingolipid	B-Chemical
and	O
25	B-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
D3	I-Chemical
analysis	O
at	O
all	O
timepoints	O
","	O
blood	O
samples	O
(	O
1	O
.	O
6	O
mg	O
/	O
mL	O
ethylenediamine	B-Chemical
tetraacetic	I-Chemical
acid	I-Chemical
(	O
EDTA	B-Chemical
)	O
as	O
anticoagulant	O
)	O
were	O
centrifuged	O
at	O
room	O
temperature	O
for	O
10	O
min	O
at	O
400	O
Ã—	O
g	O
and	O
plasma	O
aliquots	O
from	O
each	O
subject	O
were	O
immediately	O
frozen	O
at	O
âˆ’	O
80	O
Â°	O
C	O
until	O
assayed	O
.	O
The	O
concentrations	O
of	O
25	B-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
D3	I-Chemical
were	O
measured	O
by	O
125I	B-Chemical
-	O
radioimmunoassay	O
.	O
The	O
plasma	O
sphingolipid	B-Chemical
levels	O
were	O
measured	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
as	O
described	O
below	O
.	O
4	O
.	O
2	O
.	O
LC	O
-	O
MS	O
/	O
MS	O
Analysis	O
For	O
lipid	B-Chemical
extraction	O
","	O
10	O
ÂµL	O
of	O
plasma	O
was	O
mixed	O
with	O
150	O
ÂµL	O
of	O
water	B-Chemical
","	O
150	O
ÂµL	O
of	O
extraction	O
buffer	O
(	O
citric	B-Chemical
acid	I-Chemical
30	O
mM	O
","	O
disodium	B-Chemical
hydrogen	I-Chemical
phosphate	I-Chemical
40	O
mM	O
"),"	O
and	O
20	O
ÂµL	O
of	O
the	O
internal	O
standard	O
solution	O
containing	O
sphingosine	B-Chemical
-	I-Chemical
d7	I-Chemical
","	O
sphinganine	B-Chemical
-	I-Chemical
d7	I-Chemical
(	O
200	O
ng	O
/	O
mL	O
each	O
"),"	O
sphingosine	B-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
phosphate	I-Chemical
-	I-Chemical
d7	I-Chemical
","	O
C17	B-Chemical
:	I-Chemical
0	I-Chemical
Cer	I-Chemical
","	O
C16	B-Chemical
:	I-Chemical
0	I-Chemical
Cer	I-Chemical
-	I-Chemical
d31	I-Chemical
","	O
C18	B-Chemical
:	I-Chemical
0	I-Chemical
Cer	I-Chemical
-	I-Chemical
d3	I-Chemical
","	O
C17	B-Chemical
:	I-Chemical
0	I-Chemical
LacCer	I-Chemical
","	O
C18	B-Chemical
:	I-Chemical
0	I-Chemical
DHC	I-Chemical
-	I-Chemical
d3	I-Chemical
","	O
C16	B-Chemical
:	I-Chemical
0	I-Chemical
LacCer	I-Chemical
-	I-Chemical
d3	I-Chemical
","	O
C18	B-Chemical
:	I-Chemical
0	I-Chemical
GluCer	I-Chemical
-	I-Chemical
d5	I-Chemical
(	O
all	O
Avanti	O
Polar	O
Lipids	O
","	O
Alabaster	O
","	O
AL	O
","	O
USA	O
"),"	O
and	O
C24	B-Chemical
:	I-Chemical
0	I-Chemical
Cer	I-Chemical
-	I-Chemical
d4	I-Chemical
(	O
Chiroblock	O
GmbH	O
","	O
Bitterfeld	O
-	O
Wolfen	O
","	O
Germany	O
;	O
400	O
ng	O
/	O
mL	O
each	O
).	O
The	O
mixture	O
was	O
extracted	O
once	O
with	O
1000	O
ÂµL	O
methanol	B-Chemical
/	O
chloroform	B-Chemical
/	O
hydrochloric	B-Chemical
acid	I-Chemical
(	O
15	O
:	O
83	O
:	O
2	O
","	O
v	O
/	O
v	O
/	O
v	O
).	O
The	O
lower	O
organic	O
phase	O
was	O
evaporated	O
at	O
45	O
Â°	O
C	O
under	O
a	O
gentle	O
stream	O
of	O
nitrogen	B-Chemical
and	O
reconstituted	O
in	O
200	O
ÂµL	O
of	O
tetrahydrofuran	B-Chemical
/	O
water	B-Chemical
(	O
9	O
:	O
1	O
","	O
v	O
/	O
v	O
)	O
with	O
0	O
.	O
2	O
%	O
formic	B-Chemical
acid	I-Chemical
and	O
10	O
mM	O
ammonium	B-Chemical
formate	I-Chemical
.	O
Afterwards	O
","	O
the	O
amounts	O
of	O
sphingolipids	B-Chemical
were	O
analyzed	O
by	O
liquid	O
chromatography	O
coupled	O
to	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
).	O
An	O
Agilent	O
1100	O
series	O
binary	O
pump	O
(	O
Agilent	O
technologies	O
","	O
Waldbronn	O
","	O
Germany	O
)	O
equipped	O
with	O
a	O
Luna	O
C8	O
column	O
(	O
150	O
mm	O
Ã—	O
2	O
mm	O
ID	O
","	O
3	O
Î¼m	O
particle	O
size	O
","	O
100	O
Ã…	O
pore	O
size	O
;	O
Phenomenex	O
","	O
Aschaffenburg	O
","	O
Germany	O
)	O
was	O
used	O
for	O
chromatographic	O
separation	O
.	O
The	O
column	O
temperature	O
was	O
35	O
Â°	O
C	O
.	O
The	O
HPLC	O
mobile	O
phases	O
consisted	O
of	O
water	B-Chemical
with	O
0	O
.	O
2	O
%	O
formic	B-Chemical
acid	I-Chemical
and	O
2	O
mM	O
ammonium	B-Chemical
formate	I-Chemical
(	O
mobile	O
phase	O
A	O
)	O
and	O
acetonitrile	B-Chemical
/	O
isopropanol	B-Chemical
/	O
acetone	B-Chemical
(	O
50	O
:	O
30	O
:	O
20	O
","	O
v	O
/	O
v	O
/	O
v	O
)	O
with	O
0	O
.	O
2	O
%	O
formic	B-Chemical
acid	I-Chemical
(	O
mobile	O
phase	O
B	O
).	O
For	O
separation	O
","	O
a	O
gradient	O
program	O
was	O
used	O
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
3	O
mL	O
/	O
min	O
.	O
The	O
initial	O
buffer	O
composition	O
55	O
%	O
(	O
A	O
)/	O
45	O
%	O
(	O
B	O
)	O
was	O
held	O
for	O
0	O
.	O
7	O
min	O
and	O
then	O
within	O
4	O
min	O
linearly	O
changed	O
to	O
0	O
%	O
(	O
A	O
)/	O
100	O
%	O
(	O
B	O
)	O
and	O
held	O
for	O
13	O
.	O
3	O
min	O
.	O
Subsequently	O
","	O
the	O
composition	O
was	O
linearly	O
changed	O
within	O
1	O
min	O
to	O
75	O
%	O
(	O
A	O
)/	O
25	O
%	O
(	O
B	O
)	O
and	O
then	O
held	O
for	O
another	O
2	O
min	O
.	O
The	O
total	O
running	O
time	O
was	O
21	O
min	O
","	O
and	O
the	O
injection	O
volume	O
was	O
15	O
Î¼L	O
.	O
To	O
improve	O
ionization	O
","	O
acetonitrile	B-Chemical
with	O
0	O
.	O
1	O
%	O
formic	B-Chemical
acid	I-Chemical
was	O
infused	O
post	O
-	O
column	O
using	O
an	O
isocratic	O
pump	O
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
15	O
mL	O
/	O
min	O
.	O
After	O
every	O
sample	O
","	O
sample	O
solvent	O
was	O
injected	O
for	O
washing	O
the	O
column	O
with	O
a	O
12	O
min	O
run	O
.	O
The	O
MS	O
/	O
MS	O
analyses	O
were	O
performed	O
using	O
a	O
triple	O
quadrupole	O
mass	O
spectrometer	O
API4000	O
(	O
Sciex	O
","	O
Darmstadt	O
","	O
Germany	O
)	O
equipped	O
with	O
a	O
Turbo	O
V	O
Ion	O
Source	O
operating	O
in	O
positive	O
electrospray	O
ionization	O
mode	O
.	O
The	O
MS	O
parameters	O
were	O
set	O
as	O
follows	O
:	O
Ionspray	O
voltage	O
5500	O
V	O
","	O
ion	O
source	O
temperature	O
500	O
Â°	O
C	O
","	O
curtain	O
gas	O
30	O
psi	O
","	O
collision	O
gas	O
12	O
psi	O
","	O
nebulizer	O
gas	O
40	O
psi	O
","	O
and	O
heating	O
gas	O
60	O
psi	O
.	O
The	O
analysis	O
was	O
done	O
in	O
Multiple	O
Reaction	O
Monitoring	O
(	O
MRM	O
)	O
mode	O
.	O
Data	O
Acquisition	O
was	O
done	O
using	O
Analyst	O
Software	O
V	O
1	O
.	O
6	O
","	O
and	O
quantification	O
was	O
performed	O
with	O
MultiQuant	O
Software	O
V	O
3	O
.	O
0	O
(	O
both	O
Sciex	O
","	O
Darmstadt	O
","	O
Germany	O
"),"	O
employing	O
the	O
internal	O
standard	O
method	O
(	O
isotope	O
dilution	O
mass	O
spectrometry	O
).	O
Variations	O
in	O
accuracy	O
of	O
the	O
calibration	O
standards	O
were	O
less	O
than	O
15	O
%	O
over	O
the	O
whole	O
range	O
of	O
calibration	O
","	O
except	O
for	O
the	O
lower	O
limit	O
of	O
quantification	O
","	O
where	O
a	O
variation	O
in	O
accuracy	O
of	O
20	O
%	O
was	O
accepted	O
.	O
4	O
.	O
3	O
.	O
Statistical	O
Analysis	O
The	O
statistical	O
analyses	O
were	O
performed	O
with	O
GraphPad	O
Prism	O
(	O
v5	O
.	O
1	O
;	O
GraphPad	O
Software	O
Inc	O
".,"	O
San	O
Diego	O
","	O
CA	O
","	O
USA	O
).	O
Group	O
comparisons	O
were	O
conducted	O
by	O
using	O
the	O
nonparametric	O
Mann	O
Whitney	O
U	O
test	O
.	O
Differences	O
with	O
p	O
<	O
0	O
.	O
5	O
were	O
considered	O
to	O
be	O
significant	O
.	O
All	O
data	O
are	O
expressed	O
as	O
median	O
Â±	O
interquartile	O
range	O
(	O
IQR	O
).	O
5	O
.	O
Conclusions	O
Taken	O
together	O
","	O
we	O
demonstrate	O
here	O
for	O
the	O
first	O
time	O
that	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
enhances	O
the	O
plasma	O
levels	O
of	O
C18dhCer	B-Chemical
and	O
C18Cer	B-Chemical
in	O
patients	O
suffering	O
from	O
T2D	O
.	O
These	O
findings	O
offer	O
promising	O
new	O
approaches	O
to	O
understand	O
the	O
role	O
of	O
vitamin	B-Chemical
D	I-Chemical
for	O
the	O
development	O
of	O
Diabetes	O
mellitus	O
by	O
influencing	O
sphingolipid	B-Chemical
metabolism	O
.	O
Supplementary	O
Materials	O
Supplementary	O
materials	O
can	O
be	O
found	O
at	O
.	O
Author	O
Contributions	O
Concieved	O
of	O
and	O
designed	O
the	O
experiments	O
:	O
Alexander	O
Koch	O
","	O
Marissa	O
Penna	O
-	O
Martinez	O
","	O
Georgios	O
Grammatikos	O
and	O
Klaus	O
Badenhoop	O
.	O
Collected	O
samples	O
:	O
Marissa	O
Penna	O
-	O
Martinez	O
","	O
Franziska	O
Bruns	O
and	O
Klaus	O
Badenhoop	O
.	O
Carried	O
out	O
the	O
LC	O
-	O
MS	O
/	O
MS	O
experiments	O
:	O
Sandra	O
Trautmann	O
and	O
Yannick	O
Schreiber	O
.	O
Analyzed	O
the	O
data	O
:	O
Alexander	O
Koch	O
","	O
Georgios	O
Grammatikos	O
","	O
Dominique	O
Thomas	O
and	O
Marissa	O
Penna	O
-	O
Martinez	O
.	O
Wrote	O
the	O
paper	O
:	O
Alexander	O
Koch	O
","	O
Josef	O
Pfeilschifter	O
","	O
Klaus	O
Badenhoop	O
and	O
Marissa	O
Penna	O
-	O
Martinez	O
.	O
Conflicts	O
of	O
Interest	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O
Abbreviations	O
25	B-Chemical
(	I-Chemical
OH	I-Chemical
)	I-Chemical
D3	I-Chemical
25	I-Chemical
-	I-Chemical
hydroxyvitamin	I-Chemical
D3	I-Chemical
Cer	I-Chemical
ceramide	I-Chemical
CerS	O
ceramide	O
synthase	O
dhCer	B-Chemical
dihydroceramide	I-Chemical
HDL	O
high	O
densitiy	O
lipoproteins	O
LDL	O
low	O
densitiy	O
lipoprotein	O
dhS1P	B-Chemical
sphinganine	I-Chemical
1	I-Chemical
-	I-Chemical
phosphate	I-Chemical
S1P	I-Chemical
sphingosine	I-Chemical
1	I-Chemical
-	I-Chemical
phosphate	I-Chemical
T2D	O
Type	O
2	O
Diabetes	O
mellitus	O
References	O
Effect	O
of	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
on	O
plasma	O
dihydroceramide	B-Chemical
(	O
dhCer	B-Chemical
)	O
levels	O
.	O
All	O
patients	O
were	O
treated	O
for	O
6	O
months	O
with	O
either	O
a	O
placebo	O
or	O
1904	O
IU	O
/	O
d	O
vitamin	B-Chemical
D	I-Chemical
.	O
Plasma	O
sphingolipid	B-Chemical
concentrations	O
were	O
measured	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
.	O
Dates	O
are	O
shown	O
as	O
median	O
Â±	O
IQR	O
(	O
Mann	O
Whitney	O
U	O
test	O
","	O
*	O
p	O
<	O
0	O
.	O
5	O
).	O
Abbreviations	O
:	O
dhCer	B-Chemical
","	O
dihydroceramide	B-Chemical
.	O
Effect	O
of	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
on	O
plasma	O
ceramide	B-Chemical
(	O
Cer	B-Chemical
)	O
levels	O
.	O
All	O
patients	O
were	O
treated	O
for	O
6	O
months	O
with	O
either	O
a	O
placebo	O
or	O
1904	O
IU	O
/	O
d	O
vitamin	B-Chemical
D	I-Chemical
.	O
Plasma	O
sphingolipid	B-Chemical
concentrations	O
were	O
measured	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
.	O
Dates	O
are	O
shown	O
as	O
median	O
Â±	O
IQR	O
(	O
Mann	O
Whitney	O
U	O
test	O
","	O
*	O
p	O
<	O
0	O
.	O
5	O
).	O
Abbreviations	O
:	O
Cer	B-Chemical
","	O
ceramide	B-Chemical
.	O
Effect	O
of	O
vitamin	B-Chemical
D	I-Chemical
supplementation	O
on	O
plasma	O
sphinganine	B-Chemical
","	O
sphingosine	B-Chemical
","	O
and	O
1	B-Chemical
-	I-Chemical
phosphate	I-Chemical
derivate	O
levels	O
.	O
All	O
patients	O
were	O
treated	O
for	O
6	O
months	O
with	O
either	O
a	O
placebo	O
or	O
1904	O
IU	O
/	O
d	O
vitamin	B-Chemical
D	I-Chemical
.	O
Plasma	O
sphingolipid	B-Chemical
concentrations	O
were	O
measured	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
.	O
Dates	O
are	O
shown	O
as	O
median	O
Â±	O
IQR	O
(	O
Mann	O
Whitney	O
U	O
test	O
).	O
Abbreviations	O
:	O
dhS1P	B-Chemical
","	O
sphinganin	B-Chemical
1	I-Chemical
-	I-Chemical
phosphate	I-Chemical
;	O
S1P	B-Chemical
","	O
sphingosine	B-Chemical
1	I-Chemical
-	I-Chemical
phosphate	I-Chemical
.	O
Patients	O
â€™	O
characteristics	O
at	O
baseline	O
.	O
Median	O
(	O
interquartile	O
range	O
","	O
IQR	O
);	O
Mann	O
Whitney	O
U	O
test	O
.	O
Abbreviations	O
:	O
BMI	O
","	O
body	O
mass	O
index	O
;	O
T2D	O
","	O
Type	O
2	O
Diabetes	O
mellitus	O
.	O
Blood	O
lipid	O
levels	O
at	O
baseline	O
and	O
after	O
6	O
months	O
of	O
supplementation	O
.	O
Median	O
(	O
IQR	O
);	O
mg	O
/	O
dl	O
;	O
n	O
=	O
28	O
(	O
placebo	O
group	O
"),"	O
n	O
=	O
31	O
(	O
verum	O
group	O
);	O
Mann	O
Whitney	O
U	O
test	O
;	O
Missing	O
data	O
:	O
LDL	O
:	O
n	O
=	O
27	O
(	O
placebo	O
group	O
at	O
baseline	O
).	O
Abbreviations	O
:	O
HDL	O
","	O
high	O
density	O
lipoproteins	O
;	O
LDL	O
","	O
low	O
density	O
lipoproteins	O
.	O
Gluten	O
-	O
free	O
diet	O
may	O
alleviate	O
depressive	O
and	O
behavioural	O
symptoms	O
in	O
adolescents	O
with	O
coeliac	O
disease	O
:	O
a	O
prospective	O
follow	O
-	O
up	O
case	O
-	O
series	O
study	O
Background	O
Coeliac	O
disease	O
in	O
adolescents	O
has	O
been	O
associated	O
with	O
an	O
increased	O
prevalence	O
of	O
depressive	O
and	O
disruptive	O
behavioural	O
disorders	O
","	O
particularly	O
in	O
the	O
phase	O
before	O
diet	O
treatment	O
.	O
We	O
studied	O
the	O
possible	O
effects	O
of	O
a	O
gluten	O
-	O
free	O
diet	O
on	O
psychiatric	O
symptoms	O
","	O
on	O
hormonal	O
status	O
(	O
prolactin	O
","	O
thyroidal	O
function	O
)	O
and	O
on	O
large	O
neutral	O
amino	B-Chemical
acid	I-Chemical
serum	O
concentrations	O
in	O
adolescents	O
with	O
coeliac	O
disease	O
commencing	O
a	O
gluten	O
-	O
free	O
diet	O
.	O
Methods	O
Nine	O
adolescents	O
with	O
celiac	O
disease	O
","	O
aged	O
12	O
to	O
16	O
years	O
","	O
were	O
assessed	O
using	O
the	O
semi	O
-	O
structured	O
K	O
-	O
SADS	O
-	O
Present	O
and	O
Lifetime	O
Diagnostic	O
interview	O
and	O
several	O
symptom	O
scales	O
.	O
Seven	O
of	O
them	O
were	O
followed	O
at	O
1	O
to	O
2	O
","	O
3	O
","	O
and	O
6	O
months	O
on	O
a	O
gluten	O
-	O
free	O
diet	O
.	O
Results	O
Adolescent	O
coeliac	O
disease	O
patients	O
with	O
depression	O
had	O
significantly	O
lower	O
pre	O
-	O
diet	O
tryptophan	B-Chemical
/	O
competing	O
amino	B-Chemical
-	I-Chemical
acid	I-Chemical
(	O
CAA	B-Chemical
)	O
ratios	O
and	O
free	O
tryptophan	B-Chemical
concentrations	O
","	O
and	O
significantly	O
higher	O
biopsy	O
morning	O
prolactin	O
levels	O
compared	O
to	O
those	O
without	O
depression	O
.	O
A	O
significant	O
decrease	O
in	O
psychiatric	O
symptoms	O
was	O
found	O
at	O
3	O
months	O
on	O
a	O
gluten	O
-	O
free	O
diet	O
compared	O
to	O
patients	O
'	O
baseline	O
condition	O
","	O
coinciding	O
with	O
significantly	O
decreased	O
coeliac	O
disease	O
activity	O
and	O
prolactin	O
levels	O
and	O
with	O
a	O
significant	O
increase	O
in	O
serum	O
concentrations	O
of	O
CAAs	B-Chemical
.	O
Conclusion	O
Although	O
our	O
results	O
of	O
the	O
amino	B-Chemical
acid	I-Chemical
analysis	O
and	O
prolactin	O
levels	O
in	O
adolescents	O
are	O
only	O
preliminary	O
","	O
they	O
give	O
support	O
to	O
previous	O
findings	O
on	O
patients	O
with	O
coeliac	O
disease	O
","	O
suggesting	O
that	O
serotonergic	O
dysfunction	O
due	O
to	O
impaired	O
availability	O
of	O
tryptophan	B-Chemical
may	O
play	O
a	O
role	O
in	O
vulnerability	O
to	O
depressive	O
and	O
behavioural	O
disorders	O
also	O
among	O
adolescents	O
with	O
untreated	O
coeliac	O
disease	O
.	O
Background	O
Coeliac	O
disease	O
is	O
an	O
under	O
-	O
diagnosed	O
autoimmune	O
type	O
of	O
gastrointestinal	O
disorder	O
resulting	O
from	O
gluten	O
ingestion	O
in	O
genetically	O
susceptible	O
individuals	O
.	O
Non	O
-	O
specific	O
symptoms	O
such	O
as	O
fatigue	O
and	O
dyspepsia	O
are	O
common	O
","	O
but	O
the	O
disease	O
may	O
also	O
be	O
clinically	O
silent	O
.	O
Diagnosis	O
is	O
based	O
on	O
small	O
-	O
bowel	O
biopsy	O
","	O
and	O
a	O
permanent	O
gluten	O
-	O
free	O
diet	O
is	O
the	O
essential	O
treatment	O
.	O
Undetected	O
or	O
neglected	O
","	O
coeliac	O
disease	O
is	O
associated	O
with	O
serious	O
complications	O
.	O
[	O
1	O
-	O
3	O
]	O
Depressive	O
symptoms	O
[	O
4	O
","	O
5	O
]	O
and	O
disorders	O
[	O
6	O
]	O
are	O
common	O
among	O
adult	O
patients	O
with	O
coeliac	O
disease	O
","	O
and	O
depressive	O
and	O
disruptive	O
behavioural	O
disorders	O
are	O
highly	O
common	O
also	O
among	O
adolescents	O
","	O
particularly	O
in	O
the	O
phase	O
before	O
diet	O
treatment	O
[	O
7	O
].	O
Recently	O
73	O
%	O
of	O
patients	O
with	O
untreated	O
coeliac	O
disease	O
â€“	O
but	O
only	O
7	O
%	O
of	O
patients	O
adhering	O
to	O
a	O
gluten	O
-	O
free	O
diet	O
â€“	O
were	O
reported	O
to	O
have	O
cerebral	O
blood	O
flow	O
abnormalities	O
similar	O
to	O
those	O
among	O
patients	O
with	O
depressive	O
disorders	O
[	O
8	O
].	O
Improvement	O
in	O
state	O
anxiety	O
[	O
5	O
"],"	O
in	O
behavioural	O
symptoms	O
[	O
9	O
"],"	O
and	O
in	O
depressive	O
disorders	O
[	O
6	O
","	O
10	O
]	O
may	O
occur	O
after	O
the	O
start	O
of	O
a	O
standard	O
gluten	O
-	O
free	O
diet	O
","	O
and	O
after	O
a	O
vitamin	B-Chemical
B	I-Chemical
-	I-Chemical
6	I-Chemical
-	O
supplemented	O
gluten	O
-	O
free	O
diet	O
[	O
11	O
].	O
In	O
some	O
cases	O
","	O
however	O
","	O
the	O
more	O
serious	O
depressive	O
episodes	O
have	O
appeared	O
following	O
the	O
commencement	O
of	O
a	O
gluten	O
-	O
free	O
diet	O
[	O
6	O
].	O
Mechanisms	O
involved	O
have	O
remained	O
unclear	O
.	O
Some	O
studies	O
have	O
suggested	O
the	O
possibility	O
of	O
impaired	O
availability	O
of	O
tryptophan	B-Chemical
and	O
disturbances	O
in	O
central	O
serotonergic	O
function	O
as	O
playing	O
a	O
role	O
[	O
9	O
","	O
12	O
].	O
In	O
parallel	O
with	O
this	O
","	O
a	O
significant	O
increase	O
in	O
major	O
serotonin	B-Chemical
and	O
dopamine	B-Chemical
metabolite	O
concentrations	O
in	O
the	O
brain	O
has	O
been	O
reported	O
after	O
one	O
year	O
on	O
a	O
gluten	O
-	O
free	O
diet	O
[	O
13	O
].	O
The	O
present	O
work	O
is	O
a	O
preliminary	O
prospective	O
psychiatric	O
follow	O
-	O
up	O
study	O
of	O
adolescents	O
with	O
newly	O
diagnosed	O
coeliac	O
disease	O
measuring	O
psychiatric	O
symptoms	O
","	O
hormonal	O
status	O
(	O
prolactin	O
","	O
thyroidal	O
function	O
"),"	O
and	O
large	O
neutral	B-Chemical
amino	I-Chemical
acid	I-Chemical
(	O
LNAA	B-Chemical
)	O
serum	O
concentrations	O
repeatedly	O
after	O
their	O
commencement	O
of	O
a	O
gluten	O
-	O
free	O
diet	O
","	O
testing	O
the	O
hypothesis	O
that	O
the	O
treatment	O
of	O
coeliac	O
disease	O
may	O
increase	O
the	O
availability	O
of	O
tryptophan	B-Chemical
and	O
alleviate	O
psychiatric	O
symptoms	O
.	O
Methods	O
Subjects	O
The	O
study	O
sample	O
comprised	O
all	O
nine	O
adolescents	O
(	O
5	O
girls	O
","	O
4	O
boys	O
;	O
aged	O
14	O
.	O
6	O
Â±	O
0	O
.	O
8	O
)	O
consecutively	O
diagnosed	O
with	O
coeliac	O
disease	O
between	O
January	O
1999	O
and	O
December	O
2000	O
in	O
the	O
Department	O
of	O
the	O
Gastrointestinal	O
Services	O
of	O
the	O
Hospital	O
for	O
Children	O
and	O
Adolescents	O
","	O
Helsinki	O
University	O
Central	O
Hospital	O
","	O
in	O
Finland	O
.	O
None	O
of	O
the	O
patients	O
had	O
a	O
history	O
of	O
","	O
or	O
current	O
psychiatric	O
treatment	O
.	O
Duration	O
of	O
coeliac	O
disease	O
symptoms	O
and	O
signs	O
(	O
abdominal	O
pain	O
","	O
diarrhoea	O
","	O
anaemia	O
)	O
leading	O
to	O
a	O
biopsy	O
was	O
2	O
.	O
3	O
(Â±	O
1	O
.	O
5	O
)	O
years	O
.	O
The	O
study	O
was	O
approved	O
by	O
the	O
institutional	O
Ethics	O
Committee	O
.	O
Written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
patient	O
and	O
a	O
parent	O
.	O
Evaluation	O
Baseline	O
psychiatric	O
evaluation	O
was	O
conducted	O
1	O
to	O
4	O
weeks	O
after	O
the	O
diagnostic	O
biopsy	O
","	O
during	O
the	O
wait	O
for	O
the	O
diagnosis	O
of	O
coeliac	O
disease	O
to	O
be	O
established	O
by	O
the	O
pathologist	O
.	O
The	O
adolescent	O
and	O
a	O
parent	O
were	O
interviewed	O
separately	O
by	O
an	O
adolescent	O
psychiatrist	O
(	O
PP	O
)	O
using	O
a	O
semi	O
-	O
structured	O
diagnostic	O
interview	O
","	O
the	O
Schedule	O
for	O
Affective	O
Disorders	O
and	O
Schizophrenia	O
for	O
School	O
-	O
Age	O
Children	O
â€“	O
Present	O
and	O
Lifetime	O
version	O
(	O
K	O
-	O
SADS	O
-	O
PL	O
)	O
[	O
14	O
].	O
Seven	O
patients	O
attended	O
the	O
follow	O
-	O
up	O
visits	O
with	O
laboratory	O
tests	O
at	O
>	O
1	O
to	O
â‰¤	O
2	O
","	O
3	O
","	O
and	O
6	O
months	O
after	O
starting	O
a	O
gluten	O
-	O
free	O
diet	O
(	O
Table	O
1	O
).	O
Baseline	O
and	O
follow	O
-	O
up	O
behavioural	O
problems	O
were	O
assessed	O
with	O
the	O
Youth	O
Self	O
Report	O
(	O
YSR	O
)	O
[	O
15	O
]	O
and	O
the	O
Child	O
Behavior	O
Checklist	O
(	O
CBCL	O
)	O
[	O
16	O
"],"	O
completed	O
by	O
a	O
parent	O
(	O
Table	O
1	O
"),"	O
and	O
depressive	O
and	O
anxiety	O
symptoms	O
by	O
the	O
21	O
-	O
item	O
versions	O
of	O
the	O
Beck	O
Depression	O
Inventory	O
(	O
BDI	O
)	O
and	O
Beck	O
Anxiety	O
Inventory	O
(	O
BAI	O
"),"	O
the	O
17	O
-	O
item	O
version	O
of	O
the	O
Hamilton	O
Depression	O
Rating	O
Scale	O
(	O
HAM	O
-	O
D	O
"),"	O
and	O
the	O
14	O
-	O
item	O
Hamilton	O
Anxiety	O
Rating	O
Scale	O
(	O
HAM	O
-	O
A	O
).	O
CGAS	O
(	O
Children	O
'	O
s	O
Global	O
Assessment	O
)	O
served	O
as	O
a	O
part	O
of	O
the	O
K	O
-	O
SADS	O
-	O
PL	O
.	O
Psychiatric	O
symptoms	O
and	O
disease	O
activity	O
among	O
adolescent	O
CD	O
patients	O
(	O
n	O
=	O
7	O
","	O
mean	O
Â±	O
SD	O
)	O
Coeliac	O
disease	O
activity	O
was	O
followed	O
by	O
determining	O
serum	O
tissue	O
transglutaminase	O
(	O
S	O
-	O
tTGAbA	O
)	O
and	O
endomysium	O
(	O
S	O
-	O
EndoAbA	O
)	O
autoantibodies	O
[	O
17	O
].	O
Pre	O
-	O
diet	O
blood	O
samples	O
for	O
analysis	O
of	O
amino	B-Chemical
acids	I-Chemical
","	O
prolactin	O
","	O
thyroid	O
function	O
[	O
thyroxine	B-Chemical
(	O
S	B-Chemical
-	I-Chemical
T4	I-Chemical
"),"	O
thyroid	O
-	O
stimulating	O
hormone	O
(	O
TSH	O
")],"	O
vitamins	B-Chemical
B6	I-Chemical
and	I-Chemical
B12	I-Chemical
","	O
S	O
-	O
tTGAbA	O
","	O
and	O
S	O
-	O
EndoAbA	O
were	O
obtained	O
on	O
the	O
biopsy	O
morning	O
","	O
and	O
subsequent	O
ones	O
as	O
a	O
part	O
of	O
follow	O
-	O
up	O
visits	O
","	O
both	O
after	O
overnight	O
fasting	O
","	O
between	O
8	O
and	O
10	O
a	O
.	O
m	O
.	O
All	O
nine	O
patients	O
had	O
amino	B-Chemical
acid	I-Chemical
concentrations	O
measured	O
at	O
baseline	O
","	O
and	O
five	O
of	O
them	O
during	O
follow	O
-	O
up	O
(	O
1	O
â€“	O
2	O
times	O
).	O
A	O
blood	O
sample	O
(	O
2	O
ml	O
)	O
was	O
drawn	O
from	O
the	O
ulnar	O
vein	O
into	O
a	O
vacuum	O
tube	O
for	O
serum	O
total	O
and	O
free	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
","	O
and	O
for	O
other	O
large	O
neutral	B-Chemical
amino	I-Chemical
acids	I-Chemical
(	O
LNAA	B-Chemical
).	O
The	O
tube	O
was	O
cooled	O
immediately	O
and	O
stored	O
refrigerated	O
in	O
ice	O
until	O
centrifuged	O
.	O
After	O
centrifugation	O
","	O
the	O
serum	O
was	O
frozen	O
and	O
stored	O
at	O
-	O
20	O
Â°	O
C	O
for	O
4	O
to	O
14	O
months	O
(	O
median	O
7	O
.	O
5	O
)	O
until	O
its	O
assay	O
for	O
the	O
amino	B-Chemical
acids	I-Chemical
by	O
a	O
modified	O
procedure	O
described	O
by	O
Qureshi	O
et	O
al	O
.	O
[	O
18	O
].	O
All	O
the	O
samples	O
were	O
analysed	O
in	O
a	O
single	O
run	O
","	O
in	O
Kuopio	O
","	O
Finland	O
","	O
and	O
free	O
and	O
total	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
and	O
other	O
LNAA	B-Chemical
'	O
s	O
were	O
assessed	O
as	O
described	O
by	O
Tiihonen	O
et	O
al	O
.	O
[	O
19	O
].	O
Statistical	O
methods	O
Statistical	O
analysis	O
was	O
carried	O
out	O
with	O
parametric	O
and	O
non	O
-	O
parametric	O
tests	O
as	O
appropriate	O
;	O
tests	O
for	O
two	O
-	O
independent	O
groups	O
(	O
T	O
-	O
test	O
","	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
"),"	O
for	O
repeated	O
measures	O
of	O
two	O
-	O
related	O
groups	O
(	O
Wilcoxon	O
signed	O
-	O
ranks	O
test	O
"),"	O
for	O
three	O
-	O
related	O
groups	O
(	O
Friedman	O
test	O
)	O
and	O
Spearman	O
'	O
s	O
rank	O
correlation	O
testing	O
were	O
used	O
.	O
P	O
-	O
values	O
(	O
2	O
-	O
tailed	O
)	O
<	O
0	O
.	O
5	O
were	O
regarded	O
as	O
significant	O
.	O
Results	O
Baseline	O
evaluation	O
At	O
baseline	O
","	O
three	O
adolescents	O
(	O
3	O
/	O
9	O
;	O
33	O
%)	O
had	O
a	O
depressive	O
disorder	O
:	O
two	O
girls	O
had	O
major	O
depressive	O
disorder	O
(	O
MDD	O
"),"	O
one	O
with	O
a	O
learning	O
disorder	O
not	O
otherwise	O
specified	O
(	O
NOS	O
"),"	O
and	O
another	O
with	O
comorbid	O
conduct	O
disorder	O
;	O
one	O
girl	O
had	O
the	O
depressive	O
disorder	O
NOS	O
.	O
Further	O
","	O
one	O
boy	O
had	O
a	O
phobic	O
disorder	O
plus	O
attention	O
-	O
deficit	O
hyperactivity	O
disorder	O
","	O
and	O
another	O
conduct	O
disorder	O
NOS	O
.	O
Four	O
adolescents	O
(	O
44	O
%)	O
had	O
no	O
diagnosis	O
.	O
Pre	O
-	O
diet	O
free	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
was	O
positively	O
correlated	O
with	O
pre	O
-	O
diet	O
levels	O
of	O
tTGAbA	O
(	O
n	O
=	O
8	O
;	O
r	O
=	O
0	O
.	O
78	O
","	O
P	O
=	O
0	O
.	O
22	O
"),"	O
and	O
negatively	O
with	O
vitamin	B-Chemical
B	I-Chemical
-	I-Chemical
6	I-Chemical
(	O
r	O
=	O
0	O
.	O
73	O
","	O
P	O
=	O
0	O
.	O
39	O
)	O
and	O
S	B-Chemical
-	I-Chemical
T4	I-Chemical
(	O
r	O
=	O
0	O
.	O
74	O
","	O
P	O
=	O
0	O
.	O
35	O
).	O
Prolactin	O
levels	O
(	O
Table	O
1	O
)	O
from	O
the	O
biopsy	O
morning	O
showed	O
a	O
positive	O
correlation	O
with	O
BDI	O
score	O
(	O
self	O
-	O
report	O
depression	O
inventory	O
;	O
r	O
=	O
0	O
.	O
89	O
","	O
P	O
=	O
0	O
.	O
1	O
"),"	O
and	O
a	O
negative	O
correlation	O
with	O
the	O
ratio	O
of	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
to	O
amino	B-Chemical
acids	I-Chemical
competing	O
for	O
the	O
same	O
cerebral	O
uptake	O
mechanism	O
(	O
CAA	O
)	O
(	O
r	O
=	O
0	O
.	O
68	O
","	O
P	O
=	O
0	O
.	O
42	O
"),"	O
but	O
not	O
with	O
free	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
levels	O
.	O
The	O
sum	O
of	O
branched	B-Chemical
-	I-Chemical
chain	I-Chemical
amino	I-Chemical
acids	I-Chemical
(	O
BCAA	B-Chemical
:	O
valine	B-Chemical
","	O
leucine	B-Chemical
","	O
and	O
isoleucine	B-Chemical
)	O
showed	O
no	O
correlation	O
with	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
or	O
free	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
levels	O
.	O
Depressive	O
patients	O
(	O
n	O
=	O
3	O
/	O
9	O
)	O
had	O
significantly	O
higher	O
pre	O
-	O
diet	O
prolactin	O
levels	O
(	O
mU	O
/	O
l	O
:	O
mean	O
Â±	O
S	O
.	O
D	O
.	O
=	O
2450	O
Â±	O
676	O
vs	O
.	O
1194	O
Â±	O
598	O
","	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
","	O
P	O
=	O
0	O
.	O
39	O
)	O
and	O
pre	O
-	O
diet	O
S	B-Chemical
-	I-Chemical
T4	I-Chemical
levels	O
(	O
nmol	O
/	O
l	O
:	O
mean	O
102	O
Â±	O
3	O
.	O
1	O
vs	O
.	O
84	O
Â±	O
16	O
.	O
1	O
","	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
","	O
P	O
=	O
0	O
.	O
24	O
"),"	O
and	O
significantly	O
lower	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
/	O
CAA	O
ratios	O
(	O
100	O
Ã—	O
pmol	O
/	O
Î¼l	O
:	O
pmol	O
/	O
Î¼l	O
:	O
mean	O
10	O
.	O
0	O
Â±	O
0	O
.	O
2	O
vs	O
.	O
11	O
.	O
5	O
Â±	O
1	O
.	O
7	O
","	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
","	O
P	O
=	O
0	O
.	O
20	O
)	O
and	O
free	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
concentrations	O
(	O
pmol	O
/	O
Î¼l	O
:	O
mean	O
4	O
.	O
7	O
Â±	O
0	O
.	O
5	O
vs	O
.	O
8	O
.	O
4	O
Â±	O
3	O
.	O
0	O
","	O
two	O
-	O
independent	O
samples	O
T	O
-	O
test	O
","	O
P	O
=	O
0	O
.	O
29	O
).	O
Pre	O
-	O
diet	O
free	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
correlated	O
negatively	O
with	O
biopsy	O
morning	O
S	B-Chemical
-	I-Chemical
T4	I-Chemical
level	O
(	O
r	O
=	O
-	O
0	O
.	O
74	O
","	O
P	O
=	O
0	O
.	O
35	O
).	O
No	O
significant	O
differences	O
appeared	O
in	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
(	O
36	O
.	O
3	O
Â±	O
5	O
.	O
1	O
vs	O
.	O
43	O
.	O
3	O
Â±	O
6	O
.	O
1	O
)	O
or	O
in	O
L	B-Chemical
-	I-Chemical
tyrosine	I-Chemical
concentrations	O
","	O
nor	O
in	O
BCAA	B-Chemical
and	O
CAA	O
levels	O
.	O
Follow	O
-	O
up	O
Two	O
adolescents	O
with	O
conduct	O
disorders	O
","	O
one	O
a	O
girl	O
with	O
concomitant	O
MDD	O
","	O
did	O
not	O
adhere	O
to	O
the	O
gluten	O
-	O
free	O
diet	O
and	O
dropped	O
out	O
of	O
the	O
psychiatric	O
follow	O
-	O
up	O
.	O
Among	O
others	O
(	O
n	O
=	O
7	O
"),"	O
a	O
significant	O
decrease	O
in	O
most	O
of	O
the	O
problem	O
and	O
symptom	O
scores	O
of	O
YSR	O
and	O
CBCL	O
","	O
and	O
in	O
BDI	O
","	O
BAI	O
","	O
and	O
Hamilton	O
scales	O
was	O
evident	O
after	O
3	O
months	O
on	O
the	O
gluten	O
-	O
free	O
diet	O
","	O
compared	O
to	O
baseline	O
(	O
Table	O
1	O
).	O
Celiac	O
disease	O
-	O
associated	O
antibody	O
titres	O
had	O
decreased	O
in	O
all	O
by	O
the	O
first	O
month	O
on	O
a	O
gluten	O
-	O
free	O
diet	O
","	O
and	O
had	O
already	O
normalised	O
(=	O
S	O
-	O
EndoAbA	O
titre	O
<	O
5	O
and	O
S	O
-	O
tTGAbA	O
titre	O
<	O
8	O
)	O
in	O
4	O
of	O
7	O
patients	O
by	O
6	O
months	O
.	O
Boys	O
had	O
lower	O
biopsy	O
morning	O
prolactin	O
levels	O
(	O
mU	O
/	O
l	O
;	O
mean	O
972	O
","	O
SD	O
450	O
vs	O
.	O
girls	O
mean	O
2126	O
Â±	O
756	O
;	O
one	O
-	O
way	O
Anova	O
P	O
=	O
0	O
.	O
32	O
"),"	O
but	O
higher	O
levels	O
after	O
one	O
month	O
on	O
the	O
diet	O
.	O
In	O
the	O
first	O
month	O
","	O
the	O
S	B-Chemical
-	I-Chemical
T4	I-Chemical
/	O
TSH	O
ratio	O
(	O
nmol	O
/	O
l	O
:	O
mU	O
/	O
l	O
)	O
reflecting	O
thyroid	O
function	O
increased	O
significantly	O
(	O
Table	O
1	O
).	O
An	O
initial	O
increase	O
in	O
CAAs	O
","	O
also	O
in	O
tyrosine	B-Chemical
levels	O
","	O
and	O
in	O
total	O
and	O
free	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
was	O
reaching	O
significance	O
after	O
one	O
month	O
on	O
a	O
gluten	O
-	O
free	O
diet	O
.	O
By	O
3	O
months	O
","	O
the	O
increases	O
in	O
tyrosine	B-Chemical
alone	O
and	O
in	O
CAAs	O
as	O
a	O
group	O
were	O
significant	O
","	O
and	O
the	O
increase	O
in	O
free	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
was	O
approaching	O
significance	O
(	O
repeated	O
measures	O
Friedman	O
test	O
n	O
=	O
4	O
","	O
Chi	O
-	O
Square	O
6	O
","	O
0	O
","	O
df	O
2	O
","	O
P	O
=	O
0	O
.	O
50	O
).	O
(	O
Table	O
2	O
)	O
Follow	O
-	O
up	O
of	O
the	O
patients	O
(	O
n	O
=	O
5	O
):	O
psychiatric	O
symptoms	O
","	O
CD	O
activity	O
","	O
and	O
amino	O
acidconcentrations	O
[	O
median	O
(	O
min	O
-	O
max	O
)].	O
Discussion	O
We	O
observed	O
that	O
the	O
majority	O
of	O
adolescents	O
with	O
coeliac	O
disease	O
had	O
depressive	O
and	O
behavioural	O
symptoms	O
before	O
their	O
diagnosis	O
","	O
and	O
that	O
coeliac	O
disease	O
patients	O
with	O
depression	O
(	O
all	O
girls	O
)	O
had	O
significantly	O
lower	O
pre	O
-	O
diet	O
tryptophan	B-Chemical
/	O
CAA	O
ratios	O
and	O
free	O
tryptophan	B-Chemical
concentrations	O
and	O
significantly	O
higher	O
biopsy	O
morning	O
prolactin	O
levels	O
.	O
Adolescents	O
with	O
coeliac	O
disease	O
showed	O
improvement	O
in	O
psychiatric	O
symptoms	O
after	O
starting	O
a	O
gluten	O
-	O
free	O
diet	O
","	O
and	O
this	O
improvement	O
coincided	O
with	O
a	O
significant	O
decrease	O
in	O
coeliac	O
disease	O
activity	O
and	O
in	O
prolactin	O
levels	O
","	O
and	O
with	O
a	O
significant	O
increase	O
in	O
serum	O
concentrations	O
of	O
L	B-Chemical
-	I-Chemical
tyrosine	I-Chemical
and	O
other	O
CAAs	O
.	O
The	O
increase	O
in	O
free	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
levels	O
was	O
approaching	O
significance	O
.	O
The	O
findings	O
of	O
this	O
study	O
â€“	O
improvement	O
in	O
depressive	O
and	O
behavioural	O
symptoms	O
after	O
the	O
start	O
of	O
a	O
gluten	O
-	O
free	O
diet	O
â€“	O
are	O
supported	O
by	O
the	O
findings	O
of	O
our	O
larger	O
previous	O
retrospective	O
case	O
-	O
control	O
study	O
[	O
7	O
].	O
Although	O
the	O
results	O
of	O
the	O
amino	B-Chemical
acid	I-Chemical
analysis	O
and	O
prolactin	O
levels	O
are	O
only	O
preliminary	O
","	O
they	O
give	O
support	O
to	O
the	O
hypothesis	O
that	O
impaired	O
availability	O
of	O
tryptophan	B-Chemical
and	O
the	O
possible	O
consequent	O
serotonergic	O
dysfunction	O
may	O
play	O
a	O
role	O
in	O
vulnerability	O
to	O
depressive	O
disorders	O
among	O
adolescents	O
with	O
untreated	O
coeliac	O
disease	O
.	O
A	O
possible	O
role	O
for	O
tyrosine	B-Chemical
and	O
the	O
brain	O
'	O
s	O
catecholamine	B-Chemical
metabolism	O
(	O
dopamine	B-Chemical
and	O
noradrenaline	B-Chemical
)	O
in	O
these	O
disorders	O
cannot	O
","	O
however	O
","	O
be	O
excluded	O
.	O
The	O
decrease	O
observed	O
in	O
psychiatric	O
symptoms	O
took	O
place	O
regardless	O
of	O
the	O
stress	O
accompanying	O
being	O
diagnosed	O
with	O
a	O
chronic	O
and	O
restrictive	O
illness	O
","	O
and	O
improvement	O
was	O
not	O
explainable	O
in	O
terms	O
of	O
physical	O
symptoms	O
","	O
since	O
both	O
in	O
the	O
present	O
and	O
in	O
our	O
previous	O
study	O
[	O
7	O
"],"	O
the	O
presence	O
or	O
alleviation	O
of	O
depression	O
showed	O
no	O
association	O
with	O
somatic	O
symptom	O
severity	O
.	O
Our	O
results	O
from	O
adolescents	O
differ	O
from	O
those	O
reported	O
by	O
Addolorato	O
et	O
al	O
.	O
[	O
5	O
].	O
In	O
their	O
follow	O
-	O
up	O
study	O
on	O
adult	O
patients	O
with	O
coeliac	O
disease	O
","	O
a	O
significant	O
decrease	O
in	O
anxiety	O
symptoms	O
but	O
not	O
in	O
depressive	O
symptoms	O
appeared	O
after	O
one	O
year	O
on	O
a	O
gluten	O
-	O
free	O
diet	O
.	O
Although	O
converging	O
with	O
the	O
findings	O
of	O
Ljungman	O
and	O
Myrdal	O
(	O
20	O
"),"	O
the	O
few	O
symptoms	O
of	O
our	O
adolescents	O
with	O
coeliac	O
disease	O
adhering	O
to	O
a	O
gluten	O
-	O
free	O
diet	O
in	O
our	O
present	O
and	O
previous	O
[	O
7	O
]	O
studies	O
are	O
thus	O
in	O
contrast	O
to	O
the	O
findings	O
of	O
depressive	O
symptoms	O
[	O
4	O
","	O
5	O
]	O
and	O
disorders	O
[	O
6	O
]	O
as	O
being	O
common	O
among	O
adult	O
patients	O
with	O
coeliac	O
disease	O
","	O
even	O
during	O
diet	O
treatment	O
.	O
Since	O
the	O
free	O
tryptophan	B-Chemical
and	O
the	O
tryptophan	B-Chemical
/	O
CAA	B-Chemical
ratios	O
in	O
plasma	O
determine	O
the	O
availability	O
of	O
tryptophan	B-Chemical
to	O
the	O
brain	O
[	O
21	O
"],"	O
our	O
findings	O
on	O
depressive	O
patients	O
give	O
preliminary	O
support	O
to	O
suggestions	O
of	O
impaired	O
availability	O
of	O
tryptophan	B-Chemical
as	O
featuring	O
in	O
coeliac	O
-	O
associated	O
depressive	O
and	O
behavioural	O
disorders	O
associated	O
with	O
celiac	O
disease	O
[	O
9	O
","	O
12	O
","	O
13	O
].	O
As	O
we	O
did	O
not	O
have	O
a	O
control	O
group	O
of	O
healthy	O
adolescents	O
","	O
we	O
cannot	O
say	O
whether	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
or	O
L	B-Chemical
-	I-Chemical
tyrosine	I-Chemical
levels	O
or	O
both	O
are	O
generally	O
lower	O
among	O
adolescents	O
with	O
coeliac	O
disease	O
","	O
as	O
could	O
be	O
expected	O
based	O
on	O
the	O
findings	O
of	O
Hernanz	O
and	O
Polanco	O
[	O
9	O
"],"	O
who	O
reported	O
significantly	O
decreased	O
plasma	O
tryptophan	B-Chemical
and	O
tyrosine	B-Chemical
concentrations	O
in	O
untreated	O
and	O
treated	O
children	O
with	O
coeliac	O
disease	O
compared	O
to	O
levels	O
in	O
controls	O
.	O
In	O
the	O
present	O
study	O
","	O
stress	O
-	O
induced	O
biopsy	O
-	O
morning	O
prolactin	O
levels	O
were	O
significantly	O
higher	O
among	O
depressive	O
patients	O
(	O
all	O
girls	O
)	O
and	O
correlated	O
negatively	O
with	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
/	O
CAA	B-Chemical
levels	O
.	O
This	O
finding	O
is	O
only	O
preliminary	O
","	O
but	O
it	O
is	O
","	O
however	O
","	O
interesting	O
:	O
Although	O
disturbances	O
in	O
the	O
central	O
serotonergic	O
system	O
have	O
been	O
associated	O
with	O
depressive	O
and	O
impulse	O
-	O
control	O
disorders	O
among	O
adults	O
[	O
see	O
[	O
22	O
and	O
children	O
aged	O
6	O
to	O
12	O
years	O
with	O
a	O
recent	O
suicide	O
attempt	O
have	O
shown	O
lower	O
whole	O
blood	O
tryptophan	B-Chemical
content	O
[	O
23	O
"],"	O
serotonergic	O
dysfunction	O
in	O
adolescents	O
with	O
depression	O
is	O
still	O
poorly	O
studied	O
.	O
The	O
prolactin	O
hypersecretion	O
response	O
to	O
the	O
L	B-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
hydroxytryptophan	I-Chemical
challenge	O
(	O
L	B-Chemical
-	I-Chemical
5HTP	I-Chemical
)	O
test	O
reported	O
among	O
pre	O
-	O
pubertal	O
girls	O
with	O
major	O
depressive	O
disorder	O
[	O
24	O
]	O
and	O
among	O
healthy	O
children	O
at	O
high	O
risk	O
for	O
major	O
depressive	O
disorder	O
(=	O
high	O
family	O
loading	O
for	O
major	O
depression	O
)	O
[	O
25	O
"],"	O
may	O
be	O
consistent	O
with	O
dysregulation	O
of	O
the	O
central	O
serotonergic	O
system	O
in	O
childhood	O
major	O
depression	O
[	O
24	O
].	O
Moreover	O
","	O
alterations	O
in	O
neuroendocrine	O
responses	O
to	O
L	B-Chemical
-	I-Chemical
5HTP	I-Chemical
challenge	O
tests	O
","	O
such	O
as	O
the	O
prolactin	O
hypersecretion	O
and	O
hyposecretion	O
of	O
cortisol	B-Chemical
found	O
in	O
healthy	O
children	O
","	O
have	O
been	O
suggested	O
to	O
represent	O
a	O
trait	O
marker	O
for	O
depression	O
in	O
children	O
[	O
25	O
].	O
Thus	O
","	O
the	O
high	O
biopsy	O
morning	O
prolactin	O
levels	O
in	O
depressed	O
adolescents	O
with	O
untreated	O
coeliac	O
disease	O
in	O
the	O
present	O
study	O
could	O
be	O
associated	O
with	O
serotonergic	O
dysfunction	O
.	O
They	O
could	O
also	O
be	O
associated	O
with	O
dopaminergic	O
dysfunction	O
due	O
to	O
impaired	O
availability	O
of	O
tyrosine	B-Chemical
","	O
since	O
dopamine	B-Chemical
is	O
known	O
to	O
exert	O
an	O
inhibitory	O
action	O
on	O
prolactin	O
release	O
in	O
the	O
hypothalamus	O
[	O
26	O
].	O
In	O
the	O
present	O
study	O
","	O
however	O
","	O
pre	O
-	O
diet	O
prolactin	O
levels	O
did	O
not	O
correlate	O
with	O
tyrosine	B-Chemical
levels	O
.	O
Moreover	O
","	O
the	O
function	O
of	O
the	O
intestinal	O
Catechol	O
-	O
O	O
-	O
Methyl	O
Transferase	O
enzyme	O
(	O
COMT	O
)	O
â€“	O
known	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
peripheral	O
O	O
-	O
methylation	O
of	O
catecholamines	B-Chemical
â€“	O
remains	O
unstudied	O
in	O
untreated	O
coeliac	O
disease	O
.	O
It	O
is	O
of	O
some	O
theoretical	O
interest	O
that	O
reduced	O
COMT	O
activity	O
in	O
erythrocytes	O
has	O
at	O
least	O
once	O
been	O
associated	O
with	O
conditions	O
such	O
as	O
primary	O
affective	O
disorders	O
in	O
women	O
[	O
27	O
].	O
On	O
the	O
other	O
hand	O
","	O
in	O
the	O
present	O
study	O
also	O
non	O
-	O
depressed	O
adolescents	O
with	O
coeliac	O
disease	O
had	O
higher	O
than	O
normal	O
biopsy	O
morning	O
prolactin	O
levels	O
.	O
Significantly	O
higher	O
prolactin	O
levels	O
among	O
untreated	O
coeliac	O
children	O
(	O
5	O
â€“	O
18	O
years	O
)	O
compared	O
with	O
treated	O
patients	O
has	O
been	O
reported	O
by	O
Reifen	O
et	O
al	O
.	O
[	O
28	O
].	O
They	O
suggest	O
that	O
prolactin	O
may	O
play	O
a	O
part	O
in	O
the	O
immune	O
modulation	O
of	O
the	O
intestine	O
and	O
could	O
thus	O
serve	O
as	O
a	O
potential	O
marker	O
for	O
coeliac	O
disease	O
activity	O
.	O
Our	O
preliminary	O
findings	O
on	O
amino	B-Chemical
acid	I-Chemical
levels	O
in	O
adolescents	O
with	O
coeliac	O
disease	O
with	O
or	O
without	O
depression	O
are	O
unlikely	O
to	O
be	O
explained	O
by	O
malabsorption	O
","	O
since	O
pre	O
-	O
diet	O
free	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
and	O
tryptophan	B-Chemical
ratios	O
were	O
not	O
correlated	O
with	O
the	O
BCAA	B-Chemical
levels	O
that	O
reflect	O
the	O
level	O
of	O
protein	O
nutrition	O
.	O
It	O
is	O
of	O
theoretical	O
interest	O
that	O
increased	O
production	O
of	O
interferon	O
-	O
Î³	O
(	O
IFN	O
-	O
Î³	O
"),"	O
known	O
to	O
be	O
the	O
predominant	O
cytokine	O
produced	O
by	O
gluten	O
-	O
specific	O
T	O
-	O
cells	O
in	O
active	O
coeliac	O
disease	O
[	O
29	O
"],"	O
can	O
suppress	O
serotonin	B-Chemical
function	O
both	O
directly	O
and	O
indirectly	O
by	O
enhancing	O
tryptophan	B-Chemical
and	O
serotonin	B-Chemical
turnover	O
[	O
30	O
].	O
Increased	O
IFN	O
-	O
Î³	O
[	O
30	O
]	O
and	O
","	O
for	O
instance	O
","	O
such	O
events	O
as	O
a	O
stress	O
-	O
related	O
increase	O
in	O
liver	O
tryptophan	B-Chemical
pyrrolase	O
enzyme	O
activity	O
[	O
23	O
"],"	O
may	O
lead	O
to	O
lowered	O
tryptophan	B-Chemical
levels	O
by	O
the	O
enhanced	O
tryptophan	B-Chemical
catabolism	O
induced	O
by	O
increased	O
activity	O
of	O
the	O
kynurenine	B-Chemical
-	O
niacin	B-Chemical
pathway	O
[	O
30	O
-	O
32	O
"],"	O
even	O
without	O
malabsorption	O
.	O
Conclusion	O
The	O
alleviation	O
of	O
psychiatric	O
symptoms	O
found	O
among	O
adolescents	O
with	O
coeliac	O
disease	O
after	O
commencement	O
of	O
a	O
gluten	O
-	O
free	O
diet	O
coincides	O
with	O
a	O
rapid	O
decrease	O
in	O
antibody	O
titres	O
indicating	O
coeliac	O
disease	O
activity	O
and	O
in	O
their	O
prolactin	O
levels	O
","	O
and	O
with	O
a	O
significant	O
increase	O
in	O
L	B-Chemical
-	I-Chemical
tyrosine	I-Chemical
and	O
other	O
CAA	O
serum	O
concentrations	O
","	O
and	O
with	O
a	O
nearly	O
significant	O
increase	O
in	O
the	O
free	O
fraction	O
of	O
L	B-Chemical
-	I-Chemical
tryptophan	I-Chemical
.	O
Although	O
these	O
findings	O
are	O
only	O
preliminary	O
","	O
and	O
more	O
research	O
is	O
needed	O
","	O
they	O
give	O
support	O
to	O
previous	O
findings	O
on	O
patients	O
with	O
coeliac	O
disease	O
","	O
suggesting	O
that	O
serotonergic	O
dysfunction	O
due	O
to	O
impaired	O
availability	O
of	O
tryptophan	B-Chemical
may	O
play	O
a	O
role	O
in	O
vulnerability	O
to	O
depressive	O
and	O
behavioural	O
disorders	O
","	O
also	O
among	O
adolescents	O
with	O
untreated	O
celiac	O
disease	O
.	O
And	O
since	O
diet	O
treatment	O
may	O
alleviate	O
psychiatric	O
symptoms	O
","	O
and	O
earlier	O
diagnosis	O
may	O
have	O
beneficial	O
effects	O
on	O
psychological	O
and	O
even	O
on	O
neurobiological	O
vulnerability	O
to	O
depression	O
","	O
the	O
possibility	O
of	O
psychiatric	O
complications	O
of	O
coeliac	O
disease	O
needs	O
to	O
be	O
taken	O
into	O
account	O
in	O
differential	O
diagnosis	O
of	O
depressive	O
and	O
behavioural	O
disorders	O
.	O
Declaration	O
of	O
competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O
Authors	O
'	O
contributions	O
PAP	O
","	O
ETI	O
","	O
MAV	O
","	O
ES	O
","	O
VAA	O
contributed	O
to	O
the	O
conception	O
and	O
design	O
of	O
the	O
study	O
","	O
and	O
PAP	O
","	O
MAV	O
","	O
ES	O
to	O
acquisition	O
of	O
the	O
data	O
.	O
All	O
authors	O
(	O
PAP	O
","	O
ETI	O
","	O
MAV	O
","	O
SAK	O
","	O
IS	O
","	O
ES	O
","	O
VAA	O
)	O
contributed	O
to	O
the	O
analysis	O
and	O
interpretation	O
of	O
the	O
data	O
","	O
were	O
involved	O
in	O
drafting	O
and	O
revising	O
the	O
article	O
","	O
and	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
Precision	O
spherical	O
nucleic	O
acids	O
for	O
delivery	O
of	O
anticancer	O
drugs	O
â€ 	O
Highly	O
monodisperse	O
sequence	O
-	O
defined	O
spherical	O
nucleic	O
acids	O
(	O
HE12	B-Chemical
â€“	O
SNAs	O
)	O
for	O
delivery	O
of	O
small	O
-	O
molecule	O
anticancer	O
drugs	O
.	O
We	O
report	O
a	O
spherical	O
nucleic	O
acid	O
(	O
SNA	O
)	O
system	O
for	O
the	O
delivery	O
of	O
BKM120	B-Chemical
","	O
an	O
anticancer	O
drug	O
for	O
treatment	O
of	O
chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
).	O
While	O
promising	O
for	O
cancer	O
treatment	O
","	O
this	O
drug	O
crosses	O
the	O
blood	O
â€“	O
brain	O
barrier	O
causing	O
significant	O
side	O
-	O
effects	O
in	O
patients	O
.	O
The	O
DNA	O
nanoparticle	O
encapsulates	O
BKM120	B-Chemical
in	O
high	O
efficiency	O
","	O
and	O
is	O
unparalleled	O
in	O
its	O
monodispersity	O
","	O
ease	O
of	O
synthesis	O
and	O
stability	O
in	O
different	O
biological	O
media	O
and	O
in	O
serum	O
.	O
These	O
DNA	O
nanostructures	O
demonstrate	O
efficient	O
uptake	O
in	O
human	O
cervical	O
cancer	O
(	O
HeLa	O
)	O
cells	O
","	O
and	O
increased	O
internalization	O
of	O
cargo	O
.	O
In	O
vitro	O
studies	O
show	O
that	O
BKM120	B-Chemical
-	O
loaded	O
nanoparticles	O
promote	O
apoptosis	O
in	O
primary	O
patient	O
CLL	O
lymphocytes	O
","	O
and	O
act	O
as	O
sensitizers	O
of	O
other	O
antitumor	O
drugs	O
","	O
without	O
causing	O
non	O
-	O
specific	O
inflammation	O
.	O
Evaluation	O
of	O
this	O
drug	O
delivery	O
system	O
in	O
vivo	O
shows	O
long	O
circulation	O
times	O
up	O
to	O
24	O
hours	O
","	O
full	O
body	O
distribution	O
","	O
accumulation	O
at	O
tumor	O
sites	O
and	O
minimal	O
leakage	O
through	O
the	O
blood	O
â€“	O
brain	O
barrier	O
.	O
Our	O
results	O
demonstrate	O
the	O
great	O
potential	O
of	O
these	O
delivery	O
vehicles	O
as	O
a	O
general	O
platform	O
for	O
chemotherapeutic	O
drug	O
delivery	O
.	O
Introduction	O
Targeted	O
action	O
of	O
small	O
-	O
molecule	O
drugs	O
remains	O
a	O
challenge	O
in	O
medicine	O
.	O
This	O
holds	O
TRUE	O
for	O
antitumor	O
chemotherapeutic	O
drugs	O
","	O
where	O
much	O
of	O
their	O
success	O
has	O
been	O
hampered	O
by	O
off	O
-	O
target	O
side	O
-	O
effects	O
","	O
poor	O
pharmacokinetics	O
and	O
systemic	O
toxicity	O
.	O
One	O
effective	O
approach	O
to	O
tackle	O
this	O
problem	O
is	O
the	O
application	O
of	O
drug	O
delivery	O
systems	O
that	O
would	O
protect	O
the	O
cargo	O
along	O
the	O
administration	O
route	O
and	O
direct	O
it	O
to	O
its	O
target	O
site	O
.	O
Several	O
delivery	O
systems	O
are	O
currently	O
being	O
explored	O
which	O
include	O
:	O
dendrimers	O
","	O
liposomes	O
","	O
polymeric	O
nanoparticles	O
","	O
micelles	O
","	O
protein	O
nanoparticles	O
","	O
viral	O
nanoparticles	O
","	O
inorganic	O
nanoparticles	O
and	O
carbon	B-Chemical
nanotubes	I-Chemical
.	O
However	O
","	O
many	O
of	O
them	O
suffer	O
from	O
major	O
limitations	O
such	O
as	O
:	O
toxicity	O
","	O
rapid	O
clearance	O
","	O
complicated	O
synthesis	O
and	O
particle	O
heterogeneity	O
.	O
In	O
particular	O
","	O
nanostructure	O
size	O
and	O
shape	O
have	O
been	O
demonstrated	O
to	O
play	O
an	O
important	O
role	O
in	O
their	O
biodistribution	O
","	O
circulation	O
half	O
-	O
life	O
","	O
cellular	O
targeting	O
","	O
efficacy	O
and	O
immune	O
response	O
.â€“	O
With	O
most	O
current	O
drug	O
delivery	O
platforms	O
suffering	O
from	O
structural	O
polydispersity	O
","	O
the	O
generation	O
of	O
monodisperse	O
nanocarriers	O
with	O
well	O
-	O
defined	O
structures	O
will	O
be	O
essential	O
for	O
their	O
application	O
in	O
drug	O
delivery	O
.	O
Polymers	O
are	O
the	O
most	O
commonly	O
used	O
material	O
for	O
developing	O
nanoparticle	O
-	O
based	O
drug	O
carriers	O
.	O
In	O
particular	O
","	O
amphiphilic	O
block	O
copolymers	O
that	O
contain	O
a	O
water	O
-	O
soluble	O
block	O
","	O
and	O
a	O
hydrophobic	O
block	O
","	O
have	O
been	O
extensively	O
used	O
as	O
building	O
blocks	O
for	O
chemotherapeutic	O
drug	O
delivery	O
.	O
These	O
molecules	O
phase	O
-	O
separate	O
into	O
micelles	O
that	O
contain	O
a	O
hydrophobic	O
core	O
which	O
can	O
accommodate	O
lipophilic	O
drug	O
molecules	O
and	O
alter	O
their	O
kinetics	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
".,"	O
In	O
recent	O
years	O
","	O
a	O
new	O
class	O
of	O
amphiphilic	O
block	O
copolymers	O
has	O
also	O
emerged	O
which	O
contains	O
a	O
hydrophobic	O
synthetic	O
polymer	O
attached	O
to	O
a	O
hydrophilic	O
DNA	O
segment	O
","	O
called	O
DNA	O
â€“	O
polymer	O
hybrids	O
.	O
These	O
molecules	O
can	O
self	O
-	O
assemble	O
into	O
a	O
wide	O
-	O
range	O
of	O
morphologies	O
","	O
including	O
spherical	O
micellar	O
particles	O
that	O
expose	O
a	O
hydrophilic	O
DNA	O
shell	O
and	O
a	O
hydrophobic	O
core	O
".,"	O
A	O
particularly	O
successful	O
example	O
of	O
such	O
assemblies	O
are	O
spherical	O
nucleic	O
acids	O
(	O
SNAs	O
).	O
These	O
structures	O
are	O
composed	O
of	O
a	O
gold	B-Chemical
nanoparticle	O
core	O
and	O
a	O
corona	O
of	O
tightly	O
packed	O
DNA	O
strands	O
.	O
SNAs	O
have	O
shown	O
efficient	O
cellular	O
penetration	O
and	O
gene	O
silencing	O
ability	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.â€“	O
Recently	O
","	O
we	O
reported	O
a	O
highly	O
efficient	O
and	O
versatile	O
method	O
to	O
generate	O
DNA	O
â€“	O
polymer	O
conjugates	O
via	O
solid	O
-	O
phase	O
synthesis	O
.	O
Unlike	O
conventional	O
synthetic	O
polymer	O
chemistry	O
","	O
this	O
method	O
yields	O
DNA	O
â€“	O
polymer	O
conjugates	O
that	O
are	O
fully	O
monodisperse	O
and	O
sequence	O
-	O
defined	O
.	O
This	O
class	O
of	O
material	O
self	O
-	O
assembles	O
spontaneously	O
to	O
generate	O
highly	O
monodisperse	O
spherical	O
micellar	O
DNA	O
nanoparticles	O
in	O
aqueous	O
solution	O
.	O
Several	O
examples	O
in	O
recent	O
years	O
have	O
emerged	O
demonstrating	O
the	O
suitability	O
of	O
DNA	O
nanostructures	O
in	O
mimicking	O
biological	O
systems	O
",,"	O
construction	O
of	O
nanoelectronics	O
and	O
nanophotonics	O
","	O
and	O
delivery	O
of	O
cancer	O
therapeutics	O
.	O
Compared	O
to	O
DNA	O
nanostructures	O
","	O
such	O
as	O
DNA	O
origami	O
","	O
which	O
require	O
a	O
large	O
number	O
of	O
unique	O
DNA	O
strands	O
to	O
generate	O
the	O
designed	O
structure	O
","	O
limiting	O
their	O
use	O
in	O
large	O
-	O
scale	O
applications	O
","	O
micellar	O
DNA	O
nanoparticles	O
are	O
composed	O
of	O
only	O
a	O
single	O
DNA	O
â€“	O
polymer	O
conjugate	O
strand	O
.	O
This	O
type	O
of	O
hybrid	O
strand	O
also	O
offers	O
advantages	O
over	O
other	O
block	O
copolymers	O
in	O
that	O
the	O
DNA	O
portion	O
can	O
be	O
highly	O
functional	O
and	O
programmable	O
in	O
the	O
final	O
structure	O
.	O
Additionally	O
","	O
the	O
poly	B-Chemical
-	I-Chemical
phosphodiester	I-Chemical
units	O
in	O
both	O
the	O
oligonucleotide	O
and	O
hydrophobic	O
portions	O
of	O
the	O
DNA	O
â€“	O
polymer	O
strands	O
are	O
biocompatible	O
and	O
biodegradable	O
making	O
them	O
suitable	O
for	O
biological	O
applications	O
.	O
Particles	O
of	O
self	O
-	O
assembled	O
DNA	O
â€“	O
polymer	O
conjugates	O
expose	O
a	O
ssDNA	O
corona	O
","	O
and	O
have	O
been	O
used	O
in	O
ligand	O
targeting	O
",,,"	O
delivery	O
of	O
anti	O
-	O
sense	O
oligonucleotides	O
DNA	O
detection	O
","	O
formation	O
of	O
higher	O
order	O
assemblies	O
",,"	O
and	O
templating	O
organic	O
reactions	O
".,"	O
In	O
particular	O
","	O
these	O
DNA	O
particles	O
have	O
shown	O
great	O
potential	O
in	O
cancer	O
therapy	O
However	O
","	O
the	O
exploration	O
of	O
these	O
structures	O
for	O
cancer	O
therapy	O
has	O
only	O
been	O
limited	O
to	O
in	O
vitro	O
cell	O
studies	O
.	O
Our	O
interest	O
also	O
focuses	O
on	O
cancer	O
therapy	O
","	O
specifically	O
","	O
the	O
development	O
of	O
a	O
DNA	O
nanoparticle	O
delivery	O
system	O
for	O
BKM120	B-Chemical
","	O
an	O
anticancer	O
drug	O
towards	O
the	O
treatment	O
of	O
Chronic	O
Lymphocytic	O
Leukemia	O
(	O
CLL	O
).	O
Chronic	O
Lymphocytic	O
Leukemia	O
(	O
CLL	O
)	O
remains	O
the	O
most	O
common	O
type	O
of	O
leukemia	O
with	O
an	O
incidence	O
rate	O
of	O
approx	O
.	O
4	O
/	O
100	O
0	O
people	O
in	O
the	O
United	O
States	O
.	O
Current	O
treatments	O
of	O
CLL	O
include	O
chemotherapeutic	O
agents	O
such	O
as	O
alkylating	O
agents	O
(	O
chlorambucil	B-Chemical
","	O
cyclophosphamide	B-Chemical
and	O
bendamustine	B-Chemical
"),"	O
purine	B-Chemical
analogs	O
(	O
fludarabine	B-Chemical
)	O
and	O
immunotherapeutics	O
(	O
Rituximab	B-Chemical
","	O
Alemtuzumab	B-Chemical
").,"	O
The	O
current	O
gold	O
standard	O
for	O
treatment	O
is	O
through	O
chemoimmunotherapy	O
;	O
a	O
combination	O
of	O
fludarabine	B-Chemical
","	O
cyclophosphamide	B-Chemical
and	O
rituximab	B-Chemical
(	O
FCR	B-Chemical
).â€“	O
Unfortunately	O
","	O
none	O
of	O
these	O
treatments	O
results	O
in	O
curative	O
therapy	O
providing	O
strong	O
justification	O
for	O
investigating	O
new	O
therapeutic	O
approaches	O
for	O
CLL	O
.	O
The	O
phosphoinositide	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
pathway	O
has	O
been	O
shown	O
to	O
be	O
a	O
critical	O
component	O
of	O
CLL	O
survival	O
and	O
proliferation	O
.â€“	O
The	O
expression	O
of	O
PI3K	O
triggers	O
downstream	O
cellular	O
events	O
that	O
inhibit	O
cell	O
death	O
by	O
inactivating	O
pro	O
-	O
apoptotic	O
proteins	O
.â€“	O
This	O
makes	O
the	O
selective	O
inhibition	O
of	O
PI3K	O
a	O
promising	O
approach	O
for	O
the	O
treatment	O
of	O
CLL	O
and	O
a	O
focus	O
of	O
many	O
efforts	O
to	O
develop	O
novel	O
inhibitors	O
targeting	O
this	O
pathway	O
.	O
Buparlisib	B-Chemical
(	O
codenamed	O
BKM120	B-Chemical
)	O
is	O
one	O
such	O
example	O
of	O
a	O
pyrimidine	B-Chemical
-	O
derived	O
selective	O
pan	O
class	O
I	O
PI3K	O
inhibitor	O
.	O
This	O
molecule	O
has	O
shown	O
high	O
selectivity	O
and	O
potency	O
against	O
class	O
I	O
PI3Ks	O
.	O
BKM120	B-Chemical
has	O
demonstrated	O
high	O
cytotoxicity	O
in	O
B	O
-	O
chronic	O
lymphocytic	O
leukemia	O
cells	O
in	O
vitro	O
","	O
and	O
significant	O
antitumor	O
activity	O
in	O
human	O
tumor	O
xenograft	O
models	O
".,"	O
Currently	O
","	O
this	O
drug	O
is	O
under	O
clinical	O
investigation	O
in	O
advanced	O
solid	O
tumor	O
and	O
CLL	O
patients	O
.	O
However	O
","	O
BKM120	B-Chemical
can	O
cross	O
the	O
blood	O
â€“	O
brain	O
barrier	O
and	O
inhibit	O
PI3K	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
"),"	O
inducing	O
anxiety	O
","	O
low	O
serotonin	B-Chemical
levels	O
","	O
schizophrenia	O
","	O
and	O
hindering	O
its	O
success	O
for	O
translation	O
into	O
the	O
market	O
.	O
Hence	O
","	O
a	O
strategy	O
to	O
effectively	O
deliver	O
BKM120	B-Chemical
to	O
its	O
intended	O
biological	O
target	O
without	O
deleterious	O
side	O
-	O
effects	O
in	O
the	O
CNS	O
would	O
be	O
a	O
major	O
goal	O
for	O
therapy	O
with	O
this	O
small	O
-	O
molecule	O
drug	O
.	O
In	O
this	O
article	O
","	O
we	O
report	O
the	O
development	O
of	O
a	O
DNA	O
nanoparticle	O
platform	O
for	O
the	O
delivery	O
of	O
BKM120	B-Chemical
.	O
The	O
drug	O
-	O
loaded	O
structures	O
are	O
unique	O
in	O
their	O
monodispersity	O
","	O
can	O
be	O
readily	O
prepared	O
and	O
are	O
stable	O
in	O
different	O
biological	O
media	O
and	O
in	O
serum	O
.	O
We	O
show	O
the	O
increased	O
cellular	O
uptake	O
of	O
these	O
structures	O
in	O
HeLa	O
cells	O
","	O
and	O
the	O
internalization	O
of	O
their	O
cargo	O
.	O
The	O
structures	O
show	O
minimal	O
non	O
-	O
specific	O
interaction	O
with	O
human	O
serum	O
albumin	O
(	O
HSA	O
"),"	O
a	O
major	O
protein	O
component	O
of	O
blood	O
.	O
Moreover	O
","	O
BKM120	B-Chemical
-	O
loaded	O
DNA	O
particles	O
promote	O
apoptosis	O
in	O
primary	O
patient	O
CLL	O
lymphocytes	O
and	O
induce	O
cell	O
death	O
when	O
co	O
-	O
administered	O
with	O
doxorubicin	B-Chemical
in	O
HeLa	O
cells	O
","	O
without	O
eliciting	O
inflammation	O
.	O
Evaluation	O
of	O
this	O
drug	O
delivery	O
system	O
in	O
vivo	O
shows	O
long	O
circulation	O
times	O
up	O
to	O
24	O
hours	O
","	O
full	O
body	O
distribution	O
","	O
high	O
accumulation	O
at	O
tumor	O
sites	O
and	O
minimal	O
leakage	O
through	O
the	O
blood	O
â€“	O
brain	O
barrier	O
.	O
Our	O
results	O
demonstrate	O
the	O
great	O
potential	O
of	O
these	O
delivery	O
vehicles	O
as	O
a	O
general	O
platform	O
for	O
chemotherapeutic	O
drug	O
delivery	O
.	O
We	O
have	O
previously	O
shown	O
that	O
the	O
DNA	O
component	O
of	O
these	O
structures	O
is	O
able	O
to	O
silence	O
gene	O
expression	O
to	O
a	O
greater	O
extent	O
than	O
DNA	O
antisense	O
structures	O
alone	O
","	O
highlighting	O
the	O
promise	O
of	O
these	O
DNA	O
nanoparticles	O
as	O
combination	O
small	O
molecule	O
and	O
oligonucleotide	O
therapeutics	O
.	O
Results	O
and	O
discussion	O
Synthesis	O
of	O
DNA	O
nanoparticles	O
In	O
order	O
to	O
construct	O
a	O
scalable	O
and	O
highly	O
monodisperse	O
drug	O
delivery	O
system	O
","	O
we	O
generated	O
a	O
single	O
type	O
of	O
DNA	O
â€“	O
polymer	O
conjugates	O
that	O
self	O
-	O
assemble	O
in	O
aqueous	O
buffer	O
to	O
form	O
micellar	O
DNA	O
particles	O
.	O
These	O
conjugates	O
consist	O
of	O
a	O
19	O
-	O
mer	O
DNA	O
sequence	O
attached	O
to	O
12	O
dodecane	B-Chemical
(	O
hexaethylene	B-Chemical
","	O
HE	B-Chemical
)	O
units	O
(	O
HE12	B-Chemical
â€“	O
DNA	O
conjugate	O
","	O
Scheme	O
1	O
).	O
HE12	B-Chemical
units	O
were	O
appended	O
to	O
DNA	O
by	O
automated	O
solid	O
-	O
phase	O
synthesis	O
using	O
phosphoramidite	B-Chemical
chemistry	O
.	O
This	O
approach	O
offers	O
monodisperse	O
DNA	O
â€“	O
polymer	O
conjugates	O
in	O
high	O
yields	O
and	O
provides	O
control	O
over	O
the	O
length	O
and	O
sequence	O
of	O
the	O
monomer	O
units	O
in	O
the	O
final	O
structure	O
.	O
In	O
our	O
previous	O
work	O
","	O
we	O
showed	O
that	O
HE12	B-Chemical
â€“	O
DNA	O
conjugates	O
self	O
-	O
assemble	O
into	O
highly	O
monodisperse	O
spherical	O
nucleic	O
acid	O
particles	O
(	O
HE12	B-Chemical
â€“	O
SNAs	O
)	O
in	O
aqueous	O
media	O
containing	O
divalent	O
cations	O
.	O
These	O
structures	O
consist	O
of	O
an	O
exterior	O
DNA	O
corona	O
","	O
and	O
a	O
hydrophobic	O
HE12	B-Chemical
core	O
which	O
provides	O
a	O
favourable	O
environment	O
for	O
the	O
entrapment	O
of	O
hydrophobic	O
guest	O
molecules	O
.	O
We	O
also	O
showed	O
the	O
encapsulation	O
of	O
a	O
dye	O
molecule	O
","	O
Nile	B-Chemical
Red	I-Chemical
","	O
in	O
the	O
hydrophobic	O
core	O
of	O
DNA	O
nanoparticles	O
.	O
In	O
this	O
current	O
study	O
","	O
we	O
sought	O
to	O
test	O
the	O
encapsulation	O
of	O
a	O
small	O
-	O
molecule	O
protein	O
kinase	O
inhibitor	O
","	O
BKM120	B-Chemical
.	O
We	O
were	O
interested	O
in	O
BKM120	B-Chemical
because	O
(	O
1	O
)	O
despite	O
its	O
high	O
potency	O
","	O
it	O
suffers	O
from	O
deleterious	O
side	O
-	O
effects	O
in	O
the	O
CNS	O
of	O
patients	O
.	O
(	O
2	O
)	O
The	O
drug	O
dimensions	O
are	O
compatible	O
with	O
the	O
core	O
size	O
of	O
the	O
DNA	O
nanoparticle	O
system	O
and	O
(	O
3	O
)	O
BKM120	B-Chemical
exhibits	O
an	O
aqueous	O
solubility	O
of	O
<	O
1	O
mg	O
ml	O
â€“	O
1	O
","	O
which	O
makes	O
it	O
a	O
suitable	O
guest	O
for	O
our	O
system	O
.	O
Schematic	O
representation	O
of	O
the	O
synthesis	O
of	O
DNA	O
â€“	O
polymer	O
conjugates	O
and	O
BKM120	B-Chemical
encapsulation	O
method	O
.	O
Phosphoramidite	B-Chemical
monomers	O
are	O
attached	O
to	O
the	O
5	O
â€²	O
end	O
of	O
the	O
controlled	O
glass	O
pore	O
(	O
CPG	O
)	O
in	O
a	O
step	O
-	O
wise	O
and	O
sequence	O
-	O
controlled	O
fashion	O
.	O
The	O
19	O
-	O
mer	O
DNA	O
strand	O
is	O
first	O
built	O
from	O
the	O
support	O
","	O
followed	O
by	O
12	O
dodecane	B-Chemical
monomer	O
additions	O
(	O
HE12	B-Chemical
)	O
yielding	O
monodisperse	O
HE12	B-Chemical
â€“	O
DNA	O
conjugates	O
.	O
Self	O
-	O
assembly	O
of	O
the	O
polymer	O
â€“	O
DNA	O
conjugates	O
in	O
the	O
presence	O
of	O
BKM120	B-Chemical
and	O
subsequent	O
purification	O
results	O
in	O
nearly	O
monodisperse	O
BKM120	B-Chemical
-	O
loaded	O
HE12	B-Chemical
â€“	O
SNAs	O
.	O
Evaluation	O
of	O
HE12	B-Chemical
â€“	O
SNAs	O
as	O
BKM120	B-Chemical
delivery	O
vehicles	O
To	O
prepare	O
BKM120	B-Chemical
-	O
loaded	O
HE12	B-Chemical
â€“	O
SNAs	O
","	O
a	O
solution	O
of	O
BKM120	B-Chemical
in	O
ethanol	B-Chemical
was	O
allowed	O
to	O
evaporate	O
forming	O
a	O
thin	O
-	O
film	O
","	O
which	O
was	O
then	O
re	O
-	O
suspended	O
into	O
a	O
solution	O
of	O
HE12	B-Chemical
â€“	O
DNA	O
conjugates	O
in	O
water	O
","	O
followed	O
by	O
the	O
addition	O
of	O
assembly	O
buffer	O
and	O
overnight	O
thermal	O
annealing	O
(	O
95	O
â€“	O
4	O
Â°	O
C	O
over	O
4	O
h	O
).	O
Thermal	O
annealing	O
was	O
shown	O
to	O
yield	O
less	O
size	O
-	O
variability	O
compared	O
to	O
overnight	O
shaking	O
at	O
room	O
temperature	O
.	O
Following	O
the	O
encapsulation	O
process	O
","	O
the	O
products	O
were	O
purified	O
by	O
size	O
-	O
exclusion	O
chromatography	O
and	O
analyzed	O
by	O
reversed	O
-	O
phase	O
HPLC	O
(	O
RP	O
-	O
HPLC	O
)	O
(	O
Fig	O
.	O
1a	O
).	O
The	O
success	O
of	O
the	O
purification	O
method	O
was	O
critical	O
to	O
ensure	O
complete	O
removal	O
of	O
free	O
-	O
drug	O
in	O
solution	O
.	O
This	O
was	O
important	O
for	O
accurate	O
determination	O
of	O
the	O
nanoparticle	O
drug	O
-	O
loading	O
capacity	O
and	O
for	O
further	O
biological	O
studies	O
.	O
Evaluation	O
of	O
BKM120	B-Chemical
encapsulation	O
in	O
HE12	B-Chemical
â€“	O
SNAs	O
.	O
(	O
a	O
)	O
Reversed	O
phase	O
HPLC	O
analysis	O
of	O
HE12	B-Chemical
â€“	O
SNAs	O
(	O
black	O
"),"	O
ssDNA	O
control	O
(	O
red	O
)	O
and	O
buffer	O
control	O
(	O
blue	O
)	O
following	O
drug	O
purification	O
.	O
Detection	O
at	O
absorbance	O
wavelength	O
260	O
nm	O
(	O
left	O
panel	O
)	O
and	O
320	O
nm	O
(	O
right	O
panel	O
).	O
The	O
presence	O
of	O
a	O
BKM120	B-Chemical
peak	O
solely	O
in	O
HE12	B-Chemical
â€“	O
SNA	O
samples	O
suggests	O
drug	O
encapsulation	O
.	O
(	O
b	O
)	O
UV	O
-	O
Vis	O
measurements	O
of	O
BKM120	B-Chemical
-	O
incubated	O
HE12	B-Chemical
â€“	O
SNAs	O
(	O
black	O
"),"	O
ssDNA	O
control	O
(	O
red	O
)	O
and	O
buffer	O
control	O
(	O
blue	O
)	O
following	O
purification	O
.	O
Drug	O
encapsulation	O
and	O
loading	O
capacity	O
were	O
determined	O
by	O
RP	O
-	O
HPLC	O
and	O
separately	O
confirmed	O
by	O
UV	O
-	O
Vis	O
measurements	O
.	O
The	O
presence	O
of	O
a	O
diagnostic	O
drug	O
peak	O
at	O
320	O
nm	O
in	O
the	O
HE12	B-Chemical
â€“	O
DNA	O
nanoparticle	O
sample	O
indicates	O
drug	O
encapsulation	O
.	O
(	O
c	O
)	O
In	O
vitro	O
release	O
of	O
BKM120	B-Chemical
loaded	O
into	O
HE12	B-Chemical
â€“	O
SNAs	O
studied	O
by	O
a	O
dialysis	O
method	O
over	O
1	O
day	O
at	O
room	O
temperature	O
in	O
1	O
Ã—	O
TAMg	O
","	O
measured	O
in	O
triplicate	O
.	O
Error	O
bars	O
represent	O
the	O
standard	O
deviation	O
of	O
measurements	O
.	O
Data	O
from	O
RP	O
-	O
HPLC	O
confirmed	O
the	O
encapsulation	O
of	O
BKM120	B-Chemical
in	O
HE12	B-Chemical
â€“	O
SNAs	O
in	O
comparison	O
to	O
ssDNA	O
and	O
buffer	O
controls	O
.	O
Traces	O
were	O
obtained	O
at	O
two	O
different	O
channels	O
:	O
a	O
channel	O
selective	O
for	O
DNA	O
at	O
260	O
nm	O
","	O
and	O
a	O
BKM120	B-Chemical
-	O
optimal	O
channel	O
at	O
320	O
nm	O
.	O
The	O
co	O
-	O
elution	O
of	O
the	O
DNA	O
and	O
BKM120	B-Chemical
was	O
only	O
observed	O
in	O
HE12	B-Chemical
â€“	O
SNA	O
solutions	O
","	O
indicating	O
the	O
association	O
of	O
the	O
drug	O
with	O
the	O
structure	O
.	O
In	O
the	O
case	O
of	O
ssDNA	O
","	O
only	O
a	O
DNA	O
peak	O
was	O
observed	O
at	O
260	O
nm	O
","	O
reflecting	O
the	O
efficiency	O
of	O
the	O
purification	O
method	O
at	O
removing	O
free	O
drug	O
in	O
solution	O
.	O
The	O
drug	O
loading	O
capacity	O
of	O
DNA	O
nanoparticles	O
was	O
calculated	O
from	O
RP	O
-	O
HPLC	O
data	O
and	O
separately	O
confirmed	O
by	O
UV	O
-	O
Vis	O
spectroscopy	O
(	O
Fig	O
.	O
1b	O
","	O
see	O
Fig	O
.	O
SF5	O
â€ ).	O
For	O
HE12	B-Chemical
â€“	O
SNAs	O
","	O
the	O
loading	O
capacity	O
was	O
approximately	O
29	O
%	O
w	O
/	O
w	O
","	O
where	O
âˆ¼	O
9	O
molecules	O
of	O
BKM120	B-Chemical
were	O
encapsulated	O
per	O
DNA	O
â€“	O
polymer	O
conjugate	O
strand	O
.	O
The	O
aqueous	O
solubility	O
of	O
BKM120	B-Chemical
in	O
the	O
HE12	B-Chemical
â€“	O
SNAs	O
was	O
enhanced	O
to	O
24	O
.	O
4	O
Î¼g	O
ml	O
â€“	O
1	O
","	O
compared	O
to	O
<	O
1	O
Î¼g	O
ml	O
â€“	O
1	O
in	O
water	O
.	O
RP	O
-	O
HPLC	O
was	O
also	O
used	O
to	O
calculate	O
the	O
recovered	O
yield	O
following	O
purification	O
.	O
In	O
general	O
","	O
âˆ¼	O
65	O
%	O
of	O
the	O
amount	O
of	O
DNA	O
â€“	O
polymer	O
conjugates	O
was	O
retained	O
following	O
purification	O
(	O
see	O
Fig	O
.	O
SF5	O
â€ ).	O
Additionally	O
","	O
the	O
drug	O
-	O
loaded	O
structures	O
had	O
a	O
shelf	O
-	O
life	O
of	O
over	O
4	O
weeks	O
when	O
stored	O
at	O
both	O
room	O
temperature	O
and	O
4	O
Â°	O
C	O
(	O
see	O
Fig	O
.	O
SF7	O
and	O
SF8	O
â€ ).	O
Having	O
confirmed	O
BKM120	B-Chemical
encapsulation	O
","	O
we	O
then	O
studied	O
the	O
in	O
vitro	O
release	O
kinetics	O
of	O
BKM120	B-Chemical
in	O
HE12	B-Chemical
â€“	O
SNAs	O
(	O
Fig	O
.	O
1c	O
and	O
SF6	O
â€ ).	O
BKM120	B-Chemical
release	O
was	O
evaluated	O
by	O
monitoring	O
the	O
decrease	O
in	O
concentration	O
of	O
the	O
drug	O
from	O
a	O
solution	O
of	O
loaded	O
structures	O
dialyzed	O
against	O
1	O
Ã—	O
TAMg	O
at	O
room	O
temperature	O
over	O
24	O
h	O
.	O
It	O
was	O
found	O
that	O
HE12	B-Chemical
â€“	O
SNAs	O
release	O
BKM120	B-Chemical
at	O
a	O
slow	O
and	O
sustained	O
rate	O
with	O
âˆ¼	O
40	O
%	O
of	O
the	O
drug	O
retained	O
after	O
24	O
hours	O
(	O
Fig	O
.	O
1c	O
).	O
The	O
critical	O
micellar	O
concentration	O
(	O
CMC	O
"),"	O
above	O
which	O
HE12	B-Chemical
â€“	O
DNA	O
conjugates	O
aggregate	O
into	O
HE12	B-Chemical
â€“	O
SNAs	O
was	O
also	O
studied	O
.	O
It	O
was	O
found	O
that	O
HE12	B-Chemical
â€“	O
DNA	O
conjugates	O
aggregate	O
with	O
an	O
associated	O
CMC	O
of	O
0	O
.	O
5	O
Î¼M	O
Â±	O
0	O
.	O
2	O
Î¼M	O
in	O
the	O
presence	O
of	O
12	O
.	O
5	O
mM	O
Mg2	B-Chemical
+	I-Chemical
(	O
see	O
Fig	O
.	O
SF9	O
â€ ).	O
We	O
then	O
proceeded	O
to	O
characterize	O
the	O
BKM120	B-Chemical
-	O
loaded	O
products	O
.	O
The	O
sizes	O
of	O
the	O
nanoparticles	O
were	O
studied	O
by	O
agarose	B-Chemical
gel	O
electrophoresis	O
(	O
AGE	O
"),"	O
dynamic	O
light	O
scattering	O
(	O
DLS	O
"),"	O
atomic	O
force	O
microscopy	O
(	O
AFM	O
)	O
and	O
transmission	O
electron	O
microscopy	O
(	O
TEM	O
)	O
(	O
Fig	O
.	O
2	O
).	O
Data	O
from	O
AGE	O
revealed	O
the	O
maintained	O
structural	O
integrity	O
of	O
BKM120	B-Chemical
-	O
loaded	O
particles	O
with	O
no	O
observed	O
side	O
products	O
(	O
Fig	O
.	O
2a	O
).	O
DLS	O
analysis	O
revealed	O
a	O
highly	O
monodisperse	O
population	O
of	O
drug	O
-	O
loaded	O
structures	O
in	O
solution	O
with	O
a	O
hydrodynamic	O
radius	O
of	O
11	O
.	O
8	O
Â±	O
0	O
.	O
4	O
nm	O
(	O
Fig	O
.	O
2b	O
).	O
AFM	O
and	O
TEM	O
images	O
demonstrated	O
that	O
BKM	B-Chemical
-	I-Chemical
120	I-Chemical
loaded	O
particles	O
were	O
well	O
-	O
dispersed	O
on	O
surface	O
","	O
with	O
calculated	O
dry	O
-	O
state	O
diameter	O
of	O
28	O
Â±	O
4	O
nm	O
and	O
21	O
Â±	O
3	O
nm	O
","	O
respectively	O
(	O
Fig	O
.	O
2c	O
and	O
d	O
","	O
SF11	O
&	O
SF12	O
â€ ).	O
The	O
structures	O
also	O
appeared	O
to	O
retain	O
high	O
level	O
of	O
monodispersity	O
","	O
despite	O
slightly	O
widened	O
features	O
.	O
The	O
obtained	O
dimensions	O
are	O
in	O
agreement	O
with	O
solution	O
measurements	O
by	O
DLS	O
.	O
The	O
slightly	O
widened	O
morphology	O
could	O
be	O
explained	O
by	O
the	O
deposition	O
of	O
these	O
structures	O
on	O
the	O
surface	O
and	O
drying	O
effects	O
.	O
The	O
drug	O
-	O
loaded	O
nanoparticles	O
seemed	O
to	O
lose	O
their	O
spherical	O
shape	O
upon	O
deposition	O
confirmed	O
by	O
the	O
lower	O
height	O
(	O
8	O
nm	O
)	O
and	O
slightly	O
widened	O
diameter	O
as	O
calculated	O
by	O
AFM	O
.	O
Structural	O
characterization	O
of	O
BKM120	B-Chemical
-	O
loaded	O
HE12	B-Chemical
â€“	O
SNAs	O
.	O
(	O
a	O
)	O
Agarose	B-Chemical
gel	O
electrophoresis	O
(	O
AGE	O
)	O
analysis	O
of	O
drug	O
-	O
loaded	O
nanoparticles	O
showing	O
intact	O
structures	O
with	O
no	O
observed	O
side	O
products	O
.	O
(	O
b	O
)	O
Dynamic	O
light	O
scattering	O
(	O
DLS	O
)	O
data	O
showing	O
a	O
highly	O
monodisperse	O
population	O
of	O
drug	O
-	O
loaded	O
nanoparticles	O
in	O
solution	O
.	O
(	O
c	O
)	O
Atomic	O
force	O
microscopy	O
(	O
AFM	O
)	O
image	O
showing	O
a	O
spherical	O
nearly	O
monodisperse	O
population	O
of	O
drug	O
-	O
loaded	O
products	O
on	O
surface	O
.	O
(	O
d	O
)	O
Transmission	O
electron	O
microscopy	O
(	O
TEM	O
)	O
image	O
of	O
drug	O
-	O
loaded	O
products	O
reflecting	O
highly	O
monodisperse	O
structures	O
.	O
Scale	O
bars	O
=	O
200	O
nm	O
.	O
Stability	O
of	O
HE12	B-Chemical
â€“	O
SNAs	O
DNA	O
nanostructures	O
such	O
as	O
DNA	O
origami	O
and	O
3	O
-	O
dimensional	O
nanoarchitectures	O
purely	O
composed	O
of	O
DNA	O
","	O
are	O
typically	O
assembled	O
in	O
buffers	O
containing	O
moderate	O
concentrations	O
of	O
divalent	O
metal	O
cations	O
(âˆ¼	O
5	O
â€“	O
20	O
mM	O
)	O
in	O
order	O
to	O
mask	O
the	O
electrostatic	O
repulsion	O
between	O
DNA	O
strands	O
.â€“	O
Deviations	O
from	O
this	O
window	O
of	O
buffer	O
conditions	O
can	O
have	O
devastating	O
effects	O
on	O
the	O
structures	O
","	O
causing	O
shape	O
distortion	O
","	O
aggregation	O
or	O
total	O
collapse	O
of	O
structure	O
.	O
This	O
limits	O
the	O
use	O
of	O
DNA	O
nanostructures	O
for	O
biological	O
applications	O
.	O
In	O
our	O
case	O
","	O
the	O
assembly	O
of	O
HE12	B-Chemical
â€“	O
SNAs	O
was	O
also	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
presence	O
of	O
divalent	O
metal	O
cations	O
","	O
however	O
","	O
the	O
main	O
driving	O
force	O
of	O
assembly	O
is	O
hydrophobic	O
interactions	O
rather	O
than	O
Watson	O
â€“	O
Crick	O
base	O
-	O
pairing	O
.	O
With	O
this	O
in	O
mind	O
","	O
we	O
sought	O
to	O
test	O
whether	O
our	O
system	O
can	O
withstand	O
variations	O
in	O
ionic	O
concentrations	O
and	O
preserve	O
structural	O
identity	O
in	O
physiologically	O
relevant	O
environments	O
.	O
Evaluation	O
of	O
the	O
nanoparticle	O
stability	O
in	O
different	O
buffer	O
conditions	O
was	O
carried	O
out	O
by	O
DLS	O
measurements	O
(	O
Fig	O
.	O
3	O
).	O
We	O
tested	O
concentration	O
variations	O
of	O
two	O
groups	O
of	O
candidates	O
;	O
divalent	O
metal	O
ions	O
(	O
Mg2	B-Chemical
+	I-Chemical
and	O
Ca2	B-Chemical
+)	I-Chemical
in	O
Tris	B-Chemical
buffer	O
(	O
Fig	O
.	O
3a	O
and	O
SF13	O
â€“	O
15	O
â€ )	O
and	O
different	O
titrations	O
of	O
Dulbecco	O
'	O
s	O
Phosphate	B-Chemical
Saline	I-Chemical
Buffer	O
(	O
DPBS	B-Chemical
with	O
Mg2	B-Chemical
+	I-Chemical
and	O
Ca2	B-Chemical
"+),"	I-Chemical
a	O
buffer	O
used	O
in	O
cell	O
culture	O
(	O
see	O
Fig	O
.	O
SF16	O
â€ ).	O
Data	O
from	O
DLS	O
showed	O
that	O
HE12	B-Chemical
â€“	O
SNAs	O
could	O
withstand	O
large	O
variations	O
in	O
ionic	O
concentrations	O
.	O
At	O
high	O
ionic	O
concentrations	O
(	O
18	O
.	O
75	O
mM	O
Mg2	B-Chemical
+	O
and	O
2	O
Ã—	O
DPBS	B-Chemical
"),"	O
no	O
structural	O
aggregation	O
was	O
observed	O
.	O
Additionally	O
","	O
at	O
Mg2	B-Chemical
+	O
concentrations	O
as	O
low	O
as	O
0	O
.	O
25	O
mM	O
(	O
in	O
0	O
.	O
5	O
Ã—	O
DPBS	B-Chemical
"),"	O
the	O
structures	O
maintained	O
their	O
natural	O
morphology	O
with	O
no	O
observed	O
disassembly	O
.	O
The	O
structures	O
were	O
also	O
compatible	O
with	O
a	O
calcium	B-Chemical
-	O
containing	O
Tris	B-Chemical
buffer	I-Chemical
at	O
concentrations	O
similar	O
to	O
physiological	O
plasma	O
concentrations	O
(âˆ¼	O
1	O
.	O
2	O
â€“	O
1	O
.	O
5	O
mM	O
).	O
Only	O
upon	O
total	O
depletion	O
of	O
divalent	O
cations	O
did	O
the	O
structures	O
disassemble	O
into	O
monomeric	O
HE12	B-Chemical
â€“	O
DNA	O
units	O
(	O
see	O
Fig	O
.	O
SF17	O
â€ ).	O
The	O
enhanced	O
stability	O
in	O
different	O
buffer	O
conditions	O
can	O
be	O
partly	O
attributed	O
to	O
hydrophobic	O
interactions	O
providing	O
an	O
additional	O
cohesive	O
force	O
to	O
preserve	O
structural	O
morphology	O
.	O
Stability	O
of	O
HE12	B-Chemical
â€“	O
SNAs	O
under	O
biologically	O
relevant	O
conditions	O
.	O
(	O
a	O
)	O
DLS	O
histograms	O
displaying	O
the	O
hydrodynamic	O
radius	O
of	O
DNA	O
nanoparticles	O
under	O
variations	O
in	O
magnesium	B-Chemical
concentrations	O
in	O
Tris	B-Chemical
buffer	O
.	O
DLS	O
analysis	O
show	O
the	O
maintained	O
structural	O
integrity	O
of	O
HE12	B-Chemical
â€“	O
DNA	O
particles	O
under	O
large	O
variations	O
of	O
ionic	O
conditions	O
.	O
Disassembly	O
of	O
the	O
structure	O
was	O
only	O
observed	O
upon	O
full	O
ionic	O
depletion	O
.	O
(	O
b	O
)	O
Serum	O
stability	O
of	O
the	O
HE12	B-Chemical
â€“	O
SNAs	O
in	O
biological	O
conditions	O
.	O
HE12	B-Chemical
â€“	O
SNAs	O
have	O
a	O
measured	O
half	O
-	O
life	O
of	O
2	O
.	O
2	O
h	O
which	O
is	O
4	O
.	O
6	O
times	O
higher	O
than	O
that	O
of	O
ssDNA	O
.	O
Error	O
bars	O
represent	O
the	O
standard	O
deviation	O
of	O
measurements	O
.	O
We	O
then	O
proceeded	O
to	O
test	O
the	O
nuclease	O
stability	O
of	O
our	O
structures	O
in	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
solution	O
at	O
37	O
Â°	O
C	O
(	O
Fig	O
.	O
3b	O
","	O
see	O
Fig	O
.	O
SF18	O
â€ ).	O
This	O
was	O
important	O
because	O
rapid	O
nuclease	O
degradation	O
is	O
a	O
major	O
challenge	O
for	O
DNA	O
nanostructures	O
as	O
they	O
are	O
translated	O
to	O
the	O
in	O
vitro	O
culture	O
environment	O
.	O
We	O
measured	O
a	O
half	O
-	O
life	O
of	O
2	O
.	O
2	O
h	O
for	O
HE12	B-Chemical
â€“	O
SNAs	O
","	O
which	O
was	O
4	O
.	O
6	O
-	O
fold	O
higher	O
than	O
the	O
results	O
obtained	O
for	O
ssDNA	O
(	O
28	O
min	O
).	O
This	O
demonstrated	O
the	O
enhanced	O
stability	O
of	O
our	O
system	O
against	O
nuclease	O
degradation	O
and	O
could	O
be	O
due	O
to	O
the	O
dense	O
packing	O
of	O
DNA	O
creating	O
a	O
steric	O
barrier	O
.	O
We	O
further	O
assessed	O
the	O
serum	O
stability	O
in	O
phosphorothioated	O
DNA	O
nanoparticles	O
","	O
where	O
the	O
nonbridging	O
oxygen	B-Chemical
in	O
the	O
phosphate	B-Chemical
backbone	O
of	O
the	O
DNA	O
strand	O
was	O
replaced	O
with	O
a	O
sulfur	B-Chemical
.	O
This	O
simple	O
modification	O
resulted	O
in	O
nuclease	O
resistance	O
for	O
over	O
72	O
hours	O
(	O
Fig	O
.	O
SF19	O
"â€ ),"	O
and	O
could	O
be	O
easily	O
implemented	O
in	O
our	O
system	O
as	O
facile	O
strategy	O
for	O
enhanced	O
stability	O
.	O
Cellular	O
uptake	O
of	O
non	O
-	O
transfected	O
HE12	B-Chemical
â€“	O
SNAs	O
The	O
in	O
vitro	O
cellular	O
uptake	O
and	O
internalization	O
of	O
HE12	B-Chemical
â€“	O
SNAs	O
were	O
studied	O
by	O
confocal	O
fluorescence	O
microscopy	O
.	O
As	O
a	O
first	O
step	O
","	O
we	O
generated	O
Cy3	B-Chemical
-	O
labeled	O
DNA	O
nanoparticles	O
(	O
see	O
Fig	O
.	O
SF20	O
â€ ).	O
This	O
was	O
achieved	O
by	O
mixing	O
Cy3	B-Chemical
â€“	O
HE12	B-Chemical
â€“	O
DNA	O
(	O
where	O
Cy3	B-Chemical
was	O
attached	O
to	O
the	O
HE12	B-Chemical
polymer	O
at	O
the	O
opposite	O
end	O
of	O
the	O
DNA	O
)	O
and	O
unlabeled	O
HE12	B-Chemical
â€“	O
DNA	O
conjugates	O
in	O
25	O
:	O
75	O
molar	O
ratios	O
","	O
followed	O
by	O
thermal	O
annealing	O
","	O
95	O
â€“	O
4	O
Â°	O
C	O
over	O
4	O
hours	O
(	O
Fig	O
.	O
4a	O
).	O
This	O
approach	O
yielded	O
highly	O
monodisperse	O
dye	O
-	O
labeled	O
nanoparticles	O
with	O
the	O
dye	O
molecules	O
embedded	O
in	O
the	O
core	O
.	O
This	O
was	O
important	O
as	O
surface	O
projection	O
of	O
a	O
lipophilic	O
dye	O
molecule	O
could	O
alter	O
the	O
uptake	O
profile	O
of	O
the	O
nanoparticles	O
through	O
cell	O
membranes	O
.	O
Following	O
24	O
hour	O
incubation	O
in	O
HeLa	O
cells	O
","	O
fluorescence	O
data	O
indicated	O
the	O
high	O
cellular	O
uptake	O
of	O
Cy3	B-Chemical
â€“	O
DNA	O
nanoparticles	O
and	O
localization	O
in	O
the	O
cytoplasm	O
in	O
the	O
perinuclear	O
region	O
(	O
Fig	O
.	O
4b	O
).	O
Several	O
intense	O
foci	O
were	O
observed	O
indicating	O
the	O
high	O
efficiency	O
of	O
uptake	O
.	O
Cellular	O
localization	O
of	O
HE12	B-Chemical
â€“	O
DNA	O
nanoparticles	O
and	O
encapsulated	O
cargo	O
.	O
(	O
a	O
)	O
Preparation	O
of	O
Cy3	B-Chemical
â€“	O
labeled	O
nanoparticles	O
.	O
Cy3	B-Chemical
â€“	O
HE12	B-Chemical
â€“	O
DNA	O
and	O
HE12	B-Chemical
â€“	O
DNA	O
were	O
mixed	O
in	O
25	O
:	O
75	O
molar	O
ratios	O
to	O
generate	O
nearly	O
monodisperse	O
Cy3	B-Chemical
-	O
labeled	O
HE12	B-Chemical
â€“	O
DNA	O
nanoparticles	O
.	O
(	O
b	O
)	O
Confocal	O
microscopy	O
images	O
demonstrating	O
the	O
cellular	O
uptake	O
of	O
Cy3	B-Chemical
-	O
labeled	O
particles	O
in	O
HeLa	O
cells	O
after	O
24	O
hour	O
incubation	O
.	O
(	O
c	O
)	O
Preparation	O
of	O
Nile	B-Chemical
Red	I-Chemical
-	O
loaded	O
DNA	O
nanoparticles	O
.	O
(	O
d	O
)	O
Flow	O
cytometry	O
measurements	O
showing	O
the	O
increased	O
uptake	O
of	O
Nile	B-Chemical
Red	I-Chemical
when	O
delivered	O
by	O
HE12	B-Chemical
â€“	O
SNAs	O
.	O
All	O
samples	O
were	O
incubated	O
for	O
12	O
hours	O
","	O
[	O
Nile	B-Chemical
Red	I-Chemical
]	O
=	O
375	O
nM	O
in	O
cell	O
culture	O
media	O
.	O
Nile	B-Chemical
Red	I-Chemical
images	O
were	O
acquired	O
using	O
exc	O
.	O
516	O
nm	O
and	O
YellowG_670	O
/	O
30	O
filter	O
.	O
(	O
e	O
)	O
Quantification	O
of	O
Nile	B-Chemical
Red	I-Chemical
intensity	O
measured	O
by	O
flow	O
cytometry	O
.	O
All	O
measurements	O
were	O
performed	O
in	O
triplicates	O
","	O
and	O
the	O
error	O
bars	O
represent	O
the	O
standard	O
deviation	O
of	O
measurements	O
.	O
We	O
were	O
then	O
interested	O
in	O
studying	O
the	O
internalization	O
of	O
encapsulated	O
cargo	O
.	O
Knowing	O
that	O
BKM120	B-Chemical
has	O
poor	O
fluorescence	O
properties	O
","	O
we	O
decided	O
to	O
monitor	O
the	O
uptake	O
of	O
a	O
fluorescent	O
dye	O
","	O
Nile	B-Chemical
Red	I-Chemical
","	O
encapsulated	O
in	O
our	O
DNA	O
nanostructures	O
(	O
Fig	O
.	O
4c	O
","	O
see	O
Fig	O
.	O
SF21	O
â€ ).	O
The	O
encapsulation	O
of	O
Nile	B-Chemical
Red	I-Chemical
further	O
demonstrates	O
the	O
versatility	O
of	O
this	O
delivery	O
system	O
for	O
accommodating	O
different	O
guest	O
molecules	O
","	O
highlighting	O
its	O
potential	O
application	O
as	O
a	O
general	O
drug	O
delivery	O
platform	O
.	O
HeLa	O
(	O
adenocarcinoma	O
)	O
cells	O
were	O
incubated	O
with	O
Nile	B-Chemical
Red	I-Chemical
loaded	O
-	O
nanoparticles	O
","	O
Nile	B-Chemical
Red	I-Chemical
alone	O
or	O
DNA	O
nanoparticle	O
control	O
at	O
37	O
Â°	O
C	O
.	O
Flow	O
cytometry	O
was	O
used	O
to	O
quantify	O
the	O
amount	O
of	O
Nile	B-Chemical
Red	I-Chemical
uptake	O
by	O
HeLa	O
cells	O
(	O
Fig	O
.	O
4d	O
).	O
After	O
12	O
hours	O
of	O
incubation	O
and	O
several	O
washing	O
steps	O
","	O
analysis	O
of	O
the	O
flow	O
cytometry	O
data	O
revealed	O
significantly	O
higher	O
intracellular	O
fluorescence	O
of	O
Nile	B-Chemical
Red	I-Chemical
when	O
delivered	O
by	O
HE12	B-Chemical
â€“	O
DNA	O
nanoparticles	O
compared	O
to	O
low	O
non	O
-	O
specific	O
internalization	O
of	O
Nile	B-Chemical
Red	I-Chemical
control	O
(	O
Fig	O
.	O
4d	O
","	O
e	O
and	O
SF22	O
â€ ).	O
The	O
higher	O
uptake	O
of	O
Nile	B-Chemical
Red	I-Chemical
was	O
also	O
confirmed	O
by	O
confocal	O
fluorescence	O
microscopy	O
","	O
where	O
the	O
dye	O
was	O
mostly	O
observed	O
in	O
the	O
cytoplasm	O
in	O
the	O
perinuclear	O
region	O
","	O
confirming	O
high	O
uptake	O
efficiency	O
(	O
see	O
Fig	O
.	O
SF23	O
â€ ).	O
Taken	O
together	O
","	O
these	O
experiments	O
suggest	O
that	O
the	O
increase	O
in	O
Nile	B-Chemical
Red	I-Chemical
uptake	O
is	O
due	O
to	O
its	O
encapsulation	O
and	O
internalization	O
by	O
HE12	B-Chemical
â€“	O
DNA	O
nanoparticles	O
.	O
Cell	O
toxicity	O
of	O
BKM120	B-Chemical
-	O
loaded	O
HE12	B-Chemical
â€“	O
SNAs	O
Based	O
on	O
the	O
cellular	O
uptake	O
and	O
dye	O
internalization	O
studies	O
in	O
HeLa	O
cells	O
","	O
we	O
were	O
interested	O
if	O
the	O
higher	O
uptake	O
of	O
our	O
nanostructures	O
would	O
correlate	O
to	O
increased	O
therapeutic	O
activity	O
of	O
the	O
drug	O
-	O
loaded	O
constructs	O
.	O
The	O
in	O
vitro	O
cytotoxicity	O
of	O
BKM120	B-Chemical
-	O
loaded	O
HE12	B-Chemical
â€“	O
SNAs	O
was	O
measured	O
against	O
human	O
cervical	O
cancer	O
(	O
HeLa	O
)	O
cells	O
.	O
Cytotoxicity	O
was	O
evaluated	O
by	O
comparing	O
a	O
dose	O
-	O
dependent	O
administration	O
of	O
BKM120	B-Chemical
in	O
DNA	O
nanoparticles	O
with	O
naked	O
BKM120	B-Chemical
and	O
DNA	O
particles	O
as	O
controls	O
(	O
see	O
Fig	O
.	O
SF24	O
â€ ).	O
In	O
the	O
tested	O
concentration	O
range	O
","	O
HE12	B-Chemical
â€“	O
DNA	O
particles	O
loaded	O
with	O
BKM120	B-Chemical
showed	O
low	O
cellular	O
death	O
in	O
HeLa	O
cells	O
.	O
Based	O
on	O
these	O
results	O
","	O
we	O
then	O
tested	O
the	O
synergistic	O
effect	O
of	O
loaded	O
BKM120	B-Chemical
in	O
combination	O
with	O
doxorubicin	B-Chemical
(	O
Dox	B-Chemical
).	O
Our	O
platform	O
acting	O
as	O
a	O
sensitizer	O
in	O
HeLa	O
cells	O
also	O
highlights	O
the	O
versatility	O
of	O
our	O
system	O
as	O
a	O
general	O
drug	O
delivery	O
system	O
for	O
anticancer	O
drugs	O
.	O
For	O
this	O
study	O
","	O
HeLa	O
cells	O
were	O
initially	O
sensitized	O
with	O
three	O
different	O
concentrations	O
of	O
BKM120	B-Chemical
-	O
loaded	O
particles	O
prior	O
to	O
incubation	O
with	O
various	O
Dox	B-Chemical
dosages	O
(	O
Fig	O
.	O
5a	O
â€“	O
c	O
).	O
Interestingly	O
","	O
as	O
illustrated	O
in	O
Fig	O
.	O
5	O
","	O
the	O
cytotoxicity	O
of	O
Dox	B-Chemical
was	O
enhanced	O
upon	O
co	O
-	O
administration	O
with	O
BKM120	B-Chemical
-	O
loaded	O
particles	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O
The	O
effect	O
was	O
most	O
pronounced	O
at	O
higher	O
Dox	B-Chemical
concentrations	O
(	O
Fig	O
.	O
5c	O
).	O
The	O
reduced	O
cytotoxic	O
differences	O
between	O
loaded	O
BKM120	B-Chemical
versus	O
its	O
un	O
-	O
encapsulated	O
form	O
","	O
is	O
in	O
part	O
due	O
to	O
the	O
lipophilic	O
nature	O
of	O
the	O
drug	O
which	O
can	O
diffuse	O
passively	O
through	O
cell	O
membranes	O
and	O
cause	O
cytotoxicity	O
.	O
However	O
","	O
we	O
anticipate	O
that	O
this	O
nanocarrier	O
platform	O
could	O
provide	O
advantages	O
in	O
the	O
delivery	O
of	O
BKM120	B-Chemical
and	O
other	O
chemotherapeutic	O
drugs	O
by	O
altering	O
their	O
in	O
vivo	O
delivery	O
profile	O
.	O
Additionally	O
","	O
the	O
capability	O
of	O
functionalizing	O
HE12	B-Chemical
â€“	O
SNAs	O
with	O
targeting	O
ligands	O
could	O
also	O
limit	O
some	O
of	O
the	O
drug	O
'	O
s	O
manifested	O
side	O
-	O
effects	O
and	O
provide	O
a	O
targeted	O
delivery	O
regimen	O
in	O
tumors	O
.	O
In	O
vitro	O
cellular	O
toxicity	O
of	O
BKM120	B-Chemical
-	O
loaded	O
HE12	B-Chemical
â€“	O
SNAs	O
.	O
Cytotoxicity	O
of	O
BKM120	B-Chemical
-	O
loaded	O
nanoparticles	O
when	O
administered	O
at	O
concentrations	O
(	O
a	O
)	O
0	O
.	O
12	O
Î¼M	O
(	O
b	O
)	O
1	O
.	O
2	O
Î¼M	O
(	O
c	O
)	O
12	O
Î¼M	O
prior	O
to	O
doxorubicin	B-Chemical
treatment	O
","	O
measured	O
over	O
24	O
hours	O
.	O
***	O
corresponds	O
to	O
p	O
<	O
0	O
.	O
1	O
and	O
**	O
to	O
p	O
<	O
0	O
.	O
1	O
.	O
Error	O
bars	O
represent	O
the	O
standard	O
deviation	O
of	O
measurements	O
.	O
(	O
d	O
)	O
Annexin	O
/	O
PI	B-Chemical
staining	O
and	O
(	O
e	O
)	O
cleaved	O
caspase	O
-	O
3	O
assay	O
showing	O
the	O
potency	O
of	O
BKM120	B-Chemical
-	O
loaded	O
particles	O
at	O
inducing	O
apoptosis	O
in	O
primary	O
patient	O
B	O
-	O
CLL	O
lymphocytes	O
in	O
the	O
presence	O
of	O
the	O
BMS2	O
stromal	O
cells	O
support	O
(	O
cocultured	O
CLL	O
"),"	O
analyzed	O
by	O
flow	O
cytometry	O
.	O
In	O
vitro	O
studies	O
on	O
BKM120	B-Chemical
have	O
shown	O
this	O
drug	O
to	O
induce	O
cell	O
death	O
in	O
B	O
-	O
CLL	O
cells	O
and	O
promote	O
apoptosis	O
.	O
Thus	O
","	O
we	O
asked	O
whether	O
BKM120	B-Chemical
-	O
loaded	O
particles	O
can	O
promote	O
cell	O
apoptosis	O
.	O
To	O
address	O
this	O
question	O
","	O
we	O
investigated	O
the	O
induction	O
of	O
apoptosis	O
through	O
Annexin	O
V	O
/	O
propidium	B-Chemical
iodide	I-Chemical
(	O
PI	B-Chemical
)	O
staining	O
assay	O
in	O
primary	O
patient	O
Chronic	O
Lymphocytic	O
Leukemia	O
(	O
CLL	O
)	O
lymphocytes	O
(	O
Fig	O
.	O
5d	O
).	O
Earlier	O
studies	O
have	O
shown	O
that	O
stromal	O
cells	O
induce	O
drug	O
resistance	O
and	O
promote	O
cell	O
survival	O
through	O
secretion	O
of	O
chemokines	O
and	O
cell	O
â€“	O
cell	O
interaction	O
.	O
Additionally	O
","	O
the	O
bone	O
marrow	O
microenvironment	O
has	O
shown	O
to	O
prevent	O
apoptosis	O
in	O
primary	O
CLL	O
lymphocytes	O
by	O
modulating	O
the	O
PI3K	O
/	O
Akt	O
pathway	O
.	O
As	O
expected	O
","	O
the	O
stromal	O
microenvironment	O
model	O
(	O
BSM2	O
stromal	O
cells	O
)	O
protected	O
CLL	O
lymphocytes	O
from	O
spontaneous	O
apoptosis	O
as	O
seen	O
with	O
the	O
untreated	O
controls	O
(	O
Fig	O
.	O
5d	O
).	O
We	O
found	O
that	O
BKM120	B-Chemical
-	O
loaded	O
structures	O
promoted	O
apoptosis	O
in	O
primary	O
BMS2	O
cocultured	O
CLL	O
lymphocytes	O
from	O
3	O
different	O
patients	O
","	O
24	O
hours	O
after	O
treatment	O
.	O
To	O
further	O
confirm	O
these	O
findings	O
","	O
we	O
monitored	O
the	O
cleavage	O
of	O
caspase	O
-	O
3	O
","	O
a	O
catalytic	O
step	O
in	O
the	O
apoptotic	O
pathway	O
.	O
In	O
accordance	O
with	O
the	O
Annexin	O
V	O
/	O
PI	B-Chemical
analysis	O
","	O
BKM120	B-Chemical
-	O
loaded	O
particles	O
induced	O
caspase	O
-	O
3	O
activity	O
in	O
CLL	O
lymphocytes	O
;	O
both	O
in	O
the	O
presence	O
and	O
absence	O
of	O
BMS2	O
","	O
confirming	O
their	O
enhanced	O
activity	O
in	O
complex	O
patient	O
cellular	O
environments	O
(	O
Fig	O
.	O
5e	O
and	O
SF25	O
â€ ).	O
To	O
evaluate	O
the	O
potential	O
immunogenicity	O
of	O
this	O
delivery	O
system	O
","	O
we	O
investigated	O
the	O
effect	O
of	O
HE12	B-Chemical
â€“	O
SNAs	O
on	O
TNF	O
-	O
alpha	O
induction	O
(	O
see	O
Fig	O
.	O
SF26	O
â€ ).	O
TNF	O
-	O
alpha	O
is	O
a	O
signalling	O
protein	O
involved	O
in	O
systemic	O
inflammation	O
.	O
Higher	O
levels	O
of	O
this	O
protein	O
indicate	O
an	O
elicited	O
immune	O
response	O
.	O
We	O
tested	O
our	O
system	O
in	O
comparison	O
to	O
lipopolysaccharide	B-Chemical
(	O
LPS	B-Chemical
)	O
and	O
a	O
synthetic	O
dsRNA	O
(	O
PolyIC	B-Chemical
)	O
which	O
have	O
been	O
reported	O
to	O
induce	O
the	O
expression	O
TNF	O
-	O
alpha	O
".,"	O
It	O
has	O
also	O
been	O
reported	O
that	O
the	O
time	O
course	O
of	O
TNF	O
-	O
alpha	O
induction	O
shows	O
a	O
rise	O
-	O
and	O
decline	O
profile	O
with	O
peak	O
elevation	O
at	O
2	O
â€“	O
6	O
hours	O
post	O
exposure	O
".,"	O
As	O
illustrated	O
in	O
Fig	O
.	O
6	O
","	O
after	O
5	O
hours	O
of	O
incubation	O
HE12	B-Chemical
â€“	O
SNAs	O
exhibited	O
no	O
systemic	O
inflammation	O
with	O
very	O
low	O
levels	O
of	O
TNF	O
-	O
alpha	O
induction	O
compared	O
to	O
LPS	B-Chemical
and	O
PolyIC	B-Chemical
.	O
The	O
effect	O
becomes	O
less	O
pronounced	O
at	O
the	O
12	O
and	O
24	O
hour	O
mark	O
.	O
This	O
result	O
supports	O
the	O
non	O
-	O
immunogenic	O
nature	O
of	O
HE12	B-Chemical
â€“	O
SNAs	O
.	O
Evaluating	O
the	O
interaction	O
of	O
HE12	B-Chemical
â€“	O
SNAs	O
with	O
human	O
serum	O
albumin	O
(	O
HSA	O
).	O
(	O
a	O
)	O
Agarose	B-Chemical
gel	O
electrophoresis	O
of	O
HE12	B-Chemical
â€“	O
SNAs	O
prior	O
(	O
Lane	O
1	O
)	O
and	O
post	O
incubation	O
(	O
Lane	O
2	O
)	O
with	O
HSA	O
.	O
The	O
gels	O
were	O
visualized	O
under	O
Gel	B-Chemical
Red	I-Chemical
DNA	O
stain	O
channel	O
(	O
left	O
panel	O
"),"	O
Coomassie	B-Chemical
Blue	I-Chemical
protein	O
stain	O
(	O
right	O
panel	O
).	O
GelRed	B-Chemical
panel	O
shows	O
the	O
absence	O
of	O
a	O
gel	O
mobility	O
shift	O
of	O
DNA	O
nanoparticles	O
after	O
HSA	O
incubation	O
.	O
Coomassie	B-Chemical
panel	O
displays	O
the	O
lower	O
mobility	O
shift	O
of	O
HSA	O
protein	O
compared	O
to	O
DNA	O
nanoparticles	O
.	O
(	O
b	O
)	O
Denaturing	O
PAGE	O
analysis	O
of	O
dissembled	O
HE12	B-Chemical
â€“	O
DNA	O
conjugate	O
strands	O
titrated	O
with	O
different	O
HSA	O
concentrations	O
.	O
Lane	O
1	O
:	O
HE12	B-Chemical
â€“	O
DNA	O
strand	O
control	O
","	O
Lanes	O
2	O
â€“	O
8	O
","	O
HSA	O
dilutions	O
of	O
1	O
/	O
1000	O
","	O
1	O
/	O
100	O
","	O
1	O
/	O
50	O
","	O
1	O
/	O
10	O
","	O
1	O
/	O
5	O
","	O
1	O
/	O
2	O
and	O
undiluted	O
HSA	O
(	O
526	O
Î¼M	O
stock	O
).	O
Under	O
denaturing	O
conditions	O
","	O
disassembly	O
of	O
the	O
DNA	O
particle	O
exposes	O
the	O
lipophilic	O
HE12	B-Chemical
segments	O
","	O
which	O
in	O
turn	O
results	O
in	O
strong	O
binding	O
to	O
HSA	O
protein	O
.	O
Nanoparticle	O
interaction	O
with	O
serum	O
proteins	O
Previous	O
reports	O
have	O
demonstrated	O
that	O
inert	O
polymers	O
such	O
as	O
hydrophilic	O
polyethylene	B-Chemical
glycol	I-Chemical
chains	O
improve	O
the	O
efficacy	O
of	O
encapsulated	O
drugs	O
by	O
reducing	O
in	O
vivo	O
opsonisation	O
with	O
serum	O
proteins	O
","	O
mainly	O
human	O
serum	O
albumin	O
(	O
HSA	O
).	O
This	O
not	O
only	O
prevents	O
the	O
rapid	O
recognition	O
of	O
structures	O
by	O
the	O
reticuloendothelial	O
system	O
(	O
RES	O
"),"	O
but	O
also	O
provides	O
prolonged	O
blood	O
circulation	O
of	O
nanostructures	O
and	O
higher	O
accumulation	O
at	O
targeted	O
sites	O
.â€“	O
In	O
our	O
case	O
","	O
we	O
hypothesized	O
that	O
the	O
dense	O
hydrophilic	O
DNA	O
outer	O
shell	O
would	O
provide	O
a	O
surface	O
unfavorable	O
for	O
binding	O
HSA	O
protein	O
.	O
HE12	B-Chemical
â€“	O
SNAs	O
were	O
pre	O
-	O
assembled	O
then	O
incubated	O
with	O
a	O
5	O
Ã—	O
molar	O
excess	O
of	O
HSA	O
for	O
2	O
hours	O
at	O
room	O
temperature	O
","	O
and	O
analyzed	O
by	O
agarose	B-Chemical
gel	O
electrophoresis	O
(	O
AGE	O
)	O
(	O
Fig	O
.	O
6	O
).	O
Since	O
HSA	O
exhibits	O
lower	O
mobility	O
on	O
gel	O
compared	O
to	O
DNA	O
nanoparticles	O
(	O
Fig	O
.	O
6a	O
"),"	O
an	O
association	O
with	O
the	O
protein	O
should	O
results	O
in	O
a	O
gel	O
mobility	O
shift	O
of	O
the	O
structures	O
.	O
As	O
illustrated	O
in	O
Fig	O
.	O
6a	O
","	O
following	O
incubation	O
","	O
no	O
interaction	O
was	O
observed	O
between	O
the	O
DNA	O
particles	O
and	O
HSA	O
protein	O
(	O
GelRed	B-Chemical
channel	O
).	O
It	O
appears	O
that	O
the	O
outer	O
DNA	O
shell	O
dictates	O
the	O
interaction	O
between	O
HSA	O
and	O
the	O
DNA	O
structures	O
.	O
In	O
a	O
control	O
experiment	O
","	O
the	O
micellar	O
DNA	O
structures	O
were	O
denatured	O
by	O
the	O
addition	O
of	O
a	O
solution	O
of	O
urea	B-Chemical
and	O
depletion	O
of	O
magnesium	B-Chemical
cations	O
prior	O
to	O
HSA	O
addition	O
","	O
exposing	O
their	O
long	O
aliphatic	O
chains	O
(	O
Fig	O
.	O
6b	O
and	O
SF27	O
â€ ).	O
In	O
this	O
case	O
","	O
even	O
at	O
low	O
protein	O
concentrations	O
","	O
HSA	O
was	O
observed	O
to	O
strongly	O
bind	O
to	O
the	O
DNA	O
â€“	O
polymer	O
conjugates	O
.	O
These	O
findings	O
suggest	O
that	O
the	O
outer	O
hydrophilic	O
ssDNA	O
corona	O
limits	O
albumin	O
adsorption	O
","	O
and	O
indicates	O
that	O
the	O
DNA	O
structures	O
remain	O
stable	O
upon	O
exposure	O
to	O
the	O
protein	O
.	O
In	O
addition	O
","	O
we	O
used	O
Nile	B-Chemical
Red	I-Chemical
-	O
loaded	O
particles	O
as	O
a	O
visual	O
tool	O
along	O
with	O
gel	O
electrophoresis	O
to	O
further	O
confirm	O
the	O
lack	O
of	O
interaction	O
between	O
DNA	O
nanoparticles	O
and	O
HSA	O
(	O
Fig	O
.	O
SF28	O
and	O
SF29	O
â€ ).	O
In	O
vivo	O
biodistribution	O
of	O
HE12	B-Chemical
â€“	O
SNAs	O
To	O
our	O
knowledge	O
","	O
the	O
in	O
vivo	O
behaviour	O
of	O
polymeric	O
DNA	O
nanoparticles	O
has	O
not	O
been	O
previously	O
studied	O
.	O
With	O
that	O
in	O
mind	O
","	O
we	O
proceeded	O
with	O
an	O
in	O
vivo	O
screening	O
via	O
optical	O
imaging	O
which	O
would	O
allow	O
for	O
real	O
-	O
time	O
tracking	O
and	O
overall	O
biodistribution	O
profiles	O
.	O
For	O
this	O
purpose	O
","	O
highly	O
monodisperse	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
HE12	B-Chemical
â€“	O
DNA	O
nanoparticles	O
were	O
prepared	O
which	O
contained	O
the	O
dye	O
molecule	O
in	O
their	O
core	O
.	O
This	O
was	O
achieved	O
by	O
mixing	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
HE12	B-Chemical
â€“	O
DNA	O
(	O
where	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
was	O
attached	O
to	O
the	O
HE12	B-Chemical
polymer	O
at	O
the	O
opposite	O
end	O
of	O
the	O
DNA	O
)	O
and	O
unlabeled	O
HE12	B-Chemical
â€“	O
DNA	O
conjugates	O
in	O
25	O
:	O
75	O
molar	O
ratios	O
","	O
followed	O
by	O
thermal	O
annealing	O
(	O
95	O
â€“	O
4	O
Â°	O
C	O
over	O
4	O
hours	O
)	O
(	O
see	O
Fig	O
.	O
SF30	O
and	O
SF31	O
â€ ).	O
Nanoparticle	O
biodistribution	O
was	O
evaluated	O
by	O
fluorescence	O
imaging	O
","	O
following	O
intraperitoneal	O
injection	O
(	O
Fig	O
.	O
7a	O
and	O
b	O
)	O
and	O
intravenous	O
administration	O
of	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
-	O
labeled	O
structures	O
measured	O
over	O
24	O
hours	O
(	O
see	O
Fig	O
.	O
SF32	O
â€ ).	O
Remarkably	O
","	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
-	O
labeled	O
DNA	O
particles	O
showed	O
full	O
-	O
body	O
distribution	O
with	O
long	O
circulation	O
times	O
up	O
to	O
24	O
hours	O
(	O
Fig	O
.	O
7a	O
â€“	O
c	O
and	O
SF32	O
â€ ).	O
Control	O
experiments	O
using	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
-	O
labeled	O
single	O
stranded	O
DNA	O
","	O
showed	O
loss	O
of	O
fluorescence	O
","	O
most	O
likely	O
due	O
to	O
DNA	O
degradation	O
.	O
Similarly	O
","	O
the	O
dye	O
only	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
sample	O
showed	O
immediate	O
loss	O
of	O
fluorescence	O
","	O
likely	O
because	O
of	O
its	O
insolubility	O
.	O
In	O
contrast	O
","	O
the	O
prolonged	O
fluorescence	O
biodistribution	O
of	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
HE12	B-Chemical
â€“	O
DNA	O
nanoparticles	O
could	O
indicate	O
very	O
slow	O
structural	O
degradation	O
in	O
the	O
blood	O
stream	O
.	O
This	O
behavior	O
was	O
further	O
observed	O
with	O
intravenous	O
injection	O
of	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
HE12	B-Chemical
â€“	O
SNAs	O
(	O
see	O
Fig	O
.	O
SF32	O
â€ ).	O
Compared	O
to	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
ssDNA	O
which	O
showed	O
rapid	O
decrease	O
in	O
signal	O
after	O
30	O
minutes	O
","	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
HE12	B-Chemical
â€“	O
SNA	O
exhibited	O
a	O
delayed	O
decrease	O
starting	O
at	O
6	O
hours	O
.	O
These	O
results	O
also	O
corroborate	O
our	O
in	O
vitro	O
experiments	O
that	O
demonstrate	O
enhanced	O
stability	O
of	O
these	O
DNA	O
structures	O
under	O
physiological	O
conditions	O
(	O
Fig	O
.	O
3	O
and	O
4	O
"),"	O
and	O
could	O
also	O
indicate	O
that	O
the	O
DNA	O
portion	O
of	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
HE12	B-Chemical
â€“	O
SNA	O
is	O
more	O
shielded	O
as	O
the	O
nanostructure	O
circulates	O
in	O
the	O
body	O
.	O
Interestingly	O
","	O
at	O
the	O
6	O
hour	O
mark	O
","	O
the	O
rate	O
of	O
signal	O
decrease	O
in	O
both	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
ssDNA	O
and	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
HE12	B-Chemical
â€“	O
SNAs	O
appear	O
to	O
be	O
similar	O
which	O
could	O
indicate	O
that	O
at	O
this	O
point	O
","	O
the	O
DNA	O
portion	O
of	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
HE12	B-Chemical
â€“	O
SNAs	O
may	O
be	O
degraded	O
","	O
and	O
the	O
remaining	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
HE12	B-Chemical
portion	O
behaves	O
similarly	O
to	O
the	O
remaining	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
dye	O
in	O
the	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
ssDNA	O
sample	O
.	O
In	O
vivo	O
biodistribution	O
of	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
-	O
labeled	O
HE12	B-Chemical
â€“	O
DNA	O
nanoparticles	O
.	O
(	O
a	O
)	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
fluorescence	O
data	O
overlaid	O
on	O
X	O
-	O
ray	O
images	O
measured	O
over	O
time	O
after	O
intraperitoneal	O
injection	O
.	O
Top	O
:	O
unlabeled	O
HE12	B-Chemical
â€“	O
DNA	O
nanoparticle	O
","	O
2nd	O
top	O
:	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
dye	O
molecule	O
","	O
2nd	O
bottom	O
:	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
ssDNA	O
","	O
bottom	O
:	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
HE12	B-Chemical
â€“	O
DNA	O
nanoparticle	O
.	O
(	O
b	O
)	O
Quantified	O
biodistribution	O
data	O
of	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
intensity	O
measured	O
as	O
a	O
function	O
of	O
time	O
for	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
HE12	B-Chemical
â€“	O
DNA	O
nanoparticles	O
.	O
(	O
c	O
)	O
3D	O
full	O
body	O
fluorescence	O
scan	O
at	O
24	O
h	O
","	O
overlaid	O
with	O
body	O
organs	O
(	O
liver	O
highlighted	O
in	O
red	O
).	O
(	O
d	O
)	O
Biodistribution	O
of	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
-	O
labeled	O
DNA	O
nanoparticles	O
in	O
HCT116	O
colon	O
cancer	O
xenograft	O
.	O
Control	O
:	O
treated	O
with	O
unlabeled	O
particle	O
","	O
1	O
&	O
2	O
:	O
treated	O
with	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
DNA	O
particles	O
.	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
fluorescence	O
data	O
overlaid	O
on	O
X	O
-	O
ray	O
images	O
measured	O
over	O
time	O
following	O
subcutaneous	O
injection	O
.	O
(	O
e	O
)	O
Quantified	O
fluorescence	O
intensity	O
of	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
â€“	O
HE12	B-Chemical
â€“	O
DNA	O
particles	O
at	O
the	O
tumor	O
site	O
measured	O
over	O
time	O
.	O
Error	O
bars	O
represent	O
the	O
standard	O
deviation	O
of	O
measurements	O
.	O
Further	O
3D	O
fluorescence	O
imaging	O
","	O
which	O
highlights	O
organ	O
-	O
specific	O
distribution	O
","	O
indicated	O
low	O
levels	O
of	O
excretion	O
(	O
liver	O
and	O
kidney	O
)	O
(	O
Fig	O
.	O
7c	O
).	O
Notably	O
","	O
low	O
levels	O
of	O
fluorescence	O
were	O
also	O
observed	O
in	O
brain	O
and	O
lungs	O
after	O
2	O
and	O
24	O
hours	O
(	O
see	O
ESI	O
video	O
clips	O
1	O
&	O
2	O
â€ ).	O
The	O
biodistribution	O
within	O
the	O
blood	O
stream	O
without	O
accumulation	O
in	O
non	O
-	O
specific	O
organs	O
","	O
particularly	O
in	O
the	O
brain	O
where	O
BKM120	B-Chemical
manifests	O
side	O
-	O
effects	O
","	O
is	O
important	O
to	O
decrease	O
adverse	O
effects	O
observed	O
during	O
systemic	O
drug	O
treatments	O
.	O
The	O
next	O
question	O
was	O
to	O
test	O
whether	O
our	O
DNA	O
nanostructures	O
could	O
reach	O
and	O
accumulate	O
in	O
solid	O
tumors	O
.	O
To	O
address	O
that	O
","	O
the	O
biodistribution	O
of	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
-	O
labeled	O
structures	O
was	O
evaluated	O
in	O
a	O
cancer	O
xenograft	O
model	O
.	O
In	O
our	O
hands	O
","	O
the	O
success	O
of	O
forming	O
CLL	O
xenografts	O
was	O
hampered	O
by	O
the	O
inefficient	O
engraftment	O
of	O
MEC	O
-	O
1	O
(	O
CLL	O
cell	O
line	O
)	O
into	O
rag2	O
â€“/â€“	O
Î³c	O
â€“/â€“	O
mice	O
.	O
Compared	O
to	O
CLL	O
","	O
colon	O
cancer	O
xenografts	O
formed	O
solid	O
tumors	O
much	O
more	O
efficiently	O
in	O
our	O
mice	O
model	O
.	O
Therefore	O
","	O
HCT116	O
colon	O
cancer	O
xenografts	O
were	O
used	O
as	O
a	O
model	O
system	O
to	O
test	O
the	O
biodistribution	O
of	O
our	O
DNA	O
nanostructures	O
.	O
Previous	O
reports	O
have	O
demonstrated	O
that	O
nanoparticles	O
tend	O
to	O
accumulate	O
in	O
higher	O
levels	O
in	O
tumor	O
tissue	O
","	O
a	O
phenomenon	O
known	O
as	O
the	O
enhanced	O
permeation	O
and	O
retention	O
(	O
EPR	O
)	O
effect	O
".,"	O
In	O
our	O
case	O
","	O
we	O
measured	O
the	O
accumulation	O
of	O
nanoparticles	O
at	O
the	O
tumor	O
site	O
over	O
time	O
following	O
intraperitoneal	O
injection	O
(	O
Fig	O
.	O
7d	O
).	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
-	O
labeled	O
DNA	O
particles	O
showed	O
a	O
steady	O
increase	O
in	O
accumulation	O
at	O
tumor	O
sites	O
for	O
up	O
to	O
24	O
hours	O
(	O
Fig	O
.	O
7e	O
).	O
High	O
accumulation	O
in	O
tumors	O
was	O
also	O
observed	O
under	O
intravenous	O
administration	O
.	O
As	O
expected	O
","	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
-	O
labeled	O
structures	O
exhibited	O
higher	O
diffusion	O
rates	O
compared	O
to	O
intraperitoneal	O
delivery	O
with	O
accumulation	O
peaking	O
at	O
6	O
h	O
(	O
Fig	O
.	O
SF33	O
â€ ).	O
The	O
steady	O
increase	O
in	O
accumulation	O
of	O
Cy5	B-Chemical
.	I-Chemical
5	I-Chemical
-	O
labeled	O
particles	O
at	O
the	O
tumor	O
site	O
is	O
predicted	O
to	O
translate	O
into	O
the	O
same	O
pattern	O
of	O
anticancer	O
drug	O
delivery	O
by	O
HE12	B-Chemical
â€“	O
DNA	O
structures	O
","	O
which	O
will	O
provide	O
an	O
important	O
mechanism	O
to	O
minimize	O
potential	O
complications	O
of	O
this	O
drug	O
.	O
Overall	O
","	O
the	O
in	O
vivo	O
stability	O
and	O
biodistribution	O
profiles	O
of	O
HE12	B-Chemical
â€“	O
DNA	O
nanoparticles	O
highlight	O
their	O
great	O
potential	O
as	O
a	O
robust	O
drug	O
delivery	O
system	O
.	O
Conclusion	O
We	O
have	O
developed	O
a	O
highly	O
monodisperse	O
DNA	O
nanoparticle	O
delivery	O
platform	O
for	O
small	O
-	O
molecule	O
chemotherapeutics	O
.	O
Our	O
structures	O
show	O
effective	O
loading	O
and	O
slow	O
release	O
of	O
BKM120	B-Chemical
","	O
and	O
have	O
a	O
long	O
shelf	O
-	O
life	O
.	O
The	O
DNA	O
nanoparticles	O
are	O
made	O
of	O
monodisperse	O
","	O
sequence	O
-	O
defined	O
polymers	O
units	O
","	O
they	O
are	O
stable	O
under	O
physiological	O
ionic	O
concentrations	O
","	O
and	O
exhibit	O
increased	O
resistance	O
to	O
nucleases	O
in	O
biological	O
environments	O
.	O
Furthermore	O
","	O
these	O
structures	O
demonstrate	O
efficient	O
uptake	O
in	O
cancer	O
cells	O
","	O
and	O
increased	O
internalization	O
of	O
cargo	O
.	O
In	O
vitro	O
studies	O
show	O
the	O
ability	O
of	O
BKM120	B-Chemical
-	O
loaded	O
particles	O
to	O
induce	O
cellular	O
death	O
and	O
apoptosis	O
","	O
including	O
synergistic	O
effects	O
between	O
BKM120	B-Chemical
and	O
antitumor	O
drugs	O
","	O
without	O
causing	O
non	O
-	O
specific	O
inflammation	O
.	O
Moreover	O
","	O
the	O
absence	O
of	O
interaction	O
with	O
HSA	O
can	O
possibly	O
protect	O
the	O
structures	O
from	O
RES	O
uptake	O
.	O
Further	O
investigation	O
of	O
the	O
in	O
vivo	O
biodistribution	O
of	O
DNA	O
nanoparticles	O
demonstrates	O
full	O
-	O
body	O
distribution	O
and	O
long	O
circulation	O
times	O
of	O
these	O
structures	O
.	O
Furthermore	O
","	O
the	O
particles	O
are	O
not	O
observed	O
to	O
cross	O
the	O
blood	O
â€“	O
brain	O
barrier	O
an	O
important	O
feature	O
towards	O
limiting	O
the	O
side	O
-	O
effects	O
of	O
BKM120	B-Chemical
or	O
any	O
drug	O
molecule	O
with	O
CNS	O
off	O
-	O
target	O
activity	O
.	O
The	O
structures	O
also	O
show	O
high	O
tumor	O
accumulation	O
in	O
xenograft	O
models	O
highlighting	O
their	O
potential	O
for	O
targeted	O
cancer	O
therapy	O
.	O
Given	O
our	O
findings	O
","	O
HE12	B-Chemical
â€“	O
DNA	O
nanoparticles	O
show	O
great	O
promise	O
as	O
delivery	O
vehicles	O
for	O
chemotherapeutics	O
.	O
This	O
initial	O
work	O
has	O
demonstrated	O
the	O
ability	O
to	O
load	O
drugs	O
and	O
protect	O
them	O
in	O
different	O
biological	O
conditions	O
","	O
achieve	O
in	O
vitro	O
activity	O
in	O
primary	O
patient	O
cell	O
lines	O
","	O
and	O
monitor	O
the	O
in	O
vivo	O
biodistribution	O
of	O
these	O
structures	O
in	O
mice	O
to	O
understand	O
their	O
real	O
-	O
time	O
trafficking	O
and	O
stability	O
.	O
Future	O
studies	O
on	O
this	O
platform	O
will	O
focus	O
on	O
adapting	O
cross	O
-	O
linking	O
strategies	O
to	O
enhance	O
drug	O
loading	O
capacity	O
","	O
retention	O
and	O
structural	O
stability	O
in	O
vivo	O
.	O
Additionally	O
","	O
taking	O
advantage	O
of	O
the	O
DNA	O
shell	O
","	O
surface	O
modifications	O
such	O
as	O
targeting	O
ligands	O
and	O
oligonucleotide	O
therapeutics	O
will	O
be	O
implemented	O
.	O
We	O
envisage	O
this	O
system	O
to	O
see	O
applications	O
in	O
targeted	O
cancer	O
therapy	O
and	O
delivery	O
of	O
combinational	O
small	O
-	O
molecule	O
and	O
oligonucleotide	O
therapeutics	O
.	O
Design	O
","	O
Synthesis	O
","	O
and	O
Evaluation	O
of	O
Ribose	B-Chemical
-	I-Chemical
Modified	I-Chemical
Anilinopyrimidine	I-Chemical
Derivatives	I-Chemical
as	O
EGFR	O
Tyrosine	O
Kinase	O
Inhibitors	O
The	O
synthesis	O
of	O
a	O
series	O
of	O
ribose	B-Chemical
-	I-Chemical
modified	I-Chemical
anilinopyrimidine	I-Chemical
derivatives	I-Chemical
was	O
efficiently	O
achieved	O
by	O
utilizing	O
DBU	B-Chemical
or	O
tBuOLi	B-Chemical
-	O
promoted	O
coupling	O
of	O
ribosyl	B-Chemical
alcohols	I-Chemical
with	O
2	B-Chemical
","	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
trichloropyrimidine	I-Chemical
as	O
key	O
step	O
.	O
Preliminary	O
biological	O
evaluation	O
of	O
this	O
type	O
of	O
compounds	O
as	O
new	O
EGFR	O
tyrosine	O
kinase	O
inhibitors	O
for	O
combating	O
EGFR	O
L858R	O
/	O
T790M	O
mutant	O
associated	O
with	O
drug	O
resistance	O
in	O
the	O
treatment	O
of	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
revealed	O
that	O
3	B-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribose	I-Chemical
derivative	I-Chemical
1a	I-Chemical
possessed	O
potent	O
and	O
specific	O
inhibitory	O
activity	O
against	O
EGFR	O
L858R	O
/	O
T790M	O
over	O
WT	O
EGFR	O
.	O
Based	O
upon	O
molecular	O
docking	O
studies	O
of	O
the	O
binding	O
mode	O
between	O
compound	O
1a	O
and	O
EGFR	O
","	O
the	O
distance	O
between	O
the	O
Michael	O
receptor	O
and	O
the	O
pyrimidine	B-Chemical
scaffold	O
is	O
considered	O
as	O
an	O
important	O
factor	O
for	O
the	O
inhibitory	O
potency	O
and	O
future	O
design	O
of	O
selective	O
EGFR	O
tyrosine	O
kinase	O
inhibitors	O
against	O
EGFR	O
L858R	O
/	O
T790M	O
mutants	O
.	O
Introduction	O
Epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
"),"	O
a	O
transmembrane	O
protein	O
with	O
tyrosine	O
kinase	O
activity	O
","	O
is	O
essential	O
for	O
cell	O
growth	O
","	O
differentiation	O
","	O
migration	O
","	O
adhesion	O
","	O
and	O
proliferation	O
under	O
normal	O
physiological	O
conditions	O
(	O
Gschwind	O
et	O
al	O
".,"	O
).	O
However	O
","	O
overexpression	O
of	O
EGFR	O
has	O
been	O
associated	O
with	O
tumor	O
growth	O
and	O
progression	O
in	O
a	O
variety	O
of	O
cancers	O
including	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
"),"	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
","	O
and	O
pancreatic	O
cancer	O
(	O
Huang	O
and	O
Harari	O
","	O
;	O
Kris	O
et	O
al	O
".,"	O
;	O
Moore	O
et	O
al	O
".,"	O
;	O
Harrington	O
et	O
al	O
".,"	O
).	O
Therefore	O
","	O
regulation	O
of	O
EGFR	O
has	O
been	O
deemed	O
as	O
an	O
important	O
strategy	O
for	O
the	O
development	O
of	O
cancer	O
therapy	O
(	O
Huang	O
and	O
Harari	O
","	O
;	O
Gschwind	O
et	O
al	O
".,"	O
;	O
Steuer	O
et	O
al	O
".,"	O
).	O
First	O
-	O
generation	O
EGFR	O
tyrosine	O
kinase	O
inhibitors	O
(	O
TKIs	O
)	O
such	O
as	O
gefitinib	B-Chemical
and	O
erlotinib	B-Chemical
that	O
possess	O
a	O
4	B-Chemical
-	I-Chemical
anilinoquinazoline	I-Chemical
scaffold	O
","	O
reversibly	O
inhibit	O
EGFR	O
mutants	O
(	O
L858R	O
and	O
delE746_A750	O
)	O
as	O
well	O
as	O
wild	O
-	O
type	O
(	O
WT	O
)	O
EGFR	O
","	O
resulting	O
in	O
significant	O
disease	O
control	O
of	O
patients	O
with	O
NSCLC	O
(	O
Figure	O
1	O
)	O
(	O
Cohen	O
et	O
al	O
".,"	O
;	O
Cheng	O
et	O
al	O
".,"	O
).	O
However	O
","	O
drug	O
resistance	O
driven	O
by	O
activating	O
mutation	O
of	O
the	O
gatekeeper	O
T790M	O
residue	O
in	O
which	O
the	O
threonine	B-Chemical
group	O
is	O
replaced	O
with	O
the	O
methionine	B-Chemical
moiety	O
","	O
greatly	O
counteracted	O
the	O
clinical	O
efficiency	O
of	O
first	O
-	O
generation	O
TKIs	O
against	O
NSCLC	O
(	O
Ozvegy	O
-	O
Laczka	O
et	O
al	O
".,"	O
;	O
Balak	O
et	O
al	O
".,"	O
;	O
De	O
Luca	O
et	O
al	O
".,"	O
;	O
Pao	O
and	O
Chmielecki	O
","	O
).	O
To	O
address	O
this	O
issue	O
","	O
the	O
irreversible	O
EGFR	O
TKIs	O
(	O
afatinib	B-Chemical
","	O
osimertinib	B-Chemical
","	O
WZ4002	B-Chemical
","	O
and	O
CO	B-Chemical
-	I-Chemical
1686	I-Chemical
)	O
which	O
contain	O
a	O
Michael	O
acceptor	O
moiety	O
for	O
binding	O
covalently	O
to	O
the	O
thiol	B-Chemical
group	O
of	O
Cys797	B-Chemical
in	O
the	O
ATP	B-Chemical
binding	O
domain	O
of	O
EGFR	O
","	O
were	O
developed	O
to	O
treat	O
NSCLC	O
via	O
the	O
efficient	O
inhibition	O
of	O
EGFR	O
mutants	O
(	O
Figure	O
1	O
;	O
Castellanos	O
and	O
Horn	O
","	O
).	O
Among	O
them	O
","	O
second	O
-	O
generation	O
TKIs	O
such	O
as	O
afatinib	B-Chemical
potently	O
inhibited	O
both	O
EGFR	O
mutants	O
(	O
L858R	O
/	O
T790M	O
)	O
and	O
WT	O
-	O
EGFR	O
without	O
mutant	O
selectivity	O
","	O
thereby	O
leading	O
to	O
side	O
effects	O
such	O
as	O
rash	O
and	O
diarrhea	O
(	O
Dungo	O
and	O
Keating	O
","	O
).	O
In	O
contrast	O
","	O
third	O
-	O
generation	O
TKIs	O
such	O
as	O
osimertinib	B-Chemical
","	O
WZ4002	B-Chemical
","	O
and	O
CO	B-Chemical
-	I-Chemical
1686	I-Chemical
bearing	O
an	O
anilinopyrimidine	B-Chemical
core	O
","	O
showed	O
high	O
potency	O
and	O
selectivity	O
for	O
EGFR	O
L858R	O
/	O
T790M	O
over	O
WT	O
EGFR	O
","	O
therefore	O
serving	O
as	O
mutant	O
-	O
selective	O
TKIs	O
targeting	O
EGFR	O
mutants	O
involved	O
in	O
NSCLC	O
(	O
Zhou	O
et	O
al	O
".,"	O
;	O
Walter	O
et	O
al	O
".,"	O
;	O
Cross	O
et	O
al	O
".,"	O
;	O
Finlay	O
et	O
al	O
".,"	O
;	O
Gray	O
and	O
Haura	O
","	O
).	O
Structures	O
of	O
three	O
generations	O
of	O
EGFR	O
tyrosine	O
kinase	O
inhibitors	O
.	O
Considering	O
the	O
drug	O
resistance	O
is	O
rapidly	O
emerging	O
for	O
third	O
-	O
generation	O
TKIs	O
(	O
Eberlein	O
et	O
al	O
".,"	O
;	O
Niederst	O
et	O
al	O
".,"	O
;	O
Piotrowska	O
et	O
al	O
".,"	O
;	O
Thress	O
et	O
al	O
".,"	O
"),"	O
design	O
of	O
EGFR	O
inhibitors	O
with	O
new	O
structural	O
skeletons	O
could	O
lead	O
to	O
the	O
discovery	O
of	O
novel	O
types	O
of	O
TKIs	O
against	O
EGFR	O
mutants	O
such	O
as	O
the	O
triple	O
mutant	O
L858R	O
/	O
T790M	O
/	O
C797S	O
(	O
GÃ¼nther	O
et	O
al	O
".,"	O
","	O
;	O
Jia	O
et	O
al	O
".,"	O
;	O
Juchum	O
et	O
al	O
".,"	O
;	O
Park	O
et	O
al	O
".,"	O
).	O
Based	O
on	O
the	O
fact	O
that	O
most	O
commercially	O
available	O
TKIs	O
are	O
ATP	B-Chemical
-	O
competitive	O
inhibitors	O
for	O
binding	O
at	O
the	O
catalytic	O
domain	O
of	O
the	O
EGFR	O
tyrosine	O
kinase	O
(	O
Traxler	O
and	O
Furet	O
","	O
;	O
GrÃ¼nwald	O
and	O
Hidalgo	O
","	O
;	O
Normanno	O
et	O
al	O
".,"	O
"),"	O
we	O
envisioned	O
that	O
replacement	O
of	O
the	O
phenyl	O
ring	O
on	O
the	O
right	O
side	O
of	O
WZ4002	B-Chemical
with	O
a	O
chiral	O
ribosyl	O
moiety	O
would	O
provide	O
compound	O
1	O
as	O
a	O
novel	O
type	O
of	O
carbohydrate	B-Chemical
-	O
based	O
EGFR	O
TKI	O
against	O
the	O
drug	O
resistance	O
involved	O
in	O
NSCLC	O
(	O
Figure	O
2	O
).	O
Here	O
we	O
report	O
the	O
synthesis	O
","	O
preliminary	O
biological	O
evaluation	O
and	O
molecular	O
docking	O
studies	O
of	O
ribose	B-Chemical
-	I-Chemical
containing	I-Chemical
anilinopyrimidine	I-Chemical
derivatives	I-Chemical
as	O
EGFR	O
TKIs	O
against	O
EGFR	O
L858R	O
/	O
T790M	O
.	O
Design	O
of	O
novel	O
EGFR	O
tyrosine	O
kinase	O
inhibitors	O
.	O
Materials	O
and	O
methods	O
Commercial	O
reagents	O
were	O
used	O
without	O
further	O
purification	O
except	O
where	O
noted	O
.	O
Solvents	O
were	O
dried	O
and	O
redistilled	O
prior	O
to	O
use	O
in	O
the	O
usual	O
way	O
.	O
All	O
reactions	O
were	O
performed	O
in	O
oven	O
-	O
dried	O
glassware	O
with	O
magnetic	O
stirring	O
under	O
an	O
inert	O
atmosphere	O
unless	O
noted	O
otherwise	O
.	O
Analytical	O
thin	O
layer	O
chromatography	O
(	O
TLC	O
)	O
was	O
performed	O
on	O
precoated	O
plates	O
of	O
Silica	B-Chemical
Gel	O
(	O
0	O
.	O
25	O
â€“	O
0	O
.	O
3	O
mm	O
","	O
Shanghai	O
","	O
China	O
).	O
The	O
TLC	O
plates	O
were	O
visualized	O
with	O
UV	O
light	O
and	O
by	O
staining	O
with	O
sulfuric	B-Chemical
acid	I-Chemical
-	O
ethanol	B-Chemical
solution	O
.	O
Silica	B-Chemical
gel	O
column	O
chromatography	O
was	O
performed	O
on	O
Silica	B-Chemical
Gel	O
AR	O
(	O
100	O
â€“	O
200	O
mesh	O
","	O
Shanghai	O
","	O
China	O
).	O
NMR	O
spectra	O
were	O
measured	O
with	O
a	O
Bruker	O
Avance	O
III	O
400	O
or	O
Bruker	O
Avance	O
III	O
500	O
spectrometer	O
.	O
The	O
1H	B-Chemical
and	O
13C	B-Chemical
NMR	O
spectra	O
were	O
calibrated	O
against	O
the	O
residual	O
proton	B-Chemical
and	O
carbon	B-Chemical
signals	O
of	O
the	O
solvents	O
as	O
internal	O
references	O
(	O
CDCl3	B-Chemical
:	O
Î´H	O
=	O
7	O
.	O
26	O
ppm	O
and	O
Î´C	O
=	O
77	O
.	O
2	O
ppm	O
;	O
CD3OD	B-Chemical
:	O
Î´H	O
=	O
3	O
.	O
31	O
ppm	O
and	O
Î´C	O
=	O
49	O
.	O
0	O
ppm	O
).	O
Multiplicities	O
are	O
quoted	O
as	O
singlet	O
(	O
s	O
"),"	O
broad	O
singlet	O
(	O
br	O
s	O
"),"	O
doublet	O
(	O
d	O
"),"	O
doublet	O
of	O
doublets	O
(	O
dd	O
"),"	O
triplet	O
(	O
t	O
"),"	O
or	O
multiplet	O
(	O
m	O
).	O
All	O
NMR	O
chemical	O
shifts	O
(	O
Î´	O
)	O
were	O
recorded	O
in	O
ppm	O
and	O
coupling	O
constants	O
(	O
J	O
)	O
were	O
reported	O
in	O
Hz	O
.	O
Mass	O
spectra	O
were	O
recorded	O
on	O
an	O
Agilent	O
Technologies	O
6120	O
or	O
LCT	O
Premier	O
XE	O
FTMS	O
instrument	O
.	O
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
isopropylidene	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
O	I-Chemical
-(	I-Chemical
2	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
dichloropyrimidin	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
yl	I-Chemical
)-	I-Chemical
Î±	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
ribofuranoside	I-Chemical
7	O
To	O
a	O
solution	O
of	O
compound	O
5	O
(	O
0	O
.	O
60	O
g	O
","	O
2	O
.	O
47	O
mmol	O
)	O
in	O
anhydrous	O
CH2Cl2	B-Chemical
(	O
30	O
mL	O
)	O
at	O
room	O
temperature	O
","	O
was	O
added	O
DBU	B-Chemical
(	O
1	O
.	O
48	O
mL	O
","	O
5	O
.	O
94	O
mmol	O
)	O
and	O
2	B-Chemical
","	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
trichloropyrimidine	I-Chemical
6	O
(	O
0	O
.	O
57	O
mL	O
","	O
4	O
.	O
94	O
mmol	O
).	O
After	O
stirring	O
at	O
room	O
temperature	O
for	O
2	O
h	O
","	O
the	O
reaction	O
mixture	O
was	O
diluted	O
with	O
saturated	O
aqueous	O
NH4Cl	B-Chemical
","	O
and	O
extracted	O
with	O
CH2Cl2	B-Chemical
.	O
The	O
organic	O
layer	O
was	O
washed	O
with	O
brine	O
","	O
dried	O
over	O
Na2SO4	B-Chemical
","	O
and	O
concentrated	O
in	O
vacuo	O
.	O
The	O
residue	O
was	O
purified	O
by	O
silica	B-Chemical
gel	O
chromatography	O
(	O
petroleum	B-Chemical
ether	I-Chemical
/	O
EtOAc	B-Chemical
:	O
80	O
/	O
1	O
)	O
to	O
give	O
7	O
(	O
0	O
.	O
88	O
g	O
","	O
92	O
%)	O
as	O
a	O
pale	O
yellow	O
syrup	O
:	O
1H	B-Chemical
NMR	O
(	O
400	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
8	O
.	O
30	O
(	O
s	O
","	O
1	O
H	O
"),"	O
6	O
.	O
29	O
(	O
dd	O
","	O
J	O
=	O
1	O
.	O
2	O
","	O
17	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
12	O
(	O
dd	O
","	O
J	O
=	O
10	O
.	O
4	O
","	O
17	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
7	O
(	O
d	O
","	O
J	O
=	O
8	O
.	O
8	O
Hz	O
","	O
1	O
H	O
","	O
NH	O
"),"	O
5	O
.	O
90	O
(	O
d	O
","	O
J	O
=	O
3	O
.	O
6	O
Hz	O
","	O
1	O
H	O
","	O
H	O
-	O
1	O
"),"	O
5	O
.	O
69	O
(	O
dd	O
","	O
J	O
=	O
1	O
.	O
2	O
","	O
10	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
73	O
(	O
dd	O
","	O
J	O
=	O
2	O
.	O
4	O
","	O
12	O
.	O
0	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
66	O
(	O
t	O
","	O
J	O
=	O
4	O
.	O
0	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
61	O
â€“	O
4	O
.	O
55	O
(	O
m	O
","	O
2	O
H	O
"),"	O
4	O
.	O
16	O
(	O
m	O
","	O
1	O
H	O
"),"	O
1	O
.	O
57	O
(	O
s	O
","	O
3	O
H	O
"),"	O
1	O
.	O
35	O
(	O
s	O
","	O
3	O
H	O
);	O
13C	B-Chemical
NMR	O
(	O
100	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
165	O
.	O
4	O
","	O
165	O
.	O
3	O
","	O
157	O
.	O
4	O
","	O
157	O
.	O
2	O
","	O
130	O
.	O
1	O
","	O
128	O
.	O
0	O
","	O
117	O
.	O
0	O
","	O
113	O
.	O
0	O
","	O
104	O
.	O
7	O
","	O
79	O
.	O
1	O
","	O
78	O
.	O
2	O
","	O
67	O
.	O
3	O
","	O
52	O
.	O
1	O
","	O
26	O
.	O
8	O
","	O
26	O
.	O
5	O
;	O
ESI	O
-	O
MS	O
(	O
ESI	O
)	O
m	O
/	O
z	O
calcd	O
for	O
C15H17O5N3Cl2Na	B-Chemical
[	O
M	O
+	O
Na	B-Chemical
]+	O
412	O
.	O
0	O
","	O
found	O
412	O
.	O
0	O
.	O
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
isopropylidene	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
O	I-Chemical
-[	I-Chemical
5	I-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
N	I-Chemical
-(	I-Chemical
2	I-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
methylpiperazin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
phenyl	I-Chemical
)	I-Chemical
pyrimidin	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
yl	I-Chemical
]-	I-Chemical
Î±	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
ribofuranoside	I-Chemical
1a	O
To	O
a	O
solution	O
of	O
compound	O
7	O
(	O
80	O
mg	O
","	O
0	O
.	O
21	O
mmol	O
)	O
and	O
aniline	B-Chemical
derivative	I-Chemical
8	I-Chemical
(	O
91	O
mg	O
","	O
0	O
.	O
41	O
mmol	O
)	O
in	O
isobutanol	B-Chemical
(	O
3	O
mL	O
"),"	O
was	O
added	O
TFA	B-Chemical
(	O
0	O
.	O
12	O
mL	O
","	O
1	O
.	O
55	O
mmol	O
).	O
The	O
mixture	O
was	O
heated	O
to	O
100	O
Â°	O
C	O
and	O
stirred	O
for	O
5	O
h	O
.	O
After	O
cooling	O
down	O
to	O
room	O
temperature	O
","	O
the	O
mixture	O
was	O
quenched	O
with	O
Et3N	B-Chemical
(	O
3	O
mL	O
)	O
and	O
concentrated	O
in	O
vacuo	O
to	O
give	O
a	O
residue	O
","	O
which	O
was	O
purified	O
by	O
silica	B-Chemical
gel	O
column	O
chromatography	O
(	O
CH2Cl2	B-Chemical
/	O
MeOH	B-Chemical
:	O
30	O
/	O
1	O
)	O
to	O
give	O
1a	O
(	O
82	O
mg	O
","	O
69	O
%)	O
as	O
a	O
pale	O
yellow	O
powder	O
:	O
1H	B-Chemical
NMR	O
(	O
400	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
8	O
.	O
10	O
(	O
d	O
","	O
J	O
=	O
8	O
.	O
8	O
Hz	O
","	O
1	O
H	O
"),"	O
8	O
.	O
8	O
(	O
s	O
","	O
1	O
H	O
"),"	O
7	O
.	O
35	O
(	O
br	O
s	O
","	O
1	O
H	O
"),"	O
6	O
.	O
56	O
(	O
dd	O
","	O
J	O
=	O
2	O
.	O
4	O
","	O
8	O
.	O
8	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
52	O
(	O
d	O
-	O
like	O
","	O
J	O
=	O
2	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
30	O
(	O
dd	O
","	O
J	O
=	O
1	O
.	O
2	O
","	O
17	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
11	O
(	O
m	O
","	O
2	O
H	O
"),"	O
5	O
.	O
91	O
(	O
d	O
","	O
J	O
=	O
3	O
.	O
6	O
Hz	O
","	O
1	O
H	O
","	O
H	O
-	O
1	O
"),"	O
5	O
.	O
67	O
(	O
dd	O
","	O
J	O
=	O
1	O
.	O
2	O
","	O
10	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
66	O
(	O
m	O
","	O
2	O
H	O
"),"	O
4	O
.	O
59	O
â€“	O
4	O
.	O
49	O
(	O
m	O
","	O
3	O
H	O
"),"	O
4	O
.	O
22	O
(	O
m	O
","	O
1	O
H	O
"),"	O
3	O
.	O
86	O
(	O
s	O
","	O
3	O
H	O
"),"	O
3	O
.	O
16	O
(	O
t	O
-	O
like	O
","	O
J	O
=	O
5	O
.	O
2	O
Hz	O
","	O
4	O
H	O
"),"	O
2	O
.	O
58	O
(	O
t	O
-	O
like	O
","	O
J	O
=	O
5	O
.	O
2	O
Hz	O
","	O
4	O
H	O
"),"	O
2	O
.	O
34	O
(	O
s	O
","	O
3	O
H	O
"),"	O
1	O
.	O
58	O
(	O
s	O
","	O
3	O
H	O
"),"	O
1	O
.	O
35	O
(	O
s	O
","	O
3	O
H	O
);	O
13C	B-Chemical
NMR	O
(	O
100	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
165	O
.	O
4	O
","	O
164	O
.	O
1	O
","	O
157	O
.	O
9	O
","	O
156	O
.	O
5	O
","	O
149	O
.	O
2	O
","	O
147	O
.	O
5	O
","	O
130	O
.	O
2	O
","	O
127	O
.	O
8	O
","	O
122	O
.	O
0	O
","	O
120	O
.	O
0	O
","	O
112	O
.	O
9	O
","	O
108	O
.	O
3	O
","	O
106	O
.	O
2	O
","	O
104	O
.	O
8	O
","	O
100	O
.	O
6	O
","	O
79	O
.	O
1	O
","	O
78	O
.	O
2	O
","	O
66	O
.	O
6	O
","	O
55	O
.	O
8	O
","	O
55	O
.	O
3	O
","	O
52	O
.	O
7	O
","	O
50	O
.	O
2	O
","	O
46	O
.	O
2	O
","	O
26	O
.	O
8	O
","	O
26	O
.	O
5	O
;	O
HRMS	O
(	O
ESI	O
)	O
m	O
/	O
z	O
calcd	O
for	O
C27H36O6N6ClNa	B-Chemical
[	O
M	O
+	O
H	B-Chemical
]+	O
575	O
.	O
2385	O
","	O
found	O
575	O
.	O
2385	O
.	O
3	B-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
deoxy	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
O	I-Chemical
-[	I-Chemical
5	I-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
N	I-Chemical
-(	I-Chemical
2	I-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
methylpiperazin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
phenyl	I-Chemical
)	I-Chemical
pyrimidin	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
yl	I-Chemical
]-	I-Chemical
d	I-Chemical
-	I-Chemical
ribofuranose	I-Chemical
1b	O
A	O
solution	O
of	O
compound	O
1a	O
(	O
58	O
mg	O
","	O
0	O
.	O
10	O
mmol	O
)	O
in	O
TFA	B-Chemical
/	O
acetic	B-Chemical
acid	I-Chemical
/	O
water	B-Chemical
(	O
1	O
/	O
15	O
/	O
4	O
","	O
v	O
/	O
v	O
/	O
v	O
","	O
5	O
mL	O
)	O
was	O
stirred	O
at	O
70	O
Â°	O
C	O
for	O
7	O
h	O
.	O
Concentration	O
in	O
vacuo	O
and	O
elution	O
through	O
reverse	O
phase	O
C	O
-	O
18	O
column	O
(	O
H2O	B-Chemical
/	O
MeOH	B-Chemical
:	O
2	O
/	O
3	O
)	O
provided	O
1b	O
(	O
44	O
mg	O
","	O
83	O
%)	O
as	O
a	O
pale	O
yellow	O
syrup	O
:	O
1H	B-Chemical
NMR	O
(	O
400	O
MHz	O
","	O
CD3OD	B-Chemical
)	O
Î´	O
8	O
.	O
7	O
(	O
s	O
","	O
1	O
H	O
"),"	O
8	O
.	O
5	O
(	O
s	O
","	O
2	O
.	O
4	O
H	O
"),"	O
7	O
.	O
92	O
(	O
m	O
","	O
3	O
.	O
4	O
H	O
"),"	O
6	O
.	O
67	O
(	O
d	O
-	O
like	O
","	O
J	O
=	O
2	O
.	O
4	O
Hz	O
","	O
3	O
.	O
4	O
H	O
"),"	O
6	O
.	O
58	O
(	O
dd	O
","	O
J	O
=	O
2	O
.	O
8	O
","	O
8	O
.	O
8	O
Hz	O
","	O
3	O
.	O
4	O
H	O
"),"	O
6	O
.	O
35	O
(	O
m	O
","	O
3	O
.	O
4	O
H	O
"),"	O
6	O
.	O
21	O
(	O
m	O
","	O
3	O
.	O
4	O
H	O
"),"	O
5	O
.	O
67	O
(	O
m	O
","	O
3	O
.	O
4	O
H	O
"),"	O
5	O
.	O
38	O
(	O
d	O
","	O
J	O
=	O
4	O
.	O
0	O
Hz	O
","	O
1	O
H	O
"),"	O
5	O
.	O
22	O
(	O
s	O
","	O
2	O
.	O
4	O
H	O
"),"	O
4	O
.	O
67	O
(	O
m	O
","	O
2	O
.	O
4	O
H	O
"),"	O
4	O
.	O
58	O
(	O
m	O
","	O
3	O
.	O
4	O
H	O
"),"	O
4	O
.	O
49	O
(	O
m	O
","	O
4	O
.	O
4	O
H	O
"),"	O
4	O
.	O
34	O
â€“	O
4	O
.	O
24	O
(	O
m	O
","	O
4	O
.	O
4	O
H	O
"),"	O
4	O
.	O
0	O
(	O
d	O
-	O
like	O
","	O
J	O
=	O
4	O
.	O
4	O
Hz	O
","	O
2	O
.	O
4	O
H	O
"),"	O
3	O
.	O
87	O
(	O
s	O
","	O
10	O
.	O
2	O
H	O
"),"	O
3	O
.	O
78	O
(	O
m	O
","	O
6	O
.	O
8	O
H	O
"),"	O
3	O
.	O
58	O
(	O
m	O
","	O
6	O
.	O
8	O
H	O
"),"	O
3	O
.	O
26	O
(	O
m	O
","	O
6	O
.	O
8	O
H	O
"),"	O
3	O
.	O
3	O
(	O
m	O
","	O
6	O
.	O
8	O
H	O
"),"	O
2	O
.	O
96	O
(	O
s	O
","	O
10	O
.	O
2	O
H	O
);	O
HRMS	O
(	O
ESI	O
)	O
m	O
/	O
z	O
calcd	O
for	O
C24H32O6N6ClNa	B-Chemical
[	O
M	O
+	O
H	O
]+	O
535	O
.	O
2072	O
","	O
found	O
535	O
.	O
2079	O
.	O
2	B-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
isopropylidene	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
O	I-Chemical
-(	I-Chemical
2	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
dichloropyrimidin	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
yl	I-Chemical
)-	I-Chemical
Î±	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
ribofuranosyl	I-Chemical
acrylamide	I-Chemical
14	O
To	O
a	O
solution	O
of	O
compound	O
13	O
(	O
147	O
mg	O
","	O
0	O
.	O
60	O
mmol	O
)	O
in	O
anhydrous	O
CH2Cl2	B-Chemical
(	O
25	O
mL	O
)	O
at	O
room	O
temperature	O
","	O
was	O
added	O
DBU	B-Chemical
(	O
0	O
.	O
21	O
mL	O
","	O
1	O
.	O
42	O
mmol	O
)	O
and	O
2	B-Chemical
","	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
trichloropyrimidine	I-Chemical
6	O
(	O
0	O
.	O
12	O
mL	O
","	O
1	O
.	O
7	O
mmol	O
).	O
After	O
stirring	O
at	O
room	O
temperature	O
for	O
2	O
h	O
","	O
the	O
reaction	O
mixture	O
was	O
diluted	O
with	O
saturated	O
aqueous	O
NH4Cl	B-Chemical
","	O
and	O
extracted	O
with	O
CH2Cl2	B-Chemical
.	O
The	O
organic	O
layer	O
was	O
washed	O
with	O
brine	B-Chemical
","	O
dried	O
over	O
Na2SO4	B-Chemical
","	O
and	O
concentrated	O
in	O
vacuo	O
.	O
The	O
residue	O
was	O
purified	O
by	O
silica	B-Chemical
gel	O
chromatography	O
(	O
petroleum	B-Chemical
ether	I-Chemical
/	O
EtOAc	B-Chemical
:	O
5	O
/	O
1	O
)	O
to	O
give	O
14	O
(	O
217	O
mg	O
","	O
93	O
%)	O
as	O
a	O
colorless	O
syrup	O
:	O
1H	B-Chemical
NMR	O
(	O
400	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
8	O
.	O
36	O
(	O
s	O
","	O
1	O
H	O
"),"	O
6	O
.	O
58	O
(	O
d	O
","	O
J	O
=	O
9	O
.	O
2	O
Hz	O
","	O
1	O
H	O
","	O
NH	O
"),"	O
6	O
.	O
32	O
(	O
dd	O
","	O
J	O
=	O
1	O
.	O
2	O
","	O
17	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
15	O
(	O
dd	O
","	O
J	O
=	O
10	O
.	O
4	O
","	O
17	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
8	O
(	O
dd	O
","	O
J	O
=	O
4	O
.	O
0	O
","	O
9	O
.	O
2	O
Hz	O
","	O
1	O
H	O
","	O
H	O
-	O
1	O
"),"	O
5	O
.	O
72	O
(	O
dd	O
","	O
J	O
=	O
1	O
.	O
2	O
","	O
10	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
86	O
(	O
d	O
-	O
like	O
","	O
J	O
=	O
6	O
.	O
0	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
82	O
(	O
dd	O
","	O
J	O
=	O
4	O
.	O
4	O
","	O
6	O
.	O
0	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
55	O
(	O
m	O
","	O
2	O
H	O
"),"	O
4	O
.	O
45	O
(	O
t	O
","	O
J	O
=	O
2	O
.	O
8	O
Hz	O
","	O
1	O
H	O
"),"	O
1	O
.	O
57	O
(	O
s	O
","	O
3	O
H	O
"),"	O
1	O
.	O
38	O
(	O
s	O
","	O
3	O
H	O
);	O
13C	B-Chemical
NMR	O
(	O
100	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
165	O
.	O
1	O
","	O
165	O
.	O
0	O
","	O
157	O
.	O
7	O
","	O
157	O
.	O
4	O
","	O
130	O
.	O
6	O
","	O
128	O
.	O
2	O
","	O
116	O
.	O
8	O
","	O
113	O
.	O
4	O
","	O
82	O
.	O
3	O
","	O
81	O
.	O
6	O
","	O
79	O
.	O
7	O
","	O
79	O
.	O
4	O
","	O
70	O
.	O
4	O
","	O
26	O
.	O
4	O
","	O
24	O
.	O
8	O
;	O
HRMS	O
(	O
ESI	O
)	O
m	O
/	O
z	O
calcd	O
for	O
C15H17O5N3Cl2Na	B-Chemical
[	O
M	O
+	O
Na	B-Chemical
]+	O
412	O
.	O
443	O
","	O
found	O
412	O
.	O
448	O
.	O
5	B-Chemical
-	I-Chemical
O	I-Chemical
-[	I-Chemical
5	I-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
N	I-Chemical
-(	I-Chemical
2	I-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
methylpiperazin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
phenyl	I-Chemical
)	I-Chemical
pyrimidin	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
yl	I-Chemical
]-	I-Chemical
d	I-Chemical
-	I-Chemical
ribofuranosyl	I-Chemical
acrylamide	I-Chemical
1c	O
To	O
a	O
solution	O
of	O
compound	O
14	O
(	O
58	O
mg	O
","	O
0	O
.	O
15	O
mmol	O
)	O
and	O
aniline	B-Chemical
derivative	I-Chemical
8	O
(	O
66	O
mg	O
","	O
0	O
.	O
30	O
mmol	O
)	O
in	O
isobutanol	B-Chemical
(	O
3	O
mL	O
"),"	O
was	O
added	O
TFA	B-Chemical
(	O
0	O
.	O
84	O
mL	O
","	O
1	O
.	O
13	O
mmol	O
).	O
The	O
mixture	O
was	O
heated	O
to	O
100	O
Â°	O
C	O
and	O
stirred	O
for	O
5	O
h	O
.	O
After	O
cooling	O
down	O
to	O
room	O
temperature	O
","	O
the	O
mixture	O
was	O
quenched	O
with	O
Et3N	B-Chemical
(	O
3	O
mL	O
)	O
and	O
concentrated	O
in	O
vacuo	O
to	O
give	O
a	O
residue	O
","	O
which	O
was	O
purified	O
by	O
silica	B-Chemical
gel	O
column	O
chromatography	O
(	O
CH2Cl2	B-Chemical
/	O
MeOH	B-Chemical
:	O
30	O
/	O
1	O
)	O
to	O
give	O
15	O
(	O
60	O
mg	O
","	O
70	O
%)	O
as	O
a	O
pale	O
yellow	O
oil	O
:	O
HRMS	O
(	O
ESI	O
)	O
m	O
/	O
z	O
calcd	O
for	O
C27H36O6N6Cl	B-Chemical
[	O
M	O
+	O
H	O
]+	O
575	O
.	O
2385	O
","	O
found	O
575	O
.	O
2383	O
.	O
A	O
solution	O
of	O
compound	O
15	O
(	O
85	O
mg	O
","	O
0	O
.	O
15	O
mmol	O
)	O
in	O
TFA	B-Chemical
/	O
acetic	B-Chemical
acid	I-Chemical
/	O
water	B-Chemical
(	O
1	O
/	O
20	O
/	O
4	O
","	O
v	O
/	O
v	O
/	O
v	O
","	O
4	O
mL	O
)	O
was	O
stirred	O
at	O
50	O
Â°	O
C	O
for	O
5	O
h	O
.	O
Concentration	O
in	O
vacuo	O
and	O
elution	O
through	O
reverse	O
phase	O
C	O
-	O
18	O
column	O
(	O
H2O	B-Chemical
/	O
MeOH	B-Chemical
:	O
2	O
/	O
3	O
)	O
provided	O
1c	O
(	O
64	O
mg	O
","	O
80	O
%)	O
as	O
a	O
pale	O
yellow	O
syrup	O
.	O
1c	O
(	O
Î±	O
):	O
1H	B-Chemical
NMR	O
(	O
400	O
MHz	O
","	O
CD3OD	B-Chemical
)	O
Î´	O
8	O
.	O
6	O
(	O
s	O
","	O
1	O
H	O
"),"	O
7	O
.	O
88	O
(	O
d	O
","	O
J	O
=	O
8	O
.	O
8	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
63	O
(	O
d	O
-	O
like	O
","	O
J	O
=	O
2	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
53	O
(	O
dd	O
","	O
J	O
=	O
2	O
.	O
8	O
","	O
8	O
.	O
8	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
34	O
(	O
dd	O
","	O
J	O
=	O
10	O
.	O
0	O
","	O
17	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
27	O
(	O
dd	O
","	O
J	O
=	O
2	O
.	O
0	O
","	O
17	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
5	O
.	O
83	O
(	O
d	O
","	O
J	O
=	O
4	O
.	O
4	O
Hz	O
","	O
1	O
H	O
","	O
H	O
-	O
1	O
"),"	O
5	O
.	O
70	O
(	O
dd	O
","	O
J	O
=	O
2	O
.	O
0	O
","	O
10	O
.	O
0	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
57	O
(	O
dd	O
","	O
J	O
=	O
3	O
.	O
2	O
","	O
12	O
.	O
0	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
40	O
(	O
dd	O
","	O
J	O
=	O
4	O
.	O
0	O
","	O
11	O
.	O
6	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
25	O
(	O
m	O
","	O
3	O
H	O
"),"	O
3	O
.	O
85	O
(	O
s	O
","	O
3	O
H	O
"),"	O
3	O
.	O
16	O
(	O
t	O
","	O
J	O
=	O
4	O
.	O
8	O
Hz	O
","	O
4	O
H	O
"),"	O
2	O
.	O
61	O
(	O
t	O
","	O
J	O
=	O
4	O
.	O
8	O
Hz	O
","	O
4	O
H	O
"),"	O
2	O
.	O
34	O
(	O
s	O
","	O
3	O
H	O
);	O
13C	B-Chemical
NMR	O
(	O
100	O
MHz	O
","	O
CD3OD	B-Chemical
)	O
Î´	O
168	O
.	O
0	O
","	O
165	O
.	O
6	O
","	O
159	O
.	O
5	O
","	O
157	O
.	O
3	O
","	O
151	O
.	O
6	O
","	O
148	O
.	O
8	O
","	O
132	O
.	O
1	O
","	O
128	O
.	O
1	O
","	O
123	O
.	O
0	O
","	O
122	O
.	O
3	O
","	O
109	O
.	O
3	O
","	O
106	O
.	O
7	O
","	O
101	O
.	O
9	O
","	O
81	O
.	O
9	O
(	O
C	O
-	O
1	O
"),"	O
81	O
.	O
5	O
","	O
73	O
.	O
3	O
","	O
71	O
.	O
8	O
","	O
68	O
.	O
2	O
","	O
56	O
.	O
4	O
","	O
55	O
.	O
8	O
","	O
50	O
.	O
2	O
","	O
45	O
.	O
6	O
;	O
1c	O
(	O
Î²	O
):	O
1H	B-Chemical
NMR	O
(	O
400	O
MHz	O
","	O
CD3OD	B-Chemical
)	O
Î´	O
8	O
.	O
5	O
(	O
s	O
","	O
1	O
H	O
"),"	O
7	O
.	O
87	O
(	O
d	O
","	O
J	O
=	O
8	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
65	O
(	O
d	O
-	O
like	O
","	O
J	O
=	O
2	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
54	O
(	O
dd	O
","	O
J	O
=	O
2	O
.	O
4	O
","	O
8	O
.	O
8	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
23	O
(	O
m	O
","	O
2	O
H	O
"),"	O
5	O
.	O
67	O
(	O
dd	O
","	O
J	O
=	O
4	O
.	O
8	O
","	O
6	O
.	O
8	O
Hz	O
","	O
1	O
H	O
"),"	O
5	O
.	O
48	O
(	O
d	O
","	O
J	O
=	O
4	O
.	O
4	O
Hz	O
","	O
1	O
H	O
","	O
H	O
-	O
1	O
"),"	O
4	O
.	O
58	O
(	O
dd	O
","	O
J	O
=	O
3	O
.	O
6	O
","	O
12	O
.	O
0	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
41	O
(	O
dd	O
","	O
J	O
=	O
4	O
.	O
8	O
","	O
12	O
.	O
0	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
24	O
â€“	O
4	O
.	O
14	O
(	O
m	O
","	O
2	O
H	O
"),"	O
4	O
.	O
3	O
(	O
t	O
","	O
J	O
=	O
4	O
.	O
8	O
Hz	O
","	O
1	O
H	O
"),"	O
3	O
.	O
84	O
(	O
s	O
","	O
3	O
H	O
"),"	O
3	O
.	O
76	O
(	O
m	O
","	O
2	O
H	O
"),"	O
3	O
.	O
57	O
(	O
m	O
","	O
2	O
H	O
"),"	O
3	O
.	O
23	O
(	O
m	O
","	O
2	O
H	O
"),"	O
3	O
.	O
0	O
(	O
m	O
","	O
2	O
H	O
"),"	O
2	O
.	O
93	O
(	O
s	O
","	O
3	O
H	O
);	O
HRMS	O
(	O
ESI	O
)	O
m	O
/	O
z	O
calcd	O
for	O
C24H32O6N6Cl	B-Chemical
[	O
M	O
+	O
H	B-Chemical
]+	O
535	O
.	O
2072	O
","	O
found	O
535	O
.	O
2087	O
.	O
5	B-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
tert	I-Chemical
-	I-Chemical
butyldiphenylsilyl	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-(	I-Chemical
2	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
dichloropyrimidin	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
yl	I-Chemical
)-	I-Chemical
2	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
tert	I-Chemical
-	I-Chemical
butyldimethylsilyl	I-Chemical
-	I-Chemical
Î²	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
ribofuranosyl	I-Chemical
azide	I-Chemical
21	O
To	O
a	O
solution	O
of	O
compound	O
19	O
(	O
0	O
.	O
86	O
g	O
","	O
1	O
.	O
63	O
mmol	O
)	O
in	O
anhydrous	O
CH2Cl2	B-Chemical
(	O
25	O
mL	O
)	O
at	O
room	O
temperature	O
","	O
was	O
added	O
tBuOLi	B-Chemical
(	O
1	O
.	O
83	O
g	O
","	O
22	O
.	O
82	O
mmol	O
)	O
and	O
2	B-Chemical
","	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
trichloropyrimidine	I-Chemical
6	O
(	O
0	O
.	O
37	O
mL	O
","	O
3	O
.	O
26	O
mmol	O
).	O
After	O
stirring	O
under	O
reflux	O
for	O
36	O
h	O
","	O
the	O
reaction	O
mixture	O
was	O
diluted	O
with	O
saturated	O
aqueous	O
NH4Cl	B-Chemical
","	O
and	O
extracted	O
with	O
CH2Cl2	B-Chemical
.	O
The	O
organic	O
layer	O
was	O
washed	O
with	O
brine	O
","	O
dried	O
over	O
Na2SO4	B-Chemical
","	O
and	O
concentrated	O
in	O
vacuo	O
.	O
The	O
residue	O
was	O
purified	O
by	O
silica	B-Chemical
gel	O
chromatography	O
(	O
petroleum	B-Chemical
ether	I-Chemical
/	O
EtOAc	B-Chemical
:	O
80	O
/	O
1	O
)	O
to	O
give	O
21	O
(	O
0	O
.	O
88	O
g	O
","	O
80	O
%)	O
as	O
a	O
pale	O
yellow	O
syrup	O
:	O
1H	B-Chemical
NMR	O
(	O
400	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
8	O
.	O
34	O
(	O
s	O
","	O
1	O
H	O
"),"	O
7	O
.	O
71	O
â€“	O
7	O
.	O
67	O
(	O
m	O
","	O
4	O
H	O
"),"	O
7	O
.	O
45	O
â€“	O
7	O
.	O
34	O
(	O
m	O
","	O
6	O
H	O
"),"	O
5	O
.	O
66	O
(	O
t	O
","	O
J	O
=	O
4	O
.	O
8	O
Hz	O
","	O
1	O
H	O
","	O
H	O
-	O
3	O
"),"	O
5	O
.	O
25	O
(	O
d	O
","	O
J	O
=	O
3	O
.	O
6	O
Hz	O
","	O
1	O
H	O
","	O
H	O
-	O
1	O
"),"	O
4	O
.	O
40	O
(	O
dd	O
","	O
J	O
=	O
3	O
.	O
6	O
","	O
7	O
.	O
6	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
33	O
(	O
t	O
","	O
J	O
=	O
4	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
3	O
.	O
91	O
(	O
dd	O
","	O
J	O
=	O
4	O
.	O
0	O
","	O
11	O
.	O
6	O
Hz	O
","	O
1	O
H	O
"),"	O
3	O
.	O
84	O
(	O
dd	O
","	O
J	O
=	O
3	O
.	O
6	O
","	O
11	O
.	O
6	O
Hz	O
","	O
1	O
H	O
"),"	O
1	O
.	O
9	O
(	O
s	O
","	O
9	O
H	O
"),"	O
0	O
.	O
75	O
(	O
s	O
","	O
9	O
H	O
"),"	O
0	O
.	O
5	O
(	O
s	O
","	O
3	O
H	O
"),"	O
âˆ’	O
0	O
.	O
15	O
(	O
s	O
","	O
3	O
H	O
);	O
HRMS	O
(	O
ESI	O
)	O
m	O
/	O
z	O
calcd	O
for	O
C31H42O4N5Cl2Si2	B-Chemical
[	O
M	O
+	O
H	B-Chemical
]+	O
674	O
.	O
2152	O
","	O
found	O
674	O
.	O
2155	O
.	O
5	B-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
tert	I-Chemical
-	I-Chemical
butyldiphenylsilyl	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-[	I-Chemical
5	I-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
N	I-Chemical
-(	I-Chemical
2	I-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
methylpiperazin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
phenyl	I-Chemical
)	I-Chemical
pyrimidin	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
yl	I-Chemical
]-	I-Chemical
2	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
tert	I-Chemical
-	I-Chemical
butyldimethylsilyl	I-Chemical
-	I-Chemical
Î²	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
ribofuranosyl	I-Chemical
azide	I-Chemical
22	O
To	O
a	O
solution	O
of	O
compound	O
21	O
(	O
0	O
.	O
53	O
g	O
","	O
0	O
.	O
79	O
mmol	O
)	O
and	O
aniline	B-Chemical
derivative	I-Chemical
8	O
(	O
0	O
.	O
70	O
g	O
","	O
3	O
.	O
16	O
mmol	O
)	O
in	O
isobutanol	B-Chemical
(	O
12	O
mL	O
"),"	O
was	O
added	O
TFA	B-Chemical
(	O
1	O
.	O
47	O
mL	O
","	O
19	O
.	O
75	O
mmol	O
).	O
The	O
mixture	O
was	O
heated	O
to	O
100	O
Â°	O
C	O
and	O
stirred	O
for	O
5	O
h	O
.	O
After	O
cooling	O
down	O
to	O
room	O
temperature	O
","	O
the	O
mixture	O
was	O
quenched	O
with	O
Et3N	B-Chemical
(	O
8	O
mL	O
)	O
and	O
concentrated	O
in	O
vacuo	O
to	O
give	O
a	O
residue	O
","	O
which	O
was	O
purified	O
by	O
silica	B-Chemical
gel	O
column	O
chromatography	O
(	O
CH2Cl2	B-Chemical
/	O
MeOH	B-Chemical
:	O
30	O
/	O
1	O
)	O
to	O
give	O
22	O
(	O
0	O
.	O
47	O
g	O
","	O
69	O
%)	O
as	O
a	O
white	O
powder	O
:	O
1H	B-Chemical
NMR	O
(	O
400	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
8	O
.	O
12	O
(	O
s	O
","	O
1	O
H	O
"),"	O
8	O
.	O
8	O
(	O
d	O
","	O
J	O
=	O
9	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
7	O
.	O
69	O
(	O
dd	O
","	O
J	O
=	O
1	O
.	O
6	O
","	O
7	O
.	O
6	O
Hz	O
","	O
2	O
H	O
"),"	O
7	O
.	O
63	O
(	O
dd	O
","	O
J	O
=	O
1	O
.	O
6	O
","	O
8	O
.	O
0	O
Hz	O
","	O
2	O
H	O
"),"	O
7	O
.	O
43	O
â€“	O
7	O
.	O
25	O
(	O
m	O
","	O
6	O
H	O
"),"	O
6	O
.	O
54	O
(	O
m	O
","	O
2	O
H	O
"),"	O
5	O
.	O
58	O
(	O
dd	O
","	O
J	O
=	O
4	O
.	O
4	O
","	O
7	O
.	O
2	O
Hz	O
","	O
1	O
H	O
","	O
H	O
-	O
3	O
"),"	O
5	O
.	O
29	O
(	O
d	O
","	O
J	O
=	O
1	O
.	O
6	O
Hz	O
","	O
1	O
H	O
","	O
H	O
-	O
1	O
"),"	O
4	O
.	O
47	O
(	O
m	O
","	O
1	O
H	O
"),"	O
4	O
.	O
38	O
(	O
dd	O
","	O
J	O
=	O
2	O
.	O
0	O
","	O
4	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
2	O
(	O
dd	O
","	O
J	O
=	O
2	O
.	O
8	O
","	O
11	O
.	O
6	O
Hz	O
","	O
1	O
H	O
"),"	O
3	O
.	O
88	O
(	O
s	O
","	O
3	O
H	O
"),"	O
3	O
.	O
83	O
(	O
dd	O
","	O
J	O
=	O
3	O
.	O
6	O
","	O
12	O
.	O
0	O
Hz	O
","	O
1	O
H	O
"),"	O
3	O
.	O
17	O
(	O
t	O
","	O
J	O
=	O
5	O
.	O
2	O
Hz	O
","	O
4	O
H	O
"),"	O
2	O
.	O
61	O
(	O
t	O
","	O
J	O
=	O
4	O
.	O
8	O
Hz	O
","	O
4	O
H	O
"),"	O
2	O
.	O
37	O
(	O
s	O
","	O
3	O
H	O
"),"	O
1	O
.	O
6	O
(	O
s	O
","	O
9	O
H	O
"),"	O
0	O
.	O
78	O
(	O
s	O
","	O
9	O
H	O
"),"	O
âˆ’	O
0	O
.	O
7	O
(	O
s	O
","	O
3	O
H	O
"),"	O
âˆ’	O
0	O
.	O
25	O
(	O
s	O
","	O
3	O
H	O
);	O
13C	B-Chemical
NMR	O
(	O
100	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
163	O
.	O
6	O
","	O
157	O
.	O
9	O
","	O
156	O
.	O
9	O
","	O
149	O
.	O
3	O
","	O
147	O
.	O
6	O
","	O
135	O
.	O
8	O
","	O
135	O
.	O
7	O
","	O
133	O
.	O
1	O
","	O
133	O
.	O
0	O
","	O
129	O
.	O
9	O
","	O
127	O
.	O
9	O
","	O
127	O
.	O
8	O
","	O
121	O
.	O
8	O
","	O
120	O
.	O
1	O
","	O
108	O
.	O
4	O
","	O
106	O
.	O
1	O
","	O
100	O
.	O
6	O
","	O
95	O
.	O
8	O
","	O
81	O
.	O
6	O
","	O
74	O
.	O
7	O
","	O
74	O
.	O
2	O
","	O
62	O
.	O
8	O
","	O
55	O
.	O
8	O
","	O
55	O
.	O
3	O
","	O
50	O
.	O
1	O
","	O
46	O
.	O
3	O
","	O
26	O
.	O
9	O
","	O
25	O
.	O
6	O
","	O
19	O
.	O
3	O
","	O
18	O
.	O
0	O
","	O
âˆ’	O
4	O
.	O
9	O
","	O
âˆ’	O
5	O
.	O
4	O
;	O
HRMS	O
(	O
ESI	O
)	O
m	O
/	O
z	O
calcd	O
for	O
C43H60O5N8ClSi2	B-Chemical
[	O
M	O
+	O
H	O
]+	O
859	O
.	O
3914	O
","	O
found	O
859	O
.	O
3920	O
.	O
5	B-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
tert	I-Chemical
-	I-Chemical
butyldiphenylsilyl	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-[	I-Chemical
5	I-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
N	I-Chemical
-(	I-Chemical
2	I-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
methylpiperazin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
phenyl	I-Chemical
)	I-Chemical
pyrimidin	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
yl	I-Chemical
]-	I-Chemical
2	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
tert	I-Chemical
-	I-Chemical
butyldimethylsilyl	I-Chemical
-	I-Chemical
Î±	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
ribofuranosyl	I-Chemical
acrylamide	I-Chemical
23	O
A	O
mixture	O
of	O
compound	O
22	O
(	O
190	O
mg	O
","	O
0	O
.	O
22	O
mmol	O
)	O
and	O
Pd	B-Chemical
/	O
C	B-Chemical
(	O
50	O
mg	O
","	O
10	O
%)	O
in	O
EtOH	B-Chemical
(	O
7	O
mL	O
)	O
was	O
stirred	O
under	O
an	O
atmosphere	O
of	O
H2	B-Chemical
at	O
room	O
temperature	O
for	O
overnight	O
.	O
The	O
mixture	O
was	O
filtered	O
through	O
celite	B-Chemical
","	O
washed	O
with	O
EtOH	B-Chemical
and	O
concentrated	O
in	O
vacuo	O
to	O
afford	O
the	O
corresponding	O
amine	B-Chemical
for	O
the	O
next	O
step	O
without	O
further	O
purification	O
.	O
To	O
a	O
solution	O
of	O
the	O
resulting	O
amine	B-Chemical
in	O
CH2Cl2	B-Chemical
(	O
7	O
mL	O
)	O
at	O
room	O
temperature	O
","	O
was	O
added	O
DCC	B-Chemical
(	O
69	O
mg	O
","	O
0	O
.	O
33	O
mmol	O
"),"	O
DMAP	B-Chemical
(	O
41	O
mg	O
","	O
0	O
.	O
33	O
mmol	O
"),"	O
and	O
acrylic	B-Chemical
acid	I-Chemical
(	O
0	O
.	O
61	O
mL	O
","	O
0	O
.	O
89	O
mmol	O
).	O
After	O
stirring	O
at	O
room	O
temperature	O
for	O
4	O
h	O
","	O
the	O
mixture	O
was	O
concentrated	O
in	O
vacuo	O
to	O
give	O
a	O
residue	O
","	O
which	O
was	O
purified	O
by	O
silica	B-Chemical
gel	O
column	O
chromatography	O
(	O
CH2Cl2	B-Chemical
/	O
MeOH	B-Chemical
:	O
30	O
/	O
1	O
)	O
to	O
afford	O
23	O
(	O
76	O
mg	O
","	O
39	O
%	O
over	O
two	O
steps	O
)	O
as	O
a	O
pale	O
yellow	O
syrup	O
:	O
1H	B-Chemical
NMR	O
(	O
400	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
8	O
.	O
17	O
(	O
s	O
","	O
1	O
H	O
"),"	O
8	O
.	O
9	O
(	O
d	O
","	O
J	O
=	O
8	O
.	O
8	O
Hz	O
","	O
1	O
H	O
"),"	O
7	O
.	O
71	O
(	O
m	O
","	O
4	O
H	O
"),"	O
7	O
.	O
43	O
â€“	O
7	O
.	O
36	O
(	O
m	O
","	O
6	O
H	O
"),"	O
7	O
.	O
12	O
(	O
d	O
","	O
J	O
=	O
9	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
53	O
(	O
d	O
","	O
J	O
=	O
2	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
42	O
(	O
m	O
","	O
1	O
H	O
"),"	O
6	O
.	O
36	O
(	O
dd	O
","	O
J	O
=	O
1	O
.	O
2	O
","	O
16	O
.	O
8	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
14	O
(	O
dd	O
","	O
J	O
=	O
10	O
.	O
4	O
","	O
17	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
2	O
(	O
d	O
-	O
like	O
","	O
J	O
=	O
4	O
.	O
8	O
Hz	O
","	O
1	O
H	O
"),"	O
5	O
.	O
98	O
(	O
dd	O
","	O
J	O
=	O
6	O
.	O
0	O
","	O
9	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
5	O
.	O
70	O
(	O
dd	O
","	O
J	O
=	O
1	O
.	O
2	O
","	O
10	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
72	O
(	O
dd	O
","	O
J	O
=	O
5	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
36	O
(	O
br	O
s	O
","	O
1	O
H	O
"),"	O
3	O
.	O
86	O
(	O
m	O
","	O
5	O
H	O
"),"	O
3	O
.	O
7	O
(	O
br	O
s	O
","	O
4	O
H	O
"),"	O
2	O
.	O
54	O
(	O
br	O
s	O
","	O
4	O
H	O
"),"	O
2	O
.	O
35	O
(	O
s	O
","	O
3	O
H	O
"),"	O
1	O
.	O
11	O
(	O
s	O
","	O
9	O
H	O
"),"	O
0	O
.	O
68	O
(	O
s	O
","	O
9	O
H	O
"),"	O
âˆ’	O
0	O
.	O
2	O
(	O
s	O
","	O
3	O
H	O
"),"	O
âˆ’	O
0	O
.	O
9	O
(	O
s	O
","	O
3	O
H	O
);	O
13C	B-Chemical
NMR	O
(	O
100	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
165	O
.	O
9	O
","	O
164	O
.	O
0	O
","	O
157	O
.	O
8	O
","	O
157	O
.	O
0	O
","	O
149	O
.	O
3	O
","	O
147	O
.	O
6	O
","	O
135	O
.	O
8	O
","	O
135	O
.	O
5	O
","	O
133	O
.	O
4	O
","	O
132	O
.	O
5	O
","	O
131	O
.	O
0	O
","	O
130	O
.	O
1	O
","	O
130	O
.	O
0	O
","	O
128	O
.	O
9	O
","	O
128	O
.	O
0	O
","	O
127	O
.	O
4	O
","	O
121	O
.	O
5	O
","	O
120	O
.	O
0	O
","	O
108	O
.	O
1	O
","	O
105	O
.	O
8	O
","	O
100	O
.	O
4	O
","	O
82	O
.	O
2	O
","	O
80	O
.	O
4	O
","	O
77	O
.	O
4	O
","	O
71	O
.	O
0	O
","	O
64	O
.	O
2	O
","	O
55	O
.	O
7	O
","	O
55	O
.	O
2	O
","	O
49	O
.	O
9	O
","	O
46	O
.	O
2	O
","	O
27	O
.	O
0	O
","	O
25	O
.	O
4	O
","	O
19	O
.	O
5	O
","	O
17	O
.	O
7	O
","	O
âˆ’	O
5	O
.	O
1	O
","	O
âˆ’	O
5	O
.	O
3	O
;	O
HRMS	O
(	O
ESI	O
)	O
m	O
/	O
z	O
calcd	O
for	O
C46H64O6N6ClSi2	B-Chemical
[	O
M	O
+	O
H	B-Chemical
]+	O
887	O
.	O
4114	O
","	O
found	O
887	O
.	O
4116	O
.	O
3	B-Chemical
-	I-Chemical
O	I-Chemical
-[	I-Chemical
5	I-Chemical
-	I-Chemical
chloro	I-Chemical
-	I-Chemical
2	I-Chemical
-	I-Chemical
N	I-Chemical
-(	I-Chemical
2	I-Chemical
-	I-Chemical
methoxy	I-Chemical
-	I-Chemical
4	I-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
methylpiperazin	I-Chemical
-	I-Chemical
1	I-Chemical
-	I-Chemical
yl	I-Chemical
)	I-Chemical
phenyl	I-Chemical
)	I-Chemical
pyrimidin	I-Chemical
-	I-Chemical
4	I-Chemical
-	I-Chemical
yl	I-Chemical
]-	I-Chemical
2	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
tert	I-Chemical
-	I-Chemical
butyldimethylsilyl	I-Chemical
-	I-Chemical
Î±	I-Chemical
-	I-Chemical
d	I-Chemical
-	I-Chemical
ribofuranosyl	I-Chemical
acrylamide	I-Chemical
1d	O
To	O
a	O
solution	O
of	O
compound	O
23	O
(	O
91	O
mg	O
","	O
0	O
.	O
11	O
mmol	O
)	O
in	O
pyridine	B-Chemical
(	O
3	O
mL	O
)	O
at	O
room	O
temperature	O
","	O
was	O
added	O
HF	B-Chemical
Â·	O
pyridine	B-Chemical
(	O
0	O
.	O
19	O
mL	O
).	O
After	O
stirring	O
at	O
room	O
temperature	O
for	O
overnight	O
","	O
the	O
mixture	O
was	O
poured	O
into	O
saturated	O
aqueous	O
NaHCO3	B-Chemical
and	O
extracted	O
with	O
CH2Cl2	B-Chemical
.	O
The	O
combined	O
organic	O
layers	O
were	O
washed	O
with	O
brine	B-Chemical
","	O
dried	O
over	O
Na2SO4	B-Chemical
","	O
and	O
concentrated	O
in	O
vacuo	O
.	O
The	O
residue	O
was	O
purified	O
by	O
silica	B-Chemical
gel	O
column	O
chromatography	O
(	O
CH2Cl2	B-Chemical
/	O
MeOH	B-Chemical
:	O
20	O
/	O
1	O
)	O
to	O
afford	O
1d	O
(	O
40	O
mg	O
","	O
68	O
%)	O
as	O
a	O
pale	O
yellow	O
syrup	O
:	O
1H	B-Chemical
NMR	O
(	O
400	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
8	O
.	O
15	O
(	O
s	O
","	O
1	O
H	O
"),"	O
8	O
.	O
2	O
(	O
d	O
","	O
J	O
=	O
8	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
7	O
.	O
71	O
(	O
m	O
","	O
4	O
H	O
"),"	O
7	O
.	O
30	O
(	O
br	O
s	O
","	O
1	O
H	O
"),"	O
7	O
.	O
6	O
(	O
d	O
","	O
J	O
=	O
8	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
54	O
(	O
m	O
","	O
2	O
H	O
"),"	O
6	O
.	O
33	O
(	O
d	O
-	O
like	O
","	O
J	O
=	O
17	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
6	O
.	O
12	O
(	O
dd	O
","	O
J	O
=	O
10	O
.	O
0	O
","	O
16	O
.	O
8	O
Hz	O
","	O
1	O
H	O
"),"	O
5	O
.	O
90	O
(	O
dd	O
","	O
J	O
=	O
6	O
.	O
0	O
","	O
8	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
5	O
.	O
73	O
(	O
m	O
","	O
2	O
H	O
"),"	O
4	O
.	O
51	O
(	O
t	O
","	O
J	O
=	O
5	O
.	O
6	O
Hz	O
","	O
1	O
H	O
"),"	O
4	O
.	O
30	O
(	O
br	O
s	O
","	O
1	O
H	O
"),"	O
3	O
.	O
87	O
(	O
s	O
","	O
3	O
H	O
"),"	O
3	O
.	O
82	O
(	O
d	O
-	O
like	O
","	O
J	O
=	O
12	O
.	O
4	O
Hz	O
","	O
1	O
H	O
"),"	O
3	O
.	O
71	O
(	O
d	O
-	O
like	O
","	O
J	O
=	O
11	O
.	O
2	O
Hz	O
","	O
1	O
H	O
"),"	O
3	O
.	O
18	O
(	O
br	O
s	O
","	O
4	O
H	O
"),"	O
2	O
.	O
61	O
(	O
br	O
s	O
","	O
4	O
H	O
"),"	O
2	O
.	O
37	O
(	O
s	O
","	O
3	O
H	O
"),"	O
0	O
.	O
72	O
(	O
s	O
","	O
9	O
H	O
"),"	O
âˆ’	O
0	O
.	O
2	O
(	O
s	O
","	O
3	O
H	O
"),"	O
âˆ’	O
0	O
.	O
10	O
(	O
s	O
","	O
3	O
H	O
);	O
13C	B-Chemical
NMR	O
(	O
100	O
MHz	O
","	O
CDCl3	B-Chemical
)	O
Î´	O
166	O
.	O
1	O
","	O
163	O
.	O
8	O
","	O
157	O
.	O
9	O
","	O
157	O
.	O
0	O
","	O
149	O
.	O
6	O
","	O
147	O
.	O
5	O
","	O
130	O
.	O
9	O
","	O
127	O
.	O
7	O
","	O
121	O
.	O
9	O
","	O
120	O
.	O
5	O
","	O
108	O
.	O
6	O
","	O
106	O
.	O
1	O
","	O
100	O
.	O
8	O
","	O
82	O
.	O
1	O
","	O
80	O
.	O
6	O
","	O
76	O
.	O
3	O
","	O
70	O
.	O
9	O
","	O
62	O
.	O
5	O
","	O
55	O
.	O
8	O
","	O
55	O
.	O
0	O
","	O
49	O
.	O
6	O
","	O
45	O
.	O
7	O
","	O
25	O
.	O
5	O
","	O
17	O
.	O
9	O
","	O
âˆ’	O
5	O
.	O
0	O
","	O
âˆ’	O
5	O
.	O
2	O
;	O
HRMS	O
(	O
ESI	O
)	O
m	O
/	O
z	O
calcd	O
for	O
C30H46O6N6ClSi	B-Chemical
[	O
M	O
+	O
H	O
]+	O
649	O
.	O
2937	O
","	O
found	O
649	O
.	O
2940	O
.	O
Kinase	O
assay	O
Kinases	O
domain	O
of	O
EGFR	O
WT	O
and	O
EGFR	O
L858R	O
/	O
T790M	O
were	O
expressed	O
using	O
the	O
Bac	O
-	O
to	O
-	O
Bac	O
â„¢	O
baculo	O
virus	O
expression	O
system	O
(	O
Invitrogen	O
","	O
Carlsbad	O
","	O
CA	O
","	O
USA	O
)	O
and	O
purified	O
in	O
Ni	B-Chemical
-	I-Chemical
NTA	I-Chemical
columns	O
(	O
QIAGEN	O
Inc	O
".,"	O
Valencia	O
","	O
CA	O
","	O
USA	O
).	O
The	O
kinase	O
activity	O
was	O
evaluated	O
with	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
).	O
Briefly	O
","	O
20	O
Î¼g	O
/	O
mL	O
Poly	B-Chemical
(	I-Chemical
Glu	I-Chemical
","	I-Chemical
Tyr	I-Chemical
)	I-Chemical
4	I-Chemical
:	I-Chemical
1	I-Chemical
(	O
Sigma	O
","	O
St	O
.	O
Louis	O
","	O
MO	O
)	O
was	O
precoated	O
in	O
96	O
-	O
well	O
ELISA	O
plates	O
as	O
substrate	O
.	O
After	O
adding	O
50	O
Î¼L	O
of	O
10	O
Î¼mol	O
/	O
L	O
ATP	B-Chemical
solution	O
which	O
was	O
diluted	O
in	O
kinase	O
reaction	O
buffer	O
(	O
50	O
mM	O
HEPES	B-Chemical
pH	O
7	O
.	O
4	O
","	O
20	O
mM	O
MgCl2	B-Chemical
","	O
0	O
.	O
1	O
mM	O
MnCl2	B-Chemical
","	O
0	O
.	O
2	O
mM	O
Na3VO4	B-Chemical
","	O
1	O
mM	O
DTT	B-Chemical
"),"	O
the	O
plate	O
was	O
treated	O
with	O
1	O
Î¼L	O
of	O
indicated	O
concentrations	O
of	O
compounds	O
(	O
dissolved	O
in	O
DMSO	B-Chemical
)	O
per	O
well	O
.	O
Experiments	O
at	O
each	O
concentration	O
were	O
performed	O
in	O
duplicate	O
.	O
Reaction	O
was	O
initiated	O
by	O
adding	O
tyrosine	O
kinase	O
diluted	O
in	O
kinase	O
reaction	O
buffer	O
.	O
After	O
incubation	O
at	O
37	O
Â°	O
C	O
for	O
1	O
h	O
","	O
the	O
wells	O
were	O
washed	O
three	O
times	O
with	O
phosphate	B-Chemical
buffered	I-Chemical
saline	I-Chemical
(	O
PBS	B-Chemical
)	O
containing	O
0	O
.	O
1	O
%	O
Tween	B-Chemical
20	I-Chemical
(	O
T	B-Chemical
-	I-Chemical
PBS	I-Chemical
).	O
One	O
hundred	O
microliters	O
of	O
anti	O
-	O
phosphotyrosine	O
(	O
PY99	O
)	O
antibody	O
(	O
1	O
:	O
1	O
","	O
0	O
","	O
Santa	O
Cruz	O
Biotechnology	O
","	O
Santa	O
Cruz	O
","	O
CA	O
)	O
diluted	O
in	O
T	B-Chemical
-	I-Chemical
PBS	I-Chemical
containing	O
5	O
mg	O
/	O
mL	O
BSA	O
was	O
added	O
and	O
the	O
plate	O
was	O
incubated	O
at	O
37	O
Â°	O
C	O
for	O
30	O
min	O
.	O
After	O
the	O
plate	O
was	O
washed	O
three	O
times	O
","	O
100	O
Î¼L	O
horseradish	O
peroxidase	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
IgG	O
(	O
1	O
:	O
2	O
","	O
0	O
","	O
Calbiochem	O
","	O
SanDiego	O
","	O
CA	O
)	O
was	O
added	O
and	O
the	O
plate	O
was	O
incubated	O
at	O
37	O
Â°	O
C	O
for	O
30	O
min	O
.	O
The	O
plate	O
was	O
washed	O
","	O
added	O
with	O
100	O
Î¼L	O
citrate	B-Chemical
buffer	O
(	O
0	O
.	O
1	O
M	O
","	O
pH	O
5	O
.	O
5	O
)	O
containing	O
0	O
.	O
3	O
%	O
H2O2	B-Chemical
.	O
Then	O
2	O
mg	O
/	O
mL	O
o	B-Chemical
-	I-Chemical
phenylenediamine	I-Chemical
was	O
added	O
","	O
and	O
samples	O
were	O
incubated	O
at	O
room	O
temperature	O
until	O
color	O
emerged	O
.	O
The	O
reaction	O
was	O
terminated	O
immediately	O
by	O
adding	O
50	O
Î¼L	O
of	O
2	O
M	O
H2SO4	B-Chemical
.	O
Plate	O
was	O
read	O
using	O
a	O
multiwell	O
spectrophotometer	O
(	O
VERSAmax	O
"â„¢,"	O
Molecular	O
Devices	O
","	O
Sunnyvale	O
","	O
CA	O
","	O
USA	O
)	O
at	O
492	O
nm	O
.	O
The	O
inhibitory	O
rate	O
(%)	O
was	O
calculated	O
with	O
the	O
formula	O
:	O
[	O
1	O
âˆ’	O
(	O
A492	O
treated	O
/	O
A492	O
control	O
)]	O
Ã—	O
100	O
%.	O
IC50	O
values	O
were	O
calculated	O
from	O
the	O
inhibitory	O
curves	O
.	O
Molecular	O
docking	O
Protein	O
was	O
prepared	O
using	O
the	O
â€œ	O
Protein	O
Preparation	O
Wizard	O
â€	O
workflow	O
.	O
All	O
water	B-Chemical
molecules	O
were	O
removed	O
from	O
the	O
structure	O
of	O
the	O
complex	O
.	O
Hydrogen	B-Chemical
atoms	O
and	O
charges	O
were	O
added	O
during	O
a	O
brief	O
relaxation	O
.	O
After	O
optimizing	O
the	O
hydrogen	B-Chemical
bond	O
network	O
","	O
the	O
crystal	O
structure	O
was	O
minimized	O
using	O
the	O
OPLS_2005	O
force	O
field	O
with	O
the	O
maximum	O
root	O
mean	O
square	O
deviation	O
(	O
RMSD	O
)	O
value	O
of	O
0	O
.	O
3	O
Ã…	O
.	O
The	O
ligand	O
was	O
prepared	O
with	O
LigPrep	O
module	O
in	O
Maestro	O
","	O
including	O
adding	O
hydrogen	B-Chemical
atoms	O
","	O
ionizing	O
at	O
a	O
pH	O
range	O
from	O
5	O
.	O
0	O
to	O
9	O
.	O
0	O
","	O
and	O
producing	O
the	O
corresponding	O
low	O
-	O
energy	O
3D	O
structure	O
.	O
Pose	O
prediction	O
mode	O
of	O
Covalent	O
Docking	O
module	O
was	O
adopted	O
to	O
dock	O
the	O
molecules	O
into	O
the	O
ATP	B-Chemical
-	O
binding	O
site	O
with	O
the	O
default	O
parameters	O
.	O
The	O
center	O
of	O
the	O
grid	O
box	O
was	O
defined	O
with	O
the	O
intrinsic	O
ligand	O
and	O
Michael	O
addition	O
reaction	O
type	O
was	O
chosen	O
.	O
The	O
top	O
-	O
ranking	O
poses	O
of	O
molecule	O
1a	O
were	O
retained	O
.	O
EGFRT790M	O
/	O
L858R	O
structure	O
(	O
PDB	O
:	O
3IKA	O
)	O
was	O
retrieved	O
from	O
the	O
Protein	O
Data	O
Bank	O
and	O
covalent	O
docking	O
was	O
performed	O
with	O
maestro	O
(	O
SchrÃ¶dinger	O
","	O
Inc	O
".,"	O
version	O
10	O
.	O
2	O
).	O
Compound	O
1a	O
was	O
docked	O
into	O
the	O
EGFR	O
protein	O
as	O
an	O
irreversible	O
inhibitor	O
using	O
Covalent	O
Docking	O
module	O
.	O
The	O
docking	O
procedure	O
was	O
validated	O
by	O
re	O
-	O
docking	O
the	O
co	O
-	O
crystallized	O
ligand	O
WZ4002	B-Chemical
into	O
the	O
ATP	B-Chemical
binding	O
site	O
of	O
EGFRT790M	O
/	O
L858R	O
structure	O
.	O
The	O
details	O
of	O
the	O
docking	O
workflow	O
are	O
listed	O
below	O
:	O
Result	O
and	O
discussion	O
The	O
synthesis	O
of	O
3	B-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribose	I-Chemical
derivatives	I-Chemical
1a	I-Chemical
and	I-Chemical
1b	I-Chemical
commenced	O
with	O
3	B-Chemical
-	I-Chemical
amino	I-Chemical
ribose	I-Chemical
derivative	I-Chemical
3	I-Chemical
that	O
can	O
be	O
readily	O
prepared	O
from	O
d	B-Chemical
-	I-Chemical
xylose	I-Chemical
2	O
in	O
41	O
%	O
yield	O
over	O
six	O
steps	O
(	O
Scheme	O
1	O
;	O
Shie	O
et	O
al	O
".,"	O
).	O
Protection	O
of	O
the	O
primary	O
hydroxyl	O
group	O
in	O
3	O
with	O
TBDPSCl	B-Chemical
followed	O
by	O
condensation	O
with	O
acryloyl	B-Chemical
chloride	I-Chemical
using	O
Et3N	B-Chemical
as	O
base	O
gave	O
ribose	B-Chemical
derivative	I-Chemical
4	I-Chemical
in	O
92	O
%	O
yield	O
(	O
two	O
steps	O
).	O
Treatment	O
of	O
4	O
with	O
HF	B-Chemical
Â·	O
pyridine	B-Chemical
afforded	O
alcohol	B-Chemical
5	I-Chemical
in	O
71	O
%	O
yield	O
.	O
When	O
5	O
was	O
reacted	O
with	O
2	B-Chemical
","	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
trichloropyrimidine	I-Chemical
6	I-Chemical
in	O
the	O
presence	O
of	O
K2CO3	B-Chemical
or	O
DIPEA	B-Chemical
","	O
almost	O
no	O
desired	O
product	O
was	O
observed	O
.	O
Exhilaratingly	O
","	O
nucleophilic	O
reaction	O
of	O
5	O
with	O
6	O
employing	O
stronger	O
base	O
(	O
DBU	B-Chemical
)	O
as	O
promoter	O
proceeded	O
smoothly	O
to	O
provide	O
ribose	B-Chemical
derivative	I-Chemical
7	I-Chemical
in	O
excellent	O
yield	O
(	O
92	O
%).	O
Subjection	O
of	O
7	O
to	O
the	O
known	O
aniline	B-Chemical
derivative	I-Chemical
8	I-Chemical
(	O
Han	O
et	O
al	O
".,"	O
)	O
under	O
the	O
promotion	O
of	O
TFA	B-Chemical
in	O
isobutanol	B-Chemical
at	O
100	O
Â°	O
C	O
delivered	O
1a	O
in	O
69	O
%	O
yield	O
.	O
Removal	O
of	O
the	O
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
isopropylidene	I-Chemical
group	O
in	O
1a	O
with	O
TFA	B-Chemical
in	O
acetic	B-Chemical
acid	I-Chemical
and	O
water	B-Chemical
at	O
70	O
Â°	O
C	O
produced	O
1b	O
in	O
83	O
%	O
yield	O
.	O
Synthesis	O
of	O
3	B-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribose	I-Chemical
derivatives	I-Chemical
1a	I-Chemical
and	I-Chemical
1b	I-Chemical
.	O
For	O
the	O
synthesis	O
of	O
1	B-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribose	I-Chemical
derivative	I-Chemical
1c	I-Chemical
","	O
Î²	B-Chemical
-	I-Chemical
ribosyl	I-Chemical
azide	I-Chemical
10	O
was	O
conveniently	O
prepared	O
from	O
d	B-Chemical
-	I-Chemical
ribose	I-Chemical
9	I-Chemical
in	O
three	O
steps	O
and	O
53	O
%	O
yield	O
according	O
to	O
the	O
procedures	O
described	O
in	O
the	O
literature	O
(	O
Scheme	O
2	O
;	O
Bonache	O
et	O
al	O
".,"	O
).	O
The	O
acetyl	O
group	O
in	O
10	O
was	O
then	O
replaced	O
with	O
TBS	O
group	O
to	O
give	O
compound	O
11	O
in	O
85	O
%	O
yield	O
.	O
Hydrogenolysis	O
of	O
the	O
azide	B-Chemical
group	O
in	O
11	O
over	O
Pd	B-Chemical
/	O
C	B-Chemical
followed	O
by	O
condensation	O
with	O
acrylic	B-Chemical
acid	I-Chemical
in	O
the	O
presence	O
of	O
DCC	B-Chemical
and	O
DMAP	B-Chemical
afforded	O
a	O
mixture	O
of	O
ribose	B-Chemical
derivative	I-Chemical
12	I-Chemical
in	O
43	O
%	O
yield	O
(	O
Î±	O
/	O
Î²	O
=	O
1	O
:	O
1	O
;	O
Î±	O
-	O
anomer	O
:	O
Î´H	O
=	O
6	O
.	O
0	O
ppm	O
","	O
Î´C	O
=	O
81	O
.	O
4	O
ppm	O
;	O
Î²	O
-	O
anomer	O
:	O
Î´H	O
=	O
5	O
.	O
95	O
ppm	O
","	O
Î´C	O
=	O
87	O
.	O
2	O
ppm	O
"),"	O
which	O
were	O
easily	O
separated	O
by	O
silica	B-Chemical
gel	O
column	O
chromatography	O
(	O
Numao	O
et	O
al	O
".,"	O
;	O
Bonache	O
et	O
al	O
".,"	O
).	O
After	O
removal	O
of	O
the	O
TBS	O
group	O
in	O
12Î±	O
","	O
the	O
resulting	O
alcohol	B-Chemical
13	I-Chemical
reacted	O
with	O
6	O
in	O
the	O
presence	O
of	O
DBU	B-Chemical
to	O
produce	O
ribose	B-Chemical
derivative	I-Chemical
14	I-Chemical
in	O
an	O
excellent	O
93	O
%	O
yield	O
.	O
TFA	B-Chemical
-	O
promoted	O
reaction	O
of	O
14	O
with	O
aniline	B-Chemical
8	I-Chemical
led	O
to	O
15	O
in	O
70	O
%	O
yield	O
as	O
a	O
mixture	O
of	O
Î±	O
/	O
Î²	O
anomers	O
probably	O
arising	O
from	O
the	O
anomerization	O
of	O
the	O
1	B-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
ribose	I-Chemical
derivative	I-Chemical
under	O
strong	O
acidic	O
conditions	O
(	O
Boschelli	O
et	O
al	O
".,"	O
).	O
Finally	O
","	O
acidic	O
cleavage	O
of	O
the	O
isopropylidene	B-Chemical
group	O
of	O
15	O
in	O
the	O
mixture	O
of	O
TFA	B-Chemical
/	O
HOAc	B-Chemical
/	O
water	B-Chemical
provided	O
1c	O
in	O
80	O
%	O
yield	O
.	O
Synthesis	O
of	O
1	B-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribose	I-Chemical
derivative	I-Chemical
1c	I-Chemical
.	O
Synthetic	O
work	O
toward	O
1	B-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribose	I-Chemical
derivative	I-Chemical
1d	I-Chemical
started	O
from	O
replacement	O
of	O
the	O
2	B-Chemical
","	I-Chemical
3	I-Chemical
-	I-Chemical
isopropylidene	I-Chemical
group	O
of	O
azide	B-Chemical
10	I-Chemical
with	O
2	O
","	O
3	O
-	O
orthoester	O
group	O
by	O
treatment	O
with	O
TFA	B-Chemical
and	O
subsequent	O
protection	O
with	O
triethyl	B-Chemical
orthoacetate	I-Chemical
under	O
the	O
catalysis	O
of	O
TsOH	B-Chemical
Â·	I-Chemical
H2O	I-Chemical
","	O
affording	O
azide	B-Chemical
16	I-Chemical
in	O
76	O
%	O
yield	O
over	O
two	O
steps	O
(	O
Scheme	O
3	O
).	O
Substitution	O
of	O
the	O
acetyl	O
group	O
in	O
16	O
with	O
TBDPS	B-Chemical
group	O
and	O
subsequent	O
acidic	O
cleavage	O
of	O
the	O
orthoester	O
group	O
led	O
to	O
an	O
inseparable	O
mixture	O
of	O
2	B-Chemical
-	I-Chemical
acetyl	I-Chemical
and	I-Chemical
3	I-Chemical
-	I-Chemical
acetyl	I-Chemical
ribose	I-Chemical
derivatives	I-Chemical
17	I-Chemical
and	I-Chemical
18	I-Chemical
(	O
77	O
%	O
yield	O
over	O
three	O
steps	O
).	O
Treatment	O
of	O
the	O
mixture	O
of	O
17	O
and	O
18	O
with	O
TBSCl	B-Chemical
followed	O
by	O
removal	O
of	O
the	O
acetyl	O
groups	O
gave	O
alcohols	B-Chemical
19	I-Chemical
and	I-Chemical
20	I-Chemical
in	O
83	O
%	O
yield	O
","	O
allowing	O
for	O
the	O
separation	O
of	O
3	B-Chemical
-	I-Chemical
hydroxyl	I-Chemical
ribose	I-Chemical
derivative	I-Chemical
19	I-Chemical
from	O
2	B-Chemical
-	I-Chemical
hydroxyl	I-Chemical
ribose	I-Chemical
derivative	I-Chemical
20	I-Chemical
(	O
19	B-Chemical
:	O
20	B-Chemical
=	O
3	O
:	O
2	O
).	O
Nucleophilic	O
attack	O
of	O
19	O
on	O
6	O
required	O
stronger	O
basic	O
conditions	O
to	O
promote	O
the	O
reaction	O
due	O
to	O
the	O
steric	O
hindrance	O
of	O
the	O
silyl	O
groups	O
on	O
19	O
.	O
As	O
such	O
","	O
excess	O
tBuOLi	B-Chemical
in	O
dichloromethane	B-Chemical
under	O
reflux	O
was	O
employed	O
for	O
this	O
conversion	O
","	O
providing	O
ribose	B-Chemical
derivative	I-Chemical
21	I-Chemical
in	O
80	O
%	O
yield	O
.	O
TFA	B-Chemical
-	O
promoted	O
coupling	O
of	O
21	O
with	O
aniline	B-Chemical
8	I-Chemical
generated	O
ribose	B-Chemical
derivative	I-Chemical
22	I-Chemical
(	O
69	O
"%),"	O
which	O
was	O
then	O
subjected	O
to	O
hydrogenolysis	O
over	O
Pd	B-Chemical
/	O
C	B-Chemical
and	O
subsequent	O
condensation	O
with	O
acrylic	B-Chemical
acid	I-Chemical
to	O
afford	O
ribose	B-Chemical
derivative	I-Chemical
23	I-Chemical
as	O
single	O
anomer	O
in	O
moderate	O
yield	O
(	O
39	O
%	O
over	O
two	O
steps	O
).	O
Exposure	O
of	O
23	O
to	O
HF	B-Chemical
Â·	O
pyridine	B-Chemical
in	O
pyridine	B-Chemical
resulted	O
in	O
cleavage	O
of	O
the	O
TBDPS	B-Chemical
group	O
without	O
affecting	O
the	O
TBS	O
group	O
","	O
providing	O
1d	O
in	O
68	O
%	O
yield	O
.	O
Synthesis	O
of	O
1	B-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribose	I-Chemical
derivative	I-Chemical
1d	I-Chemical
.	O
To	O
determine	O
whether	O
the	O
Michael	O
acceptor	O
played	O
a	O
significant	O
role	O
in	O
the	O
inhibitory	O
activity	O
of	O
ribose	B-Chemical
-	I-Chemical
modified	I-Chemical
pyrimidine	I-Chemical
derivatives	I-Chemical
against	O
EGFR	O
tyrosine	O
kinase	O
","	O
1	B-Chemical
-	I-Chemical
azide	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribose	I-Chemical
derivative	I-Chemical
24	I-Chemical
","	O
1	B-Chemical
-	I-Chemical
azide	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribose	I-Chemical
derivative	I-Chemical
25	I-Chemical
","	O
and	O
5	B-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribose	I-Chemical
derivative	I-Chemical
26	I-Chemical
were	O
readily	O
synthesized	O
following	O
the	O
similar	O
procedures	O
described	O
for	O
1a	O
-	O
1d	O
(	O
Table	O
1	O
;	O
see	O
Supplementary	O
Material	O
for	O
details	O
).	O
In	O
vitro	O
inhibitory	O
activities	O
of	O
ribose	B-Chemical
-	I-Chemical
modified	I-Chemical
pyrimidine	I-Chemical
derivatives	I-Chemical
1a	I-Chemical
â€“	I-Chemical
1d	I-Chemical
and	I-Chemical
24	I-Chemical
â€“	I-Chemical
26	I-Chemical
against	O
EGFR	O
tyrosine	O
kinase	O
.	O
Kinase	O
activity	O
assays	O
were	O
examined	O
by	O
using	O
the	O
ELISA	O
-	O
based	O
EGFR	O
-	O
TK	O
assay	O
.	O
Data	O
are	O
averages	O
of	O
at	O
least	O
two	O
independent	O
determinations	O
and	O
reported	O
as	O
the	O
mean	O
Â±	O
SD	O
(	O
standard	O
deviation	O
).	O
Reported	O
data	O
.	O
As	O
shown	O
in	O
Table	O
1	O
","	O
compounds	O
1a	O
and	O
1b	O
containing	O
3	B-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribosyl	I-Chemical
moiety	O
potently	O
inhibited	O
EGFR	O
L858R	O
/	O
T790M	O
mutant	O
with	O
IC50	O
values	O
of	O
0	O
.	O
62	O
and	O
2	O
.	O
64	O
Î¼M	O
","	O
revealing	O
specific	O
inhibitory	O
activity	O
for	O
EGFR	O
L858R	O
/	O
T790M	O
over	O
WT	O
EGFR	O
","	O
although	O
they	O
are	O
not	O
comparable	O
to	O
the	O
positive	O
controls	O
osimertinib	B-Chemical
(	O
IC50	O
=	O
1	O
.	O
5	O
nM	O
for	O
EGFR	O
L858R	O
/	O
T790M	O
)	O
and	O
afatinib	B-Chemical
(	O
IC50	O
=	O
3	O
.	O
7	O
nM	O
for	O
EGFR	O
L858R	O
/	O
T790M	O
).	O
In	O
contrast	O
","	O
other	O
compounds	O
(	O
1c	O
","	O
1d	O
","	O
and	O
24	O
â€“	O
26	O
)	O
bearing	O
5	B-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribosyl	I-Chemical
moiety	O
","	O
1	B-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
-	I-Chemical
5	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribosyl	I-Chemical
moiety	O
","	O
1	B-Chemical
-	I-Chemical
N	I-Chemical
-	I-Chemical
acryloyl	I-Chemical
-	I-Chemical
3	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
anilinopyrimidine	I-Chemical
ribosyl	I-Chemical
moiety	O
","	O
or	O
their	O
1	B-Chemical
-	I-Chemical
azide	I-Chemical
counterparts	O
","	O
showed	O
no	O
inhibitory	O
activities	O
against	O
EGFR	O
tyrosine	O
kinases	O
.	O
In	O
order	O
to	O
better	O
understand	O
the	O
mechanism	O
of	O
this	O
type	O
of	O
compounds	O
binding	O
to	O
EGFR	O
T790M	O
","	O
molecular	O
docking	O
was	O
adopted	O
to	O
predict	O
the	O
binding	O
mode	O
of	O
the	O
representative	O
compound	O
1a	O
.	O
The	O
docking	O
procedure	O
was	O
validated	O
in	O
advance	O
by	O
re	O
-	O
docking	O
the	O
co	O
-	O
crystallized	O
ligand	O
WZ4002	B-Chemical
(	O
Zhou	O
et	O
al	O
".,"	O
)	O
into	O
the	O
ATP	B-Chemical
binding	O
site	O
of	O
EGFR	O
L858R	O
/	O
T790M	O
structure	O
(	O
PDB	O
ID	O
:	O
3IKA	O
).	O
The	O
root	O
mean	O
square	O
deviation	O
(	O
RMSD	O
)	O
between	O
the	O
crystallographic	O
and	O
docked	O
conformation	O
of	O
WZ4002	B-Chemical
is	O
0	O
.	O
57	O
Ã…	O
(	O
Figure	O
S1	O
"),"	O
demonstrating	O
that	O
the	O
present	O
docking	O
procedure	O
was	O
feasible	O
in	O
generating	O
the	O
binding	O
conformation	O
accurately	O
.	O
As	O
expected	O
based	O
upon	O
co	O
-	O
crystal	O
structure	O
of	O
the	O
anilinopyrimidine	B-Chemical
-	O
derived	O
inhibitor	O
WZ4002	B-Chemical
","	O
the	O
anilinopyrimidine	B-Chemical
core	O
of	O
compound	O
1a	O
forms	O
a	O
bidentate	O
hydrogen	B-Chemical
bonding	O
interaction	O
with	O
the	O
â€œ	O
hinge	O
â€	O
residue	O
Met793	B-Chemical
(	O
Figure	O
3	O
).	O
The	O
chlorine	B-Chemical
substituent	O
on	O
the	O
pyrimidine	B-Chemical
ring	O
could	O
form	O
hydrophobic	O
contact	O
with	O
the	O
mutant	O
gatekeeper	O
residue	O
","	O
Met790	B-Chemical
.	O
The	O
aniline	B-Chemical
ring	O
is	O
oriented	O
to	O
form	O
hydrophobic	O
interactions	O
with	O
Leu792	B-Chemical
and	O
Pro794	B-Chemical
in	O
the	O
hinge	O
region	O
.	O
Moreover	O
","	O
the	O
acrylamide	B-Chemical
group	O
attached	O
to	O
the	O
sugar	B-Chemical
ring	O
of	O
compound	O
1a	O
could	O
form	O
a	O
covalent	O
bond	O
with	O
Cys797	B-Chemical
to	O
achieve	O
irreversible	O
binding	O
.	O
The	O
sugar	B-Chemical
ring	O
acts	O
like	O
a	O
linker	O
to	O
tune	O
the	O
orientation	O
of	O
the	O
electrophilic	O
acrylamide	B-Chemical
moiety	O
that	O
can	O
covalently	O
alkylate	O
the	O
conserved	O
cysteine	B-Chemical
residue	O
Cys797	B-Chemical
.	O
For	O
the	O
1	B-Chemical
","	I-Chemical
2	I-Chemical
-	I-Chemical
O	I-Chemical
-	I-Chemical
isopropylidene	I-Chemical
moiety	O
in	O
compound	O
1a	O
","	O
it	O
could	O
form	O
favorable	O
vdW	O
interactions	O
with	O
residues	O
ARG841	B-Chemical
","	O
ASN842	B-Chemical
","	O
and	O
Thr854	B-Chemical
.	O
Therefore	O
","	O
compound	O
1b	O
without	O
that	O
protecting	O
group	O
on	O
the	O
sugar	B-Chemical
ring	O
","	O
displayed	O
less	O
potent	O
bioactivity	O
against	O
EGFR	O
T790M	O
/	O
L858R	O
compared	O
with	O
compound	O
1a	O
.	O
Lacking	O
of	O
the	O
Michael	O
receptor	O
","	O
compounds	O
24	O
â€“	O
26	O
are	O
unable	O
to	O
form	O
covalent	O
bond	O
with	O
Cys797	B-Chemical
and	O
thus	O
displayed	O
sharply	O
decreased	O
inhibitory	O
activity	O
against	O
EGFR	O
T790M	O
/	O
L858R	O
.	O
Compound	O
1c	O
displayed	O
no	O
inhibitory	O
activity	O
of	O
EGFR	O
probably	O
because	O
of	O
the	O
long	O
distance	O
between	O
the	O
Michael	O
receptor	O
and	O
Cys797	B-Chemical
.	O
Although	O
compound	O
1d	O
also	O
has	O
an	O
acrylamide	B-Chemical
group	O
attached	O
to	O
the	O
sugar	B-Chemical
ring	O
","	O
it	O
showed	O
no	O
inhibitory	O
activity	O
probably	O
due	O
to	O
the	O
conformational	O
alteration	O
of	O
compound	O
1d	O
caused	O
by	O
the	O
TBS	O
protecting	O
group	O
.	O
Briefly	O
","	O
it	O
could	O
be	O
concluded	O
that	O
the	O
distance	O
between	O
the	O
Michael	O
receptor	O
and	O
the	O
pyrimidine	B-Chemical
scaffold	O
has	O
a	O
significant	O
effect	O
on	O
the	O
inhibitory	O
potency	O
of	O
this	O
type	O
of	O
compounds	O
.	O
Employing	O
the	O
ribosyl	O
moiety	O
as	O
a	O
chiral	O
building	O
block	O
for	O
modulating	O
the	O
distance	O
between	O
the	O
Michael	O
receptor	O
and	O
the	O
pyrimidine	B-Chemical
scaffold	O
could	O
pave	O
a	O
new	O
avenue	O
for	O
future	O
design	O
of	O
EGFR	O
inhibitors	O
against	O
EGFR	O
mutants	O
.	O
Docking	O
pose	O
of	O
compound	O
1a	O
in	O
complex	O
with	O
the	O
EGFRT790M	O
/	O
L858R	O
(	O
PDB	O
ID	O
3IKA	O
).	O
The	O
EGFR	O
kinase	O
is	O
shown	O
as	O
cartoon	O
(	O
cyan	O
)	O
with	O
the	O
bound	O
inhibitor	O
in	O
a	O
stick	O
representation	O
(	O
yellow	O
).	O
Key	O
residues	O
are	O
represented	O
as	O
cyan	O
sticks	O
.	O
The	O
expected	O
hydrogen	B-Chemical
bonds	O
are	O
indicated	O
by	O
red	O
dashes	O
.	O
Conclusion	O
In	O
summary	O
","	O
we	O
have	O
described	O
a	O
DBU	B-Chemical
-	O
or	O
tBuOLi	B-Chemical
-	O
promoted	O
coupling	O
of	O
ribosyl	B-Chemical
alcohols	I-Chemical
with	O
2	B-Chemical
","	I-Chemical
4	I-Chemical
","	I-Chemical
5	I-Chemical
-	I-Chemical
trichloropyrimidine	I-Chemical
as	O
key	O
step	O
for	O
the	O
synthesis	O
of	O
a	O
series	O
of	O
ribose	B-Chemical
-	I-Chemical
modified	I-Chemical
anilinopyrimidine	I-Chemical
derivatives	I-Chemical
as	O
EGFR	O
TKIs	O
.	O
Preliminary	O
biological	O
evaluation	O
indicated	O
that	O
compound	O
1a	O
displayed	O
potent	O
inhibitory	O
activity	O
against	O
EGFR	O
L858R	O
/	O
T790M	O
with	O
an	O
IC50	O
value	O
of	O
0	O
.	O
62	O
Î¼M	O
","	O
and	O
good	O
selectivity	O
for	O
EGFR	O
L858R	O
/	O
T790M	O
over	O
WT	O
EGFR	O
.	O
Molecular	O
docking	O
studies	O
revealed	O
that	O
the	O
inhibitory	O
activities	O
of	O
this	O
type	O
of	O
compounds	O
are	O
largely	O
influenced	O
by	O
the	O
distance	O
between	O
the	O
Michael	O
receptor	O
and	O
the	O
pyrimidine	B-Chemical
scaffold	O
.	O
As	O
a	O
novel	O
type	O
of	O
EGFR	O
inhibitor	O
","	O
the	O
ribose	B-Chemical
-	I-Chemical
modified	I-Chemical
anilinopyrimidine	I-Chemical
derivative	I-Chemical
1a	I-Chemical
might	O
be	O
used	O
as	O
a	O
promising	O
lead	O
compound	O
for	O
further	O
development	O
of	O
selective	O
EGFR	O
inhibitors	O
to	O
overcome	O
EGFR	O
L858R	O
/	O
T790M	O
resistance	O
mutation	O
.	O
Author	O
contributions	O
YY	O
and	O
YX	O
designed	O
and	O
guided	O
this	O
study	O
.	O
XH	O
conducted	O
the	O
chemical	O
synthesis	O
.	O
YT	O
","	O
LT	O
","	O
LZ	O
","	O
and	O
HX	O
performed	O
the	O
kinase	O
activity	O
assays	O
.	O
DW	O
","	O
XW	O
","	O
and	O
SL	O
performed	O
the	O
molecular	O
docking	O
studies	O
.	O
XH	O
","	O
YY	O
","	O
and	O
YX	O
analyzed	O
the	O
data	O
and	O
wrote	O
the	O
manuscript	O
with	O
input	O
from	O
all	O
authors	O
.	O
Conflict	O
of	O
interest	O
statement	O
The	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O
Supplementary	O
material	O
The	O
Supplementary	O
Material	O
for	O
this	O
article	O
can	O
be	O
found	O
online	O
at	O
:	O
https	O
://	O
www	O
.	O
frontiersin	O
.	O
org	O
/	O
articles	O
/	O
10	O
.	O
3389	O
/	O
fchem	O
.	O
2017	O
.	O
101	O
/	O
full	O
#	O
supplementary	O
-	O
material	O
References	O
Metabolic	O
Effects	O
of	O
FecB	O
Gene	O
on	O
Follicular	O
Fluid	O
and	O
Ovarian	O
Vein	O
Serum	O
in	O
Sheep	O
(	O
Ovis	O
aries	O
)	O
The	O
FecB	O
gene	O
has	O
been	O
discovered	O
as	O
an	O
important	O
gene	O
in	O
sheep	O
for	O
its	O
high	O
relationship	O
with	O
the	O
ovulation	O
rate	O
","	O
but	O
its	O
regulatory	O
mechanism	O
remains	O
unknown	O
.	O
In	O
the	O
present	O
study	O
","	O
liquid	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
)	O
and	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
GC	O
-	O
MS	O
)	O
techniques	O
were	O
adopted	O
to	O
detect	O
the	O
metabolic	O
effects	O
of	O
FecB	O
gene	O
in	O
follicular	O
fluid	O
(	O
FF	O
)	O
and	O
ovarian	O
vein	O
serum	O
(	O
OVS	O
)	O
in	O
Small	O
Tail	O
Han	O
(	O
STH	O
)	O
sheep	O
.	O
ANOVA	O
and	O
random	O
forest	O
statistical	O
methods	O
were	O
employed	O
for	O
the	O
identification	O
of	O
important	O
metabolic	O
pathways	O
and	O
biomarkers	O
.	O
Changes	O
in	O
amino	B-Chemical
acid	I-Chemical
metabolism	O
","	O
redox	O
environment	O
","	O
and	O
energy	O
metabolism	O
were	O
observed	O
in	O
FF	O
from	O
the	O
three	O
FecB	O
genotype	O
STH	O
ewes	O
.	O
Principal	O
component	O
analysis	O
(	O
PCA	O
)	O
and	O
hierarchical	O
clustering	O
analysis	O
(	O
HCA	O
)	O
showed	O
that	O
metabolic	O
effects	O
of	O
FecB	O
gene	O
are	O
more	O
pronounced	O
in	O
FF	O
than	O
in	O
OVS	O
.	O
Therefore	O
","	O
the	O
difference	O
of	O
the	O
metabolic	O
profile	O
in	O
FF	O
is	O
also	O
affected	O
by	O
the	O
FecB	O
genotypes	O
.	O
In	O
Spearman	O
correlation	O
analysis	O
","	O
key	O
metabolites	O
(	O
e	O
.	O
g	O
".,"	O
glucose	B-Chemical
6	I-Chemical
-	I-Chemical
phosphate	I-Chemical
","	O
glucose	B-Chemical
1	I-Chemical
-	I-Chemical
phosphate	I-Chemical
","	O
aspartate	B-Chemical
","	O
asparagine	B-Chemical
","	O
glutathione	O
oxidized	O
(	O
GSSG	O
"),"	O
cysteine	O
-	O
glutathione	O
disulfide	O
","	O
Î³	O
-	O
glutamylglutamine	O
","	O
and	O
2	B-Chemical
-	I-Chemical
hydrosybutyrate	I-Chemical
)	O
in	O
ovine	O
FF	O
samples	O
showed	O
a	O
significant	O
correlation	O
with	O
the	O
ovulation	O
rate	O
.	O
Our	O
findings	O
will	O
help	O
to	O
explain	O
the	O
metabolic	O
mechanism	O
of	O
high	O
prolificacy	O
ewes	O
and	O
benefit	O
fertility	O
identification	O
.	O
1	O
.	O
Introduction	O
A	O
single	O
major	O
gene	O
responsible	O
for	O
high	O
fecundity	O
of	O
Booroola	O
Merino	O
was	O
named	O
the	O
FecB	O
by	O
the	O
Committee	O
on	O
Genetic	O
Nomenclature	O
of	O
Sheep	O
and	O
Goats	O
(	O
COGNOSAG	O
","	O
1989	O
)	O
[].	O
Based	O
on	O
research	O
studies	O
from	O
three	O
groups	O
","	O
the	O
FecB	O
gene	O
was	O
finally	O
located	O
in	O
the	O
BMPR1B	O
gene	O
","	O
which	O
presented	O
a	O
mutation	O
of	O
A746G	O
in	O
its	O
coding	O
region	O
and	O
caused	O
an	O
amino	B-Chemical
acid	I-Chemical
substitution	O
of	O
glutamine	B-Chemical
into	O
arginine	B-Chemical
in	O
the	O
protein	O
sequence	O
In	O
Booroola	O
ewes	O
","	O
the	O
effect	O
of	O
the	O
FecB	O
gene	O
increased	O
the	O
ovulation	O
rate	O
and	O
was	O
partially	O
dominant	O
for	O
litter	O
size	O
"[,]."	O
Monget	O
et	O
al	O
.	O
reported	O
that	O
the	O
diameter	O
of	O
the	O
ovulatory	O
follicle	O
was	O
also	O
significantly	O
correlated	O
with	O
FecB	O
genotypes	O
[].	O
Since	O
follicle	O
development	O
and	O
ovulation	O
in	O
ovaries	O
were	O
found	O
to	O
be	O
controlled	O
by	O
follicle	O
-	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
and	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
"[],"	O
it	O
was	O
predicted	O
that	O
the	O
FecB	O
gene	O
may	O
impact	O
pituitary	O
glands	O
by	O
increasing	O
the	O
release	O
of	O
hormone	O
or	O
impact	O
ovaries	O
in	O
follicular	O
cells	O
by	O
increasing	O
sensitivity	O
to	O
the	O
hormone	O
[].	O
After	O
many	O
years	O
of	O
arguments	O
","	O
the	O
majority	O
of	O
researchers	O
agree	O
that	O
the	O
FecB	O
gene	O
influences	O
the	O
ovaries	O
by	O
modulating	O
the	O
difference	O
in	O
the	O
ovulation	O
rate	O
"[,,,]."	O
With	O
regard	O
to	O
ovarian	O
tissue	O
","	O
reproduction	O
-	O
related	O
gene	O
expression	O
","	O
transcriptomics	O
","	O
and	O
proteomics	O
were	O
continuously	O
studied	O
in	O
FecB	O
carriers	O
â€™	O
ewes	O
However	O
","	O
little	O
attention	O
was	O
paid	O
to	O
the	O
effect	O
of	O
FecB	O
on	O
ovine	O
follicular	O
fluid	O
(	O
FF	O
"),"	O
as	O
well	O
as	O
the	O
unique	O
microenvironment	O
which	O
can	O
provide	O
energy	O
","	O
nutrition	O
","	O
and	O
regulatory	O
factor	O
for	O
oocyte	O
development	O
and	O
ovulation	O
.	O
The	O
message	O
from	O
compounds	O
in	O
FF	O
may	O
allow	O
an	O
oocyte	O
to	O
determine	O
its	O
own	O
developing	O
fate	O
[].	O
It	O
is	O
well	O
known	O
that	O
FecB	O
carriers	O
permitted	O
smaller	O
follicles	O
to	O
develop	O
into	O
the	O
ovulatory	O
follicle	O
[].	O
In	O
this	O
study	O
","	O
we	O
put	O
forward	O
a	O
hypothesis	O
that	O
follicular	O
fluid	O
(	O
FF	O
)	O
and	O
its	O
related	O
ovarian	O
vein	O
serum	O
(	O
OVS	O
)	O
may	O
present	O
differently	O
in	O
their	O
composition	O
between	O
FecB	O
gene	O
carriers	O
and	O
non	O
-	O
carriers	O
.	O
For	O
analyzing	O
the	O
quality	O
and	O
fate	O
of	O
an	O
oocyte	O
","	O
metabolomics	O
has	O
proven	O
to	O
be	O
a	O
powerful	O
approach	O
for	O
discovering	O
the	O
small	O
-	O
molecule	O
biomarkers	O
in	O
FF	O
and	O
culture	O
medium	O
and	O
has	O
been	O
studied	O
in	O
humans	O
","	O
cattle	O
","	O
and	O
pigs	O
Wallace	O
et	O
al	O
.	O
and	O
Bertoldo	O
et	O
al	O
.	O
found	O
separately	O
through	O
1H	B-Chemical
-	O
NMR	O
(	O
Nuclear	O
Magnetic	O
Resonance	O
)	O
spectroscopy	O
that	O
the	O
quality	O
and	O
developmental	O
potential	O
of	O
oocytes	O
for	O
humans	O
and	O
pigs	O
are	O
related	O
to	O
metabolic	O
profiles	O
in	O
FF	O
"[,]."	O
Contrasted	O
with	O
1H	B-Chemical
-	O
NMR	O
spectroscopy	O
","	O
mass	O
spectrometry	O
(	O
MS	O
)-	O
based	O
metabolomics	O
techniques	O
have	O
become	O
efficient	O
platforms	O
due	O
to	O
their	O
high	O
sensitivity	O
and	O
selectivity	O
"[,]."	O
In	O
the	O
present	O
study	O
","	O
liquid	O
chromatography	O
â€“	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
)	O
and	O
gas	O
chromatography	O
â€“	O
mass	O
spectrometry	O
(	O
GC	O
-	O
MS	O
)	O
techniques	O
were	O
adopted	O
to	O
discover	O
the	O
metabolic	O
effects	O
of	O
the	O
FecB	O
gene	O
on	O
FF	O
and	O
OVS	O
in	O
Small	O
Tail	O
Han	O
(	O
STH	O
)	O
sheep	O
.	O
Our	O
findings	O
may	O
help	O
explain	O
the	O
metabolic	O
mechanism	O
of	O
high	O
prolificacy	O
ewes	O
and	O
uncover	O
some	O
useful	O
biomarkers	O
for	O
fertility	O
identification	O
.	O
2	O
.	O
Results	O
2	O
.	O
1	O
.	O
Measurement	O
of	O
Ovulation	O
Rate	O
","	O
Number	O
","	O
and	O
Diameter	O
for	O
Pre	O
-	O
Ovulation	O
Without	O
any	O
other	O
extra	O
exogenous	O
hormones	O
that	O
may	O
induce	O
superovulation	O
in	O
ewes	O
","	O
ovulation	O
rates	O
of	O
three	O
FecB	O
genotype	O
ewes	O
were	O
successfully	O
detected	O
in	O
51	O
individuals	O
using	O
the	O
laparoscopy	O
procedure	O
after	O
treatment	O
of	O
estrus	O
synchronization	O
with	O
CIDR	O
(	O
controlled	O
internal	O
drug	O
releasing	O
)	O
(	O
Table	O
1	O
).	O
The	O
mean	O
ovulation	O
rates	O
(	O
total	O
of	O
the	O
two	O
ovaries	O
)	O
of	O
the	O
++	O
(	O
wild	O
-	O
type	O
for	O
FecB	O
gene	O
"),"	O
+	O
B	O
(	O
heterozygote	O
mutant	O
for	O
FecB	O
gene	O
"),"	O
and	O
BB	O
(	O
homozygous	O
mutant	O
for	O
FecB	O
gene	O
)	O
groups	O
were	O
1	O
.	O
6	O
Â±	O
0	O
.	O
6	O
","	O
2	O
.	O
29	O
Â±	O
0	O
.	O
17	O
","	O
and	O
3	O
.	O
6	O
Â±	O
0	O
.	O
26	O
","	O
respectively	O
.	O
Meanwhile	O
","	O
the	O
comparison	O
of	O
ovulation	O
rates	O
between	O
any	O
two	O
genotype	O
groups	O
all	O
showed	O
highly	O
significant	O
differences	O
(	O
p	O
â‰¤	O
0	O
.	O
1	O
).	O
Before	O
collecting	O
FF	O
samples	O
","	O
the	O
diameter	O
and	O
number	O
of	O
pre	O
-	O
ovulation	O
follicles	O
were	O
successfully	O
measured	O
in	O
56	O
individuals	O
(	O
Table	O
1	O
).	O
The	O
number	O
of	O
pre	O
-	O
ovulation	O
follicle	O
in	O
BB	O
ewes	O
with	O
3	O
.	O
0	O
Â±	O
0	O
.	O
38	O
was	O
significantly	O
higher	O
than	O
2	O
.	O
32	O
Â±	O
0	O
.	O
38	O
in	O
+	O
B	O
ewes	O
(	O
p	O
â‰¤	O
0	O
.	O
1	O
).	O
At	O
the	O
same	O
time	O
","	O
the	O
pre	O
-	O
ovulation	O
follicle	O
numbers	O
of	O
BB	O
and	O
+	O
B	O
ewes	O
were	O
all	O
significantly	O
higher	O
than	O
1	O
.	O
29	O
Â±	O
0	O
.	O
10	O
in	O
++	O
ewes	O
(	O
p	O
â‰¤	O
0	O
.	O
1	O
).	O
However	O
","	O
the	O
opposite	O
situation	O
emerged	O
in	O
the	O
diameter	O
of	O
pre	O
-	O
ovulation	O
follicles	O
.	O
The	O
mean	O
diameter	O
in	O
++	O
ewes	O
with	O
7	O
.	O
56	O
Â±	O
0	O
.	O
52	O
mm	O
was	O
significantly	O
larger	O
than	O
5	O
.	O
32	O
Â±	O
0	O
.	O
25	O
mm	O
in	O
+	O
B	O
ewes	O
(	O
p	O
â‰¤	O
0	O
.	O
1	O
"),"	O
and	O
the	O
mean	O
diameters	O
of	O
++	O
and	O
+	O
B	O
ewes	O
were	O
all	O
significantly	O
higher	O
than	O
the	O
4	O
.	O
20	O
Â±	O
0	O
.	O
15	O
mm	O
mean	O
diameter	O
in	O
BB	O
ewes	O
(	O
p	O
â‰¤	O
0	O
.	O
1	O
).	O
In	O
summary	O
","	O
the	O
ovulation	O
rate	O
","	O
pre	O
-	O
ovulation	O
follicle	O
number	O
","	O
and	O
diameter	O
in	O
STH	O
ewes	O
were	O
greatly	O
influenced	O
by	O
the	O
FecB	O
gene	O
effect	O
.	O
2	O
.	O
2	O
.	O
Overview	O
of	O
Metabolite	O
in	O
Pre	O
-	O
Ovulation	O
FF	O
and	O
OVS	O
Samples	O
Compared	O
with	O
the	O
authenticated	O
standards	O
library	O
of	O
Metabolon	O
Inc	O
".,"	O
a	O
total	O
of	O
236	O
and	O
310	O
known	O
biochemical	O
compounds	O
were	O
identified	O
in	O
ovine	O
FF	O
and	O
OVS	O
samples	O
","	O
respectively	O
.	O
All	O
the	O
biochemical	O
compounds	O
could	O
be	O
classified	O
into	O
eight	O
super	O
metabolic	O
pathways	O
(	O
amino	B-Chemical
acid	I-Chemical
","	O
peptide	B-Chemical
","	O
carbohydrate	B-Chemical
","	O
energy	O
","	O
lipid	B-Chemical
","	O
nucleotide	B-Chemical
","	O
xenobiotics	O
","	O
cofactors	O
","	O
and	O
vitamins	O
).	O
With	O
the	O
log	O
transformation	O
","	O
ANOVA	O
was	O
separately	O
adopted	O
in	O
FF	O
and	O
OVS	O
experimental	O
group	O
comparisons	O
.	O
The	O
significantly	O
different	O
levels	O
of	O
biochemicals	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
)	O
in	O
each	O
comparison	O
were	O
picked	O
out	O
for	O
FF	O
and	O
OVS	O
samples	O
(	O
Figure	O
1	O
).	O
Since	O
the	O
FecB	O
carriers	O
have	O
more	O
similar	O
biochemicals	O
","	O
however	O
","	O
BB	O
and	O
+	O
B	O
groups	O
were	O
accompanied	O
by	O
different	O
biochemicals	O
when	O
compared	O
with	O
the	O
wild	O
-	O
type	O
groups	O
(++)	O
for	O
both	O
samples	O
of	O
FF	O
and	O
OVS	O
.	O
Most	O
of	O
the	O
different	O
biochemicals	O
in	O
FF	O
and	O
OVS	O
from	O
BB_VS_	O
++	O
and	O
+	O
B_VS_	O
++	O
were	O
common	O
defferecese	O
(	O
40	O
and	O
39	O
).	O
Based	O
on	O
differences	O
in	O
overall	O
metabolite	O
signature	O
in	O
FF	O
and	O
OVS	O
samples	O
","	O
PCA	O
and	O
HCA	O
analyses	O
were	O
adopted	O
to	O
determine	O
whether	O
the	O
samples	O
can	O
be	O
segregated	O
as	O
BB	O
","	O
+	O
B	O
","	O
and	O
++	O
groups	O
","	O
or	O
whether	O
samples	O
from	O
the	O
same	O
group	O
can	O
cluster	O
together	O
.	O
PCA	O
of	O
FF	O
revealed	O
a	O
separation	O
between	O
the	O
group	O
of	O
++	O
genotypes	O
and	O
FecB	O
carrier	O
genotypes	O
(	O
Figure	O
2A	O
).	O
BB	O
samples	O
formed	O
the	O
least	O
variable	O
population	O
and	O
partially	O
overlapped	O
with	O
+	O
B	O
.	O
HCA	O
of	O
FF	O
showed	O
that	O
BB	O
samples	O
clustered	O
together	O
","	O
while	O
+	O
B	O
samples	O
formed	O
four	O
sub	O
-	O
clusters	O
interspersed	O
by	O
non	O
-	O
carriers	O
(++)	O
(	O
Figure	O
2C	O
).	O
PCA	O
and	O
HCA	O
analyses	O
were	O
also	O
performed	O
for	O
OVS	O
samples	O
(	O
Figure	O
2B	O
","	O
D	O
)	O
and	O
showed	O
minimal	O
group	O
separation	O
in	O
PCA	O
and	O
more	O
sub	O
-	O
clustering	O
in	O
HCA	O
based	O
on	O
genotypes	O
of	O
the	O
FecB	O
gene	O
.	O
Collectively	O
","	O
these	O
two	O
assessments	O
revealed	O
that	O
metabolic	O
effects	O
associated	O
with	O
the	O
FecB	O
gene	O
are	O
more	O
pronounced	O
in	O
FF	O
than	O
in	O
OVS	O
.	O
2	O
.	O
3	O
.	O
Identification	O
of	O
Biomarkers	O
in	O
FF	O
and	O
OVS	O
for	O
FecB	O
Gene	O
Effect	O
Random	O
forest	O
analysis	O
was	O
performed	O
for	O
FF	O
samples	O
and	O
yielded	O
a	O
good	O
predictive	O
accuracy	O
of	O
83	O
%	O
(	O
Figure	O
3A	O
);	O
random	O
chance	O
usually	O
yields	O
33	O
%.	O
The	O
top	O
30	O
ranking	O
biochemicals	O
that	O
contributed	O
to	O
the	O
differentiation	O
are	O
presented	O
in	O
Figure	O
3C	O
.	O
The	O
process	O
involved	O
redox	O
homeostasis	O
(	O
e	O
.	O
g	O
".,"	O
glutathione	O
oxidized	O
(	O
GSSG	O
"),"	O
cysteine	O
-	O
glutathione	O
disulfide	O
","	O
and	O
2	B-Chemical
-	I-Chemical
hydroxybutyrate	I-Chemical
(	O
AHB	B-Chemical
")),"	O
carbohydrate	B-Chemical
metabolism	O
(	O
e	O
.	O
g	O
".,"	O
maltose	B-Chemical
","	O
glycerate	B-Chemical
","	O
and	O
mannose	B-Chemical
"),"	O
and	O
lipid	B-Chemical
metabolism	O
(	O
e	O
.	O
g	O
".,"	O
glycerophosphocholine	B-Chemical
","	O
choline	B-Chemical
phosphate	I-Chemical
","	O
and	O
glycerol	B-Chemical
3	I-Chemical
-	I-Chemical
phosphate	I-Chemical
).	O
The	O
same	O
analysis	O
performed	O
for	O
OVS	O
samples	O
resulted	O
in	O
moderate	O
predictive	O
accuracy	O
of	O
63	O
%	O
(	O
Figure	O
3B	O
)	O
and	O
highlighted	O
microbiome	O
-	O
associated	O
biochemicals	O
(	O
e	O
.	O
g	O
".,"	O
4	B-Chemical
-	I-Chemical
ethylphenylsulfate	I-Chemical
","	O
3	B-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
hydroxyphenyl	I-Chemical
)	I-Chemical
lactate	I-Chemical
","	O
and	O
3	B-Chemical
-	I-Chemical
indoxyl	I-Chemical
sulfate	I-Chemical
"),"	O
compounds	O
related	O
to	O
nucleotide	B-Chemical
metabolism	O
(	O
e	O
.	O
g	O
".,"	O
allantoin	B-Chemical
","	O
N1	B-Chemical
-	I-Chemical
methylguanosine	I-Chemical
","	O
and	O
pseudouridine	B-Chemical
)	O
and	O
compounds	O
related	O
to	O
lipid	B-Chemical
metabolism	O
(	O
e	O
.	O
g	O
".,"	O
2	B-Chemical
-	I-Chemical
hydroxypalmitate	I-Chemical
","	O
mead	B-Chemical
acid	I-Chemical
(	O
20	O
:	O
3n9	O
"),"	O
and	O
1	B-Chemical
-	I-Chemical
linolenoyl	I-Chemical
-	I-Chemical
GPc	I-Chemical
(	O
18	O
:	O
3	O
))	O
as	O
strong	O
contributors	O
to	O
group	O
separation	O
(	O
Figure	O
3D	O
).	O
Regardless	O
of	O
what	O
the	O
samples	O
are	O
","	O
the	O
class	O
error	O
of	O
the	O
++	O
group	O
in	O
FF	O
and	O
OVS	O
samples	O
are	O
the	O
lowest	O
group	O
.	O
The	O
random	O
forest	O
model	O
showed	O
weak	O
separation	O
power	O
between	O
BB	O
and	O
+	O
B	O
while	O
also	O
having	O
an	O
excellent	O
ability	O
to	O
discriminate	O
the	O
wide	O
-	O
type	O
(++)	O
individuals	O
from	O
the	O
FecB	O
carriers	O
.	O
2	O
.	O
4	O
.	O
Changes	O
in	O
Energy	O
Metabolism	O
in	O
FF	O
FF	O
seen	O
as	O
the	O
unique	O
microenvironment	O
of	O
oocyte	O
development	O
could	O
provide	O
substrates	O
to	O
meet	O
energy	O
requirements	O
.	O
In	O
this	O
study	O
","	O
glucose	B-Chemical
6	I-Chemical
-	I-Chemical
phosphate	I-Chemical
acted	O
as	O
a	O
glycolytic	O
intermediate	O
","	O
the	O
TCA	B-Chemical
cycle	O
intermediates	O
(	O
citrate	B-Chemical
","	O
Î±	B-Chemical
-	I-Chemical
ketoglutarate	I-Chemical
","	O
and	O
malate	B-Chemical
)	O
along	O
with	O
the	O
glycolytic	O
intermediate	O
were	O
elevated	O
in	O
FF	O
obtained	O
from	O
BB	O
as	O
compared	O
to	O
++	O
individuals	O
(	O
Figure	O
4	O
).	O
Citrate	B-Chemical
","	O
in	O
addition	O
to	O
being	O
an	O
intermediate	O
of	O
the	O
TCA	B-Chemical
cycle	O
","	O
is	O
also	O
a	O
substrate	O
for	O
fatty	B-Chemical
acid	I-Chemical
biosynthesis	O
","	O
while	O
Î±	B-Chemical
-	I-Chemical
ketoglutarate	I-Chemical
can	O
be	O
used	O
to	O
synthesize	O
glutamic	B-Chemical
acid	I-Chemical
.	O
In	O
addition	O
","	O
glucose	B-Chemical
1	I-Chemical
-	I-Chemical
phosphate	I-Chemical
levels	O
were	O
lower	O
","	O
and	O
maltose	B-Chemical
was	O
elevated	O
in	O
FF	O
from	O
BB	O
animals	O
(	O
BB	O
vs	O
.	O
(++)	O
comparison	O
"),"	O
which	O
might	O
indicate	O
increased	O
glycogenolysis	O
or	O
decreased	O
storage	O
of	O
glycogen	B-Chemical
.	O
Taken	O
together	O
","	O
the	O
changes	O
observed	O
here	O
indicate	O
that	O
the	O
use	O
of	O
the	O
TCA	B-Chemical
cycle	O
as	O
well	O
as	O
possible	O
biosynthetic	O
pathways	O
utilizing	O
the	O
cycle	O
intermediates	O
are	O
different	O
between	O
BB	O
and	O
(++)	O
animals	O
.	O
2	O
.	O
5	O
.	O
Higher	O
Levels	O
of	O
Amino	B-Chemical
Acids	I-Chemical
in	O
FF	O
from	O
BB	O
Sheep	O
The	O
levels	O
of	O
several	O
amino	B-Chemical
acids	I-Chemical
were	O
higher	O
in	O
FF	O
for	O
ewes	O
carrying	O
the	O
FecB	O
gene	O
(	O
e	O
.	O
g	O
".,"	O
threonine	B-Chemical
","	O
aspartate	B-Chemical
","	O
asparagine	B-Chemical
","	O
lysine	B-Chemical
","	O
cysteine	B-Chemical
","	O
and	O
arginine	B-Chemical
)	O
(	O
Table	O
2	O
).	O
These	O
phenomena	O
might	O
reflect	O
changes	O
in	O
amino	B-Chemical
acid	I-Chemical
homeostasis	O
and	O
protein	O
synthesis	O
/	O
degradation	O
rates	O
.	O
As	O
a	O
result	O
","	O
higher	O
levels	O
of	O
amino	B-Chemical
acids	I-Chemical
may	O
provide	O
a	O
more	O
nourishing	O
microenvironment	O
for	O
oocyte	O
development	O
.	O
Additionally	O
","	O
aspartate	B-Chemical
levels	O
were	O
significantly	O
elevated	O
in	O
FF	O
with	O
increased	O
FecB	O
copies	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
).	O
2	O
.	O
6	O
.	O
Elevation	O
of	O
Antioxidant	O
Defense	O
Capacity	O
in	O
FF	O
for	O
BB	O
Sheep	O
Notably	O
","	O
the	O
level	O
of	O
oxidized	O
glutathione	O
(	O
GSSG	O
)	O
for	O
BB	O
genotype	O
in	O
FF	O
samples	O
was	O
12	O
.	O
37	O
-	O
fold	O
compared	O
with	O
the	O
++	O
genotype	O
(	O
p	O
â‰¤	O
0	O
.	O
1	O
).	O
Accompanied	O
by	O
a	O
decrease	O
in	O
FecB	O
copies	O
","	O
the	O
level	O
of	O
GSSG	O
declined	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
)	O
(	O
Table	O
3	O
).	O
The	O
levels	O
of	O
antioxidant	O
defense	O
compounds	O
of	O
cysteine	B-Chemical
","	O
cysteine	O
-	O
glutathione	O
disulfide	O
","	O
and	O
Î³	O
-	O
glutamyl	O
-	O
amino	O
acid	O
(	O
including	O
Î³	O
-	O
glutamylalanine	O
","	O
Î³	O
-	O
glutamylglutamine	O
","	O
Î³	O
-	O
glutamylisoleucine	O
","	O
Î³	O
-	O
glutamylleucine	O
","	O
Î³	O
-	O
glutamylphenylalanine	O
","	O
and	O
Î³	O
-	O
glutamyltyrosine	O
)	O
were	O
also	O
higher	O
in	O
FF	O
for	O
BB	O
and	O
+	O
B	O
ewes	O
vs	O
.	O
++	O
(	O
Table	O
3	O
and	O
Figure	O
5	O
).	O
However	O
","	O
in	O
both	O
FF	O
and	O
OVS	O
samples	O
","	O
2	B-Chemical
-	I-Chemical
hydroxybutyrate	I-Chemical
(	O
AHB	B-Chemical
)	O
was	O
all	O
lower	O
in	O
ewes	O
that	O
carried	O
the	O
FecB	O
gene	O
.	O
We	O
speculate	O
that	O
increased	O
antioxidant	O
defense	O
compounds	O
in	O
FF	O
for	O
BB	O
ewes	O
may	O
have	O
beneficial	O
effects	O
on	O
more	O
oocyte	O
development	O
.	O
2	O
.	O
7	O
.	O
Subtle	O
Alterations	O
in	O
Steroid	B-Chemical
Hormones	I-Chemical
for	O
OVS	O
Levels	O
of	O
pregn	O
steroid	B-Chemical
monosulfate	I-Chemical
in	O
OVS	O
showed	O
a	O
trend	O
toward	O
an	O
increase	O
in	O
BB	O
ewes	O
as	O
compared	O
to	O
++	O
(	O
0	O
.	O
5	O
<	O
p	O
â‰¤	O
0	O
.	O
10	O
).	O
Levels	O
of	O
cortisone	B-Chemical
also	O
showed	O
a	O
trend	O
toward	O
a	O
decrease	O
in	O
OVS	O
from	O
BB	O
animals	O
(	O
0	O
.	O
5	O
<	O
p	O
â‰¤	O
0	O
.	O
10	O
).	O
Cortisone	B-Chemical
is	O
generated	O
by	O
the	O
action	O
of	O
11	O
-	O
Î²	O
-	O
steroid	O
dehydrogenase	O
on	O
peripheral	O
cortisol	B-Chemical
.	O
Cortisone	B-Chemical
may	O
thus	O
serve	O
as	O
a	O
proxy	O
for	O
cortisol	B-Chemical
release	O
.	O
In	O
this	O
case	O
","	O
lower	O
levels	O
of	O
cortisone	B-Chemical
may	O
contribute	O
to	O
differences	O
in	O
stress	O
-	O
mediated	O
release	O
between	O
FecB	O
gene	O
carriers	O
(	O
BB	O
and	O
+	O
B	O
)	O
and	O
non	O
-	O
carriers	O
.	O
2	O
.	O
8	O
.	O
The	O
Relation	O
Between	O
Metabolic	O
Changes	O
and	O
Ovulation	O
Rates	O
Spearman	O
correlation	O
was	O
performed	O
to	O
assess	O
the	O
relationship	O
between	O
metabolic	O
changes	O
and	O
ovulation	O
rates	O
.	O
The	O
normalized	O
raw	O
area	O
counts	O
data	O
","	O
the	O
Scaled	O
Imp	O
Data	O
","	O
and	O
the	O
statistical	O
values	O
of	O
ANOVA	O
and	O
Spearman	O
correlation	O
for	O
FF	O
and	O
OVS	O
samples	O
are	O
presented	O
in	O
Tables	O
S1	O
and	O
S2	O
","	O
respectively	O
.	O
Scatter	O
plots	O
in	O
Figure	O
S1	O
show	O
the	O
dependence	O
between	O
ovulation	O
rate	O
(	O
1	O
â€“	O
4	O
)	O
and	O
the	O
level	O
of	O
some	O
key	O
metabolites	O
(	O
e	O
.	O
g	O
".,"	O
glucose	B-Chemical
6	I-Chemical
-	I-Chemical
phosphate	I-Chemical
","	O
glucose	B-Chemical
1	I-Chemical
-	I-Chemical
phosphate	I-Chemical
","	O
aspartate	B-Chemical
","	O
asparagine	B-Chemical
","	O
GSSG	O
","	O
cysteine	O
-	O
glutathione	O
disulfide	O
","	O
Î³	O
-	O
glutamylglutamine	O
","	O
and	O
2	B-Chemical
-	I-Chemical
hydrosybutyrate	I-Chemical
)	O
in	O
FF	O
samples	O
.	O
The	O
p	O
-	O
value	O
Spearman	O
correlation	O
of	O
these	O
metabolites	O
are	O
less	O
than	O
0	O
.	O
5	O
","	O
which	O
means	O
that	O
a	O
significant	O
correlation	O
and	O
the	O
correlations	O
between	O
ovulation	O
rate	O
and	O
these	O
key	O
metabolite	O
levels	O
are	O
about	O
0	O
.	O
5	O
.	O
3	O
.	O
Discussion	O
The	O
discovery	O
of	O
the	O
FecB	O
gene	O
","	O
which	O
is	O
responsible	O
for	O
the	O
ovulation	O
rate	O
and	O
litter	O
size	O
traits	O
in	O
Booroola	O
Merino	O
sheep	O
","	O
assisted	O
researchers	O
in	O
improving	O
the	O
fertility	O
in	O
other	O
sheep	O
breeds	O
After	O
that	O
","	O
several	O
major	O
genes	O
for	O
ovulation	O
or	O
litter	O
size	O
traits	O
were	O
found	O
and	O
called	O
fecundity	O
(	O
Fec	O
)	O
genes	O
","	O
some	O
of	O
which	O
include	O
FecX	O
","	O
FecG	O
","	O
and	O
FecL	O
"[,,,]."	O
Ovulation	O
is	O
a	O
sophisticated	O
process	O
controlled	O
by	O
many	O
minor	O
and	O
major	O
genes	O
"[],"	O
and	O
not	O
all	O
of	O
the	O
major	O
genes	O
found	O
explained	O
or	O
worked	O
well	O
with	O
regard	O
to	O
the	O
ovulation	O
rate	O
in	O
other	O
high	O
prolificacy	O
sheep	O
breeds	O
.	O
Therefore	O
","	O
for	O
a	O
long	O
time	O
","	O
a	O
variety	O
of	O
new	O
technologies	O
were	O
adopted	O
by	O
researches	O
to	O
find	O
new	O
Fec	O
genes	O
.	O
Nevertheless	O
","	O
no	O
matter	O
how	O
powerful	O
a	O
Fec	O
gene	O
is	O
","	O
there	O
is	O
no	O
difference	O
in	O
ovary	O
metabolism	O
between	O
high	O
and	O
low	O
prolificacy	O
sheep	O
.	O
Equally	O
","	O
metabolism	O
differences	O
may	O
provide	O
another	O
angle	O
of	O
view	O
for	O
reproduction	O
-	O
related	O
gene	O
discovery	O
and	O
understanding	O
[].	O
In	O
the	O
present	O
study	O
","	O
FF	O
and	O
OVS	O
from	O
three	O
FecB	O
genotype	O
STH	O
ewes	O
were	O
selected	O
for	O
metabolomics	O
analysis	O
.	O
Several	O
metabolic	O
pathways	O
and	O
key	O
biomarkers	O
were	O
identified	O
by	O
ANOVA	O
and	O
random	O
forest	O
.	O
We	O
have	O
verified	O
the	O
hypothesis	O
that	O
metabolites	O
in	O
ewes	O
â€™	O
FF	O
and	O
OVS	O
is	O
affected	O
by	O
FecB	O
genotypes	O
.	O
It	O
is	O
well	O
known	O
that	O
FF	O
is	O
the	O
product	O
of	O
the	O
transfer	O
of	O
blood	O
plasma	O
constituents	O
that	O
cross	O
the	O
blood	O
follicular	O
barrier	O
(	O
BFB	O
)	O
and	O
the	O
secretory	O
activity	O
of	O
granulosa	O
and	O
thecal	O
cells	O
[].	O
Owing	O
to	O
the	O
perm	O
selectivity	O
","	O
it	O
is	O
believed	O
that	O
high	O
-	O
molecular	O
-	O
weight	O
proteins	O
are	O
blocked	O
by	O
BFB	O
","	O
and	O
the	O
low	O
-	O
molecular	O
-	O
weight	O
compounds	O
","	O
which	O
could	O
be	O
detected	O
by	O
metabolomics	O
in	O
FF	O
","	O
are	O
supposed	O
to	O
be	O
similar	O
in	O
the	O
OVS	O
[].	O
However	O
","	O
our	O
result	O
showed	O
that	O
the	O
metabolic	O
effects	O
of	O
the	O
FecB	O
gene	O
are	O
more	O
pronounced	O
in	O
FF	O
than	O
in	O
OVS	O
.	O
A	O
logical	O
deduction	O
may	O
be	O
accounted	O
for	O
this	O
phenomenon	O
:	O
the	O
effect	O
of	O
the	O
FecB	O
gene	O
on	O
the	O
secretory	O
activity	O
of	O
granulosa	O
and	O
thecal	O
cells	O
may	O
be	O
strong	O
.	O
Campbell	O
et	O
al	O
.	O
showed	O
that	O
the	O
FecB	O
gene	O
affected	O
the	O
response	O
of	O
both	O
granulosa	O
and	O
theca	O
cells	O
to	O
BMP	O
","	O
gonadotropin	O
","	O
and	O
IGF	O
-	O
I	O
stimulation	O
in	O
cultivating	O
ovine	O
ovarian	O
tissue	O
[].	O
Soyun	O
et	O
al	O
.	O
found	O
that	O
FecB	O
is	O
expressed	O
in	O
cumulus	O
â€“	O
oocyte	O
complexes	O
(	O
CoCs	O
)	O
and	O
the	O
loss	O
of	O
FecB	O
in	O
mice	O
is	O
associated	O
with	O
defective	O
cumulus	O
cell	O
expansion	O
in	O
vitro	O
[].	O
Based	O
on	O
the	O
overview	O
of	O
metabolomics	O
data	O
in	O
the	O
present	O
study	O
","	O
we	O
can	O
also	O
infer	O
that	O
CoCs	O
and	O
theca	O
cells	O
","	O
which	O
are	O
composed	O
the	O
follicles	O
","	O
were	O
the	O
prime	O
location	O
for	O
FecB	O
affection	O
.	O
Glucose	B-Chemical
is	O
the	O
major	O
energy	O
source	O
for	O
cells	O
in	O
the	O
ovaries	O
","	O
and	O
glucose	B-Chemical
concentration	O
increases	O
when	O
the	O
diameter	O
of	O
follicles	O
increases	O
[].	O
Therefore	O
","	O
the	O
follicles	O
with	O
smaller	O
diameters	O
measured	O
in	O
BB	O
and	O
+	O
B	O
can	O
account	O
for	O
the	O
lower	O
concentration	O
of	O
glucose	B-Chemical
1	I-Chemical
-	I-Chemical
phosphate	I-Chemical
","	O
which	O
stands	O
for	O
a	O
lower	O
level	O
of	O
energy	O
storage	O
detected	O
in	O
FecB	O
carriers	O
.	O
However	O
","	O
as	O
an	O
intermediate	O
of	O
the	O
TCA	B-Chemical
cycle	O
","	O
especially	O
for	O
Î±	B-Chemical
-	I-Chemical
ketoglutarate	I-Chemical
","	O
which	O
can	O
be	O
synthesized	O
as	O
glutamic	B-Chemical
acid	I-Chemical
","	O
it	O
was	O
elevated	O
in	O
FF	O
for	O
BB	O
individuals	O
.	O
Together	O
with	O
the	O
high	O
level	O
of	O
Î³	O
-	O
glutamyl	O
-	O
amino	O
acid	O
and	O
GSSG	O
in	O
FecB	O
carriers	O
","	O
we	O
considered	O
that	O
the	O
capacity	O
of	O
antioxidant	O
defense	O
is	O
necessary	O
for	O
high	O
ovulation	O
rate	O
phenomenon	O
in	O
ewes	O
.	O
The	O
elevation	O
of	O
antioxidant	O
defense	O
capacity	O
in	O
FF	O
for	O
BB	O
sheep	O
attracted	O
our	O
attention	O
.	O
Previously	O
","	O
many	O
researchers	O
also	O
supported	O
that	O
antioxidant	O
defense	O
is	O
highly	O
correlated	O
with	O
oocyte	O
developmental	O
competence	O
"[,]."	O
It	O
is	O
reported	O
that	O
low	O
antioxidant	O
capacity	O
in	O
FF	O
accompanied	O
poor	O
oocyte	O
fertilization	O
The	O
levels	O
of	O
lipid	B-Chemical
peroxidation	O
(	O
a	O
proxy	O
of	O
oxidative	O
stress	O
)	O
and	O
the	O
total	O
antioxidant	O
capacity	O
of	O
FF	O
have	O
been	O
positively	O
correlated	O
with	O
pregnancy	O
rates	O
in	O
human	O
studies	O
[].	O
The	O
increase	O
in	O
oxidative	O
stress	O
was	O
associated	O
with	O
high	O
rates	O
of	O
oxidative	O
metabolism	O
.	O
Elevation	O
in	O
the	O
antioxidant	O
defense	O
has	O
been	O
linked	O
to	O
compensatory	O
mechanisms	O
to	O
counteract	O
the	O
toxic	O
effects	O
of	O
reactive	B-Chemical
oxygen	I-Chemical
species	I-Chemical
(	O
ROS	B-Chemical
)	O
[].	O
In	O
the	O
current	O
study	O
","	O
the	O
increases	O
in	O
Î³	O
-	O
glutamyl	O
-	O
amino	O
acid	O
","	O
GSSG	O
","	O
cysteine	B-Chemical
","	O
and	O
cysteine	O
-	O
glutathione	O
indicate	O
the	O
augmented	O
antioxidant	O
defense	O
capacity	O
of	O
FF	O
from	O
BB	O
ewes	O
","	O
which	O
may	O
have	O
beneficial	O
effects	O
on	O
oocyte	O
development	O
.	O
The	O
levels	O
of	O
aspartate	B-Chemical
are	O
worth	O
pointing	O
out	O
","	O
as	O
they	O
were	O
elevated	O
significantly	O
in	O
FF	O
as	O
FecB	O
copies	O
increased	O
","	O
which	O
indicates	O
that	O
the	O
correlation	O
between	O
the	O
aspartate	B-Chemical
level	O
and	O
ovulation	O
rate	O
in	O
Spearman	O
correlation	O
analysis	O
is	O
significant	O
.	O
In	O
human	O
pre	O
-	O
ovulatory	O
follicles	O
","	O
an	O
elevation	O
in	O
the	O
level	O
of	O
d	B-Chemical
-	I-Chemical
aspartate	I-Chemical
has	O
been	O
observed	O
and	O
correlated	O
with	O
the	O
quality	O
of	O
oocytes	O
and	O
a	O
positive	O
outcome	O
of	O
in	O
vitro	O
fertilization	O
[].	O
In	O
addition	O
","	O
d	B-Chemical
-	I-Chemical
aspartate	I-Chemical
was	O
shown	O
to	O
elicit	O
endocrine	O
functions	O
in	O
rats	O
by	O
increasing	O
plasma	O
luteinizing	O
hormone	O
levels	O
[].	O
In	O
our	O
research	O
","	O
it	O
was	O
not	O
possible	O
to	O
differentiate	O
between	O
d	B-Chemical
-	I-Chemical
and	I-Chemical
l	I-Chemical
-	I-Chemical
aspartate	I-Chemical
using	O
this	O
global	O
metabolomic	O
analysis	O
","	O
and	O
specific	O
details	O
need	O
to	O
be	O
included	O
in	O
further	O
study	O
.	O
Steroidogenesis	O
is	O
critical	O
for	O
follicle	O
growth	O
and	O
subsequent	O
oocyte	O
development	O
.	O
Steroid	B-Chemical
hormones	I-Chemical
are	O
synthesized	O
from	O
cholesterol	B-Chemical
through	O
a	O
series	O
of	O
cytochrome	O
P450	O
-	O
dependent	O
reactions	O
[].	O
In	O
a	O
recent	O
study	O
","	O
Foroughinia	O
et	O
al	O
.	O
showed	O
that	O
the	O
expression	O
of	O
a	O
set	O
of	O
genes	O
involved	O
in	O
the	O
synthesis	O
of	O
steroid	B-Chemical
hormones	I-Chemical
","	O
including	O
Cyp19	O
","	O
ESR1	O
","	O
and	O
ESR2	O
","	O
were	O
closely	O
associated	O
with	O
the	O
number	O
of	O
antral	O
follicles	O
in	O
ewe	O
ovaries	O
[].	O
However	O
","	O
very	O
subtle	O
changes	O
were	O
observed	O
in	O
the	O
levels	O
of	O
steroid	B-Chemical
hormones	I-Chemical
between	O
FecB	O
gene	O
carriers	O
and	O
non	O
-	O
carriers	O
.	O
The	O
levels	O
of	O
17Î±	B-Chemical
-	I-Chemical
hydroxyprogesterone	I-Chemical
in	O
FF	O
also	O
did	O
not	O
show	O
a	O
statistical	O
difference	O
.	O
This	O
might	O
be	O
due	O
","	O
at	O
least	O
in	O
part	O
","	O
to	O
the	O
fact	O
that	O
the	O
compound	O
in	O
this	O
study	O
was	O
below	O
the	O
threshold	O
of	O
detection	O
in	O
25	O
â€“	O
38	O
%	O
of	O
the	O
samples	O
from	O
the	O
experimental	O
groups	O
.	O
A	O
number	O
of	O
microbiome	O
-	O
associated	O
metabolites	O
(	O
e	O
.	O
g	O
".,"	O
3	B-Chemical
-(	I-Chemical
4	I-Chemical
-	I-Chemical
hydroxyphenyl	I-Chemical
)	I-Chemical
lactate	I-Chemical
","	O
indolepropionate	B-Chemical
","	O
3	B-Chemical
-	I-Chemical
indoxyl	I-Chemical
sulfate	I-Chemical
)	O
that	O
were	O
unexpectedly	O
elevated	O
in	O
OVS	O
","	O
also	O
followed	O
the	O
same	O
trend	O
in	O
the	O
follicular	O
fluid	O
from	O
BB	O
ewes	O
(	O
vs	O
++).	O
We	O
predicted	O
that	O
the	O
protein	O
of	O
FecB	O
(	O
BMPR1B	O
)	O
was	O
also	O
expressed	O
in	O
colonic	O
epithelial	O
cells	O
","	O
and	O
aberrant	O
BMP	O
signaling	O
was	O
associated	O
with	O
polyposis	O
"[,]."	O
Furthermore	O
","	O
disruption	O
of	O
BMP	O
signaling	O
in	O
the	O
mesenchymal	O
cells	O
of	O
the	O
colon	O
(	O
due	O
to	O
BMPR1A	O
deletion	O
)	O
resulted	O
in	O
a	O
toxic	O
microenvironment	O
with	O
changes	O
in	O
extracellular	O
matrix	O
deposition	O
and	O
secretion	O
of	O
cytokines	O
and	O
growth	O
factors	O
[].	O
Although	O
the	O
majority	O
of	O
reports	O
focus	O
on	O
BMPR1A	O
signaling	O
in	O
the	O
gut	O
","	O
it	O
is	O
possible	O
that	O
alterations	O
in	O
the	O
BMPR1B	O
signal	O
transduction	O
can	O
affect	O
the	O
colonic	O
cells	O
and	O
thus	O
influence	O
the	O
composition	O
and	O
/	O
or	O
activity	O
of	O
gut	O
microbiota	O
.	O
4	O
.	O
Materials	O
and	O
Methods	O
4	O
.	O
1	O
.	O
Animals	O
and	O
Grouping	O
Based	O
on	O
the	O
TaqMan	O
assay	O
using	O
the	O
FecB	O
mutation	O
probe	O
","	O
three	O
FecB	O
genotypes	O
with	O
a	O
total	O
of	O
59	O
pluriparous	O
ewes	O
were	O
selected	O
from	O
the	O
nucleus	O
herd	O
of	O
STH	O
sheep	O
in	O
the	O
southwest	O
region	O
of	O
the	O
province	O
of	O
Shandong	O
in	O
China	O
.	O
These	O
ewes	O
were	O
all	O
approximately	O
3	O
years	O
old	O
and	O
weighed	O
70	O
kg	O
.	O
The	O
same	O
character	O
appearance	O
and	O
health	O
condition	O
were	O
also	O
noted	O
in	O
the	O
experimental	O
animals	O
.	O
The	O
average	O
litter	O
size	O
of	O
first	O
and	O
pluriparous	O
parity	O
in	O
STH	O
ewes	O
were	O
200	O
%	O
and	O
more	O
than	O
250	O
%.	O
The	O
experimental	O
population	O
was	O
divided	O
into	O
three	O
groups	O
","	O
which	O
included	O
20	O
wild	O
-	O
type	O
individuals	O
named	O
the	O
++	O
group	O
","	O
20	O
heterozygote	O
mutant	O
individuals	O
named	O
the	O
+	O
B	O
group	O
","	O
and	O
19	O
homozygous	O
mutant	O
individuals	O
named	O
the	O
BB	O
group	O
.	O
All	O
the	O
experimental	O
procedures	O
mentioned	O
in	O
the	O
present	O
study	O
were	O
approved	O
by	O
the	O
Science	O
Research	O
Department	O
(	O
in	O
charge	O
of	O
animal	O
welfare	O
issue	O
)	O
of	O
the	O
Institute	O
of	O
Animal	O
Sciences	O
","	O
Chinese	O
Academy	O
of	O
Agricultural	O
Sciences	O
(	O
IAS	O
-	O
CAAS	O
)	O
(	O
Beijing	O
","	O
China	O
).	O
Ethical	O
approval	O
on	O
animal	O
survival	O
was	O
given	O
by	O
the	O
animal	O
ethics	O
committee	O
of	O
IAS	O
-	O
CAAS	O
(	O
No	O
.	O
IASCAAS	O
-	O
AE	O
-	O
3	O
","	O
12	O
December	O
2016	O
).	O
4	O
.	O
2	O
.	O
Collecting	O
Data	O
of	O
Ovulation	O
Rate	O
During	O
the	O
spring	O
season	O
","	O
all	O
of	O
the	O
experimental	O
ewes	O
underwent	O
estrus	O
synchronization	O
.	O
Without	O
any	O
interference	O
of	O
exogenous	O
hormones	O
","	O
which	O
may	O
induce	O
superovulation	O
in	O
ewes	O
","	O
CIDR	O
(	O
progesterone	B-Chemical
300	O
mg	O
)	O
was	O
inserted	O
into	O
the	O
animals	O
â€™	O
vaginas	O
for	O
12	O
days	O
","	O
and	O
5	O
mL	O
of	O
vitamin	B-Chemical
AD	I-Chemical
was	O
intramuscularly	O
injected	O
to	O
protect	O
the	O
vaginal	O
epithelium	O
.	O
Forage	O
and	O
drinking	B-Chemical
water	I-Chemical
were	O
provided	O
ad	O
libitum	O
over	O
the	O
duration	O
of	O
the	O
experiment	O
.	O
After	O
one	O
week	O
from	O
the	O
CIDR	O
removal	O
(	O
luteal	O
phase	O
"),"	O
a	O
laparoscopy	O
procedure	O
was	O
adopted	O
for	O
ovulation	O
rate	O
determination	O
.	O
Ovulation	O
rate	O
was	O
equal	O
to	O
the	O
total	O
number	O
of	O
corpus	O
luteum	O
on	O
both	O
sides	O
of	O
an	O
ewe	O
â€™	O
s	O
ovary	O
.	O
4	O
.	O
3	O
.	O
Sample	O
Collection	O
and	O
Follicle	O
Data	O
Measurement	O
Estrus	O
synchronization	O
mentioned	O
above	O
was	O
adopted	O
again	O
to	O
collect	O
follicular	O
fluid	O
(	O
FF	O
)	O
and	O
ovarian	O
vein	O
serum	O
(	O
OVS	O
).	O
The	O
specific	O
protocol	O
was	O
as	O
follows	O
:	O
after	O
45	O
h	O
from	O
the	O
CIDR	O
removal	O
","	O
all	O
visible	O
ovarian	O
follicles	O
with	O
a	O
diameter	O
of	O
3	O
.	O
5	O
mm	O
or	O
greater	O
were	O
selected	O
for	O
follicular	O
diameter	O
determination	O
.	O
FF	O
and	O
OVS	O
collection	O
were	O
achieved	O
through	O
minimally	O
invasive	O
surgery	O
.	O
The	O
diameter	O
of	O
a	O
follicle	O
was	O
the	O
average	O
value	O
of	O
its	O
length	O
(	O
L	O
)	O
and	O
width	O
(	O
W	O
"),"	O
which	O
was	O
measured	O
by	O
vernier	O
caliper	O
and	O
the	O
estimated	O
volume	O
(	O
V	O
)	O
of	O
FF	O
was	O
calculated	O
using	O
the	O
following	O
formula	O
:	O
V	O
=	O
4	O
/	O
3	O
Ã—	O
Ï€	O
Ã—	O
[(	O
L	O
/	O
2	O
+	O
W	O
/	O
2	O
)/	O
2	O
]	O
3	O
[].	O
FF	O
samples	O
were	O
aspirated	O
from	O
non	O
-	O
atretic	O
follicles	O
with	O
a	O
22	O
-	O
gauge	O
needle	O
attached	O
to	O
a	O
2	O
mL	O
sterile	O
syringe	O
(	O
BD	O
","	O
Franklin	O
Lakes	O
","	O
NJ	O
","	O
USA	O
)	O
Cell	O
debris	O
were	O
removed	O
from	O
FF	O
by	O
centrifuging	O
at	O
4	O
Â°	O
C	O
at	O
2000	O
rpm	O
for	O
10	O
min	O
.	O
Full	O
blood	O
was	O
aspirated	O
from	O
ovarian	O
veins	O
using	O
a	O
25	O
gauge	O
needle	O
with	O
a	O
1	O
mL	O
sterile	O
syringe	O
(	O
BD	O
","	O
Franklin	O
Lakes	O
","	O
NJ	O
","	O
USA	O
)	O
and	O
collected	O
in	O
a	O
BD	O
SST	O
tube	O
.	O
After	O
incubating	O
at	O
25	O
Â°	O
C	O
for	O
30	O
min	O
aimed	O
at	O
clotting	O
","	O
OVS	O
samples	O
were	O
collected	O
from	O
full	O
blood	O
and	O
centrifuged	O
at	O
4	O
Â°	O
C	O
at	O
3500	O
rpm	O
for	O
10	O
min	O
.	O
FF	O
samples	O
and	O
OVS	O
samples	O
were	O
all	O
frozen	O
at	O
liquid	O
nitrogen	B-Chemical
instantly	O
and	O
stored	O
at	O
âˆ’	O
80	O
Â°	O
C	O
until	O
further	O
analysis	O
.	O
Finally	O
","	O
11	O
","	O
11	O
","	O
and	O
8	O
biologic	O
repetitions	O
of	O
FF	O
were	O
collected	O
","	O
and	O
10	O
","	O
10	O
","	O
and	O
10	O
biologic	O
repetitions	O
of	O
OVS	O
were	O
collected	O
","	O
respectively	O
","	O
in	O
the	O
"++,"	O
+	O
B	O
","	O
and	O
BB	O
genotype	O
groups	O
for	O
metabolomics	O
analysis	O
.	O
4	O
.	O
4	O
.	O
LC	O
-	O
MS	O
and	O
GC	O
-	O
MS	O
Analysis	O
Metabolite	O
extraction	O
and	O
detection	O
were	O
performed	O
at	O
Metabolon	O
Inc	O
.	O
(	O
Durham	O
","	O
NC	O
","	O
USA	O
)	O
as	O
previously	O
described	O
[].	O
FF	O
and	O
OVS	O
samples	O
(	O
100	O
Î¼L	O
)	O
were	O
extracted	O
through	O
the	O
automated	O
MicroLab	O
STAR	O
Â®	O
system	O
(	O
Hamilton	O
Company	O
","	O
Bonaduz	O
","	O
Switzerland	O
"),"	O
and	O
centrifuged	O
.	O
The	O
resulting	O
supernatants	O
were	O
analyzed	O
by	O
UPLC	O
-	O
MS	O
/	O
MS	O
in	O
a	O
positive	O
and	O
negative	O
ion	O
mode	O
(	O
UPLC	O
:	O
Waters	O
","	O
Milford	O
","	O
MA	O
","	O
USA	O
;	O
mass	O
spectrometer	O
:	O
Thermo	O
-	O
Finnigan	O
LTQ	O
","	O
Thermo	O
Fisher	O
Scientific	O
","	O
Waltham	O
","	O
MA	O
","	O
USA	O
","	O
scan	O
range	O
","	O
80	O
â€“	O
1000	O
m	O
/	O
z	O
)	O
and	O
by	O
GC	O
-	O
MS	O
(	O
Thermo	O
-	O
Finnigan	O
Trace	O
DSQ	O
fast	O
-	O
scanning	O
single	O
-	O
quadrupole	O
mass	O
spectrometer	O
","	O
scan	O
range	O
50	O
â€“	O
750	O
m	O
/	O
z	O
).	O
4	O
.	O
5	O
.	O
Data	O
Extraction	O
and	O
Compound	O
Identification	O
Extraction	O
of	O
raw	O
data	O
","	O
peak	O
identification	O
","	O
and	O
QC	O
were	O
performed	O
using	O
Metabolon	O
â€™	O
s	O
hardware	O
and	O
software	O
according	O
to	O
previously	O
published	O
methods	O
[].	O
Compounds	O
were	O
identified	O
by	O
comparison	O
to	O
library	O
entries	O
of	O
purified	O
standards	O
based	O
on	O
the	O
retention	O
time	O
/	O
index	O
(	O
RI	O
"),"	O
mass	O
to	O
charge	O
ratio	O
(	O
m	O
/	O
z	O
"),"	O
and	O
chromatographic	O
data	O
(	O
including	O
MS	O
/	O
MS	O
spectral	O
data	O
)	O
on	O
all	O
molecules	O
present	O
in	O
the	O
library	O
.	O
4	O
.	O
6	O
.	O
Metabolite	O
Quantification	O
and	O
Statistical	O
Analysis	O
Peaks	O
were	O
quantified	O
based	O
on	O
the	O
area	O
under	O
the	O
curve	O
.	O
The	O
normalized	O
data	O
for	O
each	O
compound	O
were	O
corrected	O
into	O
the	O
medians	O
of	O
data	O
equaling	O
to	O
1	O
.	O
0	O
and	O
making	O
other	O
data	O
point	O
proportionate	O
.	O
The	O
normalized	O
data	O
points	O
were	O
also	O
beneficial	O
for	O
data	O
visualization	O
.	O
The	O
chi	O
-	O
square	O
test	O
was	O
used	O
to	O
analyze	O
categorical	O
variables	O
such	O
as	O
the	O
ovulation	O
rate	O
and	O
the	O
follicle	O
number	O
difference	O
.	O
One	O
-	O
way	O
ANOVA	O
was	O
adopted	O
to	O
analyze	O
continuous	O
variables	O
of	O
ovulation	O
follicle	O
diameter	O
and	O
the	O
levels	O
of	O
biochemicals	O
.	O
To	O
assess	O
the	O
relationship	O
between	O
metabolic	O
changes	O
and	O
ovulation	O
rates	O
","	O
the	O
Spearman	O
correlation	O
was	O
calculated	O
using	O
scaled	O
imputed	O
log	O
-	O
transformed	O
metabolite	O
levels	O
and	O
ovulation	O
rate	O
values	O
(	O
R	O
","	O
version	O
3	O
.	O
0	O
.	O
2	O
).	O
Principal	O
component	O
analysis	O
(	O
PCA	O
)	O
and	O
hierarchical	O
clustering	O
analysis	O
(	O
HCA	O
)	O
were	O
used	O
to	O
obtain	O
a	O
high	O
-	O
level	O
view	O
of	O
metabolomic	O
datasets	O
.	O
PCA	O
is	O
a	O
mathematical	O
procedure	O
that	O
uses	O
an	O
orthogonal	O
transformation	O
to	O
convert	O
a	O
set	O
of	O
observations	O
of	O
possibly	O
correlated	O
variables	O
into	O
a	O
set	O
of	O
values	O
of	O
linearly	O
uncorrelated	O
variables	O
called	O
principle	O
components	O
.	O
HCA	O
assesses	O
sample	O
similarity	O
by	O
grouping	O
a	O
â€œ	O
hierarchy	O
â€	O
of	O
clustered	O
samples	O
and	O
grouping	O
metabolically	O
similar	O
samples	O
close	O
to	O
one	O
another	O
.	O
Random	O
forest	O
was	O
employed	O
to	O
determine	O
key	O
biochemicals	O
and	O
to	O
differentiate	O
classification	O
groups	O
.	O
Statistical	O
analyses	O
mentioned	O
above	O
were	O
performed	O
with	O
the	O
Array	O
Studio	O
","	O
version	O
7	O
.	O
2	O
(	O
OmicsSoft	O
Corporation	O
","	O
Research	O
Triangle	O
Park	O
","	O
NC	O
","	O
USA	O
)	O
and	O
R	O
version	O
3	O
.	O
0	O
.	O
2	O
().	O
5	O
.	O
Conclusions	O
The	O
results	O
from	O
theses	O
global	O
metabolomics	O
studies	O
comparing	O
ewes	O
carrying	O
FecB	O
mutation	O
(	O
homozygous	O
and	O
heterozygous	O
)	O
in	O
relation	O
to	O
non	O
-	O
carriers	O
differed	O
in	O
a	O
number	O
of	O
metabolic	O
readouts	O
with	O
a	O
more	O
pronounced	O
metabolic	O
impact	O
of	O
the	O
FecB	O
gene	O
in	O
FF	O
than	O
in	O
OVS	O
(	O
higher	O
number	O
of	O
statistically	O
significant	O
changes	O
","	O
better	O
group	O
separation	O
in	O
PCA	O
and	O
HCA	O
).	O
In	O
FF	O
","	O
changes	O
in	O
amino	B-Chemical
acid	I-Chemical
metabolism	O
relating	O
to	O
different	O
rates	O
of	O
protein	O
biosynthesis	O
might	O
affect	O
the	O
growth	O
of	O
the	O
developing	O
oocyte	O
.	O
Differences	O
observed	O
in	O
the	O
biochemicals	O
involved	O
in	O
redox	O
homeostasis	O
reflected	O
a	O
higher	O
oxidative	O
pressure	O
of	O
rapidly	O
dividing	O
cells	O
in	O
BB	O
animals	O
","	O
which	O
indicated	O
a	O
greater	O
antioxidant	O
capacity	O
in	O
FF	O
.	O
Additionally	O
","	O
some	O
key	O
metabolites	O
in	O
ovine	O
FF	O
samples	O
were	O
found	O
to	O
significantly	O
correlate	O
with	O
ovulation	O
rate	O
.	O
Collectively	O
","	O
similar	O
to	O
the	O
ovulation	O
rate	O
","	O
the	O
differences	O
in	O
the	O
metabolic	O
profile	O
in	O
FF	O
is	O
also	O
affected	O
by	O
the	O
FecB	O
genotypes	O
.	O
Supplementary	O
Materials	O
Supplementary	O
materials	O
can	O
be	O
found	O
at	O
.	O
Author	O
Contributions	O
Xiaofei	O
Guo	O
","	O
Xiangyu	O
Wang	O
","	O
and	O
Mingxing	O
Chu	O
conceived	O
and	O
designed	O
this	O
study	O
;	O
Xiaofei	O
Guo	O
","	O
Xiangyu	O
Wang	O
","	O
Ran	O
Di	O
","	O
Qiuyue	O
Liu	O
","	O
Wenping	O
Hu	O
","	O
Xiaoyun	O
He	O
","	O
Jiarui	O
Yu	O
","	O
Xiaosheng	O
Zhang	O
","	O
and	O
Jinlong	O
Zhang	O
conducted	O
the	O
experiments	O
;	O
Xiaofei	O
Guo	O
","	O
Xiangyu	O
Wang	O
","	O
Katarzyna	O
Broniowska	O
","	O
and	O
Wei	O
Chen	O
analyzed	O
the	O
data	O
;	O
Xiaofei	O
Guo	O
","	O
Xiangyu	O
Wang	O
","	O
Mingxing	O
Chu	O
","	O
and	O
Changxin	O
Wu	O
prepared	O
the	O
manuscript	O
.	O
Conflicts	O
of	O
Interest	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O
Abbreviations	O
FF	O
follicular	O
fluid	O
OVS	O
ovarian	O
vein	O
serum	O
STH	O
Small	O
Tail	O
Han	O
PCA	O
principal	O
component	O
analysis	O
HCA	O
hierarchical	O
clustering	O
analysis	O
GC	O
-	O
MS	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
LC	O
-	O
MS	O
liquid	O
chromatography	O
-	O
mass	O
spectrometry	O
BFB	O
blood	O
follicular	O
barrier	O
ROS	B-Chemical
reactive	I-Chemical
oxygen	I-Chemical
species	I-Chemical
CoCs	O
Cumulus	O
-	O
oocyte	O
complexes	O
CIDR	O
controlled	O
internal	O
drug	O
releasing	O
References	O
Venn	O
diagrams	O
for	O
different	O
levels	O
of	O
biochemical	O
.	O
(	O
A	O
)	O
Venn	O
diagrams	O
for	O
different	O
levels	O
of	O
biochemicals	O
in	O
FF	O
samples	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
);	O
(	O
B	O
)	O
Venn	O
diagrams	O
for	O
different	O
levels	O
of	O
biochemicals	O
in	O
OVS	O
samples	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
).	O
Samples	O
clustering	O
analysis	O
using	O
PCA	O
and	O
HCA	O
:	O
(	O
A	O
)	O
PCA	O
analysis	O
of	O
FF	O
samples	O
;	O
(	O
B	O
)	O
PCA	O
analysis	O
of	O
OVS	O
samples	O
;	O
(	O
C	O
)	O
HCA	O
analysis	O
of	O
FF	O
samples	O
;	O
(	O
D	O
)	O
HCA	O
analysis	O
of	O
OVS	O
samples	O
.	O
Identification	O
of	O
biomarkers	O
for	O
the	O
FecB	O
effect	O
in	O
FF	O
and	O
OVS	O
samples	O
.	O
(	O
A	O
)	O
Random	O
forest	O
classification	O
in	O
FF	O
of	O
BB	O
compared	O
to	O
+	O
B	O
and	O
++	O
gave	O
a	O
predictive	O
accuracy	O
of	O
83	O
%.	O
(	O
B	O
)	O
Random	O
forest	O
classification	O
in	O
OVS	O
of	O
BB	O
compared	O
to	O
+	O
B	O
and	O
++	O
gave	O
a	O
predictive	O
accuracy	O
of	O
63	O
%.	O
(	O
C	O
)	O
Important	O
biochemicals	O
identified	O
in	O
FF	O
samples	O
.	O
(	O
D	O
)	O
Important	O
biochemicals	O
identified	O
in	O
OVS	O
samples	O
.	O
Changes	O
in	O
energy	O
metabolism	O
in	O
FF	O
samples	O
.	O
Note	O
:	O
a	O
","	O
b	O
represent	O
means	O
with	O
different	O
superscripts	O
in	O
box	O
plots	O
have	O
a	O
significant	O
difference	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
"),"	O
box	O
plots	O
with	O
the	O
ab	O
superscript	O
indicate	O
no	O
significant	O
difference	O
with	O
a	O
and	O
b	O
;	O
the	O
red	O
font	O
indicates	O
that	O
the	O
concentration	O
of	O
biochemicals	O
was	O
elevated	O
in	O
BB	O
with	O
a	O
significant	O
difference	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
"),"	O
and	O
the	O
green	O
font	O
indicates	O
that	O
the	O
concentration	O
of	O
biochemicals	O
declined	O
in	O
BB	O
with	O
a	O
significant	O
difference	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
).	O
(	O
A	O
)	O
Box	O
plots	O
for	O
glucose	B-Chemical
6	I-Chemical
-	I-Chemical
phosphate	I-Chemical
in	O
FF	O
samples	O
;	O
(	O
B	O
)	O
Box	O
plots	O
for	O
acetyl	B-Chemical
-	I-Chemical
CoA	I-Chemical
in	O
FF	O
samples	O
;	O
(	O
C	O
)	O
Box	O
plots	O
for	O
malate	O
in	O
FF	O
samples	O
;	O
(	O
D	O
)	O
Box	O
plots	O
for	O
glucose	B-Chemical
1	I-Chemical
-	I-Chemical
phosphate	I-Chemical
in	O
FF	O
samples	O
;	O
(	O
E	O
)	O
Box	O
plots	O
for	O
citrate	B-Chemical
in	O
FF	O
samples	O
;	O
(	O
F	O
)	O
Box	O
plots	O
for	O
alpha	B-Chemical
-	I-Chemical
ketoglutarate	I-Chemical
in	O
FF	O
samples	O
.	O
Elevation	O
of	O
antioxidant	O
defense	O
capacity	O
in	O
FF	O
.	O
Note	O
:	O
a	O
","	O
b	O
","	O
c	O
represent	O
means	O
with	O
different	O
superscripts	O
in	O
box	O
plots	O
have	O
a	O
significant	O
difference	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
);	O
box	O
plots	O
with	O
ab	O
superscript	O
indicate	O
no	O
significant	O
difference	O
with	O
a	O
and	O
b	O
;	O
red	O
font	O
indicates	O
that	O
the	O
concentration	O
of	O
biochemicals	O
was	O
elevated	O
in	O
BB	O
with	O
a	O
significant	O
difference	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
"),"	O
and	O
the	O
green	O
font	O
indicates	O
that	O
the	O
concentration	O
of	O
biochemicals	O
declined	O
in	O
BB	O
with	O
a	O
significant	O
difference	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
).	O
(	O
A	O
)	O
Box	O
plots	O
for	O
glutathione	B-Chemical
","	O
oxidized	O
(	O
GSSG	O
)	O
in	O
FF	O
samples	O
;	O
(	O
B	O
)	O
Box	O
plots	O
for	O
cysteine	B-Chemical
in	O
FF	O
samples	O
;	O
(	O
C	O
)	O
Box	O
plots	O
for	O
cysteine	O
-	O
glutathione	O
disulfide	O
in	O
FF	O
samples	O
;	O
(	O
D	O
)	O
Box	O
plots	O
for	O
5	B-Chemical
-	I-Chemical
oxoproline	I-Chemical
in	O
FF	O
samples	O
;	O
(	O
E	O
)	O
Box	O
plots	O
for	O
2	B-Chemical
-	I-Chemical
hydroxybutyrate	I-Chemical
in	O
FF	O
samples	O
;	O
(	O
F	O
)	O
Box	O
plots	O
for	O
Î³	O
-	O
glutamylleucine	O
in	O
FF	O
samples	O
;	O
(	O
G	O
)	O
Box	O
plots	O
for	O
gamma	O
-	O
glutamylglutamine	O
in	O
FF	O
samples	O
;	O
(	O
H	O
)	O
Box	O
plots	O
for	O
gamma	O
-	O
glutamylisoleucine	O
in	O
FF	O
samples	O
;	O
(	O
I	O
)	O
Box	O
plots	O
for	O
gamma	O
-	O
glutamylalanine	O
in	O
FF	O
samples	O
;	O
(	O
J	O
)	O
Box	O
plots	O
for	O
Î³	O
-	O
glutamylphenylalanine	O
in	O
FF	O
samples	O
;	O
(	O
K	O
)	O
Box	O
plots	O
for	O
gamma	O
-	O
glutamyltyrosine	O
in	O
FF	O
samples	O
;	O
(	O
L	O
)	O
The	O
biological	O
synthesis	O
of	O
GSH	O
(	O
glutathione	O
).	O
Note	O
:	O
a	O
","	O
b	O
","	O
c	O
represent	O
means	O
with	O
different	O
superscripts	O
in	O
the	O
same	O
line	O
have	O
a	O
highly	O
significant	O
difference	O
(	O
p	O
â‰¤	O
0	O
.	O
1	O
).	O
Values	O
are	O
means	O
Â±	O
SEM	O
.	O
++:	O
wild	O
-	O
type	O
for	O
FecB	O
gene	O
;	O
+	O
B	O
:	O
heterozygote	O
mutant	O
for	O
FecB	O
gene	O
;	O
BB	O
:	O
homozygous	O
mutant	O
for	O
FecB	O
gene	O
.	O
Measurements	O
of	O
ovulation	O
rate	O
","	O
number	O
","	O
and	O
diameter	O
for	O
pre	O
-	O
ovulation	O
.	O
Red	O
indicates	O
a	O
significant	O
difference	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
)	O
between	O
the	O
groups	O
shown	O
and	O
a	O
metabolite	O
ratio	O
of	O
â‰¥	O
1	O
.	O
0	O
;	O
light	O
red	O
indicates	O
a	O
narrowly	O
missed	O
statistical	O
cutoff	O
for	O
significance	O
0	O
.	O
5	O
<	O
p	O
â‰¤	O
0	O
.	O
10	O
and	O
a	O
metabolite	O
ratio	O
of	O
â‰¥	O
1	O
.	O
0	O
.	O
Levels	O
of	O
amino	B-Chemical
acids	I-Chemical
comparing	O
in	O
FF	O
.	O
Red	O
indicates	O
significant	O
difference	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
)	O
between	O
the	O
groups	O
shown	O
and	O
a	O
metabolite	O
ratio	O
of	O
â‰¥	O
1	O
.	O
0	O
;	O
light	O
red	O
indicates	O
a	O
narrowly	O
missed	O
statistical	O
cutoff	O
for	O
significance	O
0	O
.	O
5	O
<	O
p	O
â‰¤	O
0	O
.	O
10	O
and	O
a	O
metabolite	O
ratio	O
of	O
â‰¥	O
1	O
.	O
0	O
;	O
green	O
indicates	O
a	O
significant	O
difference	O
(	O
p	O
â‰¤	O
0	O
.	O
5	O
)	O
between	O
the	O
groups	O
shown	O
and	O
a	O
metabolite	O
ratio	O
of	O
â‰¤	O
1	O
.	O
0	O
.	O
Levels	O
of	O
biochemicals	O
related	O
to	O
antioxidant	O
defense	O
capacity	O
comparing	O
in	O
FF	O
.	O
Why	O
Is	O
a	O
High	O
Temperature	O
Needed	O
by	O
Thermus	O
thermophilus	O
Argonaute	O
During	O
mRNA	O
Silencing	O
:	O
A	O
Theoretical	O
Study	O
Thermus	O
thermophiles	O
Argonaute	O
(	O
TtAgo	O
)	O
is	O
a	O
complex	O
","	O
which	O
is	O
consisted	O
of	O
5	O
â€²-	O
phosphorylated	O
guide	O
DNA	O
and	O
a	O
series	O
of	O
target	O
DNA	O
with	O
catalytic	O
activities	O
at	O
high	O
temperatures	O
.	O
To	O
understand	O
why	O
high	O
temperatures	O
are	O
needed	O
for	O
the	O
catalytic	O
activities	O
","	O
three	O
molecular	O
dynamics	O
simulations	O
and	O
binding	O
free	O
energy	O
calculations	O
at	O
310	O
","	O
324	O
","	O
and	O
338K	O
were	O
performed	O
for	O
the	O
TtAgo	O
-	O
DNA	O
complex	O
to	O
explore	O
the	O
conformational	O
changes	O
between	O
16	O
-	O
mer	O
guide	O
DNA	O
/	O
15	O
-	O
mer	O
target	O
DNA	O
and	O
TtAgo	O
at	O
different	O
temperatures	O
.	O
The	O
simulation	O
results	O
indicate	O
that	O
a	O
collapse	O
of	O
a	O
small	O
Î²	O
-	O
strand	O
(	O
residues	O
507	O
â€“	O
509	O
)	O
at	O
310	O
K	O
caused	O
Glu512	B-Chemical
to	O
move	O
away	O
from	O
the	O
catalytic	O
residues	O
Asp546	B-Chemical
and	O
Asp478	B-Chemical
","	O
resulting	O
in	O
a	O
decrease	O
in	O
catalytic	O
activity	O
","	O
which	O
was	O
not	O
observed	O
in	O
the	O
simulations	O
at	O
324	O
and	O
338	O
K	O
.	O
The	O
nucleic	O
acid	O
binding	O
channel	O
became	O
enlarged	O
at	O
324	O
and	O
338K	O
","	O
thereby	O
facilitating	O
the	O
DNA	O
to	O
slide	O
in	O
.	O
Binding	O
free	O
energy	O
calculations	O
and	O
hydrogen	B-Chemical
bond	O
occupancy	O
indicated	O
that	O
the	O
interaction	O
between	O
TtAgo	O
and	O
the	O
DNA	O
was	O
more	O
stable	O
at	O
324K	O
and	O
338K	O
than	O
at	O
310	O
K	O
.	O
The	O
DNA	O
binding	O
pocket	O
residues	O
Lys575	B-Chemical
and	O
Asn590	B-Chemical
became	O
less	O
solvent	O
accessible	O
at	O
324	O
and	O
338K	O
than	O
at	O
310	O
K	O
to	O
influence	O
hydrophilic	O
interaction	O
with	O
DNA	O
.	O
Our	O
simulation	O
studies	O
shed	O
some	O
light	O
on	O
the	O
mechanism	O
of	O
TtAgo	O
and	O
explained	O
why	O
a	O
high	O
temperature	O
was	O
needed	O
by	O
TtAgo	O
during	O
gene	O
editing	O
of	O
CRISPR	O
.	O
Introduction	O
Argonaute	O
(	O
Ago	O
)	O
proteins	O
preform	O
a	O
critical	O
role	O
in	O
guide	O
target	O
RNA	O
recognition	O
","	O
cleavage	O
","	O
and	O
product	O
release	O
","	O
which	O
depend	O
on	O
key	O
components	O
of	O
a	O
RNA	O
-	O
induced	O
silencing	O
complex	O
(	O
Peters	O
and	O
Meister	O
","	O
;	O
Hutvagner	O
and	O
Simard	O
","	O
;	O
Kawamata	O
and	O
Tomari	O
","	O
;	O
Sheng	O
et	O
al	O
".,"	O
).	O
These	O
proteins	O
belong	O
to	O
the	O
TNRC6	O
/	O
GW182	O
protein	O
family	O
","	O
coordinates	O
downstream	O
silencing	O
events	O
","	O
which	O
also	O
named	O
TNRC6A	O
-	O
C	O
and	O
GW	O
proteins	O
in	O
humans	O
.	O
Ago	O
proteins	O
are	O
provided	O
with	O
four	O
domains	O
with	O
distinct	O
functions	O
(	O
Huntzinger	O
and	O
Izaurralde	O
","	O
;	O
Pfaff	O
and	O
Meister	O
","	O
;	O
Chen	O
et	O
al	O
".,"	O
;	O
Mathys	O
et	O
al	O
".,"	O
;	O
Hauptmann	O
et	O
al	O
".,"	O
).	O
The	O
N	O
-	O
terminal	O
domain	O
plays	O
a	O
key	O
role	O
for	O
small	O
RNA	O
binding	O
.	O
The	O
P	O
element	O
-	O
induced	O
wimpy	O
testis	O
(	O
PIWI	O
)â€“	O
Argonaute	O
â€“	O
Zwille	O
(	O
PAZ	O
)	O
domain	O
is	O
essential	O
for	O
recruiting	O
the	O
middle	O
domain	O
(	O
MID	O
)	O
and	O
the	O
5	O
â€²	O
end	O
of	O
a	O
small	O
RNA	O
.	O
The	O
PIWI	O
domain	O
has	O
the	O
same	O
function	O
as	O
the	O
RNase	O
H	O
domain	O
","	O
and	O
some	O
Ago	O
proteins	O
can	O
serve	O
as	O
small	O
RNA	O
-	O
guided	O
endonucleases	O
(	O
Hauptmann	O
et	O
al	O
".,"	O
).	O
The	O
PIWI	O
domain	O
is	O
essential	O
for	O
the	O
cleavage	O
activity	O
of	O
Ago	O
in	O
which	O
the	O
Asp	B-Chemical
â€“	O
Asp	B-Chemical
â€“	O
Asp	B-Chemical
/	O
His	B-Chemical
catalytic	O
triad	O
of	O
Ago	O
processes	O
the	O
identification	O
of	O
double	O
stranded	O
RNAs	O
and	O
the	O
cleaving	O
of	O
their	O
strand	O
(	O
Liu	O
et	O
al	O
".,"	O
;	O
Song	O
et	O
al	O
".,"	O
;	O
Ma	O
et	O
al	O
".,"	O
;	O
Rivas	O
et	O
al	O
".,"	O
;	O
Yuan	O
et	O
al	O
".,"	O
;	O
Parker	O
and	O
Roe	O
","	O
).	O
It	O
also	O
acts	O
on	O
guide	O
-	O
target	O
RNA	O
duplexes	O
to	O
cleave	O
their	O
target	O
strand	O
.	O
Mg2	B-Chemical
+	I-Chemical
cation	O
mediates	O
the	O
endonucleolytic	O
cleavage	O
of	O
a	O
target	O
RNA	O
strand	O
(	O
Martinez	O
and	O
Tuschl	O
","	O
;	O
Schwarz	O
et	O
al	O
".,"	O
;	O
Lingel	O
and	O
Sattler	O
","	O
;	O
Jinek	O
and	O
Doudna	O
","	O
;	O
Parker	O
","	O
"),"	O
thereby	O
forming	O
3	O
â€²-	O
OH	O
and	O
5	O
â€²-	O
phosphate	O
ends	O
(	O
Elbashir	O
et	O
al	O
".,"	O
).	O
A	O
series	O
of	O
experimental	O
structures	O
of	O
Thermus	O
thermophilus	O
Argonaute	O
(	O
TtAgo	O
)	O
binding	O
to	O
various	O
complexes	O
of	O
different	O
nucleic	O
acid	O
strands	O
provide	O
insights	O
into	O
conformational	O
changes	O
in	O
proteins	O
and	O
DNAs	O
(	O
Jung	O
et	O
al	O
".,"	O
;	O
Zhu	O
et	O
al	O
".,"	O
",;"	O
Sheng	O
et	O
al	O
".,"	O
).	O
Two	O
structures	O
","	O
namely	O
","	O
PDB	O
ID	O
3F73	O
and	O
PDB	O
ID	O
3HM9	O
","	O
whose	O
substrates	O
have	O
different	O
lengths	O
(	O
Wang	O
et	O
al	O
".,"	O
",),"	O
suggested	O
that	O
the	O
PAZ	O
domain	O
undergo	O
a	O
series	O
of	O
motions	O
during	O
a	O
catalytic	O
cycle	O
.	O
They	O
also	O
reveal	O
the	O
PAZ	O
domain	O
disassociates	O
from	O
the	O
3	O
â€²	O
end	O
of	O
the	O
guide	O
upon	O
target	O
binding	O
(	O
Xia	O
et	O
al	O
".,"	O
;	O
Wang	O
et	O
al	O
".,"	O
;	O
Nam	O
et	O
al	O
".,"	O
;	O
Swarts	O
et	O
al	O
".,"	O
;	O
Jiang	O
et	O
al	O
".,"	O
).	O
This	O
study	O
focused	O
on	O
TtAgo	O
.	O
Figure	O
1	O
shows	O
the	O
crystal	O
structure	O
of	O
TtAgo	O
(	O
PDB	O
ID	O
4NCB	O
)	O
with	O
bound	O
16	O
-	O
mer	O
guide	O
DNA	O
and	O
15	O
-	O
mer	O
target	O
DNA	O
(	O
Sheng	O
et	O
al	O
".,"	O
).	O
TtAgo	O
is	O
also	O
made	O
up	O
by	O
four	O
functional	O
domains	O
","	O
similar	O
to	O
other	O
Ago	O
proteins	O
","	O
which	O
named	O
N	O
","	O
PAZ	O
","	O
MID	O
and	O
C	O
-	O
terminal	O
PIWI	O
domain	O
.	O
These	O
four	O
domains	O
are	O
connected	O
by	O
two	O
linker	O
domains	O
L1	O
(	O
Linker	O
1	O
)	O
and	O
Linker	O
2	O
(	O
L2	O
)	O
(	O
Figures	O
1A	O
â€“	O
F	O
).	O
MID	O
bind	O
to	O
5	O
â€²	O
terminals	O
of	O
the	O
guide	O
and	O
PAZ	O
bind	O
to	O
3	O
â€²	O
terminals	O
of	O
the	O
guide	O
","	O
both	O
of	O
them	O
define	O
the	O
nucleic	O
acid	O
binding	O
channel	O
(	O
Figure	O
1C	O
and	O
Figure	O
S1	O
).	O
Driven	O
mainly	O
by	O
positively	O
charged	O
residues	O
of	O
TtAgo	O
and	O
negatively	O
charged	O
DNA	O
backbone	O
atoms	O
(	O
Zander	O
et	O
al	O
".,"	O
;	O
Swarts	O
et	O
al	O
".,"	O
;	O
Figure	O
S1A	O
"),"	O
the	O
nucleotides	B-Chemical
2	O
â€“	O
8	O
of	O
the	O
guide	O
of	O
5	O
â€²	O
segment	O
","	O
which	O
called	O
seed	O
region	O
","	O
involved	O
the	O
combination	O
of	O
the	O
channel	O
binding	O
(	O
Figures	O
S1B	O
","	O
C	O
).	O
The	O
correct	O
positioning	O
of	O
the	O
seed	O
region	O
is	O
important	O
for	O
the	O
binding	O
between	O
the	O
target	O
nucleic	O
acid	O
and	O
TtAgo	O
and	O
human	O
Ago	O
(	O
Lee	O
et	O
al	O
".,"	O
;	O
Khin	O
et	O
al	O
".,"	O
).	O
The	O
distance	O
between	O
Glu512	B-Chemical
and	O
active	O
center	O
(	O
Asp478	B-Chemical
","	O
Asp546	B-Chemical
","	O
and	O
Asp660	B-Chemical
)	O
directly	O
affects	O
the	O
activity	O
of	O
TtAgo	O
.	O
When	O
Glu512	B-Chemical
is	O
far	O
from	O
the	O
catalytic	O
pocket	O
(	O
Figure	O
S1D	O
;	O
Wang	O
et	O
al	O
".,"	O
",),"	O
it	O
turns	O
out	O
to	O
be	O
a	O
cleavage	O
-	O
incompatible	O
conformation	O
.	O
Glu512	B-Chemical
positioned	O
on	O
loop	O
L2	O
","	O
close	O
to	O
the	O
catalytic	O
pocket	O
","	O
represents	O
a	O
key	O
residue	O
for	O
a	O
cleavage	O
-	O
compatible	O
conformation	O
(	O
Figure	O
1G	O
and	O
Figure	O
S1E	O
).	O
Argonaute	O
protein	O
of	O
TtAgo	O
.	O
(	O
A	O
)	O
Domain	O
composition	O
(	O
left	O
)	O
and	O
nucleic	O
acid	O
binding	O
channel	O
(	O
right	O
)	O
of	O
TtAgo	O
(	O
PDB	O
4NCB	O
).	O
(	O
B	O
)	O
Sequence	O
and	O
pairing	O
of	O
guide	O
(	O
blue	O
)	O
and	O
target	O
(	O
red	O
)	O
strands	O
in	O
the	O
ternary	O
complex	O
of	O
4NCB	O
.	O
(	O
C	O
â€“	O
E	O
)	O
The	O
3	O
-	O
D	O
structures	O
of	O
TtAgo	O
ternary	O
complex	O
were	O
colored	O
as	O
(	O
A	O
","	O
B	O
).	O
In	O
(	O
C	O
"),"	O
the	O
TtAgo	O
protein	O
is	O
shown	O
as	O
a	O
surface	O
","	O
whereas	O
the	O
nucleic	O
acid	O
is	O
shown	O
as	O
a	O
cartoon	O
.	O
In	O
(	O
D	O
","	O
E	O
"),"	O
the	O
TtAgo	O
protein	O
is	O
shown	O
as	O
a	O
cartoon	O
","	O
whereas	O
the	O
nucleic	O
acid	O
is	O
shown	O
as	O
a	O
stick	O
.	O
(	O
G	O
)	O
Catalytic	O
residues	O
of	O
TtAgo	O
.	O
The	O
catalytic	O
residues	O
in	O
a	O
stick	O
representation	O
were	O
highlighted	O
by	O
pink	O
sticks	O
and	O
a	O
cyan	O
mesh	O
.	O
As	O
CRISPR	O
/	O
Cas9	O
becomes	O
a	O
popular	O
molecular	O
biology	O
technology	O
for	O
gene	O
editing	O
","	O
there	O
is	O
a	O
continuous	O
interest	O
in	O
searching	O
for	O
new	O
genome	O
-	O
editing	O
methods	O
.	O
Recently	O
","	O
it	O
has	O
been	O
reported	O
that	O
argonaute	O
proteins	O
prossess	O
DNA	O
-	O
guided	O
sequence	O
-	O
specific	O
DNA	O
endonuclease	O
activity	O
in	O
Pyrococcus	O
furiosus	O
","	O
Thermus	O
thermophilus	O
","	O
and	O
Methanocaldococcus	O
jannaschii	O
(	O
Beshnova	O
et	O
al	O
".,"	O
;	O
Cherstvy	O
and	O
Teif	O
","	O
;	O
Harikrishna	O
and	O
Pradeepkumar	O
","	O
)	O
and	O
it	O
can	O
be	O
as	O
a	O
host	O
defense	O
system	O
to	O
eliminate	O
invading	O
nucleic	O
acids	O
.	O
These	O
argonaute	O
proteins	O
usually	O
needs	O
high	O
temperature	O
to	O
be	O
fully	O
active	O
","	O
which	O
may	O
restrict	O
the	O
application	O
in	O
many	O
aspects	O
.	O
In	O
2016	O
","	O
the	O
argonaute	O
protein	O
(	O
NgAgo	O
)	O
from	O
Natronobacterium	O
gregoryi	O
was	O
reported	O
to	O
as	O
mesophilic	O
microbe	O
whose	O
enzymes	O
","	O
which	O
is	O
functional	O
at	O
310K	O
.	O
Compared	O
to	O
Cas9	O
","	O
it	O
have	O
higher	O
genome	O
editing	O
activity	O
in	O
mammalian	O
cells	O
(	O
Chandradoss	O
et	O
al	O
".,"	O
).	O
Since	O
NgAgo	O
does	O
not	O
require	O
a	O
PAM	O
motif	O
and	O
the	O
authors	O
reported	O
the	O
PAM	O
motif	O
is	O
not	O
essential	O
for	O
NgAgo	O
and	O
high	O
efficiency	O
to	O
targets	O
of	O
high	O
guanine	B-Chemical
-	O
cytosine	B-Chemical
content	O
","	O
NgAgo	O
was	O
once	O
considered	O
promising	O
as	O
a	O
useful	O
tool	O
for	O
genome	O
editing	O
.	O
However	O
","	O
as	O
soon	O
as	O
researchers	O
set	O
off	O
on	O
a	O
whirlwind	O
of	O
experiments	O
(	O
Chandradoss	O
et	O
al	O
".,"	O
;	O
Salomon	O
et	O
al	O
".,"	O
"),"	O
questions	O
started	O
to	O
emerge	O
and	O
the	O
hope	O
was	O
quickly	O
faded	O
.	O
Nevertheless	O
","	O
it	O
is	O
unclear	O
why	O
NgAgo	O
cannot	O
perform	O
the	O
function	O
of	O
TtAgo	O
","	O
although	O
the	O
two	O
proteins	O
have	O
significant	O
sequence	O
similarity	O
","	O
and	O
whether	O
it	O
is	O
possible	O
to	O
use	O
or	O
modify	O
argonaute	O
as	O
a	O
target	O
for	O
gene	O
editing	O
.	O
It	O
has	O
been	O
reported	O
that	O
TtAgo	O
is	O
active	O
at	O
high	O
temperatures	O
","	O
not	O
at	O
low	O
temperatures	O
.	O
But	O
how	O
temperature	O
affects	O
TtAgo	O
activity	O
","	O
it	O
has	O
not	O
been	O
clarified	O
so	O
far	O
.	O
A	O
few	O
molecular	O
dynamics	O
(	O
MD	O
)	O
studies	O
on	O
siRNA	O
â€“	O
TtAgo	O
and	O
siRNA	O
â€“	O
hAGO2	O
complexes	O
have	O
been	O
conducted	O
(	O
Wang	O
et	O
al	O
".,"	O
;	O
Nam	O
et	O
al	O
".,"	O
;	O
Hanlun	O
et	O
al	O
".,"	O
).	O
Jiang	O
et	O
al	O
.	O
constructed	O
from	O
MD	O
simulations	O
and	O
found	O
that	O
MSMs	O
can	O
elucidate	O
the	O
conformational	O
dynamics	O
of	O
AGO	O
at	O
biologically	O
relevant	O
timescales	O
(	O
Hanlun	O
et	O
al	O
".,"	O
).	O
Jinhyuk	O
Lee	O
pointed	O
out	O
that	O
they	O
revealed	O
different	O
structural	O
conformations	O
of	O
the	O
RNA	O
duplex	O
in	O
Ago2	O
","	O
depending	O
on	O
Mg2	B-Chemical
+	O
concentration	O
and	O
demonstrated	O
that	O
cation	O
effects	O
on	O
Ago2	O
structural	O
flexibility	O
are	O
critical	O
to	O
its	O
catalytic	O
/	O
functional	O
activity	O
","	O
with	O
low	O
Mg2	B-Chemical
+	O
favoring	O
greater	O
Ago2	O
flexibility	O
and	O
less	O
miRNA	O
/	O
mRNA	O
duplex	O
stability	O
","	O
thus	O
favoring	O
slicing	O
(	O
Nam	O
et	O
al	O
".,"	O
).	O
Wang	O
et	O
al	O
.	O
discovered	O
three	O
findings	O
during	O
MD	O
simulations	O
:	O
(	O
1	O
)	O
three	O
important	O
(	O
PAZ	O
","	O
Mid	O
and	O
PIWI	O
)	O
domains	O
existed	O
in	O
Argonaute	O
which	O
defined	O
the	O
global	O
dynamics	O
of	O
the	O
protein	O
;	O
(	O
2	O
)	O
the	O
interdomain	O
correlated	O
movements	O
were	O
so	O
crucial	O
for	O
the	O
interaction	O
of	O
Ago	O
-	O
RNAs	O
that	O
they	O
not	O
only	O
facilitated	O
the	O
relaxation	O
of	O
the	O
interactions	O
between	O
residues	O
surrounding	O
the	O
RNA	O
binding	O
channel	O
but	O
also	O
induced	O
certain	O
conformational	O
changes	O
;	O
and	O
(	O
3	O
)	O
it	O
was	O
just	O
these	O
conformational	O
changes	O
that	O
expand	O
the	O
cavity	O
of	O
the	O
active	O
site	O
and	O
open	O
putative	O
pathways	O
for	O
both	O
the	O
substrate	O
uptake	O
and	O
product	O
release	O
(	O
Wang	O
et	O
al	O
".,"	O
).	O
However	O
","	O
several	O
fundamental	O
questions	O
remain	O
unanswered	O
:	O
(	O
1	O
)	O
How	O
does	O
the	O
temperature	O
affect	O
the	O
catalytic	O
activity	O
of	O
Ago	O
?	O
(	O
2	O
)	O
What	O
factors	O
cause	O
the	O
conformational	O
changes	O
in	O
the	O
catalytic	O
center	O
at	O
different	O
temperatures	O
?	O
In	O
the	O
present	O
work	O
","	O
MD	O
simulations	O
and	O
binding	O
free	O
energy	O
calculations	O
(	O
molecular	O
mechanics	O
â€“	O
Poisson	O
â€“	O
Boltzmann	O
surface	O
area	O
","	O
MM	O
-	O
PBSA	O
)	O
were	O
performed	O
on	O
16	O
-	O
mer	O
guide	O
DNA	O
","	O
15	O
-	O
mer	O
target	O
DNA	O
","	O
and	O
TtAgo	O
at	O
temperatures	O
of	O
310	O
","	O
324	O
","	O
and	O
338K	O
to	O
find	O
possible	O
answers	O
to	O
these	O
questions	O
.	O
Principal	O
component	O
analysis	O
(	O
PCA	O
)	O
was	O
also	O
applied	O
to	O
investigate	O
the	O
interactions	O
between	O
TtAgo	O
and	O
DNA	O
.	O
Our	O
MD	O
results	O
provided	O
some	O
informative	O
clues	O
for	O
the	O
mechanism	O
of	O
conformational	O
changes	O
in	O
the	O
catalytic	O
center	O
at	O
different	O
temperatures	O
.	O
Materials	O
and	O
methods	O
Protein	O
preparation	O
In	O
2014	O
","	O
Sheng	O
et	O
al	O
determined	O
the	O
crystal	O
structures	O
of	O
ternary	O
Thermus	O
thermophilus	O
Argonaute	O
(	O
TtAgo	O
)	O
complexes	O
with	O
5	O
â€²-	O
phosphorylated	O
guide	O
DNA	O
and	O
a	O
series	O
of	O
DNA	O
targets	O
(	O
PDB	O
Id	O
4NCB	O
)	O
(	O
Sheng	O
et	O
al	O
".,"	O
"),"	O
in	O
which	O
the	O
complex	O
structures	O
solved	O
at	O
improved	O
resolution	O
up	O
to	O
2	O
.	O
2	O
Ã…	O
.	O
It	O
was	O
very	O
interesting	O
reliable	O
target	O
for	O
MD	O
simulation	O
.	O
And	O
so	O
we	O
chose	O
TtAgo	O
(	O
PDB	O
Id	O
4NCB	O
)	O
to	O
perform	O
simulations	O
.	O
The	O
initial	O
structure	O
of	O
TtAgo	O
â€“	O
nucleic	O
acid	O
complex	O
in	O
the	O
MD	O
simulations	O
was	O
obtained	O
from	O
the	O
Protein	O
Data	O
Bank	O
(	O
PDB	O
ID	O
4NCB	O
at	O
2	O
.	O
19	O
A	O
resolution	O
).	O
TtAgo	O
is	O
a	O
685	O
-	O
amino	B-Chemical
acid	I-Chemical
protein	O
","	O
and	O
its	O
binding	O
nucleic	O
acid	O
is	O
composed	O
of	O
16	O
-	O
mer	O
guide	O
DNA	O
and	O
15	O
-	O
mer	O
target	O
DNA	O
.	O
The	O
Mg2	B-Chemical
+	O
in	O
the	O
4NCB	O
structure	O
were	O
also	O
used	O
in	O
the	O
simulations	O
.	O
Conventional	O
MD	O
simulations	O
and	O
analysis	O
The	O
three	O
systems	O
with	O
different	O
temperatures	O
(	O
310	O
","	O
324	O
","	O
and	O
338K	O
)	O
were	O
utilized	O
in	O
200	O
ns	O
MD	O
simulations	O
with	O
NAMD2	O
.	O
10	O
b1	O
by	O
using	O
CHARMM27	O
all	O
-	O
force	O
field	O
parameters	O
(	O
Best	O
et	O
al	O
".,"	O
).	O
In	O
TtAgo	O
","	O
for	O
Mg2	B-Chemical
+	I-Chemical
and	O
nucleic	O
acids	O
(	O
guide	O
DNA	O
and	O
a	O
series	O
of	O
DNA	O
targets	O
"),"	O
generalized	O
CHARMM27	O
all	O
-	O
force	O
field	O
parameters	O
(	O
Mackerell	O
et	O
al	O
".,"	O
)	O
were	O
applied	O
.	O
In	O
three	O
system	O
","	O
the	O
complexes	O
were	O
placed	O
in	O
the	O
explicit	O
TIP3P	O
water	O
model	O
(	O
Jorgensen	O
et	O
al	O
".,"	O
"),"	O
and	O
extended	O
at	O
15	O
Ã…	O
from	O
water	O
molecules	O
in	O
a	O
cubic	O
periodic	O
box	O
.	O
The	O
systems	O
were	O
added	O
with	O
sodium	B-Chemical
and	O
chloride	B-Chemical
ions	O
to	O
obtain	O
a	O
final	O
ion	O
concentration	O
of	O
0	O
.	O
15	O
mol	O
/	O
L	O
.	O
To	O
avoid	O
steric	O
clashes	O
or	O
improper	O
geometries	O
","	O
the	O
steepest	O
descent	O
algorithm	O
with	O
50	O
","	O
0	O
steps	O
was	O
carried	O
out	O
to	O
was	O
energetically	O
minimized	O
for	O
each	O
system	O
.	O
The	O
Langevin	O
dynamics	O
(	O
Schlick	O
","	O
)	O
was	O
used	O
to	O
constant	O
temperature	O
control	O
with	O
a	O
damping	O
coefficient	O
(	O
gamma	O
)	O
of	O
1	O
.	O
0	O
ps	O
.	O
The	O
long	O
-	O
range	O
electrostatic	O
interactions	O
was	O
calculated	O
by	O
Particle	O
Mesh	O
Ewald	O
summation	O
algorithm	O
(	O
Darden	O
et	O
al	O
".,"	O
).	O
Each	O
simulation	O
was	O
performed	O
for	O
200	O
ns	O
for	O
the	O
protein	O
â€“	O
nucleic	O
acid	O
complexes	O
at	O
different	O
temperatures	O
(	O
310	O
","	O
324	O
","	O
and	O
338K	O
)	O
by	O
using	O
a	O
pressure	O
coupling	O
time	O
constant	O
of	O
2	O
.	O
0	O
ps	O
and	O
a	O
temperature	O
coupling	O
time	O
constant	O
of	O
0	O
.	O
1	O
ps	O
and	O
a	O
pressure	O
coupling	O
time	O
constant	O
of	O
2	O
.	O
0	O
ps	O
.	O
The	O
timestep	O
for	O
each	O
simulation	O
was	O
1ps	O
.	O
Cluster	O
analysis	O
Clusteringis	O
a	O
general	O
data	O
-	O
mining	O
technique	O
(	O
Cormack	O
","	O
;	O
Jain	O
et	O
al	O
".,"	O
)	O
using	O
different	O
methods	O
(	O
algorithms	O
)	O
that	O
can	O
be	O
applied	O
to	O
judge	O
structure	O
similarity	O
.	O
In	O
this	O
study	O
","	O
clustering	O
was	O
performed	O
on	O
three	O
systems	O
(	O
the	O
310K	O
","	O
324K	O
","	O
and	O
338K	O
)	O
molecular	O
dynamics	O
simulation	O
trajectories	O
using	O
the	O
RMSD	O
as	O
a	O
metric	O
according	O
to	O
hierarchical	O
method	O
(	O
Rokach	O
and	O
Maimon	O
","	O
)	O
into	O
distinct	O
groups	O
.	O
The	O
cut	O
off	O
value	O
of	O
RMSD	O
was	O
set	O
with	O
2	O
.	O
0Ã…	O
for	O
each	O
systems	O
.	O
Then	O
the	O
TtAgo	O
structure	O
in	O
the	O
200	O
ns	O
simulation	O
trajectories	O
which	O
had	O
the	O
similar	O
conformation	O
were	O
divided	O
into	O
the	O
same	O
cluster	O
.	O
The	O
proportion	O
of	O
each	O
cluster	O
were	O
calculated	O
and	O
representative	O
frame	O
of	O
the	O
two	O
largest	O
clusters	O
were	O
extracted	O
for	O
the	O
further	O
analysis	O
.	O
Binding	O
free	O
energy	O
calculation	O
The	O
Equation	O
(	O
1	O
)	O
was	O
used	O
to	O
calculate	O
the	O
binding	O
free	O
energy	O
as	O
follows	O
:	O
where	O
Î”Gb	O
is	O
the	O
total	O
binding	O
free	O
energy	O
;	O
The	O
van	O
der	O
Waals	O
interaction	O
energies	O
and	O
electrostatic	O
between	O
a	O
protein	O
and	O
its	O
ligand	O
are	O
Î”	O
and	O
Î”	O
","	O
respectively	O
;	O
TÎ”S	O
is	O
the	O
contribution	O
of	O
conformational	O
entropy	O
to	O
the	O
binding	O
;	O
Î”Gsol	O
is	O
the	O
solvation	O
energy	O
","	O
and	O
.	O
Î”	O
and	O
Î”	O
were	O
calculated	O
by	O
the	O
same	O
parameter	O
set	O
as	O
in	O
the	O
molecular	O
dynamics	O
simulation	O
","	O
but	O
no	O
cutoff	O
was	O
applied	O
to	O
the	O
calculation	O
.	O
The	O
binding	O
free	O
energies	O
of	O
nucleic	O
acids	O
and	O
TtAgo	O
in	O
different	O
temperature	O
systems	O
was	O
performed	O
by	O
MM	O
-	O
PBSA	O
calculation	O
.	O
The	O
Amber	O
14	O
package	O
was	O
used	O
to	O
perform	O
2	O
ns	O
simulation	O
with	O
the	O
Amber	O
ff99	O
force	O
field	O
parameters	O
(	O
Kollman	O
et	O
al	O
".,"	O
).	O
In	O
our	O
study	O
","	O
500	O
snapshots	O
were	O
extracted	O
from	O
the	O
last	O
1	O
.	O
5	O
ns	O
MD	O
trajectory	O
for	O
all	O
of	O
the	O
energy	O
components	O
calculating	O
.	O
Results	O
and	O
discussion	O
Stability	O
of	O
TtAgo	O
in	O
different	O
temperature	O
systems	O
To	O
analyze	O
the	O
influence	O
of	O
temperature	O
on	O
TtAgo	O
activity	O
","	O
the	O
200	O
ns	O
molecular	O
dynamics	O
simulation	O
prepared	O
at	O
three	O
temperatures	O
(	O
310	O
","	O
324	O
","	O
and	O
338K	O
)	O
were	O
prepared	O
and	O
the	O
simulation	O
of	O
each	O
temperature	O
was	O
repeated	O
three	O
times	O
.	O
The	O
root	O
mean	O
square	O
deviation	O
(	O
RMSD	O
)	O
was	O
monitored	O
with	O
the	O
three	O
different	O
temperature	O
systems	O
of	O
MD	O
trajectories	O
to	O
measure	O
the	O
stability	O
of	O
each	O
domain	O
of	O
TtAgo	O
with	O
temperature	O
variation	O
and	O
to	O
examine	O
the	O
protein	O
stability	O
during	O
the	O
MD	O
simulations	O
.	O
The	O
RMSD	O
of	O
protein	O
backbone	O
atoms	O
and	O
different	O
domain	O
backbone	O
atoms	O
was	O
conducted	O
(	O
Figure	O
2	O
and	O
Figure	O
S2	O
).	O
In	O
Figure	O
S2	O
","	O
the	O
RMSD	O
variations	O
of	O
the	O
different	O
temperature	O
systems	O
for	O
three	O
times	O
at	O
the	O
200	O
ns	O
time	O
scale	O
indicated	O
that	O
the	O
complexes	O
had	O
the	O
similar	O
atomic	O
coordinates	O
and	O
the	O
initial	O
structures	O
.	O
The	O
RMSDs	O
of	O
the	O
310	O
","	O
324	O
","	O
and	O
338K	O
systems	O
converged	O
to	O
1	O
.	O
80	O
","	O
2	O
.	O
40	O
","	O
and	O
2	O
.	O
20	O
Ã…	O
","	O
respectively	O
","	O
indicating	O
that	O
the	O
three	O
systems	O
were	O
stable	O
.	O
The	O
RMSDs	O
of	O
different	O
domains	O
in	O
the	O
three	O
systems	O
are	O
shown	O
in	O
Figures	O
2A	O
â€“	O
F	O
.	O
The	O
Linker	O
1	O
domain	O
of	O
TtAgo	O
became	O
more	O
flexible	O
in	O
the	O
324K	O
system	O
(	O
Figure	O
2B	O
)	O
than	O
that	O
of	O
the	O
310	O
and	O
338	O
K	O
systems	O
","	O
whereas	O
the	O
PIWI	O
domain	O
was	O
more	O
flexible	O
in	O
the	O
338K	O
system	O
than	O
in	O
the	O
two	O
other	O
systems	O
(	O
Figure	O
2F	O
).	O
The	O
increase	O
in	O
temperature	O
causes	O
the	O
protein	O
residues	O
to	O
fluctuate	O
dramatically	O
.	O
In	O
this	O
study	O
","	O
rising	O
the	O
temperature	O
to	O
324K	O
and	O
338K	O
resulted	O
in	O
an	O
increase	O
of	O
flexible	O
for	O
Linker	O
1	O
or	O
PIWI	O
domains	O
.	O
This	O
may	O
affect	O
the	O
relative	O
position	O
between	O
the	O
Linker	O
1	O
and	O
PIWI	O
and	O
thus	O
regulated	O
the	O
catalytic	O
activity	O
of	O
TtAgo	O
.	O
In	O
Figure	O
S3	O
","	O
the	O
total	O
energy	O
vs	O
.	O
time	O
was	O
also	O
calculated	O
and	O
it	O
can	O
be	O
seen	O
that	O
the	O
total	O
energy	O
for	O
three	O
systems	O
keep	O
steady	O
during	O
200	O
ns	O
simulation	O
.	O
In	O
addition	O
","	O
We	O
chose	O
the	O
four	O
structures	O
with	O
lower	O
energy	O
from	O
three	O
simulation	O
trajectories	O
and	O
calculated	O
the	O
Ramachandran	O
Plot	O
.	O
As	O
the	O
Figures	O
S4	O
â€“	O
S6	O
.	O
The	O
four	O
lower	O
energy	O
structures	O
for	O
each	O
system	O
had	O
the	O
same	O
Ramachandran	O
conformation	O
which	O
indicated	O
that	O
the	O
whole	O
simulation	O
process	O
was	O
stable	O
.	O
Comparison	O
of	O
the	O
RMSD	O
of	O
the	O
310K	O
","	O
324K	O
","	O
and	O
338K	O
systems	O
at	O
different	O
TtAgo	O
domains	O
.	O
(	O
A	O
â€“	O
F	O
)	O
RMSD	O
plot	O
of	O
backbone	O
atoms	O
in	O
different	O
domains	O
in	O
three	O
temperature	O
systems	O
.	O
Then	O
the	O
root	O
-	O
mean	O
-	O
square	O
fluctuation	O
(	O
RMSF	O
)	O
for	O
the	O
backbone	O
atoms	O
of	O
the	O
nucleic	O
acids	O
with	O
TtAgo	O
protein	O
in	O
different	O
temperature	O
systems	O
was	O
analyzed	O
to	O
determine	O
the	O
mobility	O
of	O
the	O
complexes	O
.	O
Figure	O
3	O
illustrates	O
that	O
the	O
large	O
punctuations	O
of	O
residues	O
mainly	O
occurred	O
in	O
the	O
324	O
and	O
338K	O
systems	O
.	O
The	O
RMSF	O
fluctuations	O
of	O
Gly38	B-Chemical
","	O
Asp62	B-Chemical
","	O
and	O
Gly83	B-Chemical
located	O
at	O
the	O
N	O
terminus	O
(	O
Figure	O
3A	O
"),"	O
Arg123	B-Chemical
and	O
Arg137	B-Chemical
located	O
at	O
Linker1	O
(	O
Figure	O
3B	O
"),"	O
Pro218	B-Chemical
located	O
at	O
PAZ	O
(	O
Figure	O
3C	O
"),"	O
Ile297	B-Chemical
and	O
Arg324	B-Chemical
located	O
at	O
Linker	O
2	O
(	O
Figure	O
3D	O
"),"	O
Gln387	B-Chemical
located	O
at	O
MID	O
(	O
Figure	O
3E	O
"),"	O
and	O
Asp478	B-Chemical
","	O
Glu507	B-Chemical
","	O
Gly547	B-Chemical
","	O
and	O
Gly612	B-Chemical
located	O
at	O
PIWI	O
(	O
Figure	O
3F	O
)	O
were	O
higher	O
in	O
the	O
324	O
and	O
338K	O
systems	O
than	O
in	O
the	O
310	O
K	O
system	O
.	O
The	O
results	O
indicated	O
that	O
the	O
protein	O
at	O
324	O
and	O
338K	O
exhibited	O
a	O
higher	O
mobility	O
than	O
at	O
310	O
K	O
during	O
MD	O
simulations	O
.	O
Asp478	B-Chemical
","	O
Glu507	B-Chemical
","	O
and	O
Gly547	B-Chemical
near	O
the	O
active	O
center	O
at	O
the	O
PIWI	O
domain	O
that	O
exhibited	O
a	O
high	O
mobility	O
in	O
the	O
324	O
and	O
338K	O
systems	O
might	O
affect	O
the	O
catalytic	O
activity	O
of	O
TtAgo	O
.	O
To	O
further	O
confirm	O
the	O
RMSF	O
results	O
","	O
we	O
calculated	O
the	O
RMSD	O
values	O
for	O
each	O
residue	O
","	O
and	O
then	O
colored	O
each	O
according	O
to	O
the	O
RMSD	O
value	O
(	O
Figures	O
3G	O
â€“	O
I	O
).	O
It	O
can	O
be	O
seen	O
that	O
the	O
intensity	O
of	O
the	O
movement	O
of	O
various	O
residues	O
in	O
the	O
324	O
or	O
338K	O
system	O
was	O
higher	O
than	O
that	O
in	O
the	O
310K	O
system	O
","	O
especially	O
in	O
the	O
Linker	O
2	O
and	O
active	O
pocket	O
domain	O
.	O
In	O
order	O
to	O
further	O
analyze	O
residual	O
atomic	O
flexibility	O
","	O
an	O
isotropic	O
temperature	O
factor	O
(	O
B	O
-	O
factor	O
)	O
has	O
been	O
calculated	O
and	O
the	O
results	O
was	O
shown	O
in	O
Figure	O
S7	O
.	O
As	O
we	O
can	O
see	O
","	O
the	O
change	O
trend	O
of	O
B	O
-	O
factor	O
was	O
consistent	O
with	O
that	O
of	O
RMSF	O
and	O
RMSD	O
of	O
individual	O
residues	O
.	O
Figure	O
S8	O
shows	O
that	O
the	O
radius	O
of	O
gyration	O
(	O
Rg	O
)	O
in	O
different	O
domains	O
in	O
the	O
three	O
systems	O
during	O
the	O
200	O
ns	O
time	O
scale	O
MD	O
was	O
stable	O
.	O
RMSF	O
and	O
backbone	O
flexibility	O
during	O
200	O
ns	O
MD	O
at	O
different	O
TtAgo	O
domains	O
.	O
(	O
A	O
)	O
RMSF	O
values	O
of	O
the	O
N	O
terminus	O
calculated	O
in	O
three	O
temperature	O
systems	O
for	O
200	O
ns	O
MD	O
trajectories	O
.	O
(	O
B	O
)	O
RMSF	O
values	O
of	O
Linker	O
1	O
calculated	O
in	O
three	O
temperature	O
systems	O
for	O
200	O
ns	O
MD	O
trajectories	O
.	O
(	O
C	O
)	O
RMSF	O
values	O
of	O
PAZ	O
calculated	O
in	O
three	O
temperature	O
systems	O
for	O
200	O
ns	O
MD	O
trajectories	O
.	O
(	O
D	O
)	O
RMSF	O
values	O
of	O
Linker	O
2	O
calculated	O
in	O
three	O
temperature	O
systems	O
for	O
200	O
ns	O
MD	O
trajectories	O
.	O
(	O
E	O
)	O
RMSF	O
values	O
of	O
MID	O
calculated	O
in	O
three	O
temperature	O
systems	O
for	O
200	O
ns	O
MD	O
trajectories	O
.	O
(	O
F	O
)	O
RMSF	O
values	O
of	O
PIWI	O
calculated	O
in	O
three	O
temperature	O
systems	O
for	O
200	O
ns	O
MD	O
trajectories	O
.	O
(	O
G	O
â€“	O
I	O
)	O
Visualizations	O
of	O
backbone	O
flexibility	O
of	O
TgAgo	O
at	O
310	O
K	O
(	O
G	O
"),"	O
324K	O
(	O
H	O
"),"	O
and	O
338	O
K	O
(	O
I	O
).	O
The	O
different	O
degrees	O
of	O
motion	O
correspond	O
to	O
tubes	O
with	O
different	O
colors	O
and	O
thicknesses	O
.	O
The	O
solvent	O
-	O
accessible	O
surface	O
area	O
(	O
SASA	O
)	O
predicts	O
the	O
number	O
of	O
residues	O
present	O
in	O
the	O
outlier	O
regions	O
(	O
surface	O
)	O
of	O
the	O
protein	O
and	O
the	O
number	O
of	O
residues	O
that	O
are	O
in	O
the	O
hydrophobic	O
core	O
(	O
buried	O
).	O
In	O
this	O
study	O
","	O
the	O
time	O
-	O
dependent	O
SASA	O
in	O
the	O
different	O
domains	O
of	O
TtAgo	O
from	O
the	O
simulations	O
was	O
also	O
calculated	O
(	O
Figure	O
S9	O
).	O
The	O
results	O
showed	O
that	O
the	O
ensembles	O
of	O
the	O
different	O
domains	O
in	O
the	O
three	O
temperature	O
systems	O
were	O
similar	O
","	O
which	O
indicated	O
that	O
the	O
change	O
in	O
temperature	O
hardly	O
influenced	O
the	O
SASA	O
value	O
of	O
each	O
domain	O
.	O
This	O
analysis	O
further	O
calculated	O
the	O
SASA	O
values	O
of	O
the	O
residues	O
that	O
interact	O
with	O
the	O
guide	O
DNA	O
and	O
target	O
DNA	O
.	O
As	O
we	O
can	O
see	O
in	O
Figure	O
S10A	O
","	O
the	O
SASA	O
of	O
the	O
hydrophilic	O
residues	O
Lys575	B-Chemical
and	O
Asp590	B-Chemical
decreased	O
in	O
the	O
324	O
and	O
338K	O
systems	O
compared	O
with	O
that	O
in	O
the	O
310K	O
system	O
","	O
thereby	O
illustrating	O
increased	O
interaction	O
with	O
the	O
DNA	O
.	O
Asp590	B-Chemical
interacted	O
with	O
the	O
G1	O
of	O
the	O
target	O
DNA	O
(	O
Figure	O
S10B	O
"),"	O
whereas	O
Lys575	B-Chemical
interacted	O
with	O
the	O
C11	O
and	O
C12	O
of	O
the	O
target	O
DNA	O
(	O
Figure	O
S10C	O
"),"	O
forming	O
a	O
tighter	O
interaction	O
with	O
DNA	O
.	O
This	O
result	O
indicated	O
that	O
TtAgo	O
at	O
324	O
and	O
338K	O
might	O
have	O
undergone	O
drifting	O
","	O
thereby	O
leading	O
to	O
its	O
transition	O
into	O
an	O
advantageous	O
conformation	O
and	O
binding	O
with	O
a	O
nucleic	O
acid	O
.	O
Conformational	O
changes	O
in	O
different	O
temperature	O
systems	O
It	O
has	O
been	O
reported	O
that	O
the	O
binary	O
complex	O
of	O
a	O
yeast	O
Ago	O
with	O
a	O
bound	O
5	O
â€²-	O
phosphorylated	O
guide	O
RNA	O
strand	O
have	O
found	O
that	O
the	O
distance	O
between	O
Glu512	O
and	O
catalytic	O
pocket	O
composed	O
of	O
three	O
Asp	B-Chemical
residues	O
","	O
namely	O
","	O
Asp478	B-Chemical
","	O
Asp546	B-Chemical
","	O
and	O
Asp660	B-Chemical
","	O
determines	O
the	O
activity	O
of	O
Ago	O
(	O
Nakanishi	O
et	O
al	O
".,"	O
).	O
The	O
activated	O
Ago	O
needs	O
to	O
insert	O
Glu512	B-Chemical
into	O
the	O
catalytic	O
pocket	O
.	O
The	O
change	O
in	O
the	O
distance	O
between	O
Glu512	B-Chemical
and	O
the	O
catalytic	O
pocket	O
during	O
MD	O
simulations	O
in	O
the	O
three	O
temperature	O
systems	O
was	O
also	O
analyzed	O
to	O
observe	O
the	O
influence	O
of	O
temperature	O
change	O
on	O
enzyme	O
catalytic	O
activity	O
.	O
In	O
Figure	O
4A	O
","	O
the	O
distance	O
between	O
Glu512	B-Chemical
and	O
Asp478	B-Chemical
in	O
the	O
310K	O
system	O
increased	O
from	O
10	O
to	O
21	O
Ã…	O
at	O
80	O
ns	O
.	O
The	O
distance	O
between	O
Glu512	B-Chemical
and	O
Asp546	B-Chemical
in	O
the	O
310K	O
system	O
also	O
increased	O
from	O
9	O
.	O
50	O
to	O
23	O
Ã…	O
at	O
80	O
ns	O
(	O
Figure	O
4B	O
).	O
In	O
the	O
324	O
and	O
338K	O
systems	O
","	O
the	O
distance	O
from	O
Glu512	B-Chemical
to	O
Asp546	B-Chemical
and	O
Asp478	B-Chemical
was	O
approximately	O
10	O
Ã…	O
during	O
MD	O
simulations	O
.	O
In	O
addition	O
","	O
the	O
distance	O
between	O
Glu512	B-Chemical
and	O
Asp478	B-Chemical
or	O
Asp546	B-Chemical
for	O
other	O
two	O
repeated	O
simulations	O
were	O
calculated	O
and	O
the	O
results	O
were	O
prepared	O
in	O
Figure	O
S11	O
.	O
It	O
can	O
be	O
seen	O
that	O
the	O
distance	O
between	O
Glu512	B-Chemical
and	O
Asp478	B-Chemical
or	O
Asp546	B-Chemical
showed	O
a	O
remarkably	O
increase	O
at	O
47	O
and	O
90	O
ns	O
in	O
310K	O
system	O
respectively	O
.	O
But	O
for	O
the	O
324	O
and	O
338K	O
systems	O
","	O
the	O
distance	O
from	O
Glu512	B-Chemical
to	O
Asp546	B-Chemical
and	O
Asp478	B-Chemical
was	O
approximately	O
10	O
Ã…	O
during	O
two	O
MD	O
simulations	O
.	O
This	O
finding	O
implied	O
that	O
the	O
distance	O
from	O
the	O
Glu512	B-Chemical
to	O
the	O
active	O
center	O
in	O
the	O
310K	O
system	O
was	O
larger	O
than	O
that	O
in	O
the	O
324	O
and	O
328K	O
systems	O
.	O
To	O
confirm	O
these	O
results	O
","	O
we	O
compared	O
the	O
structures	O
between	O
0	O
and	O
150	O
ns	O
at	O
different	O
temperatures	O
(	O
Figures	O
4C	O
â€“	O
H	O
).	O
The	O
distance	O
from	O
Glu512	B-Chemical
OE2	O
to	O
Asp546	B-Chemical
OD1	O
and	O
Asp478	B-Chemical
OD1	O
at	O
150	O
ns	O
was	O
2	O
.	O
5	O
times	O
than	O
at	O
0	O
ns	O
in	O
the	O
310K	O
system	O
(	O
Figures	O
4C	O
","	O
D	O
).	O
The	O
distance	O
between	O
0	O
and	O
150	O
ns	O
changed	O
slightly	O
in	O
the	O
324	O
and	O
338K	O
systems	O
compared	O
with	O
that	O
in	O
the	O
310	O
K	O
system	O
(	O
Figures	O
4E	O
","	O
5H	O
).	O
To	O
illustrate	O
the	O
dynamic	O
process	O
of	O
distance	O
change	O
","	O
we	O
created	O
animations	O
1	O
â€“	O
3	O
in	O
Supporting	O
information	O
of	O
the	O
distance	O
between	O
the	O
Glu512	B-Chemical
OE2	O
and	O
Asp478	B-Chemical
OD1	O
of	O
the	O
visual	O
dynamic	O
variation	O
at	O
three	O
different	O
temperatures	O
.	O
The	O
results	O
revealed	O
that	O
Glu512	B-Chemical
was	O
far	O
from	O
the	O
catalytic	O
pocket	O
at	O
310K	O
","	O
and	O
the	O
enzyme	O
activity	O
at	O
324	O
and	O
338K	O
was	O
stronger	O
than	O
that	O
at	O
310K	O
.	O
Distance	O
between	O
Glu512	B-Chemical
and	O
active	O
pocket	O
in	O
310K	O
","	O
324K	O
","	O
and	O
338K	O
systems	O
.	O
(	O
A	O
)	O
Time	O
evolution	O
of	O
distance	O
between	O
Glu512	B-Chemical
OE2	O
and	O
Asp478	B-Chemical
OD1	O
in	O
three	O
temperature	O
systems	O
.	O
(	O
B	O
)	O
Time	O
evolution	O
of	O
distance	O
between	O
Glu512	B-Chemical
OE1	O
and	O
Asp546	B-Chemical
OD1	O
in	O
three	O
temperature	O
systems	O
.	O
(	O
C	O
","	O
D	O
)	O
Distance	O
between	O
Glu512	B-Chemical
(	O
blue	O
)	O
and	O
active	O
pocket	O
(	O
Asp546	B-Chemical
","	O
cyan	O
;	O
Asp478	B-Chemical
","	O
yellow	O
)	O
in	O
310K	O
system	O
at	O
0	O
and	O
150	O
ns	O
.	O
(	O
E	O
","	O
F	O
)	O
Value	O
of	O
distance	O
between	O
Glu512	B-Chemical
(	O
blue	O
)	O
and	O
active	O
pocket	O
(	O
Asp546	B-Chemical
","	O
cyan	O
;	O
Asp478	B-Chemical
","	O
yellow	O
)	O
in	O
324K	O
system	O
at	O
0	O
and	O
150	O
ns	O
.	O
(	O
G	O
","	O
H	O
)	O
Distance	O
between	O
Glu512	B-Chemical
(	O
blue	O
)	O
and	O
active	O
pocket	O
(	O
Asp546	B-Chemical
","	O
cyan	O
;	O
Asp478	B-Chemical
","	O
yellow	O
)	O
in	O
338K	O
system	O
at	O
0	O
and	O
150	O
ns	O
.	O
Comparison	O
of	O
secondary	O
structure	O
in	O
different	O
temperature	O
systems	O
.	O
(	O
A	O
","	O
B	O
)	O
Structure	O
of	O
TtAgo	O
in	O
310K	O
system	O
at	O
1	O
.	O
5	O
ns	O
(	O
A	O
)	O
and	O
150	O
ns	O
(	O
B	O
)	O
during	O
200	O
ns	O
MD	O
","	O
and	O
residues	O
Glu507	B-Chemical
to	O
Arg513	B-Chemical
were	O
highlighted	O
with	O
orange	O
(	O
1	O
.	O
5	O
ns	O
)	O
and	O
green	O
(	O
150	O
ns	O
)	O
cartoons	O
.	O
(	O
C	O
","	O
D	O
)	O
Structure	O
of	O
TtAgo	O
in	O
324K	O
system	O
at	O
1	O
.	O
5	O
(	O
C	O
)	O
and	O
150	O
ns	O
(	O
D	O
)	O
during	O
200	O
ns	O
MD	O
","	O
and	O
residues	O
Glu507	B-Chemical
to	O
Arg513	B-Chemical
were	O
highlighted	O
with	O
split	O
-	O
pea	O
(	O
1	O
.	O
5	O
ns	O
)	O
and	O
yellow	O
(	O
150	O
ns	O
)	O
cartoons	O
.	O
(	O
E	O
","	O
F	O
)	O
Structure	O
of	O
TtAgo	O
in	O
324K	O
system	O
at	O
1	O
.	O
5	O
(	O
E	O
)	O
and	O
150	O
ns	O
(	O
F	O
)	O
during	O
200	O
ns	O
MD	O
","	O
and	O
residues	O
Glu507	B-Chemical
to	O
Arg513	B-Chemical
were	O
highlighted	O
with	O
cyan	O
(	O
1	O
.	O
5	O
ns	O
)	O
and	O
yellow	O
(	O
150	O
ns	O
)	O
cartoons	O
.	O
To	O
explain	O
the	O
cause	O
of	O
the	O
change	O
in	O
distance	O
","	O
we	O
investigated	O
the	O
secondary	O
structure	O
modifications	O
during	O
200	O
ns	O
MD	O
simulations	O
in	O
the	O
different	O
temperature	O
systems	O
(	O
Figures	O
S12A	O
â€“	O
C	O
and	O
Figure	O
5	O
;	O
Table	O
1	O
).	O
The	O
Î²	O
-	O
strand	O
of	O
Glu507	B-Chemical
to	O
Gln509	B-Chemical
near	O
Glu512	B-Chemical
disappeared	O
at	O
150	O
ns	O
compared	O
with	O
that	O
at1	O
.	O
5	O
ns	O
in	O
the	O
310K	O
system	O
(	O
Figure	O
S12A	O
).	O
The	O
Î²	O
-	O
strand	O
contents	O
of	O
Glu507	B-Chemical
to	O
Gln509	B-Chemical
in	O
the	O
310	O
","	O
324	O
","	O
and	O
338K	O
systems	O
were	O
1	O
.	O
50	O
","	O
37	O
.	O
60	O
","	O
and	O
46	O
.	O
80	O
"%,"	O
respectively	O
(	O
Table	O
1	O
","	O
the	O
Î²	O
-	O
strand	O
contents	O
of	O
Glu507	B-Chemical
to	O
Gln509	B-Chemical
in	O
the	O
310	O
","	O
324	O
","	O
and	O
338K	O
systems	O
for	O
other	O
two	O
repeated	O
simulations	O
were	O
calculated	O
and	O
the	O
results	O
were	O
prepared	O
in	O
Tables	O
S1	O
","	O
S2	O
).	O
Secondary	O
structure	O
analysis	O
revealed	O
that	O
the	O
short	O
intermediate	O
Î²	O
-	O
sheet	O
at	O
324	O
and	O
338K	O
during	O
200	O
ns	O
molecular	O
dynamics	O
simulation	O
represented	O
the	O
ordered	O
structure	O
that	O
might	O
help	O
maintain	O
the	O
close	O
distance	O
between	O
Glu512	B-Chemical
and	O
the	O
catalytic	O
pocket	O
.	O
Glu512	B-Chemical
moved	O
far	O
from	O
the	O
catalytic	O
pocket	O
when	O
Î²	O
-	O
sheet	O
disappeared	O
.	O
Probability	O
of	O
generating	O
Î²	O
-	O
bridge	O
in	O
E512	O
loop	O
and	O
D546	O
loop	O
.	O
Changes	O
in	O
nucleic	O
acid	O
binding	O
channel	O
in	O
different	O
temperature	O
systems	O
The	O
minimum	O
distances	O
from	O
Linker	O
1	O
to	O
PIWI	O
and	O
from	O
PAZ	O
to	O
PIWI	O
have	O
been	O
reported	O
to	O
determine	O
the	O
nucleic	O
acid	O
binding	O
channel	O
in	O
TtAgo	O
.	O
In	O
our	O
study	O
","	O
DCH1	O
was	O
used	O
to	O
describe	O
the	O
center	O
of	O
mass	O
(	O
c	O
.	O
o	O
.	O
m	O
.)	O
distance	O
from	O
the	O
part	O
of	O
L1	O
(	O
residues	O
165	O
â€“	O
174	O
","	O
highlighted	O
in	O
red	O
)	O
to	O
the	O
long	O
helix	O
on	O
PIWI	O
(	O
residues	O
654	O
â€“	O
668	O
","	O
highlighted	O
in	O
blue	O
).	O
DCH2	O
was	O
the	O
c	O
.	O
o	O
.	O
m	O
.	O
distance	O
from	O
the	O
part	O
of	O
PAZ	O
(	O
residues	O
192	O
â€“	O
202	O
","	O
highlighted	O
in	O
pink	O
)	O
to	O
the	O
part	O
of	O
PIWI	O
(	O
residues	O
572	O
â€“	O
581	O
","	O
highlighted	O
in	O
green	O
"),"	O
as	O
shown	O
in	O
Figure	O
6A	O
.	O
These	O
two	O
distances	O
were	O
used	O
to	O
measure	O
the	O
diameter	O
of	O
the	O
nucleic	O
acid	O
binding	O
channel	O
.	O
To	O
analyze	O
the	O
effect	O
of	O
temperature	O
change	O
on	O
the	O
nucleic	O
acid	O
binding	O
channel	O
","	O
we	O
detected	O
the	O
changes	O
in	O
DCH1	O
and	O
DCH2	O
during	O
200ns	O
MD	O
in	O
the	O
different	O
temperature	O
systems	O
(	O
Figures	O
6B	O
","	O
C	O
).	O
DCH1	O
varied	O
at	O
27	O
.	O
5	O
","	O
28	O
.	O
5	O
","	O
and	O
29	O
.	O
5	O
Ã…	O
in	O
the	O
310	O
","	O
324	O
","	O
and	O
338K	O
systems	O
","	O
respectively	O
.	O
These	O
findings	O
suggested	O
that	O
the	O
minimum	O
distance	O
from	O
Linker	O
1	O
to	O
PIWI	O
was	O
larger	O
in	O
the	O
324	O
and	O
338K	O
systems	O
than	O
that	O
in	O
the	O
310K	O
system	O
.	O
Similarly	O
","	O
DCH2	O
reached	O
31	O
and	O
30	O
Ã…	O
in	O
the	O
324	O
and	O
338K	O
systems	O
and	O
in	O
the	O
310K	O
system	O
","	O
respectively	O
.	O
Analysis	O
of	O
nucleic	O
acid	O
binding	O
channel	O
in	O
three	O
temperature	O
systems	O
.	O
(	O
A	O
)	O
DCH1	O
and	O
DCH2	O
were	O
used	O
to	O
describe	O
the	O
diameter	O
of	O
the	O
nucleic	O
acid	O
binding	O
channel	O
.	O
DCH1	O
measured	O
the	O
c	O
.	O
o	O
.	O
m	O
.	O
distance	O
in	O
residues	O
165	O
â€“	O
174	O
(	O
red	O
cartoon	O
)	O
and	O
in	O
residues	O
654	O
â€“	O
668	O
(	O
blue	O
cartoon	O
).	O
DCH2	O
was	O
the	O
c	O
.	O
o	O
.	O
m	O
.	O
distance	O
in	O
residues	O
192	O
â€“	O
202	O
(	O
orange	O
cartoon	O
)	O
and	O
in	O
residues	O
572	O
â€“	O
581	O
(	O
green	O
cartoon	O
).	O
The	O
guide	O
-	O
DNA	O
and	O
target	O
-	O
DNA	O
were	O
highlighted	O
by	O
white	O
and	O
marine	O
cartoon	O
respectively	O
.	O
(	O
B	O
)	O
Time	O
series	O
of	O
DCH1	O
in	O
three	O
temperature	O
systems	O
(	O
left	O
)	O
and	O
the	O
probability	O
distribution	O
of	O
DCH2	O
calculated	O
from	O
0	O
to	O
200	O
ns	O
trajectories	O
(	O
right	O
).	O
(	O
C	O
)	O
Time	O
series	O
of	O
the	O
value	O
for	O
DCH2	O
in	O
three	O
temperature	O
systems	O
(	O
left	O
)	O
and	O
the	O
probability	O
distribution	O
of	O
DCH2	O
calculated	O
from	O
0	O
to	O
200	O
ns	O
trajectories	O
(	O
right	O
).	O
(	O
D	O
â€“	O
F	O
)	O
2	O
-	O
D	O
(	O
top	O
)	O
and	O
3	O
-	O
D	O
(	O
bottom	O
)	O
visualization	O
of	O
the	O
channel	O
obtained	O
with	O
CHEXVIS	O
in	O
the	O
310K	O
(	O
D	O
"),"	O
324K	O
(	O
E	O
"),"	O
and	O
338K	O
systems	O
(	O
F	O
)	O
for	O
150	O
ns	O
structure	O
.	O
For	O
2	O
-	O
D	O
channel	O
profile	O
visualization	O
","	O
bulkiness	O
and	O
average	O
flexibility	O
are	O
shown	O
in	O
split	O
visualization	O
over	O
the	O
radius	O
profile	O
as	O
a	O
color	O
map	O
.	O
The	O
bottleneck	O
radius	O
was	O
highlighted	O
by	O
rectangles	O
.	O
For	O
3	O
-	O
D	O
channel	O
profile	O
visualization	O
","	O
the	O
channel	O
was	O
highlighted	O
with	O
blue	O
","	O
and	O
TtAgo	O
was	O
represented	O
by	O
a	O
cartoon	O
.	O
CHEXVIS	O
is	O
a	O
tool	O
used	O
for	O
molecular	O
channel	O
calculation	O
and	O
visualization	O
based	O
on	O
alpha	O
complex	O
representation	O
(	O
Masood	O
et	O
al	O
".,"	O
).	O
In	O
addition	O
to	O
predictive	O
channels	O
","	O
channel	O
residues	O
and	O
their	O
flexibility	O
can	O
be	O
predicted	O
by	O
CHEXVIS	O
.	O
In	O
our	O
study	O
","	O
this	O
tool	O
was	O
utilized	O
to	O
analyze	O
the	O
distinction	O
of	O
the	O
nucleic	O
acid	O
binding	O
channels	O
in	O
the	O
different	O
temperature	O
systems	O
at	O
150	O
ns	O
for	O
200	O
ns	O
MD	O
(	O
Figures	O
6D	O
â€“	O
F	O
;	O
Table	O
2	O
).	O
The	O
length	O
of	O
the	O
channel	O
in	O
TtAgo	O
in	O
the	O
310K	O
system	O
(	O
60	O
.	O
1Ã…	O
)	O
was	O
longer	O
than	O
those	O
in	O
the	O
324	O
(	O
50	O
.	O
37Ã…	O
)	O
and	O
338K	O
(	O
50	O
.	O
76Ã…	O
)	O
systems	O
.	O
Studies	O
on	O
bottlenecks	O
have	O
recommended	O
promising	O
areas	O
for	O
the	O
modification	O
of	O
channel	O
properties	O
because	O
their	O
substitutions	O
can	O
affect	O
the	O
informative	O
tunnel	O
geometry	O
when	O
protein	O
dynamics	O
is	O
considered	O
.	O
The	O
results	O
showed	O
that	O
the	O
bottleneck	O
of	O
TtAgo	O
in	O
the	O
310K	O
system	O
was	O
3	O
.	O
452	O
Ã…	O
and	O
changed	O
to	O
4	O
.	O
375	O
and	O
4	O
.	O
362	O
Ã…	O
in	O
the	O
324	O
and	O
338K	O
systems	O
","	O
respectively	O
.	O
The	O
analysis	O
of	O
bulkiness	O
and	O
average	O
flexibility	O
of	O
channel	O
residues	O
","	O
which	O
were	O
presented	O
in	O
a	O
2D	O
profile	O
","	O
suggested	O
that	O
the	O
flexibility	O
of	O
the	O
channel	O
residues	O
was	O
higher	O
in	O
the	O
324	O
and	O
338K	O
systems	O
than	O
in	O
the	O
310K	O
system	O
.	O
With	O
such	O
a	O
high	O
flexibility	O
","	O
the	O
channels	O
easily	O
become	O
wide	O
.	O
These	O
results	O
indicated	O
that	O
the	O
diameter	O
of	O
nucleic	O
acid	O
binding	O
channels	O
were	O
larger	O
and	O
the	O
binding	O
of	O
nucleic	O
acid	O
and	O
protein	O
may	O
occur	O
more	O
easily	O
in	O
the	O
324	O
and	O
338K	O
systems	O
than	O
in	O
the	O
310K	O
system	O
as	O
temperature	O
increased	O
.	O
Our	O
theoretical	O
finding	O
is	O
consistent	O
with	O
the	O
computational	O
study	O
made	O
by	O
Wang	O
et	O
al	O
.	O
().	O
Nucleic	O
acid	O
binding	O
channel	O
comparison	O
for	O
different	O
temperature	O
systems	O
.	O
Cluster	O
analysis	O
In	O
addition	O
","	O
clusteranalysis	O
was	O
performed	O
on	O
each	O
trajectory	O
of	O
the	O
three	O
systems	O
to	O
reveal	O
a	O
clear	O
-	O
cut	O
structural	O
difference	O
in	O
the	O
nucleic	O
acid	O
and	O
TtAgo	O
complex	O
in	O
the	O
different	O
temperature	O
systems	O
.	O
As	O
shown	O
in	O
Figure	O
7A	O
","	O
conformations	O
for	O
310K	O
systems	O
during	O
the	O
simulations	O
were	O
divided	O
into	O
six	O
clusters	O
and	O
the	O
percentage	O
population	O
of	O
clusters	O
was	O
43	O
.	O
1	O
","	O
34	O
.	O
3	O
","	O
9	O
.	O
2	O
","	O
6	O
.	O
7	O
","	O
4	O
.	O
3	O
","	O
8	O
","	O
2	O
.	O
4	O
","	O
5	O
","	O
and	O
4	O
%	O
respectively	O
.	O
Then	O
the	O
representative	O
structures	O
of	O
most	O
populated	O
cluster	O
in	O
cluster1	O
and	O
cluster2	O
were	O
selected	O
to	O
analyze	O
the	O
conformation	O
and	O
channel	O
.	O
It	O
can	O
be	O
seen	O
that	O
the	O
residues	O
Glu507	B-Chemical
to	O
Gln509	B-Chemical
in	O
both	O
the	O
representative	O
structures	O
of	O
cluster1	O
and	O
cluster2	O
at	O
310K	O
formed	O
a	O
loop	O
.	O
The	O
DCH1	O
and	O
DCH2	O
in	O
cluster1	O
representative	O
structures	O
were	O
27	O
.	O
43	O
and	O
29	O
.	O
37Ã…	O
while	O
they	O
were	O
27	O
.	O
28	O
and	O
29	O
.	O
69Ã…	O
in	O
cluster2	O
representative	O
structures	O
","	O
respectively	O
.	O
Analysis	O
on	O
clusters	O
in	O
the	O
310K	O
(	O
A	O
"),"	O
324K	O
(	O
B	O
"),"	O
and	O
338K	O
systems	O
(	O
C	O
).	O
Two	O
representative	O
structures	O
of	O
most	O
populated	O
clusters	O
in	O
three	O
systems	O
are	O
represented	O
as	O
cartoons	O
.	O
The	O
DCH1	O
and	O
DCH2	O
residues	O
were	O
highlighted	O
with	O
mesh	O
.	O
The	O
beta	O
strands	O
at	O
residues	O
Glu507	B-Chemical
to	O
Arg513	B-Chemical
were	O
colored	O
in	O
red	O
","	O
while	O
the	O
loops	O
at	O
residues	O
Glu507	B-Chemical
to	O
Arg513	B-Chemical
were	O
colored	O
by	O
orange	O
.	O
Figures	O
7B	O
","	O
C	O
exhibited	O
the	O
cluster	O
analysis	O
for	O
324K	O
and	O
338K	O
systems	O
","	O
respectively	O
.	O
The	O
percentage	O
population	O
of	O
cluster1	O
and	O
cluster2	O
for	O
324K	O
and	O
338K	O
systems	O
were	O
46	O
.	O
1	O
","	O
27	O
.	O
3	O
","	O
53	O
.	O
2	O
","	O
and	O
21	O
.	O
4	O
"%,"	O
respectively	O
.	O
The	O
sum	O
of	O
cluster1	O
and	O
cluster2	O
both	O
in	O
those	O
two	O
systems	O
were	O
over	O
70	O
%.	O
Two	O
representative	O
structures	O
based	O
clustering	O
approach	O
at	O
324K	O
(	O
cluster1	O
and	O
cluster2	O
)	O
were	O
extracted	O
the	O
results	O
were	O
shown	O
in	O
Figure	O
7B	O
.	O
In	O
those	O
conformations	O
","	O
the	O
residues	O
Glu507	B-Chemical
to	O
Gln509	B-Chemical
remained	O
Î²	O
-	O
sheet	O
and	O
the	O
DCH1	O
were	O
over	O
29	O
.	O
56Ã…	O
in	O
two	O
representative	O
structures	O
while	O
the	O
and	O
DCH2	O
were	O
over	O
30	O
Ã…	O
.	O
As	O
the	O
same	O
as	O
324K	O
systems	O
","	O
residues	O
Glu507	B-Chemical
to	O
Gln509	B-Chemical
in	O
cluster1	O
and	O
cluster2	O
of	O
338K	O
systems	O
for	O
representative	O
structures	O
also	O
presented	O
Î²	O
-	O
sheet	O
.	O
The	O
DCH1	O
and	O
DCH2	O
at	O
338K	O
were	O
more	O
than	O
29	O
Ã…	O
(	O
Figure	O
7C	O
).	O
These	O
findings	O
revealed	O
that	O
the	O
Î²	O
-	O
sheet	O
(	O
Glu507	B-Chemical
to	O
Gln509	B-Chemical
)	O
at	O
310K	O
formed	O
a	O
loop	O
but	O
remained	O
in	O
its	O
original	O
state	O
in	O
the	O
324	O
and	O
338K	O
systems	O
.	O
These	O
results	O
were	O
consistent	O
with	O
those	O
illustrated	O
in	O
Figure	O
6	O
.	O
The	O
different	O
nucleic	O
acid	O
binding	O
channels	O
in	O
the	O
three	O
temperature	O
systems	O
in	O
the	O
cluster1	O
and	O
cluster2	O
of	O
TtAgo	O
illustrated	O
that	O
DCH1	O
and	O
DCH2	O
in	O
the	O
310K	O
system	O
were	O
lower	O
than	O
those	O
in	O
the	O
324	O
and	O
338K	O
systems	O
.	O
Hydrogen	B-Chemical
bond	O
network	O
analysis	O
The	O
hydrogen	B-Chemical
bond	O
occupancy	O
between	O
nucleic	O
acids	O
(	O
target	O
DNA	O
and	O
guide	O
DNA	O
)	O
and	O
TtAgo	O
during	O
the	O
200	O
ns	O
MD	O
is	O
listed	O
in	O
Tables	O
S3	O
","	O
S4	O
to	O
obtain	O
insights	O
into	O
the	O
molecular	O
interactions	O
between	O
TtAgo	O
and	O
nucleic	O
acid	O
at	O
different	O
temperatures	O
.	O
The	O
MD	O
simulation	O
results	O
showed	O
that	O
the	O
number	O
of	O
hydrogen	B-Chemical
bonds	O
between	O
nucleic	O
acids	O
and	O
TtAgo	O
in	O
the	O
310K	O
system	O
was	O
more	O
than	O
that	O
in	O
the	O
324	O
and	O
338K	O
systems	O
.	O
For	O
example	O
","	O
the	O
hydrogen	O
bonds	O
","	O
R59	O
(	O
HN2	O
)â€”	O
DC5	O
(	O
O2	O
"),"	O
D590	O
(	O
OD1	O
)â€”	O
DG19	O
(	O
N1	O
)	O
that	O
connected	O
the	O
protein	O
and	O
the	O
target	O
DNA	O
","	O
and	O
R615	O
(	O
NE	O
)â€”	O
DT6	O
(	O
O5	O
â€²)	O
and	O
Y457	O
(	O
NZ	O
)â€”	O
DA3	O
(	O
O2P	O
)	O
that	O
linked	O
TtAgo	O
and	O
guide	O
DNA	O
disappeared	O
in	O
the	O
324	O
and	O
338K	O
systems	O
.	O
The	O
decrease	O
in	O
hydrogen	B-Chemical
bond	O
occupancy	O
was	O
due	O
to	O
the	O
increase	O
in	O
the	O
distance	O
between	O
hydrogen	B-Chemical
bond	O
donors	O
and	O
receptors	O
.	O
The	O
distances	O
of	O
the	O
donors	O
and	O
receptors	O
were	O
examined	O
during	O
200	O
ns	O
MD	O
(	O
Figure	O
8	O
).	O
In	O
Figure	O
8	O
","	O
the	O
distances	O
from	O
the	O
donors	O
to	O
the	O
receptors	O
were	O
larger	O
in	O
the	O
324	O
and	O
338K	O
systems	O
than	O
in	O
the	O
310K	O
system	O
.	O
The	O
rise	O
in	O
temperature	O
increased	O
the	O
entropy	O
","	O
thereby	O
promoting	O
the	O
relative	O
motion	O
of	O
proteins	O
and	O
DNA	O
.	O
Such	O
an	O
increase	O
reduced	O
the	O
stability	O
of	O
hydrogen	O
bonds	O
.	O
Hydrophobic	O
reduction	O
greatly	O
increased	O
the	O
solubility	O
of	O
TtAgo	O
and	O
nucleic	O
acids	O
in	O
solvents	O
","	O
resulting	O
in	O
TtAgo	O
was	O
easier	O
to	O
complete	O
the	O
cutting	O
action	O
of	O
nucleic	O
acid	O
.	O
Overall	O
","	O
the	O
binding	O
of	O
nucleic	O
acid	O
and	O
TtAgo	O
became	O
tighter	O
at	O
higher	O
temperature	O
and	O
TtAgo	O
has	O
high	O
activity	O
at	O
high	O
temperature	O
.	O
Distance	O
between	O
hydrogen	B-Chemical
bond	O
donors	O
and	O
receptors	O
at	O
different	O
temperatures	O
.	O
(	O
A	O
)	O
Distance	O
from	O
R59	O
(	O
HN2	O
)	O
to	O
DC5	O
(	O
O2	O
)	O
in	O
the	O
three	O
systems	O
and	O
the	O
probability	O
exhibited	O
in	O
(	O
A1	O
).	O
(	O
B	O
)	O
Distance	O
from	O
D590	O
(	O
OD1	O
)	O
to	O
DG19	O
(	O
N1	O
)	O
in	O
the	O
three	O
systems	O
and	O
the	O
probability	O
exhibited	O
in	O
(	O
B1	O
).	O
(	O
C	O
)	O
Distance	O
from	O
R615	O
(	O
NE	O
)	O
to	O
DT6	O
(	O
O5	O
)	O
in	O
the	O
three	O
systems	O
and	O
the	O
probability	O
exhibited	O
in	O
(	O
C1	O
).	O
(	O
D	O
)	O
Distance	O
from	O
Y457	O
(	O
NZ	O
)	O
to	O
DA3	O
(	O
O2P	O
)	O
in	O
the	O
three	O
systems	O
and	O
the	O
probability	O
exhibited	O
in	O
(	O
D1	O
).	O
MM	O
-	O
PBSA	O
calculations	O
It	O
was	O
well	O
known	O
that	O
the	O
arguably	O
most	O
popular	O
end	O
point	O
method	O
to	O
calculate	O
the	O
free	O
energy	O
of	O
binding	O
between	O
the	O
enzyme	O
and	O
the	O
ligands	O
is	O
the	O
topic	O
of	O
MM	O
/	O
PBSA	O
molecular	O
mechanics	O
[	O
MM	O
]	O
with	O
â€“	O
Boltzmann	O
[	O
PB	O
]	O
and	O
surface	O
area	O
solvation	O
(	O
GuimarÃ£es	O
","	O
).	O
The	O
method	O
has	O
been	O
used	O
in	O
a	O
range	O
of	O
settings	O
","	O
including	O
protein	O
design	O
by	O
free	O
energy	O
calculations	O
.	O
The	O
accuracy	O
is	O
better	O
than	O
for	O
docking	O
and	O
scoring	O
methods	O
(	O
Rifai	O
et	O
al	O
".,"	O
"),"	O
comparable	O
to	O
other	O
end	O
point	O
methods	O
","	O
such	O
as	O
LIE	O
methods	O
.	O
Furthermore	O
","	O
it	O
is	O
very	O
fast	O
and	O
thence	O
it	O
was	O
chosen	O
to	O
used	O
for	O
calculated	O
the	O
free	O
energy	O
of	O
binding	O
.	O
The	O
binding	O
free	O
energy	O
of	O
the	O
TtAgo	O
â€“	O
nucleic	O
acid	O
complex	O
was	O
evaluated	O
using	O
MM	O
â€“	O
GBSA	O
to	O
confirm	O
the	O
results	O
.	O
The	O
non	O
-	O
bonded	O
van	O
der	O
Waals	O
(	O
Î”EvdW	O
"),"	O
non	O
-	O
bonded	O
electrostatic	O
(	O
Î”Eelec	O
)	O
interactions	O
","	O
and	O
binding	O
free	O
energy	O
(	O
Î”Gbin	O
)	O
of	O
the	O
TtAgo	O
â€“	O
nucleic	O
complex	O
in	O
the	O
three	O
temperature	O
systems	O
are	O
shown	O
in	O
Table	O
3	O
.	O
The	O
binding	O
free	O
energies	O
were	O
driven	O
primarily	O
by	O
electrostatic	O
interactions	O
and	O
polar	O
solvation	O
","	O
whereas	O
the	O
vdW	O
interaction	O
","	O
polar	O
solvation	O
","	O
and	O
entropy	O
basically	O
remained	O
the	O
same	O
.	O
No	O
significance	O
was	O
found	O
in	O
the	O
variations	O
in	O
the	O
binding	O
affinity	O
between	O
nucleic	O
acid	O
and	O
TtAgo	O
in	O
the	O
different	O
temperature	O
systems	O
.	O
Table	O
3	O
shows	O
that	O
the	O
binding	O
free	O
energy	O
of	O
the	O
TtAgo	O
â€“	O
nucleic	O
complex	O
at	O
310K	O
(âˆ’	O
419	O
.	O
3667	O
kcal	O
/	O
mol	O
)	O
was	O
higher	O
than	O
those	O
at	O
324K	O
(âˆ’	O
461	O
.	O
1173	O
kcal	O
/	O
mol	O
)	O
and	O
338K	O
(âˆ’	O
434	O
.	O
8954	O
kcal	O
/	O
mol	O
).	O
(	O
Seen	O
from	O
Tables	O
S5	O
","	O
S6	O
","	O
it	O
listed	O
the	O
other	O
two	O
repeated	O
simulations	O
results	O
for	O
MM	O
-	O
GBSA	O
Calculations	O
.	O
The	O
results	O
were	O
similar	O
to	O
the	O
results	O
listed	O
in	O
Table	O
3	O
).	O
These	O
data	O
indicated	O
that	O
the	O
interaction	O
between	O
TtAgo	O
and	O
nucleic	O
acid	O
was	O
more	O
stable	O
at	O
324	O
and	O
338K	O
than	O
at	O
310K	O
.	O
MM	O
-	O
PBSA	O
results	O
(	O
kcal	O
/	O
mol	O
).	O
To	O
analyze	O
the	O
effects	O
of	O
individual	O
amino	B-Chemical
acids	I-Chemical
on	O
TtAgo	O
and	O
DNA	O
binding	O
","	O
the	O
per	O
-	O
residue	O
free	O
energy	O
decomposition	O
was	O
performed	O
to	O
characterize	O
and	O
identify	O
the	O
crucial	O
residues	O
that	O
mainly	O
contributed	O
to	O
the	O
binding	O
free	O
energy	O
(	O
Figure	O
9	O
).	O
Six	O
amino	B-Chemical
acid	I-Chemical
residues	O
","	O
namely	O
","	O
Tyr171	B-Chemical
","	O
Arg172	B-Chemical
","	O
Ile173	B-Chemical
","	O
Arg174	B-Chemical
","	O
Thr174	B-Chemical
","	O
and	O
Met413	B-Chemical
had	O
relatively	O
low	O
energies	O
in	O
the	O
three	O
temperature	O
systems	O
compared	O
with	O
other	O
residues	O
and	O
might	O
play	O
a	O
pivotal	O
role	O
in	O
combining	O
with	O
guide	O
DNA	O
(	O
Figure	O
9A	O
).	O
It	O
can	O
be	O
seen	O
that	O
Asp546	B-Chemical
","	O
Lys575	B-Chemical
","	O
and	O
Asp590	B-Chemical
had	O
lower	O
energy	O
which	O
instructed	O
the	O
important	O
role	O
in	O
the	O
process	O
of	O
the	O
combination	O
of	O
target	O
DNA	O
.	O
Free	O
energy	O
decomposition	O
analysis	O
at	O
three	O
different	O
temperatures	O
(	O
310	O
K	O
","	O
324	O
K	O
","	O
and	O
338	O
K	O
)	O
for	O
TtAgo	O
â€“	O
nucleic	O
complex	O
.	O
(	O
A	O
)	O
The	O
total	O
energy	O
for	O
residues	O
which	O
involved	O
in	O
the	O
interaction	O
with	O
guide	O
DNA	O
.	O
(	O
B	O
)	O
The	O
total	O
energy	O
for	O
residues	O
which	O
involved	O
in	O
the	O
interaction	O
with	O
target	O
DNA	O
.	O
The	O
residues	O
that	O
contributed	O
significantly	O
were	O
highlighted	O
.	O
Conclusion	O
TtAgo	O
is	O
active	O
at	O
high	O
temperatures	O
.	O
The	O
mechanism	O
by	O
which	O
the	O
temperature	O
affects	O
the	O
activity	O
of	O
TtAgo	O
remains	O
poorly	O
understood	O
.	O
In	O
the	O
present	O
study	O
","	O
MD	O
simulations	O
revealed	O
that	O
the	O
disappearance	O
of	O
Î²	O
-	O
sheet	O
from	O
Glu507	B-Chemical
to	O
Gln509	B-Chemical
at	O
310K	O
could	O
cause	O
Glu512	B-Chemical
to	O
move	O
far	O
from	O
the	O
catalytic	O
pocket	O
","	O
thereby	O
reducing	O
the	O
activity	O
of	O
TtAgo	O
.	O
The	O
binding	O
channel	O
of	O
the	O
nucleic	O
acid	O
widened	O
at	O
324	O
and	O
338K	O
.	O
Consequently	O
","	O
the	O
binding	O
of	O
nucleic	O
acids	O
and	O
proteins	O
occurred	O
more	O
easily	O
at	O
324	O
and	O
338	O
K	O
than	O
at	O
310	O
K	O
.	O
Binding	O
free	O
energy	O
(	O
MM	O
-	O
PBSA	O
)	O
calculations	O
and	O
hydrogen	B-Chemical
bond	O
occupancy	O
showed	O
that	O
the	O
binding	O
between	O
TtAgo	O
and	O
nucleic	O
acid	O
was	O
more	O
stable	O
at	O
324and	O
338K	O
than	O
at	O
310	O
K	O
.	O
These	O
results	O
suggested	O
that	O
the	O
temperature	O
influenced	O
the	O
activity	O
of	O
TtAgo	O
by	O
regulating	O
the	O
binding	O
channel	O
width	O
of	O
TtAgo	O
and	O
the	O
distance	O
from	O
Glu512	B-Chemical
to	O
the	O
active	O
center	O
.	O
The	O
activity	O
of	O
TtAgo	O
was	O
higher	O
at	O
324	O
and	O
338K	O
than	O
that	O
at	O
310K	O
.	O
Our	O
results	O
would	O
be	O
useful	O
as	O
a	O
basis	O
for	O
further	O
studies	O
on	O
the	O
influence	O
of	O
temperature	O
on	O
TtAgo	O
and	O
design	O
of	O
CRISPR	O
methods	O
.	O
Author	O
contributions	O
YL	O
wrote	O
and	O
revised	O
this	O
paper	O
.	O
ZY	O
prepared	O
the	O
tables	O
.	O
JZ	O
made	O
the	O
Supplementary	O
Materials	O
.	O
SW	O
provided	O
some	O
revision	O
advice	O
.	O
DX	O
and	O
WH	O
provided	O
the	O
ideas	O
and	O
modified	O
the	O
papers	O
.	O
Conflict	O
of	O
interest	O
statement	O
The	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O
Supplementary	O
material	O
The	O
Supplementary	O
Material	O
for	O
this	O
article	O
can	O
be	O
found	O
online	O
at	O
:	O
https	O
://	O
www	O
.	O
frontiersin	O
.	O
org	O
/	O
articles	O
/	O
10	O
.	O
3389	O
/	O
fchem	O
.	O
2018	O
.	O
223	O
/	O
full	O
#	O
supplementary	O
-	O
material	O
References	O
Study	O
of	O
Isothermal	O
","	O
Kinetic	O
","	O
and	O
Thermodynamic	O
Parameters	O
for	O
Adsorption	O
of	O
Cadmium	B-Chemical
:	O
An	O
Overview	O
of	O
Linear	O
and	O
Nonlinear	O
Approach	O
and	O
Error	O
Analysis	O
Reports	O
about	O
presence	O
and	O
toxicity	O
of	O
Cd2	B-Chemical
+	I-Chemical
in	O
different	O
chemical	O
industrial	O
effluents	O
prompted	O
the	O
researchers	O
to	O
explore	O
some	O
economical	O
","	O
rapid	O
","	O
sensitive	O
","	O
and	O
accurate	O
methods	O
for	O
its	O
determination	O
and	O
removal	O
from	O
aqueous	O
systems	O
.	O
In	O
continuation	O
of	O
series	O
of	O
investigations	O
","	O
adsorption	O
of	O
Cd2	B-Chemical
+	I-Chemical
onto	O
the	O
stem	O
of	O
Saccharum	O
arundinaceum	O
is	O
proposed	O
in	O
the	O
present	O
work	O
.	O
Optimization	O
of	O
parameters	O
affecting	O
sorption	O
potential	O
of	O
Cd2	B-Chemical
+	I-Chemical
including	O
pH	O
","	O
contact	O
time	O
","	O
temperature	O
","	O
sorbent	O
dose	O
","	O
and	O
concentration	O
of	O
sorbate	B-Chemical
was	O
carried	O
out	O
to	O
determine	O
best	O
suited	O
conditions	O
for	O
maximum	O
removal	O
of	O
sorbate	B-Chemical
.	O
To	O
understand	O
the	O
nature	O
of	O
sorption	O
process	O
","	O
linear	O
and	O
nonlinear	O
forms	O
of	O
five	O
sorption	O
isotherms	O
including	O
Freundlich	O
and	O
Langmuir	O
models	O
were	O
employed	O
.	O
Feasibility	O
and	O
viability	O
of	O
sorption	O
process	O
were	O
evaluated	O
by	O
calculating	O
kinetics	O
and	O
thermodynamics	O
of	O
the	O
process	O
","	O
while	O
error	O
analysis	O
suggested	O
best	O
fitted	O
sorption	O
model	O
on	O
sorption	O
data	O
.	O
Thermodynamic	O
studies	O
demonstrated	O
exothermic	O
nature	O
of	O
reaction	O
","	O
while	O
kinetic	O
studies	O
suggested	O
pseudo	O
-	O
second	O
order	O
of	O
reaction	O
.	O
1	O
.	O
Introduction	O
Environmental	O
pollution	O
should	O
be	O
taken	O
into	O
special	O
consideration	O
because	O
it	O
is	O
a	O
very	O
serious	O
matter	O
affecting	O
every	O
type	O
of	O
organism	O
at	O
every	O
level	O
.	O
The	O
most	O
adversely	O
affected	O
environmental	O
resource	O
is	O
water	O
[].	O
As	O
water	O
is	O
an	O
essential	O
element	O
for	O
the	O
survival	O
of	O
living	O
beings	O
","	O
it	O
is	O
very	O
necessary	O
to	O
keep	O
it	O
pure	O
and	O
clean	O
[].	O
Quality	O
of	O
drinking	O
water	O
is	O
of	O
prime	O
importance	O
for	O
mankind	O
because	O
waterborne	O
diseases	O
can	O
decimate	O
population	O
of	O
the	O
whole	O
area	O
.	O
These	O
diseases	O
arise	O
due	O
to	O
toxic	O
release	O
of	O
chemicals	O
from	O
industrial	O
zones	O
[].	O
Particularly	O
in	O
industrial	O
areas	O
","	O
these	O
waterborne	O
diseases	O
are	O
a	O
great	O
threat	O
towards	O
safety	O
of	O
water	O
supplies	O
.	O
Other	O
sources	O
which	O
may	O
pollute	O
water	O
include	O
domestic	O
waste	O
","	O
pesticides	O
run	O
off	O
from	O
agricultural	O
land	O
","	O
metal	O
plating	O
operations	O
","	O
and	O
so	O
on	O
.	O
Key	O
contaminants	O
present	O
in	O
water	O
include	O
heavy	B-Chemical
metals	I-Chemical
","	O
chlorinated	B-Chemical
hydrocarbons	I-Chemical
","	O
pathogens	O
","	O
detergents	O
","	O
pesticides	O
","	O
algal	O
nutrients	O
","	O
trace	O
organic	O
compounds	O
","	O
dyes	O
","	O
and	O
so	O
on	O
.	O
These	O
hazardous	O
substances	O
are	O
of	O
concern	O
because	O
of	O
their	O
ultimate	O
effect	O
on	O
survival	O
of	O
human	O
life	O
[].	O
Heavy	B-Chemical
metals	I-Chemical
like	O
Cd	B-Chemical
","	O
Zn	B-Chemical
","	O
Ni	B-Chemical
","	O
and	O
Pb	B-Chemical
are	O
present	O
in	O
relatively	O
major	O
amounts	O
in	O
industrial	O
effluents	O
and	O
enter	O
in	O
rivers	O
and	O
oceans	O
and	O
ultimately	O
pollute	O
groundwater	O
leading	O
to	O
adverse	O
effects	O
on	O
aquatic	O
life	O
.	O
Metals	O
resist	O
the	O
process	O
of	O
biodegradability	O
and	O
hence	O
remain	O
in	O
ecosystem	O
","	O
affecting	O
food	O
chain	O
and	O
human	O
health	O
[].	O
In	O
order	O
to	O
provide	O
clean	O
environment	O
and	O
healthy	O
lifestyle	O
to	O
our	O
coming	O
generations	O
","	O
it	O
is	O
necessary	O
to	O
remove	O
hazardous	O
pollutants	O
from	O
the	O
environment	O
.	O
In	O
environmental	O
restoration	O
areas	O
","	O
conventional	O
techniques	O
are	O
practiced	O
to	O
eradicate	O
those	O
pollutants	O
from	O
the	O
environment	O
which	O
include	O
chemical	O
precipitation	O
","	O
evaporative	O
method	O
","	O
electrolytic	O
extraction	O
","	O
reverse	O
osmosis	O
","	O
ion	O
exchange	O
","	O
and	O
electrochemical	O
and	O
membrane	O
processes	O
[].	O
All	O
these	O
methods	O
are	O
costly	O
and	O
produce	O
large	O
amount	O
of	O
sludge	O
which	O
is	O
difficult	O
to	O
dispose	O
of	O
.	O
Use	O
of	O
biological	O
materials	O
for	O
the	O
removal	O
of	O
pollutants	O
from	O
aqueous	O
media	O
is	O
considered	O
superior	O
to	O
other	O
methods	O
in	O
terms	O
of	O
cost	O
effectiveness	O
and	O
simple	O
design	O
.	O
It	O
is	O
a	O
surface	O
phenomenon	O
","	O
in	O
which	O
pollutants	O
get	O
accumulated	O
on	O
the	O
surface	O
of	O
the	O
adsorbent	O
material	O
.	O
Binding	O
nature	O
is	O
based	O
on	O
type	O
of	O
sorbent	O
and	O
sorbate	B-Chemical
","	O
but	O
mostly	O
physisorption	O
or	O
chemisorption	O
takes	O
place	O
[].	O
Materials	O
with	O
ease	O
in	O
availability	O
and	O
low	O
cost	O
are	O
preferred	O
for	O
the	O
purpose	O
.	O
In	O
this	O
context	O
","	O
agrowastes	O
are	O
considered	O
a	O
significant	O
material	O
for	O
adsorption	O
.	O
Binding	O
capacity	O
of	O
these	O
materials	O
can	O
be	O
intensified	O
by	O
physical	O
and	O
chemical	O
treatments	O
and	O
heat	O
therapy	O
[].	O
To	O
explore	O
the	O
appropriate	O
adsorbent	O
","	O
it	O
is	O
necessary	O
to	O
establish	O
equilibrium	O
correlation	O
of	O
sorbent	O
to	O
predict	O
behavior	O
of	O
sorbent	O
under	O
different	O
experimental	O
conditions	O
.	O
This	O
equilibrium	O
correlation	O
is	O
developed	O
by	O
using	O
equilibrium	O
isotherms	O
.	O
These	O
isotherms	O
express	O
way	O
of	O
sorbent	O
interaction	O
with	O
the	O
surface	O
of	O
adsorbent	O
","	O
that	O
is	O
","	O
whether	O
it	O
is	O
monolayer	O
or	O
multilayer	O
sorption	O
[].	O
Similarly	O
","	O
thermodynamic	O
studies	O
are	O
of	O
prime	O
importance	O
to	O
predict	O
whether	O
the	O
adsorption	O
is	O
spontaneous	O
or	O
not	O
.	O
Furthermore	O
","	O
it	O
provides	O
information	O
about	O
suitable	O
temperature	O
range	O
for	O
sorption	O
and	O
nature	O
of	O
sorbent	O
and	O
sorbate	B-Chemical
at	O
equilibrium	O
[].	O
The	O
aim	O
of	O
the	O
present	O
research	O
was	O
to	O
explore	O
Saccharum	O
arundinaceum	O
for	O
adsorption	O
of	O
cadmium	B-Chemical
under	O
different	O
operating	O
conditions	O
including	O
pH	O
","	O
contact	O
time	O
","	O
initial	O
concentration	O
","	O
and	O
temperature	O
.	O
The	O
application	O
of	O
linear	O
and	O
nonlinear	O
forms	O
of	O
equilibrium	O
isotherms	O
was	O
to	O
determine	O
appropriate	O
isotherm	O
for	O
the	O
purpose	O
","	O
and	O
thermodynamic	O
and	O
kinetic	O
studies	O
were	O
performed	O
to	O
check	O
reaction	O
nature	O
of	O
the	O
adsorption	O
phenomenon	O
.	O
Error	O
analysis	O
based	O
on	O
five	O
different	O
error	O
functions	O
was	O
also	O
performed	O
.	O
2	O
.	O
Materials	O
and	O
Methods	O
2	O
.	O
1	O
.	O
Preparation	O
of	O
Adsorbent	O
On	O
the	O
basis	O
of	O
literature	O
survey	O
and	O
indigenous	O
availability	O
of	O
agrowaste	O
materials	O
","	O
the	O
stem	O
of	O
Saccharum	O
arundinaceum	O
(	O
hardy	O
sugar	O
cane	O
)	O
was	O
collected	O
from	O
different	O
regions	O
of	O
Sargodha	O
District	O
","	O
Pakistan	O
.	O
After	O
collection	O
","	O
the	O
sample	O
was	O
properly	O
washed	O
with	O
deionized	O
water	B-Chemical
to	O
remove	O
dust	O
and	O
surface	O
impurities	O
.	O
The	O
sorbent	O
was	O
initially	O
dried	O
in	O
an	O
open	O
container	O
at	O
room	O
temperature	O
and	O
later	O
in	O
an	O
electric	O
oven	O
(	O
Model	O
","	O
LEB	O
-	O
1	O
-	O
20	O
)	O
at	O
105	O
Â°	O
C	O
for	O
24	O
h	O
to	O
remove	O
all	O
the	O
moisture	O
contents	O
.	O
The	O
dried	O
sorbent	O
was	O
ground	O
","	O
and	O
appropriate	O
particle	O
size	O
was	O
separated	O
by	O
sieves	O
and	O
was	O
stored	O
for	O
further	O
analyses	O
.	O
2	O
.	O
2	O
.	O
Chemicals	O
All	O
the	O
chemicals	O
","	O
reagents	O
","	O
and	O
solvents	O
used	O
in	O
the	O
present	O
work	O
were	O
of	O
analytical	O
reagent	O
grade	O
and	O
purchased	O
from	O
Merck	O
(	O
Germany	O
)	O
or	O
Sigma	O
-	O
Aldrich	O
(	O
Germany	O
).	O
Standard	O
solutions	O
were	O
prepared	O
","	O
and	O
successive	O
dilutions	O
were	O
made	O
with	O
double	O
-	O
distilled	O
water	B-Chemical
to	O
make	O
working	O
solutions	O
.	O
2	O
.	O
3	O
.	O
Pretreatment	O
of	O
Sorbents	O
Saccharum	O
arundinaceum	O
was	O
pretreated	O
with	O
HCl	B-Chemical
(	O
0	O
.	O
1	O
M	O
)	O
and	O
NaOH	B-Chemical
(	O
0	O
.	O
1	O
M	O
)	O
to	O
evaluate	O
the	O
effects	O
of	O
acid	O
and	O
base	O
treatments	O
on	O
pore	O
size	O
","	O
that	O
is	O
","	O
pore	O
area	O
","	O
pore	O
volume	O
","	O
and	O
sorption	O
capacity	O
.	O
For	O
chemical	O
treatment	O
","	O
the	O
sorbent	O
(	O
20	O
g	O
)	O
was	O
stirred	O
for	O
4	O
h	O
in	O
1	O
L	O
solution	O
of	O
0	O
.	O
1	O
M	O
NaOH	B-Chemical
or	O
HCl	B-Chemical
followed	O
by	O
filtration	O
and	O
extensive	O
washing	O
with	O
distilled	O
water	B-Chemical
to	O
remove	O
any	O
traces	O
of	O
acid	O
/	O
base	O
.	O
After	O
that	O
","	O
the	O
treated	O
sorbent	O
material	O
was	O
dried	O
at	O
110	O
Â°	O
C	O
and	O
stored	O
in	O
airtight	O
zipper	O
bags	O
at	O
âˆ’	O
4	O
Â°	O
C	O
before	O
further	O
use	O
.	O
2	O
.	O
4	O
.	O
Characterization	O
of	O
Sorbent	O
To	O
determine	O
different	O
physical	O
and	O
chemical	O
parameters	O
affecting	O
adsorption	O
","	O
it	O
is	O
necessary	O
to	O
characterize	O
the	O
sorbent	O
.	O
Therefore	O
","	O
physical	O
and	O
chemical	O
characterization	O
was	O
done	O
by	O
scanning	O
electron	O
microscopy	O
(	O
SEM	O
)	O
and	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
(	O
FTIR	O
).	O
2	O
.	O
4	O
.	O
1	O
.	O
Scanning	O
Electron	O
Microscopy	O
Surface	O
analysis	O
was	O
performed	O
using	O
scanning	O
electron	O
microscope	O
JEOL	O
model	O
2300	O
.	O
SEM	O
provides	O
information	O
about	O
surface	O
area	O
available	O
for	O
adsorption	O
and	O
morphology	O
of	O
sorbent	O
[].	O
Analysis	O
of	O
each	O
sorbent	O
was	O
carried	O
out	O
in	O
optimized	O
conditions	O
under	O
argon	B-Chemical
atmosphere	O
.	O
2	O
.	O
4	O
.	O
2	O
.	O
Fourier	O
Transform	O
Infrared	O
Spectroscopy	O
Functional	O
groups	O
present	O
in	O
structure	O
of	O
sorbent	O
were	O
determined	O
by	O
Fourier	O
transform	O
infrared	O
spectrophotometer	O
(	O
Model	O
Shimadzu	O
AIM	O
-	O
8800	O
).	O
These	O
functional	O
groups	O
are	O
responsible	O
for	O
adsorption	O
of	O
sorbate	B-Chemical
on	O
the	O
surface	O
of	O
sorbent	O
","	O
and	O
their	O
detection	O
helps	O
in	O
determining	O
the	O
nature	O
of	O
binding	O
interactions	O
between	O
sorbate	B-Chemical
and	O
sorbent	O
surface	O
[].	O
Diffused	O
reflectance	O
infrared	O
technique	O
(	O
DRIFT	O
)	O
was	O
used	O
for	O
analysis	O
taking	O
KBr	B-Chemical
as	O
a	O
background	O
reagent	O
.	O
2	O
.	O
5	O
.	O
Equilibrium	O
Isotherms	O
In	O
order	O
to	O
study	O
adsorption	O
pathway	O
and	O
equilibrium	O
relationship	O
between	O
sorbent	O
and	O
sorbate	B-Chemical
","	O
it	O
is	O
necessary	O
to	O
design	O
proper	O
adsorption	O
isotherms	O
.	O
Isotherms	O
predict	O
the	O
appropriate	O
parameters	O
and	O
behavior	O
of	O
sorbent	O
towards	O
different	O
sorption	O
systems	O
[].	O
In	O
this	O
context	O
","	O
linear	O
and	O
nonlinear	O
models	O
are	O
utilized	O
using	O
Microsoft	O
Excel	O
Â®	O
2007	O
(	O
equilibrium	O
isotherms	O
applied	O
on	O
the	O
present	O
work	O
are	O
given	O
in	O
Table	O
1s	O
of	O
supplementary	O
data	O
).	O
2	O
.	O
6	O
.	O
Error	O
Functions	O
In	O
order	O
to	O
determine	O
best	O
fitting	O
of	O
linear	O
or	O
nonlinear	O
models	O
onto	O
adsorption	O
data	O
","	O
it	O
is	O
necessary	O
to	O
calculate	O
the	O
error	O
function	O
[].	O
These	O
error	O
functions	O
include	O
sum	O
square	O
error	O
","	O
hybrid	O
functional	O
error	O
","	O
average	O
relative	O
error	O
","	O
sum	O
of	O
absolute	O
error	O
","	O
nonlinear	O
chi	O
-	O
square	O
","	O
and	O
so	O
on	O
(	O
calculated	O
error	O
functions	O
and	O
their	O
equations	O
are	O
present	O
in	O
Table	O
2s	O
of	O
supplementary	O
data	O
).	O
2	O
.	O
7	O
.	O
Thermodynamic	O
Investigations	O
Thermodynamic	O
investigations	O
are	O
another	O
important	O
parameter	O
of	O
adsorption	O
studies	O
.	O
For	O
thermodynamic	O
studies	O
","	O
the	O
adsorption	O
experiment	O
was	O
carried	O
out	O
at	O
different	O
temperature	O
conditions	O
and	O
calculated	O
parameters	O
included	O
enthalpy	O
(	O
Î”H	O
"),"	O
entropy	O
(	O
Î”S	O
"),"	O
and	O
Gibbs	O
free	O
energy	O
(	O
Î”G	O
).	O
For	O
this	O
purpose	O
","	O
(	O
1	O
)â€“(	O
3	O
)	O
were	O
applied	O
where	O
R	O
is	O
the	O
natural	O
gas	O
constant	O
and	O
K	O
C	O
is	O
the	O
constant	O
at	O
equilibrium	O
and	O
is	O
calculated	O
aswhere	O
C	O
e	O
is	O
the	O
concentration	O
of	O
sorbent	O
at	O
equilibrium	O
condition	O
.	O
2	O
.	O
8	O
.	O
Adsorption	O
Kinetics	O
In	O
batch	O
adsorption	O
process	O
","	O
kinetic	O
studies	O
provide	O
information	O
about	O
optimum	O
conditions	O
","	O
mechanism	O
of	O
sorption	O
","	O
and	O
possible	O
rate	O
controlling	O
step	O
.	O
For	O
this	O
purpose	O
","	O
linear	O
and	O
nonlinear	O
form	O
of	O
pseudo	O
-	O
first	O
-	O
and	O
pseudo	O
-	O
second	O
-	O
order	O
kinetics	O
is	O
applied	O
on	O
adsorption	O
data	O
[].	O
In	O
order	O
to	O
check	O
the	O
effect	O
of	O
contact	O
time	O
(	O
10	O
â€“	O
70	O
min	O
)	O
on	O
adsorption	O
","	O
initial	O
concentration	O
of	O
100	O
mg	O
/	O
L	O
for	O
cadmium	B-Chemical
was	O
prepared	O
and	O
100	O
ml	O
of	O
this	O
sample	O
was	O
used	O
for	O
study	O
.	O
Sorbent	O
(	O
0	O
.	O
5	O
g	O
)	O
was	O
added	O
in	O
this	O
cadmium	B-Chemical
solution	O
and	O
applied	O
for	O
shaking	O
at	O
150	O
rpm	O
speed	O
.	O
After	O
fixed	O
interval	O
of	O
time	O
","	O
the	O
sample	O
was	O
removed	O
from	O
flask	O
and	O
analyzed	O
for	O
cadmium	B-Chemical
concentration	O
by	O
atomic	O
absorption	O
spectrophotometer	O
.	O
The	O
amount	O
of	O
cadmium	B-Chemical
adsorbed	O
at	O
different	O
time	O
intervals	O
was	O
calculated	O
by	O
employing	O
the	O
following	O
formula	O
:	O
where	O
Q	O
t	O
is	O
the	O
amount	O
of	O
cadmium	B-Chemical
adsorbed	O
at	O
any	O
time	O
t	O
","	O
Q	O
o	O
and	O
Q	O
e	O
are	O
initial	O
and	O
equilibrium	O
concentrations	O
","	O
respectively	O
.	O
The	O
volume	O
of	O
cadmium	B-Chemical
solution	O
taken	O
is	O
represented	O
by	O
V	O
(	O
L	O
"),"	O
and	O
W	O
sorbent	O
is	O
the	O
amount	O
of	O
sorbent	O
in	O
g	O
.	O
2	O
.	O
8	O
.	O
1	O
.	O
Pseudo	O
-	O
First	O
-	O
Order	O
Kinetics	O
In	O
order	O
to	O
calculate	O
pseudo	O
-	O
first	O
-	O
order	O
kinetics	O
for	O
adsorption	O
system	O
","	O
following	O
equations	O
were	O
used	O
:	O
where	O
Q	O
t	O
is	O
the	O
amount	O
adsorbed	O
at	O
time	O
t	O
","	O
Q	O
e	O
is	O
the	O
equilibrium	O
amount	O
","	O
t	O
is	O
time	O
in	O
minutes	O
","	O
and	O
k	O
1	O
is	O
the	O
rate	O
constant	O
.	O
2	O
.	O
8	O
.	O
2	O
.	O
Pseudo	O
-	O
Second	O
-	O
Order	O
Kinetics	O
For	O
pseudo	O
-	O
second	O
-	O
order	O
kinetics	O
","	O
linear	O
and	O
nonlinear	O
forms	O
were	O
applied	O
as	O
follows	O
:	O
3	O
.	O
Results	O
and	O
Discussion	O
3	O
.	O
1	O
.	O
Effect	O
of	O
Pretreatment	O
Pretreatment	O
has	O
promising	O
effect	O
on	O
adsorption	O
potential	O
of	O
Saccharum	O
arundinaceum	O
.	O
Results	O
reveal	O
that	O
base	O
-	O
treated	O
(	O
97	O
.	O
5	O
%)	O
sorbent	O
shows	O
good	O
efficiency	O
for	O
cadmium	B-Chemical
sorption	O
as	O
compared	O
to	O
raw	O
(	O
91	O
.	O
15	O
%)	O
and	O
acid	O
-	O
treated	O
(	O
57	O
.	O
6	O
)	O
sorbent	O
as	O
shown	O
in	O
Figure	O
1	O
.	O
Adsorption	O
capacity	O
depends	O
upon	O
functional	O
groups	O
present	O
on	O
the	O
surface	O
of	O
sorbent	O
and	O
its	O
microporous	O
structure	O
[].	O
Increase	O
in	O
sorption	O
capacity	O
by	O
base	O
treatment	O
can	O
be	O
attributed	O
to	O
hydroxyl	O
groups	O
created	O
on	O
the	O
surface	O
of	O
adsorbent	O
by	O
base	O
treatment	O
or	O
modification	O
of	O
cell	O
wall	O
components	O
by	O
base	O
[].	O
Decrease	O
in	O
adsorption	O
after	O
acid	O
treatments	O
was	O
found	O
as	O
the	O
binding	O
sites	O
available	O
on	O
the	O
surface	O
of	O
biosorbent	O
got	O
destructed	O
due	O
to	O
acid	O
[].	O
So	O
","	O
base	O
-	O
treated	O
Saccharum	O
arundinaceum	O
was	O
used	O
for	O
adsorption	O
analysis	O
.	O
3	O
.	O
2	O
.	O
Characterization	O
of	O
Sorbents	O
Saccharum	O
arundinaceum	O
was	O
characterized	O
in	O
terms	O
of	O
surface	O
morphology	O
and	O
functional	O
group	O
analysis	O
by	O
scanning	O
electron	O
microscopy	O
and	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
.	O
3	O
.	O
2	O
.	O
1	O
.	O
Scanning	O
Electron	O
Microscopy	O
Three	O
native	O
and	O
two	O
treated	O
sorbents	O
(	O
acid	O
-	O
and	O
base	O
-	O
treated	O
Saccharum	O
arundinaceum	O
)	O
were	O
analyzed	O
through	O
scanning	O
electron	O
microscope	O
to	O
study	O
surface	O
morphology	O
.	O
Large	O
pore	O
size	O
available	O
on	O
the	O
surfaces	O
of	O
native	O
and	O
base	O
-	O
treated	O
sorbent	O
was	O
responsible	O
for	O
enhanced	O
adsorption	O
on	O
the	O
surface	O
of	O
these	O
agrowaste	O
materials	O
.	O
Results	O
for	O
SEM	O
analysis	O
are	O
given	O
in	O
Figure	O
2	O
.	O
Hollow	O
cavities	O
appear	O
in	O
the	O
structure	O
of	O
raw	O
adsorbent	O
","	O
which	O
were	O
responsible	O
for	O
binding	O
of	O
sorbate	B-Chemical
onto	O
the	O
surface	O
of	O
sorbent	O
.	O
Acid	O
treatment	O
decreases	O
these	O
cavities	O
by	O
deforming	O
surface	O
of	O
the	O
sorbent	O
","	O
so	O
adsorption	O
decreases	O
after	O
acid	O
treatment	O
because	O
surface	O
becomes	O
smooth	O
and	O
thin	O
adsorption	O
layer	O
is	O
formed	O
on	O
the	O
sorbent	O
surface	O
.	O
Raw	O
and	O
base	O
-	O
treated	O
sorbent	O
surface	O
is	O
found	O
rough	O
and	O
cylindrical	O
","	O
which	O
make	O
possible	O
multilayer	O
and	O
thick	O
adsorption	O
on	O
the	O
sorbent	O
surface	O
as	O
compared	O
to	O
smooth	O
surface	O
.	O
Results	O
obtained	O
in	O
the	O
SEM	O
micrograph	O
are	O
in	O
good	O
agreement	O
with	O
reported	O
data	O
[].	O
3	O
.	O
2	O
.	O
2	O
.	O
Fourier	O
Transform	O
Infrared	O
Spectroscopy	O
Fourier	O
transform	O
infrared	O
spectrometer	O
provides	O
information	O
about	O
functional	O
groups	O
present	O
on	O
the	O
surface	O
of	O
sorbent	O
and	O
makes	O
possible	O
attachment	O
of	O
sorbate	B-Chemical
[].	O
FTIR	O
spectra	O
of	O
sorbent	O
obtained	O
in	O
the	O
range	O
of	O
4000	O
â€“	O
450	O
cm	O
âˆ’	O
1	O
wavenumber	O
and	O
major	O
functional	O
groups	O
present	O
in	O
adsorbent	O
are	O
listed	O
in	O
Table	O
1	O
.	O
A	O
broadband	O
appears	O
in	O
the	O
range	O
of	O
3000	O
â€“	O
3700	O
cm	O
âˆ’	O
1	O
which	O
was	O
due	O
to	O
â€“	O
OH	O
stretching	O
vibration	O
of	O
hydroxyl	O
functional	O
groups	O
including	O
hydrogen	B-Chemical
bonding	O
because	O
broadband	O
of	O
â€“	O
OH	O
group	O
in	O
this	O
range	O
is	O
indication	O
of	O
hydrogen	B-Chemical
bonding	O
present	O
in	O
the	O
compound	O
.	O
This	O
peak	O
appears	O
in	O
raw	O
and	O
base	O
-	O
treated	O
sorbent	O
but	O
disappears	O
in	O
case	O
of	O
acid	O
treated	O
due	O
to	O
reaction	O
of	O
â€“	O
OH	O
group	O
with	O
acid	B-Chemical
hydrogen	I-Chemical
.	O
Stretching	O
band	O
of	O
â€“	O
CH	O
appears	O
in	O
2900	O
â€“	O
3000	O
cm	O
âˆ’	O
1	O
wavenumber	O
range	O
for	O
all	O
sorbents	O
.	O
The	O
peak	O
at	O
1750	O
cm	O
âˆ’	O
1	O
appears	O
due	O
to	O
C	O
=	O
O	O
and	O
1200	O
cm	O
âˆ’	O
1	O
due	O
to	O
C	O
-	O
O	O
functional	O
group	O
.	O
In	O
some	O
cases	O
","	O
â€“	O
CN	O
also	O
appears	O
at	O
1049	O
cm	O
âˆ’	O
1	O
value	O
.	O
Vibration	O
due	O
to	O
secondary	O
amide	B-Chemical
appears	O
at	O
1645	O
cm	O
âˆ’	O
1	O
[].	O
For	O
adsorption	O
purpose	O
","	O
significant	O
role	O
is	O
played	O
by	O
â€“	O
OH	O
group	O
and	O
heteroatoms	O
to	O
attach	O
sorbate	B-Chemical
on	O
the	O
surface	O
.	O
3	O
.	O
3	O
.	O
Adsorption	O
Study	O
Adsorption	O
study	O
was	O
performed	O
by	O
the	O
batch	O
adsorption	O
method	O
by	O
varying	O
different	O
parameters	O
including	O
pH	O
","	O
contact	O
time	O
","	O
and	O
initial	O
concentration	O
of	O
sorbate	B-Chemical
to	O
find	O
best	O
suited	O
conditions	O
for	O
the	O
removal	O
of	O
cadmium	B-Chemical
from	O
aqueous	O
media	O
.	O
3	O
.	O
3	O
.	O
1	O
.	O
Effect	O
of	O
Contact	O
Time	O
Contact	O
time	O
was	O
varied	O
from	O
10	O
to	O
100	O
minutes	O
under	O
neutral	O
conditions	O
with	O
constant	O
amount	O
of	O
sorbent	O
(	O
1	O
g	O
"),"	O
initial	O
concentration	O
(	O
60	O
ppm	O
"),"	O
and	O
shaking	O
speed	O
(	O
150	O
rpm	O
"),"	O
and	O
results	O
obtained	O
are	O
shown	O
in	O
Figure	O
1s	O
(	O
Supplementary	O
material	O
).	O
Maximum	O
adsorption	O
was	O
achieved	O
at	O
60	O
minutes	O
time	O
interval	O
and	O
no	O
significant	O
increase	O
found	O
by	O
further	O
increase	O
in	O
time	O
.	O
Initially	O
","	O
excess	O
of	O
vacant	O
places	O
are	O
available	O
on	O
the	O
surface	O
of	O
sorbent	O
","	O
and	O
uptake	O
of	O
metal	O
ions	O
was	O
more	O
","	O
so	O
there	O
was	O
continuous	O
increase	O
in	O
adsorption	O
capacity	O
by	O
increasing	O
time	O
slot	O
from	O
zero	O
to	O
60	O
minutes	O
.	O
But	O
","	O
further	O
increase	O
could	O
not	O
cause	O
sufficient	O
change	O
in	O
adsorption	O
of	O
metals	O
as	O
vacant	O
spaces	O
are	O
already	O
filled	O
","	O
and	O
equilibrium	O
is	O
achieved	O
[].	O
3	O
.	O
3	O
.	O
2	O
.	O
Effect	O
of	O
pH	O
Initial	O
pH	O
of	O
the	O
adsorption	O
system	O
has	O
significant	O
role	O
in	O
adsorption	O
of	O
sorbate	B-Chemical
","	O
as	O
it	O
affects	O
the	O
surface	O
morphology	O
of	O
the	O
sorbent	O
and	O
binding	O
nature	O
of	O
sorbate	B-Chemical
.	O
The	O
range	O
of	O
pH	O
selected	O
was	O
2	O
â€“	O
10	O
with	O
1	O
g	O
sorbent	O
and	O
60	O
ppm	O
initial	O
concentration	O
of	O
sorbate	B-Chemical
.	O
The	O
result	O
given	O
in	O
Figure	O
2s	O
(	O
Supplementary	O
material	O
)	O
reveals	O
the	O
fact	O
that	O
adsorption	O
capacity	O
is	O
quite	O
low	O
under	O
acidic	O
conditions	O
.	O
When	O
pH	O
is	O
increased	O
","	O
it	O
causes	O
increase	O
in	O
adsorbed	O
amount	O
of	O
sorbate	B-Chemical
on	O
the	O
surface	O
of	O
sorbent	O
.	O
At	O
low	O
pH	O
value	O
","	O
metals	O
have	O
to	O
compete	O
with	O
H	B-Chemical
+	I-Chemical
ions	O
for	O
adsorption	O
on	O
sorbent	O
surface	O
since	O
H	B-Chemical
+	I-Chemical
ions	O
are	O
present	O
in	O
excess	O
at	O
that	O
pH	O
value	O
.	O
But	O
when	O
pH	O
value	O
is	O
raised	O
","	O
it	O
causes	O
significant	O
increase	O
in	O
adsorption	O
due	O
to	O
attraction	O
developed	O
between	O
negatively	O
charged	O
surfaces	O
of	O
sorbent	O
by	O
â€“	O
OH	O
groups	O
and	O
positively	O
charged	O
metal	O
ions	O
[].	O
So	O
","	O
for	O
cadmium	B-Chemical
","	O
optimum	O
pH	O
range	O
was	O
found	O
from	O
6	O
to	O
8	O
;	O
in	O
this	O
range	O
","	O
cadmium	B-Chemical
shows	O
best	O
adsorption	O
behavior	O
.	O
When	O
pH	O
is	O
further	O
increased	O
","	O
there	O
is	O
decline	O
in	O
adsorption	O
capacity	O
due	O
to	O
formation	O
of	O
metal	O
hydrides	O
.	O
3	O
.	O
3	O
.	O
3	O
.	O
Effect	O
of	O
Initial	O
Concentration	O
Initial	O
concentration	O
of	O
sorbate	B-Chemical
is	O
another	O
important	O
parameter	O
","	O
which	O
affects	O
the	O
adsorption	O
phenomenon	O
.	O
For	O
this	O
purpose	O
","	O
initial	O
concentration	O
of	O
cadmium	B-Chemical
was	O
varied	O
in	O
range	O
of	O
10	O
â€“	O
100	O
ppm	O
by	O
keeping	O
all	O
other	O
parameters	O
constant	O
(	O
Figure	O
3s	O
Supplementary	O
material	O
).	O
Rapid	O
increase	O
in	O
adsorption	O
capacity	O
was	O
observed	O
initially	O
for	O
adsorption	O
of	O
cadmium	B-Chemical
on	O
Saccharum	O
arundinaceum	O
as	O
vacant	O
spaces	O
were	O
available	O
on	O
the	O
surface	O
of	O
sorbent	O
.	O
So	O
","	O
rise	O
in	O
concentration	O
also	O
raised	O
adsorption	O
of	O
sorbate	B-Chemical
on	O
available	O
sites	O
[].	O
Adsorbent	O
readily	O
occupies	O
these	O
adsorption	O
sites	O
","	O
and	O
adsorption	O
capacity	O
has	O
positive	O
influence	O
of	O
concentration	O
in	O
this	O
range	O
.	O
Further	O
increase	O
in	O
concentration	O
from	O
60	O
to	O
100	O
ppm	O
has	O
no	O
significant	O
effect	O
on	O
adsorption	O
phenomenon	O
.	O
Surface	O
of	O
adsorbent	O
becomes	O
saturated	O
with	O
sorbate	B-Chemical
","	O
and	O
after	O
establishment	O
of	O
equilibria	O
","	O
increase	O
in	O
concentration	O
has	O
no	O
significant	O
influence	O
on	O
adsorption	O
phenomenon	O
.	O
Previous	O
studies	O
also	O
report	O
that	O
accommodation	O
for	O
sorbate	B-Chemical
decreases	O
as	O
concentration	O
is	O
very	O
high	O
due	O
to	O
unavailability	O
of	O
resident	O
sites	O
[].	O
3	O
.	O
3	O
.	O
4	O
.	O
Effect	O
of	O
Temperature	O
The	O
effect	O
of	O
temperature	O
on	O
adsorption	O
was	O
studied	O
by	O
using	O
temperature	O
range	O
20	O
","	O
30	O
","	O
40	O
","	O
and	O
50	O
Â°	O
C	O
with	O
pH	O
6	O
(	O
Figure	O
4s	O
)	O
(	O
Supplementary	O
material	O
).	O
Adsorption	O
of	O
cadmium	B-Chemical
onto	O
Saccharum	O
arundinaceum	O
agrowaste	O
was	O
found	O
to	O
increase	O
with	O
increase	O
in	O
temperature	O
.	O
At	O
high	O
temperature	O
","	O
intraparticle	O
diffusion	O
increases	O
and	O
more	O
adsorption	O
sites	O
are	O
created	O
which	O
boost	O
up	O
adsorption	O
phenomenon	O
[].	O
3	O
.	O
4	O
.	O
Equilibrium	O
Isotherms	O
Adsorption	O
system	O
can	O
be	O
designed	O
by	O
adsorption	O
isotherms	O
commonly	O
known	O
as	O
equilibrium	O
isotherms	O
which	O
represent	O
the	O
amount	O
of	O
solute	O
adsorbed	O
per	O
unit	O
weight	O
of	O
sorbent	O
[].	O
These	O
isotherms	O
use	O
equilibrium	O
concentration	O
of	O
sorbent	O
at	O
constant	O
temperature	O
.	O
In	O
order	O
to	O
remove	O
effluents	O
from	O
the	O
system	O
","	O
particular	O
design	O
is	O
optimized	O
to	O
generate	O
proper	O
correlation	O
for	O
experimental	O
data	O
which	O
is	O
called	O
adsorption	O
isotherm	O
.	O
Researches	O
proposed	O
many	O
isotherms	O
in	O
this	O
regard	O
which	O
are	O
based	O
on	O
the	O
adsorption	O
system	O
including	O
Langmuir	O
","	O
Freundlich	O
","	O
Redlich	O
â€“	O
Peterson	O
","	O
Temkin	O
","	O
and	O
Elovich	O
"[,"	O
].	O
Sorption	O
was	O
carried	O
out	O
by	O
employing	O
linear	O
as	O
well	O
as	O
nonlinear	O
adsorption	O
models	O
by	O
varying	O
initial	O
concentration	O
from	O
10	O
to	O
100	O
ppm	O
.	O
3	O
.	O
4	O
.	O
1	O
.	O
Freundlich	O
Isotherm	O
Freundlich	O
adsorption	O
isotherm	O
was	O
developed	O
for	O
the	O
heterogeneous	O
system	O
","	O
and	O
it	O
gives	O
concept	O
of	O
multilayer	O
adsorption	O
on	O
the	O
surface	O
of	O
sorbent	O
(	O
Figure	O
5s	O
Supplementary	O
material	O
).	O
Parameters	O
calculated	O
for	O
Freundlich	O
isotherm	O
by	O
employing	O
its	O
linear	O
and	O
nonlinear	O
form	O
are	O
given	O
in	O
Table	O
4	O
.	O
Freundlich	O
isotherm	O
was	O
obtained	O
by	O
plotting	O
log	O
Cad	O
versus	O
log	O
Ce	O
.	O
K	O
F	O
and	O
n	O
are	O
constants	O
obtained	O
from	O
intercept	O
and	O
slope	O
","	O
respectively	O
.	O
Freundlich	O
adsorption	O
capacity	O
(	O
K	O
F	O
)	O
is	O
an	O
indicator	O
of	O
a	O
system	O
","	O
whether	O
it	O
is	O
favorable	O
for	O
adsorption	O
or	O
not	O
.	O
Adsorption	O
is	O
considered	O
promising	O
if	O
value	O
of	O
K	O
F	O
is	O
found	O
in	O
range	O
of	O
1	O
â€“	O
20	O
","	O
and	O
results	O
reveal	O
that	O
in	O
the	O
present	O
study	O
","	O
K	O
F	O
was	O
9	O
.	O
5	O
and	O
12	O
.	O
2	O
","	O
respectively	O
","	O
for	O
linear	O
and	O
nonlinear	O
approaches	O
of	O
Freundlich	O
adsorption	O
isotherm	O
.	O
Similarly	O
","	O
adsorption	O
intensity	O
represented	O
by	O
n	O
indicates	O
fitness	O
of	O
model	O
for	O
adsorption	O
purposes	O
if	O
value	O
of	O
n	O
is	O
above	O
1	O
.	O
Value	O
of	O
R	O
2	O
obtained	O
from	O
the	O
plot	O
is	O
significant	O
(	O
0	O
.	O
9446	O
)	O
representing	O
good	O
fitness	O
of	O
this	O
model	O
for	O
adsorption	O
of	O
cadmium	B-Chemical
onto	O
Saccharum	O
arundinaceum	O
.	O
3	O
.	O
4	O
.	O
2	O
.	O
Langmuir	O
Isotherm	O
Langmuir	O
adsorption	O
isotherm	O
is	O
based	O
on	O
monolayer	O
adsorption	O
of	O
metal	O
ions	O
on	O
the	O
surface	O
of	O
agrowastes	O
","	O
and	O
energy	O
of	O
adsorption	O
system	O
is	O
considered	O
constant	O
.	O
In	O
order	O
to	O
calculate	O
Langmuir	O
model	O
","	O
initial	O
concentrations	O
were	O
changed	O
from	O
10	O
to	O
100	O
ppm	O
with	O
1	O
g	O
sorbent	O
amount	O
and	O
1	O
h	O
shaking	O
time	O
.	O
Distribution	O
of	O
metal	O
ions	O
between	O
liquid	O
and	O
solid	O
surface	O
was	O
calculated	O
by	O
equations	O
given	O
in	O
Table	O
1	O
","	O
employing	O
linear	O
and	O
nonlinear	O
forms	O
of	O
the	O
model	O
.	O
Langmuir	O
adsorption	O
isotherm	O
was	O
obtained	O
by	O
plotting	O
Ce	O
/	O
Cad	O
versus	O
Ce	O
as	O
shown	O
in	O
Figure	O
6s	O
Supplementary	O
material	O
.	O
R	O
2	O
value	O
obtained	O
for	O
plot	O
was	O
found	O
satisfactory	O
showing	O
fitness	O
of	O
model	O
on	O
the	O
adsorption	O
experiment	O
.	O
Q	O
o	O
represents	O
metal	O
ion	O
uptake	O
per	O
unit	O
mass	O
of	O
adsorbent	O
(	O
mg	O
/	O
g	O
)	O
and	O
b	O
is	O
Langmuir	O
constant	O
[].	O
A	O
dimensionless	O
constant	O
R	O
L	O
is	O
calculated	O
by	O
using	O
Langmuir	O
constant	O
","	O
and	O
initial	O
concentration	O
represents	O
model	O
fitness	O
for	O
a	O
particular	O
system	O
.	O
If	O
value	O
of	O
R	O
L	O
falls	O
between	O
0	O
and	O
1	O
","	O
the	O
system	O
is	O
considered	O
appropriate	O
for	O
adsorption	O
purpose	O
and	O
Table	O
2	O
shows	O
results	O
which	O
are	O
in	O
this	O
range	O
.	O
Furthermore	O
","	O
experimental	O
data	O
and	O
predicted	O
results	O
obtained	O
for	O
the	O
present	O
work	O
were	O
found	O
in	O
close	O
correlation	O
with	O
low	O
value	O
of	O
residual	O
sum	O
of	O
square	O
(	O
0	O
.	O
6	O
)	O
making	O
this	O
model	O
applicable	O
for	O
the	O
present	O
work	O
.	O
3	O
.	O
4	O
.	O
3	O
.	O
Dubinin	O
â€“	O
Radushkevich	O
Isotherm	O
Dubinin	O
â€“	O
Radushkevich	O
isotherm	O
was	O
designed	O
as	O
an	O
empirical	O
model	O
for	O
adsorption	O
of	O
vapors	O
onto	O
solid	O
surface	O
.	O
It	O
is	O
successfully	O
applied	O
for	O
adsorption	O
of	O
heterogeneous	O
system	O
including	O
solid	O
and	O
liquid	O
.	O
This	O
model	O
is	O
considered	O
more	O
general	O
than	O
Langmuir	O
because	O
in	O
its	O
derivation	O
homogenous	O
surface	O
and	O
constant	O
sorption	O
potential	O
are	O
not	O
assumed	O
[].	O
The	O
relationship	O
given	O
in	O
Table	O
1s	O
(	O
supplementary	O
data	O
)	O
was	O
employed	O
to	O
relate	O
ln	O
Cad	O
with	O
Îµ	O
2	O
","	O
where	O
Îµ	O
2	O
is	O
Polanyi	O
potential	O
which	O
is	O
based	O
on	O
temperature	O
","	O
natural	O
gas	O
constant	O
","	O
and	O
equilibrium	O
concentration	O
as	O
given	O
in	O
the	O
following	O
equation	O
:	O
Slope	O
of	O
the	O
plot	O
gives	O
value	O
of	O
k	O
ad	O
and	O
the	O
intercept	O
is	O
q	O
s	O
.	O
The	O
model	O
showed	O
good	O
applicability	O
on	O
the	O
adsorption	O
system	O
in	O
nonlinear	O
form	O
with	O
high	O
value	O
of	O
R	O
2	O
.	O
Dubinin	O
â€“	O
Radushkevich	O
isotherm	O
has	O
found	O
very	O
promising	O
applications	O
for	O
determination	O
of	O
nature	O
of	O
sorption	O
","	O
whether	O
it	O
is	O
physical	O
or	O
chemical	O
.	O
For	O
this	O
purpose	O
","	O
k	O
ad	O
obtained	O
from	O
the	O
slope	O
of	O
the	O
plot	O
is	O
used	O
in	O
the	O
following	O
equation	O
:	O
The	O
value	O
of	O
E	O
calculated	O
for	O
the	O
present	O
research	O
was	O
0	O
.	O
764	O
and	O
suggests	O
physical	O
nature	O
of	O
sorption	O
.	O
Because	O
the	O
value	O
of	O
E	O
below	O
8	O
kj	O
/	O
mol	O
reflects	O
physical	O
sorption	O
and	O
8	O
â€“	O
16	O
kj	O
/	O
mol	O
reflects	O
chemical	O
sorption	O
(	O
Figure	O
7s	O
Supplementary	O
material	O
).	O
3	O
.	O
4	O
.	O
4	O
.	O
Temkin	O
Isotherm	O
Temkin	O
adsorption	O
isotherm	O
discusses	O
interaction	O
of	O
sorbent	O
and	O
sorbate	B-Chemical
","	O
and	O
the	O
model	O
is	O
based	O
on	O
assumption	O
that	O
heat	O
of	O
adsorption	O
will	O
not	O
remain	O
constant	O
.	O
It	O
decreases	O
due	O
to	O
interaction	O
between	O
sorbent	O
and	O
sorbate	B-Chemical
during	O
adsorption	O
phenomenon	O
[].	O
Linear	O
and	O
nonlinear	O
forms	O
of	O
Temkin	O
model	O
are	O
given	O
in	O
Table	O
1s	O
(	O
Supplementary	O
data	O
).	O
Equilibrium	O
constant	O
of	O
binding	O
K	O
T	O
provides	O
information	O
about	O
binding	O
energy	O
","	O
and	O
Î²	O
expresses	O
heat	O
of	O
adsorption	O
for	O
a	O
particular	O
adsorption	O
experiment	O
(	O
Figure	O
8s	O
Supplementary	O
material	O
).	O
Linear	O
form	O
of	O
Temkin	O
model	O
is	O
found	O
more	O
suitable	O
with	O
high	O
value	O
of	O
binding	O
constant	O
as	O
given	O
in	O
Table	O
2	O
.	O
The	O
model	O
indicates	O
the	O
exothermic	O
nature	O
of	O
adsorption	O
reaction	O
as	O
B	O
>	O
0	O
which	O
is	O
an	O
indicator	O
of	O
heat	O
release	O
during	O
the	O
process	O
[].	O
3	O
.	O
4	O
.	O
5	O
.	O
Elovich	O
Isotherm	O
According	O
to	O
Elovich	O
model	O
","	O
mechanism	O
of	O
adsorption	O
is	O
based	O
on	O
chemical	O
reactions	O
which	O
are	O
responsible	O
for	O
adsorption	O
.	O
Plot	O
of	O
ln	O
C	O
ad	O
/	O
C	O
e	O
versus	O
C	O
ad	O
gives	O
R	O
2	O
value	O
close	O
to	O
unity	O
.	O
K	O
E	O
and	O
Q	O
m	O
are	O
obtained	O
from	O
intercept	O
and	O
slope	O
of	O
plot	O
","	O
respectively	O
.	O
K	O
E	O
shows	O
initial	O
sorption	O
rate	O
and	O
Q	O
m	O
is	O
adsorption	O
constant	O
.	O
Initial	O
sorption	O
rate	O
obtained	O
from	O
linear	O
form	O
of	O
Elovich	O
model	O
is	O
quite	O
high	O
(	O
35	O
","	O
100	O
.	O
411	O
)	O
as	O
compared	O
to	O
nonlinear	O
form	O
(	O
11	O
.	O
7891	O
"),"	O
so	O
making	O
linear	O
form	O
adequate	O
to	O
describe	O
adsorption	O
of	O
cadmium	B-Chemical
onto	O
Saccharum	O
arundinaceum	O
.	O
Furthermore	O
","	O
R	O
2	O
value	O
(	O
0	O
.	O
9033	O
)	O
for	O
linear	O
form	O
is	O
also	O
high	O
than	O
nonlinear	O
form	O
(	O
0	O
.	O
835	O
)	O
(	O
Figure	O
9s	O
-	O
Supplementary	O
material	O
).	O
3	O
.	O
5	O
.	O
Error	O
Analysis	O
for	O
Equilibrium	O
Isotherms	O
In	O
order	O
to	O
check	O
the	O
fit	O
of	O
adsorption	O
model	O
to	O
experimental	O
data	O
","	O
error	O
functions	O
are	O
used	O
[].	O
In	O
the	O
present	O
work	O
","	O
six	O
error	O
functions	O
were	O
applied	O
on	O
linear	O
and	O
nonlinear	O
form	O
of	O
data	O
by	O
minimizing	O
the	O
error	O
function	O
in	O
a	O
range	O
of	O
concentration	O
used	O
for	O
analysis	O
by	O
employing	O
solver	O
add	O
-	O
in	O
with	O
Microsoft	O
Excel	O
2010	O
.	O
Results	O
for	O
optimization	O
of	O
equilibrium	O
isotherms	O
by	O
error	O
analysis	O
are	O
given	O
in	O
Table	O
3	O
.	O
For	O
meaningful	O
results	O
","	O
a	O
comparison	O
of	O
each	O
error	O
function	O
for	O
linear	O
and	O
nonlinear	O
forms	O
was	O
made	O
(	O
Figure	O
10s	O
Supplementary	O
material	O
).	O
R	O
2	O
:	O
Temkin	O
>	O
Langmuir	O
>	O
Elovich	O
>	O
Freundlich	O
>	O
Dubinin	O
â€“	O
Radushkevich	O
RSS	O
:	O
Temkin	O
>	O
Dubinin	O
â€“	O
Radushkevich	O
>	O
Elovich	O
>	O
Freundlich	O
>	O
Langmuir	O
ARE	O
:	O
Dubinin	O
â€“	O
Radushkevich	O
>	O
Temkin	O
>	O
Freundlich	O
>	O
Langmuir	O
>	O
Elovich	O
EABS	O
:	O
Dubinin	O
â€“	O
Radushkevich	O
>	O
Langmuir	O
>	O
Temkin	O
>	O
Freundlich	O
>	O
Elovich	O
Chi	O
-	O
square	O
(	O
Ï‡	O
2	O
):	O
Elovich	O
>	O
Dubinin	O
â€“	O
Radushkevich	O
>	O
Freundlich	O
>	O
Temkin	O
>	O
Langmuir	O
For	O
linear	O
form	O
of	O
adsorption	O
isotherms	O
","	O
a	O
comparison	O
of	O
error	O
functions	O
reflects	O
that	O
Langmuir	O
","	O
Freundlich	O
","	O
and	O
Elovich	O
isotherms	O
have	O
good	O
correlation	O
with	O
experimental	O
values	O
for	O
the	O
present	O
adsorption	O
study	O
.	O
These	O
isotherms	O
give	O
low	O
values	O
for	O
most	O
of	O
error	O
functions	O
.	O
Applicability	O
of	O
these	O
models	O
for	O
removal	O
of	O
cadmium	B-Chemical
ions	O
from	O
aqueous	O
media	O
is	O
also	O
studied	O
by	O
many	O
researchers	O
"[,"	O
].	O
R	O
2	O
:	O
Langmuir	O
>	O
Freundlich	O
>	O
Dubinin	O
â€“	O
Radushkevich	O
>	O
Temkin	O
>	O
Elovich	O
RSS	O
:	O
Temkin	O
>	O
Dubinin	O
â€“	O
Radushkevich	O
>	O
Freundlich	O
>	O
Langmuir	O
>	O
Elovich	O
ARE	O
:	O
Temkin	O
>	O
Dubinin	O
â€“	O
Radushkevich	O
>	O
Langmuir	O
>	O
Elovich	O
>	O
Freundlich	O
EABS	O
:	O
Temkin	O
>	O
Dubinin	O
â€“	O
Radushkevich	O
>	O
Elovich	O
>	O
Langmuir	O
>	O
Freundlich	O
Chi	O
-	O
square	O
(	O
Ï‡	O
2	O
):	O
Temkin	O
>	O
Freundlich	O
>	O
Dubinin	O
â€“	O
Radushkevich	O
>	O
Elovich	O
>	O
Langmuir	O
Similar	O
study	O
was	O
carried	O
out	O
by	O
employing	O
nonlinear	O
form	O
of	O
adsorption	O
models	O
","	O
and	O
results	O
are	O
summarized	O
below	O
.	O
Nonlinear	O
form	O
of	O
Temkin	O
isotherm	O
was	O
not	O
found	O
suitable	O
for	O
adsorption	O
of	O
cadmium	B-Chemical
onto	O
Saccharum	O
arundinaceum	O
agrowaste	O
because	O
of	O
high	O
value	O
of	O
error	O
functions	O
.	O
Freundlich	O
and	O
Elovich	O
isotherms	O
have	O
been	O
proved	O
to	O
be	O
suitable	O
models	O
for	O
this	O
study	O
with	O
low	O
value	O
for	O
error	O
functions	O
.	O
R	O
2	O
:	O
Freundlich	O
(	O
linear	O
approach	O
)	O
<	O
Freundlich	O
(	O
nonlinear	O
)	O
RSS	O
:	O
Freundlich	O
(	O
linear	O
approach	O
)	O
<	O
Freundlich	O
(	O
nonlinear	O
)	O
ARE	O
:	O
Freundlich	O
(	O
linear	O
approach	O
)	O
>	O
Freundlich	O
(	O
nonlinear	O
)	O
EABS	O
:	O
Freundlich	O
(	O
linear	O
approach	O
)	O
<	O
Freundlich	O
(	O
nonlinear	O
)	O
Chi	O
-	O
square	O
(	O
Ï‡	O
2	O
):	O
Freundlich	O
(	O
linear	O
approach	O
)	O
<	O
Freundlich	O
(	O
nonlinear	O
)	O
A	O
comparison	O
between	O
linear	O
and	O
nonlinear	O
approaches	O
of	O
each	O
adsorption	O
isotherm	O
was	O
also	O
made	O
to	O
select	O
the	O
most	O
appropriate	O
form	O
for	O
adsorption	O
study	O
.	O
Linear	O
form	O
of	O
Freundlich	O
adsorption	O
isotherm	O
was	O
found	O
superior	O
over	O
nonlinear	O
form	O
with	O
small	O
error	O
functions	O
in	O
most	O
of	O
the	O
cases	O
.	O
R	O
2	O
:	O
Langmuir	O
(	O
linear	O
approach	O
)	O
>	O
Langmuir	O
(	O
nonlinear	O
approach	O
)	O
RSS	O
:	O
Langmuir	O
(	O
linear	O
approach	O
)	O
<	O
Langmuir	O
(	O
nonlinear	O
approach	O
)	O
ARE	O
:	O
Langmuir	O
(	O
linear	O
approach	O
)	O
<	O
Langmuir	O
(	O
nonlinear	O
approach	O
)	O
EABS	O
:	O
Langmuir	O
(	O
linear	O
approach	O
)	O
<	O
Langmuir	O
(	O
nonlinear	O
approach	O
)	O
Chi	O
-	O
square	O
(	O
Ï‡	O
2	O
):	O
Langmuir	O
(	O
linear	O
approach	O
)	O
<	O
Langmuir	O
(	O
nonlinear	O
approach	O
)	O
For	O
Langmuir	O
adsorption	O
isotherm	O
","	O
error	O
function	O
for	O
nonlinear	O
form	O
was	O
obtained	O
high	O
as	O
compared	O
with	O
linear	O
to	O
exception	O
of	O
R	O
2	O
.	O
R	O
2	O
:	O
Dubinin	O
â€“	O
Radushkevich	O
(	O
linear	O
approach	O
)	O
<	O
Dubinin	O
â€“	O
Radushkevich	O
(	O
nonlinear	O
)	O
RSS	O
:	O
Dubinin	O
â€“	O
Radushkevich	O
(	O
linear	O
approach	O
)	O
<	O
Dubinin	O
â€“	O
Radushkevich	O
(	O
nonlinear	O
)	O
ARE	O
:	O
Dubinin	O
â€“	O
Radushkevich	O
(	O
linear	O
approach	O
)	O
>	O
Dubinin	O
â€“	O
Radushkevich	O
(	O
nonlinear	O
)	O
EABS	O
:	O
Dubinin	O
â€“	O
Radushkevich	O
(	O
linear	O
approach	O
)	O
<	O
Dubinin	O
â€“	O
Radushkevich	O
(	O
nonlinear	O
)	O
Chi	O
-	O
sq	O
/	O
Ï‡	O
2	O
:	O
Dubinin	O
â€“	O
Radushkevich	O
(	O
linear	O
approach	O
)	O
<	O
Dubinin	O
â€“	O
Radushkevich	O
(	O
nonlinear	O
)	O
Applicability	O
of	O
linear	O
Dubinin	O
â€“	O
Radushkevich	O
model	O
was	O
found	O
better	O
than	O
nonlinear	O
due	O
to	O
small	O
value	O
of	O
error	O
function	O
(	O
except	O
ARE	O
).	O
R	O
2	O
:	O
Elovich	O
(	O
linear	O
approach	O
)	O
>	O
Elovich	O
(	O
nonlinear	O
approach	O
)	O
RSS	O
:	O
Elovich	O
(	O
linear	O
approach	O
)	O
>	O
Elovich	O
(	O
nonlinear	O
approach	O
)	O
ARE	O
:	O
Elovich	O
(	O
linear	O
approach	O
)	O
<	O
Elovich	O
(	O
nonlinear	O
approach	O
)	O
EABS	O
:	O
Elovich	O
(	O
linear	O
approach	O
)	O
<	O
Elovich	O
(	O
nonlinear	O
approach	O
)	O
Chi	O
-	O
square	O
(	O
Ï‡	O
2	O
):	O
Elovich	O
(	O
linear	O
approach	O
)	O
>	O
Elovich	O
(	O
nonlinear	O
approach	O
)	O
Linear	O
form	O
of	O
Elovich	O
isotherm	O
","	O
which	O
is	O
also	O
based	O
on	O
multilayer	O
sorption	O
on	O
the	O
surface	O
of	O
sorbent	O
","	O
shows	O
small	O
value	O
of	O
ARE	O
and	O
EABS	O
","	O
but	O
other	O
error	O
functions	O
were	O
found	O
lower	O
for	O
nonlinear	O
form	O
.	O
R	O
2	O
:	O
Temkin	O
(	O
linear	O
approach	O
)	O
>	O
Temkin	O
(	O
nonlinear	O
approach	O
)	O
RSS	O
:	O
Temkin	O
(	O
linear	O
approach	O
)	O
<	O
Temkin	O
(	O
nonlinear	O
approach	O
)	O
ARE	O
:	O
Temkin	O
(	O
linear	O
approach	O
)	O
<	O
Temkin	O
(	O
nonlinear	O
approach	O
)	O
EABS	O
:	O
Temkin	O
(	O
linear	O
approach	O
)	O
<	O
Temkin	O
(	O
nonlinear	O
approach	O
)	O
Chi	O
-	O
square	O
(	O
Ï‡	O
2	O
):	O
Temkin	O
(	O
linear	O
approach	O
)	O
<	O
Temkin	O
(	O
nonlinear	O
approach	O
)	O
Linear	O
approach	O
for	O
Temkin	O
isotherm	O
was	O
found	O
favorable	O
for	O
adsorption	O
of	O
cadmium	B-Chemical
ions	O
onto	O
Saccharum	O
arundinaceum	O
with	O
low	O
error	O
function	O
.	O
3	O
.	O
6	O
.	O
Thermodynamic	O
Studies	O
Effect	O
of	O
temperature	O
on	O
adsorption	O
was	O
studied	O
by	O
using	O
temperature	O
range	O
20	O
","	O
30	O
","	O
40	O
","	O
and	O
50	O
Â°	O
C	O
with	O
pH	O
6	O
and	O
variable	O
initial	O
concentration	O
(	O
30	O
â€“	O
120	O
ppm	O
).	O
Adsorption	O
of	O
cadmium	B-Chemical
onto	O
Saccharum	O
arundinaceum	O
agrowaste	O
was	O
found	O
to	O
increase	O
with	O
increase	O
in	O
temperature	O
.	O
At	O
high	O
temperature	O
","	O
intraparticle	O
diffusion	O
increases	O
and	O
more	O
adsorption	O
sites	O
are	O
created	O
which	O
boost	O
up	O
adsorption	O
phenomenon	O
.	O
Results	O
for	O
thermodynamic	O
study	O
are	O
given	O
in	O
Table	O
4	O
:	O
Plot	O
of	O
log	O
Cad	O
/	O
Ce	O
versus	O
1	O
/	O
T	O
was	O
obtained	O
with	O
R	O
-	O
squared	O
value	O
0	O
.	O
927	O
.	O
Slop	O
and	O
intercept	O
provide	O
value	O
of	O
âˆ†	O
H	O
Â°	O
and	O
âˆ†	O
S	O
"Â°,"	O
respectively	O
","	O
as	O
shown	O
in	O
(	O
10	O
).	O
âˆ†	O
G	O
Â°	O
was	O
calculated	O
by	O
employing	O
(	O
1	O
)	O
given	O
in	O
Section	O
2	O
in	O
temperature	O
range	O
292	O
â€“	O
328	O
K	O
.	O
Results	O
show	O
a	O
negative	O
value	O
for	O
Gibb	O
'	O
s	O
free	O
energy	O
at	O
all	O
temperature	O
ranges	O
","	O
and	O
âˆ†	O
G	O
Â°	O
increases	O
with	O
the	O
increase	O
in	O
temperature	O
.	O
These	O
negative	O
values	O
represent	O
spontaneous	O
nature	O
as	O
well	O
as	O
feasibility	O
of	O
adsorption	O
reaction	O
[].	O
Decrease	O
in	O
âˆ†	O
G	O
Â°	O
with	O
the	O
increase	O
in	O
temperature	O
reflects	O
better	O
sorption	O
at	O
elevated	O
temperature	O
.	O
The	O
positive	O
value	O
for	O
change	O
in	O
enthalpy	O
is	O
due	O
to	O
endothermic	O
nature	O
of	O
adsorption	O
of	O
cadmium	B-Chemical
.	O
Enthalpy	O
was	O
also	O
found	O
positive	O
because	O
randomness	O
in	O
system	O
increases	O
due	O
to	O
solid	O
-	O
liquid	O
interaction	O
during	O
adsorption	O
phenomenon	O
.	O
Sorption	O
energy	O
calculated	O
by	O
Dubinin	O
â€“	O
Radushkevich	O
model	O
was	O
found	O
below	O
1	O
which	O
is	O
an	O
indication	O
of	O
physical	O
nature	O
of	O
cadmium	B-Chemical
sorption	O
on	O
the	O
surface	O
of	O
sorbent	O
.	O
E	O
<	O
8	O
kJ	O
/	O
mol	O
is	O
representative	O
of	O
physical	O
sorption	O
","	O
and	O
E	O
>	O
8	O
â€“	O
16	O
kJ	O
/	O
mol	O
is	O
due	O
to	O
chemical	O
sorption	O
[].	O
For	O
adsorption	O
of	O
cadmium	B-Chemical
value	O
of	O
E	O
is	O
found	O
below	O
8	O
","	O
so	O
adsorption	O
of	O
cadmium	B-Chemical
occurred	O
on	O
the	O
surface	O
and	O
no	O
chemical	O
bonding	O
took	O
place	O
between	O
sorbent	O
and	O
sorbate	B-Chemical
.	O
Similar	O
results	O
for	O
adsorption	O
of	O
cadmium	B-Chemical
onto	O
agrowaste	O
were	O
reported	O
in	O
the	O
literature	O
[].	O
3	O
.	O
7	O
.	O
Adsorption	O
Kinetics	O
Adsorption	O
kinetics	O
has	O
prime	O
importance	O
in	O
describing	O
solute	O
uptake	O
rate	O
and	O
time	O
required	O
for	O
adsorption	O
process	O
.	O
In	O
the	O
present	O
work	O
","	O
kinetic	O
study	O
was	O
performed	O
at	O
different	O
time	O
intervals	O
for	O
cadmium	B-Chemical
adsorption	O
by	O
employing	O
linear	O
and	O
nonlinear	O
forms	O
of	O
pseudo	O
-	O
first	O
-	O
and	O
second	O
-	O
order	O
kinetics	O
.	O
Results	O
indicate	O
that	O
amount	O
of	O
cadmium	B-Chemical
adsorbed	O
increases	O
with	O
the	O
increase	O
in	O
time	O
interval	O
;	O
however	O
","	O
this	O
increase	O
was	O
sharp	O
in	O
the	O
start	O
of	O
reaction	O
and	O
gradually	O
magnitude	O
of	O
adsorption	O
decreases	O
down	O
.	O
Initially	O
","	O
plenty	O
of	O
active	O
sites	O
were	O
available	O
on	O
the	O
surface	O
of	O
sorbent	O
","	O
so	O
sharp	O
rise	O
in	O
adsorption	O
occurred	O
","	O
but	O
these	O
sites	O
got	O
occupied	O
with	O
the	O
passage	O
of	O
time	O
","	O
so	O
magnitude	O
of	O
adsorption	O
gradually	O
decreases	O
[].	O
3	O
.	O
7	O
.	O
1	O
.	O
Pseudo	O
-	O
First	O
-	O
Order	O
Kinetics	O
For	O
pseudo	O
-	O
first	O
-	O
order	O
kinetic	O
model	O
","	O
log	O
(	O
Q	O
e	O
âˆ’	O
Q	O
t	O
)	O
was	O
plotted	O
against	O
time	O
interval	O
and	O
value	O
of	O
k	O
was	O
obtained	O
from	O
slope	O
of	O
the	O
line	O
and	O
Q	O
e	O
from	O
intercept	O
.	O
Initial	O
sorption	O
rate	O
","	O
h	O
","	O
was	O
calculated	O
by	O
the	O
following	O
equation	O
:	O
Poor	O
correlation	O
was	O
obtained	O
for	O
linear	O
form	O
of	O
the	O
model	O
with	O
low	O
value	O
of	O
R	O
2	O
(	O
0	O
.	O
918	O
).	O
Results	O
indicate	O
that	O
adsorption	O
of	O
cadmium	B-Chemical
onto	O
Saccharum	O
arundinaceum	O
does	O
not	O
follow	O
pseudo	O
-	O
first	O
-	O
order	O
kinetics	O
.	O
Nonlinear	O
form	O
of	O
pseudo	O
-	O
first	O
-	O
order	O
kinetics	O
was	O
obtained	O
by	O
using	O
Microsoft	O
Excel	O
2010	O
[].	O
3	O
.	O
7	O
.	O
2	O
.	O
Pseudo	O
-	O
Second	O
-	O
Order	O
Kinetics	O
Second	O
-	O
order	O
kinetics	O
is	O
applicable	O
on	O
small	O
amount	O
of	O
initial	O
concentration	O
for	O
determination	O
of	O
initial	O
sorption	O
rate	O
.	O
Different	O
linear	O
and	O
nonlinear	O
forms	O
of	O
pseudo	O
-	O
second	O
-	O
order	O
kinetics	O
are	O
given	O
in	O
Table	O
3s	O
(	O
Supplementary	O
material	O
).	O
These	O
four	O
linear	O
forms	O
of	O
pseudo	O
-	O
second	O
-	O
order	O
kinetic	O
models	O
were	O
applied	O
on	O
experimental	O
data	O
","	O
and	O
Figures	O
11s	O
â€“	O
15s	O
(	O
Supplementary	O
material	O
)	O
show	O
results	O
for	O
these	O
models	O
.	O
Coefficient	O
of	O
determination	O
(	O
R	O
2	O
"),"	O
found	O
for	O
type	O
1	O
","	O
was	O
quite	O
high	O
indicating	O
the	O
best	O
fitting	O
of	O
this	O
model	O
on	O
adsorption	O
data	O
of	O
cadmium	B-Chemical
.	O
Results	O
obtained	O
for	O
pseudo	O
-	O
second	O
-	O
order	O
kinetic	O
are	O
given	O
in	O
Table	O
4s	O
(	O
Supplementary	O
material	O
).	O
Theoretical	O
results	O
obtained	O
for	O
amount	O
of	O
cadmium	B-Chemical
adsorbed	O
at	O
equilibrium	O
are	O
found	O
best	O
fitted	O
with	O
experimental	O
data	O
for	O
pseudo	O
-	O
second	O
-	O
order	O
kinetics	O
.	O
For	O
nonlinear	O
form	O
of	O
pseudo	O
-	O
second	O
-	O
order	O
","	O
a	O
computer	O
-	O
based	O
procedure	O
was	O
used	O
in	O
Microsoft	O
Excel	O
2010	O
using	O
solver	O
add	O
-	O
in	O
method	O
as	O
reported	O
in	O
the	O
literature	O
[].	O
For	O
sorption	O
of	O
cadmium	B-Chemical
onto	O
Saccharum	O
arundinaceum	O
pseudo	O
-	O
second	O
-	O
order	O
kinetic	O
may	O
describe	O
the	O
method	O
of	O
adsorption	O
in	O
quite	O
appropriate	O
way	O
as	O
compared	O
to	O
pseudo	O
-	O
first	O
-	O
order	O
approach	O
.	O
Furthermore	O
","	O
nonlinear	O
form	O
of	O
pseudo	O
-	O
second	O
-	O
order	O
gives	O
close	O
results	O
to	O
experimental	O
data	O
.	O
3	O
.	O
8	O
.	O
Effect	O
of	O
Interfering	O
Ions	O
Process	O
of	O
adsorption	O
becomes	O
complicated	O
in	O
case	O
of	O
multicomponent	O
adsorption	O
as	O
many	O
interactions	O
of	O
sorbent	O
and	O
sorbate	B-Chemical
are	O
involved	O
.	O
Effect	O
of	O
interfering	O
ions	O
was	O
measured	O
by	O
observing	O
adsorption	O
of	O
one	O
metal	O
ion	O
","	O
and	O
then	O
","	O
by	O
addition	O
of	O
interfering	O
ion	O
change	O
in	O
adsorption	O
capacity	O
was	O
noted	O
.	O
Interfering	O
effect	O
was	O
calculated	O
by	O
employing	O
the	O
following	O
equation	O
:	O
where	O
C	O
mix	O
is	O
the	O
%	O
adsorption	O
of	O
mixture	O
of	O
two	O
metal	O
ions	O
and	O
C	O
is	O
the	O
%	O
adsorption	O
of	O
pure	O
metal	O
on	O
selected	O
sorbent	O
.	O
If	O
the	O
value	O
of	O
C	O
mix	O
/	O
C	O
is	O
found	O
equal	O
to	O
1	O
","	O
then	O
there	O
is	O
no	O
effect	O
of	O
interfering	O
ions	O
on	O
adsorption	O
phenomenon	O
.	O
However	O
","	O
if	O
it	O
is	O
found	O
less	O
than	O
1	O
","	O
then	O
adsorption	O
capacity	O
is	O
found	O
to	O
be	O
affected	O
by	O
addition	O
of	O
these	O
interfering	O
ions	O
.	O
To	O
study	O
interference	O
","	O
ions	O
were	O
divided	O
into	O
three	O
categories	O
as	O
monovalent	O
","	O
bivalent	O
","	O
and	O
trivalent	O
ions	O
based	O
on	O
valences	O
of	O
ions	O
.	O
One	O
ion	O
was	O
selected	O
from	O
each	O
class	O
of	O
ions	O
to	O
check	O
the	O
interfering	O
effect	O
on	O
adsorption	O
of	O
cadmium	B-Chemical
ions	O
.	O
Metals	O
are	O
attached	O
on	O
the	O
surface	O
of	O
sorbent	O
through	O
electrostatic	O
forces	O
","	O
and	O
competition	O
of	O
metals	O
for	O
sorbent	O
place	O
is	O
mainly	O
based	O
on	O
metal	O
ion	O
charge	O
and	O
its	O
attraction	O
towards	O
functional	O
groups	O
present	O
on	O
the	O
surface	O
on	O
adsorbent	O
.	O
Results	O
for	O
interference	O
of	O
metal	O
ions	O
are	O
summarized	O
in	O
Table	O
5	O
.	O
Metals	O
with	O
high	O
charge	O
value	O
were	O
found	O
to	O
have	O
maximum	O
effect	O
on	O
adsorption	O
of	O
cadmium	B-Chemical
as	O
compared	O
with	O
those	O
with	O
low	O
charge	O
.	O
Anions	O
have	O
also	O
found	O
to	O
affect	O
the	O
adsorption	O
phenomenon	O
of	O
metal	O
ions	O
but	O
their	O
interference	O
is	O
comparatively	O
very	O
less	O
than	O
cations	O
.	O
Adsorption	O
of	O
anions	O
on	O
sorbent	O
is	O
dependent	O
on	O
charge	O
present	O
on	O
the	O
surface	O
of	O
sorbent	O
.	O
Since	O
negatively	O
charged	O
hydroxyl	O
groups	O
are	O
present	O
on	O
the	O
surface	O
of	O
adsorbent	O
","	O
adsorption	O
of	O
anions	O
is	O
not	O
as	O
favored	O
as	O
cations	O
[].	O
4	O
.	O
Conclusion	O
Removal	O
of	O
cadmium	B-Chemical
was	O
performed	O
by	O
employing	O
the	O
stem	O
powder	O
of	O
Saccharum	O
arundinaceum	O
.	O
In	O
order	O
to	O
generate	O
proper	O
correlation	O
for	O
the	O
removal	O
of	O
cadmium	B-Chemical
","	O
five	O
adsorption	O
isotherms	O
were	O
applied	O
on	O
experimental	O
data	O
including	O
Freundlich	O
","	O
Langmuir	O
","	O
Dubinin	O
â€“	O
Radushkevich	O
","	O
Elovich	O
","	O
and	O
Temkin	O
.	O
Error	O
analysis	O
provides	O
information	O
about	O
fitness	O
of	O
these	O
models	O
on	O
experimental	O
data	O
.	O
The	O
model	O
with	O
minimum	O
error	O
was	O
selected	O
best	O
for	O
adsorption	O
data	O
.	O
Order	O
of	O
equilibrium	O
isotherms	O
according	O
to	O
increasing	O
RSS	O
value	O
was	O
found	O
as	O
Temkin	O
>	O
Dubinin	O
â€“	O
Radushkevich	O
>	O
Elovich	O
>	O
Freundlich	O
>	O
Langmuir	O
.	O
Linear	O
form	O
of	O
Freundlich	O
and	O
Langmuir	O
models	O
was	O
found	O
best	O
fitted	O
with	O
minimum	O
value	O
of	O
error	O
.	O
Effect	O
of	O
temperature	O
on	O
cadmium	B-Chemical
adsorption	O
was	O
investigated	O
by	O
thermodynamic	O
analysis	O
","	O
and	O
it	O
was	O
found	O
to	O
increase	O
with	O
increase	O
in	O
temperature	O
.	O
Gibb	O
'	O
s	O
free	O
energy	O
(âˆ†	O
G	O
Â°	O
=	O
âˆ’	O
612	O
.	O
34	O
at	O
303	O
K	O
)	O
revealed	O
spontaneous	O
nature	O
of	O
sorbent	O
-	O
sorbate	B-Chemical
binding	O
reaction	O
","	O
and	O
it	O
followed	O
pseudo	O
-	O
second	O
-	O
order	O
kinetics	O
.	O
Data	O
Availability	O
The	O
data	O
used	O
to	O
support	O
the	O
findings	O
of	O
this	O
study	O
are	O
available	O
from	O
the	O
corresponding	O
author	O
upon	O
request	O
.	O
Conflicts	O
of	O
Interest	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
conflicts	O
of	O
interest	O
.	O
Supplementary	O
Materials	O
Effect	O
of	O
pretreatment	O
on	O
adsorption	O
capacity	O
of	O
Saccharum	O
arundinaceum	O
(	O
0	O
.	O
1	O
M	O
HCl	B-Chemical
and	O
NaOH	B-Chemical
treated	O
sorbent	O
","	O
60	O
minutes	O
time	O
","	O
and	O
60	O
ppm	O
initial	O
concentration	O
).	O
(	O
a	O
)	O
SEM	O
image	O
of	O
raw	O
Saccharum	O
arundinaceum	O
at	O
three	O
different	O
resolutions	O
.	O
(	O
b	O
)	O
SEM	O
image	O
of	O
base	O
-	O
treated	O
Saccharum	O
arundinaceum	O
at	O
three	O
different	O
resolutions	O
.	O
(	O
c	O
)	O
SEM	O
image	O
of	O
acid	O
-	O
treated	O
Saccharum	O
arundinaceum	O
at	O
three	O
different	O
resolutions	O
.	O
Identified	O
functional	O
groups	O
present	O
in	O
Saccharum	O
arundinaceum	O
by	O
FTIR	O
spectroscopy	O
.	O
Linear	O
and	O
nonlinear	O
parameters	O
of	O
isothermal	O
models	O
for	O
sorption	O
of	O
Cd	B-Chemical
onto	O
Saccharum	O
arundinaceum	O
Error	O
functions	O
for	O
optimization	O
of	O
equilibrium	O
isotherms	O
.	O
Thermodynamic	O
parameters	O
for	O
adsorption	O
of	O
cadmium	B-Chemical
onto	O
Saccharum	O
arundinaceum	O
.	O
Effect	O
of	O
interfering	O
cations	O
and	O
anions	O
on	O
%	O
adsorption	O
of	O
cadmium	B-Chemical
.	O
